
@article{ WOS:000763501200003,
Author = {Yang, Hui and Geng, Yue-Hang and Wang, Peng and Zhang, Hong-Quan and
   Fang, Wei-Gang and Tian, Xin-Xia},
Title = {Extracellular ATP promotes breast cancer chemoresistance via HIF-1α
   signaling},
Journal = {CELL DEATH \& DISEASE},
Year = {2022},
Volume = {13},
Number = {3},
Month = {MAR 2},
Abstract = {We have previously demonstrated that extracellular adenosine
   5'-triphosphate (ATP) promotes breast cancer cell chemoresistance.
   However, the underlying mechanism remains unclear. Using a cDNA
   microarray, we demonstrated that extracellular ATP can stimulate
   hypoxia-inducible factor (HIF) signaling. In this study, we report that
   hypoxia-inducible factor 1 alpha (HIF-1 alpha) was upregulated after ATP
   treatment and mediated the ATP-driven chemoresistance process. We aimed
   to investigate the mechanisms and identify potential clinically relevant
   targets that are involved. Using mass spectrometry, we found that
   aldolase A (ALDOA) interacts with HIF-1 alpha and increases HIF-1 alpha
   expression. We then demonstrated that STAT3-ALDOA mediates ATP-HIF-1
   alpha signaling and upregulates the HIF-1 target genes adrenomedullin
   (ADM) and phosphoinositide-dependent kinase-1 (PDK1). Moreover, we show
   that PI3K/AKT acts upstream of HIF-1 alpha in ATP signaling and
   contributes to chemoresistance in breast cancer cells. In addition,
   HIF-1 alpha-knockdown or treatment with direct HIF inhibitors combined
   with the ATP hydrolase apyrase in MDA-MB-231 cells induced enhanced drug
   sensitivity in nude BALB/c mice. We then used in vitro spheroid
   formation assays to demonstrate the significance of ATP-HIF-1 alpha in
   mediating chemoresistance. Furthermore, considering that indirect HIF
   inhibitors are effective in clinical cancer therapy, we treated
   tumor-bearing BALB/c mice with STAT3 and PI3K/AKT inhibitors and found
   that the dual-targeting strategy sensitized breast cancer to cisplatin.
   Finally, using breast cancer tissue microarrays, we found that ATP-HIF-1
   alpha signaling is associated with cancer progression, poor prognosis,
   and resistance to chemotherapy. Taken together, we suggest that HIF-1
   alpha signaling is vital in ATP-driven chemoresistance and may serve as
   a potential target for breast cancer therapies.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Fang, WG; Tian, XX (Corresponding Author), Peking Univ Hlth Sci Ctr, Sch Basic Med Sci, Hosp 3,Minist Educ, Dept Pathol,Key Lab Carcinogenesis \& Translat Res, Beijing 100191, Peoples R China.
   Yang, Hui; Geng, Yue-Hang; Fang, Wei-Gang; Tian, Xin-Xia, Peking Univ Hlth Sci Ctr, Sch Basic Med Sci, Hosp 3,Minist Educ, Dept Pathol,Key Lab Carcinogenesis \& Translat Res, Beijing 100191, Peoples R China.
   Yang, Hui; Wang, Peng, Peking Univ First Hosp, Translat Canc Res Ctr, Beijing 100034, Peoples R China.
   Wang, Peng, Peking Univ Hlth Sci Ctr, Off Sci Res, Beijing 100191, Peoples R China.
   Zhang, Hong-Quan, Peking Univ Hlth Sci Ctr, Dept Anat Histol \& Embryol, Beijing 100191, Peoples R China.},
DOI = {10.1038/s41419-022-04647-6},
Article-Number = {199},
ISSN = {2041-4889},
Keywords-Plus = {TO-MESENCHYMAL TRANSITION; CISPLATIN RESISTANCE; PURINERGIC RECEPTORS;
   METABOLIC SWITCH; CELL INVASION; HYPOXIA; METASTASIS; INHIBITION; HIF-1;
   AXIS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {wgfang@bjmu.edu.cn
   tianxinxia@bjmu.edu.cn},
Affiliations = {Peking University},
ResearcherID-Numbers = {Wang, Jun/ABE-9088-2020
   },
ORCID-Numbers = {Tian, Xin-Xia/0000-0002-1593-4987
   Wang, Peng/0000-0002-2558-292X
   Yang, Hui/0000-0002-9138-1325},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81872382, 82003187]},
Funding-Text = {This work was supported by grants to X-XT, W-GF, and HY from the
   National Natural Science Foundation of China (No 81872382 and 82003187).},
Cited-References = {Aghazadeh S, 2017, BBA-GEN SUBJECTS, V1861, P1970, DOI 10.1016/j.bbagen.2017.05.009.
   Ai ZH, 2016, CANCER LETT, V373, P36, DOI 10.1016/j.canlet.2016.01.009.
   Akiyama Y, 2015, CANCER GENOM PROTEOM, V12, P133.
   Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613.
   Bardia A, 2019, NEW ENGL J MED, V380, P741, DOI 10.1056/NEJMoa1814213.
   Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992.
   Chang YC, 2017, CANCER LETT, V403, P28, DOI 10.1016/j.canlet.2017.06.001.
   Chen H, 2017, CLIN CANCER RES, V23, P5176, DOI 10.1158/1078-0432.CCR-17-0177.
   Chen X, 2014, MOL CARCINOGEN, V53, P138, DOI 10.1002/mc.21957.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206.
   Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0.
   Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008-5472.CAN-12-1600.
   Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z.
   FANG WG, 1992, J CLIN INVEST, V89, P191, DOI 10.1172/JCI115562.
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748.
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9.
   Hu XC, 2015, LANCET ONCOL, V16, P436, DOI 10.1016/S1470-2045(15)70064-1.
   Jantaratnotai N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-442.
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107.
   Jo H, 2011, P NATL ACAD SCI USA, V108, P6486, DOI 10.1073/pnas.1019062108.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koshy N, 2010, BREAST, V19, P246, DOI 10.1016/j.breast.2010.02.003.
   Li WH, 2013, BRIT J CANCER, V109, P1666, DOI 10.1038/bjc.2013.484.
   Li WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133165.
   Liu Y, 2018, CANCER LETT, V430, P1, DOI 10.1016/j.canlet.2018.04.043.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y.
   Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383.
   Pan Y, 2017, INT J BIOL SCI, V13, P794, DOI 10.7150/ijbs.18969.
   Qiu Y, 2018, ONCOL REP, V39, P138, DOI 10.3892/or.2017.6081.
   Qiu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114371.
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187.
   Shi YH, 2005, J PATHOL, V205, P530, DOI 10.1002/path.1734.
   Stagg J, 2010, ONCOGENE, V29, P5346, DOI 10.1038/onc.2010.292.
   Su WJ, 2011, CANCER LETT, V305, P94, DOI 10.1016/j.canlet.2011.02.031.
   Sun XP, 2014, FEBS J, V281, P115, DOI 10.1111/febs.12577.
   Unger C, 2014, ADV DRUG DELIVER REV, V79-80, P50, DOI 10.1016/j.addr.2014.10.015.
   Veith C, 2016, J PHYSIOL-LONDON, V594, P1167, DOI 10.1113/JP270689.
   Verhalen B, 2017, NATURE, V543, P738, DOI 10.1038/nature21414.
   Xiong GF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06893-9.
   Yamamura K, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13946.
   Yang H, 2020, ONCOGENE, V39, P5795, DOI 10.1038/s41388-020-01402-z.
   Yang H, 2019, CANCER SCI, V110, P2456, DOI 10.1111/cas.14086.
   Zhang FJ, 2015, JOINT BONE SPINE, V82, P144, DOI 10.1016/j.jbspin.2014.10.003.
   Zhang JL, 2017, CANCER SCI, V108, P1318, DOI 10.1111/cas.13273.
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064.},
Number-of-Cited-References = {47},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {ZL2HP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000763501200003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000771136200019,
Author = {Erdem, Aysegul and Marin, Silvia and Pereira-Martins, Diego A. and
   Cortes, Roldan and Cunningham, Alan and Pruis, Maurien G. and de Boer,
   Bauke and van den Heuvel, Fiona A. J. and Geugien, Marjan and Wierenga,
   Albertus T. J. and Brouwers-Vos, Annet Z. and Rego, Eduardo M. and Huls,
   Gerwin and Cascante, Marta and Schuringa, Jan Jacob},
Title = {The Glycolytic Gatekeeper PDK1 defines different metabolic states
   between genetically distinct subtypes of human acute myeloid leukemia},
Journal = {NATURE COMMUNICATIONS},
Year = {2022},
Volume = {13},
Number = {1},
Month = {MAR 1},
Abstract = {Acute myeloid leukemia (AML) is genetically a very heterogeneous
   disease. Here, Erdem et al. uncover heterogeneity in the metabolic
   landscape of AML and identify Pyruvate dehydrogenase kinase 1 (PDK1) as
   a targetable determinant of different metabolic states in distinct
   subtypes of AML.
   Acute myeloid leukemia remains difficult to treat due to strong genetic
   heterogeneity between and within individual patients. Here, we show that
   Pyruvate dehydrogenase kinase 1 (PDK1) acts as a targetable determinant
   of different metabolic states in acute myeloid leukemia (AML). PDK1(low)
   AMLs are OXPHOS-driven, are enriched for leukemic granulocyte-monocyte
   progenitor (L-GMP) signatures, and are associated with FLT3-ITD and
   NPM1cyt mutations. PDK1(high) AMLs however are OXPHOSlow, wild type for
   FLT3 and NPM1, and are enriched for stemness signatures. Metabolic
   states can even differ between genetically distinct subclones within
   individual patients. Loss of PDK1 activity releases glycolytic cells
   into an OXPHOS state associated with increased ROS levels resulting in
   enhanced apoptosis in leukemic but not in healthy stem/progenitor cells.
   This coincides with an enhanced dependency on glutamine uptake and
   reduced proliferation in vitro and in vivo in humanized xenograft mouse
   models. We show that human leukemias display distinct metabolic states
   and adaptation mechanisms that can serve as targets for treatment.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Schuringa, JJ (Corresponding Author), Univ Groningen, Univ Med Ctr Groningen, Dept Expt Hematol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.
   Erdem, Aysegul; Pereira-Martins, Diego A.; Cunningham, Alan; Pruis, Maurien G.; de Boer, Bauke; van den Heuvel, Fiona A. J.; Geugien, Marjan; Wierenga, Albertus T. J.; Brouwers-Vos, Annet Z.; Huls, Gerwin; Schuringa, Jan Jacob, Univ Groningen, Univ Med Ctr Groningen, Dept Expt Hematol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.
   Erdem, Aysegul; Marin, Silvia; Cortes, Roldan; Cascante, Marta, Fac Biol, Dept Biochem \& Mol Biol, Avinguda Diagonal 643, Barcelona 08028, Spain.
   Marin, Silvia; Cascante, Marta, Inst Hlth Carlos III, CIBER Hepat \& Digest Dis CIBEREHD, Madrid 28029, Spain.
   Marin, Silvia; Cascante, Marta, Univ Barcelona, Inst Biomed, Barcelona 08028, Spain.
   Pereira-Martins, Diego A.; Rego, Eduardo M., Univ Sao Paulo, Fac Med, Hematol Div, LIM31, Sao Paulo, SP, Brazil.
   Wierenga, Albertus T. J., Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Hanzepl 1, NL-9700 RB Groningen, Netherlands.},
DOI = {10.1038/s41467-022-28737-3},
Article-Number = {1105},
EISSN = {2041-1723},
Keywords-Plus = {HEMATOPOIETIC STEM-CELLS; PYRUVATE-DEHYDROGENASE; SELF-RENEWAL;
   DNA-DAMAGE; PHOSPHORYLATION; INHIBITION; TARGETS; DEPENDENCY; MUTATIONS;
   PROGNOSIS},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {j.j.schuringa@umcg.nl},
Affiliations = {University of Groningen; University of Barcelona; CIBER - Centro de
   Investigacion Biomedica en Red; CIBEREHD; University of Barcelona;
   Universidade de Sao Paulo; University of Groningen},
ResearcherID-Numbers = {Marin, Silvia/C-5492-2017
   CASCANTE, MARTA/AFK-5991-2022
   Huls, G.A./L-4398-2015
   Rego, Eduardo/Y-5572-2019
   Cortés, Roldán/F-7240-2015},
ORCID-Numbers = {Pereira-Martins, Diego/0000-0002-3302-4311
   Marin, Silvia/0000-0003-0693-2207
   de Boer, Bauke/0000-0002-7866-3803
   CASCANTE, MARTA/0000-0002-2062-4633
   Pruis, Maurien/0009-0007-5212-0636
   Rego, Eduardo/0000-0003-1567-4086
   Cunningham, Alan/0000-0003-4299-0367
   },
Funding-Acknowledgement = {EU {[}H2020-MSCA-ITN-2015 675790]; Marie Curie Fellowship; Icrea
   Academia (ICREA Foundation); AGAUR, Generalitat de Catalunya
   {[}2017-SGR-1033]; FAPESP {[}2017/23117-1]},
Funding-Text = {This work was supported by a grant from the EU (ITN-EJD HaemMetabolome
   (H2020-MSCA-ITN-2015 675790) awarded to J.J. Schuringa and to M.
   Cascante. A.E. and A.C. gratefully acknowledge receipt of a Marie Curie
   Fellowship and are participants in the same Initial Training Network.
   S.M., R.C., and M.C. acknowledge also the support of Icrea Academia
   (ICREA Foundation) and 2017-SGR-1033 (AGAUR, Generalitat de Catalunya).
   We thank Luise A. Simoes for technical assistance. D.A.P.M. received a
   fellowship from FAPESP (Grant \#2017/23117-1).},
Cited-References = {Adane B, 2019, CELL REP, V27, P238, DOI 10.1016/j.celrep.2019.03.009.
   Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650.
   Ansó E, 2017, NAT CELL BIOL, V19, P614, DOI 10.1038/ncb3529.
   Antonelli A, 2016, BLOOD, V128, P2949, DOI 10.1182/blood-2016-05-719021.
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556.
   Baccelli I, 2019, CANCER CELL, V36, P84, DOI 10.1016/j.ccell.2019.06.003.
   Bagger FO, 2016, NUCLEIC ACIDS RES, V44, pD917, DOI 10.1093/nar/gkv1101.
   Bonora M, 2018, EXP HEMATOL, V68, P30, DOI 10.1016/j.exphem.2018.10.012.
   Carbon S, 2021, NUCLEIC ACIDS RES, V49, pD325, DOI 10.1093/nar/gkaa1113.
   Carretta M, 2017, EXP HEMATOL, V51, P36, DOI {[}10.1016/j.exPhem.2017.04.008, 10.1016/j.exphem.2017.04.008].
   Chen WL, 2014, BLOOD, V124, P1645, DOI 10.1182/blood-2014-02-554204.
   Corces-Zimmerman MR, 2014, P NATL ACAD SCI USA, V111, P2548, DOI 10.1073/pnas.1324297111.
   de Almeida MJ, 2017, CELL STEM CELL, V21, P725, DOI 10.1016/j.stem.2017.11.002.
   de Boer B, 2018, CANCER CELL, V34, P674, DOI 10.1016/j.ccell.2018.08.014.
   de Jonge HJM, 2011, LEUKEMIA, V25, P1825, DOI 10.1038/leu.2011.172.
   Fellmann C, 2013, CELL REP, V5, P1704, DOI 10.1016/j.celrep.2013.11.020.
   Filippi MD, 2019, BLOOD, V133, P1943, DOI 10.1182/blood-2018-10-808873.
   Gallipoli P, 2018, BLOOD, V131, P1639, DOI 10.1182/blood-2017-12-820035.
   Gregory MA, 2018, EXP HEMATOL, V58, P52, DOI 10.1016/j.exphem.2017.09.007.
   Groen RWJ, 2012, BLOOD, V120, pE9, DOI 10.1182/blood-2012-03-414920.
   Halvarsson C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171714.
   Hao XX, 2019, CELL METAB, V29, P950, DOI 10.1016/j.cmet.2018.11.013.
   Huang QQ, 2018, J BIOL CHEM, V293, P3535, DOI 10.1074/jbc.M117.810101.
   Hughes AEO, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004462.
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388.
   Ito K, 2016, SCIENCE, V354, P1156, DOI 10.1126/science.aaf5530.
   Jan M, 2013, ONCOGENE, V32, P135, DOI 10.1038/onc.2012.48.
   Jayavelu AK, 2016, EXP HEMATOL, V44, P1113, DOI 10.1016/j.exphem.2016.08.008.
   Jones CL, 2019, BLOOD, V134, P389, DOI 10.1182/blood.2019898114.
   Jones CL, 2018, CANCER CELL, V34, P724, DOI 10.1016/j.ccell.2018.10.005.
   Khan N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163291.
   Klco JM, 2014, CANCER CELL, V25, P379, DOI 10.1016/j.ccr.2014.01.031.
   Klimmeck D, 2012, MOL CELL PROTEOMICS, V11, P286, DOI 10.1074/mcp.M111.016790.
   Kohlmann A, 2008, BRIT J HAEMATOL, V142, P802, DOI 10.1111/j.1365-2141.2008.07261.x.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013.
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689.
   Miller CA, 2013, NEW ENGL J MED, V369, P1473, DOI 10.1056/NEJMc1308782.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Rardin MJ, 2009, ANAL BIOCHEM, V389, P157, DOI 10.1016/j.ab.2009.03.040.
   Sallmyr A, 2008, BLOOD, V111, P3173, DOI 10.1182/blood-2007-05-092510.
   Seneviratne AK, 2019, CELL STEM CELL, V24, P621, DOI 10.1016/j.stem.2019.02.020.
   Shlush LI, 2014, NATURE, V506, P328, DOI 10.1038/nature13038.
   Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011.
   Sontakke P, 2016, LEUKEMIA, V30, P2064, DOI 10.1038/leu.2016.108.
   Stanicka J, 2015, J BIOL CHEM, V290, P9348, DOI 10.1074/jbc.M113.510495.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011.
   Vannini N, 2019, CELL STEM CELL, V24, P405, DOI 10.1016/j.stem.2019.02.012.
   Vannini N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13125.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023.
   Wierenga ATJ, 2019, CANCER METAB, V7, DOI 10.1186/s40170-019-0206-y.
   Xie SZ, 2019, CELL STEM CELL, V25, P639, DOI 10.1016/j.stem.2019.09.008.
   Yu WM, 2013, CELL STEM CELL, V12, P62, DOI 10.1016/j.stem.2012.11.022.},
Number-of-Cited-References = {55},
Times-Cited = {42},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Nat. Commun.},
Doc-Delivery-Number = {ZW3SP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000771136200019},
OA = {Green Submitted, Green Published, gold},
DA = {2026-02-04},
}

@article{ WOS:000768662900001,
Author = {Frederick, Mallory I. and Siddika, Tarana and Zhang, Pengcheng and
   Balasuriya, Nileeka and Turk, Matthew A. and O'Donoghue, Patrick and
   Heinemann, Ilka U.},
Title = {miRNA-Dependent Regulation of AKT1 Phosphorylation},
Journal = {CELLS},
Year = {2022},
Volume = {11},
Number = {5},
Month = {MAR},
Abstract = {The phosphoinositide-3-kinase (PI3K)/AKT pathway regulates cell survival
   and is over-activated in most human cancers, including ovarian cancer.
   Following growth factor stimulation, AKT1 is activated by
   phosphorylation at T308 and S473. Disruption of the AKT1 signaling
   pathway is sufficient to inhibit the epithelial-mesenchymal transition
   in epithelial ovarian cancer (EOC) cells. In metastatic disease,
   adherent EOC cells transition to a dormant spheroid state, characterized
   previously by low S473 phosphorylation in AKT1. We confirmed this
   finding and observed that T308 phosphorylation was yet further reduced
   in EOC spheroids and that the transition from adherent to spheroid
   growth is accompanied by significantly increased levels of let-7 miRNAs.
   We then used mechanistic studies to investigate the impact of let-7
   miRNAs on AKT1 phosphorylation status and activity in cells. In growth
   factor-stimulated HEK 293T cells supplemented with let-7a, we found
   increased phosphorylation of AKT1 at T308, decreased phosphorylation at
   S473, and enhanced downstream AKT1 substrate GSK-3 beta phosphorylation.
   Let-7b and let-7g also deregulated AKT signaling by rendering AKT1
   insensitive to growth factor simulation. We uncovered let-7a-dependent
   deregulation of PI3K pathway components, including PI3KC2A, PDK1, and
   RICTOR, that govern AKT1 phosphorylation and activity. Together, our
   data show a new role for miRNAs in regulating AKT signaling.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Heinemann, IU (Corresponding Author), Univ Western Ontario, Dept Biochem, 1151 Richmond St, London, ON N6A 5C1, Canada.
   Frederick, Mallory I.; Siddika, Tarana; Zhang, Pengcheng; Balasuriya, Nileeka; Turk, Matthew A.; O'Donoghue, Patrick; Heinemann, Ilka U., Univ Western Ontario, Dept Biochem, 1151 Richmond St, London, ON N6A 5C1, Canada.
   O'Donoghue, Patrick, Univ Western Ontario, Dept Chem, 1151 Richmond St, London, ON N6A 5C1, Canada.},
DOI = {10.3390/cells11050821},
Article-Number = {821},
EISSN = {2073-4409},
Keywords = {miRNA; posttranslational modification; protein phosphorylation;
   oncogenic kinase; signaling},
Keywords-Plus = {PROTEIN-KINASE B; REAL-TIME PCR; CELL-PROLIFERATION; MICRORNA LET-7;
   EXPRESSION; GROWTH; GENE; SURVIVAL; INVASION; TARGET},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {mfreder8@uwo.ca
   siddika@uwo.ca
   zhan33@uwo.ca
   bbalasur@uwo.ca
   mturk5@uwo.ca
   patrick.odonoghue@uwo.ca
   ilka.heinemann@uwo.ca},
Affiliations = {Western University (University of Western Ontario); Western University
   (University of Western Ontario)},
ResearcherID-Numbers = {Turk, Matthew/GXV-9589-2022
   },
ORCID-Numbers = {O'Donoghue, Patrick/0000-0002-9500-8640
   Zhang, Pengcheng/0000-0001-6945-309X
   Turk, Matthew/0000-0001-9806-9644
   Heinemann, Ilka/0000-0003-1721-1667},
Funding-Acknowledgement = {Canada Foundation for Innovation {[}229917] Funding Source: Medline;
   Canada Research Chairs Program {[}232341] Funding Source: Medline; CIHR
   {[}165985] Funding Source: Medline; Natural Sciences and Engineering
   Research Council {[}04282-2014, 04776-2014] Funding Source: Medline;
   Ontario Ministry of Research and Innovation {[}ER-18-14-183] Funding
   Source: Medline; Ontario Research Fund {[}229917] Funding Source:
   Medline},
Cited-References = {Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085.
   Balasuriya N, 2020, J BIOL CHEM, V295, P8120, DOI 10.1074/jbc.RA119.012425.
   Balasuriya N, 2018, J BIOL CHEM, V293, P10744, DOI 10.1074/jbc.RA118.002357.
   Barber RD, 2005, PHYSIOL GENOMICS, V21, P389, DOI 10.1152/physiolgenomics.00025.2005.
   Barh D, 2010, CURR ONCOL, V17, P70.
   Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110.
   Biamonte F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42221-x.
   Boukhalfa A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14086-1.
   Chao LM, 2018, EUR REV MED PHARMACO, V22, P7205, DOI 10.26355/eurrev\_201811\_16254.
   Chen YH, 2020, NUCLEIC ACIDS RES, V48, pD127, DOI 10.1093/nar/gkz757.
   Chirshev E, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0240-y.
   Chung CZ, 2021, RNA BIOL, V18, P397, DOI 10.1080/15476286.2021.1952540.
   Chung CZ, 2019, RNA BIOL, V16, P1022, DOI 10.1080/15476286.2019.1608754.
   Chung CZ, 2019, NUCLEIC ACIDS RES, V47, P3045, DOI 10.1093/nar/gkz043.
   Chung CZ, 2016, RNA, V22, P1239, DOI 10.1261/rna.056077.116.
   Correa RJM, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0182-y.
   Correa RJM, 2014, CARCINOGENESIS, V35, P1951, DOI 10.1093/carcin/bgu049.
   Correa RJM, 2012, CARCINOGENESIS, V33, P49, DOI 10.1093/carcin/bgr241.
   Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168.
   Dai X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126653.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Fan H, 2018, ONCOL REP, V39, P1207, DOI 10.3892/or.2018.6194.
   Fan JZ, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-021-00618-6.
   Frederick MI, 2021, BIOL CHEM, V402, P425, DOI 10.1515/hsz-2020-0325.
   Freudlsperger C, 2015, INT J CANCER, V136, P2775, DOI 10.1002/ijc.29328.
   Fu WX, 2020, GENES-BASEL, V11, DOI 10.3390/genes11091045.
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008.
   Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676.
   Hamatani T, 2004, P NATL ACAD SCI USA, V101, P10326, DOI 10.1073/pnas.0402597101.
   Hart JR, 2011, ONCOTARGET, V2, P467, DOI 10.18632/oncotarget.293.
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033.
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014.
   Karege F, 2010, GENES BRAIN BEHAV, V9, P503, DOI 10.1111/j.1601-183X.2010.00578.x.
   Kearney AL, 2019, J BIOL CHEM, V294, P16729, DOI 10.1074/jbc.RA119.010036.
   Kiyatkin A, 2006, J BIOL CHEM, V281, P19925, DOI 10.1074/jbc.M600482200.
   Kolendowski B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112408.
   Kumar M, 2015, CELL HOST MICROBE, V17, P345, DOI 10.1016/j.chom.2015.01.007.
   Kumar M, 2011, J ALLERGY CLIN IMMUN, V128, P1077, DOI 10.1016/j.jaci.2011.04.034.
   Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200.
   Lin JX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1416-4.
   Linnerth-Petrik NM, 2016, ONCOTARGET, V7, P74820, DOI 10.18632/oncotarget.11204.
   Lippa B, 2008, BIOORG MED CHEM LETT, V18, P3359, DOI 10.1016/j.bmcl.2008.04.034.
   Liu WJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1629-z.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Margaria JP, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9030104.
   McKenna M, 2021, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.619252.
   Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436.
   Naderi M, 2015, APPL IMMUNOHISTO M M, V23, P601, DOI 10.1097/PAI.0000000000000125.
   Peart TM, 2012, CLIN EXP METASTAS, V29, P293, DOI 10.1007/s10585-011-9451-3.
   Que T, 2015, ONCOGENE, V34, P4952, DOI 10.1038/onc.2014.419.
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007.
   Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Schulman BRM, 2008, CELL CYCLE, V7, P3935.
   Shi Y, 2016, LAB INVEST, V96, P652, DOI 10.1038/labinvest.2015.157.
   Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660.
   Turk MA, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060305.
   Wang XR, 2012, ONCOL LETT, V3, P955, DOI 10.3892/ol.2012.609.
   Wei WT, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0461-3.
   Xiao M, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-017-0321-8.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Zabkiewicz J, 2014, HAEMATOLOGICA, V99, P858, DOI 10.3324/haematol.2013.096487.
   Zhang HH, 2007, WORLD J GASTROENTERO, V13, P2883, DOI 10.3748/wjg.v13.i20.2883.
   Zheng NN, 2015, CELL PHYSIOL BIOCHEM, V36, P1903, DOI 10.1159/000430159.
   Zhou B, 2017, ONCOTARGET, V8, P69746, DOI 10.18632/oncotarget.19261.
   Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033.
   Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014.},
Number-of-Cited-References = {70},
Times-Cited = {21},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Cells},
Doc-Delivery-Number = {ZS7SX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000768662900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000766891200001,
Author = {Ma, Zhihui and Chen, Zhen and Zhou, Ying and Li, Yanping and Li, Shuyang
   and Wang, Hongxia and Feng, Ji},
Title = {Hsa\_circ\_0000418 promotes the progression of glioma by regulating
   microRNA-409-3p/pyruvate dehydrogenase kinase 1 axis},
Journal = {BIOENGINEERED},
Year = {2022},
Volume = {13},
Number = {3},
Pages = {7541-7552},
Month = {MAR 1},
Abstract = {Glioma is the commonest intracranial malignancy, and circRNAs are
   important regulatory factors which are implicated in the development of
   glioma. Nonetheless, the role of circRNAs in glioma is largely unknown.
   The research is performed to elaborate on the biological role of
   has\_circ\_0000418 (circ\_0000418) in glioma progression and its
   potential molecular mechanism. The differentially expressed circRNAs in
   glioblastoma patient derived cells and neural progenitor cells were
   analyzed based on the microarray data of GSE146463. Additionally,
   qRT-PCR and Western blot experiments were conducted to measure the
   expression of circ\_0000418, microRNA-409-3p (miR-409-3p) and pyruvate
   dehydrogenase kinase 1 (PDK1) in glioma tissues/cells. Cell growth and
   cell cycle distribution were monitored using CCK-8 assay, BrdU assay and
   flow cytometry. Bioinformatics prediction, dual-luciferase reporter gene
   experiment and RIP assay were conducted to verify the targeting
   relationship between circ\_0000418 and miR-409-3p, miR-409-3p and PDK1
   3MODIFIER LETTER PRIMEUTR. In this work, we observed that, circ\_0000418
   expression level was significantly up-regulated in glioma tissues and
   cell lines. Circ\_0000418 overexpression facilitated glioma cell growth
   and accelerated cell cycle progression, while knockdown of circ\_0000418
   produced the opposite effects. Circ\_0000418 specifically combined with
   miR-409-3p, and circ\_0000418 negatively modulated the expression of
   miR-409-3p. PDK1 acted as a target gene of miR-409-3p, and PDK1 could be
   positively and indirectly modulated by circ\_0000418 in glioma cells. In
   summary, circ\_0000418 enhances glioma cell growth and accelerates cell
   cycle progression by regulating miR-409-3p/PDK1 axis.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhou, Y (Corresponding Author), Third Hosp Qinhuangdao, Dept Anesthesiol, Qinhuangdao 066000, Hebei, Peoples R China.
   Ma, Zhihui; Feng, Ji, First Hosp Qinhuangdao, Dept Neurosurg, Qinhuangdao, Hebei, Peoples R China.
   Chen, Zhen, Qinglong Manchu Autonomous Cty Hosp, Dept Anesthesiol, Qinhuangdao, Hebei, Peoples R China.
   Zhou, Ying, Third Hosp Qinhuangdao, Dept Anesthesiol, Qinhuangdao 066000, Hebei, Peoples R China.
   Li, Yanping; Li, Shuyang, Qinglong Manchu Autonomous Cty Hosp, Supply Dept, Qinhuangdao, Hebei, Peoples R China.
   Wang, Hongxia, Qinglong Manchu Autonomous Cty Hosp, Operating Room, Qinhuangdao, Hebei, Peoples R China.},
DOI = {10.1080/21655979.2022.2049027},
ISSN = {2165-5979},
EISSN = {2165-5987},
Keywords = {Circ\_0000418; glioma; miR-409-3p; PDK1},
Keywords-Plus = {CELL-PROLIFERATION; RNA; PDK1; INVASION; CERNA},
Research-Areas = {Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology},
Author-Email = {helloying.86@163.com},
ResearcherID-Numbers = {Ma, Zhihui/HZI-4661-2023},
Cited-References = {Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005.
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406.
   Cao GH, 2016, EUR REV MED PHARMACO, V20, P3825.
   Cao YD, 2017, ONCOL RES, V25, P1097, DOI 10.3727/096504017X14836170586829.
   Chen R, 2017, NEUROTHERAPEUTICS, V14, P284, DOI 10.1007/s13311-017-0519-x.
   Cui X, 2022, CANCER BIOTHER RADIO, V37, P766, DOI 10.1089/cbr.2019.3392.
   Deng T, 2022, BIOENGINEERED, V13, P4757, DOI 10.1080/21655979.2022.2031673.
   Dudekulay DB, 2016, RNA BIOL, V13, P34, DOI 10.1080/15476286.2015.1128065.
   Fang BJ, 2015, BIOMED PHARMACOTHER, V75, P148, DOI 10.1016/j.biopha.2015.07.029.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112.
   Huang TH, 2017, INT J CLIN EXP PATHO, V10, P9012.
   Kim S, 2018, ONCOGENE, V37, P2982, DOI 10.1038/s41388-018-0124-4.
   Kumar A, 2018, J NEURO-ONCOL, V139, P23, DOI 10.1007/s11060-018-2840-6.
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248.
   Liu ZZ, 2020, NEOPLASMA, V67, P111, DOI 10.4149/neo\_2019\_190121N61.
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034.
   Luo DY, 2018, INT J ONCOL, V53, P2067, DOI 10.3892/ijo.2018.4525.
   Lv T, 2020, AGING-US, V12, P318, DOI 10.18632/aging.102617.
   Qu CD, 2020, IUBMB LIFE, V72, P465, DOI 10.1002/iub.2212.
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014.
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239.
   Wang Z, 2018, ONCOTARGET, V9, P192, DOI 10.18632/oncotarget.22773.
   Wu Z, 2020, AGING-US, V12, P21114, DOI 10.18632/aging.103603.
   Xia X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1056-5.
   Xie F, 2018, EUR REV MED PHARMACO, V22, P678, DOI 10.26355/eurrev\_201802\_14293.
   Xu XL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01246-x.
   Yang Y, 2020, BIOL RES, V53, DOI 10.1186/s40659-020-00309-z.
   Yang YN, 2020, AGING-US, V12, P9085, DOI 10.18632/aging.103176.
   Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166.
   Yu T, 2020, CANCER BIOMARK, V27, P471, DOI 10.3233/CBM-190314.
   Zhang LP, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.921288.
   Zhang XN, 2021, NEUROBIOL STRESS, V15, DOI 10.1016/j.ynstr.2021.100396.
   Zhou DX, 2021, BIOENGINEERED, V12, P2106, DOI 10.1080/21655979.2021.1932221.
   Zhou JX, 2021, CHINESE MED J-PEKING, V134, P81, DOI 10.1097/CM9.0000000000000979.},
Number-of-Cited-References = {35},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Bioengineered},
Doc-Delivery-Number = {ZQ1SD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000766891200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000755197200001,
Author = {Zhou, Jingchun and Zhang, Jingjing and Zhang, Wei and Ke, Zhaoyang and
   Lv, Yanlu and Zhang, Bo and Liao, Zhifang},
Title = {Ribophorin II promotes the epithelial-mesenchymal transition and aerobic
   glycolysis of laryngeal squamous cell carcinoma via regulating reactive
   oxygen species-mediated Phosphatidylinositol-3-Kinase/Protein Kinase B
   activation},
Journal = {BIOENGINEERED},
Year = {2022},
Volume = {13},
Number = {3},
Pages = {5141-5151},
Month = {MAR 1},
Abstract = {Ribophorin II (RPN2), a part of an N-oligosaccharyl transferase complex,
   plays vital roles in the development of multiple cancers. Nevertheless,
   its biological role in laryngeal squamous cell carcinoma (LSCC) remains
   unclear. The RPN2 expression levels in LSCC tissues and cell lines
   (AMC-HN-8 and TU212) were measured using real-time PCR,
   immunohistochemistry, or Western blot. The influences of RPN2 on the
   proliferation, migration, epithelial-mesenchymal transition, and aerobic
   glycolysis of LSCC cells were investigated after upregulation or
   downregulation of RPN2 in vitro and in vivo. Mechanically, we assessed
   the impact of RPN2 on the reactive oxygen species
   (ROS)/Phosphatidylinositol-3-Kinase (PI3K)/Protein Kinase B (Akt)
   signaling pathway. We found that compared with the control, RPN2 was
   highly expressed in LSCC tissues and cells. Overexpression of RPN2
   elevated the proliferation, migration, glucose uptake, lactate
   production release, and levels of Vimentin, hexokinase-2 (HK-2),
   pyruvate dehydrogenase kinase 1 (PDK1), lactate dehydrogenase A (LDHA),
   and ROS, but inhibited E-cadherin expression in AMC-HN-8 cells.
   Knockdown of RPN2 in TU212 cells showed opposite effects on the above
   indexes. Meanwhile, RPN2 upregulation increased the levels of
   p-PI3K/PI3K and p-Akt/Akt, which were attenuated by N-acetyl-L-cysteine
   (NAC), an ROS inhibitor. Both NAC and PI3K inhibitor LY294002 could
   reverse the effects of RPN2 overexpression on the malignant phenotypes
   of LSCC cells. In xenografted mice, silencing RPN2 expression reduced
   tumor growth, ROS production, and levels of Ki-67, Vimentin, LDHA, and
   p-Akt/Akt, but enhanced E-cadherin expression. In conclusion, our data
   suggested that RPN2 promoted the proliferation, migration, EMT, and
   glycolysis of LSCC via modulating ROS-mediated PI3K/Akt activation.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhou, JC (Corresponding Author), Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Otorhinolaryngol, Shenzhen 518020, Guangdong, Peoples R China.
   Zhou, JC (Corresponding Author), Southern Univ Sci \& Technol, Affiliated Hosp 1, Shenzhen 518020, Guangdong, Peoples R China.
   Zhou, Jingchun; Zhang, Wei; Ke, Zhaoyang; Lv, Yanlu; Zhang, Bo; Liao, Zhifang, Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Otorhinolaryngol, Shenzhen 518020, Guangdong, Peoples R China.
   Zhou, Jingchun; Zhang, Wei; Ke, Zhaoyang; Lv, Yanlu; Zhang, Bo; Liao, Zhifang, Southern Univ Sci \& Technol, Affiliated Hosp 1, Shenzhen 518020, Guangdong, Peoples R China.
   Zhang, Jingjing, Peking Univ, Shenzhen Hosp, Dept Otorhinolaryngol, Shenzhen, Peoples R China.},
DOI = {10.1080/21655979.2022.2036914},
ISSN = {2165-5979},
EISSN = {2165-5987},
Keywords = {RPN2; laryngeal squamous cell carcinoma; EMT; aerobic glycolysis; ROS;
   PI3K; AKT},
Keywords-Plus = {DOWN-REGULATION; CANCER; RPN2; EXPRESSION; MIGRATION; DOCETAXEL;
   INVASION; GROWTH; GENE},
Research-Areas = {Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology},
Author-Email = {zhoujingchun\_z@163.com},
Affiliations = {Jinan University; Southern University of Science \& Technology; Peking
   University},
ResearcherID-Numbers = {Zhang, Jingjing/LFU-2029-2024
   Zhang, Bo/AAI-5804-2021},
Funding-Acknowledgement = {Science, Technology \& Innovation Commission of Shenzhen Municipality
   {[}JCYJ20180305163939399]},
Funding-Text = {This study was supported by Science, Technology \& Innovation Commission
   of Shenzhen Municipality (No: JCYJ20180305163939399).},
Cited-References = {Bi CY, 2018, ONCOL REP, V40, P283, DOI 10.3892/or.2018.6434.
   Cai HS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01446.
   Chang HC, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8257238.
   Chen WS, 2021, J CLIN MED, V10, DOI 10.3390/jcm10184118.
   Fujimoto Daisuke, 2018, Oncotarget, V9, P15208, DOI {[}10.18632/oncotarget.24622, 10.18632/oncotarget.24622].
   Gao T, 2020, CANCER LETT, V469, P89, DOI 10.1016/j.canlet.2019.10.029.
   Gao W, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01279-2.
   Genden EM, 2007, ORAL ONCOL, V43, P431, DOI 10.1016/j.oraloncology.2006.08.007.
   Gioacchini FM, 2015, EUR ARCH OTO-RHINO-L, V272, P1569, DOI 10.1007/s00405-014-3117-0.
   Han CL, 2021, ONCOTARGETS THER, V14, P643, DOI 10.2147/OTT.S300480.
   Hong FL, 2018, ONCOTARGETS THER, V11, P3485, DOI 10.2147/OTT.S158355.
   Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858.
   Huang JL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0841-x.
   Lau HC, 2021, BIOENGINEERED, V12, P8738, DOI 10.1080/21655979.2021.1980177.
   Li CY, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00171-5.
   Li YS, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182448.
   Lian M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084854.
   Lian R, 2016, EUR J PHARMACOL, V792, P1, DOI 10.1016/j.ejphar.2016.10.015.
   LOFFLER C, 1991, HUM GENET, V87, P221, DOI 10.1007/BF00204188.
   Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010.
   Ono M, 2015, PATHOL INT, V65, P301, DOI 10.1111/pin.12297.
   Qin WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49480-8.
   Rodic S, 2018, INT J CANCER, V142, P440, DOI 10.1002/ijc.31069.
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004.
   Steuer CE, 2017, CA-CANCER J CLIN, V67, P32, DOI 10.3322/caac.21386.
   Sun JK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03113-5.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Takahashi R, 2013, SCI REP-UK, V3, DOI 10.1038/srep02474.
   Tominaga N, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-134.
   Vaupel P, 2019, INT J RADIAT BIOL, V95, P912, DOI 10.1080/09553002.2019.1589653.
   Wang J, 2018, J CELL BIOCHEM, V119, P5118, DOI 10.1002/jcb.26468.
   Wu YY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01215-4.
   Xu D, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0514-4.
   Zeng KX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1185582.
   Zhang T, 2019, J CELL MOL MED, V23, P3711, DOI 10.1111/jcmm.14276.
   Zhou JY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2127-7.},
Number-of-Cited-References = {36},
Times-Cited = {5},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Bioengineered},
Doc-Delivery-Number = {YZ0TY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000755197200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000761680400001,
Author = {Jiang, Cen and Li, Xia and Liu, Chao and Li, Guiyu and Zheng, Yanfeng
   and Xie, Lushuang and Wu, Wenjun and Feng, Quansheng},
Title = {HMGB1/PTEN/PI3K axis participates in the peripheral immune cell
   differentiation in two representative TCM syndromes of chronic hepatitis
   B patients(sic)(sic)(sic)},
Journal = {ANATOMICAL RECORD-ADVANCES IN INTEGRATIVE ANATOMY AND EVOLUTIONARY
   BIOLOGY},
Year = {2023},
Volume = {306},
Number = {12, SI},
Pages = {3085-3096},
Month = {DEC},
Abstract = {Liver depression and spleen deficiency syndrome (LDSDS) and
   spleen-gastric damp-heat syndrome (SGDHS) are two major traditional
   Chinese medicine syndromes observed in chronic hepatitis B (CHB). Both
   syndromes exhibit significant differences in the pathogenesis and
   prognosis, and are closely related to the immune system. However, the
   underlying mechanisms are largely unknown. This study aimed to explore
   the immunoregulatory mechanisms of the two syndromes and promote the
   differentiation precision between the two syndromes. Thirty-six patients
   with CHB (18 LDSDS patients and 18 SGDHS patients) and 14 healthy
   controls were recruited into this study and blood was collected from all
   the subjects for testing. We studied the contents of T lymphocytes by
   flow cytometry and the expression levels of HMGB1/PTEN/PI3K axis
   proteins by enzyme-linked immunosorbent assay (Elisa). Protein-protein
   interaction (PPI) networks among HMGB1/PTEN/PI3K axis were constructed
   for functional enrichment. The correlations between T lymphocytes and
   proteins were analyzed by constructing multiple regression equations.
   The results revealed that the CD8(+)T cells level in the two syndromes
   were lower than that in healthy controls, and the levels of Th17, Treg
   cells, and HMGB1, PI3K, PDK1, Akt were higher than those of the healthy
   controls (p < 0.05). Moreover, the levels of CD4(+)T, Th17 cells, and
   HMGB1, PTEN, PI3K in LDSDS were higher than SGDHS (p < 0.05). PPI
   network indicated that HMGB1/PTEN/PI3K axis participated in T cell
   activation and liver pathology. Our results revealed that
   HMGB1/PTEN/PI3K axis may play an important role in regulating the
   formation of peripheral immune differences between the two syndromes.
   CD4(+)T and Th17 are two representative immune cells that may serve as
   potential biological markers for LDSDS and SGDHS in CHB.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Li, X; Wu, WJ; Feng, QS (Corresponding Author), Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Sichuan, Peoples R China.
   Jiang, Cen; Li, Xia; Liu, Chao; Li, Guiyu; Zheng, Yanfeng; Xie, Lushuang; Wu, Wenjun; Feng, Quansheng, Chengdu Univ Tradit Chinese Med, Sch Basic Med Sci, Chengdu 611137, Sichuan, Peoples R China.},
DOI = {10.1002/ar.24899},
EarlyAccessDate = {FEB 2022},
ISSN = {1932-8486},
EISSN = {1932-8494},
Keywords = {chronic hepatitis B; HMGB1; PTEN; PI3K axis; liver depression and spleen
   deficiency syndrome; spleen-gastric damp-heat syndrome; T lymphocyte},
Keywords-Plus = {GROUP BOX-1 PROTEIN; REGULATORY T-CELLS; CHINESE MEDICINE; TH17/TREG
   IMBALANCE; LIVER-FAILURE; INFECTION; PTEN; EXPRESSION; DISEASE; INJURY},
Research-Areas = {Anatomy \& Morphology},
Web-of-Science-Categories  = {Anatomy \& Morphology},
Author-Email = {lix1106@126.com
   m13881955768@163.com
   fengqscdutcm@126.com},
Affiliations = {Chengdu University of Traditional Chinese Medicine},
ResearcherID-Numbers = {Li, Xia/NDT-1571-2025
   },
ORCID-Numbers = {李, 霞/0000-0003-0089-7666},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81803976]; National
   Major Science and Technology Project of China {[}2017ZX10205501];
   Sichuan Province Key RD Plan Project {[}2020YFS0301]; Science and
   Technology Innovation Seedling Project in Sichuan province, China
   {[}2020093]},
Funding-Text = {This study was supported by The National Natural Science Foundation of
   China (81803976); National Major Science and Technology Project of China
   (2017ZX10205501); Sichuan Province Key R\&D Plan Project (2020YFS0301),
   Science and Technology Innovation Seedling Project in Sichuan province,
   China (2020093).},
Cited-References = {Bertoletti A, 2010, ANTIVIR THER, V15, P15, DOI 10.3851/IMP1620.
   Cao W, 2014, J CLIN VIROL, V61, P40, DOI 10.1016/j.jcv.2014.06.022.
   Chen Y, 2015, EXP THER MED, V9, P573, DOI 10.3892/etm.2014.2104.
   Chung TW, 2003, CANCER RES, V63, P3453.
   Crispe IN, 2003, NAT REV IMMUNOL, V3, P51, DOI 10.1038/nri981.
   Feng XJ, 2014, AM J PHYSIOL-CELL PH, V306, pC1119, DOI 10.1152/ajpcell.00385.2013.
   Ge J, 2010, J CLIN IMMUNOL, V30, P60, DOI 10.1007/s10875-009-9328-2.
   Hou CC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219081.
   Hu YB, 2017, MINERVA MED, V108, P268, DOI 10.23736/S0026-4806.16.04865-5.
   Inkaya AC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007547.
   Jiang, 2017, ACTA CHINESE MED, V32, P1129.
   Li J, 2014, J VIRAL HEPATITIS, V21, P129, DOI 10.1111/jvh.12152.
   Li J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039307.
   Li K, 2017, CLIN RES HEPATOL GAS, V41, P399, DOI 10.1016/j.clinre.2016.12.004.
   Li Li, 2015, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V40, P1217, DOI 10.11817/j.issn.1672-7347.2015.11.009.
   Li XY, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/6714829.
   Li XF, 2010, CELL IMMUNOL, V264, P42, DOI 10.1016/j.cellimm.2010.04.009.
   Liu B, 2017, INT IMMUNOPHARMACOL, V46, P48, DOI 10.1016/j.intimp.2017.02.019.
   Liu C., 2021, EVID-BASED COMPL ALT, V2021.
   Liu J, 2019, B WORLD HEALTH ORGAN, V97, P230, DOI {[}10.2471/BLT.18.219469, 10.2471/blt.18.219469].
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594.
   Lu YY, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0275-4.
   McCulloch M, 2002, AM J PUBLIC HEALTH, V92, P1619, DOI 10.2105/AJPH.92.10.1619.
   Nan XP, 2012, VIRAL IMMUNOL, V25, P21, DOI 10.1089/vim.2011.0049.
   Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135.
   Park SG, 2010, IMMUNITY, V33, P791, DOI 10.1016/j.immuni.2010.10.014.
   PHDA NPHSDCDW, 2019, 1992 NAT VIR HEP SER.
   Pierau M, 2009, J IMMUNOL, V183, P6124, DOI 10.4049/jimmunol.0900246.
   Pompura SL, 2018, J LEUKOCYTE BIOL, V103, P1065, DOI 10.1002/JLB.2MIR0817-349R.
   Schabbauer G, 2010, J IMMUNOL, V185, P468, DOI 10.4049/jimmunol.0902221.
   Shrestha S, 2015, NAT IMMUNOL, V16, P178, DOI 10.1038/ni.3076.
   Spyrou E, 2020, GASTROENTEROL CLIN N, V49, P215, DOI 10.1016/j.gtc.2020.01.003.
   Tang LD, 2017, EXPERT OPIN DRUG DIS, V12, P5, DOI 10.1080/17460441.2017.1255195.
   Tian CH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015924.
   Wang GQ, 2012, CHIN J INTEGR MED, V18, P253, DOI 10.1007/s11655-012-1064-4.
   Wang HW, 2015, MOL CELL BIOCHEM, V407, P135, DOI 10.1007/s11010-015-2463-6.
   Wang J., 2011, RES CORRELATIONS TCM.
   Wang LW, 2010, HEPATOB PANCREAT DIS, V9, P499.
   WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1.
   Worby CA, 2014, ANNU REV BIOCHEM, V83, P641, DOI 10.1146/annurev-biochem-082411-113907.
   Yang, 2018, J CLIN HEPATOLOGY LI, V34, P1901.
   Yang HZ, 2005, WORLD J GASTROENTERO, V11, P2004, DOI 10.3748/wjg.v11.i13.2004.
   Ye YF, 2010, J CLIN IMMUNOL, V30, P546, DOI 10.1007/s10875-010-9416-3.
   You J, 2009, WORLD J GASTROENTERO, V15, P3382, DOI 10.3748/wjg.15.3382.
   Zeng XX, 2011, AM J CHINESE MED, V39, P1061, DOI 10.1142/S0192415X11009408.
   Zhang GL, 2013, J GASTROEN HEPATOL, V28, P513, DOI 10.1111/jgh.12082.
   Zhang JY, 2010, HEPATOLOGY, V51, P81, DOI 10.1002/hep.23273.
   Zhang LY, 2010, HEPATOLOGY, V51, P690, DOI 10.1002/hep.23384.
   Zhang Y, 2019, EUR REV MED PHARMACO, V23, P10950, DOI 10.26355/eurrev\_201912\_19798.
   Zhou M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01612.
   Zhuang Q.J., 2012, WORLD CHINESE J DIGE, V20, P2248.
   ,, 2018, Lancet (British edition), V392, P1789, DOI 10.1016/s0140-6736(18)32279-7.},
Number-of-Cited-References = {52},
Times-Cited = {1},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Anat. Rec.},
Doc-Delivery-Number = {Y3CA2},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000761680400001},
DA = {2026-02-04},
}

@article{ WOS:000760280700001,
Author = {Guo, Jia-qi and Wang, Chang-dong and Tang, Hu-ying and Sang, Bo-tao and
   Liu, Xing and Yi, Fa-ping and Wu, Xiang-mei},
Title = {PDGF-BB/PDGFRβ promotes epithelial-mesenchymal transition by affecting
   PI3K/AKT/mTOR-driven aerobic glycolysis in Wilms' tumor G401 cells},
Journal = {CELL BIOLOGY INTERNATIONAL},
Year = {2022},
Volume = {46},
Number = {6},
Pages = {907-921},
Month = {JUN},
Abstract = {Wilms' tumor (WT) is the most common pediatric renal malignancy. PDGFR
   beta belongs to the type III receptor tyrosine kinase family and is
   known to be involved in tumor metastasis and angiogenesis. Here, we
   studied the effect and underlying mechanism of PDGFR beta on WT G401
   cells. Transwell assay and wound-healing assay were used to detect the
   effect of PDGFR beta on G401 cells invasion and migration. Western blot
   and immunofluorescence were used to detect the expression of EMT-related
   genes. The expression of PI3K/AKT/mTOR pathway proteins was detected by
   Western blot. The relationship between PDGFR beta and aerobic glycolysis
   was studied by assessing the expression of glycolysis-related enzymes
   detected by qRT-PCR and Western blot. The activity of HK, PK, and LDH
   was detected by corresponding enzyme activity kits. The concentration of
   lactic acid and glucose was detected by Lactic Acid Assay Kit and
   Glucose Assay Kit-glucose oxidase method separately. To investigate the
   mechanism of PDGFR beta in the development of WT, the changes of glucose
   and lactic acid were analyzed after blocking PI3K pathway, aerobic
   glycolysis, or PDGFR beta. The key enzyme was screened by Western blot
   and glucose metabolism experiment after HK2, PKM2, and PDK1 were
   inhibited. The results showed that PDGFR beta promoted the EMT process
   by modulating aerobic glycolysis through PI3K/AKT/mTOR pathway in which
   PKM2 plays a key role. Therefore, our study of the mechanism of PDGFR
   beta in G401 cells provides a new target for the treatment of WT.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Wu, XM (Corresponding Author), Chongqing Med Univ, Dept Physiol, Basic Med Coll, Yixueyuan Rd, Chongqing 400016, Peoples R China.
   Guo, Jia-qi; Tang, Hu-ying; Sang, Bo-tao; Wu, Xiang-mei, Chongqing Med Univ, Dept Physiol, Basic Med Coll, Yixueyuan Rd, Chongqing 400016, Peoples R China.
   Guo, Jia-qi; Wang, Chang-dong; Tang, Hu-ying; Sang, Bo-tao; Yi, Fa-ping; Wu, Xiang-mei, Chongqing Med Univ, Basic Med Coll, Mol Med \& Canc Res Ctr, Chongqing, Peoples R China.
   Wang, Chang-dong; Yi, Fa-ping, Chongqing Med Univ, Dept Biochem \& Mol Biol, Basic Med Coll, Chongqing, Peoples R China.
   Liu, Xing, Chongqing Med Univ, Chongqing Childrens Hosp, Dept Pediat Urol, Chongqing, Peoples R China.},
DOI = {10.1002/cbin.11780},
EarlyAccessDate = {FEB 2022},
ISSN = {1065-6995},
EISSN = {1095-8355},
Keywords = {aerobic glycolysis; EMT; PDGFR beta; Wilms' tumor},
Keywords-Plus = {GROWTH-FACTOR; SIGNALING PATHWAY; CANCER; METABOLISM; RECEPTORS;
   PROGRESSION},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {xmwu@cqmu.edu.cn},
Affiliations = {Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University},
ResearcherID-Numbers = {Guo, Jiaqi/GSO-0702-2022},
Funding-Acknowledgement = {Scientific and Technological Research Program of Chongqing Municipal
   Education Commission {[}KJQN201900408]},
Funding-Text = {The authors thank the staff of the Life Sciences Academy of Chongqing
   Medical University for their technical support and cancer research
   center. This study was supported by the Scientific and Technological
   Research Program of Chongqing Municipal Education Commission (Grant no.
   KJQN201900408, 2019).},
Cited-References = {Al-Hussain T, 2014, ADV ANAT PATHOL, V21, P166, DOI 10.1097/PAP.0000000000000017.
   Aminzadeh S, 2015, TRANSL PEDIATR, V4, P20, DOI 10.3978/j.issn.2224-4336.2015.01.04.
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708.
   Aye Jamie M, 2019, Oncotarget, V10, P5534, DOI {[}10.18632/oncotarget.27165, 10.18632/oncotarget.27165].
   BALSAVER AM, 1968, CANCER, V22, P417, DOI 10.1002/1097-0142(196808)22:2<417::AID-CNCR2820220220>3.0.CO;2-X.
   Bose S, 2018, ADV EXP MED BIOL, V1063, P3, DOI 10.1007/978-3-319-77736-8\_1.
   Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002.
   Ehnman M, 2014, EXPERT OPIN INV DRUG, V23, P211, DOI 10.1517/13543784.2014.847086.
   El Maï M, 2014, CELL REP, V9, P1047, DOI 10.1016/j.celrep.2014.09.038.
   Feng J, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1528-x.
   Feng YL, 2018, INT J BIOL SCI, V14, P775, DOI 10.7150/ijbs.26077.
   Heldin CH, 2018, J INTERN MED, V283, P16, DOI 10.1111/joim.12690.
   Irtan S, 2016, SEMIN PEDIATR SURG, V25, P250, DOI 10.1053/j.sempedsurg.2016.09.003.
   Jitariu AA, 2018, CRIT REV ONCOL HEMAT, V131, P46, DOI 10.1016/j.critrevonc.2018.08.002.
   Kazlauskas A, 2017, GENE, V614, P1, DOI 10.1016/j.gene.2017.03.003.
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07.
   Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001.
   Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613.
   McLorie G A, 2001, Curr Opin Urol, V11, P567, DOI 10.1097/00042307-200111000-00002.
   Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854.
   Neri S, 2017, CANCER LETT, V395, P20, DOI 10.1016/j.canlet.2017.02.026.
   Östman A, 2017, ADV DRUG DELIVER REV, V121, P117, DOI 10.1016/j.addr.2017.09.022.
   Palsson-McDermott EM, 2013, BIOESSAYS, V35, P965, DOI 10.1002/bies.201300084.
   Paulsson J, 2014, FUTURE ONCOL, V10, P1695, DOI {[}10.2217/FON.14.83, 10.2217/fon.14.83].
   Ran C, 2013, CANCER RES, V73, P1831, DOI 10.1158/0008-5472.CAN-12-2460.
   Ribatti D, 2017, EXP CELL RES, V353, P1, DOI 10.1016/j.yexcr.2017.02.041.
   Roma-Rodrigues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040840.
   Shamsi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27303-6.
   Shi B, 2016, CLIN EXP PHARMACOL P, V43, P626, DOI 10.1111/1440-1681.12575.
   Upadhyay M, 2013, PHARMACOL THERAPEUT, V137, P318, DOI 10.1016/j.pharmthera.2012.11.003.
   Vaupel P, 2019, INT J RADIAT BIOL, V95, P912, DOI 10.1080/09553002.2019.1589653.
   WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267.
   Xiao H, 2020, ANAL CELL PATHOL, V2020, DOI 10.1155/2020/8396023.
   Xiao YB, 2017, CELL PHYSIOL BIOCHEM, V42, P1603, DOI 10.1159/000479401.
   Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686.
   Yokomori K, 1999, Contrib Nephrol, V128, P82.
   Zhang D, 2019, BIOCHEM BIOPH RES CO, V512, P360, DOI 10.1016/j.bbrc.2019.03.040.
   Zhang XF, 2010, HEPATOLOGY, V52, P954, DOI 10.1002/hep.23747.
   Zhou Q, 2019, INT J BIOL SCI, V15, P2139, DOI 10.7150/ijbs.35541.},
Number-of-Cited-References = {39},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Cell Biol. Int.},
Doc-Delivery-Number = {1P6FI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000760280700001},
DA = {2026-02-04},
}

@article{ WOS:000758942200001,
Author = {Nava, Roberto Carlos and McKenna, Zachary and Fennel, Zachary and
   Berkemeier, Quint and Ducharme, Jeremy and Magalhaes, Flavio de Castro
   and Amorim, Fabiano Trigueiro and Mermier, Christine},
Title = {Repeated sprint exercise in hypoxia stimulates HIF-1-dependent gene
   expression in skeletal muscle},
Journal = {EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY},
Year = {2022},
Volume = {122},
Number = {4},
Pages = {1097-1107},
Month = {APR},
Abstract = {Purpose Our aim was to determine the effect of repeated sprint exercise
   in hypoxia on HIF-1 and HIF-1-regulated genes involved in glycolysis,
   mitochondrial turnover and oxygen transport. We also determined whether
   genes upregulated by exercise in hypoxia were dependent on the
   activation of HIF-1 in an in vitro model of exercise in hypoxia. Methods
   Eight endurance athletes performed bouts of repeated sprint exercise in
   control and hypoxic conditions. Skeletal muscle was sampled pre, post
   and 3 h post-exercise. HIF-1 alpha protein and HIF1A, PDK1, GLUT4,
   VEGFA, BNIP3, PINK1 and PGC1A mRNA were measured. C2C12 myotubes were
   exposed to hypoxia and muscle contraction following treatment with a
   HIF-1 alpha inhibitor to determine whether hypoxia-sensitive gene
   expression was dependent on HIF-1 alpha. Results Sprint exercise in
   hypoxia increased HIF-1 alpha protein expression immediately
   post-exercise {[}fold change (FC) = 3.5 +/- 2.0]. Gene expression of
   PDK1 (FC = 2.1 +/- 1.2), BNIP3 (FC = 2.4 +/- 1.4) and VEGFA (FC = 2.7
   +/- 1.7) increased 3 h post-exercise in hypoxia but not control. PGC1A
   mRNA increased 3 h post-exercise in control (FC = 5.16) and hypoxia (FC
   = 5.7 +/- 4.1) but there was no difference between the trials. Results
   from the in vitro experiment showed that hypoxia plus contraction also
   increased PDK1, BNIP3, and VEGFA gene expression. These responses were
   inhibited when HIF-1 protein activity was suppressed. Conclusion
   Repeated sprint exercise in hypoxia upregulates some genes involved in
   glycolytic metabolism, mitochondrial turnover, and oxygen transport.
   HIF-1 alpha is necessary for the expression of these genes in skeletal
   muscle cells.},
Publisher = {SPRINGER},
Address = {ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Nava, RC (Corresponding Author), Univ New Mexico, Dept Hlth Exercise \& Sports Sci, Albuquerque, NM 87131 USA.
   Nava, RC (Corresponding Author), Joslin Diabet Ctr, Res Div, Boston, MA 02215 USA.
   Nava, RC (Corresponding Author), Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA.
   Nava, Roberto Carlos; McKenna, Zachary; Fennel, Zachary; Berkemeier, Quint; Ducharme, Jeremy; Magalhaes, Flavio de Castro; Amorim, Fabiano Trigueiro; Mermier, Christine, Univ New Mexico, Dept Hlth Exercise \& Sports Sci, Albuquerque, NM 87131 USA.
   Nava, Roberto Carlos, Joslin Diabet Ctr, Res Div, Boston, MA 02215 USA.
   Nava, Roberto Carlos, Harvard Univ, Harvard Med Sch, Boston, MA 02115 USA.
   Magalhaes, Flavio de Castro, Fed Univ Jequitinhonha \& Mucuri Valleys UFVJM, Dept Phys Educ, Diamantina, Brazil.},
DOI = {10.1007/s00421-022-04909-3},
EarlyAccessDate = {FEB 2022},
ISSN = {1439-6319},
EISSN = {1439-6327},
Keywords = {Gene expression; PGC-1; BNIP3; LLTH; RSH},
Keywords-Plus = {INDUCIBLE FACTOR-1-ALPHA; GROWTH; HIF-1; VEGF},
Research-Areas = {Physiology; Sport Sciences},
Web-of-Science-Categories  = {Physiology; Sport Sciences},
Author-Email = {roberto.nava@joslin.harvard.edu},
Affiliations = {University of New Mexico; Harvard University; Harvard University Medical
   Affiliates; Joslin Diabetes Center, Inc.; Harvard University; Harvard
   Medical School; Universidade Federal dos Vales do Jequitinhonha e Mucuri
   (UFVJM)},
ResearcherID-Numbers = {Nava, Roberto/ABC-9141-2021
   McKenna, Zachary/GXV-8465-2022
   de Castro Magalhaes, Flavio/AAB-5540-2022
   },
ORCID-Numbers = {de Castro Magalhaes, Flavio/0000-0002-1963-982X
   Ducharme, Jeremy/0000-0003-1653-8721
   Fennel, Zachary/0000-0001-9482-7815},
Funding-Acknowledgement = {National Strength and Conditioning Association Foundation; University of
   New Mexico Research Allocation Committee; College of Education and
   Health Sciences Overhead Funds Allocation Committee; New Mexico Research
   Grant},
Funding-Text = {This study was supported by the National Strength and Conditioning
   Association Foundation, the University of New Mexico Research Allocation
   Committee, College of Education and Health Sciences Overhead Funds
   Allocation Committee and the New Mexico Research Grant. We would like to
   thank Anna Welch for help collecting data and all the participants who
   made this work possible.},
Cited-References = {Berra E, 2001, EMBO REP, V2, P615, DOI 10.1093/embo-reports/kve130.
   Brahimi-Horn C, 2005, CELL SIGNAL, V17, P1, DOI 10.1016/j.cellsig.2004.04.010.
   Breen E, 2008, HIGH ALT MED BIOL, V9, P158, DOI 10.1089/ham.2008.1010.
   Brocherie F, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12851.
   Brocherie F, 2017, SPORTS MED, V47, P1651, DOI 10.1007/s40279-017-0685-3.
   D'Agostino R.B., 1986, GOODNESS OF FIT TECH.
   Egan B, 2013, CELL METAB, V17, P162, DOI 10.1016/j.cmet.2012.12.012.
   Faiss R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056522.
   Feldmann A, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.11.115001.
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604.
   Gan ZJ, 2018, CELL RES, V28, P969, DOI 10.1038/s41422-018-0078-7.
   GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761.
   Haan C, 2007, J IMMUNOL METHODS, V318, P11, DOI 10.1016/j.jim.2006.07.027.
   Higashimura Y, 2011, ARCH BIOCHEM BIOPHYS, V509, P1, DOI 10.1016/j.abb.2011.02.011.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kuang JJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196438.
   Ladner CL, 2004, ANAL BIOCHEM, V326, P13, DOI 10.1016/j.ab.2003.10.047.
   Lambernd S, 2012, DIABETOLOGIA, V55, P1128, DOI 10.1007/s00125-012-2454-z.
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106.
   LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638.
   McDonough AA, 2015, AM J PHYSIOL-CELL PH, V308, pC426, DOI 10.1152/ajpcell.00400.2014.
   McManus CJ, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.1.015007.
   Millet GP, 2019, DEUT Z SPORTMED, V2019, P115, DOI {[}10.5960/dzsm.2019.374, 10.5960/dzsm.2019.374, DOI 10.5960/DZSM.2019.374].
   Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238.
   Olfert IM, 2016, AM J PHYSIOL-HEART C, V310, pH326, DOI 10.1152/ajpheart.00635.2015.
   Rivero-Gutiérrez B, 2014, ANAL BIOCHEM, V467, P1, DOI 10.1016/j.ab.2014.08.027.
   Robergs RA, 2010, SPORTS MED, V40, P95, DOI 10.2165/11319670-000000000-00000.
   Semenza GL, 2004, PHYSIOLOGY, V19, P176, DOI 10.1152/physiol.00001.2004.
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551.
   Skovgaard C, 2016, PHYSIOL REP, V4, DOI 10.14814/phy2.12864.
   Srinivasan S, 2011, ANAL BIOCHEM, V416, P120, DOI 10.1016/j.ab.2011.04.037.
   Tang KC, 2004, RESP PHYSIOL NEUROBI, V144, P71, DOI 10.1016/j.resp.2004.04.009.
   Van Thienen R, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00676.
   Wei JW, 2012, AMINO ACIDS, V42, P2031, DOI 10.1007/s00726-011-0924-0.
   Wenger RH, 2015, HYPOXIA, V3, P35, DOI 10.2147/HP.S92198.
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200.
   Zhu LY, 2010, CELL RES, V20, P676, DOI 10.1038/cr.2010.46.},
Number-of-Cited-References = {37},
Times-Cited = {22},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Eur. J. Appl. Physiol.},
Doc-Delivery-Number = {ZU6PF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000758942200001},
DA = {2026-02-04},
}

@article{ WOS:000778349200001,
Author = {Bonafe, Gabriel Alves and Boschiero, Matheus Negri and Sodre, Andre
   Rodrigues and Ziegler, Jussara Vaz and Rocha, Thalita and Ortega,
   Manoela Marques},
Title = {Natural Plant Compounds: Does Caffeine, Dipotassium Glycyrrhizinate,
   Curcumin, and Euphol Play Roles as Antitumoral Compounds in Glioblastoma
   Cell Lines?},
Journal = {FRONTIERS IN NEUROLOGY},
Year = {2022},
Volume = {12},
Month = {FEB 17},
Abstract = {Many plant-derived compounds are shown to be promising antitumor
   therapeutic agents by enhancing apoptosis-related pathways and cell
   cycle impairment in tumor cells, including glioblastoma (GBM) cell
   lines. We aimed to review four natural plant compounds effective in GBM
   cell lines as caffeine, dipotassium glycyrrhizinate (DPG), curcumin, and
   euphol. Furthermore, antitumoral effect of these plant compounds on GBM
   cell lines through microRNAs (miRs) modulation was investigated.
   However, only DPG and curcumin were found as effective on miR
   modulation. Caffeine arrests GBM cell cycle in G0/G1 phase by
   cyclin-dependent kinases (CDK) complex inhibition and by decreasing
   BCL-2 and increasing FOXO1 expression levels causing greater apoptotic
   activity. Caffeine can also directly inhibit IP3R3, p38 phosphorylation,
   and rho-associated protein kinase (ROCK), decreasing cell invasion and
   migration capacity or indirectly by inhibiting the tissue inhibitor
   metalloproteinase-1 (TIMP-1) and integrins beta 1 and beta 3, leading to
   lower matrix metalloproteinases, MMP-2 and MMP-9. DPG presents
   antitumoral effect in GBM cells related to nuclear factor kappa B
   (NF-kappa B) pathway suppression by IRAK2 and TRAF6-mediating miR-16 and
   miR-146a, respectively. More recently, it was observed that DPG
   upregulated miR-4443 and miR-3620, responsible for post-transcriptional
   inhibition of the NF-kappa B pathway by CD209 and TNC modulation,
   respectively leading to lower MMP-9 and migration capacity. Curcumin is
   able to increase miR-223-3p, miR-133a-3p, miR-181a-5p, miR-34a-5p,
   miR-30c-5p, and miR-1290 expression leading to serine or threonine
   kinase (AKT) pathway impairment and also it decreases miR-27a-5p,
   miR-221-3p, miR-21-5p, miR-125b-5p, and miR-151-3p expression causing
   p53-BCL2 pathway inhibition and consequently, cellular apoptosis.
   Interestingly, lower expression of miR-27a by curcumin action enhanced
   the C/EBP homologous protein(CHOP) expression, leading to paraptosis.
   Curcumin can inhibit miR-21 expression and consequently activate
   apoptosis through caspase 3 and death receptor (DR) 4 and 5 activation.
   Autophagy is controlled by the LC-3 protein that interacts with Atg
   family for the LC3-II formation and autophagy activation. Euphol can
   enhance LC3-II levels directly in GBM cells or inhibits tumor invasion
   and migration through PDK1 modulation.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Ortega, MM (Corresponding Author), Sao Francisco Univ, Med Sch, Lab Cell \& Mol Tumor Biol \& Bioact Cpds, Sao Paulo, Brazil.
   Bonafe, Gabriel Alves; Boschiero, Matheus Negri; Sodre, Andre Rodrigues; Ortega, Manoela Marques, Sao Francisco Univ, Med Sch, Lab Cell \& Mol Tumor Biol \& Bioact Cpds, Sao Paulo, Brazil.
   Ziegler, Jussara Vaz, Verdi Cosmet LLC, Sao Paulo, Brazil.
   Rocha, Thalita, Pontifical Catholic Univ Sao Paulo, Fac Med Sci \& Hlth, Postgrad Program Biomat \& Regenerat Med, Sao Paulo, Brazil.},
DOI = {10.3389/fneur.2021.784330},
Article-Number = {784330},
ISSN = {1664-2295},
Keywords = {caffeine; dipotassium glycyrrhizinate; curcumin; euphol; microRNAs;
   glioblastoma cell lines},
Keywords-Plus = {MATRIX METALLOPROTEINASES; PROMYELOTIC LEUKEMIA; SIGNALING PATHWAY;
   SUPPRESSES GROWTH; GENE-EXPRESSION; STEM-CELLS; APOPTOSIS; CANCER;
   INGENOL; PROLIFERATION},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Clinical Neurology; Neurosciences},
Author-Email = {manoela.ortega@usf.edu.br},
Affiliations = {Pontificia Universidade Catolica de Sao Paulo},
ResearcherID-Numbers = {Marques Ortega, Manoela/AAH-2106-2020
   },
ORCID-Numbers = {Marques Ortega, Manoela/0000-0003-4609-7074
   Negri Boschiero, Matheus/0000-0002-2866-391X},
Funding-Acknowledgement = {National Council for Scientific and Technological Development (CNPq)
   {[}149884/2019-2, 137689/2020-9, 122513/2021-5]},
Funding-Text = {The financial support provided by the National Council for Scientific
   and Technological Development (CNPq) scholarship \#149884/2019-2,
   \#137689/2020-9, and \#122513/2021-5 is gratefully acknowledged.},
Cited-References = {Abreu CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097257.
   Akihisa T, 2001, LIPIDS, V36, P507, DOI 10.1007/s11745-001-0750-4.
   Alexandrow MG, 2012, EUR J CANCER PREV, V21, P407, DOI 10.1097/CEJ.0b013e32834ef194.
   Andersen FA, 2007, INT J TOXICOL, V26, P79, DOI 10.1080/10915810701351228.
   Anggakusuma, 2014, GUT, V63, P1137, DOI 10.1136/gutjnl-2012-304299.
   Annovazzi L, 2015, INT J ONCOL, V46, P2299, DOI 10.3892/ijo.2015.2963.
   Ashby Lynn S, 2006, Neurosurg Focus, V20, pE3, DOI 10.3171/foc.2006.20.4.3.
   Badke GL., 2014, ARQ BRAS NEUROCIR, V33, P199, DOI {[}10.1055/s-0038-1626199, DOI 10.1055/S-0038-1626199].
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5.
   Bello L, 2001, CANCER RES, V61, P8730.
   Béres T, 2018, PHYTOCHEM ANALYSIS, V29, P23, DOI 10.1002/pca.2711.
   Berman B, 2012, CLIN COSMET INVESTI, V5, P111, DOI 10.2147/CCID.S28905.
   Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035.
   Bocangel DB, 2002, CLIN CANCER RES, V8, P2725.
   Bode AM, 2007, CANCER LETT, V247, P26, DOI 10.1016/j.canlet.2006.03.032.
   Bonafé GA, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00216.
   BOUTWELL RK, 1949, CANCER RES, V9, P741.
   Brassesco M S, 2013, Chemother Res Pract, V2013, P593020, DOI 10.1155/2013/593020.
   BROWN GR, 1992, BIOCHEM J, V282, P309, DOI 10.1042/bj2820309.
   Caraballo-Miralles V, 2012, MOL CELL NEUROSCI, V49, P282, DOI 10.1016/j.mcn.2011.12.003.
   Cassileth BR, 2004, ONCOLOGIST, V9, P80, DOI 10.1634/theoncologist.9-1-80.
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622.
   Cheng YC, 2016, J NUTR BIOCHEM, V33, P63, DOI 10.1016/j.jnutbio.2016.03.004.
   Chipuk JE, 2008, P NATL ACAD SCI USA, V105, P20327, DOI 10.1073/pnas.0808036105.
   Chiu SS, 2011, ANTICANCER RES, V31, P907.
   Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011.
   Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x.
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499.
   Duarte N, 2006, PLANTA MED, V72, P162, DOI 10.1055/s-2005-873196.
   Dufour A, 2013, TRENDS PHARMACOL SCI, V34, P233, DOI 10.1016/j.tips.2013.02.004.
   Dutra RC, 2015, NEUROSCIENCE, V303, P126, DOI 10.1016/j.neuroscience.2015.06.051.
   Dutra RC, 2016, PHARMACOL RES, V112, P4, DOI 10.1016/j.phrs.2016.01.021.
   Dutra RC, 2012, BIOCHEM PHARMACOL, V83, P531, DOI 10.1016/j.bcp.2011.11.026.
   Elamin MH, 2010, MOL CARCINOGEN, V49, P302, DOI 10.1002/mc.20604.
   Franco-Salla GB, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1115-z.
   FREEDMAN LS, 1990, CANCER RES, V50, P5710.
   Galardi S, 2011, NUCLEIC ACIDS RES, V39, P3892, DOI 10.1093/nar/gkr006.
   Garrido-Armas M, 2018, TOXICOL IN VITRO, V51, P63, DOI 10.1016/j.tiv.2018.04.014.
   Gillespie SK, 2004, MOL CANCER THER, V3, P1651.
   Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026.
   Hadler-Olsen E, 2013, TUMOR BIOL, V34, P2041, DOI 10.1007/s13277-013-0842-8.
   Hampson P, 2005, BLOOD, V106, P1362, DOI 10.1182/blood-2004-10-4117.
   Harder BG, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00462.
   Hashimoto T, 2004, CANCER RES, V64, P3344, DOI 10.1158/0008-5472.CAN-03-3453.
   Heath-Engel HM, 2006, CELL DEATH DIFFER, V13, P1277, DOI 10.1038/sj.cdd.4401961.
   Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x.
   Hibasami H, 2006, INT J MOL MED, V17, P215.
   Hibasami H, 2005, INT J MOL MED, V16, P233.
   Hosny EN, 2019, NUTR NEUROSCI, V22, P789, DOI 10.1080/1028415X.2018.1446812.
   Ishiuchi S, 2002, NAT MED, V8, P971, DOI 10.1038/nm746.
   Jang MH, 2002, J KOREAN MED SCI, V17, P674, DOI 10.3346/jkms.2002.17.5.674.
   Jhanwar-Uniyal M, 2015, CANCERS, V7, P538, DOI 10.3390/cancers7020538.
   Jiang J, 2015, EUR REV MED PHARMACO, V19, P3201.
   Jovcevska I, 2013, MOL CLIN ONCOL, V1, P935, DOI 10.3892/mco.2013.172.
   Kang SS, 2010, CANCER RES, V70, P1173, DOI 10.1158/0008-5472.CAN-09-2886.
   Kaufmann WK, 2003, MUTAT RES-FUND MOL M, V532, P85, DOI 10.1016/j.mrfmmm.2003.08.012.
   Kawahara Y, 2014, CONGENIT ANOM, V54, P12, DOI 10.1111/cga.12043.
   Khan MSS, 2017, EUR J PHARMACOL, V803, P24, DOI 10.1016/j.ejphar.2017.03.031.
   Kilbride SM, 2013, ONCOGENE, V32, P2703, DOI 10.1038/onc.2012.348.
   Ku BM, 2011, MOL CELLS, V31, P275, DOI 10.1007/s10059-011-0027-5.
   Lebwohl M, 2012, NEW ENGL J MED, V366, P1010, DOI 10.1056/NEJMoa1111170.
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637-009-9311-z.
   Li KS, 2017, ONCOL LETT, V13, P1990, DOI 10.3892/ol.2017.5663.
   Li N, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5364973.
   Li S, 2014, NEUROL SCI, V35, P1115, DOI 10.1007/s10072-014-1661-4.
   Li WD, 2017, ONCOTARGET, V8, P73938, DOI 10.18632/oncotarget.17881.
   Lin MW, 2012, FOOD CHEM TOXICOL, V50, P4333, DOI 10.1016/j.fct.2012.05.029.
   Liu JD, 2015, EUR REV MED PHARMACO, V19, P3080.
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1.
   Ma XL, 2012, NEURO-ONCOLOGY, V14, P1153, DOI 10.1093/neuonc/nos145.
   MacNeil A, 2003, BRIT J CANCER, V88, P1566, DOI 10.1038/sj.bjc.6600929.
   Maes K, 2000, CELL CALCIUM, V27, P257, DOI 10.1054/ceca.2000.0121.
   Maiese K, 2008, CELL CYCLE, V7, P3829, DOI 10.4161/cc.7.24.7231.
   Menegazzi M, 2008, PHARMACOL RES, V58, P22, DOI 10.1016/j.phrs.2008.05.012.
   Meng B, 2013, CURR PHARM DESIGN, V19, P2101.
   Michaud DS, 2010, AM J CLIN NUTR, V92, P1145, DOI 10.3945/ajcn.2010.29876.
   Miranda-Filho A, 2017, NEURO-ONCOLOGY, V19, P270, DOI 10.1093/neuonc/now166.
   Mishra S, 2008, ANN INDIAN ACAD NEUR, V11, P13, DOI 10.4103/0972-2327.40220.
   Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200.
   Morelli M, 2012, EXP NEUROL, V237, P218, DOI 10.1016/j.expneurol.2012.05.023.
   Nasser JA, 2006, ARQ NEURO-PSIQUIAT, V64, P774, DOI 10.1590/S0004-282X2006000500014.
   OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612.
   Park MJ, 2002, J NEUROSURG, V97, P112, DOI 10.3171/jns.2002.97.1.0112.
   Prakash E., 2013, UNI J PLANT SCI, V1, P113, DOI DOI 10.13189/UJPS.2013.010401.
   Priyadarsini KI, 2014, MOLECULES, V19, P20091, DOI 10.3390/molecules191220091.
   Qian CF, 2019, CANCER MANAG RES, V11, P6829, DOI 10.2147/CMAR.S210076.
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053.
   Shibata N, 2000, BIOPHARM DRUG DISPOS, V21, P95, DOI 10.1002/1099-081X(200004)21:3<95::AID-BDD221>3.0.CO;2-9.
   Silva VAO, 2019, INVEST NEW DRUG, V37, P1029, DOI 10.1007/s10637-019-00728-0.
   Silva VAO, 2019, INVEST NEW DRUG, V37, P223, DOI 10.1007/s10637-018-0620-y.
   Smith D, 2008, MOL CELL BIOCHEM, V307, P141, DOI 10.1007/s11010-007-9593-4.
   Sordillo LA, 2015, ANTICANCER RES, V35, P6373.
   Sordillo PP, 2015, IN VIVO, V29, P1.
   Sun F, 2016, TUMOR BIOL, V37, P3417, DOI 10.1007/s13277-015-4180-x.
   Tan X, 2018, BIOMATER SCI-UK, V6, P407, DOI 10.1039/c7bm01088e.
   Thirugnanam S, 2008, ONCOL REP, V20, P1387, DOI 10.3892/or\_00000157.
   Vandenbroucke RE, 2014, NAT REV DRUG DISCOV, V13, P904, DOI 10.1038/nrd4390.
   Vasas A, 2012, EUR J ORG CHEM, V2012, P5115, DOI 10.1002/ejoc.201200733.
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005.
   Vigone A, 2005, EUR J GYNAECOL ONCOL, V26, P526.
   Wang DW, 2018, MED SCI MONITOR, V24, P486, DOI 10.12659/MSM.906049.
   Wang H, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-2.
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2.
   Westhoff MA, 2013, MOL CANCER RES, V11, P1611, DOI 10.1158/1541-7786.MCR-13-0435-T.
   WojtowiczPraga SM, 1997, INVEST NEW DRUG, V15, P61, DOI 10.1023/A:1005722729132.
   Wu H, 2015, MOL MED REP, V12, P5461, DOI 10.3892/mmr.2015.4087.
   Yamazaki D, 2005, CANCER SCI, V96, P379, DOI 10.1111/j.1349-7006.2005.00062.x.
   Yin HT, 2014, ONCOL REP, V32, P1610, DOI 10.3892/or.2014.3342.
   Yin S, 2018, CANCER BIOL THER, V19, P260, DOI 10.1080/15384047.2016.1250981.
   Zanotto A, 2011, BIOCHEM PHARMACOL, V81, P412, DOI 10.1016/j.bcp.2010.10.014.
   Zoi V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111562.},
Number-of-Cited-References = {111},
Times-Cited = {20},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {18},
Journal-ISO = {Front. Neurol.},
Doc-Delivery-Number = {0G9HP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000778349200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000760317000001,
Author = {Zheng, Xiaowei and Narayanan, Sampath and Xu, Cheng and Eliasson
   Angelstig, Sofie and Grunler, Jacob and Zhao, Allan and Di Toro,
   Alessandro and Bernardi, Luciano and Mazzone, Massimiliano and
   Carmeliet, Peter and Del Sole, Marianna and Solaini, Giancarlo and
   Forsberg, Elisabete A. and Zhang, Ao and Brismar, Kerstin and Schiffer,
   Tomas A. and Rajamand Ekberg, Neda and Botusan, Ileana Ruxandra and
   Palm, Fredrik and Catrina, Sergiu-Bogdan},
Title = {Repression of hypoxia-inducible factor-1 contributes to increased
   mitochondrial reactive oxygen species production in diabetes},
Journal = {ELIFE},
Year = {2022},
Volume = {11},
Month = {FEB 15},
Abstract = {Background: Excessive production of mitochondrial reactive oxygen
   species (ROS) is a central mechanism for the development of diabetes
   complications. Recently, hypoxia has been identified to play an
   additional pathogenic role in diabetes. In this study, we hypothesized
   that ROS overproduction was secondary to the impaired responses to
   hypoxia due to the inhibition of hypoxia-inducible factor-1 (HIF-1) by
   hyperglycemia. Methods: The ROS levels were analyzed in the blood of
   healthy subjects and individuals with type 1 diabetes after exposure to
   hypoxia. The relation between HIF-1, glucose levels, ROS production and
   its functional consequences were analyzed in renal mIMCD-3 cells and in
   kidneys of mouse models of diabetes. Results: Exposure to hypoxia
   increased circulating ROS in subjects with diabetes, but not in subjects
   without diabetes. High glucose concentrations repressed HIF-1 both in
   hypoxic cells and in kidneys of animals with diabetes, through a HIF
   prolyl-hydroxylase (PHD)-dependent mechanism. The impaired HIF-1
   signaling contributed to excess production of mitochondrial ROS through
   increased mitochondrial respiration that was mediated by Pyruvate
   dehydrogenase kinase 1 (PDK1). The restoration of HIF-1 function
   attenuated ROS overproduction despite persistent hyperglycemia, and
   conferred protection against apoptosis and renal injury in diabetes.
   Conclusions: We conclude that the repression of HIF-1 plays a central
   role in mitochondrial ROS overproduction in diabetes and is a potential
   therapeutic target for diabetic complications. These findings are timely
   since the first PHD inhibitor that can activate HIF-1 has been newly
   approved for clinical use. Funding: This work was supported by grants
   from the Swedish Research Council, Stockholm County Research Council,
   Stockholm Regional Research Foundation, Bert von Kantzows Foundation,
   Swedish Society of Medicine, Kung Gustaf V:s och Drottning Victorias
   Frimurarestifelse, Karolinska Institute's Research Foundations,
   Strategic Research Programme in Diabetes, and Erling-Persson Family
   Foundation for S-B.C.; grants from the Swedish Research Council and
   Swedish Heart and Lung Foundation for T.A.S.; and ERC consolidator grant
   for M.M.},
Publisher = {eLIFE SCIENCES PUBL LTD},
Address = {SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Catrina, SB (Corresponding Author), Karolinska Inst, Dept Mol Med \& Surg, Stockholm, Sweden.
   Catrina, SB (Corresponding Author), Karolinska Univ Hosp, Dept Endocrinol \& Diabet, Stockholm, Sweden.
   Catrina, SB (Corresponding Author), Acad Specialist Centrum, Ctr Diabet, Stockholm, Sweden.
   Zheng, Xiaowei; Narayanan, Sampath; Xu, Cheng; Eliasson Angelstig, Sofie; Grunler, Jacob; Zhao, Allan; Del Sole, Marianna; Forsberg, Elisabete A.; Zhang, Ao; Brismar, Kerstin; Rajamand Ekberg, Neda; Botusan, Ileana Ruxandra; Catrina, Sergiu-Bogdan, Karolinska Inst, Dept Mol Med \& Surg, Stockholm, Sweden.
   Di Toro, Alessandro, IRCCS Fdn Univ Hosp Policlin San Matteo, Ctr Inherited Cardiovasc Dis, Pavia, Italy.
   Bernardi, Luciano, Univ Helsinki, Folkalsan Inst Genet, Folkalsan Res Ctr, Helsinki, Finland.
   Mazzone, Massimiliano, Katholieke Univ KU Leuven, Vlaams Inst Biotechnol VIB, Ctr Canc Biol,Dept Oncol, Lab Tumor Inflammat \& Angiogenesis,Ctr Canc Biol, Leuven, Belgium.
   Carmeliet, Peter, Katholieke Univ KU Leuven, Vlaams Inst Biotechnol VIB, Vesalius Res Ctr, Lab Angiogenesis \& Vasc Metab,Dept Oncol, Leuven, Belgium.
   Solaini, Giancarlo, Univ Bologna, Dipartimento Biochim, Bologna, Italy.
   Schiffer, Tomas A.; Palm, Fredrik, Uppsala Univ, Dept Med Cell Biol, Uppsala, Sweden.
   Rajamand Ekberg, Neda; Botusan, Ileana Ruxandra; Catrina, Sergiu-Bogdan, Karolinska Univ Hosp, Dept Endocrinol \& Diabet, Stockholm, Sweden.
   Rajamand Ekberg, Neda; Botusan, Ileana Ruxandra; Catrina, Sergiu-Bogdan, Acad Specialist Centrum, Ctr Diabet, Stockholm, Sweden.
   Zhang, Ao, GuangDong Second Tradit Chinese Med Hosp, Dept Nephrol, Guangzhou, Peoples R China.},
DOI = {10.7554/eLife.70714; 10.7554/eLife.70714.sa0; 10.7554/eLife.70714.sa1;
   10.7554/eLife.70714.sa2},
Article-Number = {e70714},
ISSN = {2050-084X},
Keywords = {diabetes; hypoxia; hypoxia-inducible factor-1; reactive oxygen species;
   mitochondria; diabetic complications; Human; Mouse},
Keywords-Plus = {OXIDATIVE STRESS; COMPLEX-III; FACTOR-1-ALPHA; ADAPTATION; ROS},
Research-Areas = {Life Sciences \& Biomedicine - Other Topics},
Web-of-Science-Categories  = {Biology},
Author-Email = {sergiu-bogdan.catrina@ki.se},
Affiliations = {Karolinska Institutet; Folkhalsan Research Center; University of
   Helsinki; Flanders Institute for Biotechnology (VIB); KU Leuven; KU
   Leuven; Flanders Institute for Biotechnology (VIB); University of
   Bologna; Uppsala University; Karolinska Institutet; Karolinska
   University Hospital},
ResearcherID-Numbers = {Di Toro, Alessano/AAC-3139-2021
   Carmeliet, Peter/AAQ-5140-2020
   Mazzone, Massimiliano/NIV-0920-2025
   Schiffer, Tomas/X-1343-2018
   },
ORCID-Numbers = {Botusan, Ileana/0000-0002-9803-0325
   Di Toro, Alessano/0000-0001-7625-1103
   Narayanan, Sampath/0000-0001-6752-7251
   Carmeliet, Peter/0000-0001-7961-1821
   Zhao, Allan/0000-0002-2492-0923
   Mazzone, Massimiliano/0000-0001-8824-4015
   Rajamand Ekberg, Neda/0000-0001-5597-2593},
Funding-Acknowledgement = {Vetenskapsradet; Stockholms Lans Landsting; Stockholm Regional Research
   Foundation; Bert von Kantzows Foundation; Swedish Society of Medicine;
   Kung Gustaf V:s och Drottning Victorias Frimurarestifelse; Karolinska
   Institute's Research Foundation; Strategic Research Programme in
   Diabetes; Erling-Persson Family Foundation; Vetenskapsradet
   {[}2020-01645]; Swedish Heart and Lung Foundation {[}20210431]; ERC
   {[}773208]; European Research Council (ERC) {[}773208] Funding Source:
   European Research Council (ERC); Swedish Research Council {[}2020-01645]
   Funding Source: Swedish Research Council},
Funding-Text = {Vetenskapsradet Sergiu-Bogdan Catrina Stockholms Lans Landsting
   Sergiu-Bogdan Catrina Stockholm Regional Research Foundation
   Sergiu-Bogdan Catrina Bert von Kantzows Foundation Sergiu-Bogdan Catrina
   Swedish Society of Medicine Sergiu-Bogdan Catrina Kung Gustaf V:s och
   Drottning Victorias Frimurarestifelse Sergiu-Bogdan Catrina Karolinska
   Institute's Research Foundations Sergiu-Bogdan Catrina Strategic
   Research Programme in Diabetes Sergiu-Bogdan Catrina Erling-Persson
   Family Foundation Sergiu-Bogdan Catrina Vetenskapsradet 2020-01645 Tomas
   A Schiffer Swedish Heart and Lung Foundation 20210431 Tomas A Schiffer
   ERC consolidator grant 773208 Massimiliano Mazzone The funders had no
   role in study design, data collection and interpretation, or the
   decision to submit the work for publication.},
Cited-References = {Allen DA, 2003, FASEB J, V17, P908, DOI 10.1096/fj.02-0130fje.
   Bento CF, 2011, DIABETOLOGIA, V54, P1946, DOI 10.1007/s00125-011-2191-8.
   Bernardi L, 2011, DIABETOLOGIA, V54, P2164, DOI 10.1007/s00125-011-2195-4.
   Bernardi L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04947-4.
   Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002.
   Carreau A, 2011, J CELL MOL MED, V15, P1239, DOI 10.1111/j.1582-4934.2011.01258.x.
   Catrina SB, 2004, DIABETES, V53, P3226, DOI 10.2337/diabetes.53.12.3226.
   Catrina SB, 2021, DIABETOLOGIA, V64, P709, DOI 10.1007/s00125-021-05380-z.
   Catrina SB, 2014, J MOL MED, V92, P1025, DOI 10.1007/s00109-014-1166-x.
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715.
   Charlton A, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10010018.
   Chen N, 2019, NEW ENGL J MED, V381, P1001, DOI 10.1056/NEJMoa1813599.
   Dikalov SI, 2018, ANTIOXID REDOX SIGN, V28, P1433, DOI 10.1089/ars.2017.7396.
   Duennwald T, 2013, DIABETES, V62, P4220, DOI 10.2337/db13-0167.
   Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a.
   Friederich-Persson M, 2018, ACTA PHYSIOL, V223, DOI 10.1111/apha.13058.
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047.
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545.
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001.
   Haase VH, 2017, NEPHROL THER, V13, pS29, DOI 10.1016/j.nephro.2017.01.015.
   Hernansanz-Agustín P, 2020, NATURE, V586, P287, DOI 10.1038/s41586-020-2551-y.
   Honda T, 2019, KIDNEY RES CLIN PRAC, V38, P414.
   Jiang T, 2010, DIABETES, V59, P850, DOI 10.2337/db09-1342.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020.
   Miwa S, 2003, BIOCHEM SOC T, V31, P1300.
   Nauta FL, 2011, DIABETES CARE, V34, P975, DOI 10.2337/dc10-1545.
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121.
   Nordquist L, 2015, J AM SOC NEPHROL, V26, P328, DOI 10.1681/ASN.2013090990.
   Ohtomo S, 2008, NEPHROL DIAL TRANSPL, V23, P1166, DOI 10.1093/ndt/gfm715.
   Palm F, 2003, DIABETOLOGIA, V46, P1153, DOI 10.1007/s00125-003-1155-z.
   Palm F, 2006, CLIN EXP PHARMACOL P, V33, P997, DOI 10.1111/j.1440-1681.2006.04473.x.
   Prabhakar NR, 2015, PHYSIOLOGY, V30, P340, DOI 10.1152/physiol.00022.2015.
   Rosenberger C, 2008, KIDNEY INT, V73, P34, DOI 10.1038/sj.ki.5002567.
   Schiffer TA, 2018, AM J PHYSIOL-RENAL, V315, pF677, DOI 10.1152/ajprenal.00207.2018.
   Schödel J, 2019, NAT REV NEPHROL, V15, P641, DOI 10.1038/s41581-019-0182-z.
   Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204.
   Wang DT, 2010, J IMMUNOL, V184, P582, DOI 10.4049/jimmunol.0902352.
   Waypa GB, 2013, AM J RESP CRIT CARE, V187, P424, DOI 10.1164/rccm.201207-1294OC.
   Weissmann N, 2000, AM J PHYSIOL-LUNG C, V279, pL683, DOI 10.1152/ajplung.2000.279.4.L683.
   Zheng XW, 2006, MOL CELL BIOL, V26, P4628, DOI 10.1128/MCB.02236-05.},
Number-of-Cited-References = {41},
Times-Cited = {47},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {23},
Journal-ISO = {eLife},
Doc-Delivery-Number = {ZG5SD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000760317000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000754368200001,
Author = {Han, Wei and Wang, Nan and Kong, Rui and Bao, Wen and Lu, Jie},
Title = {Ligand-activated PPARδ expression promotes hepatocellular carcinoma
   progression by regulating the PI3K-AKT signaling pathway},
Journal = {JOURNAL OF TRANSLATIONAL MEDICINE},
Year = {2022},
Volume = {20},
Number = {1},
Month = {FEB 12},
Abstract = {Background: Peroxisome proliferator-activated receptor-beta/delta (PPAR
   delta) was considered as the key regulator involved in the evolution of
   various tumors. Given that PPAR delta potential role in hepatocellular
   carcinoma (HCC) is still obscure, we comprehensively assessed its
   expression pattern, prognosis, functions and correlation with tumor
   microenvironment in HCC using public database data and in vitro studies.
   Methods: Transcriptional data and clinical data in the TCGA and GEO
   database were analyzed in R software. Quantitative real-time polymerase
   chain reaction (qRT-PCR), western blotting and immunohistochemistry were
   used to detect the expression level of related RNA and proteins. The
   malignant biological characteristics were explored by cell counting
   Kit-8 (CCK8), 5-Ethynyl-2MODIFIER LETTER PRIME-deoxyuridine (EdU) assay
   and wound healing assay.
   Results: Our results illustrated that PPAR delta expression was
   significantly higher in HCC tissues and HCC cell lines. Elevated
   expression of PPAR delta suggested poor clinical staging and prognosis
   in HCC. Ligand-activated PPAR delta expression promoted the
   proliferation and invasion of HCC cells via PDK1/AKT/GSK3 beta signaling
   pathway. The expression of PPAR delta was closely related to the HCC
   tumor microenvironment.
   Conclusions: PPAR delta plays an important part in HCC progression,
   penetrating investigation of the related regulatory mechanism may shed
   light upon further biological and pharmacological value.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Lu, J (Corresponding Author), Gongli Hosp Shanghai Pudong New Area, Dept Gastroenterol, Shanghai, Peoples R China.
   Han, Wei; Wang, Nan; Kong, Rui; Bao, Wen, Tongji Univ, Shanghai Peoples Hosp 10, Dept Gastroenterol, Sch Med, Shanghai, Peoples R China.
   Lu, Jie, Gongli Hosp Shanghai Pudong New Area, Dept Gastroenterol, Shanghai, Peoples R China.},
DOI = {10.1186/s12967-022-03288-9},
Article-Number = {86},
EISSN = {1479-5876},
Keywords = {PPAR delta; HCC; Prognosis; PI3K-AKT},
Keywords-Plus = {EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL;
   RECEPTOR-DELTA; MACROPHAGES; MIGRATION; INVASION; GROWTH; BETA},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {kennisren@hotmail.com},
Affiliations = {Tongji University},
ORCID-Numbers = {Wei, Han/0000-0001-5628-3036},
Funding-Acknowledgement = {National Nature Science Foundation of China {[}81770518]},
Funding-Text = {This study was supported by the National Nature Science Foundation of
   China (No. 81770518) to Jie Lu.},
Cited-References = {Augimeri G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249721.
   Augimeri G, 2020, CANCERS, V12, DOI 10.3390/cancers12092623.
   Auwerx J, 1999, CELL, V97, P161.
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034.
   Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001.
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025.
   Castelli V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020127.
   Chan CH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-59.
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824.
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866.
   Chen K., 2021, FRONT ONCOL, V11.
   De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361.
   Di-Poï N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9.
   Foreman JE, 2011, MOL CARCINOGEN, V50, P884, DOI 10.1002/mc.20757.
   Grygiel-Górniak B, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-17.
   Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993.
   Ham SA, 2014, AM J CANCER RES, V4, P674.
   Her NG, 2013, CELL CYCLE, V12, P1521, DOI 10.4161/cc.24636.
   Kong R, 2021, PPAR RES, V2021, DOI 10.1155/2021/6663782.
   Laganà AS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17070999.
   Li Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1456-9.
   Liu Y, 2019, CANCER RES, V79, P954, DOI 10.1158/0008-5472.CAN-18-1790.
   Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277.
   Martín-Martín N, 2018, CANCER RES, V78, P399, DOI 10.1158/0008-5472.CAN-17-0908.
   Michelet X, 2018, NAT IMMUNOL, V19, P1330, DOI 10.1038/s41590-018-0251-7.
   Mirza AZ, 2019, EUR J MED CHEM, V166, P502, DOI 10.1016/j.ejmech.2019.01.067.
   Newman AM, 2015, NAT METHODS, V12, P453, DOI {[}10.1038/NMETH.3337, 10.1038/nmeth.3337].
   Patel K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186757.
   Pedchenko TV, 2008, AM J RESP CELL MOL, V39, P689, DOI 10.1165/rcmb.2007-0426OC.
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976.
   Rahmani F, 2020, J CELL PHYSIOL, V235, P4146, DOI 10.1002/jcp.29333.
   Saibil SD, 2019, CANCER RES, V79, P445, DOI 10.1158/0008-5472.CAN-17-3053.
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050.
   Skrypnyk N, 2014, CANCER RES, V74, P621, DOI 10.1158/0008-5472.CAN-13-1928.
   Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822.
   Wagner KD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121623.
   Wagner N, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051133.
   Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103.
   Wang DZ, 2019, CANCER RES, V79, P4480, DOI 10.1158/0008-5472.CAN-19-0384.
   Wang HP, 2020, NAT IMMUNOL, V21, P298, DOI 10.1038/s41590-019-0589-5.
   Watson MJ, 2021, NATURE, V591, P645, DOI 10.1038/s41586-020-03045-2.
   Wild CPWE., 2020, WORLD CANC REPORT CA, P34.
   Yang L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060715.
   Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221.
   Yang Y, 2015, MOL CARCINOGEN, V54, P1584, DOI 10.1002/mc.22231.
   Zhang C, 2020, PPAR RES, V2020, DOI 10.1155/2020/8864813.
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173.
   Zhou DY, 2019, EUR J PHARMACOL, V842, P248, DOI 10.1016/j.ejphar.2018.10.050.
   Zuo XS, 2019, GASTROENTEROLOGY, V157, P163, DOI 10.1053/j.gastro.2019.03.018.
   Zuo XS, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91419.},
Number-of-Cited-References = {52},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {J. Transl. Med.},
Doc-Delivery-Number = {YX8TJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000754368200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000754463800008,
Author = {Lin, Yingbin and Dai, Xiaoman and Zhang, Jing and Chen, Xiaochun},
Title = {Metformin alleviates the depression-like behaviors of elderly apoE4 mice
   via improving glucose metabolism and mitochondrial biogenesis},
Journal = {BEHAVIOURAL BRAIN RESEARCH},
Year = {2022},
Volume = {423},
Month = {APR 9},
Abstract = {Apolipoprotein E4 (apoE4) is closely related to late-onset depression
   (LOD). In addition, the benefits of metformin treatment of depression
   have been documented in a range of rodent studies and human trials, but
   few studies have probed into the effect of metformin on and the related
   mechanism in depressed elderly mice, especially in those APOE4 carriers.
   Here, we treated 13-month-old apoE3-targeted replacement (TR) and
   apoE4-TR mice with an intragastric administration of metformin (300
   mg/kg/d) or normal saline for 5 months. We found that metformin exerted
   antidepressant effects on apoE4 mice, including reduced immobility time
   in TST and FST, and increased ratios of time and distance in the central
   area of OFT. Importantly, compared with apoE3 mice, apoE4 mice showed a
   higher expression of lactate dehydrogenase (LDH) and pyruvate
   dehydrogenase kinase (PDK1 and PDK4) in the hippocampus. The increased
   LDH level was rescued by metformin treatment. Moreover, the metformin
   administration increased the levels of transcriptional factor NRF-1 and
   TFAM, mtDNA, and most mitochondrial complex subunits in apoE-TR mice.
   Furthermore, it upregulated the expressions of antioxidant enzymes, such
   as MnSOD, GPX1, and GSR1/2. Interestingly, apoE4 blunted the
   hypoglycemic effect of metformin in aged mice. These data suggest that
   metformin ameliorates the depression-like behaviors probably by
   improving glucose metabolism and mitochondria biogenesis in the
   hippocampus of aged apoE4 mice. These findings imply that chronic
   metformin treatment can improve apoE4-mediated LOD, providing
   mechanistic insights for apoE4- and age-based depression prevention and
   therapy.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Zhang, J; Chen, XC (Corresponding Author), Fujian Med Univ, Fujian Inst Geriatr, Union Hosp, Dept Neurol \& Geriatr, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China.
   Lin, Yingbin; Dai, Xiaoman; Zhang, Jing; Chen, Xiaochun, Fujian Med Univ, Fujian Inst Geriatr, Union Hosp, Dept Neurol \& Geriatr, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China.
   Lin, Yingbin; Dai, Xiaoman; Zhang, Jing; Chen, Xiaochun, Fujian Med Univ, Fujian Key Lab Mol Neurol, 88 Jiaotong Rd, Fuzhou 350001, Fujian, Peoples R China.
   Dai, Xiaoman; Zhang, Jing, Fujian Med Univ, Fujian Key Lab Vasc Aging, 88 Jiaotong Rd, Fuzhou 350001, Fujian, Peoples R China.},
DOI = {10.1016/j.bbr.2022.113772},
EarlyAccessDate = {FEB 2022},
Article-Number = {113772},
ISSN = {0166-4328},
EISSN = {1872-7549},
Keywords = {Late-onset depression; Apolipoprotein E4; Metformin; Glucose metabolism;
   Mitochondrial biogenesis},
Keywords-Plus = {E EPSILON-4 ALLELE; LATE-LIFE DEPRESSION; APOLIPOPROTEIN-E; POSTERIOR
   CINGULATE; HIPPOCAMPAL VOLUME; ASSOCIATION; GENOTYPE; ONSET; RISK;
   SYMPTOMS},
Research-Areas = {Behavioral Sciences; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Behavioral Sciences; Neurosciences},
Author-Email = {drzj@163.com
   chenxc998@fjmu.edu.cn},
Affiliations = {Fujian Medical University; Fujian Medical University; Fujian Medical
   University},
ORCID-Numbers = {Lin, Yingbin/0000-0002-5051-3256},
Funding-Acknowledgement = {National Natural Science Foundation of China, China {[}81871068,
   81671352, 91232709, 81401149]; Joint Fund for Science and Technology
   Innovation of Fujian, China {[}2018Y9095, 2018Y9057]; Startup Fund for
   scientific research of Fujian Medical University, China {[}2020QH2019]},
Funding-Text = {This work was supported by National Natural Science Foundation of China,
   China to Prof. Xiaochun Chen {[}grant numbers 81871068, 81671352,
   91232709] and to Prof. Jing Zhang {[}grant number 81401149], Joint Fund
   for Science and Technology Innovation of Fujian, China to Prof. Xiaochun
   Chen {[}grant number 2018Y9095] and Prof. Jing Zhang {[}grant number
   2018Y9057], and Startup Fund for scientific research of Fujian Medical
   University, China {[}grant number 2020QH2019] to Yingbin Lin.},
Cited-References = {Alexopoulos GS, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0514-6.
   Allen J, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00386.
   Bharath LP, 2020, CELL METAB, V32, P44, DOI 10.1016/j.cmet.2020.04.015.
   Brewster KK, 2018, AM J GERIAT PSYCHIAT, V26, P788, DOI 10.1016/j.jagp.2018.04.003.
   Cao X, 2013, NAT MED, V19, P773, DOI 10.1038/nm.3162.
   Chen FQ, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7392-y.
   Corsentino EA, 2009, AM J GERIAT PSYCHIAT, V17, P155, DOI 10.1097/JGP.0b013e31818f3a6b.
   Du RW, 2020, EXP BRAIN RES, V238, P2549, DOI 10.1007/s00221-020-05911-x.
   Du YY, 2017, GENE, V626, P182, DOI 10.1016/j.gene.2017.05.018.
   Fang WT, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01631-0.
   Fang WT, 2020, J AFFECT DISORDERS, V260, P302, DOI 10.1016/j.jad.2019.09.013.
   Fiske A, 2009, ANNU REV CLIN PSYCHO, V5, P363, DOI 10.1146/annurev.clinpsy.032408.153621.
   Garber AJ, 1997, AM J MED, V103, P491, DOI 10.1016/S0002-9343(97)00254-4.
   Gong Y, 2011, NEUROSCI LETT, V488, P76, DOI 10.1016/j.neulet.2010.11.006.
   Guo M, 2014, CLIN EXP PHARMACOL P, V41, P650, DOI 10.1111/1440-1681.12265.
   Hammad AM, 2021, BEHAV BRAIN RES, V414, DOI 10.1016/j.bbr.2021.113475.
   Jagust WJ, 2012, J NEUROSCI, V32, P18227, DOI 10.1523/JNEUROSCI.3266-12.2012.
   Jeste DV, 2005, BIOL PSYCHIAT, V58, P265, DOI 10.1016/j.biopsych.2005.02.004.
   Katayama Y, 2016, NATURE, V537, P675, DOI 10.1038/nature19357.
   Kessing LV, 2020, DIABETES CARE, V43, P3050, DOI 10.2337/dc20-1561.
   Kim DH, 2002, BIOL PSYCHIAT, V51, P426, DOI 10.1016/S0006-3223(01)01272-0.
   Kim JM, 2011, INT J GERIATR PSYCH, V26, P893, DOI 10.1002/gps.2621.
   Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172.
   Krishnan KRR, 1996, BIOL PSYCHIAT, V40, P69, DOI 10.1016/0006-3223(95)00424-6.
   Levi O, 2003, NEUROBIOL DIS, V13, P273, DOI 10.1016/S0969-9961(03)00045-7.
   Lin LY, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0107-2.
   Liu WN, 2019, J AFFECT DISORDERS, V246, P486, DOI 10.1016/j.jad.2018.12.112.
   Livingston G, 2020, LANCET, V396, P413, DOI 10.1016/S0140-6736(20)30367-6.
   Ly M, 2021, TRANSL PSYCHIAT, V11, DOI 10.1038/s41398-021-01269-y.
   Mackin RS, 2014, AM J GERIAT PSYCHIAT, V22, P1633, DOI 10.1016/j.jagp.2014.02.006.
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192.
   McDermott LM, 2009, J AFFECT DISORDERS, V119, P1, DOI 10.1016/j.jad.2009.04.022.
   Perkins M, 2016, J ALZHEIMERS DIS, V53, P95, DOI 10.3233/JAD-151205.
   Protas HD, 2013, JAMA NEUROL, V70, P320, DOI 10.1001/2013.jamaneurol.286.
   Qiu AQ, 2009, NEUROIMAGE, V44, P620, DOI 10.1016/j.neuroimage.2008.10.010.
   RABBITT P, 1995, PSYCHOL AGING, V10, P307, DOI 10.1037/0882-7974.10.3.307.
   Rajan KB, 2014, PSYCHOSOM MED, V76, P101, DOI 10.1097/PSY.0000000000000029.
   Rezin GT, 2008, NEUROCHEM INT, V53, P395, DOI 10.1016/j.neuint.2008.09.012.
   Rigaud AS, 2001, NEUROEPIDEMIOLOGY, V20, P268, DOI 10.1159/000054801.
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007.
   Schiepers OJG, 2012, MOL PSYCHIATR, V17, P315, DOI 10.1038/mp.2010.137.
   Sheline YI, 2012, AM J PSYCHIAT, V169, P1185, DOI 10.1176/appi.ajp.2012.12010122.
   Shu H, 2014, J AFFECT DISORDERS, V164, P5, DOI 10.1016/j.jad.2014.03.048.
   Skoog I, 2015, BIOL PSYCHIAT, V78, P730, DOI 10.1016/j.biopsych.2015.01.006.
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013.
   Soukas AA, 2019, TRENDS ENDOCRIN MET, V30, P745, DOI 10.1016/j.tem.2019.07.015.
   Sureshkumar R, 2012, J AFFECT DISORDERS, V136, P244, DOI 10.1016/j.jad.2011.12.022.
   Tyszka-Czochara M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070841.
   Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2.
   Videbech P, 2000, ACTA PSYCHIAT SCAND, V101, P11, DOI 10.1034/j.1600-0447.2000.101001011.x.
   Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44.
   Wang CP, 2017, J DIABETES COMPLICAT, V31, P679, DOI {[}10.1016/jjdiacomp.2017.01.013, 10.1016/j.jdiacomp.2017.01.013].
   Williams HC, 2020, NEUROBIOL DIS, V136, DOI 10.1016/j.nbd.2020.104742.
   Wisdom NM, 2011, NEUROBIOL AGING, V32, P63, DOI 10.1016/j.neurobiolaging.2009.02.003.
   Wu L, 2018, J NEUROSCI, V38, P6665, DOI 10.1523/JNEUROSCI.2262-17.2018.
   Xu S.Y., 2002, METHODOLOGY PHARM EX, P1861.
   Yamazaki Y, 2019, NAT REV NEUROL, V15, P501, DOI 10.1038/s41582-019-0228-7.
   Yang S, 2020, NEUROREPORT, V31, P305, DOI 10.1097/WNR.0000000000001401.
   Zhang J, 2019, FASEB J, V33, P7748, DOI 10.1096/fj.201802718R.
   Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152.},
Number-of-Cited-References = {60},
Times-Cited = {21},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Behav. Brain Res.},
Doc-Delivery-Number = {YY0DN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000754463800008},
DA = {2026-02-04},
}

@article{ WOS:000750932400001,
Author = {Bandyopadhyay, Gautam and Tang, Kechun and Webster, Nicholas J. G. and
   van den Bogaart, Geert and Mahata, Sushil K.},
Title = {Catestatin induces glycogenesis by stimulating the phosphoinositide
   3-kinase-AKT pathway},
Journal = {ACTA PHYSIOLOGICA},
Year = {2022},
Volume = {235},
Number = {1},
Month = {MAY},
Abstract = {Aim Defects in hepatic glycogen synthesis contribute to post-prandial
   hyperglycaemia in type 2 diabetic patients. Chromogranin A (CgA) peptide
   Catestatin (CST: hCgA(352-372)) improves glucose tolerance in
   insulin-resistant mice. Here, we seek to determine whether CST induces
   hepatic glycogen synthesis. Methods We determined liver glycogen,
   glucose-6-phosphate (G6P), uridine diphosphate glucose (UDPG) and
   glycogen synthase (GYS2) activities; plasma insulin, glucagon,
   noradrenaline and adrenaline levels in wild-type (WT) as well as in CST
   knockout (CST-KO) mice; glycogen synthesis and glycogenolysis in primary
   hepatocytes. We also analysed phosphorylation signals of insulin
   receptor (IR), insulin receptor substrate-1 (IRS-1),
   phosphatidylinositol-dependent kinase-1 (PDK-1), GYS2, glycogen synthase
   kinase-3 beta (GSK-3 beta), AKT (a kinase in AKR mouse that produces
   Thymoma)/PKB (protein kinase B) and mammalian/mechanistic target of
   rapamycin (mTOR) by immunoblotting. Results CST stimulated glycogen
   accumulation in fed and fasted liver and in primary hepatocytes. CST
   reduced plasma noradrenaline and adrenaline levels. CST also directly
   stimulated glycogenesis and inhibited noradrenaline and
   adrenaline-induced glycogenolysis in hepatocytes. In addition, CST
   elevated the levels of UDPG and increased GYS2 activity. CST-KO mice had
   decreased liver glycogen that was restored by treatment with CST,
   reinforcing the crucial role of CST in hepatic glycogenesis. CST
   improved insulin signals downstream of IR and IRS-1 by enhancing
   phospho-AKT signals through the stimulation of PDK-1 and mTORC2 (mTOR
   Complex 2, rapamycin-insensitive complex) activities. Conclusions CST
   directly promotes the glycogenic pathway by (a) reducing glucose
   production, (b) increasing glycogen synthesis from UDPG, (c) reducing
   glycogenolysis and (d) enhancing downstream insulin signalling.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Mahata, SK (Corresponding Author), Univ Calif San Diego, Dept Med, Metab Physiol \& Ultrastruct Biol Lab, 9500 Gilman Dr, La Jolla, CA 92093 USA.
   Bandyopadhyay, Gautam; Webster, Nicholas J. G.; Mahata, Sushil K., Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   Tang, Kechun; Webster, Nicholas J. G.; Mahata, Sushil K., VA San Diego Healthcare Syst, San Diego, CA USA.
   van den Bogaart, Geert, Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Dept Tumor Immunol, Med Ctr, Nijmegen, Netherlands.
   van den Bogaart, Geert, Univ Groningen, Groningen Biomol Sci \& Biotechnol Inst, Dept Mol Immunol \& Microbiol, Groningen, Netherlands.},
DOI = {10.1111/apha.13775},
EarlyAccessDate = {FEB 2022},
Article-Number = {e13775},
ISSN = {1748-1708},
EISSN = {1748-1716},
Keywords = {catestatin; glucose-6-phosphate; glycogen; glycogen synthase;
   hyperglycaemia; phospho-AKT},
Keywords-Plus = {HEPATIC GLUCOSE-PRODUCTION; CHROMOGRANIN-A FRAGMENT; INSULIN-RESISTANCE;
   CATECHOLAMINE RELEASE; PLASMA-CATECHOLAMINES; SYNTHASE KINASE-3;
   IN-VIVO; LIVER; METABOLISM; MECHANISMS},
Research-Areas = {Physiology},
Web-of-Science-Categories  = {Physiology},
Author-Email = {smahata@health.ucsd.edu},
Affiliations = {University of California System; University of California San Diego; US
   Department of Veterans Affairs; Veterans Health Administration (VHA); VA
   San Diego Healthcare System; Radboud University Nijmegen; University of
   Groningen},
ResearcherID-Numbers = {van den Bogaart, Geert/GLV-3283-2022
   Webster, Nick/AAI-8410-2021},
ORCID-Numbers = {van den Bogaart, Geert/0000-0003-2180-6735
   Mahata, Sushil/0000-0002-8300-9873
   },
Funding-Acknowledgement = {Veterans Affairs San Diego Healthcare System {[}I01 BX003934]},
Funding-Text = {Veterans Affairs San Diego Healthcare System, Grant/Award Number: I01
   BX003934},
Cited-References = {ABRAMSON EA, 1968, DIABETES, V17, P141, DOI 10.2337/diab.17.3.141.
   Agius L, 2010, MINI-REV MED CHEM, V10, P1175, DOI 10.2174/1389557511009011175.
   Agius L, 2008, BIOCHEM J, V414, P1, DOI 10.1042/BJ20080595.
   Aiston S, 2004, BIOCHEM J, V377, P195, DOI 10.1042/BJ20031191.
   {[}Anonymous], 2015, Nat Rev Dis Primers, V1, P15039, DOI {[}10.1038/nrdp.2015.39, 10.1038/nrdp.2015.39].
   Bandyopadhyay GK, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00020.
   Bandyopadhyay GK, 2015, DIABETES, V64, P104, DOI 10.2337/db13-1747.
   Bandyopadhyay GK, 2012, J BIOL CHEM, V287, P23141, DOI 10.1074/jbc.M111.335877.
   BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533.
   Bouskila M, 2010, CELL METAB, V12, P456, DOI 10.1016/j.cmet.2010.10.006.
   Campos C, 2012, POSTGRAD MED, V124, P90, DOI 10.3810/pgm.2012.11.2615.
   CARABAZA A, 1992, FEBS LETT, V296, P211, DOI 10.1016/0014-5793(92)80381-P.
   CARROLL NV, 1956, J BIOL CHEM, V220, P583.
   CHEN M, 1986, J CLIN ENDOCR METAB, V62, P1193, DOI 10.1210/jcem-62-6-1193.
   Chen YQ, 2008, J AM COLL CARDIOL, V52, P1468, DOI 10.1016/j.jacc.2008.07.047.
   Cherrington AD, 1999, DIABETES, V48, P1198, DOI 10.2337/diabetes.48.5.1198.
   CHRISTENSEN NJ, 1975, EUR J CLIN INVEST, V5, P415, DOI 10.1111/j.1365-2362.1975.tb00473.x.
   Chu CA, 1996, AM J PHYSIOL-ENDOC M, V271, pE127, DOI 10.1152/ajpendo.1996.271.1.E127.
   Ciraolo E, 2014, METHOD ENZYMOL, V543, P115, DOI 10.1016/B978-0-12-801329-8.00006-4.
   CIUDAD CJ, 1986, BIOCHEM BIOPH RES CO, V141, P1195, DOI 10.1016/S0006-291X(86)80171-1.
   CLINE GW, 1994, J CLIN INVEST, V94, P2369, DOI 10.1172/JCI117602.
   CLUTTER WE, 1988, DIABETES METAB REV, V4, P1, DOI 10.1002/dmr.5610040104.
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Dasgupta A, 2020, COMPUT STRUCT BIOTEC, V18, P464, DOI 10.1016/j.csbj.2020.02.005.
   DEFRONZO RA, 1982, DIABETOLOGIA, V23, P313.
   DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000.
   DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0.
   Dubois M, 2007, ENDOCRINOLOGY, V148, P1605, DOI 10.1210/en.2006-1022.
   EXTON JH, 1971, J BIOL CHEM, V246, P6166.
   Ferrer JC, 2003, FEBS LETT, V546, P127, DOI 10.1016/S0014-5793(03)00565-9.
   Gan XQ, 2011, J BIOL CHEM, V286, P10998, DOI 10.1074/jbc.M110.195016.
   Gayen JR, 2009, ENDOCRINOLOGY, V150, P5027, DOI 10.1210/en.2009-0429.
   Gayen JR, 2009, J BIOL CHEM, V284, P28498, DOI 10.1074/jbc.M109.020636.
   GERICH J, 1980, METABOLISM, V29, P1164, DOI 10.1016/0026-0495(80)90026-8.
   GERICH JE, 1974, J CLIN INVEST, V53, P1441, DOI 10.1172/JCI107692.
   Hokken R, 2021, ACTA PHYSIOL, V231, DOI 10.1111/apha.13561.
   HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x.
   HWANG JH, 1995, J CLIN INVEST, V95, P783, DOI 10.1172/JCI117727.
   Jensen J, 2007, CELL SIGNAL, V19, P204, DOI 10.1016/j.cellsig.2006.06.006.
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004.
   JUE T, 1989, P NATL ACAD SCI USA, V86, P1439, DOI 10.1073/pnas.86.5.1439.
   Kahn SE, 2006, NATURE, V444, P840, DOI 10.1038/nature05482.
   Kawahito S, 2009, WORLD J GASTROENTERO, V15, P4137, DOI 10.3748/wjg.15.4137.
   Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541.
   Luketin M, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11030456.
   Mahata SK, 2000, MOL ENDOCRINOL, V14, P1525, DOI 10.1210/me.14.10.1525.
   Mahata SK, 2003, J BIOL CHEM, V278, P32058, DOI 10.1074/jbc.M305545200.
   Mahata SK, 1997, J CLIN INVEST, V100, P1623, DOI 10.1172/JCI119686.
   Mahata SK, 2010, REGUL PEPTIDES, V162, P33, DOI 10.1016/j.regpep.2010.01.006.
   Mahatat SK, 2019, ANN NY ACAD SCI, V1455, P34, DOI 10.1111/nyas.14249.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Marchand I, 2002, J APPL PHYSIOL, V93, P1598, DOI 10.1152/japplphysiol.00585.2001.
   MARTIN BC, 1992, LANCET, V340, P925, DOI 10.1016/0140-6736(92)92814-V.
   Menke A, 2015, JAMA-J AM MED ASSOC, V314, P1021, DOI 10.1001/jama.2015.10029.
   Moore MC, 2012, ADV NUTR, V3, P286, DOI 10.3945/an.112.002089.
   MOORE MC, 1991, J CLIN INVEST, V88, P578, DOI 10.1172/JCI115342.
   Muntjewerff EM, 2021, ACTA PHYSIOL, V232, DOI 10.1111/apha.13655.
   Muntjewerff EM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02199.
   O'Connor DT, 2008, CIRCULATION, V118, P247, DOI 10.1161/CIRCULATIONAHA.107.709105.
   O'Connor DT, 2005, J CLIN ENDOCR METAB, V90, P5414, DOI 10.1210/jc.2005-0408.
   Pereda D, 2015, BEHAV BRAIN RES, V278, P98, DOI 10.1016/j.bbr.2014.09.022.
   Persson PB, 2019, ACTA PHYSIOL, V227, DOI 10.1111/apha.13405.
   PORTE D, 1969, ARCH INTERN MED, V123, P252, DOI 10.1001/archinte.123.3.252.
   POULTER L, 1988, EUR J BIOCHEM, V175, P497, DOI 10.1111/j.1432-1033.1988.tb14222.x.
   Prats C, 2005, J BIOL CHEM, V280, P23165, DOI 10.1074/jbc.M502713200.
   Rabbi MF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00985.
   Rabbi MF, 2017, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02151.
   Riopel M, 2018, J CLIN INVEST, V128, P1458, DOI 10.1172/JCI94330.
   RIZZA RA, 1980, J CLIN INVEST, V65, P682, DOI 10.1172/JCI109714.
   ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324.
   Roden M, 1996, J CLIN INVEST, V97, P642, DOI 10.1172/JCI118460.
   Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI {[}10.1002/j.2040-4603.2014.tb00548.x, 10.1002/cphy.c130024].
   SACCA L, 1980, J CLIN ENDOCR METAB, V50, P680, DOI 10.1210/jcem-50-4-680.
   SACCA L, 1983, AM J PHYSIOL, V245, pE294, DOI 10.1152/ajpendo.1983.245.3.E294.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Shoelson SE, 2007, GASTROENTEROLOGY, V132, P2169, DOI 10.1053/j.gastro.2007.03.059.
   Shulman G.I., 2000, J CLIN INVEST, V106, P171, DOI {[}DOI 10.1172/JCI10583, 10.1172/JCI10583, 10.1172/jci10583].
   SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403.
   SILVERBERG AB, 1978, AM J PHYSIOL, V234, pE252, DOI 10.1152/ajpendo.1978.234.3.E252.
   Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz.
   Syed NA, 2000, MOL CELL BIOCHEM, V211, P123, DOI 10.1023/A:1007159422667.
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837.
   TATEMOTO K, 1986, NATURE, V324, P476, DOI 10.1038/324476a0.
   Taupenot L, 2003, NEW ENGL J MED, V348, P1134, DOI 10.1056/NEJMra021405.
   VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078.
   VILLARPALASI C, 1991, BIOCHIM BIOPHYS ACTA, V1095, P261, DOI 10.1016/0167-4889(91)90109-B.
   Wen G, 2004, AM J HUM GENET, V74, P197, DOI 10.1086/381399.
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047.
   WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N.
   Yang G, 2015, CELL REP, V12, P937, DOI 10.1016/j.celrep.2015.07.016.
   Ying W, 2021, HYPERTENSION, V77, P1670, DOI 10.1161/HYPERTENSIONAHA.120.16809.
   Ying W, 2018, DIABETES, V67, P841, DOI 10.2337/db17-0788.
   Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a.},
Number-of-Cited-References = {94},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Acta Physiol.},
Doc-Delivery-Number = {0S9VT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000750932400001},
OA = {Green Submitted, Green Published, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000759919100001,
Author = {Takeuchi, Yukiko and Saino, Orie and Okinaka, Yuka and Ogawa, Yuko and
   Akamatsu, Rie and Kikuchi-Taura, Akie and Kataoka, Yosky and Maeda,
   Mitsuyo and Gul, Sheraz and Claussen, Carsten and Boltze, Johannes and
   Taguchi, Akihiko},
Title = {Increased RNA Transcription of Energy Source Transporters in Circulating
   White Blood Cells of Aged Mice},
Journal = {FRONTIERS IN AGING NEUROSCIENCE},
Year = {2022},
Volume = {14},
Month = {FEB 3},
Abstract = {Circulating white blood cells (WBC) contribute toward maintenance of
   cerebral metabolism and brain function. Recently, we showed that during
   aging, transcription of metabolism related genes, including energy
   source transports, in the brain significantly decreased at the
   hippocampus resulting in impaired neurological functions. In this
   article, we investigated the changes in RNA transcription of metabolism
   related genes (glucose transporter 1 {[}Glut1], Glut3, monocarboxylate
   transporter 4 {[}MCT4], hypoxia inducible factor 1-alpha {[}Hif1-alpha],
   prolyl hydroxylase 3 {[}PHD3] and pyruvate dehydrogenase kinase 1
   {[}PDK1]) in circulating WBC and correlated these with brain function in
   mice. Contrary to our expectations, most of these metabolism related
   genes in circulating WBC significantly increased in aged mice, and
   correlation between their increased RNA transcription and impaired
   neurological functions was observed. Bone marrow mononuclear
   transplantation into aged mice decreased metabolism related genes in WBC
   with accelerated neurogenesis in the hippocampus. In vitro analysis
   revealed that cell-cell interaction between WBC and endothelial cells
   via gap junction is impaired with aging, and blockade of the interaction
   increased their transcription in WBC. Our findings indicate that gross
   analysis of RNA transcription of metabolism related genes in circulating
   WBC has the potential to provide significant information relating to
   impaired cell-cell interaction between WBC and endothelial cells of aged
   mice. Additionally, this can serve as a tool to evaluate the change of
   the cell-cell interaction caused by various treatments or diseases.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Taguchi, A (Corresponding Author), Fdn Biomed Res \& Innovat Kobe, Dept Regenerat Med Res, Kobe, Hyogo, Japan.
   Takeuchi, Yukiko; Saino, Orie; Okinaka, Yuka; Ogawa, Yuko; Akamatsu, Rie; Kikuchi-Taura, Akie; Boltze, Johannes; Taguchi, Akihiko, Fdn Biomed Res \& Innovat Kobe, Dept Regenerat Med Res, Kobe, Hyogo, Japan.
   Kataoka, Yosky; Maeda, Mitsuyo, RIKEN, RIKEN JEOL Collaborat Ctr, Multimodal Microstruct Anal Unit, Kobe, Hyogo, Japan.
   Kataoka, Yosky; Maeda, Mitsuyo, RIKEN, RIKEN Ctr Biosyst Dynam Res, Lab Cellular Funct Imaging, Kobe, Hyogo, Japan.
   Gul, Sheraz; Claussen, Carsten, Fraunhofer Inst Translat Med \& Pharmacol ITMP, Hamburg, Germany.
   Gul, Sheraz; Claussen, Carsten, Fraunhofer Cluster Excellence Immune Mediated Dis, Hamburg, Germany.
   Boltze, Johannes, Univ Warwick, Sch Life Sci, Coventry, W Midlands, England.},
DOI = {10.3389/fnagi.2022.759159},
Article-Number = {759159},
ISSN = {1663-4365},
Keywords = {aging; white blood cell; RNA transcription; energy source transporter;
   metabolism related gene; neurogenesis; hippocampus},
Keywords-Plus = {GAP; ANGIOGENESIS; EXPRESSION; CONNEXINS; PROVIDE; CYCLE},
Research-Areas = {Geriatrics \& Gerontology; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Geriatrics \& Gerontology; Neurosciences},
Author-Email = {taguchi@fbri.org},
Affiliations = {RIKEN; RIKEN; University of Warwick},
ORCID-Numbers = {Okinaka, Yuka/0009-0002-3336-871X},
Funding-Acknowledgement = {Japan Agency for Medical Research and Development (AMED) {[}20bm0404069]},
Funding-Text = {Funding This research was supported by the Japan Agency for Medical
   Research and Development (AMED) under Grant Number 20bm0404069.},
Cited-References = {Belousov AB, 2014, J NEURAL TRANSM, V121, P837, DOI 10.1007/s00702-013-1109-7.
   Cunnane SC, 2020, NAT REV DRUG DISCOV, V19, P609, DOI 10.1038/s41573-020-0072-x.
   Filiano AJ, 2017, NAT REV NEUROSCI, V18, P375, DOI 10.1038/nrn.2017.39.
   HILL SL, 1992, ANTIMICROB AGENTS CH, V36, P1545, DOI 10.1128/AAC.36.7.1545.
   Kasahara Y, 2013, NEUROSCI RES, V76, P163, DOI 10.1016/j.neures.2013.04.001.
   Kikuchi-Taura A, 2021, STEM CELLS, V39, P904, DOI 10.1002/stem.3360.
   Kikuchi-Taura A, 2020, STROKE, V51, P1279, DOI 10.1161/STROKEAHA.119.028072.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Laird DW, 2006, BIOCHEM J, V394, P527, DOI 10.1042/BJ20051922.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Moreno-Jiménez EP, 2019, NAT MED, V25, P554, DOI 10.1038/s41591-019-0375-9.
   MUIRHEAD KA, 1986, ANN NY ACAD SCI, V468, P113, DOI 10.1111/j.1749-6632.1986.tb42034.x.
   Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207.
   Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454.
   Nielsen MS, 2012, COMPR PHYSIOL, V2, P1981, DOI {[}10.1002/j.2040-4603.2012.tb00453.x, 10.1002/cphy.c110051].
   Ogawa Y, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.535902.
   Ognibene M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187206.
   Okamoto T, 2021, BBA-MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2021.166168.
   Pasciuto E, 2020, CELL, V182, P625, DOI 10.1016/j.cell.2020.06.026.
   Pfenniger A, 2013, BBA-BIOMEMBRANES, V1828, P157, DOI 10.1016/j.bbamem.2012.05.011.
   Runtsch MC, 2021, J NEUROCHEM, V158, P36, DOI 10.1111/jnc.15169.
   Smith LK, 2018, CELL TISSUE RES, V371, P105, DOI 10.1007/s00441-017-2715-8.
   Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622.
   Taguchi A, 2004, CIRCULATION, V109, P2972, DOI 10.1161/01.CIR.0000133311.25587.DE.
   Taguchi A, 2008, J CEREBR BLOOD F MET, V28, P445, DOI 10.1038/sj.jcbfm.9600541.
   Taguchi Akihiko, 2010, J Exp Stroke Transl Med, V3, P28.
   Takeuchi Y, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00170.
   Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011.
   Tobin MK, 2019, CELL STEM CELL, V24, P974, DOI 10.1016/j.stem.2019.05.003.
   Yuan DD, 2015, MOL MED REP, V12, P7146, DOI 10.3892/mmr.2015.4273.
   Zhao YN, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/6323901.
   Zorzano A, 2005, ACTA PHYSIOL SCAND, V183, P43, DOI 10.1111/j.1365-201X.2004.01380.x.},
Number-of-Cited-References = {32},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Front. Aging Neurosci.},
Doc-Delivery-Number = {ZF9WX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000759919100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000760762000001,
Author = {De Tomi, Elisa and Campagnari, Rachele and Orlandi, Elisa and Cardile,
   Alessia and Zanre, Valentina and Menegazzi, Marta and Gomez-Lira,
   Macarena and Gotte, Giovanni},
Title = {Upregulation of miR-34a-5p, miR-20a-3p and miR-29a-3p by Onconase in
   A375 Melanoma Cells Correlates with the Downregulation of Specific
   Onco-Proteins},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2022},
Volume = {23},
Number = {3},
Month = {FEB},
Abstract = {Onconase (ONC) is an amphibian secretory ribonuclease displaying
   cytostatic and cytotoxic activities against many mammalian tumors,
   including melanoma. ONC principally damages tRNA species, but also other
   non-coding RNAs, although its precise targets are not known. We
   investigated the ONC ability to modulate the expression of 16
   onco-suppressor microRNAs (miRNAs) in the A375 BRAF-mutated melanoma
   cell line. RT-PCR and immunoblots were used to measure the expression
   levels of miRNAs and their regulated proteins, respectively. In silico
   study was carried out to verify the relations between miRNAs and their
   mRNA targets. A375 cell transfection with miR-20a-3p and miR-34a-5p
   mimics or inhibitors was performed. The onco-suppressors miR-20a-3p,
   miR-29a-3p and miR-34a-5p were highly expressed in 48-h ONC-treated A375
   cells. The cytostatic effect of ONC in A375 cells was mechanistically
   explained by the sharp inhibition of cyclins D1 and A2 expression level,
   as well as by downregulation of retinoblastoma protein and
   cyclin-dependent-kinase-2 activities. Remarkably, the expression of
   kinases ERK1/2 and Akt, as well as of the hypoxia inducible factor-1
   alpha, was inhibited by ONC. All these proteins control pro-survival
   pathways. Finally, many crucial proteins involved in migration, invasion
   and metastatic potential were downregulated by ONC. Results obtained
   from transfection of miR-20a-3p and miR-34a-5p inhibitors in the
   presence of ONC show that these miRNAs may participate in the antitumor
   effects of ONC in the A375 cell line. In conclusion, we identified many
   intracellular downregulated proteins involved in melanoma cell
   proliferation, metabolism and progression. All mRNAs coding these
   proteins may be targets of miR-20a-3p, miR-29a-3p and/or miR-34a-5p,
   which are in turn upregulated by ONC. Data suggest that several known
   ONC anti-proliferative and anti-metastatic activities in A375 melanoma
   cells might depend on the upregulation of onco-suppressor miRNAs.
   Notably, miRNAs stability depends on the upstream regulation by
   long-non-coding-RNAs or circular-RNAs that can, in turn, be damaged by
   ONC ribonucleolytic activity.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Menegazzi, M (Corresponding Author), Univ Verona, Sch Med, Dept Neurosci Biomed \& Movement Sci, Biochem Sect, I-37134 Verona, Italy.
   De Tomi, Elisa; Orlandi, Elisa; Gomez-Lira, Macarena, Univ Verona, Sch Med, Dept Neurosci Biomed \& Movement Sci, Biol \& Genet Sect, I-37134 Verona, Italy.
   Campagnari, Rachele; Cardile, Alessia; Zanre, Valentina; Menegazzi, Marta; Gotte, Giovanni, Univ Verona, Sch Med, Dept Neurosci Biomed \& Movement Sci, Biochem Sect, I-37134 Verona, Italy.},
DOI = {10.3390/ijms23031647},
Article-Number = {1647},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {ribonuclease; cyclin D1; cyclin A2; HIF1 alpha; PDK1; CREB; SIRT1; SOX2;
   Fra1; AXL; cMet},
Keywords-Plus = {TUMOR-GROWTH; RIBONUCLEASE INHIBITOR; TARGET PREDICTION; CANCER;
   EXPRESSION; INVASION; METASTASIS; PROLIFERATION; RANPIRNASE; MIGRATION},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {elisa.detomi@univr.it
   rachele.campagnari@univr.it
   elisa.orlandi@univr.it
   alessia.cardile@studenti.univr.it
   valentina.zanre@univr.it
   marta.menegazzi@univr.it
   macarena.gomezlira@univr.it
   giovanni.gotte@univr.it},
Affiliations = {University of Verona; University of Verona},
ResearcherID-Numbers = {Orlandi, Elisa/PII-2262-2026
   menegazzi, marta/AAE-7079-2019
   },
ORCID-Numbers = {Gotte, Giovanni/0000-0003-3179-7158
   menegazzi, marta/0000-0003-1310-9227
   De Tomi, Elisa/0000-0002-1368-374X
   Zanrè, Valentina/0000-0001-7336-3214
   CARDILE, ALESSIA/0009-0007-4215-3274},
Cited-References = {Adams BD, 2016, CANCER RES, V76, P927, DOI 10.1158/0008-5472.CAN-15-2321.
   Aida R, 2021, MOL BIOL REP, V48, P2291, DOI 10.1007/s11033-021-06255-7.
   Ali Syeda Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051723.
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871.
   Anders G, 2012, NUCLEIC ACIDS RES, V40, pD180, DOI 10.1093/nar/gkr1007.
   Antony J, 2019, PHYS BIOL, V16, DOI 10.1088/1478-3975/ab157a.
   ARDELT W, 1991, J BIOL CHEM, V266, P245.
   Asadi M, 2019, J GASTROINTEST CANC, V50, P304, DOI 10.1007/s12029-018-0060-0.
   Auyez A, 2021, CANCERS, V13, DOI 10.3390/cancers13194864.
   Bai FH, 2018, MOL MED REP, V17, P8145, DOI 10.3892/mmr.2018.8896.
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995.
   Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218.
   Chen GS, 2016, ONCOTARGETS THER, V9, P3067, DOI 10.2147/OTT.S96861.
   Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35.
   Chou KY, 2021, ONCOL REP, V45, P911, DOI 10.3892/or.2020.7910.
   Costanzi J, 2005, CANCER INVEST, V23, P643, DOI 10.1080/07357900500283143.
   Courtnay R, 2015, MOL BIOL REP, V42, P841, DOI 10.1007/s11033-015-3858-x.
   Czyz M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123844.
   Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1.
   Dikshit A, 2018, CANCER RES, V78, P6462, DOI 10.1158/0008-5472.CAN-18-1040.
   Ding N, 2017, ONCOTARGETS THER, V10, P4905, DOI 10.2147/OTT.S142446.
   DURSO CM, 1991, J CLIN INVEST, V87, P284, DOI 10.1172/JCI114984.
   Fagagnini A, 2017, BIOCHEM J, V474, P3767, DOI 10.1042/BCJ20170541.
   Gaidatzis D, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-69.
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348.
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615.
   Girouard SD, 2012, LAB INVEST, V92, P362, DOI 10.1038/labinvest.2011.188.
   Goparaju CM, 2011, ONCOGENE, V30, P2767, DOI 10.1038/onc.2010.643.
   Gotte G, 2021, INT J BIOL MACROMOL, V191, P560, DOI 10.1016/j.ijbiomac.2021.09.095.
   Gotte G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02626.
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952.
   Hatse S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110644.
   Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107.
   Hu Z, 2015, J DERMATOL SCI, V79, P155, DOI 10.1016/j.jdermsci.2015.04.010.
   Hüser L, 2018, INT J CANCER, V143, P3131, DOI 10.1002/ijc.31609.
   Iordanov MS, 2000, CANCER RES, V60, P1983.
   Isin M, 2015, CLIN CHIM ACTA, V444, P280, DOI 10.1016/j.cca.2015.02.046.
   Jiang XY, 2020, MOL BIOL REP, V47, P737, DOI 10.1007/s11033-019-05123-9.
   Johnson RJ, 2007, BIOCHEMISTRY-US, V46, P10308, DOI 10.1021/bi700857u.
   Juan G, 1998, LEUKEMIA, V12, P1241, DOI 10.1038/sj.leu.2401100.
   Kenessey I, 2010, CURR CANCER DRUG TAR, V10, P332, DOI 10.2174/156800910791190184.
   Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koshizuka K, 2018, ONCOTARGET, V9, P3663, DOI 10.18632/oncotarget.23194.
   KUNITZ M, 1946, J BIOL CHEM, V164, P563.
   Kuphal S, 2010, EUR J CANCER, V46, P1159, DOI 10.1016/j.ejca.2010.01.031.
   Kwon JJ, 2019, MOL THER ONCOLYTICS, V12, P173, DOI 10.1016/j.omto.2018.12.011.
   Lai KT, 2017, ONCOTARGET, V8, P49931, DOI 10.18632/oncotarget.18263.
   Laurenzana A, 2015, J MOL MED, V93, P783, DOI 10.1007/s00109-015-1266-2.
   Lee I, 2007, ANTICANCER RES, V27, P299.
   Lee JE, 2008, BIODRUGS, V22, P53, DOI 10.2165/00063030-200822010-00006.
   Li RH, 2018, CELL SIGNAL, V49, P95, DOI 10.1016/j.cellsig.2018.06.003.
   Lin ZP, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00303.
   Luengo-Gil G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194638.
   Ma G, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03938-8.
   Malekan M, 2021, BIOMED PHARMACOTHER, V141, DOI 10.1016/j.biopha.2021.111873.
   Mao ZJ, 2019, J ETHNOPHARMACOL, V243, DOI 10.1016/j.jep.2019.111966.
   Maragkakis M, 2011, NUCLEIC ACIDS RES, V39, pW145, DOI 10.1093/nar/gkr294.
   McArthur GA, 2012, J CLIN ONCOL, V30, P1628, DOI 10.1200/JCO.2011.39.1938.
   McGeary SE, 2019, SCIENCE, V366, P1470, DOI 10.1126/science.aav1741.
   MIKULSKI SM, 1990, CELL TISSUE KINET, V23, P237, DOI 10.1111/j.1365-2184.1990.tb01119.x.
   Miller MA, 2017, CLIN CANCER RES, V23, P623, DOI 10.1158/1078-0432.CCR-16-0869.
   Misso G, 2014, MOL THER NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47.
   Mizuno K, 2016, INT J ONCOL, V48, P450, DOI 10.3892/ijo.2015.3289.
   Nan P, 2019, ONCOTARGETS THER, V12, P6917, DOI 10.2147/OTT.S218043.
   Notomista E, 2000, BIOCHEMISTRY-US, V39, P8711, DOI 10.1021/bi000415x.
   Notomista E, 1999, FEBS LETT, V463, P211, DOI 10.1016/S0014-5793(99)01623-3.
   Orgaz JL, 2013, PIGM CELL MELANOMA R, V26, P39, DOI 10.1111/pcmr.12041.
   Pavlakis N, 2006, EXPERT OPIN BIOL TH, V6, P391, DOI 10.1517/14712598.6.4.391.
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47.
   Pizzimenti S, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10121942.
   Qiao M, 2012, CELL RES, V22, P1199, DOI 10.1038/cr.2012.67.
   Raineri A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235980.
   Raineri A, 2019, BIOCHEM PHARMACOL, V167, P173, DOI 10.1016/j.bcp.2019.06.006.
   Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44.
   Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631.
   Rybak SM, 1996, J NATL CANCER I, V88, P747, DOI 10.1093/jnci/88.11.747.
   Saxena A, 2009, ANTICANCER RES, V29, P1067.
   Shao NY, 2018, CELL PHYSIOL BIOCHEM, V48, P450, DOI 10.1159/000491776.
   Shi H, 2015, MELANOMA RES, V25, P15, DOI 10.1097/CMR.0000000000000124.
   Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X.
   Smith LK, 2016, PHARMACOL RES, V107, P42, DOI 10.1016/j.phrs.2016.02.009.
   SORRENTINO S, 1994, ARCH BIOCHEM BIOPHYS, V312, P340, DOI 10.1006/abbi.1994.1318.
   Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004.
   Stope M, 2019, SDRP Journal of Cellular and Molecular Physiology, V3, P1, DOI {[}10.25177/jcmp.3.1.1, 10.25177/JCMP.3.1.1, DOI 10.25177/JCMP.3.1.1].
   Sun T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0167-4.
   Sun ZF, 2015, INT J ONCOL, V47, P1339, DOI 10.3892/ijo.2015.3142.
   Talotta F, 2020, ONCOGENE, V39, P4491, DOI 10.1038/s41388-020-1306-4.
   Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436.
   Tulchinsky E, 2014, ONCOTARGET, V5, P1.
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161.
   Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408.
   Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304.
   Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851.
   Xiao Z, 2020, EXP THER MED, V19, P1605, DOI 10.3892/etm.2020.8432.
   Xie SH, 1997, ONCOGENE, V15, P2069, DOI 10.1038/sj.onc.1201358.
   Xiong Y, 2018, CELL PHYSIOL BIOCHEM, V50, P385, DOI 10.1159/000494015.
   Xu YZ, 2021, AGING-US, V13, P15538, DOI 10.18632/aging.203114.
   Yan DS, 2009, INVEST OPHTH VIS SCI, V50, P1559, DOI 10.1167/iovs.08-2681.
   Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432.
   Yu YB, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-017-0499-2.
   Zhang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0778-4.
   Zuo Q, 2018, ONCOGENE, V37, P3275, DOI 10.1038/s41388-018-0205-4.},
Number-of-Cited-References = {103},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {ZH2GF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000760762000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000762145900004,
Author = {Kim, Seong-Hyun and Park, Sang-Seo and Kim, Chang-Ju and Kim, Tae-Woon},
Title = {Exercise with 40-Hz light flicker improves hippocampal insulin signaling
   in Alzheimer disease mice},
Journal = {JOURNAL OF EXERCISE REHABILITATION},
Year = {2022},
Volume = {18},
Number = {1},
Pages = {20-27},
Month = {FEB},
Abstract = {We examined whether exercise is associated with hippocampus-mediated
   improvement in insulin signaling and cell differentiation in the triple
   transgenic mouse model of Alzheimer disease (3xTg AD) murine model
   following exposure to 40-Hz light flickering and exercise. We subjected
   12-month-old 3xTg AD mice to exercise and 40-Hz light flickering for 3
   months. The exercise session was proceeded for 12 consecutive weeks with
   gradual increase of intensity. To investigate insulin signaling
   proteins, western blot was conducted to detect the ratio of
   phosphorylated insulin receptor beta (p-IR beta)/total IR beta (t-IR
   beta), phosphorylated insulin receptor substrate 1 (p-IRS-1)/total IRS-1
   (t-IRS-1), phosphorylated phosphatidylinositide-3-kinase (p-PI3K)/total
   PI3K (t-PI3K), phosphorylated 3-phosphoinositide dependent protein
   kinase-1 (p-PDK1)Itotal PDK-1 (t-PDK1), phosphorylated protein kinase B
   (p-Akt)/total-Akt (t-Akt), and phosphorylated glycogen synthase kinase 3
   beta (p-GSK3 beta)/total GSK3 beta (t-GSK3 beta). Doublecortin
   immunohistochemistry was performed for assessing cell differentiation in
   the hippocampus. Treatments exerted a positive effect The combination of
   exercise and 40-Hz light flickering exposure was the most effective
   treatment enhancing insulin signaling. Increased ratio of p-IR beta/t-IR
   beta, p-IRS-1/t-IRS-1, p-PI3K/t-PI3K, p-PDK1/t-PDK1, p-Akt/t-Akt, and
   p-GSK3 beta/t-GSK3 beta and enhanced cell differentiation were observed
   in the 3xTg AD with exercise under 40-Hz light flickering group. Our
   results indicate that exercise under 40-Hz light flickering most
   potently improved insulin signaling, thereby promoted cell
   differentiation.},
Publisher = {KOREAN SOC EXERCISE REHABILITATION},
Address = {264 BAEKJEGOBUN-RO, SONGPA-GU, SEOUL, 138-841, SOUTH KOREA},
Type = {Article},
Language = {English},
Affiliation = {Kim, TW (Corresponding Author), Gyeongsang Natl Univ, Dept Human Hlth Care, 33 Dongiin Ro, Jinju 52725, South Korea.
   Kim, Seong-Hyun; Park, Sang-Seo; Kim, Chang-Ju, Kyung Hee Univ, Coll Med, Dept Physiol, Seoul, South Korea.
   Kim, Seong-Hyun, Korea Univ, Coll Culture \& Sports, Div Global Sport Studies, Sejong, South Korea.
   Park, Sang-Seo, Univ Nebraska, Sch Hlth \& Kinesiol, Omaha, NE 68182 USA.
   Kim, Tae-Woon, Gyeongsang Natl Univ, Dept Human Hlth Care, 33 Dongiin Ro, Jinju 52725, South Korea.},
DOI = {10.12965/jer.2244042.021},
ISSN = {2288-176X},
EISSN = {2288-1778},
Keywords = {Alzheimer disease; Exercise; 40-Hz light flicker; Insulin signaling;
   Hippocampus; Cell differentiation},
Keywords-Plus = {TREADMILL EXERCISE; AMYLOID LOAD; MOUSE MODEL; EXPRESSION; VOLUNTARY;
   IMPAIRMENT; PROTEINS; BEHAVIOR; MEMORY},
Research-Areas = {Rehabilitation},
Web-of-Science-Categories  = {Rehabilitation},
Author-Email = {twkim0806@gnu.ac.kr},
Affiliations = {Kyung Hee University; Korea University; University of Nebraska System;
   Gyeongsang National University},
ResearcherID-Numbers = {Kim, Chang/M-4216-2017},
ORCID-Numbers = {Kim, Tae-Woon/0000-0001-8832-0874
   Kim, Seong-Hyun/0000-0002-6522-4203
   },
Funding-Acknowledgement = {Ministry of Education of the Republic of Korea; National Research
   Foundation of Korea {[}NRF-2017S1A5B5A02025250]},
Funding-Text = {This work was supported by the Ministry of Education of the Republic of
   Korea and the National Research Foundation of Korea
   (NRF-2017S1A5B5A02025250).},
Cited-References = {Adaikkan C, 2019, NEURON, V102, P929, DOI 10.1016/j.neuron.2019.04.011.
   Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005.
   Aleman A, 2009, PROG NEUROBIOL, V89, P256, DOI 10.1016/j.pneurobio.2009.07.008.
   Boehme F, 2011, EUR J NEUROSCI, V33, P1799, DOI 10.1111/j.1460-9568.2011.07676.x.
   Brooker GJF, 2000, J NEUROSCI RES, V59, P332, DOI 10.1002/(SICI)1097-4547(20000201)59:3<332::AID-JNR6>3.0.CO;2-2.
   Brown BM, 2013, MOL PSYCHIATR, V18, P875, DOI 10.1038/mp.2012.107.
   Candeias E, 2012, IUBMB LIFE, V64, P951, DOI 10.1002/iub.1098.
   Cen L, 2007, BRIT J CANCER, V97, P785, DOI 10.1038/sj.bjc.6603952.
   Chen LM, 2012, J NEUROCHEM, V120, P157, DOI 10.1111/j.1471-4159.2011.07275.x.
   Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200.
   Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001.
   Hernández F, 2010, EXP NEUROL, V223, P322, DOI 10.1016/j.expneurol.2009.09.011.
   Iaccarino HF, 2016, NATURE, V540, P230, DOI 10.1038/nature20587.
   Kales HC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h369.
   Kim TW, 2020, J EXERC REHABIL, V16, P227.
   Larson EB, 2006, ANN INTERN MED, V144, P73, DOI 10.7326/0003-4819-144-2-200601170-00004.
   Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5.
   Li T, 2018, HIPPOCAMPUS, V28, P358, DOI 10.1002/hipo.22837.
   Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621.
   MOSS AM, 1990, P NATL ACAD SCI USA, V87, P4453, DOI 10.1073/pnas.87.12.4453.
   Muller AP, 2011, HIPPOCAMPUS, V21, P1082, DOI 10.1002/hipo.20822.
   Park SS, 2020, J EXERC REHABIL, V16, P118, DOI 10.12965/jer.2040234.117.
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741.
   Singer AC, 2018, NAT PROTOC, V13, P1850, DOI 10.1038/s41596-018-0021-x.
   Sousa-Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867.
   Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008.
   Townsend M, 2007, J BIOL CHEM, V282, P33305, DOI 10.1074/jbc.M610390200.
   Wang LR, 2019, J EXERC REHABIL, V15, P206, DOI 10.12965/jer.1938094.047.
   Wu YH, 2005, J PINEAL RES, V38, P145, DOI 10.1111/j.1600-079X.2004.00196.x.
   Xie L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0001.2002.
   Yang SH, 2019, INT NEUROUROL J, V23, pS54.
   Yuede CM, 2009, NEUROBIOL DIS, V35, P426, DOI 10.1016/j.nbd.2009.06.002.},
Number-of-Cited-References = {32},
Times-Cited = {7},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {8},
Journal-ISO = {J. Exerc. Rehabil.},
Doc-Delivery-Number = {ZJ2NA},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000762145900004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000789630300005,
Author = {Larijani, Banafshe and Miles, James},
Title = {Quantification of protein-protein interactions and activation dynamics:
   A new path to predictive biomarkers},
Journal = {BIOPHYSICAL CHEMISTRY},
Year = {2022},
Volume = {283},
Month = {APR},
Abstract = {Oncogene dysregulation is a driver of neoplasia development and
   progression. The use of quantitative molecular imaging to quantify
   oncogene activation will be crucial in developing companion diagnostics
   which can identify personalised patient regimens. However, the
   evaluation of oncogene activation does not necessarily correlate with
   oncoprotein activation. Post-translational modifications, such as
   phosphorylation, lipidation and methylation, may enhance oncoprotein
   functionality. It is this functionality that progresses neoplasia and
   may correlate with patient outcome. Advanced molecular imaging may be
   used to directly quantify oncoprotein, as opposed to oncogene,
   activation. Time-resolved Fo center dot rster Resonance Energy Transfer
   (TR-FRET) involves the non-radiative transfer of energy from one
   chromophore to another over distances of 1-10 nm; allowing FRET to be
   used as a ``chemical ruler{''}. TR-FRET can be utilised to directly
   elucidate spatial oncoprotein activation in single cells and patient
   tissues. In single cells, TR-FRET has uncovered the mechanisms by which
   PKC beta 1 is trafficked to the nucleus and cleaved. Additionally it has
   revealed the mechanism of activation of Akt/PKB, whereby Akt/PKB
   undergoes a conformational change, allowing the Thr308 site to be
   phosphorylated by PDK1. Moreover TR-FRET has been utilised to quantify
   HER2-HER heterodimerisation and Akt/PKB activation states in patient
   biopsies, where it is shown to be predictive of outcome/relapse. The
   role of TR-FRET is not solely limited to intracellular signalling
   events. A study has used TR-FRET to measure intercellular
   immune-checkpoint receptor-ligand interactions. Within this study it was
   seen that PD-L1 expression was not indicative of PD-1/PD-L1 interaction
   states in a range of solid tumours. Crucially, in melanoma and NSCLC,
   PD-1/PD-L1 interaction was a predictive of an improved patient outcome.
   PD-L1 expression did not predict patient outcome. Several groups have
   worked to improve Fluorescence lifetime imaging microscopy (FLIM)
   acquisition times, including the use of: window galvanometers;
   multifocal multiphoton FLIM and parallel pixel excitation coupled with
   wide-field time-gated FLIM. The development of novel quantitative
   molecular imaging will be critical in the development of personalised
   patient therapies in the future.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Larijani, B (Corresponding Author), Univ Bath, Ctr Therapeut Innovat, Bath BA2 7AY, Avon, England.
   Larijani, Banafshe; Miles, James, Univ Bath, Dept Pharm \& Pharmacol, Dept Phys, Cell Biophys Lab,Ctr Therapeut Innovat, Bath, Avon, England.
   Larijani, Banafshe; Miles, James, Univ Basque Country, Res Ctr Expt Marine Biol \& Biotechnol PiE, Cell Biophys Lab, Leioa, Biscay, Spain.
   Larijani, Banafshe; Miles, James, Univ Basque Country, Biophys Inst, UPV EHU, CSIC, Leioa, Biscay, Spain.
   Miles, James, Inst Bergonie, Early Phase Trials \& Sarcoma, Bordeaux, France.},
DOI = {10.1016/j.bpc.2022.106768},
EarlyAccessDate = {FEB 2022},
Article-Number = {106768},
ISSN = {0301-4622},
EISSN = {1873-4200},
Keywords = {FRET; FLIM; Oncoprotein; Activation State; Spatiotemporal; Chromophore;
   Donor; Acceptor},
Keywords-Plus = {BREAST-CANCER; IN-SITU; CELL; AMPLIFICATION; TECHNOLOGIES; ONCOGENES;
   MARKER},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics; Chemistry, Physical},
Author-Email = {bl666@bath.ac.uk},
Affiliations = {University of Bath; University of Basque Country; Consejo Superior de
   Investigaciones Cientificas (CSIC); University of Basque Country; CSIC -
   UPV EHU - Instituto Biofisika; UNICANCER; Institut Bergonie},
ResearcherID-Numbers = {LARIJANI, Banafshé/OPN-4239-2025
   },
ORCID-Numbers = {LARIJANI, Banafshé/0000-0003-4735-1169
   Miles, James/0009-0001-9560-6026},
Funding-Acknowledgement = {Bikaintek grant for industrial doctorates in the Basque Country {[}BFU
   2011-28566]; Spanish Ministry of Economy; Basque Government through the
   BERC; Spanish Ministry of Economy and Competitiveness (MINECO); 
   {[}3602014-2017]},
Funding-Text = {We are most grateful to Professor Peter J Parker and the many years of
   his fruitful collaboration and discussions with our teams. We thank
   Professor Stephen G Ward for his continuous scientific discussions and
   advice. We also thank Dr. Veroniqe Calleja, Dr. Lissete Sanchez-Magraner
   and Christopher J Applebee (BSc, MSc) for their crucial work which has
   led into the results discussed in this review. Lastly, we are grateful
   to Pierre Leboucher (Eng.) for the initial and continued development of
   the semi-automated high-throughput image acquisition platform that was
   utilised in Veeriah et al., 2014, Miles et al., 2017 and
   Sanchez-Magraner and Miles et al., 2020. Figs. 1-5 and the graphical
   abstract were created using Bio Render. The work reviewed from the
   manuscript, Sanchez-Magraner et al., 2020, was in part funded by the
   Bikaintek grant for industrial doctorates in the Basque Country. The
   work reviewed from Miles et al., 2017 acknowledges the funding from the
   Spanish Ministry of Economy for the grants (grant number BFU 2011-28566)
   and Basque Government through the BERC 3602014-2017; the Spanish
   Ministry of Economy and Competitiveness (MINECO) .},
Cited-References = {Bagci O, 2015, N AM J MED SCI, V7, P341, DOI 10.4103/1947-2714.163641.
   Barber PR, 2020, JNCI-J NATL CANCER I, V112, P944, DOI 10.1093/jnci/djz231.
   Bastiaens PIH, 1996, P NATL ACAD SCI USA, V93, P8407, DOI 10.1073/pnas.93.16.8407.
   Beck S, 2014, GENOME MED, V6, DOI 10.1186/gm555.
   Bernard Valeur M.N.B.S., MOL FLUORESCENCE PRI, V2021, P213.
   Bilous M, 2006, PATHOLOGY, V38, P120, DOI 10.1080/00313020600561518.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Chen L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0196-9.
   Clegg RM, 2006, REV FLUORESCENCE, V3, P1.
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367.
   Crosby D, 2020, LANCET ONCOL, V21, P1397, DOI 10.1016/S1470-2045(20)30593-3.
   Datta R, 2021, J BIOMED OPT, V26, DOI 10.1117/1.JBO.26.7.070603.
   FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692.
   Floerchinger A, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109689.
   FORSTER T, 1946, NATURWISSENSCHAFTEN, V33, P166, DOI 10.1007/BF00585226.
   Furrer D, 2015, AM J CLIN PATHOL, V144, P686, DOI 10.1309/AJCPT41TCBUEVDQC.
   Grant DM, 2007, OPT EXPRESS, V15, P15656, DOI 10.1364/OE.15.015656.
   Hill MM, 2002, PHARMACOL THERAPEUT, V93, P243, DOI 10.1016/S0163-7258(02)00193-6.
   Hirvonen LM, 2020, FRONT PHYS-LAUSANNE, V8, DOI 10.3389/fphy.2020.00161.
   Ho-Pun-Cheung A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037065.
   Jares-Erijman EA, 2003, NAT BIOTECHNOL, V21, P1387, DOI 10.1038/nbt896.
   Karpf S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15618-w.
   KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810.
   KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0.
   Kulkarni Meghana M, 2011, Curr Protoc Mol Biol, VChapter 25, DOI 10.1002/0471142727.mb25b10s94.
   Kumar S, 2007, OPT EXPRESS, V15, P12548, DOI 10.1364/OE.15.012548.
   Kumar S, 2020, FRET HIGH CONTENT AN.
   Liu L, 2006, APPL PHYS B-LASERS O, V84, P379, DOI 10.1007/s00340-006-2314-y.
   Liu WJ, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0620-6.
   M'Boutchou MN, 2016, METHODS MOL BIOL, V1458, P291, DOI 10.1007/978-1-4939-3801-8\_21.
   Malkov Vladislav A, 2009, BMC Res Notes, V2, P80, DOI 10.1186/1756-0500-2-80.
   Miles J, 2017, BBA CLIN, V8, P97, DOI 10.1016/j.bbacli.2017.10.002.
   Mukherjee A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016443.
   Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085.
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753.
   Perez EA, 2006, J CLIN ONCOL, V24, P3032, DOI 10.1200/JCO.2005.03.4744.
   Poland SP, 2015, BIOMED OPT EXPRESS, V6, P277, DOI 10.1364/BOE.6.000277.
   Reis PP, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-46.
   Ruiz-Saenz A, 2018, CANCER RES, V78, P3645, DOI 10.1158/0008-5472.CAN-18-0430.
   Sánchez-Magraner L, 2020, CANCER RES, V80, P4244, DOI 10.1158/0008-5472.CAN-20-1117.
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106.
   Söderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947.
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x.
   Spears M, 2012, BREAST CANCER RES TR, V132, P463, DOI 10.1007/s10549-011-1606-z.
   Tsikouras A, 2015, BIOMED OPT EXPRESS, V6, P3737, DOI 10.1364/BOE.6.003737.
   Tsikouras A, 2012, OPT LETT, V37, P250, DOI 10.1364/OL.37.000250.
   UK CR, 1 2 PEOPL UK WILL GE.
   van de Vijver M, 2002, ONCOLOGY-BASEL, V63, P33, DOI 10.1159/000066199.
   Veeriah S, 2014, CANCER RES, V74, P4983, DOI 10.1158/0008-5472.CAN-13-3382.
   Wang YC, 2014, CELL RES, V24, P143, DOI 10.1038/cr.2013.151.
   Weitsman G, 2016, ONCOTARGET, V7, P51012, DOI 10.18632/oncotarget.9963.
   Wilson FR, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0588-2.
   Wong F, 2017, CONVERG SCI PHYS ONC, V3, DOI 10.1088/2057-1739/aa5cbd.
   Xie J, 2005, OPT LASER TECHNOL, V37, P305, DOI 10.1016/j.optlastec.2004.04.012.},
Number-of-Cited-References = {54},
Times-Cited = {4},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Biophys. Chem.},
Doc-Delivery-Number = {0X3SJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000789630300005},
DA = {2026-02-04},
}

@article{ WOS:000747510200001,
Author = {Liu, Xuemei and Yin, Zhiping and Wu, Yanjun and Zhan, Qian and Huang,
   Honghong and Fan, Jiangtao},
Title = {Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the
   cisplatin resistance of ovarian cancer},
Journal = {BIOENGINEERED},
Year = {2022},
Volume = {13},
Number = {2},
Pages = {3739-3750},
Month = {FEB 1},
Abstract = {Circular RNA (circRNA) is considered to be an important regulator that
   mediates cancer chemoresistance. But whether circ-LPAR3 is involved in
   ovarian cancer (OC) cisplatin (DDP) resistance is unclear. The
   circ-LPAR3, miR-634 and pyruvate dehydrogenase kinase 1 (PDK1)
   expression was measured by quantitative real-time PCR (qRT-PCR). Cell
   cisplatin resistance and viability were measured by 3-(4,
   5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay.
   In addition, cell colony number, apoptosis, and metastasis were assessed
   by colony formation assay, flow cytometry and transwell assay.
   Furthermore, in vivo experiments were performed by constructing mice
   xenograft models. RNA interaction was confirmed by dual-luciferase
   reporter assay, and PDK1 protein expression was examined by Western blot
   analysis. Our results showed that circ-LPAR3 was markedly upregulated in
   DDP-resistant OC tissues and cells. Silencing of circ-LPAR3 enhanced the
   DDP sensitivity of OC cells and tumors. MiR-634 could interact with
   circ-LPAR3, and its inhibitor overturned the regulation of si-circ-LPAR3
   on cell DDP resistance. Additionally, PDK1 was targeted by miR-634, and
   its overexpression inverted the effect of miR-634 on cell DDP
   resistance. To sum up, circ-LPAR3 might contribute to the DDP resistance
   of OC via the miR-634/PDK1 axis.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Huang, HH (Corresponding Author), Guangxi Univ Chinese Med, Fac Chinese Med Sci, 13 Wuhe Ave, Nanning 530222, Guangxi, Peoples R China.
   Fan, JT (Corresponding Author), Dept Gynecol, Nanning, Peoples R China.
   Liu, Xuemei, Jinan City Peoples Hosp, Dept Gynaecol \& Obstet, Jinan, Peoples R China.
   Yin, Zhiping; Zhan, Qian, Yunnan Prov Hosp Tradit Chinese Med, Dept Lab Med, Kunming, Yunnan, Peoples R China.
   Wu, Yanjun, Liaocheng Peoples Hosp, Dept Gynaecol \& Obstet, Liaocheng, Shandong, Peoples R China.
   Huang, Honghong, Guangxi Univ Chinese Med, Fac Chinese Med Sci, Dept Pharm, Nanning, Guangxi, Peoples R China.
   Fan, Jiangtao, Guangxi Med Univ, Dept Gynecol, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.},
DOI = {10.1080/21655979.2022.2029109},
ISSN = {2165-5979},
EISSN = {2165-5987},
Keywords = {Ovarian cancer; resistance; circ-LPAR3; miR-634; PDK1},
Keywords-Plus = {IN-VITRO; CARCINOMA; MIR-634; CELLS; PROLIFERATION; EPIDEMIOLOGY;
   CONTRIBUTES; PACLITAXEL; EXPRESSION; GROWTH},
Research-Areas = {Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology},
Author-Email = {fbasvh@163.com
   jiangtaogxmu715@sina.com},
Affiliations = {Yunnan University of Chinese Medicine; Guangxi University of Chinese
   Medicine; Guangxi Medical University},
ResearcherID-Numbers = {Yin, Zhiping/AAE-1916-2020},
Cited-References = {Abbaszadeh Z, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144158.
   Cao Y, 2021, ONCOTARGETS THER, V14, P3151, DOI 10.2147/OTT.S291823.
   Chen B, 2018, CANCER LETT, V418, P41, DOI 10.1016/j.canlet.2018.01.011.
   Chen DR, 2019, EXP THER MED, V17, P3949, DOI 10.3892/etm.2019.7433.
   Cheng SQ, 2019, CANCER BIOL THER, V20, P328, DOI 10.1080/15384047.2018.1529101.
   Cui CC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01180-y.
   Das M, 2018, INT J BIOCHEM CELL B, V103, P115, DOI 10.1016/j.biocel.2018.08.011.
   Ekmann-Gade AW, 2020, ANTICANCER RES, V40, P2765, DOI 10.21873/anticanres.14248.
   Glasgow MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092131.
   Guo J, 2018, CANCER MED-US, V7, P776, DOI 10.1002/cam4.1204.
   Huang XX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0969-3.
   Jeyaraman S, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01369.
   La Vecchia C, 2017, EUR J CANCER PREV, V26, P55, DOI 10.1097/CEJ.0000000000000217.
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Luvero D, 2019, CRIT REV ONCOL HEMAT, V140, P28, DOI 10.1016/j.critrevonc.2019.05.014.
   Momenimovahed Z, 2019, INT J WOMENS HEALTH, V11, P287, DOI 10.2147/IJWH.S197604.
   Moufarrij S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0602-0.
   Peng XW, 2014, INT J CLIN EXP PATHO, V7, P6784.
   Qian Y, 2020, BRAZ J MED BIOL RES, V53, DOI {[}10.1590/1414-431X20209330, 10.1590/1414-431x20209330].
   Song W, 2020, ONCOL LETT, V19, P2175, DOI 10.3892/ol.2020.11306.
   van Jaarsveld MTM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0464-4.
   Wang JJ, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1659092.
   Wu JC, 2019, BIOMED RES INT-UK, V2019, DOI 10.1155/2019/8308694.
   Xu F, 2020, BIOCHEM BIOPH RES CO, V526, P14, DOI 10.1016/j.bbrc.2020.03.024.
   Yan JW, 2021, BIOENGINEERED, V12, P12420, DOI 10.1080/21655979.2021.2005221.
   Zhang CZ, 2016, MOL ONCOL, V10, P1532, DOI 10.1016/j.molonc.2016.09.001.
   Zhang HD, 2018, BREAST CANCER-TOKYO, V25, P1, DOI 10.1007/s12282-017-0793-9.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.
   Zhang S, 2020, MOL THER-NUCL ACIDS, V19, P718, DOI 10.1016/j.omtn.2019.12.005.
   Zhang Y, 2018, J CELL BIOCHEM, V119, P6296, DOI 10.1002/jcb.26899.
   Zhao Z, 2019, MOL THER-NUCL ACIDS, V18, P24, DOI 10.1016/j.omtn.2019.07.012.
   Zhao ZJ, 2017, RNA BIOL, V14, P514, DOI 10.1080/15476286.2015.1122162.
   Zheng SZ, 2021, BIOENGINEERED, V12, P8347, DOI 10.1080/21655979.2021.1987053.},
Number-of-Cited-References = {34},
Times-Cited = {16},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Bioengineered},
Doc-Delivery-Number = {YN8NU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000747510200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000789695000004,
Author = {Shi, Yangqian and Meng, Lingyu and Zhang, Chunliang and Zhang, Fengmin
   and Fang, Yong},
Title = {Extracellular vesicles of Lacticaseibacillus paracasei
   PC-H1 induce colorectal cancer cells apoptosis via PDK1/AKT/Bcl-2
   signaling pathway},
Journal = {MICROBIOLOGICAL RESEARCH},
Year = {2022},
Volume = {255},
Month = {FEB},
Abstract = {Colorectal cancer (CRC) is the third most common malignant tumor in the
   world. Previous research has shown that Lacticaseibacillus paracasei
   strains and its cultures have anti-colon cancer effects, but the study
   of L. paracasei- derived extracellular vesicles (LpEVs) as intercellular
   communication molecule against colon cancer has not been previously
   reported. Our research showed LpEVs were taken in by colorectal cancer
   cells. Subsequently, LpEVs inhibited the proliferation, migration,
   invasion and promote apoptosis of colorectal cancer cells. LpEVs
   inhibited the growth of CRC xenograft in nude mice and promoted tumor
   apoptosis in vivo. Transcriptome sequencing analysis revealed that
   differentially expressed genes were involved in the regulation of
   apoptosis. LpEVs significantly inhibited the phosphorylation level of
   3-phosphoinositide-dependent protein kinase-1 (PDK1) and AKT in
   colorectal cancer cells and reduced the expression of Bcl-2 protein. In
   conclusion, extracellular vesicles of Lacticaseibacillus paracasei PC-H1
   can inhibit the growth of colorectal cancer cells in vivo and vitro and
   induce apoptosis through PDK1/AKT/Bcl-2 signaling pathway. This research
   not only provides a new mechanism for the anti-tumor effects of
   probiotics, but also opens up new opportunity for the treatment of colon
   cancer.},
Publisher = {ELSEVIER GMBH},
Address = {HACKERBRUCKE 6, 80335 MUNICH, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Zhang, FM; Fang, Y (Corresponding Author), Harbin Med Univ, 157 Baojian Rd, Harbin, Peoples R China.
   Shi, Yangqian; Meng, Lingyu; Zhang, Chunliang; Zhang, Fengmin; Fang, Yong, Harbin Med Univ, Dept Microbiol, Harbin, Peoples R China.
   Zhang, Fengmin; Fang, Yong, Harbin Med Univ, Wu Lien Teh Inst, Harbin, Peoples R China.
   Zhang, Fengmin; Fang, Yong, Heilongjiang Prov Key Lab Immun \& Infect Pathogen, Harbin, Peoples R China.},
DOI = {10.1016/j.micres.2021.126921},
Article-Number = {126921},
ISSN = {0944-5013},
EISSN = {1618-0623},
Keywords = {Probiotics; Lacticaseibacillus paracasei; Extracellular vesicles; Colon
   cancer; Apoptosis},
Keywords-Plus = {COMMUNICATION; BACTERIA},
Research-Areas = {Microbiology},
Web-of-Science-Categories  = {Microbiology},
Author-Email = {fengminzhang@ems.hrbmu.edu.cn
   yong.fang@ems.hrbmu.edu.cn},
Affiliations = {Harbin Medical University; Harbin Medical University},
ResearcherID-Numbers = {shi, yangqian/HGA-4515-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81773267, 81301703]; Key
   Laboratory of Aging and Cancer Biology of Zhejiang Province, China
   {[}2020E10016]},
Funding-Text = {Funding This work was supported by the National Natural Science
   Foundation of China (grant numbers: 81773267; 81301703) ; the Key
   Laboratory of Aging and Cancer Biology of Zhejiang Province, China
   (grant number: 2020E10016) .},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Azeem Salman, 2015, Asian Pac J Cancer Prev, V16, P5389, DOI 10.7314/apjcp.2015.16.13.5389.
   Bäuerl C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75930-9.
   Behzadi E, 2017, MICROB PATHOGENESIS, V110, P1, DOI 10.1016/j.micpath.2017.06.016.
   Boyle P, 2000, BRIT MED J, V321, P805, DOI 10.1136/bmj.321.7264.805.
   Brown L, 2015, NAT REV MICROBIOL, V13, P620, DOI 10.1038/nrmicro3480.
   Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1.
   Cao ZP, 2020, J CONTROL RELEASE, V326, P396, DOI 10.1016/j.jconrel.2020.07.009.
   Casanova MR, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00044.
   Chen Y, 2021, AM J CANCER RES, V11, P1087.
   Choi JH, 2020, EXP MOL MED, V52, P423.
   Chondrou P, 2018, BENEF MICROBES, V9, P975, DOI {[}10.3920/BM2017.0183, 10.3920/bm2017.0183].
   da Silva Duarte V., 2020, MICROORGANISMS, V8.
   Gómez-Suárez M, 2016, CELL DEATH DIFFER, V23, P1060, DOI 10.1038/cdd.2015.163.
   Heo G, 2021, CANCERS, V13, DOI 10.3390/cancers13040734.
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004.
   Hu PP, 2015, FOOD FUNCT, V6, P2257, DOI 10.1039/c5fo00248f.
   Hu RJ, 2021, J ANIM SCI BIOTECHNO, V12, DOI 10.1186/s40104-020-00532-4.
   Huang-Doran I, 2017, TRENDS ENDOCRIN MET, V28, P3, DOI 10.1016/j.tem.2016.10.003.
   Kakkar P, 2007, MOL CELL BIOCHEM, V305, P235, DOI 10.1007/s11010-007-9520-8.
   Kang EA, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110522.
   Kim J.H., 2016, J ALLERGY CLIN IMMUN, V137.
   Konishi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12365.
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113.
   Li M, 2017, BMC MICROBIOL, V17, DOI 10.1186/s12866-017-0977-7.
   Li WY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.644454.
   Liu Q, 2020, MICROB CELL FACT, V19, DOI 10.1186/s12934-020-1289-4.
   Liu Y, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01502.
   Lu ZM, 2010, MOL CANCER RES, V8, P421, DOI 10.1158/1541-7786.MCR-09-0179.
   Mattiuzzi C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.91.
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641.
   Nozari S, 2019, LETT APPL MICROBIOL, V69, P148, DOI 10.1111/lam.13198.
   O'Brien K, 2020, NAT REV MOL CELL BIO, V21, P585, DOI 10.1038/s41580-020-0251-y.
   Palomino RAÑ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13468-9.
   Rafter J, 2007, AM J CLIN NUTR, V85, P488, DOI 10.1093/ajcn/85.2.488.
   Resch U, 2016, MBIO, V7, DOI 10.1128/mBio.00207-16.
   Seo MK, 2018, J DAIRY SCI, V101, P8662, DOI 10.3168/jds.2018-15014.
   Sharma M, 2020, NUTR CANCER, V72, P110, DOI 10.1080/01635581.2019.1615514.
   Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204-014-1448-7.
   Bajic SS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78920-z.
   Teng F, 2021, ADV SCI, V8, DOI 10.1002/advs.202003505.
   Tian PJ, 2015, INT J MOL SCI, V16, P20033, DOI 10.3390/ijms160820033.
   Toyofuku M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00492-w.
   Wang SH, 2020, GEROSCIENCE, V42, P333, DOI 10.1007/s11357-019-00137-4.
   West CL, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0225481.
   Wu R, 2018, MOL MED REP, V18, P5379, DOI 10.3892/mmr.2018.9556.
   Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337.},
Number-of-Cited-References = {47},
Times-Cited = {56},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {55},
Journal-ISO = {Microbiol. Res.},
Doc-Delivery-Number = {0X4RF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000789695000004},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000754496000001,
Author = {Song, Heng and Zhang, Xiaojuan and Zhai, Ruiqing and Liang, Huoyan and
   Song, Gaofei and Yuan, Yangyang and Xu, Yanan and Yan, Yan and Qiu,
   Lingxiao and Sun, Tongwen},
Title = {Metformin attenuated sepsis-associated liver injury and inflammatory
   response in aged mice},
Journal = {BIOENGINEERED},
Year = {2022},
Volume = {13},
Number = {2},
Pages = {4598-4609},
Month = {FEB 1},
Abstract = {Sepsis-associated liver injury is with poor survival in intensive care
   units. Metformin is well known for its therapeutic effects; however, its
   impact on treating liver injury due to sepsis remains poorly understood.
   This study investigated the therapeutic effects of metformin on aged
   mice suffering from sepsis-associated liver injury. Male C57BL/6 J mice
   aged (18-19 months) were divided into 3 groups: 1) intraperitoneal
   injection of sterile normal saline (C group), 12.5 mg/kg
   lipopolysaccharide (LPS) to induce sepsis-associated liver injury (LPS
   group), and 25 mg/kg metformin (MET) at 1 h after LPS injection (MET
   group). After 24 h, blood samples and liver tissue were collected for
   biochemical analysis. Histological assays revealed significantly
   elevated inflammatory infiltration and apoptosis in the liver, while
   metformin was found to relieve these aberrant features. The percentage
   of apoptotic cells decreased after metformin treatment (P < 0.05).
   Additionally, MET group had significantly reduced plasma alanine
   aminotransferase (ALT) and aspartate aminotransferase (AST) levels
   compared to the LPS group (P < 0.05). Furthermore, in the MET group, the
   mRNA levels of chemokines and inflammatory factors, TNF-alpha, IL-6,
   caspase-1, decreased markedly (P < 0.05). Metformin notably reversed the
   decreased phosphorylated AMP-activated protein kinase (p-AMPK) and PGC-1
   alpha expressions in the liver of septic rats. Metformin also inhibited
   PDK1, HIF-1 alpha expression, including downstream inflammatory
   mediators, HMGB1 and TNF-alpha. Metformin attenuated inflammation and
   liver injury in septic aged mice. Most importantly, we report the effect
   of metformin on liver injury via the AMPK-PGC1 alpha axis in septic aged
   mice for the first time.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Sun, TW (Corresponding Author), Zhengzhou Univ, Henan Key Lab Crit Care Med, Henan Engn Res Ctr Crit Care Med, Gen Intens Care Unit ICU,Affiliated Hosp 1,Zhengz, 1 Jianshe East Rd, Zhengzhou 450052, Peoples R China.
   Song, Heng; Zhang, Xiaojuan; Liang, Huoyan; Song, Gaofei; Yuan, Yangyang; Xu, Yanan; Yan, Yan; Sun, Tongwen, Zhengzhou Univ, Henan Engn Res Ctr Crit Care Med, Henan Key Lab Crit Care Med, Gen ICU,Affiliated Hosp 1,Zhengzhou Key Lab Sepsi, Zhengzhou, Peoples R China.
   Song, Heng; Liang, Huoyan; Song, Gaofei; Sun, Tongwen, Zhengzhou Univ, Acad Med Sci, Zhengzhou, Peoples R China.
   Zhai, Ruiqing, Harbin Med Univ, Coll Bioinformat Sci \& Technol, Harbin, Peoples R China.
   Qiu, Lingxiao, Zhengzhou Univ, Dept Resp Med, Affiliated Hosp 1, Zhengzhou, Peoples R China.},
DOI = {10.1080/21655979.2022.2036305},
ISSN = {2165-5979},
EISSN = {2165-5987},
Keywords = {Metformin; lipopolysaccharide; sepsis-associated liver injury; aged
   mice; inflammatory response},
Keywords-Plus = {BLOOD-STREAM INFECTIONS; INTENSIVE-CARE; AMPK; CELL; ACTIVATION; BURDEN},
Research-Areas = {Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology},
Author-Email = {suntongwen@163.com},
Affiliations = {Zhengzhou University; Zhengzhou University; Harbin Medical University;
   Zhengzhou University},
ResearcherID-Numbers = {Qiu, Lingxiao/AAX-5663-2021},
ORCID-Numbers = {Qiu, Lingxiao/0000-0002-1703-0797},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}U2004110]; Henan
   Province 2021 Young Talent Promotion Program {[}2021HYTP053]},
Funding-Text = {This study was supported by the Joint Foundation of the National Natural
   Science Foundation of China (Grant No. U2004110) and the Henan Province
   2021 Young Talent Promotion Program (Grant No. 2021HYTP053).},
Cited-References = {Ankawi G, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2181-z.
   Auciello FR, 2014, FEBS LETT, V588, P3361, DOI 10.1016/j.febslet.2014.07.025.
   Boström P, 2012, NATURE, V481, P463, DOI 10.1038/nature10777.
   Brun-Buisson C, 2004, INTENS CARE MED, V30, P580, DOI 10.1007/s00134-003-2121-4.
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445.
   Casemayou A, 2017, J AM SOC NEPHROL, V28, P3204, DOI 10.1681/ASN.2016050508.
   Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016.
   Ding XF, 2019, J CELL PHYSIOL, V234, P16582, DOI 10.1002/jcp.28329.
   Eikawa S, 2015, P NATL ACAD SCI USA, V112, P1809, DOI 10.1073/pnas.1417636112.
   Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833.
   Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131.
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018.
   Ghavimi H, 2018, IRAN J BASIC MED SCI, V21, P469, DOI 10.22038/IJBMS.2018.24610.6126.
   Gleyzer N, 2011, J BIOL CHEM, V286, P39715, DOI 10.1074/jbc.M111.291575.
   Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585.
   Hardie DG, 2008, INT J OBESITY, V32, pS7, DOI 10.1038/ijo.2008.116.
   Hattori Y, 2006, HYPERTENSION, V47, P1183, DOI 10.1161/01.HYP.0000221429.94591.72.
   Hotchkiss RS, 2013, NAT REV IMMUNOL, V13, P862, DOI 10.1038/nri3552.
   Hotchkiss RS, 2010, NEW ENGL J MED, V363, P87, DOI 10.1056/NEJMcibr1004371.
   Huang J, 2018, BRAIN BEHAV IMMUN, V72, P89, DOI 10.1016/j.bbi.2017.11.003.
   Inghammar M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243990.
   Jiang B, 2020, PHYTOTHER RES, V34, P1175, DOI 10.1002/ptr.6593.
   Komorowski M, 2018, NAT MED, V24, P1716, DOI 10.1038/s41591-018-0213-5.
   Lee CC, 2007, MEDICINE, V86, P138, DOI 10.1097/SHK.0b013e318067da56.
   Lee Y, 2016, BIOCHEM BIOPH RES CO, V469, P515, DOI 10.1016/j.bbrc.2015.12.015.
   Liang H., 2019, EUR RESPIR J, V54, P2269.
   Liang HY, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.06.010.
   Liang HY, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2346-4.
   Liu QL, 2018, CLIN CANCER RES, V24, P5622, DOI 10.1158/1078-0432.CCR-18-0420.
   Malik F, 2018, DIABETES-METAB RES, V34, DOI 10.1002/dmrr.2975.
   Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA.
   Martin-Montalvo A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3192.
   Min BK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00944.
   Nacionales DC, 2014, J IMMUNOL, V192, P612, DOI 10.4049/jimmunol.1302109.
   Ou ZR, 2018, BRAIN BEHAV IMMUN, V69, P351, DOI 10.1016/j.bbi.2017.12.009.
   Park MJ, 2019, J IMMUNOL, V203, P127, DOI 10.4049/jimmunol.1800006.
   Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454.
   Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005.
   Quan NH, 2018, J MOL CELL CARDIOL, V115, P170, DOI 10.1016/j.yjmcc.2018.01.005.
   Rutherford C, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf8566.
   Schilling J, 2011, CIRC-HEART FAIL, V4, P474, DOI 10.1161/CIRCHEARTFAILURE.110.959833.
   Shimazui T, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02976-6.
   Castanheira FVES, 2018, SHOCK, V49, P682, DOI 10.1097/SHK.0000000000000969.
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287.
   Skogberg K, 2012, CLIN MICROBIOL INFEC, V18, pE170, DOI 10.1111/j.1469-0691.2012.03845.x.
   Song YM, 2015, AUTOPHAGY, V11, P46, DOI 10.4161/15548627.2014.984271.
   Soukas AA, 2019, TRENDS ENDOCRIN MET, V30, P745, DOI 10.1016/j.tem.2019.07.015.
   Starr ME, 2010, BLOOD, V115, P4886, DOI 10.1182/blood-2009-10-246678.
   Tan Z, 2015, J IMMUNOL, V194, P6082, DOI 10.4049/jimmunol.1402469.
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986.
   Tsoyi K, 2011, BRIT J PHARMACOL, V162, P1498, DOI 10.1111/j.1476-5381.2010.01126.x.
   Turnbull IR, 2009, CRIT CARE MED, V37, P1018, DOI 10.1097/CCM.0b013e3181968f3a.
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36.
   Vincent JL, 2014, LANCET RESP MED, V2, P380, DOI 10.1016/S2213-2600(14)70061-X.
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12.
   Wester AL, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-346.
   Yahav D, 2016, VIRULENCE, V7, P341, DOI 10.1080/21505594.2015.1132142.
   Zhang MX, 2021, AM J PHYSIOL-RENAL, V320, pF262, DOI 10.1152/ajprenal.00289.2020.
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1.
   Zuo QZ, 2021, HEPATOLOGY, V73, P644, DOI 10.1002/hep.31280.},
Number-of-Cited-References = {60},
Times-Cited = {42},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Bioengineered},
Doc-Delivery-Number = {YY0PO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000754496000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000759370600001,
Author = {Wang, Na and Fu, Jianjiang and Li, Zhihua and Jiang, Ningni and Chen,
   Yanhong and Peng, Juan},
Title = {The Landscape of PDK1 in Breast Cancer},
Journal = {CANCERS},
Year = {2022},
Volume = {14},
Number = {3},
Month = {FEB},
Abstract = {Simple Summary Approximately 2,261,419 new cases of breast cancer (BC)
   and 684,996 BC-related deaths are estimated to occur in 2020 globally.
   New individualized therapeutic strategies are urgently needed for
   affected patients. The aim of our review was to assess the potential
   role of targeted PDK1 therapies in BC. We hope the information provided
   on clinical trials of PDK1-targeted therapies will benefit researchers
   and clinicians in the breast cancer field. Given that
   3-phosphoinositide-dependent kinase 1 (PDK1) plays a crucial role in the
   malignant biological behaviors of a wide range of cancers, we review the
   influence of PDK1 in breast cancer (BC). First, we describe the power of
   PDK1 in cellular behaviors and characterize the interaction networks of
   PDK1. Then, we establish the roles of PDK1 in carcinogenesis, growth and
   survival, metastasis, and chemoresistance in BC cells. More importantly,
   we sort the current preclinical or clinical trials of PDK1-targeted
   therapy in BC and find that, even though no selective PDK1 inhibitor is
   currently available for BC therapy, the combination trials of
   PDK1-targeted therapy and other agents have provided some benefit. Thus,
   there is increasing anticipation that PDK1-targeted therapy will have
   its space in future therapeutic approaches related to BC, and we hope
   the novel approaches of targeted therapy will be conducive to
   ameliorating the dismal prognosis of BC patients.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Peng, J (Corresponding Author), Guangzhou Med Univ, Key Lab Major Obstetr Dis Guangdong Prov, Key Lab Reprod \& Genet, Guangdong Higher Educ Inst,Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
   Peng, J (Corresponding Author), Guangzhou Med Univ, Clin Sch 3, Guangzhou 510150, Peoples R China.
   Wang, Na; Fu, Jianjiang; Li, Zhihua; Jiang, Ningni; Chen, Yanhong; Peng, Juan, Guangzhou Med Univ, Key Lab Major Obstetr Dis Guangdong Prov, Key Lab Reprod \& Genet, Guangdong Higher Educ Inst,Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
   Wang, Na; Fu, Jianjiang; Li, Zhihua; Jiang, Ningni; Chen, Yanhong; Peng, Juan, Guangzhou Med Univ, Clin Sch 3, Guangzhou 510150, Peoples R China.
   Li, Zhihua, Guangzhou Med Univ, Dept Fetal Med \& Prenatal Diag, Affiliated Hosp 3, Guangzhou 510150, Peoples R China.
   Chen, Yanhong, Guangzhou Med Univ, Dept Obstet \& Gynecol, Affiliated Hosp 3, Guangzhou 510150, Peoples R China.},
DOI = {10.3390/cancers14030811},
Article-Number = {811},
EISSN = {2072-6694},
Keywords = {PDK1; breast cancer; survival; prognosis; targeted therapy},
Keywords-Plus = {3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; PLECKSTRIN HOMOLOGY
   DOMAIN; MAMMARY EPITHELIAL-CELLS; TYROSINE PHOSPHORYLATION;
   PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; REGULATORY MECHANISM;
   TUMOR-GROWTH; AGC KINASES; S6 KINASE; IN-VIVO},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {wangna10197@126.com
   joe2042632928@outlook.com
   2011683132@gzhmu.edu.cn
   jiangningni@stu.gzhmu.edu.cn
   2011683122@gzhmu.edu.cn
   pengjuan1979@gzhmu.edu.cn},
Affiliations = {Guangzhou Medical University; Guangzhou Medical University; Guangzhou
   Medical University; Guangzhou Medical University},
ResearcherID-Numbers = {Peng, Juan/GXF-2029-2022
   Li, ZhiHua/GYU-9914-2022
   chen, yanhong/JVE-0289-2024},
ORCID-Numbers = {Fu, Jianjiang/0000-0002-3952-9898
   Peng, Juan/0000-0001-6308-3040
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81602631]; Student
   Laboratory Open Project of Guangzhou Medical University {[}C195015021];
   Elite Talents Training Plan of the Third Affiliated Hospital of
   Guangzhou Medical University},
Funding-Text = {FundingThis work was funded by the National Natural Science Foundation
   of China (no. 81602631), the Student Laboratory Open Project of
   Guangzhou Medical University (no. C195015021), and 2017 Elite Talents
   Training Plan of the Third Affiliated Hospital of Guangzhou Medical
   University (Juan Peng).},
Cited-References = {Alcántara-Hernández R, 2014, EUR J PHARMACOL, V740, P88, DOI 10.1016/j.ejphar.2014.06.057.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5.
   Arndt J., 2018, Heterocyclic Compounds Useful as PDK1 Inhibitors, Patent No. 2018222943.
   Arsenic R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-82.
   Axten J.M., 2010, Preparation of 6-(4-Pyrimidinyl)- 1 H-Indazole Derivatives as PDK1 Inhibitors, Patent No. {[}PCT/US2009/064891, 2009064891].
   Barile E, 2012, PHARM PAT ANAL, V1, P145, DOI {[}10.4155/ppa.12.17, 10.4155/PPA.12.17].
   Biondi RM, 2004, TRENDS BIOCHEM SCI, V29, P136, DOI 10.1016/j.tibs.2004.01.005.
   Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225.
   Boehringer Ingelheim International Gmbh, 2011, U.S. Patent, Patent No. 0269958.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   Coppé JP, 2019, NAT CELL BIOL, V21, P778, DOI 10.1038/s41556-019-0328-z.
   Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6.
   Dessain S.K., 2016, PDK1 Binding Molecules and Uses Thereof, Patent No. {[}US2016319035 (A1), 20163190351].
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Ding L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121492.
   Dittrich ACN, 2012, PLANT SIGNAL BEHAV, V7, P642, DOI 10.4161/psb.20038.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Ekici K, 2016, J BUON, V21, P958.
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290.
   Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219.
   Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0.
   Fridrichova I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111361.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gagliardi PA, 2014, J CELL BIOL, V206, P415, DOI 10.1083/jcb.201312090.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Gao LL, 2019, EBIOMEDICINE, V41, P395, DOI 10.1016/j.ebiom.2019.02.034.
   Gao Y, 2019, DEV CELL, V49, P375, DOI 10.1016/j.devcel.2019.04.012.
   Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x.
   Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005.
   Guo L, 2019, CANCER MED-US, V8, P5687, DOI 10.1002/cam4.2454.
   HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349.
   Hashimoto K, 2018, P NATL ACAD SCI USA, V115, P2204, DOI 10.1073/pnas.1717363115.
   Hauge C, 2007, EMBO J, V26, P2251, DOI 10.1038/sj.emboj.7601682.
   He YX, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1774281.
   Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062.
   Hoda S.A., 2021, ROSENS BREAST PATHOL, V5th ed., P10257.
   Iorns E, 2009, BIOCHEM J, V417, P361, DOI 10.1042/BJ20081682.
   James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709.
   Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653.
   Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168.
   Jin LT, 2018, CANCER BIOL THER, V19, P858, DOI 10.1080/15384047.2018.1456599.
   Jones CB, 2000, CANCER CHEMOTH PHARM, V45, P252, DOI 10.1007/s002800050037.
   Kelly AP, 2007, EMBO J, V26, P3441, DOI 10.1038/sj.emboj.7601761.
   Kikani CK, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003065.
   Kim S, 2018, ONCOGENE, V37, P2982, DOI 10.1038/s41388-018-0124-4.
   Komander D, 2003, BIOCHEM J, V375, P255, DOI 10.1042/BJ20031119.
   Le MTN, 2014, J CLIN INVEST, V124, P5109, DOI 10.1172/JCI75695.
   Le Rhun E, 2017, EUR J CANCER, V87, P189, DOI 10.1016/j.ejca.2017.10.006.
   Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200.
   Liang K, 2006, MOL PHARMACOL, V70, P1045, DOI 10.1124/mol.106.023333.
   Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100.
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862.
   Lin MCJ, 2014, MOL CANCER RES, V12, P940, DOI 10.1158/1541-7786.MCR-13-0555.
   Liu C, 2019, MOLECULES, V24, DOI 10.3390/molecules24071363.
   Liu JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07258-y.
   Liu QQ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163884.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Loh HY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194940.
   Lu ZM, 2010, MOL CANCER RES, V8, P421, DOI 10.1158/1541-7786.MCR-09-0179.
   Luo DY, 2018, INT J ONCOL, V53, P2067, DOI 10.3892/ijo.2018.4525.
   Ma CX, 2013, BREAST CANCER RES TR, V137, P483, DOI 10.1007/s10549-012-2378-9.
   Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Menyailo ME, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051696.
   Meuillet EJ, 2010, MOL CANCER THER, V9, P706, DOI 10.1158/1535-7163.MCT-09-0985.
   Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Mull BB, 2020, BRIT J CANCER, V122, P812, DOI 10.1038/s41416-019-0707-z.
   Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Park H, 2015, J CELL BIOL, V211, P619, DOI 10.1083/jcb.201503113.
   Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024.
   Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Petri BJ, 2020, CANCER METAST REV, V39, P837, DOI 10.1007/s10555-020-09905-7.
   Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675.
   Raimondi C, 2016, SCI REP-UK, V6, DOI 10.1038/srep26142.
   Raimondi C, 2012, J CELL SCI, V125, P3153, DOI 10.1242/jcs.100511.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005.
   Sestito S, 2019, EXPERT OPIN THER PAT, V29, P271, DOI 10.1080/13543776.2019.1597852.
   SEYNAEVE CM, 1993, CANCER RES, V53, P2081.
   Shen M, 2019, CANCER RES, V79, P3608, DOI 10.1158/0008-5472.CAN-18-4055.
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342.
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25.
   TAKAHASHI I, 1987, J ANTIBIOT, V40, P1782, DOI 10.7164/antibiotics.40.1782.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Taniyama Y, 2003, MOL CELL BIOL, V23, P8019, DOI 10.1128/MCB.23.22.8019-8029.2003.
   Tominaga N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7716.
   Tseng PH, 2006, MOL PHARMACOL, V70, P1534, DOI 10.1124/mol.106.023911.
   Van Mechelen M, 2020, BREAST CANCER RES TR, V181, P115, DOI 10.1007/s10549-020-05597-3.
   Wang GM, 2013, CANCER RES, V73, P3248, DOI 10.1158/0008-5472.CAN-12-1578.
   Weng YS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0988-0.
   World Health Organization, 2019, WHO METHODOLOGY POIN, P102.
   Wu JH, 2011, CANCER RES, V71, P2622, DOI 10.1158/0008-5472.CAN-10-3837.
   Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480.
   Xie ZH, 2003, CANCER RES, V63, P5370.
   Xie ZH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-77.
   Xue GD, 2018, SEMIN CANCER BIOL, V48, pIII, DOI 10.1016/j.semcancer.2018.01.013.
   Yamaguchi H, 2011, J CELL BIOL, V193, P1275, DOI 10.1083/jcb.201009126.
   Zeng X, 2002, CANCER RES, V62, P3538.
   Zhao S, 2020, ONCOL REP, V43, P2017, DOI 10.3892/or.2020.7577.
   Zhou WM, 2019, CELL SIGNAL, V56, P1, DOI 10.1016/j.cellsig.2018.11.016.
   Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007.},
Number-of-Cited-References = {111},
Times-Cited = {21},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {ZF1YY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000759370600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000750508600001,
Author = {Chen, Yongchang and Liu, Lu and Xia, Longzheng and Wu, Nayiyuan and
   Wang, Ying and Li, He and Chen, Xue and Zhang, Xiaoye and Liu, Zhaoyi
   and Zhu, Miaochen and Liao, Qianjin and Wang, Jing},
Title = {TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the
   growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α
   degradation},
Journal = {JOURNAL OF EXPERIMENTAL \& CLINICAL CANCER RESEARCH},
Year = {2022},
Volume = {41},
Number = {1},
Month = {JAN 31},
Abstract = {Background: Tumor cell metabolic reprogramming is crucial for the
   malignant behavior of cancer cells by promoting their proliferation.
   However, little is known on how transient receptor potential 7 (TRPM7)
   modulates metabolic reprogramming in ovarian cancer.
   Methods: The effects of TRPM7 silencing on transcriptome profile,
   glucose uptake, lactic acid production, extracellular acidification rate
   (ECAR), oxygen consumption rate (OCR), intracellular ROS and ATP levels,
   and NAD+/NADH ratios in ovarian cancer cells were examined. The impacts
   of TRPM7 silencing on the levels of glycolysis-related HK2, PDK1 and
   oxidative phosphorylation (OXPHOS)-related IDH3B and UQCRC1, HIF-1 alpha
   expression and AMPK phosphorylation were determined in ovarian cancer.
   The effect of AMPK activity on HIF-1 alpha ubiquitination degradation
   was investigated in ovarian cancer cells.
   Results: Compared with the control, TRPM7 silencing suppressed the
   proliferation of ovarian cancer cells by shifting preferable glycolysis
   to OXPHOS. In parallel, TRPM7 silencing decreased the glucose uptake of
   tumor-bearing mice and TRPM7 levels were negatively correlated with
   IDH3B and UQCRC1, but positively with HK2 and PDK1 expression in ovarian
   cancer tissues. Mechanistically, TRPM7 silencing significantly increased
   AMPK phosphorylation and decreased HIF-1 alpha protein levels in ovarian
   cancer, particularly in HIF-1 alpha silencing cells. The shifting from
   glycolysis to OXPHOS by TRPM7 silencing was abrogated by HIF-1 alpha
   over-expression and impaired by inhibiting AMPK activity in ovarian
   cancer cells. Moreover, enhanced AMPK activation inhibited glycolysis,
   which was abrogated by HIF-1 alpha over-expression in ovarian cancer
   cells. Moreover, the enhanced AMPK activation promoted HIF-1 alpha
   ubiquitination degradation.
   Conclusions: TRPM7 silencing enhanced AMPK activation to shift
   glycolysis to oxidative phosphorylation by promoting HIF-1 alpha
   ubiquitination degradation in ovarian cancer. Hence, TRPM7 may be a
   therapeutic target for intervention of ovarian cancer.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Liao, QJ; Wang, J (Corresponding Author), Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Clin Res Ctr Gynecol Canc,Hunan Key Lab Can, Changsha 410013, Hunan, Peoples R China.
   Liao, QJ; Wang, J (Corresponding Author), Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp, Changsha 410013, Hunan, Peoples R China.
   Chen, Yongchang; Liu, Lu; Xia, Longzheng; Wu, Nayiyuan; Wang, Ying; Li, He; Chen, Xue; Zhang, Xiaoye; Liu, Zhaoyi; Zhu, Miaochen; Liao, Qianjin; Wang, Jing, Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Clin Res Ctr Gynecol Canc,Hunan Key Lab Can, Changsha 410013, Hunan, Peoples R China.
   Chen, Yongchang; Liu, Lu; Xia, Longzheng; Wu, Nayiyuan; Wang, Ying; Li, He; Chen, Xue; Zhang, Xiaoye; Liu, Zhaoyi; Zhu, Miaochen; Liao, Qianjin; Wang, Jing, Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp, Changsha 410013, Hunan, Peoples R China.
   Chen, Yongchang; Zhu, Miaochen, Univ South China, Hengyang 421001, Hunan, Peoples R China.},
DOI = {10.1186/s13046-022-02252-1},
Article-Number = {44},
EISSN = {1756-9966},
Keywords = {TRPM7; AMPK; HIF-1 alpha; Glycolysis; Oxidative phosphorylation;
   Ubiquitination; Ovarian cancer},
Keywords-Plus = {CELL-GROWTH; GLYCOLYSIS; TUMORIGENESIS; PROGRESSION; EXPRESSION;
   APOPTOSIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {march-on@126.com
   wangjing0081@hnca.org.cn},
Affiliations = {Central South University; Central South University; University of South
   China},
ResearcherID-Numbers = {Li, He/JOZ-2852-2023},
ORCID-Numbers = {Li, He/0009-0004-2806-0512},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81972836]; Hunan
   Provincial Natural Science Foundation -Science and health joint project
   {[}2018JJ6027]; Key R\&D Project of Hunan Provincial Department of
   Science and Technology {[}2020SK2120]},
Funding-Text = {This study was supported by grants from National Natural Science
   Foundation of China (81972836) and Hunan Provincial Natural Science
   Foundation -Science and health joint project (2018JJ6027) and Key R\&D
   Project of Hunan Provincial Department of Science and Technology
   (2020SK2120).},
Cited-References = {Akimoto R, 2020, CELL SIGNAL, V71, DOI 10.1016/j.cellsig.2020.109618.
   Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3.
   Amin RW, 2019, SCI TOTAL ENVIRON, V697, DOI 10.1016/j.scitotenv.2019.134128.
   Chauhan AS, 2019, FASEB J, V33, P2957, DOI 10.1096/fj.201801225R.
   Chen M, 2019, THERANOSTICS, V9, P676, DOI 10.7150/thno.30224.
   Cuzzocrea S, 2000, AM J RESP CRIT CARE, V162, P1859, DOI 10.1164/ajrccm.162.5.9912125.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   Deng L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0107-0.
   Feng HR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03111-7.
   Foth M, 2018, J PATHOL, V246, P331, DOI 10.1002/path.5143.
   GUPPY M, 1993, EUR J BIOCHEM, V212, P95, DOI 10.1111/j.1432-1033.1993.tb17637.x.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hsieh YH, 2012, INT J CANCER, V131, P322, DOI 10.1002/ijc.26359.
   Hu T, 2020, THERANOSTICS, V10, P4056, DOI 10.7150/thno.40860.
   Hu YQ, 2021, AUTOPHAGY, V17, P1142, DOI 10.1080/15548627.2020.1749490.
   Huang HZ, 2020, MOLECULES, V25, DOI 10.3390/molecules25071579.
   Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81.
   Jia DY, 2019, P NATL ACAD SCI USA, V116, P3909, DOI 10.1073/pnas.1816391116.
   Jin K, 2020, FASEB J, V34, P7036, DOI 10.1096/fj.201901900R.
   Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82.
   Li S, 2019, MOL CELL, V74, P1123, DOI 10.1016/j.molcel.2019.04.003.
   Li T, 2019, PROTEIN CELL, V10, P583, DOI 10.1007/s13238-019-0618-z.
   Li YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070752.
   Lim Y, 1999, TOXICOL LETT, V108, P335, DOI 10.1016/S0378-4274(99)00107-1.
   Liu HR, 2020, CANCERS, V12, DOI 10.3390/cancers12010131.
   Liu L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1061-y.
   Ma HH, 2020, CELL REP, V30, P4235, DOI 10.1016/j.celrep.2020.03.005.
   Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005.
   Madhu V, 2020, J BONE MINER RES, V35, P1504, DOI 10.1002/jbmr.4019.
   Maeding N, 2016, CANCERS, V8, DOI 10.3390/cancers8100091.
   Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024.
   Moldogazieva NT, 2020, CANCERS, V12, DOI 10.3390/cancers12040862.
   Murata Y, 2018, BIOCHEM BIOPH RES CO, V495, P2566, DOI 10.1016/j.bbrc.2017.12.141.
   Penfold L, 2018, CANCER RES, V78, P6747, DOI 10.1158/0008-5472.CAN-18-0585.
   Qiao W, 2019, J DENT RES, V98, P304, DOI 10.1177/0022034518813359.
   Salminen A, 2016, BIOGERONTOLOGY, V17, P655, DOI 10.1007/s10522-016-9655-7.
   Salvemini D, 2001, BRIT J PHARMACOL, V132, P815, DOI 10.1038/sj.bjp.0703841.
   Katz ISS, 2016, DNA REPAIR, V37, P43, DOI 10.1016/j.dnarep.2015.11.006.
   Sfakianaki M, 2019, ANN ONCOL, V30, DOI 10.1093/annonc/mdz155.080.
   Shang Y, 2017, ONCOGENE, V36, P4191, DOI 10.1038/onc.2017.31.
   Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456.
   Torresano L, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165721.
   Tyszka-Czochara M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070841.
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039.
   Wang J, 2014, BIOCHEM BIOPH RES CO, V454, P547, DOI 10.1016/j.bbrc.2014.10.118.
   Wang J, 2014, ASIAN PAC J CANCER P, V15, P3955, DOI 10.7314/APJCP.2014.15.9.3955.
   Xiao M, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0528-y.
   Yamamoto K, 2020, CANCER RES, V80, P2087, DOI 10.1158/0008-5472.CAN-19-0928.
   Yang F, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6724810.
   Yang YC, 2018, CANCER LETT, V421, P28, DOI 10.1016/j.canlet.2018.01.075.
   Yano N, 2020, AM J PHYSIOL-ENDOC M, V318, pE791, DOI 10.1152/ajpendo.00219.2019.
   Yi Y, 2020, P NATL ACAD SCI USA, V117, P8013, DOI 10.1073/pnas.1914786117.
   Yu LL, 2017, CANCER RES, V77, P1564, DOI 10.1158/0008-5472.CAN-16-2074.
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159.
   Zhang S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14999-2.
   Zhang Z, 2020, J IMMUNOL, V204, P2575, DOI 10.4049/jimmunol.1901213.
   Zhao QY, 2020, CELL, V183, P76, DOI 10.1016/j.cell.2020.08.009.
   Zhao XL, 2018, CHEM-BIOL INTERACT, V290, P57, DOI 10.1016/j.cbi.2018.05.011.},
Number-of-Cited-References = {58},
Times-Cited = {67},
Usage-Count-Last-180-days = {8},
Usage-Count-Since-2013 = {55},
Journal-ISO = {J. Exp. Clin. Cancer Res.},
Doc-Delivery-Number = {YS2JJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000750508600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000748423300001,
Author = {Li, Yankang and Shen, Yue and Xie, Mengyu and Wang, Bowen and Wang, Teng
   and Zeng, Jiajia and Hua, Hui and Yu, Jinming and Yang, Ming},
Title = {LncRNAs LCETRL3 and LCETRL4 at chromosome 4q12 diminish
   EGFR-TKIs efficiency in NSCLC through stabilizing TDP43 and EIF2S1},
Journal = {SIGNAL TRANSDUCTION AND TARGETED THERAPY},
Year = {2022},
Volume = {7},
Number = {1},
Month = {JAN 31},
Abstract = {Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors
   (TKIs) are effective targeted therapy drugs for advanced non-small cell
   lung cancer (NSCLC) patients carrying sensitized EGFR mutations. The
   rapid development of EGFR-TKIs resistance represents a major clinical
   challenge for managing NSCLC. The chromosome 4q12 is the first
   genome-wide association study (GWAS)-reported locus associated with
   progression-free survival (PFS) of NSCLC patients treated with
   EGFR-TKIs. However, the biological significance of the noncoding
   transcripts at 4q12 in NSCLC remains elusive. In the present study, we
   identified two 4q12 long noncoding RNAs (lncRNAs) LCETRL3 and LCETRL4
   which could significantly dimmish EGFR-TKIs efficiency. In line with
   their oncogenic role, evidently higher LCETRL3 and LCETRL4 levels were
   observed in NSCLC tissues as compared with normal specimens.
   Importantly, lncRNA LCETRL3 can interact with oncoprotein TDP43 and
   inhibit ubiquitination and degradation of TDP43. Similarly, lncRNA
   LCETRL4 can bind and stabilize oncoprotein EIF2S1 through reducing
   ubiquitin-proteasome degradation of EIF2S1. In particular, elevated
   levels of LCETRL3 or LCETRL4 in NSCLC cells resulted in stabilization of
   TDP43 or EIF2S1, increased levels of NOTCH1 or phosphorylated PDK1,
   activated AKT signaling and, thus, EGFR-TKIs resistance. Taken together,
   our data revealed a novel model that integrates two lncRNAs transcribed
   from the 4q12 locus into the regulation of EGFR-TKIs resistance in
   NSCLC. These findings shed new light on the importance of functionally
   annotating lncRNAs in the GWAS loci and provided insights to declare
   novel druggable targets, i.e., lncRNAs, which may unlock the therapeutic
   potential of EGFR-TKIs resistant NSCLC in the clinic.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, M (Corresponding Author), Shandong Univ, Cheeloo Coll Med, Jinan 250112, Shandong, Peoples R China.
   Yang, M (Corresponding Author), Shandong Canc Hosp \& Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan 250117, Shandong, Peoples R China.
   Yu, JM; Yang, M (Corresponding Author), Shandong Univ Canc Ctr, Jinan 250117, Shandong, Peoples R China.
   Yu, JM (Corresponding Author), Shandong First Med Univ, Shandong Canc Hosp \& Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China.
   Yu, JM (Corresponding Author), Shandong Acad Med Sci, Jinan 250117, Shandong, Peoples R China.
   Li, Yankang; Shen, Yue; Xie, Mengyu; Wang, Bowen; Wang, Teng; Yang, Ming, Shandong Univ, Cheeloo Coll Med, Jinan 250112, Shandong, Peoples R China.
   Zeng, Jiajia; Hua, Hui; Yang, Ming, Shandong Canc Hosp \& Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan 250117, Shandong, Peoples R China.
   Yu, Jinming; Yang, Ming, Shandong Univ Canc Ctr, Jinan 250117, Shandong, Peoples R China.
   Yu, Jinming, Shandong First Med Univ, Shandong Canc Hosp \& Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China.
   Yu, Jinming, Shandong Acad Med Sci, Jinan 250117, Shandong, Peoples R China.},
DOI = {10.1038/s41392-021-00847-2},
Article-Number = {30},
ISSN = {2095-9907},
EISSN = {2059-3635},
Keywords-Plus = {CELL LUNG-CANCER; NEUROMEDIN-U; PHASE-III; TDP-43; RESISTANCE; SURVIVAL;
   ONCOGENE; PROMOTES; METASTASIS; GEFITINIB},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {sdyujinming@126.com
   aaryoung@yeah.net},
Affiliations = {Shandong University; Shandong First Medical University \& Shandong
   Academy of Medical Sciences; Shandong First Medical University \&
   Shandong Academy of Medical Sciences; University of Jinan; Shandong
   First Medical University \& Shandong Academy of Medical Sciences},
ResearcherID-Numbers = {li, yangkang/HTN-2471-2023
   Yang, Ming/G-4705-2012},
ORCID-Numbers = {Yang, Ming/0000-0003-0310-5839},
Funding-Acknowledgement = {Taishan Scholars Program of Shandong Province {[}tsqn20161060]; National
   Natural Science Foundation of China {[}82173070, 31871306]; Natural
   Science Foundation of Shandong Province {[}ZR2021LZL004]; Program of
   Science and Technology for the youth innovation team in universities of
   Shandong Province {[}2020KJL001]},
Funding-Text = {This work was supported by Taishan Scholars Program of Shandong Province
   (tsqn20161060) (to M.Y.); National Natural Science Foundation of China
   (82173070 and 31871306) (to M.Y.); Natural Science Foundation of
   Shandong Province (ZR2021LZL004) (to M.Y.); Program of Science and
   Technology for the youth innovation team in universities of Shandong
   Province (2020KJL001) (to M.Y.).},
Cited-References = {Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99.
   Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025.
   Chang IS, 2017, AM J RESP CRIT CARE, V195, P663, DOI 10.1164/rccm.201602-0300OC.
   Chen C, 2020, CANCER LETT, V486, P58, DOI 10.1016/j.canlet.2020.05.009.
   Chen X, 2021, NAT REV CANCER, V21, P71, DOI 10.1038/s41568-020-00312-2.
   Chen XW, 2018, PROTEIN CELL, V9, P848, DOI 10.1007/s13238-017-0480-9.
   Dong SY, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0140-6.
   Dunker W, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108976.
   Eliasz S, 2010, ONCOGENE, V29, P2488, DOI 10.1038/onc.2010.7.
   Evans JR, 2016, J CLIN INVEST, V126, P2775, DOI 10.1172/JCI84421.
   Graziani I, 2008, CANCER RES, V68, P9678, DOI 10.1158/0008-5472.CAN-08-0969.
   Guo FX, 2020, AM J CANCER RES, V10, P3285.
   Guo FJ, 2015, BIOCHEM BIOPH RES CO, V465, P293, DOI 10.1016/j.bbrc.2015.08.027.
   He J, 2019, J CANCER, V10, P6003, DOI 10.7150/jca.35097.
   Hebron ML, 2013, J BIOL CHEM, V288, P4103, DOI 10.1074/jbc.M112.419945.
   Hetz C, 2019, NAT CHEM BIOL, V15, P764, DOI 10.1038/s41589-019-0326-2.
   Hosomi Y, 2020, J CLIN ONCOL, V38, P115, DOI 10.1200/JCO.19.01488.
   Huang JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2683-x.
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981.
   Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115.
   King AP, 2020, CHEM SOC REV, V49, P8113, DOI 10.1039/d0cs00259c.
   Li J, 2018, DNA CELL BIOL, V37, P903, DOI 10.1089/dna.2018.4337.
   Li YK, 2020, CARCINOGENESIS, V41, P1195, DOI 10.1093/carcin/bgaa069.
   Lin TW, 2017, ONCOTARGET, V8, P56612, DOI 10.18632/oncotarget.17979.
   Modic M, 2019, MOL CELL, V74, P951, DOI 10.1016/j.molcel.2019.03.041.
   Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713.
   Nishino K, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0776-5.
   Noronha V, 2020, J CLIN ONCOL, V38, P124, DOI 10.1200/JCO.19.01154.
   Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636.
   Pan WT, 2018, J BIOL CHEM, V293, P17154, DOI 10.1074/jbc.RA118.003055.
   Scheuner D, 2005, NAT MED, V11, P757, DOI 10.1038/nm1259.
   Scotter EL, 2014, J CELL SCI, V127, P1263, DOI 10.1242/jcs.140087.
   Seyfried NT, 2010, MOL CELL PROTEOMICS, V9, P705, DOI 10.1074/mcp.M800390-MCP200.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Takahashi K, 2006, CANCER RES, V66, P9408, DOI 10.1158/0008-5472.CAN-06-1349.
   Takahashi S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084005.
   Tian BQ, 2021, ONCOGENE, V40, P3734, DOI 10.1038/s41388-021-01809-2.
   Wang Q, 2020, LUNG CANCER, V147, P99, DOI 10.1016/j.lungcan.2020.06.037.
   Wu Y, 2007, ONCOGENE, V26, P765, DOI 10.1038/sj.onc.1209835.
   Wu YL, 2017, LUNG CANCER, V104, P119, DOI 10.1016/j.lungcan.2016.11.022.
   Xing Z, 2018, CANCER RES, V78, P4524, DOI 10.1158/0008-5472.CAN-17-0385.
   Xing Z, 2014, CELL, V159, P1110, DOI 10.1016/j.cell.2014.10.013.
   Yuan JP, 2020, ONCOGENE, V39, P6664, DOI 10.1038/s41388-020-01460-3.
   Yung HW, 2012, J PATHOL, V228, P554, DOI 10.1002/path.4068.
   Zeng QH, 2017, CANCER BIOL THER, V18, P8, DOI 10.1080/15384047.2016.1250984.
   Zhang NS, 2020, THERANOSTICS, V10, P9378, DOI 10.7150/thno.48247.
   Zhang NS, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113772.
   Zhang NS, 2019, LAB INVEST, V99, P568, DOI 10.1038/s41374-018-0164-y.
   Zhang YY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00492-9.
   Zhou C, 2015, ANN ONCOL, V26, P1877, DOI 10.1093/annonc/mdv276.
   Zhou JY, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114558.},
Number-of-Cited-References = {51},
Times-Cited = {31},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Signal Transduct. Target. Ther.},
Doc-Delivery-Number = {YP1YJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000748423300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000746511200001,
Author = {Wu, Kaiming and Wang, Ziao and Huang, Yunlong and Yao, Long and Kang,
   Ningning and Ge, Wei and Zhang, Renquan and He, Wei},
Title = {LncRNA PTPRG-AS1 facilitates glycolysis and stemness properties of
   esophageal squamous cell carcinoma cells through miR-599/PDK1 axis},
Journal = {JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY},
Year = {2022},
Volume = {37},
Number = {3},
Pages = {507-517},
Month = {MAR},
Abstract = {Background and Aim Esophageal squamous cell carcinoma (ESCC) is the most
   significant subtype of esophageal cancer featured with high occurrence.
   Long noncoding RNAs (lncRNAs) have been proved to modulate the
   biological properties of cancer cells, including cell proliferation,
   invasion, migration, and apoptosis. LncRNA protein tyrosine phosphatase
   receptor type G-antisense RNA 1 (PTPRG-AS1) has been reported to play as
   an oncogene in diverse cancers. However, the detailed function PTPRG-AS1
   may exert in ESCC is unclear. Methods PTPRG-AS1 expression in ESCC cells
   was investigated via quantitative reverse transcription real-time
   polymerase chain reaction (RT-qPCR). The effects of PTPRG-AS1 on ESCC
   cell proliferation, migration, glycolysis, and stemness were verified
   through functional assays. Mechanism assays including RIP assay, RNA
   pull down assay, and luciferase reporter assays were performed to verify
   the molecular mechanism of PTPRG-AS1. Results PTPRG-AS1 silencing
   hindered the proliferation, migration, glycolysis and stemness of ESCC
   cells. PTPRG-AS1 regulated pyruvate dehydrogenase kinase 1 (PDK1)
   expression via sponging miR-599. The PTPRG-AS1/miR-599/PDK1 axis was
   further verified to aggravate the progression of ESCC cells. Conclusion
   PTPRG-AS1 sponged miR-599 to up-regulate PDK1 expression, thereby
   promoting the proliferation and migration as well as glycolysis and
   stemness properties of ESCC cells.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, RQ (Corresponding Author), Anhui Med Univ, Affiliated Hosp 1, Dept Thorac Surg, 218 Ji Xi Rd, Hefei 230000, Anhui, Peoples R China.
   He, W (Corresponding Author), Anhui Med Univ, Sch Basic Med Sci, 81 Mei Shan Rd, Hefei 230032, Anhui, Peoples R China.
   Wu, Kaiming; Wang, Ziao; Huang, Yunlong; Yao, Long; Kang, Ningning; Ge, Wei; Zhang, Renquan, Anhui Med Univ, Affiliated Hosp 1, Dept Thorac Surg, 218 Ji Xi Rd, Hefei 230000, Anhui, Peoples R China.
   He, Wei, Anhui Med Univ, Sch Basic Med Sci, 81 Mei Shan Rd, Hefei 230032, Anhui, Peoples R China.},
DOI = {10.1111/jgh.15719},
EarlyAccessDate = {JAN 2022},
ISSN = {0815-9319},
EISSN = {1440-1746},
Keywords = {Esophageal squamous cell carcinoma; Glycolysis; miR-599; PDK1; PTPRG-AS1},
Keywords-Plus = {CANCER; PROLIFERATION; PROGRESSION; CERNA},
Research-Areas = {Gastroenterology \& Hepatology},
Web-of-Science-Categories  = {Gastroenterology \& Hepatology},
Author-Email = {zhangrenquan@live.cn
   weine@ahmu.edu.cn},
Affiliations = {Anhui Medical University; Anhui Medical University},
ORCID-Numbers = {Zhang, Renquan/0009-0001-5840-3529},
Funding-Acknowledgement = {Key Clinical Departments of the 12th Five Year Plan of Anhui Health and
   Family Planning Commission {[}None] Funding Source: Medline},
Cited-References = {Arnold M, 2015, GUT, V64, P381, DOI 10.1136/gutjnl-2014-308124.
   Baylin SB, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a019505.
   Chang ZW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0724-4.
   Chen XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0962-6.
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152.
   Tallón AIG, 2012, MED CLIN-BARCELONA, V139, P588, DOI 10.1016/j.medcli.2012.05.024.
   Hu HB, 2018, EUR REV MED PHARMACO, V22, P1987, DOI 10.26355/eurrev\_201804\_14726.
   Iranpour M, 2016, TUMOR BIOL, V37, P2933, DOI 10.1007/s13277-015-4135-2.
   Jalali S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053823.
   Kang M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0845-9.
   Li BG, 2018, LIFE SCI, V197, P122, DOI 10.1016/j.lfs.2018.02.006.
   Li X, 2018, INT J ONCOL, V53, P551, DOI 10.3892/ijo.2018.4418.
   Li Y, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/5314649.
   Liang HH, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0870-5.
   Liang Y, 2018, CELL DEATH DIFFER, V25, P1980, DOI 10.1038/s41418-018-0084-9.
   Liu H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0950-9.
   Liu YN, 2016, BIOINFORMATICS, V32, P1595, DOI 10.1093/bioinformatics/btw017.
   Ma F, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0630-1.
   Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6.
   Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334.
   Qian HY, 2018, J MOL MED, V96, P753, DOI 10.1007/s00109-018-1654-5.
   Reid TD, 2012, CLIN ONCOL-UK, V24, P617, DOI 10.1016/j.clon.2012.02.001.
   Renganathan A, 2017, ADV EXP MED BIOL, V1008, P199, DOI 10.1007/978-981-10-5203-3\_7.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Sugiura K, 2019, AM J PATHOL, V189, P1863, DOI 10.1016/j.ajpath.2019.05.014.
   Wang J, 2020, INT J CANCER, V146, P906, DOI 10.1002/ijc.32277.
   Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0.
   Wei W, 2017, J CELL BIOCHEM, V118, P3349, DOI 10.1002/jcb.25988.
   Wu YY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0715-7.
   Yi L, 2019, J CELL PHYSIOL, V234, P19088, DOI 10.1002/jcp.28547.
   Yu J, 2019, MOL MED REP, V19, P5309, DOI 10.3892/mmr.2019.10213.
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7.
   Zhao LJ, 2017, CANCER RES, V77, P1369, DOI 10.1158/0008-5472.CAN-16-1615.
   Zhu H, 2018, BIOMED PHARMACOTHER, V105, P789, DOI 10.1016/j.biopha.2018.05.053.},
Number-of-Cited-References = {38},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {17},
Journal-ISO = {J. Gastroenterol. Hepatol.},
Doc-Delivery-Number = {ZO6GA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000746511200001},
DA = {2026-02-04},
}

@article{ WOS:000745491000001,
Author = {Yang, Xiao and Cheng, Yuan and Zhou, Jingyi and Zhang, Lingpu and Li,
   Xingchen and Wang, Zhiqi and Yin, Shenyi and Zhai, LiRong and Huang,
   Ting and Wu, Xiaotong and Shen, Boqiang and Dong, Yangyang and Zhao,
   Lijun and Chi, Yujing and Jia, Yuanyuan and Wang, Jiaqi and He, Yijiao
   and Dong, Xiying and Xiao, Haihua and Wang, Jianliu},
Title = {Targeting Cancer Metabolism Plasticity with JX06 Nanoparticles via
   Inhibiting PDK1 Combined with Metformin for Endometrial Cancer Patients
   with Diabetes},
Journal = {ADVANCED SCIENCE},
Year = {2022},
Volume = {9},
Number = {8},
Month = {MAR},
Abstract = {Diabetes is closely related to the occurrence of endometrial cancer (EC)
   and its poor prognosis. However, there is no effective clinical
   treatment for EC patients with diabetes (patient(EC+/dia+)). To explore
   new therapeutic targets, Ishikawa is cultured with high glucose
   (Ishikawa(HG)) mimicking hyperglycemia in patient(EC+/dia+).
   Subsequently, it is discovered that Ishikawa(HG) exhibits glucose
   metabolic reprogramming characterized by increased glycolysis and
   decreased oxidative phosphorylation. Further, pyruvate dehydrogenase
   kinase 1 (PDK1) is identified to promote glycolysis of Ishikawa(HG) by
   proteomics. Most importantly, JX06, a novel PDK1 inhibitor combined
   metformin (Met) significantly inhibits Ishikawa(HG) proliferation though
   Ishikawa(HG) is resistant to Met. Furthermore, a reduction-sensitive
   biodegradable polymer is adopted to encapsulate JX06 to form
   nanoparticles (JX06-NPs) for drug delivery. It is found that in vitro
   JX06-NPs have better inhibitory effect on the growth of Ishikawa(HG) as
   well as patient-derived EC cells (PDC) than JX06. Additionally, it is
   found that JX06-NPs can accumulate to the tumor of EC-bearing mouse with
   diabetes (mice(EC+/dia+)) after intravenous injection, and JX06-NPs
   combined Met can significantly inhibit tumor growth of mice(EC+/dia+).
   Taken together, the study demonstrates that the combination of JX06-NPs
   and Met can target the cancer metabolism plasticity, which significantly
   inhibits the growth of EC, thereby provides a new adjuvant therapy for
   patients(EC+/dia+).},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, JL (Corresponding Author), Peking Univ, Peoples Hosp, Dept Obstet \& Gynecol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   Xiao, HH (Corresponding Author), Chinese Acad Sci, Inst Chem, State Key Lab Polymer Phys \& Chem, Beijing Natl Lab Mol Sci, Beijing 100190, Peoples R China.
   Yang, Xiao; Cheng, Yuan; Zhou, Jingyi; Li, Xingchen; Wang, Zhiqi; Zhai, LiRong; Huang, Ting; Wu, Xiaotong; Shen, Boqiang; Dong, Yangyang; Zhao, Lijun; Jia, Yuanyuan; Wang, Jiaqi; He, Yijiao; Wang, Jianliu, Peking Univ, Peoples Hosp, Dept Obstet \& Gynecol, 11 Xizhimen South St, Beijing 100044, Peoples R China.
   Zhang, Lingpu; Xiao, Haihua, Chinese Acad Sci, Inst Chem, State Key Lab Polymer Phys \& Chem, Beijing Natl Lab Mol Sci, Beijing 100190, Peoples R China.
   Yin, Shenyi, Peking Univ, Coll Future Technol, Beijing 100871, Peoples R China.
   Chi, Yujing, Peking Univ, Peoples Hosp, Dept Cent Lab, Beijing 100044, Peoples R China.
   Chi, Yujing, Peking Univ, Peoples Hosp, Inst Clin Mol Biol, Beijing 100044, Peoples R China.
   Dong, Xiying, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing 100730, Peoples R China.
   Dong, Xiying, Chinese Acad Med Sci, Beijing 100730, Peoples R China.},
DOI = {10.1002/advs.202104472},
EarlyAccessDate = {JAN 2022},
Article-Number = {2104472},
EISSN = {2198-3844},
Keywords = {cell metabolic reprogramming; diabetes; endometrial cancer; high
   glucose; metformin; PDK1},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE; CELLS; MELLITUS; HYPERGLYCEMIA; MORTALITY;
   INVASION; RISK; EMT},
Research-Areas = {Chemistry; Science \& Technology - Other Topics; Materials Science},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary; Nanoscience \& Nanotechnology; Materials
   Science, Multidisciplinary},
Author-Email = {hhxiao@iccas.ac.cn
   wangjianliu@pkuph.edu.cn},
Affiliations = {Peking University; Chinese Academy of Sciences; Institute of Chemistry,
   CAS; Peking University; Peking University; Peking University; Chinese
   Academy of Medical Sciences - Peking Union Medical College; Peking Union
   Medical College; Peking Union Medical College Hospital; Chinese Academy
   of Medical Sciences - Peking Union Medical College},
ResearcherID-Numbers = {wu, xiaotong/HLG-4513-2023
   Yin, shenyi/KEI-6067-2024
   王, 志/JLL-9604-2023},
ORCID-Numbers = {Zhai, Lirong/0000-0002-5917-4289
   },
Funding-Acknowledgement = {National Key Technology R\&D Program of China {[}2019YFC1005200,
   2019YFC1005201]; National Natural Science Foundation of China
   {[}82072861, 81672571, 81874108]; Natural Science Foundation of Beijing
   {[}7202213]},
Funding-Text = {This work was supported by National Key Technology R\&D Program of China
   (Program Nos. 2019YFC1005200 and 2019YFC1005201), The National Natural
   Science Foundation of China (Grant Nos. 82072861, 81672571, and
   81874108), and Natural Science Foundation of Beijing (Grant No.
   7202213).},
Cited-References = {Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8.
   Antognelli C, 2018, J CELL MOL MED, V22, P2865, DOI 10.1111/jcmm.13581.
   Ariaans G, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3230-8.
   Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824.
   Becker Susen, 2009, Archives of Physiology and Biochemistry, V115, P86, DOI 10.1080/13813450902878054.
   Bosse T, 2015, EUR J CANCER, V51, P1742, DOI 10.1016/j.ejca.2015.05.015.
   Cai DG, 2016, INT J GYNECOL CANCER, V26, P1667, DOI 10.1097/IGC.0000000000000818.
   Chen K, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0701-0.
   Chen Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201802228.
   Dai XM, 2021, MOL ONCOL, V15, P228, DOI 10.1002/1878-0261.12838.
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447.
   Detappe A, 2019, NANOSCALE, V11, P20485, DOI 10.1039/c9nr06512a.
   DeWaal D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02733-4.
   Esposito K, 2014, ENDOCRINE, V45, P28, DOI 10.1007/s12020-013-9973-3.
   Fontaine E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00753.
   Friberg E, 2007, DIABETOLOGIA, V50, P1365, DOI 10.1007/s00125-007-0681-5.
   Gao S, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0648-4.
   García-Jiménez C, 2014, J MOL ENDOCRINOL, V52, pR51, DOI 10.1530/JME-13-0152.
   Han JJ, 2015, GYNECOL ONCOL, V138, P668, DOI 10.1016/j.ygyno.2015.06.036.
   Hui Y, 2019, ACS NANO, V13, P7410, DOI 10.1021/acsnano.9b03924.
   Kamarudin MNA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1495-2.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Karki N, 2020, CHEM-BIOL INTERACT, V327, DOI 10.1016/j.cbi.2020.109142.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Lee M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20167386.
   Lin JX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1416-4.
   Meireles CG, 2017, GYNECOL ONCOL, V147, P167, DOI 10.1016/j.ygyno.2017.07.120.
   Mitra A, 2013, TRENDS BIOTECHNOL, V31, P347, DOI 10.1016/j.tibtech.2013.03.006.
   Mookerjee SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152016.
   Nimmakayala RK, 2021, ONCOGENE, V40, P215, DOI 10.1038/s41388-020-01518-2.
   Onyido EK, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0541-3.
   Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Samuel SM, 2019, CANCERS, V11, DOI 10.3390/cancers11111737.
   Sheikh MA, 2014, FUTURE ONCOL, V10, P2561, DOI 10.2217/fon.14.192.
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590.
   Sivalingam VN, 2020, BRIT J CANCER, V122, P62, DOI 10.1038/s41416-019-0627-y.
   Stålberg K, 2019, ACTA ONCOL, V58, P1628, DOI 10.1080/0284186X.2019.1643036.
   Sun DX, 2020, ACS NANO, V14, P12281, DOI 10.1021/acsnano.9b09713.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Thakur S, 2018, CLIN CANCER RES, V24, P4030, DOI 10.1158/1078-0432.CCR-17-3167.
   Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242.
   Wu D, 2018, NATURE, V559, P637, DOI 10.1038/s41586-018-0350-5.
   Xu QJ, 2015, BREAST CANCER RES TR, V150, P43, DOI 10.1007/s10549-015-3304-8.
   Xu RH, 2005, CANCER RES, V65, P613.
   Yang X, 2019, MAT SCI ENG C-MATER, V96, P96, DOI 10.1016/j.msec.2018.10.092.
   Zhang ZH, 2013, INT J GYNECOL CANCER, V23, P294, DOI 10.1097/IGC.0b013e31827b8430.
   Zhao JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0629-4.
   Zhao Y, 2018, GYNECOL ENDOCRINOL, V34, P428, DOI 10.1080/09513590.2017.1409714.
   Zhu J, 2016, AM J TRANSL RES, V8, P4812.},
Number-of-Cited-References = {51},
Times-Cited = {39},
Usage-Count-Last-180-days = {9},
Usage-Count-Since-2013 = {90},
Journal-ISO = {Adv. Sci.},
Doc-Delivery-Number = {ZT0AK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000745491000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000791072800055,
Author = {Querfurth, Henry and Marshall, John and Parang, Keykavous and
   Rioult-Pedotti, Mengia S. and Tiwari, Rakesh and Kwon, Bumsup and
   Reisinger, Steve and Lee, Han-Kyu},
Title = {A PDK-1 allosteric agonist neutralizes insulin signaling derangements
   and beta-amyloid toxicity in neuronal cells and in vitro},
Journal = {PLOS ONE},
Year = {2022},
Volume = {17},
Number = {1},
Month = {JAN 21},
Abstract = {The Alzheimer's brain is affected by multiple pathophysiological
   processes, which include a unique, organ-specific form of insulin
   resistance that begins early in its course. An additional complexity
   arises from the four-fold risk of Alzheimer's Disease (AD) in type 2
   diabetics, however there is no definitive proof of causation. Several
   strategies to improve brain insulin signaling have been proposed and
   some have been clinically tested. We report findings on a small
   allosteric molecule that reverses several indices of insulin
   insensitivity in both cell culture and in vitro models of AD that
   emphasize the intracellular accumulation of beta-amyloid (A beta i).
   PS48, a chlorophenyl pentenoic acid, is an allosteric activator of
   PDK-1, which is an Akt-kinase in the insulin/PI3K pathway. PS48 was
   active at 10 nM to 1 mu M in restoring normal insulin-dependent Akt
   activation and in mitigating A beta i peptide toxicity. Synaptic
   plasticity (LTP) in prefrontal cortical slices from normal rat exposed
   to A beta oligomers also benefited from PS48. During these experiments,
   neither overstimulation of PI3K/Akt signaling nor toxic effects on cells
   was observed. Another neurotoxicity model producing insulin
   insensitivity, utilizing palmitic acid, also responded to PS48
   treatment, thus validating the target and indicating that its
   therapeutic potential may extend outside of beta-amyloid reliance. The
   described in vitro and cell based-in vitro coupled enzymatic assay
   systems proved suitable platforms to screen a preliminary library of new
   analogs.},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Article},
Language = {English},
Affiliation = {Querfurth, H (Corresponding Author), Tufts Med Ctr, Dept Neurol, Boston, MA USA.
   Querfurth, Henry; Lee, Han-Kyu, Tufts Med Ctr, Dept Neurol, Boston, MA USA.
   Marshall, John; Rioult-Pedotti, Mengia S., Brown Univ, Dept Mol Pharmacol Physiol \& Biotechnol, Providence, RI USA.
   Parang, Keykavous; Tiwari, Rakesh, Chapman Univ, Sch Pharmacol, Ctr Targeted Drug Delivery, Irvine, CA USA.
   Rioult-Pedotti, Mengia S., Univ Zurich, Dept Neurol, Clin Neurorehabilitat, Zurich, Switzerland.
   Kwon, Bumsup, Rhode Isl Hosp, Dept Neurol, Providence, RI USA.
   Reisinger, Steve, Med Chem Partners, Lexington, MA USA.},
DOI = {10.1371/journal.pone.0261696},
Article-Number = {e0261696},
ISSN = {1932-6203},
Keywords-Plus = {ELEMENT-BINDING PROTEIN; MILD COGNITIVE IMPAIRMENT; LONG-TERM-MEMORY;
   GLYCOGEN-SYNTHASE KINASE-3-BETA; ALZHEIMERS-DISEASE; INTRANASAL INSULIN;
   KINASE-B; PHOSPHATIDYLINOSITOL 3-KINASE; SYNAPTIC PLASTICITY;
   HUNTINGTONS-DISEASE},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {henry.querfurth@tufts.edu},
Affiliations = {Tufts Medical Center; Brown University; Chapman University System;
   Chapman University; University of Zurich; Lifespan Health Rhode Island;
   Rhode Island Hospital},
ResearcherID-Numbers = {Rioult-Pedotti, Mengia-Seraina/AAF-1377-2021},
ORCID-Numbers = {Lee, Han-Kyu/0000-0002-3787-7995
   },
Funding-Acknowledgement = {National Institute of Health, National Institute on Aging (NIA) {[}NIH
   AG044871-01]; Brown Institute for Brain Science; Bennett Foundation;
   Norman Prince Neuroscience Institute},
Funding-Text = {This study was funded by the National Institute of Health, National
   Institute on Aging (NIA): NIH AG044871-01 (HWQ), The Brown Institute for
   Brain Science and Norman Prince Neuroscience Institute (HWQ, JM), and
   through an award from the Bennett Foundation (HWQ). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.},
Cited-References = {Adamo B, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3071.
   Ahmad F, 2017, ANTIOXID REDOX SIGN, V27, P1269, DOI 10.1089/ars.2016.6860.
   Alberini CM, 2009, PHYSIOL REV, V89, P121, DOI 10.1152/physrev.00017.2008.
   Alonso M, 2002, CELL MOL NEUROBIOL, V22, P663, DOI 10.1023/A:1021848706159.
   Arnold SE, 2018, NAT REV NEUROL, V14, P168, DOI 10.1038/nrneurol.2017.185.
   Arnold SE, 2014, NEUROBIOL DIS, V67, P79, DOI 10.1016/j.nbd.2014.03.011.
   Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8.
   Barco A, 2011, MOL NEUROBIOL, V44, P330, DOI 10.1007/s12035-011-8209-x.
   Batista AF, 2018, J PATHOL, V245, P85, DOI 10.1002/path.5056.
   Benedict C, 2007, NEUROPSYCHOPHARMACOL, V32, P239, DOI 10.1038/sj.npp.1301193.
   Benito E, 2010, TRENDS NEUROSCI, V33, P230, DOI 10.1016/j.tins.2010.02.001.
   Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006.
   Bhaskar K, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-14.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Bomfim TR, 2012, J CLIN INVEST, V122, P1339, DOI 10.1172/JCI57256.
   Bondy CA, 2004, EUR J PHARMACOL, V490, P25, DOI 10.1016/j.ejphar.2004.02.042.
   Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358.
   Brami-Cherrier K, 2002, J NEUROSCI, V22, P8911.
   Brötz-Oesterhelt H, 2005, NAT MED, V11, P1082, DOI 10.1038/nm1306.
   Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7.
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4.
   Burns DK, 2021, LANCET NEUROL, V20, P537, DOI 10.1016/S1474-4422(21)00043-0.
   Caccamo A, 2011, J BIOL CHEM, V286, P8924, DOI 10.1074/jbc.M110.180638.
   Caccamo A, 2010, J BIOL CHEM, V285, P13107, DOI 10.1074/jbc.M110.100420.
   Cao B, 2018, DIABETES OBES METAB, V20, P2467, DOI 10.1111/dom.13373.
   Carlezon WA Jr, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005.
   Chen TJ, 2009, J NEUROSCI RES, V87, P2297, DOI 10.1002/jnr.22057.
   Chen YX, 2014, EXP NEUROL, V261, P610, DOI 10.1016/j.expneurol.2014.06.004.
   Chiang ACA, 2018, J EXP MED, V215, P1349, DOI 10.1084/jem.20171484.
   Colin E, 2005, EUR J NEUROSCI, V21, P1478, DOI 10.1111/j.1460-9568.2005.03985.x.
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164.
   Craft S, 2020, JAMA NEUROL, V77, P1099, DOI 10.1001/jamaneurol.2020.1840.
   Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233.
   De Felice FG, 2009, P NATL ACAD SCI USA, V106, P1971, DOI 10.1073/pnas.0809158106.
   de la Monte SM, 2008, ALCOHOL CLIN EXP RES, V32, P1630, DOI 10.1111/j.1530-0277.2008.00731.x.
   de la Monte SM, 2006, J ALZHEIMERS DIS, V10, P89.
   Dewachter I, 2009, NEUROBIOL DIS, V35, P193, DOI 10.1016/j.nbd.2009.04.003.
   Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951.
   Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377.
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661.
   Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296.
   Engel M, 2006, EMBO J, V25, P5469, DOI 10.1038/sj.emboj.7601416.
   Ezpeleta J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11333-3.
   Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100.
   Femminella GD, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3259-x.
   Ferreira LSS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00830.
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008.
   Geldmacher DS, 2011, ARCH NEUROL-CHICAGO, V68, P45, DOI 10.1001/archneurol.2010.229.
   Gold M, 2010, DEMENT GERIATR COGN, V30, P131, DOI 10.1159/000318845.
   Gouras GK, 2010, ACTA NEUROPATHOL, V119, P523, DOI 10.1007/s00401-010-0679-9.
   Griffin RJ, 2005, J NEUROCHEM, V93, P105, DOI 10.1111/j.1471-4159.2004.02949.x.
   Grillo CA, 2009, BRAIN RES, V1296, P35, DOI 10.1016/j.brainres.2009.08.005.
   Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471-4159.2001.00495.x.
   Grünblatt E, 2007, J NEUROCHEM, V101, P757, DOI 10.1111/j.1471-4159.2006.04368.x.
   Guo ZY, 2017, SCI REP-UK, V7, DOI 10.1038/srep45971.
   Guttuso T, 2019, J NEUROL SCI, V402, P121, DOI 10.1016/j.jns.2019.05.016.
   HANSEN PE, 1994, PHARMACOL TOXICOL, V75, P81, DOI 10.1111/j.1600-0773.1994.tb02005.x.
   Harrington C, 2011, CURR ALZHEIMER RES, V8, P592, DOI 10.2174/156720511796391935.
   Hernández F, 2002, J NEUROCHEM, V83, P1529, DOI 10.1046/j.1471-4159.2002.01269.x.
   Hetman M, 2000, J NEUROSCI, V20, P2567.
   Hindie V, 2009, NAT CHEM BIOL, V5, P758, DOI 10.1038/nchembio.208.
   Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje.
   Honig LS, 2018, NEW ENGL J MED, V378, P321, DOI 10.1056/NEJMoa1705971.
   Horike N, 2008, J BIOL CHEM, V283, P33902, DOI 10.1074/jbc.M802537200.
   Hoyer S, 2004, ADV EXP MED BIOL, V541, P135.
   Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0.
   Jimenez S, 2011, J BIOL CHEM, V286, P18414, DOI 10.1074/jbc.M110.209718.
   Jo J, 2011, NAT NEUROSCI, V14, P545, DOI 10.1038/nn.2785.
   Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001.
   Kapogiannis D, 2015, FASEB J, V29, P589, DOI 10.1096/fj.14-262048.
   Kawamata J, 2011, J ALZHEIMERS DIS, V24, P95, DOI 10.3233/JAD-2011-110173.
   Kennedy ME, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9704.
   Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200.
   Kimura N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040503.
   Kintscher U, 2008, J AM COLL CARDIOL, V52, P882, DOI 10.1016/j.jacc.2008.06.012.
   Klein WL, 2002, NEUROCHEM INT, V41, P345, DOI 10.1016/S0197-0186(02)00050-5.
   Knafo S, 2016, NAT NEUROSCI, V19, P443, DOI 10.1038/nn.4225.
   Lai WS, 2006, P NATL ACAD SCI USA, V103, P16906, DOI 10.1073/pnas.0604994103.
   Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448.
   Lee CC, 2005, J BIOL CHEM, V280, P18543, DOI 10.1074/jbc.M414112200.
   Lee HK, 2017, J ALZHEIMERS DIS, V56, P1015, DOI 10.3233/JAD-161029.
   Lee HK, 2009, MOL BIOL CELL, V20, P1533, DOI 10.1091/mbc.E08-07-0777.
   Leinninger GM, 2004, FASEB J, V18, P1544, DOI 10.1096/fj.04-1581fje.
   Lester-Coll N, 2006, J ALZHEIMERS DIS, V9, P13.
   Li XY, 2011, BIOCHEM BIOPH RES CO, V404, P711, DOI 10.1016/j.bbrc.2010.12.048.
   Liggett JL, 2014, CANCER LETT, V346, P217, DOI 10.1016/j.canlet.2014.01.021.
   Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0.
   Lisman J, 2018, NAT NEUROSCI, V21, P309, DOI {[}10.1038/S41593-018-0076-6, 10.1038/s41593-018-0076-6].
   Liu Y, 2011, J PATHOL, V225, P54, DOI 10.1002/path.2912.
   Lo Hui-Wen, 2010, Curr Mol Pharmacol, V3, P37.
   Lourenco MV, 2013, CELL METAB, V18, P831, DOI 10.1016/j.cmet.2013.11.002.
   Luchsinger JA, 2016, J ALZHEIMERS DIS, V51, P501, DOI 10.3233/JAD-150493.
   Lynch BA, 1997, ANAL BIOCHEM, V247, P77, DOI 10.1006/abio.1997.2042.
   Ma T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012845.
   Magrané J, 2005, J NEUROSCI, V25, P10960, DOI 10.1523/JNEUROSCI.1723-05.2005.
   Magrané J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004.
   Majumder S, 2012, AGING CELL, V11, P326, DOI 10.1111/j.1474-9726.2011.00791.x.
   Mao YF, 2016, AGING CELL, V15, P893, DOI 10.1111/acel.12498.
   Marshall J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11316-8.
   McClean PL, 2014, NEUROPHARMACOLOGY, V76, P57, DOI 10.1016/j.neuropharm.2013.08.005.
   McClean PL, 2011, J NEUROSCI, V31, P6587, DOI 10.1523/JNEUROSCI.0529-11.2011.
   Messier Claude, 2005, Neural Plasticity, V12, P311, DOI 10.1155/NP.2005.311.
   Miller BW, 2011, ANN PHARMACOTHER, V45, P1416, DOI 10.1345/aph.1Q238.
   Mintun MA, 2021, NEW ENGL J MED, V384, P1691, DOI 10.1056/NEJMoa2100708.
   Molina-Luna K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007082.
   Moloney AM, 2010, NEUROBIOL AGING, V31, P224, DOI 10.1016/j.neurobiolaging.2008.04.002.
   Muñoz-Jiménez M, 2021, DEMENT GERIATR COGN, V49, P423, DOI 10.1159/000510677.
   O'Neill C, 2012, BIOCHEM SOC T, V40, P721, DOI 10.1042/BST20120080.
   Ostrowitzki S, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0318-y.
   Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937.
   Pei JJ, 2003, ACTA NEUROPATHOL, V105, P381, DOI 10.1007/s00401-002-0657-y.
   Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506.
   Pen Y, 2016, HIPPOCAMPUS, V26, P1149, DOI 10.1002/hipo.22597.
   Perluigi M, 2014, BBA-MOL BASIS DIS, V1842, P1144, DOI 10.1016/j.bbadis.2014.04.007.
   Pietri M, 2013, NAT MED, V19, P1124, DOI 10.1038/nm.3302.
   Pizzorusso T, 2000, J NEUROSCI, V20, P2809.
   Pugazhenthi S, 1999, J BIOL CHEM, V274, P2829, DOI 10.1074/jbc.274.5.2829.
   Rajasekar N, 2017, MOL NEUROBIOL, V54, P6507, DOI 10.1007/s12035-016-0169-8.
   Reger MA, 2006, NEUROBIOL AGING, V27, P451, DOI 10.1016/j.neurobiolaging.2005.03.016.
   Relkin NR, 2017, NEUROLOGY, V88, P1768, DOI 10.1212/WNL.0000000000003904.
   Restivo L, 2009, HIPPOCAMPUS, V19, P228, DOI 10.1002/hipo.20527.
   Rickle A, 2004, NEUROREPORT, V15, P955, DOI 10.1097/00001756-200404290-00005.
   Risner ME, 2006, PHARMACOGENOMICS J, V6, P246, DOI 10.1038/sj.tpj.6500369.
   Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934.
   Salloway S, 2014, NEW ENGL J MED, V370, P322, DOI 10.1056/NEJMoa1304839.
   Sato T, 2011, NEUROBIOL AGING, V32, P1626, DOI 10.1016/j.neurobiolaging.2009.10.009.
   Saunders AM, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.666958.
   Schubert M, 2003, J NEUROSCI, V23, P7084, DOI 10.1523/JNEUROSCI.23-18-07084.2003.
   Sekar S, 2018, NEUROSCI LETT, V666, P139, DOI 10.1016/j.neulet.2017.12.049.
   Sekeres MJ, 2010, LEARN MEMORY, V17, P280, DOI 10.1101/lm.1785510.
   Shi Q, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024954.
   Shimohama S, 2001, BIOL PSYCHIAT, V49, P233, DOI 10.1016/S0006-3223(00)01100-8.
   Simon D, 2014, NEUROPATH APPL NEURO, V40, P311, DOI 10.1111/nan.12066.
   Sluggett JK, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz234.
   Steen E, 2005, J ALZHEIMERS DIS, V7, P63, DOI 10.3233/jad-2005-7107.
   Stroba A, 2009, J MED CHEM, V52, P4683, DOI 10.1021/jm9001499.
   Suhara T, 2003, NEUROBIOL AGING, V24, P437, DOI 10.1016/S0197-4580(02)00135-5.
   Talbot K, 2012, J CLIN INVEST, V122, P1316, DOI 10.1172/JCI59903.
   Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7.
   Tiwari R, 2010, BIOCHIMIE, V92, P1153, DOI 10.1016/j.biochi.2010.01.017.
   Tolar M, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00663-w.
   Townsend M, 2007, J BIOL CHEM, V282, P33305, DOI 10.1074/jbc.M610390200.
   Tramutola A, 2015, J NEUROCHEM, V133, P739, DOI 10.1111/jnc.13037.
   Uemura E, 2006, EXP NEUROL, V198, P48, DOI 10.1016/j.expneurol.2005.10.035.
   Ugi S, 2004, MOL CELL BIOL, V24, P8778, DOI 10.1128/MCB.24.19.8778-8789.2004.
   van der Heide LP, 2005, J NEUROCHEM, V94, P1158, DOI 10.1111/j.1471-4159.2005.03269.x.
   Vargas-Soria M, 2021, ALZHEIMERS RES THER, V13, DOI 10.1186/s13195-021-00853-0.
   Walton M, 1999, J NEUROCHEM, V73, P1836.
   Wisniewski H M, 1995, Neuroimaging Clin N Am, V5, P45.
   Xie L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-10-j0001.2002.
   Xu XY, 2019, J ENZYM INHIB MED CH, V34, P361, DOI 10.1080/14756366.2018.1553167.
   Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870.
   Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4.
   Yarchoan M, 2014, ACTA NEUROPATHOL, V128, P679, DOI 10.1007/s00401-014-1328-5.
   Yi JH, 2018, NEUROPHARMACOLOGY, V128, P282, DOI 10.1016/j.neuropharm.2017.10.028.
   Yu WF, 2011, J NEUROCHEM, V119, P848, DOI 10.1111/j.1471-4159.2011.07466.x.
   Yuan HH, 2015, MOL NEUROBIOL, V51, P512, DOI 10.1007/s12035-014-8717-6.
   Zhang B, 2016, DRUG DES DEV THER, V10, P1335, DOI 10.2147/DDDT.S99958.
   Zhao LX, 2004, J NEUROSCI, V24, P11120, DOI 10.1523/JNEUROSCI.2860-04.2004.
   Zhao WQ, 2008, FASEB J, V22, P246, DOI 10.1096/fj.06-7703com.
   Zhao WQ, 2009, BBA-MOL BASIS DIS, V1792, P482, DOI 10.1016/j.bbadis.2008.10.014.
   Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200.
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015.
   Zorn JA, 2010, NAT CHEM BIOL, V6, P179, DOI 10.1038/NCHEMBIO.318.},
Number-of-Cited-References = {167},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {PLoS One},
Doc-Delivery-Number = {0Z4TQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000791072800055},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000788156500002,
Author = {Peng, Fen and Zhao, Siqi and Zhang, Xuan and Long, Siyu and He, Yanling},
Title = {Calcitonin gene-related peptide upregulates IL-17A and IL-22 in γδ-T
   cells through the paracrine effect of langerhans cells on LC/γδ-T
   co-culture model},
Journal = {JOURNAL OF NEUROIMMUNOLOGY},
Year = {2022},
Volume = {364},
Month = {MAR 15},
Abstract = {Intense mental stimulation and stress often directly induce or
   exacerbate psoriasis. On the contrary, patients with nerve injury and
   nervous system dysfunction have psoriasis remission. The nervous system
   plays an important role in the inflammatory process of psoriasis, and
   neuropeptides are considered as local mediators of disease maintenance.
   To examine the molecular mechanism involved in this, first we analyzed
   calcitonin gene-related peptide (CGRP)-treated langerhans Cells and
   gamma delta-T cells separately. CGRP induced IL-23 mRNA and protein
   expression via PDK1-Rsk signaling pathway. However, CGRP had no effect
   on secretion of IL-17A and IL-22 in gamma delta-T cells. Then we treated
   LCs/gamma delta-T cells Co-culture Model with CGRP. CGRP upregulated
   IL-17A and IL-22 expression in co-culture model through the paracrine
   effect of LCs. IL-17A and IL-22 are key cytokines of psoriasis. These
   findings provide a potential mechanism by which nerve factors affect the
   development of psoriasis.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {He, YL (Corresponding Author), Capital Med Univ, Beijing Chao Yang Hosp, Natl Clin Res Ctr Skin \& Immune Dis, Dept Dermatol, Beijing, Peoples R China.
   Peng, Fen; Zhao, Siqi; Zhang, Xuan; Long, Siyu; He, Yanling, Capital Med Univ, Beijing Chao Yang Hosp, Natl Clin Res Ctr Skin \& Immune Dis, Dept Dermatol, Beijing, Peoples R China.},
DOI = {10.1016/j.jneuroim.2021.577792},
EarlyAccessDate = {JAN 2022},
Article-Number = {577792},
ISSN = {0165-5728},
EISSN = {1872-8421},
Keywords = {Peptide; IL-17A; IL-22; Psoriasis; Nerve-immunological mechanism},
Keywords-Plus = {ENDOTHELIAL GROWTH-FACTOR; DENDRITIC CELL; SKIN; PSORIASIS;
   DIFFERENTIATION; ACTIVATION; ERK1/2; CGRP; INTERLEUKIN-23; PROLIFERATION},
Research-Areas = {Immunology; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Immunology; Neurosciences},
Author-Email = {heyanling@ccmu.edu.cn},
Affiliations = {Capital Medical University},
Funding-Acknowledgement = {National Natural Science Founda-tion of China {[}81773314]},
Funding-Text = {Funding sources This study was supported by the National Natural Science
   Founda-tion of China (Grant No. 81773314) .},
Cited-References = {Almarestani L, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-56.
   Asarch A, 2008, J DERMATOL TREAT, V19, P318, DOI 10.1080/09546630802206660.
   Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Boniface K, 2008, IMMUNOL REV, V226, P132, DOI 10.1111/j.1600-065X.2008.00714.x.
   Bonner K, 2013, J ALLERGY CLIN IMMUN, V132, P942, DOI 10.1016/j.jaci.2013.04.015.
   Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001.
   Choi JE, 2018, SEMIN IMMUNOPATHOL, V40, P249, DOI 10.1007/s00281-018-0675-z.
   Dainichi T, 2016, CELL REP, V15, P1615, DOI 10.1016/j.celrep.2016.04.051.
   Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59.
   Di Meglio P, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015354.
   Ding WH, 2008, J IMMUNOL, V181, P6020, DOI 10.4049/jimmunol.181.9.6020.
   Ding WH, 2007, J INVEST DERMATOL, V127, P2357, DOI 10.1038/sj.jid.5700858.
   Ding WH, 2016, J IMMUNOL, V196, P2181, DOI 10.4049/jimmunol.1500303.
   Dong J, 2010, PEPTIDES, V31, P1860, DOI 10.1016/j.peptides.2010.07.007.
   Fehres CM, 2017, CELL MOL IMMUNOL, V14, P360, DOI 10.1038/cmi.2015.87.
   Ganor Y, 2013, J EXP MED, V210, P2161, DOI 10.1084/jem.20122349.
   Granstein RD, 2015, ACTA PHYSIOL, V213, P586, DOI 10.1111/apha.12442.
   Guo R, 2015, PHARMAZIE, V70, P88, DOI 10.1691/ph.2015.4722.
   HANAU D, 1988, J INVEST DERMATOL, V91, P274, DOI 10.1111/1523-1747.ep12470445.
   Holtmeier V, 2001, J INVEST DERMATOL, V116, P275, DOI 10.1046/j.1523-1747.2001.01250.x.
   HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0.
   Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201.
   Jiang WY, 1998, INT J DERMATOL, V37, P572, DOI 10.1046/j.1365-4362.1998.00533.x.
   Kay AB, 2011, J ALLERGY CLIN IMMUN, V127, P232, DOI 10.1016/j.jaci.2010.10.028.
   Kondo M, 2008, CYTOTHERAPY, V10, P842, DOI 10.1080/14653240802419328.
   Kondo M, 2011, JOVE-J VIS EXP, DOI 10.3791/3182.
   Kopp T, 2015, NATURE, V521, P222, DOI 10.1038/nature14175.
   Laura M., CELLS-BASEL, V10, P2636.
   Lee E, 2004, J EXP MED, V199, P125, DOI 10.1084/jem.20030451.
   Mapp PI, 2012, BRIT J PHARMACOL, V166, P1261, DOI 10.1111/j.1476-5381.2012.01848.x.
   Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414.
   Mikami N, 2011, J IMMUNOL, V186, P6886, DOI 10.4049/jimmunol.1100028.
   Ostrowski SM, 2011, J INVEST DERMATOL, V131, P1530, DOI 10.1038/jid.2011.60.
   Padro CJ, 2014, SEMIN IMMUNOL, V26, P357, DOI 10.1016/j.smim.2014.01.003.
   Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862.
   Qi C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627139.
   Qin B, 2021, J DERMATOL SCI, V102, P85, DOI 10.1016/j.jdermsci.2021.02.006.
   Reich A, 2007, EXP DERMATOL, V16, P421, DOI 10.1111/j.1600-0625.2007.00544.x.
   ROSENFELD MG, 1983, NATURE, V304, P129, DOI 10.1038/304129a0.
   Shi XY, 2013, REGUL PEPTIDES, V186, P92, DOI 10.1016/j.regpep.2013.08.001.
   Shimada S, 2015, SURG TODAY, V45, P892, DOI 10.1007/s00595-014-1064-4.
   Snast I, 2018, BRIT J DERMATOL, V178, P1044, DOI 10.1111/bjd.16116.
   Steele H.R., P NATL ACAD SCI USA, V2021, P118.
   Stewart TJ, 2018, INT J DERMATOL, V57, P1275, DOI 10.1111/ijd.13956.
   Talme T, 2008, J NEUROIMMUNOL, V196, P60, DOI 10.1016/j.jneuroim.2008.02.007.
   Woo YR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197041.
   Yamanaka K, 2021, J DERMATOL, V48, P722, DOI 10.1111/1346-8138.15913.
   Yoshiki R, 2014, J INVEST DERMATOL, V134, P1912, DOI 10.1038/jid.2014.98.
   Yu XJ, 2006, REGUL PEPTIDES, V137, P134, DOI 10.1016/j.regpep.2006.07.001.
   Zaru R, 2015, J IMMUNOL, V195, P4264, DOI 10.4049/jimmunol.1501520.
   Zhang X, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01984.
   Zhu TH, 2016, AM J CLIN DERMATOL, V17, P257, DOI 10.1007/s40257-016-0183-7.},
Number-of-Cited-References = {52},
Times-Cited = {4},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {8},
Journal-ISO = {J. Neuroimmunol.},
Doc-Delivery-Number = {0V2EI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000788156500002},
DA = {2026-02-04},
}

@article{ WOS:000756285900001,
Author = {Liu, Kun and Liu, Qiannan and Sun, Yanli and Fan, Jinwei and Zhang, Yu
   and Sakamoto, Norihiro and Kuno, Takayoshi and Fang, Yue},
Title = {Phosphoinositide-Dependent Protein Kinases Regulate Cell Cycle
   Progression Through the SAD Kinase Cdr2 in Fission Yeast},
Journal = {FRONTIERS IN MICROBIOLOGY},
Year = {2022},
Volume = {12},
Month = {JAN 10},
Abstract = {Aberration in the control of cell cycle contributes to the development
   and progression of many diseases including cancers. Ksg1 is a
   Schizosaccharomyces pombe fission yeast homolog of mammalian
   phosphoinositide-dependent protein kinase 1 (PDK1) which is regarded as
   a signaling hub for human tumorigenesis. A previous study reported that
   Ksg1 plays an important role in cell cycle progression, however, the
   underlying mechanism remains elusive. Our genomic library screen for
   novel elements involved in Ksg1 function identified two serine/threonine
   kinases, namely SAD family kinase Cdr2 and another PDK1 homolog Ppk21,
   as multicopy suppressors of the thermosensitive phenotype of ksg1-208
   mutant. We found that overexpression of Ppk21 or Cdr2 recovered the
   defective cell cycle transition of ksg1-208 mutant. In addition,
   ksg1-208 Delta ppk21 cells showed more marked defects in cell cycle
   transition than each single mutant. Moreover, overexpression of Ppk21
   failed to recover the thermosensitive phenotype of the ksg1-208 mutant
   when Cdr2 was lacking. Notably, the ksg1-208 mutation resulted in
   abnormal subcellular localization and decreased abundance of Cdr2, and
   Ppk21 deletion exacerbated the decreased abundance of Cdr2 in the
   ksg1-208 mutant. Intriguingly, expression of a mitotic inducer Cdc25 was
   significantly decreased in ksg1-208, Delta ppk21, or Delta cdr2 cells,
   and overexpression of Ppk21 or Cdr2 partially recovered the decreased
   protein level of Cdc25 in the ksg1-208 mutant. Altogether, our findings
   indicated that Cdr2 is a novel downstream effector of PDK1 homologs Ksg1
   and Ppk21, both of which cooperatively participate in regulating cell
   cycle progression, and Cdc25 is involved in this process in fission
   yeast.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Fang, Y (Corresponding Author), China Med Univ, Sch Pharm, Dept Microbial \& Biochem Pharm, Shenyang, Peoples R China.
   Liu, Kun; Liu, Qiannan; Sun, Yanli; Fan, Jinwei; Zhang, Yu; Kuno, Takayoshi; Fang, Yue, China Med Univ, Sch Pharm, Dept Microbial \& Biochem Pharm, Shenyang, Peoples R China.
   Sakamoto, Norihiro; Kuno, Takayoshi, Kobe Univ, Grad Sch Med, Div Food \& Drug Evaluat Sci, Kobe, Hyogo, Japan.},
DOI = {10.3389/fmicb.2021.807148},
Article-Number = {807148},
EISSN = {1664-302X},
Keywords = {Schizosaccharomyces pombe; Ksg1; Ppk21; Cdr2; Cdc25; cell cycle
   regulation},
Keywords-Plus = {SCHIZOSACCHAROMYCES-POMBE GENE; MITOTIC INDUCER; PDK1; MITOSIS; GROWTH;
   ACTIVATION; DIVISION; CDC25; SIZE; EXPRESSION},
Research-Areas = {Microbiology},
Web-of-Science-Categories  = {Microbiology},
Author-Email = {yfang@cmu.edu.cn},
Affiliations = {China Medical University; Kobe University},
Funding-Acknowledgement = {Natural Science Foundation of Liaoning Province, China {[}2019-MS-384];
   Innovative Talents Support Program in University of Liaoning Province in
   2020; Doctoral Start-up Foundation of Liaoning Province, China
   {[}2020-BS-096]},
Funding-Text = {Funding This work was supported by grants from the Natural Science
   Foundation of Liaoning Province, China (No. 2019-MS-384) and the
   Innovative Talents Support Program in University of Liaoning Province in
   2020 to YF. This work was also supported by research fund from Doctoral
   Start-up Foundation of Liaoning Province, China (No. 2020-BS-096) to QL.
   The funders had no role in study design, data collection, and
   interpretation, or the decision to submit the work for publication.},
Cited-References = {Abbastabar M, 2018, DNA REPAIR, V69, P63, DOI 10.1016/j.dnarep.2018.07.008.
   Akamatsu M, 2014, J CELL BIOL, V204, P977, DOI 10.1083/jcb.201307174.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Allard CAH, 2018, J CELL BIOL, V217, P1589, DOI 10.1083/jcb.201709171.
   Bai XF, 2016, TUMOR BIOL, V37, P2333, DOI 10.1007/s13277-015-4024-8.
   BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138.
   Bimbó A, 2005, MOL BIOL CELL, V16, P3162, DOI 10.1091/mbc.E04-09-0769.
   Bimbó A, 2005, EUKARYOT CELL, V4, P799, DOI 10.1128/EC.4.4.799-813.2005.
   Breeding CS, 1998, MOL BIOL CELL, V9, P3399, DOI 10.1091/mbc.9.12.3399.
   Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8.
   Crump JG, 2001, NEURON, V29, P115, DOI 10.1016/S0896-6273(01)00184-2.
   Deng L, 2014, CURR BIOL, V24, P428, DOI 10.1016/j.cub.2014.01.009.
   Facchetti G, 2019, CURR BIOL, V29, P350, DOI 10.1016/j.cub.2018.12.017.
   Fang Y, 2008, MOL BIOL CELL, V19, P1295, DOI 10.1091/mbc.E07-08-0805.
   Forsburg Susan L, 2005, Gravit Space Biol Bull, V18, P3.
   Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Glover DM, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120023.
   Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774.
   Jiang GL, 2021, MOL MICROBIOL, V115, P1323, DOI 10.1111/mmi.14678.
   Jiang QW, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01397-5.
   Kanoh J, 1998, MOL BIOL CELL, V9, P3321, DOI 10.1091/mbc.9.12.3321.
   Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002.
   Keifenheim D, 2017, CURR BIOL, V27, P1491, DOI 10.1016/j.cub.2017.04.016.
   Kim DU, 2010, NAT BIOTECHNOL, V28, P617, DOI 10.1038/nbt.1628.
   Kita A, 2004, MOL BIOL CELL, V15, P2920, DOI 10.1091/mbc.E03-09-0659.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   Liu QN, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.00079-20.
   Liu QN, 2018, ANTIMICROB AGENTS CH, V62, DOI {[}10.1128/AAC.00860-18, 10.1128/aac.00860-18].
   Madrid M, 2015, J CELL SCI, V128, P266, DOI 10.1242/jcs.158295.
   Martin SG, 2009, NATURE, V459, P852, DOI 10.1038/nature08054.
   Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298.
   MITCHISON JM, 1985, J CELL SCI, V75, P357.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   MORENO S, 1991, METHOD ENZYMOL, V194, P795.
   Moseley JB, 2009, NATURE, V459, P857, DOI 10.1038/nature08074.
   Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955.
   Opalko HE, 2019, MOL BIOL CELL, V30, P3015, DOI 10.1091/mbc.E19-08-0430.
   Pietri M, 2013, NAT MED, V19, P1124, DOI 10.1038/nm.3302.
   Rincon SA, 2017, CURR BIOL, V27, P534, DOI 10.1016/j.cub.2016.12.050.
   ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202.
   RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5.
   RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2.
   Scotchman E, 2021, J CELL SCI, V134, DOI 10.1242/jcs.251769.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Tang Y, 2004, GENETICS, V168, P1843, DOI 10.1534/genetics.104.032466.
   Toda T, 1996, MOL CELL BIOL, V16, P6752.
   Vyas A., 2021, CURR PROTOC, V1, P1.
   Wang JR, 2016, ONCOTARGETS THER, V9, P5597, DOI 10.2147/OTT.S110646.
   Willet AH, 2019, CURR BIOL, V29, P1055, DOI 10.1016/j.cub.2019.01.075.
   WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0.
   YOUNG PG, 1987, J CELL SCI, V88, P295.
   Zabkiewicz J, 2014, HAEMATOLOGICA, V99, P858, DOI 10.3324/haematol.2013.096487.
   Zheng K, 2019, THERANOSTICS, V9, P104, DOI 10.7150/thno.30308.},
Number-of-Cited-References = {56},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Front. Microbiol.},
Doc-Delivery-Number = {ZA6QL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000756285900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000740209200001,
Author = {Zuo, Bo and Wu, Na and Yang, Shen and Zhong, Zhaohui and Li, Mei and Yu,
   Xin and Liu, Yulan and Yu, Weidong},
Title = {G-protein coupled receptor 34 regulates the proliferation and growth of
   LS174T cells through differential expression of PI3K subunits and PTEN},
Journal = {MOLECULAR BIOLOGY REPORTS},
Year = {2022},
Volume = {49},
Number = {4},
Pages = {2629-2639},
Month = {APR},
Abstract = {Purpose G-protein coupled receptor (GPR 34) has been found to play
   important roles in some cancers and regulates the proliferation,
   apoptosis, and migration of these cancer cells. However, the mechanisms
   underlying how GPR34 functions to regulate growth and proliferation of
   colorectal cancer cells remains to be clarified. Methods We employed
   stable GPR34 knockdown LS174T cell models, GPR34 Mab blocking, a CCK-8
   kit, and a colony formation assay to characterize the effect of GPR34 on
   the proliferation of LS174T in vitro and xenograft tumor growth in vivo.
   The mRNA level of GPR34 was detected by RT-PCR in tumor tissues and
   adjacent normal tissues from 34 CRC patients. Results Based on RT-PCR
   results, GPR34 exhibited high level in tumor samples compared with
   adjacent normal samples. Increased expression of GPR34 is more
   associated with poor prognosis of CRC as shown in The Cancer Genome
   Atlas (TCGA) dataset by Kaplan-Meier survival analysis. Furthermore, we
   showed that GPR34 knockdown inhibited the proliferation of LS174T colon
   cancer cells and related xenograft tumor growth. Searching for the
   distinct molecular mechanism, we identified several contributors to
   proliferation of LS174T colon cancer cells: PI3K subunits/PTEN,
   PDK1/AKT, and Src/Raf/Ras/ERK. GPR34 knockdown inhibited the
   proliferation of LS174T cells by upregulating expression of PTEN, and
   downregulating expression of PI3K subunits p110-beta. Conclusion Our
   findings provide direct evidence that GPR34 regulates the proliferation
   of LS174T cells and the growth of LS174T tumor xenografts by regulating
   different pathways. High expression of GPR34 mRNA could then be used to
   predict poor prognosis of CRC.},
Publisher = {SPRINGER},
Address = {VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Yu, WD (Corresponding Author), Peking Univ, Dept Cent Lab, Peoples Hosp, Beijing 100044, Peoples R China.
   Yu, WD (Corresponding Author), Peking Univ, Inst Clin Mol Biol, Peoples Hosp, Beijing 100044, Peoples R China.
   Zuo, Bo; Wu, Na; Li, Mei; Yu, Weidong, Peking Univ, Dept Cent Lab, Peoples Hosp, Beijing 100044, Peoples R China.
   Zuo, Bo; Wu, Na; Li, Mei; Yu, Weidong, Peking Univ, Inst Clin Mol Biol, Peoples Hosp, Beijing 100044, Peoples R China.
   Yang, Shen; Zhong, Zhaohui, Peking Univ, Dept Gen Surg, Peoples Hosp, Beijing 100044, Peoples R China.
   Yu, Xin, Peking Univ, Dept Hepatobiliary Surg, Peoples Hosp, Beijing 100044, Peoples R China.
   Liu, Yulan, Peking Univ, Dept Gastroenterol, Peoples Hosp, Beijing 100044, Peoples R China.},
DOI = {10.1007/s11033-021-07068-4},
EarlyAccessDate = {JAN 2022},
ISSN = {0301-4851},
EISSN = {1573-4978},
Keywords = {GPR34; Proliferation; Xenograft tumor growth; PI3K subunits; Colorectal
   cancer},
Keywords-Plus = {UP-REGULATION; CANCER CELLS; GPR34; PATHWAY; MIGRATION; LYMPHOMA;
   ANALOGS},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {weidongyu@bjmu.edu.cn},
Affiliations = {Peking University; Peking University; Peking University; Peking
   University; Peking University},
ORCID-Numbers = {Yu, Weidong/0000-0002-7573-4979},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}30872923, 81672853,
   32070116, 31500098, 82000328]; Peking University People's Hospital
   Research and Development Foundation; RDB {[}2020-11]},
Funding-Text = {This study was supported by grant from the National Natural Science
   Foundation of China (Nos. 30872923, 81672853, 32070116, 31500098,
   82000328) and Peking University People's Hospital Research and
   Development Foundation (No. RDB 2020-11).},
Cited-References = {Ansell SM, 2012, BLOOD, V120, P3949, DOI 10.1182/blood-2011-11-389908.
   Baens M, 2012, HAEMATOL-HEMATOL J, V97, P184, DOI 10.3324/haematol.2011.052639.
   Barreto-Chang Odmara L, 2009, J Vis Exp, DOI 10.3791/1067.
   Bénistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871.
   Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998.
   Danciu TE, 2003, FEBS LETT, V536, P193, DOI 10.1016/S0014-5793(03)00055-3.
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008.
   Feng Z, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017645118.
   Gao Y, 2006, CANCER RES, V66, P11623, DOI 10.1158/0008-5472.CAN-06-2629.
   Ge Q, 2012, J CELL PHYSIOL, V227, P3044, DOI 10.1002/jcp.23046.
   Iida Y, 2015, ANTICANCER RES, V35, P1459.
   Iida Y, 2014, ANTICANCER RES, V34, P5465.
   Ikubo M, 2015, J MED CHEM, V58, P4204, DOI 10.1021/jm5020082.
   Jin ZT, 2015, CHINESE MED J-PEKING, V128, P545, DOI 10.4103/0366-6999.151114.
   Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016.
   Molinari Francesca, 2013, Front Oncol, V3, P326, DOI 10.3389/fonc.2013.00326.
   New DC, 2007, FEBS J, V274, P6025, DOI 10.1111/j.1742-4658.2007.06116.x.
   Ohori H, 2006, MOL CANCER THER, V5, P2563, DOI 10.1158/1535-7163.MCT-06-0174.
   Qin Y, 2011, PIGM CELL MELANOMA R, V24, P207, DOI 10.1111/j.1755-148X.2010.00781.x.
   Schöneberg T, 2018, PHARMACOL THERAPEUT, V189, P71, DOI 10.1016/j.pharmthera.2018.04.008.
   Siegel R. L., 2017, CA Cancer J Clin, V67, P30, DOI {[}10.3322/caac.21387, DOI 10.3322/CAAC.21387].
   Spicer LJ, 2017, DOMEST ANIM ENDOCRIN, V59, P90, DOI 10.1016/j.domaniend.2016.12.002.
   Tan YJ, 2021, ENVIRON TOXICOL PHAR, V81, DOI 10.1016/j.etap.2020.103514.
   Tang SY, 2007, PEPTIDES, V28, P708, DOI 10.1016/j.peptides.2006.10.005.
   Vermani L, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.12020.
   Wang XQ, 2021, IMMUNITY, V54, P1123, DOI 10.1016/j.immuni.2021.05.007.
   Yang R, 2018, IMMUNOLOGY, V155, P263, DOI 10.1111/imm.12949.
   Yu WD, 2014, WORLD J GASTROENTERO, V20, P16258, DOI 10.3748/wjg.v20.i43.16258.
   Yu WD, 2013, HISTOL HISTOPATHOL, V28, P1629, DOI 10.14670/HH-28.1629.
   Zuo B, 2015, LEUKEMIA LYMPHOMA, V56, P2170, DOI 10.3109/10428194.2014.981177.},
Number-of-Cited-References = {30},
Times-Cited = {8},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Mol. Biol. Rep.},
Doc-Delivery-Number = {ZU1IJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000740209200001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000746476500006,
Author = {Chen, Mengyuan and Liu, Maozhu and Luo, Ying and Cao, Jun and Zeng,
   Fanning and Yang, Lu and Yang, Junqing and Tao, Tao and Jiang, Yu},
Title = {Celastrol Protects against Cerebral Ischemia/Reperfusion Injury in Mice
   by Inhibiting Glycolysis through Targeting HIF-1α/PDK1 Axis},
Journal = {OXIDATIVE MEDICINE AND CELLULAR LONGEVITY},
Year = {2022},
Volume = {2022},
Month = {JAN 5},
Abstract = {Cerebral ischemia/reperfusion (I/R) injury is closely related to
   dysfunctional glucose metabolism. Celastrol is a bioactive compound that
   has been found to exhibit neuroprotective effects in cerebral ischemia,
   while whether it can protect against cerebral I/R injury by regulating
   glycolysis remains unclear. The goal of this study is to investigate the
   role of celastrol on cerebral I/R injury and its underlying mechanisms
   in transient middle cerebral artery occlusion (tMCAO) mice. Methods. To
   observe the protective effect of celastrol and select its optimal dosage
   for further study, neurological score, TTC staining, and HE staining
   were used to evaluate neurological function, cerebral infarct volume,
   and cortical cell damage, respectively. QRT-PCR and Western blot were
   used to detect the mRNA and protein expression of hypoxia inducible
   factor-1 alpha (HIF-1 alpha), pyruvate dehydrogenasekinase1 (PDK1),
   lactate dehydrogenase A (LDHA), glucose transporter1 (GLUT1), and
   hexokinase2 (HK2), respectively. The lactate production, ATP level, and
   glucose content were assessed by assay kits. Results. Our results
   indicated that celastrol dose-dependently improved neurological function
   and reduced cerebral infarct volume and cortical cell death of tMCAO
   mice, and its optimal dosage was 4.5 mg/kg. In addition, celastrol
   significantly blocked I/R-induced increase of LDHA, GLUT1, HK2, and
   lactate production as well as decrease of ATP level and glucose content.
   Moreover, celastrol inhibited the I/R-induced upregulation of HIF-1
   alpha and PDK1. Overexpression of HIF-1 alpha by DMOG reversed the
   protective effect of celastrol on cerebral I/R injury and blocked
   celastrol-induced suppression of glycolysis. Conclusions. Taken
   together, these results suggested that celastrol protected against
   cerebral I/R injury through inhibiting glycolysis via the HIF-1
   alpha/PDK1 axis.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Tao, T (Corresponding Author), Cent Peoples Hosp Zhanjiang, Dept Anaesthesiol, 236 Yuanzhu Rd, Zhanjiang 524045, Guangdong, Peoples R China.
   Yang, JQ (Corresponding Author), Chongqing Med Univ, Coll Pharm, Chongqing Key Lab Biochem \& Mol Pharmacol, Chongqing 400016, Peoples R China.
   Jiang, Y (Corresponding Author), Southern Med Univ, Nanfang Hosp, Dept Anaesthesiol, Guangzhou 510515, Guangdong, Peoples R China.
   Chen, Mengyuan; Liu, Maozhu; Tao, Tao, Cent Peoples Hosp Zhanjiang, Dept Anaesthesiol, 236 Yuanzhu Rd, Zhanjiang 524045, Guangdong, Peoples R China.
   Chen, Mengyuan; Liu, Maozhu; Luo, Ying; Yang, Junqing, Chongqing Med Univ, Coll Pharm, Chongqing Key Lab Biochem \& Mol Pharmacol, Chongqing 400016, Peoples R China.
   Cao, Jun; Zeng, Fanning; Yang, Lu; Jiang, Yu, Southern Med Univ, Nanfang Hosp, Dept Anaesthesiol, Guangzhou 510515, Guangdong, Peoples R China.},
DOI = {10.1155/2022/7420507},
Article-Number = {7420507},
ISSN = {1942-0900},
EISSN = {1942-0994},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; ISCHEMIA; STROKE; AUTOPHAGY; PATHWAY;
   DISEASE; GLUCOSE; OBESITY; CELLS; MODEL},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {cmy116165@126.com
   maozhu2021@126.com
   100894@cqmu.edu.cn
   21700283@i.smu.edu.cn
   eleven\_zeng@163.com
   2965046417@qq.com
   cqyangjq@cqmu.edu.cn
   taotaomzk@smu.edu.cn
   jiangyu\_00@163.com},
Affiliations = {Chongqing Medical University; Southern Medical University - China},
ResearcherID-Numbers = {Tao, Tao/S-6992-2016
   Yang, Lunan/JZE-0790-2024
   luo, ying/HJP-8548-2023
   liu, maozhu/JAC-2519-2023},
ORCID-Numbers = {Cao, Jun/0000-0002-3899-4878
   Tao, Tao/0000-0002-6348-719X
   },
Funding-Acknowledgement = {Natural Science Foundation of Guangdong Province, China
   {[}2021A1515010897]; Discipline Construction Fund of Central People's
   Hospital of Zhanjiang {[}2020A01, 2020A02]},
Funding-Text = {The authors were supported in part by grants from the Natural Science
   Foundation of Guangdong Province, China (2021A1515010897), and the
   Discipline Construction Fund of Central People's Hospital of Zhanjiang
   (2020A01 and 2020A02).},
Cited-References = {Anderson CS, 2016, NEW ENGL J MED, V374, P2313, DOI 10.1056/NEJMoa1515510.
   Avan A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1397-3.
   Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI {[}10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746].
   Burmistrova O, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48196-z.
   Cai L, 2016, NEUROSCIENCE, V318, P45, DOI 10.1016/j.neuroscience.2016.01.010.
   Cao J, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5524705.
   Chen SF, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00601-9.
   Choi BS, 2014, NEUROCHEM RES, V39, P84, DOI 10.1007/s11064-013-1193-y.
   Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5.
   Fang PH, 2019, BBA-MOL BASIS DIS, V1865, P1341, DOI 10.1016/j.bbadis.2019.02.002.
   Feigin VL, 2017, LANCET NEUROL, V16, P877, DOI 10.1016/S1474-4422(17)30299-5.
   Guo SC, 2021, BRAIN RES, V1763, DOI 10.1016/j.brainres.2021.147463.
   Ham PB, 2017, PROG NEUROBIOL, V157, P92, DOI 10.1016/j.pneurobio.2016.06.006.
   Hong DK, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00137.
   Hou W, 2020, EUR J MED CHEM, V189, DOI 10.1016/j.ejmech.2020.112081.
   Hou Y, 2019, DRUG DES DEV THER, V13, P1135, DOI 10.2147/DDDT.S194182.
   Jiang M, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1124-6.
   Kadri S, 2021, BIOMED PHARMACOTHER, V136, DOI 10.1016/j.biopha.2021.111282.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kloska A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103618.
   L Lin, 2016, Biochem Pharmacol (Los Angel), V5, DOI {[}10.4172/2167-0501.1000213, 10.4172/2167-0501.1000213].
   Lee J, 2016, NAT MED, V22, P1023, DOI 10.1038/nm.4145.
   Li GQ, 2013, INT IMMUNOPHARMACOL, V17, P1028, DOI 10.1016/j.intimp.2013.10.006.
   Li Tan, 2021, Onco Targets Ther, V14, P2379, DOI {[}10.2147/ott.s297140, 10.2147/OTT.S297140].
   Li YH, 2012, BRAIN RES, V1464, P8, DOI 10.1016/j.brainres.2012.04.054.
   Liu JL, 2015, CELL, V161, P999, DOI 10.1016/j.cell.2015.05.011.
   Luo C, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00197.
   Ma J, 2014, ONCOL REP, V32, P235, DOI 10.3892/or.2014.3211.
   Ma LP, 2020, J GENE MED, V22, DOI 10.1002/jgm.3201.
   Ma XR, 2015, CELL METAB, V22, P695, DOI 10.1016/j.cmet.2015.08.005.
   Reimann S, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0284-5.
   Robbins NM, 2014, STROKE, V45, P1881, DOI 10.1161/STROKEAHA.114.004889.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Salminen A, 2010, BIOCHEM BIOPH RES CO, V394, P439, DOI 10.1016/j.bbrc.2010.03.050.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Shen YF, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00288.
   Veerappan K, 2017, PHARM BIOL, V55, P368, DOI 10.1080/13880209.2016.1241809.
   Vojinovic D, 2021, NEUROLOGY, V96, pE1110, DOI 10.1212/WNL.0000000000011236.
   Wang HJ, 2020, PHYTOMEDICINE, V78, DOI 10.1016/j.phymed.2020.153300.
   Wang SD, 2021, NEUROCHEM RES, V46, P866, DOI 10.1007/s11064-020-03219-4.
   Wang X, 2019, STROKE, V50, P1869, DOI 10.1161/STROKEAHA.119.024564.
   Zeng ML, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111771.
   Zeng ML, 2021, J ETHNOPHARMACOL, V277, DOI 10.1016/j.jep.2021.114232.
   Zhan XJ, 2018, MOL IMMUNOL, V104, P61, DOI 10.1016/j.molimm.2018.10.021.
   Zhang B, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.00847.
   Zhang JB, 2018, BIOCHEM BIOPH RES CO, V497, P883, DOI 10.1016/j.bbrc.2018.02.163.
   Zhang XC, 2019, NEUROPHARMACOLOGY, V158, DOI 10.1016/j.neuropharm.2019.107682.
   Zhao H, 2017, INT J ONCOL, V50, P1531, DOI 10.3892/ijo.2017.3924.
   Zhao MN, 2020, EUR J PHARMACOL, V871, DOI 10.1016/j.ejphar.2020.172916.
   Zhao XY, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5173035.
   Zhao Y, 2014, J ALZHEIMERS DIS, V41, P835, DOI 10.3233/JAD-131799.},
Number-of-Cited-References = {51},
Times-Cited = {39},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {35},
Journal-ISO = {Oxidative Med. Cell. Longev.},
Doc-Delivery-Number = {YM3KR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000746476500006},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000790071000003,
Author = {Xu, Ying and Lu, Jiawei and Tang, Yinbing and Xie, Wenjie and Zhang,
   Heteng and Wang, Beibei and Zhang, Shouliang and Hou, Wenji and Zou,
   Chen and Jiang, Pengcheng and Zhang, Wenbo},
Title = {RETRACTED: PINK1 deficiency in gastric cancer compromises mitophagy,
   promotes the Warburg effect, and facilitates M2 polarization of
   macrophages (Retracted article. See vol. 549, 2022)},
Journal = {CANCER LETTERS},
Year = {2022},
Volume = {529},
Pages = {19-36},
Month = {MAR 31},
Abstract = {Cancer cells are typically characterized by abnormal quality control of
   mitochondria, production of reactive oxygen species (ROS), dysregulation
   of the cell redox state, and the Warburg effect. Mutation or depletion
   of PTEN-induced kinase 1 (PINK1) or Parkin leads to mitophagy defects
   and accumulation of malfunctioning mitochondria, and is often detected
   in a variety of tumors. However, PINK1's role in the progression of
   gastric cancer (GC) remains unclear, with its main effect being on
   mitochondrial turnover, metabolic reprogramming, and tumor
   microenvironment (TME) alteration. To address these issues, we first
   assessed the expression levels of PINK1, mitophagy-associated molecules,
   ROS, HIF-1 alpha, glycolysis-associated genes, and macrophage signatures
   in GC tissues and matched tumor-adjacent normal samples. In addition, GC
   cell lines (AGS and MKN-45) and xenograft mouse models were used to
   determine the mechanism by which PINK1 regulates mitophagy, metabolic
   reprogramming, tumor-associated macrophage (TAM) polarization, and GC
   progression. We found that PINK1 loss correlated with advanced stage GC
   and poorer overall survival. GC tissues with lower PINK1 levels showed
   compromised mitophagy signaling and enhanced glycolytic enzyme
   expression. In vitro experiments demonstrated that PINK1 deficiency
   promoted GC cell proliferation and migration through the inhibition of
   mitophagy, production of mitochondrial ROS, stabilization of HIF-1
   alpha, and facilitation of the Warburg effect under both normoxic and
   hypoxic conditions. Moreover, PINK1 deficiency in GC cells promoted TAM
   polarization toward the M2-like phenotype. Reintroduction of PINK1 or
   inhibition of HIF-1 alpha effectively repressed PINK1 deficiencymediated
   effects on GC cell growth, metabolic shift, and TAM polarization. Thus,
   mitophagy defects caused by PINK1 loss conferred a metabolic switch
   through accumulation of mtROS and stabilization of HIF-1 alpha, thereby
   facilitating the M2 polarization of TAM to remodel an immunosuppressive
   microenvironment in GC. Our results clarify the mechanism between PINK1
   and GC progression and may provide a novel strategy for the treatment of
   GC.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article; Retracted Publication},
Language = {English},
Affiliation = {Jiang, PC; Zhang, WB (Corresponding Author), Jiangsu Univ, Dept Gen Surg, Affiliated Peoples Hosp, Zhenjiang, Peoples R China.
   Xu, Ying, Jiangsu Univ, Dept Lab Ctr, Affiliated Peoples Hosp, Zhenjiang, Peoples R China.
   Lu, Jiawei; Tang, Yinbing; Xie, Wenjie; Zhang, Heteng; Wang, Beibei; Zhang, Shouliang; Hou, Wenji; Zou, Chen; Jiang, Pengcheng; Zhang, Wenbo, Jiangsu Univ, Dept Gen Surg, Affiliated Peoples Hosp, Zhenjiang, Peoples R China.},
DOI = {10.1016/j.canlet.2021.12.032},
EarlyAccessDate = {JAN 2022},
ISSN = {0304-3835},
EISSN = {1872-7980},
Keywords = {Mitochondria; ROS; HIF-1 alpha; Metabolic reprogramming;
   Tumor-associated macrophage},
Keywords-Plus = {TUMOR PROGRESSION; AUTOPHAGY; HYPOXIA; METABOLISM; PARKIN; CELLS;
   TUMORIGENESIS; INFILTRATION; MITOCHONDRIA; METASTASIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {pcasu@yahoo.com
   wb.zhan@hotmail.com},
Affiliations = {Jiangsu University; Jiangsu University},
ORCID-Numbers = {Tang, Yinbing/0000-0002-9709-0545},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81500193, 81802409];
   Natural Science Foundation of Jiangsu Province {[}BK20161353]; Key Youth
   Talents Program in Health, Jiangsu Province {[}QNRC2016454]; Social
   Development Foundation of Zhenjiang {[}SH2020024]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China to Wenbo Zhang (81500193) and Ying Xu (81802409) ,
   Natural Science Foundation of Jiangsu Province to Wenbo Zhang
   (BK20161353) , Key Youth Talents Program in Health, Jiangsu Province to
   Wenbo Zhang (QNRC2016454) , and Social Development Foundation of
   Zhenjiang to Pengcheng Jiang (SH2020024) .},
Cited-References = {Agapova LS, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1300, DOI 10.1134/S0006297908120031.
   Agnihotri S, 2016, CANCER RES, V76, P4708, DOI 10.1158/0008-5472.CAN-15-3079.
   Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519.
   Barnes EME, 2020, BRIT J CANCER, V122, P1298, DOI 10.1038/s41416-020-0777-y.
   Bernardini JP, 2017, ONCOGENE, V36, P1315, DOI 10.1038/onc.2016.302.
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580-019-0173-8.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767.
   Calabretta B, 2011, LEUKEMIA LYMPHOMA, V52, P54, DOI 10.3109/10428194.2010.546913.
   Chen Y, 2013, SCIENCE, V340, P471, DOI 10.1126/science.1231031.
   Chiu DKC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2155-3.
   Chourasia AH, 2015, EMBO REP, V16, P1145, DOI 10.15252/embr.201540759.
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734.
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490.
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Etemadi A, 2020, LANCET GASTROENTEROL, V5, P42, DOI 10.1016/S2468-1253(19)30328-0.
   Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199.
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004.
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007.
   Gupta N., 2020, MOLECULES, V25.
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457.
   Ishigami S, 2003, ANTICANCER RES, V23, P4079.
   Jiang XJ, 2015, J CLIN INVEST, V125, P47, DOI 10.1172/JCI73942.
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009.
   Kawakami H, 2016, GASTRIC CANCER, V19, P687, DOI 10.1007/s10120-015-0585-x.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392.
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023.
   Li CF, 2018, DEV CELL, V46, P441, DOI 10.1016/j.devcel.2018.07.012.
   Li WH, 2019, HEPATOLOGY, V69, P604, DOI 10.1002/hep.30191.
   Liu L, 2014, CELL RES, V24, P787, DOI 10.1038/cr.2014.75.
   Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001.
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015.
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026.
   Mu XM, 2018, CELL CYCLE, V17, P428, DOI 10.1080/15384101.2018.1444305.
   Mukhopadhyay P, 2007, NAT PROTOC, V2, P2295, DOI 10.1038/nprot.2007.327.
   Nguyen TN, 2016, TRENDS CELL BIOL, V26, P733, DOI 10.1016/j.tcb.2016.05.008.
   Ohashi T, 2017, CANCER SCI, V108, P1128, DOI 10.1111/cas.13244.
   Porporato PE, 2016, CELL MOL LIFE SCI, V73, P1349, DOI 10.1007/s00018-015-2100-2.
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155.
   Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107.
   Qian HR, 2016, ONCOTARGET, V7, P17641, DOI 10.18632/oncotarget.7508.
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039.
   Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803.
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230.
   Seth P, 2017, CANCER RES, V77, P3632, DOI 10.1158/0008-5472.CAN-16-2938.
   Soto-Heredero G, 2020, FEBS J, V287, P3350, DOI 10.1111/febs.15327.
   Sumiyoshi Y, 2006, CLIN CANCER RES, V12, P5112, DOI 10.1158/1078-0432.CCR-05-2382.
   Sun XD, 2013, CELL CYCLE, V12, P1133, DOI 10.4161/cc.24215.
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211.
   Thomas LW, 2019, CELL MOL LIFE SCI, V76, P1759, DOI 10.1007/s00018-019-03039-y.
   Titova E, 2018, CELL CYCLE, V17, P1797, DOI 10.1080/15384101.2018.1496748.
   Trastour C, 2007, INT J CANCER, V120, P1451, DOI 10.1002/ijc.22436.
   Vaupel P, 2019, INT J RADIAT BIOL, V95, P912, DOI 10.1080/09553002.2019.1589653.
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510.
   Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841.
   Wang YG, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00413.
   White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008.
   Wu H, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01768-8.
   Xie YC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.594203.
   Xu Y, 2019, J CELL MOL MED, V23, P7581, DOI 10.1111/jcmm.14627.
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004.
   Zhang H, 2015, GASTRIC CANCER, V18, P740, DOI 10.1007/s10120-014-0422-7.
   Zhu LZ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.569887.},
Number-of-Cited-References = {67},
Times-Cited = {29},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Cancer Lett.},
Doc-Delivery-Number = {0Y0EN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000790071000003},
DA = {2026-02-04},
}

@article{ WOS:000738001600028,
Author = {Zhang, Yuying and Zhu, Baoyi and Cai, Yi and Zhu, Sihua and Zhao,
   Hongjun and Ying, Xiaoling and Jiang, Chonghe and Zeng, Jianwen},
Title = {Alteration in glycolytic/cholesterogenic gene expression is associated
   with bladder cancer prognosis and immune cell infiltration},
Journal = {BMC CANCER},
Year = {2022},
Volume = {22},
Number = {1},
Month = {JAN 3},
Abstract = {Background Oncogenic metabolic reprogramming contributes to tumor growth
   and immune evasion. The intertumoral metabolic heterogeneity and
   interaction of distinct metabolic pathways may determine patient
   outcomes. In this study, we aim to determine the clinical and
   immunological significance of metabolic subtypes according to the
   expression levels of genes related to glycolysis and
   cholesterol-synthesis in bladder cancer (BCa). Methods Based on the
   median expression levels of glycolytic and cholesterogenic genes,
   patients were stratified into 4 subtypes (mixed, cholesterogenic,
   glycolytic, and quiescent) in an integrated cohort including TCGA,
   GSE13507, and IMvigor210. Clinical, genomic, transcriptomic, and tumor
   microenvironment characteristics were compared between the 4 subtypes.
   Results The 4 metabolic subtypes exhibited distinct clinical, molecular,
   and genomic patterns. Compared to quiescent subtype, mixed subtype was
   more likely to be basal tumors and was significantly associated with
   poorer prognosis even after controlling for age, gender, histological
   grade, clinical stage, and molecular phenotypes. Additionally, mixed
   tumors harbored a higher frequency of RB1 and LRP1B copy number deletion
   compared to quiescent tumors (25.7\% vs. 12.7 and 27.9\% vs. 10.2\%,
   respectively, both adjusted P value< 0.05). Furthermore, aberrant PIK3CA
   expression level was significantly correlated with those of glycolytic
   and cholesterogenic genes. The quiescent subtype was associated with
   lower stemness indices and lower signature scores for gene sets involved
   in genomic instability, including DNA replication, DNA damage repair,
   mismatch repair, and homologous recombination genes. Moreover, quiescent
   tumors exhibited lower expression levels of pyruvate dehydrogenase
   kinases 1-3 (PDK1-3) than the other subtypes. In addition, distinct
   immune cell infiltration patterns were observed across the 4 metabolic
   subtypes, with greater infiltration of M0/M2 macrophages observed in
   glycolytic and mixed subtypes. However, no significant difference in
   immunotherapy response was observed across the 4 metabolic subtypes.
   Conclusion This study proposed a new metabolic subtyping method for BCa
   based on genes involved in glycolysis and cholesterol synthesis
   pathways. Our findings may provide novel insight for the development of
   personalized subtype-specific treatment strategies targeting metabolic
   vulnerabilities.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zeng, JW (Corresponding Author), Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Dept Urol, Qingyuan 511518, Peoples R China.
   Zhang, Yuying; Zhu, Baoyi; Zhu, Sihua; Zhao, Hongjun; Jiang, Chonghe; Zeng, Jianwen, Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Dept Urol, Qingyuan 511518, Peoples R China.
   Zhang, Yuying, Shenzhen Longhua Matern \& Child Healthcare Hosp, Dept Obstet, Shenzhen 510089, Peoples R China.
   Cai, Yi, Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Dept Urol, 87 Xiangya Rd, Changsha 410008, Peoples R China.
   Ying, Xiaoling, Sun Yat Sen Univ, Affiliated Hosp 1, Dept Translat Med, Guangzhou 51000, Peoples R China.},
DOI = {10.1186/s12885-021-09064-0},
Article-Number = {2},
EISSN = {1471-2407},
Keywords = {Bladder cancer; Glycolysis; Cholesterol synthesis; Metabolic subtypes;
   Immune microenvironment},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE COMPLEX; CHOLESTEROL-METABOLISM; GENOMIC
   INSTABILITY; PHOSPHORYLATION; IDENTIFICATION; MECHANISMS; HALLMARK;
   SUBTYPES},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {zengjwen@gzhmu.edu.cn},
Affiliations = {Guangzhou Medical University; Central South University; Sun Yat Sen
   University},
ResearcherID-Numbers = {jiang, chonghe/L-4432-2014},
ORCID-Numbers = {Cai, Yi/0000-0001-7773-2064
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81802551, 81900688,
   81800590]; Chinese Postdoctoral Science Foundation {[}2020 M672593];
   Medical Research Foundation of Guangdong Province {[}B2020011,
   A2019473]; Natural Science Foundation of Guangdong Province
   {[}2016A030307033, 2019A1515011107]; Guangdong Provincial Joint Fund
   Youth Project {[}2020A1515110117]; Science and Technology Foundation of
   Qingyuan City {[}2020KJJH009]; Medical Research Foundation of Qingyuan
   People's Hospital {[}20190206, 20190205]},
Funding-Text = {This work was supported by the grants from National Natural Science
   Foundation of China (No. 81802551, No. 81900688, and No. 81800590),
   Chinese Postdoctoral Science Foundation (2020 M672593), the Medical
   Research Foundation of Guangdong Province (B2020011 and A2019473), the
   Natural Science Foundation of Guangdong Province (2016A030307033 and
   2019A1515011107), Guangdong Provincial Joint Fund Youth Project
   (2020A1515110117), the Science and Technology Foundation of Qingyuan
   City (2020KJJH009), and the Medical Research Foundation of Qingyuan
   People's Hospital (No. 20190206, and No. 20190205).},
Cited-References = {Afonso J, 2020, NAT REV UROL, V17, P77, DOI 10.1038/s41585-019-0263-6.
   Anwar S, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188568.
   Atas E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.583217.
   Avayu O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14992.
   Berdik C, 2017, NATURE, V551, pS34, DOI 10.1038/551S34a.
   Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009.
   Conroy LR, 2020, CANCERS, V12, DOI 10.3390/cancers12010237.
   Cowin PA, 2012, CANCER RES, V72, P4060, DOI 10.1158/0008-5472.CAN-12-0203.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   Ding X, 2019, AM J CANCER RES, V9, P219.
   Enríquez-Cortina C, 2017, ONCOTARGET, V8, P104136, DOI 10.18632/oncotarget.22024.
   Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473.
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909.
   Hao YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11971.
   Herzig S, 2012, SCIENCE, V337, P93, DOI 10.1126/science.1218530.
   Huang BL, 2020, NAT METAB, V2, P132, DOI 10.1038/s42255-020-0174-0.
   Jiang W, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0674-5.
   Karasinska JM, 2020, CLIN CANCER RES, V26, P135, DOI 10.1158/1078-0432.CCR-19-1543.
   Kim CJ, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5220.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613.
   Liu WY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218737.
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Meeks JJ, 2020, NAT REV UROL, V17, P259, DOI 10.1038/s41585-020-0304-1.
   Mishra D, 2019, CANCERS, V11, DOI 10.3390/cancers11060750.
   Nair VS, 2021, CANCER IMMUNOL IMMUN, V70, P2103, DOI 10.1007/s00262-020-02842-y.
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858.
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010.
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101.
   Peng XX, 2018, CELL REP, V23, P255, DOI 10.1016/j.celrep.2018.03.077.
   Qu J, 2017, J CELL BIOL, V216, P409, DOI 10.1083/jcb.201607008.
   Richters A, 2020, WORLD J UROL, V38, P1895, DOI 10.1007/s00345-019-02984-4.
   Robertson AG, 2017, CELL, V171, P540, DOI {[}10.1016/j.cell.2018.07.036, 10.1016/j.cell.2017.09.007].
   Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4.
   Samuels Y, 2011, CURR TOP MICROBIOL, V347, P21, DOI 10.1007/82\_2010\_68.
   Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026.
   Shen ZY, 2011, J MOL CELL BIOL, V3, P1, DOI 10.1093/jmcb/mjq057.
   Smith SC, 2012, NEUROBIOL DIS, V45, P1136, DOI 10.1016/j.nbd.2011.12.036.
   Sobanski T, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.633305.
   Sradhanjali S, 2018, CURR TOP MED CHEM, V18, P444, DOI 10.2174/1568026618666180523105756.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046.
   Tran LD, 2021, NAT REV CANCER, V21, P104, DOI 10.1038/s41568-020-00313-1.
   Wagner W, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0114-x.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271.
   Woolbright BL, 2019, MOL CANCER THER, V18, P1673, DOI 10.1158/1535-7163.MCT-19-0079.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Wu SJ, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.591342.
   Yang WW, 2014, CELL, V158, P1210, DOI 10.1016/j.cell.2014.08.003.
   Yuan DZ, 2017, ONCOTARGET, V8, P67663, DOI 10.18632/oncotarget.18801.
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935.
   Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10.
   Zhang YJ, 2018, MOL CELL, V71, P201, DOI 10.1016/j.molcel.2018.06.023.
   Zhang YL, 2019, CELL CYCLE, V18, P3337, DOI 10.1080/15384101.2019.1676581.},
Number-of-Cited-References = {57},
Times-Cited = {46},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {18},
Journal-ISO = {BMC Cancer},
Doc-Delivery-Number = {XZ9YR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000738001600028},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:001015362100016,
Author = {Chen, Kai-Yun and Zhu, Shu-Guang and He, Ji-Wen and Duan, Xiao-Peng},
Title = {LncRNA CRNDE is involved in radiation resistance in hepatocellular
   carcinoma via modulating the SP1/PDK1 axis},
Journal = {NEOPLASMA},
Year = {2022},
Volume = {69},
Number = {4},
Pages = {918-930},
Abstract = {Hepatocellular carcinoma (HCC) is defined as a universal malignancy
   while radiation therapy is the effective treatment for it. This study
   validated the mechanism of long non-coding RNA (lncRNA) colorectal
   neoplasia differentially expressed gene (CRNDE) in radiation resistance
   in HCC. LncRNA CRNDE upregulation was detected in HCC cells. The
   radiation-resistant cell strains Huh7R and SNU-387R were established.
   After silencing lncRNA CRNDE, the cell colony formation ability, cell
   activity, apoptosis, cell cycles, and.-H2AX positive rate in Huh7R and
   SNU-387R were detected. Silencing lncRNA CRNDE decreased the cell
   activity, colony formation ability, and cell number in the G2 phase and
   facilitated DNA damage and apoptosis. The binding relations of
   specificity protein 1 (SP1) with lncRNA CRNDE and 3-phosphoinositide
   dependent protein kinase 1 (PDK1) were verified. LncRNA CRNDE regulated
   PDK1 transcription by binding to transcription factor SP1. PDK1
   overexpression partially reversed the inhibition of silencing lncRNA
   CRNDE on radiation resistance in HCC cells. The transplanted tumor mouse
   model was established and showed that silencing lncRNA CRNDE decreased
   tumor volume and weight and Ki67-positive cells in HCC mice in vivo.
   Collectively, lncRNA CRNDE was upregulated in HCC cells and promoted
   PDK1 transcription by binding to SP1, thus enhancing radiation
   resistance in HCC cells.},
Publisher = {AEPRESS SRO},
Address = {BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA},
Type = {Article},
Language = {English},
Affiliation = {Chen, KY (Corresponding Author), South Med Univ, Jinan Univ, Guangdong Prov Gen Hosp 2,Affiliated Hosp, Dept Gen Surg,Guangdong Prov Emergency Hosp, Guangzhou, Guangdong, Peoples R China.
   Chen, Kai-Yun; He, Ji-Wen; Duan, Xiao-Peng, South Med Univ, Jinan Univ, Guangdong Prov Gen Hosp 2,Affiliated Hosp, Dept Gen Surg,Guangdong Prov Emergency Hosp, Guangzhou, Guangdong, Peoples R China.
   Zhu, Shu-Guang, Sun Yat sen Univ, Dept Hepatol Surg, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.},
DOI = {10.4149/neo\_2022\_211230N1853},
ISSN = {0028-2685},
EISSN = {1338-4317},
Keywords = {hepatocellular carcinoma; radiation resistance; lncRNA CRNDE;
   transcription factor; SP1},
Keywords-Plus = {LONG NONCODING RNAS; PDK1 EXPRESSION; DIAGNOSIS; SP1; RADIOSENSITIVITY;
   PROGNOSIS; THERAPY; CELLS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {drchenkaiyun@163.com},
Affiliations = {Jinan University; Southern Medical University - China; Guangdong Academy
   of Medical Sciences \& Guangdong General Hospital; Sun Yat Sen
   University},
ResearcherID-Numbers = {Chen, Kaiyun/AAD-7045-2022
   Duan, Xiao-Peng/KVX-7572-2024},
Funding-Acknowledgement = {Guangzhou Science and Technology Planning Project {[}201904010001];
   Natural Science Foundation of Guangdong Province {[}2019A1515010145]},
Funding-Text = {We would like to thank all the participants for their time and effort.
   This work was supported by {[}Guangzhou Science and Technology Planning
   Project] under grant {[}number 201904010001]; and {[}Natural Science
   Foundation of Guangdong Province] under grant {[}number
   2019A1515010145].},
Cited-References = {Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746.
   Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148.
   Chedid MF, 2017, ABCD-ARQ BRAS CIR DI, V30, P272.
   Chen JZ, 2018, AGING-US, V10, P3371, DOI 10.18632/aging.101645.
   Chen ZL, 2016, AM J CANCER RES, V6, P2299.
   Chi YJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091015.
   Ding QY, 2020, J CELL BIOCHEM, V121, P3358, DOI 10.1002/jcb.29607.
   Dong X, 2021, CELL SIGNAL, V85, DOI 10.1016/j.cellsig.2021.110068.
   Gandhy SU, 2015, ONCOTARGET, V6, P26359, DOI 10.18632/oncotarget.4560.
   Garin E, 2021, LANCET GASTROENTEROL, V6, P17, DOI 10.1016/S2468-1253(20)30290-9.
   Grandhi MS, 2016, SURG ONCOL, V25, P74, DOI 10.1016/j.suronc.2016.03.002.
   Hartke J, 2017, SEMIN DIAGN PATHOL, V34, P153, DOI 10.1053/j.semdp.2016.12.011.
   Hu BL, 2021, AUTOPHAGY, V17, P2166, DOI 10.1080/15548627.2020.1817279.
   Huang Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01188-4.
   Ji DG, 2019, J CELL PHYSIOL, V234, P6548, DOI 10.1002/jcp.27396.
   Li YY, 2021, MOL THER NUCL ACIDS, V23, P244, DOI 10.1016/j.omtn.2020.08.037.
   Liu LX, 2020, BIOCHEM BIOPH RES CO, V533, P779, DOI 10.1016/j.bbrc.2020.09.080.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Ma HB, 2018, J CELL BIOCHEM, V119, P8325, DOI 10.1002/jcb.26883.
   Ni W, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0449-4.
   Pan WD, 2019, MOL ONCOL, V13, P2246, DOI 10.1002/1878-0261.12553.
   Quinodoz S, 2014, TRENDS CELL BIOL, V24, P651, DOI 10.1016/j.tcb.2014.08.009.
   Saleem W, 2011, CANCER SCI, V102, P2150, DOI 10.1111/j.1349-7006.2011.02095.x.
   Schaub SK, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818790217.
   Sheng HL, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000340.
   Sim HW, 2018, CURR PROB CANCER, V42, P40, DOI 10.1016/j.currproblcancer.2017.10.007.
   Singh DK, 2013, CHROMOSOME RES, V21, P695, DOI 10.1007/s10577-013-9391-7.
   Tang D, 2019, J CELL BIOCHEM, V120, P16128, DOI 10.1002/jcb.28894.
   Vizcaíno C, 2015, PHARMACOL THERAPEUT, V152, P111, DOI 10.1016/j.pharmthera.2015.05.008.
   Wang HH, 2018, J CELL MOL MED, V22, P5862, DOI 10.1111/jcmm.13856.
   Wang JY, 2019, BIOMED PHARMACOTHER, V110, P646, DOI 10.1016/j.biopha.2018.11.080.
   Wang JR, 2016, ONCOTARGETS THER, V9, P5597, DOI 10.2147/OTT.S110646.
   Wu JJ, 2022, J ETHNOPHARMACOL, V283, DOI 10.1016/j.jep.2021.114456.
   Xiao Q, 2017, CELL PHYSIOL BIOCHEM, V43, P2353, DOI 10.1159/000484387.
   Yang WC, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/8556965.
   Yuan DH, 2021, INT J BIOL SCI, V17, P220, DOI 10.7150/ijbs.50730.
   Zhang M, 2018, ONCOL RES, V26, P1245, DOI 10.3727/096504017X14944585873668.
   Zhao H, 2017, INT J ONCOL, V50, P1531, DOI 10.3892/ijo.2017.3924.
   Zhong CM, 2022, J CELL PHYSIOL, V237, P1105, DOI 10.1002/jcp.30599.},
Number-of-Cited-References = {39},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Neoplasma},
Doc-Delivery-Number = {K3GS9},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:001015362100016},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000720353600001,
Author = {Chen, Wenli and Dai, Guangli and Qian, Yike and Wen, Lian and He,
   Xueqing and Liu, Hui and Gao, Yunxing and Tang, Xingli and Dong, Bohan},
Title = {PIK3CA mutation affects the proliferation of colorectal cancer cells
   through the PI3K-MEK/PDK1-GPT2 pathway},
Journal = {ONCOLOGY REPORTS},
Year = {2022},
Volume = {47},
Number = {1},
Month = {JAN},
Abstract = {The phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene
   is mutated in numerous human cancers. This mutation promotes the
   proliferation of tumor cells; however, the underlying mechanism is still
   not clear. In the present study, it was revealed that the PIK3CA
   mutation in colorectal cancer (CRC) HCT116 (MUT) rendered the cells more
   dependent on glutamine by regulating the glutamic-pyruvate transaminase
   2 (GPT2). The dependence of glutamine increased the proliferation of
   cells in a normal environment and resistance to a suboptimal
   environment. Further study revealed that the mutated PIK3CA could
   regulate GPT2 expression not only through signal transduction molecule
   3-phosphoinositide-dependent kinase (PDK1) but also through
   mitogen-activated protein kinase (MEK) molecules. In HCT116 cells, MEK
   inhibitor treatment could reduce the expression of GPT2 signaling
   molecules, thereby inhibiting the proliferation of CRC cells. A new
   signal transduction pathway, the PI3K/MEK/GPT2 pathway was identified.
   Based on these findings, MEK and PDK1 inhibitors were combined to
   inhibit the aforementioned pathway. It was revealed that the combined
   application of MEK and PDK1 inhibitors could promisingly inhibit the
   proliferation of MUT compared with the application of PI3K inhibitors,
   PDK1 inhibitors, or MEK inhibitors alone. In vivo, MEK inhibitors alone
   and combined inhibitors had stronger tumor-suppressing effects. There
   was no significant difference between the PDK1-inhibitor group and
   normal group in vivo. Thus, these results indicated that mutated PI3K
   affected GPT2 mediated by the MEK/PDK1 dual pathway, and that the
   PI3K/MEK/GPT2 pathway was more important in vivo. Inhibiting MEK and
   PDK1 concurrently could effectively inhibit the proliferation of CRC
   cells. Targeting the MEK and PDK1 signaling pathway may provide a novel
   strategy for the treatment of PIK3CA-mutated CRC.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Dong, BH (Corresponding Author), Wannan Med Coll, Dept Microbiol \& Immunol, 22 Wenchang West Rd, Wuhu 241002, Anhui, Peoples R China.
   Chen, Wenli, Wannan Med Coll, Dept Biochem, Wuhu 241002, Anhui, Peoples R China.
   Dai, Guangli, Wuhu Tradit Chinese Med Hosp, Dept Obstet \& Gynecol, Wuhu 241003, Anhui, Peoples R China.
   Qian, Yike; Wen, Lian; He, Xueqing, Wannan Med Coll, Dept Pharm, Wuhu 241002, Anhui, Peoples R China.
   Liu, Hui; Gao, Yunxing; Tang, Xingli; Dong, Bohan, Wannan Med Coll, Dept Microbiol \& Immunol, 22 Wenchang West Rd, Wuhu 241002, Anhui, Peoples R China.},
DOI = {10.3892/or.2021.8222},
Article-Number = {11},
ISSN = {1021-335X},
EISSN = {1791-2431},
Keywords = {phosphatidylinositol-3-kinase catalytic subunit alpha; glutamine
   transaminase 2; colorectal cancer; proliferation; mitogen-activated
   protein kinase; mutation},
Keywords-Plus = {BREAST-CANCER; PI3K/AKT; REVEALS; GROWTH},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {240151563@qq.com},
Affiliations = {Wannan Medical College; Wannan Medical College; Wannan Medical College},
Funding-Acknowledgement = {National Natural Science Foundation of China Youth Fund Project
   {[}81402351]; Natural Science Research Project of Anhui Provincial
   Department of Education {[}KJ2019A0415]; Anhui Province University
   Outstanding Young Talent Support Program (Key Program)
   {[}gxyqZD2019040]; Reserve Candidates for Academic and Technical Leaders
   of Wannan Medical College},
Funding-Text = {The present study was supported by the National Natural Science
   Foundation of China Youth Fund Project (grant no. 81402351), the Natural
   Science Research Project of Anhui Provincial Department of Education
   (grant no. KJ2019A0415), the Anhui Province University Outstanding Young
   Talent Support Program (Key Program) (grant no. gxyqZD2019040) and the
   Reserve Candidates for Academic and Technical Leaders of Wannan Medical
   College.},
Cited-References = {Aoki M, 2017, CURR TOP MICROBIOL, V407, P153, DOI 10.1007/82\_2017\_6.
   Bao HR, 2020, BRAZ J MED BIOL RES, V53, DOI {[}10.1590/1414-431X20209207, 10.1590/1414-431x20209207].
   Bartalucci Niccolo, 2013, Clin Lymphoma Myeloma Leuk, V13 Suppl 2, pS307, DOI 10.1016/j.clml.2013.07.011.
   Blackburn PR, 2020, MODERN PATHOL, V33, P420, DOI 10.1038/s41379-019-0354-1.
   Cheng H, 2016, ONCOGENE, V35, P2961, DOI 10.1038/onc.2015.377.
   Costa C, 2015, CANCER CELL, V27, P97, DOI 10.1016/j.ccell.2014.11.007.
   Dillon LM, 2015, ONCOGENE, V34, P3968, DOI 10.1038/onc.2014.328.
   Durrant TN, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-0261-6.
   Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110.
   Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010.
   Feng XJ, 2016, GENES DIS, V3, P241, DOI 10.1016/j.gendis.2016.09.001.
   Gavgani FM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123931.
   Ghodsinia AA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051116.
   Giuliani N, 2016, TRANSL CANCER RES, V5, pS885, DOI 10.21037/tcr.2016.10.09.
   Han Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202000112.
   Hao YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11971.
   Hong XT, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01437.
   Ikenoue T, 2005, CANCER RES, V65, P4562, DOI 10.1158/0008-5472.CAN-04-4114.
   Juliana CA, 2018, MOL METAB, V17, P39, DOI 10.1016/j.molmet.2018.07.007.
   Kim M, 2019, ONCOGENE, V38, P4729, DOI 10.1038/s41388-019-0751-4.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Momi N, 2016, GASTROENTEROLOGY, V150, pS606, DOI 10.1016/S0016-5085(16)32082-0.
   Murakami K, 2021, MODERN PATHOL, V34, P2071, DOI 10.1038/s41379-021-00861-3.
   Paleari L, 2016, CLIN ONCOL-UK, V28, P317, DOI 10.1016/j.clon.2015.11.008.
   Qiu QH, 2016, INT J ONCOL, V48, P2508, DOI 10.3892/ijo.2016.3481.
   Salles B, 2006, PATHOL BIOL, V54, P185, DOI 10.1016/j.patbio.2006.01.012.
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014.
   Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207.
   Slattery ML, 2011, MUTAT RES-FUND MOL M, V706, P13, DOI 10.1016/j.mrfmmm.2010.10.005.
   SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0.
   Sun B, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02806-1.
   Toth K, 2010, CANCER GENE THER, V17, P761, DOI 10.1038/cgt.2010.33.
   Tserga A, 2016, VIRCHOWS ARCH, V469, P35, DOI 10.1007/s00428-016-1938-5.
   Tzanikou E, 2019, MOL ONCOL, V13, P2515, DOI 10.1002/1878-0261.12540.
   Vasan N, 2019, SCIENCE, V366, P714, DOI 10.1126/science.aaw9032.
   Yano S, 2016, ANTICANCER RES, V36, P3817.},
Number-of-Cited-References = {36},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Oncol. Rep.},
Doc-Delivery-Number = {XA0MX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000720353600001},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000888606300005,
Author = {Chen, Xin and Luo, Can and Bai, Yuting and Yao, Lihua and Shanzhou,
   Qiyue and Xie, Yulei and Wang, Shan and Xu, Lei and Guo, Xiaolan and
   Zhong, Xiaowu and Wu, Qing},
Title = {Analysis of Hypoxia Inducible Factor-1α Expression and Its Effects on
   Glycolysis of Esophageal Carcinoma},
Journal = {CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION},
Year = {2022},
Volume = {32},
Number = {7},
Pages = {47-66},
Abstract = {We investigated the regulatory effects of hypoxia-inducible factor-1
   alpha (HIF-1 alpha) on glycolysis metabolism in esophageal carcinoma
   (ESCA) cells. A series of bioinformatics databases and tools were used
   to investigate the expression and role of HIF-1 alpha in ESCA. The
   expression of HIF-1 alpha in ESCA tissues and adjacent tissues was
   validated by real-time PCR. Small interfering RNA (siRNA) was used to
   inhibit HIF-1 alpha-related genes in human ESCA cells (Eca109 and
   KYSE150). Cell proliferation was detected by the CCK-8 assay. The
   expression of HIF-1 alpha and glycolytic enzymes were investigated by
   real-time PCR and Western blot. HIF-1 alpha is highly expressed in ESCA
   and is involved in many biological processes such as cell hypoxia
   reaction, glucose metabolic process. Further in vitro experiments showed
   that expression of HIF-1 alpha in Eca109 and KYSE150 significantly
   increased under hypoxia compared with normoxia conditions. Also, the
   glucose uptake and lactate production under hypoxia were higher. The
   expression levels of hexokinase 2 (HK2) and pyruvate dehydrogenase
   kinase 1 (PDK1), glycolysis-related genes, were significantly increased
   under hypoxia. After siRNA knockdown of HIF-1 alpha in Eca109 and
   KYSE150, the glucose uptake and lactate production, as well as cell
   proliferation were significantly decreased under hypoxia, and HK2 and
   PDK1 were significantly downregulated. HIF-1 alpha promotes glycolysis
   of ESCA cells by upregulating the expression of HK2 and PDK1 under
   hypoxia.},
Publisher = {BEGELL HOUSE INC},
Address = {50 NORTH ST, DANBURY, CT 06810 USA},
Type = {Article},
Language = {English},
Affiliation = {Wu, Q (Corresponding Author), North Sichuan Med Coll, Affiliated Hosp, Dept Rehabil Med, Nanchong 63700, Peoples R China.
   Zhong, XW (Corresponding Author), North Sichuan Med Coll, Dept Clin Lab, Affiliated Hosp, Nanchong 63700, Peoples R China.
   Chen, Xin; Xie, Yulei; Wang, Shan; Wu, Qing, North Sichuan Med Coll, Affiliated Hosp, Dept Rehabil Med, Nanchong 63700, Peoples R China.
   Chen, Xin; Luo, Can; Bai, Yuting; Shanzhou, Qiyue; Xu, Lei; Guo, Xiaolan; Zhong, Xiaowu, North Sichuan Med Coll, Translat Med Res Ctr, Nanchong 63700, Peoples R China.
   Yao, Lihua; Guo, Xiaolan; Zhong, Xiaowu, North Sichuan Med Coll, Dept Clin Lab, Affiliated Hosp, Nanchong 63700, Peoples R China.
   Guo, Xiaolan; Zhong, Xiaowu, North Sichuan Med Coll, Dept Lab Med, Nanchong 63700, Peoples R China.},
DOI = {10.1615/CritRevEukaryotGeneExpr.2022043444},
ISSN = {1045-4403},
EISSN = {2162-6502},
Keywords = {esophageal cancer; bioinformatics analysis; hypoxia; HIF-1 alpha;
   glycolysis},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; TUMOR ANGIOGENESIS; GENE-EXPRESSION;
   FACTOR-I; CANCER; SURVIVAL; PROLIFERATION; HIF-1-ALPHA; HIF-1;
   METABOLISM},
Research-Areas = {Biotechnology \& Applied Microbiology; Genetics \& Heredity},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Genetics \& Heredity},
Author-Email = {zxw\_strive@163.com
   cbkf2017@126.com},
Affiliations = {North Sichuan Medical University; North Sichuan Medical University;
   North Sichuan Medical University; North Sichuan Medical University},
ResearcherID-Numbers = {yulei, xie/AAC-7031-2022
   Chen, Xin/OGN-9969-2025},
ORCID-Numbers = {yulei, xie/0000-0003-1161-5804
   },
Funding-Acknowledgement = {Applied Basic Research Program of Sichuan Province {[}2021YJ0202];
   Medical Research Project of Sichuan {[}S20048]; Development of
   Scientific Research Plan of North Sichuan Medical College
   {[}CBY20-ZD-05, CBY20QA-Y14]},
Funding-Text = {This research was supported by the Applied Basic Research Program of
   Sichuan Province (Grant No. 2021YJ0202), the Medical Research Project of
   Sichuan (Grant No. S20048), and the Development of Scientific Research
   Plan of North Sichuan Medical College (Grant Nos. CBY20-ZD-05 and
   CBY20QA-Y14). Our study analyzed publicly available datasets, which can
   be found online, e.g., The Cancer Genome Atlas
   (https://portal.gdc.cancer.gov), cbioportal (http://www.cbioportal.org).},
Cited-References = {Azoitei N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0490-2.
   Cai HS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01446.
   Casciello F, 2020, THERANOSTICS, V10, P4515, DOI 10.7150/thno.41453.
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002.
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5.
   Cui XG, 2017, ONCOTARGET, V8, P24840, DOI 10.18632/oncotarget.15266.
   Douiev L, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020452.
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207.
   Franz M, 2018, NUCLEIC ACIDS RES, V46, pW60, DOI 10.1093/nar/gky311.
   Fu DY, 2018, CELL PHYSIOL BIOCHEM, V51, P2434, DOI 10.1159/000495900.
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088.
   Hasan D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203745.
   Hashim D, 2016, ANN ONCOL, V27, P926, DOI 10.1093/annonc/mdw027.
   He GD, 2014, ASIA PAC J CLIN NUTR, V23, P174, DOI 10.6133/apjcn.2014.23.1.14.
   Higashimura Y, 2011, ARCH BIOCHEM BIOPHYS, V509, P1, DOI 10.1016/j.abb.2011.02.011.
   Hua Q, 2020, THERANOSTICS, V10, P4762, DOI 10.7150/thno.43839.
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211.
   Huang FL, 2018, ASIAN J SURG, V41, P210, DOI 10.1016/j.asjsur.2016.10.005.
   Jiang Y, 2015, ONCOTARGET, V6, P9409, DOI 10.18632/oncotarget.3352.
   Jiao L, 2018, AUTOPHAGY, V14, P671, DOI 10.1080/15548627.2017.1381804.
   Jin CM, 2020, J BIOL CHEM, V295, P6425, DOI 10.1074/jbc.RA119.012312.
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim SY, 2010, IMMUNOLOGY, V129, P516, DOI 10.1111/j.1365-2567.2009.03203.x.
   Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Lavecchia A, 2014, EXPERT OPIN THER PAT, V24, P383, DOI 10.1517/13543776.2014.877443.
   Lee JJ, 2010, CARCINOGENESIS, V31, P427, DOI 10.1093/carcin/bgp326.
   Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307.
   Liu XS, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.715883.
   Millrud CR, 2017, ONCOTARGET, V8, P3649, DOI 10.18632/oncotarget.12278.
   Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865.
   Ravi R, 2000, GENE DEV, V14, P34.
   Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530.
   Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3.
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230.
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108.
   Taylor CT, 2017, NAT REV IMMUNOL, V17, P774, DOI 10.1038/nri.2017.103.
   Vasconcelos MG, 2015, J ORAL MAXIL SURG, V73, P1753, DOI 10.1016/j.joms.2015.03.013.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Wan W, 2017, ONCOGENE, V36, P3868, DOI 10.1038/onc.2017.13.
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304.
   Wu WB, 2020, ONCOTARGETS THER, V13, P11627, DOI 10.2147/OTT.S275956.
   Xiao HJ, 2018, PROSTATE, V78, P86, DOI 10.1002/pros.23448.
   Zhang DW, 2016, MITOCHONDRION, V30, P222, DOI 10.1016/j.mito.2016.08.009.
   Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001.
   Zhang RY, 2019, EPIGENETICS-US, V14, P118, DOI 10.1080/15592294.2019.1573066.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang XD, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0892-2.
   Zhang Y, 2017, ONCOGENE, V36, P4171, DOI 10.1038/onc.2017.51.
   Zhao JY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0132-z.
   Zhong H, 2000, CANCER RES, V60, P1541.
   Zhou CX, 2015, TUMOR BIOL, V36, P9179, DOI 10.1007/s13277-015-3453-8.},
Number-of-Cited-References = {53},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Crit. Rev. Eukaryot. Gene Expr.},
Doc-Delivery-Number = {6M0ZI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000888606300005},
DA = {2026-02-04},
}

@article{ WOS:000790037000003,
Author = {Chilamakuri, Rameswari and Rouse, Danielle C. and Yu, Yang and Kabir,
   Abbas S. and Muth, Aaron and Yang, Jianhua and Lipton, Jeffery M. and
   Agarwal, Saurabh},
Title = {BX-795 inhibits neuroblastoma growth and enhances sensitivity towards
   chemotherapy},
Journal = {TRANSLATIONAL ONCOLOGY},
Year = {2022},
Volume = {15},
Number = {1},
Month = {JAN},
Abstract = {High-risk neuroblastoma (NB) represents a major clinical challenge in
   pediatric oncology due to relapse of metastatic, drug-resistant disease,
   and treatment-related toxicities. An analysis of 1235 primary NB patient
   dataset revealed significant increase in AKT1 and AKT2 gene expression
   with cancer stage progression. Additionally, Both AKT1 and AKT2
   expression inversely correlate with poor overall survival of NB
   patients. AKT1 and AKT2 genes code for AKT that drive a major oncogenic
   cell signaling pathway known in many cancers, including NB. To inhibit
   AKT pathway, we repurposed an antiviral inhibitor BX-795 that inhibits
   PDK1, an upstream activator of AKT. BX-795 potently inhibits NB cell
   proliferation and colony growth in a dose-dependent manner. BX-795
   significantly enhances apoptosis and blocks cell cycle progression at
   mitosis phase in NB. Additionally, BX-795 potently inhibits tumor
   formation and growth in a NB spheroid tumor model. We further tested
   dual therapeutic approaches by combining BX-795 with either doxorubicin
   or crizotinib and found synergistic and significant inhibition of NB
   growth, in contrast to either drug alone. Overall, our data demonstrate
   that BX-795 inhibits AKT pathway to inhibit NB growth, and combining
   BX-795 with current therapies is an effective and clinically tractable
   therapeutic approach for NB.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Agarwal, S (Corresponding Author), St Johns Univ, Pharmaceut Sci, St Alberts Hall,Suite B-65,8000 Utopia Pkwy, New York, NY 11439 USA.
   Chilamakuri, Rameswari; Rouse, Danielle C.; Kabir, Abbas S.; Muth, Aaron; Agarwal, Saurabh, St Johns Univ, Dept Pharmaceut Sci, Coll Pharm \& Hlth Sci, New York, NY USA.
   Yu, Yang; Yang, Jianhua, Baylor Coll Med, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA.
   Lipton, Jeffery M., Feinstein Inst Med Res, Inst Mol Med, New York, NY USA.},
DOI = {10.1016/j.tranon.2021.101272},
Article-Number = {101272},
ISSN = {1936-5233},
Keywords = {PDK1; BX-795; Neuroblastoma; Pediatric cancer; AKT pathway; Drug
   repurposing; Drug synergy},
Keywords-Plus = {SMALL-MOLECULE INHIBITORS; CELL-PROLIFERATION; PATHWAY INHIBITORS;
   DRUG-COMBINATION; IN-VITRO; TBK1; RESISTANCE; APOPTOSIS; MIGRATION;
   PATHOGENESIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {agarwals@stjohns.edu},
Affiliations = {St. John's University; Texas Children's Cancer Center; Baylor College of
   Medicine; Northwell Health},
ResearcherID-Numbers = {Agarwal, Saurabh/G-2410-2015
   Chilamakuri, Rameswari/GNW-5783-2022},
ORCID-Numbers = {Chilamakuri, Rameswari/0000-0003-4938-7368},
Funding-Acknowledgement = {St. Baldrick's Foundation; St. John's University},
Funding-Text = {This work is funded by the Scholar Career Development Award from the St.
   Baldrick's Foundation, and Seed grant from the St. John's University to
   Dr. Saurabh Agarwal. RC, DR., and AK are supported by the Graduate
   Teaching Assistantships from the St. John's University.},
Cited-References = {Agarwal Saurabh, 2018, Oncotarget, V9, P20323, DOI {[}10.18632/oncotarget.24859, 10.18632/oncotarget.24859].
   Agarwal S, 2016, ONCOTARGET, V7, P24018, DOI 10.18632/oncotarget.8116.
   Agarwal S, 2015, CANCER RES, V75, P2566, DOI 10.1158/0008-5472.CAN-14-2946.
   Ananthanarayanan B, 2005, P NATL ACAD SCI USA, V102, P15081, DOI 10.1073/pnas.0502889102.
   Ashton JC, 2015, CANCER RES, V75, P2400, DOI 10.1158/0008-5472.CAN-14-3763.
   Bai LY, 2015, EUR J PHARMACOL, V769, P287, DOI 10.1016/j.ejphar.2015.11.032.
   Balasuriya N, 2020, J BIOL CHEM, V295, P8120, DOI 10.1074/jbc.RA119.012425.
   Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746.
   Berry T, 2012, CANCER CELL, V22, P117, DOI 10.1016/j.ccr.2012.06.001.
   Brenner AK, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091427.
   Chen Q, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919558.
   Chen W, 2017, J CANCER, V8, P1892, DOI 10.7150/jca.17638.
   Choi EA, 2019, CANCER LETT, V465, P82, DOI 10.1016/j.canlet.2019.08.002.
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947.
   Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414.
   Darici S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092934.
   Daunys S, 2021, ADV EXP MED BIOL, V1295, P243, DOI 10.1007/978-3-030-58174-9\_11.
   Eduati F, 2017, CANCER RES, V77, P3364, DOI 10.1158/0008-5472.CAN-17-0078.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200.
   Gómez-Villafuertes R, 2015, SCI REP-UK, V5, DOI 10.1038/srep18417.
   Guan S, 2018, ONCOTARGET, V9, P2591, DOI 10.18632/oncotarget.23515.
   Hetman M, 2000, J NEUROSCI, V20, P2567.
   Hobbs S, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13914.
   Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568-019-0216-7.
   Huang BW, 2018, J CONTROL RELEASE, V270, P246, DOI 10.1016/j.jconrel.2017.12.005.
   Huang H, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109363.
   Huang H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113448.
   Ichikawa R, 2020, ONCOL REP, V43, P1300, DOI 10.3892/or.2020.7512.
   Iqbal A, 2020, ANTIVIR RES, V180, DOI 10.1016/j.antiviral.2020.104814.
   Jaishankar D, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5861.
   Jiang NN, 2020, MOL BIOL REP, V47, P4587, DOI 10.1007/s11033-020-05435-1.
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017.
   Li H, 2019, CANCER LETT, V457, P129, DOI 10.1016/j.canlet.2019.05.011.
   Li L, 2016, ONCOTARGET, V7, P34442, DOI 10.18632/oncotarget.9120.
   Li L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.169.
   Louis CU, 2015, ANNU REV MED, V66, P49, DOI 10.1146/annurev-med-011514-023121.
   Lu HQ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131106.
   Ma JY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03001-y.
   Maris John M, 2010, N Engl J Med, V362, P2202, DOI 10.1056/NEJMra0804577.
   Mokou M, 2020, CANCERS, V12, DOI 10.3390/cancers12123519.
   Moore NF, 2014, ONCOTARGET, V5, P8737, DOI 10.18632/oncotarget.2372.
   Murányi J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225590.
   Nalairndran G, 2020, J CELL MOL MED, V24, P12188, DOI 10.1111/jcmm.15876.
   Navrátilová J, 2017, J CELL MOL MED, V21, P1859, DOI 10.1111/jcmm.13106.
   Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201.
   Qi L, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0239-4.
   Qin JL, 2020, ONCOL REP, V43, P1885, DOI 10.3892/or.2020.7571.
   Raposo TP, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000031.
   Schmitt-Hoffner F, 2021, J CLIN ONCOL, V39, P3217, DOI 10.1200/JCO.20.02540.
   Segerström L, 2011, INT J CANCER, V129, P2958, DOI 10.1002/ijc.26268.
   Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507.
   Smith V, 2018, CHILDREN-BASEL, V5, DOI 10.3390/children5090114.
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330.
   Tomolonis JA, 2018, CELL TISSUE RES, V372, P245, DOI 10.1007/s00441-017-2747-0.
   Trigg RM, 2018, CANCERS, V10, DOI 10.3390/cancers10040113.
   Umapathy G, 2019, APMIS, V127, P288, DOI 10.1111/apm.12940.
   Versteeg R, 2016, CANCER DISCOV, V6, P20, DOI 10.1158/2159-8290.CD-15-1411.
   Villasante A, 2021, TRANSL RES, V237, P82, DOI 10.1016/j.trsl.2021.06.006.
   Vu HL, 2014, MOL CANCER RES, V12, P1509, DOI 10.1158/1541-7786.MCR-14-0204.
   Wang Y, 2020, ONCOTARGETS THER, V13, P3607, DOI 10.2147/OTT.S242929.
   Wei C., PROC.
   Wei YJ, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00604-6.
   Whittle SB, 2017, EXPERT REV ANTICANC, V17, P369, DOI 10.1080/14737140.2017.1285230.
   Xiang S, 2021, DRUG DISCOV TODAY, V26, P2445, DOI 10.1016/j.drudis.2021.05.016.
   Yu T, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113797.
   Yu XY, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11913.
   Zaczek A, 2020, J CELL MOL MED, V24, P1300, DOI 10.1111/jcmm.14782.
   Zanoni M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19103.
   Zhou Y, 2020, INT J CANCER, V146, P1383, DOI 10.1002/ijc.32560.
   Zraikat M, 2020, ASSAY DRUG DEV TECHN, V18, P239, DOI 10.1089/adt.2020.978.},
Number-of-Cited-References = {71},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Transl. Oncol.},
Doc-Delivery-Number = {0X9RO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000790037000003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000835216600006,
Author = {Guo, Bo and Cai, Shuang and Li, Wen and Guo, Chen and Liu, Yijie and Ma,
   Xiaoping and Ma, Hailin and Zhao, Lingyu},
Title = {Increase in Cisplatin Resistance by MeCP2 in Human Gastric Cancer
   through the Activation of the AKT Pathway by Facilitating PDK-1
   Transcription},
Journal = {CURRENT CANCER DRUG TARGETS},
Year = {2022},
Volume = {22},
Number = {5},
Pages = {414-425},
Abstract = {Background: Increasing evidence indicates that an imbalance in oncogenes
   is implicated in cancer chemotherapy resistance. Methyl-CpG binding
   protein 2 ( MeCP2), which acts as a major epigenetic regulator of the
   expression of various genes, is involved in the carcinogenesis and
   progression of gastric cancer. However, is it not known whether the role
   of MeCP2 is vital in acquired cisplatin resistance in gastric cancer.
   Objective: This study aimed to determine whether inhibition of MeCP2
   expression could sensitize DDP-resistant GC cells to DDP and elucidate
   the underlying molecular mechanism.
   Methods: qRT-PCR and western blotting were used to evaluate MeCP2
   expression in DDP-resistant GC cells. Subsequently, cell viability,
   colony formation, cell cycle, apoptosis, and tumorigenicity assays were
   performed to explore the in vitro and in vivo roles of MeCP2. Chromatin
   immunoprecipitation-qPCR and luciferase reporter assays were used to
   identify whether 3-phosphoinositide-dependent protein kinase 1 ( PDK-1)
   was a direct target gene of MeCP2.
   Results: MeCP2 was upregulated in malignant DDP-resistant cells compared
   to non-DDP-resistant GC cells or normal gastric epithelial cells. MeCP2
   knockdown increased the sensitivity of DDP- resistant GC cells to DDP,
   resulting in reduced cell growth, G0/G1 phase arrest, and increased
   apoptosis, whereas MeCP2 overexpression attenuated DDP sensitivity of
   DDP-resistant GC cells. In addition, MeCP2 knockdown enhanced DDP
   sensitivity in vivo. MeCP2 elevated PDK-1 expression by binding to CpG
   sites in promoter regions, and inhibition of PDK- 1 reversed the
   inductive effect of MeCP2 overexpression on DDP resistance in GC cells.
   Conclusion: These findings indicate that silencing of MeCP2 may
   potentiate DDP-induced cell death, thereby providing a promising
   therapeutic strategy for GC.},
Publisher = {BENTHAM SCIENCE PUBL LTD},
Address = {EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES},
Type = {Article},
Language = {English},
Affiliation = {Zhao, LY (Corresponding Author), Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Cell Biol \& Genet, Hlth Sci Ctr, Xian, Peoples R China.
   Guo, Bo; Cai, Shuang; Li, Wen; Guo, Chen; Liu, Yijie; Ma, Xiaoping; Zhao, Lingyu, Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Cell Biol \& Genet, Hlth Sci Ctr,Key Lab Environm \& Genes Related Dis, Xian, Peoples R China.
   Guo, Bo; Cai, Shuang; Li, Wen; Guo, Chen; Liu, Yijie; Ma, Xiaoping; Zhao, Lingyu, Xi An Jiao Tong Univ, Sch Basic Med Sci, Inst Genet \& Dev Biol, Translat Med Inst,Hlth Sci Ctr, Xian, Peoples R China.
   Ma, Hailin, Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Radiat Oncol, Med Coll, Xian, Peoples R China.},
ISSN = {1568-0096},
EISSN = {1873-5576},
Keywords = {Chemotherapy resistance; cisplatin; MeCP2; PDK-1; gastric cancer; DDP
   sensitivity},
Keywords-Plus = {GENE-EXPRESSION; BINDING; INHIBITION; ONCOGENE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {zhaolingyu@xjtu.edu.cn},
Affiliations = {Xi'an Jiaotong University; Chinese Academy of Sciences; Institute of
   Genetics \& Developmental Biology, CAS; Xi'an Jiaotong University; Xi'an
   Jiaotong University},
ResearcherID-Numbers = {Cai, Shuang/JGM-5103-2023
   Lingyu, Zhao/JXN-2805-2024},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81972603, 81702765,
   51837008]; Natural Science Foundation of Shaanxi Province
   {[}2020JM-074]; Key Research and Development Program of Shaanxi Province
   {[}2018SF-179]},
Funding-Text = {This work was supported in part by the National Natural Science
   Foundation of China (81972603, 81702765, and 51837008), the Natural
   Science Foundation of Shaanxi Province (2020JM-074), and the Key
   Research and Development Program of Shaanxi Province (2018SF-179).},
Cited-References = {Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374.
   Bernard D, 2006, ONCOGENE, V25, P1358, DOI 10.1038/sj.onc.1209179.
   Cavazzuti M., 2009, J BIOL CHEM, V285, P903.
   Chahrour M, 2008, SCIENCE, V320, P1224, DOI 10.1126/science.1153252.
   Chen CT, 2012, MOL CANCER THER, V11, P660, DOI 10.1158/1535-7163.MCT-11-0754.
   Danam RP, 2005, MOL CANCER THER, V4, P61.
   Darwanto A, 2003, CANCER SCI, V94, P442, DOI 10.1111/j.1349-7006.2003.tb01462.x.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Du YP, 2016, TUMOR BIOL, V37, P1261, DOI 10.1007/s13277-015-3921-1.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Falasca M, 2010, BRIT J CANCER, V102, P104, DOI 10.1038/sj.bjc.6605408.
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8.
   Gadalla KKE, 2011, BIOCHEM J, V439, P1, DOI 10.1042/BJ20110648.
   Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989.
   Hite KC, 2009, BIOCHEM CELL BIOL, V87, P219, DOI 10.1139/O08-115.
   Iorns E, 2009, BIOCHEM J, V417, P361, DOI 10.1042/BJ20081682.
   Joss-Moore LA, 2011, BIRTH DEFECTS RES A, V91, P672, DOI 10.1002/bdra.20783.
   Kasowski M, 2010, SCIENCE, V328, P232, DOI 10.1126/science.1183621.
   Mellén M, 2012, CELL, V151, P1417, DOI 10.1016/j.cell.2012.11.022.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Müller HM, 2003, BRIT J CANCER, V89, P1934, DOI 10.1038/sj.bjc.6601392.
   Neupane M, 2016, CANCER DISCOV, V6, P45, DOI 10.1158/2159-8290.CD-15-0341.
   Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252.
   Sun XP, 2014, FEBS J, V281, P115, DOI 10.1111/febs.12577.
   Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059.
   Tong DD, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0239-7.
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262.
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007.
   Verstraelen J, 2014, MOL PHARMACEUT, V11, P2160, DOI 10.1021/mp400625z.
   Yasui DH, 2007, P NATL ACAD SCI USA, V104, P19416, DOI 10.1073/pnas.0707442104.
   Zhao LY, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.60.
   Zhao LY, 2017, EBIOMEDICINE, V16, P87, DOI 10.1016/j.ebiom.2017.01.021.
   Zheng PM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0528-y.},
Number-of-Cited-References = {33},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Curr. Cancer Drug Targets},
Doc-Delivery-Number = {3M1KK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000835216600006},
DA = {2026-02-04},
}

@article{ WOS:000759887900012,
Author = {Guo, Jia-qi and Tang, Hu-ying and Wang, Chang-dong and Sang, Bo-tao and
   Liu, Xing and Yi, Fa-ping and Liu, Ge-li and Wu, Xiang-mei},
Title = {Influence of Dichloroacetate on Wilms'Tumor in vitro},
Journal = {ANNALS OF CLINICAL AND LABORATORY SCIENCE},
Year = {2022},
Volume = {52},
Number = {1},
Pages = {101-108},
Month = {JAN-FEB},
Abstract = {Objective. To investigate the effect of dichloroacetate (DCA) on Wilms'
   tumor (WT) G401 cells. Methods. CCK-8 assay was used to detect the
   influence of DCA on G401 cells viability and 10 mmol/L DCA was selected
   for subsequent experiments. The expression of glycolysis-related
   enzymes, such as hexokikinase 1 (PDK1), and pyruvate dehydrogenase
   (PDH), were detected by qRT-PCR and western blot. The extracellular
   lactic acid and glucose concentrations were measured by the lactic acid
   assay kit and glucose oxidase method kit respectively. Flow cytometry
   was used to detect the effect of DCA on G401 cells apoptosis. The
   invasion and migration ability of G401 cells were detected by Transwell
   assay and wound-healing assay. Results. The results showed that DCA
   reduced glycolysis-related enzymes expression, inhibited lactic acid
   production, and glucose consumption. DCA also suppressed cells growth,
   induced cells apoptosis and inhibited cells invasion and migration.
   Conclusion. Inhibition of aerobic glycolysis by DCA can reduce the
   viability of G401 cells, promote cells apoptosis and inhibit cells
   invasion and migration. Therefore, aerobic glycolysis may be a potential
   therapeutic target for Wilms' tumor.},
Publisher = {ASSOC CLINICAL SCIENTISTS},
Address = {PO BOX 1287, MIDDLEBURY, VT 05753 USA},
Type = {Article},
Language = {English},
Affiliation = {Wu, XM (Corresponding Author), Chongqing Med Univ, Dept Physiol, Yixueyuan Rd, Chongqing 400016, Peoples R China.
   Guo, Jia-qi; Tang, Hu-ying; Sang, Bo-tao; Wu, Xiang-mei, Basic Med Coll, Dept Physiol, Chongqing, Peoples R China.
   Guo, Jia-qi; Tang, Hu-ying; Wang, Chang-dong; Sang, Bo-tao; Yi, Fa-ping; Liu, Ge-li; Wu, Xiang-mei, Basic Med Coll, Mol Med \& Canc Res Ctr, Chongqing, Peoples R China.
   Wang, Chang-dong; Yi, Fa-ping, Basic Med Coll, Dept Biochem \& Mol Biol, Chongqing, Peoples R China.
   Liu, Xing, Chongqing Med Univ, Chongqing Childrens Hosp, Dept Pediat Urol, Chongqing, Peoples R China.},
ISSN = {0091-7370},
EISSN = {1550-8080},
Keywords = {Wilms' tumor; dichloroacetate; aerobic glycolysis},
Keywords-Plus = {AEROBIC GLYCOLYSIS; CANCER; TUMOR; METABOLISM; THERAPY; DCA;
   SENSITIVITY; ADAPTATION; INCREASES; VIRUS},
Research-Areas = {Medical Laboratory Technology},
Web-of-Science-Categories  = {Medical Laboratory Technology},
Author-Email = {xmwu@cqmu.edu.cn},
Affiliations = {Chongqing Medical University},
ResearcherID-Numbers = {Guo, Jiaqi/GSO-0702-2022},
Funding-Acknowledgement = {Scientific and Technological Research Program of Chongqing Municipal
   Education Commission {[}KJQN201900408]},
Funding-Text = {This study was supported by Scientific and Technological Research
   Program of Chongqing Municipal Education Commission (grant no.
   KJQN201900408, 2019) . We thank the staff of the Life Sciences Academy
   of Chongqing Medical University for their technical support and cancer
   re-search center.},
Cited-References = {Allen KT, 2015, FREE RADICAL BIO MED, V89, P263, DOI 10.1016/j.freeradbiomed.2015.08.006.
   Aminzadeh S, 2015, TRANSL PEDIATR, V4, P20, DOI 10.3978/j.issn.2224-4336.2015.01.04.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y.
   Cone EB, 2016, J UROLOGY, V196, P1530, DOI 10.1016/j.juro.2016.05.100.
   Delaney LM, 2015, APOPTOSIS, V20, P63, DOI 10.1007/s10495-014-1046-4.
   Dong GC, 2016, ONCOL LETT, V11, P1980, DOI 10.3892/ol.2016.4168.
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637-013-0047-4.
   Dungwa JV, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-390.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Heck JE, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27461.
   Heshe D, 2011, CANCER CHEMOTH PHARM, V67, P647, DOI 10.1007/s00280-010-1361-6.
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005.
   Khan A, 2014, ALTERN THER HEALTH M, V20, P21.
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Lee MH, 2014, J PEDIATR ENDOCR MET, V27, P1033, DOI 10.1515/jpem-2014-0006.
   Li CY, 2015, ONCOTARGET, V6, P1544, DOI 10.18632/oncotarget.2838.
   Lis P, 2016, MOLECULES, V21, DOI 10.3390/molecules21121730.
   Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613.
   Meng G, 2020, BRIT J CANCER, V122, P111, DOI 10.1038/s41416-019-0639-7.
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728.
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014.
   Pode-Shakked N, 2011, PEDIATR NEPHROL, V26, P1535, DOI 10.1007/s00467-011-1858-1.
   Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120.
   Shi B, 2016, CLIN EXP PHARMACOL P, V43, P626, DOI 10.1111/1440-1681.12575.
   Skeberdyte A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35815-4.
   SMITH AM, 1973, NEW YORK STATE J MED, V73, P1652.
   Szychot E, 2014, TRANSL PEDIATR, V3, P12, DOI 10.3978/j.issn.2224-4336.2014.01.09.
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079.
   Treger TD, 2019, NAT REV NEPHROL, V15, P240, DOI 10.1038/s41581-019-0112-0.
   Webb BA, 2015, NATURE, V523, P111, DOI 10.1038/nature14405.
   WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.},
Number-of-Cited-References = {35},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Ann. Clin. Lab. Sci.},
Doc-Delivery-Number = {ZF9KY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000759887900012},
DA = {2026-02-04},
}

@article{ WOS:000736789700001,
Author = {Guo, Yue and Wang, Lan and Yang, Hui and Ding, Nannan},
Title = {Knockdown long non-coding RNA HCP5 enhances the radiosensitivity of
   esophageal carcinoma by modulating AKT signaling activation},
Journal = {BIOENGINEERED},
Year = {2022},
Volume = {13},
Number = {1},
Pages = {884-893},
Month = {JAN 1},
Abstract = {Recently, long noncoding RNAs (lncRNAs) have been revealed to
   participate in cancer therapy. Especial in tumor radiotherapy, lncRNAs
   usually could enhance or restrict the radiosensitivity in different
   ways. LncRNA HCP5 is highly expressed in esophageal cancer and
   influenced the malignant behaviors of esophageal cancer cells. However,
   this study dedicates to clarify if lncRNA HCP5 affects the
   radiosensitivity of esophageal carcinoma. The expression levels of HCP5
   in esophageal cancer and adjacent noncancerous tissue were first
   analyzed on the TCGA database and then detected by qRT-PCR. The related
   functional experiments were used to investigate whether the
   radiosensitivity of esophageal squamous cell carcinoma was affected by
   the inhibition of HCP5. The expression results showed HCP5 is
   upregulated in esophageal cancers compared to the normal tissues.
   Meanwhile, knockdown HCP5 further suppressed the proliferation and
   promoted the apoptosis of esophageal cancer cells treated with a 2 Gy
   dose of radiotherapy. Moreover, we uncovered that knockdown HCP5
   eliminated radiotherapy resistance by modulating the miR-216a-3p/PDK1
   axis to inhibit the AKT activation. Finally, rescue experiments pointed
   that lowering the miR-216a-3p expression weakened the inhibition effect
   of knockdown HCP5 on cells treated with radiotherapy. To summary, our
   results indicate that HCP5 is involved in esophageal carcinoma
   radiotherapy and knockdown HCP5 enhances the radiosensitivity of
   esophageal carcinoma by modulating AKT signaling activation.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Yang, H (Corresponding Author), Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Anesthesiol, 15 Jiefang Rd, Xiangyang 430065, Hubei, Peoples R China.
   Ding, NN (Corresponding Author), Hubei Univ Arts \& Sci, Xiangyang Cent Hosp, Dept Pharm, 136 Jingzhou St, Xiangyang 430065, Hubei, Peoples R China.
   Guo, Yue, Hubei Univ Med, Xiangyang 1 Peoples Hosp, Hematol Dept, Xiangyang, Peoples R China.
   Wang, Lan; Yang, Hui, Hubei Univ Med, Xiangyang 1 Peoples Hosp, Dept Anesthesiol, 15 Jiefang Rd, Xiangyang 430065, Hubei, Peoples R China.
   Ding, Nannan, Hubei Univ Arts \& Sci, Xiangyang Cent Hosp, Dept Pharm, 136 Jingzhou St, Xiangyang 430065, Hubei, Peoples R China.},
DOI = {10.1080/21655979.2021.2014386},
ISSN = {2165-5979},
EISSN = {2165-5987},
Keywords = {HCP5; esophagus cancer; AKT; radiotherapy},
Keywords-Plus = {RADIATION-RESISTANCE; CANCER-CELLS; PATHWAY; PROGRESSION; INHIBITION},
Research-Areas = {Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology},
Author-Email = {dingnannan\_hbmu@.163.com},
Affiliations = {Hubei University of Medicine; Hubei University of Medicine; Hubei
   University of Arts \& Science},
Cited-References = {Bai N, 2020, CANCER MANAG RES, V12, P4747, DOI 10.2147/CMAR.S255866.
   Chang L, 2015, CRIT REV ONCOL HEMAT, V96, P507, DOI 10.1016/j.critrevonc.2015.07.005.
   Chen J, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.108966.
   Coleman HG, 2018, GASTROENTEROLOGY, V154, P390, DOI 10.1053/j.gastro.2017.07.046.
   Cui Z, 2021, ANTI-CANCER DRUG, V32, P53, DOI 10.1097/CAD.0000000000000971.
   Demarest CT, 2021, ANN SURG ONCOL, V28, P3375, DOI 10.1245/s10434-020-09565-5.
   Estruch M, 2021, LEUKEMIA, V35, P2030, DOI 10.1038/s41375-020-01094-0.
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937.
   Gao M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.663654.
   Han S, 2021, AGING-US, V13, P15444, DOI 10.18632/aging.203102.
   Kaboli PJ, 2020, PHARMACOL RES, V156, DOI {[}10.1016/j.phrs.2020.104806, 10.1016/j.phrs.2020.10480, 10.1016/j.phrs.2020.104806].
   Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202.
   Mardanshahi A, 2021, MOL BIOL REP, V48, P6167, DOI 10.1007/s11033-021-06607-3.
   Mattiuzzi C, 2019, J EPIDEMIOL GLOB HEA, V9, P217, DOI 10.2991/jegh.k.191008.001.
   Molinaro C, 2021, FEBS LETT, V595, P2655, DOI 10.1002/1873-3468.14195.
   Ning ML, 2021, BIOENGINEERED, V12, P1543, DOI 10.1080/21655979.2021.1918537.
   Peters SJ, 2003, BIOCHEM SOC T, V31, P1274, DOI 10.1042/BST0311274.
   Qin SY, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.684531.
   Su M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0663-8.
   Tang Y, 2016, CANCER MED-US, V5, P24, DOI 10.1002/cam4.564.
   Wang CY, 2020, GENOMICS, V112, P3504, DOI 10.1016/j.ygeno.2020.04.029.
   Wang P, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1519-y.
   Wu LZ, 2021, BIOENGINEERED, V12, P3398, DOI 10.1080/21655979.2021.1949236.
   Wu YF, 2018, ONCOL RES, V26, P157, DOI 10.3727/096504017X15031557924150.
   Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3.
   Zhang FQ, 2021, RADIAT RES, V195, P366, DOI 10.1667/RADE-20-00145.1.
   Zhang HF, 2021, J CANCER RES CLIN, V147, P1275, DOI 10.1007/s00432-020-03493-3.
   Zhang W, 2018, ACS COMB SCI, V20, P660, DOI 10.1021/acscombsci.8b00104.
   Zhang WX, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173416.
   Zhang YS, 2019, CANCER CHEMOTH PHARM, V84, P1209, DOI 10.1007/s00280-019-03922-2.
   Zhao J, 2020, J CELL PHYSIOL, V235, P9718, DOI 10.1002/jcp.29783.
   Zou SB, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5236.},
Number-of-Cited-References = {32},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Bioengineered},
Doc-Delivery-Number = {XY2DL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000736789700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:001010557100003,
Author = {Li, Y. and Li, M. and Ahmed, K. and Yang, J. and Song, L. and Cui, Z. G.
   and Hiraku, Y.},
Title = {Mechanistic Study of Macranthoside B Effects on Apoptotic Cell Death in
   Human Cervical Adenocarcinoma Cells},
Journal = {FOLIA BIOLOGICA},
Year = {2022},
Volume = {68},
Number = {5-6},
Pages = {189-200},
Abstract = {Macranthoside B (MB) is a triterpenoid saponin extracted from Lonicera
   macranthoides , traditional Chinese medicine. In the current study, we
   investigated the anticancer potential of MB various cancer cells and
   elucidated its underlying mechanisms. MB exposure inhibited cell
   proliferation, induced mitochondrial membrane potential (MMP) loss,
   increased sub-G1 accumulation, and sulted in cleavage of caspase-3 and
   PARP, which are reflective of apoptosis. In HeLa cells, MB induced
   down-regulation of SOD2 and GPx1, phosphorylation of Akt and PDK1, and
   thus promoted ROS-mediated apoptosis. This was further supported by the
   protection of sub-G1 accumulation, MMP loss, cleavage caspase-3 and PARP
   in the presence of N-acetylcysteine (NAC). Additionally, MB induced cell
   death via down-regulation of ubiquitin-like with PHD and ring- finger
   domains 1 (UHRF1) and Bcl-xL. Taken together, this study provides a new
   insight into the apoptosis-inducing potential of MB, and its molecular
   mechanisms are associated with an increase in oxidative stress and
   inhibition of the PDK1/Akt pathway.},
Publisher = {CHARLES UNIV PRAGUE, FIRST FACULTY MEDICINE},
Address = {FLEMINGOVO NAM. 2, PRAGUE 6 166 37, CZECH REPUBLIC},
Type = {Article},
Language = {English},
Affiliation = {Cui, ZG; Hiraku, Y (Corresponding Author), Univ Fukui, Dept Environm Hlth, Sch Med Sci, 23-3, Matsuokashimoaizuki,Eiheiji cho, Fukui 9101193, Japan.
   Li, Y.; Yang, J.; Song, L., Henan Inst Sci \& Technol, Sch Life Sci \& Technol, Xinxiang, Peoples R China.
   Li, M., Xizang Minzu Univ, Sch Med, Xianyang, Shaanxi, Peoples R China.
   Li, M.; Cui, Z. G.; Hiraku, Y., Univ Fukui, Dept Environm Hlth, Sch Med Sci, Fukui, Japan.
   Ahmed, K., Hamdard Univ, Fac Eastern Med, Islamabad, Pakistan.
   Cui, Z. G.; Hiraku, Y., Univ Fukui, Dept Environm Hlth, Sch Med Sci, 23-3, Matsuokashimoaizuki,Eiheiji cho, Fukui 9101193, Japan.},
ISSN = {0015-5500},
Keywords-Plus = {MEMBRANE PERMEABILIZATION; CANCER; INHIBITION; PATHWAY; PROLIFERATION;
   ACCUMULATION; EXPRESSION},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Oncology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Oncology; Cell Biology},
Author-Email = {sai@u-fukui.ac.jp
   y-hiraku@u-fukui.ac.jp},
Affiliations = {Henan Institute of Science \& Technology; Xizang Minzu University;
   University of Fukui; Hamdard University; University of Fukui},
Funding-Acknowledgement = {Key technologies R\&D program of Henan Province {[}202102110166]; Key
   R\&D special projects of Henan Province {[}221111110300]; Key scientific
   and technological projects in Henan Province {[}212102310876]},
Funding-Text = {This study was supported by Key technologies R\&D program of Henan
   Province (grant No. 202102110166) , Key R\&D special projects of Henan
   Province (grant No. 221111110300) and Key scientific and technological
   projects in Henan Province (grant No. 212102310876) .},
Cited-References = {Avato P, 2017, ANTI-CANCER AGENT ME, V17, P1508, DOI 10.2174/1871520617666170727152805.
   Bagli E, 2004, CANCER RES, V64, P7936, DOI 10.1158/0008-5472.CAN-03-3104.
   Bahrami A, 2017, J CELL BIOCHEM, V118, P4163, DOI 10.1002/jcb.26118.
   Bhatla N, 2018, INT J GYNECOL OBSTET, V143, P22, DOI 10.1002/ijgo.12611.
   Chen CY, 2009, J CHROMATOGR B, V877, P159, DOI 10.1016/j.jchromb.2008.11.043.
   Chen X, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181341.
   Choi JH, 2008, ANN NY ACAD SCI, V1138, P393, DOI 10.1196/annals.1414.041.
   Cragg GM, 2005, J ETHNOPHARMACOL, V100, P72, DOI 10.1016/j.jep.2005.05.011.
   Cui ZG, 2006, J CELL PHYSIOL, V206, P468, DOI 10.1002/jcp.20482.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Fonseca-Silva F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014666.
   Guan FQ, 2011, NAT PROD RES, V25, P332, DOI 10.1080/14786411003752086.
   Harris TK, 2003, IUBMB LIFE, V55, P117, DOI 10.1080/1521654031000115951.
   Jiang P, 2014, ENVIRON TOXICOL PHAR, V38, P991, DOI 10.1016/j.etap.2014.10.019.
   Johnson-Cadwell LI, 2007, J NEUROCHEM, V101, P1619, DOI 10.1111/j.1471-4159.2007.04516.x.
   Joshi P, 2017, EUR J MED CHEM, V138, P273, DOI 10.1016/j.ejmech.2017.06.047.
   Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939.
   Lazorchak AS, 2011, PROTEIN CELL, V2, P523, DOI 10.1007/s13238-011-1077-3.
   Li ML, 2019, J CELL PHYSIOL, V234, P20249, DOI 10.1002/jcp.28625.
   Li XL, 2009, ACTA PHARMACOL SIN, V30, P458, DOI 10.1038/aps.2009.18.
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926.
   Majumder D, 2017, INT J BIOL MACROMOL, V104, P929, DOI 10.1016/j.ijbiomac.2017.06.100.
   Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597.
   Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306.
   OHTA S, 1993, YAKUGAKU ZASSHI, V113, P870, DOI 10.1248/yakushi1947.113.12\_870.
   Prasad SB, 2015, CELL ONCOL, V38, P215, DOI 10.1007/s13402-015-0224-x.
   Prasedya ES, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1199-5.
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI {[}10.1016/j.cryobiol.2017.10.064, 10.1016/j.bbamcr.2016.09.012].
   Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238.
   Sambrook J., 1989, MOL CLONING LAB MANU, V1.
   Shan Y, 2016, NUTR CANCER, V68, P280, DOI 10.1080/01635581.2016.1142587.
   Stevens M, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00804.
   Sun LN, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-30.
   Wang J, 2009, FOOD CHEM TOXICOL, V47, P1716, DOI 10.1016/j.fct.2009.04.034.
   Wang YL, 2019, BRAIN DEV-JPN, V41, P649, DOI 10.1016/j.braindev.2019.04.010.
   Webster KA, 2012, FUTUR CARDIOL, V8, P863, DOI {[}10.2217/FCA.12.58, 10.2217/fca.12.58].
   Yun SM, 2016, MOL CELL ENDOCRINOL, V422, P64, DOI 10.1016/j.mce.2015.11.016.
   Zakki SA, 2018, CELL PHYSIOL BIOCHEM, V45, P2444, DOI 10.1159/000488263.},
Number-of-Cited-References = {38},
Times-Cited = {3},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Folia Biol.-Prague},
Doc-Delivery-Number = {J6FR0},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:001010557100003},
DA = {2026-02-04},
}

@article{ WOS:000811615200011,
Author = {Li, Yitian},
Title = {Inactivation of PDH can Reduce Anaplastic Thyroid Cancer Cells'
   Sensitivity to Artemisinin},
Journal = {ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY},
Year = {2022},
Volume = {22},
Number = {9},
Pages = {1753-1760},
Abstract = {Background: Anaplastic Thyroid Cancer (ATC) is a rare subtype of thyroid
   tumors with a high mortality rate. Targeted therapies against ATC are
   ineffective and mostly transient. Artemisinin has shown excellent
   anti-tumor activity in several cancers, but its effects on ATC are still
   unknown.
   Objective: To evaluate the effects of artemisinin on ATC cells and
   assess the mechanism underlying drug resistance.
   Methods: The viability and proliferation rates of the
   artemisinin-treated CAL-62 and BHT-101 cells were analyzed by MU and EdU
   incorporation assays. The protein expression levels were determined by
   Tandem Mass Tag (TMT) labeling quantitative proteomics and western
   blotting.
   Results: Artemisinin treatment significantly decreased the expression
   levels of COX2 and COX7A2 and increased that of COX14, YEM111, ALAS1,
   and OAT after 48h. In addition, FTL was upregulated in the CAL-62 cells
   and down-regulated in BHT-101 cells. The CAL-62 cells showed transient
   and reversible resistance to artemisinin, which was correlated to
   time-dependent changes in HIF1 alpha, PDK1, and PDHA levels.
   Conclusion: Artemisinin targets the mitochondrial respiratory chain
   proteins in ATC cells. CAL-62 cells show transient resistance to
   artemisinin via PDH downregulation, indicating that PDH activation may
   enhance the cytotoxic effects of artemisinin on ATC cells.},
Publisher = {BENTHAM SCIENCE PUBL LTD},
Address = {EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES},
Type = {Article},
Language = {English},
Affiliation = {Li, YT (Corresponding Author), Jining Med Univ, Res Dept, Jining, Shandong, Peoples R China.
   Li, Yitian, Jining Med Univ, Res Dept, Jining, Shandong, Peoples R China.},
DOI = {10.2174/1871520621666210910100803},
ISSN = {1871-5206},
EISSN = {1875-5992},
Keywords = {Anaplastic thyroid cancer; artemisinin; tolerance; oxidative
   phosphorylation; HIF1 alpha; PDK1},
Keywords-Plus = {ORNITHINE AMINOTRANSFERASE; OXIDATIVE-PHOSPHORYLATION; GYRATE ATROPHY;
   TUMOR; CYTOTOXICITY; METABOLISM; DIHYDROARTEMISININ; MITOCHONDRIA;
   FIBROBLASTS; DERIVATIVES},
Research-Areas = {Oncology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Oncology; Chemistry, Medicinal},
Author-Email = {liyt@mail.jnmc.edu.cn},
Affiliations = {Jining Medical University},
ORCID-Numbers = {Li, Yitian/0000-0001-7229-1079},
Funding-Acknowledgement = {Shandong Provincial Natural Science Foundation},
Funding-Text = {The authors are thankful for the generous support of the Shandong
   Provincial Natural Science Foundation.},
Cited-References = {Asayama S, 2006, MOL PHARMACEUT, V3, P468, DOI 10.1021/mp0500667.
   Baldini E, 2014, ENDOCR-RELAT CANCER, V21, P797, DOI 10.1530/ERC-14-0299.
   Bhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422.
   Biasutto L, 2008, BIOORG MED CHEM LETT, V18, P5594, DOI 10.1016/j.bmcl.2008.08.100.
   BIRNBAUM MJ, 1987, SCIENCE, V235, P1495, DOI 10.1126/science.3029870.
   Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016.
   Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6.
   Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483.
   Crespo-Ortiz MP, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/247597.
   Cuchelkar V, 2008, MOL PHARMACEUT, V5, P776, DOI 10.1021/mp800019g.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Efferth T, 2004, FREE RADICAL BIO MED, V37, P998, DOI 10.1016/j.freeradbiomed.2004.06.023.
   Efferth T, 2003, MOL PHARMACOL, V64, P382, DOI 10.1124/mol.64.2.382.
   Efferth T, 2001, INT J ONCOL, V18, P767.
   Flaveny CA, 2015, CANCER CELL, V28, P42, DOI 10.1016/j.ccell.2015.05.007.
   FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217.
   Goradel NH, 2019, J CELL PHYSIOL, V234, P5683, DOI 10.1002/jcp.27411.
   Guillery O, 2008, BIOL CELL, V100, P315, DOI 10.1042/BC20070110.
   Hartmann B, 2016, ELIFE, V5, DOI 10.7554/eLife.16078.
   HERZFELD A, 1968, J BIOL CHEM, V243, P3327.
   Hilf R, 2007, J BIOENERG BIOMEMBR, V39, P85, DOI 10.1007/s10863-006-9064-8.
   Huang XJ, 2007, J PHARM PHARMACOL, V59, P849, DOI 10.1211/jpp.59.6.0011.
   Icard P, 2014, BBA-REV CANCER, V1846, P216, DOI 10.1016/j.bbcan.2014.06.002.
   Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626.
   Klopfenstein DV, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28948-z.
   Krishnamurthy S, 2003, J NUCL MED, V44, P499.
   Lai H, 2005, EXPERT OPIN THER TAR, V9, P995, DOI 10.1517/14728222.9.5.995.
   LAI H, 1995, CANCER LETT, V91, P41, DOI 10.1016/0304-3835(94)03716-V.
   Li F, 2015, CELL SIGNAL, V27, P860, DOI 10.1016/j.cellsig.2015.01.014.
   Li YT, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041030.
   Li Z, 2016, MOLECULES, V21, DOI 10.3390/molecules21101331.
   Limaiem F., 2020, ANAPLASTIC THYROID C.
   Ma MG, 2020, AM J TRANSL RES, V12, P974.
   Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003.
   ODONNELL JJ, 1978, SCIENCE, V200, P200, DOI 10.1126/science.635581.
   Peng F, 2012, LASER MED SCI, V27, P645, DOI 10.1007/s10103-011-1005-z.
   PERAINO C, 1969, J BIOL CHEM, V244, P2241.
   Pozdeyev N, 2020, SEMIN CANCER BIOL, V61, P23, DOI 10.1016/j.semcancer.2020.01.005.
   Qiu HY, 2016, PHARMACOL RES, V104, P86, DOI 10.1016/j.phrs.2015.12.025.
   Rainbolt TK, 2016, CELL REP, V14, P2041, DOI 10.1016/j.celrep.2016.02.011.
   Seiler N, 1997, ADV EXP MED BIOL, V420, P113.
   Seiler Nikolaus, 2000, Current Drug Targets, V1, P119, DOI 10.2174/1389450003349254.
   Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559.
   Shi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13301.
   SHIH VE, 1978, AM J HUM GENET, V30, P174.
   SLAPKE J, 1983, BIOMED BIOCHIM ACTA, V42, P1309.
   Solaini G, 2011, BBA-BIOENERGETICS, V1807, P534, DOI 10.1016/j.bbabio.2010.09.003.
   Srinivasainagendra V, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0420-6.
   Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017.
   Tomiyama A, 2006, JNCI-J NATL CANCER I, V98, P1462, DOI 10.1093/jnci/djj395.
   Ueda M, 1998, INVEST OPHTH VIS SCI, V39, P820.
   Villalba M, 2013, INT J BIOCHEM CELL B, V45, P106, DOI 10.1016/j.biocel.2012.04.024.
   Wang GL, 2007, P NATL ACAD SCI USA, V104, P2068, DOI 10.1073/pnas.0610832104.
   Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305.
   WOERDENBAG HJ, 1993, J NAT PROD, V56, P849, DOI 10.1021/np50096a007.
   Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483.
   You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200.},
Number-of-Cited-References = {57},
Times-Cited = {2},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Anti-Cancer Agents Med. Chem.},
Doc-Delivery-Number = {2D5VU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000811615200011},
DA = {2026-02-04},
}

@article{ WOS:000849629100020,
Author = {Lu, Yuting and Shao, Yongzhao},
Title = {Multicellular biomarkers of drug resistance as promising targets for
   glioma precision medicine and predictors of patient survival},
Journal = {CANCER DRUG RESISTANCE},
Year = {2022},
Volume = {5},
Number = {2},
Pages = {511-533},
Abstract = {Aim: This study aimed to translate a known drug-resistance mechanism of
   long-term CSF1R inhibition into multicellular biomarkers that can serve
   as potential therapeutic targets as well as predictive markers for the
   survival of glioma patients.
   Methods: Using existing data from a published mouse study of drug
   resistance in immunotherapy for glioma, we identified multicellular
   differentially expressed genes (DEGs) between drug-sensitive and
   drug-resistant mice and translated the DEGs in mouse genome to human
   homolog. We constructed correlation gene networks for drug resistance in
   mice and glioma patients and selected candidate genes via concordance
   analysis of human with mouse gene networks. Markers of drug resistance
   and an associated predictive signature for patient survival were
   developed using regularized Cox models with data of glioma patients from
   The Cancer Genome Atlas (TCGA) database. Predictive performance of the
   identified predictive signature was evaluated using an independent human
   dataset from the Chinese Glioma Genome Atlas (CGGA) database.
   Results: Fourteen genes (CCL22, ADCY2, PDK1, ZFP36, CP, CD2, PLAUR,
   ACAP1, COL5A1, FAM83D, PBK, FANCA, ANXA7, and TACC3) were identified as
   genetic biomarkers that were all associated with pathways in glioma
   progression and drug resistance. Five of the 14 genes (CCL22, ADCY2,
   PDK1, CD2, and COL5A1) were used to construct a signature that is
   predictive of patient survival in the proneural subtype GBM patients
   with an AUC under the time-dependent receiver operating characteristic
   (ROC) of 2-year survival equal to 0.89. This signature also shows
   promising predictive accuracy for the survival of LGG patients but not
   for non-proneural type GBMs.
   Conclusion: Our translational approach can utilize gene correlation
   networks from multiple types of cells in the tumor microenvironment of
   animals. The identified biomarkers of drug resistance have good power to
   predict patient survival in some major subtypes of gliomas (the
   proneural subtype of GBM and LGG). The expression levels of the
   biomarkers of drug resistance may be modified for the development of
   personalized immunotherapies to prolong survival for a large portion of
   glioma patients.},
Publisher = {OAE PUBLISHING INC},
Address = {245 E MAIN ST, ST122, ALHAMBRA, CA 91801 USA},
Type = {Article},
Language = {English},
Affiliation = {Shao, YZ (Corresponding Author), NYU, Grossman Sch Med, Dept Populat Hlth, 180 Madison Ave, New York, NY 10016 USA.
   Shao, YZ (Corresponding Author), NYU, Grossman Sch Med, Dept Environm Med, 180 Madison Ave, New York, NY 10016 USA.
   Lu, Yuting; Shao, Yongzhao, NYU, Grossman Sch Med, Dept Populat Hlth, 180 Madison Ave, New York, NY 10016 USA.
   Lu, Yuting; Shao, Yongzhao, NYU, Grossman Sch Med, Dept Environm Med, 180 Madison Ave, New York, NY 10016 USA.},
DOI = {10.20517/cdr.2021.145},
EISSN = {2578-532X},
Keywords = {Drug resistance; tumor microenvironment; translational research
   strategy; multicellular gene correlation network; glioma; precision
   medicine},
Keywords-Plus = {DIFFERENTIAL EXPRESSION ANALYSIS; FANCONI-ANEMIA PATHWAY; GENOMIC
   ANALYSIS; GENE-EXPRESSION; CANCER; GLIOBLASTOMA; CERULOPLASMIN;
   TRIGGERS; PACKAGE; MITOSIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {Yongzhao.Shao@nyulangone.org},
Affiliations = {New York University; New York University},
ResearcherID-Numbers = {Lu, Yuting/JUF-7279-2023},
ORCID-Numbers = {Lu, Yuting/0000-0001-6093-0195},
Funding-Acknowledgement = {National Institute of Health (NIH) {[}P30CA016087, P50CA225450,
   P30AG066512]; National Cancer Institute {[}P30CA016087, P50CA225450]
   Funding Source: NIH RePORTER; National Institute on Aging
   {[}P30AG066512] Funding Source: NIH RePORTER},
Funding-Text = {This work was partially supported by research grants P30CA016087,
   P50CA225450, P30AG066512 from the National Institute of Health (NIH).
   The funding body has no roles in the experiment design, collection,
   analysis and interpretation of data, and writing of the manuscript.},
Cited-References = {Abbas SZ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71346-7.
   Andersen BM, 2021, NAT REV CANCER, V21, P786, DOI 10.1038/s41568-021-00397-3.
   Bai RL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01290.
   Barabási AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509.
   Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y.
   Bielle F, 2018, BRAIN PATHOL, V28, P674, DOI 10.1111/bpa.12563.
   Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958.
   Brat DJ, 2015, NEW ENGL J MED, V372, P2481, DOI 10.1056/NEJMoa1402121.
   Bravo-Navas S, 2019, FASEB J, V33, P10477, DOI 10.1096/fj.201802439RR.
   Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0257-y.
   Chen YZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664845.
   Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2.
   Claus EB, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS12367.
   Deng L, 2016, ONCOL LETT, V12, P2524, DOI 10.3892/ol.2016.5024.
   Dominguez-Brauer C, 2015, MOL CELL, V60, P524, DOI 10.1016/j.molcel.2015.11.006.
   Dong CY, 2020, J MOL NEUROSCI, V70, P56, DOI 10.1007/s12031-019-01400-1.
   Ferrarese R, 2014, J CLIN INVEST, V124, P2861, DOI 10.1172/JCI68836.
   Ferrer M, 2004, CANCER GENE THER, V11, P539, DOI 10.1038/sj.cgt.7700734.
   Fu RY, 2014, MOL NEUROBIOL, V49, P1422, DOI 10.1007/s12035-013-8620-6.
   Fu XJ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02509-3.
   Gilder AS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21358-1.
   Gönen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965.
   Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118.
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025.
   Gu SJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.752694.
   Han IW, 2017, ONCOTARGET, V8, P29028, DOI 10.18632/oncotarget.15995.
   Han J, 2017, BREAST CANCER RES TR, V164, P41, DOI 10.1007/s10549-017-4234-4.
   Han ZP, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020371.
   He XW, 2021, J APPL STAT, V48, P1352, DOI 10.1080/02664763.2020.1812543.
   Henke E, 2020, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00160.
   Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30.
   Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627.
   Jin MZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00280-x.
   Joel M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0398-x.
   Kamarudin AN, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0332-6.
   Khalaf K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.656364.
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563.
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559.
   Lasorella A, 2017, NEURO-ONCOLOGY, V19, P475, DOI 10.1093/neuonc/now240.
   Li JH, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.602321.
   Luo DY, 2018, INT J ONCOL, V53, P2067, DOI 10.3892/ijo.2018.4525.
   Mao P, 2020, TRANSL ONCOL, V13, P287, DOI 10.1016/j.tranon.2019.09.011.
   Martinenaite E, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1238541.
   Mata DA, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01058-6.
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042.
   Mukae Y, 2021, ANTICANCER RES, V41, P3815, DOI 10.21873/anticanres.15174.
   Naeim F., 2018, ATLAS HEMATOPATHOLOG, P29, DOI {[}10.1016/B978-0-12-809843-1.00002-4, DOI 10.1016/B978-0-12-809843-1.00002-4, DOI 10.1016/C2015-0-05997-4].
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138.
   Pan S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01101.
   Pan SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11066.
   Patil AA, 2014, ONCOTARGET, V5, P6414, DOI 10.18632/oncotarget.2225.
   Pencheva N, 2017, CELL REP, V20, P48, DOI 10.1016/j.celrep.2017.06.036.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Pérez-Ruiz E, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100718.
   Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018.
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616.
   Selmi T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1388-5.
   Selmi T, 2012, CELL CYCLE, V11, P1977, DOI 10.4161/cc.20309.
   Signore M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.188.
   Simon N., SGL FIT GLM OR COX M.
   Snijders AM, 2017, MOL ONCOL, V11, P167, DOI 10.1002/1878-0261.12016.
   Sun XQ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1908-1.
   Sun XQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22498.
   Tsai HF, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00661-3.
   Varela AS, 1997, CANCER LETT, V121, P139, DOI 10.1016/S0304-3835(97)00340-6.
   Velpula Kiran Kumar, 2014, CNS Oncol, V3, P177, DOI 10.2217/cns.14.13.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020.
   Wainwright DA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00116.
   Walian PJ, 2016, ONCOTARGET, V7, P3322, DOI 10.18632/oncotarget.6620.
   Wang Y, 2021, ONCOLOGIST, V26, P173, DOI 10.1002/onco.13530.
   Wang Z, 2018, ONCOTARGET, V9, P192, DOI 10.18632/oncotarget.22773.
   Wang Z, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08447-7.
   Weenink B, 2020, CANCERS, V12, DOI 10.3390/cancers12030751.
   Wu PJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641469.
   Xu SC, 2020, CANCER LETT, V476, P1, DOI 10.1016/j.canlet.2020.02.002.
   Yadav AK, 2009, JAMA-J AM MED ASSOC, V302, P276, DOI 10.1001/jama.2009.1022.
   Zeng F, 2021, ONCOLOGIST, V26, pE1460, DOI 10.1002/onco.13750.
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128.
   Zhang DW, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.632189.
   Zhang JW, 2020, DNA CELL BIOL, V39, P1545, DOI 10.1089/dna.2020.5596.
   Zhang YL, 2018, BIOSTATISTICS, V19, P14, DOI 10.1093/biostatistics/kxx016.
   Zhou M, 2015, INT J CANCER, V137, P826, DOI 10.1002/ijc.29441.
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6.},
Number-of-Cited-References = {84},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Cancer Drug Resist.},
Doc-Delivery-Number = {4H1FY},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000849629100020},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000743717900008,
Author = {Shen, Si and Zhou, Wenli and Xuan, Ji and Xu, Weijun and Xu, Huabing and
   Yang, Miaofang and Zhu, Liang and Yang, Zhuoxin and Yang, Benzhao and
   Shi, Bin and Zhao, Ying and Wang, Fangyu},
Title = {Overexpression of pressure-responsive miRNA-5703 inhibits
   pressure-induced growth and metastasis of liver cancer},
Journal = {JOURNAL OF CANCER},
Year = {2022},
Volume = {13},
Number = {1},
Pages = {325-342},
Abstract = {A vast majority of liver cancers coexist with cirrhosis and/or portal
   hypertension. A high-pressure tumour microenvironment may lead to
   malignant progression of liver cancer. Through quantitative reverse
   transcription-polymerase chain reaction, we found that miRNA-5703 was
   expressed at low levels in HepG2 and Huh-7 cells and pressure-treated
   MHCC97H implanted mouse cancer tissues, while its potential target gene,
   sarcoma gene (SRC), was highly expressed. The expression of miRNA-5703
   was higher in liver cancer tissues from Barcelona Clinic Liver Cancer
   (BCLC) stage A1 patients than those from BCLC stage A2-D patients,
   whereas SRC showed the opposite expression pattern. Bioinformatics
   analysis, luciferase reporter assay, and western blotting were performed
   to verify the relationship between miRNA-5703 and its potential target
   SRC. Using intravital imaging and immunohistochemistry, we demonstrated
   that pressure promotes tumour growth in subcutaneous tumourigenesis nude
   mice, and overexpression of miRNA-5703 significantly downregulated Ki67
   and upregulated NM23 in tumour tissues of mice, implying the blockage of
   tumour growth and metastasis. The activation of proliferation,
   migration, and invasion of HepG2 and Huh-7 cells by pressure, and
   inhibition by overexpressing miRNA-5703 were observed by cell counting
   kit-8 assay, flow cycle assay, transwell assay, and wound healing assay.
   After the intervention of pressure, inhibitor, and lentivirus to
   regulated kinase-3 (SGK3), phosphoinositide dependent protein kinase 1
   (PDK1), and paxillin were upregulated, and forkhead box O1 (FOXO1) and
   cyclin dependent kinase inhibitor 1B (P27Kip1) were downregulated in
   pressure-loaded hepatoma cells, which could be reversed by
   overexpression of miRNA-5703 or SRC knockdown. In conclusion,
   upregulation of miRNA-5703 inhibited pressure-induced growth and
   metastasis by suppressing the SRC-FAK-FOXO1 axis and SRC-paxillin axis.
   This novel perspective may be conducive to the mechano-inspired
   anticancer drugs of liver cancer.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Wang, FY (Corresponding Author), Nanjing Univ, Jinling Hosp Dept Gastroenterol \& Hepatol, Sch Med, Nanjing 210002, Peoples R China.
   Shen, Si; Xuan, Ji; Xu, Weijun; Xu, Huabing; Yang, Miaofang; Yang, Zhuoxin; Wang, Fangyu, Nanjing Univ, Jinling Hosp Dept Gastroenterol \& Hepatol, Sch Med, Nanjing 210002, Peoples R China.
   Shen, Si; Zhu, Liang; Shi, Bin, Naval Med Univ, Dept Gastroenterol, Changzheng Hosp, Shanghai 200003, Peoples R China.
   Zhou, Wenli, Naval Med Univ, Dept Oncol, Changzheng Hosp, Shanghai 200003, Peoples R China.
   Yang, Benzhao, Naval Med Univ, Naval Med Ctr, Dept Cardiol, Shanghai 200005, Peoples R China.
   Zhao, Ying, Naval Med Univ, Dept Tradit Chinese Med, Changzheng Hosp, Shanghai 200003, Peoples R China.},
DOI = {10.7150/jca.64926},
ISSN = {1837-9664},
Keywords = {liver cancer; portal hypertension; pressure; proliferation; metastasis;
   miRNA-5703},
Keywords-Plus = {CELL-ADHESION; TYROSINE PHOSPHORYLATION; AUTOPHOSPHORYLATION;
   PROLIFERATION; ASSOCIATION; EXPRESSION; MIGRATION; KINASE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {wangfy65@nju.edu.cn},
Affiliations = {Nanjing University; Naval Medical University; Naval Medical University;
   Naval Medical University; Naval Medical University},
ResearcherID-Numbers = {Wang, Fang/E-7198-2014},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}11472300, 81300345];
   Royal Society of the UK {[}IE151106]},
Funding-Text = {This work was supported by funding from the National Natural Science
   Foundation of China (No. 11472300) . In addition, we thank the National
   Natural Science Foundation of China (No. 81300345) and the international
   exchange grant (ref. IE151106) from The Royal Society of the UK.},
Cited-References = {Alvarado-Estrada K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82634-1.
   Aragon-Sanabria V, 2018, ADV EXP MED BIOL, V1092, P113, DOI 10.1007/978-3-319-95294-9\_7.
   Baschieri F, 2015, CELL CYCLE, V14, P1139, DOI 10.1080/15384101.2015.1007771.
   Basnet R, 2018, ACTA PHARM SIN B, V8, P767, DOI 10.1016/j.apsb.2018.07.001.
   Basson MD, 2015, MOL ONCOL, V9, P513, DOI 10.1016/j.molonc.2014.10.008.
   BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Cazzanelli P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103601.
   Chaudhuri PK, 2018, CHEM REV, V118, P6499, DOI 10.1021/acs.chemrev.8b00042.
   Craig DH, 2008, J CLIN INVEST, V118, P3170, DOI 10.1172/JCI34279.
   Downey C, 2006, AM J SURG, V192, P631, DOI 10.1016/j.amjsurg.2006.08.006.
   Faitot F, 2015, HEPATOLOGY, V62, P179, DOI 10.1002/hep.27864.
   Felsen D, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13346.
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937.
   Fernández-Sánchez ME, 2015, NATURE, V523, P92, DOI 10.1038/nature14329.
   Heerkens EHJ, 2014, J VASC RES, V51, P305, DOI 10.1159/000365479.
   Hilscher MB, 2019, GASTROENTEROLOGY, V157, P193, DOI 10.1053/j.gastro.2019.03.013.
   Jain P, 2019, AM J HEMATOL, V94, P710, DOI 10.1002/ajh.25487.
   Kalli M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00055.
   Kim R, 2019, ACTA RADIOL, V60, P1609, DOI 10.1177/0284185119842830.
   Kole C, 2020, CANCERS, V12, DOI 10.3390/cancers12102859.
   Kudo M, 2020, CANCERS, V12, DOI 10.3390/cancers12051089.
   Liu W, 2014, CANCER MICROENVIRON, V7, P117, DOI 10.1007/s12307-014-0148-4.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Luo X, 2020, MOL MED REP, V21, P2415, DOI 10.3892/mmr.2020.11057.
   Marasco G, 2020, WORLD J GASTROENTERO, V26, P3326, DOI 10.3748/wjg.v26.i24.3326.
   Marasco G, 2019, J HEPATOL, V70, P440, DOI 10.1016/j.jhep.2018.10.022.
   Pasta S, 2020, ANN THORAC SURG, V110, P1595, DOI 10.1016/j.athoracsur.2020.03.017.
   Petho Z, 2019, CELL CALCIUM, V80, P79, DOI 10.1016/j.ceca.2019.03.007.
   POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X.
   Qi F, 2015, WORLD J GASTROENTERO, V21, P9900, DOI 10.3748/wjg.v21.i34.9900.
   Rice DC, 2002, HYPERTENSION, V39, P502, DOI 10.1161/hy0202.102834.
   Ripamonti M, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01886-9.
   Schaller MD, 2001, BIOCHEM J, V360, P57, DOI 10.1042/0264-6021:3600057.
   Sheen MR, 2019, ELIFE, V8, DOI 10.7554/eLife.45120.
   Shen JW, 2019, MOL MED REP, V19, P5105, DOI 10.3892/mmr.2019.10177.
   Shen S, 2019, MOL MED REP, V20, P375, DOI 10.3892/mmr.2019.10223.
   Stadnik PS, 2021, J PHYSIOL-LONDON, V599, P143, DOI 10.1113/JP279810.
   Sun JH, 2019, EXP CELL RES, V375, P90, DOI 10.1016/j.yexcr.2018.12.023.
   Thamilselvan V, 2007, FASEB J, V21, P1730, DOI 10.1096/fj.06-6545com.
   Turner CE, 2000, J CELL SCI, V113, P4139.
   Vashum Y, 2021, MOL BIOL REP, V48, P105, DOI 10.1007/s11033-020-05951-0.
   Wang SY, 2011, AM J PHYSIOL-CELL PH, V300, pC657, DOI 10.1152/ajpcell.00377.2010.
   Xu XF, 2019, JAMA SURG, V154, P209, DOI 10.1001/jamasurg.2018.4334.
   Zeng BX, 2017, ONCOTARGET, V8, P98051, DOI 10.18632/oncotarget.20556.},
Number-of-Cited-References = {45},
Times-Cited = {4},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {27},
Journal-ISO = {J. Cancer},
Doc-Delivery-Number = {YI2XX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000743717900008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000817994000002,
Author = {Wang, Rong and Huang, Ke-Liang and Xing, Lian-Xiang},
Title = {TRIM35 functions as a novel tumor suppressor in breast cancer by
   inducing cell apoptosis through ubiquitination of PDK1},
Journal = {NEOPLASMA},
Year = {2022},
Volume = {69},
Number = {2},
Pages = {370-382},
Abstract = {Breast cancer is the most common cancer in women. Novel mechanisms and
   targets are urgently needed to understand and treat this disease due to
   the complexity of breast cancer. In this study, we evaluated the
   expression level of tripartite motif-containing (TRIM) 35 in various
   breast cancer cell lines by qPCR and immunoblot. Cell proliferation
   assay and flow cytometry were performed upon overexpression and
   depletion of TRIM35. Xenograft tumor model was applied to validate the
   findings observed in vitro. The correlation between TRIM35 and outcomes
   of breast cancer patients was investigated by analyzing The Cancer
   Genome Atlas database. We observed differential expression of TRIM35 in
   various breast cancer cell lines. Overexpression of TRIM35 significantly
   inhibited cell proliferation and promoted cell apoptosis. On the
   contrary, depletion of TRIM35 exerted the opposite effects on cell
   proliferation and apoptosis. Mechanistically, TRIM35 reduced PDK1 by
   ubiquitination, resulting in the degradation of PDK1. Overexpression of
   TRIM35 significantly suppressed ZR7530 cell line-derived xenograft tumor
   growth by inducing apoptosis. Finally, a lower level of TRIM35 was
   associated with a poor prognosis in patients. In conclusion, TRIM35
   functions as a tumor suppressor to suppress breast cancer proliferation
   by inactivating AKT signaling through the increased ubiquitination of
   PDK1, resulting in the promotion of apoptosis.},
Publisher = {AEPRESS SRO},
Address = {BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA},
Type = {Article},
Language = {English},
Affiliation = {Wang, R (Corresponding Author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Clin Lab, Huangpu Branch,Sch Med, Shanghai, Peoples R China.
   Wang, Rong; Huang, Ke-Liang; Xing, Lian-Xiang, Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Clin Lab, Huangpu Branch,Sch Med, Shanghai, Peoples R China.},
DOI = {10.4149/neo\_2021\_210823N1205},
ISSN = {0028-2685},
EISSN = {1338-4317},
Keywords = {TRIM35; AKT; PDK1; ubiquitination},
Keywords-Plus = {MESENCHYMAL TRANSITION; B-BOX; PATHWAY; PHOSPHORYLATION; PROTEIN;
   PROLIFERATION; PI3K/AKT; INVASION; GENES},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {jyhfywr1968@163.com},
Affiliations = {Shanghai Jiao Tong University},
Funding-Acknowledgement = {Scientific research project of the Shanghai Health Committee
   {[}201940505]},
Funding-Text = {This study was funded by the Scientific research project of the Shanghai
   Health Committee (201940505).},
Cited-References = {Agrawal AK, 2018, TUMOR BIOL, V40, p101042831775092, DOI {[}10.1177/1010428317750929, DOI 10.1177/1010428317750929].
   Alkabban F.M., 2021, StatPearls.
   Altundag K, 2018, BREAST CANCER RES TR, V169, P203, DOI 10.1007/s10549-018-4672-7.
   Alvarez RH, 2018, ONCOLOGIST, V23, P660, DOI 10.1634/theoncologist.2017-0343.
   Baek SH, 2017, J CELL PHYSIOL, V232, P346, DOI 10.1002/jcp.25426.
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021.
   Chen Z, 2015, ONCOGENE, V34, P3946, DOI 10.1038/onc.2014.325.
   Chia S, 2015, CURR ONCOL, V22, P33, DOI 10.3747/co.22.2393.
   Ciechanover A, 2015, NAT REV MOL CELL BIO, V16, P322, DOI 10.1038/nrm3982.
   Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005.
   Grille SJ, 2003, CANCER RES, V63, P2172.
   Handforth C, 2018, CALCIFIED TISSUE INT, V102, P251, DOI 10.1007/s00223-017-0369-x.
   Jia DS, 2011, HEPATOLOGY, V54, P1227, DOI 10.1002/hep.24495.
   Kimura F, 2003, J BIOL CHEM, V278, P25046, DOI 10.1074/jbc.M303438200.
   Kuang WB, 2017, AM J TRANSL RES, V9, P3816.
   Lalonde JP, 2004, J BIOL CHEM, V279, P8181, DOI 10.1074/jbc.M306751200.
   Lee JH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00906-9.
   Lee KJ, 2018, BIOCHEM BIOPH RES CO, V495, P2195, DOI 10.1016/j.bbrc.2017.11.182.
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862.
   Shan SM, 2015, INT J CLIN EXP PATHO, V8, P12357.
   Song LJ, 2017, MED SCI MONITOR, V23, P1741, DOI 10.12659/MSM.900296.
   Sun N, 2020, PROTEIN CELL, V11, P894, DOI 10.1007/s13238-020-00734-6.
   Tang SL, 2018, BIOMED PHARMACOTHER, V99, P59, DOI 10.1016/j.biopha.2018.01.054.
   Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9.
   Wang YM, 2015, FEBS LETT, V589, P1322, DOI 10.1016/j.febslet.2015.04.019.
   Wei L, 2019, WORLD J GASTROENTERO, V25, P5590, DOI 10.3748/wjg.v25.i37.5590.
   Wu Y, 2017, BREAST CANCER RES TR, V163, P449, DOI 10.1007/s10549-017-4211-y.
   Yang LF, 2010, BIOCHEM BIOPH RES CO, V400, P16, DOI 10.1016/j.bbrc.2010.07.126.
   Yang Wei, 2018, Oncotarget, V9, P8810, DOI {[}10.18632/oncotarget.24256, 10.18632/oncotarget.24256].},
Number-of-Cited-References = {29},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Neoplasma},
Doc-Delivery-Number = {2M9EL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000817994000002},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000789651600008,
Author = {Ye, Xun-Jia and Xu, Rong and Liu, Si-Ying and Hu, Bo and Shi, Zi-Jian
   and Shi, Fu-Li and Zeng, Bo and Xu, Li-Hui and Huang, Yuan-Ting and
   Chen, Ming-Ye and Zha, Qing-Bing and He, Xian-Hui and Ouyang, Dong-Yun},
Title = {Taraxasterol mitigates Con A-induced hepatitis in mice by suppressing
   interleukin-2 expression and its signaling in T lymphocytes},
Journal = {INTERNATIONAL IMMUNOPHARMACOLOGY},
Year = {2022},
Volume = {102},
Month = {JAN},
Abstract = {Discovery of anti-inflammatory drugs that can suppress T lymphocyte
   activation and proliferation by inhibiting TCR/CD3 and IL-2/IL-2R
   signaling is still needed in clinic, though rapamycin and other related
   reagents have made great success. Taraxasterol (TAS) is an active
   ingredient of dandelion, an anti-inflammatory medicinal herb with low in
   vivo toxicity that has long been used in China. Yet the action mechanism
   of TAS on lymphocytes remains elusive. The anti-inflammatory effects of
   TAS were evaluated in C57BL/6 mouse primary lymphocytes stimulated with
   concanavalin A (Con A) in vitro and in mouse model of Con A-induced
   acute hepatitis in vivo. Our results showed that TAS significantly
   suppressed Con A-induced acute hepatitis in a mouse model, reducing the
   hepatic necrosis areas, the release of aminotransferases, and the
   production of IL-2 and other inflammatory cytokines. Supporting this, in
   vitro study also showed that TAS reduced the production of IL-2 and the
   expression of IL-2 receptor subunit alpha (CD25) upon the stimulation of
   Con A, which was likely mediated by suppressing NF-kappa B activation.
   The downstream pathways of IL-2/IL-2R signaling, including the
   activation of PI3K/PDK1/mTOR, STAT3 and STAT5, were also suppressed by
   TAS. Consistently, Con A-induced T cell proliferation was also inhibited
   by TAS in vitro. Our data indicate that TAS can suppress both T
   lymphocyte activation and cell pro-liferation by down-regulating IL-2
   expression and its signaling pathway thereby ameliorating Con A-induced
   acute hepatitis, highlighting TAS as a potential drug candidate for
   treating inflammatory diseases including autoimmune hepatitis.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {He, XH; Ouyang, DY (Corresponding Author), Jinan Univ, Coll Life Sci \& Technol, Dept Immunobiol, Guangzhou 510632, Peoples R China.
   Ye, Xun-Jia; Xu, Rong; Liu, Si-Ying; Shi, Fu-Li; Zeng, Bo; Huang, Yuan-Ting; Chen, Ming-Ye; He, Xian-Hui; Ouyang, Dong-Yun, Jinan Univ, Coll Life Sci \& Technol, Dept Immunobiol, Guangzhou 510632, Peoples R China.
   Hu, Bo, Jinan Univ, Dept Nephrol, Affiliated Hosp 1, Guangzhou 510632, Peoples R China.
   Shi, Zi-Jian; Zha, Qing-Bing, Jinan Univ, Dept Fetal Med, Affiliated Hosp 1, Guangzhou 510632, Peoples R China.
   Xu, Li-Hui, Jinan Univ, Coll Life Sci \& Technol, Dept Cell Biol, Guangzhou 510632, Peoples R China.},
DOI = {10.1016/j.intimp.2021.108380},
Article-Number = {108380},
ISSN = {1567-5769},
EISSN = {1878-1705},
Keywords = {Taraxasterol; mTOR; T lymphocytes; Cell proliferation; Con A-induced
   hepatitis; Interleukin-2},
Keywords-Plus = {KAPPA-B; ACTIVATION; RAPAMYCIN; INJURY; CELLS; MTOR; PROLIFERATION;
   TRANSCRIPTION; TARAXACUM; MARKERS},
Research-Areas = {Immunology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Immunology; Pharmacology \& Pharmacy},
Author-Email = {thexh@jnu.edu.cn
   dongyun1967@aliyun.com},
Affiliations = {Jinan University; Jinan University; Jinan University; Jinan University},
ResearcherID-Numbers = {He, Xian-Hui/H-3153-2019
   Ouyang, Dong-yun/P-7305-2019
   Liu, Siying/OMN-0902-2025},
ORCID-Numbers = {Ye, xunjia/0009-0004-2760-4549
   Xu, Li-hui/0000-0002-2633-9999
   He, Xian-Hui/0000-0001-7433-7392
   Ouyang, Dong-yun/0000-0002-4743-942X
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81873064, 81773965,
   81673664]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (Nos. 81873064, 81773965, and 81673664).},
Cited-References = {Abbas A.K., 2018, IL 2 BIOL THERAPEUTI, V3, DOI {[}10.1126/sciimmunol. aat1482, DOI 10.1126/SCIIMMUNOL.AAT1482].
   Azarsiz E, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22216.
   Bao TH, 2018, J MOL MED, V96, P661, DOI 10.1007/s00109-018-1652-7.
   Bucher P, 1997, IMMUNOBIOLOGY, V198, P136, DOI 10.1016/S0171-2985(97)80034-4.
   Che L, 2019, EXP THER MED, V18, P1745, DOI 10.3892/etm.2019.7736.
   Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405.
   Cho CS, 2003, INT IMMUNOL, V15, P1369, DOI 10.1093/intimm/dxg138.
   Constant SL, 1999, J IMMUNOL, V162, P5695.
   Damoiseaux J, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108515.
   Deutsch M, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.126.
   Dutta D, 2017, NAT IMMUNOL, V18, P196, DOI 10.1038/ni.3640.
   FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686.
   Gaffen SL, 2004, CYTOKINE, V28, P109, DOI 10.1016/j.cyto.2004.06.010.
   Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X.
   GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0.
   GRANELLIPIPERNO A, 1991, J IMMUNOL, V147, P2734.
   Hazem SH, 2018, INT IMMUNOPHARMACOL, V61, P376, DOI 10.1016/j.intimp.2018.06.026.
   Heymann F, 2015, LAB ANIM-UK, V49, P12, DOI 10.1177/0023677215572841.
   Holden NS, 2008, CELL SIGNAL, V20, P1338, DOI 10.1016/j.cellsig.2008.03.001.
   Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024.
   Jeurink PV, 2008, CRYOBIOLOGY, V57, P91, DOI 10.1016/j.cryobiol.2008.06.002.
   Kerkar N, 2005, AM J TRANSPLANT, V5, P1085, DOI 10.1111/j.1600-6143.2005.00801.x.
   KIRKEN RA, 1995, CYTOKINE, V7, P689, DOI 10.1006/cyto.1995.0081.
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710.
   KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0.
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011.
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001.
   Mai FY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12663.
   Margalit M, 2005, AM J PHYSIOL-GASTR L, V289, pG917, DOI 10.1152/ajpgi.00105.2005.
   MIZUHARA H, 1994, J EXP MED, V179, P1529, DOI 10.1084/jem.179.5.1529.
   Morris JC, 2000, ANN RHEUM DIS, V59, P109, DOI 10.1136/ard.59.suppl\_1.i109.
   Nowak P, 2009, J MED CHEM, V52, P7081, DOI 10.1021/jm9012642.
   Pongracz J, 2003, MOL IMMUNOL, V39, P1013, DOI 10.1016/S0161-5890(03)00044-0.
   Sang R, 2019, ARTIF CELL NANOMED B, V47, P3929, DOI 10.1080/21691401.2019.1671433.
   Sass G, 2002, CYTOKINE, V19, P115, DOI 10.1006/cyto.2002.1948.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Schütz K, 2006, J ETHNOPHARMACOL, V107, P313, DOI 10.1016/j.jep.2006.07.021.
   SEHGAL SN, 1993, ANN NY ACAD SCI, V685, P58, DOI 10.1111/j.1749-6632.1993.tb35852.x.
   Shipkova M, 2012, CLIN CHIM ACTA, V413, P1338, DOI 10.1016/j.cca.2011.11.006.
   Starska K, 2011, FOLIA HISTOCHEM CYTO, V49, P579, DOI 10.5603/FHC.2011.0081.
   TIEGS G, 1992, J CLIN INVEST, V90, P196, DOI 10.1172/JCI115836.
   Ven Chang I, 2017, MOL BIOSYST, V13, P2222, DOI 10.1039/c7mb00495h.
   Wang SS, 2016, J ETHNOPHARMACOL, V187, P42, DOI 10.1016/j.jep.2016.04.031.
   Woerly G, 1996, CLIN EXP IMMUNOL, V103, P322, DOI 10.1046/j.1365-2249.1996.d01-616.x.
   Xu L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8284107.
   Yang F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632606.
   Yang JL, 2016, ELIFE, V5, DOI 10.7554/eLife.17936.
   Yang Y, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-00309-4.
   Ye CX, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0002-5.
   Zhu SB, 2020, EUR REV MED PHARMACO, V24, P4642, DOI 10.26355/eurrev\_202005\_21150.},
Number-of-Cited-References = {50},
Times-Cited = {15},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {40},
Journal-ISO = {Int. Immunopharmacol.},
Doc-Delivery-Number = {0X4AN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000789651600008},
DA = {2026-02-04},
}

@article{ WOS:000788081000027,
Author = {Yigin, Aysel Kalayci and Donmez, Huseyin and Hitit, Mustafa and Seven,
   Sena and Eser, Nadire and Kurar, Ercan and Seven, Mehmet},
Title = {The effect of medicarpin on PTEN/AKT signal pathway in head and neck
   squamous cell carcinoma},
Journal = {JOURNAL OF CANCER RESEARCH AND THERAPEUTICS},
Year = {2022},
Volume = {18},
Number = {1},
Pages = {180-184},
Month = {JAN-MAR},
Abstract = {Background/Aim: We aimed to investigate the in vitro modulating effects
   of medicarpin on the PI3K/AKT signal pathway gene expressions in head
   and neck squamous cell carcinoma (HNSCC). Materials and Methods: The
   effect of medicarpin on PTEN and other associated genes in the PTEN/AKT
   signal pathway was investigated by
   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, real-time
   quantitative polymerase chain reaction, and Western blot analysis in the
   SCCL-MT1 (HNSCC) and control (HEK-293) cell lines. Results: The IC50
   dose was 80 mu M as a result of medicarpin treatment on HNSCC cells (P =
   0.0006). It was found that PTEN and AKT gene expressions increased after
   the medicarpin administration while PDK1 gene expression was decreased
   in SCCL-MT1 cells (P = 0.0002, P = 0.0003, and P = 0.05, respectively).
   Protein expression results showed that medicarpin-treated cells
   significantly increased in pAKT (P = 0.024), pPTEN (P = 0.032), and
   decreased pPDK1 (P = 0.059) in SCCL-MT1. Conclusions: Our data show that
   medicarpin modulates HNSCC cells by increasing the PTEN and decreasing
   PDK1 expressions. PDK1 gene expression effects mTOR pathway which may
   increase AKT gene. Our study suggests that both medicarpin extracts
   combination with the HNSCC drug may be more effective in cancer
   treatment. Future prospective studies that integrate molecular and
   pharmacogenetic studies are crucial for revealing the mechanism and
   preventive medical efforts.},
Publisher = {WOLTERS KLUWER MEDKNOW PUBLICATIONS},
Address = {WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA},
Type = {Article},
Language = {English},
Affiliation = {Yigin, AK (Corresponding Author), Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Med Genet, TR-34098 Istanbul, Turkey.
   Yigin, Aysel Kalayci; Seven, Mehmet, Univ Manchester, Fac Biol Med \& Hlth, Div Pharm \& Optometry, Manchester, England.
   Donmez, Huseyin, Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Med Genet, Istanbul, Turkey.
   Hitit, Mustafa, Kastamonu Univ, Fac Vet, Dept Genet, Kastamonu, Turkey.
   Seven, Sena, Istanbul Univ, Fac Pharm, Dept Pharmacognosy, Istanbul, Turkey.
   Eser, Nadire, Kahramanmaras Sutcu Imam Univ, Fac Med, Dept Pharmacol, Kahramanmaras, Turkey.
   Kurar, Ercan, Necmettin Erbakan Univ, Meram Med Fac, Dept Med Biol, Konya, Turkey.
   Yigin, Aysel Kalayci, Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Med Genet, TR-34098 Istanbul, Turkey.},
DOI = {10.4103/jcrt.jcrt\_641\_21},
ISSN = {0973-1482},
EISSN = {1998-4138},
Keywords = {Head and neck squamous cell carcinoma; in vitro; medicarpin; <p>PTEN/AKT
   signal pathway</p>},
Keywords-Plus = {APOPTOSIS; SATIVA},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {akyigin@iuc.edu.tr},
Affiliations = {University of Manchester; Istanbul University - Cerrahpasa; Kastamonu
   University; Istanbul University; Kahramanmaras Sutcu Imam University;
   Necmettin Erbakan University; Istanbul University - Cerrahpasa},
ResearcherID-Numbers = {ESER, Nadire/ACX-4336-2022
   Donmez, Huseyin/AAB-2318-2021
   h, m/GXV-0881-2022
   Kalayci, Aysel/A-1303-2017},
ORCID-Numbers = {Kalayci, Aysel/0000-0001-8549-5564
   Donmez, Huseyin/0000-0002-9746-0227
   },
Cited-References = {Abhishek Bhanot Abhishek Bhanot, 2011, International Journal of Phytomedicine, V3, P9.
   BRENNAN JA, 1995, NEW ENGL J MED, V332, P712, DOI 10.1056/NEJM199503163321104.
   Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399.
   Dixit M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144541.
   Du E, 2019, LARYNGOSCOPE, V129, P2506, DOI 10.1002/lary.27807.
   Gatouillat G, 2015, PHYTOMEDICINE, V22, P1186, DOI 10.1016/j.phymed.2015.09.005.
   Gatouillat G, 2014, NUTR CANCER, V66, P483, DOI 10.1080/01635581.2014.884228.
   Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239.
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107.
   Li F, 2008, BIOORGAN MED CHEM, V16, P5434, DOI 10.1016/j.bmc.2008.04.016.
   Liu R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02998-6.
   Martínez-Sotres C, 2012, INT BIODETER BIODEGR, V69, P38, DOI 10.1016/j.ibiod.2011.11.016.
   Militao GCG, 2007, BIOORGAN MED CHEM, V15, P6687, DOI 10.1016/j.bmc.2007.08.011.
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285.
   Promchai T, 2020, NAT PROD RES, V34, P1394, DOI 10.1080/14786419.2018.1512990.
   Song Y, 2014, J Med Plant Herb Ther Res, V2, P6, DOI DOI 10.14719/PST.2014.1.2.17.
   Vineis P, 2014, LANCET, V383, P549, DOI 10.1016/S0140-6736(13)62224-2.
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052.},
Number-of-Cited-References = {18},
Times-Cited = {5},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {15},
Journal-ISO = {J. Canc. Res. Ther.},
Doc-Delivery-Number = {0V1BR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000788081000027},
OA = {gold},
DA = {2026-02-04},
}

@article{ WOS:000736832100001,
Author = {Salguero, Antonieta L. and Chen, Maggie and Balana, Aaron T. and Chu,
   Nam and Jiang, Hanjie and Palanski, Brad A. and Bae, Hwan and Wright,
   Katharine M. and Nathan, Sara and Zhu, Heng and Gabelli, Sandra B. and
   Pratt, Matthew R. and Cole, Philip A.},
Title = {Multifaceted Regulation of Akt by Diverse C-Terminal Post-translational
   Modifications},
Journal = {ACS CHEMICAL BIOLOGY},
Year = {2022},
Volume = {17},
Number = {1},
Pages = {68-76},
Month = {JAN 21},
Abstract = {Akt is a Ser/Thr protein kinase that regulates cell growth and
   metabolism and is considered a therapeutic target for cancer. Regulation
   of Akt by membrane recruitment and post-translational modifications
   (PTMs) has been extensively studied. The most well-established mechanism
   for cellular Akt activation involves phosphorylation on its activation
   loop on Thr308 by PDK1 and on its C-terminal tail on Ser473 by mTORC2.
   In addition, dual phosphorylation on Ser477 and Thr479 has been shown to
   activate Akt. Other C-terminal tail PTMs have been identified, but their
   functional impacts have not been well-characterized. Here, we
   investigate the regulatory effects of phosphorylation of Tyr474 and
   O-GlcNAcylation of Ser473 on Akt. We use expressed protein ligation as a
   tool to produce semisynthetic Akt proteins containing phosphoTyr474 and
   O-GlcNAcSer473 to dissect the enzymatic functions of these PTMs. We find
   that O-GlcNAcylation at Ser473 and phosphorylation at Tyr474 can also
   partially increase Akt's kinase activity toward both peptide and protein
   substrates. Additionally, we performed kinase assays employing human
   protein microarrays to investigate global substrate specificity of Akt,
   comparing phosphorylated versus O-GlcNAcylated Ser473 forms. We observed
   a high similarity in the protein substrates phosphorylated by
   phosphoSer473 Akt and O-GlcNAcSer473 Akt. Two Akt substrates identified
   using microarrays, PPM1H, a protein phosphatase, and NEDD4L, an E3
   ubiquitin ligase, were validated in solution-phase assays and cell
   transfection experiments.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Cole, PA (Corresponding Author), Brigham \& Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.
   Cole, PA (Corresponding Author), Harvard Med Sch, Dept Biol Chem \& Mol Pharmacol, Boston, MA 02115 USA.
   Salguero, Antonieta L.; Chen, Maggie; Jiang, Hanjie; Palanski, Brad A.; Bae, Hwan; Cole, Philip A., Brigham \& Womens Hosp, Dept Med, Div Genet, 75 Francis St, Boston, MA 02115 USA.
   Salguero, Antonieta L.; Chen, Maggie; Jiang, Hanjie; Palanski, Brad A.; Bae, Hwan; Cole, Philip A., Harvard Med Sch, Dept Biol Chem \& Mol Pharmacol, Boston, MA 02115 USA.
   Salguero, Antonieta L.; Jiang, Hanjie; Zhu, Heng; Cole, Philip A., Johns Hopkins Sch Med, Dept Pharmacol \& Mol Sci, Baltimore, MD 21205 USA.
   Chen, Maggie, Harvard Univ, Dept Chem \& Chem Biol, Cambridge, MA 02138 USA.
   Balana, Aaron T.; Pratt, Matthew R., Univ Southern Calif, Dept Chem, Los Angeles, CA 90089 USA.
   Chu, Nam, Ohio State Univ, Comprehens Canc Ctr, Dept Canc Biol \& Genet, Columbus, OH 43210 USA.
   Wright, Katharine M.; Nathan, Sara; Gabelli, Sandra B., Johns Hopkins Sch Med, Dept Biophys \& Biophys Chem, Baltimore, MD 21205 USA.
   Zhu, Heng, Johns Hopkins Univ, Ctr High Throughput Biol, Sch Med, Baltimore, MD 21205 USA.
   Gabelli, Sandra B., Johns Hopkins Univ, Dept Med, Sch Med, Baltimore, MD 21205 USA.
   Gabelli, Sandra B., Johns Hopkins Univ, Dept Oncol, Sch Med, Baltimore, MD 21287 USA.},
DOI = {10.1021/acschembio.1c00632},
EarlyAccessDate = {DEC 2021},
ISSN = {1554-8929},
EISSN = {1554-8937},
Keywords-Plus = {PROTEIN-KINASE B; O-GLCNACYLATION; PHOSPHORYLATION; ACTIVATION; INSULIN;
   AKT/PKB; GLCNAC; NEDD4-2; CELLS},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {pacole@bwh.harvard.edu},
Affiliations = {Harvard University; Harvard University Medical Affiliates; Brigham \&
   Women's Hospital; Harvard University; Harvard Medical School; Johns
   Hopkins University; Johns Hopkins Medicine; Harvard University;
   University of Southern California; University System of Ohio; Ohio State
   University; James Cancer Hospital \& Solove Research Institute; Johns
   Hopkins University; Johns Hopkins Medicine; Johns Hopkins University;
   Johns Hopkins University; Johns Hopkins University},
ResearcherID-Numbers = {Chu, Nam/HOC-3099-2023
   Balana, Aaron John/GXV-8586-2022
   Gabelli, Sana/A-3705-2008
   Jiang, Hanjie/AAT-8422-2021},
ORCID-Numbers = {Chen, Maggie/0000-0002-1900-1017
   Chu, Nam/0000-0001-9717-5007
   Gabelli, Sana/0000-0003-1205-5204
   Zhu, Heng/0000-0002-8426-2889
   Jiang, Hanjie/0000-0001-6090-4552},
Funding-Acknowledgement = {NIH {[}GM62437S1, CA74305, F32 CA259214]; NCI {[}K22CA241105];  {[}R01
   GM136148];  {[}R01 GM114537]; National Cancer Institute {[}K22CA241105,
   R01CA074305, F32CA259214] Funding Source: NIH RePORTER; National
   Institute of General Medical Sciences {[}R01GM114537, R01GM136148,
   R37GM062437] Funding Source: NIH RePORTER},
Funding-Text = {We thank D. Alessi for PPM1H plasmids, D. Kim for PRAS40 plasmid, and
   Thermo Fisher Scientific's Aspire Program for RL2 antibody. P.A.C. and
   A.S. are grateful for funding from NIH grant CA74305 and the
   corresponding diversity supplement. N.C. thanks NCI for funding support
   from K22CA241105. B.A.P. is supported by an NIH postdoctoral fellowship
   (F32 CA259214). This work was partially funded by R01 GM136148 (S.B.G.)
   and R01 GM114537 (M.R.P.). The Q-Exactive mass spectrometer used here
   was obtained with NIH grant GM62437S1.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Balana AT, 2021, NAT CHEM, V13, P441, DOI 10.1038/s41557-021-00648-8.
   Berndsen K, 2019, ELIFE, V8, DOI 10.7554/eLife.50416.
   Bolduc D, 2013, ELIFE, V2, DOI 10.7554/eLife.00691.
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Calleja V, 2009, PLOS BIOL, V7, P189, DOI 10.1371/journal.pbio.1000017.
   Chen MJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag1796.
   Chu N, 2020, ELIFE, V9, DOI 10.7554/eLife.59151.
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003.
   Cole PA, 2019, CURR OPIN STRUC BIOL, V59, P47, DOI 10.1016/j.sbi.2019.02.004.
   Conus NM, 2002, J BIOL CHEM, V277, P38021, DOI 10.1074/jbc.M203387200.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Cui YX, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109327.
   Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052.
   Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028.
   Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107.
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120.
   Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21.
   Gribble FM, 2000, J BIOL CHEM, V275, P30046, DOI 10.1074/jbc.M001010200.
   Heath JM, 2014, CIRC RES, V114, P1094, DOI 10.1161/CIRCRESAHA.114.302968.
   James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709.
   Kang ES, 2008, EXP CELL RES, V314, P2238, DOI 10.1016/j.yexcr.2008.04.014.
   Kannan N, 2007, P NATL ACAD SCI USA, V104, P1272, DOI 10.1073/pnas.0610251104.
   Kostaras E, 2020, BRIT J CANCER, V123, P542, DOI 10.1038/s41416-020-0889-4.
   Lee IH, 2007, J BIOL CHEM, V282, P29866, DOI 10.1074/jbc.M701923200.
   Levine PM, 2019, P NATL ACAD SCI USA, V116, P1511, DOI 10.1073/pnas.1808845116.
   Liao Y, 2010, AM J TRANSL RES, V2, P19.
   Liu K, 2000, P NATL ACAD SCI USA, V97, P2820, DOI 10.1073/pnas.97.6.2820.
   Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079.
   Lucic I, 2018, P NATL ACAD SCI USA, V115, pE3940, DOI 10.1073/pnas.1716109115.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Manning J. A., 2021, CELL DEATH DISCOV, V12, P1.
   Marty MT, 2015, ANAL CHEM, V87, P4370, DOI 10.1021/acs.analchem.5b00140.
   Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705.
   Risso G, 2015, BIOCHEM J, V468, P203, DOI 10.1042/BJ20150041.
   Ronzaud C, 2013, J CLIN INVEST, V123, P657, DOI 10.1172/JCI61110.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Shi JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14500.
   Shi JH, 2012, FEBS LETT, V586, P2443, DOI 10.1016/j.febslet.2012.05.063.
   Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008-5472.CAN-18-2738.
   Syu GD, 2020, MOL CELL PROTEOMICS, V19, P916, DOI 10.1074/mcp.R120.001936.
   Tarrant MK, 2012, NAT CHEM BIOL, V8, P262, DOI {[}10.1038/NCHEMBIO.771, 10.1038/nchembio.771].
   Truebestein L, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101496118.
   Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870.
   Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668.
   Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200.},
Number-of-Cited-References = {49},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {ACS Chem. Biol.},
Doc-Delivery-Number = {ZL5DR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000736832100001},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000734719100021,
Author = {Gordon, Moshe T. and Ziemba, Brian P. and Falke, Joseph J.},
Title = {Single-molecule studies reveal regulatory interactions between master
   kinases PDK1, AKT1, and PKC},
Journal = {BIOPHYSICAL JOURNAL},
Year = {2021},
Volume = {120},
Number = {24},
Pages = {5657-5673},
Month = {DEC 21},
Abstract = {Leukocyte migration is controlled by a leading-edge chemosensory pathway
   that generates the regulatory lipid
   phosphatidylinositol-3,4,5-trisphosphate (PIP3), a growth signal,
   thereby driving leading-edge expansion up attractant gradients toward
   sites of infection, inflammation, or tissue damage. PIP3 also serves as
   an important growth signal in growing cells and oncogenesis. The kinases
   PDK1, AKT1 or PKB, and PKC alpha are key components of a
   plasma-membrane-based PIP3 and Ca2+ signaling circuit that regulates
   these processes. PDK1 and AKT1 are recruited to the membrane by PIP3,
   whereas PKC alpha is recruited to the membrane by Ca2+. All three of
   these master kinases phosphoregulate an array of protein targets. For
   example, PDK1 activates AKT1, PKC alpha, and other AGC kinases by
   phosphorylation at key sites. PDK1 is believed to form PDK1-AKT1 and
   PDK1-PKC alpha heterodimers stabilized by a PDK1-interacting fragment
   (PIF) interaction between the PDK1 PIF pocket and the PIF motif of the
   AGC binding partner. Here, we present the first, to our knowledge,
   single-molecule studies of full-length PDK1 and AKT1 on target membrane
   surfaces, as well as their interaction with full-length PKC alpha. These
   studies directly detect membrane-bound PDK1-AKT1 and PDK1-PKC alpha
   heterodimers stabilized by PIF interactions formed at physiological
   ligand concentrations. PKC alpha exhibits eightfold higher PDK1 affinity
   than AKT1 and can competitively displace AKT1 from PDK1-AKT1
   heterodimers. Ensemble activity measurements under matched conditions
   reveal that PDK1 activates AKT1 via a cis mechanism by phosphorylating
   an AKT1 molecule in the same PDK1-AKT1 heterodimer, whereas PKC alpha
   acts as a competitive inhibitor of this phosphoactivation reaction by
   displacing AKT1 from PDK1. Overall, the findings provide insights into
   the binding and regulatory interactions of the three master kinases on
   their target membrane and suggest that a recently described tumor
   suppressor activity of PKC isoforms may arise from its ability to
   downregulate PDK1-AKT1 phosphoactivation in the PIP3-PDK1-AKT1-mTOR
   pathway linked to cell growth and oncogenesis.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Falke, JJ (Corresponding Author), Univ Colorado, Mol Biophys Program, Boulder, CO 80309 USA.
   Falke, JJ (Corresponding Author), Univ Colorado, Dept Biochem, Boulder, CO 80309 USA.
   Gordon, Moshe T.; Ziemba, Brian P.; Falke, Joseph J., Univ Colorado, Mol Biophys Program, Boulder, CO 80309 USA.
   Gordon, Moshe T.; Ziemba, Brian P.; Falke, Joseph J., Univ Colorado, Dept Biochem, Boulder, CO 80309 USA.},
DOI = {10.1016/j.bpj.2021.10.015},
EarlyAccessDate = {DEC 2021},
ISSN = {0006-3495},
EISSN = {1542-0086},
Keywords-Plus = {PHOSPHOINOSITIDE-DEPENDENT KINASE; PROTEIN-KINASE; LEADING-EDGE; PH
   DOMAIN; IN-VIVO; EUKARYOTIC CHEMOTAXIS; ACTIVATION MECHANISM; PI3K;
   RECEPTOR; CA2+},
Research-Areas = {Biophysics},
Web-of-Science-Categories  = {Biophysics},
Author-Email = {falke@colorado.edu},
Affiliations = {University of Colorado System; University of Colorado Boulder;
   University of Colorado System; University of Colorado Boulder},
ORCID-Numbers = {FALKE, JOSEPH/0000-0002-3704-4694
   ZIEMBA, BRIAN/0000-0002-0508-6830},
Funding-Acknowledgement = {National Institutes of Health {[}R01 GM063235, T32 GM065103]; National
   Institute of General Medical Sciences {[}T32GM065103, R01GM063235]
   Funding Source: NIH RePORTER},
Funding-Text = {The authors gratefully acknowledge funding by National Institutes of
   Health grant R01 GM063235 to J.J.F. and by National Institutes of Health
   Molecular Biophysics Traineeship T32 GM065103 to M.T.G.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001.
   Artemenko Y, 2014, CELL MOL LIFE SCI, V71, P3711, DOI 10.1007/s00018-014-1638-8.
   Asokan SB, 2014, DEV CELL, V31, P747, DOI 10.1016/j.devcel.2014.10.024.
   Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200.
   Barros-Becker F, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101699.
   Beerman RW, 2015, CELL REP, V13, P2107, DOI 10.1016/j.celrep.2015.11.010.
   Bers DM, 2010, METHOD CELL BIOL, V99, P1, DOI {[}10.1016/S0091-679X(10)99001-8, 10.1016/B978-0-12-374841-6.00001-3].
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Blake JF, 2012, J MED CHEM, V55, P8110, DOI 10.1021/jm301024w.
   Blake JF, 2010, BIOORG MED CHEM LETT, V20, P5607, DOI 10.1016/j.bmcl.2010.08.053.
   Braglia L, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118731.
   Buckles TC, 2020, BIOPHYS J, V119, P2205, DOI 10.1016/j.bpj.2020.10.028.
   Buckles TC, 2017, BIOPHYS J, V113, P2396, DOI 10.1016/j.bpj.2017.09.018.
   Burke JE, 2015, TRENDS BIOCHEM SCI, V40, P88, DOI 10.1016/j.tibs.2014.12.003.
   Burke John E., 2013, Advances in Biological Regulation, V53, P97, DOI 10.1016/j.jbior.2012.09.005.
   Burke JE, 2012, P NATL ACAD SCI USA, V109, P15259, DOI 10.1073/pnas.1205508109.
   Cai HQ, 2011, SEMIN CELL DEV BIOL, V22, P834, DOI 10.1016/j.semcdb.2011.07.020.
   Corbin JA, 2004, BIOCHEMISTRY-US, V43, P16161, DOI 10.1021/bi049017a.
   Corbin JA, 2007, BIOCHEMISTRY-US, V46, P4322, DOI 10.1021/bi062140c.
   Devreotes P, 2003, J BIOL CHEM, V278, P20445, DOI 10.1074/jbc.R300010200.
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7.
   Engel M, 2006, EMBO J, V25, P5469, DOI 10.1038/sj.emboj.7601416.
   Evans JH, 2006, MOL BIOL CELL, V17, P56, DOI 10.1091/mbc.e05-06-0499.
   Evans JH, 2007, P NATL ACAD SCI USA, V104, P16176, DOI 10.1073/pnas.0707719104.
   Falke JJ, 2014, CHEM PHYS LIPIDS, V182, P73, DOI 10.1016/j.chemphyslip.2014.01.002.
   Gambardella L, 2013, J LEUKOCYTE BIOL, V94, P603, DOI 10.1189/jlb.1112564.
   Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200.
   Gao XX, 2006, BIOORG CHEM, V34, P200, DOI 10.1016/j.bioorg.2006.05.002.
   Gao XX, 2005, PROTEIN EXPRES PURIF, V43, P44, DOI 10.1016/j.pep.2005.03.017.
   Graziano BR, 2017, J CELL BIOL, V216, P2515, DOI 10.1083/jcb.201604113.
   Hanke S, 2009, MOL CELL PROTEOMICS, V8, P519, DOI 10.1074/mcp.M800407-MCP200.
   Hawkins PT, 2015, BBA-MOL CELL BIOL L, V1851, P882, DOI 10.1016/j.bbalip.2014.12.006.
   Hindie V, 2009, NAT CHEM BIOL, V5, P758, DOI 10.1038/nchembio.208.
   Hon WC, 2012, ONCOGENE, V31, P3655, DOI 10.1038/onc.2011.532.
   Iijima M, 2002, DEV CELL, V3, P469, DOI 10.1016/S1534-5807(02)00292-7.
   Itzhak DN, 2016, ELIFE, V5, DOI 10.7554/eLife.16950.
   Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6.
   Khatpe AS, 2021, CANCERS, V13, DOI 10.3390/cancers13030369.
   Knight JD, 2010, BIOPHYS J, V99, P2879, DOI 10.1016/j.bpj.2010.08.046.
   Knight JD, 2009, BIOPHYS J, V96, P566, DOI 10.1016/j.bpj.2008.10.020.
   Lin K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002618.
   Masters TA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000738.
   Mellor P, 2012, BIOCHEM J, V441, P23, DOI 10.1042/BJ20111164.
   Miralem T, 2016, FASEB J, V30, P2926, DOI 10.1096/fj.201600330RR.
   MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287.
   Newton AC, 2018, CRIT REV BIOCHEM MOL, V53, P208, DOI 10.1080/10409238.2018.1442408.
   Newton AC, 2017, TRENDS PHARMACOL SCI, V38, P438, DOI 10.1016/j.tips.2017.02.002.
   Parikh C, 2012, P NATL ACAD SCI USA, V109, P19368, DOI 10.1073/pnas.1204384109.
   Rettenmaier TJ, 2014, P NATL ACAD SCI USA, V111, P18590, DOI 10.1073/pnas.1415365112.
   Samuels Y, 2011, CURR TOP MICROBIOL, V347, P21, DOI 10.1007/82\_2010\_68.
   Sbalzarini IF, 2005, J STRUCT BIOL, V151, P182, DOI 10.1016/j.jsb.2005.06.002.
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8.
   Siempelkamp BD, 2017, J BIOL CHEM, V292, P12256, DOI 10.1074/jbc.M117.789263.
   Stroba A, 2009, J MED CHEM, V52, P4683, DOI 10.1021/jm9001499.
   Swaney KF, 2010, ANNU REV BIOPHYS, V39, P265, DOI 10.1146/annurev.biophys.093008.131228.
   Vadas O, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002165.
   Van AAN, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100445.
   Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299.
   Weiger Michael C, 2012, Subcell Biochem, V59, P217, DOI 10.1007/978-94-007-3015-1\_7.
   Wen Y, 2021, ANNU REV BIOCHEM, V90, P681, DOI 10.1146/annurev-biochem-070920-094827.
   Wu WI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012913.
   Yamamoto E, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay5736.
   Yang HW, 2016, NAT CELL BIOL, V18, P191, DOI 10.1038/ncb3292.
   Yang HW, 2012, MOL CELL, V47, P281, DOI 10.1016/j.molcel.2012.05.007.
   Ziemba BP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196678.
   Ziemba BP, 2016, BIOPHYS J, V110, P1811, DOI 10.1016/j.bpj.2016.03.001.
   Ziemba BP, 2014, BIOCHEMISTRY-US, V53, P1697, DOI 10.1021/bi4016082.
   Ziemba BP, 2013, BIOCHEMISTRY-US, V52, P4820, DOI 10.1021/bi400488f.
   Ziemba BP, 2013, CHEM PHYS LIPIDS, V172, P67, DOI 10.1016/j.chemphyslip.2013.04.005.
   Ziemba BP, 2012, BIOCHEMISTRY-US, V51, P1638, DOI 10.1021/bi201743a.},
Number-of-Cited-References = {74},
Times-Cited = {11},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Biophys. J.},
Doc-Delivery-Number = {XV1OC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000734719100021},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000738850400001,
Author = {Ge, Juan and Zhang, Na and Tang, Shoubin and Hu, Feifei and Hou,
   Xiaojing and Sun, Hongzheng and Han, Longsen and Wang, Qiang},
Title = {Loss of PDK1 Induces Meiotic Defects in Oocytes From Diabetic Mice},
Journal = {FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY},
Year = {2021},
Volume = {9},
Month = {DEC 20},
Abstract = {Maternal diabetes has been shown to impair oocyte quality; however, the
   underlying mechanisms remain unclear. Here, using a streptozotocin
   (STZ)-induced diabetic mouse model, we first detected and reduced
   expression of pyruvate dehydrogenase kinase 1 (PDK1) in diabetic
   oocytes, accompanying with the lowered phosphorylation of serine residue
   232 on alpha subunit of the pyruvate dehydrogenase (PDH) complex
   (Ser232-PDHE1 alpha). Importantly, forced expression of PDK1 not only
   elevated the phosphorylation level of Ser232-PDHE1 alpha, but also
   partly prevented the spindle disorganization and chromosome misalignment
   in oocytes from diabetic mice, with no beneficial effects on metabolic
   dysfunction. Moreover, a phospho-mimetic S232D-PDHE1 alpha mutant is
   also capable of ameliorating the maternal diabetes-associated meiotic
   defects. In sum, our data indicate that PDK1-controlled Ser232-PDHE1
   alpha phosphorylation pathway mediates the effects of diabetic
   environment on oocyte competence.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, Q (Corresponding Author), Nanjing Med Univ, Suzhou Municipal Hosp, State Key Lab Reprod Med, Nanjing, Peoples R China.
   Wang, Q (Corresponding Author), Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Peoples R China.
   Ge, Juan; Zhang, Na; Tang, Shoubin; Sun, Hongzheng; Han, Longsen; Wang, Qiang, Nanjing Med Univ, Suzhou Municipal Hosp, State Key Lab Reprod Med, Nanjing, Peoples R China.
   Hu, Feifei, Nanjing Med Univ, Dept Obstet \& Gynecol, Affiliated Hosp 2, Nanjing, Peoples R China.
   Hou, Xiaojing, Nanjing Med Univ, Womens Hosp, Nanjing Matern \& Child HealthCare Hosp, Nanjing, Peoples R China.
   Wang, Qiang, Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Peoples R China.},
DOI = {10.3389/fcell.2021.793389},
Article-Number = {793389},
ISSN = {2296-634X},
Keywords = {oocyte; meiosis; diabetes; spindle; PDK1},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; PHOSPHORYLATION SITES; MOUSE OOCYTE;
   GLUCOSE; METABOLISM; MECHANISMS; EXPRESSION; MATURATION; COMPLEX;
   QUALITY},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {qwang2012@njmu.edu.cn},
Affiliations = {Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University},
ResearcherID-Numbers = {han, longsen/JYQ-1450-2024
   ZHANG, Nannan/K-9996-2019
   Tang, Shoubin/MGA-5314-2025},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31900594, 8210061637,
   81925014]; Natural Science Foundation of Jiangsu Province {[}BK20190651]},
Funding-Text = {Funding This work was supported by National Natural Science Foundation
   of China (NO. 31900594 to LH, 8210061637 to HS and 81925014 to QW), and
   Natural Science Foundation of Jiangsu Province (BK20190651 to LH).},
Cited-References = {Akhmedov D, 2012, BBA-MOL CELL RES, V1823, P1815, DOI 10.1016/j.bbamcr.2012.07.005.
   Amaral S, 2008, CURR DIABETES REV, V4, P46, DOI 10.2174/157339908783502398.
   BIGGERS JD, 1967, P NATL ACAD SCI USA, V58, P560, DOI 10.1073/pnas.58.2.560.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Chang AS, 2005, ENDOCRINOLOGY, V146, P2445, DOI 10.1210/en.2004-1472.
   Cheng PP, 2011, REPRODUCTION, V141, P417, DOI 10.1530/REP-10-0370.
   Combelles CMH, 2003, BIOL REPROD, V68, P812, DOI 10.1095/biolreprod.102.008656.
   Ding L, 2012, THERIOGENOLOGY, V78, P784, DOI 10.1016/j.theriogenology.2012.03.026.
   EPPIG JJ, 1976, J EXP ZOOL, V198, P375, DOI 10.1002/jez.1401980311.
   FAGBOHUN CF, 1992, J REPROD FERTIL, V96, P681, DOI 10.1530/jrf.0.0960681.
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2.
   Greene MF, 1999, SEMIN REPROD ENDOCR, V17, P127, DOI 10.1055/s-2007-1016220.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Han LS, 2018, NAT GENET, V50, P432, DOI 10.1038/s41588-018-0055-6.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hou XJ, 2015, J CELL SCI, V128, P2319, DOI 10.1242/jcs.167049.
   Jungheim ES, 2008, SEMIN REPROD MED, V26, P186, DOI 10.1055/s-2008-1042957.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Kwon HS, 2006, BBA-GENE STRUCT EXPR, V1759, P141, DOI 10.1016/j.bbaexp.2006.04.005.
   Liu XH, 2017, CELL CYCLE, V16, P1302, DOI 10.1080/15384101.2017.1320004.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32.
   Rardin MJ, 2009, ANAL BIOCHEM, V389, P157, DOI 10.1016/j.ab.2009.03.040.
   Ratchford AM, 2008, MOL ENDOCRINOL, V22, P2643, DOI 10.1210/me.2007-0495.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   SAITO T, 1994, BIOL REPROD, V50, P266, DOI 10.1095/biolreprod50.2.266.
   Sirard MA, 2006, THERIOGENOLOGY, V65, P126, DOI 10.1016/j.theriogenology.2005.09.020.
   Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263.
   Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002.
   Tokmakov AA, 2009, GENE EXPR PATTERNS, V9, P158, DOI 10.1016/j.gep.2008.11.005.
   Vagnoni A, 2011, J CELL SCI, V124, P1032, DOI 10.1242/jcs.075168.
   Wang Q, 2012, ENDOCRINOLOGY, V153, P1984, DOI 10.1210/en.2011-1815.
   Wang QA, 2010, MITOCHONDRION, V10, P403, DOI 10.1016/j.mito.2010.03.002.
   Wang Q, 2009, MOL ENDOCRINOL, V23, P1603, DOI 10.1210/me.2009-0033.
   Wong SL, 2015, REPROD FERT DEVELOP, V27, P583, DOI 10.1071/RD14328.
   Xin YA, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12940.
   Yang YQ, 2016, CELL BIOCHEM FUNCT, V34, P546, DOI 10.1002/cbf.3235.
   Zeng J, 2018, AGING CELL, V17, DOI 10.1111/acel.12789.
   ZUELKE KA, 1992, ENDOCRINOLOGY, V131, P2690, DOI 10.1210/en.131.6.2690.},
Number-of-Cited-References = {41},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Front. Cell. Dev. Biol.},
Doc-Delivery-Number = {YB2LL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000738850400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000756774200001,
Author = {Han, Xiaoning and Wei, Yongjie and Ba, Ru and Sun, Lijuan and Zhao,
   Chunjie},
Title = {PDK1 Regulates the Lengthening of G1 Phase to Balance RGC Proliferation
   and Differentiation during Cortical Neurogenesis},
Journal = {CEREBRAL CORTEX},
Year = {2022},
Volume = {32},
Number = {16},
Pages = {3488-3500},
Month = {AUG 3},
Abstract = {During cortical development, the balance between progenitor self-renewal
   and neurogenesis is critical for determining the size/morphology of the
   cortex. A fundamental feature of the developing cortex is an increase in
   the length of G1 phase in RGCs over the course of neurogenesis, which is
   a key determinant of progenitor fate choice. How the G1 length is
   temporally regulated remains unclear. Here, Pdk1, a member of the AGC
   kinase family, was conditionally disrupted by crossing an Emx1-Cre mouse
   line with a Pdk1(fl/fl) line. The loss of Pdk1 led to a shorter cell
   cycle accompanied by increased RGC proliferation specifically at late
   rather than early/middle neurogenic stages, which was attributed to
   impaired lengthening of G1 phase. Coincidently, apical-to-basal
   interkinetic nuclear migration was accelerated in Pdk1 cKO cortices.
   Consequently, we detected an increased neuronal output at P0. We further
   showed the significant upregulation of the cell cycle regulator cyclin
   D1 and its activator Myc in the cKO cortices relative to those of
   control animals. Overall, we have identified a novel role for PDK1 in
   cortical neurogenesis. PDK1 functions as an upstream regulator of the
   Myc-cyclin D1 pathway to control the lengthening of G1 phase and the
   balance between RGC proliferation and differentiation.},
Publisher = {OXFORD UNIV PRESS INC},
Address = {JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhao, CJ (Corresponding Author), Southeast Univ, Sch Med, Key Lab Dev Genes \& Human Dis, Minist Educ, Nanjing 210009, Peoples R China.
   Han, Xiaoning; Wei, Yongjie; Ba, Ru; Sun, Lijuan; Zhao, Chunjie, Southeast Univ, Sch Med, Key Lab Dev Genes \& Human Dis, Minist Educ, Nanjing 210009, Peoples R China.
   Han, Xiaoning, Changzhou Univ, Inst Biomed Engn \& Hlth Sci, Changzhou 213164, Peoples R China.},
DOI = {10.1093/cercor/bhab428},
EarlyAccessDate = {DEC 2021},
ISSN = {1047-3211},
EISSN = {1460-2199},
Keywords = {cell cycle; corticogenesis; differentiation; G1 phase; PDK1;
   proliferation; RGC},
Keywords-Plus = {INTERKINETIC NUCLEAR MIGRATION; CELL-CYCLE CONTROL; NEURAL PROGENITOR
   CELLS; NEURONAL MIGRATION; STEM-CELLS; C-MYC; BRAIN; FATE;
   PHOSPHORYLATION; INHIBITION},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {zhaocj@seu.edu.cn},
Affiliations = {Southeast University - China; Changzhou University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31930045, 81870899];
   Scientific Research Foundation of Jiangsu Provincial Education
   Department, China {[}21KJB310004]},
Funding-Text = {National Natural Science Foundation of China (31930045, 81870899 to C.
   Z.). Scientific Research Foundation of Jiangsu Provincial Education
   Department, China (21KJB310004 to X.H.)},
Cited-References = {Agius E, 2015, CELL TISSUE RES, V359, P201, DOI 10.1007/s00441-014-1998-2.
   Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900.
   Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0.
   Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810.
   Borello U, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00119.
   Borrell V, 2014, NEUROSCI RES, V86, P14, DOI 10.1016/j.neures.2014.04.004.
   Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006.
   Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013.
   Bystron I, 2008, NAT REV NEUROSCI, V9, P110, DOI 10.1038/nrn2252.
   Calegari F, 2003, J CELL SCI, V116, P4947, DOI 10.1242/jcs.00825.
   Calegari F, 2005, J NEUROSCI, V25, P6533, DOI 10.1523/JNEUROSCI.0778-05.2005.
   Cappello S, 2006, NAT NEUROSCI, V9, P1099, DOI 10.1038/nn1744.
   Carabalona A, 2016, NAT NEUROSCI, V19, P253, DOI 10.1038/nn.4213.
   Del Bene F, 2008, CELL, V134, P1055, DOI 10.1016/j.cell.2008.07.017.
   Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957.
   Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245.
   Feng SF, 2017, FASEB J, V31, P4347, DOI 10.1096/fj.201700216RR.
   Ferrell JE, 2011, CELL, V144, P874, DOI 10.1016/j.cell.2011.03.006.
   Franco SJ, 2013, NEURON, V77, P19, DOI 10.1016/j.neuron.2012.12.022.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Ghosh T, 2014, CELL REP, V7, P1779, DOI 10.1016/j.celrep.2014.05.029.
   Götz M, 2005, NAT REV MOL CELL BIO, V6, P777, DOI 10.1038/nrm1739.
   Grison A, 2020, MOL NEUROBIOL, V57, P3206, DOI 10.1007/s12035-020-01958-7.
   Han XN, 2020, CEREB CORTEX, V30, P406, DOI 10.1093/cercor/bhz146.
   Hardwick LJA, 2015, CELL TISSUE RES, V359, P187, DOI 10.1007/s00441-014-1895-8.
   Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Lange C, 2009, CELL STEM CELL, V5, P320, DOI 10.1016/j.stem.2009.05.026.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Liao D. Joshua, 2007, Critical Reviews in Oncogenesis, V13, P93.
   Lim S, 2012, STEM CELLS, V30, P1509, DOI 10.1002/stem.1114.
   Liu R, 2020, J NEUROSCI, V40, P5531, DOI 10.1523/JNEUROSCI.2496-19.2020.
   Lukaszewicz A, 2005, NEURON, V47, P353, DOI 10.1016/j.neuron.2005.06.032.
   Marín O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058.
   Massagué J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094.
   Miyama S, 1997, CEREB CORTEX, V7, P678, DOI 10.1093/cercor/7.7.678.
   Miyata T, 2010, CURR OPIN NEUROBIOL, V20, P22, DOI 10.1016/j.conb.2010.01.001.
   Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106.
   Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553.
   NOWAKOWSKI RS, 1989, J NEUROCYTOL, V18, P311, DOI 10.1007/BF01190834.
   Oishi K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI 10.1073/pnas.0808400106.
   Pagano M, 2004, CELL, V118, P535, DOI 10.1016/j.cell.2004.08.013.
   Pilaz LJ, 2009, P NATL ACAD SCI USA, V106, P21924, DOI 10.1073/pnas.0909894106.
   Polleux F, 1997, J COMP NEUROL, V385, P95.
   RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116.
   Rakic P, 2003, CEREB CORTEX, V13, P541, DOI 10.1093/cercor/13.6.541.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Salomoni P, 2010, TRENDS CELL BIOL, V20, P233, DOI 10.1016/j.tcb.2010.01.006.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sauer FC, 1935, J COMP NEUROL, V62, P377, DOI 10.1002/cne.900620207.
   Shi QF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19349-w.
   SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3.
   Stouffer MA, 2016, NEUROBIOL DIS, V92, P18, DOI 10.1016/j.nbd.2015.08.003.
   Tang TX, 2019, NEURON, V101, P1117, DOI 10.1016/j.neuron.2019.01.007.
   Taverna E, 2014, ANNU REV CELL DEV BI, V30, P465, DOI 10.1146/annurev-cellbio-101011-155801.
   Uzquiano A, 2018, J NEUROCHEM, V146, P500, DOI 10.1111/jnc.14338.
   Vandenbosch R, 2007, CELL CYCLE, V6, P3065, DOI 10.4161/cc.6.24.5048.
   Wang CF, 2019, P NATL ACAD SCI USA, V116, P14620, DOI 10.1073/pnas.1903432116.
   Wang CG, 2011, CELL CYCLE, V10, P57, DOI 10.4161/cc.10.1.14449.
   Wang CL, 2007, J NEUROSCI, V27, P11334, DOI 10.1523/JNEUROSCI.3380-07.2007.
   Wei YJ, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00604-6.
   Willardsen MI, 2011, DEV DYNAM, V240, P1865, DOI 10.1002/dvdy.22684.
   Wu XJ, 2014, J NEUROSCI, V34, P1510, DOI 10.1523/JNEUROSCI.2549-13.2014.
   Xie YL, 2013, NEURON, V79, P254, DOI 10.1016/j.neuron.2013.05.027.
   Xie ZG, 2007, NEURON, V56, P79, DOI 10.1016/j.neuron.2007.08.026.
   Xu CY, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00330.
   Zaytseva O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207742.
   Zhang L, 2012, CEREB CORTEX, V22, P1510, DOI 10.1093/cercor/bhr215.},
Number-of-Cited-References = {68},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {25},
Journal-ISO = {Cereb. Cortex},
Doc-Delivery-Number = {3X3RO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000756774200001},
DA = {2026-02-04},
}

@article{ WOS:000730882700001,
Author = {Yang, Shu and Yang, Guangyan and Wu, Han and Kang, Lin and Xiang,
   Jiaqing and Zheng, Peilin and Qiu, Shanhu and Liang, Zhen and Lu, Yan
   and Jia, Lijing},
Title = {MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes
   by targeting the PDK1/Akt signalling pathway},
Journal = {DIABETOLOGIA},
Year = {2022},
Volume = {65},
Number = {3},
Pages = {563-581},
Month = {MAR},
Abstract = {Aims/hypothesis Type 2 diabetes is associated with a reduction in
   skeletal muscle mass; however, how the progression of sarcopenia is
   induced and regulated remains largely unknown. We aimed to find out
   whether a specific microRNA (miR) may contribute to skeletal muscle
   atrophy in type 2 diabetes.
   Methods Adeno-associated virus (AAV)-mediated skeletal muscle miR-193b
   overexpression in C57BLKS/J mice, and skeletal muscle miR-193b
   deficiency in db/db mice were used to explore the function of miR-193b
   in muscle loss. In C57BL/6 J mice, tibialis anterior-specific deletion
   of 3-phosphoinositide-dependent protein kinase-1 (PDK1), mediated by in
   situ AAV injection, was used to confirm whether miR-193b regulates
   muscle growth through PDK1. Serum miR-193b levels were also analysed in
   healthy individuals (n = 20) and those with type 2 diabetes (n = 20),
   and correlations of miR-193b levels with HbA(1c), fasting blood glucose
   (FBG), body composition. triacylglycerols and C-peptide were assessed.
   Results In this study, we found that serum miR-193b levels increased in
   individuals with type 2 diabetes and negatively conflated with muscle
   mass in these participants. Functional studies further showed that
   AAV-mediated overexpression of miR-193b induced muscle loss and
   dysfunction in healthy mice. In contrast, suppression of miR-193b
   attenuated muscle loss and dysfunction in db/db mice. Mechanistic
   analysis revealed that miR-193b could target Pdk1 expression to
   inactivate the Akt/mammalian target of rapamycin (mTOR)/p70S6 kinase
   (S6K) pathway, thereby inhibiting protein synthesis. Therefore,
   knockdown of PDK1 in healthy mice blocked miR-193b-induced inactivation
   of the Alct/mTOR/S6K pathway and impairment of muscle growth.
   Conclusions/interpretation Our results identified a previously
   unrecognised role of miR-193b in muscle function and mass that could he
   a potential therapeutic target for treating sarcopenia.},
Publisher = {SPRINGER},
Address = {ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Jia, LJ (Corresponding Author), Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Endocrinol, Shenzhen, Peoples R China.
   Liang, Z (Corresponding Author), Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Geriatr, Shenzhen, Peoples R China.
   Lu, Y (Corresponding Author), Fudan Univ, Zhongshan Hosp, Dept Endocrinol \& Metab, Shanghai, Peoples R China.
   Yang, Shu; Yang, Guangyan; Wu, Han; Kang, Lin; Xiang, Jiaqing; Zheng, Peilin; Qiu, Shanhu; Jia, Lijing, Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Endocrinol, Shenzhen, Peoples R China.
   Yang, Shu, Jinan Univ, Integrated Chinese \& Western Med Postdoctoral Res, Guangzhou, Peoples R China.
   Wu, Han, Peking Union Med Coll \& Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Endocrinol, Key Lab Endocrinol Natl Hlth Commiss, Beijing, Peoples R China.
   Liang, Zhen, Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Geriatr, Shenzhen, Peoples R China.
   Lu, Yan, Fudan Univ, Zhongshan Hosp, Dept Endocrinol \& Metab, Shanghai, Peoples R China.},
DOI = {10.1007/s00125-021-05616-y},
EarlyAccessDate = {DEC 2021},
ISSN = {0012-186X},
EISSN = {1432-0428},
Keywords = {Akt; miR-193b; Muscles atrophy; PDK1; Type 2 diabetes},
Keywords-Plus = {SARCOPENIA; PREVALENCE; NETWORKS; MIR-193B; ATROPHY; OBESITY; CHINA},
Research-Areas = {Endocrinology \& Metabolism},
Web-of-Science-Categories  = {Endocrinology \& Metabolism},
Author-Email = {liang.zhen@szhospital.com
   lu.yan2@zs-hospital.sh.cn
   jialijing2012@126.com},
Affiliations = {Jinan University; Jinan University; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Peking Union Medical College Hospital;
   Peking Union Medical College; Jinan University; Fudan University},
ResearcherID-Numbers = {yang, shu/GLN-3976-2022
   Zheng, Peilin/B-4360-2015
   xiang, jiaqing/ADE-2914-2022
   Lu, Yan/KIG-9399-2024},
ORCID-Numbers = {yang, shu/0000-0002-4912-777X
   Zheng, Peilin/0000-0002-4712-4903
   xiang, jiaqing/0009-0009-1130-2999
   },
Funding-Acknowledgement = {Youth Program of National Natural Science Foundation of China
   {[}82000824]; China Postdoctoral Science Foundation {[}2020M683179];
   National Key Research and Development Program of China
   {[}2018YFC2001100]},
Funding-Text = {This work was supported by grants from the Youth Program of National
   Natural Science Foundation of China (82000824 to SY), the China
   Postdoctoral Science Foundation (2020M683179 to SY) and the National Key
   Research and Development Program of China (2018YFC2001100).},
Cited-References = {Arner E, 2012, DIABETES, V61, P1986, DOI 10.2337/db11-1508.
   Belarbi Y, 2015, J CLIN ENDOCR METAB, V100, pE1084, DOI 10.1210/jc.2015-1530.
   Bevan AK, 2011, MOL THER, V19, P1971, DOI 10.1038/mt.2011.157.
   Camera DM, 2016, FREE RADICAL BIO MED, V98, P131, DOI 10.1016/j.freeradbiomed.2016.02.007.
   Chan JCN, 2014, LANCET DIABETES ENDO, V2, P969, DOI 10.1016/S2213-8587(14)70144-5.
   Chen ZH, 2020, EXP NEUROL, V327, DOI 10.1016/j.expneurol.2020.113223.
   Choi Hye-Min, 2015, Lab Anim Res, V31, P1, DOI {[}10.5625/lar.2015.31.1.1, 10.5625/lar.2015.31.1.1].
   Crossland H, 2008, J PHYSIOL-LONDON, V586, P5589, DOI 10.1113/jphysiol.2008.160150.
   Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034.
   Czech MP, 2017, NAT MED, V23, P804, DOI 10.1038/nm.4350.
   Du YT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-249.
   Esser KA, 2007, APPL PHYSIOL NUTR ME, V32, P711, DOI 10.1139/H07-058.
   Gan ZJ, 2018, CELL RES, V28, P969, DOI 10.1038/s41422-018-0078-7.
   Haetscher N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9928.
   Hang SY, 2019, EXP MOL PATHOL, V108, P80, DOI 10.1016/j.yexmp.2019.04.006.
   Huber W, 2015, NAT METHODS, V12, P115, DOI {[}10.1038/NMETH.3252, 10.1038/nmeth.3252].
   Ju BL, 2019, J CELL MOL MED, V23, P3824, DOI 10.1111/jcmm.14210.
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755.
   Kim H, 2020, J CACHEXIA SARCOPENI, V11, P1070, DOI 10.1002/jcsm.12558.
   Kim TN, 2010, DIABETES CARE, V33, P1497, DOI 10.2337/dc09-2310.
   Kinney JM, 2004, CURR OPIN CLIN NUTR, V7, P15, DOI 10.1097/00075197-200401000-00004.
   Lai NS, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01745-0.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248.
   Li XH, 2020, ONCOL LETT, V19, P2035, DOI 10.3892/ol.2020.11293.
   Li ZH, 2019, J CACHEXIA SARCOPENI, V10, P391, DOI 10.1002/jcsm.12374.
   Ma CR, 2020, THERANOSTICS, V10, P1090, DOI 10.7150/thno.38115.
   Ma RCW, 2018, DIABETOLOGIA, V61, P1249, DOI 10.1007/s00125-018-4557-7.
   Mazzu YZ, 2017, CANCER RES, V77, P5728, DOI 10.1158/0008-5472.CAN-16-2253.
   Ogama N, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030319.
   Párrizas M, 2015, J CLIN ENDOCR METAB, V100, pE407, DOI 10.1210/jc.2014-2574.
   Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162.
   Schiaffino Stefano, 2011, Skelet Muscle, V1, P4, DOI 10.1186/2044-5040-1-4.
   Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253.
   Shin YJ, 2020, J CACHEXIA SARCOPENI, V11, P1336, DOI 10.1002/jcsm.12578.
   Stepien EL, 2018, THERANOSTICS, V8, P3874, DOI 10.7150/thno.23334.
   Taylor BS, 2011, CANCER DISCOV, V1, P587, DOI 10.1158/2159-8290.CD-11-0181.
   Tinsley FC, 2004, OBES RES, V12, P150, DOI 10.1038/oby.2004.20.
   Trierweiler H, 2018, DIABETOL METAB SYNDR, V10, DOI 10.1186/s13098-018-0326-5.
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596.
   Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294.
   Yang S, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109389.
   Zhang AQ, 2018, J CACHEXIA SARCOPENI, V9, P755, DOI 10.1002/jcsm.12296.
   Zhang JZ, 2017, BIOMED PHARMACOTHER, V96, P1275, DOI 10.1016/j.biopha.2017.11.086.},
Number-of-Cited-References = {44},
Times-Cited = {19},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Diabetologia},
Doc-Delivery-Number = {YS2NS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000730882700001},
OA = {Green Accepted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000797066000001,
Author = {Jiang, Baoen and Kang, Xiuqin and Zhao, Gang and Lu, Jianshu and Wang,
   Zhitao},
Title = {RETRACTED: miR-138 Reduces the Dysfunction of T Follicular Helper Cells
   in Osteosarcoma via the PI3K/Akt/mTOR Pathway by Targeting PDK1
   (Retracted Article)},
Journal = {COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE},
Year = {2021},
Volume = {2021},
Month = {DEC 14},
Abstract = {Objective. To study the effect of miR-138 on the function of
   osteosarcoma (OS) T follicular helper cells (Tfh cells) and its
   mechanism. Methods. Peripheral blood mononuclear cells (PBMCs) were
   isolated from patients with osteosarcoma (OS group) and healthy
   volunteers (control group). CD4+CXCR5+ Tfh cells and CD9+ B cells were
   sorted by flow cytometry. qRT-PCR was used to detect the expression of
   miR-138 and PDK1 in the peripheral blood and CD4+CXCR5+ Tfh cells. Flow
   cytometry was employed to detect the proportion of CD4+CXCR5+ Tfh cells
   in CD4+ T cells, the level of CD40L in CD4+CXCR5+ Tfh cells, and the
   expression of CD27 and CD38 in B cells. Western blot was used to
   determine the protein expression of PDK1, PI3K, p-Akt, Akt, p-mTOR, and
   mTOR. In addition, dual-luciferase reporter assay was performed to
   verify the relationship between miR-138 and PDK1. ELISA method was used
   to determine the levels of IgM, IgG, IL-10, and IL-21. Results. Compared
   with that of the control group, the expression of miR-138 in PBMC and
   CD4+CXCR5+ Tfh cells of the OS group was lower; overexpression of
   miR-138 could promote the maturation of Tfh cells and immature B cells.
   The results of the dual-luciferase report experiment showed that miR-138
   can target and negatively regulate PDK1, and PDK1 can reverse the effect
   of miR-138 on the function of Tfh cells and immature B cells.
   Conclusion. miR-138 inhibits the PI3K/Akt/mTOR pathway by targeting and
   negatively regulating PDK1 to alleviate the dysfunction of T follicular
   helper cells in OS.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article; Retracted Publication},
Language = {English},
Affiliation = {Jiang, BE (Corresponding Author), Dongying Peoples Hosp, Dept Traumat Orthopaed, 317 Nanyi Rd, Dongying 257091, Shandong, Peoples R China.
   Jiang, Baoen; Zhao, Gang; Lu, Jianshu; Wang, Zhitao, Dongying Peoples Hosp, Dept Traumat Orthopaed, 317 Nanyi Rd, Dongying 257091, Shandong, Peoples R China.
   Kang, Xiuqin, Dongying Peoples Hosp, Dept Nursing, 317 Nanyi Rd, Dongying 257091, Shandong, Peoples R China.},
DOI = {10.1155/2021/2895893},
Article-Number = {2895893},
ISSN = {1748-670X},
EISSN = {1748-6718},
Keywords-Plus = {ROLES; OVEREXPRESSION; APOPTOSIS},
Research-Areas = {Mathematical \& Computational Biology},
Web-of-Science-Categories  = {Mathematical \& Computational Biology},
Author-Email = {jiangbaoen1971@163.com},
ORCID-Numbers = {Jiang, Baoen/0000-0001-9279-014X},
Funding-Acknowledgement = {Shandong Provincial Natural Science Fund Project in 2019 {[}ZR2019MH084]},
Funding-Text = {AcknowledgmentsThis study was supported by the Shandong Provincial
   Natural Science Fund Project in 2019 with grant no. ZR2019MH084.},
Cited-References = {Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022.
   Bai XM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1478-3.
   Chen GM, 2018, J CELL BIOCHEM, V119, P885, DOI 10.1002/jcb.26252.
   Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004.
   Cumpelik A, 2021, NAT IMMUNOL, V22, P757, DOI 10.1038/s41590-021-00926-0.
   Czarnecka AM, 2020, CANCERS, V12, DOI 10.3390/cancers12082130.
   Felekkis K, 2010, HIPPOKRATIA, V14, P236.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gao WW, 2017, DNA CELL BIOL, V36, P794, DOI 10.1089/dna.2017.3669.
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16.
   Gu-Trantien C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91487.
   Guo Z, 2017, SCAND J IMMUNOL, V86, P107, DOI 10.1111/sji.12566.
   He LJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08328-z.
   Hollern DP, 2019, CELL, V179, P1191, DOI 10.1016/j.cell.2019.10.028.
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895.
   Jiang BE, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0348-5.
   Li JB, 2017, J CELL MOL MED, V21, P1482, DOI 10.1111/jcmm.13074.
   Li KW, 2020, EUR REV MED PHARMACO, V24, P12655, DOI 10.26355/eurrev\_202012\_24163.
   Li L, 2019, MOL THER-NUCL ACIDS, V14, P101, DOI 10.1016/j.omtn.2018.11.009.
   Li Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0928-8.
   Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004.
   Liu XD, 2012, J EXP MED, V209, P1841, DOI 10.1084/jem.20120219.
   Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005.
   Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994.
   Pang L, 2017, ONCOL REP, V38, P1295, DOI 10.3892/or.2017.5745.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Ritter J, 2010, ANN ONCOL, V21, P320, DOI 10.1093/annonc/mdq276.
   Roberto GM, 2020, PATHOL ONCOL RES, V26, P877, DOI 10.1007/s12253-019-00633-0.
   Rochette L, 2013, PHARMACOL THERAPEUT, V140, P239, DOI 10.1016/j.pharmthera.2013.07.004.
   Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553.
   Seiter M, 2016, CASE REP SURG, V2016, DOI 10.1155/2016/5901769.
   Sun RR, 2016, ONCOTARGET, V7, P38333, DOI 10.18632/oncotarget.9518.
   Sun Y., 2017, JIANKANG QIANYAN, V26, P229.
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254.
   Wang FM, 2021, CELL IMMUNOL, V363, DOI 10.1016/j.cellimm.2021.104321.
   Wang Z, 2017, EUR REV MED PHARMACO, V21, P5624, DOI 10.26355/eurrev\_201712\_14005.
   Wei J, 2016, NEURO-ONCOLOGY, V18, P639, DOI 10.1093/neuonc/nov292.
   Wei ZJ, 2017, EUR REV MED PHARMACO, V21, P2177.
   Wu M, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109696.
   Xie F, 2018, EUR REV MED PHARMACO, V22, P678, DOI 10.26355/eurrev\_201802\_14293.
   Xu YX, 2014, TRENDS BIOCHEM SCI, V39, P268, DOI 10.1016/j.tibs.2014.04.004.
   Yang Y, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0143-3.
   Zhang J, 2015, CLIN CHIM ACTA, V444, P182, DOI 10.1016/j.cca.2014.12.041.
   Zhou Z, 2017, EXP THER MED, V14, P3665, DOI 10.3892/etm.2017.4947.},
Number-of-Cited-References = {44},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {1},
Journal-ISO = {Comput. Math. Method Med.},
Doc-Delivery-Number = {1I2LQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000797066000001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000732990700005,
Author = {Han, Tae-Hee and Park, Min Kyung and Nakamura, Hiroyuki and Ban, Hyun
   Seung},
Title = {Capsaicin inhibits HIF-1α accumulation through suppression of
   mitochondrial respiration in lung cancer cells},
Journal = {BIOMEDICINE \& PHARMACOTHERAPY},
Year = {2022},
Volume = {146},
Month = {FEB},
Abstract = {Hypoxia inducible factor (HIF)-1 alpha is an important transcription
   factor regulating cancer metabolism in hypoxic environment. Capsaicin is
   known to inhibit hypoxia-induced HIF activity in lung cancer. Hence, in
   this study we tried to elucidate its inhibitory mechanism of action. In
   lung cancer cells, including H1299, H23, A549, and H2009 cells,
   capsaicin inhibited cell growth and HIF activation. Under hypoxic
   conditions, capsaicin reduced the accumulation of HIF-1 alpha protein
   and the expression of its target genes, including pyruvate dehydrogenase
   kinase 1 (PDK1) and glucose transporter 1 (GLUT1), with no effect on
   overall HIF-1 alpha mRNA levels in the H1299 cells. In addition,
   capsaicin increased intracellular oxygen levels by suppressing
   mitochondrial respiration, resulting in a reduction of HIF-1 alpha
   accumulation. Furthermore, mitochondrial ATP production was reduced by
   capsaicin through the inhibition of mitochondrial respiration in the
   H1299, H23, A549, and H2009 cells. These results indicate that capsaicin
   potentially exhibits anticancer therapeutic effects in lung cancer under
   hypoxic conditions.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Ban, HS (Corresponding Author), Korea Res Inst Biosci \& Biotechnol, Daejeon 34141, South Korea.
   Nakamura, H (Corresponding Author), Tokyo Inst Technol, Inst Innovat Res, Lab Chem \& Life Sci, Yokohama, Kanagawa 2268503, Japan.
   Han, Tae-Hee; Park, Min Kyung; Ban, Hyun Seung, Korea Res Inst Biosci \& Biotechnol, Daejeon 34141, South Korea.
   Han, Tae-Hee; Ban, Hyun Seung, Korea Univ Sci \& Technol UST, KRIBB Sch Biosci, Dept Biomol Sci, Daejeon 34113, South Korea.
   Nakamura, Hiroyuki, Tokyo Inst Technol, Inst Innovat Res, Lab Chem \& Life Sci, Yokohama, Kanagawa 2268503, Japan.},
DOI = {10.1016/j.biopha.2021.112500},
EarlyAccessDate = {DEC 2021},
Article-Number = {112500},
ISSN = {0753-3322},
EISSN = {1950-6007},
Keywords = {Hypoxia; Capsaicin; HIF-1 alpha; Mitochondrial respiration; Lung cancer},
Keywords-Plus = {METABOLISM; EXPRESSION; MODULATION; APOPTOSIS; PROTEIN; GROWTH; HIF-1;
   TRPV1},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {hiro@res.titech.ac.jp
   banhs@kribb.re.kr},
Affiliations = {Korea Research Institute of Bioscience \& Biotechnology (KRIBB);
   University of Science \& Technology (UST); Institute of Science Tokyo;
   Tokyo Institute of Technology},
ResearcherID-Numbers = {Ban, Hyun Seung/F-9526-2014
   Nakamura, Hiro/ABD-1769-2021},
ORCID-Numbers = {Ban, Hyun Seung/0000-0002-2698-6037
   },
Funding-Acknowledgement = {National Research Foundation of Korea, South Korea
   {[}NRF-2019R1I1A2A01060951, 2019M3E5D406988221]; KRIBB Research
   Initiative Program, South Korea {[}1711134047]},
Funding-Text = {Funding source This work was supported by the National Research
   Foundation of Korea, South Korea {[}grant numbers
   NRF-2019R1I1A2A01060951, 2019M3E5D406988221] and the KRIBB Research
   Initiative Program, South Korea (1711134047) .},
Cited-References = {Al Tameemi W, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00004.
   Ban HS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.235.
   Bao ZQ, 2019, CELL CYCLE, V18, P1379, DOI 10.1080/15384101.2019.1618119.
   Chakraborty S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099743.
   Clark R, 2016, ANTICANCER RES, V36, P837.
   Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z.
   Galano A, 2012, J PHYS CHEM B, V116, P1200, DOI 10.1021/jp211172f.
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183.
   Huang SP, 2009, ANTICANCER RES, V29, P165.
   Kang JH, 2007, FEBS LETT, V581, P4389, DOI 10.1016/j.febslet.2007.07.082.
   Kim CS, 2003, CELL SIGNAL, V15, P299, DOI 10.1016/S0898-6568(02)00086-4.
   Kim HJ, 2020, BIOCHEM BIOPH RES CO, V523, P726, DOI 10.1016/j.bbrc.2020.01.031.
   Larsen JE, 2011, CANCER J, V17, P512, DOI 10.1097/PPO.0b013e31823e701a.
   Lee K, 2013, ANGEW CHEM INT EDIT, V52, P10286, DOI 10.1002/anie.201304987.
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028.
   Marchetti Philippe, 2015, Int J Cell Biol, V2015, P283145, DOI {[}10.1155/2015/283145, 10.1155/2015/283145].
   Okun JG, 1999, J BIOL CHEM, V274, P2625, DOI 10.1074/jbc.274.5.2625.
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607.
   Park MK, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.111082.
   Patel PS, 2002, J CANCER RES CLIN, V128, P461, DOI 10.1007/s00432-002-0368-8.
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155.
   Sánchez AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z.
   Sarkar Arnab, 2015, Asian Pac J Cancer Prev, V16, P6753, DOI 10.7314/apjcp.2015.16.15.6753.
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Shin MK, 2019, ARCH PHARM RES, V42, P113, DOI 10.1007/s12272-019-01127-y.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Weber LV, 2016, BREAST CANCER-TARGET, V8, P243, DOI 10.2147/BCTT.S121610.
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712.
   Xu SC, 2018, FOOD FUNCT, V9, P344, DOI 10.1039/c7fo01295k.},
Number-of-Cited-References = {30},
Times-Cited = {25},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {37},
Journal-ISO = {Biomed. Pharmacother.},
Doc-Delivery-Number = {XS6BA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000732990700005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000729413200004,
Author = {Kawano, Yawara and Sasano, Takayuki and Arima, Yuichiro and Kushima,
   Saki and Tsujita, Kenichi and Matsuoka, Masao and Hata, Hiroyuki},
Title = {A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis
   in multiple myeloma cells},
Journal = {BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS},
Year = {2022},
Volume = {587},
Pages = {153-159},
Month = {JAN 8},
Abstract = {Pyruvate dehydrogenase kinase 1 (PDK1) is a Ser/Thr kinase that
   inactivates mitochondrial pyruvate dehydrogenase (PDH), leading to
   switch of glucose metabolism from mitochondrial oxidation to aerobic
   glycolysis. We previously reported that PDK1 inhibition is a potent
   therapeutic strategy in multiple myeloma (MM). However, availability of
   PDK1 inhibitors, which are effective at low concentrations, are limited
   at present, making PDK1 inhibition difficult to apply in the clinic. In
   the present study, we examined the efficacy and mechanism of action of
   JX06, a novel PDK1 inhibitor, against MM cells. We confirmed that PDK1
   is highly expressed in normal plasma cells and MM cells using publicly
   available gene expression datasets. JX06 suppressed cell growth and
   induced apoptosis against MM cells from approximately 0.5 mu M JX06
   treatment reduced PDH phosphorylation, suggesting that JX06 is indeed
   inhibiting PDK1. Intracellular metabolite analysis revealed that JX06
   treatment reduced metabolites associated with glucose metabolism of MM
   cells. Additionally, JX06 in combination with a well-known proteasome
   inhibitor, bortezomib, significantly increased MM cell death, which
   raises the possibility of combination use of JX06 with proteasome
   inhibitors in the clinic. These findings demonstrate that PDK1 can be
   potentially targeted by JX06 in MM through glycolysis inhibition,
   leading to a novel therapeutic strategy in MM. (C) 2021 Elsevier Inc.
   All rights reserved.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Kawano, Y (Corresponding Author), Kumamoto Univ, Fac Life Sci, Grad Sch Med Sci, Dept Hematol Rheumatol \& Infect Dis,Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.
   Kawano, Yawara; Matsuoka, Masao, Kumamoto Univ, Fac Life Sci, Grad Sch Med Sci, Dept Hematol Rheumatol \& Infect Dis,Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.
   Sasano, Takayuki; Kushima, Saki; Hata, Hiroyuki, Kumamoto Univ, Fac Med Sci, Div Informat Clin Sci, Chuo Ku, 4-24-1 Kuhonji, Kumamoto 8620976, Japan.
   Arima, Yuichiro; Tsujita, Kenichi, Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.
   Arima, Yuichiro, Kumamoto Univ, Int Res Ctr Med Sci IRCMS, Chuo Ku, 2-2-1 Honjo, Kumamoto 8600811, Japan.},
DOI = {10.1016/j.bbrc.2021.11.102},
EarlyAccessDate = {DEC 2021},
ISSN = {0006-291X},
EISSN = {1090-2104},
Keywords = {Multiple myeloma; PDK1; JX06},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE; DICHLOROACETATE},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {ykawanomn@kuh.kumamoto-u.ac.jp},
Affiliations = {Kumamoto University; Kumamoto University; Kumamoto University; Kumamoto
   University},
ResearcherID-Numbers = {Matsuoka, Masao/OJU-0578-2025
   Tsujita, Kenichi/AAG-4562-2021
   Kawano, Yawara/AAH-8714-2020},
ORCID-Numbers = {Kawano, Yawara/0000-0002-8269-440X},
Funding-Acknowledgement = {Japan Society for the Promotion of Science, Japan {[}20K17382];
   Grants-in-Aid for Scientific Research {[}20K17382] Funding Source: KAKEN},
Funding-Text = {This study was supported by Grants-in-Aid for Scientific Research of
   Japan Society for the Promotion of Science, Japan (Grant number:
   20K17382) .},
Cited-References = {Abbas AR, 2005, GENES IMMUN, V6, P319, DOI 10.1038/sj.gene.6364173.
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003.
   de Padua MC, 2017, ONCOTARGET, V8, P87623, DOI 10.18632/oncotarget.21007.
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527.
   Fujiwara S, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0008-z.
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501.
   Lorenzi L, 2021, NAT BIOTECHNOL, V39, P1453, DOI 10.1038/s41587-021-00936-1.
   Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400.
   Martínez-Reyes I, 2021, NAT REV CANCER, V21, P669, DOI 10.1038/s41568-021-00378-6.
   Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120.
   Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Vacanti NM, 2014, MOL CELL, V56, P425, DOI 10.1016/j.molcel.2014.09.024.
   WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761.
   Woolbright BL, 2019, MOL CANCER THER, V18, P1673, DOI 10.1158/1535-7163.MCT-19-0079.
   Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356.
   Xu SL, 2019, CANCER RES, V79, P2748, DOI 10.1158/0008-5472.CAN-18-2799.
   Zdralevic M, 2018, J BIOL CHEM, V293, P15947, DOI 10.1074/jbc.RA118.004180.},
Number-of-Cited-References = {18},
Times-Cited = {21},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Biochem. Biophys. Res. Commun.},
Doc-Delivery-Number = {XN3MT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000729413200004},
DA = {2026-02-04},
}

@article{ WOS:000730524600001,
Author = {Zhan, Bo and Dong, Xiao and Yuan, Yulin and Gong, Zheng and Li, Bohan},
Title = {hZIP1 Inhibits Progression of Clear Cell Renal Cell Carcinoma by
   Suppressing NF-kB/HIF-1α Pathway},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2021},
Volume = {11},
Month = {DEC 2},
Abstract = {Purpose: Accumulating literature has suggested that hZIP1 and HIF-1
   alpha play vital roles in the tumor process of clear cell renal cell
   carcinoma (ccRCC). However, the functional roles of hZIP1 and HIF-1
   alpha in ccRCC remain largely unknown.
   Methods: HIF-1 alpha protein level was evaluated by a western blot in
   ccRCC tissues and cell lines. ccRCC cell lines were transfected with
   HIF-1 alpha-siRNA to downregulate the expression level of HIF-1 alpha.
   Then the proliferative, migratory and invasive abilities of ccRCC cells
   in vitro were detected by real-time cell analysis (RTCA) assay, wound
   healing assay and transwell assay, respectively. The role of HIF-1 alpha
   in vivo was explored by tumor implantation in nude mice. Then the effect
   on glycolysis-related proteins was performed by western blot after hZIP1
   knockdown (overexpression) or HIF-1 alpha knockdown. The effect on NF-kB
   pathway was detected after hZIP1 overexpression.
   Results: HIF-1 alpha was markedly downregulated in ccRCC tissues
   compared with normal areas. But HIF-1 alpha presented almost no
   expression in HK-2 and ACHN cells. Immunofluorescence indicated HIF-1
   alpha and PDK1 expression in both the cytoplasm and nucleus in ccRCC
   cells. Downregulation of HIF-1 alpha suppressed ccRCC cell
   proliferation, migration, and invasion and resulted in smaller implanted
   tumors in nude mice. Furthermore, hZIP1 knockdown elevated HIF-1 alpha
   protein levels and PDK1 protein levels in ccRCC cells. Interestingly, a
   sharp downregulated expression of HIF-1 alpha was observed after hZIP1
   overexpression in OSRC-2 and 786-O cells, which resulted from a
   downtrend of NF-kB1 moving into the cell nucleus.
   Conclusion: Our work has vital implications that hZIP1 suppresses ccRCC
   progression by inhibiting NF-kB/HIF-1 alpha pathway.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Dong, X (Corresponding Author), China Med Univ, Dept Urol, First Hosp, Shenyang, Peoples R China.
   Zhan, Bo; Dong, Xiao; Yuan, Yulin; Gong, Zheng; Li, Bohan, China Med Univ, Dept Urol, First Hosp, Shenyang, Peoples R China.},
DOI = {10.3389/fonc.2021.759818},
Article-Number = {759818},
ISSN = {2234-943X},
Keywords = {anaerobic glycolysis; ccRCC; HIF-1 alpha; hZIP1; NF-kB pathway},
Keywords-Plus = {KIDNEY CANCER; TRANSCRIPTION FACTORS; NF-KB; HYPOXIA; ZINC},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {xiao120@hotmail.com},
Affiliations = {China Medical University},
ResearcherID-Numbers = {Li, Bohan/GRR-3628-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81902591]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (81902591).},
Cited-References = {Ahmmed B, 2019, J CELL PHYSIOL, V234, P10680, DOI 10.1002/jcp.27731.
   al Taleb Z, 2016, J MOL MED, V94, P1153, DOI 10.1007/s00109-016-1439-7.
   Allison KE, 2017, IMMUNOLOGY, V152, P175, DOI 10.1111/imm.12777.
   Azoitei N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0490-2.
   Bao Y, 2019, ONCOGENE, V38, P881, DOI 10.1038/s41388-018-0452-4.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X.
   Costello LC, 2016, ARCH BIOCHEM BIOPHYS, V611, P100, DOI 10.1016/j.abb.2016.04.014.
   Desouki MM, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0169-8.
   Dong X, 2018, AM J CANCER RES, V8, P1414.
   Dong X, 2014, UROL ONCOL-SEMIN ORI, V32, P885, DOI 10.1016/j.urolonc.2014.02.021.
   Doonachar A, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0175-3.
   Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z.
   Hahne M, 2018, MICROVASC RES, V116, P34, DOI 10.1016/j.mvr.2017.09.004.
   Hoefflin R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17873-3.
   Hu MJ, 2021, BIOMETALS, V34, P909, DOI 10.1007/s10534-021-00317-w.
   Khan MN, 2011, BRIT J CANCER, V104, P1151, DOI 10.1038/bjc.2011.73.
   Kim HJ, 2020, BIOCHEM BIOPH RES CO, V523, P726, DOI 10.1016/j.bbrc.2020.01.031.
   Lalani AKA, 2019, EUR UROL, V75, P100, DOI 10.1016/j.eururo.2018.10.010.
   Lee YM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051092.
   Lim SA, 2021, CANCERS, V13, DOI 10.3390/cancers13081904.
   Michalczyk K, 2020, NUTRIENTS, V12, DOI 10.3390/nu12123732.
   Milic NS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168610.
   Motzer RJ, 2017, J NATL COMPR CANC NE, V15, P804, DOI 10.6004/jnccn.2017.0100.
   Murai M, 2004, CURR OPIN UROL, V14, P229, DOI 10.1097/01.mou.0000135078.04721.f5.
   Nardinocchi L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015048.
   Okuno Yumiko, 2020, Hinyokika Kiyo, V66, P13, DOI 10.14989/ActaUrolJap\_66\_1\_13.
   Olechnowicz J, 2018, J PHYSIOL SCI, V68, P19, DOI 10.1007/s12576-017-0571-7.
   Pirinççi N, 2016, TOXICOL IND HEALTH, V32, P193, DOI 10.1177/0748233713498924.
   Porchia M, 2020, MOLECULES, V25, DOI 10.3390/molecules25245814.
   Posadas EM, 2017, NAT REV NEPHROL, V13, P496, DOI 10.1038/nrneph.2017.82.
   Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905.
   Schödel J, 2016, EUR UROL, V69, P646, DOI 10.1016/j.eururo.2015.08.007.
   Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098.
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551.
   Spirina LV, 2017, MOL BIOL+, V51, P328, DOI 10.1134/S0026893317020194.
   Vaupel P, 2020, ADV EXP MED BIOL, V1232, P169, DOI 10.1007/978-3-030-34461-0\_21.
   You L, 2021, MED RES REV, V41, P1622, DOI 10.1002/med.21771.
   Zhao Q, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01552-w.
   Zinatizadeh MR, 2021, GENES DIS, V8, P287, DOI 10.1016/j.gendis.2020.06.005.},
Number-of-Cited-References = {40},
Times-Cited = {7},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {XO9VQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000730524600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000735955300001,
Author = {D'Aloia, Alessia and Arrigoni, Edoardo and Costa, Barbara and Berruti,
   Giovanna and Martegani, Enzo and Sacco, Elena and Ceriani, Michela},
Title = {RalGPS2 Interacts with Akt and PDK1 Promoting Tunneling Nanotubes
   Formation in Bladder Cancer and Kidney Cells Microenvironment},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {24},
Month = {DEC},
Abstract = {Simple Summary Cell-to-cell communication in the tumor microenvironment
   is a crucial process to orchestrate the different components of the
   tumoral infrastructure. Among the mechanisms of cellular interplay in
   cancer cells, tunneling nanotubes (TNTs) are dynamic connections that
   play an important role. The mechanism of the formation of TNTs among
   cells and the molecules involved in the process remain to be elucidated.
   In this study, we analyze several bladder cancer cell lines,
   representative of tumors at different stages and grades. We demonstrate
   that TNTs are formed only by mid or high-stage cell lines that show
   muscle-invasive properties and that they actively transport mitochondria
   and proteins. The formation of TNTs is triggered by stressful conditions
   and starts with the assembly of a specific multimolecular complex. In
   this study, we characterize some of the protein components of the TNTs
   complex, as they are potential novel molecular targets for future
   therapies aimed at counteracting tumor progression. RalGPS2 is a
   Ras-independent Guanine Nucleotide Exchange Factor for RalA GTPase that
   is involved in several cellular processes, including cytoskeletal
   organization. Previously, we demonstrated that RalGPS2 also plays a role
   in the formation of tunneling nanotubes (TNTs) in bladder cancer 5637
   cells. In particular, TNTs are a novel mechanism of cell-cell
   communication in the tumor microenvironment, playing a central role in
   cancer progression and metastasis formation. However, the molecular
   mechanisms involved in TNTs formation still need to be fully elucidated.
   Here we demonstrate that mid and high-stage bladder cancer cell lines
   have functional TNTs, which can transfer mitochondria. Moreover, using
   confocal fluorescence time-lapse microscopy, we show in 5637 cells that
   TNTs mediate the trafficking of RalA protein and transmembrane MHC class
   III protein leukocyte-specific transcript 1 (LST1). Furthermore, we show
   that RalGPS2 is essential for nanotubes generation, and stress
   conditions boost its expression both in 5637 and HEK293 cell lines.
   Finally, we prove that RalGPS2 interacts with Akt and PDK1, in addition
   to LST1 and RalA, leading to the formation of a complex that promotes
   nanotubes formation. In conclusion, our findings suggest that in the
   tumor microenvironment, RalGPS2 orchestrates the assembly of
   multimolecular complexes that drive the formation of TNTs.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Ceriani, M (Corresponding Author), Univ Milano Bicocca, Dept Biotechnol \& Biosci, Piazza Sci 2, I-20126 Milan, Italy.
   Ceriani, M (Corresponding Author), Univ Milano Bicocca, Milan Ctr Neurosci NeuroMI, Piazza Ateneo Nuovo 1, I-20126 Milan, Italy.
   D'Aloia, Alessia; Arrigoni, Edoardo; Costa, Barbara; Martegani, Enzo; Sacco, Elena; Ceriani, Michela, Univ Milano Bicocca, Dept Biotechnol \& Biosci, Piazza Sci 2, I-20126 Milan, Italy.
   Berruti, Giovanna, Univ Milan, Dept Biosci, Via Celoria 26, I-20133 Milan, Italy.
   Martegani, Enzo; Sacco, Elena, Res Infrastruct Syst Biol Europe, SYSBIO ISBE IT Candidate Natl Node Italy ISBE, I-20126 Milan, Italy.
   Ceriani, Michela, Univ Milano Bicocca, Milan Ctr Neurosci NeuroMI, Piazza Ateneo Nuovo 1, I-20126 Milan, Italy.},
DOI = {10.3390/cancers13246330},
Article-Number = {6330},
EISSN = {2072-6694},
Keywords = {tunneling nanotubes; bladder cancer; kidney; microenvironment; stress
   condition; RalGPS2; Akt; PDK1},
Keywords-Plus = {MEMBRANE NANOTUBES; HYDROGEN-PEROXIDE; TNT FORMATION; MITOCHONDRIAL
   TRANSFER; INTERCELLULAR TRANSFER; FUNCTIONAL-ANALYSIS; TUMOR
   PROGRESSION; DOWN-REGULATION; STROMAL CELLS; RAS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {alessia.daloia@unimib.it
   edoardo.arrigoni@unimib.it
   barbara.costa@unimib.it
   giovanna.berruti@unimi.it
   enzo.martegani@unimib.it
   elena.sacco@unimib.it
   michela.ceriani@unimib.it},
Affiliations = {University of Milano-Bicocca; University of Milan; University of
   Milano-Bicocca},
ResearcherID-Numbers = {SACCO, ELENA/T-3274-2018
   COSTA, BARBARA SIMONA/AAB-4181-2021
   Martegani, Enzo/A-4435-2008},
ORCID-Numbers = {D'Aloia, Alessia/0000-0002-6501-0379
   CERIANI, MICHELA/0000-0002-3060-5620
   SACCO, ELENA/0000-0002-3190-7671
   COSTA, BARBARA SIMONA/0000-0002-2910-6736
   },
Funding-Acknowledgement = {Italian Ministry of University and Research (MIUR) through the grants
   Research facilitation fund (Fondo per le Agevolazioni alla RicercaFAR);
   Dipartimenti di Eccellenza 2017},
Funding-Text = {This work was supported by funds from the Italian Ministry of University
   and Research (MIUR) through the grants Research facilitation fund (Fondo
   per le Agevolazioni alla RicercaFAR) to MC, ES, BC and EM, and
   Dipartimenti di Eccellenza 2017 to the University of Milano Bicocca.},
Cited-References = {Abounit S, 2016, EMBO J, V35, P2120, DOI 10.15252/embj.201593411.
   Abounit S, 2012, J CELL SCI, V125, P1089, DOI 10.1242/jcs.083279.
   Ahmad T, 2014, EMBO J, V33, P994, DOI 10.1002/embj.201386030.
   ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x.
   Andresen V, 2013, CELL DEATH DIFFER, V20, P1124, DOI 10.1038/cdd.2013.61.
   Ariazi J, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00333.
   Arkwright PD, 2010, CELL RES, V20, P72, DOI 10.1038/cr.2009.112.
   Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5.
   Bénard M, 2015, BIOL CELL, V107, P419, DOI 10.1111/boc.201500004.
   Bhat S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74013-z.
   Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3.
   Ceriani M, 2007, EXP CELL RES, V313, P2293, DOI 10.1016/j.yexcr.2007.03.016.
   Ceriani M, 2010, NEUROSCI RES, V66, P290, DOI 10.1016/j.neures.2009.11.013.
   Chauveau A, 2010, P NATL ACAD SCI USA, V107, P5545, DOI 10.1073/pnas.0910074107.
   Chen G, 1996, J BIOL CHEM, V271, P28259, DOI 10.1074/jbc.271.45.28259.
   Chinnery HR, 2008, J IMMUNOL, V180, P5779, DOI 10.4049/jimmunol.180.9.5779.
   Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x.
   Cirri P, 2011, AM J CANCER RES, V1, P482.
   D'Aloia A, 2018, EXP CELL RES, V362, P349, DOI 10.1016/j.yexcr.2017.11.036.
   Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991.
   Desir S, 2019, CANCERS, V11, DOI 10.3390/cancers11070892.
   Desir S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27649-x.
   Desir S, 2016, ONCOTARGET, V7, P43150, DOI 10.18632/oncotarget.9504.
   Dieleman J, 2017, LANCET, V389, P1981, DOI 10.1016/S0140-6736(17)30874-7.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Gerdes HH, 2008, CURR OPIN CELL BIOL, V20, P470, DOI 10.1016/j.ceb.2008.03.005.
   Gerdes HH, 2013, MECH DEVELOP, V130, P381, DOI 10.1016/j.mod.2012.11.006.
   Gongadze E, 2011, INT J NANOMED, V6, P1801, DOI {[}10.2147/IJN.S21755, 10.2147/IJN.S16982].
   Gousset K, 2013, J CELL SCI, V126, P4424, DOI 10.1242/jcs.129239.
   Gousset K, 2009, NAT CELL BIOL, V11, P328, DOI 10.1038/ncb1841.
   Gurke S, 2008, EXP CELL RES, V314, P3669, DOI 10.1016/j.yexcr.2008.08.022.
   Hao YS, 2008, MOL CELL BIOL, V28, P2851, DOI 10.1128/MCB.01917-07.
   Hase K, 2009, NAT CELL BIOL, V11, P1427, DOI 10.1038/ncb1990.
   Hekmatshoar Y, 2018, BIOCHEM J, V475, P2305, DOI 10.1042/BCJ20170712.
   Hernandez-Muñoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586.
   Howe CJ, 2004, J BIOL CHEM, V279, P44573, DOI 10.1074/jbc.M404175200.
   Huang XD, 2004, ANN NY ACAD SCI, V1012, P153, DOI 10.1196/annals.1306.012.
   Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736.
   Jalanko T, 2020, CURR UROL REP, V21, DOI 10.1007/s11934-020-0960-y.
   Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810.
   Lee LJ, 2020, CLINICOECONOMIC OUTC, V12, P693, DOI 10.2147/CEOR.S274951.
   Li C, 2005, BRIT J CANCER, V92, P80, DOI 10.1038/sj.bjc.6602272.
   Lim KH, 2005, CANCER CELL, V7, P533, DOI 10.1016/j.ccr.2005.04.030.
   Lin HJ, 2004, FEBS LETT, V570, P102, DOI 10.1016/j.febslet.2004.06.019.
   Lou E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.559548.
   Lou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033093.
   Lu JJ, 2019, INT J NANOMED, V14, P9731, DOI 10.2147/IJN.S217277.
   Martegani E, 2002, ANN NY ACAD SCI, V973, P135, DOI 10.1111/j.1749-6632.2002.tb04621.x.
   MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214.
   Mittal R, 2019, J CELL PHYSIOL, V234, P1130, DOI 10.1002/jcp.27072.
   Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728.
   Nauta TD, 2017, ANGIOGENESIS, V20, P39, DOI 10.1007/s10456-016-9527-4.
   Neyraud V, 2012, J BIOL CHEM, V287, P29397, DOI 10.1074/jbc.M112.357764.
   Ng WL, 2009, ANNU REV GENET, V43, P197, DOI 10.1146/annurev-genet-102108-134304.
   Nguyen D, 2017, PHARMACOL THERAPEUT, V178, P92, DOI 10.1016/j.pharmthera.2017.03.013.
   Nishida-Aoki Nao, 2019, Oncotarget, V10, P785, DOI {[}10.18632/oncotarget.26585, 10.18632/oncotarget.26585].
   Ohno Hiroshi, 2010, Commun Integr Biol, V3, P231.
   Oliva CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024665.
   Omsland M, 2017, ONCOTARGET, V8, P7946, DOI 10.18632/oncotarget.13853.
   Önfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476.
   Osswald M, 2015, NATURE, V528, P93, DOI 10.1038/nature16071.
   Oxford G, 2005, CANCER RES, V65, P7111, DOI 10.1158/0008-5472.CAN-04-1957.
   Parker I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11223-y.
   Pasquale V, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122669.
   Pasquier J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-94.
   Pinto G, 2021, BIOCHEM J, V478, P21, DOI 10.1042/BCJ20200710.
   Pinto G, 2020, TRENDS CANCER, V6, P874, DOI 10.1016/j.trecan.2020.04.012.
   Plotnikov EY, 2010, EXP CELL RES, V316, P2447, DOI 10.1016/j.yexcr.2010.06.009.
   Rainy N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.245.
   Ranzinger J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029537.
   Roehlecke C, 2020, CANCERS, V12, DOI 10.3390/cancers12040857.
   Rosich L, 2014, ONCOTARGET, V5, P6788, DOI 10.18632/oncotarget.2253.
   Rustom A, 2004, SCIENCE, V303, P1007, DOI 10.1126/science.1093133.
   Saito R, 2013, ONCOGENE, V32, P894, DOI 10.1038/onc.2012.101.
   Salter RD, 2006, IMMUNOL RES, V36, P211, DOI 10.1385/IR:36:1:211.
   Santha S, 2020, CANCERS, V12, DOI 10.3390/cancers12113413.
   Schiller C, 2013, J CELL SCI, V126, P767, DOI 10.1242/jcs.114033.
   Schiller C, 2013, HUM IMMUNOL, V74, P412, DOI 10.1016/j.humimm.2012.11.026.
   Schiller C, 2009, HYBRIDOMA, V28, P281, DOI 10.1089/hyb.2009.0021.
   Shin SY, 2004, CANCER LETT, V212, P225, DOI 10.1016/j.canlet.2004.03.003.
   Sisakhtnezhad S, 2015, EUR J CELL BIOL, V94, P429, DOI 10.1016/j.ejcb.2015.06.010.
   Smith SC, 2007, CLIN CANCER RES, V13, P3803, DOI 10.1158/1078-0432.CCR-06-2419.
   Smith SC, 2009, UROL ONCOL-SEMIN ORI, V27, P42, DOI 10.1016/j.urolonc.2008.04.012.
   Sowinski S, 2008, NAT CELL BIOL, V10, P211, DOI 10.1038/ncb1682.
   Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103.
   Sun X, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.177.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Thayanithy V, 2014, TRANSL RES, V164, P359, DOI 10.1016/j.trsl.2014.05.011.
   Thayanithy V, 2014, EXP CELL RES, V323, P178, DOI 10.1016/j.yexcr.2014.01.014.
   Torab P, 2020, ANAL CHEM, V92, P8768, DOI 10.1021/acs.analchem.0c00057.
   van den Bosch S, 2011, EUR UROL, V60, P493, DOI 10.1016/j.eururo.2011.05.045.
   van Rossum GSAT, 2004, BBA-MOL CELL BIOL L, V1636, P183, DOI 10.1016/j.bbalip.2003.12.008.
   Veranic P, 2008, BIOPHYS J, V95, P4416, DOI 10.1529/biophysj.108.131375.
   Vidulescu C, 2004, J CELL MOL MED, V8, P388, DOI 10.1111/j.1582-4934.2004.tb00328.x.
   Vignais ML, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6917941.
   Wang HY, 2014, INT J MED SCI, V11, P841, DOI 10.7150/ijms.8128.
   Wang X, 2015, CELL DEATH DIFFER, V22, P1181, DOI 10.1038/cdd.2014.211.
   Wang X, 2010, P NATL ACAD SCI USA, V107, P17194, DOI 10.1073/pnas.1006785107.
   Wang Y, 2011, CELL DEATH DIFFER, V18, P732, DOI 10.1038/cdd.2010.147.
   Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020.
   Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748.
   Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753.
   Xue GD, 2013, JNCI-J NATL CANCER I, V105, P393, DOI 10.1093/jnci/djs648.
   Yang YJ, 2020, MOL THER ONCOLYTICS, V18, P409, DOI 10.1016/j.omto.2020.07.010.
   Yasuda K, 2011, AGING-US, V3, P597, DOI 10.18632/aging.100341.
   Yuan Y, 2016, ONCOL REP, V35, P2499, DOI 10.3892/or.2016.4660.
   Zhu DH, 2005, J CELL SCI, V118, P3695, DOI 10.1242/jcs.02507.
   Zuiverloon TCM, 2018, BLADDER CANCER, V4, P169, DOI 10.3233/BLC-180167.},
Number-of-Cited-References = {108},
Times-Cited = {24},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {18},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {XW9UT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000735955300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000730988600001,
Author = {Mitchel, Jonathan and Bajaj, Pratima and Patil, Ketki and Gunnarson,
   Austin and Pourchet, Emilie and Kim, Yoo Na and Skolnick, Jeffrey and
   Pai, S. Balakrishna},
Title = {Computational Identification of Stearic Acid as a Potential PDK1
   Inhibitor and In Vitro Validation of Stearic Acid as Colon Cancer
   Therapeutic in Combination with 5-Fluorouracil},
Journal = {CANCER INFORMATICS},
Year = {2021},
Volume = {20},
Month = {DEC},
Abstract = {BACKGROUND: Colorectal cancer is the third largest cause of
   cancer-related mortality worldwide. Although current treatments with
   chemotherapeutics have allowed for management of colorectal cancer,
   additional novel treatments are essential. Intervening with the
   metabolic reprogramming observed in cancers called ``Warburg Effect,{''}
   is one of the novel strategies considered to combat cancers. In the
   metabolic reprogramming pathway, pyruvate dehydrogenase kinase (PDK1)
   plays a pivotal role. Identification and characterization of a PDK1
   inhibitor is of paramount importance. Further, for efficacious treatment
   of colorectal cancers, combinatorial regimens are essential. To this
   end, we opted to identify a PDK1 inhibitor using computational
   structure-based drug design FINDSITE(comb )and perform combinatorial
   studies with 5-FU for efficacious treatment of colorectal cancers.
   METHODS: Using computational structure-based drug design FINDSITEcomb,
   stearic acid (SA) was identified as a possible PDK1 inhibitor.
   Elucidation of the mechanism of action of SA was performed using flow
   cytometry, clonogenic assays.
   RESULTS: When the growth inhibitory potential of SA was tested on
   colorectal adenocarcinoma (DLD-1) cells, a 50\% inhibitory concentration
   (IC50) of 60 mu M was recorded. Moreover, SA inhibited the proliferation
   potential of DLD-1 cells as shown by the clonogenic assay and there was
   a sustained response even after withdrawal of the compound. Elucidation
   of the mechanism of action revealed, that the inhibitory effect of SA
   was through the programmed cell death pathway. There was increase in the
   number of apoptotic and multicaspase positive cells. SA also impacted
   the levels of the cell survival protein Bcl-2. With the aim of achieving
   improved treatment for colorectal cancer, we opted to combine
   5-fluorouracil (5-FU), the currently used drug in the clinic, with SA.
   Combining SA with 5-FU, revealed a synergistic effect in which the IC50
   of 5-FU decreased from 25 to 6 mu M upon combination with 60 mu M SA.
   Further, SA did not inhibit non-tumorigenic NIH-3T3 proliferation.
   CONCLUSIONS: We envision that this significant decrease in the IC50 of
   5-FU could translate into less side effects of 5-FU and increase the
   efficacy of the treatment due to the multifaceted action of SA. The data
   generated from the current studies on the inhibition of colorectal
   adenocarcinoma by SA discovered by the use of the computational program
   as well as synergistic action with 5-FU should open up novel therapeutic
   options for the management of colorectal adenocarcinomas.},
Publisher = {SAGE PUBLICATIONS LTD},
Address = {1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Pai, SB (Corresponding Author), Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.
   Pai, SB (Corresponding Author), Emory Univ, 313 Ferst Dr, Atlanta, GA 30332 USA.
   Mitchel, Jonathan; Patil, Ketki; Gunnarson, Austin; Pourchet, Emilie; Kim, Yoo Na; Pai, S. Balakrishna, Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.
   Mitchel, Jonathan; Patil, Ketki; Gunnarson, Austin; Pourchet, Emilie; Kim, Yoo Na; Pai, S. Balakrishna, Emory Univ, 313 Ferst Dr, Atlanta, GA 30332 USA.
   Bajaj, Pratima; Skolnick, Jeffrey, Georgia Inst Technol, Sch Biol Sci, Atlanta, GA 30332 USA.},
DOI = {10.1177/11769351211065979},
Article-Number = {11769351211065979},
EISSN = {1176-9351},
Keywords = {Computational tool - FINDSITEcomb; stearic acid; 5-FU; flow cytometry},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; DNA-DAMAGE; RESISTANCE; NEUROPATHY;
   MECHANISMS; APOPTOSIS},
Research-Areas = {Oncology; Mathematical \& Computational Biology},
Web-of-Science-Categories  = {Oncology; Mathematical \& Computational Biology},
Author-Email = {balakrishna.pai@bme.gatech.edu},
Affiliations = {University System of Georgia; Georgia Institute of Technology; Emory
   University; University System of Georgia; Georgia Institute of
   Technology},
ORCID-Numbers = {Bajaj, Pratima/0009-0001-0056-1719},
Funding-Acknowledgement = {Wallace H. Coulter Department Biomedical Engineering at Georgia
   Institute of Technology and Emory University; NIH {[}GM-118039]; Kern
   Family Foundation; Coulter Fund; Georgia Tech Technology Fee; National
   Institute of General Medical Sciences {[}R35GM118039] Funding Source:
   NIH RePORTER},
Funding-Text = {The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by the Wallace H. Coulter Department Biomedical
   Engineering at Georgia Institute of Technology and Emory University and
   NIH grant GM-118039 to Dr. Skolnick. Yoo Na Kim received funding for
   research from Kern Family Foundation grant. We would also like to
   acknowledge the support from Coulter Fund and Georgia Tech Technology
   Fee.},
Cited-References = {Afzal S, 2009, ANN ONCOL, V20, P1660, DOI 10.1093/annonc/mdp046.
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709.
   Benson AB., 2021, J NATL COMPR CANC NE, DOI DOI 10.6004/JNCCN.2021.0012.
   Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Brylinski M, 2008, P NATL ACAD SCI USA, V105, P129, DOI 10.1073/pnas.0707684105.
   Calcutt NA, 2009, J NEUROPATH EXP NEUR, V68, P985, DOI 10.1097/NEN.0b013e3181b40217.
   CANMAN CE, 1993, CANCER RES, V53, P5219.
   CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474.
   CDC United States Cancer Statistics: Data Visualizations, CANC STAT GLANC LEAD.
   Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y.
   Cook KM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147265.
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Evans LM, 2009, NUTR CANCER, V61, P746, DOI 10.1080/01635580902825597.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074.
   Lu HQ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131106.
   Sestito S, 2019, EXPERT OPIN THER PAT, V29, P271, DOI 10.1080/13543776.2019.1597852.
   Strese S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-331.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tso SC, 2017, J MED CHEM, V60, P1142, DOI 10.1021/acs.jmedchem.6b01540.
   Wang XX, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204402.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935.
   Zhou HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11090.},
Number-of-Cited-References = {29},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Cancer Inform.},
Doc-Delivery-Number = {XP6QT},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000730988600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000736102100001,
Author = {Wu, Yi-Hui and Huang, Yu-Fang and Chang, Tzu-Hao and Wu, Pei-Ying and
   Hsieh, Tsung-Ying and Hsiao, Sheng-Yen and Huang, Soon-Cen and Chou,
   Cheng-Yang},
Title = {miR-335 Restrains the Aggressive Phenotypes of Ovarian Cancer Cells by
   Inhibiting COL11A1},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {24},
Month = {DEC},
Abstract = {Simple Summary High collagen type XI alpha 1 (COL11A1) levels are
   associated with tumor progression, chemoresistance, and poor patient
   survival in several cancer types. We examined the role of miRNAs in
   regulating COL11A1 expression. This study highlighted the importance of
   miR-335 in downregulating COL11A1-mediated ovarian tumor progression,
   chemoresistance, and poor survival and suggested its potential
   application as a therapeutic target. High collagen type XI alpha 1
   (COL11A1) levels are associated with tumor progression, chemoresistance,
   and poor patient survival in several cancer types. MicroRNAs (miRNAs)
   are dysregulated in multiple cancers, including epithelial ovarian
   carcinoma (EOC); however, the regulation of COL11A1 by miRNAs in EOC
   remains unclear. We examined the role of miRNAs in regulating COL11A1
   expression. We identified miR-509 and miR-335 as the candidate miRNAs
   through an online database search. EOC cell treatment with miR-335
   mimics abrogated COL11A1 expression and suppressed cell proliferation
   and invasion, besides increasing the sensitivity of EOC cells to
   cisplatin. Conversely, treatment with miR-335 inhibitors prompted cell
   growth/invasiveness and chemoresistance of EOC cells. miR-335 inhibited
   COL11A1 transcription, thus reducing the invasiveness and
   chemoresistance of EOC cells via the Ets-1/MMP3 and Akt/c/EBP beta/PDK1
   axes, respectively. Furthermore, it did not directly regulate PDK1 but
   increased PDK1 ubiquitination and degradation through COL11A1
   inhibition. In vivo findings highlighted significantly decreased miR-335
   mRNA expressions in EOC samples. Furthermore, patients with low miR335
   levels were susceptible to advanced-stage cancer, poor response to
   chemotherapy, and early relapse. This study highlighted the importance
   of miR-335 in downregulating COL11A1-mediated ovarian tumor progression,
   chemoresistance, and poor survival and suggested its potential
   application as a therapeutic target.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Chou, CY (Corresponding Author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Obstet \& Gynecol, Coll Med, Tainan 704, Taiwan.
   Wu, Yi-Hui, Chi Mei Med Ctr, Dept Med Res, Tainan 736, Taiwan.
   Wu, Yi-Hui, Min Hwei Jr Coll Hlth Care Management, Dept Nursing, Tainan 736, Taiwan.
   Huang, Yu-Fang; Wu, Pei-Ying; Chou, Cheng-Yang, Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Obstet \& Gynecol, Coll Med, Tainan 704, Taiwan.
   Chang, Tzu-Hao, Taipei Med Univ, Grad Inst Biomed Informat, Taipei 110, Taiwan.
   Hsieh, Tsung-Ying; Huang, Soon-Cen, Chi Mei Med Ctr, Dept Obstet \& Gynecol, Tainan 736, Taiwan.
   Hsiao, Sheng-Yen, Chi Mei Med Ctr, Dept Hematol \& Oncol, Tainan 736, Taiwan.},
DOI = {10.3390/cancers13246257},
Article-Number = {6257},
EISSN = {2072-6694},
Keywords = {epithelial ovarian carcinoma; collagen type XI alpha 1; miR-335;
   clinical oncology; EOC cells; miRNA; miR-509},
Keywords-Plus = {PROMOTES TUMOR PROGRESSION; MICRORNAS; ACTIVATION; EXPRESSION; GENE;
   CHEMORESISTANCE; MECHANISMS; REPRESENTS; SIGNATURE; INVASION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {a80869@mail.chimei.org.tw
   yufangh@mail.ncku.edu.tw
   kevinchang@tmu.edu.tw
   anna1002ster@gmail.com
   eric99.hsieh@msa.hinet.net
   seedvirt@gmail.com
   d930817@mail.chimei.org.tw
   chougyn@mail.ncku.edu.tw},
Affiliations = {Chi Mei Hospital; National Cheng Kung University; National Cheng Kung
   University Hospital; Taipei Medical University; Chi Mei Hospital; Chi
   Mei Hospital},
ResearcherID-Numbers = {Wu, Pei-Ying/AGR-9702-2022
   },
ORCID-Numbers = {Wu, Pei-Ying/0000-0002-8168-6125
   Hsiao, Sheng-Yen/0000-0001-8621-2650
   HUANG, YU-FANG/0000-0002-3832-1294},
Funding-Acknowledgement = {National Science Council (MOST) {[}108-2314-B-384-011-MY3,
   108-2314-B-006-061-MY2, 110-2314-006-036]; Chi Mei Medical Center,
   Liouying Campus {[}CMNCKU10801, CMLMOST10901, CLFHR10911, CLFHR10921,
   CLFHR11015];  {[}108-2314-B-006-061-MY2 110-2314-006-036]},
Funding-Text = {This work was supported by grants from the National Science Council
   (MOST: No. 108-2314-B-384-011-MY3, 108-2314-B-006-061-MY2 and
   110-2314-006-036). The study was also supported by grants from the Chi
   Mei Medical Center, Liouying Campus (CMNCKU10801, CMLMOST10901,
   CLFHR10911, CLFHR10921, and CLFHR11015).},
Cited-References = {Bae IH, 2006, CANCER RES, V66, P4991, DOI 10.1158/0008-5472.CAN-05-4254.
   Brouwer J, 2016, J CLIN PATHOL, V69, P979, DOI 10.1136/jclinpath-2016-203679.
   Cao J, 2014, AM J CLIN PATHOL, V141, P437, DOI 10.1309/AJCPLYTZGB54ISZC.
   Cao J, 2013, ONCOL REP, V30, P701, DOI 10.3892/or.2013.2482.
   Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256.
   Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067.
   Colombo I, 2021, CLIN CANCER RES, V27, P5012, DOI 10.1158/1078-0432.CCR-21-1402.
   Contreras J, 2012, LEUKEMIA, V26, P404, DOI 10.1038/leu.2011.356.
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840.
   García-Pravia C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078327.
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.pathol.4.110807.092222.
   Gu SQ, 2020, MATH BIOSCI ENG, V17, P1428, DOI 10.3934/mbe.2020073.
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939.
   Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017.
   Lee J, 2017, TUMOR BIOL, V39, DOI {[}10.1177/1010428317718403, 10.1177/1010428317695534].
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3.
   Li SS, 2018, J GYNECOL ONCOL, V29, DOI 10.3802/jgo.2018.29.e32.
   Liu ZQ, 2021, FASEB J, V35, DOI 10.1096/fj.202100054RR.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Nallanthighal S, 2021, CANCERS, V13, DOI 10.3390/cancers13050935.
   Nallanthighal S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2442-z.
   Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731.
   Rada M, 2018, ONCOGENE, V37, P4809, DOI 10.1038/s41388-018-0297-x.
   Resnick KE, 2009, GYNECOL ONCOL, V112, P55, DOI 10.1016/j.ygyno.2008.08.036.
   Ronchetti D, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-37.
   Shu MF, 2012, MOL PHARMACOL, V81, P292, DOI 10.1124/mol.111.076166.
   Sokol NS, 2012, CURR OPIN GENET DEV, V22, P368, DOI 10.1016/j.gde.2012.04.001.
   Sorrentino A, 2008, GYNECOL ONCOL, V111, P478, DOI 10.1016/j.ygyno.2008.08.017.
   Srivastava SK, 2017, CANCER LETT, V407, P123, DOI 10.1016/j.canlet.2017.05.011.
   Sticht C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206239.
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487.
   Vickers MM, 2012, CLIN EXP METASTAS, V29, P123, DOI 10.1007/s10585-011-9435-3.
   Wang HB, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1066-9.
   Wang JX, 2015, INT J CLIN EXP PATHO, V8, P517.
   Wang L, 2011, INTEGR BIOL-UK, V3, P742, DOI 10.1039/c0ib00122h.
   Wang SH, 2020, BIOCHEM BIOPH RES CO, V524, P211, DOI 10.1016/j.bbrc.2020.01.063.
   White NMA, 2011, J UROLOGY, V186, P1077, DOI 10.1016/j.juro.2011.04.110.
   Wu Richard Licheng, 2015, J Cancer Sci Ther, V7, P258, DOI 10.4172/1948-5956.1000359.
   Wu YH, 2014, ONCOGENE, V33, P3432, DOI 10.1038/onc.2013.307.
   Wu YH, 2021, ONCOGENE, V40, P4503, DOI 10.1038/s41388-021-01865-8.
   Wu YH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00206.
   Wu YH, 2017, INT J CANCER, V141, P2305, DOI 10.1002/ijc.30932.
   Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250.
   Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311.
   Xu CJ, 2020, MOL MED REP, V22, P3677, DOI 10.3892/mmr.2020.11490.
   Zhu MM, 2021, INT J RADIAT BIOL, V97, P958, DOI 10.1080/09553002.2021.1928780.},
Number-of-Cited-References = {48},
Times-Cited = {22},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {XX1ZE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000736102100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000723877100005,
Author = {Jin, Ling and Cho, Minkyoung and Kim, Bo-Sung and Han, Jung Ho and Park,
   Sungmi and Lee, In-Kyu and Ryu, Dongryeol and Kim, Jae Ho and Bae,
   Sung-Jin and Ha, Ki-Tae},
Title = {Drug evaluation based on phosphomimetic PDHA1 reveals the complexity of
   activity-related cell death in A549 non-small cell lung cancer cells},
Journal = {BMB REPORTS},
Year = {2021},
Volume = {54},
Number = {11},
Pages = {563-568},
Month = {NOV 30},
Abstract = {Cancer cells predominantly generate energy via glycolysis, even in the
   presence of oxygen, to support abnormal cell proliferation. Suppression
   of PDHA1 by PDK1 prevents the conversion of cytoplasmic pyruvate into
   Acetyl-CoA. Several PDK inhibitors have been identified, but their
   clinical applications have not been successful for unclear reasons. In
   this study, endo-genous PDHA1 in A549 cells was silenced by the
   CRISPR/Cas9 system, and PDHA1(WT) and PDHA1(3SD) were transduced. Since
   PDHA1(3SD) cannot be phosphorylated by PDKs, it was used to evaluate the
   specific activity of PDK inhibitors. This study highlights that
   PDHA1(WT) and PDHA1(3SD) A549 cells can be used as a cell-based PDK
   inhibitor-distinction system to examine the relationship between PDH
   activity and cell death by established PDK inhibitors. Leelamine,
   huzhangoside A and otobaphenol induced PDH activity-dependent apoptosis,
   whereas AZD7545, VER-246608 and DCA effectively enhanced PDHA1 activity
   but little toxic to cancer cells. Furthermore, the activity of
   phosphomimetic PDHA1 revealed the complexity of its regulation, which
   requires further in-depth investigation.},
Publisher = {KOREAN SOCIETY BIOCHEMISTRY \& MOLECULAR BIOLOGY},
Address = {KOREA SCIENCE \& TECHNOLOGY CENTER, \# 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA},
Type = {Article},
Language = {English},
Affiliation = {Ha, KT (Corresponding Author), Pusan Natl Univ, Dept Korean Med Sci, Sch Korean Med, Yangsan 50612, South Korea.
   Bae, SJ; Ha, KT (Corresponding Author), Pusan Natl Univ, Korean Med Res Ctr Hlth Aging, Yangsan 50612, South Korea.
   Jin, Ling; Kim, Bo-Sung; Han, Jung Ho; Ha, Ki-Tae, Pusan Natl Univ, Dept Korean Med Sci, Sch Korean Med, Yangsan 50612, South Korea.
   Jin, Ling; Cho, Minkyoung; Kim, Bo-Sung; Han, Jung Ho; Bae, Sung-Jin; Ha, Ki-Tae, Pusan Natl Univ, Korean Med Res Ctr Hlth Aging, Yangsan 50612, South Korea.
   Park, Sungmi; Lee, In-Kyu, Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu 41944, South Korea.
   Lee, In-Kyu, Kyungpook Natl Univ, Res Inst Aging \& Metab, Daegu 41404, South Korea.
   Ryu, Dongryeol, Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon 16419, South Korea.
   Kim, Jae Ho, Pusan Natl Univ, Coll Med, Dept Physiol, Yangsan 50612, South Korea.},
DOI = {10.5483/BMBRep.2021.54.11.101},
ISSN = {1976-6696},
EISSN = {1976-670X},
Keywords = {Apoptosis; Glycolysis; PDHA1; PDK; Warburg effect},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; PHOSPHORYLATION SITES; INHIBITION;
   METABOLISM; AZD7545},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {Dr.NowOrNever@pusan.ac.kr
   hagis@pusan.ac.kr},
Affiliations = {Pusan National University; Pusan National University; Kyungpook National
   University (KNU); Kyungpook National University (KNU); Sungkyunkwan
   University (SKKU); Pusan National University},
ResearcherID-Numbers = {Ryu, Dongryeol/AAQ-3642-2020
   Bae, Sung-Jin/AAX-9144-2021
   Lee, In-Kyu/AAR-6374-2021
   Kitae, Ha/AFW-2347-2022},
ORCID-Numbers = {Ryu, Dongryeol/0000-0001-5905-6760
   Kim, Jae Ho/0000-0003-4323-4790
   Cho, Minkyoung/0000-0002-1776-7254
   Park, Sungmi/0000-0002-3074-5914
   },
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) - Korean government (MIST)
   {[}2020R1C1C1003703, 2019R1A2C2003624, 2021R1A4A1025662]},
Funding-Text = {This work was supported by the National Research Foundation of Korea
   (NRF) grants funded by the Korean government (MIST; 2020R1C1C1003703 to
   Sung-Jin Bae, 2019R1A2C2003624 and 2021R1A4A1025662 to Ki-Tae Ha).},
Cited-References = {Cai Z, 2020, MOL CELL, V80, P263, DOI 10.1016/j.molcel.2020.09.018.
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478.
   Golias T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31146.
   Guerra-Castellano A, 2016, BBA-BIOENERGETICS, V1857, P387, DOI 10.1016/j.bbabio.2016.01.011.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Jeoung Nam Ho, 2010, Korean Diabetes J, V34, P274, DOI 10.4093/kdj.2010.34.5.274.
   Jin L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79019-1.
   Jing EX, 2013, DIABETES, V62, P3404, DOI 10.2337/db12-1650.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kato M, 2008, STRUCTURE, V16, P1849, DOI 10.1016/j.str.2008.10.010.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005.
   Kwak CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176021.
   Kwak CH, 2019, CANCERS, V11, DOI 10.3390/cancers11050712.
   Li J, 2009, J BIOL CHEM, V284, P34458, DOI 10.1074/jbc.M109.065557.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Mayers RM, 2003, BIOCHEM SOC T, V31, P1165.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597.
   SALE GJ, 1981, EUR J BIOCHEM, V120, P535, DOI 10.1111/j.1432-1033.1981.tb05733.x.
   Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026.
   Sradhanjali S, 2018, CURR TOP MED CHEM, V18, P444, DOI 10.2174/1568026618666180523105756.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Wang XX, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204402.
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928.
   Zimmer AD, 2016, HYPOXIA, V4, P135, DOI 10.2147/HP.S99044.},
Number-of-Cited-References = {32},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {BMB Rep.},
Doc-Delivery-Number = {XF1ZX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000723877100005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000722971600002,
Author = {Wang, Kaidong and Zhang, Baofu and Tian, Tian and Zhang, Bingyang and
   Shi, Ge and Zhang, Chunhui and Li, Guoliang and Huang, Min},
Title = {Taurine protects dopaminergic neurons in paraquat-induced Parkinson's
   disease mouse model through PI3K/Akt signaling pathways},
Journal = {AMINO ACIDS},
Year = {2022},
Volume = {54},
Number = {1},
Pages = {1-11},
Month = {JAN},
Abstract = {Taurine (Tau) is one of the most abundant amino acids in the brain and
   regulates physiological functions in the central nervous system,
   including anti-inflammatory effects. There is growing evidence that
   microglia-mediated neuro-inflammatory responses are an integral part of
   Parkinson's disease (PD) onset and progression. Among the many factors
   regulating the inflammatory response, phosphatidylinositol-3 kinase
   (PI3K) is susceptible to activation by a variety of cytokines and
   physicochemical factors, and subsequently recruits signaling proteins
   containing the pleckstrin homology structural domain to further regulate
   protein kinase B (AKT) expression involved in the regulation of the
   intracellular immune response and inflammatory response. Therefore, we
   established a PD mouse model using paraquat (PQ) intraperitoneal
   injection staining to explore the mechanism of Tau action on PI3K/AKT
   signaling pathway. Our study showed that PD mice with Tau intervention
   recovered motor and non-motor functions to some extent, and the number
   of dopaminergic (DAc) neurons in the substantia nigra and the level of
   dopamine (DA) secretion in the striatum were also significantly
   increased compared with the PQ-dyed group, and the protein content of
   PI3K and PDK-1 and the phosphorylation level of AKT were reduced in
   parallel with the reduction in the expression of microglia and related
   inflammatory factors. In conclusion, our results suggest that Tau may
   regulate microglia-mediated inflammatory responses through inhibition of
   the PI3K/AKT pathway in the midbrain of PD mice, thereby reducing DAc
   neurons damage.},
Publisher = {SPRINGER WIEN},
Address = {Prinz-Eugen-Strasse 8-10, A-1040 Vienna, AUSTRIA},
Type = {Article},
Language = {English},
Affiliation = {Huang, M (Corresponding Author), Ningxia Med Univ, Sch Publ Hlth \& Management, Yinchuan, Ningxia, Peoples R China.
   Huang, M (Corresponding Author), Key Lab Environm Factors \& Chron Dis Control, 1160 Shengli St, Yinchuan, Ningxia, Peoples R China.
   Wang, Kaidong; Zhang, Baofu; Tian, Tian; Zhang, Bingyang; Shi, Ge; Zhang, Chunhui; Li, Guoliang; Huang, Min, Ningxia Med Univ, Sch Publ Hlth \& Management, Yinchuan, Ningxia, Peoples R China.
   Wang, Kaidong; Zhang, Baofu; Tian, Tian; Zhang, Bingyang; Shi, Ge; Zhang, Chunhui; Li, Guoliang; Huang, Min, Key Lab Environm Factors \& Chron Dis Control, 1160 Shengli St, Yinchuan, Ningxia, Peoples R China.},
DOI = {10.1007/s00726-021-03104-6},
EarlyAccessDate = {NOV 2021},
ISSN = {0939-4451},
EISSN = {1438-2199},
Keywords = {Taurine; Paraquat; PI3K; AKT; Parkinson's disease; Neuro-inflammatory
   responses},
Keywords-Plus = {PESTICIDES; FEATURES},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {hmin81@163.com},
Affiliations = {Ningxia Medical University},
ORCID-Numbers = {huang, min/0000-0003-3799-3117},
Funding-Acknowledgement = {Ningxia Natural Science Foundation {[}2020AAC02018]; National Natural
   Science Foundation of China {[}81560538]},
Funding-Text = {The present study was supported by the Ningxia Natural Science
   Foundation (2020AAC02018), National Natural Science Foundation of China
   (81560538).},
Cited-References = {Abd-Elhakim YM, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117782.
   Alkholifi FK, 2015, BRAIN RES, V1622, P409, DOI 10.1016/j.brainres.2015.06.041.
   Che YN, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0468-2.
   Chen YJ, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00044.
   Dorsey ER, 2007, NEUROLOGY, V68, P384, DOI 10.1212/01.wnl.0000247740.47667.03.
   Dwyer Z, 2021, NEUROBIOL AGING, V100, P11, DOI 10.1016/j.neurobiolaging.2020.11.013.
   Gerhard A, 2006, NEUROBIOL DIS, V21, P404, DOI 10.1016/j.nbd.2005.08.002.
   Hatcher JM, 2008, TRENDS PHARMACOL SCI, V29, P322, DOI 10.1016/j.tips.2008.03.007.
   Hernández-Benítez R, 2010, J NEUROSCI RES, V88, P1673, DOI 10.1002/jnr.22328.
   Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6.
   Huang M, 2019, CHEM-BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108743.
   HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101.
   Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045.
   Jiang TF, 2015, NEUROBIOL AGING, V36, P2304, DOI 10.1016/j.neurobiolaging.2015.03.015.
   Kalia LV, 2015, LANCET, V386, P896, DOI 10.1016/S0140-6736(14)61393-3.
   Kamel F, 2013, SCIENCE, V341, P722, DOI 10.1126/science.1243619.
   Kilic U, 2017, REDOX BIOL, V12, P657, DOI 10.1016/j.redox.2017.04.006.
   Marras C, 2018, NPJ PARKINSONS DIS, V4, DOI 10.1038/s41531-018-0058-0.
   Niu XL, 2018, MOL MED REP, V18, P4516, DOI 10.3892/mmr.2018.9465.
   Postuma RB, 2019, NAT REV NEUROL, V15, P437, DOI 10.1038/s41582-019-0215-z.
   Qaradakhi T, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092847.
   Qiu TM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1004-0.
   Ruotsalainen M, 1996, NEUROSCI LETT, V212, P175, DOI 10.1016/0304-3940(96)12821-4.
   Samii A, 2004, LANCET, V363, P1783, DOI 10.1016/S0140-6736(04)16305-8.
   Santa-María I, 2007, NEUROSCI LETT, V429, P91, DOI 10.1016/j.neulet.2007.09.068.
   Schapira AHV, 2017, NAT REV NEUROSCI, V18, P435, DOI 10.1038/nrn.2017.62.
   Shimizu K, 2001, BRAIN RES, V906, P135, DOI 10.1016/S0006-8993(01)02577-X.
   Sun J, 2021, TOXICOL IN VITRO, V72, DOI 10.1016/j.tiv.2021.105076.
   Vyas P, 2017, CURR DRUG TARGETS, V18, P1622, DOI 10.2174/1389450117666161013115225.
   Wang K, 2021, NEUROTOXICOLOGY, V83, P129, DOI 10.1016/j.neuro.2021.01.002.
   Zhang D, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-3.
   Zhang L, 2016, INT J NEUROSCI, V126, P630, DOI 10.3109/00207454.2015.1051046.},
Number-of-Cited-References = {32},
Times-Cited = {34},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {27},
Journal-ISO = {Amino Acids},
Doc-Delivery-Number = {YR8RG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000722971600002},
DA = {2026-02-04},
}

@article{ WOS:000750614100003,
Author = {Sen, Sudeshna and Sultana, Nadia and Shaffer, Scott A. and Thompson,
   Paul R.},
Title = {Proximity-Dependent Labeling of Cysteines},
Journal = {JOURNAL OF THE AMERICAN CHEMICAL SOCIETY},
Year = {2021},
Volume = {143},
Number = {46},
Pages = {19257-19261},
Month = {NOV 24},
Abstract = {Mapping protein-protein interactions is crucial for understanding
   various signaling pathways in living cells, and developing new
   techniques for this purpose has attracted significant interest. Classic
   methods (e.g., the yeast two-hybrid) have been supplanted by more
   sophisticated chemical approaches that label proximal proteins (e.g.,
   BioID, APEX). Herein we describe a proximity-based approach that
   uniquely labels cysteines. Our approach exploits the nicotinamide
   N-methyltransferase (NNMT)-catalyzed methylation of an
   alkyne-substituted 4-chloropyridine (SS6). Upon methylation of the
   pyridinium nitrogen, this latent electrophile diffuses out of the active
   site and labels proximal proteins on short time scales (<= 5 min). We
   validated this approach by identifying known (and novel) interacting
   partners of protein arginine deiminase 2 (PAD2) and pyruvate
   dehydrogenase kinase 1 (PDK1). To our knowledge, this technology
   uniquely exploits a suicide substrate to label proximal cysteines in
   live cells.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Thompson, PR (Corresponding Author), Univ Massachusetts, Sch Med, Dept Biochem \& Mol Pharmacol, Worcester, MA 01605 USA.
   Thompson, PR (Corresponding Author), Univ Massachusetts, Sch Med, Program Chem Biol, Worcester, MA 01605 USA.
   Sen, Sudeshna; Sultana, Nadia; Shaffer, Scott A.; Thompson, Paul R., Univ Massachusetts, Sch Med, Dept Biochem \& Mol Pharmacol, Worcester, MA 01605 USA.
   Sen, Sudeshna; Thompson, Paul R., Univ Massachusetts, Sch Med, Program Chem Biol, Worcester, MA 01605 USA.
   Sultana, Nadia; Shaffer, Scott A., Univ Massachusetts, Sch Med, Mass Spectrometry Facil, Shrewsbury, MA 01545 USA.},
DOI = {10.1021/jacs.1c07069},
ISSN = {0002-7863},
EISSN = {1520-5126},
Keywords-Plus = {NICOTINAMIDE N-METHYLTRANSFERASE; YEAST 2-HYBRID; PROTEINS;
   MITOCHONDRIA; APOPTOSIS; ASSAY; TIME},
Research-Areas = {Chemistry},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary},
Author-Email = {paul.thompson@umassmed.edu},
Affiliations = {University of Massachusetts System; University of Massachusetts
   Worcester; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System},
ORCID-Numbers = {Thompson, Paul/0000-0002-1621-3372
   Shaffer, Scott/0000-0002-5264-3257},
Funding-Acknowledgement = {NIH {[}R35 GM118112]},
Funding-Text = {This work was supported in part by NIH Grant R35 GM118112 to P.R.T.},
Cited-References = {AKSOY S, 1994, J BIOL CHEM, V269, P14835.
   Bodnár N, 2012, JOINT BONE SPINE, V79, P63, DOI 10.1016/j.jbspin.2011.03.010.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Branon TC, 2018, NAT BIOTECHNOL, V36, P880, DOI 10.1038/nbt.4201.
   Chen CL, 2017, WIRES DEV BIOL, V6, DOI 10.1002/wdev.272.
   Fuhrmann J, 2015, CHEM REV, V115, P5413, DOI 10.1021/acs.chemrev.5b00003.
   Jones JE, 2009, CURR OPIN DRUG DISC, V12, P616.
   Kraus D, 2014, NATURE, V508, P258, DOI 10.1038/nature13198.
   Lam SS, 2015, NAT METHODS, V12, P51, DOI 10.1038/nmeth.3179.
   Lu MC, 2016, IMMUNOBIOLOGY, V221, P76, DOI 10.1016/j.imbio.2015.07.019.
   Mondal S, 2019, ACCOUNTS CHEM RES, V52, P818, DOI 10.1021/acs.accounts.9b00024.
   Neelakantan H, 2017, BIOCHEMISTRY-US, V56, P824, DOI 10.1021/acs.biochem.6b01215.
   Parrish JR, 2006, CURR OPIN BIOTECH, V17, P387, DOI 10.1016/j.copbio.2006.06.006.
   Rhee HW, 2013, SCIENCE, V339, P1328, DOI 10.1126/science.1230593.
   Riederer M, 2009, ATHEROSCLEROSIS, V204, P412, DOI 10.1016/j.atherosclerosis.2008.09.015.
   RINI J, 1990, CLIN CHIM ACTA, V186, P359, DOI 10.1016/0009-8981(90)90322-J.
   Roux KJ, 2013, CELL MOL LIFE SCI, V70, P3657, DOI 10.1007/s00018-013-1287-3.
   Roux KJ, 2012, J CELL BIOL, V196, P801, DOI 10.1083/jcb.201112098.
   Schardon CL, 2017, CHEMBIOCHEM, V18, P1551, DOI 10.1002/cbic.201700104.
   Scott JD, 2009, SCIENCE, V326, P1220, DOI 10.1126/science.1175668.
   Sen SS, 2019, ACS CHEM BIOL, V14, P613, DOI 10.1021/acschembio.9b00211.
   Thomas MG, 2016, BIOCHEM J, V473, P3253, DOI 10.1042/BCJ20160219.
   Travers TS, 2016, J IMMUNOL, V197, P1926, DOI 10.4049/jimmunol.1600162.
   Witalison EE, 2015, CURR DRUG TARGETS, V16, P700, DOI 10.2174/1389450116666150202160954.
   YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017.
   Young KH, 1998, BIOL REPROD, V58, P302, DOI 10.1095/biolreprod58.2.302.
   Zheng L, 2019, BIOCHEMISTRY-US, V58, P3042, DOI 10.1021/acs.biochem.9b00225.},
Number-of-Cited-References = {27},
Times-Cited = {8},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {35},
Journal-ISO = {J. Am. Chem. Soc.},
Doc-Delivery-Number = {YS3XU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000750614100003},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000721473900001,
Author = {Hu, Shuqian and Li, Yanru and Nie, Chunling and Zhang, Jiahui and Bai,
   Xiaofang and Wu, Hao and Shen, Ting and Hu, Weicheng and Wang, Jianguo},
Title = {Structure and pro-inflammatory activities of bran polysaccharides from a
   novel wheat kernel},
Journal = {JOURNAL OF FOOD BIOCHEMISTRY},
Year = {2022},
Volume = {46},
Number = {1},
Month = {JAN},
Abstract = {In this study, the structure and pro-inflammatory activities of
   water-soluble wheat bran polysaccharides (WBP) were evaluated. WBP were
   heteropolysaccharides consisting 60.34\% arabinoxylan as the main
   component and 31.80\% mannose residues characterized with the
   instrumental analyses. The result of cellular experiment displayed that
   WBP had significant pro-inflammatory activities by increasing the
   concentration of nitric oxide (NO) and up-regulating the inflammatory
   cytokine expressions of inducible nitric oxide synthase (iNOS),
   interleukin-1 beta (IL-1 beta), cyclooxygenase-2 (COX-2), and tumor
   necrosis factor-alpha (TNF-alpha). WBP mediated macrophages RAW 264.7
   pro-inflammatory response through phosphatidylinositol 3
   hydroxykinase/protein kinase B (PI3K/Akt) signaling pathway by
   significantly promoting Akt and phosphoinositide-dependent kinase 1
   (PDK1) phosphorylations. Meanwhile, the expression of related
   phosphorylated proteins JNK and ERK1/2 was significantly up-regulated
   which suggested that WBP played pro-inflammatory roles by activating
   mitogen-activated protein kinases (MAPKs) signaling pathway. Practical
   applications In recent years, wheat bran generally has the phenomenon of
   high yield and low utilization rate. Wheat bran has rich nutritional
   value and contains a lot of effective biologically active substances.
   Based on our findings, the water-soluble polysaccharides extracted from
   wheat bran have significant effects on regulating immunity and can be
   utilized as sources of natural immune modulators. The research can
   develop new functions of wheat bran polysaccharides, and improve
   processing utilization rate and product added value.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, JG (Corresponding Author), Northwest A\&F Univ, Coll Food Sci \& Engn, Yangling 712100, Shaanxi, Peoples R China.
   Hu, WC (Corresponding Author), Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Peoples R China.
   Hu, Shuqian; Li, Yanru; Nie, Chunling; Zhang, Jiahui; Bai, Xiaofang; Wu, Hao; Wang, Jianguo, Northwest A\&F Univ, Coll Food Sci \& Engn, Yangling 712100, Shaanxi, Peoples R China.
   Shen, Ting; Hu, Weicheng, Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Peoples R China.},
DOI = {10.1111/jfbc.14008},
EarlyAccessDate = {NOV 2021},
Article-Number = {e14008},
ISSN = {0145-8884},
EISSN = {1745-4514},
Keywords = {characterization; MAPKs; PI3K; Akt; pro-inflammatory activities; wheat
   bran polysaccharides},
Keywords-Plus = {NITRIC-OXIDE PRODUCTION; MACROPHAGE ACTIVATION; FUNCTIONAL-PROPERTIES;
   RAW264.7 MACROPHAGES; ANTIOXIDANT ACTIVITY; GRIESS REACTION;
   BETA-GLUCAN; ARABINOXYLAN; OLIGOSACCHARIDES; CELLS},
Research-Areas = {Biochemistry \& Molecular Biology; Food Science \& Technology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Food Science \& Technology},
Author-Email = {hu\_weicheng@163.com
   wjg5118@nwafu.edu.cn},
Affiliations = {Northwest A\&F University - China; Huaiyin Normal University},
ResearcherID-Numbers = {bai, xiaofang/MBV-1226-2025
   Wang, JianGuo/L-6445-2018
   Zhang, Jiahui/PGG-4355-2026},
ORCID-Numbers = {Wang, JianGuo/0000-0001-7060-8212
   },
Funding-Acknowledgement = {National Natural Science Foundation of China (NSFC) {[}32172166,
   31501436]; Fundamental Research Funds for the Central Universities
   {[}2452020174]; Key Research and Development Program of Shaanxi Province
   {[}S2020-YF-YBNY-0142]; Beijing Key Laboratory of Quality Evaluation
   Technology for Hygiene and Safety of Plastics; Beijing Engineering and
   Technology Research Center of Food Additives; Beijing Technology \&
   Business University (BTBU); Key Laboratory of Green Chemical Process of
   Ministry of Education {[}GCP20200206]; Hubei Key Laboratory of Novel
   Reactor and Green Chemical Technology (Wuhan Institute of Technology)
   {[}K202002]; Open Science Foundation of Jiangsu Key Laboratory for
   Eco-Agricultural Biotechnology around Hongze Lake {[}HZHLAB1905]},
Funding-Text = {The National Natural Science Foundation of China (NSFC), Grant/Award
   Number: 32172166 and 31501436; The Fundamental Research Funds for the
   Central Universities, Grant/Award Number: 2452020174; The Key Research
   and Development Program of Shaanxi Province, Grant/Award Number:
   S2020-YF-YBNY-0142; Beijing Key Laboratory of Quality Evaluation
   Technology for Hygiene and Safety of Plastics; Beijing Engineering and
   Technology Research Center of Food Additives; Beijing Technology \&
   Business University (BTBU); Key Laboratory of Green Chemical Process of
   Ministry of Education, Grant/Award Number: GCP20200206; Hubei Key
   Laboratory of Novel Reactor and Green Chemical Technology (Wuhan
   Institute of Technology), Grant/Award Number: K202002; Open Science
   Foundation of Jiangsu Key Laboratory for Eco-Agricultural Biotechnology
   around Hongze Lake, Grant/Award Number: HZHLAB1905},
Cited-References = {Addoun N, 2020, INT J BIOL MACROMOL, V155, P1333, DOI 10.1016/j.ijbiomac.2019.11.106.
   AGRAWAL PK, 1992, PHYTOCHEMISTRY, V31, P3307, DOI 10.1016/0031-9422(92)83678-R.
   Ahmad A, 2012, CRIT REV FOOD SCI, V52, P201, DOI 10.1080/10408398.2010.499806.
   Amelung W, 1996, SOIL BIOL BIOCHEM, V28, P1631, DOI 10.1016/S0038-0717(96)00248-9.
   Beltrame G, 2019, FOOD CHEM, V301, DOI 10.1016/j.foodchem.2019.125255.
   Burke JE, 2015, TRENDS BIOCHEM SCI, V40, P88, DOI 10.1016/j.tibs.2014.12.003.
   Chang ZQ, 2009, J VET SCI, V10, P165, DOI 10.4142/jvs.2009.10.2.165.
   Chen Y, 2015, FOOD CHEM, V186, P231, DOI 10.1016/j.foodchem.2014.10.032.
   Choi YS, 2005, MOL CELLS, V20, P241.
   Du J, 2018, FOOD FUNCT, V9, P3930, DOI 10.1039/c8fo00603b.
   DUBOIS M, 1951, NATURE, V168, P167, DOI 10.1038/168167a0.
   Fang Y, 2017, FOOD CHEM, V219, P391, DOI 10.1016/j.foodchem.2016.09.131.
   François IEJA, 2012, BRIT J NUTR, V108, P2229, DOI 10.1017/S0007114512000372.
   Gao X, 2020, CARBOHYD POLYM, V233, DOI 10.1016/j.carbpol.2020.115849.
   Ghosh K, 2008, CARBOHYD RES, V343, P2834, DOI 10.1016/j.carres.2008.05.011.
   Han S, 2011, PLANTA MED, V77, P1431.
   Hopkins MJ, 2003, APPL ENVIRON MICROB, V69, P6354, DOI 10.1128/AEM.69.11.6354-6360.2003.
   Hu SQ, 2020, CARBOHYD POLYM, V236, DOI 10.1016/j.carbpol.2020.116052.
   Hu WC, 2014, CHEM-BIOL INTERACT, V224, P108, DOI 10.1016/j.cbi.2014.10.011.
   Huang GL, 2012, INT J FOOD SCI NUTR, V63, P739, DOI 10.3109/09637486.2011.652599.
   Huisman MMH, 2000, CARBOHYD POLYM, V43, P269, DOI 10.1016/S0144-8617(00)00154-5.
   Jahanbin K, 2011, INT J BIOL MACROMOL, V49, P567, DOI 10.1016/j.ijbiomac.2011.06.012.
   Jeong HK, 2019, CARBOHYD POLYM, V211, P100, DOI 10.1016/j.carbpol.2019.01.097.
   Ji MG, 2020, ACS OMEGA, V5, P26374, DOI 10.1021/acsomega.0c02472.
   Ji XL, 2018, FOOD CHEM, V245, P1124, DOI 10.1016/j.foodchem.2017.11.058.
   Jung KK, 2006, LIFE SCI, V79, P2022, DOI 10.1016/j.lfs.2006.06.048.
   Kale MS, 2018, CARBOHYD POLYM, V181, P119, DOI 10.1016/j.carbpol.2017.10.008.
   Khazan S, 2020, BMC PLANT BIOL, V20, DOI 10.1186/s12870-020-2306-9.
   Kosmala M, 2013, FOOD RES INT, V54, P1787, DOI 10.1016/j.foodres.2013.10.022.
   Lee JS, 2011, INT IMMUNOPHARMACOL, V11, P1226, DOI 10.1016/j.intimp.2011.04.001.
   Li J, 2015, CARBOHYD POLYM, V130, P97, DOI 10.1016/j.carbpol.2015.04.070.
   Li LY, 2020, CARBOHYD POLYM, V249, DOI 10.1016/j.carbpol.2020.116813.
   Li Q, 2018, CARBOHYD POLYM, V196, P445, DOI 10.1016/j.carbpol.2018.05.046.
   Liu CR, 2016, J AGR FOOD CHEM, V64, P3206, DOI 10.1021/acs.jafc.6b00932.
   Liu M, 2018, CARBOHYD POLYM, V201, P566, DOI 10.1016/j.carbpol.2018.08.099.
   Lu ZX, 2000, AM J CLIN NUTR, V71, P1123.
   Ma FW, 2016, CARBOHYD POLYM, V152, P699, DOI 10.1016/j.carbpol.2016.07.062.
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323.
   Maes C, 2001, J CEREAL SCI, V34, P29, DOI 10.1006/jcrs.2001.0377.
   Maity GN, 2019, CARBOHYD POLYM, V212, P297, DOI 10.1016/j.carbpol.2019.02.051.
   Malinowska E, 2018, CARBOHYD POLYM, V198, P407, DOI 10.1016/j.carbpol.2018.06.057.
   Merkx DWH, 2018, CARBOHYD POLYM, V179, P379, DOI 10.1016/j.carbpol.2017.09.074.
   Methacanon P, 2005, CARBOHYD POLYM, V60, P199, DOI 10.1016/j.carbpol.2004.12.006.
   Miao M, 2014, FOOD CHEM, V143, P156, DOI 10.1016/j.foodchem.2013.07.109.
   Minzanova ST, 2014, CHEM NAT COMPD+, V50, P54, DOI 10.1007/s10600-014-0865-4.
   Pi J, 2014, MICRON, V65, P1, DOI 10.1016/j.micron.2014.03.012.
   Prückler M, 2014, LWT-FOOD SCI TECHNOL, V56, P211, DOI 10.1016/j.lwt.2013.12.004.
   Ren DY, 2019, FOOD FUNCT, V10, P2186, DOI 10.1039/c9fo00219g.
   Ren DY, 2017, FOOD FUNCT, V8, P1299, DOI 10.1039/c6fo01699e.
   Shewry PR, 2015, J CEREAL SCI, V65, P236, DOI 10.1016/j.jcs.2015.07.014.
   Sosnina NA, 2000, CHEM NAT COMPD, V36, P40, DOI 10.1007/BF02234900.
   Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz.
   Sun J, 2003, SENSORS-BASEL, V3, P276, DOI 10.3390/s30800276.
   Tsikas D, 2007, J CHROMATOGR B, V851, P51, DOI 10.1016/j.jchromb.2006.07.054.
   Wang JG, 2009, J AGR FOOD CHEM, V57, P10565, DOI 10.1021/jf902597w.
   Wang J, 2014, FOOD CHEM, V150, P482, DOI 10.1016/j.foodchem.2013.10.121.
   Xu X, 2014, J AGR FOOD CHEM, V62, P3168, DOI 10.1021/jf405633n.
   Yang XB, 2007, J BIOCHEM MOL BIOL, V40, P636.
   Zhao C, 2006, CARBOHYD RES, V341, P485, DOI 10.1016/j.carres.2005.11.032.
   Zhao F, 2013, MOL MED REP, V8, P1575, DOI 10.3892/mmr.2013.1663.
   Zhou CS, 2012, CARBOHYD POLYM, V87, P2046, DOI 10.1016/j.carbpol.2011.10.026.},
Number-of-Cited-References = {61},
Times-Cited = {4},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {44},
Journal-ISO = {J. Food Biochem.},
Doc-Delivery-Number = {YD2IA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000721473900001},
DA = {2026-02-04},
}

@article{ WOS:000720907600008,
Author = {Senoo, Hiroshi and Murata, Daisuke and Wai, May and Arai, Kenta and
   Iwata, Wakiko and Sesaki, Hiromi and Iijima, Miho},
Title = {KARATE: PKA-induced KRAS4B-RHOA-mTORC2 supercomplex phosphorylates AKT
   in insulin signaling and glucose homeostasis},
Journal = {MOLECULAR CELL},
Year = {2021},
Volume = {81},
Number = {22},
Pages = {4622+},
Month = {NOV 18},
Abstract = {AKT is a serine/threonine kinase that plays an important role in
   metabolism, cell growth, and cytoskeletal dynamics. AKT is activated by
   two kinases, PDK1 and mTORC2. Although the regulation of PDK1 is well
   understood, the mechanism that controls mTORC2 is unknown. Here, by
   investigating insulin receptor signaling in human cells and biochemical
   reconstitution, we found that insulin induces the activation of mTORC2
   toward AKT by assembling a supercomplex with KRAS4B and RHOA GTPases,
   termed KARATE (KRAS4B-RHOAmTORC2 Ensemble). Insulin-induced KARATE
   assembly is controlled via phosphorylation of GTP-bound KRAS4B at S181
   and GDP-bound RHOA at S188 by protein kinase A. By developing a KARATE
   inhibitor, we demonstrate that KRAS4B-RHOA interaction drives KARATE
   formation. In adipocytes, KARATE controls insulin-dependent
   translocation of the glucose transporter GLUT4 to the plasma membrane
   for glucose uptake. Thus, our work reveals a fundamental mechanism that
   activates mTORC2 toward AKT in insulin -regulated glucose homeostasis.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Sesaki, H; Iijima, M (Corresponding Author), Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.
   Senoo, Hiroshi; Murata, Daisuke; Wai, May; Arai, Kenta; Iwata, Wakiko; Sesaki, Hiromi; Iijima, Miho, Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.},
DOI = {10.1016/j.molcel.2021.09.001},
EarlyAccessDate = {NOV 2021},
ISSN = {1097-2765},
EISSN = {1097-4164},
Keywords-Plus = {RHO GTPASES; RAS-GTP; 3T3-L1; MTOR; KINASE; PTEN; DIMERIZATION;
   COMPLEXES; DIMERS; CELLS},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {hsesaki@jhmi.edu
   miijima@jhmi.edu},
Affiliations = {Johns Hopkins University},
ORCID-Numbers = {Wai, May/0000-0002-1409-3442
   Sesaki, Hiromi/0000-0002-6877-3929},
Funding-Acknowledgement = {NIH {[}GM131768, NS114458, GM123266, GM130695]; Sol Goldman Pancreatic
   Cancer Research Center; Robert J. Kleberg, Jr. and Helen C. Kleberg
   Foundation; National Institute of General Medical Sciences
   {[}R35GM131768, R01GM130695] Funding Source: NIH RePORTER},
Funding-Text = {We thank past and present members of the Iijima and Sesaki labs for
   helpful discussions and technical assistance. This work was supported by
   NIH grants to M.I. (GM131768 and NS114458) and H. Sesaki (GM123266 and
   GM130695), a grant to M.I. from the Sol Goldman Pancreatic Cancer
   Research Center, and a grant to H. Sesaki from the Robert J. Kleberg,
   Jr. and Helen C. Kleberg Foundation.},
Cited-References = {Ahearn I, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031484.
   Alan JK, 2012, METHODS MOL BIOL, V827, P339, DOI 10.1007/978-1-61779-442-1\_22.
   Alberts B, 2015, MOLECULAR BIOLOGY OF THE CELL, SIXTH EDITION, P1.
   Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020.
   BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023.
   Bogan JS, 2001, MOL CELL BIOL, V21, P4785, DOI 10.1128/MCB.21.14.4785-4806.2001.
   Cai HQ, 2011, METHODS MOL BIOL, V757, P451, DOI 10.1007/978-1-61779-166-6\_26.
   Clayton NS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00222.
   Cole PA, 2019, CURR OPIN STRUC BIOL, V59, P47, DOI 10.1016/j.sbi.2019.02.004.
   DeFronzo RA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.19.
   Haeusler RA, 2018, NAT REV MOL CELL BIO, V19, P31, DOI 10.1038/nrm.2017.89.
   Nguyen HN, 2014, P NATL ACAD SCI USA, V111, pE2684, DOI 10.1073/pnas.1409433111.
   Hodge RG, 2016, NAT REV MOL CELL BIO, V17, P496, DOI 10.1038/nrm.2016.67.
   Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568-019-0216-7.
   Huang JX, 2012, METHODS MOL BIOL, V821, P75, DOI 10.1007/978-1-61779-430-8\_6.
   Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6.
   Jang H, 2016, BIOCHEM J, V473, P1719, DOI 10.1042/BCJ20160031.
   Jefcoate Colin R., 2008, V456, P173, DOI 10.1007/978-1-59745-245-8\_13.
   Katsarou Anastasia, 2017, Nat Rev Dis Primers, V3, P17016, DOI 10.1038/nrdp.2017.16.
   Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1.
   Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069.
   Leto D, 2012, NAT REV MOL CELL BIO, V13, P383, DOI 10.1038/nrm3351.
   Levi S, 2002, CELL MOTIL CYTOSKEL, V53, P177, DOI 10.1002/cm.10068.
   Li SQ, 2018, NAT REV CANCER, V18, P767, DOI 10.1038/s41568-018-0076-6.
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y.
   Lu Y, 2017, ONCOTARGET, V8, P73774, DOI 10.18632/oncotarget.17908.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   MARSH BJ, 1995, J CELL BIOL, V130, P1081, DOI 10.1083/jcb.130.5.1081.
   Mitin N, 2012, METHODS MOL BIOL, V827, P87, DOI 10.1007/978-1-61779-442-1\_6.
   Nan XL, 2015, P NATL ACAD SCI USA, V112, P7996, DOI 10.1073/pnas.1509123112.
   REED BC, 1980, P NATL ACAD SCI-BIOL, V77, P285, DOI 10.1073/pnas.77.1.285.
   Ridley A, 2000, J CELL BIOL, V150, pF107, DOI 10.1083/jcb.150.4.F107.
   RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8.
   RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7.
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128.
   Roden M, 2019, NATURE, V576, P51, DOI 10.1038/s41586-019-1797-8.
   Sabatini DM, 2017, P NATL ACAD SCI USA, V114, P11818, DOI 10.1073/pnas.1716173114.
   Sarbassov DD, 2012, METHODS MOL BIOL, V821, P59, DOI 10.1007/978-1-61779-430-8\_5.
   Senoo H, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108427.
   Senoo H, 2019, NAT CELL BIOL, V21, P867, DOI 10.1038/s41556-019-0348-8.
   Shimobayashi M, 2016, CELL RES, V26, P7, DOI 10.1038/cr.2015.146.
   Tokarz VL, 2018, J CELL BIOL, V217, P2273, DOI 10.1083/jcb.201802095.
   Uto-Kondo H, 2009, J NUTR, V139, P51, DOI 10.3945/jn.108.096131.
   Wang Y, 2013, P NATL ACAD SCI USA, V110, pE4723, DOI 10.1073/pnas.1312540110.
   Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660.
   Yang M, 2017, ONCOGENE, V36, P3673, DOI 10.1038/onc.2016.493.
   Yang WY, 2018, DIABETES CARE, V41, P917, DOI 10.2337/dci18-0007.
   Zebisch K, 2012, ANAL BIOCHEM, V425, P88, DOI 10.1016/j.ab.2012.03.005.},
Number-of-Cited-References = {49},
Times-Cited = {27},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Mol. Cell},
Doc-Delivery-Number = {XA8RL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000720907600008},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000719934000002,
Author = {Zhang, Suhong and Dai, Haiting and Li, Wenya and Wang, Runming and Wu,
   Hanyu and Shen, Ming and Hu, Ye and Xie, Lixin and Xing, Yiming},
Title = {TMEM116 is required for lung cancer cell motility and metastasis through
   PDK1 signaling pathway},
Journal = {CELL DEATH \& DISEASE},
Year = {2021},
Volume = {12},
Number = {12},
Month = {NOV 16},
Abstract = {Transmembrane protein (TMEM) is a family of protein that spans
   cytoplasmic membranes and allows cell-cell and cell-environment
   communication. Dysregulation of TMEMs has been observed in multiple
   cancers. However, little is known about TMEM116 in cancer development.
   In this study, we demonstrate that TMEM116 is highly expressed in
   non-small-cell lung cancer (NSCLC) tissues and cell lines. Inactivation
   of TMEM116 reduced cell proliferation, migration and invasiveness of
   human cancer cells and suppressed A549 induced tumor metastasis in mouse
   lungs. In addition, TMEM116 deficiency inhibited PDK1-AKT-FOXO3A
   signaling pathway, resulting in accumulation of TAp63, while activation
   of PDK1 largely reversed the TMEM116 deficiency induced defects in
   cancer cell motility, migration and invasive. Together, these results
   demonstrate that TMEM116 is a critical integrator of oncogenic signaling
   in cancer metastasis.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Xing, YM (Corresponding Author), China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China.
   Zhang, Suhong; Dai, Haiting; Li, Wenya; Wang, Runming; Wu, Hanyu; Xing, Yiming, China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China.
   Shen, Ming, Chinese Peoples Liberat Army Gen Hosp, Translat Med Lab, Beijing, Peoples R China.
   Hu, Ye; Xie, Lixin, Chinese Peoples Liberat Army Gen Hosp, Coll Pulm \& Crit Care Med, Beijing, Peoples R China.},
DOI = {10.1038/s41419-021-04369-1},
Article-Number = {1086},
ISSN = {2041-4889},
Keywords-Plus = {PI3K/AKT/MTOR PATHWAY; KINASE; OVEREXPRESSION; PROLIFERATION;
   INHIBITION; ACTIVATION; RESISTANCE; LANDSCAPE; PROTEINS; INVASION},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {ymxing@cau.edu.cn},
Affiliations = {China Agricultural University; Chinese People's Liberation Army General
   Hospital; Chinese People's Liberation Army General Hospital},
ResearcherID-Numbers = {Shen, Ming/IUN-8784-2023
   Xing, Yiming/LLM-7052-2024},
ORCID-Numbers = {Li, Wenya/0000-0002-4176-0327
   Shen, Ming/0000-0002-6248-8000
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31972566]},
Funding-Text = {This work is supported by the National Natural Science Foundation of
   China (31972566).},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Babcock JJ, 2014, ACTA PHARMACOL SIN, V35, P11, DOI 10.1038/aps.2013.142.
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655.
   Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Cuajungco MP, 2012, ACTA HISTOCHEM, V114, P705, DOI 10.1016/j.acthis.2011.12.006.
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4.
   Du L, 2016, ONCOGENE, V35, P4641, DOI 10.1038/onc.2016.1.
   Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023.
   Feng JJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1637-7.
   Feng YH, 2019, INT J EXP PATHOL, V100, P32, DOI 10.1111/iep.12307.
   Ferro R, 2014, WORLD J GASTROENTERO, V20, P10752, DOI 10.3748/wjg.v20.i31.10752.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Fukushima H, 2009, CANCER RES, V69, P9263, DOI 10.1158/0008-5472.CAN-09-1188.
   Fumarola C, 2014, BIOCHEM PHARMACOL, V90, P197, DOI 10.1016/j.bcp.2014.05.011.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gopinath SD., 2004, STEM CELL REP, V2, P26.
   Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988.
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404.
   Han F, 2017, INT J BIOL SCI, V13, P1266, DOI 10.7150/ijbs.20485.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hrasovec S, 2013, DIS MARKERS, V34, P93, DOI {[}10.1155/2013/427890, 10.3233/DMA-120948].
   Hu LS., 2007, P NATL ACAD SCI US, V114, pE3973.
   Iadevaia V, 2014, SEMIN CELL DEV BIOL, V36, P113, DOI 10.1016/j.semcdb.2014.08.004.
   Li T, 2014, INT J MOL SCI, V15, P18856, DOI 10.3390/ijms151018856.
   Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Meng DL, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.152595.
   Moses MA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143590.
   Qiao WL, 2016, TUMOR BIOL, V37, P2575, DOI 10.1007/s13277-015-4014-x.
   Rawlings AE, 2016, BIOCHEM SOC T, V44, P790, DOI 10.1042/BST20160025.
   Rawson S, 2016, MOL MEMBR BIOL, V33, P12, DOI 10.1080/09687688.2016.1221533.
   Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84.
   Sarode P, 2020, CELL SIGNAL, V65, DOI 10.1016/j.cellsig.2019.109463.
   Schmit K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01345.
   Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383.
   Sébastien M, 2020, SEMIN CANCER BIOL, V60, P96, DOI 10.1016/j.semcancer.2019.08.018.
   Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008-5472.CAN-18-2738.
   Wang GZ, 2015, ELIFE, V4, DOI 10.7554/eLife.09419.
   Wrzesinski T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1530-4.
   Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0.
   Zhang HY, 2017, BIOMED PHARMACOTHER, V90, P650, DOI 10.1016/j.biopha.2017.03.104.
   Zhou XL, 2007, CANCER GENET CYTOGEN, V177, P6, DOI 10.1016/j.cancergencyto.2007.04.007.},
Number-of-Cited-References = {44},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {WZ4IY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000719934000002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000719475600001,
Author = {Cienfuegos-Pecina, Eduardo and Moreno-Pena, Diana P. and
   Torres-Gonzalez, Liliana and Raquel Rodriguez-Rodriguez, Diana and
   Garza-Villarreal, Diana and Mendoza-Hernandez, Oscar H. and Alejandro
   Flores-Cantu, Raul and Samaniego Saenz, Brenda Alejandra and
   Alarcon-Galvan, Gabriela and Munoz-Espinosa, Linda E. and Ibarra-Rivera,
   Tannya R. and Saucedo, Alma L. and Cordero-Perez, Paula},
Title = {Treatment with sodium (S)-2-hydroxyglutarate prevents liver injury in an
   ischemia-reperfusion model in female Wistar rats},
Journal = {PEERJ},
Year = {2021},
Volume = {9},
Month = {NOV 12},
Abstract = {Background. Ischemia-reperfusion (IR) injury is one of the leading
   causes of early graft dysfunction in liver transplantation. Techniques
   such as ischemic preconditioning protect the graft through the
   activation of the hypoxia-inducible factors (HIF), which are
   downregulated by the EGLN family of prolyl-4-hydroxylases, a potential
   biological target for the development of strategies based on
   pharmacological preconditioning. For that reason, this study aims to
   evaluate the effect of the EGLN inhibitor sodium (S)-2-hydroxyglutarate
   {[}(S)-2HG] on liver IR injury in Wistar rats.
   Methods. Twenty-eight female Wistar rats were divided into the following
   groups: sham (SH, n = 7), non-toxicity (HGTox, n = 7, 25 mg/kg of
   (S)-2HG, twice per day for two days), IR (n = 7, total liver ischemia:
   20 minutes, reperfusion: 60 minutes), and (S)-2HG+IR (HGIR, n = 7, 25
   mg/kg of (S)-2HG, twice per day for two days, total liver ischemia as
   the IR group). Serum ALT, AST, LDH, ALP, glucose, and total bilirubin
   were assessed. The concentrations of IL-1 beta, IL-6, TNF,
   malondialdehyde, superoxide dismutase, and glutathione peroxidase were
   measured in liver tissue, as well as the expression of Hmox1, Vegfa, and
   Pdk1, determined by RT-qPCR. Sections of liver tissue were evaluated
   histologically, assessing the severity of necrosis, sinusoidal
   congestion, and cytoplasmatic vacuolization.
   Results. The administration of (S)-2HG did not cause any alteration in
   the assessed biochemical markers compared to SH. Preconditioning with
   (S)-2HG significantly ameliorated IR injury in the HGIR group,
   decreasing the serum activities of ALT, AST, and LDH, and the tissue
   concentrations of IL-1 beta and IL-6 compared to the IR group. IR injury
   decreased serum glucose compared to SH. There were no differences in the
   other biomarkers assessed. The treatment with (S)-2HG tended to decrease
   the severity of hepatocyte necrosis and sinusoidal congestion compared
   to the IR group. The administration of (S)-2HG did not affect the
   expression of Hmox1 but decreased the expression of both Vegfa and Pdk1
   compared to the SH group, suggesting that the HIF-1 pathway is not
   involved in its mechanism of hepatoprotection. In conclusion, (S)-2HG
   showed a hepatoprotective effect, decreasing the levels of liver injury
   and inflammation biomarkers, without evidence of the involvement of the
   HIF-1 pathway. No hepatotoxic effect was observed at the tested dose.},
Publisher = {PEERJ INC},
Address = {341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Cordero-Pérez, P (Corresponding Author), Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose E Gonzalez, Dept Internal Med, Liver Unit, Monterrey, Nuevo Leon, Mexico.
   Cienfuegos-Pecina, Eduardo; Moreno-Pena, Diana P.; Torres-Gonzalez, Liliana; Raquel Rodriguez-Rodriguez, Diana; Garza-Villarreal, Diana; Mendoza-Hernandez, Oscar H.; Alejandro Flores-Cantu, Raul; Samaniego Saenz, Brenda Alejandra; Munoz-Espinosa, Linda E.; Cordero-Perez, Paula, Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose E Gonzalez, Dept Internal Med, Liver Unit, Monterrey, Nuevo Leon, Mexico.
   Cienfuegos-Pecina, Eduardo, Univ Autonoma Nuevo Leon, Univ Hosp Dr Jose E Gonzalez, Dept Clin Pathol, Blood Bank, Monterrey, Nuevo Leon, Mexico.
   Alarcon-Galvan, Gabriela, Univ Monterrey, Sch Med, Basic Sci Dept, Monterrey, Nuevo Leon, Mexico.
   Ibarra-Rivera, Tannya R.; Saucedo, Alma L., Univ Autonoma Nuevo Leon, Sch Med, Dept Analyt Chem, Monterrey, Nuevo Leon, Mexico.},
DOI = {10.7717/peerj.12426},
Article-Number = {12426},
ISSN = {2167-8359},
Keywords = {Ischemia-reperfusion injury; 2-hydroxyglutarate; Oxidative stress;
   Proinflammatory cytokines; Hmox1; Vegfa; Pdk1; Liver},
Keywords-Plus = {WARM ISCHEMIA/REPERFUSION INJURY; HYPOXIA-INDUCIBLE FACTORS; DONOR
   TREATMENT; HEPATIC-INJURY; GRAFT INJURY; NITRIC-OXIDE; ACTIVATION;
   MECHANISM; PROTECTS; GENE},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {paula.corcleroprz@uanl.edu.mx},
Affiliations = {Universidad Autonoma de Nuevo Leon; Universidad Autonoma de Nuevo Leon;
   Universidad de Monterrey; Universidad Autonoma de Nuevo Leon},
ResearcherID-Numbers = {Cienfuegos-Pecina, Eduardo/JMP-9326-2023
   Cordero, Paula/AAF-6961-2020
   Saucedo Yáñez, Alma Leticia/D-3400-2018
   },
ORCID-Numbers = {Cienfuegos-Pecina, Eduardo/0000-0001-9734-7438
   Roiguez Roiguez, Diana Raquel/0000-0002-3176-9571
   Saucedo Yáñez, Alma Leticia/0000-0002-1028-9122
   Mendoza Hernández, Oscar Humberto/0000-0002-9461-9503},
Cited-References = {Abdel-Gaber SA, 2015, LIFE SCI, V134, P42, DOI 10.1016/j.lfs.2015.04.025.
   Abu-Amara M, 2011, LIVER TRANSPLANT, V17, P70, DOI 10.1002/lt.22204.
   Albrecht M, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-012-0314-0.
   Ali JM, 2015, LIVER TRANSPLANT, V21, P487, DOI 10.1002/lt.24072.
   Andria B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069972.
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438.
   Bachir NM, 2012, AM J MED SCI, V343, P462, DOI 10.1097/MAJ.0b013e3182308b66.
   Bailey SM, 2000, LIFE SCI, V66, P1033, DOI 10.1016/S0024-3205(99)00668-2.
   Bal D, 2002, MAGN RESON CHEM, V40, P533, DOI 10.1002/mrc.1053.
   Bernhardt WM, 2009, P NATL ACAD SCI USA, V106, P21276, DOI 10.1073/pnas.0903978106.
   BLOECHLE C, 1994, HORM METAB RES, V26, P270, DOI 10.1055/s-2007-1001682.
   Briceño J, 2010, TRANSPL P, V42, P631, DOI 10.1016/j.transproceed.2010.02.004.
   Bujaldon E, 2019, J MOL MED, V97, P1299, DOI 10.1007/s00109-019-01811-y.
   Cai ZQ, 2013, P NATL ACAD SCI USA, V110, P17462, DOI 10.1073/pnas.1317158110.
   CENATRA, 2020, B ESTADISTICO INFORM.
   Cheng MX, 2019, BIOMED PHARMACOTHER, V111, P1141, DOI 10.1016/j.biopha.2018.12.149.
   Choi JM, 2010, TRANSPL P, V42, P3414, DOI 10.1016/j.transproceed.2010.08.050.
   Cienfuegos-Pecina E, 2020, PEERJ, V8, DOI 10.7717/peerj.9438.
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617.
   Dawn B, 2005, AM J PHYSIOL-HEART C, V289, pH522, DOI 10.1152/ajpheart.00274.2005.
   Dengler VL, 2014, CRIT REV BIOCHEM MOL, V49, P1, DOI 10.3109/10409238.2013.838205.
   Dorweiler B, 2007, EUR J TRAUMA EMERG S, V33, P600, DOI 10.1007/s00068-007-7152-z.
   Du X, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.651317.
   Eckhoff DE, 2002, SURGERY, V132, P302, DOI 10.1067/msy.2002.125718.
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604.
   Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752.
   Gupta M, 1997, MOL CELL BIOCHEM, V176, P337, DOI 10.1023/A:1006829902442.
   Harada H, 2003, P NATL ACAD SCI USA, V100, P739, DOI 10.1073/pnas.0235680100.
   Hill P, 2008, J AM SOC NEPHROL, V19, P39, DOI 10.1681/ASN.2006090998.
   Intlekofer AM, 2017, NAT CHEM BIOL, V13, P494, DOI {[}10.1038/NCHEMBIO.2307, 10.1038/nchembio.2307].
   JANSEN GA, 1993, BIOCHIM BIOPHYS ACTA, V1225, P53, DOI 10.1016/0925-4439(93)90121-G.
   Pérez JCJ, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3196431.
   Jiménez-Castro MB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101131.
   Kalawaj K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249406.
   Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898.
   Kruger NJ, 2009, SPRINGER PROTOC HAND, P17, DOI 10.1007/978-1-59745-198-7\_4.
   Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375.
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022.
   MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124.
   Nishino T, 2005, J BIOL CHEM, V280, P24888, DOI 10.1074/jbc.M501830200.
   PRZYKLENK K, 1993, CIRCULATION, V87, P893, DOI 10.1161/01.CIR.87.3.893.
   Ritthausen H, 1872, J PRAKT CHEM, V5, P354, DOI 10.1002/prac.18720050132..
   Rzem R, 2006, BIOCHIMIE, V88, P113, DOI 10.1016/j.biochi.2005.06.005.
   Salvadori Maurizio, 2015, World J Transplant, V5, P52, DOI {[}10.5500/wjt.v5.i2.52, 10.5500/wjt.v5.i2.52].
   SCHOENBERG MH, 1985, ACTA PHYSIOL SCAND, V124, P581, DOI 10.1111/j.1748-1716.1985.tb00051.x.
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720.
   Shen SQ, 2007, WORLD J GASTROENTERO, V13, P1953, DOI 10.3748/wjg.v13.i13.1953.
   SUZUKI S, 1993, TRANSPLANTATION, V55, P1265.
   Torres-González L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9572803.
   Vogler M, 2015, PFLUG ARCH EUR J PHY, V467, P2141, DOI 10.1007/s00424-014-1667-z.
   Wang TM, 2017, BIOCHEM BIOPH RES CO, V485, P591, DOI 10.1016/j.bbrc.2016.12.078.
   Yildiz F, 2015, TRANSPL P, V47, P1507, DOI 10.1016/j.transproceed.2015.04.062.
   Zapata-Chavira H, 2019, J INVEST SURG, V32, P63, DOI 10.1080/08941939.2017.1375052.
   Zapata-Chavira HA, 2015, ARCH MED RES, V46, P296, DOI 10.1016/j.arcmed.2015.06.002.
   Zhang XJ, 2018, ARTIF ORGANS, V42, P280, DOI 10.1111/aor.13005.},
Number-of-Cited-References = {55},
Times-Cited = {2},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {11},
Journal-ISO = {PeerJ},
Doc-Delivery-Number = {WY7RA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000719475600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000716927900002,
Author = {Zheng, Bo and Meng, Junan and Zhu, Yuan and Ding, Min and Zhang, Yuting
   and Zhou, Jianjun},
Title = {Melatonin enhances SIRT1 to ameliorate mitochondrial membrane damage by
   activating PDK1/Akt in granulosa cells of PCOS},
Journal = {JOURNAL OF OVARIAN RESEARCH},
Year = {2021},
Volume = {14},
Number = {1},
Month = {NOV 11},
Abstract = {Mitochondrial injury in granulosa cells (GCs) is associated with the
   pathophysiological mechanism of polycystic ovary syndrome (PCOS).
   Melatonin reduces the mitochondrial injury by enhancing SIRT1
   (NAD-dependent deacetylase sirtuin-1), while the mechanism remains
   unclear. Mitochondrial membrane potential is a universal selective
   indicator of mitochondrial function. In this study, mitochondrial
   swelling and membrane defect mitochondria in granulosa cells were
   observed from PCOS patients and DHT-induced PCOS-like mice, and the
   cytochrome C level in the cytoplasm and the expression of BAX
   (BCL2-associated X protein) in mitochondria were significantly increased
   in GCs, with p-Akt decreased, showing mitochondrial membrane was damaged
   in GCs of PCOS. Melatonin treatment decreased mitochondrial permeability
   transition pore (mPTP) opening and increased the JC-1 (5,5 `,6,6
   `-tetrachloro1,1 `,3,3 `-tetramethylbenzimidazolylcarbocyanine iodide)
   aggregate/monomer ratio in the live KGN cells treated with DHT,
   indicating melatonin mediates mPTP to increase mitochondrial membrane
   potential. Furthermore, we found melatonin decreased the levels of
   cytochrome C and BAX in DHT-induced PCOS mice. PDK1/Akt played an
   essential role in improving the mitochondrial membrane function, and
   melatonin treatment increased p-PDK 1 and p-Akt in vivo and in vitro.
   The SIRT1 was also increased with melatonin treatment, while knocking
   down SIRT1 mRNA inhibiting the protective effect of melatonin to
   activate PDK1/Akt. In conclusion, melatonin enhances SIRT1 to ameliorate
   mitochondrial membrane damage by activating PDK1/Akt in granulosa cells
   of PCOS.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhou, JJ (Corresponding Author), Nanjing Univ, Med Sch, Affiliated Hosp, Reprod Med Ctr,Nanjing Drum Tower Hosp, Zhongshan Rd 32, Nanjing 210008, Peoples R China.
   Zheng, Bo; Meng, Junan; Zhu, Yuan; Ding, Min; Zhang, Yuting; Zhou, Jianjun, Nanjing Univ, Med Sch, Affiliated Hosp, Reprod Med Ctr,Nanjing Drum Tower Hosp, Zhongshan Rd 32, Nanjing 210008, Peoples R China.},
DOI = {10.1186/s13048-021-00912-y},
Article-Number = {152},
EISSN = {1757-2215},
Keywords = {Melatonin; PCOS; Akt; SIRT1; mPTP},
Keywords-Plus = {POLYCYSTIC-OVARY-SYNDROME; WOMEN; EXPRESSION; PATHWAY; ROS},
Research-Areas = {Reproductive Biology},
Web-of-Science-Categories  = {Reproductive Biology},
Author-Email = {zhou6jj@hotmail.com},
Affiliations = {Nanjing University},
ResearcherID-Numbers = {zhang, yuting/JZE-2800-2024},
ORCID-Numbers = {Zhou, Jianjun/0000-0002-9303-3623
   zhang, yuting/0000-0003-0349-7393},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81771537]; Jiangsu
   Province Key Research and Development Project {[}BE2019601]},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (81771537) and Jiangsu Province Key Research and Development
   Project (BE2019601).},
Cited-References = {Azziz R, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.57.
   Campbell GR, 2019, MBIO, V10, DOI 10.1128/mBio.02638-19.
   Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004.
   Cipolla-Neto J, 2018, ENDOCR REV, V39, P990, DOI 10.1210/er.2018-00084.
   Dela Cruz CS, 2018, MITOCHONDRION, V41, P37, DOI 10.1016/j.mito.2017.12.001.
   Ding L, 2019, GYNECOL ONCOL, V152, P177, DOI 10.1016/j.ygyno.2018.10.028.
   Eleftheriadis T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00279.
   Escobar-Morreale HF, 2007, TRENDS ENDOCRIN MET, V18, P266, DOI 10.1016/j.tem.2007.07.003.
   Fischer TW, 2008, J PINEAL RES, V44, P397, DOI 10.1111/j.1600-079X.2007.00542.x.
   Gong SS, 2014, NUCLEIC ACIDS RES, V42, P8039, DOI 10.1093/nar/gku466.
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217.
   Kim MK, 2013, REPROD BIOMED ONLINE, V26, P22, DOI 10.1016/j.rbmo.2012.10.007.
   Kinnally KW, 2007, APOPTOSIS, V12, P857, DOI 10.1007/s10495-007-0722-z.
   Knochenhauer ES, 1998, J CLIN ENDOCR METAB, V83, P3078, DOI 10.1210/jc.83.9.3078.
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006.
   Laganà AS, 2018, TRENDS ENDOCRIN MET, V29, P768, DOI 10.1016/j.tem.2018.09.001.
   Lee SH, 2011, METABOLISM, V60, P1677, DOI 10.1016/j.metabol.2011.04.010.
   Li XH, 2013, MOL NEUROBIOL, V48, P490, DOI 10.1007/s12035-013-8437-3.
   Liu CW, 2017, CARDIOVASC THER, V35, P3, DOI 10.1111/1755-5922.12225.
   Rohlenova K, 2016, BIOL CHEM, V397, P607, DOI 10.1515/hsz-2016-0130.
   Santucci R, 2019, INT J BIOL MACROMOL, V136, P1237, DOI 10.1016/j.ijbiomac.2019.06.180.
   Sheng XQ, 2019, MOL REPROD DEV, V86, P516, DOI 10.1002/mrd.23129.
   Simonyan L, 2016, FEBS LETT, V590, P13, DOI 10.1002/1873-3468.12030.
   Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591.
   Skov V, 2007, DIABETES, V56, P2349, DOI 10.2337/db07-0275.
   Slominski A, 2003, BBA-MOL BASIS DIS, V1639, P80, DOI 10.1016/S0925-4439(03)00124-8.
   Spritzer PM, 2015, REPRODUCTION, V149, pR219, DOI 10.1530/REP-14-0435.
   Tamura H, 2009, FERTIL STERIL, V92, P328, DOI 10.1016/j.fertnstert.2008.05.016.
   Tan DX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122124.
   Taylor AE, 1997, J CLIN ENDOCR METAB, V82, P2248, DOI 10.1210/jc.82.7.2248.
   Thackray VG, 2019, TRENDS ENDOCRIN MET, V30, P54, DOI 10.1016/j.tem.2018.11.001.
   Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281.
   Wu JT, 2016, PROG NEURO-PSYCHOPH, V65, DOI 10.1016/j.pnpbp.2015.09.008.
   Yi SL, 2020, AM J PHYSIOL-ENDOC M, V319, pE91, DOI 10.1152/ajpendo.00006.2020.
   Yu F, 2016, J HUAZHONG U SCI-MED, V36, P683, DOI 10.1007/s11596-016-1645-0.
   Zhang M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.467.
   Zhang MZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02825-7.
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013.},
Number-of-Cited-References = {38},
Times-Cited = {48},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {27},
Journal-ISO = {J. Ovarian Res.},
Doc-Delivery-Number = {WV0LM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000716927900002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000722584300001,
Author = {Yang, Keke and Li, Boqian and Chen, Jinghua},
Title = {Knockdown of phosphoinositide-dependent kinase 1 (PDK1) inhibits
   fibrosis and inflammation in lipopolysaccharide-induced acute lung
   injury rat model by attenuating NF-κB/p65 pathway activation},
Journal = {ANNALS OF TRANSLATIONAL MEDICINE},
Year = {2021},
Volume = {9},
Number = {22},
Month = {NOV},
Abstract = {Background: Acute lung injury (ALI) is a common inflammatory disease of
   the lung. This study aimed to investigate the effect of
   3-phosphoinositide-dependent kinase 1 (PDK1) interference on the levels
   of fibrosis and proinflammatory factors in lipopolysaccharide
   (LPS)-induced ALI and discuss the relevant mechanism.
   Methods: An ALI model was established by intravenous injection of LPS
   treatment. A total of 24 SpragueDawley (SD) rats were randomly divided
   into 4 groups: sham group; ALI group; ALI + shRNA-NC group; and ALI +
   PDK1-shRNA group. Lung injury score, minute ventilation, lung volume,
   and airway resistance were used to evaluate lung function injury.
   Reverse transcription-polymerase chain reaction (RTPCR) was used to
   detect PDK1 messenger RNA (mRNA) level. Western blot was performed to
   detect expression levels of PDK1, transforming growth factor-beta
   (TGF-beta), alpha-smooth muscle actin (alpha-SMA), toll-like receptor 4
   (TLR4), p65, and myeloid differentiation primary response gene 88
   (MyD88). The contents of interleukin-6 (IL-6), inducible nitric oxide
   synthase (iNOS), tumor necrosis factor-alpha (TNF-alpha), and monocyte
   chemoattractant protein-1 (MCP-1) were detected by enzyme-linked
   immunosorbent assay (ELISA). The pathological changes and fibrosis of
   lung tissues were estimated by hematoxylin and eosin (H\&E) and Masson
   staining.
   Results: The results revealed that high lung injury score, low minute
   ventilation, low lung volume, and small airway resistance were present
   in the ALI group. Likewise, severe histopathological damage and fibrosis
   were apparent in the ALI group. Otherwise, contents of TNF-alpha, iNOS,
   IL-6, MCP-1, and levels of alpha-SMA, TGF-beta, TLR4, phosphorylated
   (p)-p65, and MyD88 were enhanced in the ALI group. Interestingly,
   pathological changes and fibrosis were improved significantly in the ALI
   + PDK1-shRNA group. Besides, knockdown of PDK1 reduced lung injury score
   and enhanced minute ventilation, lung volume, and airway resistance.
   Moreover, knockdown of PDK1 decreased the contents of TNF-alpha, iNOS,
   IL-6, MCP-1, and levels of TGF-beta, alpha-SMA, TLR4, p-p65, and MyD88.
   Conclusions: Knockdown of PDK1 protects LPS-induced ALI via attenuating
   activation of the nuclear factor-kappa B (NF-kappa B)/p65 pathway.},
Publisher = {AME PUBLISHING COMPANY},
Address = {FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA},
Type = {Article},
Language = {English},
Affiliation = {Chen, JH (Corresponding Author), Heilongjiang Univ Tradit Chinese Med, Jiamusi Coll, 53 Guanghua St, Jiamusi 154007, Peoples R China.
   Yang, Keke; Li, Boqian; Chen, Jinghua, Heilongjiang Univ Tradit Chinese Med, Jiamusi Coll, 53 Guanghua St, Jiamusi 154007, Peoples R China.},
DOI = {10.21037/atm-21-5476},
EarlyAccessDate = {NOV 2021},
ISSN = {2305-5839},
EISSN = {2305-5847},
Keywords = {Acute lung injury (ALI); protein kinase; phosphoinositide-dependent
   kinase 1 (PDK1); nuclear factor-kappa B (NF-kappa B)/p65},
Keywords-Plus = {RESPIRATORY-DISTRESS-SYNDROME; TGF-BETA; IN-VIVO; HYPOXIA; RESVERATROL;
   MORTALITY; PDGF},
Research-Areas = {Oncology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Oncology; Medicine, Research \& Experimental},
Author-Email = {chenjinghua234678@163.com},
Affiliations = {Heilongjiang University of Chinese Medicine},
ResearcherID-Numbers = {陈, 静华/MDT-7363-2025},
Funding-Acknowledgement = {scientific research fund project of Heilongjiang University of
   Traditional Chinese Medicine {[}201839]},
Funding-Text = {Funding: This research was supported by the scientific research fund
   project of Heilongjiang University of Traditional Chinese Medicine
   (201839) .},
Cited-References = {Alghetaa H, 2018, J CELL MOL MED, V22, P2644, DOI 10.1111/jcmm.13542.
   Bellani G, 2016, JAMA-J AM MED ASSOC, V315, P788, DOI 10.1001/jama.2016.0291.
   BONNER JC, 1991, CHEST, V99, pS54, DOI 10.1378/chest.99.3\_Supplement.54S.
   Chen Hong, 2010, Expert Rev Respir Med, V4, P773, DOI 10.1586/ers.10.71.
   Dhami R, 2010, CELL PHYSIOL BIOCHEM, V26, P749, DOI 10.1159/000322342.
   Nguyen DN, 2014, AM J PHYSIOL-GASTR L, V307, pG689, DOI 10.1152/ajpgi.00193.2014.
   Frangogiannis NG, 2020, J EXP MED, V217, DOI 10.1084/jem.20190103.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Goodwin J, 2018, AM J RESP CELL MOL, V58, P216, DOI 10.1165/rcmb.2016-0186OC.
   Grassmé H, 2014, CELL PHYSIOL BIOCHEM, V34, P45, DOI 10.1159/000362983.
   Hagiwara S, 2009, CRIT CARE MED, V37, P626, DOI 10.1097/CCM.0b013e3181958d91.
   Hossen MJ, 2016, J ETHNOPHARMACOL, V190, P251, DOI 10.1016/j.jep.2016.06.019.
   Jeong SG, 2019, J ETHNOPHARMACOL, V231, P1, DOI 10.1016/j.jep.2018.11.013.
   Kang JL, 2001, AM J RESP CRIT CARE, V164, P2206, DOI 10.1164/ajrccm.164.12.2104017.
   Kim CO, 2012, ARCH GERONTOL GERIAT, V54, pE35, DOI 10.1016/j.archger.2011.07.016.
   Kingir ZB, 2019, ULUS TRAVMA ACIL CER, V25, P213, DOI 10.5505/tjtes.2018.82826.
   Kong GQ, 2016, INT IMMUNOPHARMACOL, V36, P51, DOI 10.1016/j.intimp.2016.03.039.
   Luo Q, 2017, MOL CELL BIOCHEM, V428, P129, DOI 10.1007/s11010-016-2923-7.
   Matthay MA, 2012, J CLIN INVEST, V122, P2731, DOI 10.1172/JCI60331.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Mendez JL, 2005, CURR OPIN CRIT CARE, V11, P29, DOI 10.1097/00075198-200502000-00005.
   Murakami K, 2002, SHOCK, V18, P236, DOI 10.1097/00024382-200209000-00006.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Rodriguez A, 1996, RES VET SCI, V60, P82, DOI 10.1016/S0034-5288(96)90137-X.
   Saito A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082460.
   Sato K, 2002, FASEB J, V16, P1713, DOI 10.1096/fj.02-0331com.
   Sheu CC, 2010, CHEST, V138, P559, DOI 10.1378/chest.09-2933.
   Siegmann N, 2014, CELL PHYSIOL BIOCHEM, V34, P56, DOI 10.1159/000362984.
   Singh N, 2007, LANCET, V370, P383, DOI 10.1016/S0140-6736(07)61183-0.
   Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525.
   Tao J, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/7379146.
   Todd NW, 2012, FIBROGENESIS TISSUE, V5, DOI 10.1186/1755-1536-5-11.
   Ueno M, 2011, AM J PHYSIOL-LUNG C, V300, pL740, DOI 10.1152/ajplung.00146.2010.
   Wang J, 2014, INFLAMMATION, V37, P2085, DOI 10.1007/s10753-014-9942-x.
   Wärntges S, 2002, CELL PHYSIOL BIOCHEM, V12, P135, DOI 10.1159/000063790.
   Wheeler AP, 2007, LANCET, V369, P1553, DOI 10.1016/S0140-6736(07)60604-7.
   Wilson MS, 2009, MUCOSAL IMMUNOL, V2, P103, DOI 10.1038/mi.2008.85.
   Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551.
   Xiao Q, 2017, CELL PHYSIOL BIOCHEM, V43, P2353, DOI 10.1159/000484387.
   Xu Wen-Min, 2013, Sichuan Da Xue Xue Bao Yi Xue Ban, V44, P554.
   Xu ZP, 2017, J BIOMED RES, V31, P56, DOI 10.7555/JBR.31.20160108.
   Yoshida T, 2014, RESP PHYSIOL NEUROBI, V191, P75, DOI 10.1016/j.resp.2013.11.008.
   Zhang Zhen-Bo, 2020, Sichuan Da Xue Xue Bao Yi Xue Ban, V51, P371, DOI 10.12182/20200560204.
   Zhang Z, 2014, MOL MED REP, V10, P101, DOI 10.3892/mmr.2014.2226.
   Zhu RT, 2018, BIOMED PHARMACOTHER, V97, P1689, DOI 10.1016/j.biopha.2017.12.025.},
Number-of-Cited-References = {45},
Times-Cited = {12},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {10},
Journal-ISO = {ANN. TRANSL. MED.},
Doc-Delivery-Number = {XM9DB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000722584300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000722651700005,
Author = {Umar, Sadiq and Palasiewicz, Karol and V. Volin, Michael and Zanotti,
   Brian and Al-Awqati, Mina and Sweiss, Nadera and Shahrara, Shiva},
Title = {IRAK4 inhibitor mitigates joint inflammation by rebalancing metabolism
   malfunction in RA macrophages and fibroblasts},
Journal = {LIFE SCIENCES},
Year = {2021},
Volume = {287},
Month = {DEC 15},
Abstract = {Recent studies show a connection between glycolysis and inflammatory
   response in rheumatoid arthritis (RA) macrophages (M phi s) and
   fibroblasts (FLS). Yet, it is unclear which pathways could be targeted
   to rebalance RA M phi s and FLS metabolic reprogramming. To identify
   novel targets that could normalize RA metabolic reprogramming,
   TLR7-mediated immunometabolism was characterized in RA M phi s, FLS and
   experimental arthritis. We uncovered that GLUT1, HIF1 alpha, cMYC, LDHA
   and lactate were responsible for the TLR7-potentiated metabolic rewiring
   in RA M phi s and FLS, which was negated by IRAK4i. While in RA FLS, HK2
   was uniquely expanded by TLR7 and negated by IRAK4i. Conversely,
   TLR7-driven hypermetabolism, non-oxidative PPP (CARKL) and oxidative
   phosphorylation (PPAR gamma) were narrowly dysregulated in
   TLR7-activated RA M phi s and FLS and was reversed by IRAK4i.
   Consistently, IRAK4i therapy disrupted arthritis mediated by
   miR-Let7b/TLR7 along with impairing a broad-range of glycolytic
   intermediates, GLUT1, HIF1 alpha, cMYC, HK2, PFKFB3, PKM2, PDK1 and
   RAPTOR. Notably, inhibition of the mutually upregulated glycolytic
   metabolites, HIF1 alpha and cMYC, was capable of mitigating TLR7-induced
   inflammatory imprint in RA M phi s and FLS. In keeping with IRAK4i,
   treatment with HIF1i and cMYCi intercepted TLR7-enhanced IRF5 and IRF7
   in RA M phi s, distinct from RA FLS. Interestingly, in RA M phi s and
   FLS, IRAK4i counteracted TLR7-induced CARKL reduction in line with
   HIF1i. Whereas, cMYCi in concordance with IRAK4i, overturned oxidative
   phosphorylation via PPAR gamma in TLR7-activated RA M phi s and FLS. The
   blockade of IRAK4 and its interconnected intermediates can rebalance the
   metabolic malfunction by obstructing glycolytic and inflammatory
   phenotypes in RA M phi s and FLS.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Shahrara, S (Corresponding Author), Univ Illinois, Dept Med, Div Rheumatol, 840 S Wood St,CSB Suite 1114, Chicago, IL 60612 USA.
   Umar, Sadiq; Palasiewicz, Karol; Al-Awqati, Mina; Shahrara, Shiva, Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.
   Umar, Sadiq; Palasiewicz, Karol; Al-Awqati, Mina; Sweiss, Nadera; Shahrara, Shiva, Univ Illinois, Dept Med, Div Rheumatol, 840 S Wood St,CSB Suite 1114, Chicago, IL 60612 USA.
   V. Volin, Michael; Zanotti, Brian, Midwestern Univ, Dept Microbiol \& Immunol, Downers Grove, IL 60515 USA.},
DOI = {10.1016/j.lfs.2021.120114},
EarlyAccessDate = {NOV 2021},
Article-Number = {120114},
ISSN = {0024-3205},
EISSN = {1879-0631},
Keywords = {RA macrophages; RA FLS; TLR7-induced arthritis; IRAK4; cMYC; HIF1 alpha},
Keywords-Plus = {RHEUMATOID-ARTHRITIS; TNF-ALPHA; RECEPTOR; METHOTREXATE; ACTIVATION;
   INDUCTION; DISEASE; GLUCOSE},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {shahrara@uic.edu},
Affiliations = {US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Jesse Brown VA Medical Center; University of Illinois System; University
   of Illinois Chicago; University of Illinois Chicago Hospital; Midwestern
   University; Midwestern University - Downers Grove},
ResearcherID-Numbers = {Volin, Michael/U-4115-2019
   Umar, Sadiq/H-3769-2019},
ORCID-Numbers = {Shahrara, Shiva/0000-0002-6698-8491
   Umar, Sadiq/0000-0002-4733-5751},
Funding-Acknowledgement = {Department of Veterans Affairs MERIT Award {[}BX002286]; National
   Institutes of Health {[}NIH AI147697]; National Psoriasis Foundation
   (NPF); Pfizer Investigator-Initiated Research (IIR) Program; Chicago
   Biomedical Consortium (CBC) Accelerator Award},
Funding-Text = {This work was supported in part by awards from the Department of
   Veterans Affairs MERIT Award BX002286, the National Institutes of Health
   NIH AI147697, the National Psoriasis Foundation (NPF) , Pfizer
   Investigator-Initiated Research (IIR) Program and Chicago Biomedical
   Consortium (CBC) Accelerator Award.},
Cited-References = {Abboud G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01973.
   Ahn JK, 2016, JOINT BONE SPINE, V83, P707, DOI 10.1016/j.jbspin.2015.11.009.
   ARNETT FC, 1988, ARTHRITIS RHEUM-US, V31, P315, DOI 10.1002/art.1780310302.
   Biniecka M, 2016, ANN RHEUM DIS, V75, P2192, DOI 10.1136/annrheumdis-2015-208476.
   Bustamante MF, 2018, ANN RHEUM DIS, V77, P1636, DOI 10.1136/annrheumdis-2018-213103.
   Chamberlain ND, 2013, ANN RHEUM DIS, V72, P418, DOI 10.1136/annrheumdis-2011-201203.
   Chamberlain ND, 2012, J IMMUNOL, V189, P475, DOI 10.4049/jimmunol.1102977.
   Chen K, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108875.
   Chen Y, 2020, MOL THER-METH CLIN D, V17, P1202, DOI 10.1016/j.omtm.2020.05.008.
   Cushing L, 2014, J BIOL CHEM, V289, P10865, DOI 10.1074/jbc.M113.544809.
   Diskin C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00270.
   Elshabrawy H, 2018, ANGIOGENESIS, V21, P215, DOI 10.1007/s10456-017-9589-y.
   Falconer J, 2018, ARTHRITIS RHEUMATOL, V70, P984, DOI 10.1002/art.40504.
   Garcia-Carbonell R, 2016, ARTHRITIS RHEUMATOL, V68, P1614, DOI 10.1002/art.39608.
   Geeraerts X, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00289.
   Harty LC, 2012, ANN RHEUM DIS, V71, P582, DOI 10.1136/annrheumdis-2011-200245.
   Huang CC, 2005, APOPTOSIS, V10, P895, DOI 10.1007/s10495-005-2947-z.
   Ito H, 2015, IMMUNOLOGY, V144, P621, DOI 10.1111/imm.12413.
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68.
   Kim SJ, 2020, CELL MOL IMMUNOL, V17, P728, DOI 10.1038/s41423-019-0235-z.
   Kim SJ, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-209206.
   Kim SJ, 2016, ARTHRITIS RHEUMATOL, V68, P1099, DOI 10.1002/art.39544.
   Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540.
   Lee KL, 2017, J MED CHEM, V60, P5521, DOI 10.1021/acs.jmedchem.7b00231.
   Li Q, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02191.
   McGarry T, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1237.
   McGarry T, 2018, ARTHRITIS RHEUMATOL, V70, P1959, DOI 10.1002/art.40569.
   McGarry T, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43165.
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140-6736(17)31472-1.
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008.
   Palasiewicz K, 2021, EUR J IMMUNOL, V51, P2330, DOI 10.1002/eji.202049159.
   Pålsson-McDermott EM, 2020, CELL RES, V30, P300, DOI 10.1038/s41422-020-0291-z.
   Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI {[}10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017].
   Phillips DC, 2003, BRIT J PHARMACOL, V138, P501, DOI 10.1038/sj.bjp.0705054.
   Pickens SR, 2011, ARTHRITIS RHEUM-US, V63, P914, DOI 10.1002/art.30232.
   Pickens SR, 2011, ARTHRITIS RHEUM-US, V63, P2884, DOI 10.1002/art.30493.
   Qualls JE, 2012, CELL HOST MICROBE, V12, P313, DOI 10.1016/j.chom.2012.07.012.
   Ryan DG, 2017, FEBS LETT, V591, P2992, DOI 10.1002/1873-3468.12744.
   Saas Philippe, 2017, F1000Res, V6, P456, DOI 10.12688/f1000research.11332.2.
   Umar S, 2021, CELL MOL LIFE SCI, V78, P7693, DOI 10.1007/s00018-021-03978-5.
   Umar S, 2021, CELL MOL IMMUNOL, V18, P2199, DOI 10.1038/s41423-020-0433-8.
   Van Raemdonck K., 2021, ARTHRITIS RHEUMATOL, DOI {[}10.1002/art.41792, DOI 10.1002/ART.41792].
   Van Raemdonck K, 2021, EUR J IMMUNOL, V51, P714, DOI 10.1002/eji.202048690.
   Volchenkov R, 2017, SCAND J RHEUMATOL, V46, P160, DOI 10.3109/03009742.2016.1164242.
   Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141.
   Winkler A, 2021, ARTHRITIS RHEUMATOL, V73, P2206, DOI 10.1002/art.41953.
   Wu DJ, 2016, IMMUNITY, V44, P1325, DOI 10.1016/j.immuni.2016.06.006.
   Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006.
   Zaro BW, 2019, J IMMUNOL, V202, P2737, DOI 10.4049/jimmunol.1801627.
   Zeisbrich M, 2018, ANN RHEUM DIS, V77, P1053, DOI 10.1136/annrheumdis-2017-212647.},
Number-of-Cited-References = {50},
Times-Cited = {28},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Life Sci.},
Doc-Delivery-Number = {XD3ZO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000722651700005},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000718038400002,
Author = {Wu, JingJing and Tang, XiaoJuan and Shi, Yao and Ma, ChangJu and Zhang,
   Hongyu and Zhang, Junhong and Lu, Yue and Wei, Jianan and Li, Li and
   Han, Ling},
Title = {Crosstalk of LncRNA HOTAIR and SP1-mediated repression of PDK1
   contributes to β-Elemene-inhibited proliferation of hepatocellular
   carcinoma cells},
Journal = {JOURNAL OF ETHNOPHARMACOLOGY},
Year = {2022},
Volume = {283},
Month = {JAN 30},
Abstract = {Ethnopharmacological relevance: Hepatocellular carcinoma (HCC) is a
   liver malignancy which lacks effective treatment and has a poor
   prognosis. ll-Elemene refers to a natural Curcuma wenyujin-derived
   single molecular entity, which exhibits various biological activities,
   and is especially well-known for it's antitumor properties. Aim of the
   research: LncRNA HOTAIR, SP1, and PDK1 have displayed oncogenic roles in
   many tumors, participating in the initiation and progression of cancers
   by mediating multiple signaling pathways. However, there are only a few
   reports about their roles and mutual relationship in the growth of HCC
   cells. Therefore, this study aimed to investigate the expression of
   LncRNA HOTAIR, SP1, and PDK1 and their interaction with ll-Elemene in
   HCC cells. Materials and methods: MTT, a Colony formation assay, and
   flow cytometry were employed to evaluate the growth of HCC and LO2 cells
   under ll-Elemene. LncRNA HOTAIR, SP1 and PDK1 plasmids were transfected
   into HCC cells by a transient transfection assay, and the expression and
   interaction of LncRNA HOTAIR, SP1 and PDK1 were assessed via qRT-PCR and
   western blotting. Results: ll-Elemene suppressed HCC cell growth through
   the downregulation of LncRNA HOTAIR, SP1 and PDK1. The results
   demonstrated a reciprocal interaction among LncRNA HOTAIR, SP1 and PDK1.
   Exogenous over expression LncRNA HOTAIR or SP1 eliminated the
   suppressive effects of ll-Elemene on them, and both of which regulated
   PDK1 expression in HCC cells. Additionally, exogenously overexpressed
   SP1 or LncRNA HOTAIR prevented ll-Elemene inhibition of the
   protein-level expression of PDK1, whereas overexpressing PDK1 had no
   effect on SP1, though it still weakened the inhibition of cell growth
   and LncRNA HOTAIR expression by ll-Elemene. Conclusion: ll-Elemene
   suppresses HCC cell proliferation via through the regulation of LncRNA
   HOTAIR, SP1, PDK1 and their interaction.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Wu, JJ; Han, L (Corresponding Author), Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou 510120, Guangdong, Peoples R China.
   Wu, JingJing; Tang, XiaoJuan; Ma, ChangJu; Zhang, Hongyu; Zhang, Junhong; Lu, Yue; Wei, Jianan; Li, Li; Han, Ling, Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou 510120, Guangdong, Peoples R China.
   Shi, Yao, Guangzhou Univ Chinese Med, Clin Coll 2, Guangdong Prov Hosp Chinese Med, Dept Cerebrovasc Dis, Guangzhou 510120, Peoples R China.
   Han, Ling, Guangdong Prov Key Lab Clin Res Tradit Chinese Me, Guangzhou 510120, Guangdong, Peoples R China.
   Han, Ling, Guangzhou Univ Chinese Med, Affiliated Hosp 2, State Key Lab Dampness Syndrome Chinese Med, Guangzhou 510120, Guangdong, Peoples R China.},
DOI = {10.1016/j.jep.2021.114456},
EarlyAccessDate = {NOV 2021},
Article-Number = {114456},
ISSN = {0378-8741},
EISSN = {1872-7573},
Keywords = {Hepatocellular carcinoma cells; \&beta; -Elemene; LncRNA HOTAIR; SP1;
   PDK1},
Keywords-Plus = {CANCER CELLS; ACTIVATION; EXPRESSION},
Research-Areas = {Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine},
Web-of-Science-Categories  = {Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy},
Author-Email = {wujingjing6028@gzucm.edu.cn
   linghan99@gzucm.edu.cn},
Affiliations = {Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou
   University of Chinese Medicine},
ResearcherID-Numbers = {Wu, Jingjing/CAI-9454-2022
   Wei, Jianan/IQT-6324-2023},
ORCID-Numbers = {Ma, Changju/0000-0001-9055-7272
   },
Funding-Acknowledgement = {National Nature Scientific Foundation of China {[}81902752]; Guangdong
   Province Administration of Traditional Chinese Medicine {[}20201165];
   Guangdong Province Science and Technology Planning Project
   {[}2020B1212030006, 2017B030314166]; State key laboratory of Dampness
   Syndrome of Chinese Medicine Special Fund {[}SZ2020ZZ15]},
Funding-Text = {The current work was partly funded by the National Nature Scientific
   Foundation of China (81902752). The Research Fund was provided by
   Guangdong Province Administration of Traditional Chinese Medicine
   (20201165). The current work was also funded by the Guangdong Province
   Science and Technology Planning Project (2020B1212030006,
   2017B030314166), the State key laboratory of Dampness Syndrome of
   Chinese Medicine Special Fund (SZ2020ZZ15).},
Cited-References = {Al-Salama ZT, 2019, DRUGS, V79, P665, DOI 10.1007/s40265-019-01116-x.
   Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746.
   Chang SW, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109133.
   Chen P, 2020, THERANOSTICS, V10, P5107, DOI 10.7150/thno.44705.
   Cheng D, 2018, EBIOMEDICINE, V36, P159, DOI 10.1016/j.ebiom.2018.08.055.
   Cheng HB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01413.
   Deng MM, 2019, PHYTOTHER RES, V33, P2448, DOI 10.1002/ptr.6436.
   Ding LX, 2018, MOL MED REP, V17, P1022, DOI 10.3892/mmr.2017.7965.
   Escudier B, 2019, EXPERT REV ANTICANC, V19, P177, DOI 10.1080/14737140.2019.1559058.
   Feng HB, 2017, STEM CELL TRANSL MED, V6, P830, DOI 10.5966/sctm.2016-0009.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Hao M, 2019, MOLECULES, V24, DOI 10.3390/molecules24010082.
   Hu T., 2020, BIOSCIENCE REP, V40.
   Hu ZY, 2015, ANTI-CANCER DRUG, V26, P531, DOI 10.1097/CAD.0000000000000216.
   Jiang XT, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006963.
   Li CY, 2018, ONCOL LETT, V15, P5940, DOI 10.3892/ol.2018.8001.
   Li HS, 2020, STEROIDS, V164, DOI 10.1016/j.steroids.2020.108729.
   Li XQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep21010.
   Li YH, 2021, J ETHNOPHARMACOL, V269, DOI 10.1016/j.jep.2020.113689.
   Liao YD, 2020, THERANOSTICS, V10, P5209, DOI 10.7150/thno.43640.
   Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630.
   Pan WD, 2019, MOL ONCOL, V13, P2246, DOI 10.1002/1878-0261.12553.
   Park JW, 2015, LIVER INT, V35, P2155, DOI 10.1111/liv.12818.
   Pu ZJ, 2021, BIOENGINEERED, V12, P2398, DOI 10.1080/21655979.2021.1932211.
   Qu XH, 2019, CANCER LETT, V454, P90, DOI 10.1016/j.canlet.2019.04.016.
   Ren F, 2020, CLIN SCI, V134, P3007, DOI 10.1042/CS20200970.
   Roayaie S, 2013, HEPATOLOGY, V57, P1426, DOI 10.1002/hep.25832.
   Wang YL, 2019, BREAST, V46, P64, DOI 10.1016/j.breast.2019.05.003.
   Wu BQ, 2016, ONCOL LETT, V11, P2545, DOI 10.3892/ol.2016.4243.
   Wu JJ, 2019, J ETHNOPHARMACOL, V237, P128, DOI 10.1016/j.jep.2019.03.027.
   Wu JJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00626-6.
   Xiao Q, 2018, CELL PHYSIOL BIOCHEM, V49, P1615, DOI 10.1159/000493497.
   Xiao Q, 2017, CELL PHYSIOL BIOCHEM, V43, P2353, DOI 10.1159/000484387.
   Xiao ZG, 2018, CELL PHYSIOL BIOCHEM, V46, P1275, DOI 10.1159/000489110.
   Xie H, 2020, J ETHNOPHARMACOL, V246, DOI 10.1016/j.jep.2019.01.045.
   Yang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0990-6.
   Yang XD, 2016, ONCOL REP, V35, P479, DOI 10.3892/or.2015.4397.
   Yao Y, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017813.
   Yu ZY, 2014, ACTA PHARM SIN B, V4, P424, DOI 10.1016/j.apsb.2014.10.001.
   Zang WH, 2019, ANTICANCER RES, V39, P2739, DOI 10.21873/anticanres.13400.
   Zhai BT, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108812.
   Zhai BT, 2018, INT J NANOMED, V13, P6279, DOI 10.2147/IJN.S174527.
   Zhang C, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188382.
   Zhang JL, 2013, CHINESE J CANCER RES, V25, P770, DOI 10.3978/j.issn.1000-9604.2013.12.12.
   Zhang XR, 2018, LIVER INT, V38, P2006, DOI 10.1111/liv.13757.
   Zhao SY, 2015, J CELL MOL MED, V19, P630, DOI 10.1111/jcmm.12476.},
Number-of-Cited-References = {46},
Times-Cited = {18},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {36},
Journal-ISO = {J. Ethnopharmacol.},
Doc-Delivery-Number = {WW6QK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000718038400002},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000715042800002,
Author = {Jin, Young-June and Chennupati, Ramesh and Li, Rui and Liang, Guozheng
   and Wang, ShengPeng and Iring, Andras and Graumann, Johannes and
   Wettschureck, Nina and Offermanns, Stefan},
Title = {Protein kinase N2 mediates flow-induced endothelial NOS activation and
   vascular tone regulation},
Journal = {JOURNAL OF CLINICAL INVESTIGATION},
Year = {2021},
Volume = {131},
Number = {21},
Month = {NOV 1},
Abstract = {Formation of NO by endothelial NOS (eNOS) is a central process in the
   homeostatic regulation of vascular functions including blood pressure
   regulation, and fluid shear stress exerted by the flowing blood is a
   main stimulus of eNOS activity. Previous work has identified several
   mechanosensing and -transducing processes in endothelial cells, which
   mediate this process and induce the stimulation of eNOS activity through
   phosphorylation of the enzyme via various kinases including AKT. How the
   initial mechanosensing and signaling processes are linked to eNOS
   phosphorylation is unclear. In human endothelial cells, we demonstrated
   that protein kinase N2 (PKN2), which is activated by flow through the
   mechanosensitive cation channel Piezo1 and G(q)/G(11)-mediated
   signaling, as well as by Ca2+ and phosphoinositide-dependent protein
   kinase 1 (PDK1), plays a pivotal role in this process. Active PKN2
   promoted the phosphorylation of human eNOS at serine 1177 and at a newly
   identified site, serine 1179. These phosphorylation events additively
   led to increased eNOS activity. PKN2-mediated eNOS phosphorylation at
   serine 1177 involved the phosphorylation of AKT synergistically with
   mTORC2-mediated AKT phosphorylation, whereas active PKN2 directly
   phosphorylated human eNOS at serine 1179. Mice with induced
   endothelium-specific deficiency of PKN2 showed strongly reduced
   flow-induced vasodilation and developed arterial hypertension
   accompanied by reduced eNOS activation. These results uncover a central
   mechanism that couples upstream mechanosignaling processes in
   endothelial cells to the regulation of eNOS-mediated NO formation,
   vascular tone, and blood pressure.},
Publisher = {AMER SOC CLINICAL INVESTIGATION INC},
Address = {2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA},
Type = {Article},
Language = {English},
Affiliation = {Jin, YJ; Offermanns, S (Corresponding Author), Max Planck Inst Heart \& Lung Res, Dept Pharrnacol, Ludwigstr 43, D-61231 Bad Nauheim, Germany.
   Jin, Young-June; Chennupati, Ramesh; Li, Rui; Liang, Guozheng; Wang, ShengPeng; Iring, Andras; Wettschureck, Nina; Offermanns, Stefan, Max Planck Inst Heart \& Lung Res, Dept Pharrnacol, Ludwigstr 43, D-61231 Bad Nauheim, Germany.
   Wang, ShengPeng, Xi An Jiao Tong Univ, Cardiovasc Res Ctr, Sch Basic Med Sci, Hlth Sci Ctr, Xian, Peoples R China.
   Iring, Andras, Hungarian Acad Sci, Lab Mol Med, Inst Expt Med, Budapest, Hungary.
   Graumann, Johannes, Max Planck Inst Heart \& Lung Res, Sci Serv Grp Bimol Mass Spectrometry, Bad Nauheim, Germany.
   Wettschureck, Nina; Offermanns, Stefan, Goethe Univ Frankfurt, Med Fac, Centrefor Mol Med, Frankfurt, Germany.
   Wettschureck, Nina; Offermanns, Stefan, Cardiopulm Inst CPI, Frankfurt, Germany.
   Wettschureck, Nina; Offermanns, Stefan, German Ctr Cardiovasc Res DZHK, Rhine Main Site, Frankfurt, Germany.
   Wettschureck, Nina; Offermanns, Stefan, German Ctr Cardiovasc Res DZHK, Rhine Main Site, Bad Nauheim, Germany.},
DOI = {10.1172/JCI145734},
Article-Number = {e145734},
ISSN = {0021-9738},
EISSN = {1558-8238},
Keywords-Plus = {NITRIC-OXIDE SYNTHASE; STRESS STIMULATES PHOSPHORYLATION; AUTOINHIBITORY
   CONTROL ELEMENT; TYROSINE PHOSPHORYLATION; ENOS PHOSPHORYLATION;
   BLOOD-PRESSURE; IDENTIFICATION; AKT; RHO; AKT/PKB},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {young-june.jin@mpi-bn.mpg.de
   stefan.offermanns@mpi-bn.mpg.de},
Affiliations = {Max Planck Society; Xi'an Jiaotong University; Hungarian Academy of
   Sciences; HUN-REN; HUN-REN Institute of Experimental Medicine; Max
   Planck Society; Goethe University Frankfurt; German Centre for
   Cardiovascular Research; German Centre for Cardiovascular Research},
ResearcherID-Numbers = {Offermanns, Stefan/L-3313-2017
   Iring, András/F-7092-2010
   Wettschureck, Nina/L-3651-2017
   },
ORCID-Numbers = {Chennupati, Ramesh/0000-0002-3994-5285
   Wang, ShengPeng/0000-0002-9030-1821
   Iring, András/0000-0002-3087-4337
   Wettschureck, Nina/0000-0001-6858-1460
   Graumann, Johannes/0000-0002-3015-5850
   Jin, Young-June/0000-0002-4649-8890},
Funding-Acknowledgement = {Collaborative Research Center 834 of the German Research Foundation;
   Hungarian Academy of Sciences Premium Postdoctoral Research Program
   {[}PPD2019-20/2019-439]; Alexander von Humboldt Foundation fellowship},
Funding-Text = {We thank Svea Hummer for secretarial help and Ulrike Kruger, Claudia
   Ullmann, Martina Finkbeiner, and Sylvia Jeratsch for expert technical
   support. This work was supported by the Collaborative Research Center
   834 of the German Research Foundation, the Hungarian Academy of Sciences
   Premium Postdoctoral Research Program (PPD2019-20/2019-439 to AI) , and
   an Alexander von Humboldt Foundation fellowship (to YJJ) .},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648.
   Bailey RJ, 2012, BRIT J PHARMACOL, V166, P151, DOI 10.1111/j.1476-5381.2011.01717.x.
   Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200.
   Balligand JL, 2009, PHYSIOL REV, V89, P481, DOI 10.1152/physrev.00042.2007.
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049.
   Bauer PM, 2003, J BIOL CHEM, V278, P14841, DOI 10.1074/jbc.M211926200.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Boo YC, 2003, FREE RADICAL BIO MED, V35, P729, DOI 10.1016/S0891-5849(03)00397-6.
   Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002.
   Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200.
   Bourguignon LYW, 2004, J BIOL CHEM, V279, P29654, DOI 10.1074/jbc.M403608200.
   Calautti E, 2002, J CELL BIOL, V156, P137, DOI 10.1083/jcb.200105140.
   Cox J, 2011, J PROTEOME RES, V10, P1794, DOI 10.1021/pr101065j.
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511.
   Danno S, 2017, GENES CELLS, V22, P220, DOI 10.1111/gtc.12470.
   Dettori R, 2009, J BIOL CHEM, V284, P30318, DOI 10.1074/jbc.M109.051151.
   Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224.
   Eroglu E, 2019, P NATL ACAD SCI USA, V116, P20210, DOI 10.1073/pnas.1910942116.
   Farley FW, 2000, GENESIS, V28, P106, DOI 10.1002/1526-968X(200011/12)28:3/4<106::AID-GENE30>3.0.CO;2-T.
   Fayard E, 2010, CURR TOP MICROBIOL, V346, P31, DOI 10.1007/82\_2010\_58.
   Fleming I, 2010, PFLUG ARCH EUR J PHY, V459, P793, DOI 10.1007/s00424-009-0767-7.
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218.
   Garcia V, 2019, BRIT J PHARMACOL, V176, P189, DOI 10.1111/bph.14522.
   Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898.
   Gocher AM, 2017, J BIOL CHEM, V292, P14188, DOI 10.1074/jbc.M117.778464.
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004.
   Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200.
   Hutchinson CL, 2013, BIOCHEMISTRY-US, V52, P7999, DOI 10.1021/bi401216w.
   Iring A, 2019, J CLIN INVEST, V129, P2775, DOI 10.1172/JCI123825.
   ISHII K, 1991, AM J PHYSIOL, V261, pH598, DOI 10.1152/ajpheart.1991.261.2.H598.
   Kashiwagi S, 2013, BIOCHEM BIOPH RES CO, V431, P284, DOI 10.1016/j.bbrc.2012.12.110.
   Kim HT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06833-7.
   Kiweler M, 2019, MOL CELL PROTEOMICS, V18, P1700, DOI 10.1074/mcp.TIR119.001505.
   Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200.
   Koo A, 2013, BIOPHYS J, V104, P2295, DOI 10.1016/j.bpj.2013.03.052.
   Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150.
   Lachmann S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021732.
   Lane P, 2002, J BIOL CHEM, V277, P19087, DOI 10.1074/jbc.M200258200.
   Lee MY, 2018, ARTERIOSCL THROM VAS, V38, P870, DOI 10.1161/ATVBAHA.118.310748.
   Lee SJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.296.
   Li Q, 2013, STROKE, V44, P3183, DOI 10.1161/STROKEAHA.113.002073.
   Liu CL, 2006, BRIT J PHARMACOL, V147, P506, DOI 10.1038/sj.bjp.0706639.
   Looft-Wilson R, 2007, J CLIN INVEST, V117, P1961, DOI 10.1172/JCI29877.
   Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Marrocco V, 2019, J MOL CELL CARDIOL, V128, P212, DOI 10.1016/j.yjmcc.2019.01.029.
   McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123.
   Michell BJ, 2002, J BIOL CHEM, V277, P42344, DOI 10.1074/jbc.M205144200.
   Mukai Y, 2006, J CLIN INVEST, V116, P334, DOI 10.1172/JCI26223.
   Patel H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60604-3.
   Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200.
   Qian J, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00347.
   Quétier I, 2016, CELL REP, V14, P440, DOI 10.1016/j.celrep.2015.12.049.
   Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Schleicher M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000343.
   Siragusa M, 2016, PFLUG ARCH EUR J PHY, V468, P1125, DOI 10.1007/s00424-016-1839-0.
   Sörensen I, 2009, BLOOD, V113, P5680, DOI 10.1182/blood-2008-08-174508.
   Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200.
   Taniyama Y, 2003, MOL CELL BIOL, V23, P8019, DOI 10.1128/MCB.23.22.8019-8029.2003.
   Thumkeo D, 2013, EUR J CELL BIOL, V92, P303, DOI 10.1016/j.ejcb.2013.09.002.
   Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952.
   Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639.
   Vincent S, 1997, MOL CELL BIOL, V17, P2247, DOI 10.1128/MCB.17.4.2247.
   Wang SP, 2016, J CLIN INVEST, V126, P4527, DOI 10.1172/JCI87343.
   Wang SP, 2015, J CLIN INVEST, V125, P3077, DOI 10.1172/JCI81067.
   Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645.
   Xu SW, 2016, CELL SIGNAL, V28, P117, DOI 10.1016/j.cellsig.2015.12.007.
   Zhang YJ, 2006, ARTERIOSCL THROM VAS, V26, P1281, DOI 10.1161/01.ATV.0000221230.08596.98.
   Zhao YZ, 2015, J PHARMACOL SCI, V129, P83, DOI 10.1016/j.jphs.2015.09.002.},
Number-of-Cited-References = {72},
Times-Cited = {53},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {17},
Journal-ISO = {J. Clin. Invest.},
Doc-Delivery-Number = {WS2UR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000715042800002},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000720499400001,
Author = {Kim, Eun-Ji and Ham, Young Rok and Shin, Jin Ah and Jeong, Jin Young and
   Na, Ki Ryang and Lee, Kang Wook and Kim, Jwa-Jin and Choi, Dae Eun},
Title = {Omega-3 Polyunsaturated Fatty Acid Attenuates Uremia-Induced Brain
   Damage in Mice},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2021},
Volume = {22},
Number = {21},
Month = {NOV},
Abstract = {Although the cause of neurological disease in patients with chronic
   kidney disease (CKD) has not been completely identified yet, recent
   papers have identified accumulated uremic toxin as its main cause.
   Additionally, omega-3 polyunsaturated fatty acid (omega-3 PUFA) plays an
   important role in maintaining normal nerve function, but its protective
   effects against uremic toxin is unclear. The objective of this study was
   to identify brain damage caused by uremic toxicity and determine the
   protective effects of omega-3 PUFA against uremic toxin. We divided mice
   into the following groups: wild-type (wt) sham (n = 8), omega-3 PUFA
   sham (n = 8), Fat-1 sham (n = 8), ischemia-reperfusion (IR) (n = 20),
   and omega-3 PUFA+IR (n = 20) Fat-1+IR (n = 20). Brain tissue, kidney
   tissue, and blood were collected three days after the operation of mice
   (sham and IR operation). This study showed that Ki67 and neuronal nuclei
   (NeuN) decreased in the brain of uremic mice as compared to wt mice
   brain, but increased in the omega-3 PUFA-treated uremic mice and the
   brain of uremic Fat-1 mice as compared to the brain of uremic mice. The
   pro-apoptotic protein expressions were increased, whereas anti-apoptotic
   protein expression decreased in the brain of uremic mice as compared to
   wt mice brain. However, apoptotic protein expression decreased in the
   omega-3 PUFA-treated uremic mice and the brain of uremic Fat-1 mice as
   compared to the brain of uremic mice. Furthermore, the brain of omega-3
   PUFA-treated uremic mice and uremic Fat-1 mice showed increased
   expression of p-PI3K, p-PDK1, and p-Akt as compared to the brain of
   uremic mice. We confirm that uremic toxin damages the brain and causes
   cell death. In these injuries, omega-3 PUFA plays an important role in
   neuroprotection through PI(3)K-Akt signaling.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Kim, JJ; Choi, DE (Corresponding Author), Chungnam Natl Univ, Med Sch, Dept Med Sci, Daejeon 35015, South Korea.
   Choi, DE (Corresponding Author), Chungnam Natl Univ, Med Sch, Dept Nephrol, Daejeon 35015, South Korea.
   Kim, Eun-Ji; Shin, Jin Ah; Kim, Jwa-Jin; Choi, Dae Eun, Chungnam Natl Univ, Med Sch, Dept Med Sci, Daejeon 35015, South Korea.
   Kim, Eun-Ji; Ham, Young Rok; Jeong, Jin Young; Na, Ki Ryang; Lee, Kang Wook; Choi, Dae Eun, Chungnam Natl Univ, Med Sch, Dept Nephrol, Daejeon 35015, South Korea.},
DOI = {10.3390/ijms222111802},
Article-Number = {11802},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {omega 3-PUFA; ischemia-reperfusion; uremic toxin; indoxyl sulfate; brain
   injury; apoptosis; PI(3)K-Akt signaling},
Keywords-Plus = {DOCOSAHEXAENOIC ACID; PROTEIN-KINASE; INFLAMMATION; SURVIVAL},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Affiliations = {Chungnam National University; Chungnam National University},
ResearcherID-Numbers = {Choi, Dae Eun/B-5996-2014
   },
ORCID-Numbers = {Choi, Dae Eun/0000-0003-2870-3958
   HAM, YOUNGROK/0000-0001-9140-6900},
Funding-Acknowledgement = {Basic Science Research Program through the National Research Foundation
   of Korea {[}NRF-2021R1G1A1013523]; Chungnam National University Hospital
   Research Fund},
Funding-Text = {FundingThis research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea
   (NRF-2021R1G1A1013523), by Chungnam National University Hospital
   Research Fund, 2019 (to Y.R.H.).},
Cited-References = {Adesso S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00370.
   Akbar M, 2005, P NATL ACAD SCI USA, V102, P10858, DOI 10.1073/pnas.0502903102.
   Akbar M, 2002, J NEUROCHEM, V82, P655, DOI 10.1046/j.1471-4159.2002.01015.x.
   Barreto FC, 2009, CLIN J AM SOC NEPHRO, V4, P1551, DOI 10.2215/CJN.03980609.
   Basile DP, 2012, COMPR PHYSIOL, V2, P1303, DOI {[}10.1002/j.2040-4603.2012.tb00431.x, 10.1002/cphy.c110041].
   Bi JQ, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1339.
   Borsini A, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-00908-0.
   Casanas-Sanchez Veronica, 2015, Front Physiol, V6, P203, DOI 10.3389/fphys.2015.00203.
   Chang YK, 2009, J UROLOGY, V181, P1434, DOI 10.1016/j.juro.2008.10.105.
   Chen XR, 2017, J NEUROINFLAMM, V14, DOI {[}10.1186/s12974-017-0917-3, 10.1186/s12974-018-1151-3].
   Crowder RJ, 1998, J NEUROSCI, V18, P2933.
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661.
   Dyall SC, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00052.
   Grant R, 2016, ADV NEUROBIOL, V12, P247, DOI 10.1007/978-3-319-28383-8\_13.
   Guo MQ, 2007, J MOL NEUROSCI, V33, P67, DOI 10.1007/s12031-007-0046-z.
   Huang HL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1289-z.
   Hwang TW, 2020, J NUTR BIOCHEM, V82, DOI 10.1016/j.jnutbio.2020.108394.
   Ito S, 2014, TOXINS, V6, P665, DOI 10.3390/toxins6020665.
   Kao CC, 2019, J FORMOS MED ASSOC, V118, P859, DOI 10.1016/j.jfma.2018.04.005.
   Karbowska M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66421-y.
   Kawashima A, 2010, J NUTR BIOCHEM, V21, P268, DOI 10.1016/j.jnutbio.2008.12.015.
   LANDS WEM, 1992, FASEB J, V6, P2530, DOI 10.1096/fasebj.6.8.1592205.
   Lee JH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030613.
   Lee SA, 2018, AM J KIDNEY DIS, V72, P846, DOI 10.1053/j.ajkd.2018.03.028.
   Liu MC, 2008, J AM SOC NEPHROL, V19, P1360, DOI 10.1681/ASN.2007080901.
   Luo CM, 2018, EBIOMEDICINE, V32, P50, DOI 10.1016/j.ebiom.2018.05.028.
   Marszalek JR, 2005, ANNU REV CELL DEV BI, V21, P633, DOI 10.1146/annurev.cellbio.21.122303.120624.
   Ménesi D, 2009, PROSTAG LEUKOTR ESS, V80, P33, DOI 10.1016/j.plefa.2008.11.006.
   Meng Y, 2017, EXP THER MED, V13, P2417, DOI 10.3892/etm.2017.4259.
   Shi JP, 2019, NEUROSCIENCE, V414, P112, DOI 10.1016/j.neuroscience.2019.06.027.
   Vanholder R, 2018, TOXINS, V10, DOI 10.3390/toxins10010033.
   Versteilen AMG, 2004, INT J ARTIF ORGANS, V27, P1019, DOI 10.1177/039139880402701203.},
Number-of-Cited-References = {32},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {XA2QX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000720499400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000718839000001,
Author = {Pai, Shin and Yadav, Vijesh Kumar and Kuo, Kuang-Tai and Pikatan,
   Narpati Wesa and Lin, Chun-Shu and Chien, Ming-Hsien and Lee, Wei-Hwa
   and Hsiao, Michael and Chiu, Shao-Chih and Yeh, Chi-Tai and Tsai,
   Jo-Ting},
Title = {PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral
   Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated
   Glycolysis Signaling Pathway},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2021},
Volume = {22},
Number = {21},
Month = {NOV},
Abstract = {Background: Oral squamous cell carcinoma (OSCC) has a high prevalence
   and predicted global mortality rate of 67.1\%, necessitating better
   therapeutic strategies. Moreover, the recurrence and resistance of OSCC
   after chemo/radioresistance remains a major bottleneck for its effective
   treatment. Molecular targeting is one of the new therapeutic approaches
   to target cancer. Among a plethora of targetable signaling molecules,
   PDK1 is currently rising as a potential target for cancer therapy. Its
   aberrant expression in many malignancies is observed associated with
   glycolytic re-programming and chemo/radioresistance. Methods:
   Furthermore, to better understand the role of PDK1 in OSCC, we analyzed
   tissue samples from 62 patients with OSCC for PDK1 expression. Combining
   in silico and in vitro analysis approaches, we determined the important
   association between PDK1/CD47/LDHA expression in OSCC. Next, we analyzed
   the effect of PDK1 expression and its connection with OSCC orosphere
   generation and maintenance, as well as the effect of the combination of
   the PDK1 inhibitor BX795, cisplatin and radiotherapy in targeting it.
   Results: Immunohistochemical analysis revealed that higher PDK1
   expression is associated with a poor prognosis in OSCC. The
   immunoprecipitation assay indicated PDK1/CD47 binding. PDK1 ligation
   significantly impaired OSCC orosphere formation and downregulated Sox2,
   Oct4, and CD133 expression. The combination of BX795 and cisplatin
   markedly reduced in OSCC cell's epithelial-mesenchymal transition,
   implying its synergistic effect. p-PDK1, CD47, Akt, PFKP, PDK3 and LDHA
   protein expression were significantly reduced, with the strongest
   inhibition in the combination group. Chemo/radiotherapy together with
   abrogation of PDK1 inhibits the oncogenic (Akt/CD47) and glycolytic
   (LDHA/PFKP/PDK3) signaling and, enhanced or sensitizes OSCC to the
   anticancer drug effect through inducing apoptosis and DNA damage
   together with metabolic reprogramming. Conclusions: Therefore, the
   results from our current study may serve as a basis for developing new
   therapeutic strategies against chemo/radioresistant OSCC.</p>},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Yeh, CT; Tsai, JT (Corresponding Author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.
   Yeh, CT (Corresponding Author), Taipei Med Univ, Shuang Ho Hosp, Dept Med Res \& Educ, New Taipei 235, Taiwan.
   Yeh, CT (Corresponding Author), Yuanpei Univ Med Technol, Dept Med Lab Sci \& Biotechnol, Hsinchu 300, Taiwan.
   Tsai, JT (Corresponding Author), Taipei Med Univ, Coll Med, Sch Med, Dept Radiol, Taipei 110, Taiwan.
   Tsai, JT (Corresponding Author), Taipei Med Univ, Shuang Ho Hosp, Dept Radiol, New Taipei 235, Taiwan.
   Pai, Shin; Chien, Ming-Hsien; Yeh, Chi-Tai; Tsai, Jo-Ting, Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.
   Pai, Shin, St Martin Parres Hosp, Dept Oral \& Maxillofacial Surg, Chiayi 600, Taiwan.
   Yadav, Vijesh Kumar; Pikatan, Narpati Wesa; Lee, Wei-Hwa; Yeh, Chi-Tai, Taipei Med Univ, Shuang Ho Hosp, Dept Med Res \& Educ, New Taipei 235, Taiwan.
   Yadav, Vijesh Kumar; Pikatan, Narpati Wesa; Yeh, Chi-Tai, Yuanpei Univ Med Technol, Dept Med Lab Sci \& Biotechnol, Hsinchu 300, Taiwan.
   Kuo, Kuang-Tai, Taipei Med Univ, Coll Med, Sch Med, Div Thorac Surg,Dept Surg, Taipei 110, Taiwan.
   Kuo, Kuang-Tai, Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Thorac Surg, New Taipei 235, Taiwan.
   Lin, Chun-Shu, Tri Serv Gen Hosp, Natl Def Med Ctr, Dept Radiat Oncol, Taipei 114, Taiwan.
   Lee, Wei-Hwa, Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, New Taipei 235, Taiwan.
   Hsiao, Michael, Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   Chiu, Shao-Chih, China Med Univ, Grad Inst Biomed Sci, Taichung 404, Taiwan.
   Chiu, Shao-Chih, China Med Univ Hosp, Dept Med Res, Translat Cell Therapy Ctr, Taichung 404, Taiwan.
   Chiu, Shao-Chih, China Med Univ, Drug Dev Ctr, Taichung 404, Taiwan.
   Tsai, Jo-Ting, Taipei Med Univ, Coll Med, Sch Med, Dept Radiol, Taipei 110, Taiwan.
   Tsai, Jo-Ting, Taipei Med Univ, Shuang Ho Hosp, Dept Radiol, New Taipei 235, Taiwan.},
DOI = {10.3390/ijms222111492},
Article-Number = {11492},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {OSCC; PDK1; CD47; cancer stem cells; glycolysis;
   <p>chemo/radioresistance</p>; radioresistance},
Keywords-Plus = {CANCER STEM-CELLS; IDENTIFICATION; CYTOSKELETON; ACTIVATION; KINASE;
   CAVITY; DEATH; EMT},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {einfachweiss@gmail.com
   vijeshp2@gmail.com
   doc2738h@gmail.com
   narpatiwp@gmail.com
   chunshulin@gmail.com
   mhchien1976@gmail.com
   whlpath97616@s.tmu.edu.tw
   mhsiao@gate.sinica.edu.tw
   scchiu@mail.cmu.edu.tw
   ctyeh@s.tmu.edu.tw
   10576@s.tmu.edu.tw},
Affiliations = {Taipei Medical University; Taipei Medical University; Shuang Ho
   Hospital; Taipei Medical University; Taipei Medical University; Shuang
   Ho Hospital; National Defense Medical University; Tri-Service General
   Hospital; Taipei Medical University; Shuang Ho Hospital; Academia Sinica
   - Taiwan; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; Taipei Medical University; Taipei Medical University;
   Shuang Ho Hospital},
ResearcherID-Numbers = {Hsiao, Michael/U-6238-2019
   YADAV, VIJESH/AAQ-6047-2021
   },
ORCID-Numbers = {Hsiao, Michael/0000-0001-8529-9213
   Yeh, Chi-Tai/0000-0001-5189-9755
   Lin, Chun-Shu/0000-0003-1919-8769
   Lee, Wei-Hwa/0000-0003-0932-3191
   Kuo, Kuang-Tai/0000-0003-2754-2283
   Chien, Ming-Hsien/0000-0002-0084-7231},
Funding-Acknowledgement = {Taipei Medical University-National Taiwan University of Science and
   Technology Joint Research Program {[}TMU-NTUST-103-03]; Ministry of
   Science and Technology {[}MOST 110-2314-B-038-084 -]},
Funding-Text = {This work was supported by grants from the Taipei Medical
   University-National Taiwan University of Science and Technology Joint
   Research Program (TMU-NTUST-103-03) to Chi-Tai Yeh. This study was also
   supported by grants from the Ministry of Science and Technology (MOST
   110-2314-B-038-084 -) to Jo-Ting Tsai.},
Cited-References = {Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059.
   An J, 2020, ENVIRON INT, V136, DOI 10.1016/j.envint.2019.105428.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Atashzar MR, 2020, J CELL PHYSIOL, V235, P790, DOI 10.1002/jcp.29044.
   Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746.
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193.
   Bramhecha YM, 2018, MOL CANCER RES, V16, P115, DOI 10.1158/1541-7786.MCR-17-0270.
   Bras M, 2007, MOL CELL BIOL, V27, P7073, DOI 10.1128/MCB.02116-06.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375.
   Chen C, 2008, CANCER EPIDEM BIOMAR, V17, P2152, DOI 10.1158/1055-9965.EPI-07-2893.
   Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286.
   Dahl KN, 2003, BLOOD, V101, P1194, DOI 10.1182/blood-2002-04-1187.
   Daniele S, 2017, ACS CHEM NEUROSCI, V8, P100, DOI 10.1021/acschemneuro.6b00251.
   de Francesco EM, 2018, BIOCHEM J, V475, P1611, DOI 10.1042/BCJ20170164.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568-019-0216-7.
   Huang SH, 2013, MED ORAL PATOL ORAL, V18, pE233, DOI 10.4317/medoral.18772.
   Kaur S, 2016, ONCOTARGET, V7, P10133, DOI 10.18632/oncotarget.7100.
   Lee TKW, 2014, HEPATOLOGY, V60, P179, DOI 10.1002/hep.27070.
   Li X, 2019, FOOD FUNCT, V10, P592, DOI 10.1039/c8fo01611a.
   Lian SX, 2015, ONCOTARGET, V6, P29076, DOI 10.18632/oncotarget.4931.
   Liao Q, 2019, CURR NEUROVASC RES, V16, P373, DOI 10.2174/1567202616666190906102343.
   Liu XJ, 2019, ONCOL RES, V27, P415, DOI 10.3727/096504018X15155538502359.
   Liu Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01525.
   Luo DY, 2018, INT J ONCOL, V53, P2067, DOI 10.3892/ijo.2018.4525.
   Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6.
   Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   McDermott N, 2014, INT J RADIAT BIOL, V90, P115, DOI 10.3109/09553002.2014.873557.
   Muranen TA, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3015.
   O'Donnell JS, 2018, SEMIN CANCER BIOL, V48, P91, DOI 10.1016/j.semcancer.2017.04.015.
   Pai S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121658.
   Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675.
   Rasheed ZA, 2011, STEM CELLS, V29, P883, DOI 10.1002/stem.648.
   Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383.
   Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384.
   Shukla G, 2017, CURR STEM CELL RES T, V12, P207, DOI 10.2174/1574888X11666161028143224.
   Sick E, 2011, GLIA, V59, P308, DOI 10.1002/glia.21102.
   Signore M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.188.
   Sur S, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0447-y.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Tan WG, 2019, J CELL MOL MED, V23, P5994, DOI 10.1111/jcmm.14462.
   Tangthongkum M, 2017, EUR ARCH OTO-RHINO-L, V274, P2567, DOI 10.1007/s00405-017-4540-9.
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179.
   Wang XQ, 2017, CELL DEATH DIFFER, V24, P38, DOI 10.1038/cdd.2016.84.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Wu CX, 2018, THERANOSTICS, V8, P3737, DOI 10.7150/thno.25487.
   Xie SL, 2018, INT J CANCER, V142, P1252, DOI 10.1002/ijc.31134.
   Yang ZL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0337-5.
   Zhang YP, 2020, ADV EXP MED BIOL, V1248, P201, DOI 10.1007/978-981-15-3266-5\_9.
   Zhao H, 2016, SCI REP-UK, V6, DOI 10.1038/srep29719.
   Zhao YH, 2009, ONCOGENE, V28, P3689, DOI 10.1038/onc.2009.229.},
Number-of-Cited-References = {56},
Times-Cited = {42},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {WX8KS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000718839000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000704312500001,
Author = {Sheng, Wen and Xu, Wenjing and Ding, Jin and Li, Ling and You, Xujun and
   Wu, Yongrong and He, Qinghu},
Title = {Curcumol inhibits the malignant progression of prostate cancer and
   regulates the PDK1/AKT/mTOR pathway by targeting miR-9},
Journal = {ONCOLOGY REPORTS},
Year = {2021},
Volume = {46},
Number = {5},
Month = {NOV},
Abstract = {Curcumol has been reported to exert anti-tumor activity, but its
   intrinsic molecular mechanism in prostate cancer remains to be
   elucidated. The present study aimed to analyze the effect of curcumol on
   prostate cancer and identify its possible internal regulatory pathway
   using in vitro cell culture and in vivo tumor model experiments. The
   cytotoxicity of curcumol was detected using a Cell Counting Kit-8 assay
   and it was found that curcumol had no obvious toxicity or side effects
   on RWPE-1 cells. Wound healing, Transwell and flow cytometry assays
   demonstrated that curcumol could affect the activity of PC3 cells. The
   luciferase reporter assay also indicated that microRNA (miR)-9 could
   directly target pyruvate dehydrogenase kinase 1 (PDK1). After PC3 cells
   were transfected with miR-9 inhibitor or treated with curcumol, the
   expression levels of the PDK1/AKT/mTOR signaling pathway-related
   proteins {[}PDK1, phosphorylated (p)-AKT and p-mTOR] were increased or
   decreased, respectively. Next, the prostate cancer cell xenograft model
   was established. Tumor size and the expression levels of PDK1/AKT/mTOR
   signaling pathway-related factors were altered following treatment with
   curcumol. The in vitro and in vivo experiments collectively demonstrated
   that curcumol could inhibit the PDK1/AKT/mTOR signaling pathway by
   upregulating the expression level of miR-9. The present study found that
   curcumol regulates the PDK1/AKT/mTOR signaling pathway via miR-9 and
   affects the development of prostate cancer. These findings could provide
   a possible scientific insight for research into treatments for prostate
   cancer.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {He, QH (Corresponding Author), Hunan Univ Chinese Med, Androl Lab, 300 Xueshi Rd, Changsha 410208, Hunan, Peoples R China.
   Sheng, Wen; Wu, Yongrong; He, Qinghu, Hunan Univ Chinese Med, Androl Lab, 300 Xueshi Rd, Changsha 410208, Hunan, Peoples R China.
   Xu, Wenjing, Hunan Univ Chinese Med, Dermatol Dept, Hosp 1, Changsha 410021, Hunan, Peoples R China.
   Ding, Jin; You, Xujun, Shenzhen Baoan Hosp Tradit Chinese Med, Androl Clin, Shenzhen 518133, Guangdong, Peoples R China.
   Li, Ling, Hunan Univ Chinese Med, Med Basic Teaching Expt Ctr, Changsha 410208, Hunan, Peoples R China.},
DOI = {10.3892/or.2021.8197},
Article-Number = {246},
ISSN = {1021-335X},
EISSN = {1791-2431},
Keywords = {curcumol; prostate cancer; microRNA-9; pyruvate dehydrogenase kinase 1;
   AKT; mTOR pathway},
Keywords-Plus = {GROWTH; CELLS; PROLIFERATION; METASTASIS; APOPTOSIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {qinghu\_he3418@hnucm.edu.cn},
Affiliations = {Hunan University of Chinese Medicine; Hunan University of Chinese
   Medicine; Hunan University of Chinese Medicine},
ResearcherID-Numbers = {li, ling/GWM-6951-2022
   sheng, wen/IUN-8373-2023},
ORCID-Numbers = {sheng, wen/0000-0001-8053-2434},
Funding-Acknowledgement = {National Natural Science Foundation {[}81774324]; Postgraduate
   Innovation Project of Hunan Province {[}CX2018B463]},
Funding-Text = {This work was supported by the National Natural Science Foundation
   (grant no. 81774324), and the Postgraduate Innovation Project of Hunan
   Province (grant no. CX2018B463).},
Cited-References = {Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Cordes LM, 2016, CURR OPIN ONCOL, V28, P232, DOI 10.1097/CCO.0000000000000281.
   Cristofani R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0866-5.
   Gourdin T, 2019, CURR OPIN ONCOL, V31, P188, DOI 10.1097/CCO.0000000000000521.
   Huang GQ, 2019, CELL BIOL INT, V43, P1223, DOI 10.1002/cbin.11104.
   Jing PH, 2020, EXP CELL RES, V386, DOI 10.1016/j.yexcr.2019.111746.
   Li GY, 2020, PHYTOTHER RES, V34, P1421, DOI 10.1002/ptr.6616.
   Li XM, 2018, PHYTOTHER RES, V32, P2214, DOI 10.1002/ptr.6158.
   Li YQ, 2019, BIOORG CHEM, V85, P357, DOI 10.1016/j.bioorg.2019.01.013.
   Liu HW, 2019, LIFE SCI, V221, P354, DOI 10.1016/j.lfs.2019.02.049.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Lu J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0814-3.
   Luo DY, 2018, INT J ONCOL, V53, P2067, DOI 10.3892/ijo.2018.4525.
   Ning N, 2020, J CANCER, V11, P1679, DOI 10.7150/jca.38624.
   Pickard RD, 2015, N-S ARCH PHARMACOL, V388, P793, DOI 10.1007/s00210-015-1104-7.
   Sebesta EM, 2017, SEMIN ONCOL, V44, P347, DOI 10.1053/j.seminoncol.2018.01.003.
   Siu MKY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0209-0.
   Valera VA, 2020, J CANCER, V11, P4106, DOI 10.7150/jca.37842.
   Wang GY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5438.
   Wang H, 2014, INT IMMUNOPHARMACOL, V21, P375, DOI 10.1016/j.intimp.2014.05.021.
   Wang J, 2019, BIOCHEM BIOPH RES CO, V509, P241, DOI 10.1016/j.bbrc.2018.12.114.
   Wang WX, 2019, EUR REV MED PHARMACO, V23, P6467, DOI 10.26355/eurrev\_201908\_18530.
   Wei W, 2019, INT J BIOL SCI, V15, P1600, DOI 10.7150/ijbs.34716.
   Wu HX, 2020, CANCER RES, V80, P2927, DOI 10.1158/0008-5472.CAN-19-2549.
   Xu XZ, 2019, INT J BIOCHEM CELL B, V112, P61, DOI 10.1016/j.biocel.2019.04.001.
   Yang C, 2019, WORLD J GASTROENTERO, V25, P3196, DOI 10.3748/wjg.v25.i25.3196.
   Yao XH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00755.
   Yu CL, 2016, TOXICOL MECH METHOD, V26, P635, DOI 10.1080/15376516.2016.1207735.
   Zang SL, 2017, ONCOL REP, V38, P3583, DOI 10.3892/or.2017.6028.
   Zeng C, 2020, BIOCHEM PHARMACOL, V174, DOI 10.1016/j.bcp.2020.113795.
   Zhang WW, 2011, MED ONCOL, V28, P307, DOI 10.1007/s12032-010-9431-5.
   Zhou L, 2018, BIOMED PHARMACOTHER, V104, P798, DOI 10.1016/j.biopha.2018.05.101.
   Zhou WM, 2019, CELL SIGNAL, V56, P1, DOI 10.1016/j.cellsig.2018.11.016.
   Zuo HX, 2020, J ETHNOPHARMACOL, V257, DOI 10.1016/j.jep.2020.112835.},
Number-of-Cited-References = {35},
Times-Cited = {24},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Oncol. Rep.},
Doc-Delivery-Number = {WC5QQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000704312500001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000712009200032,
Author = {Wu, Yong-Mei and Shi, Qing and Zhu, Peng-Fei and Ma, Hai-Jian and Cui,
   Shi-Chao and Li, Jia and Hou, Ai-Jun and Li, Jing-Ya},
Title = {Rhodomeroterpene alleviates macrophage infiltration and the inflammatory
   response in renal tissue to improve acute kidney injury},
Journal = {FASEB JOURNAL},
Year = {2021},
Volume = {35},
Number = {11},
Month = {NOV},
Abstract = {Inflammation is broadly recognized as an important factor in the
   pathogenesis of acute kidney injury (AKI), but pharmacological
   approaches to alleviate inflammation in AKI have not been proved
   successful in clinical trials. Macrophage infiltration into renal tissue
   promotes inflammatory responses that contribute to the pathogenesis of
   AKI. Suppression of renal tissue inflammatory responses is postulated to
   improve renal injury of patients and animals. Rhodomeroterpene (RMT) is
   a novel meroterpenoid isolated from the Rhododendron genus that was
   shown to exert anti-inflammatory action in vivo or in vitro in this
   study. We investigated the treatment effects of RMT on LPS-induced
   sepsis and two different AKI models. The results showed that
   pretreatment with RMT (30 mg kg(-1) d(-1) , ip, for 3 days)
   significantly inhibited acute inflammatory responses in LPS-induced
   septic mice. In both renal ischemia-reperfusion injury (I/R) and
   sepsis-induced AKI models, RMT (30 mg kg(-1) d(-1), ip, for 3 days)
   ameliorated renal function and injury and alleviated inflammation by
   reducing the infiltration of immune cells, including macrophages and
   neutrophils. Furthermore, our study demonstrated that RMT inhibits
   inflammatory responses in macrophages. The anti-inflammatory effects of
   RMT may be due to the inactivation of the IKK/NF-kappa B and
   PI3K/PDK1/Akt inflammatory signaling pathways in macrophages.
   Collectively, our findings indicate that RMT ameliorates renal injury
   and alleviates the renal inflammatory state in different AKI models,
   suggesting that RMT may be a potential agent for the treatment of AKI.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Li, J; Li, JY (Corresponding Author), Chinese Acad Sci, Shanghai Inst Mat Med, 189 Guo Shou Jing Rd, Shanghai, Peoples R China.
   Wu, Yong-Mei; Zhu, Peng-Fei; Li, Jia; Li, Jing-Ya, Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing, Peoples R China.
   Wu, Yong-Mei; Zhu, Peng-Fei; Cui, Shi-Chao; Li, Jia; Li, Jing-Ya, Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China.
   Shi, Qing; Ma, Hai-Jian; Hou, Ai-Jun, Fudan Univ, Sch Pharm, State Key Lab Med Neurobiol, Shanghai, Peoples R China.},
DOI = {10.1096/fj.202100981RR},
Article-Number = {e21985},
ISSN = {0892-6638},
EISSN = {1530-6860},
Keywords = {acute kidney injury; IKK/NF-kappa B; inflammation; macrophage;
   PI3K/PDK1/Akt; rhodomeroterpene},
Keywords-Plus = {RHODODENDRON; AKI; MEROTERPENOIDS; ACTIVATION; CONTRIBUTE; MECHANISM;
   SEPSIS; SYSTEM; ROLES; CELLS},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Cell Biology},
Author-Email = {jli@simm.ac.cn
   jyli@simm.ac.cn},
Affiliations = {Nanjing University of Chinese Medicine; Chinese Academy of Sciences;
   Shanghai Institute of Materia Medica, CAS; Fudan University},
ResearcherID-Numbers = {Zhu, Pengfei/JOZ-2311-2023
   Li, Jingya/F-9116-2011
   },
ORCID-Numbers = {Li, Jingya/0000-0003-3457-8153
   Cui, Shicao/0000-0002-8604-1270
   Li, Jingya/0000-0003-3457-8153},
Funding-Acknowledgement = {Ministry of Science and Technology Key Research Program
   {[}2016YFC1305505]; Fudan University-Shanghai Institute of Materia
   Medica Cooperation Program {[}FU-SIMM20181011]; Central Asian Drug
   Discovery and Development of ACS {[}CAM202001]},
Funding-Text = {The Ministry of Science and Technology Key Research Program, Grant/Award
   Number: 2016YFC1305505; The Fudan University-Shanghai Institute of
   Materia Medica Cooperation Program, Grant/Award Number: FU-SIMM20181011;
   Central Asian Drug Discovery and Development of ACS, Grant/Award Number:
   CAM202001},
Cited-References = {Abdulkhaleq LA, 2018, VET WORLD, V11, P627, DOI 10.14202/vetworld.2018.627-635.
   Alge JL, 2015, CLIN J AM SOC NEPHRO, V10, P147, DOI 10.2215/CJN.12191213.
   Arranz A, 2012, P NATL ACAD SCI USA, V109, P9517, DOI 10.1073/pnas.1119038109.
   Bonavia A, 2018, PEDIATR NEPHROL, V33, P1629, DOI 10.1007/s00467-017-3774-5.
   Chen YT, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-51.
   Chen YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-270.
   Cheng SC, 2016, NAT IMMUNOL, V17, P406, DOI 10.1038/ni.3398.
   Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8.
   Ferenbach DA, 2011, KIDNEY INT, V79, P966, DOI 10.1038/ki.2010.535.
   Fulop T, 2014, CURR OPIN IMMUNOL, V29, P105, DOI 10.1016/j.coi.2014.05.007.
   Han HI, 2019, PEDIATR NEPHROL, V34, P561, DOI 10.1007/s00467-017-3883-1.
   Han SJ, 2019, KIDNEY RES CLIN PRAC, V38, P427, DOI 10.23876/j.krcp.19.062.
   Hoste EAJ, 2018, NAT REV NEPHROL, V14, P607, DOI 10.1038/s41581-018-0052-0.
   Huang GH, 2018, J NAT PROD, V81, P1810, DOI 10.1021/acs.jnatprod.8b00273.
   Inoue T, 2017, KIDNEY INT, V91, P526, DOI 10.1016/j.kint.2016.11.026.
   Iwata N, 2010, J NAT PROD, V73, P1203, DOI 10.1021/np900543r.
   Jang HR, 2015, NAT REV NEPHROL, V11, P88, DOI 10.1038/nrneph.2014.180.
   Jou IM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/316482.
   Kim EA, 2019, J FUNCT FOODS, V52, P109, DOI 10.1016/j.jff.2018.10.030.
   Kim JH, 2014, NEPHRON EXP NEPHROL, V128, P21, DOI 10.1159/000365851.
   Kinsey GR, 2008, NEPHRON EXP NEPHROL, V109, pE102, DOI 10.1159/000142934.
   Kinsey GR, 2014, J AM SOC NEPHROL, V25, P209, DOI 10.1681/ASN.2013101110.
   Kishore N, 2019, EUR J MED CHEM, V179, P272, DOI 10.1016/j.ejmech.2019.06.034.
   Kuang Y, 2021, NAT PROD REP, V38, P83, DOI 10.1039/d0np00023j.
   Kumar S, 2018, KIDNEY INT, V93, P27, DOI 10.1016/j.kint.2017.07.030.
   Kurts C, 2013, NAT REV IMMUNOL, V13, P738, DOI 10.1038/nri3523.
   Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250.
   Lee ES, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179221.
   Li YM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01415.
   Li Y, 2013, PHYTOCHEM REV, V12, P305, DOI 10.1007/s11101-013-9299-z.
   Liao HB, 2015, ORG LETT, V17, P5040, DOI 10.1021/acs.orglett.5b02515.
   Lin FM, 2003, J AM SOC NEPHROL, V14, P1188, DOI 10.1097/01.ASN.0000061595.28546.A0.
   Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005.
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23.
   Mastora C, 2013, GENETICALLY MODIFIED, P1.
   Meng XM, 2015, KIDNEY DIS-BASEL, V1, P138, DOI 10.1159/000431214.
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339.
   Peerapornratana S, 2019, KIDNEY INT, V96, P1083, DOI 10.1016/j.kint.2019.05.026.
   Popescu R, 2013, J ETHNOPHARMACOL, V147, P42, DOI 10.1016/j.jep.2013.02.022.
   Rabb H, 2016, J AM SOC NEPHROL, V27, P371, DOI 10.1681/ASN.2015030261.
   Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2.
   Said IH, 2017, PHYTOCHEM ANALYSIS, V28, P454, DOI 10.1002/pca.2694.
   Sato Y, 2018, AM J PHYSIOL-RENAL, V315, pF1501, DOI 10.1152/ajprenal.00195.2018.
   Shi Q, 2020, PHYTOCHEMISTRY, V180, DOI 10.1016/j.phytochem.2020.112524.
   Susnik N, 2014, KIDNEY INT, V85, P1357, DOI 10.1038/ki.2013.525.
   Um Y, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113218.
   Waikar SS., 2018, CORE CONCEPTS ACUTE, P1.
   Wang P, 2015, INT J MOL SCI, V16, P20595, DOI 10.3390/ijms160920595.
   Wang S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.104.
   Wen Y, 2020, CURR OPIN NEPHROL HY, V29, P286, DOI 10.1097/MNH.0000000000000595.
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034.
   Xie XC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00473.
   Yuan A., 2020, AUTHOREA PREPRINTS.
   Zarjou A, 2011, J AM SOC NEPHROL, V22, P999, DOI 10.1681/ASN.2010050484.
   Zbakh H, 2020, MAR DRUGS, V18, DOI 10.3390/md18040207.
   Zegeye MM, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0268-4.
   Zhao JX, 2018, ORG CHEM FRONT, V5, P2202, DOI 10.1039/c8qo00469b.
   Zhong DD, 2015, SCI REP-UK, V5, DOI 10.1038/srep16910.},
Number-of-Cited-References = {58},
Times-Cited = {11},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Faseb J.},
Doc-Delivery-Number = {WN8IK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000712009200032},
DA = {2026-02-04},
}

@article{ WOS:000714105800051,
Author = {Kamal, Shimaa and Derbala, Hamed Ahmed and Alterary, Seham Soliman and
   Ben Bacha, Abir and Alonazi, Mona and El-Ashrey, Mohamed Kandeel and
   El-Sayed, Nahed Nasser Eid},
Title = {Synthesis, Biological, and Molecular Docking Studies on
   4,5,6,7-Tetrahydrobenzo{[}b]thiophene Derivatives and Their
   Nanoparticles Targeting Colorectal Cancer},
Journal = {ACS OMEGA},
Year = {2021},
Volume = {6},
Number = {43},
Pages = {28992-29008},
Month = {NOV 2},
Abstract = {Initiation of colorectal carcinogenesis may be induced by chromosomal
   instability caused by oxidative stress or indirectly by bacterial
   infections. Moreover, proliferating tumor cells are characterized by
   reprogrammed glucose metabolism, which is associated with upregulation
   of PDK1 and LDHA enzymes. In the present study, some
   4,5,6,7-tetrahydrobenzo{[}b]-thiophene derivatives in addition to Fe3O4
   and Fe3O4/SiO2 nanoparticles (NPs) supported with a new Schiff base were
   synthesized for biological evaluation as PDK1 and LDHA inhibitors as
   well as antibacterial, antioxidant, and cytotoxic agents on LoVo and
   HCT-116 cells of colorectal cancer (CRC). The results showed that
   compound 1b is the most active as PDK1 and LDHA inhibitor with IC50
   values (mu g/mL) of 57.10 and 64.10 compared to 25.75 and 15.60, which
   were produced by the standard inhibitors sodium dichloroacetate and
   sodium oxamate, respectively. NPs12a,b and compound 1b exhibited the
   strongest antioxidant properties with IC50 values (mu g/mL) of 80.0,
   95.0, and 110.0 mu g/mL, respectively, compared to 54.0 mu g/mL, which
   was produced by butylated hydroxy toluene. Moreover, NPs12a and
   carbamate derivative 3b exhibited significant cytotoxic activities with
   IC50 values (mu g/mL) of 57.15 and 81.50 (LoVo cells) and 60.35 and
   71.00 (HCT-116 cells). Thus, NPs12a and compound 3b would be considered
   as promising candidates suitable for further optimization to develop new
   chemopreventive and chemotherapeutic agents against these types of CRC
   cell lines. Besides, molecular docking in the colchicine binding site of
   the tubulin (TUB) domain revealed a good binding affinity of 3b to the
   protein; in addition, the absorption, distribution, metabolism, and
   excretion (ADME) analyses showed its desirable drug-likeness and oral
   bioavailability characteristics.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {El-Sayed, NNE (Corresponding Author), Natl Org Drug Control \& Res, Egyptian Drug Author, Giza 35521, Egypt.
   Kamal, Shimaa; Derbala, Hamed Ahmed, Ain Shams Univ, Fac Sci, Chem Dept, Cairo 11566, Egypt.
   Alterary, Seham Soliman, King Saud Univ, Coll Sci, Dept Chem, Riyadh 11523, Saudi Arabia.
   Ben Bacha, Abir; Alonazi, Mona, King Saud Univ, Coll Sci, Biochem Dept, Riyadh 11495, Saudi Arabia.
   El-Ashrey, Mohamed Kandeel, Cairo Univ, Fac Pharm, Pharmaceut Chem Dept, Mol Modeling Unit, Cairo 11562, Egypt.
   El-Ashrey, Mohamed Kandeel, King Salman Int Univ, Fac Pharm, Med Chem Dept, Ras Sedr, South Sinai, Egypt.
   El-Sayed, Nahed Nasser Eid, Natl Org Drug Control \& Res, Egyptian Drug Author, Giza 35521, Egypt.},
DOI = {10.1021/acsomega.1c04063},
EarlyAccessDate = {OCT 2021},
ISSN = {2470-1343},
Keywords-Plus = {ANTICANCER; METABOLISM; KINASES; AGENTS},
Research-Areas = {Chemistry},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary},
Author-Email = {nahed.elsayed@edaegypt.gov.eg},
Affiliations = {Egyptian Knowledge Bank (EKB); Ain Shams University; King Saud
   University; King Saud University; Egyptian Knowledge Bank (EKB); Cairo
   University; King Salman International University; National Organization
   for Drug Control \& Research (NODCAR)},
ResearcherID-Numbers = {A, Mona/AAF-6911-2019
   Ben Bacha, Abir/AFM-1328-2022
   El-Sayed, Nahed Nasser Eid/JAX-5608-2023
   El-Ashrey, Mohamed/JGD-8544-2023},
ORCID-Numbers = {Ben Bacha, Abir/0000-0003-1188-4297
   El-Sayed, Nahed Nasser Eid/0000-0001-9771-8956
   El-Ashrey, Mohamed/0000-0002-3548-3888},
Funding-Acknowledgement = {King Saud University, Riyadh, Saudi Arabia {[}RSP-2021/237]},
Funding-Text = {The authors acknowledge Researchers Supporting Project number
   RSP-2021/237, King Saud University, Riyadh, Saudi Arabia.},
Cited-References = {Al-Zalabani A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010320.
   Archna, 2020, BIOORG CHEM, V101, DOI 10.1016/j.bioorg.2020.104026.
   Atas E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.583217.
   Basak D, 2020, CANCERS, V12, DOI 10.3390/cancers12113336.
   Bersuder P, 1998, J AM OIL CHEM SOC, V75, P181, DOI 10.1007/s11746-998-0030-y.
   Boutard N, 2019, BIOORG MED CHEM LETT, V29, P607, DOI 10.1016/j.bmcl.2018.12.051.
   Cai GS, 2019, MOLECULES, V24, DOI 10.3390/molecules24010192.
   Collins D, 2011, LANCET ONCOL, V12, P504, DOI 10.1016/S1470-2045(10)70186-8.
   Das S, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e04953.
   Deng XY, 2020, J CANCER, V11, P962, DOI 10.7150/jca.34330.
   Dong YW, 2018, J AGR FOOD CHEM, V66, P3351, DOI 10.1021/acs.jafc.8b00017.
   El-Helw EA, 2019, RUSS J BIOORG CHEM+, V45, P42, DOI 10.1134/S1068162019010047.
   El-Sayed NNE, 2019, J ENZYM INHIB MED CH, V34, P672, DOI 10.1080/14756366.2019.1574780.
   Elrayess R, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14010009.
   Malekshah RE, 2020, DRUG DELIV, V27, P1201, DOI 10.1080/10717544.2020.1801890.
   Feng YB, 2018, CANCER MED-US, V7, P6124, DOI 10.1002/cam4.1820.
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234.
   Garton AJ, 2006, CANCER RES, V66, P1015, DOI 10.1158/0008-5472.CAN-05-2873.
   GERAVAND Maryam, 2019, Arq. Gastroenterol., V56, P141, DOI {[}10.1590/s0004-2803.201900000-28, 10.1590/S0004-2803.201900000-28, 10.1590/s0004-2803.201900000-28].
   GEWALD K, 1965, CHEM BER-RECL, V98, P3571, DOI 10.1002/cber.19650981120.
   Han Q, 2019, J BRAZIL CHEM SOC, V30, P1483, DOI 10.21577/0103-5053.20190044.
   Herbst RS, 2003, CANCER TREAT REV, V29, P407, DOI 10.1016/S0305-7372(03)00097-5.
   Kajal A., 2013, J CATAL, P1, DOI {[}10.1155/2013/893512, DOI 10.1155/2013/893512].
   Kavaliauskas P, 2020, ANTIBIOTICS-BASEL, V9, DOI 10.3390/antibiotics9090612.
   Kelly C, 2007, EXPERT REV ANTICANC, V7, P803, DOI 10.1586/14737140.7.6.803.
   Keri RS, 2017, EUR J MED CHEM, V138, P1002, DOI 10.1016/j.ejmech.2017.07.038.
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8.
   Kim EY, 2016, AM J CHINESE MED, V44, P1063, DOI 10.1142/S0192415X16500592.
   Kwak CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176021.
   Li WL, 2019, BIOORG CHEM, V83, P380, DOI 10.1016/j.bioorg.2018.10.027.
   Lipinski Christopher A, 2004, Drug Discov Today Technol, V1, P337, DOI 10.1016/j.ddtec.2004.11.007.
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026.
   Luo YD, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165598.
   Masini T, 2016, J ENZYM INHIB MED CH, V31, P170, DOI 10.1080/14756366.2016.1201812.
   Matosevic A, 2020, ARH HIG RADA TOKSIKO, V71, P285, DOI 10.2478/aiht-2020-71-3466.
   Mishra D, 2019, CANCERS, V11, DOI 10.3390/cancers11060750.
   Mizutani MY, 2006, PROTEINS, V63, P878, DOI 10.1002/prot.20931.
   Mohamed MF, 2017, ANTI-CANCER AGENT ME, V17, P1084, DOI 10.2174/1871520617666170110154110.
   Murthy KNC, 2018, ACS SYM SER, V1286, P383.
   Prabhu YT, 2015, INT NANO LETT, V5, P85, DOI 10.1007/s40089-015-0141-z.
   Purkey HE, 2016, ACS MED CHEM LETT, V7, P896, DOI 10.1021/acsmedchemlett.6b00190.
   Puterová Z, 2010, ARKIVOC, P209, DOI 10.3998/ark.5550190.0011.105.
   Puthran D, 2020, J CHIN CHEM SOC-TAIP, V67, P1278, DOI 10.1002/jccs.201900388.
   Rani R, 2016, J MED CHEM, V59, P487, DOI 10.1021/acs.jmedchem.5b00168.
   Revanna RH, 2016, J BRAZIL CHEM SOC, V27, P1157.
   Romagnoli R, 2020, MOLECULES, V25, DOI 10.3390/molecules25071690.
   Safarov S, 2009, J HETEROCYCLIC CHEM, V46, P552, DOI 10.1002/jhet.41.
   Shah ST, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7100306.
   Sroor FM, 2020, ARCH PHARM, V353, DOI 10.1002/ardp.202000069.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Taufiq A, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03784.
   Tavadyan LA, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020022.
   Urbanska K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092085.
   Wang CW, 2016, ELIFE, V5, DOI 10.7554/eLife.18126.
   Wang XM, 2017, ONCOTARGET, V8, P102176, DOI 10.18632/oncotarget.22250.
   Wright M, 2017, SURG CLIN N AM, V97, P683, DOI 10.1016/j.suc.2017.01.014.
   Zhang T, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00207.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.
   Zhao MH, 2019, ACS OMEGA, V4, P8874, DOI 10.1021/acsomega.9b00554.
   Zhu XX, 2020, INT J BIOL SCI, V16, P2029, DOI 10.7150/ijbs.45420.},
Number-of-Cited-References = {60},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {ACS Omega},
Doc-Delivery-Number = {WQ9CD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000714105800051},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000705529900001,
Author = {Molinaro, Caroline and Martoriati, Alain and Lescuyer, Arlette and
   Fliniaux, Ingrid and Tulasne, David and Cailliau, Katia},
Title = {3-phosphoinositide-dependent protein kinase 1 (PDK1) mediates crosstalk
   between Src and Akt pathways in MET receptor signaling},
Journal = {FEBS LETTERS},
Year = {2021},
Volume = {595},
Number = {21},
Pages = {2655-2664},
Month = {NOV},
Abstract = {The high-affinity tyrosine kinase receptor MET plays a pivotal role in
   several facets of cell regulation. Although its mitogenic effect is well
   documented, some aspects of connection patterns between signaling
   pathways involved in cell cycle progression remain to be deciphered. We
   have used a tractable heterologous expression system, the Xenopus
   oocyte, to detect connections between distinct MET signaling cascades
   involved in G2/M progression. Our results reveal that Src acts as an
   adapter via its SH2 domain to recruit 3-phosphoinositide-dependent
   protein kinase 1 (PDK1) to the MET signaling complex leading to Akt
   phosphorylation. These data define an original crosstalk between Src and
   Akt signaling pathways that contributes to MET-induced entry into the M
   phase, and deserves further investigation in pathologies harboring
   deregulation of this receptor.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Cailliau, K (Corresponding Author), Univ Lille, UGSF UMR CNRS 8576, SN3, F-59655 Villeneuve Dascq, France.
   Molinaro, Caroline; Martoriati, Alain; Lescuyer, Arlette; Cailliau, Katia, Univ Lille, Unite Glycobiol Struct \& Fonct, CNRS, UMR UGSF 8576, Lille, France.
   Fliniaux, Ingrid, Univ Lille, Inserm PHYCEL Cellular Physiol U1003, Lille, France.
   Tulasne, David, Univ Lille, Inst Pasteur Lille, Canther Canc Heterogene Plast \& Resistance Therap, CNRS,Inserm,CHU Lille, Lille, France.},
DOI = {10.1002/1873-3468.14195},
EarlyAccessDate = {OCT 2021},
ISSN = {0014-5793},
EISSN = {1873-3468},
Keywords = {Akt; G2; M transition; hepatocyte growth factor receptor; MET signaling;
   PDK1; Src; Xenopus oocyte},
Keywords-Plus = {HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE; XENOPUS OOCYTES; C-SRC;
   PHOSPHATIDYLINOSITOL 3-KINASE; TRANSDUCTION PATHWAYS; DOCKING SITE;
   PHOSPHORYLATION; ACTIVATION; EXPRESSION},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics; Cell Biology},
Author-Email = {katia.maggio@univ-lille.fr},
Affiliations = {Centre National de la Recherche Scientifique (CNRS); Universite de
   Lille; Universite de Lille; Centre National de la Recherche Scientifique
   (CNRS); Pasteur Network; Universite de Lille; Institut Pasteur Lille;
   Institut National de la Sante et de la Recherche Medicale (Inserm); CHU
   Lille},
ResearcherID-Numbers = {Tulasne, David/AAR-5287-2020
   Fliniaux, Ingrid/D-9129-2015},
ORCID-Numbers = {Tulasne, David/0000-0002-6764-7242
   Cailliau, Katia/0000-0001-7993-8437
   cailliau, katia/0000-0003-1772-1034
   Fliniaux, Ingrid/0000-0001-6377-5098},
Funding-Acknowledgement = {French ministry; CNRS; INSERM; Institut Pasteur de Lille; University of
   Lille; Ligue Contre le Cancer, Comites Nord et Aisne; Agence Nationale
   de la recherche; Canceropole Nord-Ouest; Institut National du Cancer},
Funding-Text = {C.M. is a recipient of a doctoral fellowship from the French ministry.
   This work was supported by the CNRS, INSERM, the Institut Pasteur de
   Lille, and the University of Lille, and by grants from the `Ligue Contre
   le Cancer, Comites Nord et Aisne' (K.C., A.M., and (D.T.), and the
   `Agence Nationale de la recherche' (D.T.), `Canceropole Nord-Ouest'
   (D.T.), and the `Institut National du Cancer' (D.T.).},
Cited-References = {Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535.
   BARDELLI A, 1994, J BIOTECHNOL, V37, P109, DOI 10.1016/0168-1656(94)90002-7.
   Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261.
   Bolanos-Garcia VM, 2005, MOL CELL BIOCHEM, V276, P149, DOI 10.1007/s11010-005-3696-6.
   Browaeys-Poly E, 2000, EUR J BIOCHEM, V267, P6256, DOI 10.1046/j.1432-1327.2000.01710.x.
   Browaeys-Poly E, 2005, BBA-MOL CELL RES, V1743, P1, DOI 10.1016/j.bbamcr.2004.07.003.
   Cailliau K, 2001, BBA-MOL CELL RES, V1538, P228, DOI 10.1016/S0167-4889(01)00074-X.
   Cailliau K, 2001, FEBS LETT, V496, P161, DOI 10.1016/S0014-5793(01)02410-3.
   Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865.
   Chan PC, 2003, J BIOL CHEM, V278, P44075, DOI 10.1074/jbc.M305745200.
   Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005.
   DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985.
   Emaduddin M, 2008, P NATL ACAD SCI USA, V105, P2358, DOI 10.1073/pnas.0712176105.
   Factor VM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012739.
   Fan SJ, 2009, J BIOL CHEM, V284, P7561, DOI 10.1074/jbc.M807497200.
   Ferrell JE Jr, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P.
   Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969.
   Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859.
   GURDON JB, 1983, METHOD ENZYMOL, V101, P370.
   Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695.
   Hervieu A, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00086.
   Herynk MH, 2007, J EXP THER ONCOL, V6, P205.
   Hung W, 2001, J BIOL CHEM, V276, P12395, DOI 10.1074/jbc.M010715200.
   Kim MJ, 2008, MOL CANCER RES, V6, P1872, DOI 10.1158/1541-7786.MCR-08-0084.
   Kim SJ, 2003, CLIN CANCER RES, V9, P5161.
   Li YQ, 2005, CANCER RES, V65, P9355, DOI 10.1158/0008-5472.CAN-05-1946.
   López-Hernández E, 1999, FEBS LETT, V451, P284, DOI 10.1016/S0014-5793(99)00595-5.
   Mood K, 2006, J CELL PHYSIOL, V207, P271, DOI 10.1002/jcp.20564.
   Mood K, 2006, MOL BIOL CELL, V17, P3717, DOI 10.1091/mbc.E06-03-0244.
   NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550.
   OPRESKO LK, 1990, J CELL BIOL, V111, P1661, DOI 10.1083/jcb.111.4.1661.
   PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2.
   Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Rosário M, 2003, TRENDS CELL BIOL, V13, P328, DOI 10.1016/S0962-8924(03)00104-1.
   Sam MR, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-69.
   Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005.
   Touyz RM, 2001, HYPERTENSION, V38, P56, DOI 10.1161/01.HYP.38.1.56.
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012.
   Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551.
   Turkson J, 1999, MOL CELL BIOL, V19, P7519.
   UNGER TF, 1992, MOL CELL BIOL, V12, P5485, DOI 10.1128/MCB.12.12.5485.
   Westhoff MA, 2004, MOL CELL BIOL, V24, P8113, DOI 10.1128/MCB.24.18.8113-8133.2004.
   Wojcik EJ, 2006, ONCOGENE, V25, P2773, DOI 10.1038/sj.onc.1209306.
   Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200.
   Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y.
   Zhou B, 2002, J BIOL CHEM, V277, P31818, DOI 10.1074/jbc.M203969200.},
Number-of-Cited-References = {47},
Times-Cited = {4},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {3},
Journal-ISO = {FEBS Lett.},
Doc-Delivery-Number = {WS5SD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000705529900001},
DA = {2026-02-04},
}

@article{ WOS:000708436200003,
Author = {Yuko, Antonia Elizabeth and Rigaud, Vagner Oliveira Carvalho and Kurian,
   Justin and Lee, Ji H. and Kasatkin, Nicole and Behanan, Michael and
   Wang, Tao and Luchesse, Anna Maria and Mohsin, Sadia and Koch, Walter J.
   and Wang, Hong and Khan, Mohsin},
Title = {LIN28a induced metabolic and redox regulation promotes cardiac cell
   survival in the heart after ischemic injury},
Journal = {REDOX BIOLOGY},
Year = {2021},
Volume = {47},
Month = {NOV},
Abstract = {Rationale: Cell-based therapeutics have been extensively used for
   cardiac repair yet underperform due to inability of the donated cells to
   survive in near anoxia after cardiac injury. Cellular metabolism is
   linked to maintenance of cardiac stem cell (CSC) renewal, proliferation
   and survival. Ex vivo expansion alters (CSC) metabolism increasing
   reliance on oxygen dependent respiration. Whether promoting `metabolic
   flexibility' in CSCs augments their ability to survive in near anoxia
   and repair the heart after injury remains untested.
   Objective: Determine the effect of LIN28a induced metabolic flexibility
   on cardiac tissue derived stem like cell (CTSC) survival and repair
   after cardiac injury.
   Methods and results: LIN28a expression coincides during heart
   development but is lost in adult CTSCs. Reintroduction of LIN28a in
   adult CTSC (CTSC-LIN) increased proliferation, survival, expression of
   pluripotency genes and reduced senescence compared to control
   (CTSC-GFP). Metabolomic analysis show glycolytic intermediates
   upregulated in CTSC-LIN together with increased lactate production,
   pyruvate kinase activity, glucose uptake, ECAR and expression of
   glycolytic enzymes compared to CTSC-GFP. Additionally, CTSC-LIN showed
   significantly reduced ROS generation and increase antioxidant markers.
   In response to H2O2 induced oxidative stress, CTSC-LIN showed increased
   survival and expression of glycolytic genes. LIN28a salutary effects on
   CTSCs were linked to PDK1/let-7 signaling pathway with loss of PDK1 or
   alteration of let-7 abrogating LIN28a effects. Following transplantation
   in the heart after myocardial infarction (MI), CTSC-LIN showed 6\%
   survival rate at day 7 after injection compared to control cells
   together with increased proliferation and significant increase in
   cardiac structure and function 8 weeks after MI. Finally, CSTC-LIN
   showed enhanced ability to secrete paracrine factors under hypoxic
   conditions and ability to promote cardiomyocyte proliferation following
   ischemic cardiac injury.
   Conclusions: LIN28a modification promotes metabolic flexibility in CTSCs
   enhancing proliferation and survival post transplantation including
   ability to repair the heart after myocardial injury.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Khan, M (Corresponding Author), Temple Univ, Dept Physiol, Lewis Katz Sch Med, Ctr Metab Dis Res, 3500 N Broad St,MERB 454, Philadelphia, PA 19140 USA.
   Yuko, Antonia Elizabeth; Rigaud, Vagner Oliveira Carvalho; Kurian, Justin; Lee, Ji H.; Kasatkin, Nicole; Behanan, Michael; Wang, Hong; Khan, Mohsin, Ctr Metab Dis Res, Atlanta, GA USA.
   Wang, Tao; Mohsin, Sadia, Cardiovasc Res Inst CVRC, Boston, MA USA.
   Luchesse, Anna Maria; Koch, Walter J., Temple Univ, Ctr Translat Med CTM, LKSOM, Philadelphia, PA 19140 USA.
   Mohsin, Sadia, Temple Univ, Dept Pharmacol, LKSOM, Philadelphia, PA 19140 USA.
   Khan, Mohsin, Temple Univ, Dept Physiol, LKSOM, Philadelphia, PA 19140 USA.},
DOI = {10.1016/j.redox.2021.102162},
EarlyAccessDate = {OCT 2021},
Article-Number = {102162},
ISSN = {2213-2317},
Keywords = {Metabolism; Myocardial ischemia; Cell therapy; Redox regulation;
   Survival; Oxidative stress},
Keywords-Plus = {MESENCHYMAL STEM-CELLS; MYOCARDIAL-INFARCTION; PROGENITOR CELLS; REPAIR;
   ABILITY; ACTIVATION; EXOSOMES},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {Mohsin.khan@temple.edu},
Affiliations = {Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University},
ResearcherID-Numbers = {Wang, Tao/JFJ-3720-2023
   Oliveira Carvalho Rigaud, Vagner/I-4124-2013
   Koch, Walter/LKK-1594-2024
   },
ORCID-Numbers = {Oliveira Carvalho Rigaud, Vagner/0000-0002-1194-9380
   Yuko, Antonia/0000-0003-0819-8026
   Kasatkin, Nicole/0000-0001-6094-4079
   Koch, Walter/0000-0002-8522-530X
   Lee, Ji Hyun/0000-0002-9954-6825},
Funding-Acknowledgement = {National Institute of Health {[}HL135177, H1801]; WW Smith Charitable
   Trust;  {[}HL137850];  {[}15SDG25550038]},
Funding-Text = {We thank all members of the Khan laboratory for their valuable
   discussions as well Temple Flow Cytometry core. This work was supported
   by National Institute of Health grant HL135177 and H1801 WW Smith
   Charitable Trust to M. Khan and HL137850 and 15SDG25550038 to S. Mohsin.},
Cited-References = {Ali M, 2015, MOL CELL BIOCHEM, V410, P267, DOI 10.1007/s11010-015-2560-6.
   Beegle J, 2015, STEM CELLS, V33, P1818, DOI 10.1002/stem.1976.
   Bergmann O, 2015, CELL, V161, P1566, DOI 10.1016/j.cell.2015.05.026.
   Borden A, 2019, CIRC RES, V125, P14, DOI 10.1161/CIRCRESAHA.118.314223.
   Choudhery MS, 2012, J CELL MOL MED, V16, P2518, DOI 10.1111/j.1582-4934.2012.01568.x.
   de Soysa TY, 2019, NATURE, V572, P120, DOI 10.1038/s41586-019-1414-x.
   Derlet A, 2016, STEM CELLS, V34, P2236, DOI 10.1002/stem.2394.
   Dow J, 2005, CARDIOVASC RES, V67, P301, DOI 10.1016/j.cardiores.2005.04.011.
   Duran JM, 2013, CIRC RES, V113, P539, DOI 10.1161/CIRCRESAHA.113.301202.
   Forrester JS, 2007, AM J CARDIOL, V99, P732, DOI 10.1016/j.amjcard.2006.09.125.
   Haider HK, 2008, CIRC RES, V103, P1300, DOI 10.1161/CIRCRESAHA.108.186742.
   Han D, 2017, ONCOTARGET, V8, P64853, DOI 10.18632/oncotarget.17614.
   Hong KU, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0346-0.
   Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772.
   Katare R, 2010, J MOL CELL CARDIOL, V49, P625, DOI 10.1016/j.yjmcc.2010.05.014.
   Khan M, 2015, CIRC RES, V117, P52, DOI 10.1161/CIRCRESAHA.117.305990.
   Khan M, 2014, MOL THER, V22, P178, DOI 10.1038/mt.2013.200.
   Khan M, 2013, CIRC RES, V112, P476, DOI 10.1161/CIRCRESAHA.112.280735.
   Kimura W, 2012, CARDIOVASC DIAGN THE, V2, P278, DOI 10.3978/j.issn.2223-3652.2012.12.02.
   Kishore R, 2016, CIRC RES, V118, P330, DOI 10.1161/CIRCRESAHA.115.307654.
   Kurian J, 2021, STEM CELL TRANSL MED, V10, P144, DOI 10.1002/sctm.20-0123.
   Laugwitz KL, 2005, NATURE, V433, P647, DOI 10.1038/nature03215.
   Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212.
   Martin CM, 2004, DEV BIOL, V265, P262, DOI 10.1016/j.ydbio.2003.09.028.
   Mohsin S, 2012, J AM COLL CARDIOL, V60, P1278, DOI 10.1016/j.jacc.2012.04.047.
   Moussaieff A, 2015, CELL METAB, V21, P392, DOI 10.1016/j.cmet.2015.02.002.
   Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708.
   Rigaud VOC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112490.
   Rigaud VOC, 2021, J MOL CELL CARDIOL, V154, P1, DOI 10.1016/j.yjmcc.2020.12.017.
   Salazar-Noratto GE, 2020, STEM CELLS, V38, P22, DOI 10.1002/stem.3079.
   Sanada F, 2014, CIRC RES, V114, P41, DOI 10.1161/CIRCRESAHA.114.302500.
   Shyh-Chang N, 2017, GENE DEV, V31, P336, DOI 10.1101/gad.293167.116.
   Shyh-Chang N, 2013, CELL, V155, P778, DOI 10.1016/j.cell.2013.09.059.
   Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005.
   Simpson DL, 2012, CIRCULATION, V126, pS46, DOI 10.1161/CIRCULATIONAHA.111.084699.
   Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209.
   de Carvalho AETS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15656-3.
   Ustianenko D, 2018, MOL CELL, V71, P271, DOI 10.1016/j.molcel.2018.06.029.
   van Berlo JH, 2014, NATURE, V509, P337, DOI 10.1038/nature13309.
   Wang WE, 2013, CIRC RES, V113, P288, DOI 10.1161/CIRCRESAHA.113.300929.
   Wu Q, 2019, BMC MOL CELL BIOL, V20, DOI 10.1186/s12860-019-0207-2.
   Yuan K, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0166-2.
   Zhang J, 2012, CELL STEM CELL, V11, P589, DOI 10.1016/j.stem.2012.10.005.
   Zwetsloot PP, 2016, CIRC RES, V118, P1223, DOI 10.1161/CIRCRESAHA.115.307676.},
Number-of-Cited-References = {44},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Redox Biol.},
Doc-Delivery-Number = {WI5YS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000708436200003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000708735400017,
Author = {Sestito, Simona and Bacci, Andrea and Chiarugi, Sara and Runfola,
   Massimiliano and Gado, Francesca and Margheritis, Eleonora and Gul,
   Sheraz and Riveiro, Maria E. and Vazquez, Ramiro and Huguet, Samuel and
   Manera, Clementina and Rezai, Keyvan and Garau, Gianpiero and
   Rapposelli, Simona},
Title = {Development of potent dual PDK1/AurA kinase inhibitors for cancer
   therapy: Lead-optimization, structural insights, and ADME-Tox profile},
Journal = {EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY},
Year = {2021},
Volume = {226},
Month = {DEC 15},
Abstract = {We report the synthesis of novel first-in-class 2-oxindole-based
   derivatives as dual PDK1-AurA kinase inhibitors as a novel strategy to
   treat Ewing sarcoma. The most potent compound 12 is suitable for
   progression to in vivo studies. The specific attributes of 12 included
   nanomolar inhibitory potency against both phosphoinositide-dependent
   kinase-1 (PDK1) and Aurora A (AurA) kinase, with acceptable in vitro
   ADME-Tox properties (cytotoxicity in 2 healthy and 14 hematological and
   solid cancer cell-lines; inhibition of PDE4C1, SIRT7, HDAC4, HDAC6,
   HDAC8, HDAC9, AurB, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and hERG). X-ray
   crystallography and docking studies led to the identification of the key
   AurA and PDK1/ 12 interactions. Finally, in vitro drug-intake kinetics
   and in vivo PK appear to indicate that these compounds are attractive
   lead-structures for the design and synthesis of PDK1/AurA dual-target
   molecules to further investigate the in vivo efficacy against Ewing
   Sarcoma. (C) 2021 Published by Elsevier Masson SAS.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Rapposelli, S (Corresponding Author), Univ Pisa, Dept Pharm, I-56126 Pisa, Italy.
   Garau, G (Corresponding Author), IIT NEST Ist Italian Tecnol, BioStruct Lab, I-56127 Pisa, Italy.
   Riveiro, ME (Corresponding Author), Early Drug Dev Grp, Boulogne, France.
   Sestito, Simona; Bacci, Andrea; Runfola, Massimiliano; Gado, Francesca; Manera, Clementina; Rapposelli, Simona, Univ Pisa, Dept Pharm, I-56126 Pisa, Italy.
   Chiarugi, Sara; Margheritis, Eleonora; Garau, Gianpiero, IIT NEST Ist Italian Tecnol, BioStruct Lab, I-56127 Pisa, Italy.
   Chiarugi, Sara, Scuola Normale Super Pisa, NEST, Piazza San Silvestro 12, I-56127 Pisa, Italy.
   Gul, Sheraz, Fraunhofer Inst Translat Med \& Pharmacol, D-22525 Hamburg, Germany.
   Gul, Sheraz, Fraunhofer Cluster Excellence Immune Mediated Dis, Hamburg Site, D-22525 Hamburg, Germany.
   Riveiro, Maria E.; Vazquez, Ramiro, Early Drug Dev Grp, Boulogne, France.
   Huguet, Samuel; Rezai, Keyvan, Curie Inst Rene Huguenin Hosp, Radiopharmacol Dept, St Cloud, France.
   Rapposelli, Simona, Pisa Univ, CISUP, Ctr Instrumentat Sharing, Lungarno Pacinotti 43, I-56126 Pisa, Italy.},
DOI = {10.1016/j.ejmech.2021.113895},
EarlyAccessDate = {OCT 2021},
Article-Number = {113895},
ISSN = {0223-5234},
EISSN = {1768-3254},
Keywords = {Kinases; Dual inhibitors; PDK1; Aurora A; Multitarget compounds; Ewing
   sarcoma},
Keywords-Plus = {AURORA KINASE; PDK1},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal},
Author-Email = {eugenia.riveiro@e2dg.com
   gianpiero.garau@iit.it
   simona.rapposelli@unipi.it},
Affiliations = {University of Pisa; Scuola Normale Superiore di Pisa; Rene Huguenin
   Hospital; University of Pisa},
ResearcherID-Numbers = {Garau, Gianpiero/AAM-4234-2021
   SESTITO, SIMONA/AAE-6210-2019
   GADO, FRANCESCA/GQO-8927-2022
   Rapposelli, Simona/D-1595-2010
   Runfola, Massimiliano/KBC-7057-2024
   Margheritis, Eleonora/W-4750-2019},
ORCID-Numbers = {Garau, Gianpiero/0000-0001-9473-5814
   SESTITO, SIMONA/0000-0002-6173-525X
   GADO, FRANCESCA/0000-0003-2971-0834
   Rapposelli, Simona/0000-0003-0146-6358
   Runfola, Massimiliano/0000-0002-3608-2031
   Chiarugi, Sara/0000-0003-0131-8275
   },
Funding-Acknowledgement = {COST action {[}CA15135]; International Society For Drug Development
   (ISDD srl, Milan); Synchrotron ELETTRA (Trieste, Italy)},
Funding-Text = {The authors thank the COST action CA15135 (Multitarget Paradigm for
   Innovative Ligand Identification in the Drug Discovery Process MuTaLig)
   for support the working experience of MR at the Fraunhofer-IME DE
   (Hamburg, Germany). We are grateful for the support of Prof. Giuseppe
   Saccomanni in HPLC analysis. We also thank International Society For
   Drug Development (ISDD srl, Milan) for financial support. We are
   grateful for the support of the Synchrotron ELETTRA (Trieste, Italy),
   and would like to thank Dr Nicola Demitri for assistance at the XRD2
   beamline during the X-ray data collection.},
Cited-References = {Albanese SK, 2018, BIOCHEMISTRY-US, V57, P4675, DOI 10.1021/acs.biochem.7b01081.
   Bayliss R, 2017, FEBS J, V284, P2947, DOI 10.1111/febs.14069.
   Booth L, 2016, ONCOTARGET, V7, P40398, DOI 10.18632/oncotarget.9752.
   Casari I, 2019, CANCERS, V11, DOI 10.3390/cancers11111695.
   Cote Ila L., 2017, Current Opinion in Toxicology, V6, P71, DOI {[}10.1016/j.cotox.2017.09.002, 10.1016/j.cotox.2017.09.002].
   Coumar MS, 2009, J MED CHEM, V52, P1050, DOI 10.1021/jm801270e.
   Daniele S, 2017, ACS CHEM NEUROSCI, V8, P100, DOI 10.1021/acschemneuro.6b00251.
   Daniele S, 2015, SCI REP-UK, V5, DOI 10.1038/srep09956.
   Du RJ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01305-3.
   Emmanouilidi A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1191-2.
   Erlanson DA, 2011, BIOORG MED CHEM LETT, V21, P3078, DOI 10.1016/j.bmcl.2011.03.032.
   Evans WE, 1999, SCIENCE, V286, P487, DOI 10.1126/science.286.5439.487.
   Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gul S, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0342-6.
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672.
   Lake EW, 2018, P NATL ACAD SCI USA, V115, pE11894, DOI 10.1073/pnas.1811158115.
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471.
   Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599.
   Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463.
   Park NH, 2018, J AM CHEM SOC, V140, P4244, DOI 10.1021/jacs.7b11468.
   Potterton L, 2018, ACTA CRYSTALLOGR D, V74, P68, DOI 10.1107/S2059798317016035.
   Roskoski R, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104609.
   Runfola M, 2020, DATA BRIEF, V29, DOI 10.1016/j.dib.2020.105206.
   Runfola M, 2020, EUR J MED CHEM, V188, DOI 10.1016/j.ejmech.2019.112006.
   Seeliger MA, 2005, PROTEIN SCI, V14, P3135, DOI 10.1110/ps.051750905.
   Sestito S., 2019, PROCEEDINGS, V22, P45.
   Sestito S, 2016, EUR J MED CHEM, V118, P47, DOI 10.1016/j.ejmech.2016.04.003.
   Sun DJ, 2020, EUR J MED CHEM, V188, DOI 10.1016/j.ejmech.2019.112025.
   Sun L, 1998, J MED CHEM, V41, P2588, DOI 10.1021/jm980123i.
   WHO, 2020, WHO report on cancer: setting priorities, investing wisely and providing care for all.},
Number-of-Cited-References = {31},
Times-Cited = {7},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Eur. J. Med. Chem.},
Doc-Delivery-Number = {WJ0IU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)},
Unique-ID = {WOS:000708735400017},
DA = {2026-02-04},
}

@article{ WOS:000710234500005,
Author = {Sun, Lili and Yang, Zhigang and Zhao, Wei and Chen, Qin and Bai, Haiying
   and Wang, Shanshan and Yang, Li and Bi, Chunmei and Shi, Yanbin and Liu,
   Yingqian},
Title = {Integrated lipidomics, transcriptomics and network pharmacology analysis
   to reveal the mechanisms of Danggui Buxue Decoction in the treatment of
   diabetic nephropathy in type 2 diabetes mellitus},
Journal = {JOURNAL OF ETHNOPHARMACOLOGY},
Year = {2022},
Volume = {283},
Month = {JAN 30},
Abstract = {Ethnopharmacological relevance: Danggui Buxue Decoction (DBT) is
   classical prescriptions, which contains two Traditional Chinese
   Medicines of Angelicae sinensis radix and Astragali radix. According to
   the preliminary work of our laboratory and numerous studies, it has been
   found that DBT has a therapeutic effect on diabetic ne-phropathy (DN).
   However, the mechanisms underlying its action remain unclear. Aim of the
   study: The aim of this study was to evaluate the impact of DBT on kidney
   disease in diabetic mice and further explore its protective mechanism.
   Methods: DN mice model was induced by high-fat fodder and streptozotocin
   (STZ). Qualitative and quantitative analysis of 6 compounds in DBT was
   carried out by HPLC, including calycosin-7-glucoside, ferulic acid,
   ononin, calycosin, formononetin, and levostilide A. Hematoxylin-Eosin
   (HE) staining was used to determine the degree of kidney pathological
   damage. The UPLC-Q Exactive MS technique was used to analyze the lipids
   metabolism profile of kidneys samples and multiple statistical analysis
   methods were used to screen and identify biomarkers. Transcriptomics
   analyses were carried out using RNAseq. The possible molecular mechanism
   was unraveled by network pharmacology. Results: Thirty-one significantly
   altered lipid metabolites were identified in the model group comparing
   with the control group. DBT improved aberrant expression of several
   pathways related to lipidomics, including glycer-ophospholipid
   metabolism and sphingolipid metabolism. Comprehensive analysis indicated
   that DBT interven-tion reduced the content of Cers,
   phosphatidylethanolamines and phosphatidylcholines in mouse kidneys by
   downregulating the transcription level of Degs2 and Cers, reducing lipid
   accumulation and promoting Akt phosphorylation by upregulating the
   expression of Acers and Pdk1. Network pharmacology analysis showed that
   components in DBT, such as kaempferol, ferulic acid and astragaloside
   IV, could be responsible for the phar-macological activity of DN by
   regulating the AGE-RAGE, PI3K/Akt, MAPK and NF-kappa B signaling
   pathways in diabetic complications. Conclusions: These results showed
   that DBT may improve DN by affecting insulin resistance, chronic
   inflam-mation and lipid accumulation.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, ZG (Corresponding Author), Lanzhou Univ, Sch Pharm, 199 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.
   Sun, Lili; Yang, Zhigang; Zhao, Wei; Chen, Qin; Bai, Haiying; Wang, Shanshan; Yang, Li; Bi, Chunmei; Shi, Yanbin; Liu, Yingqian, Lanzhou Univ, Sch Pharm, 199 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China.},
DOI = {10.1016/j.jep.2021.114699},
EarlyAccessDate = {OCT 2021},
Article-Number = {114699},
ISSN = {0378-8741},
EISSN = {1872-7573},
Keywords = {Diabetic nephropathy; Lipidomics; Transcriptomics; Network pharmacology;
   Danggui buxue decoction},
Keywords-Plus = {TANG},
Research-Areas = {Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine},
Web-of-Science-Categories  = {Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy},
Author-Email = {yangzg@lzu.edu.cn},
Affiliations = {Lanzhou University},
ResearcherID-Numbers = {WANG, SHANSHAN/AAT-7956-2021},
ORCID-Numbers = {Yang, Zhigang/0000-0003-0662-6496
   },
Cited-References = {Afshinnia F, 2018, SEMIN NEPHROL, V38, P127, DOI 10.1016/j.semnephrol.2018.01.004.
   Nguyen A, 2017, CURR OPIN BIOTECH, V43, P96, DOI 10.1016/j.copbio.2016.10.003.
   Blouin CM, 2010, DIABETES, V59, P600, DOI 10.2337/db09-0897.
   Choi R, 2011, EXP MOL MED, V43, P676, DOI 10.3858/emm.2011.43.12.078.
   Feng YC, 2019, INT J BIOL MACROMOL, V132, P1001, DOI 10.1016/j.ijbiomac.2019.03.242.
   Gerich JE, 1999, DIABETES OBES METAB, V1, P257, DOI 10.1046/j.1463-1326.1999.00027.x.
   Gong LL, 2020, J PHARMACEUT BIOMED, V177, DOI 10.1016/j.jpba.2019.112848.
   Hua YL, 2019, CHIN J NAT MEDICINES, V17, P275, DOI 10.1016/S1875-5364(19)30031-7.
   Hussain S, 2021, CLIN EPIDEMIOL GLOB, V9, P2, DOI 10.1016/j.cegh.2020.05.016.
   Jung SH, 2019, BMC COMPLEM ALTERN M, V19, DOI {[}10.1186/s12906-019-2460-5, 10.1186/s12879-019-4016-1, 10.1186/s12906-019-2483-y].
   Kurz J, 2019, TRENDS MOL MED, V25, P20, DOI 10.1016/j.molmed.2018.10.009.
   Lee JH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112850.
   Li L, 2017, FUND CLIN PHARMACOL, V31, P17, DOI 10.1111/fcp.12232.
   Liu JY, 2016, CHIN MED-UK, V11, DOI 10.1186/s13020-016-0075-z.
   Luan PP, 2018, FASEB J, V32, P1070, DOI 10.1096/fj.201700511RR.
   Maceyka M, 2014, NATURE, V510, P58, DOI 10.1038/nature13475.
   Mao Q, 2019, EXP THER MED, V18, P3053, DOI 10.3892/etm.2019.7887.
   Markgraf DF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111841.
   Matboli M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02320-z.
   Mitrofanova A, 2019, AM J PHYSIOL-RENAL, V317, pF1241, DOI 10.1152/ajprenal.00379.2019.
   Persson P, 2017, CURR OPIN NEPHROL HY, V26, P345, DOI 10.1097/MNH.0000000000000341.
   Sanajou D, 2018, EUR J PHARMACOL, V833, P158, DOI 10.1016/j.ejphar.2018.06.001.
   Sivaskandarajah GA, 2012, DIABETES, V61, P2958, DOI 10.2337/db11-1655.
   Sun Li-Li, 2020, Zhongguo Zhong Yao Za Zhi, V45, P636, DOI 10.19540/j.cnki.cjcmm.20191105.202.
   Sun LJ, 2002, J BIOL CHEM, V277, P18919, DOI 10.1074/jbc.M110650200.
   Tang D, 2011, PLANTA MED, V77, P729, DOI 10.1055/s-0030-1250628.
   Tian HP, 2016, J ETHNOPHARMACOL, V191, P206, DOI 10.1016/j.jep.2016.05.062.
   Tzeng Thing-Fong, 2013, J Tradit Complement Med, V3, P152, DOI 10.4103/2225-4110.114893.
   Xiang X, 2019, PHARMACOL RES, V139, P26, DOI 10.1016/j.phrs.2018.10.030.
   Yang KB, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.587995.
   Yin J, 2016, J CHROMATOGR B, V1033, P428, DOI 10.1016/j.jchromb.2016.08.042.
   Zhang R, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181740.
   Zhang YW, 2006, EXP CLIN ENDOCR DIAB, V114, P563, DOI 10.1055/s-2006-948307.
   Zhang YY, 2019, MED SCI MONITOR, V25, P1671, DOI 10.12659/MSM.915242.
   Zhang YW, 2006, HORM METAB RES, V38, P82, DOI 10.1055/s-2006-925118.},
Number-of-Cited-References = {35},
Times-Cited = {68},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {146},
Journal-ISO = {J. Ethnopharmacol.},
Doc-Delivery-Number = {WL2ID},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000710234500005},
DA = {2026-02-04},
}

@article{ WOS:000827904100003,
Author = {Kobayashi, Hiroshi and Shigetomi, Hiroshi and Imanaka, Shogo},
Title = {Nonhormonal therapy for endometriosis based on energy metabolism
   regulation},
Journal = {REPRODUCTION AND FERTILITY},
Year = {2021},
Volume = {2},
Number = {4},
Pages = {C42-C57},
Month = {OCT},
Abstract = {Ovarian function suppression is the current pharmacotherapy of
   endometriosis with limited benefit and adverse effects. New therapeutic
   strategies other than hormonal therapy are developed based on the
   molecular mechanisms involved in the hypoxic and oxidative stress
   environments and metabolism unique to endometriosis. A literature search
   was performed between January 2000 and March 2021 in the PubMed database
   using a combination of specific terms. Endometriosis-associated
   metabolic changes have been organized into four hallmarks: (1) glucose
   uptake, (2) aerobic glycolysis, (3) lactate production and accumulation,
   and (4) metabolic conversion from mitochondrial oxidative
   phosphorylation (OXPHOS) to aerobic glycolysis. Endometriotic cells
   favor glycolytic metabolism over mitochondrial OXPHOS to produce
   essential energy for cell survival. Hypoxia, a common feature of the
   endometriosis environment, is a key player in this metabolic conversion,
   which may lead to glucose transporter overexpression, pyruvate
   dehydrogenase kinase 1 (PDK1) and lactate dehydrogenase kinase A (LDHA)
   activation, and pyruvate dehydrogenase complex inactivation. Evading
   mitochondrial OXPHOS mitigates excessive generation of reactive oxygen
   species (ROS) that may trigger cell death. Therefore, the coinactivation
   of LDHA and PDK1 can induce the accumulation of mitochondrial ROS by
   converting energy metabolism to mitochondrial OXPHOS, causing
   endometriotic cell death. Metabolic pattern reconstruction in
   endometriotic lesions is a critical factor in cell survival and disease
   progression. One therapeutic strategy that may avoid hormone
   manipulation is focused on mitigating metabolic changes that have been
   detected in cells/tissues from women with endometriosis.
   Lay summary
   The most commonly used medical therapies for endometriosis have
   contraceptives and other side effects associated with hormone
   suppression and are therefore unsuitable for women desiring pregnancy.
   One therapeutic strategy that may avoid hormone manipulation is focused
   on changing metabolic profiles that have been detected in cells/tissues
   from women with endometriosis. Endometriotic cells favor glycolytic
   metabolism over mitochondrial oxidative phosphorylation (OXPHOS) to
   produce essential energy for cell growth. Furthermore, the metabolic
   conversion from mitochondrial OXPHOS to aerobic glycolysis suppresses
   cell death through the reduced generation of reactive oxygen species
   (ROS). This unique metabolic feature of endometriosis is important for
   cell survival and disease progression. Thus, changing the specific
   metabolic switch may increase mitochondrial ROS production, causing
   severe oxidative stress and cell death. This review describes new
   treatments by changing the metabolic profiles of endometriosis.},
Publisher = {BIOSCIENTIFICA LTD},
Address = {STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND},
Type = {Editorial Material},
Language = {English},
Affiliation = {Kobayashi, H (Corresponding Author), Nara Med Univ, Dept Obstet \& Gynecol, Kashihara, Nara, Japan.
   Kobayashi, H (Corresponding Author), MsClin MayOne, Dept Gynecol, Kashihara, Nara, Japan.
   Kobayashi, Hiroshi; Shigetomi, Hiroshi; Imanaka, Shogo, Nara Med Univ, Dept Obstet \& Gynecol, Kashihara, Nara, Japan.
   Kobayashi, Hiroshi; Imanaka, Shogo, MsClin MayOne, Dept Gynecol, Kashihara, Nara, Japan.
   Shigetomi, Hiroshi, Aska Ladies Clin, Nara, Japan.},
DOI = {10.1530/RAF-21-0053},
EISSN = {2633-8386},
Keywords = {endometriosis; glycolysis; hypoxia; metabolism; oxidative
   phosphorylation, Warburg effect},
Keywords-Plus = {OXIDATIVE STRESS; AEROBIC GLYCOLYSIS; FOLLICULAR-FLUID;
   LACTATE-DEHYDROGENASE; STROMAL CELLS; IN-VITRO; EXPRESSION; CANCER;
   DICHLOROACETATE; GROWTH},
Research-Areas = {Reproductive Biology},
Web-of-Science-Categories  = {Reproductive Biology},
Author-Email = {hirokoba@naramed-u.ac.jp},
Affiliations = {Nara Medical University},
ResearcherID-Numbers = {Kobayashi, Hiroshi/AAL-4089-2020},
Funding-Acknowledgement = {Japan Society for the Promotion of Science (JSPS) {[}JP16K11150,
   18K09269, 18K09234]},
Funding-Text = {This work was supported by the Japan Society for the Promotion of
   Science (JSPS), grant numbers JP16K11150, 18K09269, and 18K09234.},
Cited-References = {Anwar S, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188568.
   Arseneault R, 2013, CANCER LETT, V338, P255, DOI 10.1016/j.canlet.2013.03.034.
   Atas E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.583217.
   Atkins HM, 2019, REPROD BIOL ENDOCRIN, V17, DOI 10.1186/s12958-019-0513-8.
   Bahrami A, 2021, LIFE SCI, V272, DOI 10.1016/j.lfs.2021.119230.
   Bakalov V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241122.
   Bamm VV, 2017, FREE RADICAL BIO MED, V112, P494, DOI 10.1016/j.freeradbiomed.2017.08.022.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Chen CL, 2019, FREE RADICAL BIO MED, V136, P22, DOI 10.1016/j.freeradbiomed.2019.03.027.
   Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y.
   Ciscato F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094716.
   Dai YD, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1395-6.
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104.
   Di Tucci C, 2018, GYNECOL ENDOCRINOL, V34, P729, DOI 10.1080/09513590.2018.1462320.
   Dunford EC, 2011, AM J PHYSIOL-REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010.
   Dutta M, 2012, MOL BIOSYST, V8, P3281, DOI 10.1039/c2mb25353d.
   Duzyj CM, 2018, BJOG-INT J OBSTET GY, V125, P1441, DOI 10.1111/1471-0528.15176.
   Ferrero S, 2018, EXPERT OPIN PHARMACO, V19, P1109, DOI 10.1080/14656566.2018.1494154.
   Garon EB, 2014, J CANCER RES CLIN, V140, P443, DOI 10.1007/s00432-014-1583-9.
   Granchi C, 2011, J MED CHEM, V54, P1599, DOI 10.1021/jm101007q.
   Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457.
   Horne AW, 2019, P NATL ACAD SCI USA, V116, P25389, DOI 10.1073/pnas.1916144116.
   Hughes CL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/158490.
   Hunt TK, 2008, ADV EXP MED BIOL, V614, P73, DOI 10.1007/978-0-387-74911-2\_9.
   Ito F, 2017, REPROD SCI, V24, P1493, DOI 10.1177/1933719117704909.
   Iwabuchi T, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/848595.
   Jana SK, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/329058.
   Jodeleit H, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.036210.
   Karaer A, 2019, SYST BIOL REPROD MED, V65, P39, DOI 10.1080/19396368.2018.1478469.
   Kasvandik S, 2016, J PROTEOME RES, V15, P572, DOI 10.1021/acs.jproteome.5b00965.
   Kim BS, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9788.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kobayashi H, 2021, NAT CHEM BIOL, V17, P335, DOI 10.1038/s41589-020-00676-4.
   Kobayashi H, 2021, EUR J OBSTET GYN R B, V258, P103, DOI 10.1016/j.ejogrb.2020.12.044.
   Kobayashi H, 2009, GYNECOL ENDOCRINOL, V25, P39, DOI 10.1080/09513590802366204.
   Koninckx PR, 2019, FERTIL STERIL, V111, P327, DOI 10.1016/j.fertnstert.2018.10.013.
   Korga A, 2019, FEBS OPEN BIO, V9, P959, DOI 10.1002/2211-5463.12628.
   Kornberg MD, 2020, WIRES SYST BIOL MED, V12, DOI 10.1002/wsbm.1486.
   Kwak CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176021.
   Lapel M, 2017, AM J PHYSIOL-CELL PH, V312, pC56, DOI 10.1152/ajpcell.00250.2016.
   Laschke MW, 2012, HUM REPROD UPDATE, V18, P682, DOI 10.1093/humupd/dms026.
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107.
   Lee HC, 2019, REPROD SCI, V26, P734, DOI 10.1177/1933719118789513.
   Leow HW, 2021, PILOT FEASIBILITY ST, V7, DOI 10.1186/s40814-021-00797-0.
   Li HM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0481-1.
   Li SN, 2017, BRIT J CANCER, V117, P1518, DOI 10.1038/bjc.2017.323.
   Liao TL, 2015, ANN NY ACAD SCI, V1350, P52, DOI 10.1111/nyas.12872.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Lim SA, 2021, CANCERS, V13, DOI 10.3390/cancers13081904.
   Lin X, 2018, ENDOCRINOLOGY, V159, P1630, DOI 10.1210/en.2017-03227.
   Liu F, 2013, CLIN EXP OBSTET GYN, V40, P372.
   Marianna S, 2017, MOL BIOSYST, V13, P1213, DOI 10.1039/c7mb00181a.
   Matos L, 2009, MOL HUM REPROD, V15, P411, DOI 10.1093/molehr/gap034.
   McKinnon B, 2014, J MOL ENDOCRINOL, V52, P169, DOI 10.1530/JME-13-0194.
   McKinnon BD, 2016, HUM REPROD UPDATE, V22, P382, DOI 10.1093/humupd/dmv060.
   Menezo YJR, 2016, REPROD BIOMED ONLINE, V33, P668, DOI 10.1016/j.rbmo.2016.09.006.
   Miao P, 2013, IUBMB LIFE, V65, P904, DOI 10.1002/iub.1216.
   Muscoli C, 2003, BRIT J PHARMACOL, V140, P445, DOI 10.1038/sj.bjp.0705430.
   Oermann EK, 2012, SEMIN CELL DEV BIOL, V23, P370, DOI 10.1016/j.semcdb.2012.01.013.
   Öner-Iyidogan Y, 2004, GYNECOL OBSTET INVES, V57, P214, DOI 10.1159/000076691.
   Pocate-Cheriet K, 2020, REPROD BIOMED ONLINE, V41, P1023, DOI 10.1016/j.rbmo.2020.09.002.
   Pruett BS, 2020, SCHIZOPHR RES, V223, P29, DOI 10.1016/j.schres.2020.09.003.
   Qi XC, 2014, REPROD BIOMED ONLINE, V29, P761, DOI 10.1016/j.rbmo.2014.09.004.
   Reckzeh ES, 2019, CELL CHEM BIOL, V26, P1214, DOI 10.1016/j.chembiol.2019.06.005.
   Rytkönen KT, 2020, REPRODUCTION, V160, P39, DOI 10.1530/REP-19-0615.
   Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120.
   Santanam N, 2002, ANN NY ACAD SCI, V955, P183, DOI 10.1111/j.1749-6632.2002.tb02779.x.
   Saunders PTK, 2021, CELL, V184, P2807, DOI 10.1016/j.cell.2021.04.041.
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9.
   Tamada M, 2012, CLIN CANCER RES, V18, P5554, DOI 10.1158/1078-0432.CCR-12-0859.
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079.
   Tian DD, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.526.
   Vinatier D, 2000, EUR J OBSTET GYN R B, V91, P113, DOI 10.1016/S0301-2115(99)00263-8.
   Wang HB, 2019, J BIOL CHEM, V294, P5466, DOI 10.1074/jbc.RA118.005200.
   Wang YX, 2021, REPROD BIOL ENDOCRIN, V19, DOI 10.1186/s12958-021-00770-9.
   Wang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056631.
   Wilson RB, 2018, PLEURA PERITONEUM, V3, DOI {[}10.1515/pap-2018-0103, 10.1515/pp-2018-0103].
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108.
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003.
   Wu MH, 2019, J OBSTET GYNAECOL RE, V45, P532, DOI 10.1111/jog.13900.
   Yi M, 2019, MOL METAB, V20, P1, DOI 10.1016/j.molmet.2018.11.013.
   Young VJ, 2016, MOL HUM REPROD, V22, P648, DOI 10.1093/molehr/gaw045.
   Young VJ, 2014, J CLIN ENDOCR METAB, V99, P3450, DOI 10.1210/jc.2014-1026.
   Zheng JY, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12276.
   Zhou J, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/9864963.
   Zhou YY, 2020, INT J CANCER, V147, P139, DOI 10.1002/ijc.32756.
   Zhu XL, 2017, GASTROENT RES PRACT, V2017, DOI 10.1155/2017/5469597.
   Zondervan KT, 2020, NEW ENGL J MED, V382, P1244, DOI 10.1056/NEJMra1810764.
   Zubrzycka A, 2015, CURR MOL MED, V15, P697, DOI 10.2174/1566524015666150921105218.},
Number-of-Cited-References = {91},
Times-Cited = {34},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Reprod. Fertility},
Doc-Delivery-Number = {3B4HQ},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000827904100003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000712318000001,
Author = {Mercurio, Laura and Morelli, Martina and Scarponi, Claudia and
   Scaglione, Giovanni Luca and Pallotta, Sabatino and Albanesi, Cristina
   and Madonna, Stefania},
Title = {PI3Kδ Sustains Keratinocyte Hyperproliferation and Epithelial
   Inflammation: Implications for a Topically Druggable Target in Psoriasis},
Journal = {CELLS},
Year = {2021},
Volume = {10},
Number = {10},
Month = {OCT},
Abstract = {The phosphatidylinositol 3-kinase (PI3K)-dependent signaling pathway is
   aberrantly activated in psoriatic lesions and contributes to disease
   pathogenesis. Among PI3Ks enzymes, PI3K alpha, beta, and delta isoforms
   are known to bind the p85 regulatory subunit and mediate activation of
   AKT and other downstream effectors. In this study, we deepened our
   understanding of the expression and function of PI3K delta in skin
   lesions of patients affected by psoriasis. For the first time, we found
   that PI3K delta is overexpressed in psoriatic plaques, and its
   expression is not only confined to infiltrating immune cells but also
   accumulates in proliferating keratinocytes of the epidermal basal layer.
   We investigated the function of PI3K delta in psoriatic skin by
   evaluating the impact of seletalisib, a newly developed selective PI3K
   delta inhibitor, in both in vitro and in vivo experimental models of
   psoriasis. Of note, we found that PI3K delta sustains keratinocyte
   hyperproliferation and impaired terminal differentiation induced by
   IL-22, as well as induces epithelial inflammation and resistance to
   apoptosis mediated by TNF-alpha in human keratinocytes. Mechanistically,
   PI3K delta promotes PDK1 phosphorylation and signals through
   AKT-dependent or -independent pathways. It is worth mentioning that PI3K
   delta inhibition by seletalisib attenuates the severity of psoriasiform
   phenotype induced in the Imiquimod-induced mouse model of psoriasis by
   restoring the physiological proliferation and differentiation programs
   in epidermal keratinocytes and contrasting the cutaneous inflammatory
   responses. Therefore, we suggest PI3K delta as a potential topically
   druggable target in psoriasis and skin diseases characterized by
   epidermal hyperproliferation and skin inflammation.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Mercurio, L (Corresponding Author), Lab Expt Immunol, Ist Dermopatico dellImmacolata IDI IRCCS, Via Monti Creta 104, I-00167 Rome, Italy.
   Mercurio, Laura; Morelli, Martina; Scarponi, Claudia; Scaglione, Giovanni Luca; Albanesi, Cristina; Madonna, Stefania, Lab Expt Immunol, Ist Dermopatico dellImmacolata IDI IRCCS, Via Monti Creta 104, I-00167 Rome, Italy.
   Pallotta, Sabatino; Albanesi, Cristina; Madonna, Stefania, Integrated Ctr Res Psoriasis CRI PSO, Ist Dermopatico dellImmacolata IDI IRCCS, Via Monti Creta 104, I-00167 Rome, Italy.},
DOI = {10.3390/cells10102636},
Article-Number = {2636},
EISSN = {2073-4409},
Keywords = {PI3K isoforms; PI3K delta; AKT; cytokines; psoriasis;
   hyperproliferation; seletalisib; skin inflammation; keratinocytes},
Keywords-Plus = {NF-KAPPA-B; GENE-EXPRESSION; UP-REGULATION; AKT; GROWTH; PI3K;
   ACTIVATION; ISOFORM; IMMUNE; CELLS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {martina.morelli@idi.it},
ResearcherID-Numbers = {Pallotta, Sabatino/AAA-6996-2019
   Scaglione, Giovanni Luca/NJT-4309-2025
   Mercurio, Laura/K-2750-2018
   Albanesi, Cristina/K-4699-2016
   Madonna, Stefania/AAC-3381-2022
   Morelli, Martina/AAA-1982-2019},
ORCID-Numbers = {Scaglione, Giovanni Luca/0000-0001-5622-7843
   Mercurio, Laura/0000-0003-0629-1729
   scarponi, claudia/0000-0002-2323-8519
   Albanesi, Cristina/0000-0002-7537-6833
   Madonna, Stefania/0000-0003-0585-6783
   Morelli, Martina/0000-0001-7299-2393},
Funding-Acknowledgement = {Italian Ministry of Health {[}GR-2013-02355700]},
Funding-Text = {This work was supported by grants founded by Italian Ministry of Health
   (Young Researcher Project Grant GR-2013-02355700, P.I. Stefania Madonna,
   and Ricerca Corrente 2021).},
Cited-References = {Albanesi C, 2010, CURR DRUG METAB, V11, P210, DOI 10.2174/138920010791196328.
   Albanesi C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01549.
   Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5.
   Allen RA, 2017, J PHARMACOL EXP THER, V361, P429, DOI 10.1124/jpet.116.237347.
   Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947.
   Bénistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871.
   Bigler J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052242.
   Boniface K, 2005, J IMMUNOL, V174, P3695, DOI 10.4049/jimmunol.174.6.3695.
   Bradshaw JM, 2010, CELL SIGNAL, V22, P1175, DOI 10.1016/j.cellsig.2010.03.001.
   Buerger C, 2013, BRIT J DERMATOL, V169, P156, DOI 10.1111/bjd.12271.
   Buerger C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02786.
   Buerger C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180853.
   Cai YH, 2011, IMMUNITY, V35, P596, DOI 10.1016/j.immuni.2011.08.001.
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655.
   Chamcheu JC, 2017, ANTIOXID REDOX SIGN, V26, P49, DOI 10.1089/ars.2016.6769.
   Chamcheu JC, 2016, ACTA DERM-VENEREOL, V96, P854, DOI 10.2340/00015555-2359.
   Chen Sijia, 2020, J Autoimmun, V111, P102435, DOI {[}10.1016/j.jaut.2020.102435, 10.1016/j.jaut.2020.102435].
   Chiricozzi A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010179.
   Claerhout S, 2007, J INVEST DERMATOL, V127, P429, DOI 10.1038/sj.jid.5700533.
   Conte E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024663.
   Denley A, 2009, MOL CANCER RES, V7, P1132, DOI 10.1158/1541-7786.MCR-09-0068.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Di Meglio P, 2011, IMMUNITY, V35, P857, DOI 10.1016/j.immuni.2011.12.003.
   Eickholt BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000869.
   Ekman AK, 2019, J INVEST DERMATOL, V139, P1564, DOI 10.1016/j.jid.2019.01.014.
   Foster FM, 2003, J CELL SCI, V116, P3037, DOI 10.1242/jcs.00609.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892.
   Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173.
   Hart JR, 2011, P NATL ACAD SCI USA, V108, P13247, DOI 10.1073/pnas.1110486108.
   Helmer E, 2017, EUR J CLIN PHARMACOL, V73, P581, DOI 10.1007/s00228-017-2205-7.
   Huang T, 2014, ACTA DERM-VENEREOL, V94, P371, DOI 10.2340/00015555-1737.
   Kastelan M, 2009, ACTA DERMATOVENER CR, V17, P182.
   Kriplani Nisha, 2015, Advances in Biological Regulation, V59, P53, DOI {[}10.1016/j.jbior.2015.05.002, 10.1016/j.jbior.2015.05.002].
   Li ZJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077159.
   Madonna S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.69.
   Madonna S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133318.
   Madonna S, 2017, ONCOTARGET, V8, P24652, DOI 10.18632/oncotarget.15629.
   Madonna S, 2010, J IMMUNOL, V185, P2467, DOI 10.4049/jimmunol.1001426.
   Mercurio L, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.665647.
   Mercurio L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1143-3.
   Morelli M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/7897263.
   Nardinocchi L, 2015, EUR J IMMUNOL, V45, P922, DOI 10.1002/eji.201445052.
   Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595.
   Ogawa E, 2018, J DERMATOL, V45, P264, DOI 10.1111/1346-8138.14139.
   Ozes ON, 1999, NATURE, V401, P82.
   Patel AB, 2018, EXP DERMATOL, V27, P135, DOI 10.1111/exd.13461.
   Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Roller A, 2012, J IMMUNOL, V189, P4612, DOI 10.4049/jimmunol.1103173.
   Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474.
   Rosenberger C, 2007, J INVEST DERMATOL, V127, P2445, DOI 10.1038/sj.jid.5700874.
   Sano S, 2005, NAT MED, V11, P43, DOI 10.1038/nm1162.
   Sawyer C, 2003, CANCER RES, V63, P1667.
   Sestito R, 2011, FASEB J, V25, P916, DOI 10.1096/fj.10-172288.
   Shin JW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2495-z.
   Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112.
   van der Fits L, 2009, J IMMUNOL, V182, P5836, DOI 10.4049/jimmunol.0802999.
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882.
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012.
   Whitehead MA, 2012, BIOCHEM J, V443, P857, DOI 10.1042/BJ20112214.
   Wolk K, 2006, EUR J IMMUNOL, V36, P1309, DOI 10.1002/eji.200535503.
   Yager N, 2018, J INVEST DERMATOL, V138, P1435, DOI 10.1016/j.jid.2017.12.028.
   Yoshiki R, 2014, J INVEST DERMATOL, V134, P1912, DOI 10.1038/jid.2014.98.},
Number-of-Cited-References = {65},
Times-Cited = {13},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Cells},
Doc-Delivery-Number = {WO2VS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000712318000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000731635700011,
Author = {Scott, Jonathan and Ruchaud-Sparagano, Marie-Helene and Musgrave,
   Kathryn and Roy, I, Alistair and Wright, Stephen E. and Perry, John D.
   and Morris, Andrew Conway and Rostron, Anthony J. and Simpson, A. John},
Title = {Phosphoinositide 3-Kinase δ Inhibition Improves Neutrophil Bacterial
   Killing in Critically Ill Patients at High Risk of Infection},
Journal = {JOURNAL OF IMMUNOLOGY},
Year = {2021},
Volume = {207},
Number = {7},
Pages = {1776-1784},
Month = {OCT 1},
Abstract = {Acquired neutrophil dysfunction frequently develops during critical
   illness, independently increasing the risk for intensive care
   unit-acquired infection. PI3K delta is implicated in driving neutrophil
   dysfunction and can potentially be targeted pharmacologically. The aims
   of this study were to determine whether PI3K delta inhibition reverses
   dysfunction in neutrophils from critically ill patients and to describe
   potential mechanisms. Neutrophils were isolated from blood taken from
   critically ill patients requiring intubation and mechanical ventilation,
   renal support, or blood pressure support. In separate validation
   experiments, neutrophil dysfunction was induced pharmacologically in
   neutrophils from healthy volunteers. Phagocytosis and bacterial killing
   assays were performed, and activity of RhoA and protein kinase A (PKA)
   was assessed. Inhibitors of PI3K delta, 3-phosphoinositide-dependent
   protein kinase-1 (PDK1), and PKA were used to determine mechanisms of
   neutrophil dysfunction. Sixty-six patients were recruited. In the 27
   patients (40.9\%) with impaired neutrophil function, PI3K delta
   inhibition consistently improved function and significantly increased
   bacterial killing. These findings were validated in neutrophils from
   healthy volunteers with salbutamol-induced dysfunction and extended to
   demonstrate that PI3K delta inhibition restored killing of clinical
   isolates of nine pathogens commonly associated with intensive care
   unit-acquired infection. PI3K delta activation was associated with PDK1
   activation, which in turn phosphorylated PKA, which drove
   phosphorylation and inhibition of the key regulator of neutrophil
   phagocytosis, RhoA. These data indicate that, in a significant
   proportion of critically ill patients, PI3K delta inhibition can improve
   neutrophil function through PDK1- and PKA-dependent processes,
   suggesting that therapeutic use of PI3K delta inhibitors warrants
   investigation in this setting.},
Publisher = {AMER ASSOC IMMUNOLOGISTS},
Address = {9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA},
Type = {Article},
Language = {English},
Affiliation = {Simpson, AJ (Corresponding Author), Newcastle Univ, Fac Med Sci, Translat \& Clin Res Inst, William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne \& Wear, England.
   Scott, Jonathan; Ruchaud-Sparagano, Marie-Helene; Musgrave, Kathryn; Rostron, Anthony J.; Simpson, A. John, Newcastle Univ, Fac Med Sci, Translat \& Clin Res Inst, William Leech Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne \& Wear, England.
   Roy, Alistair, I; Rostron, Anthony J., Sunderland Royal Hosp, Integrated Crit Care Unit, Sunderland, England.
   Wright, Stephen E., Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Intens Care Unit, Newcastle Upon Tyne, Tyne \& Wear, England.
   Perry, John D., Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Microbiol Dept, Newcastle Upon Tyne, Tyne \& Wear, England.
   Morris, Andrew Conway, Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge Biomed Campus, Cambridge, England.},
DOI = {10.4049/jimmunol.2000603},
ISSN = {0022-1767},
EISSN = {1550-6606},
Keywords-Plus = {PROTEIN-KINASE-A; PHOSPHORYLATION; DYSFUNCTION; ACTIVATION; IDELALISIB;
   DISSOCIATION; INFLAMMATION; SEPSIS; CDC42; BURST},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Affiliations = {Newcastle University - UK; Sunderland Royal Hospital; Newcastle Freeman
   Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle
   Freeman Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust;
   University of Cambridge},
ORCID-Numbers = {Simpson, John/0000-0003-4731-7294
   Conway Morris, Anew/0000-0002-3211-3216
   Rostron, Anthony/0000-0002-9336-1723
   Musgrave, Kathryn M/0000-0003-4984-475X},
Funding-Acknowledgement = {UK Research and Innovation; National Institute for Health Research
   Newcastle Biomedical Research Centre {[}IS-BRC-1215-20001]; Clinical
   Research Career Development Fellowship from the Wellcome Trust {[}WT
   2055214/Z/16/Z]; MRC Clinician Scientist Fellowship {[}MR/V006118/1];
   Medical Research Council (MRC) {[}MR/N02995X/1]; National Institutes of
   Health Research (NIHR) {[}IS-BRC-1215-20001] Funding Source: National
   Institutes of Health Research (NIHR); Medical Research Council
   {[}MR/N02995X/1] Funding Source: researchfish; Wellcome Trust
   {[}205214/Z/16/Z] Funding Source: researchfish; MRC {[}MR/V006118/1,
   MR/N02995X/1, MR/P019935/1] Funding Source: UKRI},
Funding-Text = {This work was supported by a grant from the UK Research and Innovation,
   Medical Research Council (MRC) (the SHIELD Antimicrobial Resistance
   Consortium, Grant MR/N02995X/1) and by the National Institute for Health
   Research Newcastle Biomedical Research Centre (Grant IS-BRC-1215-20001)
   . A.C.M. was supported by aClinical Research Career Development
   Fellowship from the Wellcome Trust at the time of this work (WT
   2055214/Z/16/Z) and is currently supported by an MRC Clinician Scientist
   Fellowship (MR/V006118/1) . A.J.S. is a National Institute for Health
   Research Senior Investigator. The views expressed in this article are
   those of the authors and not necessarily those of the National Institute
   for Health Research or the Department of Health and Social Care.},
Cited-References = {Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292.
   Arulkumaran N, 2020, INTENS CARE MED, V46, P225, DOI 10.1007/s00134-020-05929-3.
   Burelout C, 2007, J LEUKOCYTE BIOL, V81, P1523, DOI 10.1189/jlb.0406256.
   Cahn A, 2017, PULM PHARMACOL THER, V46, P69, DOI 10.1016/j.pupt.2017.08.008.
   Cerny O, 2017, J IMMUNOL, V198, P1285, DOI 10.4049/jimmunol.1601309.
   Chastre J, 2002, AM J RESP CRIT CARE, V165, P867, DOI 10.1164/ajrccm.165.7.2105078.
   Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849.
   Chiriaco M, 2017, CLIN IMMUNOL, V178, P20, DOI 10.1016/j.clim.2015.12.008.
   Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944.
   Cox D, 1997, J EXP MED, V186, P1487, DOI 10.1084/jem.186.9.1487.
   Curigliano G, 2019, DRUG SAFETY, V42, P247, DOI 10.1007/s40264-018-0778-4.
   Demaret J, 2015, J LEUKOCYTE BIOL, V98, P1081, DOI 10.1189/jlb.4A0415-168RR.
   Forget MA, 2002, BIOCHEM J, V361, P243, DOI 10.1042/0264-6021:3610243.
   Francois B, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98960.
   Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226.
   Gambardella L, 2013, J IMMUNOL, V190, P381, DOI 10.4049/jimmunol.1201330.
   Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583.
   Hellyer TP, 2020, LANCET RESP MED, V8, P182, DOI 10.1016/S2213-2600(19)30367-4.
   Hunter JD, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3325.
   Juss JK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045933.
   Kaufmann I, 2006, SHOCK, V26, P254, DOI 10.1097/01.shk.0000223131.64512.7a.
   Kwak JY, 2000, BIOCHEM BIOPH RES CO, V267, P305, DOI 10.1006/bbrc.1999.1941.
   Kwan WH, 2013, J EXP MED, V210, P257, DOI 10.1084/jem.20121525.
   Lang P, 1996, EMBO J, V15, P510, DOI 10.1002/j.1460-2075.1996.tb00383.x.
   Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236.
   Lin P, 2005, J IMMUNOL, V174, P2981, DOI 10.4049/jimmunol.174.5.2981.
   Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC.
   McConnell B., 2017, Scottish Marine and Freshwater Science, V8, P1, DOI {[}10.1080/21541248.2017.1304855, 10.1080/21541248.2017.1304855].
   Meisel C, 2009, AM J RESP CRIT CARE, V180, P640, DOI 10.1164/rccm.200903-0363OC.
   Miller BW, 2015, CLIN CANCER RES, V21, P1525, DOI 10.1158/1078-0432.CCR-14-2522.
   Morris AC, 2018, INTENS CARE MED, V44, P627, DOI 10.1007/s00134-018-5247-0.
   Morris AC, 2011, BLOOD, V117, P5178, DOI 10.1182/blood-2010-08-304667.
   Morris AC, 2009, AM J RESP CRIT CARE, V180, P19, DOI 10.1164/rccm.200812-1928OC.
   Murray AJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.122re4.
   Park SJ, 2010, EUR RESPIR J, V36, P1448, DOI 10.1183/09031936.00106609.
   Pinder EM, 2018, THORAX, V73, P918, DOI 10.1136/thoraxjnl-2017-211323.
   Presneill JJ, 2002, AM J RESP CRIT CARE, V166, P138, DOI 10.1164/rccm.2009005.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020.
   Sadhu C, 2003, J IMMUNOL, V170, P2647, DOI 10.4049/jimmunol.170.5.2647.
   Sapey E, 2011, AM J RESP CRIT CARE, V183, P1176, DOI 10.1164/rccm.201008-1285OC.
   Schlam D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9623.
   Scott J, 2016, J ALLERGY CLIN IMMUN, V137, P535, DOI 10.1016/j.jaci.2015.07.036.
   Stark AK, 2015, CURR OPIN PHARMACOL, V23, P82, DOI 10.1016/j.coph.2015.05.017.
   STEVENS MG, 1991, VET IMMUNOL IMMUNOP, V28, P45, DOI 10.1016/0165-2427(91)90042-B.
   Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0.
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754.
   Welte T, 2018, INTENS CARE MED, V44, P438, DOI 10.1007/s00134-018-5143-7.
   WHO, 2016, Global action plan on antimicrobial resistance.
   Wong K, 2006, P NATL ACAD SCI USA, V103, P3639, DOI 10.1073/pnas.0600092103.
   Wu JF, 2013, CRIT CARE, V17, DOI 10.1186/cc11932.},
Number-of-Cited-References = {51},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {J. Immunol.},
Doc-Delivery-Number = {XQ6DH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000731635700011},
DA = {2026-02-04},
}

@article{ WOS:000699809800001,
Author = {Matsui, Kotaro and Okamoto, Keisuke and Hasegawa, Tomoka and Ohtsuka,
   Hokuto and Shimasaki, Takafumi and Ihara, Kunio and Goto, Yuhei and
   Aoki, Kazuhiro and Aiba, Hirofumi},
Title = {Identification of ksg1 mutation showing long-lived phenotype in
   fission yeast},
Journal = {GENES TO CELLS},
Year = {2021},
Volume = {26},
Number = {12},
Pages = {967-978},
Month = {DEC},
Abstract = {Fission yeast is a good model organism for the study of lifespan. To
   elucidate the mechanism, we screened for long-lived mutants. We found a
   nonsense mutation in the ksg1(+) gene, which encodes an ortholog of
   mammalian PDK1 (phosphoinositide-dependent protein kinase). The mutation
   was in the PH domain of Ksg1 and caused defect in membrane localization
   and protein stability. Analysis of the ksg1 mutant revealed that the
   reduced amounts and/or activity of the Ksg1 protein are responsible for
   the increased lifespan. Ksg1 is essential for growth and known to
   phosphorylate multiple substrates, but the substrate responsible for the
   long-lived phenotype of ksg1 mutation is not yet known. Genetic analysis
   showed that deletion of pck2 suppressed the long-lived phenotype of ksg1
   mutant, suggesting that Pck2 might be involved in the lifespan extension
   caused by ksg1 mutation.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Aiba, H (Corresponding Author), Nagoya Univ, Grad Sch Pharmaceut Sci, Dept Basic Med Sci, Lab Mol Microbiol, Nagoya, Aichi, Japan.
   Matsui, Kotaro; Okamoto, Keisuke; Hasegawa, Tomoka; Ohtsuka, Hokuto; Shimasaki, Takafumi; Aiba, Hirofumi, Nagoya Univ, Grad Sch Pharmaceut Sci, Dept Basic Med Sci, Lab Mol Microbiol, Nagoya, Aichi, Japan.
   Ihara, Kunio, Nagoya Univ, Ctr Gene Res, Nagoya, Aichi, Japan.
   Goto, Yuhei; Aoki, Kazuhiro, Natl Inst Nat Sci, Natl Inst Basic Biol, Okazaki Inst Integrat Biosci, Div Quantitat Biol, Okazaki, Aichi, Japan.
   Goto, Yuhei; Aoki, Kazuhiro, Natl Inst Nat Sci, Exploratory Res Ctr Life \& Living Syst ExCELLS, Quantitat Biol Res Grp, Okazaki, Aichi, Japan.
   Goto, Yuhei; Aoki, Kazuhiro, SOKENDAI Grad Univ Adv Studies, Sch Life Sci, Dept Basic Biol, Okazaki, Aichi, Japan.},
DOI = {10.1111/gtc.12897},
EarlyAccessDate = {SEP 2021},
ISSN = {1356-9597},
EISSN = {1365-2443},
Keywords = {aging; chronological lifespan; fission yeast; ksg1+; Schizosaccharomyces
   pombe},
Keywords-Plus = {CHRONOLOGICAL LIFE-SPAN; CELL INTEGRITY PATHWAY;
   SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASES; GENE; LOCALIZATION;
   ACTIVATION; EFFICIENT; HOMOLOGY; STRESS},
Research-Areas = {Cell Biology; Genetics \& Heredity},
Web-of-Science-Categories  = {Cell Biology; Genetics \& Heredity},
Author-Email = {aiba@ps.nagoya-u.ac.jp},
Affiliations = {Nagoya University; Nagoya University; National Institutes of Natural
   Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience
   (OIIB); National Institute for Basic Biology (NIBB); National Institutes
   of Natural Sciences (NINS) - Japan; The Exploratory Research Center on
   Life \& Living Systems (ExCELLS); Graduate University for Advanced
   Studies - Japan},
ResearcherID-Numbers = {Okamoto, Keisuke/LDF-1217-2024
   Ohtsuka, Hokuto/I-6957-2014
   Goto, Yuhei/AAX-5076-2021
   Aoki, Kazuhiro/HZI-0678-2023},
ORCID-Numbers = {Aiba, Hirofumi/0000-0002-7775-0446
   Ohtsuka, Hokuto/0000-0001-7843-2602
   Goto, Yuhei/0000-0002-5597-158X
   Aoki, Kazuhiro/0000-0001-7263-1555},
Funding-Acknowledgement = {Grants-in-Aid for Scientific Research {[}21K05363, 20H02898] Funding
   Source: KAKEN; Japan Society for the Promotion of Science {[}17K19227,
   20H02898, 17H03792] Funding Source: Medline; Joint Research of the
   Exploratory Research Center on Life and Living Systems {[}19-319]
   Funding Source: Medline},
Cited-References = {Arellano M, 1999, J CELL SCI, V112, P3569.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Bähler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y.
   Barba G, 2008, CELL SIGNAL, V20, P748, DOI 10.1016/j.cellsig.2007.12.017.
   Chen BR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069084.
   Chen YH, 2017, J CELL SCI, V130, P1003, DOI 10.1242/jcs.198457.
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539.
   Franco A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06053-x.
   Gangloff S, 2017, ELIFE, V6, DOI 10.7554/eLife.27469.
   Gangloff S, 2017, FEMS YEAST RES, V17, DOI 10.1093/femsyr/fox002.
   Gräub R, 2003, J BASIC MICROB, V43, P473, DOI 10.1002/jobm.200310287.
   Hibi T, 2018, GENES CELLS, V23, P620, DOI 10.1111/gtc.12604.
   Huang XH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121877.
   Imai Y, 2020, BIOSCI BIOTECH BIOCH, V84, P330, DOI 10.1080/09168451.2019.1676695.
   Ito H, 2010, J BIOL CHEM, V285, P34616, DOI 10.1074/jbc.M110.175562.
   Koch A, 2012, ACS CHEM BIOL, V7, P723, DOI 10.1021/cb200465c.
   Kurauchi T, 2021, FEMS MICROBIOL LETT, V368, DOI 10.1093/femsle/fnab070.
   Kurauchi T, 2017, FEMS MICROBIOL LETT, V364, DOI 10.1093/femsle/fnw257.
   Ma Y, 2006, MOL BIOL CELL, V17, P5028, DOI 10.1091/mbc.E06-08-0688.
   Madrid M, 2006, J BIOL CHEM, V281, P2033, DOI 10.1074/jbc.M506467200.
   Madrid M, 2017, J BIOL CHEM, V292, P11374, DOI 10.1074/jbc.M117.786087.
   Madrid M, 2015, J CELL SCI, V128, P266, DOI 10.1242/jcs.158295.
   Makarenko R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15880-y.
   Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298.
   Mitra P, 2004, J CELL BIOL, V166, P205, DOI 10.1083/jcb.200404150.
   Naito C, 2014, FEBS OPEN BIO, V4, P829, DOI 10.1016/j.fob.2014.09.006.
   Nakashima A, 2012, J CELL SCI, V125, P5840, DOI 10.1242/jcs.111146.
   Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955.
   Ohtsuka H, 2021, GENES CELLS, V26, P459, DOI 10.1111/gtc.12854.
   Ohtsuka H, 2021, MOL MICROBIOL, V115, P623, DOI 10.1111/mmi.14627.
   Ohtsuka H, 2013, MOL GENET GENOMICS, V288, P285, DOI 10.1007/s00438-013-0748-6.
   Oshiro T, 2003, MOL GENET GENOMICS, V269, P437, DOI 10.1007/s00438-003-0841-3.
   Rincón SA, 2009, MOL BIOL CELL, V20, P4390, DOI 10.1091/mbc.E09-03-0207.
   Rodríguez-López M, 2020, CELL REP, V30, P3240, DOI 10.1016/j.celrep.2020.02.058.
   Roelants FM, 2004, MICROBIOL-SGM, V150, P3289, DOI 10.1099/mic.0.27286-0.
   Roux AE, 2006, AGING CELL, V5, P345, DOI 10.1111/j.1474-9726.2006.00225.x.
   Roux AE, 2010, J GERONTOL A-BIOL, V65, P1, DOI 10.1093/gerona/glp152.
   Sakai K., 2021, NEAR INFRARED IMAGIN, V19, P23, DOI {[}10.1101/2021.05.19.444883, DOI 10.1101/2021.05.19.444883].
   Sánchez-Mir L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088020.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Shimasaki T, 2014, MOL GENET GENOMICS, V289, P685, DOI 10.1007/s00438-014-0845-1.
   Suga M, 2005, YEAST, V22, P799, DOI 10.1002/yea.1247.
   Takuma K, 2013, BIOSCI BIOTECH BIOCH, V77, P1548, DOI 10.1271/bbb.130223.
   Tang Y, 2004, GENETICS, V168, P1843, DOI 10.1534/genetics.104.032466.
   Uda Y, 2017, P NATL ACAD SCI USA, V114, P11962, DOI 10.1073/pnas.1707190114.
   Won M, 2001, BIOCHEM BIOPH RES CO, V289, P987, DOI 10.1006/bbrc.2001.6094.},
Number-of-Cited-References = {46},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Genes Cells},
Doc-Delivery-Number = {XN9EJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000699809800001},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000704894900003,
Author = {Jiang, Yunyao and Luo, Yanyan and Chen, Xinyi and Liu, Nan and Hou,
   Jincai and Piao, Jingpei and Song, Chao and Si, Chuanling and Hu,
   Weicheng and Li, Xueqin},
Title = {Senkyunolide H protects PC12 cells from OGD/R-induced injury via
   cAMP-PI3K/AKT signaling pathway},
Journal = {JOURNAL OF ETHNOPHARMACOLOGY},
Year = {2022},
Volume = {282},
Month = {JAN 10},
Abstract = {Ethnopharmacological relevance: Senkyunolide H (SNH) is a bioactive
   phthalide isolated from Ligusticum chuanxiong Hort rhizome and was
   reported to have multiple pharmacological effects.
   Aim of the study: The study was performed to verify the potency of SNH
   protecting PC12 cells from oxygen glucose deprivation/reperfusion
   (OGD/R)-induced injury and to elucidate the underlying mechanisms.
   Materials and methods: OGD/R model was established in PC12 cells and the
   cell viability was measured by MTT assay. The cell morphology was
   observed using scanning electron microscope (SEM). The potential targets
   of SNH and related targets of OGD/R were screened, and a merged
   protein-protein interaction (PPI) network of SNH and OGD/R was
   constructed based on the network pharmacology analysis. Kyoto
   Encyclopedia of Genes and Genomes (KEGG) database was used for pathway
   analysis. Intracellular cAMP level and the protein expression levels
   were measured to elucidate the underlying mechanisms.
   Results: SNH pretreatment protected PC12 cells against OGD/R-induced
   cell death. SNH also significantly protected the cell protrusion. A
   merged PPI network was constructed and the shared candidate targets
   significantly enriched in cAMP signaling pathway. The level of
   intracellular cAMP and the protein level of p-CREB, p-AKT, p-PDK1 and
   PKA protein were up-regulated after the treatment of SNH compared with
   OGD/R modeling.
   Conclusions: The present study indicated that SNH protected PC12 cells
   from OGD/R-induced injury via cAMP-PI3K/AKT signaling pathway.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Si, CL (Corresponding Author), Tianjin Univ Sci \& Technol, Tianjin Key Lab Pulp \& Paper, Tianjin 300457, Peoples R China.
   Hu, WC (Corresponding Author), Huaiyin Normal Univ, Sch Life Sci, Huaian 223300, Peoples R China.
   Li, XQ (Corresponding Author), Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Gen Practice, Huaian 223300, Peoples R China.
   Jiang, Yunyao; Chen, Xinyi, Tsinghua Univ, Sch Pharmaceut Sci, Inst Chinese Mat Med, Beijing 100084, Peoples R China.
   Luo, Yanyan; Si, Chuanling, Tianjin Univ Sci \& Technol, Tianjin Key Lab Pulp \& Paper, Tianjin 300457, Peoples R China.
   Liu, Nan, Beijing Increasepharm Safety \& Efficacy Co Ltd, Beijing 102206, Peoples R China.
   Hou, Jincai, Jing Jin Ji Joint Innovat Pharmaceut Beijing Co L, Beijing 100083, Peoples R China.
   Piao, Jingpei, Jilin Normal Univ, Coll Life Sci, Siping, Peoples R China.
   Song, Chao; Hu, Weicheng, Huaiyin Normal Univ, Sch Life Sci, Huaian 223300, Peoples R China.
   Li, Xueqin, Nanjing Med Univ, Affiliated Huaian Peoples Hosp 1, Dept Gen Practice, Huaian 223300, Peoples R China.},
DOI = {10.1016/j.jep.2021.114659},
EarlyAccessDate = {SEP 2021},
Article-Number = {114659},
ISSN = {0378-8741},
EISSN = {1872-7573},
Keywords = {Senkyunolide H; Oxygen glucose deprivation/reperfusion (OGD/R); Cerebral
   ischemic stroke; cAMP signaling pathway; PI3K/AKT signaling Pathway},
Keywords-Plus = {ISCHEMIC-STROKE; NEURONAL APOPTOSIS; OXYGEN},
Research-Areas = {Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine},
Web-of-Science-Categories  = {Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy},
Author-Email = {yunyao86@126.com
   lyy122525@163.com
   rosettaxinyi@163.com
   nanliu0304@163.com
   jincaihou@126.com
   parkfreedom@163.com
   hytcsongchao@163.com
   sichli@tust.edu.cn
   hu\_weicheng@163.com
   doctorlixq@sina.com},
Affiliations = {Tsinghua University; Tianjin University of Science \& Technology; Jilin
   Normal University; Huaiyin Normal University; Nanjing Medical University},
ResearcherID-Numbers = {Si, Chuanling/JOZ-2125-2023
   Chen, Xinyi/LQK-7401-2024},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81803772]; China
   Postdoctoral Science Foundation {[}2020M680592]; Key Technology Research
   and Development Program of Tianjin {[}19YFZCSN00950]},
Funding-Text = {The work was supported financially by the National Natural Science
   Foundation of China (81803772), Project Funded by China Postdoctoral
   Science Foundation (2020M680592) and Key Technology Research and
   Development Program of Tianjin (19YFZCSN00950).},
Cited-References = {Ayala CN, 2002, STROKE, V33, P1197, DOI 10.1161/01.STR.0000015028.52771.D1.
   Azedi F, 2019, BRAIN RES, V1723, DOI 10.1016/j.brainres.2019.146401.
   Candelario-Jalil E, 2009, CURR OPIN INVEST DR, V10, P644.
   Castro Liliana, 2016, Biologie Aujourd hui, V210, P191, DOI {[}10.1051/jbio/2017005, 10.1051/jbio/2017005].
   Chen ZJ, 2018, FOOD CHEM TOXICOL, V119, P309, DOI 10.1016/j.fct.2018.02.050.
   Dong ZB, 2005, J PHARMACEUT BIOMED, V38, P664, DOI 10.1016/j.jpba.2005.02.008.
   Feng C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00298.
   Flynn RWV, 2008, NEUROPHARMACOLOGY, V55, P250, DOI 10.1016/j.neuropharm.2008.05.031.
   Gao C, 2020, NEUROSCIENCE, V435, P135, DOI 10.1016/j.neuroscience.2020.03.027.
   GWAG BJ, 1995, NEUROSCIENCE, V68, P615, DOI 10.1016/0306-4522(95)00232-8.
   Hou YY, 2018, GENES DIS, V5, P245, DOI 10.1016/j.gendis.2018.06.001.
   Li HG, 2016, J ETHNOPHARMACOL, V193, P117, DOI 10.1016/j.jep.2016.08.005.
   Li YW, 2017, J NEUROL SCI, V373, P107, DOI 10.1016/j.jns.2016.12.036.
   Luo TT, 2020, CHIN J INTEGR MED, V26, P72, DOI 10.1007/s11655-019-3064-0.
   Luo YY, 2019, ENVIRON TOXICOL PHAR, V65, P73, DOI 10.1016/j.etap.2018.12.007.
   Ni Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073149.
   Pan JR, 2016, REV NEUROSCIENCE, V27, P501, DOI 10.1515/revneuro-2015-0043.
   Pang YQ, 2020, METAB BRAIN DIS, V35, P673, DOI 10.1007/s11011-020-00540-3.
   Qi HY, 2010, CHEM-BIOL INTERACT, V183, P380, DOI 10.1016/j.cbi.2009.11.029.
   Qi X, 2016, MOL CELL BIOCHEM, V421, P67, DOI 10.1007/s11010-016-2785-z.
   Shakib N, 2019, EXCLI J, V18, P229, DOI 10.17179/excli2018-1947.
   Shao JL, 2011, J MOL NEUROSCI, V43, P453, DOI 10.1007/s12031-010-9464-4.
   Song XQ, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105725.
   Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3.
   Wen ZM, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8678267.
   Wu FF, 2013, J ETHNOPHARMACOL, V148, P861, DOI 10.1016/j.jep.2013.05.026.
   Xu H, 2019, CURR NEUROVASC RES, V16, P441, DOI 10.2174/1567202616666191029113633.
   Yang DS, 2020, BIOCHEM BIOPH RES CO, V533, P510, DOI 10.1016/j.bbrc.2020.09.054.
   Zhang J, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01299.
   Zheng Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00729.
   Zheng TT, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109117.
   Zhu GL, 2019, TOXICOL LETT, V309, P10, DOI 10.1016/j.toxlet.2019.04.004.},
Number-of-Cited-References = {32},
Times-Cited = {20},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {50},
Journal-ISO = {J. Ethnopharmacol.},
Doc-Delivery-Number = {WD4EB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000704894900003},
DA = {2026-02-04},
}

@article{ WOS:000698573500001,
Author = {Pieknell, Kelvin and Sulistio, Yanuar Alan and Wulansari, Noviana and
   Darsono, Wahyu Handoko Wibowo and Chang, Mi-Yoon and Ko, Ji-Yun and
   Chang, Jong Wook and Kim, Min-Jeong and Lee, Man Ryul and Lee, Sang A.
   and Lee, Hyunbeom and Lee, Gakyung and Jung, Byung Hwa and Park, Hyunbum
   and Kim, Geun-ho and Kim, Doory and Cho, Gayoung and Kim, Chun-Hyung and
   Ly, Dat Da and Park, Kyu-Sang and Lee, Sang-Hun},
Title = {LIN28A enhances regenerative capacity of human somatic tissue stem cells
   via metabolic and mitochondrial reprogramming},
Journal = {CELL DEATH AND DIFFERENTIATION},
Year = {2022},
Volume = {29},
Number = {3},
Pages = {540-555},
Month = {MAR},
Abstract = {Developing methods to improve the regenerative capacity of somatic stem
   cells (SSCs) is a major challenge in regenerative medicine. Here, we
   propose the forced expression of LIN28A as a method to modulate cellular
   metabolism, which in turn enhances self-renewal, differentiation
   capacities, and engraftment after transplantation of various human SSCs.
   Mechanistically, in undifferentiated/proliferating SSCs, LIN28A induced
   metabolic reprogramming from oxidative phosphorylation (OxPhos) to
   glycolysis by activating PDK1-mediated glycolysis-TCA/OxPhos uncoupling.
   Mitochondria were also reprogrammed into healthy/fused mitochondria with
   improved functional capacity. The reprogramming allows SSCs to undergo
   cell proliferation more extensively with low levels of oxidative and
   mitochondrial stress. When the PDK1-mediated uncoupling was untethered
   upon differentiation, LIN28A-SSCs differentiated more efficiently with
   an increase of OxPhos by utilizing the reprogrammed mitochondria. This
   study provides mechanistic and practical approaches of utilizing LIN28A
   and metabolic reprogramming in order to improve SSCs utility in
   regenerative medicine.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Lee, SH (Corresponding Author), Hanyang Univ, Grad Sch Biomed Sci \& Engn, Seoul, South Korea.
   Sulistio, YA; Lee, SH (Corresponding Author), Hanyang Univ, Hanyang Biomed Res Inst, Seoul, South Korea.
   Lee, SH (Corresponding Author), Hanyang Univ, Coll Med, Dept Biochem \& Mol Biol, Seoul, South Korea.
   Pieknell, Kelvin; Lee, Sang-Hun, Hanyang Univ, Grad Sch Biomed Sci \& Engn, Seoul, South Korea.
   Pieknell, Kelvin; Sulistio, Yanuar Alan; Wulansari, Noviana; Darsono, Wahyu Handoko Wibowo; Chang, Mi-Yoon; Lee, Sang-Hun, Hanyang Univ, Hanyang Biomed Res Inst, Seoul, South Korea.
   Ko, Ji-Yun, Dongguk Univ, Res Inst Integrat Regenerat Biomed Engn, Goyang Si, South Korea.
   Chang, Jong Wook; Kim, Min-Jeong, Samsung Med Ctr, Stem Cell \& Regenerat Med Inst, Seoul 06351, South Korea.
   Lee, Man Ryul; Lee, Sang A., Soonchunhyang Univ, Soonchunhyang Inst Medibiosci SIMS, Cheonan 31151, Chungcheongnam, South Korea.
   Lee, Hyunbeom; Lee, Gakyung; Jung, Byung Hwa, Korea Inst Sci \& Technol, Mol Recognit Res Ctr, Seoul 02792, South Korea.
   Jung, Byung Hwa, Korea Univ Sci \& Technol, KIST Sch, Div Biomed Sci \& Technol, Seoul 02792, South Korea.
   Park, Hyunbum; Kim, Geun-ho; Kim, Doory, Hanyang Univ, Dept Chem, Seoul 04763, South Korea.
   Cho, Gayoung; Kim, Chun-Hyung, Paean Biotechnol Inc, Seoul 04552, South Korea.
   Ly, Dat Da; Park, Kyu-Sang, Yonsei Univ, Wonju Coll Med, Mitohormesis Res Ctr, 20 Ilsan Ro, Wonju 26426, Gangwon Do, South Korea.
   Lee, Sang-Hun, Hanyang Univ, Coll Med, Dept Biochem \& Mol Biol, Seoul, South Korea.},
DOI = {10.1038/s41418-021-00873-1},
EarlyAccessDate = {SEP 2021},
ISSN = {1350-9047},
EISSN = {1476-5403},
Keywords-Plus = {CYTOCHROME-C RELEASE; PROTEIN-KINASE; ANTIOXIDANT ENZYMES;
   RESPIRATORY-CHAIN; GENE-EXPRESSION; GLYCOLYSIS; REGULATOR; HOMEOSTASIS;
   PROFILE; LIN-28},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {sulistio@hanyang.ac.kr
   leesh@hanyang.ac.kr},
Affiliations = {Hanyang University; Hanyang University; Dongguk University; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Soonchunhyang University;
   Korea Institute of Science \& Technology (KIST); Korea Institute of
   Science \& Technology (KIST); Hanyang University; Yonsei University;
   Hanyang University},
ResearcherID-Numbers = {Kim, Doory/JXN-5782-2024
   Lee, Sang-Hun/Q-4650-2019
   Sulistio, Yanuar Alan/HMP-6131-2023
   Chang, Jong Wook/HJY-3619-2023},
ORCID-Numbers = {Kim, Doory/0000-0002-2675-106X
   Lee, Sang-Hun/0000-0001-7553-8188
   Park, Kyu-Sang/0000-0003-0322-9807
   chang, mi-yoon/0000-0003-4176-5520
   Ly, Dat Da/0000-0001-5092-5608
   Sulistio, Yanuar Alan/0000-0002-6701-6133
   Lee, Hyunbeom/0000-0001-6954-7520
   Park, Hyunbum/0000-0002-6054-2501
   },
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) of the Ministry of Science
   and ICT, Republic of Korea {[}2017R1A5A2015395, 2020M3A9D8039925,
   2017M3A9B4062415, 2018R1C1B6003436]},
Funding-Text = {This work was supported by the grants 2017R1A5A2015395,
   2020M3A9D8039925, 2017M3A9B4062415, and 2018R1C1B6003436 funded by the
   National Research Foundation of Korea (NRF) of the Ministry of Science
   and ICT, Republic of Korea.},
Cited-References = {Abdallah BM, 2008, GENE THER, V15, P109, DOI 10.1038/sj.gt.3303067.
   AHLIJANIAN MK, 1991, J BIOL CHEM, V266, P20192.
   Ahlqvist KJ, 2012, CELL METAB, V15, P100, DOI 10.1016/j.cmet.2011.11.012.
   AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891.
   Ansó E, 2017, NAT CELL BIOL, V19, P614, DOI 10.1038/ncb3529.
   ASH SR, 1970, AM J PATHOL, V60, P385.
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001.
   Balzer E, 2007, RNA BIOL, V4, P16, DOI 10.4161/rna.4.1.4364.
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547.
   Bonab MM, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-14.
   Carlson ME, 2007, AGING CELL, V6, P371, DOI 10.1111/j.1474-9726.2007.00286.x.
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509.
   Chen FY, 2019, EMBO J, V38, DOI 10.15252/embj.201899727.
   Cho YM, 2006, BIOCHEM BIOPH RES CO, V348, P1472, DOI 10.1016/j.bbrc.2006.08.020.
   Chung Susan, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS60, DOI 10.1038/ncpcardio0766.
   Chung S, 2010, J MOL CELL CARDIOL, V48, P725, DOI 10.1016/j.yjmcc.2009.12.014.
   Docherty CK, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0323-2.
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904.
   Ermolaeva M, 2018, NAT REV MOL CELL BIO, V19, P594, DOI 10.1038/s41580-018-0020-3.
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002.
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011.
   Frost RJA, 2011, P NATL ACAD SCI USA, V108, P21075, DOI 10.1073/pnas.1118922109.
   Fu X, 2015, J BIOL CHEM, V290, P26445, DOI 10.1074/jbc.M115.665232.
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950.
   Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6.
   Honkoop H, 2019, ELIFE, V8, DOI 10.7554/eLife.50163.
   Intlekofer AM, 2019, NAT METAB, V1, P177, DOI 10.1038/s42255-019-0032-0.
   Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772.
   Jang YC, 2011, COLD SH Q B, V76, P101, DOI 10.1101/sqb.2011.76.010652.
   Kang ML, 2014, BIOMATERIALS, V35, P9984, DOI 10.1016/j.biomaterials.2014.08.042.
   Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260.
   Khacho M, 2017, HUM MOL GENET, V26, P3327, DOI 10.1093/hmg/ddx217.
   Kim MJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21539-y.
   Kondoh H, 2007, ANTIOXID REDOX SIGN, V9, P293, DOI 10.1089/ars.2006.1467.
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-60.
   Kwon S, 2016, MOL THER, V24, P1550, DOI 10.1038/mt.2016.125.
   Laker RC, 2014, J BIOL CHEM, V289, P12005, DOI 10.1074/jbc.M113.530527.
   Lawlor MA, 2001, J CELL SCI, V114, P2903.
   Lightowlers RN, 2020, EMBO REP, V21, DOI 10.15252/embr.202050964.
   Mailloux RJ, 2013, TRENDS BIOCHEM SCI, V38, P592, DOI 10.1016/j.tibs.2013.09.001.
   Mendes SC, 2002, TISSUE ENG, V8, P911, DOI 10.1089/107632702320934010.
   Miyazono Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18582-6.
   Mohrin M, 2018, AGING CELL, V17, DOI 10.1111/acel.12756.
   Molenaar JJ, 2012, NAT GENET, V44, P1199, DOI 10.1038/ng.2436.
   Moss EG, 1997, CELL, V88, P637, DOI 10.1016/S0092-8674(00)81906-6.
   Moya A, 2018, STEM CELLS, V36, P363, DOI 10.1002/stem.2763.
   Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108.
   Nickens KP, 2013, MITOCHONDRION, V13, P662, DOI 10.1016/j.mito.2013.09.005.
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200.
   Peng SP, 2011, STEM CELLS, V29, P496, DOI 10.1002/stem.591.
   Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079.
   Pfleger J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.202.
   Porter C, 2015, AM J PHYSIOL-ENDOC M, V309, pE224, DOI 10.1152/ajpendo.00125.2015.
   Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404.
   Rera M, 2011, CELL METAB, V14, P623, DOI 10.1016/j.cmet.2011.09.013.
   Rhee YH, 2016, BRAIN, V139, P2722, DOI 10.1093/brain/aww203.
   Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51.
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007.
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616.
   Shinoda G, 2013, STEM CELLS, V31, P1563, DOI 10.1002/stem.1423.
   Shyh-Chang N, 2013, CELL, V155, P778, DOI 10.1016/j.cell.2013.09.059.
   Simsek T, 2010, CELL STEM CELL, V7, P380, DOI 10.1016/j.stem.2010.07.011.
   Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058.
   Spinelli JB, 2018, NAT CELL BIOL, V20, P745, DOI 10.1038/s41556-018-0124-1.
   Stoll EA, 2011, J BIOL CHEM, V286, P38592, DOI 10.1074/jbc.M111.252171.
   Turner WS, 2008, STEM CELLS, V26, P1547, DOI 10.1634/stemcells.2007-0863.
   Urbach A, 2014, GENE DEV, V28, P971, DOI 10.1101/gad.237149.113.
   Valente AJ, 2017, ACTA HISTOCHEM, V119, P315, DOI 10.1016/j.acthis.2017.03.001.
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914.
   Viswanathan SR, 2010, CELL, V140, P445, DOI 10.1016/j.cell.2010.02.007.
   Wang XF, 2018, HISTOL HISTOPATHOL, V33, P327, DOI 10.14670/HH-11-922.
   Yao CH, 2019, ELIFE, V8, DOI 10.7554/eLife.41351.
   Yokoyama S, 2008, GENE EXPR PATTERNS, V8, P155, DOI 10.1016/j.gep.2007.11.001.
   Yoshioka N, 2013, CELL STEM CELL, V13, P246, DOI 10.1016/j.stem.2013.06.001.
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335.
   Zhang HB, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.143420.
   Zhang HB, 2016, SCIENCE, V352, P1436, DOI 10.1126/science.aaf2693.
   Zhang J, 2016, CELL STEM CELL, V19, P66, DOI 10.1016/j.stem.2016.05.009.
   Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033.
   Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580-019-0123-5.},
Number-of-Cited-References = {80},
Times-Cited = {18},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Cell Death Differ.},
Doc-Delivery-Number = {ZO6UC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000698573500001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000700216700009,
Author = {Elmas, Abdulkadir and Tharakan, Serena and Jaladanki, Suraj and Galsky,
   Matthew D. and Liu, Tao and Huang, Kuan-lin},
Title = {Pan-cancer proteogenomic investigations identify post-transcriptional
   kinase targets},
Journal = {COMMUNICATIONS BIOLOGY},
Year = {2021},
Volume = {4},
Number = {1},
Month = {SEP 22},
Abstract = {Elmas et al. develop an algorithm, OPPTI, to identify overexpressed
   kinase proteins across 10 cancer types using global mass spectrometry
   proteomics data from over 1000 cases. They reveal that protein-level
   aberrations, which are sometimes not observed using genomics, represent
   cancer vulnerabilities that may be targeted in precision oncology.
   Identifying genomic alterations of cancer proteins has guided the
   development of targeted therapies, but proteomic analyses are required
   to validate and reveal new treatment opportunities. Herein, we develop a
   new algorithm, OPPTI, to discover overexpressed kinase proteins across
   10 cancer types using global mass spectrometry proteomics data of 1,071
   cases. OPPTI outperforms existing methods by leveraging multiple
   co-expressed markers to identify targets overexpressed in a subset of
   tumors. OPPTI-identified overexpression of ERBB2 and EGFR proteins
   correlates with genomic amplifications, while CDK4/6, PDK1, and MET
   protein overexpression frequently occur without corresponding DNA- and
   RNA-level alterations. Analyzing CRISPR screen data, we confirm
   expression-driven dependencies of multiple currently-druggable and new
   target kinases whose expressions are validated by immunochemistry.
   Identified kinases are further associated with up-regulated
   phosphorylation levels of corresponding signaling pathways.
   Collectively, our results reveal protein-level aberrations-sometimes not
   observed by genomics-represent cancer vulnerabilities that may be
   targeted in precision oncology.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Huang, KL (Corresponding Author), Icahn Sch Med Mt Sinai, Ctr Transformat Dis Modeling, Dept Genet \& Genom Sci, Tisch Canc Inst,Icahn Inst Data Sci \& Genom Techn, New York, NY 10029 USA.
   Elmas, Abdulkadir; Tharakan, Serena; Jaladanki, Suraj; Huang, Kuan-lin, Icahn Sch Med Mt Sinai, Ctr Transformat Dis Modeling, Dept Genet \& Genom Sci, Tisch Canc Inst,Icahn Inst Data Sci \& Genom Techn, New York, NY 10029 USA.
   Galsky, Matthew D., Icahn Sch Med Mt Sinai, Div Hematol \& Med Oncol, Tisch Canc Inst, New York, NY 10029 USA.
   Liu, Tao, Pacific Northwest Natl Lab, Div Biol Sci, Richland, WA 99354 USA.},
DOI = {10.1038/s42003-021-02636-7},
Article-Number = {1112},
EISSN = {2399-3642},
Keywords-Plus = {PROTEOMICS; DEPENDENCY; MECHANISMS; RESISTANCE; INHIBITOR},
Research-Areas = {Life Sciences \& Biomedicine - Other Topics; Science \& Technology -
   Other Topics},
Web-of-Science-Categories  = {Biology; Multidisciplinary Sciences},
Author-Email = {kuan-lin.huang@mssm.edu},
Affiliations = {Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; United States Department of Energy (DOE); Pacific Northwest
   National Laboratory},
ResearcherID-Numbers = {Huang, Kuanlin/KIJ-7996-2024
   Liu, Tao/A-9020-2013
   Elmas, Abdulkadir/AAH-5958-2021},
ORCID-Numbers = {Liu, Tao/0000-0001-9529-6550
   Jaladanki, Suraj/0000-0003-0406-2973
   Elmas, Abdulkadir/0000-0002-7999-5770},
Funding-Acknowledgement = {NCI CPTAC grant {[}U24CA210955]; NIGMS {[}R35GM138113]; ISMMS seed fund;
   Tisch Cancer Institute and related research facilities {[}P30 CA196521];
   National Cancer Institute {[}P30CA196521] Funding Source: NIH RePORTER;
   National Institute of General Medical Sciences {[}R35GM138113] Funding
   Source: NIH RePORTER},
Funding-Text = {We acknowledge the participating patients and family who generously
   contributed to the data sets. We also acknowledge members of the CPTAC
   for helpful discussions. We thank the Center for Comparative Medicine
   and Surgery at Mount Sinai. This work was supported by the following
   grants: NCI CPTAC grant (U24CA210955), NIGMS R35GM138113, and ISMMS seed
   fund. The Tisch Cancer Institute and related research facilities are
   supported by P30 CA196521.},
Cited-References = {Archer TC, 2018, CANCER CELL, V34, P396, DOI 10.1016/j.ccell.2018.08.004.
   Boku N, 2014, GASTRIC CANCER, V17, P1, DOI 10.1007/s10120-013-0252-z.
   Bollard J, 2017, GUT, V66, P1286, DOI 10.1136/gutjnl-2016-312268.
   Clark DJ, 2019, CELL, V179, P964, DOI 10.1016/j.cell.2019.10.007.
   Cotto Kelsy C, 2018, Nucleic Acids Res, V46, pD1068, DOI {[}10.1093/nar/gkx1143, 10.1093/nar/gkx1143].
   Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026.
   Ellis MJ, 2013, CANCER DISCOV, V3, P1108, DOI 10.1158/2159-8290.CD-13-0219.
   Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21.
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290.
   Fittall MW, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0632-z.
   Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1.
   Hershey JWB, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011528.
   Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022.
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049.
   Huang KL, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14864.
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186.
   Jiang Y, 2019, NATURE, V567, P257, DOI 10.1038/s41586-019-0987-8.
   Knudsen ES, 2017, TRENDS CANCER, V3, P39, DOI 10.1016/j.trecan.2016.11.006.
   Lapek JD, 2017, NAT BIOTECHNOL, V35, P983, DOI 10.1038/nbt.3955.
   Lim JSJ, 2016, CANCER DISCOV, V6, P697, DOI 10.1158/2159-8290.CD-16-0563.
   Liu YS, 2016, CELL, V165, P535, DOI 10.1016/j.cell.2016.03.014.
   Ma J, 2019, NUCLEIC ACIDS RES, V47, pD1211, DOI 10.1093/nar/gky869.
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762.
   Manolio TA, 2017, CELL, V169, P6, DOI 10.1016/j.cell.2017.03.005.
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003.
   Meyers RM, 2017, NAT GENET, V49, P1779, DOI {[}10.1101/160861, 10.1038/ng.3984].
   Mun DG, 2019, CANCER CELL, V35, P111, DOI 10.1016/j.ccell.2018.12.003.
   O'Connell Nathaniel S, 2017, J Biom Biostat, V8, P1, DOI {[}10.4172/2155-6180.1000334, 10.4172/2155-6180.1000334].
   Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506.
   Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095.
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106.
   Rubio-Perez C, 2015, CANCER CELL, V27, P382, DOI 10.1016/j.ccell.2015.02.007.
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035.
   Schettini F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00608.
   Sengupta S, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0564-z.
   Sinha A, 2019, CANCER CELL, V35, P414, DOI 10.1016/j.ccell.2019.02.005.
   Siravegna G, 2015, NAT MED, V21, P795, DOI {[}10.1038/nm0715-827b, 10.1038/nm.3870].
   Tabb DL, 2016, J PROTEOME RES, V15, P691, DOI 10.1021/acs.jproteome.5b00859.
   Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321.
   Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010.
   Uhlen M, 2015, SCIENCE, V347, DOI {[}10.1126/science.347.6227.1274-c, 10.1126/science.1260419].
   Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030.
   Wang J, 2017, MOL CELL PROTEOMICS, V16, P121, DOI 10.1074/mcp.M116.060301.
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438.
   Zhang LC, 2017, METHODS MOL BIOL, V1550, P185, DOI 10.1007/978-1-4939-6747-6\_14.},
Number-of-Cited-References = {45},
Times-Cited = {8},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Commun. Biol.},
Doc-Delivery-Number = {UW5SZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000700216700009},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000698341400001,
Author = {Kang, Hyeon-Ji and Min, Byong-Keol and Choi, Won-Il and Jeon, Jae-Han
   and Kim, Dong Wook and Park, Sungmi and Lee, Yun-Kyung and Kim, Hwa-jin
   and Byeon, Ju-Eun and Go, Younghoon and Ham, Hye Jin and Jeon, Yong Hyun
   and Kim, Mi-Jin and Lee, Jung Yi and Wende, Adam R. and Choi, Sung Hee
   and Harris, Robert A. and Lee, In-Kyu},
Title = {Pyruvate dehydrogenase kinase 1 and 2 deficiency reduces high-fat
   diet-induced hypertrophic obesity and inhibits the differentiation of
   preadipocytes into mature adipocytes},
Journal = {EXPERIMENTAL AND MOLECULAR MEDICINE},
Year = {2021},
Volume = {53},
Number = {9},
Pages = {1390-1401},
Month = {SEP},
Abstract = {Obesity is now recognized as a disease. This study revealed a novel role
   for pyruvate dehydrogenase kinase (PDK) in diet-induced hypertrophic
   obesity. Mice with global or adipose tissue-specific PDK2 deficiency
   were protected against diet-induced obesity. The weight of adipose
   tissues and the size of adipocytes were reduced. Adipocyte-specific PDK2
   deficiency slightly increased insulin sensitivity in HFD-fed mice. In
   studies with 3T3-L1 preadipocytes, PDK2 and PDK1 expression was strongly
   increased during adipogenesis. Evidence was found for epigenetic
   induction of both PDK1 and PDK2. Gain- and loss-of-function studies with
   3T3-L1 cells revealed a critical role for PDK1/2 in adipocyte
   differentiation and lipid accumulation. PDK1/2 induction during
   differentiation was also accompanied by increased expression of
   hypoxia-inducible factor-1 alpha (HIF1 alpha) and enhanced lactate
   production, both of which were absent in the context of PDK1/2
   deficiency. Exogenous lactate supplementation increased the stability of
   HIF1 alpha and promoted adipogenesis. PDK1/2 overexpression-mediated
   adipogenesis was abolished by HIF1 alpha inhibition, suggesting a role
   for the PDK-lactate-HIF1 alpha axis during adipogenesis. In human
   adipose tissue, the expression of PDK1/2 was positively correlated with
   that of the adipogenic marker PPAR gamma and inversely correlated with
   obesity. Similarly, PDK1/2 expression in mouse adipose tissue was
   decreased by chronic high-fat diet feeding. We conclude that PDK1 and 2
   are novel regulators of adipogenesis that play critical roles in
   obesity.
   Obesity: Effects of different forms of key enzyme The discovery that two
   forms of a key enzyme appear to play a critical role in fat production
   triggered by overeating might lead to new approaches to prevent and
   treat obesity. Hyeon-Ji Kang at Kyungpook National University, Daegu,
   South Korea, and colleagues in South Korea and the USA examined the role
   of the enzymes pyruvate dehydrogenase kinase types 1 and 2 (PDK1/2). PDK
   enzymes regulate the activity of a multi-enzyme complex that catalyzes a
   key step in the use of glucose to provide energy stores for cells. Mice
   deficient in PDK2 were protected from diet-induced obesity, and PDK 1
   and 2 activity was increased during the generation of fat cells. Studies
   using mice and human fat tissue confirmed that the enzymes regulate the
   development and growth of fat cells. Drugs inhibiting PDK enzymes might
   combat obesity.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Lee, IK (Corresponding Author), Kyungpook Natl Univ, Res Inst Aging \& Metab, Daegu, South Korea.
   Lee, IK (Corresponding Author), Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery \& Dev Diabet, Daegu, South Korea.
   Choi, SH (Corresponding Author), Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea.
   Harris, RA (Corresponding Author), Univ Kansas, Med Ctr, Dept Biochem \& Mol Biol, Kansas City, KS 66160 USA.
   Lee, IK (Corresponding Author), Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea.
   Kang, Hyeon-Ji; Jeon, Jae-Han; Kim, Mi-Jin; Lee, In-Kyu, Kyungpook Natl Univ, Res Inst Aging \& Metab, Daegu, South Korea.
   Min, Byong-Keol, Arbormed Co Ltd, Seoul, South Korea.
   Choi, Won-Il; Kim, Hwa-jin, Korea Adv Inst Sci \& Technol, Grad Sch Med Sci \& Engn, Daejeon, South Korea.
   Choi, Won-Il; Kim, Dong Wook; Park, Sungmi; Ham, Hye Jin; Jeon, Yong Hyun; Lee, Jung Yi; Lee, In-Kyu, Kyungpook Natl Univ Hosp, Leading Edge Res Ctr Drug Discovery \& Dev Diabet, Daegu, South Korea.
   Jeon, Jae-Han, Kyungpook Natl Univ, Chilgok Hosp, Sch Med, Dept Internal Med, Daegu, South Korea.
   Kim, Dong Wook, Seoul Natl Univ, Dept Biochem, Coll Vet Med, Seoul, South Korea.
   Lee, Yun-Kyung; Choi, Sung Hee, Seoul Natl Univ, Dept Internal Med, Bundang Hosp, Seongnam, South Korea.
   Byeon, Ju-Eun, Kyungpook Natl Univ, Dept Biomed Sci, BK21 Plus KNU Biomed Convergence Programs, Daegu, South Korea.
   Byeon, Ju-Eun, Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea.
   Go, Younghoon, Korea Inst Oriental Med, Korean Med Applicat Ctr, Daegu, South Korea.
   Jeon, Yong Hyun, Daegu Gyeongbuk Med Innovat Fdn, Lab Anim Ctr, Daegu, South Korea.
   Wende, Adam R., Univ Alabama Birmingham, Dept Pathol, Div Mol \& Cellular Pathol, Birmingham, AL 35294 USA.
   Harris, Robert A., Univ Kansas, Med Ctr, Dept Biochem \& Mol Biol, Kansas City, KS 66160 USA.
   Lee, In-Kyu, Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea.},
DOI = {10.1038/s12276-021-00672-1},
EarlyAccessDate = {SEP 2021},
ISSN = {1226-3613},
EISSN = {2092-6413},
Keywords-Plus = {ADIPOSE-TISSUE; RNA ACCUMULATION; PPAR-GAMMA; TRANSCRIPTION; INSULIN;
   MICE; EXPRESSION; ENHANCERS; CELLS},
Research-Areas = {Biochemistry \& Molecular Biology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Medicine, Research \& Experimental},
Author-Email = {drshchoi@snu.ac.kr
   raharris@iu.edu
   leei@knu.ac.kr},
Affiliations = {Kyungpook National University (KNU); Korea Advanced Institute of Science
   \& Technology (KAIST); Kyungpook National University (KNU); Kyungpook
   National University Hospital (KNUH); Kyungpook National University
   (KNU); Seoul National University (SNU); Seoul National University (SNU);
   Kyungpook National University (KNU); Kyungpook National University
   (KNU); Korea Institute of Oriental Medicine (KIOM); University of
   Alabama System; University of Alabama Birmingham; University of Kansas;
   University of Kansas Medical Center; Kyungpook National University
   (KNU); Kyungpook National University Hospital (KNUH)},
ResearcherID-Numbers = {Wende, Adam/AFG-8878-2022
   Lee, In-Kyu/AAR-6374-2021
   Jeon, Yong/N-6910-2019
   Lee, Yun Kyung/AFE-1810-2022
   },
ORCID-Numbers = {Wende, Adam/0000-0002-5536-4675
   CHOI, SUNG HEE/0000-0003-0740-8116
   Park, Sungmi/0000-0002-3074-5914
   CHOI, WON-IL/0000-0002-4837-0436},
Funding-Acknowledgement = {Korea Health Technology R\&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health \& Welfare, Republic
   of Korea {[}HI16C1501]; Basic Science Research Program through the
   National Research Foundation (NRF) of Korea {[}NRF-2017R1A2B3006406];
   Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education {[}NRF-2018R1A6A3A01012921]; NRF
   - Ministry of Science and ICT {[}NRF-2020R1C1C1012729,
   NRF-2018R1A5A2024425, NRF-2018R1D1A1B07047275]},
Funding-Text = {This work was supported by grants from the Korea Health Technology R\&D
   Project through the Korea Health Industry Development Institute (KHIDI)
   funded by the Ministry of Health \& Welfare, Republic of Korea
   (HI16C1501); the Basic Science Research Program through the National
   Research Foundation (NRF) of Korea (NRF-2017R1A2B3006406); the Basic
   Science Research Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education
   (NRF-2018R1A6A3A01012921); and NRF grants funded by the Ministry of
   Science and ICT (NRF-2020R1C1C1012729, NRF-2018R1A5A2024425 and
   NRF-2018R1D1A1B07047275).},
Cited-References = {Chatterjee TK, 2014, DIABETES, V63, P176, DOI 10.2337/db13-1148.
   Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215.
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107.
   De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571.
   Dusseault J, 2016, DIABETES, V65, P2652, DOI 10.2337/db15-1559.
   Giusti V, 2003, DIABETES, V52, P1673, DOI 10.2337/diabetes.52.7.1673.
   Go Y, 2016, DIABETES, V65, P2876, DOI 10.2337/db16-0223.
   Hasenfuss SC, 2014, CELL METAB, V19, P84, DOI 10.1016/j.cmet.2013.11.018.
   Hatzi K, 2013, CELL REP, V4, P578, DOI 10.1016/j.celrep.2013.06.016.
   He Q, 2011, AM J PHYSIOL-ENDOC M, V300, pE877, DOI 10.1152/ajpendo.00626.2010.
   Herman MA, 2006, J CLIN INVEST, V116, P1767, DOI 10.1172/JCI29027.
   Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731.
   Jeffery E, 2015, NAT CELL BIOL, V17, P376, DOI 10.1038/ncb3122.
   Jeoung Nam Ho, 2010, Korean Diabetes J, V34, P274, DOI 10.4093/kdj.2010.34.5.274.
   Jeoung NH, 2012, BIOCHEM J, V443, P829, DOI 10.1042/BJ20112197.
   Jiang C, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0014-4.
   Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318.
   Kang HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061411.
   Kozlov AM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65193-9.
   Lefterova MI, 2014, TRENDS ENDOCRIN MET, V25, P293, DOI 10.1016/j.tem.2014.04.001.
   Liang Y, 2020, ONCOGENE, V39, P469, DOI 10.1038/s41388-019-1035-8.
   Ma LJ, 2004, DIABETES, V53, P336, DOI 10.2337/diabetes.53.2.336.
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022.
   Mikkelsen TS, 2010, CELL, V143, P156, DOI 10.1016/j.cell.2010.09.006.
   Min BK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00944.
   Moitra J, 1998, GENE DEV, V12, P3168, DOI 10.1101/gad.12.20.3168.
   Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371.
   Nellemann B, 2012, OBESITY, V20, P57, DOI 10.1038/oby.2011.290.
   NEWBY FD, 1990, AM J PHYSIOL, V259, pE865, DOI 10.1152/ajpendo.1990.259.6.E865.
   Pradeepa MM, 2016, NAT GENET, V48, P681, DOI 10.1038/ng.3550.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Sabater D, 2014, SCI REP-UK, V4, DOI 10.1038/srep03663.
   Siersbæk R, 2011, EMBO J, V30, P1459, DOI 10.1038/emboj.2011.65.
   Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418.
   STEPHENS JM, 1993, MOL CELL BIOCHEM, V123, P63, DOI 10.1007/BF01076476.
   STEPHENS JM, 1992, J MOL ENDOCRINOL, V9, P61, DOI 10.1677/jme.0.0090061.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Tao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071997.},
Number-of-Cited-References = {38},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Exp. Mol. Med.},
Doc-Delivery-Number = {WC0BJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000698341400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000703732600015,
Author = {Yang, San-Qiao and Tang, Yi-Yun and Zeng, Dan and Tian, Qing and Wei,
   Hai-Jun and Wang, Chun-Yan and Zhang, Ping and Chen, Yong-Jun and Zou,
   Wei and Tang, Xiao-Qing},
Title = {Sodium hydrosulfide reverses β2-microglobulin-induced
   depressive-like behaviors of male Sprague-Dawley rats: Involving
   improvement of synaptic plasticity and enhancement of Warburg effect in
   hippocampus},
Journal = {BEHAVIOURAL BRAIN RESEARCH},
Year = {2022},
Volume = {417},
Month = {JAN 24},
Abstract = {Background: Our previous works demonstrated that beta 2-microglobulin
   (beta 32m), a systemic pro-aging factor, induce depressive-like
   behaviors. Hydrogen sulfide (H2S) is identified as a potential target
   for treatment of depression. The aim of the present work is to explore
   whether H2S antagonizes beta 2m-induced depressive-like behaviors and
   the underlying mechanisms.
   Methods: The depressive-like behaviors were detected using the novelty
   suppressed feeding test (NSFT), tail suspension test (TST), forced
   swimming test (FST) and open field test (OFT). The expressions of
   Warburg-related proteins, including hexokinase II (HK II), pyruvate
   kinase M2 (PKM2), Lactate dehydrogenase A (LDHA), pyruvate dehydrogenase
   (PDH) and pyruvate dehydrogenase kinase 1(PDK1), and synaptic
   plasticity-related proteins, including postsynaptic density protein 95
   (PSD95) and synaptophysin1 (SYN1), were determined by western blotting.
   Result: we found that NaHS (the donor of H2S) attenuated the
   depressive-like behaviors in the beta 2m-exposed rats, as judged by
   NSFT, TST, FST, and OFT. We also demonstrated that NaHS enhanced the
   synaptic plasticity, as evidenced by the upregulations of PSD95 and SYN1
   expressions in the hippocampus of beta 2m-exposed rats. Furthermore,
   NaHS improved the Warburg effect in the hippocampus of beta 2m-exposed
   rats, as evidenced by the upregulations of HK II, PKM2, LDHA and PDK1
   expressions, and the downregulation of PDH expression.
   Conclusion: H2S prevents beta 2m-induced depressive-like behaviors,
   which is involved in improvement of hippocampal synaptic plasticity as a
   result of enhancement of hippocampal Warburg effect.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Tang, XQ (Corresponding Author), Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Inst Neurol, Hengyang 421001, Hunan, Peoples R China.
   Yang, San-Qiao; Tang, Xiao-Qing, Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Inst Neurol, Hengyang 421001, Hunan, Peoples R China.
   Yang, San-Qiao; Tang, Yi-Yun; Tian, Qing; Wei, Hai-Jun; Wang, Chun-Yan; Tang, Xiao-Qing, Univ South China, Hengyang Med Sch, Inst Neurosci, Hengyang 421001, Hunan, Peoples R China.
   Zeng, Dan; Zhang, Ping; Chen, Yong-Jun; Zou, Wei, Univ South China, Affiliated Nanhua Hosp, Hengyang Med Sch, Dept Neurol, Hengyang 421001, Hunan, Peoples R China.},
DOI = {10.1016/j.bbr.2021.113562},
EarlyAccessDate = {SEP 2021},
Article-Number = {113562},
ISSN = {0166-4328},
EISSN = {1872-7549},
Keywords = {Hydrogen sulfide; beta 2-microglobulin; Depressive-like behavior;
   Warburg effect; Synaptic plasticity},
Keywords-Plus = {BRAIN AEROBIC GLYCOLYSIS; HYDROGEN-SULFIDE; INSIGHTS; BIOMARKERS;
   LACTATE; STRESS; MARKER; MODEL},
Research-Areas = {Behavioral Sciences; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Behavioral Sciences; Neurosciences},
Author-Email = {tangxq-usc@qq.com},
Affiliations = {University of South China; University of South China; University of
   South China},
ResearcherID-Numbers = {Tang, Xiao-Qing/J-9907-2012
   zeng, dan/HJJ-1301-2023},
Cited-References = {Muñoz AB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216498.
   Baudry M, 2016, TRENDS NEUROSCI, V39, P235, DOI 10.1016/j.tins.2016.01.007.
   Boehning D, 2003, ANNU REV NEUROSCI, V26, P105, DOI 10.1146/annurev.neuro.26.041002.131047.
   Boulanger LM, 2004, NAT REV NEUROSCI, V5, P521, DOI 10.1038/nrn1428.
   Cao L, 2018, BRAIN BEHAV IMMUN, V73, P603, DOI 10.1016/j.bbi.2018.07.005.
   Carrette O, 2003, PROTEOMICS, V3, P1486, DOI 10.1002/pmic.200300470.
   Chen HB, 2017, PHARMACOL BIOCHEM BE, V155, P16, DOI 10.1016/j.pbb.2017.03.002.
   Chen WL, 2013, BEHAV PHARMACOL, V24, P590, DOI 10.1097/FBP.0b013e3283654258.
   Corlin DB, 2005, CLIN CHEM, V51, P1177, DOI 10.1373/clinchem.2005.049544.
   Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009.
   Duman RS, 2016, NAT MED, V22, P238, DOI 10.1038/nm.4050.
   Duncan WC, 2017, BIOL PSYCHIAT, V82, P361, DOI 10.1016/j.biopsych.2017.03.011.
   Farrugia G, 2014, GASTROENTEROLOGY, V147, P303, DOI 10.1053/j.gastro.2014.04.041.
   Barros LF, 2013, TRENDS NEUROSCI, V36, P396, DOI 10.1016/j.tins.2013.04.002.
   Glynn MW, 2011, NAT NEUROSCI, V14, P442, DOI 10.1038/nn.2764.
   Goddard CA, 2007, P NATL ACAD SCI USA, V104, P6828, DOI 10.1073/pnas.0702023104.
   Goyal MS, 2014, CELL METAB, V19, P49, DOI 10.1016/j.cmet.2013.11.020.
   Hou XY, 2017, ANTIOXID REDOX SIGN, V27, P472, DOI 10.1089/ars.2016.6737.
   Hu M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2153745.
   Kamat PK, 2016, MOL NEUROBIOL, V53, P2451, DOI 10.1007/s12035-015-9212-4.
   Kimura H, 2013, NEUROCHEM INT, V63, P492, DOI 10.1016/j.neuint.2013.09.003.
   Kumar M, 2018, CNS NEUROL DISORD-DR, V17, P654, DOI 10.2174/1871527317666180605072018.
   Lamers F, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.115.
   Liu SY, 2017, INT J NEUROPSYCHOPH, V20, P867, DOI 10.1093/ijnp/pyx030.
   Magistretti PJ, 2016, P NATL ACAD SCI USA, V113, P7015, DOI 10.1073/pnas.1607423113.
   Magistretti PJ, 2014, CELL METAB, V19, P4, DOI 10.1016/j.cmet.2013.12.012.
   Marsden WN, 2013, PROG NEURO-PSYCHOPH, V43, P168, DOI 10.1016/j.pnpbp.2012.12.012.
   Meyer D, 2014, NEURON, V82, P430, DOI 10.1016/j.neuron.2014.02.031.
   Murray AM, 2008, ADV CHRONIC KIDNEY D, V15, P123, DOI 10.1053/j.ackd.2008.01.010.
   Normann C, 2018, BIOL PSYCHIAT, V84, P55, DOI 10.1016/j.biopsych.2017.10.008.
   Patel D, 2019, BEHAV BRAIN RES, V369, DOI 10.1016/j.bbr.2019.111900.
   PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0.
   Sáenz JCB, 2006, BEHAV BRAIN RES, V169, P57, DOI 10.1016/j.bbr.2005.12.001.
   Sen N, 2017, J MOL BIOL, V429, P543, DOI 10.1016/j.jmb.2016.12.015.
   Shannon BJ, 2016, P NATL ACAD SCI USA, V113, pE3782, DOI 10.1073/pnas.1604977113.
   Shefa U, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1873962.
   Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898.
   Tang XQ, 2005, BRAIN RES, V1057, P57, DOI 10.1016/j.brainres.2005.07.072.
   Tang ZJ, 2015, BEHAV PHARMACOL, V26, P427, DOI 10.1097/FBP.0000000000000143.
   THIEL G, 1993, BRAIN PATHOL, V3, P87, DOI 10.1111/j.1750-3639.1993.tb00729.x.
   Tian Q, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00399.
   Upadhyay M, 2013, PHARMACOL THERAPEUT, V137, P318, DOI 10.1016/j.pharmthera.2012.11.003.
   Wei L, 2018, NEUROMOL MED, V20, P252, DOI 10.1007/s12017-018-8489-7.
   Yang JY, 2014, P NATL ACAD SCI USA, V111, P12228, DOI 10.1073/pnas.1322912111.
   Yu J, 2019, SCI TOTAL ENVIRON, V689, P1012, DOI 10.1016/j.scitotenv.2019.06.250.
   Zhang J, 2008, AM J CLIN PATHOL, V129, P526, DOI 10.1309/W01Y0B808EMEH12L.
   Zhang P., 2018, PLOS ONE, V13, DOI {[}10.1371/journal, DOI 10.1371/JOURNAL].
   Zhang XZ, 2014, ACS CHEM NEUROSCI, V5, P876, DOI 10.1021/cn500185g.
   Zhang ZX, 2019, NEUROPEPTIDES, V77, DOI 10.1016/j.npep.2019.101959.
   Zheng P, 2013, MOL CELL PROTEOMICS, V12, P207, DOI 10.1074/mcp.M112.021816.},
Number-of-Cited-References = {50},
Times-Cited = {11},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Behav. Brain Res.},
Doc-Delivery-Number = {WB7EO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000703732600015},
DA = {2026-02-04},
}

@article{ WOS:000697322000001,
Author = {Ishino, Yuko and Komatsu, Nao and Sakata, Ken-taro and Yoshikawa, Daichi
   and Tani, Motohiro and Maeda, Tatsuya and Morishige, Kanta and
   Yoshizawa, Koushiro and Tanaka, Naotaka and Tabuchi, Mitsuaki},
Title = {Regulation of sphingolipid biosynthesis in the endoplasmic reticulum via
   signals from the plasma membrane in budding yeast},
Journal = {FEBS JOURNAL},
Year = {2022},
Volume = {289},
Number = {2},
Pages = {457-472},
Month = {JAN},
Abstract = {Saccharomyces cerevisiae LIP1 encodes a regulatory subunit that forms a
   complex with the ceramide synthase catalytic subunits, Lag1/Lac1, which
   is localized on the membrane of endoplasmic reticulum. To understand the
   underlying regulatory mechanism of sphingolipid biosynthesis, we
   generated strains upon replacing the chromosomal LIP1 promoter with a
   Tet-off promoter, which enables the expression in Dox-dependent manner.
   The lip1-1 strain, obtained through the promoter substitution, exhibits
   severe growth inhibition and remarkable decrease in sphingolipid
   synthesis in the presence of Dox. Using this strain, we investigated the
   effect of a decrease in ceramide synthesis on TOR complex 2 (TORC2)-Ypk1
   signaling, which senses the complex sphingolipid level at the plasma
   membrane and promotes sphingolipid biosynthesis. In lip1-1 cells, Ypk1
   was activated via both upstream kinases, TORC2 and yeast PDK1
   homologues, Pkh1/2, thereby inducing hyperphosphorylation of Lag1, but
   not of another Ypk1-substrate, Orm1, which is a known negative regulator
   of the first step of sphingolipid metabolism, in the presence of Dox.
   Therefore, our data suggest that the metabolic enzyme activities at each
   step of the sphingolipid biosynthetic pathway are controlled through a
   fine regulatory mechanism.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Tabuchi, M (Corresponding Author), Kagawa Univ, Fac Agr, Dept Appl Biol Sci, Miki, Kagawa 7610795, Japan.
   Ishino, Yuko; Komatsu, Nao; Sakata, Ken-taro; Yoshikawa, Daichi; Morishige, Kanta; Yoshizawa, Koushiro; Tanaka, Naotaka; Tabuchi, Mitsuaki, Kagawa Univ, Fac Agr, Dept Appl Biol Sci, Miki, Kagawa 7610795, Japan.
   Tani, Motohiro, Kyushu Univ, Fac Sci, Dept Chem, Fukuoka, Japan.
   Maeda, Tatsuya, Hamamatsu Univ Sch Med, Dept Biol, Hamamatsu, Shizuoka, Japan.},
DOI = {10.1111/febs.16189},
EarlyAccessDate = {SEP 2021},
ISSN = {1742-464X},
EISSN = {1742-4658},
Keywords = {-1 programmed ribosomal frameshifting; ceramide; Saccharomyces
   cerevisiae; sphingolipid; TOR complex},
Keywords-Plus = {COMPLEX 2 TORC2; SACCHAROMYCES-CEREVISIAE; CERAMIDE SYNTHASE; PROTEINS
   SLM1; KINASE YPK1; PHOSPHORYLATION; ACTIVATION; STRESS; SCREEN; TSC13P},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {tabuchi.mitsuaki@kagawa-u.ac.jp},
Affiliations = {Kagawa University; Kyushu University; Hamamatsu University School of
   Medicine},
ResearcherID-Numbers = {Tabuchi, Mitsuaki/E-9544-2010
   },
ORCID-Numbers = {Maeda, Tatsuya/0000-0001-9952-1612
   Tabuchi, Mitsuaki/0000-0002-2042-691X
   Sakata, Ken-taro/0000-0001-7394-3884
   Tani, Motohiro/0000-0003-4316-8260},
Funding-Acknowledgement = {JSPS KAKENHI {[}JP19K05828, 20H03251, 18H02139]; Ohsumi Frontier Science
   Foundation; HUSM; Grants-in-Aid for Scientific Research {[}18H02139,
   20H03251, 21H02118] Funding Source: KAKEN},
Funding-Text = {We express our deep appreciation to Prof Scott D. Emr for generously
   providing plasmids and strains. We also thank Profs Isamu Kameshita and
   Noriyuki Sueyoshi for providing a kPPase-expressing plasmid. We
   acknowledge the technical expertise of the DNA core facility of the Gene
   Research Center, Kagawa University. This work was supported by JSPS
   KAKENHI Grant Number JP19K05828 (to M. Tabuchi) and 20H03251 (to TM),
   18H02139 (to M. Tani) and grants from Ohsumi Frontier Science Foundation
   and HUSM Grant-in-Aid (both to TM).},
Cited-References = {Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015.
   Atkins JF, 2016, NUCLEIC ACIDS RES, V44, P7007, DOI 10.1093/nar/gkw530.
   Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384.
   Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688.
   Berchtold D, 2012, NAT CELL BIOL, V14, P542, DOI 10.1038/ncb2480.
   Breslow DK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013326.
   Breslow DK, 2010, MOL CELL, V40, P267, DOI 10.1016/j.molcel.2010.10.005.
   Breslow DK, 2010, NATURE, V463, P1048, DOI 10.1038/nature08787.
   Byun Y, 2007, COMPUT BIOL MED, V37, P1796, DOI 10.1016/j.compbiomed.2007.06.001.
   Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8.
   Dickson RC, 2006, PROG LIPID RES, V45, P447, DOI 10.1016/j.plipres.2006.03.004.
   Eltschinger S, 2016, TRENDS CELL BIOL, V26, P148, DOI 10.1016/j.tcb.2015.10.003.
   Fresques T, 2015, J BIOL CHEM, V290, P1395, DOI 10.1074/jbc.M114.621086.
   Gururaj C, 2013, J BIOL CHEM, V288, P20453, DOI 10.1074/jbc.M113.472860.
   HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164.
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329.
   HANSON BA, 1980, J LIPID RES, V21, P309.
   Holthuis JCM, 2001, PHYSIOL REV, V81, P1689, DOI 10.1152/physrev.2001.81.4.1689.
   ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983.
   Kageyama-Yahara N, 2006, BIOCHEM J, V398, P585, DOI 10.1042/BJ20060697.
   Ketteler Robin, 2012, Frontiers in Genetics, V3, P242, DOI 10.3389/fgene.2012.00242.
   Kim S, 2000, GENETICS, V156, P1519.
   Kobayashi SD, 2003, EUKARYOT CELL, V2, P284, DOI 10.1128/EC.2.2.284-294.2003.
   Kohlwein SD, 2001, MOL CELL BIOL, V21, P109, DOI 10.1128/MCB.21.1.109-125.2001.
   Kvam E, 2005, MOL BIOL CELL, V16, P3987, DOI 10.1091/mbc.E05-04-0290.
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6.
   Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U.
   Mizutani Y, 2005, BIOCHEM J, V390, P263, DOI 10.1042/BJ20050291.
   Muir A, 2014, ELIFE, V3, DOI 10.7554/eLife.03779.
   Muir A, 2015, ELIFE, V4, DOI 10.7554/eLife.09336.
   Niles BJ, 2012, P NATL ACAD SCI USA, V109, P1536, DOI 10.1073/pnas.1117563109.
   Omnus DJ, 2016, MOL BIOL CELL, V27, P1170, DOI 10.1091/mbc.E16-01-0002.
   ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936.
   Roelants FM, 2011, P NATL ACAD SCI USA, V108, P19222, DOI 10.1073/pnas.1116948108.
   Sassa T, 2016, J BIOL CHEM, V291, P7477, DOI 10.1074/jbc.M115.695858.
   Schmidt O, 2020, J BIOL CHEM, V295, P12028, DOI 10.1074/jbc.RA120.013222.
   Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417.
   SIKORSKI RS, 1989, GENETICS, V122, P19.
   Sun YD, 2012, MOL BIOL CELL, V23, P2388, DOI 10.1091/mbc.E12-03-0209.
   Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05.
   Tani M, 2016, TRENDS GLYCOSCI GLYC, V28, pE109, DOI 10.4052/tigg.1509.1E.
   Tani M, 2015, MICROBIOL-SGM, V161, P2369, DOI 10.1099/mic.0.000187.
   Uemura S, 2007, J BIOL CHEM, V282, P8613, DOI 10.1074/jbc.M606649200.
   Vallée B, 2005, EMBO J, V24, P730, DOI 10.1038/sj.emboj.7600562.
   Zhang XP, 2001, CURR GENET, V40, P221, DOI 10.1007/s00294-001-0259-6.},
Number-of-Cited-References = {45},
Times-Cited = {12},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {29},
Journal-ISO = {FEBS J.},
Doc-Delivery-Number = {YI0XH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000697322000001},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000696766300001,
Author = {Heltemes-Harris, Lynn M. and Hubbard, Gregory K. and LaRue, Rebecca S.
   and Munro, Sarah A. and Yang, Rendong and Henzler, Christine M. and
   Starr, Timothy K. and Sarver, Aaron L. and Kornblau, Steven M. and
   Farrar, Michael A.},
Title = {Identification of mutations that cooperate with defects in B cell
   transcription factors to initiate leukemia},
Journal = {ONCOGENE},
Year = {2021},
Volume = {40},
Number = {43},
Pages = {6166-6179},
Month = {OCT 28},
Abstract = {The transcription factors PAX5, IKZF1, and EBF1 are frequently mutated
   in B cell acute lymphoblastic leukemia (B-ALL). We demonstrate that
   compound heterozygous loss of multiple genes critical for B and T cell
   development drives transformation, including Pax5(+/-)xEbf1(+/-),
   Pax5(+/-)xikzf1(+/-), and Ebf1(+/-)xlkzf1(+/-) mice for B-ALL, or
   Tcf7(+/-)xlkzf1(+/-) mice for T-ALL. To identify genetic defects that
   cooperate with Pax5 and Ebf1 compound heterozygosity to initiate
   leukemia, we performed a Sleeping Beauty (SB) transposon screen that
   identified cooperating partners including gain-of-function mutations in
   Stat5b (similar to 65\%) and Jak7 (similar to 68\%), or loss-of-function
   mutations in Cblb (61\%) and Myb (32\%). These findings underscore the
   role of JAK/STAT5B signaling in B cell transformation and demonstrate
   roles for loss-of-function mutations in Cblb and Myb in transformation.
   RNA-Seq studies demonstrated upregulation of a PDK1>SGK3>MYC pathway;
   treatment of Pax5(+/-)xEbf1(+/- )leukemia cells with PDK1 inhibitors
   blocked proliferation in vitro. In addition, we identified a conserved
   transcriptional gene signature between human and murine leukemias
   characterized by upregulation of myeloid genes, most notably involving
   the GM-CSF pathway, that resemble a B cell/myeloid mixed-lineage
   leukemia. Thus, our findings identify multiple mechanisms that cooperate
   with defects in B cell transcription factors to generate either
   progenitor B cell or mixed B/myeloid-like leukemias.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Farrar, MA (Corresponding Author), Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA.
   Farrar, MA (Corresponding Author), Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   Farrar, MA (Corresponding Author), Univ Minnesota, Dept Lab Med \& Pathol, Minneapolis, MN 55455 USA.
   Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Farrar, Michael A., Univ Minnesota, Ctr Immunol, Minneapolis, MN 55455 USA.
   Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Starr, Timothy K.; Sarver, Aaron L.; Farrar, Michael A., Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
   Heltemes-Harris, Lynn M.; Hubbard, Gregory K.; Farrar, Michael A., Univ Minnesota, Dept Lab Med \& Pathol, Minneapolis, MN 55455 USA.
   LaRue, Rebecca S.; Munro, Sarah A.; Yang, Rendong; Henzler, Christine M., Univ Minnesota, Minnesota Supercomp Inst, Minneapolis, MN 55455 USA.
   Starr, Timothy K., Univ Minnesota, Dept Obstet Gynecol \& Womens Hlth, Minneapolis, MN 55455 USA.
   Kornblau, Steven M., Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
   Yang, Rendong, Univ Minnesota, Hormel Inst, Austin, MN 55912 USA.},
DOI = {10.1038/s41388-021-02012-z},
EarlyAccessDate = {SEP 2021},
ISSN = {0950-9232},
EISSN = {1476-5594},
Keywords-Plus = {STAT5 ACTIVATION; LYMPHOBLASTIC-LEUKEMIA; KAPPA-B; CBL-B;
   DIFFERENTIATION; GENE; TRANSFORMATION; RESISTANCE; DELETION; FAILURE},
Research-Areas = {Biochemistry \& Molecular Biology; Oncology; Cell Biology; Genetics \&
   Heredity},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Oncology; Cell Biology; Genetics \&
   Heredity},
Author-Email = {farra005@umn.edu},
Affiliations = {University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Minnesota System},
ResearcherID-Numbers = {Starr, Timothy/AAX-9342-2021
   Yang, Rendong/I-5552-2014
   Farrar, Michael/M-7802-2013},
ORCID-Numbers = {Starr, Timothy/0000-0002-6308-3451
   Yang, Rendong/0000-0002-9512-2240
   Heltemes Harris, Lynn/0000-0002-2668-8005
   Kornblau, Steven/0000-0002-5990-9548
   Henzler, Christine/0000-0003-4566-2211
   Farrar, Michael/0000-0002-5569-0366},
Funding-Acknowledgement = {Cancer Research Institute Investigator award; Leukemia and Lymphoma
   Society Scholar award; UMN Masonic Cancer center; NIH {[}RO1 CA232317];
   Randy Shaver Cancer Research and Community Fund; Masonic Cancer Center;
   NCI {[}CA211249]; Masonic Cancer Center Support Grant {[}CA077598];
   CPRIT MIRA RP {[}160693]; NIH/NCI {[}P50 CA100632-09]; NIH NCI {[}R21
   CA216652]; National Cancer Institute {[}R01CA232317, P30CA077598,
   P50CA100632] Funding Source: NIH RePORTER},
Funding-Text = {We thank A. Rost, for technical assistance with mouse breeding; the
   University of Minnesota's Supercomputing Institute for providing
   computing and bioinformatic resources; Dr. Meinrad Busslinger (Pax5+/-),
   Dr. Rudolf Grosschedl (Ebf1-/-), Dr. Peter Johnson (Cebpa-/-), Dr.
   Andrew Wells (Ikzf1-/-) and Dr. David Largaespada
   (Rosa26LSLSB11T2/OncxRosa26LSL-SB11) for providing the indicated mouse
   strains. The results published here are in part based upon data
   generated by the Therapeutically Applicable Research to Generate
   Effective Treatments (TARGET) initiative, phs000218, managed by the NCI.
   This work was supported by a Cancer Research Institute Investigator
   award, a Leukemia and Lymphoma Society Scholar award, funding from the
   UMN Masonic Cancer center and grants from the NIH (RO1 CA232317) to MAF.
   TKS was supported by grants from the Randy Shaver Cancer Research and
   Community Fund, NIH NCI (R21 CA216652), and the Masonic Cancer Center.
   ALS was supported by NCI (CA211249) and Masonic Cancer Center Support
   Grant (CA077598). SMK was supported by CPRIT MIRA RP 160693 and NIH/NCI
   P50 CA100632-09.},
Cited-References = {Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477.
   {[}Anonymous], 2007, VENNY INTERACTIVE TO.
   Badger-Brown KM, 2013, LEUKEMIA, V27, P1146, DOI 10.1038/leu.2012.331.
   Beckmann PJ, 2019, CANCER RES, V79, P905, DOI 10.1158/0008-5472.CAN-18-1261.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128.
   Chen F, 2007, CANCER RES, V67, P11093, DOI 10.1158/0008-5472.CAN-07-1576.
   Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235.
   Churchman ML, 2018, CANCER CELL, V33, P937, DOI 10.1016/j.ccell.2018.03.021.
   Dupuy AJ, 2009, CANCER RES, V69, P8150, DOI 10.1158/0008-5472.CAN-09-1135.
   Fahl SP, 2009, J IMMUNOL, V183, P5582, DOI 10.4049/jimmunol.0901187.
   Goetz CA, 2004, J IMMUNOL, V172, P4770, DOI 10.4049/jimmunol.172.8.4770.
   Heath V, 2004, BLOOD, V104, P1639, DOI 10.1182/blood-2003-11-3963.
   Heltemes-Harris LM, 2016, ONCOGENE, V35, P3454, DOI 10.1038/onc.2015.405.
   Heltemes-Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947.
   Katerndahl CDS, 2017, NAT IMMUNOL, V18, P694, DOI 10.1038/ni.3716.
   Kollmann S, 2019, LEUKEMIA, V33, P1583, DOI 10.1038/s41375-018-0369-5.
   Kornblau SM, 2009, BLOOD, V113, P154, DOI 10.1182/blood-2007-10-119438.
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377.
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559.
   Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014.
   LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0.
   Mullighan CG, 2008, NATURE, V453, P110, DOI 10.1038/nature06866.
   Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690.
   Mullighan CG, 2014, HEMATOL-AM SOC HEMAT, P174, DOI 10.1182/asheducation-2014.1.174.
   Mullighan CG, 2009, NEW ENGL J MED, V360, P470, DOI 10.1056/NEJMoa0808253.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7.
   Prasad MAJ, 2015, BLOOD, V125, P4052, DOI 10.1182/blood-2014-12-617282.
   Roberts KG, 2014, NEW ENGL J MED, V371, P1005, DOI 10.1056/NEJMoa1403088.
   Sarver AL, 2021, LAB INVEST, V101, P701, DOI 10.1038/s41374-021-00573-x.
   Scott MC, 2018, CANCER RES, V78, P326, DOI 10.1158/0008-5472.CAN-17-0576.
   Shah S, 2013, NAT GENET, V45, P1226, DOI 10.1038/ng.2754.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Temiz NA, 2016, GENOME RES, V26, P119, DOI 10.1101/gr.188649.114.
   URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5.
   van der Weyden L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1586-1.
   VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0.
   Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1.
   WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1.
   Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112.
   Xiao X, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2617-2.
   Zhou JJ, 2021, NAT IMMUNOL, V22, P460, DOI 10.1038/s41590-021-00888-3.},
Number-of-Cited-References = {43},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Oncogene},
Doc-Delivery-Number = {WO5HW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000696766300001},
OA = {Green Accepted},
DA = {2026-02-04},
}

@article{ WOS:000694247400001,
Author = {Shi, Yingying and Wang, You and Jiang, Huangang and Sun, Xuehua and Xu,
   Hui and Wei, Xue and Wei, Yan and Xiao, Guohui and Song, Zhiyin and
   Zhou, Fuxiang},
Title = {Mitochondrial dysfunction induces radioresistance in colorectal cancer
   by activating {[}Ca2+]m-PDP1-PDH-histone
   acetylation retrograde signaling},
Journal = {CELL DEATH \& DISEASE},
Year = {2021},
Volume = {12},
Number = {9},
Month = {SEP 6},
Abstract = {Mitochondrial retrograde signaling (mito-RTG) triggered by mitochondrial
   dysfunction plays a potential role in regulating tumor metabolic
   reprogramming and cellular sensitivity to radiation. Our previous
   studies showed phos-pyruvate dehydrogenase (p-PDH) and PDK1, which
   involved in aerobic glycolysis, were positively correlated with
   radioresistance, but how they initiate and work in the mito-RTG pathway
   is still unknown. Our further genomics analysis revealed that complex I
   components were widely downregulated in mitochondrial dysfunction model.
   In the present study, high expression of p-PDH was found in the complex
   I deficient cells and induced radioresistance. Mechanistically, complex
   I defects led to a decreased PDH both in cytoplasm and nucleus through
   {[}Ca2+](m)-PDP1-PDH axis, and decreased PDH in nucleus promote DNA
   damage repair (DDR) response via reducing histone acetylation.
   Meanwhile, NDUFS1 (an important component of the complex I)
   overexpression could enhance the complex I activity, reverse glycolysis
   and resensitize cancer cells to radiation in vivo and in vitro.
   Furthermore, low NDUFS1 and PDH expression were validated to be
   correlated with poor tumor regression grading (TRG) in local advanced
   colorectal cancer (CRC) patients underwent neoadjuvant radiotherapy.
   Here, we propose that the {[}Ca2+](m)-PDP1-PDH-histone acetylation
   retrograde signaling activated by mitochondrial complex I defects
   contribute to cancer cell radioresistance, which provides new insight in
   the understanding of the mito-RTG. For the first time, we reveal that
   NDUFS1 could be served as a promising predictor of radiosensitivity and
   modification of complex I function may improve clinical benefits of
   radiotherapy in CRC.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhou, FX (Corresponding Author), Wuhan Univ, Zhongnan Hosp, Dept Radiat \& Med Oncol, Wuhan 430071, Peoples R China.
   Zhou, FX (Corresponding Author), Wuhan Univ, Zhongnan Hosp, Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Peoples R China.
   Zhou, FX (Corresponding Author), Wuhan Univ, Zhongnan Hosp, Hubei Clin Canc Study Ctr, Wuhan 430071, Peoples R China.
   Shi, Yingying; Wang, You; Jiang, Huangang; Sun, Xuehua; Xu, Hui; Wei, Xue; Wei, Yan; Xiao, Guohui; Zhou, Fuxiang, Wuhan Univ, Zhongnan Hosp, Dept Radiat \& Med Oncol, Wuhan 430071, Peoples R China.
   Shi, Yingying; Wang, You; Jiang, Huangang; Sun, Xuehua; Xu, Hui; Wei, Xue; Wei, Yan; Xiao, Guohui; Zhou, Fuxiang, Wuhan Univ, Zhongnan Hosp, Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Peoples R China.
   Shi, Yingying; Wang, You; Jiang, Huangang; Sun, Xuehua; Xu, Hui; Wei, Xue; Wei, Yan; Xiao, Guohui; Zhou, Fuxiang, Wuhan Univ, Zhongnan Hosp, Hubei Clin Canc Study Ctr, Wuhan 430071, Peoples R China.
   Song, Zhiyin, Wuhan Univ, Coll Life Sci, Frontier Sci Ctr Immunol \& Metab, Hubei Key Lab Cell Homeostasis, Wuhan 430071, Hubei, Peoples R China.},
DOI = {10.1038/s41419-021-03984-2},
Article-Number = {837},
ISSN = {2041-4889},
Keywords-Plus = {RESPIRATORY COMPLEX I; DNA-DAMAGE RESPONSE; HISTONE DEACETYLASES;
   AEROBIC GLYCOLYSIS; CALCIUM-IONS; REPAIR; CELLS; REQUIREMENTS; HDAC1},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {happyzhoufx@sina.com},
Affiliations = {Wuhan University; Wuhan University; Wuhan University; Wuhan University},
ResearcherID-Numbers = {sun, xuehua/JTV-3135-2023
   Fuxiang, Zhou/MXL-2237-2025
   shi, yingying/E-1112-2015},
ORCID-Numbers = {Fuxiang, Zhou/0000-0001-5472-2306
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81773238]},
Funding-Text = {This study was supported by grants from the National Natural Science
   Foundation of China (81773238).},
Cited-References = {Arvizo RR, 2013, J BIOL CHEM, V288, P17610, DOI 10.1074/jbc.M112.435206.
   Benson A III, 2020, J NATL COMPR CANC NE, V18, P807, DOI 10.6004/jnccn.2020.0032.
   Botrugno OA, 2012, CLIN CANCER RES, V18, P2436, DOI 10.1158/1078-0432.CCR-11-0767.
   Carruthers RD, 2018, CANCER RES, V78, P5060, DOI 10.1158/0008-5472.CAN-18-0569.
   Chakraborty PK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14634.
   Chen JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12126-4.
   Cheng G, 2016, CANCER RES, V76, P3904, DOI 10.1158/0008-5472.CAN-15-2534.
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0.
   Fang EF, 2016, CELL METAB, V24, P566, DOI 10.1016/j.cmet.2016.09.004.
   Ferreira S, 2019, CANCER RADIOTHER, V23, P883, DOI 10.1016/j.canrad.2019.08.008.
   Giorgi C, 2018, NAT REV MOL CELL BIO, V19, P713, DOI 10.1038/s41580-018-0052-8.
   Gopal RK, 2018, P NATL ACAD SCI USA, V115, pE6283, DOI 10.1073/pnas.1711888115.
   Guerra F, 2017, BBA-BIOENERGETICS, V1858, P686, DOI 10.1016/j.bbabio.2017.01.012.
   Gustafsson NMS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06287-x.
   Jaña F, 2019, MITOCHONDRION, V49, P73, DOI 10.1016/j.mito.2019.07.004.
   Jiang HL, 2016, CANCER RES, V76, P952, DOI 10.1158/0008-5472.CAN-15-1630.
   Jiang YH, 2017, ADV EXP MED BIOL, V1026, P105, DOI 10.1007/978-981-10-6020-5\_5.
   Li Y, 2018, CANCER RES, V78, P4471, DOI 10.1158/0008-5472.CAN-17-2172.
   Li ZM, 2014, INT J BIOL SCI, V10, P757, DOI 10.7150/ijbs.9067.
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237.
   Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413.
   MCCORMACK JG, 1990, PHYSIOL REV, V70, P391, DOI 10.1152/physrev.1990.70.2.391.
   Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899.
   Mou JJ, 2018, BIOMED PHARMACOTHER, V103, P729, DOI 10.1016/j.biopha.2018.04.099.
   Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238.
   PETTIT FH, 1972, BIOCHEM BIOPH RES CO, V49, P563, DOI 10.1016/0006-291X(72)90448-2.
   Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412.
   Roos WP, 2016, NUCLEIC ACIDS RES, V44, P10017, DOI 10.1093/nar/gkw922.
   Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005.
   Sharma LK, 2009, CURR MED CHEM, V16, P1266, DOI 10.2174/092986709787846578.
   Smith ALM, 2020, NAT CANCER, V1, P976, DOI 10.1038/s43018-020-00112-5.
   Su CY, 2016, SCI REP-UK, V6, DOI 10.1038/srep31357.
   Sukonina V, 2019, NATURE, V566, P279, DOI 10.1038/s41586-019-0900-5.
   Sun C, 2019, THERANOSTICS, V9, P3595, DOI 10.7150/thno.33100.
   Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046.
   Turkan A, 2002, J BIOL CHEM, V277, P14976, DOI 10.1074/jbc.M108434200.
   Vatrinet R, 2015, INT J BIOCHEM CELL B, V63, P41, DOI 10.1016/j.biocel.2015.01.017.
   Wei YH, 2018, RADIAT RES, V190, P204, DOI 10.1667/RR15021.1.
   Won JH, 2015, J BIOL CHEM, V290, P27425, DOI 10.1074/jbc.M115.667063.
   Wu ZD, 2021, EMBO REP, V22, DOI 10.15252/embr.202050827.
   Yang YF, 2020, CANCER RES, V80, P719, DOI 10.1158/0008-5472.CAN-19-2149.
   Yao Q, 2019, DEV CELL, V49, P748, DOI 10.1016/j.devcel.2019.04.029.
   Yu MF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126915.
   Yucel N, 2019, CELL REP, V27, P3939, DOI 10.1016/j.celrep.2019.05.092.
   Zhao H, 2017, INT J ONCOL, V50, P1531, DOI 10.3892/ijo.2017.3924.
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011.},
Number-of-Cited-References = {46},
Times-Cited = {41},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {30},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {UN8GI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000694247400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000694709900002,
Author = {Padda, Jaskamal and Khalid, Khizer and Kakani, Varsha and Cooper, Ayden
   Charlene and Jean-Charles, Gutteridge},
Title = {Metabolic Acidosis in Leukemia},
Journal = {CUREUS JOURNAL OF MEDICAL SCIENCE},
Year = {2021},
Volume = {13},
Number = {9},
Month = {SEP 5},
Abstract = {In 2020, the incidence of leukemia was 474,519 with 311,594 mortality
   worldwide. In 2021, the American Cancer Society (ACS) has estimated
   61,090 new cases of leukemia to occur within the United States. It has
   also been reported that the most common cause of death in children from
   one to fourteen years old is oncological, with leukemia being the most
   frequent cause. A phenomenon known as the Warburg effect has been
   affiliated with cancer. The Warburg effect is a metabolic abnormality of
   lactic acidosis in malignancies, with most cases presenting as
   hematological malignancies such as leukemia. Although many theories have
   been formulated to clarify the role of the Warburg effect, the exact
   role still remains uncertain. Four suggested theories on why the Warburg
   effect happens to include cell signaling, adenosine triphosphate (ATP)
   synthesis, biosynthesis, and the tumor microenvironment. The Warburg
   effect occurs in leukemia with the help of enzymes such as pyrurate
   kinases M2 (PKM2), lactate dehydrogenase A (LDHA), pynavate
   dehydrogenase kinase 1 (PDK1), and fibroblast growth factor receptor 1
   (FGFR1). hi this literature, we explain the proposed hypotheses of the
   Warburg effect, along with the molecular mechanism of how leukemia is
   able to produce lactic acid, with the intent to better understand this
   phenomenon.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Padda, J (Corresponding Author), JC Med Ctr, Internal Med, Orlando, FL 32811 USA.
   Padda, Jaskamal; Khalid, Khizer; Kakani, Varsha; Cooper, Ayden Charlene; Jean-Charles, Gutteridge, JC Med Ctr, Internal Med, Orlando, FL 32811 USA.
   Jean-Charles, Gutteridge, Advent Hlth, Internal Med, Orlando, FL USA.
   Jean-Charles, Gutteridge, Orlando Hlth Hosp, Orlando, FL USA.},
DOI = {10.7759/cureus.17732},
Article-Number = {e17732},
EISSN = {2168-8184},
Keywords = {metabolic acidosis; leukemia; lactic acidosis; warburg effect; atp
   synthesis},
Keywords-Plus = {B LACTIC-ACIDOSIS; CANCER},
Research-Areas = {General \& Internal Medicine},
Web-of-Science-Categories  = {Medicine, General \& Internal},
Author-Email = {jaskamal\_padda@hotmail.com},
Affiliations = {Adventist Health Services; AdventHealth; (AdventHealth) Central Florida
   Division; Central Florida Hospital - South; AdventHealth Orlando},
Cited-References = {Alfarouk Khalid O, 2011, Cancers (Basel), V3, P408, DOI 10.3390/cancers3010408.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   De Keulenaer B, 2003, NEPHROL DIAL TRANSPL, V18, P1214, DOI 10.1093/ndt/gfg053.
   Epstein T, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-7.
   Estrella V, 2013, CANCER RES, V73, P1524, DOI 10.1158/0008-5472.CAN-12-2796.
   Friedenberg AS, 2007, MEDICINE, V86, P225, DOI 10.1097/MD.0b013e318125759a.
   Gardner Andrew John, 2015, J Med Case Rep, V9, P16, DOI {[}10.1186/1752-1947-9-16, 10.1186/1752-1947-9-16].
   Ghrewati Moutaz, 2018, Case Rep Nephrol, V2018, P1019034, DOI {[}10.1155/2018/1019034, 10.1155/2018/1019034].
   Gwangwa MV, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0088-y.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Kraut JA, 2010, NAT REV NEPHROL, V6, P274, DOI 10.1038/nrneph.2010.33.
   Kumari S, 2018, BIOMARK INSIGHTS, V13, DOI 10.1177/1177271918755391.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Liu XS, 2015, ONCOTARGET, V6, P4214, DOI 10.18632/oncotarget.2929.
   Movahed ZG, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108690.
   RACKER E, 1974, MOL CELL BIOCHEM, V5, P17, DOI 10.1007/BF01874168.
   Ruiz JP, 2011, THESCIENTIFICWORLDJO, V11, P1316, DOI 10.1100/tsw.2011.125.
   Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555.
   Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Tong L, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113960.
   Udayakumar N, 2006, J Cancer Res Ther, V2, P82.
   WAINER RA, 1973, AM J MED, V55, P255, DOI 10.1016/0002-9343(73)90177-0.
   Wang Ying-Hua, 2015, Mol Cell Oncol, V2, pe981988, DOI 10.4161/23723556.2014.981988.
   Warburg O., 1925, J CAN RES, P148, DOI {[}10.1158/jcr.1925.148, DOI 10.1158/JCR.1925.148].
   Yang Hang, 2019, Oncotarget, V10, P3066, DOI {[}10.18632/oncotarget.24684, 10.18632/oncotarget.24684].},
Number-of-Cited-References = {27},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Cureus J Med Sci},
Doc-Delivery-Number = {UO5BQ},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000694709900002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:001010269200001,
Author = {Khalil, Md Imtiaz and Madere, Christopher and Ghosh, Ishita and Adam,
   Rosalyn M. M. and De Benedetti, Arrigo},
Title = {Interaction of TLK1 and AKTIP as a Potential Regulator of AKT Activation
   in Castration-Resistant Prostate Cancer Progression},
Journal = {PATHOPHYSIOLOGY},
Year = {2021},
Volume = {28},
Number = {3},
Pages = {339-354},
Month = {SEP},
Abstract = {Prostate cancer (PCa) progression is characterized by the emergence of
   resistance to androgen deprivation therapy (ADT). AKT/PKB has been
   directly implicated in PCa progression, often due to the loss of PTEN
   and activation of PI3K>PDK1>AKT signaling. However, the regulatory
   network of AKT remains incompletely defined. Here, we describe the
   functional significance of AKTIP in PCa cell growth. AKTIP, identified
   in an interactome analysis as a substrate of TLK1B (that itself is
   elevated following ADT), enhances the association of AKT with PDK1 and
   its phosphorylation at T308 and S473. The interaction between TLK1 and
   AKTIP led to AKTIP phosphorylation at T22 and S237. The inactivation of
   TLK1 led to reduced AKT phosphorylation, which was potentiated with
   AKTIP knockdown. The TLK1 inhibitor J54 inhibited the growth of the
   LNCaP cells attributed to reduced AKT activation. However, LNCaP cells
   that expressed constitutively active, membrane-enriched Myr-AKT (which
   is expected to be active, even in the absence of AKTIP) were also
   growth-inhibited with J54. This suggested that other pathways (like
   TLK1>NEK1>YAP) regulating proliferation are also suppressed and can
   mediate growth inhibition, despite compensation by Myr-AKT. Nonetheless,
   further investigation of the potential role of TLK1>AKTIP>AKT in
   suppressing apoptosis, and conversely its reversal with J54, is
   warranted.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {De Benedetti, A (Corresponding Author), LSU Hlth Sci Ctr, Dept Biochem \& Mol Biol, Shreveport, LA 71103 USA.
   Khalil, Md Imtiaz; Madere, Christopher; Ghosh, Ishita; De Benedetti, Arrigo, LSU Hlth Sci Ctr, Dept Biochem \& Mol Biol, Shreveport, LA 71103 USA.
   Adam, Rosalyn M. M., Harvard Med Sch, Boston Childrens Hosp, Dept Urol, Boston, MA 02115 USA.
   Adam, Rosalyn M. M., Harvard Med Sch, Dept Surg, Boston, MA 02115 USA.},
DOI = {10.3390/pathophysiology28030023},
ISSN = {0928-4680},
EISSN = {1873-149X},
Keywords = {TLK1; AKTIP; FT1; FTS; PKB; AKT; prostate cancer; castration-resistant
   prostate cancer; apoptosis},
Keywords-Plus = {CELL-DEATH; KINASE; APOPTOSIS; PHOSPHORYLATION; IDENTIFICATION;
   SURVIVAL; PATHWAY; PROTEIN; BREAST; PTEN},
Research-Areas = {Pathology},
Web-of-Science-Categories  = {Pathology},
Author-Email = {mdimtiaz.khalil@lsuhs.edu
   ckmadere@yahoo.com
   Ishita.ghosh@lsuhs.edu
   Rosalyn.Adam@childrens.harvard.edu
   arrigo.debenedetti@lsuhs.edu},
Affiliations = {Louisiana State University System; Louisiana State University Health
   Sciences Center at Shreveport; Harvard University; Harvard University
   Medical Affiliates; Boston Children's Hospital; Harvard Medical School;
   Harvard University; Harvard Medical School},
ORCID-Numbers = {Khalil, Imtiaz/0000-0003-0345-2101
   Adam, Rosalyn/0000-0002-0943-6236
   de benedetti, arrigo/0000-0002-4198-8647},
Funding-Acknowledgement = {DOD Prostate Cancer Research Program {[}W81XWH-17-1-0417] Funding
   Source: Medline},
Cited-References = {Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X.
   Bhoir S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22744-5.
   Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8.
   Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2.
   Burla R, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160103.
   Burla R, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005167.
   Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318.
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008.
   Chen HX, 2016, FRONT BIOSCI-LANDMRK, V21, P1084, DOI 10.2741/4443.
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5.
   De Benedetti Arrigo, 2012, ISRN Mol Biol, V2012, P627596.
   de Bono JS, 2019, CLIN CANCER RES, V25, P928, DOI 10.1158/1078-0432.CCR-18-0981.
   Denmeade S R, 1996, Adv Pharmacol, V35, P281, DOI 10.1016/S1054-3589(08)60278-1.
   Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003.
   Gurumurthy S, 2001, CANCER METAST REV, V20, P225, DOI 10.1023/A:1015583310759.
   Han ZB, 2003, CURR BIOL, V13, P1921, DOI 10.1016/j.cub.2003.10.035.
   Khalil M.I., 2021, PROSTATE CANC CELL M.
   Khalil MI, 2020, CANCERS, V12, DOI 10.3390/cancers12123666.
   Lawlor MA, 2001, J CELL SCI, V114, P2903.
   Lesche R, 1997, MAMM GENOME, V8, P879, DOI 10.1007/s003359900604.
   Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298.
   LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1.
   Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006.
   Muthusami S, 2015, J CANCER RES CLIN, V141, P203, DOI 10.1007/s00432-014-1802-4.
   Norton KS, 2004, J SURG RES, V116, P98, DOI 10.1016/j.jss.2003.08.001.
   Oudard S, 2017, J CLIN ONCOL, V35, P3189, DOI 10.1200/JCO.2016.72.1068.
   Prabakaran DS, 2019, INT J BIOL MACROMOL, V126, P1318, DOI 10.1016/j.ijbiomac.2018.09.114.
   Remy I, 2004, MOL CELL BIOL, V24, P1493, DOI 10.1128/MCB.24.4.1493-1504.2004.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Segura-Bayona S, 2019, CELL MOL LIFE SCI, V76, P3827, DOI 10.1007/s00018-019-03208-z.
   Silljé HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6.
   Silljé HHW, 1999, EMBO J, V18, P5691, DOI 10.1093/emboj/18.20.5691.
   Singh V, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101474.
   Singh V, 2020, CELL CYCLE, V19, P363, DOI 10.1080/15384101.2019.1711317.
   Singh V, 2019, INT J CANCER, V145, P1055, DOI 10.1002/ijc.32200.
   Singh V, 2017, CELL CYCLE, V16, P915, DOI 10.1080/15384101.2017.1314421.
   Sunavala-Dossabhoy G, 2018, ORAL DIS, V24, P1390, DOI 10.1111/odi.12836.
   Sunavala-Dossabhoy G, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-1.
   Sunavala-Dossabhoy G, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-16.
   VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010.
   Zinda MJ, 2001, CLIN CANCER RES, V7, P2475.},
Number-of-Cited-References = {43},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Pathophysiology},
Doc-Delivery-Number = {J5UP4},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:001010269200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000710686000006,
Author = {Rho, Seung Bae and Lee, Keun Woo and Lee, Seung-Hoon and Byun, Hyun Jung
   and Kim, Boh-Ram and Lee, Chang Hoon},
Title = {Novel Anti-Angiogenic and Anti-Tumour Activities of the N-Terminal
   Domain of NOEY2 via Binding to VEGFR-2 in Ovarian Cancer},
Journal = {BIOMOLECULES \& THERAPEUTICS},
Year = {2021},
Volume = {29},
Number = {5},
Pages = {506-518},
Month = {SEP},
Abstract = {The imprinted tumour suppressor NOEY2 is downregulated in various cancer
   types, including ovarian cancers. Recent data suggest that NOEY2 plays
   an essential role in regulating the cell cycle, angiogenesis and
   autophagy in tumorigenesis. However, its detailed molecular function and
   mechanisms in ovarian tumours remain unclear. In this report, we
   initially demonstrated the inhibitory effect of NOEY2 on tumour growth
   by utilising a xenograft tumour model. NOEY2 attenuated the cell growth
   approximately fourfold and significantly reduced tumour vascularity.
   NOEY2 inhibited the phosphorylation of the signalling components
   downstream of phosphatidylinositol-3'-kinase (PI3K), including
   phosphoinositide-dependent protein kinase 1 (PDK-1), tuberous sclerosis
   complex 2 (TSC-2) and p70 ribosomal protein S6 kinase (p70S6K), during
   ovarian tumour progression via direct binding to vascular endothelial
   growth factor receptor-2 (VEGFR-2). Particularly, the N-terminal domain
   of NOEY2 (NOEY2-N) had a potent anti-angiogenic activity and
   dramatically downregulated VEGF and hypoxia-inducible factor-1 alpha
   (HIF-1 alpha), key regulators of angiogenesis. Since no X-ray or nuclear
   magnetic resonance structures is available for NOEY2, we constructed the
   threedimensional structure of this protein via molecular modelling
   methods, such as homology modelling and molecular dynamic simulations.
   Thereby, Lys15 and Arg16 appeared as key residues in the N-terminal
   domain. We also found that NOEY2-N acts as a potent inhibitor of
   tumorigenesis and angiogenesis. These findings provide convincing
   evidence that NOEY2-N regulates endothelial cell function and
   angiogenesis by interrupting the VEGFR-2/PDK-1/GSK-3 beta signal
   transduction and thus strongly suggest that NOEY2-N might serve as a
   novel anti-tumour and anti-angiogenic agent against many diseases,
   including ovarian cancer.},
Publisher = {KOREAN SOC APPLIED PHARMACOLOGY},
Address = {RM 805, KOREAN FEDERATION SCIENCE \& TECHNOLOGY B/D, 635-4 YEOKSAM-DONG,
   KANGNAM-GU, SEOUL, 135-703, SOUTH KOREA},
Type = {Article},
Language = {English},
Affiliation = {Kim, BR (Corresponding Author), Natl Canc Ctr, Res Inst, Div Translat Sci, Goyang 10408, South Korea.
   Kim, BR; Lee, CH (Corresponding Author), Dongguk Univ, Coll Pharm, BK21 FOUR Team, Seoul 10326, South Korea.
   Kim, BR; Lee, CH (Corresponding Author), Dongguk Univ, Integrated Res Inst Drug Dev, Coll Pharm, Seoul 10326, South Korea.
   Rho, Seung Bae; Kim, Boh-Ram, Natl Canc Ctr, Res Inst, Div Translat Sci, Goyang 10408, South Korea.
   Lee, Keun Woo, Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Dept Biochem, Div Appl Life Sci, Jinju 52828, South Korea.
   Lee, Seung-Hoon, Yong Univ, Dept Life Sci, Yongin 17092, South Korea.
   Byun, Hyun Jung; Kim, Boh-Ram; Lee, Chang Hoon, Dongguk Univ, Coll Pharm, BK21 FOUR Team, Seoul 10326, South Korea.
   Byun, Hyun Jung; Kim, Boh-Ram; Lee, Chang Hoon, Dongguk Univ, Integrated Res Inst Drug Dev, Coll Pharm, Seoul 10326, South Korea.},
DOI = {10.4062/biomolther.2021.121},
ISSN = {1976-9148},
EISSN = {2005-4483},
Keywords = {Ovarian cancer; VEGFR-2; NOEY2 N-terminal; Antiangiogenic activity;
   Homology modelling; Tumour suppressor},
Keywords-Plus = {ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTORS; TUMOR-SUPPRESSOR
   GENE; ARHI; PATHWAY; RAS; EXPRESSION; BREAST; AUTOPHAGY; HIF-1-ALPHA},
Research-Areas = {Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy},
Author-Email = {qtrami@gmail.com
   uatheone@dongguk.edu},
Affiliations = {National Cancer Center - Korea (NCC); Gyeongsang National University;
   Dongguk University; Dongguk University},
Funding-Acknowledgement = {National Cancer Center {[}NCC-0810410-3]; BK21 FOUR program; Basic
   Science Research Program, through the National Research Foundation (NRF)
   of Korea {[}NRF-2020R1A2C3004973, NRF-2018R1A5A2023127,
   NRF-2020M3E5E2038356]; NRF of Korea {[}NRF-2018H1A2A1061990]},
Funding-Text = {This study was partially supported by a grant from the National Cancer
   Center (NCC-0810410-3) , BK21 FOUR program, the Basic Science Research
   Program, through the National Research Foundation (NRF) of Korea
   (NRF-2020R1A2C3004973, NRF-2018R1A5A2023127, NRF-2020M3E5E2038356) , and
   Global PhD. Fellowship through the NRF of Korea (NRF-2018H1A2A1061990) .},
Cited-References = {Bamberger ES, 2002, J CLIN PATHOL-MOL PA, V55, P348, DOI 10.1136/mp.55.6.348.
   Bao JJ, 2002, CANCER RES, V62, P7264.
   Birner P, 2001, CLIN CANCER RES, V7, P1661.
   Byrne AM, 2005, J CELL MOL MED, V9, P777, DOI 10.1111/j.1582-4934.2005.tb00379.x.
   Conteduca V, 2014, INT J ONCOL, V44, P1417, DOI 10.3892/ijo.2014.2334.
   DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106.
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909.
   Gasper Raphael, 2010, Small GTPases, V1, P133, DOI 10.4161/sgtp.1.3.14742.
   Guo Bing-Qin, 2018, Oncotarget, V9, P30552, DOI {[}10.18632/oncotarget.25702, 10.18632/oncotarget.25702].
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081.
   Horikawa N, 2017, CLIN CANCER RES, V23, P587, DOI 10.1158/1078-0432.CCR-16-0387.
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9.
   Kang S, 2012, APOPTOSIS, V17, P989, DOI 10.1007/s10495-012-0717-2.
   Kim BR, 2015, ONCOTARGET, V6, P31830, DOI 10.18632/oncotarget.5570.
   Lheureux S, 2019, CA-CANCER J CLIN, V69, P280, DOI 10.3322/caac.21559.
   Li TL, 2018, ONCOL LETT, V16, P687, DOI 10.3892/ol.2018.8733.
   Lu Z, 2014, CELL DEATH DIFFER, V21, P1275, DOI 10.1038/cdd.2014.48.
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512.
   Lugano R, 2020, CELL MOL LIFE SCI, V77, P1745, DOI 10.1007/s00018-019-03351-7.
   Luo RZ, 2003, ONCOGENE, V22, P2897, DOI 10.1038/sj.onc.1206380.
   Maharjan S, 2019, BIOMOL THER, V27.
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022.
   Mao WQ, 2019, CANCER-AM CANCER SOC, V125, P1267, DOI 10.1002/cncr.31935.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200.
   Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130.
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0.
   Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21.
   Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128.
   Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488.
   Rho SB, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207622.
   Rho SB, 2012, CELL SIGNAL, V24, P131, DOI 10.1016/j.cellsig.2011.08.013.
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0.
   Shen W, 2017, EUR REV MED PHARMACO, V21, P2596.
   Shi R, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030678.
   Spannuth WA, 2009, INT J CANCER, V124, P1045, DOI 10.1002/ijc.24028.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI DOI 10.3322/caac.21660.
   Sutton MN, 2019, CELL REP, V29, P3448, DOI 10.1016/j.celrep.2019.11.045.
   Tuninetti V, 2020, CANCERS, V12, DOI 10.3390/cancers12082239.
   Wang XR, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.599281.
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009.
   Yu L, 2021, BIOCHEM PHARMACOL, V183, DOI 10.1016/j.bcp.2020.114339.
   Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214.
   Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.3.CO;2-N.
   Zhong C, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5643-z.},
Number-of-Cited-References = {45},
Times-Cited = {5},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Biomol. Ther.},
Doc-Delivery-Number = {WL8ZB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000710686000006},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000691118400001,
Author = {Li, Xu Dong and Wang, Min Jie and Zheng, Jiang Lin and Wu, Yue Hui and
   Wang, Xuan and Jiang, Xiao Bing},
Title = {Long noncoding RNA just proximal to X-inactive specific transcript
   facilitates aerobic glycolysis and temozolomide chemoresistance by
   promoting stability of PDK1 mRNA in an m6A-dependent manner in
   glioblastoma multiforme cells},
Journal = {CANCER SCIENCE},
Year = {2021},
Volume = {112},
Number = {11},
Pages = {4543-4552},
Month = {NOV},
Abstract = {Improving the chemotherapy resistance of temozolomide (TMZ) is of great
   significance in the treatment of glioblastoma multiforme (GBM). Long
   non-coding RNA just proximal to the X-inactive specific transcript (JPX)
   has been proven to be involved in cancer progression. However, the
   intrinsic significance and molecular mechanism by which JPX orchestrates
   GBM progression and TMZ chemotherapy resistance remain poorly
   understood. Here, JPX was found to be significantly elevated in GBM
   tissues and cell lines, and patients with high expressions of JPX showed
   significantly worse prognoses. Functional experiments revealed its
   carcinogenic roles in GBM cell proliferation, TMZ chemoresistance,
   anti-apoptosis, DNA damage repair, and aerobic glycolysis.
   Mechanistically, JPX formed a complex with phosphoinositide dependent
   kinase-1 (PDK1) messenger RNA (mRNA) and promoted its stability and
   expression. Furthermore, an RNA immunoprecipitation (RIP) experiment
   showed that JPX interacted with N6-methyladenosine (m6A) demethylase FTO
   alpha-ketoglutarate dependent dioxygenase (FTO) and enhanced
   FTO-mediated PDK1 mRNA demethylation. JPX exerted its GBM-promotion
   effects through the FTO/PDK1 axis. Taken together, these findings reveal
   the key role of JPX in promoting GBM aerobic glycolysis and TMZ
   chemoresistance in an m6A-dependent manner. Thus, it comprises a
   promising novel therapeutic target for GBM chemotherapy.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, X; Jiang, XB (Corresponding Author), Huazhong Univ Sci \& Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430022, Peoples R China.
   Li, Xu Dong; Wang, Min Jie; Zheng, Jiang Lin; Wu, Yue Hui; Wang, Xuan; Jiang, Xiao Bing, Huazhong Univ Sci \& Technol, Union Hosp, Tongji Med Coll, Dept Neurosurg, Wuhan 430022, Peoples R China.},
DOI = {10.1111/cas.15072},
EarlyAccessDate = {AUG 2021},
ISSN = {1347-9032},
EISSN = {1349-7006},
Keywords = {aerobic glycolysis; glioblastoma; just proximal to X-inactive; m6A
   methylation modification; TMZ chemoresistance},
Keywords-Plus = {ACUTE MYELOID-LEUKEMIA; RADIATION-RESISTANCE; EXPRESSION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {highprefer@126.com
   jxb917@126.com},
Affiliations = {Huazhong University of Science \& Technology},
ResearcherID-Numbers = {Li, Xudong/KVB-9994-2024
   Li, Xudong/KVB-9994-2024},
ORCID-Numbers = {Zheng, Jianglin/0000-0003-0616-2484
   Li, Xudong/0000-0002-7243-3564},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81272778, 81974390]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (81272778, 81974390).},
Cited-References = {Anjum K, 2017, BIOMED PHARMACOTHER, V92, P681, DOI 10.1016/j.biopha.2017.05.125.
   Baumeister J, 2020, LEUKEMIA, V34, P1062, DOI 10.1038/s41375-019-0629-z.
   Cao LM, 2017, ELIFE, V6, DOI 10.7554/eLife.30433.
   Chen Y, 2018, ARCH BIOCHEM BIOPHYS, V645, P117, DOI 10.1016/j.abb.2018.03.018.
   Deng XL, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00396.
   Doaei S, 2019, ARCH MED SCI, V15, P1133, DOI 10.5114/aoms.2019.87239.
   He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033.
   Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457.
   Hotchkiss KM, 2021, J NEURO-ONCOL, V151, P55, DOI 10.1007/s11060-020-03598-2.
   Jing PH, 2020, EXP CELL RES, V386, DOI 10.1016/j.yexcr.2019.111746.
   Jing ZH, 2019, CANCER BIOMARK, V26, P385, DOI 10.3233/cbm-190246.
   Koukourakis MI, 2019, INT J RADIAT BIOL, V95, P408, DOI 10.1080/09553002.2018.1490041.
   Li N, 2018, RADIAT ONCOL, V13, DOI 10.1186/s13014-018-1153-4.
   Li Q, 2019, BIOMED PHARMACOTHER, V109, P1793, DOI 10.1016/j.biopha.2018.11.003.
   Li Zejuan, 2017, Cancer Cell, V31, P127, DOI 10.1016/j.ccell.2016.11.017.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Luo HC, 2019, CANCER CELL, V36, P645, DOI 10.1016/j.ccell.2019.10.011.
   Luo KL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1263-3.
   Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7.
   Ma XK, 2018, ONCOTARGETS THER, V11, P8399, DOI 10.2147/OTT.S182573.
   Mao YH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13317-9.
   Mims J, 2015, RADIAT RES, V183, P291, DOI 10.1667/RR13828.1.
   Papaioannou D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13259-2.
   Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Su YS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01038.
   Wang GY, 2019, LEUKEMIA RES, V87, DOI 10.1016/j.leukres.2019.106265.
   Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016.
   Xu XD, 2015, ONCOL RES TREAT, V38, P117, DOI 10.1159/000375435.
   Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0.
   Zeng H, 2020, LEUKEMIA RES, V88, DOI 10.1016/j.leukres.2019.106261.
   Zimta AA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01048.},
Number-of-Cited-References = {32},
Times-Cited = {56},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Cancer Sci.},
Doc-Delivery-Number = {WV8CN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000691118400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000692765400001,
Author = {Cao, Jianghong and Shi, Dongwu and Zhu, Lili and Song, Lu},
Title = {Circ\_RASGEF1B Promotes LPS-Induced Apoptosis and Inflammatory Response
   by Targeting MicroRNA-146a-5p/Pdk1 Axis in Septic Acute Kidney Injury
   Cell Model},
Journal = {NEPHRON},
Year = {2021},
Volume = {145},
Number = {6},
Pages = {748-759},
Month = {NOV},
Abstract = {Background: We intended to investigate the function of circular RNA
   RasGEF domain family member 1B (circ\_RASGEF1B) in lipopolysaccharide
   (LPS)-induced septic acute kidney injury (AKI) cell model and its
   associated mechanism. Methods: TCMK-1 cells were exposed to 10 mu g/mL
   LPS for 24 h to establish a septic AKI cell model. Mice were
   intraperitoneally injected with 10 mg/kg LPS to establish a septic AKI
   mice model. Reverse transcription quantitative polymerase chain reaction
   (RT-qPCR) and Western blot assay were used to measure RNA and protein
   expression, respectively. Cell viability and apoptosis were assessed by
   3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and
   flow cytometry. Cell inflammatory response was analyzed using
   enzyme-linked immunosorbent assay. Dual-luciferase reporter assay was
   conducted to confirm the predicted target relationship between
   microRNA-146a-5p (miR-146a-5p) and circ\_RASGEF1B or pyruvate
   dehydrogenase kinase 1 (Pdk1). Results: The circ\_RASGEF1B level was
   upregulated in LPS-induced TCMK-1 cells and septic AKI mice models. LPS
   exposure reduced cell viability and promoted cell apoptosis and
   inflammatory response partly by upregulating circ\_RASGEF1B.
   Circ\_RASGEF1B bound to miR-146a-5p and miR-146a-5p interference partly
   overturned circ\_RASGEF1B silencing-mediated effects in LPS-induced
   TCMK-1 cells. Pdk1 was a target of miR-146a-5p, and Pdk1 accumulation
   partly counteracted miR-146a-5p-induced influences in TCMK-1 cells upon
   LPS stimulation. Conclusion: Circ\_RASGEF1B promoted LPS-induced
   apoptosis and inflammatory response in renal tubular epithelial cells
   partly by upregulating Pdk1 via acting as miR-146a-5p sponge.},
Publisher = {KARGER},
Address = {ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Shi, DW (Corresponding Author), Shanxi Prov Peoples Hosp, Dept Intens Care Unit, Taiyuan, Peoples R China.
   Cao, Jianghong; Shi, Dongwu; Zhu, Lili; Song, Lu, Shanxi Prov Peoples Hosp, Dept Intens Care Unit, Taiyuan, Peoples R China.},
DOI = {10.1159/000517475},
EarlyAccessDate = {AUG 2021},
ISSN = {1660-8151},
EISSN = {2235-3186},
Keywords = {Septic acute kidney injury; Lipopolysaccharide; Circular RNA RasGEF
   domain family member 1B; MicroRNA-146a-5p; Pyruvate dehydrogenase kinase
   1},
Keywords-Plus = {MICRORNAS},
Research-Areas = {Urology \& Nephrology},
Web-of-Science-Categories  = {Urology \& Nephrology},
Author-Email = {ngvewa@163.com},
Affiliations = {Shanxi People's Hospital},
Cited-References = {Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103.
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993.
   Ho J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1555-3.
   Lameire N, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1382-6.
   Li HY, 2021, DIABETOL METAB SYNDR, V13, DOI 10.1186/s13098-021-00625-8.
   Li W, 2017, ONCOTARGET, V8, P65143, DOI 10.18632/oncotarget.17821.
   Lin JX, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1416-4.
   Mayeux PR, 2012, PHARMACOL THERAPEUT, V134, P139, DOI 10.1016/j.pharmthera.2012.01.004.
   Netti GS, 2019, AM J PHYSIOL-RENAL, V316, pF723, DOI 10.1152/ajprenal.00491.2018.
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708.
   O'Neill LA, 2011, NAT REV IMMUNOL, V11, P163, DOI 10.1038/nri2957.
   Qin WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49480-8.
   Róka B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010200.
   Seckel MA, 2016, CRIT CARE NURS CLIN, V28, P513, DOI 10.1016/j.cnc.2016.08.001.
   Shen YZ, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102-865020190060000002.
   Shi Y, 2020, J CELL MOL MED, V24, P11397, DOI 10.1111/jcmm.15741.
   Stoyanoff TR, 2014, TOXICOLOGY, V318, P13, DOI 10.1016/j.tox.2014.01.011.
   Wang JF, 2010, BIOCHEM BIOPH RES CO, V394, P184, DOI 10.1016/j.bbrc.2010.02.145.
   Wang XD, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200527.
   Wei W, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.01.
   Wei YY, 2019, ONCOTARGETS THER, V12, P9005, DOI 10.2147/OTT.S213059.
   Ye HY, 2017, INFLAMMATION, V40, P523, DOI 10.1007/s10753-016-0498-9.
   Yuan YS, 2020, EUR REV MED PHARMACO, V24, P5592, DOI 10.26355/eurrev\_202005\_21345.
   Zafrani L, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1581-1.
   Zhang XB, 2019, NEPHRON, V143, P135, DOI 10.1159/000501038.},
Number-of-Cited-References = {25},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Nephron},
Doc-Delivery-Number = {YZ1ZP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000692765400001},
DA = {2026-02-04},
}

@article{ WOS:000687968300001,
Author = {Chen, Jing and Alduais, Yaser and Zhang, Kai and Zhu, Xiaoli and Chen,
   Baoan},
Title = {CCAT1/FABP5 promotes tumour progression through mediating fatty acid
   metabolism and stabilizing PI3K/AKT/mTOR signalling in lung
   adenocarcinoma},
Journal = {JOURNAL OF CELLULAR AND MOLECULAR MEDICINE},
Year = {2021},
Volume = {25},
Number = {19},
Pages = {9199-9213},
Month = {OCT},
Abstract = {Long non-coding RNA (lncRNA) colon cancer associated transcript 1
   (CCAT1) has been identified as an oncogene in many cancers, but its role
   in lung adenocarcinoma (LUAD) remains to be further investigated. We
   identified the upregulation of CCAT1 in LUAD tissues and LUAD cells.
   Through RNA pull-down and mass spectrometry analysis, we obtained the
   interacting proteins with CCAT1 and discovered their functional relation
   with `signal transduction', `energy pathways' and `metabolism' and
   revealed the potential of CCAT1 on fatty acid (FA) metabolism. For
   mechanism exploration, we uncovered the mediation of CCAT1 on the
   translocation of fatty acid binding protein 5 (FABP5) into nucleus by
   confirming their interaction and localization. Also, CCAT1 was
   discovered to promote the formation of the transcription complex by RXR
   and PPAR gamma so as to activate the transcription of CD36, PDK1 and
   VEGFA. Moreover, we found that CCAT1 regulated the activity of AKT by
   promoting the ubiquitination of FKBP51 through binding with USP49.
   Subsequently, cell function assays revealed the enhancement of CCAT1 on
   LUAD cell proliferation and angiogenesis in vitro and in vivo.
   Collectively, CCAT1 regulated cell proliferation and angiogenesis
   through regulating FA metabolism in LUAD, providing a novel target for
   LUAD treatment.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Chen, J (Corresponding Author), Southeast Univ, Zhongda Hosp, Sch Med, Dept Hematol \& Oncol, Dingjiaqiao 87, Nanjing 210009, Jiangsu, Peoples R China.
   Chen, Jing; Alduais, Yaser; Chen, Baoan, Southeast Univ, Zhongda Hosp, Sch Med, Dept Hematol \& Oncol, Dingjiaqiao 87, Nanjing 210009, Jiangsu, Peoples R China.
   Zhang, Kai, Nanjing First Hosp, Dept Resp Med, Nanjing, Peoples R China.
   Zhu, Xiaoli, Southeast Univ, Zhongda Hosp, Sch Med, Dept Resp Med, Nanjing, Peoples R China.},
DOI = {10.1111/jcmm.16815},
EarlyAccessDate = {AUG 2021},
ISSN = {1582-1838},
EISSN = {1582-4934},
Keywords = {angiogenesis; CCAT1; fatty acid metabolism; lung adenocarcinoma;
   ubiquitination},
Keywords-Plus = {LONG NONCODING RNAS; BINDING PROTEIN 5; HEPATOCELLULAR-CARCINOMA;
   LIPID-METABOLISM; CANCER; METASTASIS; CELLS; REGULATOR; EVOLUTION;
   HALLMARKS},
Research-Areas = {Cell Biology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Cell Biology; Medicine, Research \& Experimental},
Author-Email = {chenjing91@outlook.com},
Affiliations = {Southeast University - China; Southeast University - China},
ResearcherID-Numbers = {Chen, Jing/IAN-2749-2023},
Funding-Acknowledgement = {Jiangsu Planned Projects for Postdoctoral Research Funds; China
   Postdoctoral Science Foundation {[}2020M671534]; Fundamental Research
   Funds for the Central Universities {[}2242020R20006]; National Natural
   Science Foundation of China {[}81903089, 81903091]},
Funding-Text = {the Jiangsu Planned Projects for Postdoctoral Research Funds; the China
   Postdoctoral Science Foundation funded project, Grant/Award Number:
   2020M671534; the Fundamental Research Funds for the Central
   Universities, Grant/Award Number: 2242020R20006; National Natural
   Science Foundation of China, Grant/Award Number: 81903089 and 81903091},
Cited-References = {Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Chen J, 2016, ONCOTARGET, V7, P62474, DOI 10.18632/oncotarget.11518.
   Crunkhorn S., 2016, NAT REV DRUG DISCOV, V15, P310, DOI {[}10.1038/nrd.2016.76, DOI 10.1038/NRD.2016.76].
   Cui M, 2015, CANCER RES, V75, P846, DOI 10.1158/0008-5472.CAN-14-1192.
   Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017.
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589.
   Gettinger S, 2011, CLIN CHEST MED, V32, P839, DOI 10.1016/j.ccm.2011.08.017.
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029.
   Jiang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06081-9.
   Li JB, 2015, J HEPATOL, V63, P1378, DOI 10.1016/j.jhep.2015.07.039.
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926.
   Luo KT, 2017, EMBO J, V36, P1434, DOI 10.15252/embj.201695669.
   Ma MZ, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.541.
   McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265.
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Nissan A, 2012, INT J CANCER, V130, P1598, DOI 10.1002/ijc.26170.
   Ohata T, 2017, CANCER MED-US, V6, P1049, DOI 10.1002/cam4.1020.
   Ozawa T, 2017, ANN ONCOL, V28, P1882, DOI 10.1093/annonc/mdx248.
   Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791.
   Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016.
   Pepino MY, 2014, ANNU REV NUTR, V34, P281, DOI 10.1146/annurev-nutr-071812-161220.
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209.
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902.
   Shang CL, 2018, CANCER RES, V78, P877, DOI 10.1158/0008-5472.CAN-17-2356.
   Storch J, 2010, J BIOL CHEM, V285, P32679, DOI 10.1074/jbc.R110.135210.
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020.
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018.
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001.
   Wei YZ, 2017, ONCOTARGET, V8, P71430, DOI 10.18632/oncotarget.19864.
   Yu CW, 2016, ANGIOGENESIS, V19, P95, DOI 10.1007/s10456-015-9491-4.
   Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247.},
Number-of-Cited-References = {37},
Times-Cited = {51},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {26},
Journal-ISO = {J. Cell. Mol. Med.},
Doc-Delivery-Number = {WD3SZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000687968300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000729342100001,
Author = {Ren, Yujie and Wang, An and Fang, Yuan and Shu, Ting and Wu, Di and
   Wang, Chong and Huang, Muhan and Min, Juan and Jin, Liang and Zhou, Wei
   and Qiu, Yang and Zhou, Xi},
Title = {SARS-CoV-2 Membrane Glycoprotein M Triggers Apoptosis With the
   Assistance of Nucleocapsid Protein N in Cells},
Journal = {FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY},
Year = {2021},
Volume = {11},
Month = {AUG 25},
Abstract = {The pandemic of COVID-19 by SARS-CoV-2 has become a global disaster.
   However, we still don't know how specific SARS-CoV-2-encoded proteins
   contribute to viral pathogenicity. We found that SARS-CoV-2-encoded
   membrane glycoprotein M could induce caspase-dependent apoptosis via
   interacting with PDK1 and inhibiting the activation of PDK1-PKB/Akt
   signaling. Our investigation further revealed that SARS-CoV-2-encoded
   nucleocapsid protein N could specifically enhance the M-induced
   apoptosis via interacting with both M and PDK1, therefore strengthening
   M-mediated attenuation of PDK1-PKB/Akt interaction. Furthermore, when
   the M-N interaction was disrupted via certain rationally designed
   peptides, the PDK1-PKB/Akt signaling was restored, and the boosting
   activity of N on the M-triggered apoptosis was abolished. Overall, our
   findings uncovered a novel mechanism by which SARS-CoV-2-encoded M
   triggers apoptosis with the assistance of N, which expands our
   understanding of the two key proteins of SARS-CoV-2 and sheds light on
   the pathogenicity of this life-threatening virus.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhou, W (Corresponding Author), Guangzhou Women \& Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou, Peoples R China.
   Qiu, Y; Zhou, X (Corresponding Author), Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Ctr Biosafety Mega Sci, Wuhan, Peoples R China.
   Qiu, Y; Zhou, X (Corresponding Author), Chinese Acad Sci, Wuhan Inst Virol, Joint Lab Infect Dis \& Hlth, Wuhan, Peoples R China.
   Qiu, Y; Zhou, X (Corresponding Author), Chinese Acad Sci, Wuhan Jinyintan Hosp, Wuhan, Peoples R China.
   Qiu, Y; Zhou, X (Corresponding Author), Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China.
   Zhou, X (Corresponding Author), Jiangxi Acad Sci, Inst Microbiol, Nanchang, Jiangxi, Peoples R China.
   Ren, Yujie; Wang, Chong; Zhou, Wei, Guangzhou Women \& Childrens Med Ctr, Guangzhou Inst Pediat, Guangzhou, Peoples R China.
   Ren, Yujie; Wang, An; Fang, Yuan; Shu, Ting; Wu, Di; Wang, Chong; Huang, Muhan; Min, Juan; Qiu, Yang; Zhou, Xi, Chinese Acad Sci, Wuhan Inst Virol, State Key Lab Virol, Ctr Biosafety Mega Sci, Wuhan, Peoples R China.
   Wang, An; Shu, Ting; Wu, Di; Huang, Muhan; Qiu, Yang; Zhou, Xi, Chinese Acad Sci, Wuhan Inst Virol, Joint Lab Infect Dis \& Hlth, Wuhan, Peoples R China.
   Wang, An; Shu, Ting; Wu, Di; Huang, Muhan; Qiu, Yang; Zhou, Xi, Chinese Acad Sci, Wuhan Jinyintan Hosp, Wuhan, Peoples R China.
   Wang, An; Qiu, Yang; Zhou, Xi, Univ Chinese Acad Sci, Coll Life Sci, Beijing, Peoples R China.
   Jin, Liang; Zhou, Xi, Jiangxi Acad Sci, Inst Microbiol, Nanchang, Jiangxi, Peoples R China.},
DOI = {10.3389/fcimb.2021.706252},
Article-Number = {706252},
ISSN = {2235-2988},
Keywords = {SARS-CoV-2; nucleocapsid protein; apoptosis; PDK1-Akt signaling;
   membrane glycoprotein},
Keywords-Plus = {SARS-CORONAVIRUS; AKT; EXPRESSION; ACTIVATION; MECHANISMS; INFECTION;
   SURVIVAL; PDK1},
Research-Areas = {Immunology; Microbiology},
Web-of-Science-Categories  = {Immunology; Microbiology},
Author-Email = {zhouwei\_pu002@126.com
   yangqiu@wh.iov.cn
   zhouxi@wh.iov.cn},
Affiliations = {Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Chinese
   Academy of Sciences; Wuhan Institute of Virology, CAS; Chinese Academy
   of Sciences; Wuhan Jinyintan Hospital; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS; Jiangxi Academy of
   Sciences},
ResearcherID-Numbers = {Wang, An/MAI-0064-2025
   Wu, Di/HNP-3772-2023
   Zhou, Xi/J-1902-2012},
ORCID-Numbers = {Wang, An/0009-0004-6923-2181
   Zhou, Xi/0000-0002-3846-5079},
Funding-Acknowledgement = {Strategic Priority Research Program of CAS {[}XDB29010300]; National
   Science and Technology Major Project {[}2018ZX10101004]; National
   Natural Science Foundation of China {[}31970169, 81873964, 32000131];
   China Postdoctoral Science Foundation {[}2019M660198]; CAS Youth
   Innovation Promotion Association {[}2020332]},
Funding-Text = {Funding This work was supported by the Strategic Priority Research
   Program of CAS (XDB29010300 to XZ), National Science and Technology
   Major Project (2018ZX10101004 to XZ), National Natural Science
   Foundation of China (31970169 to XZ, 81873964 to YQ and 32000131 to DW),
   China Postdoctoral Science Foundation (2019M660198 to YR) and Grant from
   the CAS Youth Innovation Promotion Association (2020332 to YQ).},
Cited-References = {Ali SA, 2020, J INFECT PUBLIC HEAL, V13, P644, DOI {[}10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2020.02.033, 10.1016/j.jiph.2019.02.033].
   Almazán F, 2014, VIRUS RES, V189, P262, DOI 10.1016/j.virusres.2014.05.026.
   Arabi YM, 2015, INFECTION, V43, P495, DOI 10.1007/s15010-015-0720-y.
   Bagci EZ, 2013, J CLIN MONIT COMPUT, V27, P465, DOI 10.1007/s10877-013-9468-z.
   Benedict CA, 2002, NAT IMMUNOL, V3, P1013, DOI 10.1038/ni1102-1013.
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4.
   Chen Y, 2016, VIROL SIN, V31, P3, DOI 10.1007/s12250-016-3726-4.
   Cong HL, 2016, J VIROL, V90, P9862, DOI 10.1128/JVI.01499-16.
   de Wit E, 2016, NAT REV MICROBIOL, V14, P523, DOI 10.1038/nrmicro.2016.81.
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301.
   Ding YQ, 2019, VIROL SIN, V34, P78, DOI 10.1007/s12250-019-00088-2.
   Frieman M, 2008, VIRUS RES, V133, P101, DOI 10.1016/j.virusres.2007.03.015.
   Gordon DE, 2020, NATURE, V583, P459, DOI 10.1038/s41586-020-2286-9.
   Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710.
   Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179.
   Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001.
   Kuo RL, 2002, J GEN VIROL, V83, P1367, DOI 10.1099/0022-1317-83-6-1367.
   Li J, 2017, J VIROL, V91, DOI 10.1128/JVI.02016-16.
   Lu B, 2017, CELL HOST MICROBE, V22, P86, DOI 10.1016/j.chom.2017.06.013.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Martin SJ, 2012, MOL CELL, V46, P387, DOI 10.1016/j.molcel.2012.04.026.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Najafov A, 2012, BIOCHEM J, V448, P285, DOI 10.1042/BJ20121287.
   Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108.
   Ren YJ, 2020, CELL MOL IMMUNOL, V17, P881, DOI 10.1038/s41423-020-0485-9.
   Ren YJ, 2016, J BIOL CHEM, V291, P13206, DOI 10.1074/jbc.M116.718080.
   Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577.
   Schultz DR, 2003, SEMIN ARTHRITIS RHEU, V32, P345, DOI 10.1053/sarh.2003.50005.
   Shu T, 2020, VIROL SIN, V35, P321, DOI 10.1007/s12250-020-00242-1.
   Soares JAP, 2009, J VIROL, V83, P6883, DOI 10.1128/JVI.00245-09.
   Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002.
   Surjit M, 2004, BIOCHEM J, V383, P13, DOI 10.1042/BJ20040984.
   Tsoi H, 2014, BIOCHEM J, V464, P439, DOI 10.1042/BJ20131461.
   Xiong Y, 2020, EMERG MICROBES INFEC, V9, P761, DOI 10.1080/22221751.2020.1747363.
   Zhou H, 2020, VIROL SIN, V35, P436, DOI 10.1007/s12250-019-00182-5.},
Number-of-Cited-References = {35},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Front. Cell. Infect. Microbiol.},
Doc-Delivery-Number = {XN2LN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000729342100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000687404200014,
Author = {Truebestein, Linda and Hornegger, Harald and Anrather, Dorothea and
   Hartl, Markus and Fleming, Kaelin D. and Stariha, Jordan T. B. and
   Pardon, Els and Steyaert, Jan and Burke, John E. and Leonard, Thomas A.},
Title = {Structure of autoinhibited Akt1 reveals mechanism of PIP3-mediated
   activation},
Journal = {PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA},
Year = {2021},
Volume = {118},
Number = {33},
Month = {AUG 17},
Abstract = {The protein kinase Akt is one of the primary effectors of growth factor
   signaling in the cell. Akt responds specifically to the lipid second
   messengers phosphatidylinositol-3,4,5-trisphosphate {[}PI(3,4,5) P31 and
   phosphatidylinositol-3,4-bisphosphate {[}PI(3,4)P21 via its PH domain,
   leading to phosphorylation of its activation loop and the hydrophobic
   motif of its kinase domain, which are critical for activity. We have now
   determined the crystal structure of Akt1, revealing an autoinhibitory
   interface between the PH and kinase domains that is often mutated in
   cancer and overgrowth disorders. This interface persists even after
   stoichiometric phosphorylation, thereby restricting maximum Akt activity
   to PI(3,4,5)P3- or PI(3,4)P2-containing membranes. Our work helps to
   resolve the roles of lipids and phosphorylation in the activation of Akt
   and has wide implications for the spatiotemporal control of Akt and
   potentially lipid-activated kinase signaling in general.},
Publisher = {NATL ACAD SCIENCES},
Address = {2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA},
Type = {Article},
Language = {English},
Affiliation = {Leonard, TA (Corresponding Author), Vienna BioCtr, Max Perutz Labs, Dept Struct \& Computat Biol, A-1030 Vienna, Austria.
   Leonard, TA (Corresponding Author), Med Univ Vienna, Dept Med Biochem, A-1090 Vienna, Austria.
   Truebestein, Linda; Hornegger, Harald; Leonard, Thomas A., Vienna BioCtr, Max Perutz Labs, Dept Struct \& Computat Biol, A-1030 Vienna, Austria.
   Truebestein, Linda; Hornegger, Harald; Leonard, Thomas A., Med Univ Vienna, Dept Med Biochem, A-1090 Vienna, Austria.
   Anrather, Dorothea; Hartl, Markus, Vienna BioCtr, Max Perutz Labs, Mass Spectrometry Core Facil, A-1030 Vienna, Austria.
   Fleming, Kaelin D.; Stariha, Jordan T. B.; Burke, John E., Univ Victoria, Dept Biochem \& Microbiol, Victoria, BC V8W 2Y2, Canada.
   Pardon, Els; Steyaert, Jan, Vrije Univ Brussel VUB, Struct Biol Brussels, B-1050 Brussels, Belgium.
   Pardon, Els; Steyaert, Jan, Vlaams Inst Biotechnol VIB, VIB VUB Ctr Struct Biol, B-1050 Brussels, Belgium.
   Burke, John E., Univ British Columbia, Dept Biochem \& Mol Biol, Vancouver, BC V6T 1Z3, Canada.},
DOI = {10.1073/pnas.2101496118},
Article-Number = {e2101496118},
ISSN = {0027-8424},
EISSN = {1091-6490},
Keywords = {Kinase\&nbsp; signaling; lipid; PIP3; Akt},
Keywords-Plus = {PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE B/AKT; MOLECULAR-MECHANISM;
   CRYSTAL-STRUCTURE; PHOSPHORYLATION; MUTATION; AKT/PKB; COMPLEX; PH;
   PHOSPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {thomas.leonard@meduniwien.ac.at},
Affiliations = {Medical University of Vienna; University of Vienna; Vienna Biocenter
   (VBC); Max F. Perutz Laboratories (MFPL); Medical University of Vienna;
   Medical University of Vienna; University of Vienna; Vienna Biocenter
   (VBC); Max F. Perutz Laboratories (MFPL); University of Victoria; Vrije
   Universiteit Brussel; Flanders Institute for Biotechnology (VIB);
   University of British Columbia},
ResearcherID-Numbers = {Pardon, Els/AGJ-2571-2022
   Burke, John/H-3922-2019
   Leonard, Thomas/A-5143-2013
   Hartl, Markus/F-2866-2010
   Steyaert, Jan/GQP-7811-2022
   },
ORCID-Numbers = {Pardon, Els/0000-0002-2466-0172
   Trübestein, Linda/0000-0002-0596-201X
   Anrather, Dorothea/0000-0003-1677-2403
   Burke, John/0000-0001-7904-9859
   Leonard, Thomas/0000-0001-6853-666X
   Hornegger, Harald/0000-0001-7703-9710
   Hartl, Markus/0000-0002-4970-7336
   Stariha, Jordan/0000-0002-9501-3722
   Steyaert, Jan/0000-0002-3825-874X
   Fleming, Kaelin/0000-0003-3063-7865},
Funding-Acknowledgement = {Austrian Science Fund {[}P28135, P30584, P33066]; Hertha Firnberg
   Postdoctoral Fellowship {[}T915]; Michael Smith Foundation for Health
   Research Scholar award {[}17686]; Cancer Research Society {[}CRS-24368];
   Austrian Science Fund (FWF) {[}P28135, P33066, P30584, T915] Funding
   Source: Austrian Science Fund (FWF)},
Funding-Text = {We thank Montserrat Soler-Lopez for assistance with macromolecular
   crystallography data collection on beam line ID23-2 and Petra Pernot for
   SAXS data collection on BM29 at the ESRF. We also thank Aleksandra
   Levina for purified PDK1. Intact mass analyses and phosphorylation
   mapping were performed on instruments at the Vienna BioCenter Core
   Facilities. This work was supported by Austrian Science Fund Grants
   P28135, P30584, and P33066 to T.A.L. and Hertha Firnberg Postdoctoral
   Fellowship T915 to L.T. J.E.B. is supported by a Michael Smith
   Foundation for Health Research Scholar award (17686) and an operating
   grant from the Cancer Research Society (CRS-24368). We acknowledge
   INsTRuCT, part of the European Strategy Forum on Research
   Infrastructures, and the Research Foundation-Flanders for their support
   of the nanobody discovery. We thank Alison Lunqdvist for technical
   assistance in nanobody discovery.},
Cited-References = {Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308.
   Ahmad M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1258.
   Alcantara D, 2017, BRAIN, V140, P2610, DOI 10.1093/brain/awx203.
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Ananthanarayanan B, 2007, J BIOL CHEM, V282, P36634, DOI 10.1074/jbc.M706227200.
   Balasuriya N, 2018, J BIOL CHEM, V293, P10744, DOI 10.1074/jbc.RA118.002357.
   Balzano D, 2015, J BIOL CHEM, V290, P24975, DOI 10.1074/jbc.M115.651570.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Calleja Veronique, 2009, J Chem Biol, V2, P11, DOI 10.1007/s12154-009-0016-8.
   Calleja V, 2009, PLOS BIOL, V7, P189, DOI 10.1371/journal.pbio.1000017.
   Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933.
   Chan TO, 2011, P NATL ACAD SCI USA, V108, pE1120, DOI 10.1073/pnas.1109879108.
   Choi S, 2016, NAT CELL BIOL, V18, P1324, DOI 10.1038/ncb3441.
   Chu N, 2020, ELIFE, V9, DOI 10.7554/eLife.59151.
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003.
   Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044.
   Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028.
   Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158.
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120.
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075.
   Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   George S, 2004, SCIENCE, V304, P1325, DOI 10.1126/science.1096706.
   Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007.
   Han EKH, 2007, ONCOGENE, V26, P5655, DOI 10.1038/sj.onc.1210343.
   James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709.
   Jethwa N, 2015, J CELL SCI, V128, P3456, DOI 10.1242/jcs.172775.
   Jubb HC, 2017, J MOL BIOL, V429, P365, DOI 10.1016/j.jmb.2016.12.004.
   Kannan N, 2007, P NATL ACAD SCI USA, V104, P1272, DOI 10.1073/pnas.0610251104.
   Karlsson R, 2006, ANAL BIOCHEM, V349, P136, DOI 10.1016/j.ab.2005.09.034.
   Kim C, 2007, CELL, V130, P1032, DOI 10.1016/j.cell.2007.07.018.
   Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200.
   Landgraf KE, 2008, BIOCHEMISTRY-US, V47, P12260, DOI 10.1021/bi801683k.
   Lapierre JM, 2016, J MED CHEM, V59, P6455, DOI 10.1021/acs.jmedchem.6b00619.
   Lee JH, 2012, NAT GENET, V44, P941, DOI 10.1038/ng.2329.
   Leonard TA, 2018, P NATL ACAD SCI USA, V115, pE6101, DOI 10.1073/pnas.1808882115.
   Lin K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002618.
   Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017.
   Liu SL, 2018, MOL CELL, V71, P1092, DOI 10.1016/j.molcel.2018.07.035.
   Lu SY, 2015, STRUCTURE, V23, P1725, DOI 10.1016/j.str.2015.06.027.
   Lucic I, 2018, P NATL ACAD SCI USA, V115, pE3940, DOI 10.1073/pnas.1716109115.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206.
   Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271.
   Okuzumi T, 2009, NAT CHEM BIOL, V5, P484, DOI 10.1038/nchembio.183.
   Pardon E, 2014, NAT PROTOC, V9, P674, DOI 10.1038/nprot.2014.039.
   Parikh C, 2012, P NATL ACAD SCI USA, V109, P19368, DOI 10.1073/pnas.1204384109.
   Patel AK, 2011, J MOL BIOL, V409, P369, DOI 10.1016/j.jmb.2011.03.065.
   Petoukhov MV, 2007, J APPL CRYSTALLOGR, V40, pS223, DOI 10.1107/S0021889807002853.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sasaki K, 2003, J BIOL CHEM, V278, P30945, DOI 10.1074/jbc.M212167200.
   Siess KM, 2019, BIOCHEM SOC T, V47, P897, DOI 10.1042/BST20190013.
   Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7.
   Warfel NA, 2011, J BIOL CHEM, V286, P39122, DOI 10.1074/jbc.M111.278747.
   Weisner J, 2019, CANCER RES, V79, P2367, DOI 10.1158/0008-5472.CAN-18-2861.
   Wu WI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012913.
   Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Zhang XL, 2006, J BIOL CHEM, V281, P13949, DOI 10.1074/jbc.M601384200.
   Zhou XM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15189-w.},
Number-of-Cited-References = {63},
Times-Cited = {67},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Proc. Natl. Acad. Sci. U. S. A.},
Doc-Delivery-Number = {UD7SG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000687404200014},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000686656700001,
Author = {Qi, Yingying and Mo, Kexin and Zhang, Ting},
Title = {A transcription factor that promotes proliferation, migration, invasion,
   and epithelial-mesenchymal transition of ovarian cancer cells and its
   possible mechanisms},
Journal = {BIOMEDICAL ENGINEERING ONLINE},
Year = {2021},
Volume = {20},
Number = {1},
Month = {AUG 16},
Abstract = {Background Ovarian cancer is one of the most common gynecological
   malignancies with the high morbidity and mortality. This study was aimed
   to explore the role of non-structure maintenance of chromosomes
   condensin I complex subunit H (NCAPH) in the progression of ovarian
   cancer (OC) and the transcription regulatory effects of GATA binding
   protein 3 (GATA3) on this gene. Methods Firstly, NCAPH and GATA3
   expression in OC tissues and several human OC cell lines was,
   respectively, evaluated by TNMplot database and Western blot analysis.
   Then, NCAPH was silenced to assess the proliferation, migration, and
   invasion of OC cells in turn using CCK-8, wound healing, and transwell
   assays. Western blotting was used to determine the expression of
   epithelial--mesenchymal transition (EMT)-related proteins and
   PI3K/PDK1/AKT signaling proteins. The potential binding sites of GATA3
   on NCAPH promoter were predicated using JASPAR database, which were
   verified by luciferase reporter assay and chromosomal
   immunoprecipitation. Subsequently, GATA3 was overexpressed to examine
   the biological functions of OC cells with NCAPH silencing. Results NCAPH
   and GATA3 expression was significantly upregulated in OC tissues and
   cell lines. NCAPH loss-of-function notably inhibited the proliferation,
   migration, invasion, and EMT of OC cells. Moreover, the expression of
   p-PI3K, PDK1, and p-AKT was downregulated after NCAPH knockdown.
   Furthermore, GATA3 was confirmed to bind to NCAPH promoter. GATA3
   overexpression alleviated the inhibitory effects of NCAPH silencing on
   the proliferation, migration, invasion, EMT, and expression of proteins
   in PI3K/PDK1/AKT pathway of OC cells. Conclusion To sum up, NCAPH
   expression transcriptional activation by GATA3 accelerates the
   progression of OC via upregulating PI3K/PDK1/AKT pathway.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhang, T (Corresponding Author), Guangzhou Med Univ, Affiliated Hosp 5, Dept Gynecol, 621 Harbor Rd, Guangzhou 510700, Guangdong, Peoples R China.
   Qi, Yingying; Mo, Kexin; Zhang, Ting, Guangzhou Med Univ, Affiliated Hosp 5, Dept Gynecol, 621 Harbor Rd, Guangzhou 510700, Guangdong, Peoples R China.},
DOI = {10.1186/s12938-021-00919-y},
Article-Number = {83},
EISSN = {1475-925X},
Keywords = {Ovarian cancer; Non-SMC condensin I complex subunit H; GATA binding
   protein 3; Migration; Invasion},
Keywords-Plus = {GATA FAMILY; NCAPH; EXPRESSION; CONDENSINS},
Research-Areas = {Engineering},
Web-of-Science-Categories  = {Engineering, Biomedical},
Author-Email = {zhangtingzt22@163.com},
Affiliations = {Guangzhou Medical University},
Funding-Acknowledgement = {Health Science and Technology Project of Guangzhou {[}20211A011107];
   Medical Scientific Research Foundation of Guangdong Province of China
   {[}A2020536]},
Funding-Text = {This work was supported by Health Science and Technology Project of
   Guangzhou (20211A011107) and Medical Scientific Research Foundation of
   Guangdong Province of China (A2020536).},
Cited-References = {Arai T, 2019, INT J UROL, V26, P506, DOI 10.1111/iju.13911.
   Bertacchini J, 2015, CELL MOL LIFE SCI, V72, P2337, DOI 10.1007/s00018-015-1867-5.
   Cassidy LD, 2015, SCIENCE, V349, P1448, DOI 10.1126/science.aad2501.
   Chen HJ, 2018, INT J CANCER, V143, P3106, DOI 10.1002/ijc.31750.
   Cui FL, 2019, ONCOL LETT, V17, P5768, DOI 10.3892/ol.2019.10260.
   El-Arabey AA, 2020, CELL SIGNAL, V68, DOI 10.1016/j.cellsig.2020.109539.
   Elsayed AM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041882.
   Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043.
   Hirano T, 2012, GENE DEV, V26, P1659, DOI 10.1101/gad.194746.112.
   Ichikawa R, 2020, ONCOL REP, V43, P1300, DOI 10.3892/or.2020.7512.
   Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113.
   Kim B, 2020, ANTICANCER RES, V40, P3239, DOI 10.21873/anticanres.14305.
   Lan T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1106-z.
   Li XX, 2017, ONCOTARGET, V8, P47052, DOI 10.18632/oncotarget.16789.
   Li Y, 2014, CANCER BIOL THER, V15, P428, DOI 10.4161/cbt.27631.
   Lin MC, 2017, ONCOGENE, V36, P4243, DOI 10.1038/onc.2017.8.
   Lowry JA, 2000, J MOL EVOL, V50, P103, DOI 10.1007/s002399910012.
   Lu HT, 2020, MOL BIOL REP, V47, P7831, DOI 10.1007/s11033-020-05859-9.
   Ma LJ, 2018, ONCOTARGETS THER, V11, P7579, DOI 10.2147/OTT.S176534.
   Mange A, 2019, THERANOSTICS, V9, P7003, DOI 10.7150/thno.35561.
   Neuwald AF, 2000, GENOME RES, V10, P1445, DOI 10.1101/gr.147400.
   Patient RK, 2002, CURR OPIN GENET DEV, V12, P416, DOI 10.1016/S0959-437X(02)00319-2.
   Peng HW, 2015, MOL MED REP, V11, P881, DOI 10.3892/mmr.2014.2809.
   Qiu XF, 2020, ANN HUM GENET, V84, P437, DOI 10.1111/ahg.12398.
   Rodriguez-Garcia A, 2020, MOL THER, V28, P548, DOI 10.1016/j.ymthe.2019.11.028.
   Rooth Carolyn, 2013, Br J Nurs, V22, pS23.
   Shahi P, 2017, ONCOGENE, V36, P5567, DOI 10.1038/onc.2017.165.
   Sullivan R, 2008, MOL ONCOL, V1, P366, DOI 10.1016/j.molonc.2007.10.005.
   Sun CJ, 2019, MOL CARCINOGEN, V58, P2266, DOI 10.1002/mc.23114.
   Wang Jingyu, 2011, World J Oncol, V2, P113, DOI 10.4021/wjon335w.
   Wang M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03244-9.
   Wei SQ, 2017, CANCER MANAG RES, V9, P769, DOI 10.2147/CMAR.S147973.
   Yin L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.88.
   Yu WQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2062-7.
   Zhan SJ, 2018, ONCOL REP, V39, P2653, DOI 10.3892/or.2018.6383.
   Zhang Q, 2018, ONCOL RES, V26, P269, DOI 10.3727/096504017X15075967560980.
   Zhou WM, 2019, CELL SIGNAL, V56, P1, DOI 10.1016/j.cellsig.2018.11.016.},
Number-of-Cited-References = {37},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Biomed. Eng. Online},
Doc-Delivery-Number = {UC6TR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000686656700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000724581400001,
Author = {Zeng, Hao and Li, Yalun and Wang, Ye and Huang, Meijuan and Zhang, Yan
   and Tian, Panwen and Li, Weimin},
Title = {Case Report: Identification of Two Rare Fusions, PDK1-ALK and
   STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response
   to Alectinib},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2021},
Volume = {11},
Month = {AUG 13},
Abstract = {Several double ALK fusions coexisting in one patient have been reported.
   However, few studies have reported the clinical efficacy of ALK
   inhibitors in rare double ALK fusions. Here, we described a rare
   PDK1-ALK, STRN-ALK double-fusion variant in a patient with metastatic
   lung adenocarcinoma. The patient responded well to alectinib (600 mg)
   twice daily. This case shows a promising treatment option for patients
   with rare ALK double-fusion variants.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Tian, PW (Corresponding Author), Sichuan Univ, West China Hosp, Dept Resp \& Crit Care Med, Lung Canc Treatment Ctr, Chengdu, Peoples R China.
   Zeng, Hao, Sichuan Univ, West China Sch Med, West China Hosp, Dept Resp \& Crit Care Med, Chengdu, Peoples R China.
   Li, Yalun; Wang, Ye; Tian, Panwen, Sichuan Univ, West China Hosp, Dept Resp \& Crit Care Med, Lung Canc Treatment Ctr, Chengdu, Peoples R China.
   Huang, Meijuan; Zhang, Yan, Sichuan Univ, West China Hosp, Dept Thorac Oncol, Ctr Canc, Chengdu, Peoples R China.
   Li, Weimin, Sichuan Univ, West China Hosp, Dept Resp \& Crit Care Med, Chengdu, Peoples R China.},
DOI = {10.3389/fonc.2021.722843},
Article-Number = {722843},
ISSN = {2234-943X},
Keywords = {alectinib; ALK fusion; lung adenocarcinoma; targeted therapy;
   double-fusion variant},
Keywords-Plus = {CANCER; CRIZOTINIB; BIRC6-ALK},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Affiliations = {Sichuan University; Sichuan University; Sichuan University; Sichuan
   University},
ORCID-Numbers = {Tian, Panwen/0000-0002-6313-3228},
Funding-Acknowledgement = {National Science Foundation of China {[}82072598, 81871890, 91859203];
   National Key Development Plan for Precision Medicine Research of China
   {[}2017YFC0910004]; Science and Technology Program of Sichuan, China
   {[}2020YFS0572]; Major Science and Technology Innovation Project of
   Chengdu City, China {[}2020-YF08-00080-GX]},
Funding-Text = {Funding This work was supported by the National Science Foundation of
   China (grant number 82072598, 81871890, and 91859203); the National Key
   Development Plan for Precision Medicine Research of China (grant number
   2017YFC0910004); the Science and Technology Program of Sichuan, China
   (grant number 2020YFS0572) and the Major Science and Technology
   Innovation Project of Chengdu City, China (grant number
   2020-YF08-00080-GX).},
Cited-References = {Camidge DR, 2020, J CLIN ONCOL, V38, P3592, DOI 10.1200/JCO.20.00505.
   Dearden S, 2013, ANN ONCOL, V24, P2371, DOI 10.1093/annonc/mdt205.
   Gadgeel SM, 2014, LANCET ONCOL, V15, P1119, DOI 10.1016/S1470-2045(14)70362-6.
   Hong M, 2014, J THORAC ONCOL, V9, P419, DOI 10.1097/JTO.0000000000000061.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Li JJ, 2021, TRANSL LUNG CANCER R, V10, P1525, DOI 10.21037/tlcr-21-160.
   Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478.
   Nakanishi Y, 2017, J THORAC ONCOL, V12, pE202, DOI 10.1016/j.jtho.2017.08.009.
   Peters S, 2017, NEW ENGL J MED, V377, P829, DOI 10.1056/NEJMoa1704795.
   Ren HZ, 2019, CLIN LUNG CANCER, V20, pE142, DOI 10.1016/j.cllc.2018.11.002.
   Shan L, 2015, J THORAC ONCOL, V10, pE37, DOI 10.1097/JTO.0000000000000467.
   Solomon BJ, 2018, LANCET ONCOL, V19, P1654, DOI 10.1016/S1470-2045(18)30649-1.
   Tian Q, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02149-2016.
   Wang GF, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182099.
   Yang Yan, 2017, Mayo Clin Proc Innov Qual Outcomes, V1, P111, DOI {[}10.1016/j.mayocpiqo.2017.04.003, 10.1016/j.mayocpiqo.2017.04.003].
   Yin JP, 2018, J THORAC ONCOL, V13, pE43, DOI 10.1016/j.jtho.2017.10.025.
   Zhong JM, 2020, LUNG CANCER, V145, P211, DOI 10.1016/j.lungcan.2020.04.030.
   Zhou CC, 2019, LANCET RESP MED, V7, P437, DOI 10.1016/S2213-2600(19)30053-0.},
Number-of-Cited-References = {18},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {XG2II},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000724581400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000684480900001,
Author = {Zhang, Diancai and Wang, Yujie and Li, Guangzhi and Zhang, Baoxiang},
Title = {Tanshinone IIA alleviates vitiligo by suppressing AKT mediated
   CD8+ T cells activation in a mouse model},
Journal = {DERMATOLOGIC THERAPY},
Year = {2021},
Volume = {34},
Number = {5},
Month = {SEP},
Abstract = {Tanshinone IIA has been reported to exhibit anti-inflammatory effects,
   while it is not clear whether Tanshinone IIA has protective role in
   vitiligo. Premelanosome (PMEL) CD8(+) T cells were adoptive transferred
   into Krt14- Kitl{*} mice with Kit ligand (KITL) over-expressed, to
   construct the vitiligo model. Pdk1(fl/fl) and Stat3(fl/fl) mice were
   crossed with Cd8(cre) mice to establish Pdk1(TKO) and Stat3(TKO) mice.
   Tanshinone IIA (200 mu g) was intravenous injected to treat vitiligo in
   mice every 3 days. The accumulation of macrophages and CD8(+) T cells in
   the ear skin was assayed by flow cytometry. Bone marrow-derived
   macrophages (BMDMs) were induced and stimulated with lipopolysaccharides
   (LPS) and IL-4. It was found that Tanshinone IIA alleviated the
   development of vitiligo, impaired PMEL CD8(+) T cells accumulation in
   the ear skin, and inhibited LPS-induced TNF-alpha, IL-6, and IL-1 beta
   expression and secretion in BMDMs, which could also inhibit IL-4-induced
   Arg-1 and Mrc-1 expression in BMDMs. In addition, Tanshinone IIA could
   inhibit the proliferation and cytotoxic function of CD8(+) T cells
   indicated by the expression of Perforin, Granzymeb, and IFN-gamma.
   Furthermore, Tanshinone IIA treated Pdk1(TKO) mice, not Stat3(TKO) mice,
   showed impaired PMEL CD8(+) T cells accumulation in the ear skin. In
   summary, Tanshinone IIA alleviates vitiligo development with impaired
   CD8(+) T cells accumulation and activation of Pdk1-Akt pathway.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, BX (Corresponding Author), Yidu Cent Hosp Weifang, 4138 Linglongshan South Rd, Qingzhou 262500, Shandong, Peoples R China.
   Zhang, Diancai; Wang, Yujie; Li, Guangzhi; Zhang, Baoxiang, Yidu Cent Hosp Weifang, 4138 Linglongshan South Rd, Qingzhou 262500, Shandong, Peoples R China.},
DOI = {10.1111/dth.15086},
EarlyAccessDate = {AUG 2021},
Article-Number = {e15086},
ISSN = {1396-0296},
EISSN = {1529-8019},
Keywords = {Akt; BMDMs; Pdk1; Tanshinone IIA; vitiligo},
Keywords-Plus = {INFLAMMATION},
Research-Areas = {Dermatology},
Web-of-Science-Categories  = {Dermatology},
Author-Email = {wfsydzxyypfkzdc@163.com},
Funding-Acknowledgement = {Weifang Board of Health Science Program {[}WFWSJK-2020-012]},
Funding-Text = {The study was supported by the Weifang Board of Health Science Program
   (2020-4-060); the Weifang Board of Health Science Program
   (WFWSJK-2020-012).},
Cited-References = {Abdel-Malek ZA, 2020, PIGM CELL MELANOMA R, V33, P778, DOI 10.1111/pcmr.12878.
   Bergqvist C, 2020, DERMATOLOGY, V236, P571, DOI 10.1159/000506103.
   Bianchi V, 2016, J BIOL CHEM, V291, P8951, DOI 10.1074/jbc.M115.707414.
   Ding B, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01981-4.
   Ding ZY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009910.
   Du HY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00568.
   Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Harris JE, 2012, J INVEST DERMATOL, V132, P1869, DOI 10.1038/jid.2011.463.
   Konstantinova VA, 2019, CLIN COSMET INV DERM, V12, P911, DOI 10.2147/CCID.S229175.
   Liu MG, 2015, CLINICS, V70, P250, DOI 10.6061/clinics/2015(04)06.
   Liu YN, 2020, FREE RADICAL BIO MED, V152, P52, DOI 10.1016/j.freeradbiomed.2020.02.032.
   Maini MK, 2019, NAT REV IMMUNOL, V19, P201, DOI 10.1038/s41577-019-0150-7.
   Manga P, 2012, J INVEST DERMATOL, V132, P1752, DOI 10.1038/jid.2012.140.
   Paynich ML, 2017, J IMMUNOL, V198, P2689, DOI 10.4049/jimmunol.1601641.
   Qin Y, 2020, MOL THER-NUCL ACIDS, V21, P492, DOI 10.1016/j.omtn.2020.06.015.
   Rosmarin D, 2020, LANCET, V396, P110, DOI 10.1016/S0140-6736(20)30609-7.
   Seo EJ, 2018, PHARMACOL RES, V129, P262, DOI 10.1016/j.phrs.2017.11.030.
   Sestito S, 2019, EXPERT OPIN THER PAT, V29, P271, DOI 10.1080/13543776.2019.1597852.
   Song ZB, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.641848.
   Su CY, 2015, CHIN J NAT MEDICINES, V13, P163, DOI 10.1016/S1875-5364(15)30002-9.
   Wang SB, 2019, IRAN J BASIC MED SCI, V22, P160, DOI 10.22038/ijbms.2018.30598.7375.
   Wankowicz-Kalinska A, 2003, LAB INVEST, V83, P683, DOI 10.1097/01.LAB.0000069521.42488.1B.
   Xu JP, 2018, J ETHNOPHARMACOL, V225, P18, DOI 10.1016/j.jep.2018.06.029.
   Xue JL, 2019, MED SCI MONITOR, V25, P4793, DOI 10.12659/MSM.914446.
   Yang GS, 2020, THERANOSTICS, V10, P7787, DOI 10.7150/thno.46911.
   Zhang KD, 2014, AM J PHYSIOL-CELL PH, V306, pC59, DOI 10.1152/ajpcell.00070.2013.
   Zhou ZW, 2020, SCIENCE, V368, P965, DOI 10.1126/science.aaz7548.
   Zhou ZY, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109362.
   Zhu W, 2012, CHIN J INTEGR MED, V18, P496, DOI 10.1007/s11655-011-0942-5.},
Number-of-Cited-References = {30},
Times-Cited = {10},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Dermatol. Ther.},
Doc-Delivery-Number = {WG2BW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000684480900001},
DA = {2026-02-04},
}

@article{ WOS:000681737300001,
Author = {Jiang, Qiwei and Zheng, Nana and Bu, Lang and Zhang, Xiaomei and Zhang,
   Xiaoling and Wu, Yuanzhong and Su, Yaqing and Wang, Lei and Zhang,
   Xiaomin and Ren, Shancheng and Dai, Xiangpeng and Wu, Depei and Xie, Wei
   and Wei, Wenyi and Zhu, Yasheng and Guo, Jianping},
Title = {SPOP-mediated ubiquitination and degradation of PDK1 suppresses AKT
   kinase activity and oncogenic functions},
Journal = {MOLECULAR CANCER},
Year = {2021},
Volume = {20},
Number = {1},
Month = {AUG 5},
Abstract = {Background 3-phosphoinositide-dependent protein kinase-1 (PDK1) acts as
   a master kinase of protein kinase A, G, and C family (AGC) kinase to
   predominantly govern cell survival, proliferation, and metabolic
   homeostasis. Although the regulations to PDK1 downstream substrates such
   as protein kinase B (AKT) and ribosomal protein S6 kinase beta (S6K)
   have been well established, the upstream regulators of PDK1, especially
   its degrader, has not been defined yet. Method A clustered regularly
   interspaced short palindromic repeats (CRISPR)-based E3 ligase screening
   approach was employed to identify the E3 ubiquitin ligase for degrading
   PDK1. Western blotting, immunoprecipitation assays and
   immunofluorescence (IF) staining were performed to detect the
   interaction or location of PDK1 with speckle-type POZ protein (SPOP).
   Immunohistochemistry (IHC) staining was used to study the expression of
   PDK1 and SPOP in prostate cancer tissues. In vivo and in vitro
   ubiquitination assays were performed to measure the ubiquitination
   conjugation of PDK1 by SPOP. In vitro kinase assays and mass
   spectrometry approach were carried out to identify casein kinase 1 (CK1)
   and glycogen synthase kinase 3 (GSK3)-mediated PDK1 phosphorylation. The
   biological effects of PDK1 mutations and correlation with SPOP mutations
   were performed with colony formation, soft agar assays and in vivo
   xenograft mouse models. Results We identified that PDK1 underwent
   SPOP-mediated ubiquitination and subsequent proteasome-dependent
   degradation. Specifically, SPOP directly bound PDK1 by the consensus
   degron in a CK1/GSK3 beta-mediated phosphorylation dependent manner.
   Pathologically, prostate cancer patients associated mutations of SPOP
   impaired PDK1 degradation and thus activated the AKT kinase, resulting
   in tumor malignancies. Meanwhile, mutations that occurred around or
   within the PDK1 degron, by either blocking SPOP to bind the degron or
   inhibiting CK1 or GSK3 beta-mediated PDK1 phosphorylation, could
   markedly evade SPOP-mediated PDK1 degradation, and played potently
   oncogenic roles via activating the AKT kinase. Conclusions Our results
   not only reveal a physiological regulation of PDK1 by E3 ligase SPOP,
   but also highlight the oncogenic roles of loss-of-function mutations of
   SPOP or gain-of-function mutations of PDK1 in tumorigenesis through
   activating the AKT kinase.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Guo, JP (Corresponding Author), Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
   Zhu, YS (Corresponding Author), Shanghai Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.
   Wei, WY (Corresponding Author), Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Jiang, Qiwei; Bu, Lang; Zhang, Xiaomei; Su, Yaqing; Wang, Lei; Xie, Wei; Guo, Jianping, Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
   Zheng, Nana; Wu, Depei, Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou, Peoples R China.
   Zhang, Xiaoling; Dai, Xiangpeng, Jilin Univ, Inst Immunol, Hosp 1, Key Lab Organ Regenerat \& Transplantat,Minist Edu, Changchun, Jilin, Peoples R China.
   Zhang, Xiaoling; Dai, Xiangpeng, Natl Local Joint Engn Lab Anim Models Human Dis, Changchun, Jilin, Peoples R China.
   Wu, Yuanzhong, Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   Zhang, Xiaomin; Ren, Shancheng; Zhu, Yasheng, Shanghai Changhai Hosp, Dept Urol, Shanghai 200433, Peoples R China.
   Wei, Wenyi, Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.},
DOI = {10.1186/s12943-021-01397-5},
Article-Number = {100},
EISSN = {1476-4598},
Keywords = {PDK1; SPOP; AKT; Ubiquitination; Tumorigenesis},
Keywords-Plus = {PROSTATE-CANCER; PROTEIN-KINASE; PROMOTES UBIQUITINATION; PI3K/AKT
   PATHWAY; TUMOR-SUPPRESSOR; IN-VIVO; ACTIVATION; PHOSPHORYLATION;
   INSIGHTS; LIGASE},
Research-Areas = {Biochemistry \& Molecular Biology; Oncology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Oncology},
Author-Email = {wwei2@bidmc.harvard.edu
   zys0562@foxmail.com
   guojp6@mail.sysu.edu.cn},
Affiliations = {Sun Yat Sen University; Soochow University - China; Jilin University;
   Sun Yat Sen University; State Key Lab Oncology South China; Naval
   Medical University; Harvard University; Harvard University Medical
   Affiliates; Beth Israel Deaconess Medical Center; Harvard Medical School},
ORCID-Numbers = {Zhu, Yasheng/0000-0002-1397-2517},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31871410, 32070767];
   China Postdoctoral Science Foundation {[}2020M683035]},
Funding-Text = {This work was supported by National Natural Science Foundation of China
   to J.G. (31871410, 32070767), China Postdoctoral Science Foundation to
   Q.J. (2020M683035).},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   An J, 2014, CELL REP, V6, P657, DOI 10.1016/j.celrep.2014.01.013.
   Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279.
   Blattner M, 2017, CANCER CELL, V31, P436, DOI 10.1016/j.ccell.2017.02.004.
   Boehm JS, 2005, MOL CELL BIOL, V25, P6464, DOI 10.1128/MCB.25.15.6464-6474.2005.
   Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471.
   Chan CH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-59.
   Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286.
   Collins BJ, 2005, J CELL SCI, V118, P5023, DOI 10.1242/jcs.02617.
   Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026.
   Geng C, 2017, ONCOGENE, V36, P4767, DOI 10.1038/onc.2017.80.
   Geng C, 2013, P NATL ACAD SCI USA, V110, P6997, DOI 10.1073/pnas.1304502110.
   Genschik P, 2013, EMBO J, V32, P2307, DOI 10.1038/emboj.2013.173.
   Groner AC, 2016, CANCER CELL, V29, P846, DOI 10.1016/j.ccell.2016.04.012.
   Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6.
   Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434.
   Hermida Miguel A., 2017, Advances in Biological Regulation, V65, P5, DOI {[}10.1016/j.jbior.2017.06.003, 10.1016/j.jbior.2017.06.003].
   Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015.
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43.
   Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168.
   Jia JH, 2005, DEV CELL, V9, P819, DOI 10.1016/j.devcel.2005.10.006.
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li C, 2011, ONCOGENE, V30, P4350, DOI 10.1038/onc.2011.151.
   Li GQ, 2014, CANCER CELL, V25, P455, DOI 10.1016/j.ccr.2014.02.007.
   Li J, 2020, NATURE, V580, P93, DOI 10.1038/s41586-020-2135-x.
   Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050.
   Liu J, 2009, SCIENCE, V323, P1218, DOI 10.1126/science.1157669.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Marzahn MR, 2016, EMBO J, V35, P1254, DOI 10.15252/embj.201593169.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547.
   Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707.
   Robinson D, 2015, CELL, V161, P1215, DOI {[}10.1016/j.cell.2015.06.053, 10.1016/j.cell.2015.05.001].
   Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125.
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998.
   Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381.
   Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290.
   Wu YZ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.14.
   Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111.
   Xu ZL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0645-4.
   Yang SX, 2016, CANCER TREAT REV, V45, P87, DOI 10.1016/j.ctrv.2016.03.004.
   Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379.
   Zhuang M, 2009, MOL CELL, V36, P39, DOI 10.1016/j.molcel.2009.09.022.},
Number-of-Cited-References = {51},
Times-Cited = {66},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {37},
Journal-ISO = {Mol. Cancer},
Doc-Delivery-Number = {TV5BB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000681737300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000695273300017,
Author = {Chen, Wenkuan and Zhang, Tingting and Bai, Yanfang and Deng, Hong and
   Yang, Fang and Zhu, Renjie and Chen, Yingle and He, Zheng and Zeng, Qi
   and Song, Ming},
Title = {Upregulated circRAD18 promotes tumor progression by reprogramming
   glucose metabolism in papillary thyroid cancer},
Journal = {GLAND SURGERY},
Year = {2021},
Volume = {10},
Number = {8},
Pages = {2500-2510},
Month = {AUG},
Abstract = {Background: By regulating complex functional processes, circRNAs are
   crucial in the development of different cancers. Nevertheless, most
   circRNAs in papillary thyroid cancer metabolic reprogramming remain
   unknown.
   Methods: The expression of circRNA was assessed by qRT-PCR in papillary
   thyroid cancer tissues and cell lines. Cell proliferation and glucose
   intake experiments were performed by certain kit. Transwell assays and
   wound healing assays were performed to investigate the function of
   circRNA in metastasis. In addition, a serious of molecular experiments
   were conducted to determine the exact mechanism of circRAD18. Luciferase
   reporter and RNA immunoprecipitation assay were conducted to determine
   the molecular interaction between circRNA and miRNA.
   Results: We characterized circRAD18 as a significantly upregulated
   circRNA in papillary thyroid tissues and cell lines and found its
   downregulation could inhibit the growth and metastasis ability of
   papillary thyroid cancer. Interestingly, we found that circRAD18 was
   involved in glucose metabolism reprogramming of papillary thyroid
   cancer, and its silence could remarkably inhibit cell glucose uptake and
   lactate production in papillary thyroid cancer cells. Inhibition of
   circRAD18 could decrease the expression level of PDK1 protein by
   sponging miR-516b.
   Conclusions: This study verified the novel function of the
   circRAD18-miR-516b-PDK1 axis in papillary thyroid cancer metabolic
   reprogramming progression, which has potential to be a novel therapeutic
   target.},
Publisher = {AME PUBLISHING COMPANY},
Address = {FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA},
Type = {Article},
Language = {English},
Affiliation = {Song, M (Corresponding Author), Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, 651 East Dongfeng Rd, Guangzhou 510060, Peoples R China.
   Zeng, Q (Corresponding Author), Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Dept Integrat Med, 52 Mei Hua East Rd, Zhuhai 519001, Guangdong, Peoples R China.
   Chen, Wenkuan; Zhang, Tingting; Bai, Yanfang; Deng, Hong; Chen, Yingle; He, Zheng; Song, Ming, Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, 651 East Dongfeng Rd, Guangzhou 510060, Peoples R China.
   Yang, Fang; Zeng, Qi, Sun Yat Sen Univ, Affiliated Hosp 5, Ctr Canc, Dept Integrat Med, 52 Mei Hua East Rd, Zhuhai 519001, Guangdong, Peoples R China.
   Zhu, Renjie, Tongji Univ, East Hosp, Dept Clin Engn, Shanghai, Peoples R China.},
DOI = {10.21037/gs-21-481},
ISSN = {2227-684X},
EISSN = {2227-8575},
Keywords = {circRAD18; circular RNAs; PDK1; glucose metabolism; papillary thyroid
   cancer},
Keywords-Plus = {NEGATIVE BREAST-CANCER; CIRCULAR RNAS; PROLIFERATION; METASTASIS;
   DIAGNOSIS; BIOMARKER; PROTEIN},
Research-Areas = {Surgery},
Web-of-Science-Categories  = {Surgery},
Author-Email = {zengqi37@mail.sysu.edu.cn
   songming@sysucc.org.cn},
Affiliations = {State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen
   University; Tongji University},
ResearcherID-Numbers = {zeng, qi/AAE-9675-2020},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81772961]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. 81772961).},
Cited-References = {Atas E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.583217.
   Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32.
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271.
   Chen XM, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102720.
   Devaux Y, 2017, EUR J HEART FAIL, V19, P701, DOI 10.1002/ejhf.801.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Hanniford D, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju494.
   Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568.
   Huang JL, 2018, AGING-US, V10, P253, DOI 10.18632/aging.101387.
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112.
   Kong YN, 2019, EPIGENOMICS-UK, V11, P1163, DOI 10.2217/epi-2019-0093.
   Li SS, 2019, BRIEF BIOINFORM, V20, P1420, DOI 10.1093/bib/bby006.
   Liang WC, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1685-4.
   Liu J, 2020, J CELL BIOCHEM, V121, P690, DOI 10.1002/jcb.29315.
   Liu P, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00193.
   Liu WW, 2019, MOL THER NUCL ACIDS, V14, P609, DOI 10.1016/j.omtn.2019.01.003.
   LOU W, 2020, FRONT CELL DEV BIOL.
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928.
   Pan XH, 2021, CANCER SCI, V112, P2260, DOI 10.1111/cas.14913.
   Park H, 2020, CANCERS, V12, DOI 10.3390/cancers12082323.
   Pelizzo MR, 2008, MINERVA ENDOCRINOL, V33, P359.
   Peng F, 2021, AM J CHINESE MED, V49, P505, DOI 10.1142/S0192415X21500233.
   Peng F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00378.
   Peng F, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00251.
   Qiu MT, 2018, CANCER RES, V78, P2839, DOI 10.1158/0008-5472.CAN-17-2808.
   Sakai T, 2019, THYROID, V29, P59, DOI 10.1089/thy.2018.0462.
   Santiago K, 2020, J ONCOL, V2020, DOI 10.1155/2020/2052396.
   Saravana-Bawan B, 2020, SURGERY, V167, P46, DOI 10.1016/j.surg.2019.03.040.
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004.
   Shi YC, 2021, EBIOMEDICINE, V66, DOI 10.1016/j.ebiom.2021.103337.
   Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654.
   Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021.
   Wang L, 2021, AM J CHINESE MED, V49, P609, DOI 10.1142/S0192415X21500270.
   Wang YF, 2016, TRENDS GENET, V32, P211, DOI 10.1016/j.tig.2016.02.001.
   Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541.
   Wu GJ, 2020, MOL THER NUCL ACIDS, V19, P1134, DOI 10.1016/j.omtn.2019.12.025.
   Xiao WK, 2019, AGING-US, V11, P12043, DOI 10.18632/aging.102539.
   Xu XY, 2019, J ENZYM INHIB MED CH, V34, P361, DOI 10.1080/14756366.2018.1553167.
   Yang W, 2019, J CELL MOL MED, V23, P4921, DOI 10.1111/jcmm.14305.
   Yang Yibing, 2018, J Natl Cancer Inst, V110, DOI 10.1093/jnci/djx166.
   Ye F, 2019, MOL THER NUCL ACIDS, V18, P88, DOI 10.1016/j.omtn.2019.07.023.
   Yu T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0776-8.
   Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8.
   Zou YT, 2020, J CELL MOL MED, V24, P9507, DOI 10.1111/jcmm.15619.
   Zou YT, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090429.
   Zou YT, 2019, CARCINOGENESIS, V40, P1469, DOI 10.1093/carcin/bgz071.},
Number-of-Cited-References = {46},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Gland Surg.},
Doc-Delivery-Number = {UP3HE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000695273300017},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000688993600001,
Author = {De Rosa, Viviana and Iommelli, Francesca and Terlizzi, Cristina and
   Leggiero, Eleonora and Camerlingo, Rosa and Altobelli, Giovanna G. and
   Fonti, Rosa and Pastore, Lucio and Del Vecchio, Silvana},
Title = {Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through
   Macromolecular Complexes Assembly at the ER-Mitochondria Interface in
   Oncogene-Driven NSCLC},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {16},
Month = {AUG},
Abstract = {Simple Summary Co-targeting of glucose metabolism and oncogene drivers
   in patients with non-small cell lung cancer (NSCLC) has been proposed as
   a potentially effective therapeutic strategy. Here, we demonstrate that
   downregulation of pyruvate dehydrogenase kinase 1 (PDK1), an enzyme of
   glycolytic cascade, enhances maximal respiration of cancer cells by
   upregulating mitochondrial complexes of oxidative phosphorylation
   (OXPHOS) and improves tumor response to tyrosine kinase inhibitors by
   promoting apoptosis. Furthermore, we provided consistent evidence that
   PDK1 drives the formation of macromolecular complexes at the
   ER-mitochondria interface involving PKM2, Bcl-2 and Bcl-xL and serves as
   an indirect anchorage of anti-apoptotic proteins to the mitochondrial
   membrane. Our findings taken together highlighted a non-canonical role
   of PDK1 as a negative regulator of apoptosis, thus coupling the
   glycolytic phenotype to drug resistance. The major translational
   relevance of this study is to provide a rational basis for combined
   therapeutic strategies targeting PDK1 and oncogene drivers in NSCLC
   patients. Here, we tested whether co-targeting of glucose metabolism and
   oncogene drivers may enhance tumor response to tyrosine kinase
   inhibitors (TKIs) in NSCLC. To this end, pyruvate dehydrogenase kinase 1
   (PDK1) was stably downregulated in oncogene-driven NSCLC cell lines
   exposed or not to TKIs. H1993 and H1975 cells were stably transfected
   with scrambled (shCTRL) or PDK1-targeted (shPDK1) shRNA and then treated
   with MET inhibitor crizotinib (1 mu M), double mutant EGFR(L858R/T790M)
   inhibitor WZ4002 (1 mu M) or vehicle for 48 h. The effects of PDK1
   knockdown on glucose metabolism and apoptosis were evaluated in
   untreated and TKI-treated cells. PDK1 knockdown alone did not cause
   significant changes in glycolytic cascade, ATP production and glucose
   consumption, but it enhanced maximal respiration in shPDK1 cells when
   compared to controls. When combined with TKI treatment, PDK1
   downregulation caused a strong enhancement of OXPHOS and a marked
   reduction in key glycolytic enzymes. Furthermore, increased levels of
   apoptotic markers were found in shPDK1 cells as compared to shCTRL cells
   after treatment with TKIs. Co-immunoprecipitation studies showed that
   PDK1 interacts with PKM2, Bcl-2 and Bcl-xL, forming macromolecular
   complexes at the ER-mitochondria interface. Our findings showed that
   downregulation of PDK1 is able to potentiate the effects of TKIs through
   the disruption of macromolecular complexes involving PKM2, Bcl-2 and
   Bcl-xL.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Del Vecchio, S (Corresponding Author), Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy.
   De Rosa, Viviana; Iommelli, Francesca; Fonti, Rosa, CNR, Inst Biostruct \& Bioimaging, I-80145 Naples, Italy.
   Terlizzi, Cristina; Altobelli, Giovanna G.; Del Vecchio, Silvana, Univ Naples Federico II, Dept Adv Biomed Sci, I-80131 Naples, Italy.
   Leggiero, Eleonora; Pastore, Lucio, CEINGE Biotecnol Avanzate, I-80131 Naples, Italy.
   Camerlingo, Rosa, Fdn G Pascale, Dept Cell Biol \& Biotherapy, Ist Nazl Tumori, IRCCS, I-80131 Naples, Italy.
   Pastore, Lucio, Univ Naples Federico II, Dept Mol Med \& Med Biotechnol, I-80131 Naples, Italy.},
DOI = {10.3390/cancers13164133},
Article-Number = {4133},
EISSN = {2072-6694},
Keywords = {PDK1; OXPHOS; glycolysis; apoptosis; drug resistance},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; CELL LUNG-CANCER; METABOLIC SWITCH;
   RESISTANCE; DICHLOROACETATE; INHIBITORS; PHOSPHORYLATION; GLYCOLYSIS;
   REVERSAL},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {viviana.derosa@ibb.cnr.it
   francesca.iommelli@ibb.cnr.it
   cristina.terlizzi@unina.it
   leggiero@ceinge.unina.it
   r.camerlingo@istitutotumori.na.it
   ggaltobe@unina.it
   rosa.fonti@ibb.cnr.it
   lucio.pastore@unina.it
   delvecc@unina.it},
Affiliations = {Consiglio Nazionale delle Ricerche (CNR); Istituto di Biostrutture e
   Bioimmagini (IBB-CNR); University of Naples Federico II; CEINGE
   Biotecnologie Avanzate; Fondazione IRCCS Istituto Nazionale Tumori
   Milan; IRCCS Fondazione Pascale; University of Naples Federico II},
ResearcherID-Numbers = {Camerlingo, Rosa/AAB-8349-2022
   DE ROSA, VIVIANA/AAC-3427-2022
   Pastore, Lucio/AAF-3487-2019
   Terlizzi, Cristina/KEI-8700-2024
   DEL VECCHIO, Silvana/F-4972-2012
   Iommelli, Francesca/ABF-3573-2020},
ORCID-Numbers = {Camerlingo, Rosa/0000-0001-6488-9740
   DE ROSA, VIVIANA/0000-0002-0430-5608
   Pastore, Lucio/0000-0001-6894-9317
   Terlizzi, Cristina/0000-0001-5422-4737
   DEL VECCHIO, Silvana/0000-0002-5466-1213
   Iommelli, Francesca/0000-0002-5132-3593},
Funding-Acknowledgement = {AIRC, Associazione Italiana per la Ricerca sul Cancro {[}IG-17249];
   Regione Campania SATIN Project},
Funding-Text = {This work was partly supported by AIRC, Associazione Italiana per la
   Ricerca sul Cancro (project No. IG-17249), and a grant from Regione
   Campania SATIN Project 2018-2020.},
Cited-References = {Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667.
   De Rosa V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133134.
   De Rosa V, 2016, EJNMMI RES, V6, DOI 10.1186/s13550-016-0229-0.
   De Rosa V, 2015, CLIN CANCER RES, V21, P5110, DOI 10.1158/1078-0432.CCR-15-0375.
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200.
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904.
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478.
   Golias T, 2019, INT J CANCER, V144, P674, DOI 10.1002/ijc.31812.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431.
   Iommelli F, 2018, CLIN CANCER RES, V24, P3126, DOI 10.1158/1078-0432.CCR-17-3657.
   Iommelli F, 2014, CLIN CANCER RES, V20, P4806, DOI 10.1158/1078-0432.CCR-14-0264.
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kinnaird A, 2016, EUR UROL, V69, P734, DOI 10.1016/j.eururo.2015.09.014.
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238.
   Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494.
   Liang J, 2017, CELL RES, V27, P329, DOI 10.1038/cr.2016.159.
   Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023.
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7.
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039.
   Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151.
   Woolbright BL, 2019, MOL CANCER THER, V18, P1673, DOI 10.1158/1535-7163.MCT-19-0079.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Yang Z, 2018, EUR J PHARMACOL, V838, P41, DOI 10.1016/j.ejphar.2018.09.016.
   Yang Z, 2016, EUR J PHARMACOL, V789, P458, DOI 10.1016/j.ejphar.2016.08.004.
   Zannetti A, 2012, J NUCL MED, V53, P443, DOI 10.2967/jnumed.111.096503.
   Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603.},
Number-of-Cited-References = {37},
Times-Cited = {12},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {UG1AG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000688993600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000721717600008,
Author = {Jiang, Fengjuan and Liu, Hui and Peng, Fengping and Liu, Zhaoyun and
   Ding, Kai and Song, Jia and Li, Lijuan and Chen, Jin and Shao, Qing and
   Yan, Siyang and De Veirman, Kim and Vanderkerken, Karin and Fu, Rong},
Title = {Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3
   pathway in patients with multiple myeloma},
Journal = {CANCER BIOLOGY \& MEDICINE},
Year = {2021},
Volume = {18},
Number = {3},
Pages = {721+},
Month = {AUG},
Abstract = {Objective: Myeloma bone disease (MBD) is the most common complication of
   multiple myeloma (MM). Our previous study showed that the serum levels
   of C3/C4 in MM patients were significantly positively correlated with
   the severity of bone disease. However, the mechanism of C3a/C4a in
   osteoclasts MM patients remains unclear. Methods: The formation and
   function of osteoclasts were analyzed after adding C3a/C4a in vitro.
   RNA-seq analysis was used to screen the potential pathways affecting
   osteoclasts, and the results were verified by Western blot, qRT-PCR, and
   pathway inhibitors. Results: The osteoclast area per view induced by 1
   mu g/mL (mean +/- SD: 50.828 +/- 12.984\%) and 10 mu g/mL (53.663 +/-
   12.685\%) of C3a was significantly increased compared to the control
   group (0 mu g/mL) (34.635 +/- 8.916\%) (P < 0.001 and P < 0.001,
   respectively). The relative mRNA expressions of genes,
   OSCAR/TRAP/RANKL/cathepsin K, induced by 1 mu g/mL (median: 5.041,
   3.726, 1.638, and 4.752, respectively) and 10 mu g/mL (median: 5.140,
   3.702, 2.250, and 5.172, respectively) of C3a was significantly
   increased compared to the control group (median: 3.137, 2.004, 0.573,
   and 2.257, respectively) (1 mu g/mL P = 0.001, P = 0.003, P < 0.001, and
   P = 0.008, respectively; 10 mu g/mL: P < 0.001, P = 0.019, P < 0.001,
   and P = 0.002, respectively). The absorption areas of the osteoclast
   resorption pits per view induced by 1 mu g/mL (mean +/- SD: 51.464 +/-
   11.983\%) and 10 mu g/mL (50.219 +/- 12.067\%) of C3a was also
   significantly increased (33.845 +/- 8.331\%) (P < 0.001 and P < 0.001,
   respectively) compared to the control. There was no difference between
   the C4a and control groups. RNA-seq analysis showed that C3a promoted
   the proliferation of osteoclasts using the phosphoinositide 3-kinase
   (PI3K) signaling pathway. The relative expressions of
   PIK3CA/phosphoinositide dependent kinase-1 (PDK1)/serum and
   glucocorticoid inducible protein kinases (SGK3) genes and
   PI3K/PDK1/p-SGK3 protein in the C3a group were significantly higher than
   in the control group. The activation role of C3a in osteoclasts of MM
   patients was reduced by the SGK inhibitor (EMD638683). Conclusions: C3a
   activated osteoclasts by regulating the PI3K/PDK1/SGK3 pathways in MM
   patients, which was reduced using a SGK inhibitor. Overall, our results
   identified potential therapeutic targets and strategies for MBD
   patients.},
Publisher = {CHINA ANTI-CANCER ASSOC},
Address = {TIANJIN MEDICAL UNIV, CANCER INST \& HOSPITAL  TI-YUAN-BEI, HUANHU XI
   LU, HEXIQU, TIANJIN, 300060, PEOPLES R CHINA},
Type = {Article},
Language = {English},
Affiliation = {Fu, R (Corresponding Author), Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin 300052, Peoples R China.
   Jiang, Fengjuan; Liu, Hui; Peng, Fengping; Liu, Zhaoyun; Ding, Kai; Song, Jia; Li, Lijuan; Chen, Jin; Shao, Qing; Yan, Siyang; Fu, Rong, Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin 300052, Peoples R China.
   De Veirman, Kim; Vanderkerken, Karin, Vrije Univ Brussel, Dept Hematol \& Immunol, Myeloma Ctr Brussels, B-1090 Brussels, Belgium.},
DOI = {10.20892/j.issn.2095-3941.2020.0430},
ISSN = {2095-3941},
Keywords = {Multiple myeloma; complement C3a; osteoclasts; PI3K; PDK1; SGK3
   pathways; SGK inhibitor},
Keywords-Plus = {SGK INHIBITOR; BONE; CANCER; PI3K; OSTEOBLASTS; CHALLENGES; COMPONENT;
   DISEASE; GROWTH; CELLS},
Research-Areas = {Oncology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Oncology; Medicine, Research \& Experimental},
Author-Email = {florai@sina.com},
Affiliations = {Tianjin Medical University; Vrije Universiteit Brussel},
ResearcherID-Numbers = {De Veirman, Kim/JAC-9475-2023
   Vanderkerken, Karin/I-3513-2013},
ORCID-Numbers = {De Veirman, Kim/0000-0002-1313-6121
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81770110, 81900131,
   82000219]; Anticancer Major Special Project of Tianjin
   {[}12ZCDZSY18000]; Tianjin Municipal Natural Science Foundation
   {[}18JCYBJC27200, 18JCQNJC80400]; Tianjin Education Commission Research
   Project {[}2018KJ043, 2018KJ045]; Tianjin Health and Family Planning
   Commission {[}15KG150]; Youth Incubation Fund of Tianjin Medical
   University General Hospital {[}ZYYFY2019020]; Tianjin Science and
   Technology Planning Project {[}20YFZCSY00060]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 81770110, 81900131, and 82000219) , the Anticancer
   Major Special Project of Tianjin (Grant No. 12ZCDZSY18000) , the Tianjin
   Municipal Natural Science Foundation (Grant Nos. 18JCYBJC27200 and
   18JCQNJC80400) , the Tianjin Education Commission Research Project
   (Grant Nos. 2018KJ043 and 2018KJ045) , the Tianjin Health and Family
   Planning Commission (Grant No. 15KG150) , the Youth Incubation Fund of
   Tianjin Medical University General Hospital (Grant No. ZYYFY2019020) ,
   and the Tianjin Science and Technology Planning Project (Grant No.
   20YFZCSY00060) .},
Cited-References = {Ackermann TF, 2011, CELL PHYSIOL BIOCHEM, V28, P137, DOI 10.1159/000331722.
   Andrades JA, 1996, EXP CELL RES, V227, P208, DOI 10.1006/excr.1996.0269.
   Bago R, 2016, EMBO J, V35, P1902, DOI 10.15252/embj.201693929.
   Barnum SR, 2015, J INNATE IMMUN, V7, P333, DOI 10.1159/000371423.
   Basnet R, 2018, ACTA PHARM SIN B, V8, P767, DOI 10.1016/j.apsb.2018.07.001.
   Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178.
   Cock PJA, 2010, NUCLEIC ACIDS RES, V38, P1767, DOI 10.1093/nar/gkp1137.
   Dowling P, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-904.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204.
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood-2006-05-026112.
   Huang J, 2018, GIGASCIENCE, V7, DOI 10.1093/gigascience/giy144.
   Huang J, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix024.
   Ignatius A, 2011, J CELL BIOCHEM, V112, P2594, DOI 10.1002/jcb.23186.
   Jiang FJ, 2018, J CELL MOL MED, V22, P2706, DOI 10.1111/jcmm.13554.
   Jiang FJ, 2017, ANN HEMATOL, V96, P331, DOI 10.1007/s00277-016-2863-z.
   Kim D, 2015, NAT METHODS, V12, P357, DOI {[}10.1038/NMETH.3317, 10.1038/nmeth.3317].
   Kovtun A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14444-3.
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25.
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017.
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Liu H, 2017, INT J ONCOL, V50, P631, DOI 10.3892/ijo.2016.3815.
   Liu M, 2012, HEPATOLOGY, V55, P1754, DOI 10.1002/hep.25584.
   Liu ZY, 2019, INT J MOL MED, V43, P285, DOI 10.3892/ijmm.2018.3963.
   MacKay DL, 2018, J ORTHOP RES, V36, P118, DOI 10.1002/jor.23643.
   Matsuoka K, 2014, J BONE MINER RES, V29, P1522, DOI 10.1002/jbmr.2187.
   Modinger Y, 2018, SEMIN IMMUNOL, V37, P53, DOI 10.1016/j.smim.2018.01.001.
   Oranger A, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/289458.
   Palumbo A, 2015, J CLIN ONCOL, V33, P2863, DOI 10.1200/JCO.2015.61.2267.
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5.
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831.
   SAKIYAMA H, 1994, CELL TISSUE RES, V277, P239, DOI 10.1007/BF00327771.
   SATO T, 1993, ENDOCRINOLOGY, V133, P397, DOI 10.1210/en.133.1.397.
   Schoengraf P, 2013, IMMUNOBIOLOGY, V218, P1, DOI 10.1016/j.imbio.2012.01.020.
   Schraufstatter IU, 2009, J IMMUNOL, V182, P3827, DOI 10.4049/jimmunol.0803055.
   Teo BHD, 2012, BIOCHEM J, V447, P229, DOI 10.1042/BJ20120888.
   Terpos E, 2010, LEUKEMIA, V24, P1043, DOI 10.1038/leu.2010.62.
   Terpos E, 2019, BLOOD, V133, P1534, DOI 10.1182/blood-2018-11-852459.
   Towhid ST, 2013, CELL PHYSIOL BIOCHEM, V32, P838, DOI 10.1159/000354486.
   Toyoguchi T, 1996, CELL TISSUE RES, V285, P199, DOI 10.1007/s004410050637.
   Tu Z, 2010, BLOOD, V116, P4456, DOI 10.1182/blood-2010-01-263590.
   Zheng MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058504.},
Number-of-Cited-References = {43},
Times-Cited = {9},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Cancer Biol. Med.},
Doc-Delivery-Number = {XC0NQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000721717600008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000688990900001,
Author = {Kim, Ji-Eun and Lee, Duk-Shin and Park, Hana and Kim, Tae-Hyun and Kang,
   Tae-Cheon},
Title = {AMPA Receptor Antagonists Facilitate NEDD4-2-Mediated GRIA1
   Ubiquitination by Regulating PP2B-ERK1/2-SGK1 Pathway in Chronic
   Epilepsy Rats},
Journal = {BIOMEDICINES},
Year = {2021},
Volume = {9},
Number = {8},
Month = {AUG},
Abstract = {The neural precursor cell expressed by developmentally downregulated
   gene 4-2 (NEDD42) is a ubiquitin E3 ligase that has a high affinity
   toward binding and ubiquitinating glutamate ionotropic receptor
   alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type
   subunit 1 (GRIA1, also referred to GluR1 or GluA1). Since dysregulation
   of GRIA1 surface expression is relevant to the responsiveness to AMPA
   receptor (AMPAR) antagonists (perampanel and GYKI 52466) in chronic
   epilepsy rats, it is likely that NEDD4-2 may be involved in the
   pathogenesis of intractable epilepsy. However, the role of
   NEDD4-2-mediated GRIA1 ubiquitination in refractory seizures to AMPAR
   antagonists is still unknown. In the present study, both AMPAR
   antagonists recovered the impaired GRIA1 ubiquitination by regulating
   protein phosphatase 2B (PP2B)-extracellular signal-regulated kinase 1/2
   (ERK1/2)-serum and glucocorticoid-regulated kinase 1 (SGK1)-NEDD4-2
   signaling pathway in responders (whose seizure activities are responsive
   to AMPAR), but not non-responders (whose seizure activities were
   uncontrolled by AMPAR antagonists). In addition, cyclosporin A (CsA, a
   PP2B inhibitor) co-treatment improved the effects of AMPAR antagonists
   in non-responders, independent of AKT signaling pathway. Therefore, our
   findings suggest that dysregulation of PP2B-ERK1/2-SGK1-NEDD4-2-mediated
   GRIA1 ubiquitination may be responsible for refractory seizures and that
   this pathway may be a potential therapeutic target for improving the
   treatment of intractable epilepsy in response to AMPAR antagonists.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Kim, JE; Kang, TC (Corresponding Author), Hallym Univ, Coll Med, Inst Epilepsy Res, Dept Anat \& Neurobiol, Chunchon 24252, South Korea.
   Kim, Ji-Eun; Lee, Duk-Shin; Park, Hana; Kim, Tae-Hyun; Kang, Tae-Cheon, Hallym Univ, Coll Med, Inst Epilepsy Res, Dept Anat \& Neurobiol, Chunchon 24252, South Korea.},
DOI = {10.3390/biomedicines9081069},
Article-Number = {1069},
EISSN = {2227-9059},
Keywords = {3-phosphoinositide-dependent protein kinase-1; AKT; cyclosporin A;
   GluA1; GluR1; intractable epilepsy; PDK1; refractory seizure},
Keywords-Plus = {INDUCIBLE KINASE SGK; ACTIVITY-DEPENDENT UBIQUITINATION; K+ CHANNELS
   KCNQ2/3; PROTEIN-KINASE; CYCLOSPORINE-A; STATUS EPILEPTICUS;
   SODIUM-CHANNELS; SERUM; NEDD4-2; PHOSPHORYLATION},
Research-Areas = {Biochemistry \& Molecular Biology; Research \& Experimental Medicine;
   Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Medicine, Research \& Experimental;
   Pharmacology \& Pharmacy},
Author-Email = {jieunkim@hallym.ac.kr
   dslee84@hallym.ac.kr
   M19050@hallym.ac.kr
   hyun1028@hallym.ac.kr
   tckang@hallym.ac.kr},
Affiliations = {Hallym University},
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) {[}2021R1A2C4002003,
   2021R1A2B5B01001482]},
Funding-Text = {This study was supported by a grant from the National Research
   Foundation of Korea (NRF) grant (No. 2021R1A2C4002003 and No.
   2021R1A2B5B01001482).},
Cited-References = {Allen AS, 2013, NATURE, V501, P217, DOI 10.1038/nature12439.
   Anggono V, 2012, CURR OPIN NEUROBIOL, V22, P461, DOI 10.1016/j.conb.2011.12.006.
   Bruce MC, 2008, BIOCHEM J, V415, P155, DOI 10.1042/BJ20071708.
   Chandran S, 2011, J BIOL CHEM, V286, P37830, DOI 10.1074/jbc.M111.293233.
   Dibbens LM, 2007, GENES BRAIN BEHAV, V6, P750, DOI 10.1111/j.1601-183X.2007.00305.x.
   Egbenya DL, 2018, MOL CELL NEUROSCI, V92, P93, DOI 10.1016/j.mcn.2018.07.004.
   Ekberg J, 2007, J BIOL CHEM, V282, P12135, DOI 10.1074/jbc.M609385200.
   Ekberg JA, 2014, BIOCHEM J, V457, P27, DOI 10.1042/BJ20131275.
   Fiest KM, 2017, NEUROLOGY, V88, P296, DOI 10.1212/WNL.0000000000003509.
   Fritsch B, 2010, EPILEPSIA, V51, P108, DOI 10.1111/j.1528-1167.2009.02205.x.
   Gabryel B, 2006, N-S ARCH PHARMACOL, V374, P127, DOI 10.1007/s00210-006-0106-x.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   García-Tardón N, 2012, J BIOL CHEM, V287, P19177, DOI 10.1074/jbc.M112.355909.
   Goel P, 2015, GENE, V557, P1, DOI 10.1016/j.gene.2014.11.051.
   Hallengren J, 2013, CELL BIOCHEM BIOPHYS, V67, P67, DOI 10.1007/s12013-013-9634-4.
   Handreck A, 2015, EPILEPSY RES, V112, P1, DOI 10.1016/j.eplepsyres.2015.02.006.
   HASHIMOTO Y, 1988, P NATL ACAD SCI USA, V85, P7001, DOI 10.1073/pnas.85.18.7001.
   Hell JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf7067.
   Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9\_suppl\_5.S21.
   Huo YD, 2015, J NEUROCHEM, V134, P1067, DOI 10.1111/jnc.13194.
   Kim JE, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9040425.
   Kim JE, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03325-9.
   Kim JE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249633.
   Kim JE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165643.
   Kim JE, 2020, EXP NEUROL, V331, DOI 10.1016/j.expneurol.2020.113383.
   Kim JE, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1781-0.
   Kim JE, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00080.
   Ko AR, 2015, SEIZURE-EUR J EPILEP, V31, P133, DOI 10.1016/j.seizure.2015.07.019.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   Lee CT, 2007, J NEUROCHEM, V100, P1531, DOI 10.1111/j.1471-4159.2006.04284.x.
   Lee CT, 2006, EUR J NEUROSCI, V23, P1311, DOI 10.1111/j.1460-9568.2006.04650.x.
   Lee IH, 2007, J BIOL CHEM, V282, P29866, DOI 10.1074/jbc.M701923200.
   Lee KY, 2018, HUM MOL GENET, V27, P2805, DOI 10.1093/hmg/ddy189.
   Li C, 2018, NEUROPHARMACOLOGY, V135, P151, DOI 10.1016/j.neuropharm.2018.02.034.
   Lin A, 2011, J NEUROCHEM, V119, P27, DOI 10.1111/j.1471-4159.2011.07221.x.
   Lorgen JO, 2017, EPILEPSY RES, V137, P25, DOI 10.1016/j.eplepsyres.2017.08.012.
   Löscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6.
   Loscher Wolfgang, 2005, NeuroRx, V2, P86, DOI 10.1602/neurorx.2.1.86.
   Ma Y, 2017, NEUROCHEM RES, V42, P1438, DOI 10.1007/s11064-017-2200-5.
   MacDonnell SM, 2009, CIRC RES, V105, P316, DOI 10.1161/CIRCRESAHA.109.194035.
   Mohammad H, 2019, MOL NEUROBIOL, V56, P2508, DOI 10.1007/s12035-018-1230-6.
   Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024.
   PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4.
   Pérez M, 1999, BBA-MOL CELL RES, V1449, P150, DOI 10.1016/S0167-4889(99)00008-7.
   RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0.
   Schuetz F, 2008, AM J PHYSIOL-CELL PH, V295, pC73, DOI 10.1152/ajpcell.00146.2008.
   Schwarz LA, 2012, MOL CELL NEUROSCI, V49, P387, DOI 10.1016/j.mcn.2011.08.006.
   Schwarz LA, 2010, J NEUROSCI, V30, P16718, DOI 10.1523/JNEUROSCI.3686-10.2010.
   Sillanpää M, 2006, BRAIN, V129, P617, DOI 10.1093/brain/awh726.
   Snyder PM, 2004, J BIOL CHEM, V279, P45753, DOI 10.1074/jbc.M407858200.
   Tang F, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00301.
   Tauboll E, 1998, EPILEPSIA, V39, P687, DOI 10.1111/j.1528-1157.1998.tb01152.x.
   Vanli-Yavuz EN, 2015, ACTA NEUROL BELG, V115, P241, DOI 10.1007/s13760-014-0412-x.
   Vezzani A, 2019, NAT REV NEUROL, V15, P459, DOI 10.1038/s41582-019-0217-x.
   Wang LA, 2010, NEUROCHEM INT, V57, P899, DOI 10.1016/j.neuint.2010.09.009.
   WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8.
   Widagdo J, 2015, CELL REP, V10, P783, DOI 10.1016/j.celrep.2015.01.015.
   Wu LW, 2015, PHYSIOL BEHAV, V143, P104, DOI 10.1016/j.physbeh.2015.02.026.
   Yu T, 2014, J NEUROSCI, V34, P6098, DOI 10.1523/JNEUROSCI.4271-13.2014.
   Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200.
   Zhu JH, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006634.},
Number-of-Cited-References = {61},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Biomedicines},
Doc-Delivery-Number = {UG0ZF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000688990900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000689200300001,
Author = {Milic, Nives Skorja and Dolinar, Klemen and Mis, Katarina and Matkovic,
   Urska and Bizjak, Marusa and Pavlin, Mojca and Podbregar, Matej and
   Pirkmajer, Sergej},
Title = {Suppression of Pyruvate Dehydrogenase Kinase by Dichloroacetate in
   Cancer and Skeletal Muscle Cells Is Isoform Specific and Partially
   Independent of HIF-1α},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2021},
Volume = {22},
Number = {16},
Month = {AUG},
Abstract = {Inhibition of pyruvate dehydrogenase kinase (PDK) emerged as a potential
   strategy for treatment of cancer and metabolic disorders.
   Dichloroacetate (DCA), a prototypical PDK inhibitor, reduces the
   abundance of some PDK isoenzymes. However, the underlying mechanisms are
   not fully characterized and may differ across cell types. We determined
   that DCA reduced the abundance of PDK1 in breast (MDA-MB-231) and
   prostate (PC-3) cancer cells, while it suppressed both PDK1 and PDK2 in
   skeletal muscle cells (L6 myotubes). The DCA-induced PDK1 suppression
   was partially dependent on hypoxia-inducible factor-1 alpha (HIF-1
   alpha), a transcriptional regulator of PDK1, in cancer cells but not in
   L6 myotubes. However, the DCA-induced alterations in the mRNA and the
   protein levels of PDK1 and/or PDK2 did not always occur in parallel,
   implicating a role for post-transcriptional mechanisms. DCA did not
   inhibit the mTOR signaling, while inhibitors of the proteasome or gene
   silencing of mitochondrial proteases CLPP and AFG3L2 did not prevent the
   DCA-induced reduction of the PDK1 protein levels. Collectively, our
   results suggest that DCA reduces the abundance of PDK in an
   isoform-dependent manner via transcriptional and post-transcriptional
   mechanisms. Differential response of PDK isoenzymes to DCA might be
   important for its pharmacological effects in different types of cells.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Pirkmajer, S (Corresponding Author), Univ Ljubljana, Fac Med, Inst Pathophysiol, Ljubljana 1000, Slovenia.
   Milic, Nives Skorja; Dolinar, Klemen; Mis, Katarina; Matkovic, Urska; Podbregar, Matej; Pirkmajer, Sergej, Univ Ljubljana, Fac Med, Inst Pathophysiol, Ljubljana 1000, Slovenia.
   Milic, Nives Skorja, Univ Ljubljana, Fac Med, Inst Anat, Ljubljana 1000, Slovenia.
   Bizjak, Marusa; Pavlin, Mojca, Univ Ljubljana, Fac Elect Engn, Grp Nano \& Biotechnol Applicat, Ljubljana 1000, Slovenia.
   Bizjak, Marusa, Univ Ljubljana, Fac Pharm, Pharm Inst, Ljubljana 1000, Slovenia.
   Pavlin, Mojca, Univ Ljubljana, Fac Med, Inst Biophys, Ljubljana 1000, Slovenia.
   Podbregar, Matej, Univ Ljubljana, Fac Med, Dept Internal Med, Ljubljana 1000, Slovenia.
   Podbregar, Matej, Gen \& Teaching Hosp Celje, Dept Internal Intens Care, Celje 3000, Slovenia.
   Matkovic, Urska, Inst Oncol Ljubljana, Dept Expt Oncol, Ljubljana 1000, Slovenia.},
DOI = {10.3390/ijms22168610},
Article-Number = {8610},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {dichloroacetate; pyruvate dehydrogenase kinase; pyruvate dehydrogenase
   complex; cancer; skeletal muscle cells; myotubes},
Keywords-Plus = {INDUCIBLE FACTOR-I; LACTATE PRODUCTION; BREAST-CANCER; ACID
   DEHYDROGENASE; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; HYPOXIA; COMPLEX;
   PHOSPHORYLATION; METABOLISM},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {nives.skorja@mf.uni-lj.si
   klemen.dolinar@mf.uni-lj.si
   katarina.mis@mf.uni-lj.si
   umatkovic@onko-i.si
   marusa.bizjak@ffa.uni-lj.si
   mojca.pavlin@fe.uni-lj.si
   matej.podbregar@mf.uni-lj.si
   sergej.pirkmajer@mf.uni-lj.si},
Affiliations = {University of Ljubljana; University of Ljubljana; University of
   Ljubljana; University of Ljubljana; University of Ljubljana; University
   of Ljubljana; Institute of Oncology - Slovenia},
ResearcherID-Numbers = {Pavlin, Mojca/AAD-4738-2022},
ORCID-Numbers = {Škorja Milić, Nives/0000-0002-8782-6328
   Pirkmajer, Sergej/0000-0003-1459-6936
   Dolinar, Klemen/0000-0002-3903-6321
   Pavlin, Mojca/0000-0001-5477-7833},
Funding-Acknowledgement = {Slovenian research agency {[}P3-0043, J7-8276, J3-6794, J3-2523,
   P1-0055]},
Funding-Text = {This study was supported by funding from the Slovenian research agency
   (grants P3-0043, J7-8276, J3-6794, J3-2523, P1-0055, and the young
   researcher grant to N.S.M.).},
Cited-References = {Bizjak M, 2019, BIOCHEM BIOPH RES CO, V515, P296, DOI 10.1016/j.bbrc.2019.05.090.
   Bizjak M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01801-5.
   Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   BROWNING M, 1981, J NEUROCHEM, V36, P1932, DOI 10.1111/j.1471-4159.1981.tb10817.x.
   BUSCH H, 1957, J BIOL CHEM, V229, P377.
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797.
   Choi YW, 2014, CANCER LETT, V346, P300, DOI 10.1016/j.canlet.2014.01.015.
   Constantin-Teodosiu D, 2013, DIABETES METAB J, V37, P301, DOI 10.4093/dmj.2013.37.5.301.
   Crewe C, 2017, J BIOL CHEM, V292, P305, DOI 10.1074/jbc.M116.754127.
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310.
   Düvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022.
   El-Mir MY, 2000, J BIOL CHEM, V275, P223, DOI 10.1074/jbc.275.1.223.
   Fischer F, 2015, SCI REP-UK, V5, DOI 10.1038/srep18375.
   Goard CA, 2014, ONCOGENE, V33, P2690, DOI 10.1038/onc.2013.228.
   Gong F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.438.
   Goodwin J, 2018, AM J RESP CELL MOL, V58, P216, DOI 10.1165/rcmb.2016-0186OC.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Gudiksen A, 2018, PFLUG ARCH EUR J PHY, V470, P1633, DOI 10.1007/s00424-018-2164-6.
   Gudiksen A, 2017, PFLUG ARCH EUR J PHY, V469, P1615, DOI 10.1007/s00424-017-2019-6.
   Gudiksen A, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13222.
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003.
   Haugrud AB, 2014, BREAST CANCER RES TR, V147, P539, DOI 10.1007/s10549-014-3128-y.
   Ho N, 2015, EXP CELL RES, V331, P73, DOI 10.1016/j.yexcr.2014.12.006.
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim YI, 2006, DIABETES, V55, P2311, DOI 10.2337/db05-1606.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Kristensen JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053533.
   Krus U, 2010, BIOCHEM J, V429, P205, DOI 10.1042/BJ20100142.
   Li BB, 2018, INT J MOL MED, V42, P1391, DOI 10.3892/ijmm.2018.3745.
   Li B, 2016, ONCOTARGET, V7, P59458, DOI 10.18632/oncotarget.10694.
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009.
   Lindholm ME, 2014, AM J PHYSIOL-REG I, V307, pR248, DOI 10.1152/ajpregu.00036.2013.
   LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234.
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y.
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821.
   Lojk J, 2015, BIOELECTROMAGNETICS, V36, P551, DOI 10.1002/bem.21936.
   Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701.
   Mason SD, 2007, AM J PHYSIOL-REG I, V293, pR2059, DOI 10.1152/ajpregu.00335.2007.
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459.
   McAinch AJ, 2015, EUR J NUTR, V54, P1033, DOI 10.1007/s00394-014-0780-2.
   McCall CE, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99292.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Michelakis ED, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4583.
   Neznanov N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001887.
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Pendleton AL, 2019, AM J PHYSIOL-REG I, V317, pR513, DOI 10.1152/ajpregu.00106.2019.
   Piel S, 2015, ACTA PHYSIOL, V213, P171, DOI 10.1111/apha.12311.
   Pilegaard H, 2006, DIABETES, V55, P3020, DOI 10.2337/db06-0152.
   Pirkmajer S, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.566584.
   Pirkmajer S, 2010, AM J PHYSIOL-REG I, V299, pR1693, DOI 10.1152/ajpregu.00133.2010.
   POPOV KM, 1994, J BIOL CHEM, V269, P29720.
   Pópulo H, 2015, EXPERT OPIN THER TAR, V19, P733, DOI 10.1517/14728222.2015.1045416.
   Quirós PM, 2015, NAT REV MOL CELL BIO, V16, P345, DOI 10.1038/nrm3984.
   Rajh M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154747.
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4.
   Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376.
   Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447.
   SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680.
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757.
   Sradhanjali S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177744.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Stacpoole PW, 1998, ENVIRON HEALTH PERSP, V106, P989, DOI 10.1289/ehp.98106s4989.
   Sugden M. C., 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P151, DOI 10.2174/1568008023340785.
   Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002.
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Tao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071997.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Wang DW, 2019, ONCOGENE, V38, P3458, DOI 10.1038/s41388-019-0675-z.
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304.
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510.
   WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6.
   Ward NP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180061.
   Westhaus A, 2017, NEUROCHEM RES, V42, P294, DOI 10.1007/s11064-015-1733-8.
   WHITEHOUSE S, 1973, BIOCHEM J, V134, P651, DOI 10.1042/bj1340651.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Yerlikaya A, 2008, BIOCHEM J, V412, P579, DOI 10.1042/BJ20080324.
   Yoshino S, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.19.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.
   Zhao YH, 2011, CANCER RES, V71, P4585, DOI 10.1158/0008-5472.CAN-11-0127.
   Zhou J, 2006, MOL BIOL CELL, V17, P1549, DOI 10.1091/mbc.E05-08-0770.
   Zhou XK, 2016, ONCOTARGET, V7, P873, DOI 10.18632/oncotarget.6418.},
Number-of-Cited-References = {91},
Times-Cited = {27},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {UG4BP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000689200300001},
OA = {Green Submitted, Green Published, gold},
DA = {2026-02-04},
}

@article{ WOS:000678975300004,
Author = {Ramirez-Sagredo, Andrea and Quiroga, Clara and Garrido-Moreno, Valeria
   and Lopez-Crisosto, Camila and Leiva-Navarrete, Sebastian and
   Norambuena-Soto, Ignacio and Ortiz-Quintero, Jafet and Diaz-Vesga, Magda
   C. and Perez, William and Hendrickson, Troy and Parra, Valentina and
   Pedrozo, Zully and Altamirano, Francisco and Chiong, Mario and
   Lavandero, Sergio},
Title = {Polycystin-1 regulates cardiomyocyte mitophagy},
Journal = {FASEB JOURNAL},
Year = {2021},
Volume = {35},
Number = {8},
Month = {AUG},
Abstract = {Polycystin-1 (PC1) is a transmembrane protein found in different cell
   types, including cardiomyocytes. Alterations in PC1 expression have been
   linked to mitochondrial damage in renal tubule cells and in patients
   with autosomal dominant polycystic kidney disease. However, to date, the
   regulatory role of PC1 in cardiomyocyte mitochondria is not well
   understood. The analysis of mitochondrial morphology from cardiomyocytes
   of heterozygous PC1 mice (PDK1(+/-)) using transmission electron
   microscopy showed that cardiomyocyte mitochondria were smaller with
   increased mitochondria density and circularity. These parameters were
   consistent with mitochondrial fission. We knocked-down PC1 in cultured
   rat cardiomyocytes and human-induced pluripotent stem cells
   (iPSC)-derived cardiomyocytes to evaluate mitochondrial function and
   morphology. The results showed that downregulation of PC1 expression
   results in reduced protein levels of sub-units of the OXPHOS complexes
   and less functional mitochondria (reduction of mitochondrial membrane
   potential, mitochondrial respiration, and ATP production). This
   mitochondrial dysfunction activates the elimination of defective
   mitochondria by mitophagy, assessed by an increase of autophagosome
   adapter protein LC3B and the recruitment of the Parkin protein to the
   mitochondria. siRNA-mediated PC1 knockdown leads to a loss of the
   connectivity of the mitochondrial network and a greater number of
   mitochondria per cell, but of smaller sizes, which characterizes
   mitochondrial fission. PC1 silencing also deregulates the AKT-FoxO1
   signaling pathway, which is involved in the regulation of mitochondrial
   metabolism, mitochondrial morphology, and processes that are part of
   cell quality control, such as mitophagy. Together, these data provide
   new insights about the controls that PC1 exerts on mitochondrial
   morphology and function in cultured cardiomyocytes dependent on the
   AKT-FoxO1 signaling pathway.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Lavandero, S (Corresponding Author), Univ Chile, Adv Ctr Chron Dis ACCDiS, Fac Ciencias Quim \& Farmaceut, Olivos 1007, Santiago 8380492, Chile.
   Lavandero, S (Corresponding Author), Univ Chile, Fac Med, Olivos 1007, Santiago 8380492, Chile.
   Ramirez-Sagredo, Andrea; Garrido-Moreno, Valeria; Lopez-Crisosto, Camila; Leiva-Navarrete, Sebastian; Norambuena-Soto, Ignacio; Ortiz-Quintero, Jafet; Diaz-Vesga, Magda C.; Parra, Valentina; Pedrozo, Zully; Chiong, Mario; Lavandero, Sergio, Univ Chile, Adv Ctr Chron Dis ACCDiS, Fac Ciencias Quim \& Farmaceut, Olivos 1007, Santiago 8380492, Chile.
   Ramirez-Sagredo, Andrea; Garrido-Moreno, Valeria; Lopez-Crisosto, Camila; Leiva-Navarrete, Sebastian; Norambuena-Soto, Ignacio; Ortiz-Quintero, Jafet; Diaz-Vesga, Magda C.; Parra, Valentina; Pedrozo, Zully; Chiong, Mario; Lavandero, Sergio, Univ Chile, Fac Med, Olivos 1007, Santiago 8380492, Chile.
   Quiroga, Clara; Lopez-Crisosto, Camila, Pontificia Univ Catolica Chile, Fac Med, Div Enfermedades Cardiovasc, Adv Ctr Chron Dis ACCDiS, Santiago, Chile.
   Leiva-Navarrete, Sebastian; Parra, Valentina, Univ Chile, Autophagy Res Ctr, Santiago, Chile.
   Leiva-Navarrete, Sebastian; Parra, Valentina; Pedrozo, Zully, Univ Chile, Network Study High Lethal Cardiopulm Dis REECPAL, Santiago, Chile.
   Ortiz-Quintero, Jafet, Univ Nacl Autonoma Honduras, Dept Bioanal \& Inmunol, Escuela Microbiol, Fac Ciencias, Tegucigalpa, Honduras.
   Diaz-Vesga, Magda C.; Pedrozo, Zully, Univ Chile, Fac Med, Programa Fisiol \& Biofis, ICBM, Santiago, Chile.
   Diaz-Vesga, Magda C., Pontificia Univ Javeriana Cali, Grp Invest Ciencias Basicas \& Clin Salud, Cali, Colombia.
   Perez, William; Hendrickson, Troy; Altamirano, Francisco, Houston Methodist Res Inst, Dept Cardiovasc Sci, Houston, TX USA.
   Hendrickson, Troy, Texas A\&M Hlth Sci Ctr, Texas A\&M MD PhD Program, College Stn, TX USA.
   Altamirano, Francisco, Cornell Univ, Dept Cardiothorac Surg, Weill Cornell Med Coll, Ithaca, NY USA.
   Lavandero, Sergio, Corp Ctr Estudios Cient Enfermedades Cron CECEC, Santiago, Chile.
   Lavandero, Sergio, Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Div Cardiol, Dallas, TX USA.},
DOI = {10.1096/fj.202002598R},
Article-Number = {e21796},
ISSN = {0892-6638},
EISSN = {1530-6860},
Keywords = {cardiomyocyte; FoxO1; mitochondrial dynamics; mitochondrial metabolism;
   mitophagy; polycystin-1},
Keywords-Plus = {FOXO TRANSCRIPTION FACTORS; MITOCHONDRIAL DYNAMICS; OXIDATIVE STRESS;
   HEART; FISSION; AKT; PHOSPHORYLATION; DYSFUNCTION; PATHWAYS; SURVIVAL},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Cell Biology},
Author-Email = {slavander@uchile.cl},
Affiliations = {Universidad de Chile; Universidad de Chile; Pontificia Universidad
   Catolica de Chile; Universidad de Chile; Universidad de Chile;
   Universidad Nacional Autonoma de Honduras; Universidad de Chile;
   Pontificia Universidad Javeriana; Houston Methodist; Texas A\&M
   University System; Texas A\&M University College Station; Texas A\&M
   Health Science Center; Cornell University; Weill Cornell Medicine;
   University of Texas System; University of Texas Southwestern Medical
   Center},
ResearcherID-Numbers = {Altamirano, Francisco/I-1928-2013
   Ortiz-Quintero, Jafet/GPF-3377-2022
   Peozo, Zully/AAN-5350-2021
   Norambuena, Ignacio/ISS-0706-2023
   Quiroga, Clara/AAB-4180-2020
   Chiong, Mario/I-1043-2013
   Lavandero, Sergio/B-6001-2013
   Parra, Valentina/N-3972-2018
   },
ORCID-Numbers = {Perez, William/0000-0003-0344-4160
   Altamirano, Francisco/0000-0002-1612-2729
   Ortiz-Quintero, Jafet/0000-0001-7656-6367
   Díaz Vesga, Magda Carolina/0000-0002-7807-2050
   Peozo, Zully/0000-0003-4690-2803
   Ramírez Sagredo, Anea/0000-0003-1081-0704
   Norambuena, Ignacio/0000-0002-2676-2674
   Garrido Moreno, Valeria Soraya/0000-0002-3298-2622
   Quiroga, Clara/0000-0002-0251-4772
   Chiong, Mario/0000-0002-5174-6545
   Parra, Valentina/0000-0002-0080-6472
   Lopez-Crisosto, Camila/0000-0003-1055-099X},
Funding-Acknowledgement = {Agencia Nacional de Investigacion y Desarrollo (ANID), Chile {[}FONDECYT
   3190546, 1190743, 1200490, 1180613, 3210443, 3210496, FONDAP 15130011,
   21191341, 21171588]; International Centre for Genetic Engineering and
   Biotechnology (ICGEB) {[}CRP/CHL18-04]; University of Chile grant
   U-Redes Generacion {[}VID G\_2018-35]; Houston Methodist Start-Up funds},
Funding-Text = {The authors thank Gindra Latorre and Fidel Albornoz for their excellent
   technical support. This work was supported by the Agencia Nacional de
   Investigacion y Desarrollo (ANID), Chile, Grant/Award Numbers: FONDECYT
   3190546, 1190743, 1200490, 1180613, 3210443, 3210496, FONDAP 15130011,
   and PhD fellowships 21191341 and 21171588; International Centre for
   Genetic Engineering and Biotechnology (ICGEB), Grant/Award Number:
   CRP/CHL18-04; University of Chile grant U-Redes Generacion, Grant/Award
   Number: VID G\_2018-35, Houston Methodist Start-Up funds.},
Cited-References = {Altamirano F, 2019, CIRCULATION, V140, P921, DOI 10.1161/CIRCULATIONAHA.118.034731.
   Barthel A, 2005, TRENDS ENDOCRIN MET, V16, P183, DOI 10.1016/j.tem.2005.03.010.
   Boudina S, 2007, DIABETES, V56, P2457, DOI 10.2337/db07-0481.
   Bravo-San Pedro JM, 2017, CIRC RES, V120, P1812, DOI 10.1161/CIRCRESAHA.117.311082.
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4.
   Chebib FT, 2017, KIDNEY INT REP, V2, P913, DOI 10.1016/j.ekir.2017.05.014.
   Chiong M, 2010, APOPTOSIS, V15, P887, DOI 10.1007/s10495-010-0505-9.
   Córdova-Casanova A, 2018, BBA-MOL CELL RES, V1865, P289, DOI 10.1016/j.bbamcr.2017.11.001.
   Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5.
   Di Lisa F, 2006, CARDIOVASC RES, V70, P191, DOI 10.1016/j.cardiores.2006.01.016.
   Galvez A, 2001, CELL TISSUE RES, V304, P279, DOI 10.1007/s004410100358.
   Hong TT, 2014, NAT MED, V20, P624, DOI 10.1038/nm.3543.
   Huang CY, 2018, J MOL CELL CARDIOL, V122, P58, DOI 10.1016/j.yjmcc.2018.08.006.
   Ishimoto Y, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00337-17.
   Jasová M, 2017, J BIOENERG BIOMEMBR, V49, P357, DOI 10.1007/s10863-017-9720-1.
   Klawitter J, 2014, AM J PHYSIOL-RENAL, V307, pF1198, DOI 10.1152/ajprenal.00327.2014.
   Kubli DA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130707.
   Li W, 2017, ENDOCRINOLOGY, V158, P2155, DOI 10.1210/en.2016-1970.
   Lin CC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20856-6.
   MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260.
   Marín-García J, 2016, HEART FAIL REV, V21, P123, DOI 10.1007/s10741-016-9530-2.
   Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100.
   Menezes LF, 2016, EBIOMEDICINE, V5, P183, DOI 10.1016/j.ebiom.2016.01.027.
   Menezes LF, 2019, NAT REV NEPHROL, V15, P736, DOI 10.1038/s41581-019-0183-y.
   Menon V, 2011, CLIN J AM SOC NEPHRO, V6, P7, DOI 10.2215/CJN.04140510.
   Morales PE, 2020, MOL ASPECTS MED, V71, DOI 10.1016/j.mam.2019.09.006.
   Munoz JP, 2010, FREE RADICAL BIO MED, V48, P526, DOI 10.1016/j.freeradbiomed.2009.11.017.
   Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330.
   Nguyen TN, 2016, TRENDS CELL BIOL, V26, P733, DOI 10.1016/j.tcb.2016.05.008.
   Ni YG, 2007, P NATL ACAD SCI USA, V104, P20517, DOI 10.1073/pnas.0610290104.
   Ning YZ, 2015, J TOXICOL SCI, V40, P637, DOI 10.2131/jts.40.637.
   Padovano V, 2017, MOL BIOL CELL, V28, P261, DOI 10.1091/mbc.E16-08-0597.
   Parra V, 2018, CIRC RES, V122, pE20, DOI 10.1161/CIRCRESAHA.117.311522.
   Parra V, 2014, DIABETES, V63, P75, DOI 10.2337/db13-0340.
   Pedrozo Z, 2015, CIRCULATION, V131, P2131, DOI 10.1161/CIRCULATIONAHA.114.013537.
   Pennanen C, 2014, J CELL SCI, V127, P2659, DOI 10.1242/jcs.139394.
   Pernas L, 2016, ANNU REV PHYSIOL, V78, P505, DOI 10.1146/annurev-physiol-021115-105011.
   Pryde KR, 2016, J CELL BIOL, V213, P163, DOI 10.1083/jcb.201509003.
   Puri R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11636-5.
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497.
   Rowe I, 2013, NAT MED, V19, P488, DOI 10.1038/nm.3092.
   Sanchez AMJ, 2014, CELL MOL LIFE SCI, V71, P1657, DOI 10.1007/s00018-013-1513-z.
   Sengupta A, 2009, J BIOL CHEM, V284, P28319, DOI 10.1074/jbc.M109.024406.
   Shi YD, 2018, BBA-MOL BASIS DIS, V1864, P2481, DOI 10.1016/j.bbadis.2018.04.005.
   Stiles BL, 2009, ADV DRUG DELIVER REV, V61, P1276, DOI 10.1016/j.addr.2009.07.017.
   Torres VE, 2007, LANCET, V369, P1287, DOI 10.1016/S0140-6736(07)60601-1.
   Trotta AP, 2017, CELL MOL LIFE SCI, V74, P1999, DOI 10.1007/s00018-016-2451-3.
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839.
   Wallace DP, 2011, BBA-MOL BASIS DIS, V1812, P1291, DOI 10.1016/j.bbadis.2010.11.005.
   Wang D, 2020, BRIT J PHARMACOL, V177, P432, DOI 10.1111/bph.14878.
   Yang MJ, 2019, BBA-MOL BASIS DIS, V1865, P2293, DOI 10.1016/j.bbadis.2019.05.007.
   Yoo SM, 2018, MOL CELLS, V41, P18, DOI 10.14348/molcells.2018.2277.
   Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003.
   Zhan M, 2013, KIDNEY INT, V83, P568, DOI 10.1038/ki.2012.441.
   Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200.},
Number-of-Cited-References = {55},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Faseb J.},
Doc-Delivery-Number = {TR4ZX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000678975300004},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000690260800001,
Author = {Yanes-Diaz, Joaquin and Palao-Suay, Raquel and Aguilar, Maria Rosa and
   Riestra-Ayora, Juan Ignacio and Ferruelo-Alonso, Antonio and Rojo del
   Olmo, Luis and Vazquez-Lasa, Blanca and Sanz-Fernandez, Ricardo and
   Sanchez-Rodriguez, Carolina},
Title = {Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel
   AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell
   Carcinoma},
Journal = {PHARMACEUTICS},
Year = {2021},
Volume = {13},
Number = {8},
Month = {AUG},
Abstract = {Currently, new treatments are required to supplement the current
   standard of care for head and neck squamous cell carcinoma (HNSCC). The
   phosphatidylinositol3-kinase (PI3K) signaling pathway is commonly
   altered and activated in HNSCC. PHT-427 is a dual PI3K-mammalian target
   of the AKT/PDK1 inhibitor; however, to the best of our knowledge, the
   effect of the PHT-427 inhibitor on HNSCC has not been investigated. This
   study aims to evaluate the antitumoral effect of PHT-427-loaded
   polymeric nanoparticles based on alpha-tocopheryl succinate (alpha-TOS).
   The in vitro activity of PHT-427 was tested in hypopharynx carcinoma
   squamous cells (FaDu) to measure the cell viability, PI3KCA/AKT/PDK1
   gene expression, and PI3KCA/AKT/PDK1 levels. Apoptosis, epidermal growth
   factor receptor (EGFR), and reactive oxygen species (ROS) were also
   measured. The presence of PHT-427 significantly enhances its
   antiproliferative and proapoptotic activity by inactivating the
   PI3K/AKT/PDK1 pathway. Nanoparticles (NPs) effectively suppress AKT/PDK1
   expression. Additionally, NPs loaded with PHT-427 produce high oxidative
   stress levels that induce apoptosis. In conclusion, these results are
   promising in the use of this nanoformulation as a PHT-427 delivery
   system for effective HNSCC treatment.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Sánchez-Rodríguez, C (Corresponding Author), Univ Europea Madrid, Fac Biomed \& Hlth Sci, Dept Med, Madrid 28670, Spain.
   Yanes-Diaz, Joaquin; Riestra-Ayora, Juan Ignacio; Sanz-Fernandez, Ricardo, Hosp Univ Getafe, Dept Otolaryngol, Carretera Toledo,Km 12-500, Madrid 28905, Spain.
   Palao-Suay, Raquel; Aguilar, Maria Rosa; Rojo del Olmo, Luis; Vazquez-Lasa, Blanca, CSIC, Inst Polymer Sci \& Technol, Dept Polymer Nanomat \& Biomat, C Juan Cierva 3, Madrid 28006, Spain.
   Palao-Suay, Raquel; Aguilar, Maria Rosa; Rojo del Olmo, Luis; Vazquez-Lasa, Blanca, Biomed Res Ctr Bioengn Biomat \& Nanomed CIBER BBN, Madrid 28029, Spain.
   Riestra-Ayora, Juan Ignacio; Sanchez-Rodriguez, Carolina, Univ Europea Madrid, Fac Biomed \& Hlth Sci, Dept Med, Madrid 28670, Spain.
   Ferruelo-Alonso, Antonio, Hosp Univ Getafe, Fdn Invest Biomed, Carretera Toledo,Km 12-500, Madrid 28905, Spain.
   Ferruelo-Alonso, Antonio, CIBER Enfermedades Resp, Inst Invest Carlos 3, Madrid 28029, Spain.},
DOI = {10.3390/pharmaceutics13081242},
Article-Number = {1242},
EISSN = {1999-4923},
Keywords = {PHT-427 inhibitor; polymeric nanoparticle; PI3K pathway; AKT; PDK1;
   hypopharynx carcinoma squamous cells},
Keywords-Plus = {PLECKSTRIN HOMOLOGY DOMAIN; PI3K/MTOR INHIBITOR; PI3K PATHWAY; IN-VITRO;
   CANCER; DELIVERY; PF-04691502; THERAPY; TRENDS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {joaquin.yanes@salud.madrid.org
   rpsuay@ictp.csic.es
   mraguilar@ictp.csic.es
   juanignacio.riestra@salud.madrid.org
   antoniojose.ferruelo@salud.madrid.org
   rojodelolmo@ictp.csic.es
   bvazquez@ictp.csic.es
   rsanzf@salud.madrid.org
   carolina.sanchez2@universidadeuropea.es},
Affiliations = {Hospital Universitario de Getafe; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC - Instituto de Ciencia \& Tecnologia de
   Polimeros (ICTP); CIBER - Centro de Investigacion Biomedica en Red;
   CIBERBBN; European University of Madrid; Hospital Universitario de
   Getafe; CIBER - Centro de Investigacion Biomedica en Red; CIBERES},
ResearcherID-Numbers = {Vázquez, Blanca/U-9722-2018
   Sanchez Roiguez, Carolina/M-6184-2015
   Rojo del Olmo, Luis/B-3073-2009
   Aguilar, Maria Rosa/C-2593-2014},
ORCID-Numbers = {Ferruelo Alonso, Antonio José/0000-0001-9840-3569
   Vázquez, Blanca/0000-0001-5539-8026
   Sanchez Roiguez, Carolina/0000-0001-6246-0449
   Yanes Diaz, Joaquin/0000-0003-0890-084X
   Rojo del Olmo, Luis/0000-0001-6334-6736
   Riestra Ayora, Juan/0000-0003-0297-2711
   Aguilar, Maria Rosa/0000-0001-7395-5754},
Funding-Acknowledgement = {Spanish Ministry of Science, Innovation, and Universities; CIBER-BBN
   {[}MAT2017-84277-R]; European University of Madrid {[}2017/UEM21,
   2019/UEM06]},
Funding-Text = {This research was funded by the Spanish Ministry of Science, Innovation,
   and Universities and CIBER-BBN, grant number MAT2017-84277-R, and by the
   European University of Madrid, grant numbers 2017/UEM21 and 2019/UEM06.},
Cited-References = {Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Broek RV, 2015, ORAL DIS, V21, P815, DOI 10.1111/odi.12206.
   Carvalho AL, 2005, INT J CANCER, V114, P806, DOI 10.1002/ijc.20740.
   Choi MS, 2018, ONCOL LETT, V15, P6489, DOI 10.3892/ol.2018.8089.
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641.
   Dickinson SE, 2016, CANCER PREV RES, V9, P215, DOI 10.1158/1940-6207.CAPR-15-0419.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   He MX, 2020, CHINESE CHEM LETT, V31, P3178, DOI 10.1016/j.cclet.2020.05.034.
   Herzog A, 2013, CLIN CANCER RES, V19, P3808, DOI 10.1158/1078-0432.CCR-12-2716.
   Hsu CM, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0060-7.
   Keam B, 2015, ANTICANCER RES, V35, P175.
   Kobes JE, 2016, PANCREAS, V45, P1158, DOI 10.1097/MPA.0000000000000607.
   Koundouros N, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00160.
   Kundu SK, 2012, TUMOR BIOL, V33, P707, DOI 10.1007/s13277-012-0350-2.
   Li HL, 2019, CHINESE CHEM LETT, V30, P1083, DOI 10.1016/j.cclet.2019.01.003.
   Lucero-Acuña A, 2014, INT J NANOMED, V9, P5653, DOI 10.2147/IJN.S68511.
   Machiels JP, 2011, ANTI-CANCER DRUG, V22, P626, DOI 10.1097/CAD.0b013e328341071e.
   Mäemets-Allas K, 2015, MOL CANCER THER, V14, P2486, DOI 10.1158/1535-7163.MCT-15-0281.
   Meuillet EJ, 2010, MOL CANCER THER, V9, P706, DOI 10.1158/1535-7163.MCT-09-0985.
   Mitchell MJ, 2021, NAT REV DRUG DISCOV, V20, P101, DOI 10.1038/s41573-020-0090-8.
   Moon DG, 2014, INT J ONCOL, V45, P1027, DOI 10.3892/ijo.2014.2505.
   Moses SA, 2009, CANCER RES, V69, P5073, DOI 10.1158/0008-5472.CAN-08-3839.
   Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306.
   Palao-Suay R, 2016, MACROMOL BIOSCI, V16, P395, DOI 10.1002/mabi.201500265.
   Psyrri Amanda, 2013, Am Soc Clin Oncol Educ Book, P246, DOI 10.1200/EdBook\_AM.2013.33.246.
   Sánchez-Rodríguez C, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8030097.
   Shi JJ, 2017, NAT REV CANCER, V17, P20, DOI 10.1038/nrc.2016.108.
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166.
   Tian L, 2019, MOLECULES, V24, DOI 10.3390/molecules24193560.
   Tonlaar N, 2017, RADIOTHER ONCOL, V124, P504, DOI 10.1016/j.radonc.2017.08.001.
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034.
   Vigneswaran N, 2014, ORAL MAXIL SURG CLIN, V26, P123, DOI 10.1016/j.coms.2014.01.001.
   Wang Y, 2021, BIOACT MATER, V6, P1513, DOI 10.1016/j.bioactmat.2020.11.016.
   Xie FL, 2012, PLANT MOL BIOL, V80, P75, DOI 10.1007/s11103-012-9885-2.
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245.
   Zhao CY, 2018, MOLECULES, V23, DOI 10.3390/molecules23040826.},
Number-of-Cited-References = {36},
Times-Cited = {7},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Pharmaceutics},
Doc-Delivery-Number = {UH9SM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000690260800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000685457700001,
Author = {Chen, Zhoumiao and Chen, Zhao and Xu, Shaohua and Zhang, Qiang},
Title = {LncRNA SOX2-OT/miR-30d-5p/PDK1 Regulates PD-L1 Checkpoint Through the
   mTOR Signaling Pathway to Promote Non-small Cell Lung Cancer Progression
   and Immune Escape},
Journal = {FRONTIERS IN GENETICS},
Year = {2021},
Volume = {12},
Month = {JUL 30},
Abstract = {Non-small cell lung cancer (NSCLC) is the most common type of lung
   cancer. Currently, treatment methods generally cause poor prognosis.
   Therefore, in order to seek new treatment options, we explored the
   internal mechanism of NSCLC. Firstly, the SOX2-OT/miR-30d-5p/PDK1 axis
   regulated by lncRNA SOX2-OT was predicted by bioinformatics methods, and
   the expression of SOX2-OT, miR-30d-5p, and PDK1 mRNA in cells were
   detected by qRT-PCR while PDK1 protein expression was detected by
   western blot. The results expressed that in NSCLC, SOX2-OT, and PDK1
   were notably overexpressed while miR-30d-5p was markedly
   under-expressed. The interaction between them was verified by
   dual-luciferase reporter and RNA binding protein immunoprecipitation
   assays. Subsequently, through CCK8, scratch healing, cell invasion and
   flow cytometry assays, we revealed that inhibiting the expression of
   SOX2-OT could inhibit the proliferation, migration and invasion of NSCLC
   cells and promote cell apoptosis; while simultaneous overexpression of
   PDK1 or inhibition of miR-30d-5p expression could reverse the inhibitory
   effect of SOX2-OT silence-mediated malignant progression of NSCLC cells.
   Then, the combined application of overexpressed PDK1 and rapamycin
   verified that PDK1 could regulate the expression of PD-L1 in NSCLC cells
   through the mTOR signaling pathway. Co-culture of CD8(+) T cells
   verified that silencing SOX2-OT could inhibit the apoptosis of CD8(+) T
   cells through miR-30d-5p/PDK1. Finally, tumor formation assay in animals
   confirmed that overexpression of SOX2-OT could promote the growth of
   NSCLC tumor in vivo. In this study, assays in vitro and in vivo were
   conducted to elucidate the mechanism by which SOX2-OT/miR-30d-5p/PDK1
   drives PD-L1 through the mTOR signaling pathway to promote the malignant
   progression and immune escape of NSCLC.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Chen, ZM (Corresponding Author), Zhejiang Univ, Sch Med, Dept Thorac Surg, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China.
   Chen, Zhoumiao; Chen, Zhao; Xu, Shaohua; Zhang, Qiang, Zhejiang Univ, Sch Med, Dept Thorac Surg, Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China.},
DOI = {10.3389/fgene.2021.674856},
Article-Number = {674856},
EISSN = {1664-8021},
Keywords = {competing endogenous RNA; non-small cell lung cancer; SOX2-OT; mTOR;
   PD-L1},
Keywords-Plus = {MIGRATION; INVASION},
Research-Areas = {Genetics \& Heredity},
Web-of-Science-Categories  = {Genetics \& Heredity},
Author-Email = {3193084@zju.edu.cn},
Affiliations = {Zhejiang University},
ResearcherID-Numbers = {Xu, Shaohua/I-2252-2015},
Funding-Acknowledgement = {Zhejiang Provincial Natural Science Foundation of China {[}Q19H280028];
   MedicalHealth Science and Technology Project of Zhejiang Provincial
   Health Commission {[}2020KY160]},
Funding-Text = {This research was supported by Zhejiang Provincial Natural Science
   Foundation of China (No. Q19H280028), MedicalHealth Science and
   Technology Project of Zhejiang Provincial Health Commission (No.
   2020KY160).},
Cited-References = {Bai LX, 2020, CANCER MANAG RES, V12, P9125, DOI 10.2147/CMAR.S258370.
   Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310.
   Chen GM, 2018, J CELL BIOCHEM, V119, P885, DOI 10.1002/jcb.26252.
   Chen ZP, 2018, INT J ONCOL, V53, P1227, DOI 10.3892/ijo.2018.4451.
   Gao HM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191041.
   Gomez-Pinillos A, 2012, HEMATOL ONCOL CLIN N, V26, P483, DOI 10.1016/j.hoc.2012.02.014.
   Gu QQ, 2020, INFLAMM RES, V69, P667, DOI 10.1007/s00011-020-01348-8.
   He WL, 2017, CANCER RES, V77, P6375, DOI 10.1158/0008-5472.CAN-17-0381.
   Hung JJ, 2014, J CLIN ONCOL, V32, P2357, DOI 10.1200/JCO.2013.50.1049.
   Konen JM, 2019, CANCERS, V11, DOI 10.3390/cancers11040462.
   Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362.
   Li H, 2019, GASTROENTEROLOGY, V156, P1849, DOI 10.1053/j.gastro.2019.01.252.
   Li S, 2018, J CELL PHYSIOL, V233, P6679, DOI 10.1002/jcp.26325.
   Li ZQ, 2019, EUR REV MED PHARMACO, V23, P9978, DOI 10.26355/eurrev\_201911\_19564.
   Liu RR, 2019, J CELL PHYSIOL, V234, P20728, DOI 10.1002/jcp.28679.
   Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283.
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349.
   Nepstad I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082907.
   Planchard D, 2018, ANN ONCOL, V29, P192, DOI 10.1093/annonc/mdy275.
   Qian B, 2018, EUR REV MED PHARMACO, V22, P5946, DOI 10.26355/eurrev\_201809\_15925.
   Qu CX, 2019, EUR REV MED PHARMACO, V23, P247, DOI 10.26355/eurrev\_201908\_18654.
   Song XF, 2020, CANCER BIOTHER RADIO, V35, P682, DOI 10.1089/cbr.2019.3479.
   Vinay DS, 2015, SEMIN CANCER BIOL, V35, pS185, DOI 10.1016/j.semcancer.2015.03.004.
   Wo QJ, 2019, BIOCHEM BIOPH RES CO, V520, P586, DOI 10.1016/j.bbrc.2019.09.108.
   Xu W, 2020, INT J CANCER, V146, P2901, DOI 10.1002/ijc.32747.
   Zhang GD, 2020, CANCER BIOTHER RADIO, V35, P77, DOI 10.1089/cbr.2019.2991.
   Zhou CL, 2019, J CANCER RES CLIN, V145, P2663, DOI 10.1007/s00432-019-03025-8.
   Zhu JF, 2020, VIRCHOWS ARCH, V477, P637, DOI 10.1007/s00428-020-02782-z.},
Number-of-Cited-References = {28},
Times-Cited = {34},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Front. Genet.},
Doc-Delivery-Number = {UA9EP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000685457700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000696798500004,
Author = {Wan, Hin Ting and Cheung, Lok Yi and Chan, Ting Fung and Li, Marco and
   Lai, Keng Po and Wong, Chris Kong Chu},
Title = {Characterization of PFOS toxicity on in-vivo and ex-vivo
   mouse pancreatic islets},
Journal = {ENVIRONMENTAL POLLUTION},
Year = {2021},
Volume = {289},
Month = {NOV 15},
Abstract = {Considerable human data have shown that the exposure to perfluoroctane
   sulfonate (PFOS) correlates to the risk of metabolic diseases, however
   the underlying effects are not clearly elucidated. In this study, we
   investigated the impacts of PFOS treatment, using in-vivo, ex-vivo and
   in-vitro approaches, on pancreatic beta-cell functions. Mice were
   oral-gavage with 1 and 5 mu g PFOS/g body weight/day for 21 days. The
   animals showed a significant increase in liver triglycerides,
   accompanied by a reduction of triglycerides in blood sera and glycogen
   in livers and muscles. Histological examination of pancreases showed no
   noticeable changes in the size and number of islets from the control and
   treatment groups. Immunohistochemistry showed a reduction of staining
   intensities of insulin and the transcriptional factors (Pdx-1, islet-1)
   in islets of pancreatic sections from PFOS-treated groups, but no
   changes in the intensity of Glut2 and glucagon were noted.
   Transcriptomic study of isolated pancreatic islets treated ex vivo with
   1 mu M and 10 mu M PFOS for 24 h, underlined perturbations of the
   insulin signaling pathways. Western blot analysis of ex-vivo
   PFOS-treated islets revealed a significant reduction in the expression
   levels of the insulin receptor, the IGF1 receptor-beta, Pdk1-Akt-mTOR
   pathways, and Pdx-1. Using the mouse beta-cells (Min-6) treated with 1
   mu M and 10 mu M PFOS for 24 h, Western blot analysis consistently
   showed the PFOS-treatment inhibited Akt-pathway and reduced cellular
   insulin contents. Moreover, functional studies revealed the inhibitory
   effects of PFOS on glucose-stimulated insulin-secretion (GSIS) and the
   rate of ATP production. Our data support the perturbing effects of PFOS
   on animal metabolism and demonstrate the underlying molecular targets to
   impair beta-cell functions.},
Publisher = {ELSEVIER SCI LTD},
Address = {125 London Wall, London, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wong, CKC (Corresponding Author), Hong Kong Baptist Univ, Dept Biol, Hong Kong, Peoples R China.
   Wan, Hin Ting; Cheung, Lok Yi; Wong, Chris Kong Chu, Hong Kong Baptist Univ, Croucher Inst Environm Sci, Dept Biol, Hong Kong, Peoples R China.
   Chan, Ting Fung; Li, Marco, Chinese Univ Hong Kong, Sch Life Sci, Hong Kong Bioinformat Ctr, Hong Kong, Peoples R China.
   Lai, Keng Po, Guilin Med Univ, Lab Environm Pollut \& Integrat Om, Guilin, Peoples R China.},
DOI = {10.1016/j.envpol.2021.117857},
EarlyAccessDate = {JUL 2021},
Article-Number = {117857},
ISSN = {0269-7491},
EISSN = {1873-6424},
Keywords = {beta-cells; Pdk1-akt-mTOR signaling; Glucose-stimulated insulin
   secretion; ATP},
Keywords-Plus = {PERFLUOROOCTANE SULFONATE; PERFLUOROALKYL ACIDS; GLUCOSE-HOMEOSTASIS;
   PERFLUORINATED CHEMICALS; INSULIN-SECRETION; LIPID-METABOLISM; EXPOSURE;
   LIVER; RISK; RATS},
Research-Areas = {Environmental Sciences \& Ecology},
Web-of-Science-Categories  = {Environmental Sciences},
Author-Email = {ckcwong@hkbu.edu.hk},
Affiliations = {Hong Kong Baptist University; Chinese University of Hong Kong; Guilin
   Medical University},
ResearcherID-Numbers = {Chan, TingFung/A-6161-2013
   LAI, Keng Po/F-2045-2013
   Wong, Chris/C-8748-2015},
ORCID-Numbers = {Chan, TingFung/0000-0002-0489-3884
   LAI, Keng Po/0000-0001-8135-6030
   Wong, Chris/0000-0001-5449-5836},
Funding-Acknowledgement = {General Research Fund (Research Grant Council) {[}HKBU12100218];
   Inter-institutional Collaborative Research Scheme (Hong Kong Baptist
   University) {[}RC-ICRS/17-18/01]; Hong Kong SAR, Macao SAR, and Taiwan
   Province Talent Young Scientist Program of Guangxi},
Funding-Text = {This work was supported by the General Research Fund (Research Grant
   Council, HKBU12100218) and Inter-institutional Collaborative Research
   Scheme (RC-ICRS/17-18/01) to C.K.C.W. (Hong Kong Baptist University) .
   K.P.L. is supported by Hong Kong SAR, Macao SAR, and Taiwan Province
   Talent Young Scientist Program of Guangxi.},
Cited-References = {Arous C, 2015, AM J PHYSIOL-ENDOC M, V309, pE611, DOI 10.1152/ajpendo.00268.2015.
   Bjork JA, 2008, TOXICOLOGY, V251, P8, DOI 10.1016/j.tox.2008.06.007.
   Bodin J, 2016, TOXICOL REP, V3, P664, DOI 10.1016/j.toxrep.2016.08.009.
   Calafat AM, 2007, ENVIRON HEALTH PERSP, V115, P1596, DOI 10.1289/ehp.10598.
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655.
   Cardenas A, 2019, DIABETES CARE, V42, P1824, DOI 10.2337/dc18-2254.
   Chang ET, 2014, CRIT REV TOXICOL, V44, P1, DOI 10.3109/10408444.2014.905767.
   Chang-Chen KJ, 2008, REV ENDOCR METAB DIS, V9, P329, DOI 10.1007/s11154-008-9101-5.
   Château-Degat ML, 2010, ENVIRON RES, V110, P710, DOI 10.1016/j.envres.2010.07.003.
   Cui L, 2009, ARCH ENVIRON CON TOX, V56, P338, DOI 10.1007/s00244-008-9194-6.
   Donat-Vargas C, 2019, ENVIRON INT, V124, P58, DOI 10.1016/j.envint.2019.01.007.
   Duan XY, 2021, ENVIRON POLLUT, V278, DOI 10.1016/j.envpol.2021.116840.
   Ediger BN, 2014, DIABETES, V63, P4206, DOI 10.2337/db14-0096.
   Fisher M, 2013, ENVIRON RES, V121, P95, DOI 10.1016/j.envres.2012.11.006.
   Frisbee SJ, 2009, ENVIRON HEALTH PERSP, V117, P1873, DOI 10.1289/ehp.0800379.
   Fujimoto K, 2009, DIABETES OBES METAB, V11, P30, DOI 10.1111/j.1463-1326.2009.01121.x.
   Gewurtz SB, 2013, ENVIRON INT, V59, P183, DOI 10.1016/j.envint.2013.05.008.
   Guruge KS, 2006, TOXICOL SCI, V89, P93, DOI 10.1093/toxsci/kfj011.
   HAUGHOM B, 1992, BIOCHIM BIOPHYS ACTA, V1128, P65, DOI 10.1016/0005-2760(92)90258-W.
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211.
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923.
   Jaafar R, 2019, J CLIN INVEST, V129, P4124, DOI 10.1172/JCI127021.
   Lai KP, 2017, ENVIRON SCI TECHNOL, V51, P11390, DOI 10.1021/acs.est.7b02830.
   Lau C, 2007, TOXICOL SCI, V99, P366, DOI 10.1093/toxsci/kfm128.
   Legler J, 2011, AM J CLIN NUTR, V94, p1933S, DOI 10.3945/ajcn.110.001669.
   Lin CY, 2009, DIABETES CARE, V32, P702, DOI 10.2337/dc08-1816.
   Liu JX, 2012, ISLETS, V4, P199, DOI 10.4161/isl.19982.
   Loveless SE, 2006, TOXICOLOGY, V220, P203, DOI 10.1016/j.tox.2006.01.003.
   Martin MT, 2007, TOXICOL SCI, V97, P595, DOI 10.1093/toxsci/kfm065.
   Mauvais-Jarvis F, 2013, ENDOCR REV, V34, P309, DOI 10.1210/er.2012-1055.
   Olsen GW, 2007, ENVIRON HEALTH PERSP, V115, P1298, DOI 10.1289/ehp.10009.
   Parhofer KG, 2015, DIABETES METAB J, V39, P353, DOI 10.4093/dmj.2015.39.5.353.
   Paul AG, 2009, ENVIRON SCI TECHNOL, V43, P386, DOI 10.1021/es802216n.
   Predieri B, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/234358.
   Qin WP, 2020, ENVIRON SCI TECHNOL, V54, P3428, DOI 10.1021/acs.est.9b07295.
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616.
   Rosen MB, 2009, REPROD TOXICOL, V27, P278, DOI 10.1016/j.reprotox.2009.01.007.
   Sant KE, 2019, TOXICOL SCI, V167, P258, DOI 10.1093/toxsci/kfy237.
   Sant KE, 2017, ENVIRON POLLUT, V220, P807, DOI 10.1016/j.envpol.2016.10.057.
   Savage DB, 2007, PHYSIOL REV, V87, P507, DOI 10.1152/physrev.00024.2006.
   Shoeib M, 2006, ENVIRON SCI TECHNOL, V40, P7577, DOI 10.1021/es0618999.
   Stock NL, 2004, ENVIRON SCI TECHNOL, V38, P991, DOI 10.1021/es034644t.
   Su TC, 2016, ENVIRON INT, V88, P15, DOI 10.1016/j.envint.2015.11.016.
   Thorens B, 2015, DIABETOLOGIA, V58, P221, DOI 10.1007/s00125-014-3451-1.
   Wan HT, 2013, J HAZARD MATER, V261, P763, DOI 10.1016/j.jhazmat.2013.01.034.
   Wan HT, 2012, BBA-GEN SUBJECTS, V1820, P1092, DOI 10.1016/j.bbagen.2012.03.010.
   Wan HT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087137.
   Wang L, 2014, SCI REP-UK, V4, DOI 10.1038/srep04582.
   Wang T, 2009, ENVIRON SCI TECHNOL, V43, P5171, DOI 10.1021/es900464a.
   Wang Y, 2009, ENVIRON SCI TECHNOL, V43, P8283, DOI 10.1021/es902041s.
   Yan SM, 2015, SCI REP-UK, V5, DOI 10.1038/srep11029.
   Zhang H, 2008, TOXICOL APPL PHARM, V227, P16, DOI 10.1016/j.taap.2007.09.026.
   Zhang H, 2009, J MOL BIOL, V392, P566, DOI 10.1016/j.jmb.2009.07.036.
   Zhang LY, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138498.
   Zhang T, 2016, ENDOCRINOLOGY, V157, P1055, DOI 10.1210/en.2015-1852.},
Number-of-Cited-References = {55},
Times-Cited = {25},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {40},
Journal-ISO = {Environ. Pollut.},
Doc-Delivery-Number = {UR5OL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000696798500004},
DA = {2026-02-04},
}

@article{ WOS:000681621200001,
Author = {Han, Yuanyuan and Chen, Qixin and Zhang, Lili and Dissanayaka, Waruna
   Lakmal},
Title = {Indispensable Role of HIF-1α Signaling in Post-implantation Survival and
   Angio-/Vasculogenic Properties of SHED},
Journal = {FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY},
Year = {2021},
Volume = {9},
Month = {JUL 23},
Abstract = {Objectives Post-implantation survival and timely vascularization of
   stem-cell based constructs are critical factors in achieving successful
   outcomes in tissue regeneration approaches. Hypoxia inducible factor-1
   alpha (HIF-1 alpha) is known to mediate adaptive functions to ischemic
   stress in many different cell types. The current study aimed to explore
   the role of HIF-1 alpha in post-implantation survival and
   angio-/vasculogenesis of stem cells from human exfoliated deciduous
   teeth (SHED). Methods HIF-1 alpha in SHED was suppressed using siRNA or
   chemical inhibitor (YC-1) and used in Matrigel plug assay conducted on
   severe combined immunodeficient mice. The plugs were retrieved on day 3
   or 7 post-injection and analyzed for hypoxia status, ki67 expression,
   DNA fragmentation (TUNEL), cellularity, and vascularization by histology
   and immunohistochemistry for CD31, HIF-1 alpha, pyruvate dehydrogenase
   kinase-1 (PDK1), hexokinase 2 (HK2), and glucose transporter 1 (Glut1).
   Cell viability of HIF-1 alpha silenced SHED under different stress
   conditions (hypoxia, H2O2, and low glucose) in vitro was measured by
   CCK-8 assay. CM-H(2)DCFDA and MitoSOX Red were used to detect cellular
   and mitochondrial reactive oxygen species (ROS) levels, respectively.
   PDK1, HK2, and Glut1 expression were measured by western blotting and
   immunofluorescence. Secretory protein levels of vascular endothelial
   growth factor (VEGF) and the respective paracrine effects on endothelial
   cell proliferation and migration were detected by ELISA, CCK-8 assay,
   and trans-well assay, respectively. Results Histological analysis of
   Matrigel plugs showed significantly reduced cell survival in HIF-1 alpha
   silenced or chemically inhibited SHED groups, which could be attributed
   to diminished metabolic adaptations as shown by decreased PDK1, HK2, and
   Glut1 expression. HIF-1 alpha inhibition in SHED also resulted in
   significantly low blood vessel formation as observed by a low number of
   perfused and non-perfused vessels of human or mouse CD31 origin. The
   viability of HIF-1 alpha silenced SHED was significantly affected under
   hypoxia, H2O2, and low-glucose conditions in vitro, which was reflected
   in increased cytoplasmic and mitochondrial ROS levels. Significantly
   reduced levels of VEGF in HIF-1 alpha silenced SHED resulted in
   decreased paracrine angiogenic effects as shown by low proliferation and
   migration of endothelial cells. Conclusion HIF-1 alpha plays an
   indispensable role in post-implantation survival and angio-/vasculogenic
   properties of SHED by maintaining ROS homeostasis, inducing metabolic
   adaptations, and VEGF secretion.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Dissanayaka, WL (Corresponding Author), Univ Hong Kong, Appl Oral Sci \& Community Dent Care, Fac Dent, Pokfulam, Hong Kong, Peoples R China.
   Han, Yuanyuan; Chen, Qixin; Zhang, Lili; Dissanayaka, Waruna Lakmal, Univ Hong Kong, Appl Oral Sci \& Community Dent Care, Fac Dent, Pokfulam, Hong Kong, Peoples R China.},
DOI = {10.3389/fcell.2021.655073},
Article-Number = {655073},
ISSN = {2296-634X},
Keywords = {HIF-1 alpha; post-implantation survival; cell metabolism; redox balance;
   regenerative medicine; dental stem cells},
Keywords-Plus = {STEM-CELLS; HYPOXIA; VEGF; ANGIOGENESIS; ADAPTATION; METABOLISM;
   ISCHEMIA; GLUCOSE; GROWTH; CANCER},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {warunad@hku.hk},
Affiliations = {University of Hong Kong},
ResearcherID-Numbers = {Dissanayaka, Waruna/K-1850-2016},
ORCID-Numbers = {Han, Yuanyuan/0000-0001-6006-9825
   Dissanayaka, Waruna/0000-0002-3621-4866},
Funding-Acknowledgement = {Research Grants Council, Hong Kong (General Research Funds) {[}17121417,
   17117619]},
Funding-Text = {This research work was supported by grants received byWDfrom the
   Research Grants Council, Hong Kong (General Research Funds; 17121417 and
   17117619).},
Cited-References = {Ahluwalia A, 2012, CURR MED CHEM, V19, P90, DOI 10.2174/092986712803413944.
   Becquart P, 2012, TISSUE ENG PT A, V18, P2084, DOI {[}10.1089/ten.tea.2011.0690, 10.1089/ten.TEA.2011.0690].
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200.
   Chen HL, 2021, ACS APPL MATER INTER, V13, P19710, DOI 10.1021/acsami.1c03010.
   Chen J, 2016, NEOPLASMA, V63, P934, DOI 10.4149/neo\_2016\_612.
   Dai Y, 2007, J MOL CELL CARDIOL, V42, P1036, DOI 10.1016/j.yjmcc.2007.04.001.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   DeWaal D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02733-4.
   Fan JH, 2019, J CELL PHYSIOL, V234, P7695, DOI 10.1002/jcp.27767.
   Gong L, 2012, MED ONCOL, V29, P909, DOI 10.1007/s12032-011-9841-z.
   Han Y, 2020, J DENT RES, V99, P804, DOI 10.1177/0022034520912190.
   Han YY, 2021, CURR STEM CELL RES T, V16, P518, DOI 10.2174/1574888X15666200929125840.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kliche S, 2001, IUBMB LIFE, V52, P61, DOI 10.1080/15216540252774784.
   Li HS, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101109.
   Lis P, 2016, MOLECULES, V21, DOI 10.3390/molecules21121730.
   Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200.
   Moldogazieva NT, 2020, CANCERS, V12, DOI 10.3390/cancers12040862.
   Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016.
   Ramakrishnan S, 2014, J NEUROIMMUNE PHARM, V9, P142, DOI 10.1007/s11481-014-9531-7.
   Rashid I, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00659.
   Rattner A, 2019, J CLIN INVEST, V129, P3807, DOI 10.1172/JCI126655.
   Stegen S, 2016, BONE, V87, P176, DOI 10.1016/j.bone.2016.03.014.
   Sun RL, 2019, TOXICOL IN VITRO, V55, P18, DOI 10.1016/j.tiv.2018.11.005.
   Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010.
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470.
   Xu JG, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-016-0459-0.
   Xu SL, 2019, CANCER RES, V79, P5907, DOI 10.1158/0008-5472.CAN-19-1789.
   Yang C, 2016, MOL MED REP, V13, P1287, DOI 10.3892/mmr.2015.4679.
   Yao JW, 2018, J STEROID BIOCHEM, V183, P159, DOI 10.1016/j.jsbmb.2018.06.010.
   Zhang JJ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180741.
   Zhang X, 2020, ACS NANO, V14, P4045, DOI 10.1021/acsnano.9b08737.
   Zhang X, 2019, ACS NANO, V13, P5306, DOI 10.1021/acsnano.8b09786.
   Zhou DH, 2014, ADV CANCER RES, V122, P1, DOI 10.1016/B978-0-12-420117-0.00001-3.
   Zhu HM, 2014, ARTERIOSCL THROM VAS, V34, P870, DOI 10.1161/ATVBAHA.114.303194.},
Number-of-Cited-References = {36},
Times-Cited = {16},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Front. Cell. Dev. Biol.},
Doc-Delivery-Number = {TV3KD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000681621200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000674182500001,
Author = {Guo, Jianping and Cheng, Ji and Zheng, Nana and Zhang, Xiaomei and Dai,
   Xiaoming and Zhang, Linli and Hu, Changjiang and Wu, Xueji and Jiang,
   Qiwei and Wu, Depei and Okada, Hitoshi and Pandolfi, Pier Paolo and Wei,
   Wenyi},
Title = {Copper Promotes Tumorigenesis by Activating the PDK1-AKT Oncogenic
   Pathway in a Copper Transporter 1 Dependent Manner},
Journal = {ADVANCED SCIENCE},
Year = {2021},
Volume = {8},
Number = {18},
Month = {SEP},
Abstract = {Copper plays pivotal roles in metabolic homoeostasis, but its potential
   role in human tumorigenesis is not well defined. Here, it is revealed
   that copper activates the phosphoinositide 3-kinase (PI3K)-protein
   kinase B (PKB, also termed AKT) oncogenic signaling pathway to
   facilitate tumorigenesis. Mechanistically, copper binds
   3-phosphoinositide dependent protein kinase 1 (PDK1), in turn promotes
   PDK1 binding and subsequently activates its downstream substrate AKT to
   facilitate tumorigenesis. Blocking the copper transporter 1
   (CTR1)-copper axis by either depleting CTR1 or through the use of copper
   chelators diminishes the AKT signaling and reduces tumorigenesis. In
   support of an oncogenic role for CTR1, the authors find that CTR1 is
   abnormally elevated in breast cancer, and is subjected by NEDD4 like E3
   ubiquitin protein ligase (Nedd4l)-mediated negative regulation through
   ubiquitination and subsequent degradation. Accordingly, Nedd4l displays
   a tumor suppressive function by suppressing the CTR1-AKT signaling.
   Thus, the findings identify a novel regulatory crosstalk between the
   Nedd4l-CTR1-copper axis and the PDK1-AKT oncogenic signaling, and
   highlight the therapeutic relevance of targeting the CTR1-copper node
   for the treatment of hyperactive AKT-driven cancers.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Guo, JP (Corresponding Author), Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Guo, JP (Corresponding Author), Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
   Guo, Jianping; Cheng, Ji; Dai, Xiaoming; Hu, Changjiang; Wei, Wenyi, Harvard Med Sch, Dept Pathol, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
   Guo, Jianping; Zhang, Xiaomei; Wu, Xueji; Jiang, Qiwei, Sun Yat Sen Univ, Inst Precis Med, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China.
   Cheng, Ji, Huazhong Univ Sci \& Technol, Dept Gastrointestinal Surg, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China.
   Zheng, Nana; Wu, Depei, Soochow Univ, Natl Clin Res Ctr Hematol Dis, Jiangsu Inst Hematol, Affiliated Hosp 1, Suzhou 215000, Jiangsu, Peoples R China.
   Zhang, Linli, Huazhong Univ Sci \& Technol, Dept Oncol, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China.
   Okada, Hitoshi, Kindai Univ, Fac Med, Dept Biochem, 377-2 Ohno Higashi, Osaka 5898511, Japan.},
DOI = {10.1002/advs.202004303},
EarlyAccessDate = {JUL 2021},
Article-Number = {2004303},
EISSN = {2198-3844},
Keywords = {AKT; breast cancer; copper; CTR1; Nedd4l; PDK1},
Keywords-Plus = {PROTEIN-KINASE B; NF-KAPPA-B; PI3K/AKT PATHWAY; METAL-IONS; CANCER; AKT;
   EXPRESSION; CTR1; PHOSPHORYLATION; SURVIVAL},
Research-Areas = {Chemistry; Science \& Technology - Other Topics; Materials Science},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary; Nanoscience \& Nanotechnology; Materials
   Science, Multidisciplinary},
Author-Email = {guojp6@mail.sysu.edu.cn
   wwei2@bidmc.harvard.edu},
Affiliations = {Harvard University; Harvard University Medical Affiliates; Beth Israel
   Deaconess Medical Center; Harvard Medical School; Sun Yat Sen
   University; Huazhong University of Science \& Technology; Soochow
   University - China; Huazhong University of Science \& Technology; Kindai
   University (Kinki University)},
ResearcherID-Numbers = {Dai, xiaoming/PCD-4804-2025
   Cheng, Ji/HLH-4520-2023},
ORCID-Numbers = {Dai, Xiaoming/0000-0001-9671-8137
   },
Funding-Acknowledgement = {NIH {[}CA177910]; National Natural Science Foundation of China
   {[}32070767, 31871410, 81902487]; China Postdoctoral Science Foundation
   {[}2020M672954]; National Cancer Institute {[}R01CA177910] Funding
   Source: NIH RePORTER},
Funding-Text = {J.G., J.C., and N.Z. contributed equally to this work. The authors thank
   members of the Wei laboratory, Guo laboratory and Dr. Brian J. North at
   Creighton University for critical reading and kind suggestions of the
   manuscript. The authors thank Mr. Min Yuan and Dr. John Asara in BIDMC
   for the mass-spectrometry analyses. The authors thank Dr. Nam Chu in
   Brigham Women's Hospital for kindly providing the recombinant proteins
   purified from insect cells. This work was supported in part by the
   grants from NIH (W.W., CA177910), National Natural Science Foundation of
   China (J.G., 32070767,31871410; J.C., 81902487), China Postdoctoral
   Science Foundation (X.Z., 2020M672954).},
Cited-References = {Ackerman CM, 2018, J BIOL CHEM, V293, P4628, DOI 10.1074/jbc.R117.000176.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085.
   Baldari S, 2019, CANCERS, V11, DOI 10.3390/cancers11050659.
   Bompiani KM, 2016, METALLOMICS, V8, P951, DOI 10.1039/c6mt00076b.
   Brady DC, 2014, NATURE, V509, P492, DOI 10.1038/nature13180.
   Breitkopf SB, 2015, ANAL CHEM, V87, P10995, DOI 10.1021/acs.analchem.5b03040.
   Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1.
   Durham TR, 2006, EXP SUPPL, V96, P97.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Feng WK, 2009, MOL PHARMACOL, V75, P174, DOI 10.1124/mol.108.051516.
   Gaeta A, 2005, BRIT J PHARMACOL, V146, P1041, DOI 10.1038/sj.bjp.0706416.
   Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043.
   Gao XX, 2006, BIOORG CHEM, V34, P200, DOI 10.1016/j.bioorg.2006.05.002.
   Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653.
   Gumienna-Kontecka E, 2019, METAL IONS LIFE SCI, V19, P181, DOI 10.1515/9783110527872-007.
   Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6.
   Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755.
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902.
   Holzer AK, 2006, J HISTOCHEM CYTOCHEM, V54, P1041, DOI 10.1369/jhc.6A6970.2006.
   Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399.
   Ivy KD, 2013, MOL PHARMACOL, V83, P1237, DOI 10.1124/mol.113.085068.
   Kim ES, 2014, LUNG CANCER, V85, P88, DOI 10.1016/j.lungcan.2014.04.005.
   Krishnamoorthy L, 2016, NAT CHEM BIOL, V12, P586, DOI {[}10.1038/NCHEMBIO.2098, 10.1038/nchembio.2098].
   Lánczky A, 2016, BREAST CANCER RES TR, V160, P439, DOI 10.1007/s10549-016-4013-7.
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586.
   Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304.
   Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513.
   Liu J, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2015.44.
   Liu JX, 2007, TRAFFIC, V8, P1375, DOI 10.1111/j.1600-0854.2007.00616.x.
   Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079.
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4.
   MacDonald G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004870.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Mari S, 2014, STRUCTURE, V22, P1639, DOI 10.1016/j.str.2014.09.006.
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343.
   Minagawa Y, 2011, ANN NUCL MED, V25, P339, DOI 10.1007/s12149-011-0471-5.
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171.
   Öhrvika H, 2013, P NATL ACAD SCI USA, V110, pE4279, DOI 10.1073/pnas.1311749110.
   Orrenius S, 2011, TOXICOL SCI, V119, P3, DOI 10.1093/toxsci/kfq268.
   Ozes ON, 1999, NATURE, V401, P82.
   Pan Q, 2002, CANCER RES, V62, P4854.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Porcu Cristiana, 2018, Oncotarget, V9, P9325, DOI {[}10.18632/oncotarget.24282, 10.18632/oncotarget.24282].
   Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690.
   Scheffner M, 2014, BBA-MOL CELL RES, V1843, P61, DOI 10.1016/j.bbamcr.2013.03.024.
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710.
   Tsai CY, 2012, BIOCHEM PHARMACOL, V84, P1007, DOI 10.1016/j.bcp.2012.07.014.
   Tsang T, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0481-4.
   UCHIDA K, 1994, J BIOL CHEM, V269, P2405.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541.
   White AR, 1999, J NEUROSCI, V19, P9170.
   Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200.
   Xu MM, 2018, CLIN CANCER RES, V24, P4271, DOI 10.1158/1078-0432.CCR-17-3705.
   Zhang Y, 2014, DEV BIOL, V392, P15, DOI 10.1016/j.ydbio.2014.05.003.
   Zhou M, 2010, J AM CHEM SOC, V132, P15351, DOI 10.1021/ja106855m.},
Number-of-Cited-References = {58},
Times-Cited = {163},
Usage-Count-Last-180-days = {12},
Usage-Count-Since-2013 = {76},
Journal-ISO = {Adv. Sci.},
Doc-Delivery-Number = {UT3DP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000674182500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000722428200004,
Author = {Qin-Xiao and Sun, Yao-Yao and Lu, Zhan-Jun and Zhang, Tian-Zi and Li,
   Shan-Shan and Hua, Ting and Suriguga and Chen, Wen-Lin and Ran, Lin-Lin
   and Yu, Wen-Zhen and Yang, Fei and Burenbatu},
Title = {Inhibitory effects of safranal on laser-induced choroidal
   neovascularization and human choroidal microvascular endothelial cells
   and related pathways analyzed with transcriptome sequencing},
Journal = {INTERNATIONAL JOURNAL OF OPHTHALMOLOGY},
Year = {2021},
Volume = {14},
Number = {7},
Pages = {981-989},
Month = {JUL 18},
Abstract = {Y AIM: To determine the effects of safranal on choroidal
   neovascularization (CNV) and oxidative stress damage of human choroidal
   microvascular endothelial cells (HCVECs) and its possible mechanisms.
   METHODS: Forty-five rats were used as a laser-induced CNV model for
   testing the efficacy and safety of safranal (0.5 mg/kg.d,
   intraperitoneally) on CNV. CNV leakage on fluorescein angiography (FA)
   and CNV thickness on histology was compared. HCVECs were used for a
   H2O2-induced oxidative stress model to test the effect of safranal in
   vitro. MTT essay was carried to test the inhibition rate of safranal on
   cell viability at different concentrations. Tube formation was used to
   test protective effect of safranal on angiogenesis at different
   concentrations. mRNA transcriptome sequencing was performed to find the
   possible signal pathway. The expressions of different molecules and
   their phosphorylation level were validated by Western blotting.
   RESULTS: On FA, the average CNV leakage area was 0.73 +/- 0.49 and 0.31
   +/- 0.11 mm(2) (P=0.012) in the control and safranal-treated group
   respectively. The average CNV thickness was 127.4 +/- 18.75 and 100.6
   +/- 17.34 mu m (P=0.001) in control and safranal-treated group. Under
   the condition of oxidative stress, cell proliferation was inhibited by
   safranal and inhibition rates were 7.4\%-35.4\% at the different
   concentrations. For tube formation study, the number of new branches was
   364 in control group and 35, 42, and 17 in 20, 40, and 80 mu g/mL
   safranal groups respectively (P<0.01). From the KEGG pathway bubble
   graph, the PI3K-AKT signaling pathway showed a high gene ratio. The
   protein expression was elevated of insulin receptor substrate (IRS) and
   the phosphorylation level of PI3K, phosphoinositide-dependent protein
   kinase 1/2 (PDK1/2), AKT and Bcl-2 associated death promoter (BAD) was
   also elevated under oxidative stress condition but inhibited by
   safranal.
   CONCLUSION: Safranal can inhibit CNV both in vivo and in vitro, and the
   IRS-PI3K-PDK1/2-AKT-BAD signaling pathway is involved in the
   pathogenesis of CNV.},
Publisher = {IJO PRESS},
Address = {NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA},
Type = {Article},
Language = {English},
Affiliation = {Qin-Xiao (Corresponding Author), Inner Mongolia Univ Nationalities, Dept Ophthalmol, Affiliated Hosp, 1742 East Huolinhe Ave, Tongliao 028007, Inner Mongolia, Peoples R China.
   Qin-Xiao; Lu, Zhan-Jun; Zhang, Tian-Zi; Li, Shan-Shan, Inner Mongolia Univ Nationalities, Dept Ophthalmol, Affiliated Hosp, 1742 East Huolinhe Ave, Tongliao 028007, Inner Mongolia, Peoples R China.
   Sun, Yao-Yao; Yu, Wen-Zhen, Peking Univ Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   Hua, Ting; Suriguga; Chen, Wen-Lin; Ran, Lin-Lin, Inner Mongolia Univ Nationalities, Coll Mongolian Med, Tongliao 028000, Inner Mongolia, Peoples R China.
   Yang, Fei, Peking Univ, Dept Ophthalmol, Int Hosp, Beijing 100026, Peoples R China.
   Burenbatu, Inner Mongolia Univ Nationalities, Dept Hematol, Affiliated Hosp, Tongliao 028007, Inner Mongolia, Peoples R China.},
DOI = {10.18240/ijo.2021.07.04},
ISSN = {2222-3959},
EISSN = {2227-4898},
Keywords = {choroidal neovascularization; safranal; human choroidal microvascular
   endothelial cells; oxidative stress; transcriptomics},
Keywords-Plus = {CROCUS-SATIVUS SAFFRON; CONSTITUENTS},
Research-Areas = {Ophthalmology},
Web-of-Science-Categories  = {Ophthalmology},
Author-Email = {dr\_burenbatu@126.com},
Affiliations = {Inner Mongolia Minzu University; Peking University; Inner Mongolia Minzu
   University; Peking University; Inner Mongolia Minzu University},
ResearcherID-Numbers = {Yu, Wenzhen/NRY-4168-2025},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81760027, 81860763];
   Youth Innovation Project of Affiliated Hospital of Inner Mongolia
   University for Nationalities {[}2018QNJJ01]; Young and Middle-aged
   Ophthalmic Research Fund of Bethune-Lumitin},
Funding-Text = {Supported by the National Natural Science Foundation of China
   (No.81760027; No.81860763); Youth Innovation Project of Affiliated
   Hospital of Inner Mongolia University for Nationalities (No.2018QNJJ01);
   Young and Middle-aged Ophthalmic Research Fund of Bethune-Lumitin
   (No.BJ-LM202005).},
Cited-References = {Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270.
   Alavi MS, 2019, DRUG RES, V69, P323, DOI 10.1055/a-0790-8200.
   Bagchi S, 2020, INT J NEUROSCI, V130, P476, DOI 10.1080/00207454.2019.1694020.
   Bharti S, 2012, EUR J NUTR, V51, P719, DOI 10.1007/s00394-011-0251-y.
   Cerdá-Bernad D, 2022, CRIT REV FOOD SCI, V62, P3232, DOI 10.1080/10408398.2020.1864279.
   Cloutier F, 2012, INVEST OPHTH VIS SCI, V53, P1195, DOI 10.1167/iovs.11-9064.
   Delkhosh-Kasmaie F, 2018, BIOMED PHARMACOTHER, V107, P203, DOI 10.1016/j.biopha.2018.07.165.
   Erfanparast A, 2015, AVICENNA J PHYTOMEDI, V5, P392.
   Feliers D, 2005, KIDNEY INT, V68, P1648, DOI 10.1111/j.1523-1755.2005.00575.x.
   Fernández-Albarral JA, 2020, NEURAL REGEN RES, V15, P1408, DOI 10.4103/1673-5374.274325.
   Hosseinzadeh H, 2005, J PHARM PHARM SCI, V8, P394.
   Huang YJ, 2019, J CLIN NEUROSCI, V63, P13, DOI 10.1016/j.jocn.2019.02.019.
   Jafari M, 2019, J CELL PHYSIOL, V234, P2373, DOI 10.1002/jcp.27262.
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417.
   Li SS, 2015, INVEST OPHTH VIS SCI, V56, P5210, DOI 10.1167/iovs-14-16184.
   Liu ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep21146.
   Malekzadeh S, 2019, IRAN J BASIC MED SCI, V22, P1476, DOI {[}10.22038/ijbms.2019.13992, 10.22038/IJBMS.2019.13992].
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906.
   Pham B, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022031.
   Rameshrad M, 2018, EXPERT OPIN THER PAT, V28, P147, DOI 10.1080/13543776.2017.1355909.
   Ramos-García P, 2019, ORAL DIS, V25, P949, DOI 10.1111/odi.12913.
   Samarghandian S, 2013, J PHARM PHARM SCI, V16, P352, DOI 10.18433/J3ZS3Q.
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601.
   Sun YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035415.
   Totsuka K, 2019, EXP EYE RES, V181, P316, DOI 10.1016/j.exer.2018.08.019.
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2.
   Wu K, 2005, WORLD J GASTROENTERO, V11, P4461, DOI 10.3748/wjg.v11.i29.4461.
   Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713.
   Yerramothu P, 2018, EYE, V32, P491, DOI 10.1038/eye.2017.241.
   Zeinali M, 2019, IRAN J BASIC MED SCI, V22, P334, DOI 10.22038/ijbms.2019.34365.8158.
   Zhang RZ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03039-7.
   Zhao M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125150.
   Zhu MH, 2016, MOL VIS, V22, P1361.
   Zhu XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115523.
   Zhuang Z, 2015, MOL VIS, V21, P1173.},
Number-of-Cited-References = {35},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Int. J. Ophthalmol.},
Doc-Delivery-Number = {XD0VC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000722428200004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000687961000001,
Author = {Muhammad, Syed Aun and Naqvi, Syeda Tahira Qousain and Nguyen, Thanh and
   Wu, Xiaogang and Munir, Fahad and Jamshed, Muhammad Babar and Zhang,
   QiYu},
Title = {Cisplatin's potential for type 2 diabetes repositioning by inhibiting
   CDKN1A, FAS, and SESN1},
Journal = {COMPUTERS IN BIOLOGY AND MEDICINE},
Year = {2021},
Volume = {135},
Month = {AUG},
Abstract = {Cisplatin is a DNA-damaging chemotherapeutic agent used for treating
   cancer. Based on cDNA dataset analysis, we investigated how cisplatin
   modified gene expression and observed cisplatin-induced dysregulation
   and system-level variations relating to insulin resistance and type 2
   diabetes mellitus (T2DM). T2DM is a multifactorial disease affecting 462
   million people in the world, and drug-induced T2DM is a serious issue.
   To understand this etiology, we designed an integrative, system-level
   study to identify associations between cisplatin-induced differentially
   expressed genes (DEGs) and T2DM. From a list of differential expressed
   genes, cisplatin down regulated the cyclin-dependent kinase inhibitor 1
   (CDKN1A), tumor necrosis factor (FAS), and sestrin-1 (SESN1) genes
   responsible for modifying signaling pathways, including the p53,
   JAK-STAT, FOXO, MAPK, mTOR, P13AKT, Toll-like receptor (TLR),
   adipocytokine, and insulin signaling pathways. These enriched pathways
   were expressively associated with the disease. We observed significant
   gene signatures, including SMAD3, IRS, PDK1, PRKAA1, AKT, SOS, RAS,
   GRB2, MEK1/2, and ERK, interacting with source genes. This study
   revealed the value of system genetics for identifying the
   cisplatin-induced genetic variants responsible for the progression of
   T2DM. Also, by cross-validating gene expression data for T2DM islets, we
   found that downregulating IRS and PRK families is critical in insulin
   and T2DM signaling pathways. Cisplatin, by inhibiting CDKN1A, FAS, and
   SESN1, promotes IRS and PRK activity in a similar way to rosiglitazone
   (a popular drug used for T2DM treatment). Our integrative, network-based
   approach can help in understanding the drug-induced pathophysiological
   mechanisms of diabetes.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Muhammad, SA (Corresponding Author), Bahauddin Zakariya Univ, Inst Mol Biol \& Biotechnol, Multan, Pakistan.
   Zhang, QY (Corresponding Author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou, Peoples R China.
   Muhammad, Syed Aun; Naqvi, Syeda Tahira Qousain, Bahauddin Zakariya Univ, Inst Mol Biol \& Biotechnol, Multan, Pakistan.
   Nguyen, Thanh, Univ Alabama Birmingham, Sch Med, Informat Inst, Birmingham, AL USA.
   Wu, Xiaogang, Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Munir, Fahad; Jamshed, Muhammad Babar; Zhang, QiYu, Wenzhou Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Wenzhou, Peoples R China.
   Munir, Fahad; Jamshed, Muhammad Babar, Wenzhou Med Univ, Wenzhou, Zhejiang, Peoples R China.},
DOI = {10.1016/j.compbiomed.2021.104640},
EarlyAccessDate = {JUL 2021},
Article-Number = {104640},
ISSN = {0010-4825},
EISSN = {1879-0534},
Keywords = {Cisplatin-induced DEGs; T2DM; cDNA dataset; Systems biology;
   Rosiglitazone},
Keywords-Plus = {INDUCED INSULIN-RESISTANCE; INDUCED APOPTOSIS; CELL DYSFUNCTION;
   DOWN-REGULATION; BETA-CELL; EXPRESSION; CANCER; ASSOCIATION; NETWORK;
   GENES},
Research-Areas = {Life Sciences \& Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical \& Computational Biology},
Web-of-Science-Categories  = {Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical \& Computational Biology},
Author-Email = {draun@bzu.edu.pk
   qiyuz@126.com},
Affiliations = {Bahauddin Zakariya University; University of Alabama System; University
   of Alabama Birmingham; University of Texas System; UTMD Anderson Cancer
   Center; Wenzhou Medical University; Wenzhou Medical University},
ResearcherID-Numbers = {Muhammad, Syed Aun/ABF-5369-2020
   },
ORCID-Numbers = {Wu, Xiaogang/0000-0003-4373-6926
   Muhammad, Syed Aun/0000-0002-8068-4144
   Nguyen, Thanh/0000-0002-8440-1594},
Cited-References = {Affymetrix I., 2000, AFFYMETRIX MICROARRA, V1, P295.
   Almeida GM, 2008, INT J CANCER, V122, P1810, DOI 10.1002/ijc.23188.
   Alshalalfa M, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S12-S1.
   {[}Anonymous], 2011, PITUITARY PHYSL DIAG.
   {[}Anonymous], 2019, R PACKAGE 2019 25 01.
   Asechi H, 2010, INT J ONCOL, V37, P89, DOI 10.3892/ijo\_00000656.
   Awazawa M, 2017, NAT MED, V23, P1466, DOI 10.1038/nm.4420.
   Baek SM, 2003, J LAB CLIN MED, V142, P178, DOI 10.1016/S0022-2143(03)00111-2.
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x.
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995.
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185.
   Brüning A, 2013, MOL ONCOL, V7, P1012, DOI 10.1016/j.molonc.2013.07.010.
   Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A.
   Centers for Disease Control and Prevention, 2004, MMWR Morb Mortal Wkly Rep, V53, P1066.
   Chantranupong L, 2014, CELL REP, V9, P1, DOI 10.1016/j.celrep.2014.09.014.
   Chow SZ, 2014, DIABETES, V63, P2984, DOI 10.2337/db13-1121.
   Clematide Simon, 2012, J Biomed Semantics, V3 Suppl 3, pS5, DOI 10.1186/2041-1480-3-S3-S5.
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324.
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6.
   Das UN, 2007, LIPIDS HEALTH DIS, V6, DOI 10.1186/1476-511X-6-35.
   Davis AP, 2012, DATABASE-OXFORD, DOI 10.1093/database/bar065.
   Dayeh T, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004160.
   Drayton RM, 2012, BIOCHEM SOC T, V40, P821, DOI 10.1042/BST20120055.
   Ducoux M, 2001, J BIOL CHEM, V276, P49258, DOI 10.1074/jbc.M106990200.
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863.
   Elsayed MS, 2019, DIABETES METAB SYND, V13, P374, DOI 10.1016/j.dsx.2018.08.017.
   Florez JC, 2008, DIABETOLOGIA, V51, P1100, DOI 10.1007/s00125-008-1025-9.
   Fujita A, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-469.
   García-Jiménez C, 2016, BRIT J CANCER, V114, P716, DOI 10.1038/bjc.2016.37.
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666.
   Guiu-Jurado E, 2015, INT J MOL SCI, V16, P29911, DOI 10.3390/ijms161226206.
   Habib Samy L, 2013, ISRN Oncol, V2013, P583786, DOI 10.1155/2013/583786.
   Hart T, 2016, SCI REP-UK, V6, DOI 10.1038/srep20441.
   Hens B, 2020, Journal of Nanotheranostics, V1, P19, DOI {[}10.3390/jnt1010003, 10.3390/jnt1010003, DOI 10.3390/JNT1010003].
   Hershey DS, 2017, ASIA-PAC J ONCOL NUR, V4, P313, DOI 10.4103/apjon.apjon\_40\_17.
   Hou BY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/201814545321.
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211.
   Jain P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053522.
   Jin Y, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-37.
   Kanatsuna N, 2013, J BIOL CHEM, V288, P29013, DOI 10.1074/jbc.M113.478222.
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167.
   Koster R, 2010, J CLIN INVEST, V120, P3594, DOI 10.1172/JCI41939.
   Kumar A., 2005, ROBBINS COTRAN PATHO, V7, P556.
   Kutmon M, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004085.
   Lakshmanan AP, 2012, BIOCHEM PHARMACOL, V83, P653, DOI 10.1016/j.bcp.2011.11.018.
   Lee I, 2011, GENOME RES, V21, P1109, DOI 10.1101/gr.118992.110.
   Lee JO, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1204-2.
   Lee M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010160.
   Li FT, 2004, P NATL ACAD SCI USA, V101, P4781, DOI 10.1073/pnas.0305937101.
   Lin HM, 2009, J BIOL CHEM, V284, P12246, DOI 10.1074/jbc.M805379200.
   Liska F, 2017, HYPERTENSION, V69, P1084, DOI 10.1161/HYPERTENSIONAHA.116.08798.
   Ma LN, 2015, AM J MED SCI, V350, P121, DOI 10.1097/MAJ.0000000000000499.
   Ma WJ, 2015, AM J CLIN NUTR, V101, P153, DOI 10.3945/ajcn.114.092601.
   Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200.
   Manual A., 2001, AFFYMETRIX MIRCOARRA, P1.
   Margaryan S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201087.
   Muhammad SA, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00013.
   Muhammad SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136454.
   Muhammad SA, 2014, GENOMICS, V104, P24, DOI 10.1016/j.ygeno.2014.05.002.
   Nam D, 2008, BRIEF BIOINFORM, V9, P189, DOI 10.1093/bib/bbn001.
   National Center for Biotechnology Information (NCBI), 2002, GEO.
   Nguyen TM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00583.
   Nylander V, 2016, DIABETES, V65, P3573, DOI 10.2337/db16-0364.
   Obenchain V, 2014, BIOINFORMATICS, V30, P2076, DOI 10.1093/bioinformatics/btu168.
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515.
   Pivovarova O, 2015, CELL CYCLE, V14, P2293, DOI 10.1080/15384101.2015.1046647.
   Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207.
   Rachlin J, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100103.
   Rahman I, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.600824.
   Ratovitski EA, 2017, CURR GENOMICS, V18, P175, DOI 10.2174/1389202917666160803165229.
   Ripsin CM, 2009, AM FAM PHYSICIAN, V79, P29.
   Saini N, 2018, ACTA BIOCH BIOPH SIN, V50, P133, DOI 10.1093/abbs/gmx106.
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439.
   Sinkala M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0666-1.
   Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001.
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049.
   Szklarczyk D, 2011, NUCLEIC ACIDS RES, V39, pD561, DOI 10.1093/nar/gkq973.
   Taneera J, 2013, MOL CELL ENDOCRINOL, V375, P35, DOI 10.1016/j.mce.2013.05.003.
   Taneera J, 2012, CELL METAB, V16, P122, DOI 10.1016/j.cmet.2012.06.006.
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837.
   Tikoo K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-107.
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520.
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498.
   Vaisman A, 1997, CYTOMETRY, V27, P54, DOI 10.1002/(SICI)1097-0320(19970101)27:1<54::AID-CYTO7>3.0.CO;2-L.
   Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609.
   Wang DZ, 2008, PPAR RES, V2008, DOI 10.1155/2008/931074.
   Wang ML, 2017, CELL PHYSIOL BIOCHEM, V43, P1731, DOI 10.1159/000484060.
   Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674.
   Wu W, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-49.
   Youssef J, 2004, J BIOMED BIOTECHNOL, P156, DOI 10.1155/S1110724304308065.
   Zhao J, 2014, CPT-PHARMACOMET SYST, V3, DOI 10.1038/psp.2013.79.},
Number-of-Cited-References = {91},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Comput. Biol. Med.},
Doc-Delivery-Number = {UE5XP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000687961000001},
DA = {2026-02-04},
}

@article{ WOS:000671350600001,
Author = {Arai, Midori A. and Sakuraba, Kota and Makita, Yoshinori and Hara,
   Yasumasa and Ishibashi, Masami},
Title = {Evaluation of Naturally Occurring HIF-1 Inhibitors for Pulmonary
   Arterial Hypertension},
Journal = {CHEMBIOCHEM},
Year = {2021},
Volume = {22},
Number = {18},
Pages = {2799-2804},
Month = {SEP 14},
Abstract = {Pulmonary arterial hypertension (PAH) is a rare and severe progressive
   disorder characterized by high pulmonary artery pressure. Chronic
   hypoxia causes a metabolic disorder and the Warburg effect in pulmonary
   arterial smooth muscle cells (PASMCs). Pyruvate dehydrogenase kinase 1
   (PDK1) is a key enzyme in Warburg effect increased by hypoxia-inducible
   factor (HIF-1). We constructed a cell-based luciferase assay system for
   HIF-1 inhibitors. Using this system, six HIF-1 inhibitors were
   identified. Among these inhibitors, the effect of tagitinin C (1) on
   PASMC was investigated. Tagitinin C (1) clearly decreased the amount of
   HIF-1 beta and the HIF-1 target PDK1. This result indicates that HIF-1
   inhibitors effectively decrease PDK1 activity, which is a cause of the
   metabolic disorder and Warburg effect observed in PASMCs. Identifying
   naturally occurring HIF-1 inhibitors could provide novel insights into
   the development of PAH medications.},
Publisher = {WILEY-V C H VERLAG GMBH},
Address = {POSTFACH 101161, 69451 WEINHEIM, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Arai, MA (Corresponding Author), Keio Univ, Fac Sci \& Technol, Dept Biosci \& Informat, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.
   Ishibashi, M (Corresponding Author), Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.
   Arai, Midori A.; Makita, Yoshinori, Keio Univ, Fac Sci \& Technol, Dept Biosci \& Informat, Kohoku Ku, 3-14-1 Hiyoshi, Yokohama, Kanagawa 2238522, Japan.
   Sakuraba, Kota; Makita, Yoshinori; Hara, Yasumasa; Ishibashi, Masami, Chiba Univ, Grad Sch Pharmaceut Sci, Chuo Ku, 1-8-1 Inohana, Chiba 2608675, Japan.},
DOI = {10.1002/cbic.202100223},
EarlyAccessDate = {JUL 2021},
ISSN = {1439-4227},
EISSN = {1439-7633},
Keywords = {HIF-1; hypoxia; inhibitor; natural products; pulmonary arterial
   hypertension},
Keywords-Plus = {TUMOR-GROWTH},
Research-Areas = {Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Medicinal},
Author-Email = {midori\_arai@bio.keio.ac.jp
   mish@chiba-u.jp},
Affiliations = {Keio University; Chiba University},
ResearcherID-Numbers = {Ishibashi, Masami/E-5328-2015
   Hara, Yasumasa/N-7127-2019
   Arai, Midori/O-4613-2015},
ORCID-Numbers = {Sakuraba, Kota/0009-0000-1744-8360
   Ishibashi, Masami/0000-0002-2839-1045
   Hara, Yasumasa/0000-0003-0451-8731
   },
Funding-Acknowledgement = {KAKENHI from the Japan Society for the Promotion of Science {[}18H02582,
   20H03394]; Grants-in-Aid for Scientific Research {[}20H03394, 21H02639,
   18H02582] Funding Source: KAKEN},
Funding-Text = {This study was supported by KAKENHI grants (nos. 18H02582 and 20H03394)
   from the Japan Society for the Promotion of Science. This work was
   inspired by the International and Interdisciplinary Environments of the
   JSPS Core-to-Core Program ``Asian Chemical Biology Initiative{''} and
   the JSPS A3 Foresight Program.},
Cited-References = {Abud EM, 2012, P NATL ACAD SCI USA, V109, P1239, DOI 10.1073/pnas.1120385109.
   Arai MA, 2018, ACS CHEM BIOL, V13, P2551, DOI 10.1021/acschembio.8b00492.
   Arai MA, 2018, J NAT PROD, V81, P1235, DOI 10.1021/acs.jnatprod.7b01031.
   Aziz M.H, 2020, NEUROL RES, V42, P68.
   Cheng CC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061468.
   Choi H, 2006, MOL PHARMACOL, V70, P1664, DOI 10.1124/mol.106.025817.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Kamata K, 2006, J NAT PROD, V69, P1252, DOI 10.1021/np060269h.
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106.
   Lee SH, 2015, J CELL PHYSIOL, V230, P853, DOI 10.1002/jcp.24813.
   Lindhagen E, 2008, NAT PROTOC, V3, P1364, DOI 10.1038/nprot.2008.114.
   Minegishi H, 2013, ACS MED CHEM LETT, V4, P297, DOI 10.1021/ml3004632.
   Naeije Robert, 2005, Proc Am Thorac Soc, V2, P20, DOI 10.1513/pats.200407-037MS.
   Norbert F.V, 2008, AM J RESP CRIT CARE, V178, P558.
   Park K, 2017, ONCOTARGET, V8, P7801, DOI 10.18632/oncotarget.13955.
   Reece KM, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-91.
   Ryan J, 2015, J MOL MED, V93, P229, DOI 10.1007/s00109-015-1263-5.
   Skipper KA, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-92.
   Stenmark KR, 2005, ANNU REV PHYSIOL, V67, P623, DOI 10.1146/annurev.physiol.67.040403.102229.
   STERN RC, 1980, AM J DIS CHILD, V134, P267, DOI 10.1001/archpedi.1980.02130150025007.
   Strange C, 2005, CURR OPIN PULM MED, V11, P452, DOI 10.1097/01.mcp.0000174250.38188.6d.
   Thenappan T, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5492.
   Wang LH, 2015, EUR J MED CHEM, V89, P88, DOI 10.1016/j.ejmech.2014.10.036.
   Zhang L, 2014, INT J MOL SCI, V15, P8153, DOI 10.3390/ijms15058153.},
Number-of-Cited-References = {24},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {ChemBioChem},
Doc-Delivery-Number = {UP8FP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000671350600001},
DA = {2026-02-04},
}

@article{ WOS:000677344000001,
Author = {Bao, Macus Hao-Ran and Wong, Carmen Chak-Lui},
Title = {Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer},
Journal = {CELLS},
Year = {2021},
Volume = {10},
Number = {7},
Month = {JUL},
Abstract = {Hypoxia, low oxygen (O-2) level, is a hallmark of solid cancers,
   especially hepatocellular carcinoma (HCC), one of the most common and
   fatal cancers worldwide. Hypoxia contributes to drug resistance in
   cancer through various molecular mechanisms. In this review, we
   particularly focus on the roles of hypoxia-inducible factor
   (HIF)-mediated metabolic reprogramming in drug resistance in HCC.
   Combination therapies targeting hypoxia-induced metabolic enzymes to
   overcome drug resistance will also be summarized. Acquisition of drug
   resistance is the major cause of unsatisfactory clinical outcomes of
   existing HCC treatments. Extra efforts to identify novel mechanisms to
   combat refractory hypoxic HCC are warranted for the development of more
   effective treatment regimens for HCC patients.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Wong, CCL (Corresponding Author), Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China.
   Wong, CCL (Corresponding Author), Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.
   Bao, Macus Hao-Ran; Wong, Carmen Chak-Lui, Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China.
   Wong, Carmen Chak-Lui, Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China.},
DOI = {10.3390/cells10071715},
Article-Number = {1715},
EISSN = {2073-4409},
Keywords = {hypoxia; metabolism; metabolic reprogramming; drug resistance; TKIs;
   ICIs; liver cancer},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; HEPATOCELLULAR-CARCINOMA;
   GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; PHOSPHORYLATION SITES;
   SORAFENIB RESISTANCE; INDUCIBLE FACTORS; SUPPRESSOR-CELLS;
   UP-REGULATION; EXPRESSION; PROGNOSIS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {macusbao@gmail.com
   carmencl@pathology.hku.hk},
Affiliations = {University of Hong Kong; University of Hong Kong},
Funding-Acknowledgement = {Program for Guangdong Introducing Innovative and Entrepreneurial Teams
   {[}2019BT02Y198]; InnoHealth-Center for Oncology and Immunology,
   Croucher Innovation Award; University of Hong Kong Outstanding Young
   Researcher Award},
Funding-Text = {This work is funded by the Program for Guangdong Introducing Innovative
   and Entrepreneurial Teams (2019BT02Y198), the InnoHealth-Center for
   Oncology and Immunology, Croucher Innovation Award, and University of
   Hong Kong Outstanding Young Researcher Award.},
Cited-References = {Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002.
   Amann T, 2009, AM J PATHOL, V174, P1544, DOI 10.2353/ajpath.2009.080596.
   Bangoura G, 2007, WORLD J GASTROENTERO, V13, P3176, DOI 10.3748/wjg.v13.i23.3176.
   Bannoud N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.660944.
   Bao MHR, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108676.
   Beavis PA, 2013, P NATL ACAD SCI USA, V110, P14711, DOI 10.1073/pnas.1308209110.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Cao XH, 2007, CANCER CHEMOTH PHARM, V59, P495, DOI 10.1007/s00280-006-0291-9.
   Cao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104104.
   Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015.
   Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016.
   Chen C, 2017, ONCOTARGET, V8, P46691, DOI 10.18632/oncotarget.17358.
   Chen HL, 2018, CANCER MED-US, V7, P5339, DOI 10.1002/cam4.1521.
   Chen PW, 2017, P NATL ACAD SCI USA, V114, P580, DOI 10.1073/pnas.1614035114.
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7.
   Chiu DKC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2155-3.
   Chiu DKC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00530-7.
   Chiu DKC, 2016, HEPATOLOGY, V64, P797, DOI 10.1002/hep.28655.
   Cho H, 2016, NATURE, V539, P107, DOI 10.1038/nature19795.
   CLAVO AC, 1995, J NUCL MED, V36, P1625.
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490.
   Comito G, 2019, ONCOGENE, V38, P3681, DOI 10.1038/s41388-019-0688-7.
   Copur MS, 2008, NEW ENGL J MED, V359, P2498.
   Coriat R, 2012, MOL CANCER THER, V11, P2284, DOI 10.1158/1535-7163.MCT-12-0093.
   Csóka B, 2012, FASEB J, V26, P376, DOI 10.1096/fj.11-190934.
   Cui XG, 2017, ONCOTARGET, V8, P24840, DOI 10.18632/oncotarget.15266.
   Daneshmandi S, 2019, CANCERS, V11, DOI 10.3390/cancers11040450.
   de la Cruz-López KG, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01143.
   Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206.
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2.
   Engel AL, 2020, BRIT J CANCER, V122, P1391, DOI 10.1038/s41416-020-0794-x.
   Escobar G, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb9726.
   Feng J, 2017, ONCOGENE, V36, P5829, DOI 10.1038/onc.2017.188.
   Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972.
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047.
   Ganapathy-Kanniappan S, 2012, ONCOTARGET, V3, P940, DOI 10.18632/oncotarget.623.
   Gao Hengjun, 2020, Oncol Lett, V19, P691, DOI {[}10.3892/ol.2019.11191, 10.3892/ol.2019.11191].
   Guo WJ, 2015, HEPATOLOGY, V62, P1132, DOI 10.1002/hep.27929.
   Guo Y, 2019, INT J BIOL SCI, V15, P1771, DOI 10.7150/ijbs.35094.
   Gwak GY, 2005, J HEPATOL, V42, P358, DOI 10.1016/j.jhep.2004.11.020.
   Harmon C, 2019, CANCER IMMUNOL RES, V7, P335, DOI 10.1158/2326-6066.CIR-18-0481.
   Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177.
   Huang WJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119181.
   Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702.
   Ikeda M, 2016, CLIN CANCER RES, V22, P1385, DOI 10.1158/1078-0432.CCR-15-1354.
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149.
   Ji J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00569.
   Keating SE, 2016, J IMMUNOL, V196, P2552, DOI 10.4049/jimmunol.1501783.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Lai RKH, 2016, CLIN CANCER RES, V22, P3105, DOI 10.1158/1078-0432.CCR-15-1987.
   Le PH, 2014, ONCOL LETT, V7, P1430, DOI 10.3892/ol.2014.1966.
   Lee D, 2017, J CLIN INVEST, V127, P1856, DOI 10.1172/JCI90253.
   Li JY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1320011.
   Li JQ, 2017, ACTA PHARMACOL SIN, V38, P1642, DOI 10.1038/aps.2017.79.
   Li X, 2019, DIGEST DIS SCI, V64, P3215, DOI 10.1007/s10620-019-05642-2.
   Li YJ, 2019, THERANOSTICS, V9, P7599, DOI 10.7150/thno.34931.
   Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224.
   Lim KS, 2014, ONCOGENE, V33, P4433, DOI 10.1038/onc.2013.390.
   Liu SS, 2017, HEPATOLOGY, V66, P631, DOI 10.1002/hep.29202.
   Liu XB, 2014, ARTIF CELL NANOMED B, V42, P229, DOI 10.3109/21691401.2013.808647.
   Liu XC, 2016, DIGEST LIVER DIS, V48, P953, DOI 10.1016/j.dld.2016.04.015.
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857.
   Ma L, 2014, CANCER LETT, V355, P96, DOI 10.1016/j.canlet.2014.09.011.
   Ma XL, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0724-7.
   Mah AY, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95128.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676.
   Méndez-Blanco C, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835920987071.
   Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005.
   Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7.
   Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091.
   Pesce S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01242.
   Renner K, 2019, CELL REP, V29, P135, DOI 10.1016/j.celrep.2019.08.068.
   Reyes Ryan, 2017, Gene Expression-The Journal of Liver Research, V17, P129, DOI {[}10.3727/105221616x693855, 10.3727/105221616X693855].
   Riedl CC, 2008, RADIOLOGY, V248, P561, DOI 10.1148/radiol.2482071421.
   Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530.
   Scheuermann TH, 2009, P NATL ACAD SCI USA, V106, P450, DOI 10.1073/pnas.0808092106.
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559.
   Sheng SL, 2012, FEBS J, V279, P3898, DOI 10.1111/j.1742-4658.2012.08748.x.
   Shi F, 2011, INT J CANCER, V128, P887, DOI 10.1002/ijc.25397.
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843.
   Sorrentino C, 2015, ONCOTARGET, V6, P27478, DOI 10.18632/oncotarget.4393.
   Stagg J, 2012, CANCER RES, V72, P2190, DOI 10.1158/0008-5472.CAN-12-0420.
   Stagg J, 2011, CANCER RES, V71, P2892, DOI 10.1158/0008-5472.CAN-10-4246.
   Sun HX, 2013, HEPATOLOGY, V57, P1088, DOI 10.1002/hep.26188.
   Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33.
   Sun XY, 2009, HUM GENE THER, V20, P314, DOI 10.1089/hum.2008.164.
   Tello D, 2011, CELL METAB, V14, P768, DOI 10.1016/j.cmet.2011.10.008.
   Tesori V, 2015, SCI REP-UK, V5, DOI 10.1038/srep09149.
   To WKL, 2015, PLACENTA, V36, P759, DOI 10.1016/j.placenta.2015.04.005.
   Urasaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036775.
   Vaupel P, 2007, ANTIOXID REDOX SIGN, V9, P1221, DOI 10.1089/ars.2007.1628.
   Vaupel P, 2016, ADV EXP MED BIOL, V876, P177, DOI 10.1007/978-1-4939-3023-4\_22.
   Vijayan D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1312044.
   Wada H, 2006, LIVER INT, V26, P414, DOI 10.1111/j.1478-3231.2006.01243.x.
   Wang JR, 2016, ONCOTARGETS THER, V9, P5597, DOI 10.2147/OTT.S110646.
   Wang XC, 2017, CANCER LETT, V393, P113, DOI 10.1016/j.canlet.2017.01.032.
   Wang ZX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00202.
   Watson MJ, 2021, NATURE, V591, P645, DOI 10.1038/s41586-020-03045-2.
   Wei L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12606-7.
   Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109-011-0855-y.
   Xia HP, 2020, EUR J NUCL MED MOL I, V47, P787, DOI 10.1007/s00259-019-04638-4.
   Xu JJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.411.
   Yang SL, 2016, ONCOTARGET, V7, P34571, DOI 10.18632/oncotarget.8952.
   Ye JB, 2014, CANCER DISCOV, V4, P1406, DOI 10.1158/2159-8290.CD-14-0250.
   Yoo JJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061292.
   Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001.
   Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105.
   Zhang ZF, 2016, BMC GASTROENTEROL, V16, DOI 10.1186/s12876-016-0474-8.
   Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9.},
Number-of-Cited-References = {118},
Times-Cited = {257},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {138},
Journal-ISO = {Cells},
Doc-Delivery-Number = {TP1FM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000677344000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000667814100058,
Author = {Cilleros-Mane, V and Just-Borras, L. and Polishchuk, A. and Duran, M.
   and Tomas, M. and Garcia, N. and Tomas, J. M. and Lanuza, M. A.},
Title = {M1 and M2 mAChRs activate PDK1 and regulate PKC βI
   and ε and the exocytotic apparatus at the NMJ},
Journal = {FASEB JOURNAL},
Year = {2021},
Volume = {35},
Number = {7},
Month = {JUL},
Abstract = {Neuromuscular junctions (NMJ) regulate cholinergic exocytosis through
   the M-1 and M-2 muscarinic acetylcholine autoreceptors (mAChR),
   involving the crosstalk between receptors and downstream pathways.
   Protein kinase C (PKC) regulates neurotransmission but how it associates
   with the mAChRs remains unknown. Here, we investigate whether mAChRs
   recruit the classical PKC beta I and the novel PKC epsilon isoforms and
   modulate their priming by PDK1, translocation and activity on
   neurosecretion targets. We show that each M-1 and M-2 mAChR activates
   the master kinase PDK1 and promotes a particular priming of the
   presynaptic PKC beta I and epsilon isoforms. M-1 recruits both
   primed-PKCs to the membrane and promotes Munc18-1, SNAP-25, and MARCKS
   phosphorylation. In contrast, M-2 downregulates PKC epsilon through a
   PKA-dependent pathway, which inhibits Munc18-1 synthesis and PKC
   phosphorylation. In summary, our results discover a co-dependent balance
   between muscarinic autoreceptors which orchestrates the presynaptic PKC
   and their action on ACh release SNARE-SM mechanism. Altogether, this
   molecular signaling explains previous functional studies at the NMJ and
   guide toward potential therapeutic targets.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Tomàs, JM; Lanuza, MA (Corresponding Author), Univ Rovira \& Virgili, Dept Ciencies Med Basiques, Unitat Histol \& Neurobiol UHNEUROB, C St Llorenc 21, Reus 43201, Spain.
   Cilleros-Mane, V; Just-Borras, L.; Polishchuk, A.; Duran, M.; Tomas, M.; Garcia, N.; Tomas, J. M.; Lanuza, M. A., Univ Rovira \& Virgili, Fac Med \& Ciencies Salut, Dept Ciencies Med Basiques, Unitat Histol \& Neurobiol UHNEUROB, Reus, Spain.},
DOI = {10.1096/fj.202002213R},
Article-Number = {e21724},
ISSN = {0892-6638},
EISSN = {1530-6860},
Keywords = {muscarinic receptors; neuromuscular junction; PDK1; PKC; SNAP-25},
Keywords-Plus = {PROTEIN-KINASE-C; SYNAPTOSOME-ASSOCIATED PROTEIN;
   EPIDERMAL-GROWTH-FACTOR; NEUROTRANSMITTER RELEASE;
   NEUROMUSCULAR-JUNCTION; POSSIBLE INVOLVEMENT; DEPENDENT PHOSPHORYLATION;
   MUSCARINIC AUTORECEPTORS; TRANSMITTER RELEASE; SYNAPTIC ACTIVITY},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Cell Biology},
Author-Email = {josepmaria.tomas@urv.cat
   mariaangel.lanuza@urv.cat},
Affiliations = {Universitat Rovira i Virgili},
ResearcherID-Numbers = {Cilleros Mañé, Víctor/G-5251-2018
   Just Borràs, Laia/R-3303-2018
   Lanuza, Maria Angel/I-3236-2017
   Polishchuk, Aleksana/HLQ-6895-2023
   },
ORCID-Numbers = {Cilleros Mañé, Víctor/0000-0001-5690-9932
   Just Borràs, Laia/0000-0003-0473-3730
   Lanuza, Maria Angel/0000-0003-4795-4103
   Durán, Maria/0000-0003-1321-6305
   Polishchuk, Aleksana/0000-0001-6445-1538
   Tomàs, Josep/0000-0002-0406-0006},
Funding-Acknowledgement = {Ministerio de Economia y Competitividad (MINECO); Agencia Estatal de
   Investigacion (AEI); European Regional Development Fund (ERDF)
   {[}SAF2015-67143-P, PID2019-106332GB-I00]; Universitat Rovira i Virgili
   (URV) {[}2017PFR-URV-B2-85]; Catalan Government {[}2017SGR704]; European
   Social Fund (ESF); Iniciativa de Empleo Juvenil (IEJ)
   {[}LE1511314-2014PEJ-04, LE1911587-2019PEJ-04]; Spanish Ministerio de
   Ciencia Innovacion y Universidades {[}PID2019-106332GB-I00,
   PRE2020-092084]; Universitat Rovira i Virgili (URV); Contractes de
   personal investigador predoctoral en formacio {[}2018PMF-PIPF-18]},
Funding-Text = {Ministerio de Economia y Competitividad (MINECO); Agencia Estatal de
   Investigacion (AEI); European Regional Development Fund (ERDF),
   Grant/Award Number: SAF2015-67143-P and PID2019-106332GB-I00;
   Universitat Rovira i Virgili (URV), Grant/Award Number:
   2017PFR-URV-B2-85; Catalan Government, Grant/Award Number: 2017SGR704;
   European Social Fund (ESF); Iniciativa de Empleo Juvenil (IEJ),
   Grant/Award Number: LE1511314-2014PEJ-04 and LE1911587-2019PEJ-04;
   Spanish Ministerio de Ciencia Innovacion y Universidades, Grant/Award
   Number: PRE2020-092084 and PID2019-106332GB-I00; Universitat Rovira i
   Virgili (URV); Contractes de personal investigador predoctoral en
   formacio, Grant/Award Number: 2018PMF-PIPF-18},
Cited-References = {ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O.
   Barclay JW, 2003, J BIOL CHEM, V278, P10538, DOI 10.1074/jbc.M211114200.
   Besalduch N, 2010, J COMP NEUROL, V518, P211, DOI 10.1002/cne.22220.
   Brazhnik E, 2004, J NEUROSCI, V24, P9313, DOI 10.1523/JNEUROSCI.1618-04.2004.
   Callaghan B, 2004, CIRC RES, V94, P626, DOI 10.1161/01.RES.0000118248.17466.B7.
   Caulfield MP, 1998, PHARMACOL REV, V50, P279.
   CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559.
   Chotiner JK, 2003, NEUROSCIENCE, V116, P743, DOI 10.1016/S0306-4522(02)00797-2.
   Cilleros-Mañé V, 2020, FASEB J, V34, P4934, DOI 10.1096/fj.201902113R.
   de Vries KJ, 2000, EUR J NEUROSCI, V12, P385, DOI 10.1046/j.1460-9568.2000.00931.x.
   Denning MF, 2012, PIGM CELL MELANOMA R, V25, P466, DOI 10.1111/j.1755-148X.2012.01015.x.
   Di-Capua N, 2003, J NEUROCHEM, V84, P409, DOI 10.1046/j.1471-4159.2003.01563.x.
   Disatnik MH, 2004, J CELL SCI, V117, P4469, DOI 10.1242/jcs.01309.
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7.
   Ersvaer E, 2010, TOXINS, V2, P174, DOI 10.3390/toxins2010174.
   Fujita Y, 1996, J BIOL CHEM, V271, P7265, DOI 10.1074/jbc.271.13.7265.
   Garcia N, 2005, HISTOL HISTOPATHOL, V20, P733, DOI 10.14670/HH-20.733.
   GOODE NT, 1995, J BIOL CHEM, V270, P2669, DOI 10.1074/jbc.270.6.2669.
   Heise C, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00035.
   Hepp R, 2002, FEBS LETT, V532, P52, DOI 10.1016/S0014-5793(02)03629-3.
   HERGET T, 1995, EUR J BIOCHEM, V233, P448, DOI 10.1111/j.1432-1033.1995.448\_2.x.
   Hurtado E, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00270.
   Hurtado E, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00147.
   Iwasaki S, 2000, J BIOCHEM-TOKYO, V128, P407, DOI 10.1093/oxfordjournals.jbchem.a022768.
   Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962.
   Just-Borràs L, 2019, MOL NEUROBIOL, V56, P6856, DOI 10.1007/s12035-019-1550-1.
   Kang BS, 2000, ONCOGENE, V19, P4263, DOI 10.1038/sj.onc.1203779.
   Kataoka M, 2000, J NEUROCHEM, V74, P2058, DOI 10.1046/j.1471-4159.2000.0742058.x.
   Katayama N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08237-x.
   Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5.
   Knoch KP, 2006, CELL METAB, V3, P123, DOI 10.1016/j.cmet.2005.12.008.
   KRAFT AS, 1982, J BIOL CHEM, V257, P13193.
   Lanuza MA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121578.
   Lanuza MA, 2014, J ANAT, V224, P61, DOI 10.1111/joa.12106.
   Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973.
   Leenders AGM, 2005, PHARMACOL THERAPEUT, V105, P69, DOI 10.1016/j.pharmthera.2004.10.012.
   Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026.
   Lou XL, 2008, J NEUROSCI, V28, P8257, DOI 10.1523/JNEUROSCI.0550-08.2008.
   Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839.
   Valenzuela IMPY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081311.
   Minic J, 2002, EUR J NEUROSCI, V15, P439, DOI 10.1046/j.0953-816x.2001.01875.x.
   Mochly-Rosen D, 1998, FASEB J, V12, P35.
   Morgan A, 2005, BIOCHEM SOC T, V33, P1341, DOI 10.1042/BST0331341.
   Morgan A., 2004, Cell Biology Chromaffin Cell, V1, P65.
   Nadal L, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00024.
   Nadal L, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0248-9.
   Nagy G, 2002, J NEUROSCI, V22, P9278.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   NAKANO S, 1992, MUSCLE NERVE, V15, P496, DOI 10.1002/mus.880150414.
   Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0.
   Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626.
   Newton AC, 2010, AM J PHYSIOL-ENDOC M, V298, pE395, DOI 10.1152/ajpendo.00477.2009.
   Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8.
   Obis T, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0171-5.
   Obis T, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0098-x.
   OLIVIER AR, 1992, J CELL PHYSIOL, V152, P240, DOI 10.1002/jcp.1041520204.
   Osto E, 2008, CIRCULATION, V118, P2174, DOI 10.1161/CIRCULATIONAHA.108.789537.
   Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496.
   PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153.
   Perkins GA, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-17.
   Rapaport D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009759.
   Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300.
   ROSS EM, 1993, LIFE SCI, V52, P413, DOI 10.1016/0024-3205(93)90296-F.
   Santafé MM, 2007, NEUROSCIENCE, V148, P432, DOI 10.1016/j.neuroscience.2007.06.017.
   Santafé MM, 2009, J NEUROSCI RES, V87, P683, DOI 10.1002/jnr.21885.
   Santafé MM, 2004, NEUROSCIENCE, V123, P61, DOI 10.1016/j.neuroscience.2003.09.012.
   Shen A, 1998, BIOCHEM PHARMACOL, V56, P1529, DOI 10.1016/S0006-2952(98)00242-1.
   Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548.
   Shirai Y, 1998, JPN J PHARMACOL, V78, P411, DOI 10.1254/jjp.78.411.
   Shu YL, 2008, J NEUROSCI, V28, P21, DOI 10.1523/JNEUROSCI.2352-07.2008.
   Simó A, 2019, MOL NEUROBIOL, V56, P5346, DOI 10.1007/s12035-018-1462-5.
   Simó A, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00207.
   Slutsky I, 1999, J PHYSIOL-LONDON, V514, P769, DOI 10.1111/j.1469-7793.1999.769ad.x.
   Snyder DA, 2006, CELL BIOCHEM BIOPHYS, V45, P111, DOI 10.1385/CBB:45:1:111.
   Sons MS, 2003, ANN NY ACAD SCI, V998, P404, DOI 10.1196/annals.1254.052.
   Sorensen JB, 2003, CELL, V114, P75, DOI 10.1016/S0092-8674(03)00477-X.
   Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200.
   Steinberg SF, 2008, PHYSIOL REV, V88, P1341, DOI 10.1152/physrev.00034.2007.
   Südhof TC, 2013, NEURON, V80, P675, DOI 10.1016/j.neuron.2013.10.022.
   Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125.
   Wang XQ, 2007, CANCER RES, V67, P9986, DOI 10.1158/0008-5472.CAN-07-1300.
   Wang YX, 1999, J BIOL CHEM, V274, P13859, DOI 10.1074/jbc.274.20.13859.
   Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1.
   Wierda KDB, 2007, NEURON, V54, P275, DOI 10.1016/j.neuron.2007.04.001.
   Willets JM, 2007, J NEUROCHEM, V103, P2268, DOI 10.1111/j.1471-4159.2007.04931.x.
   Wright MC, 2009, J NEUROSCI, V29, P14942, DOI 10.1523/JNEUROSCI.2276-09.2009.
   Yang Y, 2007, J GEN PHYSIOL, V129, P233, DOI 10.1085/jgp.200609685.
   Zhang Y, 2015, J BIOL CHEM, V290, P8644, DOI 10.1074/jbc.M114.615021.
   Zhao LX, 2019, FASEB J, V33, P6622, DOI 10.1096/fj.201802351R.
   Zhou JZ, 2003, J BIOL CHEM, V278, P5388, DOI 10.1074/jbc.M209695200.},
Number-of-Cited-References = {90},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {1},
Journal-ISO = {Faseb J.},
Doc-Delivery-Number = {TB2YH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000667814100058},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000680437700010,
Author = {Ferreira, Bianca Lima and Figueiredo Leite, Giuseppe Gianini and Colo
   Brunialti, Milena Karina and Assuncao, Murillo and Pontes Azevedo,
   Luciano Cesar and Freitas, Flavio and Salomao, Reinaldo},
Title = {HIF-1α and Hypoxia Responsive Genes are Differentially Expressed in
   Leukocytes From Survivors and Non-Survivors Patients During Clinical
   Sepsis},
Journal = {SHOCK},
Year = {2021},
Volume = {56},
Number = {1},
Pages = {80-91},
Month = {JUL},
Abstract = {Hypoxia inducible factor 1 alpha (HIF-1 alpha) is linked to the
   metabolic and immune alterations in septic patients. Stabilization of
   HIF-1 alpha by hypoxia or inflammation promotes the expression of
   several genes related to glycolytic metabolism, angiogenesis,
   coagulation, cell proliferation, and apoptosis. Here, we analyzed public
   available blood transcriptome datasets from septic patients and
   evaluated by PCR array the expression of HIF-1 alpha and other hypoxia
   responsive genes in peripheral blood mononuclear cells from patients
   with sepsis secondary to community acquired infections. Samples were
   collected at intensive care unit admission (D0, n=29) and after 7 days
   follow-up (D7, n = 18); healthy volunteers (n = 10) were included as
   controls. Hypoxia and glycolysis were among the top scored molecular
   signatures in the transcriptome datasets. PCR array showed that 24 out
   of 78 analyzed genes were modulated in septic patients compared with
   healthy volunteers; most of them (23/24) were downregulated at
   admission. This same pattern was observed in surviving patients, while
   non-survivors presented more upregulated genes. EGLN1, EGLN2, and
   HIF1AN, inhibitors of HIF-1 alpha activation were downregulated in
   patients, regardless of the outcome, while HIF-1 alpha and other target
   genes, such as PDK1 and HMOX1, expression were higher in non-survivors
   than in survivors, mainly at D7. Non-survivor patients also presented a
   higher SOFA score and lower PaO2/FiO(2) ratio. Our results indicate a
   differential modulation of hypoxia pathway in leukocytes between septic
   patients who survived and those who did not survive with an increased
   intensity at D7, which is possibly influenced by disease severity and
   may affect the immune response in sepsis.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Salomao, R (Corresponding Author), Univ Fed Sao Paulo, Hosp Sao Paulo, Div Infect Dis, Escola Paulista Med, Rua Pedro Toledo 669,10th Floor, BR-04039032 Sao Paulo, SP, Brazil.
   Ferreira, Bianca Lima; Figueiredo Leite, Giuseppe Gianini; Colo Brunialti, Milena Karina; Salomao, Reinaldo, Univ Fed Sao Paulo, Div Infect Dis, Escola Paulista Med, Sao Paulo, Brazil.
   Assuncao, Murillo, Hosp Israelita Albert Einstein, Intens Care Unit, Sao Paulo, Brazil.
   Pontes Azevedo, Luciano Cesar, Hosp Sirio Libanes, Intens Care Unit, Sao Paulo, Brazil.
   Freitas, Flavio, Univ Fed Sao Paulo, Hosp Sao Paulo, Intens Care Unit, Escola Paulista Med, Sao Paulo, Brazil.},
DOI = {10.1097/SHK.0000000000001694},
ISSN = {1073-2322},
EISSN = {1540-0514},
Keywords = {Gene expression; hypoxia inducible factor; immunometabolism;
   inflammation; metabolism; peripheral blood mononuclear cells; sepsis},
Keywords-Plus = {INDUCIBLE FACTOR-I; TISSUE FACTOR; SEPTIC PATIENTS; ORGAN FAILURE;
   UP-REGULATION; HIF-ALPHA; MORTALITY; DEFINITIONS; ACTIVATION; COMPLEX},
Research-Areas = {General \& Internal Medicine; Hematology; Surgery; Cardiovascular System
   \& Cardiology},
Web-of-Science-Categories  = {Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease},
Author-Email = {rsalomao@unifesp.br},
Affiliations = {Universidade Federal de Sao Paulo (UNIFESP); Hospital Israelita Albert
   Einstein; Hospital Sirio Libanes; Universidade Federal de Sao Paulo
   (UNIFESP)},
ResearcherID-Numbers = {Azevedo, Luciano/H-2652-2012
   Ferreira, Bianca/C-5444-2019
   Salomao, Reinaldo/C-6419-2013
   Brunialti, Milena/C-4905-2012
   Leite, Giuseppe/MEP-0507-2025},
ORCID-Numbers = {Salomao, Reinaldo/0000-0003-1149-4598
   Brunialti, Milena/0000-0003-2874-520X
   Leite, Giuseppe/0000-0003-1848-4480},
Funding-Acknowledgement = {FAPESP {[}2017/21052-0, 2016/13855-2]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) fellowship; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) {[}17/21052-0] Funding
   Source: FAPESP},
Funding-Text = {This work was supported by FAPESP (Grant 2017/21052-0). RS is the
   recipient of a Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) fellowship. BLF has a scholarship from FAPESP
   (2016/13855-2).},
Cited-References = {Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074.
   BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644.
   Brunyanszki A, 2015, MOL MED, V21, P666, DOI 10.2119/molmed.2015.00187.
   BUGA GM, 1993, CIRC RES, V73, P808, DOI 10.1161/01.RES.73.5.808.
   Burnham KL, 2017, AM J RESP CRIT CARE, V196, P328, DOI 10.1164/rccm.201608-1685OC.
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985.
   Cheng SC, 2016, NAT IMMUNOL, V17, P406, DOI 10.1038/ni.3398.
   CREASEY AA, 1993, J CLIN INVEST, V91, P2850, DOI 10.1172/JCI116529.
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283.
   Esquerdo KF, 2017, CLIN EXP IMMUNOL, V189, P232, DOI 10.1111/cei.12971.
   Franco RF, 2000, BLOOD, V96, P554.
   Gando S, 1998, THROMB HAEMOSTASIS, V79, P1111.
   Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778.
   Hato T, 2019, J CLIN INVEST, V129, P296, DOI 10.1172/JCI123284.
   Hu YC, 2019, MED SCI MONITOR, V25, P9563, DOI 10.12659/MSM.918491.
   Imtiyaz HZ, 2010, CURR TOP MICROBIOL, V345, P105, DOI 10.1007/82\_2010\_74.
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796.
   Kim H, 2019, ANN LAB MED, V39, P454, DOI 10.3343/alm.2019.39.5.454.
   Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9.
   Kuhlicke J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001364.
   Lachmandas E, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.246.
   Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893.
   Martins PS, 2008, CRIT CARE, V12, DOI 10.1186/cc6801.
   McGettrick AF, 2020, CELL METAB, V32, P524, DOI 10.1016/j.cmet.2020.08.002.
   Mebazaa A, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2243-2.
   Nucci LA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172024.
   O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70.
   Papastathi C, 2013, GROWTH HORM IGF RES, V23, P98, DOI 10.1016/j.ghir.2013.03.005.
   Park JS, 2018, SHOCK, V50, P209, DOI 10.1097/SHK.0000000000001020.
   Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005.
   Peyssonnaux C, 2007, J IMMUNOL, V178, P7516, DOI 10.4049/jimmunol.178.12.7516.
   Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153.
   Reade MC, 2005, BRIT J ANAESTH, V94, P468, DOI 10.1093/bja/aei082.
   Rudd KE, 2020, LANCET, V395, P200, DOI 10.1016/S0140-6736(19)32989-7.
   Salomao R, 2019, BRAZ J MED BIOL RES, V52, DOI {[}10.1590/1414-431X20198595, 10.1590/1414-431x20198595].
   Santos Sidneia S, 2016, Intensive Care Med Exp, V4, P5, DOI {[}10.1186/s40635-016-0078-1, 10.1186/s40635-016-0078-1].
   Schäfer ST, 2013, ANESTHESIOLOGY, V118, P1426, DOI 10.1097/ALN.0b013e31828baa67.
   Scharte M, 2003, AM J PHYSIOL-GASTR L, V284, pG373, DOI 10.1152/ajpgi.00076.2002.
   Scicluna BP, 2017, LANCET RESP MED, V5, P816, DOI 10.1016/S2213-2600(17)30294-1.
   Shalova IN, 2015, IMMUNITY, V42, P484, DOI 10.1016/j.immuni.2015.02.001.
   Shi J, 2019, LAB INVEST, V99, P1795, DOI 10.1038/s41374-019-0286-x.
   Simon MC, 2006, ADV EXP MED BIOL, V588, P165.
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287.
   Singer M, 2014, VIRULENCE, V5, P66, DOI 10.4161/viru.26907.
   Textoris J, 2012, CRIT CARE, V16, DOI 10.1186/cc11414.
   van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36.
   Vanderhaeghen T, 2020, FEBS J, V287, P1478, DOI 10.1111/febs.15222.
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304.
   Werth N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011576.
   Zhang H, 2020, CELL HOST MICROBE, V27, P556, DOI 10.1016/j.chom.2020.02.004.},
Number-of-Cited-References = {50},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Shock},
Doc-Delivery-Number = {TT6DQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000680437700010},
DA = {2026-02-04},
}

@article{ WOS:000652564300001,
Author = {Jiang, Hui and Fan, Chang and Lu, Yunqi and Cui, Xiaoya and Liu, Jian},
Title = {Astragaloside regulates lncRNA LOC100912373 and the miR-17-5p/PDK1 axis
   to inhibit the proliferation of fibroblast-like synoviocytes in rats
   with rheumatoid arthritis},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE},
Year = {2021},
Volume = {48},
Number = {1},
Month = {JUL},
Abstract = {Previous studies have confirmed that astragaloside (AST) exerts a
   positive effect on alleviating synovial and joint injury in rheumatoid
   arthritis (RA). However, the precise mechanisms through which AST acts
   in the treatment of RA remain unclear. Long non-coding RNA (lncRNA)
   LOC100912373 was identified as a key gene related to RA and has been
   proven to interact with miR-17-5p, in order to regulate the pyruvate
   dehydrogenase kinase 1 and protein kinase B axis (PDK1/AKT axis). The
   present study aimed to determine whether AST may treat RA through the
   interaction between lncRNA LOC100912373 and the miR-17-5p/PDK1 axis. MTT
   assays and flow cytometry were used to detect the proliferation and cell
   cycle progression of AST-treated fibroblast-like synoviocytes (FLSs).
   The expression of lncRNA LOC100912373 and miR-17-5p, as well as relative
   the mRNA expression of the PDK1 and AKT genes following AST intervention
   was detected by reverse transcription-quantitative PCR (RT-qPCR),
   immunofluorescence and western blot analysis. The results revealed that
   AST inhibited FLS proliferation, reduced lncRNA LOC100912373 expression
   levels, increased miR-17-5p expression levels, and decreased the PDK1
   and p-AKT expression levels. Additionally, consecutive rescue
   experiments revealed that AST counteracted the effects of lncRNA
   LOC100912373 overexpression on FLS proliferation and cell cycle
   progression. On the whole, the present study demonstrates that AST
   inhibits FLS proliferation by regulating the expression of lncRNA
   LOC100912373 and the miR-17-5p/PDK1 axis.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Liu, J (Corresponding Author), Anhui Univ Chinese Med, Affiliated Hosp 1, Expt Ctr Clin Res, 117 Meishan Rd, Hefei 230031, Anhui, Peoples R China.
   Jiang, Hui; Fan, Chang; Cui, Xiaoya; Liu, Jian, Anhui Univ Chinese Med, Affiliated Hosp 1, Expt Ctr Clin Res, 117 Meishan Rd, Hefei 230031, Anhui, Peoples R China.
   Jiang, Hui; Fan, Chang; Cui, Xiaoya, Anhui Univ Chinese Med, Sch Pharm, Hefei 230012, Anhui, Peoples R China.
   Lu, Yunqi, Drew Univ, Dept Biochem, Madison, NJ 07940 USA.},
DOI = {10.3892/ijmm.2021.4963},
Article-Number = {130},
ISSN = {1107-3756},
EISSN = {1791-244X},
Keywords = {astragaloside; rheumatoid arthritis; fibroblast-like synoviocytes;
   lncRNA LOC100912373; miR-17-5p; PDK1 axis},
Keywords-Plus = {APOPTOSIS; INVASION; EXPRESSION; MIGRATION; PROMOTE},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {liujianahzy@ahtcm.edu.cn},
Affiliations = {Anhui University of Chinese Medicine; Anhui University of Chinese
   Medicine; Drew University},
ResearcherID-Numbers = {fan, chang/JKH-8311-2023
   },
ORCID-Numbers = {Lu, Yunqi/0000-0001-6515-0534},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81873139]; 12th Batch of
   `115' Innovation Team of Anhui Province {[}Anhui Talent Office (2019)]
   {[}1]; Key Research and Development Program of Anhui Province, China
   {[}201904a07020004]; Special Funds for Provincial TCM Development
   {[}2016ZYZJ01]},
Funding-Text = {The present study was supported by the National Natural Science
   Foundation of China (grant no. 81873139), the 12th Batch of `115'
   Innovation Team of Anhui Province {[}Anhui Talent Office (2019) no. 1],
   the Key Research and Development Program of Anhui Province, China (no.
   201904a07020004) and the Special Funds for Provincial TCM Development
   (no. 2016ZYZJ01).},
Cited-References = {Bi X, 2019, EBIOMEDICINE, V50, P408, DOI 10.1016/j.ebiom.2019.11.024.
   Blunk I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68212-x.
   Bodkhe R, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19844632.
   Bunte K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143394.
   Cappelli LC, 2020, IMMUNOL REV, V294, P106, DOI 10.1111/imr.12832.
   Chen DY, 2017, J CELL MOL MED, V21, P781, DOI 10.1111/jcmm.13020.
   Chen LJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08133.
   Chen L, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12542.
   Chen XM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00898.
   Dong ZW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02360-5.
   Fan C, 2020, AM J TRANSL RES, V12, P7709.
   Fu HY, 2018, MOL THER-NUCL ACIDS, V12, P769, DOI 10.1016/j.omtn.2018.06.006.
   Guo QY, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0921-x.
   Ham S, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0215-5.
   He JM, 2019, CELL DEATH DIFFER, V26, P1918, DOI 10.1038/s41418-018-0263-8.
   Ichikawa R, 2020, ONCOL REP, V43, P1300, DOI 10.3892/or.2020.7512.
   Jia Q, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00094.
   Jiang H, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4850.
   Jiang H, 2019, INT J MOL MED, V44, P1344, DOI 10.3892/ijmm.2019.4281.
   Jiang H, 2016, GENE, V593, P131, DOI 10.1016/j.gene.2016.08.012.
   Jiang H, 2016, BIOMED CHROMATOGR, V30, P1397, DOI 10.1002/bmc.3697.
   Li GQ, 2019, J CELL MOL MED, V23, P7116, DOI 10.1111/jcmm.14591.
   Li NN, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4849.
   Li XH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205035.
   Liu XY, 2017, INT IMMUNOPHARMACOL, V44, P105, DOI 10.1016/j.intimp.2017.01.010.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Lowin T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57772-7.
   Lucchino B, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070700.
   Luo C, 2018, BRATISL MED J, V119, P355, DOI 10.4149/BLL\_2018\_066.
   Mameli G, 2017, CLIN EXP IMMUNOL, V189, P127, DOI 10.1111/cei.12964.
   Matta R, 2009, AM J TRANSL RES, V1, P267.
   Mo BY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00702.
   Muschter D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139726.
   Pu XY, 2016, CARBOHYD POLYM, V137, P154, DOI 10.1016/j.carbpol.2015.10.053.
   Saji M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75529-0.
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014.
   Shen XK, 2019, COLLOID SURFACE B, V180, P39, DOI 10.1016/j.colsurfb.2019.04.033.
   Siu MKY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0209-0.
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8.
   Song XL, 2017, INT J BIOL SCI, V13, P782, DOI 10.7150/ijbs.18732.
   Sun C, 2017, CELL IMMUNOL, V315, P27, DOI 10.1016/j.cellimm.2016.10.007.
   Sun L, 2020, INFLAMMOPHARMACOLOGY, V28, P437, DOI 10.1007/s10787-019-00666-6.
   Wang B, 2014, ARCH PHARM RES, V37, P793, DOI 10.1007/s12272-014-0336-2.
   Wang SL, 2018, BIOMED PHARMACOTHER, V106, P813, DOI 10.1016/j.biopha.2018.07.021.
   Wang YF, 2021, J CELL PHYSIOL, V236, P2156, DOI 10.1002/jcp.30002.
   Xie YF, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/9864841.
   Xu F, 2019, J BIOMED MATER RES A, V107, P468, DOI 10.1002/jbm.a.36562.
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014.
   Yan MM, 2010, BIORESOURCE TECHNOL, V101, P7462, DOI 10.1016/j.biortech.2010.04.100.
   Yan SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02218.
   Yang YS, 2017, INT J MOL MED, V39, P307, DOI 10.3892/ijmm.2016.2843.
   Zhang TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02529.
   Zhao CC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1479-3.
   Zhao JY, 2020, IMMUNOPHARM IMMUNOT, V42, P221, DOI 10.1080/08923973.2020.1742732.
   Zhu L, 2015, BRIT J PHARMACOL, V172, P3446, DOI 10.1111/bph.13138.},
Number-of-Cited-References = {55},
Times-Cited = {29},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Int. J. Mol. Med.},
Doc-Delivery-Number = {SF2AR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000652564300001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000676493700001,
Author = {Santana-Santana, Mikel and Bayascas, Jose-Ramon and Gimenez-Llort, Lydia},
Title = {Fine-Tuning the PI3K/Akt Signaling Pathway Intensity by Sex and
   Genotype-Load: Sex-Dependent Homozygotic Threshold for Somatic Growth
   but Feminization of Anxious Phenotype in Middle-Aged PDK1 K465E Knock-In
   and Heterozygous Mice},
Journal = {BIOMEDICINES},
Year = {2021},
Volume = {9},
Number = {7},
Month = {JUL},
Abstract = {According to the Research Domain Criteria (RDoC), phenotypic differences
   among disorders may be explained by variations in the nature and degree
   of neural circuitry disruptions and/or dysfunctions modulated by several
   biological and environmental factors. We recently demonstrated the in
   vivo behavioral translation of tweaking the PI3K/Akt signaling, an
   essential pathway for regulating cellular processes and physiology, and
   its modulation through aging. Here we describe, for the first time, the
   in vivo behavioral impact of the sex and genetic-load tweaking this
   pathway. The anxiety-like phenotypes of 61 mature (11-14-month-old) male
   and female PDK1 K465E knock-in, heterozygous, and WT mice were studied.
   Forced (open-field) anxiogenic environmental conditions were sensitive
   to detect sex and genetic-load differences at middle age. Despite
   similar neophobia and horizontal activity among the six groups, females
   exhibited faster ethograms than males, with increased thigmotaxis,
   increased wall and bizarre rearing. Genotype-load unveiled increased
   anxiety in males, resembling female performances. The performance of
   mutants in naturalistic conditions (marble test) was normal.
   Homozygotic-load was needed for reduced somatic growth only in males.
   Factor interactions indicated the complex interplay in the elicitation
   of different negative valence system's items and the fine-tuning of
   PI3K/Akt signaling pathway intensity by genotype-load and sex.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Bayascas, JR; Giménez-Llort, L (Corresponding Author), Univ Autonoma Barcelona, Inst Neurociencies, Barcelona 08016, Spain.
   Giménez-Llort, L (Corresponding Author), Univ Autonoma Barcelona, Sch Med, Dept Psychiat \& Forens Med, Barcelona 08016, Spain.
   Bayascas, JR (Corresponding Author), Univ Autonoma Barcelona, Sch Med, Dept Biochem \& Mol Biol, Barcelona 08016, Spain.
   Santana-Santana, Mikel; Bayascas, Jose-Ramon; Gimenez-Llort, Lydia, Univ Autonoma Barcelona, Inst Neurociencies, Barcelona 08016, Spain.
   Santana-Santana, Mikel; Gimenez-Llort, Lydia, Univ Autonoma Barcelona, Sch Med, Dept Psychiat \& Forens Med, Barcelona 08016, Spain.
   Bayascas, Jose-Ramon, Univ Autonoma Barcelona, Sch Med, Dept Biochem \& Mol Biol, Barcelona 08016, Spain.},
DOI = {10.3390/biomedicines9070747},
Article-Number = {747},
EISSN = {2227-9059},
Keywords = {RDoC; PI3K; Akt; signaling pathway; sex; genetic load; fine tuning;
   anxiety; aging},
Keywords-Plus = {3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE; 3XTG-AD MICE; ANXIETY;
   DEFICIENCY; BEHAVIOR; GSK3; PHOSPHOINOSITIDES; MUTATION; AKT; WNT},
Research-Areas = {Biochemistry \& Molecular Biology; Research \& Experimental Medicine;
   Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Medicine, Research \& Experimental;
   Pharmacology \& Pharmacy},
Author-Email = {mikel.santana@e-campus.uab.cat
   joseramon.bayascas@uab.cat
   lidia.gimenez@uab.cat},
Affiliations = {Autonomous University of Barcelona; Autonomous University of Barcelona;
   Autonomous University of Barcelona},
ResearcherID-Numbers = {Lizcano, Jose/E-6080-2010
   Giménez-Llort, Lydia/I-3347-2015},
ORCID-Numbers = {Giménez-Llort, Lydia/0000-0002-4091-489X},
Funding-Acknowledgement = {Ministerio de Economia y Competitividad (MINECO), Programa Estatal de
   Investigacion, Desarrollo e Innovacion Orientada a los Retos de la
   Sociedad {[}SAF2014-52813-R]},
Funding-Text = {This research was funded by Ministerio de Economia y Competitividad
   (MINECO), Programa Estatal de Investigacion, Desarrollo e Innovacion
   Orientada a los Retos de la Sociedad (DSAF2014-52813-R) to J.-R.B.},
Cited-References = {Ackermann TF, 2008, CELL PHYSIOL BIOCHEM, V22, P735, DOI 10.1159/000185557.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Asher J., 2010, GENES CIRCUITRY NOT.
   Baeta-Corral R, 2014, BEHAV BRAIN RES, V258, P97, DOI 10.1016/j.bbr.2013.10.017.
   Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07.
   Beaulieu JM, 2009, ANNU REV PHARMACOL, V49, P327, DOI 10.1146/annurev.pharmtox.011008.145634.
   Beery AK, 2011, NEUROSCI BIOBEHAV R, V35, P565, DOI 10.1016/j.neubiorev.2010.07.002.
   Bergeron Y, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00102.
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016.
   BROEKKAMP CL, 1986, EUR J PHARMACOL, V126, P223, DOI 10.1016/0014-2999(86)90051-8.
   Castillo-Mariqueo L., 2021, FRONT AGING, V2, P5, DOI {[}10.3389/fragi.2021.648567, DOI 10.3389/FRAGI.2021.648567].
   Cordón-Barris L, 2016, MOL CELL BIOL, V36, P2967, DOI 10.1128/MCB.00230-16.
   Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126.
   Dahlhoff M, 2010, NEUROSCIENCE, V169, P1216, DOI 10.1016/j.neuroscience.2010.05.066.
   de Brouwer G, 2019, COGN AFFECT BEHAV NE, V19, P1, DOI 10.3758/s13415-018-00653-4.
   Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X.
   Deacon RMJ, 2006, NAT PROTOC, V1, P122, DOI 10.1038/nprot.2006.20.
   Dixit PV, 2020, J PHARMACOL TOX MET, V102, DOI 10.1016/j.vascn.2020.106676.
   Dwivedi Y, 2010, BIOL PSYCHIAT, V67, P1017, DOI 10.1016/j.biopsych.2009.12.031.
   Freyberg Z, 2010, AM J PSYCHIAT, V167, P388, DOI 10.1176/appi.ajp.2009.08121873.
   Gimenez-Llort L, 2021, FRONT BEHAV NEUROSCI, V14, DOI 10.3389/fnbeh.2020.611384.
   Giménez-Llort L, 2020, FRONT BEHAV NEUROSCI, V14, DOI 10.3389/fnbeh.2020.00061.
   Greene-Schloesser DM, 2011, BEHAV BRAIN RES, V221, P55, DOI 10.1016/j.bbr.2011.02.010.
   GYERTYAN I, 1995, BEHAV PHARMACOL, V6, P24.
   Hall C.S., 1932, U CALIFORNIA PUBLICA, V6, P1.
   Huang HF, 2021, BEHAV BRAIN RES, V411, DOI 10.1016/j.bbr.2021.113389.
   Jimenez-Gomez C, 2011, BEHAV PHARMACOL, V22, P711, DOI 10.1097/FBP.0b013e32834afebe.
   Jope RS, 2006, CURR DRUG TARGETS, V7, P1421, DOI 10.2174/1389450110607011421.
   Jope RS, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00016.
   Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412.
   Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379.
   Leibrock C, 2013, CELL PHYSIOL BIOCHEM, V32, P766, DOI 10.1159/000354478.
   Lenze Eric J, 2011, Dialogues Clin Neurosci, V13, P381.
   Mahmood HM, 2020, AUTISM RES, V13, P1311, DOI 10.1002/aur.2342.
   McLean CP, 2011, J PSYCHIATR RES, V45, P1027, DOI 10.1016/j.jpsychires.2011.03.006.
   Mitchell SJ, 2015, ANNU REV ANIM BIOSCI, V3, P283, DOI 10.1146/annurev-animal-022114-110829.
   Mitra S, 2017, PHYSIOL BEHAV, V168, P103, DOI 10.1016/j.physbeh.2016.11.002.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Muntsant A, 2020, FRONT PSYCHIATRY, V11, DOI 10.3389/fpsyt.2020.572583.
   National Institute of Mental Health, RES DOMAIN CRITERIA.
   Neasta J, 2011, BIOL PSYCHIAT, V70, P575, DOI 10.1016/j.biopsych.2011.03.019.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   PINEL JPJ, 1978, J COMP PHYSIOL PSYCH, V92, P708, DOI 10.1037/h0077494.
   Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Sachs BD, 2013, INT J NEUROPSYCHOPH, V16, P2081, DOI 10.1017/S1461145713000321.
   Savage JE, 2017, AM J MED GENET B, V174, P156, DOI 10.1002/ajmg.b.32459.
   Shi HS, 2012, NEUROPSYCHOPHARMACOL, V37, P2671, DOI 10.1038/npp.2012.131.
   Singh KK, 2013, CLIN GENET, V83, P511, DOI 10.1111/cge.12111.
   Sun LN, 2020, BEHAV BRAIN RES, V379, DOI 10.1016/j.bbr.2019.112375.
   Tao WW, 2016, BEHAV BRAIN RES, V308, P177, DOI 10.1016/j.bbr.2016.04.039.
   Torres-Lista V, 2015, BEHAV PROCESS, V116, P69, DOI 10.1016/j.beproc.2015.05.001.
   Waite K, 2010, CURR TOP MICROBIOL, V346, P245, DOI 10.1007/82\_2010\_82.
   Wang W, 2015, NEUROSCIENCE, V285, P281, DOI 10.1016/j.neuroscience.2014.11.025.
   Wong H, 2020, ELIFE, V9, DOI 10.7554/eLife.56630.
   Yang S, 2018, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00435.
   Zucker I, 2010, NATURE, V465, P690, DOI 10.1038/465690a.
   Zurashvili T, 2013, MOL CELL BIOL, V33, P1027, DOI 10.1128/MCB.01052-12.},
Number-of-Cited-References = {58},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Biomedicines},
Doc-Delivery-Number = {TN8QW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000676493700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000676542900001,
Author = {Subramaniam, Sugarniya and Jeet, Varinder and Gunter, Jennifer H. and
   Clements, Judith A. and Batra, Jyotsna},
Title = {Allele-Specific MicroRNA-Mediated Regulation of a Glycolysis Gatekeeper
   PDK1 in Cancer Metabolism},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {14},
Month = {JUL},
Abstract = {Simple Summary MicroRNAs are small non-coding RNAs that regulate gene
   expression. Single Nucleotide Polymorphisms (SNPs), which have been
   previously associated with cancer risk may interfere with the function
   of microRNAs by changing the binding of microRNA to its target gene. We
   sought to identify the role of prostate cancer risk associated SNPs in
   regulating a vital enzyme of cancer metabolism, pyruvate dehydrogenase
   kinase 1 (PDK1) via microRNAs. The microRNA and gene interaction was
   studied using computational predictions and by various laboratory
   assays. Our study highlighted the role of PDK1 and its regulation by
   microRNAs in cancer metabolism and disease progression. The findings
   from this study suggest that analysis of microRNAs and their
   interactions with SNPs could provide valuable insights into the
   complicated mechanisms of prostate cancer risk associated SNPs and
   identify suitable moleculer pathways for targeted therapy. Background:
   Emerging evidence has revealed that genetic variations in microRNA
   (miRNA) binding sites called miRSNPs can alter miRNA binding in an
   allele-specific manner and impart prostate cancer (PCa) risk. Two
   miRSNPs, rs1530865 (G > C) and rs2357637 (C > A), in the 3 `
   untranslated region of pyruvate dehydrogenase kinase 1 (PDK1) have been
   previously reported to be associated with PCa risk. However, these
   results have not been functionally validated. Methods: In silico
   analysis was used to predict miRNA-PDK1 interactions and was tested
   using PDK1 knockdown, miRNA overexpression and reporter gene assay.
   Results: PDK1 expression was found to be upregulated in PCa metastasis.
   Further, our results show that PDK1 suppression reduced the migration,
   invasion, and glycolysis of PCa cells. Computational predictions showed
   that miR-3916, miR-3125 and miR-3928 had a higher binding affinity for
   the C allele than the G allele for the rs1530865 miRSNP which was
   validated by reporter gene assays. Similarly, miR-2116 and miR-889 had a
   higher affinity for the A than C allele of the rs2357637 miRSNP.
   Overexpression of miR-3916 and miR-3125 decreased PDK1 protein levels in
   cells expressing the rs1530865 SNP C allele, and miR-2116 reduced in
   cells with the rs2357637 SNP A allele. Conclusions: The present study is
   the first to report the regulation of the PDK1 gene by miRNAs in an
   allele-dependent manner and highlights the role of PDK1 in metabolic
   adaption associated with PCa progression.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Batra, J (Corresponding Author), Queensland Univ Technol, Inst Hlth \& Biomed Innovat, Fac Hlth, Sch Biomed Sci, Brisbane, Qld 4000, Australia.
   Batra, J (Corresponding Author), Queensland Univ Technol, Translat Res Inst, Australian Prostate Canc Res Ctr Queensland APCRC, Woolloongabba, Qld 4102, Australia.
   Subramaniam, Sugarniya; Jeet, Varinder; Gunter, Jennifer H.; Clements, Judith A.; Batra, Jyotsna, Queensland Univ Technol, Inst Hlth \& Biomed Innovat, Fac Hlth, Sch Biomed Sci, Brisbane, Qld 4000, Australia.
   Subramaniam, Sugarniya; Jeet, Varinder; Gunter, Jennifer H.; Clements, Judith A.; Batra, Jyotsna, Queensland Univ Technol, Translat Res Inst, Australian Prostate Canc Res Ctr Queensland APCRC, Woolloongabba, Qld 4102, Australia.
   Jeet, Varinder, Macquarie Univ, Ctr Hlth Econ, Sydney, NSW 2109, Australia.},
DOI = {10.3390/cancers13143582},
Article-Number = {3582},
EISSN = {2072-6694},
Keywords = {PDK1; metabolic reprogramming; single-nucleotide polymorphisms;
   microRNAs},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; CELL LUNG-CANCER; EXPRESSION;
   PROGRESSION; CARCINOMA; MIGRATION; INVASION; TARGETS; SWITCH},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {ssugarniya@gmail.com
   varinder.jeet@mq.edu.au
   jennifer.gunter@qut.edu.au
   j.clements@qut.edu.au
   jyotsna.batra@qut.edu.au},
Affiliations = {Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); University of Queensland; Macquarie University},
ResearcherID-Numbers = {Gunter, Jennifer/B-8960-2016
   batra, Jyotsna/B-4130-2011},
ORCID-Numbers = {Jeet, Varinder/0000-0003-3765-5310
   Gunter, Jennifer/0000-0003-2447-5732
   batra, Jyotsna/0000-0003-4646-6247},
Funding-Acknowledgement = {Cancer Council Queensland Australia; Cure Cancer and Cancer Australia
   Young Investigator award; National Health and Medical Research Council
   (NHMRC) Career Development Fellowship},
Funding-Text = {This work was partally supported by Cancer Council Queensland Australia
   and Cure Cancer and Cancer Australia Young Investigator award to J
   Batra. J. Batra was supported by a National Health and Medical Research
   Council (NHMRC) Career Development Fellowship.},
Cited-References = {Baltazar F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00231.
   Barnes EME, 2020, BRIT J CANCER, V122, P1298, DOI 10.1038/s41416-020-0777-y.
   Cascone T, 2018, CELL METAB, V27, P977, DOI 10.1016/j.cmet.2018.02.024.
   Cutruzzolà F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00097.
   Deng XY, 2020, J CANCER, V11, P962, DOI 10.7150/jca.34330.
   Eyassu F, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170360.
   Feng X, 2021, AUTOPHAGY, V17, P723, DOI 10.1080/15548627.2020.1731266.
   Gandalovicová A, 2017, TRENDS CANCER, V3, P391, DOI 10.1016/j.trecan.2017.04.008.
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478.
   Hermansen SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188090.
   Higgins LH, 2009, BBA-BIOENERGETICS, V1787, P1433, DOI 10.1016/j.bbabio.2009.06.003.
   Hsu JY, 2017, FASEB J, V31, P4265, DOI 10.1096/fj.201700156R.
   Hua Q, 2020, THERANOSTICS, V10, P4762, DOI 10.7150/thno.43839.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Jia L, 2017, PROSTATE, V77, P1000, DOI 10.1002/pros.23356.
   Katayama Y, 2012, ONCOL LETT, V4, P817, DOI 10.3892/ol.2012.810.
   Kery M, 2019, NEOPLASMA, V66, P63, DOI 10.4149/neo\_2018\_180531N357.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373.
   Kroiss A, 2015, ONCOGENE, V34, P2846, DOI 10.1038/onc.2014.222.
   Larsen AC, 2016, INVEST OPHTH VIS SCI, V57, P4205, DOI 10.1167/iovs.16-19862.
   Liu SY, 2020, ANIM CELLS SYST, V24, P220, DOI 10.1080/19768354.2020.1784274.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212.
   Malhotra P, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5010027.
   Matin F, 2016, CLIN CHEM, V62, P1318, DOI 10.1373/clinchem.2015.242800.
   Mating F, 2019, CLIN CHEM, V65, P771, DOI 10.1373/clinchem.2018.295824.
   Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029.
   Pedroza-Torres A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01404.
   Peng F, 2018, ONCOGENE, V37, P1119, DOI 10.1038/onc.2017.407.
   Pertega-Gomes N, 2015, J PATHOL, V236, P517, DOI 10.1002/path.4547.
   Schwartz L, 2017, ANTI-CANCER AGENT ME, V17, P164, DOI 10.2174/1871520616666161031143301.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Si WG, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-018-0587-8.
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI {[}10.3322/caac.21442, 10.3322/caac.21551].
   Siu MKY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0209-0.
   Sradhanjali S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177744.
   Stegeman S, 2015, CANCER DISCOV, V5, P368, DOI 10.1158/2159-8290.CD-14-1057.
   Subramaniam S, 2019, CLIN CHEM, V65, P1090, DOI 10.1373/clinchem.2018.299651.
   Testa C, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00225.
   Wang JH, 2019, CANCER MANAG RES, V11, P251, DOI 10.2147/CMAR.S185015.
   Weng ML, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15795-8.
   Xiang LS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1291-5.
   Xu JY, 2019, THERANOSTICS, V9, P2999, DOI 10.7150/thno.31301.
   Xu LF, 2019, ENDOCR-RELAT CANCER, V26, P59, DOI 10.1530/ERC-18-0196.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.},
Number-of-Cited-References = {46},
Times-Cited = {16},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {TN9JU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000676542900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000678072200001,
Author = {Brindisi, Matteo and Frattaruolo, Luca and Mancuso, Raffaella and
   Piccionello, Antonio Palumbo and Ziccarelli, Ida and Catto, Marco and
   Nicolotti, Orazio and Altomare, Cosimo D. and Gabriele, Bartolo and
   Cappello, Anna Rita},
Title = {Anticancer potential of novel α,β-unsaturated γ-lactam derivatives
   targeting the PI3K/AKT signaling pathway},
Journal = {BIOCHEMICAL PHARMACOLOGY},
Year = {2021},
Volume = {190},
Month = {AUG},
Abstract = {Six recently synthesized alkyl (Z)-2-(2-oxopyrrolidin-3-ylidene)acetates
   were evaluated for their potential as cytotoxic and anticancer agents.
   All compounds were tested in the ER alpha positive MCF-7, triple
   negative MDA-MB-231, and Her2(+) SKBR-3 breast cancer cell lines. The
   most lipophilic derivatives, bearing the 4-isopropylphenyl (2) or
   4-tert-butylphenyl (3) group at the gamma-lactam nitrogen, proved to be
   cytotoxic against all the cancer cell lines tested (IC50 values ranging
   from 18 to 63 mu M), exerting their greatest activity in SKBR-3 cells,
   with IC50 values of 33 and 18 mu M, respectively. Biological studies
   showed that the cytotoxic effects of 2 and 3 are accompanied by
   apoptotic death in breast cancer cells, and both compounds showed no
   significant toxicity on healthy cells (e.g., MCF-10A) and red blood
   cells. An in-depth mechanistic study based on molecular biology,
   immunoblotting analysis and in silico docking calculations suggested
   that alpha,beta-unsaturated gamma-lactam derivatives could interfere
   with the functioning of PI3K and PDK-1, two key enzymes in the PI3K/AKT
   signaling pathway, whose overactivation is related to the regulation of
   cell growth and survival in several malignancies.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Cappello, AR (Corresponding Author), Univ Calabria, Dept Pharm Hlth \& Nutr Sci, Via P Bucci, I-87036 Arcavacata Di Rende, CS, Italy.
   Altomare, CD (Corresponding Author), Univ Bari Aldo Moro, Dept Pharm Pharmaceut Sci, Via E Orabona 4, I-70126 Bari, Italy.
   Brindisi, Matteo; Frattaruolo, Luca; Cappello, Anna Rita, Univ Calabria, Dept Pharm Hlth \& Nutr Sci, Via P Bucci, I-87036 Arcavacata Di Rende, CS, Italy.
   Mancuso, Raffaella; Ziccarelli, Ida; Gabriele, Bartolo, Univ Calabria, Dept Chem \& Chem Technol, Lab Ind \& Synthet Organ Chem LISOC, Via Pietro Bucci 12-C, I-87036 Arcavacata Di Rende, CS, Italy.
   Piccionello, Antonio Palumbo, Univ Palermo, Dept Biol Chem \& Pharmaceut Sci \& Technol STEBICE, Viale Sci Ed17, I-90128 Palermo, Italy.
   Catto, Marco; Nicolotti, Orazio; Altomare, Cosimo D., Univ Bari Aldo Moro, Dept Pharm Pharmaceut Sci, Via E Orabona 4, I-70126 Bari, Italy.},
DOI = {10.1016/j.bcp.2021.114659},
EarlyAccessDate = {JUN 2021},
Article-Number = {114659},
ISSN = {0006-2952},
EISSN = {1873-2968},
Keywords = {alpha,beta-Unsaturated lactams; alpha-Methylene-gamma-lactams; Breast
   cancer; Cytotoxicity; Apoptosis; PI3K/AKT signaling pathway},
Keywords-Plus = {PI3K/MTOR INHIBITORS; PI3K-AKT PATHWAY; CANCER; ALPHA; GSK2126458;
   NVP-BEZ235; DISCOVERY; NVP-BYL719; METASTASES; MUTATIONS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {cosimodamiano.altomare@uniba.it
   annarita.cappello@unical.it},
Affiliations = {University of Calabria; University of Calabria; University of Palermo;
   Universita degli Studi di Bari Aldo Moro},
ResearcherID-Numbers = {ZICCARELLI, IDA/JBS-6452-2023
   Palumbo Piccionello, Antonio/V-6634-2017
   Brindisi, Matteo/AAG-4675-2019
   cappello, anna rita/AAE-2766-2020
   Frattaruolo, Luca/AAG-3132-2019
   Nicolotti, Orazio/F-3209-2012
   Gabriele, Bartolo/L-4480-2016},
ORCID-Numbers = {ZICCARELLI, IDA/0000-0003-3591-0787
   CATTO, Marco/0000-0002-8411-304X
   Palumbo Piccionello, Antonio/0000-0003-4402-5798
   Mancuso, Raffaella/0000-0001-7514-6096
   Brindisi, Matteo/0000-0002-5022-9642
   cappello, anna rita/0000-0001-7824-3561
   Frattaruolo, Luca/0000-0002-7018-8454
   },
Funding-Acknowledgement = {Italian Ministry of Education, Universities and Research (PRIN)
   {[}201744BNST\_004]; 4FRAILTY e Sensoristica intelligente,
   infrastrutture e modelli gestionali per la sicurezza di oggetti fragili
   {[}ARS01\_00345]},
Funding-Text = {C.D.A. and M.C. acknowledge the financial support of the Italian
   Ministry of Education, Universities and Research (PRIN, Grant
   201744BNST\_004) . O.N. acknowledges the ``4FRAILTY e Sensoristica
   intelligente, infrastrutture e modelli gestionali per la sicurezza di
   oggetti fragili{''}, codex ARS01\_00345.},
Cited-References = {Albrecht A, 2008, BIOORGAN MED CHEM, V16, P4872, DOI 10.1016/j.bmc.2008.03.035.
   André F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904.
   Armentano B, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8020035.
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292.
   Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808.
   Bhat-Nakshatri P, 2016, CANCER RES, V76, P3989, DOI 10.1158/0008-5472.CAN-15-3174.
   Bonesi M, 2018, BIOMED PHARMACOTHER, V107, P967, DOI 10.1016/j.biopha.2018.08.090.
   BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1.
   Brindisi M., 2020, CELLS-BASEL, V9.
   Brindisi M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10020311.
   CARDELLINA JH, 1979, TETRAHEDRON LETT, P2007.
   Casaburi I, 2015, ONCOTARGET, V6, P25135, DOI 10.18632/oncotarget.4722.
   Cavalluzzi MM, 2017, EXPERT OPIN DRUG DIS, V12, P1087, DOI 10.1080/17460441.2017.1365056.
   Chimento A, 2012, MOL CELL ENDOCRINOL, V355, P49, DOI 10.1016/j.mce.2012.01.017.
   Chyuan IT, 2021, CANCERS, V13, DOI 10.3390/cancers13061188.
   Ciccone A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005208.pub3.
   De Marco R, 2016, CURR TOP MED CHEM, V16, P343, DOI 10.2174/1568026615666150812121614.
   Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x.
   Dodou HV, 2020, NAT PROD RES, V34, P3414, DOI 10.1080/14786419.2019.1569654.
   Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Filomena P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e01366.
   Fiorillo M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061529.
   Frattaruolo L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176014.
   Friberg S, 2015, CANCER GROWTH METAST, V8, P43, DOI 10.4137/CGM.S31244.
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o.
   Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865.
   Fu J, NOVEL DIHYDROISOXAZO.
   Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007.
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hao J, 2014, J CELL PHYSIOL, V229, P266, DOI 10.1002/jcp.24455.
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902.
   HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L.
   IKUTA H, 1987, J MED CHEM, V30, P1995, DOI 10.1021/jm00394a011.
   Islam I, 2007, BIOORG MED CHEM LETT, V17, P3814, DOI 10.1016/j.bmcl.2007.04.071.
   Jackson PA, 2017, J MED CHEM, V60, P839, DOI 10.1021/acs.jmedchem.6b00788.
   Janecki T, 2005, J MED CHEM, V48, P3516, DOI 10.1021/jm048970a.
   Knight SD, 2010, ACS MED CHEM LETT, V1, P39, DOI 10.1021/ml900028r.
   Leung E, 2011, CANCER BIOL THER, V11, P938, DOI 10.4161/cbt.11.11.15527.
   Li Y, 2018, J BIOCHEM, V164, P313, DOI 10.1093/jb/mvy054.
   Liu TX, 2015, MOL CANCER THER, V14, P429, DOI 10.1158/1535-7163.MCT-14-0548.
   Liu Z, 2015, J CELL BIOCHEM, V116, P1341, DOI 10.1002/jcb.25091.
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017.
   Majidinia M, 2020, IUBMB LIFE, V72, P855, DOI 10.1002/iub.2215.
   Mancuso R, 2021, CATALYSTS, V11, DOI 10.3390/catal11020227.
   Mazzotta S, 2020, FUTURE MED CHEM, V12, P5, DOI 10.4155/fmc-2019-0234.
   NAITO T, 1993, CHEM PHARM BULL, V41, P217.
   Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740.
   Onishi K, 2007, GENES CELLS, V12, P535, DOI 10.1111/j.1365-2443.2007.01071.x.
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd.
   Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597.
   Ruiz-Saenz A, 2018, CANCER RES, V78, P3645, DOI 10.1158/0008-5472.CAN-18-0430.
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502.
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8.
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385.
   Siddiqui TI, 2013, CURR MED CHEM, V20, P2779, DOI 10.2174/0929867311320220004.
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254.
   Tsai Ming-Ju, 2014, ISRN Biochem, V2014, P351959, DOI 10.1155/2014/351959.
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007.
   Xi JL, 2013, MOL CANCER RES, V11, P856, DOI 10.1158/1541-7786.MCR-12-0177.},
Number-of-Cited-References = {61},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Biochem. Pharmacol.},
Doc-Delivery-Number = {TQ1UK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000678072200001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000664784700001,
Author = {Jane, Esther P. and Premkumar, Daniel R. and Rajasundaram, Dhivyaa and
   Thambireddy, Swetha and Reslink, Matthew C. and Agnihotri, Sameer and
   Pollack, Ian F.},
Title = {Reversing tozasertib resistance in glioma through inhibition of pyruvate
   dehydrogenase kinases},
Journal = {MOLECULAR ONCOLOGY},
Year = {2022},
Volume = {16},
Number = {1},
Pages = {219-249},
Month = {JAN},
Abstract = {Acquired resistance to conventional chemotherapeutic agents limits their
   effectiveness and can cause cancer treatment to fail. Because enzymes in
   the aurora kinase family are vital regulators of several mitotic events,
   we reasoned that targeting these kinases with tozasertib, a pan-aurora
   kinase inhibitor, would not only cause cytokinesis defects, but also
   induce cell death in high-grade pediatric and adult glioma cell lines.
   We found that tozasertib induced cell cycle arrest, increased
   mitochondrial permeability and reactive oxygen species generation,
   inhibited cell growth and migration, and promoted cellular senescence
   and pro-apoptotic activity. However, sustained exposure to tozasertib at
   clinically relevant concentrations conferred resistance, which led us to
   examine the mechanistic basis for the emergence of drug resistance.
   RNA-sequence analysis revealed a significant upregulation of the gene
   encoding pyruvate dehydrogenase kinase isoenzyme 4 (PDK4), a pyruvate
   dehydrogenase (PDH) inhibitory kinase that plays a crucial role in the
   control of metabolic flexibility under various physiological conditions.
   Upregulation of PDK1, PDK2, PDK3, or PDK4 protein levels was positively
   correlated with tozasertib-induced resistance through inhibition of PDH
   activity. Tozasertib-resistant cells exhibited increased mitochondrial
   mass as measured by 10-N-nonyl-Acridine Orange. Inhibition of PDK with
   dichloroacetate resulted in increased mitochondrial permeability and
   cell death in tozasertib-resistant glioma cell lines. Based on these
   results, we believe that PDK is a selective target for the tozasertib
   resistance phenotype and should be considered for further preclinical
   evaluations.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Premkumar, DR (Corresponding Author), Univ Pittsburgh, Sch Med, Dept Neurol Surg, 530 45th St, Pittsburgh, PA 15201 USA.
   Jane, Esther P.; Premkumar, Daniel R.; Thambireddy, Swetha; Reslink, Matthew C.; Agnihotri, Sameer; Pollack, Ian F., Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15260 USA.
   Premkumar, Daniel R.; Agnihotri, Sameer; Pollack, Ian F., UPMC Hillman Canc Ctr, Dept Neurosurg, Pittsburgh, PA USA.
   Rajasundaram, Dhivyaa, Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA.},
DOI = {10.1002/1878-0261.13025},
EarlyAccessDate = {JUN 2021},
ISSN = {1574-7891},
EISSN = {1878-0261},
Keywords = {aurora kinase; glioma; pyruvate dehydrogenase kinase; resistance;
   tozasertib},
Keywords-Plus = {SMALL-MOLECULE INHIBITORS; EPITHELIAL CANCER-CELLS; AURORA-B KINASE;
   MITOCHONDRIAL BIOGENESIS; MALIGNANT GLIOMA; DRUG-RESISTANCE;
   OXIDATIVE-PHOSPHORYLATION; CENTROSOME AMPLIFICATION; DICHLOROACETATE
   DCA; THERAPEUTIC TARGET},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {daniel.premkumar@chp.edu},
Affiliations = {Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh},
ResearcherID-Numbers = {AGNIHOTRI, SAMEER/HHS-2255-2022},
ORCID-Numbers = {Premkumar, Daniel/0000-0001-6885-0632
   AGNIHOTRI, SAMEER/0000-0001-6584-3795},
Funding-Acknowledgement = {Connor's Cure Foundation Fund; Translational Brain Tumor Research Fund;
   Scientific Program Fund of the Children's Hospital of Pittsburgh
   Foundation},
Funding-Text = {The authors thank Alexis Styche for FACS analysis. The computational
   analysis was performed using the high-performance cluster hosted by the
   Center for Research Computing, University of Pittsburgh. This work was
   supported by the Connor's Cure Foundation Fund, the Translational Brain
   Tumor Research Fund, and the Scientific Program Fund of the Children's
   Hospital of Pittsburgh Foundation (all to IFP).},
Cited-References = {Adeva M, 2013, MITOCHONDRION, V13, P615, DOI 10.1016/j.mito.2013.08.011.
   Alafate W, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152617.
   Alafate W, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152557.
   Aldape K, 2019, NAT REV CLIN ONCOL, V16, P509, DOI 10.1038/s41571-019-0177-5.
   Attia RR, 2010, J BIOL CHEM, V285, P2375, DOI 10.1074/jbc.M109.039081.
   Bebbington D, 2009, BIOORG MED CHEM LETT, V19, P3586, DOI 10.1016/j.bmcl.2009.04.136.
   Bindokas VP, 1996, J NEUROSCI, V16, P1324.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Boss DS, 2011, ANN ONCOL, V22, P431, DOI 10.1093/annonc/mdq344.
   Buczkowicz P, 2013, BRAIN PATHOL, V23, P244, DOI 10.1111/j.1750-3639.2012.00633.x.
   Buondonno I, 2016, MOL CANCER THER, V15, P2640, DOI 10.1158/1535-7163.MCT-16-0048.
   Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788.
   Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245.
   CARTER WO, 1994, J LEUKOCYTE BIOL, V55, P253.
   Chen Hong-Chen, 2005, Methods Mol Biol, V294, P15.
   Cheung CHA, 2009, EXPERT OPIN INV DRUG, V18, P379, DOI {[}10.1517/13543780902806392, 10.1517/13543780902806392 ].
   Cho MG, 2017, FREE RADICAL BIO MED, V108, P129, DOI 10.1016/j.freeradbiomed.2017.03.025.
   Choiniere J, 2017, MOL PHARMACOL, V91, P189, DOI 10.1124/mol.116.106757.
   Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189.
   Day SE, 2012, NEUROSURG CLIN N AM, V23, P407, DOI 10.1016/j.nec.2012.04.004.
   Demoe JH, 2009, CANCER RES, V69, P1509, DOI 10.1158/0008-5472.CAN-08-3133.
   Deng YH, 2018, EXP CELL RES, V373, P171, DOI 10.1016/j.yexcr.2018.10.010.
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025.
   Dixit D, 2016, EXP CELL RES, V344, P132, DOI 10.1016/j.yexcr.2016.03.017.
   Doherty Edward, 2017, React Oxyg Species (Apex), V4, P275, DOI {[}10.20455/ros.2017.839, 10.20455/ros.2017.839].
   Dreier MR, 2009, EXP CELL RES, V315, P1085, DOI 10.1016/j.yexcr.2009.02.008.
   ERBRICH U, 1984, HISTOCHEMISTRY, V80, P385, DOI 10.1007/BF00495422.
   Falchook GS, 2015, SEMIN ONCOL, V42, P832, DOI 10.1053/j.seminoncol.2015.09.022.
   Favre C, 2010, ONCOGENE, V29, P3964, DOI 10.1038/onc.2010.146.
   Fu JY, 2007, MOL CANCER RES, V5, P1, DOI 10.1158/1541-7786.MCR-06-0208.
   Giles FJ, 2013, LEUKEMIA, V27, P113, DOI 10.1038/leu.2012.186.
   Girdler F, 2008, CHEM BIOL, V15, P552, DOI 10.1016/j.chembiol.2008.04.013.
   Goepfert TM, 2002, CANCER RES, V62, P4115.
   Guevara EL, 2017, SCI REP-UK, V7, DOI 10.1038/srep42760.
   Guidot DM, 1998, ARCH BIOCHEM BIOPHYS, V354, P9, DOI 10.1006/abbi.1998.0699.
   Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hou DS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0823-3.
   Hsieh CH, 2019, J PROTEOME RES, V18, P3850, DOI 10.1021/acs.jproteome.9b00245.
   Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200.
   Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818.
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776.
   Jane EP, 2006, J PHARMACOL EXP THER, V319, P1070, DOI 10.1124/jpet.106.108621.
   Jane EP, 2020, MOL CANCER RES, V18, P1004, DOI 10.1158/1541-7786.MCR-19-0669.
   Jane EP, 2016, J PHARMACOL EXP THER, V356, P354, DOI 10.1124/jpet.115.230052.
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57.
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005.
   Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502.
   Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907.
   Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38.
   Lee D, 2019, J MED CHEM, V62, P575, DOI 10.1021/acs.jmedchem.8b01168.
   Lee ECY, 2006, CANCER RES, V66, P4996, DOI 10.1158/0008-5472.CAN-05-2796.
   Li ML, 2010, BIOCHEM PHARMACOL, V79, P122, DOI 10.1016/j.bcp.2009.08.011.
   Li N, 2015, MOL CANCER THER, V14, P419, DOI 10.1158/1535-7163.MCT-14-0526.
   Liang Yi-Qiong, 2009, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V17, P810.
   Lin YG, 2008, CLIN CANCER RES, V14, P5437, DOI 10.1158/1078-0432.CCR-07-4922.
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8.
   Matulonis UA, 2012, GYNECOL ONCOL, V127, P63, DOI 10.1016/j.ygyno.2012.06.040.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Meulenbeld HJ, 2012, EXPERT OPIN INV DRUG, V21, P383, DOI 10.1517/13543784.2012.652303.
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Mills CC, 2017, CANCER RES, V77, P6489, DOI 10.1158/0008-5472.CAN-17-2066.
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180.
   Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2.
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138.
   PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x.
   Polewski MD, 2016, MOL CANCER RES, V14, P1229, DOI 10.1158/1541-7786.MCR-16-0028.
   Premkumar DR, 2018, MOL CARCINOGEN, V57, P469, DOI 10.1002/mc.22771.
   Qin YJ, 2020, J CANCER, V11, P4397, DOI 10.7150/jca.43459.
   Rajagopalan KN, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0134-4.
   ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440.
   Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3.
   Salem AF, 2012, CELL CYCLE, V11, P4174, DOI 10.4161/cc.22376.
   Sasai K, 2004, CELL MOTIL CYTOSKEL, V59, P249, DOI 10.1002/cm.20039.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Scutt PJ, 2009, J BIOL CHEM, V284, P15880, DOI 10.1074/jbc.M109.005694.
   Seymour JF, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.60.
   Sloane DA, 2010, ACS CHEM BIOL, V5, P563, DOI 10.1021/cb100053q.
   SMITH DR, 1969, J NEUROSURG, V31, P50, DOI 10.3171/jns.1969.31.1.0050.
   Sotgia F, 2012, CELL CYCLE, V11, P4390, DOI 10.4161/cc.22777.
   Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184.
   Sun H, 2017, ONCOTARGET, V8, P52642, DOI 10.18632/oncotarget.16991.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079.
   Traynor AM, 2011, CANCER CHEMOTH PHARM, V67, P305, DOI 10.1007/s00280-010-1318-9.
   Vellinga TT, 2015, CLIN CANCER RES, V21, P2870, DOI 10.1158/1078-0432.CCR-14-2290.
   Wang JH, 2019, CANCER MANAG RES, V11, P251, DOI 10.2147/CMAR.S185015.
   Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038.
   Woolbright BL, 2019, MOL CANCER THER, V18, P1673, DOI 10.1158/1535-7163.MCT-19-0079.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Wu CY, 2020, ENDOCR-RELAT CANCER, V27, P583, DOI 10.1530/ERC-20-0293.
   Yang C, 2019, J CELL PHYSIOL, V234, P17727, DOI 10.1002/jcp.28398.
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118.
   Yuan CX, 2015, DRUG DES DEV THER, V9, P1293, DOI 10.2147/DDDT.S74964.
   Yuan CX, 2015, DRUG DES DEV THER, V9, P487, DOI 10.2147/DDDT.S74127.
   Zekri A, 2017, ANTI-CANCER DRUG, V28, P841, DOI 10.1097/CAD.0000000000000523.
   Zhang G, 2016, J CLIN INVEST, V126, P1834, DOI 10.1172/JCI82661.
   Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496.
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110.},
Number-of-Cited-References = {101},
Times-Cited = {21},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Mol. Oncol.},
Doc-Delivery-Number = {YB5LQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000664784700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000731850300018,
Author = {Suryawan, Agus and El-Kadi, Samer W. and Nguyen, V, Hanh and Fiorotto,
   Marta L. and Davis, Teresa A.},
Title = {Intermittent Bolus Compared With Continuous Feeding Enhances Insulin and
   Amino Acid Signaling to Translation Initiation in Skeletal Muscle of
   Neonatal Pigs},
Journal = {JOURNAL OF NUTRITION},
Year = {2021},
Volume = {151},
Number = {9},
Pages = {2636-2645},
Month = {SEP},
Abstract = {Background: Nutrition administered as intermittent bolus feeds rather
   than continuously promotes greater protein synthesis rates in skeletal
   muscle and enhances lean growth in a neonatal piglet model. The
   molecular mechanisms responsible remain unclear.
   Objectives: We aimed to identify the insulin- and/or amino
   acid-signaling components involved in the enhanced stimulation of
   skeletal muscle by intermittent bolus compared to continuous feeding in
   neonatal pigs born at term.
   Methods: Term piglets (2-3 days old) were fed equal amounts of sow milk
   replacer (12.8 g protein and 155 kcal/(kg body weight.d)) by orogastric
   tube as intermittent bolus meals every 4 hours (INT) or by continuous
   infusion (CTS). After 21 days, gastrocnemius muscle samples were
   collected from CTS, INT-0 (before a meal), and INT-60 (60 minutes after
   a meal) groups (n = 6/group). Insulin- and amino acid-signaling
   components relevant to mechanistic target of rapamycin complex (mTORC) 1
   activation and protein translation were measured.
   Results: Phosphorylation of the insulin receptor, IRS-1, PDK1, mTORC2,
   pan-Akt, Akt1, Akt2, and TSC2 was 106\% to 273\% higher in the skeletal
   muscle of INT-60 piglets than in INT-0 and CTS piglets (P < 0.05), but
   phosphorylation of PTEN, PP2A, Akt3, ERK1/2, and AMPK did not differ
   among groups, nor did abundances of PHLPP SHIP2, and Ubl4A. The
   association of GATOR2 with Sestrin1/2, but not CASTOR1, was 51\% to 52\%
   lower in INT-60 piglets than in INT-0 and CTS piglets (P < 0.05), but
   the abundances of SLC7A5/LAT1, SLC38A2/SNAT2, SLC38A9, Lamtor1/2, and
   V-ATPase did not differ. Associations of mTOR with RagA, RagC, and Rheb
   and phosphorylation of S6K1 and 4EBP1, but not eIF2 alpha and eEF2, were
   101\% to 176\% higher in INT-60 piglets than in INT-0 and CTS piglets (P
   < 0.05).
   Conclusions: The enhanced rates of muscle protein synthesis and growth
   with intermittent bolus compared to continuous feeding in a neonatal
   piglet model can be explained by enhanced activation of both the
   insulin- and amino acid-signaling pathways that regulate translation
   initiation.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Davis, TA (Corresponding Author), Baylor Coll Med, ARS, IUSDA, Childrens Nutr Res Ctr,Dept Pediat, Houston, TX 77030 USA.
   Suryawan, Agus; Nguyen, Hanh, V; Fiorotto, Marta L.; Davis, Teresa A., Baylor Coll Med, ARS, IUSDA, Childrens Nutr Res Ctr,Dept Pediat, Houston, TX 77030 USA.
   El-Kadi, Samer W., Virginia Tech, Dept Anim \& Poultry Sci, Blacksburg, VA USA.},
DOI = {10.1093/jn/nxab190},
EarlyAccessDate = {JUN 2021},
ISSN = {0022-3166},
EISSN = {1541-6100},
Keywords = {neonate; insulin; amino acids; skeletal muscle; translation initiation},
Keywords-Plus = {PROTEIN-SYNTHESIS; MTOR; METABOLISM; GROWTH; AKT; STIMULATION;
   RAPAMYCIN; GLYCINE; PDK1},
Research-Areas = {Nutrition \& Dietetics},
Web-of-Science-Categories  = {Nutrition \& Dietetics},
Author-Email = {tdavis@bcm.edu},
Affiliations = {Baylor College of Medicine; Virginia Polytechnic Institute \& State
   University},
ResearcherID-Numbers = {El-Kadi, Samer/R-6040-2019},
Funding-Acknowledgement = {National Institute of Arthritis and Musculoskeletal and Skin Diseases
   {[}AR044474, AR46308]; National Institute of Child Health and Human
   Development {[}HD072891, HD085573, HD099080]; USDA National Institute of
   Agriculture {[}2013-67015-20438]; USDA/Agricultural Research Service
   {[}3092-51000-060]; NIFA {[}577883, 2013-67015-20438] Funding Source:
   Federal RePORTER; Eunice Kennedy Shriver National Institute of Child
   Health and Human Development {[}R01HD099080] Funding Source: NIH
   RePORTER},
Funding-Text = {Supported by National Institute of Arthritis and Musculoskeletal and
   Skin Diseases grants AR044474 (to TAD) and AR46308 (toMLF), National
   Institute of Child Health and Human Development grants HD072891 (to
   TAD), HD085573 (to TAD), and HD099080 (to TAD and MLF), USDA National
   Institute of Agriculture grant 2013-67015-20438 (to TAD), and by the
   USDA/Agricultural Research Service under Cooperative Agreement no.
   3092-51000-060 (to TAD).},
Cited-References = {Abou Sawan S, 2018, PHYSIOL REP, V6, P1.
   Barone G, 2013, ITAL J PEDIATR, V39, DOI 10.1186/1824-7288-39-28.
   Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810.
   Bozzetti Valentina, 2017, Pediatr Med Chir, V39, P159, DOI {[}10.4081/pmc.2017.159, 10.4081/pmc.2017.159].
   Davis TA, 2002, AM J PHYSIOL-ENDOC M, V282, pE880, DOI 10.1152/ajpendo.00517.2001.
   Davis TA, 2000, AM J PHYSIOL-ENDOC M, V279, pE1226, DOI 10.1152/ajpendo.2000.279.6.E1226.
   Davis TA, 2015, CURR OPIN CLIN NUTR, V18, P102, DOI 10.1097/MCO.0000000000000128.
   Davis TA, 2009, CURR OPIN CLIN NUTR, V12, P78, DOI 10.1097/MCO.0b013e32831cef9f.
   Dibble CC, 2015, TRENDS CELL BIOL, V25, P545, DOI 10.1016/j.tcb.2015.06.002.
   El-Kadi SW, 2020, CURR DEV NUTR, V4, DOI 10.1093/cdn/nzaa170.
   El-Kadi SW, 2018, AM J CLIN NUTR, V108, P830, DOI 10.1093/ajcn/nqy133.
   El-Kadi SW, 2012, AM J PHYSIOL-ENDOC M, V302, pE674, DOI 10.1152/ajpendo.00516.2011.
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008.
   Gazzaneo MC, 2011, PEDIATR RES, V70, P253, DOI 10.1203/PDR.0b013e3182276cfa.
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335.
   Groenewoud MJ, 2013, BIOCHEM SOC T, V41, P951, DOI 10.1042/BST20130037.
   Gu X, 2017, SCIENCE, V358, P813, DOI 10.1126/science.aao3265.
   Haddadi N, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0803-3.
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704.
   Kagawa S, 2008, ENDOCRINOLOGY, V149, P642, DOI 10.1210/en.2007-0820.
   Kido Y, 2001, J CLIN ENDOCR METAB, V86, P972, DOI 10.1210/jc.86.3.972.
   Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1.
   Lau C, 2015, ANN NUTR METAB, V66, P7, DOI 10.1159/000381361.
   Meng DL, 2020, J BIOL CHEM, V295, P2890, DOI 10.1074/jbc.AC119.011578.
   Miyazaki M, 2017, FEBS OPEN BIO, V7, P424, DOI 10.1002/2211-5463.12195.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Naberhuis JK, 2019, AM J PHYSIOL-ENDOC M, V317, pE839, DOI 10.1152/ajpendo.00151.2019.
   O'Connor PMJ, 2003, AM J PHYSIOL-ENDOC M, V284, pE110, DOI 10.1152/ajpendo.00326.2002.
   Obanda DN, 2016, SCI REP-UK, V6, DOI 10.1038/srep22222.
   Pinilla Jorge, 2011, Front Biosci (Elite Ed), V3, P1289.
   Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213.
   Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107.
   Robinson JL, 2016, ADV NUTR, V7, P523, DOI 10.3945/an.115.010843.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Schwarzenberg SJ, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-3716.
   Soliman GA, 2010, J BIOL CHEM, V285, P7866, DOI 10.1074/jbc.M109.096222.
   Sun KJ, 2016, J NUTR, V146, P2461, DOI 10.3945/jn.116.231266.
   Suryawan A, 2007, AM J PHYSIOL-ENDOC M, V293, pE1597, DOI 10.1152/ajpendo.00307.2007.
   Suryawan A, 2018, J NUTR, V148, P825, DOI 10.1093/jn/nxy044.
   Wang WW, 2014, AMINO ACIDS, V46, P2037, DOI 10.1007/s00726-014-1758-3.
   Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006.
   Wilson FA, 2009, J NUTR, V139, P1873, DOI 10.3945/jn.109.106781.
   Wolfson RL, 2017, CELL METAB, V26, P301, DOI 10.1016/j.cmet.2017.07.001.
   Wu GY, 2009, AMINO ACIDS, V37, P1, DOI 10.1007/s00726-009-0269-0.
   Xu DD, 2019, AM J PHYSIOL-ENDOC M, V316, pE817, DOI 10.1152/ajpendo.00522.2018.
   Yang ZZ, 2005, MOL CELL BIOL, V25, P10407, DOI 10.1128/MCB.25.23.10407-10418.2005.
   Yao K, 2008, J NUTR, V138, P867, DOI 10.1093/jn/138.5.867.
   Yoon MS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111176.
   Zeng N, 2019, J NUTR HEALTH AGING, V23, P354, DOI 10.1007/s12603-019-1171-4.
   Zhao Y, 2015, P NATL ACAD SCI USA, V112, P9644, DOI 10.1073/pnas.1508647112.
   Zheng LF, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101636.},
Number-of-Cited-References = {51},
Times-Cited = {2},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {J. Nutr.},
Doc-Delivery-Number = {XQ9HA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000731850300018},
OA = {Green Accepted, Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000663679100001,
Author = {Azuma, Maho and Ogata, Tsubasa and Yamazoe, Kanta and Tanaka, Yuri and
   Inoue, Yoshihiro H.},
Title = {Heat shock cognate 70 genes contribute to Drosophila
   spermatocyte growth progression possibly through the insulin signaling
   pathway},
Journal = {DEVELOPMENT GROWTH \& DIFFERENTIATION},
Year = {2021},
Volume = {63},
Number = {4-5},
Pages = {231-248},
Month = {MAY},
Abstract = {Drosophila spermatocytes grow up to 25 times their original volume
   before the onset of male meiosis. Several insulin-like peptides and
   their cognate receptors (InR) are essential for the cell growth process
   in Drosophila. Here, we aimed to identify additional signaling pathways
   and other regulatory factors required for germline cell growth in
   Drosophila males. Spermatocyte-specific expression of the
   dominant-negative form of InR inhibits cell growth. Conversely,
   constitutively active forms of signaling factors downstream of InR
   suppress growth inhibition. Furthermore, hypomorphic mutations in the
   target of rapamycin (Tor) inhibit spermatocyte growth. These data
   indicate that the insulin/TOR pathway is essential for the growth of
   premeiotic spermatocytes. RNA interference (RNAi) screening for the
   identification of other novel genes associated with cell growth showed
   that the silencing of each of the five members of heat shock cognate 70
   (Hsc70) genes significantly inhibited the process. Hsc70-silenced
   spermatocytes showed Akt inhibition downstream of the insulin signaling
   pathway. Our pleckstrin homology domain- green fluorescent protein
   (PH-GFP) reporter studies indicated that PI3K remained activated in
   Hsc70-4-silenced cells, suggesting that the Hsc70-4 protein possibly
   targets Akt or Pdk1 acting downstream of PI3K. Moreover, each of the
   Hsc70 proteins showed different subcellular localizations. Hsc70-2
   exhibited cytoplasmic colocalization with Akt in spermatocytes before
   nuclear entry of the kinase during the growth phase. These results
   indicated the involvement of Hsc70 proteins in the activation of various
   steps in the insulin signaling pathway, which is essential for
   spermatocyte growth. Our findings provide insights into the mechanism(s)
   that enhance signal transduction to stimulate the growth of Drosophila
   spermatocytes.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Inoue, YH (Corresponding Author), Kyoto Inst Technol, Insect Biomed Res Ctr, Sakyo Ku, Kyoto 6060962, Japan.
   Azuma, Maho; Ogata, Tsubasa; Yamazoe, Kanta; Tanaka, Yuri; Inoue, Yoshihiro H., Kyoto Inst Technol, Res Ctr Insect Adv Studies, Dept Insect Biomed Res, Kyoto, Japan.},
DOI = {10.1111/dgd.12734},
EarlyAccessDate = {JUN 2021},
ISSN = {0012-1592},
EISSN = {1440-169X},
Keywords = {Akt; cell growth; Drosophila; Hsc70; spermatocyte},
Keywords-Plus = {CELL-GROWTH; ACTS DOWNSTREAM; HSP90; EXPRESSION; SIZE; AKT; PROTEINS;
   KINASE; IDENTIFICATION; PROLIFERATION},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {yhinoue@kit.ac.jp},
Affiliations = {Kyoto Institute of Technology},
ORCID-Numbers = {Inoue, Yoshihiro/0000-0002-0233-6726},
Funding-Acknowledgement = {Grants-in-Aid for Scientific Research {[}21K06277] Funding Source: KAKEN},
Cited-References = {Alvino CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027488.
   Basso AD, 2002, J BIOL CHEM, V277, P39858, DOI 10.1074/jbc.M206322200.
   BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629.
   Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X.
   Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9.
   Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6.
   Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9.
   CENCI G, 1994, J CELL SCI, V107, P3521.
   Chang HC, 2004, J CELL BIOL, V164, P1055, DOI 10.1083/jcb.200311084.
   Chen X, 2005, SCIENCE, V310, P869, DOI 10.1126/science.1118101.
   CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C.
   Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X.
   Colombani J, 2012, SCIENCE, V336, P582, DOI 10.1126/science.1216689.
   Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2.
   Daugaard M, 2007, FEBS LETT, V581, P3702, DOI {[}10.1016/j.febslet.2007.05.039, 10.1016/j.febsiet.2007.05.039].
   Dienstmann R, 2014, MOL CANCER THER, V13, P1021, DOI 10.1158/1535-7163.MCT-13-0639.
   Doyle SM, 2007, NAT STRUCT MOL BIOL, V14, P114, DOI 10.1038/nsmb1198.
   Easton DP, 2000, CELL STRESS CHAPERON, V5, P276, DOI 10.1379/1466-1268(2000)005<0276:THAGSP>2.0.CO;2.
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802.
   FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425.
   Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE.
   Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200.
   Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680.
   Garelli A, 2012, SCIENCE, V336, P579, DOI 10.1126/science.1216735.
   Goberdhan DCI, 2003, DIFFERENTIATION, V71, P375, DOI 10.1046/j.1432-0436.2003.7107001.x.
   Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086.
   Hayashi D, 2016, BIOL OPEN, V5, P1011, DOI 10.1242/bio.017566.
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222.
   Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6.
   Inoue YH, 2018, ADV EXP MED BIOL, V1076, P235, DOI 10.1007/978-981-13-0529-0\_13.
   Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255.
   Kafri R, 2009, CELL, V136, P389, DOI 10.1016/j.cell.2009.01.027.
   Kakanj P, 2020, NAT PROTOC, V15, P1158, DOI 10.1038/s41596-019-0282-z.
   Katsube H, 2019, BIOL OPEN, V8, DOI 10.1242/bio.046524.
   Kim MJ, 2006, EMBO J, V25, P3056, DOI 10.1038/sj.emboj.7601180.
   Krasilnikov MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P59.
   Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x.
   LINDQUIST S, 1975, P NATL ACAD SCI USA, V72, P1117, DOI 10.1073/pnas.72.3.1117.
   MIRAULT ME, 1977, COLD SPRING HARB SYM, V42, P819, DOI 10.1101/SQB.1978.042.01.082.
   Oka S, 2015, BIOGERONTOLOGY, V16, P485, DOI 10.1007/s10522-015-9570-3.
   Okazaki R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020270.
   Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9.
   Phelps CB, 1998, METHODS, V14, P367, DOI 10.1006/meth.1998.0592.
   Pircs K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044214.
   Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6.
   Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0.
   Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1.
   RUBIN DM, 1993, GENE, V128, P155, DOI 10.1016/0378-1119(93)90558-K.
   Rybczynski R, 2000, INSECT BIOCHEM MOLEC, V30, P579, DOI 10.1016/S0965-1748(00)00031-X.
   Ryoo HD, 2007, CELL CYCLE, V6, P830, DOI 10.4161/cc.6.7.4064.
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009.
   Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996.
   Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739.
   Siddle K, 2011, J MOL ENDOCRINOL, V47, pR1, DOI 10.1530/JME-11-0022.
   Sousa-Nunes R, 2011, NATURE, V471, P508, DOI 10.1038/nature09867.
   STANCATO LF, 1993, J BIOL CHEM, V268, P21711.
   Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995.
   Swan, 2012, MEIOSIS MOL MECH CYT.
   Tanabe K, 2019, CELL STRUCT FUNCT, V44, P121, DOI 10.1247/csf.19022.
   Tanabe K, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2225.
   Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809.
   TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9.
   Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002.
   Ueishi S, 2009, CELL STRUCT FUNCT, V34, P61, DOI 10.1247/csf.08042.
   vanderStraten A, 1997, EMBO J, V16, P1961, DOI 10.1093/emboj/16.8.1961.
   White-Cooper H, 1998, DEVELOPMENT, V125, P125.
   White-Cooper Helen, 2012, Spermatogenesis, V2, P11.
   WHITECOOPER H, 1993, J CELL SCI, V106, P1035.
   Yoon MS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111176.
   Yu J, 2016, DEVELOPMENT, V143, P2930, DOI 10.1242/dev.134247.
   Zhu JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083714.},
Number-of-Cited-References = {71},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Dev. Growth Diff.},
Doc-Delivery-Number = {TB2GB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000663679100001},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000671892200037,
Author = {Ogawa, Yuko and Saino, Orie and Okinaka, Yuka and Kikuchi-Taura, Akie
   and Takeuchi, Yukiko and Taguchi, Akihiko},
Title = {Bone Marrow Mononuclear Cells Transplantation and Training Increased
   Transplantation of Energy Source Transporters in Chronic Stroke},
Journal = {JOURNAL OF STROKE \& CEREBROVASCULAR DISEASES},
Year = {2021},
Volume = {30},
Number = {8},
Month = {AUG},
Abstract = {Objectives: Bone marrow mononuclear cells (BM-MNC) show a significant
   therapeutic effect in combination with training even in the chronic
   phase of stroke. However, the mechanism of this combination therapy has
   not been investigated. Here, we examined its effects on brain metabolism
   in chronic stroke mice. Materials and methods: BM-MNC (1x10(5) cells in
   100 mu L of phosphate-buffered saline) were intravenously transplanted
   at 4 weeks (chronic stage) after the middle cerebral artery occlusion.
   At 3 h and 10 weeks after the administration of BM-MNC, we evaluated
   transcription changes of the metabolism-related genes, hypoxia inducible
   factor 1-alpha (Hif-1 alpha), prolyl hydroxylase 3 (Phd3), pyruvate
   dehydrogenase kinase 1 (Pdk1), Na+/K+-ATPase (Atp1 alpha 1. 3),
   connexins, glucose transporters, and monocarboxylate transporters, in
   the brain during chronic phase of stroke using quantitative polymerase
   chain reaction. Results: The results showed transcriptional activation
   of the metabolism-related genes in the contralateral cortex at 3 h after
   BM-MNC transplantation. Behavioral tests were performed after cell
   therapy, and the brain metabolism of mice with improved motor function
   was examined at 10 weeks after cell therapy. The therapeutic efficacy of
   the combination therapy with BM-MNC transplantation and training was
   evident in the form of transcriptional activation of ipsilateral
   anterior cerebral artery (ACA) cortex. Conclusions: BM-MNC
   transplantation combined with training for chronic stroke activated gene
   expression in both the ipsilateral and the contralateral side.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Taguchi, A (Corresponding Author), Fdn Biomed Res \& Innovat, Dept Regenerat Med Res, Kobe, Hyogo, Japan.
   Ogawa, Yuko; Saino, Orie; Okinaka, Yuka; Kikuchi-Taura, Akie; Takeuchi, Yukiko; Taguchi, Akihiko, Fdn Biomed Res \& Innovat, Dept Regenerat Med Res, Kobe, Hyogo, Japan.},
DOI = {10.1016/j.jstrokecerebrovasdis.2021.105932},
EarlyAccessDate = {JUN 2021},
Article-Number = {105932},
ISSN = {1052-3057},
EISSN = {1532-8511},
Keywords = {Chronic stroke; Combination therapy; Bone marrow mononuclear cells;
   Training; Energy source transporter},
Keywords-Plus = {FUNCTIONAL RECOVERY; MOTOR RECOVERY; ANGIOGENESIS; HEMISPHERE},
Research-Areas = {Neurosciences \& Neurology; Cardiovascular System \& Cardiology},
Web-of-Science-Categories  = {Neurosciences; Peripheral Vascular Disease},
Author-Email = {taguchi@fbri.org},
Affiliations = {Institute for Biomedical Research \& Innovation (IBRI)},
ORCID-Numbers = {Ogawa, Yuko/0000-0002-5862-4436
   Okinaka, Yuka/0009-0002-3336-871X},
Funding-Acknowledgement = {Japan Agency for Medical Research and Development (AMED)
   {[}20bm0404069h0001]; JSPS KAKENHI {[}21427943]; Grants-in-Aid for
   Scientific Research {[}21K09194] Funding Source: KAKEN},
Funding-Text = {Japan Agency for Medical Research and Development (AMED) /Grant Number
   20bm0404069h0001, and JSPS KAKENHI/Grant Number 21427943.},
Cited-References = {Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004.
   Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6.
   Cao Y, 1998, STROKE, V29, P112, DOI 10.1161/01.STR.29.1.112.
   CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112.
   Gonzalez CLR, 2004, EUR J NEUROSCI, V20, P3442, DOI 10.1111/j.1460-9568.2004.03751.x.
   Howarth C, 2012, J CEREBR BLOOD F MET, V32, P1222, DOI 10.1038/jcbfm.2012.35.
   Ikeda S, 2013, EXCLI J, V12, P641.
   Kikuchi-Taura A, 2020, STROKE, V51, P1279, DOI 10.1161/STROKEAHA.119.028072.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454.
   Obi K, 2018, BRAIN RES, V1678, P146, DOI 10.1016/j.brainres.2017.10.022.
   Ogawa Y, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.535902.
   Okinaka Y, 2019, STROKE, V50, P2883, DOI 10.1161/STROKEAHA.119.026669.
   Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622.
   Taguchi A, 2015, STEM CELLS DEV, V24, P2207, DOI 10.1089/scd.2015.0160.
   Takatsuru Y, 2009, J NEUROSCI, V29, P10081, DOI 10.1523/JNEUROSCI.1638-09.2009.
   Takeuchi Y, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.00170.
   Ward N S, 2007, Eura Medicophys, V43, P285.
   Zorzano A, 2005, ACTA PHYSIOL SCAND, V183, P43, DOI 10.1111/j.1365-201X.2004.01380.x.},
Number-of-Cited-References = {19},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {J. Stroke Cerebrovasc. Dis.},
Doc-Delivery-Number = {TH1YK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000671892200037},
DA = {2026-02-04},
}

@article{ WOS:000668650100001,
Author = {Cao, Wenpeng and Zeng, Zhirui and Pan, Runsang and Wu, Hao and Zhang,
   Xiangyan and Chen, Hui and Nie, Yingjie and Yu, Zijiang and Lei, Shan},
Title = {Hypoxia-Related Gene FUT11 Promotes Pancreatic Cancer Progression by
   Maintaining the Stability of PDK1},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2021},
Volume = {11},
Month = {JUN 17},
Abstract = {Background Hypoxia is associated with the development of pancreatic
   cancer (PC). However, genes associated with hypoxia response and their
   regulatory mechanism in PC cells were unclear. The current study aims to
   investigate the role of the hypoxia associated gene fucosyltransferase
   11 (FUT11) in the progression of PC. Methods In the preliminary study,
   bioinformatics analysis predicted FUT11 as a key hypoxia associated gene
   in PC. The expression of FUT11 in PC was evaluated using quantitative
   real-time PCR (qRT-PCR), Western blot and immunohistochemistry. The
   effects of FUT11 on PC cells proliferation and migration under normoxia
   and hypoxia were evaluated using Cell Counting Kit 8,
   5-ethynyl-2'-deoxyuridine (EDU) assay, colony formation assay and
   transwell assay. The effects of FUT11 in vivo was examined in mouse
   tumor models of liver metastasis and subcutaneous xenograft.
   Furthermore, Western blot, luciferase assay and immunoprecipitation were
   performed to explore the regulatory relationship among FUT11,
   hypoxia-inducible factor 1 alpha (HIF1 alpha) and pyruvate dehydrogenase
   kinase 1 (PDK1) in PC. Results FUT11 was markedly increased of PC cells
   with hypoxia, upregulated in the PC clinical tissues, and predicted a
   poor outcome of PC patients. Inhibition of FUT11 reduced PC cell growth
   and migratory ability of PC cells under normoxia and hypoxia conditions
   in vitro, and growth and tumor cell metastasis in vivo. FUT11 bound to
   PDK1 and regulated the expression PDK1 under normoxia and hypoxia. FUT11
   interacted with PDK1 and decreased the ubiquitination of PDK1, lead to
   the activation of AKT/mTOR signaling pathway. FUT11 knockdown
   significantly increased the degradation of PDK1 under hypoxia, while
   treatment with MG132 can relieve the degradation of PDK1 induced by
   FUT11 knockdown. Overexpression of PDK1 in PC cells under hypoxia
   conditions reversed the suppressive impacts of FUT11 knockdown on PC
   cell growth and migration. In addition, HIF1 alpha bound to the promoter
   of FUT11 and increased its expression, as well as co-expressed with
   FUT11 in PC tissues. Furthermore, overexpression of FUT11 partially
   rescued the suppressive effects of HIF1 alpha knockdown on PC cell
   growth and migration in hypoxia condition. Conclusion Our data implicate
   that hypoxia-induced FUT11 contributes to proliferation and metastasis
   of PC by maintaining the stability of PDK1, thus mediating activation of
   AKT/mTOR signaling pathway, and suggest that FUT11 could be a novel and
   effective target for the treatment of pancreatic cancer.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Cao, WP; Yu, ZJ (Corresponding Author), Guizhou Med Univ, Sch Basic Med, Dept Anat, Guiyang, Peoples R China.
   Lei, S (Corresponding Author), Guizhou Med Univ, Sch Basic Med, Dept Physiol, Guiyang, Peoples R China.
   Cao, Wenpeng; Yu, Zijiang, Guizhou Med Univ, Sch Basic Med, Dept Anat, Guiyang, Peoples R China.
   Zeng, Zhirui; Lei, Shan, Guizhou Med Univ, Sch Basic Med, Dept Physiol, Guiyang, Peoples R China.
   Pan, Runsang, Guiyang Maternal \& Child Hlth Care Hosp, Dept Orthoped, Guiyang, Peoples R China.
   Wu, Hao, Guizhou Med Univ, Dept Pediat Surg, Affiliated Hosp, Guiyang, Peoples R China.
   Zhang, Xiangyan; Chen, Hui, Guizhou Prov Peoples Hosp, NHC Key Lab Pulm, Guiyang, Peoples R China.
   Nie, Yingjie, Guizhou Prov Peoples Hosp, Clin Lab Ctr, Guiyang, Peoples R China.},
DOI = {10.3389/fonc.2021.675991},
Article-Number = {675991},
ISSN = {2234-943X},
Keywords = {pancreatic cancer; hypoxia; fucosyltransferase 11; hypoxia-inducible
   factor 1 alpha; pyruvate dehydrogenase kinase 1},
Keywords-Plus = {CELL LUNG-CANCER},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {1006074061@qq.com
   893767473@qq.com
   1109974497@qq.com},
Affiliations = {Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University},
ResearcherID-Numbers = {zeng, zhirui/HZI-2107-2023
   pan, runsang/OEO-4120-2025
   Lei, Shan/HZI-0830-2023},
ORCID-Numbers = {Cao, Wenpeng/0000-0002-7345-755X
   pan, runsang/0000-0002-8573-8789
   },
Cited-References = {Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2.
   Carrascal MA, 2018, MOL ONCOL, V12, P579, DOI 10.1002/1878-0261.12163.
   Chiba N, 2020, AM J CANCER RES, V10, P2570.
   Chin V, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011044.pub2.
   Cui XG, 2017, ONCOTARGET, V8, P24840, DOI 10.18632/oncotarget.15266.
   Du YH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1055-2.
   Ebright RY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20144-w.
   Fan Li-fang, 2002, Ai Zheng, V21, P254.
   Gan CZ, 2017, IUBMB LIFE, V69, P841, DOI 10.1002/iub.1679.
   Guo FJ, 2017, J BIOL REG HOMEOS AG, V31, P615.
   Hirata E, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026781.
   Hwang H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57274-1.
   Kumar S, 2015, ONCOGENE, V34, P4879, DOI 10.1038/onc.2014.409.
   Kurihara K, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10121086.
   Kutkowska J, 2021, CHEM-BIOL INTERACT, V333, DOI 10.1016/j.cbi.2020.109320.
   Lee KG, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-020-00801-4.
   Li FZ, 2020, AM J CANCER RES, V10, P816.
   Liang LL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.352.
   Lin GL, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.12.
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862.
   Lucero-Acuña A, 2014, INT J NANOMED, V9, P5653, DOI 10.2147/IJN.S68511.
   Lv K, 2019, EXP THER MED, V18, P451, DOI 10.3892/etm.2019.7619.
   Ma C, 2018, BIOCHEM BIOPH RES CO, V501, P654, DOI 10.1016/j.bbrc.2018.05.039.
   Sun XC, 2018, J RECEPT SIG TRANSD, V38, P352, DOI 10.1080/10799893.2018.1531887.
   Wang C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.18.
   Wang SY, 2019, CLIN EXP PHARMACOL P, V46, P955, DOI 10.1111/1440-1681.13154.
   Wozniak M, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14010013.
   Xia SH, 2009, CELL SIGNAL, V21, P502, DOI 10.1016/j.cellsig.2008.12.002.
   Zeng ZR, 2021, J CELL PHYSIOL, V236, P2087, DOI 10.1002/jcp.29995.
   Zhang Q, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11655.
   Zhang X, 2019, ONCOL LETT, V18, P6516, DOI 10.3892/ol.2019.11004.},
Number-of-Cited-References = {31},
Times-Cited = {23},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {TC5AB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000668650100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000661860600001,
Author = {Han, Hyuk Gyu and Lee, Hyo-Jung and Sim, Deok Yong and Im, Eunji and
   Park, Ji Eon and Park, Woon Yi and Kim, Seok Young and Khil, Jae-Ho and
   Shim, Bum Sang and Kim, Sung-Hoon},
Title = {Suppression of phosphoinositide 3-kinase/phosphoinositide-dependent
   kinase-1/serum and glucocorticoid-induced protein kinase pathway},
Journal = {PHYTOTHERAPY RESEARCH},
Year = {2021},
Volume = {35},
Number = {8},
Pages = {4547-4554},
Month = {AUG},
Abstract = {In the current study, the pivotal roles of serum and
   glucocorticoid-induced protein kinase (SGK1) and NF-kB related
   signalings known as prognostic biomarkers in cervical cancers were
   explored in the antitumor effect of a ginseng saponin metabolite
   compound K (CK) in HeLa and SiHa cervical cancer cells. CK exerted
   significant cytotoxicity, induced sub-G1 accumulation, and attenuated
   the expression of proPoly (ADP-ribose) polymerase (pro-PARP) and
   Pro-cysteine aspartyl-specific protease (pro-caspase3) in HeLa cells
   more than in SiHa cells. CK inhibited phosphorylation of SGK1 and its
   upstream genes, phosphoinositide 3-kinases (PI3K), and
   phosphoinositide-dependent kinase-1 (PDK1) in HeLa cells. In addition,
   CK suppressed the phosphorylation of SGK1, NF-kappa B, and inhibitor of
   kappa B (I kappa B) and also NF-kappa B target genes such as X-linked
   inhibitor of apoptosis protein and B-cell lymphoma 2 (Bcl-2) in HeLa
   cells. Notably, Immunoprecipitation revealed that SGK1 binds to PI3K or
   PDK1 and also CK disturbed the binding between SGK1 and PI3K or PDK1 in
   HeLa cells. Furthermore, PI3K inhibitor LY294002 decreased expression of
   PI3K, p-PDK1, p-SGK1, and pro-caspase3 and SGK1 inhibitor GSK650394 also
   reduced expression of NF-kappa B and pro-caspase3 just like CK in HeLa
   cells. Overall, these findings suggest that CK induces apoptosis via
   suppression of PI3K/PDK1/SGK1 and NF-kappa B signaling axis.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Shim, BS; Kim, SH (Corresponding Author), Kyung Hee Univ, Coll Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   Han, Hyuk Gyu; Lee, Hyo-Jung; Sim, Deok Yong; Im, Eunji; Park, Ji Eon; Park, Woon Yi; Kim, Seok Young; Shim, Bum Sang; Kim, Sung-Hoon, Kyung Hee Univ, Coll Korean Med, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   Sim, Deok Yong; Im, Eunji; Park, Ji Eon; Park, Woon Yi; Kim, Seok Young; Kim, Sung-Hoon, Kyung Hee Univ, Coll Korean Med, Korean Med Based Drug Repositioning Canc Res Ctr, Seoul, South Korea.
   Khil, Jae-Ho, Kyung Hee Univ, Inst Sports Sci, Yongin, South Korea.},
DOI = {10.1002/ptr.7157},
EarlyAccessDate = {JUN 2021},
ISSN = {0951-418X},
EISSN = {1099-1573},
Keywords = {apoptosis; cervical cancer; compound K; NF-kappa B; PDK1; SGK1},
Keywords-Plus = {GINSENOSIDE COMPOUND K; INDUCED APOPTOSIS; CANCER GROWTH; SGK1;
   INHIBITION; CELLS; EXPRESSION; SERUM; PI3K; ANGIOGENESIS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal; Pharmacology \& Pharmacy},
Author-Email = {eshimbs@khu.ac.kr
   sungkim7@khu.ac.kr},
Affiliations = {Kyung Hee University; Kyung Hee University; Kyung Hee University},
ResearcherID-Numbers = {Shim, Bum-sang/AAH-9081-2020},
ORCID-Numbers = {kim, sunghoon/0000-0003-2423-1973
   },
Funding-Acknowledgement = {Korea Science and Engineering Foundation (KOSEF) - Korean government
   (MEST) {[}2020R1A5A2019413, 2021R1A2C2003277]},
Funding-Text = {This work was supported by the Korea Science and Engineering Foundation
   (KOSEF) grant funded by the Korean government (MEST) (No.
   2020R1A5A2019413 and 2021R1A2C2003277).},
Cited-References = {Avni D, 2012, BIOCHEM PHARMACOL, V83, P106, DOI 10.1016/j.bcp.2011.09.025.
   BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27.
   Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894.
   Patiño-Morales CC, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101320.
   Chen HF, 2019, CELL MOL BIOL, V65, P48, DOI 10.14715/cmb/2019.65.4.8.
   Chen Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-24.
   Choi E, 2019, J GINSENG RES, V43, P692, DOI 10.1016/j.jgr.2019.07.001.
   Conza D, 2017, J CELL PHYSIOL, V232, P3735, DOI 10.1002/jcp.25850.
   Di Cristofano A, 2017, CURR TOP DEV BIOL, V123, P49, DOI 10.1016/bs.ctdb.2016.11.006.
   Ehrke-Schulz E, 2020, CANCERS, V12, DOI 10.3390/cancers12071934.
   Gao SG, 2017, ONCOL LETT, V13, P3572, DOI 10.3892/ol.2017.5927.
   Jeong A, 2010, BIOL PHARM BULL, V33, P945, DOI 10.1248/bpb.33.945.
   Lee K, 2011, BIOCHEM BIOPH RES CO, V412, P328, DOI 10.1016/j.bbrc.2011.07.098.
   Lee S, 2017, INT J ONCOL, V51, P414, DOI 10.3892/ijo.2017.4054.
   Lee SH, 2012, CELL BIOL INT, V36, P683, DOI 10.1042/CBI20110257.
   Li G, 2017, BIOMED PHARMACOTHER, V94, P974, DOI 10.1016/j.biopha.2017.07.148.
   Li YT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.407.
   Liang XC, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.184.
   Liang XC, 2017, J CANCER, V8, P2256, DOI 10.7150/jca.19566.
   Lin CC, 2018, ANTICANCER RES, V38, P2761, DOI 10.21873/anticanres.12519.
   Lippman SM, 1998, JNCI-J NATL CANCER I, V90, P1514, DOI 10.1093/jnci/90.20.1514.
   Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1.
   Liu WW, 2017, BRIT J CANCER, V117, P1139, DOI 10.1038/bjc.2017.293.
   Lou YY, 2017, FASEB J, V31, P447, DOI 10.1096/fj.201600760R.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Millimouno FM, 2014, CANCER PREV RES, V7, P1081, DOI 10.1158/1940-6207.CAPR-14-0136.
   Nasir O, 2009, IUBMB LIFE, V61, P768, DOI 10.1002/iub.209.
   Qin J, 2015, CELL PHYSIOL BIOCHEM, V35, P2069, DOI 10.1159/000374013.
   Saha B, 2012, ONCOGENE, V31, P173, DOI 10.1038/onc.2011.234.
   Salis O, 2016, TUMOR BIOL, V37, P3017, DOI 10.1007/s13277-015-4119-2.
   Sethi G, 2007, J IMMUNOL, V179, P1926, DOI 10.4049/jimmunol.179.3.1926.
   Shin KO, 2014, ARCH PHARM RES, V37, P1183, DOI 10.1007/s12272-014-0340-6.
   Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200.
   Talarico C, 2016, CELL PHYSIOL BIOCHEM, V39, P1863, DOI 10.1159/000447885.
   Waldmann A, 2013, GEBURTSH FRAUENHEILK, V73, P123, DOI 10.1055/s-0032-1328266.
   Wang K, 2010, CELL PHYSIOL BIOCHEM, V25, P271, DOI 10.1159/000276561.
   Yao HQ, 2018, ONCOL LETT, V15, P8339, DOI 10.3892/ol.2018.8414.
   Yeo-Teh NSL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061706.
   Yousef BA, 2018, PHYTOMEDICINE, V40, P140, DOI 10.1016/j.phymed.2018.01.008.
   Zhang ZY, 2013, INT J MOL SCI, V14, P2980, DOI 10.3390/ijms14022980.
   Zheng Y, 2017, BIOENGINEERED, V8, P367, DOI 10.1080/21655979.2016.1230573.
   Zheng ZZ, 2014, ONCOL REP, V32, P325, DOI 10.3892/or.2014.3171.
   Zou DM, 2005, NUTR J, V4, DOI 10.1186/1475-2891-4-25.},
Number-of-Cited-References = {43},
Times-Cited = {7},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Phytother. Res.},
Doc-Delivery-Number = {UA0GE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000661860600001},
DA = {2026-02-04},
}

@article{ WOS:000662936100003,
Author = {Cho, Kwang-Hyun and An, Sugyun and Kang, Junsoo},
Title = {Systems biology for reverse aging},
Journal = {AGING-US},
Year = {2021},
Volume = {13},
Number = {11},
Pages = {14549-14551},
Month = {JUN 15},
Publisher = {IMPACT JOURNALS LLC},
Address = {6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA},
Type = {Editorial Material},
Language = {English},
Affiliation = {Cho, KH (Corresponding Author), Korea Adv Inst Sci \& Technol, Dept Bio \& Brain Engn, Daejeon 34141, South Korea.
   Cho, Kwang-Hyun, Korea Adv Inst Sci \& Technol, Dept Bio \& Brain Engn, Daejeon 34141, South Korea.},
DOI = {10.18632/aging.203188},
ISSN = {1945-4589},
Keywords = {systems biology; cellular senescence; geroconversion; network modeling;
   PDK1; skin aging},
Keywords-Plus = {SENESCENCE; CELLS},
Research-Areas = {Cell Biology; Geriatrics \& Gerontology},
Web-of-Science-Categories  = {Cell Biology; Geriatrics \& Gerontology},
Author-Email = {ckh@kaist.ac.kr},
Affiliations = {Korea Advanced Institute of Science \& Technology (KAIST)},
ResearcherID-Numbers = {Cho, Kwang-Hyun/C-1684-2011},
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) - Korea Government; Ministry
   of Science and ICT {[}2020R1A2B5B03094920]; Electronics and
   Telecommunications Research Institute (ETRI) grant {[}21ZS1100]; KAIST
   Grand Challenge 30 Project},
Funding-Text = {This work was supported by the National Research Foundation of Korea
   (NRF) funded by the Korea Government, the Ministry of Science and ICT
   (2020R1A2B5B03094920) , the Electronics and Telecommunications Research
   Institute (ETRI) grant {[}21ZS1100, Core Technology Research for
   SelfImproving Integrated Artificial Intelligence System] , and the KAIST
   Grand Challenge 30 Project},
Cited-References = {Alderton GK, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3713.
   An S, 2020, P NATL ACAD SCI USA, V117, P31535, DOI 10.1073/pnas.1920338117.
   Blagosklonny MV, 2014, CELL CYCLE, V13, P3628, DOI 10.4161/15384101.2014.985507.
   Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116.
   Kim JR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001390.
   Lee S, 2020, MOL CANCER RES, V18, P118, DOI 10.1158/1541-7786.MCR-19-0450.
   Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2.
   Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052.},
Number-of-Cited-References = {8},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Aging-US},
Doc-Delivery-Number = {SU1XT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000662936100003},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000664856900002,
Author = {Yin, Shasha and Liu, Liu and Brobbey, Charles and Palanisamy,
   Viswanathan and Ball, Lauren E. and Olsen, Shaun K. and Ostrowski,
   Michael C. and Gan, Wenjian},
Title = {PRMT5-mediated arginine methylation activates AKT kinase to govern
   tumorigenesis},
Journal = {NATURE COMMUNICATIONS},
Year = {2021},
Volume = {12},
Number = {1},
Month = {JUN 8},
Abstract = {AKT is involved in a number of key cellular processes including cell
   proliferation, apoptosis and metabolism. Hyperactivation of AKT is
   associated with many pathological conditions, particularly cancers.
   Emerging evidence indicates that arginine methylation is involved in
   modulating AKT signaling pathway. However, whether and how arginine
   methylation directly regulates AKT kinase activity remain unknown. Here
   we report that protein arginine methyltransferase 5 (PRMT5), but not
   other PRMTs, promotes AKT activation by catalyzing symmetric
   dimethylation of AKT1 at arginine 391 (R391). Mechanistically, AKT1-R391
   methylation cooperates with phosphatidylinositol 3,4,5 trisphosphate
   (PIP3) to relieve the pleckstrin homology (PH)-in conformation, leading
   to AKT1 membrane translocation and subsequent activation by
   phosphoinositide-dependent kinase-1 (PDK1) and the mechanistic target of
   rapamycin complex 2 (mTORC2). As a result, deficiency in AKT1-R391
   methylation significantly suppresses AKT1 kinase activity and
   tumorigenesis. Lastly, we show that PRMT5 inhibitor synergizes with AKT
   inhibitor or chemotherapeutic drugs to enhance cell death. Altogether,
   our study suggests that R391 methylation is an important step for AKT
   activation and its oncogenic function. Arginine methylation has been
   reported to regulate AKT-associated signalling. Here, the authors show
   that PRMT5-mediated arginine methylation promotes AKT activity and
   induces tumourigenesis.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Gan, WJ (Corresponding Author), Med Univ South Carolina, Hollings Canc Ctr, Dept Biochem \& Mol Biol, Charleston, SC 29425 USA.
   Yin, Shasha; Liu, Liu; Brobbey, Charles; Palanisamy, Viswanathan; Ostrowski, Michael C.; Gan, Wenjian, Med Univ South Carolina, Hollings Canc Ctr, Dept Biochem \& Mol Biol, Charleston, SC 29425 USA.
   Ball, Lauren E., Med Univ South Carolina, Dept Cell \& Mol Pharmacol \& Expt, Charleston, SC USA.
   Olsen, Shaun K., Univ Texas Hlth Sci Ctr, Dept Biochem \& Struct Biol, San Antonio, TX USA.
   Yin, Shasha; Liu, Liu, Med Univ South Carolina, Hollings Canc Ctr, Dept Biochem \& Mol Biol, Charleston, SC USA.},
DOI = {10.1038/s41467-021-23833-2},
Article-Number = {3444},
EISSN = {2041-1723},
Keywords-Plus = {PROTEIN-KINASE; METHYLTRANSFERASE 5; COMPLEX INTEGRITY; CELL-SURVIVAL;
   IN-VIVO; PRMT5; PHOSPHORYLATION; PATHWAY; CANCER; EXPRESSION},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {ganw@musc.edu},
Affiliations = {Medical University of South Carolina; Medical University of South
   Carolina; University of Texas System; University of Texas at San
   Antonio; Medical University of South Carolina},
ResearcherID-Numbers = {Ostrowski, Michael/H-3108-2011
   Ball, Lauren/AAD-6972-2019},
ORCID-Numbers = {Palanisamy, Viswanathan/0000-0001-5128-2878
   Olsen, Shaun/0000-0002-1265-7101
   Gan, Wenjian/0000-0001-7599-5020
   Ostrowski, Michael/0000-0003-2948-6297
   Ball, Lauren/0000-0001-6780-1679},
Funding-Acknowledgement = {Hollings Cancer Center Abney Postdoctoral Fellowship; CPRIT
   {[}RR200030]; Hollings Cancer Center's Cancer Center Support Grant at
   the Medical University of South Carolina {[}P30 CA138313]; NIH {[}S10
   OD025126, P20GM103542, P30 DK123704, R00CA207867]; National Cancer
   Institute {[}R00CA207867, P30CA138313] Funding Source: NIH RePORTER;
   National Institute of Diabetes and Digestive and Kidney Diseases
   {[}P30DK123704] Funding Source: NIH RePORTER; National Institute of
   General Medical Sciences {[}P20GM130457] Funding Source: NIH RePORTER},
Funding-Text = {We thank members of the Dr. Long and Dr. Delaney Laboratory for helpful
   discussions. S.Y. is supported by Hollings Cancer Center Abney
   Postdoctoral Fellowship. S.K.O. is supported by CPRIT RR200030. This
   work was in part supported by pilot research funding from Hollings
   Cancer Center's Cancer Center Support Grant P30 CA138313 at the Medical
   University of South Carolina, and NIH grants S10 OD025126 (Orbitrap
   Fusion Lumos ETD MS), P20GM103542, and P30 DK123704 to L.E.B. and
   R00CA207867 to W.G.},
Cited-References = {Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Aletta JM, 2008, BIOTECHNOL ANN REV, V14, P203, DOI 10.1016/S1387-2656(08)00008-2.
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085.
   Auclair Y, 2013, DNA REPAIR, V12, P459, DOI 10.1016/j.dnarep.2013.04.006.
   Avan A, 2016, WORLD J CLIN ONCOL, V7, P352, DOI 10.5306/wjco.v7.i5.352.
   Bedford MT, 2007, J CELL SCI, V120, P4243, DOI 10.1242/jcs.019885.
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013.
   Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5.
   Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003.
   Blanco-Aparicio C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009305.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Carnero A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00252.
   Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933.
   Chan CH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-59.
   Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI {[}10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810].
   Cheng DH, 2012, METHOD ENZYMOL, V512, P71, DOI 10.1016/B978-0-12-391940-3.00004-4.
   Chiang K, 2017, CELL REP, V21, P3498, DOI 10.1016/j.celrep.2017.11.096.
   Deng WK, 2017, BRIEF BIOINFORM, V18, P647, DOI 10.1093/bib/bbw041.
   Duncan KW, 2016, ACS MED CHEM LETT, V7, P162, DOI 10.1021/acsmedchemlett.5b00380.
   El-Andaloussi N, 2006, MOL CELL, V22, P51, DOI 10.1016/j.molcel.2006.02.013.
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665.
   Fuhrich DG, 2013, ANAL QUANT CYTOL, V35, P210.
   Gan WJ, 2020, NAT CELL BIOL, V22, P246, DOI 10.1038/s41556-020-0463-6.
   Gerhart SV, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28002-y.
   Guccione E, 2019, NAT REV MOL CELL BIO, V20, P642, DOI 10.1038/s41580-019-0155-x.
   Gullà A, 2018, LEUKEMIA, V32, P996, DOI 10.1038/leu.2017.334.
   Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6.
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189.
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004.
   Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158.
   Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08.
   Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001.
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033.
   Kovalski JR, 2019, MOL CELL, V73, P830, DOI 10.1016/j.molcel.2018.12.001.
   Kumar P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183318.
   Larsen SC, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf7329.
   Lee DY, 2005, ENDOCR REV, V26, P147, DOI 10.1210/er.2004-0008.
   Lee J, 2005, J BIOL CHEM, V280, P32890, DOI 10.1074/jbc.M506944200.
   Li X, 2019, EXPERT OPIN THER PAT, V29, P97, DOI 10.1080/13543776.2019.1567711.
   Lippa B, 2008, BIOORG MED CHEM LETT, V18, P3359, DOI 10.1016/j.bmcl.2008.04.034.
   Liu F, 2015, J CLIN INVEST, V125, P3532, DOI 10.1172/JCI81749.
   Liu PD, 2013, NAT CELL BIOL, V15, P1340, DOI 10.1038/ncb2860.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024.
   Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306.
   Pal S, 2007, EMBO J, V26, P3558, DOI 10.1038/sj.emboj.7601794.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Shailesh Harshita, 2018, Oncotarget, V9, P36705, DOI {[}10.18632/oncotarget.26404, 10.18632/oncotarget.26404].
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8.
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710.
   Stopa N, 2015, CELL MOL LIFE SCI, V72, P2041, DOI 10.1007/s00018-015-1847-9.
   Treiber DK, 2013, CHEM BIOL, V20, P745, DOI 10.1016/j.chembiol.2013.06.001.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wang Z, 2018, BREAST CANCER RES TR, V168, P531, DOI 10.1007/s10549-017-4597-6.
   Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110.
   West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6.
   WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0.
   Wu WI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012913.
   Wu Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695917.
   Xiao WD, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108790.
   Xing Y, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1154-8.
   Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409.
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245.
   Zhang SK, 2019, J CELL MOL MED, V23, P1333, DOI 10.1111/jcmm.14036.
   Zhou ZW, 2010, CELL RES, V20, P1023, DOI 10.1038/cr.2010.56.},
Number-of-Cited-References = {67},
Times-Cited = {72},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Nat. Commun.},
Doc-Delivery-Number = {SW9TT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000664856900002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000666463300001,
Author = {Yue, Liduo and Ren, Yanbei and Yue, Qingxi and Ding, Zhou and Wang, Kai
   and Zheng, Tiansheng and Chen, Guojie and Chen, Xiangyun and Li, Ming
   and Fan, Lihong},
Title = {α-Lipoic Acid Targeting PDK1/NRF2 Axis Contributes to the Apoptosis
   Effect of Lung Cancer Cells},
Journal = {OXIDATIVE MEDICINE AND CELLULAR LONGEVITY},
Year = {2021},
Volume = {2021},
Month = {JUN 4},
Abstract = {As an antioxidant, alpha-lipoic acid (LA) has attracted much attention
   to cancer research. However, the exact mechanism of LA in cancer
   progression control and prevention remains to be unclear. In this study,
   we demonstrated that alpha-lipoic acid has inhibitory effects on the
   proliferation, migration, and proapoptotic effects of non-small-cell
   lung cancer (NSCLC) cell lines A549 and PC9. LA-induced NSCLC cell
   apoptosis was mediated by elevated mitochondrial reactive oxygen species
   (ROS). Further study confirmed that it is by downregulating the
   expression of PDK1 (the PDH kinase), resulted in less phospho-PDH
   phenotype which could interact with Keap1, the negative controller of
   NRF2, directly leading to NRF2 decrease. Thus, by downregulating the
   NRF2 antioxidant system, LA plays a role in promoting apoptosis through
   the ROS signaling pathway. Moreover, LA could enhance other PDK
   inhibitors with the proapoptosis effect. In summary, our study shows
   that LA promotes apoptosis and exerts its antitumor activity against
   lung cancer by regulating mitochondrial energy metabolism enzyme-related
   antioxidative stress system. Administration of LA to the tumor-bearing
   animal model further supported the antitumor effect of LA. These
   findings provided new ideas for the clinical application of LA in the
   field of cancer therapy.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yue, LD; Li, M; Fan, LH (Corresponding Author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Resp Med, Shanghai 200072, Peoples R China.
   Yue, Liduo; Ren, Yanbei; Yue, Qingxi; Ding, Zhou; Wang, Kai; Zheng, Tiansheng; Chen, Guojie; Chen, Xiangyun; Li, Ming; Fan, Lihong, Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Resp Med, Shanghai 200072, Peoples R China.
   Yue, Qingxi, Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Oncol, Shanghai 201999, Peoples R China.},
DOI = {10.1155/2021/6633419},
Article-Number = {6633419},
ISSN = {1942-0900},
EISSN = {1942-0994},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE; OXIDATIVE STRESS; MITOCHONDRIAL; DERIVATIVES;
   DYSFUNCTION; ACTIVATION; MECHANISMS; PDK1},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {2216443774@qq.com
   yanbeiren@tongji.edu.cn
   qxyue@sibs.ac.cn
   578948781@qq.com
   qinhan1983@163.com
   1810928@tongji.edu.cn
   2814843984@qq.com
   15800560893@163.com
   mlid163@163.com
   fanlih@aliyun.com},
Affiliations = {Tongji University; Shanghai Jiao Tong University},
ORCID-Numbers = {Yue, Qingxi/0000-0003-4378-4012
   Kai, wang/0000-0002-7054-704X
   Yue, Liduo/0000-0002-7184-9170
   Chen, Guojie/0009-0007-9384-4307
   Li, Ming/0000-0003-1066-6175},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81802262, 31770131,
   81473469]; Natural Science Foundation of Shanghai {[}18ZR1423000]},
Funding-Text = {Dr. Youzhong Guo has done the mother tongue polishing work of this
   paper. He is from Department of Medicinal Chemistry, Institute for
   Structural Biology, Drug Discovery and Development, School of Pharmacy,
   Virginia Common-wealth University, Richmond, VA 23219, USA. This work
   was financially supported by the National Natural Science Foundation of
   China (Nos. 81802262, 31770131, and 81473469) and the Natural Science
   Foundation of Shanghai (18ZR1423000).},
Cited-References = {Bao JP, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7517219.
   Bollong MJ, 2018, NATURE, V562, P600, DOI 10.1038/s41586-018-0622-0.
   Cimolai MC, 2014, FOOD FUNCT, V5, P3143, DOI 10.1039/c4fo00489b.
   Cosimelli B, 2019, J ENZYM INHIB MED CH, V34, P1152, DOI 10.1080/14756366.2019.1623209.
   Deng XY, 2020, J CANCER, V11, P962, DOI 10.7150/jca.34330.
   Dodson M, 2019, ANNU REV PHARMACOL, V59, P555, DOI 10.1146/annurev-pharmtox-010818-021856.
   Dörsam B, 2016, CANCER LETT, V371, P12, DOI 10.1016/j.canlet.2015.11.019.
   Fox DB, 2020, NAT METAB, V2, P318, DOI 10.1038/s42255-020-0191-z.
   {[}高婷 Gao Ting], 2018, {[}中国细胞生物学学报, Chinese Journal of Cell Biology], V40, P1767.
   Guo YZ, 2020, ACTA CRYSTALLOGR F, V76, P292, DOI 10.1107/S2053230X20007943.
   Heist Rebecca S, 2012, Cancer Cell, V21, DOI 10.1016/j.ccr.2012.03.007.
   Hlouschek J, 2018, CANCER LETT, V439, P24, DOI 10.1016/j.canlet.2018.09.002.
   Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140.
   Kaneda MM, 2016, NATURE, V539, P437, DOI 10.1038/nature19834.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Kim SL, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9296439.
   Krail EB, 2017, ELIFE, V6, DOI {[}10.7554/eLife.18970, 10.7554/eLife.33173].
   Lastra D, 2021, HANDB EXP PHARMACOL, V264, P93, DOI 10.1007/164\_2020\_381.
   Li BB, 2018, INT J MOL MED, V42, P1391, DOI 10.3892/ijmm.2018.3745.
   Liu JK, 2008, NEUROCHEM RES, V33, P194, DOI 10.1007/s11064-007-9403-0.
   Liu PF, 2019, CELL CHEM BIOL, V26, P1427, DOI 10.1016/j.chembiol.2019.07.011.
   Moungjaroen J, 2006, J PHARMACOL EXP THER, V319, P1062, DOI 10.1124/jpet.106.110965.
   Park S, 2015, J INVEST MED, V63, P882, DOI 10.1097/JIM.0000000000000233.
   Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Phiboonchaiyanan PP, 2017, CELL ONCOL, V40, P497, DOI 10.1007/s13402-017-0339-3.
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006.
   Seifert F, 2007, BIOCHEMISTRY-US, V46, P6277, DOI 10.1021/bi700083z.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Swamy SM, 2016, AM J PATHOL, V186, P1712, DOI 10.1016/j.ajpath.2016.02.022.
   Taniguchi S, 2020, SCIENCE, V369, P269, DOI 10.1126/science.aay1813.
   Tibullo D, 2017, INFLAMM RES, V66, P947, DOI 10.1007/s00011-017-1079-6.
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803.
   Visconti R, 2009, CURR OPIN DRUG DISC, V12, P240.
   Wang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02915-8.
   Waris Gulam, 2006, J Carcinog, V5, P14.
   Warth A, 2015, PATHOLOGE, V36, P194, DOI 10.1007/s00292-015-0085-0.
   Yan XJ, 2020, CANCER DRUG RESIST, V3, P947, DOI 10.20517/cdr.2020.32.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.},
Number-of-Cited-References = {39},
Times-Cited = {21},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Oxidative Med. Cell. Longev.},
Doc-Delivery-Number = {SZ3IN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000666463300001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000657901400001,
Author = {Wang, Bing and Zhang, Xiao-li and Li, Chen-xi and Liu, Ning-ning and Hu,
   Min and Gong, Zhong-cheng},
Title = {ANLN promotes carcinogenesis in oral cancer by regulating the PI3K/mTOR
   signaling pathway},
Journal = {HEAD \& FACE MEDICINE},
Year = {2021},
Volume = {17},
Number = {1},
Month = {JUN 3},
Abstract = {Background Oral cancer is a malignant disease that threatenshuman life
   and greatly reducespatientquality of life. ANLN was reported to promote
   the progression of cancer. This study aims to investigate the role of
   ANLNin oral cancer and the underlying molecular mechanism. Methods ANLN
   expression was downregulated by RNAi technology. The effect of ANLN on
   cell behaviors, including proliferation, cell cycle progression,
   invasion, and apoptosis, was detected. Western blotting analysis was
   used to explore the mechanism by whichANLN functions in oral cancer.
   Results Data from TCGA database showed that ANLN was expressed at
   significantly higher levels in tumor tissues thanin normal control
   tissues. Patients with higher ANLN expression exhibitedshorter
   survivaltimes. ANLN was alsoabundantly expressedin the cancer cell lines
   CAL27 and HN30. When ANLN was knocked down in CAL27 and HN30 cells, cell
   proliferation and colony formation weredecreased. The cell invasion
   ability was also inhibited. However, the cell apoptosis rate was
   increased. In addition, the levels of critical members of the PI3K
   signaling pathway, includingPI3K, mTOR, Akt, and PDK-1, were
   significantlyreducedafter ANLN was knocked down in CAL27 cells.
   Conclusions ANLN contributes to oral cancerprogressionand affects
   activation ofthe PI3K/mTOR signaling pathway. This study providesa new
   potential targetfor drug development and treatment in oral cancer.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Li, CX; Gong, ZC (Corresponding Author), Xinjiang Med Univ, Oncol Dept Oral \& Maxillofacial Surg, Affiliated Hosp 1, Stomatol Sch,Stomatol Res Inst Xinjiang Prov, 137 Liyushan South Rd, Urumqi 830054, Peoples R China.
   Wang, Bing; Li, Chen-xi; Gong, Zhong-cheng, Xinjiang Med Univ, Oncol Dept Oral \& Maxillofacial Surg, Affiliated Hosp 1, Stomatol Sch,Stomatol Res Inst Xinjiang Prov, 137 Liyushan South Rd, Urumqi 830054, Peoples R China.
   Zhang, Xiao-li, Peoples Hosp Xinjiang Uygur Autonomous Reg, Urumqi 830001, Peoples R China.
   Li, Chen-xi, Univ Hosp Hamburg Eppendorf UKE, Dept Oral \& Maxillofacial Surg, Lab Tumor Genet \& Regenerat Med, Head \& Neuroctr, Martinistr 52, D-20246 Hamburg, Germany.
   Liu, Ning-ning, Xinjiang Med Univ, Dept Prosthodontia, Affiliated Hosp 1, Urumqi 830054, Peoples R China.
   Hu, Min, Urumqi Myour Dent Clin, Urumqi 830002, Peoples R China.},
DOI = {10.1186/s13005-021-00269-z},
Article-Number = {18},
EISSN = {1746-160X},
Keywords = {ANLN; Oral cancer; mTOR; PI3K signaling pathway},
Keywords-Plus = {GENE; INHIBITORS; APOPTOSIS; VESSELS; HEAD; PI3K},
Research-Areas = {Dentistry, Oral Surgery \& Medicine},
Web-of-Science-Categories  = {Dentistry, Oral Surgery \& Medicine},
Author-Email = {lichenxi89@yahoo.com
   gump0904@aliyun.com},
Affiliations = {Xinjiang Medical University; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; Xinjiang Medical University},
ResearcherID-Numbers = {Zhang, Xiaoli/M-9016-2019
   Li, Chen-xi/HDN-7555-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81760191]; Xinjiang
   Special Scientific Research Project of Youth Medical Science and
   Technology {[}WJWY-201924]},
Funding-Text = {This study was supported by National Natural Science Foundation of China
   (grant number: 81760191) and Xinjiang Special Scientific Research
   Project of Youth Medical Science and Technology (WJWY-201924).},
Cited-References = {Aggarwal S, 2019, CANCER CHEMOTH PHARM, V83, P451, DOI 10.1007/s00280-018-3746-x.
   Dai XF, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00790.
   Fumarola C, 2014, BIOCHEM PHARMACOL, V90, P197, DOI 10.1016/j.bcp.2014.05.011.
   Gbadegesin RA, 2014, J AM SOC NEPHROL, V25, P1991, DOI 10.1681/ASN.2013090976.
   Hall G, 2018, J AM SOC NEPHROL, V29, P2110, DOI 10.1681/ASN.2017121338.
   Hartner Lee, 2018, Dent Clin North Am, V62, P87, DOI {[}10.1016/j.cden.2017.08.006, 10.1016/j.cden.2017.08.006].
   Hillmann P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225792.
   Idichi T, 2017, ONCOTARGET, V8, P53180, DOI 10.18632/oncotarget.18261.
   Ingham M, 2017, J CLIN ONCOL, V35, P2949, DOI 10.1200/JCO.2016.69.0032.
   Irimie AI, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030670.
   Jeggo PA, 2016, NAT REV CANCER, V16, P35, DOI 10.1038/nrc.2015.4.
   Kim MN, 2019, CANCER CHEMOTH PHARM, V84, P809, DOI 10.1007/s00280-019-03918-y.
   Koyama S, 2017, SCI REP-UK, V7, DOI 10.1038/srep45621.
   Li Chia-Cheng, 2018, Dent Clin North Am, V62, P29, DOI {[}10.1016/j.cden.2017.08.002, 10.1016/j.cden.2017.08.002].
   Long XY, 2018, ONCOL LETT, V16, P1835, DOI 10.3892/ol.2018.8858.
   Ma QL, 2018, CURR OPIN IMMUNOL, V53, P7, DOI 10.1016/j.coi.2018.03.018.
   Mohamed MS, 2017, APOPTOSIS, V22, P1487, DOI 10.1007/s10495-017-1429-4.
   Niemiec J, 2015, ANTICANCER RES, V35, P1041.
   O'Neill AC, 2018, AM J ROENTGENOL, V211, P470, DOI 10.2214/AJR.17.19425.
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934.
   Shen YW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1366-x.
   Shimizu S, 2007, ONCOL REP, V18, P1489.
   Shostak A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040873.
   Sim F, 2019, ORAL MAXIL SURG CLIN, V31, P85, DOI 10.1016/j.coms.2018.09.002.
   Suzuki C, 2005, CANCER RES, V65, P11314, DOI 10.1158/0008-5472.CAN-05-1507.
   Tuan NM, 2020, CANCERS, V12, DOI 10.3390/cancers12061600.
   Valdez Jesus Amadeo, 2018, Dent Clin North Am, V62, P143, DOI {[}10.1016/j.cden.2017.09.001, 10.1016/j.cden.2017.09.001].
   Wang AB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1340-7.
   Xia LL, 2018, CANCER MANAG RES, V10, P663, DOI 10.2147/CMAR.S162813.
   Xu J, 2019, THORAC CANCER, V10, P1702, DOI 10.1111/1759-7714.13135.
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x.
   Yu CC, 2017, ONCOTARGET, V8, P68641, DOI 10.18632/oncotarget.19817.
   Zeeshan R, 2017, BOSNIAN J BASIC MED, V17, P172, DOI 10.17305/bjbms.2017.1908.
   Zhang M, 2020, CLIN EXP PHARMACOL P, V47, P1464, DOI 10.1111/1440-1681.13307.},
Number-of-Cited-References = {34},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Head Face Med.},
Doc-Delivery-Number = {SM9EY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000657901400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000666938700001,
Author = {Lachen-Montes, Mercedes and Inigo-Marco, Ignacio and Cartas-Cejudo, Paz
   and Fernandez-Irigoyen, Joaquin and Santamaria, Enrique},
Title = {Olfactory Bulb Proteomics Reveals Widespread Proteostatic Disturbances
   in Mixed Dementia and Guides for Potential Serum Biomarkers to
   Discriminate Alzheimer Disease and Mixed Dementia Phenotypes},
Journal = {JOURNAL OF PERSONALIZED MEDICINE},
Year = {2021},
Volume = {11},
Number = {6},
Month = {JUN},
Abstract = {The most common form of mixed dementia (MixD) is constituted by abnormal
   protein deposits associated with Alzheimer's disease (AD) that coexist
   with vascular disease. Although olfactory dysfunction is considered a
   clinical sign of AD-related dementias, little is known about the impact
   of this sensorial impairment in MixD at the molecular level. To address
   this gap in knowledge, we assessed olfactory bulb (OB) proteome-wide
   expression in MixD subjects (n = 6) respect to neurologically intact
   controls (n = 7). Around 9\% of the quantified proteins were
   differentially expressed, pinpointing aberrant proteostasis involved in
   synaptic transmission, nucleoside monophosphate and carbohydrate
   metabolism, and neuron projection regeneration. In addition,
   network-driven proteomics revealed a modulation in cell-survival related
   pathways such as ERK, AKT, and the PDK1-PKC axis. Part of the
   differential OB protein set was not specific of MixD, also being
   deregulated across different tauopathies, synucleinopathies, and
   tardopathies. However, the comparative functional analysis of OB
   proteome data between MixD and pure AD pathologies deciphered
   commonalities and differences between both related phenotypes. Finally,
   olfactory proteomics allowed to propose serum Prolow-density lipoprotein
   receptor-related protein 1 (LRP1) as a candidate marker to differentiate
   AD from MixD phenotypes.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Santamaría, E (Corresponding Author), Univ Publ Navarra UPNA, Complejo Hosp Navarra CHN, Navarra Inst Hlth Res IdiSNA, Clin Neuroprote Unit,Navarrabiomed, Irunlarrea 3, Pamplona 31008, Spain.
   Lachen-Montes, Mercedes; Inigo-Marco, Ignacio; Cartas-Cejudo, Paz; Fernandez-Irigoyen, Joaquin; Santamaria, Enrique, Univ Publ Navarra UPNA, Complejo Hosp Navarra CHN, Navarra Inst Hlth Res IdiSNA, Clin Neuroprote Unit,Navarrabiomed, Irunlarrea 3, Pamplona 31008, Spain.},
DOI = {10.3390/jpm11060503},
Article-Number = {503},
EISSN = {2075-4426},
Keywords = {mixed dementia; Alzheimer's disease; vascular dementia; olfactory bulb;
   proteomics},
Keywords-Plus = {VASCULAR RISK-FACTORS; NF-KAPPA-B; NEUROFIBRILLARY PATHOLOGY;
   COMPUTATIONAL PLATFORM; ATHEROSCLEROSIS RISK; P38 MAPK; DYSFUNCTION;
   BETA; IDENTIFICATION; DEPOSITION},
Research-Areas = {Health Care Sciences \& Services; General \& Internal Medicine},
Web-of-Science-Categories  = {Health Care Sciences \& Services; Medicine, General \& Internal},
Author-Email = {mercedes.lachen.montes@navarra.es
   ignacio.inigo.marco@navarra.es
   pazcarce@hotmail.com
   jfernani@navarra.es
   esantamma@navarra.es},
Affiliations = {Servicio Navarro de Salud - Osasunbidea; University of Navarra;
   Navarrabiomed; Universidad Publica de Navarra},
ResearcherID-Numbers = {SANTAMARIA, ENRIQUE/A-6012-2017
   Lachen-Montes, Mercedes/R-6771-2019
   Fernandez-Irigoyen, Joaquin/JBR-8052-2023},
ORCID-Numbers = {SANTAMARIA, ENRIQUE/0000-0001-8046-8102
   Cartas Cejudo, Paz/0000-0002-6182-7445
   Lachen-Montes, Mercedes/0000-0003-2449-8117
   Fernandez-Irigoyen, Joaquin/0000-0001-5072-4099},
Funding-Acknowledgement = {Spanish Ministry of Science, Innovation and Universities
   {[}PID2019-110356RB-I00/AEI/10.13039/501100011033]; Department of
   Economic and Business Development from Government of Navarra
   {[}0011-1411-2020-000028]},
Funding-Text = {This work was funded by grants from the Spanish Ministry of Science,
   Innovation and Universities (Ref.
   PID2019-110356RB-I00/AEI/10.13039/501100011033). to J.F.-I. and E.S.)
   and the Department of Economic and Business Development from Government
   of Navarra (Ref. 0011-1411-2020-000028 to E.S.).},
Cited-References = {Alafuzoff I, 2008, BRAIN PATHOL, V18, P484, DOI 10.1111/j.1750-3639.2008.00147.x.
   Albensi BC, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00154.
   Allan LM, 2011, BRAIN, V134, P3713, DOI 10.1093/brain/awr273.
   Azarpazhooh MR, 2018, ALZHEIMERS DEMENT, V14, P148, DOI 10.1016/j.jalz.2017.07.755.
   Barresi M, 2012, J NEUROL SCI, V323, P16, DOI 10.1016/j.jns.2012.08.028.
   Baud V, 2008, M S-MED SCI, V24, P1083, DOI 10.1051/medsci/200824121083.
   Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z.
   Custodio Nilton, 2017, Dement. neuropsychol., V11, P364, DOI {[}10.1590/1980-57642016dn11-040005, 10.1590/1980-57642016dn11-040005].
   de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83.
   Dearborn JL, 2017, NEUROLOGY, V88, P1556, DOI 10.1212/WNL.0000000000003837.
   Doty RL, 2008, ANN NEUROL, V63, P7, DOI 10.1002/ana.21327.
   Doty RL, 2017, LANCET NEUROL, V16, P478, DOI 10.1016/S1474-4422(17)30123-0.
   Duff K, 2002, J NEUROPSYCH CLIN N, V14, P197, DOI 10.1176/appi.neuropsych.14.2.197.
   Ekström I, 2020, J GERONTOL A-BIOL, V75, P2441, DOI 10.1093/gerona/glaa221.
   Fernández-Irigoyen J, 2019, NEURAL REGEN RES, V14, P979, DOI 10.4103/1673-5374.249220.
   Fierini F, 2020, J NEUROL SCI, V410, DOI 10.1016/j.jns.2019.116662.
   Gallart-Palau X, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00623-4.
   Gottesman RF, 2017, JAMA NEUROL, V74, P1246, DOI 10.1001/jamaneurol.2017.1658.
   Gottesman RF, 2017, JAMA-J AM MED ASSOC, V317, P1443, DOI 10.1001/jama.2017.3090.
   Gray AJ, 2001, INT J GERIATR PSYCH, V16, P513, DOI 10.1002/gps.383.
   Iadecola C, 2018, CIRC RES, V123, P406, DOI 10.1161/CIRCRESAHA.118.313400.
   Jellinger KA, 2007, J NEUROL SCI, V257, P80, DOI 10.1016/j.jns.2007.01.045.
   Kanekiyo T, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00093.
   Kanekiyo T, 2013, J NEUROSCI, V33, P19276, DOI 10.1523/JNEUROSCI.3487-13.2013.
   Lachén-Montes M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218311.
   Lachén-Montes M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176371.
   Lachén-Montes M, 2019, METHODS MOL BIOL, V2044, P273, DOI 10.1007/978-1-4939-9706-0\_17.
   Lachén-Montes M, 2019, J PROTEOMICS, V201, P37, DOI 10.1016/j.jprot.2019.04.011.
   Lachén-Montes M, 2019, NEUROBIOL AGING, V73, P123, DOI 10.1016/j.neurobiolaging.2018.09.018.
   Lachen-Montes M, 2017, ONCOTARGET, V8, P69663, DOI 10.18632/oncotarget.18193.
   Lachén-Montes M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09481-x.
   Lachén-Montes M, 2016, J PROTEOMICS, V148, P149, DOI 10.1016/j.jprot.2016.07.032.
   Lee JK, 2017, MOLECULES, V22, DOI 10.3390/molecules22081287.
   Li YW, 2016, CELL PHYSIOL BIOCHEM, V40, P549, DOI 10.1159/000452568.
   Lin K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002618.
   Liu BJ, 2019, ANN INTERN MED, V170, P673, DOI 10.7326/M18-0775.
   Liu DT, 2021, J PROTEOME RES, V20, P337, DOI 10.1021/acs.jproteome.0c00426.
   McAleese KE, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0676-5.
   Murphy C, 2002, JAMA-J AM MED ASSOC, V288, P2307, DOI 10.1001/jama.288.18.2307.
   Okuda S, 2017, NUCLEIC ACIDS RES, V45, pD1107, DOI 10.1093/nar/gkw1080.
   Oughtred R, 2021, PROTEIN SCI, V30, P187, DOI 10.1002/pro.3978.
   Palmquist E, 2020, J GERONTOL A-BIOL, V75, P603, DOI 10.1093/gerona/glz265.
   Rauch JN, 2020, NATURE, V580, P381, DOI 10.1038/s41586-020-2156-5.
   Rey NL, 2018, NEUROBIOL DIS, V109, P226, DOI 10.1016/j.nbd.2016.12.013.
   ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250.
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468.
   Sun MK, 2014, PROG MOL BIOL TRANSL, V122, P31, DOI 10.1016/B978-0-12-420170-5.00002-7.
   Tepe B, 2018, CELL REP, V25, P2689, DOI 10.1016/j.celrep.2018.11.034.
   Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791.
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297.
   Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136.
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI {[}10.1038/nmeth.3901, 10.1038/NMETH.3901].
   van der Flier WM, 2005, J NEUROL NEUROSUR PS, V76, pV2, DOI 10.1136/jnnp.2005.082867.
   Zelaya MV, 2015, ONCOTARGET, V6, P39437, DOI 10.18632/oncotarget.6254.
   Wehling E, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0463-5.
   Wisniewski T, 2019, PROG MOL BIOL TRANSL, V168, P223, DOI 10.1016/bs.pmbts.2019.08.001.
   Wu YB, 2019, MITOCHONDRION, V49, P35, DOI 10.1016/j.mito.2019.07.003.
   Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00416-0.
   Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI {[}10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014].
   Zheng JJ, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011343.
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6.},
Number-of-Cited-References = {61},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {J. Pers. Med.},
Doc-Delivery-Number = {TA0II},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000666938700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000658910500003,
Author = {Lu Yuyu and Zhang Shikun and Zhang Zhenyu and Jiang Zongdan and Sun
   Weihao},
Title = {MiR-877-5p targets PDK-1 to promote aspirin-induced apoptosis in gastric
   mucosal cells},
Journal = {PHARMAZIE},
Year = {2021},
Volume = {76},
Number = {6},
Pages = {256-260},
Month = {JUN},
Abstract = {This study aimed to investigate the role of miR-877-5p in
   aspirin-induced gastric mucosal injury. MiRNA microarray analysis was
   performed using paired gastric mucosal samples to find differentially
   expressed miRNAs. miR-877-5p was selected for subsequent analyses. Used
   as a model system, gastric epithelial cells (GES-1) were transfected
   with miR-877-5p mimic/inhibitor, then treated with aspirin. The
   expression of miR-877-5p in GES-1 cells was examined using quantitative
   real-time PCR (qRT-PCR). Flow cytometry analysis was used to detect cell
   apoptosis. Western blot assay was used to measure the protein levels of
   PDK1. The interaction between miR-877-5p and PDK1 was determined by
   luciferase reporter assay. The expression of miR-877-5p in gastric
   mucosal injury samples was higher than that in normal samples. Also,
   depletion of miR-877-5p reduced the apoptosis of GES-1 cells. Luciferase
   reporting assay confirmed that PDK1 was a target gene of miR-877-5p.
   PDK1 inhibited the apoptosis of GES-1 cells treated by aspirin.
   Moreover, this inhibitory effect was abrogated after PDK1 knockdown.
   Downregulation of miR-877-5p reduced the apoptosis by targeting PDK1 in
   GES-1 cells treated by aspirin, indicating that miR-877-5p may be a
   potential therapeutic target for gastric mucosal injury caused by
   aspirin.},
Publisher = {AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH},
Address = {CARL-MANNICH-STR 26, ESCHBORN, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Jiang, ZD (Corresponding Author), Nanjing Med Univ, Nanjing Hosp 1, Dept Gastroenterol, Nanjing 210006, Peoples R China.
   Sun, WH (Corresponding Author), Nanjing Med Univ, Affiliated Hosp 1, Dept Geriatr Gastroenterol, Nanjing 210029, Peoples R China.
   Lu Yuyu, Nanjing Med Univ, Affiliated Jiangning Hosp, Dept ICU, Nanjing, Peoples R China.
   Zhang Shikun, Nanjing Med Univ, Nanjing Hosp 1, Jiangsu Police Inst, Dept Police Phys Educ, Nanjing, Peoples R China.
   Zhang Zhenyu; Jiang Zongdan, Nanjing Med Univ, Nanjing Hosp 1, Dept Gastroenterol, Nanjing 210006, Peoples R China.
   Sun Weihao, Nanjing Med Univ, Affiliated Hosp 1, Dept Geriatr Gastroenterol, Nanjing 210029, Peoples R China.},
DOI = {10.1691/ph.2021.0926},
ISSN = {0031-7144},
Keywords-Plus = {CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; PROLIFERATION; RNAS},
Research-Areas = {Pharmacology \& Pharmacy; Chemistry},
Web-of-Science-Categories  = {Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology \&
   Pharmacy},
Author-Email = {jzongdan@sina.com
   swh@njmu.edu.cn},
Affiliations = {Nanjing Medical University; Nanjing Medical University; Jiangsu Police
   Institute; Nanjing Medical University; Nanjing Medical University},
ResearcherID-Numbers = {weihao, Sun/Y-1290-2018
   Zhang, Zhen-Yu/GSN-5990-2022},
Cited-References = {Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002.
   Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577.
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1.
   Darling RL, 2004, GASTROENTEROLOGY, V127, P94, DOI 10.1053/j.gastro.2004.04.003.
   Dong XQ, 2019, EUR REV MED PHARMACO, V23, P5187, DOI 10.26355/eurrev\_201906\_18183.
   Fanaroff AC, 2016, DRUG SAFETY, V39, P715, DOI 10.1007/s40264-016-0421-1.
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8.
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16.
   Goldstein JL, 1997, CLIN THER, V19, P1496, DOI 10.1016/S0149-2918(97)80021-5.
   Hu GM, 2018, MOL MED REP, V18, P587, DOI 10.3892/mmr.2018.8971.
   Huang XL, 2015, INT J CLIN EXP PATHO, V8, P1515.
   Jiang ZD, 2011, CHIN J GASTROENTEROL, V16, P400.
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y.
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035.
   Liu CC, 2018, EXP THER MED, V15, P1626, DOI 10.3892/etm.2017.5550.
   Mitsugi R, 2016, TOXICOL LETT, V263, P34, DOI 10.1016/j.toxlet.2016.10.002.
   Mora S, 2016, JAMA INTERN MED, V176, P1195, DOI 10.1001/jamainternmed.2016.2648.
   Næsdall J, 2006, DRUG SAFETY, V29, P119.
   Oshima T, 2008, AM J PHYSIOL-CELL PH, V295, pC800, DOI 10.1152/ajpcell.00157.2008.
   Shi QQ, 2016, ONCOL LETT, V11, P1474, DOI 10.3892/ol.2015.4072.
   Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13.
   Wallace JL, 2008, PHYSIOL REV, V88, P1547, DOI 10.1152/physrev.00004.2008.},
Number-of-Cited-References = {26},
Times-Cited = {2},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Pharmazie},
Doc-Delivery-Number = {SO3XV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000658910500003},
DA = {2026-02-04},
}

@article{ WOS:000660225400001,
Author = {Schwiebs, Anja and Faqar-Uz-Zaman, Farha and Herrero San Juan, Martina
   and Radeke, Heinfried H.},
Title = {S1P Lyase Regulates Intestinal Stem Cell Quiescence via Ki-67 and FOXO3},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2021},
Volume = {22},
Number = {11},
Month = {JUN},
Abstract = {Background: Reduction of the Sphingosine-1-phosphate (S1P) degrading
   enzyme S1P lyase 1 (SGPL1) initiates colorectal cancer progression with
   parallel loss of colon function in mice. We aimed to investigate the
   effect of SGPL1 knockout on the stem cell niche in these mice. Methods:
   We performed immunohistochemical and multi-fluorescence imaging on
   tissue sections of wildtype and SGPL1 knockout colons under disease
   conditions. Furthermore, we generated SGPL1 knockout DLD-1 cells
   (SGPL1(-/-M.Ex1)) using CRISPR/Cas9 and characterized cell cycle and AKT
   signaling pathway via Western blot, immunofluorescence, and FACS
   analysis. Results: SGPL1 knockout mice were absent of anti-Ki-67
   staining in the stem cell niche under disease conditions. This was
   accompanied by an increase of the negative cell cycle regulator FOXO3
   and attenuation of CDK2 activity. SGPL1(-/-M.Ex1) cells show a similar
   FOXO3 increase but no arrest of proliferation, although we found a
   suppression of the PDK1/AKT signaling pathway, a prolonged G1-phase, and
   reduced stem cell markers. Conclusions: While already established colon
   cancer cells find escape mechanisms from cell cycle arrest, in vivo
   SGPL1 knockout in the colon stem cell niche during progression of
   colorectal cancer can contribute to cell cycle quiescence. Thus, we
   propose a new function of the S1P lyase 1 in stemness.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Schwiebs, A; Radeke, HH (Corresponding Author), Hosp Goethe Univ, Inst Gen Pharmacol \& Toxicol, Pharmazentrum Frankfurt ZAFES, D-60590 Frankfurt, Germany.
   Schwiebs, Anja; Faqar-Uz-Zaman, Farha; Herrero San Juan, Martina; Radeke, Heinfried H., Hosp Goethe Univ, Inst Gen Pharmacol \& Toxicol, Pharmazentrum Frankfurt ZAFES, D-60590 Frankfurt, Germany.},
DOI = {10.3390/ijms22115682},
Article-Number = {5682},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {S1P lyase; colon cancer; cell cycle; quiescence; Ki-67; FOXO3; CDK2; AKT
   signaling; SGPL1 knockout cell line},
Keywords-Plus = {CYCLE REGULATION; COLON-CANCER; SPHINGOSINE-1-PHOSPHATE; COLITIS;
   DIFFERENTIATION; INHIBITION; ACTIVATION; PATHWAY; MICE},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {schwiebs@med.uni-frankfurt.de
   w.farha8@gmail.com
   herrero@em.uni-frankfurt.de
   radeke@em.uni-frankfurt.de},
Affiliations = {Goethe University Frankfurt; Goethe University Frankfurt Hospital},
ResearcherID-Numbers = {Radeke, Heinfried/HKO-7880-2023},
ORCID-Numbers = {Radeke, Heinfried/0000-0002-4499-2510},
Funding-Acknowledgement = {DFG {[}SFB1039]},
Funding-Text = {This research was funded by DFG, SFB1039 granted to H.H.R.},
Cited-References = {Arlt O, 2014, CELL PHYSIOL BIOCHEM, V34, P27, DOI 10.1159/000362982.
   Begagné E, 2014, J CLIN INVEST, V124, P5368, DOI 10.1172/JCI74188.
   Booth DG, 2017, TRENDS CELL BIOL, V27, P906, DOI 10.1016/j.tcb.2017.08.001.
   Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158.
   Cidado J, 2016, ONCOTARGET, V7, P6281, DOI 10.18632/oncotarget.7057.
   Cuylen S, 2016, NATURE, V535, P308, DOI 10.1038/nature18610.
   Dreis C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01698.
   Duan RD, 2009, PROG LIPID RES, V48, P62, DOI 10.1016/j.plipres.2008.04.003.
   Faqar-Uz-Zaman WF, 2021, LIPIDS, V56, P155, DOI 10.1002/lipd.12282.
   Gao XY, 2015, ONCOL REP, V34, P1977, DOI 10.3892/or.2015.4162.
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222.
   Huang WC, 2016, FASEB J, V30, P2945, DOI 10.1096/fj.201600394R.
   Huhn M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051360.
   Ihlefeld K, 2012, BIOCHEM J, V447, P457, DOI 10.1042/BJ20120811.
   Jeon S, 2020, J LIPID RES, V61, P20, DOI 10.1194/jlr.RA119000254.
   Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572.
   Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013.
   Liu SQ, 2013, INT J ONCOL, V42, P617, DOI 10.3892/ijo.2012.1733.
   Liu Y, 2019, EBIOMEDICINE, V49, P6, DOI 10.1016/j.ebiom.2019.10.020.
   Liu Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0856-3.
   Matheson TD, 2017, MOL BIOL CELL, V28, P21, DOI 10.1091/mbc.E16-09-0659.
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115.
   Oskouian B, 2006, P NATL ACAD SCI USA, V103, P17384, DOI 10.1073/pnas.0600050103.
   Park SB, 2020, DIGEST DIS SCI, V65, P2284, DOI 10.1007/s10620-019-05971-2.
   Penrose HM, 2019, CELL MOL GASTROENTER, V7, P391, DOI 10.1016/j.jcmgh.2018.10.003.
   Safarian F, 2015, J MOL NEUROSCI, V56, P177, DOI 10.1007/s12031-014-0478-1.
   Schwiebs A, 2019, ONCOGENE, V38, P4788, DOI 10.1038/s41388-019-0758-x.
   Schwiebs A, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5187368.
   Schwiebs A, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00094.
   Sobecki M, 2017, CANCER RES, V77, P2722, DOI 10.1158/0008-5472.CAN-16-0707.
   Spencer SL, 2013, CELL, V155, P369, DOI 10.1016/j.cell.2013.08.062.
   Takahashi K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124514.
   Wang L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19229-3.
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005.},
Number-of-Cited-References = {34},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {SQ2ZK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000660225400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000700870800002,
Author = {Yasuda, Tadahito and Ishimoto, Takatsugu and Baba, Hideo},
Title = {Conflicting metabolic alterations in cancer stem cells and regulation by
   the stromal niche},
Journal = {REGENERATIVE THERAPY},
Year = {2021},
Volume = {17},
Pages = {8-12},
Month = {JUN},
Abstract = {Recent studies have revealed that cancer stem cells (CSCs) undergo
   metabolic alterations that differentiate them from non-CSCs. Inhibition
   of specific metabolic pathways in CSCs has been conducted to eliminate
   the CSC population in many types of cancer. However, there is
   conflicting evidence about whether CSCs depend on glycolysis or
   mitochondrial oxidative phosphorylation (OXPHOS) to maintain their stem
   cell properties. This review summarizes the latest knowledge regarding
   CSC-specific metabolic alterations and offers recent evidence that the
   surrounding microenvironments may play an important role in the
   maintenance of CSC properties. (C) 2021, The Japanese Society for
   Regenerative Medicine. Production and hosting by Elsevier B.V.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Ishimoto, T; Baba, H (Corresponding Author), Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.
   Yasuda, Tadahito; Ishimoto, Takatsugu; Baba, Hideo, Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto, Japan.
   Yasuda, Tadahito; Ishimoto, Takatsugu, Kumamoto Univ, Int Res Ctr Med Sci IRCMS, Gastrointestinal Canc Biol, Kumamoto, Japan.
   Baba, Hideo, Kumamoto Univ, Fac Life Sci, Ctr Metab Regulat Hlth Aging, Kumamoto, Japan.},
DOI = {10.1016/j.reth.2021.01.005},
ISSN = {2352-3204},
Keywords = {CSCs; Glycolysis; Mitochondrial OXPHOS; ROS; Stromal niche},
Keywords-Plus = {OXIDATIVE-PHOSPHORYLATION; ACTIVATION; HALLMARKS; GLUCOSE; STRESS;
   MITOCHONDRIA; RESISTANCE; PATHWAYS; TUMORS; MYC},
Research-Areas = {Cell Biology; Engineering},
Web-of-Science-Categories  = {Cell \& Tissue Engineering; Engineering, Biomedical},
Author-Email = {taka1516@kumamoto-u.ac.jp
   hdobaba@kumamoto-u.ac.jp},
Affiliations = {Kumamoto University; Kumamoto University; Kumamoto University},
ResearcherID-Numbers = {Ishimoto, Takatsugu/KIJ-3339-2024},
ORCID-Numbers = {Yasuda, Tadahito/0000-0003-4556-0100
   Ishimoto, Takatsugu/0000-0003-1852-1835},
Funding-Acknowledgement = {Japan Society for the Promotion of Science KAKENHI {[}20K08985,
   20H03531]; Takeda Science Foundation; Grants-in-Aid for Scientific
   Research {[}21K19535, 21KK0153, 20H03531, 20K08985] Funding Source:
   KAKEN},
Funding-Text = {This workwas supported by the Japan Society for the Promotion of Science
   KAKENHI, grant numbers 20K08985 and 20H03531 and by the Takeda Science
   Foundation.},
Cited-References = {Akita H, 2014, CANCER RES, V74, P5903, DOI 10.1158/0008-5472.CAN-14-0527.
   Bu L, 2019, ONCOGENE, V38, P4887, DOI 10.1038/s41388-019-0765-y.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Chang CW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0250-x.
   Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004.
   Ciavardelli D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.285.
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304.
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200.
   Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x.
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473.
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985.
   Fu LF, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8010007.
   Gaude E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13041.
   Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019.
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Ishimoto T, 2014, J GASTROENTEROL, V49, P1111, DOI 10.1007/s00535-014-0952-0.
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038.
   Janiszewska M, 2012, GENE DEV, V26, P1926, DOI 10.1101/gad.188292.112.
   Kobayashi CI, 2012, J CELL PHYSIOL, V227, P421, DOI 10.1002/jcp.22764.
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006.
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005.
   Kuehne A, 2015, MOL CELL, V59, P359, DOI 10.1016/j.molcel.2015.06.017.
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013.
   Lane N, 2010, NATURE, V467, P929, DOI 10.1038/nature09486.
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039.
   Lee KM, 2017, CELL METAB, V26, P633, DOI 10.1016/j.cmet.2017.09.009.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131.
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027.
   Marhold M, 2015, MOL CANCER RES, V13, P556, DOI 10.1158/1541-7786.MCR-14-0153-T.
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624.
   Migneco G, 2010, CELL CYCLE, V9, P2412, DOI 10.4161/cc.9.12.11989.
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016.
   Mori Y, 2019, STEM CELL REP, V13, P730, DOI 10.1016/j.stemcr.2019.08.015.
   Nagano O, 2013, ONCOGENE, V32, P5191, DOI 10.1038/onc.2012.638.
   Ohata H, 2019, CELL REP, V28, P1282, DOI 10.1016/j.celrep.2019.06.085.
   Pagliarini DJ, 2013, GENE DEV, V27, P2615, DOI 10.1101/gad.229724.113.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Prager BC, 2019, CELL STEM CELL, V24, P41, DOI 10.1016/j.stem.2018.12.009.
   Sancho P, 2016, BRIT J CANCER, V114, P1305, DOI 10.1038/bjc.2016.152.
   Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015.
   Sansone P, 2017, P NATL ACAD SCI USA, V114, pE9066, DOI 10.1073/pnas.1704862114.
   Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419.
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843.
   Sousa CM, 2016, NATURE, V536, P479, DOI 10.1038/nature19084.
   Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024.
   Valle S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18954-z.
   Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020.
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611.
   Vlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108.
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002.
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365.
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519.
   Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935.},
Number-of-Cited-References = {58},
Times-Cited = {31},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Regen. Ther.},
Doc-Delivery-Number = {UX5FX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000700870800002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000659627800001,
Author = {Yepes, Sally and Shah, Nirav N. and Bai, Jiwei and Koka, Hela and Li,
   Chuzhong and Gui, Songbai and McMaster, Mary Lou and Xiao, Yanzi and
   Jones, Kristine and Wang, Mingyi and Vogt, Aurelie and Zhu, Bin and Zhu,
   Bin and Hutchinson, Amy and Yeager, Meredith and Hicks, Belynda and
   Carter, Brian and Freedman, Neal D. and Beane-Freeman, Laura and
   Chanock, Stephen J. and Zhang, Yazhuo and Parry, Dilys M. and Yang,
   Xiaohong R. and Goldstein, Alisa M.},
Title = {Rare Germline Variants in Chordoma-Related Genes and Chordoma
   Susceptibility},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {11},
Month = {JUN},
Abstract = {Simple Summary
   Chordoma is an extremely rare bone cancer that has not been fully
   characterized and few risk factors have been identified, highlighting
   the need for improving our understanding of the disease biology. Our
   study aims to identify chordoma susceptibility genes by investigating
   265 genes involved in chordoma-related signaling pathways and other
   biological processes on germline DNA of 138 chordoma patients of
   European ancestry compared to internal control datasets and general
   population databases. Results were intersected with whole genome
   sequencing data from 80 skull-base chordoma patients of Chinese
   ancestry. Several rare loss-of-function and predicted deleterious
   missense variants were enriched in chordoma cases in both datasets,
   suggesting a complex model of pathways potentially involved in chordoma
   development and susceptibility, warranting further investigation in
   larger studies.
   Background: Chordoma is a rare bone cancer with an unknown etiology.
   TBXT is the only chordoma susceptibility gene identified to date;
   germline single nucleotide variants and copy number variants in TBXT
   have been associated with chordoma susceptibility in familial and
   sporadic chordoma. However, the genetic susceptibility of chordoma
   remains largely unknown. In this study, we investigated rare germline
   genetic variants in genes involved in TBXT/chordoma-related signaling
   pathways and other biological processes in chordoma patients from North
   America and China. Methods: We identified variants that were very rare
   in general population and internal control datasets and showed evidence
   for pathogenicity in 265 genes in a whole exome sequencing (WES) dataset
   of 138 chordoma patients of European ancestry and in a whole genome
   sequencing (WGS) dataset of 80 Chinese patients with skull base
   chordoma. Results: Rare and likely pathogenic variants were identified
   in 32 of 138 European ancestry patients (23\%), including genes that are
   part of notochord development, PI3K/AKT/mTOR, Sonic Hedgehog, SWI/SNF
   complex and mesoderm development pathways. Rare pathogenic variants in
   COL2A1, EXT1, PDK1, LRP2, TBXT and TSC2, among others, were also
   observed in Chinese patients. Conclusion: We identified several rare
   loss-of-function and predicted deleterious missense variants in germline
   DNA from patients with chordoma, which may influence chordoma
   predisposition and reflect a complex susceptibility, warranting further
   investigation in large studies.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Yepes, S; Goldstein, AM (Corresponding Author), NCI, Div Canc Epidemiol \& Genet, NIH, Bethesda, MD 20892 USA.
   Yepes, Sally; Shah, Nirav N.; Koka, Hela; McMaster, Mary Lou; Xiao, Yanzi; Jones, Kristine; Wang, Mingyi; Vogt, Aurelie; Zhu, Bin; Zhu, Bin; Hutchinson, Amy; Yeager, Meredith; Hicks, Belynda; Freedman, Neal D.; Beane-Freeman, Laura; Chanock, Stephen J.; Parry, Dilys M.; Yang, Xiaohong R.; Goldstein, Alisa M., NCI, Div Canc Epidemiol \& Genet, NIH, Bethesda, MD 20892 USA.
   Bai, Jiwei; Li, Chuzhong; Gui, Songbai; Zhang, Yazhuo, Beijing Tiantan Hosp, Beijing 100070, Peoples R China.
   Jones, Kristine; Wang, Mingyi; Vogt, Aurelie; Zhu, Bin; Hutchinson, Amy; Yeager, Meredith; Hicks, Belynda, Frederick Natl Lab Canc Res, Leidos Biomed Res, Canc Genom Res Lab, Frederick, MD 21702 USA.
   Carter, Brian, Amer Canc Soc Inc, Atlanta, GA 30303 USA.},
DOI = {10.3390/cancers13112704},
Article-Number = {2704},
EISSN = {2072-6694},
Keywords = {chordoma; germline variants; notochord development; cancer
   susceptibility; WES; WGS},
Keywords-Plus = {BRACHYURY; IDENTIFICATION; GENERATION; TARGET},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {sally.yepestorres@nih.gov
   nirav.shah2@nih.gov
   baijiwei@ccmu.edu.cn
   hela.koka@nih.gov
   lichuzhong@ccmu.edu.cn
   guisongbai@ccmu.edu.cn
   Mary.McMaster@nih.gov
   yanzi.xiao@nih.gov
   kristine.jones@nih.gov
   mingyi.wang@nih.gov
   vogta@mail.nih.gov
   bin.zhu@nih.gov
   hutchiam@mail.nih.gov
   hutchiam@mail.nih.gov
   yeagerm@mail.nih.gov
   hicksbel@mail.nih.gov
   brian.carter@cancer.org
   freedmanne@mail.nih.gov
   freemala@mail.nih.gov
   chanocks@mail.nih.gov
   zhangyazhuo@ccmu.edu.cn
   parryd@mail.nih.gov
   royang@mail.nih.gov
   goldstea@mail.nih.gov},
Affiliations = {National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); NIH National Cancer Institute- Division of Cancer Epidemiology \&
   Genetics; Capital Medical University; National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); Frederick National
   Laboratory for Cancer Research; American Cancer Society},
ResearcherID-Numbers = {Freedman, Neal/B-9741-2015
   ZHU, BIN/GLQ-8199-2022
   Freeman, Laura/C-4468-2015
   Chanock, Stephen/AGL-9345-2022
   li, chu/GPS-7224-2022},
ORCID-Numbers = {, Mary/0000-0002-2208-9320
   Yeager, Meredith/0000-0003-3871-2225
   Freedman, Neal/0000-0003-0074-1098
   Goldstein, Alisa/0000-0002-7538-3582
   Hicks, Belynda/0000-0001-8014-4888
   },
Funding-Acknowledgement = {NIH, NCI, DCEG; Beijing Municipal Science and Technology Commission
   {[}Z171100000117002]; Research Special Fund for Public Welfare Industry
   of Health {[}201402008]},
Funding-Text = {This work was supported by the Intramural Research Program of the NIH,
   NCI, DCEG. Part of this research was supported by Beijing Municipal
   Science and Technology Commission (Z171100000117002), Research Special
   Fund for Public Welfare Industry of Health (201402008).},
Cited-References = {{[}Anonymous], 2012, ARXIV12073907.
   Aszódi A, 1998, J CELL BIOL, V143, P1399, DOI 10.1083/jcb.143.5.1399.
   Choi KS, 2008, DEV DYNAM, V237, P3953, DOI 10.1002/dvdy.21805.
   Dong CL, 2015, HUM MOL GENET, V24, P2125, DOI 10.1093/hmg/ddu733.
   Gohagan JK, 2000, CONTROL CLIN TRIALS, V21, p251S, DOI 10.1016/S0197-2456(00)00097-0.
   Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b.
   Hsu W, 2011, J NEUROSURG, V115, P760, DOI 10.3171/2011.5.JNS11185.
   Jones PS, 2014, J CLIN NEUROSCI, V21, P1490, DOI 10.1016/j.jocn.2014.02.008.
   Kelley MJ, 2014, HUM GENET, V133, P1289, DOI 10.1007/s00439-014-1463-z.
   KISPERT A, 1995, EMBO J, V14, P4763, DOI 10.1002/j.1460-2075.1995.tb00158.x.
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110.
   Landrum MJ, 2020, NUCLEIC ACIDS RES, V48, pD835, DOI 10.1093/nar/gkz972.
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007.
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352.
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI {[}10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698].
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110.
   McMaster ML, 2011, J MED GENET, V48, P444, DOI 10.1136/jmg.2010.085092.
   Mirabello L, 2020, JAMA ONCOL, V6, P724, DOI 10.1001/jamaoncol.2020.0197.
   Palena C, 2007, CLIN CANCER RES, V13, P2471, DOI 10.1158/1078-0432.CCR-06-2353.
   Pillay N, 2012, NAT GENET, V44, P1185, DOI 10.1038/ng.2419.
   Presneau N, 2011, J PATHOL, V223, P327, DOI 10.1002/path.2816.
   Ramroop JR, 2019, TRENDS GENET, V35, P515, DOI 10.1016/j.tig.2019.04.005.
   Shah SR, 2017, CELL REP, V21, P495, DOI 10.1016/j.celrep.2017.09.057.
   Sharifnia T, 2019, NAT MED, V25, P292, DOI 10.1038/s41591-018-0312-3.
   Stacchiotti S, 2017, ANN ONCOL, V28, P1230, DOI 10.1093/annonc/mdx054.
   Stacchiotti S, 2015, LANCET ONCOL, V16, pE71, DOI 10.1016/S1470-2045(14)71190-8.
   Stenson PD, 2014, HUM GENET, V133, P1, DOI 10.1007/s00439-013-1358-4.
   Tarpey PS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01026-0.
   Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969.
   Wasserman JK, 2018, HEAD NECK PATHOL, V12, P261, DOI 10.1007/s12105-017-0860-8.
   Yadav R, 2014, NEURO-ONCOLOGY, V16, P372, DOI 10.1093/neuonc/not228.
   Yang XHR, 2009, NAT GENET, V41, P1176, DOI 10.1038/ng.454.},
Number-of-Cited-References = {32},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {SP4GG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000659627800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000655819800001,
Author = {Sun, Sixin and Xu, Ying and Zhu, Zhijun and Kong, Dequn and Liu,
   Hongming and Zhou, Zhao and Wang, Lei},
Title = {MicroRNA let-7i-3p affects osteoblast differentiation in ankylosing
   spondylitis via targeting PDK1},
Journal = {CELL CYCLE},
Year = {2021},
Volume = {20},
Number = {12},
Pages = {1209-1219},
Month = {JUN 18},
Abstract = {Ankylosing spondylitis (AS) is a chronic autoimmune disease in which
   let-7i has been studied to involved. But, whether let-7i-3p could
   regulate osteoblast differentiation in AS remains unclear. This research
   targeted to decipher the impact of let-7i-3p on AS progression by
   modulating pyruvate dehydrogenase kinase 1 (PDK1). The bone mineral
   density of femur and lumbar vertebra and the maximum loading and bending
   elastic modulus of tibia, tumor necrosis factor-alpha (TNF-alpha),
   matrix metalloproteinase (MMP)-3, osteoprotegerin (OPG) and receptor
   activator of nuclear factor-kappa B ligand (RANKL) in serum of AS mice,
   the pathological condition of synovial tissue were determined via
   let-7i-3p inhibitor and OE-PDK1 in animal experiment. Also, the cell
   viability and ALP activity were measured by let-7i-3p inhibitor and
   OE-PDK1 in cell experiments. let-7i-3p and PDK1 expression were
   detected. Let-7i-3p raised and PDK1 declined in AS mice. Depleted
   let-7i-3p and restored PDK1 increased bone mineral density and maximum
   loading and bending elastic modulus of tibia, reduced TNF-alpha, MMP-3
   and RANKL contents, attenuated the pathological condition of synovial
   tissue and raised OPG content in AS mice. In cell experiments,
   up-regulating PDK1 and down-regulating let-7i-3p enhanced cell viability
   and ALP activity in AS mice. Low expression of let-7i-3p could enhance
   osteoblast differentiation in AS by up-regulating PDK1.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, L (Corresponding Author), Jiangsu Univ, Dept Orthoped, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China.
   Sun, Sixin; Zhu, Zhijun; Kong, Dequn; Liu, Hongming; Zhou, Zhao, Taixing Peoples Hosp, Dept Orthopaed, Taixing, Peoples R China.
   Xu, Ying, Taixing Peoples Hosp, Dept Rehabil, Taixing, Peoples R China.
   Wang, Lei, Jiangsu Univ, Dept Orthoped, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China.},
DOI = {10.1080/15384101.2021.1930680},
EarlyAccessDate = {MAY 2021},
ISSN = {1538-4101},
EISSN = {1551-4005},
Keywords = {Ankylosing spondylitis; MicroRNA-let-7i-3p; pyruvate dehydrogenase
   kinase 1; osteoblasts; cell differentiation},
Keywords-Plus = {NECROSIS-FACTOR-ALPHA; INDUCED AUTOPHAGY; BONE-FORMATION; EXPRESSION;
   OSTEOPOROSIS; BIOMARKERS; PATHWAY; CELLS; SERUM; OPG},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {Wanglei5795@163.com},
Affiliations = {Jiangsu University},
Funding-Acknowledgement = {Social Development and Scientific-technological Foundation of Zhenjiang,
   Jiangsu province {[}SH2018040]; Top Talents in Six One Projects of
   Jiangsu Commission of Health {[}LGY2019028]},
Funding-Text = {This study was supported by the Social Development and
   Scientific-technological Foundation of Zhenjiang, Jiangsu province
   (SH2018040) and Top Talents in Six One Projects of Jiangsu Commission of
   Health (LGY2019028).},
Cited-References = {Bai Y., J CELL PHYSL, V236, P5432.
   Bai YG, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11757.
   Di GJ, 2018, BIOMED PHARMACOTHER, V97, P1243, DOI 10.1016/j.biopha.2017.11.067.
   Ethiraj P, 2020, J CELL PHYSIOL, V235, P1663, DOI 10.1002/jcp.29086.
   Gai XS, 2019, MED SCI MONITOR, V25, P4244, DOI 10.12659/MSM.913813.
   Gonzalez-Lopez L, 2017, J INT MED RES, V45, P1024, DOI 10.1177/0300060517708693.
   He DY, 2017, CLIN RHEUMATOL, V36, P1819, DOI 10.1007/s10067-017-3624-7.
   Hou CF, 2014, BIOCHEM BIOPH RES CO, V453, P728, DOI 10.1016/j.bbrc.2014.10.002.
   Hu ZY, 2015, CLINICS, V70, P738.
   Huang JC, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1711-1.
   Kim JW, 2019, CLIN RHEUMATOL, V38, P3567, DOI 10.1007/s10067-019-04743-7.
   Lai NS, 2013, CLIN EXP IMMUNOL, V173, P47, DOI 10.1111/cei.12089.
   Li Z, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003325.
   Liu HC, 2013, J MOL HISTOL, V44, P535, DOI 10.1007/s10735-013-9498-3.
   Liu W, 2019, EXP THER MED, V17, P291, DOI 10.3892/etm.2018.6921.
   Luo YD, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1470-z.
   Ma JJ, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00173.
   Ma S, 2019, J CELL BIOCHEM, V120, P15429, DOI 10.1002/jcb.28810.
   Mou YK, 2015, CLIN RHEUMATOL, V34, P1085, DOI 10.1007/s10067-015-2940-z.
   Tran N, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2536-0.
   Pan JE, 2017, BIOMED PHARMACOTHER, V95, P1549, DOI 10.1016/j.biopha.2017.08.093.
   Reyes-Loyola P, 2019, CLIN RHEUMATOL, V38, P1367, DOI 10.1007/s10067-019-04509-1.
   Rohde F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00605.
   Sasanuma H, 2017, MOL METAB, V6, P428, DOI 10.1016/j.molmet.2017.02.003.
   Soliman E, 2012, RHEUMATOL INT, V32, P1711, DOI 10.1007/s00296-011-1852-8.
   Soulard J, 2019, JMIR RES PROTOC, V8, P129, DOI 10.2196/12470.
   Taylan A, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-191.
   Tu MY, 2020, NUTRIENTS, V12, DOI 10.3390/nu12113432.
   Wang YH, 2017, CELL PHYSIOL BIOCHEM, V42, P2481, DOI 10.1159/000480211.
   Wen CP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1271-6.
   Xiao DL, 2020, MOL MED REP, V22, P1536, DOI 10.3892/mmr.2020.11209.
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677.
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922.
   Xu ZK, 2019, INT J MOL MED, V43, P1179, DOI 10.3892/ijmm.2018.4038.
   Zhang C, 2017, ONCOTARGET, V8, P113543, DOI 10.18632/oncotarget.22708.
   Zhang Y, 2016, INT J RHEUM DIS, V19, P420, DOI 10.1111/1756-185X.12305.
   Zhong HF, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891-019-2647-4.},
Number-of-Cited-References = {37},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Cell Cycle},
Doc-Delivery-Number = {TF1WK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000655819800001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000681198600024,
Author = {Anwar, Saleha and Shamsi, Anas and Mohammad, Taj and Islam, Asimul and
   Hassan, Md Imtaiyaz},
Title = {Targeting pyruvate dehydrogenase kinase signaling in the development of
   effective cancer therapy},
Journal = {BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER},
Year = {2021},
Volume = {1876},
Number = {1},
Month = {AUG},
Abstract = {Pyruvate is irreversibly decarboxylated to acetyl coenzyme A by
   mitochondrial pyruvate dehydrogenase complex (PDC). Decarboxylation of
   pyruvate is considered a crucial step in cell metabolism and energetics.
   The cancer cells prefer aerobic glycolysis rather than mitochondrial
   oxidation of pyruvate. This attribute of cancer cells allows them to
   sustain under indefinite proliferation and growth. Pyruvate
   dehydrogenase kinases (PDKs) play critical roles in many diseases
   because they regulate PDC activity. Recent findings suggest an altered
   metabolism of cancer cells is associated with impaired mitochondrial
   function due to PDC inhibition. PDKs inhibit the PDC activity via
   phosphorylation of the E1a subunit and subsequently cause a glycolytic
   shift. Thus, inhibition of PDK is an attractive strategy in anticancer
   therapy. This review highlights that PDC/PDK axis could be implicated in
   cancer's therapeutic management by developing potential small-molecule
   PDK inhibitors. In recent years, a dramatic increase in the targeting of
   the PDC/PDK axis for cancer treatment gained an attention from the
   scientific community. We further discuss breakthrough findings in the
   PDC-PDK axis. In addition, structural features, functional significance,
   mechanism of activation, involvement in various human pathologies, and
   expression of different forms of PDKs (PDK1-4) in different types of
   cancers are discussed in detail. We further emphasized the gene
   expression profiling of PDKs in cancer patients to prognosis and
   therapeutic manifestations. Additionally, inhibition of the PDK/PDC axis
   by small molecule inhibitors and natural compounds at different clinical
   evaluation stages has also been discussed comprehensively.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Review},
Language = {English},
Affiliation = {Hassan, MI (Corresponding Author), Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.
   Anwar, Saleha; Shamsi, Anas; Mohammad, Taj; Islam, Asimul; Hassan, Md Imtaiyaz, Jamia Millia Islamia, Ctr Interdisciplinary Res Basic Sci, New Delhi 110025, India.},
DOI = {10.1016/j.bbcan.2021.188568},
EarlyAccessDate = {MAY 2021},
Article-Number = {188568},
ISSN = {0304-419X},
EISSN = {1879-2561},
Keywords = {Pyruvate dehydrogenase kinase; OXPHOS; Drug targets; Cancer
   therapeutics; Drug development; Cancer signaling; Kinase inhibitors;
   Warburg effect},
Keywords-Plus = {EPITHELIAL-MESENCHYMAL TRANSITION; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL
   CARCINOMA; UP-REGULATION; BETA-CATENIN; DICHLOROACETATE DCA;
   MITOCHONDRIAL PROTEIN; COMPLEX ACTIVITY; DRUG-RESISTANCE; TUMOR-CELLS},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics; Oncology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics; Oncology},
Author-Email = {mihassan@jmi.ac.in},
Affiliations = {Jamia Millia Islamia},
ResearcherID-Numbers = {Hassan, Imtaiyaz/NYT-5165-2025
   SHAI, ANAS/AAW-2124-2020
   Mohammad, Taj/HJH-1874-2023
   Islam, Asimul/V-4526-2019
   Anwar, Saleha/GOH-0349-2022},
ORCID-Numbers = {Hassan, Imtaiyaz/0000-0002-3663-4940
   SHAI, ANAS/0000-0001-7055-7056
   Mohammad, Taj/0000-0002-0399-4835
   Anwar, Saleha/0009-0006-7730-0628},
Funding-Acknowledgement = {Indian Council of Medical Research {[}ISRM/12(22)/2020]},
Funding-Text = {This work is funded by the Indian Council of Medical Research
   (ISRM/12(22)/2020).},
Cited-References = {Abbot EL, 2005, FEBS J, V272, P3004, DOI 10.1111/j.1742-4658.2005.04713.x.
   Abdelmalak M, 2013, MOL GENET METAB, V109, P139, DOI 10.1016/j.ymgme.2013.03.019.
   Aboye TL, 2004, BIOORGAN MED CHEM, V12, P2709, DOI 10.1016/j.bmc.2004.03.019.
   Aicher TD, 1999, BIOORG MED CHEM LETT, V9, P2223, DOI 10.1016/S0960-894X(99)00380-7.
   Aicher TD, 1999, J MED CHEM, V42, P2741, DOI 10.1021/jm9902584.
   Andreassen OA, 2001, ANN NEUROL, V50, P112, DOI 10.1002/ana.1085.
   {[}Anonymous], 2014, NAT COMMUN.
   Anwar S, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050119.
   Aragonés J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62.
   Babu E, 2011, ONCOGENE, V30, P4026, DOI 10.1038/onc.2011.113.
   Bao HY, 2004, BIOCHEMISTRY-US, V43, P13442, DOI 10.1021/bi0494875.
   Baumunk D, 2013, WORLD J UROL, V31, P1191, DOI 10.1007/s00345-012-0874-5.
   Bersin RM, 1997, AM HEART J, V134, P841, DOI 10.1016/S0002-8703(97)80007-5.
   Besant PG, 2002, MOL PHARMACOL, V62, P289, DOI 10.1124/mol.62.2.289.
   Blass JP, 2000, ANN NY ACAD SCI, V903, P204, DOI 10.1111/j.1749-6632.2000.tb06370.x.
   Bobba A, 2015, APOPTOSIS, V20, P10, DOI 10.1007/s10495-014-1049-1.
   Bonner MY, 2016, ONCOTARGET, V7, P12857, DOI 10.18632/oncotarget.7289.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Boulatnikov I, 2003, BBA-PROTEINS PROTEOM, V1645, P183, DOI 10.1016/S1570-9639(02)00542-3.
   Bowker-Kinley M, 1999, BIOCHEM J, V344, P47, DOI 10.1042/0264-6021:3440047.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Brizel DM, 2001, INT J RADIAT ONCOL, V51, P349, DOI 10.1016/S0360-3016(01)01630-3.
   Cai CF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0769-4.
   Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104.
   Calcutt NA, 2009, J NEUROPATH EXP NEUR, V68, P985, DOI 10.1097/NEN.0b013e3181b40217.
   Calorini L., 2012, Experimental Oncology, V34, P79.
   Carlberg C, 2010, CHROMOSOMA, V119, P479, DOI 10.1007/s00412-010-0283-8.
   Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200.
   Casanova-Salas I, 2014, J UROLOGY, V192, P252, DOI 10.1016/j.juro.2014.01.107.
   Cassavaugh J, 2011, J CELL BIOCHEM, V112, P735, DOI 10.1002/jcb.22956.
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004.
   Chafey P, 2009, PROTEOMICS, V9, P3889, DOI 10.1002/pmic.200800609.
   Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415.
   Cheng SC, 2016, NAT IMMUNOL, V17, P406, DOI 10.1038/ni.3398.
   Chiang CH, 2013, BBA-GEN SUBJECTS, V1830, P3067, DOI 10.1016/j.bbagen.2013.01.009.
   Cho H, 2019, J MED CHEM, V62, P8461, DOI 10.1021/acs.jmedchem.9b00565.
   Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y.
   Chung TW, 2017, J ETHNOPHARMACOL, V203, P47, DOI 10.1016/j.jep.2017.03.034.
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018.
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490.
   Constantin-Teodosiu D, 2013, DIABETES METAB J, V37, P301, DOI 10.4093/dmj.2013.37.5.301.
   Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215.
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106.
   CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3.
   Dahiya R, 2019, RSC ADV, V9, P23302, DOI 10.1039/c9ra02864a.
   Dahiya R, 2019, INT J BIOL MACROMOL, V136, P1076, DOI 10.1016/j.ijbiomac.2019.06.158.
   Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556.
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200.
   Deng YH, 2018, EXP CELL RES, V373, P171, DOI 10.1016/j.yexcr.2018.10.010.
   Deuse T, 2014, NATURE, V509, P641, DOI 10.1038/nature13232.
   Dey R, 1996, BBA-GENE STRUCT EXPR, V1305, P189, DOI 10.1016/0167-4781(95)00216-2.
   Dhar S, 2009, P NATL ACAD SCI USA, V106, P22199, DOI 10.1073/pnas.0912276106.
   DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0.
   Dixit D, 2016, EXP CELL RES, V344, P132, DOI 10.1016/j.yexcr.2016.03.017.
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741.
   Dromparis P, 2010, J MOL MED, V88, P1003, DOI 10.1007/s00109-010-0670-x.
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637-013-0047-4.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0.
   Dwivedi SKD, 2011, MOL ENDOCRINOL, V25, P922, DOI 10.1210/me.2010-0512.
   Edwards PA, 2002, J LIPID RES, V43, P2.
   Eisenkop SM, 2001, GYNECOL ONCOL, V82, P143, DOI 10.1006/gyno.2001.6232.
   Feng L, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190654.
   Feng WG, 2014, STEM CELLS, V32, P1734, DOI 10.1002/stem.1662.
   Feng XG, 2020, MOL CELL BIOCHEM, V463, P127, DOI 10.1007/s11010-019-03635-3.
   Fernando CD, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1178-x.
   Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025.
   Ferriero R, 2015, J INHERIT METAB DIS, V38, P895, DOI 10.1007/s10545-014-9808-2.
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011.
   Fritzen AM, 2015, J PHYSIOL-LONDON, V593, P4765, DOI 10.1113/JP270821.
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088.
   Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012.
   Godin JD, 2010, EMBO J, V29, P2433, DOI 10.1038/emboj.2010.117.
   Goetze K, 2011, INT J ONCOL, V39, P453, DOI 10.3892/ijo.2011.1055.
   Goodwin ML, 2014, CANCER CELL, V26, P851, DOI 10.1016/j.ccell.2014.10.003.
   Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795.
   Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811.
   Green T, 2008, J BIOL CHEM, V283, P15789, DOI 10.1074/jbc.M800311200.
   Groussard C, 2000, J APPL PHYSIOL, V89, P169, DOI 10.1152/jappl.2000.89.1.169.
   Guan YJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0905-z.
   Guda MR, 2018, AM J CANCER RES, V8, P1725.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Guentsch A, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00236-16.
   Haas R, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002202.
   Häcker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369.
   Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027.
   Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9.
   HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4.
   Harris RA, 2001, ADV ENZYME REGUL, V41, P269, DOI 10.1016/S0065-2571(00)00020-0.
   Head RA, 2005, ANN NEUROL, V58, P234, DOI 10.1002/ana.20550.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hengeveld AF, 2002, CURR MED CHEM, V9, P499, DOI 10.2174/0929867023370996.
   Hensley CT, 2015, J CLIN INVEST, V125, P495, DOI 10.1172/JCI79188.
   Hiromasa Y, 2006, J BIOL CHEM, V281, P12568, DOI 10.1074/jbc.M513514200.
   Hiromasa Y, 2003, J BIOL CHEM, V278, P33681, DOI 10.1074/jbc.M212733200.
   Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457.
   Ho N, 2015, EXP CELL RES, V331, P73, DOI 10.1016/j.yexcr.2014.12.006.
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86.
   Holness MJ, 2000, DIABETES, V49, P775, DOI 10.2337/diabetes.49.5.775.
   Hong SE, 2015, J CANCER RES CLIN, V141, P1171, DOI 10.1007/s00432-014-1887-9.
   Hsu JY, 2017, FASEB J, V31, P4265, DOI 10.1096/fj.201700156R.
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021.
   Hu S, 2016, ONCOTARGET, V7, P48423, DOI 10.18632/oncotarget.10301.
   Hu TH, 2019, J DRUG TARGET, V27, P460, DOI 10.1080/1061186X.2018.1550648.
   Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014.
   Huang WD, 2006, SCIENCE, V312, P233, DOI 10.1126/science.1121435.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Iannitti T, 2011, DRUGS R\&D, V11, P227, DOI 10.2165/11591280-000000000-00000.
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149.
   Jeong SH, 2018, J CLIN INVEST, V128, P1010, DOI 10.1172/JCI95802.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Ji HT, 2013, CLIN CANCER RES, V19, P6335, DOI 10.1158/1078-0432.CCR-13-2478.
   Jiang YX, 2020, BRIT J CANCER, V123, P275, DOI 10.1038/s41416-020-0865-z.
   Johnstone TC, 2013, ACS NANO, V7, P5675, DOI 10.1021/nn401905g.
   Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012.
   Kahlon Arunpreet Singh, 2016, Proc (Bayl Univ Med Cent), V29, P313, DOI 10.1080/08998280.2016.11929449.
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438.
   Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kato M, 2008, STRUCTURE, V16, P1849, DOI 10.1016/j.str.2008.10.010.
   Khan A, 2014, ALTERN THER HEALTH M, V20, P21.
   Kim H, 2017, BRIT J CANCER, V116, P370, DOI 10.1038/bjc.2016.440.
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07.
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kinnaird A, 2016, EUR UROL, V69, P734, DOI 10.1016/j.eururo.2015.09.014.
   Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979.
   Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s.
   Kondo Y, 2000, CLIN CANCER RES, V6, P622.
   KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297.
   Korotchkina LG, 2004, FREE RADICAL RES, V38, P1083, DOI 10.1080/10715760400004168.
   Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260.
   Krishnan A, 2007, CURR MOL MED, V7, P532, DOI 10.2174/156652407781695765.
   Lai YW, 2016, UROL SCI, V27, P244, DOI 10.1016/j.urols.2015.05.004.
   Lecarpentier Y, 2017, PPAR RES, V2017, DOI 10.1155/2017/5879090.
   Lecarpentier Y, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00100.
   Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38.
   Lee D, 2019, J MED CHEM, V62, P575, DOI 10.1021/acs.jmedchem.8b01168.
   Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011.
   Lee EJ, 2018, J PHARMACOL SCI, V138, P146, DOI 10.1016/j.jphs.2018.10.005.
   Lee TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081421.
   Lei R, 2014, ONCOGENE, V33, P1287, DOI 10.1038/onc.2013.65.
   Li CY, 2015, ONCOTARGET, V6, P1544, DOI 10.18632/oncotarget.2838.
   Li FQ, 2008, J CELL BIOL, V181, P1141, DOI 10.1083/jcb.200709091.
   Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265.
   Li J, 2009, J BIOL CHEM, V284, P34458, DOI 10.1074/jbc.M109.065557.
   Liang Y, 2020, ONCOGENE, V39, P469, DOI 10.1038/s41388-019-1035-8.
   Lin Q, 2019, J CELL BIOCHEM, V120, P11604, DOI 10.1002/jcb.28440.
   Ling HH, 2017, EXP CELL RES, V350, P218, DOI 10.1016/j.yexcr.2016.11.024.
   LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227.
   Lissens W, 2000, HUM MUTAT, V15, P209, DOI 10.1002/(SICI)1098-1004(200003)15:3<209::AID-HUMU1>3.3.CO;2-B.
   Liu H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0950-9.
   Liu H, 2013, INT J COLORECTAL DIS, V28, P697, DOI 10.1007/s00384-013-1674-0.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Liu WP, 2015, J INORG BIOCHEM, V146, P14, DOI 10.1016/j.jinorgbio.2015.02.002.
   Liu YF, 2017, J MED CHEM, V60, P2227, DOI 10.1021/acs.jmedchem.6b01245.
   Liu YY, 2015, CANCER RES, V75, P5046, DOI 10.1158/0008-5472.CAN-15-0706.
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Lu GM, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0945-6.
   Lu X, 2010, J BIOL CHEM, V285, P9317, DOI 10.1074/jbc.C110.104448.
   Lubov J, 2017, ONCOTARGET, V8, P55511, DOI 10.18632/oncotarget.19224.
   Luedde T, 2011, NAT REV GASTRO HEPAT, V8, P108, DOI 10.1038/nrgastro.2010.213.
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237.
   Luo LF, 2018, PATHOL RES PRACT, V214, P1825, DOI 10.1016/j.prp.2018.09.017.
   Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098.
   Maher EA, 2012, NMR BIOMED, V25, P1234, DOI 10.1002/nbm.2794.
   Masini T, 2016, J ENZYM INHIB MED CH, V31, P170, DOI 10.1080/14756366.2016.1201812.
   Masuda T, 2017, CANCERS, V9, DOI 10.3390/cancers9090124.
   Mayrhofer M, 2017, DIS MODEL MECH, V10, P15, DOI 10.1242/dmm.026500.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Meng T, 2014, J MED CHEM, V57, P9832, DOI 10.1021/jm5010144.
   Merida Isabel, 2006, Clin Transl Oncol, V8, P711, DOI 10.1007/s12094-006-0117-6.
   Meurs KM, 2012, HUM GENET, V131, P1319, DOI 10.1007/s00439-012-1158-2.
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349.
   Milne J., 2013, STRUCTURE REGULATION.
   Mohammad T, 2021, J BIOMOL STRUCT DYN, V39, P586, DOI 10.1080/07391102.2020.1711810.
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549.
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Muñoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123.
   Muranen T, 2016, CANCER RES, V76, P7168, DOI 10.1158/0008-5472.CAN-16-0155.
   Nie Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61920-4.
   Niehrs C, 2012, EMBO J, V31, P2705, DOI 10.1038/emboj.2012.124.
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260.
   Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035.
   O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862.
   Oberhuber M., 2020, MOL SYST BIOL, V16, P9247.
   Olaniyi KS, 2019, BIOMED PHARMACOTHER, V110, P59, DOI 10.1016/j.biopha.2018.11.038.
   Osthus RC, 2000, J BIOL CHEM, V275, P21797, DOI 10.1074/jbc.C000023200.
   Otto AM, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0145-9.
   Pålsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x.
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395.
   Park H, 2016, BIOCHEM BIOPH RES CO, V469, P1049, DOI 10.1016/j.bbrc.2015.12.113.
   Park I, 2010, NEURO-ONCOLOGY, V12, P133, DOI 10.1093/neuonc/nop043.
   Park SM, 2018, CELL PHYSIOL BIOCHEM, V45, P1270, DOI 10.1159/000487460.
   Parmenter TJ, 2014, CANCER DISCOV, V4, P423, DOI 10.1158/2159-8290.CD-13-0440.
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598.
   Patel KP, 2012, MOL GENET METAB, V105, P34, DOI 10.1016/j.ymgme.2011.09.032.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   PATEL MS, 1995, FASEB J, V9, P1164, DOI 10.1096/fasebj.9.12.7672509.
   PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213.
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148.
   Pathak RK, 2014, ACS CHEM BIOL, V9, P1178, DOI 10.1021/cb400944y.
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253.
   Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454.
   Pearce EL, 2013, IMMUNITY, V38, P633, DOI 10.1016/j.immuni.2013.04.005.
   Pellizzaro C, 2002, CARCINOGENESIS, V23, P735, DOI 10.1093/carcin/23.5.735.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Pennisi E, 1998, SCIENCE, V281, P1438, DOI 10.1126/science.281.5382.1438.
   Penticuff J, 2019, J UROLOGY, V201, pE817.
   Pereira SL, 2014, HUM REPROD UPDATE, V20, P924, DOI 10.1093/humupd/dmu034.
   PETTIT FH, 1982, P NATL ACAD SCI-BIOL, V79, P3945, DOI 10.1073/pnas.79.13.3945.
   Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5.
   POPOV KM, 1993, J BIOL CHEM, V268, P26602.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Qu CD, 2020, IUBMB LIFE, V72, P465, DOI 10.1002/iub.2212.
   Rafiee A, 2018, BIOTECHNOL GENET ENG, V34, P153, DOI 10.1080/02648725.2018.1471566.
   Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653.
   Rellinger EJ, 2015, PEDIATR BLOOD CANCER, V62, P581, DOI 10.1002/pbc.25348.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Roche TE, 2003, EUR J BIOCHEM, V270, P1050, DOI 10.1046/j.1432-1033.2003.03468.x.
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Rodrigues AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131663.
   Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023.
   Ryan JJ, 2014, CIRC RES, V115, P176, DOI 10.1161/CIRCRESAHA.113.301129.
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974.
   Saha S, 2015, SCI REP-UK, V5, DOI 10.1038/srep07762.
   Saraswathy S, 2009, J NEURO-ONCOL, V91, P69, DOI 10.1007/s11060-008-9685-3.
   Sattler UGA, 2009, INT J RADIAT BIOL, V85, P963, DOI 10.3109/09553000903258889.
   Saunier E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07006-0.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Savkur RS, 2005, BIOCHEM BIOPH RES CO, V329, P391, DOI 10.1016/j.bbrc.2005.01.141.
   Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827.
   Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106.
   Sellers K, 2015, J CLIN INVEST, V125, P687, DOI 10.1172/JCI72873.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI 10.1056/NEJMc1110602.
   Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009.
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003.
   Sharma A, 2017, BIOCHIMIE, V133, P56, DOI 10.1016/j.biochi.2016.12.009.
   Shavit R, 2015, CELL ONCOL, V38, P247, DOI 10.1007/s13402-014-0212-6.
   Shen H, 2015, MOL CANCER THER, V14, P1794, DOI 10.1158/1535-7163.MCT-15-0247.
   Shrivastav S, 2013, MOL ENDOCRINOL, V27, P1564, DOI 10.1210/me.2012-1370.
   Shroads AL, 2008, J PHARMACOL EXP THER, V324, P1163, DOI 10.1124/jpet.107.134593.
   Shroads AL, 2012, J CLIN PHARMACOL, V52, P837, DOI 10.1177/0091270011405664.
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215.
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Stacpoole PW, 2012, AGING CELL, V11, P371, DOI 10.1111/j.1474-9726.2012.00805.x.
   Stacpoole PW, 2011, ENVIRON HEALTH PERSP, V119, P155, DOI 10.1289/ehp.1002554.
   STACPOOLE PW, 1983, NEW ENGL J MED, V309, P390, DOI 10.1056/NEJM198308183090702.
   Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637.
   STACPOOLE PW, 1970, METABOLIS, V19, P71, DOI 10.1016/0026-0495(70)90119-8.
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6.
   STACPOOLE PW, 1987, LIFE SCI, V41, P2167, DOI 10.1016/0024-3205(87)90535-2.
   Stenvold H, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-138.
   Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200.
   Stoops JK, 1997, J BIOL CHEM, V272, P5757, DOI 10.1074/jbc.272.9.5757.
   SUGDEN MC, 1994, FASEB J, V8, P54, DOI 10.1096/fasebj.8.1.8299890.
   Sun CB, 2020, WORLD J GASTRO ONCOL, V12, DOI 10.4251/wjgo.v12.i4.394.
   Sun H, 2017, ONCOTARGET, V8, P52642, DOI 10.18632/oncotarget.16991.
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9.
   Sun SJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.273.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Takakusagi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107995.
   Takemaru KI, 2009, CELL CYCLE, V8, P210, DOI 10.4161/cc.8.2.7394.
   Takemaru KI, 2003, NATURE, V422, P905, DOI 10.1038/nature01570.
   Tan Z, 2015, J IMMUNOL, V194, P6082, DOI 10.4049/jimmunol.1402469.
   Tokmakov AA, 2009, GENE EXPR PATTERNS, V9, P158, DOI 10.1016/j.gep.2008.11.005.
   Tomczak Katarzyna, 2015, Contemp Oncol (Pozn), V19, pA68, DOI 10.5114/wo.2014.47136.
   Trapella C, 2016, J MED CHEM, V59, P147, DOI 10.1021/acs.jmedchem.5b01165.
   Trinidad AG, 2017, ONCOGENE, V36, P6164, DOI 10.1038/onc.2017.224.
   Tso SC, 2017, J MED CHEM, V60, P1142, DOI 10.1021/acs.jmedchem.6b01540.
   Tso SC, 2014, J BIOL CHEM, V289, P4432, DOI 10.1074/jbc.M113.533885.
   Tumaneng K, 2012, CURR BIOL, V22, pR368, DOI 10.1016/j.cub.2012.03.003.
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0.
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069.
   Végran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828.
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020.
   Viswanath P, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1077922.
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002.
   Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711.
   Walenta S, 2000, CANCER RES, V60, P916.
   Wang F, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/482146.
   Wang G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20182374.
   Wang JR, 2019, CANCER BIOMARK, V24, P159, DOI 10.3233/CBM-182000.
   Wang JH, 2019, CANCER MANAG RES, V11, P251, DOI 10.2147/CMAR.S185015.
   Wang PY, 2013, ONCOL LETT, V6, P1681, DOI 10.3892/ol.2013.1593.
   Wang S, 2014, INT J CLIN EXP PATHO, V7, P3498.
   Wang YD, 2008, CELL RES, V18, P1087, DOI 10.1038/cr.2008.289.
   Wang Z, 2017, EUR REV MED PHARMACO, V21, P5624, DOI 10.26355/eurrev\_201712\_14005.
   WARBURG O, 1956, SCIENCE, V124, P269.
   Ward PS, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006783.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Wei Q, 2015, THORAC CANCER, V6, P2, DOI 10.1111/1759-7714.12164.
   Welberg L, 2009, NAT REV NEUROSCI, V10, P468, DOI 10.1038/nrn2674.
   Weng YP, 2018, BIOCHEM BIOPH RES CO, V503, P2749, DOI 10.1016/j.bbrc.2018.08.035.
   WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105.
   Wojtkowiak JW, 2015, CANCER METAB, V3, DOI 10.1186/s40170-014-0026-z.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Wu JG, 2018, HEPATOLOGY, V68, P1111, DOI 10.1002/hep.29902.
   Wu PF, 2001, BIOCHEM BIOPH RES CO, V287, P391, DOI 10.1006/bbrc.2001.5608.
   Wynn RM, 2008, J BIOL CHEM, V283, P25305, DOI 10.1074/jbc.M802249200.
   Xie Q, 2015, MOL MED REP, V11, P2935, DOI 10.3892/mmr.2014.3080.
   Xie Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep18751.
   Xie YF, 2014, STEM CELL RES, V13, P478, DOI 10.1016/j.scr.2014.07.007.
   Xie ZC, 2019, AM J TRANSL RES, V11, P4922.
   Xu B, 2018, EUR J MED CHEM, V155, P275, DOI 10.1016/j.ejmech.2018.06.012.
   Xu S, 2019, J CELL BIOCHEM, V120, P12810, DOI 10.1002/jcb.28552.
   Xue X, 2012, MOL PHARMACEUT, V9, P634, DOI 10.1021/mp200571k.
   Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441.
   Yang C, 2019, J CANCER, V10, P918, DOI 10.7150/jca.27226.
   Yang F, 2019, J CELL BIOCHEM, V120, P13202, DOI 10.1002/jcb.28594.
   Yang Z, 2018, EUR J PHARMACOL, V838, P41, DOI 10.1016/j.ejphar.2018.09.016.
   Yang ZL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0337-5.
   Yauch RL, 2005, CLIN CANCER RES, V11, P8686, DOI 10.1158/1078-0432.CCR-05-1492.
   Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001.
   YOUNT EA, 1982, J PHARMACOL EXP THER, V222, P501.
   Youssef J, 2011, BRIT J PHARMACOL, V164, P68, DOI 10.1111/j.1476-5381.2011.01383.x.
   Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8.
   Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095.
   Zhang LS, 2012, HEPATOLOGY, V56, P2336, DOI 10.1002/hep.25905.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.
   Zhang N, 2011, BIOTECHNOL BIOENG, V108, P1413, DOI 10.1002/bit.23071.
   Zhang P, 2018, FASEB J, V32, P3924, DOI 10.1096/fj.201701078R.
   Zhang SL, 2018, BIOORG MED CHEM LETT, V28, P3441, DOI 10.1016/j.bmcl.2018.09.026.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang WJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179672.
   Zhang XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084548.
   Zhang Y, 2016, J BIOL CHEM, V291, P17405, DOI 10.1074/jbc.M116.713735.
   Zhang Y, 2017, ONCOTARGET, V8, P55489, DOI 10.18632/oncotarget.18590.
   Zhang YL, 2019, AM J TRANSL RES, V11, P1084.
   Zheng CH, 2018, CELL BIOL INT, V42, P1386, DOI 10.1002/cbin.11024.
   Zhong H, 1999, CANCER RES, V59, P5830.
   Zhou X., 2015, MOL CANCER, V14, P1.
   Zhou XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5573.
   Zhu C, 2015, ACTA BIOCH BIOPH SIN, V47, P16, DOI 10.1093/abbs/gmu110.
   Zhu YP, 2016, CANCER LETT, V380, P369, DOI 10.1016/j.canlet.2016.04.030.
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011.
   Zuo RJ, 2015, J BIOL CHEM, V290, P21280, DOI 10.1074/jbc.M115.656629.},
Number-of-Cited-References = {353},
Times-Cited = {128},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {70},
Journal-ISO = {Biochim. Biophys. Acta-Rev. Cancer},
Doc-Delivery-Number = {TU7FQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000681198600024},
DA = {2026-02-04},
}

@article{ WOS:000670116800002,
Author = {Zeng, Miaolin and Zhou, Huifen and He, Yu and Wang, Zhixiong and Shao,
   Chongyu and Yin, Junjun and Du, Haixia and Yang, Jiehong and Wan,
   Haitong},
Title = {Danhong injection alleviates cerebral ischemia/reperfusion injury by
   improving intracellular energy metabolism coupling in the ischemic
   penumbra},
Journal = {BIOMEDICINE \& PHARMACOTHERAPY},
Year = {2021},
Volume = {140},
Month = {AUG},
Abstract = {Danhong injection (DHI) is a compound Chinese medicine widely used in
   China for treatment of ischemic cardiocerebrovascular diseases. However,
   limited data are available regarding the protective effect of DHI on the
   ischemic penumbra in ischemic stroke. This study aimed to investigate
   the effect of intravenous DHI on neuronal injure in the ischemic
   penumbra after cerebral ischemia/reperfusion (CI/R), focusing especially
   on the involvement of intracellular energy metabolism coupling. Male
   Sprague-Dawley rats were subjected to right middle cerebral artery
   occlusion for 60 min followed by reperfusion with or without intravenous
   DHI (0.5, 1.0, or 2.0 mL/kg) once daily for 7 days. Post-treatment with
   DHI ameliorated neurological defects, diminished cerebral infarction,
   alleviated cerebral edema, improved microcirculatory perfusion after
   7days of reperfusion, and inhibited apoptosis and enhanced neuronal
   survival in the ischemic penumbra. In addition, DHI significantly
   ameliorated oxidative stress, reduced DNA damage, and inhibited the
   activation of PARP1/AIF pathway, thereby restoring cytoplasmic
   glycolytic activity. Furthermore, this drug increased PDH activity by
   inhibiting the HIF1 alpha/ PDK1 signaling pathway, thus eliminating the
   inhibitory effect of CI/R on mitochondrial metabolism. The results of
   this study suggest that DHI can alleviate cerebral edema after CI/R and
   rescue the ischemic penumbra, and these protective effects are due to
   the regulation of intracellular energy metabolic coupling.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Yang, JH; Wan, HT (Corresponding Author), Zhejiang Chinese Med Univ, Coll Basic Med Sci, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   Wan, HT (Corresponding Author), Zhejiang Chinese Med Univ, Coll Life Sci, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   Zeng, Miaolin; Yin, Junjun; Yang, Jiehong; Wan, Haitong, Zhejiang Chinese Med Univ, Coll Basic Med Sci, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   Zhou, Huifen; Wang, Zhixiong; Shao, Chongyu; Du, Haixia; Wan, Haitong, Zhejiang Chinese Med Univ, Coll Life Sci, 548 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   He, Yu, Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.},
DOI = {10.1016/j.biopha.2021.111771},
EarlyAccessDate = {MAY 2021},
Article-Number = {111771},
ISSN = {0753-3322},
EISSN = {1950-6007},
Keywords = {Danhong injection; Cerebral ischemia reperfusion; Cerebral edema;
   Ischemic penumbra; Energy metabolism; Parthanatos; Glycolysis;
   Mitochondria},
Keywords-Plus = {MITOCHONDRIAL OXIDATIVE STRESS; NAD(+) DEPLETION; BRAIN EDEMA;
   CELL-DEATH; MECHANISMS; CHALLENGES; STROKE; AIF},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {jiehongy@yeah.net
   whaitong@126.com},
Affiliations = {Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University},
ResearcherID-Numbers = {wan, hai/GSM-9077-2022
   Du, Haixia/MGW-2678-2025},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81874366, 81873226];
   National Key R\&D Program of China {[}2019YFC1708600, 2019YFC1708604];
   Provincial Natural Science Foundation of Zhejiang {[}LZ17H270001]; Key
   Laboratory of TCM Encephalopathy of Zhejiang Province {[}2020E10012]},
Funding-Text = {This work was supported by the grants from National Natural Science
   Foundation of China (No. 81874366 for HW; No. 81873226 for YH), National
   Key R\&D Program of China (No. 2019YFC1708600, 2019YFC1708604 for HW),
   Provincial Natural Science Foundation of Zhejiang (No. LZ17H270001 for
   JY), Key Laboratory of TCM Encephalopathy of Zhejiang Province (No.
   2020E10012).},
Cited-References = {Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200.
   Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010.
   Baron JC, 2018, NAT REV NEUROL, V14, P325, DOI 10.1038/s41582-018-0002-2.
   Campbell BCV, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0118-8.
   Chen YY, 2015, SCI REP-UK, V5, DOI 10.1038/srep11802.
   Cheng Q, 2019, BRAIN RES, V1706, P166, DOI 10.1016/j.brainres.2018.11.010.
   Custodis F, 2006, CARDIOVASC RES, V71, P342, DOI 10.1016/j.cardiores.2006.04.005.
   Di-Poï N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c.
   El-Domyati MM, 2010, FERTIL STERIL, V93, P795, DOI 10.1016/j.fertnstert.2008.10.031.
   Fatokun AA, 2014, BRIT J PHARMACOL, V171, P2000, DOI 10.1111/bph.12416.
   Feng XJ, 2019, PHARMACOL RES, V139, P62, DOI 10.1016/j.phrs.2018.11.006.
   Ginsberg MD, 1999, ACTA NEUROCHIR SUPPL, V73, P45.
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X.
   Goyal M, 2016, STROKE, V47, P548, DOI 10.1161/STROKEAHA.115.011426.
   Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X.
   Holness MJ, 2003, BIOCHEM SOC T, V31, P1143.
   HOSSMANN KA, 1980, STROKE, V11, P583, DOI 10.1161/01.STR.11.6.583.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Langelier MF, 2012, SCIENCE, V336, P728, DOI 10.1126/science.1216338.
   Li M, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00308.
   Liang LP, 2004, FREE RADICAL BIO MED, V36, P542, DOI 10.1016/j.freeradbiomed.2003.11.029.
   Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106.
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84.
   Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080.
   Michinaga S, 2015, INT J MOL SCI, V16, P9949, DOI 10.3390/ijms16059949.
   Murphy MP, 2018, NAT REV DRUG DISCOV, V17, P865, DOI 10.1038/nrd.2018.174.
   Nicholls DG, 2015, J BIOENERG BIOMEMBR, V47, P63, DOI 10.1007/s10863-014-9573-9.
   Schönenberger MJ, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00042.
   Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8.
   Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010.
   Sokkar P, 2012, J MOL MODEL, V18, P1691, DOI 10.1007/s00894-011-1150-0.
   Velarde MC, 2012, AGING-US, V4, P3, DOI 10.18632/aging.100423.
   Virág L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375.
   Virag Laszlo, 2005, Current Vascular Pharmacology, V3, P209, DOI 10.2174/1570161054368625.
   Wallin MT, 2019, LANCET NEUROL, V18, P269, DOI 10.1016/S1474-4422(18)30443-5.
   Wang H, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/8949835.
   White BC, 2000, J NEUROL SCI, V179, P1, DOI 10.1016/S0022-510X(00)00386-5.
   Yang J, 2009, CANCER BIOL THER, V8, P799, DOI 10.4161/cbt.8.9.8318.
   Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221.
   Zeng HK, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-153.
   Zeng ML, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.598112.
   Zhang DL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09014-2.
   Zhang L, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.591197.},
Number-of-Cited-References = {43},
Times-Cited = {44},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {33},
Journal-ISO = {Biomed. Pharmacother.},
Doc-Delivery-Number = {TE6JK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000670116800002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000860655700005,
Author = {Hallows, Kenneth R. and Althouse, Andrew D. and Li, Hui and Saitta,
   Biagio and Abebe, Kaleab Z. and Bae, Kyongtae T. and Miskulin, Dana C.
   and Perrone, Ronald D. and Seliger, Stephen L. and Watnick, Terry J.},
Title = {Association of Baseline Urinary Metabolic Biomarkers with ADPKD Severity
   in TAME-PKD Clinical Trial Participants},
Journal = {KIDNEY360},
Year = {2021},
Volume = {2},
Number = {5},
Pages = {795-808},
Month = {MAY 27},
Abstract = {Background Recent work suggests that dysregulated cellular metabolism
   may play a key role in the pathogenesis of autosomal dominant polycystic
   kidney disease (ADPKD). The TAME-PKD clinical trial is testing the
   safety, tolerability, and efficacy of metformin, a regulator of cell
   metabolism, in patients with ADPKD. This study investigates the
   cross-sectional association of urinary metabolic biomarkers with ADPKD
   severity among TAMEPKD trial participants at baseline. Methods
   Concentrations of total protein, targeted metabolites (lactate,
   pyruvate, succinate, and cAMP), and key glycolytic enzymes (pyruvate
   kinase M2 {[}PKM2], lactate dehydrogenase A {[}LDHA], and pyruvate
   dehydrogenase kinase 1 {[}PDK1]) were measured by ELISA, enzymatic
   assays, and immunoblotting in baseline urine specimens of 95 TAME-PKD
   participants. These analytes, normalized by urinary creatinine or
   osmolality to estimate excretion, were correlated with patients'
   baseline height-adjusted total kidney volumes (ht TKVs) by MRI and eGFR.
   Additional analyses were performed, adjusting for participants' age and
   sex, using multivariable linear regression. Results Greater htm TKV
   correlated with lower eGFR (r=20.39; P=0.0001). Urinary protein
   excretion modestly correlated with eGFR (negatively) and ht TKV
   (positively). Urinary cAMP normalized to creatinine positively
   correlated with eGFR. Among glycolytic enzymes, PKM2 and LDHA excretion
   positively correlated with ht TKV, whereas PKM2 excretion negatively
   correlated with eGFR. These associations remained significant after
   adjustments for age and sex. Moreover, in adjusted models, succinate
   excretion was positively associated with eGFR, and protein excretion was
   more strongly associated with both eGFR and ht TKV in patients ,43 years
   old. Conclusions Proteinuria correlated with ADPKD severity, and urinary
   excretion of PKM2 and LDHA correlated with ADPKD severity at baseline in
   the TAME-PKD study population. These findings are the first to provide
   evidence in human urine samples that up regulated glycolytic flux is a
   feature of ADPKD severity. Future analysis may reveal if metformin
   treatment affects both disease progression and the various urinary
   metabolic biomarkers in patients throughout the study.},
Publisher = {AMER SOC NEPHROLOGY},
Address = {1401 H Street NW, Suite 900, WASHINGTON, DC 20005, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Hallows, KR (Corresponding Author), Univ Southern Calif, Dept Med, Div Nephrol \& Hypertens, 2020 Zonal Ave,IRD 806, Los Angeles, CA 90033 USA.
   Hallows, KR (Corresponding Author), Univ Southern Calif, Keck Sch Med, USC UKRO Kidney Res Ctr, 2020 Zonal Ave,IRD 806, Los Angeles, CA 90033 USA.
   Hallows, Kenneth R.; Li, Hui; Saitta, Biagio, Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   Althouse, Andrew D.; Abebe, Kaleab Z.; Bae, Kyongtae T., Univ Pittsburgh, Pittsburgh, PA USA.
   Miskulin, Dana C.; Perrone, Ronald D., Tufts Med Ctr, Boston, MA 02111 USA.
   Seliger, Stephen L.; Watnick, Terry J., Univ Maryland, Sch Med, Baltimore, MD 21201 USA.},
DOI = {10.34067/KID.0005962020},
ISSN = {2641-7650},
Keywords = {cystic kidney disease; ADPKD; biomarkers; GFR; metabolism; metformin},
Keywords-Plus = {ACTIVATED PROTEIN-KINASE; METFORMIN; VOLUME},
Research-Areas = {Urology \& Nephrology},
Web-of-Science-Categories  = {Urology \& Nephrology},
Author-Email = {hallows@usc.edu},
Affiliations = {University of Southern California; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Tufts Medical
   Center; University System of Maryland; University of Maryland Baltimore},
ResearcherID-Numbers = {Hallows, Kenneth/A-8477-2013
   Abebe, Kaleab/K-4400-2019
   Althouse, Anew/AAF-4836-2019},
ORCID-Numbers = {Seliger, Stephen/0000-0002-1693-0734
   Hallows, Kenneth/0000-0002-2964-2440
   Althouse, Anew/0000-0002-8654-5014},
Funding-Acknowledgement = {U.S. Department of Defense Congressionally Directed Medical Research
   Program {[}W81XWH-15-1-0663]; National Center for Advancing
   Translational Sciences {[}UL1TR002544, 1UL1TR003098]; Baltimore
   Polycystic Kidney Disease Research Center Clinical and Translational
   Core under National Institute of Diabetes and Digestive and Kidney
   Diseases {[}P30 DK090868]; National Center for Advancing Translational
   Sciences {[}UL1TR002544, UL1TR003098] Funding Source: NIH RePORTER},
Funding-Text = {This study was supported by the U.S. Department of Defense
   Congressionally Directed Medical Research Program (W81XWH-15-1-0663),
   and National Center for Advancing Translational Sciences awards
   UL1TR002544 and 1UL1TR003098. This work also used resources developed by
   the Baltimore Polycystic Kidney Disease Research Center Clinical and
   Translational Core under National Institute of Diabetes and Digestive
   and Kidney Diseases grant P30 DK090868.},
Cited-References = {Bergmann C, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0047-y.
   Chapman AB, 2012, CLIN J AM SOC NEPHRO, V7, P479, DOI 10.2215/CJN.09500911.
   Chebib FT, 2016, AM J KIDNEY DIS, V67, P792, DOI 10.1053/j.ajkd.2015.07.037.
   Cheon JH, 2016, TOX RESEARCH, V32, P47.
   Dekker SEI, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233213.
   Grantham JJ, 2006, NEW ENGL J MED, V354, P2122, DOI 10.1056/NEJMoa054341.
   Jayasena CN, 2014, NAT REV ENDOCRINOL, V10, P624, DOI 10.1038/nrendo.2014.102.
   Kawano H, 2015, CLIN EXP NEPHROL, V19, P968, DOI 10.1007/s10157-014-1078-7.
   Lanktree MB, 2019, NEPHROL DIAL TRANSPL, V34, P1453, DOI 10.1093/ndt/gfy261.
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006.
   Menezes LF, 2016, EBIOMEDICINE, V5, P183, DOI 10.1016/j.ebiom.2016.01.027.
   Padovano V, 2018, NAT REV NEPHROL, V14, P678, DOI 10.1038/s41581-018-0051-1.
   Rowe I, 2013, NAT MED, V19, P488, DOI 10.1038/nm.3092.
   Schrier RW, 2014, NEW ENGL J MED, V371, P2255, DOI 10.1056/NEJMoa1402685.
   Schrier RW, 2014, J AM SOC NEPHROL, V25, P2399, DOI 10.1681/ASN.2013111184.
   Seliger SL, 2018, AM J NEPHROL, V47, P352, DOI 10.1159/000488807.
   SUN T, 1985, ANN CLIN LAB SCI, V15, P32.
   Takiar V, 2011, P NATL ACAD SCI USA, V108, P2462, DOI 10.1073/pnas.1011498108.
   Torres VE, 2012, NEW ENGL J MED, V367, P2407, DOI 10.1056/NEJMoa1205511.
   Torres VE, 2012, KIDNEY INT, V81, P577, DOI 10.1038/ki.2011.411.
   Weimbs T, 2018, CLIN KIDNEY J, V11, pI27, DOI 10.1093/ckj/sfy089.
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505.},
Number-of-Cited-References = {22},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Kidney360},
Doc-Delivery-Number = {4X2CM},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000860655700005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000663774300004,
Author = {Zeng, Miaolin and Shao, Chongyu and Zhou, Huifen and He, Yu and Li,
   Wentao and Zeng, Jieqiong and Zhao, Xixi and Yang, Jiehong and Wan,
   Haitong},
Title = {Protocatechudehyde improves mitochondrial energy metabolism through the
   HIF1α/PDK1 signaling pathway to mitigate ischemic stroke-elicited
   internal capsule injury},
Journal = {JOURNAL OF ETHNOPHARMACOLOGY},
Year = {2021},
Volume = {277},
Month = {SEP 15},
Abstract = {Ethnopharmacological relevance: The internal capsule is vulnerable to
   ischemia, and mild ischemic stroke often results in lesion of the
   internal capsule, manifested as contralateral hemiplegia.
   Protocatechudehyde (PCA), a potential neuroprotective agent, has shown
   therapeutic effects in the study of a variety of nervous system
   diseases, including ischemic stroke.
   Aim of the study: The aim of this study was to evaluate the effects of
   PCA on cerebral ischemia reperfusion (CI/R)elicited internal capsule
   injury and to elucidate the role of mitochondrial energy metabolism in
   the underlying mechanism of neuroprotective effects on ischemic stroke.
   Materials and methods: A rat tMCAO model was established to investigate
   the therapeutic effects of intravenous PCA (20, 40, and 80 mg/kg, once
   per day, continued for 7 days) on CI/R-induced internal capsule injury
   and the regulation of PCA on molecules related to mitochondrial energy
   metabolism. In vitro, an OGD/R model of PC12 cells was established to
   further verify the therapeutic mechanism of PCA.
   Results: Results showed that PCA dose-dependently attenuated
   neurological deficit, reduced cerebral infarction, alleviated
   histopathological damage, and improved mitochondrial ultrastructure of
   the internal capsule after CI/R. Moreover, PCA reversed the upregulation
   of HIF1 alpha, PDK1 and pPDHA1 expression induced by CI/R and
   significantly increased the content of acetyl-CoA, ATP, and the activity
   of ATP synthase. In vitro, PCA treatment promoted cell survival,
   inhibited apoptosis, attenuated the dissipation of mitochondrial
   membrane potential in OGD/R-treated PC12 cells, and these therapeutic
   effects were reversed by the combination of cobalt chloride (CoCl2), a
   specific pharmacological inducer of HIF1a expression.
   Conclusions: These results indicate that PCA exerts a protective effect
   against CI/R-induced internal capsule injury and improves mitochondrial
   energy metabolism in the internal capsule, and the mechanism is
   associated with the inhibition of HIF1 alpha/PDK1 signaling pathway.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, JH; Wan, HT (Corresponding Author), Zhejiang Chinese Med Univ, Coll Basic Med Sci, 548 Binwen Rd, Hangzhou 310053, Peoples R China.
   Zeng, Miaolin; Zeng, Jieqiong; Zhao, Xixi; Yang, Jiehong; Wan, Haitong, Zhejiang Chinese Med Univ, Coll Basic Med Sci, 548 Binwen Rd, Hangzhou 310053, Peoples R China.
   Shao, Chongyu; Zhou, Huifen; Wan, Haitong, Zhejiang Chinese Med Univ, Coll Life Sci, Hangzhou 310053, Peoples R China.
   He, Yu; Li, Wentao, Zhejiang Chinese Med Univ, Coll Pharmaceut Sci, Hangzhou 310053, Peoples R China.},
DOI = {10.1016/j.jep.2021.114232},
EarlyAccessDate = {MAY 2021},
Article-Number = {114232},
ISSN = {0378-8741},
EISSN = {1872-7573},
Keywords = {Protocatechudehyde; Ischemic stroke; Internal capsule; Mitochondria;
   Energy metabolism; HIF1 alpha},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE COMPLEX; CEREBRAL-ISCHEMIA; KINASE; OXYGEN; BRAIN},
Research-Areas = {Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine},
Web-of-Science-Categories  = {Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy},
Author-Email = {jiehongy@yeah.net
   whaitong@126.com},
Affiliations = {Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University},
ResearcherID-Numbers = {Jin, Weifeng/C-7360-2017
   wan, hai/GSM-9077-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81874366, 81873226,
   81973560]; National Key R\&D Program of China {[}2019YFC1708600,
   2019YFC1708604]; Provincial Natural Science Foundation of Zhejiang
   {[}LZ17H270001]; Key Laboratory of TCM Encephalopathy of Zhejiang
   Province {[}2020E10012]},
Funding-Text = {This work was supported by the grants from National Natural Science
   Foundation of China (No. 81874366 for HW; No. 81873226 for YH; No.
   81973560 for JY) , National Key R\&D Program of China (No.
   2019YFC1708600, 2019YFC1708604 for HW) , Provincial Natural Science
   Foundation of Zhejiang (No. LZ17H270001 for JY) , Key Laboratory of TCM
   Encephalopathy of Zhejiang Province (No. 2020E10012) .},
Cited-References = {ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723.
   Burger KA, 2005, NEUROIMAG CLIN N AM, V15, P297, DOI 10.1016/j.nic.2005.05.005.
   Cai LP, 2016, J NEUROSCI RES, V94, P749, DOI 10.1002/jnr.23740.
   Chang CC, 2016, J ETHNOPHARMACOL, V186, P311, DOI 10.1016/j.jep.2016.04.018.
   Chen PY, 2015, FOOD FUNCT, V6, P287, DOI 10.1039/c4fo00948g.
   Chen QF, 2018, STROKE, V49, P2211, DOI 10.1161/STROKEAHA.118.021754.
   Dinh PC, 2019, PREV MED, V118, P184, DOI 10.1016/j.ypmed.2018.10.018.
   Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333.
   Eltzschig HK, 2011, NAT MED, V17, P1391, DOI 10.1038/nm.2507.
   Gao JW, 2011, J PHARMACOL SCI, V115, P36, DOI 10.1254/jphs.10271FP.
   Guo C, 2019, AGING-US, V11, P9424, DOI 10.18632/aging.102394.
   Guo C, 2017, MOL NEUROBIOL, V54, P833, DOI 10.1007/s12035-016-9690-z.
   Han JY, 2008, PHARMACOL THERAPEUT, V117, P280, DOI 10.1016/j.pharmthera.2007.09.008.
   Hankey GJ, 2017, LANCET, V389, P641, DOI 10.1016/S0140-6736(16)30962-X.
   Hawkes MA, 2019, J NEUROL SCI, V401, P1, DOI 10.1016/j.jns.2019.04.009.
   He LY, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1522-0.
   Holness MJ, 2003, BIOCHEM SOC T, V31, P1143.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kong BS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113242.
   Lao CJ, 2003, AM J CHINESE MED, V31, P191, DOI 10.1142/S0192415X03000916.
   LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84.
   Luo C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00386.
   Magistretti PJ, 2018, NAT REV NEUROSCI, V19, P235, DOI 10.1038/nrn.2018.19.
   Murphy MP, 2018, NAT REV DRUG DISCOV, V17, P865, DOI 10.1038/nrd.2018.174.
   Naia L, 2017, J NEUROSCI, V37, P2776, DOI 10.1523/JNEUROSCI.2006-14.2016.
   Ren N., 2021, BioRxiv, P2021.
   Schönenberger MJ, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00042.
   Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010.
   Sokkar P, 2012, J MOL MODEL, V18, P1691, DOI 10.1007/s00894-011-1150-0.
   Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172.
   Tai TC, 2009, J NEUROCHEM, V109, P513, DOI 10.1111/j.1471-4159.2009.05978.x.
   Vakifahmetoglu-Norberg H, 2017, BIOCHEM BIOPH RES CO, V482, P426, DOI 10.1016/j.bbrc.2016.11.088.
   Warner JJ, 2019, STROKE, V50, P3331, DOI 10.1161/STROKEAHA.119.027708.
   Zeng ML, 2021, LIFE SCI, V265, DOI 10.1016/j.lfs.2020.118766.},
Number-of-Cited-References = {34},
Times-Cited = {16},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {24},
Journal-ISO = {J. Ethnopharmacol.},
Doc-Delivery-Number = {SV4ET},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000663774300004},
DA = {2026-02-04},
}

@article{ WOS:000651193100001,
Author = {Yang, Yu-ying and Zhou, Yan-man and Xu, Jing-zun and Sun, Li-hao and
   Tao, Bei and Wang, Wei-qing and Wang, Ji-qiu and Zhao, Hong-yan and Liu,
   Jian-min},
Title = {Lgr4 promotes aerobic glycolysis and differentiation in osteoblasts via
   the canonical Wnt/β-catenin pathway},
Journal = {JOURNAL OF BONE AND MINERAL RESEARCH},
Year = {2021},
Volume = {36},
Number = {8},
Pages = {1605-1620},
Month = {AUG},
Abstract = {Lgr4, a G-protein-coupled receptor, is associated with various
   physiological and pathological processes including oncogenesis, energy
   metabolism, and bone remodeling. However, whether Lgr4 is involved in
   osteoblasts' metabolism is not clear. Here we uncover that in
   preosteoblast cell line, lacking Lgr4 results in decreased osteogenic
   function along with reduced glucose consumption, glucose uptake, and
   lactate production in the presence of abundant oxygen, which is referred
   to as aerobic glycolysis. Activating canonical Wnt/beta-catenin
   signaling rescued the glycolytic dysfunction. Lgr4 promotes the
   expression of pyruvate dehydrogenase kinase 1 (pdk1) and is abolished by
   interfering canonical Wnt/beta-catenin signaling. Mice lacking Lgr4
   specifically in osteoblasts (Lgr4(osb-/-)) exhibit decreased bone mass
   and strength due to reduced bone formation. Additionally, glycolysis of
   osteoblasts is impaired in Lgr4(osb-/-) mice. Our study reveals a novel
   function of Lgr4 in regulating the cellular metabolism of osteoblasts.
   (c) 2021 American Society for Bone and Mineral Research (ASBMR).},
Publisher = {OXFORD UNIV PRESS},
Address = {GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, JQ; Zhao, HY; Liu, JM (Corresponding Author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Sch Med, Dept Endocrine \& Metab Dis, 197 Rui Jin Er Rd, Shanghai 200025, Peoples R China.
   Yang, Yu-ying; Zhou, Yan-man; Xu, Jing-zun; Sun, Li-hao; Tao, Bei; Wang, Wei-qing; Wang, Ji-qiu; Zhao, Hong-yan; Liu, Jian-min, Shanghai Jiao Tong Univ, Ruijin Hosp, Shanghai Inst Endocrine \& Metab Dis, Dept Endocrine \& Metab Dis,Sch Med, Shanghai, Peoples R China.
   Yang, Yu-ying; Zhou, Yan-man; Xu, Jing-zun; Sun, Li-hao; Tao, Bei; Wang, Wei-qing; Wang, Ji-qiu; Zhao, Hong-yan; Liu, Jian-min, Shanghai Jiao Tong Univ, Shanghai Natl Clin Res Ctr Metab Dis, Key Lab Endocrine \& Metab Dis,Ruijin Hosp,Sch Med, Natl Hlth Commiss PR China,Shanghai Natl Ctr Tran, Shanghai, Peoples R China.},
DOI = {10.1002/jbmr.4321},
EarlyAccessDate = {MAY 2021},
ISSN = {0884-0431},
EISSN = {1523-4681},
Keywords = {Lgr4; OSTEOBLASTS; GLYCOLYSIS; BONE REMODELING; OSTEOPOROSIS},
Keywords-Plus = {BETA-CATENIN; BONE ANABOLISM; METABOLISM; RECEPTOR; CELLS; GENE},
Research-Areas = {Endocrinology \& Metabolism},
Web-of-Science-Categories  = {Endocrinology \& Metabolism},
Author-Email = {wangjq@shsmu.edu.cn
   hyanzhao@163.com
   ljm10586@rjh.com.cn},
Affiliations = {Shanghai Jiao Tong University; Shanghai Jiao Tong University},
ResearcherID-Numbers = {Yang, Yu-Ying/KEI-9974-2024
   Liu, Jian-min/KEI-9744-2024
   Wang, Jiqiu/AGM-1346-2022},
ORCID-Numbers = {Yang, Yu-Ying/0000-0001-5167-3262
   Liu, Jian-min/0000-0002-0179-1751
   Wang, Jiqiu/0000-0002-9383-7656},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81970758]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. 81970758).},
Cited-References = {BORLE AB, 1960, J BIOL CHEM, V235, P1206.
   Cai CF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0769-4.
   Cao YA, 2009, MOL CELL BIOL, V29, P5477, DOI 10.1128/MCB.00335-09.
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108.
   Chen JQ, 2013, J BONE MINER RES, V28, P1160, DOI 10.1002/jbmr.1834.
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085.
   COHN DV, 1962, J BIOL CHEM, V237, P615.
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388.
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805.
   Esen E, 2015, J BONE MINER RES, V30, P1959, DOI 10.1002/jbmr.2556.
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017.
   Fang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11662-3.
   Frey JL, 2015, MOL CELL BIOL, V35, P1979, DOI 10.1128/MCB.01343-14.
   Glass DA II, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017.
   Guntur AR, 2014, ENDOCRINOLOGY, V155, P1589, DOI 10.1210/en.2013-1974.
   Hahn JY, 2006, J BIOL CHEM, V281, P30979, DOI 10.1074/jbc.M603916200.
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200.
   Huang CK, 2020, CIRC RES, V127, P953, DOI 10.1161/CIRCRESAHA.119.315807.
   Jilka RL, 2007, BONE, V40, P1434, DOI 10.1016/j.bone.2007.03.017.
   Karner CM, 2015, J CLIN INVEST, V125, P551, DOI 10.1172/JCI78470.
   Koo BK, 2014, GASTROENTEROLOGY, V147, P289, DOI 10.1053/j.gastro.2014.05.007.
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428-09.
   Lecarpentier Y, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01248.
   Lee WC, 2017, ENDOCR REV, V38, P255, DOI 10.1210/er.2017-00064.
   Liu DM, 2016, BONE, V90, P50, DOI 10.1016/j.bone.2016.05.010.
   Luo J, 2016, NAT MED, V22, P539, DOI 10.1038/nm.4076.
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571.
   Mancini A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133434.
   PECK WA, 1964, SCIENCE, V146, P1476, DOI 10.1126/science.146.3650.1476.
   Rastogi A, 2019, J DIABETES, V11, P703, DOI 10.1111/1753-0407.12902.
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111.
   Shi GX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030564.
   Styrkarsdottir U, 2013, NATURE, V497, P517, DOI 10.1038/nature12124.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Wang JQ, 2013, NAT CELL BIOL, V15, P1455, DOI 10.1038/ncb2867.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Weng JS, 2008, P NATL ACAD SCI USA, V105, P6081, DOI 10.1073/pnas.0708257105.
   Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3.
   Yue ZY, 2018, FASEB J, V32, P2422, DOI 10.1096/fj.201700897R.
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200.
   Zhu C, 2016, CELL SIGNAL, V28, P989, DOI 10.1016/j.cellsig.2016.04.010.
   Zuo QZ, 2021, HEPATOLOGY, V73, P644, DOI 10.1002/hep.31280.},
Number-of-Cited-References = {42},
Times-Cited = {47},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {24},
Journal-ISO = {J. Bone Miner. Res.},
Doc-Delivery-Number = {TU3UB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000651193100001},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000649691500001,
Author = {Formica, Miriam and Storaci, Alessandra Maria and Bertolini, Irene and
   Carminati, Francesca and Knaevelsrud, Helene and Vaira, Valentina and
   Vaccari, Thomas},
Title = {V-ATPase controls tumor growth and autophagy in a Drosophila model of
   gliomagenesis},
Journal = {AUTOPHAGY},
Year = {2021},
Volume = {17},
Number = {12},
Pages = {4442-4452},
Month = {DEC 2},
Abstract = {Glioblastoma (GBM), a very aggressive and incurable tumor, often results
   from constitutive activation of EGFR (epidermal growth factor receptor)
   and of phosphoinositide 3-kinase (PI3K). To understand the role of
   autophagy in the pathogenesis of glial tumors in vivo, we used an
   established Drosophila melanogaster model of glioma based on
   overexpression in larval glial cells of an active human EGFR and of the
   PI3K homolog Pi3K92E/Dp110. Interestingly, the resulting hyperplastic
   glia express high levels of key components of the lysosomal-autophagic
   compartment, including vacuolar-type H+-ATPase (V-ATPase) subunits and
   ref(2)P (refractory to Sigma P), the Drosophila homolog of SQSTM1/p62.
   However, cellular clearance of autophagic cargoes appears inhibited
   upstream of autophagosome formation. Remarkably, downregulation of
   subunits of V-ATPase, of Pdk1, or of the Tor (Target of rapamycin)
   complex 1 (TORC1) component raptor prevents overgrowth and normalize
   ref(2)P levels. In addition, downregulation of the V-ATPase subunit
   VhaPPA1-1 reduces Akt and Tor-dependent signaling and restores
   clearance. Consistent with evidence in flies, neurospheres from patients
   with high V-ATPase subunit expression show inhibition of autophagy.
   Altogether, our data suggest that autophagy is repressed during glial
   tumorigenesis and that V-ATPase and MTORC1 components acting at
   lysosomes could represent therapeutic targets against GBM.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Vaccari, T (Corresponding Author), Univ Milan, Dept Biosci, Milan, Italy.
   Formica, Miriam; Carminati, Francesca; Vaccari, Thomas, Univ Milan, Dept Biosci, Milan, Italy.
   Storaci, Alessandra Maria; Bertolini, Irene; Vaira, Valentina, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Milan, Italy.
   Storaci, Alessandra Maria; Bertolini, Irene; Vaira, Valentina, Univ Milan, Dept Pathophysiol \& Transplantat, Milan, Italy.
   Knaevelsrud, Helene, Norwegian Radium Hosp, Oslo Univ Hosp, Inst Canc Res, Dept Mol Cell Biol, Oslo, Norway.
   Knaevelsrud, Helene, Univ Oslo, Fac Med, Inst Clin Med, Ctr Canc Cell Reprogramming, Oslo, Norway.},
DOI = {10.1080/15548627.2021.1918915},
EarlyAccessDate = {MAY 2021},
ISSN = {1554-8627},
EISSN = {1554-8635},
Keywords = {Autophagy; cancer model; fruit fly; glioblastoma; lysosomes;
   neurospheres; ref(2)P; V-ATPase},
Keywords-Plus = {PI3K/AKT/MTOR SIGNALING PATHWAY; CELL-GROWTH; LYSOSOMAL BIOGENESIS;
   GLIOBLASTOMA; INHIBITOR; MELANOGASTER; DEGRADATION; GENERATION; BRAIN;
   MTOR},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {thomas.vaccari@unimi.it},
Affiliations = {University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Milan; University of Oslo; University of Oslo},
ResearcherID-Numbers = {Vaira, Valentina/K-6499-2016
   vaccari, thomas/B-1945-2015
   Knævelsrud, Helene/G-9302-2016
   Formica, Miriam/Q-6336-2019},
ORCID-Numbers = {Storaci, Alessana Maria/0000-0001-9705-0618
   Knævelsrud, Helene/0000-0001-8848-8829
   BERTOLINI, IRENE/0000-0001-5824-6802
   Formica, Miriam/0000-0001-9407-9888},
Funding-Acknowledgement = {Associazione Italiana Ricerca contro il Cancro (AIRC) Investigator grant
   {[}20661]; Worldwide Cancer Research (WCR) grant {[}18-0399]; Fondazione
   Cariplo {[}2014-1148]; South-Eastern Norway Regional Health Authority
   fellowship {[}2017062]; Research Council of Norway {[}30078, 262652];
   University of Milan; European Union's Horizon 2020 research and
   innovation programme under the Marie Sklodowska-Curie {[}801133]},
Funding-Text = {TV acknowledges the support of the UNITECH Nolimits microscopy facility
   of the University of Milan. HK acknowledges the support of the core
   facility for Advanced Light Microscopy at Oslo University Hospital,
   Montebello node, for access, help and services. This work is supported
   by the Associazione Italiana Ricerca contro il Cancro (AIRC)
   Investigator grant 20661 and the Worldwide Cancer Research (WCR) grant
   18-0399 to TV, by Fondazione Cariplo (grant 2014-1148) to VV and by
   South-Eastern Norway Regional Health Authority fellowship 2017062 and
   Research Council of Norway grant 30078 to HK. The research leading to
   these results has received funding from the University of Milan and
   European Union's Horizon 2020 research and innovation programme under
   the Marie Sklodowska-Curie grant agreement No 801133. This work was
   partly supported by the Research Council of Norway through its Centres
   of Excellence funding scheme, project number 262652.},
Cited-References = {Barth JMI, 2011, CELL DEATH DIFFER, V18, P915, DOI 10.1038/cdd.2010.157.
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0.
   Bouché V, 2016, AUTOPHAGY, V12, P484, DOI 10.1080/15548627.2015.1134081.
   Buccarelli M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0864-7.
   Cho KS, 2001, P NATL ACAD SCI USA, V98, P6144, DOI 10.1073/pnas.101596998.
   Delgado-López PD, 2016, CLIN TRANSL ONCOL, V18, P1062, DOI 10.1007/s12094-016-1497-x.
   Di Cristofori A, 2015, ONCOTARGET, V6, P17514, DOI 10.18632/oncotarget.4239.
   Doherty J, 2009, J NEUROSCI, V29, P4768, DOI 10.1523/JNEUROSCI.5951-08.2009.
   Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029.
   Forgac Michael, 2018, Oncotarget, V9, P31793, DOI {[}10.18632/oncotarget.25883, 10.18632/oncotarget.25883].
   Freeman MR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020552.
   Fujiwara K, 2007, INT J ONCOL, V31, P753.
   Gammoh N, 2016, AUTOPHAGY, V12, P1431, DOI 10.1080/15548627.2016.1190053.
   Hanif Farina, 2017, Asian Pac J Cancer Prev, V18, P3.
   Harzer H, 2013, NAT PROTOC, V8, P1088, DOI 10.1038/nprot.2013.062.
   Hatanpaa KJ, 2010, NEOPLASIA, V12, P675, DOI 10.1593/neo.10688.
   Hegedus K, 2016, MOL BIOL CELL, V27, P3132, DOI 10.1091/mbc.E16-03-0205.
   Hu YH, 2013, G3-GENES GENOM GENET, V3, P1607, DOI 10.1534/g3.113.007021.
   Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549.
   Jiang YM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091945.
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359.
   Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815.
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5.
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811.
   Li XM, 2016, ONCOTARGET, V7, P33440, DOI 10.18632/oncotarget.7961.
   Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007.
   Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571.
   Natsumeda M, 2011, NEUROPATHOLOGY, V31, P486, DOI 10.1111/j.1440-1789.2010.01197.x.
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y.
   Nezis IP, 2008, J CELL BIOL, V180, P1065, DOI 10.1083/jcb.200711108.
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI {[}10.1093/neuonc/nox158, 10.1093/neuonc/nov189, 10.1093/neuonc/nou223].
   Palmieri M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14338.
   Peña-Llopis S, 2011, EMBO J, V30, P3242, DOI 10.1038/emboj.2011.257.
   Pérez E, 2015, ONCOGENE, V34, P3369, DOI 10.1038/onc.2014.285.
   Read RD, 2011, GLIA, V59, P1364, DOI 10.1002/glia.21148.
   Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374.
   Sami A, 2013, TUMOR BIOL, V34, P1991, DOI 10.1007/s13277-013-0800-5.
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447.
   Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32.
   Stransky L, 2016, PHYSIOL REV, V96, P1071, DOI 10.1152/physrev.00035.2015.
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350.
   Takamura A, 2011, GENE DEV, V25, P795, DOI 10.1101/gad.2016211.
   Takáts S, 2013, J CELL BIOL, V201, P531, DOI 10.1083/jcb.201211160.
   Terrasi A, 2019, EBIOMEDICINE, V41, P214, DOI 10.1016/j.ebiom.2019.01.052.
   Thakkar JP, 2014, CANCER EPIDEM BIOMAR, V23, P1985, DOI 10.1158/1055-9965.EPI-14-0275.
   Tognon E, 2016, AUTOPHAGY, V12, P499, DOI 10.1080/15548627.2015.1134080.
   Witte HT, 2009, NEOPLASIA, V11, P882, DOI 10.1593/neo.09576.
   Würstle S, 2017, ONCOL LETT, V14, P322, DOI 10.3892/ol.2017.6107.
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707.
   Zhang TY, 2015, J CELL SCI, V128, P2938, DOI 10.1242/jcs.173807.
   Zhao SW, 2018, CURR BIOL, V28, P3056, DOI 10.1016/j.cub.2018.07.075.},
Number-of-Cited-References = {51},
Times-Cited = {8},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Autophagy},
Doc-Delivery-Number = {XU9DW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000649691500001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000656385800002,
Author = {Hu, Rui and Chen, Shan and Yan, Jianxin},
Title = {Blocking circ-CNST suppresses malignant behaviors of osteosarcoma cells
   and inhibits glycolysis through circ-CNST-miR-578-LDHA/PDK1 ceRNA
   networks},
Journal = {JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH},
Year = {2021},
Volume = {16},
Number = {1},
Month = {MAY 7},
Abstract = {Background CircRNA CNST (circ-CNST) is a newly identified biomarker for
   prognosis of osteosarcoma (OS). However, its role in OS progression
   remains to be well documented. Methods Expression of circ-CNST, microRNA
   (miR)-578, lactate dehydrogenase A (LDHA), and pyruvate dehydrogenase
   kinase 1 (PDK1) was detected by quantitative real-time polymerase chain
   reaction and Western blotting. The physical interaction was confirmed by
   dual-luciferase reporter assay. Cell behaviors and glycolysis were
   measured by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide
   assay, colony formation assay, flow cytometry, transwell assays,
   xenograft experiment, and commercial kits. Results Circ-CNST was
   upregulated in human OS tissues and cells, accompanied with
   downregulation of miR-578 and upregulation of LDHA and PDK1. There were
   negative correlations between miR-578 expression and circ-CNST or
   LDHA/PDK1 in OS tissues. Moreover, high circ-CNST/LDHA/PDK1 or low
   miR-578 might predict shorter overall survival, advanced TNM stages, and
   lymph node metastasis. Physically, miR-578 was targeted by circ-CNST,
   and miR-578 could target LDHA/PDK1. Functionally, blocking circ-CNST and
   restoring miR-578 enhanced apoptosis rate and suppressed cell
   proliferation, colony formation, migration, and invasion in 143B and
   U2OS cells, accompanied with decreased glucose consumption, lactate
   production, and adenosine triphosphate (ATP)/adenosine diphosphate (ADP)
   ratio. Furthermore, in vivo growth of U2OS cells was retarded by
   silencing circ-CNST. Depletion of miR-578 could counteract the
   suppressive role of circ-CNST deficiency in 143B and U2OS cells, and
   restoring LDHA or PDK1 partially reversed the role of miR-578 inhibition
   as well. Conclusion Circ-CNST knockdown could antagonize malignant
   behaviors and glycolysis of OS cells by regulating miR-578-LDHA/PDK1
   axes.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yan, JX (Corresponding Author), Cent Hosp Enshi Tujia \& Miao Autonomous Prefectur, Dept Joint Surg, 158 Wuyang Ave, Enshi City 445000, Hubei, Peoples R China.
   Hu, Rui, Cent Hosp Enshi Tujia \& Miao Autonomous Prefectur, Dept Spine Surg Clin, Enshi City, Hubei, Peoples R China.
   Chen, Shan, Cent Hosp Enshi Tujia \& Miao Autonomous Prefectur, Dept Oncol, Enshi City, Hubei, Peoples R China.
   Yan, Jianxin, Cent Hosp Enshi Tujia \& Miao Autonomous Prefectur, Dept Joint Surg, 158 Wuyang Ave, Enshi City 445000, Hubei, Peoples R China.},
DOI = {10.1186/s13018-021-02427-0},
Article-Number = {300},
ISSN = {1749-799X},
Keywords = {Circ-CNST; miR-578; Osteosarcoma; Glycolysis; LDHA; PDK1},
Keywords-Plus = {LACTATE-DEHYDROGENASE; PROLIFERATION; MIGRATION; PROMOTES; RNAS;
   PROGRESSION; MAINTENANCE; INVASION; PLAYERS; MIR-578},
Research-Areas = {Orthopedics},
Web-of-Science-Categories  = {Orthopedics},
Author-Email = {yjx7401@163.com},
Cited-References = {Bielack SS, 2015, J CLIN ONCOL, V33, P2279, DOI 10.1200/JCO.2014.60.0734.
   Cao W, 2019, BIOORG MED CHEM LETT, V29, DOI 10.1016/j.bmcl.2019.126665.
   Chen HW, 2018, HUM CELL, V31, P300, DOI 10.1007/s13577-018-0215-0.
   Chen X, 2020, METABOLITES, V10, DOI 10.3390/metabo10070289.
   Chen Z, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01492-5.
   Cui XG, 2017, ONCOTARGET, V8, P24840, DOI 10.18632/oncotarget.15266.
   Danza K, 2015, ONCOTARGET, V6, P471, DOI 10.18632/oncotarget.2509.
   Du JY, 2015, ONCOL REP, V33, P1890, DOI 10.3892/or.2015.3797.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Fang AP, 2017, MEDCHEMCOMM, V8, P1720, DOI 10.1039/c7md00222j.
   Feng YB, 2018, CANCER MED-US, V7, P6124, DOI 10.1002/cam4.1820.
   Gao S, 2016, BIOMED PHARMACOTHER, V81, P388, DOI 10.1016/j.biopha.2016.04.029.
   Giang AH, 2013, J BIOL CHEM, V288, P33303, DOI 10.1074/jbc.M113.507129.
   Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345.
   Harmon C, 2020, ADV EXP MED BIOL, V1259, P113, DOI 10.1007/978-3-030-43093-1\_7.
   Ji XL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2204-y.
   Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6.
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838.
   Li SY, 2020, INT J BIOCHEM CELL B, V127, DOI 10.1016/j.biocel.2020.105826.
   Li X, 2020, AGING-US, V12, P14157, DOI 10.18632/aging.103423.
   Li Z, 2017, J CELL MOL MED, V21, P315, DOI 10.1111/jcmm.12966.
   Liu TZ, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2019.101197.
   Mao XH, 2021, HUM CELL, V34, P122, DOI 10.1007/s13577-020-00412-z.
   Pereira-Nunes A, 2020, ADV EXP MED BIOL, V1219, P51, DOI 10.1007/978-3-030-34025-4\_3.
   Qiu Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1134-1.
   Soghli N, 2020, GENOMICS, V112, P2845, DOI 10.1016/j.ygeno.2020.03.024.
   Sradhanjali S, 2018, CURR TOP MED CHEM, V18, P444, DOI 10.2174/1568026618666180523105756.
   Tu C, 2020, J CELL PHYSIOL, V235, P9037, DOI 10.1002/jcp.29754.
   Wan B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00370.
   Wang CC, 2018, INVEST NEW DRUG, V36, P1116, DOI 10.1007/s10637-018-0624-7.
   Wang DD, 2018, AM J TRANSL RES, V10, P1571.
   Wang JH, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720926147.
   Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1007-1.
   Xiong W, 2020, CELL SIGNAL, V71, DOI 10.1016/j.cellsig.2020.109603.
   Xu YN, 2020, ONCOTARGETS THER, V13, P3729, DOI 10.2147/OTT.S245366.
   Zhang ZC, 2020, GENE THER, V27, P186, DOI 10.1038/s41434-019-0112-5.
   Zheng XM, 2018, CELL MOL BIOL, V64, P31, DOI 10.14715/cmb/2018.64.11.6.},
Number-of-Cited-References = {37},
Times-Cited = {17},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {10},
Journal-ISO = {J. Orthop. Surg. Res.},
Doc-Delivery-Number = {SK7GX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000656385800002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000674217700003,
Author = {Liu, Chang and Zhu, Xiaoxia and Jia, Yuqi and Chi, Fenqing and Qin, Keru
   and Pei, Jinhong and Zhang, Chan and Mu, Xiuli and Zhang, Hongwei and
   Dong, Xiushan and Xu, Jun and Yu, Baofeng},
Title = {Dasatinib inhibits proliferation of liver cancer cells, but activation
   of Akt/mTOR compromises dasatinib as a cancer drug},
Journal = {ACTA BIOCHIMICA ET BIOPHYSICA SINICA},
Year = {2021},
Volume = {53},
Number = {7},
Pages = {823-836},
Month = {JUL},
Abstract = {Dasatinib is a multi-target protein tyrosine kinase inhibitor. Due to
   its potent inhibition of Src, Abl, the platelet-derived growth factor
   receptor (PDGFR) family kinases, and other oncogenic kinases, it has
   been investigated as a targeted therapy for a broad spectrum of cancer
   types. However, its efficacy has not been significantly extended beyond
   leukemia. The mechanism of resistance to dasatinib in a wide array of
   cancers is not clear. In the present study, we investigated the effect
   of dasatinib on hepatocellular carcinoma cell growth and explored the
   underlying mechanisms. Our results showed that dasatinib potently
   inhibited the proliferation of SNU-449 cells, but not that of other cell
   lines, such as SK-Hep-1, even though it inhibited the phosphorylation of
   Src on both negative and positive regulation sites in all these cells.
   Dasatinib activated the phosphoinositide-dependent protein kinase1
   (PDK1)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR)
   signaling pathway in SK-Hep-1 cells, but not in SNU-449 cells. Blocking
   the Akt/mTOR signaling pathway strongly promoted the efficacy of
   dasatinib in SK-Hep-1 cells. In SNU-449 cells, dasatinib promoted
   apoptosis and the cleavage of caspase-3 and caspase-7, induced cell
   cycle arrest in the G1 phase, and inhibited the expression of
   Cyclin-dependent kinase (CDK4)/6/CyclinD1 complex. These findings
   demonstrate that dasatinib exerts its anti-proliferative effect on
   hepatocellular cell proliferation by blocking the Src family kinases;
   however, it causes Akt activation, which compromises dasatinib as an
   anti-cancer drug.},
Publisher = {SCIENCE PRESS},
Address = {16 DONGHUANGCHENGGEN NORTH ST, BEIJING, 100717, PEOPLES R CHINA},
Type = {Article},
Language = {English},
Affiliation = {Yu, BF (Corresponding Author), Shanxi Med Univ, Dept Biochem \& Mol Biol, Taiyuan 030001, Peoples R China.
   Xu, J (Corresponding Author), Shanxi Med Univ, Dept Gen Surg, Hosp 1, Taiyuan 030001, Peoples R China.
   Liu, Chang; Pei, Jinhong, Changzhi Med Coll, Dept Biochem \& Mol Biol, Changzhi 046000, Peoples R China.
   Liu, Chang; Zhu, Xiaoxia; Jia, Yuqi; Chi, Fenqing; Qin, Keru; Zhang, Chan; Mu, Xiuli; Yu, Baofeng, Shanxi Med Univ, Dept Biochem \& Mol Biol, Taiyuan 030001, Peoples R China.
   Zhang, Hongwei, Shanxi Med Univ, Dept Hematol, Affiliated Tumor Hosp, Taiyuan 030013, Peoples R China.
   Dong, Xiushan, Shanxi Bethune Hosp, Dept Gen Surg, Taiyuan 030032, Peoples R China.
   Xu, Jun, Shanxi Med Univ, Dept Gen Surg, Hosp 1, Taiyuan 030001, Peoples R China.},
DOI = {10.1093/abbs/gmab061},
EarlyAccessDate = {MAY 2021},
ISSN = {1672-9145},
EISSN = {1745-7270},
Keywords = {dasatinib; SNU-449; SK-Hep-1; Akt-mTOR signaling},
Keywords-Plus = {CYTOCHROME-C RELEASE; HEPATOCELLULAR-CARCINOMA; CASPASE ACTIVATION;
   MOLECULAR TARGETS; PHASE-II; SRC; APOPTOSIS; IMATINIB; MITOCHONDRIA;
   RESISTANCE},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {shanxiyanuchengdg@163.com},
Affiliations = {Changzhi Medical College; Shanxi Medical University; Shanxi Medical
   University; Shanxi Medical University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}30901821, 82072737];
   Nature Science Project of Shanxi Province, China {[}201701D121165,
   201901D111190]; Shanxi Scholarship Council of China {[}2020194]; Key
   R\&D Projects in Shanxi Province, China {[}201703D421023]; Key
   Laboratory of Cellular Physiology (Shanxi Medical University), Ministry
   of Education, China {[}KLMEC/SXMU-202011]; Shanxi `1331 Project' Key
   Subjects Construction, China {[}1331KSC]; Scientific Research Starting
   Foundation for Doctor of Changzhi Medical College {[}BS202007]},
Funding-Text = {This work was supported by the grants from the National Natural Science
   Foundation of China (Nos. 30901821 and 82072737), Nature Science Project
   of Shanxi Province, China (Nos. 201701D121165 and 201901D111190),
   Research Project Supported by Shanxi Scholarship Council of China (No.
   2020194), Key R\&D Projects in Shanxi Province, China (No.
   201703D421023), Open Fund from Key Laboratory of Cellular Physiology
   (Shanxi Medical University), Ministry of Education, China (No.
   KLMEC/SXMU-202011), Shanxi `1331 Project' Key Subjects Construction,
   China (No. 1331KSC), and Scientific Research Starting Foundation for
   Doctor of Changzhi Medical College (No. BS202007).},
Cited-References = {Agrawal M, 2010, CURR HEMATOL MALIG R, V5, P70, DOI 10.1007/s11899-010-0045-y.
   Baro M, 2014, BRIT J CANCER, V111, P1310, DOI 10.1038/bjc.2014.432.
   Bodzin AS, 2015, WORLD J HEPATOL, V7, P1157, DOI 10.4254/wjh.v7.i9.1157.
   Bonse J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0878-1.
   Bruix J, 2013, EUR J CANCER, V49, P3412, DOI 10.1016/j.ejca.2013.05.028.
   Chan KT, 2004, CANCER CHEMOTH PHARM, V53, P519, DOI 10.1007/s00280-004-0767-4.
   Chang AY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-267.
   Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629.
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4.
   El Sayed I, 2018, LIFE SCI, V213, P248, DOI 10.1016/j.lfs.2018.10.002.
   El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090.
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6.
   Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225.
   Gao JJ, 2015, WORLD J GASTROENTERO, V21, P12059, DOI 10.3748/wjg.v21.i42.12059.
   Goldberg DS, 2017, HEPATOLOGY, V65, P864, DOI 10.1002/hep.28765.
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008.
   Haura EB, 2006, J THORAC ONCOL, V1, P403, DOI 10.1097/01243894-200606000-00003.
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704.
   Johnson FM, 2007, ANTI-CANCER AGENT ME, V7, P651, DOI 10.2174/187152007784111278.
   Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757.
   Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315.
   Kessler BE, 2019, ONCOGENE, V38, P2565, DOI 10.1038/s41388-018-0617-1.
   Kimura T, 2018, CANCER SCI, V109, P3993, DOI 10.1111/cas.13806.
   Kudo M, 2012, WORLD J GASTROENTERO, V18, P6005, DOI 10.3748/wjg.v18.i42.6005.
   Levitzki A, 2010, MOL ASPECTS MED, V31, P287, DOI 10.1016/j.mam.2010.04.001.
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857.
   Lu DSK, 2005, RADIOLOGY, V234, P954, DOI 10.1148/radiol.2343040153.
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375.
   Mayer EL, 2011, CLIN CANCER RES, V17, P6897, DOI 10.1158/1078-0432.CCR-11-0070.
   Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834.
   Miller AA, 2010, J THORAC ONCOL, V5, P380, DOI 10.1097/JTO.0b013e3181cee36e.
   Ni JY, 2014, WORLD J GASTROENTERO, V20, P17206, DOI 10.3748/wjg.v20.i45.17206.
   Nozawa H, 2008, CLIN CANCER RES, V14, P4336, DOI 10.1158/1078-0432.CCR-07-4857.
   Ottmann O, 2007, BLOOD, V110, P2309, DOI 10.1182/blood-2007-02-073528.
   Pez F, 2013, J HEPATOL, V59, P1107, DOI 10.1016/j.jhep.2013.07.001.
   Premkumar DR, 2010, INT J ONCOL, V37, P633, DOI 10.3892/ijo\_00000712.
   Puls LN, 2011, ONCOLOGIST, V16, P566, DOI 10.1634/theoncologist.2010-0408.
   Quintás-Cardama A, 2010, SEMIN HEMATOL, V47, P371, DOI 10.1053/j.seminhematol.2010.06.004.
   Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013.
   Sen B, 2009, CANCER RES, V69, P1958, DOI 10.1158/0008-5472.CAN-08-2944.
   Sharma MR, 2012, INVEST NEW DRUG, V30, P1211, DOI 10.1007/s10637-011-9681-x.
   Slotta JE, 2015, WORLD J HEPATOL, V7, P1168, DOI 10.4254/wjh.v7.i9.1168.
   Talpaz M, 2006, NEW ENGL J MED, V354, P2531, DOI 10.1056/NEJMoa055229.
   Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199.
   Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002.
   Zhong YS, 2013, DRUG DISCOV THER, V7, P164, DOI 10.5582/ddt.2013.v7.4.164.},
Number-of-Cited-References = {46},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Acta Biochim. Biophys. Sin.},
Doc-Delivery-Number = {TK5SI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000674217700003},
DA = {2026-02-04},
}

@article{ WOS:000646068400001,
Author = {Marofi, Faroogh and Shomali, Navid and Younus, Laith A. and Hassanzadeh,
   Ali and Vahedi, Ghasem and Kuznetsova, Mariya Yurievna and Solali, Saeed
   and Gharibi, Tohid and Hosseini, Arezoo and Mohammed, Rebar N. and
   Mohammadi, Hamed and Tamjidifar, Rozita and Firouzi-Amandi, Akram and
   Hagh, Majid Farshdousti},
Title = {Under hypoxic conditions, MSCs affect the expression and methylation
   level of survival-related genes in ALL independent of apoptosis pathways
   in vitro},
Journal = {BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY},
Year = {2022},
Volume = {69},
Number = {2},
Pages = {822-839},
Month = {APR},
Abstract = {Mesenchymal stem cells (MSCs) are one of the most prominent cells in the
   bone marrow. MSCs can affect acute lymphocytic leukemia (ALL) cells
   under hypoxic conditions. With this aim, we used MOLT-4 cells as
   simulators of ALL cells cocultured with bone marrow mesenchymal stem
   cells (BMMSCs) under hypoxic conditions in vitro. Then, mRNA and protein
   expression of the MAT2A, PDK1, and HK2 genes were evaluated by real-time
   PCR and Western blot which was also followed by apoptosis measurement by
   a flow-cytometric method. Next, the methylation status of the target
   genes was investigated by MS-qPCR. Additionally, candidate gene
   expressions were examined after treatment with rapamycin using
   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
   assay. We found that the mRNA expression of the candidate genes was
   augmented under the hypoxic condition in which MAT2A was upregulated in
   cocultured cells compared to MOLT-4, while HK2 and PDK1 were
   downregulated. Moreover, we found an association between gene expression
   and promoter methylation levels of target genes. Besides, expressions of
   the candidate genes were decreased, while their methylation levels were
   promoted following treatment with rapamycin. Our results suggest an
   important role for the BMMSC in regulating the methylation of genes
   involved in cell survival in hypoxia conditions; however, we found no
   evidence to prove the MSCs' effect on directing malignant lymphoblastic
   cells to apoptosis.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Hagh, MF (Corresponding Author), Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   Marofi, Faroogh; Hassanzadeh, Ali, Tabriz Univ Med Sci, Fac Med, Dept Hematol, Div Immunol, Tabriz, Iran.
   Marofi, Faroogh; Shomali, Navid; Gharibi, Tohid; Hosseini, Arezoo; Tamjidifar, Rozita; Firouzi-Amandi, Akram, Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran.
   Marofi, Faroogh; Mohammed, Rebar N., Hiwa Canc Hosp, Bone Marrow Transplant Ctr, Suleimanyah, Iraq.
   Shomali, Navid, Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   Shomali, Navid, Tabriz Univ Med Sci, Fac Med, Dept Immunol, Tabriz, Iran.
   Younus, Laith A., Jabir Ibn Hayyan Med Univ, Fac Pharm, Dept Clin Lab Sci, Al Najaf Al Ashraf, Iraq.
   Vahedi, Ghasem, Zanjan Univ Med Sci, Fac Med, Dept Immunol, Zanjan, Iran.
   Kuznetsova, Mariya Yurievna, Sechenov First Moscow State Med Univ, Moscow, Russia.
   Solali, Saeed, Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.
   Mohammadi, Hamed, Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran.
   Hagh, Majid Farshdousti, Tabriz Univ Med Sci, Hematol \& Oncol Res Ctr, Tabriz, Iran.
   Hagh, Majid Farshdousti, Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.},
DOI = {10.1002/bab.2154},
EarlyAccessDate = {MAY 2021},
ISSN = {0885-4513},
EISSN = {1470-8744},
Keywords = {acute lymphocytic leukemia; apoptosis; bone marrow mesenchymal stem
   cells; hypoxia; mesenchymal stem cells},
Keywords-Plus = {MESENCHYMAL STEM-CELLS; PYRUVATE-DEHYDROGENASE KINASE; NF-KAPPA-B;
   STROMAL CELLS; SIGNALING PATHWAY; LEUKEMIA-CELLS; GROWTH-FACTOR;
   UP-REGULATION; CANCER; HIF-1-ALPHA},
Research-Areas = {Biochemistry \& Molecular Biology; Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biotechnology \& Applied Microbiology},
Author-Email = {m.farshdousti@gmail.com},
Affiliations = {Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; Tabriz University of
   Medical Science; Jabir Ibn Hayyan University for Medical \&
   Pharmaceutical Sciences; Sechenov First Moscow State Medical University;
   Tabriz University of Medical Science; Alborz University of Medical
   Sciences; Tabriz University of Medical Science; Tabriz University of
   Medical Science},
ResearcherID-Numbers = {Shomali, Navid/AAM-4488-2021
   Mohammadi, Hamed/J-8382-2016
   Tamjidifar, Rozita/LSJ-1695-2024
   Hagh, Majid/D-9689-2017
   Mohammed, Rebar/JMD-0233-2023
   Gharibi, Tohid/HLG-3480-2023
   Ali, Laith/AAW-7559-2020},
ORCID-Numbers = {Shomali, Navid/0000-0003-4679-9658
   Hosseini, Arezoo/0000-0003-0566-8539
   Mohammadi, Hamed/0000-0002-0736-6211
   Vahedi, Ghasem/0000-0003-0357-1135
   Tamjidifar, Rozita/0000-0002-1925-4188
   Ali, Laith/0000-0003-1902-9543
   },
Cited-References = {Abe H, 2017, J ATHEROSCLER THROMB, V24, P884, DOI 10.5551/jat.RV17009.
   Ahani-Nahayati M, 2018, CELL J, V20, P188, DOI 10.22074/cellj.2018.5101.
   Arora RS, 2016, SOUTH ASIAN J CANCER, V5, P155, DOI 10.4103/2278-330X.187591.
   Baharaghdam Sina, 2018, Avicenna Journal of Medical Biotechnology, V10, P62.
   Bernardo ME, 2015, IMMUNOL LETT, V168, P215, DOI 10.1016/j.imlet.2015.06.013.
   Carroll VA, 2006, CANCER RES, V66, P6264, DOI 10.1158/0008-5472.CAN-05-2519.
   Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657.
   Corradi G, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1013-z.
   Cosse JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-61.
   Courtnay R, 2015, MOL BIOL REP, V42, P841, DOI 10.1007/s11033-015-3858-x.
   Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103.
   Dlamini Z, 2004, PHARMACOL THERAPEUT, V101, P1, DOI 10.1016/j.pharmthera.2003.08.005.
   Ejtehadifar M, 2016, ADV PHARM BULL, V6, P645, DOI 10.15171/apb.2016.079.
   Ejtehadifar M, 2015, ADV PHARM BULL, V5, P141, DOI 10.15171/apb.2015.021.
   Fan XB, 2018, BIOL BLOOD MARROW TR, V24, P1971, DOI 10.1016/j.bbmt.2018.05.029.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Giebel S, 2019, BONE MARROW TRANSPL, V54, P798, DOI 10.1038/s41409-018-0373-4.
   Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032.
   Gu X, 2017, SCIENCE, V358, P813, DOI 10.1126/science.aao3265.
   Hockel M, 1996, CANCER RES, V56, P4509.
   Holcomb JB., 2011, J TISSUE SCI ENG.
   Hong IS, 2014, MUTAT RES-FUND MOL M, V768, P98, DOI 10.1016/j.mrfmmm.2014.01.006.
   Hosseini F, 2018, BIOMED PHARMACOTHER, V98, P793, DOI 10.1016/j.biopha.2017.12.111.
   Hung SP, 2013, CELL TRANSPLANT, V22, P1869, DOI 10.3727/096368912X657954.
   Inaba H, 2013, LANCET, V381, P1943, DOI 10.1016/S0140-6736(12)62187-4.
   Iwamoto S, 2007, J CLIN INVEST, V117, P1049, DOI 10.1172/JCI30235.
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183.
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Limmer M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205285.
   Liu QY, 2011, MOL CANCER THER, V10, P1113, DOI 10.1158/1535-7163.MCT-10-1010.
   Liu TP, 2015, ANTI-CANCER DRUG, V26, P139, DOI 10.1097/CAD.0000000000000166.
   Luebeck GE, 2019, CANCER RES, V79, P495, DOI 10.1158/0008-5472.CAN-18-1682.
   Macklin PS, 2017, PLACENTA, V56, P8, DOI 10.1016/j.placenta.2017.03.010.
   Mahey S, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2405-0.
   Maldonado LY, 2018, EXP BIOL MED, V243, P107, DOI 10.1177/1535370217740860.
   Marofi F, 2019, J CELL PHYSIOL, V234, P1268, DOI 10.1002/jcp.27152.
   Marofi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01770.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Menendez MT, 2015, MBIO, V6, DOI 10.1128/mBio.00462-15.
   Milani L, 2010, BLOOD, V115, P1214, DOI 10.1182/blood-2009-04-214668.
   Mizokami Ken, 2006, World J Surg Oncol, V4, P94, DOI 10.1186/1477-7819-4-94.
   Pezzuto A, 2018, CURR MOL MED, V18, P343, DOI 10.2174/1566524018666181109121849.
   Prasad P, 2017, STEM CELLS, V35, P1468, DOI 10.1002/stem.2621.
   Prockop, 2005, SCI STKE SIG TRANSD, V2005.
   Qi L, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0239-4.
   Reckel S, 2017, LEUKEMIA, V31, P1502, DOI 10.1038/leu.2017.36.
   Rhee KJ, 2015, INT J MOL SCI, V16, P30015, DOI 10.3390/ijms161226215.
   Roberts DJ, 2015, CELL DEATH DIFFER, V22, P248, DOI 10.1038/cdd.2014.173.
   Roh JI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193182.
   Rohwer N., 2018, NONCANONICAL HIF 1 S, DOI {[}10.1101/273045, DOI 10.1101/273045].
   Saidi N, 2017, BIOMED PHARMACOTHER, V89, P719, DOI 10.1016/j.biopha.2017.02.093.
   Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225.
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016.
   Sendoel A, 2014, PHYSIOLOGY, V29, P168, DOI 10.1152/physiol.00016.2013.
   Shomali N, 2020, J CELL PHYSIOL, V235, P4120, DOI 10.1002/jcp.29324.
   Short NJ, 2019, AM J HEMATOL, V94, P257, DOI 10.1002/ajh.25338.
   Taylor CT, 2009, ANN NY ACAD SCI, V1177, P178, DOI 10.1111/j.1749-6632.2009.05024.x.
   Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10.
   Wang HA, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0280-y.
   Whitehead TP, 2016, CURR PROB PEDIATR AD, V46, P317, DOI 10.1016/j.cppeds.2016.08.004.
   Wu TY, 2014, CURR STEM CELL RES T, V9, P424, DOI 10.2174/1574888X09666140616125446.
   Yadav M, 2012, J EXP MED, V209, P1713, DOI 10.1084/jem.20120822.
   Yonekura S, 2013, ANTICANCER RES, V33, P3099.
   Yoo HS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.45.
   Zhan J, 2015, ONCOL LETT, V9, P1221, DOI 10.3892/ol.2015.2868.
   Zhang G, 2017, ONCOL LETT, V13, P77, DOI 10.3892/ol.2016.5405.
   Zhang T, 2013, ACTA HISTOCHEM, V115, P48, DOI 10.1016/j.acthis.2012.03.006.
   Zhang YB, 2014, INT J MOL SCI, V15, P10999, DOI 10.3390/ijms150610999.
   Zhang YM, 2017, EXP THER MED, V14, P2983, DOI 10.3892/etm.2017.4909.
   Zhuo CH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-153.
   Zimmer AD, 2016, HYPOXIA, V4, P135, DOI 10.2147/HP.S99044.},
Number-of-Cited-References = {72},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Biotechnol. Appl. Biochem.},
Doc-Delivery-Number = {0O5WJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000646068400001},
DA = {2026-02-04},
}

@article{ WOS:000645260100011,
Author = {Chang, Kuei-Ting and Wang, Lee-Hsin and Lin, Yu-Mei and Cheng,
   Ching-Feng and Wang, Guey-Shin},
Title = {CELF1 promotes vascular endothelial growth factor degradation resulting
   in impaired microvasculature in heart failure},
Journal = {FASEB JOURNAL},
Year = {2021},
Volume = {35},
Number = {5},
Month = {MAY},
Abstract = {Vascular rarefaction due to impaired angiogenesis is associated with
   contractile dysfunction and the transition from compensation to
   decompensation and heart failure. The regulatory mechanism controlling
   vascular rarefaction during the transition remains elusive. Increased
   expression of a nuclear RNA-binding protein CUGBP Elav-like family
   member 1 (CELF1) in the adult heart is associated with the transition
   from compensated hypertrophy to decompensated heart failure. Elevated
   CELF1 level resulted in degradation of the major cardiac gap junction
   protein, connexin 43, in dilated cardiomyopathy (DCM), the most common
   cause of heart failure. In the present study, we investigated the role
   of increased CELF1 expression in causing vascular rarefaction in DCM.
   CELF1 overexpression (CELF1-OE) in cardiomyocytes resulted in reduced
   capillary density. CELF1-OE mice administered hypoxyprobe showed
   immunoreactivity and increased mRNA levels of HIF1 alpha, Glut-1, and
   Pdk-1, which suggested the association of a reduced capillary
   density-induced hypoxic condition with CELF1 overexpression. Vegfa mRNA
   level was downregulated in mouse hearts exhibiting DCM, including
   CELF1-OE and infarcted hearts. Vegfa mRNA level was also downregulated
   to a similar extent in cardiomyocytes isolated from infarcted hearts by
   Langendorff preparation, which suggested cardiomyocyte-derived Vegfa
   expression mediated by CELF1. Cardiomyocyte-specific depletion of CELF1
   preserved the capillary density and Vegfa mRNA level in infarcted mouse
   hearts. Also, CELF1 bound to Vegfa mRNA and regulated Vegfa mRNA
   stability via the 3' untranslated region. These results suggest that
   elevated CELF1 level has dual effects on impairing the functions of
   cardiomyocytes and microvasculature in DCM.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, GS (Corresponding Author), Acad Sinica, Inst Biomed Sci, 128,Sect 2 Acad Rd, Taipei 11529, Taiwan.
   Chang, Kuei-Ting; Lin, Yu-Mei; Cheng, Ching-Feng; Wang, Guey-Shin, Acad Sinica, Inst Biomed Sci, 128,Sect 2 Acad Rd, Taipei 11529, Taiwan.
   Wang, Lee-Hsin; Wang, Guey-Shin, Natl Yang Ming Univ, Taiwan Int Grad Program Interdisciplinary Neurosc, Taipei, Taiwan.
   Wang, Lee-Hsin; Wang, Guey-Shin, Acad Sinica, Taipei, Taiwan.
   Cheng, Ching-Feng, Tzu Chi Gen Hosp, Dept Med Res, Hualien, Taiwan.
   Cheng, Ching-Feng, Tzu Chi Univ, Dept Pediat, Hualien, Taiwan.
   Wang, Guey-Shin, Natl Yang Ming Univ, Mol Med Program, Taipei, Taiwan.},
DOI = {10.1096/fj.202002553R},
Article-Number = {e21512},
ISSN = {0892-6638},
EISSN = {1530-6860},
Keywords = {cardiomyopathy; CELF1; mRNA degradation; VEGF},
Keywords-Plus = {CUGBP1; HYPERTROPHY; STABILITY},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Cell Biology},
Author-Email = {gswang@ibms.sinica.edu.tw},
Affiliations = {Academia Sinica - Taiwan; National Yang Ming Chiao Tung University;
   Academia Sinica - Taiwan; Buddhist Tzu Chi General Hospital; Hualien Tzu
   Chi Hospital; Tzu Chi University; National Yang Ming Chiao Tung
   University},
ResearcherID-Numbers = {Wang, Guey-Shin/Q-3968-2018
   Cheng, Ching-Feng/AAB-8861-2019},
ORCID-Numbers = {Wang, Guey-Shin/0000-0003-4485-1811
   Wang, Lee-Hsin/0000-0002-3824-8840
   Cheng, Ching-Feng/0000-0003-0104-0146},
Funding-Acknowledgement = {National Health Research Institute, Taiwan {[}NHRI-EX105-10342SI];
   Institute of Biomedical Science, Academia Sinica, Taiwan {[}IBMS400503]},
Funding-Text = {This work was supported by the National Health Research Institute,
   Taiwan {[}NHRI-EX105--10342SI to GSW] and Institute of Biomedical
   Science, Academia Sinica, Taiwan {[}IBMS400503 to GSW].},
Cited-References = {Abraham D, 2000, CIRC RES, V87, P644, DOI 10.1161/01.RES.87.8.644.
   Arcondéguy T, 2013, NUCLEIC ACIDS RES, V41, P7997, DOI 10.1093/nar/gkt539.
   Chang KT, 2017, CIRC RES, V121, P1140, DOI 10.1161/CIRCRESAHA.117.311281.
   Chiang CS, 2009, CIRC RES, V104, P522, DOI 10.1161/CIRCRESAHA.108.184051.
   Dibbens JA, 1999, MOL BIOL CELL, V10, P907, DOI 10.1091/mbc.10.4.907.
   Giamouzis G, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.003259.
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505.
   Heineke J, 2007, J CLIN INVEST, V117, P3198, DOI 10.1172/JCI32573.
   Kalsotra A, 2010, GENE DEV, V24, P653, DOI 10.1101/gad.1894310.
   Kalsotra A, 2008, P NATL ACAD SCI USA, V105, P20333, DOI 10.1073/pnas.0809045105.
   Koshelev M, 2010, HUM MOL GENET, V19, P1066, DOI 10.1093/hmg/ddp570.
   Kuyumcu-Martinez NM, 2007, MOL CELL, V28, P68, DOI 10.1016/j.molcel.2007.07.027.
   Merz CNB, 2017, CIRCULATION, V135, P1075, DOI 10.1161/CIRCULATIONAHA.116.024534.
   Mohammed SF, 2015, CIRCULATION, V131, P550, DOI 10.1161/CIRCULATIONAHA.114.009625.
   Nako H, 2012, HYPERTENS RES, V35, P194, DOI 10.1038/hr.2011.175.
   Oka T, 2006, CIRC RES, V98, P837, DOI 10.1161/01.RES.0000215985.18538.c4.
   Oka T, 2008, CIRC J, V72, P1359, DOI 10.1253/circj.72.1359.
   Patel KV, 2018, EUR J HEART FAIL, V20, P1557, DOI 10.1002/ejhf.1253.
   Poltorak Z, 2000, HERZ, V25, P126, DOI 10.1007/PL00001950.
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73.
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370.
   Tarnavski O, 2004, PHYSIOL GENOMICS, V16, P349, DOI 10.1152/physiolgenomics.00041.2003.
   Wang GS, 2007, J CLIN INVEST, V117, P2802, DOI 10.1172/JCI32308.
   Wang GS, 2009, J CLIN INVEST, V119, P3797, DOI 10.1172/JCI37976.},
Number-of-Cited-References = {24},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Faseb J.},
Doc-Delivery-Number = {RU6MM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000645260100011},
DA = {2026-02-04},
}

@article{ WOS:000654668900001,
Author = {Koren, Ana and Rijavec, Matija and Krumpestar, Tomaz and Kern, Izidor
   and Sadikov, Aleksander and Cufer, Tanja and Korosec, Peter},
Title = {Gene Expression Levels of the Prolyl Hydroxylase Domain Proteins
   PHD1 and PHD2 but Not PHD3 Are Decreased in Primary
   Tumours and Correlate with Poor Prognosis of Patients with Surgically
   Resected Non-Small-Cell Lung Cancer},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {10},
Month = {MAY},
Abstract = {Simple Summary
   Hypoxia correlates with poor prognosis in several cancer types,
   including lung cancer. Prolyl hydroxylase domain proteins (PHDs) belong
   to an evolutionarily conserved superfamily of dioxygenases that play a
   role in cell oxygen sensing and homeostasis. In this study, we evaluated
   PHD1, PHD2 and PHD3 mRNA expression in 60 NSCLC tumours and compared it
   to that in normal lungs and evaluated the prognostic significance of
   these differences for distinguishing the survival of NSCLC patients
   treated with radical surgery. Our results showed that the mRNA
   expression PHD1 and PHD2 in NSCLC primary tumours was decreased, which
   correlated with larger tumour size and poor prognosis of patients. PHD1
   also showed borderline independent prognostic value in multivariate
   analysis. In contrast, we found no associations between PHD3 expression
   and any of the observed parameters. Our results suggest that loss of
   PHD1 and PHD2 expression is associated with the development and
   progression of NSCLC, whereas PHD1 could be further assessed as a
   prognostic marker in NSCLC.
   Background: Hypoxia correlates with poor prognosis in several cancer
   types, including lung cancer. Prolyl hydroxylase domain proteins (PHDs)
   play a role in cell oxygen sensing, negatively regulating the
   hypoxia-inducible factor (HIF) pathway. Our study aim was to evaluate
   PHD1, PHD2 and PHD3 mRNA expression levels in primary tumours and normal
   lungs of non-small-cell lung cancer (NSCLC) patients and to correlate it
   with selected regulators of HIF signalling, with clinicopathological
   characteristics and overall survival (OS). Methods: Tumour tissue
   samples were obtained from 60 patients with surgically resected NSCLC
   who were treated with radical surgery. In 22 out of 60 cases, matching
   morphologically normal lung tissue was obtained. PHD1, PHD2 and PHD3
   mRNA expressions were measured using RT-qPCR. Results: The PHD1 and PHD2
   mRNA levels in primary tumours were significantly decreased compared to
   those in normal lungs (both p < 0.0001). PHD1 and PHD2 expression in
   tumours was positively correlated (r(s) = 0.82; p < 0.0001) and
   correlated well with HIF pathway downstream genes HIF1A, PKM2 and PDK1.
   Decreased PHD1 and PHD2 were associated with larger tumour size, higher
   tumour stage (PHD1 only) and squamous cell carcinoma. Patients with low
   PHD1 and patients with low PHD2 expression had shorter OS than patients
   with high PHD1 (p = 0.02) and PHD2 expression (p = 0.01). PHD1 showed
   borderline independent prognostic values in multivariate analysis (p =
   0.06). In contrast, we found no associations between PHD3 expression and
   any of the observed parameters. Conclusions: Our results show that
   reduced expression of PHD1 and PHD2 is associated with the development
   and progression of NSCLC. PHD1 could be further assessed as a prognostic
   marker in NSCLC.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Koren, A (Corresponding Author), Univ Clin Resp \& Allerg Dis Golnik, Golnik 4204, Slovenia.
   Koren, Ana; Rijavec, Matija; Krumpestar, Tomaz; Kern, Izidor; Cufer, Tanja; Korosec, Peter, Univ Clin Resp \& Allerg Dis Golnik, Golnik 4204, Slovenia.
   Sadikov, Aleksander, Univ Ljubljana, Fac Comp \& Informat Sci, Ljubljana 1000, Slovenia.
   Cufer, Tanja, Univ Ljubljana, Fac Med, Ljubljana 1000, Slovenia.},
DOI = {10.3390/cancers13102309},
Article-Number = {2309},
EISSN = {2072-6694},
Keywords = {non-small-cell lung cancer; prolyl hydroxylase domain proteins; mRNA
   expression; prognosis},
Keywords-Plus = {HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; KINASE; ADENOCARCINOMA; ANGIOGENESIS;
   PROGRESSION; METASTASIS; CARCINOMA; TRENDS; FIH},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {ana.koren@klinika-golnik.si
   matija.rijavec@klinika-golnik.si
   tomaz.krumpestar@gmail.com
   izidor.kern@klinika-golnik.si
   aleksander.sadikov@fri.uni-lj.si
   tanja.cufer@mf.uni-lj.si
   peter.korosec@klinika-golnik.si},
Affiliations = {University Clinic Golnik; University of Ljubljana; University of
   Ljubljana},
ORCID-Numbers = {Rijavec, Matija/0000-0002-2596-4952
   Koren, Ana/0000-0002-9671-1645
   Kern, Izidor/0000-0002-2418-5025
   Sadikov, Aleksander/0000-0001-8697-3556},
Funding-Acknowledgement = {Slovenian Research Agency {[}J3-7372, P3-0360]},
Funding-Text = {This work was funded by Slovenian Research Agency Grants J3-7372 and
   P3-0360.},
Cited-References = {Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3.
   Andersen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023847.
   Appelhoff RJ, 2004, J BIOL CHEM, V279, P38458, DOI 10.1074/jbc.M406026200.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367.
   Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373.
   Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010.
   Chen BT, 2020, CELL ONCOL, V43, P877, DOI 10.1007/s13402-020-00534-4.
   Chen SF, 2011, MOL CELL BIOCHEM, V358, P257, DOI 10.1007/s11010-011-0976-1.
   Chu X, 2019, J THORAC DIS, V11, P3941, DOI 10.21037/jtd.2019.08.124.
   Chu X, 2014, ASIAN PAC J CANCER P, V15, P5819, DOI 10.7314/APJCP.2014.15.14.5819.
   Couvelard A, 2008, CLIN CANCER RES, V14, P6634, DOI 10.1158/1078-0432.CCR-07-5258.
   Crinò L, 2010, ANN ONCOL, V21, pv103, DOI 10.1093/annonc/mdq207.
   Cufer T, 2014, EXPERT REV ANTICANC, V14, P1189, DOI 10.1586/14737140.2014.940327.
   Dehdashti F, 2003, EUR J NUCL MED MOL I, V30, P844, DOI 10.1007/s00259-003-1130-4.
   del Peso L, 2003, J BIOL CHEM, V278, P48690, DOI 10.1074/jbc.M308862200.
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4.
   Erez N, 2003, CANCER RES, V63, P8777.
   Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10.
   Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018.
   Giatromanolaki A, 2008, CANCER LETT, V262, P87, DOI 10.1016/j.canlet.2007.11.041.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Jokilehto T, 2010, J CELL MOL MED, V14, P758, DOI 10.1111/j.1582-4934.2010.01030.x.
   Kamphues C, 2012, PATHOBIOLOGY, V79, P11, DOI 10.1159/000330170.
   Kawase A, 2012, JPN J CLIN ONCOL, V42, P189, DOI 10.1093/jjco/hyr188.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koren A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9714315.
   Koren A, 2015, CELL ONCOL, V38, P387, DOI 10.1007/s13402-015-0238-4.
   Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054.
   Ma MY, 2017, ONCOTARGET, V8, P12983, DOI 10.18632/oncotarget.14677.
   Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413.
   Puderecki M, 2020, ONCOL LETT, V20, P9, DOI 10.3892/ol.2020.11541.
   Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398.
   Riaz SP, 2012, LUNG CANCER, V75, P280, DOI 10.1016/j.lungcan.2011.08.004.
   Rofstad EK, 2005, CANCER RES, V65, P2387, DOI 10.1158/0008-5472.CAN-04-3039.
   Salem A, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx160.
   Sodja E, 2012, EUR J CANCER, V48, P3378, DOI 10.1016/j.ejca.2012.06.011.
   Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3.
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064.
   Xie X, 2014, CANCER GENET-NY, V207, P188, DOI 10.1016/j.cancergen.2014.04.008.
   Yang M, 2014, HYPOXIA, V2, P127, DOI 10.2147/HP.S47968.
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159.},
Number-of-Cited-References = {44},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {SI2PT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000654668900001},
OA = {Green Published, Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000662898000012,
Author = {Tang, Qiguo and Xu, Qinqin and Ding, Cui and Zhang, Hao and Ling, Yao
   and Wu, Changxin and Fang, Meiying},
Title = {HIF-1 regulates energy metabolism of the Tibetan chicken brain during
   embryo development under hypoxia},
Journal = {AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY, INTEGRATIVE AND COMPARATIVE
   PHYSIOLOGY},
Year = {2021},
Volume = {320},
Number = {5},
Pages = {R704-R713},
Month = {MAY},
Abstract = {The Tibetan chicken (Gallus gallus; TBC) is an indigenous breed found in
   the Qinghai-Tibet Plateau that are well adapted to a hypoxic
   environment. The energy metabolism of embryonic brains in TBCs under
   hypoxia has been little reported. This study investigated changes in
   energy metabolism of the TBC brain during embryo development under
   hypoxia. We found that TBCs exhibited a change of glycolysis and the
   tricarboxylic acid cycle during embryo development under hypoxia.
   Hypoxia-inducible factor (HIF)-1 was potentially involved in this by
   directly inducing overexpression of pyruvate dehydrogenase kinase 1
   (PDK1) and the glycolytic genes hexokinase 1 (HK1) and lactate
   dehydrogenase A (LDHA) to increase glycolysis of TBCs to adapt to
   hypoxia. Although these may not be unique to TBCs, as we had also found
   similar results in Dwarf Laying Chickens, a lowland chicken breed, TBCs
   had a stronger regulating ability. In summary, our study revealed that
   HIF-1 induced energy metabolism changes in the TBC brain via
   upregulating expressions of PDK1 and other HIF-1 target genes like HK1
   and LDHA to increase glycolysis for TBC hypoxic adaptations during
   embryo development. It indicates the potential application of TBC energy
   metabolism research for other animals living on the Qinghai-Tibet
   Plateau.},
Publisher = {AMER PHYSIOLOGICAL SOC},
Address = {6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Tang, QG; Fang, MY (Corresponding Author), China Agr Univ, Coll Anim Sci \& Technol, Dept Anim Genet \& Breeding, Natl Engn Lab Anim Breeding,MOA Lab Anim Genet \&, Beijing, Peoples R China.
   Tang, Qiguo; Xu, Qinqin; Ding, Cui; Zhang, Hao; Ling, Yao; Wu, Changxin; Fang, Meiying, China Agr Univ, Coll Anim Sci \& Technol, Dept Anim Genet \& Breeding, Natl Engn Lab Anim Breeding,MOA Lab Anim Genet \&, Beijing, Peoples R China.},
DOI = {10.1152/ajpregu.00052.2020},
ISSN = {0363-6119},
EISSN = {1522-1490},
Keywords = {embryo development; energy metabolism; hypoxic adaptations;
   hypoxia-inducible factor-1; Tibetan chicken},
Keywords-Plus = {LACTATE-DEHYDROGENASE; O-2 HOMEOSTASIS; ADAPTATION; GROWTH;
   TRANSCRIPTION; HIF-1-ALPHA; EXPRESSION; PATTERNS},
Research-Areas = {Physiology},
Web-of-Science-Categories  = {Physiology},
Author-Email = {tango@cau.edu.cn
   meiying@cau.edu.cn},
Affiliations = {China Agricultural University},
ResearcherID-Numbers = {Zhang, Hao/IQW-3491-2023},
ORCID-Numbers = {Zhang, Hao/0000-0003-4093-5647},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31972532]; National
   System for Layer Production Technology Grant {[}CARS41]},
Funding-Text = {This work was supported by National Natural Science Foundation of China
   Grant 31972532 and National System for Layer Production Technology Grant
   CARS41.},
Cited-References = {Bao HG, 2007, POULTRY SCI, V86, P2210, DOI 10.1093/ps/86.10.2210.
   Caro J, 2001, HIGH ALT MED BIOL, V2, P145, DOI 10.1089/152702901750265251.
   ERBSLOH F, 1958, Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr, V196, P611, DOI 10.1007/BF00344388.
   Evans H.E., 1960, Avian Dis, V4, P541, DOI {[}10.2307/1587707, DOI 10.2307/1587707].
   Feldser D, 1999, CANCER RES, V59, P3915.
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604.
   Gou X, 2007, COMP BIOCHEM PHYS B, V147, P147, DOI 10.1016/j.cbpb.2006.11.031.
   GRAVEN KK, 1994, J BIOL CHEM, V269, P24446.
   HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104.
   Holness MJ, 2003, BIOCHEM SOC T, V31, P1143.
   Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003.
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149.
   Jassim EW, 1996, POULTRY SCI, V75, P464, DOI 10.3382/ps.0750464.
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Krishnamachary B, 2003, CANCER RES, V63, P1138.
   Kuurman WW, 2001, POULTRY SCI, V80, P710, DOI 10.1093/ps/80.6.710.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107.
   Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1.
   Lee YM, 2011, HEPATOLOGY, V53, P171, DOI 10.1002/hep.24010.
   MONGE C, 1991, PHYSIOL REV, V71, P1135, DOI 10.1152/physrev.1991.71.4.1135.
   Okur V, 2019, EUR J HUM GENET, V27, P1081, DOI 10.1038/s41431-019-0366-9.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Payne LF, 1919, J Am Assoc Instr Investig Poult Husb, V6, P9, DOI {[}10.3382/ ps.0060009a, DOI 10.3382/PS.0060009A].
   Ravi R, 2000, GENE DEV, V14, P34.
   Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005.
   Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001.
   Semenza GL, 2000, GENE DEV, V14, P1983.
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447.
   Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0.
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529.
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474.
   Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551.
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230.
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009.
   Solaini G, 2010, BBA-BIOENERGETICS, V1797, P1171, DOI 10.1016/j.bbabio.2010.02.011.
   Tang QG, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.585166.
   VLECK CM, 1980, AM ZOOL, V20, P405.
   VLECK CM, 1987, J EXP ZOOL, P111.
   VLECK CM, 1979, PHYSIOL ZOOL, V52, P363, DOI 10.1086/physzool.52.3.30155757.
   Wang MS, 2015, MOL BIOL EVOL, V32, P1880, DOI 10.1093/molbev/msv071.
   Wenger RH, 2000, J EXP BIOL, V203, P1253.
   Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev.
   Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360.
   Wu C., 2012, PHYSL GENETICS ADAPT.
   Zhang H, 2007, POULTRY SCI, V86, P1384, DOI 10.1093/ps/86.7.1384.},
Number-of-Cited-References = {47},
Times-Cited = {8},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Am. J. Physiol.-Regul. Integr. Comp. Physiol.},
Doc-Delivery-Number = {SU1JX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000662898000012},
DA = {2026-02-04},
}

@article{ WOS:000703922000025,
Author = {Kong, Wei and Tan, Shutang and Zhao, Qing and Lin, De-Li and Xu,
   Zhi-Hong and Friml, Jiri and Xue, Hong-Wei},
Title = {mRNA surveillance complex PELOTA HBS1 regulates
   phosphoinositide-dependent protein kinase1 and plant growth},
Journal = {PLANT PHYSIOLOGY},
Year = {2021},
Volume = {186},
Number = {4},
Pages = {2003-2020},
Month = {AUG},
Abstract = {The quality control system for messenger RNA (mRNA) is fundamental for
   cellular activities in eukaryotes. To elucidate the molecular mechanism
   of 3'-phosphoinositide-dependent protein kinasel (PDK1), a master
   regulator that is essential throughout eukaryotic growth and
   development, we employed a forward genetic approach to screen for
   suppressors of the loss-of-function T-DNA insertion double mutant pdk1.1
   pdk1.2 in Arabidopsis thaliana. Notably, the severe growth attenuation
   of pdk1.1 pdk1.2 was rescued by sop21 (suppressor of pdk1.1 pdk1.2),
   which harbors a loss-of-function mutation in PELOTA1 (PEL1). PEL1 is a
   homolog of mammalian PELOTA and yeast (Saccharomyces cerevisiae) DOM34p,
   which each form a heterodimeric complex with the GTPase HBS1 (HSP70
   SUBFAMILY B SUPPRESSOR1, also called SUPERKILLER PROTEIN7, SKI7), a
   protein that is responsible for ribosomal rescue and thereby assures the
   quality and fidelity of mRNA molecules during translation. Genetic
   analysis further revealed that a dysfunctional PEL1-HBS1 complex failed
   to degrade the T-DNA-disrupted PDK1 transcripts, which were truncated
   but functional, and thus rescued the growth and developmental defects of
   pdk1.1 pdk1.2. Our studies demonstrated the functionality of a
   homologous PELOTA-HBS1 complex and identified its essential regulatory
   role in plants, providing insights into the mechanism of mRNA quality
   control.},
Publisher = {OXFORD UNIV PRESS INC},
Address = {JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA},
Type = {Article},
Language = {English},
Affiliation = {Xue, HW (Corresponding Author), Shanghai Jiao Tong Univ, Joint Ctr Single Cell Biol, Sch Agr \& Biol, Shanghai 200240, Peoples R China.
   Kong, Wei; Zhao, Qing; Xu, Zhi-Hong, Chinese Acad Sci, CAS Ctr Excellence Mol Plant Sci, Natl Key Lab Plant Mol Genet, Shanghai 200032, Peoples R China.
   Tan, Shutang, Univ Sci \& Technol China, Hefei Natl Sci Ctr Phys Sci Microscale, Sch Life Sci, Div Life Sci \& Med, Hefei 230027, Peoples R China.
   Tan, Shutang, Univ Sci \& Technol China, Hefei Natl Sci Ctr Phys Sci Microscale, Div Mol \& Cell Biophys, Hefei 230027, Peoples R China.
   Tan, Shutang; Friml, Jiri, Inst Sci \& Technol Austria IST Austria, Campus 1, A-3400 Klosterneuburg, Austria.
   Lin, De-Li; Xue, Hong-Wei, Shanghai Jiao Tong Univ, Joint Ctr Single Cell Biol, Sch Agr \& Biol, Shanghai 200240, Peoples R China.},
DOI = {10.1093/plphys/kiab199},
EarlyAccessDate = {APR 2021},
ISSN = {0032-0889},
EISSN = {1532-2548},
Keywords-Plus = {SEED STORAGE PROTEINS; SIGNALING PATHWAY; ROOT HAIRS; ARABIDOPSIS; PDK1;
   PHOSPHORYLATION; TARGET; GENES; ROLES; DISSOCIATION},
Research-Areas = {Plant Sciences},
Web-of-Science-Categories  = {Plant Sciences},
Author-Email = {hwxue@sjtu.edu.cn},
Affiliations = {Chinese Academy of Sciences; Center for Excellence in Molecular Plant
   Sciences, CAS; Chinese Academy of Sciences; University of Science \&
   Technology of China, CAS; Chinese Academy of Sciences; University of
   Science \& Technology of China, CAS; Institute of Science \& Technology
   - Austria; Shanghai Jiao Tong University},
ResearcherID-Numbers = {Xu, Zhihong/B-3223-2009
   Friml, Jiri/D-9511-2012
   Tan, Shutang/AAB-6227-2020
   },
ORCID-Numbers = {Friml, Jiri/0000-0002-8302-7596
   Tan, Shutang/0000-0002-0471-8285
   Xue, Hong-Wei/0000-0002-7641-5320},
Funding-Acknowledgement = {National Natural Science Foundation of China (NSFC) {[}31721001,
   91954206]; Collaborative Innovation Center of Crop Stress Biology, Henan
   Province; Austrian Science Fund (FWF) {[}I 3630-B25]; European Molecular
   Biology Organization (EMBO) long-term postdoctoral fellowship {[}ALTF
   723-2015]; ``Ten-Thousand Talent Program{''}, Henan Province},
Funding-Text = {The study was supported by National Natural Science Foundation of China
   (NSFC, 31721001, 91954206, to H.W.X.), ``Ten-Thousand Talent Program{''}
   (to H.-W.X.) and Collaborative Innovation Center of Crop Stress Biology,
   Henan Province, and Austrian Science Fund (FWF): I 3630-B25 (to J.F.).
   S.T. was funded by a European Molecular Biology Organization (EMBO)
   long-term postdoctoral fellowship (ALTF 723-2015).},
Cited-References = {Adham IM, 2003, MOL CELL BIOL, V23, P1470, DOI 10.1128/MCB.23.4.1470-1476.2003.
   Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059.
   Allen RS, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00362.
   Alonso JM, 2003, SCIENCE, V301, P653, DOI 10.1126/science.1086391.
   Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068.
   Boron AK, 2014, J EXP BOT, V65, P5485, DOI 10.1093/jxb/eru308.
   Breitenbach HH, 2014, PLANT PHYSIOL, V165, P791, DOI 10.1104/pp.114.239665.
   Brunkard JO, 2018, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01333.
   Camehl I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002051.
   Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8.
   Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098008.
   Chen XB, 2005, PLANT PHYSIOL, V139, P909, DOI 10.1104/pp.105.066753.
   Choy MK, 2008, J EXP BOT, V59, P3869, DOI 10.1093/jxb/ern227.
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x.
   Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6.
   del Campillo E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049363.
   Dittrich ACN, 2012, PLANT PHYSIOL, V158, P1018, DOI 10.1104/pp.111.184572.
   Dyson BC, 2016, PLANT PHYSIOL, V172, P118, DOI 10.1104/pp.16.00852.
   Ferrari S, 2003, PLANT CELL, V15, P93, DOI 10.1105/tpc.005165.
   Ferrari S, 2006, MOL PLANT MICROBE IN, V19, P931, DOI 10.1094/MPMI-19-0931.
   Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618.
   Furihata T, 2006, P NATL ACAD SCI USA, V103, P1988, DOI 10.1073/pnas.0505667103.
   Gao YS, 2012, PLANT CELL PHYSIOL, V53, P592, DOI 10.1093/pcp/pcs014.
   Guo L, 2013, J EXP BOT, V64, P1755, DOI 10.1093/jxb/ert040.
   Hilal T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13521.
   HORVATH DP, 1993, PLANT PHYSIOL, V103, P1047, DOI 10.1104/pp.103.4.1047.
   Inagaki M, 1999, MOL CELL BIOL, V19, P8344.
   Jung JH, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00126.
   Kim YK, 2014, J BIOL CHEM, V289, P3901, DOI 10.1074/jbc.M113.515015.
   Lange H, 2019, NAT COMMUN, V10, DOI {[}10.1101/617894, 10.1038/s41467-019-11807-4].
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li LX, 2006, PLANT CELL, V18, P3535, DOI 10.1105/tpc.106.046151.
   Li Q, 2007, J BIOCHEM MOL BIOL, V40, P373.
   Li T, 2019, NAT PLANTS, V5, P539, DOI 10.1038/s41477-019-0419-7.
   Lin DS, 2012, CURR BIOL, V22, P1319, DOI 10.1016/j.cub.2012.05.019.
   Liu W, 2003, PLANT J, V36, P189, DOI 10.1046/j.1365-313X.2003.01866.x.
   Mahfouz MM, 2006, PLANT CELL, V18, P477, DOI 10.1105/tpc.105.035931.
   Marhava P, 2018, NATURE, V558, P297, DOI 10.1038/s41586-018-0186-z.
   Matsui H, 2010, PLANT CELL PHYSIOL, V51, P2082, DOI 10.1093/pcp/pcq167.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Müntz K, 1998, PLANT MOL BIOL, V38, P77, DOI 10.1023/A:1006020208380.
   Nakamura S, 2010, BIOSCI BIOTECH BIOCH, V74, P1315, DOI 10.1271/bbb.100184.
   Nelson BK, 2007, PLANT J, V51, P1126, DOI 10.1111/j.1365-313X.2007.03212.x.
   Page DR, 2002, NAT REV GENET, V3, P124, DOI 10.1038/nrg730.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pisareva VP, 2011, EMBO J, V30, P1804, DOI 10.1038/emboj.2011.93.
   Qin P, 2018, PLANT CELL PHYSIOL, V59, P887, DOI 10.1093/pcp/pcy056.
   Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353.
   Ringli C, 2005, PLANT CELL PHYSIOL, V46, P1046, DOI 10.1093/pcp/pci115.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Saito S, 2013, J BIOL CHEM, V288, P17832, DOI 10.1074/jbc.M112.448977.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Scholz S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007927.
   Shimada T, 2003, J BIOL CHEM, V278, P32292, DOI 10.1074/jbc.M305740200.
   Shoemaker CJ, 2010, SCIENCE, V330, P369, DOI 10.1126/science.1192430.
   Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz.
   Stotz HU, 2011, PLANT J, V67, P81, DOI 10.1111/j.1365-313X.2011.04578.x.
   Szádeczky-Kardoss I, 2018, NUCLEIC ACIDS RES, V46, P4632, DOI 10.1093/nar/gky279.
   Tan ST, 2014, CELL REP, V9, P1692, DOI 10.1016/j.celrep.2014.10.047.
   Tan ST, 2021, MOL PLANT, V14, P151, DOI 10.1016/j.molp.2020.11.004.
   Tan ST, 2020, NAT PLANTS, V6, P556, DOI 10.1038/s41477-020-0648-9.
   Tanaka N, 2017, PLANT CELL PHYSIOL, V58, P760, DOI 10.1093/pcp/pcx008.
   Tang XR, 2012, J EXP BOT, V63, P1391, DOI 10.1093/jxb/err383.
   Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107.
   Thompson A, 2003, ANAL CHEM, V75, P1895, DOI 10.1021/ac0262560.
   Tronchet M, 2010, MOL PLANT PATHOL, V11, P83, DOI {[}10.1111/j.1364-3703.2009.00578.X, 10.1111/j.1364-3703.2009.00578.x].
   Tsuboi T, 2012, MOL CELL, V46, P518, DOI 10.1016/j.molcel.2012.03.013.
   Uemura M, 1996, PLANT PHYSIOL, V111, P313, DOI 10.1104/pp.111.1.313.
   Waters BM, 2006, PLANT PHYSIOL, V141, P1446, DOI 10.1104/pp.106.082586.
   Weis C, 2014, NEW PHYTOL, V202, P1310, DOI 10.1111/nph.12759.
   Xiao Y, 2020, NAT PLANTS, V6, P544, DOI 10.1038/s41477-020-0650-2.
   Yang BJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11388.
   Zegzouti H, 2006, P NATL ACAD SCI USA, V103, P6404, DOI 10.1073/pnas.0510283103.
   Zegzouti H, 2006, J BIOL CHEM, V281, P35520, DOI 10.1074/jbc.M605167200.
   Zhang Y, 2009, PLANT J, V58, P474, DOI 10.1111/j.1365-313X.2009.03792.x.
   Zhao Q, 2019, PLANT CELL, V31, P2152, DOI 10.1105/tpc.19.00003.
   Zhu HF, 2012, PLANT PHYSIOL, V160, P1770, DOI 10.1104/pp.112.199364.
   Zourelidou M, 2009, DEVELOPMENT, V136, P627, DOI 10.1242/dev.028365.},
Number-of-Cited-References = {78},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {31},
Journal-ISO = {Plant Physiol.},
Doc-Delivery-Number = {WB9YV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000703922000025},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000658377600002,
Author = {Witzigmann, Dominik and Grossen, Philip and Quintavalle, Cristina and
   Lanzafame, Manuela and Schenk, Susanne H. and Tran, Xue-Ting and
   Englinger, Bernhard and Hauswirth, Patrick and Gruenig, David and van
   Schoonhoven, Sushilla and Krahenbuhl, Stephan and Terracciano, Luigi M.
   and Berger, Walter and Piscuoglio, Salvatore and Quagliata, Luca and
   Rommelaere, Jean and Nueesch, Juerg P. F. and Huwyler, Jorg},
Title = {Non-viral gene delivery of the oncotoxic protein NS1 for treatment of
   hepatocellular carcinoma},
Journal = {JOURNAL OF CONTROLLED RELEASE},
Year = {2021},
Volume = {334},
Pages = {138-152},
Month = {JUN 10},
Abstract = {Hepatocellular carcinoma (HCC) is related to increasing incidence rates
   and poor clinical outcomes due to lack of efficient treatment options
   and emerging resistance mechanisms. The aim of the present study is to
   exploit a nonviral gene therapy enabling the expression of the
   parvovirus-derived oncotoxic protein NS1 in HCC. This anticancer protein
   interacts with different cellular kinases mediating a multimodal
   host-cell death. Lipoplexes (LPX) designed to deliver a DNA expression
   plasmid encoding NS1 are characterized using a comprehensive set of in
   vitro assays. The mechanisms of cell death induction are assessed and
   phosphoinositide-dependent kinase 1 (PDK1) is identified as a potential
   predictive biomarker for a NS1-LPX-based gene therapy. In an HCC
   xenograft mouse model, NS1-LPX therapeutic approach results in a
   significant reduction in tumor growth and extended survival. Data
   provide convincing evidence for future studies using a targeted NS1 gene
   therapy for PDK1 overexpressing HCC.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Huwyler, J (Corresponding Author), Univ Basel, Dept Pharmaceut Sci, Div Pharmaceut Technol, CH-4056 Basel, Switzerland.
   Witzigmann, Dominik; Grossen, Philip; Schenk, Susanne H.; Tran, Xue-Ting; Hauswirth, Patrick; Huwyler, Jorg, Univ Basel, Dept Pharmaceut Sci, Div Pharmaceut Technol, CH-4056 Basel, Switzerland.
   Witzigmann, Dominik, Univ British Columbia, Dept Biochem \& Mol Biol, Vancouver, BC V6T 1Z3, Canada.
   Quintavalle, Cristina; Lanzafame, Manuela; Terracciano, Luigi M.; Piscuoglio, Salvatore; Quagliata, Luca, Univ Hosp Basel, Inst Pathol, Mol Pathol Div, CH-4003 Basel, Switzerland.
   Englinger, Bernhard; van Schoonhoven, Sushilla; Berger, Walter, Med Univ Vienna, Inst Canc Res, Appl \& Expt Oncol, A-1090 Vienna, Austria.
   Englinger, Bernhard; van Schoonhoven, Sushilla; Berger, Walter, Med Univ Vienna, Comprehens Canc Ctr, A-1090 Vienna, Austria.
   Gruenig, David; Krahenbuhl, Stephan, Univ Hosp Basel, Div Clin Pharmacol \& Toxicol, CH-4031 Basel, Switzerland.
   Piscuoglio, Salvatore, Clarunis, Visceral Surg Lab, Dept Biomed, CH-4031 Basel, Switzerland.
   Rommelaere, Jean; Nueesch, Juerg P. F., German Canc Res Ctr, Div Tumor Virol, Infect Inflammat \& Canc Program, D-69120 Heidelberg, Germany.},
DOI = {10.1016/j.jconrel.2021.04.023},
EarlyAccessDate = {APR 2021},
ISSN = {0168-3659},
EISSN = {1873-4995},
Keywords = {Hepatocellular carcinoma; Gene therapy; Parvovirus; Nanoparticles;
   Oncotoxic protein},
Keywords-Plus = {PARVOVIRUS MINUTE VIRUS; REPLICATIVE FUNCTIONS; PHASE I/IIA; CANCER;
   CELLS; H-1; ACTIVATION; EXPRESSION; THERAPY; APOPTIN},
Research-Areas = {Chemistry; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary; Pharmacology \& Pharmacy},
Author-Email = {joerg.huwyler@unibas.ch},
Affiliations = {University of Basel; University of British Columbia; University of
   Basel; Medical University of Vienna; Medical University of Vienna;
   University of Basel; Helmholtz Association; German Cancer Research
   Center (DKFZ)},
ResearcherID-Numbers = {Quintavalle, Cristina/AHH-9379-2022
   Piscuoglio, Salvatore/AAB-4959-2022
   Lanzafame, Manuela/Q-2353-2018
   TERRACCIANO, Luigi Maria/AAB-5335-2022
   Huwyler, Jörg/C-6573-2013
   Berger, Walter/AFQ-9733-2022
   Quagliata, Luca/HKE-2640-2023
   Krähenbühl, Stephan/Z-4744-2019},
ORCID-Numbers = {Hauswirth, Patrick/0000-0003-3161-4227
   Quintavalle, Cristina/0000-0002-7432-9170
   Piscuoglio, Salvatore/0000-0003-2686-2939
   Lanzafame, Manuela/0000-0002-0456-1134
   TERRACCIANO, Luigi Maria/0000-0002-9393-9660
   Huwyler, Jörg/0000-0003-1748-5676
   Quagliata, Luca/0000-0001-8249-9914
   },
Funding-Acknowledgement = {Swiss National Science Foundation (SNSF) {[}183923, CRSII5\_180257];
   Novartis Foundation; SNSF {[}PZ00P3\_168165]; Swiss Cancer League
   (Oncosuisse) {[}KFS-3995-082016]; Swiss National Science Foundation
   (SNF) {[}CRSII5\_180257] Funding Source: Swiss National Science
   Foundation (SNF)},
Funding-Text = {We thank R. Bartenschlager, M. Heikenw <spacing diaeresis>alder, and H.
   zur Hausen for fruitful discussions, critical editing, and revision of
   the manuscript, N. Zanella and T. Deigner from Charles River Discovery
   Research Services Germany GmbH for the support with xenograft
   experiments, A. Rios Quiroz and F. Stump for support with NTA
   measurements, and HE. Meyer zu Schwabedissen and C. Ferreira for support
   with PCR and western blot experiments. The research project was
   supported by the Swiss National Science Foundation (SNSF) Grants No.
   183923 (D.W.) and Sinergia CRSII5\_180257 (J.H.) and the Novartis
   Foundation (D.W.). S.P. acknowledges the support from the SNSF
   (Ambizione grant, No. PZ00P3\_168165) and Swiss Cancer League
   (Oncosuisse, KFS-3995-082016). The authors declare no competing
   financial interests.},
Cited-References = {Adeyemi RO, 2012, J VIROL, V86, P8328, DOI 10.1128/JVI.00820-12.
   Allred DC, 1998, MODERN PATHOL, V11, P155.
   Anderson WF, 2002, HUM GENE THER, V13, P1, DOI 10.1089/10430340152712610.
   Aznar MA, 2017, J IMMUNOL, V198, P31, DOI 10.4049/jimmunol.1601145.
   Angelova AL, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00055.
   Backendorf C, 2008, ANNU REV PHARMACOL, V48, P143, DOI 10.1146/annurev.pharmtox.48.121806.154910.
   Bär S, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004703.
   Bai HQ, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160616.
   Balogh J, 2016, J HEPATOCELL CARCINO, V3, P41, DOI {[}10.15586/jrenhep.v4i2.84, 10.2147/JHC.S61146].
   Baumhoer D, 2008, AM J CLIN PATHOL, V129, P899, DOI 10.1309/HCQWPWD50XHD2DW6.
   Buck J, 2019, ACS NANO, V13, P3754, DOI 10.1021/acsnano.8b07858.
   Buscail L, 2015, MOL THER, V23, P779, DOI 10.1038/mt.2015.1.
   CAILLETFAUQUET P, 1990, EMBO J, V9, P2989, DOI 10.1002/j.1460-2075.1990.tb07491.x.
   Calle MHY, 2004, INT J CANCER, V109, P76, DOI 10.1002/ijc.11626.
   Chen J, 2016, MOL THER-METH CLIN D, V3, DOI 10.1038/mtm.2016.23.
   Chira S, 2015, ONCOTARGET, V6, P30675, DOI 10.18632/oncotarget.5169.
   Corbau R, 2000, VIROLOGY, V278, P151, DOI 10.1006/viro.2000.0600.
   Cziepluch C, 2000, J VIROL, V74, P4807, DOI 10.1128/JVI.74.10.4807-4815.2000.
   Di Piazza M, 2007, J VIROL, V81, P4186, DOI 10.1128/JVI.02601-06.
   Doyle A, 2017, Current Hepatology Reports, V16, P46, DOI 10.1007/s11901-017-0333-2.
   Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006.
   Flores A, 2014, CLIN MED INSIGHTS-ON, V8, P71, DOI 10.4137/CMO.S9926.
   Fuchs Shmuel, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS89, DOI 10.1038/ncpcardio0762.
   Fujita K, 2017, CANCER GENE THER, V24, P277, DOI 10.1038/cgt.2017.15.
   Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027.
   Geletneky K, 2017, MOL THER, V25, P2620, DOI 10.1016/j.ymthe.2017.08.016.
   Geletneky K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-99.
   Grimm S, 2014, ADV EXP MED BIOL, V818, P1, DOI 10.1007/978-1-4471-6458-6\_1.
   Haegler P, 2015, TOXICOLOGY, V336, P48, DOI 10.1016/j.tox.2015.07.015.
   HALLAUER C, 1972, ARCH GES VIRUSFORSCH, V38, P366, DOI 10.1007/BF01262827.
   Hoshino K, 2006, GENE THER, V13, P1320, DOI 10.1038/sj.gt.3302793.
   Hristov G, 2010, J VIROL, V84, P5909, DOI 10.1128/JVI.01797-09.
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43.
   KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524.
   Kulkarni JA, 2019, ACCOUNTS CHEM RES, V52, P2435, DOI 10.1021/acs.accounts.9b00368.
   Lachmann S, 2008, CELL MICROBIOL, V10, P755, DOI 10.1111/j.1462-5822.2007.01082.x.
   LEGRAND C, 1992, J GEN VIROL, V73, P2003, DOI 10.1099/0022-1317-73-8-2003.
   Lewandowski RJ, 2011, RADIOLOGY, V259, P641, DOI 10.1148/radiol.11081489.
   LI X, 1990, J VIROL, V64, P4654, DOI 10.1128/JVI.64.10.4654-4660.1990.
   Lorson C, 1998, VIROLOGY, V240, P326, DOI 10.1006/viro.1997.8940.
   Los M, 2009, BBA-MOL CELL RES, V1793, P1335, DOI 10.1016/j.bbamcr.2009.04.002.
   Makowska Z, 2016, J PATHOL CLIN RES, V2, P80, DOI 10.1002/cjp2.37.
   Mansour HM, 2009, INT J NANOMED, V4, P299.
   Marchini A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01848.
   Moehler M, 2001, CANCER GENE THER, V8, P158, DOI 10.1038/sj.cgt.7700288.
   Moralès O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032197.
   MOUSSET S, 1994, J VIROL, V68, P6446, DOI 10.1128/JVI.68.10.6446-6453.1994.
   Nüesch JPF, 2007, P NATL ACAD SCI USA, V104, P12482, DOI 10.1073/pnas.0705533104.
   Nüesch JPF, 2014, ADV EXP MED BIOL, V818, P99, DOI 10.1007/978-1-4471-6458-6\_5.
   Nüesch JPF, 2012, CLIN CANCER RES, V18, P3516, DOI 10.1158/1078-0432.CCR-11-2325.
   Nüesch JPF, 2009, J VIROL, V83, P5854, DOI 10.1128/JVI.00039-09.
   Nüesch ER, 2005, VIROLOGY, V331, P159, DOI 10.1016/j.virol.2004.10.019.
   Nüesch JPF, 2003, J VIROL, V77, P433, DOI 10.1128/JVI.77.1.433-442.2003.
   NUESCH JPF, 1993, VIROLOGY, V196, P637, DOI 10.1006/viro.1993.1520.
   Nuesch JPF, 2006, J VIROL, V80, P4729, DOI 10.1128/JVI.80.10.4729-4739.2006.
   Piscuoglio S, 2016, CLIN CANCER RES, V22, P4045, DOI 10.1158/1078-0432.CCR-15-2840.
   Qi CL, 2018, ANAT REC, V301, P1061, DOI 10.1002/ar.23777.
   Quagliata L, 2014, HEPATOLOGY, V59, P911, DOI 10.1002/hep.26740.
   Quiroz AR, 2016, PHARM RES-DORDR, V33, P450, DOI 10.1007/s11095-015-1801-4.
   Ruiz Z, 2011, VIROLOGY, V410, P375, DOI 10.1016/j.virol.2010.12.009.
   Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3.
   van der Meel R, 2019, NAT NANOTECHNOL, V14, P1007, DOI 10.1038/s41565-019-0567-y.
   VANACKER JM, 1993, J VIROL, V67, P7668, DOI 10.1128/JVI.67.12.7668-7672.1993.
   Wicki A, 2015, J CONTROL RELEASE, V200, P138, DOI 10.1016/j.jconrel.2014.12.030.
   Wrzesinski C, 2003, J VIROL, V77, P3851, DOI 10.1128/JVI.77.6.3851-3858.2003.
   Zamboni CG, 2015, J VASC INTERV RADIOL, V26, pS160, DOI 10.1016/j.jvir.2014.12.430.},
Number-of-Cited-References = {66},
Times-Cited = {4},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {18},
Journal-ISO = {J. Control. Release},
Doc-Delivery-Number = {SN6DI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000658377600002},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000642907600001,
Author = {Wu, Zhongzi and Gong, Huanfa and Zhang, Mingpeng and Tong, Xinkai and
   Ai, Huashui and Xiao, Shijun and Perez-Enciso, Miguel and Yang, Bin and
   Huang, Lusheng},
Title = {A worldwide map of swine short tandem repeats and their associations
   with evolutionary and environmental adaptations},
Journal = {GENETICS SELECTION EVOLUTION},
Year = {2021},
Volume = {53},
Number = {1},
Month = {APR 23},
Abstract = {Background Short tandem repeats (STRs) are genetic markers with a
   greater mutation rate than single nucleotide polymorphisms (SNPs) and
   are widely used in genetic studies and forensics. However, most studies
   in pigs have focused only on SNPs or on a limited number of STRs.
   Results This study screened 394 deep-sequenced genomes from 22
   domesticated pig breeds/populations worldwide, wild boars from both
   Europe and Asia, and numerous outgroup Suidaes, and identified a set of
   878,967 polymorphic STRs (pSTRs), which represents the largest
   repository of pSTRs in pigs to date. We found multiple lines of evidence
   that pSTRs in coding regions were affected by purifying selection. The
   enrichment of trinucleotide pSTRs in coding sequences (CDS), 5 ` UTR and
   H3K4me3 regions suggests that trinucleotide STRs serve as important
   components in the exons and promoters of the corresponding genes. We
   demonstrated that, compared to SNPs, pSTRs provide comparable or even
   greater accuracy in determining the breed identity of individuals. We
   identified pSTRs that showed significant population differentiation
   between domestic pigs and wild boars in Asia and Europe. We also
   observed that some pSTRs were significantly associated with
   environmental variables, such as average annual temperature or altitude
   of the originating sites of Chinese indigenous breeds, among which we
   identified loss-of-function and/or expanded STRs overlapping with genes
   such as AHR, LAS1L and PDK1. Finally, our results revealed that several
   pSTRs show stronger signals in domestic pig-wild boar differentiation or
   association with the analysed environmental variables than the flanking
   SNPs within a 100-kb window. Conclusions This study provides a
   genome-wide high-density map of pSTRs in diverse pig populations based
   on genome sequencing data, enabling a more comprehensive
   characterization of their roles in evolutionary and environmental
   adaptation.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, B; Huang, LS (Corresponding Author), Jiangxi Agr Univ, State Key Lab Pig Genet Improvement \& Prod Techno, Nanchang, Jiangxi, Peoples R China.
   Wu, Zhongzi; Gong, Huanfa; Zhang, Mingpeng; Tong, Xinkai; Ai, Huashui; Xiao, Shijun; Yang, Bin; Huang, Lusheng, Jiangxi Agr Univ, State Key Lab Pig Genet Improvement \& Prod Techno, Nanchang, Jiangxi, Peoples R China.
   Perez-Enciso, Miguel, CSIC IRTA UAB UB, Ctr Res Agr Genom CRAG, Campus UAB, Barcelona, Spain.
   Perez-Enciso, Miguel, ICREA, Passeig Lluis Co 23, Barcelona, Spain.},
DOI = {10.1186/s12711-021-00631-4},
Article-Number = {39},
ISSN = {0999-193X},
EISSN = {1297-9686},
Research-Areas = {Agriculture; Genetics \& Heredity},
Web-of-Science-Categories  = {Agriculture, Dairy \& Animal Science; Genetics \& Heredity},
Author-Email = {binyang@live.cn
   LushengHuang@hotmail.com},
Affiliations = {Jiangxi Agricultural University; University of Barcelona; Consejo
   Superior de Investigaciones Cientificas (CSIC); Centre de Recerca en
   Agrigenomica (CRAG); IRTA; Autonomous University of Barcelona; ICREA},
ResearcherID-Numbers = {Perez-Enciso, Miguel/H-6057-2015
   xiao, shijun/L-9364-2015
   Ai, Huashui/JGC-9331-2023
   yang, bin/JFS-4830-2023},
ORCID-Numbers = {, Zhongzi Wu/0009-0000-9763-5288
   yang, bin/0000-0002-0689-0628},
Funding-Acknowledgement = {National Natural Science Foundation {[}31790413]; National Natural
   Science Foundation of China {[}31760657]},
Funding-Text = {LSH was supported by the National Natural Science Foundation (31790413).
   BY was supported by the National Natural Science Foundation of China
   (31760657).},
Cited-References = {Adelmann CH, 2020, NATURE, V588, P699, DOI 10.1038/s41586-020-2937-x.
   Ai HS, 2015, NAT GENET, V47, P217, DOI 10.1038/ng.3199.
   Almeida B, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00076.
   Araujo PR, 2012, COMP FUNCT GENOM, DOI 10.1155/2012/475731.
   Asgari S, 2020, NATURE, V582, P234, DOI 10.1038/s41586-020-2302-0.
   Bao WD, 2015, MOBILE DNA-UK, V6, DOI 10.1186/s13100-015-0041-9.
   Benson G, 1999, NUCLEIC ACIDS RES, V27, P573, DOI 10.1093/nar/27.2.573.
   Bolton KA, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-795.
   BRUFORD MW, 1993, CURR OPIN GENET DEV, V3, P939, DOI 10.1016/0959-437X(93)90017-J.
   Bult CJ, 2019, NUCLEIC ACIDS RES, V47, pD801, DOI 10.1093/nar/gky1056.
   Butterfield RJ, 2014, NEUROLOGY, V82, P1322, DOI 10.1212/WNL.0000000000000305.
   Campbell CD, 2012, NAT GENET, V44, P1277, DOI 10.1038/ng.2418.
   Vieira MLC, 2016, GENET MOL BIOL, V39, P312, DOI 10.1590/1678-4685-GMB-2016-0027.
   Cen ZD, 2018, BRAIN, V141, P2280, DOI 10.1093/brain/awy160.
   China National Commission of Animal Genetic Resources, 2011, ANIMAL GENETIC RESOU.
   Chung N, 2009, MOL BIOL REP, V36, P227, DOI 10.1007/s11033-007-9171-6.
   Cui CY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010009.
   Dawson DA, 2012, MOL ECOL RESOUR, V12, P501, DOI 10.1111/j.1755-0998.2012.03115.x.
   de Knijff P, 2019, FORENSIC SCI INT-GEN, V38, P175, DOI 10.1016/j.fsigen.2018.10.017.
   Dhekne HS, 2018, HUM MUTAT, V39, P333, DOI 10.1002/humu.23386.
   DORRIES KM, 1995, PHYSIOL BEHAV, V57, P255, DOI 10.1016/0031-9384(94)00225-T.
   Ellegren H, 2004, NAT REV GENET, V5, P435, DOI 10.1038/nrg1348.
   Fan WL, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00520.
   Feng J., 2011, CURR PROTOC BIOINFOR, DOI DOI 10.1002/0471250953.BI0214-34.
   Flynn JM, 2020, P NATL ACAD SCI USA, V117, P9451, DOI 10.1073/pnas.1921046117.
   Forman OP, 2015, MAMM GENOME, V26, P108, DOI 10.1007/s00335-014-9547-6.
   Fotsing SF, 2019, NAT GENET, V51, P1652, DOI 10.1038/s41588-019-0521-9.
   Frantz LAF, 2015, NAT GENET, V47, P1141, DOI 10.1038/ng.3394.
   Frantz LAF, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r107.
   Fungtammasan A, 2015, GENOME RES, V25, P736, DOI 10.1101/gr.185892.114.
   Gou X, 2014, GENOME RES, V24, P1308, DOI 10.1101/gr.171876.113.
   Gymrek M, 2017, NAT GENET, V49, P1495, DOI 10.1038/ng.3952.
   Gymrek M, 2016, NAT GENET, V48, P22, DOI 10.1038/ng.3461.
   Gymrek M, 2012, GENOME RES, V22, P1154, DOI 10.1101/gr.135780.111.
   Hannan AJ, 2018, NAT REV GENET, V19, P286, DOI 10.1038/nrg.2017.115.
   Horbach SPJM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186281.
   Hu SL, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021372.
   Jakubosky D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16482-4.
   Ji JX, 2018, MEAT SCI, V146, P160, DOI 10.1016/j.meatsci.2018.08.013.
   Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201.
   Konkel MK, 2010, EVOL ANTHROPOL, V19, P236, DOI 10.1002/evan.20283.
   Kozlowski P, 2010, NUCLEIC ACIDS RES, V38, P4027, DOI 10.1093/nar/gkq127.
   KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488.
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI {[}10.1093/molbev/msw054, 10.1093/molbev/msv279].
   Kurebayashi J, 2001, JPN J CANCER RES, V92, P1093, DOI 10.1111/j.1349-7006.2001.tb01064.x.
   Labonne JDJ, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0642-z.
   Letunic I, 2019, NUCLEIC ACIDS RES, V47, pW256, DOI 10.1093/nar/gkz239.
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI {[}10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698].
   Liu CC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02600-8.
   Liu SX, 2017, MOL GENET GENOMICS, V292, P537, DOI 10.1007/s00438-017-1289-1.
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4.
   McMurray CT, 2010, NAT REV GENET, V11, P786, DOI 10.1038/nrg2828.
   Megens HJ, 2008, GENET SEL EVOL, V40, P103, DOI 10.1051/gse:2007039.
   Patterson N, 2006, PLOS GENET, V2, P2074, DOI 10.1371/journal.pgen.0020190.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Qi XB, 2019, GENOME BIOL EVOL, V11, P72, DOI 10.1093/gbe/evy264.
   Rubin CJ, 2012, P NATL ACAD SCI USA, V109, P19529, DOI 10.1073/pnas.1217149109.
   Sano R, 2017, TRANSFUSION MED, V27, P428, DOI 10.1111/tme.12455.
   Sawaya S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054710.
   Simonson TS, 2010, SCIENCE, V329, P72, DOI 10.1126/science.1189406.
   SLATKIN M, 1995, GENETICS, V139, P457.
   Srivastava S, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5516-5.
   Tang QZ, 2015, GENE, V567, P208, DOI 10.1016/j.gene.2015.05.007.
   Tempel Sebastien, 2012, Methods Mol Biol, V859, P29, DOI 10.1007/978-1-61779-603-6\_2.
   Usdin K, 2008, GENOME RES, V18, P1011, DOI 10.1101/gr.070409.107.
   van Kuilenburg ABP, 2019, NEW ENGL J MED, V380, P1433, DOI 10.1056/NEJMoa1806627.
   Villar D, 2015, CELL, V160, P554, DOI 10.1016/j.cell.2015.01.006.
   Wang ZY, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109688.
   Warr A, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa051.
   Wheeler VC, 2007, J MED GENET, V44, P695, DOI 10.1136/jmg.2007.050930.
   Willems T, 2017, NAT METHODS, V14, P590, DOI {[}10.1038/NMETH.4267, 10.1038/nmeth.4267].
   Willems T, 2014, GENOME RES, V24, P1894, DOI 10.1101/gr.177774.114.
   Xu LY, 2017, GENOME BIOL EVOL, V9, P20, DOI 10.1093/gbe/evw256.
   Xue HB, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4822-7.
   Yang B, 2017, GENET SEL EVOL, V49, DOI 10.1186/s12711-017-0345-y.
   Yang G, 2009, ANIM GENET, V40, P247, DOI 10.1111/j.1365-2052.2008.01820.x.
   Yang Y, 2018, ZOOL RES, V39, P424, DOI 10.24272/j.issn.2095-8137.2018.068.
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118.
   Zanzottera C, 2017, AM J MED GENET A, V173, P1358, DOI 10.1002/ajmg.a.38155.
   Zhou TB, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1587915.
   Zhu YL, 2017, GENOME BIOL EVOL, V9, P2592, DOI 10.1093/gbe/evx186.},
Number-of-Cited-References = {81},
Times-Cited = {12},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Genet. Sel. Evol.},
Doc-Delivery-Number = {RR2AL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000642907600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000641582300010,
Author = {Heinemann-Yerushalmi, Lia and Bentovim, Lital and Felsenthal, Neta and
   Vinestock, Ron Carmel and Michaeli, Nofar and Krief, Sharon and
   Silberman, Alon and Cohen, Marina and Ben-Dor, Shifra and Brenner, Ori
   and Haffner-Krausz, Rebecca and Itkin, Maxim and Malitsky, Sergey and
   Erez, Ayelet and Zelzer, Elazar},
Title = {BCKDK regulates the TCA cycle through PDC in the absence of PDK family
   during embryonic development},
Journal = {DEVELOPMENTAL CELL},
Year = {2021},
Volume = {56},
Number = {8},
Pages = {1182+},
Month = {APR 19},
Abstract = {Pyruvate dehydrogenase kinases (PDK1-4) inhibit the TCA cycle by
   phosphorylating pyruvate dehydrogenase complex (PDC). Here, we show that
   PDK family is dispensable for murine embryonic development and that
   BCKDK serves as a compensatory mechanism by inactivating PDC.
   First, we knocked out all four Pdk genes one by one. Surprisingly, Pdk
   total KO embryos developed and were born in expected ratios but died by
   postnatal day 4 because of hypoglycemia or ketoacidosis. Moreover, PDC
   was phosphorylated in these embryos, suggesting that another kinase
   compensates for PDK family. Bioinformatic analysis implicated
   branched-chain ketoacid dehydrogenase kinase (Bckdk), a key regulator of
   branched-chain amino acids (BCAAs) catabolism. Indeed, knockout of Bckdk
   and Pdk family led to the loss of PDC phosphorylation, an increase in
   PDC activity and pyruvate entry into the TCA cycle, and embryonic
   lethality. These findings reveal a regulatory crosstalk hardwiring BCAA
   and glucose catabolic pathways, which feed the TCA cycle.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Zelzer, E (Corresponding Author), Weizmann Inst Sci, Dept Mol Genet, IL-7610001 Rehovot, Israel.
   Heinemann-Yerushalmi, Lia; Bentovim, Lital; Felsenthal, Neta; Vinestock, Ron Carmel; Michaeli, Nofar; Krief, Sharon; Zelzer, Elazar, Weizmann Inst Sci, Dept Mol Genet, IL-7610001 Rehovot, Israel.
   Cohen, Marina; Brenner, Ori; Haffner-Krausz, Rebecca, Weizmann Inst Sci, Dept Vet Resources, IL-7610001 Rehovot, Israel.
   Ben-Dor, Shifra, Weizmann Inst Sci, Biol Serv, Bioinformat \& Biol Comp Unit, IL-76100 Rehovot, Israel.
   Itkin, Maxim; Malitsky, Sergey, Weizmann Inst Sci, Dept Life Sci Core Facil, IL-7610001 Rehovot, Israel.
   Silberman, Alon; Erez, Ayelet, Weizmann Inst Sci, Dept Biol Regulat, IL-7610001 Rehovot, Israel.},
DOI = {10.1016/j.devcel.2021.03.007},
EarlyAccessDate = {APR 2021},
ISSN = {1534-5807},
EISSN = {1878-1551},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; OXYGEN HOMEOSTASIS; METABOLIC SWITCH;
   HYPOXIA; EXPRESSION; CARTILAGE; PHOSPHORYLATION; DIFFERENTIATION;
   MECHANISMS; HIF1-ALPHA},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {eli.zelzer@weizmann.ac.il},
Affiliations = {Weizmann Institute of Science; Weizmann Institute of Science; Weizmann
   Institute of Science; Weizmann Institute of Science; Weizmann Institute
   of Science},
ResearcherID-Numbers = {Malitsky, Sergey/LXB-6071-2024
   Ben-Dor, Shifra/M-6718-2019
   Itkin, Maxim/AFU-5181-2022
   },
ORCID-Numbers = {Malitsky, Sergey/0000-0003-4619-7219
   Felsenthal, Neta/0000-0003-4927-7679
   Ben-Dor, Shifra/0000-0001-9604-1939
   Heinemann-Yerushalmi, Lia/0000-0002-2488-9022
   Itkin, Maxim/0000-0003-1348-2814
   Vinestock, Ron Carmel/0000-0002-6773-8988},
Funding-Acknowledgement = {David and Fela Shapell Family Center for Genetic Disorders Research;
   Estate of Mr. and Mrs. van Adelsbergen},
Funding-Text = {We thank Nitzan Konstantin for expert editorial assistance, Dr. Robert
   Harris from Indiana University, who kindly provided us with PDK2 and
   PDK4 mice, Dr. Nicola Brunetti-Pierri from the Telethon Institute of
   Genetics and Medicine for his support and advice, Dr. Ron Rotkoff for
   his help with statistical analysis, Dr. Tsviya Olender for
   bioinformatics advice, and Neria Sharabi from the Department of
   Veterinary Resources for his help with mouse maintenance. Special thanks
   to all members of the Zelzer Laboratory for encouragement and advice.
   This study was supported by The David and Fela Shapell Family Center for
   Genetic Disorders Research, and by The Estate of Mr. and Mrs. van
   Adelsbergen.},
Cited-References = {Amarilio R, 2007, DEVELOPMENT, V134, P3917, DOI 10.1242/dev.008441.
   Aragonés J, 2009, CELL METAB, V9, P11, DOI 10.1016/j.cmet.2008.10.001.
   Bentovim L, 2012, DEVELOPMENT, V139, P4473, DOI 10.1242/dev.083881.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   BROQUIST HP, 1966, ANNU REV BIOCHEM, V35, P231, DOI 10.1146/annurev.bi.35.070166.001311.
   Caspi R, 2018, NUCLEIC ACIDS RES, V46, pD633, DOI 10.1093/nar/gkx935.
   Chari R, 2015, NAT METHODS, V12, P823, DOI {[}10.1038/NMETH.3473, 10.1038/nmeth.3473].
   CRABB DW, 1979, ARCH BIOCHEM BIOPHYS, V198, P145, DOI 10.1016/0003-9861(79)90405-3.
   Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437.
   Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026.
   Dunford EC, 2011, AM J PHYSIOL-REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010.
   Dunwoodie SL, 2009, DEV CELL, V17, P755, DOI 10.1016/j.devcel.2009.11.008.
   Eshkar-Oren I, 2009, DEVELOPMENT, V136, P1263, DOI 10.1242/dev.034199.
   Ferriero R, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004986.
   GARLAND PB, 1964, BIOCHEM J, V93, P665, DOI 10.1042/bj0930665.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   HALLMANN R, 1987, DIFFERENTIATION, V34, P98, DOI 10.1111/j.1432-0436.1987.tb00055.x.
   Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9.
   Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647.
   Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680.
   Jeong JY, 2012, DIABETES METAB J, V36, P328.
   Jeoung NH, 2006, BIOCHEM J, V397, P417, DOI 10.1042/BJ20060125.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Jeoung NH, 2012, BIOCHEM J, V443, P829, DOI 10.1042/BJ20112197.
   Joshi MA, 2006, BIOCHEM J, V400, P153, DOI 10.1042/BJ20060869.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979.
   Koh MY, 2012, TRENDS BIOCHEM SCI, V37, P364, DOI 10.1016/j.tibs.2012.06.004.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297.
   Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009.
   LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234.
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Maes C, 2012, J BONE MINER RES, V27, P596, DOI 10.1002/jbmr.1487.
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306.
   Nishitani S, 2005, AM J PHYSIOL-GASTR L, V288, pG1292, DOI 10.1152/ajpgi.00510.2003.
   Oppenheim RD, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004263.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Paten B, 2008, GENOME RES, V18, P1814, DOI 10.1101/gr.076554.108.
   Pettitt SJ, 2009, NAT METHODS, V6, P493, DOI 10.1038/nmeth.1342.
   POPOV KM, 1993, J BIOL CHEM, V268, P26602.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068.
   Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Schipani E, 2001, GENE DEV, V15, P2865.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1.
   Semenza GL, 2009, PHYSIOLOGY, V24, P97, DOI 10.1152/physiol.00045.2008.
   Shao D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05362-7.
   Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6.
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5.
   Stelzer G, 2009, OMICS, V13, P477, DOI 10.1089/omi.2009.0069.
   Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263.
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937.
   Tennessen JM, 2014, G3-GENES GENOM GENET, V4, P839, DOI 10.1534/g3.114.010652.
   Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025.
   Weissgerber TL, 2006, APPL PHYSIOL NUTR ME, V31, P1, DOI 10.1139/H05-003.
   WIELAND OH, 1982, REV PHYSIOL BIOCH P, V96, P123, DOI 10.1007/BFb0031008.
   Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200.
   Xu H, 2015, GENOME RES, V25, P1147, DOI 10.1101/gr.191452.115.
   Zhang SH, 2017, J ANIM SCI BIOTECHNO, V8, DOI 10.1186/s40104-016-0139-z.
   Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001.
   Zhou MY, 2012, J BIOL CHEM, V287, P23397, DOI 10.1074/jbc.M112.351031.},
Number-of-Cited-References = {69},
Times-Cited = {20},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Dev. Cell},
Doc-Delivery-Number = {RP2RX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000641582300010},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000637391200010,
Author = {Oh, Hyunju and Zhao, Jingyao and Grinberg-Bleyer, Yenkel and Postler,
   Thomas S. and Wang, Pingzhang and Park, Sung-Gyoo and Rabadan, Raul and
   Hayden, Matthew S. and Ghosh, Sankar},
Title = {PDK1 Is Required for Maintenance of CD4+ Foxp3+
   Regulatory T Cell Function},
Journal = {JOURNAL OF IMMUNOLOGY},
Year = {2021},
Volume = {206},
Number = {8},
Pages = {1776-1783},
Month = {APR 15},
Abstract = {Regulatory T (Treg) cells have an essential role in maintaining immune
   homeostasis, in part by suppressing effector T cell functions.
   Phosphoinositide-dependent kinase 1 (PDK1) is a pleiotropic kinase that
   acts as a key effector downstream of PI3K in many cell types. In T
   cells, PDK1 has been shown to be critical for activation of NF-kappa B
   and AKT signaling upon TCR ligation and is therefore essential for
   effector T cell activation, proliferation, and cytokine production.
   Using Treg cell-specific conditional deletion, we now demonstrate that
   PDK1 is also essential for Treg cell suppressive activity in vivo.
   Ablation of Pdk1 specifically in Treg cells led to systemic, lethal,
   scurfy-like inflammation in mice. Genome-wide analysis confirmed that
   PDK1 is essential for the regulation of key Treg cell signature gene
   expression and, further, suggested that PDK1 acts primarily to control
   Treg cell gene expression through regulation of the canonical NF-kappa B
   pathway. Consistent with these results, the scurfy-like phenotype of
   mice lacking PDK1 in Treg cells was rescued by enforced activation of
   NF-kappa B downstream of PDK1. Therefore, PDK1-mediated activation of
   the NF-kappa B signaling pathway is essential for regulation of Treg
   cell signature gene expression and suppressor function.},
Publisher = {OXFORD UNIV PRESS},
Address = {GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Ghosh, S (Corresponding Author), Columbia Univ, Coll Phys \& Surg, 701W 168th St,HHSC 1208, New York, NY 10032 USA.
   Oh, Hyunju; Zhao, Jingyao; Grinberg-Bleyer, Yenkel; Postler, Thomas S.; Park, Sung-Gyoo; Hayden, Matthew S.; Ghosh, Sankar, Columbia Univ, Dept Microbiol \& Immunol, Vagelos Coll Phys \& Surg, Irving Med Ctr, New York, NY 10032 USA.
   Wang, Pingzhang; Rabadan, Raul, Columbia Univ, Dept Syst Biol, Vagelos Coll Phys \& Surg, Irving Med Ctr, New York, NY 10032 USA.
   Wang, Pingzhang; Rabadan, Raul, Columbia Univ, Dept Biomed Informat, Vagelos Coll Phys \& Surg, Irving Med Ctr, New York, NY 10032 USA.
   Hayden, Matthew S., Dartmouth Hitchcock Med Ctr, Sect Dermatol, Dept Surg, Lebanon, NH 03756 USA.
   Hayden, Matthew S., Geisel Sch Med, Lebanon, NH 03756 USA.
   Grinberg-Bleyer, Yenkel, Univ Claude Bernard Lyon 1, Canc Res Ctr Lyon, UMR INSERM 1052,CNRS 5286, Ctr Leon Berard, Lyon, France.
   Park, Sung-Gyoo, Gwangju Inst Sci \& Technol, Gwangju, South Korea.},
DOI = {10.4049/jimmunol.2000051},
ISSN = {0022-1767},
EISSN = {1550-6606},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Author-Email = {sg2715@columbia.edu},
Affiliations = {Columbia University; Cornell University; Weill Cornell Medicine;
   NewYork-Presbyterian Hospital; Columbia University; Cornell University;
   Weill Cornell Medicine; NewYork-Presbyterian Hospital; Columbia
   University; Cornell University; Weill Cornell Medicine;
   NewYork-Presbyterian Hospital; Dartmouth College; Dartmouth College;
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); UNICANCER; Centre Leon Berard; Universite
   Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Gwangju Institute of Science \& Technology (GIST)},
ResearcherID-Numbers = {Ghosh, Sankar/AFG-8770-2022
   Park, Sung-Gyoo/H-8652-2019
   Rabadan, Raul/AAZ-7367-2020
   Hayden, Matthew/C-1263-2008
   },
ORCID-Numbers = {Grinberg-Bleyer, Yenkel/0000-0002-3515-8305
   Ghosh, Sankar/0000-0002-3227-0588
   Postler, Thomas/0000-0002-3558-9084
   Park, Sung-Gyoo/0000-0003-3702-5765
   Hayden, Matthew/0000-0003-1670-6430
   Wang, Pingzhang/0000-0003-1746-7216},
Funding-Acknowledgement = {National Institutes of Health, National Institute of Allergy and
   Infectious Diseases {[}R01AI068977]},
Funding-Text = {This work was supported by National Institutes of Health, National
   Institute of Allergy and Infectious Diseases grant R01AI068977 (to
   S.G.).},
Cited-References = {Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Barbi JJ, 2016, J IMMUNOL, V196.
   Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Costello PS, 2002, NAT IMMUNOL, V3, P1082, DOI 10.1038/ni848.
   Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097.
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Finlay DK, 2009, J EXP MED, V206, P2441, DOI 10.1084/jem.20090219.
   Garcon F, 2008, BLOOD, V111, P1464, DOI 10.1182/blood-2007-08-108050.
   Gotea V, 2008, NUCLEIC ACIDS RES, V36, pW133, DOI 10.1093/nar/gkn300.
   Grinberg-Bleyer Y, 2010, J CLIN INVEST, V120, P4558, DOI 10.1172/JCI42945.
   Gupta S, 2008, MOL IMMUNOL, V46, P213, DOI 10.1016/j.molimm.2008.08.275.
   Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774.
   Haxhinasto S, 2008, J EXP MED, V205, P565, DOI 10.1084/jem.20071477.
   Heuser C, 2017, CELL REP, V21, P578, DOI 10.1016/j.celrep.2017.09.082.
   Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062.
   Kelly AP, 2006, FEBS LETT, V580, P2135, DOI 10.1016/j.febslet.2006.03.022.
   Kelly AP, 2007, EMBO J, V26, P3441, DOI 10.1038/sj.emboj.7601761.
   Kerdiles YM, 2010, IMMUNITY, V33, P890, DOI 10.1016/j.immuni.2010.12.002.
   Kitz A, 2016, EMBO REP, V17, P1169, DOI 10.15252/embr.201541905.
   Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107.
   Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004.
   Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000.
   Macintyre AN, 2011, IMMUNITY, V34, P224, DOI 10.1016/j.immuni.2011.01.012.
   Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007.
   Miyazaki M, 2014, NAT IMMUNOL, V15, P767, DOI 10.1038/ni.2928.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Oh H, 2017, IMMUNITY, V47, P450, DOI 10.1016/j.immuni.2017.08.010.
   Ouyang WM, 2012, NATURE, V491, P554, DOI 10.1038/nature11581.
   Park SG, 2013, PLOS ONE, V8, DOI {[}10.1371/journal.pone.0055378, 10.1371/journal.pone.0057138].
   Park SG, 2010, IMMUNITY, V33, P791, DOI 10.1016/j.immuni.2010.10.014.
   Park SG, 2009, NAT IMMUNOL, V10, P158, DOI 10.1038/ni.1687.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Rauch KS, 2016, CELL REP, V17, P2827, DOI 10.1016/j.celrep.2016.11.045.
   Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017.
   Sauer S, 2008, P NATL ACAD SCI USA, V105, P7797, DOI 10.1073/pnas.0800928105.
   Siegmund K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175463.
   Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014.
   Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090.
   Venigalla RKC, 2013, EMBO J, V32, P1008, DOI 10.1038/emboj.2013.40.
   Zanin-Zhorov A, 2010, SCIENCE, V328, P372, DOI 10.1126/science.1186068.
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297.
   Zhang R, 2013, J CLIN INVEST, V123, P580, DOI 10.1172/JCI65013.},
Number-of-Cited-References = {44},
Times-Cited = {10},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {6},
Journal-ISO = {J. Immunol.},
Doc-Delivery-Number = {RJ1WD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000637391200010},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000640443700001,
Author = {Song, Feiluan and Cai, Anli and Ye, Qianwen and Chen, Xiang and Lin, Lin
   and Hao, Xi},
Title = {MiR-34b-3p Impaired HUVECs Viability and Migration via Targeting PDK1 in
   an In Vitro Model of Gestational Diabetes Mellitus},
Journal = {BIOCHEMICAL GENETICS},
Year = {2021},
Volume = {59},
Number = {6},
Pages = {1381-1395},
Month = {DEC},
Abstract = {Gestational diabetes mellitus (GDM) leads to poor pregnancy outcomes.
   The methods for GDM early diagnosis and treatment are still unknown.
   This study aimed to investigate the expression and diagnostic potential
   of miR-34b-3p in GDM patients and further analyzed the effects of
   miR-34b-3p on HUVECs viability and migration. The expression of
   miR-34b-3p was detected in HUVECs of GDM and normal pregnant women by
   qRT-PCR. Then the HUVECs were isolated from normal pregnant women. High
   glucose (HG) was used to treat the HUVECs to mimic the GDM in vitro. The
   cell viability and migration were determined by MTT, wound healing
   assay, and transwell assay. The interaction between miR-34b-3p and PDK1
   was evaluated by luciferase activity assay. Our results showed that
   miR-34b-3p was up-regulated in HUVECs of GDM patients. Then the HUVECs
   were isolated from normal pregnant women and they were treated with HG
   to mimic the GDM in vitro. Interestingly, knockdown of miR-34b-3p
   restored the impairment of HG treatment-induced effects in HUVECs. More
   importantly, PDK1 was proved to be a potential target of miR-34b-3p.
   Finally, the rescue experiments confirmed that miR-34b-3p impaired cell
   viability and migration ability in HUVECs by targeting PDK1. These
   findings concluded that miR-34b-3p impaired HUVECs viability and
   migration in GDM by targeting PDK1, which might provide a novel
   perspective for the pathogenesis and underlying therapeutic target for
   GDM.},
Publisher = {SPRINGER/PLENUM PUBLISHERS},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Cai, AL (Corresponding Author), Ruian Peoples Hosp, Dept Obstet \& Gynecol, 108 Wansong Rd,Yuhai St, Wenzhou 325200, Zhejiang, Peoples R China.
   Song, Feiluan; Cai, Anli; Ye, Qianwen; Chen, Xiang; Lin, Lin; Hao, Xi, Ruian Peoples Hosp, Dept Obstet \& Gynecol, 108 Wansong Rd,Yuhai St, Wenzhou 325200, Zhejiang, Peoples R China.},
DOI = {10.1007/s10528-021-10064-9},
EarlyAccessDate = {APR 2021},
ISSN = {0006-2928},
EISSN = {1573-4927},
Keywords = {Gestational diabetes mellitus; MiR-34b-3p; PDK1; Viability; Migration},
Keywords-Plus = {ANGIOPOIETIN-1; CELLS; KINASE; ACTIVATION; EXPRESSION; REGULATOR;
   PLACENTA; BLOOD},
Research-Areas = {Biochemistry \& Molecular Biology; Genetics \& Heredity},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Genetics \& Heredity},
Author-Email = {AXCVZ89h@163.com},
Cited-References = {Adameova AD, 2018, REV CARDIOVASC MED, V19, P97, DOI 10.31083/j.rcm.2018.03.3181.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Bagci H, 2018, CLIN EXP OBSTET GYN, V45, P539, DOI 10.12891/ceog4348.2018.
   Ben-Haroush A, 2004, DIABETIC MED, V21, P103, DOI 10.1046/j.1464-5491.2003.00985.x.
   Caporali A, 2011, CIRCULATION, V123, P282, DOI 10.1161/CIRCULATIONAHA.110.952325.
   Córdova-Rivas S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030545.
   Edu A, 2016, ROM J MORPHOL EMBRYO, V57, P507.
   Fang LL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122762.
   Feng HX, 2019, J CELL MOL MED, V23, P5282, DOI 10.1111/jcmm.14404.
   Harfouche R, 2003, FASEB J, V17, P1523, DOI 10.1096/fj.02-0698fje.
   Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774.
   Kalimutho M, 2011, BRIT J CANCER, V104, P1770, DOI 10.1038/bjc.2011.82.
   Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952.
   Law KP, 2017, CLIN CHIM ACTA, V468, P60, DOI 10.1016/j.cca.2017.02.008.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li J, 2017, GENE, V625, P1, DOI {[}10.1016/j.gene.2017.0.001, 10.1016/j.gene.2017.05.001].
   Liu WW, 2019, THROMB HAEMOSTASIS, V119, P1451, DOI 10.1055/s-0039-1692681.
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034.
   Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64.
   Miao M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00441-z.
   Mizuno K, 2017, J HUM GENET, V62, P671, DOI 10.1038/jhg.2017.27.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Muralimanoharan S, 2016, CLIN SCI, V130, P931, DOI 10.1042/CS20160076.
   Papapetropoulos A, 2000, J BIOL CHEM, V275, P9102, DOI 10.1074/jbc.275.13.9102.
   Papapetropoulos A, 1999, LAB INVEST, V79, P213.
   Peng HY, 2019, CURR MOL MED, V19, P494, DOI 10.2174/1566524019666190520100422.
   Peng HY, 2018, MICROVASC RES, V118, P90, DOI 10.1016/j.mvr.2018.03.002.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   Shi ZH, 2014, ENDOCRINOLOGY, V155, P1982, DOI 10.1210/en.2013-2046.
   Spaight C, 2016, ENDOCR DEV, V31, P163, DOI 10.1159/000439413.
   Sultan SA, 2015, J CELL PHYSIOL, V230, P2695, DOI 10.1002/jcp.24993.
   Tan YA, 2019, MED SCI MONITOR, V25, P1323, DOI 10.12659/MSM.913746.
   Tanase-Nakao K, 2017, DIABETES-METAB RES, V33, DOI 10.1002/dmrr.2875.
   Trout KK, 2011, CURR DIABETES REP, V11, P7, DOI 10.1007/s11892-010-0159-6.
   Tryggestad JB, 2016, CLIN SCI, V130, P1955, DOI 10.1042/CS20160305.
   Wang PP, 2019, J CELL PHYSIOL, V234, P7141, DOI 10.1002/jcp.27468.
   Westgate JA, 2006, DIABETES CARE, V29, P1345, DOI 10.2337/dc05-1677.
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215.
   Zheng S, 2015, BIOCHEM BIOPH RES CO, V460, P333, DOI 10.1016/j.bbrc.2015.03.035.},
Number-of-Cited-References = {39},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {1},
Journal-ISO = {Biochem. Genet.},
Doc-Delivery-Number = {WO6TP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000640443700001},
DA = {2026-02-04},
}

@article{ WOS:000640115200002,
Author = {Baffi, Timothy R. and Lorden, Gema and Wozniak, Jacob M. and Feichtner,
   Andreas and Yeung, Wayland and Kornev, Alexandr P. and King, Charles C.
   and Del Rio, Jason C. and Limaye, Ameya J. and Bogomolovas, Julius and
   Gould, Christine M. and Chen, Ju and Kennedy, Eileen J. and Kannan,
   Natarajan and Gonzalez, David J. and Stefan, Eduard and Taylor, Susan S.
   and Newton, Alexandra C.},
Title = {mTORC2 controls the activity of PKC and Akt by phosphorylating a
   conserved TOR interaction motif},
Journal = {SCIENCE SIGNALING},
Year = {2021},
Volume = {14},
Number = {678},
Month = {APR 13},
Abstract = {The complex mTORC2 is accepted to be the kinase that controls the
   phosphorylation of the hydrophobic motif, a key regulatory switch for
   AGC kinases, although whether mTOR directly phosphorylates this motif
   remains controversial. Here, we identified an mTOR-mediated
   phosphorylation site that we termed the TOR interaction motif (TIM;
   F-x3-F-pT), which controls the phosphorylation of the hydrophobic motif
   of PKC and Akt and the activity of these kinases. The TIM is invariant
   in mTORC2-dependent AGC kinases, is evolutionarily conserved, and
   co-evolved with mTORC2 components. Mutation of this motif in Akt1 and
   PKC.II abolished cellular kinase activity by impairing activation loop
   and hydrophobic motif phosphorylation. mTORC2 directly phosphorylated
   the PKC TIM in vitro, and this phosphorylation event was detected in
   mouse brain. Overexpression of PDK1 in mTORC2-deficient cells rescued
   hydrophobic motif phosphorylation of PKC and Akt by a mechanism
   dependent on their intrinsic catalytic activity, revealing that mTORC2
   facilitates the PDK1 phosphorylation step, which, in turn, enables
   auto-phosphorylation. Structural analysis revealed that PKC
   homodimerization is driven by a TIM-containing helix, and biophysical
   proximity assays showed that newly synthesized, unphosphorylated PKC
   dimerizes in cells. Furthermore, disruption of the dimer interface by
   stapled peptides promoted hydrophobic motif phosphorylation. Our data
   support a model in which mTORC2 relieves nascent PKC dimerization
   through TIM phosphorylation, recruiting PDK1 to phosphorylate the
   activation loop and triggering intramolecular hydrophobic motif
   autophosphorylation. Identification of TIM phosphorylation and its role
   in the regulation of PKC provides the basis for AGC kinase regulation by
   mTORC2.},
Publisher = {AMER ASSOC ADVANCEMENT SCIENCE},
Address = {1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA},
Type = {Article},
Language = {English},
Affiliation = {Newton, AC (Corresponding Author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   Baffi, Timothy R.; Lorden, Gema; Wozniak, Jacob M.; Kornev, Alexandr P.; King, Charles C.; Del Rio, Jason C.; Gould, Christine M.; Gonzalez, David J.; Taylor, Susan S.; Newton, Alexandra C., Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   Baffi, Timothy R.; Wozniak, Jacob M.; Del Rio, Jason C.; Gould, Christine M., Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA.
   Wozniak, Jacob M.; Gonzalez, David J., Univ Calif San Diego, Skaggs Sch Pharm \& Pharmaceut Sci, La Jolla, CA 92093 USA.
   Feichtner, Andreas; Stefan, Eduard, Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria.
   Feichtner, Andreas; Stefan, Eduard, Univ Innsbruck, Ctr Mol Biosci, A-6020 Innsbruck, Austria.
   Yeung, Wayland; Kannan, Natarajan, Univ Georgia, Inst Bioinformat, Athens, GA 30602 USA.
   Yeung, Wayland; Kannan, Natarajan, Univ Georgia, Dept Biochem \& Mol Biol, Athens, GA 30602 USA.
   Limaye, Ameya J.; Kennedy, Eileen J., Univ Georgia, Coll Pharm, Dept Pharmaceut \& Biomed Sci, Athens, GA 30602 USA.
   Bogomolovas, Julius; Chen, Ju, Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA.
   Taylor, Susan S., Univ Calif San Diego, Dept Chem \& Biochem, La Jolla, CA 92093 USA.},
DOI = {10.1126/scisignal.abe4509},
Article-Number = {eabe4509},
ISSN = {1945-0877},
EISSN = {1937-9145},
Keywords-Plus = {PROTEIN-KINASE-C; PHOSPHOINOSITIDE-DEPENDENT KINASE; P70 S6 KINASE; AGC
   KINASES; CRYSTAL-STRUCTURE; TRANS-PHOSPHORYLATION; CARBOXYL-TERMINUS;
   IN-VIVO; ACTIVATION; DOMAIN},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {anewton@health.ucsd.edu},
Affiliations = {University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of Innsbruck; University of Innsbruck; University System of
   Georgia; University of Georgia; University System of Georgia; University
   of Georgia; University System of Georgia; University of Georgia;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego},
ResearcherID-Numbers = {Kornev, Alexan/O-7826-2015
   Chen, Ju/E-5579-2011
   Bogomolovas, Julius/HGD-2595-2022
   Limaye, Ameya/JNS-0499-2023
   Gonzalez, David/IPU-3884-2023},
ORCID-Numbers = {Kornev, Alexan/0000-0002-1543-3795
   Baffi, Timothy/0000-0003-2862-6155
   Kannan, Natarajan/0000-0002-2833-8375
   Bogomolovas, Julius/0000-0001-8344-1909
   Limaye, Ameya/0000-0002-3582-8858
   Lorden Losada, Gema/0000-0001-9674-890X
   Del Rio, Jason/0000-0001-8540-2065
   },
Funding-Acknowledgement = {NIH {[}R35 GM122523, GM43154, GM134168, R01GM114409, U01CA239106]; PhRMA
   Foundation Pre Doctoral Fellowship in Pharmacology Toxicology
   {[}20183844]; UCSD Graduate Training Program in Cellular and Molecular
   Pharmacology {[}T32 GM007752]; UCSD Graduate Training Programs in
   Cellular and Molecular Pharmacology {[}T32 GM007752]; Rheumatic Diseases
   Research {[}T32 AR064194]; Austrian Science Fund {[}P30441, P32960];
   National Heart Lung and Blood Institute {[}R01HL155826] Funding Source:
   NIH RePORTER; National Institute of Arthritis and Musculoskeletal and
   Skin Diseases {[}T32AR064194] Funding Source: NIH RePORTER; National
   Institute of General Medical Sciences {[}R01GM134168, R35GM122523,
   T32GM007752] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported by NIH R35 GM122523 and NIH GM43154 to A.C.N.;
   NIH GM134168 to E.J.K.; and NIH R01GM114409 and U01CA239106 to N.K.
   T.R.B. was supported by the PhRMA Foundation Pre Doctoral Fellowship in
   Pharmacology Toxicology (\#20183844) and the UCSD Graduate Training
   Program in Cellular and Molecular Pharmacology (T32 GM007752). J.M.W.
   was supported by the UCSD Graduate Training Programs in Cellular and
   Molecular Pharmacology (T32 GM007752) and Rheumatic Diseases Research
   (T32 AR064194). E.S. was supported by grants from the Austrian Science
   Fund (P30441 and P32960).},
Cited-References = {Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Ali SM, 2005, J BIOL CHEM, V280, P19445, DOI 10.1074/jbc.C500125200.
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2.
   Antal CE, 2015, CELL REP, V12, P1252, DOI 10.1016/j.celrep.2015.07.039.
   Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001.
   Antal CE, 2014, CHEM BIOL, V21, P459, DOI 10.1016/j.chembiol.2014.02.008.
   Baffi TR, 2021, ANNU REV PHARMACOL, V61, P723, DOI 10.1146/annurev-pharmtox-031820-122108.
   Baffi TR, 2019, MOL CELL, V74, P378, DOI 10.1016/j.molcel.2019.02.018.
   Balasuriya N, 2018, J BIOL CHEM, V293, P10744, DOI 10.1074/jbc.RA118.002357.
   Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9.
   Beenstock J, 2016, TRENDS BIOCHEM SCI, V41, P938, DOI 10.1016/j.tibs.2016.08.006.
   Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Bornancin F, 1996, CURR BIOL, V6, P1114, DOI 10.1016/S0960-9822(02)70678-7.
   Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432.
   Cameron AJM, 2011, BIOCHEM J, V439, P287, DOI 10.1042/BJ20110678.
   Cameron AJM, 2009, NAT STRUCT MOL BIOL, V16, P624, DOI 10.1038/nsmb.1606.
   Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965.
   Chou PC, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071567.
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003.
   Cole PA, 2019, CURR OPIN STRUC BIOL, V59, P47, DOI 10.1016/j.sbi.2019.02.004.
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004.
   DATTA K, 1995, MOL CELL BIOL, V15, P2304.
   Dries DR, 2007, J BIOL CHEM, V282, P826, DOI 10.1074/jbc.C600268200.
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661.
   Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697.
   DUTIL EM, 1994, J BIOL CHEM, V269, P29359.
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7.
   Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028.
   Edwards AS, 1997, J BIOL CHEM, V272, P18382, DOI 10.1074/jbc.272.29.18382.
   Enzler F, 2020, IUBMB LIFE, V72, P1168, DOI 10.1002/iub.2241.
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120.
   FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895.
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665.
   Frech M, 1997, J BIOL CHEM, V272, P8474, DOI 10.1074/jbc.272.13.8474.
   Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001.
   Frödin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551.
   Gallegos LL, 2006, J BIOL CHEM, V281, P30947, DOI 10.1074/jbc.M603741200.
   Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   GIBBS CS, 1991, J BIOL CHEM, V266, P8923.
   Gould CM, 2011, J BIOL CHEM, V286, P28922, DOI 10.1074/jbc.M111.272526.
   Gould CM, 2009, J BIOL CHEM, V284, P4921, DOI 10.1074/jbc.M808436200.
   Grodsky N, 2006, BIOCHEMISTRY-US, V45, P13970, DOI 10.1021/bi061128h.
   Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5.
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007.
   HANNUN YA, 1986, J BIOL CHEM, V261, P9341.
   Hauge C, 2007, EMBO J, V26, P2251, DOI 10.1038/sj.emboj.7601682.
   Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950.
   Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053.
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267.
   Huang LC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24457-1.
   Huang SM, 1999, BIOCHEMISTRY-US, V38, P12020, DOI 10.1021/bi990594m.
   Hui X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00560-7.
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119.
   Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493.
   Iyer GH, 2005, J BIOL CHEM, V280, P8800, DOI 10.1074/jbc.M407586200.
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033.
   Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005.
   Kannan N, 2007, P NATL ACAD SCI USA, V104, P1272, DOI 10.1073/pnas.0610251104.
   Katoh K, 2002, NUCLEIC ACIDS RES, V30, P3059, DOI 10.1093/nar/gkf436.
   Katoh T, 2016, BIOORGAN MED CHEM, V24, P2466, DOI 10.1016/j.bmc.2016.04.008.
   Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6.
   Keshwani MM, 2012, P NATL ACAD SCI USA, V109, pE1221, DOI 10.1073/pnas.1202741109.
   Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338.
   KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342.
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169.
   Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200.
   Lapek JD, 2017, MOL CELL PROTEOMICS, V16, P1447, DOI 10.1074/mcp.M116.066019.
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042.
   Leonard TA, 2011, CELL, V144, P55, DOI 10.1016/j.cell.2010.12.013.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072.
   Lin K, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002618.
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y.
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762.
   MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194.
   McSkimming DI, 2016, MOL BIOSYST, V12, P3651, DOI 10.1039/c6mb00466k.
   Metz KS, 2018, CELL SYST, V7, P347, DOI 10.1016/j.cels.2018.07.001.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   National Research Council (NRC), 2011, GUID CAR US LAB AN.
   Neuwald AF, 2009, BIOINFORMATICS, V25, P1869, DOI 10.1093/bioinformatics/btp342.
   NEWTON AC, 1987, J BIOL CHEM, V262, P10185.
   Newton AC, 2017, TRENDS PHARMACOL SCI, V38, P438, DOI 10.1016/j.tips.2017.02.002.
   Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024.
   Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271.
   ORR JW, 1994, J BIOL CHEM, V269, P27715.
   Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x.
   Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707.
   Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963.
   Röck R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav8463.
   Röck R, 2015, SCI REP-UK, V5, DOI 10.1038/srep11133.
   Roelants FM, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7030066.
   Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200.
   Romano RA, 2009, PROTEIN SCI, V18, P1486, DOI 10.1002/pro.146.
   Ross BL, 2018, ELIFE, V7, DOI 10.7554/eLife.35458.
   Sabatini DM, 2017, P NATL ACAD SCI USA, V114, P11818, DOI 10.1073/pnas.1716173114.
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054.
   Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a.
   Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5.
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8.
   Schrodinger LLC, 2015, PYMOL MOL GRAPH SYST.
   Stefan E, 2007, P NATL ACAD SCI USA, V104, P16916, DOI 10.1073/pnas.0704257104.
   Su B, 2011, CRIT REV BIOCHEM MOL, V46, P527, DOI 10.3109/10409238.2011.618113.
   Swanson CJ, 2014, J BIOL CHEM, V289, P17812, DOI 10.1074/jbc.M113.534750.
   Sweatt JD, 1998, J NEUROCHEM, V71, P1075.
   Tatebe H, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7040077.
   Tatebe H, 2017, ELIFE, V6, DOI 10.7554/eLife.19594.
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200.
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755.
   Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0.
   Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271.
   Uphoff CC, 2011, METHODS MOL BIOL, V731, P93, DOI 10.1007/978-1-61779-080-5\_8.
   van Eis MJ, 2011, BIOORG MED CHEM LETT, V21, P7367, DOI 10.1016/j.bmcl.2011.10.025.
   Verdine GL, 2012, METHOD ENZYMOL, V503, P3, DOI 10.1016/B978-0-12-396962-0.00001-X.
   Violin JD, 2003, J CELL BIOL, V161, P899, DOI 10.1083/jcb.200302125.
   Warfel NA, 2011, J BIOL CHEM, V286, P39122, DOI 10.1074/jbc.M111.278747.
   Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200.
   Yan Lijun, 2008, Biochem J, V416, pe19, DOI 10.1042/BJ20082202.
   Yang CS, 2017, PROSTATE, V77, P1452, DOI 10.1002/pros.23400.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206.
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245.
   Ziemba BP, 2014, BIOCHEMISTRY-US, V53, P1697, DOI 10.1021/bi4016082.},
Number-of-Cited-References = {130},
Times-Cited = {77},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Sci. Signal.},
Doc-Delivery-Number = {RN1LI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000640115200002},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000636980800013,
Author = {Chen, Lin and Bao, Lei and Niu, Yanling and Wang, Jennifer E. and Kumar,
   Ashwani and Xing, Chao and Wang, Yingfei and Luo, Weibo},
Title = {LncIHAT Is Induced by Hypoxia-Inducible Factor 1 and Promotes Breast
   Cancer Progression},
Journal = {MOLECULAR CANCER RESEARCH},
Year = {2021},
Volume = {19},
Number = {4},
Pages = {678-687},
Month = {APR 1},
Abstract = {Hypoxia induces thousands of mRNAs and miRNAs to mediate tumor
   malignancy. However, hypoxia-induced long noncoding RNA (lncRNA)
   transcriptome and their role in triple-negative breast cancer (TNBC)
   have not been defined. Here we identified hypoxia-induced lncRNA
   transcriptome in two human TNBC cell lines by whole transcriptome
   sequencing. AC093818.1 was one of 26 validated lncRNAs and abundantly
   expressed in TNBC in vitro and in vivo. 5'- and 3'-rapid amplification
   of cDNA ends assays revealed that the isoform 2 was a dominant
   AC093818.1 transcript in TNBC cells and thus referred to as
   lncIHAT(lncRNA induced by hypoxia and abundant in TNBC).
   Hypoxia-inducible factor 1 (HIF1) but not HIF2 bound to the hypoxia
   response element at the promoter of lncIHAT to activate its
   transcription in hypoxic TNBC cells. LncIHAT promoted TNBC cell survival
   in vitro and tumor growth and lung metastasis in mice. Mechanistically,
   lncIHAT was required for the expression of its proximal neighboring
   oncogenic genes PDKI and ITGA6 in TNBC cells and tumors. Reexpression of
   PDK1 and ITGA6 rescued survival and growth of lncIHAT knockdown TNBC
   cells in vitro. Collectively, these findings uncovered lncIHAT as a new
   hypoxia-induced oncogenic cis-acting lncRNA in TNBC.},
Publisher = {AMER ASSOC CANCER RESEARCH},
Address = {615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, YF; Luo, WB (Corresponding Author), Univ Texas Southwestern Med Ctr Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   Chen, Lin; Bao, Lei; Niu, Yanling; Wang, Jennifer E.; Wang, Yingfei; Luo, Weibo, UT Southwestern Med Ctr, Dept Pathol, Dallas, TX USA.
   Kumar, Ashwani; Xing, Chao, UT Southwestern Med Ctr, Eugene McDermott Ctr Human Growth \& Dev, Dallas, TX USA.
   Xing, Chao, UT Southwestern Med Ctr, Dept Bioinformat, Dallas, TX USA.
   Xing, Chao, UT Southwestern Med Ctr, Dept Populat \& Data Sci, Dallas, TX USA.
   Wang, Yingfei, UT Southwestern Med Ctr, Dept Neurol, Dallas, TX USA.
   Luo, Weibo, UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX USA.},
DOI = {10.1158/1541-7786.MCR-20-0383},
ISSN = {1541-7786},
EISSN = {1557-3125},
Research-Areas = {Oncology; Cell Biology},
Web-of-Science-Categories  = {Oncology; Cell Biology},
Author-Email = {yingfei.wang@utsouthwestern.edu
   weibo.luo@utsouthwestern.edu},
Affiliations = {University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center; University of Texas System; University of
   Texas Southwestern Medical Center; University of Texas System;
   University of Texas Southwestern Medical Center; University of Texas
   System; University of Texas Southwestern Medical Center},
ResearcherID-Numbers = {Niu, Yanling/JQW-2969-2023
   },
ORCID-Numbers = {Xing, Chao/0000-0002-1838-0502
   wang, yingfei/0000-0002-8723-252X
   Luo, Weibo/0000-0002-1992-0320
   Chen, Lin/0000-0002-7552-8673},
Funding-Acknowledgement = {CPRIT {[}RR140036, RP190358, RP170671]; Mary Kay Foundation {[}08-19];
   Welch Foundation {[}I-1903-20190330, I-1939-20160319]},
Funding-Text = {This work was supported by grants from the CPRIT (RR140036 and
   RP190358), the Mary Kay Foundation (08-19), and the Welch Foundation
   (I-1903-20190330), to W. Luo, and the CPRIT (RP170671) and the Welch
   Foundation (I-1939-20160319), to Y. Wang. W. Luo is a CPRIT Scholar in
   Cancer Research.},
Cited-References = {Ata-abadi NS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232357.
   Ba MC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2245-2.
   Bao L, 2018, NUCLEIC ACIDS RES, V46, P6576, DOI 10.1093/nar/gky449.
   Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013.
   Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x.
   Cariati M, 2008, INT J CANCER, V122, P298, DOI 10.1002/ijc.23103.
   Chen Y, 2018, J CLIN INVEST, V128, P1937, DOI 10.1172/JCI95089.
   Choudhry H, 2015, ONCOGENE, V34, P4546, DOI 10.1038/onc.2014.431.
   Choudhry H, 2014, EMBO REP, V15, P70, DOI 10.1002/embr.201337642.
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606.
   Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014.
   Gómez-Maldonado L, 2015, ONCOGENE, V34, P2609, DOI 10.1038/onc.2014.200.
   Gu YZ, 1998, GENE EXPRESSION, V7, P205.
   Hirose K, 1996, MOL CELL BIOL, V16, P1706.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011.
   Lelli A, 2015, HYPOXIA, V3, P45, DOI 10.2147/HP.S90555.
   Lin Hsin-Chen, 2018, Oncotarget, V9, P10470, DOI 10.18632/oncotarget.23732.
   Liu M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006222.
   Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110.
   Luo WB, 2019, ADV EXP MED BIOL, V1136, P1, DOI 10.1007/978-3-030-12734-3\_1.
   Luo WB, 2018, CELL MOL LIFE SCI, V75, P1043, DOI 10.1007/s00018-017-2684-9.
   Niu YL, 2020, CANCER RES, V80, P964, DOI 10.1158/0008-5472.CAN-19-1532.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441.
   Semenza GL, 2016, BBA-MOL CELL RES, V1863, P382, DOI 10.1016/j.bbamcr.2015.05.036.
   Serviss JT, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00234.
   Stone JK, 2019, J BIOL CHEM, V294, P11213, DOI 10.1074/jbc.RA118.006889.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI DOI 10.3322/caac.21660.
   Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72.
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510.
   Wang YB, 2015, CELL, V163, P174, DOI 10.1016/j.cell.2015.08.063.
   Yang WL, 2019, CELL MOL LIFE SCI, V76, P453, DOI 10.1007/s00018-018-2941-6.},
Number-of-Cited-References = {35},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Mol. Cancer Res.},
Doc-Delivery-Number = {RI5XT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000636980800013},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000621534300001,
Author = {Kim, Bo-Sung and Chung, Tae-Wook and Choi, Hee-Jung and Bae, Sung-Jin
   and Cho, Hye-Rin and Lee, Syng-Ook and Choi, Jung-Hye and Joo, Jong Kil
   and Ha, Ki-Tae},
Title = {Caesalpinia sappan induces apoptotic cell death in ectopic
   endometrial 12Z cells through suppressing pyruvate dehydrogenase kinase
   1 expression},
Journal = {EXPERIMENTAL AND THERAPEUTIC MEDICINE},
Year = {2021},
Volume = {21},
Number = {4},
Month = {APR},
Abstract = {Endometriosis is a common gynecological disease defined as the growth of
   endometrial tissues outside the uterus. Although the mechanism
   underlying the progression of endometriosis has not been fully
   elucidated, cancer-like aerobic glycolysis is considered to mediate the
   elevated growth and resistance to apoptosis of endometriotic cells. The
   heartwood of Caesalpinia sappan L. (family Leguminosae) is a herbal
   medicinal product used to treat gynecological symptoms, including
   algomenorrhea and amenorrhea. The results of the present study revealed
   that endometriotic 12Z cells exhibited more rapid growth than normal
   endometrial cells (THES). The expression levels of pyruvate
   dehydrogenase kinase (PDK)1 and 3 and lactate production were higher in
   12Z cells than in THES cells. In addition, the 12Z cells were more
   sensitive to the cytotoxicity of the aqueous extract of C. sappan
   heartwood (CS) than the THES cells. CS inhibited lactate production and
   phosphorylation of pyruvate dehydrogenase A by reducing the expression
   of PDK1. CS also increased mitochondrial reactive oxygen species (ROS)
   levels, decreased mitochondrial membrane potential and consequently
   stimulated the apoptosis of 12Z cells. CS-induced cell death was
   substantially inhibited by exogenous PDK1 expression. In conclusion, CS
   may be a novel drug candidate for treating endometriosis by inhibiting
   aerobic glycolysis and inducing ROS-mitochondria-mediated apoptotic cell
   death.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Ha, KT (Corresponding Author), Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Busandaehak Ro 49, Yangsan 50612, Gyeongnam, South Korea.
   Joo, JK (Corresponding Author), Pusan Natl Univ Hosp, Sch Med, Dept Obstet \& Gynecol, Gudeok Ro 179, Busan 49241, South Korea.
   Kim, Bo-Sung; Ha, Ki-Tae, Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Busandaehak Ro 49, Yangsan 50612, Gyeongnam, South Korea.
   Kim, Bo-Sung; Chung, Tae-Wook; Choi, Hee-Jung; Bae, Sung-Jin; Ha, Ki-Tae, Pusan Natl Univ, Hlth Aging Korean Med Res Ctr, Yangsan 50612, Gyeongnam, South Korea.
   Cho, Hye-Rin; Lee, Syng-Ook, Keimyung Univ, Dept Food Sci \& Technol, Daegu 42601, South Korea.
   Choi, Jung-Hye, Kyung Hee Univ, Dept Life \& Nanopharmaceut Sci, Seoul 02453, South Korea.
   Choi, Jung-Hye, Kyung Hee Univ, Dept Oriental Pharm, Seoul 02453, South Korea.
   Joo, Jong Kil, Pusan Natl Univ Hosp, Sch Med, Dept Obstet \& Gynecol, Gudeok Ro 179, Busan 49241, South Korea.},
DOI = {10.3892/etm.2021.9788},
Article-Number = {357},
ISSN = {1792-0981},
EISSN = {1792-1015},
Keywords = {endometriosis; PDK1; Caesalpinia sappan; ROS; apoptosis},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {jongkilj@hanmail.net
   hagis@pusan.ac.kr},
Affiliations = {Pusan National University; Pusan National University; Keimyung
   University; Kyung Hee University; Kyung Hee University; Pusan National
   University; Pusan National University Hospital},
ResearcherID-Numbers = {Kitae, Ha/AFW-2347-2022
   Bae, Sung-Jin/AAX-9144-2021},
Funding-Acknowledgement = {Biomedical Research Institute Grant {[}2018B027]; Pusan National
   University Hospital},
Funding-Text = {This study was supported by Biomedical Research Institute Grant (grant
   no. 2018B027), Pusan National University Hospital (to JKJ).},
Cited-References = {Anglesio MS, 2017, NEW ENGL J MED, V376, P1835, DOI 10.1056/NEJMoa1614814.
   Braun DP, 2007, FERTIL STERIL, V87, P263, DOI 10.1016/j.fertnstert.2006.06.026.
   Cao R, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/436807.
   Chung TW, 2019, CANCERS, V11, DOI 10.3390/cancers11070963.
   Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703.
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741.
   Egorova A, 2018, GENE THER, V25, P548, DOI 10.1038/s41434-018-0042-7.
   Feng L, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190654.
   Ferrero S, 2018, EXPERT OPIN PHARMACO, V19, P1109, DOI 10.1080/14656566.2018.1494154.
   Flower A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006568.pub3.
   Flower A, 2011, J ALTERN COMPLEM MED, V17, P691, DOI 10.1089/acm.2010.0073.
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478.
   Gebel HM, 1998, FERTIL STERIL, V69, P1042, DOI 10.1016/S0015-0282(98)00073-9.
   Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274.
   Goodwin J, 2018, AM J RESP CELL MOL, V58, P216, DOI 10.1165/rcmb.2016-0186OC.
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Handayani S, 2017, ADV PHARM BULL, V7, P375, DOI 10.15171/apb.2017.045.
   Heo J., DONGUIBOGAM NAMSANDA.
   Horne AW, 2019, P NATL ACAD SCI USA, V116, P25389, DOI 10.1073/pnas.1916144116.
   Hu C, 2014, CLIMACTERIC, V17, P410, DOI 10.3109/13697137.2013.876618.
   Kim EC, 2005, AM J CHINESE MED, V33, P405, DOI 10.1142/S0192415X05003016.
   Kim JG., ILLUSTRATED NATURAL.
   Kuohung W, 2002, FERTIL STERIL, V78, P767, DOI 10.1016/S0015-0282(02)03342-3.
   Kwak CH, 2019, CANCERS, V11, DOI 10.3390/cancers11050712.
   Lee CB., COLOURED FLORA KOREA.
   Lee HC, 2019, REPROD SCI, V26, P734, DOI 10.1177/1933719118789513.
   Liu SG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166658.
   Liu XJ, 2015, ONCOL REP, V33, P157, DOI 10.3892/or.2014.3600.
   Lu Y, 2015, HUM MOL GENET, V24, P5955, DOI 10.1093/hmg/ddv306.
   Machado DE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-4.
   McKinnon BD, 2016, HUM REPROD UPDATE, V22, P382, DOI 10.1093/humupd/dmv060.
   Mehedintu C, 2014, J Med Life, V7, P349.
   Meresman GF, 2000, FERTIL STERIL, V74, P760, DOI 10.1016/S0015-0282(00)01522-3.
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Naia L, 2017, J NEUROSCI, V37, P2776, DOI 10.1523/JNEUROSCI.2006-14.2016.
   Nirmal NP, 2015, ASIAN PAC J TROP MED, V8, P421, DOI 10.1016/j.apjtm.2015.05.014.
   Nothnick Warren, 2016, F1000Res, V5, DOI 10.12688/f1000research.7504.1.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Ping SM, 2016, ARCH GYNECOL OBSTET, V293, P797, DOI 10.1007/s00404-015-3875-y.
   Qu CD, 2020, IUBMB LIFE, V72, P465, DOI 10.1002/iub.2212.
   Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052.
   Sahin C, 2018, J CELL MOL MED, V22, P5346, DOI 10.1111/jcmm.13807.
   Salmassi A, 2011, BIOIMPACTS, V1, P129, DOI 10.5681/bi.2011.017.
   Sharpe-Timms KL, 2001, ANN NY ACAD SCI, V943, P131, DOI 10.1111/j.1749-6632.2001.tb03797.x.
   Simoens S, 2012, HUM REPROD, V27, P1292, DOI 10.1093/humrep/des073.
   Sireeratawong Seeewaboon, 2010, J Med Assoc Thai, V93 Suppl 7, pS50.
   Soukupova J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12837-y.
   Su SY, 2014, COMPLEMENT THER MED, V22, P632, DOI 10.1016/j.ctim.2014.06.010.
   Suda K, 2018, CELL REP, V24, P1777, DOI 10.1016/j.celrep.2018.07.037.
   Hung TM, 2014, BIOL RES, V47, DOI 10.1186/0717-6287-47-20.
   Vetvicka V, 2016, ARCH GYNECOL OBSTET, V294, P897, DOI 10.1007/s00404-016-4195-6.
   Yadav N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.305.
   Young VJ, 2014, J CLIN ENDOCR METAB, V99, P3450, DOI 10.1210/jc.2014-1026.
   Yuan ZY, 2016, CHIN J NAT MEDICINES, V14, P441, DOI 10.1016/S1875-5364(16)30041-3.
   Zhang T, 2018, AUTOIMMUN REV, V17, P945, DOI 10.1016/j.autrev.2018.03.017.
   Zhang ZZ, 2013, REPROD SCI, V20, P1215, DOI 10.1177/1933719113483008.
   Zhong X, 2009, NEOPLASMA, V56, P387, DOI 10.4149/neo\_2009\_05\_387.},
Number-of-Cited-References = {58},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Exp. Ther. Med.},
Doc-Delivery-Number = {QM1JD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000621534300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000643953700001,
Author = {Lim, Seon Ah and Moon, Yunwon and Shin, Min Hwa and Kim, Tae-Jin and
   Chae, Sehyun and Yee, Cassian and Hwang, Daehee and Park, Hyunsung and
   Lee, Kyung-Mi},
Title = {Hypoxia-Driven HIF-1α Activation Reprograms Pre-Activated NK Cells
   towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {8},
Month = {APR},
Abstract = {Simple Summary
   In patients with advanced cancer, hypoxic stress shapes NK cells toward
   tumor-resistant and immunosuppressive phenotypes. Therefore, a strategy
   to restore NK cell function within hypoxia would be crucial for
   successful tumor immunotherapy. By manipulating pO(2) exposure to naive
   vs. pre-activated NK cells, we found that HIF-1 alpha-dependent
   metabolic reprogramming of NK cells is the key to overcoming
   hypoxia-mediated NK cell impairment. Exposure of pre-activated NK cells
   to hypoxia with 1.5\% pO(2) initiated metabolic shift from oxidative
   phosphorylation to glycolysis and reduction of p21/p53-dependent
   apoptotic pathways, with concomitant upregulation of cell
   cycle-promoting genes and downregulation of cell cycle-arrest genes via
   HIF-1a/ERK/STAT3 activation. Furthermore, upregulation of NKp44
   activating receptor in hypoxia-exposed pre-activated NK cells elevated
   cytotoxicity of K562, CEM, and A375 tumor cells, in both in-vitro and
   in-vivo tumor-clearance assays. Therefore, HIF-1 alpha-mediated
   metabolic reprogramming of NK cells could reverse their impaired
   phenotype, generating functionally robust NK cells for adoptive therapy
   and clinical evaluation.
   NK cells are the predominant innate lymphocyte subsets specialized to
   kill malignant tumor cells. In patients with advanced cancer, hypoxic
   stress shapes NK cells toward tumor-resistant and immunosuppressive
   phenotypes, hence a strategy to restore NK function is critical for
   successful tumor immunotherapy. Here, we present evidence that
   pre-activation and subsequent HIF-1 alpha-dependent metabolic shift of
   NK cells from oxidative phosphorylation into glycolysis are keys to
   overcome hypoxia-mediated impairment in NK cell survival, proliferation,
   and tumor cytotoxicity. Specifically, exposing NK cells to 7-9 days of
   normoxic culture followed by a pO(2) of 1.5\% hypoxia led to a highly
   potent effector phenotype via HIF-1 alpha stabilization and upregulation
   of its target genes, BNIP3, PDK1, VEGF, PKM2, and LDHA. RNA sequencing
   and network analyses revealed that concomitant reduction of p21/p53
   apoptotic pathways along with upregulation of cell cycle-promoting
   genes, CCNE1, CDC6, CDC20, and downregulation of cell cycle-arrest
   genes, CDKN1A, GADD45A, and MDM2 were accountable for superior expansion
   of NK cells via ERK/STAT3 activation. Furthermore, HIF-1 alpha-dependent
   upregulation of the NKp44 receptor in hypoxia-exposed NK cells resulted
   in increased killing against K562, CEM, and A375 tumor targets both
   in-vitro and in-vivo tumor clearance assays. Therefore, hypoxic exposure
   on pre-activated proliferating NK cells triggered HIF-1 alpha-dependent
   pathways to initiate coordinated regulation of cell cycle, apoptosis,
   and cytotoxicity at the global gene transcription level. Our results
   uncover a previously unidentified role of HIF-1 alpha-mediated metabolic
   reprogramming that can reverse impaired NK effector phenotypes to
   generate requisite numbers of functionally robust NK cells for adoptive
   cellular therapy for clinical evaluation.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Lee, KM (Corresponding Author), Korea Univ, Dept Biochem \& Mol Biol, Coll Med, Seoul 02841, South Korea.
   Park, H (Corresponding Author), Univ Seoul, Dept Life Sci, Seoul 02504, South Korea.
   Lee, KM (Corresponding Author), Northwestern Univ, Dept Biomed Engn, Simpson Querrey Inst, Ctr Biointegrated Elect, Evanston, IL 60208 USA.
   Lim, Seon Ah; Shin, Min Hwa; Kim, Tae-Jin; Lee, Kyung-Mi, Korea Univ, Dept Biochem \& Mol Biol, Coll Med, Seoul 02841, South Korea.
   Moon, Yunwon; Park, Hyunsung, Univ Seoul, Dept Life Sci, Seoul 02504, South Korea.
   Chae, Sehyun, Korea Brain Res Inst, Korea Brain Bank, Daegu 41068, South Korea.
   Yee, Cassian, Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77054 USA.
   Yee, Cassian, Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77054 USA.
   Hwang, Daehee, Seoul Natl Univ, Sch Biol Sci, Seoul 08826, South Korea.
   Lee, Kyung-Mi, Northwestern Univ, Dept Biomed Engn, Simpson Querrey Inst, Ctr Biointegrated Elect, Evanston, IL 60208 USA.},
DOI = {10.3390/cancers13081904},
Article-Number = {1904},
EISSN = {2072-6694},
Keywords = {NK cells; hypoxia; HIF-1; ERK; STAT3; tumor microenvironment},
Keywords-Plus = {NATURAL-KILLER-CELLS; INDUCIBLE FACTOR 1-ALPHA; CANCER-CELLS;
   TUMOR-GROWTH; EXPRESSION; PHOSPHORYLATION; OVEREXPRESSION;
   INTERLEUKIN-21; TRANSCRIPTION; CYTOTOXICITY},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {reallysun@gmail.com
   wind520@hanmail.net
   mhshin0423@gmail.com
   anaros33@gmail.com
   implish@postech.ac.kr
   cyee@mdanderson.org
   daehee@snu.ac.kr
   hspark@uos.ac.kr
   kyunglee@korea.ac.kr},
Affiliations = {Korea University; Korea University Medicine (KU Medicine); University of
   Seoul; Korea Brain Research Institute (KBRI); University of Texas
   System; UTMD Anderson Cancer Center; University of Texas System; UTMD
   Anderson Cancer Center; Seoul National University (SNU); Northwestern
   University},
ResearcherID-Numbers = {Lim, Seon/AAQ-6274-2021},
ORCID-Numbers = {Lee, Kyung-Mi/0000-0002-5378-9258
   },
Funding-Acknowledgement = {National Research Foundation (NRF) {[}NRF2016M3A9B6948342,
   NRF-2018M3A9D3079288, NRF-2020R1A2C2103061, NRF-2013M3A9D3046248,
   NRF-2018R1A4A1025985, NRF-2018R1D1A1B07041442]; Korea University Grant},
Funding-Text = {This study was supported by the National Research Foundation (NRF)
   grants {[}NRF2016M3A9B6948342, NRF-2018M3A9D3079288 and
   NRF-2020R1A2C2103061]. H. Park was supported by NRF
   {[}NRF-2013M3A9D3046248, NRF-2018R1A4A1025985]. M.H.S. was supported by
   NRF {[}NRF-2018R1D1A1B07041442] and a Korea University Grant.},
Cited-References = {Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200.
   Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972.
   Balsamo M, 2013, EUR J IMMUNOL, V43, P2756, DOI 10.1002/eji.201343448.
   Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923.
   Barrow AD, 2018, CELL, V172, P534, DOI 10.1016/j.cell.2017.11.037.
   Berrien-Elliott MM, 2015, CURR OPIN ORGAN TRAN, V20, P671, DOI 10.1097/MOT.0000000000000243.
   Bhatt S, 2015, BLOOD, V126, P1555, DOI 10.1182/blood-2015-01-624585.
   Birner P, 2000, CANCER RES, V60, P4693.
   Brillantes M, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00102.
   Chae S, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003266.
   Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016.
   Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005.
   Deenick EK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00168.
   Donnelly RP, 2015, MOL IMMUNOL, V68, P513, DOI 10.1016/j.molimm.2015.07.034.
   Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558.
   Dratwa M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589929.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Garg SM, 2017, MOL PHARMACEUT, V14, P2570, DOI 10.1021/acs.molpharmaceut.6b01119.
   Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001.
   Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518.
   Hasmim M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00482.
   Hodgins JJ, 2019, J CLIN INVEST, V129, P3499, DOI 10.1172/JCI129338.
   Hoxhaj G, 2020, NAT REV CANCER, V20, P74, DOI 10.1038/s41568-019-0216-7.
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211.
   Jögi A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226150.
   Kidger AM, 2017, P NATL ACAD SCI USA, V114, pE317, DOI 10.1073/pnas.1614684114.
   Kim TJ, 2010, J LEUKOCYTE BIOL, V88, P1089, DOI 10.1189/jlb.0310148.
   Krzywinska E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01599-w.
   Lee HY, 2013, CARCINOGENESIS, V34, P2706, DOI 10.1093/carcin/bgt256.
   Lee KM, 2006, BLOOD, V107, P3181, DOI 10.1182/blood-2005-01-0185.
   Lim SA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00496.
   Lim SA, 2013, CANCER RES, V73, P2598, DOI 10.1158/0008-5472.CAN-12-2893.
   Liu Q, 2015, INT J CLIN EXP MED, V8, P22073.
   Macleod KF, 2020, ANNU REV CANC BIOL, V4, P41, DOI 10.1146/annurev-cancerbio-030419-033405.
   Martins M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200.
   Melaiu O, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03038.
   Moon Y, 2018, BBA-MOL CELL RES, V1865, P334, DOI 10.1016/j.bbamcr.2017.11.008.
   Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5.
   Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7.
   Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238.
   Naik PP, 2019, CELL MOL LIFE SCI, V76, P27, DOI 10.1007/s00018-018-2922-9.
   Nakayama K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133278.
   Nakhle J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124405.
   O'Sullivan TE, 2015, IMMUNITY, V43, P331, DOI 10.1016/j.immuni.2015.07.012.
   Parodi M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02358.
   Paul S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01124.
   Paul S, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1235106.
   Pawlus MR, 2014, ONCOGENE, V33, P1670, DOI 10.1038/onc.2013.115.
   Pazina T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00369.
   Pietra G, 2016, CANCER IMMUNOL IMMUN, V65, P465, DOI 10.1007/s00262-015-1744-y.
   Pol JG, 2020, J EXP MED, V217, DOI 10.1084/jem.20191247.
   Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631.
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25.
   Romee R, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2341.
   Ross SH, 2018, ANNU REV IMMUNOL, V36, P411, DOI 10.1146/annurev-immunol-042617-053352.
   Salmond RJ, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00122.
   Sarkar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064835.
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720.
   Shin MH, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e14.
   Siewiera J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10183.
   Solocinski K, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000246.
   Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665.
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120.
   Wang G, 2008, INT J BIOCHEM CELL B, V40, P461, DOI 10.1016/j.biocel.2007.08.008.
   Wang X, 2013, CLIN EXP IMMUNOL, V172, P104, DOI 10.1111/cei.12034.
   Wang ZX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00202.
   Warfel NA, 2013, CELL CYCLE, V12, P3689, DOI 10.4161/cc.26930.
   Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381.
   Zhao X, 2014, CANCER RES, V74, P2455, DOI 10.1158/0008-5472.CAN-13-3009.},
Number-of-Cited-References = {69},
Times-Cited = {29},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {RS7KI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000643953700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000636980800001,
Author = {Nussinov, Ruth and Zhang, Mingzhen and Tsai, Chung-Jung and Jang,
   Hyunbum},
Title = {Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition},
Journal = {MOLECULAR CANCER RESEARCH},
Year = {2021},
Volume = {19},
Number = {4},
Pages = {543-548},
Month = {APR 1},
Abstract = {PI3K and PTEN are the second and third most highly mutated proteins in
   cancer following only p53. Their actions oppose each other. PI3K
   phosphorylates signaling lipid PIP2 to PIP3. PTEN dephosphorylates it
   back. Driver mutations in both proteins accrue PIP3. PIP3 recruits AKT
   and PDKI to the membrane, promoting cell-cycle progression. Here we
   review phosphorylation events and mutations in autoinhibition in PI3K
   and PTEN from the structural standpoint Our purpose is to clarify how
   they control the autoinhibited states. In autoinhibition, a segment or a
   subunit of the protein occludes its functional site. Protein-protein
   interfaces are often only marginally stable, making them sensitive to
   changes in conditions in living cells. Phosphorylation can stabilize or
   destabilize the interfaces. Driver mutations commonly destabilize them.
   In analogy to ``passenger mutations,{''} we coin ``passenger
   phosphorylation{''} to emphasize that the presence of a phosphorylation
   recognition sequence logo does not necessarily imply function. Rather,
   it may simply reflect a statistical occurrence. In both PI3K and PTEN,
   autoinhibiting phosphorylation events are observed in the occluding
   ``piece.{''} In PI3K alpha, the ``piece{''} is the p85 alpha subunit. In
   PTEN, it is the C-terminal segment. In both enzymes the stabilized
   interface covers the domain that attaches to the membrane. Driver
   mutations that trigger rotation of the occluding piece or its deletion
   prompt activation. To date, both enzymes lack specific, potent drugs. We
   discuss the implications of detailed structural and mechanistic insight
   into oncogenic activation and how it can advance allosteric precision
   oncology.},
Publisher = {AMER ASSOC CANCER RESEARCH},
Address = {615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA},
Type = {Review},
Language = {English},
Affiliation = {Nussinov, R (Corresponding Author), NCI, Leidos Biomed Res Inc, Frederick, MD 21702 USA.
   Nussinov, Ruth; Zhang, Mingzhen; Tsai, Chung-Jung; Jang, Hyunbum, NCI, Computat Struct Biol Sect, Frederick Natl Lab Canc Res, Lab Canc Immunometab, Frederick, MD 21702 USA.
   Nussinov, Ruth, Tel Aviv Univ, Dept Human Mol Genet \& Biochem, Sackler Sch Med, Tel Aviv, Israel.},
DOI = {10.1158/1541-7786.MCR-20-0818},
ISSN = {1541-7786},
EISSN = {1557-3125},
Research-Areas = {Oncology; Cell Biology},
Web-of-Science-Categories  = {Oncology; Cell Biology},
Author-Email = {NussinoR@mail.nih.gov},
Affiliations = {National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Frederick National Laboratory for Cancer Research; Tel Aviv
   University; Sackler Faculty of Medicine},
ORCID-Numbers = {Nussinov, Ruth/0000-0002-8115-6415
   Tsai, Chung-Jung/0000-0003-1524-9928
   Jang, Hyunbum/0000-0001-9402-4051},
Funding-Acknowledgement = {NCI, NIH {[}HHSN26120080001E]; Intramural Research Program of the NIH,
   NCI, Center for Cancer Research; National Cancer Institute
   {[}ZIABC010441, ZIABC010440] Funding Source: NIH RePORTER},
Funding-Text = {This project has been funded in whole or in part with federal funds from
   the NCI, NIH, under contract HHSN26120080001E. This Research was
   supported (in part) by the Intramural Research Program of the NIH, NCI,
   Center for Cancer Research.},
Cited-References = {Adrián FJ, 2006, NAT CHEM BIOL, V2, P95, DOI 10.1038/nchembio760.
   Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103.
   Brown AL, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006981.
   Buckles TC, 2017, BIOPHYS J, V113, P2396, DOI 10.1016/j.bpj.2017.09.018.
   Burke JE, 2012, P NATL ACAD SCI USA, V109, P15259, DOI 10.1073/pnas.1205508109.
   Chakrabarti M, 2020, STRUCTURE, V28, P465, DOI 10.1016/j.str.2020.01.010.
   Chavan TS, 2015, BIOPHYS J, V109, P2602, DOI 10.1016/j.bpj.2015.09.034.
   Chen Z, 2016, J BIOL CHEM, V291, P14160, DOI 10.1074/jbc.M116.728980.
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385.
   Cordier F, 2012, J AM CHEM SOC, V134, P20533, DOI 10.1021/ja310214g.
   del Sol A, 2009, STRUCTURE, V17, P1042, DOI 10.1016/j.str.2009.06.008.
   Eide CA, 2019, CANCER CELL, V36, P431, DOI 10.1016/j.ccell.2019.08.004.
   Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109.
   Foukas LC, 2004, MOL CELL BIOL, V24, P966, DOI 10.1128/MCB.24.3.966-975.2004.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Geering B., 2006, REGULATION CLASS IA.
   Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182.
   HAYASHI H, 1993, J BIOL CHEM, V268, P7107.
   Hon WC, 2012, ONCOGENE, V31, P3655, DOI 10.1038/onc.2011.532.
   Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799.
   Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016.
   Kang SY, 2005, P NATL ACAD SCI USA, V102, P802, DOI 10.1073/pnas.0408864102.
   Kotelevets L, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036095.
   Koul D, 2002, ONCOGENE, V21, P2357, DOI 10.1038/sj/onc/1205296.
   Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979.
   Layton MJ, 2012, BMC BIOCHEM, V13, DOI 10.1186/1471-2091-13-30.
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3.
   Lu XY, 2018, MED RES REV, V38, P1550, DOI 10.1002/med.21488.
   Lu YL, 2003, J BIOL CHEM, V278, P40057, DOI 10.1074/jbc.M303621200.
   Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713.
   Masson GR, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036152.
   Masson GR, 2016, BIOCHEM J, V473, P135, DOI 10.1042/BJ20150931.
   Mellor P, 2012, BIOCHEM J, V441, P23, DOI 10.1042/BJ20111164.
   Miled N, 2007, SCIENCE, V317, P239, DOI 10.1126/science.1135394.
   Ngeow J, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a036087.
   Nguyen HN, 2015, ONCOGENE, V34, P3737, DOI 10.1038/onc.2014.293.
   Nussinov R, 2020, TRENDS BIOCHEM SCI, V45, P554, DOI 10.1016/j.tibs.2020.03.013.
   Nussinov R, 2020, FASEB J, V34, P16, DOI 10.1096/fj.201901341R.
   Nussinov R, 2019, TRENDS PHARMACOL SCI, V40, P919, DOI 10.1016/j.tips.2019.10.003.
   Nussinov Ruth, 2018, Biophys Rev, V10, P1263, DOI {[}10.1007/s12551-018-0461-0, 10.1007/s12551-018-0461-0].
   Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968.
   Rotow J, 2017, NAT REV CANCER, V17, P637, DOI 10.1038/nrc.2017.84.
   Saito Y, 2020, NATURE, V582, P95, DOI 10.1038/s41586-020-2175-2.
   Scheffler M, 2015, ONCOTARGET, V6, P10577, DOI 10.18632/oncotarget.3387.
   Schoepfer J, 2018, J MED CHEM, V61, P8120, DOI 10.1021/acs.jmedchem.8b01040.
   Shaw AT, 2016, NEW ENGL J MED, V374, P54, DOI 10.1056/NEJMoa1508887.
   Smith IN, 2019, J BIOMOL STRUCT DYN, V37, P1766, DOI 10.1080/07391102.2018.1465854.
   Sun MH, 2010, P NATL ACAD SCI USA, V107, P15547, DOI 10.1073/pnas.1009652107.
   Sun Z, 2014, CELL REP, V6, P844, DOI 10.1016/j.celrep.2014.01.030.
   To C, 2019, CANCER DISCOV, V9, P926, DOI 10.1158/2159-8290.CD-18-0903.
   Tsai CJ, 1999, P NATL ACAD SCI USA, V96, P9970, DOI 10.1073/pnas.96.18.9970.
   Vadas O, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002165.
   Vasan N, 2019, SCIENCE, V366, P714, DOI 10.1126/science.aaw9032.
   Vatte C, 2019, ONCOL LETT, V18, P2427, DOI 10.3892/ol.2019.10565.
   Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319.
   Wang XX, 2018, NEOPLASIA, V20, P574, DOI 10.1016/j.neo.2018.03.002.
   Wu HY, 2009, P NATL ACAD SCI USA, V106, P20258, DOI 10.1073/pnas.0902369106.
   Xu DZ, 2010, J BIOL CHEM, V285, P39935, DOI 10.1074/jbc.M110.166462.
   Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675.
   Zhang MZ, 2021, CANCER RES, V81, P237, DOI 10.1158/0008-5472.CAN-20-0911.
   Zhang MZ, 2020, J MOL BIOL, V432, P5849, DOI 10.1016/j.jmb.2020.09.002.
   Zhang MZ, 2020, CHEM SCI, V11, P5855, DOI 10.1039/d0sc01676d.
   Zhang MZ, 2019, PHYS CHEM CHEM PHYS, V21, P12021, DOI 10.1039/c9cp00101h.
   Zhang MZ, 2019, CHEM SCI, V10, P3671, DOI 10.1039/c8sc04498h.
   Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105.},
Number-of-Cited-References = {65},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Mol. Cancer Res.},
Doc-Delivery-Number = {RI5XT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000636980800001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000637211900003,
Author = {Su, Ruei-Yu and Hsueh, Shu-Ching and Chen, Cheng-Yen and Hsu, Ming-Jie
   and Lu, Hsu-Feng and Peng, Shu-Fen and Chen, Po-Yuan and Lien,
   Jin-Cherng and Chen, Yung-Liang and Chueh, Fu-Shin and Chung, Jing-Gung
   and Yeh, Ming-Yang and Huang, Yi-Ping},
Title = {Demethoxycurcumin Suppresses Proliferation, Migration, and Invasion of
   Human Brain Glioblastoma Multiforme GBM 8401 Cells via PI3K/Akt
   Pathway},
Journal = {ANTICANCER RESEARCH},
Year = {2021},
Volume = {41},
Number = {4},
Pages = {1859-1870},
Month = {APR},
Abstract = {Background/Aim: Demethoxycurcumin (DMC), one of the derivatives of
   curcumin, has been shown to induce apoptotic cell death in many human
   cancer cell lines. However, there is no available information on whether
   DMC inhibits metastatic activity in human glioblastoma cancer cells in
   vitro. Materials and Methods: DMC at 1.0-3.0 ,uM significantly decreased
   the proliferation of GBM 8401 cells; thus, we used 2.0 ,uM for further
   investigation regarding anti-metastatic activity in human glioblastoma
   GBM 8401 cells. Results: The internalized amount of DMC has reached the
   highest level in GBM 8401 cells after 3 h treatment.},
Publisher = {INT INST ANTICANCER RESEARCH},
Address = {EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Yeh, MY (Corresponding Author), Cheng Hsin Gen Hosp, Dept Educ \& Res, 45 Cheng Hsin St, Taipei, Taiwan.
   Huang, YP (Corresponding Author), China Med Univ, Sch Med, Dept Physiol, 91 Hsueh Shih Rd, Taichung, Taiwan.
   Su, Ruei-Yu, Natl Def Med Ctr, Triserv Gen Hosp, Dept Pathol, Div Clin Pathol, Taipei, Taiwan.
   Su, Ruei-Yu, Taoyuan Armed Forces Gen Hosp, Dept Pathol \& Lab Med, Taoyuan, Taiwan.
   Hsueh, Shu-Ching, Cheng Hsin Gen Hosp, Div Hematol \& Oncol, Taipei, Taiwan.
   Chen, Cheng-Yen; Hsu, Ming-Jie; Chen, Po-Yuan; Chung, Jing-Gung, China Med Univ, Dept Biol Sci \& Technol, Taichung, Taiwan.
   Lu, Hsu-Feng, Cheng Hsin Gen Hosp, Dept Clin Pathol, Taipei, Taiwan.
   Lu, Hsu-Feng, Fu Jen Catholic Univ, Dept Restaurant Hotel \& Inst Management, New Taipei, Taiwan.
   Peng, Shu-Fen, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.
   Lien, Jin-Cherng, China Med Univ, Sch Pharm, Taichung, Taiwan.
   Chen, Yung-Liang, Yuanpei Univ, Dept Med Lab Sci \& Biotechnol, Hsinchu, Taiwan.
   Chueh, Fu-Shin, Asia Univ, Dept Food Nutr \& Hlth Biotechnol, Taichung, Taiwan.
   Yeh, Ming-Yang, Cheng Hsin Gen Hosp, Dept Educ \& Res, 45 Cheng Hsin St, Taipei, Taiwan.
   Huang, Yi-Ping, China Med Univ, Sch Med, Dept Physiol, 91 Hsueh Shih Rd, Taichung, Taiwan.},
DOI = {10.21873/anticanres.14952},
ISSN = {0250-7005},
EISSN = {1791-7530},
Keywords = {Key Words; Demethoxycurcumin (DMC); migration; invasion; NF-?B; human
   glioblastoma multiforme (GBM 8401) cells},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {ch1009@chgh.org.tw
   yphuang@mail.cmu.edu.tw},
Affiliations = {Tri-Service General Hospital; National Defense Medical University; Cheng
   Hsin General Hospital; China Medical University Taiwan; Cheng Hsin
   General Hospital; Fu Jen Catholic University; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; Asia University Taiwan; Cheng Hsin General Hospital;
   China Medical University Taiwan},
ORCID-Numbers = {Chen, Cheng-Yen/0000-0002-1219-4530},
Funding-Acknowledgement = {Cheng Hsin General Hospital, Taipei, Taiwan {[}109-31]},
Funding-Text = {This work was supported by Grant 109-31 from Cheng Hsin General
   Hospital, Taipei, Taiwan. Experiments and data analysis were performed
   in part through the use of the Medical Research Core Facilities Center,
   Office of Research \& Development at China Medical University, Taichung,
   Taiwan.},
Cited-References = {Adamson C, 2009, EXPERT OPIN INV DRUG, V18, P1061, DOI 10.1517/13543780903052764.
   Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001.
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401.
   Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659.
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543.
   Chan-Hui PY, 1998, BIOCHEM J, V336, P599, DOI 10.1042/bj3360599.
   Chang JW, 2015, SCI REP-UK, V5, DOI 10.1038/srep18208.
   Chang YM, 2013, BIOMEDICINE-TAIWAN, V3, P148, DOI 10.1016/j.biomed.2013.05.001.
   Chien CS, 2010, MOL CELL BIOCHEM, V333, P169, DOI 10.1007/s11010-009-0217-z.
   Chiu YJ, 2011, J ORTHOP RES, V29, P1448, DOI 10.1002/jor.21398.
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9.
   Dong R, 2007, BRAZ J MED BIOL RES, V40, P1071, DOI 10.1590/S0100-879X2007000800007.
   Dutta A, 2014, CANCER RES, V74, P1598, DOI 10.1158/0008-5472.CAN-13-1796.
   Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372.
   Gao R, 2018, ONCOL LETT, V15, P8253, DOI 10.3892/ol.2018.8432.
   Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011.
   Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914.
   Guo K, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-100.
   Guo LY, 2008, ARCH PHARM RES, V31, P490, DOI 10.1007/s12272-001-1183-8.
   Guttridge DC, 1999, MOL CELL BIOL, V19, P5785.
   Hatcher H, 2008, CELL MOL LIFE SCI, V65, P1631, DOI 10.1007/s00018-008-7452-4.
   Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7.
   Hsiao YT, 2018, AM J CHINESE MED, V46, P1145, DOI 10.1142/S0192415X1850060X.
   Huang TY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/396573.
   Huang WW, 2010, MOL NUTR FOOD RES, V54, P1585, DOI 10.1002/mnfr.201000005.
   Jayaprakasha GK, 2005, TRENDS FOOD SCI TECH, V16, P533, DOI 10.1016/j.tifs.2005.08.006.
   Ji BC, 2015, ANTICANCER RES, V35, P729.
   Kawano H, 2015, BRIT J NEUROSURG, V29, P206, DOI 10.3109/02688697.2014.967750.
   Kim DSHL, 2001, NEUROSCI LETT, V303, P57, DOI 10.1016/S0304-3940(01)01677-9.
   Kumar R, 2018, TOXICOL APPL PHARM, V345, P75, DOI 10.1016/j.taap.2018.02.020.
   Lai KC, 2019, TOXICOL APPL PHARM, V382, DOI 10.1016/j.taap.2019.114734.
   Lai KC, 2015, J CELL MOL MED, V19, P474, DOI 10.1111/jcmm.12486.
   Lai KC, 2011, HUM EXP TOXICOL, V30, P1045, DOI 10.1177/0960327110386257.
   Lee JW, 2010, KOREAN J UROL, V51, P870, DOI 10.4111/kju.2010.51.12.870.
   Lee WJ, 2008, TOXICOL APPL PHARM, V226, P178, DOI 10.1016/j.taap.2007.09.013.
   Leng L, 2016, TUMOR BIOL, V37, P15847, DOI 10.1007/s13277-016-5399-x.
   Li H, 2018, BIOMED PHARMACOTHER, V103, P1272, DOI 10.1016/j.biopha.2018.04.120.
   Li S, 2018, BRAIN RES, V1692, P154, DOI 10.1016/j.brainres.2018.05.023.
   Liao CL, 2012, FOOD CHEM TOXICOL, V50, P1734, DOI 10.1016/j.fct.2012.02.033.
   Liu Z, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-270.
   Matsumura T, 2014, ANN SURG ONCOL, V21, pS743, DOI 10.1245/s10434-014-3889-x.
   Merdad A, 2014, ANTICANCER RES, V34, P1355.
   Nair S, 2008, J NEPHROL, V21, P400.
   Park SJ, 2015, AM J CANCER RES, V5, P2127.
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014.
   Reuben SC, 2012, MOL NUTR FOOD RES, V56, P14, DOI 10.1002/mnfr.201100619.
   Rose P, 2005, TOXICOL APPL PHARM, V209, P105, DOI 10.1016/j.taap.2005.04.010.
   Sandur SK, 2007, CARCINOGENESIS, V28, P1765, DOI 10.1093/carcin/bgm123.
   SATO F, 1994, BIOCHEM BIOPH RES CO, V204, P578, DOI 10.1006/bbrc.1994.2498.
   Seton-Rogers Sarah, 2013, Nat Rev Cancer, V13, P753, DOI 10.1038/nrc3616.
   Shang HS, 2016, ENVIRON TOXICOL, V31, P1751, DOI 10.1002/tox.22177.
   Shih YL, 2017, ENVIRON TOXICOL, V32, P2097, DOI 10.1002/tox.22417.
   Silbergeld DL, 1997, J NEUROSURG, V86, P525, DOI 10.3171/jns.1997.86.3.0525.
   Simon A, 1998, CANCER LETT, V129, P111, DOI 10.1016/S0304-3835(98)00092-5.
   Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961.
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330.
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7.
   Takino T, 2016, CLIN EXP METASTAS, V33, P45, DOI 10.1007/s10585-015-9756-8.
   Tamvakopoulos C, 2007, CLIN CANCER RES, V13, P1269, DOI 10.1158/1078-0432.CCR-06-1839.
   Tang NY, 2016, ONCOL REP, V35, P2089, DOI 10.3892/or.2016.4577.
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024.
   Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060.
   Wu ZY, 2016, MOLECULES, V21, DOI 10.3390/molecules21030384.
   Yuan Y, 2018, INT J ONCOL, V52, P461, DOI 10.3892/ijo.2017.4230.
   Zhang KJ, 2011, HEPATO-GASTROENTEROL, V58, P1.
   Zhang LJ, 2008, NEUROSCI LETT, V447, P48, DOI 10.1016/j.neulet.2008.09.067.
   Zhu JL, 2017, NEOPLASIA, V19, P672, DOI 10.1016/j.neo.2017.06.002.},
Number-of-Cited-References = {67},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Anticancer Res.},
Doc-Delivery-Number = {RI9FX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000637211900003},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000636270800015,
Author = {Ocklenburg, Tobias and Neumann, Fabian and Wolf, Alexandra and Vogel,
   Julia and Goepelt, Kirsten and Baumann, Melanie and Baumann, Jennifer
   and Kranz, Philip and Metzen, Eric and Brockmeier, Ulf},
Title = {In oxygen-deprived tumor cells ERp57 provides radioprotection and
   ensures proliferation via c-Myc, PLK1 and the AKT pathway},
Journal = {SCIENTIFIC REPORTS},
Year = {2021},
Volume = {11},
Number = {1},
Month = {MAR 30},
Abstract = {The disulfide isomerase ERp57, originally found in the endoplasmic
   reticulum, is located in multiple cellular compartments, participates in
   diverse cell functions and interacts with a huge network of binding
   partners. It was recently suggested as an attractive new target for
   cancer therapy due to its critical role in tumor cell proliferation.
   Since a major bottleneck in cancer treatment is the occurrence of
   hypoxic areas in solid tumors, the role of ERp57 in cell growth was
   tested under oxygen depletion in the colorectal cancer cell line HCT116.
   We observed a severe growth inhibition when ERp57 was knocked down in
   hypoxia (1\% O-2) as a consequence of downregulated c-Myc, PLK1, PDPK1
   (PDK1) and AKT (PKB). Further, irradiation experiments revealed also a
   radiosensitizing effect of ERp57 depletion under oxygen deprivation.
   Compared to ERp57, we do not favour PDPK1 as a suitable pharmaceutical
   target as its efficient knockdown/chemical inhibition did not show an
   inhibitory effect on proliferation.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Brockmeier, U (Corresponding Author), Univ Hosp Essen, Dept Neurol, Essen, Germany.
   Ocklenburg, Tobias; Neumann, Fabian; Wolf, Alexandra; Vogel, Julia; Goepelt, Kirsten; Baumann, Melanie; Baumann, Jennifer; Kranz, Philip; Metzen, Eric, Univ Duisburg Essen, Inst Physiol, Duisburg, Germany.
   Brockmeier, Ulf, Univ Hosp Essen, Dept Neurol, Essen, Germany.},
DOI = {10.1038/s41598-021-86658-5},
Article-Number = {7199},
ISSN = {2045-2322},
Keywords-Plus = {PROTEIN DISULFIDE-ISOMERASE; FAMILY-MEMBERS; CANCER-CELLS; HYPOXIA;
   ACTIVATION; STAT3; PDK1; CHEMOTHERAPY; RESISTANCE; INHIBITORS},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {ulf.brockmeier@uni-due.de},
Affiliations = {University of Duisburg Essen; University of Duisburg Essen},
Funding-Acknowledgement = {Deutsche Forschungs gemeinschaft {[}GRK1739]},
Funding-Text = {This study was funded by the research training group GRK1739 of the
   Deutsche Forschungs gemeinschaft. We are indebted to George Iliakis,
   Institut fur Strahlenbiologie, Universitat Duisburg-Essen, for providing
   radiation equipment.},
Cited-References = {Aureli C, 2013, GENE, V524, P390, DOI 10.1016/j.gene.2013.04.004.
   Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001.
   Chichiarelli S, 2010, ARCH BIOCHEM BIOPHYS, V494, P178, DOI 10.1016/j.abb.2009.12.004.
   Chichiarelli S, 2007, J CELL PHYSIOL, V210, P343, DOI 10.1002/jcp.20824.
   Cicchillitti L, 2010, INT J ONCOL, V37, P445, DOI 10.3892/ijo\_00000693.
   Coe H, 2010, J BIOL CHEM, V285, P6725, DOI 10.1074/jbc.M109.054015.
   Cole KS, 2018, BIOCHEMISTRY-US, V57, P2035, DOI 10.1021/acs.biochem.8b00178.
   De Rosa M, 2015, ONCOL REP, V34, P1087, DOI 10.3892/or.2015.4108.
   Ellwood-Yen K, 2011, CANCER RES, V71, P3052, DOI 10.1158/0008-5472.CAN-10-2282.
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339.
   Gocher AM, 2017, J BIOL CHEM, V292, P14188, DOI 10.1074/jbc.M117.778464.
   Graham K, 2018, INT J NANOMED, V13, P6049, DOI 10.2147/IJN.S140462.
   Grillo C, 2006, FREE RADICAL BIO MED, V41, P1113, DOI 10.1016/j.freeradbiomed.2006.06.016.
   Guo GG, 2002, J INTERF CYTOK RES, V22, P555, DOI 10.1089/10799900252982034.
   Hettinghouse A, 2018, PHARMACOL THERAPEUT, V181, P34, DOI 10.1016/j.pharmthera.2017.07.011.
   Hussmann M, 2015, ONCOTARGET, V6, P39247, DOI 10.18632/oncotarget.5746.
   Janke K, 2013, J CELL SCI, V126, P2629, DOI 10.1242/jcs.117564.
   Kilic M, 2007, ONCOGENE, V26, P2027, DOI 10.1038/sj.onc.1210008.
   Kinoshita M, 2001, INT J CANCER, V91, P322, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P.
   Kozlov G, 2006, STRUCTURE, V14, P1331, DOI 10.1016/j.str.2006.06.019.
   Kranz P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.369.
   Krynetskaia NF, 2009, MOL CANCER THER, V8, P864, DOI 10.1158/1535-7163.MCT-08-0695.
   KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542.
   Kyani A, 2018, CHEMMEDCHEM, V13, P164, DOI 10.1002/cmdc.201700629.
   Leys CM, 2007, SURGERY, V141, P41, DOI 10.1016/j.surg.2006.05.009.
   Li FS, 2016, ONCOL LETT, V12, P3059, DOI 10.3892/ol.2016.5124.
   Liao CJ, 2011, CANCER SCI, V102, P2255, DOI 10.1111/j.1349-7006.2011.02102.x.
   Liu HT, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-91.
   Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Nussinov R, 2014, ONCOTARGET, V5, P7285, DOI 10.18632/oncotarget.2439.
   Pandurangan AK, 2018, WORLD J GASTRO ONCOL, V10, P244, DOI 10.4251/wjgo.v10.i9.244.
   Pettersen EO, 2015, J ENZYM INHIB MED CH, V30, P689, DOI 10.3109/14756366.2014.966704.
   Ramírez-Rangel I, 2011, MOL CELL BIOL, V31, P1657, DOI 10.1128/MCB.00824-10.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199.
   Rutkevich LA, 2010, MOL BIOL CELL, V21, P3093, DOI 10.1091/mbc.E10-04-0356.
   Samanta S, 2017, ONCOTARGET, V8, P103543, DOI 10.18632/oncotarget.21569.
   Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Vacante M, 2018, WORLD J CLIN CASES, V6, P869, DOI 10.12998/wjcc.v6.i15.869.
   Vatolin S, 2016, CANCER RES, V76, P3340, DOI 10.1158/0008-5472.CAN-15-3099.
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009.
   Won JK, 2017, HEPATOLOGY, V66, P855, DOI 10.1002/hep.29237.
   Xu SL, 2012, P NATL ACAD SCI USA, V109, P16348, DOI 10.1073/pnas.1205226109.
   Zhang Y, 2009, J BIOL CHEM, V284, P10160, DOI 10.1074/jbc.M808356200.},
Number-of-Cited-References = {46},
Times-Cited = {9},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {RH5PQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000636270800015},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000637721400001,
Author = {Chu, Guangdi and Xu, Ting and Zhu, Guanqun and Liu, Shuaihong and Niu,
   Haitao and Zhang, Mingxin},
Title = {Identification of a Novel Protein-Based Signature to Improve Prognosis
   Prediction in Renal Clear Cell Carcinoma},
Journal = {FRONTIERS IN MOLECULAR BIOSCIENCES},
Year = {2021},
Volume = {8},
Month = {MAR 25},
Abstract = {Background
   Clear cell renal cell carcinoma (ccRCC) is one of the most common types
   of malignant adult kidney cancer, and its incidence and mortality are
   not optimistic. It is well known that tumor-related protein markers play
   an important role in cancer detection, prognosis prediction, or
   treatment selection, such as carcinoembryonic antigen (CEA), programmed
   cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1), and
   cytotoxic T lymphocyte antigen 4 (CTLA-4), so a comprehensive analysis
   was performed in this study to explore the prognostic value of protein
   expression in patients with ccRCC.
   Materials and Methods
   Protein expression data were obtained from The Cancer Proteome Atlas
   (TCPA), and clinical information were downloaded from The Cancer Genome
   Atlas (TCGA). We selected 445 patients with complete information and
   then separated them into a training set and testing set. We performed
   univariate, least absolute shrinkage and selection operator (LASSO) Cox
   analyses to find prognosis-related proteins (PRPs) and constructed a
   protein signature. Then, we used stratified analysis to fully verify the
   prognostic significance of the prognostic-related protein signature
   score (PRPscore). Besides, we also explored the differences in
   immunotherapy response and immune cell infiltration level in high and
   low score groups. The consensus clustering analysis was also performed
   to identify potential cancer subgroups.
   Results
   From the training set, a total of 233 PRPs were selected, and a
   seven-protein signature was constructed, including ACC1, AR, MAPK, PDK1,
   PEA15, SYK, and BRAF. Based on the PRPscore, patients could be divided
   into two groups with significantly different overall survival rates.
   Univariate and multivariate Cox regression analyses proved that this
   signature was an independent prognostic factor for patients (P < 0.001).
   Moreover, the signature showed a high ability to distinguish prognostic
   outcomes among subgroups, and the low score group had a better prognosis
   (P < 0.001) and better immunotherapy response (P = 0.003) than the high
   score group.
   Conclusion
   We constructed a novel protein signature with robust predictive power
   and high clinical value. This will help to guide the disease management
   and individualized treatment of ccRCC patients.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Niu, HT; Zhang, MX (Corresponding Author), Qingdao Univ, Dept Urol, Affiliated Hosp, Qingdao, Peoples R China.
   Chu, Guangdi; Zhu, Guanqun; Liu, Shuaihong; Niu, Haitao; Zhang, Mingxin, Qingdao Univ, Dept Urol, Affiliated Hosp, Qingdao, Peoples R China.
   Xu, Ting, 971th Hosp PLA Navy, Dept Geratol, Qingdao, Peoples R China.},
DOI = {10.3389/fmolb.2021.623120},
Article-Number = {623120},
EISSN = {2296-889X},
Keywords = {clear cell renal cell carcinoma; proteomics; immunotherapy; TCGA; TCPA},
Keywords-Plus = {CANCER-CELLS; PROGRESSION; MICROARRAYS; VALIDATION; RESOURCE; PLATFORM;
   EXPLORE; LINES; TCPA; RAS},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {niuht0532@126.com
   dr.zmx@foxmail.com},
Affiliations = {Qingdao University},
ResearcherID-Numbers = {Chu, Guangdi/AED-1835-2022},
ORCID-Numbers = {Chu, Guangdi/0000-0002-2963-1741},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81772713, 81472411,
   81981260351, 81972378]; Taishan Scholar Program of Shandong Province
   {[}tsqn20161077]; Natural Science Foundation of Shandong Province
   {[}ZR2016HQ18]; Key Research and Development Program of Shandong
   Province {[}2018GSF118197]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China under grant numbers 81772713, 81472411, 81981260351, and 81972378;
   Taishan Scholar Program of Shandong Province under grant number
   tsqn20161077; Natural Science Foundation of Shandong Province under
   grant number ZR2016HQ18; and Key Research and Development Program of
   Shandong Province under grant number 2018GSF118197.},
Cited-References = {Aggen DH, 2020, CLIN CANCER RES, V26, P2087, DOI 10.1158/1078-0432.CCR-19-3323.
   Bartelt A, 2020, BIOL CHEM, V401, P1019, DOI 10.1515/hsz-2019-0427.
   Burki TK, 2017, LANCET ONCOL, V18, pE511, DOI 10.1016/S1470-2045(17)30564-8.
   Chang C, 2014, ONCOGENE, V33, P3225, DOI 10.1038/onc.2013.274.
   Chen MJM, 2019, MOL CELL PROTEOMICS, V18, pS15, DOI 10.1074/mcp.RA118.001260.
   Cremer A, 2020, BRIT J CANCER, V122, P1121, DOI 10.1038/s41416-020-0728-7.
   Dong FY, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108856.
   Fang XS, 2020, INT J MED SCI, V17, P2718, DOI 10.7150/ijms.47224.
   Fendler A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14700-7.
   Gong DK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1223-y.
   Gossage L, 2015, NAT REV CANCER, V15, P55, DOI 10.1038/nrc3844.
   Gulati S, 2020, CURR ONCOL REP, V22, DOI 10.1007/s11912-020-0892-1.
   Gupta PP, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1011-5.
   Han GC, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4026-6.
   Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y.
   Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022.
   Hoshida Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001195.
   Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI {[}10.1038/nrdp.2017.10, 10.1038/nrdp.2017.9].
   Hu C, 2020, GENOMICS, V112, P1926, DOI 10.1016/j.ygeno.2019.11.005.
   Hua XL, 2020, AGING-US, V12, P2302, DOI 10.18632/aging.102746.
   Huang QB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00701-6.
   Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1.
   Jiang X, 2019, ONCOL REP, V41, P1949, DOI 10.3892/or.2018.6934.
   Leibovich BC, 2007, J CLIN ONCOL, V25, P4757, DOI 10.1200/JCO.2007.12.1087.
   Li J, 2017, CANCER RES, V77, pE51, DOI 10.1158/0008-5472.CAN-17-0369.
   Li J, 2017, CANCER CELL, V31, P225, DOI 10.1016/j.ccell.2017.01.005.
   Li J, 2015, CANCER RES, V75, P3728, DOI 10.1158/0008-5472.CAN-15-0273.
   Li J, 2013, NAT METHODS, V10, P1046, DOI {[}10.1038/nmeth.2650, 10.1038/NMETH.2650].
   Linehan WM, 2019, NAT REV UROL, V16, P539, DOI 10.1038/s41585-019-0211-5.
   Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052.
   Ljungberg B, 2019, EUR UROL, V75, P799, DOI 10.1016/j.eururo.2019.02.011.
   Luo QZ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7147824.
   Luo YH, 2020, J CANCER, V11, P1424, DOI 10.7150/jca.32886.
   Maruschke M, 2018, UROL INT, V101, P417, DOI 10.1159/000493149.
   Menschaert G, 2017, MASS SPECTROM REV, V36, P584, DOI 10.1002/mas.21483.
   Menschaert G, 2010, J PROTEOME RES, V9, P2051, DOI 10.1021/pr900929m.
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487.
   Nishizuka S, 2003, P NATL ACAD SCI USA, V100, P14229, DOI 10.1073/pnas.2331323100.
   Post JB, 2020, TRENDS CANCER, V6, P111, DOI 10.1016/j.trecan.2019.12.005.
   Qu L, 2018, EUR UROL, V74, P756, DOI 10.1016/j.eururo.2018.07.032.
   Raimondo S, 2018, J PROTEOMICS, V173, P1, DOI 10.1016/j.jprot.2017.11.017.
   Ricketts CJ, 2016, CANCER CELL, V30, P515, DOI 10.1016/j.ccell.2016.09.016.
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77.
   Roh W, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah3560.
   Russell MR, 2019, BRIT J CANCER, V121, P483, DOI 10.1038/s41416-019-0544-0.
   Sheehan KM, 2005, MOL CELL PROTEOMICS, V4, P346, DOI 10.1074/mcp.T500003-MCP200.
   Shinde A, 2019, CANCER RES, V79, P1831, DOI 10.1158/0008-5472.CAN-18-2636.
   Siegel R.L., CA-CANCER J CLIN, V2020, P7, DOI {[}DOI 10.3322/CAAC.21590, 10.3322/CAAC.21590].
   Spurrier B, 2008, NAT PROTOC, V3, P1796, DOI 10.1038/nprot.2008.179.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Sulzmaier FJ, 2012, ONCOGENE, V31, P3547, DOI 10.1038/onc.2011.514.
   Sun N, 2020, CANCER SCI, V111, P1739, DOI 10.1111/cas.14387.
   Sun ZL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01430.
   Tang B, 2019, ONCOL REP, V41, P43, DOI 10.3892/or.2018.6825.
   Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334.
   Torresano L, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165721.
   Vahed SZ, 2017, BIOMED PHARMACOTHER, V94, P1094, DOI 10.1016/j.biopha.2017.08.033.
   Wan BB, 2019, AGING-US, V11, P11474, DOI 10.18632/aging.102548.
   Wang JL, 2018, ENVIRON TOXICOL PHAR, V62, P227, DOI 10.1016/j.etap.2018.08.002.
   Wang KF, 2017, CANCER LETT, V394, P1, DOI 10.1016/j.canlet.2016.12.036.
   Wang M, 2018, ANN NY ACAD SCI, V1434, P59, DOI 10.1111/nyas.13863.
   Wang S, 2020, J CANCER, V11, P4996, DOI 10.7150/jca.45296.
   Wang XM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14601-9.
   Wang YJ, 2019, J CELL BIOCHEM, V120, P126, DOI 10.1002/jcb.27152.
   Wu ZH, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07229-x.
   Wu ZH, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720929308.
   Xu WX, 2020, NAT REV UROL, V17, P137, DOI 10.1038/s41585-020-0282-3.
   Xue S, 2018, BMC UROL, V18, DOI 10.1186/s12894-018-0395-7.
   Yang J, 2020, BRIT J CANCER, V122, P1175, DOI 10.1038/s41416-020-0731-z.
   Yue TH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/6135060.
   Zhang J, 2018, SCIENCE, V361, P290, DOI 10.1126/science.aap8411.
   Zhou JC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.121.},
Number-of-Cited-References = {72},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Front. Mol. Biosci.},
Doc-Delivery-Number = {RJ6PD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000637721400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000630146400001,
Author = {Pfeiffer, Shona and Tomascova, Anna and Mamrak, Uta and Haunsberger,
   Stefan J. and Connolly, Niamh M. C. and Resler, Alexa and Dussmann,
   Heiko and Weisova, Petronela and Jirstrom, Elisabeth and D'Orsi,
   Beatrice and Chen, Gang and Cremona, Mattia and Hennessy, Bryan T. and
   Plesnila, Nikolaus and Prehn, Jochen H. M.},
Title = {AMPK-regulated miRNA-210-3p is activated during ischaemic neuronal
   injury and modulates PI3K-p70S6K signalling},
Journal = {JOURNAL OF NEUROCHEMISTRY},
Year = {2021},
Volume = {159},
Number = {4},
Pages = {710-728},
Month = {NOV},
Abstract = {Progressive neuronal injury following ischaemic stroke is associated
   with glutamate-induced depolarization, energetic stress and activation
   of AMP-activated protein kinase (AMPK). We here identify a molecular
   signature associated with neuronal AMPK activation, as a critical
   regulator of cellular response to energetic stress following ischaemia.
   We report a robust induction of microRNA miR-210-3p both in vitro in
   primary cortical neurons in response to acute AMPK activation and
   following ischaemic stroke in vivo. Bioinformatics and reverse phase
   protein array analysis of neuronal protein expression changes in vivo
   following administration of a miR-210-3p mimic revealed altered
   expression of phosphatase and tensin homolog (PTEN),
   3-phosphoinositide-dependent protein kinase 1 (PDK1), ribosomal protein
   S6 kinase (p70S6K) and ribosomal protein S6 (RPS6) signalling in
   response to increasing miR-210-3p. In vivo, we observed a corresponding
   reduction in p70S6K activity following ischaemic stroke. Utilizing
   models of glutamate receptor over-activation in primary neurons, we
   demonstrated that induction of miR-210-3p was accompanied by sustained
   suppression of p70S6K activity and that this effect was reversed by
   miR-210-3p inhibition. Collectively, these results provide new molecular
   insight into the regulation of cell signalling during ischaemic injury,
   and suggest a novel mechanism whereby AMPK regulates miR-210-3p to
   control p70S6K activity in ischaemic stroke and excitotoxic injury.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Pfeiffer, S (Corresponding Author), Royal Coll Surgeons Ireland, Dept Physiol \& Med Phys, 123 St Stephens Green, Dublin, Ireland.
   Pfeiffer, Shona; Tomascova, Anna; Connolly, Niamh M. C.; Dussmann, Heiko; Weisova, Petronela; Jirstrom, Elisabeth; D'Orsi, Beatrice; Chen, Gang; Prehn, Jochen H. M., Royal Coll Surgeons Ireland, Dept Physiol \& Med Phys, 123 St Stephens Green, Dublin, Ireland.
   Pfeiffer, Shona; Haunsberger, Stefan J.; Connolly, Niamh M. C.; Resler, Alexa; Dussmann, Heiko; Jirstrom, Elisabeth; Cremona, Mattia; Hennessy, Bryan T.; Prehn, Jochen H. M., Royal Coll Surgeons Ireland, Ctr Syst Med, Dublin, Ireland.
   Tomascova, Anna, Comenius Univ, Biomed Ctr Martin, Bratislava, Slovakia.
   Mamrak, Uta; Plesnila, Nikolaus, Inst Stroke \& Dementia Res ISD, Munich, Germany.
   Jirstrom, Elisabeth; Prehn, Jochen H. M., Royal Coll Surgeons Ireland, FutureNeuro SFI Res Ctr, Dublin, Ireland.
   D'Orsi, Beatrice, CNR, Italian Natl Res Council, Inst Neurosci, Pisa, Italy.
   Cremona, Mattia; Hennessy, Bryan T., Royal Coll Surgeons Ireland, Med Oncol Grp, Dept Mol Med, Dublin, Ireland.
   Hennessy, Bryan T., Beaumont Hosp, Dept Med Oncol, Dublin, Ireland.
   Plesnila, Nikolaus, Munich Cluster Syst Neurol Synergy, Munich, Germany.},
DOI = {10.1111/jnc.15347},
EarlyAccessDate = {MAR 2021},
ISSN = {0022-3042},
EISSN = {1471-4159},
Keywords = {AMPK; ischaemia; microRNA; neuronal injury; stroke},
Keywords-Plus = {PROTEIN-KINASE 1; APOPTOSIS-INDUCING FACTOR; IN-VIVO; BREAST-CANCER; S6
   PHOSPHORYLATION; NERVOUS-SYSTEM; ENERGY SENSOR; CELL-DEATH; STROKE;
   EXPRESSION},
Research-Areas = {Biochemistry \& Molecular Biology; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Neurosciences},
Author-Email = {shonapfeiffer@rcsi.ie},
Affiliations = {Royal College of Surgeons - Ireland; Royal College of Surgeons -
   Ireland; Comenius University Bratislava; University of Munich; Royal
   College of Surgeons - Ireland; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Neuroscienze (IN-CNR); Royal College of Surgeons - Ireland;
   Beaumont Hospital Dublin; University of Munich},
ResearcherID-Numbers = {Connolly, Niamh/U-6083-2019
   D'Orsi, Beatrice/AAC-8990-2021
   Prehn, Jochen/A-3928-2010
   Weisova, Petronela/AAM-5989-2020},
ORCID-Numbers = {Connolly, Niamh/0000-0002-6005-1307
   Pfeiffer, Shona/0000-0002-8728-1620
   Jirström, Elisabeth/0000-0003-4060-3300
   D'Orsi, Beatrice/0000-0002-4335-3995
   Hennessy, Bryan/0000-0002-7871-6477
   },
Funding-Acknowledgement = {Science Foundation Ireland {[}13/IA/1881, 17/COEN/3474]; Munich Cluster
   of Systems Neurology {[}EXC2145/ID390857198]; Science Foundation Ireland
   (SFI) {[}17/COEN/3474, 13/IA/1881] Funding Source: Science Foundation
   Ireland (SFI)},
Funding-Text = {Science Foundation Ireland, Grant/Award Number: 13/IA/1881 and
   17/COEN/3474; Munich Cluster of Systems Neurology, Grant/Award Number:
   EXC2145/ID390857198},
Cited-References = {Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5.
   Anilkumar U, 2013, J NEUROCHEM, V124, P721, DOI 10.1111/jnc.12108.
   {[}Anonymous], 2014, R LANG ENV STAT COMP, V2014.
   Arumugam TV, 2018, PROG NEUROBIOL, V165, P103, DOI 10.1016/j.pneurobio.2018.03.002.
   Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403.
   Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400.
   Biever A, 2015, FRONT MOL NEUROSCI, V8, DOI 10.3389/fnmol.2015.00075.
   Brennan-Minnella AM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.111.
   Calzavara E, 2008, J CELL BIOCHEM, V103, P1405, DOI 10.1002/jcb.21527.
   Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005.
   Chagpar RB, 2010, P NATL ACAD SCI USA, V107, P5471, DOI 10.1073/pnas.0908899107.
   Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006.
   Chen L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03867-9.
   Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067.
   Concannon CG, 2008, J NEUROCHEM, V105, P891, DOI 10.1111/j.1471-4159.2007.05187.x.
   Concannon CG, 2010, J CELL BIOL, V189, P83, DOI 10.1083/jcb.200909166.
   Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45.
   Culmsee C, 2005, J NEUROSCI, V25, P10262, DOI 10.1523/JNEUROSCI.2818-05.2005.
   D'Orsi B, 2012, J NEUROSCI, V32, P1847, DOI 10.1523/JNEUROSCI.2345-11.2012.
   Davila D, 2012, CELL DEATH DIFFER, V19, P1677, DOI 10.1038/cdd.2012.49.
   Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157.
   Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0.
   Gao X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1260-6.
   Gong X, 2016, AM J TRANSL RES, V8, P2127.
   Green AR, 2006, DRUG DISCOV TODAY, V11, P681, DOI 10.1016/j.drudis.2006.06.001.
   Green A. Richard, 2004, Critical Reviews in Neurobiology, V16, P91, DOI 10.1615/CritRevNeurobiol.v16.i12.100.
   Grego-Bessa J, 2016, ELIFE, V5, DOI 10.7554/eLife.12034.
   Hann SS, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-149.
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311.
   Hardie DG, 2011, BIOCHEM SOC T, V39, P1, DOI 10.1042/BST0390001.
   Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717.
   Hausenloy DJ, 2004, CARDIOVASC RES, V63, P305, DOI 10.1016/j.cardiores.2004.04.011.
   Hennessy Bryan T, 2010, Clin Proteomics, V6, P129, DOI 10.1007/s12014-010-9055-y.
   Hutchinson JA, 2011, J BIOL CHEM, V286, P8688, DOI 10.1074/jbc.M110.141754.
   Iwanami A, 2009, GENE DEV, V23, P1699, DOI 10.1101/gad.1832909.
   Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168.
   Jiang TT, 2021, ACTA PHARM SIN B, V11, P355, DOI 10.1016/j.apsb.2020.05.004.
   Jimenez-Mateos EM, 2012, NAT MED, V18, P1087, DOI 10.1038/nm.2834.
   Jimenez-Mateos EM, 2011, AM J PATHOL, V179, P2519, DOI 10.1016/j.ajpath.2011.07.036.
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027.
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003.
   Kalogeris T, 2012, INT REV CEL MOL BIO, V298, P229, DOI 10.1016/B978-0-12-394309-5.00006-7.
   Karagkouni D, 2018, NUCLEIC ACIDS RES, V46, pD239, DOI 10.1093/nar/gkx1141.
   Khoshnam SE, 2017, J STROKE, V19, P166, DOI 10.5853/jos.2016.01368.
   Kim JI, 2011, NAT NEUROSCI, V14, P1447, DOI 10.1038/nn.2937.
   Kirdajova DB, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00051.
   Koh PO, 2013, NEUROSCI LETT, V555, P7, DOI 10.1016/j.neulet.2013.09.001.
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141.
   Dang K, 2015, INT J MOL SCI, V16, P6353, DOI 10.3390/ijms16036353.
   Lai TW, 2014, PROG NEUROBIOL, V115, P157, DOI 10.1016/j.pneurobio.2013.11.006.
   Lee ST, 2010, STROKE, V41, P1646, DOI 10.1161/STROKEAHA.110.579649.
   Lehman JA, 2002, BIOCHEM BIOPH RES CO, V293, P463, DOI 10.1016/S0006-291X(02)00238-3.
   Li J, 2010, J CEREBR BLOOD F MET, V30, P480, DOI 10.1038/jcbfm.2009.255.
   Li Y, 2017, CELL MOL BIOL LETT, V22, P1, DOI 10.1186/s11658-017-0033-5.
   Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4.
   Lu WJ, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00223.
   Maas MB, 2009, BIOMARK MED, V3, P363, DOI 10.2217/BMM.09.30.
   Majid Arshad, 2014, ISRN Neurol, V2014, P515716, DOI 10.1155/2014/515716.
   Marathe S, 2015, CELL DEATH DIFFER, V22, P1775, DOI 10.1038/cdd.2015.23.
   Marsin AS, 2002, J BIOL CHEM, V277, P30778, DOI 10.1074/jbc.M205213200.
   McCullough LD, 2005, J BIOL CHEM, V280, P20493, DOI 10.1074/jbc.M409985200.
   Molloy Niamh H, 2011, Cancers (Basel), V3, P510, DOI 10.3390/cancers3010510.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Pasculli B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51581-3.
   Pfeiffer S, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.41.
   Pfeiffer S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.426.
   Pfeiffer S, 2021, J NEUROCHEM, V159, P710, DOI 10.1111/jnc.15347.
   Plesnila N, 2004, J CEREBR BLOOD F MET, V24, P458, DOI 10.1097/00004647-200404000-00011.
   Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298.
   Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184.
   Ren CX, 2016, EXPERT OPIN THER TAR, V20, P1325, DOI 10.1080/14728222.2016.1206890.
   Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200.
   Rytter A, 2003, J CEREBR BLOOD F MET, V23, P23, DOI 10.1097/01.WCB.0000034361.37277.1B.
   Saito N, 2019, CANCERS, V11, DOI 10.3390/cancers11010121.
   Sharp FR, 2011, J CEREBR BLOOD F MET, V31, P1513, DOI 10.1038/jcbfm.2011.45.
   Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296.
   Sun Y, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00193.
   Templeton DJ, 2001, CURR BIOL, V11, pR596, DOI 10.1016/S0960-9822(01)00361-X.
   Tokar T, 2018, NUCLEIC ACIDS RES, V46, pD360, DOI 10.1093/nar/gkx1144.
   van Rooij E, 2007, SCIENCE, V316, P575, DOI 10.1126/science.1139089.
   Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290.
   Venna VR, 2012, NEUROSCIENCE, V201, P280, DOI 10.1016/j.neuroscience.2011.11.014.
   Vijayan M, 2016, BBA-MOL BASIS DIS, V1862, P1984, DOI 10.1016/j.bbadis.2016.08.003.
   Vuokila N, 2020, NEUROSCIENCE, V433, P21, DOI 10.1016/j.neuroscience.2020.02.045.
   Weisová P, 2011, ANTIOXID REDOX SIGN, V14, P1863, DOI 10.1089/ars.2010.3544.
   Weisová P, 2009, J NEUROSCI, V29, P2997, DOI 10.1523/JNEUROSCI.0354-09.2009.
   Weng HC, 2011, BIOMED RES-TOKYO, V32, P135, DOI 10.2220/biomedres.32.135.
   Wickham H, 2011, J STAT SOFTW, V40, P1, DOI 10.18637/jss.v040.i01.
   Wilczynska A, 2015, CELL DEATH DIFFER, V22, P22, DOI 10.1038/cdd.2014.112.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Wu SB, 2012, BBA-MOL BASIS DIS, V1822, P233, DOI 10.1016/j.bbadis.2011.09.014.
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e.
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118.
   Zeng Lili, 2011, Front Biosci (Elite Ed), V3, P1265.
   Zhang RP, 2017, ONCOTARGET, V8, P26079, DOI 10.18632/oncotarget.15317.},
Number-of-Cited-References = {95},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {J. Neurochem.},
Doc-Delivery-Number = {WV3WJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000630146400001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000634515700001,
Author = {Quiroga, John and Alarcon, Pablo and Manosalva, Carolina and Teuber,
   Stefanie and Taubert, Anja and Hermosilla, Carlos and Hidalgo, Maria
   Angelica and Carretta, Maria Daniella and Burgos, Rafael Agustin},
Title = {Metabolic Reprogramming and Inflammatory Response Induced by D-Lactate
   in Bovine Fibroblast-Like Synoviocytes Depends on HIF-1 Activity},
Journal = {FRONTIERS IN VETERINARY SCIENCE},
Year = {2021},
Volume = {8},
Month = {MAR 16},
Abstract = {Acute ruminal acidosis (ARA) occurs after an excessive intake of rapidly
   fermentable carbohydrates and is characterized by the overproduction of
   D-lactate in the rumen that reaches the bloodstream. Lameness
   presentation, one of the primary consequences of ARA in cattle, is
   associated with the occurrence of laminitis and aseptic polysynovitis.
   Fibroblast-like synoviocytes (FLS) are predominant cells of synovia and
   play a key role in the pathophysiology of joint diseases, thus
   increasing the chances of the release of pro-inflammatory cytokines.
   Increased D-lactate levels and disturbances in the metabolism of
   carbohydrates, pyruvates, and amino acids are observed in the synovial
   fluid of heifers with ARA-related polysynovitis prior to neutrophil
   infiltration, suggesting an early involvement of metabolic disturbances
   in joint inflammation. We hypothesized that D-lactate induces metabolic
   reprogramming, along with an inflammatory response, in bovine exposed
   FLS. Gas chromatography-mass spectrometry (GC-MS)-based metabolomics
   revealed that D-lactate disrupts the metabolism of bovine FLS, mainly
   enhancing glycolysis and gluconeogenesis, pyruvate metabolism, and
   galactose metabolism. The reverse-transcription quantitative PCR
   (RT-qPCR) analysis revealed an increased expression of metabolic-related
   genes, including hypoxia-inducible factor 1 (HIF-1)alpha, glucose
   transporter 1 (Glut-1), L-lactate dehydrogenase subunit A (L-LDHA), and
   pyruvate dehydrogenase kinase 1 (PDK-1). Along with metabolic
   disturbances, D-lactate also induced an overexpression and the secretion
   of IL-6. Furthermore, the inhibition of HIF-1, PI3K/Akt, and NF-kappa B
   reduced the expression of IL-6 and metabolic-related genes. The results
   of this study reveal a potential role for D-lactate in bFLS metabolic
   reprogramming and support a close relationship between inflammation and
   metabolism in cattle.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Burgos, RA (Corresponding Author), Univ Austral Chile, Lab Inflammat Pharmacol, Inst Pharmacol \& Morphophysiol, Fac Vet Sci, Valdivia, Chile.
   Burgos, RA (Corresponding Author), Univ Austral Chile, Lab Immunometab, Fac Vet Sci, Inst Pharmacol \& Morphophysiol, Valdivia, Chile.
   Quiroga, John; Alarcon, Pablo; Teuber, Stefanie; Hidalgo, Maria Angelica; Carretta, Maria Daniella; Burgos, Rafael Agustin, Univ Austral Chile, Lab Inflammat Pharmacol, Inst Pharmacol \& Morphophysiol, Fac Vet Sci, Valdivia, Chile.
   Quiroga, John; Alarcon, Pablo; Teuber, Stefanie; Hidalgo, Maria Angelica; Carretta, Maria Daniella; Burgos, Rafael Agustin, Univ Austral Chile, Lab Immunometab, Fac Vet Sci, Inst Pharmacol \& Morphophysiol, Valdivia, Chile.
   Manosalva, Carolina, Univ Austral Chile, Fac Sci, Inst Pharm, Valdivia, Chile.
   Taubert, Anja; Hermosilla, Carlos, Justus Liebig Univ Giessen, Biomed Res Ctr Seltersberg, Inst Parasitol, Giessen, Germany.},
DOI = {10.3389/fvets.2021.625347},
Article-Number = {625347},
EISSN = {2297-1769},
Keywords = {bovine fibroblast-like synoviocyte; D-lactate; metabolic reprogramming;
   inflammation; hypoxia inducible factor 1},
Research-Areas = {Veterinary Sciences},
Web-of-Science-Categories  = {Veterinary Sciences},
Author-Email = {rburgos1@uach.cl},
Affiliations = {Universidad Austral de Chile; Universidad Austral de Chile; Universidad
   Austral de Chile; Justus Liebig University Giessen},
ORCID-Numbers = {Hidalgo, Maria A/0000-0003-2072-2556
   Carretta Munoz, Maria Daniella/0000-0002-2124-9812
   Burgos, Rafael A/0000-0002-8182-2502
   Taubert, Anja/0000-0001-8649-1020},
Funding-Acknowledgement = {Agencia Nacional de Investigacion y Desarrollo (ANID) Scholarship
   {[}21171843]; Fondo Nacional de Desarrollo Cientifico y Tecnologico
   (FONDECYT) {[}1180946]; Fondo de Equipamiento Cientifico y Tecnologico
   (FONDEQUIP) {[}EQM130257]},
Funding-Text = {The present study was supported by the Agencia Nacional de Investigacion
   y Desarrollo (ANID) Scholarship No 21171843, Fondo Nacional de
   Desarrollo Cientifico y Tecnologico (FONDECYT) No 1180946, and Fondo de
   Equipamiento Cientifico y Tecnologico (FONDEQUIP) No EQM130257.},
Cited-References = {Ahn JK, 2008, RHEUMATOLOGY, V47, P834, DOI 10.1093/rheumatology/ken086.
   Ahn JK, 2016, JOINT BONE SPINE, V83, P707, DOI 10.1016/j.jbspin.2015.11.009.
   Akhtar M, 2020, ACTA TROP, V207, DOI 10.1016/j.actatropica.2020.105458.
   Alarcon P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42007-1.
   Alarcón P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00975.
   Alvergnas M, 2019, LIVEST SCI, V222, P54, DOI 10.1016/j.livsci.2019.02.011.
   Armstrong DW, 1999, TETRAHEDRON-ASYMMETR, V10, P37, DOI 10.1016/S0957-4166(98)00476-5.
   Bao YY, 2015, ONCOL REP, V34, P1805, DOI 10.3892/or.2015.4158.
   Biniecka M, 2016, ANN RHEUM DIS, V75, P2192, DOI 10.1136/annrheumdis-2015-208476.
   Blancher C, 2001, CANCER RES, V61, P7349.
   Blouin CC, 2004, BLOOD, V103, P1124, DOI 10.1182/blood-2003-07-2427.
   BORENSTEIN DG, 1982, ARTHRITIS RHEUM-US, V25, P947, DOI 10.1002/art.1780250806.
   Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190.
   Bustamante MF, 2018, ANN RHEUM DIS, V77, P1636, DOI 10.1136/annrheumdis-2018-213103.
   Cai WW, 2020, INFLAMM RES, V69, P1087, DOI 10.1007/s00011-020-01391-5.
   Cheng ZX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11129-5.
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310.
   Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0.
   Danscher AM, 2011, LIVEST SCI, V135, P62, DOI 10.1016/j.livsci.2010.06.009.
   Danscher AM, 2010, J COMP PATHOL, V142, P129, DOI 10.1016/j.jcpa.2009.09.001.
   Danscher AM, 2010, J DAIRY SCI, V93, P53, DOI 10.3168/jds.2009-2038.
   Danscher AM, 2009, J DAIRY SCI, V92, P607, DOI 10.3168/jds.2008-1271.
   DAWES E, 1994, CLIN MATER, V17, P157, DOI 10.1016/0267-6605(94)90031-0.
   de Bari L, 2002, BIOCHEM J, V365, P391, DOI 10.1042/BJ20020139.
   Doss F, 2007, SCAND J RHEUMATOL, V36, P136, DOI 10.1080/03009740701250785.
   DUNLOP RH, 1965, ANN NY ACAD SCI, V119, P1109, DOI 10.1111/j.1749-6632.1965.tb47466.x.
   Falconer J, 2018, ARTHRITIS RHEUMATOL, V70, P984, DOI 10.1002/art.40504.
   Fernández-Torres J, 2017, REV BRAS REUMATOL, V57, P162, DOI {[}10.1016/j.rbr.2016.04.006, 10.1016/j.rbre.2016.07.008].
   Fiehn O., 2016, CURR PROTOC MOL BIOL, V114, p30.34, DOI DOI 10.1002/0471142727.MB3004S114.
   Flick MJ, 2002, BIOCHEM BIOPH RES CO, V295, P910, DOI 10.1016/S0006-291X(02)00768-4.
   Gaber T, 2017, NAT REV RHEUMATOL, V13, P267, DOI 10.1038/nrrheum.2017.37.
   Garcia-Carbonell R, 2016, ARTHRITIS RHEUMATOL, V68, P1614, DOI 10.1002/art.39608.
   GILL W, 1985, J DAIRY SCI, V68, P2886, DOI 10.3168/jds.S0022-0302(85)81182-6.
   Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901.
   HARMON DL, 1985, J ANIM SCI, V60, P560, DOI 10.2527/jas1985.602560x.
   Hartmann H, 2008, GASTROENTEROLOGY, V134, P756, DOI 10.1053/j.gastro.2007.12.008.
   Hellwig-Bürgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06\_1561\_1567.
   Hernandez Joaquin, 2014, ScientificWorldJournal, V2014, P702572, DOI 10.1155/2014/702572.
   Hidalgo AI, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-1974-x.
   JAY GD, 1992, CONNECT TISSUE RES, V28, P71, DOI 10.3109/03008209209014228.
   Jellusova J, 2016, CRIT REV BIOCHEM MOL, V51, P359, DOI 10.1080/10409238.2016.1215288.
   Jia QY, 2015, INT IMMUNOPHARMACOL, V29, P884, DOI 10.1016/j.intimp.2015.08.026.
   Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363.
   Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771.
   Jiang T, 2018, ONCOTARGETS THER, V11, P7865, DOI 10.2147/OTT.S176818.
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koyasu S, 2018, CANCER SCI, V109, P560, DOI 10.1111/cas.13483.
   Lee JW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.26.
   Lenski M, 2014, CLIN BIOCHEM, V47, P49, DOI 10.1016/j.clinbiochem.2013.10.019.
   Li BB, 2018, INT J MOL MED, V42, P1391, DOI 10.3892/ijmm.2018.3745.
   Li GQ, 2013, MOL IMMUNOL, V53, P227, DOI 10.1016/j.molimm.2012.08.018.
   Li HX, 2018, EXP THER MED, V16, P4737, DOI 10.3892/etm.2018.6770.
   Lindsay DB, 1978, BIOCHEM SOC T, V6, P1152, DOI 10.1042/bst0061152.
   Liu SY, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1394-4.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Luo XJ, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2399.
   Manosalva C, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10112105.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324.
   Melstrom LG, 2008, PANCREAS, V37, P426, DOI 10.1097/MPA.0b013e3181735ccb.
   Miao HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep13092.
   Nagaraja TG, 2007, J DAIRY SCI, V90, pE17, DOI 10.3168/jds.2006-478.
   Nakamura H, 2005, J IMMUNOL, V174, P7592, DOI 10.4049/jimmunol.174.12.7592.
   Narazaki M, 2017, EXPERT REV CLIN IMMU, V13, P535, DOI 10.1080/1744666X.2017.1295850.
   NAUGHTON D, 1993, FEBS LETT, V317, P135, DOI 10.1016/0014-5793(93)81508-W.
   Nocek JE, 1997, J DAIRY SCI, V80, P1005, DOI 10.3168/jds.S0022-0302(97)76026-0.
   Noss EH, 2008, IMMUNOL REV, V223, P252, DOI 10.1111/j.1600-065X.2008.00648.x.
   O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70.
   O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570.
   Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865.
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096.
   Plaizier JC, 2008, VET J, V176, P21, DOI 10.1016/j.tvjl.2007.12.016.
   Priori R, 2013, AUTOIMMUN REV, V12, P1022, DOI 10.1016/j.autrev.2013.04.002.
   Qian D, 2004, BIOL REPROD, V70, P1822, DOI 10.1095/biolreprod.103.025031.
   Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003.
   RAY A, 1995, DNA CELL BIOL, V14, P795, DOI 10.1089/dna.1995.14.795.
   Sadiq MB, 2017, ANIMALS-BASEL, V7, DOI 10.3390/ani7110079.
   Saini RK, 2018, LIFE SCI, V203, P255, DOI 10.1016/j.lfs.2018.04.049.
   Sartori-Cintra AR, 2012, CLINICS, V67, P35, DOI 10.6061/clinics/2012(01)06.
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1.
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Shao Y, 2014, AM J PHYSIOL-REG I, V307, pR237, DOI 10.1152/ajpregu.00093.2014.
   Slomiany MG, 2006, J PHARMACOL EXP THER, V318, P666, DOI 10.1124/jpet.106.104158.
   SWANN DA, 1972, J BIOL CHEM, V247, P8069.
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241.
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510.
   Wang XG, 2020, MICROB BIOTECHNOL, V13, P1103, DOI 10.1111/1751-7915.13565.
   Wei LB, 2015, ONCOTARGET, V6, P16198, DOI 10.18632/oncotarget.3838.
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014.
   Yamaguchi R, 2016, J BONE JOINT SURG AM, V98, P1122, DOI 10.2106/JBJS.15.01209.
   Yang XY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132695.
   Yudoh K, 2005, ARTHRITIS RES THER, V7, pR904, DOI 10.1186/ar1765.
   Zhang N, 2019, CELL MOL BIOL, V65, P85, DOI 10.14715/cmb/2019.65.6.14.
   Zhang SQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00467.
   Zhao CX, 2019, J DAIRY RES, V86, P171, DOI 10.1017/S0022029919000323.
   Zheng KD, 2017, J ORTHOP RES, V35, P1973, DOI 10.1002/jor.23482.
   Zou YY, 2017, BRIT J PHARMACOL, V174, P893, DOI 10.1111/bph.13762.},
Number-of-Cited-References = {99},
Times-Cited = {22},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Front. Vet. Sci.},
Doc-Delivery-Number = {RF0CI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000634515700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000629564500012,
Author = {Zhang, Qiang and Wu, Jiaqi and Zhang, Xiangfeng and Cao, Le and Wu,
   Yongping and Miao, Xudong},
Title = {Transcription factor ELK1 accelerates aerobic glycolysis to enhance
   osteosarcoma chemoresistance through miR-134/PTBP1 signaling cascade},
Journal = {AGING-US},
Year = {2021},
Volume = {13},
Number = {5},
Pages = {6804-6819},
Month = {MAR 15},
Abstract = {Osteosarcoma is a malignancy that primarily affects children and young
   adults. The poor survival is largely attributed to acquisition of
   chemoresistance. Thus, the current study aimed to elucidate the role of
   ELK1/miR-134/PTBP1 signaling cascade in osteosarcoma chemoresistance.
   Doxorubicin (DXR)-resistant human osteosarcoma cells were initially
   self-established by continuous exposure of MG-63, U2OS and HOS cells to
   increasing DXR doses. Osteosarcoma chemoresistance in vitro was
   evaluated using CCK-8 assays and EdU staining. Aerobic glycolysis was
   evaluated by lactic acid production, glucose consumption, ATP levels,
   and Western blot analysis of GLUT3, HK2 and PDK1 proteins. The nude mice
   were injected with 5.0 mg/kg DXR following the subcutaneous
   transplantation of osteosarcomas. PTBP1 was upregulated in tumor tissues
   derived from non-responders to DXR treatment and correlated with patient
   poor survival. PTBP1 enhanced chemoresistance in cultured osteosarcoma
   cells in vitro and in vivo by increasing aerobic glycolysis.
   Additionally, miR-134 inhibited translation of PTBP1. ELK1 bound to
   miR-134 promoter and inhibited its expression. Overexpressed ELK1
   enhanced chemoresistance and increased aerobic glycolysis by
   downregulating miR-134 and upregulating PTBP1 in DXR-resistant cells.
   Altogether, the key findings of the present study highlight
   ELK1/miR-134/PTBP1 signaling cascade as a novel molecular mechanism
   underlying the acquisition of osteosarcoma chemoresistance.},
Publisher = {IMPACT JOURNALS LLC},
Address = {6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA},
Type = {Article},
Language = {English},
Affiliation = {Miao, XD (Corresponding Author), Zhejiang Univ, Sch Med, Hosp 2, Foot \& Ankle Grp,Dept Orthopaed, Hangzhou 310000, Peoples R China.
   Zhang, Qiang; Cao, Le; Wu, Yongping; Miao, Xudong, Zhejiang Univ, Sch Med, Hosp 2, Foot \& Ankle Grp,Dept Orthopaed, Hangzhou 310000, Peoples R China.
   Wu, Jiaqi; Zhang, Xiangfeng, Zhejiang Univ, Sch Med, Hosp 2, Trauma Grp Orthopaed, Hangzhou 310000, Peoples R China.},
DOI = {10.18632/aging.202538},
ISSN = {1945-4589},
Keywords = {osteosarcoma; chemoresistance; aerobic glycolysis; ELK1; microRNA-134},
Keywords-Plus = {BLADDER-CANCER CELLS; PANCREATIC-CANCER; PROMOTES; PROLIFERATION;
   METASTASIS; ANDROGEN; GROWTH; PTBP1},
Research-Areas = {Cell Biology; Geriatrics \& Gerontology},
Web-of-Science-Categories  = {Cell Biology; Geriatrics \& Gerontology},
Author-Email = {zrmxd@zju.edu.cn},
Affiliations = {Zhejiang University; Zhejiang University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81601878]; Zhejiang
   Medical and Health Science and Technology Program {[}2016RCA016]},
Funding-Text = {This research was supported by grants from the National Natural Science
   Foundation of China (No. 81601878), and the Zhejiang Medical and Health
   Science and Technology Program (No. 2016RCA016).},
Cited-References = {Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5.
   Calabretta S, 2016, ONCOGENE, V35, P2031, DOI 10.1038/onc.2015.270.
   Chen CL, 2019, FEBS LETT, V593, P1089, DOI 10.1002/1873-3468.13387.
   Han K, 2015, ONCOTARGET, V6, P8875, DOI 10.18632/oncotarget.3560.
   He HT, 2014, ONCOL LETT, V7, P1352, DOI 10.3892/ol.2014.1935.
   He MJ, 2019, ONCOGENE, V38, P5551, DOI 10.1038/s41388-019-0817-3.
   Hollander D, 2016, GENOME RES, V26, P541, DOI 10.1101/gr.193169.115.
   Hou CH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-236.
   Jiang BE, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0348-5.
   Jin H, 2017, ONCOTARGET, V8, P25571, DOI 10.18632/oncotarget.16104.
   Kawahara T, 2015, AM J CANCER RES, V5, P2959.
   Kawahara T, 2015, ONCOTARGET, V6, P29860, DOI 10.18632/oncotarget.5007.
   Lages E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020600.
   Li XN, 2018, B CANCER, V105, P1193, DOI 10.1016/j.bulcan.2018.08.013.
   Liu YJ, 2018, ONCOL REP, V39, P491, DOI 10.3892/or.2017.6142.
   Minami K, 2017, ONCOTARGET, V8, P33064, DOI 10.18632/oncotarget.16524.
   Odrowaz Z, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002694.
   Patki M, 2013, J BIOL CHEM, V288, P11047, DOI 10.1074/jbc.M112.438473.
   Pu YG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3002-x.
   Shuang T, 2017, ONCOTARGET, V8, P24853, DOI 10.18632/oncotarget.15267.
   Wang JD, 2018, INT J ONCOL, V52, P77, DOI 10.3892/ijo.2017.4187.
   Ye Q, 2017, CELL PHYSIOL BIOCHEM, V43, P1617, DOI 10.1159/000482025.
   Zhang Y, 2018, ADV SCI, V5, DOI 10.1002/advs.201700821.},
Number-of-Cited-References = {23},
Times-Cited = {21},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Aging-US},
Doc-Delivery-Number = {QX8AE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000629564500012},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000653677500008,
Author = {Grabowska, Monika E. and Chun, Bryan and Moya, Raquel and Saucerman,
   Jeffrey J.},
Title = {Computational model of cardiomyocyte apoptosis identifies mechanisms of
   tyrosine kinase inhibitor-induced cardiotoxicity},
Journal = {JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY},
Year = {2021},
Volume = {155},
Pages = {66-77},
Month = {JUN},
Abstract = {Despite clinical observations of cardiotoxicity among cancer patients
   treated with tyrosine kinase inhibitors (TKIs), the molecular mechanisms
   by which these drugs affect the heart remain largely unknown.
   Mechanistic understanding of TKI-induced cardiotoxicity has been limited
   in part due to the complexity of tyrosine kinase signaling pathways and
   the multi-targeted nature of many of these drugs. TKI treatment has been
   associated with reactive oxygen species generation, mitochondrial
   dysfunction, and apoptosis in cardiomyocytes. To gain insight into the
   mechanisms mediating TKI-induced cardiotoxicity, this study constructs
   and validates a computational model of cardiomyocyte apoptosis,
   integrating intrinsic apoptotic and tyrosine kinase signaling pathways.
   The model predicts high levels of apoptosis in response to sorafenib,
   sunitinib, ponatinib, trastuzumab, and gefitinib, and lower levels of
   apoptosis in response to nilotinib and erlotinib, with the highest level
   of apoptosis induced by sorafenib. Knockdown simulations identified AP1,
   ASK1, JNK, MEK47, p53, and ROS as positive functional regulators of
   sorafenib-induced apoptosis of cardiomyocytes. Overexpression
   simulations identified Akt, IGF1, PDK1, and PI3K among the negative
   functional regulators of sorafenib-induced cardiomyocyte apoptosis. A
   combinatorial screen of the positive and negative regulators of
   sorafenib-induced apoptosis revealed ROS knockdown coupled with
   overexpression of FLT3, FGFR, PDGFR, VEGFR, or KIT as a particularly
   potent combination in reducing sorafenib-induced apoptosis. Network
   simulations of combinatorial treatment with sorafenib and the
   antioxidant N-acetyl cysteine (NAC) suggest that NAC may protect
   cardiomyocytes from sorafenib-induced apoptosis.},
Publisher = {ELSEVIER SCI LTD},
Address = {125 London Wall, London, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Saucerman, JJ (Corresponding Author), Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA.
   Grabowska, Monika E.; Chun, Bryan; Moya, Raquel; Saucerman, Jeffrey J., Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA.},
DOI = {10.1016/j.yjmcc.2021.02.014},
EarlyAccessDate = {MAR 2021},
ISSN = {0022-2828},
EISSN = {1095-8584},
Keywords = {Cardiotoxicity; Tyrosine kinase inhibitor; Cardiomyocyte; Apoptosis;
   Computational model; Systems biology},
Keywords-Plus = {IN-VIVO; SUNITINIB; CANCER; NILOTINIB},
Research-Areas = {Cardiovascular System \& Cardiology; Cell Biology},
Web-of-Science-Categories  = {Cardiac \& Cardiovascular Systems; Cell Biology},
Author-Email = {jsaucerman@virginia.edu},
Affiliations = {University of Virginia},
ORCID-Numbers = {Moya, Raquel/0000-0002-0214-7490
   Grabowska, Monika/0000-0003-0708-676X},
Funding-Acknowledgement = {Beckman Scholar Fellowship; National Institutes of Health {[}HL137755,
   HL137100, HL127624]},
Funding-Text = {This study was funded by a Beckman Scholar Fellowship and the National
   Institutes of Health (HL137755, HL137100, HL127624) .},
Cited-References = {Cao SL, 2020, PHILOS T R SOC A, V378, DOI 10.1098/rsta.2019.0336.
   Chen M.H, 2008, CIRCULATION, V118.
   Chen Z, 2016, MOL CLIN ONCOL, V4, P675, DOI 10.3892/mco.2016.800.
   Cheng H, 2011, CIRC RES, V109, P1401, DOI 10.1161/CIRCRESAHA.111.255695.
   Chiusa M, 2012, J MOL CELL CARDIOL, V52, P1164, DOI 10.1016/j.yjmcc.2012.01.022.
   Clements M, 2015, TOXICOL SCI, V148, P241, DOI 10.1093/toxsci/kfv180.
   Cohen JD, 2011, TOXICOL APPL PHARM, V257, P74, DOI 10.1016/j.taap.2011.08.020.
   Daher IN, 2012, TEX HEART I J, V39, P190.
   Damiano S, 2018, J CELL BIOCHEM, V119, P4845, DOI 10.1002/jcb.26686.
   Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027.
   ElZarrad MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079543.
   Florescu Maria, 2013, Maedica (Bucur), V8, P59.
   Frank DU, 2018, J MOL CELL CARDIOL, V121, P180, DOI 10.1016/j.yjmcc.2018.07.243.
   Harvey PA, 2015, CARDIOVASC RES, V107, P66, DOI 10.1093/cvr/cvv152.
   Hasinoff BB, 2017, CARDIOVASC TOXICOL, V17, P297, DOI 10.1007/s12012-016-9386-7.
   Hasinoff BB, 2010, TOXICOL APPL PHARM, V249, P132, DOI 10.1016/j.taap.2010.08.026.
   HU L, 2016, BIOSCIENCE REP, V30, P36.
   Kalkavan H, 2018, CELL DEATH DIFFER, V25, P46, DOI 10.1038/cdd.2017.179.
   Kawabata M, 2015, TOXICOL SCI, V143, P374, DOI 10.1093/toxsci/kfu235.
   Khalilimeybodi A, 2020, PLOS COMPUT BIOL, V16, DOI 10.1371/journal.pcbi.1008490.
   Korashy HM, 2016, TOXICOL LETT, V252, P50, DOI 10.1016/j.toxlet.2016.04.011.
   Kraeutler MJ, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-157.
   Kurokawa YK, 2018, TOXICOL LETT, V285, P74, DOI 10.1016/j.toxlet.2018.01.001.
   Lekes D, 2016, PHYSIOL RES, V65, pS505, DOI 10.33549/physiolres.933504.
   Maayah ZH, 2014, ARCH TOXICOL, V88, P725, DOI 10.1007/s00204-013-1159-5.
   Mohan N, 2016, MOL CANCER THER, V15, P1321, DOI 10.1158/1535-7163.MCT-15-0741.
   Pophali PA, 2016, CANCER J, V22, P40, DOI 10.1097/PPO.0000000000000165.
   Rainer PP, 2012, BJU INT, V110, P1455, DOI 10.1111/j.1464-410X.2012.11134.x.
   Rana P, 2012, TOXICOL SCI, V130, P117, DOI 10.1093/toxsci/kfs233.
   Research, QUESTIONS ANSWERS FD.
   Ryall KA, 2012, J BIOL CHEM, V287, P42259, DOI 10.1074/jbc.M112.382937.
   Sharma A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf2584.
   Shim JV, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00651.
   Singh KK, 2011, BIOCHEM BIOPH RES CO, V411, P421, DOI 10.1016/j.bbrc.2011.06.169.
   Soltis AR, 2011, BIOINFORMATICS, V27, P2888, DOI 10.1093/bioinformatics/btr496.
   Stuhlmiller TJ, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006635.
   Talbert DR, 2015, TOXICOL SCI, V143, P147, DOI 10.1093/toxsci/kfu215.
   Tan PM, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005854.
   Teppo HR, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1485283.
   Wang BH, 2009, BIOCHEM BIOPH RES CO, V389, P105, DOI 10.1016/j.bbrc.2009.08.097.
   Wang H, 2019, CELL SYST, V8, P412, DOI 10.1016/j.cels.2019.03.009.
   Weng MS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0728-0.
   Wittayanukorn S, 2017, J ONCOL PHARM PRACT, V23, P93, DOI 10.1177/1078155215621150.
   Yaniv G, 2005, BIOCHEM BIOPH RES CO, V336, P740, DOI 10.1016/j.bbrc.2005.08.167.
   Zeigler AC, 2016, J MOL CELL CARDIOL, V94, P72, DOI 10.1016/j.yjmcc.2016.03.008.
   2010, TOXICOL APPL PHARM, V248, P20.},
Number-of-Cited-References = {46},
Times-Cited = {23},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {J. Mol. Cell. Cardiol.},
Doc-Delivery-Number = {SG8GK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000653677500008},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000631858200006,
Author = {Li, Yueyong and Zhang, Yingjun and Zhang, Shuai and Huang, Deyou and Li,
   Baosheng and Liang, Gencheng and Wu, Yingning and Jiang, Qiulan and Li,
   Longhua and Lin, Cheng and Wei, Zhonghen and Meng, Lingzhang},
Title = {circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma
   Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis},
Journal = {MOLECULAR THERAPY NUCLEIC ACIDS},
Year = {2021},
Volume = {23},
Pages = {244-254},
Month = {MAR 5},
Abstract = {Circular RNA (circRNA) is a novel subclass of noncoding-RNA molecules
   that participate in development and progression of a variety of human
   diseases via sponging microRNAs (miRNAs). Until now, the contributions
   of circRNAs in chemoresistance of hepatocellular carcinoma (HCC) remain
   largely unknown. In the present study, we aimed to investigate the role
   of circRNA in cisplatin resistance of HCC. We investigated the
   expression of circRNAs in 5 paired cisplatin-sensitive and
   cisplatin-resistant HCC tissues by microarray analysis. The qRT-PCR
   analysis was to investigate the expression pattern of circARNT2 in HCC
   patient tissues and cell lines. Then, the effects of circARNT2 on
   cisplatin resistance, cell proliferation, and apoptosis were assessed in
   HCC in vitro and in vivo. circARNT2 was significantly upregulated in HCC
   tissues and cell lines. Overexpression of circARNT2 in HCC was
   significantly correlated with aggressive characteristics and served as
   an independent risk factor for overall survival in patients with HCC. In
   vitro experiments showed that knockdown of circARNT2 inhibited cell
   proliferation and enhances the cisplatin sensitivity of HCC cells.
   Furthermore, circARNT2 facilitates HCC progression in vivo. We
   demonstrated that circARNT2 acts as a sponge for miR-155-5p and verified
   that PDK1 is a novel target of miR-155-5p. In summary, our study
   demonstrated that circARNT2 modulates cisplatin resistance through
   miR-155-5p/PDK1 pathway. Our findings indicated that circARNT2 may serve
   as a promising therapeutic target for overcoming cisplatin resistance
   for HCC.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Wei, ZH (Corresponding Author), Youjiang Med Univ Nationalities, Dept Intervent Med, Affiliated Hosp, Baise 533000, Peoples R China.
   Meng, LZ (Corresponding Author), Youjiang Med Univ Nationalities, Ctr Syst Inflammat Res, Sch Preclin Med, Baise City 533000, Guangxi Provinc, Peoples R China.
   Li, Yueyong; Liang, Gencheng; Wu, Yingning; Jiang, Qiulan; Li, Longhua; Lin, Cheng; Wei, Zhonghen, Youjiang Med Univ Nationalities, Dept Intervent Med, Affiliated Hosp, Baise 533000, Peoples R China.
   Zhang, Yingjun, Hunan Univ Med, Dept Med Imageol, Huaihua 418000, Peoples R China.
   Zhang, Shuai, Guizhou Med Univ, Dept Intervent Radiol, Affiliated Hosp, Guiyang 550000, Peoples R China.
   Zhang, Shuai, Guizhou Med Univ, Dept Intervent Radiol, Affiliated Canc Hosp, Guiyang 550000, Peoples R China.
   Huang, Deyou; Li, Baosheng, Youjiang Med Univ Nationalities, Dept Radiol, Affiliated Hosp, Baise 533000, Peoples R China.
   Meng, Lingzhang, Youjiang Med Univ Nationalities, Ctr Syst Inflammat Res, Sch Preclin Med, Baise City 533000, Guangxi Provinc, Peoples R China.},
DOI = {10.1016/j.omtn.2020.08.037},
ISSN = {2162-2531},
Keywords-Plus = {CIRCULAR RNAS; PROMOTES; GROWTH},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {yougang1619@163.com
   lingzhang.meng@ymcn.edu.cn},
Affiliations = {Youjiang Medical University for Nationalities; Hunan University of
   Medicine; Guizhou Medical University; Guizhou Medical University;
   Youjiang Medical University for Nationalities; Youjiang Medical
   University for Nationalities},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81860320]; Guangxi
   Traditional Chinese Medicine and Ethnic Medicine {[}gzzc1576];
   Scientific Research and Technology Development Project of Baise City,
   Guangxi {[}20120113]},
Funding-Text = {This project was funded by National Natural Science Foundation of China
   81860320, Guangxi Traditional Chinese Medicine and Ethnic Medicine
   SelfFunded Research Project gzzc1576, and Scientific Research and
   Technology Development Project of Baise City, Guangxi 20120113. We have
   received consent from individual patients who have participated in this
   study. The consent forms will be provided upon request.},
Cited-References = {Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Chan AWH, 2018, J HEPATOL, V69, P1284, DOI 10.1016/j.jhep.2018.08.027.
   El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090.
   El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683.
   Fu LY, 2018, CANCER MED-US, V7, P3101, DOI 10.1002/cam4.1574.
   Fu LY, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22239.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020.
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993.
   Harlan LC, 2015, LIVER CANCER, V4, P70, DOI 10.1159/000367729.
   Huang XY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1529-9.
   Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890.
   Kalyan A, 2015, CLIN LIVER DIS, V19, P421, DOI 10.1016/j.cld.2015.01.009.
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811.
   Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82.
   Li Z, 2019, CANCER SCI, V110, P3630, DOI 10.1111/cas.14211.
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928.
   Qiu LP, 2018, J CANCER, V9, P1548, DOI 10.7150/jca.24566.
   Shen YC, 2013, LIVER CANCER, V2, P345, DOI 10.1159/000343850.
   Wang M, 2018, CANCERS, V10, DOI 10.3390/cancers10080258.
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071.
   Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100.
   Yao T, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22572.
   Zhang HY, 2019, ONCOGENE, V38, P2844, DOI 10.1038/s41388-018-0619-z.
   Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215.},
Number-of-Cited-References = {25},
Times-Cited = {47},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Mol. Ther. Nucl. Acids},
Doc-Delivery-Number = {RB1DZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000631858200006},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000635182200008,
Author = {Nielsen, Marlene L. and Lildballe, Dorte L. and Rasmussen, Maria and
   Bojesen, Anders and Birn, Henrik and Sunde, Lone},
Title = {Clinical genetic diagnostics in Danish autosomal dominant polycystic
   kidney disease patients reveal possible founder variants},
Journal = {EUROPEAN JOURNAL OF MEDICAL GENETICS},
Year = {2021},
Volume = {64},
Number = {4},
Month = {APR},
Abstract = {Background: Autosomal dominant polycystic kidney disease (ADPKD) is the
   most common heritable kidney disease. ADPKD leads to cysts, kidney
   enlargement and end-stage renal disease. ADPKD is mainly caused by
   variants in PKD1 and PKD2, with truncating PKD1 variants causing the
   most severe phenotype. This study aimed to characterize variants in
   Danish patients referred for screening of genes related to cystic kidney
   disease. Methods: 147 families were analysed for variants in PKD1, PKD2
   and GANAB using next generation sequencing and multiplex
   ligation-dependent probe amplification. If a variant was identified,
   relatives were analysed for the specific variant using Sanger
   sequencing. Results: A pathogenic or possibly pathogenic variant was
   identified in 87\% (103/118) of patients suspected to suffer from ADPKD,
   according to the requisition form. In total, 112 pathogenic or possibly
   pathogenic variants were observed, of which 94 were unique; 74 (79\%) in
   PKD1 and 20 (21\%) in PKD2, while 41 variants were novel. No variants in
   GANAB were observed. Ten recurrent variants were observed in 26 (26\%)
   families. These were either PKD2 variants (N = 6) or non-truncating PKD1
   variants (N = 4). Five of these were likely founder variants.
   Conclusions: The distribution of pathogenic or possibly pathogenic
   variants in the Danish ADPKD population is similar to that in other
   populations, except that recurrent truncating PKD1 variants appear to be
   rare, i.e. founder variants tend to be variant types associated with a
   mild phenotype. Patients with a mild phenotype may remain undiagnosed,
   consequently the frequency of founder variants and prevalence of ADPKD
   may be underestimated.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Nielsen, ML (Corresponding Author), Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 3, DK-8000 Aarhus C, Denmark.
   Nielsen, Marlene L.; Birn, Henrik; Sunde, Lone, Aarhus Univ, Dept Biomed, Wilhelm Meyers Alle 3, DK-8000 Aarhus C, Denmark.
   Nielsen, Marlene L.; Bojesen, Anders, Aarhus Univ Hosp, Dept Clin Genet, Brendstrupgaardsvej 21C, DK-8200 Aarhus N, Denmark.
   Lildballe, Dorte L.; Rasmussen, Maria, Univ Hosp Southern Denmark, Lillebaelt Hosp, Dept Clin Genet, Beriderbakken 4, DK-7100 Vejle, Denmark.
   Rasmussen, Maria, Univ Southern Denmark, Dept Reg Hlth Res, Winloewsparken 19,3, DK-5000 Odense C, Denmark.
   Birn, Henrik, Aarhus Univ Hosp, Dept Nephrol, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
   Sunde, Lone, Aalborg Univ Hosp, Dept Clin Genet, Ladegaardsgade 5, DK-9000 Aalborg C, Denmark.},
DOI = {10.1016/j.ejmg.2021.104183},
EarlyAccessDate = {MAR 2021},
Article-Number = {104183},
ISSN = {1769-7212},
EISSN = {1878-0849},
Keywords = {ADPKD; Founder variants; Recurrent variants; Targeted NGS; Variant
   classification},
Research-Areas = {Genetics \& Heredity},
Web-of-Science-Categories  = {Genetics \& Heredity},
Author-Email = {marlene.n@biomed.au.dk},
Affiliations = {Aarhus University; Aarhus University; University of Southern Denmark;
   Lillebaelt Hospital; University of Southern Denmark; Aarhus University;
   Aalborg University},
ResearcherID-Numbers = {Birn, Henrik/C-3931-2009
   Sunde, Lone/AAG-7303-2019
   Bojesen, Anders/G-6308-2010},
ORCID-Numbers = {Birn, Henrik/0000-0003-3715-7266
   Lildballe, Dorte/0000-0003-0223-1673
   Rasmussen, Maria/0000-0003-1635-819X
   Nielsen, Marlene/0000-0001-8589-3167
   Sunde, Lone/0000-0002-8479-165X
   },
Funding-Acknowledgement = {Vanforefonden; Cand. Jur. Torkil Steenbecks Grant; Danish Kidney
   Association; Danish Society of Nephrology; Central Denmark Region},
Funding-Text = {This work was supported by Vanforefonden, Cand. Jur. Torkil Steenbecks
   Grant, Independent order of Odd Fellows nr. 73 Svend Faelding, Karen
   Elise Jensen, Danish Kidney Association, Danish Society of Nephrology,
   and Central Denmark Region.},
Cited-References = {Audrézet MP, 2012, HUM MUTAT, V33, P1239, DOI 10.1002/humu.22103.
   Carrera P, 2016, SCI REP-UK, V6, DOI 10.1038/srep30850.
   Chen JM, 2010, SEMIN CANCER BIOL, V20, P222, DOI 10.1016/j.semcancer.2010.05.007.
   Cornec-Le Gall E, 2018, AM J HUM GENET, V102, P832, DOI 10.1016/j.ajhg.2018.03.013.
   Cornec-Le Gall E, 2014, HUM MUTAT, V35, P1393, DOI 10.1002/humu.22708.
   DALGAARD O Z, 1957, Dan Med Bull, V4, P128.
   Eggermann T, 2006, J MED GENET, V43, P615, DOI 10.1136/jmg.2005.038687.
   Harris PC, 2014, J CLIN INVEST, V124, P2315, DOI 10.1172/JCI72272.
   Heyer CM, 2016, J AM SOC NEPHROL, V27, P2872, DOI 10.1681/ASN.2015050583.
   Hwang YH, 2016, J AM SOC NEPHROL, V27, P1861, DOI 10.1681/ASN.2015060648.
   Kopanos C, 2019, BIOINFORMATICS, V35, P1978, DOI 10.1093/bioinformatics/bty897.
   Lohmueller KE, 2013, AM J HUM GENET, V93, P1072, DOI 10.1016/j.ajhg.2013.11.005.
   Paul BM, 2014, WIRES DEV BIOL, V3, P465, DOI 10.1002/wdev.152.
   Porath B, 2016, AM J HUM GENET, V98, P1193, DOI 10.1016/j.ajhg.2016.05.004.
   RAVINE D, 1994, LANCET, V343, P824, DOI 10.1016/S0140-6736(94)92026-5.
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30.
   Rossetti S, 2001, AM J HUM GENET, V68, P46, DOI 10.1086/316939.
   Rossetti S, 2007, J AM SOC NEPHROL, V18, P2143, DOI 10.1681/ASN.2006121387.
   Rossetti S, 2009, KIDNEY INT, V75, P848, DOI 10.1038/ki.2008.686.
   Solazzo A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190430.
   Stenson PD, 2003, HUM MUTAT, V21, P577, DOI 10.1002/humu.10212.
   Torres VE, 2009, KIDNEY INT, V76, P149, DOI 10.1038/ki.2009.128.},
Number-of-Cited-References = {22},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {Eur. J. Med. Genet.},
Doc-Delivery-Number = {RF9TZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000635182200008},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000629156300001,
Author = {Padder, Rayees Ahmad and Bhat, Zafar Iqbal and Ahmad, Zaki and Singh,
   Neetu and Husain, Mohammad},
Title = {DRP1 Promotes BRAFV600E-Driven Tumor Progression and
   Metabolic Reprogramming in Colorectal Cancer},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2021},
Volume = {10},
Month = {MAR 2},
Abstract = {Background
   Mitochondria are highly dynamic organelles which remain in a continuous
   state of fission/ fusion dynamics to meet the metabolic needs of a cell.
   However, this fission/fusion dynamism has been reported to be
   dysregulated in most cancers. Such enhanced mitochondrial fission is
   demonstrated to be positively regulated by some activating oncogenic
   mutations; such as those of KRAS (Kristen rat sarcoma viral oncogene
   homologue) or BRAF (B- rapidly accelerated fibrosarcoma), thereby
   increasing tumor progression/ chemotherapeutic resistance and metabolic
   deregulation. However, the underlying mechanism(s) are still not clear,
   thus highlighting the need to further explore possible mechanism(s) of
   intervention. We sought to investigate how BRAF(V600E) driven CRC
   (colorectal cancer) progression is linked to mitochondrial
   fission/fusion dynamics and whether this window could be exploited to
   target CRC progression.
   Methods
   Western blotting was employed to study the differences in expression
   levels of key proteins regulating mitochondrial dynamics, which was
   further confirmed by confocal microscopy imaging of mitochondria in
   endogenously expressing BRAF(WT) and BRAF(V600E) CRC cells.
   Proliferation assays, soft agar clonogenic assays, glucose
   uptake/lactate production, ATP/ NADPH measurement assays were employed
   to study the extent of carcinogenesis and metabolic reprograming in
   BRAF(V600E) CRC cells. Genetic knockdown (shRNA/ siRNA) and/or
   pharmacologic inhibition of Dynamin related protein1/Pyruvate
   dehydrogenase kinase1 (DRP1/PDK1) and/or BRAF(V600E) were employed to
   study the involvement and possible mechanism of these proteins in
   BRAF(V600E) driven CRC. Statistical analyses were carried out using
   Graph Pad Prism v 5.0, data was analyzed by unpaired t-test and two-way
   ANOVA with appropriate post hoc tests.
   Results
   Our results demonstrate that BRAF(V600E) CRC cells have higher protein
   levels of mitochondrial fission factor- DRP1/pDRP1(S616) leading to a
   more fragmented mitochondrial state compared to those harboring BRAF(WT)
   . This fragmented mitochondrial state was found to confer glycolytic
   phenotype, clonogenic potential and metastatic advantage to cells
   harboring BRAF(V600E) . Interestingly, such fragmented mitochondrial
   state seemed positively regulated by mitochondrial PDK1 as observed
   through pharmacologic as well as genetic inhibition of PDK1.
   Conclusion
   In conclusion, our data suggest that BRAF(V600E) driven colorectal
   cancers have fragmented mitochondria which confers glycolytic phenotype
   and growth advantage to these tumors, and such phenotype is dependent at
   least in part on PDK1- thus highlighting a potential therapeutic target.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Husain, M (Corresponding Author), Jamia Millia Islamia, Dept Biotechnol, 409 Canc Biol Lab, New Delhi, India.
   Padder, Rayees Ahmad; Ahmad, Zaki; Husain, Mohammad, Jamia Millia Islamia, Dept Biotechnol, 409 Canc Biol Lab, New Delhi, India.
   Bhat, Zafar Iqbal, Devi Ahilya Vishwavidyalaya, Dept Zool, PMB Gujrati Sci Coll, Indore, India.
   Singh, Neetu, Jawaharlal Nehru Univ, Adv Instrumentat Res Facil, New Delhi, India.},
DOI = {10.3389/fonc.2020.592130},
Article-Number = {592130},
ISSN = {2234-943X},
Keywords = {BRAF(V600E); DRP1; mitochondrial dynamics; metabolic reprogramming;
   colorectal cancer},
Keywords-Plus = {MITOCHONDRIAL DYNAMICS; APOPTOSIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {mhusain2@jmi.ac.in},
Affiliations = {Jamia Millia Islamia; Devi Ahilya University; Jawaharlal Nehru
   University, New Delhi},
ResearcherID-Numbers = {Rayees, Rayees Padder/G-4701-2016
   },
ORCID-Numbers = {Rayees, Rayees Padder/0000-0002-7159-9036
   Husain, Mohammad/0000-0003-3876-8181},
Funding-Acknowledgement = {Ministry of AYUSH, Government of India {[}3-7/2009-CCRUM/EMR]; Indian
   Council of Medical Research (ICMR) {[}3/2/2/356/2016/NCDIII]},
Funding-Text = {The research received no external funding support; however, some support
   was utilized from other extra mural funding grant of MH (Ministry of
   AYUSH, Government of India grant no. 3-7/2009-CCRUM/EMR). The Indian
   Council of Medical Research (ICMR) is highly acknowledged for providing
   fellowship (ICMRSRF; 3/2/2/356/2016/NCDIII) to RP.},
Cited-References = {Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Bordi M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00081.
   Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Bylsma LC, 2020, CANCER MED-US, V9, P1044, DOI 10.1002/cam4.2747.
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004.
   Chan DC, 2020, ANNU REV PATHOL-MECH, V15, P235, DOI 10.1146/annurev-pathmechdis-012419-032711.
   Chen KH, 2014, FASEB J, V28, P382, DOI 10.1096/fj.13-230037.
   Cho SJ, 2018, CLIN CANCER RES, V24, P6556, DOI 10.1158/1078-0432.CCR-17-1679.
   Dasgupta S, 2018, NATURE, V556, P249, DOI 10.1038/s41586-018-0018-1.
   Desmoulins L, 2019, MOL METAB, V20, P166, DOI 10.1016/j.molmet.2018.11.007.
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Ferretta A, 2016, BBA-MOL CELL RES, V1863, P2710, DOI 10.1016/j.bbamcr.2016.08.007.
   Gabriel AM, 2009, INT J BIOCHEM CELL B, V41, P2062, DOI 10.1016/j.biocel.2009.02.002.
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Haq R, 2014, CLIN CANCER RES, V20, P2257, DOI 10.1158/1078-0432.CCR-13-0898.
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Huang SB, 2010, MOL CANCER THER, V9, P742, DOI 10.1158/1535-7163.MCT-09-1004.
   Hutton JE, 2016, MOL CELL PROTEOMICS, V15, P2924, DOI 10.1074/mcp.M116.058925.
   Inoue-Yamauchi A, 2012, BIOCHEM BIOPH RES CO, V421, P81, DOI 10.1016/j.bbrc.2012.03.118.
   Kashatus DF, 2011, NAT CELL BIOL, V13, P1108, DOI 10.1038/ncb2310.
   Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim YY, 2018, ACTA BIOCH BIOPH SIN, V50, P209, DOI 10.1093/abbs/gmx137.
   Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289.
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596.
   Lea IA, 2007, CARCINOGENESIS, V28, P1851, DOI 10.1093/carcin/bgm176.
   Lewis MR, 1914, SCIENCE, V39, P330, DOI 10.1126/science.39.1000.330.
   Li HJ, 2017, CELL PHYSIOL BIOCHEM, V44, P2073, DOI 10.1159/000485946.
   Liesa M, 2013, CELL METAB, V17, P491, DOI 10.1016/j.cmet.2013.03.002.
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906.
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392.
   Liu L, 2016, NAT CHEM BIOL, V12, P345, DOI {[}10.1038/NCHEMBIO.2047, 10.1038/nchembio.2047].
   Lo RS, 2012, CELL RES, V22, P945, DOI 10.1038/cr.2012.78.
   Ma JT, 2019, J CANCER, V10, P4045, DOI 10.7150/jca.29756.
   Margonis GA, 2018, JAMA SURG, V153, DOI 10.1001/jamasurg.2018.0996.
   Martinou JC, 2011, DEV CELL, V21, P92, DOI 10.1016/j.devcel.2011.06.017.
   Mitra K, 2013, BIOESSAYS, V35, P955, DOI 10.1002/bies.201300011.
   Nagdas S, 2019, CELL REP, V28, P1845, DOI 10.1016/j.celrep.2019.07.031.
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901.
   Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Picard M, 2016, MITOCHONDRION, V30, P105, DOI 10.1016/j.mito.2016.07.003.
   Qian W, 2012, J CELL SCI, V125, P5745, DOI 10.1242/jcs.109769.
   Ratnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198.
   Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543.
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690.
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Rolland SG, 2009, J CELL BIOL, V186, P525, DOI 10.1083/jcb.200905070.
   Roy M, 2015, CURR OPIN CELL BIOL, V33, P111, DOI 10.1016/j.ceb.2015.02.001.
   Scatena R, 2012, ADV EXP MED BIOL, V942, P287, DOI 10.1007/978-94-007-2869-1\_13.
   Sebastián D, 2018, CURR OPIN PHYSIOL, V3, P34, DOI 10.1016/j.cophys.2018.02.006.
   Senft D, 2016, CURR OPIN CELL BIOL, V39, P43, DOI 10.1016/j.ceb.2016.02.001.
   Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003.
   Sjöberg E, 2019, CLIN CANCER RES, V25, P3702, DOI 10.1158/1078-0432.CCR-18-1294.
   Thiel A, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00281.
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104.
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160.
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235.
   Vaquero J, 2017, J HEPATOL, V66, P424, DOI 10.1016/j.jhep.2016.09.010.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122.
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002.
   Wieder SY, 2015, J INVEST DERMATOL, V135, P2544, DOI 10.1038/jid.2015.196.
   Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972.
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697.
   Yu MF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126915.
   Zhang GE, 2013, INT J MOL SCI, V14, P13005, DOI 10.3390/ijms140713005.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.
   Zhang Z, 2020, BRIT J CANCER, V122, P209, DOI 10.1038/s41416-019-0658-4.
   Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494.
   Zinecker H, 2017, ONCOTARGET, V8, P106764, DOI 10.18632/oncotarget.22264.},
Number-of-Cited-References = {82},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {QX2CU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000629156300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000612859500001,
Author = {Gao, Lu and Li, Jun and He, Junyu and Liang, Lin and He, Zhengxi and
   Yue, Chunxue and Jin, Xi and Luo, Gengqiu and Zhou, Yanhong},
Title = {CD90 affects the biological behavior and energy metabolism level of
   gastric cancer cells by targeting the PI3K/AKT/HIF-1α signaling pathway},
Journal = {ONCOLOGY LETTERS},
Year = {2021},
Volume = {21},
Number = {3},
Month = {MAR},
Abstract = {CD90, also known as Thy-1 cell surface antigen, is located on human
   chromosome 11q23.3, and encodes a glycosylphosphatidylinositol-linked
   cell surface glycoprotein. CD90 serves a key role in malignancy by
   regulating cell proliferation, metastasis and angiogenesis. Gastric
   cancer is one of the most common types of malignancy. Patients with
   advanced gastric cancer have a poor prognosis. CD90 plays a key role in
   the occurrence and progression of gastric cancer. However, the molecular
   mechanism of CD90 in gastric cancer is currently unclear. In order to
   identify the molecular mechanism by which CD90 affects the biological
   behavior and energy metabolism of gastric cancer cells, the present
   study used Cell Counting Kit-8 assays, lactate concentration
   determination and ATP content determination. The results demonstrated
   that CD90 promotes proliferation and inhibits senescence in gastric
   cancer cells. In addition, CD90 enhanced the invasion and migration
   abilities of AGS gastric cancer cells. Overexpression of CD90 resulted
   in the accumulation of intracellular lactic acid in AGS cells. CD90
   upregulated lactate dehydrogenase levels and increased the NADPH/NADP(+)
   ratio in AGS cells. CD90 overexpression decreased the ATP concentration
   in AGS cells. PI3K, PDK1, phosphorylated-AKT-Ser473, HIF-1 alpha, MDM2
   and SIRT1 levels were upregulated in CD90-overexpressing AGS cells,
   compared with AGS cells transfected with the empty vector. In contrast,
   PTEN, p53, SIRT2, SIRT3 and SIRT6 were downregulated. The results
   indicate that CD90 affects the biological behavior and levels of energy
   metabolism of gastric cancer cells by targeting the PI3K/AKT/HIF-1 alpha
   signaling pathway.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Zhou, YH (Corresponding Author), Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
   Zhou, YH (Corresponding Author), Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
   Luo, GQ (Corresponding Author), Cent South Univ, Basic Sch Med, Xiangya Hosp, Dept Pathol, 88 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
   Gao, Lu; He, Zhengxi; Zhou, Yanhong, Cent South Univ, Xiangya Sch Med, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
   Gao, Lu; He, Zhengxi; Zhou, Yanhong, Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
   Gao, Lu; He, Junyu; Liang, Lin; Yue, Chunxue; Jin, Xi; Zhou, Yanhong, Cent South Univ, Basic Sch Med, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.
   Li, Jun, Cent South Univ, Xiangya Hosp, Dept Nursing, Changsha 410008, Hunan, Peoples R China.
   Luo, Gengqiu, Cent South Univ, Basic Sch Med, Xiangya Hosp, Dept Pathol, 88 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.},
DOI = {10.3892/ol.2021.12451},
Article-Number = {191},
ISSN = {1792-1074},
EISSN = {1792-1082},
Keywords = {CD90; gastric cancer; proliferation; energy metabolism; PI3K},
Keywords-Plus = {OXIDATIVE STRESS; LACTATE; DEHYDROGENASE; METASTASIS; MIGRATION;
   PI3K/AKT; HYPOXIA; TISSUES; ROLES; GENE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {luogengqiu@csu.edu.cn
   zhouyanhong@csu.edu.cn},
Affiliations = {Central South University; Central South University; Central South
   University; Central South University; Central South University},
Funding-Acknowledgement = {National Natural Sciences Foundation of China {[}81672685]; Science and
   Technology Foundation Survey Project of Ministry of Science and
   Technology of China {[}2018FY100900, 2018FY10090004]},
Funding-Text = {The present study was supported by the National Natural Sciences
   Foundation of China (grant no. 81672685) and the Science and Technology
   Foundation Survey Project of Ministry of Science and Technology of China
   (grant nos. 2018FY100900 and 2018FY10090004).},
Cited-References = {Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71.
   Alvarez A, 2016, BBA-MOL CELL RES, V1863, P2175, DOI 10.1016/j.bbamcr.2016.05.018.
   {[}Anonymous], 1994, IARC MONOGRAPHS EVAL, V61, P177.
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480.
   Baumann F, 2009, NEURO-ONCOLOGY, V11, P368, DOI 10.1215/15228517-2008-106.
   Bringman-Rodenbarger LR, 2018, ANTIOXID REDOX SIGN, V28, P677, DOI 10.1089/ars.2017.7264.
   Buglioni S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1457602.
   Cai Z, 2010, MOL CELL PROTEOMICS, V9, P2617, DOI 10.1074/mcp.M110.000661.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Choi SYC, 2018, CANCER MED-US, V7, P3385, DOI 10.1002/cam4.1587.
   Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531.
   De Matteis S, 2017, DIGEST DIS SCI, V62, P1872, DOI 10.1007/s10620-017-4615-x.
   Devignes CS, 2018, P NATL ACAD SCI USA, V115, pE992, DOI 10.1073/pnas.1718009115.
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fang W G, 2017, Beijing Da Xue Xue Bao Yi Xue Ban, V49, P188.
   He JY, 2015, INT J ONCOL, V47, P1725, DOI 10.3892/ijo.2015.3146.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hu LP, 2019, CLIN CANCER RES, V25, P1318, DOI 10.1158/1078-0432.CCR-18-2297.
   Jemal A, 2010, CA-CANCER J CLIN, V60, P300, DOI 10.3322/caac.20073.
   Jeng CJ, 1998, J CELL BIOL, V140, P685, DOI 10.1083/jcb.140.3.685.
   Jin EH, 2018, INT J MED SCI, V15, P1329, DOI 10.7150/ijms.26881.
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308.
   Kawamura K, 2013, AM J CLIN PATHOL, V140, P544, DOI 10.1309/AJCPM2Z4NGIIPBGE.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Kumar A, 2016, TUMOR BIOL, V37, P11611, DOI 10.1007/s13277-016-5112-0.
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107.
   Liao S, 2014, ONCOL REP, V32, P2703, DOI 10.3892/or.2014.3537.
   Lu JW, 2011, ACTA HISTOCHEM, V113, P833, DOI 10.1016/j.acthis.2011.01.001.
   Lung HL, 2010, INT J CANCER, V127, P304, DOI 10.1002/ijc.25047.
   Ma B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08618-y.
   Malfertheiner P, 2018, NEW ENGL J MED, V378, P1154, DOI 10.1056/NEJMe1800147.
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P113, DOI 10.1038/nrclinonc.2017.1.
   Matsuoka T, 2014, CANCERS, V6, P1441, DOI 10.3390/cancers6031441.
   Ohashi T, 2017, CANCER SCI, V108, P1128, DOI 10.1111/cas.13244.
   Pirozzi G, 2013, ONCOL REP, V29, P1763, DOI 10.3892/or.2013.2294.
   Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726.
   Pormohammad A, 2018, MICROB PATHOGENESIS, V118, P214, DOI 10.1016/j.micpath.2018.03.004.
   Sáenz-de-Santa-María I, 2017, ONCOTARGET, V8, P13730, DOI 10.18632/oncotarget.14629.
   Sambrook Joseph, 2006, CSH Protoc, V2006, DOI 10.1101/pdb.prot4022.
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447.
   Shaikh MV, 2016, CANCER BIOMARK, V16, P301, DOI 10.3233/CBM-160590.
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138.
   Song H, 2011, ONCOL REP, V26, P431, DOI 10.3892/or.2011.1302.
   Takai E, 2012, J CELL SCI, V125, P5051, DOI 10.1242/jcs.104976.
   Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991.
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2.
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039.
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002.
   WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230.
   Wang HL, 2019, J CELL BIOCHEM, V120, P3447, DOI 10.1002/jcb.27618.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Warburg OH, 2010, CLIN ORTHOP RELAT R, V468, P2833, DOI 10.1007/s11999-010-1534-y.
   Wu H, 2010, ANAL BIOANAL CHEM, V396, P1385, DOI 10.1007/s00216-009-3317-4.
   Yao H, 2018, BIOMED PHARMACOTHER, V107, P1712, DOI 10.1016/j.biopha.2018.08.119.
   Yokota H, 2007, J MAGN RESON IMAGING, V25, P992, DOI 10.1002/jmri.20902.
   Yuan LW, 2016, WORLD J GASTROENTERO, V22, P2046, DOI 10.3748/wjg.v22.i6.2046.
   Zhu GC, 2015, ONCOL REP, V34, P2497, DOI 10.3892/or.2015.4243.
   Zhu JH, 2014, PLOS ONE, V9, DOI {[}10.1371/journal.pone.0115507, 10.1371/journal.pone.0097616].},
Number-of-Cited-References = {59},
Times-Cited = {14},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Oncol. Lett.},
Doc-Delivery-Number = {PZ6OP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000612859500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000612862000001,
Author = {Raina, Ritu and Pramodh, Sreepoorna and Rais, Naushad and Haque, Shafiul
   and Shafarin, Jasmin and Bajbouj, Khuloud and Hamad, Mawieh and Hussain,
   Arif},
Title = {Luteolin inhibits proliferation, triggers apoptosis and modulates
   Akt/mTOR and MAP kinase pathways in HeLa cells},
Journal = {ONCOLOGY LETTERS},
Year = {2021},
Volume = {21},
Number = {3},
Month = {MAR},
Abstract = {Flavonoids, a subclass of polyphenols, have been shown to be effective
   against several types of cancer, by decreasing proliferation and
   inducing apoptosis. Therefore, the aim of the present study was to
   assess the anti-carcinogenic potential of luteolin on HeLa human
   cervical cancer cells, through the use of a cell viability assay, DNA
   fragmentation assay, mitochondrial membrane potential assay, cell cycle
   analysis using Annexin/PI staining and flow cytometry, gene expression
   analysis and a protein profiling array. Luteolin treatment exhibited
   cytotoxicity towards HeLa cells in a dose- and time-dependent manner,
   and its anti-proliferative properties were confirmed by accumulation of
   luteolin-treated cells in sub-G(1) phases. Cytotoxicity induced by
   luteolin treatment resulted in apoptosis, which was mediated through
   depolarization of the mitochondrial membrane potential and DNA
   fragmentation. Furthermore, luteolin treatment increased the expression
   of various proapoptotic genes, including APAF1, BAX, BAD, BID, BOK,
   BAK1, TRADD, FADD, FAS, and Caspases 3 and 9, whereas the expression of
   anti-apoptotic genes, including NAIP, MCL-1 and BCL-2, was decreased.
   Cell cycle regulatory genes, including CCND1, 2 and 3, CCNE2, CDKN1A,
   CDKN2B, CDK4 and CDK2, were decreased following treatment. Expression of
   TRAILR2/DR5, TRAILR1/DR4, Fas/TNFRSF6/CD95 and TNFR1/TNFRSF1A, as well
   as pro-apoptotic proteins, including BAD, BAX and Cytochrome C were
   consistently increased, and the expression of antiapoptotic proteins,
   HIF1 alpha, BCL-X, MCL1 and BCL2, were found to be decreased following
   treatment. Expression of AKT1 and 2, ELK1, PIK3C2A, PIK3C2B, MAPK14,
   MAP3K5, MAPK3 and MAPK1 was significantly decreased at the
   transcriptional level. Expression of GSK3b (p-ser9), PRAS 40
   (p-Ther246), BAD (p-ser112), PTEN (p-ser380), AKT (p-ser473), ERK2
   (p-Y185/Y187), RISK2 (p-ser386), P70S6k (p-Thr421/ser424),
   PDK1(p-ser241), ERK1 (p-T202/Y204) and MTOR (p-ser2448) was
   downregulated and expression of P53 (p-ser241) and P27(p-Thr198) was
   upregulated by luteolin in a dose-dependent manner, indicating its
   anti-proliferative and apoptosis enabling properties, and this may have
   been mediated via inhibition of the AKT and the MAPK pathways.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Hussain, A (Corresponding Author), Manipal Acad Higher Educ, Sch Life Sci, Block A,POB 345050, Dubai, U Arab Emirates.
   Pramodh, S (Corresponding Author), Zayed Univ, Dept Life \& Environm Sci, Coll Nat \& Hlth Sci, POB 19282, Dubai, U Arab Emirates.
   Raina, Ritu; Rais, Naushad; Hussain, Arif, Manipal Acad Higher Educ, Sch Life Sci, Block A,POB 345050, Dubai, U Arab Emirates.
   Pramodh, Sreepoorna, Zayed Univ, Dept Life \& Environm Sci, Coll Nat \& Hlth Sci, POB 19282, Dubai, U Arab Emirates.
   Haque, Shafiul, Jazan Univ, Coll Nursing \& Allied Hlth Sci, Res \& Sci Studies Unit, Jazan 45142, Saudi Arabia.
   Shafarin, Jasmin; Bajbouj, Khuloud; Hamad, Mawieh, Univ Sharjah, Coll Med, Sharjah, U Arab Emirates.},
DOI = {10.3892/ol.2021.12452},
Article-Number = {192},
ISSN = {1792-1074},
EISSN = {1792-1082},
Keywords = {cancer; apoptosis; anticancer; chemoprevention; antiproliferation},
Keywords-Plus = {INTRINSIC SIGNALING PATHWAYS; BREAST-CANCER; CYCLE ARREST;
   TUMOR-SUPPRESSOR; SOLID TUMORS; ACTIVATION; FLAVONOIDS; CHRYSIN;
   CHEMOPREVENTION; METHYLATION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {sreepoorna.Unni@zu.ac.ae
   dr.arifhussain@yahoo.co.in},
Affiliations = {Zayed University; Jazan University; University of Sharjah},
ResearcherID-Numbers = {Haque, Shafiul/AAN-2946-2020
   },
ORCID-Numbers = {Pramodh, Sreepoorna/0000-0002-1478-338X
   Haque, Shafiul/0000-0002-2989-121X
   Bajbouj, Khuloud/0000-0001-7344-6095
   Raina, Ritu/0000-0002-1912-3073},
Funding-Acknowledgement = {Zayed University {[}R19056]; MAHE internal research grant
   {[}R\&DP/MUD/RL-06/2018]},
Funding-Text = {The present study was supported by the Zayed University (RIF grant no.
   R19056) and a MAHE internal research grant (grant no.
   R\&DP/MUD/RL-06/2018).},
Cited-References = {Abdal Dayem Ahmed, 2016, Nutrients, V8, DOI 10.3390/nu8090581.
   Abotaleb M, 2019, CANCERS, V11, DOI 10.3390/cancers11010028.
   Aggarwal R, 2015, BIOCHEMISTRY-MOSCOW+, V80, P972, DOI 10.1134/S0006297915080027.
   Aneknan P, 2014, ASIAN PAC J CANCER P, V15, P5071, DOI 10.7314/APJCP.2014.15.12.5071.
   Attoub S, 2011, EUR J PHARMACOL, V651, P18, DOI 10.1016/j.ejphar.2010.10.063.
   Badgujar NV, 2018, ASIAN PAC J TROP MED, V11, P666, DOI 10.4103/1995-7645.248338.
   Cao ZJ, 2017, CELL PHYSIOL BIOCHEM, V43, P1803, DOI 10.1159/000484066.
   Chen P, 2017, ONCOTARGET, V8, P27471, DOI 10.18632/oncotarget.15832.
   Costea T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123787.
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI {[}10.2217/epi.11.105, 10.2217/EPI.11.105].
   Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076.
   George VC, 2013, ASIAN PAC J CANCER P, V14, P631, DOI 10.7314/APJCP.2013.14.2.631.
   Gul-e-Saba, 2018, INT J RES PHARM SCI, V9.
   Ham S, 2014, ONCOL REP, V31, P2683, DOI 10.3892/or.2014.3157.
   Hu Chunping, 2012, Zhongguo Zhong Yao Za Zhi, V37, P1259.
   Huang LM, 2019, ONCOL LETT, V17, P3842, DOI 10.3892/ol.2019.10052.
   Hussain A, 2019, FLAVONES COMBAT CANC.
   Hussain A, 2013, ASIAN PAC J CANCER P, V14, P5855, DOI 10.7314/APJCP.2013.14.10.5855.
   Imran M, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108612.
   Islam S, 2000, BIOCHEM BIOPH RES CO, V270, P793, DOI 10.1006/bbrc.2000.2536.
   Khan MA, 2015, ONCOL REP, V33, P1976, DOI 10.3892/or.2015.3802.
   Khoo BY, 2010, INT J MOL SCI, V11, P2188, DOI 10.3390/ijms11052188.
   Ko JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122589.
   Koosha S, 2016, INT J MED SCI, V13, P374, DOI 10.7150/ijms.14485.
   Lee DH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/515901.
   Lennarz W.J., 2013, ENCY BIOL CHEM, V2nd.
   Li J, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00516.
   Lu XY, 2017, ONCOL LETT, V14, P1993, DOI 10.3892/ol.2017.6380.
   de Melo FHM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00644.
   Maru Girish B, 2016, World J Biol Chem, V7, P88, DOI {[}10.4331/wjbc.v7.i1.88, 10.4331/wjbc.v7.i1.88].
   Mary V, 2017, J CHEM INF MODEL, V57, P2237, DOI 10.1021/acs.jcim.6b00747.
   Masters JR, 2002, NAT REV CANCER, V2, P315, DOI 10.1038/nrc775.
   Masui K, 2013, CARCINOGENESIS, V34, P725, DOI 10.1093/carcin/bgt086.
   Meng GM, 2016, CHEM-BIOL INTERACT, V257, P26, DOI 10.1016/j.cbi.2016.07.028.
   Mocanu MM, 2015, MOLECULES, V20, P22578, DOI 10.3390/molecules201219864.
   Okkenhaug K, 2002, SCIENCE, V297, P1031.
   Park SH, 2014, J ENVIRON PATHOL TOX, V33, P219, DOI 10.1615/JEnvironPatholToxicolOncol.2014010923.
   Patterson SL, 2013, CLIN CHEM, V59, P94, DOI 10.1373/clinchem.2012.185389.
   Ren X, 2017, ONCOL LETT, V14, P6833, DOI 10.3892/ol.2017.7039.
   Ruan JS, 2012, MOL MED REP, V6, P232, DOI 10.3892/mmr.2012.884.
   Samarghandian S, 2014, ANTI-CANCER AGENT ME, V14, P901, DOI 10.2174/1871520614666140209144042.
   Sauter ER, 2018, EUR J BREAST HEALTH, V14, P64, DOI 10.5152/ejbh.2018.3978.
   Cardose MDS, 2017, MUTAT RES-REV MUTAT, V773, P161, DOI 10.1016/j.mrrev.2017.06.002.
   Shariffa K, 2018, U J SURG SURG SPEC, V4.
   Song KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.462.
   Srivastava S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24049.
   Sundaram MK, 2019, GENES-BASEL, V10, DOI 10.3390/genes10120955.
   Sundaram MK, 2019, BIOSCIENCE REP, V39, DOI {[}10.1042/BSR20190720, 10.1042/bsr20190720].
   Sur S, 2017, NUTRITION, V43-44, P8, DOI 10.1016/j.nut.2017.06.006.
   Theodoratou E, 2017, ANNU REV NUTR, V37, P293, DOI 10.1146/annurev-nutr-071715-051004.
   Tripathi K.D., 2013, Essentials of medical pharmacology.
   Tu LY, 2016, SCANNING, V38, P644, DOI 10.1002/sca.21312.
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128.
   Wang SP, 2013, EXPERT OPIN DRUG DEL, V10, P1411, DOI 10.1517/17425247.2013.807795.
   Wang SW, 2018, MOL CARCINOGEN, V57, P866, DOI 10.1002/mc.22807.
   Willett WC, 1995, ENVIRON HEALTH PERSP, V103, P165, DOI 10.2307/3432305.
   Wu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05467-z.
   Xue CY, 2016, ONCOL LETT, V12, P4813, DOI 10.3892/ol.2016.5251.
   You YJ, 2019, ONCOTARGETS THER, V12, P2383, DOI 10.2147/OTT.S191158.
   Yuan ZP, 2006, CLIN CANCER RES, V12, P3193, DOI 10.1158/1078-0432.CCR-05-2365.
   Zhang B, 2015, GENET MOL RES, V14, P6605, DOI 10.4238/2015.June.18.3.
   Zhang Y, 2018, EUR J MED CHEM, V147, P218, DOI 10.1016/j.ejmech.2018.01.084.
   Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515.},
Number-of-Cited-References = {63},
Times-Cited = {57},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Oncol. Lett.},
Doc-Delivery-Number = {PZ6PO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000612862000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000627337800001,
Author = {Goel, Yugal and Yadav, Saveg and Pandey, Shrish Kumar and Temre,
   Mithlesh Kumar and Maurya, Babu Nandan and Verma, Ashish and Kumar, Ajay
   and Singh, Sukh Mahendra},
Title = {Tumor Decelerating and Chemo-Potentiating Action of Methyl Jasmonate on
   a T Cell Lymphoma In Vivo: Role of Altered Regulation of
   Metabolism, Cell Survival, Drug Resistance, and Intratumoral Blood Flow},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2021},
Volume = {11},
Month = {FEB 25},
Abstract = {Methyl jasmonate (MJ), a natural oxylipin, possesses a broad spectrum of
   antineoplastic potential in vitro. However, its tumor growth impeding
   and chemo-potentiating action has not been adequately investigated in
   vivo. Using a murine thymus-derived tumor named Dalton's Lymphoma (DL),
   in the present study, we examined if intra-tumoral administration of MJ
   can cause tumor growth impedance. We also explored the associated
   molecular mechanisms governing cell survival, carbohydrate \& lipid
   metabolism, chemo-potentiation, and angiogenesis. MJ administration to
   tumor-transplanted mice caused deceleration of tumor growth accompanying
   prolonged survival of the tumor-bearing mice. MJ-dependent tumor growth
   retardation was associated with the declined blood supply in tumor
   milieu, cell cycle arrest, augmented induction of apoptosis and
   necrosis, deregulated glucose and lipid metabolism, enhanced membrane
   fragility of tumor cells, and altered cytokine repertoire in the tumor
   microenvironment. MJ administration modulated molecular network
   implicating Hsp70, Bcl-2, TERT, p53, Cyt c, BAX, GLUT-1, HK 2, LDH A,
   PDK-1, HIF-1 alpha, ROS, MCT-1, FASN, ACSS2, SREBP1c, VEGF, cytokine
   repertoire, and MDR1, involved in the regulation of cell survival,
   carbohydrate and fatty acid metabolism, pH homeostasis, and drug
   resistance. Thus, the present study unveils novel molecular mechanisms
   of the tumor growth decelerating action of MJ. Besides, this preclinical
   study also establishes the adjunct therapeutic potential of MJ. Hence,
   the present investigation will help to design novel anti-cancer
   therapeutic regimens for the treatment of hematological malignancies.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Singh, SM (Corresponding Author), Banaras Hindu Univ, Inst Sci, Sch Biotechnol, Varanasi, Uttar Pradesh, India.
   Goel, Yugal; Yadav, Saveg; Pandey, Shrish Kumar; Temre, Mithlesh Kumar; Singh, Sukh Mahendra, Banaras Hindu Univ, Inst Sci, Sch Biotechnol, Varanasi, Uttar Pradesh, India.
   Maurya, Babu Nandan; Verma, Ashish, Banaras Hindu Univ, Inst Med Sci, Dept Radiodiag \& Imaging, Varanasi, Uttar Pradesh, India.
   Kumar, Ajay, Banaras Hindu Univ, Inst Sci, Dept Zool, Varanasi, Uttar Pradesh, India.},
DOI = {10.3389/fonc.2021.619351},
Article-Number = {619351},
ISSN = {2234-943X},
Keywords = {methyl jasmonate; tumor growth impedance; cell survival and metabolic
   regulation; chemo-potentiation; intra-tumoral blood flow},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {smsinghbiotech@bhu.ac.in},
Affiliations = {Banaras Hindu University (BHU); Banaras Hindu University (BHU); Banaras
   Hindu University (BHU)},
ResearcherID-Numbers = {Yadav, Saveg/IXN-1209-2023
   Goel, Yugal/MFJ-7858-2025
   PANDEY, SHRISH KUMAR/AAC-8107-2021
   temre, mithlesh/PDW-9484-2025
   },
ORCID-Numbers = {Yadav, Saveg/0000-0001-8401-7894
   PANDEY, SHRISH KUMAR/0000-0002-3891-134X
   Temre, Mithlesh Kumar/0000-0002-1933-7004},
Funding-Acknowledgement = {ICMR, New Delhi {[}3/1/3/JRF-2016/LS/HRD-10(80666),
   3/1/3/JRF-2015(2)HRD]; CSIR, New Delhi {[}09/013(0577)/2015-EMR-I]; 
   {[}DBT/JRF/BET-18/I/2018/AL/154]},
Funding-Text = {We thankfully acknowledge fellowship support to YG {[}Award No.
   3/1/3/JRF-2016/LS/HRD-10(80666)] from ICMR, New Delhi, SY. {[}Award No.
   09/013(0577)/2015-EMR-I] from CSIR, New Delhi, SKP {[}Award No.
   3/1/3/JRF-2015(2)HRD] from ICMR, New Delhi, and MKT {[}Award No.
   DBT/JRF/BET-18/I/2018/AL/154]. Infrastructural support from DBT, New
   Delhi, ISLS, DST-PURSE program, and UGC-UPE, Banaras Hindu University,
   is acknowledged. The work contained in this manuscript is a component of
   the Ph.D. dissertation of YG.},
Cited-References = {Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010.
   Basingnaa A, 2019, DISEASES-BASEL, V7, DOI 10.3390/diseases7010002.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3.
   Brahimi-Horn MC, 2007, ESSAYS BIOCHEM, V43, P165, DOI 10.1042/bse0430165.
   Braverman J, 2016, J IMMUNOL, V197, P1287, DOI 10.4049/jimmunol.1600266.
   Campbell KJ, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180002.
   Cesari Italo Mario, 2014, Int J Cell Biol, V2014, P572097, DOI 10.1155/2014/572097.
   Chen JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098882.
   Choi K, 2010, CELL DEATH DIFFER, V17, P833, DOI 10.1038/cdd.2009.154.
   Ciccone V, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0975-0.
   Cohen S, 2009, PHYTOCHEMISTRY, V70, P1600, DOI 10.1016/j.phytochem.2009.06.007.
   Cook AD, 2003, J IMMUNOL, V171, P4816, DOI 10.4049/jimmunol.171.9.4816.
   Cui XG, 2017, ONCOTARGET, V8, P24840, DOI 10.18632/oncotarget.15266.
   da Silva RJ, 2002, MEDIAT INFLAMM, V11, P197, DOI 10.1080/0962935029000041.
   Dahmani A, 2018, CANCERS, V10, DOI 10.3390/cancers10060194.
   Das L, 2018, ANTI-CANCER AGENT ME, V18, P1779, DOI 10.2174/1871520618666180604093802.
   Del Bufalo D, 2005, CELL DEATH DIFFER, V12, P1429, DOI 10.1038/sj.cdd.4401670.
   DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299.
   Elena-Real CA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0408-1.
   Ezzeddini R, 2019, LIFE SCI, V224, P169, DOI 10.1016/j.lfs.2019.03.056.
   Fadus Matthew C, 2017, J Tradit Complement Med, V7, P339, DOI {[}10.1016/j.jtcme.2016.08.002, 10.1016/j.jtcme.2016.08.002].
   FELLER N, 1995, BRIT J CANCER, V72, P543, DOI 10.1038/bjc.1995.371.
   Frezza C, 2020, BRIT J CANCER, V122, P133, DOI 10.1038/s41416-019-0667-3.
   Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489.
   Garcia SN, 2019, CURR MED CHEM, V26, P7285, DOI 10.2174/0929867326666181213092652.
   Gewies A, 2000, CANCER RES, V60, P2163.
   GOLDIE H, 1951, CANCER RES, V11, P73.
   Goldin N, 2008, ONCOGENE, V27, P4636, DOI 10.1038/onc.2008.108.
   Harris AL., 2019, OXFORD TXB CANC BIOL, P221.
   Jiang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.220.
   Kant S, 2014, BBA-GEN SUBJECTS, V1840, P294, DOI 10.1016/j.bbagen.2013.09.020.
   Kant S, 2012, BBA-GEN SUBJECTS, V1820, P1764, DOI 10.1016/j.bbagen.2012.07.010.
   Klippel S, 2012, BRIT J HAEMATOL, V159, P340, DOI 10.1111/j.1365-2141.2012.09253.x.
   Kumar A, 2013, ANTI-CANCER DRUG, V24, P158, DOI 10.1097/CAD.0b013e3283586743.
   Kumar A, 2012, CHEM-BIOL INTERACT, V199, P29, DOI 10.1016/j.cbi.2012.06.005.
   Lazarev VF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0160-y.
   Li JJ, 2017, ONCOTARGET, V8, P45965, DOI 10.18632/oncotarget.17469.
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Naeini MB, 2019, J CELL PHYSIOL, V234, P14743, DOI 10.1002/jcp.28262.
   Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238.
   Peng NN, 2016, AM J TRANSL RES, V8, P1005.
   Peng Z, 2017, MOL MED REP, V15, P957, DOI 10.3892/mmr.2016.6061.
   Pestana A, 2017, J MOL ENDOCRINOL, V58, pR129, DOI 10.1530/JME-16-0195.
   Pezzuto A, 2018, CURR MOL MED, V18, P343, DOI 10.2174/1566524018666181109121849.
   Raj Kumar K., 2017, Int. J. Immunother. Cancer Res, V3, P001, DOI {[}10.17352/2455-8591.000011, DOI 10.17352/2455-8591.000011].
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI {[}10.1016/j.cryobiol.2017.10.064, 10.1016/j.bbamcr.2016.09.012].
   Reischer D, 2007, BRIT J PHARMACOL, V150, P738, DOI 10.1038/sj.bjp.0707146.
   Rieger AM, 2011, JOVE-J VIS EXP, DOI 10.3791/2597.
   Samudrala PK, 2015, PHARMACOGN RES, V7, P66, DOI 10.4103/0974-8490.147211.
   Shen YQ, 2017, BIO-PROTOCOL, V7, DOI 10.21769/BioProtoc.2517.
   Shewry PR., 1995, METHODS PLANT BIOCH, V10, P101.
   Sucu BO, 2019, BIOORG CHEM, V91, DOI 10.1016/j.bioorg.2019.103146.
   van Harten AM, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0147-x.
   VERTOSICK FT, 1994, J NEURO-ONCOL, V19, P97, DOI 10.1007/BF01306450.
   Vishvakarma NK, 2011, BIOCHIMIE, V93, P1786, DOI 10.1016/j.biochi.2011.06.022.
   Wang M, 2011, EUR J PHARMACOL, V650, P41, DOI 10.1016/j.ejphar.2010.09.049.
   Wang Y, 2018, ONCOL LETT, V16, P1231, DOI 10.3892/ol.2018.8779.
   Yadav S, 2018, BIOMED PHARMACOTHER, V99, P970, DOI 10.1016/j.biopha.2018.01.149.
   Yadav S, 2018, TOXICOL APPL PHARM, V339, P52, DOI 10.1016/j.taap.2017.12.004.
   Yadav S, 2017, CHEM-BIOL INTERACT, V270, P73, DOI 10.1016/j.cbi.2017.04.015.
   Yeruva L, 2008, ANTI-CANCER DRUG, V19, P766, DOI 10.1097/CAD.0b013e32830b5894.
   Yi DD, 2019, CELL BIOL INT, V43, P12, DOI 10.1002/cbin.11071.
   Yousefi S, 2020, J BIOENERG BIOMEMBR, V52, P103, DOI 10.1007/s10863-019-09811-w.
   Yuan XT, 2019, ONCOGENE, V38, P6172, DOI 10.1038/s41388-019-0872-9.
   Zalba S, 2017, CANCER TREAT REV, V52, P48, DOI 10.1016/j.ctrv.2016.10.008.
   Zhang M, 2015, PLANT SIGNAL BEHAV, V10, DOI 10.1080/15592324.2015.1062199.
   Zhang MT, 2016, AM J CANCER RES, V6, P187.},
Number-of-Cited-References = {68},
Times-Cited = {12},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {QU5RE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000627337800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000626043200001,
Author = {Zentelyte, Aiste and Zukauskaite, Deimante and Jaceryte, Ieva and
   Borutinskaite, Veronika V. and Navakauskiene, Ruta},
Title = {Small Molecule Treatments Improve Differentiation Potential of Human
   Amniotic Fluid Stem Cells},
Journal = {FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY},
Year = {2021},
Volume = {9},
Month = {FEB 22},
Abstract = {Human amniotic fluid stem cells (AFSC) are an exciting and very
   promising source of stem cells for therapeutic applications. In this
   study we investigated the effects of short-term treatments of small
   molecules to improve stem cell properties and differentiation
   capability. For this purpose, we used epigenetically active compounds,
   such as histone deacetylase inhibitors Trichostatin A (TSA) and sodium
   butyrate (NaBut), as well as multifunctional molecules of natural
   origin, such as retinoic acid (RA) and vitamin C (vitC). We observed
   that combinations of these compounds triggered upregulation of genes
   involved in pluripotency (KLF4, OCT4, NOTCH1, SOX2, NANOG, LIN28a,
   CMYC), but expression changes of these proteins were mild with only
   significant downregulation of Notch1. Also, some alterations in cell
   surface marker expression was established by flow cytometry with the
   most explicit changes in the expression of CD105 and CD117. Analysis of
   cellular energetics performed using Seahorse analyzer and assessment of
   gene expression related to cell metabolism and respiration (NRF1, HIF1
   alpha, PPARGC1A, ERR alpha, PKM, PDK1, LDHA, NFKB1, NFKB2, RELA, RELB,
   REL) revealed that small molecule treatments stimulate AFSCs toward a
   more energetically active phenotype. To induce cells to differentiate
   toward neurogenic lineage several different protocols including
   commercial supplements N2 and B27 together with RA were used and
   compared to the same differentiation protocols with the addition of a
   pre-induction step consisting of a combination of small molecules (vitC,
   TSA and RA). During differentiation the expression of several neural
   marker genes was analyzed (Nestin, MAP2, TUBB3, ALDH1L1, GFAP, CACNA1D,
   KCNJ12, KCNJ2, KCNH2) and the beneficial effect of small molecule
   treatment on differentiation potential was observed with upregulated
   gene expression. Differentiation was also confirmed by staining TUBB3,
   NCAM1, and Vimentin and assessed by secretion of BDNF. The results of
   this study provide valuable insights for the potential use of short-term
   small molecule treatments to improve stem cell characteristics and boost
   differentiation potential of AFSCs.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Zentelyte, A (Corresponding Author), Vilnius Univ, Inst Biochem, Life Sci Ctr, Dept Mol Cell Biol, Vilnius, Lithuania.
   Zentelyte, Aiste; Zukauskaite, Deimante; Jaceryte, Ieva; Borutinskaite, Veronika V.; Navakauskiene, Ruta, Vilnius Univ, Inst Biochem, Life Sci Ctr, Dept Mol Cell Biol, Vilnius, Lithuania.},
DOI = {10.3389/fbioe.2021.623886},
Article-Number = {623886},
ISSN = {2296-4185},
Keywords = {amniotic fluid stem cells; neurogenic differentiation; small molecules;
   trichostatin A; vitamin C; retinoic acid},
Keywords-Plus = {RETINOIC ACID; SOMATIC-CELLS; 5-AZACYTIDINE; COMBINATION; METABOLISM;
   INDUCTION; ROLES},
Research-Areas = {Biotechnology \& Applied Microbiology; Engineering},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Engineering, Biomedical},
Author-Email = {aiste.zentelyte@bchi.vu.lt},
Affiliations = {Vilnius University},
ResearcherID-Numbers = {Žukauskaitė, Deimantė/NFS-6109-2025
   Borutinskaite, Veronika Viktorija/AAU-6531-2021
   Zentelytė, Aistė/NFS-4707-2025},
ORCID-Numbers = {Žukauskaitė, Deimantė/0000-0002-5608-7358
   Borutinskaite, Veronika Viktorija/0000-0001-6077-0136
   Zentelytė, Aistė/0000-0002-2707-7724},
Funding-Acknowledgement = {COST (European Cooperation in Science and Technology) {[}CA17116]},
Funding-Text = {We thank Natalija Krasovskaja (Vilnius University, Faculty of Medicine)
   for providing samples of human amniotic fluid and Veronika Dedonyte
   (Vilnius University, Life Sciences Center) for assistance in karyotype
   analysis. We acknowledge the COST Action CA17116 International Network
   for Translating Research on Perinatal Derivatives into Therapeutic
   Approaches (SPRINT), supported by COST (European Cooperation in Science
   and Technology) for the development of ideas and valuable discussions in
   scientific research in the field of perinatal derivatives.},
Cited-References = {Alessio N, 2018, J CELL PHYSIOL, V233, P8996, DOI 10.1002/jcp.26845.
   Bakkar N, 2012, J CELL BIOL, V196, P497, DOI 10.1083/jcb.201108118.
   Baranek M, 2017, MOL BIOSYST, V13, P277, DOI 10.1039/c6mb00595k.
   Blaschke K, 2013, NATURE, V500, P222, DOI 10.1038/nature12362.
   Bonaventura G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140790.
   Bossolasco P, 2006, CELL RES, V16, P329, DOI 10.1038/sj.cr.7310043.
   Cacchiarelli D, 2015, CELL, V162, P412, DOI 10.1016/j.cell.2015.06.016.
   Cao Y, 2015, EMBO J, V34, P609, DOI 10.15252/embj.201490441.
   Chen YS, 2012, STEM CELL TRANSL MED, V1, P83, DOI 10.5966/sctm.2011-0022.
   Cipriano M, 2017, ARCH TOXICOL, V91, P2469, DOI 10.1007/s00204-016-1901-x.
   Da Sacco S, 2011, CURR OPIN ORGAN TRAN, V16, P101, DOI 10.1097/MOT.0b013e3283424f6e.
   De Angelis MT, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0028-1.
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274.
   Deng FX, 2016, CELL TISSUE BANK, V17, P147, DOI 10.1007/s10561-015-9514-9.
   Esteban MA, 2012, NAT GENET, V44, P366, DOI 10.1038/ng.2222.
   Esteban MA, 2010, CELL STEM CELL, V6, P71, DOI 10.1016/j.stem.2009.12.001.
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011.
   Han B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081781.
   Han JN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012297.
   Hore TA, 2016, P NATL ACAD SCI USA, V113, P12202, DOI 10.1073/pnas.1608679113.
   Hou PP, 2013, SCIENCE, V341, P651, DOI 10.1126/science.1239278.
   Huang PY, 2011, NATURE, V475, P386, DOI 10.1038/nature10116.
   Huangfu DW, 2008, NAT BIOTECHNOL, V26, P795, DOI 10.1038/nbt1418.
   Janesick A, 2015, CELL MOL LIFE SCI, V72, P1559, DOI 10.1007/s00018-014-1815-9.
   Kalle AM, 2019, bioRxiv, DOI {[}10.1101/578062, 10.1101/578062, DOI 10.1101/578062].
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724.
   Kida YS, 2015, CELL STEM CELL, V16, P547, DOI 10.1016/j.stem.2015.03.001.
   Kim HJ, 2016, BIOTECHNOL LETT, V38, P167, DOI 10.1007/s10529-015-1949-3.
   Kim Y, 2020, EXP MOL MED, V52, P213.
   Kretsovali A, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/184154.
   Lathia JD, 2008, J NEUROCHEM, V107, P1471, DOI 10.1111/j.1471-4159.2008.05715.x.
   Ma XJ, 2017, PROTEIN CELL, V8, P328, DOI 10.1007/s13238-016-0362-6.
   Maioli M, 2013, DRUG DES DEV THER, V7, P1063, DOI 10.2147/DDDT.S44706.
   Mali P, 2010, STEM CELLS, V28, P713, DOI 10.1002/stem.402.
   Mark P, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/698076.
   Markmee R, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02018.
   Mauro C, 2011, NAT CELL BIOL, V13, P1272, DOI 10.1038/ncb2324.
   Na T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118168.
   Öz S, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku775.
   Pang YB, 2019, ONCOL LETT, V18, P4457, DOI 10.3892/ol.2019.10788.
   Panta W, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123016.
   Pourjafar M, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12315.
   Qin H, 2017, CELL MOL LIFE SCI, V74, P3553, DOI 10.1007/s00018-017-2586-x.
   Roubelakis MG, 2007, STEM CELLS DEV, V16, P931, DOI 10.1089/scd.2007.0036.
   Sarlak G, 2016, MOL NEUROBIOL, V53, P1679, DOI 10.1007/s12035-015-9123-4.
   Savickiene J, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/319238.
   Son MJ, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0185-z.
   Song Y, 2018, BIOCHEM BIOPH RES CO, V503, P352, DOI 10.1016/j.bbrc.2018.06.033.
   Stadtfeld M, 2012, NAT GENET, V44, P398, DOI 10.1038/ng.1110.
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024.
   Tsai MS, 2004, HUM REPROD, V19, P1450, DOI 10.1093/humrep/deh279.
   Wang W, 2011, P NATL ACAD SCI USA, V108, P18283, DOI 10.1073/pnas.1100893108.
   Xu GS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53007-6.
   Yan ZJ, 2013, CELL MOL NEUROBIOL, V33, P465, DOI 10.1007/s10571-013-9922-y.
   Yoshida Y, 2017, CIRC RES, V120, P1958, DOI 10.1161/CIRCRESAHA.117.311080.
   Zhang Y, 2012, J CELL SCI, V125, P5609, DOI 10.1242/jcs.096032.},
Number-of-Cited-References = {56},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Front. Bioeng. Biotechnol.},
Doc-Delivery-Number = {QS6YL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000626043200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000621088700001,
Author = {Sun, Zhen and Yao, Yingpeng and You, Menghao and Liu, Jingjing and Guo,
   Wenhui and Qi, Zhihong and Wang, Zhao and Wang, Fang and Yuan, Weiping
   and Yu, Shuyang},
Title = {The kinase PDK1 is critical for promoting T follicular helper cell
   differentiation},
Journal = {ELIFE},
Year = {2021},
Volume = {10},
Month = {FEB 17},
Abstract = {The kinase PDK1 is a crucial regulator for immune cell development by
   connecting PI3K to downstream AKT signaling. However, the roles of PDK1
   in CD4(+) T cell differentiation, especially in T follicular helper
   (Tfh) cell, remain obscure. Here we reported PDK1 intrinsically promotes
   the Tfh cell differentiation and germinal center responses upon acute
   infection by using conditional knockout mice. PDK1 deficiency in T cells
   caused severe defects in both early differentiation and late maintenance
   of Tfh cells. The expression of key Tfh regulators was remarkably
   downregulated in PDK1-deficient Tfh cells, including Tcf7, Bcl6, Icos,
   and Cxcr5. Mechanistically, ablation of PDK1 led to impaired
   phosphorylation of AKT and defective activation of mTORC1, resulting in
   substantially reduced expression of Hif1 alpha and p-STAT3. Meanwhile,
   decreased p-AKT also suppresses mTORC2-associated GSK3 beta activity in
   PDK1-deficient Tfh cells. These integrated effects contributed to the
   dramatical reduced expression of TCF1 and ultimately impaired the Tfh
   cell differentiation.},
Publisher = {eLIFE SCIENCES PUBL LTD},
Address = {SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yu, SY (Corresponding Author), China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China.
   Sun, Zhen; Yao, Yingpeng; You, Menghao; Liu, Jingjing; Guo, Wenhui; Qi, Zhihong; Wang, Zhao; Wang, Fang; Yu, Shuyang, China Agr Univ, Coll Biol Sci, State Key Lab Agrobiotechnol, Beijing, Peoples R China.
   Yuan, Weiping, Chinese Acad Med Sci \& Peking Union Med Coll, State Key Lab Expt Hematol, Inst Hematol \& Blood Dis Hosp, Tianjin, Peoples R China.
   Yuan, Weiping, Chinese Acad Med Sci \& Peking Union Med Coll, Ctr Stem Cell Med, Tianjin, Peoples R China.},
DOI = {10.7554/eLife.61406},
Article-Number = {e61406},
ISSN = {2050-084X},
Keywords-Plus = {ANTIGEN RECEPTOR; METABOLISM; GENERATION; RESPONSES; MTORC1; BCL6},
Research-Areas = {Life Sciences \& Biomedicine - Other Topics},
Web-of-Science-Categories  = {Biology},
Author-Email = {ysy@cau.edu.cn},
Affiliations = {China Agricultural University; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Peking Union Medical College; Institute of
   Hematology \& Blood Diseases Hospital - CAMS; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College},
ResearcherID-Numbers = {Qi, Zhihong/HIZ-8633-2022
   Wang, Fang/GLV-0025-2022
   Guo, Wenhui/KVB-4479-2024},
ORCID-Numbers = {You, Menghao/0000-0002-7394-0939
   Yu, Shuyang/0000-0002-4686-3296
   Liu, Jingjing/0000-0002-3266-7331
   Yao, Yingpeng/0000-0002-5415-2443
   Yuan, Weiping/0000-0001-8288-5022
   Wang, Fang/0000-0002-2604-4429
   Guo, Wenhui/0000-0002-9177-8568},
Funding-Acknowledgement = {National Key Research and Development Program of China
   {[}2017YFA0104401]; National Natural Science Foundation of China
   {[}31970831, 31630038, 31571522, 31422037, 81770105]; State Key
   Laboratory of Agrobiotechnology, China Agricultural University
   {[}2019SKLAB6-6, 2019SKLAB6-7, 2018SKLAB6-30]},
Funding-Text = {National Key Research and Development Program of China 2017YFA0104401
   Shuyang Yu National Natural Science Foundation of China 31970831 Shuyang
   Yu National Natural Science Foundation of China 31630038 Shuyang Yu
   National Natural Science Foundation of China 31571522 Shuyang Yu
   National Natural Science Foundation of China 31422037 Shuyang Yu
   National Natural Science Foundation of China 81770105 Weiping Yuan State
   Key Laboratory of Agrobiotechnology, China Agricultural University
   2019SKLAB6-6 Shuyang Yu State Key Laboratory of Agrobiotechnology, China
   Agricultural University 2019SKLAB6-7 Shuyang Yu State Key Laboratory of
   Agrobiotechnology, China Agricultural University 2018SKLAB6-30 Shuyang
   Yu The funders had no role in study design, data collection and
   interpretation, or the decision to submit the work for publication.},
Cited-References = {Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Baumjohann D, 2013, IMMUNITY, V38, P596, DOI 10.1016/j.immuni.2012.11.020.
   Bauquet AT, 2009, NAT IMMUNOL, V10, P167, DOI 10.1038/ni.1690.
   Cho SH, 2019, P NATL ACAD SCI USA, V116, P8975, DOI 10.1073/pnas.1811702116.
   Choi YS, 2015, NAT IMMUNOL, V16, P980, DOI 10.1038/ni.3226.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011.
   Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004.
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400.
   Deenick EK, 2010, IMMUNITY, V33, P241, DOI 10.1016/j.immuni.2010.07.015.
   Dong L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111450.
   Fayard E, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3135re5.
   Fazilleau N, 2009, NAT IMMUNOL, V10, P375, DOI 10.1038/ni.1704.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Gigoux M, 2009, P NATL ACAD SCI USA, V106, P20371, DOI 10.1073/pnas.0911573106.
   Hao YX, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01127.
   Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870.
   Künzli M, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay5552.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Leavenworth JW, 2015, NAT IMMUNOL, V16, P96, DOI 10.1038/ni.3050.
   Liu JJ, 2019, FASEB J, V33, P5615, DOI 10.1096/fj.201802072R.
   Lucas CL, 2014, NAT IMMUNOL, V15, P88, DOI 10.1038/ni.2771.
   Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676.
   Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O.
   Park SG, 2009, NAT IMMUNOL, V10, P158, DOI 10.1038/ni.1687.
   Preite S, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03079.
   Preite S, 2018, NAT IMMUNOL, V19, P986, DOI 10.1038/s41590-018-0182-3.
   Qin L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01884.
   Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999.
   Rolf J, 2010, J IMMUNOL, V185, P4042, DOI 10.4049/jimmunol.1001730.
   Shao P, 2019, J IMMUNOL, V203, P801, DOI 10.4049/jimmunol.1900581.
   Shrestha S, 2015, NAT IMMUNOL, V16, P178, DOI 10.1038/ni.3076.
   Stone EL, 2015, IMMUNITY, V42, P239, DOI 10.1016/j.immuni.2015.01.017.
   Tubo NJ, 2013, CELL, V153, P785, DOI 10.1016/j.cell.2013.04.007.
   Venigalla RKC, 2013, EMBO J, V32, P1008, DOI 10.1038/emboj.2013.40.
   Wu TQ, 2015, CELL REP, V12, P2099, DOI 10.1016/j.celrep.2015.08.049.
   Xu LF, 2017, IMMUNITY, V47, P538, DOI 10.1016/j.immuni.2017.08.011.
   Xu LF, 2015, NAT IMMUNOL, V16, P991, DOI 10.1038/ni.3229.
   Yang JL, 2016, ELIFE, V5, DOI 10.7554/eLife.17936.
   Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703.
   Yao YP, 2018, RNA BIOL, V15, P1477, DOI 10.1080/15476286.2018.1551705.
   Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002.
   Yu MJ, 2015, J INVEST DERMATOL, V135, P2688, DOI 10.1038/jid.2015.232.
   Zeng H, 2016, IMMUNITY, V45, P540, DOI 10.1016/j.immuni.2016.08.017.
   Zhao DM, 2010, J IMMUNOL, V184, P1191, DOI 10.4049/jimmunol.0901199.
   Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002.},
Number-of-Cited-References = {46},
Times-Cited = {20},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {21},
Journal-ISO = {eLife},
Doc-Delivery-Number = {QL5AE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000621088700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000617522600001,
Author = {Kim, Hyemin and Lee, Jinyoung and Cho, Yongcheol},
Title = {PDK1 is a negative regulator of axon regeneration},
Journal = {MOLECULAR BRAIN},
Year = {2021},
Volume = {14},
Number = {1},
Month = {FEB 12},
Abstract = {Axon regeneration in the central nervous system is inefficient. However,
   the neurons in the peripheral nervous system display robust regeneration
   after injury, indicating that axonal regeneration is differentially
   controlled under various conditions. To identify those molecules
   regulating axon regeneration, comparative analysis from dorsal root
   ganglion neurons at embryonic or adult stages is utilized, which reveals
   that PDK1 is functions as a negative regulator of axon regeneration.
   PDK1 is downregulated in embryonic neurons after axotomy. In contrast,
   sciatic nerve axotomy upregulated PDK1 at protein levels from adult
   mice. The knockdown of PDK1 or the chemical inhibition of PDK1 promotes
   axon regeneration in vitro and in vivo. Here we present PDK1 as a new
   player to negatively regulate axon regeneration and as a potential
   target in the development of therapeutic applications.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Cho, Y (Corresponding Author), Korea Univ, Dept Life Sci, Anam Ro 145, Seoul 02841, South Korea.
   Kim, Hyemin; Lee, Jinyoung; Cho, Yongcheol, Korea Univ, Dept Life Sci, Anam Ro 145, Seoul 02841, South Korea.},
DOI = {10.1186/s13041-021-00748-z},
Article-Number = {31},
EISSN = {1756-6606},
Keywords = {PDPK1; PDK1; PNS; CNS; Axon regeneration; DLK; Kinase},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {ycho77@korea.ac.kr},
Affiliations = {Korea University},
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) - Korean government (MSIT)
   {[}2019R1A2C1005380]},
Funding-Text = {This work was supported by the National Research Foundation of Korea
   (NRF). Grant funded by the Korean government (MSIT) 2019R1A2C1005380 to
   Y.C.},
Cited-References = {Abe N, 2008, CURR OPIN NEUROBIOL, V18, P276, DOI 10.1016/j.conb.2008.06.005.
   Adib EA, 2018, CURR OPIN NEUROBIOL, V53, P110, DOI 10.1016/j.conb.2018.07.002.
   Al-Ali H, 2017, J NEUROSCI, V37, P7079, DOI 10.1523/JNEUROSCI.0931-17.2017.
   Artamonov M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058703.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Cho Y, 2015, NEURON, V88, P720, DOI 10.1016/j.neuron.2015.09.050.
   Cho Y, 2015, J BIOL CHEM, V290, P22759, DOI 10.1074/jbc.M115.638445.
   Cho Y, 2014, J BIOL CHEM, V289, P15820, DOI 10.1074/jbc.M113.536607.
   Cho Y, 2013, CELL, V155, P894, DOI 10.1016/j.cell.2013.10.004.
   Cho Y, 2012, EMBO J, V31, P3063, DOI 10.1038/emboj.2012.160.
   Frey E, 2018, ENEURO, V5, DOI 10.1523/ENEURO.0095-18.2018.
   He ZG, 2016, NEURON, V90, P437, DOI 10.1016/j.neuron.2016.04.022.
   Hirai S, 2006, J NEUROSCI, V26, P11992, DOI 10.1523/JNEUROSCI.2272-06.2006.
   Hubert T, 2014, J NEUROSCI, V34, P758, DOI 10.1523/JNEUROSCI.2886-13.2014.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Jeon Y, 2021, MOL NEUROBIOL, V58, P750, DOI 10.1007/s12035-020-02155-2.
   Komander D, 2005, J BIOL CHEM, V280, P18797, DOI 10.1074/jbc.M500977200.
   Larhammar M, 2017, ELIFE, V6, DOI 10.7554/eLife.20725.
   Le Pichon CE, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0394.
   Lee J, 2021, FEBS J, V288, P4786, DOI 10.1111/febs.15646.
   Lee J, 2020, P NATL ACAD SCI USA, V117, P15955, DOI 10.1073/pnas.1920829117.
   Mahar M, 2018, NAT REV NEUROSCI, V19, P323, DOI 10.1038/s41583-018-0001-8.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Neto E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181612.
   Nix P, 2011, P NATL ACAD SCI USA, V108, P10738, DOI 10.1073/pnas.1104830108.
   Patel S, 2017, J MED CHEM, V60, P8083, DOI 10.1021/acs.jmedchem.7b00843.
   Pietri M, 2013, NAT MED, V19, P1124, DOI 10.1038/nm.3302.
   Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Raimondi C, 2012, J CELL SCI, V125, P3153, DOI 10.1242/jcs.100511.
   Rao SNR, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00033.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Sato S, 2002, J BIOL CHEM, V277, P39360, DOI 10.1074/jbc.M205141200.
   Shin JE, 2014, EXP NEUROL, V252, P1, DOI 10.1016/j.expneurol.2013.11.007.
   Shin JE, 2012, P NATL ACAD SCI USA, V109, pE3696, DOI 10.1073/pnas.1216204109.
   Shin JE, 2012, NEURON, V74, P1015, DOI 10.1016/j.neuron.2012.04.028.
   Siu M, 2018, J MED CHEM, V61, P8078, DOI 10.1021/acs.jmedchem.8b00370.
   Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6.
   Tedeschi A, 2016, NEURON, V92, P419, DOI 10.1016/j.neuron.2016.09.026.
   Tedeschi A, 2013, EMBO REP, V14, P605, DOI 10.1038/embor.2013.64.
   Valakh V, 2015, NEUROBIOL DIS, V77, P13, DOI 10.1016/j.nbd.2015.02.014.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wang G, 2012, PROG NEUROBIOL, V98, P207, DOI 10.1016/j.pneurobio.2012.06.003.
   Welsbie DS, 2018, INVEST OPHTH VIS SCI, V59.
   Wood CD, 2007, FEBS LETT, V581, P3494, DOI 10.1016/j.febslet.2007.06.060.
   Xiong X, 2012, J NEUROSCI, V32, P610, DOI 10.1523/JNEUROSCI.3586-11.2012.
   Xu X, 1997, P NATL ACAD SCI USA, V94, P12655, DOI 10.1073/pnas.94.23.12655.
   Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200.
   Yang L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6416.},
Number-of-Cited-References = {49},
Times-Cited = {2},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Mol. Brain},
Doc-Delivery-Number = {QG3XO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000617522600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000628752700005,
Author = {Song, Lijun and Zhong, Peicheng and Zhu, Xuemei and Zhou, Ruoxia and
   Gao, Mengyue and Lan, Qian and Chen, Jiabo and Chen, Yang and Zhao,
   Wenchang},
Title = {The anti-rotavirus effect of baicalin via the gluconeogenesis-related
   p-JNK-PDK1-AKT-SIK2 signaling pathway},
Journal = {EUROPEAN JOURNAL OF PHARMACOLOGY},
Year = {2021},
Volume = {897},
Month = {APR 15},
Abstract = {Rotavirus (RV) infection is a leading cause of severe, dehydrating
   gastroenteritis in children < 5 years of age, and by now, the prevention
   and treatment of RV are still the major public health problems due to a
   lack of specific clinical drugs. Thus, the aims of this study are to
   explore the anti-RV effect of baicalin and its influence on glucose
   metabolism. Here, we demonstrated for the first time that baicalin had
   an anti-RV attachment effect with the strongest effect at a
   concentration of 100 mu M, and also inhibited the replication of RV at
   concentrations of 100, 125, 150, 175, and 200 mu M. Moreover, baicalin
   helped to overcome the weight loss and reduced the diarrhea rate and
   score with the best therapeutic effect at a concentration of 0.3 mg/g in
   RV-infected neonatal mice. Interestingly, baicalin decreased glucose
   consumption in RV-infected Caco-2 cells with the optimal concentration
   of 125 mu M. Next, metabolomic analysis indicated that there were 68
   differentially expressed metabolites, including an increase in pyruvic
   acid, asparagine, histidine and serine, and a decrease in
   dihydroxyacetone phosphate, which suggested that the underlying
   signaling pathway was gluconeogenesis. Further studies demonstrated that
   baicalin inhibited gluconeogenesis via improving glucose 6-phosphatase
   (G-6-Pase) and phosphoenolpyruvate carboxylase (PEPCK). Moreover,
   baicalin upregulated the potential gluconeogenesis proteins named salt
   inducible kinase 2, pyruvate dehydrogenase kinase 1, AKT
   serine/threonine kinase 1 and downregulated phosphorylated c-Jun
   NH2-terminal kinase, which are associated with G-6-Pase and PEPCK
   expressions. Therefore, baicalin improved the gluconeogenesis disruption
   caused by RV.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Zhao, WC (Corresponding Author), 1 Xincheng Rd, Dongguan 523808, Guangdong, Peoples R China.
   Song, Lijun; Zhong, Peicheng; Zhu, Xuemei; Zhou, Ruoxia; Gao, Mengyue; Lan, Qian; Chen, Jiabo; Chen, Yang; Zhao, Wenchang, Guangdong Med Univ, Sch Pharm, Dongguan 523808, Guangdong, Peoples R China.
   Song, Lijun; Zhao, Wenchang, Guangdong Med Univ, Guangdong Key Lab Res \& Dev Nat Drugs, Zhanjiang 524023, Guangdong, Peoples R China.},
DOI = {10.1016/j.ejphar.2021.173927},
EarlyAccessDate = {FEB 2021},
Article-Number = {173927},
ISSN = {0014-2999},
EISSN = {1879-0712},
Keywords = {Rotavirus; Baicalin; Gluconeogenesis},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {zhaowenchang@126.com},
Affiliations = {Guangdong Medical University; Guangdong Medical University},
ResearcherID-Numbers = {song, lijun/ABB-7049-2021
   chen, yang/GRO-6792-2022
   },
ORCID-Numbers = {chen, yang/0000-0002-5840-0897
   zhao, wenchang/0000-0003-2332-5804
   Zhong, Peicheng/0000-0003-3382-8042},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81973548, 81473401]; Key
   Project of Social Science and Technology Development of Dongguan
   {[}20185071521658]; 2018 Guangdong Graduate Education Innovation Program
   {[}2019XSLT29]},
Funding-Text = {This work was supported by National Natural Science Foundation of China
   (No. 81973548 and No. 81473401), Key Project of Social Science and
   Technology Development of Dongguan (NO. 20185071521658) and 2018
   Guangdong Graduate Education Innovation Program (NO. 2019XSLT29) and
   Lijun Song and Peicheng Zhong were co-first authors.},
Cited-References = {Alfajaro Mia Madel, 2014, VirusDisease, V25, P186, DOI 10.1007/s13337-014-0197-9.
   Arias CF, 2015, J VIROL, V89, P890, DOI 10.1128/JVI.01787-14.
   Canettieri G, 2005, CELL METAB, V2, P331, DOI 10.1016/j.cmet.2005.09.008.
   Chen XZ, 1995, BIOPHYS J, V69, P2405, DOI 10.1016/S0006-3495(95)80110-4.
   Chen Y, 2018, POULTRY SCI, V97, P2722, DOI 10.3382/ps/pey155.
   Crawford SE, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.83.
   Deng L, 2011, J VIROL, V85, P8556, DOI 10.1128/JVI.00146-11.
   Dentin R, 2007, NATURE, V449, P366, DOI 10.1038/nature06128.
   Ding Y, 2014, ARCH VIROL, V159, P3269, DOI 10.1007/s00705-014-2192-2.
   Du C., 2016, J CLIN HEMATOLOGY BL, V29, P609, DOI {[}10.13201/j.issn.1004-2806-b.2016.08.001, DOI 10.13201/J.ISSN.1004-2806-B.2016.08.001].
   Fang PH, 2018, LIFE SCI, V196, P156, DOI 10.1016/j.lfs.2018.01.022.
   Ge J., 2010, J ANHUI AGR SCI, V38, P16769, DOI 10.3969/j.
   Gong SQ, 2011, INT IMMUNOPHARMACOL, V11, P2176, DOI 10.1016/j.intimp.2011.09.015.
   Halaihel N, 2000, AM J PHYSIOL-GASTR L, V279, pG587, DOI 10.1152/ajpgi.2000.279.3.G587.
   Honeyman MC, 2000, DIABETES, V49, P1319, DOI 10.2337/diabetes.49.8.1319.
   Huang HH, 2015, ARCH VIROL, V160, P1421, DOI 10.1007/s00705-015-2404-4.
   Jacobi SK, 2013, WORLD J GASTROENTERO, V19, P5094, DOI 10.3748/wjg.v19.i31.5094.
   Jalilvand S, 2015, ARCH IRAN MED, V18, P604, DOI 0151809/AIM.0010.
   Liu Y, 2009, PROG BIOCHEM BIOPHYS, V36, P274, DOI 10.3724/SP.J.1206.2008.00494.
   Lorrot M, 2007, ARCH PEDIATRIE, V14, pS145, DOI 10.1016/S0929-693X(07)80018-2.
   Parvaiz F, 2014, ARCH VIROL, V159, P1017, DOI 10.1007/s00705-013-1892-3.
   Paul SP, 2014, INDIAN J PEDIATR, V81, P111, DOI 10.1007/s12098-013-1189-2.
   Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715.
   Rechtman MM, 2010, FEBS LETT, V584, P2485, DOI 10.1016/j.febslet.2010.04.067.
   Shi HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep35851.
   Shrinet J, 2018, J PROTEOME RES, V17, P3348, DOI 10.1021/acs.jproteome.8b00211.
   Solinas G, 2017, MOL METAB, V6, DOI 10.1016/j.molmet.2016.12.001.
   van den Berg RA, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-142.
   Wang Guang-Ji, 2008, Chinese Journal of Natural Medicines, V6, P89, DOI 10.3724/SP.J.100910.3724/SP.J.1009.2008.00089.
   Wright EM, 2004, PHYSIOLOGY, V19, P370, DOI 10.1152/physiol.00026.2004.
   Xu JY, 2018, PHARMACOL RES, V136, P62, DOI 10.1016/j.phrs.2018.08.018.
   Yang SN, 2019, FEBS LETT, V593, P175, DOI 10.1002/1873-3468.13305.
   Zhang T, 2013, J PROTEOME RES, V12, P505, DOI 10.1021/pr3009572.
   Zhao Q, 2016, SCI BULL, V61, P1391, DOI 10.1007/s11434-016-1136-5.},
Number-of-Cited-References = {34},
Times-Cited = {13},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Eur. J. Pharmacol.},
Doc-Delivery-Number = {QW6JE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000628752700005},
DA = {2026-02-04},
}

@article{ WOS:000684765700002,
Author = {Kuramoto, Naoki and Nomura, Kazuhiro and Kohno, Daisuke and Kitamura,
   Tadahiro and Karsenty, Gerard and Hosooka, Tetsuya and Ogawa, Wataru},
Title = {Role of PDK1 in skeletal muscle hypertrophy induced by mechanical load},
Journal = {SCIENTIFIC REPORTS},
Year = {2021},
Volume = {11},
Number = {1},
Month = {FEB 10},
Abstract = {Phosphatidylinositol 3-kinase (PI3K) plays an important role in protein
   metabolism and cell growth. We here show that mice (M-PDK1KO mice) with
   skeletal muscle-specific deficiency of 3 ` -phosphoinositide-dependent
   kinase 1 (PDK1), a key component of PI3K signaling pathway, manifest a
   reduced skeletal muscle mass under the static condition as well as
   impairment of mechanical load-induced muscle hypertrophy. Whereas
   mechanical load-induced changes in gene expression were not affected,
   the phosphorylation of ribosomal protein S6 kinase (S6K) and S6 induced
   by mechanical load was attenuated in skeletal muscle of M-PDK1KO mice,
   suggesting that PDK1 regulates muscle hypertrophy not through changes in
   gene expression but through stimulation of kinase cascades such as the
   S6K-S6 axis, which plays a key role in protein synthesis. Administration
   of the beta (2)-adrenergic receptor (AR) agonist clenbuterol activated
   the S6K-S6 axis in skeletal muscle and induced muscle hypertrophy in
   mice. These effects of clenbuterol were attenuated in M-PDK1KO mice, and
   mechanical load-induced activation of the S6K-S6 axis and muscle
   hypertrophy were inhibited in mice with skeletal muscle-specific
   deficiency of beta (2)-AR. Our results suggest that PDK1 regulates
   skeletal muscle mass under the static condition and that it contributes
   to mechanical load-induced muscle hypertrophy, at least in part by
   mediating signaling from beta (2)-AR.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Ogawa, W (Corresponding Author), Kobe Univ, Div Diabet \& Endocrinol, Dept Internal Med, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
   Kuramoto, Naoki; Nomura, Kazuhiro; Hosooka, Tetsuya; Ogawa, Wataru, Kobe Univ, Div Diabet \& Endocrinol, Dept Internal Med, Grad Sch Med,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
   Kohno, Daisuke; Kitamura, Tadahiro, Gunma Univ, Inst Mol \& Cellular Regulat, Metab Signal Res Ctr, Maebashi, Gumma, Japan.
   Karsenty, Gerard, Columbia Univ, Dept Genet \& Dev, Irving Med Ctr, New York, NY USA.
   Hosooka, Tetsuya, Kobe Univ, Div Dev Adv Therapy Metab Dis, Dept Internal Med, Grad Sch Med, Kobe, Hyogo, Japan.},
DOI = {10.1038/s41598-021-83098-z},
Article-Number = {3447},
ISSN = {2045-2322},
Keywords-Plus = {INSULIN SENSITIVITY; OLDER-ADULTS; MASS; EXPRESSION; HEALTH; GROWTH},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {ogawa@med.kobe-u.ac.jp},
Affiliations = {Kobe University; Gunma University; Columbia University; Cornell
   University; Weill Cornell Medicine; NewYork-Presbyterian Hospital; Kobe
   University},
ResearcherID-Numbers = {OGAWA, Wataru/AAQ-9586-2020},
Funding-Acknowledgement = {KAKENHI Grants from the Japan Society for the Promotion of Science
   {[}19K22637, 17K09832]; Grants-in-Aid for Scientific Research
   {[}20KK0198, 21H03355, 17K09832, 19K22637] Funding Source: KAKEN},
Funding-Text = {The authors thank S.J. Burden for providing Mlc1f.-Cre mice. This work
   was supported by KAKENHI Grants from the Japan Society for the Promotion
   of Science (19K22637 to W.O., and 17K09832 to K.N.).},
Cited-References = {Bothe GWM, 2000, GENESIS, V26, P165, DOI 10.1002/(SICI)1526-968X(200002)26:2<165::AID-GENE22>3.0.CO;2-F.
   Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0.
   Clarkson PM, 1997, SPORTS MED, V24, P366, DOI 10.2165/00007256-199724060-00003.
   Cohen S, 2015, NAT REV DRUG DISCOV, V14, P58, DOI 10.1038/nrd4467.
   Distefano G, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029785.
   Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774.
   Hinoi E, 2008, J CELL BIOL, V183, P1235, DOI 10.1083/jcb.200809113.
   Hirata Y, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124952.
   Hong S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188650.
   Hosooka T, 2020, P NATL ACAD SCI USA, V117, P11674, DOI 10.1073/pnas.1921015117.
   Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009.
   Jessen S, 2018, SCAND J MED SCI SPOR, V28, P2114, DOI 10.1111/sms.13221.
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27.
   Kjær M, 2004, PHYSIOL REV, V84, P649, DOI 10.1152/physrev.00031.2003.
   Koziczak-Holbro M, 2019, J PHARMACOL EXP THER, V369, P188, DOI 10.1124/jpet.118.255307.
   Luo J, 2006, CELL METAB, V3, P355, DOI 10.1016/j.cmet.2006.04.003.
   Lynch GS, 2008, PHYSIOL REV, V88, P729, DOI 10.1152/physrev.00028.2007.
   Matsui S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07033-z.
   McCarthy JJ, 2011, DEVELOPMENT, V138, P3657, DOI 10.1242/dev.068858.
   Mesinovic J, 2019, DIABET METAB SYND OB, V12, P1057, DOI 10.2147/DMSO.S186600.
   Morais JA, 2018, EXP GERONTOL, V108, P262, DOI 10.1016/j.exger.2018.04.025.
   O'Neill BT, 2016, J CLIN INVEST, V126, P3433, DOI 10.1172/JCI86522.
   O'Neill BT, 2015, CELL REP, V11, P1220, DOI 10.1016/j.celrep.2015.04.037.
   Okamoto Y, 2007, DIABETES, V56, P1000, DOI 10.2337/db06-1322.
   Park SW, 2007, DIABETES CARE, V30, P1507, DOI 10.2337/dc06-2537.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Petersen MC, 2018, PHYSIOL REV, V98, P2133, DOI 10.1152/physrev.00063.2017.
   Son JW, 2017, DIABETOLOGIA, V60, P865, DOI 10.1007/s00125-016-4196-9.
   Srikanthan P, 2011, J CLIN ENDOCR METAB, V96, P2898, DOI 10.1210/jc.2011-0435.
   Sugimoto K, 2019, J DIABETES INVEST, V10, P1471, DOI 10.1111/jdi.13070.
   Takashima M, 2010, DIABETES, V59, P1608, DOI 10.2337/db09-1679.
   Wang TT, 2016, SCI REP-UK, V6, DOI 10.1038/srep38937.
   Yang CW, 2017, EXP GERONTOL, V95, P34, DOI 10.1016/j.exger.2017.05.006.},
Number-of-Cited-References = {33},
Times-Cited = {10},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {TZ9CK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000684765700002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000620700500001,
Author = {He, Junming and Zhao, Jun and Quan, Yuhe and Hou, Xinlei and Yang,
   Meixiang and Dong, Zhongjun},
Title = {Full Activation of Kinase Protein Kinase B by Phosphoinositide-Dependent
   Protein Kinase-1 and Mammalian Target of Rapamycin Complex 2 Is Required
   for Early Natural Killer Cell Development and Survival},
Journal = {FRONTIERS IN IMMUNOLOGY},
Year = {2021},
Volume = {11},
Month = {FEB 9},
Abstract = {The role of PI3K-mTOR pathway in regulating NK cell development has been
   widely reported. However, it remains unclear whether NK cell development
   depends on the protein kinase B (PKB), which links PI3K and mTOR,
   perhaps due to the potential redundancy of PKB. PKB has two
   phosphorylation sites, threonine 308 (T308) and serine 473 (S473), which
   can be phosphorylated by phosphoinositide-dependent protein kinase-1
   (PDK1) and mTORC2, respectively. In this study, we established a mouse
   model in which PKB was inactivated through the deletion of PDK1 and
   Rictor, a key component of mTORC2, respectively. We found that the
   single deletion of PDK1 or Rictor could lead to a significant defect in
   NK cell development, while combined deletion of PDK1 and Rictor severely
   hindered NK cell development at the early stage. Notably, ectopic
   expression of myristoylated PKB significantly rescued this defect. In
   terms of mechanism, in PDK1/Rictor-deficient NK cells, E4BP4, a
   transcription factor for NK cell development, was less expressed, and
   the exogenous supply of E4BP4 could alleviate the developmental defect
   of NK cell in these mice. Besides, overexpression of Bcl-2 also helped
   the survival of PDK1/Rictor-deficient NK cells, suggesting an
   anti-apoptotic role of PKB in NK cells. In summary, complete
   phosphorylation of PKB at T308 and S473 by PDK1 and mTORC2 is necessary
   for optimal NK cell development, and PKB regulates NK cell development
   by promoting E4BP4 expression and preventing cell apoptosis.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Dong, ZJ (Corresponding Author), Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.
   Dong, ZJ (Corresponding Author), Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.
   Yang, MX (Corresponding Author), Jinan Univ, Zhuhai Precis Med Ctr, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Guangdong, Peoples R China.
   Yang, MX (Corresponding Author), Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Guangdong, Peoples R China.
   He, Junming; Zhao, Jun; Quan, Yuhe; Hou, Xinlei; Dong, Zhongjun, Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.
   He, Junming; Zhao, Jun; Quan, Yuhe; Hou, Xinlei; Dong, Zhongjun, Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.
   Yang, Meixiang, Jinan Univ, Zhuhai Precis Med Ctr, Zhuhai Peoples Hosp, Zhuhai Hosp, Zhuhai, Guangdong, Peoples R China.
   Yang, Meixiang, Jinan Univ, Fac Med Sci, Biomed Translat Res Inst, Guangzhou, Guangdong, Peoples R China.},
DOI = {10.3389/fimmu.2020.617404},
Article-Number = {617404},
ISSN = {1664-3224},
Keywords = {natural killer (NK) cell; protein kinase B (PKB);
   phosphoinositide-dependent protein kinase-1 (PDK1); mammalian target of
   rapamycin complex 2; development; survival},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Author-Email = {yangmxqilu@163.com
   dongzj@mail.tsinghua.edu.cn},
Affiliations = {Tsinghua University; Tsinghua University; Jinan University; Jinan
   University},
ResearcherID-Numbers = {Zhao, Jun/JFA-7606-2023},
Funding-Acknowledgement = {Natural Science Foundation of China {[}31830027, 81725007, 91942308,
   31821003, 81771666, 31700771]; National Key Research \& Developmental
   Program of China {[}2018YFC1003900]; Natural Science Foundation of
   Guangdong Province {[}2019A1515011707]; Guangzhou Science and Technology
   Project {[}201707010395]; China Postdoctoral Science Foundation
   {[}2020M670296]; Tsinghua-Peking Center for Life Sciences},
Funding-Text = {Research reported in this publication was supported by the Natural
   Science Foundation of China (to Z.D, 31830027, 81725007, 91942308, and
   31821003; to MY, 81771666; to WX, 31700771), National Key Research \&
   Developmental Program of China (2018YFC1003900), Natural Science
   Foundation of Guangdong Province (to MY, 2019A1515011707), Guangzhou
   Science and Technology Project (to MY, 201707010395) and the China
   Postdoctoral Science Foundation (to JH, 2020M670296). The Dong
   laboratory was also supported by Tsinghua-Peking Center for Life
   Sciences.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Ali AK, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00355.
   Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179.
   Cooper MA, 2002, BLOOD, V100, P3633, DOI 10.1182/blood-2001-12-0293.
   Guo HL, 2008, J EXP MED, V205, P2419, DOI 10.1084/jem.20072327.
   Hayakawa Y, 2006, J IMMUNOL, V176, P1517, DOI 10.4049/jimmunol.176.3.1517.
   He JM, 2019, CELL DEATH DIFFER, V26, P1918, DOI 10.1038/s41418-018-0263-8.
   Kamizono S, 2009, J EXP MED, V206, P2977, DOI 10.1084/jem.20092176.
   Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771.
   Luo W, 2019, NAT IMMUNOL, V20, P736, DOI 10.1038/s41590-019-0376-3.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936.
   Minagawa M, 2002, J IMMUNOL, V169, P4153, DOI 10.4049/jimmunol.169.8.4153.
   Parham P, 2018, ANNU REV IMMUNOL, V36, P519, DOI 10.1146/annurev-immunol-042617-053149.
   Rogel A, 2017, P NATL ACAD SCI USA, V114, pE1178, DOI 10.1073/pnas.1611299114.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Tassi I, 2007, IMMUNITY, V27, P214, DOI 10.1016/j.immuni.2007.07.014.
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866.
   Vergadi E, 2017, J IMMUNOL, V198, P1006, DOI 10.4049/jimmunol.1601515.
   Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582.
   Wang FJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07277-9.
   Yang C, 2018, ELIFE, V7, DOI 10.7554/eLife.35619.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703.
   Zhao X, 2014, MOL CELL BIOL, V34, P1966, DOI 10.1128/MCB.00144-14.},
Number-of-Cited-References = {27},
Times-Cited = {6},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Front. Immunol.},
Doc-Delivery-Number = {QK9LU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000620700500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000629633800022,
Author = {Xu, Biao and Wang, Zhi-Peng and Liu, Qingwang and Yang, Xiaohong and Li,
   Xuemin and Huang, Ding and Qiu, Yanfei and Tam, Kin Yip and Zhang,
   Shao-Lin and He, Yun},
Title = {Synthesis, biological evaluation and structure-activity relationship of
   novel dichloroacetophenones targeting pyruvate dehydrogenase kinases
   with potent anticancer activity},
Journal = {EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY},
Year = {2021},
Volume = {214},
Month = {MAR 15},
Abstract = {Pyruvate dehydrogenase kinases (PDKs) are promising therapeutic targets
   that have received increasing attentions in cancer metabolism. In this
   paper, we report the synthesis and biological evaluation of a series of
   novel dichloroacetophenones as potent PDKs inhibitors.
   Structure-activity relationship analysis enabled us to identify a potent
   compound 6u, which inhibited PDKs with an EC50 value of 0.09 mu M, and
   reduced various cancer cells proliferation with IC50 values ranging from
   1.1 to 3.8 mu M, while show weak effect against non-cancerous L02 cell
   (IC50 > 10 mu M). In the A375 xenograft model, 6u displayed an obvious
   antitumor activity at a dose of 5 mg/kg, but with no negative effect to
   the mice weight. Molecular docking suggested that 6u formed direct
   hydrogen bond interactions with Ser75 and Gln61 in PDK1, and meanwhile
   the aniline skeleton in 6u was sandwiched by the conserved hydrophobic
   residues Phe78 and Phe65, which contribute to the biochemical activity
   improvement. Moreover, 6u induced A375 cell apoptosis and cell arrest in
   G1 phase, and inhibited cancer cell migration. In addition, 6u altered
   glucose metabolic pathway in A375 cell by decreasing lactate formation
   and increasing ROS production and OCR consumption, which could serve as
   a potential modulator to reprogram the glycolysis pathway in cancer
   cell. (C) 2021 Elsevier Masson SAS. All rights reserved.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Zhang, SL; He, Y (Corresponding Author), Chongqing Univ, Sch Pharmaceut Sci, Chongqing Key Lab Nat Prod Synth \& Drug Res, Chongqing 401331, Peoples R China.
   Xu, Biao; Yang, Xiaohong; Li, Xuemin; Huang, Ding; Qiu, Yanfei; Zhang, Shao-Lin; He, Yun, Chongqing Univ, Sch Pharmaceut Sci, Chongqing Key Lab Nat Prod Synth \& Drug Res, Chongqing 401331, Peoples R China.
   Wang, Zhi-Peng, Chinese Acad Sci, Chongqing Inst Green \& Intelligent Technol, Chongqing, Peoples R China.
   Tam, Kin Yip, Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.
   Wang, Zhi-Peng, Univ Chinese Acad Sci Chongqing, Chongqing Sch, Chongqing, Peoples R China.
   Liu, Qingwang, Chinese Acad Sci, Inst Hlth \& Med Technol, Hefei Inst Phys Sci, Hefei 230031, Anhui, Peoples R China.},
DOI = {10.1016/j.ejmech.2021.113225},
EarlyAccessDate = {FEB 2021},
Article-Number = {113225},
ISSN = {0223-5234},
EISSN = {1768-3254},
Keywords = {Pyruvate dehydrogenase kinase; Proliferation; Cancer metabolism;
   Structure-activity relationship},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal},
Author-Email = {zhangsl@cqu.edu.cn
   yun.he@cqu.edu.cn},
Affiliations = {Chongqing University; Chinese Academy of Sciences; Chongqing Institute
   of Green \& Intelligent Technology, CAS; University of Macau; Chinese
   Academy of Sciences; Hefei Institutes of Physical Science, CAS},
ResearcherID-Numbers = {Li, Xuemin/PBW-3999-2025
   Xu, Biao/IST-0512-2023
   Tam, Kin/A-7812-2011
   Zhang, Shao-Lin/AAN-1808-2020
   he, yun/JMB-6362-2023},
ORCID-Numbers = {Xu, Biao/0000-0002-4857-3815
   Tam, Kin/0000-0001-5507-8524
   Zhang, Shao-Lin/0000-0002-2259-7704
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}21807008]; Chongqing
   Science and Technology Bureau {[}csts2019jcyj-zdxmX0021]; Science and
   Technology Development Fund, Macau SAR {[}0057/2018/A2]; University of
   Macau {[}MYRG2019-00034-FHS]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. 21807008), Chongqing Science and Technology Bureau
   (csts2019jcyj-zdxmX0021), the Science and Technology Development Fund,
   Macau SAR (File no. 0057/2018/A2) and University of Macau (File no.
   MYRG2019-00034-FHS).},
Cited-References = {Brautigam CA, 2009, J BIOL CHEM, V284, P13086, DOI 10.1074/jbc.M806563200.
   Brough PA, 2017, J MED CHEM, V60, P2271, DOI 10.1021/acs.jmedchem.6b01478.
   Chen GL, 1996, J BIOL CHEM, V271, P28064, DOI 10.1074/jbc.271.45.28064.
   Counihan JL, 2018, CHEM REV, V118, P6893, DOI 10.1021/acs.chemrev.7b00775.
   ESPINAL J, 1995, DRUG DEVELOP RES, V35, P130, DOI 10.1002/ddr.430350303.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373.
   Koukourakis MI, 2007, CANCER BIOL THER, V6, P1476, DOI 10.4161/cbt.6.9.4635.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Liu YF, 2017, J MED CHEM, V60, P2227, DOI 10.1021/acs.jmedchem.6b01245.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Meng T, 2014, J MED CHEM, V57, P9832, DOI 10.1021/jm5010144.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728.
   Stapoole PW, 2008, ADV DRUG DELIVER REV, V60, P1478, DOI 10.1016/j.addr.2008.02.014.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Tso SC, 2017, J MED CHEM, V60, P1142, DOI 10.1021/acs.jmedchem.6b01540.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Xiang SC, 2020, EUR J MED CHEM, V203, DOI 10.1016/j.ejmech.2020.112579.
   Xu B, 2018, EUR J MED CHEM, V155, P275, DOI 10.1016/j.ejmech.2018.06.012.
   Zhang SL, 2018, BIOORG MED CHEM LETT, V28, P3441, DOI 10.1016/j.bmcl.2018.09.026.
   Zhang SL, 2018, EUR J PHARM SCI, V123, P43, DOI 10.1016/j.ejps.2018.07.026.
   Zhang SL, 2018, DRUG DISCOV TODAY, V23, P1407, DOI 10.1016/j.drudis.2018.05.014.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.},
Number-of-Cited-References = {27},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {27},
Journal-ISO = {Eur. J. Med. Chem.},
Doc-Delivery-Number = {QX9AH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)},
Unique-ID = {WOS:000629633800022},
DA = {2026-02-04},
}

@article{ WOS:000618538500001,
Author = {McKenna, McShane and Balasuriya, Nileeka and Zhong, Shanshan and Li,
   Shawn Shun-Cheng and O'Donoghue, Patrick},
Title = {Phospho-Form Specific Substrates of Protein Kinase B (AKT1)},
Journal = {FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY},
Year = {2021},
Volume = {8},
Month = {FEB 3},
Abstract = {Protein kinase B (AKT1) is hyper-activated in diverse human tumors. AKT1
   is activated by phosphorylation at two key regulatory sites, Thr308 and
   Ser473. Active AKT1 phosphorylates many, perhaps hundreds, of downstream
   cellular targets in the cytosol and nucleus. AKT1 is well-known for
   phosphorylating proteins that regulate cell survival and apoptosis,
   however, the full catalog of AKT1 substrates remains unknown. Using
   peptide arrays, we recently discovered that each phosphorylated form of
   AKT1 (pAKT1(S473), pAKT1(T308), and ppAKT1(S473,T308)) has a distinct
   substrate specificity, and these data were used to predict potential new
   AKT1 substrates. To test the high-confidence predictions, we synthesized
   target peptides representing putative AKT1 substrates. Peptides
   substrates were synthesized by solid phase synthesis and their purity
   was confirmed by mass spectrometry. Most of the predicted peptides
   showed phosphate accepting activity similar to or greater than that
   observed with a peptide derived from a well-established AKT1 substrate,
   glycogen synthase kinase 3 beta (GSK-3 beta). Among the novel
   substrates, AKT1 was most active with peptides representing PIP3-binding
   protein Rab11 family-interacting protein 2 and cysteinyl leukotriene
   receptor 1, indicating their potential role in AKT1-dependent cellular
   signaling. The ppAKT1(S473,T308) enzyme was highly selective for
   peptides containing a patch of basic residues at -5, -4, -3 and aromatic
   residues (Phe/Tyr) at +1 positions from the phosphorylation site. The
   pAKT1(S473) variant preferred more acidic peptides, Ser or Pro at +4,
   and was agnostic to the residue at -5. The data further support our
   hypothesis that Ser473 phosphorylation plays a key role in modulating
   AKT1 substrate selectivity.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {O'Donoghue, P (Corresponding Author), Univ Western Ontario, Dept Biochem, London, ON, Canada.
   McKenna, McShane; Balasuriya, Nileeka; Zhong, Shanshan; Li, Shawn Shun-Cheng; O'Donoghue, Patrick, Univ Western Ontario, Dept Biochem, London, ON, Canada.
   O'Donoghue, Patrick, Univ Western Ontario, Dept Chem, London, ON, Canada.},
DOI = {10.3389/fbioe.2020.619252},
Article-Number = {619252},
ISSN = {2296-4185},
Keywords = {genetic code expansion; AKT1; kinase; phosphoserine; tRNASep; PDK1},
Research-Areas = {Biotechnology \& Applied Microbiology; Engineering},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Engineering, Biomedical},
Author-Email = {Patrick.odonoghue@uwo.ca},
Affiliations = {Western University (University of Western Ontario); Western University
   (University of Western Ontario)},
ResearcherID-Numbers = {Li, Shawn/A-9007-2012},
ORCID-Numbers = {O'Donoghue, Patrick/0000-0002-9500-8640
   Li, Shawn/0000-0003-3610-9035},
Funding-Acknowledgement = {Natural Sciences and Engineering Research Council of Canada
   {[}04282-2014]; Canadian Cancer Society Research Institute innovation
   grant {[}704324]; Canada Foundation for Innovation {[}229917]; Ontario
   Research Foundation {[}229917]; Canada Research Chairs {[}232341];
   Canadian Institutes of Health Research {[}165985]},
Funding-Text = {This work was supported from the Natural Sciences and Engineering
   Research Council of Canada {[}04282-2014 to PO'D], the Canadian Cancer
   Society Research Institute innovation grant {[}704324 to PO'D and SL],
   Canada Foundation for Innovation {[}229917 to PO'D], the Ontario
   Research Foundation {[}229917 to PO'D], Canada Research Chairs {[}232341
   to PO'D], and the Canadian Institutes of Health Research {[}165985 to
   PO'D].},
Cited-References = {Aerni HR, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gku1087.
   Agarwal E, 2013, CELL SIGNAL, V25, P1711, DOI 10.1016/j.cellsig.2013.03.025.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085.
   Antonelli M, 2012, NEUROPATHOLOGY, V32, P133, DOI 10.1111/j.1440-1789.2011.01252.x.
   Balasuriya N, 2020, J BIOL CHEM, V295, P8120, DOI 10.1074/jbc.RA119.012425.
   Balasuriya N, 2018, GENES-BASEL, V9, DOI 10.3390/genes9090450.
   Balasuriya N, 2018, J BIOL CHEM, V293, P10744, DOI 10.1074/jbc.RA118.002357.
   Bei CH, 2017, ONCOTARGETS THER, V10, P5439, DOI 10.2147/OTT.S149786.
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017.
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0.
   Cederquist CT, 2017, MOL METAB, V6, P125, DOI 10.1016/j.molmet.2016.10.007.
   Cheng JQ, 2005, ONCOGENE, V24, P7482, DOI 10.1038/sj.onc.1209088.
   Chrifi I, 2019, ANGIOGENESIS, V22, P75, DOI 10.1007/s10456-018-9638-1.
   Chung CZ, 2019, RNA BIOL, V16, P1022, DOI 10.1080/15476286.2019.1608754.
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004.
   Dai DL, 2005, J CLIN ONCOL, V23, P1473, DOI 10.1200/JCO.2005.07.168.
   El-Hashim AZ, 2012, BRIT J PHARMACOL, V166, P1964, DOI 10.1111/j.1476-5381.2012.01905.x.
   Fabbro D, 1999, PROTEIN EXPRES PURIF, V17, P83, DOI 10.1006/prep.1999.1102.
   Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226, DOI 10.1164/ajrccm.163.1.2003101.
   Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313.
   Gentilini D, 2007, MOL HUM REPROD, V13, P317, DOI 10.1093/molehr/gam001.
   George S, 2017, BBA-GEN SUBJECTS, V1861, P3038, DOI 10.1016/j.bbagen.2017.06.023.
   George S, 2016, FEBS LETT, V590, P1530, DOI 10.1002/1873-3468.12182.
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335.
   Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016.
   Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6.
   Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755.
   Hart JR, 2011, ONCOTARGET, V2, P467, DOI 10.18632/oncotarget.293.
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004.
   Hohn MJ, 2006, P NATL ACAD SCI USA, V103, P18095, DOI 10.1073/pnas.0608762103.
   Hornbeck PV, 2004, PROTEOMICS, V4, P1551, DOI 10.1002/pmic.200300772.
   Huang JX, 2009, BIOCHEM SOC T, V37, P217, DOI 10.1042/BST0370217.
   JUNGTESTAS I, 1989, ENDOCRINOLOGY, V125, P2083.
   Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040.
   Käll L, 2004, J MOL BIOL, V338, P1027, DOI 10.1016/j.jmb.2004.03.016.
   Klein S, 2005, PROTEIN EXPRES PURIF, V41, P162, DOI 10.1016/j.pep.2005.01.003.
   Kunkel MT, 2005, J BIOL CHEM, V280, P5581, DOI 10.1074/jbc.M411534200.
   Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200.
   Lee S, 2013, ANGEW CHEM INT EDIT, V52, P5771, DOI 10.1002/anie.201300531.
   Li T, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0236-4.
   Liao Y, 2010, AM J TRANSL RES, V2, P19.
   Lindsay AJ, 2004, J CELL SCI, V117, P4365, DOI 10.1242/jcs.01280.
   Lippa B, 2008, BIOORG MED CHEM LETT, V18, P3359, DOI 10.1016/j.bmcl.2008.04.034.
   Liu CL, 2015, J MASS SPECTROM, V50, P625, DOI 10.1002/jms.3570.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Mattmann ME, 2011, EXPERT OPIN THER PAT, V21, P1309, DOI 10.1517/13543776.2011.587959.
   McManus EJ, 2004, EMBO J, V23, P2071, DOI 10.1038/sj.emboj.7600218.
   Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669.
   Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306.
   Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200.
   Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584.
   Parikh C, 2012, P NATL ACAD SCI USA, V109, P19368, DOI 10.1073/pnas.1204384109.
   Park HS, 2011, SCIENCE, V333, P1151, DOI 10.1126/science.1207203.
   Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540.
   Peters-Golden M, 2006, CLIN EXP ALLERGY, V36, P689, DOI 10.1111/j.1365-2222.2006.02498.x.
   Ren B, 2010, J CLIN INVEST, V120, P1217, DOI 10.1172/JCI39837.
   Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179.
   Rodriguez M, 2004, J BIOL CHEM, V279, P8802, DOI 10.1074/jbc.M311886200.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Spencer A, 2014, BLOOD, V124, P2190, DOI 10.1182/blood-2014-03-559963.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Suzuki Y, 2010, J RADIAT RES, V51, P343, DOI 10.1269/jrr.09109.
   Tsai MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23979.
   Turowec JP, 2010, METHOD ENZYMOL, V484, P471, DOI {[}10.1016/S0076-6879(10)84023-6, 10.1016/B978-0-12-381298-8.00023-X].
   van der Vos KE, 2011, ANTIOXID REDOX SIGN, V14, P579, DOI 10.1089/ars.2010.3419.
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882.
   Vitari AC, 2004, BIOCHEM J, V378, P257, DOI 10.1042/BJ20031692.
   Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1.
   Wang ZX, 2018, FEBS LETT, V592, P1882, DOI 10.1002/1873-3468.13080.
   Wei R, 2018, MOL CELL PROTEOMICS, V17, P2216, DOI 10.1074/mcp.RA117.000114.
   WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Xu CL, 2016, BIOCHEM BIOPH RES CO, V470, P397, DOI 10.1016/j.bbrc.2016.01.031.
   Xue H, 2019, ACTA BIOCH BIOPH SIN, V51, P915, DOI 10.1093/abbs/gmz084.
   Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206.
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065.},
Number-of-Cited-References = {79},
Times-Cited = {34},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Front. Bioeng. Biotechnol.},
Doc-Delivery-Number = {QH8RA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000618538500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000627895900117,
Author = {Song, Nuan and Wang, Wei and Wang, Yue and Guan, Yalin and Xu, Shiwen
   and Guo, Meng-Yao},
Title = {Hydrogen sulfide of air induces macrophage extracellular traps to
   aggravate inflammatory injury via the regulation of miR-15b-5p on MAPK
   and insulin signals in trachea of chickens},
Journal = {SCIENCE OF THE TOTAL ENVIRONMENT},
Year = {2021},
Volume = {771},
Month = {JUN 1},
Abstract = {Hydrogen sulfide (H2S) is an environmental contaminant to cause the
   airway damage. The release of macrophage extracellular traps (METs) is
   the mechanism of immune protection to harmful stimulation via microRNAs,
   but excessive METs cause the injury. However, few studies have attempted
   to interpret the mechanism of an organism injury due to H2S via METs in
   chickens. Here, we investigated the transcriptome profiles, pathological
   morphologic changes and METs release from chicken trachea after H2S
   exposure. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes
   (KEGG) analysis revealed that 10 differentially expressed genes were
   related to the METs release, the MAPK and insulin signaling pathways.
   Morphological and immunofluorescence analysis showed that H2S caused
   airway injury and MET release. H2S activated the targeting effect of
   miRNA-156-5p on activating transcription factor 2 (ATF2). Western
   blotting and real time quantitative PCR results showed that H2S
   down-regulated the levels of dual specificity protein phosophatasel
   (DUSP1) but up-regulated p38 MAP Kinase (p38) in the MAPK signal
   pathway. And the expression of phosphoinositide-dependent protein kinase
   1 (PDK1), serine/threonine kinase (Ant), and protein kinase zeta
   subtypes (PKC zeta) in the insulin signal pathway were increased after
   H2S exposure. These promoted the release of myeloperoxidase (MPO) and
   degradation histone 4 (H4) to induce the release of METs. Taken
   together, miR-15b-5p targeted ATF2 to mediate METs release, which
   triggered trachea inflammatory injury via MAPK and insulin signals after
   H2S exposure. These results will provide new insights into the
   toxicological mechanisms of H2S and environmental ecotoxicology. (C)
   2021 Elsevier B.V. All rights reserved.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Guo, MY (Corresponding Author), Northeast Agr Univ, Coll Vet Med, Harbin 150030, Peoples R China.
   Guo, MY (Corresponding Author), Dept Heilongjiang Common Anim Dis Prevent \& Treat, Key Lab Prov Educ, Harbin 150030, Peoples R China.
   Song, Nuan; Wang, Wei; Wang, Yue; Xu, Shiwen; Guo, Meng-Yao, Northeast Agr Univ, Coll Vet Med, Harbin 150030, Peoples R China.
   Song, Nuan; Wang, Wei; Wang, Yue; Xu, Shiwen; Guo, Meng-Yao, Dept Heilongjiang Common Anim Dis Prevent \& Treat, Key Lab Prov Educ, Harbin 150030, Peoples R China.
   Guan, Yalin, Northeast Agr Univ, Coll Life Sci, Harbin 150030, Peoples R China.},
DOI = {10.1016/j.scitotenv.2021.145407},
EarlyAccessDate = {FEB 2021},
Article-Number = {145407},
ISSN = {0048-9697},
EISSN = {1879-1026},
Keywords = {Hydrogen sulfide; miRNA; Signaling pathway; Macrophage extracellular
   trap; Trachea inflammatory injury},
Keywords-Plus = {TISSUE},
Research-Areas = {Environmental Sciences \& Ecology},
Web-of-Science-Categories  = {Environmental Sciences},
Author-Email = {gmy@neau.edu.cn},
Affiliations = {Northeast Agricultural University - China; Northeast Agricultural
   University - China},
ResearcherID-Numbers = {Guo, meng-yao/JOZ-4503-2023
   Xu, Shiwen/H-4355-2018},
ORCID-Numbers = {Guo, meng-yao/0000-0002-7596-3632
   },
Funding-Acknowledgement = {National Key Research and Development Program of China
   {[}2016YFD0500501]},
Funding-Text = {This work was supported by the National Key Research and Development
   Program of China (No. 2016YFD0500501).},
Cited-References = {Ahmed T, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105090.
   Allison SJ, 2018, NAT REV NEPHROL, V14, P141, DOI 10.1038/nrneph.2018.5.
   Amini P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05387-y.
   Aulik NA, 2012, INFECT IMMUN, V80, P1923, DOI 10.1128/IAI.06120-11.
   Bonne-Année S, 2014, MICROBES INFECT, V16, P502, DOI 10.1016/j.micinf.2014.02.012.
   Bustaffa E, 2020, SCI TOTAL ENVIRON, V706, DOI 10.1016/j.scitotenv.2019.135998.
   Chen DC, 2020, SCI TOTAL ENVIRON, V729, DOI 10.1016/j.scitotenv.2020.139017.
   Chen JQ, 2020, SCI TOTAL ENVIRON, V717, DOI 10.1016/j.scitotenv.2020.137081.
   Chen MH, 2019, J HAZARD MATER, V368, P243, DOI 10.1016/j.jhazmat.2019.01.054.
   Cui Y, 2020, ECOTOX ENVIRON SAFE, V206, DOI 10.1016/j.ecoenv.2020.111151.
   Doster RS, 2018, J INNATE IMMUN, V10, P3, DOI 10.1159/000480373.
   El Shikh MEM, 2019, J AUTOIMMUN, V105, DOI 10.1016/j.jaut.2019.06.008.
   Gao H, 2018, MOL CELL ENDOCRINOL, V470, P259, DOI 10.1016/j.mce.2017.11.007.
   Ge YN, 2019, MOL THER-NUCL ACIDS, V17, P741, DOI 10.1016/j.omtn.2019.07.007.
   George L, 2019, IMMUNOL INVEST, V48, P451, DOI 10.1080/08820139.2019.1566355.
   Guo JM, 2019, SCI TOTAL ENVIRON, V663, P380, DOI 10.1016/j.scitotenv.2019.01.360.
   Han Q, 2020, ECOTOX ENVIRON SAFE, V203, DOI 10.1016/j.ecoenv.2020.110974.
   Hawez A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02462.
   Hosseinzadeh A, 2016, J LEUKOCYTE BIOL, V100, P1105, DOI 10.1189/jlb.3AB0815-379RR.
   Hu XY, 2019, CHEMOSPHERE, V237, DOI 10.1016/j.chemosphere.2019.124427.
   Je S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155685.
   Ji J, 2018, PART FIBRE TOXICOL, V15, DOI 10.1186/s12989-018-0256-2.
   Jing HY, 2020, SCI TOTAL ENVIRON, V726, DOI 10.1016/j.scitotenv.2020.138686.
   King PT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12474-5.
   Lefrançais E, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98178.
   Li L, 2018, DEV COMP IMMUNOL, V88, P206, DOI 10.1016/j.dci.2018.07.024.
   Li S., 2020, SCI TOTAL ENVIRON, V206.
   Li XJ, 2020, SCI TOTAL ENVIRON, V699, DOI 10.1016/j.scitotenv.2019.134296.
   Lian CY, 2020, J INORG BIOCHEM, V212, DOI 10.1016/j.jinorgbio.2020.111231.
   Liu JB, 2021, ENVIRON POLLUT, V269, DOI 10.1016/j.envpol.2020.116186.
   Liu P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090042.
   Liu Q, 2020, CHEMOSPHERE, V247, DOI 10.1016/j.chemosphere.2020.125901.
   Liu Z, 2020, ENVIRON RES, V191, DOI 10.1016/j.envres.2020.110204.
   Mohanan S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00067.
   Moreau R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01044.
   Neeli I, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00038.
   O'Sullivan KM, 2015, KIDNEY INT, V88, P1030, DOI 10.1038/ki.2015.202.
   Papayannopoulos V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028526.
   Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34.
   Pertiwi KR, 2019, J PATHOL, V247, P505, DOI 10.1002/path.5212.
   Qu CD, 2020, IUBMB LIFE, V72, P465, DOI 10.1002/iub.2212.
   Radermecker C, 2019, NAT IMMUNOL, V20, P1444, DOI 10.1038/s41590-019-0496-9.
   Roth SW, 2018, CELL REP, V22, P2550, DOI 10.1016/j.celrep.2018.02.033.
   Rumbeiha W, 2016, ANN NY ACAD SCI, V1378, P5, DOI 10.1111/nyas.13148.
   SeleneJ C.-H, 2003, concise international chemical assessment document, V53, P7.
   Sorvillo N, 2019, CIRC RES, V125, P470, DOI 10.1161/CIRCRESAHA.119.314581.
   Stetka J, 2020, CANCERS, V12, DOI 10.3390/cancers12040903.
   Szabo C, 2018, BIOCHEM PHARMACOL, V149, P5, DOI 10.1016/j.bcp.2017.09.010.
   Tian F, 2012, GENOMICS, V99, P152, DOI 10.1016/j.ygeno.2011.11.004.
   Wang H, 2020, SCI TOTAL ENVIRON, V742, DOI 10.1016/j.scitotenv.2020.140532.
   Wang W, 2018, CHEMOSPHERE, V208, P241, DOI 10.1016/j.chemosphere.2018.05.152.
   Wang YH, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108953.
   Wang Y, 2021, ECOTOX ENVIRON SAFE, V208, DOI 10.1016/j.ecoenv.2020.111473.
   Wooding DJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01495-2019.
   Yang J, 2021, J CELL PHYSIOL, V236, P157, DOI 10.1002/jcp.29831.
   Zhang Y., 2019, J VIS EXP, V153.
   Zhang YG, 2019, CELL CYCLE, V18, P2674, DOI 10.1080/15384101.2019.1654797.
   Zhang ZW, 2020, FOOD FUNCT, V11, P1312, DOI {[}10.1039/c9fo02861g, 10.1039/C9FO02861G].
   Zhao HJ, 2021, SCI TOTAL ENVIRON, V762, DOI 10.1016/j.scitotenv.2020.143054.},
Number-of-Cited-References = {59},
Times-Cited = {48},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {85},
Journal-ISO = {Sci. Total Environ.},
Doc-Delivery-Number = {QV3SV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000627895900117},
DA = {2026-02-04},
}

@article{ WOS:000601069500001,
Author = {Bai, Yiguang and Zhang, Qiong and Zhou, Quan and Zhang, Yanan and Nong,
   Haibin and Liu, Mingfu and Shi, Zhuohua and Zeng, Gaofeng and Zong,
   Shaohui},
Title = {Effects of inhibiting PDK-1 expression in bone marrow mesenchymal stem
   cells on osteoblast differentiation in vitro},
Journal = {MOLECULAR MEDICINE REPORTS},
Year = {2021},
Volume = {23},
Number = {2},
Month = {FEB},
Abstract = {Osteoblasts are the main functional cells in bone formation, which are
   responsible for the synthesis, secretion and mineralization of bone
   matrix. The PI3K/AKT signaling pathway is strongly associated with the
   differentiation and survival of osteoblasts. The
   3-phosphoinositide-dependent protein kinase-1 (PDK-1) protein is
   considered the master upstream lipid kinase of the PI3K/AKT cascade. The
   present study aimed to investigate the role of PDK-1 in the process of
   mouse osteoblast differentiation in vitro. In the BX-912 group, BX-912,
   a specific inhibitor of PDK-1, was added to osteoblast induction medium
   (OBM) to treat bone marrow mesenchymal stem cells (BMSCs), whereas the
   control group was treated with OBM alone. Homozygote PDK1(flox/flox)
   mice were designed and generated, and were used to obtain
   BMSCsPDK1flox/flox. Subsequently, an adenovirus containing Cre
   recombinase enzyme (pHBAd-cre-EGFP) was used to disrupt the PDK-1 gene
   in BMSCsPDK1flox/flox; this served as the pHBAd-cre-EGFP group and the
   efficiency of the disruption was verified. Western blot analysis
   demonstrated that the protein expression levels of phosphorylated
   (p)-PDK1 and p-AKT were gradually increased during the osteoblast
   differentiation process. Notably, BX-912 treatment and disruption of the
   PDK-1 gene with pHBAd-cre-EGFP effectively reduced the number of
   alkaline phosphatase (ALP)-positive cells and the optical density value
   of ALP activity, as well as the formation of cell mineralization. The
   mRNA expression levels of PDK-1 in the pHBAd-cre-EGFP group were
   significantly downregulated compared with those in the empty vector
   virus group on days 3-7. The mRNA expression levels of the
   osteoblast-related genes RUNX2, osteocalcin and collagen I were
   significantly decreased in the BX-912 and pHBAd-cre-EGFP groups on days
   7 and 21 compared with those in the control and empty vector virus
   groups. Overall, the results indicated that BX-912 and disruption of the
   PDK-1 gene in vitro significantly inhibited the differentiation and
   maturation of osteoblasts. These experimental results provided an
   experimental and theoretical basis for the role of PDK-1 in osteoblasts.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Zong, SH (Corresponding Author), Guangxi Med Univ, Affiliated Hosp 1, Dept Spine Osteopathia, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zeng, GF (Corresponding Author), Guangxi Med Univ, Coll Publ Hyg, Dept Nutr \& Food Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Bai, Yiguang; Nong, Haibin; Liu, Mingfu; Shi, Zhuohua; Zong, Shaohui, Guangxi Med Univ, Affiliated Hosp 1, Dept Spine Osteopathia, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Bai, Yiguang, North Sichuan Med Coll, Inst Clin 2, Nanchong Cent Hosp, Dept Orthoped, Nanchong 637000, Sichuan, Peoples R China.
   Zhang, Qiong; Zeng, Gaofeng, Guangxi Med Univ, Coll Publ Hyg, Dept Nutr \& Food Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zhou, Quan; Zhang, Yanan, Guangxi Med Univ, Collaborat Innovat Ctr Guangxi Biol Med, Nanning 530021, Guangxi, Peoples R China.
   Zhou, Quan, Mudanjiang Med Univ, Hongqi Hosp, Dept Emergency, Mudanjiang 157001, Heilongjiang, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.},
DOI = {10.3892/mmr.2020.11757},
Article-Number = {118},
ISSN = {1791-2997},
EISSN = {1791-3004},
Keywords = {osteoblasts; gene knockout; adenovirus; Cre reco-mbinase enzyme;
   3-phosphoinositide-dependent protein kinase 1},
Keywords-Plus = {3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE; PI3K/AKT SIGNALING PATHWAY;
   RAPAMYCIN; PROLIFERATION; OSTEOGENESIS; REVEALS},
Research-Areas = {Oncology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Oncology; Medicine, Research \& Experimental},
Author-Email = {1685858372@qq.com
   xiaohui3008@126.com},
Affiliations = {Guangxi Medical University; North Sichuan Medical University; Guangxi
   Medical University; Guangxi Medical University; Mudanjiang Medical
   University; Guangxi Medical University; Guangxi Medical University},
ResearcherID-Numbers = {yiguang, bai/AAC-7732-2021},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81860402]; Guangxi
   Natural Science Foundation of China {[}2017GXNSFAA198073]; Guangxi Key
   Research and Development Project {[}GuikeAB17195001]; High Level
   Innovation Team and Excellence Scholars Program of Guangxi High
   Education Institutions; Guangxi Medical High-level Key Talents Training
   `139' Program Training Project},
Funding-Text = {The present study was supported by the National Natural Science
   Foundation of China (grant no. 81860402), the Guangxi Natural Science
   Foundation of China (grant no. 2017GXNSFAA198073), the Guangxi Key
   Research and Development Project (grant no. GuikeAB17195001), and the
   High Level Innovation Team and Excellence Scholars Program of Guangxi
   High Education Institutions and Guangxi Medical High-level Key Talents
   Training `139' Program Training Project.},
Cited-References = {Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008.
   Agas D, 2013, J CELL PHYSIOL, V228, P2149, DOI 10.1002/jcp.24382.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Berendsen AD, 2015, BONE, V80, P14, DOI 10.1016/j.bone.2015.04.035.
   Coppé JP, 2019, NAT CELL BIOL, V21, P778, DOI 10.1038/s41556-019-0328-z.
   Dai Y, 2021, J CELL BIOCHEM, V122, P1251, DOI 10.1002/jcb.29497.
   Föger-Samwald U, 2016, EXP GERONTOL, V73, P49, DOI 10.1016/j.exger.2015.11.012.
   Frödin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924.
   Fu XJ, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0400-6.
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377.
   Hadzir SN, 2014, CYTOTHERAPY, V16, P674, DOI 10.1016/j.jcyt.2013.07.013.
   Huang RX, 2020, MOL MED REP, V22, P145, DOI 10.3892/mmr.2020.11116.
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015.
   Isomoto S, 2007, J ORTHOP SCI, V12, P83, DOI 10.1007/s00776-006-1079-9.
   Jeon HL, 2020, J BONE MINER METAB, V38, P254, DOI 10.1007/s00774-019-01052-6.
   Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795.
   Liu P, 2017, CELL DEATH DIFFER, V24, P672, DOI 10.1038/cdd.2016.165.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Owen Thomas A., 2008, V455, P3, DOI 10.1007/978-1-59745-104-8\_1.
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061.
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403.
   Peng XM, 2018, REJUV RES, V21, P44, DOI 10.1089/rej.2017.1956.
   Phornphutkul C, 2009, J ORTHOP RES, V27, P1157, DOI 10.1002/jor.20894.
   Qian XJ, 2015, PATHOL BIOL, V63, P91, DOI 10.1016/j.patbio.2014.12.004.
   Qiu ZX, 2019, CANCER CELL, V36, P179, DOI 10.1016/j.ccell.2019.07.001.
   Sakaue H, 2003, J BIOL CHEM, V278, P38870, DOI 10.1074/jbc.M306151200.
   Selim AA, 2007, MED SCI MONITOR, V13, pBR259.
   Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120.
   Singha UK, 2008, J CELL BIOCHEM, V103, P434, DOI 10.1002/jcb.21411.
   Son KM, 2010, BIOMED MATER, V5, DOI 10.1088/1748-6041/5/4/044107.
   Ulici V, 2009, BONE, V45, P1133, DOI 10.1016/j.bone.2009.08.003.
   Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005.
   Wang J, 2017, BIOL TRACE ELEM RES, V179, P284, DOI 10.1007/s12011-017-0948-8.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Wu J, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/1540148.
   Xi YM, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112189.
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677.
   Yoon JY, 2018, TISSUE ENG REGEN MED, V15, P333, DOI 10.1007/s13770-018-0116-z.
   Zhu YR, 2015, CANCER BIOL THER, V16, P602, DOI 10.1080/15384047.2015.1017155.},
Number-of-Cited-References = {39},
Times-Cited = {8},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Mol. Med. Rep.},
Doc-Delivery-Number = {PI4NP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000601069500001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000623780500001,
Author = {Elsayed, Abdelrahman M. and Bayraktar, Emine and Amero, Paola and
   Salama, Salama A. and Abdelaziz, Abdelaziz H. and Ismail, Raed S. and
   Zhang, Xinna and Ivan, Cristina and Sood, Anil K. and Lopez-Berestein,
   Gabriel and Rodriguez-Aguayo, Cristian},
Title = {PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and
   Chemoresistance via the PI3K/AKT/mTOR Pathway},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2021},
Volume = {22},
Number = {4},
Month = {FEB},
Abstract = {Many long noncoding RNAs have been implicated in tumorigenesis and
   chemoresistance; however, the underlying mechanisms are not well
   understood. We investigated the role of PRKAR1B-AS2 long noncoding RNA
   in ovarian cancer (OC) and chemoresistance and identified potential
   downstream molecular circuitry underlying its action. Analysis of The
   Cancer Genome Atlas OC dataset, in vitro experiments, proteomic
   analysis, and a xenograft OC mouse model were implemented. Our findings
   indicated that overexpression of PRKAR1B-AS2 is negatively correlated
   with overall survival in OC patients. Furthermore, PRKAR1B-AS2
   knockdown-attenuated proliferation, migration, and invasion of OC cells
   and ameliorated cisplatin and alpelisib resistance in vitro. In
   proteomic analysis, silencing PRKAR1B-AS2 markedly inhibited protein
   expression of PI3K-110 alpha and abrogated the phosphorylation of PDK1,
   AKT, and mTOR, with no significant effect on PTEN. The RNA
   immunoprecipitation detected a physical interaction between PRKAR1B-AS2
   and PI3K-110 alpha. Moreover, PRKAR1B-AS2 knockdown by systemic
   administration of 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine
   nanoparticles loaded with PRKAR1B-AS2-specific small interfering RNA
   enhanced cisplatin sensitivity in a xenograft OC mouse model. In
   conclusion, PRKAR1B-AS2 promotes tumor growth and confers
   chemoresistance by modulating the PI3K/AKT/mTOR pathway. Thus, targeting
   PRKAR1B-AS2 may represent a novel therapeutic approach for the treatment
   of OC patients.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Rodriguez-Aguayo, C (Corresponding Author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA.
   Rodriguez-Aguayo, C (Corresponding Author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference \& Noncoding RNA, Houston, TX 77054 USA.
   Elsayed, Abdelrahman M.; Bayraktar, Emine; Amero, Paola; Ivan, Cristina; Lopez-Berestein, Gabriel; Rodriguez-Aguayo, Cristian, Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA.
   Elsayed, Abdelrahman M.; Salama, Salama A.; Abdelaziz, Abdelaziz H.; Ismail, Raed S., Al Azhar Univ, Dept Pharmacol \& Toxicol, Fac Pharm, Cairo 11675, Egypt.
   Bayraktar, Emine; Sood, Anil K., Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol \& Reprod Med, Houston, TX 77030 USA.
   Zhang, Xinna, Indiana Univ Sch Med, Dept Med \& Mol Genet, Indianapolis, IN 46202 USA.
   Ivan, Cristina; Sood, Anil K.; Lopez-Berestein, Gabriel; Rodriguez-Aguayo, Cristian, Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference \& Noncoding RNA, Houston, TX 77054 USA.},
DOI = {10.3390/ijms22041882},
Article-Number = {1882},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {lncRNA; PRKAR1B-AS2; AC147651; 5; cisplatin resistance; PI3K; AKT; mTOR;
   ovarian cancer},
Keywords-Plus = {OVARIAN-CANCER; CISPLATIN; PI3K; CARCINOGENESIS; PROGRESSION;
   EXPRESSION; RESISTANCE; REGULATORS; APOPTOSIS; TARGET},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {AMHamoda@mdanderson.org
   EBayraktar@mdanderson.org
   PAmero@mdanderson.org
   salama@azhar.edu.eg
   abdelazizhamed@azhar.edu.eg
   raedismail@azhar.edu.eg
   xz48@iu.edu
   CIvan@mdanderson.org
   asood@mdanderson.org
   glopez@mdanderson.org
   CRodriguez2@mdanderson.org},
Affiliations = {University of Texas System; UTMD Anderson Cancer Center; Egyptian
   Knowledge Bank (EKB); Al Azhar University; University of Texas System;
   UTMD Anderson Cancer Center; Indiana University System; Indiana
   University Bloomington; University of Texas System; UTMD Anderson Cancer
   Center},
ResearcherID-Numbers = {Xinna, Zhang/HTT-1251-2023
   Elsayed, Abdelrahman M./ABH-3539-2021},
ORCID-Numbers = {ROIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723
   Amero, Paola/0000-0002-7503-0381
   Ivan, Cristina/0000-0002-4848-0168
   salama, salama/0000-0001-6129-6616
   Hamoda, Abdelrahman/0000-0003-0277-0917
   Bayraktar, Emine/0000-0002-5189-1507
   },
Funding-Acknowledgement = {National Institutes of Health/National Cancer Institute
   {[}5U01CA213759-02, P30CA016672]; American Cancer Society; National
   Science Foundation {[}CHE-1411859]; John P. Gaines Foundation; Egyptian
   Ministry of Higher Education; National Institutes of Health through the
   Ovarian SPORE Career Enhancement Program; National Cancer Institute
   {[}FP00000019]; National Cancer Institute {[}P30CA016672] Funding
   Source: NIH RePORTER},
Funding-Text = {This work was supported in part by grants from the National Institutes
   of Health/National Cancer Institute (5U01CA213759-02, P30CA016672),
   American Cancer Society, and National Science Foundation (CHE-1411859)
   and an endowment grant from the John P. Gaines Foundation. Abdelrahman
   M. Elsayed was supported by a scholarship from the Egyptian Ministry of
   Higher Education. Cristian Rodriguez-Aguayo was supported by the
   National Institutes of Health through the Ovarian SPORE Career
   Enhancement Program and National Cancer Institute grant FP00000019.},
Cited-References = {Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556.
   Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988.
   Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305.
   Bookman MA, 2009, J CLIN ONCOL, V27, P1419, DOI 10.1200/JCO.2008.19.1684.
   Carden CP, 2012, MOL CANCER THER, V11, P1609, DOI 10.1158/1535-7163.MCT-11-0996.
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824.
   Cheaib B, 2015, CHIN J CANCER, V34, P4, DOI 10.5732/cjc.014.10289.
   Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003.
   Creighton CJ, 2015, DRUG DES DEV THER, V9, P3519, DOI 10.2147/DDDT.S38375.
   DeSantis CE, 2019, CA-CANCER J CLIN, V69, P452, DOI 10.3322/caac.21577.
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233.
   du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036.
   Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865.
   Harries LW, 2012, BIOCHEM SOC T, V40, P902, DOI 10.1042/BST20120020.
   Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008.
   Huang J, 2011, GENE CHROMOSOME CANC, V50, P606, DOI 10.1002/gcc.20883.
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981.
   Johnson SW, 1996, EXP CELL RES, V226, P133, DOI 10.1006/excr.1996.0211.
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107.
   KASAMY K, 2002, CANCER RES, V62, P4929.
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167.
   Kim S, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0063-0.
   Konstantinopoulos PA, 2019, LANCET ONCOL, V20, P570, DOI 10.1016/S1470-2045(18)30905-7.
   Kriplani Nisha, 2015, Advances in Biological Regulation, V59, P53, DOI {[}10.1016/j.jbior.2015.05.002, 10.1016/j.jbior.2015.05.002].
   Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011.
   Landen CN Jr, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530.
   Le Naour Augustin, 2018, Oncotarget, V9, P27220, DOI {[}10.18632/oncotarget.25513, 10.18632/oncotarget.25513].
   Li JH, 2015, FRONT BIOENG BIOTECH, V2, DOI 10.3389/fbioe.2014.00088.
   Li S, 2019, J CELL BIOCHEM, V120, P4092, DOI 10.1002/jcb.27694.
   Mabuchi S, 2015, GYNECOL ONCOL, V137, P173, DOI 10.1016/j.ygyno.2015.02.003.
   Mabuchi S, 2009, CLIN CANCER RES, V15, P5404, DOI 10.1158/1078-0432.CCR-09-0365.
   Matulonis UA, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.61.
   McGuire WP, 1996, NEW ENGL J MED, V334, P1, DOI 10.1056/NEJM199601043340101.
   Musa F, 2015, TRANSL CANCER RES, V4, P97, DOI 10.3978/j.issn.2218-676X.2015.01.10.
   Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200.
   Noh JH, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1471.
   Oncul S, 2020, RNA BIOL, V17, P1523, DOI 10.1080/15476286.2019.1702283.
   Pauli A, 2011, NAT REV GENET, V12, P136, DOI 10.1038/nrg2904.
   Peng DJ, 2010, BIOCHEM BIOPH RES CO, V394, P600, DOI 10.1016/j.bbrc.2010.03.029.
   Plastaras JP, 2008, CANCER BIOL THER, V7, P2047, DOI 10.4161/cbt.7.12.7570.
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209.
   Rodriguez-Aguayo C, 2019, EBIOMEDICINE, V40, P290, DOI 10.1016/j.ebiom.2018.11.045.
   Rodriguez-Aguayo C, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.29.
   Roelants Caroline, 2018, Oncotarget, V9, P30066, DOI {[}10.18632/oncotarget.25700, 10.18632/oncotarget.25700].
   SCANLON KJ, 1990, CANCER TREAT REV, V17, P27, DOI 10.1016/0305-7372(90)90013-6.
   Schmitt AM, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026492.
   Shen HF, 2013, CLIN CANCER RES, V19, P1806, DOI 10.1158/1078-0432.CCR-12-2764.
   Shulkla S, 2007, INT J CANCER, V121, P1424, DOI 10.1002/ijc.22862.
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551.
   Singh P, 2016, FEBS LETT, V590, P3071, DOI 10.1002/1873-3468.12377.
   Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621.
   Sun QY, 2018, TRENDS GENET, V34, P142, DOI 10.1016/j.tig.2017.11.005.
   Tai YL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/690690.
   Tang JY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11447-8.
   Vance KW, 2014, TRENDS GENET, V30, P348, DOI 10.1016/j.tig.2014.06.001.
   Wang H, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1148-y.
   Wang Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1105-0.
   Whitehead J, 2009, BBA-GEN SUBJECTS, V1790, P936, DOI 10.1016/j.bbagen.2008.10.007.
   Yan B, 2012, DNA CELL BIOL, V31, pS34, DOI 10.1089/dna.2011.1544.
   Yang J, 2019, MOL THER-NUCL ACIDS, V18, P1, DOI {[}10.1016/j.omtn.2019.08.003, 10.1186/s12943-019-0954-x].
   Yang YX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1280-8.
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245.
   Zhang EB, 2014, ONCOTARGET, V5, P2276, DOI 10.18632/oncotarget.1902.
   Zhu Y, 2016, ONCOTARGET, V7, P14429, DOI 10.18632/oncotarget.7418.},
Number-of-Cited-References = {64},
Times-Cited = {17},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {QP4BE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000623780500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000622354500001,
Author = {Venturoli, Carolina and Piga, Ilaria and Curtarello, Matteo and Verza,
   Martina and Esposito, Giovanni and Venuto, Santina and Navaglia, Filippo
   and Grassi, Angela and Indraccolo, Stefano},
Title = {Genetic Perturbation of Pyruvate Dehydrogenase Kinase 1 Modulates
   Growth, Angiogenesis and Metabolic Pathways in Ovarian Cancer Xenografts},
Journal = {CELLS},
Year = {2021},
Volume = {10},
Number = {2},
Month = {FEB},
Abstract = {Pyruvate dehydrogenase kinase 1 (PDK1) blockade triggers are well
   characterized in vitro metabolic alterations in cancer cells, including
   reduced glycolysis and increased glucose oxidation. Here, by gene
   expression profiling and digital pathology-mediated quantification of in
   situ markers in tumors, we investigated effects of PDK1 silencing on
   growth, angiogenesis and metabolic features of tumor xenografts formed
   by highly glycolytic OC316 and OVCAR3 ovarian cancer cells. Notably, at
   variance with the moderate antiproliferative effects observed in vitro,
   we found a dramatic negative impact of PDK1 silencing on tumor growth.
   These findings were associated with reduced angiogenesis and increased
   necrosis in the OC316 and OVCAR3 tumor models, respectively. Analysis of
   viable tumor areas uncovered increased proliferation as well as
   increased apoptosis in PDK1-silenced OVCAR3 tumors. Moreover, RNA
   profiling disclosed increased glucose catabolic pathways-comprising both
   oxidative phosphorylation and glycolysis-in PDK1-silenced OVCAR3 tumors,
   in line with the high mitotic activity detected in the viable rim of
   these tumors. Altogether, our findings add new evidence in support of a
   link between tumor metabolism and angiogenesis and remark on the
   importance of investigating net effects of modulations of metabolic
   pathways in the context of the tumor microenvironment.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Indraccolo, S (Corresponding Author), Veneto Inst Oncol IOV IRCCS, Immunol \& Mol Oncol Unit, I-35128 Padua, Italy.
   Indraccolo, S (Corresponding Author), Univ Padua, Dept Surg Oncol \& Gastroenterol, I-35128 Padua, Italy.
   Venturoli, Carolina; Piga, Ilaria; Curtarello, Matteo; Verza, Martina; Esposito, Giovanni; Grassi, Angela; Indraccolo, Stefano, Veneto Inst Oncol IOV IRCCS, Immunol \& Mol Oncol Unit, I-35128 Padua, Italy.
   Piga, Ilaria; Indraccolo, Stefano, Univ Padua, Dept Surg Oncol \& Gastroenterol, I-35128 Padua, Italy.
   Venuto, Santina, Univ Padua, Dept Biol, I-35128 Padua, Italy.
   Navaglia, Filippo, Univ Hosp Padova, Dept Lab Med, I-35128 Padua, Italy.},
DOI = {10.3390/cells10020325},
Article-Number = {325},
EISSN = {2073-4409},
Keywords = {ovarian cancer; PDK1; metabolism; glycolysis; angiogenesis},
Keywords-Plus = {TOTAL LESION GLYCOLYSIS; F-18-FDG PET/CT; TUMOR VOLUME; CELL-LINES;
   PROGNOSIS; LACTATE; AXIS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {carolinaventuroli@live.it
   ilaria.piga1992@gmail.com
   matteo.curtarello@iov.veneto.it
   martina2.verza@gmail.com
   giovanni.esposito@iov.veneto.it
   santina.venuto@studenti.unipd.it
   filippo.navaglia@aopd.veneto.it
   angela.grassi@iov.veneto.it
   stefano.indraccolo@unipd.it},
Affiliations = {IRCCS Istituto Oncologico Veneto (IOV); University of Padua; University
   of Padua; University of Padua; Azienda Ospedaliera - Universita di
   Padova},
ResearcherID-Numbers = {Grassi, Angela/N-3085-2013
   PIGA, Ilaria/AAC-1074-2022
   Inaccolo, Stefano/E-9541-2012
   Curtarello, Matteo/P-8120-2019},
ORCID-Numbers = {Grassi, Angela/0000-0002-8313-8384
   PIGA, Ilaria/0000-0002-4948-0709
   Inaccolo, Stefano/0000-0002-4810-7136
   Curtarello, Matteo/0000-0003-3133-4807},
Funding-Acknowledgement = {AIRC {[}IG 2020-ID, 25179]},
Funding-Text = {The research leading to these results has received funding from AIRC
   under IG 2020-ID. 25179 project-P.I. Indraccolo Stefano.},
Cited-References = {Allal AS, 2002, J CLIN ONCOL, V20, P1398, DOI 10.1200/JCO.20.5.1398.
   Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Choi ES, 2013, EUR J NUCL MED MOL I, V40, P1836, DOI 10.1007/s00259-013-2511-y.
   Chung HW, 2014, J CANCER RES CLIN, V140, P89, DOI 10.1007/s00432-013-1545-7.
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fabian C, 2012, FEBS J, V279, P882, DOI 10.1111/j.1742-4658.2012.08479.x.
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478.
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015.
   Lee JW, 2014, EUR J NUCL MED MOL I, V41, P1898, DOI 10.1007/s00259-014-2803-x.
   Liang WJ, 2016, ONCOTARGET, V7, P15444, DOI 10.18632/oncotarget.6999.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Martinez-Outschoorn UE, 2011, INT J BIOCHEM CELL B, V43, P1045, DOI 10.1016/j.biocel.2011.01.023.
   Mayers JR, 2015, TRENDS BIOCHEM SCI, V40, P130, DOI 10.1016/j.tibs.2015.01.004.
   Nardo G, 2011, CANCER RES, V71, P4214, DOI 10.1158/0008-5472.CAN-11-0242.
   Pastò A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043379.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Payen VL, 2020, MOL METAB, V33, P48, DOI 10.1016/j.molmet.2019.07.006.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Piga I, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01277.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Smyth GK., 2004, Stat Appl Genet Mol Biol, V3, DOI {[}10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027].
   Sonveaux P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033418.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079.
   Tudrej P, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9030120.
   Végran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828.
   Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004.
   Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711.
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.},
Number-of-Cited-References = {35},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Cells},
Doc-Delivery-Number = {QN3HG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000622354500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000618015400013,
Author = {Zuo, Qiaozhu and He, Jia and Zhang, Shu and Wang, Hui and Jin, Guangzhi
   and Jin, Haojie and Cheng, Zhuoan and Tao, Xuemei and Yu, Chengtao and
   Li, Botai and Yang, Chen and Wang, Siying and Lv, Yuanyuan and Zhao,
   Fangyu and Yao, Ming and Cong, Wenming and Wang, Cun and Qin, Wenxin},
Title = {PPARγ Coactivator-1α Suppresses Metastasis of Hepatocellular Carcinoma
   by Inhibiting Warburg Effect by PPARγ-Dependent WNT/β-Catenin/Pyruvate
   Dehydrogenase Kinase Isozyme 1 Axis},
Journal = {HEPATOLOGY},
Year = {2021},
Volume = {73},
Number = {2},
Pages = {644-660},
Month = {FEB},
Abstract = {Background and Aims Peroxisome proliferator-activated receptor-gamma
   (PPAR gamma) coactivator-1 alpha (PGC1 alpha) is a key regulator of
   mitochondrial biogenesis and respiration. PGC1 alpha is involved in the
   carcinogenesis, progression, and metabolic state of cancer. However, its
   role in the progression of hepatocellular carcinoma (HCC) remains
   unclear.
   Approach and Results In this study, we observed that PGC1 alpha was
   down-regulated in human HCC. A clinical study showed that low levels of
   PGC1 alpha expression were correlated with poor survival, vascular
   invasion, and larger tumor size. PGC1 alpha inhibited the migration and
   invasion of HCC cells with both in vitro experiments and in vivo mouse
   models. Mechanistically, PGC1 alpha suppressed the Warburg effect
   through down-regulation of pyruvate dehydrogenase kinase isozyme 1
   (PDK1) mediated by the WNT/beta-catenin pathway, and inhibition of the
   WNT/beta-catenin pathway was induced by activation of PPAR gamma.
   Conclusions Low levels of PGC1 alpha expression indicate a poor
   prognosis for HCC patients. PGC1 alpha suppresses HCC metastasis by
   inhibiting aerobic glycolysis through regulating the
   WNT/beta-catenin/PDK1 axis, which depends on PPAR gamma. PGC1 alpha is a
   potential factor for predicting prognosis and a therapeutic target for
   HCC patients.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, C; Qin, WX (Corresponding Author), Shanghai Jiao Tong Univ, Shanghai Canc Inst, Renji Hosp, State Key Lab Oncogenes \& Related Genes,Sch Med, 25 Ln 2200 Xie Tu Rd, Shanghai 200032, Peoples R China.
   Zuo, Qiaozhu; He, Jia; Wang, Hui; Jin, Haojie; Tao, Xuemei; Wang, Siying; Lv, Yuanyuan; Zhao, Fangyu; Yao, Ming; Wang, Cun; Qin, Wenxin, Shanghai Jiao Tong Univ, Shanghai Canc Inst, Renji Hosp, State Key Lab Oncogenes \& Related Genes,Sch Med, 25 Ln 2200 Xie Tu Rd, Shanghai 200032, Peoples R China.
   Zhang, Shu, Fudan Univ, Liver Canc Inst, Zhongshan Hosp, Shanghai, Peoples R China.
   Zhang, Shu, Fudan Univ, Key Lab Carcinogenesis \& Canc Invas, Minist Educ, Shanghai, Peoples R China.
   Jin, Guangzhi; Cong, Wenming, Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Pathol, Shanghai, Peoples R China.
   Cheng, Zhuoan; Yu, Chengtao; Li, Botai, Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.
   Yang, Chen, Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.},
DOI = {10.1002/hep.31280},
ISSN = {0270-9139},
EISSN = {1527-3350},
Research-Areas = {Gastroenterology \& Hepatology},
Web-of-Science-Categories  = {Gastroenterology \& Hepatology},
Author-Email = {cwang@shsci.org
   wxqin@sjtu.edu.cn},
Affiliations = {Shanghai Jiao Tong University; Fudan University; Fudan University; Naval
   Medical University; Shanghai Jiao Tong University; Fudan University},
ResearcherID-Numbers = {Yu, Caoyang/AAB-4785-2020
   Wang, Siying/KHX-1894-2024
   Zhang, Shu/J-9235-2015},
ORCID-Numbers = {Qin, Wenxin/0000-0002-1989-3027
   Wang, Siying/0000-0003-0810-8828
   },
Cited-References = {Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055.
   Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006.
   Baumunk D, 2013, WORLD J UROL, V31, P1191, DOI 10.1007/s00345-012-0874-5.
   Beyoglu D, 2013, HEPATOLOGY, V58, P229, DOI 10.1002/hep.26350.
   Bhalla K, 2011, CANCER RES, V71, P6888, DOI 10.1158/0008-5472.CAN-11-1011.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Carracedo A, 2013, NAT REV CANCER, V13, P227, DOI 10.1038/nrc3483.
   Chafey P, 2009, PROTEOMICS, V9, P3889, DOI 10.1002/pmic.200800609.
   Chen JQ, 2012, BBA-REV CANCER, V1826, P370, DOI 10.1016/j.bbcan.2012.06.004.
   Chen ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0616-8.
   Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114.
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649.
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017.
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794.
   Gerhold DL, 2002, ENDOCRINOLOGY, V143, P2106, DOI 10.1210/en.143.6.2106.
   Han H, 2016, J MOL CELL BIOL, V8, P400, DOI 10.1093/jmcb/mjw010.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Iansante V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8882.
   Jin JL, 2013, J BIOL CHEM, V288, P14451, DOI 10.1074/jbc.M113.460840.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kitamura K, 2011, J HEPATOL, V55, P846, DOI 10.1016/j.jhep.2011.01.038.
   Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260.
   LaGory EL, 2015, CELL REP, V12, P116, DOI 10.1016/j.celrep.2015.06.006.
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039.
   Lecarpentier Y, 2017, PPAR RES, V2017, DOI 10.1155/2017/5879090.
   Lee SY, 2012, CANCER RES, V72, P3607, DOI 10.1158/0008-5472.CAN-12-0006.
   Li D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0494-0.
   Lim JH, 2014, CANCER RES, V74, P3535, DOI 10.1158/0008-5472.CAN-13-2893-T.
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004.
   Liu HJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001249.
   Liu R, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695031.
   Luo C, 2016, NATURE, V537, P422, DOI 10.1038/nature19347.
   Mastropasqua F, 2018, GENES-BASEL, V9, DOI 10.3390/genes9010048.
   Moldes M, 2003, BIOCHEM J, V376, P607, DOI 10.1042/BJ20030426.
   Ni ZH, 2018, AUTOPHAGY, V14, P685, DOI 10.1080/15548627.2017.1407887.
   Nie HZ, 2015, HEPATOLOGY, V62, P1145, DOI 10.1002/hep.27940.
   Paradis V, 2009, HEPATOLOGY, V49, P851, DOI 10.1002/hep.22734.
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598.
   Piccinin E, 2019, NAT REV GASTRO HEPAT, V16, P160, DOI 10.1038/s41575-018-0089-3.
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Sherwood V, 2015, MOL CELL BIOL, V35, P2, DOI 10.1128/MCB.00992-14.
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024.
   Storey KB, 2003, ADV EXP MED BIOL, V543, P21.
   Tennakoon JB, 2014, ONCOGENE, V33, P5251, DOI 10.1038/onc.2013.463.
   Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196.
   Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357.
   Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020.
   Wang B, 2012, HEPATOLOGY, V56, P186, DOI 10.1002/hep.25632.
   Wang JR, 2016, ONCOTARGETS THER, V9, P5597, DOI 10.2147/OTT.S110646.
   Zucman-Rossi J, 2015, GASTROENTEROLOGY, V149, P1226, DOI 10.1053/j.gastro.2015.05.061.},
Number-of-Cited-References = {50},
Times-Cited = {124},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {80},
Journal-ISO = {Hepatology},
Doc-Delivery-Number = {QH1DA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000618015400013},
DA = {2026-02-04},
}

@article{ WOS:000604943800007,
Author = {Li, Xiao-Na and Yang, San-Qiao and Li, Min and Li, Xue-Song and Tian,
   Qing and Xiao, Fan and Tang, Yi-Yun and Kang, Xuan and Wang, Chun-Yan
   and Zou, Wei and Zhang, Ping and Tang, Xiao-Qing},
Title = {Formaldehyde induces ferroptosis in hippocampal neuronal cells by
   upregulation of the Warburg effect},
Journal = {TOXICOLOGY},
Year = {2021},
Volume = {448},
Month = {JAN 30},
Abstract = {The mechanisms underlying formaldehyde (FA)-induced neurotoxicity have
   not yet been fully clarified. Ferroptosis is a novel regulatory cell
   death and the Warburg effect is involved in regulating neural function.
   In this study, we investigated whether FA-induced neurotoxicity is
   implicated in neuronal ferroptosis and determined whether the Warburg
   effect mediates FA-induced neuronal ferroptosis. We found that FA (0.1,
   0.5 and 1.0 mM, 6 h) induced cell death in HT22 cells (a cell line of
   mouse hippocampal neuron), as evidenced by a decrease in cell viability
   and an increase in cell mortality; enhanced oxidative stress, as
   evidenced by a decrease in glutathione (GSH) and increases in
   malondialdehyde (MDA), 4-Hydroxynonenal (4-HNE), as well as reactive
   oxygen species (ROS); increased the iron content; and upregulated the
   ferroptosis-associated genes, including Ptgs2
   (prostaglandin-endoperoxide synthase 2), GLS2 (glutaminase 2), solute
   carrier family 1 member 5 (SLC1A5), and solute carrier family 38 member
   1 (SLC38A1) in HT22 cells, indicating the inductive role of FA in the
   ferroptosis of HT22 cells. Meanwhile, we found that FA (0.1, 1, 10 mu
   mol) decreased the cross-sectional of mitochondria, increased the level
   of lipid ROS and iron content in primary hippocampal cells. We showed
   that FA (0.1, 0.5 and 1.0 mM, 6 h) upregulated the Warburg effect in
   HT22 cells, as evidenced by up-regulations of pyruvate kinase M2 (PKM2),
   pyruvate dehydrogenase kinase 1(PDK-1), and lactate dehydrogenase (LDHA)
   proteins; down-regulation of pyruvate dehydrogenase (PDH); and an
   increase in lactate production. Also, we found that FA (0.1, 1, 10 mu
   mol, 7 d) upregulated the Warburg effect in hippocampal tissue, as
   evidenced by up-regulations of PKM2, PDK-1, and LDHA proteins;
   down-regulation of PDH. Furthermore, the inhibition of the Warburg
   effect by dichloroacetate (DCA) protected HT22 cells against FA-induced
   ferroptosis and cell death. Collectively, these data indicated that FA
   induces ferroptosis in hippocampal neuronal cells by upregulation of the
   Warburg effect.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, CY; Tang, XQ (Corresponding Author), Univ South China, Hengyang Med Coll, Inst Neurosci, Hengyang 421001, Hunan, Peoples R China.
   Li, Xiao-Na; Li, Xue-Song, Guangzhou Med Univ, Huizhou Peoples Hosp 3, Dept Neurosurg, Huizhou 516002, Guangdong, Peoples R China.
   Li, Xiao-Na; Li, Min; Tian, Qing; Xiao, Fan; Tang, Yi-Yun; Kang, Xuan; Wang, Chun-Yan; Tang, Xiao-Qing, Univ South China, Hengyang Med Coll, Inst Neurosci, Hengyang 421001, Hunan, Peoples R China.
   Li, Min; Xiao, Fan; Zou, Wei; Zhang, Ping, Univ South China, Affiliated Nanhua Hosp, Dept Neurol, Hengyang 421001, Hunan, Peoples R China.
   Yang, San-Qiao; Kang, Xuan; Tang, Xiao-Qing, Univ South China, Affiliated Hosp 1, Inst Neurol, Hengyang 421001, Hunan, Peoples R China.
   Wang, Chun-Yan, Univ South China, Hengyang Med Coll, Dept Pathophysiol, Hengyang 421001, Hunan, Peoples R China.},
DOI = {10.1016/j.tox.2020.152650},
Article-Number = {152650},
ISSN = {0300-483X},
EISSN = {1879-3185},
Keywords = {Formaldehyde; Warburg effect; Ferroptosis; Neurotoxicity},
Keywords-Plus = {AEROBIC GLYCOLYSIS; GLUTATHIONE EXPORT; PC12 CELLS; BRAIN; IRON;
   INHIBITION; OXIDATION; TOXICITY; EXPOSURE; MEMORY},
Research-Areas = {Pharmacology \& Pharmacy; Toxicology},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy; Toxicology},
Author-Email = {wcy\_5353@163.com
   tangxq-usc@qq.com},
Affiliations = {Guangzhou Medical University; University of South China; University of
   South China; University of South China; University of South China},
ResearcherID-Numbers = {li, xuedong/JYP-4367-2024
   Tang, Xiao-Qing/J-9907-2012},
ORCID-Numbers = {Li, Xuesong/0000-0003-4632-6623
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81771178]; Natural
   Science Foundation of Hunan Province {[}2019JJ80057, 2019JJ50556]; Major
   Research Topics of the Health Commission of Hunan province {[}20201911]},
Funding-Text = {This research was funded by National Natural Science Foundation of China
   (grant number 81771178), the Natural Science Foundation of Hunan
   Province (grant number 2019JJ80057, 2019JJ50556), and the Major Research
   Topics of the Health Commission of Hunan province ((grant number
   20201911).},
Cited-References = {Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064.
   Berg D, 2001, J NEUROCHEM, V79, P225, DOI 10.1046/j.1471-4159.2001.00608.x.
   CHANG CC, 1992, REGUL TOXICOL PHARM, V16, P150, DOI 10.1016/0273-2300(92)90054-D.
   Chen BB, 2019, FREE RADICAL BIO MED, V141, P253, DOI 10.1016/j.freeradbiomed.2019.06.024.
   Chen LJ, 2015, J BIOL CHEM, V290, P28097, DOI 10.1074/jbc.M115.680090.
   Chen Y, 2017, CLIN EXP PHARMACOL P, V44, P595, DOI 10.1111/1440-1681.12741.
   Chen Z, 2018, J CELL PHYSIOL, V233, P2839, DOI 10.1002/jcp.25998.
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042.
   Do Van B, 2016, NEUROBIOL DIS, V94, P169, DOI 10.1016/j.nbd.2016.05.011.
   Duong A, 2011, MUTAT RES-REV MUTAT, V728, P118, DOI 10.1016/j.mrrev.2011.07.003.
   Dusek P, 2015, J TRACE ELEM MED BIO, V31, P193, DOI 10.1016/j.jtemb.2014.05.007.
   Emeis D, 2010, CONTACT DERMATITIS, V63, P57, DOI 10.1111/j.1600-0536.2010.01708.x.
   Gebregiworgis T, 2016, J PROTEOME RES, V15, P659, DOI 10.1021/acs.jproteome.5b01111.
   HECK HD, 1985, AM IND HYG ASSOC J, V46, P1, DOI 10.1080/15298668591394275.
   Itoh Y, 2003, P NATL ACAD SCI USA, V100, P4879, DOI 10.1073/pnas.0831078100.
   Jomova K, 2010, MOL CELL BIOCHEM, V345, P91, DOI 10.1007/s11010-010-0563-x.
   Kato S, 2001, ANAL CHEM, V73, P2992, DOI 10.1021/ac001498q.
   Kilburn KH, 2000, AM J MED SCI, V320, P249, DOI 10.1097/00000441-200010000-00005.
   KILBURN KH, 1987, ARCH ENVIRON HEALTH, V42, P117, DOI 10.1080/00039896.1987.9935806.
   Kim KH, 2011, J ENVIRON SCI HEAL C, V29, P277, DOI 10.1080/10590501.2011.629972.
   Lei P, 2012, NAT MED, V18, P291, DOI 10.1038/nm.2613.
   Li Yi-qiao, 2010, Zhejiang Da Xue Xue Bao Yi Xue Ban, V39, P272.
   Liang XJ, 2018, ASIA-PAC J PUBLIC HE, V30, P551, DOI 10.1177/1010539518800348.
   Liu Y, 2019, ACCOUNTS CHEM RES, V52, P2026, DOI 10.1021/acs.accounts.9b00248.
   Luo WH, 2001, J CHROMATOGR B, V753, P253, DOI 10.1016/S0378-4347(00)00552-1.
   Mezzaroba L, 2019, NEUROTOXICOLOGY, V74, P230, DOI 10.1016/j.neuro.2019.07.007.
   Nazarian A, 2009, J BIOMECH, V42, P82, DOI 10.1016/j.jbiomech.2008.09.037.
   Nijland PG, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0261-8.
   Sarsilmaz M, 2007, BRAIN RES, V1145, P157, DOI 10.1016/j.brainres.2007.01.139.
   Shaughnessy CN, 2014, J AM ACAD DERMATOL, V70, P102, DOI 10.1016/j.jaad.2013.08.046.
   Tang XQ, 2011, CLIN EXP PHARMACOL P, V38, P208, DOI 10.1111/j.1440-1681.2011.05485.x.
   Tang XJ, 2009, ENVIRON INT, V35, P1210, DOI 10.1016/j.envint.2009.06.002.
   Tavazzi B, 2011, MULT SCLER INT, V2011, DOI 10.1155/2011/167156.
   Tong ZQ, 2013, AGE, V35, P583, DOI 10.1007/s11357-012-9388-8.
   Tulpule K, 2013, J NEUROCHEM, V127, P7, DOI 10.1111/jnc.12356.
   Tulpule K, 2013, J NEUROCHEM, V125, P260, DOI 10.1111/jnc.12170.
   Tulpule K, 2012, NEUROCHEM INT, V61, P1302, DOI 10.1016/j.neuint.2012.09.007.
   Tulpule K, 2012, GLIA, V60, P582, DOI 10.1002/glia.22292.
   Vallée A, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-017-0343-6.
   van Belle NJC, 2010, CHEMOSPHERE, V81, P794, DOI 10.1016/j.chemosphere.2010.06.080.
   Vexler ZS, 2003, BRAIN RES, V960, P90, DOI 10.1016/S0006-8993(02)03777-0.
   Vlassenko AG, 2018, NEUROBIOL AGING, V67, P95, DOI 10.1016/j.neurobiolaging.2018.03.014.
   Vlassenko AG, 2015, CLIN TRANSL IMAGING, V3, P27, DOI 10.1007/s40336-014-0094-7.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Wu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062827.
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158.
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010.
   Yu J, 2009, BRAIN RES, V1257, P102, DOI 10.1016/j.brainres.2008.12.030.},
Number-of-Cited-References = {48},
Times-Cited = {40},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {56},
Journal-ISO = {Toxicology},
Doc-Delivery-Number = {PO1PX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000604943800007},
DA = {2026-02-04},
}

@article{ WOS:000610668000002,
Author = {Huang, Chi-Ruei and Chang, Ting-Wei and Lee, Chung-Ta and Shen, Chih-Jie
   and Chang, Wen-Chang and Chen, Ben-Kuen},
Title = {ARNT deficiency represses pyruvate dehydrogenase kinase 1 to trigger ROS
   production and melanoma metastasis},
Journal = {ONCOGENESIS},
Year = {2021},
Volume = {10},
Number = {1},
Month = {JAN 14},
Abstract = {The metabolic changes in melanoma cells that are required for tumor
   metastasis have not been fully elucidated. In this study, we show that
   the increase in glucose uptake and mitochondrial oxidative
   phosphorylation confers metastatic ability as a result of aryl
   hydrocarbon receptor nuclear translocator (ARNT) deficiency. In clinical
   tissue specimens, increased ARNT, pyruvate dehydrogenase kinase 1
   (PDK1), and NAD(P)H quinine oxidoreductase-1 (NQO1) was observed in
   benign nevi, whereas lower expression was observed in melanoma. The
   depletion of ARNT dramatically repressed PDK1 and NQO1 expression, which
   resulted in an increase of ROS levels. The elimination of ROS using
   N-acetylcysteine (NAC) and inhibition of oxidative phosphorylation using
   carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and rotenone inhibited
   the ARNT and PDK1 deficiency-induced cell migration and invasion. In
   addition, ARNT deficiency in tumor cells manipulated the glycolytic
   pathway through enhancement of the glucose uptake rate, which reduced
   glucose dependence. Intriguingly, CCCP and NAC dramatically inhibited
   ARNT and PDK1 deficiency-induced tumor cell extravasation in mouse
   models. Our work demonstrates that downregulation of ARNT and PDK1
   expression serves as a prognosticator, which confers metastatic
   potential as the metastasizing cells depend on metabolic changes.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Chen, BK (Corresponding Author), Natl Cheng Kung Univ, Dept Biotechnol \& Bioind Sci, Coll Biosci \& Biotechnol, Tainan 701, Taiwan.
   Chang, WC (Corresponding Author), Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei 110, Taiwan.
   Huang, Chi-Ruei; Chen, Ben-Kuen, Natl Cheng Kung Univ, Dept Biotechnol \& Bioind Sci, Coll Biosci \& Biotechnol, Tainan 701, Taiwan.
   Huang, Chi-Ruei; Shen, Chih-Jie; Chang, Wen-Chang, Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei 110, Taiwan.
   Chang, Ting-Wei; Chen, Ben-Kuen, Natl Cheng Kung Univ, Inst Basic Med Sci, Coll Med, Tainan 701, Taiwan.
   Lee, Chung-Ta, Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Pathol, Coll Med, Tainan 701, Taiwan.
   Chen, Ben-Kuen, Natl Cheng Kung Univ, Dept Pharmacol, Coll Med, Tainan 701, Taiwan.
   Chen, Ben-Kuen, Taipei Med Univ, Inst Canc Biol \& Drug Discovery, Coll Med Sci \& Technol, Taipei 110, Taiwan.},
DOI = {10.1038/s41389-020-00299-3},
Article-Number = {11},
ISSN = {2157-9024},
Keywords-Plus = {GENE-EXPRESSION; ACTIVATION; PATHWAY; GLUCOSE; GROWTH; CELLS;
   MECHANISMS; HYPOXIA; TUMORS; STRESS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {wcchang@tmu.edu.tw
   bkchen58@mail.ncku.edu.tw},
Affiliations = {National Cheng Kung University; Taipei Medical University; National
   Cheng Kung University; National Cheng Kung University; National Cheng
   Kung University Hospital; National Cheng Kung University; Taipei Medical
   University},
ResearcherID-Numbers = {SHEN, CHIH-JIE/JHU-1108-2023
   },
ORCID-Numbers = {SHEN, CHIH-JIE/0000-0001-7392-056X
   Chen, Ben-Kuen/0000-0002-4720-4364},
Funding-Acknowledgement = {Ministry of Science and Technology of Taiwan {[}NSC
   102-2628-B-006-011-MY3, 102-2320-B-038-046-MY3, MOST-108-2320-B-006-031]},
Funding-Text = {This work was supported by the Ministry of Science and Technology of
   Taiwan {[}Grant NSC 102-2628-B-006-011-MY3; 102-2320-B-038-046-MY3;
   MOST-108-2320-B-006-031]. Cell lines of A375 and A2058 were kindly
   provided from our cooperator Dr. Hua-Lin Wu (National Cheng Kung
   University). The seahorse assay was kindly supported by Dr. Yau-Sheng
   Tsai (National Cheng Kung University).},
Cited-References = {Al-Mehdi AB, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002712.
   Bagati A, 2019, ONCOGENE, V38, P3585, DOI 10.1038/s41388-019-0689-6.
   Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799.
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003.
   Batandier C, 2002, J CELL MOL MED, V6, P175, DOI 10.1111/j.1582-4934.2002.tb00185.x.
   Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340.
   Chan YY, 2013, MOL PHARMACOL, V84, P591, DOI 10.1124/mol.113.087197.
   Chang KY, 2009, J BIOL CHEM, V284, P9908, DOI 10.1074/jbc.M806210200.
   Cichon MA, 2014, ONCOTARGET, V5, P2827, DOI 10.18632/oncotarget.1940.
   Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452.
   Corre S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06951-2.
   Di Meglio P, 2014, IMMUNITY, V40, P989, DOI 10.1016/j.immuni.2014.04.019.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fujii-Kuriyama Y, 2005, BIOCHEM BIOPH RES CO, V338, P311, DOI 10.1016/j.bbrc.2005.08.162.
   Gonzalez D, 2013, BRIT J DERMATOL, V168, P700, DOI 10.1111/bjd.12248.
   Haq R, 2014, CLIN CANCER RES, V20, P2257, DOI 10.1158/1078-0432.CCR-13-0898.
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hsu TI, 2012, ONCOGENE, V31, P3973, DOI 10.1038/onc.2011.568.
   Huang CR, 2015, ONCOTARGET, V6, P11530, DOI 10.18632/oncotarget.3448.
   Huang WC, 2010, CELL MOL LIFE SCI, V67, P3523, DOI 10.1007/s00018-010-0392-9.
   JAISWAL AK, 1991, BIOCHEMISTRY-US, V30, P10647, DOI 10.1021/bi00108a007.
   Kaiser S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-7-r131.
   Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11.
   Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5.
   Khozin S, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx187.
   Kouidhi S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00353.
   Kurashina K, 2008, CANCER SCI, V99, P1835, DOI 10.1111/j.1349-7006.2008.00881.x.
   Laiho P, 2007, ONCOGENE, V26, P312, DOI 10.1038/sj.onc.1209778.
   Lee YJ, 2007, AM J PHYSIOL-RENAL, V293, pF1036, DOI 10.1152/ajprenal.00034.2007.
   Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje.
   Liemburg-Apers DC, 2015, ARCH TOXICOL, V89, P1209, DOI 10.1007/s00204-015-1520-y.
   Lim SO, 2016, CANCER RES, V76, P1284, DOI 10.1158/0008-5472.CAN-15-2478.
   Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Lopez-Bergami P, 2011, PIGM CELL MELANOMA R, V24, P902, DOI 10.1111/j.1755-148X.2011.00908.x.
   Lv JW, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12557.
   McIntosh BE, 2010, ANNU REV PHYSIOL, V72, P625, DOI 10.1146/annurev-physiol-021909-135922.
   Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166.
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200.
   Qin WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49480-8.
   Reid JF, 2009, GENE CHROMOSOME CANC, V48, P953, DOI 10.1002/gcc.20697.
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2.
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653.
   Scortegagna M, 2015, CANCER RES, V75, P1399, DOI 10.1158/0008-5472.CAN-14-2785.
   Shieh JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099242.
   Simmons Steven O, 2011, Curr Chem Genomics, V5, P1, DOI 10.2174/1875397301105010001.
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005.
   Stewart GD, 2010, BJU INT, V105, P8, DOI 10.1111/j.1464-410X.2009.08921.x.
   Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683.
   Tsuji G, 2012, J INVEST DERMATOL, V132, P59, DOI 10.1038/jid.2011.194.
   Verhaegen M, 2006, CANCER RES, V66, P11348, DOI 10.1158/0008-5472.CAN-06-1748.
   Villano CM, 2006, TOXICOL APPL PHARM, V210, P212, DOI 10.1016/j.taap.2005.05.001.
   Werner-Klein M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02674-y.
   Williams K, 2012, CANCER RES, V72, P5407, DOI 10.1158/0008-5472.CAN-12-1158.
   Yoshioka K, 1996, APPL MICROBIOL BIOT, V46, P400.
   Yu L, 2017, J CANCER, V8, P3430, DOI 10.7150/jca.21125.
   Yu M, 2007, TOXICOL LETT, V170, P83, DOI 10.1016/j.toxlet.2007.02.013.},
Number-of-Cited-References = {58},
Times-Cited = {16},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Oncogenesis},
Doc-Delivery-Number = {PW4VG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000610668000002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000606371000005,
Author = {Zheng, Linli and Chen, Weishen and Xian, Guoyan and Pan, Baiqi and Ye,
   Yongyu and Gu, Minghui and Ma, Yinyue and Zhang, Ziji and Sheng, Puyi},
Title = {Identification of abnormally methylated-differentially expressed genes
   and pathways in osteoarthritis: a comprehensive bioinformatic study},
Journal = {CLINICAL RHEUMATOLOGY},
Year = {2021},
Volume = {40},
Number = {8},
Pages = {3247-3256},
Month = {AUG},
Abstract = {Objectives To investigate abnormally methylated-differentially expressed
   genes (DEGs) and their related pathways in osteoarthritis (OA) by
   comprehensive bioinformatic analysis.
   Methods Gene expression profiles of GSE51588 and GSE114007, and a gene
   methylation microarray data GSE63695 were downloaded from the Gene
   Expression Omnibus (GEO) repository. Abnormally methylated DEGs were
   identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and
   Genomes (KEGG) pathway enrichment analyses of these genes were
   subsequently performed using the Database for Annotation, Visualization
   and Integrated Discovery (DAVID). The protein-protein interaction (PPI)
   network was built from STRING. Module analysis and hub gene
   identification were performed by using Cytoscape. Co-expression analysis
   was also constructed using the CEMiTool package.
   Results In total, 133 abnormally methylated DEGs were identified,
   including 85 hypomethylation high-expression genes and 48
   hypermethylation low-expression genes. Among biological processes and
   KEGG pathways of abnormally methylated DEGs, collagen fibril
   organization was enriched most frequently, and pathways of oxidative
   stress and aging were enriched, including HIF-1 signaling pathway, AMPK
   signaling pathway, and FoxO signaling pathway. In PPI networks, the hub
   genes of hypomethylation high-expression genes were COL1A1, COL3A1,
   COL1A2, COL5A2, LUM, MMP2, SPARC, COL2A1, COL6A2, and COL7A1, and the
   hub genes of hypermethylation low-expression genes were VEGFA, SLC2A1,
   LDHA, PDK1, and BNIP3. Combined with co-expression analysis, COL3A1,
   LUM, and MMP2 were the critical hypomethylation high-expression hub
   genes in medial tibia subchondral bone.
   Conclusions Our study implied abnormally methylated DEGs and
   dysregulated pathways in OA. Common methylation biomarkers included
   COL3A1, LUM, and MMP2, and we also found that THBS2 may serve as a novel
   biomarker in end-stage OA.},
Publisher = {SPRINGER LONDON LTD},
Address = {236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhang, ZJ; Sheng, PY (Corresponding Author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Joint Surg, Guangzhou 510080, Guangdong, Peoples R China.
   Zheng, Linli; Chen, Weishen; Xian, Guoyan; Pan, Baiqi; Ye, Yongyu; Gu, Minghui; Zhang, Ziji; Sheng, Puyi, Sun Yat Sen Univ, Affiliated Hosp 1, Dept Joint Surg, Guangzhou 510080, Guangdong, Peoples R China.
   Ma, Yinyue, South China Agr Univ, Coll Life Sci, Dept Biol Sci, Guangzhou 510642, Guangdong, Peoples R China.},
DOI = {10.1007/s10067-020-05539-w},
EarlyAccessDate = {JAN 2021},
ISSN = {0770-3198},
EISSN = {1434-9949},
Keywords = {Bioinformatics; Co-expression analysis; DNA methylation; Gene
   expression; Osteoarthritis},
Keywords-Plus = {PI3K/AKT/MTOR SIGNALING PATHWAY; BIOCONDUCTOR PACKAGE; PERICELLULAR
   MATRIX; ARTICULAR-CARTILAGE; DNA METHYLATION; II COLLAGEN; CHONDROCYTES;
   METABOLISM; APOPTOSIS; SPARC},
Research-Areas = {Rheumatology},
Web-of-Science-Categories  = {Rheumatology},
Author-Email = {zhangziji@mail.sysu.edu.cn
   shengpy@mail.sysu.edu.cn},
Affiliations = {Sun Yat Sen University; South China Agricultural University},
ResearcherID-Numbers = {Zhang, Ziji/MDT-9723-2025},
ORCID-Numbers = {Chen, Weishen/0000-0003-3469-842X
   Zhang, Ziji/0000-0002-7040-8576},
Funding-Acknowledgement = {Project of National Natural Science Foundation of China {[}81672149,
   81672198]; Natural Science Foundation of Guangdong Province
   {[}2017A030313593]},
Funding-Text = {This study was supported by the Project of National Natural Science
   Foundation of China (81672149, 81672198) and the Natural Science
   Foundation of Guangdong Province (2017A030313593).},
Cited-References = {Akasaki Y, 2014, OSTEOARTHR CARTILAGE, V22, P162, DOI 10.1016/j.joca.2013.11.004.
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049.
   Asthana C, 2020, CLIN THER, V42, pE140, DOI 10.1016/j.clinthera.2020.06.009.
   Barreto G, 2020, OSTEOARTHR CARTILAGE, V28, P92, DOI 10.1016/j.joca.2019.10.011.
   Bouaziz W, 2016, P NATL ACAD SCI USA, V113, P5453, DOI 10.1073/pnas.1514854113.
   Chou CH, 2013, OSTEOARTHR CARTILAGE, V21, P450, DOI 10.1016/j.joca.2012.11.016.
   Dai ML, 2018, BIOMATERIALS, V180, P91, DOI 10.1016/j.biomaterials.2018.07.011.
   Deguchi T, 2019, OSTEOARTHR CARTILAGE, V27, P1501, DOI 10.1016/j.joca.2019.06.001.
   Dennis G Jr, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60.
   Felka T, 2016, OSTEOARTHR CARTILAGE, V24, P1200, DOI 10.1016/j.joca.2016.02.001.
   Ge QT, 2017, TISSUE CELL, V49, P719, DOI 10.1016/j.tice.2017.10.004.
   Gu HY, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00275.
   Hamilton JL, 2016, J BONE MINER RES, V31, P911, DOI 10.1002/jbmr.2828.
   Henrotin Y, 2007, CURR OPIN RHEUMATOL, V19, P444, DOI 10.1097/BOR.0b013e32829fb3b5.
   Hosseininia S, 2016, OSTEOARTHR CARTILAGE, V24, P1029, DOI 10.1016/j.joca.2016.01.001.
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140-6736(19)30417-9.
   Imagawa K, 2011, BIOCHEM BIOPH RES CO, V405, P362, DOI 10.1016/j.bbrc.2011.01.007.
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324.
   Johnson K, 2000, ARTHRITIS RHEUM-US, V43, P1560, DOI 10.1002/1529-0131(200007)43:7<1560::AID-ANR21>3.3.CO;2-J.
   Kos K, 2010, NAT REV ENDOCRINOL, V6, P225, DOI 10.1038/nrendo.2010.18.
   Kuttapitiya A, 2017, ANN RHEUM DIS, V76, P1764, DOI 10.1136/annrheumdis-2017-211396.
   {[}Anonymous], 2016, Nat Rev Dis Primers, V2, P16073, DOI {[}10.1038/nrdp.2016.73, 10.1038/nrdp.2016.72, 10.1038/nrdp.2016.73].
   Miranda-Duarte Antonio, 2018, Open Rheumatol J, V12, P37, DOI {[}10.2174/1874312901812010037, 10.2174/1874312901812010037].
   Mobasheri A, 2005, CELL BIOL INT, V29, P249, DOI 10.1016/j.cellbi.2004.11.024.
   Mobasheri A, 2017, NAT REV RHEUMATOL, V13, P302, DOI 10.1038/nrrheum.2017.50.
   Nagai T, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0427-y.
   Nakamura S, 1996, ARTHRITIS RHEUM, V39, P539, DOI 10.1002/art.1780390402.
   O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862.
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293.
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014.
   Rai MF, 2020, CARTILAGE, V11, P458, DOI 10.1177/1947603518796122.
   Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591.
   Rice SJ, 2020, NAT REV RHEUMATOL, V16, P268, DOI 10.1038/s41584-020-0407-3.
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007.
   Russo PST, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2053-1.
   Schulze-Tanzil G, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090990.
   Shu CC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030579.
   Steinberg J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09335-6.
   Sun K, 2020, OSTEOARTHR CARTILAGE, V28, P400, DOI 10.1016/j.joca.2020.02.027.
   Szklarczyk D, 2023, NUCLEIC ACIDS RES, V51, pD638, DOI {[}10.1093/nar/gky1131, 10.1093/nar/gkac1000].
   Terkeltaub R, 2011, ARTHRITIS RHEUM-US, V63, P1928, DOI 10.1002/art.30333.
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190.
   Veron V, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-5048-4.
   Xue JF, 2017, BIOMED PHARMACOTHER, V89, P1252, DOI 10.1016/j.biopha.2017.01.130.
   Zelenski NA, 2015, ARTHRITIS RHEUMATOL, V67, P1286, DOI 10.1002/art.39034.
   Zeng GQ, 2015, GENET MOL RES, V14, P14811, DOI 10.4238/2015.November.18.46.},
Number-of-Cited-References = {46},
Times-Cited = {10},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {27},
Journal-ISO = {Clin. Rheumatol.},
Doc-Delivery-Number = {TL1UH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000606371000005},
DA = {2026-02-04},
}

@article{ WOS:000623164500007,
Author = {Zhang, Ji and He, Yang and Zhou, Jing and Shen, Ting and Hu, Weicheng},
Title = {Immunomodulatory effects of wheat bran arabinoxylan on RAW264.7
   macrophages via the NF-κB signaling pathway using RNA-seq analysis},
Journal = {FOOD RESEARCH INTERNATIONAL},
Year = {2021},
Volume = {140},
Month = {FEB},
Abstract = {Arabinoxylan (AX) extracted from wheat bran has attracted much attention
   due to its immunomodulatory activity. However, the molecular mechanisms
   underlying this activity remain unclear. In this study, we conducted a
   comprehensive transcriptional study to investigate genetic changes
   related to AX and identified 2325 differentially expressed genes (DEGs).
   Gene Ontology classification revealed that the DEGs were mainly enriched
   in a series of immune-related processes. Kyoto Encyclopedia of Genes and
   Genomes pathway analysis revealed that immune-related pathways were
   significantly enriched in top 20 pathways, including the nuclear
   factor-kappa B (NF-kappa B) signaling pathway and the TNF signaling
   pathway. Validation using quantitative polymerase chain reaction
   analysis revealed dynamic changes in the mRNA levels of immune-related
   Cd40, Csf1, Csf2, Fas, IL-1 beta, IL 6, IL-5, Irf1, and Tnfaip3, which
   were significantly up-regulated in the AX-treated group. Moreover, AX
   treatment led to the up-regulation of the nuclear translocation of
   NF-kappa B and its upstream target proteins such as PDK1, Akt, I kappa
   B-alpha, and GSK-3 beta. The dataset compiled from this study provides
   valuable information for further research on the complex molecular
   mechanisms associated with AX and the identification of target genes.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Zhou, J; Hu, WC (Corresponding Author), Huaiyin Normal Univ, Sch Life Sci, Huaian 223300, Peoples R China.
   Zhang, Ji; He, Yang; Zhou, Jing; Shen, Ting; Hu, Weicheng, Huaiyin Normal Univ, Sch Life Sci, Huaian 223300, Peoples R China.},
DOI = {10.1016/j.foodres.2020.110067},
EarlyAccessDate = {JAN 2021},
Article-Number = {110067},
ISSN = {0963-9969},
EISSN = {1873-7145},
Keywords = {Arabinoxylan; Immunomodulatory; Nuclear factor-kappa B; Transcriptome
   analyses},
Research-Areas = {Food Science \& Technology},
Web-of-Science-Categories  = {Food Science \& Technology},
Author-Email = {shenting1019@163.com
   hu\_weicheng@163.com},
Affiliations = {Huaiyin Normal University},
ResearcherID-Numbers = {He, Yangzheng/GXW-0786-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31700304]; Natural
   Science Foundation of Jiangsu Province {[}BK20201480]},
Funding-Text = {This study was financially supported by National Natural Science
   Foundation of China (31700304) and Natural Science Foundation of Jiangsu
   Province (BK20201480).},
Cited-References = {Akhtar M, 2012, CARBOHYD POLYM, V90, P333, DOI 10.1016/j.carbpol.2012.05.048.
   Bai YJ, 2019, J ETHNOPHARMACOL, V228, P179, DOI 10.1016/j.jep.2018.09.032.
   Brüne B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785.
   Buksa K, 2016, J FOOD SCI TECH MYS, V53, P1389, DOI 10.1007/s13197-015-2135-2.
   Cao L, 2011, INT J BIOL MACROMOL, V48, P160, DOI 10.1016/j.ijbiomac.2010.10.014.
   Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169.
   Edelblum KL, 2008, J BIOL CHEM, V283, P29485, DOI 10.1074/jbc.M801269200.
   Fadel A, 2018, INT J BIOL MACROMOL, V109, P819, DOI 10.1016/j.ijbiomac.2017.11.055.
   Geraylou Z, 2013, FISH SHELLFISH IMMUN, V35, P766, DOI 10.1016/j.fsi.2013.06.014.
   Geraylou Z, 2012, FISH SHELLFISH IMMUN, V33, P718, DOI 10.1016/j.fsi.2012.06.010.
   Haider S, 2009, PLACENTA, V30, P111, DOI 10.1016/j.placenta.2008.10.012.
   Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983.
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86.
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485.
   Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651.
   Lee JS, 2011, INT IMMUNOPHARMACOL, V11, P1226, DOI 10.1016/j.intimp.2011.04.001.
   Li F, 2019, J GINSENG RES, V43, P600, DOI 10.1016/j.jgr.2018.09.004.
   Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910.
   MacEwan DJ, 2002, BRIT J PHARMACOL, V135, P855, DOI 10.1038/sj.bjp.0704549.
   Mendis M, 2014, FOOD HYDROCOLLOID, V42, P239, DOI 10.1016/j.foodhyd.2013.07.022.
   Mendis M, 2016, CARBOHYD POLYM, V139, P159, DOI 10.1016/j.carbpol.2015.11.068.
   Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065.
   Onipe OO, 2015, INT J FOOD SCI TECH, V50, P2509, DOI 10.1111/ijfs.12935.
   Pérez-Martínez A, 2015, CYTOTHERAPY, V17, P601, DOI 10.1016/j.jcyt.2014.11.001.
   Plato A, 2013, INT REV IMMUNOL, V32, P134, DOI 10.3109/08830185.2013.777065.
   Pramudya M, 2019, VET WORLD, V12, P735, DOI 10.14202/vetworld.2019.735-739.
   Prashanth MRS, 2015, J FOOD SCI TECH MYS, V52, P6049, DOI 10.1007/s13197-014-1664-4.
   Prückler M, 2014, LWT-FOOD SCI TECHNOL, V56, P211, DOI 10.1016/j.lwt.2013.12.004.
   Ramseyer DD, 2011, CEREAL CHEM, V88, P209, DOI 10.1094/CCHEM-10-10-0148.
   Sahasrabudhe NM, 2016, MOL NUTR FOOD RES, V60, P458, DOI 10.1002/mnfr.201500582.
   Shen CY, 2017, J FUNCT FOODS, V34, P118, DOI 10.1016/j.jff.2017.03.060.
   Shen T, 2017, FOOD NUTR RES, V61, DOI 10.1080/16546628.2017.1344523.
   Sheu SC, 2013, PROCESS BIOCHEM, V48, P1402, DOI 10.1016/j.procbio.2013.06.012.
   Song M, 2016, J FUNCT FOODS, V21, P312, DOI 10.1016/j.jff.2015.12.001.
   Sun HX, 2015, CARBOHYD POLYM, V121, P388, DOI 10.1016/j.carbpol.2014.12.023.
   Suzuki T, 2015, P NATL ACAD SCI USA, V112, P7809, DOI 10.1073/pnas.1503885112.
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022.
   Tian H, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108709.
   Vinogradov S, 2014, NANOMEDICINE-UK, V9, P695, DOI {[}10.2217/NNM.14.13, 10.2217/nnm.14.13].
   Wang DD, 2018, INT J BIOL MACROMOL, V120, P1039, DOI 10.1016/j.ijbiomac.2018.08.147.
   Wang JY, 2020, FOOD AGR IMMUNOL, V31, P575, DOI 10.1080/09540105.2020.1747407.
   Xu XF, 2014, CRIT REV FOOD SCI, V54, P474, DOI 10.1080/10408398.2011.587616.
   Yu Y, 2018, CARBOHYD POLYM, V183, P91, DOI 10.1016/j.carbpol.2017.12.009.
   Zhao MM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006347.
   Zhou SM, 2010, CARBOHYD POLYM, V81, P784, DOI 10.1016/j.carbpol.2010.03.040.},
Number-of-Cited-References = {45},
Times-Cited = {25},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {45},
Journal-ISO = {Food Res. Int.},
Doc-Delivery-Number = {QO5ED},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000623164500007},
DA = {2026-02-04},
}

@article{ WOS:000600686100033,
Author = {Hua, Dan and Zhao, Qian and Yu, Yang and Yu, Huan and Yu, Lin and Zhou,
   Xuexia and Wang, Qian and Sun, Cuiyun and Shi, Cuijuan and Luo, Wenjun
   and Jiang, Zhendong and Wang, Weiting and Wang, Lingli and Zhang, Dongli
   and Tang, Shengan and Yu, Shizhu},
Title = {Eucalyptal A inhibits glioma by rectifying oncogenic splicing of
   MYO1B mRNA via suppressing SRSF1 expression},
Journal = {EUROPEAN JOURNAL OF PHARMACOLOGY},
Year = {2021},
Volume = {890},
Month = {JAN 5},
Abstract = {Glioma is the most common primary intracranial tumor, in which
   glioblastoma (GBM) is the most malignant and lethal. However, the
   current chemotherapy drugs are still unsatisfactory for GBM therapy. As
   the natural products mainly extracted from Eucalyptus species,
   phloroglucinol-terpene adducts have the potential to be anticancer lead
   compounds that attracted increasing attention. In order to discover the
   new lead compounds with the anti-GBM ability, we isolated Eucalyptal A
   with a phloroglucinol-terpene skeleton from the fruit of E. globulus and
   investigated its anti-GBM activity in vitro and in vivo. Functionally,
   we verified that Eucalyptal A could inhibit the proliferation, growth
   and invasiveness of GBM cells in vitro. Moreover, Eucalyptal A had the
   same anti-GBM activity in tumor-bearing mice as in vitro and prolonged
   the overall survival time by maintaining mice body weight. Further
   mechanism research revealed that Eucalyptal A downregulated SRSF1
   expression and rectified SRSF1-guided abnormal alternative splicing of
   MYO1B mRNA, which led to anti-GBM activity through the PDK1/AKT/c-Myc
   and PAK/Cofilin axes. Taken together, we identified Eucalyptal A as an
   important antiGBM lead compound, which represents a novel direction for
   glioma therapy.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Yu, SZ (Corresponding Author), Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Dept Neuropathol, 154 Anshan Rd, Tianjin 300052, Peoples R China.
   Tang, SA (Corresponding Author), Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
   Hua, Dan; Zhou, Xuexia; Wang, Qian; Sun, Cuiyun; Shi, Cuijuan; Luo, Wenjun; Jiang, Zhendong; Yu, Shizhu, Tianjin Med Univ Gen Hosp, Tianjin Neurol Inst, Dept Neuropathol, 154 Anshan Rd, Tianjin 300052, Peoples R China.
   Hua, Dan; Zhou, Xuexia; Wang, Qian; Sun, Cuiyun; Shi, Cuijuan; Luo, Wenjun; Jiang, Zhendong; Yu, Shizhu, Tianjin Key Lab Injuries Variat \& Regenerat Nervo, Tianjin 300052, Peoples R China.
   Hua, Dan; Zhou, Xuexia; Wang, Qian; Sun, Cuiyun; Shi, Cuijuan; Luo, Wenjun; Jiang, Zhendong; Yu, Shizhu, Minist Educ, Key Lab Posttrauma Neurorepair \& Regenerat Cent N, Tianjin 300052, Peoples R China.
   Zhao, Qian, Tianjin Univ Tianjin Hosp, Dept Sports Injury \& Arthroscopy, Tianjin 300221, Peoples R China.
   Yu, Yang, Tianjin Chest Hosp, Dept Pulm \& Crit Care Med, Tianjin 300222, Peoples R China.
   Yu, Huan; Wang, Lingli; Zhang, Dongli; Tang, Shengan, Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
   Yu, Lin, Tianjin Med Univ, Dept Biochem \& Mol Biol, Sch Basic Med Sci, Tianjin 300070, Peoples R China.
   Wang, Weiting, Tianjin Inst Pharmaceut Res, Tianjin 300301, Peoples R China.},
DOI = {10.1016/j.ejphar.2020.173669},
Article-Number = {173669},
ISSN = {0014-2999},
EISSN = {1879-0712},
Keywords = {Eucalyptal a; Glioma; Oncogenic splicing; Serine/arginine-rich splicing
   factor 1; Myosin 1B},
Keywords-Plus = {INVASION; PHLOROGLUCINOL; COFILIN},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {tangshengan@tmu.edu.cn
   tjyushizhu@163.com},
Affiliations = {Tianjin Medical University; Tianjin University; Tianjin University;
   Tianjin Medical University; Tianjin Medical University},
ResearcherID-Numbers = {Tang, Sheng An/AAF-9069-2021
   Yu, Lin/AEF-1426-2022},
ORCID-Numbers = {Tang, Sheng An/0000-0001-8473-0972
   Yu, Lin/0000-0002-9972-3799},
Funding-Acknowledgement = {China Scholarship Council {[}201606945004]; National Natural Science
   Foundation of China {[}81402050, 81502166, 81672592, 81872061,
   81972354]; Programs of Science and Technology Bureau Foundation of
   Tianjin Municipality {[}16JCQNJC13400, 17JCYBJC27100, 19JCZDJC64900
   (Z)]; Program of Tianjin Municipal Health Bureau {[}15KG147]; ``New
   Century{''} Talent Training Project of TMUGH; Tianjin Higher Education
   Science and Technology Development Project {[}2019ZD031]},
Funding-Text = {This study was supported by grants from the China Scholarship Council
   {[}No. 201606945004], the National Natural Science Foundation of China
   {[}No. 81402050, 81502166, 81672592, 81872061 and 81972354], the
   Programs of Science and Technology Bureau Foundation of Tianjin
   Municipality {[}No. 16JCQNJC13400, 17JCYBJC27100 and 19JCZDJC64900 (Z)],
   the Program of Tianjin Municipal Health Bureau {[}No. 15KG147], the
   ``New Century{''} Talent Training Project of TMUGH {[}2016, to X. Zhou
   and 2018, to C. Shi], and the Tianjin Higher Education Science and
   Technology Development Project {[}No. 2019ZD031].},
Cited-References = {Chautard E, 2014, J NEURO-ONCOL, V117, P205, DOI 10.1007/s11060-014-1382-9.
   Dehm SM, 2013, CANCER RES, V73, P5309, DOI 10.1158/0008-5472.CAN-13-0444.
   Donaldson LF, 2016, DRUG DISCOV TODAY, V21, P1787, DOI 10.1016/j.drudis.2016.06.017.
   GONCALVES V, 2017, GENES, V9, pE9, DOI DOI 10.3390/GENES9010009.
   Gouveia DN, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2018.11.026.
   Jian KL, 2017, PHYTOMEDICINE, V25, P71, DOI 10.1016/j.phymed.2016.12.014.
   Lefranc F, 2009, MOL CANCER THER, V8, P1739, DOI 10.1158/1535-7163.MCT-08-0932.
   Li HN, 2017, ONCOTARGET, V8, P19723, DOI 10.18632/oncotarget.14975.
   Luo WJ, 2019, AM J PATHOL, V189, P162, DOI 10.1016/j.ajpath.2018.08.019.
   Ma YJ, 2011, J NEUROSCI RES, V89, P1079, DOI 10.1002/jnr.22616.
   Ohashi K, 2015, DEV GROWTH DIFFER, V57, P275, DOI 10.1111/dgd.12213.
   Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533.
   Park JB, 2014, ONCOTARGET, V5, P9382, DOI 10.18632/oncotarget.2412.
   Pohl M, 2013, BIOSYSTEMS, V114, P31, DOI 10.1016/j.biosystems.2013.07.003.
   Poke FS, 2005, GENETICA, V125, P79, DOI 10.1007/s10709-005-5082-4.
   Qin XJ, 2018, J NAT PROD, V81, P2638, DOI 10.1021/acs.jnatprod.8b00430.
   Shang ZC, 2016, CHEM-EUR J, V22, P11778, DOI 10.1002/chem.201601732.
   Shi CJ, 2017, BRIT J CANCER, V117, P1036, DOI 10.1038/bjc.2017.255.
   Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053.
   Pham TA, 2019, J NAT PROD, V82, P859, DOI 10.1021/acs.jnatprod.8b00920.
   Tirosh I, 2018, NEURO-ONCOLOGY, V20, P37, DOI 10.1093/neuonc/nox126.
   Vuong QV, 2015, CHEM BIODIVERS, V12, P907, DOI 10.1002/cbdv.201400327.
   Wang BD, 2018, CANCERS, V10, DOI 10.3390/cancers10110458.
   Wang J, 2018, NEURO-ONCOLOGY, V20, P885, DOI 10.1093/neuonc/nox207.
   Yang SP, 2012, J MED CHEM, V55, P8183, DOI 10.1021/jm3007454.
   Yin S, 2007, ORG LETT, V9, P5549, DOI 10.1021/ol7025075.
   Zhou XX, 2019, INT J BIOCHEM CELL B, V113, P75, DOI 10.1016/j.biocel.2019.06.003.
   Zhou XX, 2019, J CLIN INVEST, V129, P676, DOI 10.1172/JCI120279.},
Number-of-Cited-References = {28},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Eur. J. Pharmacol.},
Doc-Delivery-Number = {PH8WR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000600686100033},
DA = {2026-02-04},
}

@article{ WOS:000616965100005,
Author = {Cenigaonandia-Campillo, Aiora and Serna-Blasco, Roberto and Gomez-Ocabo,
   Laura and Solanes-Casado, Sonia and Banos-Herraiz, Natalia and Del
   Puerto-Nevado, Laura and Canas, Jose Antonio and Acenero, Maria Jesus
   and Garcia-Foncillas, Jesus and Aguilera, Oscar},
Title = {Vitamin C activates pyruvate dehydrogenase (PDH) targeting the
   mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS
   mutant colon cancer},
Journal = {THERANOSTICS},
Year = {2021},
Volume = {11},
Number = {8},
Pages = {3595-3606},
Abstract = {Background: In hypoxic tumors, positive feedback between oncogenic KRAS
   and HIF-1 alpha involves impressive metabolic changes correlating with
   drug resistance and poor prognosis in colorectal cancer. Up to date,
   designed KRAS-targeting molecules do not show clear benefits in patient
   overall survival (POS) so pharmacological modulation of aberrant
   tricarboxylic acid (TCA) cycle in hypoxic cancer has been proposed as a
   metabolic vulnerability of KRAS-driven tumors.
   Methods: Annexin V-FITC and cell viability assays were carried out in
   order to verify vitamin C citotoxicity in KRAS mutant SW480 and DLD1 as
   well as in Immortalized Human Colonic Epithelial Cells (HCEC). HIF1a
   expression and activity were determined by western blot and functional
   analysis assays. HIF1a direct targets GLUT1 and PDK1 expression was
   checked using western blot and qRT-PCR. Inmunohistochemical assays were
   perfomed in tumors derived from murine xenografts in order to validate
   previous observations in vivo. Vitamin C dependent PDH expression and
   activity modulation were detected by western blot and colorimetric
   activity assays. Acetyl-Coa levels and citrate synthase activity were
   assessed using colorimetric/fluorometric activity assays. Mitochondrial
   membrane potential (Delta psi) and cell ATP levels were assayed using
   fluorometric and luminescent test.
   Results: PDK-1 in KRAS mutant CRC cells and murine xenografts was
   downregulated using pharmacological doses of vitamin C through the
   proline hydroxylation (Pro402) of the Hypoxia inducible
   factor-1(HIF-1)alpha, correlating with decreased expression of the
   glucose transporter 1 (GLUT-1) in both models. Vitamin C induced
   remarkable ATP depletion, rapid mitochondrial Delta psi dissipation and
   diminished pyruvate dehydrogenase E1-alpha phosphorylation at Serine
   293, then boosting PDH and citrate synthase activity.
   Conclusion: We report a striking and previously non reported role of
   vitamin C in the regulation of the pyruvate dehydrogenase (PDH)
   activity, then modulating the TCA cycle and mitochondrial metabolism in
   KRAS mutant colon cancer. Potential impact of vitamin C in the clinical
   management of anti-EGFR chemoresistant colorectal neoplasias should be
   further considered.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {García-Foncillas, J; Aguilera, O (Corresponding Author), IIS Fdn Jimenez Diaz UAM, Oncohlth Inst, Translat Oncol Div, Madrid, Spain.
   Cenigaonandia-Campillo, Aiora; Gomez-Ocabo, Laura; Solanes-Casado, Sonia; Banos-Herraiz, Natalia; Del Puerto-Nevado, Laura; Garcia-Foncillas, Jesus; Aguilera, Oscar, IIS Fdn Jimenez Diaz UAM, Oncohlth Inst, Translat Oncol Div, Madrid, Spain.
   Serna-Blasco, Roberto, Hosp Puerta Hierro Majadahonda, Majadahonda, Madrid, Spain.
   Canas, Jose Antonio, IIS Fdn Jimenez Diaz UAM, Dept Immunol, Madrid, Spain.
   Acenero, Maria Jesus, Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Madrid, Spain.
   Aguilera, Oscar, Univ Catolica San Antonio, Murcia, Spain.},
DOI = {10.7150/thno.51265},
ISSN = {1838-7640},
Keywords = {cancer; metabolism; PDK-1; vitamin C; KRAS; chemoresistance; hypoxia},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {jgfoncillas@quironsalud.es
   oscar.aguilera@fjd.es},
Affiliations = {Fundacion Jimenez Diaz; Hospital Puerta de Hierro-Majadahonda; Fundacion
   Jimenez Diaz; Complutense University of Madrid; General University
   Gregorio Maranon Hospital; Universidad Catolica de Murcia},
ResearcherID-Numbers = {del Puerto Nevado, Laura/LMO-1460-2024
   Serna-Blasco, Roberto/KHZ-2892-2024
   J, Garcia-Foncillas/E-6857-2010},
ORCID-Numbers = {del Puerto Nevado, Laura/0000-0003-0594-9656
   , Sonia Solanes Casado/0009-0008-8998-4523
   Serna-Blasco, Roberto/0000-0002-7563-9613
   aguilera, oscar/0000-0002-8296-9178
   J, Garcia-Foncillas/0000-0002-7591-8006},
Funding-Acknowledgement = {Ministerio de Ciencia e Innovacion, Centro para el Desarrollo
   Tecnologico Industrial (CDTI); Universidad Catolica San Antonio (Murcia)},
Funding-Text = {We would like to thank Julia Bocea for her careful review of this
   manuscript. This research is supported by Ministerio de Ciencia e
   Innovacion, Centro para el Desarrollo Tecnologico Industrial (CDTI) and
   Universidad Catolica San Antonio (Murcia).},
Cited-References = {Aguilera O, 2016, ONCOTARGET, V7, P47954, DOI 10.18632/oncotarget.10087.
   Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238-017-0451-1.
   Baba Y, 2010, AM J PATHOL, V176, P2292, DOI 10.2353/ajpath.2010.090972.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104.
   CAMERON E, 1976, P NATL ACAD SCI USA, V73, P3685, DOI 10.1073/pnas.73.10.3685.
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394.
   Chowdhury R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12673.
   Chun SY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-293.
   Di Tano M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16243-3.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Eser S, 2014, BRIT J CANCER, V111, P817, DOI 10.1038/bjc.2014.215.
   Fedorova MS, 2015, MOL BIOL+, V49, P608, DOI {[}10.1134/S0026893315040044, 10.7868/S0026898415040047].
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834.
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385.
   Kikuchi H, 2009, CANCER RES, V69, P8499, DOI 10.1158/0008-5472.CAN-09-2213.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Liu R, 2017, ONCOTARGET, V8, P39476, DOI 10.18632/oncotarget.17073.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Lu HQ, 2013, MOL CANCER THER, V12, P2187, DOI 10.1158/1535-7163.MCT-12-1245.
   Luo FX, 2019, CHINESE J CANCER RES, V31, P521, DOI 10.21147/j.issn.1000-9604.2019.03.14.
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501.
   Marquez J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122161.
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013.
   Qin WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49480-8.
   Sajnani K, 2017, BIOCHIMIE, V135, P164, DOI 10.1016/j.biochi.2017.02.008.
   Salnikow K, 2002, ENVIRON HEALTH PERSP, V110, P831, DOI 10.1289/ehp.02110s5831.
   Savini I, 2008, AMINO ACIDS, V34, P347, DOI 10.1007/s00726-007-0555-7.
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187.
   Serebriiskii IG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11530-0.
   Smith H, 2016, J CELL BIOCHEM, V117, P1890, DOI 10.1002/jcb.25488.
   Sradhanjali S, 2018, CURR TOP MED CHEM, V18, P444, DOI 10.2174/1568026618666180523105756.
   Su X, 2019, THERANOSTICS, V9, P4461, DOI 10.7150/thno.35219.
   Takanaga H, 2004, PFLUG ARCH EUR J PHY, V447, P677, DOI 10.1007/s00424-003-1104-1.
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803.
   Trinidad AG, 2017, ONCOGENE, V36, P6164, DOI 10.1038/onc.2017.224.
   Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986.
   Yang J, 2019, THERANOSTICS, V9, P6856, DOI 10.7150/thno.37794.
   Ye LC, 2013, J CLIN ONCOL, V31, P1931, DOI 10.1200/JCO.2012.44.8308.
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058.
   Yonashiro R, 2018, CANCER RES, V78, P1592, DOI 10.1158/0008-5472.CAN-17-1751.
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004.
   Zhang X, 2019, THERANOSTICS, V9, P8109, DOI 10.7150/thno.35378.},
Number-of-Cited-References = {43},
Times-Cited = {44},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Theranostics},
Doc-Delivery-Number = {QF5WS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000616965100005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000604898900005,
Author = {Chen, Hongtao and Qian, Zhanyang and Zhang, Sheng and Tang, Jian and
   Fang, Le and Jiang, Fan and Ge, Dawei and Chang, Jie and Cao, Jiang and
   Yang, Lei and Cao, Xiaojian},
Title = {Silencing COX-2 blocks PDK1/TRAF4-induced AKT activation to inhibit
   fibrogenesis during skeletal muscle atrophy},
Journal = {REDOX BIOLOGY},
Year = {2021},
Volume = {38},
Month = {JAN},
Abstract = {Skeletal muscle atrophy with high prevalence can induce weakness and
   fatigability and place huge burden on both health and quality of life.
   During skeletal muscle degeneration, excessive fibroblasts and
   extracellular matrix (ECM) accumulated to replace and impair the
   resident muscle fiber and led to loss of muscle mass. Cyclooxygenase-2
   (COX-2), the rate-limiting enzyme in synthesis of prostaglandin, has
   been identified as a positive regulator in pathophysiological process
   like inflammation and oxidative stress. In our study, we found injured
   muscles of human subjects and mouse model overexpressed COX-2 compared
   to the non-damaged region and COX-2 was also upregulated in fibroblasts
   following TGF-beta stimulation. Then we detected the effect of selective
   COX-2 inhibitor celecoxib on fibmgenesis. Celecoxib mediated
   anti-fibrotic effect by inhibiting fibroblast differentiation,
   proliferation and migration as well as inactivating TGF-beta-dependent
   signaling pathway, noncanonical TGF-beta pathways and suppressing
   generation of reactive oxygen species (ROS) and oxidative stress. In
   vivo pharmacological inhibition of COX-2 by celecoxib decreased tissue
   fibrosis and increased skeletal muscle fiber preservation reflected by
   less ECM formation and myofibmblast accumulation with decreased
   p-ERK1/2, p-Smad2/3, TGF-beta R1, VEGF, NOX2 and NOX4 expression.
   Expression profiling further found that celecoxib could suppress PDK1
   expression. The interaction between COX-2 and PDK1/AKT signaling
   remained unclear, here we found that COX-2 could bind to PDK1/AKT to
   form compound. Knockdown of COX-2 in fibroblasts by pharmacological
   inactivation or by siRNA restrained PDK1 expression and AKT
   phosphorylation induced by TGF-beta treatment. Besides, si-COX-2
   prevented TGF-beta-induced K63-ubiquitination of AKT by blocking the
   interaction between AKT and E3 ubiquitin ligase TRAF4. In summary, we
   found blocking COX-2 inhibited fibmgenesis after muscle atrophy induced
   by injury and suppressed AKT signaling pathway by inhibiting upstream
   PDK1 expression and preventing the recruitment of TRAF4 to AKT,
   indicating that COX-2/PDK1/AKT signaling pathway promised to be target
   for treating muscle atrophy in the future.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Cao, XJ (Corresponding Author), Nanjing Med Univ, Dept Orthoped, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   Yang, L (Corresponding Author), Nanjing Med Univ, Nanjing Hosp 1, Dept Orthoped, 68 Changle Rd, Nanjing 210001, Jiangsu, Peoples R China.
   Chen, Hongtao; Zhang, Sheng; Jiang, Fan; Chang, Jie; Cao, Jiang; Cao, Xiaojian, Nanjing Med Univ, Dept Orthoped, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
   Qian, Zhanyang, Southeast Univ, Dept Orthoped, Zhongda Hosp, Nanjing, Jiangsu, Peoples R China.
   Fang, Le, Nanjing Med Univ, Affiliated Hosp 1, Dept Crit Care Med, Nanjing, Jiangsu, Peoples R China.
   Ge, Dawei; Yang, Lei, Nanjing Med Univ, Nanjing Hosp 1, Dept Orthoped, 68 Changle Rd, Nanjing 210001, Jiangsu, Peoples R China.
   Tang, Jian, Nanjing Med Univ, Affiliated Hosp 1, Dept Plast \& Burn Surg, Nanjing, Jiangsu, Peoples R China.},
DOI = {10.1016/j.redox.2020.101774},
Article-Number = {101774},
ISSN = {2213-2317},
Keywords = {COX-2; Skeletal muscle atrophy; Fibrogenesis; PDK1/AKT; TRAF4},
Keywords-Plus = {NEOADJUVANT CHEMOTHERAPY; EXTRACELLULAR-MATRIX; CELECOXIB; FIBROSIS;
   MANAGEMENT; SURGERY; TRIAL; ANGIOGENESIS; MULTICENTER; PREVENTION},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {leiyang@njmu.edu.cn
   xiaojiancao001@163.com},
Affiliations = {Nanjing Medical University; Southeast University - China; Nanjing
   Medical University; Nanjing Medical University; Nanjing Medical
   University},
ResearcherID-Numbers = {Ge, Dawei/KHX-0100-2024
   Cao, Jiang/E-7943-2019
   TANG, JIAN/JEZ-6308-2023
   YANG, LEI/GQH-4271-2022},
ORCID-Numbers = {cao, xiaojian/0000-0001-5567-0536
   Qian, Zhanyang/0000-0002-6431-9008
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81871773, 81672152,
   81802149]; Natural Science Foundation of Jiangsu Province
   {[}BK20171089]; Primary Research and Development Plan of Jiangsu
   Province {[}BE2018132]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (81871773, 81672152 to XC; 81802149 to LY), Natural
   Science Foundation of Jiangsu Province (BK20171089 to JT) and Primary
   Research and Development Plan of Jiangsu Province (BE2018132 to XC).},
Cited-References = {Bochaton-Piallat Marie-Luce, 2016, F1000Res, V5, DOI {[}10.12688/f1000research.8190.1, 10.12688/f1000research.8190.1].
   Bora H, 2001, INT J RADIAT ONCOL, V51, P507, DOI 10.1016/S0360-3016(01)01647-9.
   Bryn T, 2008, INT IMMUNOL, V20, P235, DOI 10.1093/intimm/dxm134.
   Buvanendran A, 2003, JAMA-J AM MED ASSOC, V290, P2411, DOI 10.1001/jama.290.18.2411.
   Cahill RA, 2006, ANN SURG, V244, P327, DOI 10.1097/01.sla.0000230021.24473.cf.
   Cao RY, 2018, ADV EXP MED BIOL, V1088, P605, DOI 10.1007/978-981-13-1435-3\_29.
   Casares L, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101321.
   Chan CH, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-59.
   Chaudhary NI, 2007, EUR RESPIR J, V29, P976, DOI 10.1183/09031936.00152106.
   Chen JH, 2015, NAT MED, V21, P327, DOI 10.1038/nm.3831.
   Chou R, 2016, J PAIN, V17, P131, DOI 10.1016/j.jpain.2015.12.008.
   Dey A, 2020, NAT REV DRUG DISCOV, V19, P480, DOI 10.1038/s41573-020-0070-z.
   Ebert SM, 2019, PHYSIOLOGY, V34, P232, DOI 10.1152/physiol.00003.2019.
   Edelman MJ, 2012, J CLIN ONCOL, V30, P2019, DOI 10.1200/JCO.2011.41.4581.
   Fabbrini P, 2009, NEPHROL DIAL TRANSPL, V24, P3669, DOI 10.1093/ndt/gfp384.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gao JH, 2016, ANGIOGENESIS, V19, P501, DOI 10.1007/s10456-016-9522-9.
   Giacchetti S, 2017, EUR J CANCER, V75, P323, DOI 10.1016/j.ejca.2017.01.008.
   Giblin S.P., 2020, MATRIX BIOL, P1.
   Gomez-Cabrera MC, 2020, REDOX BIOL, V35, DOI 10.1016/j.redox.2020.101531.
   Greene AK, 2005, ANN SURG, V242, P140, DOI 10.1097/01.sla.0000167847.53159.c1.
   Gupta A, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0591-7.
   Haak AJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau6296.
   Hamy AS, 2019, J CLIN ONCOL, V37, P624, DOI 10.1200/JCO.18.00636.
   Harish P, 2019, J CACHEXIA SARCOPENI, V10, P1016, DOI 10.1002/jcsm.12438.
   HAUTEKEETE ML, 1990, J INTERN MED, V228, P533, DOI 10.1111/j.1365-2796.1990.tb00274.x.
   Herrera J, 2018, J CLIN INVEST, V128, P45, DOI 10.1172/JCI93557.
   Horii N, 2018, FASEB J, V32, P3547, DOI 10.1096/fj.201700772RRR.
   Hui AY, 2004, J HEPATOL, V41, P251, DOI 10.1016/j.jhep.2004.04.033.
   Husain MI, 2020, LANCET PSYCHIAT, V7, P515, DOI 10.1016/S2215-0366(20)30138-3.
   Jia SJ, 2018, AM J RESP CELL MOL, V59, P295, DOI 10.1165/rcmb.2017-0419OC.
   Jiang SC, 2014, BIOMATERIALS, V35, P9920, DOI 10.1016/j.biomaterials.2014.08.028.
   Jones MG, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86375.
   Jun JI, 2018, J CLIN INVEST, V128, P97, DOI 10.1172/JCI93563.
   Kelly JD, 2019, EUR UROL, V75, P593, DOI 10.1016/j.eururo.2018.09.020.
   Lampi MC, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao0475.
   Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev.
   Li LF, 2016, MAT SCI ENG C-MATER, V61, P220, DOI 10.1016/j.msec.2015.12.028.
   Li PW, 2015, GUT, V64, P1419, DOI 10.1136/gutjnl-2014-308260.
   Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008-5472.CAN-13-0913.
   Liu F, 2015, AM J PHYSIOL-LUNG C, V308, pL344, DOI 10.1152/ajplung.00300.2014.
   Lynch PM, 2016, GUT, V65, P286, DOI 10.1136/gutjnl-2014-307235.
   Madaro L, 2018, NAT CELL BIOL, V20, P917, DOI 10.1038/s41556-018-0151-y.
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705.
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434.
   Mitchell JA, 2021, PHARMACOL THERAPEUT, V217, DOI 10.1016/j.pharmthera.2020.107624.
   Moore RA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008659.pub3.
   Niranjan R, 2018, MOL NEUROBIOL, V55, P8038, DOI 10.1007/s12035-018-0950-y.
   Paik YH, 2009, GUT, V58, P1517, DOI 10.1136/gut.2008.157420.
   Prakash J, 2017, ADV DRUG DELIVER REV, V121, P1, DOI 10.1016/j.addr.2017.11.008.
   Rebolledo DL, 2019, MATRIX BIOL, V82, P20, DOI 10.1016/j.matbio.2019.01.002.
   Regulski M, 2016, DRUG DISCOV TODAY, V21, P598, DOI 10.1016/j.drudis.2015.12.003.
   Richter K, 2015, REDOX BIOL, V6, P344, DOI 10.1016/j.redox.2015.08.015.
   Silva SV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165061.
   Strippoli R, 2015, EMBO MOL MED, V7, P102, DOI 10.15252/emmm.201404127.
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309.
   Thompson HA, 2016, AM SOC POLIT MOV TW, P108.
   Tian JY, 2019, CANCER LETT, V448, P1, DOI 10.1016/j.canlet.2019.01.002.
   Tschumperlin DJ, 2018, J CLIN INVEST, V128, P74, DOI 10.1172/JCI93561.
   TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2.
   Valle-Tenney R, 2020, MATRIX BIOL, V87, P48, DOI 10.1016/j.matbio.2019.09.003.
   Varrassi G, 2020, DRUGS, V80, P1443, DOI 10.1007/s40265-020-01369-x.
   Vietti G, 2016, NANOTOXICOLOGY, V10, P488, DOI 10.3109/17435390.2015.1088588.
   Vogel V, 2018, ANNU REV PHYSIOL, V80, P353, DOI 10.1146/annurev-physiol-021317-121312.
   Wilkinson DJ, 2018, AGEING RES REV, V47, P123, DOI 10.1016/j.arr.2018.07.005.
   Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412.
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015.
   Xia H, 2017, J CLIN INVEST, V127, P2586, DOI 10.1172/JCI90832.
   Xie HN, 2020, MOL THER-NUCL ACIDS, V22, P114, DOI 10.1016/j.omtn.2020.08.014.
   Yeomans ND, 2018, ALIMENT PHARM THER, V47, P1453, DOI 10.1111/apt.14610.
   Zerr P, 2016, ANN RHEUM DIS, V75, P226, DOI 10.1136/annrheumdis-2014-205740.
   Zhang F, 2019, DRUG DELIV, V26, P812, DOI 10.1080/10717544.2019.1648590.
   Zhang M, 2006, AM J PATHOL, V169, P1282, DOI 10.2353/ajpath.2006.050921.
   Zhang P, 2019, J CACHEXIA SARCOPENI, V10, P557, DOI 10.1002/jcsm.12414.
   Zhang PX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7221.},
Number-of-Cited-References = {75},
Times-Cited = {47},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Redox Biol.},
Doc-Delivery-Number = {PO0YX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000604898900005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000648193000001,
Author = {Ding, Leilei and Ren, Chenchen and Yang, Li and Wu, Zimeng and Li,
   Feiyan and Jiang, Dongyuan and Zhu, Yuanhang and Lu, Jie},
Title = {OSU-03012 Disrupts Akt Signaling and Prevents Endometrial Carcinoma
   Progression in vitro and in vivo},
Journal = {DRUG DESIGN DEVELOPMENT AND THERAPY},
Year = {2021},
Volume = {15},
Pages = {1797-1810},
Abstract = {Purpose: OSU-03012 is a celecoxib derivative lacking cyclooxygenase-2
   inhibitory activity and a potent PDK1 inhibitor which has been shown to
   inhibit tumor growth in various ways. However, the role of OSU-03012 in
   endometrial carcinoma (EC) in which the PI3K/Akt signaling pathway
   highly activated has not been studied. Here, we determined the potency
   of OSU-03012 in suppressing EC progression in vitro and in vivo, and
   studied the underlined mechanisms.
   Methods: The human EC Ishikawa and HEC-1A cells were used as the in
   vitro models. CCK8 assay and flow cytometry were conducted to evaluate
   cell proliferation, cell cycle progression, and apoptosis. The
   metastatic ability was evaluated using the transwell migration assay.
   The Ishikawa xenograft tumor model was used to study the inhibitory
   effects of OSU-03012 on EC growth in vivo. Western blot analysis was
   performed to evaluate expressions of the cell cycle and apoptosis
   associated proteins.
   Results: OSU-03012 could inhibit the progression of EC both in vitro and
   in vivo by disrupting Akt signaling. It reduced the metastatic ability
   of EC, led to G2/M cell cycle arrest and induced apoptosis via the
   mitochondrial apoptosis pathway.
   Conclusion: Our data indicated that OSU-03012 could inhibit the
   progression of EC in vitro and in vivo. It can potentially be used as
   the targeted drug for the treatment of EC by inhibiting Akt signaling.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Article},
Language = {English},
Affiliation = {Ren, CC; Yang, L (Corresponding Author), Zhengzhou Univ, Affiliated Hosp 3, 7 Front Kangfu St, Zhengzhou, Henan, Peoples R China.
   Ding, Leilei; Ren, Chenchen; Yang, Li; Wu, Zimeng; Li, Feiyan; Jiang, Dongyuan; Zhu, Yuanhang; Lu, Jie, Zhengzhou Univ, Dept Obstet \& Gynecol, Affiliated Hosp 3, Zhengzhou, Henan, Peoples R China.},
DOI = {10.2147/DDDT.S304128},
ISSN = {1177-8881},
Keywords = {OSU-03012; endometrial carcinoma; Akt signaling; the mitochondrial
   apoptosis pathway},
Keywords-Plus = {CANCER-CELLS; CELECOXIB; APOPTOSIS; GROWTH; SUPPRESSION; INHIBITION;
   EXPRESSION; PROTEINS; SURVIVAL},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal; Pharmacology \& Pharmacy},
Author-Email = {zdsfy\_renchenchen@163.com
   zdsfyyangli@163.com},
Affiliations = {Zhengzhou University},
Funding-Acknowledgement = {Key Project of Science and Technology of Henan {[}144/22170001]; Henan
   Key Laboratory of Digestive Organ Transplantation},
Funding-Text = {This research was funded by the Key Project of Science and Technology of
   Henan, grant number 144/22170001. We thank the research group of
   Professor Ya Xie from the First Affiliated Hospital of Zhengzhou
   University for great support in Ishikawa cell line. Thanks for the
   support and guidance provided by Henan Key Laboratory of Digestive Organ
   Transplantation.},
Cited-References = {Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102.
   Basho RK, 2017, JAMA ONCOL, V3, P509, DOI 10.1001/jamaoncol.2016.5281.
   Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5.
   Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216.
   Ediriweera MK, 2019, SEMIN CANCER BIOL, V59, P147, DOI 10.1016/j.semcancer.2019.05.012.
   Fleming GF, 2007, J CLIN ONCOL, V25, P2983, DOI 10.1200/JCO.2007.10.8431.
   Gao M, 2008, CANCER RES, V68, P9348, DOI 10.1158/0008-5472.CAN-08-1642.
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113.
   Ha DP, 2020, CELL SIGNAL, V75, DOI 10.1016/j.cellsig.2020.109736.
   Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706.
   Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938.
   Johnson AJ, 2005, BLOOD, V105, P2504, DOI 10.1182/blood-2004-05-1957.
   Kale J, 2018, CELL DEATH DIFFER, V25, P65, DOI 10.1038/cdd.2017.186.
   Kalkavan H, 2018, CELL DEATH DIFFER, V25, P46, DOI 10.1038/cdd.2017.179.
   Khosravi-Far R, 2004, CANCER BIOL THER, V3, P1051, DOI 10.4161/cbt.3.11.1173.
   Kucab JE, 2005, BREAST CANCER RES, V7, pR796, DOI 10.1186/bcr1294.
   Liu J, 2013, ANTI-CANCER DRUG, V24, P690, DOI 10.1097/CAD.0b013e328362469f.
   Liu Z, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5273969.
   Makker V, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.02627.
   Mateo J, 2013, 1 IN HUMAN PHASE 1 T.
   Megino-Luque C, 2020, CANCERS, V12, DOI 10.3390/cancers12102751.
   Muñoz-Alonso MJ, 2005, J BIOL CHEM, V280, P18120, DOI 10.1074/jbc.M500758200.
   Murata M, 2015, MOL PHARMACEUT, V12, P1422, DOI 10.1021/mp5007129.
   Nagaraj NS, 2010, J NUTR BIOCHEM, V21, P405, DOI 10.1016/j.jnutbio.2009.01.015.
   Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597.
   Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580.
   Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201.
   Pore SK, 2020, MOL CANCER THER, V19, P420, DOI 10.1158/1535-7163.MCT-19-0611.
   Qian DC, 2017, CLIN CANCER RES, V23, P399, DOI 10.1158/1078-0432.CCR-16-0623.
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155.
   Rodriguez-Cupello C, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00146.
   Romano G, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/317186.
   Roncolato F, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012160.pub2.
   Rossé T, 1998, NATURE, V391, P496, DOI 10.1038/35160.
   Salomons GS, 1997, INT J CANCER, V71, P959, DOI 10.1002/(SICI)1097-0215(19970611)71:6<959::AID-IJC9>3.0.CO;2-X.
   Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106.
   Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9.
   Shi N, 2019, ONCOTARGETS THER, V12, P7637, DOI 10.2147/OTT.S205457.
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135.
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312.
   Uegaki K, 2005, ONCOL REP, V14, P389.
   Wang YC, 2008, CANCER RES, V68, P2820, DOI 10.1158/0008-5472.CAN-07-1336.
   Weng SC, 2008, MOL CANCER THER, V7, P800, DOI 10.1158/1535-7163.MCT-07-0434.
   West NW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-256.
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x.
   Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063.
   Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549.},
Number-of-Cited-References = {47},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Drug Des. Dev. Ther.},
Doc-Delivery-Number = {RY8ZK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000648193000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000705513100007,
Author = {Feng, Peiran and Yang, Quanli and Luo, Liang and Sun, Yadong and Lv,
   Wenkai and Wan, Shuo and Guan, Zerong and Xiao, Zhiqiang and Liu, Feng
   and Li, Zehua and Dong, Zhongjun and Yang, Meixiang},
Title = {The kinase PDK1 regulates regulatory T cell survival via controlling
   redox homeostasis},
Journal = {THERANOSTICS},
Year = {2021},
Volume = {11},
Number = {19},
Pages = {9503-9518},
Abstract = {Rationale: Regulatory T cells (Treg cells) play an important role in
   maintaining peripheral tolerance by suppressing over-activation of
   effector T cells. The kinase PDK1 plays a pivotal role in conventional T
   cell development. However, whether PDK1 signaling affects the
   homeostasis and function of Treg cells remains elusive.
   Methods: In order to evaluate the role of PDK1 in Treg cells from a
   genetic perspective, mice carrying the floxed PDK1 allele were crossbred
   with Foxp3(Cre) mice to efficiently deleted PDK1 in Foxp3(+) Treg cells.
   Flow cytometry was used to detect the immune cell homeostasis of WT and
   PDK1(fl/fl)Foxp3(Cre) mice. RNA-seq was used to assess the differences
   in transcriptional expression profile of WT and PDK1-deficient Treg
   cells. The metabolic profiles of WT and PDK1-deficient Treg cells were
   tested using the Glycolysis Stress Test and Mito Stress Test Kits by the
   Seahorse XFe96 Analyser.
   Results: PDK1 was essential for the establishment and maintenance of
   Treg cell homeostasis and function. Disruption of PDK1 in Treg cells led
   to a spontaneous fatal systemic autoimmune disorder and multi-tissue
   inflammatory damage, accompanied by a reduction in the number and
   function of Treg cells. The deletion of PDK1 in Treg cells destroyed the
   iron ion balance through regulating MEK-ERK signaling and CD71
   expression, resulting in excessive production of intracellular ROS,
   which did not depend on the down-regulation of mTORC1 signaling.
   Inhibition of excessive ROS, activated MEK-Erk signaling or overload
   Fe2+ could partially rescue the survival of PDK1-deficient Treg cells.
   Conclusion: Our results defined a key finding on the mechanism by which
   PDK1 regulates Treg cell survival via controlling redox homeostasis.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Dong, ZJ (Corresponding Author), Tsinghua Univ, Med Blvd D328, Beijing 100086, Peoples R China.
   Yang, MX (Corresponding Author), 601 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.
   Feng, Peiran; Yang, Quanli; Luo, Liang; Sun, Yadong; Lv, Wenkai; Wan, Shuo; Guan, Zerong; Xiao, Zhiqiang; Liu, Feng; Yang, Meixiang, Jinan Univ, Zhuhai Hosp, Zhuhai Peoples Hosp, Zhuhai Inst Translat Med, Zhuhai 519000, Guangdong, Peoples R China.
   Feng, Peiran; Yang, Quanli; Luo, Liang; Sun, Yadong; Lv, Wenkai; Wan, Shuo; Guan, Zerong; Xiao, Zhiqiang; Liu, Feng; Yang, Meixiang, Jinan Univ, Biomed Translat Res Inst, Fac Med Sci, Guangzhou 510632, Guangdong, Peoples R China.
   Li, Zehua; Dong, Zhongjun, Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China.
   Li, Zehua; Dong, Zhongjun, Tsinghua Univ, Beijing Key Lab Immunol Res Chron Dis, Inst Immunol, Beijing 100084, Peoples R China.},
DOI = {10.7150/thno.63992},
ISSN = {1838-7640},
Keywords = {Treg cell; PDK1; ROS; Iron homeostasis; MAPK; Immune cell death},
Keywords-Plus = {DIFFERENTIATION; RECEPTOR; MTOR},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {dongzj@mail.tsinghua.edu.cn
   mxyang@jnu.edu.cn},
Affiliations = {Jinan University; Jinan University; Tsinghua University; Tsinghua
   University},
ResearcherID-Numbers = {Li, Ze-Hua/P-2281-2017
   Sun, Yadong/ODK-9299-2025
   },
ORCID-Numbers = {Wan, Shuo/0000-0003-2765-6002},
Funding-Acknowledgement = {Natural Science Foundation of China {[}81771666, 81471523, 82071737,
   81725007, 31830027, 31821003, 91942308, 32000615, 82101831]; National
   Key Research \& Developmental Program of China {[}2018YFC1003900];
   Natural Science Foundation of Guangdong Province {[}2019A1515011707];
   111 Project {[}B16201]; China Postdoctoral Science Foundation
   {[}2019M663374, 2021M691236]; Guangdong Basic and Applied Basic Research
   Fund {[}2020A1515111081]},
Funding-Text = {Research reported in this publication was supported by the Natural
   Science Foundation of China (to MY, 81771666, 81471523 and 82071737; to
   DZ, 81725007, 31830027, 31821003 and 91942308; to QY, 32000615; to SW,
   82101831) , National Key Research \& Developmental Program of China (to
   ZD, 2018YFC1003900) , Natural Science Foundation of Guangdong Province
   (to MY, 2019A1515011707) and by 111 Project (B16201) . China
   Postdoctoral Science Foundation (to QY, 2019M663374; to SW, 2021M691236)
   , Guangdong Basic and Applied Basic Research Fund (to QY,
   2020A1515111081) .},
Cited-References = {Allan SE, 2008, IMMUNOL REV, V223, P391, DOI 10.1111/j.1600-065X.2008.00634.x.
   Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Chapman NM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04392-5.
   Chapman NM, 2014, IMMUNOTHERAPY-UK, V6, P1295, DOI 10.2217/imt.14.84.
   Degirmenci U, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010198.
   DESOUSA M, 1989, CLIN EXP IMMUNOL, V75, P1.
   Dominguez-Villar M, 2018, NAT IMMUNOL, V19, P665, DOI 10.1038/s41590-018-0120-4.
   Feng YH, 2019, INT J EXP PATHOL, V100, P32, DOI 10.1111/iep.12307.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Franchina DG, 2018, TRENDS IMMUNOL, V39, P489, DOI 10.1016/j.it.2018.01.005.
   Gozzelino R, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010130.
   Guo ZL, 2020, J CLIN INVEST, V130, P5893, DOI 10.1172/JCI136466.
   He JM, 2019, CELL DEATH DIFFER, V26, P1918, DOI 10.1038/s41418-018-0263-8.
   He NH, 2017, P NATL ACAD SCI USA, V114, P12542, DOI 10.1073/pnas.1715363114.
   Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062.
   Kuang FM, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586578.
   Li MO, 2016, NAT REV IMMUNOL, V16, P220, DOI 10.1038/nri.2016.26.
   Lu L, 2017, NAT REV IMMUNOL, V17, P703, DOI 10.1038/nri.2017.75.
   Lucca LE, 2020, NAT REV IMMUNOL, V20, P680, DOI 10.1038/s41577-020-0296-3.
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006.
   Mu QD, 2021, SCI BULL, V66, P1806, DOI 10.1016/j.scib.2021.02.010.
   Oh H, 2021, J IMMUNOL, V206, P1776, DOI 10.4049/jimmunol.2000051.
   Park SG, 2010, IMMUNITY, V33, P791, DOI 10.1016/j.immuni.2010.10.014.
   Park SG, 2009, NAT IMMUNOL, V10, P158, DOI 10.1038/ni.1687.
   Porto G, 2007, WORLD J GASTROENTERO, V13, P4707, DOI 10.3748/wjg.v13.i35.4707.
   Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017.
   Soares MP, 2016, IMMUNITY, V44, P492, DOI 10.1016/j.immuni.2016.02.016.
   Stockis J, 2019, IMMUNOLOGY, V157, P219, DOI 10.1111/imm.13064.
   Sun Z, ELIFE, V2021, P10.
   Tang SC, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.590789.
   Yang K, 2017, NATURE, V548, P602, DOI 10.1038/nature23665.
   Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703.
   Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297.
   Zhong JH, 2020, ANTIOXID REDOX SIGN, V32, P161, DOI 10.1089/ars.2019.7788.},
Number-of-Cited-References = {34},
Times-Cited = {28},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {26},
Journal-ISO = {Theranostics},
Doc-Delivery-Number = {WE3HD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000705513100007},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000637324000025,
Author = {Gan, Guifang and Shi, Zhaopeng and Shangguan, Chengfang and Zhang,
   Jieying and Yuan, Yuan and Chen, Lei and Liu, Weiren and Li, Biao and
   Meng, Songshu and Xiong, Wujun and Mi, Jun},
Title = {The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to
   sorafenib by upregulating phosphatases},
Journal = {THERANOSTICS},
Year = {2021},
Volume = {11},
Number = {12},
Pages = {6006-6018},
Abstract = {Objectives: Sorafenib is the only FDA-approved first-line target drug
   for HCC patients. However, sorafenib merely confers 3-5 months of
   survival benefit with less than 30\% of HCC patients sensitive to
   sorafenib therapy. Thus, it's necessary to develop a sensitizer for
   hepatocellular carcinoma (HCC) to sorafenib. Methods: The principal
   component analysis, gene ontology, and KEGG analysis are utilized
   following RNA-sequencing. The mass spectrometry analysis following
   immunoprecipitation is performed to discover the phosphatase targets.
   Most importantly, both the cell line-derived xenograft (CDX) and the
   patient-derived xenograft (PDX) mouse model are used to determine the
   effect of 3-HAA on sorafenib-resistant HCC in vivo. Results: In nude
   mice carrying HCC xenograft, tumor growth is inhibited by sorafenib or
   3-HAA alone. When used in combination, the treatment particularly
   prevents the xenograft from growing. Combined treatment also suppresses
   the growth of sorafenib-resistant (>= 30mg/kg) PDXs. In a set of
   mechanistic experiments, we find enhanced AKT activation and decreased
   apoptotic cells in de novo and acquired sorafenib-resistant HCC cells
   and tissues. 3-HAA decreases AKT phosphorylation and increases the
   apoptosis of HCC in both cultured cells and mouse xenografts by
   upregulation of phosphatases PPP1R15A/DUSP6. PPP1R15A/PPP1 alpha
   directly reduces Akt phosphorylation while DUSP6 decreases Akt activity
   through inhibiting PDK1. The AKT activator abolishes 3-HAA inhibition of
   HCC growth in vitro and in mice. Conclusion: This study demonstrates
   that 3-HAA sensitizes HCC cells to sorafenib by upregulation of
   phosphatases, suggesting it as a promising molecule for HCC therapy.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Mi, J (Corresponding Author), Shanghai Jiao Tong Univ, Key Lab Cell Differentiat \& Apoptosis, Chinese Minist Educ, Sch Med, Shanghai 200025, Peoples R China.
   Li, B (Corresponding Author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Nucl Med, Sch Med, Shanghai 200025, Peoples R China.
   Li, B (Corresponding Author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Oncol, Sch Med, Shanghai 200025, Peoples R China.
   Xiong, WJ (Corresponding Author), Fudan Univ, Shanghai Pudong Hosp, Dept Gastroenterol, Pudong Med Ctr, Shanghai 201399, Peoples R China.
   Mi, J (Corresponding Author), Shanghai Jiao Tong Univ, Sch Med, Dept Biochem \& Mol Cell Biol, Shanghai 200025, Peoples R China.
   Meng, SS (Corresponding Author), Dalian Med Univ, 9 South Lvshun Rd West, Dalian 116041, Liaoning, Peoples R China.
   Gan, Guifang; Shi, Zhaopeng; Zhang, Jieying; Yuan, Yuan; Mi, Jun, Shanghai Jiao Tong Univ, Sch Med, Basic Med Inst, Shanghai 200025, Peoples R China.
   Gan, Guifang; Shi, Zhaopeng; Zhang, Jieying; Yuan, Yuan; Mi, Jun, Shanghai Jiao Tong Univ, Key Lab Cell Differentiat \& Apoptosis, Chinese Minist Educ, Sch Med, Shanghai 200025, Peoples R China.
   Shangguan, Chengfang; Li, Biao; Mi, Jun, Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Nucl Med, Sch Med, Shanghai 200025, Peoples R China.
   Shangguan, Chengfang; Li, Biao; Mi, Jun, Shanghai Jiao Tong Univ, Rui Jin Hosp, Dept Oncol, Sch Med, Shanghai 200025, Peoples R China.
   Gan, Guifang, Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Coll Stomatol, Sch Med, Shanghai 200011, Peoples R China.
   Zhang, Jieying, Tongji Univ, East Hosp, Translat Med Ctr Stem Cell Therapy, Sch Med, 150 Jimo Rd, Shanghai 200120, Peoples R China.
   Chen, Lei, Marine Mil Med Univ, Eastern Hepatobiliary Surg Inst, Int Cooperat Lab Signal Transduct, Shanghai 200438, Peoples R China.
   Liu, Weiren, Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Dept Liver Surg, Shanghai 200032, Peoples R China.
   Meng, Songshu, Dalian Med Univ, Inst Canc Stem Cell, Dalian 116044, Liaoning, Peoples R China.
   Xiong, Wujun, Fudan Univ, Shanghai Pudong Hosp, Dept Gastroenterol, Pudong Med Ctr, Shanghai 201399, Peoples R China.},
DOI = {10.7150/thno.59841},
ISSN = {1838-7640},
Keywords = {3-hydroxyanthranilc acid; sorafenib resistance; AKT; DUSP6; PPP1R15A},
Keywords-Plus = {RESISTANCE; CANCER; CELLS; PATHWAY},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {lb103636@rjh.com.cn
   ssmeng@dmu.edu.cn
   xiongwujun@126.com
   jmei@sjtu.edu.cn},
Affiliations = {Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong
   University; Tongji University; Naval Medical University; Fudan
   University; Dalian Medical University; Fudan University},
ResearcherID-Numbers = {Menezes Echaniz, Regina/L-3792-2014},
Funding-Acknowledgement = {Ministry of Science and Technology of China {[}2018YFC1313205]; Shanghai
   Committee of Science and Technology {[}11DZ2260200]; National Natural
   Science Foundation of China {[}82073040, 81872342, 81471686, 81801725]},
Funding-Text = {This study was supported by grants from the Ministry of Science and
   Technology of China (2018YFC1313205), the Shanghai Committee of Science
   and Technology (11DZ2260200) and the National Natural Science Foundation
   of China (82073040) (81872342) to Dr. Mi, and the National Natural
   Science Foundation of China (81471686) (81801725) to Dr. Li and Dr.
   Shangguan, respectively.},
Cited-References = {Asghar U, 2012, J HEPATOL, V56, P686, DOI 10.1016/j.jhep.2011.07.031.
   Brenner C, 2013, J HEPATOL, V59, P583, DOI 10.1016/j.jhep.2013.03.033.
   Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786.
   Cheng J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8209.
   Guo BB, 2020, EMBO J, V39, DOI 10.15252/embj.2019102190.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hayashi T, 2007, P NATL ACAD SCI USA, V104, P18619, DOI 10.1073/pnas.0709261104.
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814.
   Huynh H, 2006, CLIN CANCER RES, V12, P4306, DOI 10.1158/1078-0432.CCR-05-2568.
   Kabir TD, 2018, HEPATOLOGY, V67, P216, DOI 10.1002/hep.29478.
   Lei NJ, 2014, ONCOL REP, V32, P1689, DOI 10.3892/or.2014.3375.
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857.
   Llovet Josep M, 2004, Liver Transpl, V10, pS115, DOI 10.1002/lt.20034.
   Nakakura EK, 2000, ONCOLOGY-NY, V14, P1085.
   Ni CX, 2016, ONCOTARGET, V7, P79530, DOI 10.18632/oncotarget.12822.
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491.
   Platten M, 2012, CANCER RES, V72, P5435, DOI 10.1158/0008-5472.CAN-12-0569.
   Rimola J, 2018, HEPATOLOGY, V67, P612, DOI 10.1002/hep.29515.
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028.
   Sokolosky M, 2014, CELL CYCLE, V13, P820, DOI 10.4161/cc.27728.
   Sordillo PP, 2017, ANTICANCER RES, V37, P2159, DOI 10.21873/anticanres.11551.
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262.
   Tovar V, 2017, GUT, V66, P530, DOI 10.1136/gutjnl-2015-309501.
   Zhai B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138485.
   Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5.},
Number-of-Cited-References = {25},
Times-Cited = {21},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Theranostics},
Doc-Delivery-Number = {RJ0WI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000637324000025},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000612523700006,
Author = {Kim, Myung-Jun and O'Connor, Michael B.},
Title = {Drosophila Activin signaling promotes muscle growth through
   InR/TORC1-dependent and -independent processes},
Journal = {DEVELOPMENT},
Year = {2021},
Volume = {148},
Number = {1},
Month = {JAN},
Abstract = {The Myostatin/Activin branch of the TGF-beta superfamily acts as a
   negative regulator of vertebrate skeletal muscle size, in part, through
   downregulation of insulin/insulin-like growth factor 1 (IGF-1)
   signaling. Surprisingly, recent studies in Drosophila indicate that
   motoneuron-derived Activin signaling acts as a positive regulator of
   muscle size. Here we demonstrate that Drosophila Activin signaling
   promotes the growth of muscle cells along all three axes: width,
   thickness and length. Activin signaling positively regulates the insulin
   receptor (InR)/TORC1 pathway and the level of Myosin heavy chain (Mhc),
   an essential sarcomeric protein, via increased Pdki and Akti expression.
   Enhancing InR/TORC1 signaling in the muscle of Activin pathway mutants
   restores Mhc levels close to those of the wild type, but only increases
   muscle width. In contrast, hyperactivation of the Activin pathway in
   muscles increases overall larval body and muscle fiber length, even when
   Mhc levels are lowered by suppression of TORC1. Together, these results
   indicate that the Drosophila Activin pathway regulates larval muscle
   geometry and body size via promoting InR/TORC1-dependent Mhc production
   and the differential assembly of sarcomeric components into either
   pre-existing or new sarcomeric units depending on the balance of
   InWTORC1 and Activin signals.},
Publisher = {COMPANY BIOLOGISTS LTD},
Address = {BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {O'Connor, MB (Corresponding Author), Univ Minnesota, Dept Genet Cell Biol \& Dev, Minneapolis, MN 55455 USA.
   Kim, Myung-Jun; O'Connor, Michael B., Univ Minnesota, Dept Genet Cell Biol \& Dev, Minneapolis, MN 55455 USA.},
DOI = {10.1242/dev.190868},
Article-Number = {dev190868},
ISSN = {0950-1991},
EISSN = {1477-9129},
Keywords = {Activin; Drosophila; Insulin; Muscle},
Keywords-Plus = {SKELETAL-MUSCLE; INSULIN-RESISTANCE; UBIQUITIN-PROTEASOME;
   PROTEIN-SYNTHESIS; CANCER CACHEXIA; TGF-BETA; MYOSTATIN; HYPERTROPHY;
   OBESITY; SMAD3},
Research-Areas = {Developmental Biology},
Web-of-Science-Categories  = {Developmental Biology},
Author-Email = {moconnor@umn.edu},
Affiliations = {University of Minnesota System; University of Minnesota Twin Cities},
ResearcherID-Numbers = {Kim, Myung Jun/MVW-7431-2025
   O'Connor, Michael/C-9977-2014},
ORCID-Numbers = {O'Connor, Michael/0000-0002-3067-5506},
Funding-Acknowledgement = {National Institutes of Health {[}1R35 GM-118029]; National Institute of
   General Medical Sciences {[}R35GM118029] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported by the National Institutes of Health (1R35
   GM-118029 to M.B.O.). Deposited in PMC for release after 12 months.},
Cited-References = {Amirouche A, 2009, ENDOCRINOLOGY, V150, P286, DOI 10.1210/en.2008-0959.
   Amthor H, 2009, P NATL ACAD SCI USA, V106, P7479, DOI 10.1073/pnas.0811129106.
   Bergen HR, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0047-5.
   Bhattacharya TK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44217-z.
   Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154.
   Bonaldo P, 2013, DIS MODEL MECH, V6, P25, DOI 10.1242/dmm.010389.
   Brummel T, 1999, GENE DEV, V13, P98, DOI 10.1101/gad.13.1.98.
   Chen JL, 2017, P NATL ACAD SCI USA, V114, pE5266, DOI 10.1073/pnas.1620013114.
   Chen JL, 2015, MOL THER, V23, P434, DOI 10.1038/mt.2014.221.
   Chen JL, 2014, FASEB J, V28, P1711, DOI 10.1096/fj.13-245894.
   Cheng L, 2011, J CELL BIOL, V194, P921, DOI 10.1083/jcb.201101042.
   Demontis F, 2014, CELL REP, V7, P1481, DOI 10.1016/j.celrep.2014.05.001.
   Demontis F, 2009, DEVELOPMENT, V136, P983, DOI 10.1242/dev.027466.
   Egerman MA, 2014, CRIT REV BIOCHEM MOL, V49, P59, DOI 10.3109/10409238.2013.857291.
   Gao YP, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00088.
   Ghosh AC, 2014, P NATL ACAD SCI USA, V111, P5729, DOI 10.1073/pnas.1319116111.
   Goodman CA, 2013, MOL ENDOCRINOL, V27, P1946, DOI 10.1210/me.2013-1194.
   GUNN HM, 1989, J ANAT, V167, P225.
   Gustafsson T, 2010, J APPL PHYSIOL, V109, P721, DOI 10.1152/japplphysiol.00110.2009.
   Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069.
   Hietakangas V, 2007, GENE DEV, V21, P632, DOI 10.1101/gad.416307.
   Hitachi K, 2014, INT J BIOCHEM CELL B, V47, P93, DOI 10.1016/j.biocel.2013.12.003.
   Hulmi JJ, 2013, AM J PHYSIOL-ENDOC M, V304, pE41, DOI 10.1152/ajpendo.00389.2012.
   Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910.
   Kim MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107443.
   Kockel L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000990.
   Lee SJ, 2012, P NATL ACAD SCI USA, V109, pE2353, DOI 10.1073/pnas.1206410109.
   Lee SJ, 2005, P NATL ACAD SCI USA, V102, P18117, DOI 10.1073/pnas.0505996102.
   Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098.
   Lindquist RA, 2011, GENOME RES, V21, P433, DOI 10.1101/gr.111492.110.
   Lokireddy S, 2012, BIOCHEM J, V446, P23, DOI 10.1042/BJ20112024.
   Lokireddy S, 2011, AM J PHYSIOL-CELL PH, V301, pC1316, DOI 10.1152/ajpcell.00114.2011.
   Loumaye A, 2015, J CLIN ENDOCR METAB, V100, P2030, DOI 10.1210/jc.2014-4318.
   Marden JH, 2000, ANNU REV PHYSIOL, V62, P157, DOI 10.1146/annurev.physiol.62.1.157.
   Marino FE, 2015, J CACHEXIA SARCOPENI, V6, P365, DOI 10.1002/jcsm.12031.
   McCabe BD, 2003, NEURON, V39, P241, DOI 10.1016/S0896-6273(03)00426-4.
   McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0.
   Moss-Taylor L, 2019, GENETICS, V213, P1447, DOI 10.1534/genetics.119.302394.
   Pedersen BK, 2012, NAT REV ENDOCRINOL, V8, P457, DOI 10.1038/nrendo.2012.49.
   Piccirillo R, 2014, DEV DYNAM, V243, P201, DOI 10.1002/dvdy.24036.
   Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707.
   Reardon KA, 2001, MUSCLE NERVE, V24, P893, DOI 10.1002/mus.1086.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sartori R, 2014, TRENDS ENDOCRIN MET, V25, P464, DOI 10.1016/j.tem.2014.06.002.
   Sartori R, 2013, NAT GENET, V45, P1309, DOI 10.1038/ng.2772.
   Sartori R, 2009, AM J PHYSIOL-CELL PH, V296, pC1248, DOI 10.1152/ajpcell.00104.2009.
   Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253.
   Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4.
   Schmidt EK, 2009, NAT METHODS, V6, P275, DOI {[}10.1038/NMETH.1314, 10.1038/nmeth.1314].
   Schuelke M, 2004, NEW ENGL J MED, V350, P2682, DOI 10.1056/NEJMoa040933.
   Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026.
   Souza TA, 2008, MOL ENDOCRINOL, V22, P2689, DOI 10.1210/me.2008-0290.
   Spletter ML, 2018, ELIFE, V7, DOI 10.7554/eLife.34058.
   Stantzou A, 2017, DEVELOPMENT, V144, P2737, DOI 10.1242/dev.144089.
   Stump CS, 2006, ANN MED, V38, P389, DOI 10.1080/07853890600888413.
   Tan CK, 2011, DIABETES, V60, P464, DOI 10.2337/db10-0801.
   Ting CY, 2007, NEURON, V56, P793, DOI 10.1016/j.neuron.2007.09.033.
   Trendelenburg AU, 2009, AM J PHYSIOL-CELL PH, V296, pC1258, DOI 10.1152/ajpcell.00105.2009.
   Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866.
   Upadhyay A, 2020, ELIFE, V9, DOI 10.7554/eLife.51710.
   Upadhyay A, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022152.
   Watanabe H, 2014, NATURE, V515, P112, DOI 10.1038/nature13666.
   Wehling M, 2000, FASEB J, V14, P103, DOI 10.1096/fasebj.14.1.103.
   Weitkunat M, 2014, CURR BIOL, V24, P705, DOI 10.1016/j.cub.2014.02.032.
   White TA, 2014, GERONTOLOGY, V60, P289, DOI 10.1159/000356740.
   Winbanks CE, 2013, J CELL BIOL, V203, P345, DOI 10.1083/jcb.201211134.
   Winbanks CE, 2012, J CELL BIOL, V197, P997, DOI 10.1083/jcb.201109091.
   Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103.
   Zhang J, 2008, J BIOL CHEM, V283, P35375, DOI 10.1074/jbc.M806480200.
   Zhou XL, 2010, CELL, V142, P531, DOI 10.1016/j.cell.2010.07.011.
   Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525.},
Number-of-Cited-References = {72},
Times-Cited = {18},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Development},
Doc-Delivery-Number = {PZ1UA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000612523700006},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000590779400001,
Author = {Lopez-Canovas, Juan L. and del Rio-Moreno, Mercedes and
   Garcia-Fernandez, Helena and Jimenez-Vacas, Juan M. and Trinidad
   Moreno-Montilla, M. and Sanchez-Frias, Marina E. and Amado, Victor and
   L-Lopez, Fernando and Fondevila, Marcos F. and Ciria, Ruben and
   Gomez-Luque, Irene and Briceno, Javier and Nogueiras, Ruben and de la
   Mata, Manuel and Castano, Justo P. and Rodriguez-Peralvarez, Manuel and
   Luque, Raul M. and Gahete, Manuel D.},
Title = {Splicing factor SF3B1 is overexpressed and implicated in the
   aggressiveness and survival of hepatocellular carcinoma},
Journal = {CANCER LETTERS},
Year = {2021},
Volume = {496},
Pages = {72-83},
Month = {JAN 1},
Abstract = {Splicing alterations represent an actionable cancer hallmark. Splicing
   factor 3B subunit 1 (SF3B1) is a crucial splicing factor that can be
   targeted pharmacologically (e.g. pladienolide-B). Here, we show that
   SF3B1 is overexpressed (RNA/protein) in hepatocellular carcinoma (HCC)
   in two retrospective (n = 154 and n = 172 samples) and in five in silico
   cohorts (n > 900 samples, including TCGA) and that its expression is
   associated with tumor aggressiveness, oncogenic splicing variants
   expression (KLF6-SV1, BCL-XL) and decreased overall survival. In vitro,
   SF3B1 silencing reduced cell viability, proliferation and migration and
   its pharmacological blockade with pladienolide-B inhibited
   proliferation, migration, and formation of tumorspheres and colonies in
   liver cancer cell lines (HepG2, Hep3B, SNU-387), whereas its effects on
   normal-like hepatocyte-derived THLE-2 proliferation were negligible.
   Pladienolide-B also reduced the in vivo growth and the expression of
   tumor-markers in Hep3B-induced xenograft tumors. Moreover, SF3B1
   silencing and/or blockade markedly modulated the activation of key
   signaling pathways (PDK1, GSK3b, ERK, JNK, AMPK) and the expression of
   cancer-associated genes (CDK4, CD24) and oncogenic SVs (KLF6-SV1).
   Therefore, the genetic and/or pharmacological inhibition of SF3B1 may
   represent a promising novel therapeutic strategy worth to be explored
   through randomized controlled trials.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Gahete, MD (Corresponding Author), Maim onides Inst Biomed Res Cordoba IMIBIC, Dept Cell Biol Physiol \& Immunol, Av Menendez Pidal S-N, Cordoba 14004, Spain.
   Lopez-Canovas, Juan L.; del Rio-Moreno, Mercedes; Garcia-Fernandez, Helena; Jimenez-Vacas, Juan M.; Trinidad Moreno-Montilla, M.; Sanchez-Frias, Marina E.; Amado, Victor; L-Lopez, Fernando; Ciria, Ruben; Gomez-Luque, Irene; Briceno, Javier; de la Mata, Manuel; Castano, Justo P.; Rodriguez-Peralvarez, Manuel; Luque, Raul M.; Gahete, Manuel D., Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba 14004, Spain.
   Lopez-Canovas, Juan L.; del Rio-Moreno, Mercedes; Garcia-Fernandez, Helena; Jimenez-Vacas, Juan M.; Trinidad Moreno-Montilla, M.; L-Lopez, Fernando; Castano, Justo P.; Luque, Raul M.; Gahete, Manuel D., Univ Cordoba, Dept Cell Biol Physiol \& Immunol, Cordoba 14004, Spain.
   Lopez-Canovas, Juan L.; del Rio-Moreno, Mercedes; Garcia-Fernandez, Helena; Jimenez-Vacas, Juan M.; Trinidad Moreno-Montilla, M.; Sanchez-Frias, Marina E.; L-Lopez, Fernando; Castano, Justo P.; Luque, Raul M.; Gahete, Manuel D., Reina Sofia Univ Hosp, Cordoba 14004, Spain.
   Lopez-Canovas, Juan L.; del Rio-Moreno, Mercedes; Garcia-Fernandez, Helena; Jimenez-Vacas, Juan M.; Trinidad Moreno-Montilla, M.; L-Lopez, Fernando; Fondevila, Marcos F.; Nogueiras, Ruben; Castano, Justo P.; Luque, Raul M.; Gahete, Manuel D., CIBER Pathophysiol Obes \& Nutr CIBERobn, Cordoba 14004, Spain.
   Amado, Victor; de la Mata, Manuel; Rodriguez-Peralvarez, Manuel, Reina Sofia Univ Hosp, Dept Hepatol \& Liver Transplantat, Cordoba 14004, Spain.
   Amado, Victor; de la Mata, Manuel; Rodriguez-Peralvarez, Manuel, CIBER Hepat \& Digest Dis CIBERehd, Cordoba 14004, Spain.
   Fondevila, Marcos F.; Nogueiras, Ruben, Univ Santiago de Compostela, Dept Physiol, CIMUS, Inst Invest Sanitaria, Santiago De Compostela 15782, Spain.
   Ciria, Ruben; Gomez-Luque, Irene; Briceno, Javier, Reina Sofia Univ Hosp, Unit Hepatobiliary Surg \& Liver Transplantat, Cordoba 14004, Spain.},
DOI = {10.1016/j.canlet.2020.10.010},
ISSN = {0304-3835},
EISSN = {1872-7980},
Keywords = {Liver cancer; Spliceosome; KLF6-SV1; Pladienolide-B; Xenograft},
Keywords-Plus = {PLADIENOLIDE B; SPLICEOSOME; HEPATOCARCINOGENESIS; INHIBITION;
   ACTIVATION; RESISTANCE; PATHWAY; MODELS; DEATH},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {bc2gaorm@uco.es},
Affiliations = {Universidad de Cordoba; Hospital Universitario Reina Sofia - Cordoba;
   CIBER - Centro de Investigacion Biomedica en Red; CIBEROBN; CIBER -
   Centro de Investigacion Biomedica en Red; CIBEREHD; Universidade de
   Santiago de Compostela; Hospital Universitario Reina Sofia - Cordoba},
ResearcherID-Numbers = {CIRIA, RUBEN/AAA-3560-2019
   Moreno Montilla, María Trinidad/OFO-3383-2025
   Jiménez-Vacas, Juan M/AEY-4956-2022
   Castaño, Justo P/A-7124-2010
   López-Cánovas, Juan L/KPA-8215-2024
   Gahete, Manuel D/C-4969-2009
   Rodríguez-perálvarez, Manuel/AAO-8616-2021
   Garcia Fernandez, Helena/OUH-1510-2025
   del Rio-Moreno, Mercedes/M-8050-2019
   Fondevila, Marcos/ABE-9087-2021
   Nogueiras, Ruben/AAS-9427-2021
   Raul, Luque/M-6948-2018},
ORCID-Numbers = {Lopez, Fernando/0000-0002-0534-2304
   CIRIA, RUBEN/0000-0002-7839-2329
   Moreno Montilla, María Trinidad/0000-0002-5942-7768
   Jiménez-Vacas, Juan M/0000-0003-4391-3726
   Castaño, Justo P/0000-0002-3145-7287
   López-Cánovas, Juan L/0000-0001-9032-6124
   Gahete, Manuel D/0000-0002-4578-2179
   Rodríguez-perálvarez, Manuel/0000-0002-1795-2919
   Garcia Fernandez, Helena/0000-0002-7277-852X
   del Rio-Moreno, Mercedes/0000-0002-6282-7439
   Fernandez Fondevila, Marcos/0000-0002-5099-3421
   },
Funding-Acknowledgement = {Instituto de Salud Carlos III; European Union (ERDF/ESF, ``Investing in
   your future{''}) {[}PI17/02287, CP15/00156, PI16/00264]; MINECO/MECD
   {[}BFU2016-80360-R]; Junta de Andalucia {[}BIO-0139]; CIBERobn},
Funding-Text = {Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF,
   ``Investing in your future{''}) {[}PI17/02287, CP15/00156, PI16/00264],
   MINECO/MECD (BFU2016-80360-R), Junta de Andalucia (BIO-0139), and
   CIBERobn.},
Cited-References = {Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046.
   Alqahtani A, 2019, 2019 IEEE INTERNATIONAL CONFERENCE ON ELECTRO INFORMATION TECHNOLOGY (EIT), P58, DOI {[}10.1109/EIT.2019.8833903, 10.1109/isspit47144.2019.9001802].
   Alsafadi S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10615.
   Anufrieva KS, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0557-y.
   Bonnal SC, 2020, NAT REV CLIN ONCOL, V17, P457, DOI 10.1038/s41571-020-0350-x.
   Craig A.J., 2019, NATURE REV GASTROENT.
   Del Rio-Moreno M, 2019, TRANSL RES, V211, P147, DOI 10.1016/j.trsl.2019.02.013.
   del Río-Moreno M, 2019, J CLIN ENDOCR METAB, V104, P3389, DOI 10.1210/jc.2019-00021.
   Deschênes-Simard X, 2013, GENE DEV, V27, P900, DOI 10.1101/gad.203984.112.
   Dolatshad H, 2015, LEUKEMIA, V29, P1798, DOI 10.1038/leu.2015.178.
   Domoto T, 2016, CANCER SCI, V107, P1363, DOI 10.1111/cas.13028.
   Dowhan DH, 2005, MOL CELL, V17, P429, DOI 10.1016/j.molcel.2004.12.025.
   Effenberger K.A., 2017, MODULATING SPLICING, P8.
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019.
   Forner A, 2018, LANCET, V391, P1301, DOI 10.1016/S0140-6736(18)30010-2.
   Gahete MD, 2018, EBIOMEDICINE, V37, P356, DOI 10.1016/j.ebiom.2018.10.056.
   Hardie DG, 2015, CLIN CANCER RES, V21, P3836, DOI 10.1158/1078-0432.CCR-14-3300.
   Hepburn Lydia A, 2018, Oncotarget, V9, P23029, DOI {[}10.18632/oncotarget.25196, 10.18632/oncotarget.25196].
   Hormaechea-Agulla D, 2017, FASEB J, V31, P4682, DOI 10.1096/fj.201601264RRR.
   Hormaechea-Agulla D, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0713-9.
   Huang WT, 2013, PLOS ONE, V8, DOI {[}10.1371/journal.pone.0058827, 10.1371/journal.pone.0083627].
   Hwang HM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1546-z.
   Jimenez M, 2018, TRANSL GASTROENT HEP, V3, DOI 10.21037/tgh.2018.10.11.
   Jiménez-Vacas JM, 2019, TRANSL RES, V212, P89, DOI 10.1016/j.trsl.2019.07.001.
   Kashyap MK, 2015, HAEMATOLOGICA, V100, P945, DOI 10.3324/haematol.2014.122069.
   Kelemen O, 2013, GENE, V514, P1, DOI 10.1016/j.gene.2012.07.083.
   Kissel M, 2017, ONCOTARGET, V8, P107096, DOI 10.18632/oncotarget.22334.
   Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI {[}10.1038/nrclinonc.2015.121, 10.1038/nrclinonc.2015.103].
   Malz M, 2012, J HEPATOL, V57, P186, DOI 10.1016/j.jhep.2011.11.029.
   Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110.
   Nault JC, 2020, HEPATOLOGY, V71, P164, DOI 10.1002/hep.30811.
   Porteiro B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15111.
   Rincón-Fernández D, 2018, CARCINOGENESIS, V39, P447, DOI 10.1093/carcin/bgx146.
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607.
   Sato M, 2014, CANCER SCI, V105, P110, DOI 10.1111/cas.12317.
   Schwabe RF, 2006, GASTROENTEROLOGY, V131, P314, DOI 10.1053/j.gastro.2006.05.029.
   Seiler M, 2018, NAT MED, V24, P497, DOI 10.1038/nm.4493.
   Shah MR, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-84.
   Shen QY, 2018, BMB REP, V51, P57, DOI 10.5483/BMBRep.2018.51.2.021.
   Sugioka Y, 2004, INT J CANCER, V109, P867, DOI 10.1002/ijc.20095.
   Sveen A, 2016, ONCOGENE, V35, P2413, DOI 10.1038/onc.2015.318.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870.
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034.
   Vetter D, 2012, HEPATOLOGY, V56, P1361, DOI 10.1002/hep.25810.
   Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263.
   Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009.
   Wang H, 2019, HEPATOLOGY, V69, P179, DOI 10.1002/hep.30147.
   Watanabe J, 2002, INT J ONCOL, V21, P515.
   Widmeier E, 2017, AM J PHYSIOL-RENAL, V312, pF157, DOI 10.1152/ajprenal.00386.2016.
   Wu G, 2018, RNA, V24, P1886, DOI 10.1261/rna.068544.118.
   Wurmbach E, 2007, HEPATOLOGY, V45, P938, DOI 10.1002/hep.21622.
   Yoshimoto R, 2017, RNA, V23, P47, DOI 10.1261/rna.058065.116.
   Zhang J, 2019, MOL CELL, V76, P82, DOI 10.1016/j.molcel.2019.07.017.
   Zhang QJ, 2019, ARTIF CELL NANOMED B, V47, P1273, DOI 10.1080/21691401.2019.1596922.},
Number-of-Cited-References = {55},
Times-Cited = {61},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Cancer Lett.},
Doc-Delivery-Number = {OT3VZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000590779400001},
DA = {2026-02-04},
}

@article{ WOS:000605791200001,
Author = {Marti-Diaz, Roman and Montenegro, Maria F. and Cabezas-Herrera, Juan and
   Goding, Colin R. and Neptuno Rodriguez-Lopez, Jose and
   Sanchez-del-Campo, Luis},
Title = {Acriflavine, a Potent Inhibitor of HIF-1α, Disturbs Glucose Metabolism
   and Suppresses ATF4-Protective Pathways in Melanoma under Non-hypoxic
   Conditions},
Journal = {CANCERS},
Year = {2021},
Volume = {13},
Number = {1},
Month = {JAN},
Abstract = {Simple Summary
   Hypoxia is a common feature in solid tumors such as melanoma,
   contributing locally and systemically to tumor progression. Although the
   hypoxia response in tumor cells is well understood, the role of
   constitutively activated hypoxia-inducible factor (HIF)-1 alpha in
   normoxic conditions is less known. Here, we used acriflavine, a chemical
   inhibitor of HIF-1 alpha, to investigate the role of this transcription
   factor on the progression of melanoma under normoxic conditions. The
   data indicated that acriflavine disturbs glucose metabolism and induces
   melanoma cell death under normoxia. As a result, we describe a possible
   clinical option that may target melanoma cells irrespective of the
   hypoxic microenvironment of the tumors. However, the translational
   importance of these findings should be confirmed in pre-clinical models.
   Hypoxia-inducible factor (HIF)-1 alpha is constitutively expressed in
   melanoma cells under normoxic conditions and its elevated expression
   correlates with the aggressiveness of melanoma tumors. Here, we used
   acriflavine, a potent inhibitor of HIF-1 alpha dimerization, as a tool
   to investigate whether HIF-1 alpha-regulated pathways contribute to the
   growth of melanoma cells under normoxia. We observed that acriflavine
   differentially modulated HIF-1 alpha-regulated targets in melanoma under
   normoxic conditions, although acriflavine treatment resulted in
   over-expression of vascular endothelial growth factor (VEGF), its action
   clearly downregulated the expression of pyruvate dehydrogenase kinase 1
   (PDK1), a well-known target of HIF-1 alpha. Consequently, downregulation
   of PDK1 by acrifavine resulted in reduced glucose availability and
   suppression of the Warburg effect in melanoma cells. In addition, by
   inhibiting the AKT and RSK2 phosphorylation, acriflavine also avoided
   protective pathways necessary for survival under conditions of oxidative
   stress. Interestingly, we show that acriflavine targets activating
   transcription factor 4 (ATF4) for proteasomal degradation while
   suppressing the expression of microphthalmia-associated transcription
   factor (MITF), a master regulator of melanocyte development and a
   melanoma oncogene. Since acriflavine treatment results in the consistent
   death of melanoma cells, our results suggest that inhibition of HIF-1
   alpha function in melanoma could open new avenues for the treatment of
   this deadly disease regardless of the hypoxic condition of the tumor.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Rodríguez-López, JN; Sánchez-del-Campo, L (Corresponding Author), Univ Murcia, Sch Biol, Dept Biochem \& Mol Biol A, IMIB, Murcia 30100, Spain.
   Marti-Diaz, Roman; Montenegro, Maria F.; Neptuno Rodriguez-Lopez, Jose; Sanchez-del-Campo, Luis, Univ Murcia, Sch Biol, Dept Biochem \& Mol Biol A, IMIB, Murcia 30100, Spain.
   Cabezas-Herrera, Juan, Univ Hosp Virgen de la Arrixaca, IMIB, Translat Canc Res Grp, Murcia 30120, Spain.
   Goding, Colin R., Univ Oxford, Ludwig Inst Canc Res, Nuffield Dept Clin Med, Oxford OX3 7DQ, England.},
DOI = {10.3390/cancers13010102},
Article-Number = {102},
EISSN = {2072-6694},
Keywords = {melanoma; acriflavine; MITF; HIF-1 alpha; ATF4; glucose metabolism;
   oxygen homeostasis},
Keywords-Plus = {HYPOXIA-INDUCIBLE FACTORS; TRANSCRIPTIONAL ACTIVITY; ER STRESS; CANCER;
   HIF-1; PROTEIN; GROWTH; MITF; FACTOR-1-ALPHA; MELANOCYTES},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {roman.marti@um.es
   fermontenegro@um.es
   juan.cabezas@carm.es
   colin.goding@ludwig.ox.ac.uk
   neptuno@um.es
   sancampo@um.es},
Affiliations = {University of Murcia; Hospital Clinico Universitario Virgen de la
   Arrixaca; University of Oxford; Ludwig Institute for Cancer Research},
ResearcherID-Numbers = {Sanchez del Campo, Luis/R-1308-2018
   Montenegro, Maria/AAF-2695-2021
   Roiguez-Lopez, Jose Neptuno/F-5012-2016
   Cabezas-Herrera, Juan/J-9434-2015
   Goding, Colin/KHU-7882-2024},
ORCID-Numbers = {Sanchez del Campo, Luis/0000-0002-9537-7761
   Roiguez-Lopez, Jose Neptuno/0000-0001-6863-1173
   Cabezas-Herrera, Juan/0000-0001-9053-5380
   Martí-Díaz, Román/0000-0001-5792-7665
   },
Funding-Acknowledgement = {Ministerio de Economia y Competitividad (MINECO) {[}SAF2016-77241-R];
   Fundacion Seneca, the Region de Murcia (FS-RM) {[}20809/PI/18]; Ramon y
   Cajal Program {[}RYC-2016-20036]; Ludwig Institute for Cancer Research;
   Fondos FEDER;  {[}eRYC-2016-20036]},
Funding-Text = {This work was supported by grants from the Ministerio de Economia y
   Competitividad (MINECO; Co-financing with Fondos FEDER)
   (SAF2016-77241-R), and the Fundacion Seneca, the Region de Murcia
   (FS-RM) (20809/PI/18). L.S.-d.-C. is contracted by the Ramon y Cajal
   Program (RYC-2016-20036). R.M.D. is contracted by the eRYC-2016-20036
   project. C.R.G is funded by the Ludwig Institute for Cancer Research.},
Cited-References = {Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003.
   Banerjee A, 2017, ONCOTARGET, V8, P26142, DOI 10.18632/oncotarget.15393.
   Bedogni B, 2009, PIGM CELL MELANOMA R, V22, P166, DOI 10.1111/j.1755-148X.2009.00553.x.
   Befani CD, 2012, J MOL MED, V90, P45, DOI 10.1007/s00109-011-0805-8.
   Buscà R, 2005, J CELL BIOL, V170, P49, DOI 10.1083/jcb.200501067.
   Dekervel J, 2017, TRANSL ONCOL, V10, P59, DOI 10.1016/j.tranon.2016.11.008.
   Denat L, 2014, J INVEST DERMATOL, V134, P1512, DOI 10.1038/jid.2014.65.
   Deng XY, 2020, J CANCER, V11, P962, DOI 10.7150/jca.34330.
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904.
   Falletta P, 2017, GENE DEV, V31, P18, DOI 10.1101/gad.290940.116.
   Feige E, 2011, P NATL ACAD SCI USA, V108, pE924, DOI 10.1073/pnas.1106351108.
   Ferguson J, 2017, ONCOTARGET, V8, P32946, DOI 10.18632/oncotarget.16514.
   Frödin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924.
   Goding CR, 2019, GENE DEV, V33, P983, DOI 10.1101/gad.324657.119.
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003.
   Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77.
   Hulse M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007394.
   Iurlaro R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00479-16.
   Jun Jonathan C, 2017, Curr Sleep Med Rep, V3, P1, DOI {[}10.1007/s40675-017-0062-7, 10.1007/s40675-017-0062-7].
   Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim SG, 1997, J PHARM PHARMACOL, V49, P216, DOI 10.1111/j.2042-7158.1997.tb06783.x.
   Kuphal S, 2010, EUR J CANCER, V46, P1159, DOI 10.1016/j.ejca.2010.01.031.
   Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106.
   Louphrasitthiphol P, 2019, PIGM CELL MELANOMA R, V32, P792, DOI 10.1111/pcmr.12802.
   Munoz-Munoz JL, 2009, BBA-PROTEINS PROTEOM, V1794, P1017, DOI 10.1016/j.bbapap.2009.04.002.
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022.
   Mills CN, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-104.
   Movahed ZG, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108690.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Pereira ER, 2014, J BIOL CHEM, V289, P3352, DOI 10.1074/jbc.M113.507194.
   Petrova V, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-017-0011-9.
   Phadngam S, 2016, ONCOTARGET, V7, P84999, DOI 10.18632/oncotarget.13113.
   Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112.
   Powis G, 2004, MOL CANCER THER, V3, P647.
   Priebe A, 2011, GYNECOL ONCOL, V122, P389, DOI 10.1016/j.ygyno.2011.04.024.
   Roybal CN, 2005, J BIOL CHEM, V280, P20331, DOI 10.1074/jbc.M411275200.
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005.
   Singleton DC, 2012, EXPERT OPIN THER TAR, V16, P1189, DOI 10.1517/14728222.2012.728207.
   Strowitzki MJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050384.
   Vivas-Garcia Y, 2020, MOL CELL, V77, P120, DOI 10.1016/j.molcel.2019.10.014.
   Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593.
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009.
   Woo YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132285.
   Wortel IMN, 2017, TRENDS ENDOCRIN MET, V28, P794, DOI 10.1016/j.tem.2017.07.003.
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092-8674(04)00344-7.
   Zeniou-Meyer M, 2010, CELL MOL NEUROBIOL, V30, P1401, DOI 10.1007/s10571-010-9578-9.
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1.},
Number-of-Cited-References = {48},
Times-Cited = {32},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {PP3UK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000605791200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000604613600008,
Author = {Park, Min Kyung and Ji, Jun and Haam, Keeok and Han, Tae-Hee and Lim,
   Seona and Kang, Mi-Jung and Lim, Soon Sung and Ban, Hyun Seung},
Title = {Licochalcone A inhibits hypoxia-inducible factor-1 α accumulation by
   suppressing mitochondrial respiration in hypoxic cancer cells},
Journal = {BIOMEDICINE \& PHARMACOTHERAPY},
Year = {2021},
Volume = {133},
Month = {JAN},
Abstract = {Hypoxia-inducible factor (HIF)-1 is an important regulator of the
   cellular response in the hypoxic tumor environment. While searching for
   HIF inhibitors derived from natural products that act as anticancer
   agents, we found that Glycyrrhiza uralensis exerts HIF-1 inhibitory
   activity in hypoxic cancer cells. Among the five components of G.
   uralensis, licochalcone A was found to potently suppress hypoxia-induced
   HIF-1 alpha accumulation and expression of HIF-1 alpha target genes,
   including GLUT1 and PDK1 in HCT116 cells. Licochalcone A also enhances
   intracellular oxygen content by directly inhibiting mitochondrial
   respiration, resulting in oxygen-dependent HIF-1 alpha degradation.
   Hence, licochalcone A may effectively inhibit ATP production, primarily
   by reducing the mitochondrial respiration-mediated ATP production rate
   rather than the glycolysis-mediated ATP production rate. This effect
   subsequently suppresses cancer cell viability, including that of HCT116,
   H1299, and H322 cells. Consequently, these results suggest that
   licochalcone A has therapeutic potential in hypoxic cancer cells.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Ban, HS (Corresponding Author), Korea Res Inst Biosci \& Biotechnol, Daejeon 34141, South Korea.
   Lim, SS (Corresponding Author), Hallym Univ, Inst Nat Med, Chunchon 24252, South Korea.
   Lim, SS (Corresponding Author), Hallym Univ, Dept Food Sci \& Nutr, Chunchon 24252, South Korea.
   Park, Min Kyung, Dongguk Univ Seoul, Coll Pharm, Goyang 10326, South Korea.
   Park, Min Kyung; Haam, Keeok; Han, Tae-Hee; Lim, Seona; Kang, Mi-Jung; Ban, Hyun Seung, Korea Res Inst Biosci \& Biotechnol, Daejeon 34141, South Korea.
   Ji, Jun; Lim, Soon Sung, Hallym Univ, Inst Nat Med, Chunchon 24252, South Korea.
   Lim, Soon Sung, Hallym Univ, Dept Food Sci \& Nutr, Chunchon 24252, South Korea.},
DOI = {10.1016/j.biopha.2020.111082},
Article-Number = {111082},
ISSN = {0753-3322},
EISSN = {1950-6007},
Keywords = {Licochalcone A; Hypoxia; Hypoxia-inducible factor; Mitochondria; Cancer
   metabolism},
Keywords-Plus = {PLASMODIUM-FALCIPARUM; SIGNALING PATHWAY; HIF-1; TARGET; VITRO},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {limss@hallym.ac.kr
   banhs@kribb.re.kr},
Affiliations = {Dongguk University; Korea Research Institute of Bioscience \&
   Biotechnology (KRIBB); Hallym University; Hallym University},
ResearcherID-Numbers = {Ban, Hyun Seung/F-9526-2014},
ORCID-Numbers = {Ban, Hyun Seung/0000-0002-2698-6037},
Funding-Acknowledgement = {National Research Foundation of Korea {[}NRF-2018R1D1A1A09081945,
   NRF-2019R1I1A2A01060951]; KRIBB Research Initiative Program},
Funding-Text = {This work was supported by the National Research Foundation of Korea
   {[}grant number NRF-2018R1D1A1A09081945, NRF-2019R1I1A2A01060951] and
   the KRIBB Research Initiative Program.},
Cited-References = {Arita M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020506.
   Asl MN, 2008, PHYTOTHER RES, V22, P709, DOI 10.1002/ptr.2362.
   Ban HS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.235.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   CHEN M, 1994, ANTIMICROB AGENTS CH, V38, P1470, DOI 10.1128/AAC.38.7.1470.
   Chu X, 2012, J AGR FOOD CHEM, V60, P3947, DOI 10.1021/jf2051587.
   Furusawa JI, 2009, CELL SIGNAL, V21, P778, DOI 10.1016/j.cellsig.2009.01.021.
   Hammoudi Naima, 2011, Chin J Cancer, V30, P508, DOI 10.5732/cjc.011.10267.
   Han X, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.30616.
   Hao YL, 2019, ONCOTARGETS THER, V12, P4427, DOI 10.2147/OTT.S201728.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021.
   Kondo K, 2007, BIOL PHARM BULL, V30, P1271, DOI 10.1248/bpb.30.1271.
   Kuramoto K, 2017, FEBS OPEN BIO, V7, P835, DOI 10.1002/2211-5463.12226.
   Lee K, 2013, ANGEW CHEM INT EDIT, V52, P10286, DOI 10.1002/anie.201304987.
   Lin RC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111441.
   Mi-Ichi F, 2005, ANN NY ACAD SCI, V1056, P46, DOI 10.1196/annals.1352.037.
   Mishra LC, 2009, ACTA TROP, V109, P194, DOI 10.1016/j.actatropica.2008.11.006.
   Naik R, 2017, J MED CHEM, V60, P8631, DOI 10.1021/acs.jmedchem.7b01231.
   Pia GDM, 2019, MINI-REV MED CHEM, V19, P647, DOI 10.2174/1389557518666180601095420.
   Piao W, 2013, ANGEW CHEM INT EDIT, V52, P13028, DOI 10.1002/anie.201305784.
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016.
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187.
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230.
   Si LL, 2018, ONCOL REP, V39, P2160, DOI 10.3892/or.2018.6329.
   Tsai JP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086537.
   Yuan X, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/474272.
   Zhang QY, 2009, J CHROMATOGR A, V1216, P1954, DOI 10.1016/j.chroma.2008.07.072.
   Zhu S, 2009, J NAT MED-TOKYO, V63, P137, DOI 10.1007/s11418-008-0303-7.},
Number-of-Cited-References = {29},
Times-Cited = {31},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Biomed. Pharmacother.},
Doc-Delivery-Number = {PN6VC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000604613600008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000601156900001,
Author = {Peng, Peng and Jin, Juan and Zou, Guoliang and Sui, Yanbo and Han, Yubo
   and Zhao, Dapeng and Liu, Li},
Title = {Hesperidin prevents hyperglycemia in diabetic rats by activating the
   insulin receptor pathway},
Journal = {EXPERIMENTAL AND THERAPEUTIC MEDICINE},
Year = {2021},
Volume = {21},
Number = {1},
Month = {JAN},
Abstract = {Diabetes, a disease with high prevalence in China, is a major risk
   factor of cardiovascular disease. Hesperidin is a flavanone glycoside
   with anti-hyperglycemic and anti-hyperlipidemic activities. Therefore,
   the present study aimed to investigate the potential preventive effect
   of hesperidin against type 2 diabetes mellitus (T2DM) using a rat model
   of alloxan and high fat diet (HFD)-induced insulin resistance. Male
   Sprague Dawley rats were orally administered with 100 mg/kg hesperidin
   or vehicle (sodium carboxy methyl cellulose) for 35 days. Insulin
   resistance was induced by feeding animals a HFD for 3 weeks (from day 7)
   and then with an alloxan injection on day 28. Results from the in vivo
   study demonstrated that hesperidin improved fasting serum glucose (from
   19.8 to 10.6 mmol/l) without changing the fasting insulin level,
   suggesting that hesperidin prevented the development of insulin
   resistance and diabetes by improving insulin sensitivity. In the oral
   glucose tolerance test, the development of impaired glucose tolerance
   was also prevented by hesperidin treatment. Hesperidin was found to
   regulate glycolysis and gluconeogenesis by enhancing the activity of
   glucokinase, inducing the phosphorylation of insulin receptor (IR) and
   phosphoinositide-dependent kinase 1 (PDK1), while decreasing the
   activity of glucose-6-phosphatase and phosphoenolpyruvate carboxykinase
   in the liver. In a cell-based assay, hesperidin increased glucose uptake
   in primary rat adipocytes. Collectively, the present study identified
   the potent preventive effect of hesperidin against HFD-induced insulin
   resistance by activating the IR/PDK1 pathway. The current results may
   provide a potential strategy lacking sides effects to improve metabolic
   health and reduce risks.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Liu, L (Corresponding Author), Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Cardiovasc 1, 26 Heping Rd, Harbin 150040, Heilongjiang, Peoples R China.
   Peng, Peng; Han, Yubo, Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Grad Sch, Harbin 150040, Heilongjiang, Peoples R China.
   Jin, Juan; Zou, Guoliang; Sui, Yanbo; Liu, Li, Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Cardiovasc 1, 26 Heping Rd, Harbin 150040, Heilongjiang, Peoples R China.
   Zhao, Dapeng, Heilongjiang Univ Chinese Med, Affiliated Hosp 1, Dept Nephropathy, Harbin 150040, Heilongjiang, Peoples R China.},
DOI = {10.3892/etm.2020.9485},
Article-Number = {53},
ISSN = {1792-0981},
EISSN = {1792-1015},
Keywords = {type 2 diabetes mellitus; insulin resistance; animal model; glucose
   uptake},
Keywords-Plus = {GLUCOSE-UPTAKE; PREVALENCE; RESISTANCE; LIVER; GLUCOSE-6-PHOSPHATASE;
   STIMULATION; ADIPONECTIN; EXPRESSION; HESPERETIN; TRANSPORT},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {liu\_liii@163.com},
Affiliations = {Heilongjiang University of Chinese Medicine; Heilongjiang University of
   Chinese Medicine; Heilongjiang University of Chinese Medicine},
ORCID-Numbers = {Sui, Yanbo/0009-0003-7988-7643},
Funding-Acknowledgement = {General Program of National Natural Science Foundation of China
   {[}81573935]; Scientific and Technological Projects of Educational
   Bureau of Heilongjiang Province {[}12531604]; Research and Development
   Program of Application Technology of Harbin (Out Standing Academic
   Leader; Category B) {[}2015RAXYJ053]},
Funding-Text = {This work was supported by the General Program of National Natural
   Science Foundation of China (grant no. 81573935), Scientific and
   Technological Projects of Educational Bureau of Heilongjiang Province
   (grant no. 12531604) and Research and Development Program of Application
   Technology of Harbin (Out Standing Academic Leader; Category B; grant
   no. 2015RAXYJ053).},
Cited-References = {Ahmed Osama M., 2012, Diabetologia Croatica, V41, P53.
   Akiyama S, 2009, BIOSCI BIOTECH BIOCH, V73, P2779, DOI 10.1271/bbb.90576.
   Al-Quraishy S, 2015, INT J NANOMED, V10, P6741, DOI 10.2147/IJN.S91377.
   ALEGRE M, 1988, ANAL BIOCHEM, V173, P185, DOI 10.1016/0003-2697(88)90176-5.
   {[}Anonymous], 2015, DIABETES CARE, V38, pS8, DOI {[}10.2337/dc17-s005, 10.2337/dc15-S005].
   BENTLE LA, 1976, J BIOL CHEM, V251, P2916.
   Calixto JB, 2000, BRAZ J MED BIOL RES, V33, P179, DOI 10.1590/S0100-879X2000000200004.
   China Food and Drug Administration (CFDA), 2003, TECHNICAL STANDARDS.
   CHOI JS, 1991, PLANTA MED, V57, P208, DOI 10.1055/s-2006-960075.
   Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0.
   DAVIDSON AL, 1987, ARCH BIOCHEM BIOPHYS, V253, P156, DOI 10.1016/0003-9861(87)90648-5.
   DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173.
   DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667.
   Dhanya R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132429.
   Ganugapati J, 2012, BIOINFORMATION, V8, P216, DOI 10.6026/97320630008216.
   Garg A, 2001, PHYTOTHER RES, V15, P655, DOI 10.1002/ptr.1074.
   Geloneze B, 2009, ARQ BRAS ENDOCRINOL, V53, P281, DOI 10.1590/S0004-27302009000200020.
   Govers R, 2014, ADV CLIN CHEM, V66, P173, DOI 10.1016/B978-0-12-801401-1.00006-2.
   Hsu FL, 2003, J NAT PROD, V66, P788, DOI 10.1021/np0203887.
   IYNEDJIAN PB, 1988, J BIOL CHEM, V263, P740.
   Jung UJ, 2004, J NUTR, V134, P2499, DOI 10.1093/jn/134.10.2499.
   Leto D, 2012, NAT REV MOL CELL BIO, V13, P383, DOI 10.1038/nrm3351.
   Liu Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152728.
   Lochhead PA, 2000, DIABETES, V49, P896, DOI 10.2337/diabetes.49.6.896.
   Elizabeth MPM, 2017, CURR DIABETES REV, V13, P108, DOI 10.2174/1573399812666151020101222.
   Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228.
   Natali A, 2006, DIABETOLOGIA, V49, P434, DOI 10.1007/s00125-006-0141-7.
   Nordlie RC, 2010, LIFE SCI, V87, P339, DOI 10.1016/j.lfs.2010.06.021.
   Ong KC, 1996, BIOCHEM PHARMACOL, V51, P423, DOI 10.1016/0006-2952(95)02195-7.
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215.
   REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473.
   Shi XP, 2012, MOLECULES, V17, P12868, DOI 10.3390/molecules171112868.
   SHISHEVA A, 1992, BIOCHEMISTRY-US, V31, P8059, DOI 10.1021/bi00149a041.
   Valli G, 2002, J AM COLL CARDIOL, V39, P1083, DOI 10.1016/S0735-1097(02)01749-7.
   Wallace TM, 2004, DIABETES CARE, V27, P1487, DOI 10.2337/diacare.27.6.1487.
   Wang LM, 2017, JAMA-J AM MED ASSOC, V317, P2515, DOI 10.1001/jama.2017.7596.
   Wei W., 2010, EXPT METHODOLOGY PHA.
   Wu XD, 2003, DIABETES, V52, P1355, DOI 10.2337/diabetes.52.6.1355.
   Xu Y, 2013, JAMA-J AM MED ASSOC, V310, P948, DOI 10.1001/jama.2013.168118.
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984.
   Yang LL, 2016, J DIABETES INVEST, V7, P845, DOI 10.1111/jdi.12514.
   Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292.
   Yang Y, 2013, CELL BIOCHEM FUNCT, V31, P374, DOI 10.1002/cbf.2905.
   Zhang H, 2010, EUR J INTEGR MED, V2, P41, DOI 10.1016/j.eujim.2010.02.004.
   Zhang YL, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/8492780.
   Zygmunt K, 2010, BIOCHEM BIOPH RES CO, V398, P178, DOI 10.1016/j.bbrc.2010.06.048.},
Number-of-Cited-References = {46},
Times-Cited = {42},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {27},
Journal-ISO = {Exp. Ther. Med.},
Doc-Delivery-Number = {PI5UY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000601156900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000627906600017,
Author = {Raina, R. and Afroze, N. and Sundaram, M. Kedhari and Haque, S. and
   Bajbouj, K. and Hamad, M. and Hussain, A.},
Title = {Chrysin inhibits propagation of HeLa cells by attenuating cell survival
   and inducing apoptotic pathways},
Journal = {EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES},
Year = {2021},
Volume = {25},
Number = {5},
Pages = {2206-2220},
Abstract = {OBJECTIVE: Chrysin, one of the main active constituents of flavonoids,
   is known for demonstrating protective effects against various types of
   cancer including cervical cancer. The aim of this study was to determine
   apoptosis induction and antiproliferative action of chrysin on human
   cervical cancer cells.
   MATERIALS AND METHODS: In this study, attempts have been made to
   establish anticancer role of chrysin on HeLa cells. MTT, mitochondrial
   potential, DNA fragmentation, annexin V/propidium iodide assays, qPCR
   and protein profiling were performed.
   RESULTS: Chrysin treated HeLa cells showed time and dose dependent
   decrease in cell viability and demonstrated profound effects on nuclear
   morphology and DNA fragmentation. Chrysin treatment increased the
   expression of proapoptotic genes BAD, BAX, BID, BOK and APAF1, TNF,
   FASL, FAS, FADD and caspases (like caspase 3, caspase 7, caspase 8 and
   caspase 9), whereas it decreased the expression level of antiapoptotic
   genes MCL-1, NAIP, XIAP and BcI-2 and cell cycle regulatory genes CCNB1,
   CCNB2, CCND1, CCND2, CCND3, CCNE2, CDK4 and CDK2 at transcript level.
   Furthermore, chrysin significantly upregulated pro-apoptotic proteins,
   like TRAILR2/DR5, TRAILR1/DR4, Fas/TNFRSF6/CD95, phosphoP53(S15), BAD,
   BAX, cleaved caspase 3, procaspase 3, HTRA2/Omi and SMAC/Diablo, while
   downregulated anti-apoptotic proteins like BCL-X, BCL2, XIAP and CIAPs
   that support chrysin mediated apoptosis in HeLa cells. Remarkably,
   chrysin downregulated the phosphorylated AKT pathway proteins, (p-473)
   AKT, (p-Ser 2448) mTOR, (p-Ser241) PDK1, (p-Ser112) BAD, and upregulated
   (p-Ser21) GSK3b, (p-Thr172) AMPKa, P27 (p-Thr198) and (p-Ser15) P53,
   which endorses chrysin mediated apoptosis.
   CONCLUSIONS: Chrysin significantly inhibited proliferation and induced
   apoptosis by modulation of various apoptotic genes and AKT/MAPK pathway
   genes.},
Publisher = {VERDUCI PUBLISHER},
Address = {VIA GREGORIO VII, ROME, 186-00165, ITALY},
Type = {Article},
Language = {English},
Affiliation = {Hussain, A (Corresponding Author), Manipal Acad Higher Educ, Sch Life Sci, Dubai, U Arab Emirates.
   Raina, R.; Afroze, N.; Sundaram, M. Kedhari; Hussain, A., Manipal Acad Higher Educ, Sch Life Sci, Dubai, U Arab Emirates.
   Haque, S., Jazan Univ, Coll Nursing \& Allied Hlth Sci, Res \& Sci Studies Unit, Jazan, Saudi Arabia.
   Bajbouj, K.; Hamad, M., Univ Sharjah, Coll Med, Sharjah, U Arab Emirates.},
DOI = {10.26355/eurrev\_202103\_25253},
ISSN = {1128-3602},
Keywords = {Chrysin; Apoptosis; AKT; MAP kinase; Anticancer; Chemoprevention},
Keywords-Plus = {COLON-CANCER CELLS; FLAVONOIDS; PREVENTION; BAX},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {dr.arifhussain@yahoo.co.in},
Affiliations = {College Nursing \& Allied Health Science Saudi Arabia; Jazan University;
   University of Sharjah},
ResearcherID-Numbers = {Kedhari Sundaram, Madhumitha/ABC-6223-2021
   },
ORCID-Numbers = {Kedhari Sundaram, Madhumitha/0000-0002-5717-1789
   Raina, Ritu/0000-0002-1912-3073},
Funding-Acknowledgement = {MAHE Internal Research Grant {[}R\&DP/MUD/RL06/2018]},
Funding-Text = {The financial support for this work was provided by MAHE Internal
   Research Grant (Grant No: R\&DP/MUD/RL06/2018).},
Cited-References = {Abotaleb M, 2019, CANCERS, V11, DOI 10.3390/cancers11010028.
   Alam MN, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4154185.
   Bahadori M, 2016, IRAN J BIOTECHNOL, V14, P117, DOI 10.15171/ijb.1374.
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337.
   Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076.
   Gage JC, 2015, INT J CANCER, V136, P1665, DOI 10.1002/ijc.29143.
   Hoensch HP, 2015, Clinical Nutrition Experimental, V3, P8, DOI {[}10.1016/j.yclnex.2015.09.001, 10.1016/j.yclnex.2015.09.001, DOI 10.1016/J.YCLNEX.2015.09.001].
   Hussain A, 2012, INTEGR CANCER THER, V11, P154, DOI 10.1177/1534735411400313.
   Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x.
   Kadali VN, 2010, INDIAN J TRADIT KNOW, P211.
   Kasala ER, 2015, TOXICOL LETT, V233, P214, DOI 10.1016/j.toxlet.2015.01.008.
   Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097.
   Khacha-ananda S, 2016, INVEST NEW DRUG, V34, P707, DOI 10.1007/s10637-016-0392-1.
   Khoo BY, 2010, INT J MOL SCI, V11, P2188, DOI 10.3390/ijms11052188.
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277-016-5035-9.
   Koosha S, 2016, INT J MED SCI, V13, P374, DOI 10.7150/ijms.14485.
   Lall RK, 2015, INT J MOL SCI, V16, P3350, DOI 10.3390/ijms16023350.
   Lee DH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/515901.
   Lirdprapamongkol K, 2013, INT J ONCOL, V43, P329, DOI 10.3892/ijo.2013.1926.
   Mocanu MM, 2015, MOLECULES, V20, P22578, DOI 10.3390/molecules201219864.
   Pal-Bhadra M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-180.
   Sak Katrin, 2014, Pharmacogn Rev, V8, P122, DOI 10.4103/0973-7847.134247.
   Samarghandian S, 2016, PHARMACOGN MAG, V12, pS436, DOI 10.4103/0973-1296.191453.
   Samarghandian S, 2014, ANTI-CANCER AGENT ME, V14, P901, DOI 10.2174/1871520614666140209144042.
   Sawicka D, 2012, FOLIA HISTOCHEM CYTO, V50, P25, DOI {[}10.2478/18693, 10.5603/FHC.2012.0004].
   Seydi E, 2018, NUTR CANCER, V70, P594, DOI 10.1080/01635581.2018.1460679.
   Shankar Eswar, 2017, Curr Pharmacol Rep, V3, P423, DOI {[}10.1007/s40495-017-0113-2, 10.1007/s40495-017-0113-2].
   Shehzad Adeeb, 2016, Anales de la Real Academia Nacional de Farmacia, V82, P297.
   Shi MD, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0186-0.
   Shukla S, 2014, CARCINOGENESIS, V35, P452, DOI 10.1093/carcin/bgt316.
   Song KH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.462.
   Souza RP, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/1512745.
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412.
   Sundaram MK, 2019, BIOSCIENCE REP, V39, DOI {[}10.1042/BSR20190720, 10.1042/bsr20190720].
   Tuorkey MJ, 2016, EUR J CANCER PREV, V25, P65, DOI 10.1097/CEJ.0000000000000128.
   Venturelli S, 2016, NUTRITION, V32, P1171, DOI 10.1016/j.nut.2016.03.020.
   Wang WQ, 2004, NUTR CANCER, V48, P106, DOI 10.1207/s15327914nc4801\_14.
   Wang YC, 2015, LAT AM J PHARM, V34, P993.
   Woo KJ, 2004, BIOCHEM BIOPH RES CO, V325, P1215, DOI 10.1016/j.bbrc.2004.09.225.
   Xue CY, 2016, ONCOL LETT, V12, P4813, DOI 10.3892/ol.2016.5251.
   Yang B, 2014, J APPL TOXICOL, V34, P105, DOI 10.1002/jat.2941.
   Yin K. Boon, 2014, CHRYSIN PI3K AKT OTH.
   Zhang B, 2015, GENET MOL RES, V14, P6605, DOI 10.4238/2015.June.18.3.
   Zhang MM, 2016, INT J CLIN EXP MED, V9, P22784.
   Zhang QY, 2016, EXP THER MED, V12, P469, DOI 10.3892/etm.2016.3282.
   Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080515.},
Number-of-Cited-References = {46},
Times-Cited = {34},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Eur. Rev. Med. Pharmacol. Sci.},
Doc-Delivery-Number = {QV3WY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000627906600017},
DA = {2026-02-04},
}

@article{ WOS:000607577300004,
Author = {Wang, He and Liu, Mengjia and Zou, Gang and Wang, Long and Duan, Wenbin
   and He, Xue and Ji, Muhuo and Zou, Xiaochuan and Hu, Yimin and Yang,
   Jianjun and Chen, Guiquan},
Title = {Deletion of PDK1 in oligodendrocyte lineage cells causes white matter
   abnormality and myelination defect in the central nervous system},
Journal = {NEUROBIOLOGY OF DISEASE},
Year = {2021},
Volume = {148},
Month = {JAN},
Abstract = {PDK1 (3-Phosphoinositide dependent protein kinase-1) is a member in the
   PI3K (phosphatidylinositol 3 kinase) pathway and is implicated in
   neurodevelopmental disease with microcephaly. Although the role of PDK1
   in neurogenesis has been broadly studied, it remains unknown how PDK1
   may regulate oligogenesis in the central nervous system (CNS). To
   address this question, we generated oligodendrocyte (OL) lineage cells
   specific PDKI conditional knockout (cKO) mice. We find that PDKI cKOs
   display abnormal white matter (WM), massive loss of mature OLs and
   severe defect in myelination in the CNS. In contrast, these mutants
   exhibit normal neuronal development and unchanged apoptosis in the CNS.
   We demonstrate that deletion of PDK1 severely impairs OL
   differentiation. We show that genetic or pharmacological inhibition of
   PDK1 causes deficit in the mammalian target of rapamycin (mTor)
   signaling and down-regulation of Sox10. Together, these results
   highlight a critical role of PDK1 in OL differentiation during postnatal
   CNS development.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Yang, JJ (Corresponding Author), Zhengzhou Univ, Dept Anesthesiol Pain \& Perioperat Med, Affiliated Hosp 1, 1 East Jianshe Rd, Zhengzhou 450052, Peoples R China.
   Chen, GQ (Corresponding Author), Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, MOE Key Lab Model Anim Dis Study, 12 Xuefu Ave, Nanjing 210061, Jiangsu, Peoples R China.
   Hu, YM (Corresponding Author), Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Gen Surg, Shenzhen 518000, Peoples R China.
   Wang, He; He, Xue; Ji, Muhuo; Yang, Jianjun, Zhengzhou Univ, Dept Anesthesiol Pain \& Perioperat Med, Affiliated Hosp 1, 1 East Jianshe Rd, Zhengzhou 450052, Peoples R China.
   Liu, Mengjia; Wang, Long; Zou, Xiaochuan; Chen, Guiquan, Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, MOE Key Lab Model Anim Dis Study, 12 Xuefu Ave, Nanjing 210061, Jiangsu, Peoples R China.
   Zou, Gang, Nanjing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 121 Jiangjiayuan Ave, Nanjing 210003, Jiangsu, Peoples R China.
   Duan, Wenbin; Hu, Yimin, Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Gen Surg, Shenzhen 518000, Peoples R China.},
DOI = {10.1016/j.nbd.2020.105212},
Article-Number = {105212},
ISSN = {0969-9961},
EISSN = {1095-953X},
Keywords = {PDK1; White matter disease; Oligodendrocyte precursor cells;
   Oligodendrocytes; Differentiation},
Keywords-Plus = {MAMMALIAN TARGET; RAPAMYCIN PATHWAY; DIFFERENTIATION; AKT; EXPRESSION;
   GENERATION; REGULATOR; EVOLUTION; MUTATION; SOX10},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {guyueym@njmu.edu.cn
   yjyangjj@126.com
   chenguiquan@nju.edu.cn},
Affiliations = {Zhengzhou University; Nanjing University; Nanjing Medical University;
   Jinan University},
ResearcherID-Numbers = {Yang, Jianjun/AAN-4960-2021
   Zou, Gang-Ming/HIR-4227-2022
   Chen, Guiquan/HOA-8468-2023},
ORCID-Numbers = {Yang, Jianjun/0000-0001-6785-9627
   Chen, Guiquan/0000-0002-4674-5548},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}91849113, 81800284];
   Natural Science Foundation of Jiangsu {[}BK20201255, BK20180144];
   Jiangsu Provincial Key Medical Discipline {[}ZDXKA2016020]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (91849113 and 81800284), the Natural Science
   Foundation of Jiangsu (BK20201255 and BK20180144) and the Jiangsu
   Provincial Key Medical Discipline (ZDXKA2016020).},
Cited-References = {Ahrendsen JT, 2018, J NEUROSCI, V38, P787, DOI 10.1523/JNEUROSCI.2864-16.2017.
   Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07.
   Bercury KK, 2014, J NEUROSCI, V34, P4466, DOI 10.1523/JNEUROSCI.4314-13.2014.
   Britsch S, 2001, GENE DEV, V15, P66, DOI 10.1101/gad.186601.
   Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609.
   Cordón-Barris L, 2016, MOL CELL BIOL, V36, P2967, DOI 10.1128/MCB.00230-16.
   Dohare P, 2018, NEUROBIOL DIS, V118, P22, DOI 10.1016/j.nbd.2018.06.015.
   Elbaz B, 2019, TRENDS NEUROSCI, V42, P263, DOI 10.1016/j.tins.2019.01.002.
   Emery B, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020461.
   Emery B, 2009, CELL, V138, P172, DOI 10.1016/j.cell.2009.04.031.
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879.
   Figlia G, 2018, GLIA, V66, P693, DOI 10.1002/glia.23273.
   Figlia G, 2017, ELIFE, V6, DOI 10.7554/eLife.29241.
   Flores AI, 2008, J NEUROSCI, V28, P7174, DOI 10.1523/JNEUROSCI.0150-08.2008.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Han XN, 2020, CEREB CORTEX, V30, P406, DOI 10.1093/cercor/bhz146.
   Hornig J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003907.
   Huang CL, 2020, CEREB CORTEX, V30, P4183, DOI 10.1093/cercor/bhaa042.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Küspert M, 2011, NUCLEIC ACIDS RES, V39, P1280, DOI 10.1093/nar/gkq951.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lebrun-Julien F, 2014, J NEUROSCI, V34, P8432, DOI 10.1523/JNEUROSCI.1105-14.2014.
   Lee JY, 2016, MOL NEUROBIOL, V53, P6568, DOI 10.1007/s12035-016-0013-1.
   Li HL, 2016, BRAIN RES, V1641, P111, DOI 10.1016/j.brainres.2015.10.013.
   Liu M, 2018, GLIA, V66, P175, DOI 10.1002/glia.23236.
   Liu ZX, 2019, NEURON, V102, P587, DOI 10.1016/j.neuron.2019.02.018.
   Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Narayanan SP, 2009, J NEUROSCI, V29, P6860, DOI 10.1523/JNEUROSCI.0232-09.2009.
   Nave KA, 2008, ANNU REV NEUROSCI, V31, P535, DOI 10.1146/annurev.neuro.30.051606.094309.
   Nicks J, 2014, NEUROBIOL DIS, V70, P224, DOI 10.1016/j.nbd.2014.06.023.
   Nishiyama A, 2009, NAT REV NEUROSCI, V10, P9, DOI 10.1038/nrn2495.
   Pereira GB, 2011, J NEUROSCI RES, V89, P1070, DOI 10.1002/jnr.22625.
   Rowitch DH, 2010, NATURE, V468, P214, DOI 10.1038/nature09611.
   Stolt CC, 2002, GENE DEV, V16, P165, DOI 10.1101/gad.215802.
   Tyler WA, 2011, GLIA, V59, P1754, DOI 10.1002/glia.21221.
   Wahl SE, 2014, J NEUROSCI, V34, P4453, DOI 10.1523/JNEUROSCI.4311-13.2014.
   Watatani K, 2012, GENES CELLS, V17, P326, DOI 10.1111/j.1365-2443.2012.01591.x.
   Xu CY, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00330.
   Xu M, 2019, CEREB CORTEX, V29, P1185, DOI 10.1093/cercor/bhy024.
   Yang S, 2018, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00435.
   Zhang LG, 2016, DEV CELL, V36, P316, DOI 10.1016/j.devcel.2016.01.002.
   Zhu XQ, 2012, DEVELOPMENT, V139, P2299, DOI 10.1242/dev.078873.
   Zou Y, 2014, J NEUROSCI, V34, P15764, DOI 10.1523/JNEUROSCI.2267-14.2014.},
Number-of-Cited-References = {45},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Neurobiol. Dis.},
Doc-Delivery-Number = {PR9VC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000607577300004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000618816100010,
Author = {Xu, Jian and Zhu, Yue and Qian, Jun},
Title = {Expression and clinical significance of PDK family in breast cancer
   based on data mining},
Journal = {INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY},
Year = {2021},
Volume = {14},
Number = {1},
Pages = {97-106},
Abstract = {The pyruvate dehydrogenase kinase (PDK) family, including PDK1, PDK2,
   PDK3, and PDK4, is involved in tumor progression. However, its role in
   breast cancer (BC) remains unknown. This study aims to mine the
   expression, clinical significance, and downstream pathways of PDK family
   in BC. By analyzing data downloaded from The Cancer Genome Atlas (TCGA)
   database, we found an enhanced level of PDK3 and decreased expression of
   PDK2 and PDK4 in BC tissues compared to normal tissues. Also, the
   expression of PDK3 mRNA is negatively related to that of PDK2 and PDK4,
   while there is a positive relation between PDK2 mRNA expression and PDK3
   mRNA expression. Moreover, we found that PDK2 expression is related to
   lymph node metastasis, and PDK4 is associated with T stage and stage
   using analysis of data obtained from TCGA database. Finally, we
   identified several gene sets related to cancer initiation and
   progression regulated by PDK2-4 after performing Gene set enrichment
   analysis (GSEA). In conclusion, PDK2-4 possess potential as targets for
   BC treatment.},
Publisher = {E-CENTURY PUBLISHING CORP},
Address = {40 WHITE OAKS LN, MADISON, WI 53711 USA},
Type = {Article},
Language = {English},
Affiliation = {Qian, J (Corresponding Author), Bengbu Med Coll, Dept Oncol Surg, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China.
   Xu, Jian; Qian, Jun, Bengbu Med Coll, Dept Oncol Surg, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China.
   Zhu, Yue, Bengbu Med Coll, Dept Med Oncol, Affiliated Hosp 1, Bengbu, Peoples R China.},
ISSN = {1936-2625},
Keywords = {PDK; The cancer genome atlas; breast cancer; gene set enrichment
   analysis},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; DOWN-REGULATION; TUMOR-GROWTH;
   METASTASIS; RESISTANCE; OVEREXPRESSION; INHIBITION; INDUCTION; CELLS},
Research-Areas = {Oncology; Pathology},
Web-of-Science-Categories  = {Oncology; Pathology},
Author-Email = {qianjun215036@sina.com},
Affiliations = {Bengbu Medical University; Bengbu Medical University},
Cited-References = {Arsenic R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-82.
   Cui LZ, 2020, CANCER GENE THER, V27, P15, DOI 10.1038/s41417-018-0071-9.
   DeSantis CE, 2016, CA-CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Feng YH, 2019, INT J EXP PATHOL, V100, P32, DOI 10.1111/iep.12307.
   Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021.
   Guda MR, 2018, AM J CANCER RES, V8, P1725.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hu TH, 2019, J DRUG TARGET, V27, P460, DOI 10.1080/1061186X.2018.1550648.
   Ignatiadis M, 2015, ANN ONCOL, V26, P1519, DOI 10.1093/annonc/mdv259.
   Ilic BB, 2018, J MED BIOCHEM, V37, P31, DOI 10.1515/jomb-2017-0030.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Kato M, 2008, STRUCTURE, V16, P1849, DOI 10.1016/j.str.2008.10.010.
   Li L, 2017, CANCER LETT, V400, P89, DOI 10.1016/j.canlet.2017.04.034.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Newington JT, 2012, J BIOL CHEM, V287, P37245, DOI 10.1074/jbc.M112.366195.
   Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868.
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007.
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Tambe Y, 2019, MOL CARCINOGEN, V58, P1726, DOI 10.1002/mc.23045.
   Walter W, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1444-2.
   Wang JH, 2019, CANCER MANAG RES, V11, P251, DOI 10.2147/CMAR.S185015.
   Xu JY, 2019, THERANOSTICS, V9, P2999, DOI 10.7150/thno.31301.
   Yang C, 2019, J CANCER, V10, P918, DOI 10.7150/jca.27226.
   Yonashiro R, 2018, CANCER RES, V78, P1592, DOI 10.1158/0008-5472.CAN-17-1751.
   Zeng X, 2002, CANCER RES, V62, P3538.},
Number-of-Cited-References = {31},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {0},
Journal-ISO = {Int. J. Clin. Exp. Pathol.},
Doc-Delivery-Number = {QI2PE},
Web-of-Science-Index = {Emerging Sources Citation Index (ESCI)},
Unique-ID = {WOS:000618816100010},
DA = {2026-02-04},
}

@article{ WOS:000591957000002,
Author = {Yao, Shasha and Shang, Wenwen and Huang, Lei and Xu, Rui and Wu, Ming
   and Wang, Fang},
Title = {The oncogenic and prognostic role of PDK1 in the progression and
   metastasis of ovarian cancer},
Journal = {JOURNAL OF CANCER},
Year = {2021},
Volume = {12},
Number = {3},
Pages = {630-643},
Abstract = {Ovarian cancer (OC) is the most lethal of gynecological tumors in women.
   Tumor metabolism has become a new opportunity in the treatment of
   tumors. Pyruvate dehydrogenase kinase 1 (PDK1), as a key regulatory
   enzyme implicated in metabolic reprogramming of tumors, abnormally high
   expressed in various tumors and involved in the regulation of tumor cell
   biological behavior. However, the role of PDK1 in the occurrence and
   development of ovarian cancer remains unclear. Our team identified the
   expression of PDK1 in ovarian cancer cell lines and tissues through
   RT-PCR and immunohistochemical staining and evaluated the correlation of
   PDK1 expression with clinicopathologic features of patients and survival
   analyses. We used a variety of in vitro experiments to explore the
   influence of PDK1 on proliferation, invasion, migration, colony
   formation, apoptosis and the cell cycle of ovarian cancer cell lines
   CAOV3 and SKOV3. PDK1 was highly expressed in ovarian cancer cell lines
   and OC tissues. High expression of PDK1 was closely correlated to tumor
   size, FIGO stage, extraovarian metastases status and distribution.
   Univariate and multivariate Cox regression analysis identified that PDK1
   was an independent prognostic factor for overall survival. Moreover,
   PDK1 was a superior predictor in prognosis of ovarian cancer and the
   incorporation of CA125 into PDK1 generated a predictive combination that
   displayed better predictive accuracy for overall survival.
   Downregulation of PDK1 suppressed the biological behavior of ovarian
   cancer cells due to S phase arrest and cellular apoptosis. PDK1 may
   serve as a novel prognostic biomarker, even a promising antineoplastic
   target of ovarian cancer.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Wang, F (Corresponding Author), Nanjing Med Univ, Affiliated Hosp 1, Dept Lab Med, Natl Key Clin Dept Lab Med, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
   Yao, Shasha; Shang, Wenwen; Huang, Lei; Xu, Rui; Wu, Ming; Wang, Fang, Nanjing Med Univ, Affiliated Hosp 1, Dept Lab Med, Nanjing 210029, Peoples R China.
   Yao, Shasha; Shang, Wenwen; Huang, Lei; Xu, Rui; Wu, Ming; Wang, Fang, Natl Key Clin Dept Lab Med, Nanjing 210029, Peoples R China.
   Yao, Shasha, Nanjing Med Univ, Affiliated Jiangning Hosp, Dept Lab Med, Nanjing 211100, Peoples R China.},
DOI = {10.7150/jca.47278},
ISSN = {1837-9664},
Keywords = {Pyruvate dehydrogenase kinase 1; ovarian cancer; tumor metabolic;
   biological behavior; prognostic biomarker},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; EXPRESSION; TARGET; DICHLOROACETATE;
   PHOSPHORYLATION; STATISTICS; COMPLEX},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {wangfang@njmu.edu.cn},
Affiliations = {Nanjing Medical University; Nanjing Medical University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81772779];
   ``Professionals from Six-Pronged Top-Talent Program{''} of Jiangsu
   Province {[}LGY2017068]; ``The Six Top Talent Project{''} of Jiangsu
   Province {[}2015-WSN-034]; Medical Talent of Empowering Medicine through
   Science and Education Program of Jiangsu Province {[}ZDRCA2016003]; Key
   Laboratory for Medicine of Jiangsu Province of China {[}ZDXKB2016005];
   Jiangning Science and Technology Development program {[}2019SHSY0032]},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (No. 81772779), ``Professionals from Six-Pronged Top-Talent
   Program{''} of Jiangsu Province (No. LGY2017068), ``The Six Top Talent
   Project{''} of Jiangsu Province (No. 2015-WSN-034), Medical Talent of
   Empowering Medicine through Science and Education Program of Jiangsu
   Province (No. ZDRCA2016003), Key Laboratory for Medicine of Jiangsu
   Province of China (No. ZDXKB2016005) and Jiangning Science and
   Technology Development program (No. 2019SHSY0032).},
Cited-References = {Baig MH, 2019, SEMIN CANCER BIOL, V56, P1, DOI 10.1016/j.semcancer.2017.12.003.
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004.
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338.
   Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138.
   Dong LF, 2014, PROG MOL BIOL TRANSL, V127, P211, DOI 10.1016/B978-0-12-394625-6.00008-8.
   Fang AP, 2017, BIOORG MED CHEM LETT, V27, P5450, DOI 10.1016/j.bmcl.2017.10.073.
   Ferrari A, 2019, PHARMACOL THERAPEUT, V193, P178, DOI 10.1016/j.pharmthera.2018.08.008.
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527.
   Furrer D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218621.
   Herzog TJ, 2004, CLIN CANCER RES, V10, P7439, DOI 10.1158/1078-0432.CCR-04-0683.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hollis RL, 2016, CANCER BIOL MED, V13, P236, DOI 10.20892/j.issn.2095-3941.2016.0024.
   Hsu JY, 2017, FASEB J, V31, P4265, DOI 10.1096/fj.201700156R.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43.
   Jiang Y, 2014, PROTEIN EXPRES PURIF, V97, P9, DOI 10.1016/j.pep.2014.02.002.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Lee CK, 2019, SCIENCE, V363, P644, DOI 10.1126/science.aav0173.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Pópulo H, 2015, EXPERT OPIN THER TAR, V19, P733, DOI 10.1517/14728222.2015.1045416.
   Riedinger JM, 2006, ANN ONCOL, V17, P1234, DOI 10.1093/annonc/mdl120.
   Saha S, 2015, SCI REP-UK, V5, DOI 10.1038/srep07762.
   Santillan A, 2005, J CLIN ONCOL, V23, P9338, DOI 10.1200/JCO.2005.02.2582.
   Siu MKY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0209-0.
   Sradhanjali S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177744.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tan W, 2019, SEMIN CANCER BIOL, V56, P56, DOI 10.1016/j.semcancer.2018.09.005.
   Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Wang JJ, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1659092.
   WIELAND OH, 1982, REV PHYSIOL BIOCH P, V96, P123, DOI 10.1007/BFb0031008.
   Xiang GZ, 2016, PATHOL RES PRACT, V212, P1102, DOI 10.1016/j.prp.2016.10.006.
   Zhang M, 2019, J HOSP MARKET MANAG, V28, P28, DOI 10.1080/19368623.2018.1493711.
   Zhang SL, 2018, EUR J PHARM SCI, V123, P43, DOI 10.1016/j.ejps.2018.07.026.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.
   Zhang W, 2017, EUR J PHARM SCI, V110, P93, DOI 10.1016/j.ejps.2017.04.018.},
Number-of-Cited-References = {41},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {J. Cancer},
Doc-Delivery-Number = {OV1CN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000591957000002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000610494400003,
Author = {Yuan, Kai and Wang, Xiao and Dong, Haojie and Min, Wenjian and Hao,
   Haiping and Yang, Peng},
Title = {Selective inhibition of CDK4/6: A safe and effective strategy for
   developing anticancer drugs},
Journal = {ACTA PHARMACEUTICA SINICA B},
Year = {2021},
Volume = {11},
Number = {1},
Pages = {30-54},
Month = {JAN},
Abstract = {The sustained cell proliferation resulting from dysregulation of the
   cell cycle and activation of cyclin-dependent kinases (CDKs) is a
   hallmark of cancer. The inhibition of CDKs is a highly promising and
   attractive strategy for the development of anticancer drugs. In
   particular, third-generation CDK inhibitors can selectively inhibit
   CDK4/6 and regulate the cell cycle by suppressing the G1 to S phase
   transition, exhibiting a perfect balance between anticancer efficacy and
   general toxicity. To date, three selective CDK4/6 inhibitors have
   received approval from the U.S. Food and Drug Administration (FDA), and
   15 CDK4/6 inhibitors are in clinical trials for the treatment of
   cancers. In this perspective, we discuss the crucial roles of CDK4/6 in
   regulating the cell cycle and cancer cells, analyze the rationale for
   selectively inhibiting CDK4/6 for cancer treatment, review the latest
   advances in highly selective CDK4/6 inhibitors with different chemical
   scaffolds, explain the mechanisms associated with CDK4/6 inhibitor
   resistance and describe solutions to overcome this issue, and briefly
   introduce proteolysis targeting chimera (PROTAC), a new and
   revolutionary technique used to degrade CDK4/6. (C) 2021 Chinese
   Pharmaceutical Association and Institute of Materia Medica, Chinese
   Academy of Medical Sciences. Production and hosting by Elsevier B.V.},
Publisher = {INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES},
Address = {C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA},
Type = {Review},
Language = {English},
Affiliation = {Hao, HP; Yang, P (Corresponding Author), China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.
   Hao, HP; Yang, P (Corresponding Author), China Pharmaceut Univ, Jiangsu Key Lab Drug Design \& Optimizat, Nanjing 210009, Peoples R China.
   Hao, HP; Yang, P (Corresponding Author), China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing 210009, Peoples R China.
   Yuan, Kai; Wang, Xiao; Dong, Haojie; Min, Wenjian; Hao, Haiping; Yang, Peng, China Pharmaceut Univ, State Key Lab Nat Med, Nanjing 210009, Peoples R China.
   Yuan, Kai; Wang, Xiao; Dong, Haojie; Min, Wenjian; Hao, Haiping; Yang, Peng, China Pharmaceut Univ, Jiangsu Key Lab Drug Design \& Optimizat, Nanjing 210009, Peoples R China.
   Yuan, Kai; Wang, Xiao; Dong, Haojie; Min, Wenjian; Hao, Haiping; Yang, Peng, China Pharmaceut Univ, Sch Pharm, Dept Med Chem, Nanjing 210009, Peoples R China.},
DOI = {10.1016/j.apsb.2020.05.001},
ISSN = {2211-3835},
EISSN = {2211-3843},
Keywords = {CDK4/6; Cell cycle; Cancer; Selectivity; Drug resistance; PROTAC},
Keywords-Plus = {DEPENDENT KINASE-INHIBITOR; DINACICLIB SCH 727965; MANTLE-CELL LYMPHOMA;
   PHASE-II TRIAL; BREAST-CANCER; HIGHLY POTENT; AMG 925; BIOLOGICAL
   EVALUATION; ANTITUMOR PROPERTIES; G1 PHASE},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {hhp\_770505@hotmail.com
   pengyang@cpu.edu.cn},
Affiliations = {China Pharmaceutical University; China Pharmaceutical University; China
   Pharmaceutical University},
ResearcherID-Numbers = {Dong, Haojie/HLG-4891-2023
   Hao, Haiping/JNE-7319-2023
   Yang, Peng/HPH-5119-2023},
ORCID-Numbers = {Dong, Haojie/0000-0002-4502-3340
   Hao, Haiping/0000-0003-2522-7546
   Yuan, Kai/0000-0002-3030-6460
   Yang, Peng/0000-0002-2613-941X},
Funding-Acknowledgement = {Project Program of State Key Laboratory of Natural Medicines, China
   Pharmaceutical University (China) {[}SKLNMZZRC07]; 111 Project (China)
   {[}B16046]; ``Double First-Class{''} University Project (China)
   {[}CPU2018GF04]; Jiangsu Key Laboratory of Drug Design and Optimization
   (China) {[}DDORC201801]; 65th China Postdoctoral Science Foundation
   {[}2019M652030]},
Funding-Text = {This study was supported by the Project Program of State Key Laboratory
   of Natural Medicines, China Pharmaceutical University (SKLNMZZRC07,
   China), 111 Project (B16046, China), ``Double First-Class{''} University
   Project (CPU2018GF04, China), Jiangsu Key Laboratory of Drug Design and
   Optimization (DDORC201801, China), and 65th China Postdoctoral Science
   Foundation (2019M652030).},
Cited-References = {Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320.
   Al-Awar RS, 2004, BIOORG MED CHEM LETT, V14, P3217, DOI 10.1016/j.bmcl.2004.03.105.
   {[}Anonymous], {[}No title captured].
   {[}Anonymous], 2014, Oncology Times, V36, P91.
   Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504.
   Baba Y, 2014, CLIN CANCER RES, V20, P1114, DOI 10.1158/1078-0432.CCR-13-1645.
   Barroso-Sousa R, 2016, BREAST CARE, V11, P167, DOI 10.1159/000447284.
   Bartkowiak B, 2010, GENE DEV, V24, P2303, DOI 10.1101/gad.1968210.
   Barvian M, 2000, J MED CHEM, V43, P4606, DOI 10.1021/jm000271k.
   Behenna DC, 2018, CDK2/4/6 Inhibitors; United States, Patent No. {[}US20180044344, 20180044344].
   BERCHUCK A, 1994, AM J OBSTET GYNECOL, V170, P246.
   Bilgin B, 2017, CURR MED RES OPIN, V33, P1559, DOI 10.1080/03007995.2017.1348344.
   Bisi JE, 2017, ONCOTARGET, V8, P42343, DOI 10.18632/oncotarget.16216.
   Bisi JE, 2016, MOL CANCER THER, V15, P783, DOI 10.1158/1535-7163.MCT-15-0775.
   Bose P, 2013, EXPERT OPIN INV DRUG, V22, P723, DOI 10.1517/13543784.2013.789859.
   Boss DS, 2010, ANN ONCOL, V21, P884, DOI 10.1093/annonc/mdp377.
   Brand M, 2019, CELL CHEM BIOL, V26, P300, DOI 10.1016/j.chembiol.2018.11.006.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399.
   Byth KF, 2009, MOL CANCER THER, V8, P1856, DOI 10.1158/1535-7163.MCT-08-0836.
   Camidge DR, 2007, CANCER CHEMOTH PHARM, V60, P391, DOI 10.1007/s00280-006-0371-x.
   Cao J, 2019, ONCOGENE, V38, P4125, DOI 10.1038/s41388-019-0708-7.
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492.
   Cassaday RD, 2015, CL LYMPH MYELOM LEUK, V15, P392, DOI 10.1016/j.clml.2015.02.021.
   Chen P, 2016, MOL CANCER THER, V15, P2273, DOI 10.1158/1535-7163.MCT-16-0300.
   Cho YS, 2012, ACS MED CHEM LETT, V3, P445, DOI 10.1021/ml200241a.
   Cho YS, 2010, J MED CHEM, V53, P7938, DOI 10.1021/jm100571n.
   Condorelli R, 2018, ANN ONCOL, V29, P640, DOI 10.1093/annonc/mdx784.
   Corona SP, 2017, CRIT REV ONCOL HEMAT, V112, P208, DOI 10.1016/j.critrevonc.2017.02.022.
   Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0.
   Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154.
   Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915.
   Dhillon S, 2015, DRUGS, V75, P543, DOI 10.1007/s40265-015-0379-9.
   Dickson MA, 2013, J CLIN ONCOL, V31, P2024, DOI 10.1200/JCO.2012.46.5476.
   Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72.
   DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772.
   Engler TA, 2003, BIOORG MED CHEM LETT, V13, P2261, DOI 10.1016/S0960-894X(03)00461-X.
   Ferguson FM, 2018, NAT REV DRUG DISCOV, V17, P353, DOI 10.1038/nrd.2018.21.
   Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303.
   Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419.
   Firestein R, 2008, NATURE, V455, P547, DOI 10.1038/nature07179.
   Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509.
   Fry DW, 2004, MOL CANCER THER, V3, P1427.
   Gavet O, 2010, J CELL BIOL, V189, P247, DOI 10.1083/jcb.200909144.
   Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7.
   Ghia P, 2017, BLOOD, V129, P1876, DOI 10.1182/blood-2016-10-748210.
   GILLETT C, 1994, CANCER RES, V54, P1812.
   Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465.
   Gojo I, 2010, BLOOD, V116, P1346.
   Guarducci C, 2017, BREAST CARE, V12, P304, DOI 10.1159/000484167.
   Hamilton E, 2016, CANCER TREAT REV, V45, P129, DOI 10.1016/j.ctrv.2016.03.002.
   Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6.
   Hartwell LH, 2002, BIOSCIENCE REP, V22, P373, DOI 10.1023/A:1020918107706.
   He G, 2010, Patent, Patent No. {[}WO2010020675A1, 2010020675].
   He SH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3986.
   Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728.
   HINDS PW, 1995, CURR OPIN GENET DEV, V5, P79, DOI 10.1016/S0959-437X(95)90057-8.
   Honma T, 2001, J MED CHEM, V44, P4615, DOI 10.1021/jm0103256.
   Honma T, 2001, J MED CHEM, V44, P4628, DOI 10.1021/jm010326y.
   Horiuchi T, 2011, CHEM PHARM BULL, V59, P991, DOI 10.1248/cpb.59.991.
   Horiuchi T, 2009, BIOORGAN MED CHEM, V17, P7850, DOI 10.1016/j.bmc.2009.10.039.
   Horiuchi T, 2009, BIOORG MED CHEM LETT, V19, P305, DOI 10.1016/j.bmcl.2008.11.090.
   Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709.
   Italiano A, 2009, CLIN CANCER RES, V15, P5696, DOI 10.1158/1078-0432.CCR-08-3185.
   Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653.
   Jiang BS, 2019, ANGEW CHEM INT EDIT, V58, P6321, DOI 10.1002/anie.201901336.
   Jorda R, 2018, J MED CHEM, V61, P9105, DOI 10.1021/acs.jmedchem.8b00049.
   Joshi KS, 2007, MOL CANCER THER, V6, P918, DOI 10.1158/1535-7163.MCT-06-0613.
   KATO J, 1993, GENE DEV, V7, P331.
   Keegan K, 2014, MOL CANCER THER, V13, P880, DOI 10.1158/1535-7163.MCT-13-0858.
   Kim ES, 2017, DRUGS, V77, P2063, DOI 10.1007/s40265-017-0840-z.
   Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131.
   Knudsen ES, 2017, ONCOTARGET, V8, P43678, DOI 10.18632/oncotarget.18435.
   Knudsen ES, 2017, TRENDS CANCER, V3, P39, DOI 10.1016/j.trecan.2016.11.006.
   Kouroukis CT, 2003, J CLIN ONCOL, V21, P1740, DOI 10.1200/JCO.2003.09.057.
   Kwapisz D, 2017, BREAST CANCER RES TR, V166, P41, DOI 10.1007/s10549-017-4385-3.
   LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350.
   Lavoie G, 2011, BIOCHEM BIOPH RES CO, V409, P187, DOI 10.1016/j.bbrc.2011.04.115.
   Le Tourneau C, 2010, EUR J CANCER, V46, P3243, DOI 10.1016/j.ejca.2010.08.001.
   Lee KM, 2005, MOL BIOL CELL, V16, P2734, DOI 10.1091/mbc.e04-11-0982.
   Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298.
   Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203.
   Li C, 2015, MOL CANCER THER, V14, P375, DOI 10.1158/1535-7163.MCT-14-0388.
   Li X, 2016, Patent No. {[}WO2016015605A1, 2016015605].
   Li X, 2016, Preparation of acetylcy- clopentylmethylaminopyridopyrimidinone derivatives for use as CDK small-molecule inhibitors, Patent No. {[}WO2016015597A1, 2016015597].
   Li X, 2016, Patent No. {[}WO2016015598A1, 2016015598].
   Li ZH, 2014, J MED CHEM, V57, P3430, DOI 10.1021/jm500118j.
   Li ZQ, 2018, CANCER CELL, V34, P893, DOI 10.1016/j.ccell.2018.11.006.
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744.
   Lin TS, 2010, J CLIN ONCOL, V28, P418, DOI 10.1200/JCO.2009.24.1570.
   Lin ZP, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00303.
   Long F, 2019, CANCER SCI, V110, P1420, DOI 10.1111/cas.13957.
   Loyer P, 2008, J BIOL CHEM, V283, P7721, DOI 10.1074/jbc.M708188200.
   Lu H, 2006, J MED CHEM, V49, P3826, DOI 10.1021/jm0600388.
   Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753.
   Luzzio M, 2011, Preparation of pyrrolopyrimidine derivatives for use as CDK4/6 inhibitors., Patent No. {[}WO2011101409A1, 2011101409].
   Lynce F, 2018, PHARMACOL THERAPEUT, V191, P65, DOI 10.1016/j.pharmthera.2018.06.008.
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602.
   Marais A, 2010, J BIOL CHEM, V285, P35728, DOI 10.1074/jbc.M110.154005.
   Martin CA, 2018, INT J CANCER, V142, P2139, DOI 10.1002/ijc.31220.
   MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650.
   MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066.
   MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4.
   McClue SJ, 2002, INT J CANCER, V102, P463, DOI 10.1002/ijc.10738.
   Mita MM, 2014, CLIN BREAST CANCER, V14, P169, DOI 10.1016/j.clbc.2013.10.016.
   Nemunaitis JJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-259.
   Nie B, 2016, Preparation of CDK small molecule inhibitors, Patent No. {[}CN105294737A, 105294737].
   Niesvizky R, 2015, LEUKEMIA LYMPHOMA, V56, P3320, DOI 10.3109/10428194.2015.1030641.
   Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594.
   Nurse PM, 2002, BIOSCIENCE REP, V22, P487, DOI 10.1023/A:1022017701871.
   O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264.
   O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26.
   OKAMOTO A, 1991, CANCER RES, V51, P5171.
   Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9.
   Ottis P, 2017, ACS CHEM BIOL, V12, P892, DOI 10.1021/acschembio.6b01068.
   Parry D, 2010, MOL CANCER THER, V9, P2344, DOI 10.1158/1535-7163.MCT-10-0324.
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382.
   Parylo S, 2019, J ONCOL PHARM PRACT, V25, P110, DOI 10.1177/1078155218770904.
   Patel P, 2018, MOL CANCER RES, V16, P361, DOI 10.1158/1541-7786.MCR-17-0602.
   Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640.
   Peng Y, 2017, Preparation of substituted pyrrolopyrimidine derivative as CDK inhibitor, Patent No. {[}WO2017162215A1, 2017162215].
   Raje N, 2009, LEUKEMIA, V23, P961, DOI 10.1038/leu.2008.378.
   Rana S, 2019, BIOORG MED CHEM LETT, V29, P1375, DOI 10.1016/j.bmcl.2019.03.035.
   Reck M, 2019, J THORAC ONCOL, V14, P701, DOI 10.1016/j.jtho.2019.01.010.
   Reddy MVR, 2014, J MED CHEM, V57, P578, DOI 10.1021/jm401073p.
   Robb CM, 2017, CHEM COMMUN, V53, P7577, DOI 10.1039/c7cc03879h.
   Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002.
   Roskoski R Jr, 2019, PHARMACOL RES, V139, P471, DOI 10.1016/j.phrs.2018.11.035.
   Roskoski R, 2016, PHARMACOL RES, V107, P249, DOI 10.1016/j.phrs.2016.03.012.
   Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111.
   Sanchez-Martinez C, 2003, BIOORG MED CHEM LETT, V13, P3835, DOI 10.1016/S0960-894X(03)00791-1.
   Sanchez-Martinez C, 2003, BIOORG MED CHEM LETT, V13, P3841, DOI 10.1016/S0960-894X(03)00792-3.
   Sánchez-Martínez C, 2015, BIOORG MED CHEM LETT, V25, P3420, DOI {[}10.1002/chin.201540270, 10.1016/j.bmcl.2015.05.100].
   Santamaría D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046.
   Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143.
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9.
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0.
   Shao H, 2013, J MED CHEM, V56, P640, DOI 10.1021/jm301475f.
   Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689.
   Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021.
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672.
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501.
   SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0.
   Shimamura T, 2006, BIOORG MED CHEM LETT, V16, P3751, DOI 10.1016/j.bmcl.2006.04.048.
   Shin C, 2004, NAT REV MOL CELL BIO, V5, P727, DOI 10.1038/nrm1467.
   Siemeister G, 2012, MOL CANCER THER, V11, P2265, DOI 10.1158/1535-7163.MCT-12-0286.
   Smith BE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08027-7.
   Spring LM, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0769-3.
   Stephenson JJ, 2014, LUNG CANCER, V83, P219, DOI 10.1016/j.lungcan.2013.11.020.
   Stice JP, 2017, MOL CANCER RES, V15, P660, DOI 10.1158/1541-7786.MCR-17-0028.
   Su S, 2019, J MED CHEM, V62, P7575, DOI 10.1021/acs.jmedchem.9b00871.
   Sun YS, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110013.
   Sun YS, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2019.104616.
   Syed YY, 2017, DRUGS, V77, P799, DOI 10.1007/s40265-017-0742-0.
   Tadesse S, 2018, BRIT J PHARMACOL, V175, P2399, DOI 10.1111/bph.13974.
   Tadesse S, 2017, FUTURE MED CHEM, V9, P1495, DOI 10.4155/fmc-2017-0076.
   Tadesse S, 2017, J MED CHEM, V60, P1892, DOI 10.1021/acs.jmedchem.6b01670.
   Tomashevski A, 2010, CELL DEATH DIFFER, V17, P1189, DOI 10.1038/cdd.2009.221.
   Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h.
   Toure M, 2016, ANGEW CHEM INT EDIT, V55, P1966, DOI {[}10.1002/ange.201507978, 10.1002/anie.201507978].
   TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8.
   VanderWel SN, 2005, J MED CHEM, V48, P2371, DOI 10.1021/jm049355+.
   Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020.
   Wang B, 2014, Patent No. {[}WO2014183520A1, 2014183520].
   Wang JY, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1231-7.
   Wang J, 2019, J AGR FOOD CHEM, V67, P3341, DOI 10.1021/acs.jafc.9b00324.
   Wang P, 2016, EUR J MED CHEM, V122, P546, DOI 10.1016/j.ejmech.2016.07.020.
   Wang SD, 2004, J MED CHEM, V47, P1662, DOI 10.1021/jm0309957.
   Wang SD, 2010, CHEM BIOL, V17, P1111, DOI 10.1016/j.chembiol.2010.07.016.
   Wang Y, 2018, BIOORG MED CHEM LETT, V28, P974, DOI 10.1016/j.bmcl.2017.12.068.
   Wang Y, 2020, ACTA PHARMACOL SIN B, V10, P207, DOI 10.1016/j.apsb.2019.08.001.
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052.
   Whittaker SR, 2017, PHARMACOL THERAPEUT, V173, P83, DOI 10.1016/j.pharmthera.2017.02.008.
   Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776.
   Yamamoto T, 2019, BREAST CANCER RES TR, V174, P615, DOI 10.1007/s10549-018-05104-9.
   Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044.
   Yang C, 2017, ONCOGENE, V36, P2255, DOI 10.1038/onc.2016.379.
   Yu DS, 2010, EMBO REP, V11, P876, DOI 10.1038/embor.2010.153.
   Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012.
   Yu QY, 2005, ONCOGENE, V24, P7114, DOI 10.1038/sj.onc.1208853.
   Zardavas D, 2017, EXPERT OPIN INV DRUG, V26, P1357, DOI 10.1080/13543784.2017.1389896.
   Zha CT, 2018, EUR J MED CHEM, V148, P140, DOI 10.1016/j.ejmech.2018.02.022.
   Zhang F, 2020, J AGR FOOD CHEM, V68, P213, DOI 10.1021/acs.jafc.9b07103.
   Zhang YY, 2019, J AGR FOOD CHEM, V67, P7378, DOI 10.1021/acs.jafc.9b02759.
   Zhao BS, 2019, CHEM COMMUN, V55, P2704, DOI 10.1039/c9cc00163h.
   Zhu GX, 2003, BIOORG MED CHEM LETT, V13, P1231, DOI 10.1016/S0960-894X(03)00133-1.
   Zou YT, 2019, CELL BIOCHEM FUNCT, V37, P21, DOI 10.1002/cbf.3369.},
Number-of-Cited-References = {187},
Times-Cited = {115},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {194},
Journal-ISO = {Acta Pharm. Sin. B},
Doc-Delivery-Number = {PW2HA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000610494400003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000702608300008,
Author = {Zhang, Chen and Chen, Min and Tao, Qi and Chi, Zhangcai},
Title = {Cobalt chloride-stimulated hypoxia promotes the proliferation of
   cholesteatoma keratinocytes via the PI3K/Akt signaling pathway},
Journal = {INTERNATIONAL JOURNAL OF MEDICAL SCIENCES},
Year = {2021},
Volume = {18},
Number = {15},
Pages = {3403-3411},
Abstract = {Herein, we purposed to explore whether hypoxia triggers proliferation of
   cholesteatoma keratinocytes via the PI3K-Akt signaling cascade. Cells
   were inoculated with different concentration of CoCl2. The proliferation
   and cellular HIF-1 alpha, p-PDK1 and p-Akt expression levels of
   cholesteatoma keratinocytes were assessed in vitro. Hypoxia escalated
   cell proliferation via upregulating p-PDK1 and p-Akt expressions.
   Specific inhibitor of the PI3K-Akt signaling cascade, LY294002 markedly
   inhibited the expression of p-Akt and significantly reduces the
   hypoxia-induced proliferation of cholesteatoma keratinocytes. Our data
   provides research evidence confirming that hypoxia participates in the
   onset and progress of cholesteatoma.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Chi, ZC (Corresponding Author), Fudan Univ, Eye \& ENT Hosp, Dept Otolaryngol, 83 Fenyang Rd, Shanghai, Peoples R China.
   Chi, ZC (Corresponding Author), Fudan Univ, NHC Key Lab Hearing Med, Shanghai 200031, Peoples R China.
   Zhang, Chen; Chen, Min; Chi, Zhangcai, Fudan Univ, Eye \& ENT Hosp, Dept Otolaryngol, 83 Fenyang Rd, Shanghai, Peoples R China.
   Chen, Min; Chi, Zhangcai, Fudan Univ, NHC Key Lab Hearing Med, Shanghai 200031, Peoples R China.
   Tao, Qi, Fudan Univ, Eye \& ENT Hosp, Dept Nursing, 83 Fenyang Rd, Shanghai, Peoples R China.},
DOI = {10.7150/ijms.60617},
ISSN = {1449-1907},
Keywords = {hypoxia; cholesteatoma; HIF-1 alpha; cell proliferation; PI3K/Akt
   signaling pathway},
Keywords-Plus = {CELL-PROLIFERATION; MIDDLE-EAR; EXPRESSION; PROTEIN},
Research-Areas = {General \& Internal Medicine},
Web-of-Science-Categories  = {Medicine, General \& Internal},
Author-Email = {zhangcai.chi@fdeent.org},
Affiliations = {Fudan University; Fudan University; Fudan University},
ResearcherID-Numbers = {tao, qilin/NIS-7557-2025
   },
ORCID-Numbers = {Chen, Min/0000-0002-2334-8320},
Funding-Acknowledgement = {Science Project of Shanghai Municipal Health Bureau {[}20174Y0062]},
Funding-Text = {This work was funded by Science Project of Shanghai Municipal Health
   Bureau (No.20174Y0062).},
Cited-References = {Adunka O, 2003, LARYNGOSCOPE, V113, P1210, DOI 10.1097/00005537-200307000-00018.
   Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200.
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655.
   Chai XY, 2018, INT J MOL MED, V41, P2461, DOI 10.3892/ijmm.2018.3462.
   Chi ZC, 2015, MOL CELL BIOCHEM, V400, P189, DOI 10.1007/s11010-014-2275-0.
   Cogo A, 2003, J APPL PHYSIOL, V94, P1403, DOI 10.1152/japplphysiol.00363.2002.
   Darby IA, 2016, CELL TISSUE RES, V365, P553, DOI 10.1007/s00441-016-2461-3.
   Elorza A, 2012, MOL CELL, V48, P681, DOI 10.1016/j.molcel.2012.09.017.
   Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006.
   Hodson EJ, 2016, J PHYSIOL-LONDON, V594, P1179, DOI 10.1113/JP271050.
   Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y.
   Liu Yang, 2005, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V19, P4.
   Liu YL, 2012, TOXICOL APPL PHARM, V264, P212, DOI 10.1016/j.taap.2012.08.003.
   Loboda A, 2010, MOL CELLS, V29, P435, DOI 10.1007/s10059-010-0067-2.
   Muñoz-Sánchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749.
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd.
   Rana NK, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0221-z.
   Shen C, 2011, CANCER DISCOV, V1, P222, DOI 10.1158/2159-8290.CD-11-0098.
   Shih CP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18536-y.
   Sudhoff H, 2000, AM J OTOL, V21, P786.
   Torres-Capelli M, 2016, SCI REP-UK, V6, DOI 10.1038/srep25357.
   TOS M, 1974, ANN OTO RHINOL LARYN, V83, P44, DOI 10.1177/0003489474083S1105.
   Xie SM, 2016, LARYNGOSCOPE, V126, P1923, DOI 10.1002/lary.25834.
   Xie YB, 2019, MOL MED REP, V19, P783, DOI 10.3892/mmr.2018.9713.
   Zhang C, 2020, PPAR RES, V2020, DOI 10.1155/2020/8864813.
   Zhang D, 2019, BIOCHEM BIOPH RES CO, V512, P360, DOI 10.1016/j.bbrc.2019.03.040.
   Zheng WW, 2019, MOL MED REP, V20, P4315, DOI 10.3892/mmr.2019.10656.},
Number-of-Cited-References = {27},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Int. J. Med. Sci.},
Doc-Delivery-Number = {WA0TJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000702608300008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000692835800025,
Author = {Zhang, Qian and Xiao, Xinhua and Zheng, Jia and Li, Ming and Yu, Miao
   and Ping, Fan and Wang, Tong and Wang, Xiaojing},
Title = {Vildagliptin, a dipeptidyl peptidase-4 inhibitor, attenuated endothelial
   dysfunction through miRNAs in diabetic rats},
Journal = {ARCHIVES OF MEDICAL SCIENCE},
Year = {2021},
Volume = {17},
Number = {5},
Pages = {1378-1387},
Abstract = {Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors have various
   cellular effects that are associated with vascular protection. Here, we
   examined whether vildagliptin protected endothelial function in diabetic
   rats and explored the involved mechanism.
   Material and methods: Experimental diabetic rats were obtained by
   feeding a high-fat diet and administering an intraperitoneal injection
   of streptozotocin. Rats were randomly divided into four groups: controls
   (CON), diabetes (DM), diabetes + low dose of vildagliptin (Lvil, 10
   mg/kg/day), and diabetes + high dose of vildagliptin (Hvil, 20
   mg/kg/day). The metabolic parameters, endothelial function, and whole
   miRNA expression were measured.
   Results: After a 12-week treatment, vildagliptin-treated rats showed a
   significant reduction in blood glucose and blood lipid levels. Moreover,
   vildagliptin recovered aortic endothelial function in diabetic rats. We
   identified 31 miRNAs that were differentially expressed in the Hvil
   group compared with the diabetic group. Importantly, through miRNA
   target biological function and pathway analysis, we found that
   vildagliptin activated miR-190-5p to inhibit Cc12 expression and
   inhibited miR-134-5p and miR-375-3p to increase Bdnf and Pdk1 expression
   in the aorta.
   Conclusions: Our present study indicates that vildagliptin can recover
   endothelial function in diabetic rats. Anti-inflammatory and
   anti-apoptosis mechanisms and endothelial moderation may be the
   intervention targets of vildagliptin to protect the cardiovascular
   system through miRNA regulation.},
Publisher = {TERMEDIA PUBLISHING HOUSE LTD},
Address = {KLEEBERGA ST 2, POZNAN, 61-615, POLAND},
Type = {Article},
Language = {English},
Affiliation = {Xiao, XH (Corresponding Author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Key Lab Endocrinol,Minist Hlth,Dept Endocrinol, Beijing 100730, Peoples R China.
   Zhang, Qian; Xiao, Xinhua; Zheng, Jia; Li, Ming; Yu, Miao; Ping, Fan; Wang, Tong; Wang, Xiaojing, Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Key Lab Endocrinol,Minist Hlth,Dept Endocrinol, Beijing 100730, Peoples R China.},
DOI = {10.5114/aoms.2019.86609},
ISSN = {1734-1922},
EISSN = {1896-9151},
Keywords = {glucagon-like peptide-1; dipeptidyl peptidase-4 inhibitor; endothelial
   function; diabetes; miRNA},
Keywords-Plus = {NEUROTROPHIC FACTOR; GLYCEMIC CONTROL; MICRORNA EXPRESSION; SITAGLIPTIN;
   BRAIN; APOPTOSIS; CELLS; BDNF; ATHEROSCLEROSIS; INFLAMMATION},
Research-Areas = {General \& Internal Medicine},
Web-of-Science-Categories  = {Medicine, General \& Internal},
Author-Email = {xiaoxh2014@vip.163.com},
Affiliations = {Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College},
ResearcherID-Numbers = {Li, Ming/I-1323-2018},
ORCID-Numbers = {Zhang, Qian/0000-0001-9846-0141
   , Jia/0000-0002-6480-3422
   },
Funding-Acknowledgement = {National Key R\&D Program of China {[}2017YFC1309603]; National Key
   Research and Development Program of China {[}2016YFA0101002]; National
   Natural Science Foundation of China {[}81170736, 81570715, 81870579,
   81870545]; National Natural Science Foundation for Young Scholars of
   China {[}81300649]; China Scholarship Council foundation
   {[}201308110443]; PUMC Youth Fund {[}33320140022]; Fundamental Research
   Funds for the Central Universities; Scientific Activities Foundation for
   Selected Returned Overseas Professionals of Human Resources and Social
   Security Ministry},
Funding-Text = {This work was supported by the grants from National Key R\&D Program of
   China (2017YFC1309603), National Key Research and Development Program of
   China (2016YFA0101002), National Natural Science Foundation of China
   (No. 81170736, 81570715, 81870579, 81870545), National Natural Science
   Foundation for Young Scholars of China (No. 81300649), China Scholarship
   Council foundation (201308110443), PUMC Youth Fund (33320140022) and
   Fundamental Research Funds for the Central Universities, and Scientific
   Activities Foundation for Selected Returned Overseas Professionals of
   Human Resources and Social Security Ministry. We are very grateful to
   Beijing Compass Biotechnology Company for excellent technical assistance
   with the microarray experiments.},
Cited-References = {Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415.
   Apaijai N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102374.
   Apaijai N, 2013, BRIT J PHARMACOL, V169, P1048, DOI 10.1111/bph.12176.
   Apaijai N, 2012, ENDOCRINOLOGY, V153, P3878, DOI 10.1210/en.2012-1262.
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381.
   Chaldakov GN, 2004, PROG BRAIN RES, V146, P279, DOI 10.1016/S0079-6123(03)46018-4.
   Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258.
   Chrysant SG, 2012, AM J CARDIOL, V109, P1681, DOI 10.1016/j.amjcard.2012.01.398.
   Dennis G Jr, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60.
   Dicker D, 2011, DIABETES CARE, V34, pS276, DOI 10.2337/dc11-s229.
   Dobrian AD, 2011, AM J PHYSIOL-ENDOC M, V300, pE410, DOI 10.1152/ajpendo.00463.2010.
   Drucker DJ, 2006, LANCET, V368, P1696, DOI 10.1016/S0140-6736(06)69705-5.
   El Ouaamari A, 2008, DIABETES, V57, P2708, DOI 10.2337/db07-1614.
   Elia L, 2015, J MOL CELL CARDIOL, V89, P11, DOI 10.1016/j.yjmcc.2015.07.012.
   Fadini GP, 2010, DIABETES OBES METAB, V12, P570, DOI 10.1111/j.1463-1326.2010.01210.x.
   Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008.
   Gao H, 2014, CELL BIOCHEM BIOPHYS, V69, P27, DOI 10.1007/s12013-013-9762-x.
   Golden E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010099.
   Guo C, 2018, CLIN INVEST MED, V41, pE16, DOI 10.25011/cim.v41i1.29459.
   Jeyaseelan K, 2008, STROKE, V39, P959, DOI 10.1161/STROKEAHA.107.500736.
   Ji RR, 2007, CIRC RES, V100, P1579, DOI 10.1161/CIRCRESAHA.106.141986.
   Keller DM, 2012, MOL ENDOCRINOL, V26, P989, DOI 10.1210/me.2011-1205.
   Krabbe KS, 2007, DIABETOLOGIA, V50, P431, DOI 10.1007/s00125-006-0537-4.
   Kuang HX, 2014, GYNECOL ENDOCRINOL, V30, P57, DOI 10.3109/09513590.2013.850659.
   Kubota Y, 2012, J KOREAN MED SCI, V27, P1364, DOI 10.3346/jkms.2012.27.11.1364.
   Lee IS, 2016, OBES RES CLIN PRACT, V10, P315, DOI 10.1016/j.orcp.2015.07.011.
   Li J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173576.
   Li Y, 2017, CELL MOL BIOL LETT, V22, P1, DOI 10.1186/s11658-017-0033-5.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Lorgis L, 2010, FUND CLIN PHARMACOL, V24, P525, DOI 10.1111/j.1472-8206.2009.00790.x.
   Manni L, 2005, INT J CARDIOL, V102, P169, DOI 10.1016/j.ijcard.2004.10.041.
   Martin BJ, 2009, CAN J CARDIOL, V25, p15A, DOI 10.1016/S0828-282X(09)71049-9.
   Mason RP, 2011, J ATHEROSCLER THROMB, V18, P774, DOI 10.5551/jat.7666.
   Matsumoto S, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-30.
   Moritoh Y, 2008, EUR J PHARMACOL, V588, P325, DOI 10.1016/j.ejphar.2008.04.018.
   Pathania AS, 2013, FOOD CHEM TOXICOL, V62, P246, DOI 10.1016/j.fct.2013.08.037.
   Prigent-Tessier A, 2013, CARDIOVASC RES, V100, P374, DOI 10.1093/cvr/cvt219.
   Quintavalle M, 2011, VASC PHARMACOL, V55, P106, DOI 10.1016/j.vph.2011.08.216.
   ROLLINS BJ, 1991, CANCER CELL-MON REV, V3, P517.
   Rollins BJ, 1996, MOL MED TODAY, V2, P198, DOI 10.1016/1357-4310(96)88772-7.
   Rosenstock J, 2009, CURR MED RES OPIN, V25, P2401, DOI 10.1185/03007990903178735.
   Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5.
   Shah Z, 2011, VASC PHARMACOL, V55, P2, DOI 10.1016/j.vph.2011.03.001.
   Shang J, 2015, MOL ENDOCRINOL, V29, P1243, DOI 10.1210/me.2014-1335.
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303.
   Sliwinska A, 2017, ARCH MED SCI, V13, P885, DOI 10.5114/aoms.2017.65229.
   Tomovic K, 2019, MED RES REV, V39, P404, DOI 10.1002/med.21513.
   Verhamme P, 2002, CARDIOVASC RES, V56, P135, DOI 10.1016/S0008-6363(02)00515-1.
   Wang M, 2011, ARTERIOSCL THROM VAS, V31, P2046, DOI 10.1161/ATVBAHA.111.229559.
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002.
   Yao Y, 2017, BIOMED PHARMACOTHER, V96, P497, DOI 10.1016/j.biopha.2017.10.049.
   Ye YM, 2010, AM J PHYSIOL-HEART C, V298, pH1454, DOI 10.1152/ajpheart.00867.2009.
   YOSHIMURA T, 1989, J EXP MED, V169, P1449, DOI 10.1084/jem.169.4.1449.
   Yoshimura T, 1992, Cytokines, V4, P131.
   Zhang Q, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101767.
   Zhang Y, 2017, ENDOCRINE, V56, P65, DOI 10.1007/s12020-016-1197-x.},
Number-of-Cited-References = {56},
Times-Cited = {12},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Arch. Med. Sci.},
Doc-Delivery-Number = {UL7OI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000692835800025},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000603363500001,
Author = {Bai, Yiguang and Zhang, Qiong and Chen, Qiaoling and Zhou, Quan and
   Zhang, Yanan and Shi, Zhuohua and Nong, Haibin and Liu, Mingfu and Zeng,
   Gaofeng and Zong, Shaohui},
Title = {Conditional knockout of the PDK-1 gene in osteoblasts affects osteoblast
   differentiation and bone formation},
Journal = {JOURNAL OF CELLULAR PHYSIOLOGY},
Year = {2021},
Volume = {236},
Number = {7},
Pages = {5432-5445},
Month = {JUL},
Abstract = {Osteoblasts are the main functional cells of bone formation, and they
   are responsible for the synthesis, secretion, and mineralization of the
   bone matrix. Phosphatidylinositol-3-kinase/Akt is an important signaling
   pathway involved in the regulation of cell proliferation, death, and
   survival. Some studies have shown that 3-phosphoinositide-dependent
   protein kinase-1 (PDK-1) plays an important role in the phosphorylation
   of Akt. In the present study, an osteocalcin (OCN) promoter-driven
   Cre-LoxP system was established to specifically delete the PDK-1 gene in
   osteoblasts. It was found that the size and weight of PDK-1 conditional
   gene knockout (cKO) mice were significantly reduced. von Kossa staining
   and microcomputed tomography showed that the trabecular thickness,
   trabecular number, and bone volume were significantly decreased, whereas
   trabecular separation was increased, as compared with wide-type
   littermates, which were characterized by a decreased bone mass. A model
   of distal femoral defect was established, and it was found that cKO mice
   delayed bone defect repair. In osteoblasts derived from PDK-1 cKO mice,
   the alkaline phosphatase (ALP) secretion and ability of calcium
   mineralization were significantly decreased, and the expressions of
   osteoblast-related proteins, runt-related transcription factor 2, OCN,
   and ALP were also clearly decreased. Moreover, the phosphorylation level
   of Akt and downstream factor GSK3 beta and their response to
   insulin-like growth factor-1 (IGF-1) decreased clearly. Therefore, we
   believe that PDK-1 plays a very important role in osteoblast
   differentiation and bone formation by regulating the PDK-1/Akt/GSK3 beta
   signaling pathway.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zong, SH (Corresponding Author), Guangxi Med Univ, Dept Spine Osteopathia, Affiliated Hosp 1, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zeng, GF (Corresponding Author), Guangxi Med Univ, Dept Nutr \& Food Hyg, Coll Publ Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Bai, Yiguang; Shi, Zhuohua; Nong, Haibin; Liu, Mingfu; Zong, Shaohui, Guangxi Med Univ, Dept Spine Osteopathia, Affiliated Hosp 1, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Bai, Yiguang, Nanchong Cent Hosp, Clin Inst 2, Dept Orthopaed, North Sichuan Med Coll, Nanchong, Sichuan, Peoples R China.
   Zhang, Qiong; Zeng, Gaofeng, Guangxi Med Univ, Dept Nutr \& Food Hyg, Coll Publ Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Chen, Qiaoling, Nanchong Cent Hosp, Clin Inst 2, Dept Oncol, North Sichuan Med Coll, Nanchong, Sichuan, Peoples R China.
   Zhou, Quan; Zhang, Yanan, Guangxi Med Univ, Collaborat Innovat Ctr Guangxi Biol Med, Nanning, Guangxi, Peoples R China.
   Zhou, Quan, Mudanjiang Med Univ, Dept Emergency, Hongqi Hosp, Mudanjiang, Heilongjiang, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.},
DOI = {10.1002/jcp.30249},
EarlyAccessDate = {DEC 2020},
ISSN = {0021-9541},
EISSN = {1097-4652},
Keywords = {Akt; bone remodeling; conditional gene knockout; GSK3\&\#946;
   osteoblasts; PDK\&\#8208; 1},
Keywords-Plus = {SIGNALING PATHWAY; KINASE 1; PI3K/AKT; ACTIVATION; GROWTH; MTOR;
   PHOSPHORYLATION; PROLIFERATION; APOPTOSIS},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {1685858372@qq.com
   xiaohui3008@126.com},
Affiliations = {Guangxi Medical University; North Sichuan Medical University; Guangxi
   Medical University; North Sichuan Medical University; Guangxi Medical
   University; Mudanjiang Medical University; Guangxi Medical University;
   Guangxi Medical University},
ResearcherID-Numbers = {yiguang, bai/AAC-7732-2021},
ORCID-Numbers = {yiguang, bai/0000-0002-5656-6199},
Funding-Acknowledgement = {Guangxi Medical High-level Key Talents Training ``139{''} Program
   Training Project; Guangxi Key Research and Development Project
   {[}GuikeAB17195001]; High-Level Innovation Team and Excellence Scholars
   Program of Guangxi High Education Institutions; National Natural Science
   Foundation of China {[}81860402]; Guangxi Natural Science Foundation of
   China {[}2017GXNSFAA198073]},
Funding-Text = {Guangxi Medical High-level Key Talents Training ``139{''} Program
   Training Project; Guangxi Key Research and Development Project,
   Grant/Award Number: Grant no. GuikeAB17195001; High-Level Innovation
   Team and Excellence Scholars Program of Guangxi High Education
   Institutions; National Natural Science Foundation of China, Grant/Award
   Number: Grant no. 81860402; Guangxi Natural Science Foundation of China,
   Grant/Award Number: Grant no. 2017GXNSFAA198073},
Cited-References = {Abuna RPF, 2021, J CELL PHYSIOL, V236, P3906, DOI 10.1002/jcp.30131.
   Boot-Handford RP, 1998, INT J EXP PATHOL, V79, P329, DOI 10.1046/j.1365-2613.1998.790411.x.
   Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0.
   Gao JY, 2020, INT J MOL MED, V45, P647, DOI 10.3892/ijmm.2019.4437.
   Han L, 2021, J OBSTET GYNAECOL RE, V47, P63, DOI 10.1111/jog.14412.
   Ida-Yonemochi H, 2019, J CELL PHYSIOL, V234, P13602, DOI 10.1002/jcp.28039.
   Indran IR, 2016, PHARMACOL THERAPEUT, V162, P188, DOI 10.1016/j.pharmthera.2016.01.015.
   Kilic U, 2017, REDOX BIOL, V12, P657, DOI 10.1016/j.redox.2017.04.006.
   Kim C, 2018, ENDOCR CONNECT, V7, P443, DOI 10.1530/EC-17-0350.
   Kitahara Y, 2004, BONE, V35, P1100, DOI 10.1016/j.bone.2004.06.016.
   Li S, 2017, SCI REP-UK, V7, DOI {[}10.1038/srep40505, 10.1038/srep43956].
   Lin JY, 2020, AGING-US, V12, P6852, DOI 10.18632/aging.103046.
   Linz A, 2015, J BONE MINER RES, V30, P1481, DOI 10.1002/jbmr.2484.
   Liu WQ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12794.
   Liu Y, 2019, AGING-US, V11, P5334, DOI 10.18632/aging.102105.
   Ma P, 2010, METABOLISM, V59, P359, DOI 10.1016/j.metabol.2009.08.003.
   Ma YG, 2021, SCI TOTAL ENVIRON, V750, DOI 10.1016/j.scitotenv.2020.141638.
   Pan JM, 2019, J RECEPT SIG TRANSD, V39, P80, DOI 10.1080/10799893.2019.1625061.
   Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Son KM, 2010, BIOMED MATER, V5, DOI 10.1088/1748-6041/5/4/044107.
   Takarada T, 2013, J BONE MINER RES, V28, P2064, DOI 10.1002/jbmr.1945.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647.
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793.
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677.
   Yamaguchi H, 2020, BIOCHEM BIOPH RES CO, V533, P739, DOI 10.1016/j.bbrc.2020.09.033.
   Yoon JY, 2018, TISSUE ENG REGEN MED, V15, P333, DOI 10.1007/s13770-018-0116-z.
   Zhan JD, 2020, FOOD FUNCT, V11, P7830, DOI {[}10.1039/d0fo00837k, 10.1039/D0FO00837K].
   Zhang JZ, 2016, J BONE MINER RES, V31, P2001, DOI 10.1002/jbmr.2877.
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200.
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205.
   Zhao R, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118044.
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751.},
Number-of-Cited-References = {36},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {J. Cell. Physiol.},
Doc-Delivery-Number = {RI3KP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000603363500001},
DA = {2026-02-04},
}

@article{ WOS:000609477900001,
Author = {Zhang, Chen and Liu, Yang-Wenyi and Chi, Zhangcai and Chen, Bing},
Title = {Ligand-Activated Peroxisome Proliferator-Activated Receptor β/δ
   Facilitates Cell Proliferation in Human Cholesteatoma Keratinocytes},
Journal = {PPAR RESEARCH},
Year = {2020},
Volume = {2020},
Month = {DEC 28},
Abstract = {Cholesteatoma is characterized by both the overgrowth of
   hyperkeratinized squamous epithelium and bone erosion. However, the
   exact mechanism underlying the hyperproliferative ability of
   cholesteatoma remains unknown. In this study, we investigated PPAR
   beta/delta expression in human surgical specimens of cholesteatoma and
   analyzed its functional role as a regulator of epithelial keratinocyte
   hyperproliferation. We found that the expression of PPAR beta/delta was
   significantly upregulated in cholesteatoma and ligand-activated PPAR
   beta/delta markedly promoted the proliferation of cholesteatoma
   keratinocytes. Furthermore, we showed that PPAR beta/delta activation
   increased PDK1 expression and decreased PTEN generation, which led to
   increased phosphorylation of AKT and GSK3 beta and increased the
   expression level of Cyclin D1. Overall, our data suggested that the
   proliferating effect of PPAR beta/delta on the cholesteatoma
   keratinocytes was mediated by the positive regulation of the
   PDK1/PTEN/AKT/GSK3 beta/Cyclin D1 pathway. These findings warranted
   further investigation of PPAR beta/delta as a therapeutic target for
   recurrent or residual cholesteatoma.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Chi, ZC; Chen, B (Corresponding Author), Fudan Univ, ENT Inst, Eye \& ENT Hosp, Shanghai 200031, Peoples R China.
   Chi, ZC; Chen, B (Corresponding Author), Fudan Univ, Dept Otolaryngol, Eye \& ENT Hosp, Shanghai 200031, Peoples R China.
   Chi, ZC; Chen, B (Corresponding Author), Fudan Univ, NHC Key Lab Hearing Med, Shanghai 200031, Peoples R China.
   Zhang, Chen; Liu, Yang-Wenyi; Chi, Zhangcai; Chen, Bing, Fudan Univ, ENT Inst, Eye \& ENT Hosp, Shanghai 200031, Peoples R China.
   Zhang, Chen; Liu, Yang-Wenyi; Chi, Zhangcai; Chen, Bing, Fudan Univ, Dept Otolaryngol, Eye \& ENT Hosp, Shanghai 200031, Peoples R China.
   Zhang, Chen; Liu, Yang-Wenyi; Chi, Zhangcai; Chen, Bing, Fudan Univ, NHC Key Lab Hearing Med, Shanghai 200031, Peoples R China.},
DOI = {10.1155/2020/8864813},
Article-Number = {8864813},
ISSN = {1687-4757},
EISSN = {1687-4765},
Keywords-Plus = {EXPRESSION; DELTA; PTEN},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {17211260019@fudan.edu.cn
   18317086712@163.com
   zhangcai.chi@fdeent.org
   bingchen@fudan.edu.cn},
Affiliations = {Fudan University; Fudan University; Fudan University},
ResearcherID-Numbers = {Liu, Yang/KII-1964-2024},
Funding-Acknowledgement = {Science Project of Shanghai Municipal Health Bureau {[}20174Y0062]},
Funding-Text = {This work was supported by the Science Project of Shanghai Municipal
   Health Bureau (No. 20174Y0062).},
Cited-References = {Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016.
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824.
   Chi ZC, 2015, MOL CELL BIOCHEM, V400, P189, DOI 10.1007/s11010-014-2275-0.
   Di-Poï N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9.
   Gupta M, 2015, ARCH DERMATOL RES, V307, P767, DOI 10.1007/s00403-015-1571-1.
   Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993.
   Hilton CW, 2011, LARYNGOSCOPE, V121, P372, DOI 10.1002/lary.21352.
   Hopkins BD, 2014, TRENDS BIOCHEM SCI, V39, P183, DOI 10.1016/j.tibs.2014.02.006.
   Huisman MA, 2007, ACTA OTO-LARYNGOL, V127, P424, DOI 10.1080/00016480600868430.
   Hwang SJ, 2006, LARYNGOSCOPE, V116, P58, DOI 10.1097/01.mlg.0000184507.49254.f9.
   Kuenzli S, 2003, BRIT J DERMATOL, V149, P229, DOI 10.1046/j.1365-2133.2003.05532.x.
   Peters JM, 2008, CLIN SCI, V115, P107, DOI 10.1042/CS20080022.
   Ruvolo Peter P., 2017, Advances in Biological Regulation, V65, P26, DOI {[}10.1016/j.jbior.2017.05.001, 10.1016/j.jbior.2017.05.001].
   Schraff SA, 2006, INT J PEDIATR OTORHI, V70, P385, DOI 10.1016/j.ijporl.2005.10.006.
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050.
   Server EA, 2019, J INT ADV OTOL, V15, P38, DOI 10.5152/iao.2018.4976.
   Si Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep16683.
   Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103.
   Xie SM, 2017, ACTA OTO-LARYNGOL, V137, P797, DOI 10.1080/00016489.2017.1284343.
   Xie SM, 2016, LARYNGOSCOPE, V126, P1923, DOI 10.1002/lary.25834.
   Yune TY, 2009, ACTA OTO-LARYNGOL, V129, P501, DOI 10.1080/00016480802258802.},
Number-of-Cited-References = {21},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {PPAR Res.},
Doc-Delivery-Number = {PU7JP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000609477900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000603399600018,
Author = {Luo, Yanyan and Jiang, Yunyao and He, Yang and Shen, Ting and Ji, Lilian
   and Li, Fu and Hu, Weicheng},
Title = {Vina-Ginsenoside R4 from Panax ginseng Leaves Alleviates
   6-OHDA-Induced Neurotoxicity in PC12 Cells Via the PI3K/Akt/GSK-3β
   Signaling Pathway},
Journal = {JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY},
Year = {2020},
Volume = {68},
Number = {51},
Pages = {15239-15248},
Month = {DEC 23},
Abstract = {Vina-ginsenoside R4 (VGN4) is the first example of protopanaxatriol
   saponin possessing sugar chains located at C-3 and C-20 of aglycone.
   However, to the best of our knowledge, no report has been published on
   the neuroprotective effect of VGN4. In the present work, we investigated
   the neuroprotective effect of VGN4 against 6-hydroxydopamine
   (6-OHDA)-induced toxicity and its potential mechanism. Pretreatment of
   PC12 cells with VGN4 attenuated 6-OHDA-induced cell damage and cell
   apoptosis, which was correlated with the decrease of reactive oxygen
   species and the increase of antioxidant enzyme activities including
   superoxide dismutase and catalase. In addition, VGN4 markedly decreased
   nuclear translation of the nuclear factor-kappa B and PI3K/Akt/GSK/3
   beta signaling pathway including p85, PDK1, Akt, and GSK-3 beta. Further
   studies revealed that PI3K siRNA attenuated the neuroprotective effect
   of VGN4 on caspase-3 activity. These data indicate that VGN4 might have
   the potential to be developed as a new neuroprotective functional food.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Hu, WC (Corresponding Author), Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Peoples R China.
   Li, F (Corresponding Author), Chinese Acad Sci, Nat Prod Res Ctr, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China.
   Luo, Yanyan; He, Yang; Shen, Ting; Ji, Lilian; Hu, Weicheng, Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Peoples R China.
   Luo, Yanyan; Li, Fu, Chinese Acad Sci, Nat Prod Res Ctr, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China.
   Jiang, Yunyao, Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China.},
DOI = {10.1021/acs.jafc.0c06474},
ISSN = {0021-8561},
EISSN = {1520-5118},
Keywords = {neuroprotection; vina-ginsenoside R4; apoptosis; oxidative stress},
Keywords-Plus = {DAMMARANE-TYPE SAPONINS; B TRANSCRIPTIONAL ACTIVITY; FLOWER BUDS;
   UP-REGULATION; PARKINSONS; ACTIVATION; APOPTOSIS; PROTECTS; INHIBITION;
   INJURY},
Research-Areas = {Agriculture; Chemistry; Food Science \& Technology},
Web-of-Science-Categories  = {Agriculture, Multidisciplinary; Chemistry, Applied; Food Science \&
   Technology},
Author-Email = {lifu@cib.ac.cn
   ha\_weicheng@163.com},
Affiliations = {Huaiyin Normal University; Chinese Academy of Sciences; Chengdu
   Institute of Biology, CAS; Tsinghua University},
ResearcherID-Numbers = {He, Yangzheng/GXW-0786-2022},
Funding-Acknowledgement = {Natural Science Foundation of the Higher Education Institutions of
   Jiangsu Province {[}17KJA550001]},
Funding-Text = {This research was financially supported by the Natural Science
   Foundation of the Higher Education Institutions of Jiangsu Province
   (17KJA550001).},
Cited-References = {Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067.
   Blaszczyk JW, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00269.
   Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682.
   Chang DW, 2002, EMBO J, V21, P3704, DOI 10.1093/emboj/cdf356.
   Chao JF, 2010, J NUTR BIOCHEM, V21, P482, DOI 10.1016/j.jnutbio.2009.02.004.
   Chapple ILC, 1997, J CLIN PERIODONTOL, V24, P287, DOI 10.1111/j.1600-051X.1997.tb00760.x.
   Cho K, 2014, BIOMOL THER, V22, P55, DOI 10.4062/biomolther.2013.096.
   Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383.
   He H, 2015, INFLAMMATION, V38, P2178, DOI 10.1007/s10753-015-0200-7.
   He M, 2018, BIOMED PHARMACOTHER, V106, P747, DOI 10.1016/j.biopha.2018.06.125.
   Hsieh HM, 2011, LIFE SCI, V88, P82, DOI 10.1016/j.lfs.2010.10.021.
   Hu WC, 2016, FOOD FUNCT, V7, P1002, DOI 10.1039/c5fo01212k.
   Islam MT, 2017, NEUROL RES, V39, P73, DOI 10.1080/01616412.2016.1251711.
   Iurlaro R, 2016, FEBS J, V283, P2640, DOI 10.1111/febs.13598.
   Kawamoto Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122144.
   Kermanizadeh A, 2015, ENVIRON MOL MUTAGEN, V56, P111, DOI 10.1002/em.21926.
   Kim HG, 2014, FOOD CHEM TOXICOL, V65, P293, DOI 10.1016/j.fct.2013.12.037.
   Kim JH, 2017, J GINSENG RES, V41, P435, DOI 10.1016/j.jgr.2016.08.004.
   Kiraz Y, 2016, TUMOR BIOL, V37, P8471, DOI 10.1007/s13277-016-5035-9.
   Lee DY, 2015, INT J MOL SCI, V16, P1677, DOI 10.3390/ijms16011677.
   Lee SM, 2015, J GINSENG RES, V39, P384, DOI 10.1016/j.jgr.2015.04.009.
   Li S, 2016, J NEURAL TRANSM, V123, P1279, DOI 10.1007/s00702-016-1603-9.
   Liao KK, 2012, J AGR FOOD CHEM, V60, P433, DOI 10.1021/jf203290r.
   Liu M., 1995, Yaoxue Xuebao, V30, P674.
   Luo YY, 2019, ENVIRON TOXICOL PHAR, V65, P73, DOI 10.1016/j.etap.2018.12.007.
   Marshall KA, 1997, BIOCHEM BIOPH RES CO, V240, P84, DOI 10.1006/bbrc.1997.7604.
   Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836.
   NAGATSU T, 2000, ADV RES NEURODEGENER, P143, DOI DOI 10.1007/9783-70916284-212.
   Nakamura S, 2007, HETEROCYCLES, V71, P577.
   Nguyen M D, 1993, Chem Pharm Bull (Tokyo), V41, P2010.
   Niranjan R, 2014, MOL NEUROBIOL, V49, P28, DOI 10.1007/s12035-013-8483-x.
   Peng SJ, 2017, FOOD FUNCT, V8, P997, DOI 10.1039/c7fo00054e.
   Postuma RB, 2015, MOVEMENT DISORD, V30, P1591, DOI 10.1002/mds.26424.
   Qiu L, 2014, HELV CHIM ACTA, V97, P102, DOI 10.1002/hlca.201300155.
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI {[}10.1016/j.cryobiol.2017.10.064, 10.1016/j.bbamcr.2016.09.012].
   Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x.
   Selkoe DJ, 2004, NAT CELL BIOL, V6, P1054, DOI 10.1038/ncb1104-1054.
   Shi Y, 2013, ACTA PHARMACOL SIN, V34, P1140, DOI 10.1038/aps.2013.59.
   Shin BK, 2015, J GINSENG RES, V39, P287, DOI 10.1016/j.jgr.2014.12.005.
   Song SB, 2012, J GINSENG RES, V36, P146, DOI 10.5142/jgr.2012.36.2.146.
   Sophia J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1126-4.
   Tung NH, 2010, J AGR FOOD CHEM, V58, P868, DOI 10.1021/jf903334g.
   Tung NH, 2009, CHEM PHARM BULL, V57, P1412, DOI 10.1248/cpb.57.1412.
   Um HC, 2011, NITRIC OXIDE-BIOL CH, V25, P161, DOI 10.1016/j.niox.2011.06.001.
   Xiao HB, 2011, TOXICOLOGY, V290, P286, DOI 10.1016/j.tox.2011.10.007.
   Yan MH, 2013, FREE RADICAL BIO MED, V62, P90, DOI 10.1016/j.freeradbiomed.2012.11.014.
   Yang JQ, 2014, PATHOL RES PRACT, V210, P357, DOI 10.1016/j.prp.2014.02.005.
   Yang Y, 2017, AGING DIS, V8, P708, DOI 10.14336/AD.2017.0707.
   Yang YW, 2015, J AGR FOOD CHEM, V63, P10243, DOI 10.1021/acs.jafc.5b04156.
   Yoshizaki K, 2013, CHEM PHARM BULL, V61, P273, DOI 10.1248/cpb.c12-00794.
   Zeng KW, 2010, NEUROPHARMACOLOGY, V59, P542, DOI 10.1016/j.neuropharm.2010.07.020.
   Zhan JM, 2020, CARBOHYD POLYM, V230, DOI 10.1016/j.carbpol.2019.115576.
   Zhang C, 2017, REDOX BIOL, V11, P1, DOI 10.1016/j.redox.2016.10.019.
   Zhang Xinmu, 2016, Am J Neurodegener Dis, V5, P52.
   Zhao D, 2019, BIOMOL THER, V27, P92.
   Zhu TG, 2012, NEUROSCI LETT, V506, P175, DOI 10.1016/j.neulet.2011.10.075.
   Zhu Tingting, 2016, Chinese Journal of Applied and Environmental Biology, V22, P70, DOI {[}10.3724/sp.j.1145.2015.06008, 10.3724/SP.J.1145.2015.06008].},
Number-of-Cited-References = {57},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {31},
Journal-ISO = {J. Agric. Food Chem.},
Doc-Delivery-Number = {PL8YI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000603399600018},
DA = {2026-02-04},
}

@article{ WOS:000605227300001,
Author = {Wang, Lin and Xu, Hai-li and Liang, Jing-wei and Ding, Ying-ying and
   Meng, Fan-hao},
Title = {An Integrated Network, RNA Sequencing, and Experiment Pharmacology
   Approach Reveals the Active Component, Potential Target, and Mechanism
   of Gelsemium elegans in the Treatment of Colorectal Cancer},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2020},
Volume = {10},
Month = {DEC 23},
Abstract = {In this study, a combination of network pharmacology, bioinformatics
   analysis, molecular docking and transcriptomics was used to investigate
   the active ingredient and potential target of Gelsemium elegans in the
   treatment of colorectal cancer. Koumine was screened as the active
   component by targeting PDK1 through network pharmacology and reverse
   docking. RNA-Seq, enrichment analysis and validation experiment were
   then further employed to reveal koumine might function in inhibiting
   Akt/mTOR/HK2 pathway to regulate cell glycolysis and detachment of HK2
   from mitochondria and VDAC-1 to activate cell apoptosis both in vitro
   and in vivo. In the present study, we provide a systematical approach
   for the identification of effective ingredient and potential target of
   herbal medicine. Our results have important implication for the
   intensive study of koumine as novel anticancer agents for colorectal
   cancer and could be supportive in its further structural modification.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Meng, FH (Corresponding Author), China Med Univ, Sch Pharm, Shenyang, Liaoning, Peoples R China.
   Wang, Lin; Xu, Hai-li; Liang, Jing-wei; Ding, Ying-ying; Meng, Fan-hao, China Med Univ, Sch Pharm, Shenyang, Liaoning, Peoples R China.},
DOI = {10.3389/fonc.2020.616628},
Article-Number = {616628},
ISSN = {2234-943X},
Keywords = {Gelsemium elegans; koumine; PDK1; Akt; mTOR; HK2; glycolysis},
Keywords-Plus = {ALKALOIDS; PDK1},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {fhmeng@cmu.edu.cn},
Affiliations = {China Medical University},
ResearcherID-Numbers = {ying, ding/CAJ-3034-2022},
Funding-Acknowledgement = {National Nature Science Foundation of China {[}81703405, 81573687]; Key
   R\&D Projects in Liaoning Province {[}2019026]},
Funding-Text = {This work was supported by the National Nature Science Foundation of
   China (81703405, 81573687). Key R\&D Projects in Liaoning Province
   (2019026).},
Cited-References = {Changou CA, 2021, ONCOLOGIST, V26, pE367, DOI 10.1002/onco.13582.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152.
   Gao X, 2018, J CELL BIOCHEM, V119, P4967, DOI 10.1002/jcb.26742.
   Gill KS, 2016, BBA-REV CANCER, V1866, P87, DOI 10.1016/j.bbcan.2016.06.005.
   Guo ZR, 2017, ACTA PHARM SIN B, V7, P119, DOI 10.1016/j.apsb.2016.06.003.
   Gurunathan S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082269.
   Hu YY, 2013, J ETHNOPHARMACOL, V149, P601, DOI 10.1016/j.jep.2013.07.030.
   Hung YP, 2017, ELIFE, V6, DOI 10.7554/eLife.27293.
   Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9.
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001.
   Jia LJ, 2018, LIFE SCI, V208, P123, DOI 10.1016/j.lfs.2018.07.027.
   Jiang P, 2014, PROTEIN CELL, V5, P592, DOI 10.1007/s13238-014-0082-8.
   Jin GL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00989.
   Jin GL, 2019, J NAT MED-TOKYO, V73, P217, DOI 10.1007/s11418-018-1229-3.
   Jin GL, 2018, NEURAL PLAST, V2018, DOI 10.1155/2018/9347696.
   Jin GL, 2014, J ETHNOPHARMACOL, V152, P33, DOI 10.1016/j.jep.2014.01.003.
   Kitazawa M, 2020, CANCER SCI, V111, P658, DOI 10.1111/cas.14275.
   Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379.
   Li FS, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.109.
   Li LJ, 2015, DRUG DISCOV TODAY, V20, P1074, DOI 10.1016/j.drudis.2015.04.009.
   Li MM, 2020, J CELL MOL MED, V24, P3091, DOI 10.1111/jcmm.14971.
   Liang JW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44538-z.
   Liu M, 2013, PSYCHOPHARMACOLOGY, V225, P839, DOI 10.1007/s00213-012-2867-x.
   Mazure NM, 2017, BBA-BIOENERGETICS, V1858, P665, DOI 10.1016/j.bbabio.2017.03.002.
   Rugo H, 2007, BREAST CANCER RES TR, V105, P17, DOI 10.1007/s10549-006-9430-6.
   Rujjanawate C, 2003, J ETHNOPHARMACOL, V89, P91, DOI 10.1016/S0378-8741(03)00267-8.
   Wang L, 2017, FITOTERAPIA, V120, P131, DOI 10.1016/j.fitote.2017.06.005.
   Wang L, 2018, MOLECULES, V23, DOI 10.3390/molecules23071693.
   Xu ZL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0645-4.
   Yao H, 2017, EXPERT OPIN DRUG DIS, V12, P121, DOI 10.1080/17460441.2016.1272757.
   Yuan ZH, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100559.
   Yuan ZH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030430.
   Zhang XH, 2015, CELL BIOCHEM BIOPHYS, V72, P411, DOI 10.1007/s12013-014-0479-2.},
Number-of-Cited-References = {34},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {33},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {PO5RV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000605227300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000600832800014,
Author = {Hou, Tianliang and Ma, Haiping and Wang, Haixia and Chen, Chunling and
   Ye, Jianrong and Ahmed, Ahmed Mohamed and Zheng, Hong},
Title = {Sevoflurane preconditioning attenuates hypoxia/reoxygenation injury of
   H9c2 cardiomyocytes by activation of the HIF-1/PDK-1 pathway},
Journal = {PEERJ},
Year = {2020},
Volume = {8},
Month = {DEC 21},
Abstract = {Background. Sevoflurane preconditioning (SPC) can provide myocardial
   protective effects similar to ischemic preconditioning (IPC). However,
   the underlying molecular mechanism of SPC remains unclear. Studies
   confirm that hypoxia-inducible factor-1 (HIF-1) can transform cells from
   aerobic oxidation to anaerobic glycolysis by activating the switch
   protein pyruvate dehydrogenase kinase-1 (PDK-1), thus providing energy
   for the normal life activities of cells under hypoxic conditions. The
   purpose of this study was to investigate whether the cardioprotective
   effects of SPC are associated with activation of the HIF-1a/PDK-1 signal
   pathway.
   Methods. The H9c2 cardiomyocytes hypoxia/reoxygenation model was
   established and treated with 2.4\% sevoflurane at the end of
   equilibration. Lactate dehydrogenase (LDH) level, cell viability, cell
   apoptosis, mitochondrial membrane potential, key enzymes of glycolysis,
   ATP concentration of glycolysis were assessed after the intervention.
   Apoptosis related protein(Bcl-2, Bax), HIF-1a protein, and PDK-1 protein
   were assessed by western blot.
   Results. Compared with the H/R group, SPC significantly increased the
   expression of HIF-1a, PDK-1, and Bcl-2 and reduced the protein
   expression of Bax, which markedly decreased the apoptosis ratio and
   Lactate dehydrogenase (LDH) level, increasing the cell viability,
   content of key enzymes of glycolysis, ATP concentration of glycolysis
   and stabilizing the mitochondrial membrane potential. However, the
   cardioprotective effects of SPC were disappeared by treatment with a
   HIF- 1a selective inhibitor.
   Conclusion. This study demonstrates that the cardioprotective effects of
   SPC are associated with the activation of the HIF-1a/PDK-1 signaling
   pathway. The mechanism may be related to increasing the content of key
   enzymes and ATP of glycolysis in the early stage of hypoxia.},
Publisher = {PEERJ INC},
Address = {341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Ye, JR; Zheng, H (Corresponding Author), Xinjiang Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Ummqi, Xinjiang, Peoples R China.
   Hou, Tianliang; Ma, Haiping; Chen, Chunling; Ye, Jianrong; Zheng, Hong, Xinjiang Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Ummqi, Xinjiang, Peoples R China.
   Wang, Haixia, Xinjiang Maternal \& Child Hlth Hosp, Dept Mastol, Urumqi, Xinjiang, Peoples R China.
   Ahmed, Ahmed Mohamed, Yardimeli Hosp, Dept Intens Care Unit ICU, Mogadishu, Somalia.},
DOI = {10.7717/peerj.10603},
Article-Number = {e10603},
ISSN = {2167-8359},
Keywords = {Sevoflurane preconditioning; Myocardial protective effect;
   Hypoxia-inducible factor-1; Glycolysis; Hypoxia/reoxygenation injury;
   Pyruvate dehydrogenase kinase-1},
Keywords-Plus = {MITOCHONDRIAL PERMEABILITY TRANSITION; PYRUVATE-DEHYDROGENASE COMPLEX;
   GLUCOSE-OXIDATION; CARDIOPROTECTION; GLYCOLYSIS; HEARTS; METABOLISM;
   MECHANISMS; EXPRESSION; HYPOXIA},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {616227972@qq.com
   xj\_zhenghong@sina.com},
Affiliations = {Xinjiang Medical University},
ResearcherID-Numbers = {hou, tianliang/PAU-4558-2025},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81660522]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. U1603129) and the National Natural Science Foundation of
   China (No. 81660522). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.},
Cited-References = {Akram M, 2013, J CANCER EDUC, V28, P454, DOI 10.1007/s13187-013-0486-9.
   Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A.
   Dang Yong-ming, 2005, Zhonghua Shao Shang Za Zhi, V21, P339.
   De Hert SG, 2004, ANESTHESIOLOGY, V101, P299, DOI 10.1097/00000542-200408000-00009.
   Devereaux PJ, 2017, JAMA-J AM MED ASSOC, V317, P1642, DOI 10.1001/jama.2017.4360.
   Eckle T, 2008, CIRCULATION, V118, P166, DOI 10.1161/CIRCULATIONAHA.107.758516.
   Guo H, 2017, PEERJ, V5, DOI 10.7717/peerj.3662.
   Halestrap AP, 2015, J MOL CELL CARDIOL, V78, P129, DOI 10.1016/j.yjmcc.2014.08.018.
   Heusch G, 2013, LANCET, V381, P166, DOI 10.1016/S0140-6736(12)60916-7.
   Holness MJ, 2003, BIOCHEM SOC T, V31, P1143.
   ITOI T, 1993, PEDIATR RES, V34, P735, DOI 10.1203/00006450-199312000-00008.
   Kolwicz SC, 2013, CIRC RES, V113, P603, DOI 10.1161/CIRCRESAHA.113.302095.
   Kunst G, 2015, ANAESTHESIA, V70, P467, DOI 10.1111/anae.12975.
   Li WL, 2018, BIOMED PHARMACOTHER, V102, P153, DOI 10.1016/j.biopha.2018.03.002.
   Lopaschuk GD, 2010, PHYSIOL REV, V90, P207, DOI 10.1152/physrev.00015.2009.
   Lucchinetti E, 2018, ANESTH ANALG, V126, P1739, DOI 10.1213/ANE.0000000000002676.
   Guerrero-Orriach JL, 2017, DRUG DES DEV THER, V11, P837, DOI 10.2147/DDDT.S127916.
   Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155.
   Obal D, 2005, ANESTH ANALG, V101, P1252, DOI 10.1213/01.ANE.0000181336.96511.32.
   Prabhakar NR, 2015, PHYSIOLOGY, V30, P340, DOI 10.1152/physiol.00022.2015.
   Qian B, 2018, DRUG DES DEV THER, V12, P769, DOI 10.2147/DDDT.S162577.
   Ritterhoff J, 2017, CARDIOVASC RES, V113, P411, DOI 10.1093/cvr/cvx017.
   Semenza GL, 2011, NEW ENGL J MED, V365, P537, DOI 10.1056/NEJMc1110602.
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009.
   Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002.
   Taegtmeyer H, 2004, ANN NY ACAD SCI, V1015, P202, DOI 10.1196/annals.1302.017.
   Teng M, 2010, AM J PHYSIOL-HEART C, V298, pH1919, DOI 10.1152/ajpheart.01039.2009.
   VOLKER KW, 1995, COMP BIOCHEM PHYS B, V112, P503, DOI 10.1016/0305-0491(95)00096-8.
   Wei J, 2017, MOL THER-NUCL ACIDS, V9, P428, DOI 10.1016/j.omtn.2017.10.020.
   Wu JJ, 2017, PEERJ, V5, DOI 10.7717/peerj.3196.
   Xie N, 2015, AM J RESP CRIT CARE, V192, P1462, DOI 10.1164/rccm.201504-0780OC.
   Yang L, 2019, PEERJ, V7, DOI 10.7717/peerj.7165.
   Yu J, 2016, PEERJ, V4, DOI 10.7717/peerj.2659.
   Zhang FJ, 2012, SHOCK, V37, P485, DOI 10.1097/SHK.0b013e318249b7b6.},
Number-of-Cited-References = {34},
Times-Cited = {19},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {11},
Journal-ISO = {PeerJ},
Doc-Delivery-Number = {PI1BA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000600832800014},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000591143600001,
Author = {Jiang, Yao and Xin, Xiaoping and Pan, Xiangchun and Zhang, Ailing and
   Zhang, Zhe and Li, Jiaqi and Yuan, Xiaolong},
Title = {STAT4 targets KISS1 to promote the apoptosis of ovarian granulosa
   cells},
Journal = {JOURNAL OF OVARIAN RESEARCH},
Year = {2020},
Volume = {13},
Number = {1},
Month = {DEC 20},
Abstract = {Background In mammals, it is known that the estradiol-17 beta (E2) is
   mainly synthetized in ovarian granulosa cells (GCs), and the excessive
   apoptosis of GCs induces the follicular atresia. Many studies have
   implicated the essential role of KISS1, with the pro-synthetic effect of
   E2 and the anti-apoptotic effect on GCs, in the mammalian
   folliculogenesis, and several STAT4 potential binding sites were
   previously predicted on the promoter of KISS1 in pigs. However, the
   biological effects of STAT4 on GCs and the molecular regulation between
   STAT4 and KISS1 remained largely unknown. Methods Using the porcine GCs
   as the cellular model, the overexpression plasmid, small interfering
   RNA, 5 `-deletion and luciferase assay were applied to investigate the
   molecular mechanisms for STAT4 regulating the expression of KISS1.
   Results In this study, the STAT4 negatively regulated the mRNA and
   protein levels of KISS1 in porcine GCs, and the mRNA level of STAT4 was
   observed to significantly decrease from immature to mature follicles,
   which was inversed with that of KISS1. The relative luciferase activity
   of KISS1 promoter was significantly increased with deletion of the
   fourth potential binding site (- 305/- 295), and ChIP further confirmed
   that the STAT4 bound at - 305/- 295 region of KISS1. Besides, the STAT4
   significantly regulated the mRNA levels of PDK1, FOXO3 and TSC2 of PI3K
   signaling pathway to promote the cell apoptosis and the percentage of
   cells at G0/G1 phase of cell cycle in GCs. Alternatively, the STAT4
   significantly decreased the mRNA levels of CYP17, 3B-HSD, 17B-33 HSD,
   ESR1, and ESR2, as well as the concentration of E2 in GCs. Furthermore,
   interfering with the expression of STAT4 was observed to significantly
   stimulate the pro-synthetic effect of E2 and anti-apoptotic effect of
   KISS1 in GCs. Conclusions Collectively, the STAT4 might directly target
   at - 305/- 295 region of KISS1 to negatively regulate the transcription
   of KISS1, promote the cell apoptosis via PI3K signaling pathway,
   suppress the synthesis of E2 through the estrogen signaling pathway in
   porcine GCs. These proposed works could provide useful insight in
   further investigations on the molecular functionalities of STAT4 and
   KISS1 in the folliculogenesis of mammals.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Li, JQ; Yuan, XL (Corresponding Author), South China Agr Univ, Guangdong Prov Key Lab Agroanim Genom \& Mol Breed, Natl Engn Res Ctr Breeding Swine Ind, Coll Anim Sci, Guangzhou, Guangdong, Peoples R China.
   Jiang, Yao; Xin, Xiaoping; Pan, Xiangchun; Zhang, Zhe; Li, Jiaqi; Yuan, Xiaolong, South China Agr Univ, Guangdong Prov Key Lab Agroanim Genom \& Mol Breed, Natl Engn Res Ctr Breeding Swine Ind, Coll Anim Sci, Guangzhou, Guangdong, Peoples R China.
   Jiang, Yao; Yuan, Xiaolong, Guangdong Lab Anim Monitoring Inst, Guangdong Prov Key Lab Lab Anim, Guangzhou, Guangdong, Peoples R China.
   Zhang, Ailing, Guangdong Univ Educ, Ctr Appl Ecol \& Ecol Engn Univ, Coll Biol \& Food Engn Dev, Guangzhou 510303, Peoples R China.},
DOI = {10.1186/s13048-020-00741-5},
Article-Number = {135},
EISSN = {1757-2215},
Keywords = {STAT4; KISS1; Cell apoptosis; Synthesis of E2; Ovarian granulosa cells},
Keywords-Plus = {FOLLICULAR-GROWTH; GENE-EXPRESSION; FSH; STEROIDOGENESIS; RECEPTOR;
   KINASE; TRANSDUCER; KISSPEPTIN; FOLLICLES; ACTIVATOR},
Research-Areas = {Reproductive Biology},
Web-of-Science-Categories  = {Reproductive Biology},
Author-Email = {jqli@scau.edu.cn
   yxl@scau.du.cn},
Affiliations = {South China Agricultural University; Guangdong University of Education},
ResearcherID-Numbers = {zhang, ailing/KJL-5844-2024
   Xin, Xiaoping/ACJ-8703-2022},
Funding-Acknowledgement = {National Key R\&D Program of China {[}2018YFD0501200]; Youth Innovative
   fund of Guangdong Education Department {[}2018KQNCX019]; Special Fund
   for Science and Technology Innovation of Guangdong Province
   {[}2018B020203003]; Natural Science Foundation of Guangdong Province
   {[}2019A1515010676]; earmarked fund for China Agriculture Research
   System {[}CARS-35]},
Funding-Text = {This research was funded by National Key R\&D Program of China
   (2018YFD0501200), the Youth Innovative fund of Guangdong Education
   Department (2018KQNCX019), the Special Fund for Science and Technology
   Innovation of Guangdong Province (2018B020203003), the Natural Science
   Foundation of Guangdong Province (2019A1515010676), and the earmarked
   fund for China Agriculture Research System (CARS-35).},
Cited-References = {Adhikari D, 2009, MOL HUM REPROD, V15, P765, DOI 10.1093/molehr/gap092.
   Almeida CP, 2018, CELL BIOL INT, V42, P1276, DOI 10.1002/cbin.11036.
   Basini G, 2018, THERIOGENOLOGY, V115, P1, DOI 10.1016/j.theriogenology.2018.04.006.
   Blasco V, 2019, J ASSIST REPROD GEN, V36, P113, DOI 10.1007/s10815-018-1338-7.
   Bourguignon JP, 2012, ENDOCR DEV, V22, P11, DOI 10.1159/000326624.
   Cao XH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00512.
   Castellano JM, 2006, ENDOCRINOLOGY, V147, P4852, DOI 10.1210/en.2006-0117.
   Chou CH, 2018, VITAM HORM, V107, P155, DOI 10.1016/bs.vh.2018.01.013.
   Cielesh ME, 2017, REPROD DOMEST ANIM, V52, P24, DOI 10.1111/rda.12841.
   Colledge WH, 2009, PEPTIDES, V30, P34, DOI 10.1016/j.peptides.2008.05.006.
   CONLEY AJ, 1994, BIOL REPROD, V51, P655, DOI 10.1095/biolreprod51.4.655.
   Rodrigues NPD, 2019, ARCH GYNECOL OBSTET, V300, P1423, DOI 10.1007/s00404-019-05307-5.
   Depalo R, 2009, REPROD BIOMED ONLINE, V19, P808, DOI 10.1016/j.rbmo.2009.09.024.
   Dobrian AD, 2015, J ENDOCRINOL, V227, P13, DOI 10.1530/JOE-15-0098.
   Douville G, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-50.
   Fragouli E, 2014, HUM REPROD UPDATE, V20, P1, DOI 10.1093/humupd/dmt044.
   Garg D, 2016, REPROD BIOL ENDOCRIN, V14, DOI 10.1186/s12958-016-0205-6.
   Gasperin BG, 2015, THERIOGENOLOGY, V83, P353, DOI 10.1016/j.theriogenology.2014.09.026.
   Hall SE, 2018, REPROD FERT DEVELOP, V30, P624, DOI 10.1071/RD17024.
   Hannesdóttir L, 2012, INT J DEV BIOL, V56, P279, DOI 10.1387/ijdb.113397lh.
   Hasegawa T, 2017, J STEROID BIOCHEM, V172, P160, DOI 10.1016/j.jsbmb.2017.07.002.
   Hennet ML, 2012, INT J DEV BIOL, V56, P819, DOI 10.1387/ijdb.120133cc.
   Hu CL, 2004, MOL ENDOCRINOL, V18, P326, DOI 10.1210/me.2003-0178.
   Ieda N, 2014, J REPROD DEVELOP, V60, P312, DOI 10.1262/jrd.2013-129.
   Ilha GF, 2015, REPRODUCTION, V150, P395, DOI 10.1530/REP-15-0026.
   Khan MIUR, 2016, REPROD FERT DEVELOP, V28, P795, DOI 10.1071/RD14089.
   Khristi V, 2018, MOL CELL ENDOCRINOL, V474, P214, DOI 10.1016/j.mce.2018.03.012.
   Koch MA, 2012, IMMUNITY, V37, P501, DOI 10.1016/j.immuni.2012.05.031.
   Králícková M, 2020, ARCH GYNECOL OBSTET, V301, P1, DOI 10.1007/s00404-019-05358-8.
   Lapatto R, 2007, ENDOCRINOLOGY, V148, P4927, DOI 10.1210/en.2007-0078.
   Li Q, 2013, MOL ENDOCRINOL, V27, P1468, DOI 10.1210/me.2013-1082.
   Li SS, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170650.
   Lin PF, 2010, MOL REPROD DEV, V77, P670, DOI 10.1002/mrd.21202.
   Liu ZL, 2013, MOL ENDOCRINOL, V27, P238, DOI 10.1210/me.2012-1296.
   Lomniczi A, 2015, FRONT NEUROENDOCRIN, V36, P90, DOI 10.1016/j.yfrne.2014.08.003.
   Lomniczi A, 2013, NAT NEUROSCI, V16, P281, DOI 10.1038/nn.3319.
   Lv L, 2008, ARCH MED RES, V39, P582, DOI 10.1016/j.arcmed.2008.06.001.
   Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176.
   Matsuda F, 2012, J REPROD DEVELOP, V58, P44, DOI 10.1262/jrd.2011-012.
   Michalovic L, 2018, MOL REPROD DEV, V85, P909, DOI 10.1002/mrd.23066.
   Nejad SZ, 2017, INT J ENDOCRINOL MET, V15, DOI 10.5812/ijem.44337.
   Owens LA, 2018, HUM REPROD, V33, P292, DOI 10.1093/humrep/dex357.
   Reddy P, 2009, HUM MOL GENET, V18, P2813, DOI 10.1093/hmg/ddp217.
   Robker RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101182.
   Saatcioglu HD, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006215.
   Schams D, 2002, DOMEST ANIM ENDOCRIN, V23, P53, DOI 10.1016/S0739-7240(02)00145-5.
   Shahed A, 2009, MOL REPROD DEV, V76, P444, DOI 10.1002/mrd.20972.
   Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159.
   Tanyapanyachon P, 2018, THERIOGENOLOGY, V117, P40, DOI 10.1016/j.theriogenology.2018.05.019.
   Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622.
   Valdez KE, 2005, MOL CELL ENDOCRINOL, V243, P66, DOI 10.1016/j.mce.2005.09.004.
   Vetvicka V, 2016, ARCH GYNECOL OBSTET, V294, P897, DOI 10.1007/s00404-016-4195-6.
   Wang Yaming, 2012, JAKSTAT, V1, P23, DOI 10.4161/jkst.19418.
   Wen LH, 2006, REPRODUCTION, V132, P511, DOI 10.1530/rep.1.01055.
   Xin XP, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9020054.
   Yuan XL, 2018, IN VITRO CELL DEV-AN, V54, P715, DOI 10.1007/s11626-018-0292-0.
   Yuan XL, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060295.
   Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660.
   Zhang Z, 2020, CANCER LETT, V469, P54, DOI 10.1016/j.canlet.2019.10.021.
   Zheng WJ, 2012, MOL CELL ENDOCRINOL, V356, P24, DOI 10.1016/j.mce.2011.05.027.
   Zhou JL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103515.
   Zhuo Y, 2014, NUTRITION, V30, P890, DOI 10.1016/j.nut.2013.12.019.
   {[}No title captured].},
Number-of-Cited-References = {63},
Times-Cited = {15},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {J. Ovarian Res.},
Doc-Delivery-Number = {OT9FQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000591143600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000603370500001,
Author = {Atas, Emine and Oberhuber, Monika and Kenner, Lukas},
Title = {The Implications of PDK1-4 on Tumor Energy Metabolism, Aggressiveness
   and Therapy Resistance},
Journal = {FRONTIERS IN ONCOLOGY},
Year = {2020},
Volume = {10},
Month = {DEC 15},
Abstract = {A metabolic shift from oxidative phosphorylation (OXPHOS) to
   glycolysis-known as the Warburg effect-is characteristic for many
   cancers. It gives the cancer cells a survival advantage in the hypoxic
   tumor microenvironment and protects them from cytotoxic effects of
   oxidative damage and apoptosis. The main regulators of this metabolic
   shift are the pyruvate dehydrogenase complex and pyruvate dehydrogenase
   kinase (PDK) isoforms 1-4. PDK is known to be overexpressed in several
   cancers and is associated with bad prognosis and therapy resistance.
   Whereas the expression of PDK1-3 is tissue specific, PDK4 expression is
   dependent on the energetic state of the whole organism. In contrast to
   other PDK isoforms, not only oncogenic, but also tumor suppressive
   functions of PDK4 have been reported. In tumors that profit from high
   OXPHOS and high de novo fatty acid synthesis, PDK4 can have a protective
   effect. This is the case for prostate cancer, the most common cancer in
   men, and makes PDK4 an interesting therapeutic target. While most work
   is focused on PDK in tumors characterized by high glycolytic activity,
   little research is devoted to those cases where PDK4 acts protective and
   is therefore highly needed.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Kenner, L (Corresponding Author), Med Univ Vienna, Dept Pathol, Vienna, Austria.
   Kenner, L (Corresponding Author), CBmed Ctr Biomarker Res Med GmbH, Area Data \& Technol, Graz, Austria.
   Kenner, L (Corresponding Author), Univ Vet Med Vienna, Unit Pathol Lab Anim, Vienna, Austria.
   Kenner, L (Corresponding Author), Med Univ Vienna, Dept Biomed Imaging \& Image Guided Therapy, Div Nucl Med, Christian Doppler Lab Appl Metabol CDL AM, Vienna, Austria.
   Atas, Emine; Oberhuber, Monika; Kenner, Lukas, Med Univ Vienna, Dept Pathol, Vienna, Austria.
   Oberhuber, Monika; Kenner, Lukas, CBmed Ctr Biomarker Res Med GmbH, Area Data \& Technol, Graz, Austria.
   Kenner, Lukas, Univ Vet Med Vienna, Unit Pathol Lab Anim, Vienna, Austria.
   Kenner, Lukas, Med Univ Vienna, Dept Biomed Imaging \& Image Guided Therapy, Div Nucl Med, Christian Doppler Lab Appl Metabol CDL AM, Vienna, Austria.},
DOI = {10.3389/fonc.2020.583217},
Article-Number = {583217},
ISSN = {2234-943X},
Keywords = {pyruvate dehydrogenase kinase; tricarboxylic acid cycle; oxidative
   phosphorylation; Warburg effect; aerobic glycolysis; prostate cancer;
   cancer metabolism; therapy resistance},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; POOR-PROGNOSIS; GASTRIC-CANCER; PDK4;
   INCREASES; DICHLOROACETATE; PHOSPHORYLATION; TRANSCRIPTION; LIPOGENESIS;
   INHIBITION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {lukas.kenner@meduniwien.ac.at},
Affiliations = {Medical University of Vienna; University of Veterinary Medicine Vienna;
   Medical University of Vienna},
ORCID-Numbers = {Atas, Emine/0009-0000-3720-1461
   Kenner, Lukas/0000-0003-2184-1338
   Oberhuber, Monika/0000-0002-5691-3605},
Funding-Acknowledgement = {Austrian Science Fund (FWF): IPPTO project {[}DOC 59-B33]; COMET
   Competence Center CBmed-Center for Biomarker Research in Medicine
   {[}FA791A0906]; Austrian Federal Ministry for Transport, Innovation and
   Technology (BMVIT); Austrian Federal Ministry for Digital and Economic
   Affairs (BMDW); Land Steiermark (Department 12, Business and
   Innovation); Styrian Business Promotion Agency (SFG); Vienna Business
   Agency; FWF {[}P26011]; Christian Doppler Lab for Applied Metabolomics;
   Austrian Federal Ministry for Transport, Innovation and Technology;
   National Foundation for Research, Technology and Development},
Funding-Text = {EA and LK are funded by the Austrian Science Fund (FWF): IPPTO project
   number DOC 59-B33. MO and LK were funded by the COMET Competence Center
   CBmed-Center for Biomarker Research in Medicine (FA791A0906. FFG). The
   COMET Competence Center CBmed is funded by the Austrian Federal Ministry
   for Transport, Innovation and Technology (BMVIT); the Austrian Federal
   Ministry for Digital and Economic Affairs (BMDW); Land Steiermark
   (Department 12, Business and Innovation); the Styrian Business Promotion
   Agency (SFG); and the Vienna Business Agency. The COMET program is
   executed by the FFG. LK was in addition funded by the FWF grant P26011
   and the Christian Doppler Lab for Applied Metabolomics. The financial
   support by the Austrian Federal Ministry for Transport, Innovation and
   Technology and the National Foundation for Research, Technology and
   Development is gratefully acknowledged.},
Cited-References = {Bhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422.
   Chen JJ, 2018, NAT GENET, V50, P219, DOI 10.1038/s41588-017-0026-3.
   Choiniere J, 2017, MOL PHARMACOL, V91, P189, DOI 10.1124/mol.116.106757.
   Connaughton S, 2010, MOL CELL ENDOCRINOL, V315, P159, DOI 10.1016/j.mce.2009.08.011.
   Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215.
   Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17.
   Cui LZ, 2020, CANCER GENE THER, V27, P15, DOI 10.1038/s41417-018-0071-9.
   Cutruzzolà F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00097.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   Duan XL, 2020, TOXICOL IN VITRO, V62, DOI 10.1016/j.tiv.2019.104693.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Eidelman E, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00131.
   Fan J, 2014, MOL CELL, V53, P534, DOI 10.1016/j.molcel.2013.12.026.
   Fendt SM, 2013, CANCER RES, V73, P4429, DOI 10.1158/0008-5472.CAN-13-0080.
   Feng L, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190654.
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2.
   Grunt TW, 2018, TRENDS ENDOCRIN MET, V29, P86, DOI 10.1016/j.tem.2017.11.003.
   Guda MR, 2018, AM J CANCER RES, V8, P1725.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   He ZY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0564-3.
   Hirschey MD, 2015, SEMIN CANCER BIOL, V35, pS129, DOI 10.1016/j.semcancer.2015.10.002.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979.
   Klyuyeva A, 2019, J BIOL CHEM, V294, P838, DOI 10.1074/jbc.RA118.006433.
   Kolobova E, 2001, REGULATION PYRUVATE, V9, P69, DOI {[}10.1042/0264-6021:3580069, DOI 10.1042/0264-6021:3580069].
   Latonen L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03573-6.
   Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38.
   Lee IK, 2014, DIABETES METAB J, V38, P181, DOI 10.4093/dmj.2014.38.3.181.
   Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265.
   Liang Y, 2020, ONCOGENE, V39, P469, DOI 10.1038/s41388-019-1035-8.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028.
   Martínez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3.
   Masisi BK, 2020, HISTOPATHOLOGY, V76, P498, DOI 10.1111/his.14014.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Oberhuber M, 2020, THESIS.
   Oberhuber M, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199247.
   Orang AV, 2019, MOL METAB, V23, P98, DOI 10.1016/j.molmet.2019.01.014.
   Park BY, 2018, DIABETES, V67, P2054, DOI 10.2337/db17-1529.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Peng F, 2018, ONCOGENE, V37, P1119, DOI 10.1038/onc.2017.407.
   Pin F, 2019, FASEB J, V33, P7778, DOI 10.1096/fj.201802799R.
   Qian Y, 2020, BRAZ J MED BIOL RES, V53, DOI {[}10.1590/1414-431X20209330, 10.1590/1414-431x20209330].
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Qin WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49480-8.
   Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023.
   Sanmai S, 2019, ONCOL LETT, V17, P5275, DOI 10.3892/ol.2019.10185.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Shan CL, 2014, J BIOL CHEM, V289, P21413, DOI 10.1074/jbc.M114.581124.
   Siu MKY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0209-0.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Strowitzki MJ, 2019, BRIT J CANCER, V120, P675, DOI 10.1038/s41416-019-0406-9.
   Sun H, 2017, ONCOTARGET, V8, P52642, DOI 10.18632/oncotarget.16991.
   Sun WY, 2009, CLIN CANCER RES, V15, P476, DOI 10.1158/1078-0432.CCR-08-0930.
   Sun Y, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-20.
   Swinnen JV, 2002, INT J CANCER, V98, P19, DOI 10.1002/ijc.10127.
   Tao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071997.
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079.
   Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039.
   Walter W, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1444-2.
   Wang JH, 2019, CANCER MANAG RES, V11, P251, DOI 10.2147/CMAR.S185015.
   Wang L, 2012, ACTA PHYSIOL, V204, P525, DOI 10.1111/j.1748-1716.2011.02354.x.
   Wang LY, 2016, CELL REP, V16, P3016, DOI 10.1016/j.celrep.2016.08.018.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Woolbright BL, 2019, MOL CANCER THER, V18, P1673, DOI 10.1158/1535-7163.MCT-19-0079.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Wu JG, 2018, HEPATOLOGY, V68, P1111, DOI 10.1002/hep.29902.
   Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946.
   Xie ZC, 2019, AM J TRANSL RES, V11, P4922.
   Xu JY, 2019, THERANOSTICS, V9, P2999, DOI 10.7150/thno.31301.
   Xuan Y, 2014, EXP CELL RES, V321, P219, DOI 10.1016/j.yexcr.2013.12.009.
   Xue YN, 2019, CANCER MED-US, V8, P2462, DOI 10.1002/cam4.2130.
   Yang C, 2019, J CANCER, V10, P918, DOI 10.7150/jca.27226.
   Yang RH, 2018, MEDCHEMCOMM, V9, P1843, DOI 10.1039/c8md00453f.
   Yu QF, 2020, CELL BIOL INT, V44, P117, DOI 10.1002/cbin.11207.
   Zadra G, 2019, P NATL ACAD SCI USA, V116, P631, DOI 10.1073/pnas.1808834116.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.
   Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.},
Number-of-Cited-References = {87},
Times-Cited = {79},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {25},
Journal-ISO = {Front. Oncol.},
Doc-Delivery-Number = {PL8ND},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000603370500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000600633600009,
Author = {Li, Tiao and Fanning, Kristen V. and Nyunoya, Toru and Chen, Yan and
   Zou, Chunbin},
Title = {Cigarette smoke extract induces airway epithelial cell death via
   repressing PRMT6/AKT signaling},
Journal = {AGING-US},
Year = {2020},
Volume = {12},
Number = {23},
Pages = {24301-24317},
Month = {DEC 15},
Abstract = {Chronic obstructive pulmonary disease (COPD) is a severe public health
   threat world-wide. Cigarette smoke (CS)-induced airway epithelial cell
   death is a major pathway of pathogenesis in emphysema, a subtype of
   COPD. Protein arginine methyltransferase 6 (PRMT6) is a type I PRMT that
   catalyzes monoand di-methylation on arginine residues within histone and
   non-histone proteins to modulate a variety of life processes, such as
   apoptosis. However, its role in CS-induced lung epithelial death has not
   been fully elucidated. Here we report that PRMT6 was decreased in mouse
   lung tissues from a cigarette smoke extract (CSE)-mediated experimental
   emphysematous model and in CSE treated or cigarette smoke exposed lung
   epithelial cells. Depletion of PRMT6 increased the protein levels of
   phosphatase PTEN and PI3K regulatory subunit p85 but decreased a
   downstream kinase PDK1, resulting in AKT dephosphorylation and
   thereafter, lung epithelial cell death. Knockout of PRMT6 inhibited
   epithelial survival and promoted CSE-mediated epithelial cell death,
   while ectopic expression of PRMT6 protein partially reversed epithelial
   cell death via PI3K/AKT-mediated cell survival signaling in CSE cellular
   models. These findings demonstrate that PRMT6 plays a crucial role in
   CS-induced bronchial epithelial cell death that may be a potential
   therapeutic target against the airway cell death in CS-induced COPD.},
Publisher = {IMPACT JOURNALS LLC},
Address = {6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA},
Type = {Article},
Language = {English},
Affiliation = {Chen, Y (Corresponding Author), Cent South Univ, Xiangya Hosp 2, Dept Pulm \& Crit Care Med, Changsha 410011, Hunan, Peoples R China.
   Chen, Y; Zou, CB (Corresponding Author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy \& Crit Care Med, Pittsburgh, PA 15213 USA.
   Li, Tiao; Chen, Yan, Cent South Univ, Xiangya Hosp 2, Dept Pulm \& Crit Care Med, Changsha 410011, Hunan, Peoples R China.
   Li, Tiao; Fanning, Kristen V.; Nyunoya, Toru; Chen, Yan; Zou, Chunbin, Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy \& Crit Care Med, Pittsburgh, PA 15213 USA.},
ISSN = {1945-4589},
Keywords = {cigarette smoke; cell death; lung epithelia; PRMT6; PI3K/AKT},
Keywords-Plus = {PROTEIN ARGININE METHYLTRANSFERASES; CORTICOSTEROID RESISTANCE; INNATE
   IMMUNE; SENESCENCE; METHYLATION; PATHOGENESIS; EMPHYSEMA; COPD;
   OVEREXPRESSION; PHOSPHATASE},
Research-Areas = {Cell Biology; Geriatrics \& Gerontology},
Web-of-Science-Categories  = {Cell Biology; Geriatrics \& Gerontology},
Author-Email = {chenyan99727@csu.edu.cn
   zouc@upmc.edu},
Affiliations = {Central South University; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh},
ResearcherID-Numbers = {NYUNOYA, TORU/AAX-1482-2021
   Zou, Chunbin/L-7488-2019},
Funding-Acknowledgement = {National Institutes of Health {[}HL125435, HL142997]; National Science
   Foundation of China {[}81270100, 81873410]; National Key Clinical
   Specialty Construction Projects of China; Fundamental Research Funds for
   the Central Universities of Central South University {[}2018zzts046];
   NIH {[}HL149719]; U.S. Department of Veterans Affairs (VA) Office of
   Research and Development, Biomedical Laboratory Research and Development
   VA Merit Review award {[}CX000105]; National Heart Lung and Blood
   Institute {[}R01HL142997] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported, in part, by National Institutes of Health R01
   grants HL125435 and HL142997 (to CZ); the National Science Foundation of
   China grants No. 81270100 and No. 81873410 (to YC); the National Key
   Clinical Specialty Construction Projects of China and the Fundamental
   Research Funds for the Central Universities of Central South University
   2018zzts046 (to TL), and NIH R01 grant HL149719 and the U.S. Department
   of Veterans Affairs (VA) Office of Research and Development, Biomedical
   Laboratory Research and Development VA Merit Review award (CX000105) (to
   TN). We thank Dr. Corrine R. Kliment for providing us the robot smoking
   exposed cell samples and in-depth discussion.},
Cited-References = {Agustí A, 2019, NEW ENGL J MED, V381, P1248, DOI 10.1056/NEJMra1900475.
   Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1.
   Almeida-Rios D, 2016, ONCOTARGET, V7, P53018, DOI 10.18632/oncotarget.10061.
   Auclair Y, 2013, DNA REPAIR, V12, P459, DOI 10.1016/j.dnarep.2013.04.006.
   Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564.
   Barnes PJ, 2009, ANNU REV PHYSIOL, V71, P451, DOI 10.1146/annurev.physiol.010908.163257.
   Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003.
   Borgas D, 2016, AM J RESP CELL MOL, V54, P683, DOI 10.1165/rcmb.2015-0149OC.
   Chan LH, 2018, CELL REP, V25, P690, DOI 10.1016/j.celrep.2018.09.053.
   Chen Y, 2009, AM J PHYSIOL-LUNG C, V296, pL648, DOI 10.1152/ajplung.90270.2008.
   Di Lorenzo A, 2014, NUCLEIC ACIDS RES, V42, P8297, DOI 10.1093/nar/gku530.
   Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107.
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008.
   Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166.
   Guccione E, 2019, NAT REV MOL CELL BIO, V20, P642, DOI 10.1038/s41580-019-0155-x.
   He X, 2017, INT J CHRONIC OBSTR, V12, P3245, DOI 10.2147/COPD.S144881.
   Hosgood HD, 2009, RESP MED, V103, P1866, DOI 10.1016/j.rmed.2009.06.016.
   Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366.
   Hyllus D, 2007, GENE DEV, V21, P3369, DOI 10.1101/gad.447007.
   Ito S, 2015, AUTOPHAGY, V11, P547, DOI 10.1080/15548627.2015.1017190.
   Kamo N, 2013, HEPATOLOGY, V57, P289, DOI 10.1002/hep.25958.
   Kang MJ, 2008, J CLIN INVEST, V118, P2771, DOI 10.1172/JCI32709.
   Kang NX, 2015, INT IMMUNOPHARMACOL, V24, P95, DOI 10.1016/j.intimp.2014.10.029.
   Kim SY, 2016, AM J RESP CELL MOL, V54, P284, DOI 10.1165/rcmb.2014-0377OC.
   Lai YD, 2017, J CELL SCI, V130, P3578, DOI 10.1242/jcs.206904.
   Long C, 2020, AM J PHYSIOL-LUNG C, V318, pL252, DOI 10.1152/ajplung.00142.2019.
   Malek M, 2017, MOL CELL, V68, P566, DOI 10.1016/j.molcel.2017.09.024.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Messner B, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.162.
   Milara J, 2014, J ALLERGY CLIN IMMUN, V134, P314, DOI 10.1016/j.jaci.2014.02.001.
   Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985.
   Neault M, 2012, NUCLEIC ACIDS RES, V40, P9513, DOI 10.1093/nar/gks764.
   Okuno K, 2019, CARCINOGENESIS, V40, P15, DOI 10.1093/carcin/bgy147.
   Padmanabhan S, 2009, CELL, V136, P939, DOI 10.1016/j.cell.2009.01.025.
   Phalke S, 2012, NUCLEIC ACIDS RES, V40, P9534, DOI 10.1093/nar/gks858.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sarker RSJ, 2019, AM J PHYSIOL-LUNG C, V317, pL602, DOI 10.1152/ajplung.00441.2018.
   Sarker RSJ, 2015, AM J RESP CELL MOL, V53, P769, DOI 10.1165/rcmb.2014-0216OC.
   Sauler M, 2019, ANNU REV PHYSIOL, V81, P375, DOI 10.1146/annurev-physiol-020518-114320.
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73.
   Stein C, 2012, NUCLEIC ACIDS RES, V40, P9522, DOI 10.1093/nar/gks767.
   Sundar IK, 2014, J PROTEOME RES, V13, P982, DOI 10.1021/pr400998n.
   Tsai KD, 2018, J CELL BIOCHEM, V119, P3404, DOI 10.1002/jcb.26511.
   Tzortzaki EG, 2013, CURR DRUG TARGETS, V14, P141.
   Vogelmeier CF, 2017, AM J RESP CRIT CARE, V195, P557, DOI 10.1164/rccm.201701-0218PP.
   Watson ZL, 2019, CANCER RES, V79, P3, DOI 10.1158/0008-5472.CAN-18-3552.
   Wu H, 2016, BIOCHEM J, V473, P3049, DOI 10.1042/BCJ20160537.
   Yanagisawa S, 2017, AM J PHYSIOL-LUNG C, V313, pL230, DOI 10.1152/ajplung.00382.2016.
   Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409.
   Yao HW, 2012, J CLIN INVEST, V122, P2032, DOI 10.1172/JCI60132.
   Yao HW, 2011, TOXICOL APPL PHARM, V254, P72, DOI 10.1016/j.taap.2009.10.022.
   Yoshida M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10991-7.
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366.
   Zakrzewicz D, 2012, INT J MOL SCI, V13, P12383, DOI 10.3390/ijms131012383.
   Zhang H, 2019, CELL MOL IMMUNOL, V16, P800, DOI 10.1038/s41423-018-0057-4.
   Zhao XX, 2016, J BIOL CHEM, V291, P402, DOI 10.1074/jbc.M115.666347.},
Number-of-Cited-References = {56},
Times-Cited = {27},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Aging-US},
Doc-Delivery-Number = {PH8CN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000600633600009},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000600105700039,
Author = {Jin, Ling and Kim, Eun-Yeong and Chung, Tae-Wook and Han, Chang Woo and
   Park, So Young and Han, Jung Ho and Bae, Sung-Jin and Lee, Jong Rok and
   Kim, Young Woo and Jang, Se Bok and Ha, Ki-Tae},
Title = {Hemistepsin A suppresses colorectal cancer growth through inhibiting
   pyruvate dehydrogenase kinase activity},
Journal = {SCIENTIFIC REPORTS},
Year = {2020},
Volume = {10},
Number = {1},
Month = {DEC 14},
Abstract = {Most cancer cells primarily produce their energy through a high rate of
   glycolysis followed by lactic acid fermentation even in the presence of
   abundant oxygen. Pyruvate dehydrogenase kinase (PDK) 1, an enzyme
   responsible for aerobic glycolysis via phosphorylating and inactivating
   pyruvate dehydrogenase (PDH) complex, is commonly overexpressed in
   tumors and recognized as a therapeutic target in colorectal cancer.
   Hemistepsin A (HsA) is a sesquiterpene lactone isolated from Hemistepta
   lyrata Bunge (Compositae). Here, we report that HsA is a PDK1 inhibitor
   can reduce the growth of colorectal cancer and consequent activation of
   mitochondrial ROS-dependent apoptotic pathway both in vivo and in vitro.
   Computational simulation and biochemical assays showed that HsA directly
   binds to the lipoamide-binding site of PDK1, and subsequently inhibits
   the interaction of PDK1 with the E2 subunit of PDH complex. As a result
   of PDK1 inhibition, lactate production was decreased, but oxygen
   consumption was increased. Mitochondrial ROS levels and mitochondrial
   damage were also increased. Consistent with these observations, the
   apoptosis of colorectal cancer cells was promoted by HsA with enhanced
   activation of caspase-3 and -9. These results suggested that HsA might
   be a potential candidate for developing a novel anti-cancer drug through
   suppressing cancer metabolism.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Ha, KT (Corresponding Author), Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Busandaehak Ro 49, Yangsan 50612, Gyeonsangnam Do, South Korea.
   Ha, KT (Corresponding Author), Pusan Natl Univ, Hlth Aging Korean Med Res Ctr, Yangsan 50612, Gyeonsangnam Do, South Korea.
   Jin, Ling; Kim, Eun-Yeong; Ha, Ki-Tae, Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Busandaehak Ro 49, Yangsan 50612, Gyeonsangnam Do, South Korea.
   Jin, Ling; Kim, Eun-Yeong; Chung, Tae-Wook; Han, Jung Ho; Bae, Sung-Jin; Ha, Ki-Tae, Pusan Natl Univ, Hlth Aging Korean Med Res Ctr, Yangsan 50612, Gyeonsangnam Do, South Korea.
   Han, Chang Woo; Park, So Young; Jang, Se Bok, Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, Busan 46241, South Korea.
   Lee, Jong Rok, Daegu Haany Univ, Dept Pharmaceut Engn, Gyongsan 38610, Gyeongsangbuk D, South Korea.
   Kim, Young Woo, Dongguk Univ, Sch Korean Med, Gyeongju 38066, South Korea.},
DOI = {10.1038/s41598-020-79019-1},
Article-Number = {21940},
ISSN = {2045-2322},
Keywords-Plus = {TYROSINE PHOSPHORYLATION; NATURAL-PRODUCTS; DICHLOROACETATE; METABOLISM;
   MECHANISMS; APOPTOSIS; COMPLEX; CELLS; PDK1},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {hagis@pusan.ac.kr},
Affiliations = {Pusan National University; Pusan National University; Pusan National
   University; Daegu Haany University; Dongguk University},
ResearcherID-Numbers = {Kitae, Ha/AFW-2347-2022
   Bae, Sung-Jin/AAX-9144-2021},
ORCID-Numbers = {Han, Changwoo/0000-0001-9596-1151
   },
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) - Ministry of Science, ICT
   \& Future Planning (MISP), of the Korean Government
   {[}2014R1A5A20009936, 2019R1A2C2003624]},
Funding-Text = {This work was supported by a grant from the National Research Foundation
   of Korea (NRF) funded by the Ministry of Science, ICT \& Future Planning
   (MISP), of the Korean Government (Grant No. 2014R1A5A20009936 and
   2019R1A2C2003624).},
Cited-References = {Aicher TD, 2000, J MED CHEM, V43, P236, DOI 10.1021/jm990358+.
   {[}Anonymous], 2016, GUT.
   Baek SY, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050713.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Chung TW, 2017, J ETHNOPHARMACOL, V203, P47, DOI 10.1016/j.jep.2017.03.034.
   Dai Dao-Fu, 2014, Longev Healthspan, V3, P6, DOI 10.1186/2046-2395-3-6.
   Fan J, 2011, MOL CELL BIOL, V31, P4938, DOI 10.1128/MCB.06120-11.
   Fang ST, 2016, BIOMED REP, V5, P289, DOI 10.3892/br.2016.719.
   Feron O, 2009, RADIOTHER ONCOL, V92, P329, DOI 10.1016/j.radonc.2009.06.025.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Holness M, 2003, REGULATION PYRUVATE, DOI {[}10.1042/bst0311143, DOI 10.1042/BST0311143].
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Jang DS, 1999, PLANTA MED, V65, P765, DOI 10.1055/s-2006-960863.
   Jeong JY, 2012, DIABETES METAB J, V36, P328.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Jourdan M, 2009, BLOOD, V114, P5173, DOI 10.1182/blood-2009-07-235960.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kato M, 2008, STRUCTURE, V16, P1849, DOI 10.1016/j.str.2008.10.010.
   Kim JK, 2020, FOOD CHEM TOXICOL, V135, DOI 10.1016/j.fct.2019.111044.
   Kim JK, 2018, FOOD CHEM TOXICOL, V111, P176, DOI 10.1016/j.fct.2017.11.014.
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501.
   Klein DK, 2007, AM J PHYSIOL-ENDOC M, V293, pE1242, DOI 10.1152/ajpendo.00382.2007.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005.
   Kushnareva Y, 2002, BIOCHEM J, V368, P545, DOI 10.1042/BJ20021121.
   Kwak CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176021.
   Kwak CH, 2019, CANCERS, V11, DOI 10.3390/cancers11050712.
   Li J, 2009, J BIOL CHEM, V284, P34458, DOI 10.1074/jbc.M109.065557.
   LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Mariño G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016.
   Mayers R, 2003, AZD7545 NOVEL INHIBI, DOI {[}10.1042/bst0311165, DOI 10.1042/BST0311165].
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Rodrigues T, 2016, NAT CHEM, V8, P531, DOI {[}10.1038/NCHEM.2479, 10.1038/nchem.2479].
   Saunier E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07006-0.
   Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026.
   Soga S, 2003, CURR CANCER DRUG TAR, V3, P359, DOI 10.2174/1568009033481859.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Venkatraman P, 2010, MINI-REV MED CHEM, V10, P540, DOI 10.2174/138955710791384090.
   Yadav N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.305.
   Yang Z, 2018, EUR J PHARMACOL, V838, P41, DOI 10.1016/j.ejphar.2018.09.016.
   Zhang W, 2018, ACS COMB SCI, V20, P660, DOI 10.1021/acscombsci.8b00104.
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928.},
Number-of-Cited-References = {50},
Times-Cited = {29},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {PH0HR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000600105700039},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000598990900024,
Author = {An, Sugyun and Cho, Si-Young and Kang, Junsoo and Lee, Soobeom and Kim,
   Hyung-Su and Min, Dae-Jin and Son, EuiDong and Cho, Kwang-Hyun},
Title = {Inhibition of 3-phosphoinositide-dependent protein kinase 1 (PDK1) can
   revert cellular senescence in human dermal fibroblasts},
Journal = {PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA},
Year = {2020},
Volume = {117},
Number = {49},
Pages = {31535-31546},
Month = {DEC 8},
Abstract = {Cellular senescence is defined as a stable, persistent arrest of cell
   proliferation. Here, we examine whether senescent cells can lose
   senescence hallmarks and reenter a reversible state of cell-cycle arrest
   (quiescence). We constructed a molecular regulatory network of cellular
   senescence based on previous experimental evidence. To infer the
   regulatory logic of the network, we performed phosphoprotein array
   experiments with normal human dermal fibroblasts and used the data to
   optimize the regulatory relationships between molecules with an
   evolutionary algorithm. From ensemble analysis of network models, we
   identified 3-phosphoinositide-dependent protein kinase 1 (PDK1) as a
   promising target for inhibitors to convert the senescent state to the
   quiescent state. We showed that inhibition of PDK1 in senescent human
   dermal fibroblasts eradicates senescence hallmarks and restores entry
   into the cell cycle by suppressing both nuclear factor kappa B and mTOR
   signaling, resulting in restored skin regeneration capacity. Our
   findings provide insight into a potential therapeutic strategy to treat
   age-related diseases associated with the accumulation of senescent
   cells.},
Publisher = {NATL ACAD SCIENCES},
Address = {2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA},
Type = {Article},
Language = {English},
Affiliation = {Cho, KH (Corresponding Author), Korea Adv Inst Sci \& Technol, Dept Bio \& Brain Engn, Daejeon 34141, South Korea.
   An, Sugyun; Kang, Junsoo; Lee, Soobeom; Cho, Kwang-Hyun, Korea Adv Inst Sci \& Technol, Dept Bio \& Brain Engn, Daejeon 34141, South Korea.
   Cho, Si-Young; Kim, Hyung-Su; Min, Dae-Jin; Son, EuiDong, Amorepacific Corp, R\&D Unit, Gyeonggi Do 17074, South Korea.},
ISSN = {0027-8424},
EISSN = {1091-6490},
Keywords = {cellular senescence; systems biology; network modeling; PDK1; skin aging},
Keywords-Plus = {SECRETORY PHENOTYPE; STEM-CELLS; EXPRESSION; CLEARANCE; ALGORITHM;
   NETWORKS; CULTURE; GENES; ROLES},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {ckh@kaist.ac.kr},
Affiliations = {Korea Advanced Institute of Science \& Technology (KAIST)},
ResearcherID-Numbers = {Cho, Kwang-Hyun/C-1684-2011},
ORCID-Numbers = {Lee, Soobeom/0009-0003-1626-0544
   },
Funding-Acknowledgement = {National Research Foundation of Korea - Korea Government; Ministry of
   Science and Information \& Communication Technology (ICT)
   {[}2020R1A2B5B03094920]; Electronics and Telecommunications Research
   Institute - Korean government {[}20ZS1100]; Korea Advanced Institute of
   Science and Technology Grand Challenge 30 Project; Amorepacific RD
   Center},
Funding-Text = {This work was supported by National Research Foundation of Korea grants
   funded by the Korea Government, the Ministry of Science and Information
   \& Communication Technology (ICT) (2020R1A2B5B03094920) and an
   Electronics and Telecommunications Research Institute grant funded by
   the Korean government (20ZS1100, Core Technology Research for
   Self-Improving Integrated Artificial Intelligence System). It was also
   partially supported by Korea Advanced Institute of Science and
   Technology Grand Challenge 30 Project and a research grant from
   Amorepacific R\&D Center. We thank Sea Choi for her critical reading and
   valuable comments.},
Cited-References = {Abdian N, 2015, CELL TISSUE BANK, V16, P487, DOI 10.1007/s10561-015-9494-9.
   Alderton GK, 2014, NAT REV CANCER, V14, DOI 10.1038/nrc3713.
   Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031.
   Bafna V, 1999, SIAM J DISCRETE MATH, V12, P289, DOI 10.1137/S0895480196305124.
   Beauséjour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417.
   Biscani F., 2010, ARXIV10043824.
   Blagosklonny MV, 2018, CELL CYCLE, V17, P2655, DOI 10.1080/15384101.2018.1554781.
   Blagosklonny MV, 2014, CELL CYCLE, V13, P3628, DOI 10.4161/15384101.2014.985507.
   Blagosklonny MV, 2011, AGING-US, V3, P94, DOI 10.18632/aging.100281.
   Bonzanni N, 2013, BIOINFORMATICS, V29, P80, DOI 10.1093/bioinformatics/btt243.
   Brest J, 2006, IEEE C EVOL COMPUTAT, P215, DOI 10.1109/CEC.2006.1688311.
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233.
   Campisi J, 2019, NATURE, V571, P183, DOI 10.1038/s41586-019-1365-2.
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010.
   Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711.
   Childs BG, 2017, NAT REV DRUG DISCOV, V16, P718, DOI 10.1038/nrd.2017.116.
   Choi M, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003363.
   Coppé JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144.
   Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241.
   Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606.
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363.
   Fiedler B, 2013, J DYN DIFFER EQU, V25, P563, DOI 10.1007/s10884-013-9312-7.
   Figueroa R, 2000, CANCER RES, V60, P2770.
   Gates AJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep24456.
   Giangreco A, 2010, J INVEST DERMATOL, V130, P604, DOI 10.1038/jid.2009.297.
   Helikar T, 2008, P NATL ACAD SCI USA, V105, P1913, DOI 10.1073/pnas.0705088105.
   Herranz N, 2018, J CLIN INVEST, V128, P1238, DOI 10.1172/JCI95148.
   Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701.
   Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x.
   Jeon OH, 2017, NAT MED, V23, P775, DOI 10.1038/nm.4324.
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27.
   Kim HG, 2002, EXP CELL RES, V272, P199, DOI 10.1006/excr.2001.5420.
   Lee HS, 2015, SCI REP-UK, V5, DOI 10.1038/srep10305.
   Lee S, 2019, NAT CELL BIOL, V21, P94, DOI 10.1038/s41556-018-0249-2.
   Martinez-Zamudio Ricardo Ivan, 2017, Cell, V170, P816, DOI {[}10.1016/j.cell.2017.07.049, 10.1016/j.cell.2017.07.049].
   McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092.
   Michalewicz Z., 1994, International Transactions in Operational Research, V1, P223, DOI {[}10.1111/1475-3995.d01-23, DOI 10.1111/1475-3995.D01-23].
   Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167.
   Niedernhofer LJ, 2018, NAT REV DRUG DISCOV, V17.
   Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052.
   Park S, 2018, FASEB J, V32, P1510, DOI 10.1096/fj.201700693R.
   Polikar R., 2006, IEEE Circuits and Systems Magazine, V6, P21, DOI 10.1109/MCAS.2006.1688199.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094.
   Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764.
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005.
   Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006.
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937.
   Tilstra JS, 2012, J CLIN INVEST, V122, P2601, DOI 10.1172/JCI45785.
   Türei D, 2016, NAT METHODS, V13, P965, DOI 10.1038/nmeth.4077.
   Wang Y, 2011, FEBS LETT, V585, P986, DOI 10.1016/j.febslet.2010.11.047.
   Werner S, 2001, TRENDS CELL BIOL, V11, P143, DOI 10.1016/S0962-8924(01)01955-9.
   Wu DY, 2018, CELL DEATH DIFFER, V25, P169, DOI 10.1038/cdd.2017.187.
   Wu ZJ, 2007, LECT NOTES COMPUT SC, V4490, P1131.
   Xiong W, 2003, NATURE, V426, P460, DOI 10.1038/nature02089.
   Xu YX, 2014, TRENDS BIOCHEM SCI, V39, P268, DOI 10.1016/j.tibs.2014.04.004.
   Young ARJ, 2009, EMBO REP, V10, P228, DOI 10.1038/embor.2009.22.
   Yu Y, 2018, CANCER CELL, V33, P322, DOI 10.1016/j.ccell.2018.01.002.
   Zañudo JGT, 2017, P NATL ACAD SCI USA, V114, P7234, DOI 10.1073/pnas.1617387114.},
Number-of-Cited-References = {59},
Times-Cited = {49},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Proc. Natl. Acad. Sci. U. S. A.},
Doc-Delivery-Number = {PF3XE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000598990900024},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000597351000001,
Author = {Yang, JinRan and Li, Xinchang and Yang, Hua and Long, Chenmei},
Title = {Oleanolic Acid Improves the Symptom of Renal Ischemia Reperfusion Injury
   via the PI3K/AKT Pathway},
Journal = {UROLOGIA INTERNATIONALIS},
Year = {2021},
Volume = {105},
Number = {3-4},
Pages = {215-220},
Month = {FEB},
Abstract = {Purpose: The aim of this study was to investigate the therapeutic effect
   of oleanolic acid (OA) on the renal ischemia reperfusion injury (RIRI)
   and the possible mechanism. Methods: The RIRI model was successfully
   established in rats. OA, LY294002 (a PI3K inhibitor), and OA combined
   with LY294002 were dosed to rats in 3 therapeutic groups, respectively.
   The blood was collected to detect the concentration of Cr and BUN by
   ELISA. The kidney of each rat was collected to detect the concentration
   of renal injury factor (Kim-1) and the HE staining was performed.
   Western blot was used to detect the expression level of PI3K, p-AKT,
   AKT, PDK1, Skp2, and p27 in the renal tissue homogenate. Results: The
   symptom of vacuolar degeneration and interstitial edema was greatly
   improved in the rat kidney from the 3 therapeutic groups, compared with
   that from the RIRI model group. No significant difference was observed
   among the 3 therapeutic groups. The concentration of Cr in the 3
   therapeutic groups was greatly lower than that in the RIRI model group.
   The expression level of p-AKT/AKT, PI3K, PDK1, Skp2, and p27 in OA
   group, LY294002 group, and OA combined with LY294002 group was
   significantly lower than that in the RIRI model group, respectively.
   Conclusion: OA could improve the symptom of RIRI, possibly by inhibiting
   PI3K/AKT signal pathway.},
Publisher = {KARGER},
Address = {ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Long, CM (Corresponding Author), Jiangxi Prov Peoples Hosp, Dept Organ Transplantat, 92 Aiguo Rd, Nanchang 330006, Jiangxi, Peoples R China.
   Yang, JinRan; Li, Xinchang; Yang, Hua; Long, Chenmei, Jiangxi Prov Peoples Hosp, Dept Organ Transplantat, 92 Aiguo Rd, Nanchang 330006, Jiangxi, Peoples R China.},
DOI = {10.1159/000506778},
EarlyAccessDate = {DEC 2020},
ISSN = {0042-1138},
EISSN = {1423-0399},
Keywords = {Oleanolic acid; LY294002; PI3K; AKT signal pathway; PDK1; Renal ischemia},
Keywords-Plus = {INHIBITOR P27; CANCER},
Research-Areas = {Urology \& Nephrology},
Web-of-Science-Categories  = {Urology \& Nephrology},
Author-Email = {longchengmei\_mei@163.com},
ORCID-Numbers = {Li, Xinchang/0000-0003-2765-1236},
Funding-Acknowledgement = {National Natural Science Foundation of Jiangxi Province
   {[}20181BAB205018]},
Funding-Text = {The entire work was supported by grants from the National Natural
   Science Foundation of Jiangxi Province (Grant No. 20181BAB205018).},
Cited-References = {Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6.
   Brisco MA, 2013, CIRC-HEART FAIL, V6, P233, DOI 10.1161/CIRCHEARTFAILURE.112.968230.
   Chen SF, 2019, MOL MED REP, V19, P3633, DOI 10.3892/mmr.2019.10018.
   Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0.
   Hu C, 2018, J IMMUNOL, V201, P3717, DOI 10.4049/jimmunol.1800987.
   Jiang M, 2010, AM J PATHOL, V176, P1181, DOI 10.2353/ajpath.2010.090594.
   Korkmaz A, 2013, CAN J SURG, V56, P6, DOI 10.1503/cjs.004811.
   Lafrance JP, 2010, J AM SOC NEPHROL, V21, P345, DOI 10.1681/ASN.2009060636.
   Liu HB, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/362158.
   Miskimins WK, 2001, MOL CELL BIOL, V21, P4960, DOI 10.1128/MCB.21.15.4960-4967.2001.
   Mu DW, 2015, INT J CLIN EXP PATHO, V8, P13864.
   Muratsubaki S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05667-5.
   Pollier J, 2012, PHYTOCHEMISTRY, V77, P10, DOI 10.1016/j.phytochem.2011.12.022.
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937.
   van Timmeren MM, 2007, J PATHOL, V212, P209, DOI 10.1002/path.2175.
   Yan SL, 2010, TOXICOL IN VITRO, V24, P842, DOI 10.1016/j.tiv.2009.12.008.
   Zhang W, 2018, MOL MED REP, V18, P3641, DOI 10.3892/mmr.2018.9354.
   Zhou ZW, 2018, MOL MED REP, V18, P1560, DOI 10.3892/mmr.2018.9115.
   Zhu Wenhui, 2018, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V43, P35, DOI 10.11817/j.issn.1672-7347.2018.01.006.},
Number-of-Cited-References = {19},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Urol.Int.},
Doc-Delivery-Number = {QR5ED},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000597351000001},
DA = {2026-02-04},
}

@article{ WOS:000597282700018,
Author = {Campbell, Iain and Campbell, Harry},
Title = {Mechanisms of insulin resistance, mitochondrial dysfunction and the
   action of the ketogenic diet in bipolar disorder. Focus on the
   PI3K/AKT/HIF1-a pathway},
Journal = {MEDICAL HYPOTHESES},
Year = {2020},
Volume = {145},
Month = {DEC},
Abstract = {Over the past decade evidence from multiple research trajectories have
   converged to provide evidence that impaired glucose metabolism and
   mitochondrial dysfunction in the brain are the critical issues laying at
   the root of Bipolar Disorder (BD). These developments have been
   paralleled by increasing recognition of the systemic metabolic
   dysfunction accompanying mood disorders. Significant insulin resistance
   (IR) occurs in BD patients and this has been demonstrated to be related
   to illness severity independent of medication status. Preliminary
   evidence for a therapeutic effect of a Ketogenic Diet (KD) in BD and
   other neuropsychiatric conditions has recently refocused interest in the
   role of IR in BD pathogenesis.
   In this paper we review evidence of hyperinsulinemia in BD as the
   primary cause of mitochondrial dysfunction mediated by impairment of the
   PI3K/AKT/HIF1-a insulin signaling pathway. This cascade of dysfunction
   directly suppresses the Pyruvate Dehydrogenase Complex through HIF1-a
   mediated activation of Pyruvate dehydrogenase kinase 1 (PDK1) leading to
   the Warburg effect and mitochondrial dysfunction. We review evidence
   that the KD acts directly on each of these mechanisms and propose that a
   trial of KD in BD with a mechanistic component is needed to further
   investigate the role of IR in BD.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Campbell, I (Corresponding Author), Univ Edinburgh, Usher Inst Populat Hlth Sci \& Informat, Edinburgh EH8 9AG, Midlothian, Scotland.
   Campbell, Iain; Campbell, Harry, Usher Inst Populat Hlth Sci \& Informat, Edinburgh, Midlothian, Scotland.},
DOI = {10.1016/j.mehy.2020.110299},
Article-Number = {110299},
ISSN = {0306-9877},
EISSN = {1532-2777},
Keywords-Plus = {HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DIABETES-MELLITUS; OXIDATIVE STRESS;
   LOW-CARBOHYDRATE; FACTOR-I; DEHYDROGENASE; BRAIN; SCHIZOPHRENIA;
   COGNITION; PROTEINS},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {iain.campbell@ed.ac.uk},
ResearcherID-Numbers = {Campbell, Harry/E-2959-2010},
Cited-References = {{[}Anonymous], GLOBAL REGIONAL NATL.
   {[}Anonymous], 2016, Lancet, V388, P1603, DOI {[}10.1016/S0140-6736(16)31460-X, DOI 10.1016/S0140-6736(16)31460-X].
   Arora N, 2020, CLIN NEUROL NEUROSUR, V192, DOI 10.1016/j.clineuro.2020.105727.
   Brietzke E, 2008, PROG NEURO-PSYCHOPH, V32, P1355, DOI 10.1016/j.pnpbp.2008.01.006.
   Brietzke E, 2018, NEUROSCI BIOBEHAV R, V94, P11, DOI 10.1016/j.neubiorev.2018.07.020.
   Burns JS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122755.
   Calkin CV, 2019, ANN MED, V51, P281, DOI 10.1080/07853890.2019.1659511.
   Calkin CV, 2015, BRIT J PSYCHIAT, V206, P52, DOI 10.1192/bjp.bp.114.152850.
   Calkin CV, 2013, ANN MED, V45, P171, DOI 10.3109/07853890.2012.687835.
   Campbell IH, 2019, BJPSYCH OPEN, V5, DOI 10.1192/bjo.2019.49.
   Campbell L, 2019, MED HYPOTHESES, V130, DOI 10.1016/j.mehy.2019.109263.
   Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112.
   Cerniglia GJ, 2015, MOL CANCER THER, V14, P1928, DOI 10.1158/1535-7163.MCT-14-0888.
   Charles EF, 2016, INT J BIPOLAR DISORD, V4, DOI 10.1186/s40345-016-0054-4.
   Chen SF, 2020, J AFFECT DISORDERS, V263, P458, DOI 10.1016/j.jad.2019.12.007.
   Chow HM, 2019, NAT NEUROSCI, V22, P1806, DOI 10.1038/s41593-019-0505-1.
   Croarkin PE, 2015, BIPOLAR DISORD, V17, P450, DOI 10.1111/bdi.12285.
   Cunnane SC, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00053.
   Cuperfain AB, 2020, NEUROSCI BIOBEHAV R, V111, P125, DOI 10.1016/j.neubiorev.2020.01.022.
   Gabbouj S, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00629.
   Goldstein BI, 2009, J CLIN PSYCHIAT, V70, P1078, DOI 10.4088/JCP.08r04505.
   Hajek T, 2014, NEUROPSYCHOPHARMACOL, V39, P2910, DOI 10.1038/npp.2014.148.
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hemmings BA, 2015, CSH PERSPECT BIOL, V7.
   Hicks CW, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1212-8.
   Ho KL, 2019, CARDIOVASC RES, V115, P1606, DOI 10.1093/cvr/cvz045.
   Hopkins BD, 2020, NAT REV ENDOCRINOL, V16, P276, DOI 10.1038/s41574-020-0329-9.
   Huang XJ, 2018, INT J BIOL SCI, V14, P1483, DOI 10.7150/ijbs.27173.
   Hurd TR, 2007, J BIOL CHEM, V282, P22040, DOI 10.1074/jbc.M703591200.
   Hussain TA, 2012, NUTRITION, V28, P1016, DOI 10.1016/j.nut.2012.01.016.
   Jackson CA, 2019, DIABETES CARE, V42, P1879, DOI 10.2337/dc18-2152.
   James AM, 2012, TRENDS ENDOCRIN MET, V23, P429, DOI 10.1016/j.tem.2012.06.008.
   Jarrett SG, 2008, J NEUROCHEM, V106, P1044, DOI 10.1111/j.1471-4159.2008.05460.x.
   Kageyama Y, 2017, PSYCHIAT CLIN NEUROS, V71, P115, DOI 10.1111/pcn.12461.
   Katerji M, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1279250.
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1.
   KATO T, 1994, J AFFECT DISORDERS, V31, P125, DOI 10.1016/0165-0327(94)90116-3.
   Kato T, 2000, BIPOLAR DISORD, V2, P180, DOI 10.1034/j.1399-5618.2000.020305.x.
   Kato T, 2000, LANCET, V2, P180.
   Kim B, 2011, ENDOCRINOLOGY, V152, P3638, DOI 10.1210/en.2011-0029.
   Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472.
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim Y, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00030.
   Kraft BD, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-10.
   Kuang HD, 2018, PSYCHIAT CLIN NEUROS, V72, P546, DOI 10.1111/pcn.12671.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Lojko D, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071132.
   Lü JM, 2010, J CELL MOL MED, V14, P840, DOI 10.1111/j.1582-4934.2009.00897.x.
   Maffei A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124098.
   Mahadik SP, 1996, SCHIZOPHR RES, V19, P1, DOI 10.1016/0920-9964(95)00049-6.
   Manninen A, 2004, J INT SOC SPORTS NUT, V1.
   Munakata K, 2004, GENOMICS, V84, P1041, DOI 10.1016/j.ygeno.2004.08.015.
   Ng F, 2009, CHEMINFORM, V40.
   OBRIEN JS, 1965, J LIPID RES, V6, P537.
   PACHECO A, 1965, AM J PSYCHIAT, V121, P1110, DOI 10.1176/ajp.121.11.1110.
   Palmer CM, 2017, SCHIZOPHR RES, V189, P208, DOI 10.1016/j.schres.2017.01.053.
   Phelps JR, 2013, NEUROCASE, V19, P423, DOI 10.1080/13554794.2012.690421.
   Phillips MCL, 2018, MOVEMENT DISORD, V33, P1306, DOI 10.1002/mds.27390.
   Plum L, 2005, TRENDS ENDOCRIN MET, V16, P59, DOI 10.1016/j.tem.2005.01.008.
   Regenold WT, 2009, BIOL PSYCHIAT, V65, P489, DOI 10.1016/j.biopsych.2008.11.010.
   Regenold WT, 2002, J AFFECT DISORDERS, V70, P19, DOI 10.1016/S0165-0327(01)00456-6.
   Reger MA, 2004, NEUROBIOL AGING, V25, P311, DOI 10.1016/S0197-4580(03)00087-3.
   Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430.
   Rusek M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163892.
   Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637.
   Sarnyai Z, 2020, INT J NEUROPSYCHOPH, V23, P434, DOI 10.1093/ijnp/pyaa036.
   Shibata T, 2013, PROG NEURO-PSYCHOPH, V43, P222, DOI 10.1016/j.pnpbp.2013.01.003.
   Shichiri M, 2014, J CLIN BIOCHEM NUTR, V54, P151, DOI 10.3164/jcbn.14-10.
   Strakowski S., BIPOLAR BRAIN INTEGR.
   Vincent AM, 2004, DIABETES, V53, P726, DOI 10.2337/diabetes.53.3.726.
   Wang L, 2017, BIOCHEM BIOPH RES CO, V491, P545, DOI 10.1016/j.bbrc.2017.03.128.
   Yoshimi N, 2016, MOL PSYCHIATR, V21, P1504, DOI 10.1038/mp.2015.217.},
Number-of-Cited-References = {74},
Times-Cited = {41},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Med. Hypotheses},
Doc-Delivery-Number = {PC8XR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000597282700018},
DA = {2026-02-04},
}

@article{ WOS:000599622800002,
Author = {Ding, Chunyong and Song, Zilan and Shen, Ancheng and Chen, Tingting and
   Zhang, Ao},
Title = {Small molecules targeting the innate immune cGAS-STING-TBK1 signaling
   pathway},
Journal = {ACTA PHARMACEUTICA SINICA B},
Year = {2020},
Volume = {10},
Number = {12},
Pages = {2272-2298},
Month = {DEC},
Abstract = {Multiple cancer immunotherapies including chimeric antigen receptor T
   cell and immune checkpoint inhibitors (ICIs) have been successfully
   developed to treat various cancers by motivating the adaptive anti-tumor
   immunity. Particularly, the checkpoint blockade approach has achieved
   great clinic success as evidenced by several U.S. Food and Drug
   Administration (FDA)-approved anti-programmed death receptor 1/ligand 1
   or anti-cytotoxic T lymphocyte associated protein 4 antibodies. However,
   the majority of cancers have low clinical response rates to these ICIs
   due to poor tumor immunogenicity. Indeed, the cyclic guanosine
   monophosphate-adenosine monophosphate synthase-stimulator of interferon
   genes-TANK-binding kinase 1 (cGAS-STING-TBK1) axis is now appreciated as
   the major signaling pathway in innate immune response across different
   species. Aberrant signaling of this pathway has been closely linked to
   multiple diseases, including auto-inflammation, virus infection and
   cancers. In this perspective, we provide an updated review on the latest
   progress on the development of small molecule modulators targeting the
   cGAS-STING-TBK1 signaling pathway and their preclinical and clinical use
   as a new immune stimulatory therapy. Meanwhile, highlights on the
   clinical candidates, limitations and challenges, as well as future
   directions in this field are also discussed. Further, small molecule
   inhibitors targeting this signaling axis and their potential therapeutic
   use for various indications are discussed as well. (C) 2020 Chinese
   Pharmaceutical Association and Institute of Materia Medica, Chinese
   Academy of Medical Sciences. Production and hosting by Elsevier B.V.},
Publisher = {INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES},
Address = {C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA},
Type = {Review},
Language = {English},
Affiliation = {Zhang, A (Corresponding Author), Shanghai Jiao Tong Univ, Sch Pharm, Res Lab Med Chem Biol \& Frontiers Drug Discovery, Shanghai 200240, Peoples R China.
   Zhang, A (Corresponding Author), Chinese Acad Sci, Shanghai Inst Mat Med SIMM, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.
   Zhang, A (Corresponding Author), Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   Ding, Chunyong; Zhang, Ao, Shanghai Jiao Tong Univ, Sch Pharm, Res Lab Med Chem Biol \& Frontiers Drug Discovery, Shanghai 200240, Peoples R China.
   Ding, Chunyong; Song, Zilan; Shen, Ancheng; Chen, Tingting; Zhang, Ao, Chinese Acad Sci, Shanghai Inst Mat Med SIMM, CAS Key Lab Receptor Res, Shanghai 201203, Peoples R China.
   Ding, Chunyong; Song, Zilan; Shen, Ancheng; Chen, Tingting; Zhang, Ao, Univ Chinese Acad Sci, Beijing 100049, Peoples R China.},
DOI = {10.1016/j.apsb.2020.03.001},
ISSN = {2211-3835},
EISSN = {2211-3843},
Keywords = {Immunotherapy; Anti-tumor; cGAS; STING; TBK1; Small molecule modulators},
Keywords-Plus = {CYCLIC GMP-AMP; CANCER-IMMUNOTHERAPY; STING PATHWAY; CRYSTAL-STRUCTURE;
   NEXT-GENERATION; DNA; TBK1; ACTIVATION; INHIBITORS; DISCOVERY},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {aozhang@simm.ac.cn},
Affiliations = {Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Materia Medica, CAS; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS},
ResearcherID-Numbers = {Ding, Chunyong/AAA-7906-2019},
Funding-Acknowledgement = {Natural Science Foundation of China (China) {[}81773565, 21877120,
   81703327, 81430080, 81573452, 81773767]; Key Program of the Frontier
   Science of the Chinese Academy of Sciences (China) {[}160621]; Strategic
   Priority Research Program of the Chinese Academy of Sciences (China)
   {[}XDA12020374]; Shanghai Jiao Tong University (China)},
Funding-Text = {This work was supported by grants from Natural Science Foundation of
   China (Nos. 81773565, 21877120, 81703327, 81430080, 81573452, and
   81773767, China). Supporting grants from the Key Program of the Frontier
   Science of the Chinese Academy of Sciences (No. 160621, China), the
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (No. XDA12020374, China), and a start-up grant to the Research
   Laboratory of Medicinal Chemical Biology \& Frontiers on Drug Discovery
   from Shanghai Jiao Tong University (China) are also appreciated.},
Cited-References = {Ablasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657.
   Adams JL, 2015, NAT REV DRUG DISCOV, V14, P603, DOI 10.1038/nrd4596.
   Altman MD, 2018, PCT Int Appl., P1, Patent No. {[}WO2018067423A1, 2018067423, WO 2018067423 A1].
   An J, 2018, ARTHRITIS RHEUMATOL, V70, P1807, DOI 10.1002/art.40559.
   An J, 2015, J IMMUNOL, V194, P4089, DOI 10.4049/jimmunol.1402793.
   Andreeva L, 2017, NATURE, V549, P394, DOI 10.1038/nature23890.
   {[}Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210.
   Bai JL, 2019, DIABETES, V68, P1099, DOI 10.2337/dbi18-0052.
   Banerjee M., 2018, Patent, Patent No. {[}WO2018234805, 2018234805].
   Banerjee M, 2018, Small molecule modula tors of human STING, Patent No. {[}WO2018234808A1, 2018234808, WO 2018234808 A1].
   Banerjee M., 2018, Heterocyclic small mole cule modulators of human STING, Patent No. {[}WO2018234807, 2018234807].
   Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921.
   Barber GN, 2014, TRENDS IMMUNOL, V35, P88, DOI 10.1016/j.it.2013.10.010.
   Berger G, 2019, TRENDS MOL MED, V25, P412, DOI 10.1016/j.molmed.2019.02.007.
   Beyett TS, 2018, BIOORGAN MED CHEM, V26, P5443, DOI 10.1016/j.bmc.2018.09.020.
   Beyett TS, 2018, MOL PHARMACOL, V94, P1210, DOI 10.1124/mol.118.112185.
   Bose D, 2016, CELL CHEM BIOL, V23, P1539, DOI 10.1016/j.chembiol.2016.10.014.
   Burdette Dara L, 2013, Nat Immunol, V14, P19, DOI 10.1038/ni.2491.
   Cavlar T, 2013, EMBO J, V32, P1440, DOI 10.1038/emboj.2013.86.
   Cemerski S., 2019, Benzobthio phene STING agonists for cancer treatment, Patent No. {[}WO2019027858, 2019027858].
   Cemerski S, 2019, PCT Int Appl., P1, Patent No. {[}WO2019027857A1, 2019027857, WO 2019027857 A1].
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349.
   Chen SL, 2019, CURR TOP MED CHEM, V19, P180, DOI 10.2174/1568026619666190308131805.
   Cheng BB, 2018, EUR J MED CHEM, V157, P582, DOI 10.1016/j.ejmech.2018.08.028.
   Civril F, 2013, NATURE, V498, P332, DOI 10.1038/nature12305.
   Clark K, 2011, P NATL ACAD SCI USA, V108, P17093, DOI 10.1073/pnas.1114194108.
   Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414.
   Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892.
   Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031.
   Crew AP, 2018, J MED CHEM, V61, P583, DOI 10.1021/acs.jmedchem.7b00635.
   Cui XL, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111591.
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1.
   Dempke WCM, 2017, EUR J CANCER, V74, P55, DOI 10.1016/j.ejca.2017.01.001.
   Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019.
   Dhanak D, 2017, CELL CHEM BIOL, V24, P1148, DOI 10.1016/j.chembiol.2017.08.019.
   Dialer CR, 2019, CHEM-EUR J, V25, P2089, DOI 10.1002/chem.201805409.
   Ergun SL, 2019, CELL, V178, P290, DOI 10.1016/j.cell.2019.05.036.
   Fritz JM, 2019, J EXP MED, V216, P1244, DOI 10.1084/jem.20182395.
   Fu Y, 2020, ACTA PHARMACOL SIN B, V10, P414, DOI 10.1016/j.apsb.2019.08.010.
   Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011.
   Gao P., 2013, CELL, V153, P1094, DOI DOI 10.1016/J.CELL.2013.04.046.
   Gao P, 2014, CELL REP, V8, P1668, DOI 10.1016/j.celrep.2014.08.010.
   Gao P, 2013, CELL, V154, P748, DOI 10.1016/j.cell.2013.07.023.
   Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z.
   Haag SM, 2018, NATURE, V559, P269, DOI 10.1038/s41586-018-0287-8.
   Hall JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169121.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hargadon KM, 2018, INT IMMUNOPHARMACOL, V62, P29, DOI 10.1016/j.intimp.2018.06.001.
   Huck BR, 2018, ANGEW CHEM INT EDIT, V57, P4412, DOI 10.1002/anie.201707816.
   Hwang J, 2019, ORG BIOMOL CHEM, V17, P1869, DOI 10.1039/c8ob01798k.
   Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317.
   Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476.
   Kato K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06922-7.
   Kato K, 2017, ANNU REV BIOCHEM, V86, P541, DOI 10.1146/annurev-biochem-061516-044813.
   Kato K, 2012, P NATL ACAD SCI USA, V109, P16876, DOI 10.1073/pnas.1208017109.
   Kerr WG, 2019, J IMMUNOL, V202, P11, DOI 10.4049/jimmunol.1800991.
   Kruger S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1266-0.
   Lama L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08620-4.
   Larabi A, 2013, CELL REP, V3, P734, DOI 10.1016/j.celrep.2013.01.034.
   Lee SJ, 2019, INT IMMUNOPHARMACOL, V73, P482, DOI 10.1016/j.intimp.2019.05.051.
   Lesterhuis WJ, 2011, NAT REV DRUG DISCOV, V10, P591, DOI 10.1038/nrd3500.
   Li AP, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0721-x.
   Li J, 2019, PCT Int Appl., P1, Patent No. {[}WO 2019134705 A1, 2019134705].
   Li J, 2012, PROTEIN CELL, V3, P383, DOI 10.1007/s13238-012-2929-1.
   Li JJ, 2014, INT J CANCER, V134, P1972, DOI 10.1002/ijc.28507.
   Li LY, 2014, NAT CHEM BIOL, V10, P1043, DOI {[}10.1038/NChemBio.1661, 10.1038/nchembio.1661].
   Li SL, 2018, CELL REP, V25, P3405, DOI 10.1016/j.celrep.2018.11.097.
   Li TJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19049.
   Li ZH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0684-3.
   Lioux T, 2016, J MED CHEM, V59, P10253, DOI 10.1021/acs.jmedchem.6b01300.
   Liu BW, 2017, ANTIVIR RES, V147, P37, DOI 10.1016/j.antiviral.2017.10.001.
   Mashima E, 2015, ONCOTARGETS THER, V8, P2045, DOI 10.2147/OTT.S62102.
   Mayes PA, 2018, NAT REV DRUG DISCOV, V17, P509, DOI 10.1038/nrd.2018.75.
   Mazzarella L, 2019, EUR J CANCER, V117, P14, DOI 10.1016/j.ejca.2019.04.035.
   Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576-019-0151-1.
   Ndubaku CO, 2019, Patent No. {[}WO2019055750, 2019055750].
   Ng KW, 2018, TRENDS IMMUNOL, V39, P44, DOI 10.1016/j.it.2017.07.013.
   O'Donovan DH, 2020, CURR MED CHEM, V27, P5654, DOI 10.2174/0929867326666190620103105.
   Patel S, 2019, GENES IMMUN, V20, P82, DOI 10.1038/s41435-018-0029-9.
   Prantner D, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.382986.
   Ramanjulu JM, 2018, NATURE, V564, P439, DOI 10.1038/s41586-018-0705-y.
   Richters A, 2015, ACS CHEM BIOL, V10, P289, DOI 10.1021/cb500908d.
   Robert P.T., 2012, Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, Processes for their preparation, and pharmaceutical compositions containing them, Patent No. {[}WO 2012010826, 2012010826, WO 2012010826 A1].
   Salama AKS, 2017, ANN ONCOL, V28, P57, DOI 10.1093/annonc/mdw534.
   Sali TM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005324.
   Shang GJ, 2019, NATURE, V567, P389, DOI 10.1038/s41586-019-0998-5.
   Shang GJ, 2012, NAT STRUCT MOL BIOL, V19, P725, DOI 10.1038/nsmb.2332.
   Sheridan C, 2019, NAT BIOTECHNOL, V37, P199, DOI 10.1038/s41587-019-0060-z.
   Siu T, 2019, ACS MED CHEM LETT, V10, P92, DOI 10.1021/acsmedchemlett.8b00466.
   Sondak VK, 2011, NAT REV DRUG DISCOV, V10, P411, DOI 10.1038/nrd3463.
   Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458.
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022.
   Tan M, 2015, J CLIN PHARM THER, V40, P504, DOI 10.1111/jcpt.12304.
   Thomson DW, 2019, ACS MED CHEM LETT, V10, P780, DOI 10.1021/acsmedchemlett.9b00027.
   Thorsson V, 2019, IMMUNITY, V51, P411, DOI {[}10.1016/j.immuni.2018.03.023, 10.1016/j.immuni.2019.08.004].
   Torphy RJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122642.
   van der Woude LL, 2017, TRENDS CANCER, V3, P797, DOI 10.1016/j.trecan.2017.09.006.
   Vargas TR, 2017, EUR J CANCER, V75, P86, DOI 10.1016/j.ejca.2016.12.028.
   Vincent J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00833-9.
   Wang M, 2018, FUTURE MED CHEM, V10, P1301, DOI 10.4155/fmc-2017-0322.
   Weinmann H, 2016, CHEMMEDCHEM, V11, P450, DOI 10.1002/cmdc.201500566.
   Wolchok J, 2018, CELL, V175, P1452, DOI 10.1016/j.cell.2018.11.006.
   Yu T, 2015, EXPERT OPIN THER PAT, V25, P1385, DOI 10.1517/13543776.2015.1081168.
   Zhang CG, 2019, NATURE, V567, P394, DOI 10.1038/s41586-019-1000-2.
   Zhang HM, 2018, J CANCER, V9, P1773, DOI 10.7150/jca.24577.
   Zhang XH, 2019, ACS INFECT DIS, V5, P1139, DOI 10.1021/acsinfecdis.9b00010.
   Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022.
   Zhang YB, 2018, CHEMMEDCHEM, V13, P2057, DOI 10.1002/cmdc.201800481.
   Zhao BY, 2019, NATURE, V569, P718, DOI 10.1038/s41586-019-1228-x.
   Zhao CY, 2019, EXPERT OPIN THER TAR, V23, P437, DOI 10.1080/14728222.2019.1601702.},
Number-of-Cited-References = {110},
Times-Cited = {249},
Usage-Count-Last-180-days = {19},
Usage-Count-Since-2013 = {267},
Journal-ISO = {Acta Pharm. Sin. B},
Doc-Delivery-Number = {PG3ET},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000599622800002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000603086500001,
Author = {Kim, Da Hyun and Auh, Joong-Hyuck and Oh, Jeongyeon and Hong, Seungpyo
   and Choi, Sungbin and Shin, Eun Ju and Woo, Soon Ok and Lim, Tae-Gyu and
   Byun, Sanguine},
Title = {Propolis Suppresses UV-Induced Photoaging in Human Skin through Directly
   Targeting Phosphoinositide 3-Kinase},
Journal = {NUTRIENTS},
Year = {2020},
Volume = {12},
Number = {12},
Month = {DEC},
Abstract = {Propolis is a resinous substance generated by bees using materials from
   various plant sources. It has been known to exhibit diverse
   bioactivities including anti-oxidative, anti-microbial,
   anti-inflammatory, and anti-cancer effects. However, the direct
   molecular target of propolis and its therapeutic potential against skin
   aging in humans is not fully understood. Herein, we investigated the
   effect of propolis on ultraviolet (UV)-mediated skin aging and its
   underlying molecular mechanism. Propolis suppressed UV-induced matrix
   metalloproteinase (MMP)-1 production in human dermal fibroblasts. More
   importantly, propolis treatment reduced UV-induced MMP-1 expression and
   blocked collagen degradation in human skin tissues, suggesting that the
   anti-skin-aging activity of propolis can be recapitulated in clinically
   relevant conditions. While propolis treatment did not display any
   noticeable effects against extracellular signal-regulated kinase (ERK),
   p38, and c-jun N-terminal kinase (JNK) pathways, propolis exerted
   significant inhibitory activity specifically against phosphorylations of
   phosphoinositide-dependent protein kinase-1 (PDK1) and protein kinase B
   (Akt). Kinase assay results demonstrated that propolis can directly
   suppress phosphoinositide 3-kinase (PI3K) activity, with preferential
   selectivity towards PI3K with p110 alpha and p110 delta catalytic
   subunits over other kinases. The content of active compounds was
   quantified, and among the compounds identified from the propolis
   extract, caffeic acid phenethyl ester, quercetin, and apigenin were
   shown to attenuate PI3K activity. These results demonstrate that
   propolis shows anti-skin-aging effects through direct inhibition of PI3K
   activity.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Byun, S (Corresponding Author), Yonsei Univ, Dept Biotechnol, Seoul 03722, South Korea.
   Kim, Da Hyun; Oh, Jeongyeon; Byun, Sanguine, Yonsei Univ, Dept Biotechnol, Seoul 03722, South Korea.
   Auh, Joong-Hyuck, Chung Ang Univ, Dept Food Sci \& Technol, Anseong 456756, South Korea.
   Hong, Seungpyo; Shin, Eun Ju, Korea Food Res Inst, Wonju 55365, South Korea.
   Choi, Sungbin, Incheon Natl Univ, Div Bioengn, Incheon 22012, South Korea.
   Woo, Soon Ok, Natl Inst Agr Sci, Rural Dev Adm, Dept Agr Biol, Wonju 55365, South Korea.
   Lim, Tae-Gyu, Sejong Univ, Dept Food Sci \& Biotechnol, Seoul 05006, South Korea.},
DOI = {10.3390/nu12123790},
Article-Number = {3790},
EISSN = {2072-6643},
Keywords = {propolis; skin; matrix metalloproteinase-1; UV; phosphoinositide
   3-kinase},
Keywords-Plus = {PATHWAY; P110-ALPHA; P110-BETA},
Research-Areas = {Nutrition \& Dietetics},
Web-of-Science-Categories  = {Nutrition \& Dietetics},
Author-Email = {dahyun.kim@yonsei.ac.kr
   jhauh@cau.ac.kr
   ojo1661@naver.com
   hsp@kfri.re.kr
   201921148@inu.ac.kr
   sej296@naver.com
   wooso1@korea.kr
   tglim@sejong.ac.kr
   sanguine@yonsei.ac.kr},
Affiliations = {Yonsei University; Chung Ang University; Korea Food Research Institute
   (KFRI); Incheon National University; Rural Development Administration
   (RDA), Republic of Korea; National Institute of Agricultural Sciences;
   Sejong University},
ResearcherID-Numbers = {Byun, Sanguine/AAR-5451-2021
   Auh, Joong Hyuck/ABG-9137-2021
   Lim, Tae-Gyu/AAO-8475-2020
   Hong, Seungpyo/ABA-4461-2021},
ORCID-Numbers = {Lim, Tae-Gyu/0000-0001-6930-9565
   Hong, Seungpyo/0000-0003-1273-0740},
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) - Korean government (MSIP)
   {[}NRF-2020R1A2C1010703]; Yonsei University {[}2020-22-0073]; Brain
   Korea 21 (BK21) program; BK21 program},
Funding-Text = {This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (MSIP)
   (NRF-2020R1A2C1010703), and by the Yonsei University Research Fund of
   2020-22-0073. This research was supported in part by the Brain Korea 21
   (BK21) program; D.H.K. is a fellowship awardee by BK21 program.},
Cited-References = {Ambi A, 2017, PHYTOMEDICINE, V30, P50, DOI 10.1016/j.phymed.2017.03.006.
   Amzel LM, 2008, NAT REV CANCER, V8, P665, DOI 10.1038/nrc2443.
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235.
   Bode Ann M, 2003, Sci STKE, V2003, pRE2, DOI 10.1126/stke.2003.167.re2.
   Bondonno NP, 2020, CLIN NUTR, V39, P141, DOI 10.1016/j.clnu.2019.01.004.
   Chen LH, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040503.
   Farrand L, 2017, CURR PHARM DESIGN, V23, P4311, DOI 10.2174/1381612823666170710144106.
   Fisher GJ, 2002, ARCH DERMATOL, V138, P1462, DOI 10.1001/archderm.138.11.1462.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Huang SA, 2014, MOLECULES, V19, P19610, DOI 10.3390/molecules191219610.
   Hwang YP, 2011, J DERMATOL SCI, V61, P23, DOI 10.1016/j.jdermsci.2010.10.016.
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033.
   Lee WJ, 2008, TOXICOL APPL PHARM, V226, P178, DOI 10.1016/j.taap.2007.09.013.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Matheny RW, 2010, CELL DEATH DIFFER, V17, P677, DOI 10.1038/cdd.2009.150.
   Maurya AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160686.
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256.
   Noh EM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6354261.
   Oh JH, 2006, J CELL PHYSIOL, V209, P775, DOI 10.1002/jcp.20754.
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41.
   Philips Neena, 2011, Enzyme Res, V2011, P427285, DOI 10.4061/2011/427285.
   Rittié L, 2002, AGEING RES REV, V1, P705, DOI 10.1016/S1568-1637(02)00024-7.
   Shin EJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215262.
   Shin EJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123055.
   TALWAR HS, 1995, J INVEST DERMATOL, V105, P285, DOI 10.1111/1523-1747.ep12318471.
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529.
   Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112.
   Wagh VD, 2013, ADV PHARMACOL SCI, V2013, DOI 10.1155/2013/308249.
   Walker E H, 2000, Mol Cell, V6, P909.
   Zhang Y, 2015, EUR J HISTOCHEM, V59, P98, DOI 10.4081/ejh.2015.2467.},
Number-of-Cited-References = {30},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Nutrients},
Doc-Delivery-Number = {PL4IB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000603086500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000594775100033,
Author = {Lee, Jung-Hoon and Jeon, Jisu and Bai, Fang and Wu, Weihui and Ha,
   Un-Hwan},
Title = {Negative regulation of interleukin 1β expression in response to DnaK
   from Pseudomonas aeruginosa via the PI3K/PDK1/FoxO1 pathways},
Journal = {COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES},
Year = {2020},
Volume = {73},
Month = {DEC},
Abstract = {Interleukin (IL)-1 beta is crucial for a wide range of inflammatory
   responses. Previously, we reported that IL-1 beta is produced in
   response to Pseudomonas aeruginosa-derived DnaK via NF-kappa B and JNK
   pathways; however, the signaling pathways that counter the process to
   maintain IL-1 beta homeostasis are unknown. Here, we show that
   DnaK-mediated expression of IL1 beta is increased markedly in
   macrophages upon blockade of PI3K/PDK1. This was verified by measuring
   released IL-1 beta protein. The negative effect of PI3K on IL-1 beta
   production was dependent on suppression of both NF-kappa B and JNK
   activation. Intriguingly, PDK1 (an underlying mediator of PI3K) acted as
   an upstream regulator for the activation of NF-kappa B, but
   downregulated JNK activation. Furthermore, production of IL-1 beta and
   activation of JNK were triggered by inhibition of phosphorylated FoxO1;
   phosphorylation of FoxO1 was controlled by PDK1 signaling in response to
   DnaK. Thus, IL-1 beta production is modulated by P. aeruginosaderived
   DnaK via cross-talk between JNK and PI3K/PDK1/FoxO1 pathways.},
Publisher = {ELSEVIER SCI LTD},
Address = {125 London Wall, London, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Ha, UH (Corresponding Author), Korea Univ, Dept Biotechnol \& Bioinformat, 2511 Sejong Ro, Sejong 30019, South Korea.
   Lee, Jung-Hoon; Jeon, Jisu; Ha, Un-Hwan, Korea Univ, Dept Biotechnol \& Bioinformat, 2511 Sejong Ro, Sejong 30019, South Korea.
   Bai, Fang; Wu, Weihui, Nankai Univ, Dept Microbiol, Minist Educ, State Key Lab Med Chem Biol,Key Lab Mol Microbiol, Tianjin 300071, Peoples R China.},
DOI = {10.1016/j.cimid.2020.101543},
Article-Number = {101543},
ISSN = {0147-9571},
EISSN = {1878-1667},
Keywords = {DnaK; FoxO1; IL-1 beta; PDK1; PI3K; Pseudomonas aeruginosa},
Keywords-Plus = {HEAT-SHOCK PROTEINS; EXTRACELLULAR HSP70; ACTIVATION; INFECTION;
   CYTOKINE; CELLS; LUNG; PHOSPHORYLATION; TRANSCRIPTION; INFLAMMASOME},
Research-Areas = {Immunology; Microbiology; Veterinary Sciences},
Web-of-Science-Categories  = {Immunology; Microbiology; Veterinary Sciences},
Author-Email = {haunhwan@korea.ac.kr},
Affiliations = {Korea University; Nankai University},
ResearcherID-Numbers = {Ha, Un-Hwan/ABH-8017-2020},
Funding-Acknowledgement = {Korea-China Joint Research Program {[}NRF-2018K1A3A1A20019872]; Ministry
   of Science and Technology of China {[}SQ2017FYGH002134]},
Funding-Text = {This work was supported by Korea-China Joint Research Program
   (NRF-2018K1A3A1A20019872) and Ministry of Science and Technology of
   China (SQ2017FYGH002134).},
Cited-References = {Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200.
   Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697.
   Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340.
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613.
   Bernal-Rosas Y, 2015, REV MVZ CORDOBA, V20, P4937, DOI 10.21897/rmvz.9.
   Binder RJ, 2004, TISSUE ANTIGENS, V64, P442, DOI 10.1111/j.1399-0039.2004.00299.x.
   Borges TJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00095.
   Cai SS, 2012, J IMMUNOL, V188, P5623, DOI 10.4049/jimmunol.1200195.
   CRAIG EA, 1993, MICROBIOL REV, V57, P402, DOI 10.1128/MMBR.57.2.402-414.1993.
   De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001.
   DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745.
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612.
   Douglas TA, 2009, EUR RESPIR J, V33, P305, DOI 10.1183/09031936.00043108.
   Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268.
   Fong JJ, 2015, EMBO J, V34, P2775, DOI 10.15252/embj.201591407.
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x.
   Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200.
   Hersh D, 1998, CURR OPIN MICROBIOL, V1, P43, DOI 10.1016/S1369-5274(98)80141-0.
   Ju YH, 2014, INT J ONCOL, V44, P1284, DOI 10.3892/ijo.2014.2269.
   Kawano Y, 2012, DIABETES, V61, P1935, DOI 10.2337/db11-0770.
   Kernacki KA, 1998, INFECT IMMUN, V66, P376, DOI 10.1128/IAI.66.1.376-379.1998.
   LATHIGRA RB, 1991, CURR TOP MICROBIOL, V167, P125.
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452.
   Lau GW, 2005, TRENDS MICROBIOL, V13, P389, DOI 10.1016/j.tim.2005.05.011.
   Lee JH, 2019, COMP IMMUNOL MICROB, V67, DOI 10.1016/j.cimid.2019.101373.
   Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849.
   Miao HM, 2015, CLIN SCI, V128, P493, DOI 10.1042/CS20140414.
   Park HS, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10080419.
   Plum L, 2006, J CLIN INVEST, V116, P1886, DOI 10.1172/JCI27123.
   Plum L, 2006, J CLIN INVEST, V116, P1761, DOI 10.1172/JCI29063.
   Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707.
   Reiniger N, 2007, INFECT IMMUN, V75, P1598, DOI 10.1128/IAI.01980-06.
   RETZLAFF C, 1994, INFECT IMMUN, V62, P5689, DOI 10.1128/IAI.62.12.5689-5693.1994.
   Rudner XL, 2000, J IMMUNOL, V164, P6576, DOI 10.4049/jimmunol.164.12.6576.
   Schilling D, 2001, CYTOKINE, V16, P51, DOI 10.1006/cyto.2001.0948.
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040.
   Sen P, 2007, BLOOD, V109, P653, DOI 10.1182/blood-2006-04-017368.
   SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992.
   Shin H, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00935-16.
   Su DM, 2009, DIABETES, V58, P2624, DOI 10.2337/db09-0232.
   Szretter KJ, 2007, J VIROL, V81, P2736, DOI 10.1128/JVI.02336-06.
   Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200.
   Thakur A, 2002, INFECT IMMUN, V70, P2187, DOI 10.1128/IAI.70.4.2187-2197.2002.
   Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wang YC, 2016, CLIN REV ALLERG IMMU, V51, P353, DOI 10.1007/s12016-016-8531-1.
   Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209.
   Zhao HF, 2015, INT J ONCOL, V47, P429, DOI 10.3892/ijo.2015.3052.
   Zhe Y, 2016, TUMOR BIOL, V37, P13951, DOI 10.1007/s13277-016-5189-5.},
Number-of-Cited-References = {49},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Comp. Immunol. Microbiol. Infect. Dis.},
Doc-Delivery-Number = {OZ2PT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000594775100033},
DA = {2026-02-04},
}

@article{ WOS:000597672500001,
Author = {Wang, Shoubi and Liu, Yurun and Liu, Ying and Li, Chaoyang and Wan, Qi
   and Yang, Liu and Su, Yaru and Cheng, Yaqi and Liu, Chang and Wang,
   Xiaoran and Wang, Zhichong},
Title = {Reversed Senescence of Retinal Pigment Epithelial Cell by Coculture With
   Embryonic Stem Cell via the TGFβ and PI3K Pathways},
Journal = {FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY},
Year = {2020},
Volume = {8},
Month = {NOV 26},
Abstract = {Retinal pigment epithelium (RPE) cellular senescence is an important
   etiology of age-related macular degeneration (AMD). Aging interventions
   based on the application of stem cells to delay cellular senescence have
   shown good prospects in the treatment of age-related diseases. This
   study aimed to investigate the potential of the embryonic stem cells
   (ESCs) to reverse the senescence of RPE cells and to elucidate its
   regulatory mechanism. The hydrogen peroxide (H2O2)-mediated premature
   and natural passage-mediated replicative senescent RPE cells were
   directly cocultured with ESCs. The results showed that the proliferative
   capacity of premature and replicative senescent RPE cells was increased,
   while the positive rate of senescence-associated galactosidase
   (SA-beta-GAL) staining and levels of reactive oxygen species (ROS) and
   mitochondrial membrane potential (MMP) were decreased. The positive
   regulatory factors of cellular senescence (p53, p21(WAF1/CIP1),
   p16(INK4a)) were downregulated, while the negative regulatory factors of
   cellular senescence (Cyclin A2, Cyclin B1, Cyclin D1) were upregulated.
   Furthermore, replicative senescent RPE cells entered the S and G(2)/M
   phases from the G(0)/G(1) phase. TGF beta (TGFB1, SMAD3, ID1, ID3) and
   PI3K (PIK3CG, PDK1, PLK1) pathway-related genes were upregulated in
   premature and replicative senescent RPE cells after ESCs application,
   respectively. We further treated ESCs-cocultured premature and
   replicative senescent RPE cells with SB531542 and LY294002 to inhibit
   the TGF beta and PI3K pathways, respectively, and found that p53,
   p21(WAF1/CIP1) and p16(INK4a) were upregulated, while Cyclin A2, Cyclin
   B1, Cyclin D1, TGF beta, and PI3K pathway-related genes were
   downregulated, accompanied by decreased proliferation and cell cycle
   transition and increased positive rates of SA-beta-GAL staining and
   levels of ROS and MMP. In conclusion, we demonstrated that ESCs can
   effectively reverse the senescence of premature and replicative
   senescent RPE cells by a direct coculture way, which may be achieved by
   upregulating the TGF beta and PI3K pathways, respectively, providing a
   basis for establishing a new therapeutic option for AMD.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, XR; Wang, ZC (Corresponding Author), Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.
   Wang, Shoubi; Liu, Yurun; Liu, Ying; Li, Chaoyang; Wan, Qi; Yang, Liu; Su, Yaru; Cheng, Yaqi; Liu, Chang; Wang, Xiaoran; Wang, Zhichong, Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Peoples R China.},
DOI = {10.3389/fcell.2020.588050},
Article-Number = {588050},
ISSN = {2296-634X},
Keywords = {embryonic stem cell; age-related macular degeneration; retinal pigment
   epithelium cell; reversing cellular senescence; regulatory mechanism},
Keywords-Plus = {INDUCED PREMATURE SENESCENCE; OXIDATIVE STRESS; RPE CELLS; DNA-DAMAGE;
   KINASE 1; CYCLE; EXPRESSION; MICROENVIRONMENT; ACTIVATION; APOPTOSIS},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {wxran@mail2.sysu.edu.cn
   wangzhichong@gzzoc.com},
Affiliations = {Sun Yat Sen University},
ResearcherID-Numbers = {Yang, Liu/GQH-1315-2022
   Wang, Shuangyong/KJL-9776-2024},
Funding-Acknowledgement = {National Key R\&D Program of China {[}2018YFC1106000]},
Funding-Text = {This work was supported by the National Key R\&D Program of China
   (2018YFC1106000).},
Cited-References = {de Mera-Rodriguez JA, 2019, DEV DYNAM, V248, P850, DOI 10.1002/dvdy.74.
   Aravinthan A, 2015, HUM CELL, V28, P51, DOI 10.1007/s13577-015-0110-x.
   Bae YU, 2016, FASEB J, V30, P1276, DOI 10.1096/fj.15-278846.
   Banerjee K, 2015, REDOX BIOL, V5, P153, DOI 10.1016/j.redox.2015.04.009.
   Bendris N, 2015, CELL CYCLE, V14, P1786, DOI 10.1080/15384101.2014.998085.
   Blasiak J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6819736.
   Campisi J, 2014, INTERD T GERONT GERI, V39, P45, DOI 10.1159/000358899.
   Chai C, 2018, CNS NEUROSCI THER, V24, P369, DOI 10.1111/cns.12785.
   Chen R., 2006, CHIN J PATHOPHYSIOL, V22, P7.
   Chen XB, 2017, REDOX BIOL, V12, P987, DOI 10.1016/j.redox.2017.04.031.
   da Costa JP, 2016, AGEING RES REV, V29, P90, DOI 10.1016/j.arr.2016.06.005.
   de Magalhaes JP, 2018, MECH AGEING DEV, V170, P2, DOI 10.1016/j.mad.2017.07.001.
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011.
   Guo Y, 2006, STEM CELLS, V24, P850, DOI 10.1634/stemcells.2005-0457.
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696.
   Jing YH, 2018, EXP GERONTOL, V108, P77, DOI 10.1016/j.exger.2018.04.005.
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010.
   Kida Y, 2016, CAN J CARDIOL, V32, P634, DOI 10.1016/j.cjca.2015.11.022.
   Kim HJ, 2013, J GERONTOL A-BIOL, V68, P1145, DOI 10.1093/gerona/glt017.
   Lee JS, 2006, ARCH TOXICOL, V80, P337, DOI 10.1007/s00204-005-0052-2.
   Liang YY, 2009, CELL RES, V19, P140, DOI 10.1038/cr.2008.321.
   Liu JH, 2019, THERANOSTICS, V9, P4764, DOI 10.7150/thno.33139.
   Liu Y, 2010, TISSUE ENG PART C-ME, V16, P793, DOI {[}10.1089/ten.tec.2009.0380, 10.1089/ten.TEC.2009.0380].
   Lu XY, 2010, MOL VIS, V16, P611.
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI {[}10.1056/nejmc1706274, 10.1056/NEJMoa1608368].
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011.
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2.
   Mowla SN, 2014, AGING CELL, V13, P773, DOI 10.1111/acel.12242.
   Nacarelli T, 2017, MOL CELL ENDOCRINOL, V455, P83, DOI 10.1016/j.mce.2016.08.049.
   Notohamiprodjo S, 2012, BIOL CHEM, V393, P1463, DOI 10.1515/hsz-2012-0188.
   Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366.
   Piechota M, 2016, ONCOTARGET, V7, P81099, DOI 10.18632/oncotarget.12752.
   Qin D, 2013, MOL VIS, V19, P2227.
   Rabin DM, 2013, AGING-US, V5, P51.
   Rebo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13363.
   Santa-Gonzalez GA, 2016, REDOX BIOL, V9, P124, DOI 10.1016/j.redox.2016.07.004.
   Scharpfenecker M, 2009, INT J RADIAT ONCOL, V73, P506, DOI 10.1016/j.ijrobp.2008.09.052.
   Shao C, 2018, ONCOGENE, V37, P810, DOI 10.1038/onc.2017.379.
   Sikora E, 2016, CURR DRUG TARGETS, V17, P377, DOI 10.2174/1389450116666151019094724.
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Velarde MC, 2012, AGING-US, V4, P3, DOI 10.18632/aging.100423.
   Wang SB, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3632169.
   Wang WP, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171454.
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1.
   Xia HW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0302-x.
   Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092.
   Zhang RT, 2015, ONCOL REP, V33, P1235, DOI 10.3892/or.2015.3723.
   Zhang YT, 2016, CELL STRESS CHAPERON, V21, P687, DOI 10.1007/s12192-016-0693-5.
   Zhou CJ, 2014, STEM CELLS DEV, V23, P1741, DOI 10.1089/scd.2013.0585.
   Zhou J, 2011, INT J BIOCHEM CELL B, V43, P1168, DOI 10.1016/j.biocel.2011.04.010.
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732.
   Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029.},
Number-of-Cited-References = {53},
Times-Cited = {18},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Front. Cell. Dev. Biol.},
Doc-Delivery-Number = {PD4QZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000597672500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000592137600004,
Author = {Spirina, L. V. and Avgustinovich, A. V. and Afanas'ev, S. G. and
   Kondakova, I. V. and Volkov, M. Yu. and Dobrodeev, A. Yu. and Boronkina,
   A. I.},
Title = {AKT/mTOR Signal Cascade and Expression of PD-1, PD-L1, and PD-L2 in
   Gastric Cancer},
Journal = {BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE},
Year = {2020},
Volume = {170},
Number = {1},
Pages = {75-78},
Month = {NOV},
Abstract = {The peculiarities of gastric cancer development associated with the
   expression levels of components of the AKT/mTOR signaling cascade and
   PD, PD-L1, PD-L2 have not yet been identified. We revealed the
   fundamental changes in the expression AKT/mTOR and PD receptors and
   their ligands associated with dissemination of gastric cancer. An
   increase in the mRNA level of all components of this cascade was
   demonstrated. The expression of mTOR and AKT decreased against the
   background of enhanced expression of PTEN phosphatase. The increase in
   the expression of PD-1 receptors and PD-L1 and PD-L2 ligands was most
   pronounced in patients with distant metastases.},
Publisher = {SPRINGER},
Address = {ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Spirina, LV (Corresponding Author), Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia.
   Spirina, L. V.; Avgustinovich, A. V.; Afanas'ev, S. G.; Kondakova, I. V.; Volkov, M. Yu.; Dobrodeev, A. Yu., Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia.
   Spirina, L. V.; Boronkina, A. I., Siberian State Med Univ, Minist Hlth Russian Federat, Tomsk, Russia.},
DOI = {10.1007/s10517-020-05007-0},
EarlyAccessDate = {NOV 2020},
ISSN = {0007-4888},
EISSN = {1573-8221},
Keywords = {gastric cancer; AKT; mTOR signaling cascade; PD; PD-L1; PD-L2},
Keywords-Plus = {PATHWAY; AKT},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {spirinalvl@mail.ru},
Affiliations = {Russian Academy of Sciences; Tomsk National Research Medical Center;
   Cancer Research Institute of the RAS; Siberian State Medical University;
   Ministry of Health of the Russian Federation},
ResearcherID-Numbers = {Spirina, Liudmila V/A-7760-2012
   Afanasyev, Sergey/D-2084-2012
   Dobrodeev, Alexey/B-5644-2017
   Kondakova, Irina/C-8658-2012
   Avgustinovich, Alexandra/D-6062-2012},
ORCID-Numbers = {Spirina, Liudmila V/0000-0002-5269-736X
   },
Cited-References = {Guri Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00578.
   Kim LC, 2017, ONCOGENE, V36, P2191, DOI 10.1038/onc.2016.363.
   Murakami D, 2007, GASTRIC CANCER, V10, P45, DOI 10.1007/s10120-006-0410-7.
   Sasaki T, 2014, INT J ONCOL, V45, P2187, DOI 10.3892/ijo.2014.2678.
   Spirina Liudmila V, 2018, {[}中国肺癌杂志, Chinese Journal of Lung Cancer], V21, P63.
   Spirina LV, 2019, KLIN EKSP TIREOIDOL, V15, P110.
   Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4.
   Yang LY, 2017, INT J GYNECOL CANCER, V27, P196, DOI 10.1097/IGC.0000000000000875.
   Zhao CJ, 2019, CANCER LETT, V453, P107, DOI 10.1016/j.canlet.2019.03.043.},
Number-of-Cited-References = {9},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Bull. Exp. Biol. Med.},
Doc-Delivery-Number = {PE5ZS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000592137600004},
DA = {2026-02-04},
}

@article{ WOS:000587764900001,
Author = {Jiao, Yafei and Zhu, Shaoqian and Li, Jiaojiao and Jam Zaheer, Ahmed and
   Li, Mengmei and Huang, Ben},
Title = {PS48 promotes in vitro maturation and developmental competence of
   porcine oocytes through activating PI3K/Akt signalling pathway},
Journal = {REPRODUCTION IN DOMESTIC ANIMALS},
Year = {2020},
Volume = {55},
Number = {12},
Pages = {1678-1687},
Month = {DEC},
Abstract = {Oocyte maturation plays a vitally important role in porcine
   reproduction. Regrettably, the quality of oocytes matured in vitro is
   weaker than that of in vivo matured oocytes. We collected and cultivated
   porcine cumulus oocyte complexes (COCs) in vitro with
   phosphoinositide-dependent kinase 1 (PDK1) activator
   5-(4-chloro-phenyl)-3-phenyl-pent-2-enoic acid (PS48), whose
   concentrations were 0, 2, 5, 10 and 20 mu M to investigate whether the
   phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt) signalling
   pathway would impact the oocyte quality. The results showed that 10 mu M
   PS48 increased the oocyte proportion of metaphase II (MII) stage and
   improved the expansion of cumulus cells (CCs). What's more, the
   activation of PI3K/Akt signalling pathway could regulate the expression
   of maturation-related genes and proteins. The results of quantitative
   real-time PCR showed that 10 mu M PS48 increased the mRNA and protein
   levels of Akt and regulated maturation-related genes, including cyclin
   B1, MOS, BMP15, GDF9, CDC2, mTOR, BAX, BCL2 and caspase-3. The results
   of Western blot indicated that 10 mu M PS48 increased the protein
   abundance of Akt, phosphorylation of Akt Thr308 (p-Akt(Thr308)) and
   cyclin B1, but decreased the protein abundance of pro-apoptotic BAX.
   These results suggested that adding 10 mu M PS48 to mature culture
   medium could promote the maturation of porcine oocytes, potentially
   through activating the PI3K/Akt signalling pathway.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Li, MM; Huang, B (Corresponding Author), Guangxi Univ, State Key Lab Conservat \& Utilizat Subtrop Agrobi, Nanning 530004, Guangxi, Peoples R China.
   Jiao, Yafei; Zhu, Shaoqian; Li, Jiaojiao; Jam Zaheer, Ahmed; Huang, Ben, Guangxi Univ, State Key Lab Conservat \& Utilizat Subtrop Agrobi, Nanning 530004, Guangxi, Peoples R China.
   Jiao, Yafei; Zhu, Shaoqian; Li, Jiaojiao; Jam Zaheer, Ahmed; Li, Mengmei; Huang, Ben, Guangxi Univ, Sch Anim Sci \& Technol, Nanning, Peoples R China.},
DOI = {10.1111/rda.13818},
EarlyAccessDate = {NOV 2020},
ISSN = {0936-6768},
EISSN = {1439-0531},
Keywords = {in vitro maturation; phosphoinositide\&\#8208; dependent kinase 1; PI3K;
   Akt; porcine oocyte; PS48},
Keywords-Plus = {GROWTH-DIFFERENTIATION FACTOR-9; MOS PROTOONCOGENE; CELL-CYCLE; PROTEIN;
   EXPRESSION; MPF; STARFISH; PRODUCT; FEMALE; PDK1},
Research-Areas = {Agriculture; Reproductive Biology; Veterinary Sciences},
Web-of-Science-Categories  = {Agriculture, Dairy \& Animal Science; Reproductive Biology; Veterinary
   Sciences},
Author-Email = {sunkislemon@126.com
   arihuangben@yahoo.com},
Affiliations = {Guangxi University; Guangxi University},
ResearcherID-Numbers = {Huang, Ben/JFK-8430-2023},
ORCID-Numbers = {Huang, Ben/0000-0002-7223-3984},
Funding-Acknowledgement = {Chinese National Natural Science Foundation {[}31660342, 31960160];
   Guangxi Natural Science Foundation {[}2017GXNSFDA198035, AB18221072,
   2018GXNSFAA138148]},
Funding-Text = {Chinese National Natural Science Foundation, Grant/Award Number:
   31660342 and 31960160; Guangxi Natural Science Foundation, Grant/Award
   Number: 2017GXNSFDA198035, AB18221072 and 2018GXNSFAA138148},
Cited-References = {Adhikari D, 2009, ENDOCR REV, V30, P438, DOI 10.1210/er.2008-0048.
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Andrade GM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185045.
   Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003.
   DAEN FP, 1994, J REPROD FERTIL, V101, P667, DOI 10.1530/jrf.0.1010667.
   Dong JW, 1996, NATURE, V383, P531, DOI 10.1038/383531a0.
   DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X.
   García-Hernandez J, 2020, THERIOGENOLOGY, V146, P1, DOI 10.1016/j.theriogenology.2020.01.049.
   GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1.
   GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509.
   Hindie V, 2009, NAT CHEM BIOL, V5, P758, DOI 10.1038/nchembio.208.
   Hoshino Y, 2008, DEV BIOL, V314, P215, DOI 10.1016/j.ydbio.2007.12.005.
   Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9.
   Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183.
   Jiao YF, 2020, REPROD DOMEST ANIM, V55, P351, DOI 10.1111/rda.13620.
   John GB, 2009, DEV BIOL, V331, P292, DOI 10.1016/j.ydbio.2009.05.546.
   Kim J, 2010, MOL REPROD DEV, V77, P330, DOI 10.1002/mrd.21148.
   Knowles MA, 2009, CANCER METAST REV, V28, P305, DOI 10.1007/s10555-009-9198-3.
   LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X.
   Lapasset L, 2008, MOL REPROD DEV, V75, P1617, DOI 10.1002/mrd.20905.
   Li LY, 2016, REPROD DOMEST ANIM, V51, P649, DOI 10.1111/rda.12725.
   Liu LL, 2019, CELL CYCLE, V18, P2986, DOI 10.1080/15384101.2019.1666596.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Makker A, 2014, J MOL ENDOCRINOL, V53, pR103, DOI 10.1530/JME-14-0220.
   MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301.
   Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0.
   Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257.
   SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853.
   Shi PF, 2019, REPROD DOMEST ANIM, V54, P1104, DOI 10.1111/rda.13483.
   Song BS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205495.
   Spate LD, 2015, MOL REPROD DEV, V82, P315, DOI 10.1002/mrd.22474.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Tay J, 2000, DEV BIOL, V221, P1, DOI 10.1006/dbio.2000.9669.
   Xi Q., 2013, J INT REPROD HLTH FA, V32, P471.
   Yan CN, 2001, MOL ENDOCRINOL, V15, P854, DOI 10.1210/me.15.6.854.
   Yang MY, 2002, ANIM REPROD SCI, V70, P159, DOI 10.1016/S0378-4320(01)00186-5.
   Zhang DX, 2011, J REPROD DEVELOP, V57, P49, DOI 10.1262/jrd.10-087H.
   Zhao MH, 2014, IN VITRO CELL DEV-AN, V50, P945, DOI 10.1007/s11626-014-9784-8.
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015.},
Number-of-Cited-References = {41},
Times-Cited = {8},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {18},
Journal-ISO = {Reprod. Domest. Anim.},
Doc-Delivery-Number = {PH6LK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000587764900001},
DA = {2026-02-04},
}

@article{ WOS:000591766900015,
Author = {Ghode, Abhijeet and Gross, Lissy Z. F. and Tee, Wei-Ven and Guarnera,
   Enrico and Berezovsky, Igor N. and Biondi, Ricardo M. and Anand, Ganesh
   S.},
Title = {Synergistic Allostery in Multiligand-Protein Interactions},
Journal = {BIOPHYSICAL JOURNAL},
Year = {2020},
Volume = {119},
Number = {9},
Pages = {1833-1848},
Month = {NOV 3},
Abstract = {Amide hydrogen-deuterium exchange mass spectrometry is powerful for
   describing combinatorial coupling effects of a cooperative ligand pair
   binding at noncontiguous sites: adenosine at the ATP-pocket and a
   docking peptide (PIFtide) at the PIF-pocket, on a model protein kinase
   PDK1. Binding of two ligands to PDK1 reveal multiple hot-spots of
   synergistic allostery with cumulative effects greater than the sum of
   individual effects mediated by each ligand. We quantified this synergism
   and ranked these hotspots using a difference in deuteration-based
   approach, which showed that the strongest synergistic effects were
   observed at three of the critical catalytic loci of kinases: the alpha
   B-alpha C helices, and HRD-motif loop, and DFG-motif. Additionally, we
   observed weaker synergistic effects at a distal GHI-subdomain locus.
   Synergistic changes in deuterium exchange observed at a distal site but
   not at the intermediate sites of the large lobe of the kinase reveals
   allosteric propagation in proteins to operate through two modes. Direct
   electrostatic interactions between polar and charged amino acids that
   mediate targeted relay of allosteric signals, and diffused relay of
   allosteric signals through soft matter-like hydrophobic core amino
   acids. Furthermore, we provide evidence that the conserved beta-3 strand
   lysine of protein kinases (Lys111 of PDK1) functions as an integrator
   node to coordinate allosteric coupling of the two ligandbinding sites.
   It maintains indirect interactions with the ATP-pocket and mediates a
   critical salt bridge with a glutamate (Glu130) of alpha C helix, which
   is conserved across all kinases. In summary, allosteric propagation in
   cooperative, dual-liganded enzyme targets is bidirectional and
   synergistic and offers a strategy for combinatorial drug development.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Anand, GS (Corresponding Author), Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   Ghode, Abhijeet; Tee, Wei-Ven; Berezovsky, Igor N.; Anand, Ganesh S., Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore.
   Gross, Lissy Z. F.; Biondi, Ricardo M., Max Planck Gesell, Partner Inst, CONICET, Inst Invest Biomed Buenos Aires, Buenos Aires, DF, Argentina.
   Tee, Wei-Ven; Guarnera, Enrico; Berezovsky, Igor N., Agcy Sci Technol \& Res, Bioinformat Inst, Matrix, Singapore.},
DOI = {10.1016/j.bpj.2020.09.019},
ISSN = {0006-3495},
EISSN = {1542-0086},
Keywords-Plus = {KINASES},
Research-Areas = {Biophysics},
Web-of-Science-Categories  = {Biophysics},
Author-Email = {dbsgsa@nus.edu.sg},
Affiliations = {National University of Singapore; Max Planck Society; Consejo Nacional
   de Investigaciones Cientificas y Tecnicas (CONICET); Agency for Science
   Technology \& Research (A{*}STAR); A{*}STAR - Bioinformatics Institute
   (BII)},
ResearcherID-Numbers = {Guarnera, Enrico/JPA-2524-2023
   Anand, Ganesh/H-8473-2012
   Biondi, Ricardo/IWU-9368-2023},
ORCID-Numbers = {Gross, Lissy/0000-0001-6182-0086
   Guarnera, Enrico/0000-0002-6780-3313
   Tee, Wei Ven/0000-0001-8295-6265
   Ghode, Abhijeet/0000-0002-8619-703X
   Biondi, Ricardo/0000-0002-8873-7167},
Funding-Acknowledgement = {Competitive Research Proposal grant - National Research Foundation,
   Singapore {[}R-154-000-B12-281]; RSB from Singapore Ministry of
   Education {[}MOE2019-T1-B24-114]},
Funding-Text = {This work was supported by a Competitive Research Proposal grant
   (R-154-000-B12-281) funded by the National Research Foundation,
   Singapore awarded to G.S.A. A.G. was supported by an RSB-funded Research
   Fellowship from Singapore Ministry of Education Academic Research Fund
   (MOE2019-T1-B24-114) awarded to G.S.A.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Anand G. S, 2014, Bacteriophage, V4.
   Anand GS, 2002, J MOL BIOL, V323, P377, DOI 10.1016/S0022-2836(02)00919-1.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Badireddy S, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.110.004390.
   Bateman RH, 2002, J AM SOC MASS SPECTR, V13, P792, DOI 10.1016/S1044-0305(02)00420-8.
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2.
   Biondi RM, 2002, EMBO J, V21, P4219, DOI 10.1093/emboj/cdf437.
   Boehr DD, 2009, NAT CHEM BIOL, V5, P789, DOI 10.1038/nchembio.232.
   Busschots K, 2012, CHEM BIOL, V19, P1152, DOI 10.1016/j.chembiol.2012.07.017.
   Chandramohan A, 2017, ANAL CHEM, V89, P7876, DOI 10.1021/acs.analchem.7b00587.
   Chandramohan A, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004840.
   Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849.
   COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625.
   Cui KP, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.185501.
   CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267.
   Heras-Martínez GD, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50742-8.
   del Sol A, 2009, STRUCTURE, V17, P1042, DOI 10.1016/j.str.2009.06.008.
   Dennis PB, 1998, J BIOL CHEM, V273, P14845, DOI 10.1074/jbc.273.24.14845.
   Engel M, 2006, EMBO J, V25, P5469, DOI 10.1038/sj.emboj.7601416.
   Fabbro D, 2015, BRIT J PHARMACOL, V172, P2675, DOI 10.1111/bph.13096.
   Galstyan V, 2019, J PHYS CHEM B, V123, P2792, DOI 10.1021/acs.jpcb.8b12517.
   Guarnera E, 2019, STRUCTURE, V27, P866, DOI 10.1016/j.str.2019.01.014.
   Guarnera E, 2019, CURR OPIN STRUC BIOL, V56, P18, DOI 10.1016/j.sbi.2018.10.008.
   Guarnera E, 2017, BIOINFORMATICS, V33, P3996, DOI 10.1093/bioinformatics/btx430.
   Guarnera E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004678.
   Gunasekaran K, 2004, PROTEINS, V57, P433, DOI 10.1002/prot.20232.
   HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115.
   Hertig S, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004746.
   Hindie V, 2009, NAT CHEM BIOL, V5, P758, DOI 10.1038/nchembio.208.
   Hinsen K, 2000, CHEM PHYS, V261, P25, DOI 10.1016/S0301-0104(00)00222-6.
   Hoofnagle AN, 2003, ANNU REV BIOPH BIOM, V32, P1, DOI 10.1146/annurev.biophys.32.110601.142417.
   Hughes CA, 2001, J MOL BIOL, V307, P967, DOI 10.1006/jmbi.2001.4523.
   Iturriaga-Vásquez P, 2015, PHARMACOL RES, V101, P9, DOI 10.1016/j.phrs.2015.08.018.
   Iyer GH, 2005, J MOL BIOL, V351, P1110, DOI 10.1016/j.jmb.2005.06.011.
   Johnson B, 2018, CELL REP, V23, P2795, DOI 10.1016/j.celrep.2018.04.096.
   JOHNSON RS, 1994, PROTEIN SCI, V3, P2411, DOI 10.1002/pro.5560031224.
   Kang JA, 2013, J IMMUNOL, V190, P4508, DOI 10.4049/jimmunol.1202923.
   Kornev AP, 2015, TRENDS BIOCHEM SCI, V40, P628, DOI 10.1016/j.tibs.2015.09.002.
   KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047.
   Lavoie H, 2014, TRENDS BIOCHEM SCI, V39, P475, DOI 10.1016/j.tibs.2014.08.004.
   Leroux AE, 2020, TRENDS BIOCHEM SCI, V45, P27, DOI 10.1016/j.tibs.2019.09.007.
   Leroux AE, 2019, ADV EXP MED BIOL, V1163, P279, DOI 10.1007/978-981-13-8719-7\_12.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762.
   Markwick PRL, 2019, BIOPHYS J, V116, P49, DOI 10.1016/j.bpj.2018.11.023.
   Masters TA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000738.
   Mazzoletti M, 2011, CANCER RES, V71, P4573, DOI 10.1158/0008-5472.CAN-10-4322.
   MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1.
   Moorthy BS, 2012, J MOL BIOL, V417, P468, DOI 10.1016/j.jmb.2012.01.052.
   Moorthy BS, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002295.
   Motlagh HN, 2014, NATURE, V508, P331, DOI 10.1038/nature13001.
   Nussinov R, 2013, ANNU REV BIOPHYS, V42, P169, DOI 10.1146/annurev-biophys-083012-130257.
   Nussinov R, 2013, CELL, V153, P293, DOI 10.1016/j.cell.2013.03.034.
   PERUTZ MF, 1970, NATURE, V228, P726, DOI 10.1038/228726a0.
   Rettenmaier TJ, 2014, P NATL ACAD SCI USA, V111, P18590, DOI 10.1073/pnas.1415365112.
   Sadowsky JD, 2011, P NATL ACAD SCI USA, V108, P6056, DOI 10.1073/pnas.1102376108.
   Scheeff ED, 2005, PLOS COMPUT BIOL, V1, P359, DOI 10.1371/journal.pcbi.0010049.
   Schulze JO, 2016, CELL CHEM BIOL, V23, P1193, DOI 10.1016/j.chembiol.2016.06.017.
   Shi ZS, 2006, CURR OPIN STRUC BIOL, V16, P686, DOI 10.1016/j.sbi.2006.10.011.
   Sieghart W, 2015, ADV PHARMACOL, V72, P53, DOI 10.1016/bs.apha.2014.10.002.
   Silva JC, 2005, ANAL CHEM, V77, P2187, DOI 10.1021/ac048455k.
   Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8.
   Taylor SS, 2012, NAT REV MOL CELL BIO, V13, P646, DOI 10.1038/nrm3432.
   Taylor SS, 2011, TRENDS BIOCHEM SCI, V36, P65, DOI 10.1016/j.tibs.2010.09.006.
   Tee WV, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006228.
   Tulsian NK, 2017, BIOPHYS J, V112, P2552, DOI 10.1016/j.bpj.2017.04.045.
   Weis DD, 2006, J AM SOC MASS SPECTR, V17, P1498, DOI 10.1016/j.jasms.2006.05.014.
   Zhang H, 2014, CHEM BIOL, V21, P754, DOI 10.1016/j.chembiol.2014.04.007.
   Zhang JM, 2010, NATURE, V463, P501, DOI 10.1038/nature08675.
   ZHANG ZQ, 1993, PROTEIN SCI, V2, P522.},
Number-of-Cited-References = {73},
Times-Cited = {33},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Biophys. J.},
Doc-Delivery-Number = {OU8IP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000591766900015},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000574852000007,
Author = {Ommati, Mohammad Mehdi and Shi, Xiong and Li, Huifeng and Zamiri,
   Mohammad Javad and Farshad, Omid and Jamshidzadeh, Akram and Heidari,
   Reza and Ghaffari, Hasti and Zaker, Ladan and Sabouri, Samira and Chen,
   Yuanyu},
Title = {The mechanisms of arsenic-induced ovotoxicity, ultrastructural
   alterations, and autophagic related paths: An enduring developmental
   study in folliculogenesis of mice},
Journal = {ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY},
Year = {2020},
Volume = {204},
Month = {NOV},
Abstract = {Arsenic (As) exerts a wide range of adverse effects on biological
   systems, including the reproductive organs in males and females.
   However, the mechanisms of As-induced reproductive toxicity are mostly
   obscure. Recently, we showed that autophagy is an essential route for
   As2O3-induced reprotoxicity through the
   hypothalamic-pituitary-gonadal-sperm (HPG-S) axis in pubertal and
   matured F1-male mice. However, the role of autophagy in As2O3-induced
   ovarian toxicity is mostly unknown. Hence, this study aimed to elucidate
   the role of oxidative stress, mitochondrial impairment, and autophagic
   processes in the ovary of As-exposed female mice. For this purpose,
   mature female mice were challenged with O, low (0.2), medium (2), and
   high (20 ppm) As2O3 from 35-days before mating till weaning their pups,
   and the F1-females from weaning until maturity. Then, all the mice were
   sacrificed, and oxidative stress parameters, mitochondrial indices,
   electron microscopic evaluation of the ovaries, expression of
   autophagic-related genes and proteins, and autophagosome formation were
   assessed. It was shown that medium and high As2O3 doses were a potent
   inducer of oxidative stress, mitochondrial dysfunction, and autophagy in
   the ovary of F1-generation. A dose-dependent increment in the gene
   expression of PDK1, PI3K, TSC2, AMPK, ULK1, ATG13, Beclin1, ATG12, ATG5,
   LC3, P62, ATG3, ATG7, and p62, as well as protein expression of Beclin1,
   and LC3- I, II, was evident in the ovaries of the As-treated animals.
   Moreover, a dose-dependent decrease in the expression of mTOR and Bcl-2
   genes, and mTOR protein was detected with increasing doses of As,
   suggesting that As treatment-induced autophagy. Along with a
   dose-dependent increase in the number of MDC-labeled autophagic
   vacuoles, transmission electron microscopy also confirmed more
   autophagosomes and injured mitochondria in medium and high As2O3 doses
   groups. As2O3 also negatively affected the mean body weight, litter
   size, organ coefficient, and stereological indices in female mice.
   Finally, in physiological conditions, arsenic trioxide (As2O3) leads to
   an increased level of autophagy in the oocyte when many oocytes were
   being lost. These findings indicated that an imbalance in the
   oxidant-antioxidant system, mitochondrial impairment, and the autophagic
   process, through inhibition of mTOR, dependent and independent pathways,
   and Bcl-2, as well as activation of AMPK/PI3K/Beclin1/LC3 mutes, could
   play a pivotal role in As-induced reproductive toxicity through ovarian
   dysfunction in females.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Ommati, MM (Corresponding Author), Shanxi Agr Univ, Coll Life Sci, Dept Bioinformat, Taigu 030801, Shanxi, Peoples R China.
   Heidari, R (Corresponding Author), Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz 158371345, Iran.
   Ommati, Mohammad Mehdi; Shi, Xiong; Li, Huifeng; Sabouri, Samira; Chen, Yuanyu, Shanxi Agr Univ, Coll Life Sci, Dept Bioinformat, Taigu 030801, Shanxi, Peoples R China.
   Zamiri, Mohammad Javad, Shiraz Univ, Dept Anim Sci, Shiraz, Iran.
   Farshad, Omid; Jamshidzadeh, Akram; Heidari, Reza, Shiraz Univ Med Sci, Pharmaceut Sci Res Ctr, Shiraz 158371345, Iran.
   Ghaffari, Hasti, Islamic Azad Univ, Dept Vet Sci, Urmia Branch, Orumiyeh, Iran.
   Zaker, Ladan, Univ Tehran Med Sci, Sch Med, Dept Hematol, Tehran, Iran.},
DOI = {10.1016/j.ecoenv.2020.110973},
Article-Number = {110973},
ISSN = {0147-6513},
EISSN = {1090-2414},
Keywords = {Arseniasis; Fertility; Mitochondria; Oogenesis; Oxidative stress;
   Reproduction},
Keywords-Plus = {ENDOPLASMIC-RETICULUM STRESS; CELL-DEATH; OXIDATIVE STRESS;
   MITOCHONDRIAL DYSFUNCTION; SEMINAL CHARACTERISTICS; N-ACETYLCYSTEINE;
   EXPOSURE; TRIOXIDE; SPERM; GROWTH},
Research-Areas = {Environmental Sciences \& Ecology; Toxicology},
Web-of-Science-Categories  = {Environmental Sciences; Toxicology},
Author-Email = {mehdi.ommati@gmail.com
   reza.heidari@hotmail.com},
Affiliations = {Shanxi Agricultural University; Shiraz University; Tehran University of
   Medical Sciences; Shiraz University of Medical Science; Islamic Azad
   University; Tehran University of Medical Sciences},
ResearcherID-Numbers = {Heidari, Reza/F-6625-2013
   Zamiri, Javad/AAD-7806-2021
   Ommati, Mohammad Mehdi/AAQ-7091-2020},
ORCID-Numbers = {Heidari, Reza/0000-0002-7038-9838
   Ommati, Mohammad Mehdi/0000-0003-0514-2414},
Funding-Acknowledgement = {Shanxi Government (National Natural Science Foundation of China (CN))
   {[}2018YJ33]; outstanding doctors volunteering to work in Shanxi
   Province, Shanxi province, China {[}K271999031]; Pharmaceutical Sciences
   Research Center of Shiraz University of Medical Sciences, Shiraz, Iran
   {[}98-01-36-19357]},
Funding-Text = {This study was supported by Shanxi Government Scholarship for
   International Research Assistant (National Natural Science Foundation of
   China (CN); Grant No. 2018YJ33; provided by Dr. M. Mehdi Ommati), and
   outstanding doctors volunteering to work in Shanxi Province (No.
   K271999031; by Dr. M. Mehdi Ommati), Shanxi province, China; as well as
   Pharmaceutical Sciences Research Center of Shiraz University of Medical
   Sciences, Shiraz, Iran (No. 98-01-36-19357, by Dr. Reza Heidari). Also,
   the authors would like to extend their sincere appreciation to the
   Department of Life Sciences, Shanxi Agricultural University to provide
   all the necessary facilities.},
Cited-References = {Aldawood N, 2020, ECOTOX ENVIRON SAFE, V197, DOI 10.1016/j.ecoenv.2020.110595.
   {[}Anonymous], 1999, Arsenic in Drinking Water, DOI {[}10.17226/6444, DOI 10.17226/6444].
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3.
   Bolt AM, 2010, ARSEN ENVIR, P291.
   Bolt AM, 2010, TOXICOL LETT, V199, P153, DOI 10.1016/j.toxlet.2010.08.017.
   Caglayan C, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12720.
   Caldwell KK, 2018, NEUROTOXICOL TERATOL, V66, P102, DOI 10.1016/j.ntt.2017.11.003.
   Caro AA, 2012, TOXICOL LETT, V214, P166, DOI 10.1016/j.toxlet.2012.08.017.
   Chan EY, 2009, AUTOPHAGY, V5, P758, DOI 10.4161/auto.8709.
   da Silva RF, 2017, J TOXICOL ENV HEAL A, V80, P1166, DOI 10.1080/15287394.2017.1376405.
   Davey JC, 2008, ENVIRON HEALTH PERSP, V116, P165, DOI 10.1289/ehp.10131.
   Dávila-Esqueda ME, 2012, EXP TOXICOL PATHOL, V64, P25, DOI 10.1016/j.etp.2010.06.001.
   Gao M, 2018, TOXICOL LETT, V284, P195, DOI 10.1016/j.toxlet.2017.12.009.
   Ghosh Debidas, 1999, Journal of Environmental Sciences (China), V11, P419.
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697.
   Guo Q, 2020, CHEMOSPHERE, V241, DOI 10.1016/j.chemosphere.2019.124861.
   Guvvala PR, 2016, ENVIRON SCI POLLUT R, V23, P18200, DOI 10.1007/s11356-016-6870-3.
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910.
   Heaney CD, 2015, ENVIRON RES, V142, P273, DOI 10.1016/j.envres.2015.07.004.
   Heidari R, 2018, TREND PHARM SCI, V4, P41.
   Heidari R, 2019, BIOMED PHARMACOTHER, V109, P271, DOI 10.1016/j.biopha.2018.10.104.
   Heidari R, 2018, BIOMED PHARMACOTHER, V107, P834, DOI 10.1016/j.biopha.2018.08.050.
   Heidari R, 2016, TOXICOL REP, V3, P870, DOI 10.1016/j.toxrep.2016.04.002.
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200.
   IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004, IARC Monogr Eval Carcinog Risks Hum, V84, P1.
   Ince S, 2016, ANDROLOGIA, V48, P518, DOI 10.1111/and.12472.
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080.
   Jamshidzadeh Akram, 2017, PharmaNutrition, V5, P58, DOI {[}10.1016/j.phanu.2017.02.004, 10.1016/j.phanu.2017.02.004].
   Jamshidzadeh A, 2017, BIOMED PHARMACOTHER, V86, P514, DOI 10.1016/j.biopha.2016.11.095.
   Johnson J, 2010, RESIDENTIAL CARE TRANSFORMED: REVISITING THE LAST REFUGE, P17.
   Kanninen TT, 2013, EUR J OBSTET GYN R B, V171, P3, DOI 10.1016/j.ejogrb.2013.07.020.
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717.
   Laine JE, 2015, ENVIRON HEALTH PERSP, V123, P186, DOI 10.1289/ehp.1307476.
   Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009.
   Li SW, 2018, ECOTOX ENVIRON SAFE, V148, P125, DOI 10.1016/j.ecoenv.2017.10.018.
   Li XH, 2018, CHEMOSPHERE, V202, P119, DOI 10.1016/j.chemosphere.2018.03.095.
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426.
   Lim HJ, 2014, INT J DEV BIOL, V58, P183, DOI 10.1387/ijdb.130337hl.
   Lin P.-H., 2019, ADV AUTOPHAGY TISSUE.
   Liu JJ, 2019, CHEMOSPHERE, V219, P227, DOI 10.1016/j.chemosphere.2018.11.188.
   Ma BY, 2014, CELL RES, V24, P912, DOI 10.1038/cr.2014.84.
   Manthari RK, 2018, ARCH TOXICOL, V92, P3255, DOI 10.1007/s00204-018-2304-y.
   Manthari RK, 2018, J AGR FOOD CHEM, V66, P8602, DOI 10.1021/acs.jafc.8b02654.
   Matsunaga K, 2010, J CELL BIOL, V190, P511, DOI 10.1083/jcb.200911141.
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639.
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026.
   Niknahad H, 2016, PHARM SCI-IRAN, V22, P217, DOI 10.15171/ps.2016.35.
   Nordstrom DK, 2002, SCIENCE, V296, P2143, DOI 10.1126/science.1072375.
   Ommati MM, 2019, CHEMOSPHERE, V236, DOI 10.1016/j.chemosphere.2019.07.056.
   Ommati MM, 2018, ANDROLOGY-US, V6, P199, DOI 10.1111/andr.12448.
   Ommati MM, 2013, ANIM PROD SCI, V53, P548, DOI 10.1071/AN12257.
   Ommati M.M., 2019, BIOL TRACE ELEM RES.
   Ommati MM, 2020, TOXICOL LETT, V326, P83, DOI 10.1016/j.toxlet.2020.02.013.
   Ommati MM, 2019, TOXICOL LETT, V316, P60, DOI 10.1016/j.toxlet.2019.09.009.
   Ommati MM, 2019, BIOL TRACE ELEM RES, V187, P151, DOI 10.1007/s12011-018-1358-2.
   Ommati Mohammad Mehdi, 2017, PharmaNutrition, V5, P141, DOI {[}10.1016/j.phanu.2017.10.003, 10.1016/j.phanu.2017.10.003].
   Ommati MM, 2018, TOXICOL LETT, V284, P46, DOI 10.1016/j.toxlet.2017.11.034.
   Pierdominici M, 2017, ONCOTARGET, V8, P8522, DOI 10.18632/oncotarget.14338.
   Prabu S.M., 2019, RES REV J TOXICOL, V4, P14.
   Pucer A, 2010, BIOL CHEM, V391, P519, DOI 10.1515/BC.2010.050.
   Qi YL, 2014, EXP TOXICOL PATHOL, V66, P163, DOI 10.1016/j.etp.2014.01.004.
   Qian WB, 2007, LEUKEMIA RES, V31, P329, DOI 10.1016/j.leukres.2006.06.021.
   Ratnaike RN, 2003, POSTGRAD MED J, V79, P391, DOI 10.1136/pmj.79.933.391.
   Reddy PS, 2011, J TRACE ELEM MED BIO, V25, P247, DOI 10.1016/j.jtemb.2011.08.145.
   Reilly MP, 2014, REPROD TOXICOL, V44, P41, DOI 10.1016/j.reprotox.2013.09.005.
   Rodríguez-Lado L, 2013, SCIENCE, V341, P866, DOI 10.1126/science.1237484.
   Saemi F, 2012, POULTRY SCI, V91, P2310, DOI 10.3382/ps.2012-02304.
   SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4.
   Sengupta M, 2013, SYST BIOL REPROD MED, V59, P199, DOI 10.3109/19396368.2013.783143.
   Shao YZ, 2018, POULTRY SCI, V97, P3248, DOI 10.3382/ps/pey156.
   Sohrabi M, 2015, SINGAP MED J, V56, P573, DOI {[}10.11622/smedj.2015085, 10.11622/smedj.2015085].
   Sou Y, 2008, MOL BIOL CELL, V19, P4762, DOI 10.1091/mbc.E08-03-0309.
   Torner H, 2004, THERIOGENOLOGY, V61, P1675, DOI 10.1016/j.theriogenology.2003.09.013.
   Wang LY, 2009, J ZHEJIANG UNIV-SC B, V10, P483, DOI 10.1631/jzus.B0820379.
   Wang YJ, 2019, ELECTROPHORESIS, V40, P969, DOI 10.1002/elps.201800302.
   Weyhenmeyer B., 2012, EXPT ONCOLOGY.
   WHO, 1998, HLTH CRIT OTH SUPP I, V2.
   Winchester V., 1998, ARC SOC VIRG ANN M.
   Wirth M, 2013, SEMIN CANCER BIOL, V23, P301, DOI 10.1016/j.semcancer.2013.05.007.
   Wu BW, 2018, BIOCHEM BIOPH RES CO, V496, P167, DOI 10.1016/j.bbrc.2018.01.018.
   Wu W, 2018, FOOD CHEM TOXICOL, V111, P19, DOI 10.1016/j.fct.2017.10.043.
   Xi SH, 2010, BIOL TRACE ELEM RES, V134, P84, DOI 10.1007/s12011-009-8455-1.
   Yi Y, 2020, J ETHNOPHARMACOL, V247, DOI 10.1016/j.jep.2018.10.037.
   Young ARJ, 2006, J CELL SCI, V119, P3888, DOI 10.1242/jcs.03172.
   Yu Y., 2017, BIOL TRACE ELEMENT R.
   Yu YX, 2018, BIOL TRACE ELEM RES, V181, P95, DOI 10.1007/s12011-017-1023-1.
   Yuan JY, 2010, GENE DEV, V24, P2592, DOI 10.1101/gad.1984410.
   Zhao YH, 2019, J BIOCHEM MOL TOXIC, V33, DOI 10.1002/jbt.22334.
   Zhou JW, 2019, INT J BIOL SCI, V15, P726, DOI 10.7150/ijbs.30369.},
Number-of-Cited-References = {89},
Times-Cited = {56},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Ecotox. Environ. Safe.},
Doc-Delivery-Number = {NW2PM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000574852000007},
DA = {2026-02-04},
}

@article{ WOS:000588362700013,
Author = {Pataki, Emese and Simhaev, LubFtablea and Engel, Hamutal and Cohen,
   Adiel and Kupiec, Martin and Weisman, Ronit},
Title = {TOR Complex 2-independent mutations in the regulatory PIF pocket of
   Gad8AKT1/SGK1 define separate branches of the stress response
   mechanisms in fission yeast},
Journal = {PLOS GENETICS},
Year = {2020},
Volume = {16},
Number = {11},
Month = {NOV},
Abstract = {The Target of rapamycin (TOR) protein kinase forms part of TOR complex 1
   (TORC1) and TOR complex 2 (TORC2), two multi-subunit protein complexes
   that regulate growth, proliferation, survival and developmental
   processes by phosphorylation and activation of AGC-family kinases. In
   the fission yeast, Schizosaccharomyces pombe, TORC2 and its target, the
   AGC kinase Gad8 (an orthologue of human AKT or SGK1) are required for
   viability under stress conditions and for developmental processes in
   response to starvation cues. In this study, we describe the isolation of
   gad8 mutant alleles that bypass the requirement for TORC2 and reveal a
   separation of function of TORC2 and Gad8 under stress conditions. In
   particular, osmotic and nutritional stress responses appear to form a
   separate branch from genotoxic stress responses downstream of
   TORC2-Gad8. Interestingly, TORC2-independent mutations map into the
   regulatory PIF pocket of Gad8, a highly conserved motif in AGC kinases
   that regulates substrate binding in PDK1 (phosphoinositide dependent
   kinase-1) and kinase activity in several AGC kinases. Gad8 activation is
   thought to require a two-step mechanism, in which phosphorylation by
   TORC2 allows further phosphorylation and activation by Ksg1 (an
   orthologue of PDK1). We focus on the Gad8-K263C mutation and demonstrate
   that it renders the Gad8 kinase activity independent of TORC2 in vitro
   and independent of the phosphorylation sites of TORC2 in vivo. Molecular
   dynamics simulations of Gad8-K263C revealed abnormal high flexibility at
   T387, the phosphorylation site for Ksg1, suggesting a mechanism for the
   TORC2-independent Gad8 activity. Significantly, the K263 residue is
   highly conserved in the family of AGC-kinases, which may suggest a
   general way of keeping their activity in check when acting downstream of
   TOR complexes.
   Author summary
   Protein kinases catalyze the transfer of phosphate from high-energy,
   phosphate-donating molecules, such as ATP, to their substrates. This
   process is pivotal for regulation of almost any aspect of cellular
   biology. Many human diseases are associated with aberrant functions of
   protein kinases due to mutations. Accordingly, there is a growing number
   of kinase inhibitors that have been approved for clinical use. A better
   understanding of how protein kinases become active and how their
   activity is relayed to regulate their cellular functions is much needed
   for rational design of kinase inhibitors and for their optimal use in
   the clinic. The AGC-family of protein kinases play key roles in
   regulating cellular growth, proliferation and survival. In human cells,
   as well as in the fission yeast, our cellular model system, a subgroup
   of the AGC kinases is activated by the TOR protein kinases. Here we
   report the isolation of mutations in the AGC kinase Gad8 (AKT or SGK1 in
   human) that bypass the requirement for activation by TOR. Analyses of
   how these mutations affect cellular growth revealed separate branches of
   stress response mechanisms downstream of Gad8, while computer simulation
   methods suggested a molecular mechanism that keeps the activity of Gad8
   in check.},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Article},
Language = {English},
Affiliation = {Weisman, R (Corresponding Author), Open Univ Israel, Dept Nat \& Life Sci, Raanana, Israel.
   Pataki, Emese; Cohen, Adiel; Weisman, Ronit, Open Univ Israel, Dept Nat \& Life Sci, Raanana, Israel.
   Simhaev, LubFtablea; Engel, Hamutal, Tel Aviv Univ, Blavatnik Ctr Drug Discovery, Tel Aviv, Israel.
   Kupiec, Martin, Tel Aviv Univ, Shmunis Sch Biomed \& Canc Res, Tel Aviv, Israel.},
DOI = {10.1371/journal.pgen.1009196},
Article-Number = {e1009196},
ISSN = {1553-7404},
Keywords-Plus = {AGC KINASE; MOTIF PHOSPHORYLATION; PROTEIN-KINASES; BINDING POCKET;
   PDK1; ACTIVATION; MTOR; TARGET; PATHWAY; RICTOR},
Research-Areas = {Genetics \& Heredity},
Web-of-Science-Categories  = {Genetics \& Heredity},
Author-Email = {ronitwe@openu.ac.il},
Affiliations = {Open University Israel; Tel Aviv University; Tel Aviv University},
ORCID-Numbers = {Weisman, Ronit/0000-0003-4832-180X
   Engel, Hamutal/0000-0002-3662-0979},
Funding-Acknowledgement = {Israel Science foundation (ISF) {[}688/14]; Open University of Israel
   {[}31054]; ISF grant},
Funding-Text = {This research was supported by grants to R.W from the Israel Science
   foundation (ISF grant 688/14) and the Open University of Israel (grant
   31054). Please note that the ISF grant was completed thre years ago and
   funded only the beginning of the project. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.},
Cited-References = {ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2.
   {[}Anonymous], 2017, CANC DISCOVERY, V7, pOF12.
   {[}Anonymous], 2020, ANESTHESIOLOGY, V133, pA12, DOI 10.1097/ALN.0000000000003457.
   {[}Anonymous], 2011, CANC DISCOV, V1, pOF1.
   {[}Anonymous], 2018, DIABETES CARE S1, V2018, pS1.
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI {[}10.1093/nar/gkh131, 10.1093/nar/gkw1099].
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015.
   Baker K, 2016, J CELL SCI, V129, P2613, DOI 10.1242/jcs.190124.
   Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012.
   Berchtold D, 2012, NAT CELL BIOL, V14, P542, DOI 10.1038/ncb2480.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Bochevarov AD, 2013, INT J QUANTUM CHEM, V113, P2110, DOI 10.1002/qua.24481.
   Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432.
   Carr AM, 2002, DNA REPAIR, V1, P983, DOI 10.1016/S1568-7864(02)00165-9.
   Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8.
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003.
   Cohen A, 2016, J BIOL CHEM, V291, P9371, DOI 10.1074/jbc.M115.705251.
   Cohen A, 2014, J BIOL CHEM, V289, P21727, DOI 10.1074/jbc.M114.573824.
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397.
   deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135.
   Dutta C, 2008, MOL CELL BIOL, V28, P5977, DOI 10.1128/MCB.00596-08.
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120.
   Frödin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007.
   Hatano T, 2015, CELL CYCLE, V14, P848, DOI 10.1080/15384101.2014.1000215.
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5.
   Ikeda K, 2008, CELL CYCLE, V7, P358, DOI 10.4161/cc.7.3.5245.
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119.
   Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493.
   Jacinto E, 2008, BIOCHEM J, V410, P19, DOI 10.1042/BJ20071518.
   Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005.
   Kawai M, 2001, CURR GENET, V39, P166.
   Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1.
   Laboucarie T, 2017, EMBO REP, DOI {[}10.15252/embr.201744942, DOI 10.15252/EMBR.20174494229079657].
   Laribee RN, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060641.
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944.
   Leskoske KL, 2017, GENETICS, V207, P179, DOI 10.1534/genetics.117.1124.
   Liu GY, 2020, NAT REV MOL CELL BIO, V21, P183, DOI 10.1038/s41580-019-0199-y.
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6.
   Loewith R, 2011, GENETICS, V189, P1177, DOI 10.1534/genetics.111.133363.
   Madrid M, 2016, SCI REP-UK, V6, DOI 10.1038/srep37515.
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255.
   Maiyar AC, 2003, MOL BIOL CELL, V14, P1221, DOI 10.1091/mbc.E02-03-0170.
   Martín R, 2017, CURR BIOL, V27, P175, DOI 10.1016/j.cub.2016.11.037.
   Masui K, 2020, CANCER LETT, V478, P1, DOI 10.1016/j.canlet.2020.03.001.
   Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298.
   MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D.
   MORENO S, 1991, METHOD ENZYMOL, V194, P795.
   Morigasaki S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236133.
   Muir A, 2014, ELIFE, V3, DOI 10.7554/eLife.03779.
   Nakashima A, 2012, J CELL SCI, V125, P5840, DOI 10.1242/jcs.111146.
   Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955.
   Niles BJ, 2012, P NATL ACAD SCI USA, V109, P1536, DOI 10.1073/pnas.1117563109.
   Oya E, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0292-7.
   Pastor-Flores D, 2013, ACS CHEM BIOL, V8, P2283, DOI 10.1021/cb400452z.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Petersen J, 2007, NAT CELL BIOL, V9, P1263, DOI 10.1038/ncb1646.
   Saitoh M, 2002, J BIOL CHEM, V277, P20104, DOI 10.1074/jbc.M201745200.
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054.
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780.
   Schonbrun M, 2013, J BIOL CHEM, V288, P19649, DOI 10.1074/jbc.M113.464974.
   Schonbrun M, 2009, MOL CELL BIOL, V29, P4584, DOI 10.1128/MCB.01879-08.
   Schulze JO, 2016, CELL CHEM BIOL, V23, P1193, DOI 10.1016/j.chembiol.2016.06.017.
   Shimada K, 2013, MOL CELL, V51, P829, DOI 10.1016/j.molcel.2013.08.019.
   The Lancet Global Health, 2016, LANCET GLOB HLTH, V4, pe427.
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673.
   Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020.
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291.
   Wan SH, 1999, YEAST, V15, P821, DOI 10.1002/(SICI)1097-0061(199907)15:10A<821::AID-YEA422>3.0.CO;2-\#.
   Wang JM, 2006, J MOL GRAPH MODEL, V25, P247, DOI 10.1016/j.jmgm.2005.12.005.
   Weisman R, 2001, J BIOL CHEM, V276, P7027, DOI 10.1074/jbc.M010446200.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Zhao B, 2007, PROTEIN SCI, V16, P2761, DOI 10.1110/ps.073161707.
   2015, CORSALUD, V6.},
Number-of-Cited-References = {80},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {PLoS Genet.},
Doc-Delivery-Number = {OP8TD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000588362700013},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000582699600076,
Author = {Rahnasto-Rilla, Minna and Jarvenpaa, Joni and Huovinen, Marjo and
   Schroderus, Anna-Mari and Ihantola, Emmi-Leena and Kublbeck, Jenni and
   Khadeer, Mohammed and Moaddel, Ruin and Lahtela-Kakkonen, Maija},
Title = {Effects of galloflavin and ellagic acid on sirtuin 6 and its
   anti-tumorigenic activities},
Journal = {BIOMEDICINE \& PHARMACOTHERAPY},
Year = {2020},
Volume = {131},
Month = {NOV},
Abstract = {Sirtuin 6 (SIRT6), a member of sirtuin family (SIRT1 -7), regulates
   distinct cellular functions; genome stability, DNA repair, and
   inflammation related diseases. Recently, we demonstrated that
   anthocyanidins in berries induce the catalytic activity of SIRT6. In
   this study, we explored the effects of Galloflavin and Ellagic acid, the
   most common polyphenols in berries, on SIRT6.
   SIRT6 deacetylation was investigated using HPLC and immunoblotting
   assays. The expression levels of SIRT6, glycolytic proteins and cellular
   metabolism were studied on human colon adenocarcinoma cells (Caco2).
   Molecular docking studies were carried out to study possible
   interactions of the compounds with sirtuins.
   Ellagic acid increased the deacetylase activity of SIRT6 by up to
   50-fold; it showed moderate inhibition of SIRT1-3. Galloflavin and
   Ellagic acid showed anti-proliferative effects on Caco2. The compounds
   also upregulated SIRT6 expression whereas key proteins in glycolysis
   were downregulated. Galloflavin decreased glucose transporter 1 (GLUT1)
   expression, and Ellagic acid affected the expression of protein
   dehydrogenase kinase 1 (PDK1). Interestingly, both compounds caused
   reduction in glucose uptake and lactate production. Both Galloflavin and
   Ellagic acid were able to form hydrogen bonds with Asp188 and Glyn in
   SIRT6.
   In this study, we showed that Galloflavin and Ellagic acid increased
   SIRT6 activity and decreased the expression of SIRT6 associated proteins
   involved in cancer development. Taken together, Galloflavin and Ellagic
   acid targeting SIRT6 activity may provide a new insight in the
   development of anti-cancer therapy.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Rahnasto-Rilla, M; Lahtela-Kakkonen, M (Corresponding Author), Univ Eastern Finland, Sch Pharm, POB 1627, Kuopio 70210, Finland.
   Moaddel, R (Corresponding Author), NIA, Biomed Res Ctr, NIH, Baltimore, MD 21224 USA.
   Rahnasto-Rilla, Minna; Jarvenpaa, Joni; Huovinen, Marjo; Kublbeck, Jenni; Lahtela-Kakkonen, Maija, Univ Eastern Finland, Sch Pharm, POB 1627, Kuopio 70210, Finland.
   Schroderus, Anna-Mari; Ihantola, Emmi-Leena, Univ Eastern Finland, Inst Clin Med, Dept Clin Microbiol, Kuopio, Finland.
   Khadeer, Mohammed; Moaddel, Ruin, NIA, Biomed Res Ctr, NIH, Baltimore, MD 21224 USA.},
DOI = {10.1016/j.biopha.2020.110701},
Article-Number = {110701},
ISSN = {0753-3322},
EISSN = {1950-6007},
Keywords = {Berries; Cancer; Polyphenol; Sirtuin; Tannin},
Keywords-Plus = {HISTONE DEACETYLASE SIRT6; LACTATE-DEHYDROGENASE INHIBITOR; CANCER
   CELL-LINES; CYCLE ARREST; DNA-REPAIR; METABOLISM; ACTIVATION;
   EXPRESSION; APOPTOSIS; TUMOR},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {minna.rahnasto@uef.fi
   moaddelru@grc.nia.nih.gov
   maija.lahtela-kakkonen@uef.fi},
Affiliations = {University of Eastern Finland; University of Eastern Finland; National
   Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)},
ResearcherID-Numbers = {Ihantola, Emmi-Leena/C-6675-2019
   Moaddel, Ruin/AAE-3378-2020
   Küblbeck, Jenni/ABE-3846-2021},
ORCID-Numbers = {Järvenpää, Joni/0000-0002-7605-1432
   Schroderus, Anna-Mari/0000-0002-8517-0943
   Moaddel, Ruin/0000-0002-6812-0127
   Küblbeck, Jenni/0000-0002-6439-4403},
Funding-Acknowledgement = {Academy of Finland {[}315824, 269341]; Orion-Farmos Research Foundation;
   Finnish Cultural Foundation; National Cancer Institute, National
   Institutes of Health {[}HHSN 261200800001E]; Intramural Research Program
   of the National Institute on Aging, NIH; Foundation of Saastamoinen;
   Academy of Finland (AKA) {[}315824] Funding Source: Academy of Finland
   (AKA)},
Funding-Text = {The authors thank Sari Ukkonen for her skillful technical assistance,
   Biocenter Kuopio for the facilities, and the CSC-IT Center of Science
   Limited for providing computational resources.. This work was supported
   by the Academy of Finland {[}grant numbers315824,269341]; Orion-Farmos
   Research Foundation; the Foundation of Saastamoinen; Finnish Cultural
   Foundation; the National Cancer Institute, National Institutes of
   Health{[}under contract HHSN 261200800001E. government], and the
   Intramural Research Program of the National Institute on Aging, NIH.},
Cited-References = {Chen HS, 2015, INT J ONCOL, V46, P1730, DOI 10.3892/ijo.2015.2870.
   Desantis V, 2018, HAEMATOLOGICA, V103, P1, DOI 10.3324/haematol.2017.182675.
   Dominy JE, 2012, MOL CELL, V48, P900, DOI 10.1016/j.molcel.2012.09.030.
   Etchegaray JP, 2013, CURR TOP MED CHEM, V13, P2991, DOI 10.2174/15680266113136660213.
   Farabegoli F, 2012, EUR J PHARM SCI, V47, P729, DOI 10.1016/j.ejps.2012.08.012.
   Feldman JL, 2013, J BIOL CHEM, V288, P31350, DOI 10.1074/jbc.C113.511261.
   Ferlemi AV, 2016, ANTIOXIDANTS-BASEL, V5, DOI 10.3390/antiox5020017.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Geng CH, 2018, J CELL BIOCHEM, V119, P3957, DOI 10.1002/jcb.26539.
   Gertz M, 2013, P NATL ACAD SCI USA, V110, pE2772, DOI 10.1073/pnas.1303628110.
   González-Sarrías A, 2009, MOL NUTR FOOD RES, V53, P686, DOI 10.1002/mnfr.200800150.
   Han XY, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-014-0097-x.
   Huang ZM, 2018, NAT CHEM BIOL, V14, P1118, DOI 10.1038/s41589-018-0150-0.
   Huovinen M, 2011, TOXICOL IN VITRO, V25, P1007, DOI 10.1016/j.tiv.2011.03.018.
   Ismail T, 2016, TOXINS, V8, DOI 10.3390/toxins8050151.
   Jiang H, 2013, NATURE, V496, P110, DOI 10.1038/nature12038.
   Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815.
   Kiviranta PH, 2007, BIOORG MED CHEM LETT, V17, P2448, DOI 10.1016/j.bmcl.2007.02.023.
   Li TM, 2005, ANTICANCER RES, V25, P971.
   Lombard DB, 2008, J INTERN MED, V263, P128, DOI 10.1111/j.1365-2796.2007.01902.x.
   Losso JN, 2004, J NUTR BIOCHEM, V15, P672, DOI 10.1016/j.jnutbio.2004.06.004.
   Manerba M, 2017, EUR J PHARM SCI, V96, P37, DOI 10.1016/j.ejps.2016.09.014.
   Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723.
   Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736.
   Michishita E, 2009, CELL CYCLE, V8, P2664, DOI 10.4161/cc.8.16.9367.
   Misikangas M, 2007, J NUTR, V137, P2285, DOI 10.1093/jn/137.10.2285.
   Moniot S, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00016.
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013.
   Rahnasto-Rilla M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22388-5.
   Rahnasto-Rilla M, 2016, METHODS MOL BIOL, V1436, P259, DOI 10.1007/978-1-4939-3667-0\_17.
   Rahnasto-Rilla M, 2016, CHEMBIOCHEM, V17, P77, DOI 10.1002/cbic.201500482.
   Rahnasto-Rilla MK, 2017, MAR DRUGS, V15, DOI 10.3390/md15060190.
   Roos K, 2019, J CHEM THEORY COMPUT, V15, P1863, DOI 10.1021/acs.jctc.8b01026.
   Rumpf T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7263.
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047.
   Smeriglio A, 2017, BRIT J PHARMACOL, V174, P1244, DOI 10.1111/bph.13630.
   Takiyama Y, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/837421.
   Wang J, 2017, ONCOTARGET, V8, P16875, DOI 10.18632/oncotarget.15171.
   Yamamoto Norio, 2015, Curr Protoc Pharmacol, V71, DOI {[}10.1002/0471141755.ph1214s71, 10.1002/0471141755.ph1214s71].
   You WJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55654-1.
   You WJ, 2017, ANGEW CHEM INT EDIT, V56, P1007, DOI 10.1002/anie.201610082.
   Zhang Hong-Mei, 2014, Cancer Biology Medicine, V11, P92, DOI 10.7497/j.issn.2095-3941.2014.02.004.
   Zhao X, 2013, J MED CHEM, V56, P963, DOI 10.1021/jm301431y.
   Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041.
   Zwaans BMM, 2014, DIS MODEL MECH, V7, P1023, DOI 10.1242/dmm.016287.},
Number-of-Cited-References = {45},
Times-Cited = {23},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {33},
Journal-ISO = {Biomed. Pharmacother.},
Doc-Delivery-Number = {OH6KI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000582699600076},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000574855100007,
Author = {Wang, Wenjuan and Zheng, Fanyan and Lin, Changhu and Zhang, Aihua},
Title = {Changes in energy metabolism and macrophage polarization: Potential
   mechanisms of arsenic-induced lung injury},
Journal = {ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY},
Year = {2020},
Volume = {204},
Month = {NOV},
Abstract = {Exposure to arsenic is epidemiologically associated with increased lung
   disease. In detailing the mechanism by which arsenic exposure leads to
   disease, studies have emphasized that metabolic reprogramming and immune
   dysfunction are related to arsenic-induced lung injury. However, the
   association between the mechanisms listed above is not well understood.
   Thus, the current study aimed to investigate the interaction of energy
   metabolism and macrophage polarization, by which arsenic exposure
   adversely induced lung injury in both in vitro and human studies. First,
   we confirmed a shift to glycolytic metabolism resulting from
   mitochondrial dysfunction. This shift was accompanied by an increase in
   the levels of phosphorylated PDHEla (5293) and PDK1 and a concomitant
   marked increase in several key markers of the HIF-1 alpha signaling
   pathway (HIF-1 alpha, p-PKM2, GLUT1 and HK-2). In addition, utilizing an
   in vitro model in which lung epithelial cells are cultured with
   macrophages, we determined that arsenic treatment polarizes macrophages
   towards the M2 phenotype through lactate. In the human study, the serum
   lactate and TGF-beta levels were higher in arsenic-exposed subjects than
   that in reference subjects (t= 4.50, 6.24, both p < 0.05), while FVC and
   FEV1 were both lower (t= 5.47, 7.59, both p < 0.05). Pearson correlation
   analyses showed a significant negative correlation between the serum
   TGF-beta and lactate levels and the lung function parameters
   (p(correlation) <0.05). In mediation analyses, lactate and TGF-p
   significantly mediated 24.3\% and 9.0\%, respectively, of the
   association between arsenic and FVC (p(mediation)<0.05), while lactate
   and TGF-p significantly mediated 22.2\% and 12.5\%, respectively, of the
   association between arsenic and FEV1 (P-mediation <0.05). Together, the
   results of the in vitro and human studies indicated that there is
   complex communication between metabolic reprogramming and immune
   dysfunction, resulting in exacerbated effects in a feedback loop with
   increased arsenic-induced lung damage.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, AH (Corresponding Author), Guizhou Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Pollut Monitoring \& Dis Control, Guiyang 550025, Guizhou, Peoples R China.
   Wang, Wenjuan; Zheng, Fanyan; Lin, Changhu; Zhang, Aihua, Guizhou Med Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Pollut Monitoring \& Dis Control, Guiyang 550025, Guizhou, Peoples R China.},
DOI = {10.1016/j.ecoenv.2020.110948},
Article-Number = {110948},
ISSN = {0147-6513},
EISSN = {1090-2414},
Keywords = {Arsenic; Energy metabolism; Macrophage polarization; Lung function;
   Coculture},
Keywords-Plus = {COAL-FIRED STOVES; DRINKING-WATER; GUIZHOU PROVINCE; WEST-BENGAL;
   IN-UTERO; EXPOSURE; CANCER; CELLS; INFLAMMATION; HIF-1-ALPHA},
Research-Areas = {Environmental Sciences \& Ecology; Toxicology},
Web-of-Science-Categories  = {Environmental Sciences; Toxicology},
Author-Email = {97349238@qq.com},
Affiliations = {Guizhou Medical University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81872569, 81430077,
   U1812403]},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (No. 81872569, No. 81430077, No. U1812403).},
Cited-References = {Abdul NS, 2020, TOXICOL LETT, V318, P74, DOI 10.1016/j.toxlet.2019.10.013.
   An D, 2007, ENVIRON HEALTH PERSP, V115, P659, DOI 10.1289/ehp.9273.
   BERTOLERO F, 1981, TOXICOLOGY, V20, P35, DOI 10.1016/0300-483X(81)90103-7.
   Blaurock-Busch Eleonor, 2011, Maedica (Bucur), V6, P247.
   Buchsteiner M, 2018, BIOTECHNOL BIOENG, V115, P2315, DOI 10.1002/bit.26724.
   Certo M, 2020, WIRES SYST BIOL MED, V12, DOI 10.1002/wsbm.1474.
   Chen TT, 2019, KIDNEY INT, V95, P760, DOI 10.1016/j.kint.2018.10.041.
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490.
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322.
   D'Ippoliti D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138182.
   Farhood B, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104745.
   Gao AW, 2014, EMBO MOL MED, V6, P580, DOI 10.1002/emmm.201303782.
   George CM, 2015, ENVIRON HEALTH-GLOB, V14, DOI 10.1186/s12940-015-0069-9.
   He J, 2019, TOXICOL APPL PHARM, V378, DOI 10.1016/j.taap.2019.114606.
   He J, 2014, ENVIRON HEALTH PERSP, V122, P255, DOI 10.1289/ehp.1307545.
   He SY, 2019, NANOMED-NANOTECHNOL, V18, P259, DOI 10.1016/j.nano.2019.03.010.
   Henderson MW, 2017, ENVIRON HEALTH PERSP, V125, DOI {[}10.1289/EHP1878, 10.1289/ehp1878].
   Huber V, 2017, SEMIN CANCER BIOL, V43, P74, DOI 10.1016/j.semcancer.2017.03.001.
   Hughes MF, 2011, TOXICOL SCI, V123, P305, DOI 10.1093/toxsci/kfr184.
   Kamalian L, 2015, TOXICOL IN VITRO, V29, P732, DOI 10.1016/j.tiv.2015.02.011.
   Kozul CD, 2009, ENVIRON HEALTH PERSP, V117, P1108, DOI 10.1289/ehp.0800199.
   Li ZG, 2015, CELL CYCLE, V14, P3030, DOI 10.1080/15384101.2015.1080397.
   Liu J, 2002, ENVIRON HEALTH PERSP, V110, P119, DOI 10.1289/ehp.02110119.
   Luo F, 2017, CARCINOGENESIS, V38, P615, DOI 10.1093/carcin/bgx034.
   Luo F, 2016, BBA-MOL BASIS DIS, V1862, P1685, DOI 10.1016/j.bbadis.2016.06.004.
   Luz AL, 2016, TOXICOL SCI, V152, P349, DOI 10.1093/toxsci/kfw093.
   Ma L, 2016, TOXICOL APPL PHARM, V302, P52, DOI 10.1016/j.taap.2016.03.015.
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001.
   Marquez J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122161.
   Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13.
   Mazumder DNG, 2000, INT J EPIDEMIOL, V29, P1047, DOI 10.1093/ije/29.6.1047.
   Nardone A, 2017, ENVIRON RES, V158, P710, DOI 10.1016/j.envres.2017.06.024.
   Preacher KJ, 2007, MULTIVAR BEHAV RES, V42, P185, DOI 10.1080/00273170701341316.
   Recio-Vega R, 2015, J APPL TOXICOL, V35, P358, DOI 10.1002/jat.3023.
   Reddy SS, 2018, J MOL CELL CARDIOL, V123, P46, DOI 10.1016/j.yjmcc.2018.08.017.
   Romero-Garcia S, 2011, CANCER BIOL THER, V12, P939, DOI 10.4161/cbt.12.11.18140.
   SAADY JJ, 1989, J ANAL TOXICOL, V13, P310, DOI 10.1093/jat/13.5.310.
   Sanchez TR, 2018, CURR ENV HLTH REP, V5, P244, DOI 10.1007/s40572-018-0192-1.
   Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC.
   Shaykhiev R, 2009, J IMMUNOL, V183, P2867, DOI 10.4049/jimmunol.0900473.
   Smith AH, 2006, ENVIRON HEALTH PERSP, V114, P1293, DOI 10.1289/ehp.8832.
   Spano A, 2013, CELL PROLIFERAT, V46, P328, DOI 10.1111/cpr.12030.
   Steinmaus C, 2016, TOXICOL APPL PHARM, V313, P10, DOI 10.1016/j.taap.2016.10.006.
   Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC.
   von Ehrenstein OS, 2005, AM J EPIDEMIOL, V162, P533, DOI 10.1093/aje/kwi236.
   Wang DP, 2019, ENVIRON INT, V129, P18, DOI 10.1016/j.envint.2019.05.005.
   Wang HB, 2019, J BIOL CHEM, V294, P5466, DOI 10.1074/jbc.RA118.005200.
   Wang WJ, 2020, ECOTOX ENVIRON SAFE, V190, DOI 10.1016/j.ecoenv.2020.110174.
   Xu WC, 2019, INT J NANOMED, V14, P441, DOI 10.2147/IJN.S188439.
   Zeng QB, 2019, SCI TOTAL ENVIRON, V680, P1, DOI 10.1016/j.scitotenv.2019.05.042.
   Zhang AH, 2007, ENVIRON HEALTH PERSP, V115, P653, DOI 10.1289/ehp.9272.
   Zhang L, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111846.
   Zhao F, 2013, TOXICOL APPL PHARM, V271, P72, DOI 10.1016/j.taap.2013.04.020.},
Number-of-Cited-References = {53},
Times-Cited = {28},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Ecotox. Environ. Safe.},
Doc-Delivery-Number = {NW2QR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000574855100007},
DA = {2026-02-04},
}

@article{ WOS:000590968600011,
Author = {Jia-yuan, Xu and Wei, Song and Fang-fang, Lu and Zhi-jian, Dai and
   Long-he, Cao and Sen, Lin},
Title = {miR-375 Inhibits the Proliferation and Invasion of Nasopharyngeal
   Carcinoma Cells by Suppressing PDK1 (vol 2020, 9704245, 2020)},
Journal = {BIOMED RESEARCH INTERNATIONAL},
Year = {2020},
Volume = {2020},
Month = {OCT 31},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Correction},
Language = {English},
Affiliation = {Sen, L (Corresponding Author), Wenzhou Med Univ, Affiliated Hosp 3, Dept Otolaryngol, Ruian, Zhejiang, Peoples R China.
   Jia-yuan, Xu; Wei, Song; Fang-fang, Lu; Zhi-jian, Dai; Long-he, Cao; Sen, Lin, Wenzhou Med Univ, Affiliated Hosp 3, Dept Otolaryngol, Ruian, Zhejiang, Peoples R China.},
DOI = {10.1155/2020/3595402},
Article-Number = {3595402},
ISSN = {2314-6133},
EISSN = {2314-6141},
Research-Areas = {Biotechnology \& Applied Microbiology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Medicine, Research \&
   Experimental},
Author-Email = {shellyjiayuan@163.com
   szy100034295@163.com
   963081008@qq.com
   wsjjzj@163.com
   clh991329@126.com
   lnns@163.com},
Affiliations = {Wenzhou Medical University},
Cited-References = {Xu JY, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9704245.
   Wang GZ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5798356.},
Number-of-Cited-References = {2},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Biomed Res. Int.},
Doc-Delivery-Number = {OT6QM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000590968600011},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000583937400001,
Author = {Liu, Jingjin and Xie, Xiang and Yan, Dan and Wang, Yongshun and Yuan,
   Hongbin and Cai, Yin and Luo, Jierong and Xu, Aimin and Huang, Yu and
   Cheung, Chi Wai and Irwin, Michael G. and Xia, Zhengyuan},
Title = {Up-regulation of FoxO1 contributes to adverse vascular remodelling in
   type 1 diabetic rats},
Journal = {JOURNAL OF CELLULAR AND MOLECULAR MEDICINE},
Year = {2020},
Volume = {24},
Number = {23},
Pages = {13727-13738},
Month = {DEC},
Abstract = {Vascular complications from diabetes often result in poor outcomes for
   patients, even after optimized interventions. Forkhead box protein O1
   (FoxO1) is a key regulator of cellular metabolism and plays an important
   role in vessel formation and maturation. Alterations of FoxO1 occur in
   the cardiovascular system in diabetes, yet the role of FoxO1 in diabetic
   vascular complications is poorly understood. In Streptozotocin
   (STZ)-induced type 1 diabetic rats, FoxO1 expression was up-regulated in
   carotid arteries at 8 weeks of diabetes that was accompanied with
   adverse vascular remodelling characterized as increased wall thickness,
   carotid medial cross-sectional area, media-to-lumen ratio and decreased
   carotid artery lumen area. This adverse vascular remodelling induced by
   hyperglycaemia in diabetic rats required FoxO1 activation as
   pharmacological inhibition of FoxO1 with 50mg/kg AS1842856 (AS) reversed
   vascular remodelling in type 1 diabetic rats. The adverse vascular
   remodelling in type 1 diabetes mellitus (T1DM) occurred concomitantly
   with increases in pro-inflammatory factors, adhesion factors, apoptosis,
   NOD-like receptor family protein-3 inflammasome activation and the
   phenotypic switch of arterial smooth muscle cells, which were all
   reversed by AS. In addition, FoxO1 inhibition counteracted the
   down-regulation of its upstream mediator PDK1 in T1DM. PDK1 activator
   reduced FoxO1 nuclear translocation, which serves as the basis for
   subsequent transcriptional regulation during hyperglycaemia. Taken
   together, our data suggest that FoxO1 is a critical trigger for type 1
   diabetes-induced vascular remodelling in rats, and inhibition of FoxO1
   thus offers a potential therapeutic option for diabetes-associated
   cardiovascular diseases.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Irwin, MG; Xia, ZY (Corresponding Author), Univ Hong Kong, Dept Anesthesiol, Hong Kong, Peoples R China.
   Liu, Jingjin; Xie, Xiang; Yan, Dan; Cai, Yin; Cheung, Chi Wai; Irwin, Michael G.; Xia, Zhengyuan, Univ Hong Kong, Dept Anesthesiol, Hong Kong, Peoples R China.
   Xie, Xiang, Wenzhou Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Wenzhou, Peoples R China.
   Xie, Xiang, Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   Wang, Yongshun, Univ Hong Kong, Dept Biomed Sci, Hong Kong, Peoples R China.
   Yuan, Hongbin, Second Mil Med Univ, Dept Anesthesiol, Changzheng Hosp, Shanghai, Peoples R China.
   Luo, Jierong, Guangzhou Med Univ, Guangzhou Peoples Hosp 1, Dept Anesthesiol, Guangzhou, Peoples R China.
   Xu, Aimin; Xia, Zhengyuan, Univ Hong Kong, State Key Lab Pharmaceut Biotechnol, Hong Kong, Peoples R China.
   Huang, Yu, Chinese Univ Hong Kong, Heart \& Vasc Inst, Hong Kong, Peoples R China.
   Huang, Yu, Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.},
DOI = {10.1111/jcmm.15935},
EarlyAccessDate = {OCT 2020},
ISSN = {1582-1838},
EISSN = {1582-4934},
Keywords = {cardiovascular diseases; diabetes; Forkhead box protein O1; vascular
   remodeling},
Keywords-Plus = {TRANSCRIPTION FACTOR FOXO1; MATRIX METALLOPROTEINASES; INSULIN
   SENSITIVITY; PDK1; INHIBITION; EXPRESSION; CORONARY; MICE},
Research-Areas = {Cell Biology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Cell Biology; Medicine, Research \& Experimental},
Author-Email = {mgirwin@hku.hk
   zyxia@hku.hk},
Affiliations = {University of Hong Kong; Wenzhou Medical University; Wenzhou Medical
   University; University of Hong Kong; Naval Medical University; South
   China University of Technology; Guangzhou Medical University; University
   of Hong Kong; Chinese University of Hong Kong; Chinese University of
   Hong Kong},
ResearcherID-Numbers = {Irwin, Michael/C-4286-2009
   Huang, Yu/K-2866-2017
   },
ORCID-Numbers = {Irwin, Michael/0000-0001-5801-274X
   Huang, Yu/0000-0002-1277-6784
   Wang, Yongshun/0000-0002-6643-1845
   Cai, Yin/0000-0002-7763-0612},
Funding-Acknowledgement = {Research Grants Council of Hong Kong {[}17124614M, 17118619M, 17123718M,
   17117217M]; University of Hong Kong},
Funding-Text = {This research was supported by the General Research Fund (17124614M,
   17118619M, 17123718M to ZX and 17117217M to MGI) from Research Grants
   Council of Hong Kong and The University of Hong Kong Seeding grant for
   Basic Science.},
Cited-References = {Alblowi J, 2009, AM J PATHOL, V175, P1574, DOI 10.2353/ajpath.2009.090148.
   Altomonte J, 2004, J CLIN INVEST, V114, P1493, DOI 10.1172/JCI200419992.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Austin KM, 2013, J BIOL CHEM, V288, P23105, DOI 10.1074/jbc.M113.467019.
   Behl Y, 2009, DIABETES, V58, P917, DOI 10.2337/db08-0537.
   Burke AP, 2004, ARTERIOSCL THROM VAS, V24, P1266, DOI 10.1161/01.ATV.0000131783.74034.97.
   Cai Y, 2015, CELL CYCLE, V14, P3580, DOI 10.1080/15384101.2015.1100771.
   Calleja V, 2014, BIOCHEM SOC T, V42, P1435, DOI 10.1042/BST20140222.
   Castro MM, 2012, ARTERIOSCL THROM VAS, V32, P662, DOI 10.1161/ATVBAHA.111.242685.
   Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396.
   Diep CH, 2013, CELL CYCLE, V12, P1433, DOI 10.4161/cc.24550.
   Fan WQ, 2010, EMBO J, V29, P4223, DOI 10.1038/emboj.2010.268.
   Fukumoto H, 1998, J Atheroscler Thromb, V5, P29.
   Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251.
   GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431.
   Gross DN, 2008, ONCOGENE, V27, P2320, DOI 10.1038/onc.2008.25.
   Jansen F, 2017, J MOL CELL CARDIOL, V112, P91, DOI 10.1016/j.yjmcc.2017.09.004.
   Johnson Jason Lee, 2007, Expert Rev Cardiovasc Ther, V5, P265, DOI 10.1586/14779072.5.2.265.
   Kandula V, 2016, CARDIOVASC DIABETOL, V15, DOI 10.1186/s12933-016-0361-1.
   Karbasforooshan H, 2018, BIOMED PHARMACOTHER, V97, P190, DOI 10.1016/j.biopha.2017.10.075.
   Kim DH, 2017, J NUTR BIOCHEM, V45, P104, DOI 10.1016/j.jnutbio.2017.04.014.
   Klen J, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/616747.
   Leng WL, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/6305735.
   Li HB, 2016, DIABETES, V65, P942, DOI 10.2337/db15-0782.
   Li W, 2017, ENDOCRINOLOGY, V158, P2155, DOI 10.1210/en.2016-1970.
   Li Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057130.
   Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/j.cmet.2007.08.006.
   Matsumoto M, 2006, J CLIN INVEST, V116, P2464, DOI 10.1172/JCI27047.
   Moe KT, 2013, J VASC RES, V50, P228, DOI 10.1159/000350542.
   Nagashima T, 2010, MOL PHARMACOL, V78, P961, DOI 10.1124/mol.110.065714.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Nakae J, 2003, DEV CELL, V4, P119, DOI 10.1016/S1534-5807(02)00401-X.
   Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890.
   Potente M, 2005, J CLIN INVEST, V115, P2382, DOI 10.1172/JCI23126.
   Shi X, 2015, J STROKE CEREBROVASC, V24, P2455, DOI 10.1016/j.jstrokecerebrovasdis.2015.03.024.
   Stitt TN, 2004, MOL CELL, V14, P395, DOI 10.1016/S1097-2765(04)00211-4.
   Su DM, 2009, DIABETES, V58, P2624, DOI 10.2337/db09-0232.
   Tawaramoto K, 2012, MOL ENDOCRINOL, V26, P95, DOI 10.1210/me.2010-0412.
   Tsuzuki K, 2019, FEBS LETT, V593, P369, DOI 10.1002/1873-3468.13314.
   Wang MY, 2015, HYPERTENSION, V65, P698, DOI 10.1161/HYPERTENSIONAHA.114.03618.
   Wang Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/925350.
   Watanabe S, 2017, CAN J PHYSIOL PHARM, V95, P459, DOI 10.1139/cjpp-2016-0372.
   Watanabe S, 2016, PFLUG ARCH EUR J PHY, V468, P667, DOI 10.1007/s00424-015-1759-4.
   Westerhof N., 2019, SNAPSHOTS HEMODYNAMI, P245.
   Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209.
   Wu QP, 2018, EUR HEART J, V39, P1028, DOI 10.1093/eurheartj/ehx030.
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922.
   Yahagi K, 2017, ARTERIOSCL THROM VAS, V37, P191, DOI 10.1161/ATVBAHA.116.306256.
   Yan D, 2020, J CELL MOL MED, V24, P7850, DOI 10.1111/jcmm.15418.
   Zhang H, 2019, CARDIOVASC RES, V115, P2008, DOI 10.1093/cvr/cvz014.
   Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200.},
Number-of-Cited-References = {51},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {J. Cell. Mol. Med.},
Doc-Delivery-Number = {PB5NP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000583937400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000591329900002,
Author = {Gao, Wei and Zhang, Yuliang and Luo, Hongjie and Niu, Min and Zheng,
   Xiwang and Hu, Wanglai and Cui, Jiajia and Xue, Xuting and Bo, Yunfeng
   and Dai, Fengsheng and Lu, Yan and Yang, Dongli and Guo, Yujia and Guo,
   Huina and Li, Huizheng and Zhang, Yu and Yang, Tao and Li, Li and Zhang,
   Linshi and Hou, Rui and Wen, Shuxin and An, Changming and Ma, Teng and
   Jin, Lei and Xu, Wei and Wu, Yongyan},
Title = {Targeting SKA3 suppresses the proliferation and chemoresistance of
   laryngeal squamous cell carcinoma via impairing PLK1-AKT axis-mediated
   glycolysis},
Journal = {CELL DEATH \& DISEASE},
Year = {2020},
Volume = {11},
Number = {10},
Month = {OCT 26},
Abstract = {Spindle and kinetochore-associated complex subunit 3 (SKA3) is a
   well-known regulator of chromosome separation and cell division, which
   plays an important role in cell proliferation. However, the mechanism of
   SKA3 regulating tumor proliferation via reprogramming metabolism is
   unknown. Here, SKA3 is identified as an oncogene in laryngeal squamous
   cell carcinoma (LSCC), and high levels of SKA3 are closely associated
   with malignant progression and poor prognosis. In vitro and in vivo
   experiments demonstrate that SKA3 promotes LSCC cell proliferation and
   chemoresistance through a novel role of reprogramming glycolytic
   metabolism. Further studies reveal the downstream mechanisms of SKA3,
   which can bind and stabilize polo-like kinase 1 (PLK1) protein via
   suppressing ubiquitin-mediated degradation. The accumulation of PLK1
   activates AKT and thus upregulates glycolytic enzymes HK2, PFKFB3, and
   PDK1, resulting in enhancement of glycolysis. Furthermore, our data
   reveal that phosphorylation at Thr360 of SKA3 is critical for its
   binding to PLK1 and the increase in glycolysis. Collectively, the novel
   oncogenic signal axis ``SKA3-PLK1-AKT{''} plays a critical role in the
   glycolysis of LSCC. SKA3 may serve as a prognostic biomarker and
   therapeutic target, providing a potential strategy for proliferation
   inhibition and chemosensitization in tumors, especially for LSCC
   patients with PLK1 inhibitor resistance.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wu, YY (Corresponding Author), Shanxi Med Univ, Shanxi Key Lab Otorhinolaryngol Head \& Neck Canc, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.
   Wen, SX; Wu, YY (Corresponding Author), Shanxi Med Univ, Shanxi Prov Clin Med Res Ctr Precis Med Head \& Ne, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.
   Wu, YY (Corresponding Author), Shanxi Med Univ, Dept Otolaryngol Head \& Neck Surg, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.
   Wu, YY (Corresponding Author), Shanxi Med Univ, Key Lab Cellular Physiol, Minist Educ, Taiyuan 030001, Shanxi, Peoples R China.
   Wu, YY (Corresponding Author), Shanxi Med Univ, Dept Biochem \& Mol Biol, Taiyuan 030001, Shanxi, Peoples R China.
   Wen, SX (Corresponding Author), Shanxi Bethune Hosp, Dept Otolaryngol Head \& Neck Surg, Taiyuan 030032, Shanxi, Peoples R China.
   An, CM (Corresponding Author), Chinese Acad Med Sci, Dept Head \& Neck Surg, Canc Inst \& Hosp, Beijing 100021, Peoples R China.
   Ma, T (Corresponding Author), Beijing TB \& Thorac Tumor Res Inst, Dept Cellular \& Mol Biol, Beijing 101149, Peoples R China.
   Jin, L (Corresponding Author), Univ Newcastle, Sch Med \& Publ Hlth, Callaghan, NSW 2308, Australia.
   Xu, W (Corresponding Author), Shandong Univ, Dept Head \& Neck Surg, Shandong Prov ENT Hosp, Jinan 250022, Shandong, Peoples R China.
   Xu, W (Corresponding Author), Shandong Prov Inst Otolaryngol, Jinan 250022, Shandong, Peoples R China.
   Xu, W (Corresponding Author), Shandong Univ, Key Lab Otolaryngol, Minist Hlth, Jinan 250022, Shandong, Peoples R China.
   Gao, Wei; Zhang, Yuliang; Luo, Hongjie; Niu, Min; Zheng, Xiwang; Cui, Jiajia; Xue, Xuting; Dai, Fengsheng; Yang, Dongli; Guo, Yujia; Guo, Huina; Wu, Yongyan, Shanxi Med Univ, Shanxi Key Lab Otorhinolaryngol Head \& Neck Canc, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.
   Gao, Wei; Zhang, Yuliang; Niu, Min; Zheng, Xiwang; Cui, Jiajia; Xue, Xuting; Guo, Yujia; Guo, Huina; Wen, Shuxin; Wu, Yongyan, Shanxi Med Univ, Shanxi Prov Clin Med Res Ctr Precis Med Head \& Ne, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.
   Gao, Wei; Dai, Fengsheng; Yang, Dongli; Wu, Yongyan, Shanxi Med Univ, Dept Otolaryngol Head \& Neck Surg, Hosp 1, Taiyuan 030001, Shanxi, Peoples R China.
   Gao, Wei; Zhang, Yu; Wu, Yongyan, Shanxi Med Univ, Key Lab Cellular Physiol, Minist Educ, Taiyuan 030001, Shanxi, Peoples R China.
   Gao, Wei; Li, Li, Shanxi Med Univ, Dept Cell Biol \& Genet, Taiyuan 030001, Shanxi, Peoples R China.
   Hu, Wanglai, Anhui Med Univ, Sch Basic Med Sci, Hefei 230032, Anhui, Peoples R China.
   Bo, Yunfeng, Shanxi Canc Hosp, Dept Pathol, Taiyuan 030013, Shanxi, Peoples R China.
   Lu, Yan, Jinzhou Med Univ, Dept Otolaryngol Head \& Neck Surg, Affiliated Hosp 1, Jinzhou 121001, Liaoning, Peoples R China.
   Li, Huizheng, Dalian Municipal Friendship Hosp, Dept Otolaryngol Head \& Neck Surg, Dalian 116100, Liaoning, Peoples R China.
   Zhang, Yu, Shanxi Med Univ, Dept Physiol, Taiyuan 030001, Shanxi, Peoples R China.
   Yang, Tao; Wu, Yongyan, Shanxi Med Univ, Dept Biochem \& Mol Biol, Taiyuan 030001, Shanxi, Peoples R China.
   Zhang, Linshi, Zhejiang Univ, Dept Thyroid Surg, Sch Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   Hou, Rui, Univ Western Australia, QEII Med Ctr, Harry Perkins Inst Med Res, Perth, WA 6009, Australia.
   Hou, Rui, Univ Western Australia, Ctr Med Res, Perth, WA 6009, Australia.
   Wen, Shuxin, Shanxi Bethune Hosp, Dept Otolaryngol Head \& Neck Surg, Taiyuan 030032, Shanxi, Peoples R China.
   An, Changming, Chinese Acad Med Sci, Dept Head \& Neck Surg, Canc Inst \& Hosp, Beijing 100021, Peoples R China.
   Ma, Teng, Beijing TB \& Thorac Tumor Res Inst, Dept Cellular \& Mol Biol, Beijing 101149, Peoples R China.
   Jin, Lei, Univ Newcastle, Sch Med \& Publ Hlth, Callaghan, NSW 2308, Australia.
   Xu, Wei, Shandong Univ, Dept Head \& Neck Surg, Shandong Prov ENT Hosp, Jinan 250022, Shandong, Peoples R China.
   Xu, Wei, Shandong Prov Inst Otolaryngol, Jinan 250022, Shandong, Peoples R China.
   Xu, Wei, Shandong Univ, Key Lab Otolaryngol, Minist Hlth, Jinan 250022, Shandong, Peoples R China.},
DOI = {10.1038/s41419-020-03104-6},
Article-Number = {919},
ISSN = {2041-4889},
Keywords-Plus = {CANCER; KINETOCHORE; COMPONENT; COMPLEX; THERAPY; MYC},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {wensxsx@163.com
   anchangming@cicams.ac.cn
   mateng82913@163.com
   lei.jin@newcastle.edu.au
   xuwhns@126.com
   wuyongyan@sxent.org},
Affiliations = {Shanxi Medical University; Shanxi Medical University; Shanxi Medical
   University; Shanxi Medical University; Shanxi Medical University; Anhui
   Medical University; Jinzhou Medical University; Shanxi Medical
   University; Shanxi Medical University; Zhejiang University; Harry
   Perkins Institute of Medical Research; University of Western Australia;
   University of Western Australia; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Cancer Institute \& Hospital - CAMS;
   University of Newcastle; Shandong University; Shandong University},
ResearcherID-Numbers = {Zheng, Xiwang/HHC-2470-2022
   Jin, Lei/K-2315-2019
   dai, fengsheng/AGR-2898-2022
   Zhang, Linshi/AFK-3550-2022
   Ma, Teng/C-3274-2014
   xuting, xue/IQR-8623-2023
   Wu, Yongyan/AAH-1471-2019
   Gao, Wei/E-8505-2013},
ORCID-Numbers = {Zheng, Xiwang/0000-0001-8269-9166
   Hou, Rui/0000-0001-6571-1514
   Jin, Lei/0000-0001-7187-9671
   Wen, Shuxin/0000-0002-8377-2481
   dai, fengsheng/0000-0002-4202-9173
   Ma, Teng/0000-0002-8360-1543
   xuting, xue/0000-0002-0654-3263
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81572670, 81602394,
   81872210, 81802948]; China Postdoctoral Science Foundation
   {[}2017M610174]; Excellent talent science and technology innovation
   project of Shanxi Province {[}201605D211029, 201705D211018,
   201805D211007]; Shanxi Province Scientific and Technological
   Achievements Transformation Guidance Foundation {[}201804D131043]; Youth
   Foundation of The First Hospital; Shanxi Medical University {[}YQ1503];
   Startup Foundation for Doctors of Shanxi Medical University
   {[}BS03201624]; Youth Top Talent Program Fund of Shanxi Province (2018);
   Fund of Shanxi ``1331{''} Project (2018); Non-Profit Central Research
   Institute Fund of Chinese Academy of Medical Sciences {[}2019-RC-HL-004]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (81572670, 81602394, 81872210, and 81802948), China Postdoctoral
   Science Foundation (2017M610174), The Excellent talent science and
   technology innovation project of Shanxi Province (201605D211029,
   201705D211018, and 201805D211007), Shanxi Province Scientific and
   Technological Achievements Transformation Guidance Foundation
   (201804D131043), Youth Foundation of The First Hospital Affiliated with
   Shanxi Medical University (YQ1503), Startup Foundation for Doctors of
   Shanxi Medical University (BS03201624), Youth Top Talent Program Fund of
   Shanxi Province (2018), Fund of Shanxi ``1331{''} Project (2018), and
   The Non-Profit Central Research Institute Fund of Chinese Academy of
   Medical Sciences (2019-RC-HL-004). We thank Prof. Tao Bai from the
   Department of Pathology, First Hospital of Shanxi Medical University for
   the pathological analysis of LSCC sections.},
Cited-References = {Alves AP, 2019, CURR CANCER DRUG TAR, V19, P26, DOI 10.2174/1568009618666180430144441.
   Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633.
   Apicella M, 2018, CELL METAB, V28, P848, DOI 10.1016/j.cmet.2018.08.006.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Chakraborty PK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14634.
   Cheeseman IM, 2004, GENE DEV, V18, P2255, DOI 10.1101/gad.1234104.
   Colicino EG, 2019, MOL BIOL CELL, V30, P1598, DOI 10.1091/mbc.E18-12-0817.
   Daum JR, 2009, CURR BIOL, V19, P1467, DOI 10.1016/j.cub.2009.07.017.
   Dreos R, 2015, NUCLEIC ACIDS RES, V43, pD92, DOI 10.1093/nar/gku1111.
   Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097.
   Gaitanos TN, 2009, EMBO J, V28, P1442, DOI 10.1038/emboj.2009.96.
   Gao W, 2019, MOL THER, V27, P365, DOI 10.1016/j.ymthe.2018.09.018.
   Grandjean G, 2016, CANCER RES, V76, P4259, DOI 10.1158/0008-5472.CAN-16-0401.
   Groome PA, 2003, J CLIN ONCOL, V21, P496, DOI 10.1200/JCO.2003.10.106.
   Gutteridge REA, 2016, MOL CANCER THER, V15, P1427, DOI 10.1158/1535-7163.MCT-15-0897.
   Hou YC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2163-3.
   Hu DD, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194335.
   Hu R, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0670-4.
   Hu XC, 2015, LANCET ONCOL, V16, P436, DOI 10.1016/S1470-2045(15)70064-1.
   Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n.
   Jeyaprakash AA, 2012, MOL CELL, V46, P274, DOI 10.1016/j.molcel.2012.03.005.
   Kettenbach AN, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aaq1441.
   Lancho O, 2018, TRENDS CANCER, V4, P810, DOI 10.1016/j.trecan.2018.10.003.
   Lee M, 2015, CLIN EXP METASTAS, V32, P769, DOI 10.1007/s10585-015-9745-y.
   Leoncini E, 2018, EUR J EPIDEMIOL, V33, P1205, DOI 10.1007/s10654-018-0409-5.
   Li R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2232-7.
   Li ZG, 2014, MOL CELL BIOL, V34, P3642, DOI 10.1128/MCB.00814-14.
   Liu ZX, 2017, TRANSL ONCOL, V10, P22, DOI 10.1016/j.tranon.2016.10.003.
   Ma XY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01647-5.
   Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005.
   Qian XL, 2017, ONCOTARGET, V8, P47691, DOI 10.18632/oncotarget.17868.
   Raaijmakers JA, 2009, J CELL SCI, V122, P2436, DOI 10.1242/jcs.051912.
   Ren Y, 2018, J CLIN INVEST, V128, P5517, DOI 10.1172/JCI122533.
   Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023.
   Simon-Molas H, 2018, MOL CELL BIOCHEM, V448, P187, DOI 10.1007/s11010-018-3325-9.
   Steuer CE, 2017, CA-CANCER J CLIN, V67, P32, DOI 10.3322/caac.21386.
   Suzuki Hidenori, 2018, Oncotarget, V9, P19115, DOI {[}10.18632/oncotarget.24914, 10.18632/oncotarget.24914].
   Tang D, 2018, ACTA OTO-LARYNGOL, V138, P1043, DOI 10.1080/00016489.2018.1500711.
   Tang DY, 2019, J CELL BIOCHEM, V120, P9522, DOI 10.1002/jcb.28228.
   Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430.
   Theis M, 2009, CELL CYCLE, V8, P3435, DOI 10.4161/cc.8.21.9813.
   Theis M, 2009, EMBO J, V28, P1453, DOI 10.1038/emboj.2009.114.
   Zhang Q, 2017, CURR BIOL, V27, P1477, DOI 10.1016/j.cub.2017.03.060.},
Number-of-Cited-References = {43},
Times-Cited = {65},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {OU1YD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000591329900002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000615379800017,
Author = {Abd-El-Raouf, Romaila and Ouf, Salama A. and Gabr, Mahmoud M. and
   Zakaria, Mahmoud M. and El-Yasergy, Khaled F. and Ali-El-Dein, Bedeir},
Title = {Escherichia coli foster bladder cancer cell line progression via
   epithelial mesenchymal transition, stemness and metabolic reprogramming},
Journal = {SCIENTIFIC REPORTS},
Year = {2020},
Volume = {10},
Number = {1},
Month = {OCT 22},
Abstract = {Bacteria is recognized as opportunistic tumor inhabitant, giving rise to
   an environmental stress that may alter tumor microenvironment, which
   directs cancer behavior. In vitro infection of the T24 cell line with E.
   coli was performed to study the bacterial impact on bladder cancer
   cells. EMT markers were assessed using immunohistochemistry, western
   blot and RT-PCR. Stemness characteristics were monitored using RT-PCR.
   Furthermore, the metabolic reprograming was investigated by detection of
   ROS and metabolic markers. A significant (p <= 0.001) upregulation of
   vimentin as well as downregulation of CK19 transcription and protein
   levels was reported. A significant increase (p <= 0.001) in the
   expression level of stemness markers (CD44, NANOG, SOX2 and OCT4) was
   reported. ROS level was elevated, that led to a significant increase (p
   <= 0.001) in UCP2. This enhanced a significant increase (p <= 0.001) in
   PDK1 to significantly downregulate PDH (p <= 0.001) in order to block
   oxidative phosphorylation in favor of glycolysis. This resulted in a
   significant decrease (p <= 0.001) of AMPK, and a significant elevation
   (p <= 0.001) of MCT1 to export the produced lactate to extracellular
   matrix. Thus, bacteria may induce alteration to the heterogonous tumor
   cell population through EMT, CSCs and metabolic reprogramming, which may
   improve cancer cell ability to migrate and self-renew.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Ouf, SA (Corresponding Author), Cairo Univ, Fac Sci, Bot \& Microbiol Dept, Giza, Egypt.
   Abd-El-Raouf, Romaila; Gabr, Mahmoud M.; Zakaria, Mahmoud M., Mansoura Univ, Fac Med, Urol \& Nephrol Ctr, Res Dept, Mansoura, Egypt.
   Ouf, Salama A.; El-Yasergy, Khaled F., Cairo Univ, Fac Sci, Bot \& Microbiol Dept, Giza, Egypt.
   Ali-El-Dein, Bedeir, Mansoura Univ, Urol \& Nephrol Ctr, Fac Med, Urol Dept, Mansoura, Egypt.},
DOI = {10.1038/s41598-020-74390-5},
Article-Number = {18024},
ISSN = {2045-2322},
Keywords-Plus = {CD44; EXPRESSION; INFECTION; INFLAMMATION; BACTERIA; GROWTH},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {salama@sci.cu.edu.eg},
Affiliations = {Egyptian Knowledge Bank (EKB); Mansoura University; Egyptian Knowledge
   Bank (EKB); Cairo University; Egyptian Knowledge Bank (EKB); Mansoura
   University},
ResearcherID-Numbers = {Zakaria, Mahmoud/MCJ-5482-2025
   Ali-El-Dein, Bedeir/I-5694-2018
   },
ORCID-Numbers = {Ouf, Salama/0000-0001-6786-2703
   Zakaria, Mahmoud/0000-0002-7288-8374
   Ali-El-Dein, Bedeir/0000-0003-3811-2481
   Abd-El-Raouf, Romaila/0000-0002-8657-3074},
Cited-References = {Abdulkareem AA, 2018, CELL ADHES MIGR, V12, P127, DOI 10.1080/19336918.2017.1322253.
   Akhtar S, 2018, WORLD J UROL, V36, P839, DOI 10.1007/s00345-018-2206-x.
   Basati G, 2020, J GASTROINTEST CANC, V51, P41, DOI 10.1007/s12029-018-00200-x.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345.
   Chen C, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0605-5.
   Cordani M, 2017, Translational Medicine Reports, V1, DOI {[}10.4081/tmr.6451, 10.4081/tmr.6451, DOI 10.4081/TMR.6451].
   Cummins J, 2013, INFECT AGENTS CANCER, V8, DOI 10.1186/1750-9378-8-11.
   El Shobaky A, 2015, EGYPT J BAS APPL SCI, V2, P176, DOI {[}10.1016/j.ejbas.2015.05.006, DOI 10.1016/J.EJBAS.2015.05.006].
   Golias T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31146.
   Guerra F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00295.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632.
   Hofman P, 2012, GUT MICROBES, V3, P176, DOI 10.4161/gmic.20288.
   Huang DY, 2016, ONCOL LETT, V12, P5052, DOI 10.3892/ol.2016.5315.
   Huang R, 2017, CRIT REV ONCOL HEMAT, V115, P13, DOI 10.1016/j.critrevonc.2017.04.005.
   Ivanov AV, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3496043.
   Jordan AR, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00182.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Leone L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146365.
   Masaki T, 2013, CELL, V152, P51, DOI 10.1016/j.cell.2012.12.014.
   Migita T, 2017, LAB INVEST, V97, P567, DOI 10.1038/labinvest.2017.17.
   Popovic VB, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29054-w.
   Rabinovitch RC, 2017, CELL REP, V21, P1, DOI 10.1016/j.celrep.2017.09.026.
   Rouschop KMA, 2006, J IMMUNOL, V177, P7225, DOI 10.4049/jimmunol.177.10.7225.
   Russo V, 2017, CYTOKINE GROWTH F R, V36, P79, DOI 10.1016/j.cytogfr.2017.06.005.
   Saxena M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208314.
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590.
   Smith HA, 2013, CLIN CANCER RES, V19, P4547, DOI 10.1158/1078-0432.CCR-13-1524.
   Song SY, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0180-y.
   Song Y, 2014, REPROD BIOL ENDOCRIN, V12, DOI 10.1186/1477-7827-12-42.
   Sun Jun, 2010, Cancers (Basel), V3, P285, DOI 10.3390/cancers3010285.
   van der Windt GJW, 2010, AM J PATHOL, V177, P2483, DOI 10.2353/ajpath.2010.100562.
   Xu GP, 2007, CELL MOL BIOL LETT, V12, P457, DOI 10.2478/s11658-007-0018-x.
   Zhang J, 2016, EMBO J, V35, P899, DOI 10.15252/embj.201694054.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.},
Number-of-Cited-References = {36},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {QD2UK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000615379800017},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000584550400001,
Author = {Lang, Florian and Rajaxavier, Janet and Singh, Yogesh and Brucker, Sara
   Y. and Salker, Madhuri S.},
Title = {The Enigmatic Role of Serum \& Glucocorticoid Inducible Kinase 1 in the
   Endometrium},
Journal = {FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY},
Year = {2020},
Volume = {8},
Month = {OCT 21},
Abstract = {The serum- and glucocorticoid-inducible kinase 1 (SGK1) is subject to
   genetic up-regulation by diverse stimulators including glucocorticoids,
   mineralocorticoids, dehydration, ischemia, radiation and hyperosmotic
   shock. To become active, the expressed kinase requires phosphorylation,
   which is accomplished by PI3K/PDK1 and mTOR dependent signaling. SGK1
   enhances the expression/activity of various transport proteins including
   Na+/K+-ATPase as well as ion-, glucose-, and amino acid- carriers in the
   plasma membrane. SGK1 can further up-regulate diverse ion channels, such
   as Na+-, Ca2+-, K+- and Cl- channels. SGK1 regulates expression/activity
   of a wide variety of transcription factors (such as FKHRL1/Foxo3a,
   beta-catenin, NF kappa B and p53). SGK1 thus contributes to the
   regulation of transport, glycolysis, angiogenesis, cell survival, immune
   regulation, cell migration, tissue fibrosis and tissue calcification. In
   this review we summarized the current findings that SGK1 plays a crucial
   function in the regulation of endometrial function. Specifically, it
   plays a dual role in the regulation of endometrial receptivity necessary
   for implantation and, subsequently in pregnancy maintenance.
   Furthermore, fetal programming of blood pressure regulation requires
   maternal SGK1. Underlying mechanisms are, however, still ill-defined and
   there is a substantial need for additional information to fully
   understand the role of SGK1 in the orchestration of embryo implantation,
   embryo survival and fetal programming.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Lang, F (Corresponding Author), Eberhard Karls Univ Tubingen, Dept Physiol, Tubingen, Germany.
   Salker, MS (Corresponding Author), Eberhard Karls Univ Tubingen, Res Inst Womens Hlth, Tubingen, Germany.
   Lang, Florian, Eberhard Karls Univ Tubingen, Dept Physiol, Tubingen, Germany.
   Rajaxavier, Janet; Singh, Yogesh; Brucker, Sara Y.; Salker, Madhuri S., Eberhard Karls Univ Tubingen, Res Inst Womens Hlth, Tubingen, Germany.
   Singh, Yogesh, Eberhard Karls Univ Tubingen, Inst Med Genet \& Appl Genom, Tubingen, Germany.},
DOI = {10.3389/fcell.2020.556543},
Article-Number = {556543},
ISSN = {2296-634X},
Keywords = {SGK1; cell survival; cell migration; pregnancy; infertility},
Keywords-Plus = {DELTA T-CELLS; EPITHELIAL SODIUM-CHANNEL; NATURAL-KILLER-CELLS;
   NF-KAPPA-B; PROTEIN-KINASE; REGULATED KINASE-1; ORAI1 EXPRESSION;
   BLOOD-PRESSURE; CANCER-CELLS; DIFFERENTIAL EXPRESSION},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {florian.lang@uni-tuebingen.de
   madhuri.salker@med.uni-tuebingen.de},
Affiliations = {Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University of Tubingen},
ResearcherID-Numbers = {Singh, Yogesh/T-8230-2017
   Brucker, Sara/PGL-7775-2026},
ORCID-Numbers = {Singh, Yogesh/0000-0001-6919-6273
   Salker, Madhuri Sonal/0000-0002-7939-289X
   },
Funding-Acknowledgement = {Tubingen University {[}IZKF 2510 -0-0]; Deutsche Forschungsgemeinschaft
   {[}ZUK 63]; Margarete von Wrangell habilitation scholarship {[}MvW
   31-7635.41/118/3]; Ministry of Science, Research and the arts (MWK) of
   the state of Baden-Wurttemberg; European Social Funds; Deutsche
   Forschungsgemeinschaft; Open Access Publishing Fund of University of
   Tubingen},
Funding-Text = {This work was supported by the intramural funds of Tubingen University
   (IZKF 2510 -0-0), the Excellence Initiative (Deutsche
   Forschungsgemeinschaft, ZUK 63) and by the Margarete von Wrangell (MvW
   31-7635.41/118/3) habilitation scholarship co-funded by the Ministry of
   Science, Research and the arts (MWK) of the state of Baden-Wurttemberg
   and by the European Social Funds. The figures were created with
   biorender.com. We acknowledge support by the Deutsche
   Forschungsgemeinschaft and Open Access Publishing Fund of University of
   Tubingen.},
Cited-References = {Aghajanova L, 2008, SEMIN CELL DEV BIOL, V19, P204, DOI 10.1016/j.semcdb.2007.10.008.
   Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810.
   Alauddin M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00770.
   Alowayed N, 2016, CELL PHYSIOL BIOCHEM, V39, P815, DOI 10.1159/000447792.
   Amato R, 2013, ONCOGENE, V32, P4572, DOI 10.1038/onc.2012.470.
   Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Arteaga MF, 2006, P NATL ACAD SCI USA, V103, P11178, DOI 10.1073/pnas.0604816103.
   Arteaga MF, 2005, AM J PHYSIOL-RENAL, V289, pF90, DOI 10.1152/ajprenal.00390.2004.
   Bano G, 2013, BEST PRACT RES CL OB, V27, P715, DOI 10.1016/j.bpobgyn.2013.02.007.
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002.
   Belova L, 2006, BIOCHEM J, V400, P235, DOI 10.1042/BJ20060905.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Boeddeker SJ, 2015, J REPROD IMMUNOL, V108, P114, DOI 10.1016/j.jri.2015.02.002.
   Bogusz AM, 2006, FEBS J, V273, P2913, DOI 10.1111/j.1742-4658.2006.05304.x.
   Borst O, 2012, BLOOD, V119, P251, DOI 10.1182/blood-2011-06-359976.
   Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507.
   Brickley DR, 2002, J BIOL CHEM, V277, P43064, DOI 10.1074/jbc.M207604200.
   Brighton PJ, 2017, ELIFE, V6, DOI 10.7554/eLife.31274.
   Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001.
   Bulmer Judith N, 2019, F1000Res, V8, DOI {[}10.12688/f1000research.19132.1, 10.12688/f1000research.19132.1].
   Busjahn A, 2004, CELL PHYSIOL BIOCHEM, V14, P135, DOI 10.1159/000078105.
   Caglayan E, 2011, J AM COLL CARDIOL, V57, P2527, DOI 10.1016/j.jacc.2011.02.037.
   Calhaz-Jorge C, 2016, HUM REPROD, V31, P1638, DOI 10.1093/humrep/dew151.
   Carding SR, 2002, NAT REV IMMUNOL, V2, P336, DOI 10.1038/nri797.
   Catela C, 2010, DEV DYNAM, V239, P2149, DOI 10.1002/dvdy.22345.
   Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012.
   Chan HC, 2009, J PHYSIOL-LONDON, V587, P2187, DOI 10.1113/jphysiol.2008.164970.
   Cheroutre H, 2011, NAT REV IMMUNOL, V11, P445, DOI 10.1038/nri3007.
   Chilukoti RK, 2013, INT J CARDIOL, V168, P2100, DOI 10.1016/j.ijcard.2013.01.007.
   Christopher Ajay Francis, 2016, Perspect Clin Res, V7, P68, DOI {[}10.4103/2229-3485.179431, 10.4103/2229-3485.179431].
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   Croy BA, 2003, REPRODUCTION, V126, P149, DOI 10.1530/rep.0.1260149.
   Dag ZÖ, 2015, J TURK-GER GYNECOL A, V16, P111, DOI 10.5152/jtgga.2015.15232.
   Das S, 2012, CIRCULATION, V126, P2208, DOI 10.1161/CIRCULATIONAHA.112.115592.
   Dattilo V, 2017, SCI REP-UK, V7, DOI 10.1038/srep45361.
   Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052.
   Dehner M, 2008, J BIOL CHEM, V283, P19201, DOI 10.1074/jbc.M710366200.
   Delpire E, 2018, COMPR PHYSIOL, V8, P871, DOI {[}10.1002/j.2040-4603.2018.tb00016.x, 10.1002/cphy.c170018].
   Dey SK, 2004, ENDOCR REV, V25, P341, DOI 10.1210/er.2003-0020.
   Di Cristofano A, 2017, CURR TOP DEV BIOL, V123, P49, DOI 10.1016/bs.ctdb.2016.11.006.
   Di Pietro N, 2010, MOL ENDOCRINOL, V24, P370, DOI 10.1210/me.2009-0265.
   Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09.
   Dieter M, 2004, OBES RES, V12, P862, DOI 10.1038/oby.2004.104.
   Dörsam AF, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040840.
   Domhan S, 2014, CURR PHARM DESIGN, V20, P88, DOI 10.2174/138161282001140113125549.
   Eylenstein A, 2012, J BIOL CHEM, V287, P2719, DOI 10.1074/jbc.M111.275925.
   Eylenstein A, 2011, FASEB J, V25, P2012, DOI 10.1096/fj.10-178210.
   Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303.
   Feroze-Zaidi F, 2007, ENDOCRINOLOGY, V148, P5020, DOI 10.1210/en.2007-0659.
   Feyaerts D, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03191-0.
   Figueiredo AS, 2016, IMMUNOLOGY, V148, P13, DOI 10.1111/imm.12595.
   Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244.
   Fisher SJ, 2011, NAT MED, V17, P1348, DOI 10.1038/nm.2549.
   Flannery CA, 2018, J CLIN ENDOCR METAB, V103, P2843, DOI 10.1210/jc.2017-01759.
   Galliano D, 2014, FERTIL STERIL, V101, P1531, DOI 10.1016/j.fertnstert.2014.04.023.
   Gao S, 2009, MOL CELL, V36, P457, DOI 10.1016/j.molcel.2009.09.043.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   Gellersen B, 2003, J ENDOCRINOL, V178, P357, DOI 10.1677/joe.0.1780357.
   Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014-1045.
   Giebisch G, 1998, AM J PHYSIOL-RENAL, V274, pF817, DOI 10.1152/ajprenal.1998.274.5.F817.
   Gnecco JS, 2017, ANN BIOMED ENG, V45, P1758, DOI 10.1007/s10439-017-1797-5.
   Gong X, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/393707.
   González-Echevarría AM, 2019, J PSYCHOSOM OBST GYN, V40, P138, DOI 10.1080/0167482X.2018.1450384.
   Groot M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9041044.
   Gulyaeva LF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0893-x.
   Guo YY, 2016, CELL PHYSIOL BIOCHEM, V40, P579, DOI 10.1159/000452571.
   Hall BA, 2012, BREAST CANCER RES TR, V135, P469, DOI 10.1007/s10549-012-2161-y.
   Han WX, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00921.
   Harada Y, 2010, J EXP MED, V207, P1381, DOI 10.1084/jem.20100004.
   Harries LW, 2012, MECH AGEING DEV, V133, P556, DOI 10.1016/j.mad.2012.07.003.
   Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867.
   Heise CJ, 2010, J BIOL CHEM, V285, P25161, DOI 10.1074/jbc.M110.103432.
   Hibaoui Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00084.
   Hocher B, 2007, J PHYSIOL-LONDON, V579, P287, DOI 10.1113/jphysiol.2007.127738.
   Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027.
   Jeyaraj S, 2007, BIOCHEM BIOPH RES CO, V356, P629, DOI 10.1016/j.bbrc.2007.03.029.
   Jones RL, 2006, REPRODUCTION, V132, P217, DOI 10.1530/rep.1.01076.
   Joswig Anike, 2003, Reprod Biol Endocrinol, V1, P44.
   Juzenas S, 2017, NUCLEIC ACIDS RES, V45, P9290, DOI 10.1093/nar/gkx706.
   Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118.
   Kalkunte SS, 2009, J IMMUNOL, V182, P4085, DOI 10.4049/jimmunol.0803769.
   Kalra B, 2015, N AM J MED SCI, V7, P6, DOI 10.4103/1947-2714.150081.
   Kauma S, 1996, J CLIN ENDOCR METAB, V81, P1261, DOI 10.1210/jc.81.3.1261.
   Khorram O, 2010, AM J PHYSIOL-REG I, V298, pR1366, DOI 10.1152/ajpregu.00704.2009.
   Kim MJ, 2007, EMBO J, V26, P3075, DOI 10.1038/sj.emboj.7601755.
   Kitawaki J, 2002, J STEROID BIOCHEM, V83, P149, DOI 10.1016/S0960-0760(02)00260-1.
   Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868.
   Klemmt PAB, 2018, CURR WOMENS HEALTH R, V14, P106, DOI 10.2174/1573404813666170306163448.
   Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   Koot YEM, 2012, BBA-MOL BASIS DIS, V1822, P1943, DOI 10.1016/j.bbadis.2012.05.017.
   Kozomara A, 2019, NUCLEIC ACIDS RES, V47, pD155, DOI 10.1093/nar/gky1141.
   Kurian NK, 2019, J ASSIST REPROD GEN, V36, P189, DOI 10.1007/s10815-018-1343-x.
   Kusama K, 2013, PLACENTA, V34, P212, DOI 10.1016/j.placenta.2012.12.017.
   Lamireau D, 2002, STROKE, V33, P2992, DOI 10.1161/01.STR.0000039340.62995.F2.
   Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005.
   Lang F, 2019, CELL STRESS, V3, P1, DOI 10.15698/cst2019.01.170.
   Lang F, 2014, MOL MEMBR BIOL, V31, P29, DOI 10.3109/09687688.2013.874598.
   Lang F, 2013, HORM-INT J ENDOCRINO, V12, P160, DOI 10.14310/horm.2002.1401.
   Lang F, 2013, EXPERT OPIN INV DRUG, V22, P701, DOI 10.1517/13543784.2013.778971.
   Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230.
   Lang F, 2009, EXPERT OPIN THER TAR, V13, P1303, DOI 10.1517/14728220903260807.
   LANGLEYEVANS SC, 1994, CLIN NUTR, V13, P319, DOI 10.1016/0261-5614(94)90056-6.
   Lee LYW, 2019, CLIN CANCER RES, V25, P629, DOI 10.1158/1078-0432.CCR-18-1033.
   Lee SM, 2012, J ETHNOPHARMACOL, V141, P368, DOI 10.1016/j.jep.2012.02.048.
   Leitao B, 2010, FASEB J, V24, P1541, DOI 10.1096/fj.09-149153.
   Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200.
   Li P, 2013, DIABETES RES CLIN PR, V102, P35, DOI 10.1016/j.diabres.2013.08.009.
   Lissauer D, 2017, PLACENTA, V60, P140, DOI 10.1016/j.placenta.2017.09.003.
   Liu TY, 2018, BIOMED PHARMACOTHER, V98, P286, DOI 10.1016/j.biopha.2017.12.064.
   Lou YY, 2017, FASEB J, V31, P447, DOI 10.1096/fj.201600760R.
   Lucas ES, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0763-1.
   Lucas ES, 2013, REPROD BIOMED ONLINE, V27, P506, DOI 10.1016/j.rbmo.2013.06.012.
   Lyo D, 2010, BIOCHEM BIOPH RES CO, V396, P562, DOI 10.1016/j.bbrc.2010.04.148.
   Manning J, 2002, AM J PHYSIOL-RENAL, V283, pF202, DOI 10.1152/ajprenal.00358.2001.
   Matschke V, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00387.
   McCaig C, 2011, BIOCHEM BIOPH RES CO, V411, P227, DOI 10.1016/j.bbrc.2011.06.092.
   McMullen S, 2005, AM J PHYSIOL-REG I, V288, pR85, DOI 10.1152/ajpregu.00435.2004.
   Mincheva-Nilsson Lucia, 2003, Reprod Biol Endocrinol, V1, P120, DOI 10.1186/1477-7827-1-120.
   MinchevaNilsson L, 1997, J IMMUNOL, V159, P3266.
   Mizuno H, 2001, GENES CELLS, V6, P261, DOI 10.1046/j.1365-2443.2001.00418.x.
   Monsivais D, 2016, FERTIL STERIL, V105, P1266, DOI 10.1016/j.fertnstert.2016.01.012.
   Mor G, 2010, AM J REPROD IMMUNOL, V63, P425, DOI 10.1111/j.1600-0897.2010.00836.x.
   Murakami Y, 2010, BIOCHEM BIOPH RES CO, V396, P376, DOI 10.1016/j.bbrc.2010.04.100.
   Na T, 2013, AM J PHYSIOL-RENAL, V304, pF8, DOI 10.1152/ajprenal.00284.2012.
   Negishi Y, 2018, J OBSTET GYNAECOL RE, V44, P2025, DOI 10.1111/jog.13759.
   Norlander AE, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92801.
   Norton M, 2014, NAT IMMUNOL, V15, P411, DOI 10.1038/ni.2875.
   Ohashi T, 2011, CLIN EXP NEPHROL, V15, P688, DOI 10.1007/s10157-011-0479-0.
   Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024.
   Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103.
   Pelzl L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06451-1.
   Pires KMP, 2006, LIFE SCI, V79, P2128, DOI 10.1016/j.lfs.2006.07.006.
   Hara CDP, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7154524.
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046.
   Pladys P, 2005, AM J PHYSIOL-REG I, V289, pR1580, DOI 10.1152/ajpregu.00031.2005.
   Politi K, 2004, AM J PATHOL, V164, P325, DOI 10.1016/S0002-9440(10)63122-7.
   Quenby S, 2009, HUM REPROD, V24, P45, DOI 10.1093/humrep/den348.
   Raglan O, 2020, TRANSL RES, V218, P57, DOI 10.1016/j.trsl.2019.12.003.
   Research G.V., 2020, IN VITRO FERTILIZATI.
   Rexhepaj R, 2008, AM J PHYSIOL-REG I, V294, pR2008, DOI 10.1152/ajpregu.00737.2007.
   Rosario FJ, 2016, AM J PHYSIOL-REG I, V310, pR87, DOI 10.1152/ajpregu.00356.2015.
   Rosario FJ, 2011, ENDOCRINOLOGY, V152, P1119, DOI 10.1210/en.2010-1153.
   Rosner M, 2009, EUR J CLIN INVEST, V39, P1033, DOI 10.1111/j.1365-2362.2009.02213.x.
   Rotte A, 2011, CELL PHYSIOL BIOCHEM, V28, P305, DOI 10.1159/000331746.
   Ruan YC, 2012, NAT MED, V18, P1112, DOI 10.1038/nm.2771.
   Rughani A, 2020, CURR DIABETES REP, V20, DOI 10.1007/s11892-020-01328-6.
   Rusai K, 2010, BIOCHEM PHARMACOL, V79, P1173, DOI 10.1016/j.bcp.2009.11.022.
   Saad S, 2005, KIDNEY INT, V68, P985, DOI 10.1111/j.1523-1755.2005.00492.x.
   Sahin P, 2013, NEUROPATH APPL NEURO, V39, P623, DOI 10.1111/nan.12023.
   Saito S, 2010, AM J REPROD IMMUNOL, V63, P601, DOI 10.1111/j.1600-0897.2010.00852.x.
   Salker M. S., 2012, EXP REV OBSTET GYNEC, V7, P101, DOI {[}10.1586/eog.12.1, DOI 10.1586/EOG.12.1].
   Salker M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010287.
   Salker MS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11674-3.
   Salker MS, 2016, CELL PHYSIOL BIOCHEM, V39, P2077, DOI 10.1159/000447903.
   Salker MS, 2011, NAT MED, V17, P1509, DOI 10.1038/nm.2498.
   Schmid E, 2013, AM J PHYSIOL-CELL PH, V304, pC49, DOI 10.1152/ajpcell.00179.2012.
   Schmidt EM, 2012, FEBS J, V279, P1231, DOI 10.1111/j.1742-4658.2012.08515.x.
   Schmidt S, 2014, MOL HUM REPROD, V20, P139, DOI 10.1093/molehr/gat066.
   Schwab M, 2008, CELL PHYSIOL BIOCHEM, V21, P151, DOI 10.1159/000113757.
   Seebohm G, 2005, CELL PHYSIOL BIOCHEM, V16, P255, DOI 10.1159/000089851.
   Shelly C, 2002, J CELL SCI, V115, P1985.
   Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161.
   Sojka DK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00960.
   Solano ME, 2019, BEST PRACT RES CL OB, V60, P3, DOI 10.1016/j.bpobgyn.2019.05.009.
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342.
   Soundararajan R, 2010, J BIOL CHEM, V285, P39905, DOI 10.1074/jbc.M110.161133.
   Sourial Samer, 2014, Int J Reprod Med, V2014, P179515, DOI 10.1155/2014/179515.
   Stock C, 2009, PFLUG ARCH EUR J PHY, V458, P981, DOI 10.1007/s00424-009-0677-8.
   Stone KP, 2011, CELL PHYSIOL BIOCHEM, V28, P115, DOI 10.1159/000331720.
   SUZUKI T, 1995, J IMMUNOL, V154, P4476.
   Sykes L, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/967629.
   Szebeni B, 2010, J PEDIATR GASTR NUTR, V50, P147, DOI 10.1097/MPG.0b013e3181b47608.
   Talarico C, 2016, CELL PHYSIOL BIOCHEM, V39, P1863, DOI 10.1159/000447885.
   Tamaru S, 2020, MED MOL MORPHOL, V53, P131, DOI 10.1007/s00795-020-00252-8.
   Tan Q, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030645.
   Teklenburg G, 2010, MOL HUM REPROD, V16, P886, DOI 10.1093/molehr/gaq079.
   Terada Y, 2008, J AM SOC NEPHROL, V19, P298, DOI 10.1681/ASN.2007050531.
   Thomanetz V, 2013, J CELL BIOL, V201, P293, DOI 10.1083/jcb.201205030.
   Thong EP, 2020, LANCET DIABETES ENDO, V8, P134, DOI 10.1016/S2213-8587(19)30345-6.
   Treins C, 2010, ONCOGENE, V29, P1003, DOI 10.1038/onc.2009.401.
   Tsai V, 2014, CEREB CORTEX, V24, P315, DOI 10.1093/cercor/bhs310.
   Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003.
   Vehaskari VM, 2001, KIDNEY INT, V59, P238, DOI 10.1046/j.1523-1755.2001.00484.x.
   Voelkl J, 2018, J CLIN INVEST, V128, P3024, DOI 10.1172/JCI96477.
   Voelkl J, 2015, CELL PHYSIOL BIOCHEM, V37, P603, DOI 10.1159/000430380.
   Voelkl J, 2013, CELL PHYSIOL BIOCHEM, V32, P25, DOI 10.1159/000350120.
   Voelkl J, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-011-0236-2.
   Wahid F, 2010, BBA-MOL CELL RES, V1803, P1231, DOI 10.1016/j.bbamcr.2010.06.013.
   Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440.
   Walker-Allgaier B, 2017, THROMB HAEMOSTASIS, V117, P1002, DOI 10.1160/TH16-09-0690.
   Wang DS, 2005, AM J PHYSIOL-CELL PH, V289, pC802, DOI 10.1152/ajpcell.00597.2004.
   WEBSTER MK, 1993, J BIOL CHEM, V268, P11482.
   Weiler M, 2014, P NATL ACAD SCI USA, V111, P409, DOI 10.1073/pnas.1314469111.
   Welham SJM, 2005, PHYSIOL GENOMICS, V22, P48, DOI 10.1152/physiolgenomics.00167.2004.
   Woods LL, 2001, PEDIATR RES, V49, P460, DOI 10.1203/00006450-200104000-00005.
   Wu C, 2018, CELL REP, V22, P653, DOI 10.1016/j.celrep.2017.12.068.
   Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984.
   Xu PL, 2012, FEBS LETT, V586, P1871, DOI 10.1016/j.febslet.2012.05.010.
   Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804.
   Yang B, 2010, CELL DEATH DIFFER, V17, P68, DOI 10.1038/cdd.2009.84.
   Yang JZ, 2004, CELL BIOL INT, V28, P433, DOI 10.1016/j.cellbi.2004.03.011.
   Yang M, 2012, ARTERIOSCL THROM VAS, V32, P1675, DOI 10.1161/ATVBAHA.112.248732.
   Yanokura M, 2015, EXCLI J, V14, P190, DOI 10.17179/excli2014-590.
   Zambrano E, 2006, J PHYSIOL-LONDON, V571, P221, DOI 10.1113/jphysiol.2005.100313.
   Zarrinpashneh E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080268.
   Zhang LP, 2005, CANCER RES, V65, P457.
   Zhang S, 2013, MOL ASPECTS MED, V34, P939, DOI 10.1016/j.mam.2012.12.011.
   Zhao B, 2007, PROTEIN SCI, V16, P2761, DOI 10.1110/ps.073161707.
   Zhao GX, 2012, KIDNEY INT, V82, P34, DOI 10.1038/ki.2012.40.
   Zhong W, 2014, CELL SIGNAL, V26, P2765, DOI 10.1016/j.cellsig.2014.08.002.
   Zhou LY, 2020, CHINESE MED J-PEKING, V133, P1961, DOI 10.1097/CM9.0000000000000976.
   Zhou RF, 2005, J BIOL CHEM, V280, P4518, DOI 10.1074/jbc.M411053200.
   Zhu RZ, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920940946.
   Ziauddeen N, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026220.
   Zygmunt M, 2003, EUR J OBSTET GYN R B, V110, pS10, DOI 10.1016/S0301-2115(03)00168-4.},
Number-of-Cited-References = {217},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Front. Cell. Dev. Biol.},
Doc-Delivery-Number = {OK3JT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000584550400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000585147800020,
Author = {Smith, Edward R. and Hewitson, Timothy D.},
Title = {TGF-β1 is a regulator of the pyruvate dehydrogenase complex in
   fibroblasts},
Journal = {SCIENTIFIC REPORTS},
Year = {2020},
Volume = {10},
Number = {1},
Month = {OCT 21},
Abstract = {TGF-beta 1 reprograms metabolism in renal fibroblasts, inducing a switch
   from oxidative phosphorylation to aerobic glycolysis. However, molecular
   events underpinning this are unknown. Here we identify that TGF-beta 1
   downregulates acetyl-CoA biosynthesis via regulation of the pyruvate
   dehydrogenase complex (PDC). Flow cytometry showed that TGF-beta 1
   reduced the PDC subunit PDH-E1 alpha in fibroblasts derived from
   injured, but not normal kidneys. An increase in expression of PDH kinase
   1 (PDK1), and reduction in the phosphatase PDP1, were commensurate with
   net phosphorylation and inactivation of PDC. Over-expression of mutant
   PDH-E1 alpha, resistant to phosphorylation, ameliorated effects of
   TGF-beta 1, while inhibition of PDC activity with CPI-613 was sufficient
   to induce alpha SMA and pro-collagen I expression, markers of
   myofibroblast differentiation and fibroblast activation. The effect of
   TGF-beta 1 on PDC activity, acetyl-CoA, alpha SMA and pro-collagen I was
   also ameliorated by sodium dichloroacetate, a small molecule inhibitor
   of PDK. A reduction in acetyl-CoA, and therefore acetylation substrate,
   also resulted in a generalised loss of protein acetylation with TGF-beta
   1. In conclusion, TGF-beta 1 in part regulates fibroblast activation via
   effects on PDC activity.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Hewitson, TD (Corresponding Author), Royal Melbourne Hosp RMH, Dept Nephrol, Grattan St, Parkville, Vic 3050, Australia.
   Hewitson, TD (Corresponding Author), Univ Melbourne, Dept Med, RMH, Parkville, Vic, Australia.
   Smith, Edward R.; Hewitson, Timothy D., Royal Melbourne Hosp RMH, Dept Nephrol, Grattan St, Parkville, Vic 3050, Australia.
   Smith, Edward R.; Hewitson, Timothy D., Univ Melbourne, Dept Med, RMH, Parkville, Vic, Australia.},
DOI = {10.1038/s41598-020-74919-8},
Article-Number = {17914},
ISSN = {2045-2322},
Keywords-Plus = {LYSINE ACETYLATION; PHOSPHORYLATION SITES; METABOLIC-REGULATION; TCA
   CYCLE; TGF-BETA; KINASE; DIFFERENTIATION; SPECIFICITY; GLYCOLYSIS;
   SUBSTRATE},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {tim.hewitson@mh.org.au},
Affiliations = {Melbourne Health; Royal Melbourne Hospital; Melbourne Health; Royal
   Melbourne Hospital; University of Melbourne},
ResearcherID-Numbers = {Smith, Edward/AAY-1174-2021},
ORCID-Numbers = {Smith, Edward/0000-0002-2651-1787},
Funding-Acknowledgement = {National Health and Medical Research Council (NHMRC) of Australia
   {[}APP1078694]},
Funding-Text = {The work was supported by a specific project grant from the National
   Health and Medical Research Council (NHMRC) of Australia (APP1078694).},
Cited-References = {Ardehali H, 2012, EUR J HEART FAIL, V14, P120, DOI 10.1093/eurjhf/hfr173.
   Baeza J, 2016, TRENDS BIOCHEM SCI, V41, P231, DOI 10.1016/j.tibs.2015.12.006.
   Barcena-Varela M, 2021, GUT, V70, P388, DOI 10.1136/gutjnl-2019-320205.
   Bates J, 2020, J HEPATOL, V73, P896, DOI 10.1016/j.jhep.2020.04.037.
   Bernard K, 2015, J BIOL CHEM, V290, P25427, DOI 10.1074/jbc.M115.646984.
   BORDER WA, 1990, CELL DIFFER DEV, V32, P425, DOI 10.1016/0922-3371(90)90059-6.
   Boukouris AE, 2016, TRENDS BIOCHEM SCI, V41, P712, DOI 10.1016/j.tibs.2016.05.013.
   Brosse S.D.D., 2013, MITOCHONDRIAL DISORD, V9781461437222, P301, DOI {[}DOI 10.1007/978-1-4614-3722-2\_19, 10.1007/978-1-4614-3722-2\_19].
   Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981.
   Chen JJ, 2018, NAT GENET, V50, P219, DOI 10.1038/s41588-017-0026-3.
   Chen Z, 2018, J CELL PHYSIOL, V233, P2839, DOI 10.1002/jcp.25998.
   Choudhary C, 2014, NAT REV MOL CELL BIO, V15, P536, DOI 10.1038/nrm3841.
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371.
   Clayton AL, 2006, MOL CELL, V23, P289, DOI 10.1016/j.molcel.2006.06.017.
   Darby IA, 2007, INT REV CYTOL, V257, P143, DOI 10.1016/S0074-7696(07)57004-X.
   Evertts AG, 2013, J BIOL CHEM, V288, P12142, DOI 10.1074/jbc.M112.428318.
   Fouque F, 2003, PEDIATR RES, V53, P793, DOI 10.1203/01.PDR.0000057987.46622.64.
   Ghosh-Choudhary S, 2020, TRENDS CELL BIOL, V30, P201, DOI 10.1016/j.tcb.2019.12.005.
   Gürtler A, 2013, ANAL BIOCHEM, V433, P105, DOI 10.1016/j.ab.2012.10.010.
   Hewitson TD, 2016, LIFE SCI, V158, P130, DOI 10.1016/j.lfs.2016.06.022.
   Hewitson TD, 2009, AM J PHYSIOL-RENAL, V296, pF1239, DOI 10.1152/ajprenal.90521.2008.
   Hewitson TD, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00307.
   Hyndman KA, 2017, AM J PHYSIOL-RENAL, V313, pF842, DOI 10.1152/ajprenal.00313.2017.
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026.
   Kori Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09918-3.
   KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Leung AKL, 2006, NUCLEIC ACIDS RES, V34, pD218, DOI 10.1093/nar/gkj004.
   Li Q, 2018, BIOCHEM BIOPH RES CO, V496, P641, DOI 10.1016/j.bbrc.2018.01.068.
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009.
   Liu XJ, 2018, CELL, V175, P502, DOI 10.1016/j.cell.2018.08.040.
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028.
   Lundby A, 2012, CELL REP, V2, P419, DOI 10.1016/j.celrep.2012.07.006.
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48.
   Nagaraj R, 2017, CELL, V168, P210, DOI 10.1016/j.cell.2016.12.026.
   Negmadjanov U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123046.
   Para R, 2019, AM J MED SCI, V357, P394, DOI 10.1016/j.amjms.2019.02.003.
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32.
   Pavkovic M, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0095-5.
   Pietrocola F, 2015, CELL METAB, V21, P805, DOI 10.1016/j.cmet.2015.05.014.
   Rinschen MM, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aax9760.
   Ryder DJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136247.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x.
   Si MJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5341.
   Sivanand S, 2018, TRENDS BIOCHEM SCI, V43, P61, DOI 10.1016/j.tibs.2017.11.004.
   Smith ER, 2019, AM J PHYSIOL-RENAL, V316, pF517, DOI 10.1152/ajprenal.00513.2018.
   Smith ER, 2017, INT J BIOCHEM CELL B, V92, P63, DOI 10.1016/j.biocel.2017.09.009.
   Smith ER, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02709-w.
   Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Sun KH, 2016, AM J PHYSIOL-LUNG C, V310, pL824, DOI 10.1152/ajplung.00350.2015.
   Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046.
   Thomas B, 2010, MOVEMENT DISORD, V25, pS155, DOI 10.1002/mds.22781.
   Weinert BT, 2018, CELL, V174, P231, DOI 10.1016/j.cell.2018.04.033.
   Williams V, 2020, KIDNEY INT, V98, P116, DOI 10.1016/j.kint.2020.01.029.
   Winbanks CE, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/212819.
   Xie N, 2015, AM J RESP CRIT CARE, V192, P1462, DOI 10.1164/rccm.201504-0780OC.
   Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8.
   Zhang J, 2019, ONCOGENE, V38, P4669, DOI 10.1038/s41388-019-0749-y.
   Zhao X, 2020, NAT REV DRUG DISCOV, V19, P57, DOI 10.1038/s41573-019-0040-5.
   Zimmer AD, 2016, HYPOXIA, V4, P135, DOI 10.2147/HP.S99044.},
Number-of-Cited-References = {62},
Times-Cited = {29},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {OL2CG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000585147800020},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000579394600001,
Author = {Zhou, Situo and Liang, Pengfei and Zhang, Pihong and Zhang, Minghua and
   Huang, Xiaoyuan},
Title = {The long noncoding RNA PDK1-AS/miR-125b-5p/VEGFA axis modulates human
   dermal microvascular endothelial cell and human umbilical vein
   endothelial cell angiogenesis after thermal injury},
Journal = {JOURNAL OF CELLULAR PHYSIOLOGY},
Year = {2021},
Volume = {236},
Number = {4},
Pages = {3129-3142},
Month = {APR},
Abstract = {Our previous study confirmed the critical role of miR-125b and vascular
   endothelial growth factor (VEGF) in burn wound repair., The present
   study was aimed to identify the role of long noncoding RNAs (lncRNAs)
   related to the function of miR-125b and VEGF in burn wound repair and
   the underlying mechanism. First, we found that lncRNA PDK1-AS and VEGFA
   expression was significantly increased in heat-denatured dermal tissue
   samples and in human dermal microvascular endothelial cells (HDMECs) and
   human umbilical vein endothelial cells (HUVECs) after thermal injury.
   PDK1-AS knockdown significantly inhibited cell viability, cumulative
   tube length, cell migratory ability, and cell invasion of thermally
   injured HDMECs and HUVECs. PDK1-AS knockdown decreased VEGFA protein
   levels in HDMECs and HUVECs. While overexpression of PDK1-AS showed the
   opposite effects. Online tools prediction and luciferase assay confirmed
   that miR-125b-5p targeted PDK1-AS and VEGFA 3 `-untranslated region.
   miR-125b-5p inhibition significantly increased VEGFA protein levels and
   enhanced viability, cumulative tube length, migratory ability, and
   invasion of HUVECs and HDMECs. Furthermore, the effects of PDK1-AS
   knockdown on VEGFA protein levels in the two cell lines were partially
   reversed by miR-125b-5p inhibition. Finally, in the tissue samples,
   PDK1-AS and VEGFA expression was increased, while miR-125b-5p expression
   was decreased in heat-denatured dermal tissues; the expression of
   miR-125b-5p had a negative correlation with PDK1-AS and VEGFA,
   respectively, and PDK1-AS and VEGFA were positively correlated with each
   other in tissue samples. In conclusion, PDK1-AS relieves
   miR-125b-5p-induced inhibition on VEGFA by acting as a endogenous RNA,
   therefore modulating HDMEC and HUVEC angiogenesis after thermal injury.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Huang, XY (Corresponding Author), 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
   Zhou, Situo; Liang, Pengfei; Zhang, Pihong; Zhang, Minghua; Huang, Xiaoyuan, Cent South Univ, Xiangya Hosp, Dept Burns \& Reconstruct Surg, Changsha, Hunan, Peoples R China.},
DOI = {10.1002/jcp.30081},
EarlyAccessDate = {OCT 2020},
ISSN = {0021-9541},
EISSN = {1097-4652},
Keywords = {angiogenesis; human dermal microvascular endothelial cells (HDMECs);
   human umbilical vein endothelial cells (HUVECs); RNA PDK1-AS;
   miR-125b-5p; VEGFA axis; thermal injury},
Keywords-Plus = {MESENCHYMAL STEM-CELLS; EXPRESSION; PATHWAY; SKIN; MECHANISMS; ANRIL;
   VEGFA},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {huxzhongxy@163.com},
Affiliations = {Central South University},
ResearcherID-Numbers = {zhang, xuyang/GQH-3712-2022},
Cited-References = {Arodz T, 2013, ADV WOUND CARE, V2, P499, DOI 10.1089/wound.2012.0386.
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028.
   Cao W, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0260-5.
   Cassidy JT, 2014, BURNS, V40, P805, DOI 10.1016/j.burns.2013.10.010.
   Cesana M, 2013, P NATL ACAD SCI USA, V110, P7112, DOI 10.1073/pnas.1305322110.
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028.
   Ciarlillo D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180586.
   Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019.
   Congrains A, 2012, BIOCHEM BIOPH RES CO, V419, P612, DOI 10.1016/j.bbrc.2012.02.050.
   D'Andrea LD, 2006, CHEM BIOL DRUG DES, V67, P115, DOI 10.1111/j.1747-0285.2006.00356.x.
   DiPietro LA, 2013, CURR OPIN RHEUMATOL, V25, P87, DOI 10.1097/BOR.0b013e32835b13b6.
   Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110.
   Ferracin M, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-130.
   Flegg JA, 2012, J THEOR BIOL, V300, P309, DOI 10.1016/j.jtbi.2012.01.043.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313.
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336.
   Guo L, 2018, J CELL BIOCHEM, V119, P1463, DOI 10.1002/jcb.26307.
   He J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056647.
   HEIMBACH D, 1988, ANN SURG, V208, P313, DOI 10.1097/00000658-198809000-00008.
   Holdt LM, 2010, ARTERIOSCL THROM VAS, V30, P620, DOI 10.1161/ATVBAHA.109.196832.
   Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027.
   Karamysheva AF, 2008, BIOCHEMISTRY-MOSCOW+, V73, P751, DOI 10.1134/S0006297908070031.
   Li JT, 2016, J INVEST DERMATOL, V136, P746, DOI 10.1016/j.jid.2015.12.030.
   Liu H, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0950-9.
   Liu P, 2008, ARTIF ORGANS, V32, P925, DOI 10.1111/j.1525-1594.2008.00654.x.
   Liu Y, 2016, ANAL SCI, V32, P735, DOI 10.2116/analsci.32.735.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Lopez-Pajares V, 2015, DEV CELL, V32, P693, DOI 10.1016/j.devcel.2015.01.028.
   Motamedi MHK, 2015, J ORAL MAXIL SURG, V73, P676, DOI 10.1016/j.joms.2014.11.015.
   Rasulov MF, 2005, B EXP BIOL MED+, V139, P141, DOI 10.1007/s10517-005-0232-3.
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014.
   Suárez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270.
   Sun Y, 2020, HUM CELL, V33, P479, DOI 10.1007/s13577-019-00315-8.
   Wang XQ, 2017, CELL DEATH DIFFER, V24, P38, DOI 10.1038/cdd.2016.84.
   Wang Y, 2018, ADV DRUG DELIVER REV, V123, P3, DOI 10.1016/j.addr.2017.09.018.
   Xu S, 2019, ARCH MED RES, V50, P225, DOI 10.1016/j.arcmed.2019.08.010.
   Yang Xing-Hua, 2005, Zhonghua Shao Shang Za Zhi, V21, P27.
   Yin GN, 2017, ANDROLOGY-US, V5, P327, DOI 10.1111/andr.12307.
   Zhou ST, 2015, BURNS, V41, P803, DOI 10.1016/j.burns.2014.10.012.},
Number-of-Cited-References = {40},
Times-Cited = {14},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {17},
Journal-ISO = {J. Cell. Physiol.},
Doc-Delivery-Number = {QG3DR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000579394600001},
DA = {2026-02-04},
}

@article{ WOS:000582582100019,
Author = {Shen, Chih-che and Lin, Mei-Wei and Thi Nguyen, Bao Khanh and Chang,
   Chin-Wei and Shih, Jie-Ru and Thi Nguyen, Mai Thanh and Chang, Yi-Hao
   and Hu, Yu-Chen},
Title = {CRISPR-Cas13d for Gene Knockdown and Engineering of CHO Cells},
Journal = {ACS SYNTHETIC BIOLOGY},
Year = {2020},
Volume = {9},
Number = {10},
Pages = {2808-2818},
Month = {OCT 16},
Abstract = {Chinese hamster ovary (CHO) cells are the predominant cell chassis for
   biopharmaceutical production. Engineering cellular pathways related to
   cell death, metabolism, and glycosylation in CHO cells is desired but
   challenging. Here, we present a novel approach that exploits
   CRISPR-Cas13d for gene silencing and CHO cell engineering. CRISPR-Cas13d
   is a burgeoning system that exploits Cas13d nuclease and guide RNA
   (gRNA) for RNA cleavage and gene knockdown. We first showed that
   CRISPR-Cas13d effectively knocked down exogenous genes in CHO cell lines
   (K1, DG44, and DUXB11) commonly used for recombinant protein production.
   We next demonstrated that CRISPR-Cas13d robustly suppressed the
   expression of exogenous genes and various endogenous genes involved in
   gene amplification, apoptosis, metabolism, and glycosylation (e.g., GS,
   BAK, BAX, PDK1, and FUT8) in CHO cells with efficiencies ranging from
   60\% to 80\%, simply by transient transfection. By integrating the
   entire CRISPR-Cas13d system with the Sleeping Beauty system and optimal
   gRNA design, we further improved the knockdown efficiency and rapidly
   generated stable cells with approximate to 80\%-90\% knockdown. With
   this approach, we knocked down FUT8 expression for >90\% and
   significantly attenuated the IgG fucosylation. These data altogether
   implicated the potentials of CRISPR-Cas13d for gene regulation,
   glycoengineering, and cell engineering of CHO cells.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Hu, YC (Corresponding Author), Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 30003, Taiwan.
   Hu, YC (Corresponding Author), Natl Tsing Hua Univ, Frontier Res Ctr Fundamental \& Appl Sci Matters, Hsinchu 30003, Taiwan.
   Shen, Chih-che; Lin, Mei-Wei; Thi Nguyen, Bao Khanh; Chang, Chin-Wei; Chang, Yi-Hao; Hu, Yu-Chen, Natl Tsing Hua Univ, Dept Chem Engn, Hsinchu 30003, Taiwan.
   Lin, Mei-Wei, Ind Technol Res Inst, Biomed Technol \& Device Res Labs, Hsinchu 30003, Taiwan.
   Shih, Jie-Ru, Mycenax Biotech Inc, Miaoli 35053, Taiwan.
   Thi Nguyen, Mai Thanh, Vietnam Natl Univ Ho Chi Minh City, Univ Sci, Fac Chem, Ho Chi Minh City 72711, Vietnam.
   Hu, Yu-Chen, Natl Tsing Hua Univ, Frontier Res Ctr Fundamental \& Appl Sci Matters, Hsinchu 30003, Taiwan.},
DOI = {10.1021/acssynbio.0c00338},
ISSN = {2161-5063},
Keywords = {Cas13d; CRISPR; CHO; cell engineering; gene knockdown},
Keywords-Plus = {HAMSTER OVARY CELLS; RNA; EXPRESSION; TRANSCRIPTION; SUPPRESSION;
   ANTIBODIES},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemical Research Methods},
Author-Email = {yuchen@che.nthu.edu.tw},
Affiliations = {National Tsing Hua University; Industrial Technology Research Institute
   - Taiwan; Vietnam National University Ho Chi Minh City (VNUHCM) System;
   National Tsing Hua University},
ResearcherID-Numbers = {Hu, Yu-Chen/E-7825-2012},
ORCID-Numbers = {Nguyen, Mai Thanh Thi/0000-0001-8006-4028
   Hu, Yu-Chen/0000-0002-9997-4467},
Funding-Acknowledgement = {Ministry of Science and Technology (MOST) {[}107-2622-E-007003-CC1,
   108-2622-E-007-012-CC1, 109-2634-F-007-023]; Frontier Research Center on
   Fundamental and Applied Sciences of Matters from The Featured Areas
   Research Center Program within the framework of the Higher Education
   Sprout Project by the Ministry of Education (MOE), Taiwan {[}109QR001I5]},
Funding-Text = {The authors acknowledge the financial support from the Ministry of
   Science and Technology (MOST 107-2622-E-007003-CC1,
   108-2622-E-007-012-CC1, 109-2634-F-007-023). This work was also
   financially supported by the Frontier Research Center on Fundamental and
   Applied Sciences of Matters from The Featured Areas Research Center
   Program within the framework of the Higher Education Sprout Project by
   the Ministry of Education (MOE 109QR001I5), Taiwan.},
Cited-References = {Abudayyeh OO, 2017, NATURE, V550, P280, DOI 10.1038/nature24049.
   Abudayyeh OO, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5573.
   Ali Z, 2018, TRENDS PLANT SCI, V23, P374, DOI 10.1016/j.tplants.2018.03.003.
   Amann T, 2019, BIOTECHNOL BIOENG, V116, P2778, DOI 10.1002/bit.27101.
   Amann T, 2019, METAB ENG, V52, P143, DOI 10.1016/j.ymben.2018.11.014.
   Beuger V, 2009, BIOTECHNOL APPL BIOC, V53, P31, DOI 10.1042/BA20080220.
   Brown AJ, 2016, BIOTECHNOL ADV, V34, P492, DOI 10.1016/j.biotechadv.2015.12.012.
   Brown AJ, 2015, BIOTECHNOL J, V10, P1019, DOI 10.1002/biot.201400744.
   Chavez A, 2015, NAT METHODS, V12, P326, DOI {[}10.1038/NMETH.3312, 10.1038/nmeth.3312].
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023.
   Cox DBT, 2017, SCIENCE, V358, P1019, DOI 10.1126/science.aaq0180.
   Doudna JA, 2020, NATURE, V578, P229, DOI 10.1038/s41586-020-1978-5.
   East-Seletsky A, 2017, MOL CELL, V66, P373, DOI 10.1016/j.molcel.2017.04.008.
   East-Seletsky A, 2016, NATURE, V538, P270, DOI 10.1038/nature19802.
   Fischer S, 2015, BIOTECHNOL ADV, V33, P1878, DOI 10.1016/j.biotechadv.2015.10.015.
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044.
   Grav LM, 2015, BIOTECHNOL J, V10, P1446, DOI 10.1002/biot.201500027.
   Ha TK, 2020, METAB ENG, V57, P182, DOI 10.1016/j.ymben.2019.11.008.
   Hansen HG, 2017, BIOTECHNOL ADV, V35, P64, DOI 10.1016/j.biotechadv.2016.11.008.
   He BB, 2020, PROTEIN CELL, V11, P518, DOI 10.1007/s13238-020-00700-2.
   Hsu MN, 2019, BIOTECHNOL ADV, V37, DOI 10.1016/j.biotechadv.2019.107447.
   Imai-Nishiya H, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-84.
   Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831.
   Karottki KJL, 2020, BIOTECHNOL BIOENG, V117, P593, DOI 10.1002/bit.27199.
   Kim CL, 2019, METAB ENG, V52, P57, DOI 10.1016/j.ymben.2018.11.003.
   Konermann S, 2018, CELL, V173, P665, DOI 10.1016/j.cell.2018.02.033.
   Kushawah G, 2020, DEV CELL, V1.
   Lim SF, 2006, METAB ENG, V8, P509, DOI 10.1016/j.ymben.2006.05.005.
   Mishra N., 2020, J BIOTECHNOL, V5.
   Mori K, 2004, BIOTECHNOL BIOENG, V88, P901, DOI 10.1002/bit.20326.
   Noh SM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23720-9.
   O'Connell MR, 2019, J MOL BIOL, V431, P66, DOI 10.1016/j.jmb.2018.06.029.
   Pickar-Oliver A, 2019, NAT REV MOL CELL BIO, V20, P490, DOI 10.1038/s41580-019-0131-5.
   Ronda C, 2014, BIOTECHNOL BIOENG, V111, P1604, DOI 10.1002/bit.25233.
   Shen CC, 2017, ACS SYNTH BIOL, V6, P1509, DOI 10.1021/acssynbio.7b00020.
   Smargon AA, 2017, MOL CELL, V65, P618, DOI 10.1016/j.molcel.2016.12.023.
   Sun T, 2015, ENG LIFE SCI, V15, P660, DOI 10.1002/elsc.201400218.
   Sung LY, 2019, BIOTECHNOL BIOENG, V116, P1066, DOI 10.1002/bit.26915.
   Walsh G, 2018, NAT BIOTECHNOL, V36, P1136, DOI 10.1038/nbt.4305.
   Wang F, 2019, BIOTECHNOL ADV, V37, P708, DOI 10.1016/j.biotechadv.2019.03.016.
   Wright AV, 2016, CELL, V164, P29, DOI 10.1016/j.cell.2015.12.035.
   Xiong K, 2019, BIOTECHNOL BIOENG, V116, P1813, DOI 10.1002/bit.26969.
   Yan WX, 2018, MOL CELL, V70, P327, DOI 10.1016/j.molcel.2018.02.028.
   Yeo NC, 2018, NAT METHODS, V15, P611, DOI 10.1038/s41592-018-0048-5.
   Zhang Y, 2022, OCUL IMMUNOL INFLAMM, V30, P623, DOI 10.1080/09273948.2020.1821902.
   Zhou CY, 2020, NATL SCI REV, V7, P835, DOI 10.1093/nsr/nwaa033.
   Zhou HB, 2020, CELL, V181, P590, DOI 10.1016/j.cell.2020.03.024.
   Zhou MX, 2011, J BIOTECHNOL, V153, P27, DOI 10.1016/j.jbiotec.2011.03.003.},
Number-of-Cited-References = {48},
Times-Cited = {21},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {59},
Journal-ISO = {ACS Synth. Biol.},
Doc-Delivery-Number = {OH4YF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000582582100019},
DA = {2026-02-04},
}

@article{ WOS:000579534800012,
Author = {Yang, Zhang-Hua and Wu, Xiao-Nan and He, Peng and Wang, Xuekun and Wu,
   Jianfeng and Ai, Tingting and Zhong, Chuan-Qi and Wu, Xiurong and Cong,
   Yu and Zhu, Rongfeng and Li, Hongda and Cai, Zhi-Yu and Mo, Wei and Han,
   Jiahuai},
Title = {A Non-canonical PDK1-RSK Signal Diminishes Pro-caspase-8-Mediated
   Necroptosis Blockade},
Journal = {MOLECULAR CELL},
Year = {2020},
Volume = {80},
Number = {2},
Pages = {296+},
Month = {OCT 15},
Abstract = {Necroptosis induction in vitro often requires caspase-8 (Casp8)
   inhibition by zVAD because pro-Casp8 cleaves RIP1 to disintegrate the
   necrosome. It has been unclear how the Casp8 blockade of necroptosis is
   eliminated naturally. Here, we show that pro-Casp8 within the necrosome
   can be inactivated by phosphorylation at Thr265 (pC8(T265)), pC8(T265)
   occurs in vitro in various necroptotic cells and in the cecum of
   TNF-treated mice. p90 RSK is the kinase of pro-Casp8. It is activated by
   a mechanism that does not need ERK but PDK1, which is recruited to the
   RIP1-RIP3-MLKL-containing necrosome. Phosphorylation of proCasp8 at
   Thr265 can substitute for zVAD to permit necroptosis in vitro, pC8(T265
   )mimic T265E knockin mice are embryonic lethal due to unconstrained
   necroptosis, and the pharmaceutical inhibition of RSK-mediated pC8(T265)
   diminishes TNF-induced cecum damage and lethality in mice by halting
   necroptosis. Thus, phosphorylation of pro-Casp8 at Thr265 by RSK is an
   intrinsic mechanism for passing the Casp8 checkpoint of necroptosis.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Mo, W; Han, JH (Corresponding Author), Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.
   Mo, W; Han, JH (Corresponding Author), Xiamen Univ, Xiangan Hosp, Canc Res Ctr, Sch Med,Res Unit Cellular Stress CAMS, Xiamen 361102, Fujian, Peoples R China.
   Yang, Zhang-Hua; He, Peng; Wang, Xuekun; Wu, Jianfeng; Ai, Tingting; Zhong, Chuan-Qi; Wu, Xiurong; Cong, Yu; Zhu, Rongfeng; Li, Hongda; Cai, Zhi-Yu; Mo, Wei; Han, Jiahuai, Xiamen Univ, Innovat Ctr Cell Biol, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China.
   Mo, Wei; Han, Jiahuai, Xiamen Univ, Xiangan Hosp, Canc Res Ctr, Sch Med,Res Unit Cellular Stress CAMS, Xiamen 361102, Fujian, Peoples R China.
   Wu, Xiao-Nan, Xiamen Univ, Sch Pharmaceut Sci, Xiamen 361102, Fujian, Peoples R China.},
DOI = {10.1016/j.molcel.2020.09.004},
ISSN = {1097-2765},
EISSN = {1097-4164},
Keywords-Plus = {MIXED LINEAGE KINASE; DOMAIN-LIKE PROTEIN; RIBOSOMAL S6 KINASE;
   CELL-DEATH; PROGRAMMED NECROSIS; DOCKING SITE; APOPTOSIS; RIP3;
   PHOSPHORYLATION; CASPASE-8},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {wmo@xmu.edu.cn
   jhan@xmu.edu.cn},
Affiliations = {Xiamen University; Xiamen University; Xiamen University},
ResearcherID-Numbers = {Yang, Zhang-Hua/LIF-8820-2024
   Ai, Tingting/NOF-6732-2025
   li, hongda/LLM-0123-2024},
ORCID-Numbers = {He, Peng/0000-0002-7779-5265
   Yang, Zhang-Hua/0000-0001-8713-1879
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81788101, 81630042,
   31701204]; National Scientific and Technological Major Project
   {[}2017ZX10202203-003]; 111 Project {[}B12001]; Chinese Academy of
   Medical Sciences {[}2019RU054]; China Postdoctoral Science Foundation
   {[}2017M610396, 2018T110648]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (81788101 and 81630042 to J.H. and 31701204 to Z.-H.Y.), the
   National Scientific and Technological Major Project (2017ZX10202203-003
   to J.H.), the 111 Project (B12001 to J.H.), research unit fund from the
   Chinese Academy of Medical Sciences (2019RU054 to J.H.), and the China
   Postdoctoral Science Foundation (2017M610396 and 2018T110648 to
   Z.-H.Y.).},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509.
   BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848.
   Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883.
   Chen WZ, 2015, NAT CELL BIOL, V17, P434, DOI 10.1038/ncb3120.
   Chen WZ, 2013, J BIOL CHEM, V288, P16247, DOI 10.1074/jbc.M112.435545.
   Chen X, 2014, CELL RES, V24, P105, DOI 10.1038/cr.2013.171.
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037.
   Coburn B, 2005, INFECT IMMUN, V73, P3219, DOI 10.1128/IAI.73.6.3219-3227.2005.
   Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496.
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711.
   Dillon CP, 2012, CELL REPORTS, V1, P401, DOI 10.1016/j.celrep.2012.03.010.
   Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026.
   Feng SS, 2007, CELL SIGNAL, V19, P2056, DOI 10.1016/j.cellsig.2007.05.016.
   Fisher TL, 1996, MOL CELL BIOL, V16, P1212.
   Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6.
   Frödin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924.
   Green DR, 2011, MOL CELL, V44, P9, DOI 10.1016/j.molcel.2011.09.003.
   Günther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400.
   Han JH, 2011, NAT IMMUNOL, V12, P1143, DOI 10.1038/ni.2159.
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021.
   Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732.
   Houles T, 2018, SEMIN CANCER BIOL, V48, P53, DOI 10.1016/j.semcancer.2017.04.016.
   Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168.
   Jouan-Lanhouet S, 2014, SEMIN CELL DEV BIOL, V35, P2, DOI 10.1016/j.semcdb.2014.08.010.
   Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857.
   Lalaoui N, 2020, NATURE, V577, P103, DOI 10.1038/s41586-019-1828-5.
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019.
   Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514.
   Lu JV, 2011, P NATL ACAD SCI USA, V108, P15312, DOI 10.1073/pnas.1102779108.
   Newton K, 2019, NATURE, V575, P679, DOI 10.1038/s41586-019-1752-8.
   Newton K, 2019, NATURE, V574, P428, DOI 10.1038/s41586-019-1548-x.
   Newton K, 2014, SCIENCE, V343, P1357, DOI 10.1126/science.1249361.
   O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362.
   Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852.
   Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191.
   Peng C, 2011, J BIOL CHEM, V286, P6946, DOI 10.1074/jbc.M110.172338.
   Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893.
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031.
   Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200.
   Tao PF, 2020, NATURE, V577, P109, DOI 10.1038/s41586-019-1830-y.
   Vanlangenakker N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.111.
   Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3.
   Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252.
   Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477.
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003.
   Wu JF, 2013, CELL RES, V23, P994, DOI 10.1038/cr.2013.91.
   Wu XN, 2014, CELL DEATH DIFFER, V21, P1709, DOI 10.1038/cdd.2014.77.
   Yang ZT, 2018, NAT CELL BIOL, V20, P186, DOI 10.1038/s41556-017-0022-y.
   Zamaraev AV, 2017, TRENDS CELL BIOL, V27, P322, DOI 10.1016/j.tcb.2017.01.003.
   Zaru R, 2007, NAT IMMUNOL, V8, P1227, DOI 10.1038/ni1517.
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308.
   Zhang HB, 2011, NATURE, V471, P373, DOI 10.1038/nature09878.
   Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109.
   Zhong CQ, 2015, CELL STEM CELL, V17, P221, DOI 10.1016/j.stem.2015.06.005.},
Number-of-Cited-References = {55},
Times-Cited = {59},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {56},
Journal-ISO = {Mol. Cell},
Doc-Delivery-Number = {OD0HF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000579534800012},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000582678700011,
Author = {Sakle, Nikhil S. and More, Shweta A. and Mokale, Santosh N.},
Title = {A network pharmacology-based approach to explore potential targets of
   Caesalpinia pulcherima: an updated prototype in drug discovery},
Journal = {SCIENTIFIC REPORTS},
Year = {2020},
Volume = {10},
Number = {1},
Month = {OCT 14},
Abstract = {Caesalpinia pulcherima (CP) is a traditional herb used for the treatment
   of asthma, bronchitis, cancer, anti-bacterial, anti-fungal and as
   abortifacient. In the present study, bioactive components and potential
   targets in the treatment of breast cancer validated through in silico,
   in vitro and in vivo approach. The results for the analysis were as
   among 29 components, only four components were found active for further
   study which proved the use of CP as a multi-target herb for betterment
   of clinical uses. The results found by PPI states that our network has
   significant interactions which include the ESR-1, ESR-2, ESRRA, MET,
   VEGF, FGF, PI3K, PDK-1, MAPK, PLK-1, NEK-2, and GRK. Compound-target
   network involves 4 active compound and 150 target genes which elucidate
   the mechanisms of drug action in breast cancer treatment. Furthermore,
   on the basis of the above results the important proteins were fetched
   for the docking study which helps in predicting the possible interaction
   between components and targets. The results of the western blotting
   showed that CP regulates ER and EGFR expression in MCF-7 cell. In
   addition to this animal experimentation showed that CP significantly
   improved immunohistological status in MNU induced carcinoma rats.
   Network pharmacology approach not only helps us to confirm the study of
   the chosen target but also gave an idea of compound-target network as
   well as pathways associated to the CP for treating the complex metabolic
   condition as breast cancer and they importance for experimental
   verification.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Mokale, SN (Corresponding Author), YB Chavan Coll Pharm, Dr Rafiq Zakaria Campus, Aurangabad 431001, Maharashtra, India.
   Sakle, Nikhil S.; More, Shweta A.; Mokale, Santosh N., YB Chavan Coll Pharm, Dr Rafiq Zakaria Campus, Aurangabad 431001, Maharashtra, India.},
DOI = {10.1038/s41598-020-74251-1},
Article-Number = {17217},
ISSN = {2045-2322},
Keywords-Plus = {TRADITIONAL CHINESE MEDICINE; IN-VITRO; APOPTOSIS; DATABASE;
   IDENTIFICATION; NECROPTOSIS; QUERCETIN; MECHANISM; PATHWAYS; EXTRACT},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {santoshmokale@rediffmail.com},
Affiliations = {Y. B. Chavan College of Pharmacy},
ResearcherID-Numbers = {Mokale, Santosh/L-7048-2018
   Sakle, Nikhil/D-8572-2019},
ORCID-Numbers = {Sakle, Nikhil/0000-0003-2614-1920},
Funding-Acknowledgement = {Department of Science and Technology (DST), New Delhi, India
   {[}SR/FT/LS-132/2012, SERB/F/4302/2012-13]},
Funding-Text = {The authors thankful to the Mrs. Fatima Rafiq Zakaria, Chairman Maulana
   Azad Educational Trust, Dr. Rafiq Zakaria Campus, Aurangabad 431001(MS),
   India for providing the laboratory facility. This work was supported by
   the Department of Science and Technology (DST), New Delhi, India
   {[}Project File No. SR/FT/LS-132/2012 and Sanction Diary No.
   SERB/F/4302/2012-13].},
Cited-References = {Alvarado A, 2017, PATHOL RES PRACT, V213, P441, DOI 10.1016/j.prp.2017.02.014.
   Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279.
   Bento AP, 2014, NUCLEIC ACIDS RES, V42, pD1083, DOI 10.1093/nar/gkt1031.
   Bi YH, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/4509892.
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711.
   Chandran U, 2015, COMB CHEM HIGH T SCR, V18, P846, DOI 10.2174/1386207318666151019093606.
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939.
   Chen PN, 2005, NUTR CANCER, V53, P232, DOI 10.1207/s15327914nc5302\_12.
   Chien SY, 2009, HUM EXP TOXICOL, V28, P493, DOI 10.1177/0960327109107002.
   Delgado L, 2014, FOOD FUNCT, V5, P797, DOI 10.1039/c3fo60441a.
   Din FU, 2017, INT J NANOMED, V12, P7291, DOI 10.2147/IJN.S146315.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Gertsch J, 2011, PLANTA MED, V77, P1086, DOI 10.1055/s-0030-1270904.
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118.
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769.
   Hu RF, 2017, CHIN J NAT MEDICINES, V15, P436, DOI 10.1016/S1875-5364(17)30065-1.
   Huang JH, 2017, MOL MED REP, V16, P4583, DOI 10.3892/mmr.2017.7149.
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951.
   Li HY, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/495840.
   Li S, 2007, IET SYST BIOL, V1, P51, DOI 10.1049/iet-syb:20060032.
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI {[}10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0].
   Lokwani D, 2012, J COMPUT AID MOL DES, V26, P267, DOI 10.1007/s10822-011-9540-z.
   Losso JN, 2004, J NUTR BIOCHEM, V15, P672, DOI 10.1016/j.jnutbio.2004.06.004.
   Pereira ASP, 2017, MOL DIVERS, V21, P809, DOI 10.1007/s11030-017-9769-0.
   Rath GK, 2014, INDIAN J MED PAEDIAT, V35, P288, DOI 10.4103/0971-5851.144991.
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758-2946-6-13.
   Saha T, 2019, EUR J MED CHEM, V177, P116, DOI 10.1016/j.ejmech.2019.05.023.
   Sakle NS, 2020, NUTR CANCER, V72, P1243, DOI 10.1080/01635581.2019.1670855.
   Sakle NS, 2019, PHARMACOGN MAG, V15, P288, DOI 10.4103/pm.pm\_100\_19.
   Seeram NP, 2005, J NUTR BIOCHEM, V16, P360, DOI 10.1016/j.jnutbio.2005.01.006.
   Srinivas KVNS, 2003, PHYTOCHEMISTRY, V63, P789, DOI 10.1016/S0031-9422(03)00325-X.
   Stelzer G, 2016, Current Protocols in Bioinformatics, V54, DOI {[}10.1002/cpbi.5, 10.1002/cpbi.5, DOI 10.1002/CPBI.5].
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937.
   Wei SZ, 2019, MOL GENET GENOMICS, V294, P1159, DOI 10.1007/s00438-019-01569-5.
   Wellberg EA, 2017, HORM CANCER-US, V8, P269, DOI 10.1007/s12672-017-0302-9.
   Xue RC, 2013, NUCLEIC ACIDS RES, V41, pD1089, DOI 10.1093/nar/gks1100.
   Yue SJ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00694.
   Zhou X, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00201.},
Number-of-Cited-References = {38},
Times-Cited = {77},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {OH6DJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000582678700011},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000578600600001,
Author = {Li, Jinglin and Guan, Canghai and Hu, Zengtao and Liu, Lang and Su,
   Zhilei and Kang, Pengcheng and Jiang, Xingming and Cui, Yunfu},
Title = {Yin Yang 1-induced LINC00667 up-regulates pyruvate dehydrogenase kinase
   1 to promote proliferation, migration and invasion of cholangiocarcinoma
   cells by sponging miR-200c-3p},
Journal = {HUMAN CELL},
Year = {2021},
Volume = {34},
Number = {1},
Pages = {187-200},
Month = {JAN},
Abstract = {Cholangiocarcinoma (CCA) is one of the most aggressive and lethal
   malignancies. Long noncoding RNAs (lncRNAs) are being found to play
   crucial roles in CCA progression. This work aims to investigate the
   roles of long intergenic non-protein coding RNA 667 (LINC00667) in
   progression of CCA. RT-qPCR and western blot were applied to detect gene
   expression. Clinical correlation and survival were analyzed by
   statistical methods. Overexpression and RNA interference approaches were
   used to investigate the effects of LINC00667 on CCA cells. Tumor
   xenograft assay was performed to detect the function of LINC00667 in
   vivo. Transcriptional regulation and competing endogenous RNA (ceRNA)
   mechanism were predicted via bioinformatics analysis. ChIP, luciferase
   reporter, and Ago2 RIP assays further confirmed the predicted results.
   Our data indicated that LINC00667 was highly expressed in CCA tissues
   and cells, and transcription factor Yin Yang 1 (YY1) induced LINC00667
   expression in CCA cells. Up-regulated LINC00667 was significantly
   associated with lymph node metastasis, advanced TNM stage, and poor
   prognosis. Knockdown of LINC00667 suppressed the proliferation,
   migration, invasion and epithelial-mesenchymal transition (EMT) of CCA
   cells, while overexpression of LINC00667 acquired opposite effects.
   Moreover, knockdown of LINC00667 inhibited tumor growth in vivo. In
   addition, LINC00667 was demonstrated to function as a ceRNA for
   miR-200c-3p, and then LINC00667 up-regulated pyruvate dehydrogenase
   kinase 1 (PDK1) to promote CCA development by inhibiting miR-200c-3p.
   These findings identified a pivotal role of LINC00667 in tumorigenesis
   and development of CCA. Targeting the YY1/LINC00667/miR-200c-3p/PDK1
   axis may provide a new therapeutic strategy for CCA treatment.},
Publisher = {SPRINGER JAPAN KK},
Address = {SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN},
Type = {Article},
Language = {English},
Affiliation = {Jiang, XM; Cui, YF (Corresponding Author), Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, 148 Baojian St, Harbin 150086, Heilongjiang, Peoples R China.
   Li, Jinglin; Guan, Canghai; Hu, Zengtao; Liu, Lang; Su, Zhilei; Kang, Pengcheng; Jiang, Xingming; Cui, Yunfu, Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 2, 148 Baojian St, Harbin 150086, Heilongjiang, Peoples R China.},
DOI = {10.1007/s13577-020-00448-1},
EarlyAccessDate = {OCT 2020},
ISSN = {0914-7470},
EISSN = {1749-0774},
Keywords = {Cholangiocarcinoma; LncRNA; LINC00667; miR-200c-3p; PDK1},
Keywords-Plus = {METASTASIS; EXPRESSION; CARCINOMA},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {xmjiang@hrbmu.edu.cn
   yfcui777@hotmail.com},
Affiliations = {Harbin Medical University},
ResearcherID-Numbers = {li, jinglin/KYQ-2014-2024
   Jiang, Xingming/ABA-1971-2021},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81602088]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. 81602088).},
Cited-References = {Bai JH, 2020, HUM CELL, V33, P98, DOI 10.1007/s13577-019-00265-1.
   Chen W, 2019, CELL SIGNAL, V54, P102, DOI 10.1016/j.cellsig.2018.10.016.
   Chen XX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0962-6.
   Danarto R, 2020, TURK J UROL, V46, P26, DOI 10.5152/tud.2019.19163.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Hoyos S, 2018, BBA-MOL BASIS DIS, V1864, P1461, DOI 10.1016/j.bbadis.2017.07.027.
   Hsu JY, 2017, FASEB J, V31, P4265, DOI 10.1096/fj.201700156R.
   Jiang YT, 2018, CHEMOSPHERE, V199, P694, DOI 10.1016/j.chemosphere.2018.01.095.
   Li C, 2019, J CELL MOL MED, V23, P4386, DOI 10.1111/jcmm.14331.
   Li JL, 2019, J CELL PHYSIOL, V234, P22947, DOI 10.1002/jcp.28856.
   Li JL, 2019, J CELL PHYSIOL, V234, P17113, DOI 10.1002/jcp.28470.
   Li P, 2019, HUM CELL, V32, P522, DOI 10.1007/s13577-019-00273-1.
   Liu P, 2020, CELL BIOL INT, V44, P1382, DOI 10.1002/cbin.11334.
   Ma QH, 2020, HUM CELL, V33, P232, DOI 10.1007/s13577-019-00287-9.
   Maolakuerban N, 2018, CANCER BIOL THER, V19, P282, DOI 10.1080/15384047.2017.1394551.
   Molist C, 2020, CANCER LETT, V477, P49, DOI 10.1016/j.canlet.2020.02.035.
   Qiao K, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1421-7.
   Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0.
   Shen SN, 2020, MOL THER-NUCL ACIDS, V20, P331, DOI 10.1016/j.omtn.2019.12.036.
   Shen YF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2485-1.
   Shen Y, 2018, GENE, V666, P64, DOI 10.1016/j.gene.2018.05.001.
   Siu MKY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0209-0.
   Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3.
   Wang D, 2019, MOL THER-NUCL ACIDS, V14, P465, DOI 10.1016/j.omtn.2018.12.017.
   Wang L, 2020, HUM CELL, V33, P195, DOI 10.1007/s13577-019-00296-8.
   Wu M, 2019, J CELL MOL MED, V23, P29, DOI 10.1111/jcmm.13658.
   Yang F, 2018, CELL DEATH DIFFER, V25, P2209, DOI 10.1038/s41418-018-0123-6.
   Yang YB, 2019, ONCOTARGETS THER, V12, P9927, DOI 10.2147/OTT.S221339.},
Number-of-Cited-References = {28},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Hum. Cell},
Doc-Delivery-Number = {PP2RN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000578600600001},
DA = {2026-02-04},
}

@article{ WOS:000574775800011,
Author = {Liu, Rangru and Yu, Zutao and Chen, Zhuo and Liu, Danqi and Huang,
   Fengying and Li, Qianbin and Hu, Gaoyun and Yi, Xinan and Li, Xi and
   Zhou, Honghao and Liu, Zhaoqian},
Title = {A novel dual MEK/PDK1 inhibitor 9za retards the cell cycle at
   G0/G1 phase and induces mitochondrial apoptosis in
   non-small cell lung cancer cells},
Journal = {PEERJ},
Year = {2020},
Volume = {8},
Month = {OCT 2},
Abstract = {Background. A novel dual MEK/PDK1 inhibitor named 9za has been
   synthesized by our research team. Preliminary study showed that 9za
   possessed potent cytotoxicity and proapoptosis in non-small cell lung
   cancer (NSCLC) cells. Nevertheless, the precise underlying mechanism is
   vague.
   Methods. In this work, we adopted the MTT assay, the Cell Cycle
   Detection Kit, and the JC-1 staining assay to detect the cell viability,
   the cell cycle distribution and the mitochondrial membrane potential
   (MMP), respectively. Cell apoptosis was measured by the morphology
   observation under a light microscope, Annexin V-FITC/propidium iodide
   (PI) apoptosis detection and the colorimetric TUNEL assay. Western blot
   was used to monitor the cell cycle-, apoptosis-related proteins and
   relevant proteins involved in the signaling pathways.
   Results. The MIT assay demonstrated that 9za sharply decreased the
   viability of NSCLC cells. Cell cycle analysis revealed that low
   concentrations of 9za arrested the cell cycle at the G(0)/G(1) phase ,
   which was further confirmed by the decreased levels of Cyclin D1,
   cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6).
   Additionally, morphological observations, Annexin V-FITC/propidium
   iodide (PI) apoptosis analysis and TUNEL assays indicated that high
   concentrations of 9za induced cell apoptosis. Furthermore, the JC-1
   staining assay revealed that the mitochondrial membrane potential was
   downregulated following 9za exposure. Western blot also showed that 9za
   markedly decreased the expression levels of total Bcl-2, Cytochrome C in
   the mitochondria and BCL2 associated X (BAX) in the cytoplasm. However,
   the levels of BAX in the mitochondria, Cytochrome C in the cytoplasm,
   active caspase-9, active caspase-3 and cleaved-PARP showed the opposite
   changes. Moreover, the dose-dependent decreased phosphorylation levels
   of PDK1, protein kinase B (Akt), MEK and extracellular signal regulated
   kinase 1/2 (ERK1/2) after 9za treatment verified that 9za was indeed a
   dual MEK/PDK1 inhibitor, as we expected. Compared with a single MEK
   inhibitor PD0325901 or a single PDK1 inhibitor BX517, the dual MEK/PDK1
   inhibitor 9za could strengthen the cytotoxic and proapoptotic effect,
   indicating that the double blocking of the MEK and PDK1 signaling
   pathways plays stronger cell growth inhibition and apoptosis induction
   roles than the single blocking of the MEK or PDK1 signaling pathway in
   NSCLC cells. Our work elucidated the molecular mechanisms for 9za as a
   novel drug candidate against NSCLC.},
Publisher = {PEERJ INC},
Address = {341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Liu, ZQ (Corresponding Author), Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China.
   Liu, ZQ (Corresponding Author), Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Hunan Key Lab Pharmacogenet, Changsha, Peoples R China.
   Liu, Rangru, Hainan Med Univ, Sch Pharm, Key Lab Trop Translat Med, Minist Educ, Haikou, Hainan, Peoples R China.
   Liu, Rangru, Hainan Med Univ, Sch Pharm, Hainan Key Lab Res \& Dev Trop Herbs, Haikou, Hainan, Peoples R China.
   Liu, Rangru; Li, Xi; Zhou, Honghao; Liu, Zhaoqian, Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China.
   Liu, Rangru; Li, Xi; Zhou, Honghao; Liu, Zhaoqian, Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Hunan Key Lab Pharmacogenet, Changsha, Peoples R China.
   Yu, Zutao; Chen, Zhuo; Li, Qianbin; Hu, Gaoyun, Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Med Chem, Changsha, Peoples R China.
   Liu, Danqi, Cent South Univ, Xiangya Hosp, Dept Pharm, Changsha, Peoples R China.
   Huang, Fengying, Hainan Med Univ, Key Lab Trop Dis \& Translat Med, Minist Educ, Haikou, Hainan, Peoples R China.
   Huang, Fengying, Hainan Med Univ, Hainan Prov Key Lab Trop Med, Haikou, Hainan, Peoples R China.
   Yi, Xinan, Hainan Med Univ, United Lab Neurosci, Haikou, Hainan, Peoples R China.
   Yi, Xinan, Fourth Mil Med Univ, Haikou, Hainan, Peoples R China.},
DOI = {10.7717/peerj.9981},
Article-Number = {e9981},
ISSN = {2167-8359},
Keywords = {A dual MEK/PDK1 inhibitor; 9za; Cytotoxicity; Cell cycle arrest;
   Mitochondrial apoptosis; Non-small cell lung cancer},
Keywords-Plus = {DISCOVERY; AXIS; NIVOLUMAB; AUTOPHAGY; DOCETAXEL; PATHWAY; MAPK},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {zqliu@csu.edu.cn},
Affiliations = {Hainan Medical University; Hainan Medical University; Central South
   University; Central South University; Central South University; Central
   South University; Hainan Medical University; Hainan Medical University;
   Hainan Medical University; Air Force Medical University},
ResearcherID-Numbers = {Yu, Zutao/HNI-7729-2023
   Zhou, Honghao/JWO-4641-2024},
ORCID-Numbers = {Yu, Zutao/0000-0003-1389-0818
   },
Funding-Acknowledgement = {Key Research and Development Project of Hainan Province {[}ZDYF2016128,
   ZDYF2017092]; National Natural Science Foundation of China {[}21102184,
   81573508, 81773640, 81874327]; National Key Research and Development
   Program of China {[}2016YFC1306900, 2016YFC0905002]; Strategy-Oriented
   Special Project of Central South University in China {[}ZLXD2017003]},
Funding-Text = {This work was supported by Key Research and Development Project of
   Hainan Province (grant number: ZDYF2016128, ZDYF2017092), the National
   Natural Science Foundation of China (grant number: 21102184, 81573508,
   81773640, 81874327), the National Key Research and Development Program
   of China (grant number: 2016YFC1306900, 2016YFC0905002) and the
   Strategy-Oriented Special Project of Central South University in China
   (grant number: ZLXD2017003). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.},
Cited-References = {Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643.
   Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013.
   Chen X, 2018, BIOMED PHARMACOTHER, V97, P75, DOI 10.1016/j.biopha.2017.10.030.
   Ciuffreda L, 2014, CURR PHARM DESIGN, V20, P3944, DOI 10.2174/13816128113196660763.
   Fan XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep29865.
   Fu YF, 2016, MOL MED REP, V14, P394, DOI 10.3892/mmr.2016.5249.
   Houédé N, 2015, PHARMACOL THERAPEUT, V145, P1, DOI 10.1016/j.pharmthera.2014.06.004.
   Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930.
   Huang W, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0564-4.
   Li QB, 2010, BIOORG MED CHEM LETT, V20, P4526, DOI 10.1016/j.bmcl.2010.06.030.
   Li XJ, 2014, INT J BIOL MACROMOL, V66, P108, DOI 10.1016/j.ijbiomac.2014.02.019.
   Lin YC, 2018, MAR DRUGS, V16, DOI 10.3390/md16120479.
   Liu C, 2019, MOLECULES, V24, DOI 10.3390/molecules24071363.
   Liu RR, 2019, J CELL PHYSIOL, V234, P20728, DOI 10.1002/jcp.28679.
   McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740.
   Meng Jieru, 2010, PLoS One, V5, pe14124, DOI 10.1371/journal.pone.0014124.
   Park H, 2012, BIOORG MED CHEM LETT, V22, P4946, DOI 10.1016/j.bmcl.2012.06.041.
   Qi BH, 2019, EUR J MED CHEM, V163, P10, DOI 10.1016/j.ejmech.2018.11.057.
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590.
   Tait SWG, 2010, NAT REV MOL CELL BIO, V11, P621, DOI 10.1038/nrm2952.
   Taylor RC, 2008, NAT REV MOL CELL BIO, V9, P231, DOI 10.1038/nrm2312.
   VanArsdale T, 2015, CLIN CANCER RES, V21, P2905, DOI 10.1158/1078-0432.CCR-14-0816.
   Xie HQ, 2019, J ETHNOPHARMACOL, V231, P230, DOI 10.1016/j.jep.2018.11.028.
   Yu ZT, 2019, BIOORGAN MED CHEM, V27, P944, DOI 10.1016/j.bmc.2019.01.028.
   Yu ZT, 2015, FUTURE MED CHEM, V7, P269, DOI {[}10.4155/FMC.14.143, 10.4155/fmc.14.143].
   Zhang P, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12543.},
Number-of-Cited-References = {26},
Times-Cited = {4},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {15},
Journal-ISO = {PeerJ},
Doc-Delivery-Number = {NW1MO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000574775800011},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000565646300012,
Author = {Heilman, Christian and Ibarreta, Janeen and Salonga, Glecille Ann and
   Hon, Michelle C. and Caracci, Angela M. and Badial, Tajinder and
   Crivello, Selina and Henry, Stacy A. and Nguyen, Tina M. and So,
   Christopher H.},
Title = {G protein coupled receptor kinases modulate Caenorhabditis
   elegans reactions to heat stresses},
Journal = {BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS},
Year = {2020},
Volume = {530},
Number = {4},
Pages = {692-698},
Month = {OCT 1},
Abstract = {In this report, we explored if G protein coupled receptor kinases (GRKs)
   can help modulate the heat stress responses of Caenorhabditis (C.)
   elegans. Loss of function grk-2 C. elegans mutants were more tolerant to
   increases in heat and display an ability for heat stress-associated
   hormesis at a longer exposure time unlike the wild type N2 animals and
   the loss of function grk-1 C. elegans mutants. The loss of function
   grk-1 mutants recovered more from acute heat stress compared to the wild
   type N2 animals. Animals with low Ce-GRK2 protein expression showed
   increased DAF-16 nuclear localization during the early stages of heat
   stress exposure compared to the other RNAi-treated animals,
   demonstrating altered insulin/insulin-like growth factor signaling (IIS)
   pathway activity in response to the stress. pdk-1 and akt-1 may play key
   roles in conjunction with Ce-GRK2 in the heat stress response.
   Collectively, these findings demonstrate that GRKs influence C. elegans
   heat stress behaviors. (c) 2020 Elsevier Inc. All rights reserved.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {So, CH (Corresponding Author), Roseman Univ Hlth Sci, Sch Pharm, 11 Sunset Way, Henderson, NV 89014 USA.
   Heilman, Christian; Ibarreta, Janeen; Salonga, Glecille Ann; Hon, Michelle C.; Caracci, Angela M.; Crivello, Selina; Henry, Stacy A.; Nguyen, Tina M.; So, Christopher H., Roseman Univ Hlth Sci, Sch Pharm, 11 Sunset Way, Henderson, NV 89014 USA.
   Badial, Tajinder, Touro Univ Nevada, Henderson, NV 89014 USA.},
DOI = {10.1016/j.bbrc.2020.07.121},
ISSN = {0006-291X},
EISSN = {1090-2104},
Keywords = {Aging; Biological control; Caenorhabditis elegans (C. elegans); G
   protein coupled receptor (GPCR); G protein coupled receptor kinase
   (GRK); Heat stress; Resistance; Stress response},
Keywords-Plus = {HORMESIS; GRKS},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {cso@roseman.edu},
Affiliations = {Roseman University of Health Sciences},
ORCID-Numbers = {So, Christopher/0000-0002-1393-0333},
Cited-References = {Chen XQ, 2010, J BIOL CHEM, V285, P12823, DOI 10.1074/jbc.M109.094243.
   Cypser JR, 2006, EXP GERONTOL, V41, P935, DOI 10.1016/j.exger.2006.09.004.
   Cypser JR, 2002, J GERONTOL A-BIOL, V57, pB109, DOI 10.1093/gerona/57.3.B109.
   Fukuto HS, 2004, NEURON, V42, P581, DOI 10.1016/S0896-6273(04)00252-1.
   Gurevich EV, 2012, PHARMACOL THERAPEUT, V133, P40, DOI 10.1016/j.pharmthera.2011.08.001.
   Henderson ST, 2001, CURR BIOL, V11, P1975, DOI 10.1016/S0960-9822(01)00594-2.
   Hunt PR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021922.
   Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002.
   Kleibeuker W, 2008, J NEUROCHEM, V104, P979, DOI 10.1111/j.1471-4159.2007.05023.x.
   Kumsta C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14337.
   Lagman J, 2019, MOL CELL BIOCHEM, V461, P103, DOI 10.1007/s11010-019-03594-9.
   Landis GN, 2005, MECH AGEING DEV, V126, P365, DOI 10.1016/j.mad.2004.08.012.
   Martini JS, 2008, P NATL ACAD SCI USA, V105, P12457, DOI 10.1073/pnas.0803153105.
   McCulloch D, 2003, EXP GERONTOL, V38, P129, DOI 10.1016/S0531-5565(02)00147-X.
   Moore CAC, 2007, ANNU REV PHYSIOL, V69, P451, DOI 10.1146/annurev.physiol.69.022405.154712.
   Nogués L, 2016, EBIOMEDICINE, V13, P132, DOI 10.1016/j.ebiom.2016.09.030.
   Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793.
   Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200.
   Rodriguez M, 2013, TRENDS GENET, V29, P367, DOI 10.1016/j.tig.2013.01.010.
   Steury MD, 2017, BIOCHEM J, V474, P2301, DOI 10.1042/BCJ20170093.
   Stiernagle Theresa, 2006, WormBook, P1.
   Sun WY, 2018, ACTA PHARMACOL SIN, V39, P1699, DOI 10.1038/s41401-018-0049-z.
   Wang JJ, 2017, J BIOL CHEM, V292, P5943, DOI {[}10.1074/jbc.M116.760850, 10.1074/jbc.m116.760850].
   Zevian SC, 2014, METHODS, V68, P450, DOI 10.1016/j.ymeth.2014.04.015.
   Zheng HY, 2012, P NATL ACAD SCI USA, V109, P7055, DOI 10.1073/pnas.1118359109.
   Zou CG, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003660.},
Number-of-Cited-References = {26},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Biochem. Biophys. Res. Commun.},
Doc-Delivery-Number = {NI9DP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000565646300012},
DA = {2026-02-04},
}

@article{ WOS:000579310000037,
Author = {Yang, Cheng-Wei and Hsu, Hsing-Yu and Chang, Hsin-Yu and Lee, Yue-Zhi
   and Lee, Shiow-Ju},
Title = {Natural cardenolides suppress coronaviral replication by downregulating
   JAK1 via a Na+/K+-ATPase independent proteolysise},
Journal = {BIOCHEMICAL PHARMACOLOGY},
Year = {2020},
Volume = {180},
Month = {OCT},
Abstract = {An unprecedented biological function of natural cardenolides independent
   of their membrane target Na+/K+-ATPase is disclosed. Previously, we
   reported that cardenolides impart anti-transmissible gastroenteritis
   coronavirus (anti-TGEV) activity through the targeting of Na+/K+-ATPase
   and its associated PI3K\_PDK1\_RSK2 signaling. Swine testis cells with
   Na+/K+-ATPase alpha 1 knocked down exhibited decreased susceptibility to
   TGEV infectivity and attenuated PI3K\_PDK1\_RSK2 signaling. Herein, we
   further explored a Na+/K+-ATPase-independent signaling axis induced by
   natural cardenolides that also afforded significant anti-coronaviral
   activity for porcine TGEV and human HCoV-OC43. Using pharmacological
   inhibition and gene silencing techniques, we found that this anti-TGEV
   or anti-HCoV-OC43 activity was caused by JAK1 proteolysis and mediated
   through upstream activation of Ndfip1/2 and its effector NEDD4. This
   study provides novel insights into the pharmacological effects of
   natural cardenolides, and is expected to inform their future development
   as antiviral agents.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Lee, SJ (Corresponding Author), Natl Hlth Res Inst, Inst Biotechnol \& Pharmaceut Res, Miaoli 35053, Taiwan.
   Yang, Cheng-Wei; Hsu, Hsing-Yu; Chang, Hsin-Yu; Lee, Yue-Zhi; Lee, Shiow-Ju, Natl Hlth Res Inst, Inst Biotechnol \& Pharmaceut Res, Miaoli 35053, Taiwan.},
DOI = {10.1016/j.bcp.2020.114122},
Article-Number = {114122},
ISSN = {0006-2952},
EISSN = {1873-2968},
Keywords = {Coronavirus; Janus kinase; Na+/K+-ATPase; NEDD4; Ouabain; Proteolysis},
Keywords-Plus = {CARDIAC-GLYCOSIDES; MEDIATED DEGRADATION; CELL; SPIRONOLACTONE;
   INHIBITOR; DIGITALIS; RECEPTOR; VIRUS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {slee@nhri.org.tw},
Affiliations = {National Health Research Institutes - Taiwan},
ResearcherID-Numbers = {Yang, Cheng-Wei/F-7729-2011},
ORCID-Numbers = {Yang, Cheng-Wei/0000-0002-3994-475X},
Funding-Acknowledgement = {National Health Research Institutes, Taiwan, R.O.C. {[}MOST
   106-2320-B-400-009-MY3, MOST 106-2811-B-400-025, MOST
   107-2811-B-400-529, MOST 108-2811-B-400-511]; Ministry of Science and
   Technology, Taiwan, R.O.C. {[}MOST 106-2320-B-400-009-MY3, MOST
   106-2811-B-400-025, MOST 107-2811-B-400-529, MOST 108-2811-B-400-511]},
Funding-Text = {This work was funded by the National Health Research Institutes, Taiwan,
   R.O.C. and the Ministry of Science and Technology, Taiwan, R.O.C.
   (grants of MOST 106-2320-B-400-009-MY3, MOST 106-2811-B-400-025, MOST
   107-2811-B-400-529 and MOST 108-2811-B-400-511). We also would like to
   acknowledge the assistance from Taiwan and National RNAi Core Facility,
   Academia Sinica, Taiwan.},
Cited-References = {Aditya S, 2012, J PHARMACOL PHARMACO, V3, P353, DOI 10.4103/0976-500X.103705.
   {[}Anonymous], 2017, SCI REP.
   Bauer L, 2017, CURR OPIN VIROL, V24, P1, DOI 10.1016/j.coviro.2017.03.009.
   Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549-005-9053-3.
   Choy EHS, 2019, CLIN EXP RHEUMATOL, V37, P694.
   Diederich M, 2017, BIOCHEM PHARMACOL, V125, P1, DOI 10.1016/j.bcp.2016.08.017.
   Ferrari P, 2006, AM J PHYSIOL-REG I, V290, pR529, DOI 10.1152/ajpregu.00518.2005.
   Ferrari P, 2010, BBA-MOL BASIS DIS, V1802, P1254, DOI 10.1016/j.bbadis.2010.01.009.
   Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4.
   Gekle M, 1998, J PHYSIOL-LONDON, V511, P255, DOI 10.1111/j.1469-7793.1998.255bi.x.
   Gu SS, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201700247.
   Hughes P, 2007, BIOTECHNIQUES, V43, P575, DOI 10.2144/000112598.
   Lee Y, 2008, BLOOD, V111, P885, DOI 10.1182/blood-2007-03-082941.
   Mattera GG, 2007, AM J CARDIOL, V99, p33A, DOI 10.1016/j.amjcard.2006.09.004.
   Mund T, 2014, P NATL ACAD SCI USA, V111, P16736, DOI 10.1073/pnas.1412152111.
   Nan YC, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10040196.
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8.
   Nguyen ANT, 2011, AM J PHYSIOL-RENAL, V301, pF897, DOI 10.1152/ajprenal.00095.2011.
   O'Leary CE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11226.
   PITA JC, 1975, ENDOCRINOLOGY, V97, P1521, DOI 10.1210/endo-97-6-1521.
   Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682.
   RIFKA SM, 1978, J CLIN ENDOCR METAB, V46, P338, DOI 10.1210/jcem-46-2-338.
   Samarasinghe RA, 2011, P NATL ACAD SCI USA, V108, P16657, DOI 10.1073/pnas.1102821108.
   Sarcar B, 2004, VIROLOGY, V322, P51, DOI 10.1016/j.virol.2004.01.008.
   Shah SJ, 2009, AM HEART J, V157, P1035, DOI 10.1016/j.ahj.2009.03.007.
   Song H, 2014, J PHYSIOL-LONDON, V592, P941, DOI 10.1113/jphysiol.2013.266866.
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884.
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898.
   Tamura S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20663-z.
   TISCHKAU SA, 1993, P NATL ACAD SCI USA, V90, P1285, DOI 10.1073/pnas.90.4.1285.
   Wang J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001058.
   Wen W, 2014, MOL CANCER THER, V13, P3037, DOI 10.1158/1535-7163.MCT-14-0077.
   Wu CY, 2003, J CELL BIOCHEM, V90, P1026, DOI 10.1002/jcb.10727.
   Yang C.W., 2017, TOXICOL APPL PHARM.
   Yang CW, 2007, ANTIMICROB AGENTS CH, V51, P3924, DOI 10.1128/AAC.00408-07.
   Yang CW, 2018, TOXICOL APPL PHARM, V356, P90, DOI 10.1016/j.taap.2018.07.028.
   Yang CW, 2013, CARCINOGENESIS, V34, P1304, DOI 10.1093/carcin/bgt039.
   Yang CW, 2010, ANTIVIR RES, V88, P160, DOI 10.1016/j.antiviral.2010.08.009.
   Zouein FA, 2011, GROWTH FACTORS, V29, P245, DOI 10.3109/08977194.2011.614949.},
Number-of-Cited-References = {39},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Biochem. Pharmacol.},
Doc-Delivery-Number = {OC7BF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000579310000037},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000576675900019,
Author = {Burggraaff, Lindsey and Lenselink, Eelke B. and Jespers, Willem and van
   Engelen, Jesper and Bongers, Brandon J. and Gonzalez, Marina Gorostiola
   and Liu, Rongfang and Hoos, Holger H. and van Vlijmen, Herman W. T. and
   IJzerman, Adriaan P. and van Westen, Gerard J. P.},
Title = {Successive Statistical and Structure-Based Modeling to Identify
   Chemically Novel Kinase Inhibitors},
Journal = {JOURNAL OF CHEMICAL INFORMATION AND MODELING},
Year = {2020},
Volume = {60},
Number = {9},
Pages = {4283-4295},
Month = {SEP 28},
Abstract = {Kinases are frequently studied in the context of anticancer drugs. Their
   involvement in cell responses, such as proliferation, differentiation,
   and apoptosis, makes them interesting subjects in multitarget drug
   design. In this study, a workflow is presented that models the
   bioactivity spectra for two panels of kinases: (1) inhibition of RET,
   BRAF, SRC, and S6K, while avoiding inhibition of MKNK1, TTK, ERK8, PDK1,
   and PAK3, and (2) inhibition of AURKA, PAK1, FGFR1, and LKB1, while
   avoiding inhibition of PAK3, TAK1, and PIK3CA. Both statistical and
   structure-based models were included, which were thoroughly benchmarked
   and optimized. A virtual screening was performed to test the workflow
   for one of the main targets, RET kinase. This resulted in 5 novel and
   chemically dissimilar RET inhibitors with remaining RET activity of
   <60\% (at a concentration of 10 mu M) and similarities with known RET
   inhibitors from 0.18 to 0.29 (Tanimoto, ECFP6). The four more potent
   inhibitors were assessed in a concentration range and proved to be
   modestly active with a pIC(50) value of 5.1 for the most active
   compound. The experimental validation of inhibitors for RET strongly
   indicates that the multitarget workflow is able to detect novel
   inhibitors for kinases, and hence, this workflow can potentially be
   applied in polypharmacology modeling. We conclude that this approach can
   identify new chemical matter for existing targets. Moreover, this
   workflow can easily be applied to other targets as well.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {van Westen, GJP (Corresponding Author), Leiden Univ, Leiden Acad Ctr Drug Res, Div Drug Discovery \& Safety, NL-2333 CC Leiden, Netherlands.
   Burggraaff, Lindsey; Lenselink, Eelke B.; Jespers, Willem; Bongers, Brandon J.; Gonzalez, Marina Gorostiola; Liu, Rongfang; van Vlijmen, Herman W. T.; IJzerman, Adriaan P.; van Westen, Gerard J. P., Leiden Univ, Leiden Acad Ctr Drug Res, Div Drug Discovery \& Safety, NL-2333 CC Leiden, Netherlands.
   Jespers, Willem, Uppsala Univ, Dept Cell \& Mol Biol, S-75124 Uppsala, Sweden.
   van Engelen, Jesper; Hoos, Holger H., Leiden Univ, Leiden Inst Adv Comp Sci, Dept Comp Sci, NL-2333 CA Leiden, Netherlands.
   van Vlijmen, Herman W. T., Janssen Res \& Dev, B-2340 Beerse, Belgium.},
DOI = {10.1021/acs.jcim.9b01204},
ISSN = {1549-9596},
EISSN = {1549-960X},
Keywords-Plus = {LARGE-SCALE; DISCOVERY; FINGERPRINTS; PREDICTION; DATABASE; DESIGN;
   CANCER},
Research-Areas = {Pharmacology \& Pharmacy; Chemistry; Computer Science},
Web-of-Science-Categories  = {Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications},
Author-Email = {gerard@lacdr.leidenuniv.nl},
Affiliations = {Leiden University; Leiden University - Excl LUMC; Uppsala University;
   Leiden University - Excl LUMC; Leiden University; Johnson \& Johnson;
   Janssen Pharmaceuticals},
ResearcherID-Numbers = {IJzerman, Ad/ABG-1353-2020
   van Westen, Gerard/D-7432-2011
   Hoos, Holger/B-1461-2008
   },
ORCID-Numbers = {Gorostiola González, Marina/0000-0003-1568-0881
   Bongers, Brandon J/0000-0003-1322-2369
   van Westen, Gerard/0000-0003-0717-1817
   Jespers, Willem/0000-0002-4951-9220
   Burggraaff, Lindsey/0000-0002-2442-0443},
Funding-Acknowledgement = {Dutch Scientific Council (NWO); Applied and Engineering Sciences (AES)
   {[}14410]},
Funding-Text = {G.J.P.v.W. thanks the Dutch Scientific Council (NWO) and Applied and
   Engineering Sciences (AES) for funding (VENI no. 14410).},
Cited-References = {Atzori A, 2014, J CHEM INF MODEL, V54, P2764, DOI 10.1021/ci5003334.
   Bemis GW, 1996, J MED CHEM, V39, P2887, DOI 10.1021/jm9602928.
   Bento AP, 2014, NUCLEIC ACIDS RES, V42, pD1083, DOI 10.1093/nar/gkt1031.
   Bergstra J, 2012, J MACH LEARN RES, V13, P281.
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235.
   Burggraaff L, 2019, J CHEMINFORMATICS, V11, DOI 10.1186/s13321-019-0337-8.
   Christmann-Franck S, 2016, J CHEM INF MODEL, V56, P1654, DOI 10.1021/acs.jcim.6b00122.
   Clark AJ, 2016, J CHEM THEORY COMPUT, V12, P2990, DOI 10.1021/acs.jctc.6b00201.
   Da C, 2014, J CHEM INF MODEL, V54, P2555, DOI 10.1021/ci500319f.
   Dar AC, 2012, NATURE, V486, P80, DOI 10.1038/nature11127.
   Dassault Syste`mes BIOVIA, 2016, BIOVIA PIP PIL.
   de Lera AR, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0271-9.
   Dimitrov S, 2005, J CHEM INF MODEL, V45, P839, DOI 10.1021/ci0500381.
   Eckert H, 2007, DRUG DISCOV TODAY, V12, P225, DOI 10.1016/j.drudis.2007.01.011.
   Feurer M, 2015, ADV NEUR IN, V28.
   Frey BJ, 2007, SCIENCE, V315, P972, DOI 10.1126/science.1136800.
   Gaulton A, 2017, NUCLEIC ACIDS RES, V45, pD945, DOI 10.1093/nar/gkw1074.
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864.
   Kotthoff L, 2017, J MACH LEARN RES, V18.
   Lenselink E. B., 2017, BIORXIV, DOI {[}10.1101/168914v1, DOI 10.1101/168914V1.].
   Lenselink EB, 2016, J CHEM INF MODEL, V56, P2053, DOI 10.1021/acs.jcim.6b00314.
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1.
   Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799.
   Lyu J, 2019, NATURE, V566, P224, DOI 10.1038/s41586-019-0917-9.
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762.
   Miljkovic F., 2019, J MED CHEM, DOI {[}10.1021/ acs.jmedchem.9b00867., DOI 10.1021/ACS.JMEDCHEM.9B00867.].
   Mysinger MM, 2012, J MED CHEM, V55, P6582, DOI 10.1021/jm300687e.
   Papadatos G, 2016, NUCLEIC ACIDS RES, V44, pD1220, DOI 10.1093/nar/gkv1253.
   Papadatos G, 2015, J COMPUT AID MOL DES, V29, P885, DOI 10.1007/s10822-015-9860-5.
   Paricharak S, 2016, ACS CHEM BIOL, V11, P1255, DOI 10.1021/acschembio.6b00029.
   Pedregosa F, 2011, J MACH LEARN RES, V12, P2825, DOI 10.1145/2786984.2786995.
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t.
   Sastry GM, 2013, J CHEM INF MODEL, V53, P1531, DOI 10.1021/ci300463g.
   Schlessinger A, 2017, CELL CHEM BIOL, V24, P1434, DOI 10.1016/j.chembiol.2017.12.006.
   Schro<spacing diaeresis>dinger, 2017, SCHROD MAESTR REL 20.
   Sonoshita M, 2018, NAT CHEM BIOL, V14, P291, DOI {[}10.1038/NCHEMBIO.2556, 10.1038/nchembio.2556].
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559.
   Sun JM, 2017, J CHEMINFORMATICS, V9, DOI 10.1186/s13321-017-0203-5.
   Tiwary P, 2015, J PHYS CHEM B, V119, P736, DOI 10.1021/jp504920s.
   Truchon JF, 2007, J CHEM INF MODEL, V47, P488, DOI 10.1021/ci600426e.
   van Leeuwen RWF, 2015, ANN ONCOL, V26, P992, DOI 10.1093/annonc/mdv029.
   van Westen GJP, 2011, MEDCHEMCOMM, V2, P16, DOI 10.1039/c0md00165a.
   van Westen GJP, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003559.
   van Westen GJP, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-42.
   van Westen GJP, 2013, J CHEMINFORMATICS, V5, DOI 10.1186/1758-2946-5-41.
   Vijayan RSK, 2015, J MED CHEM, V58, P466, DOI 10.1021/jm501603h.},
Number-of-Cited-References = {46},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {J. Chem Inf. Model.},
Doc-Delivery-Number = {NY9AK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000576675900019},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000615918600004,
Author = {Kolb, David and Kolishetti, Nagesh and Surnar, Bapurao and Sarkar,
   Shrita and Guin, Subham and Shah, Anuj S. and Dhar, Shanta},
Title = {Metabolic Modulation of the Tumor Microenvironment Leads to Multiple
   Checkpoint Inhibition and Immune Cell Infiltration},
Journal = {ACS NANO},
Year = {2020},
Volume = {14},
Number = {9},
Pages = {11055-11066},
Month = {SEP 22},
Abstract = {Cancer cells are known to be glycolytic, driving increased glucose
   consumption and its conversion to lactate. This process modulates the
   tumor microenvironment (TME). In the TME, glycolytically activated
   immune cells often become anergic, leading to an increase in immune
   checkpoint proteins such as programmed cell death protein-1 (PD-1) and
   cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Most glycolytic
   inhibitors not only inhibit glycolysis of cancer but also of immune
   cells. Therefore, using a nanoparticle-delivered agent to preferentially
   inhibit glycolysis in tumor cells, and not in immune cells, has the
   potential to attenuate the expression of checkpoint proteins. Pyruvate
   dehydrogenase kinase 1 (PDK1) can be an important target to achieve
   tumor specific glycolysis inhibition. We report TME modulation by a
   mitochondrion-targeted nanoparticle (NP) containing a prodrug of
   dichloroacetate (DCA), a PDK1 inhibitor. We demonstrated that the
   targeted NP alters the TME which results in increased immunological
   activation against cancer cells, causing a decrease in mean tumor
   volume. Here, we also show findings that when Mito-DCA, a prodrug of
   DCA, was combined with anti-PD-1, a checkpoint inhibitor, results from
   in vivo syngeneic models showed an upregulation in the number of tumor
   infiltrating lymphocytes. This work provides a platform to bring
   therapeutic efficacy by selectively inhibiting glycolysis of cancer
   cells.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Dhar, S (Corresponding Author), Univ Miami, Dept Biochem \& Mol Biol, Miller Sch Med, Miami, FL 33136 USA.
   Dhar, S (Corresponding Author), Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA.
   Kolb, David; Kolishetti, Nagesh, Partikula LLC, Hollywood, FL 33024 USA.
   Kolishetti, Nagesh; Surnar, Bapurao; Sarkar, Shrita; Guin, Subham; Shah, Anuj S.; Dhar, Shanta, Univ Miami, Dept Biochem \& Mol Biol, Miller Sch Med, Miami, FL 33136 USA.
   Kolishetti, Nagesh, Florida Int Univ, Herbert Wertheim Coll Med, Dept Immunol \& Nanomed, Miami, FL 33199 USA.
   Surnar, Bapurao; Sarkar, Shrita; Guin, Subham; Dhar, Shanta, Univ Miami, Sylvester Comprehens Canc Ctr, Miller Sch Med, Miami, FL 33136 USA.},
DOI = {10.1021/acsnano.9b10037},
ISSN = {1936-0851},
EISSN = {1936-086X},
Keywords = {tumor microenvironment; altered metabolism; immune suppression;
   aggressive cancer; mitochondrial nanomedicine},
Research-Areas = {Chemistry; Science \& Technology - Other Topics; Materials Science},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience \&
   Nanotechnology; Materials Science, Multidisciplinary},
Author-Email = {shantadhar@med.miami.edu},
Affiliations = {University of Miami; State University System of Florida; Florida
   International University; University of Miami},
ResearcherID-Numbers = {Kolishetti, Nagesh/ABD-5430-2020
   },
ORCID-Numbers = {SARKAR, SHRITA/0000-0002-9244-0681
   Dhar, Shanta/0000-0003-3042-5272
   Kolishetti, Nagesh/0000-0001-5574-673X
   Shah, Anuj/0009-0007-4626-924X
   Surnar, Bapurao/0000-0001-5997-3120},
Funding-Acknowledgement = {Sylvester Comprehensive Cancer Center; Florida Department of Health
   {[}8BC10]; Partikula LLC},
Funding-Text = {This work was supported, in whole or in part, by the Sylvester
   Comprehensive Cancer Center and Bankhead-Coley Grant (8BC10) from the
   Florida Department of Health to S.D. D.K. and N.K. thanks Partikula LLC
   for supporting this work.},
Cited-References = {Aston WJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3677-7.
   Bannon AE, 2017, CLIN CANCER RES, V23, P6733, DOI 10.1158/1078-0432.CCR-17-1397.
   Baugh EH, 2018, CELL DEATH DIFFER, V25, P154, DOI 10.1038/cdd.2017.180.
   Carmona-Fontaine C, 2017, P NATL ACAD SCI USA, V114, P2934, DOI 10.1073/pnas.1700600114.
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637-013-0047-4.
   Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0.
   Gelao L, 2014, TOXINS, V6, P914, DOI 10.3390/toxins6030914.
   Goldblatt EM, 2010, AM J TRANSL RES, V2, P1.
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2.
   Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Huang J, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00242.
   Jin JF, 2015, PATIENT PREFER ADHER, V9, P923, DOI 10.2147/PPA.S87271.
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509.
   Keating GM, 2009, DRUGS, V69, P223, DOI 10.2165/00003495-200969020-00006.
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x.
   Kim S, 2013, SPRINGERPLUS, V2, DOI 10.1186/2193-1801-2-299.
   Lena A, 2010, FEBS J, V277, P2853, DOI 10.1111/j.1742-4658.2010.07702.x.
   Lin K, 2013, BRIT J HAEMATOL, V160, P53, DOI 10.1111/bjh.12092.
   Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3.
   Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003.
   Marin-Acevedo JA, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0582-8.
   Marrache Sean, 2015, Methods Mol Biol, V1265, P103, DOI 10.1007/978-1-4939-2288-8\_8.
   Marrache S, 2014, P NATL ACAD SCI USA, V111, P10444, DOI 10.1073/pnas.1405244111.
   Marrache S, 2012, P NATL ACAD SCI USA, V109, P16288, DOI 10.1073/pnas.1210096109.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Mir N, 2017, CURR CANCER DRUG TAR, V17, P698, DOI 10.2174/1568009617666170427104356.
   Mookerjee SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152016.
   Morrot A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00081.
   Nancolas B, 2016, BIOCHEM J, V473, P929, DOI 10.1042/BJ20151120.
   O'Sullivan D, 2019, NAT REV IMMUNOL, V19, P324, DOI 10.1038/s41577-019-0140-9.
   Pathak RK, 2014, ACS CHEM BIOL, V9, P1178, DOI 10.1021/cb400944y.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Qiu J, 2019, CELL REP, V27, P2063, DOI 10.1016/j.celrep.2019.04.022.
   Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151.
   San-Millán I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127.
   Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499.
   SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292.
   Surnar B, 2018, P NATL ACAD SCI USA, V115, pE12333, DOI 10.1073/pnas.1816429115.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774.
   Toledo FGS, 2018, DIABETOLOGIA, V61, P466, DOI 10.1007/s00125-017-4496-8.
   Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600.
   van der Windt GJW, 2012, IMMUNOL REV, V249, P27, DOI 10.1111/j.1600-065X.2012.01150.x.
   Wang JC, 2018, J CELL BIOCHEM, V119, P4279, DOI 10.1002/jcb.26645.
   Wong HH, 2015, LANCET ONCOL, V16, P1287, DOI 10.1016/S1470-2045(15)00248-X.
   Wu CY, 2018, J BIOL CHEM, V293, P9604, DOI 10.1074/jbc.RA118.002838.
   Yang L, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0804-8.
   Zahavi T, 2016, ONCOTARGET, V7, P4860, DOI 10.18632/oncotarget.6638.
   Zheng Y, 2009, J IMMUNOL, V183, P6095, DOI 10.4049/jimmunol.0803510.},
Number-of-Cited-References = {52},
Times-Cited = {114},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {158},
Journal-ISO = {ACS Nano},
Doc-Delivery-Number = {QE0SU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000615918600004},
DA = {2026-02-04},
}

@article{ WOS:000571839500005,
Author = {Sun, Xiaowen and Klinger, Francesca Gioia and Liu, Jing and De Felici,
   Massimo and Shen, Wei and Sun, Xiaofeng},
Title = {miR-378-3p maintains the size of mouse primordial follicle pool by
   regulating cell autophagy and apoptosis},
Journal = {CELL DEATH \& DISEASE},
Year = {2020},
Volume = {11},
Number = {9},
Month = {SEP 10},
Abstract = {Primordial follicle pool provides all available oocytes throughout the
   whole reproductive life span. Abnormal regulation in primordial follicle
   assembly leads to abnormal size of primordial follicle pool, even causes
   infertility. Here, miR-378-3p was proved to regulate mouse primordial
   follicle assembly both in vivo and in vitro. The expression of
   miR-378-3p significantly increased in mice ovaries from 17.5dpc (days
   post coitum) up to 3dpp (day post partum) compared with the expression
   of 16.5dpc ovaries, which suggested that miR-378-3p was involved in
   primordial follicle assembly. To uncover the underlying mechanism,
   newborn mice ovaries were cultured in vitro in the presence of rapamycin
   and 3-methyladenine, which showed that the expression of miR-378-3p
   changed together with the percentage of primordial follicle. Moreover,
   during the normal process of primordial follicle assembly between
   17.6dpc and 3dpp, autophagy is activated, while, apoptosis is inhibited.
   The in vivo results showed that newborn mice starved for 1.5 days
   showing the increased miR-378-3p, activated autophagy and inhibited
   apoptosis in the ovaries, had more percentage of primordial follicles.
   Over-expression of miR-378-3p using miR-378-3p agomir caused increased
   percentage of primordial follicle, increased level of autophagy, and
   decreased level of apoptosis. Knockdown of miR-378-3p by miR-378-3p
   antiagomir had the opposite results. Using pmirGLO Dual-Luciferase miRNA
   Target Expression system, we confirmed both PDK1 and Caspase9 were
   targets of miR-378-3p, which suggested that miR-378-3p activated
   autophagy by targeting PDK1 and inhibited apoptosis by targeting
   Caspase9. MiR-378-3p could be used as a biomarker of diseases caused by
   abnormal size of primordial follicle pool for diagnosis, prevention, or
   therapy.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Sun, XF (Corresponding Author), Qingdao Agr Univ, Coll Life Sci, Qingdao 266109, Peoples R China.
   Sun, Xiaowen, Qingdao Agr Univ, Coll Anim Sci \& Technol, Qingdao 266109, Peoples R China.
   Sun, Xiaowen; Shen, Wei; Sun, Xiaofeng, Qingdao Agr Univ, Coll Life Sci, Qingdao 266109, Peoples R China.
   Klinger, Francesca Gioia; De Felici, Massimo, Univ Roma Tor Vergata, Dept Biomed \& Prevent, I-00133 Rome, Italy.
   Liu, Jing, Cent Iaboratory Qingdao Agr Univ, Qingdao 266109, Peoples R China.},
DOI = {10.1038/s41419-020-02965-1},
Article-Number = {737},
ISSN = {2041-4889},
Keywords-Plus = {ACTIVATION; DEATH; STARVATION; CROSSTALK; OOCYTES},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {xfsun@qau.edu.cn},
Affiliations = {Qingdao Agricultural University; Qingdao Agricultural University;
   University of Rome Tor Vergata},
ResearcherID-Numbers = {Klinger, Francesca Gioia/K-6587-2018},
ORCID-Numbers = {Sun, Xiaofeng/0000-0003-3755-3269
   Klinger, Francesca Gioia/0000-0001-6744-0850},
Funding-Acknowledgement = {Natural Science Foundation of Shandong Province of China
   {[}ZR2017MC033]; Taishan Scholar Construction Foundation of Shandong
   province of China {[}ts20190946]},
Funding-Text = {This work was supported by the Natural Science Foundation of Shandong
   Province of China (ZR2017MC033) and the Taishan Scholar Construction
   Foundation of Shandong province of China (ts20190946).},
Cited-References = {Barth JMI, 2011, CELL DEATH DIFFER, V18, P915, DOI 10.1038/cdd.2010.157.
   Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269.
   Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z.
   Delcour C, 2019, GENET MED, V21, P930, DOI 10.1038/s41436-018-0287-y.
   Gawriluk TR, 2011, REPRODUCTION, V141, P759, DOI 10.1530/REP-10-0489.
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007.
   Guo CQ, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00091.
   He JL, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109189.
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023.
   Li Y, 2018, P NATL ACAD SCI USA, V115, pE10849, DOI 10.1073/pnas.1803377115.
   Liu KH, 2017, TOXICOL APPL PHARM, V329, P9, DOI 10.1016/j.taap.2017.05.024.
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689.
   Maiuri MC, 2010, EMBO J, V29, P515, DOI 10.1038/emboj.2009.377.
   Marcozzi S, 2018, MINERVA GINECOL, V70, P549, DOI 10.23736/S0026-4784.18.04274-0.
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004.
   Morita Y, 1999, DEV BIOL, V213, P1, DOI 10.1006/dbio.1999.9344.
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2.
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2.
   Nishida K, 2008, CIRC RES, V103, P343, DOI 10.1161/CIRCRESAHA.108.175448.
   Ong SK, 2010, DEV BIOL, V337, P84, DOI 10.1016/j.ydbio.2009.10.018.
   Pan B, 2015, AM J PHYSIOL-ENDOC M, V308, pE525, DOI 10.1152/ajpendo.00480.2014.
   Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269.
   Schilling C, 2006, HUM REPROD UPDATE, V12, P555, DOI {[}10.1093/humupd/dml022, DOI 10.1093/HUMUPD/DML022].
   Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192.
   Song ZH, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.559.
   Sun XF, 2018, CELL CYCLE, V17, P2230, DOI 10.1080/15384101.2018.1520557.
   Sun YC, 2018, AGING-US, V10, P197, DOI 10.18632/aging.101376.
   Tilly JL, 2001, NAT REV MOL CELL BIO, V2, P838, DOI 10.1038/35099086.
   Vicencio JM, 2008, GERONTOLOGY, V54, P92, DOI 10.1159/000129697.
   Wang C, 2017, CELL MOL LIFE SCI, V74, P2547, DOI 10.1007/s00018-017-2480-6.
   Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005.
   Wang YY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.3.
   Watanabe R, 2018, J REPROD DEVELOP, V64, P89, DOI 10.1262/jrd.2017-126.
   Watanabe-Asano T, 2014, BIOCHEM BIOPH RES CO, V445, P334, DOI 10.1016/j.bbrc.2014.01.180.
   Yan H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1208-3.
   Zhang H, 2015, HUM REPROD UPDATE, V21, P779, DOI 10.1093/humupd/dmv037.
   Zhang H, 2014, REPRODUCTION, V148, P43, DOI 10.1530/REP-13-0508.},
Number-of-Cited-References = {37},
Times-Cited = {24},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {NR8VF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000571839500005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000569347400001,
Author = {Wang, Lu-Ming and Gan, Ye-Hua},
Title = {Cancer-derived IgG involved in cisplatin resistance through
   PTP-BAS/Src/PDK1/AKT signaling pathway},
Journal = {ORAL DISEASES},
Year = {2021},
Volume = {27},
Number = {3},
Pages = {464-474},
Month = {APR},
Abstract = {Objectives This study aimed to explore whether knockdown of
   cancer-derived IgG (CIgG) could enhance cisplatin-induced anti-cancer
   effects. Materials and methods Cancer-derived IgG was knocked down by
   siRNA or Tet-on shRNA in the absence or presence of cisplatin in WSU-HN6
   or CAL27 cells. Cell proliferation, apoptosis, and mobility were
   evaluated using CCK-8, flow cytometry, and transwell assays,
   respectively. Molecular events were investigated using real-time PCR and
   Western blot assays. Results Knockdown of CIgG significantly promoted
   cisplatin-induced apoptosis and inhibition of cell proliferation,
   migration, and invasion. Cisplatin upregulated CIgG expression and
   phosphorylation of AKT and PDK1, while knockdown of CIgG downregulated
   phosphorylation of AKT and PDK1, and blocked cisplatin-induced
   upregulation of AKT and PDK1 phosphorylation. Moreover, knockdown of
   CIgG blocked cisplatin-induced upregulation of Src phosphorylation, and
   knockdown of Src blocked cisplatin-induced upregulation of AKT and PDK1
   phosphorylation. Overexpression of Src upregulated AKT and PDK1
   phosphorylation. Furthermore, knockdown of CIgG upregulated PTP-BAS mRNA
   and protein expression, whereas cisplatin downregulated PTP-BAS protein,
   but not mRNA expression; knockdown of PTP-BAS upregulated
   phosphorylation of Src, PDK1, AKT, and blocked CIgG knockdown-mediated
   enhancement of cisplatin-induced inhibition of cell proliferation.
   Conclusion Knockdown of CIgG enhanced the anti-cancer effects of
   cisplatin through PTP-BAS/Src/PDK1/AKT signaling pathway in oral
   squamous cell carcinoma.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Gan, YH (Corresponding Author), Peking Univ Sch \& Hosp Stomatol, Cent Lab, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China.
   Wang, Lu-Ming; Gan, Ye-Hua, Peking Univ Sch \& Hosp Stomatol, Cent Lab, 22 Zhongguancun Ave South, Beijing 100081, Peoples R China.
   Wang, Lu-Ming; Gan, Ye-Hua, Peking Univ Sch \& Hosp Stomatol, Dept Oral \& Maxillofacial, Beijing, Peoples R China.},
DOI = {10.1111/odi.13583},
EarlyAccessDate = {SEP 2020},
ISSN = {1354-523X},
EISSN = {1601-0825},
Keywords = {cancer-derived IgG; cisplatin resistance; head and neck squamous cell
   carcinoma; PTP-BAS; Src},
Keywords-Plus = {PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR GENE; IMMUNOGLOBULIN-G;
   EXPRESSION; SRC; SURVIVAL; PHOSPHORYLATION; CARCINOMA; PTPN13;
   PROLIFERATION},
Research-Areas = {Dentistry, Oral Surgery \& Medicine},
Web-of-Science-Categories  = {Dentistry, Oral Surgery \& Medicine},
Author-Email = {kqyehuagan@bjmu.edu.cn},
Affiliations = {Peking University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81472764]},
Funding-Text = {We are grateful to Professor Xiaoyan Qiu and her team for the generous
   gifts of CIgG antibody RP215 as well as their patient guidance. This
   work was supported by the National Natural Science Foundation of China
   (Grant No. 81472764).},
Cited-References = {Abu N, 2018, FUTURE ONCOL, V14, P3085, DOI 10.2217/fon-2018-0303.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Amable L, 2016, PHARMACOL RES, V106, P27, DOI 10.1016/j.phrs.2016.01.001.
   Amit M, 2013, CANCER-AM CANCER SOC, V119, P4242, DOI 10.1002/cncr.28357.
   Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200.
   CAO SS, 1989, CANCER CHEMOTH PHARM, V24, P181, DOI 10.1007/BF00300240.
   Chen J, 2015, ARCH BIOCHEM BIOPHYS, V575, P38, DOI 10.1016/j.abb.2014.11.008.
   Chen SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174136.
   Chen ZS, 2010, CANCER-AM CANCER SOC, V116, P1953, DOI 10.1002/cncr.24892.
   Cheraghlou S, 2018, LARYNGOSCOPE, V128, P2762, DOI 10.1002/lary.27315.
   D'Hondt V, 2017, ONCOTARGET, V8, P95662, DOI 10.18632/oncotarget.21175.
   Dangelmaier C, 2014, THROMB HAEMOSTASIS, V111, P508, DOI 10.1160/TH13-06-0484.
   Ettinger KS, 2019, ORAL MAXIL SURG CLIN, V31, P13, DOI 10.1016/j.coms.2018.08.002.
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937.
   Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568.
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384.
   Gassmann M, 2009, ELECTROPHORESIS, V30, P1845, DOI 10.1002/elps.200800720.
   Ghosh S, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.102925.
   Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368.
   Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x.
   Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251.
   Huang SH, 2013, MED ORAL PATOL ORAL, V18, pE233, DOI 10.4317/medoral.18772.
   Huang WC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1166-3.
   Inazawa J, 1996, GENOMICS, V31, P240, DOI 10.1006/geno.1996.0039.
   Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912.
   Jeon GA, 2004, INT J CANCER, V112, P249, DOI 10.1002/ijc.20399.
   Kuo YC, 2008, J BIOL CHEM, V283, P1882, DOI 10.1074/jbc.M709585200.
   Lee G, 2008, CANCER BIOL THER, V7, P2007, DOI 10.4161/cbt.7.12.6984.
   Liao QY, 2015, ONCOTARGET, V6, P40081, DOI 10.18632/oncotarget.5542.
   Liu Y, 2015, HISTOPATHOLOGY, V67, P645, DOI 10.1111/his.12686.
   Lv ZJ, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0100-y.
   Qiu XY, 2003, CANCER RES, V63, P6488.
   Révillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989.
   Szturz P, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00086.
   Tang JS, 2018, CANCER LETT, V430, P148, DOI 10.1016/j.canlet.2018.05.024.
   Thapa N, 2015, J BIOL CHEM, V290, P18843, DOI 10.1074/jbc.M114.596742.
   Tominaga H, 1999, ANAL COMMUN, V36, P47, DOI 10.1039/a809656b.
   Wang JT, 2015, NEUROSCIENCE, V292, P90, DOI 10.1016/j.neuroscience.2015.02.025.
   Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096.
   Wang ZH, 2020, CELL MOL IMMUNOL, V17, P1148, DOI 10.1038/s41423-019-0327-9.
   Xu SP, 2007, WORLD J GASTROENTERO, V13, P250, DOI 10.3748/wjg.v13.i2.250.
   Yang BK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058706.
   Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200.
   Yang ZJ, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5664-7.
   Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383.
   Zhan H, 2016, TUMOR BIOL, V37, P9691, DOI 10.1007/s13277-016-4843-2.
   Zhao L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0774-8.
   Zhu XH, 2008, APPL IMMUNOHISTO M M, V16, P232, DOI 10.1097/PAI.0b013e31814c915a.},
Number-of-Cited-References = {48},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Oral Dis.},
Doc-Delivery-Number = {QO4CS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000569347400001},
DA = {2026-02-04},
}

@article{ WOS:000566483200001,
Author = {Lin, Xiaoqian and Chen, Yusha and Fang, Zhuanji and Chen, Qingshan and
   Chen, Lichun and Han, Qing and Yan, Jianying},
Title = {Effects of cytomegalovirus infection on extravillous trophoblast cells
   invasion and immune function of NK cells at the maternal-fetal interface},
Journal = {JOURNAL OF CELLULAR AND MOLECULAR MEDICINE},
Year = {2020},
Volume = {24},
Number = {19},
Pages = {11170-11176},
Month = {OCT},
Abstract = {Cytomegalovirus (CMV) is one of the most common intrauterine infection
   virus, which can cause intrauterine transmission through the placenta,
   resulting in abortion, stillbirth and congenital malformations. In this
   study, the co-culture extravillous trophoblast (EVT) HTR8/SVneo cell
   model of CMV infection was established in vitro. The toxicity of CMV
   infected EVT was determined, and then, the cell invasion experiment was
   conducted to evaluate the effect on the invasion ability of EVT cell
   lines. Western blot and real-time PCR were used to detect the related
   cytokines in the PI3K/AKT signalling pathway in cells. Flow cytometry
   was used to detect the immune function related factors of the
   supernatant of CMV culture on decidual NK cells. The TCID50 of CMV virus
   was 10(-5.4). The results of immunofluorescence showed that a large
   number of fluorescent green of CMV pp65 antigen signals appeared in the
   cytoplasm of CMV infection group. CMV could infect and replicate EVT
   cells and inhibited cell proliferation. The expression of proteins PDK1,
   AKT-S473 and AKT-S308 was significantly increased in CMV infection
   group. The levels of IL-17, IL-4 and IFN-gamma were 8.7 +/- 0.48\%,
   12.17 +/- 0.61\% and 6.66 +/- 0.25\%, respectively, in CMV infection
   group. The above results indicated that CMV infection inhibited EVT
   cells proliferation, weakened the invasion ability and inhibited the
   immune function of NK cells at the maternal-fetal interface, resulting
   in the abnormal maternal-fetal crosstalk.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Yan, JY (Corresponding Author), Fujian Med Univ, Affiliated Hosp, Dept Obstet, Fujian Matern \& Child Hlth Hosp, 18 Daoshan Rd, Fuzhou 350001, Peoples R China.
   Lin, Xiaoqian; Fang, Zhuanji; Chen, Qingshan; Chen, Lichun; Han, Qing; Yan, Jianying, Fujian Med Univ, Affiliated Hosp, Dept Obstet, Fujian Matern \& Child Hlth Hosp, 18 Daoshan Rd, Fuzhou 350001, Peoples R China.
   Lin, Xiaoqian; Yan, Jianying, Fujian Women \& Childrens Hosp, Fujian Matern \& Child Hlth Hosp, Fujian Key Lab Women \& Childrens Crit Dis Res, Fuzhou, Peoples R China.
   Chen, Yusha, Fujian Med Univ, Affiliated Hosp, Cerv Dis Diag \& Treatment Hlth Ctr, Fujian Matern \& Child Hlth Hosp, Fuzhou, Peoples R China.},
DOI = {10.1111/jcmm.15638},
EarlyAccessDate = {SEP 2020},
ISSN = {1582-1838},
EISSN = {1582-4934},
Keywords = {cytomegalovirus; extravillous trophoblast; maternal-fetal immune;
   proliferation},
Keywords-Plus = {DIFFERENTIATION; TOLERANCE},
Research-Areas = {Cell Biology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Cell Biology; Medicine, Research \& Experimental},
Author-Email = {michaelqian88@126.com
   675472752@qq.com
   fangzhuanji198208@126.com
   1340157213@qq.com
   848177531@qq.com
   fjcherry22@163.com
   yanjy2019@fjmu.edu.cn},
Affiliations = {Fujian Medical University; Fujian Medical University},
ResearcherID-Numbers = {Chen, Qing/OCL-3990-2025
   Yan, Jianying/ISS-1790-2023},
ORCID-Numbers = {Yan, Jianying/0000-0003-4289-3444},
Funding-Acknowledgement = {Fujian Science and Technology Project {[}2019J05138]; Fujian Provincial
   Health Technology Project {[}2019-ZQN-25]; Technology Project of Fujian
   Maternity and Child Health Hospital, Affiliated Hospital of Fujian
   Medical University {[}YCXQ1808]; National Health and Family Planning
   Commission Science Foundation {[}2019WJ-04]; Key Clinical Specialty
   Discipline Construction of Fujian, China {[}2015] {[}593]},
Funding-Text = {Fujian Science and Technology Project (2019J05138). Fujian Provincial
   Health Technology Project (2019-ZQN-25). Technology Project of Fujian
   Maternity and Child Health Hospital, Affiliated Hospital of Fujian
   Medical University (YCXQ1808). National Health and Family Planning
   Commission Science Foundation (2019WJ-04). Key Clinical Specialty
   Discipline Construction of Fujian, China ({[}2015] No.593).},
Cited-References = {Cristea IM, 2010, J VIROL, V84, P7803, DOI 10.1128/JVI.00139-10.
   Du MR, 2014, J IMMUNOL, V192, P1502, DOI 10.4049/jimmunol.1203425.
   Emery Vincent C, 2017, F1000Res, V6, P138, DOI {[}10.12688/f1000research.10276.1, 10.12688/f1000research.10276.1].
   Fisher S, 2000, J VIROL, V74, P6808, DOI 10.1128/JVI.74.15.6808-6820.2000.
   Hazeki K, 2007, BIOL PHARM BULL, V30, P1617, DOI 10.1248/bpb.30.1617.
   Huang Y, 2008, J IMMUNOL, V180, P2367, DOI 10.4049/jimmunol.180.4.2367.
   Jabrane-Ferrat N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01397.
   Jackson SE, 2011, VIRUS RES, V157, P151, DOI 10.1016/j.virusres.2010.10.031.
   James JL, 2006, HUM REPROD, V21, P2699, DOI 10.1093/humrep/del212.
   Kabani N, 2020, J INFECT DIS, V221, P9, DOI 10.1093/infdis/jiz446.
   Lin XQ, 2016, J CLIN VIROL, V79, P54, DOI 10.1016/j.jcv.2016.04.002.
   Liu T, 2015, INT J CLIN EXP MED, V8, P17248.
   Liu T, 2011, J HUAZHONG U SCI-MED, V31, P819, DOI 10.1007/s11596-011-0683-x.
   Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218.
   Mor G, 2017, NAT REV IMMUNOL, V17, P469, DOI 10.1038/nri.2017.64.
   Shimamura M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001170.
   Tabata T, 2019, MED MICROBIOL IMMUN, V208, P475, DOI 10.1007/s00430-019-00613-w.
   Tabata T, 2015, J VIROL, V89, P5134, DOI 10.1128/JVI.03674-14.
   Waldorf KMA, 2010, PLACENTA, V31, P589, DOI 10.1016/j.placenta.2010.04.013.
   Yao YY, 2016, IMMUNOL CELL BIOL, V94, P458, DOI 10.1038/icb.2015.119.
   {[}张磊 ZHANG Lei], 2006, {[}实用妇产科杂志, Journal of Practical Obstetrics and Gynecology], V22, P232.},
Number-of-Cited-References = {21},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {J. Cell. Mol. Med.},
Doc-Delivery-Number = {OH1OW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000566483200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000571063300070,
Author = {Tanaka, Kosuke and Watanabe, Takaaki and Ozawa, Junichi and Ito, Masato
   and Nagano, Nobuhiko and Arai, Yukio and Miyake, Fuyu and Matsumura,
   Shun and Kobayashi, Shingo and Itakura, Ryuta and Namba, Fumihiko},
Title = {Difference in pyruvic acid metabolism between neonatal and adult mouse
   lungs exposed to hyperoxia},
Journal = {PLOS ONE},
Year = {2020},
Volume = {15},
Number = {9},
Month = {SEP 3},
Abstract = {Objective Neonatal lungs are more tolerant to hyperoxic injury than are
   adult lungs. This study investigated differences in the response to
   hyperoxic exposure between neonatal and adult mouse lungs using
   metabolomics analysis with capillary electrophoresis time-of-flight mass
   spectrometry (CE- TOFMS). Methods Neonatal and adult mice were exposed
   to 21\% or 95\% O(2)for four days. Subsequently, lung tissue samples
   were collected and analyzed by CE-TOFMS. Pyruvate dehydrogenase (PDH)
   enzyme activity was determined using a microplate assay kit. PDH kinase
   (Pdk) 1,Pdk2,Pdk3, andPdk4mRNA expression levels were determined using
   quantitative reverse transcription-polymerase chain reaction. Pdk4
   protein expression was quantified by Western blotting and Pdk4 protein
   localization was evaluated by immunohistochemistry. Results Levels of
   3-phosphoglyceric acid, 2-phosphoglyceric acid, phosphoenolpyruvic acid,
   and lactic acid were significantly elevated in the lungs of
   hyperoxia-exposed versus normoxia-exposed adult mice, whereas no
   significant differences were observed with hyperoxia exposure in
   neonatal mice. PDH activity was reduced in the lungs of adult mice
   only.Pdk4mRNA expression levels after hyperoxic exposure were
   significantly elevated in adult mice compared with that in neonatal
   mice. Conversely, gene expression levels ofPdk1,Pdk2, andPdk3did not
   differ after hyperoxic exposure in either neonatal or adult mice. Pdk4
   protein levels were also significantly increased in adult mouse lungs
   exposed to hyperoxia and were localized mainly to the epithelium of
   terminal bronchiole. Conclusions Specific metabolites associated with
   glycolysis and gluconeogenesis were altered after hyperoxia exposure in
   the lungs of adult mice, but not in neonates, which was likely a result
   of reduced PDH activity due toPdk4mRNA upregulation under hyperoxia.},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Article},
Language = {English},
Affiliation = {Namba, F (Corresponding Author), Saitama Med Univ, Saitama Med Ctr, Dept Pediat, Kawagoe, Saitama, Japan.
   Tanaka, Kosuke; Watanabe, Takaaki; Ozawa, Junichi; Ito, Masato; Nagano, Nobuhiko; Arai, Yukio; Miyake, Fuyu; Matsumura, Shun; Kobayashi, Shingo; Itakura, Ryuta; Namba, Fumihiko, Saitama Med Univ, Saitama Med Ctr, Dept Pediat, Kawagoe, Saitama, Japan.},
DOI = {10.1371/journal.pone.0238604},
Article-Number = {e0238604},
ISSN = {1932-6203},
Keywords-Plus = {EXPRESSION; NEWBORN; INJURY; MICE},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {nambaf@saitama-med.ac.jp},
Affiliations = {Saitama Medical University},
ResearcherID-Numbers = {Ito, Masato/GPX-3685-2022
   Nagano, Nobuhiko/GNM-8267-2022},
ORCID-Numbers = {Tanaka, Kosuke/0000-0001-5436-6399
   Ito, Masato/0000-0002-8084-4451
   },
Funding-Acknowledgement = {Saitama Medical University {[}17-C-1-2, 29-F-1-01]; Kawano Masanori
   Memorial Public Interest Incorporated Foundation for Promotion of
   Pediatrics {[}29-7]; Japan Society for the Promotion of Science
   {[}18K15729]; Grants-in-Aid for Scientific Research {[}18K15729] Funding
   Source: KAKEN},
Funding-Text = {This research was supported by the Saitama Medical University Internal
   Research Grant (Grant no. 17-C-1-2) (SK) and Saitama Medical University
   Young Doctors Educational Grant (Grant no. 29-F-1-01) (RI) from Saitama
   Medical University, a grant from Kawano Masanori Memorial Public
   Interest Incorporated Foundation for Promotion of Pediatrics (Grant no.
   29-7) (FN), and Grants-in-Aid for Scientific Research (KAKENHI) from the
   Japan Society for the Promotion of Science (Grant no. 18K15729) (SK).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.},
Cited-References = {Velázquez JA, 2015, TECNOL CIENC AGUA, V6, P17.
   Allen CB, 1998, AM J PHYSIOL-LUNG C, V274, pL320, DOI 10.1152/ajplung.1998.274.3.L320.
   BALIN AK, 1976, J CELL PHYSIOL, V89, P235, DOI 10.1002/jcp.1040890207.
   BASSETT DJP, 1986, J APPL PHYSIOL, V60, P1605, DOI 10.1152/jappl.1986.60.5.1605.
   BASSETT DJP, 1992, AM J PHYSIOL, V262, pL495, DOI 10.1152/ajplung.1992.262.4.L495.
   BASSETT DJP, 1989, J APPL PHYSIOL, V66, P989, DOI 10.1152/jappl.1989.66.2.989.
   Buczynski BW, 2013, SEMIN PERINATOL, V37, P69, DOI 10.1053/j.semperi.2013.01.002.
   D'Angio CT, 1998, EXP LUNG RES, V24, P685, DOI 10.3109/01902149809099588.
   Das KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073358.
   FRANK L, 1978, J APPL PHYSIOL, V45, P699, DOI 10.1152/jappl.1978.45.5.699.
   Gerik SM, 2003, AM J RESP CELL MOL, V29, P506, DOI 10.1165/rcmb.2002-0123OC.
   Ito M, 2017, PEDIATR RES, V81, P926, DOI 10.1038/pr.2017.17.
   Junker BH, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-219.
   Kallet RH, 2013, RESP CARE, V58, P123, DOI 10.4187/respcare.01963.
   KEENEY SE, 1992, PEDIATR RES, V31, P441, DOI 10.1203/00006450-199205000-00005.
   KIMURA RE, 1983, J APPL PHYSIOL, V55, P1501, DOI 10.1152/jappl.1983.55.5.1501.
   Lee SJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/327167.
   Li Q, 2016, AM J RESP CELL MOL, V55, P419, DOI 10.1165/rcmb.2015-0228OC.
   Lingappan K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101581.
   Namba F, 2016, EXP LUNG RES, V42, P57, DOI 10.3109/01902148.2016.1141264.
   Namba F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090936.
   O'Reilly MA, 2012, AM J PATHOL, V181, P441, DOI 10.1016/j.ajpath.2012.05.005.
   SCHOONEN WGEJ, 1990, J BIOL CHEM, V265, P11118.
   SIMON LM, 1979, J APPL PHYSIOL, V47, P98, DOI 10.1152/jappl.1979.47.1.98.
   Uetaki M, 2015, SCI REP-UK, V5, DOI 10.1038/srep13896.
   Vallotton MB, 1989, AM J PHYSIOL, V257, pE617.
   Wakayama Masataka, 2015, Methods Mol Biol, V1277, P113, DOI 10.1007/978-1-4939-2377-9\_9.
   Yuan K, 2016, AM J PATHOL, V186, P2500, DOI 10.1016/j.ajpath.2016.05.016.
   Zhang Y, 2019, ANTIOXID REDOX SIGN, V30, P1775, DOI 10.1089/ars.2018.7514.},
Number-of-Cited-References = {29},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {PLoS One},
Doc-Delivery-Number = {NQ7QD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000571063300070},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000565482600004,
Author = {Su, Yao and Wang, Xueying and Guo, Zhen and Wang, Jun},
Title = {Aberrant JmjC domain-containing protein 8 (JMJD8) expression promotes
   activation of AKT and tumor epithelial-mesenchymal transition},
Journal = {ONCOGENE},
Year = {2020},
Volume = {39},
Number = {41},
Pages = {6451-6467},
Month = {OCT 8},
Abstract = {Posttranslational modifications of histone and nonhistone proteins
   greatly influence numerous molecular events in multiple diseases.
   Jumonji domain-containing proteins are a family functioning as histone
   demethylase. Jumonji domain-containing protein 8 (JMJD8) is Jumonji C
   (JmjC) domain-only member of this family, and its physiological
   functions remain largely unknown. In this study, we investigated the
   mechanism by which aberrant JMJD8 stimulates phosphorylation of AKT and
   activate AKT/GSK3 beta/beta-catenin signaling pathway thereby promotes
   tumor cell epithelial-mesenchymal transition (EMT). We demonstrated that
   knockdown of JMJD8 increased the interaction of SETDB1 and
   phosphoinositide-dependent kinase 1 (PDK1) with AKT1 and resulted in
   enhanced trimethylation of AKT1 at lysine 142 (K142), which is crucial
   for cell membrane recruitment, phosphorylation, and activation of AKT.
   Moreover, the mutation of histidine 200 of JMJD8 (JMJD8-H200Q) disrupted
   its binding with AKT1 and increased interaction of SETDB1 and PDK1 with
   AKT1. Furthermore, histone demethylase jumonji domain-containing protein
   2B functioned as an adapter to recruit beta-catenin to the methylated
   AKT1 upon JMJD8 depression, which facilitated the phosphorylation of
   beta-catenin at Ser552 and its accumulation in cell nucleus where the
   activated beta-catenin transcriptionally stimulated the expression of
   genes involved in EMT. In conclusion, our data unraveled a novel role of
   JMJD8 in regulating the migration and invasion of tumor via modulating
   AKT methylation and activation. In addition, this study showed that
   JMJD8 is a potential biomarker and drug design target for tumor EMT.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, J (Corresponding Author), Chinese Acad Sci, HFIPS, Key Lab High Magnet Field \& Ion Beam Phys Biol, Hefei 230031, Peoples R China.
   Guo, Z (Corresponding Author), Univ Sci \& Technol China, Sch Life Sci, Anhui Key Lab Cellular Dynam \& Chem Biol, Hefei 230027, Peoples R China.
   Su, Yao; Wang, Jun, Chinese Acad Sci, HFIPS, Key Lab High Magnet Field \& Ion Beam Phys Biol, Hefei 230031, Peoples R China.
   Wang, Xueying; Guo, Zhen, Univ Sci \& Technol China, Sch Life Sci, Anhui Key Lab Cellular Dynam \& Chem Biol, Hefei 230027, Peoples R China.},
DOI = {10.1038/s41388-020-01446-1},
EarlyAccessDate = {SEP 2020},
ISSN = {0950-9232},
EISSN = {1476-5594},
Keywords-Plus = {BETA-CATENIN; CELL-MIGRATION; KINASE; PHOSPHORYLATION; EPIGENOMICS;
   METHYLATION; METASTASIS; INHIBITION; PATHWAY; FAMILY},
Research-Areas = {Biochemistry \& Molecular Biology; Oncology; Cell Biology; Genetics \&
   Heredity},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Oncology; Cell Biology; Genetics \&
   Heredity},
Author-Email = {zhenguo@ustc.edu.cn
   wangjun0457@ipp.ac.cn},
Affiliations = {Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS;
   Chinese Academy of Sciences; University of Science \& Technology of
   China, CAS},
Funding-Acknowledgement = {National Natural Science Foundation {[}11575232, 31471268]; National Key
   Research and Development Program of China (Stem Cell and Translational
   Research) {[}2016YFA0101202]; International Partnership Program of
   Chinese Academy of Sciences {[}116134KYSB20160084]; Innovative Program
   of Development Foundation of Hefei Center for Physical Science and
   Technology {[}2016FXCX005]},
Funding-Text = {This study was supported by the National Natural Science Foundation
   (11575232, 31471268), the National Key Research and Development Program
   of China (Stem Cell and Translational Research) 2016YFA0101202, the
   International Partnership Program of Chinese Academy of Sciences
   (116134KYSB20160084), and the Innovative Program of Development
   Foundation of Hefei Center for Physical Science and Technology
   (2016FXCX005).},
Cited-References = {Alam H, 2015, CELL MOL LIFE SCI, V72, P4577, DOI 10.1007/s00018-015-2023-y.
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028.
   Boeckel JN, 2016, ARTERIOSCL THROM VAS, V36, P1425, DOI 10.1161/ATVBAHA.116.307695.
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003.
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013.
   De Santis MC, 2019, BBA-REV CANCER, V1871, P361, DOI 10.1016/j.bbcan.2019.03.003.
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005.
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200.
   Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13.
   Ghahhari NM, 2015, EUR J CANCER, V51, P1638, DOI 10.1016/j.ejca.2015.04.021.
   Guo JP, 2019, CELL CYCLE, V18, P917, DOI 10.1080/15384101.2019.1609832.
   Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6.
   Hamamoto R, 2015, NAT REV CANCER, V15, P110, DOI 10.1038/nrc3884.
   Henderson V, 2015, CELL ADHES MIGR, V9, P255, DOI 10.1080/19336918.2015.1013383.
   Hermida Miguel A., 2017, Advances in Biological Regulation, V65, P5, DOI {[}10.1016/j.jbior.2017.06.003, 10.1016/j.jbior.2017.06.003].
   Hino S, 2005, MOL CELL BIOL, V25, P9063, DOI 10.1128/MCB.25.20.9063-9072.2005.
   Jamieson C, 2012, INT J BIOCHEM CELL B, V44, P847, DOI 10.1016/j.biocel.2012.03.001.
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029.
   Kelly AD, 2017, CURR OPIN GENET DEV, V42, P68, DOI 10.1016/j.gde.2017.03.015.
   Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920.
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758.
   Li Q, 2015, INT J CLIN EXP PATHO, V8, P6334.
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2.
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343.
   Oh S, 2019, BBA-REV CANCER, V1871, P406, DOI 10.1016/j.bbcan.2019.04.002.
   Revathidevi S, 2019, SEMIN CANCER BIOL, V59, P80, DOI 10.1016/j.semcancer.2019.06.002.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sechler M, 2017, ONCOGENE, V36, P4150, DOI 10.1038/onc.2017.44.
   Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x.
   Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147.
   Skrypek N, 2017, TRENDS GENET, V33, P943, DOI 10.1016/j.tig.2017.08.004.
   Song Y, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712617.
   Su Y, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118541.
   Sun LD, 2016, CELL MOL LIFE SCI, V73, P4493, DOI 10.1007/s00018-016-2303-1.
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184.
   Tang B, 2016, CANCER RES, V76, P6520, DOI 10.1158/0008-5472.CAN-15-3029.
   Tang B, 2015, ONCOTARGET, V6, P12723, DOI 10.18632/oncotarget.3713.
   Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002.
   Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1.
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028.
   Yang F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09289-5.
   Yang Q, 2019, SEMIN CANCER BIOL, V59, P112, DOI 10.1016/j.semcancer.2019.04.001.
   Yeo KS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15676-z.
   Yeo KS, 2016, SCI REP-UK, V6, DOI 10.1038/srep34125.
   Zhang HH, 2006, MOL CELL, V24, P185, DOI 10.1016/j.molcel.2006.09.019.
   Zhang J, 2019, MOL MED REP, V19, P3963, DOI 10.3892/mmr.2019.10111.
   Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254.},
Number-of-Cited-References = {47},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {43},
Journal-ISO = {Oncogene},
Doc-Delivery-Number = {OA1JL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000565482600004},
DA = {2026-02-04},
}

@article{ WOS:000580354500001,
Author = {Chedeville, Agathe L. and Lourdusamy, Anbarasu and Monteiro, Ana Rita
   and Hill, Richard and Madureira, Patricia A.},
Title = {Investigating Glioblastoma Response to Hypoxia},
Journal = {BIOMEDICINES},
Year = {2020},
Volume = {8},
Number = {9},
Month = {SEP},
Abstract = {Glioblastoma (GB) is the most common and deadly type of primary
   malignant brain tumor with an average patient survival of only 15-17
   months. GBs typically have hypoxic regions associated with
   aggressiveness and chemoresistance. Using patient derived GB cells, we
   characterized how GB responds to hypoxia. We noted a hypoxia-dependent
   glycolytic switch characterized by the up-regulation of HK2, PFKFB3,
   PFKFB4, LDHA, PDK1,SLC2A1/GLUT-1,CA9/CAIX, andSLC16A3/MCT-4. Moreover,
   many proangiogenic genes and proteins, including VEGFA, VEGFC,
   VEGFD,PGF/PlGF, ADM, ANGPTL4, andSERPINE1/PAI-1 were up-regulated during
   hypoxia. We detected the hypoxic induction of invasion proteins,
   including the plasminogen receptor, S100A10, and the urokinase
   plasminogen activator receptor, uPAR. Furthermore, we observed a
   hypoxia-dependent up-regulation of the autophagy genes,BNIP-3andDDIT4and
   of the multi-functional protein, NDRG1 associated with GB
   chemoresistance; and down-regulation ofEGR1andTFRC(Graphical abstract).
   Analysis of GB patient cohorts' revealed differential expression of
   these genes in patient samples (exceptSLC16A3) compared to
   non-neoplastic brain tissue. High expression
   ofSLC2A1,LDHA,PDK1,PFKFB4,HK2,VEGFA,SERPINE1,TFRC, andADMwas associated
   with significantly lower overall survival. Together these data provide
   important information regarding GB response to hypoxia which could
   support the development of more effective treatments for GB patients.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Madureira, PA (Corresponding Author), Univ Portsmouth, Inst Biomed \& Biomol Sci, Portsmouth PO1 2DT, Hants, England.
   Madureira, PA (Corresponding Author), Univ Algarve, Ctr Biomed Res, Gambelas Campus,Room 2-22, P-8005099 Faro, Portugal.
   Chedeville, Agathe L.; Monteiro, Ana Rita; Hill, Richard; Madureira, Patricia A., Univ Portsmouth, Inst Biomed \& Biomol Sci, Portsmouth PO1 2DT, Hants, England.
   Lourdusamy, Anbarasu, Univ Nottingham, Biodiscovery Inst, Sch Med, Childrens Brain Tumour Res Ctr, Nottingham NG7 2RD, England.
   Monteiro, Ana Rita; Madureira, Patricia A., Univ Algarve, Ctr Biomed Res, Gambelas Campus,Room 2-22, P-8005099 Faro, Portugal.},
DOI = {10.3390/biomedicines8090310},
Article-Number = {310},
EISSN = {2227-9059},
Keywords = {glioblastoma; hypoxia; glycolysis; invasion; autophagy; tumor
   angiogenesis},
Keywords-Plus = {ENDOTHELIAL GROWTH-FACTOR; RANDOMIZED PHASE-III; PLASMINOGEN-ACTIVATOR;
   ANNEXIN A2; ADJUVANT TEMOZOLOMIDE; TUMOR ANGIOGENESIS; INDUCIBLE
   FACTORS; CELL INVASION; UP-REGULATION; EXPRESSION},
Research-Areas = {Biochemistry \& Molecular Biology; Research \& Experimental Medicine;
   Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Medicine, Research \& Experimental;
   Pharmacology \& Pharmacy},
Author-Email = {agathe.chedeville@etu.univ-rouen.fr
   anbarasu.lourdusamy@nottingham.ac.uk
   rita.monteiro95@gmail.com
   drrjhill@gmail.com
   pamadureira@ualg.pt},
Affiliations = {University of Portsmouth; University of Nottingham; Universidade do
   Algarve},
ResearcherID-Numbers = {Lourdusamy, Anbarasu/P-6606-2014
   Hill, Richard/F-4875-2012
   Madureira, Patricia/C-9666-2013},
ORCID-Numbers = {Lourdusamy, Anbarasu/0000-0002-1978-6301
   Monteiro, Ana Rita/0000-0001-5694-5335
   Chédeville, Agathe/0009-0001-8002-1738
   Madureira, Patricia/0000-0002-4856-3908},
Funding-Acknowledgement = {FCT Investigator contract from the Foundation for Science and Technology
   (FCT), Portugal {[}IF/00614/2014]; FCT exploratory grant
   {[}IF/00614/2014/CP12340006]; FCT Research Center Grant
   {[}UID/BIM/04773/2013CBMR1334]; ERASMUS fellowship
   {[}:2017-1-PT01-KA103-035561]; Erasmus+ EU; University Rouen-Normandy
   (AMI); University Rouen-Normandy (IDEFI REMIS); Normandy Region
   {[}810sbaAtW9]},
Funding-Text = {P.A.M. is funded by an FCT Investigator contract from the Foundation for
   Science and Technology (FCT), Portugal (ref:IF/00614/2014) and FCT
   exploratory grant, ref:IF/00614/2014/CP12340006. CBMR is financed by FCT
   Research Center Grant ref:UID/BIM/04773/2013CBMR1334. R.M. was a
   recipient of an ERASMUS fellowship, ref:2017-1-PT01-KA103-035561. A.C.
   received financial support from Erasmus+ EU funds and the University
   Rouen-Normandy (AMI and IDEFI REMIS financial instruments), as well as
   the Normandy Region (ref:810sbaAtW9).},
Cited-References = {Adachi Y, 2002, ONCOGENE, V21, P87, DOI 10.1038/sj.onc.1204999.
   Alapati K, 2014, STEM CELL RES, V12, P716, DOI 10.1016/j.scr.2014.02.008.
   Arai Y, 1998, ACTA NEUROCHIR, V140, P377, DOI 10.1007/s007010050112.
   Burton TR, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.100.
   Burton TR, 2009, J NEUROSCI, V29, P4189, DOI 10.1523/JNEUROSCI.5747-08.2009.
   Calogero A, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-1.
   Castaldo SA, 2019, CANCERS, V11, DOI 10.3390/cancers11040492.
   Castaldo SA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/8413032.
   Chen L, 2019, PHYTOTHER RES, V33, P1736, DOI 10.1002/ptr.6363.
   Clarke K, 2001, BRIT J CANCER, V84, P1322, DOI 10.1054/bjoc.2001.1805.
   DeYoung MP, 2008, GENE DEV, V22, P239, DOI 10.1101/gad.1617608.
   Foltyn M, 2019, BRIT J CANCER, V120, P481, DOI 10.1038/s41416-018-0368-3.
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721.
   Fujiwara S, 2007, INT J ONCOL, V30, P793.
   Gilbert MR, 2013, J CLIN ONCOL, V31, P4085, DOI 10.1200/JCO.2013.49.6968.
   Gonzalez-Avila G, 2020, ADV EXP MED BIOL, V1245, P97, DOI 10.1007/978-3-030-40146-7\_5.
   Guo L, 2014, INFLAMM RES, V63, P13, DOI 10.1007/s00011-013-0678-0.
   HEATON J, 1995, AM J PHYSIOL-HEART C, V268, pH2211, DOI 10.1152/ajpheart.1995.268.6.H2211.
   Howarth A, 2019, TRANSL ONCOL, V12, P1375, DOI 10.1016/j.tranon.2019.07.007.
   Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868.
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831.
   Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318.
   Jougasaki M, 2000, LIFE SCI, V66, P855, DOI 10.1016/S0024-3205(99)00358-6.
   Katanasaka Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-31.
   Kim Jin Wook, 2014, Genes Cancer, V5, P165.
   Kitamuro T, 2000, J NEUROCHEM, V75, P1826, DOI 10.1046/j.1471-4159.2000.0751826.x.
   Kolb R, 2019, ONCOGENE, V38, P2351, DOI 10.1038/s41388-018-0592-6.
   Krishnamachary B, 2003, CANCER RES, V63, P1138.
   Kubala MH, 2019, CANCER METAST REV, V38, P483, DOI 10.1007/s10555-019-09806-4.
   Labak CM, 2016, AM J CANCER RES, V6, P1599.
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017.
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001.
   Liu CT, 2000, J BIOL CHEM, V275, P20315, DOI 10.1074/jbc.M909046199.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Madureira PA, 2013, INT J MOL SCI, V14, P3568, DOI 10.3390/ijms14023568.
   Madureira PA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/353687.
   Madureira PA, 2011, BLOOD, V118, P4789, DOI 10.1182/blood-2011-06-334672.
   Madureira PA, 2011, ONCOTARGET, V2, P1075, DOI 10.18632/oncotarget.375.
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022.
   Metellus P, 2011, EUR J CANCER, V47, P1727, DOI 10.1016/j.ejca.2011.02.021.
   Mihajluk K, 2019, CANCER LETT, V458, P29, DOI 10.1016/j.canlet.2019.05.028.
   Miller VA, 2017, THROMB HAEMOSTASIS, V117, P1058, DOI 10.1160/TH16-12-0936.
   Mongiardi MP, 2016, ONCOTARGET, V7, P33257, DOI 10.18632/oncotarget.8921.
   Monteiro AR, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6040045.
   Mori T, 2000, J NEURO-ONCOL, V46, P115, DOI 10.1023/A:1006339717748.
   Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811.
   Osmak M, 1999, ANTICANCER RES, V19, P3193.
   Osmak M, 1999, J NEURO-ONCOL, V42, P95, DOI 10.1023/A:1006125629887.
   Pinto JA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01207-3.
   PLATE KH, 1995, EXP TOXICOL PATHOL, V47, P89, DOI 10.1016/S0940-2993(11)80292-7.
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0.
   Riddick G, 2017, SCI REP-UK, V7, DOI 10.1038/srep43605.
   Rong Y, 2006, CANCER RES, V66, P7067, DOI 10.1158/0008-5472.CAN-06-0346.
   Said HM, 2009, MOL MED REP, V2, P757, DOI 10.3892/mmr\_00000169.
   Said HM, 2009, ONCOL REP, V21, P237, DOI 10.3892/or\_00000214.
   Said HM, 2017, ONCOL REP, V37, P3625, DOI 10.3892/or.2017.5620.
   Sakakini N, 2016, J BIOL CHEM, V291, P10684, DOI 10.1074/jbc.M116.720698.
   Sanzey M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123544.
   Saxena K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080339.
   Schonkeren SL, 2019, NEUROGENETICS, V20, P173, DOI 10.1007/s10048-019-00587-0.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Shen Y, 2018, AM J CANCER RES, V8, P916.
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0.
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330.
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7.
   Tsai YT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225625.
   Wang MH, 2015, NEURO-ONCOLOGY, V17, P999, DOI 10.1093/neuonc/nov009.
   Weiler M, 2014, P NATL ACAD SCI USA, V111, P409, DOI 10.1073/pnas.1314469111.
   Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843.
   YAMAMOTO M, 1994, CANCER RES, V54, P5016.
   YAMAMOTO M, 1994, CANCER RES, V54, P3656.
   Yu XX, 2016, ONCOTARGET, V7, P14161, DOI 10.18632/oncotarget.7416.
   Zhang X, 2000, J CLIN NEUROSCI, V7, P116, DOI 10.1054/jocn.1999.0161.
   Zhong H, 2000, CANCER RES, V60, P1541.
   Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102.},
Number-of-Cited-References = {75},
Times-Cited = {43},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Biomedicines},
Doc-Delivery-Number = {OE2GB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000580354500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000573218700001,
Author = {Kang, Jung-Woo and Yan, Jie and Ranjan, Kishu and Zhang, Xuchen and
   Turner, Jerrold R. and Abraham, Clara},
Title = {Myeloid Cell Expression of LACC1 Is Required for Bacterial Clearance and
   Control of Intestinal Inflammation},
Journal = {GASTROENTEROLOGY},
Year = {2020},
Volume = {159},
Number = {3},
Pages = {1051-1067},
Month = {SEP},
Abstract = {BACKGROUND \& AIMS: Loss-of-function variants in the laccase domain
   containing 1 (LACC1) gene are associated with immune-mediated diseases,
   including inflammatory bowel disease. It is not clear how LACC1 balances
   defenses against intestinal bacteria vs intestinal inflammation or what
   cells are responsible for this balance in humans or mice. METHODS:
   Lacc1(-1- )mice and mice with myeloid-specific disruption of Lacc1
   (Lacc1(Delta mye)) were given oral Salmonella Typhimurium or dextran
   sodium sulfate. CD45RB(hi)CD4(+)T cells were transferred to
   Lacc1(-/-)Rag2(-/-) mice to induce colitis. Organs were collected and
   analyzed by histology and protein expression. Bone marrow-derived
   macrophages and dendritic cells, lamina propria macrophages, and
   mesenteric lymph node dendritic cells were examined. We performed assays
   to measure intestinal permeability, cell subsets, bacterial uptake and
   clearance, reactive oxygen species, nitrite production, autophagy,
   signaling, messenger RNA, and cytokine levels. RESULTS: Lacc1(-/-) mice
   developed more severe T-cell transfer colitis than wild-type mice and
   had an increased burden of bacteria in intestinal lymphoid organs, which
   expressed lower levels of T helper (Th) 1 and Th17 cytokines and higher
   levels of Th2 cytokines. Intestinal lymphoid organs from mice with
   deletion of LACC1 had an increased burden of bacteria after oral
   administration of S Typhimurium and after administration of dextran
   sodium sulfate compared with wild-type mice. In macrophages, expression
   of LACC1 was required for toll-like receptor-induced uptake of bacteria,
   which required PDK1, and of mitogen-activated protein kinase (MAPK)- and
   nuclear factor kappa B-dependent induction of reactive oxygen species,
   reactive nitrogen species, and autophagy. Expression of LACC1 by
   dendritic cells was required for increasing expression of Th1 and Th17
   cytokines and reducing expression of Th2 cytokines upon coculture with
   CD4(+)T cells. Mice with LACC1-deficient myeloid cells had an increased
   burden of bacteria and altered T-cell cytokines in intestinal lymphoid
   organs, similar to Lacc1(-/-) mice. Complementation of cytokines
   produced by myeloid cells to cocultures of LACC1-deficient myeloid cells
   and wild-type CD4(+)T cells restored T-cell cytokine regulation. When S
   Typhimurium-infected Lacc1(Delta mye) mice were injected with these
   myeloid cell-derived cytokines, intestinal tissues increased production
   of Th1 and Th17 cytokines, and bacteria were reduced. CONCLUSIONS:
   Disruption of Lacc1 in mice increases the burden of bacteria in
   intestinal lymphoid organs and intestinal inflammation after induction
   of chronic colitis. LACC1 expression by myeloid cells in mice is
   required to clear bacteria and to regulate adaptive T-cell responses
   against microbes.},
Publisher = {W B SAUNDERS CO-ELSEVIER INC},
Address = {1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA},
Type = {Article},
Language = {English},
Affiliation = {Abraham, C (Corresponding Author), Dept Internal Med, 333 Cedar St LMP 1080, New Haven, CT 06520 USA.
   Kang, Jung-Woo; Yan, Jie; Ranjan, Kishu; Abraham, Clara, Yale Univ, Dept Internal Med, New Haven, CT USA.
   Zhang, Xuchen, Yale Univ, Dept Pathol, New Haven, CT USA.
   Turner, Jerrold R., Harvard Med Sch, Brigham \& Womens Hosp, Dept Pathol, Boston, MA 02115 USA.},
DOI = {10.1053/j.gastro.2020.07.024},
ISSN = {0016-5085},
EISSN = {1528-0012},
Keywords = {Innate Immunity; Genetics; Crohn's Disease; Signaling},
Keywords-Plus = {VARIANTS; ACCUMULATION; ASSOCIATION; MACROPHAGES; RECEPTORS; MUTATION;
   OXIDASE},
Research-Areas = {Gastroenterology \& Hepatology},
Web-of-Science-Categories  = {Gastroenterology \& Hepatology},
Author-Email = {clara.abraham@yale.edu},
Affiliations = {Yale University; Yale University; Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Brigham \& Women's
   Hospital},
ResearcherID-Numbers = {Ranjan, Kishu/J-9371-2019
   },
ORCID-Numbers = {Ranjan, Kishu/0000-0003-1256-181X
   Zhang, Xuchen/0000-0002-1484-4672},
Funding-Acknowledgement = {Department of Defense {[}PR151130]; National Institutes of Health
   {[}R01DK099097, P30-DK034989, R01DK068271]; National Institute of
   Diabetes and Digestive and Kidney Diseases {[}P30DK034989, R01DK099097,
   R01DK068271] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported by Department of Defense PR151130 and National
   Institutes of Health R01DK099097, P30-DK034989, and R01DK068271.},
Cited-References = {Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012.
   Arpaia N, 2011, CELL, V144, P675, DOI 10.1016/j.cell.2011.01.031.
   Assadi G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168276.
   Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89.
   Cader MZ, 2016, NAT IMMUNOL, V17, P1046, DOI 10.1038/ni.3532.
   Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328.
   Danoy P, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001195.
   Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061.
   Dawson PA, 2009, GUT, V58, P910, DOI 10.1136/gut.2007.147595.
   Dhillon SS, 2014, GASTROENTEROLOGY, V147, P680, DOI 10.1053/j.gastro.2014.06.005.
   Eckmann L, 2008, P NATL ACAD SCI USA, V105, P15058, DOI 10.1073/pnas.0808216105.
   Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836.
   Freeman SA, 2014, IMMUNOL REV, V262, P193, DOI 10.1111/imr.12212.
   Hedl M, 2016, CELL REP, V16, P2442, DOI 10.1016/j.celrep.2016.07.060.
   Huang C, 2019, CELL REP, V29, P4525, DOI 10.1016/j.celrep.2019.11.105.
   Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001.
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582.
   Lahiri A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15614.
   Lahiri A, 2014, GASTROENTEROLOGY, V147, P835, DOI 10.1053/j.gastro.2014.06.024.
   Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105.
   MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857.
   Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860.
   Mills CD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00212.
   Patel S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00311.
   Raingeaud J, 1996, MOL CELL BIOL, V16, P1247.
   Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56.
   Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540.
   Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7.
   Skon-Hegg C, 2019, J IMMUNOL, V202, P183, DOI 10.4049/jimmunol.1800636.
   Ulland TK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13180.
   Wakil SM, 2015, ARTHRITIS RHEUMATOL, V67, P288, DOI 10.1002/art.38877.
   West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973.
   Woting A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060685.
   Wu XX, 2014, J IMMUNOL, V192, P3409, DOI 10.4049/jimmunol.1302436.
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003.
   Zhang FR, 2009, NEW ENGL J MED, V361, P2609, DOI 10.1056/NEJMoa0903753.},
Number-of-Cited-References = {36},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Gastroenterology},
Doc-Delivery-Number = {NT8WR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000573218700001},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000569651100001,
Author = {Kwak, Choong-Hwan and Jin, Ling and Han, Jung Ho and Han, Chang Woo and
   Kim, Eonmi and Cho, MyoungLae and Chung, Tae-Wook and Bae, Sung-Jin and
   Jang, Se Bok and Ha, Ki-Tae},
Title = {Ilimaquinone Induces the Apoptotic Cell Death of Cancer Cells by
   Reducing Pyruvate Dehydrogenase Kinase 1 Activity},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2020},
Volume = {21},
Number = {17},
Month = {SEP},
Abstract = {In cancer cells, aerobic glycolysis rather than oxidative
   phosphorylation (OxPhos) is generally preferred for the production of
   ATP. In many cancers, highly expressed pyruvate dehydrogenase kinase 1
   (PDK1) reduces the activity of pyruvate dehydrogenase (PDH) by inducing
   the phosphorylation of its E1 alpha subunit (PDHA1) and subsequently,
   shifts the energy metabolism from OxPhos to aerobic glycolysis. Thus,
   PDK1 has been regarded as a target for anticancer treatment. Here, we
   report that ilimaquinone (IQ), a sesquiterpene quinone isolated from the
   marine spongeSmenospongia cerebriformis, might be a novel PDK1
   inhibitor. IQ decreased the cell viability of human and murine cancer
   cells, such as A549, DLD-1, RKO, and LLC cells. The phosphorylation of
   PDHA1, the substrate of PDK1, was reduced by IQ in the A549 cells. IQ
   decreased the levels of secretory lactate and increased oxygen
   consumption. The anticancer effect of IQ was markedly reduced in
   PDHA1-knockout cells. Computational simulation and biochemical assay
   revealed that IQ interfered with the ATP binding pocket of PDK1 without
   affecting the interaction of PDK1 and the E2 subunit of the PDH complex.
   In addition, similar to other pyruvate dehydrogenase kinase inhibitors,
   IQ induced the generation of mitochondrial reactive oxygen species (ROS)
   and depolarized the mitochondrial membrane potential in the A549 cells.
   The apoptotic cell death induced by IQ treatment was rescued in the
   presence of MitoTEMPO, a mitochondrial ROS inhibitor. In conclusion, we
   suggest that IQ might be a novel candidate for anticancer therapeutics
   that act via the inhibition of PDK1 activity.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Ha, KT (Corresponding Author), Pusan Natl Univ, Korean Med Res Ctr Hlth Aging, Sch Korean Med, Gyeongnam 50612, South Korea.
   Ha, KT (Corresponding Author), Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Gyeongnam 50612, South Korea.
   Kwak, Choong-Hwan; Chung, Tae-Wook; Bae, Sung-Jin; Ha, Ki-Tae, Pusan Natl Univ, Korean Med Res Ctr Hlth Aging, Sch Korean Med, Gyeongnam 50612, South Korea.
   Jin, Ling; Han, Jung Ho; Ha, Ki-Tae, Pusan Natl Univ, Sch Korean Med, Dept Korean Med Sci, Gyeongnam 50612, South Korea.
   Han, Chang Woo; Jang, Se Bok, Pusan Natl Univ, Coll Nat Sci, Dept Mol Biol, Busan 46241, South Korea.
   Kim, Eonmi; Cho, MyoungLae, Natl Inst Korean Med Dev, Korea, Gyongsan 38540, Gyeongbuk, South Korea.},
DOI = {10.3390/ijms21176021},
Article-Number = {6021},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {ilimaquinone; Warburg effect; pyruvate dehydrogenase kinase 1;
   glycolysis; apoptosis},
Keywords-Plus = {SPONGE METABOLITE; LUNG-CANCER; EXPRESSION; INHIBITORS; ACTIVATION;
   AUTOPHAGY; POTENT; AXIS; P53},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {hahaaaa@nate.com
   jinling0122@pusan.ac.kr
   hanjh1013@pusan.ac.kr
   hotorses@naver.com
   minnie60@nikom.or.kr
   meanglae@nikom.or.kr
   twchung@pusan.ac.kr
   Dr.NowOrNever@pusan.ac.kr
   sbjang@pusan.ac.kr
   hagis@pusan.ac.kr},
Affiliations = {Pusan National University; Pusan National University; Pusan National
   University},
ResearcherID-Numbers = {Ha, Kitae/AFW-2347-2022
   Bae, Sung-Jin/AAX-9144-2021},
ORCID-Numbers = {Han, Changwoo/0000-0001-9596-1151
   Ha, Kitae/0000-0001-6283-0171
   },
Funding-Acknowledgement = {National Research Foundation of Korea (NRF) - Ministry of Science, ICT
   \& Future Planning (MISP) of the Korean Government {[}2014R1A5A20009936,
   2019R1I1A1A01062912]},
Funding-Text = {This study was supported by a grant from the National Research
   Foundation of Korea (NRF), funded by the Ministry of Science, ICT \&
   Future Planning (MISP) of the Korean Government (grant no.
   2014R1A5A20009936 to K.T.H. and 2019R1I1A1A01062912 to C.H.K.).},
Cited-References = {Anwar S, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050119.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Cao SG, 2004, J NAT PROD, V67, P1716, DOI 10.1021/np049849+.
   Cesi G, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0667-y.
   Chang CW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0250-x.
   Chen XZ, 2015, FREE RADICAL BIO MED, V79, P253, DOI 10.1016/j.freeradbiomed.2014.08.027.
   Cho H, 2019, J MED CHEM, V62, P8461, DOI 10.1021/acs.jmedchem.9b00565.
   Chung TW, 2017, J ETHNOPHARMACOL, V203, P47, DOI 10.1016/j.jep.2017.03.034.
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143.
   Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215.
   Do MT, 2014, FOOD CHEM TOXICOL, V71, P51, DOI 10.1016/j.fct.2014.06.001.
   Dymock BW, 2005, J MED CHEM, V48, P4212, DOI 10.1021/jm050355z.
   Fan J, 2011, MOL CELL BIOL, V31, P4938, DOI 10.1128/MCB.06120-11.
   Giatromanolaki A, 2017, EXP LUNG RES, V43, P167, DOI 10.1080/01902148.2017.1328714.
   Golias T, 2019, INT J CANCER, V144, P674, DOI 10.1002/ijc.31812.
   Huang X, 2019, AUTOPHAGY, V15, P1258, DOI 10.1080/15548627.2019.1580105.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kim BG, 2009, BIOORGAN MED CHEM, V17, P6707, DOI 10.1016/j.bmc.2009.07.061.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373.
   Kwak CH, 2019, CANCERS, V11, DOI 10.3390/cancers11050712.
   La Clair JJ, 2010, NAT PROD REP, V27, P969, DOI 10.1039/b909989c.
   Lee EJ, 2018, J PHARMACOL SCI, V138, P146, DOI 10.1016/j.jphs.2018.10.005.
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543.
   Li X, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4528616.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Lu PH, 2007, EUR J PHARMACOL, V556, P45, DOI 10.1016/j.ejphar.2006.10.061.
   LUIBRAND RT, 1979, TETRAHEDRON, V35, P609, DOI 10.1016/0040-4020(79)87004-0.
   Kiem PV, 2017, BIOORG MED CHEM LETT, V27, P1525, DOI 10.1016/j.bmcl.2017.02.040.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Shi G, 2017, CELL REP, V18, P1458, DOI 10.1016/j.celrep.2017.01.029.
   Simithy J, 2018, BBA-PROTEINS PROTEOM, V1866, P731, DOI 10.1016/j.bbapap.2018.04.007.
   Son H, 2019, MAR DRUGS, V17, DOI 10.3390/md17030171.
   Son H, 2019, J PHARMACEUT BIOMED, V166, P291, DOI 10.1016/j.jpba.2019.01.030.
   Sun S, 2015, BIOORG MED CHEM LETT, V25, P2181, DOI 10.1016/j.bmcl.2015.03.057.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7.
   Tso SC, 2014, J BIOL CHEM, V289, P4432, DOI 10.1074/jbc.M113.533885.
   Woolbright BL, 2019, MOL CANCER THER, V18, P1673, DOI 10.1158/1535-7163.MCT-19-0079.
   Yang Z, 2018, EUR J PHARMACOL, V838, P41, DOI 10.1016/j.ejphar.2018.09.016.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.},
Number-of-Cited-References = {44},
Times-Cited = {23},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {NO7EN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000569651100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000564331000022,
Author = {Lee, Pureun-Haneul and Hong, Jisu and Jang, An-Soo},
Title = {N-acetylcysteine decreases airway inflammation and responsiveness in
   asthma by modulating claudin 18 expression},
Journal = {KOREAN JOURNAL OF INTERNAL MEDICINE},
Year = {2020},
Volume = {35},
Number = {5},
Pages = {1229-1237},
Month = {SEP},
Abstract = {Background Aims: N-acetylcysteine (NAC) affects signaling pathways
   involved in apoptosis, angiogenesis, cell growth and arrest,
   redox-regulated gene expression, and the inflammatory response. However,
   it is not known how the signal mechanism for tight junctional protein
   claudin (CLDN) 18 is regulated in asthma patients.
   Methods: To investigate the effects of NAC on CLDN18 expression in a
   mouse model of asthma, and to assess plasma levels of CLDN18 in asthma
   patients. A murine model of asthma induced by ovalbumin (OVA) was
   established using wild-type BALB/c female mice, and the levels of CLDNs,
   phosphorylated-pyruvate dehydrogenase kinase 1 (p-PDK1), and protein
   kinase B (Akt) pathway proteins following NAC treatment were examined by
   Western blotting and immunohistochemistry. In addition, the plasma
   levels of CLDN18 were evaluated in asthmatic patients and control
   subjects.
   Results: NAC diminished OVA-induced airway hyper-responsiveness and
   inflammation. Levels of CLDN18 protein were higher in lung tissue from
   OVA mice than tissue from control mice, and were increased by treatment
   with NAC or dexamethasone. Treatment with NAC or dexamethasone decreased
   the OVA-induced increase in interleukin-1 alpha protein levels. Although
   treatment with NAC increased OVA-induced p-PDK1 protein levels, it
   decreased phosphorylated Akt (pAkt)/Akt levels. Soluble CLDN18 levels
   were lower in patients with asthma than in controls and were correlated
   with the percentage of neutrophils, forced expiratory volume in 1 second
   (FEV1)/forced vital capacity \% (FVC\%) and FEV1\%.
   Conclusions: CLDN18 plays a role in the pathogenesis of asthma and NAC
   diminishes airway inflammation and responsiveness by modulating CLDN18
   expression.},
Publisher = {KOREAN ASSOC INTERNAL MEDICINE},
Address = {101-2501 LOTTE CASTLE PRESIDENT, 109 MAPO-DAERO, MAPO-GU, SEOUL, SOUTH
   KOREA},
Type = {Article},
Language = {English},
Affiliation = {Jang, AS (Corresponding Author), Soonchunhyang Univ, Dept Internal Med, Bucheon Hosp, Div Allergy \& Resp Med, 170 Jomaru Ro, Bucheon 14584, South Korea.
   Lee, Pureun-Haneul; Hong, Jisu; Jang, An-Soo, Soonchunhyang Univ, Dept Internal Med, Bucheon Hosp, Bucheon, South Korea.},
DOI = {10.3904/kjim.2019.105},
ISSN = {1226-3303},
EISSN = {2005-6648},
Keywords = {Asthma; Claudin 18; N-acetylcysteine; Plasma; Tight junction},
Keywords-Plus = {EPITHELIAL BARRIER DYSFUNCTION; TIGHT JUNCTION; MOLECULES; OCCLUDIN;
   STRANDS},
Research-Areas = {General \& Internal Medicine},
Web-of-Science-Categories  = {Medicine, General \& Internal},
Author-Email = {jas877@schmc.ac.kr},
Affiliations = {Soonchunhyang University},
ORCID-Numbers = {Lee, Pureun-Haneul/0000-0002-1431-2393},
Funding-Acknowledgement = {Korea Health Technology R\&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health and Welfare, Republic
   of Korea {[}HI15C2032]; Soonchunhyang University Hospital},
Funding-Text = {This research was supported by a grant from the Korea Health Technology
   R\&D Project through the Korea Health Industry Development Institute
   (KHIDI) funded by the Ministry of Health and Welfare, Republic of Korea
   (HI15C2032) and Soonchunhyang University Hospital.},
Cited-References = {Cereijido M, 2008, BBA-BIOMEMBRANES, V1778, P770, DOI 10.1016/j.bbamem.2007.09.001.
   Cording J, 2013, J CELL SCI, V126, P554, DOI 10.1242/jcs.114306.
   Davies Donna E, 2014, Ann Am Thorac Soc, V11 Suppl 5, pS244, DOI 10.1513/AnnalsATS.201407-304AW.
   EBINA M, 1990, AM REV RESPIR DIS, V141, P1327, DOI 10.1164/ajrccm/141.5\_Pt\_1.1327.
   FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375.
   Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391.
   Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539.
   Georas SN, 2014, J ALLERGY CLIN IMMUN, V134, P509, DOI 10.1016/j.jaci.2014.05.049.
   Global Initiative for Asthma, 2014, ASTHM COPD ASTHM COP.
   Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946.
   Harkness LM, 2017, J CELL MOL MED, V21, P3288, DOI 10.1111/jcmm.13232.
   Jin HJ, 2018, ALLERGY ASTHMA IMMUN, V10, P4, DOI 10.4168/aair.2018.10.1.4.
   Koval M, 2013, ANNU REV PHYSIOL, V75, P551, DOI 10.1146/annurev-physiol-030212-183809.
   Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511.
   Ohta H, 2012, AM J PHYSIOL-LUNG C, V302, pL193, DOI 10.1152/ajplung.00349.2010.
   Ouban A, 2010, HISTOL HISTOPATHOL, V25, P83, DOI 10.14670/HH-25.83.
   Park CS., 1983, ALLERGY, V3, P1.
   Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046.
   Schlingmann B, 2015, SEMIN CELL DEV BIOL, V42, P47, DOI 10.1016/j.semcdb.2015.04.009.
   Shimobaba S, 2016, BBA-MOL CELL RES, V1863, P1170, DOI 10.1016/j.bbamcr.2016.02.015.
   Soini Y, 2005, HISTOPATHOLOGY, V46, P551, DOI 10.1111/j.1365-2559.2005.02127.x.
   Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035.
   Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088.
   Van Itallie CM, 2013, TISSUE BARRIERS, V1, DOI 10.4161/tisb.25247.
   VAN MEER G, 1986, NATURE, V322, P639, DOI 10.1038/322639a0.
   Wilson J, 2000, CLIN EXP ALLERGY, V30, P51.},
Number-of-Cited-References = {26},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Korean J. Intern. Med.},
Doc-Delivery-Number = {NG9WB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000564331000022},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000566570600002,
Author = {Putta, Priya and Creque, Emily and Piontkivska, Helen and Kooijman,
   Edgar E.},
Title = {Lipid - protein interactions for ECA1 an N-ANTH domain protein involved
   in stress signaling in plants},
Journal = {CHEMISTRY AND PHYSICS OF LIPIDS},
Year = {2020},
Volume = {231},
Month = {SEP},
Abstract = {Epsin-like Clathrin Adaptor 1 (ECA1/PICALM1A) is an A/ENTH domain
   protein that acts as an adaptor protein in clathrin-mediated
   endocytosis. ECA1 is recruited to the membrane during salt stress
   signaling in plants in a phosphatidic acid (PA)-dependent manner. PA is
   a lipid second messenger that rapidly and transiently increases in
   concentration under stress stimuli. Upon an increase in PA concentration
   another lipid, diacylglycerol pyrophosphate (DGPP), starts to
   accumulate. The accumulation of DGPP is suggested to be a cue for
   attenuating PA signaling during stress in plants. We showed in vitro
   that ECA1-PA binding is modulated as a function of membrane curvature
   stress and charge. In this work, we investigate ECA1 binding to DGPP in
   comparison with PA. We show that ECA1 has more affinity for the less
   charged PA, and this binding is pH dependent. Additionally, plant PA
   binding proteins SnRK2.10, TGD2C, and PDK1-PH2 were investigated for
   their interaction with DGPP, since no known DGPP binding proteins are
   available in the literature to date. Our results shed further light on
   DGPP and its interactions with membrane proteins which brings us closer
   toward understanding the complexity of protein interactions with anionic
   lipids, especially the enigmatic anionic lipid DGPP.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Putta, P (Corresponding Author), Kent State Univ, Biol Sci, POB 5109, Kent, OH 44242 USA.
   Putta, P (Corresponding Author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9620 Carnegie Ave ND Bldg, Cleveland, OH 44106 USA.
   Putta, Priya; Creque, Emily; Piontkivska, Helen; Kooijman, Edgar E., Kent State Univ, Biol Sci, POB 5109, Kent, OH 44242 USA.
   Putta, Priya, Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9620 Carnegie Ave ND Bldg, Cleveland, OH 44106 USA.
   Creque, Emily, Akron Childrens Hosp, Genet Ctr, 214W Bowery St, Akron, OH 44308 USA.},
DOI = {10.1016/j.chemphyslip.2020.104919},
Article-Number = {104919},
ISSN = {0009-3084},
EISSN = {1873-2941},
Keywords = {Signaling lipids; Diacylglycerol pyrophosphate; Plant stress-signaling
   protein; Membrane curvature stress; Electrostatic interactions; Surface
   charge density},
Keywords-Plus = {PHOSPHATIDIC-ACID; DIACYLGLYCEROL PYROPHOSPHATE; SPONTANEOUS CURVATURE;
   MEMBRANE CURVATURE; PRESSURE PROFILE; PHOSPHOLIPASE-D; ENTH DOMAIN;
   BINDING; CLATHRIN; CHARGE},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {pputta@kent.edu
   ecreque@kent.edu
   opiontki@kent.edu
   ekooijma@kent.edu},
Affiliations = {University System of Ohio; Kent State University; Kent State University
   Kent; Kent State University Salem; Cleveland Clinic Foundation; Akron
   Children's Hospital},
ResearcherID-Numbers = {Piontkivska, Helen/AAK-3915-2020
   Putta, Priya/ABC-5216-2021},
ORCID-Numbers = {Putta, Priya/0000-0002-6499-3836},
Funding-Acknowledgement = {National Science Foundation {[}CHE-1412920, 1058719]; National
   Institutes of Health {[}R21AG064479-01]; Brain Health Research Institute
   Pilot Award from Kent State University; Division Of Chemistry; Direct
   For Mathematical \& Physical Scien {[}1058719] Funding Source: National
   Science Foundation},
Funding-Text = {This work was supported by the National Science Foundation under Grant
   No. CHE-1412920 and 1058719. HP is supported by National Institutes of
   Health grant R21AG064479-01, and Brain Health Research Institute Pilot
   Award from Kent State University. Our sincere thanks to Dr. Richard
   Meindl for his assistance with the statistical analysis and to Dr.
   Elizabeth K. Mann for a critical reading and editing of the manuscript.},
Cited-References = {Baral A, 2015, IUBMB LIFE, V67, P677, DOI 10.1002/iub.1425.
   Barkla BJ, 2011, PLANT CELL MONOGR, V19, P457, DOI 10.1007/978-3-642-13431-9\_21.
   Breidigan JM, 2017, J LIPID RES, V58, P2255, DOI 10.1194/jlr.M077909.
   Cantor RS, 1999, BIOPHYS J, V76, P2625, DOI 10.1016/S0006-3495(99)77415-1.
   Cazzolli R, 2006, IUBMB LIFE, V58, P457, DOI 10.1080/15216540600871142.
   Cho H, 2012, PROTEOMICS, V12, P3273, DOI 10.1002/pmic.201200255.
   Cho WH, 2005, ANNU REV BIOPH BIOM, V34, P119, DOI 10.1146/annurev.biophys.33.110502.133337.
   De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3.
   Duncan MC, 2003, TRENDS CELL BIOL, V13, P211, DOI 10.1016/S0962-8924(03)00076-X.
   Eaton JM, 2013, J BIOL CHEM, V288, P9933, DOI 10.1074/jbc.M112.441493.
   Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051.
   Ford MGJ, 2002, NATURE, V419, P361, DOI 10.1038/nature01020.
   Graber Z.T., 2020, ELECTROSTATIC UNPUB.
   Graber ZT, 2012, CHEM PHYS LIPIDS, V165, P696, DOI 10.1016/j.chemphyslip.2012.07.003.
   He J, 2008, J LIPID RES, V49, P1807, DOI 10.1194/jlr.M800150-JLR200.
   Hirama T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01554-9.
   Hom RA, 2007, J MOL BIOL, V373, P412, DOI 10.1016/j.jmb.2007.08.016.
   Hurley JH, 2002, CELL, V111, P143, DOI 10.1016/S0092-8674(02)01044-9.
   Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047.
   Jeannette E, 2010, PLANT CELL MONOGR, V16, P263, DOI 10.1007/978-3-642-03873-0\_17.
   Julkowska MM, 2015, PLANT CELL ENVIRON, V38, P614, DOI 10.1111/pce.12421.
   Kooijman EE, 2007, J BIOL CHEM, V282, P11356, DOI 10.1074/jbc.M609737200.
   Kooijman EE, 2014, CHEM PHYS LIPIDS, V182, P1, DOI 10.1016/j.chemphyslip.2014.06.004.
   Kooijman EE, 2010, BIOPHYS J, V98, p275A, DOI 10.1016/j.bpj.2009.12.1504.
   Kooijman EE, 2009, BIOCHEMISTRY-US, V48, P9360, DOI 10.1021/bi9008616.
   Kooijman EE, 2010, PLANT CELL MONOGR, V16, P203, DOI 10.1007/978-3-642-03873-0\_14.
   Kooijman EE, 2009, BBA-MOL CELL BIOL L, V1791, P881, DOI 10.1016/j.bbalip.2009.04.001.
   Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P17007, DOI 10.1021/bi0518794.
   Kooijman EE, 2005, BIOCHEMISTRY-US, V44, P2097, DOI 10.1021/bi0478502.
   Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x.
   Kozlov Michael M., 2007, V400, P355.
   KOZLOV MM, 1992, J PHYS II, V2, P175, DOI 10.1051/jp2:1992122.
   Kulik A, 2011, OMICS, V15, P859, DOI 10.1089/omi.2011.0091.
   Kumar S, 2017, MOL BIOL EVOL, V34, P1812, DOI 10.1093/molbev/msx116.
   Lee SA, 2005, P NATL ACAD SCI USA, V102, P13052, DOI 10.1073/pnas.0503900102.
   Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328.
   Loew S, 2013, CHEM PHYS LIPIDS, V169, P9, DOI 10.1016/j.chemphyslip.2013.01.008.
   Lu BB, 2009, J BIOL CHEM, V284, P17420, DOI 10.1074/jbc.M109.016014.
   Astorquiza PL, 2016, PLANT PHYSIOL BIOCH, V101, P88, DOI 10.1016/j.plaphy.2016.01.012.
   MCLAUGHLIN S, 1989, ANNU REV BIOPHYS BIO, V18, P113, DOI 10.1146/annurev.bb.18.060189.000553.
   McLoughlin F, 2013, BIOCHEM J, V450, P573, DOI 10.1042/BJ20121639.
   McLoughlin F, 2012, PLANT J, V72, P436, DOI 10.1111/j.1365-313X.2012.05089.x.
   Misra S, 2000, BIOCHEMISTRY-US, V39, P11282, DOI 10.1021/bi0013546.
   Munnik T, 2000, PLANT J, V22, P147, DOI 10.1046/j.1365-313x.2000.00725.x.
   Munnik T, 1996, J BIOL CHEM, V271, P15708, DOI 10.1074/jbc.271.26.15708.
   Munnik T, 2001, FEBS LETT, V498, P172, DOI 10.1016/S0014-5793(01)02492-9.
   Munnik T, 2001, TRENDS PLANT SCI, V6, P227, DOI 10.1016/S1360-1385(01)01918-5.
   Munnik T, 2009, J LIPID RES, V50, pS260, DOI 10.1194/jlr.R800098-JLR200.
   Nakamura Y, 2017, TRENDS PLANT SCI, V22, P1027, DOI 10.1016/j.tplants.2017.09.002.
   Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232.
   Platre MP, 2017, PLANT SIGNAL BEHAV, V12, DOI 10.1080/15592324.2017.1282022.
   Putta P, 2016, BBA-BIOMEMBRANES, V1858, P2709, DOI 10.1016/j.bbamem.2016.07.014.
   Rosenthal JA, 1999, J BIOL CHEM, V274, P33959, DOI 10.1074/jbc.274.48.33959.
   Roston RL, 2012, J BIOL CHEM, V287, P21406, DOI 10.1074/jbc.M112.370213.
   ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316.
   Schmidt O, 2020, DEV CELL, V52, P395, DOI 10.1016/j.devcel.2020.01.035.
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089.
   Scott JL, 2012, INTEGR BIOL-UK, V4, P247, DOI 10.1039/c2ib00143h.
   Shin JJH, 2020, DEV CELL, V52, P461, DOI 10.1016/j.devcel.2019.12.010.
   Shin JJH, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-85.
   Silkov A, 2011, J BIOL CHEM, V286, P34155, DOI 10.1074/jbc.M111.265611.
   Song K, 2012, PLANT PHYSIOL, V159, P1013, DOI 10.1104/pp.112.199380.
   Stahelin RV, 2009, J LIPID RES, V50, pS299, DOI 10.1194/jlr.R800078-JLR200.
   Strawn L, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00040.
   Tanguy E, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020020.
   Vamparys L, 2013, BIOPHYS J, V104, P585, DOI 10.1016/j.bpj.2012.11.3836.
   van der Luit AH, 2000, PLANT PHYSIOL, V123, P1507, DOI 10.1104/pp.123.4.1507.
   VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2.
   Villasuso AL, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00371.
   Wiley Dianne., 2016, ENCY MEMBRANES, P1864.
   Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066.
   Yoo J, 2009, BIOPHYS J, V97, P2267, DOI 10.1016/j.bpj.2009.07.051.
   Young BP, 2010, SCIENCE, V329, P1085, DOI 10.1126/science.1191026.
   Zalejski C, 2005, PLANT J, V42, P145, DOI 10.1111/j.1365-313X.2005.02373.x.
   Zouhar J, 2014, PLANT CELL, V26, P4232, DOI 10.1105/tpc.114.131680.},
Number-of-Cited-References = {75},
Times-Cited = {14},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Chem. Phys. Lipids},
Doc-Delivery-Number = {NK2MI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000566570600002},
DA = {2026-02-04},
}

@article{ WOS:000563562900009,
Author = {Xu, Huadan and He, Yichun and Ma, Jiaoyan and Zhao, Yuanxin and Liu,
   Yanan and Sun, Liankun and Su, Jing},
Title = {Inhibition of pyruvate dehydrogenase kinase-1 by dicoumarol enhances the
   sensitivity of hepatocellular carcinoma cells to oxaliplatin via
   metabolic reprogramming},
Journal = {INTERNATIONAL JOURNAL OF ONCOLOGY},
Year = {2020},
Volume = {57},
Number = {3},
Pages = {733-742},
Month = {SEP},
Abstract = {The Warburg effect is a unique metabolic feature of the majority of
   tumor cells and is closely related to chemotherapeutic resistance.
   Pyruvate dehydrogenase kinase 1 (PDK1) is considered a `switch' that
   controls the fate of pyruvate in glucose metabolism. However, to date,
   to the best of our knowledge, there are only a few studies to available
   which had studied the reduction of chemotherapeutic resistance via the
   metabolic reprogramming of tumor cells with PDK1 as a target. In the
   present study, it was found dicoumarol (DIC) reduced the phosphorylation
   of pyruvate dehydrogenase (PDH) by inhibiting the activity of PDK1,
   which converted the metabolism of human hepatocellular carcinoma (HCC)
   cells to oxidative phosphorylation, leading to an increase in
   mitochondrial reactive oxygen species ROS (mtROS) and a decrease in
   mitochondrial membrane potential (MMP), thereby increasing the apoptosis
   induced by oxaliplatin (OXA). Furthermore, the present study elucidated
   that the targeting of PDK1 may be a potential strategy for targeting
   metabolism in the chemotherapy of HCC. In addition, DIC as an `old drug'
   exhibits novel efficacy, bringing new hope for antitumor therapy.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Sun, LK; Su, J (Corresponding Author), Jilin Univ, Coll Basic Med Sci, Dept Pathophysiol, Key Lab Pathobiol,Minist Educ, 126 Xinmin St, Changchun 130021, Jilin, Peoples R China.
   Xu, Huadan; Ma, Jiaoyan; Zhao, Yuanxin; Liu, Yanan; Sun, Liankun; Su, Jing, Jilin Univ, Coll Basic Med Sci, Dept Pathophysiol, Key Lab Pathobiol,Minist Educ, 126 Xinmin St, Changchun 130021, Jilin, Peoples R China.
   He, Yichun, Jilin Univ, China Japan Union Hosp, Dept Neurosurg, Changchun 130021, Jilin, Peoples R China.},
DOI = {10.3892/ijo.2020.5098},
ISSN = {1019-6439},
EISSN = {1791-2423},
Keywords = {apoptosis; glucose metabolism; hepatocellular carcinoma; pyruvate
   dehydrogenase kinase 1; Warburg effect; chemotherapeutic resistance},
Keywords-Plus = {LUNG-CANCER; PDK1; EXPRESSION; RESISTANCE; PROLIFERATION; DEFICIENCY;
   PROGNOSIS; EFFICACY},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {sunlk@jlu.edu.cn
   sujing@jlu.edu.cn},
Affiliations = {Jilin University; Jilin University},
ORCID-Numbers = {Zhao, Yuanxin/0000-0001-5641-3179},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81672948, 81772794];
   Jilin Provincial Research Foundation for Health Technology Innovation
   {[}2019J009]; Jilin Provincial Research Foundation for the Development
   of Science and Technology Projects {[}20191004004TC]; Jilin Provincial
   Industrial Innovation Project {[}2018C052-7]; Fundamental Research Funds
   for the Central Universities, Jilin University (JLU)},
Funding-Text = {The present study was supported by grants from the National Natural
   Science Foundation of China (nos. 81672948 and 81772794), the Jilin
   Provincial Research Foundation for Health Technology Innovation (no.
   2019J009), the Jilin Provincial Research Foundation for the Development
   of Science and Technology Projects (no. 20191004004TC), the Jilin
   Provincial Industrial Innovation Project (no. 2018C052-7) and `the
   Fundamental Research Funds for the Central Universities, Jilin
   University (JLU)'.},
Cited-References = {Abdel-Rahman O, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-014-0394-0.
   Amoedo ND, 2017, BBA-BIOENERGETICS, V1858, P674, DOI 10.1016/j.bbabio.2017.02.005.
   Battello N, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0141-0.
   Bhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422.
   Choiniere J, 2017, MOL PHARMACOL, V91, P189, DOI 10.1124/mol.116.106757.
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947.
   Dai YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092962.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Fekir K, 2019, CANCER RES, V79, P1869, DOI 10.1158/0008-5472.CAN-18-2110.
   Guo WH, 2011, J CANCER RES CLIN, V137, P65, DOI 10.1007/s00432-010-0860-5.
   He YC, 2018, ANAT REC, V301, P1390, DOI 10.1002/ar.23839.
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373.
   Lian QY, 2018, GENOM PROTEOM BIOINF, V16, P269, DOI 10.1016/j.gpb.2018.07.003.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Lu X, 2018, CANCER MANAG RES, V10, P1231, DOI 10.2147/CMAR.S156530.
   Ma JL, 2017, CANCER LETT, V411, P117, DOI {[}10.1016/j.canlet.2017.09.041, 10.1016/j.canlet.2017.10.026].
   Morandi A, 2017, BBA-REV CANCER, V1868, P1, DOI 10.1016/j.bbcan.2016.12.004.
   Ngan CY, 2008, CANCER SCI, V99, P129, DOI 10.1111/j.1349-7006.2007.00637.x.
   Ngoi NYL, 2020, ANTIOXID REDOX SIGN, V32, P285, DOI 10.1089/ars.2019.7947.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Rodea-Palomares I, 2010, WATER RES, V44, P427, DOI 10.1016/j.watres.2009.07.026.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Sheng JY, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12609.
   Shi HS, 2010, CANCER SCI, V101, P1447, DOI 10.1111/j.1349-7006.2010.01562.x.
   Shin YK, 2009, ELECTROPHORESIS, V30, P2182, DOI 10.1002/elps.200800806.
   Stacpoole PW, 2019, INT REV NEUROBIOL, V145, P211, DOI 10.1016/bs.irn.2019.05.003.
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6.
   Sun CC, 2018, AGING-US, V10, P973, DOI 10.18632/aging.101441.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247.
   Tataranni T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8201079.
   Wada M, 2015, J DERMATOL SCI, V78, P44, DOI 10.1016/j.jdermsci.2015.01.015.
   Wallace MC, 2015, EXPERT REV GASTROENT, V9, P765, DOI 10.1586/17474124.2015.1028363.
   Wang JR, 2016, ONCOTARGETS THER, V9, P5597, DOI 10.2147/OTT.S110646.
   Xu HD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00127.
   Xu YJ, 2018, INT J ONCOL, V53, P1055, DOI 10.3892/ijo.2018.4476.
   Yin X, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0637-7.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.},
Number-of-Cited-References = {41},
Times-Cited = {12},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {26},
Journal-ISO = {Int. J. Oncol.},
Doc-Delivery-Number = {NF8SM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000563562900009},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000563333300001,
Author = {Rao, V, Chinthalapally and Farooqui, Mudassir and Madhavaram, Avanish
   and Zhang, Yuting and Asch, Adam S. and Yamada, Hiroshi Y.},
Title = {GSK3-ARC/Arg3.1 and GSK3-Wnt signaling axes trigger amyloid-β
   accumulation and neuroinflammation in middle-aged Shugoshin 1 mice},
Journal = {AGING CELL},
Year = {2020},
Volume = {19},
Number = {10},
Month = {OCT},
Abstract = {The cerebral amyloid-beta accumulation that begins in middle age is
   considered the critical triggering event in the pathogenesis of
   late-onset Alzheimer's disease (LOAD). However, the molecular mechanism
   remains elusive. The Shugoshin 1 (Sgo1(-/+)) mouse model, a model for
   mitotic cohesinopathy-genomic instability that is observed in human AD
   at a higher rate, showed spontaneous accumulation of amyloid-beta in the
   brain at old age. With the model, novel insights into the molecular
   mechanism of LOAD development are anticipated. In this study, the
   initial appearance of cerebral amyloid-beta accumulation was determined
   as 15-18 months of age (late middle age) in the Sgo1(-/+)model. The
   amyloid-beta accumulation was associated with unexpected GSK3 alpha/beta
   inactivation, Wnt signaling activation, and ARC/Arg3.1 accumulation,
   suggesting involvement of both the GSK3-Arc/Arg3.1 axis and the GSK3-Wnt
   axis. As observed in human AD brains, neuroinflammation with IFN-gamma
   expression occurred with amyloid-beta accumulation and was pronounced in
   the aged (24-month-old) Sgo1(-/+)model mice. AD-relevant protein panels
   (oxidative stress defense, mitochondrial energy metabolism, and
   beta-oxidation and peroxisome) analysis indicated (a) early increases in
   Pdk1 and Phb in middle-aged Sgo1(-/+)brains, and (b) misregulations in
   32 proteins among 130 proteins tested in old age. Thus, initial
   amyloid-beta accumulation in the Sgo1(-/+)model is suggested to be
   triggered by GSK3 inactivation and the resulting Wnt activation and
   ARC/Arg3.1 accumulation. The model displayed characteristics and
   affected pathways similar to those of human LOAD including
   neuroinflammation, demonstrating its potential as a study tool for the
   LOAD development mechanism and for preclinical AD drug research and
   development.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Rao, CV; Yamada, HY (Corresponding Author), Univ Oklahoma, Ctr Canc Prevent \& Drug Dev, Dept Med, Hematol Oncol Sect,Hlth Sci Ctr OUHSC, 975 NE 10th St BRC1207, Oklahoma City, OK 73104 USA.
   Rao, Chinthalapally, V; Zhang, Yuting; Yamada, Hiroshi Y., Univ Oklahoma, Ctr Canc Prevent \& Drug Dev, Dept Med, Hematol Oncol Sect,Hlth Sci Ctr OUHSC, 975 NE 10th St BRC1207, Oklahoma City, OK 73104 USA.
   Farooqui, Mudassir, Univ Iowa Hosp \& Clin, Dept Neurol, Iowa City, IA 52242 USA.
   Madhavaram, Avanish, Univ N Carolina, Biol Exercise \& Sports Sci, Chapel Hill, NC 27515 USA.
   Asch, Adam S., Univ Oklahoma, Stephenson Canc Ctr, Dept Med, Hematol Oncol Sect,Hlth Sci Ctr OUHSC, Oklahoma City, OK 73104 USA.},
DOI = {10.1111/acel.13221},
EarlyAccessDate = {AUG 2020},
Article-Number = {e13221},
ISSN = {1474-9718},
EISSN = {1474-9726},
Keywords = {amyloid-beta; cohesinopathy; genomic instability; late-onset Alzheimer's
   disease; mitosis; mouse model; neuroinflammation; Shugoshin1},
Keywords-Plus = {ALZHEIMERS-DISEASE; CHROMOSOMAL INSTABILITY; MITOCHONDRIAL ACONITASE;
   ALPHA; COHESION; ANEUPLOIDY; DISORDERS; PATHWAY; MODELS; CANCER},
Research-Areas = {Cell Biology; Geriatrics \& Gerontology},
Web-of-Science-Categories  = {Cell Biology; Geriatrics \& Gerontology},
Author-Email = {cv-rao@ouhsc.edu
   hiroshi-yamada@ouhsc.edu},
Affiliations = {University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Iowa; University of North Carolina; University of
   North Carolina Chapel Hill; University of Oklahoma System; University of
   Oklahoma Health Sciences Center},
ResearcherID-Numbers = {Farooqui, Mudassir/K-8382-2019
   Rao, Chinthalapally/B-3633-2010},
ORCID-Numbers = {Yamada, Hiroshi/0000-0002-0536-5581
   Madhavaram, Avanish/0000-0003-3865-4491
   Rao, Chinthalapally/0000-0002-5715-7979},
Funding-Acknowledgement = {Kerley-Cade Chair fund; Stephenson Cancer Center; Oklahoma Nathan Shock
   Center for Excellence in the Basic Biology of Aging; Cancer
   Undergraduate Research Experience (CURE) program fund from the
   Stephenson Cancer Center},
Funding-Text = {This work was supported by the Kerley-Cade Chair fund to C.V. Rao; by
   research funds from the Stephenson Cancer Center and by a Pilot Project
   Award from the Oklahoma Nathan Shock Center for Excellence in the Basic
   Biology of Aging to H.Y. Yamada; and by the Cancer Undergraduate
   Research Experience (CURE) program fund from the Stephenson Cancer
   Center to A. Madhavaram.},
Cited-References = {Andrew RJ, 2016, J BIOL CHEM, V291, P19235, DOI 10.1074/jbc.R116.746032.
   Andriani GA, 2017, MECH AGEING DEV, V161, P19, DOI 10.1016/j.mad.2016.03.007.
   Avrahami L, 2013, J BIOL CHEM, V288, P1295, DOI 10.1074/jbc.M112.409250.
   Bajic V, 2015, NEUROSCI BIOBEHAV R, V55, P365, DOI 10.1016/j.neubiorev.2015.05.010.
   Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432.
   Beck JS, 2016, CURR ALZHEIMER RES, V13, P610, DOI 10.2174/1567205013666151221145445.
   Belkhelfa M, 2014, J INTERF CYTOK RES, V34, P839, DOI 10.1089/jir.2013.0085.
   Bhaskar K, 2014, NEUROBIOL DIS, V62, P273, DOI 10.1016/j.nbd.2013.10.007.
   Bredesen D., 2017, The end of Alzheimers: The first program to prevent and reverse cognitive decline.
   Bredesen DE, 2015, AGING-US, V7, P595, DOI 10.18632/aging.100801.
   Butterfield DA, 2006, NEUROBIOL DIS, V22, P223, DOI 10.1016/j.nbd.2005.11.002.
   Carmona Susana, 2018, Handb Clin Neurol, V148, P395, DOI 10.1016/B978-0-444-64076-5.00026-0.
   Chiasserini D, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0276-4.
   Cummings J, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0207-9.
   Cummings JL, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt269.
   De Chiara G, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007617.
   Drummond E, 2017, ACTA NEUROPATHOL, V133, P155, DOI 10.1007/s00401-016-1662-x.
   Fan LY, 2020, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01312.
   Giri M, 2016, CLIN INTERV AGING, V11, P665, DOI 10.2147/CIA.S105769.
   Gozdz A, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00192.
   Höglund K, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2016.252.
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718.
   Hou YJ, 2017, MECH AGEING DEV, V161, P83, DOI 10.1016/j.mad.2016.04.005.
   Huang LK, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0609-7.
   Jankowsky JL, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0231-7.
   Jimenez S, 2011, J BIOL CHEM, V286, P18414, DOI 10.1074/jbc.M110.209718.
   Khodagholi F, 2018, CURR DRUG TARGETS, V19, P973, DOI 10.2174/1389450118666170816124203.
   Lachén-Montes M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09481-x.
   Lee SL, 2015, MUTAT RES-FUND MOL M, V776, P54, DOI 10.1016/j.mrfmmm.2014.12.012.
   Mangialasche F, 2015, J ALZHEIMERS DIS, V44, P649, DOI 10.3233/JAD-142052.
   Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640.
   Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3.
   Rao CV, 2020, AGING CELL, V19, DOI 10.1111/acel.13109.
   Rao CV, 2018, CELL CYCLE, V17, P2321, DOI 10.1080/15384101.2018.1515554.
   Rao CV, 2018, AGING CELL, V17, DOI 10.1111/acel.12797.
   Rao CV, 2017, MOL CARCINOGEN, V56, P791, DOI 10.1002/mc.22539.
   Rochoy M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220174.
   Saito Takashi, 2018, Clin Exp Neuroimmunol, V9, P211, DOI {[}10.1111/cen3.12475, 10.1111/cen3.12475].
   Salic A, 2004, CELL, V118, P567, DOI 10.1016/j.cell.2004.08.016.
   Sansregret L, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a028373.
   Sasaguri H, 2017, EMBO J, V36, P2473, DOI 10.15252/embj.201797397.
   Schöckel L, 2011, NAT CELL BIOL, V13, P966, DOI 10.1038/ncb2280.
   Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781.
   Shepherd CE, 2018, NEUROSCIENCE, V374, P326, DOI 10.1016/j.neuroscience.2018.01.050.
   Simon Judith E, 2015, Recent Results Cancer Res, V200, P39, DOI 10.1007/978-3-319-20291-4\_2.
   Skaper SD, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00072.
   Takata H, 2007, CURR BIOL, V17, P1356, DOI 10.1016/j.cub.2007.07.009.
   Waltereit R, 2001, J NEUROSCI, V21, P5484, DOI 10.1523/JNEUROSCI.21-15-05484.2001.
   Wilkins HM, 2017, BRAIN RES BULL, V133, P71, DOI 10.1016/j.brainresbull.2016.08.009.
   Wu J, 2011, CELL, V147, P615, DOI 10.1016/j.cell.2011.09.036.
   Yamada HY, 2015, CARCINOGENESIS, V36, P429, DOI 10.1093/carcin/bgv011.
   Yamada HY, 2012, CELL CYCLE, V11, P479, DOI 10.4161/cc.11.3.18994.
   Yates SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114050.
   Zhang L, 2015, GENET MOL RES, V14, P7218, DOI 10.4238/2015.June.29.15.
   Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150.
   Zivkovic L, 2010, J GERONTOL A-BIOL, V65, P1269, DOI 10.1093/gerona/glq148.},
Number-of-Cited-References = {56},
Times-Cited = {21},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Aging Cell},
Doc-Delivery-Number = {OL3DN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000563333300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000558826900016,
Author = {Yan, Jie and Hedl, Matija and Abraham, Clara},
Title = {Myeloid Cell-Intrinsic IRF5 Promotes T Cell Responses through Multiple
   Distinct Checkpoints In Vivo, and IRF5 Immune-Mediated Disease
   Risk Variants Modulate These Myeloid Cell Functions},
Journal = {JOURNAL OF IMMUNOLOGY},
Year = {2020},
Volume = {205},
Number = {4},
Pages = {1024-1038},
Month = {AUG 15},
Abstract = {Common IRF5 genetic risk variants associated with multiple
   immune-mediated diseases are a major determinant of interindividual
   variability in pattern-recognition receptor (PRR)-induced cytokines in
   myeloid cells. However, how myeloid cell-intrinsic IRF5 regulates the
   multiple distinct checkpoints mediating T cell outcomes in vivo and
   IRF5-dependent mechanisms contributing to these distinct checkpoints are
   not well defined. Using an in vivo Ag-specific adoptive T cell transfer
   approach into Irf5(-/-) mice, we found that T cell-extrinsic IRF5
   regulated T cell outcomes at multiple critical checkpoints, including
   chemokine-mediated T cell trafficking into lymph nodes and
   PDK1-dependent soluble Ag uptake, costimulatory molecule upregulation,
   and secretion of Thl (IL-12)- and Th17 (IL-23, IL-1 beta, and
   IL-6)-conditioning cytokines by myeloid cells, which then
   cross-regulated Th2 and regulatory T cells. IRF5 was required for
   PRR-induced MAPK and NF-kappa B activation, which, in turn, regulated
   these key outcomes in myeloid cells. Importantly, mice with IRF5 deleted
   from myeloid cells demonstrated T cell outcomes similar to those
   observed in Irf5(-/-) mice. Complementation of IL-12 and IL-23 was able
   to restore T cell differentiation both in vitro and in vivo in the
   context of myeloid cell-deficient IRF5. Finally, human monocyte-derived
   dendritic cells from IRF5 disease-associated genetic risk carriers
   leading to increased IRF5 expression demonstrated increased Ag uptake
   and increased PRR-induced costimulatory molecule expression and
   chemokine and cytokine secretion compared with monocyte-derived
   dendritic cells from low-expressing IRF5 genetic variant carriers. These
   data establish that myeloid cell-intrinsic IRF5 regulates multiple
   distinct checkpoints in T cell activation and differentiation and that
   these are modulated by IRF5 disease risk variants.},
Publisher = {OXFORD UNIV PRESS},
Address = {GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Abraham, C (Corresponding Author), Dept Internal Med, Sect Digest Dis, 333 Cedar St,LMP 1080, New Haven, CT 06520 USA.
   Yan, Jie; Hedl, Matija; Abraham, Clara, Yale Univ, Dept Internal Med, New Haven, CT 06520 USA.},
DOI = {10.4049/jimmunol.1900743},
ISSN = {0022-1767},
EISSN = {1550-6606},
Keywords-Plus = {INTERFERON REGULATORY FACTOR; TRANSCRIPTION FACTOR; MACROPHAGE
   POLARIZATION; CYTOKINE SECRETION; DENDRITIC CELLS; EXPRESSION;
   CHEMOKINE; LUPUS; DIFFERENTIATION; DEFICIENCY},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Author-Email = {clara.abraham@yale.edu},
Affiliations = {Yale University},
Funding-Acknowledgement = {National Institutes of Health {[}R01AI120369, R01DK099097]; Crohn's and
   Colitis Foundation; National Institute of Diabetes and Digestive and
   Kidney Diseases {[}R01DK099097] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported by National Institutes of Health R01AI120369 and
   R01DK099097 and the Crohn's and Colitis Foundation.},
Cited-References = {Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647.
   Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200.
   Byrne AJ, 2017, MUCOSAL IMMUNOL, V10, P716, DOI 10.1038/mi.2016.92.
   Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053.
   CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591.
   Courties G, 2014, J AM COLL CARDIOL, V63, P1556, DOI 10.1016/j.jacc.2013.11.023.
   Dalmas E, 2015, NAT MED, V21, P610, DOI 10.1038/nm.3829.
   Eames HL, 2016, TRANSL RES, V167, P167, DOI 10.1016/j.trsl.2015.06.018.
   Feng D, 2012, EUR J IMMUNOL, V42, P1477, DOI 10.1002/eji.201141642.
   Foreman HCC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033098.
   Förster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8.
   Graham RR, 2006, NAT GENET, V38, P550, DOI 10.1038/ng1782.
   Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451.
   Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258.
   Hedl M, 2016, CELL REP, V16, P2442, DOI 10.1016/j.celrep.2016.07.060.
   Hedl M, 2012, J IMMUNOL, V188, P5348, DOI 10.4049/jimmunol.1103319.
   Inoue M, 2014, P NATL ACAD SCI USA, V111, P5295, DOI 10.1073/pnas.1321427111.
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582.
   Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731.
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990.
   Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744.
   Li J, 2016, INFLAMMATION, V39, P1704, DOI 10.1007/s10753-016-0405-4.
   Lopez-Pelaez M, 2014, P NATL ACAD SCI USA, V111, P17432, DOI 10.1073/pnas.1418399111.
   Min J, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.292.
   Oriss TB, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91019.
   Pandey SP, 2019, MUCOSAL IMMUNOL, V12, P874, DOI 10.1038/s41385-019-0165-1.
   Paun A, 2008, J BIOL CHEM, V283, P14295, DOI 10.1074/jbc.M800501200.
   Paun A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001246.
   Saigusa R, 2015, P NATL ACAD SCI USA, V112, P15136, DOI 10.1073/pnas.1520997112.
   Saliba DG, 2014, CELL REP, V8, P1308, DOI 10.1016/j.celrep.2014.07.034.
   Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308.
   Voo KS, 2009, P NATL ACAD SCI USA, V106, P4793, DOI 10.1073/pnas.0900408106.
   Watkins AA, 2015, J IMMUNOL, V194, P1467, DOI 10.4049/jimmunol.1402807.
   Weiss M, 2015, P NATL ACAD SCI USA, V112, P11001, DOI 10.1073/pnas.1506254112.
   Xu M, 2018, NATURE, V554, P373, DOI 10.1038/nature25500.
   Xu Y, 2012, J IMMUNOL, V188, P4113, DOI 10.4049/jimmunol.1103113.
   Xu ZP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16035.
   Zheng SS, 2013, MOL CELL BIOL, V33, P4857, DOI 10.1128/MCB.00797-13.
   Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878.},
Number-of-Cited-References = {39},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {J. Immunol.},
Doc-Delivery-Number = {MZ0PY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000558826900016},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000563913600001,
Author = {Lindner, Andreas U. and Carberry, Steven and Monsefi, Naser and Barat,
   Ana and Salvucci, Manuela and O'Byrne, Robert and Zanella, Eugenia R.
   and Cremona, Mattia and Hennessy, Bryan T. and Bertotti, Andrea and
   Trusolino, Livio and Prehn, Jochen H. M.},
Title = {Systems analysis of protein signatures predicting cetuximab responses in
   KRAS, NRAS, BRAF and PIK3CA wild-type
   patient-derived xenograft models of metastatic colorectal cancer},
Journal = {INTERNATIONAL JOURNAL OF CANCER},
Year = {2020},
Volume = {147},
Number = {10},
Pages = {2891-2901},
Month = {NOV 15},
Abstract = {Antibodies targeting the human epidermal growth factor receptor (EGFR)
   are used for the treatment ofRASwild-type metastatic colorectal cancer.
   A significant proportion of patients remains unresponsive to this
   therapy. Here, we performed a reverse-phase protein array-based
   (phospho)protein analysis of 63KRAS,NRAS,BRAFandPIK3CAwild-type
   metastatic CRC tumours. Responses of tumours to anti-EGFR therapy with
   cetuximab were recorded in patient-derived xenograft (PDX) models.
   Unsupervised hierarchical clustering of pretreatment tumour tissue
   identified three clusters, of which Cluster C3 was exclusively composed
   of responders. Clusters C1 and C2 exhibited mixed responses. None of the
   three protein clusters exhibited a significant correlation with
   transcriptome-based subtypes. Analysis of protein signatures across all
   PDXs identified 14 markers that discriminated cetuximab-sensitive and
   cetuximab-resistant tumours: PDK1 (S241), caspase-8, Shc (Y317), Stat3
   (Y705), p27, GSK-3 beta (S9), HER3, PKC-alpha (S657), EGFR (Y1068), Akt
   (S473), S6 ribosomal protein (S240/244), HER3 (Y1289), NF-kappa B-p65
   (S536) and Gab-1 (Y627). Least absolute shrinkage and selection operator
   and binominal logistic regression analysis delivered refined protein
   signatures for predicting response to cetuximab. (Phospo-)protein
   analysis of matched pretreated and posttreated models furthermore showed
   significant reduction of Gab-1 (Y627) and GSK-3 beta (S9) exclusively in
   responding models, suggesting novel targets for treatment.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Prehn, JHM (Corresponding Author), Royal Coll Surgeons Ireland, Dept Physiol \& Med Phys, 123 St Stephens Green, Dublin 2, Ireland.
   Prehn, JHM (Corresponding Author), Royal Coll Surgeons Ireland, Ctr Syst Med, 123 St Stephens Green, Dublin 2, Ireland.
   Lindner, Andreas U.; Carberry, Steven; Monsefi, Naser; Barat, Ana; Salvucci, Manuela; O'Byrne, Robert; Prehn, Jochen H. M., Royal Coll Surgeons Ireland, Dept Physiol \& Med Phys, 123 St Stephens Green, Dublin 2, Ireland.
   Lindner, Andreas U.; Carberry, Steven; Monsefi, Naser; Barat, Ana; Salvucci, Manuela; O'Byrne, Robert; Prehn, Jochen H. M., Royal Coll Surgeons Ireland, Ctr Syst Med, 123 St Stephens Green, Dublin 2, Ireland.
   Zanella, Eugenia R.; Bertotti, Andrea; Trusolino, Livio, Fdn Piemonte Oncol IRCCS, Translat Canc Med Surg Oncol \& Clin Trials Coordi, Candiolo Canc Inst, Turin, Italy.
   Cremona, Mattia; Hennessy, Bryan T., Royal Coll Surgeons Ireland, Beaumont Hosp, Dept Med Oncol, Dublin, Ireland.
   Bertotti, Andrea; Trusolino, Livio, Univ Turin, Dept Oncol, Med Sch, Turin, Italy.},
DOI = {10.1002/ijc.33226},
EarlyAccessDate = {AUG 2020},
ISSN = {0020-7136},
EISSN = {1097-0215},
Keywords = {anti-EGFR; apoptosis; deterministic modelling; metastatic colorectal
   cancer; molecular subtyping; proliferation; reverse-phase protein array},
Keywords-Plus = {GENOMIC LANDSCAPE; PROLIFERATION; ASSOCIATION; ACTIVATION; RESISTANCE;
   INHIBITORS; EXPRESSION; EFFICACY; SUBTYPES; ANTIBODY},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {prehn@rcsi.ie},
Affiliations = {Royal College of Surgeons - Ireland; Royal College of Surgeons -
   Ireland; IRCCS Fondazione del Piemonte per l'Oncologia; Beaumont
   Hospital Dublin; Royal College of Surgeons - Ireland; University of
   Turin},
ResearcherID-Numbers = {Zanella, Eugenia Rosalinda/AAC-2369-2022
   Prehn, Jochen/A-3928-2010
   Trusolino, Livio/A-3896-2011},
ORCID-Numbers = {Zanella, Eugenia Rosalinda/0000-0002-8036-3789
   Bertotti, Anea/0000-0001-8196-7608
   Hennessy, Bryan/0000-0002-7871-6477
   Lindner, Aneas/0000-0003-1590-3547
   Trusolino, Livio/0000-0002-6379-3365},
Funding-Acknowledgement = {Science Foundation Ireland; Health Research Board {[}13/IA/1881,
   14/IA/2582, 15/ERACSM/3268, 16/US/3301]; AIRC (Associazione Italiana per
   la Ricerca sul Cancro) Investigator Grant {[}22802]; AIRC 5x1000 grant
   {[}21091]; AIRC/CRUK/FC AECC Accelerator Award {[}22795]; Fondazione
   Piemontese per la Ricerca sul Cancro-ONLUS; 5x1000 Ministero della
   Salute 2014; 5x1000 Ministero della Salute 2015; 5x1000 Ministero della
   Salute 2016},
Funding-Text = {Our study was supported by grants from Science Foundation Ireland and
   the Health Research Board to JHMP (13/IA/1881, 14/IA/2582,
   15/ERACSM/3268 and 16/US/3301). LT is supported by AIRC (Associazione
   Italiana per la Ricerca sul Cancro) Investigator Grant 22802, AIRC
   5x1000 grant 21091 (to LT), AIRC/CRUK/FC AECC Accelerator Award 22795,
   Fondazione Piemontese per la Ricerca sul Cancro-ONLUS and 5x1000
   Ministero della Salute 2014, 2015 and 2016. LT is a member of the
   EuroPDX Consortium.},
Cited-References = {Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969.
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109.
   Bosch-Vilaró A, 2017, ONCOTARGET, V8, P4277, DOI 10.18632/oncotarget.13834.
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476.
   Brunet JP, 2004, P NATL ACAD SCI USA, V101, P4164, DOI 10.1073/pnas.0308531101.
   Campbell MR, 2010, CLIN CANCER RES, V16, P1373, DOI 10.1158/1078-0432.CCR-09-1218.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Chiorean EG, 2020, JCO GLOB ONCOL, V6, P414, DOI 10.1200/JGO.19.00367.
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6.
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3.
   Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102.
   Flanagan L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.7.
   Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2.
   Frolov A, 2007, CANCER BIOL THER, V6, P548, DOI 10.4161/cbt.6.4.3849.
   Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367.
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046.
   Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9.
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313.
   Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393.
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967.
   Guo HF, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-56.
   Isella C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15107.
   Lee DD, 1999, NATURE, V401, P788, DOI 10.1038/44565.
   Lenz HJ, 2019, J CLIN ONCOL, V37, P1876, DOI 10.1200/JCO.18.02258.
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157.
   Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200.
   Lindner AU, 2017, GUT, V66, P2141, DOI 10.1136/gutjnl-2016-312287.
   Lindner AU, 2013, CANCER RES, V73, P519, DOI 10.1158/0008-5472.CAN-12-2269.
   Maeng YS, 2016, SCI REP-UK, V6, DOI 10.1038/srep20739.
   Martinez A, 2008, MED RES REV, V28, P773, DOI 10.1002/med.20119.
   Marzi L, 2016, BRIT J CANCER, V115, P1223, DOI 10.1038/bjc.2016.313.
   Napolitano S, 2015, CLIN CANCER RES, V21, P2975, DOI 10.1158/1078-0432.CCR-15-0020.
   Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282.
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370.
   Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789.
   Puig I, 2013, CLIN CANCER RES, V19, P6787, DOI 10.1158/1078-0432.CCR-12-1740.
   Rehm M, 2006, EMBO J, V25, P4338, DOI 10.1038/sj.emboj.7601295.
   Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000.
   Salvucci M, 2017, CLIN CANCER RES, V23, P1200, DOI 10.1158/1078-0432.CCR-16-1084.
   Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-05-1554.
   Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807.
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041.
   Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x.
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299.
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498.
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235.
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019.
   Woodgett J R, 2001, Sci STKE, V2001, pre12, DOI 10.1126/stke.2001.100.re12.
   Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013.
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004.
   Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445.
   Zheng Y, 2013, NATURE, V499, P166, DOI 10.1038/nature12308.
   Zhu Q, 2011, PROSTATE, V71, P835, DOI 10.1002/pros.21300.},
Number-of-Cited-References = {53},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {1},
Journal-ISO = {Int. J. Cancer},
Doc-Delivery-Number = {NS2WX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000563913600001},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000563031500001,
Author = {Chu, Nam and Viennet, Thibault and Bae, Hwan and Salguero, Antonieta and
   Boeszoermenyi, Andras and Arthanari, Haribabu and Cole, Philip A.},
Title = {The structural determinants of PH domain-mediated regulation of Akt
   revealed by segmental labeling},
Journal = {ELIFE},
Year = {2020},
Volume = {9},
Month = {AUG 3},
Abstract = {Akt is a critical protein kinase that governs cancer cell growth and
   metabolism. Akt appears to be autoinhibited by an intramolecular
   interaction between its N-terminal pleckstrin homology (PH) domain and
   kinase domain, which is relieved by C-tail phosphorylation, but the
   precise molecular mechanisms remain elusive. Here, we use a combination
   of protein semisynthesis, NMR, and enzymological analysis to
   characterize structural features of the PH domain in its autoinhibited
   and activated states. We find that Akt autoinhibition depends on the
   length/flexibility of the PH-kinase linker. We identify a role for a
   dynamic short segment in the PH domain that appears to regulate
   autoinhibition and PDK1-catalyzed phosphorylation of Thr308 in the
   activation loop. We determine that Akt allosteric inhibitor MK2206
   drives distinct PH domain structural changes compared to baseline
   autoinhibited Akt. These results highlight how the conformational
   plasticity of Akt governs the delicate control of its catalytic
   properties.},
Publisher = {ELIFE SCIENCES PUBLICATIONS LTD},
Address = {SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Cole, PA (Corresponding Author), Brigham \& Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
   Arthanari, H; Cole, PA (Corresponding Author), Harvard Med Sch, Dept Biol Chem \& Mol Pharmacol, Boston, MA 02115 USA.
   Cole, PA (Corresponding Author), Johns Hopkins Sch Med, Dept Pharmacol \& Mol Sci, Baltimore, MD 21205 USA.
   Arthanari, H (Corresponding Author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
   Chu, Nam; Bae, Hwan; Salguero, Antonieta; Cole, Philip A., Brigham \& Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
   Chu, Nam; Viennet, Thibault; Bae, Hwan; Salguero, Antonieta; Boeszoermenyi, Andras; Arthanari, Haribabu; Cole, Philip A., Harvard Med Sch, Dept Biol Chem \& Mol Pharmacol, Boston, MA 02115 USA.
   Chu, Nam; Salguero, Antonieta; Cole, Philip A., Johns Hopkins Sch Med, Dept Pharmacol \& Mol Sci, Baltimore, MD 21205 USA.
   Viennet, Thibault; Boeszoermenyi, Andras; Arthanari, Haribabu, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.},
DOI = {10.7554/eLife.59151},
Article-Number = {e59151},
ISSN = {2050-084X},
Keywords-Plus = {PLECKSTRIN HOMOLOGY DOMAIN; PROTEIN-KINASE-B; INHIBITOR MK-2206;
   IN-VITRO; ACTIVATION; BINDING; PHOSPHORYLATION; MECHANISM; DISCOVERY;
   LIGATION},
Research-Areas = {Life Sciences \& Biomedicine - Other Topics},
Web-of-Science-Categories  = {Biology},
Author-Email = {hari\_arthanari@hms.harvard.edu
   pacole@bwh.harvard.edu},
Affiliations = {Harvard University; Harvard University Medical Affiliates; Brigham \&
   Women's Hospital; Harvard University; Harvard Medical School; Johns
   Hopkins University; Johns Hopkins Medicine; Harvard University; Harvard
   University Medical Affiliates; Dana-Farber Cancer Institute},
ResearcherID-Numbers = {Boeszoermenyi, Anas/AAD-9808-2020
   Viennet, Thibault/F-1576-2016
   Chu, Nam/AAY-8247-2021},
ORCID-Numbers = {Boeszoermenyi, Anas/0000-0001-9810-7241
   Bae, Hwan/0000-0001-5252-252X
   Arthanari, Haribabu/0000-0002-7281-1289
   Viennet, Thibault/0000-0001-5349-0179
   Chu, Nam/0000-0001-9717-5007},
Funding-Acknowledgement = {National Cancer Institute {[}CA74305]; Claudia Adams Barr Program in
   Innovative Cancer Research; Austrian Science Fund Schroedinger
   Fellowship; American Heart Association {[}19POST34380800]; National
   Institutes of Health {[}EB002026]; Kwanjeong Educational Foundation
   Pre-doctoral fellowship; National Cancer Institute {[}R01CA074305]
   Funding Source: NIH RePORTER; National Institute of General Medical
   Sciences {[}T32GM080189] Funding Source: NIH RePORTER; American Heart
   Association (AHA) {[}19POST34380800] Funding Source: American Heart
   Association (AHA)},
Funding-Text = {National Cancer Institute CA74305 Philip A ColeClaudia Adams Barr
   Program in Innovative Cancer Research Haribabu ArthanariAustrian Science
   Fund Schroedinger Fellowship Andras BoeszoermenyiAmerican Heart
   Association 19POST34380800 Andras BoeszoermenyiNational Institutes of
   Health EB002026 Haribabu ArthanariKwanjeong Educational Foundation
   Pre-doctoral fellowship Hwan BaeThe funders had no role in study design,
   data collection and interpretation, or the decision to submit the work
   for publication.},
Cited-References = {Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Ashwell MA, 2012, J MED CHEM, V55, P5291, DOI 10.1021/jm300276x.
   Askham JM, 2010, ONCOGENE, V29, P150, DOI 10.1038/onc.2009.315.
   Auguin D, 2004, J BIOMOL NMR, V28, P137, DOI 10.1023/B:JNMR.0000013836.62154.c2.
   Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947.
   Bolduc D, 2013, ELIFE, V2, DOI 10.7554/eLife.00691.
   Bozulic L, 2008, MOL CELL, V30, P203, DOI 10.1016/j.molcel.2008.02.024.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Calleja V, 2009, PLOS BIOL, V7, P189, DOI 10.1371/journal.pbio.1000017.
   Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933.
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003.
   Cole PA, 2019, CURR OPIN STRUC BIOL, V59, P47, DOI 10.1016/j.sbi.2019.02.004.
   Coote PW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05400-4.
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809.
   Dempsey DR, 2018, J AM CHEM SOC, V140, P9374, DOI 10.1021/jacs.8b05098.
   Ebner M, 2017, MOL CELL, V65, P416, DOI 10.1016/j.molcel.2016.12.028.
   Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600.
   Haeusler RA, 2018, NAT REV MOL CELL BIO, V19, P31, DOI 10.1038/nrm.2017.89.
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012.
   Hyberts SG, 2012, J BIOMOL NMR, V52, P315, DOI 10.1007/s10858-012-9611-z.
   Lapierre JM, 2016, J MED CHEM, V59, P6455, DOI 10.1021/acs.jmedchem.6b00619.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Liao Y, 2010, AM J TRANSL RES, V2, P19.
   Liu DS, 2009, METHOD ENZYMOL, V462, P151, DOI 10.1016/S0076-6879(09)62008-5.
   Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079.
   Lucic I, 2018, P NATL ACAD SCI USA, V115, pE3940, DOI 10.1073/pnas.1716109115.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Meuillet EJ, 2011, CURR MED CHEM, V18, P2727.
   Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229.
   Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705.
   Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306.
   Pace CN, 1998, BIOPHYS J, V75, P422, DOI 10.1016/S0006-3495(98)77529-0.
   Parikh C, 2012, P NATL ACAD SCI USA, V109, P19368, DOI 10.1073/pnas.1204384109.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366.
   Qiu C, 2009, BIOCHEMISTRY-US, V48, P6624, DOI 10.1021/bi900755n.
   Sangai T, 2012, CLIN CANCER RES, V18, P5816, DOI 10.1158/1078-0432.CCR-12-1141.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Schumann FH, 2007, J BIOMOL NMR, V39, P275, DOI 10.1007/s10858-007-9197-z.
   Seamon KJ, 2015, NUCLEIC ACIDS RES, V43, P6486, DOI 10.1093/nar/gkv633.
   Shimada I, 2005, METHOD ENZYMOL, V394, P483, DOI 10.1016/S0076-6879(05)94020-2.
   Takahashi H, 2000, NAT STRUCT BIOL, V7, P220.
   Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7.
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449.
   Weisner J, 2015, ANGEW CHEM INT EDIT, V54, P10313, DOI {[}10.1002/ange.201502142, 10.1002/anie.201502142].
   Wu WI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012913.
   Wüthrich K, 2000, NAT STRUCT BIOL, V7, P188, DOI 10.1038/73278.
   Xu R, 1999, P NATL ACAD SCI USA, V96, P388, DOI 10.1073/pnas.96.2.388.
   Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263.},
Number-of-Cited-References = {53},
Times-Cited = {62},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {eLife},
Doc-Delivery-Number = {NF0ZJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000563031500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000575211000001,
Author = {Ahsan, Md Kaimul and Figueroa-Hall, Leandra and Baratta, Vanessa and
   Garcia-Milian, Rolando and Lam, TuKiet T. and Hoque, Kazi and Salas,
   Pedro J. and Ameen, Nadia A.},
Title = {Glucocorticoids and serum- and glucocorticoid-inducible kinase 1 are
   potent regulators of CFTR in the native intestine: implications for
   stress-induced diarrhea},
Journal = {AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY},
Year = {2020},
Volume = {319},
Number = {2},
Pages = {G121-G132},
Month = {AUG},
Abstract = {Nongenomic glucocorticoid (GC) and serum- and glucocorticoid-inducible
   kinase 1 (SGK1) signaling regulate ion transport, but CFTR has not been
   investigated in the intestine. We examined GC. SGK1, and
   phosphatidylinositol 3-kinase (PI3K) kinase signaling of CFTR ion
   transport in native intestine and the role of GCs on mRNA, protein,
   surface expression, and cyclic guanosine monophosphate (cGMP)-elicited
   diarrhea. Rats were treated with dexamethasone (DEXA: 2 mg/kg ip) or
   DMSO for 1. 4, and 24 h. Cyclic adenosine monophosphate (cAMP)-activated
   ion transport was examined in the presence or absence of SGK1 and P13K
   inhibitors. Phosphorylation of SGK1, phosphoinositide-dependent kinase
   1, and Akt kinases was confirmed by immunoblots using phosphor-specific
   antibodies. Tissue lysates were analyzed by mass spectrometry. CFTR and
   SGK1 mRNA were measured by quantitative PCR. Changes in total and
   surface CFTR protein were determined. The role of GC in cGMP-activated
   CFTR ion transport was examined. GC synergistically increased CFTR ion
   transport by SGK1 and P13K signaling and increased CFTR protein without
   altering SGK1 or CFTR mRNA. GC induced highest levels of CI-TR protein
   at 4 h that were associated with marked increase in surface CFTR.
   phosphorylation of the ubiquitin ligase neural precursor cell expressed
   developmentally downregulated 4-like (Nedd4-2). and 14-3-3 epsilon,
   supporting their roles in surface retention and stability.
   Coimmunoprecipitation of CFTR, Nedd4-2, and 14-3-3 epsilon indicated
   that assembly of this complex is a likely effector of the SGK and Akt
   pathways. Mass spectrometry identified phosphorylated peptides in
   relevant proteins. GC-SGK1 potently regulates CFTR in the intestine and
   is implicated in diarrheal disease.
   NEW \& NOTEWORTHY This is the first study to examine the mechanisms of
   glucocorticoid. serum- and glucocorticoid-inducible kinase 1, and
   nongenomic kinase signaling of CFTR in the native intestine. We
   identified unique and druggable intestine-specific factors of the
   pathway that are targets for treating stress-induced diarrhea.},
Publisher = {AMER PHYSIOLOGICAL SOC},
Address = {6120 Executive Blvd, Suite 600, Rockville, MD, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Ameen, NA (Corresponding Author), Yale Sch Med, Dept Pediat Gastroenterol \& Hepatol, New Haven, CT 06510 USA.
   Ameen, NA (Corresponding Author), Yale Sch Med, Dept Pediat Cellular \& Mol Physiol, New Haven, CT 06510 USA.
   Ahsan, Md Kaimul; Figueroa-Hall, Leandra; Ameen, Nadia A., Yale Sch Med, Dept Pediat Gastroenterol \& Hepatol, New Haven, CT 06510 USA.
   Baratta, Vanessa, Yale Sch Med, Dept Surg, New Haven, CT USA.
   Garcia-Milian, Rolando, Yale Sch Med, Cushing Whitney Med Lib, Bioinformat Support Program, New Haven, CT USA.
   Lam, TuKiet T., Yale Univ, Dept Mol Biophys \& Biochem, New Haven, CT USA.
   Lam, TuKiet T., Yale Univ, WM Keck Biotechnol Resource Lab, Mass Spectrometry \& Prote Resource, New Haven, CT USA.
   Hoque, Kazi, Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.
   Salas, Pedro J., Univ Miami, Miller Sch Med, Dept Cell Biol, Miami, FL 33136 USA.
   Ameen, Nadia A., Yale Sch Med, Dept Pediat Cellular \& Mol Physiol, New Haven, CT 06510 USA.},
DOI = {10.1152/ajpgi.00076.2020},
ISSN = {0193-1857},
EISSN = {1522-1547},
Keywords = {CFTR; glucocorticoids; PDK1; PI3K; SGK1},
Keywords-Plus = {TRANSMEMBRANE CONDUCTANCE REGULATOR; EPITHELIAL-CELLS; SGK1; ACTIVATION;
   NHE3; PHOSPHORYLATION; TRAFFICKING; CHANNEL; TRANSPORT; REQUIRES},
Research-Areas = {Gastroenterology \& Hepatology; Physiology},
Web-of-Science-Categories  = {Gastroenterology \& Hepatology; Physiology},
Author-Email = {nadia.ameen@yale.edu},
Affiliations = {Yale University; Yale University; Yale University; Yale University; Yale
   University; University System of Maryland; University of Maryland
   Baltimore; University of Miami; Yale University},
ResearcherID-Numbers = {Garcia-Milian, Rolando/F-3913-2011
   Salas, Peo/AAS-9455-2021
   Figueroa-Hall, Leandra/JVN-0821-2024
   Lam, TuKiet/B-6343-2008
   Kazi, Mirajul/AAR-5291-2021},
ORCID-Numbers = {Kazi, Mirajul/0000-0001-5604-8650
   Garcia-Milian, Rolando/0000-0003-1557-566X
   Salas, Peo/0000-0002-7411-1366
   },
Funding-Acknowledgement = {National Institute of General Medical Sciences {[}5R01GM127953];
   Department of Internal Medicine, Yale University National Institute of
   Diabetes and Digestive and Kidney Diseases {[}T32 NIH DK007017-41]; Yale
   School of Medicine; NIH SIG {[}S10ODOD018034]; National Institute of
   General Medical Sciences {[}R01GM127953] Funding Source: NIH RePORTER},
Funding-Text = {This study was supported by National Institute of General Medical
   Sciences Grant 5R01GM127953 to P. J. Salas and Department of Internal
   Medicine, Yale University National Institute of Diabetes and Digestive
   and Kidney Diseases Grant T32 NIH DK007017-41 and Yale School of
   Medicine funds to N. A. Ameen. Proteomics data were collected on a mass
   spectrometer supported by NIH SIG S10ODOD018034 and Yale School of
   Medicine.},
Cited-References = {Ahsan MK, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13299.
   Al-Balool FY, 2004, PHYSIOL RES, V53, P669, DOI 10.33549/physiolres.930532.
   Ameen NA, 1999, J CELL SCI, V112, P887.
   Ameen N, 2007, J CYST FIBROS, V6, P1, DOI 10.1016/j.jcf.2006.09.002.
   Bhalla V, 2005, MOL ENDOCRINOL, V19, P3073, DOI 10.1210/me.2005-0193.
   Bomberger JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089599.
   Borowitz D, 2013, CURR OPIN PULM MED, V19, P676, DOI 10.1097/MCP.0b013e3283659ef2.
   Bossmann M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081807.
   Bozoky Z, 2013, P NATL ACAD SCI USA, V110, pE4427, DOI 10.1073/pnas.1315104110.
   Caohuy H, 2014, J BIOL CHEM, V289, P35953, DOI 10.1074/jbc.M114.598649.
   Caohuy H, 2009, J BIOL CHEM, V284, P25241, DOI 10.1074/jbc.M109.035345.
   Cha B, 2005, J BIOL CHEM, V280, P16642, DOI 10.1074/jbc.M500505200.
   Chandran S, 2011, J BIOL CHEM, V286, P37830, DOI 10.1074/jbc.M111.293233.
   Chen TN, 2019, AM J PHYSIOL-CELL PH, V317, pC737, DOI 10.1152/ajpcell.00351.2018.
   Collaco A, 2010, AM J PHYSIOL-CELL PH, V299, pC1450, DOI 10.1152/ajpcell.00029.2010.
   Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272.
   Fejes-Tóth G, 2008, AM J PHYSIOL-RENAL, V294, pF1298, DOI 10.1152/ajprenal.00579.2007.
   Forteza R, 2019, MOL BIOL CELL, V30, P3076, DOI 10.1091/mbc.E18-07-0415.
   Foulke-Abel J, 2016, GASTROENTEROLOGY, V150, P638, DOI 10.1053/j.gastro.2015.11.047.
   Golin-Bisello F, 2005, AM J PHYSIOL-CELL PH, V289, pC708, DOI 10.1152/ajpcell.00544.2004.
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267.
   Ismail NAS, 2014, EUR J PHARMACOL, V732, P32, DOI 10.1016/j.ejphar.2014.03.005.
   Jakab RL, 2012, AM J PHYSIOL-GASTR L, V303, pG937, DOI 10.1152/ajpgi.00452.2011.
   Jakab RL, 2011, AM J PHYSIOL-GASTR L, V300, pG82, DOI 10.1152/ajpgi.00245.2010.
   Jang SJ, 2017, IN VIVO, V31, P637, DOI 10.21873/invivo.11105.
   Jiang C, 2017, J BIOL CHEM, V292, P3137, DOI 10.1074/jbc.M116.770065.
   Koeppen K, 2014, J BIOL CHEM, V289, P17142, DOI 10.1074/jbc.M114.555599.
   Kravtsov DV, 2016, AM J PHYSIOL-GASTR L, V311, pG142, DOI 10.1152/ajpgi.00041.2016.
   Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005.
   Lang F, 2014, MOL MEMBR BIOL, V31, P29, DOI 10.3109/09687688.2013.874598.
   Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230.
   Laube M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124833.
   Liang XB, 2012, MOL BIOL CELL, V23, P996, DOI 10.1091/mbc.E11-08-0662.
   Lösel RM, 2003, PHYSIOL REV, V83, P965, DOI 10.1152/physrev.00003.2003.
   Löwenberg M, 2008, STEROIDS, V73, P1025, DOI 10.1016/j.steroids.2007.12.002.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Manning JA, 2018, TRENDS BIOCHEM SCI, V43, P635, DOI 10.1016/j.tibs.2018.06.004.
   Manning JA, 2018, CELL CYCLE, V17, P1, DOI 10.1080/15384101.2017.1386514.
   Monroy FP, 2008, EXP PARASITOL, V118, P134, DOI 10.1016/j.exppara.2007.07.008.
   Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057.
   Park J, 2013, LIFE SCI, V93, P700, DOI 10.1016/j.lfs.2013.09.007.
   Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2.
   Prota LFM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047405.
   Silvis MR, 2009, MOL BIOL CELL, V20, P2337, DOI 10.1091/mbc.E08-01-0084.
   Smith F, 2010, AM J PHYSIOL-GASTR L, V298, pG352, DOI 10.1152/ajpgi.00081.2009.
   Stahn C, 2008, NAT CLIN PRACT RHEUM, V4, P525, DOI 10.1038/ncprheum0898.
   Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935.
   Wang DS, 2007, AM J PHYSIOL-CELL PH, V292, pC396, DOI 10.1152/ajpcell.00345.2006.
   Wang DS, 2005, AM J PHYSIOL-CELL PH, V289, pC802, DOI 10.1152/ajpcell.00597.2004.
   WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031.
   WEBSTER MK, 1993, J BIOL CHEM, V268, P11482.
   Wiemuth D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012163.
   Yang L, 2017, AM J PHYSIOL-RENAL, V312, pF65, DOI 10.1152/ajprenal.00257.2016.
   Yun CC, 2002, J BIOL CHEM, V277, P7676, DOI 10.1074/jbc.M107768200.},
Number-of-Cited-References = {54},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Am. J. Physiol.-Gastroint. Liver Physiol.},
Doc-Delivery-Number = {NW7PL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000575211000001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000539426400037,
Author = {Wang, Wei and Zhao, Minghui and Zhao, Yong and Shen, Wei and Yin, Shen},
Title = {PDGFRα/β-PI3K-Akt pathway response to the interplay of mitochondrial
   dysfunction and DNA damage in Aroclor 1254-exposed porcine granulosa
   cells},
Journal = {ENVIRONMENTAL POLLUTION},
Year = {2020},
Volume = {263},
Number = {A},
Month = {AUG},
Abstract = {Metabolic dysfunction and genomic instability are known to affect female
   fertility. Aroclor 1254 (A1254) is an endocrine disruptor that affects
   mitochondrial function following ingestion, inhalation, or dermal
   exposure. Numerous studies to date have addressed associations between
   A1254 toxicity and chronic neurological disorders, while A1254 exposure
   is little known to have a toxic effect on the female reproductive
   system. Furthermore, interactive mechanisms between metabolic
   dysfunction and the repair of DNA damage deserve further investigation.
   In this paper, an in vitro porcine primary granulosa cell (GC) culture
   model was used to investigate the mechanisms of exposure and effects of
   the exogenous chemical carcinogen A1254 on reproductive toxicology.
   High-throughput RNA sequencing obtained 2329 differentially expressed
   genes (DEGs) to be analyzed using COG classification, GO, and KEGG. When
   combined with immunofluorescence, Western blot analysis, and real-time
   RT-PCR analysis, this data showed that the mitochondrial-ROS-driven
   feed-forward loop increased phospho-PDGFR alpha/beta, which stimulates
   apoptosis by suppressing the PI3K-Akt pathway. We also noticed that
   inhibition of the Akt-PDP1-PDK1 axis attenuated mitochondrial function.
   In contrast, following iPath analysis, partial metabolic pathways were
   enhanced. Importantly, we found that A1254 activated a DNA damage
   response, the major regulators of which belong to the PI3K-related
   protein kinases (PIKKs) and oncogenes, which led to the ``Warburg
   effect{''}. It is not easy to restore the damage that A1254 causes to
   metabolism through dysregulation and the Warburg effect, owing to the
   fact that oncogenes can regulate cytoplasmic metabolism. Therefore, we
   suspect that the PDGFR-PI3K-Akt pathway may be a latent interaction
   between mitochondrial dysfunction and the response of DNA damage. (c)
   2020 Elsevier Ltd. All rights reserved.},
Publisher = {ELSEVIER SCI LTD},
Address = {125 London Wall, London, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yin, S (Corresponding Author), Qingdao Agr Univ, Coll Life Sci, Inst Reprod Sci, Key Lab Anim Reprod \& Germplasm Enhancement,Univ, Qingdao 266109, Peoples R China.
   Wang, Wei; Zhao, Minghui; Zhao, Yong; Shen, Wei; Yin, Shen, Qingdao Agr Univ, Coll Life Sci, Inst Reprod Sci, Key Lab Anim Reprod \& Germplasm Enhancement,Univ, Qingdao 266109, Peoples R China.},
DOI = {10.1016/j.envpol.2020.114534},
Article-Number = {114534},
ISSN = {0269-7491},
EISSN = {1873-6424},
Keywords = {Polychlorinated biphenyls; Female reproductive health; ROS; Genomic
   instability},
Keywords-Plus = {IN-VITRO; METABOLISM; EXPRESSION; EXPOSURE; PACKAGE; PCBS},
Research-Areas = {Environmental Sciences \& Ecology},
Web-of-Science-Categories  = {Environmental Sciences},
Author-Email = {syin@qau.edu.cn},
Affiliations = {Qingdao Agricultural University},
ResearcherID-Numbers = {Zhao, Minghui/AAW-3267-2021},
Cited-References = {Alcigir ME, 2018, CNS NEUROL DISORD-DR, V17, P132, DOI 10.2174/1871527317666180315170146.
   Aly HAA, 2009, FOOD CHEM TOXICOL, V47, P1733, DOI 10.1016/j.fct.2009.03.019.
   Buck T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40329-8.
   Carpenter David O., 2006, Reviews on Environmental Health, V21, P1.
   Chaudhuri L, 2010, FREE RADICAL BIO MED, V49, P40, DOI 10.1016/j.freeradbiomed.2010.03.012.
   Chen R, 2019, ENVIRON INT, V130, DOI 10.1016/j.envint.2019.104914.
   Cheng SU, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35786-6.
   Chu S, 2008, GYNECOL ONCOL, V108, P182, DOI 10.1016/j.ygyno.2007.09.017.
   Crosby HA, 2010, MOL MICROBIOL, V76, P874, DOI 10.1111/j.1365-2958.2010.07127.x.
   Demel HR, 2015, AM J CANCER RES, V5, P1649.
   Drummond J, 2017, ECOTOXICOLOGY, V26, P141, DOI 10.1007/s10646-016-1749-0.
   Gonul LT, 2018, ENVIRON SCI POLLUT R, V25, P25162, DOI 10.1007/s11356-018-2528-7.
   González-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447.
   Haraguchi M, 2013, BIOCHEM BIOPH RES CO, V432, P618, DOI 10.1016/j.bbrc.2013.02.035.
   HSU ST, 1985, ENVIRON HEALTH PERSP, V59, P5, DOI 10.2307/3429867.
   Kessel DH, 2012, AUTOPHAGY, V8, P1333, DOI 10.4161/auto.20792.
   Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494.
   Liu QS, 2013, CANCER RES, V73, P2574, DOI 10.1158/0008-5472.CAN-12-1702.
   Maidarti M, 2019, HUM REPROD, V34, P297, DOI 10.1093/humrep/dey354.
   Mariño G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735.
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863.
   Needham TP, 2019, ENVIRON POLLUT, V246, P390, DOI 10.1016/j.envpol.2018.12.016.
   Pajokh M, 2018, IRAN J VET RES, V19, P298.
   Peluso JJ, 2019, BIOL REPROD, V100, P1571, DOI 10.1093/biolre/ioz043.
   Read RD, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.164285.
   Ren J, 2015, APPL ENVIRON MICROB, V81, P5675, DOI 10.1128/AEM.01009-15.
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616.
   Rude KM, 2019, ENVIRON POLLUT, V253, P708, DOI 10.1016/j.envpol.2019.07.066.
   Salha S, 2018, CLIN HEMORHEOL MICRO, V70, P543, DOI 10.3233/CH-189319.
   Saller S, 2012, ENDOCRINOLOGY, V153, P1472, DOI 10.1210/en.2011-1769.
   Selvakumar K, 2011, EXP TOXICOL PATHOL, V63, P105, DOI 10.1016/j.etp.2009.10.003.
   Su SH, 2018, FREE RADICAL BIO MED, V124, P122, DOI 10.1016/j.freeradbiomed.2018.06.003.
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120.
   Wang W, 2019, J AGR FOOD CHEM, V67, P19, DOI 10.1021/acs.jafc.8b05194.
   Wang W, 2018, ENVIRON TOXICOL PHAR, V64, P172, DOI 10.1016/j.etap.2018.11.002.
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519.
   Wei QW, 2019, REPROD FERT DEVELOP, V31, P1017, DOI 10.1071/RD18406.
   Yang FX, 2019, ENVIRON TOXICOL PHAR, V68, P52, DOI 10.1016/j.etap.2019.03.005.
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118.},
Number-of-Cited-References = {39},
Times-Cited = {11},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {25},
Journal-ISO = {Environ. Pollut.},
Doc-Delivery-Number = {LW8XJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000539426400037},
DA = {2026-02-04},
}

@article{ WOS:000567188300098,
Author = {Xiao, Dongliang and Zhou, Quan and Bai, Yiguang and Cao, Baichuan and
   Zhang, Qiong and Zeng, Gaofeng and Zong, Shaohui},
Title = {Deficiency of PDK1 in osteoclasts delays fracture healing and repair},
Journal = {MOLECULAR MEDICINE REPORTS},
Year = {2020},
Volume = {22},
Number = {2},
Pages = {1536-1546},
Month = {AUG},
Abstract = {Bone fractures are common traumatic injuries of the musculoskeletal
   system. However, delayed union and non-union fractures are a major
   clinical problem that present significant socioeconomic burden to
   patients and the public health sector. The bone-resorbing osteoclasts
   and bone-forming osteoblasts serve important roles in the fracture
   repair/healing process. Osteoclast deficiency or decreased osteoblast
   activity negatively impacts fracture healing. We previously demonstrated
   that the specific deletion of the serine/threonine kinase
   3-phosphoinositide-dependent protein kinase 1 (PDK1) in osteoclasts
   leads to abrogated osteoclast formation and bone resorption in response
   to receptor activator of nuclear factor-kappa B in vitro and protected
   mice against ovariectomized-induced bone loss and
   lipopolysaccharide-induced osteolysis in vivo. Given the importance of
   osteoclasts in fracture repair, we hypothesized that the specific loss
   of PDK1 in osteoclasts will alter the fracture healing process. Mice of
   tibial fracture were constructed, and tibial specimens were sampled at
   7-, 14-, 21- and 28-days post-fracture to observe the effect of PDK1
   gene regulated osteoclasts on fracture healing process by X-ray
   radiography, microcomputed tomography scanning, histomorphological
   staining and biomechanical testing. The present study revealed, using
   the tibial fracture model, that the specific deletion of the PDK1 gene
   in osteoclasts impeded the fracture healing process by delaying the
   resorption of the cartilaginous callus and subsequent remodeling of
   immature woven bone to structurally and mechanically ensure lamellar
   bone is stronger. No effect on osteoblast bone formation and
   osteogenesis was observed, thus indicating that delayed fracture healing
   is primarily due to defective osteoclast activity. These results provide
   important clinical implications for the use of anti-resorptive agents,
   such as bisphosphonates, for the treatment of osteolytic conditions.
   Such anti-resorptive therapies may detrimentally delay fracture healing
   and repair.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Zong, SH (Corresponding Author), Guangxi Med Univ, Dept Spine Osteopathia, Affiliated Hosp 1, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zeng, GF (Corresponding Author), Guangxi Med Univ, Coll Publ Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Xiao, Dongliang; Bai, Yiguang; Cao, Baichuan; Zong, Shaohui, Guangxi Med Univ, Dept Spine Osteopathia, Affiliated Hosp 1, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zhou, Quan, Guangxi Med Univ, Collaborat Innovat Ctr Guangxi Biol Med, Nanning 530021, Guangxi, Peoples R China.
   Zhou, Quan, Mudanjiang Med Univ, Dept Emergency, Hongqi Hosp, Mudanjiang 157001, Heilongjiang, Peoples R China.
   Zhang, Qiong; Zeng, Gaofeng, Guangxi Med Univ, Coll Publ Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Res Ctr Regenerat Med, Nanning 530021, Guangxi, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Guangxi, Peoples R China.},
DOI = {10.3892/mmr.2020.11209},
ISSN = {1791-2997},
EISSN = {1791-3004},
Keywords = {osteoclasts; gene knockout; bone fracture; callus;
   3-phosphoinositide-dependent protein kinase 1},
Keywords-Plus = {BONE; ALENDRONATE; EXPRESSION},
Research-Areas = {Oncology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Oncology; Medicine, Research \& Experimental},
Author-Email = {1685858372@qq.com
   xiaohui3008@126.com},
Affiliations = {Guangxi Medical University; Guangxi Medical University; Mudanjiang
   Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University},
ResearcherID-Numbers = {yiguang, bai/AAC-7732-2021
   xiao, dongliang/PGA-0716-2026},
ORCID-Numbers = {zhou, quan/0000-0002-0769-5517
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81860402]; Guangxi
   Natural Science Foundation of China {[}2017GXNSFAA 198073]; Guangxi Key
   Research and Development Project {[}GuikeAB17195001]; High Level
   Innovation Team and Excellence Scholars Program of Guangxi High
   Education Institutions; Guangxi Medical High-level Key Talents Training
   `139' Program Training Project},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (grant no. 81860402), Guangxi Natural Science Foundation of China
   (grant no. 2017GXNSFAA 198073), Guangxi Key Research and Development
   Project (grant no. GuikeAB17195001), High Level Innovation Team and
   Excellence Scholars Program of Guangxi High Education Institutions and
   Guangxi Medical High-level Key Talents Training `139' Program Training
   Project.},
Cited-References = {2019, PEDIATR PHYS THER, V31, pE31, DOI {[}10.1097/pep.0000000000000581, 10.1097/PEP.0000000000000581, DOI 10.1097/PEP.0000000000000581].
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237.
   Chang Xin, 2006, Hua Xi Kou Qiang Yi Xue Za Zhi, V24, P164.
   Claes L, 2012, NAT REV RHEUMATOL, V8, P133, DOI 10.1038/nrrheum.2012.1.
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559.
   Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7.
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164.
   Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2.
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736-0266(03)00011-1.
   FROST HM, 1992, BONE MINER, V18, P227, DOI 10.1016/0169-6009(92)90809-R.
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435.
   Gerstenfeld LC, 2009, J BONE MINER RES, V24, P196, DOI 10.1359/JBMR.081113.
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI {[}10.1016/j.bonr.2017.03.002, 10.1016/j.bonr.2017.03.002].
   Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200.
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002.
   He LH, 2017, SCI REP-UK, V7, DOI 10.1038/srep42385.
   Inada Masaki, 2011, Clin Calcium, V21, P164.
   Kamimura M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128210.
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198-012-1964-3.
   Li JL, 2000, J BONE MINER RES, V15, P2042, DOI 10.1359/jbmr.2000.15.10.2042.
   Lin HN, 2017, J ORTHOP RES, V35, P1699, DOI 10.1002/jor.23440.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020.
   Marsell R, 2011, INJURY, V42, P551, DOI 10.1016/j.injury.2011.03.031.
   McDonald MM, 2008, BONE, V43, P653, DOI 10.1016/j.bone.2008.05.019.
   Mi M, 2013, GENE, V512, P211, DOI 10.1016/j.gene.2012.09.130.
   Morshed Saam, 2014, Adv Med, V2014, P708574, DOI 10.1155/2014/708574.
   Ota N, 2009, ENDOCRINOLOGY, V150, P4823, DOI 10.1210/en.2009-0452.
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004.
   Shefelbine SJ, 2005, J ORTHOP RES, V23, P489, DOI 10.1016/j.orthres.2004.08.007.
   Takahara M, 2004, J ORTHOPAED RES, V22, P1050, DOI 10.1016/j.orthres.2004.01.011.
   Tzioupis C, 2007, INJURY, V38, pS3, DOI 10.1016/S0020-1383(07)80003-9.
   van't Hof RJ, 2017, BONE, V99, P69, DOI 10.1016/j.bone.2017.03.051.
   Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677.},
Number-of-Cited-References = {34},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Mol. Med. Rep.},
Doc-Delivery-Number = {NL1MP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000567188300098},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000558101600005,
Author = {Kim, Kidae and Park, Sung Goo and Park, Byoung Chul and Kim, Jeong-Hoon
   and Kim, Sunhong},
Title = {Serine 389 phosphorylation of 3-phosphoinositide-dependent kinase 1 by
   UNC-51-like kinase 1 affects its ability to regulate Akt and p70
   S6kinase},
Journal = {BMB REPORTS},
Year = {2020},
Volume = {53},
Number = {7},
Pages = {373-378},
Month = {JUL 31},
Abstract = {Phosphorylation of the signaling component by protein kinase often leads
   to a kinase cascade or feedback loop. 3-Phosphoinositide-dependent
   kinase 1 (PDK1) signaling pathway diverges into various kinases
   including Akt and p70 S6 kinase (p70S6k). However, the PDK1 feedback
   mechanism remains elusive. Here, we demonstrated that UNC-51-like kinase
   (ULK1), an autophagy initiator kinase downstream of mechanistic target
   of rapamycin (mTOR), directly phosphorylated PDK1 on serine 389 at the
   linker region. Furthermore, our data showed that this phosphorylation
   affected the kinase activity of PDK1 toward downstream substrates. These
   results suggest a possible negative feedback loop between PDK1 and ULK1.},
Publisher = {KOREAN SOCIETY BIOCHEMISTRY \& MOLECULAR BIOLOGY},
Address = {KOREA SCIENCE \& TECHNOLOGY CENTER, \# 801,  635-4 , YEOKSAM-DONG,
   KANGNAM-KU, SEOUL, 135-703, SOUTH KOREA},
Type = {Article},
Language = {English},
Affiliation = {Park, BC; Kim, JH; Kim, S (Corresponding Author), Korea Res Inst Biosci \& Biotechnol, Dis Target Struct Res Ctr, Daejeon 34141, South Korea.
   Park, BC (Corresponding Author), Korea Univ Sci \& Technol, KRIBB Sch Biosci, Dept Proteome Struct Biol, Daejeon 34113, South Korea.
   Kim, JH (Corresponding Author), Korea Univ Sci \& Technol, KRIBB Sch Biosci, Dept Funct Genom, Daejeon 34113, South Korea.
   Kim, S (Corresponding Author), Korea Univ Sci \& Technol, KRIBB Sch Biosci, Dept Biomol Sci, Daejeon 34113, South Korea.
   Kim, Kidae; Park, Sung Goo; Park, Byoung Chul; Kim, Jeong-Hoon; Kim, Sunhong, Korea Res Inst Biosci \& Biotechnol, Dis Target Struct Res Ctr, Daejeon 34141, South Korea.
   Kim, Kidae; Park, Byoung Chul, Korea Univ Sci \& Technol, KRIBB Sch Biosci, Dept Proteome Struct Biol, Daejeon 34113, South Korea.
   Park, Sung Goo; Kim, Jeong-Hoon, Korea Univ Sci \& Technol, KRIBB Sch Biosci, Dept Funct Genom, Daejeon 34113, South Korea.
   Kim, Sunhong, Korea Univ Sci \& Technol, KRIBB Sch Biosci, Dept Biomol Sci, Daejeon 34113, South Korea.},
DOI = {10.5483/BMBRep.2020.53.7.299},
ISSN = {1976-6696},
EISSN = {1976-670X},
Keywords = {Feedback loop; Linker; PDK1; Phosphorylation; ULK1},
Keywords-Plus = {PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; PLASMA-MEMBRANE; ACTIVATION;
   ULK1; IDENTIFICATION; PDK1; TRANSLOCATION; MECHANISM; AUTOPHAGY},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {parkbc@kribb.re.kr
   jhoonkim@kribb.re.kr
   sunhong@kribb.re.kr},
Affiliations = {Korea Research Institute of Bioscience \& Biotechnology (KRIBB);
   University of Science \& Technology (UST); University of Science \&
   Technology (UST); University of Science \& Technology (UST)},
Funding-Acknowledgement = {National Research Foundation, Ministry of Science and ICT
   {[}NRF-2019M3E5D4069882]; KRIBB initiative program},
Funding-Text = {This work was supported by a grant (NRF-2019M3E5D4069882) from the
   National Research Foundation, Ministry of Science and ICT, and another
   grant from KRIBB initiative program.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   Dunlop EA, 2011, AUTOPHAGY, V7, P737, DOI 10.4161/auto.7.7.15491.
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7.
   Gao XX, 2006, J BIOL CHEM, V281, P21670, DOI 10.1074/jbc.M602448200.
   Gao XX, 2011, P NATL ACAD SCI USA, V108, P14509, DOI 10.1073/pnas.1019386108.
   Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168.
   Jung CH, 2011, AUTOPHAGY, V7, P1212, DOI 10.4161/auto.7.10.16660.
   Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507.
   Kamada Y, 2010, MOL CELL BIOL, V30, P1049, DOI 10.1128/MCB.01344-09.
   Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200.
   King CC, 2000, J BIOL CHEM, V275, P18108, DOI 10.1074/jbc.M909663199.
   Kuroyanagi H, 1998, GENOMICS, V51, P76, DOI 10.1006/geno.1998.5340.
   Lang F, 2001, Sci STKE, V2001, pre17, DOI 10.1126/stke.2001.108.re17.
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042.
   Lee SB, 2007, EMBO REP, V8, P360, DOI 10.1038/sj.embor.7400917.
   Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100.
   Löffler AS, 2011, AUTOPHAGY, V7, P696, DOI 10.4161/auto.7.7.15451.
   Masters TA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000738.
   Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X.
   Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200.
   Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707.
   Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710.
   Wick MJ, 2003, J BIOL CHEM, V278, P42913, DOI 10.1074/jbc.M304172200.
   Yan J, 1998, BIOCHEM BIOPH RES CO, V246, P222, DOI 10.1006/bbrc.1998.8546.
   Ziemba BP, 2013, BIOCHEMISTRY-US, V52, P4820, DOI 10.1021/bi400488f.},
Number-of-Cited-References = {32},
Times-Cited = {1},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {BMB Rep.},
Doc-Delivery-Number = {MY0IJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000558101600005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000559271400001,
Author = {Du, Juan and Li, Guoli and Hua, Mingxi and Han, Junyan and Hao, Yu and
   Zeng, Hui and Li, Ang and Kong, Yaxian},
Title = {PDK1/mTOR Signaling in Myeloid Cells Differentially Regulates the Early
   and Late Stages of Sepsis},
Journal = {MEDIATORS OF INFLAMMATION},
Year = {2020},
Volume = {2020},
Month = {JUL 25},
Abstract = {The cecal ligation and perforation (CLP) model is the gold standard for
   the polymicrobial sepsis. In the CLP mice, the myeloid cells play an
   important role in septic shock. The phenotypes and the activation state
   of the macrophage and neutrophil correlate with their metabolism. In the
   present study, we generated the specific myeloid deletion of PDK1 and
   mTOR mice, which was the important regulator of metabolic signaling. We
   found that the deletion of PDK1 in the myeloid cells could aggravate the
   early septic shock in the CLP mice, as well as the deletion of mTORC1
   and mTORC2. Moreover, PDK1 deletion attenuated the inflammation induced
   by LPS in the late stage on CLP mice, which was exacerbated in mTORC1
   and mTORC2 knockout mice. Both PDK1 and mTORC1/2 could not only regulate
   the cellular metabolism but also play important roles on the myeloid
   cells in the secondary stimulation of sepsis. The present study will
   provide a theoretical prospect for the therapy of the septic shock in
   different stages.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Kong, YX (Corresponding Author), Capital Med Univ, Inst Infect Dis, Beijing Ditan Hosp, Beijing Key Lab Emerging Infect Dis, Beijing 100015, Peoples R China.
   Du, Juan; Li, Guoli; Hua, Mingxi; Han, Junyan; Hao, Yu; Zeng, Hui; Li, Ang; Kong, Yaxian, Capital Med Univ, Inst Infect Dis, Beijing Ditan Hosp, Beijing Key Lab Emerging Infect Dis, Beijing 100015, Peoples R China.},
DOI = {10.1155/2020/5437175},
Article-Number = {5437175},
ISSN = {0962-9351},
EISSN = {1466-1861},
Keywords-Plus = {METABOLISM; PATHWAY; ACTIVATION; EXPRESSION; APOPTOSIS; 3-KINASE},
Research-Areas = {Cell Biology; Immunology},
Web-of-Science-Categories  = {Cell Biology; Immunology},
Author-Email = {duj656@163.com
   gary\_lgl@163.com
   huamingxi1@ccmu.edu.cn
   hanjunyan@ccmu.edu.cn
   haoyu\_111@sohu.com
   zenghui@ccmu.edu.cn
   liang@ccmu.edu.cn
   yaxiankong@126.com},
Affiliations = {Capital Medical University},
ORCID-Numbers = {Kong, Yaxian/0000-0003-2804-8682
   Han, Junyan/0000-0002-5266-033X},
Funding-Acknowledgement = {Beijing Natural Science Foundation {[}7184218]; National Natural Science
   Foundation of China {[}81772123, 81401624]; National Key Sci-Tech
   Special Project of China {[}2018ZX10302207]; Beijing Municipal
   Administration of Hospitals Clinical Medicine Development of Special
   Funding Support {[}ZYLX201802]; Capital Health Research and Development
   of Special {[}2018-1-2171]; Beijing Hospital Authority {[}DFL20191801]},
Funding-Text = {This work was supported by Beijing Natural Science Foundation (7184218),
   National Natural Science Foundation of China (81772123, 81401624),
   National Key Sci-Tech Special Project of China (2018ZX10302207), Beijing
   Municipal Administration of Hospitals Clinical Medicine Development of
   Special Funding Support (ZYLX201802), the Capital Health Research and
   Development of Special (2018-1-2171), and Beijing Hospital Authority
   (grant numbers DFL20191801).},
Cited-References = {Adib-Conquy M, 2009, THROMB HAEMOSTASIS, V101, P36, DOI 10.1160/TH08-07-0421.
   Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797.
   Arts RJW, 2017, J LEUKOCYTE BIOL, V101, P151, DOI 10.1189/jlb.4MR0216-066R.
   Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Chabrier-Roselló Y, 2013, EUKARYOT CELL, V12, P12, DOI 10.1128/EC.00235-12.
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824.
   Cheng SC, 2016, NAT IMMUNOL, V17, P406, DOI 10.1038/ni.3398.
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684.
   Dejager L, 2011, TRENDS MICROBIOL, V19, P198, DOI 10.1016/j.tim.2011.01.001.
   Emerling BM, 2011, CANCER RES, V71, P7351, DOI 10.1158/0008-5472.CAN-11-1699.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Gardiner CM, 2016, SEMIN IMMUNOL, V28, P343, DOI 10.1016/j.smim.2016.03.001.
   Guha M, 2002, J BIOL CHEM, V277, P32124, DOI 10.1074/jbc.M203298200.
   Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062.
   Howie D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02678.
   Levy MM, 2010, CRIT CARE MED, V38, P367, DOI 10.1097/CCM.0b013e3181cb0cdc.
   Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413.
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926.
   Luyt CE, 2007, AM J RESP CRIT CARE, V175, P935, DOI 10.1164/rccm.200609-1322OC.
   Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000.
   Mastelic-Gavillet B, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0719-5.
   McClure C, 2016, J LEUKOCYTE BIOL, V99, P201, DOI 10.1189/jlb.4A0415-171RR.
   Monneret G, 2008, MOL MED, V14, P64, DOI 10.2119/2007-00102.Monneret.
   Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098.
   Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355.
   Rizzetto L, 2016, J BIOL CHEM, V291, P7961, DOI 10.1074/jbc.M115.699645.
   Romanova M, 2019, J VIS COMMUN MED, V42, P195, DOI 10.1080/17453054.2019.1666659.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Schefold JC, 2008, CRIT CARE MED, V36, P3118, DOI 10.1097/CCM.0b013e31818bdd8f.
   Ward NS, 2008, CLIN CHEST MED, V29, P617, DOI 10.1016/j.ccm.2008.06.010.
   Whitfield C, 2014, ANNU REV BIOCHEM, V83, P99, DOI 10.1146/annurev-biochem-060713-035600.
   Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703.
   Zhao JG, 2019, CANCERS, V11, DOI 10.3390/cancers11060874.},
Number-of-Cited-References = {33},
Times-Cited = {1},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Mediat. Inflamm.},
Doc-Delivery-Number = {MZ6XF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000559271400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000552376200001,
Author = {Sun, Haijian and Wang, Jiaying and Xing, Yutong and Pan, Yi-Hsuan and
   Mao, Xiuguang},
Title = {Gut transcriptomic changes during hibernation in the greater horseshoe
   bat (Rhinolophus ferrumequinum)},
Journal = {FRONTIERS IN ZOOLOGY},
Year = {2020},
Volume = {17},
Number = {1},
Month = {JUL 17},
Abstract = {Background The gut is the major organ for nutrient absorption and immune
   response in the body of animals. Although effects of fasting on the gut
   functions have been extensively studied in model animals (e.g. mice),
   little is known about the response of the gut to fasting in a natural
   condition (e.g. hibernation). During hibernation, animals endure the
   long term of fasting and hypothermia. Results Here we generated the
   first gut transcriptome in a wild hibernating bat (Rhinolophus
   ferrumequinum). We identified 1614 differentially expressed genes (DEGs)
   during four physiological states (Torpor, Arousal, Winter Active and
   Summer Active). Gene co-expression network analysis assigns 926 DEGs
   into six modules associated with Torpor and Arousal. Our results reveal
   that in response to the stress of luminal nutrient deficiency during
   hibernation, the gut helps to reduce food intake by overexpressing genes
   (e.g.CCKandGPR17) that regulate the sensitivity to insulin and leptin.
   At the same time, the gut contributes energy supply by overexpressing
   genes that increase capacity for ketogenesis (HMGCS2) and selective
   autophagy (TEX264). Furthermore, we identified separate sets of multiple
   DEGs upregulated in Torpor and Arousal whose functions are involved in
   innate immunity. Conclusion This is the first gut transcriptome of a
   hibernating mammal. Our study identified candidate genes associated with
   regulation of food intake and enhance of innate immunity in the gut
   during hibernation. By comparing with previous studies, we found that
   two DEGs (CPEandHSPA8) were also significantly elevated during torpor in
   liver and brain ofR. ferrumequinumand several DEGs (e.g.TXNIPandPDK1/4)
   were commonly upregulated during torpor in multiple tissues of different
   mammals. Our results support that shared expression changes may underlie
   the hibernation phenotype by most mammals.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Mao, XG (Corresponding Author), East China Normal Univ, Sch Ecol \& Environm Sci, Shanghai 200062, Peoples R China.
   Mao, XG (Corresponding Author), East China Normal Univ, Inst Ecochongming IEC, Shanghai 200062, Peoples R China.
   Sun, Haijian; Mao, Xiuguang, East China Normal Univ, Sch Ecol \& Environm Sci, Shanghai 200062, Peoples R China.
   Wang, Jiaying; Xing, Yutong, East China Normal Univ, Inst Estuarine \& Coastal Res, Shanghai 200062, Peoples R China.
   Pan, Yi-Hsuan, East China Normal Univ, Sch Life Sci, Minist Educ, Key Lab Brain Funct Genom, Shanghai 200062, Peoples R China.
   Mao, Xiuguang, East China Normal Univ, Inst Ecochongming IEC, Shanghai 200062, Peoples R China.},
DOI = {10.1186/s12983-020-00366-w},
Article-Number = {21},
ISSN = {1742-9994},
Keywords = {RNA-Seq; Food intake; Immune system; Intestine; Mammals},
Keywords-Plus = {GROUND-SQUIRREL; FOOD-INTAKE; IMMUNE-SYSTEM; AGRP NEURONS; PROTEIN;
   GENE; EXPRESSION; PEPTIDE; PACKAGE; LEPTIN},
Research-Areas = {Zoology},
Web-of-Science-Categories  = {Zoology},
Author-Email = {xgmao6721@gmail.com},
Affiliations = {East China Normal University; East China Normal University; East China
   Normal University; East China Normal University},
ResearcherID-Numbers = {Pan, Yi-Hsuan/ABG-6271-2020},
ORCID-Numbers = {mao, xiuguang/0000-0002-3432-7509
   Pan, Yi-Hsuan/0000-0001-5156-9887},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31570378]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. 31570378).},
Cited-References = {An H, 2019, MOL CELL, V74, P891, DOI 10.1016/j.molcel.2019.03.034.
   Andrews MT, 2019, J EXP BIOL, V222, DOI 10.1242/jeb.160606.
   {[}Anonymous], 2003, HORSESHOE BATS WORLD.
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556.
   Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547.
   Bai L, 2019, CELL, V179, P1129, DOI 10.1016/j.cell.2019.10.031.
   Banerjee S, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7040055.
   Banoth B, 2015, ELIFE, V4, DOI 10.7554/eLife.05648.
   Barrachina MD, 1997, P NATL ACAD SCI USA, V94, P10455, DOI 10.1073/pnas.94.19.10455.
   Bogren LK, 2017, J COMP PHYSIOL B, V187, P735, DOI 10.1007/s00360-017-1073-x.
   Bohr J, 2014, CLIN EXP GASTROENTER, V7, P273, DOI 10.2147/CEG.S63905.
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170.
   Bouma HR, 2010, J LEUKOCYTE BIOL, V88, P619, DOI 10.1189/jlb.0310174.
   Buchfink B, 2015, NAT METHODS, V12, P59, DOI 10.1038/nmeth.3176.
   Cain BM, 1997, ENDOCRINOLOGY, V138, P4034, DOI 10.1210/en.138.9.4034.
   CARACENI P, 1994, AM J PHYSIOL, V266, pG799, DOI 10.1152/ajpgi.1994.266.5.G799.
   Carey HV, 2014, J THERM BIOL, V44, P78, DOI 10.1016/j.jtherbio.2014.02.015.
   Carey HV, 2013, AM J PHYSIOL-REG I, V304, pR33, DOI 10.1152/ajpregu.00387.2012.
   Carey HV, 2003, PHYSIOL REV, V83, P1153, DOI 10.1152/physrev.00008.2003.
   Carey HV, 2001, GUT, V49, P459, DOI 10.1136/gut.49.4.459.
   CAREY HV, 1991, AM J PHYSIOL, V261, pG37, DOI 10.1152/ajpgi.1991.261.1.G37.
   Chino H, 2019, MOL CELL, V74, P909, DOI 10.1016/j.molcel.2019.03.033.
   Choi JS, 2015, MUCOSAL IMMUNOL, V8, P1285, DOI 10.1038/mi.2015.19.
   Cooper ST, 2016, PHYSIOL GENOMICS, V48, P513, DOI 10.1152/physiolgenomics.00120.2015.
   Cordomi A, 2016, CURR OPIN PHARMACOL, V31, P63, DOI 10.1016/j.coph.2016.09.001.
   CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X.
   Cummings DE, 2007, J CLIN INVEST, V117, P13, DOI 10.1172/JCI30227.
   Delanghe JR, 2001, CLIN CHIM ACTA, V312, P13, DOI 10.1016/S0009-8981(01)00586-1.
   Dockray GJ, 2013, CURR OPIN PHARMACOL, V13, P954, DOI 10.1016/j.coph.2013.09.007.
   Donaldson GP, 2016, NAT REV MICROBIOL, V14, P20, DOI 10.1038/nrmicro3552.
   Ebersole JL, 2000, PERIODONTOL 2000, V23, P19, DOI 10.1034/j.1600-0757.2000.2230103.x.
   Faherty SL, 2018, MOL ECOL, V27, P709, DOI 10.1111/mec.14483.
   Faherty SL, 2016, GENOME BIOL EVOL, V8, P2413, DOI 10.1093/gbe/evw163.
   Field KA, 2018, MOL ECOL, V27, P3727, DOI 10.1111/mec.14827.
   Florant GL, 2012, J COMP PHYSIOL B, V182, P451, DOI 10.1007/s00360-011-0630-y.
   Geiser F, 2004, ANNU REV PHYSIOL, V66, P239, DOI 10.1146/annurev.physiol.66.032102.115105.
   Grabherr MG, 2011, NAT BIOTECHNOL, V29, P644, DOI 10.1038/nbt.1883.
   Grosse J, 2014, P NATL ACAD SCI USA, V111, P11133, DOI 10.1073/pnas.1411413111.
   Hahm S, 1999, NEURON, V23, P537, DOI 10.1016/S0896-6273(00)80806-5.
   Hahm S, 2002, J NEUROSCI, V22, P6929.
   Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9.
   Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259.
   Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276.
   HURLBERT SH, 1984, ECOL MONOGR, V54, P187, DOI 10.2307/1942661.
   Janseng HT, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0574-4.
   Jethwa PH, 2007, ENDOCRINOLOGY, V148, P4044, DOI 10.1210/en.2007-0038.
   Kim MS, 2006, NAT NEUROSCI, V9, P901, DOI 10.1038/nn1731.
   Kitamura T, 2006, NAT MED, V12, P534, DOI 10.1038/nm1392.
   KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853.
   Kurtz CC, 2007, DEV COMP IMMUNOL, V31, P415, DOI 10.1016/j.dci.2006.07.003.
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563.
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559.
   Langfelder P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061505.
   Langmead B, 2012, NAT METHODS, V9, P357, DOI {[}10.1038/nmeth.1923, 10.1038/NMETH.1923].
   Leek JT, 2012, BIOINFORMATICS, V28, P882, DOI 10.1093/bioinformatics/bts034.
   Lei M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107746.
   Levi A, 2004, CELL MOL NEUROBIOL, V24, P517, DOI 10.1023/B:CEMN.0000023627.79947.22.
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323.
   Li WZ, 2006, BIOINFORMATICS, V22, P1658, DOI 10.1093/bioinformatics/btl158.
   Lilley TM, 2019, OECOLOGIA, V191, P295, DOI 10.1007/s00442-019-04499-6.
   Long AT, 2016, J THROMB HAEMOST, V14, P427, DOI 10.1111/jth.13235.
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8.
   Maniero GD, 2002, DEV COMP IMMUNOL, V26, P563, DOI 10.1016/S0145-305X(02)00006-X.
   Marakasova ES, 2017, BIOESSAYS, V39, DOI 10.1002/bies.201700014.
   Martin SL, 2008, AM J PHYSIOL-REG I, V295, pR316, DOI 10.1152/ajpregu.00418.2007.
   Mathew AG, 2001, BIOTECHNOLOGY FEED I.
   McCue MD, 2010, COMP BIOCHEM PHYS A, V156, P1, DOI 10.1016/j.cbpa.2010.01.002.
   MORAN TH, 1995, CRIT REV NEUROBIOL, V9, P1.
   Mugahid DA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56007-8.
   Nespolo RF, 2018, MOL ECOL, V27, P4489, DOI 10.1111/mec.14876.
   Olivier E, 2000, BIOCHEM J, V350, P589, DOI 10.1042/0264-6021:3500589.
   Ombrellino M, 2001, SHOCK, V15, P181, DOI 10.1097/00024382-200115030-00004.
   Paksuz EP, 2014, ACTA HISTOCHEM, V116, P1480, DOI 10.1016/j.acthis.2014.10.004.
   PEIKIN SR, 1989, GASTROENTEROL CLIN N, V18, P757.
   Plum L, 2009, NAT MED, V15, P1195, DOI 10.1038/nm.2026.
   Prendergast BJ, 2002, AM J PHYSIOL-REG I, V282, pR1054, DOI 10.1152/ajpregu.00562.2001.
   Quaye IK, 2008, T ROY SOC TROP MED H, V102, P735, DOI 10.1016/j.trstmh.2008.04.010.
   Ren HX, 2012, CELL, V149, P1314, DOI 10.1016/j.cell.2012.04.032.
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616.
   SCARPIGNATO C, 1993, J PHYSIOL-PARIS, V87, P291, DOI 10.1016/0928-4257(93)90035-R.
   Schwartz C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058427.
   Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534.
   Shamay A, 2005, J DAIRY SCI, V88, P569, DOI 10.3168/jds.S0022-0302(05)72719-3.
   Simao FA, 2015, BIOINFORMATICS, V31, P3210, DOI 10.1093/bioinformatics/btv351.
   Stawski C, 2014, J ZOOL, V292, P86, DOI 10.1111/jzo.12105.
   Stutchfield BM, 2015, GASTROENTEROLOGY, V149, P1896, DOI 10.1053/j.gastro.2015.08.053.
   Szklarczyk D, 2023, NUCLEIC ACIDS RES, V51, pD638, DOI {[}10.1093/nar/gky1131, 10.1093/nar/gkac1000].
   Tseng CF, 2004, PROTEOMICS, V4, P2221, DOI 10.1002/pmic.200300787.
   van Breukelen F, 2015, PHYSIOLOGY, V30, P273, DOI 10.1152/physiol.00010.2015.
   Varela L, 2012, EMBO REP, V13, P1079, DOI 10.1038/embor.2012.174.
   Volkow ND, 2011, TRENDS COGN SCI, V15, P37, DOI 10.1016/j.tics.2010.11.001.
   Wang YH, 1997, AM J PHYSIOL-REG I, V273, pR833, DOI 10.1152/ajpregu.1997.273.2.R833.
   Wijenayake S, 2017, J THERM BIOL, V69, P199, DOI 10.1016/j.jtherbio.2017.07.010.
   Xiao GH, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02247.
   Xiao YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145702.
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118.
   Zhang L, 2014, CELL BIOCHEM BIOPHYS, V70, P233, DOI 10.1007/s12013-014-9887-6.
   Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3.},
Number-of-Cited-References = {98},
Times-Cited = {3},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {30},
Journal-ISO = {Front. Zool.},
Doc-Delivery-Number = {MP7IX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000552376200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000549853700001,
Author = {Gan, Delu and Yue, Shujun and Jiang, Yulin and Zhang, Dian and Shi, He
   and Qian, Husun and Zhou, Ting and Fang, Wenli and Yao, Mengli and Zuo,
   Guowei and Chen, Tingmei},
Title = {Nucleus-located PDK1 regulates growth, invasion and migration of breast
   cancer cells},
Journal = {LIFE SCIENCES},
Year = {2020},
Volume = {253},
Month = {JUL 15},
Abstract = {Aims: It is well known that pyruvate dehydrogenase kinase 1 (PDK1) is
   highly expressed in breast cancer (BC) tissues and promotes tumor
   growth, but the underlying mechanisms of this process are unclear. Here,
   we investigated the effects of nuclear PDK1 on growth, migration and
   invasion in human BC cells.
   Main methods: The sub-cellular localization of PDK1 in BC cells was
   performed with subcellular fractionation followed by Western blot and
   immunofluorescence. The localization of PDK1 in breast normal tissue and
   breast duct carcinoma was detected by Immunohistochemistry. Then the
   protein-protein interaction between PDK1 and Importin beta was verified
   by co-immunoprecipitation assay. Finally, the effects of nuclear PDK1 on
   cell proliferation, apoptosis, migration and invasion of BC cells were
   assessed.
   Key findings: In addition to its well-known sub-cellular localization,
   PDK1 was present in the nucleus of BC cells, and EGF treatment increased
   nucleus distribution of PDK1. Moreover, the level of nuclear PDK1
   accumulation facilitated the growth of BC cells. We also found that the
   entry of PDK1 into nucleus mainly relied on the nuclear localization
   signal (NLS), and NLS mutation inhibited the entry of PDK1 into nucleus;
   as a result, the migration and invasion abilities of BC cells were
   impaired, and the number of apoptotic cells was significantly increased.
   Significance: Our findings provided a new supplement to the sub-cellular
   localization of PDK1 in BC cells and uncovered the function of nuclear
   PDK1 in facilitating BC cells growth, migration and invasion.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Chen, TM (Corresponding Author), Chongqing Med Univ, Coll Lab Med, Key Lab Clin Lab Diagnost, Minist Educ, Chongqing 400016, Peoples R China.
   Gan, Delu; Yue, Shujun; Jiang, Yulin; Zhang, Dian; Shi, He; Qian, Husun; Zhou, Ting; Fang, Wenli; Yao, Mengli; Zuo, Guowei; Chen, Tingmei, Chongqing Med Univ, Coll Lab Med, Key Lab Clin Lab Diagnost, Minist Educ, Chongqing 400016, Peoples R China.},
DOI = {10.1016/j.lfs.2020.117722},
Article-Number = {117722},
ISSN = {0024-3205},
EISSN = {1879-0631},
Keywords = {Nuclear PDK1; Breast cancer; Apoptosis; Migration; Invasion},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; PROMOTES GENE-TRANSCRIPTION; LUNG-CANCER;
   DICHLOROACETATE; PHOSPHATASE; EXPRESSION; INHIBITORS; TRANSPORT;
   PHOSPHORYLATION; MECHANISMS},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {tingmeichen@cqmu.edu.cn},
Affiliations = {Chongqing Medical University},
ResearcherID-Numbers = {qian, husun/KHW-3778-2024
   Jiang, Yulin/GPS-5813-2022},
ORCID-Numbers = {qian, husun/0009-0001-7894-5907
   Chen, Tingmei/0000-0003-4250-674X
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81772844]},
Funding-Text = {This work was funded by National Natural Science Foundation of China
   (No. 81772844).},
Cited-References = {Baumunk D, 2013, WORLD J UROL, V31, P1191, DOI 10.1007/s00345-012-0874-5.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Cautain B, 2015, FEBS J, V282, P445, DOI 10.1111/febs.13163.
   Chang LF, 2019, NUCLEIC ACIDS RES, V47, P824, DOI 10.1093/nar/gky1199.
   Chu QSC, 2015, INVEST NEW DRUG, V33, P603, DOI 10.1007/s10637-015-0221-y.
   Dey N, 2017, PHARMACOL THERAPEUT, V175, P91, DOI 10.1016/j.pharmthera.2017.02.037.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fang YH, 2019, CANCER MANAG RES, V11, P8539, DOI 10.2147/CMAR.S222278.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Harrison PT, 2020, SEMIN CANCER BIOL, V61, P167, DOI 10.1016/j.semcancer.2019.09.015.
   Herranz M, 2012, J ONCOL, V2012, DOI 10.1155/2012/863747.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680.
   Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010.
   Jans DA, 2019, CURR OPIN CELL BIOL, V58, P50, DOI 10.1016/j.ceb.2019.01.001.
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57.
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kau TR, 2004, NAT REV CANCER, V4, P106, DOI 10.1038/nrc1274.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim JW, 2005, TRENDS BIOCHEM SCI, V30, P142, DOI 10.1016/j.tibs.2005.01.005.
   Li HY, 2019, ONCOTARGETS THER, V12, P7785, DOI 10.2147/OTT.S199452.
   Li XJ, 2017, MOL CELL, V66, P684, DOI 10.1016/j.molcel.2017.04.026.
   Lim RYH, 2008, INT REV CEL MOL BIO, V267, P299, DOI 10.1016/S1937-6448(08)00632-1.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Liu Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06841-7.
   Lyssiotis CA, 2017, TRENDS CELL BIOL, V27, P873, DOI 10.1016/j.tcb.2017.06.003.
   Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9.
   Moroianu J, 1997, CRIT REV EUKAR GENE, V7, P61, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.40.
   Nguyen LK, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-52.
   Noman MZ, 2015, AM J PHYSIOL-CELL PH, V309, pC569, DOI 10.1152/ajpcell.00207.2015.
   Oka M, 2018, P JPN ACAD B-PHYS, V94, P259, DOI 10.2183/pjab.94.018.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093.
   Qin ZY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1131-1.
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Shah NR, 2014, WORLD J CLIN ONCOL, V5, P48, DOI 10.5306/wjco.v5.i2.48.
   Shan CL, 2014, J BIOL CHEM, V289, P21413, DOI 10.1074/jbc.M114.581124.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Steelman LS, 2016, CURR PHARM DESIGN, V22, P2358, DOI 10.2174/1381612822666160304151011.
   Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046.
   Wang ZH, 2019, CANCER MANAG RES, V11, P8463, DOI 10.2147/CMAR.S221877.
   Xiang GZ, 2016, PATHOL RES PRACT, V212, P1102, DOI 10.1016/j.prp.2016.10.006.
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018.
   Yogev O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000328.},
Number-of-Cited-References = {48},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Life Sci.},
Doc-Delivery-Number = {MM0MF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000549853700001},
DA = {2026-02-04},
}

@article{ WOS:000549831000001,
Author = {Liu, Rui and Xu, Min and Zhang, Xiao-Yang and Zhou, Min-Jie and Zhou,
   Bing-Yao and Qi, Cui and Song, Bo and Fan, Qi and You, Wei-Yan and Zhu,
   Jing-Ning and Yang, Zhong-Zhou and Gao, Jun},
Title = {PDK1 Regulates the Maintenance of Cell Body and the Development of
   Dendrites of Purkinje Cells by pS6 and PKCγ},
Journal = {JOURNAL OF NEUROSCIENCE},
Year = {2020},
Volume = {40},
Number = {29},
Pages = {5531-5548},
Month = {JUL 15},
Abstract = {3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a critical
   role in the development of mammalian brain. Here, we investigated the
   role of PDK1 in Purkinje cells (PCs) by generating the PDK1-conditional
   knock-out mice (cKO) through crossing PV-cre or Pcp2-cre mice with
   Pdk1(fl/fl) mice. The male mice were used in the behavioral testing, and
   the other experiments were performed on mice of both sexes. These
   PDK1-cKO mice displayed decreased cerebellar size and impaired motor
   balance and coordination. By the electrophysiological recording, we
   observed the reduced spontaneous firing of PCs from the cerebellar
   slices of the PDK1-cKO mice. Moreover, the cell body size of PCs in the
   PDK1-cKO mice was time dependently reduced compared with that in the
   control mice. And the morphologic complexity of PCs was also decreased
   after PDK1 deletion. These effects may have contributed to the reduction
   of the rpS6 (reduced ribosomal protein S6) phosphorylation and the PKC
   gamma expression in PDK1-cKO mice since the upregulation of pS6 by
   treatment of 3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-1,
   the agonist of mTOR1, partly rescued the reduction in the cell body size
   of the PCs, and the delivery of recombinant adeno-associated virus-PKC
   gamma through cerebellar injection rescued the reduced complexity of the
   dendritic arbor in PDK1-cKO mice. Together, our data suggest that PDK1,
   by regulating rpS6 phosphorylation and PKC gamma expression, controls
   the cell body maintenance and the dendritic development in PCs and is
   critical for cerebellar motor coordination.},
Publisher = {SOC NEUROSCIENCE},
Address = {11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Gao, J (Corresponding Author), Nanjing Med Univ, Dept Neurobiol, Key Lab Human Funct Genom Jiangsu, Nanjing 211166, Jiangsu, Peoples R China.
   Gao, J (Corresponding Author), Nanjing Med Univ, Jiangsu Shengze Hosp, Dept Rehabil Med, Suzhou 215228, Jiangsu, Peoples R China.
   Liu, Rui; Xu, Min; Zhou, Min-Jie; Zhou, Bing-Yao; Qi, Cui; Fan, Qi; You, Wei-Yan; Gao, Jun, Nanjing Med Univ, Dept Neurobiol, Key Lab Human Funct Genom Jiangsu, Nanjing 211166, Jiangsu, Peoples R China.
   Gao, Jun, Nanjing Med Univ, Jiangsu Shengze Hosp, Dept Rehabil Med, Suzhou 215228, Jiangsu, Peoples R China.
   Zhang, Xiao-Yang; Song, Bo; Zhu, Jing-Ning, Nanjing Univ, Key Lab Pharmaceut Biotechnol, Sch Life Sci, Dept Physiol, Nanjing 210023, Peoples R China.
   Zhang, Xiao-Yang; Song, Bo; Zhu, Jing-Ning, Nanjing Univ, Sch Life Sci, Inst Brain Sci, Nanjing 210023, Peoples R China.
   Yang, Zhong-Zhou, Nanjing Univ, Sch Med, Affiliated Hosp,Dept Cardiol, State Key Lab Pharmaceut Biotechnol,Nanjing Drum, Nanjing 210061, Peoples R China.
   Yang, Zhong-Zhou, Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing 210061, Peoples R China.},
DOI = {10.1523/JNEUROSCI.2496-19.2020},
ISSN = {0270-6474},
EISSN = {1529-2401},
Keywords = {cell body; cerebellum; PDK1; PKC gamma; pS6; Purkinje cells},
Keywords-Plus = {PROTEIN-KINASE-C; DISTINCT FUNCTIONS; ROR-ALPHA; PATHWAY; BRAIN;
   DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; DISRUPTION; CEREBELLUM},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {gaojun@njmu.edu.cn},
Affiliations = {Nanjing Medical University; Nanjing Medical University; Nanjing
   University; Nanjing University; Nanjing University; Nanjing University},
ResearcherID-Numbers = {Zhu, Jing-Ning/C-7482-2014
   Yang, Zhongzhou/H-3015-2014},
ORCID-Numbers = {Zhu, Jing-Ning/0000-0002-3695-9200
   Zhang, Xiao-Yang/0009-0005-5114-2732
   },
Funding-Acknowledgement = {Natural Science Foundation of Jiangsu Province, China {[}BK20171063];
   China Postdoctoral Science Foundation {[}2018M632336]; National Natural
   Science Foundation of China {[}81671107]; Key R\&D Program of Jiangsu
   Province {[}BE2016761, 2017CX010]},
Funding-Text = {This work was financially supported by the Natural Science Foundation of
   Jiangsu Province, China (Grant BK20171063) and the China Postdoctoral
   Science Foundation (Grants 2018M632336) to R.L.; and the National
   Natural Science Foundation of China (Grants 81973308 and 81673416) and
   the Key R\&D Program of Jiangsu Province (Grants BE2016761 and
   2017CX010) to J.G.; and the National Natural Science Foundation of China
   (Grants 81671107) to J.-N.Z. We thank Dr. Dario Alessi for providing the
   Pdk1fl/fl mice, Prof. Li-Huei Tsai for providing the PV-cre
   mice, Prof. Chun-Jie Zhao for ROSA26-LSL-EYFP mice and Prof. Ying Shen
   for providing the Pcp2-cre mice. We also thank Prof. Ying Shen for
   technical advice and helpful discussions.},
Cited-References = {Angliker N, 2015, EUR J NEUROSCI, V42, P2595, DOI 10.1111/ejn.13051.
   Barski JJ, 2000, GENESIS, V28, P93, DOI 10.1002/1526-968X(200011/12)28:3/4<93::AID-GENE10>3.3.CO;2-N.
   Buttermore ED, 2012, J NEUROSCI, V32, P4724, DOI 10.1523/JNEUROSCI.5602-11.2012.
   Carter R J, 2001, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0812s15.
   Carter RJ, 1999, J NEUROSCI, V19, P3248.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609.
   Chen XR, 2013, J NEUROSCI, V33, P9546, DOI 10.1523/JNEUROSCI.2977-12.2013.
   Cordón-Barris L, 2016, MOL CELL BIOL, V36, P2967, DOI 10.1128/MCB.00230-16.
   Cupolillo D, 2016, NEUROPSYCHOPHARMACOL, V41, P1457, DOI 10.1038/npp.2015.339.
   Dainichi T, 2016, CELL REP, V15, P1615, DOI 10.1016/j.celrep.2016.04.051.
   Edamakanti CR, 2018, J CLIN INVEST, V128, P2252, DOI 10.1172/JCI96765.
   Ferreira TA, 2014, NAT METHODS, V11, P982, DOI 10.1038/nmeth.3125.
   Gibson DA, 2011, JOVE-J VIS EXP, DOI 10.3791/2823.
   Grego-Bessa J, 2016, ELIFE, V5, DOI 10.7554/eLife.12034.
   Hirai H, 2018, CEREBELLUM, V17, P23, DOI 10.1007/s12311-017-0898-x.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Liu CY, 2017, P NATL ACAD SCI USA, V114, P346, DOI 10.1073/pnas.1608576114.
   Liu R, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0144-8.
   Lui NC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15079.
   Mucha BE, 2019, GENET MED, V21, P1058, DOI 10.1038/s41436-018-0290-3.
   Nakazono A, 2018, J BIOL CHEM, V293, P14758, DOI 10.1074/jbc.RA118.002913.
   Nam SM, 2019, BIOL TRACE ELEM RES, V190, P446, DOI 10.1007/s12011-018-1572-y.
   Oishi K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI 10.1073/pnas.0808400106.
   Peng N, 2014, SCI REP-UK, V4, DOI 10.1038/srep05519.
   Popa LS, 2019, NEUROSCIENTIST, V25, P241, DOI 10.1177/1073858418785628.
   Schrenk K, 2002, NEUROSCIENCE, V110, P675, DOI 10.1016/S0306-4522(01)00559-0.
   Shimobayashi E, 2017, MOL BRAIN, V10, DOI 10.1186/s13041-017-0313-z.
   Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4.
   Stanko JP, 2015, REPROD TOXICOL, V54, P129, DOI 10.1016/j.reprotox.2014.11.004.
   Takahashi H, 2015, HUM MOL GENET, V24, P525, DOI 10.1093/hmg/ddu472.
   Takahashi N, 2017, J NEUROCHEM, V143, P660, DOI 10.1111/jnc.14239.
   Takeo YH, 2015, J NEUROSCI, V35, P12518, DOI 10.1523/JNEUROSCI.0075-15.2015.
   Thomanetz V, 2013, J CELL BIOL, V201, P293, DOI 10.1083/jcb.201205030.
   Tolias KF, 2005, NEURON, V45, P525, DOI 10.1016/j.neuron.2005.01.024.
   Trzesniewski J, 2019, EXP NEUROL, V311, P205, DOI 10.1016/j.expneurol.2018.10.004.
   Wang JR, 2017, MOL MED REP, V16, P3769, DOI 10.3892/mmr.2017.7112.
   Wang XQ, 2017, CELL DEATH DIFFER, V24, P38, DOI 10.1038/cdd.2016.84.
   Wang Y, 2017, CURR BIOL, V27, P2661, DOI 10.1016/j.cub.2017.07.035.
   Wong MMK, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-018-0600-7.
   Xenos D, 2018, CEREB CORTEX, V28, P3399, DOI 10.1093/cercor/bhx173.
   Xu CY, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00330.
   Xu M, 2019, CEREB CORTEX, V29, P1185, DOI 10.1093/cercor/bhy024.
   Yoshida S, 1999, TOHOKU J EXP MED, V187, P249, DOI 10.1620/tjem.187.249.
   Zurashvili T, 2013, MOL CELL BIOL, V33, P1027, DOI 10.1128/MCB.01052-12.},
Number-of-Cited-References = {48},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {J. Neurosci.},
Doc-Delivery-Number = {MM0DN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000549831000001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000551794700001,
Author = {Hosseini Khorami, Somayeh Alsadat and Abd Mutalib, Mohd Sokhini and
   Feili Shiraz, Mohammad and Abdullah, Joseph Anthony and Rejali, Zulida
   and Ali, Razana Mohd and Khaza'ai, Huzwah},
Title = {Genetic determinants of obesity heterogeneity in type II diabetes},
Journal = {NUTRITION \& METABOLISM},
Year = {2020},
Volume = {17},
Number = {1},
Month = {JUL 9},
Abstract = {Background Although obesity is considered as the main cause of Type II
   diabetes (T2DM), non-obese individuals may still develop T2DM and obese
   individuals may not. Method The mRNA expression ofPI3K/AKTaxis from 100
   non-obese and obese participants with insulin sensitivity and insulin
   resistance states were compared in this study toward the understanding
   of obesity heterogeneity molecular mechanism. Result In present study,
   there was no statistically significant difference in gene expression
   levels ofIRS1andPTENbetween groups, whereasPI3K,AKT2andGLUT4genes were
   expressed at a lower level in obese diabetic group compared to other
   groups and were statistically significant.PDK1gene was expressed at a
   higher level in non-obese diabetic group compared to obese diabetic and
   non-obese non-diabetics groups. No statistically significant difference
   was identified in gene expression pattern ofPI3K/AKTpathway between
   obese non-diabetics and non-obese non-diabetics. Conclusion The
   components ofPI3K/AKTpathway which is related to the fasting state,
   showed reduced expression in obese diabetic group due to the chronic
   over-nutrition which may induced insensitivity and reduced gene
   expression. The pathogenesis of insulin resistance in the absence of
   obesity in non-obese diabetic group could be due to disturbance in
   another pathway related to the non-fasting state like gluconeogenesis.
   Therefore, the molecular mechanism of insulin signalling in non-obese
   diabetic individuals is different from obese diabetics which more
   investigations are required to study insulin signalling pathways in
   greater depth, in order to assess nutritional factors, contribute to
   insulin resistance in obese diabetic and non-obese diabetic individuals.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Khaza'ai, H (Corresponding Author), Univ Putra Malaysia, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia.
   Hosseini Khorami, Somayeh Alsadat; Abd Mutalib, Mohd Sokhini, Univ Putra Malaysia, Dept Nutr \& Dietet, Serdang 43400, Selangor, Malaysia.
   Feili Shiraz, Mohammad, Islamic Azad Univ, Qazvin Branch, Dept Artificial Intelligence \& Comp Engn, Fac Elect Engn Comp \& IT, Qazvin, Iran.
   Abdullah, Joseph Anthony, Perak Community Hosp, Ipoh, Malaysia.
   Rejali, Zulida, Univ Putra Malaysia, Dept Obstet \& Gynaecol, Serdang 43400, Selangor, Malaysia.
   Ali, Razana Mohd, Univ Putra Malaysia, Dept Pathol, Serdang 43400, Selangor, Malaysia.
   Khaza'ai, Huzwah, Univ Putra Malaysia, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia.},
DOI = {10.1186/s12986-020-00476-6},
Article-Number = {55},
EISSN = {1743-7075},
Keywords = {Obesity paradox; PI3K; AKTpathway; PDK1; Non-obese diabetic; Type II
   diabetes; Gene expression; RT-PCR},
Keywords-Plus = {HEPATIC INSULIN-RESISTANCE; PROTEIN-KINASE-B; GLUCOSE-HOMEOSTASIS;
   IN-VIVO; PTEN; METABOLISM; MUSCLE; MICE; STRESS; PHOSPHATASE},
Research-Areas = {Nutrition \& Dietetics},
Web-of-Science-Categories  = {Nutrition \& Dietetics},
Author-Email = {huzwah@upm.edu.my},
Affiliations = {Universiti Putra Malaysia; Islamic Azad University; Universiti Putra
   Malaysia; Universiti Putra Malaysia; Universiti Putra Malaysia},
ResearcherID-Numbers = {Mohd Ali, Razana/JGD-7571-2023},
Funding-Acknowledgement = {Fundamental Research Grant Scheme {[}14-554-20427]},
Funding-Text = {This work was supported by the Fundamental Research Grant Scheme (grant
   number: 14-554-20427).},
Cited-References = {{[}Anonymous], ONCOTARGET.
   Barth E, 2007, CRIT CARE MED, V35, pS508, DOI 10.1097/01.CCM.0000278047.06965.20.
   Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780.
   Chang JS, 2013, DIABETES METAB J, V37, P475.
   Chen D, 2004, MOL CELL BIOL, V24, P320, DOI 10.1128/MCB.24.1.320-329.2004.
   Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728.
   Choi CS, 2002, AM J PHYSIOL-ENDOC M, V283, pE233, DOI 10.1152/ajpendo.00557.2001.
   Chuang HC, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-016-0307-7.
   Collins QF, 2006, J BIOL CHEM, V281, P24336, DOI 10.1074/jbc.M602177200.
   Delibegovic M, 2007, MOL CELL BIOL, V27, P7727, DOI 10.1128/MCB.00959-07.
   EIGLER N, 1979, J CLIN INVEST, V63, P114, DOI 10.1172/JCI109264.
   Fragoso Rita, 2014, Advances in Biological Regulation, V56, P22, DOI 10.1016/j.jbior.2014.05.005.
   Frangioudakis G, 2005, ENDOCRINOLOGY, V146, P5596, DOI 10.1210/en.2005-0481.
   Gehart H, 2010, EMBO REP, V11, P834, DOI 10.1038/embor.2010.160.
   George AM, 2015, WORLD J DIABETES, V6, P613, DOI 10.4239/wjd.v6.i4.613.
   Gual P, 2003, DIABETES METAB, V29, P566, DOI 10.1016/S1262-3636(07)70071-X.
   Hatting M, 2018, ANN NY ACAD SCI, V1411, P21, DOI 10.1111/nyas.13435.
   KANG GG, 2020, INT J MOL SCI, V21.
   Khorami S.A. H., 2015, AMBS, V1, P46.
   Lawan A, 2015, MOL CELL BIOL, V35, P26, DOI 10.1128/MCB.00503-14.
   Leslie Nick R, 2012, Adv Biol Regul, V52, P205.
   Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0.
   Liu XX, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-356.
   Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7.
   Lu MJ, 2012, NAT MED, V18, P388, DOI 10.1038/nm.2686.
   Luo GH, 2016, SCI REP-UK, V6, P1, DOI {[}10.1038/srep35231, 10.1038/srep37473, 10.1038/s41598-016-0027-y].
   MacLaren R, 2008, J LIPID RES, V49, P308, DOI 10.1194/jlr.M700199-JLR200.
   Manna P, 2011, J BIOL CHEM, V286, P39848, DOI 10.1074/jbc.M111.270884.
   McLaughlin T, 2004, METABOLISM, V53, P495, DOI 10.1016/j.metabol.2003.10.032.
   Mechanick JI, 2006, JPEN-PARENTER ENTER, V30, P157, DOI 10.1177/0148607106030002157.
   Miao DS, 2001, J BIOL CHEM, V276, P32204, DOI 10.1074/jbc.M101084200.
   Morino K, 2006, DIABETES, V55, pS9, DOI 10.2337/db06-S002.
   Nakashima N, 2000, J BIOL CHEM, V275, P12889, DOI 10.1074/jbc.275.17.12889.
   Neto-Ferreira R, 2013, DIABETOL METAB SYNDR, V5, DOI 10.1186/1758-5996-5-32.
   Nonogaki K, 2000, DIABETOLOGIA, V43, P533, DOI 10.1007/s001250051341.
   O'Brien RM, 2001, BIOCHEM SOC T, V29, P552, DOI 10.1042/BST0290552.
   Olsen Karina Standahl, 2015, Curr Nutr Rep, V4, P377, DOI {[}10.1007/s13668-015-0143-5, 10.1007/s13668-015-0143-5].
   Ono H, 2001, MOL ENDOCRINOL, V15, P1411, DOI 10.1210/me.15.8.1411.
   Ortega A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061188.
   Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7.
   Perry JRB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002741.
   Rains JL, 2011, FREE RADICAL BIO MED, V50, P567, DOI 10.1016/j.freeradbiomed.2010.12.006.
   Rajkovic N, 2014, INT J ENV RES PUB HE, V11, P4049, DOI 10.3390/ijerph110404049.
   Ryu D, 2011, DIABETES, V60, P1072, DOI 10.2337/db10-1046.
   Samuel VT, 2007, J CLIN INVEST, V117, P739, DOI 10.1172/JCI30400.
   Samuel VT, 2016, J CLIN INVEST, V126, P12, DOI 10.1172/JCI77812.
   Samuel VT, 2004, J BIOL CHEM, V279, P32345, DOI 10.1074/jbc.M313478200.
   Santoleri D, 2019, CELL MOL GASTROENTER, V7, P447, DOI 10.1016/j.jcmgh.2018.10.016.
   Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200.
   Singh LP, 2001, J DIABETES COMPLICAT, V15, P88, DOI 10.1016/S1056-8727(00)00140-9.
   Surwit RS, 2002, DIABETES CARE, V25, P30, DOI 10.2337/diacare.25.1.30.
   Tong Z, 2009, CELL RES, V19, P710, DOI 10.1038/cr.2009.42.
   Valenti L, 2008, DIABETES, V57, P1355, DOI 10.2337/db07-0714.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wasserman DH, 2005, CLIN EXP PHARMACOL P, V32, P319, DOI 10.1111/j.1440-1681.2005.04191.x.
   Wijesekara N, 2005, MOL CELL BIOL, V25, P1135, DOI 10.1128/MCB.25.3.1135-1145.2005.
   Willett W, 2002, AM J CLIN NUTR, V76, p274S, DOI 10.1093/ajcn/76.1.274S.
   Ye YM, 2013, AM J PHYSIOL-HEART C, V304, pH131, DOI 10.1152/ajpheart.00609.2012.
   Zhou J, 2017, CELL PHYSIOL BIOCHEM, V43, P1841, DOI 10.1159/000484070.},
Number-of-Cited-References = {59},
Times-Cited = {2},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Nutr. Metab.},
Doc-Delivery-Number = {MO8UY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000551794700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000544902000001,
Author = {Peng, Cheng and Hou, Sheng-Tao and Deng, Chu-Xia and Zhang, Yandong},
Title = {Function of DHX33 in promoting Warburg effect via regulation of
   glycolytic genes},
Journal = {JOURNAL OF CELLULAR PHYSIOLOGY},
Year = {2021},
Volume = {236},
Number = {2},
Pages = {981-996},
Month = {FEB},
Abstract = {Cancer cells metabolize glucose through glycolysis to promote cell
   proliferation even with abundant oxygen. Multiple glycolysis genes are
   deregulated during cancer development. Despite intensive effort, the
   cause of their deregulation remains incompletely understood. Here in
   this study, we discovered that DHX33 plays a critical role in Warburg
   effect of cancer cells. DHX33 deficient cells have markedly reduced
   glycolysis activity. Through RNA-seq analysis, we found multiple
   critical genes involved in Warburg effect were downregulated after DHX33
   deficiency. These genes include lactate dehydrogenase A (LDHA), pyruvate
   dehydrogenase kinase 1 (PDK1), pyruvate kinase muscle isoform 2 (PKM2),
   enolase 1 (ENO1), ENO2, hexokinase 1/2, among others. With LDHA, PDK1,
   and PKM2 as examples, we further revealed that DHX33 altered the
   epigenetic marks around the promoter of glycolytic genes. This is
   through DHX33 in complex with Gadd45a-a growth arrest and DNA damage
   protein. DHX33 is required for the loading of Gadd45a and DNA
   dioxygenase Tet1 at the promoter sites, which resulted in active DNA
   demethylation and enhanced histone H4 acetylation. We conclude that
   DHX33 changes local epigenetic marks in favor of the transcription of
   glycolysis genes to promote cancer cell proliferation. Our study
   highlights the significance of RNA helicase DHX33 in Warburg effect and
   cancer therapeutics.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, YD (Corresponding Author), Southern Univ Sci \& Technol, Dept Biol, 1088 Xueyuan Blvd, Shenzhen 518055, Guangdong, Peoples R China.
   Deng, CX (Corresponding Author), Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.
   Peng, Cheng; Hou, Sheng-Tao; Zhang, Yandong, Southern Univ Sci \& Technol, Dept Biol, 1088 Xueyuan Blvd, Shenzhen 518055, Guangdong, Peoples R China.
   Peng, Cheng; Deng, Chu-Xia, Univ Macau, Fac Hlth Sci, Taipa, Macao, Peoples R China.
   Zhang, Yandong, Shenzhen KeYe Life Technol Co Ltd, Shenzhen, Guangdong, Peoples R China.},
DOI = {10.1002/jcp.29909},
EarlyAccessDate = {JUL 2020},
ISSN = {0021-9541},
EISSN = {1097-4652},
Keywords = {demethylation; DHX33; Gadd45a; glycolysis; RNA helicase; Warburg effect},
Keywords-Plus = {RNA; EXPRESSION; GROWTH; TRANSCRIPTION; TRANSLATION; ADAPTATION;
   ACTIVATION; KINASE; TUMORS; CELLS},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {cxdeng@umac.mo
   zhangyd@sustech.edu.cn},
Affiliations = {Southern University of Science \& Technology; University of Macau},
ResearcherID-Numbers = {Hou, Sheng Tao/AAM-7756-2020
   Zhang, Yandong/AAE-2231-2019},
ORCID-Numbers = {Hou, Sheng Tao/0000-0001-9736-342X
   Zhang, Yandong/0000-0002-1900-7224},
Funding-Acknowledgement = {Shenzhen KeYe Life Technologies, Co., Ltd.; Science and Technology
   Innovation Committee of Shenzhen Municipality {[}CKCY2017072116462727]},
Funding-Text = {Shenzhen KeYe Life Technologies, Co., Ltd.; Science and Technology
   Innovation Committee of Shenzhen Municipality, Grant/Award Number:
   CKCY2017072116462727},
Cited-References = {Arab K, 2019, NAT GENET, V51, P217, DOI 10.1038/s41588-018-0306-6.
   Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001.
   Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281.
   Dumelie JG, 2017, ELIFE, V6, DOI 10.7554/eLife.28306.
   Fraile JM, 2018, J BIOL CHEM, V293, P2183, DOI 10.1074/jbc.M117.788430.
   Fu JJ, 2017, CARCINOGENESIS, V38, P649, DOI 10.1093/carcin/bgx041.
   Goetze K, 2011, INT J ONCOL, V39, P453, DOI 10.3892/ijo.2011.1055.
   Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795.
   Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172.
   Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110.
   Kienhöfer S, 2015, DIFFERENTIATION, V90, P59, DOI 10.1016/j.diff.2015.10.003.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Linder P, 2011, NAT REV MOL CELL BIO, V12, P505, DOI 10.1038/nrm3154.
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796.
   Lüking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233.
   Mitoma H, 2013, IMMUNITY, V39, P123, DOI 10.1016/j.immuni.2013.07.001.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Patel SS, 2006, J BIOL CHEM, V281, P18265, DOI 10.1074/jbc.R600008200.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Schüle KM, 2019, GENE DEV, V33, P782, DOI 10.1101/gad.325696.119.
   Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002.
   Sciacovelli M, 2014, METHOD ENZYMOL, V542, P1, DOI 10.1016/B978-0-12-416618-9.00001-7.
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040.
   Tian QH, 2016, BIOCHEM BIOPH RES CO, V473, P1163, DOI 10.1016/j.bbrc.2016.04.033.
   Villar J, 2012, MOL CELL BIOL, V32, P1566, DOI 10.1128/MCB.06002-11.
   Wahlström T, 2015, BBA-GENE REGUL MECH, V1849, P563, DOI 10.1016/j.bbagrm.2014.07.004.
   Wang J., 2019, MOL CELL BIOL, P39.
   Wang XS, 2019, BIOCHEMISTRY-US, V58, P250, DOI 10.1021/acs.biochem.8b00166.
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519.
   Xiao R, 2019, CELL, V178, P107, DOI 10.1016/j.cell.2019.06.001.
   Yuan BL, 2016, MOL CELL BIOL, V36, P2903, DOI 10.1128/MCB.00314-16.
   Zhang YD, 2015, MOL CELL BIOL, V35, P2918, DOI 10.1128/MCB.00315-15.
   Zhang YD, 2013, MOL CELL BIOL, V33, P1594, DOI 10.1128/MCB.01220-12.
   Zhang YD, 2011, MOL CELL BIOL, V31, P4676, DOI 10.1128/MCB.05832-11.},
Number-of-Cited-References = {34},
Times-Cited = {15},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {J. Cell. Physiol.},
Doc-Delivery-Number = {OU0IY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000544902000001},
DA = {2026-02-04},
}

@article{ WOS:000546681500025,
Author = {Chakrabarti, Anirikh and Eiden, Michael and Morin-Rivron, Delphine and
   Christinat, Nicolas and Monteiro, Jacqueline P. and Kaput, Jim and
   Masoodi, Mojgan},
Title = {Impact of multi-micronutrient supplementation on lipidemia of children
   and adolescents},
Journal = {CLINICAL NUTRITION},
Year = {2020},
Volume = {39},
Number = {7},
Pages = {2211-2219},
Month = {JUL},
Abstract = {Background: Micronutrient supplementation has been extensively explored
   as a strategy to improve health and reduce risk of chronic diseases.
   Fat-soluble vitamins like A and E with their antioxidant properties and
   mechanistic interactions with lipoproteins, have potentially a key
   impact on lipid metabolism and lipidemia.
   Objective: The impact of micronutrients on lipid metabolism requires
   further investigation including characterization of plasma lipidome
   following supplementation and any cause-effect on circulating lipids.
   Design: In this study, we elucidate the effect and associations of a
   multi-micronutrient intervention in Brazilian children and teens with
   lipoprotein alterations and lipid metabolism.
   Results: Our analysis suggests a combination of short and long-term
   impact of supplementation on lipid metabolism, potentially mediated
   primarily by alpha-tocopherol (vitamin E) and retinol (vitamin A). Among
   the lipid classes, levels of phospholipids, lysophospholipids, and
   cholesterol esters were impacted the most along with differential
   incorporation of stearic, palmitic, oleic and arachidonic acids.
   Integrated analysis with proteomic data suggested potential links to
   supplementation-mediated alterations in protein levels of phospholipases
   and pyruvate dehydrogenase kinase 1 (PDK1).
   Conclusions: Associations between the observed differences in lipidemia,
   total triglyceride, and VLDL-cholesterol levels suggest that
   micronutrients may play a role in reducing these risk factors for
   cardiovascular disease in children. This would require further
   investigation. (C) 2019 The Author(s). Published by Elsevier Ltd.},
Publisher = {CHURCHILL LIVINGSTONE},
Address = {JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND},
Type = {Article},
Language = {English},
Affiliation = {Masoodi, M (Corresponding Author), Univ Bern, Bern Univ Hosp, Inselspital, Inst Clin Chem, Bern, Switzerland.
   Chakrabarti, Anirikh; Eiden, Michael; Morin-Rivron, Delphine; Christinat, Nicolas; Masoodi, Mojgan, EPFL Innovat Pk, Lipid Metab, Nestle Res, CH-1015 Lausanne, Switzerland.
   Kaput, Jim, EPFL Innovat Pk, Nestle Res, CH-1015 Lausanne, Switzerland.
   Eiden, Michael, Eidea Biosci Ltd, Cambridge, England.
   Monteiro, Jacqueline P., Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Bandeirantes Ave 3900, BR-14049900 Ribeirao Preto, Brazil.
   Monteiro, Jacqueline P., Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Hlth Sci, Bandeirantes Ave 3900, BR-14049900 Ribeirao Preto, Brazil.
   Masoodi, Mojgan, Bern Univ Hosp, Inst Clin Chem, Inselspital, Bern, Switzerland.},
DOI = {10.1016/j.clnu.2019.09.010},
ISSN = {0261-5614},
EISSN = {1532-1983},
Keywords = {Micronutrients; Vitamins; Lipoproteins; Lipidomics; Lipidemia;
   Cardiovascular health},
Keywords-Plus = {TOCOTRIENOL-RICH FRACTION; VITAMIN-A-DEFICIENCY; SERUM 25-HYDROXYVITAMIN
   D; CARDIOVASCULAR-DISEASE; WOMENS HEALTH; METABOLISM; LIPOPROTEINS;
   PREVENTION; EFFICACY; CANCER},
Research-Areas = {Nutrition \& Dietetics},
Web-of-Science-Categories  = {Nutrition \& Dietetics},
Author-Email = {mojgan.maoodi@insel.ch},
Affiliations = {Swiss Federal Institutes of Technology Domain; Ecole Polytechnique
   Federale de Lausanne; Nestle SA; Nestle Research Center; Swiss Federal
   Institutes of Technology Domain; Ecole Polytechnique Federale de
   Lausanne; Nestle SA; Nestle Research Center; Universidade de Sao Paulo;
   Universidade de Sao Paulo; University of Bern; University Hospital of
   Bern},
ResearcherID-Numbers = {Pontes Monteiro, Jacqueline/F-6987-2012
   MASOODI, MOJGAN/P-1499-2019
   Kaput, Jim/GSD-5978-2022},
ORCID-Numbers = {Pontes Monteiro, Jacqueline/0000-0001-7141-7776
   Delphine, Morin-Rivron/0000-0002-9168-3163
   },
Funding-Acknowledgement = {Nestle Institute of Health Sciences},
Funding-Text = {AC, DMR, NC and MM were employees of Nestle SA. MM currently works at
   University Hospital Bern. ME works for Eidea Bioscience Ltd., JK works
   for Vydiant Inc. The study was funded by Nestle Institute of Health
   Sciences.},
Cited-References = {Adaikalakoteswari A, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/s12933-014-0129-4.
   Al-Attas O, 2014, CLIN MED INSIGHTS-EN, V7, P1, DOI 10.4137/CMED.S13573.
   Alexander DD, 2013, J AM COLL NUTR, V32, P339, DOI 10.1080/07315724.2013.839909.
   Vega VA, 2009, NUTRITION, V25, P828, DOI 10.1016/j.nut.2009.01.008.
   {[}Anonymous], 2005, JAMA-J AM MED ASSOC, V293, P1338.
   Ashraf AP, 2011, OBESITY, V19, P2214, DOI 10.1038/oby.2011.110.
   Barbagallo Mario, 2003, Molecular Aspects of Medicine, V24, P39, DOI 10.1016/S0098-2997(02)00090-0.
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x.
   Birjmohun RS, 2005, J AM COLL CARDIOL, V45, P185, DOI 10.1016/j.jacc.2004.10.031.
   Briassoulis G, 2017, CRIT CARE MED, V45, P376, DOI 10.1097/CCM.0000000000002122.
   Burdeos GC, 2012, LIPIDS, V47, P471, DOI 10.1007/s11745-012-3659-0.
   CAO YZ, 1987, BIOCHEM J, V247, P135, DOI 10.1042/bj2470135.
   Carta G, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00902.
   Cheng TY, 2001, J NUTR BIOCHEM, V12, P388, DOI 10.1016/S0955-2863(01)00153-X.
   Christinat N, 2017, J PROTEOME RES, V16, P2947, DOI 10.1021/acs.jproteome.7b00236.
   Clarke BL, 2012, YB ENDOCRINOL, V2012, P192.
   Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI {[}10.1172/JCI200523621, 10.1172/JCI23621].
   Doshi SN, 2002, CIRCULATION, V105, P22, DOI 10.1161/hc0102.101388.
   Earnest C, 2002, NUTRITION, V18, P738, DOI 10.1016/S0899-9007(02)00808-0.
   Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351.
   FIDANZA A, 1982, Acta Vitaminologica et Enzymologica, V4, P105.
   Fitrolaki MD, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004651.
   Gersh BJ, 2009, YB CARDIOL, V2009, P319.
   Gibson S, 2003, PUBLIC HEALTH NUTR, V6, P815, DOI 10.1079/PHN2003493.
   Gimenez MS, 2011, INT J MOL SCI, V12, P2408, DOI 10.3390/ijms12042408.
   Gold L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015004.
   Grodstein F, 2013, ANN INTERN MED, V159, P806, DOI 10.7326/0003-4819-159-12-201312170-00006.
   Heng EC, 2013, EUR J NUTR, V52, P1811, DOI 10.1007/s00394-012-0485-3.
   Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335.
   Kelishadi R, 2014, INT J FOOD SCI NUTR, V65, P404, DOI 10.3109/09637486.2014.886186.
   Khaw KT, 2014, AM J CLIN NUTR, V100, P1361, DOI 10.3945/ajcn.114.086413.
   Lavine JE, 2000, J PEDIATR-US, V136, P734, DOI 10.1016/S0022-3476(00)05040-X.
   Lavine JE, 2011, JAMA-J AM MED ASSOC, V305, P1659, DOI 10.1001/jama.2011.520.
   Lee Howell M, 2012, FOOD SCI NUTR.
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56.
   Liu SM, 2006, DIABETES, V55, P2856, DOI 10.2337/db06-0456.
   Mathias MG, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700613.
   Mikirova N, 2014, VITAM MINER, V3.
   Oliveros LB, 2007, BRIT J NUTR, V97, P263, DOI 10.1017/S0007114507182659.
   Partida-Hernández G, 2006, BIOMED PHARMACOTHER, V60, P161, DOI 10.1016/j.biopha.2006.02.004.
   Qureshi AA, 2001, J NUTR BIOCHEM, V12, P318, DOI 10.1016/S0955-2863(01)00144-9.
   Rai KN, 2013, J CLIN DIAGN RES, V7, P1314, DOI 10.7860/JCDR/2013/6127.3124.
   Rautiainen S, 2016, NAT REV ENDOCRINOL, V12, P407, DOI 10.1038/nrendo.2016.54.
   REDDY TS, 1983, INT J VITAM NUTR RES, V53, P9.
   SAKURAGI T, 1959, J AM OIL CHEM SOC, V36, P251, DOI 10.1007/BF02640070.
   Sauvant P, 2011, J PHYSIOL BIOCHEM, V67, P487, DOI 10.1007/s13105-011-0101-7.
   Siddharth J, 2017, AGING-US, V9, P1698, DOI 10.18632/aging.101262.
   Surma MA, 2015, EUR J LIPID SCI TECH, V117, P1540, DOI 10.1002/ejlt.201500145.
   Toffano RBD, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020154.
   Vacek JL, 2012, AM J CARDIOL, V109, P359, DOI 10.1016/j.amjcard.2011.09.020.
   Vanhees K, 2014, CELL MOL LIFE SCI, V71, P271, DOI 10.1007/s00018-013-1427-9.
   Visioli F, 2007, PHARMACOL RES, V55, P199, DOI 10.1016/j.phrs.2007.01.008.
   Ward E, 2014, NUTR J, V13, DOI 10.1186/1475-2891-13-72.
   Winzenberg T, 2013, CALCIFIED TISSUE INT, V92, P140, DOI 10.1007/s00223-012-9615-4.
   Wu SJ, 2008, MOL NUTR FOOD RES, V52, P921, DOI 10.1002/mnfr.200700418.
   Yakoob MY, 2017, J DEV BEHAV PEDIATR, V38, P665, DOI 10.1097/DBP.0000000000000482.},
Number-of-Cited-References = {56},
Times-Cited = {17},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Clin. Nutr.},
Doc-Delivery-Number = {MH4DI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000546681500025},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000538199100013,
Author = {Jothi, Jayalakshmi and Janardhanam, Vanisree Arambakkam and Rama, K.},
Title = {Connexin 30 mediated rewiring of glucose metabolism in rat C6 xenograft
   and grades of glioma},
Journal = {MOLECULAR AND CELLULAR BIOCHEMISTRY},
Year = {2020},
Volume = {470},
Number = {1-2},
Pages = {157-164},
Month = {JUL},
Abstract = {Connexin 30 (Cx30), a tumour-suppressive gap junctional protein, impacts
   on insulin-like growth factor receptor 1-mediated progression and
   stemness of glioma. Of late, metabolic reprogramming, a recently
   adjudged hall mark of malignancy, could reasonably associated with the
   changes in gap junctional communication in glioma. This newly recognized
   hallmark of reprogramming of metabolism to maintain the rapid
   proliferation necessitates further probing to establish the stronger
   hall marks. Hence, the current study attempted to link the association
   between the expression of Cx30 with glucose uptake and glucose
   metabolism in glioma. We have transfected Cx30 in C6 glioma cells,
   characterized by a low level of intercellular communication and
   developed xenografts to study the status of glucose transporters
   (GLUTs), hexokinase 2 and Pyruvate dehydrogenase kinase 1 (PDK 1) along
   with human glioma tissues by RT-PCR and immunoblotting. The results
   showed a significant increase in the levels of GLUTs, hexokinase 2 and
   PDK 1 in C6-implanted rat xenografts and high grades compared to their
   respective controls, whereas Cx30-transfected C6-implanted rat xenograft
   and low grades show no significant change compared to that of controls
   supporting the association between Gap junctional communications and
   glucose metabolism. We strongly speculate the impact of Cx30 over the
   glucose metabolism that might provide therapeutic prospects and
   challenges for anti-glycolytic cancer therapy.},
Publisher = {SPRINGER},
Address = {VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Janardhanam, VA (Corresponding Author), Univ Madras, Dept Biochem, Chennai 600025, Tamil Nadu, India.
   Jothi, Jayalakshmi; Janardhanam, Vanisree Arambakkam, Univ Madras, Dept Biochem, Chennai 600025, Tamil Nadu, India.
   Rama, K., Madras Med Coll \& Govt Gen Hosp, Dept Neuropathol, Chennai 600003, Tamil Nadu, India.
   Rama, K., Govt Gen Hosp, Chennai 600003, Tamil Nadu, India.},
DOI = {10.1007/s11010-020-03757-z},
ISSN = {0300-8177},
EISSN = {1573-4919},
Keywords = {Connexin 30; Altered metabolism; Glucose; Glioma},
Keywords-Plus = {INTERCELLULAR COMMUNICATION; ASTROCYTES; EXPRESSION; ENDOTHELIN-1;
   TRANSPORTER; PROLIFERATION; GROWTH},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {journalsvuom@gmail.com},
Affiliations = {University of Madras; Madras Medical College \& General Hospital},
ResearcherID-Numbers = {Vanisree, AJ/ABC-9361-2020},
ORCID-Numbers = {AJ, Vanisree/0000-0001-8909-6552
   },
Funding-Acknowledgement = {University Grants Commission {[}GCCO/a-2/UGC-MERITORIOUS/2015/284]
   Funding Source: Medline},
Cited-References = {Aasen T, 2016, NAT REV CANCER, V16, P775, DOI 10.1038/nrc.2016.105.
   Abdel-Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511.
   Arun S, 2017, J NEURO-ONCOL, V135, P473, DOI 10.1007/s11060-017-2608-4.
   Arun S, 2016, BRAIN RES, V1643, P80, DOI 10.1016/j.brainres.2016.04.061.
   Cidad P, 2001, J NEUROCHEM, V79, P17, DOI 10.1046/j.1471-4159.2001.00523.x.
   Farahani R, 2005, GLIA, V50, P351, DOI 10.1002/glia.20213.
   GALARRAGA J, 1986, METAB BRAIN DIS, V1, P279, DOI 10.1007/BF00999357.
   González-Sánchez A, 2016, ONCOTARGET, V7, P49819, DOI 10.18632/oncotarget.10454.
   Herrero-González S, 2009, GLIA, V57, P222, DOI 10.1002/glia.20748.
   Jayalakshmi J, 2019, INT J NEUROSCI, V129, P273, DOI 10.1080/00207454.2018.1526802.
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57.
   Jin Z, 2013, CELL MOL NEUROBIOL, V33, P1143, DOI 10.1007/s10571-013-9980-1.
   Landis CJ, 2018, BBA-REV CANCER, V1869, P175, DOI 10.1016/j.bbcan.2018.01.004.
   Lin JG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1214-z.
   LOEWENSTEIN WR, 1966, NATURE, V209, P1248, DOI 10.1038/2091248a0.
   Marbaniang Casterland, 2018, Asian Pac J Cancer Prev, V19, P2377.
   NAGAMATSU S, 1993, J NEUROCHEM, V61, P2048, DOI 10.1111/j.1471-4159.1993.tb07441.x.
   NAUS CCG, 1991, NEUROSCI LETT, V126, P33, DOI 10.1016/0304-3940(91)90364-Y.
   Sánchez-Alvarez R, 2004, J NEUROCHEM, V89, P703, DOI 10.1046/j.1471-4159.2004.02398.x.
   Simmons R A., 2017, Fetal and Neonatal Physiology, VFifth, P428.
   Sirnes S, 2011, EPIGENETICS-US, V6, P602, DOI 10.4161/epi.6.5.15237.
   Smyth JW, 2013, CELL REP, V5, P611, DOI 10.1016/j.celrep.2013.10.009.
   Tabernero A, 1996, GLIA, V16, P187, DOI 10.1002/(SICI)1098-1136(199603)16:3<187::AID-GLIA1>3.0.CO;2-\#.
   Tabernero A, 2006, J NEUROCHEM, V99, P1049, DOI 10.1111/j.1471-4159.2006.04088.x.
   Vartanian A, 2016, ONCOTARGET, V7, P69518, DOI 10.18632/oncotarget.11680.},
Number-of-Cited-References = {25},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Mol. Cell. Biochem.},
Doc-Delivery-Number = {LV1JV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000538199100013},
DA = {2026-02-04},
}

@article{ WOS:000548729200028,
Author = {Tan, Shutang and Zhang, Xixi and Kong, Wei and Yang, Xiao-Li and Molnar,
   Gergely and Vondrakova, Zuzana and Filepova, Roberta and Petrasek, Jan
   and Friml, Jiri and Xue, Hong-Wei},
Title = {The lipid code-dependent phosphoswitch PDK1-D6PK activates PIN-mediated
   auxin efflux in Arabidopsis (vol 6, pg 556, 2020)},
Journal = {NATURE PLANTS},
Year = {2020},
Volume = {6},
Number = {7},
Pages = {897},
Month = {JUL},
Abstract = {An amendment to this paper has been published and can be accessed via a
   link at the top of the paper.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Correction},
Language = {English},
DOI = {10.1038/s41477-020-0719-y},
ISSN = {2055-026X},
EISSN = {2055-0278},
Research-Areas = {Plant Sciences},
Web-of-Science-Categories  = {Plant Sciences},
Author-Email = {jiri.friml@ist.ac.at
   hwxue@sjtu.edu.cn},
ResearcherID-Numbers = {Tan, Shutang/AAB-6227-2020
   Friml, Jiri/D-9511-2012
   Petrasek, Jan/AAW-1081-2021
   Vonakova, Zuzana/HJI-7442-2023},
ORCID-Numbers = {Vonakova, Zuzana/0000-0001-6280-2381},
Cited-References = {Tan ST, 2020, NAT PLANTS, V6, P556, DOI 10.1038/s41477-020-0648-9.},
Number-of-Cited-References = {1},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Nat. Plants},
Doc-Delivery-Number = {MK4BP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000548729200028},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000558947400002,
Author = {Wang, Hui and Zhang, Zhengdong and Yan, Zhe and Ma, Shihong},
Title = {PD-L1, PDK-1 and p-Akt are correlated in patients with papillary thyroid
   carcinoma},
Journal = {ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE},
Year = {2020},
Volume = {29},
Number = {7},
Pages = {785-792},
Month = {JUL},
Abstract = {Background. Papillary thyroid carcinoma (PTC) is the most common type of
   thyroid carcinoma.
   Objectives. To investigate the clinical significance of programmed death
   ligand 1 (PD-L1) and phosphoinositide-dependent protein kinase 1 (PDK1)
   in PTC.
   Material and methods. A total of 194 PTC patients were recruited.
   Contralateral normal thyroid tissues were obtained and used as controls
   (n = 80). The expression levels of PD-L1, PDK1 and p-Akt were determined
   using immunohistochemistry.
   Results. The PD-L1, PDK1 and p-Akt were upregulated in cancer tissues
   compared to the normal tissues. The mean optical density (MOD) values of
   PD-L1, PDK1 and p-Akt were significantly higher in the PTC tissues. The
   expression of PD-L1 positively correlated with the levels of PDK1 and
   p-Akt. In addition, the expression of PD-L1, PDK1 and p-Akt in PTC
   patients without chronic lymphocytic thyroiditis (CLT) was significantly
   higher than the expression of those proteins in the CLT patients. The
   patients with higher expression levels of PD-L1, PDK1 or p-Akt had
   remarkably larger tumors and higher rates of TNM III-IV, capsular
   infiltration, lymph node metastasis, and of recurrence. The Kaplan-Meier
   curve showed that patients with lower expression of PD-L1, PDK1 or p-Akt
   had significantly longer recurrence-free time. The logistic regression
   analysis revealed that only CLT, PD-L and capsular infiltration were
   risk factors for patients' five-year recurrence.
   Conclusions. The PD-L1, PDK1 and p-Akt were found to be positively
   correlated with a poor prognosis in PTC.},
Publisher = {WROCLAW MEDICAL UNIV},
Address = {UL K MARCINKOWSKIEGO 2-6, WROCLAW, 50-368, POLAND},
Type = {Article},
Language = {English},
Affiliation = {Ma, SH (Corresponding Author), Shanghai Xuhui Ctr Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   Wang, Hui; Zhang, Zhengdong; Yan, Zhe; Ma, Shihong, Shanghai Xuhui Ctr Hosp, Dept Gen Surg, Shanghai, Peoples R China.},
DOI = {10.17219/acem/121518},
ISSN = {1899-5276},
EISSN = {2451-2680},
Keywords = {prognosis; papillary thyroid carcinoma; p-Akt; sPD-L1; PDK-1},
Keywords-Plus = {CANCER; EXPRESSION},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {msh191203@yeah.net},
Funding-Acknowledgement = {Foundation for Development of Clinical Medical Science and Technology
   {[}JLY20180041]; Research Foundation of Xuhui Center Hospital
   {[}2018XHYY-10]},
Funding-Text = {The study was funded by the Foundation for Development of Clinical
   Medical Science and Technology (grant No. JLY20180041) and the Research
   Foundation of Xuhui Center Hospital (grant No. 2018XHYY-10).},
Cited-References = {Abdullah MI, 2019, INT J MED SCI, V16, P450, DOI 10.7150/ijms.29935.
   Aghajani MJ, 2019, ENDOCR CONNECT, V8, P1040, DOI 10.1530/EC-19-0210.
   Arianpoor A, 2020, ACTA CHIR BELG, V120, P173, DOI 10.1080/00015458.2019.1576447.
   Bongiovanni M, 2017, ENDOCR-RELAT CANCER, V24, pL35, DOI 10.1530/ERC-17-0104.
   Boos LA, 2019, CANCERS, V11, DOI 10.3390/cancers11060885.
   Chen JM, 2018, INT J CLIN EXP MED, V11, P1401.
   Chintakuntlawar AV, 2017, J CLIN ENDOCR METAB, V102, P1943, DOI 10.1210/jc.2016-3756.
   de Paiva CR, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00053.
   Dincel O, 2017, BRATISL MED J, V118, P153, DOI 10.4149/BLL\_2017\_030.
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527.
   Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020.
   Ji WS, 2018, PLOS ONE, V13.
   Jiao SP, 2017, CLIN CANCER RES, V23, P3711, DOI 10.1158/1078-0432.CCR-16-3215.
   Lai XJ, 2017, ONCOTARGET, V8, P62414, DOI 10.18632/oncotarget.18620.
   LeBoeuf B, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-2887.
   Lian SX, 2015, ONCOTARGET, V6, P29076, DOI 10.18632/oncotarget.4931.
   Liang JL, 2018, J PATHOL, V244, P215, DOI 10.1002/path.5005.
   Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719.
   Liu W, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008365.
   Lubin D, 2018, ENDOCR PATHOL, V29, P317, DOI 10.1007/s12022-018-9540-9.
   Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746.
   Pilli T, 2018, J ENDOCRINOL INVEST, V41, P703, DOI 10.1007/s40618-017-0794-8.
   Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186.
   Tanaka T, 2017, ONCOTARGET, V8, P24706, DOI 10.18632/oncotarget.14960.
   Trotter DEG, 2017, J NUCL MED, V58, P1852, DOI 10.2967/jnumed.117.191718.
   Vita R, 2018, REV ENDOCR METAB DIS, V19, P301, DOI 10.1007/s11154-018-9474-z.
   Wang JJ, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1659092.
   Xu JY, 2015, ONCOL REP, V34, P1424, DOI 10.3892/or.2015.4096.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.},
Number-of-Cited-References = {29},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Adv. Clin. Exp. Med.},
Doc-Delivery-Number = {MZ2IN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000558947400002},
OA = {gold},
DA = {2026-02-04},
}

@article{ WOS:000547330300005,
Author = {Wu, Zhou-Wei and Li, Wei-Bo and Zhou, Jing and Liu, Xin and Wang, Lun
   and Chen, Bin and Wang, Ming-Kui and Ji, Lilian and Hu, Wei-Cheng and
   Li, Fu},
Title = {Oleanane- and Ursane-Type Triterpene Saponins from Centella
   asiatica Exhibit Neuroprotective Effects},
Journal = {JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY},
Year = {2020},
Volume = {68},
Number = {26},
Pages = {6977-6986},
Month = {JUL 1},
Abstract = {Six new pentacyclic triterpenoid saponins, centelloside F (1),
   centelloside G (2), 11-oxo-asiaticoside B (3), 11-oxo-madecassoside (4),
   11(beta)-methoxy asiaticoside B (5), and 11(beta)-methoxy madecassoside
   (6), along with seven known ones, asiaticoside (7), asiaticoside B (8),
   madecassoside (9), centellasaponin A (10), isoasiaticoside (11),
   scheffoleoside A (12), and centelloside E (13), were separated from the
   80\% MeOH extract of the whole plant of Centella asiatica, which has
   been used as a medicinal plant and is now commercially available as a
   diatery supplement in many countries. Compounds 1 and 2, 3 and 4, and 5
   and 6 are three pairs of isomers with oleanane- or ursane-type
   triterpenes as aglycones. The chemical structures of the new triterpene
   saponins were fully characterized by extensive analysis of their nuclear
   magnetic resonance and high-resolution electrospray ionization mass
   spectrometry data. The protective effects of compounds 1-13 on PC12
   cells induced by 6-OHDA were screened, and compound 3 displayed the best
   neuroprotective effect, with 91.75\% cell viability at the concentration
   of 100 mu M. Moreover, compound 3 also attenuated cell apoptosis and
   increased the mRNA expression of antioxidant enzymes, including
   superoxide dismutase and catalase. Additionally, compound 3 activated
   the phosphatidylinositol 3-kinase/Akt pathway, including PDK1, Akt, and
   GSK-3 beta. These findings suggested that triterpene saponins from C.
   asiatica were worthy of further biological research to develop new
   neuroprotective agents.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Hu, WC (Corresponding Author), Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Jiangsu, Peoples R China.
   Li, F (Corresponding Author), Chinese Acad Sci, Nat Prod Res Ctr, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China.
   Li, Wei-Bo; Zhou, Jing; Ji, Lilian; Hu, Wei-Cheng, Huaiyin Normal Univ, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Huaian 223300, Jiangsu, Peoples R China.
   Wu, Zhou-Wei; Wang, Lun; Chen, Bin; Wang, Ming-Kui; Li, Fu, Chinese Acad Sci, Nat Prod Res Ctr, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China.
   Liu, Xin, Tech Ctr Beijing Customs Dist, Beijing 100026, Peoples R China.},
DOI = {10.1021/acs.jafc.0c01476},
ISSN = {0021-8561},
EISSN = {1520-5118},
Keywords = {Centella asiatica; triterpene saponins; neuroprotective activity},
Keywords-Plus = {NF-KAPPA-B; PENTACYCLIC TRITERPENOIDS; PARKINSONS-DISEASE; MEDICINAL
   FOODSTUFFS; INDUCED APOPTOSIS; GOTU-KOLA; CELLS; CANCER; IDENTIFICATION;
   PROLIFERATION},
Research-Areas = {Agriculture; Chemistry; Food Science \& Technology},
Web-of-Science-Categories  = {Agriculture, Multidisciplinary; Chemistry, Applied; Food Science \&
   Technology},
Author-Email = {hu\_weicheng@163.com
   lifu@cib.ac.cn},
Affiliations = {Huaiyin Normal University; Chinese Academy of Sciences; Chengdu
   Institute of Biology, CAS},
ResearcherID-Numbers = {Chen, Bin/T-4634-2019},
Funding-Acknowledgement = {Natural Science Foundation of the Higher Education Institutions of
   Jiangsu Province {[}17KJA550001]},
Funding-Text = {This research was financially supported by the Natural Science
   Foundation of the Higher Education Institutions of Jiangsu Province
   (17KJA550001).},
Cited-References = {AHMAD VU, 1986, PHYTOCHEMISTRY, V25, P1487.
   Angelova PR, 2016, FREE RADICAL BIO MED, V100, P81, DOI 10.1016/j.freeradbiomed.2016.06.005.
   Asadi N, 2017, J CLIN DIAGN RES, V11, DOI 10.7860/JCDR/2017/23927.9886.
   Brinkhaus B, 2000, PHYTOMEDICINE, V7, P427, DOI 10.1016/S0944-7113(00)80065-3.
   Cheng SY, 2011, J NAT PROD, V74, P1744, DOI 10.1021/np2002435.
   Cui C, 2016, BIOCHEM BIOPH RES CO, V470, P375, DOI 10.1016/j.bbrc.2016.01.035.
   Dalmagro AP, 2019, CHEM-BIOL INTERACT, V314, DOI 10.1016/j.cbi.2019.108843.
   Fang JY, 2017, NEUROPSYCH DIS TREAT, V13, P723, DOI 10.2147/NDT.S113998.
   Fukuda Y, 2006, J NAT PROD, V69, P142, DOI 10.1021/np0581014.
   Gray NE, 2018, PHYTOCHEM REV, V17, P161, DOI 10.1007/s11101-017-9528-y.
   Harischandra DS, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.165533.
   He LL, 2019, J CELL PHYSIOL, V234, P4267, DOI 10.1002/jcp.27195.
   Hou YA, 2019, J AGR FOOD CHEM, V67, P8227, DOI 10.1021/acs.jafc.9b02680.
   Hu WC, 2014, CHEM-BIOL INTERACT, V224, P108, DOI 10.1016/j.cbi.2014.10.011.
   James J, 2011, JPC-J PLANAR CHROMAT, V24, P82, DOI 10.1556/JPC.24.2011.1.16.
   Jin X, 2019, J CELL MOL MED, V23, P3897, DOI 10.1111/jcmm.14263.
   Kai GQ, 2014, J CHROMATOGR SCI, V52, P532, DOI 10.1093/chromsci/bmt132.
   KOJIMA H, 1987, PHYTOCHEMISTRY, V26, P1107, DOI 10.1016/S0031-9422(00)82359-6.
   Kumar S, 2018, ISS ONLINE EDUC, P3.
   Kwon KJ, 2014, MOL MED REP, V10, P503, DOI 10.3892/mmr.2014.2159.
   Lee DJ, 2018, NEURAL REGEN RES, V13, P1342, DOI 10.4103/1673-5374.235220.
   Li F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08203-7.
   Li R, 2017, NEUROCHEM RES, V42, P3005, DOI 10.1007/s11064-017-2333-6.
   Li Y, 2017, BIOMED PHARMACOTHER, V93, P435, DOI 10.1016/j.biopha.2017.06.058.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4.
   MAEDA C, 1994, PHYTOCHEMISTRY, V37, P1131, DOI 10.1016/S0031-9422(00)89543-6.
   Matsuda H, 2001, HETEROCYCLES, V55, P1499.
   Matsuda H, 2001, CHEM PHARM BULL, V49, P1368, DOI 10.1248/cpb.49.1368.
   Nhiem Nguyen Xuan, 2011, Bioorg Med Chem Lett, V21, P1777, DOI 10.1016/j.bmcl.2011.01.066.
   Sabaragamuwa R, 2018, TRENDS FOOD SCI TECH, V79, P88, DOI 10.1016/j.tifs.2018.07.024.
   SAHU NP, 1989, PHYTOCHEMISTRY, V28, P2852, DOI 10.1016/S0031-9422(00)98106-8.
   Shao Y, 2015, HELV CHIM ACTA, V98, P683, DOI 10.1002/hlca.201400283.
   Shao Y, 2014, HELV CHIM ACTA, V97, P992, DOI 10.1002/hlca.201300382.
   Shen XQ, 2019, BIOSCI BIOTECH BIOCH, V83, P561, DOI 10.1080/09168451.2018.1547627.
   Shukla A, 1999, J ETHNOPHARMACOL, V65, P1, DOI 10.1016/S0378-8741(98)00141-X.
   Song ZL, 2020, J AGR FOOD CHEM, V68, P2214, DOI 10.1021/acs.jafc.9b06360.
   Subaraja M, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2019.152833.
   Viswanathan G, 2019, J ETHNOPHARMACOL, V236, P474, DOI 10.1016/j.jep.2019.03.017.
   Wang YN, 2017, BIOMED PHARMACOTHER, V93, P1230, DOI 10.1016/j.biopha.2017.07.024.
   Weng XX, 2012, HELV CHIM ACTA, V95, P255, DOI 10.1002/hlca.201100287.
   Woo SU, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.86.
   Wu X, 2018, NEUROCHEM RES, V43, P886, DOI 10.1007/s11064-018-2494-y.
   Xu CL, 2013, FITOTERAPIA, V90, P112, DOI 10.1016/j.fitote.2013.07.009.
   Yan TX, 2019, EXP GERONTOL, V128, DOI 10.1016/j.exger.2019.110743.
   Yu QL, 2007, CHINESE CHEM LETT, V18, P62, DOI 10.1016/j.cclet.2006.11.033.
   Zhang JM, 2018, CARBOHYD POLYM, V198, P537, DOI 10.1016/j.carbpol.2018.06.121.
   Zhu J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.488.},
Number-of-Cited-References = {48},
Times-Cited = {39},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {57},
Journal-ISO = {J. Agric. Food Chem.},
Doc-Delivery-Number = {MI3SK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)},
Unique-ID = {WOS:000547330300005},
DA = {2026-02-04},
}

@article{ WOS:000563273900010,
Author = {Yan, Meiyu and Liu, Qiliang and Jiang, Yumei and Wang, Bo and Ji, Yi and
   Liu, Huizhu and Xie, Yun},
Title = {Long Noncoding RNA LNC\_000898 Alleviates Cardiomyocyte Apoptosis and
   Promotes Cardiac Repair After Myocardial Infarction Through Modulating
   the miR-375/PDK1 Axis},
Journal = {JOURNAL OF CARDIOVASCULAR PHARMACOLOGY},
Year = {2020},
Volume = {76},
Number = {1},
Pages = {77-85},
Month = {JUL},
Abstract = {Increasing evidence has confirmed that both long noncoding RNAs
   (lncRNAs) and microRNAs (miRNAs) exert key roles in the pathogenesis of
   myocardial infarction (MI). Previous microarray assay results revealed
   that lncRNA LNC\_000898 expression was significantly downregulated in
   acute MI. However, the specific function of LNC\_000898 on MI is still
   unclear. Our study was aimed to explore the role of LNC\_000898 on
   cardiac MI injury and investigate its underlying mechanism. The male
   C57BL/6 mouse was used as cardiac MI injury animal models, and neonatal
   mouse ventricular cardiomyocytes (NMCMs) exposed to hypoxia were used as
   an in vitro model. Quantitative real-time polymerase chain reaction
   analysis, Western blot analysis, Tunel immunofluorescence staining
   assay, and cardiac echocardiography measurement were conducted to detect
   corresponding indicators. The results indicated that LNC\_000898
   expression was downregulated in marginal tissue of MI and in NMCMs
   exposed to hypoxia. Overexpression of LNC\_000898 decreased
   cardiomyocyte apoptosis both in vivo and in vitro. In addition, we
   elaborated that LNC\_000898 exerts its inhibitory effect on apoptosis
   after MI through the miR-375/PDK1 axis. Through miR-375 overexpression
   or silencing PDK1, the biological effects of LNC\_000898 on
   hypoxia-induced NMCM injury were partially reversed. These data not only
   demonstrate that LNC\_000898 could protect the heart against MI injury
   by regulating miR-375/PDK1 but also provide a new understanding to
   better protection of MI injury through the LNC\_000898/miR-375/PDK1
   axis.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Xie, Y (Corresponding Author), Tongji Univ, Dept Cardiol, Putuo Peoples Hosp, 1291 Jiangning Rd, Shanghai 200060, Peoples R China.
   Yan, Meiyu; Liu, Qiliang; Jiang, Yumei; Wang, Bo; Ji, Yi; Liu, Huizhu; Xie, Yun, Tongji Univ, Dept Cardiol, Putuo Peoples Hosp, 1291 Jiangning Rd, Shanghai 200060, Peoples R China.},
DOI = {10.1097/FJC.0000000000000845},
ISSN = {0160-2446},
EISSN = {1533-4023},
Keywords = {myocardial infarction; apoptosis; lncRNA LNC\_000898; miR-375; PDK1; AKT},
Keywords-Plus = {INJURY; PROLIFERATION; CARCINOMA; LNCRNA; CELLS; PDK1},
Research-Areas = {Cardiovascular System \& Cardiology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Cardiac \& Cardiovascular Systems; Pharmacology \& Pharmacy},
Author-Email = {yxputuo@yeah.net},
Affiliations = {Tongji University},
ResearcherID-Numbers = {Liu, Huizhu/MVW-6724-2025},
Funding-Acknowledgement = {Fundamental Research Funds for the Central Universities {[}22120180346]},
Funding-Text = {Supported by the Fundamental Research Funds for the Central Universities
   (NO. 22120180346).},
Cited-References = {Cao L, 2012, INT J MOL MED, V30, P1095, DOI 10.3892/ijmm.2012.1092.
   Cheng SY, 2016, AM J TRANSL RES, V8, P4657.
   Chhatriwalla AK, 2013, JAMA-J AM MED ASSOC, V309, P1022, DOI 10.1001/jama.2013.1556.
   Dai MM, 2019, DEV COMP IMMUNOL, V100, DOI 10.1016/j.dci.2019.103414.
   Fassett J, 2019, J MOL CELL CARDIOL, V130, P49, DOI 10.1016/j.yjmcc.2019.03.015.
   Forteza MJ, 2014, EUR J CLIN INVEST, V44, P46, DOI 10.1111/eci.12189.
   Gong LC, 2017, CELL PHYSIOL BIOCHEM, V44, P857, DOI 10.1159/000485354.
   Huang L, 2020, IUBMB LIFE, V72, P373, DOI 10.1002/iub.2187.
   Li H, 2019, MOL MED REP, V19, P302, DOI 10.3892/mmr.2018.9658.
   Long JK, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0085-2.
   Ma H., 2012, ADV PHYS CHEM, V2012, DOI DOI 10.1100/2012/541786.
   Scofield SLC, 2016, COMPR PHYSIOL, V6, P527, DOI {[}10.1002/j.2040-4603.2016.tb00684.x, 10.1002/cphy.c150025].
   Su Q, 2020, AM J PHYSIOL-HEART C, V318, pH332, DOI 10.1152/ajpheart.00444.2019.
   Tavaglione F, 2016, NUTR METAB CARDIOVAS, V26, P109, DOI 10.1016/j.numecd.2015.10.009.
   Wang JL, 2018, ENVIRON TOXICOL PHAR, V62, P227, DOI 10.1016/j.etap.2018.08.002.
   Wang T, 2019, INT J MOL MED, V44, P630, DOI 10.3892/ijmm.2019.4240.
   Wu Y., 2011, JOVE, V16, P2464, DOI {[}10.3791/2464, DOI 10.3791/2464].
   Xu H, 2019, EXP THER MED, V17, P1509, DOI 10.3892/etm.2018.7106.
   Yan YY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8079372.
   Yu SY, 2018, J CELL MOL MED, V22, P4886, DOI 10.1111/jcmm.13754.
   Zhai H, 2017, ONCOTARGET, V8, P31449, DOI 10.18632/oncotarget.16355.
   Zhang X, 2019, SHOCK, V52, P249, DOI 10.1097/SHK.0000000000001213.
   Zhong ZX, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013066.
   Zhou J, 2014, INT J MOL MED, V33, P950, DOI 10.3892/ijmm.2014.1638.},
Number-of-Cited-References = {24},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {J. Cardiovasc. Pharmacol.},
Doc-Delivery-Number = {NF4NF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000563273900010},
DA = {2026-02-04},
}

@article{ WOS:000546016600011,
Author = {Yu, Tengteng and Du, Chenxing and Ma, Xiaoke and Sui, Weiwei and Yu,
   Zhen and Liu, Lanting and Zhao, Lei and Li, Zhongqing and Xu, Jie and
   Wei, Xiaojing and Zhou, Wen and Deng, Shuhui and Zou, Dehui and An, Gang
   and Tai, Yu-Tzu and Tricot, Guido and Anderson, Kenneth C. and Qiu,
   Lugui and Zhan, Fenghuang and Hao, Mu},
Title = {Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in
   Multiple Myeloma and Is Regulated by miRNA-15a},
Journal = {MOLECULAR CANCER RESEARCH},
Year = {2020},
Volume = {18},
Number = {7},
Pages = {1063-1073},
Month = {JUL},
Abstract = {Multiple myeloma remains incurable due to the persistence of a minor
   population of multiple myeloma cells that exhibit drug resistance, which
   leads to relapsed and/or refractory multiple myeloma. Elucidating the
   mechanism underlying drug resistance and developing an effective
   treatment are critical for clinical management of multiple myeloma. Here
   we showed that promoting expression of the gene for polycomb-like
   protein 3 (PHF19) induced multiple myeloma cell growth and multidrug
   resistance in vitro and in vivo. PHF19 was overexpressed in high-risk
   and drug-resistant primary cells from patients. High levels of PHF19
   were correlated with inferior survival of patients with multiple
   myeloma, in the Total Therapy 2 cohort and in the Intergroup Francophone
   du Myeloma (IFM) cohort. Enhancing PHF19 expression levels increased
   Bcl-xL, Mcl-1, and HIF-1a expression in multiple myeloma cells. PHF19
   also bound directly with EZH2 and promoted the phosphorylation of EZH2
   through PDK1/AKT signaling. iniR-15a is a small noncoding RNA that
   targeted the 3'UTR of PHF19. We found that downregulation of miR-15a led
   to high levels of PHF19 in multiple myeloma cells. These findings
   revealed that PHF19 served a crucial role in multiple myeloma
   proliferation and drug resistance and suggested that the
   miR-15a/PHF19/EZH2 pathway made a pivotal contribution to multiple
   myeloma pathogenesis, offering a promising approach to multiple myeloma
   treatment.},
Publisher = {AMER ASSOC CANCER RESEARCH},
Address = {615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA},
Type = {Article},
Language = {English},
Affiliation = {Hao, M (Corresponding Author), Chinese Acad Med Sci \& Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Hematol Disorders, Inst Hematol \& Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
   Yu, Tengteng; Du, Chenxing; Sui, Weiwei; Yu, Zhen; Liu, Lanting; Li, Zhongqing; Xu, Jie; Wei, Xiaojing; Deng, Shuhui; Zou, Dehui; An, Gang; Qiu, Lugui; Hao, Mu, Chinese Acad Med Sci \& Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Hematol Disorders, Inst Hematol \& Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China.
   Yu, Tengteng; Tai, Yu-Tzu; Anderson, Kenneth C., Harvard Med Sch, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA.
   Ma, Xiaoke, Xidian Univ, Sch Comp Sci \& Technol, Xian, Shaanxi, Peoples R China.
   Zhao, Lei, Univ Iowa, Roy J \& Lucille A Carver Coll Med, Dept Biophys \& Mol Phys, Iowa City, IA USA.
   Zhou, Wen, Cent South Univ, Key Lab Carcinogenesis, Minist Hlth,Xiangya Hosp,Canc Res Inst,Sch Basic, Key Lab Carcinogenesis \& Canc Invas,Minist Educ, Changsha, Hunan, Peoples R China.
   Tricot, Guido; Zhan, Fenghuang, Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR 72205 USA.},
DOI = {10.1158/1541-7786.MCR-19-0852},
ISSN = {1541-7786},
EISSN = {1557-3125},
Keywords-Plus = {PHF19; TRANSCRIPTION; EXPRESSION; THERAPY; PRC2},
Research-Areas = {Oncology; Cell Biology},
Web-of-Science-Categories  = {Oncology; Cell Biology},
Author-Email = {haomu@ihcams.ac.cn},
Affiliations = {Chinese Academy of Medical Sciences - Peking Union Medical College;
   Institute of Hematology \& Blood Diseases Hospital - CAMS; Peking Union
   Medical College; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Dana-Farber Cancer Institute; Xidian
   University; University of Iowa; Central South University; University of
   Arkansas System; University of Arkansas Medical Sciences},
ResearcherID-Numbers = {Yu, Tengteng/AAT-3312-2021
   Anderson, Kenneth/ACP-5073-2022
   },
ORCID-Numbers = {Li, ZhongQing/0000-0002-0417-2147},
Funding-Acknowledgement = {Natural Science Foundation of China {[}81570181, 81400174, 81630007,
   81920108006]; Chinese Academy of Medical Sciences (CAMS) Innovation Fund
   for Medical Sciences {[}CAMS-2016-I2M-3-031, CAMS-2017-I2M-1-005, CAMS
   2017-I2M-1-015]; Tianjin Science and Technology Supporting Program
   {[}17JCYBJC27900]; Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences {[}2018RC320012]; National Cancer Institute
   {[}P01CA155258] Funding Source: NIH RePORTER},
Funding-Text = {The authors acknowledge the patients and physicians who participated in
   sample collections. We thank Drs. Sonal Jhaveri-Schneider (Postdoc and
   Graduate Student Affairs Office, Dana-Farber Cancer Institute) and Jie
   Ni (South Eastern Sydney Local Health District) for editing some drafts
   of the manuscript. We thank Dr. Teru Hideshima, Kenneth Wen, and Dr.
   Wenjuan Yang (Dana-Farber Cancer Institute) for their assistance and
   constructive advice on this project. This work was supported by Natural
   Science Foundation of China (81570181 and 81400174, to M. Hao; 81630007
   and 81920108006, to L. Qiu); Chinese Academy of Medical Sciences (CAMS)
   Innovation Fund for Medical Sciences CAMS-2016-I2M-3-031,
   CAMS-2017-I2M-1-005, and CAMS 2017-I2M-1-015 (to M. Hao and L. Qiu);
   Tianjin Science and Technology Supporting Program (17JCYBJC27900, to M.
   Hao) and the Non-profit Central Research Institute Fund of Chinese
   Academy of Medical Sciences (2018RC320012, to M. Hao).},
Cited-References = {Ballaré C, 2012, NAT STRUCT MOL BIOL, V19, P1257, DOI 10.1038/nsmb.2434.
   Bolli N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms3997.
   Brien GL, 2012, NAT STRUCT MOL BIOL, V19, P1273, DOI 10.1038/nsmb.2449.
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947.
   Deng Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1082-z.
   Dupéré-Richer D, 2017, CURR OPIN HEMATOL, V24, P336, DOI 10.1097/MOH.0000000000000358.
   Fan F, 2017, LEUKEMIA, V31, P1570, DOI 10.1038/leu.2016.358.
   Ferrari KJ, 2014, MOL CELL, V53, P49, DOI 10.1016/j.molcel.2013.10.030.
   Franqui-Machin R, 2018, J CLIN INVEST, V128, P2877, DOI 10.1172/JCI98765.
   Ghislin S, 2012, CELL CYCLE, V11, P1634, DOI 10.4161/cc.20095.
   Hao M, 2016, ONCOTARGET, V7, P19589, DOI 10.18632/oncotarget.7319.
   Hao M, 2015, INT J CANCER, V136, P1835, DOI 10.1002/ijc.29199.
   Hao M, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-37.
   Hao M, 2011, LEUKEMIA LYMPHOMA, V52, P1787, DOI 10.3109/10428194.2011.576791.
   Hauri S, 2016, CELL REP, V17, P583, DOI 10.1016/j.celrep.2016.08.096.
   Ikink GJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13567.
   Issa ME, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0319-5.
   Ji Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09882-8.
   Kikuchi J, 2015, J CLIN INVEST, V125, P4375, DOI 10.1172/JCI80325.
   Krzeminski P, 2016, ONCOTARGET, V7, P80664, DOI 10.18632/oncotarget.13025.
   Kumar SK, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.46.
   Li F, 2015, ONCOTARGET, V6, P38270, DOI 10.18632/oncotarget.5681.
   Li G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1675.
   Li HJ, 2017, NATURE, V549, P287, DOI 10.1038/nature23881.
   Lu J, 2018, BIOCHEM BIOPH RES CO, V503, P1610, DOI 10.1016/j.bbrc.2018.07.089.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Moreau P, 2015, BLOOD, V125, P3076, DOI 10.1182/blood-2014-09-568915.
   Ning FY, 2018, AM J TRANSL RES, V10, P200.
   Pan MR, 2015, SCI REP-UK, V5, DOI 10.1038/srep18709.
   Qin Y, 2017, LEUKEMIA, V31, P1123, DOI 10.1038/leu.2016.325.
   Ramakrishnan VG, 2019, HAEMATOLOGICA, V104, P2061, DOI 10.3324/haematol.2018.211110.
   Ren ZH, 2019, BLOOD, V134, P1176, DOI 10.1182/blood.2019000578.
   Samur AA, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0199-3.
   Sariman M, 2019, BALK MED J, V36, P23, DOI 10.4274/balkanmedj.2018.0356.
   Tao FF, 2018, FASEB J, V32, P6330, DOI 10.1096/fj.201800495RR.
   Wang SW, 2004, GENE, V343, P69, DOI 10.1016/j.gene.2004.09.006.
   Xu H, 2015, ONCOL REP, V34, P175, DOI 10.3892/or.2015.3957.
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood-2005-11-013458.
   Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001.},
Number-of-Cited-References = {39},
Times-Cited = {28},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Mol. Cancer Res.},
Doc-Delivery-Number = {MG4PZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000546016600011},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000548143900001,
Author = {Liu, Shengyuan and Huang, Feng and Ye, Qing and Li, Yangming and Chen,
   Jinhu and Huang, Hong},
Title = {SPRY4-IT1 promotes survival of colorectal cancer cells through
   regulating PDK1-mediated glycolysis},
Journal = {ANIMAL CELLS AND SYSTEMS},
Year = {2020},
Volume = {24},
Number = {4},
Pages = {220-227},
Month = {JUL 3},
Abstract = {Colorectal cancer (CRC) becomes the third leading cause of
   cancer-related deaths worldwide recently. The prognosis of CRC is still
   poor in decades, and targeted therapy is still a potential effective
   treatment. Long non-coding RNAs (lncRNAs) could regulate series of
   cellular functions and developmental processes. LncRNA-SPRY4-IT1
   (GenBank ID AK024556) is derived from an intron of the SPRY4 gene, which
   was highly expressed in melanoma cells and affected the progression of
   multiple types of cancers. However, the mechanism of SPRY4-IT1 in CRC
   progression remains unclear. Herein, we found the high level of
   SPRY4-IT1 in human colorectal cancer (CRC) tissues and cells, and
   correlated with patients' prognosis. We further noticed that SPRY4-IT1
   regulated CRC cell growth and glycolysis, and promoting PDK1 expression.
   Our data further confirmed that SPRY4-IT1 regulated CRC progression
   targeting PDK1. We therefore thought SPRY4-IT1 could serve as a
   promising molecular target for the treatment of CRC.},
Publisher = {TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Huang, F (Corresponding Author), Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Gastroenterol, 420 Fuma Rd, Fuzhou 350014, Fujian, Peoples R China.
   Liu, Shengyuan; Huang, Feng; Ye, Qing; Li, Yangming; Chen, Jinhu; Huang, Hong, Fujian Med Univ Canc Hosp, Fujian Canc Hosp, Dept Gastroenterol, 420 Fuma Rd, Fuzhou 350014, Fujian, Peoples R China.},
DOI = {10.1080/19768354.2020.1784274},
EarlyAccessDate = {JUN 2020},
ISSN = {1976-8354},
EISSN = {2151-2485},
Keywords = {SPRY4-IT1; colorectal cancer (CRC); proliferation; glycolysis; molecular
   target},
Keywords-Plus = {NONCODING RNA SPRY4-IT1; PREDICTS POOR-PROGNOSIS; LNCRNA SPRY4-IT1;
   UP-REGULATION; INVASION; PROLIFERATION; MIGRATION},
Research-Areas = {Cell Biology; Zoology},
Web-of-Science-Categories  = {Cell Biology; Zoology},
Author-Email = {fenghuangfkl@163.com},
ResearcherID-Numbers = {YE, QING/KIG-8170-2024},
Funding-Acknowledgement = {Starup Fund for scientific research, Fujian Medical University
   {[}2018QH1227]},
Funding-Text = {This work was supported by Starup Fund for scientific research, Fujian
   Medical University {[}grant number 2018QH1227].},
Cited-References = {Arsenic R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-82.
   Ba MC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2245-2.
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012.
   Cao D, 2016, ONCOTARGETS THER, V9, P5417, DOI 10.2147/OTT.S111794.
   Cao SG, 2019, MOL THER NUCL ACIDS, V17, P455, DOI 10.1016/j.omtn.2019.04.030.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fan MJ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181339.
   Guo WH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193483.
   Gupta S, 2020, GASTROINTEST ENDOSC, V91, P463, DOI 10.1016/j.gie.2020.01.014.
   Ihemelandu C, 2019, COLORECTAL CANCER, V8, DOI 10.2217/crc-2019-0009.
   Jin JG, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317716250.
   Jing W, 2016, ONCOL REP, V36, P1085, DOI 10.3892/or.2016.4859.
   Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460.
   Li JF, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709991.
   Li S, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109889.
   Li ZQ, 2019, INT J CLIN EXP PATHO, V12, P477.
   Lian SX, 2015, ONCOTARGET, V6, P29076, DOI 10.18632/oncotarget.4931.
   Liu D, 2017, CANCER LETT, V388, P281, DOI 10.1016/j.canlet.2016.12.005.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Liu T, 2016, FEBS OPEN BIO, V6, P147, DOI 10.1002/2211-5463.12030.
   Numata K, 2020, ONCOL RES TREAT, V43, P125, DOI 10.1159/000505930.
   Palm RF, 2020, JCO ONCOL PRACT, V16, P28, DOI 10.1200/JOP.19.00654.
   Peng W, 2015, TUMOR BIOL, V36, P6751, DOI 10.1007/s13277-015-3376-4.
   Rosch JG, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020133.
   Song XY, 2020, J CELL MOL MED, V24, P772, DOI 10.1111/jcmm.14786.
   Sun C, 2019, PATHOL ONCOL RES, V25, P89, DOI 10.1007/s12253-017-0327-y.
   Tan WL, 2017, MED SCI MONITOR, V23, P309, DOI 10.12659/MSM.898369.
   Wang HM, 2020, FRONT GENET, V10, DOI 10.3389/fgene.2019.01385.
   Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35.
   Xiang YQ, 2019, INT J CLIN EXP PATHO, V12, P1003.
   Xu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0747-x.
   Yu JT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0896-y.
   Zhou M, 2017, BIOMED PHARMACOTHER, V85, P348, DOI 10.1016/j.biopha.2016.11.035.
   Zhu W, 2020, J CELL MOL MED, V24, P3521, DOI 10.1111/jcmm.15042.
   Zou YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079598.},
Number-of-Cited-References = {36},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Anim. Cells Syst.},
Doc-Delivery-Number = {NG4IV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000548143900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000541260400001,
Author = {Xu, Jie and Li, Deng and Cai, Zhiqing and Sun, Hao and Su, Baohua and
   Qiu, Meiling and Ma, Ruofan},
Title = {ExosomallncRNAs NONMMUT000375.2 andNONMMUT071578.2 derived from titanium
   particle treatedRAW264.7 cells regulate osteogenic differentiation
   ofMC3T3-E1cells},
Journal = {JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A},
Year = {2020},
Volume = {108},
Number = {11},
Pages = {2251-2262},
Month = {NOV 1},
Abstract = {Periprosthetic osteolysis and the subsequent aseptic loosening can lead
   to the failure of joint replacement. Wear particles are well known to be
   the initiative cause inducing osteolysis through enhancing
   osteoclast-mediated bone resorption and reducing osteogenic
   differentiation. The purpose of this study was to investigate the
   effects of osteoclast-secreted exosomal long noncoding RNAs (lncRNAs) on
   osteogenesis in the process of particle-induced osteolysis. RAW264.7
   cells were treated by titanium particles (TI). The inflammatory
   cytokines were increased, and expression of Receptor Activator of
   Nuclear Factor-kappa B and Nuclear factor of activated T cells c1 were
   also increased, indicating osteoclast differentiation occurred. The
   purified exosomes from RAW264.7 cells induced with TI inhibited
   osteogenic differentiation of MC3T3-E1 cells. RNA sequencing generated
   lncRNAs expression profiles (458 up-regulated and 1641 down-regulated)
   of the exosomes derived from RAW264.7 cells treated with TI. Based on
   the results of gene ontology/Kyoto Encyclopedia of Genes and Genomes
   analysis and quantitative real time polymerase chain reaction
   validation, we confirmed two candidate lncRNAs, NONMMUT000375.2 and
   NONMMUT071578.2. The regulation network presented that some vital genes
   involved in osteoclast differentiation, such as Bcl2, Wnt11, TGF-beta,
   and Pdk1, were under the regulation of NONMMUT000375.2 and
   NONMMUT071578.2. Taken together, exosomes derived from TI treated
   RAW264.7 cells inhibit the osteogenic activity of MC3T3-E1 cells.
   Exosomal lncRNAs, NONMMUT000375.2 and NONMMUT071578.2 may potentially
   play their roles in promoting osteoclast differentiation and suppressing
   osteogenesis, which aggravates the osteoclastogenesis/osteogenesis
   imbalance.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Ma, RF (Corresponding Author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Joint Surg, Guangzhou, Peoples R China.
   Xu, Jie; Li, Deng; Cai, Zhiqing; Sun, Hao; Su, Baohua; Qiu, Meiling; Ma, Ruofan, Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Joint Surg, Guangzhou, Peoples R China.},
DOI = {10.1002/jbm.a.36983},
EarlyAccessDate = {JUN 2020},
ISSN = {1549-3296},
EISSN = {1552-4965},
Keywords = {exosomes; lncRNA; osteoclast differentiation; osteogenesis; wear
   particle},
Keywords-Plus = {OSTEOCLAST DIFFERENTIATION; EXTRACELLULAR VESICLES; EXPRESSION;
   MODULATION; OSTEOLYSIS; RANKL; DANCR},
Research-Areas = {Engineering; Materials Science},
Web-of-Science-Categories  = {Engineering, Biomedical; Materials Science, Biomaterials},
Author-Email = {maruofan@mail.sysu.edu.cn},
Affiliations = {Sun Yat Sen University},
ResearcherID-Numbers = {Sun, Hao/IZP-9285-2023
   Li, Deng/IST-5827-2023},
ORCID-Numbers = {Sun, Hao/0000-0001-8829-0468
   Ma, Ruofan/0000-0002-4346-1443
   },
Funding-Acknowledgement = {Fundamental Research Funds for the Central Universities {[}18zxxt61];
   Guangdong Basic and Applied Basic Research Foundation
   {[}2019A1515011647]; Guangzhou Science, Technology and Innovation
   Commission {[}201803010011]; Natural Science Foundation of Guangdong
   Province {[}2018A030310231]},
Funding-Text = {Fundamental Research Funds for the Central Universities, Grant/Award
   Number: 18zxxt61; Guangdong Basic and Applied Basic Research Foundation,
   Grant/Award Number: 2019A1515011647; Guangzhou Science, Technology and
   Innovation Commission, Grant/Award Number: 201803010011; Natural Science
   Foundation of Guangdong Province, Grant/Award Number: 2018A030310231},
Cited-References = {Adamopoulos IE, 2006, VIRCHOWS ARCH, V449, P69, DOI 10.1007/s00428-006-0200-y.
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658.
   Bu YM, 2018, CONNECT TISSUE RES, V59, P534, DOI 10.1080/03008207.2017.1413362.
   Ding Y, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/4/045019.
   Foers AD, 2017, ARTHRITIS RHEUMATOL, V69, P1350, DOI 10.1002/art.40076.
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108.
   Goodman S, 2005, ORTHOP CLIN N AM, V36, P41, DOI 10.1016/j.ocl.2004.06.015.
   Guiglia R, 2013, MED ORAL PATOL ORAL, V18, pE93, DOI 10.4317/medoral.18298.
   Hannafon BN, 2013, INT J MOL SCI, V14, P14240, DOI 10.3390/ijms140714240.
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301-620X.83B6.10905.
   Jacobs JJ, 2001, CLIN ORTHOP RELAT R, P71.
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036.
   Kim HJ, 2012, BONE, V51, P643, DOI 10.1016/j.bone.2012.07.015.
   KOCH AE, 1991, J IMMUNOL, V147, P2187.
   Lettesjö H, 1998, SCAND J IMMUNOL, V48, P286.
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872.
   McManus S, 2016, J BONE MINER RES, V31, P1334, DOI 10.1002/jbmr.2806.
   Nagase Y, 2009, J BIOL CHEM, V284, P36659, DOI 10.1074/jbc.M109.016915.
   Qiang YW, 2010, BRIT J HAEMATOL, V148, P726, DOI 10.1111/j.1365-2141.2009.08009.x.
   Qin CQ, 2011, ARTIF ORGANS, V35, P706, DOI 10.1111/j.1525-1594.2010.01175.x.
   Qin J, 2014, ACTA POL PHARM, V71, P537.
   Qin YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050712.
   Raimondi L, 2015, ONCOTARGET, V6, P13772, DOI 10.18632/oncotarget.3830.
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508.
   Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306.
   Saá P, 2014, J BIOL CHEM, V289, P29247, DOI 10.1074/jbc.M114.589564.
   SUDA T, 1992, ENDOCR REV, V13, P66, DOI 10.1210/er.13.1.66.
   SUDA T, 1995, BONE, V17, pS87, DOI 10.1016/8756-3282(95)00185-G.
   Sukur Erhan, 2016, Open Orthop J, V10, P241, DOI {[}10.2174/1874325001610010241, 10.2174/1874325001610010241].
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15.
   Tang ZY, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0406-8.
   Taverna S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03460-y.
   Tong X, 2015, BIOSCI BIOTECH BIOCH, V79, P732, DOI 10.1080/09168451.2014.998617.
   Valladares RD, 2014, J BIOMED MATER RES A, V102, P3004, DOI 10.1002/jbm.a.34972.
   Yang XC, 2018, INT J MOL MED, V41, P1536, DOI 10.3892/ijmm.2018.3363.
   Yarilina A, 2011, P NATL ACAD SCI USA, V108, P1573, DOI 10.1073/pnas.1010030108.
   Zhao HY, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170302.
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036.
   Zuo CQ, 2013, MOL MED REP, V8, P463, DOI 10.3892/mmr.2013.1540.},
Number-of-Cited-References = {39},
Times-Cited = {14},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {18},
Journal-ISO = {J. Biomed. Mater. Res. Part A},
Doc-Delivery-Number = {NH7YK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000541260400001},
DA = {2026-02-04},
}

@article{ WOS:000539197200001,
Author = {Gao, Weinian and Guo, Na and Zhao, Shuguang and Chen, Ziying and Zhang,
   Wenli and Yan, Fang and Liao, Hongjuan and Chi, Kui},
Title = {HTR2A promotes the development of cardiac hypertrophy by activating
   PI3K-PDK1-AKT-mTOR signaling},
Journal = {CELL STRESS \& CHAPERONES},
Year = {2020},
Volume = {25},
Number = {6},
Pages = {899-908},
Month = {NOV},
Abstract = {5-Hydroxytryptamine receptor 2A (HTR2A) is a central regulator of fetal
   brain development and cognitive function in adults. However, the roles
   of HTR2A in the cardiovascular system are not fully understood. Here in
   this study, we explored the function of HTR2A in cardiac hypertrophy.
   Significantly, the expression levels ofHTR2AmRNA and protein levels were
   upregulated in hypertrophic hearts of human patients. Besides, the
   expression of HTR2A was also upregulated in isoproterenol (ISO)-induced
   cardiac hypertrophy in the mouse. Next, the expression ofHTR2Awas
   knocked down with shRNA or overexpressed with adenovirus in neonatal rat
   cardiomyocytes, and ISO was used to induce cardiomyocyte hypertrophy. We
   showed thatHTR2Aknockdown repressed ISO-induced cardiomyocyte
   hypertrophy, which was demonstrated by decreased cardiomyocyte size and
   repressed expression of hypertrophic fetal genes (e.g., myosin heavy
   chain beta (beta-Mhc), atrial natriuretic peptide (Anp), and brain
   natriuretic peptide (Bnp)). By contrast, HTR2A overexpression promoted
   cardiomyocyte hypertrophy. Of note, we observed that HTR2A promoted the
   activation (phosphorylation) of AKT-mTOR (mammalian target of rapamycin)
   signaling in cardiomyocytes, and repression of AKT-mTOR with perifosine
   or rapamycin blocked the effects of HTR2A on cardiomyocyte hypertrophy.
   Finally, we showed that HTR2A regulated AKT-mTOR signaling through
   activating the PI3K-PDK1 pathway, and inhibition of either PI3K or PDK1
   blocked the roles of HTR2A in regulating AKT-mTOR signaling and
   cardiomyocyte hypertrophy. Altogether, these findings demonstrated that
   HTR2A activated PI3K-PDK1-AKT-mTOR signaling and promoted cardiac
   hypertrophy.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhao, SG (Corresponding Author), Hebei Med Univ, Dept Cardiac Macrovasc Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China.
   Gao, Weinian; Zhao, Shuguang; Chen, Ziying; Zhang, Wenli; Yan, Fang; Liao, Hongjuan, Hebei Med Univ, Dept Cardiac Macrovasc Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China.
   Guo, Na, Shijiazhuang Tradit Chinese Med Hosp, Dept Cardiol, Shijiazhuang 050000, Hebei, Peoples R China.
   Chi, Kui, Hebei Med Univ, Dept Vasc Surg, Hosp 2, Shijiazhuang 050000, Hebei, Peoples R China.},
DOI = {10.1007/s12192-020-01124-x},
EarlyAccessDate = {JUN 2020},
ISSN = {1355-8145},
EISSN = {1466-1268},
Keywords = {Cardiac hypertrophy; HTR2A; PI3K; PDK1; Akt; mTOR},
Keywords-Plus = {SEROTONIN; MTOR; METHYLATION; PRESSURE},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {64129632@qq.com},
Affiliations = {Hebei Medical University; Hebei Medical University},
Funding-Acknowledgement = {Health Commission of Hebei Province {[}20190058]},
Funding-Text = {This study was supported by the Health Commission of Hebei Province
   (20190058).},
Cited-References = {Agrawal R, 2010, PHARMACOL RES, V61, P269, DOI 10.1016/j.phrs.2009.11.012.
   Aoyagi T, 2011, CURR PHARM DESIGN, V17, P1818, DOI 10.2174/138161211796390976.
   Ayme-Dietrich E, 2015, J HYPERTENS, V33, P2310, DOI 10.1097/HJH.0000000000000695.
   Cai L, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00356.
   Chen XF, 2020, CLIN SCI, V134, P657, DOI 10.1042/CS20200128.
   Choi JR, 2020, BMC MED GENET, V21, DOI 10.1186/s12881-019-0927-3.
   Genis-Mendoza AD, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1286.
   Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584.
   Gong H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00414.
   Halder Indrani, 2007, Metabolic Syndrome and Related Disorders, V5, P323, DOI 10.1089/met.2007.0008.
   Hranilovic D, 2016, AUTISM RES, V9, P204, DOI 10.1002/aur.1519.
   Jia YY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097999.
   Kemi OJ, 2008, J CELL PHYSIOL, V214, P316, DOI 10.1002/jcp.21197.
   Lairez O, 2013, J NEURAL TRANSM, V120, P927, DOI 10.1007/s00702-013-1011-3.
   Lombaert N, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-018-0404-5.
   Luo YX, 2017, EUR HEART J, V38, P1389, DOI 10.1093/eurheartj/ehw138.
   Nakamura M, 2018, NAT REV CARDIOL, V15, P387, DOI 10.1038/s41569-018-0007-y.
   Paquette AG, 2014, J CELL BIOCHEM, V115, P2065, DOI 10.1002/jcb.24883.
   Paquette AG, 2013, EPIGENETICS-US, V8, P796, DOI 10.4161/epi.25358.
   Ren J, 2018, TRENDS ENDOCRIN MET, V29, P699, DOI 10.1016/j.tem.2018.08.001.
   Rudman SS, 2015, ARCH GYNECOL OBSTET, V291, P779, DOI 10.1007/s00404-014-3461-8.
   Sciarretta S, 2018, CIRC RES, V122, P489, DOI 10.1161/CIRCRESAHA.117.311147.
   Shende P, 2016, CARDIOVASC RES, V109, P103, DOI 10.1093/cvr/cvv252.
   Shimizu I, 2016, J MOL CELL CARDIOL, V97, P245, DOI 10.1016/j.yjmcc.2016.06.001.
   Tang XQ, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00280.
   Tang XQ, 2017, CLIN SCI, V131, P2063, DOI 10.1042/CS20160685.
   Tang XQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36576.
   Xu LF, 2016, BBA-MOL CELL RES, V1863, P1894, DOI 10.1016/j.bbamcr.2016.01.003.
   Zhou S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00748.},
Number-of-Cited-References = {29},
Times-Cited = {27},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Cell Stress Chaperones},
Doc-Delivery-Number = {OK3XP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000539197200001},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000545975700012,
Author = {Tian, Lian and Wu, Danchen and Dasgupta, Asish and Chen, Kuang-Hueih and
   Mewburn, Jeffrey and Potus, Francois and Lima, Patricia D. A. and Hong,
   Zhigang and Zhao, Yuan-Yuan and Hindmarch, Charles C. T. and Kutty,
   Shelby and Provencher, Steeve and Bonnet, Sebastien and Sutendra,
   Gopinath and Archer, Stephen L.},
Title = {Epigenetic Metabolic Reprogramming of Right Ventricular Fibroblasts in
   Pulmonary Arterial Hypertension A Pyruvate Dehydrogenase
   Kinase-Dependent Shift in Mitochondrial Metabolism Promotes Right
   Ventricular Fibrosis},
Journal = {CIRCULATION RESEARCH},
Year = {2020},
Volume = {126},
Number = {12},
Pages = {1723-1745},
Month = {JUN 5},
Abstract = {RATIONALE: Right ventricular (RV) fibrosis in pulmonary arterial
   hypertension contributes to RV failure. While RV fibrosis reflects
   changes in the function of resident RV fibroblasts (RVfib), these cells
   are understudied.
   OBJECTIVE: Examine the role of mitochondrial metabolism of RVfib in RV
   fibrosis in human and experimental pulmonary arterial hypertension.
   METHODS AND RESULTS: Male Sprague-Dawley rats received monocrotaline
   (MCT; 60 mg/kg) or saline. Drinking water containing no supplement or
   the PDK (pyruvate dehydrogenase kinase) inhibitor dichloroacetate was
   started 7 days post-MCT. At week 4, treadmill testing, echocardiography,
   and right heart catheterization were performed. The effects of PDK
   activation on mitochondrial dynamics and metabolism, RVfib
   proliferation, and collagen production were studied in RVfib in cell
   culture. Epigenetic mechanisms for persistence of the profibrotic RVfib
   phenotype in culture were evaluated. PDK expression was also studied in
   the RVfib of patients with decompensated RV failure (n=11) versus
   control (n=7). MCT rats developed pulmonary arterial hypertension, RV
   fibrosis, and RV failure. MCT-RVfib (but not left ventricular
   fibroblasts) displayed excess mitochondrial fission and had increased
   expression of PDK isoforms 1 and 3 that persisted for >5 passages in
   culture. PDK-mediated decreases in pyruvate dehydrogenase activity and
   oxygen consumption rate were reversed by dichloroacetate (in RVfib and
   in vivo) or siRNA targeting PDK 1 and 3 (in RVfib). These interventions
   restored mitochondrial superoxide and hydrogen peroxide production and
   inactivated HIF (hypoxia-inducible factor)-1 alpha, which was
   pathologically activated in normoxic MCT-RVfib. Redox-mediated HIF-1
   alpha inactivation also decreased the expression of TGF-beta 1
   (transforming growth factor-beta-1) and CTGF (connective tissue growth
   factor), reduced fibroblast proliferation, and decreased collagen
   production. HIF-1 alpha activation in MCT-RVfib reflected increased DNMT
   (DNA methyltransferase) 1 expression, which was associated with a
   decrease in its regulatory microRNA, miR-148b-3p. In MCT rats,
   dichloroacetate, at therapeutic levels in the RV, reduced
   phospho-pyruvate dehydrogenase expression, RV fibrosis, and hypertrophy
   and improved RV function. In patients with pulmonary arterial
   hypertension and RV failure, RVfib had increased PDK1 expression.
   CONCLUSIONS: MCT-RVfib manifest a DNMT1-HIF-1 alpha-PDK-mediated,
   chamber-specific, metabolic memory that promotes collagen production and
   RV fibrosis. This epigenetic mitochondrial-metabolic pathway is a
   potential antifibrotic therapeutic target.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Archer, SL (Corresponding Author), Queens Univ, Dept Med, Etherington Hall,Room 3041,94 Stuart St, Kingston, ON K7L 3N6, Canada.
   Tian, Lian; Wu, Danchen; Dasgupta, Asish; Chen, Kuang-Hueih; Mewburn, Jeffrey; Potus, Francois; Archer, Stephen L., Queens Univ, Dept Med, Etherington Hall,Room 3041,94 Stuart St, Kingston, ON K7L 3N6, Canada.
   Lima, Patricia D. A.; Hindmarch, Charles C. T.; Archer, Stephen L., Queens Univ, Queens CardioPulm Unit, Dept Med, Translat Inst Med, Kingston, ON, Canada.
   Hong, Zhigang, Univ Illinois, Dept Pharmacol, Chicago, IL 60680 USA.
   Zhao, Yuan-Yuan, Univ Alberta, Dept Agr Food \& Nutr Sci, Edmonton, AB, Canada.
   Sutendra, Gopinath, Univ Alberta, Dept Med, Edmonton, AB, Canada.
   Kutty, Shelby, Johns Hopkins Univ, Dept Med, Baltimore, MD USA.
   Provencher, Steeve; Bonnet, Sebastien, Laval Univ, Pulm Hypertens Res Grp, Dept Med, Heart \& Lung Inst Quebec, Quebec City, PQ, Canada.},
DOI = {10.1161/CIRCRESAHA.120.316443},
ISSN = {0009-7330},
EISSN = {1524-4571},
Keywords = {dichloroacetate; DNA methyltransferase 1 (DNMT1); hypoxia-inducible
   factor 1-alpha (HIF-1 alpha); transforming growth factor beta-1
   (TGF-beta 1); Warburg metabolism},
Keywords-Plus = {POSITRON-EMISSION-TOMOGRAPHY; HEART-FAILURE; DOWN-REGULATION; CARDIAC
   FIBROBLASTS; UP-REGULATION; HYPOXIA; SURVIVAL; DYSFUNCTION; FISSION;
   ECHOCARDIOGRAPHY},
Research-Areas = {Cardiovascular System \& Cardiology; Hematology},
Web-of-Science-Categories  = {Cardiac \& Cardiovascular Systems; Hematology; Peripheral Vascular
   Disease},
Author-Email = {stephen.archer@queensu.ca},
Affiliations = {Queens University - Canada; Queens University - Canada; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital; University of Alberta; University of Alberta; Johns
   Hopkins University; Laval University; Quebec Heart \& Lung Institute},
ResearcherID-Numbers = {Hindmarch, Charles/AAM-3385-2021
   Wu, Danchen/W-4727-2019
   },
ORCID-Numbers = {Hindmarch, Charles/0000-0002-6036-1292
   Wu, Danchen/0000-0003-3901-5907
   Tian, Lian/0000-0002-9699-8009},
Funding-Acknowledgement = {US National Institutes of Health (NIH) {[}NIH R01HL113003, NIH
   R01HL071115]; Canada Foundation for Innovation {[}229252, 33012]; Tier 1
   Canada Research Chair in Mitochondrial Dynamics and Translational
   Medicine {[}950-229252]; William J. Henderson Foundation; Canadian
   Vascular Network Scholar Award; Queen's CardioPulmonary Unit; Paroian
   Family PHA Canada scholarship},
Funding-Text = {This study was supported, in part, by the US National Institutes of
   Health (NIH) grants NIH R01HL113003 (S.L. Archer) and NIH R01HL071115
   (S.L. Archer), Canada Foundation for Innovation 229252 and 33012 (S.L.
   Archer), Tier 1 Canada Research Chair in Mitochondrial Dynamics and
   Translational Medicine 950-229252 (S.L. Archer), the William J.
   Henderson Foundation (S.L. Archer), the Paroian Family PHA Canada
   scholarship (F. Potus), and Canadian Vascular Network Scholar Award (L.
   Tian, D. Wu, A. Dasgupta, and F. Potus). This research is supported by
   Queen's CardioPulmonary Unit.},
Cited-References = {Agocha AE, 1997, MOL CELL BIOCHEM, V172, P195, DOI 10.1023/A:1006848512174.
   Andersen MJ, 2015, CIRC-HEART FAIL, V8, P542, DOI 10.1161/CIRCHEARTFAILURE.114.002114.
   Andersen S, 2019, PULM CIRC, V9, DOI 10.1177/2045894019848659.
   Andersen S, 2019, CIRCULATION, V139, P269, DOI 10.1161/CIRCULATIONAHA.118.035326.
   Archer SL, 2017, CIRCULATION, V136, P2486, DOI 10.1161/CIRCULATIONAHA.117.031655.
   Archer SL, 2010, CIRCULATION, V121, P2661, DOI 10.1161/CIRCULATIONAHA.109.916098.
   Archer SL, 2010, CIRCULATION, V121, P2045, DOI 10.1161/CIRCULATIONAHA.108.847707.
   Basu S, 2007, MOL IMAGING BIOL, V9, P333, DOI 10.1007/s11307-007-0102-7.
   Bogaard HJ, 2009, CIRCULATION, V120, P1951, DOI 10.1161/CIRCULATIONAHA.109.883843.
   Bogaard HJ, 2019, AM J RESP CRIT CARE, V199, P1458, DOI 10.1164/rccm.201812-2307ED.
   Bonnet S, 2006, CIRCULATION, V113, P2630, DOI 10.1161/CIRCULATIONAHA.105.609008.
   Bonnet S, 2020, AM J PHYSIOL-CELL PH, V318, pC1, DOI 10.1152/ajpcell.00078.2019.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297.
   Bruns DR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220573.
   Campo A, 2011, EUR RESPIR J, V38, P359, DOI 10.1183/09031936.00148310.
   Campo A, 2010, AM J RESP CRIT CARE, V182, P252, DOI 10.1164/rccm.200912-1820OC.
   Caruso P, 2017, CIRCULATION, V136, P2451, DOI 10.1161/CIRCULATIONAHA.117.028034.
   Chen KH, 2018, CIRCULATION, V138, P287, DOI 10.1161/CIRCULATIONAHA.117.031258.
   Crnkovic S, 2019, AM J RESP CRIT CARE, V199, P1550, DOI 10.1164/rccm.201809-1737OC.
   DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343.
   Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485.
   Fang YH, 2012, J MOL MED, V90, P31, DOI 10.1007/s00109-011-0804-9.
   Fijalkowska I, 2010, AM J PATHOL, V176, P1130, DOI 10.2353/ajpath.2010.090832.
   Freed BH, 2012, J CARDIOVASC MAGN R, V14, DOI 10.1186/1532-429X-14-11.
   Friedberg MK, 2013, AM J RESP CELL MOL, V49, P1019, DOI 10.1165/rcmb.2013-0149OC.
   Ghio S, 2010, INT J CARDIOL, V140, P272, DOI 10.1016/j.ijcard.2008.11.051.
   Gomez-Arroyo J, 2015, EUR RESPIR J, V45, P449, DOI 10.1183/09031936.00188013.
   Guazzi M, 2013, AM J PHYSIOL-HEART C, V305, pH1373, DOI 10.1152/ajpheart.00157.2013.
   Guazzi M, 2015, CHEST, V148, P226, DOI 10.1378/chest.14-2065.
   Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004.
   Hong ZG, 2017, AM J RESP CRIT CARE, V195, P515, DOI 10.1164/rccm.201604-0814OC.
   Humbert M, 2010, CIRCULATION, V122, P156, DOI 10.1161/CIRCULATIONAHA.109.911818.
   Jiang BH, 2016, AM J RESP CELL MOL, V54, P461, DOI 10.1165/rcmb.2014-0488OC.
   Kaewpila S, 2008, CANCER RES, V68, P2781, DOI 10.1158/0008-5472.CAN-07-2635.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979.
   Li M, 2016, CIRCULATION, V134, P1105, DOI 10.1161/CIRCULATIONAHA.116.023171.
   Lourenço AP, 2006, AM J PHYSIOL-HEART C, V291, pH1587, DOI 10.1152/ajpheart.01004.2005.
   Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770.
   Lund J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091101.
   Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958.
   Marsboom G, 2012, CIRC RES, V110, P1484, DOI 10.1161/CIRCRESAHA.111.263848.
   Marsboom G, 2012, AM J RESP CRIT CARE, V185, P670, DOI 10.1164/rccm.201108-1562OC.
   McMurtry MS, 2004, CIRC RES, V95, P830, DOI 10.1161/01.RES.0000145360.16770.9f.
   Melenovsky V, 2014, EUR HEART J, V35, P3452, DOI 10.1093/eurheartj/ehu193.
   Michelakis ED, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4583.
   Nadadur RD, 2012, J APPL PHYSIOL, V113, P149, DOI 10.1152/japplphysiol.01349.2011.
   Neuss M, 1996, CELL TISSUE RES, V286, P145, DOI 10.1007/s004410050683.
   Oikawa M, 2005, J AM COLL CARDIOL, V45, P1849, DOI 10.1016/j.jacc.2005.02.065.
   Paulin R, 2015, CIRC RES, V116, P56, DOI 10.1161/CIRCRESAHA.115.303910.
   Paulin R, 2014, CIRC RES, V115, P148, DOI 10.1161/CIRCRESAHA.115.301130.
   Piao L, 2013, J MOL MED, V91, P333, DOI 10.1007/s00109-012-0982-0.
   Piao L, 2010, J MOL MED, V88, P47, DOI 10.1007/s00109-009-0524-6.
   Plecitá-Hlavatá L, 2016, AM J RESP CELL MOL, V55, P47, DOI 10.1165/rcmb.2015-0142OC.
   Potus F, 2015, CIRCULATION, V132, P932, DOI 10.1161/CIRCULATIONAHA.115.016382.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Prins KW, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.006195.
   Prins KW, 2016, PULM CIRC, V6, P576, DOI 10.1086/688879.
   Rafikov R, 2015, REDOX BIOL, V6, P278, DOI 10.1016/j.redox.2015.07.016.
   Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543.
   Ryan JJ, 2014, CIRC RES, V115, P176, DOI 10.1161/CIRCRESAHA.113.301129.
   Sachdev A, 2011, CHEST, V139, P1299, DOI 10.1378/chest.10-2015.
   SANDOVAL J, 1994, CIRCULATION, V89, P1733, DOI 10.1161/01.CIR.89.4.1733.
   Semenza GL, 2014, ANNU REV PHYSIOL, V76, P39, DOI 10.1146/annurev-physiol-021113-170322.
   Sutendra G, 2013, J MOL MED, V91, P1315, DOI 10.1007/s00109-013-1059-4.
   Sztrymf B, 2010, EUR RESPIR J, V35, P1286, DOI 10.1183/09031936.00070209.
   Tian L, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00828.
   Tian L, 2017, J MOL MED, V95, P381, DOI 10.1007/s00109-017-1522-8.
   Umar S, 2012, CIRC-ARRHYTHMIA ELEC, V5, P181, DOI 10.1161/CIRCEP.111.967265.
   Urboniene D, 2010, AM J PHYSIOL-LUNG C, V299, pL401, DOI 10.1152/ajplung.00114.2010.
   van Wolferen SA, 2008, EUR HEART J, V29, P120, DOI 10.1093/eurheartj/ehm567.
   VLAHAKES GJ, 1981, CIRCULATION, V63, P87, DOI 10.1161/01.CIR.63.1.87.
   Voelkel NF, 2015, PULM CIRC, V5, P81, DOI 10.1086/679702.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Xu WL, 2007, P NATL ACAD SCI USA, V104, P1342, DOI 10.1073/pnas.0605080104.
   Zhang H, 2017, CIRCULATION, V136, P2468, DOI 10.1161/CIRCULATIONAHA.117.028069.
   Zhao L, 2013, CIRCULATION, V128, P1214, DOI 10.1161/CIRCULATIONAHA.113.004136.
   Zhou GF, 2009, AM J PHYSIOL-LUNG C, V297, pL1120, DOI 10.1152/ajplung.00007.2009.},
Number-of-Cited-References = {79},
Times-Cited = {126},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {35},
Journal-ISO = {Circ.Res.},
Doc-Delivery-Number = {MG4AU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000545975700012},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000531020400014,
Author = {Chang, Christopher and Greenspan, Adam and Gershwin, M. Eric},
Title = {The pathogenesis, diagnosis and clinical manifestations of
   steroid-induced osteonecrosis},
Journal = {JOURNAL OF AUTOIMMUNITY},
Year = {2020},
Volume = {110},
Month = {JUN},
Abstract = {Corticosteroid associated osteonecrosis is bone death resulting from the
   use of chronic glucocorticoids and most commonly affects the femoral
   head, although the bones such as around knee joint, wrist joint and
   ankle joint can be affected. The pathogenesis is likely multifactorial,
   with genetic and environmental factors playing a role. Epigenetics may
   be the mechanism by which environment exerts it effects. In spite of
   recent discoveries, the exact pathogenesis of corticosteroid associated
   osteonecrosis is unknown. Over the past few years, more miRNA's have
   been found to be associated with osteonecrosis. The older mechanisms
   such as a coagulopathy, abnormalities in apoptosis and lipid metabolism
   dysfunction are still believed to play a role. The role of inflammatory
   pathways including the PDK1/AKT/mTOR signaling pathway, the PERK and
   Parkin pathways have been increasingly recognized as playing a
   mechanistic role. Histological damage to the joint can occur before the
   presence of symptoms. The most common symptoms are pain and an inability
   to bear weight. Differential diagnosis includes infection, bone marrow
   edema syndrome or subchondral fracture. Early detection is important for
   successful management of the condition. MRI is the best radiologic
   technique to diagnosis femoral head osteonecrosis. Multiple staging
   systems for osteonecrosis have been used over the years, including the
   Ficat and Arlet system and the Steinberg criteria. The later stages of
   these staging systems are irreversible. Both nonsurgical (conservative)
   and surgical modes of therapy are used in the treatment of
   osteonecrosis.},
Publisher = {ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD},
Address = {24-28 OVAL RD, LONDON NW1 7DX, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Chang, C (Corresponding Author), Joe DiMaggio Childrens Hosp, Div Pediat Immunol \& Allergy, 1131 N 35th Ave,Suite 220, Hollywood, FL 33021 USA.
   Gershwin, ME (Corresponding Author), Univ Calif Davis, Div Rheumatol Allergy \& Clin Immunol, Sch Med, 451 Hlth Sci Dr,Suite 6510, Davis, CA 95616 USA.
   Chang, Christopher; Gershwin, M. Eric, Joe DiMaggio Childrens Hosp, Div Pediat Immunol \& Allergy, 1131 N 35th Ave,Suite 220, Hollywood, FL 33021 USA.
   Chang, Christopher, Univ Calif Davis, Div Rheumatol Allergy \& Clin Immunol, Davis, CA 95616 USA.
   Greenspan, Adam, Univ Calif Davis, Sch Med, Dept Radiol, Sacramento, CA 95817 USA.},
DOI = {10.1016/j.jaut.2020.102460},
Article-Number = {102460},
ISSN = {0896-8411},
EISSN = {1095-9157},
Keywords = {Corticosteroids A; dverse reactions; Femoral head; Avascular necrosis;
   Epigenetics; Biomarkers},
Keywords-Plus = {HUMAN FEMORAL-HEAD; AVASCULAR NECROSIS; OSTEOGENIC DIFFERENTIATION;
   INDUCED ADIPOGENESIS; BONE; POLYMORPHISM; APOPTOSIS; PREVENTS; GENE;
   RISK},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Author-Email = {chrchang@mhs.net
   megershwin@ucdavis.edu},
Affiliations = {University of California System; University of California Davis;
   University of California System; University of California Davis},
Cited-References = {Bai YM, 2019, INT J MOL MED, V43, P850, DOI 10.3892/ijmm.2018.4007.
   BOSKEY AL, 1983, CLIN ORTHOP RELAT R, P289.
   Calder JDF, 2004, J BONE JOINT SURG BR, V86B, P1209, DOI 10.1302/0301-620X.86B8.14834.
   CHANDLER F A, 1948, J Int Coll Surg, V11, P34.
   Chen GY, 2020, BONE, V133, DOI 10.1016/j.bone.2020.115258.
   Chmielnicka M, 2014, POSTEP DERM ALERGOL, V31, P281, DOI 10.5114/pdia.2014.44016.
   Civinini R, 2012, INT ORTHOP, V36, P1583, DOI 10.1007/s00264-012-1525-6.
   Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623-199707000-00012.
   Cui QJ, 1997, CLIN ORTHOP RELAT R, P8.
   Dai ZP, 2019, BIOMED PHARMACOTHER, V109, P1112, DOI 10.1016/j.biopha.2018.10.166.
   Deng GY, 2018, INT J NANOMED, V13, P1809, DOI 10.2147/IJN.S159776.
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138.
   Feng Y, 2010, BONE, V46, P32, DOI 10.1016/j.bone.2009.09.001.
   Ficat RF., 1980, ISCHEMIA NECROSIS BO.
   Gao YC, 2020, INT J BIOL SCI, V16, P543, DOI 10.7150/ijbs.35256.
   Geith T, 2017, RADIOLOGY, V283, P478, DOI 10.1148/radiol.2016152665.
   GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P273.
   GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P284.
   GLIMCHER MJ, 1979, CLIN ORTHOP RELAT R, P283.
   Glueck CJ, 2008, J BONE JOINT SURG AM, V90A, P2220, DOI 10.2106/JBJS.G.00616.
   Glueck CJ, 2008, CLIN ORTHOP RELAT R, V466, P1034, DOI 10.1007/s11999-008-0148-0.
   Glueck CJ, 1999, CLIN ORTHOP RELAT R, P133.
   Gray E, 1996, HAEMOSTASIS, V26, P92.
   Hao YQ, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-018-0827-0.
   HARPER RN, 1978, MICROVASC RES, V16, P369, DOI 10.1016/0026-2862(78)90070-5.
   HENCH PS, 1949, ANN RHEUM DIS, V8, P90, DOI 10.1136/ard.8.2.90.
   HENCH PS, 1949, ANN RHEUM DIS, V8, P97, DOI 10.1136/ard.8.2.97.
   Hirata T, 2007, J ORTHOP SCI, V12, P199, DOI 10.1007/s00776-007-1110-9.
   Hirata T, 2007, J RHEUMATOL, V34, P516.
   JACOBS B, 1978, CLIN ORTHOP RELAT R, P51.
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43.
   Jones J P Jr, 1999, Acta Orthop Belg, V65 Suppl 1, P5.
   JONES JP, 1993, CLIN ORTHOP RELAT R, P256.
   JONES JP, 1993, CLIN ORTHOP RELAT R, P294.
   Jones LC, 2003, J RHEUMATOL, V30, P783.
   Karol SE, 2015, BLOOD, V126, P1770, DOI 10.1182/blood-2015-05-643601.
   KAWAI K, 1985, J BONE JOINT SURG AM, V67A, P755, DOI 10.2106/00004623-198567050-00010.
   KENZORA JE, 1985, ORTHOP CLIN N AM, V16, P669.
   Kerachian MA, 2006, ENDOTHELIUM-J ENDOTH, V13, P237, DOI 10.1080/10623320600904211.
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007.
   Kong LC, 2020, INT J BIOL SCI, V16, P655, DOI 10.7150/ijbs.38713.
   Koo KH, 2002, CLIN RHEUMATOL, V21, P299, DOI 10.1007/s100670200078.
   Koo KH, 2006, J ORTHOP RES, V24, P1722, DOI 10.1002/jor.20164.
   Kuribayashi M, 2010, ACTA ORTHOP, V81, P154, DOI {[}10.3109/17453671003628772, 10.3109/17453671003587101].
   Li G, 2020, CELL CYCLE, V19, P551, DOI 10.1080/15384101.2020.1717043.
   Li PF, 2017, ONCOTARGET, V8, P42638, DOI 10.18632/oncotarget.17333.
   Liao W, 2019, CLIN SCI, V133, P1955, DOI 10.1042/CS20181064.
   Liu YS, 2015, INT J CLIN EXP MED, V8, P10979.
   Meng CY, 2020, ORTHOP SURG, V12, P277, DOI 10.1111/os.12603.
   Miyanishi K, 2002, BONE, V30, P185, DOI 10.1016/S8756-3282(01)00663-9.
   Peng WX, 2017, EXP BIOL MED, V242, P1234, DOI 10.1177/1535370217703975.
   Powell C, 2010, AUTOIMMUN REV, V9, P721, DOI 10.1016/j.autrev.2010.06.007.
   Qi YX, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.519.
   Schwarzer M, 2016, SCIENCE, V351, P854, DOI 10.1126/science.aad8588.
   Shigemura T, 2011, RHEUMATOLOGY, V50, P2023, DOI 10.1093/rheumatology/ker277.
   SPENCER JD, 1988, CLIN ORTHOP RELAT R, P127.
   Steinberg ME, 2004, ORTHOP CLIN N AM, V35, P273, DOI 10.1016/j.ocl.2004.02.005.
   Sun ZB, 2019, CURR PHARM DESIGN, V25, P4806, DOI 10.2174/1381612825666190930094019.
   VANGIEZEN JJJ, 1992, ANN NY ACAD SCI, V667, P199.
   Wang C, 2019, MOL THER-NUCL ACIDS, V18, P841, DOI 10.1016/j.omtn.2019.09.030.
   Wang GJ, 2000, CLIN ORTHOP RELAT R, P295, DOI 10.1097/00003086-200001000-00030.
   Wang T, 2019, INT ORTHOP, V43, P519, DOI 10.1007/s00264-018-4172-8.
   Wei X, 2012, ORAL DIS, V18, P602, DOI 10.1111/j.1601-0825.2012.01916.x.
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538.
   Weinstein RS, 2000, J CLIN ENDOCR METAB, V85, P2907, DOI 10.1210/jc.85.8.2907.
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455.
   Wu XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8140595.
   Xie Y, 2018, EUR REV MED PHARMACO, V22, P4053, DOI 10.26355/eurrev\_201807\_15393.
   Xu HJ, 2019, FASEB J, V33, P8055, DOI 10.1096/fj.201801618RRR.
   Xu WH, 2019, MOL MED REP, V20, P4594, DOI 10.3892/mmr.2019.10710.
   Xu WN, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00922.
   Yan J, 2017, CURR OSTEOPOROS REP, V15, P376, DOI 10.1007/s11914-017-0382-z.
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113.
   Yoon BH, 2019, J ARTHROPLASTY, V34, P163, DOI 10.1016/j.arth.2018.09.005.
   Yu LJ, 2019, J CELL PHYSIOL, V234, P4314, DOI 10.1002/jcp.27210.
   Yuan HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep20046.
   Zeng Z, 2015, INT J CLIN EXP MED, V8, P20337.
   Zhao JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159805.
   Zhao J, 2020, MOL MED REP, V21, P533, DOI 10.3892/mmr.2019.10866.
   Zhao SY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01292.
   Zhao ZQ, 2017, GENET TEST MOL BIOMA, V21, P322, DOI 10.1089/gtmb.2016.0260.
   Zhao ZQ, 2020, ORTHOP SURG, V12, P645, DOI 10.1111/os.12630.
   Zheng L, 2014, ACM T KNOWL DISCOV D, V9, DOI 10.1145/2611380.
   Zhou ZB, 2019, INT IMMUNOL, V31, P263, DOI 10.1093/intimm/dxz002.},
Number-of-Cited-References = {84},
Times-Cited = {186},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {53},
Journal-ISO = {J. Autoimmun.},
Doc-Delivery-Number = {LK7CO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000531020400014},
DA = {2026-02-04},
}

@article{ WOS:000553878800001,
Author = {Gibadulinova, Adriana and Bullova, Petra and Strnad, Hynek and Pohlodek,
   Kamil and Jurkovicova, Dana and Takacova, Martina and Pastorekova,
   Silvia and Svastova, Eliska},
Title = {CAIX-Mediated Control of LIN28/let-7Axis Contributes to Metabolic
   Adaptation of Breast Cancer Cells to Hypoxia},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2020},
Volume = {21},
Number = {12},
Month = {JUN},
Abstract = {Solid tumors, including breast cancer, are characterized by the hypoxic
   microenvironment, extracellular acidosis, and chemoresistance. Hypoxia
   marker, carbonic anhydrase IX (CAIX), is a pH regulator providing a
   selective survival advantage to cancer cells through intracellular
   neutralization while facilitating tumor invasion by extracellular
   acidification. The expression of CAIX in breast cancer patients is
   associated with poor prognosis and metastases. Importantly,
   CAIX-positive hypoxic tumor regions are enriched in cancer stem cells
   (CSCs). Here we investigated the biological effects ofCA9-silencing in
   breast cancer cell lines. We found that CAIX-downregulation in hypoxia
   led to increased levels oflet-7(lethal-7) family members. Simultaneously
   with the increase oflet-7miRNAs in CAIX-suppressed cells, LIN28 protein
   levels decreased, along with downstream metabolic pathways: pyruvate
   dehydrogenase kinase 1 (PDK1) and phosphorylation of its substrate,
   pyruvate dehydrogenase (PDH) at Ser-232, causing attenuation of
   glycolysis. In addition to perturbed glycolysis, CAIX-knockouts, in
   correlation with decreased LIN28 (as CSC reprogramming factor), also
   exhibit reduction of the further CSC-associated markers NANOG (Homeobox
   protein NANOG) and ALDH1 (Aldehyde dehydrogenase isoform 1). Oppositely,
   overexpression of CAIX leads to the enhancement of LIN28, ALDH1, and
   NANOG. In conclusion, CAIX-driven regulation of the LIN28/let-7axis
   augments glycolytic metabolism and enhances stem cell markers expression
   during CAIX-mediated adaptation to hypoxia and acidosis in
   carcinogenesis.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Svastova, E (Corresponding Author), Slovak Acad Sci, Biomed Res Ctr, Inst Virol, Dept Tumor Biol, Dubravska Cesta 9, Bratislava 84505, Slovakia.
   Gibadulinova, Adriana; Bullova, Petra; Takacova, Martina; Pastorekova, Silvia; Svastova, Eliska, Slovak Acad Sci, Biomed Res Ctr, Inst Virol, Dept Tumor Biol, Dubravska Cesta 9, Bratislava 84505, Slovakia.
   Strnad, Hynek, Czech Acad Sci, Inst Mol Genet, Videnska 1083, Prague 14220, Czech Republic.
   Pohlodek, Kamil, Comenius Univ, Fac Med, Dept Gynecol \& Obstet 2, Ruzinovska 6, Bratislava 82101, Slovakia.
   Jurkovicova, Dana, Slovak Acad Sci, Biomed Res Ctr, Canc Res Inst, Dubravska Cesta 9, Bratislava 84505, Slovakia.},
DOI = {10.3390/ijms21124299},
Article-Number = {4299},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {carbonic anhydrase IX; hypoxia; LIN28; let-7axis; metabolism},
Keywords-Plus = {CARBONIC-ANHYDRASE-IX; REPROGRAMMING FACTOR LIN28; INTERLEUKIN-8
   EXPRESSION; STEM-CELLS; ACIDIC PH; LET-7; ACIDOSIS; THERAPY; GROWTH;
   PATHWAY},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {virugiba@savba.sk
   petra.bullova@ki.se
   strnad@img.cas.cz
   kpohlodek@gmail.com
   Dana.Jurkovicova@savba.sk
   martina.takacova@savba.sk
   virusipa@savba.sk
   viruelis@savba.sk},
Affiliations = {Slovak Academy of Sciences; Institute of Virology, SAS; Biomedical
   Research Center, SAS; Czech Academy of Sciences; Institute of Molecular
   Genetics of the Czech Academy of Sciences; Comenius University
   Bratislava; Slovak Academy of Sciences; Biomedical Research Center, SAS;
   Cancer Research Institute, SAS},
ResearcherID-Numbers = {Pohlodek, Kamil/ABE-1522-2020
   Takacova, Martina/JVO-0849-2024
   Pastoreková, Silvia/C-6685-2018
   Svastova, Eliska/AAD-9768-2019
   Strnad, Hynek/B-7361-2008
   Bullova, Petra/ABG-5262-2020},
ORCID-Numbers = {Pohlodek, Kamil/0000-0002-2765-3680
   Takacova, Martina/0000-0002-1634-6247
   Pastoreková, Silvia/0000-0001-8203-405X
   Svastova, Eliska/0000-0003-0679-1061
   Jurkovicova, Dana/0000-0002-7997-6932
   },
Funding-Acknowledgement = {Slovak Scientific Grant Agency {[}VEGA 2/0155/15, VEGA 2/0076/20, VEGA
   2/0105/19]; Research and Development Support Agency {[}APVV-14-0816,
   APVV-15-0697]},
Funding-Text = {This work was supported by grants from the Slovak Scientific Grant
   Agency VEGA 2/0155/15, VEGA 2/0076/20, and VEGA 2/0105/19; Research and
   Development Support Agency APVV-14-0816 and APVV-15-0697.},
Cited-References = {AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891.
   Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549.
   Balzeau J, 2017, FRONT GENET, V8, P1, DOI 10.3389/fgene.2017.00031.
   Boyd NH, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92928.
   Chafe SC, 2015, CANCER RES, V75, P996, DOI 10.1158/0008-5472.CAN-14-3000.
   Debreova M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112745.
   Deev I E, 2006, Dokl Biochem Biophys, V408, P184, DOI 10.1134/S1607672906030203.
   Faes S, 2016, ONCOTARGET, V7, P36666, DOI 10.18632/oncotarget.9134.
   Fukumura D, 2001, CANCER RES, V61, P6020.
   García-Venzor A, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118523.
   Gatenby RA, 2007, BRIT J CANCER, V97, P646, DOI 10.1038/sj.bjc.6603922.
   Gibadulinova A, 2016, ONCOTARGET, V7, P22508, DOI 10.18632/oncotarget.7999.
   Golias T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31146.
   Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514.
   Halpern H.J., 2017, OXYGEN TRANSPORT TIS, P119, DOI {[}10.1007/978-3-319-55231-6\_16, DOI 10.1007/978-3-319-55231-6\_16].
   Hashim A.A.I., 2017, P ANN M AM ASS CANC, V77, P5932, DOI {[}10.1158/1538-7445, DOI 10.1158/1538-7445].
   Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5.
   Hedlund EME, 2019, CANCERS, V11, DOI 10.3390/cancers11071002.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Heo I, 2008, MOL CELL, V32, P276, DOI 10.1016/j.molcel.2008.09.014.
   Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116.
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014.
   Jurkovicova D, 2015, NEOPLASMA, V62, P949, DOI 10.4149/neo\_2015\_115.
   Kaelin WG, 2010, NATURE, V465, P562, DOI 10.1038/465562a.
   Kery M, 2019, NEOPLASMA, V66, P63, DOI 10.4149/neo\_2018\_180531N357.
   Kim BR, 2012, CELL SIGNAL, V24, P1406, DOI 10.1016/j.cellsig.2012.03.002.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310.
   Ledaki I, 2015, ONCOTARGET, V6, P19413, DOI 10.18632/oncotarget.4989.
   Lock FE, 2013, ONCOGENE, V32, P5210, DOI 10.1038/onc.2012.550.
   Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212.
   McDonald PC, 2019, GASTROENTEROLOGY, V157, P823, DOI 10.1053/j.gastro.2019.05.004.
   Nguyen LH, 2015, TRANSL PEDIATR, V4, P4, DOI 10.3978/j.issn.2224-4336.2015.01.05.
   Orlowski A, 2012, AM J PHYSIOL-CELL PH, V303, pC69, DOI 10.1152/ajpcell.00431.2011.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579.
   Pastorek J, 2015, SEMIN CANCER BIOL, V31, P52, DOI 10.1016/j.semcancer.2014.08.002.
   PASTOREKOVA S, 1992, VIROLOGY, V187, P620, DOI 10.1016/0042-6822(92)90464-Z.
   Peng F, 2018, ONCOGENE, V37, P1119, DOI 10.1038/onc.2017.407.
   Peppicelli S, 2013, CLIN EXP METASTAS, V30, P957, DOI 10.1007/s10585-013-9595-4.
   Pore N, 2015, NEOPLASIA, V17, P473, DOI 10.1016/j.neo.2015.05.001.
   Radvak P, 2013, ONCOL REP, V29, P1147, DOI 10.3892/or.2013.2226.
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607.
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009.
   Shyh-Chang N, 2013, CELL STEM CELL, V12, P395, DOI 10.1016/j.stem.2013.03.005.
   Svastová E, 2004, FEBS LETT, V577, P439, DOI 10.1016/j.febslet.2004.10.043.
   Svastova E, 2012, J BIOL CHEM, V287, P3392, DOI 10.1074/jbc.M111.286062.
   Swietach P, 2009, J BIOL CHEM, V284, P20299, DOI 10.1074/jbc.M109.006478.
   Thornton JE, 2012, TRENDS CELL BIOL, V22, P474, DOI 10.1016/j.tcb.2012.06.001.
   Tsanov KM, 2017, NAT CELL BIOL, V19, P60, DOI 10.1038/ncb3453.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040.
   Wang TZ, 2016, ONCOTARGET, V7, P79591, DOI 10.18632/oncotarget.12869.
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110.
   Xiong QH, 2001, J INTERF CYTOK RES, V21, P529, DOI 10.1089/10799900152434411.
   Xu L, 2000, CANCER RES, V60, P4610.
   Yang XJ, 2010, CANCER RES, V70, P9463, DOI 10.1158/0008-5472.CAN-10-2388.
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054.
   Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607.
   Zhou JB, 2013, INT J BIOCHEM CELL B, V45, P973, DOI 10.1016/j.biocel.2013.02.006.
   Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033.},
Number-of-Cited-References = {61},
Times-Cited = {40},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {MR8ZM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000553878800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000530710200026,
Author = {Han, Zhonglin and Wu, Xiang and Gao, Yuan and Liu, Xuehua and Bai, Jian
   and Gu, Rong and Lan, RongFang and Xu, Biao and Xu, Wei},
Title = {PDK1-AKT signaling pathway regulates the expression and function of
   cardiac hyperpolarization-activated cyclic nucleotide-modulated channels},
Journal = {LIFE SCIENCES},
Year = {2020},
Volume = {250},
Month = {JUN 1},
Abstract = {Aim: The enzyme 3-phosphoinositide-dependent protein kinase-1 (PDK1) is
   associated with cardiac and pathological remodeling and ion channel
   function regulation. However, whether it regulates
   hyperpolarization-activated cyclic nucleotide-modulated channels (HCNs)
   remains unclear.
   Main methods: In the atrial myocytes of heart-specific PDK1
   ``knockout{''} mouse model and neonatal mice, protein kinase B
   (AKT)-related inhibitors or agonists as well as knockdown or
   overexpression plasmids were used to study the relationship between PDK1
   and HCNs.
   Key findings: HCN1 expression and AKT phosphorylation at the Thr308 site
   were significantly decreased in atrial myocytes after PDK1 knockout or
   inhibition; in contrast, HCN2 and HCN4 levels were significantly
   increased. Also, a similar trend of HCNs expression has been observed in
   cultured atrial myocytes after PDK1 inhibition, as further demonstrated
   via immunofluorescence and patch-clamp experiments. Moreover, these
   results of PDK1 overexpression indicate an opposite trend compared with
   the previous experimental results. However, the results of PDK1
   inhibition or overexpression could be reversed by activating or
   inhibiting AKT, respectively.
   Significance: These results indicate that the PDK1-AKT signaling pathway
   is involved in the regulation of HCN mRNA transcription, protein
   expression, HCN current density, and cell membrane location.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Xu, W (Corresponding Author), Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Cardiol, Zhongshan Rd 321, Nanjing 210000, Peoples R China.
   Han, Zhonglin; Wu, Xiang; Gao, Yuan; Liu, Xuehua; Bai, Jian; Gu, Rong; Lan, RongFang; Xu, Biao; Xu, Wei, Nanjing Univ, Sch Med, Affiliated Nanjing Drum Tower Hosp, Dept Cardiol, Zhongshan Rd 321, Nanjing 210000, Peoples R China.},
DOI = {10.1016/j.lfs.2020.117546},
Article-Number = {117546},
ISSN = {0024-3205},
EISSN = {1879-0631},
Keywords = {3-phosphoinositide-dependent protein kinase-1; Protein kinase B; PDK1;
   AKT; Hyperpolarization-activated cyclic nucleotide-modulated channels;
   HCN},
Keywords-Plus = {ATRIAL-FIBRILLATION; HEART-FAILURE; I-F; SENSITIVITY; INHIBITION; CAMP;
   ASSOCIATION; IVABRADINE; MUTATIONS; INCREASES},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {13390900868@163.com},
Affiliations = {Nanjing University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81600267]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (grant number 81600267).},
Cited-References = {Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008.
   {[}Anonymous], NANOSCALE, DOI DOI 10.1109/TENCON.2015.7372768.
   Ballou LM, 2015, CIRC RES, V116, P127, DOI 10.1161/CIRCRESAHA.116.303975.
   Biel M, 2009, PHYSIOL REV, V89, P847, DOI 10.1152/physrev.00029.2008.
   Chang YH, 2017, SPRINGER THESES-RECO, P7, DOI 10.1007/978-981-10-3824-2\_2.
   de Campaigno EP, 2017, BRIT J CLIN PHARMACO, V83, P1544, DOI 10.1111/bcp.13238.
   Ezeani M, 2017, OPEN HEART, V4, DOI 10.1136/openhrt-2017-000596.
   Ganatra S, 2018, JACC-CLIN ELECTROPHY, V4, P1491, DOI 10.1016/j.jacep.2018.06.004.
   Guellich A, 2014, PFLUG ARCH EUR J PHY, V466, P1163, DOI 10.1007/s00424-014-1515-1.
   Han ZL, 2015, INT J CLIN EXP MED, V8, P5485.
   Herrmann S, 2011, J MOL CELL CARDIOL, V51, P997, DOI 10.1016/j.yjmcc.2011.09.005.
   Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200.
   Ito K, 2009, P NATL ACAD SCI USA, V106, P8689, DOI 10.1073/pnas.0900064106.
   Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235.
   Kuwabara Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000150.
   Lamothe SM, 2013, J BIOL CHEM, V288, P15075, DOI 10.1074/jbc.M113.453670.
   Lentz R, 2019, LEUKEMIA LYMPHOMA, V60, P1447, DOI 10.1080/10428194.2018.1533129.
   Li YD, 2015, MED SCI MONITOR, V21, P1414, DOI {[}10.12659/msm.894320, 10.12659/MSM.894320].
   Li YD, 2014, MED SCI MONITOR, V20, P2292, DOI 10.12659/MSM.892505.
   Lin RZ, 2019, J GEN PHYSIOL, V151, P1051, DOI 10.1085/jgp.201812293.
   Liu SH, 2016, J CARDIOVASC ELECTR, V27, P1093, DOI 10.1111/jce.13026.
   Lolicato M, 2014, NAT CHEM BIOL, V10, P457, DOI {[}10.1038/NCHEMBIO.1521, 10.1038/nchembio.1521].
   Lu Z, 2012, SCI TRANSL MED, V4, P131, DOI DOI 10.1126/SCITRANSLMED.3003623.
   McMullen JR, 2014, BLOOD, V124, P3829, DOI 10.1182/blood-2014-10-604272.
   Mengesha HG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00874.
   Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Moslehi JJ, 2016, NEW ENGL J MED, V375, P1457, DOI 10.1056/NEJMra1100265.
   Nanchen D, 2013, EUR J HEART FAIL, V15, P581, DOI 10.1093/eurjhf/hfs195.
   Nelson ER, 2013, SCIENCE, V342, P1094, DOI 10.1126/science.1241908.
   Ock S, 2016, ENDOCRINOLOGY, V157, P336, DOI 10.1210/en.2015-1709.
   Oliva F, 2018, INT J CARDIOL, V253, P97, DOI 10.1016/j.ijcard.2017.09.191.
   Pal A, 2012, NEW ENGL J MED, V367, P1002, DOI 10.1056/NEJMoa1113966.
   Pretorius L, 2009, AM J PATHOL, V175, P998, DOI 10.2353/ajpath.2009.090126.
   Priori SG, 2015, EUR HEART J, V36, P2793, DOI 10.1093/eurheartj/ehv316.
   Sartiani L, 2017, PHARMACOL REV, V69, P354, DOI 10.1124/pr.117.014035.
   Schweizer PA, 2010, CIRC-ARRHYTHMIA ELEC, V3, P542, DOI 10.1161/CIRCEP.110.949768.
   Stewart S, 2002, AM J MED, V113, P359, DOI 10.1016/S0002-9343(02)01236-6.
   Stillitano F, 2013, J CARDIOVASC ELECTR, V24, P1391, DOI 10.1111/jce.12212.
   Suffredini S, 2012, BRIT J PHARMACOL, V165, P1457, DOI 10.1111/j.1476-5381.2011.01627.x.
   Swedberg K, 2010, LANCET, V376, P875, DOI 10.1016/S0140-6736(10)61198-1.
   Terashima Y, 2010, J MOL CELL CARDIOL, V49, P762, DOI 10.1016/j.yjmcc.2010.08.001.
   VanSchouwen B, 2017, HANDB EXP PHARMACOL, V238, P123, DOI 10.1007/164\_2016\_5006.
   Verkerk AO, 2015, INT J MOL SCI, V16, P3071, DOI 10.3390/ijms16023071.
   Verrier RL, 2013, HEART RHYTHM, V10, P1692, DOI 10.1016/j.hrthm.2013.08.007.
   Wang J, 2019, J CARDIOVASC ELECTR, V30, P242, DOI 10.1111/jce.13772.
   Weber S, 2017, CELL SIGNAL, V38, P76, DOI 10.1016/j.cellsig.2017.06.020.
   Wu XQ, 2018, ANATOL J CARDIOL, V20, P266, DOI 10.14744/AnatolJCardiol.2018.46338.
   Wu XQ, 2013, AM J PATHOL, V182, P2005, DOI 10.1016/j.ajpath.2013.02.012.
   Yampolsky P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11261-2.
   Zhabyeyev P, 2014, J MOL CELL CARDIOL, V77, P155, DOI 10.1016/j.yjmcc.2014.10.008.
   Zhou M, 2015, PROG NEURO-PSYCHOPH, V56, P207, DOI 10.1016/j.pnpbp.2014.09.010.},
Number-of-Cited-References = {52},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Life Sci.},
Doc-Delivery-Number = {LK2SC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000530710200026},
DA = {2026-02-04},
}

@article{ WOS:000530363200015,
Author = {Qin, Jianli and Fu, Minglei and Wang, Juan and Huang, Fengxiang and Liu,
   Haiping and Huangfu, Mengjie and Yu, Dan and Liu, Haowei and Li, Xumei
   and Guan, Xiao and Chen, Xu},
Title = {PTEN/AKT/mTOR signaling mediates anticancer effects of
   epigallocatechin-3-gallate in ovarian cancer},
Journal = {ONCOLOGY REPORTS},
Year = {2020},
Volume = {43},
Number = {6},
Pages = {1885-1896},
Month = {JUN},
Abstract = {Epigallocatechin-3-gallate (EGCG), a polyphenol present in green tea,
   exhibits anticancer effects in various types of cancer. A number of
   studies have focused on the effects of EGCG on lung cancer, but not
   ovarian cancer. Previous reports have implicated that EGCG suppressed
   ovarian cancer cell proliferation and induced apoptosis, but its
   potential anticancer mechanisms and signaling pathways remain unclear.
   Thus, it is necessary to determine the anti-ovarian cancer effects of
   EGCG and explore the underlying mechanisms. In the present study, EGCG
   exerted stronger proliferation inhibition on SKOV3 cells compared with
   A549 cells and induced apoptosis in SKOV3 cells, as well as upregulated
   PTEN expression and downregulated the expression of
   phosphoinositide-dependent kinase-1 (PDK1), phosphor (p)-AKT and p-mTOR.
   These effects were reversed by the PTEN inhibitor VO-Ohpic trihydrate.
   The results of the mouse xenograft experiment demonstrated that 50 mg/kg
   EGCG exhibited increased tumor growth inhibition compared with 5 mg/kg
   paclitaxel. In addition, PTEN expression was upregulated, whereas the
   expression levels of PDK1, p-AKT and p-mTOR were downregulated in the
   EGCG treatment group compared with those in untreated mice in vivo. In
   conclusion, the results of the present study provided a new underlying
   mechanism of the effect of EGCG on ovarian cancer and may lead to the
   development of EGCG as a candidate drug for ovarian cancer therapy.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Chen, X (Corresponding Author), Guilin Med Univ, Coll Pharm, 109 North Second Ring Rd, Guilin 541004, Guangxi, Peoples R China.
   Qin, Jianli; Huang, Fengxiang; Huangfu, Mengjie; Yu, Dan; Liu, Haowei; Li, Xumei; Guan, Xiao; Chen, Xu, Guilin Med Univ, Coll Pharm, 109 North Second Ring Rd, Guilin 541004, Guangxi, Peoples R China.
   Fu, Minglei, Guilin Med Univ, Affiliated Hosp 2, Dispensary, Guilin 541004, Guangxi, Peoples R China.
   Wang, Juan, Guilin Med Univ, Res Ctr Sci, Guilin 541004, Guangxi, Peoples R China.
   Liu, Haiping, Guilin Med Univ, Sci \& Technol Dept, Guilin 541004, Guangxi, Peoples R China.
   Guan, Xiao, Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.},
DOI = {10.3892/or.2020.7571},
ISSN = {1021-335X},
EISSN = {1791-2431},
Keywords = {epigallocatechin-3-gallate; ovarian cancer; proliferation; apoptosis;
   VO-Ohpic trihydrate},
Keywords-Plus = {NF-KAPPA-B; LUNG-CANCER; PI3K/AKT/MTOR PATHWAY; CARCINOMA CELLS;
   PHASE-I; EGCG; CHEMOTHERAPY; APOPTOSIS; PROLIFERATION; RESISTANCE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {chenxu@glmc.edu.cn},
Affiliations = {Guilin Medical University; Guilin Medical University; Guilin Medical
   University; Guilin Medical University; Central South University},
ResearcherID-Numbers = {Huang, Feng/JXM-4708-2024
   Fu, Minglei/R-4651-2016},
ORCID-Numbers = {Fu, Minglei/0009-0005-0712-2515},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31460229, 81760443,
   81760663]; Guangxi Natural Science Foundation {[}2017GXNSFDA198029];
   Small Talent Highland Fund in Guangxi {[}201707]; Scientific Research
   and Technology Development Plan of Guilin {[}20170109-38]},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (grant nos. 31460229, 81760443 and 81760663), the Guangxi Natural
   Science Foundation (grant no. 2017GXNSFDA198029), the Small Talent
   Highland Fund in Guangxi (grant no. 201707) and The Scientific Research
   and Technology Development Plan of Guilin (grant no. 20170109-38).},
Cited-References = {Bhardwaj V, 2019, MOLECULES, V24, DOI 10.3390/molecules24020368.
   Biswas R, 2015, ANTICANCER RES, V35, P3901.
   Cai J, 2014, ONCOLOGIST, V19, P528, DOI 10.1634/theoncologist.2013-0333.
   Chen HP, 2013, EXP CELL RES, V319, P697, DOI 10.1016/j.yexcr.2012.12.026.
   Chen JZ, 2014, CURR MED CHEM, V21, P3070, DOI 10.2174/0929867321666140414095605.
   Chen Q, 2019, J PATHOL, V247, P266, DOI 10.1002/path.5189.
   Chen Y, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060572.
   Chuffa LGD, 2017, CARCINOGENESIS, V38, P945, DOI 10.1093/carcin/bgx054.
   Deng PB, 2019, CANCER MANAG RES, V11, P2425, DOI 10.2147/CMAR.S187750.
   Dhatwalia SK, 2018, NUTR CANCER, V70, P334, DOI 10.1080/01635581.2018.1445762.
   Ediriweera MK, 2019, SEMIN CANCER BIOL, V59, P147, DOI 10.1016/j.semcancer.2019.05.012.
   Flores-Pérez A, 2016, PROTEOM CLIN APPL, V10, P172, DOI 10.1002/prca.201500008.
   Gasparri ML, 2017, GEBURTSH FRAUENHEILK, V77, P1095, DOI 10.1055/s-0043-118907.
   Hong OY, 2017, ONCOL LETT, V14, P441, DOI 10.3892/ol.2017.6108.
   Khan NA, 2018, NUTRIENTS, V10, DOI 10.3390/nu10040396.
   Li M, 2016, ONCOL REP, V35, P2339, DOI 10.3892/or.2016.4587.
   Lin YT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071343.
   Liu CW, 2019, MOLECULES, V24, DOI 10.3390/molecules24091726.
   Liu HY, 2019, EUR REV MED PHARMACO, V23, P4149, DOI 10.26355/eurrev\_201905\_17917.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Luo KW, 2017, J NUTR BIOCHEM, V41, P56, DOI 10.1016/j.jnutbio.2016.12.004.
   Ma YC, 2014, ONCOL REP, V31, P1343, DOI 10.3892/or.2013.2933.
   Mabuchi S, 2015, GYNECOL ONCOL, V137, P173, DOI 10.1016/j.ygyno.2015.02.003.
   Madariaga A, 2019, CANCERS, V11, DOI 10.3390/cancers11030416.
   Mahalaxmi I, 2019, EUR J PHARMACOL, V852, P51, DOI 10.1016/j.ejphar.2019.03.003.
   Meng J, 2019, ONCOTARGETS THER, V12, P6033, DOI 10.2147/OTT.S209441.
   Padmakumar S, 2019, J CONTROL RELEASE, V305, P29, DOI 10.1016/j.jconrel.2019.05.022.
   Pan H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124775.
   Pérez-Ramírez C, 2015, PHARMACOGENOMICS, V16, P1843, DOI 10.2217/pgs.15.122.
   Pétigny-Lechartier C, 2017, MOL CANCER THER, V16, P102, DOI 10.1158/1535-7163.MCT-16-0342.
   Pisanic TR II, 2018, CLIN CANCER RES, V24, P6536, DOI 10.1158/1078-0432.CCR-18-1199.
   Rawangkan A, 2018, MOLECULES, V23, DOI 10.3390/molecules23082071.
   Roane BM, 2019, CANCERS, V11, DOI 10.3390/cancers11050668.
   Russell MR, 2019, BRIT J CANCER, V121, P483, DOI 10.1038/s41416-019-0544-0.
   Sanna V, 2017, SCI REP-UK, V7, DOI 10.1038/srep41573.
   Shen JY, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0578-1.
   Shi JL, 2015, ONCOL REP, V33, P2972, DOI 10.3892/or.2015.3889.
   Steffensen KD, 2014, INT J ONCOL, V44, P1736, DOI 10.3892/ijo.2014.2311.
   Tian M, 2019, J CELL PHYSIOL, V234, P21126, DOI 10.1002/jcp.28715.
   Tomao F, 2017, EXPERT OPIN PHARMACO, V18, P1443, DOI 10.1080/14656566.2017.1328055.
   Wainberg ZA, 2017, TARGET ONCOL, V12, P775, DOI 10.1007/s11523-017-0530-5.
   Wang F, 2014, MOL MED REP, V9, P1085, DOI 10.3892/mmr.2014.1909.
   Wang J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0981-0.
   Wang L, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109173.
   Wang LX, 2019, MOLECULES, V24, DOI 10.3390/molecules24050954.
   Wang YQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23092334.
   Xinqiang S, 2017, CTS-CLIN TRANSL SCI, V10, P302, DOI 10.1111/cts.12470.
   Xu JL, 2012, ASIAN PAC J CANCER P, V13, P2157, DOI 10.7314/APJCP.2012.13.5.2157.
   Yan CX, 2012, ARCH GYNECOL OBSTET, V285, P459, DOI 10.1007/s00404-011-1942-6.
   Yang CS, 2013, ANNU REV NUTR, V33, P161, DOI 10.1146/annurev-nutr-071811-150717.
   Yap TA, 2014, CLIN CANCER RES, V20, P5672, DOI 10.1158/1078-0432.CCR-14-0868.
   Yap TA, 2009, NAT REV CANCER, V9, P167, DOI 10.1038/nrc2583.
   Yarmolinsky J, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002893.
   Ying L, 2018, CLIN EXP PHARMACOL P, V45, P58, DOI 10.1111/1440-1681.12854.
   Yu CX, 2017, INT J BIOL SCI, V13, P1560, DOI 10.7150/ijbs.18830.
   Zhang LY, 2019, J CANCER, V10, P6543, DOI 10.7150/jca.34285.
   ZHANG LY, 2019, CELLS-BASEL, V8, DOI DOI 10.3390/cells8070745.
   Zhang X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0137-x.
   Zhao HX, 2014, RADIOTHER ONCOL, V110, P132, DOI 10.1016/j.radonc.2013.10.014.},
Number-of-Cited-References = {59},
Times-Cited = {56},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {26},
Journal-ISO = {Oncol. Rep.},
Doc-Delivery-Number = {LJ7TE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000530363200015},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000530363200026,
Author = {Zhao, Shuai and Li, Xiaohua and Yin, Lei and Hou, Lili and Lan, Jing and
   Zhu, Xun},
Title = {TCRP1 induces tamoxifen resistance by promoting the activation of SGK1
   in MCF-7 cells},
Journal = {ONCOLOGY REPORTS},
Year = {2020},
Volume = {43},
Number = {6},
Pages = {2017-2027},
Month = {JUN},
Abstract = {Tamoxifen is widely used as a highly effective drug for treating
   estrogen-receptor (ER) alpha-positive breast cancer. However, tamoxifen
   resistance developed during cancer treatment remains a significant
   challenge. Tongue cancer resistance-related protein1 (TCRP1), which is
   recognized as a novel drug target, is related to chemo-resistance in
   human cancers, moreover, it is often overexpressed in various cancer
   cells, such as in lung cancer, breast cancer, and tongue cancer.
   However, the effects of TCRP1 on tamoxifen-resistant breast cancer cells
   and tissues are far from clear. The present study revealed that TCRP1
   induced tamoxifen resistance in breast cancer cells. Western blotting,
   quantitative real-time polymerase chain reaction (RT-PCR) and
   immunohistochemical staining were performed to detect the expression
   level of TCRP1 in vivo and in vitro between primary breast cancer
   tissues and tamoxifen-resistant breast cancer tissues. The data revealed
   that the expression of TCRP1 was upregulated in the tamoxifen-resistant
   breast cancer tissues and human breast cancer cell line, MCF-7. Further
   study revealed that knocking down TCRP1 inhibited the growth of MCF-7
   cells with tamoxifen-resistance (MCF7-R cells) and induced cell
   apoptosis. Moreover, TCRP1 promoted serum- and glucocorticoid-inducible
   kinase 1 (SGK1) activation via phosphorylation of
   phosphoinositide-dependent kinase 1 (PDK1) in MCF7-R cells. In addition,
   it was also observed that knocking down TCRP1 inhibited tumorigenesis of
   MCF-7 cells in nude mice. In conclusion, these data indicated that TCRP1
   could induce tamoxifen resistance by regulating the PDK1/SGK1 signaling
   pathway. Thus, TCRP1 could be explored as a promising candidate for
   treating tamoxifen-resistant breast cancer in the future.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Lan, J (Corresponding Author), Suzhou Univ, Hosp 1, Dept Gen Surg, 899 Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China.
   Zhu, X (Corresponding Author), Suzhou Univ, Affiliated Hosp 2, Dept Breast \& Thyroid Surg, 1055 San Xiang Rd, Suzhou 215004, Jiangsu, Peoples R China.
   Zhao, Shuai; Li, Xiaohua; Yin, Lei; Hou, Lili, Wuzhong Peoples Hosp Suzhou City, Dept Breast \& Thyroid Surg, Suzhou 215128, Jiangsu, Peoples R China.
   Lan, Jing, Suzhou Univ, Hosp 1, Dept Gen Surg, 899 Pinghai Rd, Suzhou 215006, Jiangsu, Peoples R China.
   Zhu, Xun, Suzhou Univ, Affiliated Hosp 2, Dept Breast \& Thyroid Surg, 1055 San Xiang Rd, Suzhou 215004, Jiangsu, Peoples R China.},
DOI = {10.3892/or.2020.7577},
ISSN = {1021-335X},
EISSN = {1791-2431},
Keywords = {breast cancer; tamoxifen-resistant; tongue cancer resistance-related
   protein1; glucocorticoid-inducible kinase 1; MCF-7 cells},
Keywords-Plus = {BREAST-CANCER; PDK1; MECHANISMS; PATHWAY; TONGUE; GROWTH},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {kakahaha\_2008@qq.com
   zhuxunsdfey@163.com},
Cited-References = {Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Egeland NG, 2015, INT J MOL SCI, V16, P24243, DOI 10.3390/ijms161024243.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Fan P, 2009, ENDOCRINOLOGY, V150, P2036, DOI 10.1210/en.2008-1195.
   Fyffe Chanse, 2013, Cancer Manag Res, V5, P271, DOI 10.2147/CMAR.S35026.
   Gee JMW, 2006, ENDOCR-RELAT CANCER, V13, pS77, DOI 10.1677/erc.1.01274.
   Ginsburg O, 2017, LANCET, V389, P847, DOI 10.1016/S0140-6736(16)31392-7.
   Gu YX, 2011, MOL CELL BIOCHEM, V357, P107, DOI 10.1007/s11010-011-0880-8.
   Gu YX, 2011, FEBS LETT, V585, P881, DOI 10.1016/j.febslet.2010.12.045.
   Hayes EL, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0542-y.
   Jia XT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03763-0.
   Jiang Q, 2013, FUTURE MED CHEM, V5, P1023, DOI 10.4155/fmc.13.63.
   Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886.
   Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620.
   Leung EY, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00221.
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862.
   Lin YS, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2204-y.
   Liu XR, 2017, ONCOL LETT, V13, P1398, DOI 10.3892/ol.2016.5534.
   Liu XR, 2015, MOL CELL BIOCHEM, V398, P175, DOI 10.1007/s11010-014-2217-x.
   Merikhian P, 2017, EXPERT REV ANTICANC, V17, P607, DOI 10.1080/14737140.2017.1340837.
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713.
   Nass N, 2015, PATHOL RES PRACT, V211, P189, DOI 10.1016/j.prp.2015.01.004.
   Nass N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101473.
   NAWATA H, 1981, J BIOL CHEM, V256, P5016.
   Parsons R, 2004, SEMIN CELL DEV BIOL, V15, P171, DOI 10.1016/j.semcdb.2003.12.021.
   Peng B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051413.
   Peng B, 2012, PROTEIN EXPRES PURIF, V82, P360, DOI 10.1016/j.pep.2012.02.002.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Rao RD, 2012, ONCOLOGY-NY, V26, P541.
   Shi YW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0928-7.
   Viedma-Rodríguez R, 2014, ONCOL REP, V32, P3, DOI 10.3892/or.2014.3190.
   Wang C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.18.
   Zhou CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3144.},
Number-of-Cited-References = {37},
Times-Cited = {8},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Oncol. Rep.},
Doc-Delivery-Number = {LJ7TE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000530363200026},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000528253100002,
Author = {Zhou, Xiaofeng and He, Yingting and Jiang, Yao and He, Bo and Deng, Xi
   and Zhang, Zhe and Yuan, Xiaolong and Li, Jiaqi},
Title = {MiR-126-3p inhibits apoptosis and promotes proliferation by targeting
   phosphatidylinositol 3-kinase regulatory subunit 2 in porcine ovarian
   granulosa cells},
Journal = {ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES},
Year = {2020},
Volume = {33},
Number = {6},
Pages = {879-887},
Month = {JUN},
Abstract = {Objective: Numerous studies have indicated that the apoptosis and
   proliferation of granulosa cells (GCs) are closely related to the normal
   growth and development of follicles and ovaries. Previous evidence has
   suggested that miR-126-3p might get involved in the apoptosis and
   proliferation of GCs, and phosphatidylinositol 3-kinase regulatory
   subunit 2 (PIK3R2) gene has been predicted as one target of miR-126-3p.
   However, the molecular regulation of miR-126-3p on PIK3R2 and the
   effects of PIK3R2 on porcine GCs apoptosis and proliferation remain
   virtually unexplored.
   Methods: In this study, using porcine GCs as a cellular model,
   luciferase report assay, mutation and deletion were applied to verify
   the targeting relationship between miR-126-3p and PIK3R2. Annexin-V/PI
   staining and 5-ethynyl-2'-deoxyuridine assay were applied to explore the
   effect of PIK3R2 on GCs apoptosis and proliferation, respectively.
   Real-time quantitative polymerase chain reaction and Western Blot were
   applied to explore the regulation of miR-126-3p on PIK3R2 expression.
   Results: We found that miR-126-3p targeted at PIK3R2 and inhibited its
   mRNA and protein expression. Knockdown of PIK3R2 significantly inhibited
   the apoptosis and promoted the proliferation of porcine GCs, and
   significantly down-regulated the mRNA expression of several key genes of
   PI3K pathway such as insulin-like growth factor 1 receptor (IGF1R),
   insulin receptor (INSR), pyruvate dehydrogenase kinase 1 (PDK1), and
   serine/threonine kinase 1 (AKT1).
   Conclusion: MiR-126-3p might target and inhibit the mRNA and protein
   expressions of PIK3R2, thereby inhibiting GC apoptosis and promoting GC
   proliferation by down-regulating several key genes of the PI3K pathway,
   IGF1R, INSR, PDK1, and AKT1. These findings would provide great insight
   into further exploring the molecular regulation of miR-126-3p and PIK3R2
   on the functions of GCs during the folliculogenesis in female mammals.},
Publisher = {ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC},
Address = {ROOM 708 SAMMO SPOREX, 1638-32, SEOWON-DONG, GWANAK-GU, SEOUL 151-730,
   SOUTH KOREA},
Type = {Article},
Language = {English},
Affiliation = {Yuan, XL; Li, JQ (Corresponding Author), South China Agr Univ, Coll Anim Sdence, Natl Engn Res Ctr Breeding Swine Ind, Guangdong Prov Key Lab Agroanim Genom \& Mol Breed, Guangzhou 510642, Guangdong, Peoples R China.
   Zhou, Xiaofeng; He, Yingting; Jiang, Yao; He, Bo; Deng, Xi; Zhang, Zhe; Yuan, Xiaolong; Li, Jiaqi, South China Agr Univ, Coll Anim Sdence, Natl Engn Res Ctr Breeding Swine Ind, Guangdong Prov Key Lab Agroanim Genom \& Mol Breed, Guangzhou 510642, Guangdong, Peoples R China.},
DOI = {10.5713/ajas.19.0290},
ISSN = {1011-2367},
EISSN = {1976-5517},
Keywords = {Ovarian Granulosa Cells; miR-126-3p; Phosphatidylinositol 3-Kinase
   Regulatory Subunit 2 (PIK3R2); Cell Apoptosis; Cell Proliferation},
Keywords-Plus = {PROTEIN-KINASE-B; FOLLICULAR DEVELOPMENT; MOUSE; HORMONE; GROWTH; BETA;
   IDENTIFICATION; ACTIVATION; EXPRESSION; PATHWAYS},
Research-Areas = {Agriculture},
Web-of-Science-Categories  = {Agriculture, Dairy \& Animal Science},
Author-Email = {yxl@scau.edu.cn
   jqli@scau.edu.cn},
Affiliations = {South China Agricultural University},
ResearcherID-Numbers = {Zhang, Zhe/AAG-9641-2019},
ORCID-Numbers = {Zhou, Xiaofeng/0000-0002-7847-4383
   Yuan, Xiaolong/0000-0002-3743-0130
   He, Yingting/0000-0003-3004-1308
   },
Funding-Acknowledgement = {special fund for science and technology innovation of Guangdong Province
   {[}2018B02020 3003]; National Natural Science Foundation of China
   {[}31902131]; National Natural Science Foundation of Guangdong Province
   {[}2019A1515010676]; Youth Innovation fund of Guangdong Education
   Department {[}2018 KQNCX019]; earmarked fund for the China Agriculture
   Research System {[}CARS-35]},
Funding-Text = {This work was supported by the special fund for science and technology
   innovation of Guangdong Province (2018B02020 3003), the National Natural
   Science Foundation of China (31902131), the National Natural Science
   Foundation of Guangdong Province (2019A1515010676), the Youth Innovation
   fund of Guangdong Education Department (2018 KQNCX019), and the
   earmarked fund for the China Agriculture Research System (CARS-35).},
Cited-References = {Bachelot A, 2002, ENDOCRINOLOGY, V143, P4104, DOI 10.1210/en.2002-220087.
   Bai X, 2009, J ETHNOPHARMACOL, V125, P482, DOI 10.1016/j.jep.2009.07.007.
   Baker J, 1996, MOL ENDOCRINOL, V10, P903, DOI 10.1210/me.10.7.903.
   Bernstein C, 2002, MUTAT RES-REV MUTAT, V511, P145, DOI 10.1016/S1383-5742(02)00009-1.
   Brown C, 2010, BIOL REPROD, V82, P246, DOI 10.1095/biolreprod.109.077925.
   Cui W, 2011, MOL CELL BIOCHEM, V355, P17, DOI 10.1007/s11010-011-0834-1.
   Dai L, 2014, REPROD DOMEST ANIM, V49, P913, DOI 10.1111/rda.12400.
   Eppig JJ, 2001, REPRODUCTION, V122, P829, DOI 10.1530/rep.0.1220829.
   Fan HY, 2010, MOL ENDOCRINOL, V24, P286, DOI 10.1210/me.2009-0251.
   Fiedler SD, 2008, BIOL REPROD, V79, P1030, DOI 10.1095/biolreprod.108.069690.
   Gao J, 2016, EXP MOL PATHOL, V100, P192, DOI 10.1016/j.yexmp.2015.12.015.
   Gareis NC, 2018, ANIM REPROD SCI, V192, P298, DOI 10.1016/j.anireprosci.2018.03.031.
   Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283.
   Hamm ML, 2004, BIOL REPROD, V71, P66, DOI 10.1095/biolreprod.104.027292.
   Hong XM, 2008, ENDOCRINOLOGY, V149, P6207, DOI 10.1210/en.2008-0294.
   Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632.
   Lei L, 2010, MOL CELL ENDOCRINOL, V315, P63, DOI 10.1016/j.mce.2009.09.021.
   Lin F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038640.
   Ma TH, 2011, J APPL GENET, V52, P481, DOI 10.1007/s13353-011-0055-z.
   Maneix L, 2015, P NATL ACAD SCI USA, V112, P5135, DOI 10.1073/pnas.1504944112.
   Mao ZH, 2018, REPROD SCI, V25, P372, DOI 10.1177/1933719117715129.
   McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200.
   Nagaraja AK, 2008, MOL ENDOCRINOL, V22, P2336, DOI 10.1210/me.2008-0142.
   Alves APNR, 2019, CANCER LETT, V456, P59, DOI 10.1016/j.canlet.2019.04.030.
   Pepling ME, 2001, DEV BIOL, V234, P339, DOI 10.1006/dbio.2001.0269.
   Qu Y, 2016, ONCOTARGET, V7, P74217, DOI 10.18632/oncotarget.12487.
   Reddy P, 2005, DEV BIOL, V281, P160, DOI 10.1016/j.ydbio.2005.02.013.
   Reddy P, 2009, HUM MOL GENET, V18, P2813, DOI 10.1093/hmg/ddp217.
   Rodriguez KF, 2010, ENDOCRINOLOGY, V151, P2826, DOI 10.1210/en.2009-1446.
   Sambandam V, 2019, CLIN CANCER RES, V25, P3329, DOI 10.1158/1078-0432.CCR-18-3276.
   Sessa R, 2012, BBA-MOL CELL RES, V1823, P1925, DOI 10.1016/j.bbamcr.2012.07.011.
   Shimizu T, 2009, ANIM REPROD SCI, V116, P28, DOI 10.1016/j.anireprosci.2009.01.009.
   Sirotkin AV, 2010, J CELL PHYSIOL, V223, P49, DOI 10.1002/jcp.21999.
   Sirotkin AV, 2009, J CELL PHYSIOL, V219, P415, DOI 10.1002/jcp.21689.
   Wang B, 2019, CANCER LETT, V447, P93, DOI 10.1016/j.canlet.2019.01.008.
   Woodruff TK, 2005, ENDOCRINOLOGY, V146, P3244, DOI 10.1210/en.2005-0630.
   Wu XJ, 2016, ONCOTARGET, V7, P36614, DOI 10.18632/oncotarget.9311.
   Yao GD, 2010, MOL ENDOCRINOL, V24, P540, DOI 10.1210/me.2009-0432.
   Yuan XL, 2018, IN VITRO CELL DEV-AN, V54, P715, DOI 10.1007/s11626-018-0292-0.
   Zeleznik AJ, 2003, ENDOCRINOLOGY, V144, P3985, DOI 10.1210/en.2003-0293.
   Zhang PJ, 2018, BIOMED PHARMACOTHER, V105, P1141, DOI 10.1016/j.biopha.2018.06.101.
   Zheng WJ, 2012, MOL CELL ENDOCRINOL, V356, P24, DOI 10.1016/j.mce.2011.05.027.},
Number-of-Cited-References = {42},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {18},
Journal-ISO = {Asian Australas. J. Anim. Sci.},
Doc-Delivery-Number = {LG7CA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000528253100002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000536797100064,
Author = {Hosooka, Tetsuya and Hosokawa, Yusei and Matsugi, Kaku and Shinohara,
   Masakazu and Senga, Yoko and Tamori, Yoshikazu and Aoki, Chikako and
   Matsui, Sho and Sasaki, Tsutomu and Kitamura, Tadahiro and Kuroda,
   Masashi and Sakaue, Hiroshi and Nomura, Kazuhiro and Yoshino, Kei and
   Nabatame, Yuko and Itoh, Yoshito and Yamaguchi, Kanji and Hayashi,
   Yoshitake and Nakae, Jun and Accili, Domenico and Yokomizo, Takehiko and
   Seino, Susumu and Kasuga, Masato and Ogawa, Wataru},
Title = {The PDK1-FoxO1 signaling in adipocytes controls systemic insulin
   sensitivity through the 5-lipoxygenase-leukotriene B4 axis},
Journal = {PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA},
Year = {2020},
Volume = {117},
Number = {21},
Pages = {11674-11684},
Month = {MAY 26},
Abstract = {Although adipocytes are major targets of insulin, the influence of
   impaired insulin action in adipocytes on metabolic homeostasis remains
   unclear. We here show that adipocyte-specific PDK1
   (3'-phosphoinositide-dependent kinase 1)-deficient (A-PDK1KO) mice
   manifest impaired metabolic actions of insulin in adipose tissue and
   reduction of adipose tissue mass. A-PDK1KO mice developed insulin
   resistance, glucose intolerance, and hepatic steatosis, and this
   phenotype was suppressed by additional ablation of FoxO1 specifically in
   adipocytes (A-PDK1/FoxO1KO mice) without an effect on adipose tissue
   mass. Neither circulating levels of adiponectin and leptin nor
   inflammatory markers in adipose tissue differed between A-PDK1KO and
   A-PDK1/FoxO1KO mice. Lipidomics and microarray analyses revealed that
   leukotriene B-4 (LTB4) levels in plasma and in adipose tissue as well as
   the expression of 5-lipoxygenase (5-LO) in adipose tissue were increased
   and restored in A-PDK1KO mice and A-PDK1/FoxO1KO mice, respectively.
   Genetic deletion of the LTB4 receptor BLT1 as well as pharmacological
   intervention to 5-LO or BLT1 ameliorated insulin resistance in A-PDK1KO
   mice. Furthermore, insulin was found to inhibit LTB4 production through
   downregulation of 5-LO expression via the PDK1-FoxO1 pathway in isolated
   adipocytes. Our results indicate that insulin signaling in adipocytes
   negatively regulates the production of LTB4 via the PDK1-FoxO1 pathway
   and thereby maintains systemic insulin sensitivity.},
Publisher = {NATL ACAD SCIENCES},
Address = {2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA},
Type = {Article},
Language = {English},
Affiliation = {Ogawa, W (Corresponding Author), Kobe Univ, Div Diabet \& Endocrinol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.
   Hosooka, Tetsuya; Hosokawa, Yusei; Matsugi, Kaku; Senga, Yoko; Tamori, Yoshikazu; Aoki, Chikako; Nomura, Kazuhiro; Yoshino, Kei; Nabatame, Yuko; Ogawa, Wataru, Kobe Univ, Div Diabet \& Endocrinol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.
   Shinohara, Masakazu, Kobe Univ, Div Epidemiol, Grad Sch Med, Kobe, Hyogo 6500017, Japan.
   Shinohara, Masakazu, Kobe Univ, Integrated Ctr Mass Spectrometry, Grad Sch Med, Kobe, Hyogo 6500017, Japan.
   Tamori, Yoshikazu, Chibune Gen Hosp, Dept Internal Med, Osaka 5550001, Japan.
   Matsui, Sho; Sasaki, Tsutomu; Kitamura, Tadahiro, Gunma Univ, Inst Mol \& Cellular Regulat, Metab Signal Res Ctr, Maebashi, Gunma 3718512, Japan.
   Kuroda, Masashi; Sakaue, Hiroshi, Tokushima Univ, Inst Biomed Sci, Dept Nutr \& Metab, Grad Sch, Tokushima 7708503, Japan.
   Itoh, Yoshito; Yamaguchi, Kanji, Kyoto Prefectural Univ Med, Dept Gastroenterol \& Hepatol, Kyoto 6028566, Japan.
   Hayashi, Yoshitake, Kobe Univ, Div Mol Med \& Med Genet, Grad Sch Med, Kobe, Hyogo 6500017, Japan.
   Nakae, Jun, Keio Univ, Dept Internal Med, Sch Med, Tokyo 1608582, Japan.
   Accili, Domenico, Columbia Univ, Dept Med, New York, NY 10032 USA.
   Accili, Domenico, Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10032 USA.
   Yokomizo, Takehiko, Juntendo Univ, Dept Biochem, Sch Med, Tokyo 1138421, Japan.
   Seino, Susumu, Kobe Univ, Div Mol \& Metab Med, Grad Sch Med, Kobe, Hyogo 6500017, Japan.
   Kasuga, Masato, Asahi Life Fdn, Inst Adult Dis, Tokyo 1030002, Japan.},
DOI = {10.1073/pnas.1921015117},
ISSN = {0027-8424},
EISSN = {1091-6490},
Keywords = {insulin resistance; leukotriene B4; 5-lipoxygenase; PDK1; FoxO1},
Keywords-Plus = {ADIPOSE-TISSUE; LEUKOTRIENE B-4; BEIGE FAT; RESISTANCE; RECEPTOR;
   OBESITY; LIPODYSTROPHY; INFLAMMATION; ADIPONECTIN; MACROPHAGES},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {ogawa@med.kobe-u.ac.jp},
Affiliations = {Kobe University; Kobe University; Kobe University; Gunma University;
   Tokushima University; Kyoto Prefectural University of Medicine; Kobe
   University; Keio University; Columbia University; Columbia University;
   Juntendo University; Kobe University; Asahi Life Foundation},
ResearcherID-Numbers = {Matsui, Sho/AGT-3007-2022
   OGAWA, Wataru/AAQ-9586-2020
   Yokomizo, Takehiko/P-5673-2016
   Sakaue, Hiroshi/ABE-2337-2021
   Shinohara, Masakazu/AFV-1408-2022
   Sasaki, Tsutomu/IXN-6449-2023
   Hosokawa, Yusei/NAZ-1689-2025},
ORCID-Numbers = {Matsui, Sho/0000-0003-1256-1182
   Itoh, Yoshito/0000-0001-9890-3635
   Sakaue, Hiroshi/0000-0002-2468-2363
   Sasaki, Tsutomu/0000-0001-8041-1915
   Hosokawa, Yusei/0000-0003-1684-8121},
Funding-Acknowledgement = {Japan Society for the Promotion of Science KAKENHI {[}JP19H03709,
   JP15K09389, JP18K08478]; Yamaguchi Endocrine Research Foundation;
   Suzuken Memorial Foundation; Novartis; Kobe University; Eli Lilly,
   Japan; Grants-in-Aid for Scientific Research {[}20K08214, 20K19709]
   Funding Source: KAKEN},
Funding-Text = {We thank E. D. Rosen and J. Eguchi for generating and providing
   Adipoq-Cre mice. We are also grateful to M. Murakami for technical
   assistance. This study was supported, in part, by Japan Society for the
   Promotion of Science KAKENHI Grants JP19H03709 (to W.O.), JP15K09389,
   and JP18K08478 (to T.H.) as well as by grants from Yamaguchi Endocrine
   Research Foundation (to T.H.), from Suzuken Memorial Foundation (to
   T.H.), and from Novartis (to W.O. and T.H.). T.H. was supported by the
   grant ``Collaborative Research Program{''} between Kobe University and
   Eli Lilly, Japan (to S.S.).},
Cited-References = {Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0.
   Blüher M, 2002, DEV CELL, V3, P25, DOI 10.1016/S1534-5807(02)00199-5.
   Boucher J, 2016, DIABETES, V65, P2201, DOI 10.2337/db16-0212.
   Colas RA, 2014, AM J PHYSIOL-CELL PH, V307, pC39, DOI 10.1152/ajpcell.00024.2014.
   Eguchi J, 2011, CELL METAB, V13, P249, DOI 10.1016/j.cmet.2011.02.005.
   Fasshauer M, 2003, DIABETOLOGIA, V46, P1594, DOI 10.1007/s00125-003-1228-z.
   Fève B, 2005, BEST PRACT RES CL EN, V19, P483, DOI 10.1016/j.beem.2005.07.007.
   Giorgino F, 2005, ACTA PHYSIOL SCAND, V183, P13, DOI 10.1111/j.1365-201X.2004.01385.x.
   GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517.
   Hosooka T, 2008, NAT MED, V14, P188, DOI 10.1038/nm1706.
   Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485.
   Huang-Doran I, 2010, J ENDOCRINOL, V207, P245, DOI 10.1677/JOE-10-0272.
   Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009.
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126.
   Kajimura S, 2015, CELL METAB, V22, P546, DOI 10.1016/j.cmet.2015.09.007.
   Kitamura T, 1999, MOL CELL BIOL, V19, P6286.
   Li PP, 2015, NAT MED, V21, P239, DOI 10.1038/nm.3800.
   Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672.
   Mothe-Satney I, 2012, DIABETES, V61, P2311, DOI 10.2337/db11-1455.
   Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876.
   Norseen J, 2012, MOL CELL BIOL, V32, P2010, DOI 10.1128/MCB.06193-11.
   Okada K, 2018, BIOCHEM BIOPH RES CO, V505, P29, DOI 10.1016/j.bbrc.2018.09.081.
   Osher E, 2006, MOL CELL ENDOCRINOL, V252, P201, DOI 10.1016/j.mce.2006.03.038.
   Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Rådmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002.
   Sakai T, 2007, J BIOL CHEM, V282, P2038, DOI 10.1074/jbc.M608144200.
   Sasaki T, 2015, ENDOCR J, V62, P787, DOI 10.1507/endocrj.EJ15-0255.
   Sasaki T, 2014, DIABETOLOGIA, V57, P819, DOI 10.1007/s00125-013-3140-5.
   Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448.
   Sidossis L, 2015, J CLIN INVEST, V125, P478, DOI 10.1172/JCI78362.
   Softic S, 2016, DIABETES, V65, P2187, DOI 10.2337/db16-0213.
   Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9.
   Spite M, 2011, J IMMUNOL, V187, P1942, DOI 10.4049/jimmunol.1100196.
   Stables MJ, 2011, PROG LIPID RES, V50, P35, DOI 10.1016/j.plipres.2010.07.005.
   Terawaki K, 2005, J IMMUNOL, V175, P4217, DOI 10.4049/jimmunol.175.7.4217.
   Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200.
   Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984.
   Ying W, 2017, J CLIN INVEST, V127, P1019, DOI 10.1172/JCI90350.
   Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506.},
Number-of-Cited-References = {40},
Times-Cited = {34},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Proc. Natl. Acad. Sci. U. S. A.},
Doc-Delivery-Number = {LT0WM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000536797100064},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000531787500006,
Author = {Tan, Shutang and Zhang, Xixi and Kong, Wei and Yang, Xiao-Li and Molnar,
   Gergely and Vondrakova, Zuzana and Filepova, Roberta and Petrasek, Jan
   and Friml, Jiff and Xue, Hong-Wei},
Title = {The lipid code-dependent phosphoswitch PDK1-D6PK activates PIN-mediated
   auxin efflux in Arabidopsis},
Journal = {NATURE PLANTS},
Year = {2020},
Volume = {6},
Number = {5},
Pages = {556+},
Month = {MAY},
Abstract = {The PDK1 lipid-dependent kinase controls PIN1 and auxin transport
   through a phosphorylation cascade that includes AGC-type kinase D6PK.
   The double pdk1 mutant reveals auxin-related phenotypes such as reduced
   gravitropism and lateral roots.
   Directional intercellular transport of the phytohormone auxin mediated
   by PIN-FORMED (PIN) efflux carriers has essential roles in both
   coordinating patterning processes and integrating multiple external cues
   by rapidly redirecting auxin fluxes. PIN activity is therefore regulated
   by multiple internal and external cues, for which the underlying
   molecular mechanisms are not fully elucidated. Here, we demonstrate that
   3 `-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE1 (PDK1), which is
   conserved in plants and mammals, functions as a molecular hub that
   perceives upstream lipid signalling and modulates downstream substrate
   activity through phosphorylation. Using genetic analysis, we show that
   the loss-of-function Arabidopsis pdk1.1 pdk1.2 mutant exhibits a
   plethora of abnormalities in organogenesis and growth due to defective
   polar auxin transport. Further cellular and biochemical analyses reveal
   that PDK1 phosphorylates D6 protein kinase, a well-known upstream
   activator of PIN proteins. We uncover a lipid-dependent phosphorylation
   cascade that connects membrane-composition-based cellular signalling
   with plant growth and patterning by regulating morphogenetic auxin
   fluxes.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Friml, J (Corresponding Author), Inst Sci \& Technol Austria IST Austria, Klosterneuburg, Austria.
   Xue, HW (Corresponding Author), Chinese Acad Sci, CAS Ctr Excellence Mol Plant Sci, Shanghai Inst Plant Physiol \& Ecol, Natl Key Lab Plant Mol Genet, Shanghai, Peoples R China.
   Xue, HW (Corresponding Author), Shanghai Jiao Tong Univ, Joint Ctr Single Cell Biol, Sch Agr \& Biol, Shanghai, Peoples R China.
   Tan, Shutang; Zhang, Xixi; Molnar, Gergely; Friml, Jiff, Inst Sci \& Technol Austria IST Austria, Klosterneuburg, Austria.
   Zhang, Xixi; Molnar, Gergely, Univ Nat Resources \& Life Sci BOKU, Dept Appl Genet \& Cell Biol, Vienna, Austria.
   Kong, Wei; Yang, Xiao-Li; Xue, Hong-Wei, Chinese Acad Sci, CAS Ctr Excellence Mol Plant Sci, Shanghai Inst Plant Physiol \& Ecol, Natl Key Lab Plant Mol Genet, Shanghai, Peoples R China.
   Vondrakova, Zuzana; Filepova, Roberta; Petrasek, Jan, Czech Acad Sci, Inst Expt Bot, Prague, Czech Republic.
   Xue, Hong-Wei, Shanghai Jiao Tong Univ, Joint Ctr Single Cell Biol, Sch Agr \& Biol, Shanghai, Peoples R China.},
DOI = {10.1038/s41477-020-0648-9},
EarlyAccessDate = {MAY 2020},
ISSN = {2055-026X},
EISSN = {2055-0278},
Keywords-Plus = {D6 PROTEIN-KINASE; PLASMA-MEMBRANE; PHOSPHATIDIC-ACID; ROOT
   GRAVITROPISM; TRANSPORT; PHOSPHORYLATION; PDK1; TRAFFICKING; POLARITY;
   BIOSYNTHESIS},
Research-Areas = {Plant Sciences},
Web-of-Science-Categories  = {Plant Sciences},
Author-Email = {jiri.friml@ist.ac.at
   hwxue@sjtu.edu.cn},
Affiliations = {Institute of Science \& Technology - Austria; BOKU University; Chinese
   Academy of Sciences; Center for Excellence in Molecular Plant Sciences,
   CAS; Czech Academy of Sciences; Institute of Experimental Botany of the
   Czech Academy of Sciences; Shanghai Jiao Tong University},
ResearcherID-Numbers = {Tan, Shutang/AAB-6227-2020
   Petrasek, Jan/C-8240-2009
   Friml, Jiri/D-9511-2012
   Vonakova, Zuzana/HJI-7442-2023
   },
ORCID-Numbers = {Tan, Shutang/0000-0002-0471-8285
   Xue, Hong-Wei/0000-0002-7641-5320
   Petrasek, Jan/0000-0002-6719-2735
   Friml, Jiri/0000-0002-8302-7596
   Molnar, Gergely/0000-0001-6205-4723
   Vonakova, Zuzana/0000-0001-6280-2381
   Zhang, Xixi/0000-0001-7048-4627},
Funding-Acknowledgement = {Chinese Ten-Thousand Talent Program; European Union {[}742985]; European
   Molecular Biology Organization (EMBO) long-term postdoctoral fellowship
   {[}ALTF 723-2015]; China Scholarship Council},
Funding-Text = {We thank C. Schwechheimer and B. Scheres for sharing published
   materials; M. Glanc for providing pET28a-PIN2/3 plasmids; X. Gao for
   help with SEM imaging, L. Rodriguez for advice on co-IP; staff at the
   bioimaging and life science facilities of IST Austria for continuous
   service and assistance; and the Nottingham Arabidopsis Stock Centre
   (NASC) and the Arabidopsis Biological Resource Centre (ABRC) for
   providing T-DNA insertional mutants. J.P. acknowledges the support from
   imaging facility of IEB CAS. The research leading to these results has
   received funding from Chinese Ten-Thousand Talent Program (to H.-W.X.)
   and the European Union's Horizon2020 program (ERC grant agreement no.
   742985, to J.F.). S.T. was funded by a European Molecular Biology
   Organization (EMBO) long-term postdoctoral fellowship (ALTF 723-2015).
   X.Z. was supported by a PhD scholarship from China Scholarship Council.},
Cited-References = {Abas L, 2006, NAT CELL BIOL, V8, P249, DOI 10.1038/ncb1369.
   Adamowski M, 2015, PLANT CELL, V27, P20, DOI 10.1105/tpc.114.134874.
   Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068.
   Anthony RG, 2006, J BIOL CHEM, V281, P37536, DOI 10.1074/jbc.M607341200.
   Armengot L, 2016, J EXP BOT, V67, P4015, DOI 10.1093/jxb/erw216.
   Band LR, 2012, P NATL ACAD SCI USA, V109, P4668, DOI 10.1073/pnas.1201498109.
   Barbosa ICR, 2016, DEVELOPMENT, V143, P4687, DOI 10.1242/dev.137117.
   Baster P, 2013, EMBO J, V32, P260, DOI 10.1038/emboj.2012.310.
   Benková E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3.
   Brumos J, 2018, DEV CELL, V47, P306, DOI 10.1016/j.devcel.2018.09.022.
   Camehl I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002051.
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x.
   Dai MQ, 2012, PLANT CELL, V24, P2497, DOI 10.1105/tpc.112.098905.
   Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6.
   Dhonukshe P, 2010, DEVELOPMENT, V137, P3245, DOI 10.1242/dev.052456.
   Dory M, 2018, FEBS LETT, V592, P89, DOI 10.1002/1873-3468.12929.
   Franklin KA, 2011, P NATL ACAD SCI USA, V108, P20231, DOI 10.1073/pnas.1110682108.
   Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618.
   Friml J, 2002, NATURE, V415, P806, DOI 10.1038/415806a.
   Friml J, 2002, CELL, V108, P661, DOI 10.1016/S0092-8674(02)00656-6.
   Friml J, 2003, NATURE, V426, P147, DOI 10.1038/nature02085.
   Gao HB, 2013, MOL PLANT, V6, P1692, DOI 10.1093/mp/sst076.
   Geisler M, 2005, PLANT J, V44, P179, DOI 10.1111/j.1365-313X.2005.02519.x.
   Geldner N, 2003, CELL, V112, P219, DOI 10.1016/S0092-8674(03)00003-5.
   Gray WM, 1998, P NATL ACAD SCI USA, V95, P7197, DOI 10.1073/pnas.95.12.7197.
   Grones P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28188-1.
   Guo XL, 2015, PLANT PHYSIOL, V167, P1058, DOI 10.1104/pp.114.249904.
   Ischebeck T, 2013, PLANT CELL, V25, P4894, DOI 10.1105/tpc.113.116582.
   Jia WY, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002550.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lewis DR, 2009, NAT PROTOC, V4, P437, DOI 10.1038/nprot.2009.1.
   Liu W, 2003, PLANT J, V36, P189, DOI 10.1046/j.1365-313X.2003.01866.x.
   Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175.
   Marhava P, 2018, NATURE, V558, P297, DOI 10.1038/s41586-018-0186-z.
   Mei Y, 2012, CELL RES, V22, P581, DOI 10.1038/cr.2011.150.
   Michniewicz M, 2007, CELL, V130, P1044, DOI 10.1016/j.cell.2007.07.033.
   Noack LC, 2017, CURR OPIN PLANT BIOL, V40, P22, DOI 10.1016/j.pbi.2017.06.017.
   Parry G, 2006, CURR OPIN CELL BIOL, V18, P152, DOI 10.1016/j.ceb.2006.02.001.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Petrásek J, 2006, SCIENCE, V312, P914, DOI 10.1126/science.1123542.
   Platre MP, 2019, SCIENCE, V364, P57, DOI 10.1126/science.aav9959.
   Prát T, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007177.
   Rademacher EH, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00250.
   Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353.
   Rigó G, 2013, PLANT CELL, V25, P1592, DOI 10.1105/tpc.113.110452.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Rook F, 1998, PLANT J, V15, P253, DOI 10.1046/j.1365-313X.1998.00205.x.
   Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Scholz S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007927.
   Simon MLA, 2016, NAT PLANTS, V2, DOI {[}10.1038/NPLANTS.2016.89, 10.1038/nplants.2016.89].
   Stepanova AN, 2008, CELL, V133, P177, DOI 10.1016/j.cell.2008.01.047.
   Swarup K, 2008, NAT CELL BIOL, V10, P946, DOI 10.1038/ncb1754.
   Swarup R, 2005, NAT CELL BIOL, V7, P1057, DOI 10.1038/ncb1316.
   Tan ST, 2020, CURR BIOL, V30, P381, DOI 10.1016/j.cub.2019.11.058.
   Tejos R, 2014, PLANT CELL, V26, P2114, DOI 10.1105/tpc.114.126185.
   van Leeuwen W, 2004, TRENDS PLANT SCI, V9, P378, DOI 10.1016/j.tplants.2004.06.008.
   Wang PP, 2019, PLANT CELL, V31, P250, DOI 10.1105/tpc.18.00528.
   Weller B, 2017, P NATL ACAD SCI USA, V114, pE887, DOI 10.1073/pnas.1614380114.
   Xiao Y, 2020, NAT PLANTS, V6, P544, DOI 10.1038/s41477-020-0650-2.
   Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449.
   Xu J, 2006, SCIENCE, V311, P385, DOI 10.1126/science.1121790.
   Zádníková P, 2010, DEVELOPMENT, V137, P607, DOI 10.1242/dev.041277.
   Zegzouti H, 2006, P NATL ACAD SCI USA, V103, P6404, DOI 10.1073/pnas.0510283103.
   Zegzouti H, 2006, J BIOL CHEM, V281, P35520, DOI 10.1074/jbc.M605167200.
   Zhang J, 2011, DEV CELL, V20, P855, DOI 10.1016/j.devcel.2011.05.013.
   Zhang J, 2010, P NATL ACAD SCI USA, V107, P918, DOI 10.1073/pnas.0909460107.
   Zourelidou M, 2014, ELIFE, V3, DOI 10.7554/eLife.02860.
   Zourelidou M, 2009, DEVELOPMENT, V136, P627, DOI 10.1242/dev.028365.},
Number-of-Cited-References = {69},
Times-Cited = {49},
Usage-Count-Last-180-days = {5},
Usage-Count-Since-2013 = {86},
Journal-ISO = {Nat. Plants},
Doc-Delivery-Number = {LO1FF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000531787500006},
DA = {2026-02-04},
}

@article{ WOS:000531787500004,
Author = {Xiao, Yao and Offringa, Remko},
Title = {PDK1 regulates auxin transport and Arabidopsis vascular
   development through AGC1 kinase PAX},
Journal = {NATURE PLANTS},
Year = {2020},
Volume = {6},
Number = {5},
Pages = {544+},
Month = {MAY},
Abstract = {The PDK1 lipid-dependent kinase controls PINs and auxin transport
   through a phosphorylation cascade that includes AGC-type kinase PAX. The
   double pdk1 mutant reveals auxin-related phenotypes in vascular
   development.
   The 3-phosphoinositide-dependent protein kinase 1 (PDK1) is a conserved
   master regulator of AGC kinases in eukaryotic organisms. pdk1 loss of
   function causes a lethal phenotype in animals and yeasts, but only mild
   phenotypic defects in Arabidopsis thaliana (Arabidopsis). The
   Arabidopsis genome contains two PDK1-encoding genes, PDK1 and PDK2.
   Here, we used clustered regularly interspaced short palindromic repeat
   (CRISPR)/CRISPR-associated protein 9 (Cas9) to generate true
   loss-of-function pdk1 alleles, which, when combined with pdk2 alleles,
   showed severe developmental defects including fused cotyledons, a short
   primary root, dwarf stature and defects in male fertility. We obtained
   evidence that PDK1 is responsible for AGC1 kinase PROTEIN KINASE
   ASSOCIATED WITH BRX (PAX) activation by phosphorylation during vascular
   development, and that the PDK1 phospholipid-binding Pleckstrin Homology
   domain is not required for this process. Our data indicate that PDK1
   regulates polar auxin transport by activating AGC1 clade kinases,
   resulting in PIN phosphorylation.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Offringa, R (Corresponding Author), Leiden Univ, Inst Biol Leiden, Plant Dev Genet, Leiden, Netherlands.
   Xiao, Yao; Offringa, Remko, Leiden Univ, Inst Biol Leiden, Plant Dev Genet, Leiden, Netherlands.
   Xiao, Yao, Tech Univ Munich, TUM Sch Life Sci Weihenstephan, Plant Syst Biol, Freising Weihenstephan, Germany.},
DOI = {10.1038/s41477-020-0650-2},
EarlyAccessDate = {MAY 2020},
ISSN = {2055-026X},
EISSN = {2055-0278},
Keywords-Plus = {PROTEIN-KINASE; AGCVIII KINASES; ARF-GAP; PHOSPHORYLATION; EFFLUX;
   GROWTH; GENE; POLARITY; ACTIVATION; EXPRESSION},
Research-Areas = {Plant Sciences},
Web-of-Science-Categories  = {Plant Sciences},
Author-Email = {r.offringa@biology.leidenuniv.nl},
Affiliations = {Leiden University; Leiden University - Excl LUMC; Technical University
   of Munich},
ORCID-Numbers = {Xiao, Yao/0000-0002-3078-7225},
Funding-Acknowledgement = {China Scholarship Council},
Funding-Text = {We thank A. Rodriguez-Villalon, C. Hardtke, C. Schwechheimer, I.
   Heilmann and J. Chang (Jia Li's laboratory) for providing mutants cvp2
   cvl1, pax paxl, d6pk012, pip5k1 pip5k2 and gnom, respectively. We thank
   T. Devarenne for providing yeast strain p416GPD, S. de Pater for
   providing the CRISPR/Cas9 plasmids, X. Men for sharing preliminary data
   on PIN2HL phosphorylation by PDK1, K. Boot for help with auxin transport
   assays and G. Lamers and J. Willemse for help with microscopy. We are
   grateful to N. Surtel, W. de Winter and J. Vink for their help with
   plant growth and media preparation. This project was supported by the
   China Scholarship Council.},
Cited-References = {Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068.
   Anthony RG, 2006, J BIOL CHEM, V281, P37536, DOI 10.1074/jbc.M607341200.
   Bao F, 2004, PLANT PHYSIOL, V134, P1624, DOI 10.1104/pp.103.036897.
   Benjamins R, 2001, DEVELOPMENT, V128, P4057.
   Benková E, 2003, CELL, V115, P591, DOI 10.1016/S0092-8674(03)00924-3.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Blilou I, 2005, NATURE, V433, P39, DOI 10.1038/nature03184.
   Camehl I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002051.
   Carland F, 2009, PLANT J, V59, P895, DOI 10.1111/j.1365-313X.2009.03920.x.
   Casamayor A, 1999, CURR BIOL, V9, P186, DOI 10.1016/S0960-9822(99)80088-8.
   Christensen SK, 2000, CELL, V100, P469, DOI 10.1016/S0092-8674(00)80682-0.
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x.
   Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979.
   Devarenne TP, 2006, EMBO J, V25, P255, DOI 10.1038/sj.emboj.7600910.
   Dhonukshe P, 2010, DEVELOPMENT, V137, P3245, DOI 10.1242/dev.052456.
   Dittrich ACN, 2012, PLANT SIGNAL BEHAV, V7, P642, DOI 10.4161/psb.20038.
   Dittrich ACN, 2012, PLANT PHYSIOL, V158, P1018, DOI 10.1104/pp.111.184572.
   Fauser F, 2014, PLANT J, V79, P348, DOI 10.1111/tpj.12554.
   Friml J, 2004, SCIENCE, V306, P862, DOI 10.1126/science.1100618.
   Frödin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551.
   Furutani M, 2004, DEVELOPMENT, V131, P5021, DOI 10.1242/dev.01388.
   Galván-Ampudia CS, 2007, TRENDS PLANT SCI, V12, P541, DOI 10.1016/j.tplants.2007.10.004.
   GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910.
   Gray JW, 2013, BBA-PROTEINS PROTEOM, V1834, P1099, DOI 10.1016/j.bbapap.2013.03.006.
   Haga K, 2018, PLANT CELL PHYSIOL, V59, P1060, DOI 10.1093/pcp/pcy048.
   Huang F, 2010, PLANT CELL, V22, P1129, DOI 10.1105/tpc.109.072678.
   Inagaki M, 1999, MOL CELL BIOL, V19, P8344.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li E, 2018, MOL PLANT, V11, P1198, DOI 10.1016/j.molp.2018.07.004.
   Marhava P, 2018, NATURE, V558, P297, DOI 10.1038/s41586-018-0186-z.
   Matsui H, 2010, PLANT CELL PHYSIOL, V51, P2082, DOI 10.1093/pcp/pcq167.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7.
   Niederberger C, 1999, MOL GEN GENET, V261, P177, DOI 10.1007/s004380050955.
   Okushima Y, 2005, PLANT CELL, V17, P444, DOI 10.1105/tpc.104.028316.
   Parry G, 2009, P NATL ACAD SCI USA, V106, P22540, DOI 10.1073/pnas.0911967106.
   PATTON DA, 1991, MOL GEN GENET, V227, P337, DOI 10.1007/BF00273921.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Richter S, 2010, EUR J CELL BIOL, V89, P138, DOI 10.1016/j.ejcb.2009.11.020.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Sabatini S, 1999, CELL, V99, P463, DOI 10.1016/S0092-8674(00)81535-4.
   Schirawski J, 2000, J VIROL METHODS, V86, P85, DOI 10.1016/S0166-0934(99)00173-1.
   Scholz S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007927.
   Sieburth LE, 2006, PLANT CELL, V18, P1396, DOI 10.1105/tpc.105.039008.
   Simon MLA, 2016, NAT PLANTS, V2, DOI {[}10.1038/NPLANTS.2016.89, 10.1038/nplants.2016.89].
   Tan S, 2019, LIPID CODE DEPENDENT, DOI {[}10.1101/755504, DOI 10.1101/755504].
   Tejos R, 2014, PLANT CELL, V26, P2114, DOI 10.1105/tpc.114.126185.
   Truernit E, 2008, PLANT CELL, V20, P1494, DOI 10.1105/tpc.107.056069.
   Voordeckers K, 2011, J BIOL CHEM, V286, P22017, DOI 10.1074/jbc.M110.200071.
   Willige BC, 2013, PLANT CELL, V25, P1674, DOI 10.1105/tpc.113.111484.
   Won SK, 2009, PLANT PHYSIOL, V150, P1459, DOI 10.1104/pp.109.140905.
   Xu J, 2005, PLANT CELL, V17, P525, DOI 10.1105/tpc.104.028449.
   Yan LH, 2015, MOL PLANT, V8, P1820, DOI 10.1016/j.molp.2015.10.004.
   Zádníková P, 2010, DEVELOPMENT, V137, P607, DOI 10.1242/dev.041277.
   Zegzouti H, 2006, P NATL ACAD SCI USA, V103, P6404, DOI 10.1073/pnas.0510283103.
   Zegzouti H, 2006, J BIOL CHEM, V281, P35520, DOI 10.1074/jbc.M605167200.
   Zhang Y, 2009, PLANT J, V58, P474, DOI 10.1111/j.1365-313X.2009.03792.x.
   Zourelidou M, 2009, DEVELOPMENT, V136, P627, DOI 10.1242/dev.028365.},
Number-of-Cited-References = {58},
Times-Cited = {37},
Usage-Count-Last-180-days = {7},
Usage-Count-Since-2013 = {67},
Journal-ISO = {Nat. Plants},
Doc-Delivery-Number = {LO1FF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000531787500004},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000531216100002,
Author = {Zhu, Jinfeng and Zheng, Guihua and Xu, Haifei and Jin, Xiaoxia and Tang,
   Ting and Wang, Xiaolin},
Title = {Expression and prognostic significance of pyruvate dehydrogenase kinase
   1 in bladder urothelial carcinoma},
Journal = {VIRCHOWS ARCHIV},
Year = {2020},
Volume = {477},
Number = {5},
Pages = {637-649},
Month = {NOV},
Abstract = {Muscular infiltrating bladder urothelial carcinoma (MIBC) is a highly
   malignant disease with a poor prognosis. Radical cystectomy is the
   standard treatment. However, due to surgery and postoperative
   complications, the quality of life of patients is seriously affected.
   Therefore, it is increasingly important to find prognostic markers and
   new therapeutic targets for MIBC. Here, we investigated the expression
   of PDK1, a key regulator of glucose metabolism, in bladder urothelial
   carcinoma (BLCA) and its effect on prognosis. The expression pattern of
   PDK1 was examined by bioinformatics analysis and immunohistochemistry. A
   total of 101 cases of BLCA were selected for tissue microarrays (TMAs)
   that contained both tumour and paired normal tissues. We demonstrated
   that PDK1 expression was correlated with tumour grade and Ki67expression
   in our TMA cohort (all p values < 0.05). Kaplan-Meier survival analysis
   showed that patients with MIBC with high PDK1 expression had a worse
   prognosis than patients with low PDK1 expression (p = 0.016).
   Multifactor risk analysis showed that increased PDK1 expression was an
   independent prognostic factor affecting the overall survival of MIBC
   patients. GSEA showed that the mTOR pathway, HIF pathway, glycolysis,
   PI3K/AKT/mTOR signalling, etc. were differentially enriched in the PDK1
   high expression phenotype. Hence, PDK1 may be a prognostic and
   therapeutic target for MIBC.},
Publisher = {SPRINGER},
Address = {ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES},
Type = {Article},
Language = {English},
Affiliation = {Wang, XL (Corresponding Author), Nantong Univ, Affiliated Tumor Hosp, Dept Urol, Nantong 226361, Jiangsu, Peoples R China.
   Tang, T (Corresponding Author), Nantong Univ, Canc Res Ctr Nantong, Tumor Hosp, Nantong 226361, Jiangsu, Peoples R China.
   Zhu, Jinfeng; Xu, Haifei; Wang, Xiaolin, Nantong Univ, Affiliated Tumor Hosp, Dept Urol, Nantong 226361, Jiangsu, Peoples R China.
   Zheng, Guihua; Jin, Xiaoxia, Nantong Univ, Affiliated Tumor Hosp, Dept Pathol, Nantong 226361, Jiangsu, Peoples R China.
   Tang, Ting, Nantong Univ, Canc Res Ctr Nantong, Tumor Hosp, Nantong 226361, Jiangsu, Peoples R China.},
DOI = {10.1007/s00428-020-02782-z},
EarlyAccessDate = {MAY 2020},
ISSN = {0945-6317},
EISSN = {1432-2307},
Keywords = {Pyruvate dehydrogenase kinase 1; BLCA; IHC; TCGA; GSEA; Prognosis},
Keywords-Plus = {AEROBIC GLYCOLYSIS; CANCER; HYPOXIA; GLIOBLASTOMA; PROGRESSION;
   ADAPTATION; GLUCOSE},
Research-Areas = {Pathology},
Web-of-Science-Categories  = {Pathology},
Author-Email = {tangting710@126.com
   cxhwyc2010@163.com},
Affiliations = {Nantong University; Nantong University; Nantong University},
ResearcherID-Numbers = {Zhu, Jinfeng/ACP-3605-2022
   wang, xiaolin/HZK-6809-2023},
Funding-Acknowledgement = {Jiangsu Provincial Commission of Health and Family Planning {[}H201663];
   Project of Science and Technology Bureau of Nantong {[}MS22019010]},
Funding-Text = {Our work was granted by Jiangsu Provincial Commission of Health and
   Family Planning (H201663) and the Project of Science and Technology
   Bureau of Nantong (MS22019010).},
Cited-References = {Babjuk M, 2013, EUR UROL, V64, P639, DOI 10.1016/j.eururo.2013.06.003.
   Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029.
   Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033.
   Cai CF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0769-4.
   Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104.
   Conde VR, 2015, EXP CELL RES, V335, P91, DOI 10.1016/j.yexcr.2015.04.007.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937.
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002.
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001.
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Klyuyeva A, 2019, J BIOL CHEM, V294, P838, DOI 10.1074/jbc.RA118.006433.
   Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212.
   Massari F, 2016, CANCER TREAT REV, V45, P46, DOI 10.1016/j.ctrv.2016.03.005.
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Shen H, 2015, MOL CANCER THER, V14, P1794, DOI 10.1158/1535-7163.MCT-15-0247.
   Song L, 2019, PATHOL RES PRACT, V215, P478, DOI 10.1016/j.prp.2018.12.038.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Yang Z, 2018, EUR J PHARMACOL, V838, P41, DOI 10.1016/j.ejphar.2018.09.016.
   Yang Z, 2017, EUR J PHARMACOL, V815, P80, DOI 10.1016/j.ejphar.2017.08.037.
   Yang Z, 2016, EUR J PHARMACOL, V789, P458, DOI 10.1016/j.ejphar.2016.08.004.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.
   Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10.},
Number-of-Cited-References = {30},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Virchows Arch.},
Doc-Delivery-Number = {PP6NR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000531216100002},
DA = {2026-02-04},
}

@article{ WOS:000536780600001,
Author = {Gimenez-Llort, Lydia and Santana-Santana, Mikel and Ramon Bayascas, Jose},
Title = {The Impact of the PI3K/Akt Signaling Pathway in Anxiety and Working
   Memory in Young and Middle-Aged PDK1 K465E Knock-In Mice},
Journal = {FRONTIERS IN BEHAVIORAL NEUROSCIENCE},
Year = {2020},
Volume = {14},
Month = {MAY 8},
Abstract = {Dysfunction and dysregulation at the genetic, neural, and behavioral
   levels point at the fine-tuning of broadly spread networks as critical
   for a wide array of behaviors and mental processes through the life
   span. This brain-based evidence, from basic to behavioral neuroscience
   levels, is leading to a new conceptualization of mental health and
   disease. Thus, the Research Domain Criteria considers phenotypic
   differences observed among disorders as explained by variations in the
   nature and degree of neural circuitry disruptions, under the modulation
   of several developmental, compensatory, environmental, and epigenetic
   factors. In this context, we aimed to describe for the first time the in
   vivo behavioral impact of tweaking the PI3K/Akt signaling pathway known
   to play an essential role in the regulation of cellular processes,
   leading to diverse physiological responses. We explored the effects in
   young (YA, 3-4 months of age) and mature (MA, 11-14 months of age) male
   and female PDK1 K465E knock-in mice in a battery of tests under
   different anxiogenic conditions. The results evidenced that the double
   mutation of the PDK1 pleckstrin homology (PH) domain resulted in an
   enhancement of the negative valence system shown as an increase of
   responses of fear- and anxiety-like behaviors in anxiogenic situations.
   Interestingly, this seemed to be specific of YA and found regulated at
   middle age. In contrast, cognitive deficits, as measured in a spatial
   working memory task, were found in both YA and MA mutants and
   independently of the level of their anxious-like profiles. These
   distinct age- and function-dependent impacts would be in agreement with
   the distinct cortical and limbic deficits in the Akt signaling in the
   brain we have recently described in these same animals. The elicitation
   of age- and neuronal-dependent specific patterns suggests that
   fine-tuning the intensity of the PKB/Akt signal that enables diverse
   physiological response has also its in vivo translation into the
   negative valence system and age is a key regulatory factor.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Giménez-Llort, L (Corresponding Author), Univ Autonoma Barcelona, Inst Neurociencies, Barcelona, Spain.
   Giménez-Llort, L (Corresponding Author), Univ Autonoma Barcelona, Sch Med, Dept Psychiat \& Forens Med, Barcelona, Spain.
   Gimenez-Llort, Lydia; Santana-Santana, Mikel; Ramon Bayascas, Jose, Univ Autonoma Barcelona, Inst Neurociencies, Barcelona, Spain.
   Gimenez-Llort, Lydia; Santana-Santana, Mikel, Univ Autonoma Barcelona, Sch Med, Dept Psychiat \& Forens Med, Barcelona, Spain.
   Ramon Bayascas, Jose, Univ Autonoma Barcelona, Sch Med, Dept Biochem \& Mol Biol, Barcelona, Spain.},
DOI = {10.3389/fnbeh.2020.00061},
Article-Number = {61},
ISSN = {1662-5153},
Keywords = {RDoC; PI3K; Akt; signaling pathway; anxiety; cognition; animal model;
   aging; fine tuning},
Keywords-Plus = {ANIMAL-MODEL; 3XTG-AD MICE; KINASE; BEHAVIOR; AMYGDALA;
   PHOSPHOINOSITIDES; DEFICIENCY; DEPRESSION; INSIGHTS; MUTATION},
Research-Areas = {Behavioral Sciences; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Behavioral Sciences; Neurosciences},
Author-Email = {lidia.gimenez@uab.cat},
Affiliations = {Autonomous University of Barcelona; Autonomous University of Barcelona;
   Autonomous University of Barcelona},
ResearcherID-Numbers = {Giménez-Llort, Lydia/I-3347-2015
   Lizcano, Jose/E-6080-2010},
ORCID-Numbers = {Giménez-Llort, Lydia/0000-0002-4091-489X
   },
Funding-Acknowledgement = {Ministerio de Economia y Competitividad (MINECO), Programa Estatal de
   Investigacion, Desarrollo e Innovacion Orientada a los Retos de la
   Sociedad {[}SAF2014-52813-R]},
Funding-Text = {This work was funded by the Ministerio de Economia y Competitividad
   (MINECO), Programa Estatal de Investigacion, Desarrollo e Innovacion
   Orientada a los Retos de la Sociedad (SAF2014-52813-R) to JB.},
Cited-References = {Ackermann TF, 2008, CELL PHYSIOL BIOCHEM, V22, P735, DOI 10.1159/000185557.
   Asher J., 2010, GENES CIRCUITRY NOT.
   Asth L, 2012, BRAIN RES BULL, V87, P526, DOI 10.1016/j.brainresbull.2012.02.008.
   Baeta-Corral R, 2014, BEHAV BRAIN RES, V258, P97, DOI 10.1016/j.bbr.2013.10.017.
   Bardin L, 2006, NEUROPSYCHOPHARMACOL, V31, P1869, DOI 10.1038/sj.npp.1300940.
   Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810.
   Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07.
   Chen ZY, 2006, SCIENCE, V314, P140, DOI 10.1126/science.1129663.
   Cordón-Barris L, 2016, MOL CELL BIOL, V36, P2967, DOI 10.1128/MCB.00230-16.
   de Brouwer G, 2019, COGN AFFECT BEHAV NE, V19, P1, DOI 10.3758/s13415-018-00653-4.
   Deacon RMJ, 2002, BEHAV BRAIN RES, V133, P57, DOI 10.1016/S0166-4328(01)00451-X.
   Duman RS, 2006, BIOL PSYCHIAT, V59, P1116, DOI 10.1016/j.biopsych.2006.02.013.
   GOLDMANRAKIC PS, 1994, J NEUROPSYCH CLIN N, V6, P348.
   Guayerbas N, 2000, ANIMAL RES WELFARE P, P159.
   Hyman SE, 2007, NAT REV NEUROSCI, V8, P725, DOI 10.1038/nrn2218.
   Jimenez-Gomez C, 2011, BEHAV PHARMACOL, V22, P711, DOI 10.1097/FBP.0b013e32834afebe.
   Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379.
   LAT J, 1973, ACTA NEUROBIOL EXP, V33, P771.
   Leibrock C, 2013, CELL PHYSIOL BIOCHEM, V32, P766, DOI 10.1159/000354478.
   Martinowich K, 2007, NAT NEUROSCI, V10, P1089, DOI 10.1038/nn1971.
   Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Morris Sarah E, 2012, Dialogues Clin Neurosci, V14, P29.
   National Institute of Mental Health, 2020, RES DOM CRIT.
   Ou LC, 2006, NEUROPSYCHOPHARMACOL, V31, P287, DOI 10.1038/sj.npp.1300830.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Sanderson DJ, 2012, HIPPOCAMPUS, V22, P981, DOI 10.1002/hipo.20896.
   Shi HS, 2012, NEUROPSYCHOPHARMACOL, V37, P2671, DOI 10.1038/npp.2012.131.
   Tao WW, 2016, BEHAV BRAIN RES, V308, P177, DOI 10.1016/j.bbr.2016.04.039.
   Torres-Lista V, 2015, BEHAV PROCESS, V116, P69, DOI 10.1016/j.beproc.2015.05.001.
   Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703.
   Waite K, 2010, CURR TOP MICROBIOL, V346, P245, DOI 10.1007/82\_2010\_82.
   Wang W, 2015, NEUROSCIENCE, V285, P281, DOI 10.1016/j.neuroscience.2014.11.025.
   Yang S, 2018, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00435.
   Yen YC, 2012, NEUROBIOL LEARN MEM, V98, P56, DOI 10.1016/j.nlm.2012.04.009.
   Zhou XY, 2014, CELL CYCLE, V13, P3164, DOI 10.4161/15384101.2014.962954.
   Zurashvili T, 2013, MOL CELL BIOL, V33, P1027, DOI 10.1128/MCB.01052-12.},
Number-of-Cited-References = {38},
Times-Cited = {20},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Front. Behav. Neurosci.},
Doc-Delivery-Number = {LT0QD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000536780600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000533936800015,
Author = {Rao, Ling and Mak, Victor C. Y. and Zhou, Yuan and Zhang, Dong and Li,
   Xinran and Fung, Chloe C. Y. and Sharma, Rakesh and Gu, Chao and Lu,
   Yiling and Tipoe, George L. and Cheung, Annie N. Y. and Mills, Gordon B.
   and Cheung, Lydia W. T.},
Title = {p85β regulates autophagic degradation of AXL to activate oncogenic
   signaling},
Journal = {NATURE COMMUNICATIONS},
Year = {2020},
Volume = {11},
Number = {1},
Month = {MAY 8},
Abstract = {PIK3R2 encodes the p85 beta regulatory subunit of phosphatidylinositol
   3-kinase and is frequently amplified in cancers. The signaling mechanism
   and therapeutic implication of p85 beta are poorly understood. Here we
   report that p85 beta upregulates the protein level of the receptor
   tyrosine kinase AXL to induce oncogenic signaling in ovarian cancer. p85
   beta activates p110 activity and AKT-independent PDK1/SGK3 signaling to
   promote tumorigenic phenotypes, which are all abolished upon inhibition
   of AXL. At the molecular level, p85 beta alters the phosphorylation of
   TRIM2 (an E3 ligase) and optineurin (an autophagy receptor), which
   mediate the selective regulation of AXL by p85 beta, thereby disrupting
   the autophagic degradation of the AXL protein. Therapeutically, p85 beta
   expression renders ovarian cancer cells vulnerable to inhibitors of AXL,
   p110, or PDK1. Conversely, p85 beta -depleted cells are less sensitive
   to these inhibitors. Together, our findings provide a rationale for
   pharmacological blockade of the AXL signaling axis in PIK3R2-amplified
   ovarian cancer. p85 beta (PIK3R2), a regulatory subunit of PI3K, has
   oncogenic properties. Here the authors show that p85 beta promotes AXL
   protein stability, which in turn activates p110 to induce PDK1/SGK3
   signaling, and therapeutically, p85 beta -expressing ovarian cancer
   cells are sensitive to AXL inhibition.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Cheung, LWT (Corresponding Author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.
   Rao, Ling; Mak, Victor C. Y.; Zhou, Yuan; Li, Xinran; Fung, Chloe C. Y.; Tipoe, George L.; Cheung, Lydia W. T., Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Hong Kong, Peoples R China.
   Zhang, Dong; Mills, Gordon B., Oregon Hlth \& Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
   Sharma, Rakesh, Univ Hong Kong, Li Ka Shing Fac Med, Prote \& Metabol Core Facil, Hong Kong, Peoples R China.
   Gu, Chao, Fudan Univ, Obstet \& Gynecol Hosp, Dept Obstet \& Gynecol, Shanghai, Peoples R China.
   Lu, Yiling, Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   Cheung, Annie N. Y., Univ Hong Kong, Li Ka Shing Fac Med, Dept Pathol, Hong Kong, Peoples R China.},
DOI = {10.1038/s41467-020-16061-7},
Article-Number = {2291},
EISSN = {2041-1723},
Keywords-Plus = {UBIQUITIN; OPTINEURIN; PHOSPHORYLATION; MUTATIONS; MECHANISM;
   METASTASIS; DOWNSTREAM; P110-ALPHA; RESISTANCE; RECEPTORS},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {lydiacwt@hku.hk},
Affiliations = {University of Hong Kong; Oregon Health \& Science University; University
   of Hong Kong; Fudan University; University of Texas System; UTMD
   Anderson Cancer Center; University of Hong Kong},
ResearcherID-Numbers = {Tipoe, George/C-4418-2009
   Mills, Gordon/L-5416-2014
   },
ORCID-Numbers = {Sharma, Rakesh/0000-0002-5306-3457
   Cheung, Lydia Wai Ting/0000-0003-1137-3200
   Mills, Gordon/0000-0002-0144-9614
   Rao, Ling/0000-0002-2519-8848},
Funding-Acknowledgement = {Hong Kong Research Grants Council {[}17111618]; NCI {[}CA217685,
   CA217842, CA098258, CA016672]; Adelson Medical Research Foundation;
   Ovarian Cancer Research Foundation; Breast Cancer Research Foundation;
   Komen Foundation {[}SAC110052]; National Cancer Institute
   {[}U01CA217842] Funding Source: NIH RePORTER},
Funding-Text = {This study was supported by Hong Kong Research Grants Council (17111618)
   to L.W.C. We thank the RPPA Core Facility (funded by NCI \#CA016672) of
   the MD Anderson Cancer Center (Houston, TX) and the Faculty Core
   Facility of the LKS Faculty of Medicine HKU for the help with confocal
   microscopy. G.B.M. is supported by a kind gift from the Adelson Medical
   Research Foundation, the Ovarian Cancer Research Foundation, The Breast
   Cancer Research Foundation, The Komen Foundation SAC110052, and NCI
   grants CA217685, CA217842, and CA098258. We also thank Professor Axel
   Ullrich (Max Planck Institute of Biochemistry, Germany) for generously
   providing the AXL plasmids and Professor Heike Allgayer (University of
   Heidelberg, Germany) for the human AXL gene promoter.},
Cited-References = {Afzal S, 1998, HUM PATHOL, V29, P155, DOI 10.1016/S0046-8177(98)90226-X.
   Badarni M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125341.
   Balastik M, 2008, P NATL ACAD SCI USA, V105, P12016, DOI 10.1073/pnas.0802261105.
   Bansal M, 2018, J BIOL CHEM, V293, P132, DOI 10.1074/jbc.M117.801944.
   Buehler M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/238284.
   Cariaga-Martínez AE, 2014, BIOL OPEN, V3, P924, DOI 10.1242/bio.20148185.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095.
   Chamberlain MD, 2010, CELL SIGNAL, V22, P1562, DOI 10.1016/j.cellsig.2010.05.025.
   Cheung LWT, 2014, CANCER CELL, V26, P479, DOI 10.1016/j.ccell.2014.08.017.
   Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039.
   Cortés I, 2012, P NATL ACAD SCI USA, V109, P11318, DOI 10.1073/pnas.1118138109.
   Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023.
   Gatica D, 2018, NAT CELL BIOL, V20, P233, DOI 10.1038/s41556-018-0037-z.
   Gay CM, 2017, BRIT J CANCER, V116, P415, DOI 10.1038/bjc.2016.428.
   Gioia R, 2015, J PATHOL, V237, P14, DOI 10.1002/path.4561.
   Gleason CE, 2011, J BIOL CHEM, V286, P35663, DOI 10.1074/jbc.M111.267567.
   Guillermet-Guibert J, 2008, P NATL ACAD SCI USA, V105, P8292, DOI 10.1073/pnas.0707761105.
   Heo JM, 2015, MOL CELL, V60, P7, DOI 10.1016/j.molcel.2015.08.016.
   Huang Z, 2015, ONCOGENE, V34, P1105, DOI 10.1038/onc.2014.56.
   Kachaner D, 2012, MOL CELL, V45, P553, DOI 10.1016/j.molcel.2011.12.030.
   Kim JH, 2002, JAMA-J AM MED ASSOC, V287, P1671, DOI 10.1001/jama.287.13.1671.
   Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026.
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI {[}10.1080/15548627.2015.1100356, 10.1016/j.pneurobio.2023.102483].
   Krishnamoorthy GP, 2013, J BIOL CHEM, V288, P17481, DOI 10.1074/jbc.M112.439422.
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048.
   Li FX, 2018, AUTOPHAGY, V14, P66, DOI 10.1080/15548627.2017.1391970.
   Li XR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08574-7.
   Lin YC, 2015, SCI REP-UK, V5, DOI 10.1038/srep08997.
   Lozneanu L, 2016, ANTICANCER RES, V36, P4155.
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314.
   Mohapatra B, 2013, BBA-MOL CELL RES, V1833, P122, DOI 10.1016/j.bbamcr.2012.10.010.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057.
   Paolino M, 2014, NATURE, V507, P508, DOI 10.1038/nature12998.
   Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106.
   Rankin EB, 2014, P NATL ACAD SCI USA, V111, P13373, DOI 10.1073/pnas.1404848111.
   Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267.
   Revach OY, 2019, CANCER RES, V79, P2634, DOI 10.1158/0008-5472.CAN-18-2316.
   Richter B, 2016, P NATL ACAD SCI USA, V113, P4039, DOI 10.1073/pnas.1523926113.
   Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336.
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72.
   Sharma K, 2014, CELL REP, V8, P1583, DOI 10.1016/j.celrep.2014.07.036.
   Stenmark H, 2009, NAT REV MOL CELL BIO, V10, P513, DOI 10.1038/nrm2728.
   Sun WS, 2004, ONCOLOGY-BASEL, V66, P450, DOI 10.1159/000079499.
   Thorpe LM, 2017, P NATL ACAD SCI USA, V114, P7095, DOI 10.1073/pnas.1704706114.
   Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334.
   Utermark T, 2012, GENE DEV, V26, P1573, DOI 10.1101/gad.191973.112.
   Valverde P, 2005, BIOCHEM BIOPH RES CO, V333, P180, DOI 10.1016/j.bbrc.2005.05.086.
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012.
   Verma N, 2017, CANCER RES, V77, P86, DOI 10.1158/0008-5472.CAN-16-1797.
   Vittal V, 2015, J BIOL CHEM, V290, P21244, DOI 10.1074/jbc.R115.675165.
   Vouri M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.66.
   Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405.
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI {[}10.1038/NMETH.1322, 10.1038/nmeth.1322].
   Yin H, 2017, INT J ONCOL, V51, P1191, DOI 10.3892/ijo.2017.4117.
   Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379.},
Number-of-Cited-References = {58},
Times-Cited = {28},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Nat. Commun.},
Doc-Delivery-Number = {LO9IB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000533936800015},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000538620300001,
Author = {Devis-Jauregui, Laura and Eritja, Nuria and Davis, Meredith Leigh and
   Matias-Guiu, Xavier and Llobet-Navas, David},
Title = {Autophagy in the physiological endometrium and cancer},
Journal = {AUTOPHAGY},
Year = {2021},
Volume = {17},
Number = {5},
Pages = {1077-1095},
Month = {MAY 4},
Abstract = {Autophagy is a highly conserved catabolic process and a major cellular
   pathway for the degradation of long-lived proteins and cytoplasmic
   organelles. An increasing body of evidence has unveiled autophagy as an
   indispensable biological function that helps to maintain normal tissue
   homeostasis and metabolic fitness that can also lead to severe
   consequences for the normal cellular functioning when altered. Recent
   accumulating data point to autophagy as a key player in a wide variety
   of physiological and pathophysiological conditions in the human
   endometrium, one of the most proficient self-regenerating tissues in the
   human body and an instrumental player in placental species reproductive
   function. The current review highlights the most recent findings
   regarding the process of autophagy in the normal and cancerous
   endometrial tissue. Current research efforts aiming to therapeutically
   exploit autophagy and the methodological approaches used are discussed.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Review},
Language = {English},
Affiliation = {Llobet-Navàs, D (Corresponding Author), Bellvitge Biomed Res Inst IDIBELL, Lab Precis Med, Oncobell Program, Gran Via Hospitalet,199, Barcelona 08908, Spain.
   Devis-Jauregui, Laura; Matias-Guiu, Xavier; Llobet-Navas, David, Bellvitge Biomed Res Inst IDIBELL, Lab Precis Med, Oncobell Program, Gran Via Hospitalet,199, Barcelona 08908, Spain.
   Eritja, Nuria; Matias-Guiu, Xavier, Univ Lleida, Hosp Univ Arnau Vilanova, Dept Pathol, IRBLLEIDA,CIBERONC, Lleida, Spain.
   Davis, Meredith Leigh, Newcastle Univ, Int Ctr Life, Inst Genet Med, Cent Pkwy, Newcastle Upon Tyne, Tyne \& Wear, England.
   Matias-Guiu, Xavier, Univ Bellvitge, Dept Pathol Hosp, Barcelona, Spain.},
DOI = {10.1080/15548627.2020.1752548},
EarlyAccessDate = {MAY 2020},
ISSN = {1554-8627},
EISSN = {1554-8635},
Keywords = {Autophagy; endometrial cancer; endometrial hyperplasia; endometrium;
   menstrual cycle; obesity; reproduction},
Keywords-Plus = {EXTERNAL-BEAM RADIOTHERAPY; ENDOTHELIAL GROWTH-FACTOR; CELL-CYCLE
   ARREST; MOLECULAR-MECHANISMS; MTOR INHIBITION; CARCINOMA-CELLS;
   METFORMIN; KINASE; CHEMOTHERAPY; EXPRESSION},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {dllobet@idibell.cat},
Affiliations = {Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); CIBER - Centro
   de Investigacion Biomedica en Red; CIBERONC; Universitat de Lleida;
   University Hospital Arnau de Vilanova; Newcastle University - UK;
   University of Barcelona},
ResearcherID-Numbers = {Devis-Jauregui, Laura/ABH-5740-2020
   Eritja, Nuria/M-1347-2015
   Llobet-Navas, David/B-5660-2009
   Eritja, Núria/M-1347-2015
   Matias-Guiu, Xavier/C-3039-2009
   },
ORCID-Numbers = {Devis-Jauregui, Laura/0000-0003-3736-3983
   Eritja, Nuria/0000-0003-1018-6649
   Llobet-Navas, David/0000-0003-1443-7003
   Eritja, Núria/0000-0003-2131-7915
   Matias-Guiu, Xavier/0000-0002-7201-6605
   Davis, Meredith/0000-0002-0589-8222},
Funding-Acknowledgement = {Instituto de Salud Carlos III (ISCIII) (European Regional Development
   Fund. ERDF, a way to build Europe) {[}PI18/00795, CP17/00063,
   MS17/00063]; AECC Scientific Foundation (FC\_AECC) {[}LABAE19004LLOB]},
Funding-Text = {This study has been funded by Instituto de Salud Carlos III (ISCIII)
   through the projects PI18/00795, CP17/00063 and MS17/00063 (Cofunded by
   European Regional Development Fund. ERDF, a way to build Europe) and by
   the AECC Scientific Foundation (FC\_AECC \#LABAE19004LLOB). We also want
   to thank CERCA Programme/Generalitat de Catalunya for institutional
   support. DLN and NE are recipients of a Miguel Servet scheme; Ministerio
   de Ciencia, Innovacion y Universidades, Gobierno de Espana (ES).},
Cited-References = {Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292.
   Avagliano L, 2015, REPROD SCI, V22, P838, DOI 10.1177/1933719114565036.
   Baak JPA, 2005, J CLIN PATHOL, V58, P1, DOI 10.1136/jcp.2004.021071.
   BAO XX, 2014, CHIN MED J, V464, P315.
   Befani CD, 2012, J MOL MED, V90, P45, DOI 10.1007/s00109-011-0805-8.
   Beier HM, 1998, HUM REPROD UPDATE, V4, P448, DOI 10.1093/humupd/4.5.448.
   Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769.
   Blake P, 2009, LANCET, V373, P137, DOI 10.1016/S0140-6736(08)61767-5.
   BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7.
   Boots CE, 2014, FERTIL STERIL, V102, P455, DOI 10.1016/j.fertnstert.2014.05.005.
   Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616.
   Bruix J, 2011, HEPATOLOGY, V54, P1, DOI 10.1002/hep.24468.
   Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831.
   Bulun SE, 2007, Williams Textbook of Endocrinology, P587.
   Cakmak H, 2011, HUM REPROD UPDATE, V17, P242, DOI 10.1093/humupd/dmq037.
   Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752.
   CHOI J, 2012, BIOL REPROD, V86.
   Conza D, 2017, J CELL PHYSIOL, V232, P3735, DOI 10.1002/jcp.25850.
   CORNILLIE FJ, 1985, GYNECOL OBSTET INVES, V20, P113, DOI 10.1159/000298983.
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153.
   De U, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092743.
   Deng L, 2005, CLIN CANCER RES, V11, P8258, DOI 10.1158/1078-0432.CCR-05-1189.
   Deng L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.9.
   Dizon DS, 2010, GYNECOL ONCOL, V117, P373, DOI 10.1016/j.ygyno.2010.02.007.
   Dolcet X, 2006, J BIOL CHEM, V281, P22118, DOI 10.1074/jbc.M601350200.
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401.
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867.
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028.
   Eckschlager T, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071414.
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031.
   Eritja N, 2017, AUTOPHAGY, V13, P608, DOI 10.1080/15548627.2016.1271512.
   Eritja N, 2017, ADV EXP MED BIOL, V943, P149, DOI 10.1007/978-3-319-43139-0\_6.
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655.
   Farré JC, 2016, NAT REV MOL CELL BIO, V17, P537, DOI 10.1038/nrm.2016.74.
   Felip I, 2019, GYNECOL ONCOL, V153, P425, DOI 10.1016/j.ygyno.2019.03.002.
   Feng LF, 2017, THERANOSTICS, V7, P1890, DOI 10.7150/thno.19135.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   FILIPPICHIELA EC, 2018, MOL PHARM, V68, P7.
   Fleming GF, 2007, J CLIN ONCOL, V25, P2983, DOI 10.1200/JCO.2007.10.8431.
   FUKUDA T, 2007, ONCOL LETT, V25, P2983.
   Fukuda T, 2015, GYNECOL ONCOL, V137, P538, DOI 10.1016/j.ygyno.2015.03.053.
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697.
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22.
   GARCIAMARTINEZ JM, 1985, BIOCHEM J, V20, P113.
   Gayle S, 2017, BLOOD, V129, P1768, DOI 10.1182/blood-2016-09-736892.
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113.
   GEYER CE, 2004, NEW ENGL J MED, V10, P29.
   Giatromanolaki A, 2011, GYNECOL ONCOL, V123, P147, DOI 10.1016/j.ygyno.2011.06.023.
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940.
   Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360.
   Gu CJ, 2017, AM J TRANSL RES, V9, P4071.
   Harada T, 2004, HUM REPROD UPDATE, V10, P29, DOI 10.1093/humupd/dmh007.
   Haraguchi H, 1998, BIOORGAN MED CHEM, V6, P339, DOI 10.1016/S0968-0896(97)10034-7.
   Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190.
   Hong YS, 2012, INT J ONCOL, V41, P76, DOI 10.3892/ijo.2012.1448.
   Jarboe EA, 2010, SEMIN DIAGN PATHOL, V27, P215, DOI 10.1053/j.semdp.2010.09.007.
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834.
   Kaizuka T, 2016, MOL CELL, V64, P835, DOI 10.1016/j.molcel.2016.09.037.
   Kamat AA, 2007, CLIN CANCER RES, V13, P7487, DOI 10.1158/1078-0432.CCR-07-1017.
   Kanda R, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4570-8.
   Kao C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.468.
   Kasznicki J, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.06.01.
   Kaushik S, 2012, MOL BIOL CELL, V23.
   KIM J, 2010, CLIN EXP RHEUMATOL S, V28.
   KIM S, 2017, PEER J, V21.
   Klionsky D.J., 2016, Autophagy, V12.
   Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787.
   KONDRATSKYI A, 2010, FRONT PHYSIOL, V27, P272.
   LANG F, 2015, FASEB J, V14, P3.
   LAWN AM, 1971, J REPROD FERTIL, V26, P85.
   Lebovitz CB, 2015, AUTOPHAGY, V11, P1668, DOI 10.1080/15548627.2015.1067362.
   LEMAY MA, 2013, BMC GENOMICS, V14.
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1.
   LI L, 2001, J AM SOC NEPHROL, V276, P9406.
   Li T, 2004, CANCER LETT, V207, P27, DOI 10.1016/j.canlet.2003.10.023.
   Lin BC, 2009, CANCER RES, V69, P5415, DOI 10.1158/0008-5472.CAN-08-1622.
   Lin QY, 2017, ONCOL LETT, V13, P3567, DOI 10.3892/ol.2017.5894.
   Liu H, 2017, ONCOTARGETS THER, V10, P2865, DOI 10.2147/OTT.S95267.
   Liu SL, 2015, INT J ONCOL, V46, P2399, DOI 10.3892/ijo.2015.2937.
   Llobet D, 2010, EUR J CANCER, V46, P836, DOI 10.1016/j.ejca.2009.12.025.
   Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101.
   Luzzo KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049217.
   Martin KR, 2018, ISCIENCE, V8, P74, DOI 10.1016/j.isci.2018.09.012.
   Matias-Guiu X, 2014, VIRCHOWS ARCH, V464, P315, DOI 10.1007/s00428-013-1509-y.
   Matias-Guiu X, 2013, HISTOPATHOLOGY, V62, P111, DOI 10.1111/his.12053.
   McMeekin DS, 2007, GYNECOL ONCOL, V106, P16, DOI 10.1016/j.ygyno.2007.04.032.
   Meng SM, 2015, J BIOL CHEM, V290, P3793, DOI 10.1074/jbc.M114.604421.
   Mestrom L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215263.
   Mijaljica D, 2011, AUTOPHAGY, V7, P673, DOI 10.4161/auto.7.7.14733.
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113.
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005.
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823.
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001.
   Moore MJ, 2007, J CLIN ONCOL, V25, p18S.
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006.
   MOTZER RJ, 2012, NEW ENGL J MED, V22, P407.
   Mutter GL, 2000, GYNECOL ONCOL, V76, P287, DOI 10.1006/gyno.1999.5580.
   Nadkarni P, 2014, PROG MOL BIOL TRANSL, V121, P23, DOI 10.1016/B978-0-12-800101-1.00002-8.
   Nakashima A, 2017, J OBSTET GYNAECOL RE, V43, P633, DOI 10.1111/jog.13292.
   Nimeiri HS, 2010, GYNECOL ONCOL, V117, P37, DOI 10.1016/j.ygyno.2010.01.013.
   Ninomiya Y, 2004, CANCER RES, V64, P2759, DOI 10.1158/0008-5472.CAN-3487-2.
   Noda NN, 2015, ANNU REV BIOPHYS, V44, P101, DOI 10.1146/annurev-biophys-060414-034248.
   Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015.
   Nout RA, 2010, LANCET, V375, P816, DOI 10.1016/S0140-6736(09)62163-2.
   Orfanelli T, 2014, INT J CANCER, V135, P519, DOI 10.1002/ijc.28524.
   Pasquier B, 2015, AUTOPHAGY, V11, P725, DOI 10.1080/15548627.2015.1033601.
   Pasquier B, 2015, J MED CHEM, V58, P376, DOI 10.1021/jm5013352.
   Periyasamy-Thandavan S, 2010, AUTOPHAGY, V6, P19, DOI 10.4161/auto.6.1.10323.
   PERROTTI N, 2019, J BIOL CHEM, V20, P9406.
   Quinn BJ, 2013, TRENDS ENDOCRIN MET, V24, P469, DOI 10.1016/j.tem.2013.05.004.
   Ran XM, 2017, INT J ONCOL, V51, P644, DOI 10.3892/ijo.2017.4047.
   Ran XM, 2015, INT J CLIN EXP PATHO, V8, P6617.
   Rhee JS, 2016, HUM REPROD, V31, P1315, DOI 10.1093/humrep/dew048.
   Richardson Paul G, 2003, Clin Adv Hematol Oncol, V1, P596.
   Ronan B, 2014, NAT CHEM BIOL, V10, P1013, DOI 10.1038/nchembio.1681.
   Ruiz-Alonso M, 2012, BBA-MOL BASIS DIS, V1822, P1931, DOI 10.1016/j.bbadis.2012.05.004.
   Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8.
   Sanderson PA, 2017, HUM REPROD UPDATE, V23, P232, DOI 10.1093/humupd/dmw042.
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884.
   SANTORO N, 2011, OBSTET GYNECOL CLIN, V38.
   Santos A, 2018, CURR RHEUMATOL REP, V20, DOI 10.1007/s11926-018-0710-z.
   Sharma G, 2019, AUTOPHAGY, V15, P1694, DOI 10.1080/15548627.2019.1586257.
   SHEPHERD FA, 2011, NEW ENGL J MED, V333, P1109.
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993.
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590.
   Sivridis E, 2011, AUTOPHAGY, V7, P74, DOI 10.4161/auto.7.1.13947.
   Sorbe B, 2008, INT J GYNECOL CANCER, V18, P803, DOI 10.1111/j.1525-1438.2007.01094.x.
   Sorosky JI, 2012, OBSTET GYNECOL, V120, P383, DOI 10.1097/AOG.0b013e3182605bf1.
   Strissel PL, 2008, INT J CANCER, V123, P2871, DOI 10.1002/ijc.23900.
   Su RW, 2015, ADV ANAT EMBRYOL CEL, V216, P189, DOI 10.1007/978-3-319-15856-3\_10.
   Sun HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep28255.
   Sun MY, 2017, BIOTECHNOL LETT, V39, P1477, DOI 10.1007/s10529-017-2392-4.
   Takahashi A, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-53.
   Talbi S, 2006, ENDOCRINOLOGY, V147, P1097, DOI 10.1210/en.2005-1076.
   Talmor A, 2015, BEST PRACT RES CL OB, V29, P498, DOI 10.1016/j.bpobgyn.2014.10.014.
   TAMIR S, 2018, J STEROID BIOCHEM, V18, P291.
   Tangjitgamol S, 2011, INT J GYNECOL CANCER, V21, P885, DOI 10.1097/IGC.0b013e3182169239.
   TAWATA M, 2008, EUR J PHARMACOL, V18, P87.
   Vandenput I, 2009, INT J GYNECOL CANCER, V19, P1147, DOI 10.1111/IGC.0b013e3181ad3dcb.
   WANG H, 2016, J CAN RES THER S, V12.
   Wu CH, 2016, ONCOTARGET, V7, P73432, DOI 10.18632/oncotarget.12369.
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491.
   Yemelyanova A, 2009, AM J SURG PATHOL, V33, P1504, DOI 10.1097/PAS.0b013e3181ac35f5.
   Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y.
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838.
   Yu Y, 2007, CANCER-AM CANCER SOC, V109, P2374, DOI 10.1002/cncr.22659.
   Zhang D, 2015, BIOMED ENG ONLINE, V14, DOI 10.1186/s12938-015-0074-9.
   Zhao Jian-Hong, 2006, Ai Zheng, V25, P753.
   Zhao SJ, 2013, ONCOL LETT, V5, P139, DOI 10.3892/ol.2012.975.
   Zhou WJ, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0412-9.
   Zhou WJ, 2018, NEOPLASIA, V20, P69, DOI 10.1016/j.neo.2017.11.003.
   Zhuo ZH, 2016, ARCH GYNECOL OBSTET, V294, P1055, DOI 10.1007/s00404-016-4148-0.
   Zingoni A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01194.},
Number-of-Cited-References = {153},
Times-Cited = {172},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {53},
Journal-ISO = {Autophagy},
Doc-Delivery-Number = {SD5PN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000538620300001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000533499900002,
Author = {Wei, Yongjie and Han, Xiaoning and Zhao, Chunjie},
Title = {PDK1 regulates the survival of the developing cortical interneurons},
Journal = {MOLECULAR BRAIN},
Year = {2020},
Volume = {13},
Number = {1},
Month = {MAY 4},
Abstract = {Inhibitory interneurons are critical for maintaining the
   excitatory/inhibitory balance. During the development cortical
   interneurons originate from the ganglionic eminence and arrive at the
   dorsal cortex through two tangential migration routes. However, the
   mechanisms underlying the development of cortical interneurons remain
   unclear. 3-Phosphoinositide-dependent protein kinase-1 (PDK1) has been
   shown to be involved in a variety of biological processes, including
   cell proliferation and migration, and plays an important role in the
   neurogenesis of cortical excitatory neurons. However, the function of
   PDK1 in interneurons is still unclear. Here, we reported that the
   disruption of Pdk1 in the subpallium achieved by crossing the
   Dlx5/6-Cre-IRES-EGFP line with Pdk1(fl/fl) mice led to the severely
   increased apoptosis of immature interneurons, subsequently resulting in
   a remarkable reduction in cortical interneurons. However, the tangential
   migration, progenitor pools and cell proliferation were not affected by
   the disruption of Pdk1. We further found the activity of AKT-GSK3 beta
   signaling pathway was decreased after Pdk1 deletion, suggesting it might
   be involved in the regulation of the survival of cortical interneurons.
   These results provide new insights into the function of PDK1 in the
   development of the telencephalon.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhao, CJ (Corresponding Author), Southeast Univ, Sch Med, MOE, Key Lab Dev Genes \& Human Dis, Nanjing 210009, Peoples R China.
   Wei, Yongjie; Han, Xiaoning; Zhao, Chunjie, Southeast Univ, Sch Med, MOE, Key Lab Dev Genes \& Human Dis, Nanjing 210009, Peoples R China.},
DOI = {10.1186/s13041-020-00604-6},
Article-Number = {65},
EISSN = {1756-6606},
Keywords = {Interneuron; Apoptosis; Cell migration; Cell proliferation; PDK1; AKT
   signal; Telencephalon},
Keywords-Plus = {CAUDAL GANGLIONIC EMINENCE; PI3K/AKT SIGNALING PATHWAY; TANGENTIAL
   MIGRATION; CELL-PROLIFERATION; INDUCED APOPTOSIS; CYCLIN D2; PTEN;
   KINASE; PHOSPHORYLATION; EXPRESSION},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {zhaocj@seu.edu.cn},
Affiliations = {Southeast University - China},
ORCID-Numbers = {Han, Xiaoning/0000-0003-0291-7966},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31930045, 81870899];
   National Key R\&D Program of China {[}2016YFA0501001]},
Funding-Text = {This work was supported by grants 31930045, 81870899 from the National
   Natural Science Foundation of China, and 2016YFA0501001 from the
   National Key R\&D Program of China to Z.},
Cited-References = {Alzu'bi A, 2017, BRAIN STRUCT FUNCT, V222, P2309, DOI 10.1007/s00429-016-1343-5.
   Anderson SA, 2001, DEVELOPMENT, V128, P353.
   Ang ESBC, 2003, J NEUROSCI, V23, P5805.
   Bandler RC, 2017, CURR OPIN NEUROBIOL, V42, P17, DOI 10.1016/j.conb.2016.10.003.
   Bourgeron T, 2009, CURR OPIN NEUROBIOL, V19, P231, DOI 10.1016/j.conb.2009.06.003.
   Butt SJB, 2005, NEURON, V48, P591, DOI 10.1016/j.neuron.2005.09.034.
   Casarosa S, 1999, DEVELOPMENT, V126, P525.
   Chiarini A, 2015, INT J MOL MED, V36, P845, DOI 10.3892/ijmm.2015.2290.
   Choy MS, 2006, NEUROSCI LETT, V405, P120, DOI 10.1016/j.neulet.2006.06.037.
   Crandall SR, 2016, NEURON, V90, P4, DOI 10.1016/j.neuron.2016.03.022.
   delPeso L, 1997, SCIENCE, V278, P687.
   Denaxa M, 2018, CELL REP, V22, P1710, DOI 10.1016/j.celrep.2018.01.064.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499.
   Du J, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287-018-1073-0.
   Dupont J, 2002, J CLIN INVEST, V110, P815, DOI {[}10.1172/JCI0213829, 10.1172/JCI200213829].
   Fyffe Chanse, 2013, Cancer Manag Res, V5, P271, DOI 10.2147/CMAR.S35026.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gelman DM, 2009, J NEUROSCI, V29, P9380, DOI 10.1523/JNEUROSCI.0604-09.2009.
   Glickstein SB, 2007, CEREB CORTEX, V17, P632, DOI 10.1093/cercor/bhk008.
   Glickstein SB, 2007, DEVELOPMENT, V134, P4083, DOI 10.1242/dev.008524.
   Glickstein SB, 2009, J NEUROSCI, V29, P9614, DOI 10.1523/JNEUROSCI.2284-09.2009.
   Gómez-Sintes R, 2007, EMBO J, V26, P2743, DOI 10.1038/sj.emboj.7601725.
   Han X, 2019, INT WINT WORKSH BR, P17, DOI 10.1109/iww-bci.2019.8737318.
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870.
   Inan M, 2012, CEREB CORTEX, V22, P820, DOI 10.1093/cercor/bhr148.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Jiménez D, 2002, DEV BIOL, V244, P155, DOI 10.1006/dbio.2002.0586.
   Kim EJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1702-7.
   Kohn M, 2003, GENE EXPR PATTERNS, V3, P173, DOI 10.1016/S1567-133X(03)00004-8.
   Kurosu T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079478.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lawlor MA, 2001, J CELL SCI, V114, P2903.
   Li L, 2002, MOL CELL NEUROSCI, V20, P21, DOI 10.1006/mcne.2002.1115.
   Lin HJ, 2005, BRIT J CANCER, V93, P1372, DOI 10.1038/sj.bjc.6602862.
   Liu AH, 2019, NEUROSCI BULL, V35, P471, DOI 10.1007/s12264-018-0324-5.
   Liu B, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-018-0350-2.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Mao D, 2015, INVEST OPHTH VIS SCI, V56, P5519, DOI 10.1167/iovs.15-16757.
   Marín O, 2001, NAT REV NEUROSCI, V2, P780, DOI 10.1038/35097509.
   Marín O, 2012, NAT REV NEUROSCI, V13, P107, DOI 10.1038/nrn3155.
   Markram H, 2004, NAT REV NEUROSCI, V5, P793, DOI 10.1038/nrn1519.
   Martini FJ, 2009, DEVELOPMENT, V136, P41, DOI 10.1242/dev.025502.
   Mi D, 2018, SCIENCE, V360, P81, DOI 10.1126/science.aar6821.
   Miyoshi G, 2007, J NEUROSCI, V27, P7786, DOI 10.1523/JNEUROSCI.1807-07.2007.
   Miyoshi G, 2010, J NEUROSCI, V30, P1582, DOI 10.1523/JNEUROSCI.4515-09.2010.
   Moore CI, 2010, CELL, V142, P184, DOI 10.1016/j.cell.2010.07.005.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Morgan-Smith M, 2014, ELIFE, V3, DOI 10.7554/eLife.02663.
   Nery S, 2002, NAT NEUROSCI, V5, P1279, DOI 10.1038/nn971.
   Oishi K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI 10.1073/pnas.0808400106.
   Onishi K, 2007, GENES CELLS, V12, P535, DOI 10.1111/j.1365-2443.2007.01071.x.
   Otaegi G, 2006, J CELL SCI, V119, P2739, DOI 10.1242/jcs.03012.
   Park H, 2015, J CELL BIOL, V211, P619, DOI 10.1083/jcb.201503113.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Peng Y, 2017, LIFE SCI, V185, P63, DOI 10.1016/j.lfs.2017.07.024.
   Polleux F, 2002, DEVELOPMENT, V129, P3147.
   PORTEUS MH, 1994, J NEUROSCI, V14, P6370.
   Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x.
   Rudy B, 2011, DEV NEUROBIOL, V71, P45, DOI 10.1002/dneu.20853.
   Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067.
   Shen W, 2019, CEREB CORTEX, V29, P1547, DOI 10.1093/cercor/bhy051.
   Stenman J, 2003, J NEUROSCI, V23, P167.
   Stiles BL, 2009, INT J BIOCHEM CELL B, V41, P757, DOI 10.1016/j.biocel.2008.09.022.
   Sultan KT, 2014, CURR OPIN NEUROBIOL, V26, P125, DOI 10.1016/j.conb.2014.01.010.
   Takebayashi H, 2000, MECH DEVELOP, V99, P143, DOI 10.1016/S0925-4773(00)00466-4.
   Tian CX, 2012, J NEUROSCI, V32, P2931, DOI 10.1523/JNEUROSCI.5240-11.2012.
   Tuncdemir SN, 2015, CEREB CORTEX, V25, P1842, DOI 10.1093/cercor/bht426.
   Venigalla RKC, 2013, EMBO J, V32, P1008, DOI 10.1038/emboj.2013.40.
   Vivanco I, 2014, ELIFE, V3, DOI 10.7554/eLife.03751.
   Vogt D, 2015, CELL REP, V11, P944, DOI 10.1016/j.celrep.2015.04.019.
   Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101.
   Wan X, 2002, CELL DEATH DIFFER, V9, P414, DOI 10.1038/sj.cdd.4400982.
   Wang WL, 2018, STEM CELL RES, V30, P192, DOI 10.1016/j.scr.2018.05.020.
   Whittington MA, 2003, TRENDS NEUROSCI, V26, P676, DOI 10.1016/j.tins.2003.09.016.
   Wiedenhoft H, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00326.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Wonders C, 2005, NEUROSCIENTIST, V11, P199, DOI 10.1177/1073858404270968.
   Wonders CP, 2006, NAT REV NEUROSCI, V7, P687, DOI 10.1038/nrn1954.
   Wu XJ, 2014, J NEUROSCI, V34, P1510, DOI 10.1523/JNEUROSCI.2549-13.2014.
   Xu CY, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00330.
   Xu M, 2019, CEREB CORTEX, V29, P1185, DOI 10.1093/cercor/bhy024.
   Xu Q, 2004, J NEUROSCI, V24, P2612, DOI 10.1523/JNEUROSCI.5667-03.2004.
   Yang Y, 2017, CEREB CORTEX, V27, P793, DOI 10.1093/cercor/bhv297.
   Yoshida S, 1999, TOHOKU J EXP MED, V187, P249, DOI 10.1620/tjem.187.249.
   Zhang Y, 2017, CELL PHYSIOL BIOCHEM, V42, P1177, DOI 10.1159/000478873.
   Zhong Y, 2012, J NEUROL SCI, V320, P38, DOI 10.1016/j.jns.2012.06.003.
   Zhou BH, 2018, CHEMOSPHERE, V199, P297, DOI 10.1016/j.chemosphere.2018.02.057.
   Zhu Y, 2006, APOPTOSIS, V11, P197, DOI 10.1007/s10495-006-3714-5.},
Number-of-Cited-References = {90},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Mol. Brain},
Doc-Delivery-Number = {LO2ZW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000533499900002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000526743200002,
Author = {Ma, Xiaojie and Jin, Lan and Lei, Xiaoqin and Tong, Jingan and Wang,
   Runsheng},
Title = {MicroRNA-363-3p inhibits cell proliferation and induces apoptosis in
   retinoblastoma cells via the Akt/mTOR signaling pathway by targeting
   PIK3CA},
Journal = {ONCOLOGY REPORTS},
Year = {2020},
Volume = {43},
Number = {5},
Pages = {1365-1374},
Month = {MAY},
Abstract = {There is extensive evidence suggesting that microRNAs (miRs) can
   modulate the activity of oncogenes and tumor suppressors, and are
   associated with the occurrence of cancer. In the present study, the
   function of miR-363-3p in the progression of retinoblastoma (RB) was
   investigated. miR-363-3p expression in RB was decreased, and miR-363-3p
   protein levels were found to be inversely correlated with
   phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
   (PIK3CA) levels. Overexpression of miR-363-3p in an in vitro model of RB
   revealed that miR-363-3p had anticancer effects on RB and regulated
   PIK3CA, pyruvate dehydrogenase kinase 1 (PDK1) and phosphorylated
   protein kinase B (p-AKT) protein expression. Downregulation of
   miR-363-3p promoted cell proliferation of RB cells through PIK3CA, PDK1
   and p-AKT protein expression. Knockdown of PIK3CA increased the
   anticancer effects of miR-363-3p in RB cells. Treatment with OSU-03012,
   a PDK1 inhibitor, accelerated the anticancer effects of miR-363-3p in RB
   cells. Taken together, the results demonstrate that miR-363-3p functions
   as a tumor suppressor in RB by targeting PIK3CA.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Jin, L (Corresponding Author), Xian Hosp Tradit Chinese Med, Dept Ophthalmol, 69 Fengcheng 8th Rd, Xian 710021, Shaanxi, Peoples R China.
   Ma, Xiaojie; Jin, Lan, Xian Hosp Tradit Chinese Med, Dept Ophthalmol, 69 Fengcheng 8th Rd, Xian 710021, Shaanxi, Peoples R China.
   Lei, Xiaoqin; Wang, Runsheng, Xian 4 Hosp, Dept Ophthalmol, Xian 710004, Shaanxi, Peoples R China.
   Tong, Jingan, Shaanxi Univ Chinese Med, Dept Ophthalmol, Affiliated Hosp 1, Xianyang 712000, Shaanxi, Peoples R China.},
DOI = {10.3892/or.2020.7544},
ISSN = {1021-335X},
EISSN = {1791-2431},
Keywords = {microRNA-363-3p; retinoblastoma; PIK3CA; AKT;
   3-phosphoinositide-dependent protein kinase-1},
Keywords-Plus = {BREAST-CANCER; PROGRESSION; PROTEINS; BCL-2; P53},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {32844610@qq.com},
Affiliations = {Shaanxi University of Chinese Medicine},
Cited-References = {Choy E, 2012, CANCER-AM CANCER SOC, V118, P2905, DOI 10.1002/cncr.26617.
   DeMichele A, 2015, CLIN CANCER RES, V21, P995, DOI 10.1158/1078-0432.CCR-14-2258.
   Eo SH, 2015, ONCOL RES, V22, P147, DOI 10.3727/096504015X14298122915583.
   Friedman DN, 2014, PEDIATR BLOOD CANCER, V61, P1440, DOI 10.1002/pbc.24835.
   Gui F, 2016, CELL BIOL INT, V40, P1294, DOI 10.1002/cbin.10678.
   Kommoss S, 2007, BRIT J CANCER, V96, P306, DOI 10.1038/sj.bjc.6603531.
   La Thangue NB, 2005, NAT CELL BIOL, V7, P101, DOI 10.1038/ncb0205-101.
   Lai JH, 2015, HUM PATHOL, V46, P1290, DOI 10.1016/j.humpath.2015.05.008.
   Liu J, 2017, AM J CANCER RES, V7, P148.
   Liu SS, 2014, BIOMED REP, V2, P424, DOI 10.3892/br.2014.246.
   Lumbroso-Le Rouic L, 2016, EYE, V30, P46, DOI 10.1038/eye.2015.179.
   Martin J, 2013, GENE, V512, P294, DOI 10.1016/j.gene.2012.09.129.
   Qi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106032.
   Singh L, 2015, CLIN EXP OPHTHALMOL, V43, P259, DOI 10.1111/ceo.12397.
   Song W, 2016, EUR REV MED PHARMACO, V20, P1093.
   Tomosugi M, 2012, CANCER SCI, V103, P2139, DOI 10.1111/cas.12012.
   Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020.
   Wang GH, 2013, MOL CANCER THER, V12, P2100, DOI 10.1158/1535-7163.MCT-12-0920.
   Wei TYW, 2012, CANCER SCI, V103, P1640, DOI 10.1111/j.1349-7006.2012.02367.x.
   Wei YZ, 2017, BIOTECHNOL LETT, V39, P197, DOI 10.1007/s10529-016-2251-8.
   Xiao W, 2014, MOL MED REP, V10, P453, DOI 10.3892/mmr.2014.2213.},
Number-of-Cited-References = {21},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Oncol. Rep.},
Doc-Delivery-Number = {LE5FB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000526743200002},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000529296200022,
Author = {Manne, Bhanu Kanth and Bhatlekar, Seema and Middleton, Elizabeth A. and
   Weyrich, Andrew S. and Borst, Oliver and Rondina, Matthew T.},
Title = {Phospho-inositide-dependent kinase 1 regulates signal dependent
   translation in megakaryocytes and platelets},
Journal = {JOURNAL OF THROMBOSIS AND HAEMOSTASIS},
Year = {2020},
Volume = {18},
Number = {5},
Pages = {1183-1196},
Month = {MAY},
Abstract = {Background Regulated protein synthesis is essential for megakaryocyte
   (MK) and platelet functions, including platelet production and
   activation. PDK1 (phosphoinositide-dependent kinase 1) regulates
   platelet functional responses and has been associated with circulating
   platelet counts. Whether PDK1 also directly regulates protein synthetic
   responses in MKs and platelets, and platelet production by MKs, remains
   unknown.
   Objective To determine if PDK1 regulates protein synthesis in MKs and
   platelets.
   Methods Pharmacologic PDK1 inhibitors (BX-795) and mice where PDK1 was
   selectively ablated in MKs and platelets (PDK1(-/-)) were used. PDK1
   signaling in MKs and platelets (human and murine) were assessed by
   immunoblots. Activation-dependent translation initiation and protein
   synthesis in MKs and platelets was assessed by probing for dissociation
   of eIF4E from 4EBP1, and using m7-GTP pulldowns and S-35 methionine
   incorporation assays. Proplatelet formation by MKs, synthesis of Bcl-3
   and MARCKs protein, and clot retraction were employed for functional
   assays.
   Results Inhibiting or ablating PDK1 in MKs and platelets abolished the
   phosphorylation of 4EBP1 and eIF4E by preventing activation of the PI3K
   and MAPK pathways. Inhibiting PDK1 also prevented dissociation of eIF4E
   from 4EBP1, decreased binding of eIF4E to m7GTP (required for
   translation initiation), and significantly reduced de novo protein
   synthesis. Inhibiting PDK1 reduced proplatelet formation by human MKs
   and blocked MARCKs protein synthesis. In both human and murine
   platelets, PDK1 controlled Bcl-3 synthesis. Inhibition of PDK1 led to
   complete failure of clot retraction in vitro.
   Conclusions PDK1 is a previously unidentified translational regulator in
   MKs and platelets, controlling protein synthetic responses, proplatelet
   formation, and clot retraction.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Rondina, MT (Corresponding Author), Univ Utah, Mol Med Program, Dept Internal Med, EIHG 4220,15 N 230 E, Salt Lake City, UT 84112 USA.
   Manne, Bhanu Kanth; Bhatlekar, Seema; Middleton, Elizabeth A.; Weyrich, Andrew S.; Rondina, Matthew T., Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA.
   Manne, Bhanu Kanth; Bhatlekar, Seema; Middleton, Elizabeth A.; Weyrich, Andrew S.; Rondina, Matthew T., Univ Utah, Mol Med Program, Salt Lake City, UT 84112 USA.
   Weyrich, Andrew S.; Rondina, Matthew T., Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA.
   Borst, Oliver, Univ Tubingen, Dept Cardiol \& Cardiovasc Med, Tubingen, Germany.
   Rondina, Matthew T., George E Wahlen VAMC, GRECC, Dept Internal Med, Salt Lake City, UT USA.},
DOI = {10.1111/jth.14748},
ISSN = {1538-7933},
EISSN = {1538-7836},
Keywords = {platelet activation; platelets; protein translation; signal
   transduction; thrombosis},
Keywords-Plus = {THROMBOPOIETIN-INDUCED PROLIFERATION; INITIATION-FACTOR 4E; MAMMALIAN
   TARGET; CELL-LINES; PROTEIN; PDK1; PATHWAY; MTOR; AKT; PHOSPHORYLATION},
Research-Areas = {Hematology; Cardiovascular System \& Cardiology},
Web-of-Science-Categories  = {Hematology; Peripheral Vascular Disease},
Author-Email = {matthew.rondina@hsc.utah.edu},
Affiliations = {Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah; Eberhard Karls University of Tubingen; US Department
   of Veterans Affairs; Geriatric Research Education \& Clinical Center},
ORCID-Numbers = {Borst, Oliver/0000-0003-4002-4085},
Funding-Acknowledgement = {National Heart Lung and Blood Institute {[}R35HL145237, R01HL142804]
   Funding Source: NIH RePORTER; NHLBI NIH HHS {[}R35 HL145237, R01
   HL142804] Funding Source: Medline; NIA NIH HHS {[}R56 AG059877, R01
   AG048022] Funding Source: Medline; CSRD VA {[}I01 CX001696] Funding
   Source: Medline},
Cited-References = {Balduini A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021015.
   Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003.
   Chanprasert S, 2006, CELL SIGNAL, V18, P1212, DOI 10.1016/j.cellsig.2005.09.010.
   Chen X, 2013, BLOOD, V121, P3718, DOI 10.1182/blood-2012-10-461897.
   Chinen Y, 2014, CANCER RES, V74, P7418, DOI 10.1158/0008-5472.CAN-14-1420.
   Dan HC, 2014, J BIOL CHEM, V289, P25227, DOI 10.1074/jbc.M114.554881.
   Dangelmaier C, 2014, THROMB HAEMOSTASIS, V111, P508, DOI 10.1160/TH13-06-0484.
   Deutsch VR, 2006, BRIT J HAEMATOL, V134, P453, DOI 10.1111/j.1365-2141.2006.06215.x.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   El Amri M, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0445-1.
   Eto K, 2007, BLOOD, V110, P3637, DOI 10.1182/blood-2007-04-085860.
   Ge QT, 2017, TISSUE CELL, V49, P719, DOI 10.1016/j.tice.2017.10.004.
   Geddis AE, 2001, J BIOL CHEM, V276, P34473, DOI 10.1074/jbc.M105178200.
   Geue S, 2019, BLOOD, V134, P1847, DOI 10.1182/blood.2019000185.
   Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422.
   Guerriero R, 2006, J CELL SCI, V119, P744, DOI 10.1242/jcs.02784.
   HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0.
   Hu TY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05213-3.
   Italiano JE Jr, 2003, J THROMB HAEMOST, V1, P1174, DOI 10.1046/j.1538-7836.2003.00290.x.
   Jossé L, 2016, BIOCHEM J, V473, P4651, DOI 10.1042/BCJ20160845.
   Kalous J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030698.
   Larson MK, 2006, BLOOD, V108, P1509, DOI 10.1182/blood-2005-11-011957.
   Li DD, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4690-1.
   Liebman HA, 2014, THROMB RES, V133, pS63, DOI 10.1016/S0049-3848(14)50011-4.
   Lindemann S, 2001, J BIOL CHEM, V276, P33947, DOI 10.1074/jbc.M104281200.
   Luff SA, 2016, J BIOL CHEM, V291, P7831, DOI 10.1074/jbc.M115.707174.
   Luo DY, 2018, INT J ONCOL, V53, P2067, DOI 10.3892/ijo.2018.4525.
   Machlus KR, 2016, BLOOD, V127, P1468, DOI {[}10.1182/blood-2015-08-663146, 10.1182/blood-2015-08663146].
   Machlus KR, 2016, BLOOD, V127, P921, DOI 10.1182/blood-2015-05-644583.
   Machlus KR, 2014, BRIT J HAEMATOL, V165, P227, DOI 10.1111/bjh.12758.
   Machlus KR, 2013, J CELL BIOL, V201, P785, DOI 10.1083/jcb.201304054.
   Manne BK, 2018, J THROMB HAEMOST, V16, P1211, DOI 10.1111/jth.14005.
   Mazharian A, 2009, EXP HEMATOL, V37, P1238, DOI 10.1016/j.exphem.2009.07.006.
   Miyazaki R, 2001, ANN HEMATOL, V80, P284, DOI 10.1007/s002770000285.
   Münzer P, 2016, ARTERIOSCL THROM VAS, V36, P1507, DOI 10.1161/ATVBAHA.115.307105.
   Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4.
   Nakao T, 2008, CELL CYCLE, V7, P257, DOI 10.4161/cc.7.2.5148.
   Nandagopal N, 2015, TRANSLATION, V3, DOI 10.4161/21690731.2014.983402.
   Patel P, 2018, J THROMB HAEMOST, V16, P1901, DOI 10.1111/jth.14232.
   Pelzl L, 2012, BIOCHEM BIOPH RES CO, V425, P1, DOI 10.1016/j.bbrc.2012.07.026.
   Ruggero D, 2005, ONCOGENE, V24, P7426, DOI 10.1038/sj.onc.1209098.
   Schulze H, 2005, J THROMB HAEMOST, V3, P1717, DOI 10.1111/j.1538-7836.2005.01426.x.
   Sekiyama N, 2015, P NATL ACAD SCI USA, V112, pE4036, DOI 10.1073/pnas.1512118112.
   Showkat Mehvish, 2014, Mol Biol Int, V2014, P686984, DOI 10.1155/2014/686984.
   Shveygert M, 2010, MOL CELL BIOL, V30, P5160, DOI 10.1128/MCB.00448-10.
   Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899.
   Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083.
   Tominaga Y, 2005, MOL CELL BIOL, V25, P8465, DOI 10.1128/MCB.25.19.8465-8475.2005.
   Wada M, 2015, J DERMATOL SCI, V78, P44, DOI 10.1016/j.jdermsci.2015.01.015.
   Wang CM, 2015, HEPATOLOGY, V61, P200, DOI 10.1002/hep.27396.
   Wang WL, 2018, STEM CELL RES, V30, P192, DOI 10.1016/j.scr.2018.05.020.
   Weyrich AS, 2007, BLOOD, V109, P1975, DOI 10.1182/blood-2006-08-042192.
   Weyrich AS, 1998, P NATL ACAD SCI USA, V95, P5556, DOI 10.1073/pnas.95.10.5556.
   Wu N, 2017, ONCOL RES, V25, P1153, DOI 10.3727/096504017X14845839228545.
   Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004.},
Number-of-Cited-References = {56},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {J. Thromb. Haemost.},
Doc-Delivery-Number = {LI2ER},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529296200022},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000535695900170,
Author = {Maruca, Annalisa and Lanzillotta, Delia and Rocca, Roberta and Lupia,
   Antonio and Costa, Giosue and Catalano, Raffaella and Moraca, Federica
   and Gaudio, Eugenio and Ortuso, Francesco and Artese, Anna and Trapasso,
   Francesco and Alcaro, Stefano},
Title = {Multi-Targeting Bioactive Compounds Extracted from Essential Oils as
   Kinase Inhibitors},
Journal = {MOLECULES},
Year = {2020},
Volume = {25},
Number = {9},
Month = {MAY},
Abstract = {Essential oils (EOs) are popular in aromatherapy, a branch of
   alternative medicine that claims their curative effects. Moreover,
   several studies reported EOs as potential anti-cancer agents by inducing
   apoptosis in different cancer cell models. In this study, we have
   considered EOs as a potential resource of new kinase inhibitors with a
   polypharmacological profile. On the other hand, computational methods
   offer the possibility to predict the theoretical activity profile of
   ligands, discovering dangerous off-targets and/or synergistic effects
   due to the potential multi-target action. With this aim, we performed a
   Structure-Based Virtual Screening (SBVS) against X-ray models of several
   protein kinases selected from the Protein Data Bank (PDB) by using a
   chemoinformatics database of EOs. By evaluating theoretical binding
   affinity, 13 molecules were detected among EOs as new potential kinase
   inhibitors with a multi-target profile. The two compounds with higher
   percentages in the EOs were studied more in depth by means Induced Fit
   Docking (IFD) protocol, in order to better predict their binding modes
   taking into account also structural changes in the receptor. Finally,
   given its good binding affinity towards five different kinases, cinnamyl
   cinnamate was biologically tested on different cell lines with the aim
   to verify the antiproliferative activity. Thus, this work represents a
   starting point for the optimization of the most promising EOs structure
   as kinase inhibitors with multi-target features.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Alcaro, S (Corresponding Author), Magna Graecia Univ Catanzaro, Dipartimento Sci Salute, Campus Univ S Venuta,Viale Europa, I-88100 Catanzaro, Italy.
   Alcaro, S (Corresponding Author), Magna Graecia Univ Catanzaro, Net4Sci Srl, Campus Univ S Venuta,Viale Europa, I-88100 Catanzaro, Italy.
   Maruca, Annalisa; Costa, Giosue; Catalano, Raffaella; Ortuso, Francesco; Artese, Anna; Alcaro, Stefano, Magna Graecia Univ Catanzaro, Dipartimento Sci Salute, Campus Univ S Venuta,Viale Europa, I-88100 Catanzaro, Italy.
   Maruca, Annalisa; Rocca, Roberta; Lupia, Antonio; Costa, Giosue; Catalano, Raffaella; Moraca, Federica; Ortuso, Francesco; Artese, Anna; Alcaro, Stefano, Magna Graecia Univ Catanzaro, Net4Sci Srl, Campus Univ S Venuta,Viale Europa, I-88100 Catanzaro, Italy.
   Lanzillotta, Delia; Rocca, Roberta; Trapasso, Francesco, Magna Graecia Univ Catanzaro, Dept Expt \& Clin Med, Campus Univ S Venuta,Viale Europa, I-88100 Catanzaro, Italy.
   Moraca, Federica, Univ Federico II Naples, Dept Pharm, Via Montesano 49, I-80131 Naples, Italy.
   Gaudio, Eugenio, Inst Oncol Res, Lymphoma \& Genom Res Program, CH-6500 Bellinzona, Switzerland.},
DOI = {10.3390/molecules25092174},
Article-Number = {2174},
EISSN = {1420-3049},
Keywords = {essential oils; multi-target; polypharmacology; kinases; anti-cancer;
   SBVS},
Keywords-Plus = {LEAF ESSENTIAL OIL; CHEMICAL-COMPOSITION; ANTIOXIDANT ACTIVITIES;
   ANTICANCER ACTIVITY; IDENTIFICATION; BINDERS; L.},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {maruca@unicz.it
   delialanzillotta@unicz.it
   rocca@unicz.it
   lupia@unicz.it
   gcosta@unicz.it
   catalano@unicz.it
   federica.moraca@unina.it
   eugenio.gaudio@ior.usi.ch
   ortuso@unicz.it
   artese@unicz.it
   trapasso@unicz.it
   alcaro@unicz.it},
Affiliations = {Magna Graecia University of Catanzaro; Magna Graecia University of
   Catanzaro; Magna Graecia University of Catanzaro; University of Naples
   Federico II; Institute of Oncology Research (IOR)},
ResearcherID-Numbers = {Catalano, Raffaella/HDO-3350-2022
   Costa, Giosuè/K-8461-2016
   Lupia, Antonio/CAH-2362-2022
   Rocca, Roberta/L-7431-2016},
ORCID-Numbers = {Maruca, Annalisa/0000-0002-6537-552X
   Gaudio, Eugenio/0009-0006-6956-6135
   Catalano, Raffaella/0000-0003-3936-3573
   Costa, Giosuè/0000-0003-0947-9479
   Lanzillotta, Delia/0000-0001-6439-3876
   Lupia, Antonio/0000-0003-0870-2376
   ALCARO, Stefano/0000-0002-0437-358X
   Rocca, Roberta/0000-0002-0680-7097},
Funding-Acknowledgement = {Mu.Ta.Lig. COST ACTION {[}CA15135]},
Funding-Text = {The authors acknowledge Mu.Ta.Lig. COST ACTION CA15135 and the POR
   CALABRIA FESR-FSE 2014-2020 SISTABENE project.},
Cited-References = {Al-Snafi A E., 2016, IOSR Journal of Pharmacy, V6, P2250, DOI DOI 10.9790/3013-067031742.
   Andrade MA, 2018, CURR CANCER DRUG TAR, V18, P957, DOI 10.2174/1568009618666180102105843.
   Anighoro A, 2015, J CHEM INF MODEL, V55, P676, DOI 10.1021/ci5006959.
   Anighoro A, 2014, J MED CHEM, V57, P7874, DOI 10.1021/jm5006463.
   {[}Anonymous], 2018, SCHROD REL 2018 4 GL.
   {[}Anonymous], 2016, SCHROD REL 2018 4 PR.
   {[}Anonymous], 2018, SCHROD REL 2018 4 LI.
   Artese A, 2013, FUTURE MED CHEM, V5, P907, DOI {[}10.4155/FMC.13.59, 10.4155/fmc.13.59].
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a.
   Bakkali F, 2008, FOOD CHEM TOXICOL, V46, P446, DOI 10.1016/j.fct.2007.09.106.
   Bettaieb I, 2010, J AGR FOOD CHEM, V58, P10410, DOI 10.1021/jf102248j.
   Buckle J, 1999, ALTERN THER HEALTH M, V5, P42.
   Caputo L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17121999.
   Catalano R, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111715.
   Catalano R, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111627.
   Catalogna G, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111675.
   Charles D., 2012, Antioxidant properties of spices, herbs and other sources.
   Cho SM, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-275.
   Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773.
   Corigliano DM, 2018, PEERJ, V6, DOI 10.7717/peerj.5386.
   Costa G, 2019, EUR J MED CHEM, V181, DOI 10.1016/j.ejmech.2019.111565.
   Costa G, 2016, J AGR FOOD CHEM, V64, P5295, DOI 10.1021/acs.jafc.6b02004.
   Dhifi Wissal, 2016, Medicines (Basel), V3, DOI {[}10.3390/medicines3040025, 10.3390/medicines3040025].
   El-Ghorab AH, 2010, J AGR FOOD CHEM, V58, P8231, DOI 10.1021/jf101202x.
   El-Readi MZ, 2013, J PHARM PHARMACOL, V65, P1653, DOI 10.1111/jphp.12142.
   Fogang HPD, 2014, CHEM BIODIVERS, V11, P161, DOI 10.1002/cbdv.201300237.
   Heinrich M, 2006, CURR DRUG TARGETS, V7, P239, DOI 10.2174/138945006776054988.
   Ho YC, 2017, CHEM-BIOL INTERACT, V271, P9, DOI 10.1016/j.cbi.2017.04.017.
   Lee IK, 2014, BIOORG MED CHEM LETT, V24, P3503, DOI 10.1016/j.bmcl.2014.05.065.
   Li XJ, 2016, INT J MOL MED, V38, P1661, DOI 10.3892/ijmm.2016.2794.
   Loizzo MR, 2008, CELL PROLIFERAT, V41, P1002, DOI 10.1111/j.1365-2184.2008.00561.x.
   Martin J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012460.
   Maruca A, 2019, EUR J MED CHEM, V181, DOI 10.1016/j.ejmech.2019.111579.
   Maruca A, 2019, PHYS SCI REV, V4, DOI 10.1515/psr-2018-0113.
   Maruca A, 2017, MOLECULES, V22, DOI 10.3390/molecules22091571.
   Mimica-Dukic N, 2004, J AGR FOOD CHEM, V52, P2485, DOI 10.1021/jf030698a.
   MITSCHER LA, 1992, MUTAT RES, V267, P229, DOI 10.1016/0027-5107(92)90067-C.
   Murata S, 2013, ONCOL REP, V30, P2647, DOI 10.3892/or.2013.2763.
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v.
   Ortuso F, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00130.
   Rashid S, 2013, FOOD CHEM, V138, P693, DOI 10.1016/j.foodchem.2012.10.102.
   Rastelli G, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00157.
   Reddy AS, 2014, J CHEM INF MODEL, V54, P2536, DOI 10.1021/ci500092j.
   Rocca R, 2018, ACS MED CHEM LETT, V9, P848, DOI 10.1021/acsmedchemlett.8b00275.
   Rocca R, 2017, BBA-GEN SUBJECTS, V1861, P1329, DOI 10.1016/j.bbagen.2016.12.023.
   Russo R, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/397821.
   Sharifi-Rad J, 2017, MOLECULES, V22, DOI 10.3390/molecules22010070.
   Sun Y, 2015, J RECEPT SIG TRANSD, V35, P600, DOI 10.3109/10799893.2015.1030412.
   Sylvestre M, 2006, J ETHNOPHARMACOL, V103, P99, DOI 10.1016/j.jep.2005.07.011.
   Sylvestre M, 2005, PHYTOMEDICINE, V12, P299, DOI 10.1016/j.phymed.2003.12.004.
   Vasile F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32084-z.
   Wei J, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/474509.
   Yang C, 2017, MOLECULES, V22, DOI 10.3390/molecules22081391.
   Yang XQ, 2015, J BUON, V20, P1518.
   Yousefzadi M, 2014, J IMMUNOTOXICOL, V11, P50, DOI 10.3109/1547691X.2013.789939.
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559.},
Number-of-Cited-References = {56},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Molecules},
Doc-Delivery-Number = {LR4VZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000535695900170},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000512734000011,
Author = {Jones, Richard and Pena, Juan and Mystal, Elana and Marsit, Carmen and
   Lee, Men-Jean and Stone, Joanne and Lambertini, Luca},
Title = {Mitochondrial and glycolysis-regulatory gene expression profiles are
   associated with intrauterine growth restriction},
Journal = {JOURNAL OF MATERNAL-FETAL \& NEONATAL MEDICINE},
Year = {2020},
Volume = {33},
Number = {8},
Pages = {1336-1345},
Month = {APR 17},
Abstract = {Introduction: Intrauterine growth restriction (IUGR) is a major
   pregnancy complication with significant postnatal implications. IUGR is
   characterized by high placental oxidative stress (OS) and increased
   mitochondrial DNA (mtDNA) abundance that altogether alter the placental
   metabolism. Such alterations may be captured by changes in the
   expression of mitochondrial-encoded oxidative phosphorylation genes and
   glycolysis-regulatory genes. Study design: We aimed here to determine
   the association between the placental expression of all 13
   protein-coding mitochondrial-encoded genes and seven key nuclear
   glycolysis-regulatory genes, PDK1, PDK2, PDK3, PDK4, PKLR, PKM, OGT,
   with IUGR, within a case-control study including 50 IUGR and 100 control
   pregnancies. We additionally assessed placental mtDNA abundance and OS.
   Results: Three mitochondrial genes, MT-ND5, MT-ND6, and MT-ATP6 were
   found negatively associated with IUGR, while one glycolysis-regulatory
   gene, PDK1 was positively associated with IUGR. mtDNA abundance and OS
   were positively associated with IUGR. Our study confirmed the existing
   data on IUGR inducing increased placental OS and mtDNA abundance.
   Further, our data highlighted the significant involvement of
   mitochondria and glucose metabolism in the OS-challenged IUGR placentas,
   which might modulate the placental expression of genes affecting the
   OXPHOS and promoting glycolysis. Brief rationale: By using banked
   placenta samples available at Icahn School of Medicine at Mount Sinai,
   this study aims at laying the foundation for the characterization of the
   role of mitochondria epi/genetics in IUGR. IUGR is a highly prevalent
   pregnancy outcome with long-term effects on the progeny that, at
   present, has limited tools that can be used for its diagnosis and
   characterization, thus limiting the efficacy of both clinical and public
   health interventions. The alterations of mitochondrial copy number, OS
   and mitochondrial and glycolysis-regulatory gene expression that we
   detected, together, provide the first evidence that these phenomena are
   playing an important role in the pathophysiology of IUGR. These findings
   suggest possible new research paths for the full characterization of
   mitochondrial biomarkers of IUGR.},
Publisher = {TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Lambertini, L (Corresponding Author), Diabet Obes \& Metab Inst, One Gustave L Levi Pl, New York, NY 10029 USA.
   Jones, Richard; Pena, Juan; Mystal, Elana; Lambertini, Luca, Icahn Sch Med Mt Sinai, Dept Environm Med \& Publ Hlth, New York, NY 10029 USA.
   Marsit, Carmen, Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA.
   Lee, Men-Jean, Mt Sinai Beth Israel Hosp, Dept Obstet \& Gynecol, New York, NY USA.
   Stone, Joanne; Lambertini, Luca, Icahn Sch Med Mt Sinai, Dept Obstet Gynecol \& Reprod Sci, New York, NY 10029 USA.},
DOI = {10.1080/14767058.2018.1518419},
ISSN = {1476-7058},
EISSN = {1476-4954},
Keywords = {Gene expression; glycolysis; IUGR; mitochondria; oxidative stress;
   placenta},
Keywords-Plus = {OXIDATIVE STRESS; CYTOCHROME-B; DNA CONTENT; BLOOD-FLOW; METABOLISM;
   OXYGEN},
Research-Areas = {Obstetrics \& Gynecology},
Web-of-Science-Categories  = {Obstetrics \& Gynecology},
Author-Email = {luca.lambertini@mssm.edu},
Affiliations = {Icahn School of Medicine at Mount Sinai; Emory University; Rollins
   School Public Health; Icahn School of Medicine at Mount Sinai},
ORCID-Numbers = {Marsit, Carmen/0000-0003-4566-150X
   Lambertini, Luca/0000-0003-3326-219X},
Cited-References = {Adeva M, 2013, MITOCHONDRION, V13, P615, DOI 10.1016/j.mito.2013.08.011.
   ALDORETTA PW, 1995, CLIN PERINATOL, V22, P15.
   {[}Anonymous], 2017, GLOB DAT BOD MASS IN.
   Bakke J, 2015, SEMIN CELL DEV BIOL, V37, P58, DOI 10.1016/j.semcdb.2014.09.020.
   Bettaieb A, 2013, J BIOL CHEM, V288, P17360, DOI 10.1074/jbc.M112.441469.
   Burton GJ, 2009, J ANAT, V215, P27, DOI 10.1111/j.1469-7580.2008.00978.x.
   Cataldi A, 2010, CURR PHARM DESIGN, V16, P1387, DOI 10.2174/138161210791033969.
   Damas J, 2014, NUCLEIC ACIDS RES, V42, pD1261, DOI 10.1093/nar/gkt982.
   Diplas AI, 2009, EPIGENETICS-US, V4, P235, DOI 10.4161/epi.9019.
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786.
   Fuku N, 2002, BIOCHEM BIOPH RES CO, V290, P1199, DOI 10.1006/bbrc.2002.6330.
   Gibson K, 2008, PEDIATRICS, V122, P1003, DOI 10.1542/peds.2007-3502.
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2.
   Hori A, 2009, NUCLEIC ACIDS RES, V37, P749, DOI 10.1093/nar/gkn993.
   Howerton CL, 2014, P NATL ACAD SCI USA, V111, P9639, DOI 10.1073/pnas.1401203111.
   Jauniaux E, 2003, AM J PATHOL, V162, P115, DOI 10.1016/S0002-9440(10)63803-5.
   Jha MK, 2015, J NEUROSCI, V35, P14353, DOI 10.1523/JNEUROSCI.1910-15.2015.
   Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012.
   Kakogawa J, 2010, AM J PERINAT, V27, P463, DOI 10.1055/s-0030-1247600.
   Kappil MA, 2016, ENVIRON EPIGENETICS, V2, DOI 10.1093/eep/dvv013.
   Lambertini L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138929.
   Lattuada D, 2008, PLACENTA, V29, P1029, DOI 10.1016/j.placenta.2008.09.012.
   Lazarou M, 2009, FEBS J, V276, P6701, DOI 10.1111/j.1742-4658.2009.07384.x.
   Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425.
   Lee MJ, 2001, ANN NY ACAD SCI, V943, P326, DOI 10.1111/j.1749-6632.2001.tb03813.x.
   Li Q, 2015, EPIGENETICS-US, V10, P793, DOI 10.1080/15592294.2015.1066960.
   Liguori R, 2006, NUTR METAB CARDIOVAS, V16, P466, DOI 10.1016/j.numecd.2005.06.009.
   Mimaki M, 2012, BBA-BIOENERGETICS, V1817, P851, DOI 10.1016/j.bbabio.2011.08.010.
   MOLINA RD, 1990, P SOC EXP BIOL MED, V195, P379, DOI 10.3181/00379727-195-43158AA.
   Morrison JL, 2010, PEDIATR NEPHROL, V25, P669, DOI 10.1007/s00467-009-1407-3.
   MUIRHEAD H, 1990, BIOCHEM SOC T, V18, P193, DOI 10.1042/bst0180193.
   Myatt L, 2004, HISTOCHEM CELL BIOL, V122, P369, DOI 10.1007/s00418-004-0677-x.
   National Institutes of Health, 2016, GEN HOM REF LEIGH SY.
   Novielli C, 2017, PLACENTA, V55, P63, DOI 10.1016/j.placenta.2017.05.008.
   Papa S, 2012, ADV EXP MED BIOL, V942, P3, DOI 10.1007/978-94-007-2869-1\_1.
   Rando OJ, 2015, CELL, V161, P93, DOI 10.1016/j.cell.2015.02.021.
   Sovio U, 2015, LANCET, V386, P2089, DOI 10.1016/S0140-6736(15)00131-2.
   Standardized Coefficients in Logistic Regression, 2007, STANDARDIZED COEFFIC.
   Ugalde C, 2004, HUM MOL GENET, V13, P2461, DOI 10.1093/hmg/ddh262.
   Wolpert L., 2010, PRINCIPLES DEV.
   Wright JD, 2013, OBSTET GYNECOL, V121, P1217, DOI {[}10.1097/AOG.0b013e31828ec686, 10.1097/01.AOG.0000429658.85846.f9].
   Yanicostas C, 2011, SEMIN FETAL NEONAT M, V16, P175, DOI 10.1016/j.siny.2011.05.005.
   Zhu MY, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.10.004.},
Number-of-Cited-References = {43},
Times-Cited = {26},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {22},
Journal-ISO = {J. Matern.-Fetal Neonatal Med.},
Doc-Delivery-Number = {KK4SO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000512734000011},
DA = {2026-02-04},
}

@article{ WOS:000529248900004,
Author = {Tao Heyun and Ding Xuelian and Wu Jian and Liu Shenlin and Sun Wei and
   Nie Mengjun and Pan Xiaoting and Zou Xi},
Title = {β-Asarone Increases Chemosensitivity by Inhibiting Tumor
   Glycolysis in Gastric Cancer},
Journal = {EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE},
Year = {2020},
Volume = {2020},
Month = {APR 10},
Abstract = {beta-asarone is the main active ingredient of the Chinese herb Rhizoma
   Acori Tatarinowii, which exhibits a wide range of biological activities.
   It was confirmed to be an efficient cytotoxic agent against
   gastroenteric cancer cells. However, the exact mechanism of beta-asarone
   in gastric cancer (GC) remains to be elucidated. The present study
   showed the inhibitory effect of beta-asarone on three types of different
   differentiation stage GC cell lines (MGC803, SGC7901, and MKN74) in a
   dose-dependent manner. Meanwhile, the synergistic sensitivity of
   beta-asarone and cisplatin was confirmed by using the median-effect
   principle. Flow cytometry assay revealed that under both normoxia and
   CoCl2-induced hypoxia conditions, beta-asarone can induce apoptosis of
   GC cells, which can block GC cells in the cell cycle G2/M phase, showing
   obvious subdiploid peak. Moreover, the activity of lactic dehydrogenase
   (LDH), an enzyme that plays an important role in the final step of tumor
   glycolysis, was significantly decreased in GC cells following treatment
   with beta-asarone. Mechanistically, beta-asarone can reduce pyruvate
   dehydrogenase kinase (PDK) 1, phospho(p)-PDK1, PDK4, hypoxia-inducible
   factor 1-alpha (HIF1 alpha), c-myc, STAT5, and p-STAT5 expression, which
   revealed how beta-asarone affects tumor glycolysis. In conclusion, the
   present study provided evidence in support of the hypothesis that the
   increase of chemotherapy sensitization by beta-asarone is associated
   with the inhibition of tumor glycolysis.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zou, X (Corresponding Author), Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China.
   Tao Heyun; Ding Xuelian; Wu Jian; Liu Shenlin; Sun Wei; Nie Mengjun; Pan Xiaoting; Zou Xi, Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China.
   Tao Heyun; Ding Xuelian; Nie Mengjun; Pan Xiaoting, Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing 210023, Jiangsu, Peoples R China.},
DOI = {10.1155/2020/6981520},
Article-Number = {6981520},
ISSN = {1741-427X},
EISSN = {1741-4288},
Keywords-Plus = {GLUCOSE-METABOLISM; RESISTANCE; DICHLOROACETATE; MODULATION; EXPRESSION;
   APOPTOSIS; WARBURG; HYPOXIA},
Research-Areas = {Integrative \& Complementary Medicine},
Web-of-Science-Categories  = {Integrative \& Complementary Medicine},
Author-Email = {2296975246@qq.com
   lian73550@163.com
   czcyg@sina.com
   lsl186618555@sina.com
   paphy@163.com
   nmj852387312@126.com
   353140647@qq.com
   zxvery@126.com},
Affiliations = {Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine},
ResearcherID-Numbers = {Zou, Xi/MGA-5007-2025},
ORCID-Numbers = {Zou, Xi/0000-0003-2893-3526},
Funding-Acknowledgement = {Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD) {[}{[}2018]87]; Open Projects of the Discipline of
   Chinese Medicine of Nanjing University of Chinese Medicine - Subject of
   Academic Priority Discipline of Jiangsu Higher Education Institutions},
Funding-Text = {This work was supported by the Foundation of A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD) (no. {[}2018]87) and the Open Projects of the
   Discipline of Chinese Medicine of Nanjing University of Chinese Medicine
   supported by the Subject of Academic Priority Discipline of Jiangsu
   Higher Education Institutions.},
Cited-References = {Abildgaard C, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0247-5.
   Andrzejewski S, 2017, CELL METAB, V26, P778, DOI 10.1016/j.cmet.2017.09.006.
   {[}Anonymous], CANC CHEMOTHERAPY BI.
   Bhatt AN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1368-9.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Clarke RH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111199.
   Dang CV, 2008, ERNST SCHERING FOUND, V4, P35, DOI 10.1007/2789\_2008\_088.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Geng YT, 2010, BIOL PHARM BULL, V33, P836, DOI 10.1248/bpb.33.836.
   Gill KS, 2016, BBA-REV CANCER, V1866, P87, DOI 10.1016/j.bbcan.2016.06.005.
   Granchi C, 2014, BIOORG MED CHEM LETT, V24, P4915, DOI 10.1016/j.bmcl.2014.09.041.
   Guan F, 2010, FASEB J, V24, P4889, DOI 10.1096/fj.10-162107.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77.
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001.
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595.
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494.
   Liu L, 2012, EUR J PHARMACOL, V680, P34, DOI 10.1016/j.ejphar.2012.01.016.
   Marchiq I, 2015, ONCOTARGET, V6, P24636, DOI 10.18632/oncotarget.4323.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Papandreou I, 2011, INT J CANCER, V128, P1001, DOI 10.1002/ijc.25728.
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x.
   Perego P, 2016, CANCER CHEMOTH PHARM, V77, P5, DOI 10.1007/s00280-015-2901-x.
   Poli V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00121.
   Raz S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.39.
   Shen YC, 2013, BRIT J CANCER, V108, P72, DOI 10.1038/bjc.2012.559.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519.
   Wartenberg M, 2010, J CELL BIOCHEM, V109, P434, DOI 10.1002/jcb.22422.
   Wu J, 2015, ONCOL REP, V34, P3043, DOI 10.3892/or.2015.4316.
   Zou X, 2012, ASIAN PAC J CANCER P, V13, P5291, DOI 10.7314/APJCP.2012.13.10.5291.},
Number-of-Cited-References = {36},
Times-Cited = {17},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Evid.-based Complement Altern. Med.},
Doc-Delivery-Number = {LI1MM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529248900004},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000523590100001,
Author = {Cassina, Laura and Chiaravalli, Marco and Boletta, Alessandra},
Title = {Increased mitochondrial fragmentation in polycystic kidney disease acts
   as a modifier of disease progression},
Journal = {FASEB JOURNAL},
Year = {2020},
Volume = {34},
Number = {5},
Pages = {6493-6507},
Month = {MAY},
Abstract = {Autosomal dominant polycystic kidney disease (ADPKD) is a common
   monogenic disorder, characterized by bilateral renal cyst formation.
   Multiple pathways are de-regulated in cystic epithelia offering good
   opportunities for therapy. Others and we have previously reported that
   metabolic reprogramming, including alterations of the TCA cycle, are
   prominent features of ADPKD. Several lines of evidence suggest that
   mitochondrial impairment might be responsible for the metabolic
   alterations. Here, we performed morphologic and morphometric evaluation
   of mitochondria by TEM in an orthologous mouse model of PKD caused by
   mutations in the Pkd1 gene (Ksp-Cre;Pkd1(flox/-)). Furthermore, we
   measured mitochondrial respiration by COX and SDH enzymatic activity in
   situ. We found several alterations including reduced mitochondrial mass,
   altered structure and fragmentation of the mitochondrial network in
   cystic epithelia of Ksp-Cre;Pkd1(flox/-) mice. At the molecular level,
   we found reduced expression of the pro-fusion proteins OPA1 and MFN1 and
   up-regulation of the pro-fission protein DRP1. Importantly,
   administration of Mdivi-1, which interferes with DRP1 rescuing
   mitochondrial fragmentation, significantly reduced kidney/body weight,
   cyst formation, and improved renal function in Ksp-Cre;Pkd1(flox/-)
   mice. Our data indicate that impaired mitochondrial structure and
   function play a role in disease progression, and that their improvement
   can significantly modify the course of the disease.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Boletta, A (Corresponding Author), IRCCS San Raffaele Sci Inst, Div Genet \& Cell Biol, Mol Basis Cyst Kidney Disorders Unit, Via Olgettina 58, I-20132 Milan, Italy.
   Cassina, Laura; Chiaravalli, Marco; Boletta, Alessandra, IRCCS San Raffaele Sci Inst, Div Genet \& Cell Biol, Mol Basis Cyst Kidney Disorders Unit, Via Olgettina 58, I-20132 Milan, Italy.},
DOI = {10.1096/fj.201901739RR},
EarlyAccessDate = {APR 2020},
ISSN = {0892-6638},
EISSN = {1530-6860},
Keywords = {cellular respiration; Mdivi-1; mitochondrial fragmentation; polycystic
   kidney disease},
Keywords-Plus = {METABOLISM; ACTIVATION; OXIDATION; DYNAMICS; FISSION},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Cell Biology},
Author-Email = {boletta.alessandra@hsr.it},
Affiliations = {Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele},
ResearcherID-Numbers = {Cassina, Laura/AAN-3804-2020},
ORCID-Numbers = {Boletta, Alessana/0000-0002-4704-4006
   Cassina, Laura/0000-0002-7350-3069},
Funding-Acknowledgement = {PKD Foundation (PKDF) {[}PKD-218G18A]; Associazione Italiana Rene
   Policistico (AIRP)},
Funding-Text = {PKD Foundation (PKDF), Grant/Award Number: PKD-218G18A; Associazione
   Italiana Rene Policistico (AIRP)},
Cited-References = {Bhargava P, 2017, NAT REV NEPHROL, V13, P629, DOI 10.1038/nrneph.2017.107.
   Bordt EA, 2017, DEV CELL, V40, P583, DOI 10.1016/j.devcel.2017.02.020.
   Brand CS, 2018, CELL SIGNAL, V50, P48, DOI 10.1016/j.cellsig.2018.06.012.
   Brooks C, 2009, J CLIN INVEST, V119, P1275, DOI 10.1172/JCI37829.
   Cai J, 2018, GENE DEV, V32, P781, DOI 10.1101/gad.315127.118.
   Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019.
   Gaeggeler HP, 2005, J AM SOC NEPHROL, V16, P878, DOI 10.1681/ASN.2004121110.
   Hajarnis S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14395.
   Harris PC, 2009, ANNU REV MED, V60, P321, DOI {[}10.21931/rb/2016.01.01.7, 10.1146/annurev.med.60.101707.125712].
   Ishimoto Y, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00337-17.
   Iuso A, 2017, METHODS MOL BIOL, V1567, P217, DOI 10.1007/978-1-4939-6824-4\_13.
   Kuo IY, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aat7397.
   Lakhia R, 2018, AM J PHYSIOL-RENAL, V314, pF122, DOI 10.1152/ajprenal.00352.2017.
   Lin CC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20856-6.
   Manczak M, 2019, HUM MOL GENET, V28, P177, DOI 10.1093/hmg/ddy335.
   Menezes LF, 2016, EBIOMEDICINE, V5, P183, DOI 10.1016/j.ebiom.2016.01.027.
   Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036.
   Nigro EA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53061-0.
   Padovano V, 2018, NAT REV NEPHROL, V14, P678, DOI 10.1038/s41581-018-0051-1.
   Padovano V, 2017, MOL BIOL CELL, V28, P261, DOI 10.1091/mbc.E16-08-0597.
   Podrini C, 2020, CELL SIGNAL, V68, DOI 10.1016/j.cellsig.2019.109495.
   Podrini C, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0200-x.
   Rappold PM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6244.
   Rogers GW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021746.
   Rossi A, 2019, BBA-MOL CELL RES, V1866, P1068, DOI 10.1016/j.bbamcr.2018.10.016.
   Rowe I, 2014, NEPHROL DIAL TRANSPL, V29, P1480, DOI 10.1093/ndt/gft521.
   Rowe I, 2013, NAT MED, V19, P488, DOI 10.1038/nm.3092.
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2.
   Shao XL, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000016444.90348.50.
   Shibazaki S, 2008, HUM MOL GENET, V17, P1505, DOI 10.1093/hmg/ddn039.
   Sumida M, 2015, J AM SOC NEPHROL, V26, P2378, DOI 10.1681/ASN.2014080750.
   Torres VE, 2007, LANCET, V369, P1287, DOI 10.1016/S0140-6736(07)60601-1.
   Wang WJ, 2012, CELL METAB, V15, P186, DOI 10.1016/j.cmet.2012.01.009.
   Wodarczyk C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007137.},
Number-of-Cited-References = {34},
Times-Cited = {41},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Faseb J.},
Doc-Delivery-Number = {LL1OX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000523590100001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000522798800009,
Author = {Baumeister, Julian and Chatain, Nicolas and Hubrich, Annika and Maie,
   Tiago and Costa, Ivan G. and Denecke, Bernd and Han, Lijuan and
   Kuestermann, Caroline and Sontag, Stephanie and Sere, Kristin and
   Strathmann, Klaus and Zenke, Martin and Schuppert, Andreas and
   Bruemmendorf, Tim H. and Kranc, Kamil R. and Koschmieder, Steffen and
   Gezer, Deniz},
Title = {Hypoxia-inducible factor 1 (HIF-1) is a new therapeutic target in
   JAK2V617F-positive myeloproliferative neoplasms},
Journal = {LEUKEMIA},
Year = {2020},
Volume = {34},
Number = {4},
Pages = {1062-1074},
Month = {APR},
Abstract = {Classical Philadelphia chromosome-negative myeloproliferative neoplasms
   (MPN) are a heterogeneous group of hematopoietic malignancies including
   polycythemia vera (PV), essential thrombocythemia (ET), and primary
   myelofibrosis (PMF). The JAK2V617F mutation plays a central role in
   these disorders and can be found in 90\% of PV and similar to 50-60\% of
   ET and PMF. Hypoxia-inducible factor 1 (HIF-1) is a master
   transcriptional regulator of the response to decreased oxygen levels. We
   demonstrate the impact of pharmacological inhibition and shRNA-mediated
   knockdown (KD) of HIF-1 alpha in JAK2V617F-positive cells. Inhibition of
   HIF-1 binding to hypoxia response elements (HREs) with echinomycin,
   verified by ChIP, impaired growth and survival by inducing apoptosis and
   cell cycle arrest in Jak2V617F-positive 32D cells, but not Jak2WT
   controls. Echinomycin selectively abrogated clonogenic growth of
   JAK2V617F cells and decreased growth, survival, and colony formation of
   bone marrow and peripheral blood mononuclear cells and iPS cell-derived
   progenitor cells from JAK2V617F-positive patients, while cells from
   healthy donors were unaffected. We identified HIF-1 target genes
   involved in the Warburg effect as a possible underlying mechanism, with
   increased expression of Pdk1, Glut1, and others. That was underlined by
   transcriptome analysis of primary patient samples. Collectively, our
   data show that HIF-1 is a new potential therapeutic target in
   JAK2V617F-positive MPN.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Gezer, D (Corresponding Author), Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol \& Stem Cell Transp, Aachen, Germany.
   Baumeister, Julian; Chatain, Nicolas; Hubrich, Annika; Han, Lijuan; Kuestermann, Caroline; Bruemmendorf, Tim H.; Koschmieder, Steffen; Gezer, Deniz, Rhein Westfal TH Aachen, Fac Med, Dept Hematol Oncol Hemostaseol \& Stem Cell Transp, Aachen, Germany.
   Maie, Tiago; Costa, Ivan G.; Schuppert, Andreas, Rhein Westfal TH Aachen, Joint Res Ctr Computat Biomed, Aachen, Germany.
   Denecke, Bernd, Rhein Westfal TH Aachen, Fac Med, Interdisciplinary Ctr Clin Res Aachen, Aachen, Germany.
   Kuestermann, Caroline; Sontag, Stephanie; Sere, Kristin; Zenke, Martin, Rhein Westfal TH Aachen, Med Sch, Dept Cell Biol, Inst Biomed Engn, Aachen, Germany.
   Kuestermann, Caroline; Sontag, Stephanie; Sere, Kristin; Zenke, Martin, Rhein Westfal TH Aachen, Helmholtz Inst Biomed Engn, Aachen, Germany.
   Strathmann, Klaus, Rhein Westfal TH Aachen, Med Sch, Inst Transfus Med, Aachen, Germany.
   Kranc, Kamil R., Queen Mary Univ London, Barts Canc Inst, Ctr Haematooncol, Lab Haematopoiet Stem Cell \& Leukaemia Biol, Charterhouse Sq, London, England.},
DOI = {10.1038/s41375-019-0629-z},
ISSN = {0887-6924},
EISSN = {1476-5551},
Keywords-Plus = {ACUTE MYELOID-LEUKEMIA; OF-FUNCTION MUTATION; CANCER STEM-CELLS;
   HEMATOPOIETIC STEM; SIGNALING PATHWAYS; HIF-1-ALPHA; SURVIVAL; JAK2;
   HIF-2-ALPHA; INHIBITOR},
Research-Areas = {Oncology; Hematology},
Web-of-Science-Categories  = {Oncology; Hematology},
Author-Email = {dgezer@ukaachen.de},
Affiliations = {RWTH Aachen University; RWTH Aachen University; RWTH Aachen University;
   RWTH Aachen University; RWTH Aachen University; Helmholtz Association;
   RWTH Aachen University; University of London; Queen Mary University
   London},
ResearcherID-Numbers = {Kranc, Kamil/B-3449-2009
   Gesteira Costa Filho, Ivan/D-5335-2014
   Chatain, Nicolas/MBH-4445-2025
   },
ORCID-Numbers = {Koschmieder, Steffen/0000-0002-1011-8171
   Kranc, Kamil/0009-0001-9522-6437
   Baumeister, Julian/0000-0001-6096-1952
   Gesteira Costa Filho, Ivan/0000-0003-2890-8697
   Maié, Tiago/0000-0003-4857-4014},
Funding-Acknowledgement = {Genomics Facility, a core facility of the Interdisciplinary Center for
   Clinical Research (IZKF) Aachen within the Faculty of Medicine at RWTH
   Aachen University; German Research Foundation {[}DFG KO2155/6-1];
   Interdisciplinary Centre for Clinical Research within the faculty of
   Medicine at the RWTH Aachen University {[}O3-3]; START grant by the
   Faculty of Medicine in Aachen; Medical Research Council; Barts Charity;
   Bloodwise; Kay Kendall Leukaemia Fund; Cancer Research UK; Core Facility
   Flow Cytometry, a Core Facility of the Interdisciplinary Center for
   Clinical Research (IZKF) Aachen within the Faculty of Medicine at RWTH
   Aachen University; Barts Charity {[}MGU0418] Funding Source:
   researchfish; Cancer Research UK {[}26787, 14633] Funding Source:
   researchfish; Medical Research Council {[}MR/P010008/1] Funding Source:
   researchfish; MRC {[}MR/P010008/1, MR/P010008/2] Funding Source: UKRI},
Funding-Text = {This work was supported by the Genomics Facility, a core facility of the
   Interdisciplinary Center for Clinical Research (IZKF) Aachen within the
   Faculty of Medicine at RWTH Aachen University. This work was supported
   by the Core Facility Flow Cytometry, a Core Facility of the
   Interdisciplinary Center for Clinical Research (IZKF) Aachen within the
   Faculty of Medicine at RWTH Aachen University. This study was supported
   by a research grant from the German Research Foundation (DFG KO2155/6-1)
   to SK, from the Interdisciplinary Centre for Clinical Research within
   the faculty of Medicine at the RWTH Aachen University (O3-3) and by
   START grant by the Faculty of Medicine in Aachen to DG. Biomaterial
   samples were provided by the RWTH centralized Biomaterial Bank Aachen
   (RWTH cBMB, Aachen, Germany) in accordance with the regulations of the
   biomaterial bank and the approval of the ethics committee of the medical
   faculty, RWTH Aachen. The Kranc laboratory is funded by Cancer Research
   UK (Senior Fellowship and Programme Grant), Medical Research Council,
   The Barts Charity, Bloodwise, and the Kay Kendall Leukaemia Fund. The
   pMSCV-IRES-GFP plasmids containing Jak2WT or Jak2V617F were a kind gift
   from the lab of Dr. Gary Gilliland. Parts of this work were part of the
   PhD thesis of JB and the bachelor's thesis of AH.},
Cited-References = {Abd-Aziz N, 2015, ONCOL LETT, V10, P2192, DOI 10.3892/ol.2015.3545.
   Ahn JS, 2016, ONCOGENE, V35, P2235, DOI 10.1038/onc.2015.285.
   AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1.
   Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019.
   Bose P, 2017, BLOOD, V130, P115, DOI 10.1182/blood-2017-04-742288.
   Chen E, 2010, CANCER CELL, V18, P524, DOI 10.1016/j.ccr.2010.10.013.
   Cokic VP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135463.
   Dokucu AI, 2009, INT UROL NEPHROL, V41, P101, DOI 10.1007/s11255-008-9460-6.
   Gardie B, 2014, HYPOXIA, V2, P71, DOI 10.2147/HP.S54455.
   Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025.
   Gezer D, 2014, STEM CELLS, V32, P1390, DOI 10.1002/stem.1657.
   Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287.
   Graham AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179545.
   Guitart AV, 2013, BLOOD, V122, P1741, DOI 10.1182/blood-2013-02-484923.
   Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Iommarini L, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00286.
   Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032.
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009.
   Klampfl T, 2013, NEW ENGL J MED, V369, P2379, DOI 10.1056/NEJMoa1311347.
   Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235.
   Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113.
   Kucharzewska P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116740.
   Lu L, 2017, ONCOTARGET, V8, P62793, DOI 10.18632/oncotarget.19513.
   Lv BK, 2017, AM J TRANSL RES, V9, P1521.
   Machado-Neto João Agostinho, 2016, Rev. Bras. Hematol. Hemoter., V38, P179, DOI {[}10.1016/j.bjhh.2016.04.009, 10.1016/j.bjhh.2016.04.009].
   Marty C, 2013, LEUKEMIA, V27, P2187, DOI 10.1038/leu.2013.102.
   Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063.
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007.
   Menrad H, 2010, HEPATOLOGY, V51, P2183, DOI 10.1002/hep.23597.
   Mesa RA, 2017, LANCET HAEMATOL, V4, pE225, DOI 10.1016/S2352-3026(17)30027-3.
   Mitsumori T, 2014, EXP HEMATOL, V42, P783, DOI 10.1016/j.exphem.2014.05.007.
   Nagel R, 2016, EMBO REP, V17, P1516, DOI 10.15252/embr.201643030.
   Nombela-Arrieta C, 2013, NAT CELL BIOL, V15, P533, DOI 10.1038/ncb2730.
   Oku S, 2010, BRIT J HAEMATOL, V150, P334, DOI 10.1111/j.1365-2141.2010.08249.x.
   Peng G, 2015, TRENDS PHARMACOL SCI, V36, P374, DOI 10.1016/j.tips.2015.03.003.
   Percy MJ, 2008, NEW ENGL J MED, V358, P162, DOI 10.1056/NEJMoa073123.
   Pikman Y, 2006, PLOS MED, V3, P1140, DOI 10.1371/journal.pmed.0030270.
   Rao TN, 2019, BLOOD, V134, P1832, DOI 10.1182/blood.2019000162.
   Reddy MM, 2012, LEUKEMIA, V26, P481, DOI 10.1038/leu.2011.225.
   Romanov VS, 2010, CELL CYCLE, V9, P3945, DOI 10.4161/cc.9.19.13160.
   Ruiz A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18844-3.
   Scheuermann TH, 2013, NAT CHEM BIOL, V9, P271, DOI {[}10.1038/NCHEMBIO.1185, 10.1038/nchembio.1185].
   Schulz K, 2012, FEBS LETT, V586, P1652, DOI 10.1016/j.febslet.2012.04.039.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Shah S, 2017, BLOOD CANCER J, V7, DOI 10.1038/s41408-017-0024-9.
   Spivak JL, 2004, SEMIN HEMATOL, V41, P1, DOI 10.1053/j.seminhematol.2004.02.011.
   Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020.
   Tefferi A, 2005, NEW ENGL J MED, V353, P1416.
   Vainchenker William, 2018, F1000Res, V7, P82, DOI {[}10.12688/f1000research.13167.1, 10.12688/f1000research.13167.1].
   Vener C, 2010, EXP HEMATOL, V38, P1058, DOI 10.1016/j.exphem.2010.07.005.
   Vukovic M, 2016, BLOOD, V127, P2841, DOI 10.1182/blood-2015-10-677138.
   Wang Y, 2014, BLOOD, V124, P1127, DOI 10.1182/blood-2013-12-544221.
   Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006.
   Wellmann S, 2004, LEUKEMIA, V18, P926, DOI 10.1038/sj.leu.2403332.
   Xu Qian, 2016, Sichuan Da Xue Xue Bao Yi Xue Ban, V47, P669.
   Yamaguchi Y, 2018, J CELL MOL MED, V22, P1138, DOI 10.1111/jcmm.13367.
   Zhang HJ, 2012, BLOOD, V119, P2595, DOI 10.1182/blood-2011-10-387381.
   Zhang JF, 2017, ONCOTARGET, V8, P7625, DOI 10.18632/oncotarget.13825.
   Zhou HS, 2016, CANCER BIOL MED, V13, P248, DOI 10.20892/j.issn.2095-3941.2016.0023.},
Number-of-Cited-References = {60},
Times-Cited = {48},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Leukemia},
Doc-Delivery-Number = {KY8CI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000522798800009},
DA = {2026-02-04},
}

@article{ WOS:000533783000050,
Author = {Huang, L. and Kuang, F. and Xie, Q. -Y. and Jing, R.},
Title = {STRAP reduces endoplasmic reticulum stress and apoptosis in
   cardiomyocytes and attenuates myocardial ischemia-reperfusion injury by
   activating PI3K/PDK1/Akt signaling pathway},
Journal = {EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES},
Year = {2020},
Volume = {24},
Number = {8},
Pages = {4430-4439},
Month = {APR},
Abstract = {OBJECTIVE: Myocardial ischemia-reperfusion injury (MIRI) is a common
   problem in heart-related diseases. The aim of this study was to explore
   the protective effects of STRAP on cardiomyocytes in the MIRI process
   and its mechanisms.
   MATERIALS AND METHODS: We used SD rats to construct a MIRI model and
   increased the expression of STRAP in myocardial tissue by Entranster to
   detect the effect of STRAP on rat myocardial tissue. In addition, we
   cultured rat cardiomyocyte cell line H9c2 cells and constructed a
   hypoxia-reoxygenation model to detect the protective effect of STRAP on
   H9c2 cells. LY294002, an inhibitor of the PI3K/PDK1/Akt signaling
   pathway, was used to validate the mechanism by which STRAP protects
   cardiomyocytes.
   RESULTS: Overexpression of STRAP significantly reduced the activity of
   MDA in myocardial tissue and increased the activity of SOD. STRAP also
   substantially lowered CK and LDH levels in rat serum and increased
   Na+-K+-ATPase and Ca2+-Mg2+-ATPase activity. In addition, overexpression
   of STRAP considerably reduced endoplasmic reticulum stress (ERS) and
   apoptosis levels in H9c2 cells. However, LY294002 attenuated the
   protective effect of STRAP on cardiomyocytes.
   CONCLUSIONS: STRAP reduces ERS and apoptosis in cardiomyocytes by
   activating the PI3K/PDK1/Akt signaling pathway, thereby reducing
   myocardial MIRI.},
Publisher = {VERDUCI PUBLISHER},
Address = {VIA GREGORIO VII, ROME, 186-00165, ITALY},
Type = {Article},
Language = {English},
Affiliation = {Jing, R (Corresponding Author), Cent South Univ, Xiangya Hosp, Dept Cardiol, Changsha, Peoples R China.
   Huang, L., Peking Univ, Dept Cardiovasc Surg, Shenzhen Hosp, Shenzhen, Peoples R China.
   Kuang, F., Xiamen Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, Xiamen, Peoples R China.
   Xie, Q. -Y.; Jing, R., Cent South Univ, Xiangya Hosp, Dept Cardiol, Changsha, Peoples R China.},
ISSN = {1128-3602},
Keywords = {STRAP; Endoplasmic reticulum stress; Apoptosis; Myocardial
   ischemia-reperfusion injury; PI3K/PDK1/Akt signaling pathway},
Keywords-Plus = {PROTECTS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {29732617@qq.com},
Affiliations = {Peking University; Xiamen University; Central South University},
Cited-References = {Cao Y, 2017, LIFE SCI, V186, P33, DOI 10.1016/j.lfs.2017.08.003.
   Fang SJ, 2017, PEPTIDES, V88, P196, DOI 10.1016/j.peptides.2016.12.009.
   Frank A, 2012, SEMIN CARDIOTHORAC V, V16, P123, DOI 10.1177/1089253211436350.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874.
   Huh HD, 2017, CELL IMMUNOL, V318, P55, DOI 10.1016/j.cellimm.2017.06.005.
   Huh HD, 2016, SCI REP-UK, V6, DOI 10.1038/srep38849.
   Lejay A, 2016, J MOL CELL CARDIOL, V91, P11, DOI 10.1016/j.yjmcc.2015.12.020.
   Manoharan R, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5241524.
   Naline Charlotte, 2015, Soins Gerontol, P45.
   Oakes SA, 2017, AM J PHYSIOL-CELL PH, V312, pC93, DOI 10.1152/ajpcell.00266.2016.
   Seong HA, 2014, CELL CYCLE, V13, P3357, DOI 10.4161/15384101.2014.952165.
   Shu LL, 2017, CELL PHYSIOL BIOCHEM, V44, P1939, DOI 10.1159/000485884.
   Tobisawa T, 2017, BASIC RES CARDIOL, V112, DOI 10.1007/s00395-017-0621-6.
   Wang CC, 2018, EUR REV MED PHARMACO, V22, P5339, DOI 10.26355/eurrev\_201808\_15735.
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041.},
Number-of-Cited-References = {16},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Eur. Rev. Med. Pharmacol. Sci.},
Doc-Delivery-Number = {LO7BQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000533783000050},
DA = {2026-02-04},
}

@article{ WOS:000523753100024,
Author = {Ichikawa, Ryoko and Kawasaki, Rie and Iwata, Aya and Otani, Sayaka and
   Nishio, Eiji and Nomura, Hiroyuki and Fujii, Takuma},
Title = {MicroRNA-126-3p suppresses HeLa cell proliferation, migration and
   invasion, and increases apoptosis via the PI3K/PDK1/AKT pathway},
Journal = {ONCOLOGY REPORTS},
Year = {2020},
Volume = {43},
Number = {4},
Pages = {1300-1308},
Month = {APR},
Abstract = {We previously reported that relative to normal cervical mucus, microRNA
   126-3p (miR-126-3p) is present in significantly greater amounts in the
   cervical mucus of patients with overt cervical cancer or precursor
   lesions. Here, we investigated the effects of enforced miR-126-3p
   expression in the cervical cancer cell line, HeLa, on proliferation,
   migration, invasion, apoptosis and protein expression. We transfected
   HeLa cells with miR-126-3p miRNA and found that proliferation, migration
   and invasion by cell counting, wound healing, cell migration and
   invasion assay were significantly reduced in these cells relative to
   those transfected with a negative control mimic. The levels of
   phosphoinositide 3 kinase (PI3K), phosphorylated
   3-phosphoinositide-dependent protein kinase-1 (p-PDK1) and p-AKT
   proteins were lower in the miR-126-3p-transfected cells. Phosphorylated
   70S6K (p-p70S6K), phosphorylated glycogen synthase kinase 3 beta (p-GSK3
   beta), phosphorylated S6K (p-S6K), cyclin D1, phosphorylated
   p21-activated kinase 1 (p-PAK1), Rho associated coiled-coil containing
   protein kinase 1 (ROCK1), myotonic dystrophy-related CDC42-binding
   kinases alpha (MRCK alpha) and phospholipase C gamma 1 (p-PLC gamma 1)
   were also downregulated. This suggests that downstream effectors of the
   PI3K/PDK1/AKT pathway are targets for inhibition by miR-126-3p. In
   contrast, apoptotic-related proteins including the BCL-2-associated
   agonist of cell death (Bad), B-cell lymphoma-extra-large (Bcl-xL) and
   BCL-2-associated X (Bax), were all upregulated by miR-126-3p, resulting
   in increased caspase 3/7 activity and apoptosis. Thus, enforced
   expression of miR-126-3p inhibited cell migration and invasion and also
   induced apoptosis by regulating the PI3K/PDK1/AKT pathway in HeLa cells.
   Hence, high levels of miR-126-3p may inhibit cervical carcinogenesis,
   and targeting the PI3K/PDK1/AKT pathway via miR-126-3p could represent a
   new approach for treating patients with cervical cancer.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Fujii, T (Corresponding Author), Fujita Hlth Univ, Sch Med, Dept Obstet \& Gynecol, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan.
   Ichikawa, Ryoko; Kawasaki, Rie; Iwata, Aya; Otani, Sayaka; Nishio, Eiji; Nomura, Hiroyuki; Fujii, Takuma, Fujita Hlth Univ, Sch Med, Dept Obstet \& Gynecol, 1-98 Dengakugakubo, Toyoake, Aichi 4701192, Japan.},
DOI = {10.3892/or.2020.7512},
ISSN = {1021-335X},
EISSN = {1791-2431},
Keywords = {HeLa cells; microRNA; cell migration; apoptosis; signal transduction},
Keywords-Plus = {CERVICAL-CANCER; MIR-126-3P SUPPRESSES; TARGETING PI3K; UP-REGULATION;
   PHASE-I; EXPRESSION; CARCINOMA; GROWTH; INHIBITION; ANGIOGENESIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {fujiit44@fujita-hu.ac.jp},
Affiliations = {Fujita Health University},
Funding-Acknowledgement = {JSPS KAKENHI {[}JP 26462540]; Fujita Health University Research;
   Grants-in-Aid for Scientific Research {[}20K09681] Funding Source: KAKEN},
Funding-Text = {This study was partly supported by JSPS KAKENHI (grant no. JP 26462540),
   and a Fujita Health University Research Grant-in-Aid.},
Cited-References = {{[}Anonymous], 2008, PLOS ONE, DOI DOI 10.1371/JOURNAL.PONE.0002557.
   Bahrami A, 2017, J CELL BIOCHEM, V118, P4163, DOI 10.1002/jcb.26118.
   Bregar AJ, 2016, GYNECOL ONCOL, V140, P333, DOI 10.1016/j.ygyno.2015.09.083.
   Cheung TH, 2012, CELL CYCLE, V11, P2876, DOI 10.4161/cc.21278.
   Cho SY, 2017, ONCOTARGET, V8, P8095, DOI 10.18632/oncotarget.14098.
   Ding H, 2014, ASIAN PAC J CANCER P, V15, P1675, DOI 10.7314/APJCP.2014.15.4.1675.
   Du CL, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0259-1.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074.
   Faried LS, 2008, MOL CARCINOGEN, V47, P446, DOI 10.1002/mc.20402.
   Fujii Tomomi, 2015, Biochem Biophys Res Commun, V456, P183, DOI 10.1016/j.bbrc.2014.11.056.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335.
   López AJG, 2014, INT J MOL SCI, V15, P15700, DOI 10.3390/ijms150915700.
   Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596.
   Gupta S, 2018, CURR PROB CANCER, V42, P161, DOI 10.1016/j.currproblcancer.2018.03.003.
   Hou MM, 2014, ONCOTARGET, V5, P11168, DOI 10.18632/oncotarget.2584.
   Huang TH, 2014, ONCOGENE, V33, P3636, DOI 10.1038/onc.2013.335.
   International Agency for Research on Cancer, 2012, GLOBOCAN 2012 EST CA.
   Kawai S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25310-1.
   Kim MS, 2012, NUTR CANCER, V64, P1236, DOI 10.1080/01635581.2012.718405.
   Lee CM, 2006, CLIN CANCER RES, V12, P250, DOI 10.1158/1078-0432.CCR-05-1084.
   Liu D, 2014, CANCER EPIDEMIOL, V38, P85, DOI 10.1016/j.canep.2013.12.005.
   Liu LY, 2014, INT J ONCOL, V45, P1257, DOI 10.3892/ijo.2014.2516.
   Liu R, 2019, EUR REV MED PHARMACO, V23, P679, DOI 10.26355/eurrev\_201901\_16881.
   Luo WZ, 2019, LIFE SCI, V226, P98, DOI 10.1016/j.lfs.2019.04.023.
   Ma D, 2012, CHINESE MED J-PEKING, V125, P4270, DOI 10.3760/cma.j.issn.0366-6999.2012.23.020.
   Macville M, 1999, CANCER RES, V59, P141.
   McCubrey JA, 2017, ONCOTARGET, V8, P14221, DOI 10.18632/oncotarget.13991.
   Meng QY, 2015, J CELL BIOCHEM, V116, P1613, DOI 10.1002/jcb.25115.
   Otsubo T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016617.
   Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024.
   Qu Y, 2016, ONCOTARGET, V7, P74217, DOI 10.18632/oncotarget.12487.
   Rashmi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092948.
   Suprynowicz FA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180897.
   Tavares MR, 2015, LIFE SCI, V131, P1, DOI 10.1016/j.lfs.2015.03.001.
   Temkin SM, 2010, GYNECOL ONCOL, V117, P473, DOI 10.1016/j.ygyno.2010.02.022.
   Tinker AV, 2013, GYNECOL ONCOL, V130, P269, DOI 10.1016/j.ygyno.2013.05.008.
   Tomao F, 2014, CURR DRUG TARGETS, V15, P1107, DOI 10.2174/1389450115666141010145547.
   Vazquez-Mena O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032667.
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215.
   Wilting SM, 2016, PAPILLOMAVIRUS RES, V2, P85, DOI 10.1016/j.pvr.2016.04.003.
   Wright AA, 2013, CANCER-AM CANCER SOC, V119, P3776, DOI 10.1002/cncr.28288.
   Xiao J, 2016, ONCOTARGETS THER, V9, P5181, DOI 10.2147/OTT.S105198.
   Xie GF, 2017, CANCER LETT, V388, P12, DOI 10.1016/j.canlet.2016.11.024.
   Xu JQ, 2019, HEREDITAS, V156, DOI 10.1186/s41065-019-0087-7.
   Yang Y, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0220-x.
   Yu Q, 2013, ASIAN PAC J CANCER P, V14, P6569, DOI 10.7314/APJCP.2013.14.11.6569.
   Yu Q, 2011, J SEP SCI, V34, P278, DOI 10.1002/jssc.201000749.},
Number-of-Cited-References = {49},
Times-Cited = {29},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Oncol. Rep.},
Doc-Delivery-Number = {LA1ZN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000523753100024},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000526301600011,
Author = {Lan, Zi-Jian and Lei, Zhenmin and Yiannikouris, Alexandros and
   Yerramreddy, Thirupathi Reddy and Li, Xian and Kincaid, Hayley and
   Eastridge, Katie and Gadberry, Hannah and Power, Chloe and Xiao, Rijin
   and Lei, Lei and Seale, Olivia and Dawson, Karl and Power, Ronan},
Title = {Non-peptidyl small molecule, adenosine, 5′-Se-methyl-5′-seleno-,
   2′,3′-diacetate, activates insulin receptor and attenuates hyperglycemia
   in type 2 diabetic Leprdb/db mice},
Journal = {CELLULAR AND MOLECULAR LIFE SCIENCES},
Year = {2020},
Volume = {77},
Number = {8},
Pages = {1623-1643},
Month = {APR},
Abstract = {The pathophysiology of type 2 diabetes mellitus (T2D) is characterized
   by reduced or absent insulin receptor (INSR) responsiveness to its
   ligand, elevated hepatic glucose output and impaired glucose uptake in
   peripheral tissues, particularly skeletal muscle. Treatments to reduce
   hyperglycemia and reestablish normal insulin signaling are much sought
   after. Any agent which could be orally administered to restore INSR
   function, in an insulin-independent manner, would have major
   implications for the management of this global disease. We have
   discovered a non-peptidyl small molecule, adenosine, 5 `-Se-methyl-5
   `-seleno-, 2 `,3 `-diacetate {[}referred to as non-peptidyl compound
   \#43 (NPC43)], which restores INSR signaling in the complete absence of
   insulin. Initial screening of numerous compounds in human HepG2 liver
   cells revealed that NPC43 significantly inhibited glucose production.
   The compound was potently anti-hyperglycemic and anti-hyperinsulinemic
   in vivo, in insulin-resistant T2D Lepr(db/db) mice, following either
   acute or chronic treatment by oral gavage and intraperitoneal injection,
   respectively. The compound acted at the level of INSR and activated it
   in both liver and skeletal muscle of Lepr(db/db) mice. In cell culture,
   the compound activated INSR in both liver and skeletal muscle cells;
   furthermore, it cooperated with insulin to depress glucose-6-phosphatase
   catalytic subunit (G6pc) expression and stimulate glucose uptake,
   respectively. Our results indicated that the compound directly
   interacted with INSR alpha, triggering appropriate phosphorylation and
   activation of the receptor and its downstream targets. Unlike insulin,
   NPC43 did not activate insulin-like growth factor 1 receptor in either
   liver or skeletal muscle. We believe this compound represents a
   potential oral and/or injectable insulin replacement therapy for
   diabetes and diseases associated with insulin resistance.},
Publisher = {SPRINGER BASEL AG},
Address = {PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Lan, ZJ; Power, R (Corresponding Author), Alltech Inc, Div Life Sci, 3031 Catnip Hill Rd, Nicholasville, KY 40356 USA.
   Lan, Zi-Jian; Kincaid, Hayley; Eastridge, Katie; Gadberry, Hannah; Power, Chloe; Xiao, Rijin; Seale, Olivia; Dawson, Karl; Power, Ronan, Alltech Inc, Div Life Sci, 3031 Catnip Hill Rd, Nicholasville, KY 40356 USA.
   Lei, Zhenmin; Li, Xian; Lei, Lei, Univ Louisville, Sch Med, Dept OB GYN, MDR Building,Room 121,511 South Floyd St, Louisville, KY 40202 USA.
   Yiannikouris, Alexandros; Yerramreddy, Thirupathi Reddy; Dawson, Karl, Alltech Inc, Chem Dept, Nicholasville, KY 40356 USA.},
DOI = {10.1007/s00018-019-03249-4},
ISSN = {1420-682X},
EISSN = {1420-9071},
Keywords = {Glucose intolerance; Gluconeogenesis; PDK1; AKT; AS160; FOXO1
   phosphorylation; In vitro phosphorylation; AML-12},
Keywords-Plus = {HEPATIC GLUCOSE-PRODUCTION; ANTIDIABETIC ACTIVITY; SIGNAL-TRANSDUCTION;
   PROTEIN; IDENTIFICATION; POTENT; DISCOVERY; AS160},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {zlan@alltech.com
   rpower@alltech.com},
Affiliations = {Alltech United States; University of Louisville; Alltech United States},
ResearcherID-Numbers = {Lan, Zi-Jian/F-2747-2012},
ORCID-Numbers = {Yiannikouris, Alexanos/0000-0001-9220-8201
   Lan, Zi-Jian/0000-0002-5904-6834},
Cited-References = {Björnholm M, 2005, BIOCHEM SOC T, V33, P354.
   Campbell RK, 2009, J AM PHARM ASSOC, V49, pS3, DOI 10.1331/JAPhA.2009.09077.
   Cao YY, 2013, J MOL ENDOCRINOL, V51, P15, DOI 10.1530/JME-12-0171.
   Cefalu WT, 2018, DIABETES CARE, V41, P1299, DOI 10.2337/dci18-0019.
   Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023.
   COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772.
   DEFRONZO RA, 1985, J CLIN INVEST, V76, P149, DOI 10.1172/JCI111938.
   DEFRONZO RA, 1989, METABOLISM, V38, P387, DOI 10.1016/0026-0495(89)90129-7.
   DEFRONZO RA, 1981, J CLIN INVEST, V68, P1468, DOI 10.1172/JCI110399.
   He KY, 2011, J BIOL CHEM, V286, P37379, DOI 10.1074/jbc.M111.247387.
   Hemkens LG, 2009, DIABETOLOGIA, V52, P1732, DOI 10.1007/s00125-009-1418-4.
   Hua XY, 2016, JAMA-J AM MED ASSOC, V315, P1400, DOI 10.1001/jama.2016.0126.
   Kramer HF, 2006, J BIOL CHEM, V281, P31478, DOI 10.1074/jbc.M605461200.
   Lan ZJ, 1998, BIOL REPROD, V58, P197, DOI 10.1095/biolreprod58.1.197.
   Lan ZJ, 2003, EMBO J, V22, P4070, DOI 10.1093/emboj/cdg405.
   Li Z, 2008, INT J BIOL SCI, V4, P29.
   Lin B, 2007, J PHARMACOL EXP THER, V323, P579, DOI 10.1124/jpet.107.126102.
   Liu K, 2000, J MED CHEM, V43, P3487, DOI 10.1021/jm000285q.
   Matsumoto M, 2007, CELL METAB, V6, P208, DOI 10.1016/j.cmet.2007.08.006.
   Menting JG, 2013, NATURE, V493, P241, DOI 10.1038/nature11781.
   Mîinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887.
   Misu H, 2010, CELL METAB, V12, P483, DOI 10.1016/j.cmet.2010.09.015.
   Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667.
   Qiang GF, 2014, DIABETES, V63, P1394, DOI 10.2337/db13-0334.
   Qureshi SA, 2000, J BIOL CHEM, V275, P36590, DOI 10.1074/jbc.M006287200.
   Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257.
   Roglic G., 2016, GLOBAL REPORT DIABET.
   Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a.
   Schmoll D, 2000, J BIOL CHEM, V275, P36324, DOI 10.1074/jbc.M003616200.
   Tsai HJ, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-68.
   Tylee T, 2015, JAMA-J AM MED ASSOC, V314, P665, DOI 10.1001/jama.2015.7032.
   Ward CW, 2013, BIOESSAYS, V35, P945, DOI 10.1002/bies.201300065.
   WHITE MF, 1988, J BIOL CHEM, V263, P2969.
   Wilkie N, 2001, J NEUROCHEM, V78, P1135, DOI 10.1046/j.1471-4159.2001.00504.x.
   Wilson Carol, 2011, Nat Rev Endocrinol, V7, P499, DOI 10.1038/nrendo.2011.112.
   Yang Hui, 2017, Proceedings of the SPIE, V10255, DOI 10.1117/12.2268397.
   Zhang B, 1999, SCIENCE, V284, P974, DOI 10.1126/science.284.5416.974.
   Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457.},
Number-of-Cited-References = {38},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Cell. Mol. Life Sci.},
Doc-Delivery-Number = {LD8UB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000526301600011},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000530914200076,
Author = {Miao, Yushan and Wang, Wei and Dong, Yaping and Hu, Jiaxun and Wei,
   Kunchen and Yang, Shuo and Lai, Xueli and Tang, Hao},
Title = {Hypoxia induces tumor cell growth and angiogenesis in non-small cell
   lung carcinoma via the Akt-PDK1-HIF1α-YKL-40 pathway},
Journal = {TRANSLATIONAL CANCER RESEARCH},
Year = {2020},
Volume = {9},
Number = {4},
Pages = {2904+},
Month = {APR},
Abstract = {Background: As one of the most common forms of cancer, non-small cell
   lung carcinoma (NSCLC), is characterized by oxygen deprivation
   (hypoxia). The transcription factor hypoxia-inducible factor (HIF)-1
   alpha is a major mediator which responds hypoxia and regulates many
   contributing factors. The various modes of hypoxia regulation are
   frequently the focus of research studies. With reference to previous
   published research, we hypothesized that hypoxia promotes the growth and
   angiogenesis of NSCLC via the Akt-PDKI-HIF1 alpha-YKL-40 pathway, and
   verified it.
   Methods: We mainly investigated changes in related factor expression
   between differently treated CL1-5 cells. We carried out overexpression
   and underexpression transfection, Western blot, rt-PCR and ELISA, and
   observed cellular biological behaviors by CCK-8 migration and invasion
   assay, and tube formation assay.
   Results: A hypoxic environment significantly increased the
   phosphorylation of Akt and PDK1 in mitochondria. The hypoxia-induced
   accumulation of p-Akt in mitochondria activated PDK1 phosphorylation,
   promoted the expression of HIF1 alpha, and the expression of YKL-40. The
   overexpression of YKL-40 promoted the proliferation, migration, invasion
   and tubule formation of CL1-5 cells.
   Conclusion: A hypoxic tumor microenvironment can promote the expansion
   and angiogenesis of NSCLC cells through the Akt-PDK1-HIF1 alpha-YKL-40
   pathway. This may provide a new mechanism and potential interventional
   target for anti-vascular lung cancer therapy.},
Publisher = {AME PUBLISHING COMPANY},
Address = {FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA},
Type = {Article},
Language = {English},
Affiliation = {Tang, H (Corresponding Author), Second Mil Med Univ, Changzheng Hosp, Dept Resp \& Crit Care Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
   Lai, XL (Corresponding Author), Second Mil Med Univ, Shanghai Changhai Hosp, Dept Nephrol, 168 Changhai Rd, Shanghai 200433, Peoples R China.
   Miao, Yushan; Wang, Wei; Hu, Jiaxun; Wei, Kunchen; Yang, Shuo; Tang, Hao, Second Mil Med Univ, Changzheng Hosp, Dept Resp \& Crit Care Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
   Dong, Yaping, Fujian Med Univ, Grad Sch, Fuzhou 350122, Peoples R China.
   Lai, Xueli, Second Mil Med Univ, Shanghai Changhai Hosp, Dept Nephrol, 168 Changhai Rd, Shanghai 200433, Peoples R China.},
DOI = {10.21037/tcr.2020.03.80},
ISSN = {2218-676X},
EISSN = {2219-6803},
Keywords = {Hypoxia; Akt; hypoxia-inducible factor-1 alpha (HIF-1 alpha); YKL-40;
   non-small cell lung carcinoma (NSCLC)},
Keywords-Plus = {AKT; MITOCHONDRIA; CANCER; PROLIFERATION; ACCUMULATION; HIF-1; SMAD3;
   BETA},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {laixueli\_changhai@163.com
   tanghao\_0921@126.com},
Affiliations = {Naval Medical University; Fujian Medical University; Naval Medical
   University},
ResearcherID-Numbers = {Wei, Kunchen Wei/ODL-2666-2025
   miao, yushan/HOF-6412-2023},
ORCID-Numbers = {Wei, Kunchen Wei/0009-0006-1543-8728
   },
Funding-Acknowledgement = {General Program of National Nature Science Foundation of China
   {[}81670015, 81370137]; Shanghai Pujiang Program {[}16PJD006]},
Funding-Text = {General Program of National Nature Science Foundation of China (Grant
   No. 81670015 and Grant No. 81370137), Shanghai Pujiang Program
   (16PJD006).},
Cited-References = {Bijur GN, 2003, NEUROREPORT, V14, P2415, DOI 10.1097/00001756-200312190-00025.
   Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x.
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220.
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004.
   Cheng XH, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.08.79.
   Francescone R, 2014, ONCOGENE, V33, P2110, DOI 10.1038/onc.2013.160.
   Francescone RA, 2011, J BIOL CHEM, V286, P15332, DOI 10.1074/jbc.M110.212514.
   Ghosh JC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju502.
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004.
   Höckel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266.
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796.
   Jefri M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1592-3.
   Joseph JV, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.395.
   Kawada M, 2012, ONCOGENE, V31, P3111, DOI 10.1038/onc.2011.498.
   Ke SZ, 2017, HEPATOLOGY, V65, P134, DOI 10.1002/hep.28889.
   Konisti S, 2012, NAT REV RHEUMATOL, V8, P153, DOI 10.1038/nrrheum.2011.205.
   Kushida N, 2016, AM J NEPHROL, V44, P276, DOI 10.1159/000449323.
   Kzhyshkowska J, 2016, BIOL CHEM, V397, P231, DOI 10.1515/hsz-2015-0269.
   Libreros S, 2015, J LEUKOCYTE BIOL, V98, P931, DOI 10.1189/jlb.3VMR0415-142R.
   Lu HS, 2005, J BIOL CHEM, V280, P41928, DOI 10.1074/jbc.M508718200.
   Ma R., 2018, Biomedical Research (India), V29, P268.
   Maynard MA, 2007, CELL MOL LIFE SCI, V64, P2170, DOI 10.1007/s00018-007-7082-2.
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054.
   Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010.
   Qiu QC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33239-8.
   Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075.
   Serrano-Gomez SJ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0502-x.
   Shao R, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00122.
   Shi X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.282.
   Soni S, 2017, ACTA ONCOL, V56, P503, DOI 10.1080/0284186X.2017.1301680.
   Stiles BL, 2009, ADV DRUG DELIVER REV, V61, P1276, DOI 10.1016/j.addr.2009.07.017.
   Sun WY, 2009, CLIN CANCER RES, V15, P476, DOI 10.1158/1078-0432.CCR-08-0930.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Suwanabol PA, 2012, J VASC SURG, V56, P446, DOI 10.1016/j.jvs.2011.12.038.
   Tsai S, 2009, AM J PHYSIOL-HEART C, V297, pH540, DOI 10.1152/ajpheart.91478.2007.
   Weber M, 2019, TRANSL CANCER RES, V8, pS141, DOI 10.21037/tcr.2018.12.08.
   Yang YP, 2019, TRANSL LUNG CANCER R, V8, P989, DOI 10.21037/tlcr.2019.12.23.
   Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483.},
Number-of-Cited-References = {38},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Transl. Cancer Res.},
Doc-Delivery-Number = {LK5NZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000530914200076},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000519622500007,
Author = {Ozaki, Michitaka},
Title = {Cellular and molecular mechanisms of liver regeneration: Proliferation,
   growth, death and protection of hepatocytes},
Journal = {SEMINARS IN CELL \& DEVELOPMENTAL BIOLOGY},
Year = {2020},
Volume = {100},
Number = {SI},
Pages = {62-73},
Month = {APR},
Abstract = {Liver regeneration is an important and necessary process that the liver
   depends on for recovery from injury. The regeneration process consists
   of a complex network of cells and organs, including liver cells
   (parenchymal and non-parenchymal cells) and extrahepatic organs
   (thyroid, adrenal glands, pancreas, duodenum, spleen, and autonomic
   nervous system). The regeneration process of a normal, healthy liver
   depends mainly on hepatocyte proliferation, growth, and programmed cell
   death. Cell proliferation and growth are regulated in a cooperative
   manner by interleukin (IL)-6/janus kinase (Jak)/signal transducers and
   activators of transcription-3 (STAT3), and phosphoinositide 3-kinase
   (PI3-K)/phosphoinositide-dependent protein kinase 1 (PDK1)/Akt pathways.
   The IL-6/Jak/STAT3 pathway regulates hepatocyte proliferation and
   protects against cell death and oxidative stress. The PI3-K/PDK1/Akt
   pathway is primarily responsible for the regulation of cell size,
   sending mitotic signals in addition to pro-survival, antiapoptotic and
   antioxidative signals. Though programmed cell death may interfere with
   liver regeneration in a pathological situation, it seems to play an
   important role during the termination phase, even in a normal, healthy
   liver regeneration. However, further study is needed to fully elucidate
   the mechanisms regulating the processes of liver regeneration with
   regard to cell-to-cell and organ-to-organ networks at the molecular and
   cellular levels.},
Publisher = {ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD},
Address = {24-28 OVAL RD, LONDON NW1 7DX, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Ozaki, M (Corresponding Author), Hokkaido Univ, Fac Hlth Sci, Dept Biol Response \& Regulat, Kita Ku, N12,W5, Sapporo, Hokkaido 0600812, Japan.
   Ozaki, Michitaka, Hokkaido Univ, Fac Hlth Sci, Dept Biol Response \& Regulat, Kita Ku, N12,W5, Sapporo, Hokkaido 0600812, Japan.},
DOI = {10.1016/j.semcdb.2019.10.007},
ISSN = {1084-9521},
EISSN = {1096-3634},
Keywords = {Liver regeneration; Cell proliferation; Cell growth; Programmed cell
   death; Liver protection; Fatty liver},
Keywords-Plus = {FATTY LIVER; PARTIAL-HEPATECTOMY; PROTEIN-SYNTHESIS; TRANSFORMING
   GROWTH-FACTOR-BETA-1; HEPATIC REGENERATION; RAT HEPATOCYTES;
   DNA-REPLICATION; UP-REGULATION; AKT; ACTIVATION},
Research-Areas = {Cell Biology; Developmental Biology},
Web-of-Science-Categories  = {Cell Biology; Developmental Biology},
Author-Email = {ozaki-m@med.hokudai.ac.jp},
Affiliations = {Hokkaido University},
Funding-Acknowledgement = {JSPS {[}19H05564]; Grants-in-Aid for Scientific Research {[}20K20472]
   Funding Source: KAKEN},
Funding-Text = {The author is grateful to Dr. S. Haga for her advice regarding the
   manuscript and figures, and Mr. \& Mrs. Fujikawa for their kind support.
   This study was supported by a JSPS Grants-in-Aid for Scientific Research
   (KAKENHI) {[}Grant No. 19H05564 (to M.O.)].},
Cited-References = {ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0.
   Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515.
   Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101.
   Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476.
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5.
   Cai XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26802.
   Calkin AC, 2012, NAT REV MOL CELL BIO, V13, P213, DOI 10.1038/nrm3312.
   Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1.
   Caraceni P, 2005, J SURG RES, V124, P160, DOI 10.1016/j.jss.2004.10.007.
   Chipuk JE, 2008, TRENDS CELL BIOL, V18, P157, DOI 10.1016/j.tcb.2008.01.007.
   Clarke P, 2009, NAT REV MICROBIOL, V7, P144, DOI 10.1038/nrmicro2071.
   Clavien PA, 2008, SWISS MED WKLY, V138, P361.
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117.
   CORNELL RP, 1990, HEPATOLOGY, V11, P916, DOI 10.1002/hep.1840110603.
   Costa RH, 2003, HEPATOLOGY, V38, P1331, DOI 10.1016/j.hep.2003.09.034.
   Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379.
   CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1002/hep.1840210531.
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455.
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630.
   DeLeve LD, 2013, J CLIN INVEST, V123, P1861, DOI 10.1172/JCI66025.
   Deshpande S.S., 2000, FASEB J, V14.
   Desmots F, 2002, J BIOL CHEM, V277, P17892, DOI 10.1074/jbc.M112351200.
   Diehl AM, 1996, FASEB J, V10, P215, DOI 10.1096/fasebj.10.2.8641555.
   Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584.
   Enkhbold C, 2015, J GASTROEN HEPATOL, V30, P1217, DOI 10.1111/jgh.12930.
   Faridi J, 2003, AM J PHYSIOL-ENDOC M, V285, pE964, DOI 10.1152/ajpendo.00239.2003.
   Fausto N, 2001, LIVER TRANSPLANT, V7, P835, DOI 10.1053/jlts.2001.27865.
   Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2.
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802.
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665.
   Fujiyoshi M, 2011, J HEPATO-BIL-PAN SCI, V18, P13, DOI 10.1007/s00534-010-0304-2.
   G-Amlak M, 2002, BIOCHEM BIOPH RES CO, V297, P760, DOI 10.1016/S0006-291X(02)02278-7.
   Gardai SJ, 2004, J BIOL CHEM, V279, P21085, DOI 10.1074/jbc.M400063200.
   Geier A, 2007, BBA-MOL CELL RES, V1773, P283, DOI 10.1016/J.BBAMCR.2006.04.014.
   Georgiev P, 2006, CURR PHARM DESIGN, V12, P2911, DOI 10.2174/138161206777947588.
   Haga S, 2005, J HEPATOL, V43, P799, DOI 10.1016/j.jhep.2005.03.027.
   Haga S, 2003, J CLIN INVEST, V112, P989, DOI 10.1172/JCI200317970.
   Haga S., 2014, ANTIOXIDANTS REDOX S, V21.
   Haga S, 2008, J HEPATOL, V48, P422, DOI 10.1016/j.jhep.2007.11.018.
   Haga S, 2018, ONCOL RES, V26, P503, DOI 10.3727/096504017X15005102445191.
   Haga S, 2017, BMC GASTROENTEROL, V17, DOI 10.1186/s12876-016-0568-3.
   Haga S, 2010, LAB INVEST, V90, P1718, DOI 10.1038/labinvest.2010.119.
   Haga S, 2009, HEPATOLOGY, V49, P204, DOI 10.1002/hep.22583.
   Heo SR, 2009, NEUROSCI LETT, V450, P45, DOI 10.1016/j.neulet.2008.11.011.
   Huda KASM, 2006, TRANSPL INT, V19, P415, DOI 10.1111/j.1432-2277.2006.00285.x.
   Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101.
   Ikeda O, 2009, J SURG RES, V152, P218, DOI 10.1016/j.jss.2008.02.059.
   Inoue H, 2004, NAT MED, V10, P168, DOI 10.1038/nm980.
   Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649.
   Jackson LN, 2008, AM J PHYSIOL-GASTR L, V294, pG1401, DOI 10.1152/ajpgi.00062.2008.
   Kiba T, 2002, DIGESTION, V66, P79, DOI 10.1159/000065594.
   Kirillova I, 1999, CELL GROWTH DIFFER, V10, P819.
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021.
   Koniaris LG, 2003, J AM COLL SURGEONS, V197, P634, DOI 10.1016/S1072-7515(03)00374-0.
   Kooby DA, 2003, J GASTROINTEST SURG, V7, P1034, DOI 10.1016/j.gassur.2003.09.012.
   Kopplow K, 2005, INT J ONCOL, V27, P1551.
   Kosai K, 1999, HEPATOLOGY, V30, P151, DOI 10.1002/hep.510300102.
   Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200.
   Kruidering M, 2000, IUBMB LIFE, V50, P85, DOI 10.1080/15216540050212088.
   Latronico MVG, 2004, ANN NY ACAD SCI, V1015, P250, DOI 10.1196/annals.1302.021.
   Lauschke VM, 2017, BIOCHEM BIOPH RES CO, V482, P399, DOI 10.1016/j.bbrc.2016.10.084.
   Lavia P, 1999, BIOESSAYS, V21, P221.
   Lee SC, 2015, J SURG RES, V196, P270, DOI 10.1016/j.jss.2015.02.025.
   Leifeld L, 2006, LIVER INT, V26, P872, DOI 10.1111/j.1478-3231.2006.01300.x.
   Lesurtel M, 2006, SCIENCE, V312, P104, DOI 10.1126/science.1123842.
   Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200.
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327.
   Liu YG, 2007, BIOCHEM BIOPH RES CO, V352, P329, DOI 10.1016/j.bbrc.2006.11.024.
   Loforese G, 2017, EMBO MOL MED, V9, P46, DOI 10.15252/emmm.201506089.
   Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484.
   Lu YB, 2001, J EXP MED, V193, P545, DOI 10.1084/jem.193.4.545.
   Malik R, 2005, AM J TRANSPLANT, V5, P1801, DOI 10.1111/j.1600-6143.2005.00949.x.
   Mangnall D, 2003, LIVER INT, V23, P124, DOI 10.1034/j.1600-0676.2003.00812.x.
   MARTI U, 1989, HEPATOLOGY, V9, P126, DOI 10.1002/hep.1840090122.
   Matheny RW, 2009, EXP BIOL MED, V234, P1264, DOI 10.3181/0904-MR-138.
   Mendes-Braz M., 2018, MEDIAT INFLAMM, V2018, P1.
   Moro L, 2004, ENDOCRINOLOGY, V145, P5121, DOI 10.1210/en.2004-0909.
   Mourani PM, 2004, CIRCULATION, V109, P1299, DOI 10.1161/01.CIR.0000118462.22970.BE.
   Mullany LK, 2007, J BIOL CHEM, V282, P21244, DOI 10.1074/jbc.M702110200.
   Munugalavadla V, 2005, BLOOD, V106, P103, DOI 10.1182/blood-2004-10-4041.
   Murata H, 2007, J GASTROEN HEPATOL, V22, P2173, DOI 10.1111/j.1440-1746.2006.04798.x.
   Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197.
   Nygard Ingvild E, 2012, Comp Hepatol, V11, P3, DOI 10.1186/1476-5926-11-3.
   Okano J, 2003, BIOCHEM BIOPH RES CO, V309, P298, DOI 10.1016/j.bbrc.2003.04.002.
   Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173.
   Ozaki M, 2003, CELL DEATH DIFFER, V10, P508, DOI 10.1038/sj.cdd.4401172.
   Ozaki M, 2000, FASEB J, V14, P418, DOI 10.1096/fasebj.14.2.418.
   Ozaki M, 2012, THERANOSTICS, V2, P207, DOI 10.7150/thno.3806.
   Pahlavan PS, 2006, J SURG RES, V134, P238, DOI 10.1016/j.jss.2005.12.011.
   Pennarun B, 2010, BBA-REV CANCER, V1805, P123, DOI 10.1016/j.bbcan.2009.11.004.
   Puri KD, 2005, BLOOD, V106, P150, DOI 10.1182/blood-2005-01-0023.
   Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003.
   Sabugal R, 1996, BIOCHEM J, V318, P597, DOI 10.1042/bj3180597.
   Sasaki M, 2017, CLIN RES HEPATOL GAS, V41, P129, DOI 10.1016/j.clinre.2016.08.002.
   Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157.
   Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005.
   Selzner M, 2001, SEMIN LIVER DIS, V21, P105, DOI 10.1055/s-2001-12933.
   Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818.
   Stiles B, 2004, P NATL ACAD SCI USA, V101, P2082, DOI 10.1073/pnas.0308617100.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Strey CW, 2003, J EXP MED, V198, P913, DOI 10.1084/jem.20030374.
   Takahashi-Yanaga F, 2008, CELL SIGNAL, V20, P581, DOI 10.1016/j.cellsig.2007.10.018.
   Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200.
   Tang TX, 1997, J SURG RES, V72, P8, DOI 10.1006/jsre.1997.5165.
   Tanoue S, 2011, BIOCHEM BIOPH RES CO, V407, P163, DOI 10.1016/j.bbrc.2011.02.131.
   Tao YC, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4256352.
   Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489.
   Terui K, 2005, DRUG TODAY, V41, P461, DOI 10.1358/dot.2005.41.7.893622.
   Terui K, 2004, J HEPATOL, V41, P957, DOI 10.1016/j.jhep.2004.08.019.
   Tomiya T, 2000, AM J PATHOL, V157, P1693, DOI 10.1016/S0002-9440(10)64806-7.
   Tuzlak S, 2016, GENE DEV, V30, P2133, DOI 10.1101/gad.289298.116.
   Ueda S, 2003, LAB INVEST, V83, P1595, DOI 10.1097/01.LAB.0000095686.10639.C8.
   Valizadeh A., 2019, J Cell Physiol.
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970.
   Veteläinen R, 2007, ANN SURG, V245, P20, DOI 10.1097/01.sla.0000225113.88433.cf.
   Viebahn CS, 2008, INT J BIOCHEM CELL B, V40, P855, DOI 10.1016/j.biocel.2007.11.025.
   Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055.
   Wakahara R, 2012, GENES CELLS, V17, P132, DOI 10.1111/j.1365-2443.2011.01575.x.
   Wang Qiwen, 2015, Yichuan, V37, P1116, DOI 10.16288/j.yczz.15-162.
   Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025.
   Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509.
   Williams JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043961.
   Yamamoto K, 2007, TRANSPLANTATION, V83, P257, DOI 10.1097/01.tp.0000250671.06456.3f.
   Yin S, 2014, HEPATOLOGY, V60, P1356, DOI 10.1002/hep.27128.
   Zimmers TA, 2003, HEPATOLOGY, V38, P326, DOI 10.1053/jhep.2003.50318.},
Number-of-Cited-References = {128},
Times-Cited = {72},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {35},
Journal-ISO = {Semin. Cell Dev. Biol.},
Doc-Delivery-Number = {KU3PB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000519622500007},
DA = {2026-02-04},
}

@article{ WOS:000528563800010,
Author = {Pang, Yingqiao and Zhu, Shaozhi and Pei, Haitao},
Title = {Pachymic acid protects against cerebral ischemia/reperfusion injury by
   the PI3K/Akt signaling pathway},
Journal = {METABOLIC BRAIN DISEASE},
Year = {2020},
Volume = {35},
Number = {4},
Pages = {673-680},
Month = {APR},
Abstract = {Pachymic acid (PA) from medicinal fungus Poria cocos has a variety of
   pharmacological potentials. However, there are no reports of the effects
   of PA on cerebral ischemia/reperfusion (I/R) injury. The purpose of this
   study was to investigate the mechanisms of PA on cerebral I/R injury in
   rats. The effects of PA on cerebral infarction size, brain water
   content, neurological symptoms and cerebral blood flow were evaluated.
   Nissl staining was used to observe the damage of ischemic brain neurons
   after I/R in rats. Apoptosis of ischemic brain neurons after I/R was
   observed by TUNEL staining. The effect of PA on the expression of some
   components of PI3K/Akt was detected by Western blotting. PA
   significantly increased cerebral blood flow after I/R in rats, reduced
   infarct volume and brain water content, and downgrade neurological
   function scores, significantly reduced neuronal damage after I/R in
   rats, and significantly decreased neuronal apoptosis. The effect of PA
   on rat I/R can be eliminated by LY294002. In addition, PA significantly
   up-regulated the protein expression of p-PTEN (Ser380), p-PDK1 (Ser241),
   p-Akt (Ser473), pc-Raf (Ser259) and p-BAD (Ser136), and down-regulated
   Cleaved caspase protein expression. LY294002 can reverse the effect of
   PA on the expression of PI3K / Akt signaling pathway related protein in
   rats after I/R. PA had obviously neuroprotective effects on brain I/R
   injury and neuronal apoptosis, and its mechanism may be related to
   activation of PI3K / Akt signaling pathway.},
Publisher = {SPRINGER/PLENUM PUBLISHERS},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Pei, HT (Corresponding Author), Qingdao Univ, Dept Neurol, Affiliated Hosp, 19 Jiangsu Rd, Qingdao 266011, Shandong, Peoples R China.
   Pang, Yingqiao; Zhu, Shaozhi, Qingdao Univ, Med Sch, 38 Dengzhou Rd, Qingdao 266021, Shandong, Peoples R China.
   Pei, Haitao, Qingdao Univ, Dept Neurol, Affiliated Hosp, 19 Jiangsu Rd, Qingdao 266011, Shandong, Peoples R China.},
DOI = {10.1007/s11011-020-00540-3},
ISSN = {0885-7490},
EISSN = {1573-7365},
Keywords = {Citric acid; PI3K; Akt; Apoptosis; I; R injury},
Keywords-Plus = {ISCHEMIC CEREBROVASCULAR-DISEASE; APOPTOSIS; INHIBITION; PROLIFERATION;
   MECHANISMS; PTEN; RATS},
Research-Areas = {Endocrinology \& Metabolism; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Endocrinology \& Metabolism; Neurosciences},
Author-Email = {peihaitao\_123@163.com},
Affiliations = {Qingdao University; Qingdao University},
Cited-References = {Akaza Hideyuki, 2004, Gan To Kagaku Ryoho, V31, P1285.
   Andreadou I, 2017, BRIT J PHARM, V174.
   Bondonno CP, 2017, STROKE, V48, P1724, DOI {[}10.1161/STROKEAHA.117.016844, 10.1161/strokeaha.117.016844].
   Caplan L, 2012, GOLDMANS CECIL MED, V125, P2310.
   Chen YT, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-51.
   Chow FC, 2014, AIDS, V28, P2573, DOI 10.1097/QAD.0000000000000452.
   Delgado-Esteban M, 2007, J NEUROCHEM, V102, P194, DOI 10.1111/j.1471-4159.2007.04450.x.
   Dumitrascu OM, 2018, J STROKE CEREBROVASC, V27, P1960, DOI 10.1016/j.jstrokecerebrovasdis.2018.02.041.
   Enneking FK, 2018, REGION ANESTH PAIN M, V43, P223, DOI 10.1097/AAP.0000000000000771.
   Flynn LMC, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00357.
   Gao AH, 2015, INT J CLIN EXP PATHO, V8, P2235.
   Han JC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00456.
   Han XR, 2017, J CELL PHYSL.
   Hu GQ, 2017, NEURAL REGEN RES, V12, P96, DOI 10.4103/1673-5374.198992.
   Huang BM, 2017, FREE RADICAL BIO MED, V108, pS32, DOI 10.1016/j.freeradbiomed.2017.04.131.
   Jeong JW, 2015, PHYTOTHER RES, V29, P1516, DOI 10.1002/ptr.5402.
   Jiang BH, 2009, ADV CANCER RES, V102, P19, DOI 10.1016/S0065-230X(09)02002-8.
   Jiao SJ, 2016, BIOMED PHARMACOTHER, V84, P1533, DOI 10.1016/j.biopha.2016.11.028.
   Kilic U, 2017, REDOX BIOL, V12, P657, DOI 10.1016/j.redox.2017.04.006.
   Kroes R, 2004, FOOD CHEM TOXICOL, V42, P65, DOI 10.1016/j.fct.2003.08.006.
   Li JY, 2017, EUR REV MED PHARMACO, V21, P1904.
   Ling H, 2011, BREAST CANCER RES TR, V126, P609, DOI 10.1007/s10549-010-0929-5.
   Liu H, 2017, COMPLEMENT THER MED, V32, P85, DOI 10.1016/j.ctim.2017.03.014.
   Ma J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0230-0.
   Ma XH, 2015, INT J NEUROSCI, V125, P140, DOI 10.3109/00207454.2014.912217.
   Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947-2714.100998.
   Manea MM, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013347.
   MITSIAS P, 1992, CEPHALALGIA, V12, P341, DOI 10.1111/j.1468-2982.1992.00341.x.
   Shah VK, 2014, BIOMOL THER, V22, P314, DOI 10.4062/biomolther.2014.045.
   Sheng LL, 2017, EXP THER MED, V13, P55, DOI 10.3892/etm.2016.3917.
   Strbian D, 2013, STROKE, V44, P2913, DOI 10.1161/STROKEAHA.111.000819.
   Wang CM, 2017, EXP THER MED, V13, P3315, DOI 10.3892/etm.2017.4424.
   Wang XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182777.
   Wen H, 2017, J NAT MED, V72, P1.
   Wu QL, 2017, SCIENCE, V355, DOI 10.1126/science.aal1325.
   Xing SH, 2012, AUTOPHAGY, V8, P63, DOI 10.4161/auto.8.1.18217.
   Yang Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.161.
   Ye LC, 2015, EXP THER MED, V10, P1493, DOI 10.3892/etm.2015.2672.
   You LH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.93.
   Yu Z, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00064.
   Zhang HF, 2016, ANESTH ANALG, V122, P1377, DOI 10.1213/ANE.0000000000001172.},
Number-of-Cited-References = {41},
Times-Cited = {35},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Metab. Brain Dis.},
Doc-Delivery-Number = {LH1QL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000528563800010},
DA = {2026-02-04},
}

@article{ WOS:000522932000001,
Author = {Qian, Yan and Song, Wei and Wu, Xu and Hou, Guowei and Wang, Haixiao and
   Hang, Xiao and Xia, Tianfang},
Title = {DLX6 Antisense RNA 1 Modulates Glucose Metabolism and Cell Growth in
   Gastric Cancer by Targeting microRNA-4290},
Journal = {DIGESTIVE DISEASES AND SCIENCES},
Year = {2021},
Volume = {66},
Number = {2},
Pages = {460-473},
Month = {FEB},
Abstract = {Background Gastric cancer (GC) is one of the most commonly diagnosed
   malignancy worldwide. DLX6 antisense RNA 1 (DLX6-AS1) is a long
   noncoding RNA (lncRNA) that exhibits oncogenic effects on multiple human
   carcinomas. Aims This study aimed to investigate the regulatory effect
   of DLX6-AS1 in GC progression. Methods The expression of DLX6-AS1 in GC
   tissues and cell lines was examined. The cell viability, number of
   clones, and apoptosis, aerobic glycolysis, and mitochondrial respiration
   was assessed. The effect of DLX6-AS1 on tumor growth in nude mice was
   also evaluated. Results DLX6-AS1 was overexpressed in GC tissues and
   cell lines. DLX6-AS1 knockdown by short hairpin RNA (shRNA)
   significantly inhibited cell viability and colony formation, and induced
   apoptosis. DLX6-AS1 silencing impaired aerobic glycolysis but stimulated
   mitochondrial respiration in GC cells. miR-4290 was confirmed as a
   downstream target of DLX6-AS1, and their expression levels were
   inversely correlated. GC cells expressing sh-DLX6-AS1 showed
   significantly lower level of 3-phosphoinositide-dependent protein kinase
   1 (PDK1), a target of miR-4290, compared to cells expressing control
   shRNA. In addition, the suppressed GC cell malignancy upon DLX6-AS1
   knockdown could be prominently reversed by PDK1 overexpression.
   Meanwhile, PDK1 overexpression enhanced aerobic glycolysis but repressed
   mitochondrial respiration under sh-DLX6-AS1 treatment. Furthermore,
   DLX6-AS1 knockdown significantly delayed the tumor growth in a mouse
   xenograft model inoculated with GC cells. Conclusions LncRNA DLX6-AS1
   regulated tumor growth and aerobic glycolysis in GC by targeting
   miR-4290 and PDK1, suggesting DLX6-AS1 might serve as a novel potential
   therapeutic target for GC treatment from bench to clinic.},
Publisher = {SPRINGER},
Address = {VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Xia, TF (Corresponding Author), Nanjing Med Univ, Dept Gastr, Affiliated Huaian 1 Peoples Hosp, 1 Huanghe West Rd, Huaian City 223300, Jiangsu, Peoples R China.
   Qian, Yan; Wu, Xu; Hou, Guowei; Wang, Haixiao; Hang, Xiao; Xia, Tianfang, Nanjing Med Univ, Dept Gastr, Affiliated Huaian 1 Peoples Hosp, 1 Huanghe West Rd, Huaian City 223300, Jiangsu, Peoples R China.
   Song, Wei, Nanjing Med Univ, Dept Gastroenterol, Affiliated Huaian 1 Peoples Hosp, Huaian City 223300, Jiangsu, Peoples R China.},
DOI = {10.1007/s10620-020-06223-4},
EarlyAccessDate = {APR 2020},
ISSN = {0163-2116},
EISSN = {1573-2568},
Keywords = {DLX6-AS1; Gastric cancer; Long noncoding RNA; microRNA; miR-4290; PDK1},
Keywords-Plus = {LONG NONCODING RNAS; ACTIVATION; EXPRESSION},
Research-Areas = {Gastroenterology \& Hepatology},
Web-of-Science-Categories  = {Gastroenterology \& Hepatology},
Author-Email = {TianfangXiaaji@163.com},
Affiliations = {Nanjing Medical University; Nanjing Medical University},
ResearcherID-Numbers = {HOU, GUOWEI/AAD-7648-2020
   },
ORCID-Numbers = {WU, XU/0000-0003-4555-0076
   Xia, Tianfang/0000-0001-9533-3913},
Cited-References = {Alenzi FQB, 2004, BRIT J BIOMED SCI, V61, P99, DOI 10.1080/09674845.2004.11732652.
   {[}Anonymous], 1996, GUIDE CARE USE LAB A.
   Balakrishnan Maya, 2017, Curr Gastroenterol Rep, V19, P36, DOI {[}10.1007/s11894-017-0575-8, 10.1007/s11894-017-0575-8].
   Beitzinger M, 2007, RNA BIOL, V4, P76, DOI 10.4161/rna.4.2.4640.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chen JF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0756-y.
   Chen LL, 2010, WIRES RNA, V1, P2, DOI 10.1002/wrna.5.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023.
   Fu XD, 2019, EXP THER MED, V17, P4715, DOI 10.3892/etm.2019.7521.
   Gao S, 2018, ONCOTARGETS THER, V11, P4877, DOI 10.2147/OTT.S169823.
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478.
   Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hong XH, 2016, ONCOTARGET, V7, P22092, DOI 10.18632/oncotarget.8020.
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981.
   Justus CR, 2015, INT J MOL SCI, V16, P11055, DOI 10.3390/ijms160511055.
   Katai H, 2018, GASTRIC CANCER, V21, P144, DOI 10.1007/s10120-017-0716-7.
   Li J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0201-5.
   Lin MT, 2018, WORLD J GASTROENTERO, V24, P3724, DOI 10.3748/wjg.v24.i33.3724.
   Ngo DC, 2015, MOL BIOL REP, V42, P819, DOI 10.1007/s11033-015-3857-y.
   Paraskevopoulou MD, 2016, METHODS MOL BIOL, V1402, P271, DOI 10.1007/978-1-4939-3378-5\_21.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Rawla P, 2019, GASTROENTEROL REV, V14, P26, DOI 10.5114/pg.2018.80001.
   Salehi Z, 2018, MIDDLE EAST J CANCER, V9, P113.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053.
   Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250.
   Yoon JH, 2014, SEMIN CELL DEV BIOL, V34, P9, DOI 10.1016/j.semcdb.2014.05.015.
   Yuan LW, 2016, WORLD J GASTROENTERO, V22, P2046, DOI 10.3748/wjg.v22.i6.2046.
   Zeng X, 2017, CELL CYCLE, V16, P2212, DOI 10.1080/15384101.2017.1361072.
   Zhang C, 2018, WORLD J GASTROENTERO, V24, P1206, DOI 10.3748/wjg.v24.i11.1206.
   Zhang L, 2017, BIOMED PHARMACOTHER, V96, P884, DOI 10.1016/j.biopha.2017.10.056.
   Zhang L, 2016, J BIOSCIENCES, V41, P77, DOI 10.1007/s12038-016-9586-0.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z.
   Zhao Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0820-2.
   Zhu ZW, 2002, AM J SURG, V184, P78, DOI 10.1016/S0002-9610(02)00884-X.},
Number-of-Cited-References = {38},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Dig. Dis. Sci.},
Doc-Delivery-Number = {QD1HR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000522932000001},
DA = {2026-02-04},
}

@article{ WOS:000520509000010,
Author = {Qian, Yan and Wu, Xu and Wang, Haixiao and Hou, Guowei and Han, Xiao and
   Song, Wei},
Title = {PAK1 silencing is synthetic lethal with CDK4/6 inhibition in gastric
   cancer cells via regulating PDK1 expression},
Journal = {HUMAN CELL},
Year = {2020},
Volume = {33},
Number = {2},
Pages = {377-385},
Month = {APR},
Abstract = {Gastric cancer (GC) is one of the most common malignancies worldwide.
   The prognosis of GC is unsatisfied owning to widespread metastasis.
   P21-activated kinase 1 (PAK1), a member of serine/threonine kinases, is
   associated with the progression of multiple types of human cancers.
   Here, we demonstrated that CDK4/6 inhibitor reduced GC cell viability
   and decreased PAK1 expression. Consistently, PAK1 ablation increased GC
   cell sensitivity exposed to CDK4/6 inhibitor and promoted DNA damage. We
   also revealed PAK1 depletion notably affected PDK1-AKT pathway, and PDK1
   overexpression totally abrogated the effect of PAK1 deletion on DNA
   damage in GC cells. Additionally, PDK1 overexpression also rescued the
   increased GC cell sensitivity towards CDK4/6 inhibitor and the cell
   cycle arrest caused by PAK1 depletion. Our findings, therefore,
   suggested that PAK1 silencing increased sensitivity to CDK4/6 inhibition
   in gastric cancer cells via PDK1-AKT pathway. We, therefore, thought
   PAK1 as a promising therapeutic target for the treatment of CDK4/6
   inhibitor-resistant gastric cancer.},
Publisher = {SPRINGER JAPAN KK},
Address = {SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN},
Type = {Article},
Language = {English},
Affiliation = {Song, W (Corresponding Author), Nanjing Med Univ, Dept Gastroenterl, Affiliated Huaian Peoples Hosp 1, 1 Huanghe West Rd, Huaian 223300, Jiangsu, Peoples R China.
   Qian, Yan; Wu, Xu; Wang, Haixiao; Hou, Guowei; Han, Xiao, Nanjing Med Univ, Dept Gastr, Affiliated Huaian Peoples Hosp 1, Huaian 223300, Jiangsu, Peoples R China.
   Song, Wei, Nanjing Med Univ, Dept Gastroenterl, Affiliated Huaian Peoples Hosp 1, 1 Huanghe West Rd, Huaian 223300, Jiangsu, Peoples R China.},
DOI = {10.1007/s13577-019-00317-6},
ISSN = {1749-0774},
Keywords = {P21-activated kinase 1 (PAK1); Gastric cancer (GC); PDK1 pathway;
   Proliferation; CDK4; 6 inhibitor},
Keywords-Plus = {LUNG-CANCER; P21-ACTIVATED-KINASE-1},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {WeiSongdjk@163.com},
Affiliations = {Nanjing Medical University; Nanjing Medical University},
ResearcherID-Numbers = {HOU, GUOWEI/AAD-7648-2020},
Cited-References = {Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453.
   Arias-Romero Luis E, 2010, Small GTPases, V1, P124, DOI 10.4161/sgtp.1.2.14109.
   Cao J, 2019, ONCOGENE, V38, P4125, DOI 10.1038/s41388-019-0708-7.
   Chen MJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34933.
   Duarte HO, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12523.
   Fu HY, 2018, MOL THER-NUCL ACIDS, V12, P769, DOI 10.1016/j.omtn.2018.06.006.
   Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653.
   Jeremiasen M, 2020, DIS ESOPHAGUS, V33, DOI 10.1093/dote/doz070.
   Kou B, 2014, UROL ONCOL-SEMIN ORI, V32, P846, DOI 10.1016/j.urolonc.2014.01.003.
   Li LH, 2017, ONCOL REP, V38, P193, DOI 10.3892/or.2017.5643.
   Lin XQ, 2020, FRONT BIOSCI-LANDMRK, V25, P452, DOI 10.2741/4813.
   Liu JS, 2015, WORLD J GASTROENTERO, V21, P9945, DOI 10.3748/wjg.v21.i34.9945.
   Malecka KA, 2013, J BIOL CHEM, V288, P8887, DOI 10.1074/jbc.M112.428904.
   Murphy CG, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0651-4.
   Padgaonkar Amol, 2018, Oncotarget, V9, P37753, DOI {[}10.18632/oncotarget.26514, 10.18632/oncotarget.26514].
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74.
   Pavey S, 2006, MELANOMA RES, V16, P285, DOI 10.1097/01.cmr.0000222589.30117.f2.
   Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645.
   Song YJ, 2017, BRIT J CANCER, V116, P973, DOI 10.1038/bjc.2017.54.
   Strochlic TI, 2010, MOL CELL, V40, P493, DOI 10.1016/j.molcel.2010.10.015.
   Symeonidis N, 2019, CLIN MED INSIGHTS-ON, V13, DOI 10.1177/1179554919831990.
   Tempka D, 2018, REDOX BIOL, V15, P316, DOI 10.1016/j.redox.2017.12.017.
   Vauhkonen M, 2006, BEST PRACT RES CL GA, V20, P651, DOI 10.1016/j.bpg.2006.03.016.
   Cruz OV, 2016, ONCOTARGET, V7, P76590, DOI 10.18632/oncotarget.12576.
   Wang G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.50.
   Wang GL, 2015, ONCOTARGET, V6, P9877, DOI 10.18632/oncotarget.3185.
   Yasui W, 2001, Gastric Cancer, V4, P113, DOI 10.1007/PL00011733.
   Ye Diana Zi, 2012, Cell Logist, V2, P105.
   Yi CL, 2010, BIOCHEM PHARMACOL, V80, P683, DOI 10.1016/j.bcp.2010.03.012.
   Zavros Y, 2017, CELL MOL GASTROENTER, V4, P55, DOI 10.1016/j.jcmgh.2017.03.003.
   Zheng MF, 2015, CANCER MED-US, V4, P1781, DOI 10.1002/cam4.524.
   Zhou Y, 2019, ANAT REC, V302, P1571, DOI 10.1002/ar.24095.},
Number-of-Cited-References = {32},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Hum. Cell},
Doc-Delivery-Number = {KV5FS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000520509000010},
DA = {2026-02-04},
}

@article{ WOS:000527969500012,
Author = {Ulum, Baris and Mammadova, Aynura and Ozyuncu, Ozgur and
   Uckan-Cetinkaya, Duygu and Yanik, Tulin and Aerts-Kaya, Fatima},
Title = {Neuropeptide Y is involved in the regulation of quiescence of
   hematopoietic stem cells},
Journal = {NEUROPEPTIDES},
Year = {2020},
Volume = {80},
Month = {APR},
Abstract = {Differentiation, self-renewal and quiescence of Hematopoietic stem cells
   (HSCs) is tightly regulated in order to protect the HSCs from the strain
   of constant cell division and depletion of the stem cell pool. The
   neurotransmitter Neuropeptide Y (NPY) is released from sympathetic
   nerves in the bone marrow and has been shown to indirectly affect HSC
   function through effects on bone marrow (BM) multipotent Mesenchymal
   Stromal Cells (MSCs), osteoblasts (OBs) and macrophages. Although the
   absence of NPY has been shown to be accompanied by severe BM impairment
   and delayed engraftment of HSCs, the direct effects of NPY on HSCs have
   never been assessed. Here, we aimed to explore the effect of NPY on the
   regulation of HSCs. All NPY receptors Y1, Y2, Y4 and Y5 were found to be
   highly expressed on most HSCs and mature hematopoietic cell subsets. In
   culture, in particularly expression of the Y1 receptor was shown to
   decrease in time. Doses of 300 nM NPY suppressed HSC proliferation in
   cell cultures, as confirmed by an increase of HSCs in G(0) phase and an
   increase in the gene expression levels of FOXO3, DICERI, SMARCA2 and
   PDK1, which all have been shown to play an important role in the
   regulation of cell quiescence. These data support the idea that NPY may
   have a direct effect on the regulation of HSC fate by modulating cell
   quiescence.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Aerts-Kaya, F (Corresponding Author), Hacettepe Univ, Ctr Stem Cell Res \& Dev, TR-06100 Ankara, Turkey.
   Ulum, Baris; Mammadova, Aynura; Uckan-Cetinkaya, Duygu; Aerts-Kaya, Fatima, Hacettepe Univ, Ctr Stem Cell Res, Ankara, Turkey.
   Ulum, Baris; Yanik, Tulin, Middle East Tech Univ, Dept Biol Sci, Ankara, Turkey.
   Mammadova, Aynura; Uckan-Cetinkaya, Duygu; Aerts-Kaya, Fatima, Hacettepe Univ, Dept Stem Cell Sci, Grad Sch Hlth Sci, Ankara, Turkey.
   Ozyuncu, Ozgur, Hacettepe Univ, Dept Obstet \& Gynecol, Med Fac, Ankara, Turkey.},
DOI = {10.1016/j.npep.2020.102029},
Article-Number = {102029},
ISSN = {0143-4179},
EISSN = {1532-2785},
Keywords = {Neuropeptide Y; Hematopoietic stem cells; Quiescence},
Keywords-Plus = {SELF-RENEWAL; NERVE INJURY; RECEPTOR; NPY; PROLIFERATION; MAINTENANCE;
   EXPRESSION; DIFFERENTIATION; MOBILIZATION; HIBERNATION},
Research-Areas = {Endocrinology \& Metabolism; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Endocrinology \& Metabolism; Neurosciences},
Author-Email = {fatima.aerts@hacettepe.edu.tr},
Affiliations = {Hacettepe University; Middle East Technical University; Hacettepe
   University; Hacettepe University},
ResearcherID-Numbers = {Aerts-Kaya, Fatima/J-1494-2013
   Yanik, Tulin/HPF-2739-2023
   UÇKAN ÇETINKAYA, DUYGU/X-2067-2019
   Ulum, Baris/KFX-5984-2024},
ORCID-Numbers = {Aerts-Kaya, Fatima/0000-0002-9583-8572
   UÇKAN ÇETINKAYA, DUYGU/0000-0003-3593-6493
   },
Funding-Acknowledgement = {Scientific and Technological Research Council of Turkey (TUBITAK)
   {[}318S073]; Hacettepe University Scientific Research Projects
   Coordination Unit, Turkey {[}THD-2018-17209]; Middle East Technical
   University Scientific Research Projects Coordination Unit, Turkey
   {[}07-02-2017-010]},
Funding-Text = {This study has been supported grants from the Scientific and
   Technological Research Council of Turkey (TUBITAK), project number:
   318S073; the Hacettepe University Scientific Research Projects
   Coordination Unit, Turkey, project number: THD-2018-17209; and the
   Middle East Technical University Scientific Research Projects
   Coordination Unit, Turkey, project number: 07-02-2017-010.},
Cited-References = {Aerts-Kaya F, 2020, ADV EXP MED BIOL, V1212, P127, DOI 10.1007/5584\_2019\_398.
   Arai F, 2009, ANN NY ACAD SCI, V1176, P36, DOI 10.1111/j.1749-6632.2009.04561.x.
   Bedoui S, 2003, J NEUROIMMUNOL, V134, P1, DOI 10.1016/S0165-5728(02)00424-1.
   Blank U, 2015, BLOOD, V125, P3542, DOI 10.1182/blood-2014-12-618090.
   Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012.
   Brothers SP, 2010, EMBO MOL MED, V2, P429, DOI 10.1002/emmm.201000100.
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591.
   Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834.
   Farzi A, 2015, ACTA PHYSIOL, V213, P603, DOI 10.1111/apha.12445.
   Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785.
   Fukada SI, 2007, STEM CELLS, V25, P2448, DOI 10.1634/stemcells.2007-0019.
   Herzog H, 1997, GENOMICS, V41, P315, DOI 10.1006/geno.1997.4684.
   Holliday ND, 2005, MOL PHARMACOL, V67, P655, DOI 10.1124/mol.104.006114.
   Igura K, 2011, REJUV RES, V14, P393, DOI 10.1089/rej.2010.1129.
   Itkin T, 2017, J CLIN INVEST, V127, P4231, DOI 10.1172/JCI98323.
   Kawamura N, 1998, NEUROIMMUNOMODULAT, V5, P9, DOI 10.1159/000026321.
   Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279.
   Kitlinska J, 2005, CANCER RES, V65, P1719, DOI 10.1158/0008-5472.CAN-04-2192.
   Körner M, 2008, CLIN CANCER RES, V14, P5043, DOI 10.1158/1078-0432.CCR-07-4551.
   KOGNER P, 1992, BLOOD, V80, P1324.
   Larhammar D, 2004, NEUROPEPTIDES, V38, P141, DOI 10.1016/j.npep.2004.06.002.
   Lee NJ, 2010, J BONE MINER RES, V25, P1736, DOI 10.1002/jbmr.61.
   Lee NJ, 2009, NEUROPEPTIDES, V43, P457, DOI 10.1016/j.npep.2009.08.006.
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994.
   Liu S, 2016, NEUROPEPTIDES, V56, P105, DOI 10.1016/j.npep.2015.12.008.
   Lucas D, 2013, NAT MED, V19, P695, DOI 10.1038/nm.3155.
   Marchese A, 2003, TRENDS BIOCHEM SCI, V28, P369, DOI 10.1016/S0968-0004(03)00134-8.
   Michel MC, 1998, PHARMACOL REV, V50, P143.
   Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001.
   Nakamura K, 2008, J BIOL CHEM, V283, P17702, DOI 10.1074/jbc.M802589200.
   Park MH, 2018, ANIM CELLS SYST, V22, P281.
   Park MH, 2016, STEM CELLS, V34, P2145, DOI 10.1002/stem.2383.
   Park MH, 2015, BMB REP, V48, P645, DOI 10.5483/BMBRep.2015.48.12.22.
   Park MH, 2015, EMBO J, V34, P1648, DOI 10.15252/embj.201490174.
   Peng S, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/6823917.
   PETITTO JM, 1994, J NEUROIMMUNOL, V54, P81, DOI 10.1016/0165-5728(94)90234-8.
   Qi Y, 2016, NEUROPEPTIDES, V55, P91, DOI 10.1016/j.npep.2015.09.009.
   Scarselli M, 2009, J BIOL CHEM, V284, P3577, DOI 10.1074/jbc.M806819200.
   Seshadri M, 2016, CURR OPIN HEMATOL, V23, P339, DOI 10.1097/MOH.0000000000000251.
   Singh P, 2017, J CLIN INVEST, V127, P4527, DOI 10.1172/JCI94687.
   Son MY, 2011, J CELL MOL MED, V15, P152, DOI 10.1111/j.1582-4934.2009.00956.x.
   Strand F.L., 1999, BIOSYNTHESIS PROCESS.
   Straub RH, 2000, J NEUROCHEM, V75, P2464, DOI 10.1046/j.1471-4159.2000.0752464.x.
   Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003.
   Wagner L, 2016, NEUROPEPTIDES, V57, P21, DOI 10.1016/j.npep.2016.02.007.
   Wee NKY, 2019, NEUROPEPTIDES, V73, P78, DOI 10.1016/j.npep.2018.11.009.
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048.
   Wolfe BL, 2007, TRAFFIC, V8, P462, DOI 10.1111/j.1600-0854.2007.00551.x.
   Wu JQ, 2017, STEM CELL RES, V21, P74, DOI 10.1016/j.scr.2017.04.001.
   Yamazaki S, 2006, EMBO J, V25, P3515, DOI 10.1038/sj.emboj.7601236.
   Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053.
   Yi M, 2018, CELL PHYSIOL BIOCHEM, V45, P88, DOI 10.1159/000486225.
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010.
   Zukowska-Grojec Z, 1998, CIRC RES, V83, P187, DOI 10.1161/01.RES.83.2.187.},
Number-of-Cited-References = {54},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Neuropeptides},
Doc-Delivery-Number = {LG2XG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000527969500012},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000527342900021,
Author = {Yu, Tao and Wang, Zhibin and Jie, Wang and Fu, Xiuxiu and Li, Bing and
   Xu, Hong and Liu, Yan and Li, Min and Kim, Eunji and Yang, Yanyan and
   Cho, Jae Youl},
Title = {The kinase inhibitor BX795 suppresses the inflammatory response via
   multiple kinases},
Journal = {BIOCHEMICAL PHARMACOLOGY},
Year = {2020},
Volume = {174},
Month = {APR},
Abstract = {BX795, a small molecule with an aminopyrimidine backbone, is a potent
   ATP-competitive inhibitor of phosphoinositide-dependent kinase 1 (PDK1)
   and TANK-binding kinase 1 (TBK1). BX795 has significant functions in
   various immune responses and cancer. Few reports on the
   anti-inflammatory effect of BX795 are available, and its molecular
   mechanisms have not been fully elucidated. In this study,
   lipopolysaccharide (LPS)-treated macrophages (RAW264.7 cells),
   luciferase reporter gene assay, knock-down and overexpression
   strategies, kinase assay, protein chip, immunoprecipitation, and
   immunoblotting analyses were employed to clarify the anti-inflammatory
   mechanism of BX795. BX795 was found to dose-dependently inhibit the
   production of pro-inflammatory mediators without exhibiting
   cytotoxicity. Luciferase assay and immunoblotting analysis with nuclear
   fractions showed that activator protein-1 (AP-1), signal transducer and
   activator of transcription 1 (STAT1), and interferon regulatory factor 3
   (IRF3) are targeted by BX795 rather than nuclear factor (NF)-kappa B.
   Moreover, TBK1 and AKT, transforming growth factor activated kinase
   (TAK)-1/c-Jun N-terminal kinase (JNK)/ mitogen-activated protein kinase
   kinase 4 (MKK4) for AP-1 activation, and Janus kinase 2 (JAK2)/STAT1
   were inhibited by BX795. Consistent with these findings, BX795 strongly
   ameliorated inflammatory symptoms in colitis models. These results
   suggest that BX795 can suppress inflammatory responses triggered by
   Gram-positive bacteria by suppressing multiple pathways.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yu, T (Corresponding Author), Qingdao Univ, Dept Cardiac Ultrasound, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
   Kim, E; Cho, JY (Corresponding Author), Sungkyunkwan Univ, Dept Integrat Biotechnol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Yang, YY (Corresponding Author), Qingdao Univ, Inst Translat Med, Ctr Vasc Biol, 38 Deng Zhou Rd, Qingdao 266021, Peoples R China.
   Yu, Tao; Wang, Zhibin; Fu, Xiuxiu; Liu, Yan; Li, Min, Qingdao Univ, Dept Cardiac Ultrasound, Affiliated Hosp, Qingdao 266000, Shandong, Peoples R China.
   Yu, Tao; Yang, Yanyan, Qingdao Univ, Inst Translat Med, Qingdao, Peoples R China.
   Yu, Tao; Kim, Eunji; Cho, Jae Youl, Sungkyunkwan Univ, Dept Integrat Biotechnol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Jie, Wang, Qingdao Haici Med Treatment Grp, Pharm Dept, 4 Renmin Rd, Qingdao, Peoples R China.
   Li, Bing, Qingdao Univ, Dept Biol, Med Coll, Qingdao, Peoples R China.
   Xu, Hong, Qingdao Univ, Dept Orthodont, Affiliated Hosp, Qingdao, Peoples R China.
   Xu, Hong, Qingdao Univ, Sch Stomatol, Qingdao, Peoples R China.},
DOI = {10.1016/j.bcp.2020.113797},
Article-Number = {113797},
ISSN = {0006-2952},
EISSN = {1873-2968},
Keywords = {BX795; Inflammation; Kinase; Colitis; Inhibitor},
Keywords-Plus = {COMPOUND K; ANTIINFLAMMATORY ROLE; SIGNALING PATHWAY; IMMUNE-SYSTEM;
   T-CELLS; KAPPA-B; COLITIS; CANCER; INVOLVEMENT; DISEASE},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {yutao0112@qdu.edu.cn
   msl88@skku.edu
   yangyy1201@qdu.edu.cn
   jaecho@skku.edu},
Affiliations = {Qingdao University; Qingdao University; Sungkyunkwan University (SKKU);
   Qingdao University; Qingdao University; Qingdao University},
ResearcherID-Numbers = {Wang, Zhibin/AAD-5283-2021
   Li, Min/KLE-1784-2024
   Yu, tao/JGM-1974-2023
   },
ORCID-Numbers = {Yu, tao/0000-0002-0925-2242
   Yang, Yanyan/0000-0002-6927-1904},
Funding-Acknowledgement = {Basic Science Research Program through the National Research Foundation
   of Korea (NRF) {[}2017R1A6A1A03015642]},
Funding-Text = {This research was funded by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) (Grant number:
   2017R1A6A1A03015642).},
Cited-References = {Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012.
   Ahuja A, 2018, J GINSENG RES, V42, P248, DOI 10.1016/j.jgr.2017.04.009.
   Bai LY, 2015, EUR J PHARMACOL, V769, P287, DOI 10.1016/j.ejphar.2015.11.032.
   Bellido M., 2012, ADV HEMATOL, V2012.
   Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106.
   Benderska N, 2015, INFLAMM BOWEL DIS, V21, P2039, DOI 10.1097/MIB.0000000000000453.
   Brannigan AE, 2000, SHOCK, V13, P361, DOI 10.1097/00024382-200005000-00003.
   CARTER L, 1995, DIGEST DIS SCI, V40, P192, DOI 10.1007/BF02063966.
   Choi E, 2019, J GINSENG RES, V43, P692, DOI 10.1016/j.jgr.2019.07.001.
   Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414.
   Coskun M, 2013, PHARMACOL RES, V76, P1, DOI 10.1016/j.phrs.2013.06.007.
   Cristóbal I, 2015, INFLAMM BOWEL DIS, V21, pE24, DOI 10.1097/MIB.0000000000000572.
   De Vries LCS, 2019, INFLAMM BOWEL DIS, V25, P647, DOI 10.1093/ibd/izy364.
   Dinallo V, 2019, J CROHNS COLITIS, V13, P772, DOI 10.1093/ecco-jcc/jjy215.
   DRISCOLL KE, 1994, EXP LUNG RES, V20, P473, DOI 10.3109/01902149409031733.
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491.
   El-Salhy M, 2016, INT J MOL MED, V37, P556, DOI 10.3892/ijmm.2016.2481.
   Esmailbeig M, 2017, EUR CYTOKINE NETW, V28, P127, DOI 10.1684/ecn.2018.0401.
   Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x.
   Garrido-Mesa J, 2018, BIOCHEM PHARMACOL, V155, P524, DOI 10.1016/j.bcp.2018.07.044.
   Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004.
   Ghonim AE, 2019, EUR J MED CHEM, V180, P154, DOI 10.1016/j.ejmech.2019.07.002.
   Han SY, 2018, J GINSENG RES, V42, P496, DOI 10.1016/j.jgr.2017.06.003.
   Hwang Y, 2016, ATHEROSCLEROSIS, V249, P44, DOI 10.1016/j.atherosclerosis.2016.03.038.
   Jaishankar D, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5861.
   Jones GR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02764.
   Josse C, 2016, ADV EXP MED BIOL, V937, P53, DOI 10.1007/978-3-319-42059-2\_3.
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582.
   Kang BY, 2003, PLANTA MED, V69, P687, DOI 10.1055/s-2003-42779.
   Kang YC, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00154.
   Kim E, 2018, J GINSENG RES, V42, P233.
   Kim MH, 2013, BIOCHEM PHARMACOL, V86, P1747, DOI 10.1016/j.bcp.2013.10.006.
   Kim TW, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101163.
   Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0.
   Kralovics R, 2008, LEUKEMIA, V22, P1841, DOI 10.1038/leu.2008.233.
   Kwon Y, 2015, J BIOL CHEM, V290, P14245, DOI 10.1074/jbc.M115.645580.
   Lee JO, 2019, J GINSENG RES, V43, P154, DOI 10.1016/j.jgr.2018.10.003.
   Leighton SP, 2018, MOL PSYCHIATR, V23, P48, DOI 10.1038/mp.2017.205.
   Liu SY, 2018, ATHEROSCLEROSIS, V272, P153, DOI 10.1016/j.atherosclerosis.2018.03.036.
   Liu W, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/612593.
   Marra F, 2014, GASTROENTEROLOGY, V147, P577, DOI 10.1053/j.gastro.2014.06.043.
   Martineau C, 2017, ALIMENT PHARM THER, V46, P1077, DOI 10.1111/apt.14371.
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0.
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043.
   Mulero MC, 2019, ADV EXP MED BIOL, V1172, P207, DOI 10.1007/978-981-13-9367-9\_10.
   Na Y.R., 2019, NUCL TECHNOL, P1.
   Nasr R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071867.
   OU Z, 2016, CURR DRUG TARGETS, V17, DOI DOI 10.1177/1470320316672349.
   PALMEN MJHJ, 1995, CLIN EXP IMMUNOL, V99, P226.
   Park EJ, 2018, FEBS OPEN BIO, V8, P1119, DOI 10.1002/2211-5463.12456.
   Rashidian A, 2016, INFLAMMOPHARMACOLOGY, V24, P109, DOI 10.1007/s10787-016-0263-6.
   Sandberg EM, 2005, J MED CHEM, V48, P2526, DOI 10.1021/jm049470k.
   Schreiner Philipp, 2019, Inflamm Intest Dis, V4, P79, DOI {[}10.1159/000500721, 10.1159/000500721].
   Shi L, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201600924.
   Singh K, 2018, CANCER RES, V78, P4303, DOI 10.1158/0008-5472.CAN-18-0116.
   Sohn KH, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/457370.
   Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759.
   Su AR, 2017, ACTA PHARMACOL SIN, V38, P402, DOI 10.1038/aps.2016.160.
   Suh W, 2017, BIOMOL THER, V25, P165, DOI 10.4062/biomolther.2016.063.
   Sun JL, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0309-x.
   Tang NN, 2018, CARDIOVASC THER, V36, DOI 10.1111/1755-5922.12436.
   Tili E, 2017, CURR OPIN PHARMACOL, V37, P142, DOI 10.1016/j.coph.2017.10.010.
   Wang YJ, 2016, BIOCHEM PHARMACOL, V101, P71, DOI 10.1016/j.bcp.2015.11.015.
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005.
   Yang YY, 2017, EXPERT OPIN THER PAT, V27, P1021, DOI 10.1080/13543776.2017.1344217.
   Yang Y, 2014, BIOCHEM PHARMACOL, V88, P201, DOI 10.1016/j.bcp.2014.01.022.
   Yang Y, 2012, J ETHNOPHARMACOL, V139, P616, DOI 10.1016/j.jep.2011.12.003.
   Yu T., 2015, EXPERT OPIN THER PAT, V25.
   Yu T, 2012, BIOCHEM PHARMACOL, V83, P1540, DOI 10.1016/j.bcp.2012.02.018.},
Number-of-Cited-References = {69},
Times-Cited = {50},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {26},
Journal-ISO = {Biochem. Pharmacol.},
Doc-Delivery-Number = {LF3TK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000527342900021},
DA = {2026-02-04},
}

@article{ WOS:000527342900017,
Author = {Zhang, Xiaohan and Min, Xiao and Zhu, Anlin and Kim, Kyeong-Man},
Title = {A novel molecular mechanism involved in the crosstalks between
   homologous and PKC-mediated heterologous regulatory pathway of dopamine
   D2 receptor},
Journal = {BIOCHEMICAL PHARMACOLOGY},
Year = {2020},
Volume = {174},
Month = {APR},
Abstract = {Protein kinase C (PKC) is one of the major effectors involved in the
   heterologous regulatory pathways of G protein-coupled receptors (GPCRs).
   On the other hand, GRK2 and beta-arrestins are the players of homologous
   regulatory pathway of GPCRs that affect the receptor functions in
   agonist-selective manner. Even though two pathways can occur
   independently, crosstalks between two pathways add more diverse modes of
   regulations on GPCR functions. Even if extensive studies have been
   conducted, a commonly applicable molecular mechanism involved in the
   crosstalks between two regulatory pathways has yet to be elucidated.
   Here we show that PKC beta II was phosphorylated at its activation loop
   of kinase domain (T500) through constitutive interaction with
   phosphoinositide-dependent kinase 1 (PDK1) that is phosphorylated at
   S214. With agonist stimulation, dopamine D2 receptor interacted with
   14-3-3 eta in GRK2/beta-arrestin2-dependent manner, resulting in the
   recruitment of PDK1. The PDK1 recruited to 14-3-3. was dephosphorylated
   at S241 and dissociated from PKC beta II, abrogating the phosphorylation
   of PKC beta II at T500. This signaling cascade resulted in the
   inhibition of PKC beta II functions, including its phosphorylation in
   the C-terminal tail, intracellular translocation, and kinase activity.
   Thus, this study revealed a novel and commonly applicable molecular
   mechanism involved in the inhibition of PKC beta II functions through
   GRK2/beta-arrestin2-mediated homologous pathway of GPCRs. The results
   obtained in this study could be expanded to other GPCRs and provide new
   strategies for the treatment of PKC beta II-related disorders.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Kim, KM (Corresponding Author), Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Gwang Ju 61186, South Korea.
   Zhang, Xiaohan; Min, Xiao; Zhu, Anlin; Kim, Kyeong-Man, Chonnam Natl Univ, Coll Pharm, Dept Pharmacol, Gwang Ju 61186, South Korea.},
DOI = {10.1016/j.bcp.2020.113791},
Article-Number = {113791},
ISSN = {0006-2952},
EISSN = {1873-2968},
Keywords = {PKC beta II; GRK2; beta-Arrestin2; 14-3-3; PDK1},
Keywords-Plus = {PROTEIN-KINASE-C; BETA-ADRENERGIC-RECEPTOR; PHOSPHOINOSITIDE-DEPENDENT
   KINASE; COUPLED RECEPTORS; D-3 RECEPTORS; PHOSPHORYLATION;
   DESENSITIZATION; BETA-ARRESTIN2; ACTIVATION; BINDING},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {kmkim@jnu.ac.kr},
Affiliations = {Chonnam National University},
ResearcherID-Numbers = {Kim, Kyeong-Man/AAA-9847-2020
   Zhang, Xiaohan/KBC-0720-2024},
ORCID-Numbers = {Kim, Kyeong-Man/0000-0002-8138-4135
   Zhang, Xiaohan/0000-0003-1531-3061},
Funding-Acknowledgement = { {[}KRF-2017R1A2A2A05001227]},
Funding-Text = {This work was funded by KRF-2017R1A2A2A05001227. We thank the Korea
   Basic Science Institute for their technical support.},
Cited-References = {Adler J, 2010, CYTOM PART A, V77A, P733, DOI 10.1002/cyto.a.20896.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8.
   Antal CE, 2015, CELL REP, V12, P1252, DOI 10.1016/j.celrep.2015.07.039.
   ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882.
   Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1.
   BENOVIC JL, 1985, J BIOL CHEM, V260, P7094.
   BENOVIC JL, 1989, SCIENCE, V246, P235, DOI 10.1126/science.2552582.
   Beom SR, 2004, J BIOL CHEM, V279, P28304, DOI 10.1074/jbc.M403899200.
   Bossenmaier B, 1997, DIABETOLOGIA, V40, P863, DOI 10.1007/s001250050761.
   Bunda S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08087-9.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Cho DI, 2010, ARCH PHARM RES, V33, P1521, DOI 10.1007/s12272-010-1005-8.
   Cho D, 2010, MOL ENDOCRINOL, V24, P574, DOI 10.1210/me.2009-0369.
   Cho EY, 2007, MOL ENDOCRINOL, V21, P2242, DOI 10.1210/me.2007-0202.
   CLEMENS MJ, 1992, J CELL SCI, V103, P881.
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7.
   Freeley M, 2011, CELL SIGNAL, V23, P753, DOI 10.1016/j.cellsig.2010.10.013.
   Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206.
   Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200.
   GIROS B, 1990, CR ACAD SCI III-VIE, V311, P501.
   Gómez-Suárez M, 2016, CELL DEATH DIFFER, V23, P1060, DOI 10.1038/cdd.2015.163.
   Greenham J, 1998, HUM GENET, V103, P483, DOI 10.1007/s004390050854.
   Guo Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022559.
   Huang JA, 2007, AM J PHYSIOL-GASTR L, V292, pG867, DOI 10.1152/ajpgi.00326.2006.
   INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059.
   Jeon YH, 2013, BBA-MOL CELL RES, V1833, P2135, DOI 10.1016/j.bbamcr.2013.05.005.
   Ji SP, 2003, FRONT BIOSCI, V8, pA34, DOI 10.2741/987.
   Kelly E, 2008, BRIT J PHARMACOL, V153, pS379, DOI 10.1038/sj.bjp.0707604.
   Kim KM, 2001, J BIOL CHEM, V276, P37409, DOI 10.1074/jbc.M106728200.
   KUNAPULI P, 1994, J BIOL CHEM, V269, P1099.
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042.
   LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110.
   Lorenz K, 2003, NATURE, V426, P574, DOI 10.1038/nature02158.
   Mancini M., 2011, PHARM EXP THER, V336.
   Min C, 2013, BRIT J PHARMACOL, V170, P1112, DOI 10.1111/bph.12357.
   Min X, 2019, BIOCHEM PHARMACOL, V170, DOI 10.1016/j.bcp.2019.113675.
   Mohammad DK, 2013, MOL CELL BIOL, V33, P3214, DOI 10.1128/MCB.00247-13.
   Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3.
   Namkung Y, 2009, J BIOL CHEM, V284, P34103, DOI 10.1074/jbc.M109.055707.
   Nava P, 2014, MOL BIOL CELL, V25, P2894, DOI 10.1091/mbc.E13-09-0512.
   Nelson CD, 2007, SCIENCE, V315, P663, DOI 10.1126/science.1134562.
   Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801.
   Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952.
   NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571.
   PEARSON RB, 1991, METHOD ENZYMOL, V200, P62.
   Sato S., 2002, J BIOL CHEM, V277.
   Schulze JO, 2016, CELL CHEM BIOL, V23, P1193, DOI 10.1016/j.chembiol.2016.06.017.
   Seong HA, 2014, CELL CYCLE, V13, P3357, DOI 10.4161/15384101.2014.952165.
   Seong HA, 2012, J BIOL CHEM, V287, P20811, DOI 10.1074/jbc.M111.331827.
   SIBLEY DR, 1984, BIOCHEM BIOPH RES CO, V121, P973, DOI 10.1016/0006-291X(84)90772-1.
   Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823.
   Wang CY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05449-1.
   Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x.
   Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105.
   Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0.
   Yang XL, 2003, WORLD J GASTROENTERO, V9, P800, DOI 10.3748/wjg.v9.i4.800.
   Yoshizaki H, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-546.
   Zhang XH, 2018, BBA-MOL CELL RES, V1865, P142, DOI 10.1016/j.bbamcr.2017.10.009.
   Zhang XH, 2017, BIOMOL THER, V25, P26, DOI 10.4062/biomolther.2016.186.
   Zhang XQ, 2008, J NEUROCHEM, V106, P781, DOI 10.1111/j.1471-4159.2008.05431.x.
   Zheng M, 2015, FEBS LETT, V589, P3929, DOI 10.1016/j.febslet.2015.10.031.
   Zheng M, 2016, BBA-MOL CELL RES, V1863, P77, DOI 10.1016/j.bbamcr.2015.10.007.
   Zheng M, 2011, MOL CELL BIOL, V31, P4887, DOI 10.1128/MCB.05690-11.},
Number-of-Cited-References = {64},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Biochem. Pharmacol.},
Doc-Delivery-Number = {LF3TK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000527342900017},
DA = {2026-02-04},
}

@article{ WOS:000522949300007,
Author = {Li, Min and Cheng, Jingmin and Ma, Yuan and Guo, Heng and Shu, Haifeng
   and Huang, Haidong and Kuang, Yongqin and Yang, Tao},
Title = {The histone demethylase JMJD2A promotes glioma cell growth via targeting
   Akt-mTOR signaling},
Journal = {CANCER CELL INTERNATIONAL},
Year = {2020},
Volume = {20},
Number = {1},
Month = {MAR 30},
Abstract = {Background A number of JmjC domain-containing histone demethylases have
   been identified and biochemically characterized in mammalian models and
   humans. JMJD2A is a transcriptional co-factor and enzyme that catalyzes
   the demethylation of histone H3 lysine 9 and 36 (H3K9 and H3K36). Here
   in this study, we reported the role of JMJD2A in human glioma. Methods
   Quantitative real-time PCR and western blot were performed to analyzed
   JMJD2A expression in glioma. Log-rank was performed to plot the survival
   curve. JMJD2A was knocked or overexpressed with lentivirus. Cell
   proliferation and colony formation were performed to assess the effects
   of JMJD2A on glioma cell growth. Xenograft experiment was performed the
   evaluate the growth rate of glioma cells in vivo. The signaling pathway
   was analyzed with western blot and mTOR was inhibited with rapamycin.
   Results Quantitative real-time PCR and western blot experiments revealed
   higher expression of JMJD2A and lower levels of H3K9me3/H3K36me3 in
   glioma tissues than that in normal brain tissues. We showed that
   knockdown of JMJD2A expression attenuated the growth and colony
   formation in three lines of glioma cells (U251, T98G, and U87MG),
   whereas JMJD2A overexpression resulted in opposing effects. Furthermore,
   we performed in vivo xenograft experiments and our data demonstrated
   that JMJD2A knockdown reduced the growth of glioma T98G cells in vivo.
   Further mechanism study implicated that JMJD2A activated the Akt-mTOR
   pathway and promoted protein synthesis in glioma cells via promoting
   phosphoinositide-dependent kinase-1 (PDK1) expression. The activation of
   the Akt-mTOR pathway was also validated in human glioma tissues.
   Finally, we showed that inhibition of mTOR with rapamycin blocked the
   effects of JMJD2A on protein synthesis, cell proliferation and colony
   formation of glioma cells. Conclusions These findings demonstrated that
   JMJD2A regulated glioma growth and implicated that JMJD2A might be a
   promising target for intervention.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, T (Corresponding Author), Gen Hosp Western Theater Command, Dept Neurosurg, 270 Rongdu Ave, Chengdu, Peoples R China.
   Li, Min; Cheng, Jingmin; Ma, Yuan; Guo, Heng; Shu, Haifeng; Huang, Haidong; Kuang, Yongqin; Yang, Tao, Gen Hosp Western Theater Command, Dept Neurosurg, 270 Rongdu Ave, Chengdu, Peoples R China.},
DOI = {10.1186/s12935-020-01177-z},
Article-Number = {101},
EISSN = {1475-2867},
Keywords = {JMJD2A; Glioma; mTOR; Rapamycin; PDK1},
Keywords-Plus = {MUTATIONS; METHYLATION; EXPRESSION; REPRESSION; APOPTOSIS; PROTEIN;
   MUTANT; GENES; H3.3},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {yang-tao@139.com},
ResearcherID-Numbers = {Huang, Haidong/MFH-1487-2025},
ORCID-Numbers = {li, min/0000-0003-3518-683X
   Yang, Tao/0000-0002-0422-2036
   },
Funding-Acknowledgement = {Innovation talent project of the General Hospital of Western Theater
   Command {[}41732C11R]},
Funding-Text = {This work was sponsored by the Innovation talent project of the General
   Hospital of Western Theater Command (No.41732C11R).},
Cited-References = {Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006.
   Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300.
   Berry WL, 2012, INT J ONCOL, V41, P1701, DOI 10.3892/ijo.2012.1618.
   Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426.
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051.
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006.
   Carbonneau M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12700.
   Chan KM, 2013, GENE DEV, V27, P985, DOI 10.1101/gad.217778.113.
   Couture JF, 2007, NAT STRUCT MOL BIOL, V14, P689, DOI 10.1038/nsmb1273.
   Dienstmann R, 2014, MOL CANCER THER, V13, P1021, DOI 10.1158/1535-7163.MCT-13-0639.
   Fontebasso AM, 2013, ACTA NEUROPATHOL, V125, P659, DOI 10.1007/s00401-013-1095-8.
   Gajjar A, 2015, J CLIN ONCOL, V33, P2986, DOI 10.1200/JCO.2014.59.9217.
   Gray SG, 2005, J BIOL CHEM, V280, P28507, DOI 10.1074/jbc.M413687200.
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008.
   Hu Y, 2019, J CLIN INVEST, V129, P3072, DOI 10.1172/JCI124979.
   Hütt-Cabezas M, 2013, NEURO-ONCOLOGY, V15, P1604, DOI 10.1093/neuonc/not132.
   Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758.
   Kim TD, 2012, J CELL BIOCHEM, V113, P1368, DOI 10.1002/jcb.24009.
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939.
   Kogure M, 2013, CANCER LETT, V336, P76, DOI 10.1016/j.canlet.2013.04.009.
   Lee K, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan0316.
   Li BX, 2013, INDIAN J EXP BIOL, V51, P208.
   Li BX, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-90.
   Li X, 2016, Oncotarget, V7.
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4.
   Mallette FA, 2012, CELL REP, V2, P1233, DOI 10.1016/j.celrep.2012.09.033.
   Mu WL, 2014, SCI CHINA LIFE SCI, V57, P915, DOI 10.1007/s11427-014-4687-1.
   Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015.
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI {[}10.1038/nature10833, 10.1007/s13311-012-0137-6].
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024.
   Teissandier A, 2017, EMBO J, V36, P1471, DOI 10.15252/embj.201796812.
   Van Rechem C, 2015, CANCER DISCOV, V5, P255, DOI 10.1158/2159-8290.CD-14-1326.
   Wang LY, 2016, CELL REP, V16, P3016, DOI 10.1016/j.celrep.2016.08.018.
   Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102.
   Zhang DZ, 2005, MOL CELL BIOL, V25, P6404, DOI 10.1128/MCB.25.15.6404-6414.2005.},
Number-of-Cited-References = {35},
Times-Cited = {18},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Cancer Cell Int.},
Doc-Delivery-Number = {KZ0FY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000522949300007},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000524502100014,
Author = {Sriskandarajah, Priya and De Haven Brandon, Alexis and MacLeod, Kenneth
   and Carragher, Neil O. and Kirkin, Vladimir and Kaiser, Martin and
   Whittaker, Steven R.},
Title = {Combined targeting of MEK and the glucocorticoid receptor for the
   treatment of RAS-mutant multiple myeloma},
Journal = {BMC CANCER},
Year = {2020},
Volume = {20},
Number = {1},
Month = {MAR 30},
Abstract = {BackgroundMultiple myeloma (MM) remains incurable despite recent
   therapeutic advances. RAS mutations are frequently associated with
   relapsed/refractory disease. Efforts to target the mitogen-activated
   protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra)
   have been limited by toxicities and the development of resistance.
   Dexamethasone (Dex) is a corticosteroid commonly used in clinical
   practice, to enhance efficacy of anti-myeloma therapy. Therefore, we
   hypothesised that the combination of Tra and Dex would yield synergistic
   activity in RAS-mutant MM.MethodsThe response of human MM cell lines to
   drug treatment was analysed using cell proliferation assays, Western
   blotting, Annexin V and propidium iodide staining by flow cytometry and
   reverse phase protein arrays. The efficacy of trametinib and
   dexamethasone treatment in the MM.1S xenograft model was assessed by
   measuring tumor volume over time.ResultsThe Tra/Dex combination
   demonstrated synergistic cytotoxicity in KRAS(G12A) mutant lines MM.1S
   and RPMI-8226. The induction of apoptosis was associated with decreased
   MCL-1 expression and increased BIM expression. Reverse phase proteomic
   arrays revealed suppression of FAK, PYK2, FLT3, NDRG1 and 4EBP1
   phosphorylation with the Tra/Dex combination. Notably, NDRG1 expression
   was associated with the synergistic response to Tra/Dex. MM cells were
   sensitive to PDK1 inhibition and IGF1-induced signalling partially
   protected from Tra/Dex treatment, highlighting the importance of this
   pathway. In the MM.1S tumor xenograft model, only the combination of
   Tra/Dex resulted in a significant inhibition of tumor
   growth.ConclusionsOverall Tra/Dex demonstrates antiproliferative
   activity in RAS-mutant MM cell lines associated with suppression of
   pro-survival PDK1 signalling and engagement of apoptotic pathways. Our
   data support further investigation of this combination in RAS-mutant MM.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Whittaker, SR (Corresponding Author), Inst Canc Res, Div Canc Therapeut, London SW7 3RP, England.
   Sriskandarajah, Priya; De Haven Brandon, Alexis; Kirkin, Vladimir; Whittaker, Steven R., Inst Canc Res, Div Canc Therapeut, London SW7 3RP, England.
   Sriskandarajah, Priya; Kaiser, Martin, Royal Marsden NHS Fdn Trust, London, England.
   MacLeod, Kenneth; Carragher, Neil O., Univ Edinburgh, Inst Genet \& Mol Med, Canc Res UK Edinburgh Ctr, Edinburgh, Midlothian, Scotland.
   Kaiser, Martin, Inst Canc Res, Div Mol Pathol, London, England.},
DOI = {10.1186/s12885-020-06735-2},
EISSN = {1471-2407},
Keywords = {Multiple myeloma; Trametinib; Dexamethasone; Apoptosis; RAS},
Keywords-Plus = {CELL-LINES; PROTEIN-KINASE; RESISTANCE; COMBINATION; GROWTH; APOPTOSIS;
   MODEL; LENALIDOMIDE; POMALIDOMIDE; ACTIVATION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {steven.whittaker@icr.ac.uk},
Affiliations = {Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of
   Edinburgh; Royal Marsden NHS Foundation Trust; University of London;
   Institute of Cancer Research - UK},
ResearcherID-Numbers = {MacLeod, Kenneth/GWU-8940-2022
   Kaiser, Martin/LTD-2019-2024
   Whittaker, Steven/AAS-9874-2020
   Sriskandarajah, Priya/IXW-6754-2023},
ORCID-Numbers = {Kaiser, Martin/0000-0002-3677-4804
   Carragher, Neil/0000-0001-5541-9747
   Whittaker, Steven/0000-0001-9062-7947
   Sriskandarajah, Priya/0000-0003-4178-8909},
Funding-Acknowledgement = {Cancer Research UK-Institute of Cancer Research Clinical Research
   Fellowship; The Institute of Cancer Research; Betty Lawes Foundation;
   Jacquelin Forbes-Nixon Fellowship; MRC {[}MC\_PC\_13062] Funding Source:
   UKRI; Medical Research Council {[}MC\_PC\_13062] Funding Source:
   researchfish},
Funding-Text = {This work was funded by a Cancer Research UK-Institute of Cancer
   Research Clinical Research Fellowship to P. Sriskandarajah, start-up
   funds from The Institute of Cancer Research to S.R. Whittaker and by the
   Betty Lawes Foundation. M. Kaiser was supported by a Jacquelin
   Forbes-Nixon Fellowship.},
Cited-References = {Abe H, 2011, ACS MED CHEM LETT, V2, P320, DOI 10.1021/ml200004g.
   Alberobello AT, 2010, J BIOL CHEM, V285, P6563, DOI 10.1074/jbc.M109.097410.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   {[}Anonymous], SEMIN CANC BIOL.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Chenard-Poirier M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15\_suppl.2506.
   Chiron D, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.18.
   Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x.
   Fok JHL, 2018, CLIN CANC RES.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   Garza AS, 2009, LEUKEMIA RES, V33, P717, DOI 10.1016/j.leukres.2008.10.006.
   Genty V, 2004, LEUKEMIA RES, V28, P307, DOI 10.1016/j.leukres.2003.08.009.
   Greenstein S, 2003, EXP HEMATOL, V31, P271, DOI 10.1016/S0301-472X(03)00023-7.
   Heuck CJ, 2016, LEUKEMIA, V30, P976, DOI 10.1038/leu.2015.208.
   Hideshima T, 2001, CANCER RES, V61, P3071.
   Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423.
   Kortüm KM, 2016, BLOOD, V128, P1226, DOI 10.1182/blood-2016-02-698092.
   Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005.
   Leow CCY, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.1.
   Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015.
   Macleod KG, 2017, METHODS MOL BIOL, V1647, P153, DOI 10.1007/978-1-4939-7201-2\_10.
   McFarland JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06916-5.
   Meyers RM, 2017, NAT GENET, V49, P1779, DOI {[}10.1101/160861, 10.1038/ng.3984].
   Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984.
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257.
   Murray JT, 2004, BIOCHEM J, V384, P477, DOI 10.1042/BJ20041057.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Ocio EM, 2015, LEUKEMIA, V29, P705, DOI 10.1038/leu.2014.238.
   Polak A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155893.
   Qiang YW, 2002, BLOOD, V99, P4138, DOI 10.1182/blood.V99.11.4138.
   Rambal AA, 2009, LEUKEMIA, V23, P1744, DOI 10.1038/leu.2009.80.
   Rees-Unwin KS, 2007, BRIT J HAEMATOL, V139, P559, DOI 10.1111/j.1365-2141.2007.06837.x.
   Robert F, 2014, P NATL ACAD SCI USA, V111, P13421, DOI 10.1073/pnas.1402650111.
   Rychak E, 2016, BRIT J HAEMATOL, V172, P889, DOI 10.1111/bjh.13905.
   Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281.
   Schueler J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079939.
   Sharma S, 2008, BLOOD, V112, P1338, DOI 10.1182/blood-2007-11-124156.
   Stein S, 2004, J BIOL CHEM, V279, P48930, DOI 10.1074/jbc.M400386200.
   Talarico C, 2016, CELL PHYSIOL BIOCHEM, V39, P1863, DOI 10.1159/000447885.
   Tolcher AW, 2015, CANCER CHEMOTH PHARM, V75, P183, DOI 10.1007/s00280-014-2615-5.
   Ummanni R, 2014, BBA-PROTEINS PROTEOM, V1844, P950, DOI 10.1016/j.bbapap.2013.11.017.
   Wagner S, 2018, ONCOGENE.
   Welsh SJ, 2015, THER ADV MED ONCOL, V7, P122, DOI 10.1177/1758834014566428.
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642.
   Wuillème-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784.
   Yang CM, 2017, ONCOTARGET, V8, P39185, DOI 10.18632/oncotarget.16642.
   Yang W.C., 2015, BioMed Research International, V2015, P1, DOI DOI 10.1016/J.PEDNE0.2015.02.001.
   Zhang J, 2008, GENE, V417, P5, DOI 10.1016/j.gene.2008.03.002.
   Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867.},
Number-of-Cited-References = {50},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {BMC Cancer},
Doc-Delivery-Number = {LB2XT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000524502100014},
OA = {Green Submitted, Green Published, gold},
DA = {2026-02-04},
}

@article{ WOS:000524517700009,
Author = {Jia-yuan, Xu and Wei, Song and Fang-fang, Lu and Zhi-jian, Dai and
   Long-he, Cao and Sen, Lin},
Title = {miR-375 Inhibits the Proliferation and Invasion of Nasopharyngeal
   Carcinoma Cells by Suppressing PDK1},
Journal = {BIOMED RESEARCH INTERNATIONAL},
Year = {2020},
Volume = {2020},
Month = {MAR 23},
Abstract = {Purpose. In patients with nasopharyngeal carcinoma (NPC), the expression
   of PDK1 is remarkably improved in NPC tissue and correlated with the
   clinicopathological severity of NPC. We expressed miR-375 in NPC cells
   to study the effects on PDK1 gene expression. We also investigated the
   mechanism by which miR-375 affects the biological behavior of NPC cells
   through effects on PDK1. Methods. qRT-PCR was carried out to analyze
   miR-375 and PDK1 levels in NPC cells. NPC cells were transfected with
   miR-375 inhibitor or miR-375 mimic. CCK-8 testing, colony formation
   testing, transwell testing, and flow cytometry analysis were carried out
   to quantify the cells' biological behavior. Rescue experiments
   demonstrated that the recovery of PDK1 expression was able to reverse
   the influence of miR-375 inhibition on NPC diffusion and intrusion. The
   interaction between miR-375 and PDK1 was verified by dual-luciferase
   reporter gene testing. Results. The results revealed that miR-375 has a
   negative regulatory effect on PDK1 expression in NPC cells. Furthermore,
   PDK1 is a target gene for miR-375. The empirical results obtained
   demonstrated a negative correlation between tumor development and the
   level of miR-375 expression in NPC tissues. The excessive expression of
   miR-375 and the downregulation of PDK1 facilitated the diffusion and
   invasion of NPC cells. Conclusion. The diffusion and incursion of NPC
   cells may be inhibited by direct targeting of PDK1 and decreasing the
   expression of miR-375. Our study highlights efforts to target PDK1 and
   miR-375 as potential therapeutic strategies for use in the treatment of
   NPC.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Sen, L (Corresponding Author), Wenzhou Med Univ, Affiliated Hosp 3, Dept Otolaryngol, Ruian, Zhejiang, Peoples R China.
   Jia-yuan, Xu; Wei, Song; Fang-fang, Lu; Zhi-jian, Dai; Long-he, Cao; Sen, Lin, Wenzhou Med Univ, Affiliated Hosp 3, Dept Otolaryngol, Ruian, Zhejiang, Peoples R China.},
DOI = {10.1155/2020/9704245},
Article-Number = {9704245},
ISSN = {2314-6133},
EISSN = {2314-6141},
Keywords-Plus = {MICRORNA-375},
Research-Areas = {Biotechnology \& Applied Microbiology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Medicine, Research \&
   Experimental},
Author-Email = {shellyjiayuan@163.com
   szy100034295@163.com
   963081008@qq.com
   wsjjzj@163.com
   clh991329@126.com
   lnns@163.com},
Affiliations = {Wenzhou Medical University},
ORCID-Numbers = {Lin, Sen/0000-0002-1175-0232},
Cited-References = {Cai CF, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0769-4.
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338.
   Deng Q, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.324.
   Dharmawardana N, 2019, CLIN EXP METASTAS, V36, P291, DOI 10.1007/s10585-019-09961-6.
   Gong CW, 2016, EXP BIOL MED, V241, P387, DOI 10.1177/1535370215609694.
   Guo Y, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0507-6.
   Harris T, 2012, AM J PATHOL, V180, P917, DOI 10.1016/j.ajpath.2011.12.004.
   Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347.
   Li XL, 2011, DIGEST DIS SCI, V56, P2849, DOI 10.1007/s10620-011-1711-1.
   Lu J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0814-3.
   Peng H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196730.
   Razak ARA, 2010, EUR J CANCER, V46, P1967, DOI 10.1016/j.ejca.2010.04.004.
   Romeo P, 2018, ENDOCR-RELAT CANCER, V25, P217, DOI 10.1530/ERC-17-0389.
   Sabarimurugan S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209760.
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777.
   Wang C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.18.
   Wee LM, 2012, CELL, V151, P1055, DOI 10.1016/j.cell.2012.10.036.
   Xiang GZ, 2016, PATHOL RES PRACT, V212, P1102, DOI 10.1016/j.prp.2016.10.006.
   Yan JW, 2014, INT J CANCER, V135, P1011, DOI 10.1002/ijc.28563.
   Yi JL, 2006, INT J RADIAT ONCOL, V65, P161, DOI 10.1016/j.ijrobp.2005.12.003.
   Zhang B, 2017, CELL PHYSIOL BIOCHEM, V42, P2105, DOI 10.1159/000479913.
   Zhang X, 2018, CHINESE MED J-PEKING, V131, P1944, DOI 10.4103/0366-6999.238153.},
Number-of-Cited-References = {22},
Times-Cited = {16},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Biomed Res. Int.},
Doc-Delivery-Number = {LB3DI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000524517700009},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000524183100001,
Author = {Feng, Xing and Zhang, Heng and Meng, Lingbing and Song, Huiwen and Zhou,
   Qingxin and Qu, Chao and Zhao, Pan and Li, Qinghua and Zou, Chang and
   Liu, Xing and Zhang, Zhiyong},
Title = {Hypoxia-induced acetylation of PAK1 enhances autophagy and promotes
   brain tumorigenesis via phosphorylating ATG5},
Journal = {AUTOPHAGY},
Year = {2021},
Volume = {17},
Number = {3},
Pages = {723-742},
Month = {MAR 4},
Abstract = {Although the treatment of brain tumors by targeting kinase-regulated
   macroautophagy/autophagy, is under investigation, the precise mechanism
   underlying autophagy initiation and its significance in glioblastoma
   (GBM) remains to be defined. Here, we report that PAK1 (p21 {[}RAC1]
   activated kinase 1) is significantly upregulated and promotes GBM
   development. The Cancer Genome Atlas analysis suggests that the
   oncogenic role of PAK1 in GBM is mainly associated with autophagy.
   Subsequent experiments demonstrate that PAK1 indeed serves as a positive
   modulator for hypoxia-induced autophagy in GBM. Mechanistically, hypoxia
   induces ELP3-mediated PAK1 acetylation at K420, which suppresses the
   dimerization of PAK1 and enhances its activity, thereby leading to
   subsequent PAK1-mediated ATG5 (autophagy related 5) phosphorylation at
   the T101 residue. This event not only protects ATG5 from
   ubiquitination-dependent degradation but also increases the affinity
   between the ATG12-ATG5 complex and ATG16L1 (autophagy related 16 like
   1). Consequently, ELP3-dependent PAK1 (K420) acetylation and
   PAK1-mediated ATG5 (T101) phosphorylation are required for
   hypoxia-induced autophagy and brain tumorigenesis by promoting
   autophagosome formation. Silencing PAK1 with shRNA or small molecule
   inhibitor FRAX597 potentially blocks autophagy and GBM growth.
   Furthermore, SIRT1-mediated PAK1-deacetylation at K420 hinders autophagy
   and GBM growth. Clinically, the levels of PAK1 (K420) acetylation
   significantly correlate with the expression of ATG5 (T101)
   phosphorylation in GBM patients. Together, this report uncovers that the
   acetylation modification and kinase activity of PAK1 plays an
   instrumental role in hypoxia-induced autophagy initiation and
   maintaining GBM growth. Therefore, PAK1 and its regulator in the
   autophagy pathway might represent potential therapeutic targets for GBM
   treatment.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, ZY (Corresponding Author), Guilin Med Univ, Guangxi Neurol Dis Clin Res Ctr, Guangxi Key Lab Brain \& Cognit Neurosci, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
   Zou, C (Corresponding Author), Jinan Univ, Southern Univ Sci \& Technol, Shenzhen Peoples Hosp, Clin Med Res Ctr,Affiliated Hosp 1,Clin Med Coll, Shenzhen, Peoples R China.
   Zou, C (Corresponding Author), Jinan Univ, Shenzhen Peoples Hosp, Shenzhen Publ Serv Platform Tumor Precis Med \& Mo, Clin Med Coll 2, Shenzhen, Peoples R China.
   Li, QH (Corresponding Author), Guilin Med Univ, Dept Neurol, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
   Liu, X (Corresponding Author), Beijing Neurosurg Inst, Beijing, Peoples R China.
   Zhang, ZY (Corresponding Author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Surg, Univ Hosp, New Brunswick, NJ 08854 USA.
   Feng, Xing; Zhang, Zhiyong, Guilin Med Univ, Guangxi Neurol Dis Clin Res Ctr, Guangxi Key Lab Brain \& Cognit Neurosci, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
   Feng, Xing, Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA.
   Zhang, Heng, Cent South Univ, Xiang Ya Sch Med, Dept Histol \& Embryol, Changsha, Peoples R China.
   Meng, Lingbing, Beijing Hosp, Natl Ctr Gerontol, Neurol Dept, Beijing, Peoples R China.
   Song, Huiwen, Shanghai Univ Med \& Hlth Sci, Dept Cardiol, Jiading Dist Cent Hosp, Shanghai, Peoples R China.
   Zhou, Qingxin, Harbin Med Univ, Dept Oncol, Affiliated Hosp 3, Harbin, Peoples R China.
   Zhou, Qingxin, Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ USA.
   Qu, Chao, First Hosp Jilin Univ, Dept Radiat Oncol, Changchun, Peoples R China.
   Zhao, Pan; Zou, Chang, Jinan Univ, Southern Univ Sci \& Technol, Shenzhen Peoples Hosp, Clin Med Res Ctr,Affiliated Hosp 1,Clin Med Coll, Shenzhen, Peoples R China.
   Zhao, Pan; Zou, Chang, Jinan Univ, Shenzhen Peoples Hosp, Shenzhen Publ Serv Platform Tumor Precis Med \& Mo, Clin Med Coll 2, Shenzhen, Peoples R China.
   Li, Qinghua, Guilin Med Univ, Dept Neurol, Affiliated Hosp, Guilin, Guangxi, Peoples R China.
   Liu, Xing, Beijing Neurosurg Inst, Beijing, Peoples R China.
   Zhang, Zhiyong, Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Surg, Univ Hosp, New Brunswick, NJ 08854 USA.},
DOI = {10.1080/15548627.2020.1731266},
EarlyAccessDate = {MAR 2020},
ISSN = {1554-8627},
EISSN = {1554-8635},
Keywords = {Acetylation; ATG5; dimerization; ELP3; glioblastoma; PAK1;
   phosphorylation; SIRT1; ubiquitination},
Keywords-Plus = {KINASE; CANCER; ACETYLTRANSFERASE; ACTIVATION; APOPTOSIS; PROTEINS;
   HISTONE},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {qhli1999@163.com
   15846591696@126.com
   zhangz2@rwjms.rutgers.edu},
Affiliations = {Guilin Medical University; Yale University; Central South University;
   Beijing Hospital; Shanghai University of Medicine \& Health Sciences;
   Harbin Medical University; Rutgers University System; Rutgers University
   New Brunswick; Rutgers University Biomedical \& Health Sciences; Rutgers
   Cancer Institute of New Jersey; Jilin University; Jinan University;
   Southern University of Science \& Technology; Jinan University; Guilin
   Medical University; Beijing Neurosurgical Institute; Rutgers University
   System; Rutgers University New Brunswick; Rutgers University Biomedical
   \& Health Sciences},
ResearcherID-Numbers = {Zou, Chang/AAS-3356-2021
   },
ORCID-Numbers = {Li, Qinghua/0000-0002-4547-8513
   zhang, zhiyong/0000-0003-4061-7374
   Feng, Xing/0000-0002-2253-4180
   Zou, Chang/0000-0002-2003-7834
   ZHANG, ZHIYONG/0000-0001-8576-1607
   feng, xing/0000-0001-8226-3389},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81560582, 81702387];
   Natural Science Foundation of Guangxi {[}2016GXNSFAA380324]; Science and
   Technology Foundation of Shenzhen {[}JCYJ20170412155231633,
   JCYJ20180305164128430]; Shenzhen Economic and Information Committee
   ``Innovation Chain and Industry Chain{''} integration special support
   plan project {[}20180225112449943]; Shenzhen Public Service Platform on
   Tumor Precision Medicine and Molecular Diagnosis; Shenzhen Cell Therapy
   Public Service Platform; Shanghai Research Project {[}18ZR1432400];
   Shanghai University of Medicine\&Health Sciences Seed Fund
   {[}SFP-18-21-16-001, SFP-18-20-16-006]},
Funding-Text = {This work was supported by grants from National Natural Science
   Foundation of China (81560582, and 81702387), Natural Science Foundation
   of Guangxi (2016GXNSFAA380324), The Science and Technology Foundation of
   Shenzhen (JCYJ20170412155231633, JCYJ20180305164128430), the Shenzhen
   Economic and Information Committee ``Innovation Chain and Industry
   Chain{''} integration special support plan project (20180225112449943),
   the Shenzhen Public Service Platform on Tumor Precision Medicine and
   Molecular Diagnosis, the Shenzhen Cell Therapy Public Service Platform.
   Shanghai Research Project(18ZR1432400), Shanghai University of
   Medicine\&Health Sciences Seed Fund (SFP-18-21-16-001,
   SFP-18-20-16-006).},
Cited-References = {Bhat KPL, 2013, CANCER CELL, V24, P331, DOI 10.1016/j.ccr.2013.08.001.
   Cinti A, 2016, MBIO, V7, DOI 10.1128/mBio.00329-16.
   Coles LC, 2002, ONCOGENE, V21, P2236, DOI 10.1038/sj.onc.1205302.
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887.
   Feng X, 2019, AUTOPHAGY, V15, P1130, DOI 10.1080/15548627.2019.1570063.
   Fletcher K, 2018, EMBO J, V37, DOI 10.15252/embj.201797840.
   Guan KL, 2010, NAT PROTOC, V5, P1583, DOI 10.1038/nprot.2010.117.
   Hong XH, 2018, ELIFE, V7, DOI 10.7554/eLife.29511.
   Hong XH, 2014, GUT, V63, P1635, DOI 10.1136/gutjnl-2013-305302.
   Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820.
   Jacobs T, 2007, J NEUROSCI, V27, P8604, DOI 10.1523/JNEUROSCI.0765-07.2007.
   Jacquin S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131940.
   Keil E, 2013, CELL DEATH DIFFER, V20, P321, DOI 10.1038/cdd.2012.129.
   Köenig A, 2010, GASTROENTEROLOGY, V138, P1189, DOI 10.1053/j.gastro.2009.10.045.
   Kumar D, 2010, CELL, V140, P731, DOI 10.1016/j.cell.2010.02.012.
   Licciulli S, 2013, J BIOL CHEM, V288, P29105, DOI 10.1074/jbc.M113.510933.
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254.
   Mayhew MW, 2007, J CELL SCI, V120, P3911, DOI 10.1242/jcs.008177.
   Otomo C, 2013, NAT STRUCT MOL BIOL, V20, P59, DOI 10.1038/nsmb.2431.
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x.
   Papakonstanti EA, 2002, MOL BIOL CELL, V13, P2946, DOI 10.1091/mbc.02-01-0599.
   Parvathy M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2263-8.
   Poux AN, 2003, BIOCHEMISTRY-US, V42, P14366, DOI 10.1021/bi035632n.
   Qian X, 2017, MOL CELL, V65, P917, DOI 10.1016/j.molcel.2017.01.027.
   Qu C, 2016, J HEPATOL, V64, P1076, DOI 10.1016/j.jhep.2016.01.005.
   Rai S, 2019, AUTOPHAGY, V15, P599, DOI 10.1080/15548627.2018.1534507.
   Romanov J, 2012, EMBO J, V31, P4304, DOI 10.1038/emboj.2012.278.
   Shin YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071495.
   Shin YJ, 2013, MOL BIOL CELL, V24, P2990, DOI 10.1091/mbc.E13-04-0204.
   Song HW, 2018, AUTOPHAGY, V14, P825, DOI 10.1080/15548627.2017.1389357.
   Song HW, 2015, AUTOPHAGY, V11, P1308, DOI 10.1080/15548627.2015.1060386.
   Stilger KL, 2013, J BIOL CHEM, V288, P25318, DOI 10.1074/jbc.M113.491373.
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35.
   Wesselborg S, 2015, CELL MOL LIFE SCI, V72, P4721, DOI 10.1007/s00018-015-2034-8.
   Xiao Aizhen, 2019, Oncotarget, V10, P1716, DOI {[}10.18632/oncotarget.26733, 10.18632/oncotarget.26733].
   Xie YC, 2015, AUTOPHAGY, V11, P28, DOI 10.4161/15548627.2014.984267.
   Zhang YJ, 2018, MOL CELL, V71, P201, DOI 10.1016/j.molcel.2018.06.023.
   Zhu YK, 2019, CELL DEATH DIFFER, V26, P306, DOI 10.1038/s41418-018-0119-2.},
Number-of-Cited-References = {38},
Times-Cited = {134},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {60},
Journal-ISO = {Autophagy},
Doc-Delivery-Number = {RJ0QV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000524183100001},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000520018100001,
Author = {Zhang, Hao and Tian, Yikui and Jiang, Degang and Fu, Qiang and Jia,
   Liqun and Wu, Dawei and Zhu, Xinyuan},
Title = {The Effects of Inhibition of MicroRNA-375 in a Mouse Model of
   Doxorubicin-Induced Cardiac Toxicity},
Journal = {MEDICAL SCIENCE MONITOR},
Year = {2020},
Volume = {26},
Month = {MAR 18},
Abstract = {Background: Doxorubicin-induced myocardial toxicity is associated with
   oxidative stress, cardiomyocyte, apoptosis, and loss of contractile
   function. Previous studies showed that microRNA-375 (miR-375) expression
   was increased in mouse models of heart failure and clinically, and that
   inhibition of miR-375 reduced inflammation and increased survival of
   cardiomyocytes. This study aimed to investigate the effects and
   mechanisms of inhibition of miR-375 in a mouse model of
   doxorubicin-induced cardiac toxicity in vivo and in doxorubicin-treated
   rat and mouse cardiomyocytes in vitro.
   Material/Methods: The mouse model of doxorubicin-induced cardiac
   toxicity was developed using an intraperitoneal injection of doxorubicin
   (15 mg/kg diluted in 0.9\% saline) for eight days. Treatment was
   followed by a single subcutane-ous injection of miR-375 inhibitor. H9c2
   rat cardiac myocytes and adult murine cardiomyocytes (AMCs) were
   cultured in vitro and treated with doxorubicin, with and without
   pretreatment with miR-375 inhibitor.
   Results: Doxorubicin significantly upregulated miR-375 expression in
   vitro and in vivo, and inhibition of miR-375 re- established myocardial
   redox homeostasis, prevented doxorubicin-induced oxidative stress and
   cardiomyocyte apoptosis, and activated the PDK1/AKT axis by reducing the
   direct binding of miR-375 to 3' UTR of the PDK1 gene. Inhibition of PDK1
   and AKT abolished the protective role of miR-375 inhibition on
   doxorubicin-induced oxidative damage.
   Conclusions: Inhibition of miR-375 prevented oxidative damage in a mouse
   model of doxorubicin-induced cardiac toxicity in vivo and in
   doxorubicin-treated rat and mouse cardiomyocytes in vitro through the
   PDK1/AKT signaling pathway.},
Publisher = {INT SCIENTIFIC INFORMATION, INC},
Address = {150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhu, XY (Corresponding Author), Tianjin Med Univ Gen Hosp, Dept Cardiovasc Surg, Tianjin, Peoples R China.
   Zhang, Hao; Tian, Yikui; Jiang, Degang; Fu, Qiang; Jia, Liqun; Wu, Dawei; Zhu, Xinyuan, Tianjin Med Univ Gen Hosp, Dept Cardiovasc Surg, Tianjin, Peoples R China.},
DOI = {10.12659/MSM.920557},
Article-Number = {e920557},
EISSN = {1643-3750},
Keywords = {Apoptosis; Doxorubicin; Oxidative Stress},
Keywords-Plus = {INDUCED CARDIOTOXICITY; CARDIOMYOCYTE APOPTOSIS; OXIDATIVE STRESS;
   CELL-DEATH; ADRIAMYCIN; PROTECTS; DAMAGE; HEART},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {zxytmu@163.com},
Affiliations = {Tianjin Medical University},
ResearcherID-Numbers = {Wu, Dawei/J-5981-2017
   jia, liqun/HNR-4156-2023
   Tian, Yikui/U-2247-2018},
Cited-References = {Afonso MB, 2018, CELL DEATH DIFFER, V25, P857, DOI 10.1038/s41418-017-0019-x.
   Chaiswing L, 2004, TOXICOL PATHOL, V32, P536, DOI 10.1080/01926230490502601.
   Deshwal S, 2018, CELL DEATH DIFFER, V25, P1518, DOI 10.1038/s41418-018-0071-1.
   Efentakis P, 2019, CARDIOVASC RES.
   Feng HJ, 2019, J CELL PHYSIOL, V234, P14198, DOI 10.1002/jcp.28116.
   Fomison-Nurse I, 2018, CELL DEATH DIFFER, V25, P1336, DOI 10.1038/s41418-017-0047-6.
   Gabisonia K, 2019, NATURE, V569, P418, DOI 10.1038/s41586-019-1191-6.
   Ganjam GK, 2018, CELL DEATH DIFFER, V25, P1394, DOI 10.1038/s41418-017-0046-7.
   Garikipati VNS, 2017, CARDIOVASC RES, V113, P938, DOI 10.1093/cvr/cvx052.
   GOORMAGHTIGH E, 1980, BIOCHEM PHARMACOL, V29, P3003, DOI 10.1016/0006-2952(80)90050-7.
   Guo R, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0727-2.
   Hu C, 2019, ACTA PHARM SIN B, V9, P690, DOI 10.1016/j.apsb.2019.03.003.
   Jeong SH, 2018, J CLIN INVEST, V128, P1010, DOI 10.1172/JCI95802.
   Jiao QB, 2012, CELL CALCIUM, V51, P31, DOI 10.1016/j.ceca.2011.10.003.
   Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178.
   Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200.
   Li X, 2019, ACTA PHARM SIN B, V9, P639, DOI 10.1016/j.apsb.2018.12.002.
   Luo MY, 2018, CELL DEATH DIFFER, V25, P1457, DOI 10.1038/s41418-017-0053-8.
   Mughal W, 2018, CELL DEATH DIFFER, V25, P1732, DOI 10.1038/s41418-018-0073-z.
   MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547.
   Nezami BG, 2014, GASTROENTEROLOGY, V146, P473, DOI 10.1053/j.gastro.2013.10.053.
   Prola A, 2017, CELL DEATH DIFFER, V24, P343, DOI 10.1038/cdd.2016.138.
   Sarikhani M, 2018, CELL DEATH DIFFER, V25, P1638, DOI 10.1038/s41418-018-0069-8.
   SILBER JH, 1995, NEW ENGL J MED, V333, P1359.
   Tai Y, 2018, ACTA PHARM SIN B, V8, P909, DOI 10.1016/j.apsb.2018.07.010.
   VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e.
   VONHOFF DD, 1979, ANN INTERN MED, V91, P710, DOI 10.7326/0003-4819-91-5-710.
   Wang KK, 2018, ACTA PHARM SIN B, V8, P795, DOI 10.1016/j.apsb.2018.06.003.
   Wang XD, 2018, CELL DEATH DIFFER, V25, P2181, DOI 10.1038/s41418-018-0109-4.
   Wang XH, 2018, CELL DEATH DIFFER, V25, P966, DOI 10.1038/s41418-017-0036-9.
   Zhang M, 2015, J AM COLL CARDIOL, V66, P261, DOI 10.1016/j.jacc.2015.05.020.
   Zhang Q, 2018, ACTA PHARM SIN B, V8, P449, DOI 10.1016/j.apsb.2017.12.006.
   Zhang TT, 2018, ACTA PHARM SIN B, V8, P440, DOI 10.1016/j.apsb.2018.03.004.
   Zhang X, 2020, CELL DEATH DIFFER, V27, P540, DOI 10.1038/s41418-019-0372-z.
   Zhang X, 2019, INT J BIOL SCI, V15, P556, DOI 10.7150/ijbs.29907.
   Zhang X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0123-3.
   Zhao LS, 2018, REDOX BIOL, V16, P189, DOI 10.1016/j.redox.2018.02.026.
   Zhao LS, 2018, REDOX BIOL, V15, P284, DOI 10.1016/j.redox.2017.12.013.},
Number-of-Cited-References = {38},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {21},
Journal-ISO = {Med. Sci. Monitor},
Doc-Delivery-Number = {KU9CA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000520018100001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000526786900027,
Author = {Kim, Hwee-Jin and Cho, Hyun-Soo and Ban, Hyun Seung and Nakamura,
   Hiroyuki},
Title = {Suppression of HIF-1α accumulation by betulinic acid through proteasome
   activation in hypoxic cervical cancer},
Journal = {BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS},
Year = {2020},
Volume = {523},
Number = {3},
Pages = {726-732},
Month = {MAR 12},
Abstract = {Betulinic acid (BA) exhibits various biological activities such as
   anti-bacterial, anti-inflammatory, antihuman papilloma virus (HPV), and
   anti-cancer activities. HPV infection is associated with a high risk of
   cervical cancer, which is the leading cause of deaths among women
   worldwide. Therefore, BA is an attractive therapeutic agent for treating
   cervical cancer. In this study, we investigated the role of BA in
   regulating the hypoxia-mediated response in HeLa cells and clarified the
   underlying mechanism of action. We found that BA inhibited the
   hypoxia-induced accumulation of HIF-1 alpha without affecting HIF-1
   alpha mRNA levels and suppressed the expression of HIF target genes,
   including VEGF, GLUT1, and PDK1 in HeLa cells. Additionally, BA enhanced
   the 131,132, and 135 activities of the proteasome, which resulted in
   reduced levels of ubiquitinated proteins and HIF-1 alpha protein in HeLa
   cells. However, BA treatment did not affect the deubiquitinase enzyme
   activity in HeLa cells. These results indicate that inhibition of HIF-1
   alpha accumulation by BA is mediated by activation of the proteasome,
   and BA is a potential anticancer agent for the regulation of the HIF
   signaling pathway. (C) 2020 Elsevier Inc. All rights reserved.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Ban, HS (Corresponding Author), Korea Res Inst Biosci \& Biotechnol, Daejeon 34141, South Korea.
   Nakamura, H (Corresponding Author), Tokyo Inst Technol, Inst Innovat Res, Lab Chem \& Life Sci, Yokohama, Kanagawa 2268503, Japan.
   Kim, Hwee-Jin; Cho, Hyun-Soo; Ban, Hyun Seung, Korea Res Inst Biosci \& Biotechnol, Daejeon 34141, South Korea.
   Nakamura, Hiroyuki, Tokyo Inst Technol, Inst Innovat Res, Lab Chem \& Life Sci, Yokohama, Kanagawa 2268503, Japan.},
DOI = {10.1016/j.bbrc.2020.01.031},
ISSN = {0006-291X},
EISSN = {1090-2104},
Keywords = {Betulinic acid; Hypoxia; Hypoxia-inducible factor; Proteasome;
   Ubiquitination; Cancer},
Keywords-Plus = {TUMOR HYPOXIA; APOPTOSIS; CELLS; ASSOCIATION; INHIBITION; IMPACT; GROWTH},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {banhs@kribb.re.kr
   hiro@res.titech.ac.jp},
Affiliations = {Korea Research Institute of Bioscience \& Biotechnology (KRIBB);
   Institute of Science Tokyo; Tokyo Institute of Technology},
ResearcherID-Numbers = {Nakamura, Hiroyuki/E-8627-2014
   Ban, Hyun Seung/F-9526-2014},
ORCID-Numbers = {Nakamura, Hiroyuki/0000-0002-4511-2984
   Ban, Hyun Seung/0000-0002-2698-6037},
Funding-Acknowledgement = {National Research Foundation of Korea {[}NRF-2019R1I1A2A01060951]; KRIBB
   Research Initiative Program},
Funding-Text = {This work was supported by the National Research Foundation of Korea
   {[}grant number NRF-2019R1I1A2A01060951] and KRIBB Research Initiative
   Program.},
Cited-References = {Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Chintharlapalli S, 2007, CANCER RES, V67, P2816, DOI 10.1158/0008-5472.CAN-06-3735.
   Courtney KD, 2018, J CLIN ONCOL, V36, P867, DOI 10.1200/JCO.2017.74.2627.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Eiznhamer DA, 2004, IDRUGS, V7, P359.
   Fallah J, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0752-z.
   Fulda S, 1997, CANCER RES, V57, P4956.
   Fyles A, 2002, J CLIN ONCOL, V20, P680, DOI 10.1200/JCO.20.3.680.
   Gheorgheosu D, 2014, ANTI-CANCER AGENT ME, V14, P936, DOI 10.2174/1871520614666140223192148.
   Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001.
   Hockel M, 1996, CANCER RES, V56, P4509.
   Karna E, 2010, MOL CELL BIOCHEM, V340, P15, DOI 10.1007/s11010-010-0395-8.
   Kessler JH, 2007, CANCER LETT, V251, P132, DOI 10.1016/j.canlet.2006.11.003.
   Krahn JH, 2017, CELL CHEM BIOL, V24, P653, DOI 10.1016/j.chembiol.2017.06.005.
   Kristiansen M, 2007, MOL CELL, V26, P175, DOI 10.1016/j.molcel.2007.04.001.
   Leestemaker Y, 2017, CELL CHEM BIOL, V24, P725, DOI 10.1016/j.chembiol.2017.05.010.
   Li Q, 2011, MOL CARCINOGEN, V50, P760, DOI 10.1002/mc.20673.
   Movva S, 2009, CANCER-AM CANCER SOC, V115, P3166, DOI 10.1002/cncr.24364.
   PISHA E, 1995, NAT MED, V1, P1046, DOI 10.1038/nm1095-1046.
   Rice AM, 2001, J BIOL CHEM, V276, P42722, DOI 10.1074/jbc.M106583200.
   Rubinsztein DC, 2006, NATURE, V443, P780, DOI 10.1038/nature05291.
   Schito L, 2016, TRENDS CANCER, V2, P758, DOI 10.1016/j.trecan.2016.10.016.
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187.
   Thibaudeau TA, 2019, PHARMACOL REV, V71, P170, DOI 10.1124/pr.117.015370.
   Wang X, 2017, NEUROCHEM RES, V42, P1130, DOI 10.1007/s11064-016-2147-y.
   Yu YC, 2019, DRUG DISCOV TODAY, V24, P2332, DOI 10.1016/j.drudis.2019.09.008.},
Number-of-Cited-References = {26},
Times-Cited = {19},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Biochem. Biophys. Res. Commun.},
Doc-Delivery-Number = {LE5UW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000526786900027},
DA = {2026-02-04},
}

@article{ WOS:000529337400223,
Author = {Bamodu, Oluwaseun Adebayo and Chang, Hang-Lung and Ong, Jiann-Ruey and
   Lee, Wei-Hwa and Yeh, Chi-Tai and Tsai, Jo-Ting},
Title = {Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes
   Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular
   Carcinoma},
Journal = {CELLS},
Year = {2020},
Volume = {9},
Number = {3},
Month = {MAR},
Abstract = {Resistance to radiotherapy (IR), with consequent disease recurrence,
   continues to limit the efficacy of contemporary anticancer treatment for
   patients with hepatocellular carcinoma (HCC), especially in late stage.
   Despite accruing evidence implicating the PI3K/AKT signaling pathway in
   cancer-promoting hypoxia, cancerous cell proliferation and
   radiotherapy-resistance, it remains unclear which molecular constituent
   of the pathway facilitates adaptation of aggressive HCC cells to tumoral
   stress signals and drives their evasion of repeated IR-toxicity. This
   present study investigated the role of PDK1 signaling in IR-resistance,
   enhanced DNA damage repair and post-IR relapse, characteristic of
   aggressive HCC cells, while exploring potential PDK1-targetability to
   improve radiosensitivity. The study employed bioinformatics analyses of
   gene expression profile and functional protein-protein interaction,
   generation of IR-resistant clones, flow cytometry-based ALDH activity
   and side-population (SP) characterization, siRNA-mediated
   loss-of-PDK1function, western-blotting, immunohistochemistry and
   functional assays including cell viability, migration, invasion,
   clonogenicity and tumorsphere formation assays. We showed that the
   aberrantly expressed PDK1 characterizes poorly differentiated HCC
   CVCL\_7955, Mahlavu, SK-HEP1 and Hep3B cells, compared to the
   well-differentiated Huh7 or normal adult liver epithelial THLE-2 cells,
   and independently activates the PI3K/AKT/mTOR signaling. Molecular
   ablation of PDK1 function enhanced susceptibility of HCC cells to IR and
   was associated with deactivated PI3K/AKT/mTOR signaling. Additionally,
   PDK1-driven IR-resistance positively correlated with activated PI3K
   signaling, enhanced HCC cell motility and invasiveness, augmented EMT,
   upregulated stemness markers ALDH1A1, PROM1, SOX2, KLF4 and POU5F1,
   increased tumorsphere-formation efficiency and suppressed biomarkers of
   DNA damage-RAD50, MSH3, MLH3 and ERCC2. Furthermore, the acquired
   IR-resistant phenotype of Huh7 cells was strongly associated with
   significantly increased ALDH activity, SP-enrichment, and direct
   ALDH1-PDK1 interaction. Moreover, BX795-mediated pharmacological
   inhibition of PDK1 synergistically enhances the radiosensitivity of
   erstwhile resistant cells, increased Bax/Bcl-2 apoptotic ratio, while
   suppressing oncogenicity and clonogenicity. We provide preclinical
   evidence implicating PDK1 as an active driver of IR-resistance by
   activation of the PI3K/AKT/mTOR signaling, up-modulation of cancer
   stemness signaling and suppression of DNA damage, thus, projecting
   PDK1-targeting as a putative enhancer of radiosensitivity and a
   potential new therapeutic approach for patients with IR-resistant HCC.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Tsai, JT (Corresponding Author), Taipei Med Univ, Coll Med, Sch Med, Dept Radiol, Taipei 110, Taiwan.
   Tsai, JT (Corresponding Author), Taipei Med Univ, Dept Radiol, Shuang Ho Hosp, New Taipei 235, Taiwan.
   Tsai, JT (Corresponding Author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.
   Bamodu, Oluwaseun Adebayo; Yeh, Chi-Tai, Taipei Med Univ, Canc Ctr, Dept Hematol \& Oncol, Shuang Ho Hosp, New Taipei 235, Taiwan.
   Bamodu, Oluwaseun Adebayo; Yeh, Chi-Tai, Taipei Med Univ, Dept Med Res \& Educ, Shuang Ho Hosp, New Taipei 235, Taiwan.
   Chang, Hang-Lung, En Chu Kong Hosp, Dept Gen Surg, New Taipei 237, Taiwan.
   Chang, Hang-Lung, Yuanpei Univ Med Technol, Dept Hlth Care Management, Hsinchu 300, Taiwan.
   Ong, Jiann-Ruey, Taipei Med Univ, Sch Med, Dept Emergency Med, Taipei 110, Taiwan.
   Ong, Jiann-Ruey, Taipei Med Univ, Dept Emergency Med, Shuang Ho Hosp, New Taipei 235, Taiwan.
   Lee, Wei-Hwa, Taipei Med Univ, Dept Pathol, Shuang Ho Hosp, New Taipei 235, Taiwan.
   Yeh, Chi-Tai, Yuanpei Univ Med Technol, Dept Med Lab Sci \& Biotechnol, Hsinchu 300, Taiwan.
   Tsai, Jo-Ting, Taipei Med Univ, Coll Med, Sch Med, Dept Radiol, Taipei 110, Taiwan.
   Tsai, Jo-Ting, Taipei Med Univ, Dept Radiol, Shuang Ho Hosp, New Taipei 235, Taiwan.
   Tsai, Jo-Ting, Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei 110, Taiwan.},
DOI = {10.3390/cells9030746},
Article-Number = {746},
EISSN = {2073-4409},
Keywords = {hepatocellular cancer; HCC; LIHC; PDK1; PI3K; AKT; mTOR pathway; BX795;
   selective inhibitor; radiotherapy; radioresistance; combination therapy;
   stemness; DNA damage},
Keywords-Plus = {ONCOGENE; RADIORESISTANCE; ACTIVATION},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {dr\_bamodu@yahoo.com
   changh10321@gmail.com
   12642@s.tmu.edu.tw
   whlpath97616@s.tmu.edu.tw
   ctyeh@s.tmu.edu.tw
   10576@s.tmu.edu.tw},
Affiliations = {Taipei Medical University; Shuang Ho Hospital; Taipei Medical
   University; Shuang Ho Hospital; Taipei Medical University; Taipei
   Medical University; Shuang Ho Hospital; Taipei Medical University;
   Shuang Ho Hospital; Taipei Medical University; Taipei Medical
   University; Shuang Ho Hospital; Taipei Medical University},
ResearcherID-Numbers = {Bamodu, Oluwaseun Adebayo/B-9784-2018},
ORCID-Numbers = {Yeh, Chi-Tai/0000-0001-5189-9755
   Lee, Wei-Hwa/0000-0003-0932-3191
   Bamodu, Oluwaseun Adebayo/0000-0001-8229-0408},
Funding-Acknowledgement = {Taipei Medical University {[}102TMU-SHH-02]},
Funding-Text = {This study was also supported by grants from Taipei Medical University
   (102TMU-SHH-02) to Wei-Hwa Lee.},
Cited-References = {Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055.
   Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407.
   Cojoc M, 2015, CANCER RES, V75, P1482, DOI 10.1158/0008-5472.CAN-14-1924.
   Crissien Ana Maria, 2014, Gastroenterol Hepatol (N Y), V10, P153.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Enane FO, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0919-9.
   Fedorov O, 2010, NAT CHEM BIOL, V6, P166, DOI 10.1038/nchembio.297.
   Ferlay J., 2021, Global cancer observatory: cancer today.
   Fernandez-Alonso R, 2017, J MOL BIOL, V429, P1504, DOI 10.1016/j.jmb.2017.04.013.
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gaianigo N, 2017, CANCERS, V9, DOI 10.3390/cancers9090122.
   Goldstein M, 2015, ANNU REV MED, V66, P129, DOI 10.1146/annurev-med-081313-121208.
   Horn D, 2015, EXPERT OPIN THER TAR, V19, P795, DOI 10.1517/14728222.2015.1012157.
   Kalogeridi MA, 2015, WORLD J HEPATOL, V7, P101, DOI 10.4254/wjh.v7.i1.101.
   Klein J, 2013, INT J RADIAT ONCOL, V87, P22, DOI 10.1016/j.ijrobp.2012.08.043.
   Li Z, 2012, J HEPATOL, V56, P419, DOI 10.1016/j.jhep.2011.07.025.
   Lin JZ, 2019, CLIN CANCER RES, V25, P4701, DOI 10.1158/1078-0432.CCR-19-0127.
   Lomax ME, 2013, CLIN ONCOL-UK, V25, P578, DOI 10.1016/j.clon.2013.06.007.
   Lorentz Holly I., 2011, ARVO Annual Meeting Abstract Search and Program Planner, V2011, P6479.
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024.
   Lurje I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061465.
   Park J, 2009, J BIOL CHEM, V284, P6169, DOI 10.1074/jbc.C800210200.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Santamaría PG, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050676.
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44.
   Szymonowicz K, 2018, CANCERS, V10, DOI 10.3390/cancers10030078.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263.
   Villanueva A, 2011, GASTROENTEROLOGY, V140, P1410, DOI 10.1053/j.gastro.2011.03.006.
   Wang NZ, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918816287.
   Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293.
   Xu SB, 2018, CANCER LETT, V420, P38, DOI 10.1016/j.canlet.2018.01.067.},
Number-of-Cited-References = {34},
Times-Cited = {133},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {27},
Journal-ISO = {Cells},
Doc-Delivery-Number = {LI2TV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529337400223},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000509438100060,
Author = {Chi Xin and Shi Guangliang and Zhang Qing and Liu Qingqing and Yin Hang
   and Zhang Yiming and Li Shu},
Title = {Astilbin protects chicken peripheral blood lymphocytes from
   cadmium-induced necroptosis via oxidative stress and the PI3K/Akt
   pathway},
Journal = {ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY},
Year = {2020},
Volume = {190},
Month = {MAR 1},
Abstract = {Astilbin (ASB), a dihydroflavonol glycoside, is widely found in a
   variety of plants and in functional foods and acts as a powerful
   antioxidant. The aim of this study was to investigate the underlying
   mechanisms involved in the antagonistic effects of ASH on cadmium
   (Cd)-induced necroptosis in chicken peripheral blood lymphocytes.
   Peripheral blood lymphocytes were aseptically collected from Roman white
   hens and then randomly divided into five groups: the control group was
   incubated without additional reagents, while the other groups were
   incubated with Cd, ASH, a combination of Cd and ASB, and 0.1\% DMSO.
   After a 24 h treatment, cell samples were collected. The results showed
   that some morphological changes consistent with necroptosis were
   observed in the Cd-treated groups, suggesting the occurrence of
   necroptosis. Simultaneously, antioxidant activity markers (CAT, SOD,
   GSH, GSH-px, and T-AOC) decreased and indicators of oxidative stress
   (MDA, iNOS, NO, H2O2, center dot OH and ROS) increased. The production
   of ROS induced the activation of the PI3K/Akt signaling pathway, as the
   expression levels of PI3K, Akt and PDK1 were significantly elevated.
   Additionally, the expression levels of RIPK3, RIPK1, MLKL, TAK1, TAB2
   and TAB3 were increased and that of Caspase-8 was decreased, which could
   cause the necroptosis. However, the most important our results was that
   ASB supplements remarkably attenuated the Cd-induced effects. We
   conclude that the Cd treatment promoted an imbalance of the antioxidant
   status and activated the PI3K/Akt pathway, leading to necroptosis in
   chicken peripheral blood lymphocytes, and that ASB was able to partially
   ameliorate the effect of Cd-induced necroptosis.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Li, S (Corresponding Author), Northeast Agr Univ, Coll Vet Med, Harbin 150030, Heilongjiang, Peoples R China.
   Chi Xin; Shi Guangliang; Zhang Qing; Liu Qingqing; Yin Hang; Zhang Yiming; Li Shu, Northeast Agr Univ, Coll Vet Med, Harbin 150030, Heilongjiang, Peoples R China.},
DOI = {10.1016/j.ecoenv.2019.110064},
Article-Number = {110064},
ISSN = {0147-6513},
EISSN = {1090-2414},
Keywords = {Astilbin; Cadmium; Oxidative stress; PI3K/Akt pathway; Necroptosis;
   Lymphocytes},
Keywords-Plus = {PHOSPHATIDYLINOSITOL 3-KINASE; INDUCED APOPTOSIS; HYDROGEN-SULFIDE;
   INJURY; INFLAMMATION; ANTIOXIDANT; EXTRACTS; EXPOSURE; SELENIUM; DAMAGE},
Research-Areas = {Environmental Sciences \& Ecology; Toxicology},
Web-of-Science-Categories  = {Environmental Sciences; Toxicology},
Author-Email = {lishu@neau.edu.cn},
Affiliations = {Northeast Agricultural University - China},
ResearcherID-Numbers = {SHI, Guangliang/AAM-8206-2020},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31702282]; University
   Nursing Program for Young Scholars with Creative Talents in Heilongjiang
   Province {[}UNPYSCT-2016139]; Northeast Agricultural
   University/Scientific Observing and Experimental Station of Animal
   Nutrition and Feed Science in Northeast, Ministry of Agriculture. P.R.
   China {[}yy-2017-09]},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (31702282), University Nursing Program for Young Scholars with
   Creative Talents in Heilongjiang Province (UNPYSCT-2016139) and
   Northeast Agricultural University/Scientific Observing and Experimental
   Station of Animal Nutrition and Feed Science in Northeast, Ministry of
   Agriculture. P.R. China(yy-2017-09).},
Cited-References = {Agullo G, 1997, BIOCHEM PHARMACOL, V53, P1649, DOI 10.1016/S0006-2952(97)82453-7.
   {[}Anonymous], 1964, OBSERVATIONS EARLY E, V149, P23.
   Cai JZ, 2017, RSC ADV, V7, P44438, DOI 10.1039/c7ra07952d.
   Chen X, 2012, MOLECULES, V17, P14565, DOI 10.3390/molecules171214565.
   COSMA GN, 1991, J TOXICOL ENV HEALTH, V34, P39, DOI 10.1080/15287399109531547.
   Desai J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15106-0.
   Di TT, 2016, INT IMMUNOPHARMACOL, V32, P32, DOI 10.1016/j.intimp.2015.12.035.
   Diao HL, 2014, FOOD CHEM TOXICOL, V63, P104, DOI 10.1016/j.fct.2013.10.045.
   Fay MJ, 2018, TOXICS, V6, DOI 10.3390/toxics6010016.
   Han CH, 2018, BIOCHEM BIOPH RES CO, V495, P2178, DOI 10.1016/j.bbrc.2017.12.100.
   Hu XY, 2019, CHEMOSPHERE, V237, DOI 10.1016/j.chemosphere.2019.124427.
   Hu XY, 2018, ECOTOX ENVIRON SAFE, V164, P201, DOI 10.1016/j.ecoenv.2018.08.029.
   Jin X, 2018, J HAZARD MATER, V357, P355, DOI 10.1016/j.jhazmat.2018.06.003.
   Kang KH, 2009, TRENDS MOL MED, V15, P191, DOI 10.1016/j.molmed.2009.03.005.
   Karaca S, 2013, BIOL TRACE ELEM RES, V155, P423, DOI 10.1007/s12011-013-9804-7.
   Kitur K, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004820.
   Kong GQ, 2016, INT IMMUNOPHARMACOL, V36, P51, DOI 10.1016/j.intimp.2016.03.039.
   Landrault N, 2002, J AGR FOOD CHEM, V50, P2046, DOI 10.1021/jf010794g.
   Lee SE, 2001, EXP MOL MED, V33, P263, DOI 10.1038/emm.2001.43.
   Li JL, 2013, ECOTOX ENVIRON SAFE, V96, P103, DOI 10.1016/j.ecoenv.2013.07.007.
   Li ZG, 2019, FREE RADICAL BIO MED, V130, P576, DOI 10.1016/j.freeradbiomed.2018.11.020.
   Liang WJ, 2017, INT J MOL MED, V40, P201, DOI 10.3892/ijmm.2017.3006.
   Liu F, 2017, TOXICOLOGY, V383, P13, DOI 10.1016/j.tox.2017.03.016.
   Liu JC, 2002, AM J CHINESE MED, V30, P629, DOI 10.1142/S0192415X02000454.
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926.
   Liu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.69.
   Lu CL, 2015, MOLECULES, V20, P625, DOI 10.3390/molecules20010625.
   MATTER WF, 1992, BIOCHEM BIOPH RES CO, V186, P624, DOI 10.1016/0006-291X(92)90792-J.
   McNamara CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056576.
   Mizumura K, 2018, FASEB J, V32, P1880, DOI 10.1096/fj.201700571R.
   Monteiro C, 2018, J TOXICOL ENV HEAL A, V81, P705, DOI 10.1080/15287394.2018.1485122.
   Mostafa DG, 2019, NEUROL RES, V41, P594, DOI 10.1080/01616412.2019.1596206.
   Ognjanovic BI, 2008, PHYSIOL RES, V57, P403, DOI 10.33549/physiolres.931197.
   Pathak N, 2006, TOXICOLOGY, V220, P26, DOI 10.1016/j.tox.2005.11.027.
   Pham TND, 2006, TOXICOL IN VITRO, V20, P1331, DOI 10.1016/j.tiv.2006.05.005.
   Saeedi A, 2015, INT J OCCUP ENV MED, V6, P20, DOI 10.15171/ijoem.2015.482.
   Saxena M., 2009, INTERNET J VET MED, V5, P1.
   Sun ZP, 2018, METALLOMICS, V10, P759, DOI 10.1039/c8mt00039e.
   Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860.
   Tuma Demir F., 2019, ENVIRON POLLUT, V15.
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241.
   Wang DM, 2017, CELL MOL NEUROBIOL, V37, P695, DOI 10.1007/s10571-016-0405-9.
   Wang M, 2016, BIOMED PHARMACOTHER, V83, P975, DOI 10.1016/j.biopha.2016.07.025.
   Wang S, 2019, ECOTOX ENVIRON SAFE, V183, DOI 10.1016/j.ecoenv.2019.109578.
   Wang Y, 2018, METALLOMICS, V10, P1805, DOI 10.1039/c8mt00234g.
   Wang Y, 2018, CHEMOSPHERE, V206, P597, DOI 10.1016/j.chemosphere.2018.05.013.
   Yang TS, 2018, REDOX BIOL, V15, P159, DOI 10.1016/j.redox.2017.11.025.
   Yang ZT, 2018, NAT CELL BIOL, V20, P186, DOI 10.1038/s41556-017-0022-y.
   Yaprak E, 2017, J PERIODONTAL RES, V52, P83, DOI 10.1111/jre.12371.
   Zhang M, 2011, J VET MED SCI, V73, P199, DOI 10.1292/jvms.10-0236.
   Zhang QF, 2012, FOOD CHEM, V133, P140, DOI 10.1016/j.foodchem.2012.01.008.
   Zhang YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14329.
   Zhao HJ, 2018, CHEMOSPHERE, V210, P76, DOI 10.1016/j.chemosphere.2018.06.165.
   Zhao PP, 2017, CHEMOSPHERE, V166, P238, DOI 10.1016/j.chemosphere.2016.09.060.},
Number-of-Cited-References = {54},
Times-Cited = {73},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {57},
Journal-ISO = {Ecotox. Environ. Safe.},
Doc-Delivery-Number = {KF7SE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000509438100060},
DA = {2026-02-04},
}

@article{ WOS:000516796900026,
Author = {Ghinet, Alina and Thuru, Xavier and Floquet, Emilie and Dubois, Joelle
   and Farce, Amaury and Rigo, Benoit},
Title = {Enhanced antitumor potential induced by chloroacetate-loaded
   benzophenones acting as fused tubulin-pyruvate dehydrogenase kinase 1
   (PDHK1) ligands},
Journal = {BIOORGANIC CHEMISTRY},
Year = {2020},
Volume = {96},
Month = {MAR},
Abstract = {The majority of cancers detected every year are treated with anti-cancer
   compounds. Unfortunately, many tumors become resistant to antineoplastic
   drugs. One option is to use cocktails of compounds acting on different
   targets to try to overcome the resistant cells. This type of approach
   can produce good results, but is often accompanied by a sharp increase
   of associated side effects.
   The strategy presented herein focuses on the use of a single compound
   acting on two different biological targets enhancing potency and
   lowering the toxicity of the chemotherapy. In this light, the approach
   presented in the current study involves the dual inhibition of human
   pyruvate dehydrogenase kinase-1 (PDHK1) and tubulin polymerization using
   mono-, di- and tri-chloroacetate-loaded benzophenones and
   benzothiophenones.
   Synthesized molecules were evaluated in vitro on tubulin polymerization
   and on pyruvate dehydrogenase kinase 1. The cell cycle distribution
   after treatment of DA1-3b leukemic cells with active compounds was
   tested.
   Twenty-two benzo(thio)phenones have been selected by the National Cancer
   Institute (USA) for evaluation of their anti-proliferative potential
   against NCI-60 cancer cell lines including multidrug-resistant tumor
   cell lines. Seventeen molecules proved to be very effective in combating
   the growth of tumor cells exhibiting inhibitory activities up to
   nanomolar range.
   The molecular docking of best antitumor molecules in the study was
   realized with GOLD in the tubulin and PDHK1 binding sites, and allowed
   to understand the positioning of active molecules.
   Chloroacetate-loaded benzo(thio)phenones are dual targeted tubulin- and
   pyruvate dehydrogenase kinase 1 (PDHK1)-binding antitumor agents and
   exhibited superior antitumor activity compared to non-chlorinated
   congeners particularly on leukemia, colon, melanoma and breast cancer
   cell lines.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Ghinet, A (Corresponding Author), UCLille, Yncrea Hauts de France, Hlth \& Environm Dept, Team Sustainable Chem,Lab Chim Durable \& Sante,HE, 13 Rue Toul, F-59046 Lille, France.
   Ghinet, Alina; Rigo, Benoit, UCLille, Yncrea Hauts de France, Hlth \& Environm Dept, Team Sustainable Chem,Lab Chim Durable \& Sante,HE, 13 Rue Toul, F-59046 Lille, France.
   Ghinet, Alina; Rigo, Benoit, Univ Lille, CHU Lille, Inst Pasteur Lille, U1167,RID AGE,Facteurs Risque \& Determinants Mole, F-59000 Lille, France.
   Ghinet, Alina, Alexandru Ioan Cuza Univ, Fac Chem, Bd Carol I 11, Iasi 700506, Romania.
   Thuru, Xavier; Floquet, Emilie, Univ Lille, CHU Lille, Canc Heterogene Plastic \& Resistance Therapies, UMR9020,UMR1277,Canther, F-59000 Lille, France.
   Floquet, Emilie, BICeL Campus Hosp Univ, BioImaging Ctr Lille Nord de France, Plateau Cytometrie, Lille, France.
   Dubois, Joelle, Ctr Rech Gif, Inst Chim Subst Nat, UPR2301, CNRS, Ave Terrasse, F-91198 Gif Sur Yvette, France.
   Farce, Amaury, Univ Lille, Fac Sci Pharmaceut \& Biol, Rue Pr Laguesse,BP 83, F-59006 Lille, France.},
DOI = {10.1016/j.bioorg.2020.103643},
Article-Number = {103643},
ISSN = {0045-2068},
EISSN = {1090-2120},
Keywords = {DCA, dichloroacetic acid; PDHK1 (h), human pyruvate dehydrogenase kinase
   1; SAR, structure-activity relationship; Benzophenone; Chloroacetate},
Keywords-Plus = {BIOLOGICAL EVALUATION; DICHLOROACETATE},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Organic},
Author-Email = {alina.ghinet@yncrea.fr},
Affiliations = {Pasteur Network; Universite de Lille; Institut Pasteur Lille; CHU Lille;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Alexandru Ioan Cuza University; Universite de Lille; CHU Lille;
   Universite Paris Saclay; Centre National de la Recherche Scientifique
   (CNRS); CNRS - Institute of Chemistry (INC); Universite de Lille},
ResearcherID-Numbers = {Farce, Amaury/N-2909-2019
   GHINET, ALINA/ODI-7071-2025
   Rigo, Benoit/K-5110-2019
   Thuru, Xavier/F-7695-2018},
ORCID-Numbers = {Farce, Amaury/0000-0003-3992-9629
   GHINET, ALINA/0000-0001-6468-4331
   Floquet, Emilie/0000-0002-5053-0419
   Thuru, Xavier/0000-0002-0998-4160},
Cited-References = {Barron DM, 2003, ANAL BIOCHEM, V315, P49, DOI 10.1016/S0003-2697(02)00691-7.
   Boyd R.B., 1997, NCI IN VITRO ANTICAN, P23.
   Cho H, 2019, J MED CHEM, V62, P8461, DOI 10.1021/acs.jmedchem.9b00565.
   Curphey TJ, 2002, J ORG CHEM, V67, P6461, DOI 10.1021/jo0256742.
   Ghinet A, 2016, BIOORGAN MED CHEM, V24, P2307, DOI 10.1016/j.bmc.2016.04.001.
   Ghinet A, 2014, CHEM-EUR J, V20, P10117, DOI 10.1002/chem.201402377.
   Ghinet A, 2012, REV ROUM CHIM, V57, P1065.
   Ghinet A, 2013, BIOORGAN MED CHEM, V21, P2932, DOI 10.1016/j.bmc.2013.03.064.
   Ghinet A, 2011, BIOORGAN MED CHEM, V19, P6042, DOI 10.1016/j.bmc.2011.08.047.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Liou JP, 2004, J MED CHEM, V47, P2897, DOI 10.1021/jm0305974.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Makita N, 2017, J PHARM PHARMACOL, V69, P43, DOI 10.1111/jphp.12655.
   Pettit GR, 1998, J MED CHEM, V41, P1688, DOI 10.1021/jm970644q.
   SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765.
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951.
   Smolinski MP, 2018, J MED CHEM, V61, P4704, DOI 10.1021/acs.jmedchem.8b00164.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Trapella C, 2016, J MED CHEM, V59, P147, DOI 10.1021/acs.jmedchem.5b01165.
   Vereecque R, 2004, J GENE MED, V6, P751, DOI 10.1002/jgm.568.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Zhang SL, 2018, BIOORG MED CHEM LETT, V28, P3441, DOI 10.1016/j.bmcl.2018.09.026.},
Number-of-Cited-References = {22},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Bioorganic Chem.},
Doc-Delivery-Number = {KQ2ZN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)},
Unique-ID = {WOS:000516796900026},
DA = {2026-02-04},
}

@article{ WOS:000518042300001,
Author = {Yan, Chang and Luo, Zhuo and Li, Wen and Li, Xue and Dallmann, Robert
   and Kurihara, Hiroshi and Li, Yi-Fang and He, Rong-Rong},
Title = {Disturbed Yin-Yang balance: stress increases the susceptibility to
   primary and recurrent infections of herpes simplex virus type 1},
Journal = {ACTA PHARMACEUTICA SINICA B},
Year = {2020},
Volume = {10},
Number = {3},
Pages = {383-398},
Month = {MAR},
Abstract = {Herpes simplex virus type 1 (HSV-1), a neurotropic herpes virus, is able
   to establish a lifelong latent infection in the human host. Following
   primary replication in mucosal epithelial cells, the virus can enter
   sensory neurons innervating peripheral tissues via nerve termini. The
   viral genome is then transported to the nucleus where it can be
   maintained without producing infectious progeny, and thus latency is
   established in the cell. Yin-Yang balance is an essential concept in
   traditional Chinese medicine (TCM) theory. Yin represents stable and
   inhibitory factors, and Yang represents the active and aggressive
   factors. When the organism is exposed to stress, especially
   psychological stress caused by emotional stimulation, the Yin-Yang
   balance is disturbed and the virus can re-engage in productive
   replication, resulting in recurrent diseases. Therefore, a better
   understanding of the stress-induced susceptibility to HSV-1 primary
   infection and reactivation is needed and will provide helpful insights
   into the effective control and treatment of HSV-1. Here we reviewed the
   recent advances in the studies of HSV-1 susceptibility, latency and
   reactivation. We included mechanisms involved in primary infection and
   the regulation of latency and described how stress-induced changes
   increase the susceptibility to primary and recurrent infections. (C)
   2020 Chinese Pharmaceutical Association and Institute of Materia Medica,
   Chinese Academy of Medical Sciences. Production and hosting by Elsevier
   B.V.},
Publisher = {INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES},
Address = {C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA},
Type = {Review},
Language = {English},
Affiliation = {Kurihara, H; Li, YF; He, RR (Corresponding Author), Jinan Univ, Guangdong Engn Res Ctr Chinese Med \& Dis Suscepti, Guangzhou 510632, Peoples R China.
   Kurihara, H; Li, YF; He, RR (Corresponding Author), Jinan Univ, Sch Pharm, Int Cooperat Lab Tradit Chinese Med Modernizat \&, Chinese Minist Educ MOE, Guangzhou 510632, Peoples R China.
   Yan, Chang; Luo, Zhuo; Li, Wen; Kurihara, Hiroshi; Li, Yi-Fang; He, Rong-Rong, Jinan Univ, Guangdong Engn Res Ctr Chinese Med \& Dis Suscepti, Guangzhou 510632, Peoples R China.
   Yan, Chang; Luo, Zhuo; Li, Wen; Kurihara, Hiroshi; Li, Yi-Fang; He, Rong-Rong, Jinan Univ, Sch Pharm, Int Cooperat Lab Tradit Chinese Med Modernizat \&, Chinese Minist Educ MOE, Guangzhou 510632, Peoples R China.
   Li, Xue, Jinan Univ, Inst Atmospher Environm Safety \& Pollut Control, Guangzhou 510632, Peoples R China.
   Dallmann, Robert, Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England.},
DOI = {10.1016/j.apsb.2019.06.005},
ISSN = {2211-3835},
EISSN = {2211-3843},
Keywords = {Herpes simplex virus type 1; HSV-1; Susceptibility; Latency;
   Reactivation; Stress},
Keywords-Plus = {LATENCY-ASSOCIATED TRANSCRIPT; NERVE GROWTH-FACTOR; TRADITIONAL CHINESE
   MEDICINE; T-CELL RESPONSE; GENE-EXPRESSION; ANTIVIRAL THERAPY; HSV-1
   LATENCY; PRODUCTIVE INFECTION; TRIGEMINAL GANGLIA; AMPK/SIRT1 AXIS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {hiroshi\_kurihara@163.com
   liyifang706@jnu.edu.cn
   rongronghe@jnu.edu.cn},
Affiliations = {Jinan University; Jinan University; Jinan University; University of
   Warwick},
ResearcherID-Numbers = {Dallmann, Robert/AAA-4929-2022
   Li, Yifang/HTO-9769-2023},
ORCID-Numbers = {Dallmann, Robert/0000-0002-7490-0218
   HE, Rong-Rong/0000-0001-5505-5672
   Li, Wen/0000-0001-7530-199X
   },
Funding-Acknowledgement = {National Key Research and Development Program of China, China
   {[}2017YFC1700404]; Natural Science Foundation of China, China
   {[}81622050, 81573675, 81673709, 81560661, 81873209]; Young Top-notch
   Talent Support Program of Guangdong Province, China {[}2014TQ01R229,
   2016TQ03R586]; Guangdong Province Ocean and Fisheries Bureau-Key
   Technology Research and Development Program, China {[}A201701A02];
   Guangdong Science and Technology Foundation for Distinguished Young
   Scholars, China {[}2017A030306004]; Science and Technology Program of
   Guangzhou, China {[}201604046016, 201610010182]},
Funding-Text = {This work was supported, in part, by the National Key Research and
   Development Program of China, China (grant number 2017YFC1700404);
   Natural Science Foundation of China, China (grant numbers 81622050,
   81573675, 81673709, 81560661 and 81873209); the Young Top-notch Talent
   Support Program of Guangdong Province, China (grant numbers 2014TQ01R229
   and 2016TQ03R586); Guangdong Province Ocean and Fisheries Bureau-Key
   Technology Research and Development Program, China (grant number
   A201701A02); Guangdong Science and Technology Foundation for
   Distinguished Young Scholars, China (grant number 2017A030306004) and
   the Science and Technology Program of Guangzhou, China (grant numbers
   201604046016 and 201610010182).},
Cited-References = {Agostini S, 2016, BRAIN BEHAV IMMUN, V58, P254, DOI 10.1016/j.bbi.2016.07.153.
   Al-Dujaili LJ, 2011, FUTURE MICROBIOL, V6, P877, DOI 10.2217/FMB.11.73.
   Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107.
   {[}Anonymous], 2014, FRONT AGING NEUROSCI.
   Antinone SE, 2010, J VIROL, V84, P13019, DOI 10.1128/JVI.01296-10.
   Aravantinou M, 2017, J MED PRIMATOL, V46, P121, DOI 10.1111/jmp.12293.
   Ashcraft KA, 2008, BRAIN BEHAV IMMUN, V22, P1231, DOI 10.1016/j.bbi.2008.06.008.
   Ashcraft KA, 2008, PSYCHONEUROENDOCRINO, V33, P951, DOI 10.1016/j.psyneuen.2008.04.010.
   Audas TE, 2016, EUR J CELL BIOL, V95, P611, DOI 10.1016/j.ejcb.2016.10.006.
   Avgousti DC, 2015, CELL HOST MICROBE, V18, P639, DOI 10.1016/j.chom.2015.11.011.
   Bartels LJ, 2016, Operative Techniques in Otolaryngology-Head and Neck Surgery, V27, P225, DOI {[}10.1016/j.otot.2016.10.009, 10.1016/j.otot.2016.10.009, DOI 10.1016/J.OTOT.2016.10.009].
   Bedadala GR, 2010, CELL RES, V20, P587, DOI 10.1038/cr.2010.50.
   Bernstein DI, 2013, CLIN INFECT DIS, V56, P344, DOI 10.1093/cid/cis891.
   Bieniasz PD, 2004, NAT IMMUNOL, V5, P1109, DOI 10.1038/ni1125.
   Bigley NJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00015.
   Bloom DC, 2010, BBA-GENE REGUL MECH, V1799, P246, DOI 10.1016/j.bbagrm.2009.12.001.
   Bradley H, 2014, J INFECT DIS, V209, P325, DOI 10.1093/infdis/jit458.
   Bussmann Caroline, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000756.
   Cai Y, 2015, BIOMED RES INT, V2015, P1.
   Camarena V, 2010, CELL HOST MICROBE, V8, P320, DOI 10.1016/j.chom.2010.09.007.
   Cao HJ, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/236539.
   Carpenter D, 2007, VIROLOGY, V369, P12, DOI 10.1016/j.virol.2007.07.023.
   Carpenter D, 2015, J NEUROVIROL, V21, P568, DOI 10.1007/s13365-015-0361-z.
   Chen F, 2014, SOJ PHARM PHARM SCI, V1, P7.
   Chen F, 2016, J NEUROVIROL, V22, P555, DOI 10.1007/s13365-016-0423-x.
   Chen H, 2017, PHYTOMEDICINE, V27, P52, DOI 10.1016/j.phymed.2017.02.004.
   Chen MX, 2016, MOL CELL, V64, P105, DOI 10.1016/j.molcel.2016.08.025.
   Clement C, 2011, INVEST OPHTH VIS SCI, V52, P1770, DOI 10.1167/iovs.09-5019.
   Cunningham AL, 2006, SEX TRANSM INFECT, V82, P164, DOI 10.1136/sti.2005.016899.
   Cunningham A, 2012, J CLIN VIROL, V53, P6, DOI 10.1016/j.jcv.2011.08.003.
   Curtin NM, 2009, BRAIN BEHAV IMMUN, V23, P535, DOI 10.1016/j.bbi.2009.02.003.
   Danaher RJ, 1999, J NEUROVIROL, V5, P258, DOI 10.3109/13550289909015812.
   Danaher RJ, 2013, J NEUROVIROL, V19, P32, DOI 10.1007/s13365-012-0137-7.
   Dong-Newsom P, 2010, BRAIN BEHAV IMMUN, V24, P273, DOI 10.1016/j.bbi.2009.10.003.
   Du T, 2012, P NATL ACAD SCI USA, V109, P14616, DOI 10.1073/pnas.1212661109.
   Duan F, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/192791.
   Duan F, 2012, CLIN EXP OPHTHALMOL, V40, P195, DOI 10.1111/j.1442-9071.2011.02668.x.
   Edgar RS, 2016, P NATL ACAD SCI USA, V113, P10085, DOI 10.1073/pnas.1601895113.
   Egan KP, 2013, J NEUROVIROL, V19, P328, DOI 10.1007/s13365-013-0189-3.
   Elftman MD, 2010, J IMMUNOL, V184, P1867, DOI 10.4049/jimmunol.0902469.
   Ellison AR, 2000, VIROLOGY, V268, P17, DOI 10.1006/viro.1999.0158.
   Enquist LW, 2017, J VIROL, V91, DOI 10.1128/JVI.01200-16.
   Figliozzi RW, 2014, J NEUROL SCI, V346, P164, DOI 10.1016/j.jns.2014.08.017.
   Finsterbusch K, 2015, J INVEST DERMATOL, V135, P2565, DOI 10.1038/jid.2015.293.
   Flores O, 2013, J VIROL, V87, P6589, DOI 10.1128/JVI.00504-13.
   Frank GM, 2010, J IMMUNOL, V184, P277, DOI 10.4049/jimmunol.0902373.
   Fukuda Masahiko, 2008, Semin Ophthalmol, V23, P217, DOI 10.1080/08820530802111366.
   Ghiasi H, 2013, J VIROL, V191.
   Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571.
   Gu PQ, 2014, BRIEF BIOINFORM, V15, P984, DOI 10.1093/bib/bbt063.
   Guo JJ, 2018, ACTA PHARM SIN B, V8, P900, DOI 10.1016/j.apsb.2018.08.007.
   Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836.
   Hafezi W, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002679.
   Harris SA, 2015, J ALZHEIMERS DIS, V48, P319, DOI 10.3233/JAD-142853.
   He F, 2017, J INORG MATER, V32, P449, DOI 10.15541/jim20160380.
   He RR, 2009, BIOL PHARM BULL, V32, P247, DOI 10.1248/bpb.32.247.
   He RR, 2011, J HEALTH SCI, V57, P255, DOI 10.1248/jhs.57.255.
   He RR, 2011, J AGR FOOD CHEM, V59, P3730, DOI 10.1021/jf104982y.
   Held K, 2011, J NEUROVIROL, V17, P518, DOI 10.1007/s13365-011-0063-0.
   Higaki S, 2015, JPN J OPHTHALMOL, V59, P131, DOI 10.1007/s10384-014-0369-6.
   Hill JM, 1997, J NEUROVIROL, V3, P206, DOI 10.3109/13550289709018295.
   Hsia SC, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-24.
   Huang J, 2006, J VIROL, V80, P5740, DOI 10.1128/JVI.00169-06.
   Ives AM, 2017, J VIROL, V91, DOI 10.1128/JVI.00582-17.
   Jiang CY, 2018, INT J PHARMACOL, V14, P342, DOI 10.3923/ijp.2018.342.351.
   Jiang XZ, 2016, J NEUROVIROL, V22, P38, DOI 10.1007/s13365-015-0362-y.
   Jiang XZ, 2015, J NEUROVIROL, V21, P199, DOI 10.1007/s13365-015-0319-1.
   Jiang XZ, 2011, J VIROL, V85, P2325, DOI 10.1128/JVI.01791-10.
   Jie C, 2017, ONCOTARGET, V8, P105615, DOI 10.18632/oncotarget.22350.
   Jones Clinton, 2013, J Cell Death, V6, P1, DOI 10.4137/JCD.S10803.
   Katzenell S, 2016, J VIROL, V90, P4706, DOI 10.1128/JVI.02908-15.
   Kaufman HE, 2005, INVEST OPHTH VIS SCI, V46, P241, DOI 10.1167/iovs.04-0614.
   Kaufman HE, 2008, J OCUL PHARMACOL TH, V24, P34, DOI 10.1089/jop.2007.0084.
   Kaye SB, 2000, BRIT J OPHTHALMOL, V84, P563, DOI 10.1136/bjo.84.6.563.
   Kennedy DP, 2011, CORNEA, V30, P251, DOI 10.1097/ICO.0b013e3181ef241d.
   Kennedy PGE, 2015, J GEN VIROL, V96, P1581, DOI 10.1099/vir.0.000128.
   Kennedy PGE, 2010, J NEUROVIROL, V16, P411, DOI 10.3109/13550284.2010.515652.
   Kim J C, 2008, Mol Biol (Mosk), V42, P470.
   Kim JY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002540.
   Kimberlin DW, 2007, HUMAN HERPESVIRUSES: BIOLOGY, THERAPY, AND IMMUNOPROPHYLAXIS, P1153.
   Knickelbein JE, 2008, SCIENCE, V322, P268, DOI 10.1126/science.1164164.
   Kobayashi M, 2012, GENE DEV, V26, P1527, DOI 10.1101/gad.190157.112.
   Kolokotronis A, 2006, CLIN MICROBIOL INFEC, V12, P202, DOI 10.1111/j.1469-0691.2005.01336.x.
   Kook I, 2016, VIRUS RES, V222, P106, DOI 10.1016/j.virusres.2016.06.007.
   Koyuncu OO, 2015, MBIO, V6, DOI 10.1128/mBio.00276-15.
   Kubat NJ, 2004, J VIROL, V78, P12508, DOI 10.1128/JVI.78.22.12508-12518.2004.
   Kukhanova MK, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1635, DOI 10.1134/S0006297914130124.
   Kumar SP, 2016, J ORAL MAX SURG MED, V28, P350, DOI 10.1016/j.ajoms.2016.01.006.
   Kushnir AS, 2010, J VIROL, V84, P188, DOI 10.1128/JVI.01377-09.
   Lambiase A, 2008, GRAEF ARCH CLIN EXP, V246, P121, DOI 10.1007/s00417-007-0593-6.
   Leib DA, 2009, J VIROL, V83.
   Levett PN, 2005, MED MICROBIOL IMMUN, V194, P105, DOI 10.1007/s00430-004-0222-5.
   Leyton L, 2015, VIRUS RES, V205, P63, DOI 10.1016/j.virusres.2015.05.015.
   Li LH, 2016, J VIROL, V90, P790, DOI 10.1128/JVI.02258-15.
   Li P, 2009, J TRADIT CHIN MED, V29, P153, DOI 10.1016/S0254-6272(09)60054-6.
   Li S, 2013, CHIN J NAT MEDICINES, V11, P110, DOI {[}10.3724/SP.J.1009.2013.00110, 10.1016/S1875-5364(13)60037-0].
   Li W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103266.
   Li YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033190.
   Liang QM, 2014, CELL HOST MICROBE, V15, P228, DOI 10.1016/j.chom.2014.01.009.
   Lin HJ, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-69.
   Liu XQ, 2015, VIROLOGY, V479, P568, DOI 10.1016/j.virol.2015.02.040.
   Lövheim H, 2015, ALZHEIMERS DEMENT, V11, P593, DOI 10.1016/j.jalz.2014.04.522.
   Lövheim H, 2015, ALZHEIMERS DEMENT, V11, P587, DOI 10.1016/j.jalz.2014.07.157.
   Ma JZ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004237.
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017.
   Marketon JIW, 2008, CELL IMMUNOL, V252, P16, DOI 10.1016/j.cellimm.2007.09.006.
   Martin C, 2014, J ALZHEIMERS DIS, V42, P301, DOI 10.3233/JAD-140237.
   Mattila RK, 2015, J GEN VIROL, V96, P2304, DOI 10.1099/vir.0.000138.
   Mott KR, 2016, J VIROL, V90, P5059, DOI 10.1128/JVI.00255-16.
   Mott KR, 2014, J VIROL, V88, P6599, DOI 10.1128/JVI.00590-14.
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918.
   Neumann DM, 2007, J VIROL, V81, P13248, DOI 10.1128/JVI.01569-07.
   Nicoll MP, 2012, J VIROL, V86, P8848, DOI 10.1128/JVI.00652-12.
   Nicoll MP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005539.
   Noisakran S, 1998, J IMMUNOL, V160, P5441.
   O'Connell D, 2016, AUTOPHAGY, V12, P451, DOI 10.1080/15548627.2016.1139262.
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06.
   Ortiz GC, 2003, BRAIN BEHAV IMMUN, V17, P329, DOI 10.1016/S0889-1591(03)00027-8.
   Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001.
   Ostler JB, 2019, J VIROL, V93, DOI 10.1128/JVI.02063-18.
   Paludan SR, 2011, NAT REV IMMUNOL, V11, P143, DOI 10.1038/nri2937.
   PAVANLANGSTON D, 1989, ACTA OPHTHALMOL, V67, P135.
   Perlejewski K, 2015, J VIROL METHODS, V226, P1, DOI 10.1016/j.jviromet.2015.09.010.
   Perng GC, 2000, J VIROL, V74, P1885, DOI 10.1128/JVI.74.4.1885-1891.2000.
   Perng GC, 2016, CURR EYE RES, V41, P284, DOI 10.3109/02713683.2015.1020172.
   Piedade D, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060156.
   Roizman B, 2011, J VIROL, V85, P7474, DOI 10.1128/JVI.00180-11.
   Rongrong H., 2008, World Sci Technol, V10, P37, DOI {[}10.1016/S1876-3553(09)60024-7, DOI 10.1016/S1876-3553(09)60024-7].
   Rosato PC, 2016, VIROLOGY, V497, P323, DOI 10.1016/j.virol.2016.06.016.
   Rosato PC, 2015, FUTURE VIROL, V10, P699, DOI 10.2217/fvl.15.45.
   Rosato PC, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005028.
   Sanchez EL, 2015, VIROLOGY, V479, P609, DOI 10.1016/j.virol.2015.02.038.
   Shen CY, 2017, BRIT J PHARMACOL, V174, P1395, DOI 10.1111/bph.13631.
   Shen JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134178.
   Shen WW, 2009, J VIROL, V83, P9131, DOI 10.1128/JVI.00871-09.
   Sheridan BS, 2009, J VIROL, V83, P2237, DOI 10.1128/JVI.01699-08.
   SHIMOMURA Y, 1993, JPN J OPHTHALMOL, V37, P318.
   Shimomura Yoshikazu, 2008, Nippon Ganka Gakkai Zasshi, V112, P247.
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993.
   Sinani D, 2013, J VIROL, V87, P13042, DOI 10.1128/JVI.02476-13.
   Snoeck R, 2000, INT J ANTIMICROB AG, V16, P157, DOI 10.1016/S0924-8579(00)00233-8.
   Sommershof A, 2011, BRAIN BEHAV IMMUN, V25, P340, DOI 10.1016/j.bbi.2010.10.016.
   Srivastava R, 2016, J VIROL, V90, P3913, DOI 10.1128/JVI.02450-15.
   Steiner I, 2007, LANCET NEUROL, V6, P1015, DOI 10.1016/S1474-4422(07)70267-3.
   STOW ND, 1986, J GEN VIROL, V67, P2571, DOI 10.1099/0022-1317-67-12-2571.
   Su CH, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0495-5.
   Tang LP, 2014, EUR J INTEGR MED, V6, P637, DOI 10.1016/j.eujim.2014.07.018.
   Thompson RL, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000352.
   Toma Hassanain S, 2008, Semin Ophthalmol, V23, P249, DOI 10.1080/08820530802111085.
   Umbach JL, 2008, NATURE, V454, P780, DOI 10.1038/nature07103.
   VALYINAGY T, 1994, J GEN VIROL, V75, P2059, DOI 10.1099/0022-1317-75-8-2059.
   van Velzen M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003547.
   Vilibic-Cavlek T, 2011, SCAND J INFECT DIS, V43, P918, DOI 10.3109/00365548.2011.588611.
   Wang CY, 2014, AM J CHINESE MED, V42, P543, DOI 10.1142/S0192415X14500359.
   Wang QY, 2005, P NATL ACAD SCI USA, V102, P16055, DOI 10.1073/pnas.0505850102.
   Wang S, 2012, PROTEIN CELL, V3, P372, DOI 10.1007/s13238-012-2021-x.
   Wang XJ, 2011, J PHARMACEUT BIOMED, V55, P859, DOI 10.1016/j.jpba.2011.01.042.
   Whitley RJ, 2006, ANTIVIR RES, V71, P141, DOI 10.1016/j.antiviral.2006.04.002.
   WILCOX CL, 1990, J NEUROSCI, V10, P1268.
   Wozniak MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025152.
   Xu P, 2017, P NATL ACAD SCI USA, V114, pE3823, DOI 10.1073/pnas.1703395114.
   Xu P, 2016, P NATL ACAD SCI USA, V113, pE3022, DOI 10.1073/pnas.1605513113.
   Yordy B, 2013, AUTOPHAGY, V9, P236, DOI 10.4161/auto.22506.
   Yordy B, 2012, CELL HOST MICROBE, V12, P334, DOI 10.1016/j.chom.2012.07.013.
   You Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.139.
   Zhao J, 2010, BRIEF BIOINFORM, V11, P417, DOI 10.1093/bib/bbp063.
   Zheng XD, 1999, INVEST OPHTH VIS SCI, V40, P2490.
   Zhou GY, 2013, VIRUSES-BASEL, V5, P1208, DOI 10.3390/v5051208.
   Zhou GY, 2013, P NATL ACAD SCI USA, V110, pE498, DOI 10.1073/pnas.1222497110.
   Zhu Si-Rui, 2018, Zhongguo Zhong Yao Za Zhi, V43, P1529, DOI 10.19540/j.cnki.cjcmm.20180104.021.},
Number-of-Cited-References = {170},
Times-Cited = {65},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {57},
Journal-ISO = {Acta Pharm. Sin. B},
Doc-Delivery-Number = {KS1AF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000518042300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000529890200004,
Author = {Zhang, Hongxia and Jin, Kunlin},
Title = {Peripheral Circulating Exosomal miRNAs Potentially Contribute to the
   Regulation of Molecular Signaling Networks in Aging},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2020},
Volume = {21},
Number = {6},
Month = {MAR},
Abstract = {People are living longer than ever. Consequently, they have a greater
   chance for developing a functional impairment or aging-related disease,
   such as a neurodegenerative disease, later in life. Thus, it is
   important to identify and understand mechanisms underlying aging as well
   as the potential for rejuvenation. Therefore, we used next-generation
   sequencing to identify differentially expressed microRNAs (miRNAs) in
   serum exosomes isolated from young (three-month-old) and old
   (22-month-old) rats and then used bioinformatics to explore candidate
   genes and aging-related pathways. We identified 2844 mRNAs and 68 miRNAs
   that were differentially expressed with age. TargetScan revealed that 19
   of these miRNAs are predicated to target the 766 mRNAs. Pathways
   analysis revealed signaling components targeted by these miRNAs: mTOR,
   AMPK, eNOS, IGF, PTEN, p53, integrins, and growth hormone. In addition,
   the most frequently predicted target genes regulated by these miRNAs
   were EIF4EBP1, insulin receptor, PDK1, PTEN, paxillin, and IGF-1
   receptor. These signaling pathways and target genes may play critical
   roles in regulating aging and lifespan, thereby validating our analysis.
   Understanding the causes of aging and the underlying mechanisms may lead
   to interventions that could reverse certain aging processes and slow
   development of aging-related diseases.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Jin, KL (Corresponding Author), Univ North Texas, Hlth Sci Ctr, Dept Pharmacol \& Neurosci, Ft Worth, TX 76107 USA.
   Zhang, Hongxia; Jin, Kunlin, Univ North Texas, Hlth Sci Ctr, Dept Pharmacol \& Neurosci, Ft Worth, TX 76107 USA.},
DOI = {10.3390/ijms21061908},
Article-Number = {1908},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {exosomes; aging; serum; functional enrichment analysis; ingenuity
   pathway analysis; miRNA-mRNA networks; aging-related disease},
Keywords-Plus = {LIFE-SPAN; EXTRACELLULAR VESICLES; COGNITIVE IMPAIRMENT; PATHWAYS;
   MICRORNAS; CELLS; BRAIN; BIOMARKERS; RAPAMYCIN; TARGET},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {Hongxia.Zhang@unthsc.edu
   kunlin.jin@unthsc.edu},
Affiliations = {University of North Texas System; University of North Texas Denton},
ResearcherID-Numbers = {zhang, Hongxia/AAB-8995-2022},
ORCID-Numbers = {zhang, Hongxia/0000-0003-1594-6707},
Funding-Acknowledgement = {American Heart Association {[}18PRE34020126]; National Institutes of
   Health {[}5R21-NS094859-02]; American Heart Association (AHA)
   {[}18PRE34020126] Funding Source: American Heart Association (AHA)},
Funding-Text = {American Heart Association: 18PRE34020126; National Institutes of
   Health: 5R21-NS094859-02.},
Cited-References = {Alvarez-Erviti L, 2011, NAT BIOTECHNOL, V29, P341, DOI 10.1038/nbt.1807.
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002.
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090.
   Carlson ME, 2008, EXP CELL RES, V314, P1951, DOI 10.1016/j.yexcr.2008.03.017.
   Chung HY, 2019, AGING DIS, V10, P367, DOI 10.14336/AD.2018.0324.
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260.
   Cossetti C, 2014, MOL CELL, V56, P193, DOI 10.1016/j.molcel.2014.08.020.
   Dharap A, 2010, J NEUROCHEM, V113, P1685, DOI 10.1111/j.1471-4159.2010.06735.x.
   Dluzen DF, 2018, AGING CELL, V17, DOI 10.1111/acel.12785.
   Dragovic RA, 2011, NANOMED-NANOTECHNOL, V7, P780, DOI 10.1016/j.nano.2011.04.003.
   Eitan E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01386-z.
   Feng LB, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0155-4.
   Gomez GG, 2014, CANCER RES, V74, P1429, DOI 10.1158/0008-5472.CAN-13-2117.
   Greer EL, 2008, J CELL SCI, V121, P407, DOI 10.1242/jcs.021519.
   Hansen M, 2007, AGING CELL, V6, P95, DOI 10.1111/j.1474-9726.2006.00267.x.
   Hara N, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0414-z.
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221.
   Hatse S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110644.
   Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119.
   Henderson ST, 2006, J GERONTOL A-BIOL, V61, P444, DOI 10.1093/gerona/61.5.444.
   Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298.
   Inukai S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040028.
   Iwanami A, 2009, GENE DEV, V23, P1699, DOI 10.1101/gad.1832909.
   Jin KL, 2019, AGING DIS, V10, P676, DOI 10.14336/AD.2019.0315.
   Jin KL, 2010, AGING DIS, V1, P72.
   Jones A, 2017, OBESITY, V25, P1734, DOI 10.1002/oby.21950.
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092.
   Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059.
   Kennedy BK, 2016, CELL METAB, V23, P990, DOI 10.1016/j.cmet.2016.05.009.
   Kim JH, 2017, MOL THER-NUCL ACIDS, V6, P106, DOI 10.1016/j.omtn.2016.11.005.
   Kovanda A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23139-2.
   Lafferty-Whyte K, 2009, BBA-MOL BASIS DIS, V1792, P341, DOI 10.1016/j.bbadis.2009.02.003.
   Lee BP, 2017, SCI REP-UK, V7, DOI 10.1038/srep44620.
   Lee BR, 2018, INT J NANOMED, V13, P5335, DOI 10.2147/IJN.S170680.
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3.
   Locke JM, 2014, DIABETOLOGIA, V57, P122, DOI 10.1007/s00125-013-3089-4.
   Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015.
   Markowska AL, 1998, NEUROSCIENCE, V87, P559, DOI 10.1016/S0306-4522(98)00143-2.
   Matsumoto J, 2017, CURR PHARM DESIGN, V23, P6206, DOI 10.2174/1381612823666170913164738.
   Miller RA, 2014, AGING CELL, V13, P468, DOI 10.1111/acel.12194.
   Mushtaq G, 2016, MED CHEM, V12, P217, DOI 10.2174/1573406411666151030112140.
   Newgard CB, 2014, J GERONTOL A-BIOL, V69, pS21, DOI 10.1093/gerona/glu058.
   Noren Hooten N, 2013, AGING-US, V5, P725, DOI 10.18632/aging.100603.
   Noren Hooten N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010724.
   Pan H, 2017, J BIOL CHEM, V292, P6452, DOI 10.1074/jbc.R116.771915.
   Pedersen ME, 2013, SCIENCE, V341, P1404, DOI 10.1126/science.1242528.
   Pulliam L, 2019, J NEUROVIROL, V25, P702, DOI 10.1007/s13365-018-0695-4.
   Qu MK, 2018, J CONTROL RELEASE, V287, P156, DOI 10.1016/j.jconrel.2018.08.035.
   Rani A, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00323.
   Schwarzenbach H, 2014, NAT REV CLIN ONCOL, V11, P145, DOI 10.1038/nrclinonc.2014.5.
   Sebastiani P, 2017, AGING CELL, V16, P329, DOI 10.1111/acel.12557.
   Sheinerman KS, 2013, AGING-US, V5, P925, DOI 10.18632/aging.100624.
   Sun B, 2017, AIDS, V31, pF9, DOI {[}10.1097/QAD.0000000000001595, 10.1097/qad.0000000000001595].
   Syntichaki P, 2007, NATURE, V445, P922, DOI 10.1038/nature05603.
   Tait IS, 2013, BIOMEDICINES, V1, P17, DOI 10.3390/biomedicines1010017.
   Tan CL, 2013, SCIENCE, V342, P1254, DOI 10.1126/science.1244193.
   Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447.
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604.
   Tsai HP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191195.
   Urbanelli L, 2013, GENES-BASEL, V4, P152, DOI 10.3390/genes4020152.
   Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216.
   Xia Xian, 2017, F1000Res, V6, P860, DOI {[}10.12688/f1000research.10692.1, 10.12688/f1000research.10692.1].
   Xiao H, 2018, PEERJ, V6, DOI 10.7717/peerj.5774.
   Yang TZ, 2015, PHARM RES-DORDR, V32, P2003, DOI 10.1007/s11095-014-1593-y.
   Zhang HX, 2019, GEROSCIENCE, V41, P275, DOI 10.1007/s11357-019-00075-1.
   Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282.
   Zhao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069756.
   Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339.},
Number-of-Cited-References = {68},
Times-Cited = {20},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {LJ0UU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529890200004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000516959700004,
Author = {Zuo, Yuchao and Sun, Hongwei and Song, Laijun and Hu, Yan and Guo, Fuyou},
Title = {LncRNA FTX Involves in the Nogo-66-Induced Inhibition of Neurite
   Outgrowth Through Regulating PDK1/PKB/GSK-3β Pathway},
Journal = {CELLULAR AND MOLECULAR NEUROBIOLOGY},
Year = {2020},
Volume = {40},
Number = {7},
Pages = {1143-1153},
Month = {OCT},
Abstract = {Nogo-66 can inhibit neurite outgrowth, while its regulation mechanisms
   have not been fully elucidated. Recent studies prove that lncRNAs are
   involved in neurite outgrowth. This study was aimed to investigate
   whether lncRNA FTX was involved in Nogo-66-induced inhibition of neurite
   outgrowth and explore the potential mechanism. The expression of
   relative genes was detected by qRT-PCR and western blot. The function of
   FTX was determined by overexpression and knockdown techniques. The
   interaction between FTX and PDK1 was evaluated by RIP and RNA pull-down
   assays. FTX expression was downregulated by Nogo-66 in PC12 cells.
   Nogo-66-induced inhibition of neurite outgrowth was relieved by FTX
   overexpression. FTX bound to PDK1 protein to disturb the interaction
   between PDK1 and E3 ubiquitin ligase RNF126, thereby blocked the
   ubiquitination degradation of PDK1 and elevated PDK1 protein level.
   Mechanically, FTX involved in the Nogo-66-induced inhibition of neurite
   outgrowth through the PDK1/PKB/GSK-3 beta pathway. In SCI rats, FTX
   knockdown inhibited neurite outgrowth induced by the receptor antagonist
   of Nogo-66. The present results suggested that FTX took part in
   Nogo-66-inhibited neurite outgrowth, and FTX exerted its function
   through regulating PDK1/PKB/GSK-3 beta pathway.},
Publisher = {SPRINGER/PLENUM PUBLISHERS},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Zuo, YC (Corresponding Author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Jianshedong Rd, Zhengzhou 450052, Henan, Peoples R China.
   Zuo, Yuchao; Sun, Hongwei; Song, Laijun; Hu, Yan; Guo, Fuyou, Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Jianshedong Rd, Zhengzhou 450052, Henan, Peoples R China.},
DOI = {10.1007/s10571-020-00803-8},
EarlyAccessDate = {FEB 2020},
ISSN = {0272-4340},
EISSN = {1573-6830},
Keywords = {LncRNA FTX; PDK1; PKB; GSK-3 beta; Nogo-66; Neurite outgrowth},
Keywords-Plus = {NONCODING RNA; NEURONAL POLARITY; NOGO-A; APOPTOSIS; GROWTH; PDK1;
   INACTIVATION; ACTIVATION; EXPRESSION; ROLES},
Research-Areas = {Cell Biology; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Cell Biology; Neurosciences},
Author-Email = {zuoyuchao328@126.com},
Affiliations = {Zhengzhou University},
ResearcherID-Numbers = {Guo, Fuyou/J-3531-2019},
Funding-Acknowledgement = {First Affiliated Hospital of Zhengzhou University},
Funding-Text = {This study was supported by The First Affiliated Hospital of Zhengzhou
   University.},
Cited-References = {Arimura N, 2007, NAT REV NEUROSCI, V8, P194, DOI 10.1038/nrn2056.
   Cao Y, 2008, NEUROREHAB NEURAL RE, V22, P262, DOI 10.1177/1545968307308550.
   Chen L, 2016, J CELL MOL MED, V20, P2102, DOI 10.1111/jcmm.12904.
   Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219.
   Chureau C, 2011, HUM MOL GENET, V20, P705, DOI 10.1093/hmg/ddq516.
   Chytrova G, 2008, EUR J NEUROSCI, V27, P1, DOI 10.1111/j.1460-9568.2007.05982.x.
   Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072.
   Ishida N, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00347-16.
   Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033.
   Jiang YP, 2019, LIFE SCI, V228, P208, DOI 10.1016/j.lfs.2019.05.002.
   Kim WY, 2006, NEURON, V52, P981, DOI 10.1016/j.neuron.2006.10.031.
   Li D, 2018, MOL MED REP, V18, P2850, DOI 10.3892/mmr.2018.9278.
   Li EY, 2019, CELL CYCLE, V18, P156, DOI 10.1080/15384101.2018.1560202.
   Li XD, 2019, BIOCHEM BIOPH RES CO, V512, P79, DOI 10.1016/j.bbrc.2019.03.019.
   Li X, 2018, INT J ONCOL, V53, P551, DOI 10.3892/ijo.2018.4418.
   Liang XS, 2018, EUR REV MED PHARMACO, V22, P5214, DOI 10.26355/eurrev\_201808\_15719.
   Liu B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0706-7.
   Liu GM, 2016, MOL MED REP, V13, P4431, DOI 10.3892/mmr.2016.5072.
   Liu ZH, 2016, ONCOTARGET, V7, P25350, DOI 10.18632/oncotarget.8129.
   Long B, 2018, BIOCHEM BIOPH RES CO, V495, P312, DOI 10.1016/j.bbrc.2017.11.030.
   Lv HR, 2017, BIOCHEM BIOPH RES CO, V490, P948, DOI 10.1016/j.bbrc.2017.06.145.
   Malagelada C, 2008, J NEUROSCI, V28, P14363, DOI 10.1523/JNEUROSCI.3928-08.2008.
   Mo YC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317690999.
   Ni W, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0449-4.
   Shen Jian-ying, 2011, Neurosci Lett, V505, P165, DOI 10.1016/j.neulet.2011.10.012.
   Stefen H, 2018, CELL MOL NEUROBIOL, V38, P1557, DOI 10.1007/s10571-018-0620-7.
   Viniegra JG, 2005, J BIOL CHEM, V280, P4029, DOI 10.1074/jbc.M410344200.
   Wang F, 2007, NEUROSCI LETT, V417, P255, DOI 10.1016/j.neulet.2007.02.080.
   Wang HJ, 2011, NEUROREPORT, V22, P733, DOI 10.1097/WNR.0b013e32834a58e8.
   Xu CY, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00330.
   Yang Y, 2018, GENE THER, V25, P321, DOI 10.1038/s41434-018-0026-7.
   Yao C, 2015, EUR J NEUROSCI, V42, P1718, DOI 10.1111/ejn.12966.
   Yoshimura T, 2006, BIOCHEM BIOPH RES CO, V340, P62, DOI 10.1016/j.bbrc.2005.11.147.
   Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069.
   Zhong Y, 2012, J NEUROL SCI, V320, P38, DOI 10.1016/j.jns.2012.06.003.
   Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011.
   Zuo YC, 2016, NEUROSCI BULL, V32, P577, DOI 10.1007/s12264-016-0068-z.
   Zuo YC, 2016, J HUAZHONG U SCI-MED, V36, P548, DOI 10.1007/s11596-016-1623-6.},
Number-of-Cited-References = {38},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Cell. Mol. Neurobiol.},
Doc-Delivery-Number = {NA4SR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000516959700004},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000515439400001,
Author = {Kim, Hyebeen and Cho, Sung Chun and Jeong, Hyeon-Ju and Lee, Hye-Young
   and Jeong, Myong-Ho and Pyun, Jung-Hoon and Ryu, Dongryeol and Kim,
   MinSeok and Lee, Young-Sam and Kim, Minseok S. and Park, Sang Chul and
   Lee, Yun-Il and Kang, Jong-Sun},
Title = {Indoprofen prevents muscle wasting in aged mice through activation of
   PDK1/AKT pathway},
Journal = {JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE},
Year = {2020},
Volume = {11},
Number = {4},
Pages = {1070-1088},
Month = {AUG},
Abstract = {Background Muscle wasting, resulting from aging or pathological
   conditions, leads to reduced quality of life, increased morbidity, and
   increased mortality. Much research effort has been focused on the
   development of exercise mimetics to prevent muscle atrophy and weakness.
   In this study, we identified indoprofen from a screen for peroxisome
   proliferator-activated receptor gamma coactivator alpha (PGC-1 alpha)
   inducers and report its potential as a drug for muscle wasting.
   Methods The effects of indoprofen treatment on dexamethasone-induced
   atrophy in mice and in 3-phosphoinositide-dependent protein kinase-1
   (PDK1)-deleted C2C12 myotubes were evaluated by immunoblotting to
   determine the expression levels of myosin heavy chain and
   anabolic-related and oxidative metabolism-related proteins. Young, old,
   and disuse-induced muscle atrophic mice were administered indoprofen (2
   mg/kg body weight) by gavage. Body weight, muscle weight, grip strength,
   isometric force, and muscle histology were assessed. The expression
   levels of muscle mass-related and function-related proteins were
   analysed by immunoblotting or immunostaining.
   Results In young (3-month-old) and aged (22-month-old) mice, indoprofen
   treatment activated oxidative metabolism-related enzymes and led to
   increased muscle mass. Mechanistic analysis using animal models and
   muscle cells revealed that indoprofen treatment induced the sequential
   activation of AKT/p70S6 kinase (S6K) and AMP-activated protein kinase
   (AMPK), which in turn can augment protein synthesis and PGC-1 alpha
   induction, respectively. Structural prediction analysis identified PDK1
   as a target of indoprofen and, indeed, short-term treatment with
   indoprofen activated the PDK1/AKT/S6K pathway in muscle cells.
   Consistent with this finding, PDK1 inhibition abrogated
   indoprofen-induced AKT/S6K activation and hypertrophic response.
   Conclusions Our findings demonstrate the effects of indoprofen in
   boosting skeletal muscle mass through the sequential activation of
   PDK1/AKT/S6K and AMPK/PGC-1 alpha. Taken together, our results suggest
   that indoprofen represents a potential drug to prevent muscle wasting
   and weakness related to aging or muscle diseases.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Kang, JS (Corresponding Author), Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Lee, YI (Corresponding Author), DGIST, Div Biotechnol, Well Aging Res Ctr, 333 Techno Jungang Daero, Daegu 42988, South Korea.
   Cho, SC (Corresponding Author), DGIST, Well Aging Res Ctr, 333 Techno Jungang Daero, Daegu 42988, South Korea.
   Kim, Hyebeen; Jeong, Hyeon-Ju; Lee, Hye-Young; Jeong, Myong-Ho; Pyun, Jung-Hoon; Ryu, Dongryeol; Kang, Jong-Sun, Sungkyunkwan Univ, Dept Mol Cell Biol, Single Cell Network Res Ctr, Suwon, South Korea.
   Ryu, Dongryeol; Kang, Jong-Sun, Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea.
   Cho, Sung Chun; Park, Sang Chul; Lee, Yun-Il, DGIST, Well Aging Res Ctr, Div Biotechnol, Daegu, South Korea.
   Kim, MinSeok, DGIST, Sch Undergrad Studies, Daegu, South Korea.
   Lee, Young-Sam; Kim, Minseok S., DGIST, Dept New Biol, Daegu, South Korea.},
DOI = {10.1002/jcsm.12558},
EarlyAccessDate = {FEB 2020},
ISSN = {2190-5991},
EISSN = {2190-6009},
Keywords = {Exercise mimetic; Hypertrophic response; Indoprofen; Muscle wasting;
   Muscle weakness; PDK1},
Keywords-Plus = {RECEPTOR-GAMMA COACTIVATOR-1-ALPHA; SKELETAL-MUSCLE; DIFFERENTIAL
   ACTIVATION; SIGNALING PATHWAYS; FIBER HYPERTROPHY; PROTEIN; EXERCISE;
   PGC-1-ALPHA; MITOCHONDRIAL; PHOSPHORYLATION},
Research-Areas = {Geriatrics \& Gerontology; General \& Internal Medicine},
Web-of-Science-Categories  = {Geriatrics \& Gerontology; Medicine, General \& Internal},
Author-Email = {sccho@dgist.ac.kr
   ylee56@dgist.ac.kr
   kangj01@skku.edu},
Affiliations = {Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung
   Medical Center; Daegu Gyeongbuk Institute of Science \& Technology
   (DGIST); Daegu Gyeongbuk Institute of Science \& Technology (DGIST);
   Daegu Gyeongbuk Institute of Science \& Technology (DGIST)},
ResearcherID-Numbers = {Kim, Minseok/AAJ-4797-2020
   Ryu, Dongryeol/AAQ-3642-2020
   Park, SangChul/CAF-6192-2022
   Lee, Young-Sam/A-2499-2013
   Lee, Hye-Young/JEP-8044-2023
   },
ORCID-Numbers = {Jeong, Hyeon-Ju/0000-0001-9025-2559
   Ryu, Dongryeol/0000-0001-5905-6760
   Jeong, Myong-Ho/0000-0001-8185-9869},
Funding-Acknowledgement = {National Research Foundation of Korea Grant - Korean Government (MSIP)
   {[}NRF-2019R1A2C2006233, NRF-2017M3A9D8048710, NRF-2016R1A5A2945889,
   NRF2016H1A2A1908679]; DGIST {[}2017010054]},
Funding-Text = {This research was supported by the National Research Foundation of Korea
   Grant funded by the Korean Government (MSIP) NRF-2019R1A2C2006233,
   NRF-2017M3A9D8048710, and NRF-2016R1A5A2945889 to J.S.K.,
   NRF2016H1A2A1908679 to H.K. This work was also supported by DGIST
   (2017010054) to Y.I.L.},
Cited-References = {Abraham J, 2007, SCI TECHNOL HUM VAL, V32, P399, DOI 10.1177/0162243907301002.
   Akimoto T, 2005, J BIOL CHEM, V280, P19587, DOI 10.1074/jbc.M408862200.
   Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018.
   Arnold AS, 2011, GERONTOLOGY, V57, P37, DOI 10.1159/000281883.
   Aschenbach WG, 2002, DIABETES, V51, P567, DOI 10.2337/diabetes.51.3.567.
   Avruch J, 2001, Prog Mol Subcell Biol, V26, P115.
   Bae GU, 2010, MOL BIOL CELL, V21, P2399, DOI 10.1091/mbc.E09-12-1011.
   Bar-Shai M, 2008, FREE RADICAL BIO MED, V44, P202, DOI 10.1016/j.freeradbiomed.2007.03.019.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874.
   Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2.
   Bross R, 1999, J CLIN ENDOCR METAB, V84, P3420, DOI 10.1210/jc.84.10.3420.
   Brown JL, 2017, ACTA PHYSIOL, V220, P275, DOI 10.1111/apha.12826.
   Cai XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep26802.
   Camera DM, 2016, FREE RADICAL BIO MED, V98, P131, DOI 10.1016/j.freeradbiomed.2016.02.007.
   Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965.
   Collins BJ, 2003, EMBO J, V22, P4202, DOI 10.1093/emboj/cdg407.
   Crossland H, 2008, J PHYSIOL-LONDON, V586, P5589, DOI 10.1113/jphysiol.2008.160150.
   Czubryt MP, 2003, P NATL ACAD SCI USA, V100, P1711, DOI 10.1073/pnas.0337639100.
   Dardevet Dominique, 2012, ScientificWorldJournal, V2012, P269531, DOI 10.1100/2012/269531.
   Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377.
   Egan B, 2010, J PHYSIOL-LONDON, V588, P1779, DOI 10.1113/jphysiol.2010.188011.
   EVANS WJ, 1995, J GERONTOL A-BIOL, V50, P5, DOI 10.1093/gerona/50A.Special\_Issue.5.
   Goreham C, 1999, AM J PHYSIOL-ENDOC M, V276, pE489.
   Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200.
   Hindie V, 2009, NAT CHEM BIOL, V5, P758, DOI 10.1038/nchembio.208.
   HUSKISSON EC, 1979, RHEUMATOL REHABIL, V18, P49, DOI 10.1093/rheumatology/18.1.49.
   Jäger S, 2007, P NATL ACAD SCI USA, V104, P12017, DOI 10.1073/pnas.0705070104.
   Jin YY, 2017, ONCOTARGET, V8, P24635, DOI 10.18632/oncotarget.15601.
   Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698.
   Kwon YR, 2014, STEM CELL RES, V13, P262, DOI 10.1016/j.scr.2014.07.004.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li JR, 2013, ORG BIOMOL CHEM, V11, P8375, DOI 10.1039/c3ob41161c.
   Lunn MR, 2004, CHEM BIOL, V11, P1489, DOI 10.1016/j.chembiol.2004.08.024.
   McCall GE, 1996, J APPL PHYSIOL, V81, P2004, DOI 10.1152/jappl.1996.81.5.2004.
   Mitchell WK, 2017, CLIN SCI, V131, P2643, DOI 10.1042/CS20171230.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477.
   Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051.
   Pournelle G. H., 1953, Journal of Mammalogy, V34, P133.
   Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2.
   Puppa MJ, 2012, J CACHEXIA SARCOPENI, V3, P117, DOI 10.1007/s13539-011-0047-1.
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033.
   Rettenmaier TJ, 2015, J MED CHEM, V58, P8285, DOI 10.1021/acs.jmedchem.5b01216.
   Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22.
   Ruas JL, 2012, CELL, V151, P1319, DOI 10.1016/j.cell.2012.10.050.
   Ryu D, 2014, CELL METAB, V20, P856, DOI 10.1016/j.cmet.2014.08.001.
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Schiaffino S, 2013, FEBS J, V280, P4294, DOI 10.1111/febs.12253.
   Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4.
   Schmidt EK, 2009, NAT METHODS, V6, P275, DOI {[}10.1038/NMETH.1314, 10.1038/nmeth.1314].
   Sczelecki S, 2014, AM J PHYSIOL-ENDOC M, V306, pE157, DOI 10.1152/ajpendo.00578.2013.
   Song YH, 2005, J INVEST MED, V53, P135, DOI 10.2310/6650.2005.00309.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527.
   Suwa M, 2008, METABOLISM, V57, P986, DOI 10.1016/j.metabol.2008.02.017.
   Tang JE, 2006, APPL PHYSIOL NUTR ME, V31, P495, DOI 10.1139/H06-026.
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120.
   von Haehling S, 2019, J CACHEXIA SARCOPENI, V10, P1143, DOI 10.1002/jcsm.12501.
   Vuong TA, 2020, CELL DEATH DIFFER, V27, P15, DOI 10.1038/s41418-019-0334-5.
   Walston JD, 2012, CURR OPIN RHEUMATOL, V24, P623, DOI 10.1097/BOR.0b013e328358d59b.
   Washington TA, 2011, ACTA PHYSIOL, V202, P657, DOI 10.1111/j.1748-1716.2011.02281.x.
   White JP, 2009, ACTA PHYSIOL, V197, P321, DOI 10.1111/j.1748-1716.2009.02029.x.
   Wright DC, 2007, J BIOL CHEM, V282, P18793, DOI 10.1074/jbc.M611252200.
   Yan XQ, 2019, MOLECULES, V24, DOI 10.3390/molecules24091685.
   Zhang HB, 2016, SCIENCE, V352, P1436, DOI 10.1126/science.aaf2693.},
Number-of-Cited-References = {67},
Times-Cited = {32},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {23},
Journal-ISO = {J. Cachexia Sarcopenia Muscle},
Doc-Delivery-Number = {NA8HA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000515439400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000514853400008,
Author = {Abt, Evan R. and Rosser, Ethan W. and Durst, Matthew A. and Lok, Vincent
   and Poddar, Soumya and Le, Thuc M. and Cho, Arthur and Kim, Woosuk and
   Wei, Liu and Song, Janet and Capri, Joseph R. and Xu, Shili and Wu,
   Nanping and Slavik, Roger and Jung, Michael E. and Damoiseaux, Robert
   and Czernin, Johannes and Donahue, Timothy R. and Lavie, Arnon and Radu,
   Caius G.},
Title = {Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase
   Inhibitors within Nucleotide Metabolism},
Journal = {CELL CHEMICAL BIOLOGY},
Year = {2020},
Volume = {27},
Number = {2},
Pages = {197+},
Month = {FEB 20},
Abstract = {Biosynthesis of the pyrimidine nucleotide uridine monophosphate (UMP) is
   essential for cell proliferation and is achieved by the activity of
   convergent de novo and salvage metabolic pathways. Here we report the
   development and application of a cell-based metabolic modifier screening
   platform that leverages the redundancy in pyrimidine metabolism for the
   discovery of selective UMP biosynthesis modulators. In evaluating a
   library of protein kinase inhibitors, we identified multiple compounds
   that possess nucleotide metabolism modifying activity. The JNK inhibitor
   JNK-IN-8 was found to potently inhibit nucleoside transport and engage
   ENT1. The PDK1 inhibitor OSU-03012 (also known as AR-12) and the RAF
   inhibitor TAK-632 were shown to inhibit the therapeutically relevant de
   novo pathway enzyme DHODH and their affinities were unambiguously
   confirmed through in vitro assays and co-crystallization with human
   DHODH.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Radu, CG (Corresponding Author), Univ Calif Los Angeles, Dept Mol \& Med Pharmacol, Los Angeles, CA 90095 USA.
   Radu, CG (Corresponding Author), Univ Calif Los Angeles, Ahmanson Translat Imaging Div, Los Angeles, CA 90095 USA.
   Abt, Evan R.; Lok, Vincent; Poddar, Soumya; Le, Thuc M.; Kim, Woosuk; Wei, Liu; Song, Janet; Capri, Joseph R.; Slavik, Roger; Damoiseaux, Robert; Czernin, Johannes; Donahue, Timothy R.; Radu, Caius G., Univ Calif Los Angeles, Dept Mol \& Med Pharmacol, Los Angeles, CA 90095 USA.
   Abt, Evan R.; Rosser, Ethan W.; Lok, Vincent; Poddar, Soumya; Le, Thuc M.; Kim, Woosuk; Wei, Liu; Song, Janet; Capri, Joseph R.; Xu, Shili; Wu, Nanping; Slavik, Roger; Czernin, Johannes; Donahue, Timothy R.; Radu, Caius G., Univ Calif Los Angeles, Ahmanson Translat Imaging Div, Los Angeles, CA 90095 USA.
   Rosser, Ethan W.; Jung, Michael E., Univ Calif Los Angeles, Dept Chem \& Biochem, 405 Hilgard Ave, Los Angeles, CA 90024 USA.
   Durst, Matthew A.; Lavie, Arnon, Univ Illinois, Dept Biochem \& Mol Genet, Chicago, IL USA.
   Durst, Matthew A.; Lavie, Arnon, Jesse Brown VA Med Ctr, Chicago, IL USA.
   Cho, Arthur, Yonsei Univ, Dept Nucl Med, Coll Med, Seoul, South Korea.
   Xu, Shili; Wu, Nanping; Donahue, Timothy R., Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
   Damoiseaux, Robert, Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90024 USA.
   Donahue, Timothy R., Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
   Donahue, Timothy R., Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.},
DOI = {10.1016/j.chembiol.2019.10.012},
ISSN = {2451-9456},
EISSN = {2451-9448},
Keywords-Plus = {HUMAN DIHYDROOROTATE DEHYDROGENASE; POSITRON-EMISSION-TOMOGRAPHY;
   NUCLEOSIDE TRANSPORTERS; DESIGN; POTENT; ANALOG; PHOSPHORYLATION;
   DIFFERENTIATION; BIOSYNTHESIS; ENGAGEMENT},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {cradu@mednet.ucla.edu},
Affiliations = {University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical
   Center; Yonsei University; Yonsei University Health System; University
   of California System; University of California Los Angeles; University
   of California System; University of California Los Angeles; University
   of California System; University of California Los Angeles; University
   of California Los Angeles Medical Center; David Geffen School of
   Medicine at UCLA; University of California System; University of
   California Los Angeles; UCLA Jonsson Comprehensive Cancer Center},
ResearcherID-Numbers = {Lavie, Arnon/H-4927-2012
   Xu, Shili/H-4820-2015
   Damoiseaux, Robert/F-1086-2011
   Lok, Vincent/IAC-0485-2023
   Radu, Caius/MZQ-3513-2025},
ORCID-Numbers = {Lavie, Arnon/0000-0001-5591-8722
   Xu, Shili/0000-0002-4933-8673
   Cho, Arthur/0000-0001-8670-2473
   Damoiseaux, Robert/0000-0002-7611-7534
   Rosser, Ethan Wan/0000-0003-1060-7634
   Durst, Matthew/0000-0001-9513-2361
   Abt, Evan/0000-0002-3160-7134
   Lok, Vincent/0000-0001-8704-3174
   Radu, Caius/0000-0002-9338-5397},
Funding-Acknowledgement = {NCI NIH HHS {[}T32 CA009120, R01 CA187678, P30 CA016042, R01 CA260678]
   Funding Source: Medline; BLRD VA {[}I01 BX001919] Funding Source:
   Medline; National Cancer Institute {[}P30CA016042, T32CA009120] Funding
   Source: NIH RePORTER},
Cited-References = {Arroyo JD, 2016, CELL METAB, V24, P875, DOI 10.1016/j.cmet.2016.08.017.
   Baumgartner R, 2006, J MED CHEM, V49, P1239, DOI 10.1021/jm0506975.
   Bonavia A, 2011, P NATL ACAD SCI USA, V108, P6739, DOI 10.1073/pnas.1017142108.
   Bonomo S, 2013, J MOL MODEL, V19, P1099, DOI 10.1007/s00894-012-1643-5.
   Byrne KT, 2016, J IMMUNOL, V197, P179, DOI 10.4049/jimmunol.1600146.
   Campbell DO, 2012, J BIOL CHEM, V287, P446, DOI 10.1074/jbc.M111.314666.
   CAO Q, 2018, J NUCL MED, V59, DOI DOI 10.2967/JNUMED.118.212365..
   COLLINS KD, 1971, J BIOL CHEM, V246, P6599.
   Damaraju VL, 2016, J BIOL CHEM, V291, P18809, DOI 10.1074/jbc.M116.741074.
   Das P, 2013, ACS MED CHEM LETT, V4, P517, DOI 10.1021/ml300464h.
   Davies M, 2009, J MED CHEM, V52, P2683, DOI 10.1021/jm800963t.
   Deng XY, 2014, J MED CHEM, V57, P5381, DOI 10.1021/jm500481t.
   Erra M, 2011, BIOORG MED CHEM LETT, V21, P7268, DOI 10.1016/j.bmcl.2011.10.052.
   Evans DR, 2004, J BIOL CHEM, V279, P33035, DOI 10.1074/jbc.R400007200.
   Fang JX, 2013, BIOSCIENCE REP, V33, P217, DOI 10.1042/BSR20120097.
   Garcia-Bermudez J, 2018, NAT CELL BIOL, V20, P775, DOI 10.1038/s41556-018-0118-z.
   Gohil VM, 2010, NAT BIOTECHNOL, V28, P249, DOI 10.1038/nbt.1606.
   Hafner M, 2016, NAT METHODS, V13, P521, DOI {[}10.1038/nmeth.3853, 10.1038/NMETH.3853].
   Horvath IB, 2016, NAT METHODS, V13, P9, DOI 10.1038/nmeth.3692.
   Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200.
   Hurt DE, 2006, BIOORG MED CHEM LETT, V16, P1610, DOI 10.1016/j.bmcl.2005.12.029.
   Kim W, 2016, P NATL ACAD SCI USA, V113, P4027, DOI 10.1073/pnas.1524212113.
   Ladds MJGW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04198-5.
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u.
   Le TM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00221-3.
   Lewis TA, 2016, ACS MED CHEM LETT, V7, P1112, DOI 10.1021/acsmedchemlett.6b00316.
   Liu SP, 2000, STRUCT FOLD DES, V8, P25, DOI 10.1016/S0969-2126(00)00077-0.
   Lolli ML, 2018, RECENT PAT ANTI-CANC, V13, P86, DOI 10.2174/1574892812666171108124218.
   Mackey JR, 1998, CANCER RES, V58, P4349.
   Madak JT, 2019, PHARMACOL THERAPEUT, V195, P111, DOI 10.1016/j.pharmthera.2018.10.012.
   McLean LR, 2010, BIOORG MED CHEM LETT, V20, P1981, DOI 10.1016/j.bmcl.2010.01.115.
   Molina DM, 2016, ANNU REV PHARMACOL, V56, P141, DOI 10.1146/annurev-pharmtox-010715-103715.
   Morris AD, 1997, SYNTHETIC COMMUN, V27, P1259, DOI 10.1080/00397919708003363.
   Nathanson DA, 2014, J EXP MED, V211, P473, DOI 10.1084/jem.20131738.
   Okaniwa M, 2013, J MED CHEM, V56, P6478, DOI 10.1021/jm400778d.
   Okesli A, 2017, CURR OPIN BIOTECH, V48, P127, DOI 10.1016/j.copbio.2017.03.010.
   Paproski RJ, 2010, J NUCL MED, V51, P1447, DOI 10.2967/jnumed.110.076356.
   Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002.
   Peters GJ, 2018, NUCLEOS NUCLEOT NUCL, V37, P329, DOI 10.1080/15257770.2018.1460479.
   Radu CG, 2008, NAT MED, V14, P783, DOI 10.1038/nm1724.
   Sainas S, 2018, J MED CHEM, V61, P6034, DOI 10.1021/acs.jmedchem.8b00373.
   Santana-Codina N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07472-8.
   Shields AF, 1998, NAT MED, V4, P1334, DOI 10.1038/3337.
   Sykes DB, 2016, CELL, V167, P171, DOI 10.1016/j.cell.2016.08.057.
   Van Rompay AR, 2001, MOL PHARMACOL, V59, P1181, DOI 10.1124/mol.59.5.1181.
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127.
   Walse B, 2008, BIOCHEMISTRY-US, V47, P8929, DOI 10.1021/bi8003318.
   Wang QY, 2011, J VIROL, V85, P6548, DOI 10.1128/JVI.02510-10.
   Wright NJ, 2019, NAT STRUCT MOL BIOL, V26, P599, DOI 10.1038/s41594-019-0245-7.
   Yang CF, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0191-1.
   Yao SYM, 2018, BIOCHEM J, V475, P3293, DOI 10.1042/BCJ20180543.
   York AG, 2015, CELL, V163, P1716, DOI 10.1016/j.cell.2015.11.045.
   Young JD, 2013, MOL ASPECTS MED, V34, P529, DOI 10.1016/j.mam.2012.05.007.
   Yuan TL, 2018, CELL REP, V22, P1889, DOI 10.1016/j.celrep.2018.01.051.
   Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897.
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206.
   Zhang T, 2012, CHEM BIOL, V19, P140, DOI 10.1016/j.chembiol.2011.11.010.
   Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063.},
Number-of-Cited-References = {58},
Times-Cited = {28},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Cell Chem. Biol.},
Doc-Delivery-Number = {KN5BX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000514853400008},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000517272600001,
Author = {Siu, Michelle K. Y. and Jiang, Yu-xin and Wang, Jing-jing and Leung,
   Thomas H. Y. and Ngu, Siew Fei and Cheung, Annie N. Y. and Ngan, Hextan
   Y. S. and Chan, Karen K. L.},
Title = {PDK1 promotes ovarian cancer metastasis by modulating tumor-mesothelial
   adhesion, invasion, and angiogenesis via α5β1 integrin and JNK/IL-8
   signaling},
Journal = {ONCOGENESIS},
Year = {2020},
Volume = {9},
Number = {2},
Month = {FEB 18},
Abstract = {Ovarian cancer is the most lethal gynecological malignancies owing to
   the lack of definitive symptoms until development of widespread
   metastases. Identification of novel prognostic and therapeutic targets
   is therefore an urgent need to improve survival. Here, we demonstrated
   high expression of the mitochondrial gatekeeping enzyme, pyruvate
   dehydrogenase kinase 1 (PDK1), in both clinical samples and cell lines
   of ovarian cancer. PDK1 expression was significantly associated with
   metastasis, reduced chemosensitivity, and poor overall and disease-free
   survival, and further highlighted as an independent prognostic factor.
   Silencing of PDK1 retarded lactate production, ovarian cancer cell
   adhesion, migration, invasion, and angiogenesis, and consequently
   metastasis, concomitant with decreased alpha 5 beta 1 integrin
   expression. Phospho-kinase array profiling and RNA sequencing analyses
   further revealed reduction of JNK activation and IL-8 expression in
   PDK1-depleted cells. Conversely, PDK1 overexpression promoted cell
   adhesion via modulation of alpha 5 beta 1 integrins, along with cell
   migration, invasion, and angiogenesis through activation of JNK/IL-8
   signaling. PDK1 depletion additionally hindered tumor growth and
   dissemination in nude mice in vivo. Importantly, PDK1 levels were
   upregulated upon treatment with conditioned medium from omental tissues,
   which in turn promoted metastasis. Our findings suggest that PDK1, which
   is regulated by the tumor microenvironment, controls lactate production
   and promotes ovarian cancer cell metastasis via modulation of alpha 5
   beta 1 integrin and JNK/IL-8 signaling. To our knowledge, this is the
   first report to demonstrate an association between PDK1 and survival in
   patients with ovarian cancer, supporting its efficacy as a valuable
   prognostic marker and therapeutic molecular target for the disease.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Chan, KKL (Corresponding Author), Univ Hong Kong, Dept Obstet, Hong Kong, Peoples R China.
   Chan, KKL (Corresponding Author), Univ Hong Kong, Dept Gynaecol, Hong Kong, Peoples R China.
   Siu, Michelle K. Y.; Jiang, Yu-xin; Wang, Jing-jing; Leung, Thomas H. Y.; Ngu, Siew Fei; Ngan, Hextan Y. S.; Chan, Karen K. L., Univ Hong Kong, Dept Obstet, Hong Kong, Peoples R China.
   Siu, Michelle K. Y.; Jiang, Yu-xin; Wang, Jing-jing; Leung, Thomas H. Y.; Ngu, Siew Fei; Ngan, Hextan Y. S.; Chan, Karen K. L., Univ Hong Kong, Dept Gynaecol, Hong Kong, Peoples R China.
   Cheung, Annie N. Y., Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China.},
DOI = {10.1038/s41389-020-0209-0},
Article-Number = {24},
ISSN = {2157-9024},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE; POOR-PROGNOSIS; E-CADHERIN; CELLS; FIBROBLASTS;
   METABOLISM; MIGRATION; PROLIFERATION; CONTRIBUTES; EXPRESSION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {kklchan@hku.hk},
Affiliations = {University of Hong Kong; University of Hong Kong; University of Hong
   Kong},
ResearcherID-Numbers = {JIANG, Yuxin/AAB-9309-2022
   Ngu, SF/HKW-6889-2023},
ORCID-Numbers = {Ngan, Hextan Y S/0000-0003-3945-159X
   },
Funding-Acknowledgement = {Hong Kong Research Grants Council {[}HKU 17101414]; Department of
   Obstetrics and Gynaecology, the University of Hong Kong},
Funding-Text = {This work was supported by the Hong Kong Research Grants Council General
   Research Fund (HKU 17101414); and the Research Fund from the Department
   of Obstetrics and Gynaecology, the University of Hong Kong.},
Cited-References = {Bogoyevitch MA, 2006, MICROBIOL MOL BIOL R, V70, P1061, DOI 10.1128/MMBR.00025-06.
   Caneba CA, 2012, AM J PHYSIOL-ENDOC M, V303, pE1036, DOI 10.1152/ajpendo.00151.2012.
   Chan KKL, 2014, J ENDOCRINOL, V221, P325, DOI 10.1530/JOE-13-0500.
   Cheung LWT, 2013, MOL THER, V21, P78, DOI 10.1038/mt.2012.187.
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50.
   Fabian C, 2012, FEBS J, V279, P882, DOI 10.1111/j.1742-4658.2012.08479.x.
   Fong MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019963.
   Goetze K, 2011, INT J ONCOL, V39, P453, DOI 10.3892/ijo.2011.1055.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hansen JM, 2016, EUR J CANCER, V56, P131, DOI 10.1016/j.ejca.2015.12.016.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Ke HN, 2013, J INVEST DERMATOL, V133, P221, DOI 10.1038/jid.2012.253.
   Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778.
   Kenny HA, 2009, CANCER TREAT RES, V149, P335, DOI 10.1007/978-0-387-98094-2\_16.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Ksiazek K, 2009, AM J PATHOL, V174, P1230, DOI 10.2353/ajpath.2009.080613.
   Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105.
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323.
   Mainiero F, 2000, IMMUNITY, V12, P7, DOI 10.1016/S1074-7613(00)80154-5.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024.
   Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206.
   Nieman KM, 2011, NAT MED, V17, P1498, DOI 10.1038/nm.2492.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Rynne-Vidal A, 2015, CANCERS, V7, P1994, DOI 10.3390/cancers7040872.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167.
   Schauer IG, 2011, NEOPLASIA, V13, P393, DOI 10.1593/neo.101720.
   Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706.
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387.
   Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363.
   Siu MKY, 2010, P NATL ACAD SCI USA, V107, P18622, DOI 10.1073/pnas.0907481107.
   Slack-Davis JK, 2009, CANCER RES, V69, P1469, DOI 10.1158/0008-5472.CAN-08-2678.
   Sodek KL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-223.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1.
   Thibault B, 2014, CANCER METAST REV, V33, P17, DOI 10.1007/s10555-013-9456-2.
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Wilson RB, 2019, PLEURA PERITONEUM, V4, DOI 10.1515/pp-2019-0003.
   Winiarski BK, 2013, TRANSL ONCOL, V6, P703, DOI 10.1593/tlo.13529.
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.},
Number-of-Cited-References = {53},
Times-Cited = {59},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Oncogenesis},
Doc-Delivery-Number = {KQ9WP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000517272600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000517599100002,
Author = {Zhang, Yu and Ye, Qingjian and He, Junxian and Chen, Peigen and Wan,
   Jing and Li, Jing and Yang, Yuebo and Li, Xiaomao},
Title = {Recurrence-Associated Multi-RNA Signature to Predict Disease-Free
   Survival for Ovarian Cancer Patients},
Journal = {BIOMED RESEARCH INTERNATIONAL},
Year = {2020},
Volume = {2020},
Month = {FEB 15},
Abstract = {Ovarian cancer (OvCa) is an intractable gynecological malignancy due to
   the high recurrence rate. Several molecular biomarkers have been
   previously screened for early identifying patients with a high
   recurrence risk and poor prognosis. However, all the known studies
   focused on a single type of RNAs, not integrating various types. This
   study was to construct a new multi-RNA-based model to predict the
   recurrence and prognosis for OvCa patients by using the messenger RNA
   (mRNA, including long noncoding RNA (lncRNA)) and microRNA (miRNA)
   sequencing data of The Cancer Genome Atlas database. After univariate
   Cox regression and least absolute shrinkage and selection operator
   analyses, a multi-RNA-based signature (2 miRNAs: hsa-miR-508,
   hsa-miR-506; 1 lncRNA: TM4SF1-AS1; 11 mRNAs: MAGI3, SLAMF7, GLI2, PDK1,
   ARID3A, PLEKHG4B, TNFAIP8L3, C1QTNF3, NDUFAF1, CH25H, TMEM129) was
   generated and used to establish a risk score model. The high- and
   low-risk patients classified by the median risk score exhibited
   significantly different recurrence risks (89\% versus 61\%, p<0.001) and
   survival time (the area under the receiver operating characteristic
   curve (AUC) = 0.901 for 5-year disease-free survival (DFS)). This risk
   model was independent of other clinical features and superior to
   pathologic staging for DFS prediction (AUC, 0.906 versus 0.524; C-index,
   0.633 versus 0.510). Furthermore, some new interaction axes were
   revealed to explain the possible functions of these RNAs (competing
   endogenous RNA: TM4SF1-AS1-miR-186-STEAP2, LINC00536-miR-508-STEAP2,
   LINC00475-miR-506-TMEM129; coexpression: LINC00598-PLEKHG4B). In
   conclusion, this multi-RNA-based risk model may be clinically useful to
   stratify OvCa patients with different recurrence risks and survival
   outcomes and included RNAs may be potential therapeutic targets.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, YB; Li, XM (Corresponding Author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gynecol, Guangzhou 510630, Peoples R China.
   Zhang, Yu; Ye, Qingjian; He, Junxian; Chen, Peigen; Wan, Jing; Li, Jing; Yang, Yuebo; Li, Xiaomao, Sun Yat Sen Univ, Affiliated Hosp 3, Dept Gynecol, Guangzhou 510630, Peoples R China.},
DOI = {10.1155/2020/1618527},
Article-Number = {1618527},
ISSN = {2314-6133},
EISSN = {2314-6141},
Keywords-Plus = {PROSTATE-CANCER; CELL-PROLIFERATION; EXPRESSION; GENE; SUPPRESSES;
   PROGNOSIS; STEAP2; METASTASIS; STATISTICS; TRANSITION},
Research-Areas = {Biotechnology \& Applied Microbiology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Medicine, Research \&
   Experimental},
Author-Email = {zhangyu6@mail.sysu.edu.cn
   yeqjian@mail.sysu.edu.cn
   hejx53@mail2.sysu.edu.cn
   chenpg@mail2.sysu.edu.cn
   wanjing@mail.sysu.edu.cn
   lijing49@mail2.sysu.edu.cn
   yangyueb@mail.sysu.edu.cn
   lixmao@mail.sysu.edu.cn},
Affiliations = {Sun Yat Sen University},
ResearcherID-Numbers = {HE, Junxian/OHV-2278-2025
   wan, jing/PGN-0594-2026
   Chen, Peigen/ABE-6596-2021},
ORCID-Numbers = {Ye, Qingjian/0000-0002-8455-6967
   Chen, Peigen/0000-0002-0843-7739},
Cited-References = {{[}Anonymous], LINGNAN MODERN CLIN.
   Baek Su-Jin, 2008, J Gynecol Oncol, V19, P223, DOI 10.3802/jgo.2008.19.4.223.
   Bagnoli M, 2016, LANCET ONCOL, V17, P1137, DOI 10.1016/S1470-2045(16)30108-5.
   Burnell SEA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220456.
   Burnell SEA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24655-x.
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338.
   Dong JW, 2019, ONCOL REP, V41, P3233, DOI 10.3892/or.2019.7108.
   Edwards HM, 2016, ACTA ONCOL, V55, P36, DOI 10.1080/0284186X.2016.1182641.
   Fan YY, 2019, DIGEST DIS SCI, V64, P2823, DOI 10.1007/s10620-019-05626-2.
   Goeman JJ, 2010, BIOMETRICAL J, V52, P70, DOI 10.1002/bimj.200900028.
   Gouy S, 2018, INT J GYNECOL CANCER, V28, P493, DOI 10.1097/IGC.0000000000001202.
   Hong L, 2018, J CELL BIOCHEM, V119, P7431, DOI 10.1002/jcb.27052.
   Hou Wanting, 2019, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V36, P267, DOI 10.7507/1001-5515.201801057.
   Hua X, 2016, AM J CANCER RES, V6, P1650.
   Huang TH, 2018, CANCER BIOMARK, V21, P221, DOI 10.3233/CBM-170670.
   Jeong OS, 2016, SCI REP-UK, V6, DOI 10.1038/srep32172.
   Kempf E, 2017, CLIN TRANSL ONCOL, V19, P173, DOI 10.1007/s12094-016-1517-x.
   Kikuchi J, 2020, LEUKEMIA, V34, P180, DOI 10.1038/s41375-019-0525-6.
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377.
   Leffers N, 2008, GYNECOL ONCOL, V110, P365, DOI 10.1016/j.ygyno.2008.04.043.
   Li JL, 2018, ARCH BIOCHEM BIOPHYS, V640, P53, DOI 10.1016/j.abb.2018.01.002.
   Li MT, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-16.
   Li R, 2019, EXP CELL RES, V378, P32, DOI 10.1016/j.yexcr.2019.03.009.
   Lian KL, 2017, ONCOTARGET, V8, P48889, DOI 10.18632/oncotarget.16522.
   Liu G, 2014, J PATHOL, V233, P308, DOI 10.1002/path.4348.
   Long JY, 2018, J CELL MOL MED, V22, P5928, DOI 10.1111/jcmm.13863.
   Ma Q, 2015, ONCOTARGET, V6, P35851, DOI 10.18632/oncotarget.5323.
   Mariani A, 2019, GYNECOL ONCOL, V154, P495, DOI 10.1016/j.ygyno.2019.06.010.
   Mo XY, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22692.
   Nam EJ, 2016, ONCOTARGET, V7, P70524, DOI 10.18632/oncotarget.12045.
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pD239, DOI 10.1093/nar/gks1246.
   Porkka KP, 2002, LAB INVEST, V82, P1573, DOI 10.1097/01.LAB.0000038554.26102.C6.
   Povey S, 2001, HUM GENET, V109, P678, DOI 10.1007/s00439-001-0615-0.
   Ries J, 2017, ONCOL REP, V37, P3467, DOI 10.3892/or.2017.5639.
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007.
   Schröder MS, 2011, BIOINFORMATICS, V27, P3206, DOI 10.1093/bioinformatics/btr511.
   Shukla S, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw200.
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI {[}10.3322/caac.21442, 10.3322/caac.21551].
   Sradhanjali S, 2018, CURR TOP MED CHEM, V18, P444, DOI 10.2174/1568026618666180523105756.
   Sun Y, 2015, J PATHOL, V235, P25, DOI 10.1002/path.4443.
   Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003.
   Tian XL, 2017, MOL ONCOL, V11, P1544, DOI 10.1002/1878-0261.12117.
   Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3.
   Timmermans M, 2018, EUR J CANCER, V88, P31, DOI 10.1016/j.ejca.2017.10.030.
   Tsujioka T, 2015, SCI REP-UK, V5, DOI 10.1038/srep16709.
   van den Boomen DJH, 2014, P NATL ACAD SCI USA, V111, P11425, DOI 10.1073/pnas.1409099111.
   Vistad I, 2017, ACTA OBSTET GYN SCAN, V96, P1162, DOI 10.1111/aogs.13199.
   Wang W, 2019, EXP THER MED, V17, P3814, DOI 10.3892/etm.2019.7332.
   Wang X, 2018, ONCOL REP, V40, P2659, DOI 10.3892/or.2018.6707.
   Whiteland H, 2014, CLIN EXP METASTAS, V31, P909, DOI 10.1007/s10585-014-9679-9.
   Xiong YF, 2017, ONCOTARGET, V8, P85463, DOI 10.18632/oncotarget.20013.
   Xu J, 2019, MOL MED REP, V20, P5021, DOI 10.3892/mmr.2019.10736.
   Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056.
   Yang JD, 2011, J KOREAN MED SCI, V26, P1428, DOI 10.3346/jkms.2011.26.11.1428.
   Yang K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00763-y.
   Yao K, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0372-3.
   Yoon G, 2019, ANTICANCER RES, V39, P2845, DOI 10.21873/anticanres.13413.
   {[}张德龙 Zhang Delong], 2019, {[}第三军医大学学报, Journal of Third Military Medical University], V41, P213.
   Zhang H, 2019, J CANCER, V10, P990, DOI 10.7150/jca.26478.
   Zhao HY, 2016, ONCOTARGET, V7, P43924, DOI 10.18632/oncotarget.9721.
   Zhou JT, 2018, MOL MED REP, V18, P3589, DOI 10.3892/mmr.2018.9362.
   Zhu X, 2016, ONCOGENE, V35, P323, DOI 10.1038/onc.2015.84.},
Number-of-Cited-References = {62},
Times-Cited = {23},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Biomed Res. Int.},
Doc-Delivery-Number = {KR4OI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000517599100002},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000512808900001,
Author = {Xiao, Dongliang and Zhou, Quan and Gao, Yunbing and Cao, Baichuan and
   Zhang, Qiong and Zeng, Gaofeng and Zong, Shaohui},
Title = {PDK1 is important lipid kinase for RANKL-induced osteoclast formation
   and function via the regulation of the Akt-GSK3β-NFATc1 signaling
   cascade},
Journal = {JOURNAL OF CELLULAR BIOCHEMISTRY},
Year = {2020},
Volume = {121},
Number = {11},
Pages = {4542-4557},
Month = {NOV},
Abstract = {Perturbations in the balanced process of osteoblast-mediated bone
   formation and osteoclast-mediated bone resorption leading to excessive
   osteoclast formation and/or activity is the cause of many pathological
   bone conditions such as osteoporosis. The osteoclast is the only cell in
   the body capable of resorbing and degrading the mineralized bone matrix.
   Osteoclast formation from monocytic precursors is governed by the
   actions of two key cytokines macrophage-colony-stimulating factor and
   receptor activator of nuclear factor-kappa B ligand (RANKL). Binding of
   RANKL binding to receptor RANK initiates a series of downstream
   signaling responses leading to monocytic cell differentiation and
   fusion, and subsequent mature osteoclast bone resorption and survival.
   The phosphoinositide-3-kinase (PI3K)-protein kinase B (Akt) signaling
   cascade is one such pathway activated in response to RANKL. The
   3-phosphoinositide-dependent protein kinase 1 (PDK1), is considered the
   master upstream lipid kinase of the PI3K-Akt cascade. PDK1 functions to
   phosphorylate and partially activate Akt, triggering the activation of
   downstream effectors. However, the role of PDK1 in osteoclasts has yet
   to be clearly defined. In this study, we specifically deleted the PDK1
   gene in osteoclasts using the cathepsin-K promoter driven Cre-LoxP
   system. We found that the specific genetic ablation of PDK1 in
   osteoclasts leads to an osteoclast-poor osteopetrotic phenotype in mice.
   In vitro cellular assays further confirmed the impairment of osteoclast
   formation in response to RANKL by PDK1-deficient bone marrow macrophage
   (BMM) precursor cells. PDK1-deficient BMMs exhibited reduced ability to
   reorganize actin cytoskeleton to form a podosomal actin belt as a result
   of diminished capacity to fuse into giant multinucleated osteoclasts.
   Notably, biochemical analyses showed that PDK1 deficiency attenuated the
   phosphorylation of Akt and downstream effector GSK3 beta, and reduced
   induction of NFATc1. GSK3 beta is a reported negative regulator of
   NFATc1. GSK3 beta activity is inhibited by Akt-dependent
   phosphorylation. Thus, our data provide clear genetic and mechanistic
   insights into the important role for PDK1 in osteoclasts.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zong, SH (Corresponding Author), Guangxi Med Univ, Affiliated Hosp 1, Dept Spine Osteopathia, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zeng, GF (Corresponding Author), Guangxi Med Univ, Coll Publ Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Xiao, Dongliang; Gao, Yunbing; Cao, Baichuan; Zong, Shaohui, Guangxi Med Univ, Affiliated Hosp 1, Dept Spine Osteopathia, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zhou, Quan, Guangxi Med Univ, Collaborat Innovat Ctr Guangxi Biol Med, Nanning, Guangxi, Peoples R China.
   Zhang, Qiong; Zeng, Gaofeng, Guangxi Med Univ, Coll Publ Hyg, 22 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
   Zong, Shaohui, Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.},
DOI = {10.1002/jcb.29677},
EarlyAccessDate = {FEB 2020},
ISSN = {0730-2312},
EISSN = {1097-4644},
Keywords = {Akt; gene knockout; GSK3 beta; NFATc1; osteoclasts; osteoporosis; PDK1},
Keywords-Plus = {3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN-KINASE; GLYCOGEN-SYNTHASE KINASE-3;
   GENE-EXPRESSION; NFATC1; ACTIVATION; DIFFERENTIATION; OSTEOPOROSIS;
   FRACTURE; AKT/PKB; RICTOR},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {1685858372@qq.com
   xiaohui3008@126.com},
Affiliations = {Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University; Guangxi Medical University},
ResearcherID-Numbers = {xiao, dongliang/PGA-0716-2026
   },
ORCID-Numbers = {, xiao/0000-0003-0417-4916
   zhou, quan/0000-0002-0769-5517},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81860402]; Guangxi
   Natural Science Foundation of China {[}2017GXNSFAA198073]; Guangxi
   Medical High-level Key Talents Training ``139{''} Program Training
   Project; High Level Innovation Team and Excellence Scholars Program of
   Guangxi High Education Institutions},
Funding-Text = {National Natural Science Foundation of China, Grant/Award Number:
   81860402; Guangxi Natural Science Foundation of China, Grant/Award
   Number: 2017GXNSFAA198073; Guangxi Medical High-level Key Talents
   Training ``139{''} Program Training Project; High Level Innovation Team
   and Excellence Scholars Program of Guangxi High Education Institutions},
Cited-References = {Åkesson K, 2013, OSTEOPOROSIS INT, V24, P2135, DOI 10.1007/s00198-013-2348-z.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741.
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150.
   Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930.
   Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X.
   Bhattarai G, 2017, J BIOMED MATER RES A, V105, P2510, DOI 10.1002/jbm.a.36109.
   Chellaiah MA, 2006, EUR J CELL BIOL, V85, P311, DOI 10.1016/j.ejcb.2006.01.008.
   Chen X, 2013, BLOOD, V121, P3718, DOI 10.1182/blood-2012-10-461897.
   Crandall CJ, 2018, MENOPAUSE, V25, P11, DOI 10.1097/GME.0000000000000956.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Dangelmaier C, 2014, THROMB HAEMOSTASIS, V111, P508, DOI 10.1160/TH13-06-0484.
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003.
   Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005.
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035.
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703.
   Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200.
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768.
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4.
   Kawamura N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001058.
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237.
   Kurra S, 2014, ENDOCRIN METAB CLIN, V43, P233, DOI 10.1016/j.ecl.2013.09.004.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3.
   Linz A, 2015, J BONE MINER RES, V30, P1481, DOI 10.1002/jbmr.2484.
   Lorentzon M, 2015, J INTERN MED, V277, P650, DOI 10.1111/joim.12369.
   Lu Y, 2019, GERIATR ORTHOP SURG, V10, DOI 10.1177/2151459319859139.
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115.
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200.
   Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99.
   Pang MH, 2019, J CELL BIOCHEM, V120, P12382, DOI 10.1002/jcb.28504.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Segeletz S, 2016, PROTEOMICS, V16, P2545, DOI 10.1002/pmic.201500519.
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047.
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200.
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001.
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534-5807(02)00369-6.
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752.
   Touaitahuata H, 2016, J CELL SCI, V129, P3449, DOI 10.1242/jcs.184622.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4.
   Wu MR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13700.
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710.},
Number-of-Cited-References = {47},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {17},
Journal-ISO = {J. Cell. Biochem.},
Doc-Delivery-Number = {NT6UY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000512808900001},
DA = {2026-02-04},
}

@article{ WOS:000513500600007,
Author = {Li, Yang and Gruber, Joshua J. and Litzenburger, Ulrike M. and Zhou,
   Yiren and Miao, Yu Rebecca and LaGory, Edward L. and Li, Albert M. and
   Hu, Zhen and Yip, Michaela and Hart, Lori S. and Maris, John M. and
   Chang, Howard Y. and Giaccia, Amato J. and Ye, Jiangbin},
Title = {Acetate supplementation restores chromatin accessibility and promotes
   tumor cell differentiation under hypoxia},
Journal = {CELL DEATH \& DISEASE},
Year = {2020},
Volume = {11},
Number = {2},
Month = {FEB 6},
Abstract = {Despite the fact that Otto H. Warburg discovered the Warburg effect
   almost one hundred years ago, why cancer cells waste most of the glucose
   carbon as lactate remains an enigma. Warburg proposed a connection
   between the Warburg effect and cell dedifferentiation. Hypoxia is a
   common tumor microenvironmental stress that induces the Warburg effect
   and blocks tumor cell differentiation. The underlying mechanism by which
   this occurs is poorly understood, and no effective therapeutic strategy
   has been developed to overcome this resistance to differentiation. Using
   a neuroblastoma differentiation model, we discovered that hypoxia
   repressed cell differentiation through reducing cellular acetyl-CoA
   levels, leading to reduction of global histone acetylation and chromatin
   accessibility. The metabolic switch triggering this global histone
   hypoacetylation was the induction of pyruvate dehydrogenase kinases
   (PDK1 and PDK3). Inhibition of PDKs using dichloroacetate (DCA) restored
   acetyl-CoA generation and histone acetylation under hypoxia. Knocking
   down PDK1 induced neuroblastoma cell differentiation, highlighting the
   critical role of PDK1 in cell fate control. Importantly, acetate or
   glycerol triacetate (GTA) supplementation restored differentiation
   markers expression and neuron differentiation under hypoxia. Moreover,
   ATAC-Seq analysis demonstrated that hypoxia treatment significantly
   reduced chromatin accessibility at RAR/RXR binding sites, which can be
   restored by acetate supplementation. In addition, hypoxia-induced
   histone hypermethylation by increasing 2-hydroxyglutarate (2HG) and
   reducing alpha-ketoglutarate (alpha KG). alpha KG supplementation
   reduced histone hypermethylation upon hypoxia, but did not restore
   histone acetylation or differentiation markers expression. Together,
   these findings suggest that diverting pyruvate flux away from acetyl-CoA
   generation to lactate production is the key mechanism that Warburg
   effect drives dedifferentiation and tumorigenesis. We propose that
   combining differentiation therapy with acetate/GTA supplementation might
   represent an effective therapy against neuroblastoma.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Ye, JB (Corresponding Author), Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
   Li, Yang; Zhou, Yiren; Miao, Yu Rebecca; LaGory, Edward L.; Li, Albert M.; Yip, Michaela; Giaccia, Amato J.; Ye, Jiangbin, Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
   Gruber, Joshua J., Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA.
   Litzenburger, Ulrike M.; Chang, Howard Y., Stanford Univ, Ctr Personal Dynam Regulomes, Sch Med, Stanford, CA 94305 USA.
   Hu, Zhen, Olivia Consulting Serv, Redwood City, CA 94063 USA.
   Hart, Lori S.; Maris, John M., Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
   Hart, Lori S.; Maris, John M., Childrens Hosp Philadelphia, Ctr Childhood Canc Res, Philadelphia, PA 19104 USA.
   Hart, Lori S.; Maris, John M., Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   Chang, Howard Y., Stanford Univ, Howard Hughes Med Inst, Stanford, CA 94305 USA.},
DOI = {10.1038/s41419-020-2303-9},
Article-Number = {102},
ISSN = {2041-4889},
Keywords-Plus = {HISTONE ACETYLATION; METABOLIC SWITCH; RETINOIC ACID; NEUROBLASTOMA;
   CANCER; OXYGEN; PROLIFERATION; ADAPTATION; EXPRESSION; MAINTAINS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {yej1@stanford.edu},
Affiliations = {Stanford University; Stanford University; Stanford University;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia; University of Pennsylvania; Howard
   Hughes Medical Institute; Stanford University},
ResearcherID-Numbers = {Li, Yang/R-9468-2018
   Ye, Jiangbin/A-1094-2007
   },
ORCID-Numbers = {Li, Yang/0000-0002-1914-5598
   Yip, Michaela/0000-0002-7637-2746
   LaGory, Edward/0000-0002-0552-1695
   Ye, Jiangbin/0000-0003-1117-4869
   Li, Albert/0000-0002-0865-6915},
Funding-Acknowledgement = {NIH R00 Grant {[}CA184239]; Stanford Child Health Research Institute;
   Stanford NIHNCATS-CTSA {[}UL1 TR001085];  {[}P50-HG007735]; 
   {[}R35-CA209919]; National Cancer Institute {[}R35CA209919] Funding
   Source: NIH RePORTER},
Funding-Text = {This work was supported by a NIH R00 Grant (CA184239) and a Stanford
   Child Health Research Institute and the Stanford NIHNCATS-CTSA (UL1
   TR001085) Pilot Early Career Award to J.Y., and by P50-HG007735 and
   R35-CA209919 (to H.Y.C.). H.Y.C. is an Investigator of the Howard Hughes
   Medical Institute. We thank Dr. Curt R. Fischer (Stanford ChEM-H
   Institute) for the support and facilities. We thank Dr. Beverly S.
   Mitchell (Stanford Cancer Institute) for critically reviewing the paper
   and helpful comments.},
Cited-References = {Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397.
   Bray NL, 2016, NAT BIOTECHNOL, V34, P888, DOI 10.1038/nbt.3519.
   Buchman VL, 1998, NAT NEUROSCI, V1, P101, DOI 10.1038/349.
   BUCKLEY BM, 1977, BIOCHEM J, V166, P539, DOI 10.1042/bj1660539.
   Bulusu V, 2017, CELL REP, V18, P647, DOI 10.1016/j.celrep.2016.12.055.
   Chlapek P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010132.
   Colon Nadja C, 2011, Adv Pediatr, V58, P297, DOI 10.1016/j.yapd.2011.03.011.
   Comerford SA, 2014, CELL, V159, P1591, DOI 10.1016/j.cell.2014.11.020.
   Corces MR, 2017, NAT METHODS, V14, P959, DOI {[}10.1038/NMETH.4396, 10.1038/nmeth.4396].
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617.
   Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9.
   Durinck K, 2018, CELL TISSUE RES, V372, P309, DOI 10.1007/s00441-017-2773-y.
   Dzieran J, 2018, P NATL ACAD SCI USA, V115, pE1229, DOI 10.1073/pnas.1710901115.
   Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49.
   Fredlund E, 2008, P NATL ACAD SCI USA, V105, P14094, DOI 10.1073/pnas.0804455105.
   Gao X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11960.
   Hero B, 2008, J CLIN ONCOL, V26, P1504, DOI 10.1200/JCO.2007.12.3349.
   HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567.
   Hubbi ME, 2015, AM J PHYSIOL-CELL PH, V309, pC775, DOI 10.1152/ajpcell.00279.2015.
   Intlekofer AM, 2015, CELL METAB, V22, P304, DOI 10.1016/j.cmet.2015.06.023.
   Jögi A, 2003, CANCER LETT, V197, P145, DOI 10.1016/S0304-3835(03)00095-8.
   Jögi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199.
   Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508.
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82.
   Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703.
   Koster J, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.COMPSYSBIO-B1-05.
   Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111.
   Langmead B, 2012, NAT METHODS, V9, P357, DOI {[}10.1038/nmeth.1923, 10.1038/NMETH.1923].
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25.
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI {[}10.1093/bioinformatics/btp324, 10.1093/bioinformatics/btp698].
   Lorizio W, 2011, GENOME MED, V3, DOI 10.1186/gm280.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Martins M., 2011, EMBNET J, V17, P10, DOI DOI 10.14806/EJ.17.1.200.
   Mashimo T, 2014, CELL, V159, P1603, DOI 10.1016/j.cell.2014.11.025.
   Matthay KK, 1999, NEW ENGL J MED, V341, P1165, DOI 10.1056/NEJM199910143411601.
   Meijering E, 2004, CYTOM PART A, V58A, P167, DOI 10.1002/cyto.a.20022.
   Mews P, 2017, NATURE, V546, P381, DOI 10.1038/nature22405.
   Oldham WM, 2015, CELL METAB, V22, P291, DOI 10.1016/j.cmet.2015.06.021.
   Påhlman S, 2018, CELL TISSUE RES, V372, P269, DOI 10.1007/s00441-017-2701-1.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324.
   Pugh TJ, 2013, NAT GENET, V45, P279, DOI 10.1038/ng.2529.
   Ramírez F, 2016, NUCLEIC ACIDS RES, V44, pW160, DOI 10.1093/nar/gkw257.
   Rao Y, 2013, SCI CHINA LIFE SCI, V56, P495, DOI 10.1007/s11427-013-4487-z.
   Reynolds CP, 2003, CANCER LETT, V197, P185, DOI 10.1016/S0304-3835(03)00108-3.
   REYNOLDS CP, 1986, JNCI-J NATL CANCER I, V76, P375.
   Riester M, 2018, ANN ONCOL, V29, P264, DOI 10.1093/annonc/mdx645.
   Schell JC, 2017, NAT CELL BIOL, V19, P1027, DOI 10.1038/ncb3593.
   Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026.
   Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002.
   SIDELL N, 1982, JNCI-J NATL CANCER I, V68, P589.
   Tan B, 2014, ANAL BIOCHEM, V465, P134, DOI 10.1016/j.ab.2014.07.027.
   van Groningen T, 2017, NAT GENET, V49, P1261, DOI 10.1038/ng.3899.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Warburg O, 1924, BIOCHEM Z, V152, P309.
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519.
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097.
   Xie H, 2017, J BIOL CHEM, V292, P16825, DOI 10.1074/jbc.R117.799973.
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014.
   Yoshii Y, 2009, CANCER SCI, V100, P821, DOI 10.1111/j.1349-7006.2009.01099.x.
   Yun Zhong, 2003, Methods Mol Biol, V223, P485.
   Zhang C, 2017, CELL REP, V21, P2058, DOI 10.1016/j.celrep.2017.10.098.
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137.
   Zheng X, 2016, ELIFE, V5, DOI DOI 10.7554/ELIFE.13374.},
Number-of-Cited-References = {66},
Times-Cited = {51},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {KL5ZG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000513500600007},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000529522400006,
Author = {Palmieri, Erika M. and Gonzalez-Cotto, Marieli and Baseler, Walter A.
   and Davies, Luke C. and Ghesquiere, Bart and Maio, Nunziata and Rice,
   Christopher M. and Rouault, Tracey A. and Cassel, Teresa and Higashi,
   Richard M. and Lane, Andrew N. and Fan, Teresa W-M and Wink, David A.
   and McVicar, Daniel W.},
Title = {Nitric oxide orchestrates metabolic rewiring in M1 macrophages by
   targeting aconitase 2 and pyruvate dehydrogenase},
Journal = {NATURE COMMUNICATIONS},
Year = {2020},
Volume = {11},
Number = {1},
Month = {FEB 4},
Abstract = {Profound metabolic changes are characteristic of macrophages during
   classical activation and have been implicated in this phenotype. Here we
   demonstrate that nitric oxide (NO) produced by murine macrophages is
   responsible for TCA cycle alterations and citrate accumulation
   associated with polarization. C-13 tracing and mitochondrial respiration
   experiments map NO-mediated suppression of metabolism to mitochondrial
   aconitase (ACO2). Moreover, we find that inflammatory macrophages
   reroute pyruvate away from pyruvate dehydrogenase (PDH) in an
   NO-dependent and hypoxia-inducible factor 1 alpha (Hif1
   alpha)-independent manner, thereby promoting glutamine-based
   anaplerosis. Ultimately, NO accumulation leads to suppression and loss
   of mitochondrial electron transport chain (ETC) complexes. Our data
   reveal that macrophages metabolic rewiring, in vitro and in vivo, is
   dependent on NO targeting specific pathways, resulting in reduced
   production of inflammatory mediators. Our findings require modification
   to current models of macrophage biology and demonstrate that
   reprogramming of metabolism should be considered a result rather than a
   mediator of inflammatory polarization. Production of inflammatory
   mediators by M1-polarized macrophages is thought to rely on suppression
   of mitochondrial metabolism in favor of glycolysis. Refining this
   concept, here the authors define metabolic targets of nitric oxide as
   responsible for the mitochondrial rewiring resulting from polarization.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {McVicar, DW (Corresponding Author), NCI, Leukocyte Signaling Sect, Canc \& Inflammat Program, Frederick, MD 21701 USA.
   Palmieri, Erika M.; Gonzalez-Cotto, Marieli; Baseler, Walter A.; Davies, Luke C.; Rice, Christopher M.; McVicar, Daniel W., NCI, Leukocyte Signaling Sect, Canc \& Inflammat Program, Frederick, MD 21701 USA.
   Davies, Luke C., Cardiff Univ, Div Infect \& Immun, Sch Med, Tenovus Bldg,Heath Pk, Cardiff CF14 4XN, Wales.
   Ghesquiere, Bart, VIB, Vesalius Res Ctr, Metabol Expertise Ctr, Leuven 3000, Belgium.
   Ghesquiere, Bart, Katholieke Univ Leuven, Dept Oncol, Metabol Expertise Ctr, Leuven 3000, Belgium.
   Maio, Nunziata; Rouault, Tracey A., Eunice Kennedy Shriver Natl Inst Child Hlth \& Hum, Mol Med Branch, Bethesda, MD USA.
   Rice, Christopher M., Univ Bristol, Fac Life Sci, Sch Cellular \& Mol Med, Bristol BS8 1TD, Avon, England.
   Cassel, Teresa; Higashi, Richard M.; Lane, Andrew N.; Fan, Teresa W-M, Univ Kentucky, Dept Toxicol \& Canc Biol, Lexington, KY USA.
   Cassel, Teresa; Higashi, Richard M.; Lane, Andrew N.; Fan, Teresa W-M, Univ Kentucky, Markey Canc Ctr, Lexington, KY USA.
   Cassel, Teresa; Higashi, Richard M.; Lane, Andrew N.; Fan, Teresa W-M, Univ Kentucky, Ctr Environm \& Syst Biochem, Lexington, KY USA.
   Wink, David A., NCI, Chem \& Mol Inflammat Sect, Canc \& Inflammat Program, Frederick, MD 21701 USA.},
DOI = {10.1038/s41467-020-14433-7},
Article-Number = {698},
EISSN = {2041-1723},
Keywords-Plus = {MITOCHONDRIAL RESPIRATORY-CHAIN; SUCCINATE-DEHYDROGENASE; DENDRITIC
   CELL; ACTIVATED MACROPHAGES; MURINE MACROPHAGES; INTERFERON-GAMMA;
   TUMOR-CELLS; COMPLEX-I; INHIBITION; ITACONATE},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {mcvicard@mail.nih.gov},
Affiliations = {National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Cardiff University; Flanders Institute for Biotechnology (VIB);
   KU Leuven; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy
   Shriver National Institute of Child Health \& Human Development (NICHD);
   University of Bristol; University of Kentucky; University of Kentucky;
   University of Kentucky; National Institutes of Health (NIH) - USA; NIH
   National Cancer Institute (NCI)},
ResearcherID-Numbers = {Palmieri, Erika M/AAL-5897-2020
   Maio, Nunziata/IWU-8373-2023
   McVicar, Daniel/G-1970-2015
   Ghesquière, Bart/HGU-8736-2022
   },
ORCID-Numbers = {Palmieri, Erika M/0000-0002-4237-5324
   Maio, Nunziata/0000-0002-6225-6058
   Davies, Luke/0000-0001-7767-4060
   McVicar, Daniel/0000-0002-1112-5111
   Wink, David/0000-0002-5652-7480
   Ghesquière, Bart/0000-0003-1547-1705
   Rice, Christopher/0000-0002-8158-4022
   Rouault, Tracey/0000-0003-0062-0245},
Funding-Acknowledgement = {NIH, National Cancer Institute USA {[}1U24DK097215-01A1]; University of
   Kentucky Markey Cancer Center {[}P30CA177558]; Henry Wellcome Trust, UK
   {[}WT103973MA]; National Cancer Institute {[}ZIABC011190, ZIABC010300,
   ZIASC007281] Funding Source: NIH RePORTER; Wellcome Trust
   {[}103973/Z/14/Z] Funding Source: Wellcome Trust; Wellcome Trust
   {[}103973/Z/14/Z] Funding Source: researchfish},
Funding-Text = {We thank Prof. Bernhard Brune at Goethe-University Frankfurt-Faculty of
   Medicine for providing Hif alpha 1-/- BMDMs, Jeffrey Subleski
   (Leukocyte Signaling Section, Cancer \& Inflammation Program, National
   Cancer Institute, Frederick, MD, USA) for its technical assistance and
   Daniel R. Crooks (Urologic Oncology Branch, National Cancer Institute,
   Bethesda, MD, USA) for helpful discussions. This research was supported,
   in part, by the intramural Research Program of the NIH, National Cancer
   Institute USA, 1U24DK097215-01A1 (to RMH, TWMF, and ANL), and Redox
   Metabolism Shared Resource(s) of the University of Kentucky Markey
   Cancer Center (P30CA177558). L.C.D. is funded in part by and the Henry
   Wellcome Trust, UK (WT103973MA). The content of this publication does
   not reflect views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organization simply endorsement by the U.S.Government.},
Cited-References = {Amura CR, 1997, J IMMUNOL, V159, P5079.
   Babot M, 2014, BBA-BIOENERGETICS, V1837, P1083, DOI 10.1016/j.bbabio.2014.02.018.
   Balamurugan K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2677.
   Baseler WA, 2016, REDOX BIOL, V10, P12, DOI 10.1016/j.redox.2016.09.005.
   Basudhar D, 2017, P NATL ACAD SCI USA, V114, P13030, DOI 10.1073/pnas.1709119114.
   BOLANOS JP, 1994, J NEUROCHEM, V63, P910.
   BOLANOS JP, 1995, J NEUROCHEM, V64, P1965.
   Buescher JM, 2015, CURR OPIN BIOTECH, V34, P189, DOI 10.1016/j.copbio.2015.02.003.
   CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2.
   Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631.
   Cordes T, 2016, J BIOL CHEM, V291, P14274, DOI 10.1074/jbc.M115.685792.
   Davies LC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02092-0.
   DRAPIER JC, 1988, J IMMUNOL, V140, P2829.
   DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642.
   Everts B, 2014, NAT IMMUNOL, V15, P323, DOI 10.1038/ni.2833.
   Everts B, 2012, BLOOD, V120, P1422, DOI 10.1182/blood-2012-03-419747.
   Freemerman AJ, 2019, J IMMUNOL, V202, P1265, DOI 10.4049/jimmunol.1800002.
   Galkin A, 2007, J BIOL CHEM, V282, P37448, DOI 10.1074/jbc.M707543200.
   Giordano D, 2011, J LEUKOCYTE BIOL, V89, P443, DOI 10.1189/jlb.0610329.
   GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527.
   HEREMANS H, 1990, J EXP MED, V171, P1853, DOI 10.1084/jem.171.6.1853.
   HINMAN LM, 1981, J BIOL CHEM, V256, P6583.
   Huang D, 2014, CELL REP, V8, P1930, DOI 10.1016/j.celrep.2014.08.028.
   Infantino V, 2014, BBA-GENE REGUL MECH, V1839, P1217, DOI 10.1016/j.bbagrm.2014.07.013.
   Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535.
   Jablonski KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145342.
   Jha AK, 2015, IMMUNITY, V42, P419, DOI 10.1016/j.immuni.2015.02.005.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624.
   Korzeniewski B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117145.
   Lachmandas E, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.246.
   Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004.
   Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009.
   Lei MG, 2005, INFECT IMMUN, V73, P8136, DOI 10.1128/IAI.73.12.8136-8143.2005.
   Lin AP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8768.
   Llufrio EM, 2018, REDOX BIOL, V16, P381, DOI 10.1016/j.redox.2018.03.004.
   MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06.
   MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323.
   Maio N, 2017, CELL METAB, V25, P945, DOI 10.1016/j.cmet.2017.03.010.
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015.
   Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303.
   MCFADDEN BA, 1977, J BACTERIOL, V131, P136, DOI 10.1128/JB.131.1.136-144.1977.
   Meiser J, 2016, J BIOL CHEM, V291, P3932, DOI 10.1074/jbc.M115.676817.
   Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110.
   Mishra BB, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.72.
   Mycielska ME, 2009, BIOESSAYS, V31, P10, DOI 10.1002/bies.080137.
   Nair S, 2018, J EXP MED, V215, P1035, DOI 10.1084/jem.20180118.
   Németh B, 2016, FASEB J, V30, P286, DOI 10.1096/fj.15-279398.
   Netea MG, 2017, CELL HOST MICROBE, V21, P297, DOI 10.1016/j.chom.2017.02.003.
   Newsholme P, 2001, J NUTR, V131, p2515S, DOI 10.1093/jn/131.9.2515S.
   Noe JT, 2019, J LEUKOCYTE BIOL, V106, P359, DOI 10.1002/JLB.3RU1218-496R.
   O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570.
   O'Neill LAJ, 2015, IMMUNITY, V42, P393, DOI 10.1016/j.immuni.2015.02.017.
   Palmieri EM, 2015, BBA-BIOENERGETICS, V1847, P729, DOI 10.1016/j.bbabio.2015.04.009.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Piantadosi CA, 2012, BBA-GEN SUBJECTS, V1820, P712, DOI 10.1016/j.bbagen.2011.03.008.
   Qualls JE, 2012, CELL HOST MICROBE, V12, P313, DOI 10.1016/j.chom.2012.07.012.
   Rodríguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698.
   Salabei JK, 2014, NAT PROTOC, V9, P421, DOI 10.1038/nprot.2014.018.
   Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362.
   Somasundaram V, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101354.
   Spinella-Jaegle S, 2001, EUR CYTOKINE NETW, V12, P280.
   STADLER J, 1991, AM J PHYSIOL, V260, pC910, DOI 10.1152/ajpcell.1991.260.5.C910.
   Tan Z, 2015, J BIOL CHEM, V290, P46, DOI 10.1074/jbc.M114.603589.
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986.
   Thwe PM, 2018, CANCER LETT, V412, P236, DOI 10.1016/j.canlet.2017.10.032.
   Weiss JM, 2018, J CLIN INVEST, V128, P3794, DOI 10.1172/JCI99169.
   Yan Liang-Jun, 2012, Sheng Wu Wu Li Hsueh Bao, V28, P341.
   Zinchenko V. P., 2007, CYTOLOGY, V49, P1023.},
Number-of-Cited-References = {69},
Times-Cited = {346},
Usage-Count-Last-180-days = {8},
Usage-Count-Since-2013 = {164},
Journal-ISO = {Nat. Commun.},
Doc-Delivery-Number = {LI5JP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529522400006},
OA = {Green Submitted, Green Accepted, Green Published, gold},
DA = {2026-02-04},
}

@article{ WOS:000513837100005,
Author = {Liu, Yaozhong and Bai, Fan and Liu, Na and Zhang, Baojian and Qin, Fen
   and Tu, Tao and Li, Biao and Li, Jiayi and Ma, Yingxu and Ouyang, Feifan
   and Liu, Qiming},
Title = {Metformin improves lipid metabolism and reverses the Warburg effect in a
   canine model of chronic atrial fibrillation},
Journal = {BMC CARDIOVASCULAR DISORDERS},
Year = {2020},
Volume = {20},
Number = {1},
Month = {FEB 3},
Abstract = {Background: Previous studies demonstrated impaired lipid metabolism and
   augmented aerobic glycolysis in AF. The authors aimed to investigate
   whether the use of metformin, an AMPK activator, could reverse this
   metabolic remodeling in chronic AF and to explore the underlying
   mechanisms.
   Methods: We conducted chronic AF animal models with 18 beagle dogs and
   divided them into SR (pacemaker implanted without pacing), AF (pacemaker
   implanted with sustained pacing at a frequency of 400 beats/min for 6
   weeks), and metformin+AF group (daily oral administration of metformin
   was initiated 1 week before surgery and continued throughout the study
   period). After electrophysiological measurements, the left atrial
   appendage tissue samples were taken from the beating heart for further
   analysis. Protein expression, histological analysis, and biochemical
   measurements were conducted.
   Results: The AF groups showed decreased expression of FAT/CD36, CPT-1,
   VLCAD, increased concentration of free fatty acid and triglyceride, and
   increased lipid deposition. The activation of AMPK/PGC-1 alpha/PPAR
   alpha pathway was decreased. The key factors of the Warburg effect,
   including HIF-1 alpha, GLUT-1, PDK1, HK, and LDH, increased in AF group
   compared to SR group. The expression of PDH decreased significantly,
   accompanied by increased atrial lactate production. The extent of
   fibrosis increased significantly in the left atrial appendage of AF
   group. dERP, Sigma WOV, and AF inducibility increased while ERP
   decreased in AF group compared to SR group. The use of metformin
   attenuated all these changes effectively.
   Conclusions: Metformin improves lipid metabolism and reverses the
   Warburg effect in chronic AF via AMPK activation. It attenuates atrial
   electrical and structural remodeling.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Liu, QM (Corresponding Author), Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Cardiac Catheterizat Lab, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
   Liu, Yaozhong; Bai, Fan; Liu, Na; Zhang, Baojian; Qin, Fen; Tu, Tao; Li, Biao; Li, Jiayi; Ma, Yingxu; Liu, Qiming, Cent South Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Cardiac Catheterizat Lab, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
   Zhang, Baojian, Xinjiang Med Univ, CCU Dept, Affiliated Hosp Tradit Chinese Med, Urumqi, Xinjiang Provin, Peoples R China.
   Ouyang, Feifan, Asklepios Klin St Georg, Dept Cardiol, Hamburg, Germany.},
DOI = {10.1186/s12872-020-01359-7},
Article-Number = {50},
ISSN = {1471-2261},
Keywords = {Atrial fibrillation; Metabolism; Metformin; Warburg effect; AMPK},
Keywords-Plus = {GROWTH; TISSUE; AMPK},
Research-Areas = {Cardiovascular System \& Cardiology},
Web-of-Science-Categories  = {Cardiac \& Cardiovascular Systems},
Author-Email = {qimingliu@csu.edu.cn},
Affiliations = {Central South University; Xinjiang Medical University; Asklepios Klinik
   St. Georg},
ResearcherID-Numbers = {tu, tao/KVB-7209-2024},
ORCID-Numbers = {Liu, Yaozhong/0000-0001-6187-6055
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81570310, 81770331]},
Funding-Text = {This work was supported by the grants from the National Natural Science
   Foundation of China (no. 81570310 and no.81770331). They had no role in
   the design of the study and collection, analysis, and interpretation of
   data and in writing the manuscript.},
Cited-References = {Bertero E, 2018, NAT REV CARDIOL, V15, P457, DOI 10.1038/s41569-018-0044-6.
   C. National Research Council Committee for the update of the guide for the A. use of laboratory. The National Academies Collection: reports funded by National Institutes of Health {[}M], 2011, GUIDE CARE USE LAB A.
   Chen MX, 2015, J CARDIOVASC PHARM, V66, P593, DOI 10.1097/FJC.0000000000000309.
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684.
   D'Onofrio N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051153.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001.
   Harada M, 2015, J AM COLL CARDIOL, V66, P47, DOI 10.1016/j.jacc.2015.04.056.
   Hu YF, 2015, NAT REV CARDIOL, V12, P230, DOI 10.1038/nrcardio.2015.2.
   Huss JM, 2004, CIRC RES, V95, P568, DOI 10.1161/01.RES.0000141774.29937.e3.
   Kirchhof P, 2016, EUR HEART J, V37, P2893, DOI 10.1093/eurheartj/ehw210.
   Liu GZ, 2016, BRIT J PHARMACOL, V173, P1095, DOI 10.1111/bph.13438.
   Liu YZ, 2019, CLIN CHIM ACTA, V499, P4, DOI 10.1016/j.cca.2019.08.029.
   Liu YZ, 2018, J MOL CELL CARDIOL, V123, P198, DOI 10.1016/j.yjmcc.2018.09.007.
   Lu ZB, 2008, CIRC-ARRHYTHMIA ELEC, V1, P184, DOI 10.1161/CIRCEP.108.784272.
   Mohan M, 2019, EUR HEART J, V40, P3409, DOI 10.1093/eurheartj/ehz203.
   MORILLO CA, 1995, CIRCULATION, V91, P1588, DOI 10.1161/01.CIR.91.5.1588.
   O'Neill LAJ, 2013, NATURE, V493, P346, DOI 10.1038/nature11862.
   Opacic D, 2016, CARDIOVASC RES, V109, P527, DOI 10.1093/cvr/cvw007.
   Pierotti MA, 2013, ONCOGENE, V32, P1475, DOI 10.1038/onc.2012.181.
   Rena G, 2018, CIRCULATION, V137, P422, DOI 10.1161/CIRCULATIONAHA.117.031735.
   Sardu C, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0931-0.
   Sardu C, 2019, DIABETES CARE, V42, P1946, DOI 10.2337/dc18-2356.
   Sardu C, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01030.
   Schotten U, 2011, PHYSIOL REV, V91, P265, DOI 10.1152/physrev.00031.2009.
   Tu T, 2014, CIRC J, V78, P993, DOI 10.1253/circj.CJ-13-1365.
   Yu LL, 2012, HEART RHYTHM, V9, P804, DOI 10.1016/j.hrthm.2011.12.023.},
Number-of-Cited-References = {27},
Times-Cited = {24},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {17},
Journal-ISO = {BMC Cardiovasc. Disord.},
Doc-Delivery-Number = {KM0WD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000513837100005},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000521944900217,
Author = {Chiba, Kazuyoshi},
Title = {Oocyte Maturation in Starfish},
Journal = {CELLS},
Year = {2020},
Volume = {9},
Number = {2},
Month = {FEB},
Abstract = {Oocyte maturation is a process that occurs in the ovaries, where an
   immature oocyte resumes meiosis to attain competence for normal
   fertilization after ovulation/spawning. In starfish, the hormone
   1-methyladenine binds to an unidentified receptor on the plasma membrane
   of oocytes, inducing a conformational change in the heterotrimeric
   GTP-binding protein alpha-subunit (G alpha), so that the alpha-subunit
   binds GTP in exchange of GDP on the plasma membrane. The GTP-binding
   protein beta gamma-subunit (G beta gamma) is released from G alpha, and
   the released G beta gamma activates phosphatidylinositol-3 kinase
   (PI3K), followed by the target of rapamycin kinase complex2 (TORC2) and
   3-phosphoinositide-dependent protein kinase 1 (PDK1)-dependent
   phosphorylation of serum- and glucocorticoid-regulated kinase (SGK) of
   ovarian oocytes. Thereafter, SGK activates Na+/H+ exchanger (NHE) to
   increase the intracellular pH (pHi) from -6.7 to -6.9. Moreover, SGK
   phosphorylates Cdc25 and Myt1, thereby inducing the de-phosphorylation
   and activation of cyclin B-Cdk1, causing germinal vesicle breakdown
   (GVBD). Both pHi increase and GVBD are required for spindle assembly at
   metaphase I, followed by MI arrest at pHi 6.9 until spawning. Due to MI
   arrest or SGK-dependent pHi control, spawned oocytes can be fertilized
   normally},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Review},
Language = {English},
Affiliation = {Chiba, K (Corresponding Author), Ochanomizu Univ, Dept Biol Sci, Tokyo 1128610, Japan.
   Chiba, Kazuyoshi, Ochanomizu Univ, Dept Biol Sci, Tokyo 1128610, Japan.},
DOI = {10.3390/cells9020476},
Article-Number = {476},
EISSN = {2073-4409},
Keywords = {starfish; oocyte maturation; SGK; intracellular pH; fertilization},
Keywords-Plus = {BETA-GAMMA-SUBUNIT; CYCLIN B-CDK1 ACTIVATION; NPR2 GUANYLYL CYCLASE;
   GTP-BINDING PROTEIN; METAPHASE-I ARREST; LUTEINIZING-HORMONE; SIGNALING
   PATHWAY; MEIOTIC MATURATION; INTRACELLULAR PH; MEIOSIS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {chiba.kazuyoshi@ocha.ac.jp},
Affiliations = {Ochanomizu University},
ORCID-Numbers = {Chiba, Kazuyoshi/0000-0003-0416-1090},
Funding-Acknowledgement = {JSPS KAKENHI {[}17K07405]; Takeda Science Foundation; Grants-in-Aid for
   Scientific Research {[}17K07405] Funding Source: KAKEN},
Funding-Text = {This research was funded by JSPS KAKENHI grant numbers 17K07405, and
   Takeda Science Foundation.},
Cited-References = {Abbara A, 2018, ENDOCR REV, V39, P593, DOI 10.1210/er.2017-00236.
   Bago R, 2014, BIOCHEM J, V463, P413, DOI 10.1042/BJ20140889.
   Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178.
   Bun P, 2018, ELIFE, V7, DOI 10.7554/eLife.31469.
   Chi MN, 2015, ONCOTARGET, V6, P39891, DOI 10.18632/oncotarget.5359.
   CHIBA K, 1992, EUR J BIOCHEM, V207, P833, DOI 10.1111/j.1432-1033.1992.tb17114.x.
   CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027.
   Chiba K, 2011, MOL REPROD DEV, V78, P808, DOI 10.1002/mrd.21378.
   Conti M, 2013, BIOLOGY AND PATHOLOGY OF THE OOCYTE: ROLE IN FERTILITY, MEDICINE, AND NUCLEAR REPROGRAMMING, 2ND EDITION, P109.
   Das D, 2017, MOL REPROD DEV, V84, P444, DOI 10.1002/mrd.22806.
   Egbert JR, 2014, DEVELOPMENT, V141, P3594, DOI 10.1242/dev.112219.
   Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023.
   Harada K, 2003, DEVELOPMENT, V130, P4581, DOI 10.1242/dev.00649.
   He PJ, 2011, MOL BIOL CELL, V22, P3812, DOI 10.1091/mbc.E11-04-0328.
   Hiraoka D, 2019, J CELL BIOL, V218, P3597, DOI 10.1083/jcb.201812122.
   Hiraoka D, 2016, J CELL SCI, V129, P3153, DOI 10.1242/jcs.182170.
   Holt JE, 2013, CURR TOP DEV BIOL, V102, P207, DOI 10.1016/B978-0-12-416024-8.00007-6.
   Hosoda E, 2019, J CELL BIOL, V218, P3612, DOI 10.1083/jcb.201812133.
   IWAMATSU T, 1971, J REPROD FERTIL, V26, P197, DOI 10.1530/jrf.0.0260197.
   JAFFE LA, 1993, J CELL BIOL, V121, P775, DOI 10.1083/jcb.121.4.775.
   Jaffe LA, 2017, ANNU REV PHYSIOL, V79, P237, DOI 10.1146/annurev-physiol-022516-034102.
   KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0.
   Kishimoto T, 2018, P JPN ACAD B-PHYS, V94, P180, DOI 10.2183/pjab.94.013.
   Lénárt P, 2005, NATURE, V436, P812, DOI 10.1038/nature03810.
   Malik N, 2018, BIOCHEM J, V475, P117, DOI 10.1042/BCJ20170650.
   Mehlmann LM, 2006, DEV BIOL, V299, P345, DOI 10.1016/j.ydbio.2006.07.039.
   Mehlmann LM, 2004, SCIENCE, V306, P1947, DOI 10.1126/science.1103974.
   Mita M, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00182.
   Mori M, 2014, CURR BIOL, V24, P1421, DOI 10.1016/j.cub.2014.05.019.
   Mori M, 2011, CURR BIOL, V21, P606, DOI 10.1016/j.cub.2011.03.002.
   Moriwaki K, 2013, ZOOL SCI, V30, P975, DOI 10.2108/zsj.30.975.
   Nakano T, 1999, DEV BIOL, V209, P200, DOI 10.1006/dbio.1999.9248.
   Norris RP, 2009, DEVELOPMENT, V136, P1869, DOI 10.1242/dev.035238.
   Oita E, 2004, J BIOL CHEM, V279, P18633, DOI 10.1074/jbc.M311122200.
   Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741.
   PLACHOT M, 1990, BRIT MED BULL, V46, P675, DOI 10.1093/oxfordjournals.bmb.a072424.
   Putney LK, 2003, J BIOL CHEM, V278, P44645, DOI 10.1074/jbc.M308099200.
   Robinson JW, 2012, DEV BIOL, V366, P308, DOI 10.1016/j.ydbio.2012.04.019.
   Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869.
   SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8.
   TADENUMA H, 1992, BIOCHEM BIOPH RES CO, V186, P114, DOI 10.1016/S0006-291X(05)80782-X.
   TADENUMA H, 1991, ARCH BIOCHEM BIOPHYS, V290, P411, DOI 10.1016/0003-9861(91)90560-6.
   Usui K, 2008, DEV GROWTH DIFFER, V50, P357, DOI {[}10.1111/j.1440-169x.2008.01036.x, 10.1111/j.1440-169X.2008.01036.x].
   Vaccari S, 2009, BIOL REPROD, V81, P595, DOI 10.1095/biolreprod.109.077768.
   Voronina E, 2003, CURR TOP DEV BIOL, V58, P53, DOI 10.1016/S0070-2153(03)58003-6.
   Zhang MJ, 2010, SCIENCE, V330, P366, DOI 10.1126/science.1193573.},
Number-of-Cited-References = {46},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Cells},
Doc-Delivery-Number = {KX5UC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000521944900217},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000513554900033,
Author = {Gao, Jiayin and Song, Tiefang and Che, Dehong and Li, Changmin and
   Jiang, Jing and Pang, Jingyao and Yang, Yujuan and Li, Peiling},
Title = {Deficiency of Pdk1 contributes to primordial follicle activation
   via the upregulation of YAP expression and the pro-inflammatory response},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE},
Year = {2020},
Volume = {45},
Number = {2},
Pages = {647-657},
Month = {FEB},
Abstract = {The molecular mechanisms underlying the activation of primordial
   follicles are poorly understood. The serine/threonine protein kinase
   phosphoinositide-dependent kinase 1 (PDK1), a pivotal downstream
   effector of phosphatidyl inositol-3 kinase (PI3K) signaling, plays a
   vital role in cellular signaling. In order to identify the function of
   PDK1 in ovarian follicle development, this study used conditional Pdk1
   deletion in mouse oocytes by crossing Pdk1(loxP/loxP) mice with
   transgenic mice carrying Gdf-9 promoter-mediated Cre recombinase and
   found that Pdk1(flx/flx)Gdf9Cre mice were subfertile with increased
   serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
   levels compared with Pdk1(flx/flx) mice. The deletion of Pdk1 in oocytes
   induced massive primordial follicle activation, leading to premature
   ovarian failure (POF). Further investigation revealed that enhanced
   Yes-associated protein (YAP) expression and an increased
   pro-inflammatory response also contributed to massive primordial
   follicle activation. PDK1 formed the complex with the core kinases of
   Hippo signaling and regulated the expression levels of YAP. On the
   whole, the findings of the present study demonstrate that PDK1 serves as
   an indispensable gatekeeper for maintaining the primordial follicle pool
   and provide a deeper understanding of POF treatment.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Li, PL (Corresponding Author), Harbin Med Univ, Dept Obstet \& Gynecol, Affiliated Hosp 2, 246 Xuefu Rd, Harbin 150081, Heilongjiang, Peoples R China.
   Gao, Jiayin; Song, Tiefang; Che, Dehong; Li, Changmin; Jiang, Jing; Pang, Jingyao; Yang, Yujuan; Li, Peiling, Harbin Med Univ, Dept Obstet \& Gynecol, Affiliated Hosp 2, 246 Xuefu Rd, Harbin 150081, Heilongjiang, Peoples R China.},
DOI = {10.3892/ijmm.2019.4437},
ISSN = {1107-3756},
EISSN = {1791-244X},
Keywords = {female fertility; PDK1; ovary; YAP; pro-inflammatory response},
Keywords-Plus = {HIPPO SIGNALING PATHWAY; OVARIAN FAILURE; GROWTH; OVULATION; OOCYTES},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {peiley@126.com},
Affiliations = {Harbin Medical University},
ResearcherID-Numbers = {Li, PL/CAF-8426-2022},
Funding-Acknowledgement = {China Postdoctoral Science Foundation {[}2017M611391]; Hei Long Jiang
   Postdoctoral Foundation {[}LBH-Z17139]},
Funding-Text = {This study was financially supported by grants from the China
   Postdoctoral Science Foundation (Project no. 2017M611391) and the Hei
   Long Jiang Postdoctoral Foundation (Project no. LBH-Z17139).},
Cited-References = {{[}Anonymous], TREATMENT POSTMENOPA.
   Bazan NG, 2002, PROSTAG OTH LIPID M, V68-9, P197, DOI 10.1016/S0090-6980(02)00031-X.
   Erbas O, 2014, TAIWAN J OBSTET GYNE, V53, P498, DOI 10.1016/j.tjog.2013.11.008.
   ESPEY LL, 1994, BIOL REPROD, V50, P233, DOI 10.1095/biolreprod50.2.233.
   ESPEY LL, 1980, BIOL REPROD, V22, P73, DOI 10.1095/biolreprod22.1.73.
   Fan Y, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0309-0.
   Goswami D, 2005, HUM REPROD UPDATE, V11, P391, DOI 10.1093/humupd/dmi012.
   Grijalva JL, 2014, AM J PHYSIOL-GASTR L, V307, pG196, DOI 10.1152/ajpgi.00077.2014.
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500.
   Hergovich A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3349.
   Hu LL, 2019, J CELL PHYSIOL, V234, P1578, DOI 10.1002/jcp.27024.
   Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007.
   Kawamura K, 2013, P NATL ACAD SCI USA, V110, P17474, DOI 10.1073/pnas.1312830110.
   Kim HB, 2017, GASTROENTEROLOGY, V152, P616, DOI 10.1053/j.gastro.2016.11.005.
   Konturek SJ, 2005, J PHYSIOL PHARMACOL, V56, P507.
   Laml T, 2000, GYNECOL ENDOCRINOL, V14, P292, DOI 10.3109/09513590009167696.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Malizia BA, 2010, FERTIL STERIL, V93, P537, DOI 10.1016/j.fertnstert.2008.11.033.
   Meskhi A, 2006, CURR OPIN OBSTET GYN, V18, P418, DOI 10.1097/01.gco.0000233937.36554.d3.
   Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007.
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011.
   PEDERSEN T, 1968, J REPROD FERTIL, V17, P555, DOI 10.1530/jrf.0.0170555.
   Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200.
   Reddy P, 2009, HUM MOL GENET, V18, P2813, DOI 10.1093/hmg/ddp217.
   Wei JL, 2018, METHODS MOL BIOL, V1806, P305, DOI 10.1007/978-1-4939-8559-3\_20.
   Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200.
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907.
   Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210.},
Number-of-Cited-References = {28},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Int. J. Mol. Med.},
Doc-Delivery-Number = {KL6UA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000513554900033},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000514753800003,
Author = {Pan, Lanlan and Hu, Liangyu and Zhang, Lihu and Xu, Hongtao and Chen,
   Yuping and Bian, Qingya and Zhu, Anhong and Wu, Hongyan},
Title = {Deoxyelephantopin decreases the release of inflammatory cytokines in
   macrophage associated with attenuation of aerobic glycolysis via
   modulation of PKM2},
Journal = {INTERNATIONAL IMMUNOPHARMACOLOGY},
Year = {2020},
Volume = {79},
Month = {FEB},
Abstract = {Growing evidence suggests that activated immune cells undergo metabolic
   reprogramming in the regulation of the innate inflammatory response.
   Remarkably, macrophages activated by lipopolysaccharide (LPS) induce a
   switch from oxidative phosphorylation to aerobic glycolysis, and
   consequently results in release of proinflammatory cytokines. Pyruvate
   Kinase M2 (PKM2) plays a vital role in the process of macrophage
   activation, promoting the inflammatory response in sepsis and septic
   shock. Deoxyelephantopin (DET), a naturally occurring sesquiterpene
   lactone from Elephantopus scaber, has been shown to counteracts
   inflammation during fulminant hepatitis progression, but the underlying
   mechanism remains unclear. Here, we studied the function of the DET on
   macrophage activation and investigated the anti-inflammatory effects of
   DET associated with interfering with glycolysis in macrophage. Our
   results first demonstrated that DET attenuates LPS-induced interleukin-1
   beta (IL-1 beta ) and high-mobility group box 1 (HMGB1) release in vitro
   and in vivo and protected mice against lethal endotoxemia. Furthermore,
   DET decreased the expression of pyruvate dehydrogenase kinase 1 (PDK1),
   glucose transporter 1(GLUT1), lactate dehydrogenase A (LDHA), and
   reduced lactate production dosedependently in macrophages. Moreover, we
   further revealed that DET attenuates aerobic glycolysis in macrophages
   associated with regulating the nuclear localization of PKM2. Our results
   provided a novel mechanism for DET suppression of macrophages activation
   implicated in anti-inflammatory therapy.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Wu, HY (Corresponding Author), Jiangsu Vocat Coll Med, Inst Biomed Technol, POB 224005,283 Jiefang South Rd, Yancheng, Peoples R China.
   Pan, Lanlan; Hu, Liangyu; Zhang, Lihu; Xu, Hongtao; Chen, Yuping; Bian, Qingya; Wu, Hongyan, Jiangsu Vocat Coll Med, Yancheng, Peoples R China.
   Chen, Yuping; Wu, Hongyan, Jiangsu Vocat Coll Med, Inst Biomed Technol, POB 224005,283 Jiefang South Rd, Yancheng, Peoples R China.
   Zhu, Anhong, Nanjing Univ Chinese Med, Dept Pharmacol, Hanlin Coll, Taizhou, Peoples R China.},
DOI = {10.1016/j.intimp.2019.106048},
Article-Number = {106048},
ISSN = {1567-5769},
EISSN = {1878-1705},
Keywords = {Deoxyelephantopin (DET); Sepsis; Macrophage; Aerobic glycolysis;
   Pyruvate kinase M2 (PKM2)},
Keywords-Plus = {PYRUVATE-KINASE M2; LATE MEDIATOR; SEPTIC SHOCK; IL-1-BETA; CANCER;
   METABOLISM; SEPSIS},
Research-Areas = {Immunology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Immunology; Pharmacology \& Pharmacy},
Author-Email = {wuhongyan@jsmc.edu.cn},
Affiliations = {Jiangsu Vocational College of Medicine; Jiangsu Vocational College of
   Medicine; Nanjing University of Chinese Medicine},
ORCID-Numbers = {Zhang, Lihu/0000-0002-3770-8681},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81873134, 81903879];
   China Postdoctoral Science Foundation {[}2017M611873]; Postdoctoral
   Science Foundation of Jiangsu Province {[}1701120C]; Natural Science
   Foundation of Jiangsu Province {[}BK20161320]; Natural Science
   Foundation of the Jiangsu Higher Education Institutions of China
   {[}16KJB360008,17KJB360003,17KJB360011]},
Funding-Text = {This work was supported by National Natural Science Foundation of China
   (No. 81873134, 81903879), China Postdoctoral Science Foundation (No.
   2017M611873) and Postdoctoral Science Foundation of Jiangsu Province
   (No. 1701120C), Natural Science Foundation of Jiangsu Province (No.
   BK20161320). Natural Science Foundation of the Jiangsu Higher Education
   Institutions of China (No. 16KJB360008,17KJB360003,17KJB360011).},
Cited-References = {{[}Anonymous], BRAIN BEHAV IMMUN.
   Calis J, 2013, NEW ENGL J MED, V369, P2062, DOI 10.1056/NEJMc1312359.
   Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137.
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734.
   Corcoran SE, 2016, J CLIN INVEST, V126, P3699, DOI 10.1172/JCI84431.
   Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033.
   DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G.
   Gao W, 2019, BIOCHEM BIOPH RES CO, V516, P1222, DOI 10.1016/j.bbrc.2019.07.015.
   Huang CC, 2013, J NUTR BIOCHEM, V24, P516, DOI 10.1016/j.jnutbio.2012.01.013.
   Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001.
   Krawczyk CM, 2010, BLOOD, V115, P4742, DOI 10.1182/blood-2009-10-249540.
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452.
   Mehmood T, 2017, MOLECULES, V22, DOI 10.3390/molecules22061013.
   Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325.
   Palsson-McDermott EM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01300.
   Palsson-McDermott EM, 2013, BIOESSAYS, V35, P965, DOI 10.1002/bies.201300084.
   Semba H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11635.
   Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278.
   Shirai T, 2016, J EXP MED, V213, P337, DOI 10.1084/jem.20150900.
   Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287.
   Srivastava A, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00070.
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986.
   TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0.
   Vincent JL, 2009, JAMA-J AM MED ASSOC, V302, P2323, DOI 10.1001/jama.2009.1754.
   Wang F, 2017, CELL REP, V19, P2331, DOI 10.1016/j.celrep.2017.05.065.
   Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248.
   Wang HH, 2001, AM J RESP CRIT CARE, V164, P1768, DOI 10.1164/ajrccm.164.10.2106117.
   Wiersinga WJ, 2014, VIRULENCE, V5, P36, DOI 10.4161/viru.25436.
   Wu HY, 2018, CLIN EXP PHARMACOL P, V45, P1265, DOI 10.1111/1440-1681.13017.
   Xie M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13280.
   Yang LC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5436.
   Zahari Z, 2014, PHYTOMEDICINE, V21, P282, DOI 10.1016/j.phymed.2013.09.011.
   Zhang ZX, 2016, MOL MED, V22, DOI 10.2119/molmed.2015.00250.},
Number-of-Cited-References = {33},
Times-Cited = {26},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {33},
Journal-ISO = {Int. Immunopharmacol.},
Doc-Delivery-Number = {KN3PW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000514753800003},
DA = {2026-02-04},
}

@article{ WOS:000562876700002,
Author = {Kalhori, Mohammad Reza and Arefian, Ehsan and Atanaki, Fereshteh Fallah
   and Kavousi, Kaveh and Soleimani, Masoud},
Title = {miR-548x and miR-4698 controlled cell proliferation by affecting the
   PI3K/AKT signaling pathway in Glioblastoma cell lines},
Journal = {SCIENTIFIC REPORTS},
Year = {2020},
Volume = {10},
Number = {1},
Month = {JAN 31},
Abstract = {Glioblastoma multiforme (GBM) is the most aggressive and prevalent form
   of brain tumor cancers that originate from glial cells. This study
   proposed to investigate the effect of miR-548x and miR-4698 on the
   proliferation and the PI3K/AKT signaling pathway in glioblastoma cell
   lines. The molecular features of glioblastoma were studied using KEGG
   and TCGA sites. Next, by using miRwalk 2.0 and TargetScan version 7.1,
   the microRNAs that target critical genes in the PI3k/AKT pathway were
   selected according to score. The pre-miR-548x and pre-miR-4698 were
   cloned in a pCDH plasmid to produced lentiviral vector. The expression
   levels of miR-548x, miR-4698 and target genes were detected by qRT-PCR.
   The MTT, cell cycle, annexin and colony formation assay was used to
   detect the cell proliferation. MiR-548x and miR-4698 predicted target
   genes (Rheb, AKT1, mTOR, PDK1) were also evaluated by luciferase assay.
   The expression of AKT was detected by western blotting. Our results
   described that overexpression of miR-548x and miR-4698 could inhibit
   proliferation of A-172 and U251 cells. Also, miR-548x promoted the cell
   cycle arrest of GBM cell lines. The luciferase reporter assay results
   showed the 3' UTR of PDK1, RHEB, and mTOR are direct targets of the
   miR-548x and miR-4698. Too, the western blot analysis revealed that
   miR-548x and miR-4698 could downregulate the AKT1 protein expression.
   Overall, our findings suggest that miR-548x and miR-4698 could function
   as tumor suppressor genes in glioblastoma by controlling the PI3K/AKT
   signaling pathway and may act as gene therapy for clinical treatment of
   glioblastoma multiforme.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Arefian, E (Corresponding Author), Univ Tehran, Sch Biol, Dept Microbiol, Mol Virol Lab,Coll Sci, Tehran, Iran.
   Kalhori, Mohammad Reza, Kermanshah Univ Med Sci, Hlth Technol Inst, Med Biol Res Ctr, Kermanshah, Iran.
   Arefian, Ehsan, Univ Tehran, Sch Biol, Dept Microbiol, Mol Virol Lab,Coll Sci, Tehran, Iran.
   Atanaki, Fereshteh Fallah; Kavousi, Kaveh, Univ Tehran, Dept Bioinformat, Inst Biochem \& Biophys IBB, Lab Complex Biol Syst \& Bioinformat CBB, Tehran, Iran.
   Soleimani, Masoud, Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.},
DOI = {10.1038/s41598-020-57588-5},
Article-Number = {1558},
ISSN = {2045-2322},
Keywords-Plus = {MICRORNA EXPRESSION PROFILE; AKT KINASES; CANCER; MUTATION},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {arefian@ut.ac.ir},
Affiliations = {Kermanshah University of Medical Sciences; University of Tehran;
   University of Tehran; Tarbiat Modares University},
ResearcherID-Numbers = {kalhori, Mohammad Reza/O-3345-2019
   Arefian, Ehsan/N-3912-2017
   Kavousi, Kaveh/A-9450-2009},
ORCID-Numbers = {kalhori, Mohammad Reza/0000-0002-3652-0927
   Arefian, Ehsan/0000-0002-0758-4710
   },
Funding-Acknowledgement = {National Institute for Medical Research Development (NIMAD) {[}942974]},
Funding-Text = {The authors would like to thank the National Institute for Medical
   Research Development (NIMAD) for the financial support of this work
   (Grant No. 942974).},
Cited-References = {Amer Magid H, 2014, Mol Cell Ther, V2, P27.
   Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5.
   Bellacosa A, 2004, CANCER BIOL THER, V3, P268, DOI 10.4161/cbt.3.3.703.
   Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014.
   Dharmendra K. M., 2017, COLONYCOUNTJ USER FR.
   Ding QP, 2018, PATHOL RES PRACT, V214, P1330, DOI 10.1016/j.prp.2018.05.012.
   Fischer U, 2007, ONCOGENE, V26, P7809, DOI 10.1038/sj.onc.1210878.
   Flintoft L, 2011, NAT REV GENET, V12, P380, DOI 10.1038/nrg3004.
   He YY, 2017, ONCOTARGETS THER, V10, P5915, DOI 10.2147/OTT.S151432.
   Hermansen SK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188090.
   Hu BC, 2014, CANCER RES, V74, P2283, DOI 10.1158/0008-5472.CAN-13-3279.
   Imran A, 2017, IRAN J PUBLIC HEALTH, V46, P1475.
   Kalhori MR, 2019, J CELL BIOCHEM, V120, P16760, DOI 10.1002/jcb.28935.
   Khan MB, 2017, NEURO-ONCOLOGY, V19, P73, DOI 10.1093/neuonc/nox168.301.
   Liang T., 2012, BIOMED RES INT, V2012.
   Liu JM, 2014, ACTA BIOCH BIOPH SIN, V46, P92, DOI 10.1093/abbs/gmt135.
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908.
   Mikkelsen L. H., 2019, MELANOMA RES.
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI {[}10.1093/neuonc/now207, 10.1093/neuonc/nov189].
   Piwecka M, 2015, MOL ONCOL, V9, P1324, DOI 10.1016/j.molonc.2015.03.007.
   Rodríguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337.
   Shen ZY, 2017, INT J MOL MED, V40, P193, DOI 10.3892/ijmm.2017.2996.
   Sudhakar Akulapalli, 2009, J Cancer Sci Ther, V1, P1.
   Tan SK, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0822-0.
   Wang N., 2018, ONCOLOGY RES.
   Wang YY, 2012, J NEURO-ONCOL, V106, P217, DOI 10.1007/s11060-011-0679-1.
   Waseem Mohammad, 2017, Asian Pac J Cancer Prev, V18, P2185.
   Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005.
   Xu J, 2014, TRANSL ONCOL, V7, P196, DOI 10.1016/j.tranon.2014.02.004.
   Zhang Z, 2017, MOL MED REP, V16, P9317, DOI 10.3892/mmr.2017.7826.},
Number-of-Cited-References = {32},
Times-Cited = {27},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {NE8SY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000562876700002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000514321000001,
Author = {Xu, Wen-Ning and Zheng, Huo-Liang and Yang, Run-Ze and Jiang, Lei-Sheng
   and Jiang, Sheng-Dan},
Title = {HIF-1α Regulates Glucocorticoid-Induced Osteoporosis Through
   PDK1/AKT/mTOR Signaling Pathway},
Journal = {FRONTIERS IN ENDOCRINOLOGY},
Year = {2020},
Volume = {10},
Month = {JAN 28},
Abstract = {Long-term and high dose glucocorticoid treatment can cause decreased
   viability and function of osteoblasts, which leads to osteoporosis and
   osteonecrosis. In this study, we investigated the role and mechanism of
   action of HIF-1 alpha in glucocorticoid-induced osteogenic inhibition in
   MC3T3-E1 cells. Our results showed that HIF-1 alpha protein expression
   was reduced when MC3T3-E1 cells were exposed to dexamethasone (Dex) at
   varying concentrations ranging from 10(-9) to 10(-6) M. PDK1 expression
   was also decreased in MC3T3-E1 cells after dexamethasone treatment.
   MC3T3-E1 cells when treated with the glucocorticoid receptor antagonist
   RU486 along with dexamethasone showed enhanced HIF-1 alpha expression.
   In addition, upregulated expression of HIF-1 alpha was capable of
   promoting the osteogenic ability of MC3T3-E1 cells and PDK1 expression.
   However, the HIF-1 alpha antagonist 2-methoxyestradiol (2-ME) had a
   reverse effect in MC3T3-E1 cells exposed to dexamethasone. Furthermore,
   the PDK1 antagonist dichloroacetate could repress the osteogenic ability
   of MC3T3-E1 cells, although HIF-1 alpha was upregulated when transduced
   with adenovirus-HIF-1 alpha construct. The PDK1 agonist PS48 was able to
   promote the osteogenic ability of MC3T3-E1 cells treated with
   dexamethasone. Importantly, the protein levels of p-AKT and p-mTOR were
   increased in MC3T3-E1 cells treated with dexamethasone after PS48
   treatment. in vivo, the PDK1 agonist PS48 could maintain the bone mass
   of mice treated with dexamethasone. This study provides a new
   understanding of the mechanism of glucocorticoid-induced osteoporosis.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Jiang, LS; Jiang, SD (Corresponding Author), Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Clin, Sch Med,Spine Ctr, Shanghai, Peoples R China.
   Xu, Wen-Ning; Zheng, Huo-Liang; Yang, Run-Ze; Jiang, Lei-Sheng; Jiang, Sheng-Dan, Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Clin, Sch Med,Spine Ctr, Shanghai, Peoples R China.},
DOI = {10.3389/fendo.2019.00922},
Article-Number = {922},
ISSN = {1664-2392},
Keywords = {glucocorticoid; HIF-1 alpha; PDK1; osteoblast; osteoporosis},
Keywords-Plus = {HYPOXIA-INDUCIBLE FACTOR; OSTEOBLASTS; INHIBITION; MTOR; ANGIOGENESIS;
   OSTEOGENESIS; ACTIVATION; APOPTOSIS; RECEPTOR; CELLS},
Research-Areas = {Endocrinology \& Metabolism},
Web-of-Science-Categories  = {Endocrinology \& Metabolism},
Author-Email = {winningxu@sjtu.edu.cn
   jiangleisheng@xinhuamed.com.cn
   jiangshengdan@xinhuamed.com.cn},
Affiliations = {Shanghai Jiao Tong University},
ResearcherID-Numbers = {Yang, Runze/NXX-4657-2025},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81672206]},
Funding-Text = {This research was supported by the National Natural Science Foundation
   of China (No. 81672206).},
Cited-References = {Chen L, 2010, LAB INVEST, V90, P762, DOI 10.1038/labinvest.2010.36.
   Compston J, 2010, NAT REV RHEUMATOL, V6, P82, DOI 10.1038/nrrheum.2009.259.
   Ford-Hutchinson AF, 2007, J BONE MINER RES, V22, P1245, DOI 10.1359/JBMR.070420.
   Han F, 2017, INT J BIOL SCI, V13, P1266, DOI 10.7150/ijbs.20485.
   Heitzer MD, 2007, REV ENDOCR METAB DIS, V8, P321, DOI 10.1007/s11154-007-9059-8.
   Henneicke H, 2014, TRENDS ENDOCRIN MET, V25, P197, DOI 10.1016/j.tem.2013.12.006.
   Hiraga T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113523.
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029.
   Lee Ji-Won, 2004, Experimental \& Molecular Medicine, V36, P1.
   Li BB, 2018, INT J MOL MED, V42, P1391, DOI 10.3892/ijmm.2018.3745.
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348.
   Liu C, 2019, MOLECULES, V24, DOI 10.3390/molecules24071363.
   Liu RR, 2019, J CELL PHYSIOL, V234, P20728, DOI 10.1002/jcp.28679.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Marinho HS, 2014, REDOX BIOL, V2, P535, DOI 10.1016/j.redox.2014.02.006.
   McLaughlin F, 2002, BONE, V30, P924, DOI 10.1016/S8756-3282(02)00737-8.
   Migliaccio Silvia, 2007, Aging Clin Exp Res, V19, P5.
   Niu XL, 2019, CYTOKINE, V113, P117, DOI 10.1016/j.cyto.2018.06.022.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   Rabinowitz MH, 2013, J MED CHEM, V56, P9369, DOI 10.1021/jm400386j.
   Rankin EB, 2012, CELL, V149, P63, DOI 10.1016/j.cell.2012.01.051.
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005.
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720.
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005.
   Tait AS, 2008, J LEUKOCYTE BIOL, V84, P924, DOI 10.1189/jlb.0208104.
   Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104.
   Vogel J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020436.
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105.
   Wan C, 2010, ANN NY ACAD SCI, V1192, P322, DOI 10.1111/j.1749-6632.2009.05238.x.
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581.
   Weinstein RS, 2010, AGING CELL, V9, P147, DOI 10.1111/j.1474-9726.2009.00545.x.
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799.
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647.
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160.
   Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023965.
   Zaidi M, 2010, P NATL ACAD SCI USA, V107, P8782, DOI 10.1073/pnas.0912176107.
   Zhou ZZ, 2018, BIOCHEM BIOPH RES CO, V498, P667, DOI 10.1016/j.bbrc.2018.03.040.
   Zhu C, 2016, CELL SIGNAL, V28, P989, DOI 10.1016/j.cellsig.2016.04.010.},
Number-of-Cited-References = {41},
Times-Cited = {50},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {41},
Journal-ISO = {Front. Endocrinol.},
Doc-Delivery-Number = {KM7LD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000514321000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000511462900001,
Author = {Ba, Ming-chen and Ba, Zheng and Long, Hui and Cui, Shu-zhong and Gong,
   Yuan-feng and Yan, Zhao-fei and Lin, Kun-peng and Wu, Yin-bing and Tu,
   Yi-nuo},
Title = {LncRNA AC093818.1 accelerates gastric cancer metastasis by
   epigenetically promoting PDK1 expression},
Journal = {CELL DEATH \& DISEASE},
Year = {2020},
Volume = {11},
Number = {1},
Month = {JAN 27},
Abstract = {Gastric cancer (GC) is a highly prevalent type of metastatic tumor. The
   mechanisms underlying GC metastasis are poorly understood. Some long
   noncoding RNAs (lncRNAs) reportedly play key roles in regulating
   metastasis of GC. However, the biological roles of five natural
   antisense lncRNAs (AC093818.1, CTD-2541M15.1, BC047644, RP11-597M12.1,
   and RP11-40A13.1) in GC metastasis remain unclear. In this study, the
   expression of these lncRNAs was measured by quantitative reverse
   transcription-polymerase chain reaction. Migration and invasion were
   evaluated by wound-healing and the Transwell assay, respectively. Stable
   cells were injected into the tail veins of nude mice. Sections of
   collected lung and liver tissues were stained using hematoxylin and
   eosin. Protein expression was analyzed by western blot. RNA
   immunoprecipitation (RIP) assay was used to verify whether the STAT3 and
   SP1 transcription factors bound to AC093818.1 in GC cells. Expression
   levels of the five lncRNAs, especially AC093818.1, were significantly
   upregulated in metastatic GC tissues relative to those in nonmetastatic
   GC tissues. AC093818.1 expression was correlated with invasion,
   lymphatic metastasis, distal metastasis, and tumor-node-metastasis
   stage. AC093818.1 expression was highly sensitive and specific in the
   diagnosis of metastatic or nonmetastatic GC. AC093818.1 overexpression
   promoted GC migration and invasion in vitro and in vivo. AC093818.1
   overexpression increased PDK1, p-AKT1, and p-mTOR expression levels.
   AC093818.1 silencing decreased these expressions. AC093818.1 bound to
   transcription factors STAT3 and SP1, and SP1 or STAT3 silencing could
   alleviated the effect of AC093818.1 overexpression. The data demonstrate
   that lncRNA AC093818.1 accelerates gastric cancer metastasis by
   epigenetically promoting PDK1 expression. LncRNA AC093818.1 may be a
   potential therapeutic target for metastatic GC.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Ba, MC (Corresponding Author), Guangzhou Med Univ, Affiliated Canc Hosp \& Inst, Intracelom Hypertherm Perfus Therapy Ctr, Guangzhou 510095, Peoples R China.
   Ba, Z (Corresponding Author), Southern Med Univ, Zhujiang Hosp, Intens Care Unit, Guangzhou 510282, Peoples R China.
   Ba, Ming-chen; Cui, Shu-zhong; Gong, Yuan-feng; Yan, Zhao-fei; Lin, Kun-peng; Wu, Yin-bing; Tu, Yi-nuo, Guangzhou Med Univ, Affiliated Canc Hosp \& Inst, Intracelom Hypertherm Perfus Therapy Ctr, Guangzhou 510095, Peoples R China.
   Ba, Zheng, Southern Med Univ, Zhujiang Hosp, Intens Care Unit, Guangzhou 510282, Peoples R China.
   Long, Hui, Guangzhou Dermatol Inst, Dept Pharm, Guangzhou 510095, Peoples R China.},
DOI = {10.1038/s41419-020-2245-2},
ISSN = {2041-4889},
Keywords-Plus = {LONG NONCODING RNAS; POOR-PROGNOSIS},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {bamingchen@126.com
   icubazheng@163.com},
Affiliations = {Guangzhou Medical University; Southern Medical University - China},
ORCID-Numbers = {ba, mingchen/0000-0003-1939-3927},
Funding-Acknowledgement = {Guangzhou Key Medical Discipline Construction Project {[}2017];
   Guangdong Science and Technology Plan Project {[}20160918]; Guangzhou
   Science Technology and Innovation Commission {[}2014Y2-00152,
   2014Y2-00548]},
Funding-Text = {This study was supported by grants from the Guangzhou Key Medical
   Discipline Construction Project (No. 2017), Guangdong Science and
   Technology Plan Project (No. 20160918), and Guangzhou Science Technology
   and Innovation Commission (No. 2014Y2-00152 and 2014Y2-00548).},
Cited-References = {Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06.
   Cui H, 2018, ONCOGENE, V37, P4358, DOI 10.1038/s41388-018-0285-1.
   Dong PX, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0231-0.
   Picco ME, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-018-0265-8.
   Guo HJ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2593-6.
   Huang GW, 2017, INT J BIOCHEM CELL B, V90, P59, DOI 10.1016/j.biocel.2017.07.017.
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43.
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107.
   Khorkova O, 2015, ADV DRUG DELIVER REV, V87, P15, DOI 10.1016/j.addr.2015.05.012.
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021.
   Latgé G, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010123.
   Li CY, 2017, ONCOTARGET, V8, P93476, DOI 10.18632/oncotarget.19281.
   Li Y, 2017, CANCER LETT, V395, P31, DOI 10.1016/j.canlet.2017.02.035.
   Lian DN, 2018, CANCER BIOMARK, V21, P151, DOI 10.3233/CBM-170462.
   Liu D, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1042-y.
   Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630.
   Luo YJ, 2018, INT J BIOCHEM CELL B, V103, P125, DOI 10.1016/j.biocel.2018.08.012.
   Morris KV, 2009, EPIGENETICS-US, V4, P296, DOI 10.4161/epi.4.5.9282.
   Muro EM, 2010, BMC EVOL BIOL, V10, DOI 10.1186/1471-2148-10-338.
   Nie L, 2012, AM J TRANSL RES, V4, P127.
   Pan YQ, 2016, BIOMED PHARMACOTHER, V83, P1398, DOI 10.1016/j.biopha.2016.08.058.
   Peng BY, 2017, ONCOTARGET, V8, P93608, DOI 10.18632/oncotarget.20549.
   Renganathan A, 2017, ADV EXP MED BIOL, V1008, P199, DOI 10.1007/978-981-10-5203-3\_7.
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022.
   Song W, 2016, J GASTROENTEROL, V51, P119, DOI 10.1007/s00535-015-1091-y.
   Wang JY, 2018, CANCER MANAG RES, V10, P1479, DOI 10.2147/CMAR.S164842.
   Wang Y, 2018, ONCOL LETT, V16, P6051, DOI 10.3892/ol.2018.9343.
   Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003.
   Wang Z, 2018, ONCOTARGET, V9, P192, DOI 10.18632/oncotarget.22773.
   Wu BH, 2019, HUM CELL, V32, P31, DOI 10.1007/s13577-018-0217-y.
   Xia HW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0302-x.
   Xiao Q, 2017, CELL PHYSIOL BIOCHEM, V43, P2353, DOI 10.1159/000484387.
   Xu CJ, 2017, BIOMED PHARMACOTHER, V91, P1167, DOI 10.1016/j.biopha.2017.05.056.
   Yamashita K, 2011, WORLD J GASTROENTERO, V17, P3390, DOI 10.3748/wjg.v17.i29.3390.
   Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002.
   Yin DD, 2015, TUMOR BIOL, V36, P4851, DOI 10.1007/s13277-015-3139-2.
   Zhang CL, 2017, CANCER LETT, V396, P66, DOI 10.1016/j.canlet.2017.03.018.
   Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z.
   Zhou LH, 2018, EUR REV MED PHARMACO, V22, P2297, DOI 10.26355/eurrev\_201804\_14818.},
Number-of-Cited-References = {39},
Times-Cited = {36},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Cell Death Dis.},
Doc-Delivery-Number = {KI6MF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000511462900001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000510871300001,
Author = {Xue, Rui and Zhai, Ruonan and Xie, Ling and Zheng, Zening and Jian,
   Guihua and Chen, Teng and Su, Jun and Gao, Chongting and Wang, Niansong
   and Yang, Xifei and Xu, Youhua and Gui, Dingkun},
Title = {Xuesaitong Protects Podocytes from Apoptosis in Diabetic Rats through
   Modulating PTEN-PDK1-Akt-mTOR Pathway},
Journal = {JOURNAL OF DIABETES RESEARCH},
Year = {2020},
Volume = {2020},
Month = {JAN 21},
Abstract = {Diabetic kidney disease (DKD) is a major cause of end-stage renal
   disease (ESRD), and therapeutic strategies for delaying its progression
   are limited. Loss of podocytes by apoptosis characterizes the early
   stages of DKD. To identify novel therapeutic options, we investigated
   the effects of Xuesaitong (XST), consisting of total saponins from Panax
   notoginseng, on podocyte apoptosis in streptozotocin- (STZ-) induced
   diabetic rats. XST (5 mg/kg center dot d) or Losartan (10 mg/kg center
   dot d) was given to diabetic rats for 12 weeks. Albuminuria, renal
   function markers, and renal histopathology morphological changes were
   examined. Podocyte apoptosis was determined by triple immunofluorescence
   labelling including a TUNEL assay, WT1, and DAPI. Renal expression of
   Nox4, miRNA-214, PTEN, PDK1, phosphorylated Akt, mTOR, and mTORC1 was
   detected. In diabetic rats, severe hyperglycaemia and albuminuria
   developed, and apoptotic podocytes were markedly increased in diabetic
   kidneys. However, XST attenuated albuminuria, mesangial expansion,
   podocyte apoptosis, and morphological changes of podocytes in diabetic
   rats. Decreased expression of PTEN, as well as increased expression of
   Nox4, miRNA-214, PDK1, phosphorylated Akt, mTOR, and mTORC1, was
   detected. These abnormalities were partially restored by XST treatment.
   Thus, XST ameliorated podocyte apoptosis partly through modulating the
   PTEN-PDK1-Akt-mTOR pathway. These novel findings might point the way to
   a natural therapeutic strategy for treating DKD.},
Publisher = {HINDAWI LTD},
Address = {ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Gui, DK (Corresponding Author), Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Nephrol, Shanghai 200233, Peoples R China.
   Yang, XF (Corresponding Author), Shenzhen Ctr Dis Control \& Prevent, Key Lab Modern Toxicol Shenzhen, Shenzhen 518055, Peoples R China.
   Xu, YH (Corresponding Author), Macau Univ Sci \& Technol, Fac Chinese Med, State Key Lab Qual Res Chinese Med, Taipa 999078, Macao, Peoples R China.
   Xue, Rui; Zhai, Ruonan; Jian, Guihua; Su, Jun; Gao, Chongting; Wang, Niansong; Gui, Dingkun, Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Nephrol, Shanghai 200233, Peoples R China.
   Xie, Ling, Shanghai Ocean Univ, Shanghai 201306, Peoples R China.
   Zheng, Zening, Guangzhou Univ Tradit Chinese Med, Guangzhou 510405, Peoples R China.
   Chen, Teng, Shanghai Univ Tradit Chinese Med, Shanghai 201203, Peoples R China.
   Yang, Xifei, Shenzhen Ctr Dis Control \& Prevent, Key Lab Modern Toxicol Shenzhen, Shenzhen 518055, Peoples R China.
   Xu, Youhua, Macau Univ Sci \& Technol, Fac Chinese Med, State Key Lab Qual Res Chinese Med, Taipa 999078, Macao, Peoples R China.},
DOI = {10.1155/2020/9309768},
Article-Number = {9309768},
ISSN = {2314-6745},
EISSN = {2314-6753},
Keywords-Plus = {NADPH OXIDASE; DOWN-REGULATION; PTEN; INHIBITION; INJURY; NEPHROPATHY;
   ACTIVATION; KIDNEY; DEPLETION; BARRIER},
Research-Areas = {Endocrinology \& Metabolism; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Endocrinology \& Metabolism; Medicine, Research \& Experimental},
Author-Email = {1103978012@qq.com
   2545038624@qq.com
   sdxl1993@163.com
   mirrondo@foxmail.com
   gh238@qq.com
   229373106@qq.com
   junsu2018@126.com
   gao\_tutu@sjtu.edu.cn
   wangniansong2012@163.com
   xifeiyang@gmail.com
   yhxu@must.edu.mo
   dingkungui@alu.fudan.edu.cn},
Affiliations = {Shanghai Jiao Tong University; Shanghai Ocean University; Guangzhou
   University of Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Shenzhen Center for Disease Control \& Prevention
   (SZCDC); Macau University of Science \& Technology},
ResearcherID-Numbers = {Xue, Ruihong/ADT-7187-2022
   },
ORCID-Numbers = {Zhai, Ruonan/0000-0003-4429-658X},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81774052, 81573738];
   Science and Technology Development Fund of Shanghai Pudong New Area
   {[}PKJ2015-Y10]; Shanghai Pujiang Program {[}17PJD031]; Three-Year
   Action Plan for Shanghai Further Accelerating the Development of
   Traditional Chinese Medicine {[}(2018-2020)-CCCX-4007]},
Funding-Text = {This research was supported by grants from the National Natural Science
   Foundation of China (81774052 and 81573738), Science and Technology
   Development Fund of Shanghai Pudong New Area (PKJ2015-Y10), Shanghai
   Pujiang Program (17PJD031), and Three-Year Action Plan for Shanghai
   Further Accelerating the Development of Traditional Chinese Medicine
   (ZY(2018-2020)-CCCX-4007).},
Cited-References = {{[}Anonymous], 2003, Am J Kidney Dis, V42, P1.
   Bera A, 2017, AM J PHYSIOL-CELL PH, V313, pC430, DOI 10.1152/ajpcell.00081.2017.
   Brosius FC, 2014, ADV CHRONIC KIDNEY D, V21, P304, DOI 10.1053/j.ackd.2014.03.011.
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615.
   Chen YF, 2014, CELL PHYSIOL BIOCHEM, V33, P1975, DOI 10.1159/000362974.
   Eid AA, 2013, DIABETES, V62, P2935, DOI 10.2337/db12-1504.
   Eid AA, 2009, DIABETES, V58, P1201, DOI 10.2337/db08-1536.
   Etoh T, 2003, DIABETOLOGIA, V46, P1428, DOI 10.1007/s00125-003-1205-6.
   Fan Y, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/5326382.
   FARQUHAR MG, 1975, KIDNEY INT, V8, P197, DOI 10.1038/ki.1975.103.
   Gill PS, 2006, ANTIOXID REDOX SIGN, V8, P1597, DOI 10.1089/ars.2006.8.1597.
   Gödel M, 2011, J CLIN INVEST, V121, P2197, DOI 10.1172/JCI44774.
   Gui DK, 2014, CELL PHYSIOL BIOCHEM, V34, P1849, DOI 10.1159/000366384.
   Gui DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039824.
   Han F, 2017, INT J BIOL SCI, V13, P1266, DOI 10.7150/ijbs.20485.
   Harachi M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103267.
   Holterman CE, 2015, CURR OPIN NEPHROL HY, V24, P81, DOI 10.1097/MNH.0000000000000081.
   Hu SN, 2018, MOLECULES, V23, DOI 10.3390/molecules23112781.
   Hu ZY, 2010, DIABETES, V59, P1312, DOI 10.2337/db09-1155.
   Inoki K, 2011, J CLIN INVEST, V121, P2181, DOI 10.1172/JCI44771.
   Jha JC, 2014, J AM SOC NEPHROL, V25, P1237, DOI 10.1681/ASN.2013070810.
   Kirk JA, 2014, ANTIOXID REDOX SIGN, V21, P1945, DOI 10.1089/ars.2014.6124.
   Li FF, 2019, CNS NEUROL DISORD-DR, V18, P115, DOI 10.2174/1871527317666181114140340.
   Li JM, 2003, J AM SOC NEPHROL, V14, pS221, DOI 10.1097/01.ASN.0000077406.67663.E7.
   Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236.
   Lin JS, 2015, J PATHOL, V236, P30, DOI 10.1002/path.4508.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Meyer TW, 1999, DIABETOLOGIA, V42, P1341, DOI 10.1007/s001250051447.
   Pagtalunan ME, 1997, J CLIN INVEST, V99, P342, DOI 10.1172/JCI119163.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   Pritchard-Jones K, 1999, PEDIATR NEPHROL, V13, P620.
   Reddy P, 2008, SCIENCE, V319, P611, DOI 10.1126/science.1152257.
   Reddy P, 2009, HUM MOL GENET, V18, P2813, DOI 10.1093/hmg/ddp217.
   Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010.
   Saurus P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.125.
   Saurus P, 2016, SCI REP-UK, V6, DOI 10.1038/srep21664.
   Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.01.06.db05-0894.
   Verzola D, 2007, KIDNEY INT, V72, P1262, DOI 10.1038/sj.ki.5002531.
   Wang HZ, 2018, AM J PHYSIOL-RENAL, V314, pF1096, DOI 10.1152/ajprenal.00575.2017.
   Wang XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep31506.
   Xu X, 2015, INT J CLIN EXP MED, V8, P1768.
   Zhao XP, 2017, MOL BIOSYST, V13, P1504, DOI 10.1039/c7mb00140a.
   Zhong Shang-qian, 2005, Chin J Integr Med, V11, P128.},
Number-of-Cited-References = {44},
Times-Cited = {19},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {26},
Journal-ISO = {J. Diabetes Res.},
Doc-Delivery-Number = {KH8AL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000510871300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000507443300001,
Author = {Chen, Chenyang and Luo, Fei and Wu, Panyun and Huang, Yiyuan and Das,
   Avash and Chen, Shenglan and Chen, Jingyuan and Hu, Xinqun and Li, Fei
   and Fang, Zhenfei and Zhou, Shenhua},
Title = {Metabolomics reveals metabolite changes of patients with pulmonary
   arterial hypertension in China},
Journal = {JOURNAL OF CELLULAR AND MOLECULAR MEDICINE},
Year = {2020},
Volume = {24},
Number = {4},
Pages = {2484-2496},
Month = {FEB},
Abstract = {The specific mechanism of pulmonary arterial hypertension (PAH) remains
   elusive. The present study aimed to explore the underlying mechanism of
   PAH through the identity of novel biomarkers for PAH using metabolomics
   approach. Serum samples from 40 patients with idiopathic PAH (IPAH), 20
   patients with congenital heart disease-associated PAH (CHD-PAH) and 20
   healthy controls were collected and analysed by ultra-high-performance
   liquid chromatography coupled with high-resolution mass spectrometry
   (UPLC-HRMS). Orthogonal partial least square-discriminate analysis
   (OPLS-DA) was applied to screen potential biomarkers. These results were
   validated in monocrotaline (MCT)-induced PAH rat model. The OPLS-DA
   model was successful in screening distinct metabolite signatures which
   distinguished IPAH and CHD-PAH patients from healthy controls,
   respectively (26 and 15 metabolites). Unbiased analysis from OPLS-DA
   identified 31 metabolites from PAH patients which were differentially
   regulated compared to the healthy controls. Our analysis showed
   dysregulation of the different metabolic pathways, including lipid
   metabolism, glucose metabolism, amino acid metabolism and phospholipid
   metabolism pathways in PAH patients compared to their healthy
   counterpart. Among these metabolites from dysregulated metabolic
   pathways, a panel of metabolites from lipid metabolism and fatty acid
   oxidation (lysophosphatidylcholine, phosphatidylcholine, perillic acid,
   palmitoleic acid, N-acetylcholine-D-sphingomyelin, oleic acid, palmitic
   acid and 2-Octenoylcarnitine metabolites) were found to have a close
   association with PAH. The results from the analysis of both real-time
   quantitative PCR and Western blot showed that expression of LDHA, CD36,
   FASN, PDK1 GLUT1 and CPT-1 in right heart/lung were significantly
   up-regulated in MCT group than the control group.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Fang, ZF; Zhou, SH (Corresponding Author), Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha 410011, Hunan, Peoples R China.
   Chen, Chenyang; Luo, Fei; Wu, Panyun; Huang, Yiyuan; Chen, Shenglan; Chen, Jingyuan; Hu, Xinqun; Fang, Zhenfei; Zhou, Shenhua, Cent S Univ, Xiangya Hosp 2, Dept Cardiovasc Med, Changsha 410011, Hunan, Peoples R China.
   Chen, Chenyang, Cent S Univ, Xiangya Hosp 3, Dept Cardiovasc Med, Changsha, Peoples R China.
   Das, Avash, Univ Texas Southwestern Med Ctr Dallas, Dept Mol Genet, Dallas, TX USA.
   Li, Fei, Chinese Acad Sci, Kunming Inst Bot, Kunming, Yunnan, Peoples R China.},
DOI = {10.1111/jcmm.14937},
EarlyAccessDate = {JAN 2020},
ISSN = {1582-1838},
EISSN = {1582-4934},
Keywords = {lipid metabolism; metabolomics; pulmonary arterial hypertension},
Keywords-Plus = {DYSFUNCTION; ACCUMULATION; DIAGNOSIS; OXIDATION; METFORMIN; OUTCOMES},
Research-Areas = {Cell Biology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Cell Biology; Medicine, Research \& Experimental},
Author-Email = {fangzhenfei@csu.edu.cn
   zhoushenghua@csu.edu.cn},
Affiliations = {Central South University; Central South University; University of Texas
   System; University of Texas Southwestern Medical Center; Chinese Academy
   of Sciences; Kunming Institute of Botany, CAS},
ResearcherID-Numbers = {Das, Avash/ABD-2132-2020
   Huang, Yi-yuan/AAG-7324-2020
   },
ORCID-Numbers = {chen, chenyang/0000-0002-9002-9207
   Luo, Fei/0000-0001-7173-7710},
Funding-Acknowledgement = {Hunan Provincial Natural Science Foundation of China {[}2018JJ2587];
   National Natural Science Foundation of China {[}81570267]; Hunan
   Provincial Innovation Foundation for Postgraduate {[}CX2018B068]},
Funding-Text = {Hunan Provincial Natural Science Foundation of China, Grant/Award
   Number: 2018JJ2587; National Natural Science Foundation of China,
   Grant/Award Number: 81570267; Hunan Provincial Innovation Foundation for
   Postgraduate, Grant/Award Number: CX2018B068},
Cited-References = {Agard C, 2009, BRIT J PHARMACOL, V158, P1285, DOI 10.1111/j.1476-5381.2009.00445.x.
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x.
   Blasco H, 2013, J PROTEOME RES, V12, P3746, DOI 10.1021/pr400376e.
   Brittain EL, 2016, CIRCULATION, V133, P1936, DOI 10.1161/CIRCULATIONAHA.115.019351.
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023.
   Farber HW, 2015, CHEST, V148, P1043, DOI 10.1378/chest.15-0300.
   Galiè N, 2016, REV ESP CARDIOL, V69, P177, DOI 10.1016/j.rec.2016.01.002.
   Guo Y, 2018, J CELL MOL MED, V22, P1489, DOI 10.1111/jcmm.13412.
   Habets DDJ, 2007, BIOCHEM BIOPH RES CO, V355, P204, DOI 10.1016/j.bbrc.2007.01.141.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Huang D, 2014, CELL REP, V8, P1930, DOI 10.1016/j.celrep.2014.08.028.
   Huang YY, 2016, VASC PHARMACOL, V85, P66, DOI 10.1016/j.vph.2016.08.009.
   Lee YS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03389-2.
   Lewis GD, 2016, J AM COLL CARDIOL, V67, P174, DOI 10.1016/j.jacc.2015.10.072.
   Luo F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02080-w.
   MacLean MR, 2000, BRIT J PHARMACOL, V131, P161, DOI 10.1038/sj.bjp.0703570.
   Marsboom G, 2012, AM J RESP CRIT CARE, V185, P670, DOI 10.1164/rccm.201108-1562OC.
   Oikawa M, 2005, J AM COLL CARDIOL, V45, P1849, DOI 10.1016/j.jacc.2005.02.065.
   Paulin R, 2014, CIRC RES, V115, P148, DOI 10.1161/CIRCRESAHA.115.301130.
   Piao L, 2013, J MOL MED, V91, P333, DOI 10.1007/s00109-012-0982-0.
   Rafikova O, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150480.
   Rhodes CJ, 2017, CIRCULATION, V135, P460, DOI 10.1161/CIRCULATIONAHA.116.024602.
   Rubin LJ, 2010, CELL METAB, V12, P313, DOI 10.1016/j.cmet.2010.09.006.
   Rygula A, 2015, ANALYST, V140, P2185, DOI 10.1039/c4an01998a.
   Sharma S, 2008, AM J PHYSIOL-LUNG C, V294, pL46, DOI 10.1152/ajplung.00247.2007.
   Sharma S, 2013, PEDIATR RES, V74, P39, DOI 10.1038/pr.2013.71.
   Sutendra G, 2014, CELL METAB, V19, P558, DOI 10.1016/j.cmet.2014.01.004.
   Talati M, 2015, PULM CIRC, V5, P269, DOI 10.1086/681227.
   Talati MH, 2016, AM J RESP CRIT CARE, V194, P719, DOI 10.1164/rccm.201507-1444OC.
   Vuckovic D, 2012, ANAL BIOANAL CHEM, V403, P1523, DOI 10.1007/s00216-012-6039-y.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Zhang TB, 2015, INT J CLIN EXP MED, V8, P2423.
   Zhao YD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088727.},
Number-of-Cited-References = {33},
Times-Cited = {72},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {30},
Journal-ISO = {J. Cell. Mol. Med.},
Doc-Delivery-Number = {KM4OO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000507443300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000507716000013,
Author = {Jing, Peihang and Zhou, Shengli and Xu, Pengpeng and Cui, Peng and Liu,
   Xianfang and Liu, Xiaofei and Liu, Xiuxiu and Wang, Haibo and Xu, Wei},
Title = {PDK1 promotes metastasis by inducing epithelial-mesenchymal transition
   in hypopharyngeal carcinoma via the Notchl signaling pathway},
Journal = {EXPERIMENTAL CELL RESEARCH},
Year = {2020},
Volume = {386},
Number = {2},
Month = {JAN 15},
Abstract = {Hypopharyngeal squamous cell carcinoma (HSCC) is a relatively rare
   malignancy and has the worst prognosis among head and neck cancer.
   Metastasis is the major cause of poor prognosis in HSCC patients. In
   this study, we found that 3-phosphoinositide-dependent protein kinase 1
   (PDK1 or PDPK1) was overexpressed in HSCC. The overexpression was
   positively correlated lymph node metastasis, clinical stage, and distant
   metastasis and indicated poor outcome. Loss and gain-of-function
   revealed that PDK1 increased cell proliferation, migration and invasion
   in vitro as well as tumor growth and metastasis in vivo. Mechanically,
   PDK1 induced epithelial-mesenchymal transition and promoted metastasis
   by activating the Notchl signaling pathway. We further illustrated that
   PDK1 bound with the Notchl intracellular domain, thereby inhibiting its
   ubiquitin-mediated degradation in a protein kinase B (Akt-) independent
   manner. In summary, PDK1/Notchl axis played an important role in HSCC
   metastasis, and this investigation provided a new perspective on
   potential therapeutic targets for HSCC.},
Publisher = {ELSEVIER INC},
Address = {525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, HB; Xu, W (Corresponding Author), Shandong Univ, Shandong Prov ENT Hosp, Dept Otolaryngol Head \& Neck Surg, 4 Duanxing West Rd, Jinan 250021, Peoples R China.
   Jing, Peihang; Zhou, Shengli; Xu, Pengpeng; Cui, Peng; Liu, Xianfang; Liu, Xiaofei; Liu, Xiuxiu; Wang, Haibo; Xu, Wei, Shandong Univ, Shandong Prov ENT Hosp, Jinan, Peoples R China.
   Zhou, Shengli; Xu, Pengpeng; Liu, Xianfang; Liu, Xiaofei; Liu, Xiuxiu; Wang, Haibo; Xu, Wei, Shandong Prov Key Lab Otol, Jinan, Peoples R China.},
DOI = {10.1016/j.yexcr.2019.111746},
Article-Number = {111746},
ISSN = {0014-4827},
EISSN = {1090-2422},
Keywords = {PDK1; EMT; Metastasis; Notchl; HSCC},
Keywords-Plus = {CELL-MIGRATION; PROTEIN-KINASE; SURGICAL-TREATMENT; CANCER; INVASION;
   ACTIVATION; EXPRESSION; BREAST; AKT; RECONSTRUCTION},
Research-Areas = {Oncology; Cell Biology},
Web-of-Science-Categories  = {Oncology; Cell Biology},
Author-Email = {jingpeihang@126.com
   shenglizhou@163.com
   xuppxmu@163.com
   sducuipeng@126.com
   liuxianfang198729@163.com
   liuxiaofei91@163.com
   18660105027@163.com
   whboto11@163.com
   xuwhns@126.com},
Affiliations = {Shandong University},
ResearcherID-Numbers = {xu, pengpeng/AAE-6567-2022
   Wang, Haibo/P-3026-2015},
Funding-Acknowledgement = {Natural Science Foundation of China {[}81702679, 81670932]; Natural
   Science Foundation of Shandong Province {[}ZR2017BH060, ZR2016QZ007];
   Key Project of Shandong Provincial Programs for Research and Development
   {[}2018GSF118225, 2017CXGC1213]},
Funding-Text = {The study was supported by the Natural Science Foundation of China
   (No.81702679, No.81670932), the Natural Science Foundation of Shandong
   Province (No.ZR2017BH060, No.ZR2016QZ007) and the Key Project of
   Shandong Provincial Programs for Research and Development
   (No.2018GSF118225, No.2017CXGC1213).},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770.
   Bai XF, 2016, TUMOR BIOL, V37, P2333, DOI 10.1007/s13277-015-4024-8.
   Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803.
   Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543.
   Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286.
   Chu PY, 2009, J CHIN MED ASSOC, V72, P351, DOI 10.1016/S1726-4901(09)70386-7.
   Dainichi T, 2016, CELL REP, V15, P1615, DOI 10.1016/j.celrep.2016.04.051.
   Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7.
   Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gagliardi PA, 2014, J CELL BIOL, V206, P415, DOI 10.1083/jcb.201312090.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Hassan WA, 2014, LUNG CANCER, V86, P304, DOI 10.1016/j.lungcan.2014.10.007.
   Hoffman HT, 1997, LARYNGOSCOPE, V107, P1005, DOI 10.1097/00005537-199708000-00001.
   Inamura N, 2017, AURIS NASUS LARYNX, V44, P447, DOI 10.1016/j.anl.2016.08.003.
   Jiang DY, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.117.005537.
   Jing PH, 2016, EXP MOL PATHOL, V100, P132, DOI 10.1016/j.yexmp.2015.12.008.
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104.
   Kelly AP, 2007, EMBO J, V26, P3441, DOI 10.1038/sj.emboj.7601761.
   Kim S, 2001, HEAD NECK-J SCI SPEC, V23, P713, DOI 10.1002/hed.1101.
   King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200.
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037.
   Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002.
   Lian SX, 2015, ONCOTARGET, V6, P29076, DOI 10.18632/oncotarget.4931.
   Liao Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-487.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Milburn CC, 2003, BIOCHEM J, V375, P531, DOI 10.1042/BJ20031229.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085.
   Mura F, 2013, ACTA OTORHINOLARYNGO, V33, P299.
   Pal D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0810-8.
   Patel RS, 2010, HEAD NECK-J SCI SPEC, V32, P109, DOI 10.1002/hed.21169.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503.
   Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Revathidevi S., 2019, SEMIN CANC BIOL.
   Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383.
   Shao S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0295-3.
   Takeshita K, 2007, CIRC RES, V100, P70, DOI 10.1161/01.RES.0000254788.47304.6e.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Tian JJ, 2018, ONCOTARGETS THER, V11, P7395, DOI 10.2147/OTT.S175423.
   Yang ZL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0337-5.
   Yasumatsu R, 2013, ACTA OTO-LARYNGOL, V133, P1110, DOI 10.3109/00016489.2013.815365.
   Yu J, 2012, ASIAN PAC J CANCER P, V13, P4147, DOI 10.7314/APJCP.2012.13.8.4147.
   Zabkiewicz J, 2014, HAEMATOLOGICA, V99, P858, DOI 10.3324/haematol.2013.096487.
   Zhang Y, 2018, FRONT MED-PRC, V12, P361, DOI 10.1007/s11684-018-0656-6.
   Zhao J, 2017, ONCOGENE, V36, P5023, DOI 10.1038/onc.2017.131.
   Zhou W, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.375.},
Number-of-Cited-References = {53},
Times-Cited = {16},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Exp. Cell Res.},
Doc-Delivery-Number = {KD2QO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000507716000013},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000496792900009,
Author = {Abdul, Naeem Sheik and Nagiah, Savania and Chuturgoon, Anil A.},
Title = {The neglected foodborne mycotoxin Fusaric acid induces bioenergetic
   adaptations by switching energy metabolism from mitochondrial processes
   to glycolysis in a human liver (HepG2) cell line},
Journal = {TOXICOLOGY LETTERS},
Year = {2020},
Volume = {318},
Pages = {74-85},
Month = {JAN},
Abstract = {Metabolic flexibility defines the capacity of cells to respond to
   changes in nutrient status. Mitochondria are important mediators of
   metabolic flexibility and dysfunction is associated with metabolic
   inflexibility and pathology. Foodborne toxins are often overlooked as
   potential factors contributing to metabolic toxicity. Fusaric acid (FA),
   a neglected mycotoxin, is known to disrupt mitochondrial function. The
   aim of this study was to investigate the molecular mechanisms underlying
   a metabolic switch in response to FA. This study investigated the
   effects of FA on energy homeostasis in cultured human liver (HepG2)
   cells. HepG2 cells poised to undergo oxidative and glycolytic metabolism
   were exposed to a range of FA concentrations (4, 63 and 250 mu g/mL) for
   6 h. We determined mitochondrial toxicity, acetyl CoA levels and cell
   viability using luminometric, fluorometric and spectrophotometric
   methods. Expression of metabolic proteins (PDK1, PKM2,
   phosphorylated-PDH E1 alpha and HIF-1 alpha) and mRNAs (HIF-1 alpha,
   PKM2, LDHa and PDK1) were determined using western blot and qPCR
   respectively. Our data connects a constitutive expression of HIF-1 alpha
   in response to FA, to the inhibition of pyruvate decarboxylation through
   up-regulation of PDK-1 and phosphorylation of Pyruvate Dehydrogenase E1
   alpha subunit. Moreover, we highlight the potential of FA to induce a
   glucose ``addiction{''} and phenotype reminiscent of the Warburg effect.
   The findings provide novel insights into the impact of this neglected
   foodborne mycotoxin in the dysregulation of energy metabolism.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Chuturgoon, AA (Corresponding Author), Univ KwaZulu Natal, Discipline Med Biochem, Fac Hlth Sci, Howard Coll, George Campbell Bldg, ZA-4041 Durban, South Africa.
   Abdul, Naeem Sheik; Nagiah, Savania; Chuturgoon, Anil A., Univ KwaZulu Natal, Coll Hlth Sci, Sch Lab Med \& Med Sci, Discipline Med Biochem, Durban, South Africa.},
DOI = {10.1016/j.toxlet.2019.10.013},
ISSN = {0378-4274},
EISSN = {1879-3169},
Keywords = {Metabolic inflexibility; Mitochondria; Pyruvate dehydrogenase complex;
   Warburg effect; Fusaric acid},
Keywords-Plus = {PYRUVATE-KINASE M2; FUMONISIN B-1; DEHYDROGENASE ACTIVITY; HYPOXIA;
   PHOSPHORYLATION; EXPRESSION; APOPTOSIS; STRESS; HIF-1-ALPHA; MECHANISM},
Research-Areas = {Toxicology},
Web-of-Science-Categories  = {Toxicology},
Author-Email = {chutur@ukzn.ac.za},
Affiliations = {University of Kwazulu Natal},
ResearcherID-Numbers = {Chuturgoon, Anil/AAE-5068-2021
   Nagiah, Savania/AAC-4388-2020
   Sheik Abdul, Naeem/AAL-7013-2020},
ORCID-Numbers = {Sheik Abdul, Naeem/0000-0001-6026-3759},
Funding-Acknowledgement = {German Academic Exchange Service-National research foundation of South
   Africa (DAAD-NRF) joint in-country scholarship programme {[}UID:
   101837]; College of Health Sciences (University of KwaZulu-Natal)},
Funding-Text = {This work was supported by the German Academic Exchange Service-National
   research foundation of South Africa (DAAD-NRF) joint in-country
   scholarship programme (UID: 101837) and the College of Health Sciences
   (University of KwaZulu-Natal).},
Cited-References = {Abdul NS, 2016, TOXICON, V119, P336, DOI 10.1016/j.toxicon.2016.07.002.
   {[}Anonymous], {[}No title captured].
   {[}Anonymous], {[}No title captured].
   Bacon CW, 1996, APPL ENVIRON MICROB, V62, P4039, DOI 10.1128/AEM.62.11.4039-4043.1996.
   BACON CW, 1995, MYCOPATHOLOGIA, V129, P29, DOI 10.1007/BF01139334.
   Brown DW, 2015, MOL PLANT MICROBE IN, V28, P319, DOI 10.1094/MPMI-09-14-0264-R.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Calabrese EJ, 2003, TOXICOL SCI, V71, P246, DOI 10.1093/toxsci/71.2.246.
   Chuturgoon A, 2014, TOXICOLOGY, V315, P65, DOI 10.1016/j.tox.2013.11.004.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Devnarain N, 2017, TOXICON, V126, P4, DOI 10.1016/j.toxicon.2016.12.006.
   Dhani S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03183-0.
   Dong TF, 2015, BIOMED PHARMACOTHER, V69, P277, DOI 10.1016/j.biopha.2014.12.010.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Selim ME, 2015, Journal of Bioprocessing \& Biotechniques, V5, DOI {[}10.4172/2155-9821.1000255, 10.4172/2155-9821.1000255, DOI 10.4172/2155-9821.1000255].
   Edmunds LR, 2014, J BIOL CHEM, V289, P25382, DOI 10.1074/jbc.M114.580662.
   Europa AF, 2000, BIOTECHNOL BIOENG, V67, P25, DOI 10.1002/(SICI)1097-0290(20000105)67:1<25::AID-BIT4>3.0.CO;2-K.
   Fan J, 2014, J BIOL CHEM, V289, P26533, DOI 10.1074/jbc.M114.593970.
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023.
   Gao AW, 2014, EMBO MOL MED, V6, P580, DOI 10.1002/emmm.201303782.
   Ghazi T, 2019, EPIGENETICS, V14, P1.
   Ghazi T, 2017, J CELL BIOCHEM, V118, P3866, DOI 10.1002/jcb.26037.
   Golias T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31146.
   Goodpaster BH, 2017, CELL METAB, V25, P1027, DOI 10.1016/j.cmet.2017.04.015.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hirai T, 2005, BIOL TRACE ELEM RES, V108, P77, DOI 10.1385/BTER:108:1-3:077.
   Iwahashi H, 1999, CHEM-BIOL INTERACT, V118, P201, DOI 10.1016/S0009-2797(99)00080-0.
   Kamalian L, 2015, TOXICOL IN VITRO, V29, P732, DOI 10.1016/j.tiv.2015.02.011.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200.
   Kubis HP, 2005, BBA-MOL CELL RES, V1745, P187, DOI 10.1016/j.bbamcr.2005.05.007.
   Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027.
   Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200.
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200.
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054.
   Malovrh T, 2010, FOOD CHEM TOXICOL, V48, P2907, DOI 10.1016/j.fct.2010.07.026.
   Mariño G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016.
   Marroquin LD, 2007, TOXICOL SCI, V97, P539, DOI 10.1093/toxsci/kfm052.
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459.
   Metallo CM, 2013, MOL CELL, V49, P388, DOI 10.1016/j.molcel.2013.01.018.
   Metallo CM, 2010, GENE DEV, V24, P2717, DOI 10.1101/gad.2010510.
   Milosevic J, 2009, NEUROTOX RES, V15, P367, DOI 10.1007/s12640-009-9043-z.
   MIZUGAKI M, 1986, J BIOCHEM, V99, P469, DOI 10.1093/oxfordjournals.jbchem.a135501.
   Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI {[}10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017].
   Pereira CV, 2012, TOXICOL APPL PHARM, V264, P167, DOI 10.1016/j.taap.2012.07.030.
   Porter James K., 1995, Natural Toxins, V3, P91, DOI 10.1002/nt.2620030206.
   Reddy RV, 1996, B ENVIRON CONTAM TOX, V57, P354, DOI 10.1007/s001289900198.
   Rodrigues I, 2012, TOXINS, V4, P663, DOI 10.3390/toxins4090663.
   Schulz N, 2013, INT J MOL SCI, V14, P18989, DOI 10.3390/ijms140918989.
   Serrano Jose C E, 2016, Diseases, V4, DOI {[}10.3390/diseases4010014, 10.3390/diseases4010014].
   Singh VK, 2017, PLANT PHYSIOL BIOCH, V118, P320, DOI 10.1016/j.plaphy.2017.06.028.
   Smith MC, 2016, TOXINS, V8, DOI 10.3390/toxins8040094.
   Stanton RC, 2012, IUBMB LIFE, V64, P362, DOI 10.1002/iub.1017.
   Streit E, 2013, TOXINS, V5, P504, DOI 10.3390/toxins5030504.
   Swamy HVLN, 2002, POULTRY SCI, V81, P966, DOI 10.1093/ps/81.7.966.
   Szabó A, 2018, TOXINS, V10, DOI 10.3390/toxins10010004.
   Telles-Pupulin AR, 1998, COMP BIOCHEM PHYS C, V120, P43, DOI 10.1016/S0742-8413(98)00004-8.
   Wang HX, 1999, LIFE SCI, V65, P849, DOI 10.1016/S0024-3205(99)00083-1.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Wong CCL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115036.
   Yin ES, 2015, BIOMETALS, V28, P783, DOI 10.1007/s10534-015-9855-7.
   Zhang S, 2014, NUTR METAB, V11, DOI 10.1186/1743-7075-11-10.
   Zhang Y, 2017, ONCOTARGET, V8, P15205, DOI 10.18632/oncotarget.14837.
   Zhu AP, 2011, ANAL BIOCHEM, V419, P266, DOI 10.1016/j.ab.2011.08.037.},
Number-of-Cited-References = {67},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Toxicol. Lett.},
Doc-Delivery-Number = {JN3IK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000496792900009},
DA = {2026-02-04},
}

@article{ WOS:000575563300003,
Author = {Bai, Lanxiang and Peng, Xiaonu and Sun, Ruimei},
Title = {Knockdown of circPRKCA Restrained Cell Growth, Migration, and Invasion
   of NSCLC Cells Both in vitro and in vivo via Regulating
   miR-330-5p/PDK1/AKT Pathway},
Journal = {CANCER MANAGEMENT AND RESEARCH},
Year = {2020},
Volume = {12},
Pages = {9125-9137},
Abstract = {Background: Protein kinase Ca (PRKCA) is an oncogene in multiple cancers
   including non-small-cell lung cancer (NSCLC) and can be transcribed into
   a number of circular PRKCAs (circPRKCAs). Here, we aimed to elaborate
   the role and mechanism of circPRKCA\_024 (circPRKCA) in malignant
   progression of NSCLC.
   Methods: Expression of circPRKCA, miRNA (miR)-330-5p and
   3-phosphoinositide-dependent protein kinase-1 (PDK1) was measured by
   real-time quantitative PCR and Western blotting, and their relationship
   was testified by dual-luciferase reporter assay, RNA
   immunoprecipitation, and RNA pull-down assay. Cell behaviors were
   evaluated by cell counting kit (CCK)-8, flow cytometry, and transwell
   assays. AKT activity was confirmed by Western blotting. Xenograft
   experiment assessed tumor growth.
   Results: Expression of circPRKCA and PDK1 was upregulated, and
   miR-330-5p was downregulated in NSCLC tissues and cell lines. High
   circPRKCA was correlated with TNM stage and lymph node metastasis of
   NSCLC patients. Silencing circPRKCA could suppress cell viability,
   migration, and invasion in A549 and H1299 cells, accompanied with
   apoptosis rate promotion. Moreover, circPRKCA knockdown retarded tumor
   growth of A549 cells in vivo. Molecularly, miR-330-5p was sponged by
   circPRKCA, and PDK1 was a target of miR-330-5p. Inhibiting miR-330-5p
   could attenuate the suppression of circPRKCA knockdown on cell growth,
   migration, and invasion; contrarily, promoting miR-330-5p caused
   inhibition on those cell behaviors by downregulating PDK1. Analogously,
   AKT activity was suppressed by circPRKCA downregulation and miR-330-5p
   upregulation in NSCLC cells both in vitro and in vivo.
   Conclusion: Depleting circPRKCA inhibited PDK1 to suppress NSCLC cell
   malignant behaviors through miR-330-5p/PDK1/AKT pathway.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Article},
Language = {English},
Affiliation = {Sun, RM (Corresponding Author), Weifang 2 Peoples Hosp, Dept Lab, Weifang 261041, Shandong, Peoples R China.
   Bai, Lanxiang, Yantai Yuhuangding Hosp, Disinfect Supply Ctr, Yantai 264000, Shandong, Peoples R China.
   Peng, Xiaonu, Yantai Yuhuangding Hosp, Dept Thorac Surg, Yantai 264000, Shandong, Peoples R China.
   Sun, Ruimei, Weifang 2 Peoples Hosp, Dept Lab, Weifang 261041, Shandong, Peoples R China.},
DOI = {10.2147/CMAR.S258370},
ISSN = {1179-1322},
Keywords = {circPRKCA; miR-330-5p; PDK1; AKT; NSCLC},
Keywords-Plus = {LUNG-CANCER; PROLIFERATION; PROGRESSION; SUPPRESSES; EXPRESSION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {sunruimeiweifang@163.com},
ResearcherID-Numbers = {SUN, Ruimei/NRY-6575-2025},
Cited-References = {Balata H, 2019, J THORAC ONCOL, V14, P1513, DOI 10.1016/j.jtho.2019.06.011.
   Bibby BAS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134180.
   Braicu C, 2019, CELL MOL LIFE SCI, V76, P1559, DOI 10.1007/s00018-019-03016-5.
   Cognini R, 2013, IN C IND ENG ENG MAN, P1, DOI 10.1109/IEEM.2013.6962363.
   Cui LH, 2018, ONCOTARGETS THER, V11, P7715, DOI 10.2147/OTT.S178597.
   de Fraipont F, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00390.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Ding G, 2013, MOL CELL BIOCHEM, V384, P173, DOI 10.1007/s11010-013-1795-3.
   Feng LS, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170019.
   Hang D, 2018, CANCER MED-US, V7, P2783, DOI 10.1002/cam4.1514.
   Hill KS, 2014, ONCOGENE, V33, P2134, DOI 10.1038/onc.2013.147.
   Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8.
   Hodzic J, 2011, NUCLEOS NUCLEOT, V30, P12, DOI {[}10.1080/15257770.2011.62927132, DOI 10.1080/15257770.2011.62927132].
   Jiang HH, 2019, ONCOL LETT, V18, P4936, DOI 10.3892/ol.2019.10812.
   Kong RR, 2017, ONCOL REP, V38, P2572, DOI 10.3892/or.2017.5927.
   Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7.
   Lahn Michael, 2004, Clin Lung Cancer, V6, P184, DOI 10.3816/CLC.2004.n.032.
   Li CY, 2019, J CANCER RES CLIN, V145, P2875, DOI 10.1007/s00432-019-03045-4.
   Li J, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0201-5.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Liu DC, 2019, J CELL PHYSIOL, V234, P12727, DOI 10.1002/jcp.27893.
   Liu RR, 2019, J CELL PHYSIOL, V234, P20728, DOI 10.1002/jcp.28679.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Mansoori B, 2020, J CELL PHYSIOL, V235, P920, DOI 10.1002/jcp.29007.
   Mason J, 2017, LUNG CANCER MANAG, V6, P129, DOI 10.2217/lmt-2017-0019.
   Massacesi C, 2016, ONCOTARGETS THER, V9, P203, DOI 10.2147/OTT.S89967.
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565.
   Mu YY, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017601.
   Pérez-Ramírez C, 2015, PHARMACOGENOMICS, V16, P1843, DOI 10.2217/pgs.15.122.
   Qiu BQ, 2019, J CELL PHYSIOL, V234, P11256, DOI 10.1002/jcp.27783.
   Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008-5472.CAN-18-2738.
   Su M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1002-6.
   Tan AC, 2020, THORAC CANCER, V11, P511, DOI 10.1111/1759-7714.13328.
   Wang CD, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1061-8.
   Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7.
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071.
   Wang R, 2018, J CELL PHYSIOL, V233, P7447, DOI 10.1002/jcp.26590.
   Wang YY, 2019, TRANSL LUNG CANCER R, V8, P862, DOI 10.21037/tlcr.2019.11.04.
   Wang Y, 2016, ARCH TOXICOL, V90, P1239, DOI 10.1007/s00204-015-1551-4.
   Wei YY, 2019, ONCOTARGETS THER, V12, P9005, DOI 10.2147/OTT.S213059.
   Wen YK, 2018, CELL CYCLE, V17, P2819, DOI 10.1080/15384101.2018.1558860.
   Wu KL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071611.
   Yao J, 2020, ONCOTARGETS THER, V13, P549, DOI 10.2147/OTT.S230795.
   Yoo HI, 2016, ONCOL REP, V36, P3023, DOI 10.3892/or.2016.5092.
   Zhan JW, 2017, THORAC CANCER, V8, P461, DOI 10.1111/1759-7714.12467.},
Number-of-Cited-References = {45},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Cancer Manag. Res.},
Doc-Delivery-Number = {NX2SB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000575563300003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@incollection{ WOS:000556133800061,
Author = {Bao, Jinku and Liu, Bo and Wu, Chuanfang},
Editor = {Le, W},
Title = {Progress of Anti-aging Drugs Targeting Autophagy},
Booktitle = {AUTOPHAGY: BIOLOGY AND DISEASES: CLINICAL SCIENCE},
Series = {Advances in Experimental Medicine and Biology},
Year = {2020},
Volume = {1207},
Pages = {681-688},
Abstract = {Senescence is a progressive process of degeneration that occurs when
   cells and organisms mature. Many studies have shown that autophagy is
   closely related to senescence. Autophagy gradually decreases with the
   senescence activity of cells, and vice versa. Therefore, moderate
   autophagy can protect the body and inhibit cell senescence. The
   inactivation of genes encoding nematode insulin-like tyrosine kinase
   receptor (daf-2) inhibited the activity of type I PI3K (age-1), Akt
   molecules (akt1, akt2), PDK (pdk-1), and TOR, and increased the lifespan
   and autophagy of Caenorhabditis elegans.},
Publisher = {SPRINGER-VERLAG SINGAPORE PTE LTD},
Address = {152 BEACH ROAD, \#21-01/04 GATEWAY EAST, SINGAPORE, 189721, SINGAPORE},
Type = {Article; Book Chapter},
Language = {English},
Affiliation = {Bao, JK (Corresponding Author), Sichuan Univ, Coll Life Sci, Minist Educ, Key Lab Bioresource \& Ecoenvironm, Chengdu 610065, Sichuan, Peoples R China.
   Bao, Jinku; Wu, Chuanfang, Sichuan Univ, Coll Life Sci, Minist Educ, Key Lab Bioresource \& Ecoenvironm, Chengdu 610065, Sichuan, Peoples R China.
   Liu, Bo, Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu 610065, Sichuan, Peoples R China.},
DOI = {10.1007/978-981-15-4272-5\_50},
ISSN = {0065-2598},
EISSN = {2214-8019},
ISBN = {978-981-15-4272-5; 978-981-15-4271-8},
Keywords = {Senescence; Autophagy; Insulin-like/PI3K pathway},
Research-Areas = {Research \& Experimental Medicine; Neurosciences \& Neurology},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Clinical Neurology},
Author-Email = {baojinku@scu.edu.cn
   wuchuanfang@scu.edu.cn},
Affiliations = {Sichuan University; Sichuan University},
ResearcherID-Numbers = {Liu, Bo/LSL-4796-2024
   chuanfang, wu/LCD-4356-2024},
ORCID-Numbers = {Liu, Bo/0000-0003-3900-9486
   chuanfang, wu/0000-0001-9441-9897},
Cited-References = {Ahmet I, 2005, CIRCULATION, V112, P3115, DOI 10.1161/CIRCULATIONAHA.105.563817.
   Androutsopoulos VP, 2011, EUR J MED CHEM, V46, P2586, DOI 10.1016/j.ejmech.2011.03.049.
   Bi S, 2018, MECH AGEING DEV.
   Burkewitz K, 2016, AMPK PROLONGEVITY TA.
   Cerletti M, 2012, CELL STEM CELL, V10, P515, DOI 10.1016/j.stem.2012.04.002.
   Cheng CL, 2005, WORLD J GASTROENTERO, V11, P1891.
   Horne BD, 2015, AM J CLIN NUTR, V102, P464, DOI 10.3945/ajcn.115.109553.
   Jiang Hao, 2009, J Exp Ther Oncol, V8, P25.
   LaRocca TJ, 2013, MECH AGEING DEV, V134, P314, DOI 10.1016/j.mad.2013.04.004.
   Li LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066069.
   Shen CY, 2017, BRIT J PHARMACOL, V174, P1395, DOI 10.1111/bph.13631.
   Zuo L, 2016, FRONT PHYSIOL, V7, DOI {[}10.3389/fphys.2076.00350, 10.3389/fphys.2016.00350].},
Number-of-Cited-References = {12},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Adv.Exp.Med.Biol.},
Doc-Delivery-Number = {BP5KY},
Web-of-Science-Index = {Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000556133800061},
DA = {2026-02-04},
}

@article{ WOS:000507308900078,
Author = {Canet, Geoffrey and Pineau, Fanny and Zussy, Charleine and Hernandez,
   Celia and Hunt, Hazel and Chevallier, Nathalie and Perrier, Veronique
   and Torrent, Joan and Belanoff, Joseph K. and Meijer, Onno C. and
   Desrumaux, Catherine and Givalois, Laurent},
Title = {Glucocorticoid receptors signaling impairment potentiates amyloid-β
   oligomers-induced pathology in an acute model of Alzheimer's disease},
Journal = {FASEB JOURNAL},
Year = {2020},
Volume = {34},
Number = {1},
Pages = {1150-1168},
Month = {JAN},
Abstract = {Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis occurs
   early in Alzheimer's disease (AD), associated with elevated circulating
   glucocorticoids (GC) and glucocorticoid receptors (GR) signaling
   impairment. However, the precise role of GR in the pathophysiology of AD
   remains unclear. Using an acute model of AD induced by the
   intracerebroventricular injection of amyloid-beta oligomers (oA beta),
   we analyzed cellular and behavioral hallmarks of AD, GR signaling
   pathways, processing of amyloid precursor protein, and enzymes involved
   in Tau phosphorylation. We focused on the prefrontal cortex (PFC),
   particularly rich in GR, early altered in AD and involved in HPA axis
   control and cognitive functions. We found that oA beta impaired
   cognitive and emotional behaviors, increased plasma GC levels, synaptic
   deficits, apoptosis and neuroinflammatory processes. Moreover, oA beta
   potentiated the amyloidogenic pathway and enzymes involved both in Tau
   hyperphosphorylation and GR activation. Treatment with a selective GR
   modulator (sGRm) normalized plasma GC levels and all behavioral and
   biochemical parameters analyzed. GR seems to occupy a central position
   in the pathophysiology of AD. Deregulation of the HPA axis and a
   feed-forward effect on PFC GR sensitivity could participate in the
   etiology of AD, in perturbing A beta and Tau homeostasis. These results
   also reinforce the therapeutic potential of sGRm in AD.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Givalois, L (Corresponding Author), INSERM, U1198, Mol Mech Neurodegenerat Dementia MMDN Lab, Team Environm Impact Alzheimers Dis \& Related Dis, Pl E Bataillon, F-34095 Montpellier, France.
   Canet, Geoffrey; Pineau, Fanny; Zussy, Charleine; Hernandez, Celia; Chevallier, Nathalie; Perrier, Veronique; Torrent, Joan; Desrumaux, Catherine; Givalois, Laurent, INSERM, U1198, Mol Mech Neurodegenerat Dementia MMDN Lab, Team Environm Impact Alzheimers Dis \& Related Dis, Pl E Bataillon, F-34095 Montpellier, France.
   Canet, Geoffrey; Pineau, Fanny; Zussy, Charleine; Hernandez, Celia; Chevallier, Nathalie; Perrier, Veronique; Torrent, Joan; Desrumaux, Catherine; Givalois, Laurent, Univ Montpellier, Montpellier, France.
   Canet, Geoffrey; Pineau, Fanny; Zussy, Charleine; Hernandez, Celia; Chevallier, Nathalie; Perrier, Veronique; Torrent, Joan; Desrumaux, Catherine; Givalois, Laurent, EPHE, Paris, France.
   Hunt, Hazel; Belanoff, Joseph K., Corcept Therapeut, Menlo Pk, CA USA.
   Meijer, Onno C., Leiden Univ, Div Endocrinol, Dept Med, Einthoven Lab,Med Ctr, Leiden, Netherlands.},
DOI = {10.1096/fj.201900723RRR},
ISSN = {0892-6638},
EISSN = {1530-6860},
Keywords = {Cdk5; GSK-3 beta; PDK1; ROCK; selective GR modulator},
Keywords-Plus = {TAU PHOSPHORYLATION; RHO-KINASE; IN-VIVO; HIPPOCAMPAL-NEURONS;
   PREFRONTAL CORTEX; MOUSE MODEL; PROTEIN; INHIBITION; STRESS; ACTIVATION},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology; Cell Biology},
Author-Email = {laurent.givalois@umontpellier.fr},
Affiliations = {Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; Universite PSL;
   Ecole Pratique des Hautes Etudes (EPHE); Leiden University; Leiden
   University Medical Center (LUMC); Leiden University - Excl LUMC},
ResearcherID-Numbers = {perrier, veronique/AAK-3594-2020
   TORRENT, Joan/KRP-1228-2024
   Givalois, Laurent/OMM-6161-2025
   CANET, Geoffrey/KBB-6305-2024
   Desrumaux, Catherine/O-1925-2018
   Meijer, Onno/D-8070-2018},
ORCID-Numbers = {perrier, veronique/0000-0002-6570-7504
   TORRENT, Joan/0000-0002-6908-4084
   Givalois, Laurent/0000-0002-6698-5346
   CANET, Geoffrey/0000-0001-7291-4512
   Desrumaux, Catherine/0009-0004-7067-602X
   Meijer, Onno/0000-0002-8394-6859},
Funding-Acknowledgement = {Association France Alzheimer (French Alzheimer's Association) {[}1512];
   Agence Nationale de la Recherche (ANR) {[}ANR-11-LABEX-0021-LipSTIC];
   Corcept Therapeutics (Menlo Park, CA, USA); University of Montpellier,
   France; University of Montpellier, France, CBS2 PhD program},
Funding-Text = {Association France Alzheimer (French Alzheimer's Association),
   Grant/Award Number: SM2016\#1512 -LG; Agence Nationale de la Recherche
   (ANR), Grant/Award Number: ANR-11-LABEX-0021-LipSTIC - CD; Corcept
   Therapeutics (Menlo Park, CA, USA), Grant/Award Number: Exceptional
   subvention - LG; University of Montpellier, France, Grant/Award Number:
   CBS2 PhD program - GC; University of Montpellier, France, Grant/Award
   Number: CBS2 PhD program - CH},
Cited-References = {Alleaume-Butaux A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005073.
   Almeida OFX, 2000, FASEB J, V14, P779, DOI 10.1096/fasebj.14.5.779.
   Amano M, 2003, J NEUROCHEM, V87, P780, DOI 10.1046/j.1471-4159.2003.02054.x.
   Baglietto-Vargas D, 2013, BIOL PSYCHIAT, V74, P357, DOI 10.1016/j.biopsych.2012.12.003.
   Beaudry JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091248.
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016.
   Braak H, 1996, ACTA NEUROL SCAND, V93, P3.
   Brureau A, 2013, NEUROBIOL AGING, V34, P1426, DOI 10.1016/j.neurobiolaging.2012.11.015.
   Catania C, 2009, MOL PSYCHIATR, V14, P95, DOI 10.1038/sj.mp.4002101.
   Chang J, 2006, P NATL ACAD SCI USA, V103, P14495, DOI 10.1073/pnas.0601911103.
   Chen YM, 2014, J NEUROSCI, V34, P2464, DOI 10.1523/JNEUROSCI.0151-13.2014.
   Choi GE, 2017, J NEUROSCI, V37, P8459, DOI 10.1523/JNEUROSCI.0074-17.2017.
   Clark RD, 2008, BIOORG MED CHEM LETT, V18, P1312, DOI 10.1016/j.bmcl.2008.01.027.
   Crochemore C, 2005, MOL PSYCHIATR, V10, P790, DOI 10.1038/sj.mp.4001679.
   Davidson RJ, 2002, BIOL PSYCHIAT, V51, P68, DOI 10.1016/S0006-3223(01)01328-2.
   Deng J, 2015, J NEUROCHEM, V135, P630, DOI 10.1111/jnc.13351.
   Dey A, 2017, NEUROBIOL AGING, V57, P75, DOI 10.1016/j.neurobiolaging.2017.05.010.
   DIORIO D, 1993, J NEUROSCI, V13, P3839.
   Dou F, 2003, P NATL ACAD SCI USA, V100, P721, DOI 10.1073/pnas.242720499.
   Castro-Alvarez JF, 2011, BEHAV NEUROSCI, V125, P465, DOI 10.1037/a0023167.
   Fung J, 2004, J NEUROCHEM, V91, P1398, DOI 10.1111/j.1471-4159.2004.02828.x.
   Galliher-Beckley AJ, 2009, IUBMB LIFE, V61, P979, DOI 10.1002/iub.245.
   García-Rojo G, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00483.
   Gentry EG, 2016, J NEUROSCI, V36, P1316, DOI 10.1523/JNEUROSCI.2336-15.2016.
   Gray JD, 2017, NAT REV ENDOCRINOL, V13, P661, DOI 10.1038/nrendo.2017.97.
   Green KN, 2006, J NEUROSCI, V26, P9047, DOI 10.1523/JNEUROSCI.2797-06.2006.
   Groeneweg FL, 2012, MOL CELL ENDOCRINOL, V350, P299, DOI 10.1016/j.mce.2011.06.020.
   Groeneweg FL, 2011, J ENDOCRINOL, V209, P153, DOI 10.1530/JOE-10-0472.
   Gruden MA, 2007, J NEUROIMMUNOL, V186, P181, DOI 10.1016/j.jneuroim.2007.03.023.
   Hamano T, 2012, NEUROBIOL AGING, V33, P2306, DOI 10.1016/j.neurobiolaging.2011.10.020.
   Hartmann A, 1997, NEUROBIOL AGING, V18, P285, DOI 10.1016/S0197-4580(97)80309-0.
   Henderson BW, 2016, J NEUROCHEM, V138, P525, DOI 10.1111/jnc.13688.
   Herskowitz JH, 2013, J NEUROSCI, V33, P19086, DOI 10.1523/JNEUROSCI.2508-13.2013.
   Ho GJ, 2005, NEUROBIOL AGING, V26, P625, DOI 10.1016/j.neurobiolaging.2004.06.016.
   Hoogendijk WJG, 2006, NEUROBIOL AGING, V27, DOI 10.1016/j.neurobiolaging.2005.07.017.
   Hu YB, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00253.
   Huang GX, 2017, CANCER LETT, V410, P1, DOI 10.1016/j.canlet.2017.09.005.
   Hunt HJ, 2015, BIOORG MED CHEM LETT, V25, P5720, DOI 10.1016/j.bmcl.2015.10.097.
   Jankord R, 2008, ANN NY ACAD SCI, V1148, P64, DOI 10.1196/annals.1410.012.
   Jin NN, 2015, SCI REP-UK, V5, DOI 10.1038/srep08187.
   Jozic I, 2017, J INVEST DERMATOL, V137, P1144, DOI 10.1016/j.jid.2016.11.036.
   Kaneko I, 2001, NEUROSCIENCE, V104, P1003, DOI 10.1016/S0306-4522(01)00155-5.
   Kirschke E, 2014, CELL, V157, P1685, DOI 10.1016/j.cell.2014.04.038.
   Kubo T, 2002, J NEUROSCI RES, V70, P474, DOI 10.1002/jnr.10391.
   Kurbatskaya K, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0299-2.
   Lackie RE, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00254.
   Lahiri DK, 2004, ANN NY ACAD SCI, V1030, P282, DOI 10.1196/annals.1329.035.
   Lai AY, 2018, J NEUROCHEM, V144, P659, DOI 10.1111/jnc.14130.
   Lanté F, 2015, NEUROPSYCHOPHARMACOL, V40, P1772, DOI 10.1038/npp.2015.25.
   LAPING NJ, 1994, ENDOCRINOLOGY, V135, P1928, DOI 10.1210/en.135.5.1928.
   Le Menuet D, 2014, STEROIDS, V91, P11, DOI 10.1016/j.steroids.2014.05.018.
   Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636.
   Lesort M, 1999, J NEUROCHEM, V72, P576, DOI 10.1046/j.1471-4159.1999.0720576.x.
   Lesuis SL, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-018-0101-2.
   Li XH, 2007, CHIN MED J, V120, P66974.
   Lin DW, 2012, BEHAV BRAIN RES, V228, P319, DOI 10.1016/j.bbr.2011.12.010.
   Liu DZ, 2014, J NEUROTRAUM, V31, P1268, DOI 10.1089/neu.2013.3250.
   Liu D, 2014, CELL PHYSIOL BIOCHEM, V33, P1654, DOI 10.1159/000362948.
   Loirand G, 2015, PHARMACOL REV, V67, P1074, DOI 10.1124/pr.115.010595.
   Löwenberg M, 2005, BLOOD, V106, P1703, DOI 10.1182/blood-2004-12-4790.
   Lv Z., 2016, J Diabetes Res, P5671803, DOI {[}DOI 10.1155/2016/5671803, 10.1155/2016/].
   McEwen BS, 2008, EUR J PHARMACOL, V583, P174, DOI 10.1016/j.ejphar.2007.11.071.
   Meijer OC, 2018, ANN ENDOCRINOL-PARIS, V79, P107, DOI 10.1016/j.ando.2018.03.004.
   Meunier J, 2013, EUR J PHARMACOL, V698, P193, DOI 10.1016/j.ejphar.2012.10.033.
   Meyer M, 2018, NEUROSCIENCE, V384, P384, DOI 10.1016/j.neuroscience.2018.05.042.
   Naert G, 2015, EUR NEUROPSYCHOPHARM, V25, P2170, DOI 10.1016/j.euroneuro.2015.03.018.
   Notarianni E, 2013, CURR ALZHEIMER RES, V10, P714, DOI 10.2174/15672050113109990137.
   Oakley RH, 2013, J ALLERGY CLIN IMMUN, V132, P1033, DOI 10.1016/j.jaci.2013.09.007.
   Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159.
   Paxinos G., 1998, RAT BRAIN STEROTAXIC, VFourth.
   Pietri M, 2013, NAT MED, V19, P1124, DOI 10.1038/nm.3302.
   PIKE CJ, 1995, J NEUROCHEM, V64, P253, DOI 10.1046/j.1471-4159.1995.64010253.x.
   PIKE CJ, 1993, J NEUROSCI, V13, P1676.
   Pineau F, 2016, NEUROBIOL AGING, V45, P109, DOI 10.1016/j.neurobiolaging.2016.05.018.
   Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138.
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142.
   REUL JMHM, 1985, ENDOCRINOLOGY, V117, P2505, DOI 10.1210/endo-117-6-2505.
   Roozendaal B, 2000, PSYCHONEUROENDOCRINO, V25, P213, DOI 10.1016/S0306-4530(99)00058-X.
   Rothman SM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.005.
   Rubenstein NM, 2007, BIOCHEM BIOPH RES CO, V354, P603, DOI 10.1016/j.bbrc.2007.01.024.
   Sambamurti K, 2004, FASEB J, V18, P1034, DOI 10.1096/fj.03-1378fje.
   Scales TME, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-12.
   Selkoe DJ, 2016, EMBO MOL MED, V8, P595, DOI 10.15252/emmm.201606210.
   Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741.
   Solomon MB, 2014, HORM BEHAV, V65, P363, DOI 10.1016/j.yhbeh.2014.02.002.
   Sullivan RM, 2002, PSYCHONEUROENDOCRINO, V27, P99, DOI 10.1016/S0306-4530(01)00038-5.
   Sun LH, 2015, J NEUROCHEM, V134, P1139, DOI 10.1111/jnc.13212.
   Swanger SA, 2015, Cellular Logistics, V5, pe1133266, DOI {[}10.1080/21592799.2015.1133266, 10.1080/21592799.2015.1133266, DOI 10.1080/21592799.2015.1133266].
   Varadarajan S, 2001, J AM CHEM SOC, V123, P5625, DOI 10.1021/ja010452r.
   Wang Z, 2002, J BIOL CHEM, V277, P26573, DOI 10.1074/jbc.M110530200.
   Yamada K, 2000, PHARMACOL THERAPEUT, V88, P93, DOI 10.1016/S0163-7258(00)00081-4.
   YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531.
   Zalachoras I, 2013, P NATL ACAD SCI USA, V110, P7910, DOI 10.1073/pnas.1219411110.
   Zussy C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053117.
   Zussy C, 2011, AM J PATHOL, V179, P315, DOI 10.1016/j.ajpath.2011.03.021.},
Number-of-Cited-References = {95},
Times-Cited = {29},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Faseb J.},
Doc-Delivery-Number = {KC6TY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000507308900078},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000535963000001,
Author = {Chen, Zhong-Jun and Zhao, Xu-Sheng and Fan, Tie-Ping and Qi, Heng-Xu and
   Li, Di},
Title = {Glycine Improves Ischemic Stroke Through miR-19a-3p/AMPK/GSK-3β/HO-1
   Pathway},
Journal = {DRUG DESIGN DEVELOPMENT AND THERAPY},
Year = {2020},
Volume = {14},
Pages = {2021-2031},
Abstract = {Purpose: To explore the molecular mechanism of glycine in improving
   ischemic stroke.
   Patients and Methods: The serum samples of patients with ischemic stroke
   and healthy people were compared. The ischemic stroke model of PC12
   cells was established by oxygen-glucose deprivation (OGD). qPCR
   quantified miR-19a-3p and AMPK mRNA, and protein expression was detected
   by Western blot. MTT was used to detect cell activity. Flow cytometry
   was used to detect cells. Glucose metabolism kit was used to detect
   glucose intake and formation amount of lactic acid.
   Results: Compared with the control group, OGD group (OGDG) showed lower
   cell activity and increased cell apoptosis. TNF-alpha, IL-1 beta I, L-6,
   Caspase 3, Caspase 9 and Bax were upregulated, and Glut1, HK2, LDHA,
   PDK1, PKM2 and Bcl2 were down-regulated. At the same time, glucose
   intake, formation amount of lactic acid and cell apoptosis rate were
   reduced, and AMPK/GSK-3 beta/HO-1 pathway activity was down-regulated.
   Glycine could counteract the above phenomena in OGDG. miR-19a-3p and
   AMPK decreased and increased, respectively, during glycine therapy. AMPK
   was the target gene of miR-19a-3p. Rescue experiments demonstrated that
   glycine improved cell apoptosis, inflammatory response and glucose
   metabolism disorder of ischemic stroke through miR-19a-3p/AMPK/GSK-3
   beta/HO-1 pathway.
   Conclusion: Glycine improves ischemic stroke through
   miR-19a-3p/AMPK/GSK-3 beta/HO-1 pathway.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Article},
Language = {English},
Affiliation = {Li, D (Corresponding Author), Dalian Municipal Cent Hosp, Neurol Intervent Dept, Dalian, Liaoning, Peoples R China.
   Chen, Zhong-Jun; Zhao, Xu-Sheng; Fan, Tie-Ping; Qi, Heng-Xu; Li, Di, Dalian Municipal Cent Hosp, Neurol Intervent Dept, Dalian, Liaoning, Peoples R China.},
DOI = {10.2147/DDDT.S248104},
ISSN = {1177-8881},
Keywords = {ischemic stroke; AMPK/GSK-3 beta/HO-1 pathway; miR-19a-3p; glycine},
Keywords-Plus = {AMPK; GLUCOSE},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal; Pharmacology \& Pharmacy},
Author-Email = {xiangqing14740@163.com},
Cited-References = {Bai R, 2019, MOL CARCINOGEN, V58, P2254, DOI 10.1002/mc.23113.
   Bayliss JA, 2016, J NEUROSCI, V36, P3049, DOI 10.1523/JNEUROSCI.4373-15.2016.
   Bjerkreim AT, 2019, J NEUROL SCI, V403, P31, DOI 10.1016/j.jns.2019.06.007.
   Cai CC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4248529.
   Carling D, 2017, CURR OPIN CELL BIOL, V45, P31, DOI 10.1016/j.ceb.2017.01.005.
   Dagon Y, 2005, J BIOL CHEM, V280, P42142, DOI 10.1074/jbc.M507607200.
   Day EA, 2017, TRENDS ENDOCRIN MET, V28, P545, DOI 10.1016/j.tem.2017.05.004.
   Duan JL, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1406-7.
   Gallo A, 2019, J THROMB THROMBOLYS, V48, P336, DOI 10.1007/s11239-019-01893-y.
   Ge XL, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0160-2.
   GOLLMANNTEPEKOY.C, 2019, CARDIOVASC RES.
   Gupta AP, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.108959.
   Jiang XM, 2018, BIOMED PHARMACOTHER, V105, P1147, DOI 10.1016/j.biopha.2018.06.097.
   Khoshnam SE, 2017, NEUROL SCI, V38, P1167, DOI 10.1007/s10072-017-2938-1.
   Lee S, 2016, SCI REP-UK, V6, DOI 10.1038/srep30005.
   Li XW, 2019, J CELL MOL MED, V23, P2920, DOI 10.1111/jcmm.14200.
   Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009.
   Liu R, 2019, J IMMUNOL, V202, P1704, DOI 10.4049/jimmunol.1801166.
   Lu QG, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181995.
   Nave Alexander Heinrich, 2019, Clin Res Cardiol Suppl, V14, P28, DOI {[}10.1007/s11789-019-00101-8, 10.1007/s11789-019-00101-8].
   Navis A, 2019, J STROKE CEREBROVASC, V28, P84, DOI 10.1016/j.jstrokecerebrovasdis.2018.09.013.
   Shakib N, 2019, EXCLI J, V18, P229, DOI 10.17179/excli2018-1947.
   Sun LL, 2019, NAT MED, V25, P569, DOI 10.1038/s41591-019-0366-x.
   Sun P, 2019, BIOSCIENCE REP, V39, DOI {[}10.1042/BSR20180902, 10.1042/bsr20180902].
   Urabe T, 2009, STROKE, V40, P1289, DOI 10.1161/STROKEAHA.108.522557.
   Varbo A, 2019, ANN NEUROL, V85, P550, DOI 10.1002/ana.25432.
   Veno SK, 2019, STROKE, V50, P274, DOI 10.1161/STROKEAHA.118.023384.
   Zhang B, 2019, ONCOL LETT, V17, P414, DOI 10.3892/ol.2018.9592.},
Number-of-Cited-References = {28},
Times-Cited = {28},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {26},
Journal-ISO = {Drug Des. Dev. Ther.},
Doc-Delivery-Number = {LR8RC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000535963000001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000502829200022,
Author = {Deng, Xinyue and Wang, Quan and Cheng, Meiyu and Chen, Yingying and Yan,
   Xiaoyu and Guo, Rui and Sun, Liankun and Li, Yang and Liu, Yanan},
Title = {Pyruvate dehydrogenase kinase 1 interferes with glucose metabolism
   reprogramming and mitochondrial quality control to aggravate stress
   damage in cancer},
Journal = {JOURNAL OF CANCER},
Year = {2020},
Volume = {11},
Number = {4},
Pages = {962-973},
Abstract = {Pyruvate dehydrogenase kinase 1 (PDK1) is a key factor in the connection
   between glycolysis and the tricarboxylic acid cycle. Restoring the
   mitochondrial OXPHOS function by inhibiting glycolysis through targeting
   PDK1 has become a hot spot for tumor therapy. However, the specific
   mechanism by which metabolic changes affect mitochondrial function
   remains unclear. Recent studies have found that mitochondrial quality
   control such as mitochondrial protein homeostasis plays an important
   role in maintaining mitochondrial function. Here, we focused on PDK1 and
   explored the specific mechanism by which metabolic changes affect
   mitochondrial OXPHOS function. We showed that glucose metabolism in
   HepG2 and HepG3B cells switched from anaerobic glycolysis to the
   mitochondrial tricarboxylic acid cycle under different concentrations of
   dichloroacetate (DCA) or short hairpin PDK1. After DCA treatment or
   knockdown of PDK1, the mitochondrial morphology was gradually condensed
   and exhibited shorter and more fragmented filaments. Additionally,
   expression of the mitochondrial autophagy proteins parkin and
   PTEN-induced kinase was down-regulated, and the biosynthetic protein
   peroxisome proliferator-activated receptor gamma coactivator 1 alpha
   (PGC1 alpha) and its regulated complex I, Ill, IV, and V protein were
   down-regulated. This indicated that PDK1 inhibition affected the level
   of mitochondrial quality control. Analysis of mitochondrial function
   revealed significantly increased mitochondrial reactive oxygen species
   and decreased membrane potential. Therefore, glucose metabolism
   reprogramming by PDK1 inhibition could induce mitochondrial quality
   control disorders to aggravate mitochondrial stress damage.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Li, Y; Liu, YN (Corresponding Author), Jilin Univ, Coll Basic Med Sci, Dept Pathophysiol, 126 Xinmin St, Changchun 130021, Jilin, Peoples R China.
   Deng, Xinyue; Cheng, Meiyu; Chen, Yingying; Yan, Xiaoyu; Guo, Rui; Sun, Liankun; Li, Yang; Liu, Yanan, Jilin Univ, Coll Basic Med Sci, Dept Pathophysiol, 126 Xinmin St, Changchun 130021, Jilin, Peoples R China.
   Wang, Quan, Jilin Univ, China Japan Union Hosp, Dept Radiat Oncol, Changchun, Jilin, Peoples R China.},
DOI = {10.7150/jca.34330},
ISSN = {1837-9664},
Keywords = {DCA; glucose metabolic reprogramming; mitochondiral quality control;
   oxidative phosphorylation; PDK1},
Keywords-Plus = {FUSION; MECHANISMS; MITOPHAGY; APOPTOSIS; FISSION; ROLES},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {lyang@jlu.edu.cn
   ynliu@jlu.edu.cn},
Affiliations = {Jilin University; Jilin University},
ResearcherID-Numbers = {yan, xiaoyu/KQV-2239-2024},
ORCID-Numbers = {Li, Yang/0000-0003-4399-1505
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81772794, 81672948,
   81472419, 81501982]; Jilin Provincial Research Foundation for the
   Development of Science and Technology Projects {[}20170623021TC,
   20160414005GH]; Jilin Provincial Industrial Innovation Project
   {[}2018C052-7]},
Funding-Text = {This study was supported by National Natural Science Foundation of China
   (81772794, 81672948, 81472419, 81501982), Jilin Provincial Research
   Foundation for the Development of Science and Technology Projects
   (20170623021TC, 20160414005GH) and Jilin Provincial Industrial
   Innovation Project (2018C052-7).},
Cited-References = {Andreux PA, 2013, NAT REV DRUG DISCOV, V12, P465, DOI 10.1038/nrd4023.
   {[}Anonymous], 2016, VIRCHOWS ARCH INT J, V2013, P1.
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81.
   Baker MJ, 2014, BRIT J PHARMACOL, V171, P1870, DOI 10.1111/bph.12430.
   Baker MJ, 2011, COLD SPRING HARBOR P, V3, P1656.
   Chang JS, 2017, J BIOL CHEM, V292, P9958, DOI 10.1074/jbc.M117.778373.
   Chaudhary AK, 2016, BRIT J CANCER, V114, P1090, DOI 10.1038/bjc.2016.88.
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200.
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026.
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326.
   Deblois G, 2013, ONCOGENE, V32, P3483, DOI 10.1038/onc.2012.529.
   Dey R, 2000, J BIOL CHEM, V275, P7087, DOI 10.1074/jbc.275.10.7087.
   Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200.
   Griparic L, 2001, TRAFFIC, V2, P235, DOI 10.1034/j.1600-0854.2001.1r008.x.
   Haynes CM, 2010, J CELL SCI, V123, P3849, DOI 10.1242/jcs.075119.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Held NM, 2015, BIOESSAYS, V37, P867, DOI 10.1002/bies.201500013.
   Khalil AA, 2011, BBA-REV CANCER, V1816, P89, DOI 10.1016/j.bbcan.2011.05.001.
   Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s.
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005.
   Krumschnabel G, 2014, METHOD ENZYMOL, V542, P163, DOI 10.1016/B978-0-12-416618-9.00009-1.
   Leone TC, 2005, PLOS BIOL, V3, P672, DOI 10.1371/journal.pbio.0030101.
   Lin G, 2014, BRIT J CANCER, V111, P375, DOI 10.1038/bjc.2014.281.
   Liu T., 2016, ONCOL REP, V37, P193.
   Livnat-Levanon N, 2011, BBA-GENE REGUL MECH, V1809, P80, DOI 10.1016/j.bbagrm.2010.07.005.
   Ngo H, 2015, MOL BIOL REP, V42, P1.
   Pajuelo-Reguera D, 2015, INT J ONCOL, V46, P2409, DOI 10.3892/ijo.2015.2953.
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148.
   Pickrell AM, 2015, NEURON, V87, P371, DOI 10.1016/j.neuron.2015.06.034.
   Sanderson TH, 2013, MOL NEUROBIOL, V47, P9, DOI 10.1007/s12035-012-8344-z.
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019.
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025.
   Shen H, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0130-0.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Sugiura A, 2014, EMBO J, V33, P2142, DOI 10.15252/embj.201488104.
   Sun RC, 2010, BREAST CANC RES, V120.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013.
   Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972.
   Vella S, 2012, INT J CANCER, V130, P1484, DOI 10.1002/ijc.26173.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X.
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697.
   Zhang Y, 2016, BIOCHEM SOC T, V44, P1717, DOI 10.1042/BST20160071C.
   Zhou X, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0331-3.
   Zhu DX, 2016, SCI REP-UK, V6, DOI 10.1038/srep37478.},
Number-of-Cited-References = {46},
Times-Cited = {22},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {27},
Journal-ISO = {J. Cancer},
Doc-Delivery-Number = {JW1OS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000502829200022},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000605594400008,
Author = {Fan, Chang and Cu, Xiaoya and Chen, Sen and Huang, Shaopeng and Jiang,
   Hui},
Title = {LncRNA L0C100912373 modulates PDKI expression by sponging miR-17-5p to
   promote the proliferation of fibroblast-like synoviocytes in rheumatoid
   arthritis},
Journal = {AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH},
Year = {2020},
Volume = {12},
Number = {12},
Pages = {7709-7723},
Abstract = {Rheumatoid arthritis (RA) is a common autoimmune disease and
   characterized by chronic inflammation, abnormal synovial cell
   proliferation, and joint swelling and tenderness, and it causes patients
   substantial pain. To date, the pathogenesis of RA remains unclear, and
   specific treatment is still lacking in the clinic. Evidence from
   previous research indicated that the long noncoding RNA (lncRNA)
   LOC100912373 is a key lncRNA and involved in RA. However, our
   understanding of the specific mechanism of lncRNA LOC100912373 in RA
   development and progression is still in its infancy. In this study,
   fibroblast-like synoviocytes (FLSs) were cultured by enzyme-dispersed
   and substrate-attached explant methods. The MTT method, flow cytometry
   and transmission electron microscopy were used to determine the effect
   of lncRNA LOC100912373 on FLSs. The expression of key genes such as
   lncRNA LOC100912373, miR-17-5p, PDK1 and AKT in FLSs was detected by
   RT-qPCR, immunofluorescence and Western blot. The localization of lncRNA
   LOC100912373 was determined by fluorescence in situ hybridization. The
   specific targeting relationship between lncRNA LOC100912373 and
   miR-17-5p/PDK1 was verified by RNA immunoprecipitation and luciferase
   reporter gene analysis. The results showed that lncRNA LOC100912373
   localized in the cytoplasm and was highly expressed in the synovial
   tissues and FLSs of AA rats. LncRNA LOC100912373 overexpression promoted
   the proliferation of FLSs. In addition, lncRNA LOC100912373 could bind
   to miR-17-5p, and the expression of IncRNA LOC100912373 was negatively
   correlated with miR 17 5p and positively correlated with PDK1/AKT. In
   conclusion, lncRNA LOC100912373 may upregulate the expression of PDK1 by
   sponging miR-17-5p, accelerating the phosphorylation of AKT and inducing
   the proliferation of FLSs, thus promoting the occurrence and development
   of RA.},
Publisher = {E-CENTURY PUBLISHING CORP},
Address = {40 WHITE OAKS LN, MADISON, WI 53711 USA},
Type = {Article},
Language = {English},
Affiliation = {Jiang, H (Corresponding Author), Anhui Univ Chinese Med, Affiliated Hosp 1, Expt Ctr Clin Res, 117 Meishan Rd, Hefei, Anhui, Peoples R China.
   Fan, Chang; Cu, Xiaoya; Chen, Sen; Huang, Shaopeng; Jiang, Hui, Anhui Univ Chinese Med, Affiliated Hosp 1, Expt Ctr Clin Res, 117 Meishan Rd, Hefei, Anhui, Peoples R China.
   Fan, Chang; Cu, Xiaoya; Chen, Sen; Huang, Shaopeng; Jiang, Hui, Anhui Univ Chinese Med, Sch Pharm, Hefei, Anhui, Peoples R China.
   Jiang, Hui, Anhui Prov Lab Appl Basis \& Dev Internal Med Mode, Hefei, Anhui, Peoples R China.},
ISSN = {1943-8141},
Keywords = {Rheumatoid arthritis; fibroblast-like synoviocytes; lncRNA
   LOC100912373/miR-17-5p/PDK1 axis; ceRNA theory},
Keywords-Plus = {ADJUVANT-INDUCED ARTHRITIS; LONG NONCODING RNA; TNF-ALPHA;
   CELL-PROLIFERATION; APOPTOSIS; DIFFERENTIATION; AUTOPHAGY; TREG; TH17},
Research-Areas = {Oncology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Oncology; Medicine, Research \& Experimental},
Author-Email = {13866777701@163.com},
Affiliations = {Anhui University of Chinese Medicine; Anhui University of Chinese
   Medicine},
ResearcherID-Numbers = {fan, chang/JKH-8311-2023},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81873139]; 12th Batch of
   ``115{''} Innovation Team of Anhui Province (Anhui Talent Office
   {[}2019]) {[}1]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (grant no. 81873139), and the 12th Batch of ``115{''} Innovation
   Team of Anhui Province (Anhui Talent Office {[}2019] No. 1). We are
   grateful to Mr. Qiang Fan (Ao Ji Bio-tech Co. Ltd. Shanghai, China) for
   providing help with data analysis.},
Cited-References = {Adawi M, 2019, ISR MED ASSOC J, V21, P460.
   Akhtar N, 2016, J IMMUNOL, V197, P2219, DOI 10.4049/jimmunol.1600360.
   Bamodu OA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030746.
   Bi X, 2019, EBIOMEDICINE, V50, P408, DOI 10.1016/j.ebiom.2019.11.024.
   Blum A, 2019, AUTOIMMUN REV, V18, P679, DOI 10.1016/j.autrev.2019.05.005.
   Bystrom J, 2018, CYTOKINE, V101, P4, DOI 10.1016/j.cyto.2016.09.001.
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023.
   Chen J, 2020, BIOMATER SCI-UK, V8, P3430, DOI 10.1039/c9bm01761e.
   Ding CY, 2020, STEM CELLS, V38, P1137, DOI 10.1002/stem.3204.
   Dong LY, 2014, J CELL MOL MED, V18, P2213, DOI 10.1111/jcmm.12353.
   Ferreira CD, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1854-6.
   Han ZL, 2020, LIFE SCI, V250, DOI 10.1016/j.lfs.2020.117546.
   Hossen MJ, 2016, J ETHNOPHARMACOL, V190, P251, DOI 10.1016/j.jep.2016.06.019.
   Jiang H, 2017, MOL BIOSYST, V13, P1182, DOI 10.1039/c7mb00094d.
   Jiang H, 2016, GENE, V593, P131, DOI 10.1016/j.gene.2016.08.012.
   Jiang H, 2016, BIOMED CHROMATOGR, V30, P1397, DOI 10.1002/bmc.3697.
   Li GQ, 2019, J CELL MOL MED, V23, P7116, DOI 10.1111/jcmm.14591.
   Liang JY, 2019, J TRANSL INTERN MED, V7, P3, DOI 10.2478/jtim-2019-0002.
   Liang YJ, 2020, INFLAMMATION, V43, P1044, DOI 10.1007/s10753-020-01189-x.
   Liu F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02847.
   Lu MC, 2016, IMMUNOL RES, V64, P576, DOI 10.1007/s12026-015-8756-8.
   Luo C, 2018, BRATISL MED J, V119, P355, DOI 10.4149/BLL\_2018\_066.
   Ma JD, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1935-6.
   Ma SC, 2018, ONCOL REP, V39, P1441, DOI 10.3892/or.2018.6208.
   Meng N, 2020, ADV SCI, V7, DOI 10.1002/advs.201903233.
   Nadiv O, 2007, MOL IMMUNOL, V44, P3147, DOI 10.1016/j.molimm.2007.02.001.
   Nie JY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00852.
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014.
   Sparks JA, 2019, ANN INTERN MED, V170, pITC1, DOI 10.7326/AITC201901010.
   Sun C, 2017, CELL IMMUNOL, V315, P27, DOI 10.1016/j.cellimm.2016.10.007.
   Wang J, 2020, INT IMMUNOPHARMACOL, V84, DOI 10.1016/j.intimp.2020.106497.
   Wang JX, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-01641-6.
   {[}王兰生 Wang Lansheng], 2020, {[}成都理工大学学报. 自然科学版, Journal of Chengdu University of Technology. Science \& Technonogy Edition], V47, P1.
   Wanigasooriya K, 2020, CANCERS, V12, DOI 10.3390/cancers12051278.
   Wei ST, 2015, MED SCI MONITOR, V21, P4030, DOI 10.12659/MSM.895116.
   Wei XJ, 2017, EUR REV MED PHARMACO, V21, P3886.
   Wei YJ, 2020, MOL BRAIN, V13, DOI 10.1186/s13041-020-00604-6.
   Wu JN, 2020, EPIGENOMICS-UK, V12, P1193, DOI 10.2217/epi-2020-0084.
   Wu Y, 2019, J CELL BIOCHEM, V120, P9768, DOI 10.1002/jcb.28257.
   Xu HS, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00955.
   Yan MY, 2020, J CARDIOVASC PHARM, V76, P77, DOI 10.1097/FJC.0000000000000845.
   Yang FL, 2017, ONCOTARGETS THER, V10, P543, DOI 10.2147/OTT.S127723.
   Yang KY, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/631737.
   Yin JH, 2020, BMC MED GENOMICS, V13, DOI 10.1186/s12920-020-00741-w.
   Yu ML, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20191449.
   Yu ZH, 2018, TISSUE CELL, V53, P15, DOI 10.1016/j.tice.2018.05.011.
   Zhang F, 2020, ANTI-CANCER AGENT ME, V20, P2082, DOI 10.2174/1871520620666200804104243.
   Zhang Y, 2020, CANCER MED-US, V9, P1855, DOI 10.1002/cam4.2860.
   Zhang Y, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1129-4.
   Zhao F, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112136.
   Zhao JJ, 2016, ARTERIOSCL THROM VAS, V36, P2088, DOI 10.1161/ATVBAHA.116.307879.
   Zhu WH, 2017, CLIN IMMUNOL, V175, P56, DOI 10.1016/j.clim.2016.11.017.},
Number-of-Cited-References = {52},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Am. J. Transl. Res.},
Doc-Delivery-Number = {PP0XW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000605594400008},
DA = {2026-02-04},
}

@article{ WOS:000605595700005,
Author = {Gui, Liang and Xu, Qiang and Huang, Juju and Wu, Gaojue and Tang, Hong
   and Hui, Li and Hua, Ping and Zhang, Lili and Zhu, Yingwei},
Title = {CYP2J2 promotes the development of hepatocellular carcinoma by
   increasing the EETs production to improve HIF-1α stability},
Journal = {AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH},
Year = {2020},
Volume = {12},
Number = {12},
Pages = {7923-7937},
Abstract = {Objective: This study aimed to explore the function and mechanism of
   Cytochrome P450 2J2 (CYP2J2) epoxygenase and epoxyeicosatrienoic acids
   (EETs) in the malignant development of hepatocellular carcinoma (HCC).
   Method: The expressional levels of EETs and CYP2J2 in HCC tissues and
   cell lines were quantified by ELISA, western blot and RT-qPCR,
   respectively. The effects of EET and CYP2J2 on HCC development were
   analyzed by CCK-8 assays, flow cytometry analysis, colony formation and
   transwell assays. The effect of CYP2J2-EET metabolism on stability of
   HIF-1 alpha was detected by western blot experiments. HIF-1 alpha
   inhibitor, YC-1, was used to probe the relationship between HIF-1 alpha
   and metastasis of HCC cells. Finally, xenograft experiments were
   established to investigate the function of CYP2J2-EETs metabolism in HCC
   tumorigenesis in vivo. Result: CYP2J2, 11, 12-EET and 14, 15-EET were
   up-regulated in HCC tissues and Huh-7, HepG2 cell lines. Addition of
   exogenous 14, 15-EET accelerated proliferation and metastasis of HCC
   cells. Knockdown of CYP2J2 inhibited growth and metastasis of HCC cells
   and malignant xenograft, which was obviously reversed by addition of 14,
   15-EET. Moreover, in Huh-7 and HepG2 cells, CYP2J2-EET metabolism
   elevated the expression of HIF-1 alpha and its downstream factors
   including VEGFA, PDK1, GLUT1 and DDIT4 through suppressing the
   expression of PHD. Treatment of YC-1 remarkably suppressed the HCC cells
   proliferation and restored the effect of 14, 15-EET on tumor size in
   vivo. Conclusion: The up-regulated levels of CYP2J2 and 14, 15-EET in
   HCC cells improved the stability of HIF-1 alpha thourgh inhibiting PHD
   expression, which further promoted the malignant development of HCC.},
Publisher = {E-CENTURY PUBLISHING CORP},
Address = {40 WHITE OAKS LN, MADISON, WI 53711 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, LL; Zhu, YW (Corresponding Author), Nanjing Med Univ, Affiliated Wuxi 2 Peoples Hosp, Dept Gastroenterol, 68 Zhongshan Rd, Wuxi 214002, Jiangsu, Peoples R China.
   Gui, Liang, Beijing Hosp, Natl Ctr Gerontol, Dept Vasc Surg, Beijing 100730, Peoples R China.
   Gui, Liang, Chinese Acad Med Sci, Inst Geriatr Med, Beijing 100730, Peoples R China.
   Xu, Qiang, Jiangsu Univ, Wujin Hosp, Dept Intervent, Changzhou 213002, Jiangsu, Peoples R China.
   Huang, Juju; Wu, Gaojue; Tang, Hong; Hui, Li; Hua, Ping; Zhang, Lili; Zhu, Yingwei, Nanjing Med Univ, Affiliated Wuxi 2 Peoples Hosp, Dept Gastroenterol, 68 Zhongshan Rd, Wuxi 214002, Jiangsu, Peoples R China.},
ISSN = {1943-8141},
Keywords = {Hepatocellular carcinoma; CYP2J2; 14; 15-EET; HIF-1 alpha; PHD},
Keywords-Plus = {HYPOXIA-INDUCIBLE FACTORS; EPOXYEICOSATRIENOIC ACIDS; CYTOCHROME-P450
   2J2; EPOXYGENASES; INHIBITION; RESISTANCE; PHYSIOLOGY; BIOLOGY},
Research-Areas = {Oncology; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Oncology; Medicine, Research \& Experimental},
Author-Email = {Lilizhang\_asd@163.com
   ywzhu\_research@163.com},
Affiliations = {Beijing Hospital; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Jiangsu University; Nanjing Medical University},
ResearcherID-Numbers = {ZHANG, Lili/HTO-3220-2023},
Funding-Acknowledgement = {Gastroenterology of key disciplines from Wuxi {[}DXK002]; Academician
   Workstation of No. 2 People's Hospital of Wuxi City {[}CYR1705]; Wuxi
   Medical Key Talent Project {[}ZDRC029]; Wuxi Sci-Tech Development Fund
   {[}CSE31N1603]; Technical achievements and appropriate technology
   promotion project of Wuxi Municipal Commission of Health and Family
   Planning {[}T201603]; Wuxi municipal commission of health and family
   planning project {[}MS201814, MS201720]; Wujin district Changzhou
   Sci-Tech Development Fund {[}WS201811]; Jiangsu commission of health
   project {[}LGY2018021]; Jiangsu University clinical medical science and
   technology development fund {[}JLY20180090]},
Funding-Text = {This study was supported by grants from Gastroenterology of key
   disciplines from Wuxi (DXK002); Academician Workstation of No. 2
   People's Hospital of Wuxi City (CYR1705); Wuxi Medical Key Talent
   Project (ZDRC029); Wuxi Sci-Tech Development Fund (CSE31N1603);
   Technical achievements and appropriate technology promotion project of
   Wuxi Municipal Commission of Health and Family Planning (T201603); Wuxi
   municipal commission of health and family planning project (MS201720);
   Wuxi municipal commission of health and family planning project
   (MS201814); Wujin district Changzhou Sci-Tech Development Fund
   (WS201811); Jiangsu commission of health project (LGY2018021); Jiangsu
   University clinical medical science and technology development fund
   (JLY20180090).},
Cited-References = {Caicedo LA, 2018, TRANSPL P, V50, P485, DOI 10.1016/j.transproceed.2017.11.040.
   Chen C, 2011, J PHARMACOL EXP THER, V336, P344, DOI 10.1124/jpet.110.174805.
   Critelli RM, 2015, DIGEST DIS, V33, P635, DOI 10.1159/000438472.
   Fleming I, 2008, TRENDS CARDIOVAS MED, V18, P20, DOI 10.1016/j.tcm.2007.11.002.
   Fleming I, 2007, PROSTAG OTH LIPID M, V82, P60, DOI 10.1016/j.prostaglandins.2006.05.003.
   He ZW, 2015, CARDIOVASC RES, V105, P304, DOI 10.1093/cvr/cvv018.
   Huang XY, 2017, BIOCHEM BIOPH RES CO, V490, P123, DOI 10.1016/j.bbrc.2017.06.007.
   Hwang GH, 2017, ONCOL LETT, V14, P5484, DOI 10.3892/ol.2017.6846.
   Jeon YJ, 2015, EUR J PHARMACOL, V764, P480, DOI 10.1016/j.ejphar.2015.07.047.
   Jiang JG, 2005, CANCER RES, V65, P4707, DOI 10.1158/0008-5472.CAN-04-4173.
   Li XY, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110338.
   Li YL, 2012, UROL INT, V88, P95, DOI 10.1159/000331881.
   Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224.
   Luo DJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/409272.
   Luo J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0694-6.
   Lv X, 2017, GENES DIS, V4, P19, DOI 10.1016/j.gendis.2016.11.003.
   Ng VY, 2007, DRUG METAB DISPOS, V35, P1126, DOI 10.1124/dmd.106.013839.
   Nieszporek A, 2019, ACTA BIOCHIM POL, V66, P509, DOI 10.18388/abp.2019\_2899.
   Park SK, 2018, J BIOL CHEM, V293, P10675, DOI 10.1074/jbc.RA117.001297.
   Pozzi A, 2005, J BIOL CHEM, V280, P27138, DOI 10.1074/jbc.M501730200.
   Prabhakar NR, 2012, PHYSIOL REV, V92, P967, DOI 10.1152/physrev.00030.2011.
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021.
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590.
   Spector AA, 2007, AM J PHYSIOL-CELL PH, V292, pC996, DOI 10.1152/ajpcell.00402.2006.
   Spector AA, 2009, J LIPID RES, V50, pS52, DOI 10.1194/jlr.R800038-JLR200.
   Wang XK, 2018, CANCER MED-US, V7, P966, DOI 10.1002/cam4.1299.
   Wray JA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007421.
   Xu XZ, 2016, ADV NUTR, V7, P1122, DOI 10.3945/an.116.012245.
   Xu XZ, 2011, ADV DRUG DELIVER REV, V63, P597, DOI 10.1016/j.addr.2011.03.006.},
Number-of-Cited-References = {29},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Am. J. Transl. Res.},
Doc-Delivery-Number = {PP0YJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000605595700005},
DA = {2026-02-04},
}

@article{ WOS:000515101400030,
Author = {Han, Xiaoning and Wei, Yongjie and Wu, Xiaojing and Gao, Jun and Yang,
   Zhongzhou and Zhao, Chunjie},
Title = {PDK1 Regulates Transition Period of Apical Progenitors to Basal
   Progenitors by Controlling Asymmetric Cell Division},
Journal = {CEREBRAL CORTEX},
Year = {2020},
Volume = {30},
Number = {1},
Pages = {406-420},
Month = {JAN},
Abstract = {The six-layered neocortex consists of diverse neuron subtypes.
   Deeper-layer neurons originate from apical progenitors (APs), while
   upper-layer neurons are mainly produced by basal progenitors (BPs),
   which are derivatives of APs. As development proceeds, an AP generates
   two daughter cells that comprise an AP and a deeper-layer neuron or a
   BP. How the transition of APs to BPs is spatiotemporally regulated is a
   fundamental question. Here, we report that conditional deletion of
   phoshpoinositide-dependent protein kinase 1 (PDK1) in mouse developing
   cortex achieved by crossing Emx1Cre line with Pdk1(fl/fl) leads to a
   delayed transition of APs to BPs and subsequently causes an increased
   output of deeper-layer neurons. We demonstrate that PDK1 is involved in
   the modulation of the aPKC-Par3 complex and further regulates the
   asymmetric cell division (ACD). We also find Hes1, a downstream effecter
   of Notch signal pathway is obviously upregulated. Knockdown of Hes1 or
   treatment with Notch signal inhibitor DAPT recovers the ACD defect in
   the Pdk1 cKO. Thus, we have identified a novel function of PDK1 in
   controlling the transition of APs to BPs.},
Publisher = {OXFORD UNIV PRESS INC},
Address = {JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhao, CJ (Corresponding Author), Southeast Univ, Sch Med, Key Lab Dev Genes \& Human Dis, Nanjing 210009, Peoples R China.
   Han, Xiaoning; Wei, Yongjie; Wu, Xiaojing; Zhao, Chunjie, Southeast Univ, Sch Med, Key Lab Dev Genes \& Human Dis, Minist Educ, Nanjing 210009, Peoples R China.
   Gao, Jun, Nanjing Med Univ, Dept Neurobiol, Nanjing 211166, Peoples R China.
   Gao, Jun, Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu, Nanjing 211166, Peoples R China.
   Yang, Zhongzhou, Nanjing Univ, Nanjing Biomed Res Inst, State Key Lab Pharmaceut Biotechnol, Nanjing 210061, Peoples R China.
   Yang, Zhongzhou, Nanjing Univ, Nanjing Biomed Res Inst, Model Anim Res Ctr, Minist Educ,Key Lab Model Anim Dis Study, Nanjing 210061, Peoples R China.},
DOI = {10.1093/cercor/bhz146},
ISSN = {1047-3211},
EISSN = {1460-2199},
Keywords = {apical progenitor; asymmetric cell division; basal progenitors; Notch
   signal; PDK1},
Keywords-Plus = {RADIAL GLIAL-CELLS; SPINDLE ORIENTATION; NEURONAL MIGRATION;
   CEREBRAL-CORTEX; POSTMITOTIC NEURONS; GABAERGIC NEURONS; NERVOUS-SYSTEM;
   NEURAL STEM; PAR-COMPLEX; NOTCH},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {zhaocj@seu.edu.cn},
Affiliations = {Southeast University - China; Nanjing Medical University; Nanjing
   Medical University; Nanjing University; Nanjing University},
ResearcherID-Numbers = {Yang, Zhongzhou/H-3015-2014
   },
ORCID-Numbers = {Han, Xiaoning/0000-0003-0291-7966},
Funding-Acknowledgement = {National Key R\&D Program of China {[}2016YFA0501001]; National Natural
   Science Foundation of China {[}81870899, 31500844]},
Funding-Text = {National Key R\&D Program of China (grant 2016YFA0501001), National
   Natural Science Foundation of China to (grants 81870899 C.Z. and
   31500844 X.W.).},
Cited-References = {Anthony TE, 2004, NEURON, V41, P881, DOI 10.1016/S0896-6273(04)00140-0.
   Arai Y, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00384.
   Arai Y, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1155.
   Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810.
   Bultje RS, 2009, NEURON, V63, P189, DOI 10.1016/j.neuron.2009.07.004.
   Bystron I, 2008, NAT REV NEUROSCI, V9, P110, DOI 10.1038/nrn2252.
   Cappello S, 2006, NAT NEUROSCI, V9, P1099, DOI 10.1038/nn1744.
   Carnero A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00252.
   CAVINESS VS, 1978, ANNU REV NEUROSCI, V1, P297, DOI 10.1146/annurev.ne.01.030178.001501.
   Chang KC, 2010, DEV CELL, V19, P778, DOI 10.1016/j.devcel.2010.10.007.
   Chen J, 2013, EXP CELL RES, V319, P1357, DOI 10.1016/j.yexcr.2013.03.021.
   CHENN A, 1995, CELL, V82, P631, DOI 10.1016/0092-8674(95)90035-7.
   Chou FS, 2018, CELL MOL LIFE SCI, V75, P1027, DOI 10.1007/s00018-017-2680-0.
   Costa MR, 2008, DEVELOPMENT, V135, P11, DOI 10.1242/dev.009951.
   Dainichi T, 2016, CELL REP, V15, P1615, DOI 10.1016/j.celrep.2016.04.051.
   Daudet N, 2007, DEVELOPMENT, V134, P2369, DOI 10.1242/dev.001842.
   DeAzevedo LC, 2003, J NEUROBIOL, V55, P288, DOI 10.1002/neu.10205.
   Englund C, 2005, J NEUROSCI, V25, P247, DOI 10.1523/JNEUROSCI.2899-04.2005.
   Fang WQ, 2014, CELL REP, V9, P1635, DOI 10.1016/j.celrep.2014.11.003.
   Franco SJ, 2013, NEURON, V77, P19, DOI 10.1016/j.neuron.2012.12.022.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Goldstein B, 2007, DEV CELL, V13, P609, DOI 10.1016/j.devcel.2007.10.007.
   Gorski JA, 2002, J NEUROSCI, V22, P6309.
   Götz M, 2005, NEURON, V46, P369, DOI 10.1016/j.neuron.2005.04.012.
   Guilgur LG, 2012, DEVELOPMENT, V139, P503, DOI 10.1242/dev.071027.
   Guillemot F, 2007, DEVELOPMENT, V134, P3771, DOI 10.1242/dev.006379.
   Haenfler JM, 2012, DEV BIOL, V365, P219, DOI 10.1016/j.ydbio.2012.02.027.
   Hapak SM, 2018, CELL MOL LIFE SCI, V75, P2735, DOI 10.1007/s00018-018-2828-6.
   Hatakeyama J, 2014, DEVELOPMENT, V141, P1671, DOI 10.1242/dev.102988.
   Haubensak W, 2004, P NATL ACAD SCI USA, V101, P3196, DOI 10.1073/pnas.0308600100.
   HenkeFahle S, 1996, J NEUROSCI, V16, P4195.
   Hohmann CF, 1998, INT J DEV NEUROSCI, V16, P645, DOI 10.1016/S0736-5748(98)00075-6.
   Horikoshi Y, 2009, J CELL SCI, V122, P1595, DOI 10.1242/jcs.043174.
   Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639.
   Inaba M, 2015, ELIFE, V4, DOI 10.7554/eLife.04960.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Itoh Y, 2013, CURR OPIN NEUROBIOL, V23, P957, DOI 10.1016/j.conb.2013.08.003.
   Kechad A, 2012, J NEUROSCI, V32, P17197, DOI 10.1523/JNEUROSCI.4127-12.2012.
   Kwan KY, 2012, DEVELOPMENT, V139, P1535, DOI 10.1242/dev.069963.
   Laguesse S, 2015, CELL TISSUE RES, V359, P17, DOI 10.1007/s00441-014-1979-5.
   Lancaster MA, 2012, CURR OPIN NEUROBIOL, V22, P737, DOI 10.1016/j.conb.2012.04.003.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299.
   Li R, 2013, DEV CELL, V25, P439, DOI 10.1016/j.devcel.2013.05.003.
   Liu B, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-018-0350-2.
   Liu F, 2017, NEUROSCI BULL, V33, P1, DOI 10.1007/s12264-016-0086-x.
   Liu JH, 2014, MOL BRAIN, V7, DOI 10.1186/s13041-014-0084-8.
   Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926.
   Liu Y, 2007, DEVELOPMENT, V134, P1111, DOI 10.1242/dev.02806.
   Lui JH, 2011, CELL, V146, P18, DOI 10.1016/j.cell.2011.06.030.
   Marín O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058.
   Meng XQ, 2004, J REPROD DEVELOP, V50, P97, DOI 10.1262/jrd.50.97.
   Miyata T, 2004, DEVELOPMENT, V131, P3133, DOI 10.1242/dev.01173.
   Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Morais-de-Sá E, 2010, CELL, V141, P509, DOI 10.1016/j.cell.2010.02.040.
   Nagai-Tamai Y, 2002, GENES CELLS, V7, P1161, DOI 10.1046/j.1365-2443.2002.00590.x.
   Namba T, 2017, WIRES DEV BIOL, V6, DOI 10.1002/wdev.256.
   Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553.
   Noctor SC, 2004, NAT NEUROSCI, V7, P136, DOI 10.1038/nn1172.
   Noctor SC, 2008, J COMP NEUROL, V508, P28, DOI 10.1002/cne.21669.
   Oishi K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI 10.1073/pnas.0808400106.
   ORourke NA, 1997, DEVELOPMENT, V124, P997.
   Peyre E, 2012, DEV GROWTH DIFFER, V54, P287, DOI 10.1111/j.1440-169X.2012.01350.x.
   Pierfelice T, 2011, NEURON, V69, P840, DOI 10.1016/j.neuron.2011.02.031.
   Pinkin NK, 2015, ORG BIOMOL CHEM, V13, P10939, DOI 10.1039/c5ob01649e.
   Pontious A, 2008, DEV NEUROSCI-BASEL, V30, P24, DOI 10.1159/000109848.
   Postiglione MP, 2011, NEURON, V72, P269, DOI 10.1016/j.neuron.2011.09.022.
   RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116.
   Rakic P, 2003, CEREB CORTEX, V13, P541, DOI 10.1093/cercor/13.6.541.
   RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105.
   RAKIC P, 1995, TRENDS NEUROSCI, V18, P383, DOI 10.1016/0166-2236(95)93934-P.
   Shen Q, 2002, DEVELOPMENT, V129, P4843.
   Shen Q, 2006, NAT NEUROSCI, V9, P743, DOI 10.1038/nn1694.
   Shen W, 2019, CEREB CORTEX, V29, P1547, DOI 10.1093/cercor/bhy051.
   Shitamukai A, 2011, J NEUROSCI, V31, P3683, DOI 10.1523/JNEUROSCI.4773-10.2011.
   SIDMAN RL, 1973, BRAIN RES, V62, P1, DOI 10.1016/0006-8993(73)90617-3.
   TAKAHASHI T, 1995, J NEUROSCI, V15, P6058.
   Tan SS, 1998, NEURON, V21, P295, DOI 10.1016/S0896-6273(00)80539-5.
   Taverna E, 2014, ANNU REV CELL DEV BI, V30, P465, DOI 10.1146/annurev-cellbio-101011-155801.
   Tian CX, 2012, J NEUROSCI, V32, P2931, DOI 10.1523/JNEUROSCI.5240-11.2012.
   Toma K, 2014, J NEUROSCI, V34, P13259, DOI 10.1523/JNEUROSCI.2334-14.2014.
   Uzquiano A, 2018, J NEUROCHEM, V146, P500, DOI 10.1111/jnc.14338.
   Vitali I, 2018, CELL, V174, P1264, DOI 10.1016/j.cell.2018.06.036.
   Vorhagen S, 2014, EXP CELL RES, V328, P296, DOI 10.1016/j.yexcr.2014.08.008.
   Wang L, 2016, NAT NEUROSCI, V19, P888, DOI 10.1038/nn.4307.
   Watatani K, 2012, GENES CELLS, V17, P326, DOI 10.1111/j.1365-2443.2012.01591.x.
   Wirtz-Peitz F, 2008, CELL, V135, P161, DOI 10.1016/j.cell.2008.07.049.
   Xu CY, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00330.
   Xu M, 2019, CEREB CORTEX, V29, P1185, DOI 10.1093/cercor/bhy024.
   Yang Y, 2017, CEREB CORTEX, V27, P793, DOI 10.1093/cercor/bhv297.
   Yoon K, 2005, NAT NEUROSCI, V8, P709, DOI 10.1038/nn1475.
   Zhang RR, 2018, CELL TISSUE RES, V371, P73, DOI 10.1007/s00441-017-2641-9.
   Zhou Y, 2007, CELL, V129, P163, DOI 10.1016/j.cell.2007.02.037.},
Number-of-Cited-References = {94},
Times-Cited = {8},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Cereb. Cortex},
Doc-Delivery-Number = {KN8NH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000515101400030},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000546805100001,
Author = {He, Yuexi and Du, Juan and Dong, Zhongjun},
Title = {Myeloid deletion of phosphoinositide-dependent kinase-1 enhances NK
   cell-mediated antitumor immunity by mediating macrophage polarization},
Journal = {ONCOIMMUNOLOGY},
Year = {2020},
Volume = {9},
Number = {1},
Abstract = {A large number of heterogeneous macrophages can be observed in solid
   tumor lesions. Classically activated M1 macrophages are a powerful
   killer of cancer cells. In contrast, tumor-associated macrophages (TAMs)
   are often referred to as M2 phenotype and usually impair tumor immunity
   mediated by cytotoxic lymphocytes, natural killer (NK) cells and CD8(+)T
   cells. Therefore, orchestrating M2 to M1 reprogramming will provide a
   promising approach to tumor immunotherapy. Here we used a PyMT-induced
   spontaneous breast cancer model in which M2-polarized macrophages were
   abundant. This M2 phenotype was closely related to tumor progression and
   immune dysfunction of NK cells and CD8(+)T cells. We then found that
   these TAMs showed increased energy expenditure and over-activation of
   two kinases, Akt and mammalian target of rapamycin (mTOR). Myeloid
   inactivation of phosphoinositide-dependent kinase-1 (PDK1), the upstream
   regulator for Akt and mTOR signaling, significantly reduced excessive
   metabolic activation of macrophages. Notably, the loss of PDK1
   significantly led to regression of breast cancer and prevented lung
   metastasis. Mechanistically, PDK1 deficiency mainly inhibited the
   activation of mTOR complex 1 (mTORC1), transforming TAMs into M1
   phenotype, thereby reversing tumor-related dysfunction of T cells and NK
   cells. Therefore, targeting PDK1 may be a new approach for M2
   macrophage-enriched solid tumor immunotherapy.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Dong, ZJ (Corresponding Author), Tsinghua Univ, Inst Immunol, Med Blvd D328, Beijing 100086, Peoples R China.
   He, Yuexi; Dong, Zhongjun, Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   He, Yuexi; Dong, Zhongjun, Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing, Peoples R China.
   Du, Juan, Capital Med Univ, Beijing Key Lab Emerging Infect Dis, Inst Infect Dis, Beijing Ditan Hosp, Beijing, Peoples R China.},
DOI = {10.1080/2162402X.2020.1774281},
Article-Number = {1774281},
ISSN = {2162-402X},
Keywords = {Macrophage; NK cells; PDK1; macrophage polarization; mTOR},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; TUMOR-ASSOCIATED MACROPHAGES;
   SUPPRESSOR-CELLS; ALTERNATIVE ACTIVATION; PDK1; EXPRESSION; CANCER;
   MTOR; METABOLISM; INDUCTION},
Research-Areas = {Oncology; Immunology},
Web-of-Science-Categories  = {Oncology; Immunology},
Author-Email = {dongzj@mail.tsinghua.edu.cn},
Affiliations = {Tsinghua University; Tsinghua University; Capital Medical University},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81725007, 31830027,
   31821003, 91942308]; National Key Research \& Developmental Program of
   China {[}2018YFC1003900]; Beijing Natural Science Foundation {[}5172018,
   7184218]; Beijing Municipal Administration of Hospital Clinical Medicine
   Development of Special Funding Support {[}ZYLX201802]},
Funding-Text = {National Natural Science Foundation of China {[}81725007, 31830027,
   31821003 and 91942308]; National Key Research \& Developmental Program
   of China {[}2018YFC1003900] and Beijing Natural Science Foundation
   {[}5172018, 7184218]; Beijing Municipal Administration of Hospital
   Clinical Medicine Development of Special Funding Support {[}ZYLX201802].},
Cited-References = {Alter G, 2004, J IMMUNOL METHODS, V294, P15, DOI 10.1016/j.jim.2004.08.008.
   Arnold JN, 2014, CANCER IMMUNOL RES, V2, P121, DOI 10.1158/2326-6066.CIR-13-0150.
   Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013.
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937.
   Burga RA, 2015, CANCER IMMUNOL IMMUN, V64, P817, DOI 10.1007/s00262-015-1692-6.
   Cantor JM, 2012, J CELL SCI, V125, P1373, DOI 10.1242/jcs.096040.
   Carretero R, 2015, NAT IMMUNOL, V16, P609, DOI 10.1038/ni.3159.
   Chan G, 2008, J IMMUNOL, V181, P698, DOI 10.4049/jimmunol.181.1.698.
   Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523.
   Chen SS, 2016, IMMUNITY, V45, P292, DOI 10.1016/j.immuni.2016.07.013.
   Cibrian D, 2016, NAT IMMUNOL, V17, P985, DOI 10.1038/ni.3504.
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007.
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5.
   Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010.
   De Henau O, 2016, NATURE, V539, P443, DOI 10.1038/nature20554.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Düvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022.
   Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010.
   Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733.
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978.
   Guerra AD, 2017, THERANOSTICS, V7, P3732, DOI 10.7150/thno.20251.
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954.
   Habashy HO, 2010, BREAST CANCER RES TR, V119, P283, DOI 10.1007/s10549-009-0345-x.
   Hallowell RW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14208.
   Han QL, 2016, INT IMMUNOPHARMACOL, V34, P101, DOI 10.1016/j.intimp.2016.01.023.
   He JM, 2019, CELL DEATH DIFFER, V26, P1918, DOI 10.1038/s41418-018-0263-8.
   Huang SCC, 2014, NAT IMMUNOL, V15, P846, DOI 10.1038/ni.2956.
   Ip H, 2016, INT J BIOCHEM CELL B, V81, P148, DOI 10.1016/j.biocel.2016.11.005.
   Ivanova A, 2005, GENESIS, V43, P129, DOI 10.1002/gene.20162.
   Kang JA, 2017, MOL CELLS, V40, P37, DOI 10.14348/molcells.2017.2236.
   Kawano Y, 2012, DIABETES, V61, P1935, DOI 10.2337/db11-0770.
   Kim J, 2019, NAT CELL BIOL, V21, P63, DOI 10.1038/s41556-018-0205-1.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kohanbash G, 2013, CANCER RES, V73, P6413, DOI 10.1158/0008-5472.CAN-12-4124.
   Laoui D, 2014, CANCER RES, V74, P24, DOI 10.1158/0008-5472.CAN-13-1196.
   Lesokhin AM, 2012, CANCER RES, V72, P876, DOI 10.1158/0008-5472.CAN-11-1792.
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005.
   Liu LL, 2017, BIOMATERIALS, V134, P166, DOI 10.1016/j.biomaterials.2017.04.043.
   Loftus RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04719-2.
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5.
   Mantovani A, 2008, EUR J IMMUNOL, V38, P3269, DOI 10.1002/eji.200838918.
   Marsee DK, 2010, AM J CLIN PATHOL, V134, P429, DOI 10.1309/AJCPCRK3MOAOJ6AT.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Mehla K, 2019, TRENDS CANCER, V5, P822, DOI 10.1016/j.trecan.2019.10.007.
   Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672.
   Nawaz A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00231-1.
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044.
   Niu ZY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00523-6.
   Palmieri EM, 2017, CELL REP, V20, P1654, DOI 10.1016/j.celrep.2017.07.054.
   Palsson-McDermott EM, 2015, CELL METAB, V21, P65, DOI {[}10.1016/j.cmet.2014.12.005, 10.1016/j.cmet.2015.01.017].
   Palumbo JS, 2007, BLOOD, V110, P133, DOI 10.1182/blood-2007-01-065995.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Park SG, 2009, NAT IMMUNOL, V10, P158, DOI 10.1038/ni.1687.
   Petty AJ, 2019, J CLIN INVEST, V129, P5151, DOI 10.1172/JCI128644.
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256.
   Powell JD, 2012, ANNU REV IMMUNOL, V30, P39, DOI 10.1146/annurev-immunol-020711-075024.
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014.
   Rodríguez-Prados JC, 2010, J IMMUNOL, V185, P605, DOI 10.4049/jimmunol.0901698.
   Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006.
   Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Shaul ME, 2010, DIABETES, V59, P1171, DOI 10.2337/db09-1402.
   Shrivastava R, 2019, LIFE SCI, V224, P222, DOI 10.1016/j.lfs.2019.03.062.
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643.
   Sinclair LV, 2013, NAT IMMUNOL, V14, P500, DOI 10.1038/ni.2556.
   Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4.
   Su SC, 2014, CANCER CELL, V25, P605, DOI 10.1016/j.ccr.2014.03.021.
   Tan Z, 2015, J IMMUNOL, V194, P6082, DOI 10.4049/jimmunol.1402469.
   Thapa B, 2019, BMB REP, V52, P360, DOI 10.5483/BMBRep.2019.52.6.140.
   Travers M, 2019, CANCER RES, V79, P3445, DOI 10.1158/0008-5472.CAN-18-4018.
   Ugel S, 2015, J CLIN INVEST, V125, P3365, DOI 10.1172/JCI80006.
   Valeta-Magara A, 2019, CANCER RES, V79, P3360, DOI 10.1158/0008-5472.CAN-17-2158.
   Vats D, 2006, CELL METAB, V4, P255, DOI 10.1016/j.cmet.2006.08.006.
   Verreck FAW, 2004, P NATL ACAD SCI USA, V101, P4560, DOI 10.1073/pnas.0400983101.
   Wanderley CW, 2018, CANCER RES, V78, P5891, DOI 10.1158/0008-5472.CAN-17-3480.
   Wang FJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07277-9.
   Xie ZH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-77.
   Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703.
   Zeng X, 2002, CANCER RES, V62, P3538.
   Zhang XQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13032-5.
   Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421.},
Number-of-Cited-References = {85},
Times-Cited = {20},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {OncoImmunology},
Doc-Delivery-Number = {MH5YU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000546805100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000531553500010,
Author = {Jo, Minkyeong and Yi, Young-Su and Cho, Jae Youl},
Title = {Archidendron lucidum Exerts Anti-Inflammatory Effects by
   Targeting PDK1 in the NF-κB Pathway},
Journal = {AMERICAN JOURNAL OF CHINESE MEDICINE},
Year = {2020},
Volume = {48},
Number = {2},
Pages = {429-444},
Abstract = {Pharmacological activities of some Leguminosae family members were
   reported. Pharmacological activities of Archidendron lucidum, a
   Leguminosae family member have never been explored. Therefore, this
   study investigated anti-inflammatory effects of an Archidendron lucidum
   methanol extract (Al-ME). In this study, anti-inflammatory effects of
   Al-ME were investigated in LPS-stimulated RAW264.7 cells and
   HCl/EtOH-induced gastritis mice by MTT assay, nitric oxide (NO)
   production assay, semi-quantitative reverse transcriptase-polymerase
   chain reaction (RT-PCR), luciferase reporter assay, and Western
   blotting. High-performance liquid chromatography (HPLC) analysis
   identified ethnopharmacological compounds in Al-ME. Al-ME inhibited NO
   production without cytotoxicity in peritoneal macrophages and RAW264.7
   cells stimulated with LPS or Pam3CSK4. Al-ME downregulated mRNA
   expression of inflammatory genes (inducible NO synthase (iNOS) and
   cyclooxygenase-2 (COX-2)) and pro-inflammatory cytokines (tumor necrosis
   factor-alpha (TNF-alpha), interleukin-1 beta (IL-1 beta), and IL-6).
   Al-ME exerted anti-inflammatory activity in LPS-stimulated RAW264.7
   cells by inhibiting nuclear factor-kappa B (NF-kappa B) signaling
   pathway. HPLC analysis identified quercetin, luteolin, and kaempferol as
   major anti-inflammatory components in Al-ME. Al-ME ameliorated
   HCl/EtOH-induced gastritis symptoms in mice by suppressing iNOS and IL-6
   mRNA expressions and I kappa B alpha phosphorylation. Therefore, these
   results suggest that Al-ME exhibited anti-inflammatory activity by
   targeting NF-kappa B signaling pathway, implying that Al-ME could be
   potent anti-inflammatory medications to prevent and treat inflammatory
   diseases.},
Publisher = {WORLD SCIENTIFIC PUBL CO PTE LTD},
Address = {5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE},
Type = {Article},
Language = {English},
Affiliation = {Cho, JY (Corresponding Author), Sungkyunkwan Univ, Dept Integrat Biotechnol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Jo, Minkyeong; Cho, Jae Youl, Sungkyunkwan Univ, Dept Integrat Biotechnol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Yi, Young-Su, Kyonggi Univ, Dept Life Sci, Suwon 16227, South Korea.},
DOI = {10.1142/S0192415X20500226},
ISSN = {0192-415X},
EISSN = {1793-6853},
Keywords = {Al-ME; Anti-Inflammatory Effect; Macrophage; Gastritis; PDK1; NF-kappa B},
Keywords-Plus = {CYTOTOXIC CONSTITUENTS; INHIBITION; PROLIFERATION; PLAYS; COX-2; INOS},
Research-Areas = {Integrative \& Complementary Medicine; General \& Internal Medicine},
Web-of-Science-Categories  = {Integrative \& Complementary Medicine; Medicine, General \& Internal},
Author-Email = {jaecho@skku.edu},
Affiliations = {Sungkyunkwan University (SKKU); Kyonggi University},
ResearcherID-Numbers = {Yi, Young-Su/AAS-4823-2020},
ORCID-Numbers = {Yi, Young-Su/0000-0002-7166-3659},
Funding-Acknowledgement = {Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Republic of Korea
   {[}2017R1A6A1A03015642]},
Funding-Text = {This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Republic of Korea (2017R1A6A1A03015642).},
Cited-References = {Ahn H, 2019, J GINSENG RES, V43, P291, DOI 10.1016/j.jgr.2018.03.003.
   BYEON SE, 2012, MEDIAT INFLAMM, V2012, DOI DOI 10.1155/2012/512926.
   Chae HS, 2009, AM J CHINESE MED, V37, P181, DOI 10.1142/S0192415X0900676X.
   Choi E, 2019, J ETHNOPHARMACOL, V238, DOI 10.1016/j.jep.2019.111848.
   Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024.
   Guevara I, 1998, CLIN CHIM ACTA, V274, P177, DOI 10.1016/S0009-8981(98)00060-6.
   Han SY, 2018, AM J CHINESE MED, V46, P1281, DOI 10.1142/S0192415X18500672.
   Han SY, 2018, J GINSENG RES, V42, P496, DOI 10.1016/j.jgr.2017.06.003.
   Harvey A, 2000, DRUG DISCOV TODAY, V5, P294, DOI 10.1016/S1359-6446(00)01511-7.
   Harvey AL, 1999, TRENDS PHARMACOL SCI, V20, P196, DOI 10.1016/S0165-6147(99)01346-2.
   Herwald H, 2016, J INNATE IMMUN, V8, P427, DOI 10.1159/000448437.
   Hong YH, 2019, PHYTOTHER RES, V33, P676, DOI 10.1002/ptr.6256.
   Janeway CA Jr, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359.
   Kim H.G, 2018, ALTERNAT MED.
   Layoun A, 2015, JOVE-J VIS EXP, DOI 10.3791/52749.
   Lee JO, 2019, J GINSENG RES, V43, P154, DOI 10.1016/j.jgr.2018.10.003.
   Lee JH, 2018, J GINSENG RES, V42, P476, DOI 10.1016/j.jgr.2017.05.005.
   Lee SO, 2019, J GINSENG RES, V43, P218, DOI 10.1016/j.jgr.2017.11.007.
   LI LP, 1993, J NAT PROD, V56, P690, DOI 10.1021/np50095a005.
   Mar W, 2001, ARCH PHARM RES, V24, P211, DOI 10.1007/BF02978259.
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4.
   Mujoo K, 2001, CANCER RES, V61, P5486.
   Murakami A, 2007, INT J CANCER, V121, P2357, DOI 10.1002/ijc.23161.
   Nakamura ES, 2002, CANCER LETT, V177, P119, DOI 10.1016/S0304-3835(01)00708-X.
   Park G, 2017, PHARM BIOL, V55, P2074, DOI 10.1080/13880209.2017.1362011.
   Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27.
   Serafini M, 2010, P NUTR SOC, V69, P273, DOI 10.1017/S002966511000162X.
   Sharma J. N., 2007, Inflammopharmacology, V15, P252, DOI 10.1007/s10787-007-0013-x.
   Song P, 2013, J ASIAN NAT PROD RES, V15, P624, DOI 10.1080/10286020.2013.793181.
   Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022.
   Yang Y, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/352371.
   Yi YS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e41.
   Yi YS, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800147.
   Yi YS, 2018, KOREAN J PHYSIOL PHA, V22, P1, DOI 10.4196/kjpp.2018.22.1.1.
   Yi YS, 2016, IMMUNE NETW, V16, P337, DOI 10.4110/in.2016.16.6.337.
   Yi YS, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/270302.
   Yi YS, 2014, PHARMAZIE, V69, P461, DOI 10.1691/ph.2014.3880.
   Yu T., 2012, MEDIAT INFLAMM, V2012, P1, DOI DOI 10.1155/2012/979105.},
Number-of-Cited-References = {38},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Am. J. Chin. Med.},
Doc-Delivery-Number = {LL4UY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000531553500010},
DA = {2026-02-04},
}

@article{ WOS:000534740200056,
Author = {Katsuyama, Atsuko and Kusuhara, Sentaro and Asahara, Shun-Ichiro and
   Nakai, Shun-Ichiro and Mori, Sotaro and Matsumiya, Wataru and Miki,
   Akiko and Kurimoto, Takuji and Imai, Hisanori and Kido, Yoshiaki and
   Ogawa, Wataru and Nakamura, Makoto},
Title = {En face slab optical coherence tomography imaging successfully monitors
   progressive degenerative changes in the innermost layer of the diabetic
   retina},
Journal = {BMJ OPEN DIABETES RESEARCH \& CARE},
Year = {2020},
Volume = {8},
Number = {1},
Month = {JAN},
Abstract = {ObjectiveTo evaluate the usefulness of en face slab optical coherence
   tomography (OCT) imaging for monitoring diabetic retinal
   neurodegeneration with supporting animal experimental data.Research
   design and methodsWe retrospectively examined 72 diabetic eyes over 3
   years using Cirrus-HD OCT. Two-dimensional en face slab OCT images of
   the innermost retina were reconstructed and graded according to the
   ratio of dark area to total area, and relative red, green, and blue
   color area ratios were calculated and used as indexes for each en face
   slab OCT image. Values from en face OCT images were used for statistical
   analyses. To obtain insight into the pathogenesis of diabetic retinal
   neurodegeneration, we used the InsPr-Cre;Pdk1(flox/flox) diabetic mouse
   model.ResultsBoth OCT grade and relative red color area ratio
   significantly increased with the advancing stage of diabetic retinopathy
   (p=0.018and 0.006, respectively). After a mean follow-up period of 4.6
   years, the trend was unchanged in the analyses of 42 untreated eyes
   (p<0.001and 0.001, respectively). Visual acuity showed a weak but
   significant negative correlation with the red color ratio on en face
   slab OCT images, but central retinal thickness did not exhibit a
   clinically meaningful correlation with values obtained from en face slab
   OCT images. Immunohistochemical analyses of InsPr-Cre;Pdk1(flox/flox)
   diabetic mice demonstrated the loss of ganglion axon bundles and
   thinning of laminin without apparent retinal vascular change at the age
   of 20 weeks.ConclusionsEn face slab OCT imaging would be a novel useful
   modality for the assessment of diabetic retinal neurodegeneration as it
   could detect subtle optical changes occurring in the innermost retina in
   diabetic eyes. Our animal experimental data suggest that dark areas
   observed on en face slab OCT images might be the impairment of the
   extracellular matrix as well as neurons.},
Publisher = {BMJ PUBLISHING GROUP},
Address = {BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Kusuhara, S (Corresponding Author), Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
   Katsuyama, Atsuko; Kusuhara, Sentaro; Nakai, Shun-Ichiro; Mori, Sotaro; Matsumiya, Wataru; Miki, Akiko; Kurimoto, Takuji; Imai, Hisanori; Nakamura, Makoto, Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol, Kobe, Hyogo, Japan.
   Asahara, Shun-Ichiro; Kido, Yoshiaki, Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet \& Endocrinol, Kobe, Hyogo, Japan.
   Kido, Yoshiaki, Kobe Univ, Grad Sch Hlth Sci, Dept Biophys, Div Metab \& Dis, Kobe, Hyogo, Japan.
   Ogawa, Wataru, Kobe Univ, Grad Sch Med, Dept Internal Med, Div Diabet Metab \& Endocrinol, Kobe, Hyogo, Japan.},
DOI = {10.1136/bmjdrc-2019-001120},
Article-Number = {e001120},
EISSN = {2052-4897},
Keywords = {imaging; neurovascular; eye exam; eye disease},
Keywords-Plus = {VISUAL-ACUITY; MOUSE MODEL; RETINOPATHY; CELLS; DISORGANIZATION;
   NEURODEGENERATION; RANIBIZUMAB; APPEARANCE; THICKNESS; INSULIN},
Research-Areas = {Endocrinology \& Metabolism},
Web-of-Science-Categories  = {Endocrinology \& Metabolism},
Author-Email = {kusu@med.kobe-u.ac.jp},
Affiliations = {Kobe University; Kobe University; Kobe University; Kobe University},
ResearcherID-Numbers = {OGAWA, Wataru/AAQ-9586-2020
   Asahara, Shun-ichiro/I-6645-2019
   Mori, Sotaro/AAD-2574-2022},
ORCID-Numbers = {Kusuhara, Sentaro/0000-0002-6458-539X
   Imai, Hisanori/0000-0001-8879-3604
   Mori, Sotaro/0000-0003-1991-3232},
Funding-Acknowledgement = {Novartis Pharma KK, Japan; Japan Society for the Promotion of Science
   {[}15K10865]; Bayer, Japan; Grants-in-Aid for Scientific Research
   {[}15K10865] Funding Source: KAKEN},
Funding-Text = {This work was supported by Novartis Pharma KK, Japan (to SK), Bayer,
   Japan (SK), and the Japan Society for the Promotion of Science (grant
   number (Grants-in-Aid for Scientific Research (C) 15K10865) to SK).},
Cited-References = {Bearse MA, 2006, PROG RETIN EYE RES, V25, P425, DOI 10.1016/j.preteyeres.2006.07.001.
   Chew EY, 2010, NEW ENGL J MED, V363, P233, DOI 10.1056/NEJMoa1001288.
   Chhablani J, 2015, INVEST OPHTH VIS SCI, V56, P6333, DOI 10.1167/iovs.15-17334.
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016.
   Das R, 2018, JAMA OPHTHALMOL, V136, P202, DOI 10.1001/jamaophthalmol.2017.6256.
   Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751.
   Feit-Leichman RA, 2005, INVEST OPHTH VIS SCI, V46, P4281, DOI 10.1167/iovs.04-1361.
   Gastinger MJ, 2008, INVEST OPHTH VIS SCI, V49, P2635, DOI 10.1167/iovs.07-0683.
   Hashimoto N, 2006, NAT GENET, V38, P589, DOI 10.1038/ng1774.
   Herrera PL, 2000, DEVELOPMENT, V127, P2317.
   Hood DC, 2015, INVEST OPHTH VIS SCI, V56, P6208, DOI 10.1167/iovs.15-17259.
   IMURA H, 1993, NEW ENGL J MED, V329, P683, DOI 10.1056/NEJM199309023291002.
   Inoue H, 2006, CELL METAB, V3, P267, DOI 10.1016/j.cmet.2006.02.009.
   Jackson GR, 2012, BRIT J OPHTHALMOL, V96, P699, DOI 10.1136/bjophthalmol-2011-300467.
   Kim K, 2018, AM J OPHTHALMOL, V196, P165, DOI 10.1016/j.ajo.2018.08.053.
   Kim K, 2016, AM J OPHTHALMOL, V170, P15, DOI 10.1016/j.ajo.2016.06.038.
   Kishimoto Hayato, 2011, International Ophthalmology, V31, P385, DOI 10.1007/s10792-011-9474-4.
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506.
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006.
   Kusuhara S, 2018, DIABETES METAB J, V42, P364, DOI 10.4093/dmj.2018.0182.
   Kusuhara S, 2014, OPHTHALMOLOGICA, V232, P170, DOI 10.1159/000364811.
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039.
   Marques IP, 2019, DIABETES, V68, P648, DOI 10.2337/db18-1077.
   Martin PM, 2004, INVEST OPHTH VIS SCI, V45, P3330, DOI 10.1167/iovs.04-0247.
   Matsumiya W, 2012, INVEST OPHTH VIS SCI, V53, P8029, DOI 10.1167/iovs.12-10781.
   Matsumoto Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171880.
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031.
   Miwa Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep29064.
   Ogura S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90905.
   Park HYL, 2011, BRIT J OPHTHALMOL, V95, P1223, DOI 10.1136/bjo.2010.191841.
   Pinilla I, 2020, RETINA-J RET VIT DIS, V40, P1379, DOI 10.1097/IAE.0000000000002576.
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039.
   Sakamoto M, 2019, INVEST OPHTH VIS SCI, V60, P2811, DOI 10.1167/iovs.18-25910.
   Sergeys J, 2019, INVEST OPHTH VIS SCI, V60, P807, DOI 10.1167/iovs.18-25372.
   Shin HJ, 2012, GRAEF ARCH CLIN EXP, V250, P61, DOI 10.1007/s00417-011-1774-x.
   Simó R, 2019, DIABETES, V68, P457, DOI 10.2337/db18-0682.
   Simó R, 2018, DIABETOLOGIA, V61, P1902, DOI 10.1007/s00125-018-4692-1.
   Sohn EH, 2016, P NATL ACAD SCI USA, V113, pE2655, DOI 10.1073/pnas.1522014113.
   Solomon SD, 2017, DIABETES CARE, V40, P412, DOI 10.2337/dc16-2641.
   Sun JK, 2015, DIABETES, V64, P2560, DOI 10.2337/db14-0782.
   Sun JK, 2014, JAMA OPHTHALMOL, V132, P1309, DOI 10.1001/jamaophthalmol.2014.2350.
   Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6.
   Wanek J, 2016, INVEST OPHTH VIS SCI, V57, pOCT341, DOI 10.1167/iovs.15-18715.
   Wong TY, 2018, OPHTHALMOLOGY, V125, P1608, DOI 10.1016/j.ophtha.2018.04.007.
   Yang Y, 2012, MOL VIS, V18, P1411.
   Yao Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4413.},
Number-of-Cited-References = {46},
Times-Cited = {8},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {2},
Journal-ISO = {BMJ Open Diab. Res. Care},
Doc-Delivery-Number = {LQ0ZE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000534740200056},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000577334500011,
Author = {Klungsaeng, Sirinapha and Kukongviriyapan, Veerapol and Prawan, Auemduan
   and Kongpetch, Sarinya and Senggunprai, Laddawan},
Title = {Targeted Modulation of FAK/PI3K/PDK1/AKT and FAK/p53 Pathways by
   Cucurbitacin B for the Antiproliferation Effect Against Human
   Cholangiocarcinoma Cells},
Journal = {AMERICAN JOURNAL OF CHINESE MEDICINE},
Year = {2020},
Volume = {48},
Number = {6},
Pages = {1475-1489},
Abstract = {Inadequate responses to traditional chemotherapeutic agents in
   cholangiocarcinoma (CCA) emphasize a requirement for new effective
   compounds for the treatment of this malignancy. This study aimed to
   investigate the antiproliferative property of cucurbitacin B on KKU-100
   CCA cells. The determination of underlying molecular mechanisms was also
   carried out. The results revealed that cucurbitacin B suppressed growth
   and replicative ability to form colonies of CCA cells, suggesting the
   antiproliferative effect of this compound against the cells. Flow
   cytometry analysis demonstrated that the interfering effect of
   cucurbitacin B on the CCA cell cycle at the G2/M phase was accountable
   for its antiproliferation property. Accompanied with cell cycle
   disruption, cucurbitacin B altered the expression of proteins involved
   in the G2/M phase transition including downregulation of cyclin A,
   cyclin D1, and cdc25A, and upregulation of p21. Additional molecular
   studies demonstrated that cucurbitacin B suppressed the activation of
   focal adhesion kinase (FAK) which consequently resulted in inhibition of
   its kinase-dependent and kinase-independent downstream targets
   contributing to the regulation of cell proliferation including
   PI3K/PDK1/AKT and p53 proteins. In this study, the transient knockdown
   of FAK using siRNA was employed to ascertain the role of FAK in CCA cell
   proliferation. Finally, the effect of cucurbitacin B on upstream
   receptor tyrosine kinases regulating FAK activation was elucidated. The
   results showed that the inhibitory effect of cucurbitacin B on FAK
   activation in CCA cells is mediated via interference of EGFR and HER2
   expression. Collectively, cucurbitacin B might be a promising drug for
   CCA treatment by targeting FAK protein.},
Publisher = {WORLD SCIENTIFIC PUBL CO PTE LTD},
Address = {5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE},
Type = {Article},
Language = {English},
Affiliation = {Senggunprai, L (Corresponding Author), Khon Kaen Univ, Dept Pharmacol, Fac Med, Mittraphap Rd, Khon Kaen 40002, Thailand.
   Klungsaeng, Sirinapha; Kukongviriyapan, Veerapol; Prawan, Auemduan; Kongpetch, Sarinya; Senggunprai, Laddawan, Khon Kaen Univ, Dept Pharmacol, Fac Med, Mittraphap Rd, Khon Kaen 40002, Thailand.
   Kukongviriyapan, Veerapol; Prawan, Auemduan; Kongpetch, Sarinya; Senggunprai, Laddawan, Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand.},
DOI = {10.1142/S0192415X2050072X},
ISSN = {0192-415X},
EISSN = {1793-6853},
Keywords = {Cucurbitacin B; Cholangiocarcinoma; Antiproliferation; Focal Adhesion
   Kinase; p53; FAK Pathway},
Keywords-Plus = {FOCAL ADHESION KINASE; IN-VITRO; PROLIFERATION; EXPRESSION; APOPTOSIS;
   HER2; FAK; PHOSPHORYLATION; PROGRESSION; MIGRATION},
Research-Areas = {Integrative \& Complementary Medicine; General \& Internal Medicine},
Web-of-Science-Categories  = {Integrative \& Complementary Medicine; Medicine, General \& Internal},
Author-Email = {laddas@kku.ac.th},
Affiliations = {Khon Kaen University; Khon Kaen University},
ResearcherID-Numbers = {prawan, aueuan/B-1639-2015
   Senggunprai, Laddawan/HHR-9565-2022},
ORCID-Numbers = {prawan, aueuan/0000-0001-6713-567X
   Kongpetch, Sarinya/0000-0001-9767-4906
   },
Funding-Acknowledgement = {Khon Kaen University, Thailand {[}KKU600905]; Invitation Research grant
   from the Faculty of Medicine, Khon Kaen University, Thailand
   {[}IN62203]; Graduate School, Khon Kaen University, Thailand {[}581H217]},
Funding-Text = {This research was supported by the grant from Khon Kaen University,
   Thailand (KKU600905), and the Invitation Research grant from the Faculty
   of Medicine, Khon Kaen University, Thailand (IN62203). Sirinapha
   Klungsaeng received a scholarship from Graduate School, Khon Kaen
   University, Thailand (581H217). The authors would like to thank Prof.
   James A. Will, University of Wisconsin-Madison, for editing the
   manuscript via the English Editing Publication Clinic, Faculty of
   Medicine, Khon Kaen University, Thailand. Also, we wish to thank the
   Research Instrument Center, Khon Kaen University, for the service
   support of flow cytometry.},
Cited-References = {Alghasham AA, 2013, INT J HEALTH SCI-IJH, V7, P77, DOI 10.12816/0006025.
   Aneknan P, 2014, ASIAN PAC J CANCER P, V15, P5071, DOI 10.7314/APJCP.2014.15.12.5071.
   Ding Q, 2005, J BIOL CHEM, V280, P6802, DOI 10.1074/jbc.M409180200.
   Garg S, 2018, INT J ONCOL, V52, P19, DOI 10.3892/ijo.2017.4203.
   Harder J, 2009, WORLD J GASTROENTERO, V15, P4511, DOI 10.3748/wjg.15.4511.
   Hou J, 2016, ONCOTARGET, V7, P45186, DOI 10.18632/oncotarget.9870.
   Itoh S, 2004, CLIN CANCER RES, V10, P2812, DOI 10.1158/1078-0432.CCR-1046-03.
   Jung MJ, 2017, PATHOLOGY, V49, P582, DOI 10.1016/j.pathol.2017.06.001.
   Klungsaeng S, 2019, N-S ARCH PHARMACOL, V392, P271, DOI 10.1007/s00210-018-1584-3.
   Kristjánsdóttir K, 2004, CHEM BIOL, V11, P1043, DOI 10.1016/j.chembiol.2004.07.007.
   Liao NC, 2019, AM J CHINESE MED, V47, P635, DOI 10.1142/S0192415X19500332.
   Lim ST, 2008, MOL CELL, V29, P9, DOI 10.1016/j.molcel.2007.11.031.
   Luo WW, 2018, CHIN J NAT MEDICINES, V16, P10, DOI 10.1016/S1875-5364(18)30025-6.
   Marin JJG, 1864, BIOCH BIOPHYS ACTA M, P1444.
   Ohta R, 2006, ONCOLOGY-BASEL, V71, P417, DOI 10.1159/000107109.
   Reif S, 2003, J BIOL CHEM, V278, P8083, DOI 10.1074/jbc.M212927200.
   Sripa B, 2011, ACTA TROP, V120, pS158, DOI 10.1016/j.actatropica.2010.07.006.
   Swaffer MP, 2016, CELL, V167, P1750, DOI 10.1016/j.cell.2016.11.034.
   Tai YL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16408.
   Tai YL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/690690.
   Tancioni I, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0551-x.
   Touihri-Barakati I, 2017, EUR J PHARMACOL, V797, P153, DOI 10.1016/j.ejphar.2017.01.006.
   Vadlamudi RK, 2003, FEBS LETT, V543, P76, DOI 10.1016/S0014-5793(03)00404-6.
   Yasuda S, 2010, MOL NUTR FOOD RES, V54, P559, DOI 10.1002/mnfr.200900165.
   Yoon H, 2015, J HISTOCHEM CYTOCHEM, V63, P114, DOI 10.1369/0022155414561498.
   Zhang M, 2014, MOL MED REP, V10, P2905, DOI 10.3892/mmr.2014.2581.
   Zhang ZR, 2017, EXP THER MED, V14, P805, DOI 10.3892/etm.2017.4547.
   Zhou JK, 2019, J CELL PHYSIOL, V234, P4655, DOI 10.1002/jcp.27264.
   Zhou XY, 2012, HEPATOL RES, V42, P401, DOI 10.1111/j.1872-034X.2011.00933.x.},
Number-of-Cited-References = {29},
Times-Cited = {23},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Am. J. Chin. Med.},
Doc-Delivery-Number = {NZ8EI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000577334500011},
DA = {2026-02-04},
}

@article{ WOS:000516884500009,
Author = {Li, Hua and Park, Hye-Mi and Ji, Hyeon-Seon and Han, Jisu and Kim,
   Sang-Kyum and Park, Ho-Yong and Jeong, Tae-Sook},
Title = {Phenolic-enriched blueberry-leaf extract attenuates glucose homeostasis,
   pancreatic β-cell function, and insulin sensitivity in high-fat
   diet-induced diabetic mice},
Journal = {NUTRITION RESEARCH},
Year = {2020},
Volume = {73},
Pages = {83-96},
Month = {JAN},
Abstract = {Blueberry fruit exhibits strong antioxidant activity owing to the
   presence of anthocyanin. As blueberry-leaf extract (BLE) contains
   chlorogenic acid and flavonol glycosides, we hypothesized that
   phenolic-enriched BLE would improve glucose homeostasis and insulin
   sensitivity. In this study, we examined whether BLE administration
   decreases the glucose levels and enhances the pancreatic function in
   mice with high-fat diet (HFD)-induced obesity and diabetes. C57BL/6J
   mice were divided into the following four groups: control diet (CD), HFD
   (60 kcal\% fat diet), BLE (HFD with 1\% BLE wt/wt diet), and yerba mate
   extract (YME; HFD with 0.5\% YME wt/wt diet). Dietary BLE and YME
   reduced glucose tolerance, body weight, and plasma glucose, glycated
   hemoglobin, insulin, homeostasis model assessment of insulin resistance,
   triglyceride (TG), and non-esterified fatty acid levels. Compared with
   those of the HFD group, BLE was found to significantly reduce the
   pancreatic islet size and insulin content. Moreover, it increased the
   mRNA levels of pancreatic beta-cell proliferation related genes, Ngn3,
   MafA, Pax4, Ins1, and Ins2, and pancreatic insulin signaling-related
   genes, IRS-1, IRS-2, PIK3ca, PDK1, PKC epsilon, and GLUT-2, and
   decreased the transcriptional expression of the beta-cell
   apoptosis-related gene, FoxO1. Both BLE and YME improved insulin
   sensitivity by inhibiting TG synthesis and enhancing lipid utilization
   in the liver and white adipose tissue (WAT). In pancreatic MIN6
   beta-cells, BLE and its main component (chlorogenic acid) increased
   beta-cell proliferation and promoted insulin signaling. Overall, BLE
   enriched with phenolic compounds has the capacity to prevent HFD-induced
   glucose tolerance and hyperglycemia by improving the pancreatic
   beta-cell function. (C) 2019 Elsevier Inc. All rights reserved.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Jeong, TS (Corresponding Author), Korea Res Inst Biosci \& Biotechnol, Ind Biomat Res Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea.
   Li, Hua; Park, Hye-Mi; Ji, Hyeon-Seon; Han, Jisu; Park, Ho-Yong; Jeong, Tae-Sook, Korea Res Inst Biosci \& Biotechnol, Ind Biomat Res Ctr, 125 Gwahak Ro, Daejeon 34141, South Korea.
   Han, Jisu; Kim, Sang-Kyum, Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.},
DOI = {10.1016/j.nutres.2019.09.005},
ISSN = {0271-5317},
EISSN = {1879-0739},
Keywords = {Blueberry-leaf extract; Chlorogenic acid; Hyperglycemia; Pancreatic
   beta-cell; Insulin sensitivity},
Keywords-Plus = {ASHEI-READE LEAVES; CHLOROGENIC ACID; IN-VIVO; ILEX-PARAGUARIENSIS;
   LIPID-METABOLISM; RESISTANCE; MECHANISMS; PROLIFERATION; ANTIOXIDANT;
   GLYCOSIDES},
Research-Areas = {Nutrition \& Dietetics},
Web-of-Science-Categories  = {Nutrition \& Dietetics},
Author-Email = {leewhua@naver.com
   hyemi0707@nate.com
   gustjs1693@naver.com
   hanjs@kribb.re.kr
   sangkim@cnu.ac.kr
   hypark@kribb.re.kr
   tsjeong@kribb.re.kr},
Affiliations = {Korea Research Institute of Bioscience \& Biotechnology (KRIBB);
   Chungnam National University},
ResearcherID-Numbers = {PARK, HO-YONG/AAP-2225-2021},
Funding-Acknowledgement = {Bio \& Medical Technology Development Program of the National Research
   Foundation (NRF) {[}2016 K1A1A8A01938885]; Creative Allied Project of
   the National Research Council of Science \& Technology (NST) grant by
   the Korea government (MSIT) {[}CAP-18-06-KRIBB]},
Funding-Text = {This work was supported by the Bio \& Medical Technology Development
   Program (2016 K1A1A8A01938885) of the National Research Foundation
   (NRF)and the Creative Allied Project (CAP-18-06-KRIBB) of the National
   Research Council of Science \& Technology (NST) grant by the Korea
   government (MSIT). The authors have declared no conflict of interest.},
Cited-References = {Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014.
   Bagchi D, 2004, BIOCHEMISTRY-MOSCOW+, V69, P75, DOI 10.1023/B:BIRY.0000016355.19999.93.
   Baglioni S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036569.
   Ben-Othman N, 2013, DIABETES RES CLIN PR, V101, P1, DOI 10.1016/j.diabres.2013.01.013.
   Breneman CB, 2013, BRIT J NUTR, V110, P375, DOI 10.1017/S0007114512004953.
   Cignarella A, 1996, THROMB RES, V84, P311, DOI 10.1016/S0049-3848(96)00195-8.
   Courtney M, 2011, DIABETES OBES METAB, V13, P47, DOI 10.1111/j.1463-1326.2011.01441.x.
   Donath MY, 2014, NAT REV DRUG DISCOV, V13, P465, DOI 10.1038/nrd4275.
   Fall CHD, 2001, BRIT MED BULL, V60, P33, DOI 10.1093/bmb/60.1.33.
   Ferlemi AV, 2016, EXP EYE RES, V145, P258, DOI 10.1016/j.exer.2016.01.012.
   Ghorbani A, 2017, BIOMED PHARMACOTHER, V96, P305, DOI 10.1016/j.biopha.2017.10.001.
   Han XX, 2019, BIOMED PHARMACOTHER, V110, P561, DOI 10.1016/j.biopha.2018.12.012.
   Heck CI, 2007, J FOOD SCI, V72, pR138, DOI 10.1111/j.1750-3841.2007.00535.x.
   Hostetler GL, 2017, ADV NUTR, V8, P423, DOI 10.3945/an.116.012948.
   Huang XL, 2017, ONCOTARGET, V8.
   Jayachandran M, 2018, EUR J PHARMACOL, V829, P112, DOI 10.1016/j.ejphar.2018.04.015.
   Jewell JL, 2010, AM J PHYSIOL-REG I, V298, pR517, DOI 10.1152/ajpregu.00597.2009.
   Kaneto H, 2015, INT J MOL SCI, V16, P6281, DOI 10.3390/ijms16036281.
   Kang Young-Rye, 2012, Lab Anim Res, V28, P23, DOI 10.5625/lar.2012.28.1.23.
   Kim SM, 2010, PHYTOCHEM ANALYSIS, V21, P457, DOI 10.1002/pca.1218.
   Kitao N, 2018, METABOLISM, V85, P48, DOI 10.1016/j.metabol.2018.03.010.
   Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880.
   Leavens KF, 2011, CRIT REV BIOCHEM MOL, V46, P200, DOI 10.3109/10409238.2011.562481.
   Lee In-Chul, 2014, J Cancer Prev, V19, P209, DOI 10.15430/JCP.2014.19.3.209.
   Leibiger IB, 2008, ANNU REV NUTR, V28, P233, DOI 10.1146/annurev.nutr.28.061807.155530.
   Li H, 2019, J AGR FOOD CHEM, V67, P90, DOI 10.1021/acs.jafc.8b04527.
   Li H, 2015, J AGR FOOD CHEM, V63, P7198, DOI 10.1021/acs.jafc.5b01639.
   Ma YJ, 2015, PHARM RES-DORDR, V32, P1200, DOI 10.1007/s11095-014-1526-9.
   Martineau LC, 2006, PHYTOMEDICINE, V13, P612, DOI 10.1016/j.phymed.2006.08.005.
   Menini T, 2007, PLANTA MED, V73, P1141, DOI 10.1055/s-2007-981585.
   Miyazaki M, 2005, P NATL ACAD SCI USA, V102, P12501, DOI 10.1073/pnas.0503132102.
   Nagao K, 2008, BIOSCI BIOTECH BIOCH, V72, P1619, DOI 10.1271/bbb.80036.
   Pang J, 2008, ARCH BIOCHEM BIOPHYS, V476, P178, DOI 10.1016/j.abb.2008.02.019.
   Ravussin E, 2002, ANN NY ACAD SCI, V967, P363.
   Samuel VT, 2012, CELL, V148, P852, DOI 10.1016/j.cell.2012.02.017.
   Stumvoll M, 2005, LANCET, V365, P1333, DOI 10.1016/S0140-6736(05)61032-X.
   Swales N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037055.
   Tajik N, 2017, EUR J NUTR, V56, P2215, DOI 10.1007/s00394-017-1379-1.
   Terauchi Y, 2007, J CLIN INVEST, V117, P246, DOI 10.1172/JCI17645.
   Thom E, 2007, J INT MED RES, V35, P900, DOI 10.1177/147323000703500620.
   Vasavada RC, 2007, DIABETES, V56, P2732, DOI 10.2337/db07-0461.
   Verma N, 2013, INDIAN J EXP BIOL, V51, P65.
   Vetere A, 2014, NAT REV DRUG DISCOV, V13, P278, DOI 10.1038/nrd4231.
   White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001.
   Wu Y, 2018, INT J FOOD SCI NUTR, V69, P566, DOI 10.1080/09637486.2017.1394449.
   Yuji K, 2013, J OLEO SCI, V62, P89, DOI 10.5650/jos.62.89.
   Zhou Q, 2008, NATURE, V455, P627, DOI 10.1038/nature07314.},
Number-of-Cited-References = {47},
Times-Cited = {39},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {43},
Journal-ISO = {Nutr. Res.},
Doc-Delivery-Number = {KQ4HA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000516884500009},
DA = {2026-02-04},
}

@article{ WOS:000534475000007,
Author = {Mansi, Iman and Al-Sha'er, Mahmoud A. and Mhaidat, Nizar and Taha,
   Mutasem},
Title = {Ligand Based Pharmacophore Modeling Followed by Biological Screening
   Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents},
Journal = {ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY},
Year = {2020},
Volume = {20},
Number = {4},
Pages = {476-485},
Abstract = {Background: Phosphoinositide-Dependent Kinase-1 (PDK1) is a
   serine/threonine kinase, which belongs to AGC kinase family required by
   cancer cells.
   Methods: Pharmacophoric space of 86 PDK1 inhibitors using six diverse
   sets of inhibitors was explored to identify high-quality pharmacophores.
   The best combination of pharmacophoric models and physicochemical
   descriptors was selected by genetic algorithm-based QSAR analysis that
   can elucidate the variation of bioactivity within the training
   inhibitors. Two successful orthogonal pharmacophores emerged in the
   optimum QSAR equation (r(69)(2) = 0.90, r(LOO)(2)= 0.86, F= 51.92,
   r(PRESS)(2) against 17 test inhibitors = 0.79). Receiver Operating
   Characteristic (ROC) curve analyses were used to estimate the
   QSAR-selected pharmacophores.
   Results: 5 out of 11 compounds tested had shown potential intracellular
   PDK1 inhibition with the highest inhibition percent for compounds 92 and
   93 as follows; 90 and 92\% PDK1 inhibition, respectively.
   Conclusion: PDK1 inhibitors are potential anticancer agents that can be
   discovered by combination method of ligand based design with QSAR and
   ROC analysis.},
Publisher = {BENTHAM SCIENCE PUBL LTD},
Address = {EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES},
Type = {Article},
Language = {English},
Affiliation = {Mansi, I (Corresponding Author), Hashemite Univ, Fac Pharmaceut Sci, POB 330127, Zarqa 13133, Jordan.
   Al-Sha'er, MA (Corresponding Author), Zarqa Univ, Fac Pharm, Zarqa 13132, Jordan.
   Mansi, Iman, Hashemite Univ, Fac Pharmaceut Sci, POB 330127, Zarqa 13133, Jordan.
   Al-Sha'er, Mahmoud A., Zarqa Univ, Fac Pharm, Zarqa 13132, Jordan.
   Mhaidat, Nizar, Jordan Univ Sci \& Technol, Fac Pharm, Clin Pharm Dept, Irbid, Jordan.
   Taha, Mutasem, Univ Jordan, Fac Pharm, Drug Design Ctr, Amman, Jordan.},
DOI = {10.2174/1871520620666191224110600},
ISSN = {1871-5206},
EISSN = {1875-5992},
Keywords = {PDK1; anticancer; 3D QSAR; pharmacophores; ROC analysis; ligand based
   design},
Keywords-Plus = {POTENT; DESIGN; KINASE; APOPTOSIS; DATABASE; REVEALS},
Research-Areas = {Oncology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Oncology; Chemistry, Medicinal},
Author-Email = {iman\_mansi@hu.edu.jo
   a.mahmoud@zu.edu.jo},
Affiliations = {Hashemite University; Zarqa University; Jordan University of Science \&
   Technology; University of Jordan},
ResearcherID-Numbers = {Al-Sha'er, Mahmoud/M-7318-2015
   Mansi, Iman/ITV-2152-2023
   TAHA, MUTASEM/F-2548-2011},
ORCID-Numbers = {Al-Sha'er, Mahmoud/0000-0001-9962-1971
   TAHA, MUTASEM/0000-0002-4453-072X},
Funding-Acknowledgement = {deanship of Scientific Research at the Hashemite University {[}12/2015]},
Funding-Text = {The project was funded by the deanship of Scientific Research at the
   Hashemite University (Grant number 12/2015), which is highly
   appreciated.},
Cited-References = {Abu Hammad AM, 2009, J CHEM INF MODEL, V49, P978, DOI 10.1021/ci8003682.
   Al-masri IM, 2008, CHEMMEDCHEM, V3, P1763, DOI 10.1002/cmdc.200800213.
   Al-Nadaf A, 2010, BIOORGAN MED CHEM, V18, P3088, DOI 10.1016/j.bmc.2010.03.043.
   Al-Sha'er MA, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2080-4.
   Al-Sha'er MA, 2013, J MOL GRAPH MODEL, V42, P104, DOI 10.1016/j.jmgm.2013.03.003.
   Al-Sha'er MA, 2010, EUR J MED CHEM, V45, P4316, DOI 10.1016/j.ejmech.2010.06.034.
   Al-Sha'er MA, 2010, J CHEM INF MODEL, V50, P1706, DOI 10.1021/ci100222k.
   {[}Anonymous], 2016, CERIUS2 QSAR US MAN.
   {[}Anonymous], 2000, Pharmacophore Perception, DeVelopment.
   {[}Anonymous], 2016, CAT US GUID.
   {[}Anonymous], 2000, LIGANDFIT USER MANUA.
   {[}Anonymous], J SILICO IN VITRO PH.
   Bersuker IB, 2000, IUL BIOTECH, V2, P455.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Fisher RA., 1966, DESIGN EXPT, V8th ed, P11.
   Fyffe Chanse, 2013, Cancer Manag Res, V5, P271, DOI 10.2147/CMAR.S35026.
   Gopalsamy A, 2007, J MED CHEM, V50, P5547, DOI 10.1021/jm070851i.
   Gu Y, 2013, ONCOL LETT, V5, P483, DOI 10.3892/ol.2012.1049.
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+.
   Islam I, 2007, BIOORG MED CHEM LETT, V17, P3814, DOI 10.1016/j.bmcl.2007.04.071.
   Islam I, 2007, BIOORG MED CHEM LETT, V17, P3819, DOI 10.1016/j.bmcl.2007.05.060.
   Johnson MC, 2011, J COMPUT AID MOL DES, V25, P689, DOI 10.1007/s10822-011-9456-7.
   Kirubakaran P, 2012, INDIAN J PHARM SCI, V74, P141, DOI 10.4103/0250-474X.103846.
   Kurogi Y, 2001, CURR MED CHEM, V8, P1035, DOI 10.2174/0929867013372481.
   Li H, 2000, IUL BIOTECH, V2, P171.
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0.
   Messoussi A, 2014, MOLECULES, V19, P16223, DOI 10.3390/molecules191016223.
   Mhaidat NM, 2007, CLIN CANCER RES, V13, P1308, DOI 10.1158/1078-0432.CCR-06-2216.
   Mhaidat NM, 2012, PHYTOTHER RES, V26, P926, DOI 10.1002/ptr.3666.
   Murphy ST, 2011, J MED CHEM, V54, P8490, DOI 10.1021/jm201019k.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Peifer C, 2008, CHEMMEDCHEM, V3, P1810, DOI 10.1002/cmdc.200800195.
   Poptodorov K., 2006, METHODS PRINCIPLES M, V2.
   Shahin R, 2018, J MOL GRAPH MODEL, V80, P327, DOI 10.1016/j.jmgm.2018.01.004.
   Sheridan RP, 2002, DRUG DISCOV TODAY, V7, P903, DOI 10.1016/S1359-6446(02)02411-X.
   Taha MO, 2008, J MED CHEM, V51, P6478, DOI 10.1021/jm800718k.
   Taha MO, 2008, BIOORGAN MED CHEM, V16, P1218, DOI 10.1016/j.bmc.2007.10.076.
   Taha MO, 2008, J MED CHEM, V51, P2062, DOI 10.1021/jm7009765.
   Taha MO, 2007, J MOL GRAPH MODEL, V25, P870, DOI 10.1016/j.jmgm.2006.08.008.
   Triballeau N., 2005, CURVE APPROACH APPL, P2534, DOI {[}10.1021 jm049092j, DOI 10.1021/JM049092J].
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n.
   Zhang W, 2013, MED CHEM RES, V22, P3416, DOI 10.1007/s00044-012-0338-x.},
Number-of-Cited-References = {42},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Anti-Cancer Agents Med. Chem.},
Doc-Delivery-Number = {LP7CN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000534475000007},
DA = {2026-02-04},
}

@article{ WOS:000589443500003,
Author = {Mansi, Iman A. and Al-Sha'er, Mahmoud A. and Mhaidat, Nizar M. and Taha,
   Mutasem O. and Shahin, Rand},
Title = {Investigation of Binding Characteristics of Phosphoinositide-dependent
   Kinase-1 (PDK1) Co-crystallized Ligands Through Virtual Pharmacophore
   Modeling Leading to Novel Anti-PDK1 Hits},
Journal = {MEDICINAL CHEMISTRY},
Year = {2020},
Volume = {16},
Number = {7},
Pages = {860-880},
Abstract = {Background: 3-Phosphoinositide Dependent Protein Kinase-1 (PDK1) is
   being lately considered as an attractive and forthcoming anticancer
   target. A Protein Data Bank (PDB) co-crystallized crystal provides not
   only rigid theoretical data but also a realistic molecular recognition
   data that can be explored and used to discover new hits.
   Objective: This incited us to investigate the co-crystallized ligands'
   contacts inside the PDK1 binding pocket via a structure-based
   receptor-ligand pharmacophore generation technique in Discovery Studio
   4.5 (DS 4.5).
   Methods: Accordingly, 35 crystals for PDK1 were collected and studied.
   Every single receptor-ligand interaction was validated and the
   significant ones were converted into their corresponding pharmacophoric
   features. The generated pharmacophores were scored by the Receiver
   Operating Characteristic (ROC) curve analysis.
   Results: Consequently, 169 pharmacophores were generated and sorted, 11
   pharmacophores acquired good ROC-AUC results of 0.8 and a selectivity
   value above 8. Pharmacophore 1UU3\_2\_01 was used in particular as a
   searching filter to screen NCI database because of its acceptable
   validity criteria and its distinctive positive ionizable feature.
   Several low micromolar PDK1 inhibitors were revealed. The most potent
   hit illustrated anti-PDK1 IC50 values of 200 nM with 70\% inhibition
   against SW480 cell lines.
   Conclusion: Eventually, the active hits were docked inside the PDK1
   binding pocket and the recognition points between the active hits and
   the receptor were analyzed that led to the discovery of new scaffolds as
   potential PDK1 inhibitors.},
Publisher = {BENTHAM SCIENCE PUBL LTD},
Address = {EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES},
Type = {Article},
Language = {English},
Affiliation = {Mansi, IA (Corresponding Author), Hashemite Univ, Fac Pharmaceut Sci, POB 330127, Zarqa 13133, Jordan.
   Al-Sha'er, MA (Corresponding Author), Zarqa Univ, Fac Pharm, Zarqa 13132, Jordan.
   Mansi, Iman A.; Shahin, Rand, Hashemite Univ, Fac Pharmaceut Sci, POB 330127, Zarqa 13133, Jordan.
   Al-Sha'er, Mahmoud A., Zarqa Univ, Fac Pharm, Zarqa 13132, Jordan.
   Mhaidat, Nizar M., Jordan Univ Sci \& Technol, Fac Pharm, Clin Pharm Dept, Irbid, Jordan.
   Taha, Mutasem O., Univ Jordan, Fac Pharm, Drug Design Ctr, Amman, Jordan.
   Taha, Mutasem O., Appl Sci Univ, Fac Pharm, Amman, Jordan.},
DOI = {10.2174/1573406415666190724131048},
ISSN = {1573-4064},
EISSN = {1875-6638},
Keywords = {PDK; cancer; co-crystallized structure; docking; pharmacophore; ROC
   analysis; discovery studio molecular design},
Keywords-Plus = {AIDED DRUG DESIGN; INHIBITORS; DISCOVERY; DOCKING; POTENT},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal},
Author-Email = {iman\_mansi@hu.edu.jo
   a.mahmoud@zu.edu.jo},
Affiliations = {Hashemite University; Zarqa University; Jordan University of Science \&
   Technology; University of Jordan; Applied Science University - Jordan},
ResearcherID-Numbers = {Mansi, Iman/ITV-2152-2023
   Al-Sha'er, Mahmoud/M-7318-2015
   Shahin, Rand/AFZ-1612-2022
   taha, mutasem/F-2548-2011},
ORCID-Numbers = {Al-Sha'er, Mahmoud/0000-0001-9962-1971
   Shahin, Rand/0000-0001-7330-4433
   },
Funding-Acknowledgement = {deanship of Scientific Research at the Hashemite University {[}12/2015]},
Funding-Text = {The project was funded by the deanship of Scientific Research at the
   Hashemite University (Grant number 12/2015), which is highly
   appreciated.},
Cited-References = {Al-Sha'er MA, 2019, COMPUT BIOL CHEM, V80, P102, DOI 10.1016/j.compbiolchem.2019.03.011.
   Al-Sha'er MA, 2019, MED CHEM, V15, P588, DOI 10.2174/1573406415666190222125333.
   Al-Sha'er MA, 2018, J MOL GRAPH MODEL, V83, P153, DOI 10.1016/j.jmgm.2018.02.001.
   Al-Sha'er MA, 2016, J ENZYM INHIB MED CH, V31, P64, DOI 10.1080/14756366.2016.1218485.
   Al-Sha'er MA, 2015, J MOL GRAPH MODEL, V62, P213, DOI 10.1016/j.jmgm.2015.10.004.
   Al-Sha'er MA, 2012, J MOL MODEL, V18, P4843, DOI 10.1007/s00894-012-1479-z.
   Backes AC, 2008, EXPERT OPIN DRUG DIS, V3, P1409, DOI 10.1517/17460440802579975.
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235.
   Bhola NE, 2012, MOL CANCER THER, V11, P1236, DOI 10.1158/1535-7163.MCT-11-0936.
   BIOVIA, 2016, DISCOVERY STUDIO MOD, DOI {[}10.1016/0040-4020(80)80168-2, DOI 10.1016/0040-4020(80)80168-2].
   Fyffe Chanse, 2013, Cancer Manag Res, V5, P271, DOI 10.2147/CMAR.S35026.
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2.
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777.
   Gopalsamy A, 2007, J MED CHEM, V50, P5547, DOI 10.1021/jm070851i.
   Gu ZN, 2013, CARCINOGENESIS, V34, P1968, DOI 10.1093/carcin/bgt147.
   Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+.
   Islam I, 2007, BIOORG MED CHEM LETT, V17, P3819, DOI 10.1016/j.bmcl.2007.05.060.
   Johnson MC, 2011, J COMPUT AID MOL DES, V25, P689, DOI 10.1007/s10822-011-9456-7.
   Kirchmair J, 2008, J COMPUT AID MOL DES, V22, P213, DOI 10.1007/s10822-007-9163-6.
   Kirchmair J, 2009, J CHEM INF MODEL, V49, P678, DOI 10.1021/ci8004226.
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0.
   McGaughey G, 2017, J COMPUT AID MOL DES, V31, P293, DOI 10.1007/s10822-016-9994-0.
   Medina JR, 2013, J MED CHEM, V56, P2726, DOI 10.1021/jm4000227.
   Medina JR, 2011, J MED CHEM, V54, P1871, DOI 10.1021/jm101527u.
   Mhaidat NM, 2007, BRIT J CANCER, V97, P1225, DOI 10.1038/sj.bjc.6604017.
   Mhaidat NM, 2012, PHYTOTHER RES, V26, P926, DOI 10.1002/ptr.3666.
   Muegge I, 2017, J COMPUT AID MOL DES, V31, P275, DOI 10.1007/s10822-016-9975-3.
   Murphy ST, 2011, J MED CHEM, V54, P8490, DOI 10.1021/jm201019k.
   Peifer Christian, 2009, Biochem J, V417, pe5, DOI 10.1042/BJ20082243.
   Shahin R, 2018, J MOL GRAPH MODEL, V80, P327, DOI 10.1016/j.jmgm.2018.01.004.
   Shahin R, 2012, J COMPUT AID MOL DES, V26, P249, DOI 10.1007/s10822-011-9509-y.
   Swellmeen L, 2017, BIOORGAN MED CHEM, V25, P4855, DOI 10.1016/j.bmc.2017.07.036.
   Thermofisher, 2019, Z LYTE KIN ASS.
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n.
   Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X.
   Wolber G, 2005, J CHEM INF MODEL, V45, P160, DOI 10.1021/ci049885e.
   Wolber G, 2008, DRUG DISCOV TODAY, V13, P23, DOI 10.1016/j.drudis.2007.09.007.},
Number-of-Cited-References = {37},
Times-Cited = {9},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {26},
Journal-ISO = {Med. Chem.},
Doc-Delivery-Number = {OR4LI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000589443500003},
DA = {2026-02-04},
}

@article{ WOS:000507526800012,
Author = {Meng, Gang and Li, Binghua and Chen, Anxian and Zheng, Meihong and Xu,
   Tiancheng and Zhang, Hailin and Dong, Jie and Wu, Junhua and Yu, Decai
   and Wei, Jiwu},
Title = {Targeting aerobic glycolysis by dichloroacetate improves Newcastle
   disease virus-mediated viro-immunotherapy in hepatocellular carcinoma},
Journal = {BRITISH JOURNAL OF CANCER},
Year = {2020},
Volume = {122},
Number = {1},
Pages = {111-120},
Month = {JAN},
Abstract = {Background Oncolytic viro-immunotherapy holds promise for cancer
   treatment. While immune activation can be robustly triggered by
   oncolytic viruses, negative feedback is often upregulated in the tumour
   microenvironment (TME). Lactate accumulation, signal transducer and
   activator of transcription 3 (STAT3) activation, indoleamine
   2,3-dioxygenase 1 (IDO1) expression, and myeloid-derived suppressor cell
   (MDSC) infiltration coordinate to shape the immunosuppressive TME.
   Methods Representative hepatocellular carcinoma (HCC) cell lines and
   HCC-bearing mice were treated with oncolytic Newcastle disease virus
   (NDV), alone or in combination with dichloroacetate (DCA, a pyruvate
   dehydrogenase kinase (PDK) inhibitor). Results We found that infection
   with oncolytic NDV led to significant induction of the aforementioned
   suppressive factors. Interestingly, DCA significantly reduced lactate
   release, STAT3 activation, IDO1 upregulation, and MDSC infiltration in
   NDV-treated HCC. Consequently, DCA significantly enhanced the antitumour
   immune responses, leading to improved antitumour efficacy and prolonged
   survival in mouse models of ascitic and subcutaneous HCC. Furthermore,
   DCA increased NDV replication in a PDK-1-dependent manner in HCC.
   Conclusions Targeting aerobic glycolysis by DCA improves NDV-mediated
   viro-immunotherapy in HCC by mitigating immune negative feedback and
   promoting viral replication. These findings provide a rationale for
   targeting reprogrammed metabolism together with oncolytic virus-mediated
   viro-immunotherapy for HCC treatment.},
Publisher = {SPRINGERNATURE},
Address = {CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yu, DC (Corresponding Author), Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Nanjing 210008, Peoples R China.
   Wei, JW (Corresponding Author), Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210093, Peoples R China.
   Meng, Gang; Li, Binghua; Xu, Tiancheng; Yu, Decai, Nanjing Univ, Sch Med, Affiliated Drum Tower Hosp, Dept Hepatobiliary Surg, Nanjing 210008, Peoples R China.
   Meng, Gang; Chen, Anxian; Zheng, Meihong; Zhang, Hailin; Dong, Jie; Wu, Junhua; Wei, Jiwu, Nanjing Univ, Sch Med, Jiangsu Key Lab Mol Med, Nanjing 210093, Peoples R China.},
DOI = {10.1038/s41416-019-0639-7},
ISSN = {0007-0920},
EISSN = {1532-1827},
Keywords-Plus = {GLUCOSE-METABOLISM; SUPPRESSOR-CELLS; ONCOLYTIC VIRUS; LACTIC-ACID;
   TUMOR; THERAPY; REPLICATION; CHEMOTHERAPY; COMBINATION; COMPETITION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {yudecai@nju.edu.cn
   wjw@nju.edu.cn},
Affiliations = {Nanjing University; Nanjing University},
ResearcherID-Numbers = {Wu, Junhua/JTT-4742-2023
   YU, Decai/D-4129-2009
   Meng, Gang/J-9032-2017},
ORCID-Numbers = {Wu, Junhua/0000-0003-4753-2648
   YU, Decai/0000-0002-3006-2531
   Li, Binghua/0000-0001-7209-2854
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81773255, 81700037,
   81871967, 81903147]; Natural Science Foundation of Jiangsu Province of
   China {[}BK20171098]; Social Development Foundation of Jiangsu Province
   of China {[}BE2018604]; Six talent peaks project in Jiangsu Province;
   Jiangsu Provincial Medical Talent; China Postdoctoral Science Foundation
   {[}2018M642223]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (81773255, 81700037, 81871967, and 81903147), the Natural Science
   Foundation of Jiangsu Province of China (BK20171098), Social Development
   Foundation of Jiangsu Province of China (BE2018604), Six talent peaks
   project in Jiangsu Province to J.W., Jiangsu Provincial Medical Talent
   to D.Y., and Project funded by China Postdoctoral Science Foundation
   (2018M642223).},
Cited-References = {Bénéteau M, 2012, P NATL ACAD SCI USA, V109, P20071, DOI 10.1073/pnas.1206360109.
   Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6.
   Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627.
   Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016.
   Demaria Marco, 2012, JAKSTAT, V1, P194, DOI 10.4161/jkst.20662.
   Dubé MP, 2000, CLIN INFECT DIS, V31, P1467, DOI 10.1086/317491.
   Fiola C, 2006, INT J CANCER, V119, P328, DOI 10.1002/ijc.21821.
   Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972.
   Freeman AI, 2006, MOL THER, V13, P221, DOI 10.1016/j.ymthe.2005.08.016.
   Hanafi LA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099211.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Heo J, 2013, NAT MED, V19, P329, DOI 10.1038/nm.3089.
   Holmgaard RB, 2015, CELL REP, V13, P412, DOI 10.1016/j.celrep.2015.08.077.
   Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702.
   Li CY, 2015, ONCOTARGET, V6, P1544, DOI 10.18632/oncotarget.2838.
   Li W, 2018, CELL METAB, V28, P87, DOI 10.1016/j.cmet.2018.04.022.
   Mace TA, 2013, CANCER RES, V73, P3007, DOI 10.1158/0008-5472.CAN-12-4601.
   Mansour M, 2011, J VIROL, V85, P6015, DOI 10.1128/JVI.01537-10.
   Martin NT, 2018, MOL THER, V26, P1414, DOI 10.1016/j.ymthe.2018.04.001.
   Meng G, 2019, MOL THER-ONCOLYTICS, V13, P22, DOI 10.1016/j.omto.2019.03.004.
   Meng G, 2014, ONCOTARGET, V5, P6365, DOI 10.18632/oncotarget.2219.
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Mu XM, 2018, CELL CYCLE, V17, P428, DOI 10.1080/15384101.2018.1444305.
   Munn DH, 2016, CURR OPIN IMMUNOL, V39, P1, DOI 10.1016/j.coi.2015.10.009.
   Nie XH, 2015, DRUG DES DEV THER, V9, P5611, DOI 10.2147/DDDT.S93912.
   Ninomiya S, 2015, BLOOD, V125, P3905, DOI 10.1182/blood-2015-01-621474.
   Ohashi T, 2013, INT J CANCER, V133, P1107, DOI 10.1002/ijc.28114.
   Pol J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115641.
   Ricca JM, 2018, MOL THER, V26, P1008, DOI 10.1016/j.ymthe.2018.01.019.
   Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287.
   Schirrmacher V, 2005, CANCER IMMUNOL IMMUN, V54, P587, DOI 10.1007/s00262-004-0602-0.
   Schirrmacher V, 2015, EXPERT OPIN BIOL TH, V15, P1757, DOI 10.1517/14712598.2015.1088000.
   Schwaiger T, 2017, INT J CANCER, V141, P2505, DOI 10.1002/ijc.31026.
   Sukumar M, 2015, CELL, V162, P1206, DOI 10.1016/j.cell.2015.08.064.
   Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589.
   Thai M, 2014, CELL METAB, V19, P694, DOI 10.1016/j.cmet.2014.03.009.
   Yang H, 2015, CANCER RES, V75, P3812, DOI 10.1158/0008-5472.CAN-15-1122.
   Yu YJ, 2011, TRENDS MICROBIOL, V19, P360, DOI 10.1016/j.tim.2011.04.002.
   Zamarin D, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008095.
   Zamarin D, 2012, FUTURE MICROBIOL, V7, P347, DOI {[}10.2217/FMB.12.4, 10.2217/fmb.12.4].},
Number-of-Cited-References = {41},
Times-Cited = {57},
Usage-Count-Last-180-days = {4},
Usage-Count-Since-2013 = {48},
Journal-ISO = {Br. J. Cancer},
Doc-Delivery-Number = {KC9YB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000507526800012},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000498874200004,
Author = {Pan, Tianhui and Liu, Jingwen and Xu, Song and Yu, Qiao and Wang,
   Hongping and Sun, Hongxiang and Wu, Jia and Zhu, Yue and Zhou, Jianwei
   and Zhu, Yongliang},
Title = {ANKRD22, a novel tumor microenvironment-induced mitochondrial protein
   promotes metabolic reprogramming of colorectal cancer cells},
Journal = {THERANOSTICS},
Year = {2020},
Volume = {10},
Number = {2},
Pages = {516-536},
Abstract = {Background: The leading cause of poor prognosis in colorectal cancer
   (CRC) is the presence of colorectal cancer-initiating cells (CCICs). The
   interplay between the tumor microenvironment (TME) and CRC cells induces
   reacquisition of initiating cell characteristics, but the underlying
   mechanisms remain elusive.
   Methods: Candidate molecules were screened by global differential cDNA
   expression profiles of CCICs, which were enriched from patient-derived
   tumor xenograft models. Luciferase reporters and chromatin
   immunoprecipitation assays were used to explore the mechanism of TME
   factors regulating the transcription of ANKRD22. The effects of Ankyrin
   repeat domain-containing protein 22 (ANKRD22) on energy metabolism were
   monitored by extracellular flux and C-13-based metabolic flux analysis.
   Mass spectrometry was used to identify the interacting partners of
   ANKRD22. Morphological changes of CCICs overexpressing ANKRD22 were
   observed by electron microscopy. The effects of ANKRD22 on mitochondrial
   lipid metabolism were analyzed by lipidomics.
   Results: We identified a novel nucleus-encoded mitochondrial membrane
   protein, ANKRD22, which was upregulated in CCICs. We found that ANKRD22
   was induced by the p38/MAX pathway activated by different TME stimuli.
   As a key transcription factor, MAX promoted the transcription of
   ANKRD22. Expression of ANKRD22 promoted glycolysis associated with a
   decrease in ATP/ADP and an increase in AMP/ATP levels, which were
   related to its interaction with pyruvate dehydrogenase kinase isoform 1
   (PDK1) and multiple subunits of ATP synthase. Further, in CCICs, ANKRD22
   cooperated with the lipid transport protein, Extended Synaptotagmin-1
   (E-Syt1), to transport excess lipids into mitochondria and reduced the
   number of mitochondria in an autophagy-independent manner, thus meeting
   the metabolic requirements of CCICs.
   Conclusion: ANKRD22 induced by TME promotes the metabolic reprogramming
   of CRC cells. Our study has identified ANKRD22/E-Syt1 as a potential
   target for eradicating CCICs.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Zhu, YL (Corresponding Author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Lab Gastroenterol Dept, Hangzhou 310009, Zhejiang, Peoples R China.
   Zhou, JW (Corresponding Author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gynecol, Hangzhou 310009, Zhejiang, Peoples R China.
   Pan, Tianhui; Liu, Jingwen; Xu, Song; Yu, Qiao; Wang, Hongping; Wu, Jia; Zhu, Yongliang, Zhejiang Univ, Sch Med, Affiliated Hosp 2, Lab Gastroenterol Dept, Hangzhou 310009, Zhejiang, Peoples R China.
   Zhou, Jianwei, Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gynecol, Hangzhou 310009, Zhejiang, Peoples R China.
   Sun, Hongxiang, Zhejiang Univ, Coll Anim Sci, Lab Nat Drug, Hangzhou 310058, Zhejiang, Peoples R China.
   Zhu, Yongliang, Key Lab Tumor Microenviroment \& Immune Therapy Zh, Hangzhou 310009, Zhejiang, Peoples R China.
   Zhu, Yue, Wenzhou Med Univ, Coll Stormotologry, Wenzhou 325035, Zhejiang, Peoples R China.},
DOI = {10.7150/thno.37472},
ISSN = {1838-7640},
Keywords = {Colorectal cancer; Tumor microenvironment; Cancer-initiating cells;
   ANKRD22; Metabolic reprogramming},
Keywords-Plus = {STEM-CELLS; PLURIPOTENCY; GLYCOLYSIS; PLASTICITY; CARCINOMA; MARKERS},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {2195045@zju.edu.cn
   ylzhu@zju.edu.cn},
Affiliations = {Zhejiang University; Zhejiang University; Zhejiang University; Wenzhou
   Medical University},
ResearcherID-Numbers = {Liu, Jingwen/J-5058-2019
   yu, qiao/KFT-2125-2024
   Sun, Hongxiang/AGQ-9249-2022},
ORCID-Numbers = {Sun, Hongxiang/0000-0003-4849-7127},
Funding-Acknowledgement = {National Science of Foundation Committee of China {[}81672898, 81472723,
   81602584, 81700455]},
Funding-Text = {We thank Ms. Dong Qi at Cancer Institute of Zhejiang University for her
   excellent skills in Confocal microscopy. This work was supported by
   grants from the National Science of Foundation Committee of China
   (81672898, 81472723, 81602584 and 81700455).},
Cited-References = {Ancey PB, 2018, FEBS J, V285, P2926, DOI 10.1111/febs.14577.
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409.
   Bhute VJ, 2017, THERANOSTICS, V7, P2078, DOI 10.7150/thno.19390.
   Caba O, 2014, DIGEST DIS SCI, V59, P2714, DOI 10.1007/s10620-014-3291-3.
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005.
   Chakrabarty Broto, 2014, BMC Bioinformatics, V15, P6599, DOI 10.1186/s12859-014-0440-9.
   Chevrollier A, 2011, BBA-BIOENERGETICS, V1807, P562, DOI 10.1016/j.bbabio.2010.10.008.
   El Kasmi KC, 2015, SEMIN IMMUNOL, V27, P267, DOI 10.1016/j.smim.2015.09.001.
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011.
   Gao RF, 2018, THERANOSTICS, V8, P6248, DOI 10.7150/thno.28721.
   Giordano F, 2013, CELL, V153, P1494, DOI 10.1016/j.cell.2013.05.026.
   Ji YP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15308.
   Khacho M, 2016, CELL STEM CELL, V19, P232, DOI 10.1016/j.stem.2016.04.015.
   Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689.
   Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010.
   Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06.
   Le Bras M, 2006, CANCER RES, V66, P9143, DOI 10.1158/0008-5472.CAN-05-4407.
   Li L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07127-8.
   Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320.
   Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167.
   Milioli HH, 2017, BMC MED GENOMICS, V10, DOI 10.1186/s12920-017-0250-9.
   Muñoz-Galván S, 2019, ONCOGENE, V38, P1309, DOI 10.1038/s41388-018-0527-2.
   Naik PP, 2019, CELL MOL LIFE SCI, V76, P27, DOI 10.1007/s00018-018-2922-9.
   Nascimbeni AC, 2017, EMBO J, V36, P2018, DOI 10.15252/embj.201797006.
   Parra RG, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004659.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Potter EA, 2017, ONCOTARGET, V8, P9425, DOI 10.18632/oncotarget.14116.
   Saheki Y, 2017, BBA-MOL CELL RES, V1864, P1490, DOI 10.1016/j.bbamcr.2017.03.013.
   Saheki Y, 2016, NAT CELL BIOL, V18, P504, DOI 10.1038/ncb3339.
   Schramek D, 2014, SCIENCE, V343, P309, DOI 10.1126/science.1248627.
   Song IS, 2015, GASTROENTEROLOGY, V149, P1006, DOI 10.1053/j.gastro.2015.06.007.
   Teslaa T, 2015, EMBO J, V34, P138, DOI 10.15252/embj.201490446.
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262.
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031.
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368.
   Valli A, 2019, MOL CANCER RES, V17, P1531, DOI 10.1158/1541-7786.MCR-18-0315.
   Venner JM, 2014, AM J TRANSPLANT, V14, P2565, DOI 10.1111/ajt.12946.
   Visciano C, 2015, ONCOGENE, V34, P5175, DOI 10.1038/onc.2014.441.
   Wanet A, 2015, STEM CELLS DEV, V24, P1957, DOI 10.1089/scd.2015.0117.
   Wang LH, 2017, EMBO J, V36, P1330, DOI 10.15252/embj.201695417.
   Want EJ, 2013, NAT PROTOC, V8, P17, DOI 10.1038/nprot.2012.135.
   Wen ZZ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0590-2.
   Wu H, 2016, ONCOTARGET, V7, P40621, DOI 10.18632/oncotarget.9746.
   Wu ZM, 2015, CELL STEM CELL, V17, P47, DOI 10.1016/j.stem.2015.05.016.
   Xing YZ, 2015, FEBS J, V282, P3892, DOI 10.1111/febs.13402.
   Xu XL, 2013, CELL METAB, V18, P325, DOI 10.1016/j.cmet.2013.06.005.
   Yang CS, 2014, CELL REP, V8, P326, DOI 10.1016/j.celrep.2014.07.002.
   Yin J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04818-y.
   Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001.
   Zhang Y, 2018, GASTROENTEROLOGY, V155, P210, DOI 10.1053/j.gastro.2018.03.041.
   Zhang ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22151.
   Zhou TJ, 2017, THERANOSTICS, V7, P1389, DOI 10.7150/thno.17647.
   Zhu ZX, 2017, CELL STEM CELL, V20, P274, DOI 10.1016/j.stem.2016.11.002.},
Number-of-Cited-References = {53},
Times-Cited = {59},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {35},
Journal-ISO = {Theranostics},
Doc-Delivery-Number = {JQ3UN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000498874200004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000529344200001,
Author = {Qian, Yan and Wu, Xu and Wang, Haixiao and Hou, Guowei and Han, Xiao and
   Song, Wei},
Title = {MicroRNA-4290 suppresses PDK1-mediated glycolysis to enhance the
   sensitivity of gastric cancer cell to cisplatin},
Journal = {BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH},
Year = {2020},
Volume = {53},
Number = {5},
Abstract = {The development of chemotherapy resistance significantly impairs the
   efficiency of chemotherapy, but the underlying mechanisms of
   chemotherapy resistance in gastric cancer (GC) are complicated and still
   need to be further explored. Here, we aimed to reveal the effects of
   miR-4290/PDK1 (pyruvate dehydrogenase kinase 1) axis on chemotherapy
   resistance of GC in vitro. The expression patterns of miR-4290 in GC
   tissues and cell lines were determined by real-time quantitative PCR.
   Kaplan-Meier was used to assess the relationship between miR-4290
   expression levels and patients' overall survival. CCK-8 and flow
   cytometry technologies were applied to detect cell proliferation and
   apoptosis. The luciferase gene reporter assay was used to evaluate the
   interaction between miR-4290 and PDK1. miR-4290 was lowly expressed in
   GC tissues and cell lines, which was closely associated with the shorter
   overall survival of GC patients. miR-4290 mimics significantly inhibited
   cell proliferation and induced cell apoptosis, as well as induced a
   significant reduction in the expression of PDK1. Moreover, miR-4290
   significantly inhibited glycolysis and decreased the IC50 value to
   cisplatin in SGC7901 cells, whereas these effects were abolished and
   cell apoptosis was promoted when PDK1 was overexpressed. In conclusion,
   this study revealed that miR-4290 suppressed PDK1-mediated glycolysis to
   enhance the sensitivity of GC cells to cisplatin.},
Publisher = {ASSOC BRAS DIVULG CIENTIFICA},
Address = {FACULDADE MEDICINA, CASA 10, 14049 RIBEIRAO PRETO, RIBEIRAO PRETO, SP
   14049, BRAZIL},
Type = {Article},
Language = {English},
Affiliation = {Song, W (Corresponding Author), Nanjing Med Univ, Affiliated Huaian 1 Peoples Hosp, Dept Gastroenterol, Huaian, Jiangsu, Peoples R China.
   Qian, Yan; Wu, Xu; Wang, Haixiao; Hou, Guowei; Han, Xiao, Nanjing Med Univ, Affiliated Huaian 1 Peoples Hosp, Dept Gastr Surg, Huaian, Jiangsu, Peoples R China.
   Song, Wei, Nanjing Med Univ, Affiliated Huaian 1 Peoples Hosp, Dept Gastroenterol, Huaian, Jiangsu, Peoples R China.},
DOI = {10.1590/1414-431X20209330},
Article-Number = {e9330},
ISSN = {0100-879X},
EISSN = {1414-431X},
Keywords = {miR-4290; PDK1; Cisplatin; Chemoresistance; Gastric cancer},
Keywords-Plus = {MULTIDRUG-RESISTANCE; PDK1},
Research-Areas = {Life Sciences \& Biomedicine - Other Topics; Research \& Experimental
   Medicine},
Web-of-Science-Categories  = {Biology; Medicine, Research \& Experimental},
Author-Email = {WeiSongagh@163.com},
Affiliations = {Nanjing Medical University; Nanjing Medical University},
ResearcherID-Numbers = {HOU, GUOWEI/AAD-7648-2020},
Cited-References = {Bhattacharya B, 2014, BRIT J PHARMACOL, V171, P3255, DOI 10.1111/bph.12668.
   Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856.
   Chen D, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00502.
   Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152.
   Gill KS, 2016, BBA-REV CANCER, V1866, P87, DOI 10.1016/j.bbcan.2016.06.005.
   Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258.
   Gong XF, 2019, CANCER MANAG RES, V11, P6615, DOI 10.2147/CMAR.S208708.
   Huang CH, 2020, INT J CANCER, V146, P1937, DOI 10.1002/ijc.32609.
   Iwasaki H, 2019, J GASTROENTEROL, V54, P1061, DOI 10.1007/s00535-019-01601-w.
   Li M, 2019, ONCOL LETT, V18, P145, DOI 10.3892/ol.2019.10304.
   Li Wang, 2019, ONCOTARGETS THER, V12, P5359, DOI 10.2147/OTT.S212465.
   Liu C, 2019, ONCOL RES, V27, P389, DOI 10.3727/096504018X15223159811838.
   Liu Z, 2018, ONCOL REP, V40, P2955, DOI 10.3892/or.2018.6695.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Martins MR, 2019, MED ONCOL, V36, DOI 10.1007/s12032-019-1305-x.
   Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s-0034-1397344.
   Newton AD, 2015, J GASTROINTEST ONCOL, V6, P534, DOI 10.3978/j.issn.2078-6891.2015.047.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Peng F, 2018, ONCOGENE, V37, P1119, DOI 10.1038/onc.2017.407.
   Peng QP, 2018, CELL MOL BIOL, V64, P62, DOI 10.14715/cmb/2017.64.15.10.
   Qian XL, 2017, ONCOTARGET, V8, P47691, DOI 10.18632/oncotarget.17868.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Roche TE, 2001, PROG NUCLEIC ACID RE, V70, P33, DOI 10.1016/S0079-6603(01)70013-X.
   Sugano K, 2015, BEST PRACT RES CL GA, V29, P895, DOI 10.1016/j.bpg.2015.09.013.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501.
   Yu JH, 2018, ONCOL REP, V40, P1959, DOI 10.3892/or.2018.6632.
   Zarich SW, 2006, REV CARDIOVASC MED, V7, pS35.
   Zheng XB, 2018, ONCOTARGET, V9, P14741, DOI {[}10.18632/oncotarget.10819, 10.18632/oncotarget.10819, DOI 10.18632/ONCOTARGET.10819].},
Number-of-Cited-References = {31},
Times-Cited = {29},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Brazilian J. Med. Biol. Res.},
Doc-Delivery-Number = {LI2WL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529344200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000536447000011,
Author = {Qin, Yu-Juan and Lin, Tao-Yan and Lin, Xiao-Lin and Liu, Yu and Zhao,
   Wen-Tao and Li, Xiao-Yan and Lian, Mei and Chen, Heng-Wei and Li,
   Yong-Long and Zhang, Xiao-Ling and Xiao, Dong and Jia, Jun-Shuang and
   Sun, Yan},
Title = {Loss of PDK4 expression promotes proliferation, tumorigenicity, motility
   and invasion of hepatocellular carcinoma cells},
Journal = {JOURNAL OF CANCER},
Year = {2020},
Volume = {11},
Number = {15},
Pages = {4397-4405},
Abstract = {Although the roles and underlying mechanisms of other PDK family members
   (i.e., PDK1, PDK2 and PDK3) in tumor progression have been extensively
   investigated and are well understood, the functions and underlying
   molecular mechanisms of pyruvate dehydrogenase kinase 4 (PDK4) in the
   tumorigenesis and progression of various cancers {[}including
   hepatocellular carcinoma (HCC)] remain largely unknown. In this study,
   we examined the expression profile of PDK4 in HCC clinical tissue
   specimens and the roles of PDK4 in the proliferation, tumorigenicity,
   motility and invasion of HCC cells. The immunohistochemistry (IHC) and
   quantitative real-time PCR (qRT-PCR) results revealed that PDK4 was
   significantly downregulated in the cohort of HCC clinical specimens.
   Additionally, PDK4 protein was found in both the nucleus and cytoplasm
   of HCC cells based on an immunofluorescence (ICC) assay, and PDK4
   protein was also found in the nucleus and cytoplasm of cancer cells
   contained in HCC clinical specimens based on IHC. The CCK-8 assay and
   cell colony formation assay demonstrated that stable depletion of
   endogenous PDK4 by lentivirus-mediated RNA interference (RNAi) markedly
   promoted the proliferation of HCC cell lines (i.e., BEL-7402 and
   BEL-7404 cells) in vitro, while PDK4 silencing significantly enhanced
   the tumorigenic ability of BEL-7404 cells in vivo. In addition to
   enhance proliferation and tumorigenesis induced by PDK4 silencing,
   additional studies demonstrated that knockdown of PDK4 led to increase
   migration and invasion of BEL-7402 and BEL-7404 cells in vitro. Taken
   together, these findings suggest that the loss of PDK4 expression
   contributes to HCC malignant progression.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Xiao, D; Jia, JS (Corresponding Author), Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangdong Prov Key Lab Canc Immunotherapy Res, Guangzhou 510515, Peoples R China.
   Xiao, D; Jia, JS (Corresponding Author), Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangzhou Key Lab Tumor Immunol Res, Guangzhou 510515, Peoples R China.
   Sun, Y (Corresponding Author), Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510080, Peoples R China.
   Xiao, D (Corresponding Author), Southern Med Univ, Inst Comparat Med, Guangzhou 510515, Peoples R China.
   Xiao, D (Corresponding Author), Southern Med Univ, Lab Anim Ctr, Guangzhou 510515, Peoples R China.
   Qin, Yu-Juan; Lin, Tao-Yan; Lin, Xiao-Lin; Xiao, Dong; Jia, Jun-Shuang, Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangdong Prov Key Lab Canc Immunotherapy Res, Guangzhou 510515, Peoples R China.
   Qin, Yu-Juan; Lin, Tao-Yan; Lin, Xiao-Lin; Xiao, Dong; Jia, Jun-Shuang, Southern Med Univ, Sch Basic Med Sci, Canc Res Inst, Guangzhou Key Lab Tumor Immunol Res, Guangzhou 510515, Peoples R China.
   Sun, Yan, Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou 510080, Peoples R China.
   Qin, Yu-Juan; Liu, Yu; Li, Xiao-Yan; Lian, Mei; Chen, Heng-Wei; Li, Yong-Long; Xiao, Dong, Southern Med Univ, Inst Comparat Med, Guangzhou 510515, Peoples R China.
   Qin, Yu-Juan; Liu, Yu; Li, Xiao-Yan; Lian, Mei; Chen, Heng-Wei; Li, Yong-Long; Xiao, Dong, Southern Med Univ, Lab Anim Ctr, Guangzhou 510515, Peoples R China.
   Qin, Yu-Juan, Sun Yat Sen Univ, Affiliated Hosp 5, Dept Radiol, Zhuhai 519000, Peoples R China.
   Lin, Tao-Yan, Southern Med Univ, Nanfang Hosp, Dept Pharm, Guangzhou 510515, Peoples R China.
   Zhao, Wen-Tao, Kunming Med Univ, Tumor Hosp Yunnan Prov, Affiliated Hosp 3, Dept Med Oncol, Kunming 650118, Yunnan, Peoples R China.
   Zhang, Xiao-Ling, Guilin Med Univ, Fac Basic Med Sci, Dept Physiol, Guilin 541004, Peoples R China.},
DOI = {10.7150/jca.43459},
ISSN = {1837-9664},
Keywords = {Hepatocellular carcinoma; Pyruvate dehydrogenase kinase 4; Cell
   proliferation; Migration; Invasion},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {Xiao\_d@hotmail.com
   Jiajsh4@126.com
   suny69@mail.sysu.edu.cn},
Affiliations = {Southern Medical University - China; Southern Medical University -
   China; Sun Yat Sen University; Southern Medical University - China;
   Southern Medical University - China; Sun Yat Sen University; Southern
   Medical University - China; Kunming Medical University; Guilin Medical
   University},
ResearcherID-Numbers = {Zhao, Wentao/JDM-7367-2023},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81872209, 81672689,
   81372896, 81172587, 81600086, 81770100, 81600488, 81870602, 81702778,
   81660485]; Natural Science Foundation of Guangdong Province of China
   {[}2014A030313294]; Science and Technology Planning Project of Guangdong
   Province of China {[}2013B060300013, 2017A010105017, 2009B060300008,
   2017A030303018, 2015A030302024]; China Postdoctoral Science Foundation
   {[}2015M572338, 2016T90792, 2017M622740, 2018T110884]; Medical
   Scientific Research Foundation of Guangdong Province of China
   {[}A2017420]},
Funding-Text = {We express our deepest gratitude to Dr. Didier Trono (University of
   Geneva, Geneva, Switzerland) for kindly providing the lentiviral
   packaging plasmids psPAX2 and pMD2.G. This work was supported by the
   National Natural Science Foundation of China (Grant No. 81872209,
   81672689, 81372896 and 81172587, to D. Xiao; Grant No. 81600086 and
   81770100, to Y. Sun; Grant No. 81600488 and 81870602, to X.-L. Lin;
   Grant No. 81702778, to J.S. Jia; Grant No. 81660485, to X.L. Zhang), the
   Natural Science Foundation of Guangdong Province of China (Grant No.
   2014A030313294 to D. Xiao), the Science and Technology Planning Project
   of Guangdong Province of China (Grant No. 2013B060300013, 2017A010105017
   and 2009B060300008, to D. Xiao; Grant No. 2017A030303018, to J.S. Jia;
   Grant No. 2015A030302024, to X.-L. Lin), the China Postdoctoral Science
   Foundation (Grant No. 2015M572338, 2016T90792, 2017M622740 and
   2018T110884, to X.-L. Lin) and the Medical Scientific Research
   Foundation of Guangdong Province of China (Grant No. A2017420, to J.S.
   Jia).},
Cited-References = {Ban D, 2018, ANN GASTROENT SURG, V2, P137, DOI 10.1002/ags3.12065.
   Blouin JM, 2011, INT J CANCER, V128, P2591, DOI 10.1002/ijc.25599.
   Brown ZJ, 2018, NATURE REV GASTROENT.
   Cheng XQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10397.
   Choiniere J, 2017, MOL PHARMACOL, V91, P189, DOI 10.1124/mol.116.106757.
   da Motta Girardi D, 2018, J GASTROINTESTINAL C.
   Gao F, 2013, BIOCHEM BIOPH RES CO, V431, P610, DOI 10.1016/j.bbrc.2012.12.097.
   Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811.
   Iñarrairaegui M, 2018, CLIN CANCER RES, V24, P1518, DOI 10.1158/1078-0432.CCR-17-0289.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38.
   Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265.
   Liu XH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09163-8.
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821.
   Morgan A, 2019, DISABIL REHABIL, V41, P2832, DOI 10.1080/09638288.2018.1480667.
   Nault JC, 2017, J HEPATOLOGY.
   Nault JC, 2018, J HEPATOL, V69, P237, DOI 10.1016/j.jhep.2018.02.016.
   Pant A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041593.
   Pfeifer GP, DEFINING DRIVER DNA.
   Raoul JL, 2018, CANCER TREAT REV, V68, P16, DOI 10.1016/j.ctrv.2018.05.006.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Sugden MC, 2003, AM J PHYSIOL-ENDOC M, V284, pE855, DOI 10.1152/ajpendo.00526.2002.
   Sun SJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.273.
   Sun Y, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-20.
   Woolbright BL, 2018, MOL CANC THERAPEUTIC.
   Wu J, 2018, HEPATOLOGY BALTIMORE.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.},
Number-of-Cited-References = {29},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {J. Cancer},
Doc-Delivery-Number = {LS5TT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000536447000011},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000538724800001,
Author = {Su, Pengyu and Ahmad, Bashir and Zou, Kun and Zou, Lijuan},
Title = {β-Elemene Enhances the Chemotherapeutic Effect of 5-Fluorouracil in
   Triple-Negative Breast Cancer via PI3K/AKT, RAF-MEK-ErK, and NF-κB
   Signaling Pathways},
Journal = {ONCOTARGETS AND THERAPY},
Year = {2020},
Volume = {13},
Pages = {5207-5222},
Abstract = {Background: The most common chemotherapeutic drug for triple-negative
   breast cancer (TNBC) treatment is 5-fluorouracil (5-FU), but its
   therapeutic index is low due to its toxicity. beta-Elemene (ELE)
   possesses antitumor activity against different cancers, but it has never
   been used in combination with 5-FU to improve its chemotherapeutic
   effect against TNBC.
   Materials and Methods: We treated MDA-MB-231 and BT549 cells of TNBC
   with ELE alone, 5-FU alone, or their combination to investigate their
   treatment effects on cell viability, proliferation, migration, invasion,
   and colony formation. We verified the molecular mechanisms of our
   results through confocal immunofluorescence, immunohistochemistry, and
   Western blot analysis in vitro and in vivo.
   Results: Our result revealed that ELE enhanced the 5-FU effect against
   cell viability, proliferation, migration, invasion, and colony formation
   through different mechanisms in MDA-MB-231 and BT549 cell lines. In
   molecular mechanisms, ELE and 5-FU in combination enhances apoptosis in
   both cell lines through Bl-2 family protein and caspase cascade
   modulation, thereby inhibiting NF-kB pathway through IKK beta, IKK
   alpha, and p65 downregulation in the cytoplasm and p50 and p65
   downregulation in the nucleus. ELE and 5-FU in combination regulated the
   PI3K/AKT pathway through p-AKT, P-85, p110r, p-PDK1, and p110a protein
   and RAF-MEK-ERK pathway inhibition through the p-c-raf and p-ERK
   downregulation. The PI3K inhibitor LY294002 or RAF-MEK-ERK inhibitor
   U0126 in combination with ELE and 5-FU decreased cell viability in both
   cell lines significantly, thereby showing the involvement of these
   pathways in cell apoptosis. In mouse xenograft model, ELE and 5-FU in
   combination inhibited the tumor growth and modulated its molecular
   markers.
   Conclusion: The conclusion obtained, considering that the results
   suggest that the combination may be important specifically in the
   treatment of TNBC.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Article},
Language = {English},
Affiliation = {Zou, K; Zou, LJ (Corresponding Author), Dalian Med Univ, Affiliated Hosp 2, Dalian 116044, Peoples R China.
   Su, Pengyu; Zou, Kun; Zou, Lijuan, Dalian Med Univ, Affiliated Hosp 2, Dalian 116044, Peoples R China.
   Ahmad, Bashir, Dalian Med Univ, Coll Basic Med Sci, Dalian, Peoples R China.},
DOI = {10.2147/OTT.S242820},
ISSN = {1178-6930},
Keywords = {5-fluorouracil; 5-FU; beta-elemene; triple-negative breast cancer;
   PI3K/AKT; NF-kB; COX2},
Keywords-Plus = {COMBINATION CHEMOTHERAPY; ANTICANCER PROPERTIES; MULTIDRUG-RESISTANCE;
   MOLECULAR PORTRAITS; CARNOSIC ACID; CELL-LINE; IN-VITRO; APOPTOSIS;
   INHIBITION; INFLAMMATION},
Research-Areas = {Biotechnology \& Applied Microbiology; Oncology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Oncology},
Author-Email = {zoukun29@163.com
   zoulijuan1963@sina.com},
Affiliations = {Dalian Medical University; Dalian Medical University},
ResearcherID-Numbers = {Ahmad, Bashir/ABE-7592-2020},
ORCID-Numbers = {Zou, Lijuan/0000-0003-0619-3213
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81703904 KZ, 81473452
   LZ]},
Funding-Text = {This work was funded by the National Natural Science Foundation of China
   (grant nos. 81703904 KZ and 81473452 LZ).},
Cited-References = {Abraha AM, 2016, WORLD J GASTRO ONCOL, V8, P583, DOI 10.4251/wjgo.v8.i8.583.
   Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275.
   Brown GT, 2015, J PATHOL, V237, P273, DOI 10.1002/path.4586.
   CANELLOS GP, 1974, BRIT MED J, V1, P218, DOI 10.1136/bmj.1.5901.218.
   Chang TH, 2010, PLANT CELL, V22, P454, DOI 10.1105/tpc.109.071738.
   Chen XX, 2017, FOOD CHEM TOXICOL, V110, P49, DOI 10.1016/j.fct.2017.10.017.
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022.
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641.
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983.
   Ding XF, 2013, ONCOL LETT, V5, P1554, DOI 10.3892/ol.2013.1213.
   Edris AE, 2009, CURR CLIN PHARMACOL, V4, P43, DOI 10.2174/157488409787236137.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Gao Y, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12380.
   Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182.
   Guan XM, 2015, ACTA PHARM SIN B, V5, P402, DOI 10.1016/j.apsb.2015.07.005.
   Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943.
   Kamalakannan V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003675.
   Khan M, 2012, INT J BIOL SCI, V8, P533, DOI 10.7150/ijbs.3753.
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412.
   Li PH, 2017, MED SCI MONITOR, V23, P809, DOI 10.12659/MSM.903197.
   Li QQ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0488-9.
   Li QQ, 2013, ANTICANCER RES, V33, P65.
   Lien GS, 2016, EUR J PHARMACOL, V776, P124, DOI 10.1016/j.ejphar.2016.02.044.
   Liu JM, 2008, ADV THER, V25, P389, DOI 10.1007/s12325-008-0050-x.
   Liu J, 2012, J PHARM PHARMACOL, V64, P146, DOI 10.1111/j.2042-7158.2011.01371.x.
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183.
   Liu MN, 2015, ONCOL LETT, V10, P3682, DOI 10.3892/ol.2015.3801.
   Liu Y, 2017, BIOMED PHARMACOTHER, V93, P490, DOI 10.1016/j.biopha.2017.06.073.
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074.
   Lu JJ, 2012, J ETHNOPHARMACOL, V143, P406, DOI 10.1016/j.jep.2012.07.009.
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205.
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261.
   Maryam A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06535-y.
   Misra S, 2014, CURR DRUG TARGETS, V15, P347, DOI 10.2174/1389450115666140127102915.
   MUSS HB, 1977, ARCH INTERN MED, V137, P1711, DOI 10.1001/archinte.137.12.1711.
   Negroni A, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/250762.
   Patra S, 2016, INT IMMUNOPHARMACOL, V34, P199, DOI 10.1016/j.intimp.2016.02.027.
   Pengyu S, 2018, N AM J ACAD RES, V1, P27.
   Perdiki M, 2007, MOL CELL BIOCHEM, V295, P75, DOI 10.1007/s11010-006-9275-7.
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093.
   Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805.
   SEGALOFF A, 1985, BREAST CANCER RES TR, V5, P311, DOI 10.1007/BF01806026.
   Seyfried TN, 2015, CANCER LETT, V356, P289, DOI 10.1016/j.canlet.2014.07.015.
   Shao Hua-Min, 2010, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V18, P296.
   Shi XJ, 2014, ASIAN PAC J CANCER P, V15, P2785, DOI 10.7314/APJCP.2014.15.6.2785.
   Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296.
   Tang B, 2016, INT J NANOMED, V11, P6401, DOI 10.2147/IJN.S101285.
   Tao L, 2006, CANCER CHEMOTH PHARM, V58, P24, DOI 10.1007/s00280-005-0137-x.
   Todoric J, 2016, CANCER PREV RES, V9, P895, DOI 10.1158/1940-6207.CAPR-16-0209.
   Tornatore L, 2012, TRENDS CELL BIOL, V22, P557, DOI 10.1016/j.tcb.2012.08.001.
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262.
   Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518.
   Wang G, 2005, CELL MOL LIFE SCI, V62, P881, DOI 10.1007/s00018-005-5017-3.
   Wang J, 2014, MOL MED REP, V10, P2535, DOI 10.3892/mmr.2014.2539.
   Wang R, 2012, CHIN J INTEGR MED, V18, P934, DOI 10.1007/s11655-012-1297-z.
   Xia S, 2010, CANCER BIOTHER RADIO, V25, P317, DOI 10.1089/cbr.2009.0707.
   Xu HB, 2012, PHARMACOLOGY, V89, P303, DOI 10.1159/000337178.
   Yi XL, 2019, THERANOSTICS, V9, P1614, DOI 10.7150/thno.30398.
   Zhan YH, 2012, ASIAN PAC J CANCER P, V13, P2739, DOI 10.7314/APJCP.2012.13.6.2739.
   Zhang J, 2015, CELL PHYSIOL BIOCHEM, V36, P2274, DOI 10.1159/000430191.
   Zhang Y, 2013, INT J MOL SCI, V14, P10075, DOI 10.3390/ijms140510075.
   Zhang Y, 2017, MOL MED REP, V16, P794, DOI 10.3892/mmr.2017.6638.
   Zhao J, 2007, INT J ONCOL, V31, P241.
   Zheng Cui-Ping, 2009, Zhonghua Xue Ye Xue Za Zhi, V30, P821.
   Zhu L, 2014, CANCER LETT, V354, P355, DOI 10.1016/j.canlet.2014.08.038.
   Zong S, 2019, J CELL PHYSIOL, V234, P15548, DOI 10.1002/jcp.28202.},
Number-of-Cited-References = {66},
Times-Cited = {36},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {28},
Journal-ISO = {OncoTargets Ther.},
Doc-Delivery-Number = {LV8XA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000538724800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000522397800003,
Author = {Wang, H. and Zhao, W. and Tian, Q-J and Xin, L. and Cui, M. and Li, Y-K},
Title = {Effect of lncRNA AK023948 on rats with postmenopausal osteoporosis
   via PI3K/AKT signaling pathway},
Journal = {EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES},
Year = {2020},
Volume = {24},
Number = {5},
Pages = {2181-2188},
Abstract = {OBJECTIVE: To investigate the effect of long non-coding ribonucleic acid
   (lncRNA) AK023948 (AK0) on rats with postmenopausal osteoporosis via the
   phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway.
   MATERIALS AND METHODS: Firstly, postmenopausal osteoporosis rat models
   were established to obtain osteoblasts. The phosphorylation level of AKT
   was analyzed by controlling the expression of AK0 gene in osteoblasts.
   Finally, XTT was used to analyze the proliferation of osteoblasts and
   the messenger ribonucleic acid (mRNA) expression level of caspase in AK0
   gene knockout (KO) rat model.
   RESULTS: In the bone tissue of postmenopausal osteoporosis rats, the
   levels of phospho-PI3K (p-PI3K), p-Akt, and p-phosphoinositide-dependent
   kinase-1(PDK1) were significantly decreased (p<0.05). In rat model
   osteoblasts, the overexpression of AK0 gene upregulated the
   phosphorylation level of AKT, while the interference with small
   interfering RNA (siRNA) in AK0 gene decreased that of AKT. Knocking out
   AK0 gene led to the down-regulation of phosphorylation level of AKT in
   cells. Moreover, if the AKO gene was re-expressed in the KO rat model
   cells, the phosphorylation level of AKT was restored to a certain
   extent, but still lower than that after the overexpression of AK0 gene.
   Although the proliferation rate of osteoblasts in estrogen
   deficiency-related osteoporosis rats was low, the growth rate of
   osteoblasts with AK0 KO was remarkably lower than that in blank control
   group (p<0.05). It was also found that there was a certain correlation
   between AK0 gene and osteoblast apoptosis.
   CONCLUSIONS: LncRNA AK0 can regulate the phosphorylation level of AKT in
   osteoblasts of rats with estrogen deficiency-related osteoporosis
   through the PI3K/AKT signaling pathway, thus regulating the
   proliferation of osteoblasts. It is speculated that lncRNA AK0 may be an
   important factor in regulating the PI3K/AKT signaling pathway.},
Publisher = {VERDUCI PUBLISHER},
Address = {VIA GREGORIO VII, ROME, 186-00165, ITALY},
Type = {Article},
Language = {English},
Affiliation = {Li, YK (Corresponding Author), 4 Hosp Jinan Shangdong, Dept Orthoped, Jinan, Peoples R China.
   Wang, H.; Xin, L.; Cui, M., Jinan Tradit Chinese Med Hosp, Dept Orthoped, Jinan, Peoples R China.
   Zhao, W.; Tian, Q-J; Li, Y-K, 4 Hosp Jinan Shangdong, Dept Orthoped, Jinan, Peoples R China.},
DOI = {10.26355/eurrev\_202003\_20483},
ISSN = {1128-3602},
Keywords = {LncRNA; AK023948 gene; PI3K/AKT signaling pathway; Postmenopausal
   osteoporosis},
Keywords-Plus = {OSTEOCLASTOGENESIS},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {28981612@qq.com},
Cited-References = {Abdelazim IA, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657-014-0189-9.
   Ballantyne MD, 2016, CLIN PHARMACOL THER, V99, P494, DOI 10.1002/cpt.355.
   Banhidy NF, 2017, NEW ENGL J MED, V376, P395.
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724.
   Botti G, 2017, CURR DRUG TARGETS, V18, P27, DOI 10.2174/1389450117666151209122950.
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14-2-187.
   Gosch M, 2014, PANMINERVA MED, V56, P133.
   Jiang H, 2016, GENE, V593, P131, DOI 10.1016/j.gene.2016.08.012.
   Koirala P, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14422.
   Li Z, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12404.
   Luo Q, 2016, CLIN INTERV AGING, V11, P867, DOI 10.2147/CIA.S107037.
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856.
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647.
   Yamashita A, 2016, BBA-GENE REGUL MECH, V1859, P147, DOI 10.1016/j.bbagrm.2015.08.003.
   Yuan FL, 2015, BONE, V75, P128, DOI 10.1016/j.bone.2015.02.017.
   Zhang JF, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368-019-0046-1.
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010.
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205.
   Zhou RB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161254.},
Number-of-Cited-References = {19},
Times-Cited = {14},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Eur. Rev. Med. Pharmacol. Sci.},
Doc-Delivery-Number = {KY2JG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000522397800003},
DA = {2026-02-04},
}

@article{ WOS:000510740500097,
Author = {Wang, Jinming and Xu, Huimiao and Cheng, Xiaofang and Yang, Jiarong and
   Yan, Zipeng and Ma, Haili and Zhao, Yangfei and Ommati, Mohammad Mehdi
   and Manthari, Ram Kumar and Wang, Jundong},
Title = {Calcium relieves fluoride-induced bone damage through the PI3K/AKT
   pathway},
Journal = {FOOD \& FUNCTION},
Year = {2020},
Volume = {11},
Number = {1},
Pages = {1155-1164},
Month = {JAN 1},
Abstract = {Bone is the main target of fluorosis, and it has been perfectly
   elaborated that a moderate dosage of calcium (Ca) can alleviate bone
   fluorosis. However, whether Ca can alleviate fluorosis through the
   phosphatidylinositol 3 kinase (PI3K)/protein kinase B (AKT) signaling
   pathway has not yet been reported. Hence, we evaluated the
   histopathological structure, the imbalance of the biochemical index of
   bone metabolism, and the expression levels of PI3K/AKT apoptosis
   signaling pathway-related genes in rats treated with sodium fluoride
   (NaF, F) and/or calcium carbonate (CaCO3) for 120 days. Our results
   suggest that 100 mg L-1 NaF induced histopathological injury as alkaline
   phosphatase (ALP) and tartrate-resistant acid phosphatase (StrACP)
   activity increased, with a decrease in the serum Ca levels (p < 0.05).
   Moreover, the results of qRT-PCR and western blotting showed that F
   increased the expression levels of transglutaminase 2 (TGM2), focal
   adhesion kinase (FAK), PI3K, AKT, forkhead box O1 (Foxo1), Bcl-2
   interacting mediator of cell death (BIM), Bcl2-associated x protein
   (Bax) and Caspase 3 (p < 0.05, p < 0.01). It also decreased the
   expression of AnnexinA5 (Anxa5), 3 `-phosphoinositide-dependent kinase 1
   (PDK1) and B-cell lymphoma-2 (Bcl-2) (p < 0.05, p < 0.01), which finally
   activated the PI3K/AKT pathway. On the other hand, CaCO3 supplementation
   reversed the histopathological injury along with the levels of ALP,
   StrACP and serum Ca, alleviating the gene expression levels of PI3K/AKT
   pathway-related markers. Altogether, we can conclude that CaCO3
   supplementation mitigated F-induced bone damage via the PI3K/AKT
   signaling pathway.},
Publisher = {ROYAL SOC CHEMISTRY},
Address = {THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, JM; Wang, JD (Corresponding Author), Shanxi Agr Univ, Coll Anim Sci \& Vet Med, Taigu 030801, Shanxi, Peoples R China.
   Wang, JM; Wang, JD (Corresponding Author), Shanxi Agr Univ, Shanxi Key Lab Environm Vet Med, Taigu 030801, Shanxi, Peoples R China.
   Wang, Jinming; Xu, Huimiao; Yang, Jiarong; Yan, Zipeng; Ma, Haili; Zhao, Yangfei; Manthari, Ram Kumar; Wang, Jundong, Shanxi Agr Univ, Coll Anim Sci \& Vet Med, Taigu 030801, Shanxi, Peoples R China.
   Wang, Jinming; Xu, Huimiao; Yang, Jiarong; Yan, Zipeng; Ma, Haili; Zhao, Yangfei; Manthari, Ram Kumar; Wang, Jundong, Shanxi Agr Univ, Shanxi Key Lab Environm Vet Med, Taigu 030801, Shanxi, Peoples R China.
   Cheng, Xiaofang, Shanxi Agr Univ, Coll Arts \& Sci, Taigu 030801, Shanxi, Peoples R China.
   Ommati, Mohammad Mehdi, Shanxi Agr Univ, Coll Life Sci, Taigu 030801, Shanxi, Peoples R China.},
DOI = {10.1039/c9fo02491c},
ISSN = {2042-6496},
EISSN = {2042-650X},
Keywords-Plus = {ENDOPLASMIC-RETICULUM STRESS; ANNEXIN A5 EXPRESSION; TISSUE
   TRANSGLUTAMINASE; LEUKEMIA-CELLS; APOPTOSIS; INHIBITION; MECHANISMS;
   PROTEINS; BCL-2},
Research-Areas = {Biochemistry \& Molecular Biology; Food Science \& Technology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Food Science \& Technology},
Author-Email = {jm50408@163.com
   wangjd53@outlook.com},
Affiliations = {Shanxi Agricultural University; Shanxi Agricultural University; Shanxi
   Agricultural University; Shanxi Agricultural University},
ResearcherID-Numbers = {Ommati, Mohammad Mehdi/AAQ-7091-2020
   Manthari, Ram Kumar/AAN-8218-2021},
ORCID-Numbers = {Ommati, Mohammad Mehdi/0000-0003-0514-2414
   Manthari, Ram Kumar/0000-0002-1294-9788},
Funding-Acknowledgement = {China National Natural Science Foundation {[}31972751]; Shanxi Province
   Excellent Doctoral Work Reward Fund {[}SXYBKY201731]; Shanxi Province
   innovation project for graduate students {[}2019SY219]},
Funding-Text = {This research was supported by the China National Natural Science
   Foundation (Grant No. 31972751), Shanxi Province Excellent Doctoral Work
   Reward Fund (Grant No. SXYBKY201731), Shanxi Province innovation project
   for graduate students (Grant No. 2019SY219).},
Cited-References = {Akimov SS, 2001, BLOOD, V98, P1567, DOI 10.1182/blood.V98.5.1567.
   Amit V., 2006, CANCER RES, V66, P10525.
   Battiprolu PK, 2012, J CLIN INVEST, V122, P1109, DOI 10.1172/JCI60329.
   Bin F., 2015, INT J CLIN EXP PATHO, V8, P1226.
   Eckert RL, 2014, PHYSIOL REV, V94, P383, DOI 10.1152/physrev.00019.2013.
   Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5.
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001.
   Haworth Charles S, 2004, J Cyst Fibros, V3, P233, DOI 10.1016/j.jcf.2004.08.002.
   Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324.
   Hu CJ, 2015, ONCOL REP, V33, P3146, DOI 10.3892/or.2015.3896.
   Jha SK, 2011, REV ENVIRON CONTAM T, V211, P121, DOI 10.1007/978-1-4419-8011-3\_4.
   Ji CX, 2018, J NEURO-ONCOL, V138, P469, DOI 10.1007/s11060-018-2818-4.
   Jiménez-Córdova MI, 2018, TOXICOL APPL PHARM, V352, P97, DOI 10.1016/j.taap.2018.05.027.
   Jyotsana M., 2009, TROP ANIM HLTH PROD, V41, P295.
   Li DY, 2017, ONCOL LETT, V13, P2607, DOI 10.3892/ol.2017.5761.
   Li JD, 2018, BIOL TRACE ELEM RES, V181, P104, DOI 10.1007/s12011-017-1015-1.
   Li LJ, 2018, MOL MED REP, V17, P7886, DOI 10.3892/mmr.2018.8840.
   Li Xin-lei, 2019, Journal of Ecology and Rural Environment, V35, P63, DOI 10.19741/j.issn.1673-4831.2018.0236.
   Liu Y, 2019, J AGR FOOD CHEM, V67, P5240, DOI 10.1021/acs.jafc.9b01114.
   Lou DD, 2014, FLUORIDE, V47, P199.
   Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071.
   Mishra S, 2007, J BIOL CHEM, V282, P18108, DOI 10.1074/jbc.M607413200.
   Mohammadi AA, 2017, DATA BRIEF, V13, P312, DOI 10.1016/j.dib.2017.05.045.
   Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890.
   Park N, 2014, J TOXICOL ENV HEAL A, V77, P1467, DOI 10.1080/15287394.2014.955834.
   Sebastian Shibu Thomas, 2016, Indian J Dent Res, V27, P151, DOI {[}10.4103/0970-9290.183126, 10.4103/0970-9290.183126].
   Shi ZY, 2016, BIOL TRACE ELEM RES, V173, P333, DOI 10.1007/s12011-016-0656-9.
   Shin DW, 2017, BIOMOL THER, V25, P177, DOI 10.4062/biomolther.2016.223.
   Song Yu-e, 2011, Environmental Health and Preventive Medicine, V16, P158, DOI 10.1007/s12199-010-0181-y.
   Susana R., 2010, CARDIOVASC RES, V88, P304.
   Tanaka K, 2007, MATRIX BIOL, V26, P409, DOI 10.1016/j.matbio.2007.04.005.
   Tang JY, 2017, INT J ONCOL, V50, P1839, DOI 10.3892/ijo.2017.3942.
   Tatsukawa H, 2009, GASTROENTEROLOGY, V136, P1783, DOI 10.1053/j.gastro.2009.01.007.
   tenCate JM, 1997, EUR J ORAL SCI, V105, P461.
   Wang HW, 2009, ENVIRON TOXICOL, V24, P218, DOI 10.1002/tox.20421.
   Wang J, 2013, APOPTOSIS, V18, P751, DOI 10.1007/s10495-013-0820-z.
   Wang JM, 2019, J AGR FOOD CHEM, V67, P10832, DOI 10.1021/acs.jafc.9b04295.
   Wang JM, 2019, J AGR FOOD CHEM, V67, P10285, DOI 10.1021/acs.jafc.9b03835.
   Wei Y, 2018, TOXICOL LETT, V291, P39, DOI 10.1016/j.toxlet.2018.04.006.
   Wu ZY, 2017, J CARDIOVASC PHARM, V70, P184, DOI 10.1097/FJC.0000000000000504.
   Xu J, 2018, ONCOL REP, V40, P3469, DOI 10.3892/or.2018.6718.
   Yan XY, 2015, CHEMOSPHERE, V128, P36, DOI 10.1016/j.chemosphere.2014.12.090.
   Yang SY, 2011, BIOCHEM BIOPH RES CO, V410, P910, DOI 10.1016/j.bbrc.2011.06.094.
   Yang X, 2019, ENVIRON POLLUT, V251, P372, DOI 10.1016/j.envpol.2019.05.023.
   Zhang JH, 2017, BIOL TRACE ELEM RES, V175, P156, DOI 10.1007/s12011-016-0753-9.
   Zhang Y, 2016, ARCH ORAL BIOL, V69, P95, DOI 10.1016/j.archoralbio.2016.05.015.
   Zhou BH, 2018, CHEMOSPHERE, V199, P297, DOI 10.1016/j.chemosphere.2018.02.057.
   Zhu FQ, 2018, EXP THER MED, V16, P192, DOI 10.3892/etm.2018.6141.
   {[}朱志坚 Zhu Zhijian], 2015, {[}中国公共卫生, China Journal of Public Health], V31, P574.
   Zita B., 2002, J BIOL CHEM, V277, P16567.},
Number-of-Cited-References = {50},
Times-Cited = {32},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Food Funct.},
Doc-Delivery-Number = {KH6DK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000510740500097},
DA = {2026-02-04},
}

@article{ WOS:000519666300004,
Author = {Wang, Pengzhen and Xiong, Xifeng and Zhang, Jinli and Qin, Shengnan and
   Wang, Wen and Liu, Zhihe},
Title = {Icariin increases chondrocyte vitality by promoting hypoxia-inducible
   factor-1α expression and anaerobic glycolysis},
Journal = {KNEE},
Year = {2020},
Volume = {27},
Number = {1},
Pages = {18-25},
Month = {JAN},
Abstract = {Background: Articular cartilage is a unique avascular tissue in which
   chondrocytes are embedded in extracellular matrix (ECM). The decreased
   ECM resulting from the loss of articular chondrocyte viability leads to
   degenerative diseases such as osteoarthritis (OA). This study aims to
   investigate the effect of icariin (ICA) on ECM synthesis and chondrocyte
   viability.
   Methods: Micromass culture, alcian blue, and Safran O (SO)/fast green
   staining were used to investigate chondrocyte viability and ECM
   synthesis in chondrocytes treated with ICA. The expression of
   hypoxia-inducible factor-1 alpha (HIF-1 alpha), SOX9, and anaerobic
   glycolysis enzymes were detected by western blot and reverse
   transcription-quantitative polymerase chain reaction.
   Results: ICA, an active flavonoid component of Herba epimedii, was
   demonstrated to increase chondrocyte viability and ECM synthesis. HIF-1
   alpha is a key mediator of chondrocyte response to fluctuations in
   oxygen availability during cartilage development or damage, and its
   expression was unregulated by ICA treatment. Meanwhile, ICA treatment
   increased SOX9 expression, which is a key regulator of ECM synthesis.
   Furthermore, ICA treatment increased the expression of glucose
   transporter 1 (GLUT1), glucose-6-phosphate dehydrogenase (G6PD),
   phosphoglycerate kinase 1 (PCK1), and pyruvate dehydrogenase kinase 1
   (PDK1), which contribute to glucose transfer and anaerobic glycolysis.
   Conclusions: The present study revealed that ICA treatment facilitates
   chondrocyte vitality by promoting HIF-1 alpha expression and anaerobic
   glycolysis. Therefore, ICA could be a novel clinical treatment for OA.
   (C) 2019 Elsevier B.V. All rights reserved.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Wang, W; Liu, ZH (Corresponding Author), Jinan Univ, Guangzhou Red Cross Hosp, Med Coll, 396 Tongfu Zhong Rd, Guangzhou 510220, Guangdong, Peoples R China.
   Wang, Pengzhen; Xiong, Xifeng; Zhang, Jinli; Qin, Shengnan; Liu, Zhihe, Jinan Univ, Guangzhou Red Cross Hosp, Med Coll, Guangzhou Inst Traumat Surg, Guangzhou, Guangdong, Peoples R China.
   Wang, Wen, Jinan Univ, Guangzhou Red Cross Hosp, Med Coll, Dept Orthopaed, Guangzhou, Guangdong, Peoples R China.},
DOI = {10.1016/j.knee.2019.09.012},
ISSN = {0968-0160},
EISSN = {1873-5800},
Keywords = {Icariin (ICA); Articular chondrocyte; Extracellular matrix (ECM);
   Hypoxia-inducible factor-1 alpha (HIF-1 alpha); Anaerobic glycolysis},
Keywords-Plus = {GENE-EXPRESSION; CARTILAGE; OSTEOARTHRITIS; METABOLISM; ACTIVATION},
Research-Areas = {Orthopedics; Sport Sciences; Surgery},
Web-of-Science-Categories  = {Orthopedics; Sport Sciences; Surgery},
Author-Email = {wangwarren88@hotmail.com
   zliu0731@163.com},
Affiliations = {Jinan University; Jinan University},
ResearcherID-Numbers = {xiong, xifeng/JCN-5469-2023
   },
ORCID-Numbers = {xiong, xifeng/0000-0003-3257-0879
   Qin, Shengnan/0000-0003-1307-0481},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81272222]; Traditional
   Chinese Medicine Bureau of Guangdong Province {[}20181206]; Guangzhou
   Science and Technology Program key projects {[}201704020145]; Guangzhou
   Municipal Health and Family Planning Commission {[}20192A010009];
   Medical Science and Technology Foundation of Guangdong Province
   {[}B2016018, A2018063]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (grant no. 81272222, to Z.L), the research grants of Traditional
   Chinese Medicine Bureau of Guangdong Province (grant no. 20181206 to
   Z.L), Guangzhou Science and Technology Program key projects (grant no.
   201704020145, to W.W.), the research grants of Guangzhou Municipal
   Health and Family Planning Commission (grant no. 20192A010009 to P.W.)
   and the Medical Science and Technology Foundation of Guangdong Province
   (grant nos. B2016018 and A2018063, to X.X.).},
Cited-References = {Bentovim L, 2012, DEVELOPMENT, V139, P4473, DOI 10.1242/dev.083881.
   Bonnet CS, 2005, RHEUMATOLOGY, V44, P7, DOI 10.1093/rheumatology/keh344.
   Bracken CP, 2003, CELL MOL LIFE SCI, V60, P1376, DOI 10.1007/s00018-003-2370-y.
   Chen W, 2004, ENDOCRINOLOGY, V145, P627, DOI 10.1210/en.2003-1274.
   Choi H, 2010, CANCER RES, V70, P10101, DOI 10.1158/0008-5472.CAN-10-0505.
   Corredor M, 2016, BIOPHYS J, V110, P1291, DOI 10.1016/j.bpj.2016.01.033.
   Courtnay R, 2015, MOL BIOL REP, V42, P841, DOI 10.1007/s11033-015-3858-x.
   Eltawil NM, 2009, OSTEOARTHR CARTILAGE, V17, P695, DOI 10.1016/j.joca.2008.11.003.
   Emery CA, 2015, BRIT J SPORT MED, V49, P865, DOI 10.1136/bjsports-2015-094639.
   Fan HB, 2010, J BIOMED MATER RES A, V95A, P982, DOI 10.1002/jbm.a.32899.
   Idelevich A, 2011, ARTERIOSCL THROM VAS, V31, pE55, DOI 10.1161/ATVBAHA.111.230904.
   Kumar D, 2009, MOL CELL BIOL, V29, P4262, DOI 10.1128/MCB.01779-08.
   Laverty S, 2010, OSTEOARTHR CARTILAGE, V18, pS53, DOI 10.1016/j.joca.2010.05.029.
   Lee RB, 1997, BIOCHEM J, V321, P95, DOI 10.1042/bj3210095.
   Li TF, 2006, J BIOL CHEM, V281, P21296, DOI 10.1074/jbc.M600514200.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Luyten FP, 2009, BONE, V44, P522, DOI 10.1016/j.bone.2008.12.006.
   Peansukmanee S, 2009, J ORTHOP RES, V27, P529, DOI 10.1002/jor.20772.
   Pritchett J, 2011, TRENDS MOL MED, V17, P166, DOI 10.1016/j.molmed.2010.12.001.
   Saito T, 2010, OSTEOARTHR CARTILAGE, V18, P1552, DOI 10.1016/j.joca.2010.10.006.
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048.
   Tang HY, 2015, ANTIOXID REDOX SIGN, V22, P744, DOI 10.1089/ars.2014.6142.
   van der Kraan PM, 2012, CELL TISSUE RES, V347, P257, DOI 10.1007/s00441-011-1194-6.
   Wang PZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148372.
   Wang ZC, 2014, EXP THER MED, V8, P1528, DOI 10.3892/etm.2014.1950.
   Yang HS, 2011, TISSUE ENG PT A, V17, P1809, DOI 10.1089/ten.tea.2010.0540.
   Yang LJ, 2015, CELL BIOCHEM BIOPHYS, V71, P1379, DOI 10.1007/s12013-014-0360-3.
   Yao D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041264.
   Zhou JM, 2011, INT IMMUNOPHARMACOL, V11, P890, DOI 10.1016/j.intimp.2011.01.007.},
Number-of-Cited-References = {29},
Times-Cited = {38},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {28},
Journal-ISO = {Knee},
Doc-Delivery-Number = {KU4FV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000519666300004},
DA = {2026-02-04},
}

@article{ WOS:000529142800001,
Author = {Wang, Yao and Zhang, Duo and Li, Yao and Fang, Fang},
Title = {MiR-138 Suppresses the PDK1 Expression to Decrease the Oxaliplatin
   Resistance of Colorectal Cancer},
Journal = {ONCOTARGETS AND THERAPY},
Year = {2020},
Volume = {13},
Pages = {3607-3618},
Abstract = {Background: Oxaliplatin is one kind of platinum-based drug. It is
   effective and commonly used in the treatment of colorectal cancer (CRC).
   However, development of acquired drug resistance is still a big obstacle
   during the oxaliplatin therapy. It is urgent to take strategies to
   decrease the oxaliplatin resistance of CRC.
   Materials and Methods: Oxaliplatin-resistant HT29 and SW480 (HT29/R and
   SW480/R) cells were acquired through long-term exposure to oxaliplatin
   by using the routine HT29 and SW480 cells. Relative glucose consumption,
   lactate generation and LDH activity were tested to evaluate the
   glycolysis of CRC cell lines. MTT assays were conducted to evaluate the
   differences of oxaliplatin sensitivity between HT29/R (SW480/R) cells
   and their parental HT29 (SW480) cells. Regulation of miR-138 on PDK1 was
   confirmed through qRT-PCR, Western blot and dual-luciferase reporter
   assays. Reactive oxygen species (ROS) levels were measured by flow
   cytometry.
   Results: HT29/R and SW480/R cells exhibited higher glucose consumption,
   lactate production and LDH activity compared to their parental HT29 and
   SW480 cells. However, oxygen consumption rate (OCR) in HT29/R and
   SW480/R cells is lower than that in HT29 and SW480 cells, respectively.
   Results of MTT assays showed that treatment with miR-138 can increase
   the cytotoxicity of oxaliplatin to HT29/R and SW480/R cells. Research on
   mechanisms showed that PDK1 was the target of miR-138. Overexpression of
   miR-138 can inhibit the expression of PDK1, and thus increase the OCR of
   HT29/R and SW480/R cells. Under the treatment of oxaliplatin, the
   miR-138-overexpressed HT29/R and SW480/R cells generated more amount of
   ROS to get into the apoptosis process.
   Conclusion: Overexpression of miR-138 suppressed the PDK1 expression to
   decrease the oxaliplatin resistance of CRC.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Article},
Language = {English},
Affiliation = {Fang, F (Corresponding Author), 5 Jilin St, Jilin 132013, Jilin, Peoples R China.
   Wang, Yao; Zhang, Duo; Li, Yao; Fang, Fang, Jilin Med Univ, Inspect Inst, Jilin, Jilin, Peoples R China.},
DOI = {10.2147/OTT.S242929},
ISSN = {1178-6930},
Keywords = {miR-138; oxaliplatin; colorectal cancer; PDK1},
Keywords-Plus = {CISPLATIN SENSITIVITY; APOPTOSIS; CELLS; CARCINOMA; ROS;
   DICHLOROACETATE; PROLIFERATION; CHEMOTHERAPY; KNOCKDOWN; MICRORNAS},
Research-Areas = {Biotechnology \& Applied Microbiology; Oncology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology; Oncology},
Author-Email = {fangfangmed@126.com},
Affiliations = {Jilin Medical University},
Funding-Acknowledgement = {Natural Scientific Foundation of China {[}81202031]; Scientific Research
   Project of Jilin Province Science and Technology Department
   {[}20160204033YY]; Technical Innovation Project of Jilin Province Health
   Department {[}2016J100]},
Funding-Text = {This study is supported by the Natural Scientific Foundation of China
   (grant no. 81202031); the Scientific Research Project of Jilin Province
   Science and Technology Department (grant no. 20160204033YY); the
   Technical Innovation Project of Jilin Province Health Department (grant
   no. 2016J100).},
Cited-References = {Balacescu O, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123711.
   Cao PH, 2019, INT J BIOL SCI, V15, P1676, DOI 10.7150/ijbs.35265.
   Chambers Kari T, 2011, J Biol Chem, V286, P11155, DOI 10.1074/jbc.M110.217349.
   Ciombor KK, 2015, ANNU REV MED, V66, P83, DOI 10.1146/annurev-med-051513-102539.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840.
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290.
   Gao Y, 2014, BIOCHEM BIOPH RES CO, V446, P179, DOI 10.1016/j.bbrc.2014.02.073.
   Golubovskaya VM, 2014, ANTI-CANCER AGENT ME, V14, P18, DOI 10.2174/187152061401140108113435.
   Halasi M, 2013, BIOCHEM J, V454, P201, DOI 10.1042/BJ20130282.
   Hong SW, 2011, CANCER BIOL THER, V12, P421, DOI 10.4161/cbt.12.5.15972.
   Hsu HH, 2019, CANCERS, V11, DOI 10.3390/cancers11101576.
   Hsu HH, 2018, J CELL PHYSIOL, V233, P5458, DOI 10.1002/jcp.26406.
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107.
   Jia GQ, 2019, AM J TRANSL RES, V11, P2181.
   Li LS, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-163.
   Liang T, 2014, INT J MOL SCI, V15, P15754, DOI 10.3390/ijms150915754.
   Liu YH, 2016, AM J TRANSL RES, V8, P2159.
   Liu Z, 2019, ADV CLIN EXP MED, V28, P1459, DOI 10.17219/acem/108552.
   Low SY, 2012, CANCER LETT, V314, P166, DOI 10.1016/j.canlet.2011.09.025.
   Lu WQ, 2017, ONCOTARGET, V8, P44171, DOI 10.18632/oncotarget.17396.
   Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf.
   Palit S, 2015, J CELL PHYSIOL, V230, P1729, DOI 10.1002/jcp.24818.
   Pang L, 2017, ONCOL REP, V38, P1295, DOI 10.3892/or.2017.5745.
   Peng F, 2018, ONCOGENE, V37, P1062, DOI {[}10.1038/onc.2017.368, 10.1038/onc.2017.407].
   Qin Y, 2018, CELL PHYSIOL BIOCHEM, V48, P1627, DOI 10.1159/000492284.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Ruggieri V, 2015, ONCOTARGET, V6, P1217, DOI 10.18632/oncotarget.2721.
   Seo SU, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0138-6.
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254.
   Song YD, 2017, CELL MOL BIOL, V63, P75, DOI 10.14715/cmb/2017.63.9.14.
   Stander XX, 2015, CELL PHYSIOL BIOCHEM, V35, P1499, DOI 10.1159/000369710.
   Virag P, 2011, CELL BIOCHEM FUNCT, V29, P351, DOI 10.1002/cbf.1754.
   Wang CQ, 2019, EUR REV MED PHARMACO, V23, P3771, DOI 10.26355/eurrev\_201905\_17803.
   Wang D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013067.
   Wang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4123-1.
   Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349.
   Yao YY, 2019, ONCOL REP, V42, P131, DOI 10.3892/or.2019.7136.
   Zhang LY, 2018, CELL PHYSIOL BIOCHEM, V47, P1432, DOI 10.1159/000490834.
   Zhang PC, 2019, CELL ONCOL, V42, P847, DOI 10.1007/s13402-019-00471-x.
   Zhang YC, 2019, AM J TRANSL RES, V11, P5134.
   Zhang YY, 2018, ONCOTARGETS THER, V11, P809, DOI 10.2147/OTT.S151867.
   Zheng RN, 2016, MOL MED REP, V13, P1570, DOI 10.3892/mmr.2015.4715.
   Zheng SY, 2017, CANCER BIOMARK, V20, P49, DOI 10.3233/CBM-170079.
   Zhu DY, 2019, PATHOL RES PRACT, V215, P861, DOI 10.1016/j.prp.2019.01.029.
   Zhu ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106049.},
Number-of-Cited-References = {46},
Times-Cited = {22},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {OncoTargets Ther.},
Doc-Delivery-Number = {LH9ZG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000529142800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000537737100001,
Author = {Wang, Zhiwei and Han, Yanfen and Tian, Shujuan and Bao, Junqiang and
   Wang, Yahui and Jiao, Junping},
Title = {Lupeol Alleviates Cerebral lschemia-Reperfusion Injury in Correlation
   with Modulation of PI3K/Akt Pathway},
Journal = {NEUROPSYCHIATRIC DISEASE AND TREATMENT},
Year = {2020},
Volume = {16},
Pages = {1381-1390},
Abstract = {Background/Aim: This study aimed to investigate the effect and mechanism
   of lupeol on cerebral ischemia-reperfusion injury in rats.
   Methods: The effects of lupeol on cerebral infarction, cerebral water
   content, neurological symptoms and cerebral blood flow in rats were
   evaluated. Nissl staining was carried out to assess the neuronal damage
   of ischemic brain after I/R in rats. Apoptosis of ischemic brain neurons
   after I/R was detected by TUNEL staining. Western blotting was carried
   out to detect the effects of lupeol on the expression of p-PDK1, p-Akt,
   pc-Raf, p-BAD, cleaved caspase-3 and p-PTEN.
   Results: Lupeol significantly increased cerebral blood flow after I/R in
   rats, reduced brain water content and infarct volume, and decreased
   neurological function scores. It significantly reduced neuronal damage
   after I/R in rats, and significantly reduced neuronal cell loss. PI3K
   inhibitor (LY294002) can eliminate the effect of lupeol on I/R in rats.
   In addition, lupeol significantly increased the protein expression of
   p-PDK1, p-Akt, pc-Raf, p-BAD, and down-regulated the expression of
   cleaved caspase-3. LY294002 reversed the effects of lupeol on the
   expression of PI3K/Akt signaling pathway-related proteins and cleaved
   caspase-3 after I/R in rats.
   Conclusion: Lupeol had significant neuroprotective effects on brain I/R
   injury and neuronal apoptosis, and its mechanism may be related to the
   activation of PI3K/Akt signaling pathway.},
Publisher = {DOVE MEDICAL PRESS LTD},
Address = {PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND},
Type = {Article},
Language = {English},
Affiliation = {Tian, SJ (Corresponding Author), Hebei Med Univ, Dept Internal Med Neurol, Hosp 1, 89 Donggang Rd, Shijiazhuang 050031, Hebei, Peoples R China.
   Wang, Zhiwei; Tian, Shujuan; Bao, Junqiang; Jiao, Junping, Hebei Med Univ, Dept Internal Med Neurol, Hosp 1, 89 Donggang Rd, Shijiazhuang 050031, Hebei, Peoples R China.
   Han, Yanfen, Army Med Univ, Dept Internal Med Neurol, Affiliated Hosp, Shijiazhuang 050000, Hebei, Peoples R China.
   Wang, Yahui, Hebei Med Univ, Dept Rehabil, Hosp 1, Shijiazhuang 050031, Hebei, Peoples R China.},
DOI = {10.2147/NDT.S237406},
EISSN = {1178-2021},
Keywords = {lupeol; PI3K/Akt; apoptosis; cerebral ischemia/reperfusion (I/R) injury},
Keywords-Plus = {ISCHEMIC-STROKE; CASPASE-3 ACTIVATION; OXIDATIVE STRESS; HEART-DISEASE;
   APOPTOSIS; AMERICAN; DAMAGE; CELLS},
Research-Areas = {Neurosciences \& Neurology; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Psychiatry},
Author-Email = {prbdmhflsoxh81@163.com},
Affiliations = {Hebei Medical University; Army Medical University; Hebei Medical
   University},
Cited-References = {Blanco Miguel, 2006, Cerebrovasc Dis, V21 Suppl 2, P38, DOI 10.1159/000091702.
   Chen CH, 2013, CNS NEUROSCI THER, V19, P566, DOI 10.1111/cns.12114.
   Faigle R, 2015, NEURORADIOLOGY, V57, P171, DOI 10.1007/s00234-014-1453-9.
   Fevrier B, 2004, P NATL ACAD SCI USA, V101, P9683, DOI 10.1073/pnas.0308413101.
   Gao F, 2002, CIRCULATION, V105, P1497, DOI 10.1161/01.CIR.0000012529.00367.0F.
   Geetha T, 2001, J ETHNOPHARMACOL, V76, P77, DOI 10.1016/S0378-8741(01)00175-1.
   Gharbi SI, 2007, BIOCHEM J, V404, P15, DOI 10.1042/BJ20061489.
   Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006.
   Guo MB, 2018, EUR SPINE J, P1.
   Hashmi WJ, 2018, DARU, V26, P179, DOI 10.1007/s40199-018-0223-3.
   JAESCHKE H, 1991, AM J PHYSIOL, V260, pG355, DOI 10.1152/ajpgi.1991.260.3.G355.
   Jonkman EJ, 1998, ACTA NEUROL SCAND, V98, P169, DOI 10.1111/j.1600-0404.1998.tb07289.x.
   Kono S, 2013, J STROKE CEREBROVASC, V22, P1175, DOI 10.1016/j.jstrokecerebrovasdis.2013.02.010.
   Kumari A, 2012, LIFE SCI, V90, P561, DOI 10.1016/j.lfs.2012.01.012.
   Lee CD, 2001, AM J EPIDEMIOL, V154, P758, DOI 10.1093/aje/154.8.758.
   Manabat C, 2003, STROKE, V34, P207, DOI 10.1161/01.STR.0000047101.87575.3C.
   MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218.
   Nagaraj M, 2000, J APPL TOXICOL, V20, P413, DOI 10.1002/1099-1263(200009/10)20:5<413::AID-JAT706>3.0.CO;2-Y.
   Olmez I, 2012, NEUROCHEM INT, V60, P208, DOI 10.1016/j.neuint.2011.11.009.
   POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302.
   Prasad S, 2008, ASIAN J ANDROL, V10, P313, DOI 10.1111/j.1745-7262.2008.00313.x.
   Preetha SP, 2006, COMP BIOCHEM PHYS C, V143, P333, DOI 10.1016/j.cbpc.2006.03.008.
   Qi Y, 2013, EXP EYE RES, V107, P44, DOI 10.1016/j.exer.2012.11.011.
   Roger VL, 2011, CIRCULATION, V123, P459, DOI 10.1161/CIR.0b013e31820c7a50.
   Saleem M, 2004, ONCOGENE, V23, P5203, DOI 10.1038/sj.onc.1207641.
   Saleem M, 2009, CANCER LETT, V285, P109, DOI 10.1016/j.canlet.2009.04.033.
   Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222.
   Tu XK, 2016, NEUROCHEM RES, V41, P2779, DOI 10.1007/s11064-016-1994-x.
   Wang CM, 2017, EXP THER MED, V13, P3315, DOI 10.3892/etm.2017.4424.
   Wen Y, 2005, FEBS LETT, V579, P4591, DOI 10.1016/j.febslet.2005.07.028.
   Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018.
   Yu Y, 2014, MOL MED REP, V10, P536, DOI 10.3892/mmr.2014.2156.
   Zhang JY, 2013, J CEREBR BLOOD F MET, V33, P567, DOI 10.1038/jcbfm.2012.202.},
Number-of-Cited-References = {33},
Times-Cited = {26},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Neuropsychiatr. Dis. Treat.},
Doc-Delivery-Number = {LU4OS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000537737100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000827925100009,
Author = {Zhang, Xiaohua and Zhong, Shan},
Title = {PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a
   Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway},
Journal = {ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY},
Year = {2020},
Volume = {20},
Number = {7},
Pages = {828-833},
Abstract = {Background: Phosphoinositide-Dependent Kinase 1 (PDK1) is now widely
   studied in malignant solid tumors. Researchers have previously revealed
   that targeting PDK1 is thought of as a promising anticancer treatment
   strategy. The aim of this study was designed to evaluate the anticancer
   activity of GSK-470, a novel and highly specific inhibitor of PDK1, in
   Pheochromocytoma (PCC) tumor model.
   Methods: PC12 cells were xenografted into nude mice to build PCC tumor
   model. Animals were treated with GSK-470 vs vehicle. Mean tumor volume
   was calculated and compared across groups. TUNEL was used to detect
   apoptosis. The effects of PDK1 inhibitor GSK-470 on activation of the
   Akt signaling and its downstream Akt/mTOR pathway in xenotransplant
   tumor tissues were examined by western bolt.
   Results: The mean tumor volume in GSK-470 group was significantly less
   than that in control group. TUNEL results found that cell apoptosis was
   markedly increased in GSK-470 group compared with the control group. The
   western bolt analysis showed that the phosphorylation of Akt at
   threonine 308 was significantly reduced in GSK-470 group. Also, GSK-470
   strongly inhibited phosphorylation of mTOR on Ser2448, a marker for
   mTORC1 activity, as well as phosphorylation of p70S6K, best
   characterized targets of mTOR.
   Conclusion: Our results showed that GSK-470 exhibited potent anticancer
   activity in PC12 tumor-bearing mice. Also, we found that this effect
   appeared to be mediated by the inhibition of the Akt/mTOR pathway. The
   present study once again provides new insights into the therapeutic
   effects of inhibiting PDK1 in the treatment of malignant PCC. Therefore,
   we propose that GSK-470 might be an effective therapeutic agent for the
   treatment of malignant PCC.},
Publisher = {BENTHAM SCIENCE PUBL LTD},
Address = {EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES},
Type = {Article},
Language = {English},
Affiliation = {Zhong, S (Corresponding Author), Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China.
   Zhang, Xiaohua; Zhong, Shan, Fudan Univ, Huashan Hosp, Dept Urol, Shanghai, Peoples R China.},
DOI = {10.2174/1871520620666200318100701},
ISSN = {1871-5206},
EISSN = {1875-5992},
Keywords = {Pheochromocytoma; PDK1; GSK2334470; Akt; mTOR; anticancer},
Research-Areas = {Oncology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Oncology; Chemistry, Medicinal},
Author-Email = {340515913@163.com},
Affiliations = {Fudan University},
ResearcherID-Numbers = {zhong, shan/HZJ-4647-2023},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81502315]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (No. 81502315).},
Cited-References = {Breen W, 2018, ADV RADIAT ONCOL, V3, P25, DOI 10.1016/j.adro.2017.11.002.
   Coant N, 2018, ONCOGENE, V37, P3852, DOI 10.1038/s41388-018-0236-x.
   Corssmit EPM, 2020, CURR OPIN ONCOL, V32, P20, DOI 10.1097/CCO.0000000000000589.
   Daniele S, 2017, ACS CHEM NEUROSCI, V8, P100, DOI 10.1021/acschemneuro.6b00251.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Hamidi O, 2017, J CLIN ENDOCR METAB, V102, P3296, DOI 10.1210/jc.2017-00992.
   Jasim S, 2017, ENDOCRINE, V57, P220, DOI 10.1007/s12020-017-1359-5.
   Jimenez C, 2019, CANCERS, V11, DOI 10.3390/cancers11071018.
   Jimenez C, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00277.
   Jimenez C, 2013, CURR ONCOL REP, V15, P356, DOI 10.1007/s11912-013-0320-x.
   Jing PH, 2020, EXP CELL RES, V386, DOI 10.1016/j.yexcr.2019.111746.
   Keane NA, 2014, EXPERT OPIN THER TAR, V18, P897, DOI 10.1517/14728222.2014.924507.
   Knight Zachary A, 2011, Biochem J, V433, pe1, DOI 10.1042/BJ20102038.
   Kotecka-Blicharz A, 2018, ENDOKRYNOL POL, V69, P246, DOI 10.5603/EP.a2018.0024.
   Lenders JWM, 2017, ENDOCRINOL METAB, V32, P152, DOI 10.3803/EnM.2017.32.2.152.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Niemeijer ND, 2014, CLIN ENDOCRINOL, V81, P642, DOI 10.1111/cen.12542.
   Parenti G, 2012, J ONCOL, V2012, DOI 10.1155/2012/872713.
   Peifer C, 2008, CHEMMEDCHEM, V3, P1810, DOI 10.1002/cmdc.200800195.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Raimondi C, 2016, SCI REP-UK, V6, DOI 10.1038/srep26142.
   Roman-Gonzalez A, 2017, CURR OPIN ENDOCRINOL, V24, P174, DOI 10.1097/MED.0000000000000330.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sestito S, 2019, EXPERT OPIN THER PAT, V29, P271, DOI 10.1080/13543776.2019.1597852.
   Su AR, 2017, ACTA PHARMACOL SIN, V38, P402, DOI 10.1038/aps.2016.160.
   Toledo Rodrigo, 2018, F1000Res, V7, DOI {[}10.12688/f1000research.13995.1, 10.12688/f1000research.13995.1].
   Wada M, 2015, J DERMATOL SCI, V78, P44, DOI 10.1016/j.jdermsci.2015.01.015.
   Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005.
   Wang YH, 2017, CANCER LETT, V393, P8, DOI 10.1016/j.canlet.2017.01.036.
   Yang CM, 2017, ONCOTARGET, V8, P39185, DOI 10.18632/oncotarget.16642.
   Zhang J, 2018, ONCOL REP, V39, P2951, DOI 10.3892/or.2018.6369.
   Zhang X, 2019, CLIN TRANSL ONCOL, V21, P1312, DOI 10.1007/s12094-019-02055-5.},
Number-of-Cited-References = {36},
Times-Cited = {4},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Anti-Cancer Agents Med. Chem.},
Doc-Delivery-Number = {VL3FA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000827925100009},
DA = {2026-02-04},
}

@article{ WOS:000505918400008,
Author = {Zhong, Mengya and Li, Nini and Qiu, Xingfeng and Ye, Yuhan and Chen,
   Huiyu and Hua, Jianyu and Yin, Ping and Zhuang, Guohong},
Title = {TIPE regulates VEGFR2 expression and promotes angiogenesis in colorectal
   cancer},
Journal = {INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES},
Year = {2020},
Volume = {16},
Number = {2},
Pages = {272-283},
Abstract = {Background: Metastasis is the leading cause of death in colorectal
   cancer (CRC) patients. It is regulated mainly by tumor cell
   angiogenesis, and angiogenesis is caused by the binding of vascular
   endothelial growth factor (VEGF) to vascular endothelial growth factor
   receptor 2 (VEGFR2). Tumor necrosis factor-alpha-induced protein 8
   (TNFAIP8, hereto after TIPE) plays an important role in tumorigenesis,
   development, and prognosis. However, the relationship between TIPE and
   VEGFR2 in CRC angiogenesis and the mechanism of action remain unknown.
   Method: In this study, we used quantitative real-time PCR, Western
   blotting and immunohistochemistry to detect TIPE and VEGFR2 expression
   in 55 specimens from CRC patients. We also used HCT116 CRC cells and
   human umbilical vein endothelial cells (HUVECs) for in vitro experiments
   by stably transducing shTIPE and shRNA control lentivirus into HCT116
   cells, detecting VEGFR2 expression after TIPE knockdown and repurposing
   the culture supernatant as conditioned medium to stimulate angiogenesis
   of HUVECs. In vivo experiments with chicken chorioallantoic membranes
   (CAMs) and a nude mouse matrix subcutaneous tumor model were performed
   to validate the effects of TIPE on angiogenesis. Additionally, we
   analyzed the expression and phosphorylation levels of PDK1 and blocked
   PDK1 expression using inhibitors to determine whether TIPE-induced
   changes in VEGFR2-mediated angiogenesis acted via the PI3K-Akt pathway.
   Results: We found that TIPE and VEGFR2 are highly expressed in CRC and
   act as oncogenes. TIPE knockdown also downregulated VEGFR2 expression,
   which resulted in simultaneous inhibition of cell proliferation, cell
   migration and angiogenesis. Then, in vivo experiments further
   demonstrated that TIPE promotes angiogenesis in CRC. Finally, we found
   that TIPE promotes VEGFR2-mediated angiogenesis by upregulating PDK1
   expression and phosphorylation and that blocking PDK1 expression can
   inhibit this process.
   Conclusion: TIPE promotes angiogenesis in CRC by regulating the
   expression of VEGFR2, which may be a target for antiangiogenic cancer
   therapy.},
Publisher = {IVYSPRING INT PUBL},
Address = {PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA},
Type = {Article},
Language = {English},
Affiliation = {Zhuang, GH (Corresponding Author), Xiamen Univ, Sch Med, Canc Res Ctr, Xiamen, Fujian, Peoples R China.
   Yin, P (Corresponding Author), Xiamen Univ, Zhongshan Hosp, Dept Pathol, 201-209 Hu Bin Nan Rd, Xiamen 361004, Fujian, Peoples R China.
   Zhuang, GH (Corresponding Author), Xiamen Univ, Sch Med, Fujian Prov Key Lab Organ \& Tissue Regenerat, Organ Transplantat Inst, 4221-122 Xiang An South Rd, Xiamen 361102, Fujian, Peoples R China.
   Zhong, Mengya; Chen, Huiyu; Zhuang, Guohong, Xiamen Univ, Sch Med, Canc Res Ctr, Xiamen, Fujian, Peoples R China.
   Li, Nini, Yangtze Univ, Affiliated Hosp 1, Dept Pathol, Jingzhou, Hubei, Peoples R China.
   Qiu, Xingfeng, Xiamen Univ, Zhongshan Hosp, Dept Gastrointestinal Surg, Xiamen, Fujian, Peoples R China.
   Ye, Yuhan; Yin, Ping, Xiamen Univ, Zhongshan Hosp, Dept Pathol, 201-209 Hu Bin Nan Rd, Xiamen 361004, Fujian, Peoples R China.
   Hua, Jianyu; Zhuang, Guohong, Xiamen Univ, Sch Med, Fujian Prov Key Lab Organ \& Tissue Regenerat, Organ Transplantat Inst, 4221-122 Xiang An South Rd, Xiamen 361102, Fujian, Peoples R China.},
DOI = {10.7150/ijbs.37906},
ISSN = {1449-2288},
Keywords = {CRC; TIPE; angiogenesis; VEGFR2; PDK1; PI3K-Akt},
Keywords-Plus = {SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASIS; INDUCED PROTEIN 8;
   TNFAIP8 OVEREXPRESSION; POOR-PROGNOSIS; SCC-S2; PROLIFERATION; INVASION;
   DISEASE; IDENTIFICATION},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology},
Author-Email = {yinping2002@163.com
   zhgh@xmu.edu.cn},
Affiliations = {Xiamen University; Yangtze University; Xiamen University; Xiamen
   University; Xiamen University},
ResearcherID-Numbers = {Zhuang, GH/G-3483-2010
   Zhong, Mengya/AAA-6082-2021
   Hua, Jianyu/MHR-4267-2025},
Funding-Acknowledgement = {National Natural Scientific Foundation of China {[}81272720]; Natural
   Science Foundation of Fujian Province {[}2018J01138]; Joint Research
   Project of Health and Education of Fujian Province {[}WKJ2016-2-17]},
Funding-Text = {The authors would like to thank the Zhongshan Hospital of Xiamen
   University for providing clinical samples and the entire research team
   for their contributions and support. This study was supported by the
   National Natural Scientific Foundation of China (No. 81272720), the
   Natural Science Foundation of Fujian Province (Grant No. 2018J01138),
   and the Joint Research Project of Health and Education of Fujian
   Province (WKJ2016-2-17).},
Cited-References = {Akgül Ö, 2014, WORLD J GASTROENTERO, V20, P6113, DOI 10.3748/wjg.v20.i20.6113.
   Auyeung KK, 2017, CURR PHARM DESIGN, V23, P3952, DOI 10.2174/1381612823666170228124105.
   Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478.
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4.
   D K, 2000, J BIOL CHEM, V275, p2973 .
   Dong QZ, 2010, CANCER SCI, V101, P1562, DOI 10.1111/j.1349-7006.2010.01557.x.
   Duan D, 2014, TUMOR BIOL, V35, P4331, DOI 10.1007/s13277-013-1568-3.
   Fayngerts SA, 2014, CANCER CELL, V26, P465, DOI 10.1016/j.ccr.2014.07.025.
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4.
   Freundt EC, 2008, CELL, V133, P401, DOI 10.1016/j.cell.2008.04.017.
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075.
   G YJ, 2015, PRACTICAL GERIATRICS, pR273.
   Gao HY, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12331.
   Goldsmith JR, 2017, CELL MOL IMMUNOL, V14, P482, DOI 10.1038/cmi.2017.4.
   Ha JY, 2014, J NEUROCHEM, V129, P527, DOI {[}10.1111/j.1471-4159.2013.12643.x, 10.1111/jnc.12643].
   Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006.
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502.
   Koch S, 2011, BIOCHEM J, V437, P169, DOI 10.1042/BJ20110301.
   Kumar D, 2004, ONCOGENE, V23, P612, DOI 10.1038/sj.onc.1207123.
   Kumar D, 2000, J BIOL CHEM, V275, P2973, DOI 10.1074/jbc.275.4.2973.
   Li XL, 2019, CELL MOL IMMUNOL, V16, P28, DOI 10.1038/s41423-018-0086-z.
   Li YS, 2015, MOL MED REP, V12, P2636, DOI 10.3892/mmr.2015.3690.
   Liu K, 2012, ASIAN PAC J CANCER P, V13, P847, DOI 10.7314/APJCP.2012.13.3.847.
   Liu T, 2013, BRIT J CANCER, V109, P1685, DOI 10.1038/bjc.2013.501.
   Liu TB, 2014, TUMOR BIOL, V35, P5805, DOI 10.1007/s13277-014-1770-y.
   Liu TB, 2014, HUM PATHOL, V45, P1251, DOI 10.1016/j.humpath.2014.02.005.
   Lou YW, 2011, MOL IMMUNOL, V49, P4, DOI 10.1016/j.molimm.2011.08.006.
   Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002.
   Miao ZF, 2012, TUMOR BIOL, V33, P2099, DOI 10.1007/s13277-012-0469-1.
   Padmavathi G, 2018, CANCER LETT, V432, P260, DOI 10.1016/j.canlet.2018.06.017.
   Pàez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027.
   Patel S, 1997, ORAL ONCOL, V33, P197, DOI 10.1016/S0964-1955(96)00065-6.
   Peach CJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041264.
   Shi TY, 2013, CARCINOGENESIS, V34, P770, DOI 10.1093/carcin/bgt001.
   Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026.
   Sun ZG, 2016, TUMOR BIOL, V37, P10923, DOI 10.1007/s13277-016-4978-1.
   Xing Y, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0254-x.
   Yang M, 2014, HISTOPATHOLOGY, V65, P517, DOI 10.1111/his.12413.
   Yeh CC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40862-6.
   Zachary I, 2014, CHEM IMMUNOL ALLERGY, V99, P37, DOI 10.1159/000354169.
   Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407.
   Zhang CB, 2006, MOL THER, V13, P947, DOI 10.1016/j.ymthe.2005.11.020.},
Number-of-Cited-References = {42},
Times-Cited = {66},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {31},
Journal-ISO = {Int. J. Biol. Sci.},
Doc-Delivery-Number = {KA6PJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000505918400008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000514904800008,
Author = {Holditch, Sara J. and Brown, Carolyn N. and Atwood, Daniel J. and
   Pokhrel, Deepak and Brown, Sara E. and Lombardi, Andrew M. and Khoa
   Nguyen and Hill, Ryan C. and Lanaspa, Miguel and Hopp, Katharina and
   Weiser-Evans, Mary C. M. and Edelstein, Charles L.},
Title = {The consequences of increased 4E-BP1 in polycystic kidney disease},
Journal = {HUMAN MOLECULAR GENETICS},
Year = {2019},
Volume = {28},
Number = {24},
Pages = {4132-4147},
Month = {DEC 15},
Abstract = {Autosomal dominant polycystic kidney disease (ADPKD) is the most common
   hereditary renal disease, characterized by cyst formation and growth.
   Hyperproliferation is a major contributor to cyst growth. At the nexus
   of regulating proliferation, is 4E-BP1. We demonstrate that ADPKD mouse
   and rat models, ADPKD patient renal biopsies and PKD1(-/-) cells
   exhibited hyperphosphorylated 4E-BP1, a biomarker of increased
   translation and proliferation. We hypothesized that expression of
   constitutively active 4E-BP1 constructs (4E-BP1(F113A) and
   4E-BP1R13A(F113A)) would decrease proliferation and reduce cyst
   expansion. Utilizing the Pkd1(RC/RC) mouse, we determined the effect of
   4E-BP1(F113A) on PKD. Unexpectedly, 4E-BP1(F113A) resulted in increased
   cyst burden and suppressed apoptosis markers, increased anti-apoptotic
   Bcl-2 protein and increased mitochondrial proteins. Exogenous 4E-BP1
   enhanced proliferation, decreased apoptosis, increased anti-apoptotic
   Bcl-2 protein, impaired NADPH oxidoreductase activity, increased
   mitochondrial proteins and increased superoxide production in PKD
   patient-derived renal epithelial cells. Reduced 4E-BP1 expression
   suppressed proliferation, restored apoptosis and improved cellular
   metabolism. These findings provide insight into how cyst-lining cells
   respond to 4E-BP1.},
Publisher = {OXFORD UNIV PRESS},
Address = {GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Edelstein, CL (Corresponding Author), Univ Colorado, Div Renal Dis \& Hypertens, Box C281,12700 East,19th Ave, Denver, CO 80045 USA.
   Holditch, Sara J.; Brown, Carolyn N.; Atwood, Daniel J.; Pokhrel, Deepak; Brown, Sara E.; Lombardi, Andrew M.; Khoa Nguyen; Lanaspa, Miguel; Hopp, Katharina; Weiser-Evans, Mary C. M.; Edelstein, Charles L., Univ Colorado, Div Renal Dis \& Hypertens, Box C281,12700 East,19th Ave, Denver, CO 80045 USA.
   Hill, Ryan C., Univ Colorado, Dept Biochem \& Mol Genet, Anschutz Med Campus, Aurora, CO 80045 USA.},
DOI = {10.1093/hmg/ddz244},
ISSN = {0964-6906},
EISSN = {1460-2083},
Keywords = {4E-BP1; polycystic kidney disease; proliferation; apoptosis;
   mitochondrial proteins},
Keywords-Plus = {DEPENDENT PHOSPHORYLATION; MITOCHONDRIAL ACTIVITY; EPITHELIAL-CELLS;
   ACTIVATION; INITIATION; INHIBITOR; CANCER; GROWTH; MTOR; TRANSLATION},
Research-Areas = {Biochemistry \& Molecular Biology; Genetics \& Heredity},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Genetics \& Heredity},
Author-Email = {Charles.edelstein@cuanschutz.edu},
Affiliations = {University of Colorado System; University of Colorado Denver; University
   of Colorado System; University of Colorado Anschutz Medical Campus},
ResearcherID-Numbers = {Hopp, Katharina/AAQ-3335-2021
   Lanaspa, Miguel/AAO-4971-2020
   Brown, Carolyn Nicole/HOF-9859-2023
   },
ORCID-Numbers = {Brown, Carolyn Nicole/0000-0002-3612-1125
   Atwood, Daniel/0000-0001-9647-8524},
Funding-Acknowledgement = {PKD Foundation Fellowship (2018); PKD Foundation Fellowship (2019);
   Department of Defense {[}W81XWH-16-1-0172]; Department of Veteran's
   Affairs Merit {[}BX003803-01A1]},
Funding-Text = {PKD Foundation Fellowship (2018 \& 2019, SJH); Department of Defense
   (W81XWH-16-1-0172 to C.L.E.); Department of Veteran's Affairs Merit
   (BX003803-01A1 to C.L.E.)},
Cited-References = {Arciuch VGA, 2012, ANTIOXID REDOX SIGN, V16, P1150, DOI 10.1089/ars.2011.4085.
   Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200.
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Chiavarina B, 2011, CANCER BIOL THER, V12, P1101, DOI 10.4161/cbt.12.12.18703.
   de Stephanis L, 2017, CLIN EXP NEPHROL, V21, P203, DOI 10.1007/s10157-016-1289-1.
   Dere R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009239.
   Dias N, 1999, J BASIC MICROB, V39, P103, DOI 10.1002/(SICI)1521-4028(199905)39:2<103::AID-JOBM103>3.0.CO;2-D.
   Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P372, DOI 10.1089/ars.2012.4886.
   Ding M, 2018, MOL CANCER RES, V16, P682, DOI 10.1158/1541-7786.MCR-17-0696.
   Distefano G, 2009, MOL CELL BIOL, V29, P2359, DOI 10.1128/MCB.01259-08.
   Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532.
   Edelstein CL, 2005, CELL CYCLE, V4, P1550, DOI 10.4161/cc.4.11.2185.
   Fan QW, 2017, CANCER CELL, V31, P424, DOI 10.1016/j.ccell.2017.01.014.
   Gingras AC, 2001, GENE DEV, V15, P2852.
   Goilav B, 2011, BBA-MOL BASIS DIS, V1812, P1272, DOI 10.1016/j.bbadis.2011.01.006.
   Goo CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045806.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Holditch SJ, 2017, KIDNEY INT, V92, P657, DOI 10.1016/j.kint.2017.02.017.
   Holditch SJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep25623.
   Holditch SJ, 2015, HYPERTENSION, V66, P199, DOI 10.1161/HYPERTENSIONAHA.115.05610.
   Hopp K, 2015, J AM SOC NEPHROL, V26, P39, DOI 10.1681/ASN.2013121312.
   Hopp K, 2012, J CLIN INVEST, V122, P4257, DOI 10.1172/JCI64313.
   HOSKINS DD, 1961, J BIOL CHEM, V236, P177.
   Ishimoto Y, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00337-17.
   Jiang H, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-2.
   Jossé L, 2016, BIOCHEM J, V473, P4651, DOI 10.1042/BCJ20160845.
   Kamp DW, 2011, ONCOLOGY-NY, V25, P400.
   Kimball SR, 2008, J BIOL CHEM, V283, P3465, DOI 10.1074/jbc.M706643200.
   Liemburg-Apers DC, 2015, ARCH TOXICOL, V89, P1209, DOI 10.1007/s00204-015-1520-y.
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554.
   Livingstone Mark, 2012, F1000Res, V1, P4, DOI 10.12688/f1000research.1-4.v1.
   Loghman-Adham M, 2003, AM J PHYSIOL-RENAL, V285, pF397, DOI 10.1152/ajprenal.00310.2002.
   Mao ZG, 2015, NEPHROL DIAL TRANSPL, V30, P197, DOI 10.1093/ndt/gfu044.
   Mokhtari B, 2015, EUR J PHARMACOL, V765, P316, DOI 10.1016/j.ejphar.2015.08.056.
   Moreno-Sánchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x.
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001.
   Nishio S, 2005, J CLIN INVEST, V115, P910, DOI 10.1172/JCI200522850.
   Parker E, 2007, KIDNEY INT, V72, P157, DOI 10.1038/sj.ki.5002229.
   Powelka AM, 2006, J CLIN INVEST, V116, P125, DOI 10.1172/JCI26040.
   Qin XY, 2016, CELL CYCLE, V15, P781, DOI 10.1080/15384101.2016.1151581.
   Rooney JP, 2015, METHODS MOL BIOL, V1241, P23, DOI 10.1007/978-1-4939-1875-1\_3.
   Rousseau D, 1996, ONCOGENE, V13, P2415.
   Rowe I, 2013, NAT MED, V19, P488, DOI 10.1038/nm.3092.
   Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4.
   Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5.
   Shibazaki S, 2008, HUM MOL GENET, V17, P1505, DOI 10.1093/hmg/ddn039.
   Showkat Mehvish, 2014, Mol Biol Int, V2014, P686984, DOI 10.1155/2014/686984.
   So L, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad8463.
   Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002.
   Tsai S, 2015, J CLIN INVEST, V125, P2952, DOI 10.1172/JCI77361.
   Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128.
   Wallace DP, 2014, KIDNEY INT, V85, P845, DOI 10.1038/ki.2013.488.
   Wilson PD, 2004, INT J BIOCHEM CELL B, V36, P1868, DOI 10.1016/j.biocel.2004.03.012.
   Yin H, 2004, HYPERTENSION, V43, P109, DOI 10.1161/01.HYP.0000103696.60047.55.
   Zhang DH, 2010, J CLIN INVEST, V120, P2805, DOI 10.1172/JCI43008.
   Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222.
   Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034.},
Number-of-Cited-References = {58},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {1},
Journal-ISO = {Hum. Mol. Genet.},
Doc-Delivery-Number = {KN5VM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000514904800008},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000503161500001,
Author = {Beker, Mustafa C. and Caglayan, Berrak and Caglayan, Ahmet B. and
   Kelestemur, Taha and Yalcin, Esra and Caglayan, Aysun and Kilic, Ulkan
   and Baykal, Ahmet T. and Reiter, Russel J. and Kilic, Ertugrul},
Title = {Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway
   components and cellular survival},
Journal = {SCIENTIFIC REPORTS},
Year = {2019},
Volume = {9},
Month = {DEC 13},
Abstract = {The circadian rhythm is driven by a master clock within the
   suprachiasmatic nucleus which regulates the rhythmic secretion of
   melatonin. Bmal1 coordinates the rhythmic expression of transcriptome
   and regulates biological activities, involved in cell metabolism and
   aging. However, the role of Bmal1 in cellular- survival, signaling, its
   interaction with intracellular proteins, and how melatonin regulates its
   expression is largely unclear. Here we observed that melatonin increases
   the expression of Bmal1 and both melatonin and Bmal1 increase cellular
   survival after oxygen glucose deprivation (OGD) while the inhibition of
   Bmal1 resulted in the decreased cellular survival without affecting
   neuroprotective effects of melatonin. By using a planar surface
   immunoassay for PI3K/AKT signaling pathway components, we revealed that
   both melatonin and Bmal1 increased phosphorylation of AKT, ERK-1/2,
   PDK1, mTOR, PTEN, GSK-3 alpha beta, and p70S6K. In contrast, inhibition
   of Bmal1 resulted in decreased phosphorylation of these proteins, which
   the effect of melatonin on these signaling molecules was not affected by
   the absence of Bmal1 . Besides, the inhibition of PI3K/AKT decreased
   Bmal1 expression and the effect of melatonin on Bmal1 after both OGD in
   vitro and focal cerebral ischemia in vivo. Our data demonstrate that
   melatonin controls the expression of Bmal1 via PI3K/AKT signaling, and
   Bmal1 plays critical roles in cellular survival via activation of
   survival kinases.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Kilic, E (Corresponding Author), Istanbul Medipol Univ, Regenerat \& Restorat Med Res Ctr, TR-34810 Istanbul, Turkey.
   Kilic, E (Corresponding Author), Istanbul Medipol Univ, Sch Med, Dept Physiol, TR-34810 Istanbul, Turkey.
   Beker, Mustafa C.; Caglayan, Berrak; Caglayan, Ahmet B.; Kelestemur, Taha; Yalcin, Esra; Caglayan, Aysun; Kilic, Ertugrul, Istanbul Medipol Univ, Regenerat \& Restorat Med Res Ctr, TR-34810 Istanbul, Turkey.
   Beker, Mustafa C.; Caglayan, Ahmet B.; Kelestemur, Taha; Yalcin, Esra; Caglayan, Aysun; Kilic, Ertugrul, Istanbul Medipol Univ, Sch Med, Dept Physiol, TR-34810 Istanbul, Turkey.
   Caglayan, Berrak, Istanbul Medipol Univ, Int Sch Med, Dept Med Biol, TR-34810 Istanbul, Turkey.
   Kilic, Ulkan, Univ Hlth Sci, Sch Med, Dept Med Biol, TR-34668 Istanbul, Turkey.
   Baykal, Ahmet T., Acibadem Mehmet Ali Aydinlar Univ, Sch Med, Dept Med Biochem, TR-34752 Istanbul, Turkey.
   Reiter, Russel J., UT Hlth San Antonio, Dept Cell Syst \& Anat, San Antonio, TX 78229 USA.},
DOI = {10.1038/s41598-019-55663-0},
Article-Number = {19082},
ISSN = {2045-2322},
Keywords-Plus = {FOCAL CEREBRAL-ISCHEMIA; CLOCK GENE-EXPRESSION; CIRCADIAN-RHYTHM;
   BRAIN-INJURY; MECHANISMS; RECEPTORS; SLEEP; PHOSPHORYLATION;
   HIPPOCAMPUS; DISRUPTION},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {kilic44@yahoo.com},
Affiliations = {Istanbul Medipol University; Istanbul Medipol University; Istanbul
   Medipol University; Acibadem University; University of Texas System;
   University of Texas at San Antonio},
ResearcherID-Numbers = {Baykal, Ahmet Tarik/C-3948-2013
   caglayan, ahmet burak/NUP-8504-2025
   CAGLAYAN, AYSUN/HII-9128-2022
   Reiter, Russel/D-3221-2009
   Beker, Mustafa Caglar/ABH-2222-2020
   Kilic, Ertugrul/W-4563-2018
   Çelik, Ulkan/PEV-4125-2025},
ORCID-Numbers = {Baykal, Ahmet Tarik/0000-0002-8814-7351
   caglayan, ahmet burak/0000-0002-6242-3709
   CAGLAYAN, AYSUN/0000-0002-2657-3515
   Yalcin, Esra/0000-0002-1064-7989
   Caglayan, Berrak/0000-0002-5072-132X
   Beker, Mustafa Caglar/0000-0002-9476-8488
   Hasanova, Konul/0009-0003-4052-3367
   Kelestemur, Taha/0000-0003-3616-1204
   Kilic, Ertugrul/0000-0001-6494-8923
   },
Funding-Acknowledgement = {Turkish Academy of Sciences (TUBA); Scientific and Technological
   Research Council of Turkey (TUBITAK) {[}118S306]},
Funding-Text = {This work was supported by Turkish Academy of Sciences (TUBA) and The
   Scientific and Technological Research Council of Turkey (TUBITAK,
   118S306).},
Cited-References = {Acioglu C, 2016, BRAIN BEHAV IMMUN, V56, P310, DOI 10.1016/j.bbi.2016.03.027.
   Alghamdi BS, 2018, J NEUROSCI RES, V96, P1136, DOI 10.1002/jnr.24220.
   Ali A, 2017, SEMIN CELL DEV BIOL, V69, P34, DOI 10.1016/j.semcdb.2017.06.005.
   Beker MC, 2015, ONCOTARGET, V6, P30604, DOI 10.18632/oncotarget.5773.
   Beker MC, 2018, MOL NEUROBIOL, V55, P2565, DOI 10.1007/s12035-017-0524-4.
   Buhr Ethan D, 2013, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-25950-0\_1.
   Cao YW, 2017, AGING DIS, V8, P314, DOI 10.14336/AD.2016.1101.
   Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076.
   Gregório AC, 2018, CRIT REV ONCOL HEMAT, V125, P89, DOI 10.1016/j.critrevonc.2018.03.008.
   Gu ZQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15891.
   Haçariz O, 2014, PROTEOMICS, V14, P1519, DOI 10.1002/pmic.201400012.
   Holloway PM, 2016, STROKE, V47, P561, DOI 10.1161/STROKEAHA.115.011932.
   Hood S, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00170.
   Ichihara-Tanaka K, 2017, J HISTOCHEM CYTOCHEM, V65, P513, DOI 10.1369/0022155417723914.
   Ikeno T, 2015, HIPPOCAMPUS, V25, P142, DOI 10.1002/hipo.22358.
   Ishaq M, 2009, J CELL BIOCHEM, V106, P296, DOI 10.1002/jcb.22004.
   Johnston JD, 2006, ENDOCRINOLOGY, V147, P959, DOI 10.1210/en.2005-1100.
   Kelestemur T, 2016, NEUROSCI LETT, V612, P92, DOI 10.1016/j.neulet.2015.11.043.
   Khapre RV, 2011, CELL CYCLE, V10, P4162, DOI 10.4161/cc.10.23.18381.
   Kilic U, 2013, NEUROSCIENCE, V237, P268, DOI 10.1016/j.neuroscience.2013.01.059.
   Kilic U, 2017, REDOX BIOL, V12, P657, DOI 10.1016/j.redox.2017.04.006.
   Kilic U, 2012, J PINEAL RES, V52, P228, DOI 10.1111/j.1600-079X.2011.00932.x.
   Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009.
   Kodadek T, 2006, CELL, V127, P261, DOI 10.1016/j.cell.2006.10.002.
   Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206.
   Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742.
   Mack JM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3472032.
   Manfredini R, 2005, CHRONOBIOL INT, V22, P417, DOI 10.1081/CBI-200062927.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Miao ZP, 2017, CANCER SCI, V108, P1953, DOI 10.1111/cas.13344.
   Motzkus D, 2007, CHRONOBIOL INT, V24, P783, DOI 10.1080/07420520701672481.
   Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049.
   Musiek ES, 2016, SCIENCE, V354, P1004, DOI 10.1126/science.aah4968.
   Musiek ES, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00029.
   Musiek ES, 2013, J CLIN INVEST, V123, P5389, DOI 10.1172/JCI70317.
   Park EJ, 2014, J PINEAL RES, V56, P97, DOI 10.1111/jpi.12102.
   Ramírez-Rodríguez G, 2009, NEUROPSYCHOPHARMACOL, V34, P2180, DOI 10.1038/npp.2009.46.
   Robinson I, 2014, FEBS LETT, V588, P2477, DOI 10.1016/j.febslet.2014.06.005.
   Sagrillo-Fagundes L, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12520.
   Sahar S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008561.
   Sancar A, 2010, FEBS LETT, V584, P2618, DOI 10.1016/j.febslet.2010.03.017.
   Sato F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030781.
   Serhatli M, 2014, J PROTEOME RES, V13, P5071, DOI 10.1021/pr5006586.
   Shukla M, 2017, CURR NEUROPHARMACOL, V15, P1010, DOI 10.2174/1570159X15666170313123454.
   Song CL, 2017, GENE DEV, V31, P1370, DOI 10.1101/gad.300624.117.
   Vriend J, 2015, J PINEAL RES, V58, P1, DOI 10.1111/jpi.12189.
   Waly Nermien E., 2015, Journal of Circadian Rhythms, V13, P1, DOI {[}10.5334/jcr.ab, 10.5334/jcr.ab].
   WEAVER DR, 1993, J CLIN ENDOCR METAB, V76, P295, DOI 10.1210/jc.76.2.295.
   Wulff K, 2010, NAT REV NEUROSCI, V11, P589, DOI 10.1038/nrn2868.
   Yalcin E, 2019, TOXICOL APPL PHARM, V379, DOI 10.1016/j.taap.2019.114686.
   Yang ZT, 2016, SCI TRANSL MED, V8, DOI {[}10.1126/scitranslmed.aaf3006, 10.1126/scitranslmed.aad3305].
   Yazdi PG, 2013, CTS-CLIN TRANSL SCI, V6, P347, DOI 10.1111/cts.12083.
   Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075.
   Zeng CW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0884-z.
   Zhang RN, 2010, INT J BIOL MACROMOL, V47, P255, DOI 10.1016/j.ijbiomac.2010.04.013.
   Zhang SH, 2016, GENE, V581, P14, DOI 10.1016/j.gene.2016.01.013.
   Zheng JY, 2017, ONCOTARGET, V8, P90238, DOI 10.18632/oncotarget.21655.
   Zisapel N, 2018, BRIT J PHARMACOL, V175, P3190, DOI 10.1111/bph.14116.},
Number-of-Cited-References = {58},
Times-Cited = {85},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {JW6LQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000503161500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000502059100001,
Author = {Qu, Changda and Yan, Chang and Cao, Weifan and Li, Fangqin and Qu, Yewei
   and Guan, Ke and Si, Chengqing and Yu, Ze and Qu, Zhangyi},
Title = {miR-128-3p contributes to mitochondrial dysfunction and induces
   apoptosis in glioma cells via targeting pyruvate dehydrogenase kinase 1},
Journal = {IUBMB LIFE},
Year = {2020},
Volume = {72},
Number = {3},
Pages = {465-475},
Month = {MAR},
Abstract = {Glioma, like most cancers, possesses a unique bioenergetic state of
   aerobic glycolysis known as the Warburg effect, which is a dominant
   phenotype of most tumor cells. Glioma tumors exhibit high glycolytic
   metabolism with increased lactate production. Data derived from the gene
   expression profiling interactive analysis (GEPIA) database show that
   pyruvate dehydrogenase kinase 1 (PDK1) is significantly highly expressed
   in glioma tissues compared with corresponding normal tissues. PDK1 is a
   key enzyme in the transition of glycolysis to tricarboxylic acid cycle,
   via inactivating PDH and converting oxidative phosphorylation to Warburg
   effect, resulting in increment of lactate production. Silencing of PDK1
   expression resulted in reduced lactate and ATP, accumulation of ROS,
   mitochondrial damage, decreased cell growth, and increased cell
   apoptosis. Aberrant expression of miR-128 has been observed in many
   human malignancies. Mechanistically, we discover that overexpressed
   miR-128-3p disturbs the Warburg effect in glioma cells via reducing
   PDK1. Our experiments confirmed that the miR-128-3p/PDK1 axis played a
   pivotal role in cancer cell metabolism and growth. Collectively, these
   findings suggest that therapeutic strategies to modulate the Warburg
   effect, such as targeting of PDK1, might act as a potential therapeutic
   target for glioma treatment.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Yu, Z (Corresponding Author), Guangzhou Med Univ, Canc Ctr, Guangzhou Inst Oncol, Guangzhou 510000, Guangdong, Peoples R China.
   Qu, ZY (Corresponding Author), Harbin Med Univ, Publ Hlth Coll, Dept Microbiol, Harbin 150076, Heilongjiang, Peoples R China.
   Qu, Changda; Li, Fangqin; Qu, Yewei; Guan, Ke; Si, Chengqing, Harbin Med Univ, Affiliated Hosp 1, Dept Neurol, Harbin, Heilongjiang, Peoples R China.
   Yan, Chang, Harbin Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Harbin, Heilongjiang, Peoples R China.
   Cao, Weifan, Northeast Forestry Univ, Coll Life Sci, Harbin, Heilongjiang, Peoples R China.
   Yu, Ze, Guangzhou Med Univ, Canc Ctr, Guangzhou Inst Oncol, Guangzhou 510000, Guangdong, Peoples R China.
   Qu, Zhangyi, Harbin Med Univ, Publ Hlth Coll, Dept Microbiol, Harbin 150076, Heilongjiang, Peoples R China.},
DOI = {10.1002/iub.2212},
EarlyAccessDate = {DEC 2019},
ISSN = {1521-6543},
EISSN = {1521-6551},
Keywords = {glioma; miR-128-3p; PDK1; Warburg effect},
Keywords-Plus = {GENE-EXPRESSION; METABOLIC SWITCH; CANCER; GLIOBLASTOMA; PROMOTES;
   MICRORNAS; GROWTH; AXIS},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {zeyunfu@163.com
   qurainbow@126.com},
Affiliations = {Harbin Medical University; Harbin Medical University; Northeast Forestry
   University - China; Guangzhou Medical University; Harbin Medical
   University},
ResearcherID-Numbers = {LI, fangqin/NIU-0543-2025},
ORCID-Numbers = {Yu, Ze/0000-0002-5849-3413
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31370074]},
Funding-Text = {National Natural Science Foundation of China, Grant/Award Number:
   31370074},
Cited-References = {Aguirre-Gamboa R, 2014, BIOINFORMATICS, V30, P1630, DOI 10.1093/bioinformatics/btu087.
   Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250.
   Bai FL, 2019, AGING-US, V11, P3198, DOI 10.18632/aging.101974.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Brand KA, 1997, FASEB J, V11, P388, DOI 10.1096/fasebj.11.5.9141507.
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002.
   Chen R, 2017, NEUROTHERAPEUTICS, V14, P284, DOI 10.1007/s13311-017-0519-x.
   Chen Y, 2008, CANCER LETT, V272, P197, DOI 10.1016/j.canlet.2008.06.034.
   Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047.
   Cui JG, 2010, J NEURO-ONCOL, V98, P297, DOI 10.1007/s11060-009-0077-0.
   Evangelisti C, 2009, FASEB J, V23, P4276, DOI 10.1096/fj.09-134965.
   Fu C, 2018, NEUROTHERAPEUTICS, V15, P1139, DOI 10.1007/s13311-018-0649-9.
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088.
   Gao L, 2018, PATHOL RES PRACT, V214, P732, DOI 10.1016/j.prp.2018.03.002.
   Huang DQ, 2015, MOL BIOL+, V49, P40, DOI 10.1134/S0026893315010069.
   Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Ma XY, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6212.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Pathria G, 2018, EMBO J, V37, DOI 10.15252/embj.201899735.
   Pontén F, 2011, J INTERN MED, V270, P428, DOI 10.1111/j.1365-2796.2011.02427.x.
   Poteet E, 2013, J BIOL CHEM, V288, P9153, DOI 10.1074/jbc.M112.440354.
   Reifenberger G, 2017, NAT REV CLIN ONCOL, V14, P434, DOI 10.1038/nrclinonc.2016.204.
   Schwartz L, 2017, ANTI-CANCER AGENT ME, V17, P164, DOI 10.2174/1871520616666161031143301.
   Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337.
   Shi ZM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032709.
   Soni S, 2017, ACTA ONCOL, V56, P503, DOI 10.1080/0284186X.2017.1301680.
   Strickland M, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00043.
   Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041.
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247.
   Tüfekci KU, 2014, METHODS MOL BIOL, V1107, P33, DOI 10.1007/978-1-62703-748-8\_3.
   Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Wang BC, 2015, CHINESE MED J-PEKING, V128, P1238, DOI 10.4103/0366-6999.156141.
   Wang Q, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-97.
   Weeraratne SD, 2011, NEURO-ONCOLOGY, V13, P165, DOI 10.1093/neuonc/noq179.
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470.
   Xu JZ, 2010, INT J CANCER, V126, P1029, DOI 10.1002/ijc.24823.
   Xu JY, 2019, THERANOSTICS, V9, P2999, DOI 10.7150/thno.31301.
   Ye XY, 2017, ONCOTARGET, V8, P26394, DOI 10.18632/oncotarget.14445.
   Ye Y, 2018, EUR REV MED PHARMACO, V22, P8781, DOI 10.26355/eurrev\_201812\_16645.
   Yu WW, 2017, ONCOTARGET, V8, P39280, DOI 10.18632/oncotarget.16849.
   Yu Z, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12568.
   Yu Z, 2019, J CELL PHYSIOL, V234, P20648, DOI 10.1002/jcp.28670.
   Yuen Carlen A, 2016, CNS Oncol, V5, P101, DOI {[}10.2217/cns-2015-0006, 10.2217/cns-2015-0006].
   Zhang Y, 2009, J MOL MED, V87, P43, DOI 10.1007/s00109-008-0403-6.},
Number-of-Cited-References = {48},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {IUBMB Life},
Doc-Delivery-Number = {KM9XA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000502059100001},
DA = {2026-02-04},
}

@article{ WOS:000507382100007,
Author = {Watanabe, Daisuke and Nogami, Ayako and Okada, Keigo and Akiyama, Hiroki
   and Umezawa, Yoshihiro and Miura, Osamu},
Title = {FLT3-ITD Activates RSK1 to Enhance Proliferation and Survival of AML
   Cells by Activating mTORC1 and eIF4B Cooperatively with PIM or PI3K and
   by Inhibiting Bad and BIM},
Journal = {CANCERS},
Year = {2019},
Volume = {11},
Number = {12},
Month = {DEC},
Abstract = {FLT3-ITD is the most frequent tyrosine kinase mutation in acute myeloid
   leukemia (AML) associated with poor prognosis. We previously found that
   FLT3-ITD activates the mTORC1/S6K/4EBP1 pathway cooperatively through
   the STAT5/PIM and PI3K/AKT pathways to promote proliferation and
   survival by enhancing the eIF4F complex formation required for
   cap-dependent translation. Here, we show that, in contrast to BCR/ABL
   causing Ph-positive leukemias, FLT3-ITD distinctively activates the
   serine/threonine kinases RSK1/2 through activation of the MEK/ERK
   pathway and PDK1 to transduce signals required for FLT3-ITD-dependent,
   but not BCR/ABL-dependent, proliferation and survival of various cells,
   including MV4-11. Activation of the MEK/ERK pathway by FLT3-ITD and its
   negative feedback regulation by RSK were mediated by Gab2/SHP2
   interaction. RSK1 phosphorylated S6RP on S235/S236, TSC2 on S1798, and
   eIF4B on S422 and, in cooperation with PIM, on S406, thus activating the
   mTORC1/S6K/4EBP1 pathway and eIF4B cooperatively with PIM. RSK1 also
   phosphorylated Bad on S75 and downregulated BIM-EL in cooperation with
   ERK. Furthermore, inhibition of RSK1 increased sensitivities to BH3
   mimetics inhibiting Mcl-1 or Bcl-2 and induced activation of Bax,
   leading to apoptosis, as well as inhibition of proliferation
   synergistically with inhibition of PIM or PI3K. Thus, RSK1 represents a
   promising target, particularly in combination with PIM or PI3K, as well
   as anti-apoptotic Bcl-2 family members, for novel therapeutic strategies
   against therapy-resistant FLT3-ITD-positive AML.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Miura, O (Corresponding Author), Tokyo Med \& Dent Univ, Grad Sch Med \& Dent Sci, Dept Hematol, Tokyo 1138519, Japan.
   Watanabe, Daisuke; Nogami, Ayako; Okada, Keigo; Akiyama, Hiroki; Umezawa, Yoshihiro; Miura, Osamu, Tokyo Med \& Dent Univ, Grad Sch Med \& Dent Sci, Dept Hematol, Tokyo 1138519, Japan.
   Nogami, Ayako, Tokyo Med \& Dent Univ, Med Hosp, Dept Clin Lab, Tokyo 1138519, Japan.},
DOI = {10.3390/cancers11121827},
Article-Number = {1827},
EISSN = {2072-6694},
Keywords = {RSK; FLT3-ITD; acute myeloid leukemia; PIM; mTOR; eIF4B; BIM; Bad},
Keywords-Plus = {INTERNAL TANDEM DUPLICATION; PROTEIN-KINASE; INDUCED APOPTOSIS;
   TUMOR-GROWTH; BAF3 CELLS; PHOSPHORYLATION; TARGET; POTENT; ASSOCIATION;
   PATHWAYS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {dwathema@tmd.ac.jp
   nogahema@tmd.ac.jp
   keighema@tmd.ac.jp
   hakihema@tmd.ac.jp
   umehema@tmd.ac.jp
   miura.hema@tmd.ac.jp},
Affiliations = {Institute of Science Tokyo; Tokyo Medical \& Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical \& Dental University (TMDU)},
ResearcherID-Numbers = {Watanabe, Daisuke/AAG-2962-2021
   },
ORCID-Numbers = {Umezawa, Yoshihiro/0000-0003-1027-1552
   Miura, Osamu/0000-0002-0981-3054},
Funding-Acknowledgement = {Ministry of Education, Culture, Sports, Science and Technology of Japan
   {[}15K09467, 18K08349, 19K17852]; Grants-in-Aid for Scientific Research
   {[}18K08349, 19K17852, 15K09467] Funding Source: KAKEN},
Funding-Text = {This work was supported in part by grants from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan (grant
   numbers 15K09467, 18K08349, and 19K17852).},
Cited-References = {Akiyama H, 2019, CANCER LETT, V453, P84, DOI 10.1016/j.canlet.2019.03.046.
   Altman JK, 2011, ONCOTARGET, V2, P510, DOI 10.18632/oncotarget.290.
   Arnaud M, 2004, J IMMUNOL, V173, P3962, DOI 10.4049/jimmunol.173.6.3962.
   Aronchik I, 2014, MOL CANCER RES, V12, P803, DOI 10.1158/1541-7786.MCR-13-0595.
   Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253.
   Beharry Z, 2011, P NATL ACAD SCI USA, V108, P528, DOI 10.1073/pnas.1013214108.
   Bui NLC, 2018, CANCER LETT, V415, P177, DOI 10.1016/j.canlet.2017.11.017.
   Burger MT, 2015, J MED CHEM, V58, P8373, DOI 10.1021/acs.jmedchem.5b01275.
   Carrière A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078.
   Casalvieri KA, 2017, TRENDS CANCER, V3, P302, DOI 10.1016/j.trecan.2017.03.004.
   Cen B, 2014, MOL CELL BIOL, V34, P2517, DOI 10.1128/MCB.00147-14.
   Chen SD, 2015, CELL, V160, P1246, DOI 10.1016/j.cell.2015.02.038.
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4.
   Cilloni D, 2012, CLIN CANCER RES, V18, P930, DOI 10.1158/1078-0432.CCR-10-1613.
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722.
   Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020.
   Dibble CC, 2015, TRENDS CELL BIOL, V25, P545, DOI 10.1016/j.tcb.2015.06.002.
   Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437.
   Elf S, 2011, BLOOD, V117, P6885, DOI 10.1182/blood-2010-10-315721.
   Gores GJ, 2012, GENE DEV, V26, P305, DOI 10.1101/gad.186189.111.
   Hospital MA, 2018, LEUKEMIA, V32, P597, DOI 10.1038/leu.2017.284.
   Hospital MA, 2017, ONCOTARGETS THER, V10, P607, DOI 10.2147/OTT.S103790.
   Houles T, 2018, SEMIN CANCER BIOL, V48, P53, DOI 10.1016/j.semcancer.2017.04.016.
   Ishida Shinya, 2018, Oncotarget, V9, P26834, DOI {[}10.18632/oncotarget.25515, 10.18632/oncotarget.25515].
   Jain R, 2015, J MED CHEM, V58, P6766, DOI 10.1021/acs.jmedchem.5b00450.
   Keeton EK, 2014, BLOOD, V123, P905, DOI 10.1182/blood-2013-04-495366.
   Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927\_3927\_3934.
   Kuang ES, 2011, J BIOL CHEM, V286, P41171, DOI 10.1074/jbc.M111.280982.
   Kurosu T, 2007, ONCOGENE, V26, P2975, DOI 10.1038/sj.onc.1210117.
   Kurosu T, 2009, CANCER RES, V69, P3927, DOI 10.1158/0008-5472.CAN-08-2978.
   Lu J, 2013, BLOOD, V122, P1610, DOI 10.1182/blood-2013-01-481457.
   Masson K, 2009, BRIT J HAEMATOL, V146, P193, DOI 10.1111/j.1365-2141.2009.07725.x.
   Meshinchi S, 2009, CLIN CANCER RES, V15, P4263, DOI 10.1158/1078-0432.CCR-08-1123.
   Minami Y, 2003, BLOOD, V102, P2969, DOI 10.1182/blood-2002-12-3813.
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070.
   Nagao T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084746.
   Nogami A, 2019, TRANSL ONCOL, V12, P336, DOI 10.1016/j.tranon.2018.11.001.
   Nogami A, 2015, ONCOTARGET, V6, P9189, DOI 10.18632/oncotarget.3279.
   Nordigården A, 2009, BLOOD, V113, P2302, DOI 10.1182/blood-2008-07-167023.
   Okada Keigo, 2018, Oncotarget, V9, P8870, DOI 10.18632/oncotarget.22926.
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034.
   Oshikawa G, 2011, J BIOL CHEM, V286, P30263, DOI 10.1074/jbc.M111.232348.
   Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001.
   Rolfe M, 2005, BIOCHEM J, V388, P973, DOI 10.1042/BJ20041888.
   Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200.
   Roux PP, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00070-18.
   Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101.
   Sarosiek KA, 2013, MOL CELL, V51, P751, DOI 10.1016/j.molcel.2013.08.048.
   Scheijen B, 2004, ONCOGENE, V23, P3338, DOI 10.1038/sj.onc.1207456.
   Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166.
   Shimamura A, 2000, CURR BIOL, V10, P127, DOI 10.1016/S0960-9822(00)00310-9.
   Sionov RV, 2015, ONCOTARGET, V6, P23058, DOI 10.18632/oncotarget.5492.
   Springuel L, 2015, HAEMATOLOGICA, V100, P1240, DOI 10.3324/haematol.2015.132142.
   Tamburini J, 2009, BLOOD, V114, P1618, DOI 10.1182/blood-2008-10-184515.
   van Gorp AGM, 2009, ONCOGENE, V28, P95, DOI 10.1038/onc.2008.367.
   Verma Sheetal, 2012, Adv Hematol, V2012, P380635, DOI 10.1155/2012/380635.
   Wang LJ, 2018, FASEB J, V32, P875, DOI 10.1096/fj.201700672RR.
   Wöhrle FU, 2009, CELL COMMUN SIGNAL, V7, DOI 10.1186/1478-811X-7-22.
   Yang JL, 2013, CANCER RES, V73, P4898, DOI 10.1158/0008-5472.CAN-12-4277.
   Yang XP, 2005, CANCER RES, V65, P7338, DOI 10.1158/0008-5472.CAN-04-2263.
   Zhang F, 2009, CANCER BIOL THER, V8, P846, DOI 10.4161/cbt.8.9.8210.
   Zhang SL, 2000, BIOCHEM BIOPH RES CO, V277, P195, DOI 10.1006/bbrc.2000.3662.
   Zhang X, 2010, J MED CHEM, V53, P2482, DOI 10.1021/jm901645u.
   Zhang XC, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00357-16.
   Zhang XC, 2013, MOL CELL BIOL, V33, P1657, DOI 10.1128/MCB.01353-12.},
Number-of-Cited-References = {65},
Times-Cited = {42},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {KC7VZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000507382100007},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000499934700001,
Author = {Du, Xinyue and Zhang, Yang and Li, Xiao and Li, Qi and Wu, Chenyun and
   Chen, Guangjie and Guo, XiaoKui and Weng, Yongqiang and Wang, Zhaojun},
Title = {PRL2 serves as a negative regulator in cell adaptation to oxidative
   stress},
Journal = {CELL AND BIOSCIENCE},
Year = {2019},
Volume = {9},
Number = {1},
Month = {NOV 29},
Abstract = {High levels of ROS cause oxidative stress, which plays a critical role
   in cell death. As a ROS effector protein, PRL2 senses ROS and controls
   phagocyte bactericidal activity during infection. Here we report PRL2
   regulates oxidative stress induced cell death. PRL2 senses oxidative
   stress via highly reactive cysteine residues at 46 and 101. The
   oxidation of PRL2 causes protein degradation and supports pro-survival
   PDK1/AKT signal which in turn to protect cells against oxidative stress.
   As a result, PRL2 levels have a high correlation with oxidative stress
   induced cell death. In vivo experiments showed PRL2 deficient cells
   survive better in inflammatory oxidative environment and resist to
   ionizing radiation. Our finding suggests PRL2 serves as a negative
   regulator in cell adaptation to oxidative stress. Therefore, PRL2 could
   be targeted to modulate cell viability in inflammation or irradiation
   associated therapy.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, ZJ (Corresponding Author), Shanghai Jiao Tong Univ, Sch Med, Dept Immunol \& Microbiol, Rm 709 Bldg 5,280 S Chongqing Rd, Shanghai 200025, Peoples R China.
   Weng, YQ (Corresponding Author), Fudan Univ, Shanghai Med Coll, Huadong Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.
   Du, Xinyue; Zhang, Yang; Li, Xiao; Li, Qi; Wu, Chenyun; Chen, Guangjie; Wang, Zhaojun, Shanghai Jiao Tong Univ, Sch Med, Dept Immunol \& Microbiol, Rm 709 Bldg 5,280 S Chongqing Rd, Shanghai 200025, Peoples R China.
   Weng, Yongqiang, Fudan Univ, Shanghai Med Coll, Huadong Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China.
   Guo, XiaoKui, Shanghai Jiao Tong Univ, Inst Global Hlth, Sch Med, Chinese Ctr Trop Dis Res, Shanghai 200025, Peoples R China.},
DOI = {10.1186/s13578-019-0358-z},
Article-Number = {96},
EISSN = {2045-3701},
Keywords = {PRL2; Oxidative stress; Cell death; Inflammation; Ionizing radiation},
Keywords-Plus = {TYROSINE-PHOSPHATASE 4A2; REDOX REGULATION; PROTEIN-KINASE; EXPRESSION;
   CANCER; ACTIVATION; SURVIVAL; DEATH; AKT},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {wyq1415@hotmail.com
   zjwang@sjtu.edu.cn},
Affiliations = {Shanghai Jiao Tong University; Fudan University; Shanghai Jiao Tong
   University},
ResearcherID-Numbers = {Wang, Zhaojun/GKS-9141-2022
   Li, Qi/GSM-8045-2022},
ORCID-Numbers = {Guo, Xiao-Kui/0000-0002-1595-9965
   Wang, Zhaojun/0000-0003-2853-1850
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}NSF-81971486]; Natural
   Science Foundation of Shanghai {[}19ZR1428500]; innovative research team
   of high-level local universities in Shanghai},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (NSF-81971486), Natural Science Foundation of
   Shanghai (19ZR1428500) and innovative research team of high-level local
   universities in Shanghai. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Andres SA, 2013, HORM CANCER-US, V4, P208, DOI 10.1007/s12672-013-0141-2.
   Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012.
   Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Campa Carlo C, 2015, Small GTPases, V6, P71, DOI {[}10.4161/21541248.2014.989789, 10.4161/21541248.2014.989789].
   Campbell AM, 2014, EXPERT OPIN THER TAR, V18, P555, DOI 10.1517/14728222.2014.892926.
   Dainiak N, 2002, EXP HEMATOL, V30, P513, DOI 10.1016/S0301-472X(02)00802-0.
   {[}杜新月 Du Xinyue], 2019, {[}现代免疫学, Current Immunology], V39, P282.
   Dumaual CM, 2006, J HISTOCHEM CYTOCHEM, V54, P1401, DOI 10.1369/jhc.6A7019.2006.
   Dupré-Crochet S, 2013, J LEUKOCYTE BIOL, V94, P657, DOI 10.1189/jlb.1012544.
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600.
   Funato Y, 2014, METHODS, V65, P184, DOI 10.1016/j.ymeth.2013.06.032.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Hardy S, 2018, FEBS J, V285, P3886, DOI 10.1111/febs.14503.
   James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709.
   Kuwabara M, 2008, J CLIN BIOCHEM NUTR, V43, P51, DOI 10.3164/jcbn.2008045.
   Navarro-Yepes J, 2014, ANTIOXID REDOX SIGN, V21, P66, DOI 10.1089/ars.2014.5837.
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008.
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI {[}10.1016/j.cryobiol.2017.10.064, 10.1016/j.bbamcr.2016.09.012].
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006.
   Rios P, 2013, FEBS J, V280, P505, DOI 10.1111/j.1742-4658.2012.08565.x.
   Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817.
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034.
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957.
   Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624.
   Wang YJ, 2007, AM J RESP CELL MOL, V36, P68, DOI 10.1165/rcmb.2006-0165OC.
   Xu Jianming, 2005, Curr Protoc Mol Biol, VChapter 28, DOI 10.1002/0471142727.mb2801s70.
   Yin CN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02609.
   Yu L, 2007, BBA-MOL CELL RES, V1773, P1473, DOI 10.1016/j.bbamcr.2007.06.005.
   Zhao D, 2015, ONCOTARGETS THER, V8, P1707, DOI 10.2147/OTT.S85899.},
Number-of-Cited-References = {31},
Times-Cited = {5},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Cell Biosci.},
Doc-Delivery-Number = {JR9KH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000499934700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000499645800011,
Author = {Geue, Sascha and Aurbach, Katja and Manke, Mailin-Christin and Manukjan,
   Georgi and Muenzer, Patrick and Stegner, David and Braehler, Caroline
   and Walker-Allgaier, Britta and Marklin, Melanie and Borst, Carla E. and
   Quintanilla-Fend, Leticia and Rath, Dominik and Geisler, Tobias and
   Salih, Helmut R. and Seizer, Peter and Lang, Florian and Nieswandt,
   Bernhard and Gawaz, Meinrad and Schulze, Harald and Pleines, Irina and
   Borst, Oliver},
Title = {Pivotal role of PDK1 in megakaryocyte cytoskeletal dynamics and
   polarization during platelet biogenesis},
Journal = {BLOOD},
Year = {2019},
Volume = {134},
Number = {21},
Pages = {1847-1858},
Month = {NOV 21},
Abstract = {During thrombopoiesis, megakaryocytes (MKs) form proplatelets within the
   bone marrow (BM) and release platelets into BM sinusoids.
   Phosphoinositide-dependent protein kinase-1 (PDK1) is required for
   Ca2+-dependent platelet activation, but its role in MK development and
   regulation of platelet production remained elusive. The present study
   explored the role of PDK1 in the regulation of MK maturation and
   polarization during thrombopoiesis using a MK/platelet-specific knockout
   approach. Pdk1-deficient mice (Pdk1(-/-)) developed a significant
   macrothrombocytopenia as compared with wild-type mice (Pdk1(fl/fl)).
   Pdk1 deficiency further dramatically increased the number of MKs without
   sinusoidal contact within the BM hematopoietic compartment, resulting in
   a pronounced MK hyperplasia and a significantly increased extramedullary
   thrombopoiesis. Cultured Pdk1(-/-) BM-MKs showed impaired spreading on
   collagen, associated with an altered actin cytoskeleton structure with
   less filamentous actin (F-actin) and diminished podosome formation,
   whereas the tubulin cytoskeleton remained unaffected. This phenotype was
   associated with abrogated phosphorylation of p21-activated kinase (PAK)
   as well as its substrates LIM domain kinase and cofilin, supporting the
   hypothesis that the defective F-actin assembly results from increased
   cofilin activity in Pdk1-deficient MKs. Pdk1(-/-) BM-MKs developed
   increased ploidy and exhibited an abnormal ultrastructure with disrupted
   demarcation membrane system (DMS). Strikingly, Pdk1(-/-) BM-MKs
   displayed a pronounced defect in DMS polarization and produced
   significantly less proplatelets, indicating that PDK1 is critically
   required for proplatelet formation. In human MKs, genetic PDK1 knockdown
   resulted in increased maturity but reduced platelet-like particles
   formation. The present observations reveal a pivotal role of PDK1 in the
   regulation of MK cytoskeletal dynamics and polarization, proplatelet
   formation, and thrombopoiesis.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Borst, O (Corresponding Author), Univ Tubingen, Dept Cardiol Angiol \& Cardiovasc Med, Otfried Muller Str 10, D-72076 Tubingen, Germany.
   Geue, Sascha; Manke, Mailin-Christin; Muenzer, Patrick; Walker-Allgaier, Britta; Rath, Dominik; Geisler, Tobias; Seizer, Peter; Lang, Florian; Gawaz, Meinrad; Borst, Oliver, Univ Tubingen, Dept Cardiol Angiol \& Cardiovasc Med, Otfried Muller Str 10, D-72076 Tubingen, Germany.
   Aurbach, Katja; Stegner, David; Nieswandt, Bernhard; Pleines, Irina, Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany.
   Aurbach, Katja; Manukjan, Georgi; Stegner, David; Braehler, Caroline; Nieswandt, Bernhard; Schulze, Harald; Pleines, Irina, Univ Hosp Wurzburg, Inst Expt Biomed, Wurzburg, Germany.
   Marklin, Melanie; Salih, Helmut R., German Canc Consortium DKTK, Clin Cooperat Unit Translat Immunol, DKFZ Partner Site Tubingen, Tubingen, Germany.
   Borst, Carla E., Univ Tubingen, Dept Hematol \& Oncol, Tubingen, Germany.
   Quintanilla-Fend, Leticia, Univ Tubingen, Dept Pathol, Tubingen, Germany.
   Lang, Florian, Univ Tubingen, Dept Physiol, Tubingen, Germany.},
DOI = {10.1182/blood.2019000185},
ISSN = {0006-4971},
EISSN = {1528-0020},
Keywords-Plus = {DEMARCATION MEMBRANE SYSTEM; PROTEIN-KINASE; ACTIVATION; PKC;
   DEFICIENCY; 3-KINASE; PATHWAY; THROMBOPOIESIS; PROLIFERATION;
   ENDOMITOSIS},
Research-Areas = {Hematology},
Web-of-Science-Categories  = {Hematology},
Author-Email = {oliver.borst@med.uni-tuebingen.de},
Affiliations = {Eberhard Karls University of Tubingen; University of Wurzburg;
   University of Wurzburg; Helmholtz Association; German Cancer Research
   Center (DKFZ); Eberhard Karls University of Tubingen; Eberhard Karls
   University of Tubingen; Eberhard Karls University Hospital; Eberhard
   Karls University of Tubingen},
ResearcherID-Numbers = {Stegner, David/AAA-4948-2019
   Geisler, Tobias/AAO-4472-2020
   Märklin, Melanie/AAN-9222-2021},
ORCID-Numbers = {Borst, Oliver/0000-0003-4002-4085
   Münzer, Patrick/0000-0001-5357-038X
   Stegner, David/0000-0003-1059-9865
   },
Funding-Acknowledgement = {Deutsche Forschungsgemeinschaft (German Research Foundation)
   {[}374031971-TR 240]; Open Access Publishing Fund of the University of
   Tubingen},
Funding-Text = {This study was funded by the Deutsche Forschungsgemeinschaft (German
   Research Foundation), project number 374031971-TR 240. The authors
   acknowledge support by the Open Access Publishing Fund of the University
   of Tubingen.},
Cited-References = {Antkowiak A, 2016, J THROMB HAEMOST, V14, P1268, DOI 10.1111/jth.13318.
   Baatout S, 1998, ANTICANCER RES, V18, P3347.
   Bender M, 2010, BLOOD, V116, P3347, DOI 10.1182/blood-2010-06-289108.
   Borst O, 2012, CIRC RES, V111, P1297, DOI 10.1161/CIRCRESAHA.112.276444.
   Borst O, 2012, BLOOD, V119, P251, DOI 10.1182/blood-2011-06-359976.
   Chen X, 2013, BLOOD, V121, P3718, DOI 10.1182/blood-2012-10-461897.
   Chen YM, 2006, P NATL ACAD SCI USA, V103, P8534, DOI 10.1073/pnas.0509955103.
   Dan HC, 2016, ONCOTARGET, V7, P21064, DOI 10.18632/oncotarget.8383.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Dütting S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15838.
   Eckly A, 2014, BLOOD, V123, P921, DOI 10.1182/blood-2013-03-492330.
   Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8.
   Feng QT, 2010, MOL CELL BIOL, V30, P3711, DOI 10.1128/MCB.00420-10.
   Gagliardi PA, 2014, J CELL BIOL, V206, P415, DOI 10.1083/jcb.201312090.
   Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521.
   Italiano JE, 1999, J CELL BIOL, V147, P1299, DOI 10.1083/jcb.147.6.1299.
   Junt T, 2007, SCIENCE, V317, P1767, DOI 10.1126/science.1146304.
   Kauskot A, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88643.
   King CC, 2000, J BIOL CHEM, V275, P41201, DOI 10.1074/jbc.M006553200.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   Kosoff RE, 2015, BLOOD, V125, P2995, DOI 10.1182/blood-2014-10-604504.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042.
   Lordier L, 2008, BLOOD, V112, P3164, DOI 10.1182/blood-2008-03-144956.
   Machlus KR, 2016, BLOOD, V127, P921, DOI 10.1182/blood-2015-05-644583.
   Machlus KR, 2013, J CELL BIOL, V201, P785, DOI 10.1083/jcb.201304054.
   Manne BK, 2018, J THROMB HAEMOST, V16, P1904, DOI 10.1111/jth.14230.
   Mashukova A, 2012, MOL BIOL CELL, V23, P1664, DOI 10.1091/mbc.E11-12-0988.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469.
   Münzer P, 2017, BLOOD, V130, P2774, DOI 10.1182/blood-2017-05-784413.
   Münzer P, 2016, ARTERIOSCL THROM VAS, V36, P1507, DOI 10.1161/ATVBAHA.115.307105.
   Nakao T, 2008, CELL CYCLE, V7, P257, DOI 10.4161/cc.7.2.5148.
   Patel SR, 2005, J CLIN INVEST, V115, P3348, DOI 10.1172/JCI26891.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pietri M, 2013, NAT MED, V19, P1124, DOI 10.1038/nm.3302.
   Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675.
   Pleines I, 2016, BLOOD, V128, P3025, DOI 10.1182/blood-2016-11-746685.
   Pleines I, 2013, BLOOD, V122, P3178, DOI 10.1182/blood-2013-03-487942.
   Pleines I, 2012, BLOOD, V119, P1054, DOI 10.1182/blood-2011-08-372193.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Rojnuckarin P, 1999, BLOOD, V94, P1273, DOI 10.1182/blood.V94.4.1273.416k04\_1273\_1282.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Schachtner H, 2013, BLOOD, V121, P2542, DOI 10.1182/blood-2012-07-443457.
   Schulze H, 2006, BLOOD, V107, P3868, DOI 10.1182/blood-2005-07-2755.
   Spindler M, 2018, BLOOD, V132, P635, DOI 10.1182/blood-2018-01-829259.
   Suzuki A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069315.
   TABLIN F, 1990, J CELL SCI, V97, P59.
   Thomas SG, 2017, PLATELETS, V28, P372, DOI 10.1080/09537104.2016.1235688.
   Weisberg E, 2008, BLOOD, V111, P3723, DOI 10.1182/blood-2007-09-114454.
   Whyte J, 2010, J CELL SCI, V123, P3316, DOI 10.1242/jcs.065243.
   Zabkiewicz J, 2014, HAEMATOLOGICA, V99, P858, DOI 10.3324/haematol.2013.096487.
   Zaru R, 2008, J BIOL CHEM, V283, P929, DOI 10.1074/jbc.M708069200.},
Number-of-Cited-References = {54},
Times-Cited = {30},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Blood},
Doc-Delivery-Number = {JR5DO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000499645800011},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000495611100072,
Author = {Sharma, Gaurav and Wu, Cheng-Yang and Wynn, R. Max and Gui, Wenjun and
   Malloy, Craig R. and Sherry, A. Dean and Chuang, David T. and Khemtong,
   Chalermchai},
Title = {Real-time hyperpolarized 13C magnetic resonance detects
   increased pyruvate oxidation in pyruvate dehydrogenase kinase 2/4-double
   knockout mouse livers},
Journal = {SCIENTIFIC REPORTS},
Year = {2019},
Volume = {9},
Month = {NOV 11},
Abstract = {The pyruvate dehydrogenase complex (PDH) critically regulates
   carbohydrate metabolism. Phosphorylation of PDH by one of the pyruvate
   dehydrogenase kinases 1-4 (PDK1-4) decreases the flux of carbohydrates
   into the TCA cycle. Inhibition of PDKs increases oxidative metabolism of
   carbohydrates, so targeting PDKs has emerged as an important therapeutic
   approach to manage various metabolic diseases. Therefore, it is highly
   desirable to begin to establish imaging tools for noninvasive
   measurements of PDH flux in rodent models. In this study, we used
   hyperpolarized (HP) C-13-magnetic resonance spectroscopy to study the
   impact of a PDK2/PDK4 double knockout (DKO) on pyruvate metabolism in
   perfused livers from lean and diet-induced obese (DIO) mice and
   validated the HP observations with high-resolution C-13-nuclear magnetic
   resonance (NMR) spectroscopy of tissue extracts and steady-state
   isotopomer analyses. We observed that PDK-deficient livers produce more
   HP-bicarbonate from HP-{[}1-C-13]pyruvate than age-matched control
   livers. A steady-state C-13-NMR isotopomer analysis of tissue extracts
   confirmed that flux rates through PDH, as well as pyruvate carboxylase
   and pyruvate cycling activities, are significantly higher in
   PDK-deficient livers. Immunoblotting experiments confirmed that
   HP-bicarbonate production from HP-{[}1-C-13]pyruvate parallels decreased
   phosphorylation of the PDH E1 alpha subunit (pE1 alpha) in liver tissue.
   Our findings indicate that combining real-time hyperpolarized C-13 NMR
   spectroscopy and C-13 isotopomer analysis provides quantitative insights
   into intermediary metabolism in PDK-knockout mice. We propose that this
   method will be useful in assessing metabolic disease states and
   developing therapies to improve PDH flux.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Khemtong, C (Corresponding Author), Univ Texas Southwestern Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA.
   Khemtong, C (Corresponding Author), Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
   Sharma, Gaurav; Wu, Cheng-Yang; Malloy, Craig R.; Sherry, A. Dean; Khemtong, Chalermchai, Univ Texas Southwestern Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA.
   Wynn, R. Max; Gui, Wenjun; Chuang, David T., Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, Dallas, TX USA.
   Wynn, R. Max; Malloy, Craig R.; Chuang, David T., Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, Dallas, TX USA.
   Malloy, Craig R.; Sherry, A. Dean; Khemtong, Chalermchai, Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA.
   Sherry, A. Dean, Univ Texas Dallas, Dept Chem, Dallas, TX USA.},
DOI = {10.1038/s41598-019-52952-6},
Article-Number = {16480},
ISSN = {2045-2322},
Keywords-Plus = {CITRIC-ACID CYCLE; HEPATIC STEATOSIS; SUBSTRATE SELECTION; ISOTOPOMER
   ANALYSIS; ALTERNATE PATHWAYS; CARBON FLUX; GLUCOSE; GLUCONEOGENESIS;
   CARBOXYLASE; ANAPLEROSIS},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {charlie.khemtong@utsouthwestern.edu},
Affiliations = {University of Texas System; University of Texas Southwestern Medical
   Center; University of Texas System; University of Texas Southwestern
   Medical Center; University of Texas System; University of Texas
   Southwestern Medical Center; University of Texas System; University of
   Texas Southwestern Medical Center; University of Texas System;
   University of Texas Dallas},
ResearcherID-Numbers = {Sharma, Gaurav/L-3259-2018
   Sherry, Dean/P-2348-2018
   GUI, WEN/KIJ-6966-2024},
ORCID-Numbers = {Sharma, Gaurav/0000-0002-1754-7163
   Sherry, Dean/0000-0001-7150-8301
   Wu, Cheng-Yang/0000-0002-3582-083X
   Khemtong, Chalermchai/0000-0003-1976-8098
   },
Funding-Acknowledgement = {NIH {[}R37-HL034557, P41-EB015908, DK62306]; Welch Foundation
   {[}I-1286]; American Heart Association {[}18POST34050049]; American
   Heart Association (AHA) {[}18POST34050049] Funding Source: American
   Heart Association (AHA); National Institute of Biomedical Imaging and
   Bioengineering {[}P41EB015908] Funding Source: NIH RePORTER},
Funding-Text = {Xiaodong Wen and Thomas Hever are acknowledged for their technical
   support in the perfusion experiments. We thank the following agencies
   for financial support: NIH R37-HL034557 (ADS), NIH P41-EB015908 (CRM),
   NIH DK62306 (DTC), Welch Foundation I-1286 (DTC), and American Heart
   Association 18POST34050049 (GS).},
Cited-References = {Alves TC, 2011, HEPATOLOGY, V53, P1175, DOI 10.1002/hep.24170.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Burgess SC, 2004, J BIOL CHEM, V279, P48941, DOI 10.1074/jbc.M407120200.
   Burgess SC, 2006, J BIOL CHEM, V281, P19000, DOI 10.1074/jbc.M600050200.
   Cunningham CH, 2016, CIRC RES, V119, P1177, DOI 10.1161/CIRCRESAHA.116.309769.
   Dunford EC, 2011, AM J PHYSIOL-REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010.
   Ferriero R, 2015, J INHERIT METAB DIS, V38, P895, DOI 10.1007/s10545-014-9808-2.
   Go Y, 2016, DIABETES, V65, P2876, DOI 10.2337/db16-0223.
   Gray LR, 2014, CELL MOL LIFE SCI, V71, P2577, DOI 10.1007/s00018-013-1539-2.
   Holness MJ, 2000, DIABETES, V49, P775, DOI 10.2337/diabetes.49.5.775.
   Hwang B, 2012, FEBS J, V279, P1883, DOI 10.1111/j.1742-4658.2012.08569.x.
   Jeoung NH, 2008, AM J PHYSIOL-ENDOC M, V295, pE46, DOI 10.1152/ajpendo.00536.2007.
   Jeoung NH, 2014, REV ENDOCR METAB DIS, V15, P99, DOI 10.1007/s11154-013-9284-2.
   Jeoung NH, 2012, BIOCHEM J, V443, P829, DOI 10.1042/BJ20112197.
   Jin ES, 2004, ANAL BIOCHEM, V327, P149, DOI 10.1016/j.ab.2003.12.036.
   Jin ES, 2016, NMR BIOMED, V29, P466, DOI 10.1002/nbm.3479.
   Kakimoto PA, 2016, REDOX BIOL, V8, P216, DOI 10.1016/j.redox.2016.01.009.
   Kumashiro N, 2013, DIABETES, V62, P2183, DOI 10.2337/db12-1311.
   Kurhanewicz J, 2019, NEOPLASIA, V21, P1, DOI 10.1016/j.neo.2018.09.006.
   Lee P, 2013, HEPATOLOGY, V57, P515, DOI 10.1002/hep.26028.
   Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699.
   Malloy CR, 1996, MAGN RESON MATER PHY, V4, P35, DOI 10.1007/BF01759778.
   MALLOY CR, 1987, FEBS LETT, V212, P58, DOI 10.1016/0014-5793(87)81556-9.
   MALLOY CR, 1988, J BIOL CHEM, V263, P6964.
   Merritt ME, 2007, P NATL ACAD SCI USA, V104, P19773, DOI 10.1073/pnas.0706235104.
   Merritt ME, 2011, P NATL ACAD SCI USA, V108, P19084, DOI 10.1073/pnas.1111247108.
   Moller DE, 2001, NATURE, V414, P821, DOI 10.1038/414821a.
   Moreno KX, 2015, METABOLOMICS, V11, P1144, DOI 10.1007/s11306-014-0768-1.
   Moreno KX, 2014, J BIOL CHEM, V289, P35859, DOI 10.1074/jbc.M114.613265.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32.
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148.
   Perry RJ, 2016, J BIOL CHEM, V291, P12161, DOI 10.1074/jbc.M116.720631.
   Pesta DH, 2015, AGING-US, V7, P1086, DOI 10.18632/aging.100854.
   Rahimi Y, 2014, P NATL ACAD SCI USA, V111, P16508, DOI 10.1073/pnas.1419104111.
   Ronnebaum SM, 2006, J BIOL CHEM, V281, P30593, DOI 10.1074/jbc.M511908200.
   Serrao EM, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00059.
   TAEGTMEYER H, 1980, BIOCHEM J, V186, P701, DOI 10.1042/bj1860701.
   Tao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071997.
   Tso SC, 2014, J BIOL CHEM, V289, P4432, DOI 10.1074/jbc.M113.533885.
   von Morze C, 2017, MAGN RESON MED, V77, P1429, DOI 10.1002/mrm.26245.
   WIELAND OH, 1982, REV PHYSIOL BIOCH P, V96, P123, DOI 10.1007/BFb0031008.
   Wu CY, 2018, MOL METAB, V12, P12, DOI 10.1016/j.molmet.2018.03.014.
   Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.},
Number-of-Cited-References = {45},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {JL5ZV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000495611100072},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000494401200001,
Author = {Liu, Ya and He, Xiaocui and Chen, Yuli and Cao, Dan},
Title = {Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian
   cancer through inhibition of miR-1244},
Journal = {MOLECULAR AND CELLULAR BIOCHEMISTRY},
Year = {2020},
Volume = {464},
Number = {1-2},
Pages = {39-50},
Month = {JAN},
Abstract = {Ovarian cancer (OC) is the most lethal gynecologic malignancy and long
   non-coding RNAs (lncRNAs) have been acknowledged as important regulators
   in human OC. This study aimed to investigate the function and underlying
   mechanisms of LINC00504 in OC. The expression levels of LINC00504 in
   human OC tissues and cell lines were investigated by qRT-PCR analysis.
   The OC cell proliferation, and apoptosis were evaluated by MTT assay,
   colony-formation assay, Caspase-3 activity assay, and nucleosome ELISA
   assay, respectively. The metabolic shift in OC cells was examined by
   aerobic glycolysis analysis. Dual-luciferase activity reporter assay and
   mRNA-miRNA pull-down assay were conducted to validate the interaction
   between LINC00504 and miR-1244. LINC00504 was upregulated in OC cell
   lines and specimens. Knockdown of LINC00504 inhibited cell
   proliferation, enhanced apoptosis, decreased glycolysis-related gene
   (PKM2, HK2, and PDK1) expression, and altered aerobic glycolysis in OC
   cells and vice versa. LINC00504 downregulated miR-1244 expression levels
   by acting as an endogenous sponge of miR-1244. Inhibition of miR-1244
   diminished the effects of LINC00504 on OC cells. Our study shows that
   LINC00504 promotes OC cell progression and stimulates aerobic glycolysis
   by interacting with miR-1244, which indicates that LINC00504 might act
   as a promising therapeutic target for OC treatment.},
Publisher = {SPRINGER},
Address = {VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Cao, D (Corresponding Author), Heze Municipal Hosp, Dept Gynecol, 2888 Caozhou Rd, Heze 274000, Shandong, Peoples R China.
   Liu, Ya; Cao, Dan, Heze Municipal Hosp, Dept Gynecol, 2888 Caozhou Rd, Heze 274000, Shandong, Peoples R China.
   He, Xiaocui; Chen, Yuli, Heze Municipal Hosp, Dept Gynecol \& Obstet, 2888 Caozhou Rd, Heze 274000, Shandong, Peoples R China.},
DOI = {10.1007/s11010-019-03647-z},
EarlyAccessDate = {NOV 2019},
ISSN = {0300-8177},
EISSN = {1573-4919},
Keywords = {Ovarian cancer (OC); Long non-coding RNAs (lncRNAs); LINC00504; Aerobic
   glycolysis; miR-1244},
Keywords-Plus = {DIAGNOSIS; MECHANISMS; MANAGEMENT},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {caodan20171109@163.com},
Cited-References = {Bhoola S, 2006, OBSTET GYNECOL, V107, P1399, DOI 10.1097/01.AOG.0000220516.34053.48.
   Cao JN, 2014, BIOL PROCED ONLINE, V16, DOI 10.1186/1480-9222-16-11.
   Desai Arpita, 2014, World J Transl Med, V3, P1.
   Dianatpour Ali, 2017, Asian Pac J Cancer Prev, V18, P2601.
   Doubeni CA, 2016, AM FAM PHYSICIAN, V93, P937.
   Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006.
   Feng JF, 2019, J CELL BIOCHEM, V120, P14725, DOI 10.1002/jcb.28733.
   Gao JY, 2015, ONCOL REP, V34, P3212, DOI 10.3892/or.2015.4318.
   Gao Y, 2015, HUM MOL GENET, V24, P841, DOI 10.1093/hmg/ddu502.
   Huang B, 2014, MOL BIOL REP, V41, P3915, DOI 10.1007/s11033-014-3259-6.
   Hubé F, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00140.
   Ji DL, 2018, PATHOL RES PRACT, V214, P1524, DOI 10.1016/j.prp.2018.08.014.
   LEE JY, 2018, BMC CANC, V18.
   Lei RL, 2017, ONCOTARGETS THER, V10, P35, DOI 10.2147/OTT.S112686.
   LI J, 2017, BIOSCI REP.
   Liu Shi-Ping, 2013, Cancer Biology Medicine, V10, P138, DOI 10.7497/j.issn.2095-3941.2013.03.003.
   Ma NN, 2018, EXP THER MED, V16, P73, DOI 10.3892/etm.2018.6188.
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046.
   Orr B, 2018, HEMATOL ONCOL CLIN N, V32, P943, DOI 10.1016/j.hoc.2018.07.010.
   Paraskevopoulou MD, 2016, METHODS MOL BIOL, V1402, P271, DOI 10.1007/978-1-4939-3378-5\_21.
   Qiu JJ, 2014, ONCOL REP, V31, P1613, DOI 10.3892/or.2014.3000.
   Rauh-Hain Jose A, 2011, Rev Obstet Gynecol, V4, P15.
   Razi S., 2016, ecancermedicalscience, V10, P628.
   Reid BM, 2017, CANCER BIOL MED, V14, P9, DOI 10.20892/j.issn.2095-3941.2016.0084.
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010.
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660.
   Thin KZ, 2018, PATHOL RES PRACT, V214, P801, DOI 10.1016/j.prp.2018.04.003.
   Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456.
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018.
   Wei CW, 2017, ONCOTARGET, V8, P55901, DOI 10.18632/oncotarget.18362.
   Xu JH, 2018, MOL MED REP, V17, P6472, DOI 10.3892/mmr.2018.8694.
   Yang JX, 2016, ADV EXP MED BIOL, V886, P13, DOI 10.1007/978-94-017-7417-8\_2.
   Yu YJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0725-5.
   Zampetaki A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01201.
   Zeng ST, 2019, CANCER BIOMARK, V24, P421, DOI 10.3233/CBM-182160.
   Zhang Y, 2017, THERANOSTICS, V7, P3155, DOI 10.7150/thno.19646.},
Number-of-Cited-References = {36},
Times-Cited = {43},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Mol. Cell. Biochem.},
Doc-Delivery-Number = {KI4DN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000494401200001},
DA = {2026-02-04},
}

@article{ WOS:000498861100046,
Author = {Xie, Li and Miao, Junqing and Li, Xiangchao and Yi, Xiaoping and Chu, Ju},
Title = {Regulation of the pyruvate metabolism node by monogene and polygene
   engineering of HEK-293 cells},
Journal = {RSC ADVANCES},
Year = {2019},
Volume = {9},
Number = {61},
Pages = {35760-35770},
Month = {NOV 3},
Abstract = {HEK-293 cells are increasingly being used in the production of human
   adenovirus (HAdV) vaccines. However, the production of HAdV vaccine has
   not met the requirements of industrial production. Recently, we
   investigated the effects of various regulatory genes of the pyruvate
   metabolism node on the substance and energy metabolism and adenovirus
   reproduction in HEK-293 cells. Initially, single regulatory genes,
   including pkm2, pdh alpha, pyc2, mpc3, aralar1, ldha and pdk1, were
   studied. We found that metabolic performance and adenovirus reproduction
   capacity in HEK-293 cells were improved, and maximum adenovirus titre
   was increased approximately 15-fold. Next, we co-overexpressed the key
   genes, including pkm2, pyc2 and aralar1. The PYC2-A-P-L cells that had
   the appropriate co-overexpression levels of three genes had the most
   pronounced regulatory effect. The maximum cell density and maximum
   specific growth rate were increased by 21\% compared with that in the
   control. The Delta Lac/Delta Glc and Delta NH3/Delta Gln were decreased
   by 26\% and 27\%, respectively. The ATP production rate and the ATP/O-2
   ratio were increased by 110\% and 20\%, respectively. The level of
   reactive oxygen species (ROS) was reduced by 60\%. The adenovirus
   reproductive ability of the PYC2-A-P-L cells was approximately 30-fold
   higher than that of the control. The results showed that proper
   overexpression of the aralar1, pkm2 and pyc2 genes can significantly
   improve the substance and energy metabolism efficiency in HEK-293 cells,
   maximize the metabolic balance of pyruvate, and ultimately improve HAdV
   reproduction. This study provides a method of regulation of pyruvate
   metabolism and polygenic metabolic engineering in mammalian cells
   cultured in vitro and suggests an effective method for efficient HAdV
   production.},
Publisher = {ROYAL SOC CHEMISTRY},
Address = {THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yi, XP (Corresponding Author), East China Univ Sci \& Technol, Sch Bioengn, State Key Lab Bioreactor Engn, 130 Mei Long Rd, Shanghai 200237, Peoples R China.
   Xie, Li; Miao, Junqing; Li, Xiangchao; Yi, Xiaoping; Chu, Ju, East China Univ Sci \& Technol, Sch Bioengn, State Key Lab Bioreactor Engn, 130 Mei Long Rd, Shanghai 200237, Peoples R China.},
DOI = {10.1039/c9ra07418j},
EISSN = {2046-2069},
Keywords-Plus = {ENERGY-METABOLISM; GLUCOSE; EXPRESSION; ADENOVIRUS; LACTATE;
   IMPROVEMENT; GLUTAMINE; INSECT; OVEREXPRESSION; OPTIMIZATION},
Research-Areas = {Chemistry},
Web-of-Science-Categories  = {Chemistry, Multidisciplinary},
Author-Email = {xpyi@ecust.edu.cn},
Affiliations = {East China University of Science \& Technology},
Funding-Acknowledgement = {Shanghai Zhangjiang National Innovation Demonstration Zone Key projects
   of Special Development Funds {[}201310-FX-B2-002]; Chinese National
   Programs for High Technology Research and Development {[}2015AA020801]},
Funding-Text = {This work was supported by grants from the Shanghai Zhangjiang National
   Innovation Demonstration Zone Key projects of Special Development Funds
   (201310-FX-B2-002) and the Chinese National Programs for High Technology
   Research and Development (2015AA020801).},
Cited-References = {Alves JC, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00145.
   {[}Anonymous], SCIENCE.
   Bricker DK, 2012, SCIENCE, V337, P96, DOI 10.1126/science.1218099.
   CARAVOKYRI C, 1993, J GEN VIROL, V74, P2819, DOI 10.1099/0022-1317-74-12-2819.
   DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615.
   Gupta SK, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00463.
   Haut LH, 2009, J LEUKOCYTE BIOL, V86, P779, DOI 10.1189/jlb.0209094.
   Henry O, 2005, METAB ENG, V7, P467, DOI 10.1016/j.ymben.2005.08.002.
   Henry O, 2011, BIOPROC BIOSYST ENG, V34, P263, DOI 10.1007/s00449-010-0468-9.
   Hill AVS, 2010, HUM VACCINES, V6, P78, DOI 10.4161/hv.6.1.10116.
   INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736.
   Irani N, 2002, J BIOTECHNOL, V93, P269, DOI 10.1016/S0168-1656(01)00409-6.
   Jeong DW, 2006, MOL CELL BIOCHEM, V284, P1, DOI 10.1007/s11010-005-9004-7.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Jeoung NH, 2014, REV ENDOCR METAB DIS, V15, P99, DOI 10.1007/s11154-013-9284-2.
   Jonsson F, 2017, VIRUS GENES, V53, P692, DOI 10.1007/s11262-017-1498-z.
   Kamen A, 2004, J GENE MED, V6, pS184, DOI 10.1002/jgm.503.
   Karengera E, 2017, J BIOTECHNOL, V242, P73, DOI 10.1016/j.jbiotec.2016.12.003.
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005.
   Lasaro MO, 2009, MOL THER, V17, P1333, DOI 10.1038/mt.2009.130.
   Lin J, 2019, RSC ADV, V9, P27369, DOI 10.1039/c9ra05128g.
   Liste-Calleja L, 2015, APPL MICROBIOL BIOT, V99, P9951, DOI 10.1007/s00253-015-6855-z.
   Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027.
   Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952.
   McShane H, 2005, MICROBES INFECT, V7, P962, DOI 10.1016/j.micinf.2005.03.009.
   MIZOCK BA, 1992, CRIT CARE MED, V20, P80, DOI 10.1097/00003246-199201000-00020.
   Monteiro F, 2017, BIOTECHNOL BIOENG, V114, P674, DOI 10.1002/bit.26089.
   Monteiro F, 2014, BIOTECHNOL BIOENG, V111, P816, DOI 10.1002/bit.25142.
   Mulukutla BC, 2010, TRENDS BIOTECHNOL, V28, P476, DOI 10.1016/j.tibtech.2010.06.005.
   Neermann J, 1996, J CELL PHYSIOL, V166, P152.
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148.
   PETCH D, 1994, J CELL PHYSIOL, V161, P71, DOI 10.1002/jcp.1041610110.
   Petiot E, 2015, VACCINE, V33, P5974, DOI 10.1016/j.vaccine.2015.05.097.
   Rodrigues AF, 2014, TRENDS BIOTECHNOL, V32, P602, DOI 10.1016/j.tibtech.2014.09.010.
   Roth E, 2002, NUTRITION, V18, P217, DOI 10.1016/S0899-9007(01)00797-3.
   Rubi B, 2004, J BIOL CHEM, V279, P55659, DOI 10.1074/jbc.M409303200.
   Sharon D, 2018, BIOTECHNOL BIOENG, V115, P25, DOI 10.1002/bit.26461.
   Stáfková J, 2016, MOL MICROBIOL, V100, P442, DOI 10.1111/mmi.13325.
   Vallée C, 2014, J BIOTECHNOL, V169, P63, DOI 10.1016/j.jbiotec.2013.11.002.
   Wang XY, 2017, J CELL MOL MED, V21, P3044, DOI 10.1111/jcmm.13216.
   Wu N, 2014, GENE THER, V21, P629, DOI 10.1038/gt.2014.40.
   Xia ZW, 2016, RSC ADV, V6, P61268, DOI 10.1039/c6ra06343h.
   Zhao HW, 2014, J IND MICROBIOL BIOT, V41, P869, DOI 10.1007/s10295-014-1421-8.},
Number-of-Cited-References = {43},
Times-Cited = {0},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {10},
Journal-ISO = {RSC Adv.},
Doc-Delivery-Number = {JQ3PM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000498861100046},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000502290100077,
Author = {Casari, Ilaria and Domenichini, Alice and Sestito, Simona and Capone,
   Emily and Sala, Gianluca and Rapposelli, Simona and Falasca, Marco},
Title = {Dual PDK1/Aurora Kinase A Inhibitors Reduce Pancreatic Cancer Cell
   Proliferation and Colony Formation},
Journal = {CANCERS},
Year = {2019},
Volume = {11},
Number = {11},
Month = {NOV},
Abstract = {Deregulation of different intracellular signaling pathways is a common
   feature in cancer. Numerous studies indicate that persistent activation
   of the phosphoinositide 3-kinase (PI3K) pathway is often observed in
   cancer cells. 3-phosphoinositide dependent protein kinase-1 (PDK1), a
   transducer protein that functions downstream of PI3K, is responsible for
   the regulation of cell proliferation and migration and it also has been
   found to play a key role in different cancers, pancreatic and breast
   cancer amongst others. As PI3K is being described to be aberrantly
   expressed in several cancer types, designing inhibitors targeting
   various downstream molecules of PI3K has been the focus of anticancer
   agent development for a long time. In particular, dual inhibitory drugs
   targeting key signaling molecules in the PI3K pathway have attracted the
   attention of scientists. Several drugs have progressed to clinical
   trials, with limited success due to toxicity and bioavailability
   concerns. Very few anticancer drugs targeting the PI3K pathway have been
   approved for clinical use and their efficacy is particularly limited
   towards certain tumors such as pancreatic cancer. Here, we tested two
   drugs displaying dual inhibitory activity towards PDK1 and Aurora kinase
   A in a panel of pancreatic cancer cell lines and in two in vivo models
   of pancreatic cancer. Our data show that both inhibitors are able to
   impair cell proliferation and clonogenic potential in pancreatic cancer
   cells. However, the limited activity of both compounds in vivo indicates
   that further optimization of the pharmacokinetics properties is
   required.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Falasca, M (Corresponding Author), Curtin Univ, Sch Pharm \& Biomed Sci, Curtin Hlth Innovat Res Inst, Metab Signalling Grp, Bentley, WA 6102, Australia.
   Casari, Ilaria; Domenichini, Alice; Falasca, Marco, Curtin Univ, Sch Pharm \& Biomed Sci, Curtin Hlth Innovat Res Inst, Metab Signalling Grp, Bentley, WA 6102, Australia.
   Sestito, Simona; Rapposelli, Simona, Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy.
   Capone, Emily; Sala, Gianluca, Univ G dAnnunzio, CAST, Dipartimento Sci Med Orali \& Biotecnol, I-66100 Chieti, Italy.},
DOI = {10.3390/cancers11111695},
Article-Number = {1695},
EISSN = {2072-6694},
Keywords = {3-phosphoinositide-dependent protein kinase 1; aurora kinase;
   PDK1/aurora A inhibitor; dual inhibitor; pancreatic cancer; cell
   proliferation; cell migration},
Keywords-Plus = {AURORA KINASE; PDK1; PATHWAY; STRATEGY; TARGET},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {ilaria.casari@curtin.edu.au
   alice.domenchini@curtin.edu.au
   simona.sestito@for.unipi.it
   caponemily@gmail.com
   g.sala@unich.it
   simona.rapposelli@unipi.it
   marco.falasca@curtin.edu.au},
Affiliations = {Curtin University; University of Pisa; G d'Annunzio University of
   Chieti-Pescara},
ResearcherID-Numbers = {Falasca, Marco/S-4020-2016
   Rapposelli, Simona/D-1595-2010
   SESTITO, SIMONA/AAE-6210-2019
   Sala, Gianluca/C-2056-2017
   Capone, Emily/AAH-7904-2021},
ORCID-Numbers = {Falasca, Marco/0000-0002-9801-7235
   Rapposelli, Simona/0000-0003-0146-6358
   SESTITO, SIMONA/0000-0002-6173-525X
   Sala, Gianluca/0000-0002-4494-915X
   Capone, Emily/0000-0001-6719-2535},
Funding-Acknowledgement = {Avner Pancreatic Cancer Foundation},
Funding-Text = {This project is made possible by an Avner Pancreatic Cancer Foundation
   grant (http://www.avnersfoundation.org.au).},
Cited-References = {Adamska Aleksandra, 2018, Advances in Biological Regulation, V68, P77, DOI {[}10.1016/j.jbior.2017.11.007, 10.1016/j.jbior.2017.11.007].
   Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009.
   Bavetsias V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00278.
   Bavetsias V, 2012, J MED CHEM, V55, P8721, DOI 10.1021/jm300952s.
   Bearss DJ, 2011, MOL CANCER THER, V10, P2012, DOI 10.1158/1535-7163.MCT-11-0720.
   Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Cicenas J, 2016, J CANCER RES CLIN, V142, P1995, DOI 10.1007/s00432-016-2136-1.
   D'Assoro AB, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00295.
   Damodaran AP, 2017, TRENDS PHARMACOL SCI, V38, P687, DOI 10.1016/j.tips.2017.05.003.
   Daniele S, 2017, ACS CHEM NEUROSCI, V8, P100, DOI 10.1021/acschemneuro.6b00251.
   de Groot CO, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00285.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Emmanouilidi A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1191-2.
   Erlanson DA, 2011, BIOORG MED CHEM LETT, V21, P3078, DOI 10.1016/j.bmcl.2011.03.032.
   Falasca M, 2010, CURR PHARM DESIGN, V16, P1410, DOI 10.2174/138161210791033950.
   Ferro R, 2014, WORLD J GASTROENTERO, V20, P10752, DOI 10.3748/wjg.v20.i31.10752.
   Friedberg JW, 2014, J CLIN ONCOL, V32, P44, DOI 10.1200/JCO.2012.46.8793.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x.
   Konings IRHM, 2009, CURR CANCER DRUG TAR, V9, P439, DOI 10.2174/156800909788166556.
   Kusum B., 2010, Int. J. Pharm. Sci.Rev. Res, V4, P76.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   LoRusso PM, 2016, J CLIN ONCOL, V34, P3803, DOI 10.1200/JCO.2014.59.0018.
   Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185.
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Raimondi C, 2016, SCI REP-UK, V6, DOI 10.1038/srep26142.
   Raimondi C, 2012, J CELL SCI, V125, P3153, DOI 10.1242/jcs.100511.
   Sabbah DA, 2011, CURR MED CHEM, V18, P5528.
   Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425.
   Sestito S, 2019, EXPERT OPIN THER PAT, V29, P271, DOI 10.1080/13543776.2019.1597852.
   Sestito S, 2016, EUR J MED CHEM, V118, P47, DOI 10.1016/j.ejmech.2016.04.003.
   Toker Alex, 2014, Advances in Biological Regulation, V55, P28, DOI 10.1016/j.jbior.2014.04.001.
   Westerfield M., 1995, ZEBRAFISH BOOK GUIDE.},
Number-of-Cited-References = {39},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {JV3UB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000502290100077},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000505937100024,
Author = {Filimonova, M. V. and Podosinnikova, T. S. and Samsonova, A. S. and
   Makarchuk, V. M. and Shevchenko, L. I. and Filimonov, A. S.},
Title = {Comparison of Antitumor Effects of Combined and Separate Treatment with
   NO Synthase Inhibitor T1023 and PDK1 Inhibitor Dichloroacetate},
Journal = {BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE},
Year = {2019},
Volume = {168},
Number = {1},
Pages = {92-94},
Month = {NOV},
Abstract = {Combined chronic treatment of Ehrlich solid carcinoma (EC) with an NOS
   inhibitor 1-isobutanoyl-2-isopropylisothiourea hydrobromide (T1023) and
   a PDK1 inhibitor dichloroacetate was accompanied by statistically
   significant synergetic antitumor effects manifested in a significant and
   stable suppression of neoplasm growth (by 55-65\%). Separate treatment
   with T1023 and dichloroacetate induced moderate short-term inhibition of
   tumor growth (by 30-35\%) followed by weakening of tumor sensitivity to
   these substances. These results attest to synergetic antitumor effects
   NOS inhibitor T1023 and PDK1 inhibitor dichloroacetate producing
   antiangiogenic and hypoxia-targeted cytotoxic effects, during their
   combined administration, which allows overcoming the adaptive potential
   of the tumors.},
Publisher = {SPRINGER},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Podosinnikova, TS (Corresponding Author), Minist Hlth Russian Federat, AF Tsyb Med Radiol Res Ctr, Branch Natl Med Res Ctr Radiol, Obninsk, Russia.
   Filimonova, M. V.; Podosinnikova, T. S.; Samsonova, A. S.; Makarchuk, V. M.; Shevchenko, L. I.; Filimonov, A. S., Minist Hlth Russian Federat, AF Tsyb Med Radiol Res Ctr, Branch Natl Med Res Ctr Radiol, Obninsk, Russia.},
DOI = {10.1007/s10517-019-04655-1},
ISSN = {0007-4888},
EISSN = {1573-8221},
Keywords = {NOS inhibitors; PDK1 inhibitor; Ehrlich carcinoma; hypoxic resistance},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {tanchitto@mail.ru},
Affiliations = {Ministry of Health of the Russian Federation},
ResearcherID-Numbers = {Saburova, Alina/O-5174-2017
   Filimonova, MV/AAQ-9017-2020
   Filimonov, AS/ABC-6039-2020
   Makarchuk, Viktoriya/ABC-5834-2020
   Shevchenko, Ludmila/ABC-6087-2020},
ORCID-Numbers = {Saburova, Alina/0000-0002-7703-0393
   Filimonova, MV/0000-0002-9690-4746
   Filimonov, AS/0000-0002-4398-1764
   },
Cited-References = {Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442.
   Duan Y, 2013, ONCOTARGETS THER, V6, P189, DOI 10.2147/OTT.S40992.
   Filimononva MV, 2014, P REG COMP BAS RES P, V19, P151.
   {[}Филимонова М.В. Filimonova M.V.], 2015, {[}Молекулярная медицина, Molekulyarnaya meditsina], P61.
   Koblyakov V.A., 2014, Usp. Molekul. Onkologii, V1, P44, DOI DOI 10.17650/2313-805X.2014.1.2.44-49.
   {[}Каприн А.Д. Kaprin A.D.], 2017, {[}Радиация и риск (Бюллетень Национального радиационно-эпидемиологического регистра), Radiation and Risk, Radiatsiya i risk (Byulleten' Natsional'nogo radiatsionno-epidemiologicheskogo registra)], V26, P26, DOI {[}10.21870/0131-3878-2017-26-2-26-40, 10.21870/0131-3878-2017-26-2-26-40].
   Osinskii S, 2009, MICROPHYSIOLOGY TUMO.
   Pyaskovskaya O. N., 2015, Experimental Oncology, V37, P192, DOI 10.31768/2312-8852.2015.37(3):192-196.},
Number-of-Cited-References = {8},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Bull. Exp. Biol. Med.},
Doc-Delivery-Number = {KA6WD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000505937100024},
DA = {2026-02-04},
}

@article{ WOS:000489945600020,
Author = {Han, Chae Young and Patten, David A. and Lee, Seung Gee and Parks, Robin
   J. and Chan, David W. and Harper, Mary-Ellen and Tsang, Enjamin K.},
Title = {p53 Promotes chemoresponsiveness by regulating hexokinase II gene
   transcription and metabolic reprogramming in epithelial ovarian cancer},
Journal = {MOLECULAR CARCINOGENESIS},
Year = {2019},
Volume = {58},
Number = {11},
Pages = {2161-2174},
Month = {NOV},
Abstract = {Metabolic reprogramming (including the Warburg effect) is a hallmark of
   cancer, yet the association between the altered metabolism and
   chemoresistance remains elusive. Hexokinase II (HKII) is a key metabolic
   enzyme and is upregulated in multiple cancers. In this study, we
   examined the impact of targeting metabolism via silencing of HKII on
   chemoresistance in ovarian cancer (OVCA). In addition, the regulatory
   molecular mechanism of tumor metabolism was examined using gain- and
   loss-of-function approaches in epithelial OVCA cell lines of various
   histological subtypes. We demonstrated that cisplatin (CDDP)-induced
   p53-mediated HKII downregulation is a determinant of chemosensitivity in
   OVCA. Silencing of HKII sensitized chemoresistant OVCA cells to
   apoptosis in a p53-dependent manner. As a negative regulator, p53
   suppressed HKII transcription by promoter binding and decreased
   glycolysis. Pyruvate dehydrogenase kinase-1 (PDK1) is a key regulator of
   cell proliferation involved in Akt signaling axis. Our Gene Expression
   Profiling Interactive Analysis (GEPIA) and molecular studies also
   revealed that PDK1, an upstream activator strongly correlates with HKII
   expression and regulates its metabolic activity. Finally, we
   demonstrated that the clinically approved drug metformin sensitizes
   chemoresistant OVCA cells to CDDP via PDK1-HKII pathway. Collectively,
   our data implicate that p53--PDK1-HKII axis is a central regulatory
   component of metabolism conferring chemoresistance in OVCA.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Tsang, EK (Corresponding Author), Ottawa Hosptial Res Inst, Gen Campus,501 Smyth Rd,Mail Box 511, Ottawa, ON K1H 8L6, Canada.
   Han, Chae Young; Lee, Seung Gee; Tsang, Enjamin K., Univ Ottawa, Dept Obstet \& Gynecol \& Cellular \& Mol Med, Ottawa, ON, Canada.
   Han, Chae Young; Lee, Seung Gee; Tsang, Enjamin K., Ottawa Hosp Res Inst, Chron Dis Program, Ottawa, ON, Canada.
   Patten, David A.; Parks, Robin J.; Harper, Mary-Ellen, Univ Ottawa, Dept Biochem Microbiol \& Immunol, Ottawa, ON, Canada.
   Patten, David A.; Harper, Mary-Ellen, Inst Syst Biol, Ottawa, ON, Canada.
   Parks, Robin J., Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON, Canada.
   Chan, David W., Univ Hong Kong, Dept Obstet \& Gynecol, Hong Kong, Peoples R China.},
DOI = {10.1002/mc.23106},
ISSN = {0899-1987},
EISSN = {1098-2744},
Keywords = {chemoresistance; hexokinase II; metabolism; ovarian cancer; p53},
Keywords-Plus = {TUMOR-SUPPRESSOR; CISPLATIN-RESISTANCE; CELLS; CHEMORESISTANCE; KINASE;
   UBIQUITINATION; PHOSPHORYLATES; ASSOCIATION; INHIBITION; MECHANISMS},
Research-Areas = {Biochemistry \& Molecular Biology; Oncology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Oncology},
Author-Email = {btsang@ohri.ca},
Affiliations = {University of Ottawa; University of Ottawa; Ottawa Hospital Research
   Institute; University of Ottawa; University of Ottawa; Ottawa Hospital
   Research Institute; University of Hong Kong},
ResearcherID-Numbers = {Harper, Mary-Ellen/C-3103-2009
   Chan, David/O-9896-2018},
ORCID-Numbers = {Parks, Robin/0000-0002-4959-2233
   HAN, CHAE YOUNG/0000-0002-5196-1579
   Chan, David/0000-0002-6951-3467},
Funding-Acknowledgement = {Canadian Institutes of Health Research (CIHR)},
Funding-Text = {This work was supported by the Canadian Institutes of Health Research
   (CIHR) to BKT (MOP 126144) and to MEH (FDN 143278). CYH and DAP are
   recipients of a University of Ottawa doctoral scholarship and a Canadian
   Nuclear Laboratories postdoctoral fellowship, respectively.},
Cited-References = {Abedini MR, 2008, CANCER RES, V68, P4511, DOI 10.1158/0008-5472.CAN-08-0673.
   Abedini MR, 2004, ONCOGENE, V23, P6997, DOI 10.1038/sj.onc.1207925.
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev.
   Cepeda V, 2007, ANTI-CANCER AGENT ME, V7, P3, DOI 10.2174/187152007779314044.
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Dwarakanath BS, 2009, J CANCER RES THER, V5, P21, DOI 10.4103/0973-1482.55136.
   ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45.
   Fraser M, 2008, INT J CANCER, V122, P534, DOI 10.1002/ijc.23086.
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384.
   Ha JH, 2018, CANCER RES, V78, P1923, DOI 10.1158/0008-5472.CAN-17-1624.
   Han Chae Young, 2018, Genes Cancer, V9, P155, DOI {[}10.18632/genesandcancer.176, 10.18632/genesandcancer.176].
   Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6.
   Nguyen HN, 2014, P NATL ACAD SCI USA, V111, pE2684, DOI 10.1073/pnas.1409433111.
   Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4.
   Kong B, 2014, J BIOL CHEM, V289, P27134, DOI 10.1074/jbc.M114.594812.
   Kurman RJ, 2008, INT J GYNECOL PATHOL, V27, P151, DOI 10.1097/PGP.0b013e318161e4f5.
   LANDAU BR, 1958, JNCI-J NATL CANCER I, V21, P485.
   Lengyel E, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2014.10.026.
   Liefke R, 2010, GENE DEV, V24, P590, DOI 10.1101/gad.563210.
   Lim JJ, 2017, ENDOCRINOLOGY, V158, P993, DOI 10.1210/en.2016-1866.
   Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603.
   Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200.
   Meng XH, 2017, J ENDOCRINOL, V233, pR43, DOI 10.1530/JOE-16-0450.
   Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200.
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014.
   Reles A, 2001, CLIN CANCER RES, V7, P2984.
   Roberts DJ, 2013, J BIOL CHEM, V288, P23798, DOI 10.1074/jbc.M113.482026.
   Rosen DG, 2009, FRONT BIOSCI-LANDMRK, V14, P2089, DOI 10.2741/3364.
   Salani B, 2013, SCI REP-UK, V3, DOI 10.1038/srep02070.
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387.
   Sigal A, 2000, CANCER RES, V60, P6788.
   Suh DH, 2014, CLIN EXP MED, V14, P345, DOI 10.1007/s10238-013-0250-9.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715.
   Wang L, 2014, CELL REP, V8, P1461, DOI 10.1016/j.celrep.2014.07.053.
   Wang X, 2017, SCI REP-UK, V7, DOI 10.1038/srep45983.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Yang X, 2008, BRIT J CANCER, V98, P803, DOI 10.1038/sj.bjc.6604223.
   Yung MMH, 2016, INTEGR CANCER THER, V15, P376, DOI 10.1177/1534735415611747.
   Yung MMH, 2016, ACTA BIOCH BIOPH SIN, V48, P301, DOI 10.1093/abbs/gmv128.
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935.
   Zhou YF, 2012, CANCER RES, V72, P304, DOI 10.1158/0008-5472.CAN-11-1674.},
Number-of-Cited-References = {48},
Times-Cited = {36},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Mol. Carcinog.},
Doc-Delivery-Number = {JD4KD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000489945600020},
DA = {2026-02-04},
}

@article{ WOS:000494843800011,
Author = {Hosoda, Enako and Hiraoka, Daisaku and Hirohashi, Noritaka and Omi, Saki
   and Kishimoto, Takeo and Chiba, Kazuyoshi},
Title = {SGK regulates pH increase and cyclin B-Cdk1 activation to resume meiosis
   in starfish ovarian oocytes},
Journal = {JOURNAL OF CELL BIOLOGY},
Year = {2019},
Volume = {218},
Number = {11},
Pages = {3612-3629},
Month = {NOV},
Abstract = {Tight regulation of intracellular pH (pH(i)) is essential for biological
   processes. Fully grown oocytes, having a large nucleus called the
   germinal vesicle, arrest at meiotic prophase I. Upon hormonal stimulus,
   oocytes resume meiosis to become fertilizable. At this time, the pH(i)
   increases via Na+/H+. exchanger activity, although the regulation and
   function of this change remain obscure. Here, we show that in starfish
   oocytes, serum- and glucocorticoid-regulated kinase (SGK) is activated
   via PI3K/TORC2/PDK1 signaling after hormonal stimulus and that SGK is
   required for this pH(i) increase and cyclin B-Cdk1 activation. When we
   clamped the pH(i) at 6.7, corresponding to the pH(i) of unstimulated
   ovarian oocytes, hormonal stimulation induced cyclin B-Cdk1 activation;
   thereafter, oocytes failed in actin-dependent chromosome transport and
   spindle assembly after germinal vesicle breakdown. Thus, this
   SGK-dependent pH(i) increase is likely a prerequisite for these events
   in ovarian oocytes. We propose a model that SGK drives meiotic
   resumption via concomitant regulation of the pH(i) and cell cycle
   machinery.},
Publisher = {ROCKEFELLER UNIV PRESS},
Address = {950 THIRD AVE, 2ND FLR, NEW YORK, NY 10022 USA},
Type = {Article},
Language = {English},
Affiliation = {Chiba, K (Corresponding Author), Ochanomizu Univ, Dept Biol Sci, Tokyo, Japan.
   Hosoda, Enako; Hirohashi, Noritaka; Omi, Saki; Chiba, Kazuyoshi, Ochanomizu Univ, Dept Biol Sci, Tokyo, Japan.
   Hiraoka, Daisaku; Kishimoto, Takeo, Ochanomizu Univ, Sci \& Educ Ctr, Tokyo, Japan.
   Hirohashi, Noritaka, Educ \& Res Ctr Biol Resources, Oki Marine Biol Stn, Matsue, Shimane, Japan.},
DOI = {10.1083/jcb.201812133},
ISSN = {0021-9525},
EISSN = {1540-8140},
Keywords-Plus = {MATURATION-PROMOTING FACTOR; NUCLEAR-ENVELOPE BREAKDOWN; METAPHASE-I
   ARREST; SEA-URCHIN EGGS; INTRACELLULAR PH; NA+/H+ EXCHANGER; SIGNALING
   PATHWAY; PROTEIN-KINASE; CELL-CYCLE; MOTIF PHOSPHORYLATION},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {chiba.kazuyoshi@ocha.ac.jp},
Affiliations = {Ochanomizu University; Ochanomizu University},
ORCID-Numbers = {Hiraoka, Daisaku/0000-0002-3875-2684
   Chiba, Kazuyoshi/0000-0003-0416-1090
   Hosoda, Enako/0000-0001-5199-3792
   Kishimoto, Takeo/0000-0003-1042-6921},
Funding-Acknowledgement = {Japan Society for the Promotion of Science KAKENHI {[}17K07405]; Takeda
   Science Foundation; Atmosphere and Ocean Research Institute, University
   of Tokyo; Grants-in-Aid for Scientific Research {[}17K07405] Funding
   Source: KAKEN},
Funding-Text = {This work was supported by Japan Society for the Promotion of Science
   KAKENHI grant no. 17K07405, the Takeda Science Foundation, and the
   Cooperative Program provided by the Atmosphere and Ocean Research
   Institute, University of Tokyo.},
Cited-References = {BALTZ JM, 1993, BIOESSAYS, V15, P523, DOI 10.1002/bies.950150805.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Bun P, 2018, ELIFE, V7, DOI 10.7554/eLife.31469.
   Burdyniuk M, 2018, J CELL BIOL, V217, P2661, DOI 10.1083/jcb.201802080.
   CHIBA K, 1992, EUR J BIOCHEM, V207, P833, DOI 10.1111/j.1432-1033.1992.tb17114.x.
   CHIBA K, 1993, MOL BIOL CELL, V4, P1027, DOI 10.1091/mbc.4.10.1027.
   Chiba K, 2011, MOL REPROD DEV, V78, P808, DOI 10.1002/mrd.21378.
   Dube F, 1997, DEV BIOL, V190, P41, DOI 10.1006/dbio.1997.8682.
   Eltschinger S, 2016, TRENDS CELL BIOL, V26, P148, DOI 10.1016/j.tcb.2015.10.003.
   Flament S, 1996, INT J DEV BIOL, V40, P471.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023.
   GRANDIN N, 1990, J CELL BIOL, V111, P523, DOI 10.1083/jcb.111.2.523.
   Grillo-Hill BK, 2015, ELIFE, V4, DOI 10.7554/eLife.03270.
   Hamaguchi MS, 1997, CELL STRUCT FUNCT, V22, P387, DOI 10.1247/csf.22.387.
   Harada K, 2003, DEVELOPMENT, V130, P4581, DOI 10.1242/dev.00649.
   Harada K, 2010, J BIOL CHEM, V285, P24044, DOI 10.1074/jbc.M109.072553.
   HARRIS PJ, 1992, J CELL SCI, V102, P557.
   Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200.
   He PJ, 2011, MOL BIOL CELL, V22, P3812, DOI 10.1091/mbc.E11-04-0328.
   Hijikata A, 2011, PROTEINS, V79, P1868, DOI 10.1002/prot.23011.
   Hiraoka D, 2004, DEV BIOL, V276, P330, DOI 10.1016/j.ydbio.2004.08.036.
   Hiraoka D, 2011, ONCOGENE, V30, P4487, DOI 10.1038/onc.2011.155.
   Hiraoka D., 2019, J CELL BIOL, DOI {[}10.1093/jcb.201812122, DOI 10.1093/JCB.201812122].
   Hiraoka D, 2016, J CELL SCI, V129, P3153, DOI 10.1242/jcs.182170.
   Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555.
   Hunt T, 1989, CURR OPIN CELL BIOL, V1, P268, DOI 10.1016/0955-0674(89)90099-9.
   KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0.
   Kanellos G, 2016, J CELL SCI, V129, P3211, DOI 10.1242/jcs.187849.
   Kinoshita E, 2006, MOL CELL PROTEOMICS, V5, P749, DOI 10.1074/mcp.T500024-MCP200.
   KISHIMOTO T, 1986, METHOD CELL BIOL, V27, P379, DOI 10.1016/S0091-679X(08)60359-3.
   Kishimoto T, 2018, P JPN ACAD B-PHYS, V94, P180, DOI 10.2183/pjab.94.013.
   Kishimoto T, 2015, CHROMOSOMA, V124, P417, DOI 10.1007/s00412-015-0508-y.
   Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   LEE SC, 1981, DEV BIOL, V85, P358, DOI 10.1016/0012-1606(81)90267-0.
   Lénárt P, 2005, NATURE, V436, P812, DOI 10.1038/nature03810.
   Lénárt P, 2003, J CELL BIOL, V160, P1055, DOI 10.1083/jcb.200211076.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Liu Y, 2017, ELIFE, V6, DOI 10.7554/eLife.26002.
   Lu M, 2010, J AM SOC NEPHROL, V21, P811, DOI 10.1681/ASN.2009111168.
   Malik N, 2018, BIOCHEM J, V475, P117, DOI 10.1042/BCJ20170650.
   Masui Y, 2001, DIFFERENTIATION, V69, P1, DOI 10.1046/j.1432-0436.2001.690101.x.
   MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9.
   MIYAZAKI SI, 1975, J PHYSIOL-LONDON, V246, P55, DOI 10.1113/jphysiol.1975.sp010880.
   Mori M, 2014, CURR BIOL, V24, P1421, DOI 10.1016/j.cub.2014.05.019.
   Mori M, 2011, CURR BIOL, V21, P606, DOI 10.1016/j.cub.2011.03.002.
   Moriwaki K, 2013, ZOOL SCI, V30, P975, DOI 10.2108/zsj.30.975.
   NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0.
   Ochi H, 2016, MOL REPROD DEV, V83, P79, DOI 10.1002/mrd.22599.
   Oita E, 2004, J BIOL CHEM, V279, P18633, DOI 10.1074/jbc.M311122200.
   Okano-Uchida T, 1998, DEV BIOL, V197, P39, DOI 10.1006/dbio.1998.8881.
   Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741.
   Okumura E, 1996, J CELL BIOL, V132, P125, DOI 10.1083/jcb.132.1.125.
   Orlowski J, 2004, PFLUG ARCH EUR J PHY, V447, P549, DOI 10.1007/s00424-003-1110-3.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   REGULA CS, 1981, J CELL BIOL, V89, P45, DOI 10.1083/jcb.89.1.45.
   REZAI K, 1994, AM J PHYSIOL-CELL PH, V267, pC1717, DOI 10.1152/ajpcell.1994.267.6.C1717.
   RODEAU JL, 1987, DEV BIOL, V120, P481, DOI 10.1016/0012-1606(87)90251-X.
   Sadler KC, 1998, DEV BIOL, V197, P25, DOI 10.1006/dbio.1998.8869.
   SCHATTEN G, 1986, ANN NY ACAD SCI, V466, P940, DOI 10.1111/j.1749-6632.1986.tb38480.x.
   Sellier C, 2006, J CELL BIOCHEM, V98, P287, DOI 10.1002/jcb.20764.
   SHILLING F, 1989, DEV BIOL, V133, P605, DOI 10.1016/0012-1606(89)90063-8.
   STITH BJ, 1985, DEV BIOL, V107, P460, DOI 10.1016/0012-1606(85)90327-6.
   Strickland L, 2004, METHOD CELL BIOL, V74, P371.
   Tachibana K, 1997, EMBO J, V16, P4333, DOI 10.1093/emboj/16.14.4333.
   Tachibana K, 2000, P NATL ACAD SCI USA, V97, P14301, DOI 10.1073/pnas.97.26.14301.
   Takahashi E, 1999, J BIOL CHEM, V274, P20206, DOI 10.1074/jbc.274.29.20206.
   Tessier M, 2006, J BIOL CHEM, V281, P23978, DOI 10.1074/jbc.M604333200.
   Tessier M, 2006, J CELL BIOCHEM, V98, P1391, DOI 10.1002/jcb.20894.
   Usui K, 2008, DEV GROWTH DIFFER, V50, P357, DOI {[}10.1111/j.1440-169x.2008.01036.x, 10.1111/j.1440-169X.2008.01036.x].
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882.
   Wang DS, 2005, AM J PHYSIOL-CELL PH, V289, pC802, DOI 10.1152/ajpcell.00597.2004.
   Watanabe K, 1997, CELL MOTIL CYTOSKEL, V37, P263, DOI 10.1002/(SICI)1097-0169(1997)37:3<263::AID-CM8>3.0.CO;2-7.
   Wesolowska N., 2018, bioRxiv, P480434, DOI DOI 10.1101/480434.
   Yeoh S, 2002, J MOL BIOL, V315, P911, DOI 10.1006/jmbi.2001.5280.
   Yun CC, 2003, CELL PHYSIOL BIOCHEM, V13, P29, DOI 10.1159/000070247.},
Number-of-Cited-References = {77},
Times-Cited = {9},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {J. Cell Biol.},
Doc-Delivery-Number = {JK4VV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000494843800011},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000502786800256,
Author = {Lazzarino, Giacomo and Amorini, Angela Maria and Signoretti, Stefano and
   Musumeci, Giuseppe and Lazzarino, Giuseppe and Caruso, Giuseppe and
   Pastore, Francesco Saverio and Di Pietro, Valentina and Tavazzi, Barbara
   and Belli, Antonio},
Title = {Pyruvate Dehydrogenase and Tricarboxylic Acid Cycle Enzymes Are
   Sensitive Targets of Traumatic Brain Injury Induced Metabolic
   Derangement},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2019},
Volume = {20},
Number = {22},
Month = {NOV},
Abstract = {Using a closed-head impact acceleration model of mild or severe
   traumatic brain injury (mTBI or sTBI, respectively) in rats, we
   evaluated the effects of graded head impacts on the gene and protein
   expressions of pyruvate dehydrogenase (PDH), as well as major enzymes of
   mitochondrial tricarboxylic acid cycle (TCA). TBI was induced in
   anaesthetized rats by dropping 450 g from 1 (mTBI) or 2 m height (sTBI).
   After 6 h, 12 h, 24 h, 48 h, and 120 h gene expressions of enzymes and
   subunits of PDH. PDH kinases and phosphatases (PDK1-4 and PDP1-2,
   respectively), citrate synthase (CS), isocitrate dehydrogenase (IDH),
   oxoglutarate dehydrogenase (OGDH), succinate dehydrogenase (SDH),
   succinyl-CoA synthase (SUCLG), and malate dehydrogenase (MDH) were
   determined in whole brain extracts (n = 6 rats at each time for both TBI
   levels). In the same samples, the high performance liquid
   chromatographic (HPLC) determination of acetyl-coenzyme A (acetyl-CoA)
   and free coenzyme A (CoA-SH) was performed. Sham-operated animals (n =
   6) were used as controls. After mTBI, the results indicated a general
   transient decrease, followed by significant increases, in PDH and TCA
   gene expressions. Conversely, permanent PDH and TCA downregulation
   occurred following sTBI. The inhibitory conditions of PDH (caused by
   PDP1-2 downregulations and PDK1-4 overexpression) and SDH appeared to
   operate only after sTBI. This produced almost no change in acetyl-CoA
   and free CoA-SH following mTBI and a remarkable depletion of both
   compounds after sTBI. These results again demonstrated temporary or
   steady mitochondrial malfunctioning, causing minimal or profound
   modifications to energy-related metabolites, following mTBI or sTBI,
   respectively. Additionally, PDH and SDH appeared to be highly sensitive
   to traumatic insults and are deeply involved in mitochondrial-related
   energy metabolism imbalance.},
Publisher = {MDPI},
Address = {MDPI AG, Grosspeteranlage 5, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Lazzarino, G (Corresponding Author), Univ Catania, Dept Biomed \& Biotechnol Sci, Div Med Biochem, Viale A Doria 6, I-95125 Catania, Italy.
   Di Pietro, V (Corresponding Author), Univ Birmingham, Neurotrauma \& Ophthalmol Res Grp, Sch Clin \& Expt Med, Coll Med \& Dent Sci, Birmingham B15 2TT, W Midlands, England.
   Di Pietro, V (Corresponding Author), Queen Elizabeth Hosp, Natl Inst Hlth Res Surg Reconstruct \& Microbiol R, Birmingham B15 2TT, W Midlands, England.
   Tavazzi, B (Corresponding Author), Univ Cattolica Sacro Cuore, Inst Biochem \& Clin Biochem, Largo F Vito 1, I-00168 Rome, Italy.
   Tavazzi, B (Corresponding Author), Fdn Policlin Univ A Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy.
   Lazzarino, Giacomo, UniCamillus St Camillus Int Univ Hlth Sci, Via St Alessandro 8, I-00131 Rome, Italy.
   Amorini, Angela Maria; Lazzarino, Giuseppe, Univ Catania, Dept Biomed \& Biotechnol Sci, Div Med Biochem, Viale A Doria 6, I-95125 Catania, Italy.
   Signoretti, Stefano, S Eugenio Hosp, Div Emergency Urgency, UOC Neurosurg, Via Filippo Meda 35, I-00157 Rome, Italy.
   Musumeci, Giuseppe, Sch Med, Dept Biomed \& Biotechnol Sci, Human Anat \& Histol Sect, Via S Sofia 97, I-95123 Catania, Italy.
   Caruso, Giuseppe, Oasi Res Inst IRCCS, Via Conte Ruggero 73, I-94018 Troina, EN, Italy.
   Pastore, Francesco Saverio, Univ Roma Tor Vergata, Dept Syst Med, Via Montpellier 1, I-00133 Rome, Italy.
   Di Pietro, Valentina; Belli, Antonio, Univ Birmingham, Neurotrauma \& Ophthalmol Res Grp, Sch Clin \& Expt Med, Coll Med \& Dent Sci, Birmingham B15 2TT, W Midlands, England.
   Di Pietro, Valentina; Belli, Antonio, Queen Elizabeth Hosp, Natl Inst Hlth Res Surg Reconstruct \& Microbiol R, Birmingham B15 2TT, W Midlands, England.
   Tavazzi, Barbara, Univ Cattolica Sacro Cuore, Inst Biochem \& Clin Biochem, Largo F Vito 1, I-00168 Rome, Italy.
   Tavazzi, Barbara, Fdn Policlin Univ A Gemelli IRCCS, Largo A Gemelli 8, I-00168 Rome, Italy.},
DOI = {10.3390/ijms20225774},
Article-Number = {5774},
ISSN = {1661-6596},
EISSN = {1422-0067},
Keywords = {traumatic brain injury; mitochondrial dysfunction; pyruvate
   dehydrogenase; tricarboxylic acid cycle; acetyl-CoA; concussion},
Keywords-Plus = {MITOCHONDRIAL DYSFUNCTION; TEMPORAL WINDOW; CEREBRAL-CORTEX;
   MESSENGER-RNA; INBORN-ERRORS; COENZYME-A; GLUCOSE; EXPRESSION;
   VULNERABILITY; MODEL},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {giacomo.lazzarino@unicamillus.org
   amorini@unict.it
   stefano.signoretti@aslroma2.it
   g.musumeci@unict.it
   lazzarig@unict.it
   forgiuseppecaruso@gmail.com
   pastore@uniroma2.it
   dipietro@bham.ac.uk
   barbara.tavazzi@unicatt.it
   a.belli@bham.ac.uk},
Affiliations = {University of Catania; Sant'Eugenio Hospital; IRCCS - Oasi Research
   Institute; University of Rome Tor Vergata; University of Birmingham;
   University of Birmingham; Catholic University of the Sacred Heart;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli},
ResearcherID-Numbers = {SIGNORETTI, Stefano/AAL-5631-2020
   pastore, francesco saverio/D-3827-2012
   Belli, Antonio/I-3799-2015
   Musumeci, Giuseppe/K-9955-2016
   TAVAZZI, BARBARA/AAB-9830-2019
   Caruso, Giuseppe/C-1435-2018
   Lazzarino, Giacomo/IQT-0407-2023
   lazzarino, giuseppe/K-2277-2015},
ORCID-Numbers = {SIGNORETTI, Stefano/0000-0002-8086-1622
   pastore, francesco saverio/0000-0002-2041-5161
   Belli, Antonio/0000-0002-3211-9933
   Musumeci, Giuseppe/0000-0002-8260-8890
   TAVAZZI, BARBARA/0000-0001-8743-0895
   Caruso, Giuseppe/0000-0003-1571-5327
   Lazzarino, Giacomo/0000-0003-1639-0966
   AMORINI, Angela Maria/0000-0003-3525-9955
   lazzarino, giuseppe/0000-0002-5917-7279},
Funding-Acknowledgement = {University of Birmingham; Catholic University of Rome},
Funding-Text = {This research was funded in part by research funds of the University of
   Birmingham and of the Catholic University of Rome.},
Cited-References = {Amorini AM, 2017, J CELL MOL MED, V21, P530, DOI 10.1111/jcmm.12998.
   Amorini AM, 2016, BBA-MOL BASIS DIS, V1862, P679, DOI 10.1016/j.bbadis.2016.01.023.
   Bartnik-Olson BL, 2010, J NEUROTRAUM, V27, P2191, DOI 10.1089/neu.2010.1508.
   Bhowmick S, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8010011.
   Caravas J, 2014, DIABETES OBES METAB, V16, P21, DOI 10.1111/dom.12333.
   Carpenter KLH, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00112.
   Carteri RB, 2019, J NEUROTRAUM, V36, P2246, DOI 10.1089/neu.2018.6266.
   Dai W, 2009, BRAIN RES, V1251, P287, DOI 10.1016/j.brainres.2008.11.034.
   Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822.
   Dewan MC, 2019, J NEUROSURG, V130, P1080, DOI 10.3171/2017.10.JNS17352.
   Di Meo I, 2019, J INHERIT METAB DIS, V42, P49, DOI 10.1002/jimd.12026.
   Di Pietro V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09587-2.
   Di Pietro V, 2014, MOL MED, V20, P147, DOI 10.2119/molmed.2013.00153.
   Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032.
   Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2.
   Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00029.
   Gerbatin RD, 2017, MOL NEUROBIOL, V54, P7585, DOI 10.1007/s12035-016-0238-z.
   Harris JJ, 2012, J NEUROSCI, V32, P356, DOI 10.1523/JNEUROSCI.3430-11.2012.
   Hill RL, 2018, NEUROSCIENCE, V386, P265, DOI 10.1016/j.neuroscience.2018.06.028.
   Jalloh I, 2015, J CEREBR BLOOD F MET, V35, P111, DOI 10.1038/jcbfm.2014.177.
   Jiang XB, 1999, NEUROL MED-CHIR, V39, P649, DOI 10.2176/nmc.39.649.
   Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16.
   Kilbaugh TJ, 2015, EXP NEUROL, V271, P136, DOI 10.1016/j.expneurol.2015.05.009.
   Lama S, 2014, J BIOL CHEM, V289, P20200, DOI 10.1074/jbc.M114.570978.
   Lapel M, 2017, AM J PHYSIOL-CELL PH, V312, pC56, DOI 10.1152/ajpcell.00250.2016.
   Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013.
   Lazzarino G, 2017, MOL NEUROBIOL, V54, P7520, DOI 10.1007/s12035-016-0257-9.
   Lehmann S, 2013, J MOL MED, V91, P665, DOI 10.1007/s00109-013-1044-y.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291.
   Mergenthaler P, 2013, TRENDS NEUROSCI, V36, P587, DOI 10.1016/j.tins.2013.07.001.
   Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229.
   Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323.
   Sen AK, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00175.
   Shi L, 2015, CURR OPIN CELL BIOL, V33, P125, DOI 10.1016/j.ceb.2015.02.003.
   Shumar SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130013.
   Sibon OCM, 2016, NAT REV MOL CELL BIO, V17, P605, DOI 10.1038/nrm.2016.110.
   Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9.
   Singh K, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3764.
   Stovell MG, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00426.
   Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002.
   Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6.
   Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F.
   Üçal M, 2017, J NEUROTRAUM, V34, P475, DOI 10.1089/neu.2016.4411.
   Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74.
   Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8.
   Vakifahmetoglu-Norberg H, 2017, BIOCHEM BIOPH RES CO, V482, P426, DOI 10.1016/j.bbrc.2016.11.088.
   Walczak J, 2019, FASEB J, V33, P4388, DOI 10.1096/fj.201801843R.
   Wu Q, 2017, HISTOL HISTOPATHOL, V32, P551, DOI 10.14670/HH-11-841.
   Xing GQ, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00196.
   Xing GQ, 2012, NEUROSCI LETT, V525, P140, DOI 10.1016/j.neulet.2012.07.055.
   Xing GQ, 2012, EXP NEUROL, V234, P31, DOI 10.1016/j.expneurol.2011.12.007.
   Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047.
   Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263.
   Xu Z, 2018, MOL NEUROBIOL, V55, P3499, DOI 10.1007/s12035-017-0576-5.
   Yang MY, 2019, MITOCHONDRION, V46, P380, DOI 10.1016/j.mito.2018.10.002.
   Ye CY, 2015, NEUROPHARMACOLOGY, V95, P29, DOI 10.1016/j.neuropharm.2015.02.020.
   Zhou J, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00231.},
Number-of-Cited-References = {58},
Times-Cited = {40},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {18},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {JW0YW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000502786800256},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000502290100167,
Author = {Lin, Ching-Yu and Wang, Bi-Juan and Chen, Bo-Chih and Tseng, Jen-Chih
   and Jiang, Shih Sheng and Tsai, Kelvin K. and Shen, Ying-Ying and Yuh,
   Chiou Hwa and Sie, Zong-Lin and Wang, Wen-Ching and Kung, Hsing-Jien and
   Chuu, Chih-Pin},
Title = {Histone Demethylase KDM4C Stimulates the Proliferation of Prostate
   Cancer Cells via Activation of AKT and c-Myc},
Journal = {CANCERS},
Year = {2019},
Volume = {11},
Number = {11},
Month = {NOV},
Abstract = {Our three-dimensional organotypic culture revealed that human histone
   demethylase (KDM) 4C, a histone lysine demethylase, hindered the acini
   morphogenesis of RWPE-1 prostate cells, suggesting its potential
   oncogenic role. Knockdown (KD) of KDM4C suppressed cell proliferation,
   soft agar colony formation, and androgen receptor (AR) transcriptional
   activity in PCa cells as well as reduced tumor growth of human PCa cells
   in zebrafish xenotransplantation assay. Micro-Western array (MWA)
   analysis indicated that KD of KDM4C protein decreased the
   phosphorylation of AKT, c-Myc, AR, mTOR, PDK1, phospho-PDK1 S241, KDM8,
   and proteins involved in cell cycle regulators, while it increased the
   expression of PTEN. Fluorescent microscopy revealed that KDM4C
   co-localized with AR and c-Myc in the nuclei of PCa cells.
   Overexpression of either AKT or c-Myc rescued the suppressive effect of
   KDM4C KD on PCa cell proliferation. Echoing the above findings, the mRNA
   and protein expression of KDM4C was higher in human prostate tumor
   tissues as compared to adjacent normal prostate tissues, and higher
   KDM4C protein expression in prostate tumors correlated to higher protein
   expression level of AKT and c-Myc. In conclusion, KDM4C promotes the
   proliferation of PCa cells via activation of c-Myc and AKT.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Chuu, CP (Corresponding Author), Natl Hlth Res Inst, Inst Cellular \& Syst Med, Miaoli 35053, Taiwan.
   Chuu, CP (Corresponding Author), China Med Univ, Grad Program Aging, Taichung 404, Taiwan.
   Chuu, CP (Corresponding Author), China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan.
   Chuu, CP (Corresponding Author), Natl Chung Hsing Univ, Biotechnol Ctr, Taichung 402, Taiwan.
   Chuu, CP (Corresponding Author), Natl Hlth Res Inst, Inst Cellular \& Syst Med, Room R2-2021,35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan.
   Lin, Ching-Yu; Wang, Bi-Juan; Chen, Bo-Chih; Tseng, Jen-Chih; Chuu, Chih-Pin, Natl Hlth Res Inst, Inst Cellular \& Syst Med, Miaoli 35053, Taiwan.
   Jiang, Shih Sheng; Tsai, Kelvin K., Natl Hlth Res Inst, Nat Inst Canc Res, Miaoli 35053, Taiwan.
   Tsai, Kelvin K., Taipei Med Univ, Grad Inst Clin Med, Taipei 110, Taiwan.
   Shen, Ying-Ying, Natl Hlth Res Inst, Pathol Core Lab, Miaoli 35053, Taiwan.
   Yuh, Chiou Hwa; Sie, Zong-Lin, Natl Hlth Res Inst, Inst Mol \& Genom Med, Miaoli 35053, Taiwan.
   Wang, Wen-Ching, Natl Tsing Hua Univ, Inst Mol \& Cellular Biol, Hsinchu 300, Taiwan.
   Kung, Hsing-Jien, Taipei Med Univ, Grad Inst Canc Biol \& Drug Discovery, Taipei 110, Taiwan.
   Chuu, Chih-Pin, China Med Univ, Grad Program Aging, Taichung 404, Taiwan.
   Chuu, Chih-Pin, China Med Univ, Grad Inst Basic Med Sci, Taichung 404, Taiwan.
   Chuu, Chih-Pin, Natl Chung Hsing Univ, Biotechnol Ctr, Taichung 402, Taiwan.
   Chuu, Chih-Pin, Natl Hlth Res Inst, Inst Cellular \& Syst Med, Room R2-2021,35 Keyan Rd, Zhunan Town 350, Miaoli County, Taiwan.},
DOI = {10.3390/cancers11111785},
Article-Number = {1785},
EISSN = {2072-6694},
Keywords = {KDM4C; prostate cancer; c-Myc; AKT; Micro-Western Array},
Keywords-Plus = {ANDROGEN RECEPTOR; 3-DIMENSIONAL CULTURE; LYSINE DEMETHYLASE; RIBOSOMAL
   DNA; EXPRESSION; BREAST; PTEN; GENE; SUPPRESSES; INHIBITION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {cylin071@nhri.org.tw
   bijuanwang@nhri.org.tw
   Kimchen1026@gmail.com
   mark0918@nhri.org.tw
   ssjiang@nhri.org.tw
   kelvin.k.tsai@gmail.com
   minaka47@yahoo.com.tw
   chyuh@nhri.edu.tw
   zonlins@gmail.com
   wenching.wc@gmail.com
   hkung@tmu.edu.tw
   cpchuu@nhri.org.tw},
Affiliations = {National Health Research Institutes - Taiwan; National Health Research
   Institutes - Taiwan; Taipei Medical University; National Health Research
   Institutes - Taiwan; National Health Research Institutes - Taiwan;
   National Tsing Hua University; Taipei Medical University; China Medical
   University Taiwan; China Medical University Taiwan; National Chung Hsing
   University; National Health Research Institutes - Taiwan},
ResearcherID-Numbers = {Tsai, Kelvin/C-1371-2010
   Wang, Wen-Ching/ABI-2253-2020
   Jiang, Shih Sheng/C-6187-2011
   Shen, Yingying/GQO-9549-2022
   Lin, Ching Yu/AAN-9581-2020
   Yuh, Chiou-Hwa/AAL-3531-2020
   Chuu, Chih-Pin/N-6697-2019
   Sie, Zong-Lin/LOS-6407-2024
   Kung, Hsing-Jien/C-7651-2013
   Tseng, Jen-Chih/AAK-3386-2020},
ORCID-Numbers = {Tsai, Kelvin/0000-0002-1612-2868
   Wang, Wen-Ching/0000-0002-7422-3667
   Jiang, Shih Sheng/0000-0003-1909-437X
   Lin, Ching Yu/0000-0001-9041-5653
   Yuh, Chiou-Hwa/0000-0002-2356-1551
   Sie, Zong-Lin/0000-0002-3063-9927
   },
Funding-Acknowledgement = {Ministry of Science and Technology (Taiwan) {[}MOST 108-2314-B-400-021,
   MOST 107-2314-B-400-002, MOST 106-2314-B-400-006, MOST
   105-2314-B-400-020, MOST 104-2321-B-400-010]; National Health Research
   Institutes (Taiwan) {[}CS-106-PP-03, CA-106-SP-01, CS-106-SP-05]},
Funding-Text = {This research was funded by the Ministry of Science and Technology
   (Taiwan), MOST 108-2314-B-400-021, MOST 107-2314-B-400-002, MOST
   106-2314-B-400-006, MOST 105-2314-B-400-020, MOST 104-2321-B-400-010 and
   the National Health Research Institutes (Taiwan), CS-106-PP-03,
   CA-106-SP-01, and CS-106-SP-05.},
Cited-References = {Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225.
   Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477.
   Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091.
   Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215.
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240.
   Chen YK, 2017, ACS MED CHEM LETT, V8, P869, DOI 10.1021/acsmedchemlett.7b00220.
   Chu CH, 2014, J MED CHEM, V57, P5975, DOI 10.1021/jm500249n.
   Chuu CP, 2012, CANCER PREV RES, V5, P788, DOI 10.1158/1940-6207.CAPR-12-0004-T.
   Chuu CP, 2011, CANCER SCI, V102, P2022, DOI 10.1111/j.1349-7006.2011.02043.x.
   Ciaccio MF, 2010, NAT METHODS, V7, P148, DOI {[}10.1038/NMETH.1418, 10.1038/nmeth.1418].
   Coffey K, 2013, NUCLEIC ACIDS RES, V41, P4433, DOI 10.1093/nar/gkt106.
   FLEMING WH, 1986, CANCER RES, V46, P1535.
   Grandori C, 2005, NAT CELL BIOL, V7, P311, DOI 10.1038/ncb1224.
   Grewal SS, 2005, NAT CELL BIOL, V7, P295, DOI 10.1038/ncb1223.
   Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111.
   Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655.
   Hammarsten P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047994.
   Härmä V, 2012, ONCOGENE, V31, P2075, DOI 10.1038/onc.2011.396.
   Katoh Y, 2007, INT J MOL MED, V20, P269.
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005.
   Kreisberg JI, 2004, CANCER RES, V64, P5232, DOI 10.1158/0008-5472.CAN-04-0272.
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015.
   Leurs U, 2012, BIOORG MED CHEM LETT, V22, P5811, DOI 10.1016/j.bmcl.2012.07.091.
   Li CR, 2013, AM J PATHOL, V182, P363, DOI 10.1016/j.ajpath.2012.10.024.
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943.
   Liang Y, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005145.
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297.
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109.
   McCall P, 2008, BRIT J CANCER, V98, P1094, DOI 10.1038/sj.bjc.6604152.
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946.
   Nottke A, 2009, DEVELOPMENT, V136, P879, DOI 10.1242/dev.020966.
   Ponnaluri VKC, 2009, BIOCHEM BIOPH RES CO, V390, P280, DOI 10.1016/j.bbrc.2009.09.107.
   Rebello RJ, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020071.
   Reuter JA, 2009, CANCER CELL, V15, P477, DOI 10.1016/j.ccr.2009.04.002.
   Rigotti Nancy A., 1996, Cardiology Clinics, V14, P51.
   Rotili Dante, 2011, Genes Cancer, V2, P663, DOI 10.1177/1947601911417976.
   Sarker D, 2009, CLIN CANCER RES, V15, P4799, DOI 10.1158/1078-0432.CCR-08-0125.
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012.
   Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179.
   Sircar K, 2009, J PATHOL, V218, P505, DOI 10.1002/path.2559.
   Suikki HE, 2010, PROSTATE, V70, P889, DOI 10.1002/pros.21123.
   True L, 2006, P NATL ACAD SCI USA, V103, P10991, DOI 10.1073/pnas.0603678103.
   Wan M, 2013, J BIOL CHEM, V288, P5039, DOI 10.1074/jbc.M112.424515.
   Wang HJ, 2019, ONCOGENE, V38, P17, DOI 10.1038/s41388-018-0414-x.
   Wang JL, 2010, BIOL REPROD, V82, P105, DOI 10.1095/biolreprod.109.078055.
   Wang WY, 2013, GASTROENTEROLOGY, V145, P1110, DOI 10.1053/j.gastro.2013.07.040.
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231.
   Webber MM, 1997, CARCINOGENESIS, V18, P1225, DOI 10.1093/carcin/18.6.1225.
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546.
   Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174.
   Zhang XP, 2009, MOL CANCER THER, V8, P499, DOI 10.1158/1535-7163.MCT-08-0544.},
Number-of-Cited-References = {51},
Times-Cited = {21},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {6},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {JV3UB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000502290100167},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000478018200140,
Author = {Liu, Rangru and Chen, Zhuo and Yi, Xinan and Huang, Fengying and Hu,
   Gaoyun and Liu, Danqi and Li, Xi and Zhou, Honghao and Liu, Zhaoqian},
Title = {RETRACTED: 9za plays cytotoxic and proapoptotic roles and induces
   cytoprotective autophagy through the PDK1/Akt/mTOR axis in
   non-small-cell lung cancer (Retracted Article)},
Journal = {JOURNAL OF CELLULAR PHYSIOLOGY},
Year = {2019},
Volume = {234},
Number = {11},
Pages = {20728-20741},
Month = {NOV},
Abstract = {Non-small-cell lung cancer (NSCLC) is an aggressive subtype of pulmonary
   carcinomas with high mortality. However, chemotherapy drug resistance
   and high recurrence rates hinder the curative effect of platinum-based
   first-line chemotherapy, which makes it urgent to develop new antitumor
   drugs for NSCLC. 9za, a new candidate drug synthesized by our research
   group, has been verified with potent antilung cancer activity in
   preliminary experiments. However, the underlying molecular mechanism of
   9za remains largely vague. This work revealed that 9za could play
   important cytotoxic and proapoptotic roles in NSCLC cells. Moreover, 9za
   could induce autophagy and promote autophagy flux. Interestingly, the
   cytotoxic and proapoptotic roles were significantly dependent on
   9za-induced cytoprotective autophagy. That is, the coadministration of
   9za with an autophagy inhibitor such as chloroquine or 3-methyladenine
   exhibited increased cytotoxic and proapoptotic effects compared with 9za
   treatment alone. In addition, 9za exposure suppressed the
   phosphorylation of phosphoinositide-dependent protein kinase 1 (PDK1),
   protein kinase B (Akt), mammalian targets of rapamycin (mTOR), p70 S6
   kinase, and 4E binding protein 1 by a dose-dependent way, manifesting
   that the Akt/mTOR axis was implicated in 9za-induced autophagy. In
   addition, the overexpression of PDK1 resulted in increased
   phosphorylation of PDK1 and Akt and blocking of 9za-mediated autophagy.
   These data showed that the PDK1/Akt/mTOR pathway was involved in
   9za-induced autophagy. Hence, this work provides a theoretical basis for
   exploiting 9za as a new antilung cancer candidate drug and hints that
   the combination of 9za with an autophagy inhibitor is a feasible
   alternative approach for the therapy of NSCLC.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article; Retracted Publication},
Language = {English},
Affiliation = {Liu, ZQ (Corresponding Author), Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China.
   Liu, ZQ (Corresponding Author), Cent S Univ, Inst Clin Pharmacol, Changsha 410008, Hunan, Peoples R China.
   Liu, ZQ (Corresponding Author), Hunan Key Lab Pharmacogenet, Changsha 410008, Hunan, Peoples R China.
   Liu, Rangru; Li, Xi; Zhou, Honghao; Liu, Zhaoqian, Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Hunan, Peoples R China.
   Liu, Rangru; Li, Xi; Zhou, Honghao; Liu, Zhaoqian, Cent S Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.
   Liu, Rangru; Huang, Fengying, Hainan Med Univ, Hainan Prov Key Lab Trop Med, Minist Educ, Key Lab Trop Dis \& Translat Med, Haikou, Hainan, Peoples R China.
   Chen, Zhuo; Hu, Gaoyun, Cent S Univ, Xiangya Sch Pharmaceut Sci, Dept Med Chem, Changsha, Hunan, Peoples R China.
   Yi, Xinan, Hainan Med Univ, United Lab Neurosci, Haikou, Hainan, Peoples R China.
   Yi, Xinan, Fourth Mil Med Univ, Haikou, Hainan, Peoples R China.
   Liu, Danqi, Cent S Univ, Xiangya Hosp, Dept Pharm, Changsha, Hunan, Peoples R China.},
DOI = {10.1002/jcp.28679},
ISSN = {0021-9541},
EISSN = {1097-4652},
Keywords = {9za; autophagy; cytotoxicity; non-small-cell lung cancer; PDK1; Akt;
   mTOR signaling pathway},
Keywords-Plus = {INDUCED APOPTOSIS; IN-VIVO; KINASE; INHIBITION; SURVIVAL; PATHWAY; PDK1;
   REGISTRY; BREAST; PI3K},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {liuzhaoqian63@126.com},
Affiliations = {Central South University; Central South University; Hainan Medical
   University; Central South University; Hainan Medical University; Air
   Force Medical University; Central South University},
ResearcherID-Numbers = {Zhou, Honghao/JWO-4641-2024},
Funding-Acknowledgement = {National Key Research and Development Program of China
   {[}2016YFC1306900, 2016YFC0905002]; Strategy-Oriented Special Project of
   Central South University in China {[}ZLXD2017003]; Hainan Province Key
   Research and Development Project {[}ZDYF2016128, ZDYF2017092]; Hunan
   Provincial Science and Technology Plan Project {[}2016JC2066]; National
   Natural Science Foundation of China {[}81874327, 81402968, 81573508];
   Hunan Province Strategic Emerging Industry Science and Technology Key
   Project {[}2016GK4028]; Central South University in China
   {[}ZLXD2017003]},
Funding-Text = {National Key Research and Development Program of China, Grant/Award
   Numbers: 2016YFC1306900, 2016YFC0905002; The Strategy-Oriented Special
   Project of Central South University in China, Grant/Award Number:
   ZLXD2017003; Hainan Province Key Research and Development Project,
   Grant/Award Numbers: ZDYF2016128, ZDYF2017092; Hunan Provincial Science
   and Technology Plan Project, Grant/Award Number: 2016JC2066; National
   Natural Science Foundation of China, Grant/Award Numbers: 81874327,
   81402968, 81573508; Hunan Province Strategic Emerging Industry Science
   and Technology Key Project, Grant/Award Number: 2016GK4028; Central
   South University in China, Grant/Award Number: ZLXD2017003},
Cited-References = {Anding AL, 2015, CURR TOP DEV BIOL, V114, P67, DOI 10.1016/bs.ctdb.2015.07.012.
   Asamura H, 2008, J THORAC ONCOL, V3, P46, DOI 10.1097/JTO.0b013e31815e8577.
   Bai LC, 2014, ANNU REV MED, V65, P139, DOI 10.1146/annurev-med-010713-141310.
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Collins I, 2009, ANTI-CANCER AGENT ME, V9, P32, DOI 10.2174/187152009787047734.
   Deng Q, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.324.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890.
   Fu YF, 2016, MOL MED REP, V14, P394, DOI 10.3892/mmr.2016.5249.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966.
   He ZJ, 2017, FOOD CHEM TOXICOL, V101, P55, DOI 10.1016/j.fct.2017.01.002.
   Huang WT, 2016, TOXICOLOGY, V373, P41, DOI 10.1016/j.tox.2016.11.006.
   Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196.
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017.
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Michaud M, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.944047.
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207.
   Ou SHI, 2007, CANCER-AM CANCER SOC, V110, P1532, DOI 10.1002/cncr.22938.
   Park JH, 2014, ONCOL REP, V31, P2365, DOI 10.3892/or.2014.3071.
   Peng Y, 2017, LIFE SCI, V185, P63, DOI 10.1016/j.lfs.2017.07.024.
   Poklepovic A, 2014, AUTOPHAGY, V10, P1478, DOI 10.4161/auto.29428.
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422.
   Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584.
   Scortegagna M, 2014, ONCOGENE, V33, P4330, DOI 10.1038/onc.2013.383.
   Sebolt-Leopold JS, 2008, CLIN CANCER RES, V14, P3651, DOI 10.1158/1078-0432.CCR-08-0333.
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034.
   She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006.
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138.
   Suh DH, 2012, ANN NY ACAD SCI, V1271, P20, DOI 10.1111/j.1749-6632.2012.06739.x.
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777.
   Yang ZL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0337-5.
   Zabkiewicz J, 2014, HAEMATOLOGICA, V99, P858, DOI 10.3324/haematol.2013.096487.
   Zeng W, 2017, CELL PHYSIOL BIOCHEM, V43, P1487, DOI 10.1159/000481971.
   Zheng M, 2016, SURG ONCOL CLIN N AM, V25, P447, DOI 10.1016/j.soc.2016.02.003.
   Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210.},
Number-of-Cited-References = {38},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {23},
Journal-ISO = {J. Cell. Physiol.},
Doc-Delivery-Number = {IM5EX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000478018200140},
DA = {2026-02-04},
}

@article{ WOS:000502266700035,
Author = {Reyes-Gordillo, Karina and Shah, Ruchi and Arellanes-Robledo, Jaime and
   Cheng, Ying and Ibrahim, Joseph and Tuma, Pamela L.},
Title = {Akt1 and Akt2 Isoforms Play Distinct Roles in Regulating the Development
   of Inflammation and Fibrosis Associated with Alcoholic Liver Disease},
Journal = {CELLS},
Year = {2019},
Volume = {8},
Number = {11},
Month = {NOV},
Abstract = {Akt kinase isoforms (Akt1, Akt2, and Akt3) have generally been thought
   to play overlapping roles in phosphoinositide 3-kinase
   (PI3K)-mediated-signaling. However, recent studies have suggested that
   they display isoform-specific roles in muscle and fat. To determine
   whether such isoform-specificity is observed with respect to alcoholic
   liver disease (ALD) progression, we examined the role of Akt1, Akt2, and
   Akt3 in hepatic inflammation, and pro-fibrogenic proliferation and
   migration using Kupffer cells, hepatic stellate cells (HSC), and
   hepatocytes in an ethanol and lipopolysaccharide (LPS)-induced two-hit
   model in vitro and in vivo. We determined that siRNA-directed silencing
   of Akt2, but not Akt1, significantly suppressed cell inflammatory
   markers in HSC and Kupffer cells. Although both Akt1 and Akt2 inhibited
   cell proliferation in HSC, only Akt2 inhibited cell migration. Both Akt1
   and Akt2, but not Akt3, inhibited fibrogenesis in hepatocytes and HSC.
   In addition, our in vivo results show that administration of chronic
   ethanol, binge ethanol and LPS (EBL) in wild-type C57BL/6 mice activated
   all three Akt isoforms with concomitant increases in activated forms of
   phosphoinositide dependent kinase-1 (PDK1), mammalian
   target-of-rapamycin complex 2 (mTORC2), and PI3K, resulting in
   upregulation in expression of inflammatory, proliferative, and
   fibrogenic genes. Moreover, pharmacological blocking of Akt2, but not
   Akt1, inhibited EBL-induced inflammation while blocking of both Akt1 and
   Akt2 inhibited pro-fibrogenic marker expression and progression of
   fibrosis. Our findings indicate that Akt isoforms play unique roles in
   inflammation, cell proliferation, migration, and fibrogenesis during
   EBL-induced liver injury. Thus, close attention must be paid when
   targeting all Akt isoforms as a therapeutic intervention.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Tuma, PL (Corresponding Author), Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA.
   Reyes-Gordillo, Karina; Shah, Ruchi; Arellanes-Robledo, Jaime; Cheng, Ying; Ibrahim, Joseph, VA Med Ctr, Lipid Res Lab, Washington, DC 98100 USA.
   Reyes-Gordillo, Karina; Shah, Ruchi; Arellanes-Robledo, Jaime; Cheng, Ying; Ibrahim, Joseph, George Washington Univ, Dept Biochem \& Mol Med, Med Ctr, Washington, DC 20037 USA.
   Reyes-Gordillo, Karina; Tuma, Pamela L., Catholic Univ Amer, Dept Biol, Washington, DC 20064 USA.
   Arellanes-Robledo, Jaime, Catedras CONACYT, Lab Hepat Dis, Cdmx 64460, Mexico.
   Arellanes-Robledo, Jaime, Natl Inst Genom Med INMEGEN, Cdmx 64460, Mexico.},
DOI = {10.3390/cells8111337},
Article-Number = {1337},
EISSN = {2073-4409},
Keywords = {Akt1; Akt2; Akt3; Akt isoforms; alcoholic liver disease; liver fibrosis;
   inflammation; proliferation; migration},
Keywords-Plus = {STELLATE CELL ACTIVATION; UP-REGULATION; TNF-ALPHA; ACETALDEHYDE;
   PATHOGENESIS; ACCUMULATION; METABOLITES; MIGRATION; ENDOTOXIN; PATHWAY},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {karrygor@gwu.edu
   Ruchi.Shah@cshs.org
   jarellanes@gmail.com
   yingcheng2004@gmail.com
   bimoib@yahoo.com
   tuma@cua.edu},
Affiliations = {George Washington University; Catholic University of America; Consejo
   Nacional de Ciencia y Tecnologia (CONACyT); Instituto Nacional de
   Medicina Genomica},
ResearcherID-Numbers = {Arellanes-Robledo, Jaime/P-3926-2017
   Shah, Ruchi/I-6386-2019},
ORCID-Numbers = {Arellanes-Robledo, Jaime/0000-0001-7363-4870
   Shah, Ruchi/0000-0002-9533-1747},
Funding-Acknowledgement = {NIH {[}K01 AA025140-01]; National Institute on Alcohol Abuse and
   Alcoholism {[}R01AA017626] Funding Source: NIH RePORTER},
Funding-Text = {This work is supported by the NIH Grant K01 AA025140-01 (Karina
   Reyes-Gordillo). This material is the result of work supported with
   resources and the use of facilities at the Washington DC Veterans A
   ffairs Medical Center.},
Cited-References = {Arias I.M., 2009, The Liver Biology and Pathobiology, DOI {[}10.1002/9781119436812, DOI 10.1002/9781119436812].
   Arranz A, 2012, P NATL ACAD SCI USA, V109, P9517, DOI 10.1073/pnas.1119038109.
   Bertola A, 2013, NAT PROTOC, V8, P627, DOI 10.1038/nprot.2013.032.
   Bibaki E, 2018, MOL MED REP, V17, P7105, DOI 10.3892/mmr.2018.8778.
   Cariaga-Martinez AE, 2013, CELL SIGNAL, V25, P1586, DOI 10.1016/j.cellsig.2013.03.019.
   Ceni E, 2014, WORLD J GASTROENTERO, V20, P17756, DOI 10.3748/wjg.v20.i47.17756.
   Cianciulli A, 2016, INT IMMUNOPHARMACOL, V36, P282, DOI 10.1016/j.intimp.2016.05.007.
   Cohen JI, 2011, J DIGEST DIS, V12, P3, DOI 10.1111/j.1751-2980.2010.00468.x.
   Cohen-Naftaly Michal, 2011, Therap Adv Gastroenterol, V4, P391, DOI 10.1177/1756283X11413002.
   Cubero FJ, 2006, REV ESP ENFERM DIG, V98, P460.
   Di Lorenzo A, 2009, P NATL ACAD SCI USA, V106, P14552, DOI 10.1073/pnas.0904073106.
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202.
   Donohue TM, 2006, INT J BIOCHEM CELL B, V38, P92, DOI 10.1016/j.biocel.2005.07.010.
   Easton RM, 2005, MOL CELL BIOL, V25, P1869, DOI 10.1128/MCB.25.5.1869-1878.2005.
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6.
   Gao B, 2011, GASTROENTEROLOGY, V141, P1572, DOI 10.1053/j.gastro.2011.09.002.
   Gong M, 2007, METABOLISM, V56, P1241, DOI 10.1016/j.metabol.2007.04.022.
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335.
   Grabinski N, 2011, CELL SIGNAL, V23, P1952, DOI 10.1016/j.cellsig.2011.07.003.
   Greenwel P, 2000, HEPATOLOGY, V31, P109, DOI 10.1002/hep.510310118.
   Hay N, 2011, TRENDS ENDOCRIN MET, V22, P66, DOI 10.1016/j.tem.2010.09.003.
   Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5.
   Hoek JB, 1999, HEPATOLOGY, V29, P1602, DOI 10.1002/hep.510290536.
   JONES AW, 1995, ALCOHOL ALCOHOLISM, V30, P271.
   Lan AP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105451.
   Liao Y, 2010, AM J TRANSL RES, V2, P19.
   LIEBER CS, 1982, ALCOHOL CLIN EXP RES, V6, P523, DOI 10.1111/j.1530-0277.1982.tb05017.x.
   Lu MJ, 2012, NAT MED, V18, P388, DOI 10.1038/nm.2686.
   Luo Y, 2005, MOL CANCER THER, V4, P977, DOI 10.1158/1535-7163.MCT-05-0005.
   Ma KL, 2008, HEPATOLOGY, V48, P770, DOI 10.1002/hep.22423.
   Mann J, 2010, GASTROENTEROLOGY, V138, P705, DOI 10.1053/j.gastro.2009.10.002.
   Mukherjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093040.
   Nag A, 2013, ANGEW CHEM INT EDIT, V52, P13975, DOI 10.1002/anie.201305882.
   Nakamura Y, 1999, ALCOHOL CLIN EXP RES, V23, p92S, DOI 10.1111/j.1530-0277.1999.tb04542.x.
   Nakamura Y, 2004, J GASTROENTEROL, V39, P140, DOI 10.1007/s00535-003-1278-5.
   Nie YJ, 2017, J IMMUNOL, V198, P4470, DOI 10.4049/jimmunol.1601503.
   Ock S, 2018, BBA-MOL BASIS DIS, V1864, P1183, DOI 10.1016/j.bbadis.2018.01.022.
   Olinga P, 2001, J HEPATOL, V35, P187, DOI 10.1016/S0168-8278(01)00103-9.
   Orman ES, 2013, J GASTROEN HEPATOL, V28, P77, DOI 10.1111/jgh.12030.
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403.
   Reyes-Gordillo K, 2011, AM J PATHOL, V178, P2100, DOI 10.1016/j.ajpath.2011.01.025.
   Riaz A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032081.
   Riggio M, 2017, SCI REP-UK, V7, DOI 10.1038/srep44244.
   Roberts MS, 2004, MOL CELL BIOL, V24, P1505, DOI 10.1128/MCB.24.4.1505-1515.2004.
   Schaffert CS, 2009, WORLD J GASTROENTERO, V15, P1209, DOI 10.3748/wjg.15.1209.
   Shafiei MS, 2011, AM J PATHOL, V178, P2690, DOI 10.1016/j.ajpath.2011.02.035.
   Shen Z, 2009, AM J PHYSIOL-GASTR L, V296, pG1047, DOI 10.1152/ajpgi.00016.2009.
   Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3.
   Swaminathan K, 2013, LIFE SCI, V92, P325, DOI 10.1016/j.lfs.2012.12.014.
   Tamai H, 2002, ALCOHOL CLIN EXP RES, V26, p75S, DOI 10.1097/01.ALC.0000026981.32386.FD.
   Tsukamoto H, 2011, HEPATOL RES, V41, P675, DOI 10.1111/j.1872-034X.2011.00804.x.
   Virtakoivu R, 2012, MOL BIOL CELL, V23, P3357, DOI 10.1091/mbc.E12-03-0213.
   Wheeler MD, 2003, ALCOHOL RES HEALTH, V27, P300.
   Yang J, 2002, NAT STRUCT BIOL, V9, P940, DOI 10.1038/nsb870.
   Yang ZZ, 2003, J BIOL CHEM, V278, P32124, DOI 10.1074/jbc.M302847200.
   Yap TA, 2011, MOL CANCER THER, V10, P360, DOI 10.1158/1535-7163.MCT-10-0760.
   Zhu QS, 2008, CANCER RES, V68, P2895, DOI 10.1158/0008-5472.CAN-07-6268.},
Number-of-Cited-References = {57},
Times-Cited = {54},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {30},
Journal-ISO = {Cells},
Doc-Delivery-Number = {JV3LB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000502266700035},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000494483700021,
Author = {Siddique, Mohammad Abdul Hai and Satoh, Kimio and Kurosawa, Ryo and
   Kikuchi, Nobuhiro and Elias-Al-Mamun, Md. and Omura, Junichi and Satoh,
   Taijyu and Nogi, Masamichi and Sunamura, Shinichiro and Miyata, Satoshi
   and Ueda, Hirofumi and Tokuyama, Hidetoshi and Shimokawa, Hiroaki},
Title = {Identification of Emetine as a Therapeutic Agent for Pulmonary Arterial
   Hypertension Novel Effects of an Old Drug},
Journal = {ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY},
Year = {2019},
Volume = {39},
Number = {11},
Pages = {2367-2385},
Month = {NOV},
Abstract = {Objective: Excessive proliferation and apoptosis resistance are special
   characteristics of pulmonary artery smooth muscle cells (PASMCs) in
   pulmonary arterial hypertension (PAH). However, the drugs in clinical
   use for PAH target vascular dilatation, which do not exert adequate
   effects in patients with advanced PAH. Here, we report a novel
   therapeutic effect of emetine, a principal alkaloid extracted from the
   root of ipecac clinically used as an emetic and antiprotozoal drug.
   Approach and Results: We performed stepwise screenings for 5562
   compounds from original library. First, we performed high-throughput
   screening with PASMCs from patients with PAH (PAH-PASMCs) and found 80
   compounds that effectively inhibited proliferation. Second, we performed
   the repeatability and counter assay. Finally, we performed a
   concentration-dependent assay and found that emetine inhibits PAH-PASMC
   proliferation. Interestingly, emetine significantly reduced protein
   levels of HIFs (hypoxia-inducible factors; HIF-1 alpha and HIF-2 alpha)
   and downstream PDK1 (pyruvate dehydrogenase kinase 1). Moreover, emetine
   significantly reduced the protein levels of RhoA (Ras homolog gene
   family, member A), Rho-kinases (ROCK1 and ROCK2 {[}rho-associated
   coiled-coil containing protein kinases 1 and 2]), and their downstream
   CyPA (cyclophilin A), and Bsg (basigin) in PAH-PASMCs. Consistently,
   emetine treatment significantly reduced the secretion of
   cytokines/chemokines and growth factors from PAH-PASMCs. Interestingly,
   emetine reduced protein levels of BRD4 (bromodomain-containing protein
   4) and downstream survivin, both of which are involved in many cellular
   functions, such as cell cycle, apoptosis, and inflammation. Finally,
   emetine treatment ameliorated pulmonary hypertension in 2 experimental
   rat models, accompanied by reduced inflammatory changes in the lungs and
   recovered right ventricular functions. Conclusions: Emetine is an old
   but novel drug for PAH that reduces excessive proliferation of
   PAH-PASMCs and improves right ventricular functions.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Shimokawa, H (Corresponding Author), Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.
   Siddique, Mohammad Abdul Hai; Satoh, Kimio; Kurosawa, Ryo; Kikuchi, Nobuhiro; Elias-Al-Mamun, Md.; Omura, Junichi; Satoh, Taijyu; Nogi, Masamichi; Sunamura, Shinichiro; Miyata, Satoshi; Shimokawa, Hiroaki, Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi, Japan.
   Ueda, Hirofumi; Tokuyama, Hidetoshi, Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi, Japan.},
DOI = {10.1161/ATVBAHA.119.313309},
ISSN = {1079-5642},
EISSN = {1524-4636},
Keywords = {emetine; hypertension; mitochondria; pulmonary artery; reactive oxygen
   species},
Keywords-Plus = {RHO-KINASE INHIBITOR; PROMOTING INFLAMMATION; MITOCHONDRIAL DYNAMICS;
   PRESSURE-OVERLOAD; OXIDATIVE STRESS; CYCLOPHILIN-A; CRUCIAL ROLE;
   FASUDIL; TARGET; CANCER},
Research-Areas = {Hematology; Cardiovascular System \& Cardiology},
Web-of-Science-Categories  = {Hematology; Peripheral Vascular Disease},
Author-Email = {shimo@cardio.med.tohoku.ac.jp},
Affiliations = {Tohoku University; Tohoku University},
ResearcherID-Numbers = {Ueda, Hirofumi/NTP-9920-2025
   Tokuyama, Hidetoshi/AAM-5122-2020
   Kikuchi, Nobuhiro/JVZ-5784-2024
   },
ORCID-Numbers = {Satoh, Taijyu/0000-0002-1795-6872
   Ueda, Hirofumi/0000-0002-9114-8531
   Tokuyama, Hidetoshi/0000-0002-6519-7727
   Kikuchi, Nobuhiro/0000-0002-5382-8886
   Siddique, Mohammad Abdul Hai/0000-0003-1004-7825},
Funding-Acknowledgement = {Ministry of Education, Culture, Sports, Science and Technology, Tokyo,
   Japan {[}15H02535, 15H04816, 15K15046]; Ministry of Health, Labour, and
   Welfare, Tokyo, Japan {[}10102895]; Japan Agency for Medical Research
   and Development, Tokyo, Japan {[}15ak0101035h0001, 16ek0109176h0001,
   17ek0109227h0001]; Grants-in-Aid for Scientific Research {[}15K15046,
   15H02535, 15H04816] Funding Source: KAKEN},
Funding-Text = {This work was supported in part by the grants-in-aid for Scientific
   Research (15H02535, 15H04816 and 15K15046), all of which are from the
   Ministry of Education, Culture, Sports, Science and Technology, Tokyo,
   Japan, the grantsin-aid for Scientific Research from the Ministry of
   Health, Labour, and Welfare, Tokyo, Japan (10102895), and the
   grants-in-aid for Scientific Research from the Japan Agency for Medical
   Research and Development, Tokyo, Japan (15ak0101035h0001,
   16ek0109176h0001, 17ek0109227h0001).},
Cited-References = {Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94.
   Abe K, 2010, CIRCULATION, V121, P2747, DOI 10.1161/CIRCULATIONAHA.109.927681.
   Aoki T, 2017, ONCOTARGET, V8, P13085, DOI 10.18632/oncotarget.14393.
   Archer SL, 2013, NEW ENGL J MED, V369, P2236, DOI 10.1056/NEJMra1215233.
   Archer SL, 2010, CIRCULATION, V121, P2661, DOI 10.1161/CIRCULATIONAHA.109.916098.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Bonnet S, 2006, CIRCULATION, V113, P2630, DOI 10.1161/CIRCULATIONAHA.105.609008.
   Boucherat O, 2018, AM J RESP CRIT CARE, V198, P90, DOI 10.1164/rccm.201708-1751OC.
   Boucherat O, 2017, PULM CIRC, V7, P285, DOI 10.1177/2045893217701438.
   Valadao ALC, 2015, MOLECULES, V20, P11474, DOI 10.3390/molecules200611474.
   Chin KM, 2008, J AM COLL CARDIOL, V51, P1527, DOI 10.1016/j.jacc.2008.01.024.
   Cowburn AS, 2016, P NATL ACAD SCI USA, V113, P8801, DOI 10.1073/pnas.1602978113.
   Deng L, 2007, J VIROL, V81, P13392, DOI 10.1128/JVI.00770-07.
   Do E Z, 2009, CIRC J, V73, P1731, DOI 10.1253/circj.CJ-09-0135.
   Elias-Al-Mamun M, 2014, CIRC J, V78, P967, DOI 10.1253/circj.CJ-13-1174.
   Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401.
   Fukumoto Y, 2005, HEART, V91, P391, DOI 10.1136/hrt.2003.029470.
   Galiè N, 2010, EUR HEART J, V31, P2080, DOI 10.1093/eurheartj/ehq152.
   Ikeda S, 2014, ARTERIOSCL THROM VAS, V34, P1260, DOI 10.1161/ATVBAHA.114.303320.
   Jiang BH, 2007, J CARDIOVASC PHARM, V49, P85, DOI 10.1097/FJC.0b013e31802df112.
   Kanitani M, 1999, JPN PHARMACOL THER, V27, P891.
   Kawaguchi M, 2013, ACS CHEM BIOL, V8, P1713, DOI 10.1021/cb400150c.
   Kikuchi N, 2018, CIRCULATION, V138, P600, DOI 10.1161/CIRCULATIONAHA.117.033113.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kong HS, 2010, MOL PHARMACOL, V78, P1072, DOI 10.1124/mol.110.066514.
   Lai YC, 2014, CIRC RES, V115, P115, DOI 10.1161/CIRCRESAHA.115.301146.
   Malenfant S, 2013, PULM CIRC, V3, P278, DOI 10.4103/2045-8932.114752.
   MASTRANGELO MJ, 1973, CANCER-AM CANCER SOC, V31, P1170, DOI 10.1002/1097-0142(197305)31:5<1170::AID-CNCR2820310520>3.0.CO;2-4.
   McLaughlin VV, 2002, CIRCULATION, V106, P1477, DOI 10.1161/01.CIR.0000029100.82385.58.
   Meloche J, 2015, CIRC RES, V117, P525, DOI 10.1161/CIRCRESAHA.115.307004.
   Meloche J, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.005157.
   Montani D, 2014, PHARMACOL THERAPEUT, V141, P172, DOI 10.1016/j.pharmthera.2013.10.002.
   Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI {[}10.4103/0976-0105.177703, 10.4103/0976-0105.177703].
   Nakamura K, 2012, INT J CARDIOL, V159, P100, DOI 10.1016/j.ijcard.2011.02.024.
   Nigro P, 2011, J EXP MED, V208, P53, DOI 10.1084/jem.20101174.
   Novac O, 2004, NUCLEIC ACIDS RES, V32, P902, DOI 10.1093/nar/gkh235.
   Okada-Iwabu M, 2013, NATURE, V503, P493, DOI 10.1038/nature12656.
   Omura J, 2016, CIRC RES, V119, P197, DOI 10.1161/CIRCRESAHA.115.308178.
   PANETTIEF, 1971, CANCER-AM CANCER SOC, V27, P835, DOI DOI 10.1002/1097-0142(197104)27:4<835::AID-CNCR2820270413>3.0.CO;2-K.
   Rabinovitch M, 2012, J CLIN INVEST, V122, P4306, DOI 10.1172/JCI60658.
   Ryan JJ, 2015, CIRCULATION, V131, P1691, DOI 10.1161/CIRCULATIONAHA.114.006979.
   Ryan JJ, 2013, AM J RESP CRIT CARE, V187, P865, DOI 10.1164/rccm.201209-1687OC.
   Satoh K, 2008, CIRCULATION, V117, P3088, DOI 10.1161/CIRCULATIONAHA.107.756106.
   Satoh K, 2017, CIRC J, V81, P1557, DOI 10.1253/circj.CJ-17-1029.
   Satoh K, 2015, TOHOKU J EXP MED, V235, P1, DOI 10.1620/tjem.235.1.
   Satoh K, 2014, CIRC RES, V115, P738, DOI 10.1161/CIRCRESAHA.115.304563.
   Satoh K, 2011, AM J PHYSIOL-HEART C, V301, pH287, DOI 10.1152/ajpheart.00327.2011.
   Satoh K, 2010, CIRC J, V74, P2249, DOI 10.1253/circj.CJ-10-0904.
   Satoh K, 2010, ANTIOXID REDOX SIGN, V12, P675, DOI 10.1089/ars.2009.2875.
   Satoh K, 2009, NAT MED, V15, P649, DOI 10.1038/nm.1958.
   Satoh T, 2017, CIRC RES, V120, P1246, DOI 10.1161/CIRCRESAHA.117.310640.
   Savai R, 2014, NAT MED, V20, P1289, DOI 10.1038/nm.3695.
   Shimizu T, 2013, ARTERIOSCL THROM VAS, V33, P2780, DOI 10.1161/ATVBAHA.113.301357.
   Shimokawa H, 2005, ARTERIOSCL THROM VAS, V25, P1767, DOI 10.1161/01.ATV.0000176193.83629.c8.
   Shimokawa H, 2016, CIRC RES, V118, P352, DOI 10.1161/CIRCRESAHA.115.306532.
   SHRAPNEL BC, 1946, AM J TROP MED, V26, P293.
   Sun Q, 2015, INT J ONCOL, V46, P389, DOI 10.3892/ijo.2014.2703.
   Sunamura S, 2018, P NATL ACAD SCI USA, V115, pE7129, DOI 10.1073/pnas.1721298115.
   Sutendra G, 2011, J MOL MED, V89, P771, DOI 10.1007/s00109-011-0762-2.
   Sutendra G, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001327.
   Suzuki J, 2006, CIRC RES, V98, P811, DOI 10.1161/01.RES.0000216405.85080.a6.
   Suzuki K, 2016, ARTERIOSCL THROM VAS, V36, P636, DOI 10.1161/ATVBAHA.115.306686.
   Tsuchida K, 2017, FREE RADICAL BIO MED, V103, P236, DOI 10.1016/j.freeradbiomed.2016.12.041.
   Upcroft P, 2001, CLIN MICROBIOL REV, V14, P150, DOI 10.1128/CMR.14.1.150-164.2001.
   Voelkel NF, 1998, CHEST, V114, p225S, DOI 10.1378/chest.114.3\_Supplement.225S.
   Yaoita N, 2016, ARTERIOSCL THROM VAS, V36, pE97, DOI 10.1161/ATVBAHA.116.308263.},
Number-of-Cited-References = {66},
Times-Cited = {28},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Arterioscler. Thromb. Vasc. Biol.},
Doc-Delivery-Number = {JJ9PK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000494483700021},
DA = {2026-02-04},
}

@article{ WOS:000488997900007,
Author = {Mao, Zhu-Jun and Weng, Si-Ying and Lin, Min and Chai, Ke-Fu},
Title = {Yunpi Heluo decoction attenuates insulin resistance by regulating
   liver miR-29a-3p in Zucker diabetic fatty rats},
Journal = {JOURNAL OF ETHNOPHARMACOLOGY},
Year = {2019},
Volume = {243},
Month = {OCT 28},
Abstract = {Background and objective: Yunpiheluo (YPHL) decoction is a Chinese
   herbal formula with unique advantages for the treatment of type 2
   diabetes mellitus (T2DM). The aim of the present study was to
   investigate changes in miRNA expression and downstream gene expression
   in Zucker diabetic fatty (ZDF) rats treated with YPHL to determine
   whether YPHL could be used as an adjuvant treatment of T2DM.
   Methods: Serum and liver total cholesterol (TC) and triglycerides (TG)
   levels, insulin resistance index (IR) and differentially expressed
   miRNAs were detected in a T2DM ZDF rat model. miRNA target prediction
   was based on bioinformatic algorithms and dual luciferase reporter
   assay. Protein expression of genes in the insulin receptor signaling
   pathway was detected by Western blot. The IR cell model was established
   and the effects of lyophilized YPHL powder on the protein expressions
   were observed by transfecting specific miRNA mimics and inhibitors.
   Results: The miR-29a-3p expression level was significantly increased in
   the liver of ZDF rats. Insulin receptor substrate 1 (IRS1) was the
   target gene of miR-29a-3p. IRS1 mRNA and protein expressions of IRSI,
   IRS1 (phospho S307), protein kinase B (Akt), Akt (phosphor ser473) and
   pyruvate dehydrogenase lipoamide kinase isozyme 1 (PDK1) were decreased
   significantly. miR-29a-3p over-expression decrease IRS1 and the others
   protein expressions in the HepG2 IR cell model while anti-miR-29a-3p
   showed the opposite result. The miR-29a-3p level was decreased, and the
   expressions of IRS1 mRNA and the above proteins were all increased after
   YPHL treatment.
   Conclusion: miR-29a-3p played a functional role in insulin receptor
   signaling in the liver of ZDF rats. YPHL decoction attenuated IR in T2DM
   probably by down-regulating or maintaining the miR-29a-3p level,
   increasing the expression of IRS1 mRNA and its phosphorylated proteins,
   and regulating the expression of insulin receptor signaling-related
   proteins. YPHL may prove to be an alternative treatment for T2DM.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Chai, KF (Corresponding Author), Zhejiang Chinese Med Univ, Coll Basic Med, 584 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.
   Mao, Zhu-Jun, Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Zhejiang, Peoples R China.
   Weng, Si-Ying, Ningbo Municipal TCM Hosp, Endocrinol Dept, Ningbo 315010, Zhejiang, Peoples R China.
   Lin, Min; Chai, Ke-Fu, Zhejiang Chinese Med Univ, Coll Basic Med, 584 Binwen Rd, Hangzhou 310053, Zhejiang, Peoples R China.},
DOI = {10.1016/j.jep.2019.111966},
Article-Number = {111966},
ISSN = {0378-8741},
EISSN = {1872-7573},
Keywords = {Yunpiheluo decoction; Insulin resistance; miRNA; IRS1; Insulin receptor
   signaling pathway},
Keywords-Plus = {RADIX-PAEONIAE RUBRA; FLAVONOIDS; MICRORNAS; MEDICINES; GROWTH; CANCER;
   INJURY; CELLS},
Research-Areas = {Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine},
Web-of-Science-Categories  = {Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy},
Author-Email = {maozhujun0107@163.com
   alicewsy@163.com
   mlin2009@163.com
   ckf666@163.com},
Affiliations = {Zhejiang Chinese Medical University; Zhejiang Chinese Medical University},
ResearcherID-Numbers = {翁, 思颖/HTM-5266-2023},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81774177, 81603351]},
Funding-Text = {We would like to thank the Experimental Animal Centre and Pathology
   Laboratory of Zhejiang University of Traditional Chinese Medicine for
   their expertise and technical help. This study was supported by the
   grants from the National Natural Science Foundation of China (81774177,
   No. 81603351).},
Cited-References = {Baena M, 2017, J NUTR BIOCHEM, V40, P105, DOI 10.1016/j.jnutbio.2016.10.015.
   Bensky D., 1990, Chinese Herbal Medicine: Materia Medico.
   Brown AE, 2016, CURR CARDIOL REP, V18, DOI 10.1007/s11886-016-0755-4.
   Chai K., 2013, CHIN ARCH TRADIT CHI, DOI {[}10.13193/j.archtcm.2013.05.12.chaikf.084, DOI 10.13193/J.ARCHTCM.2013.05.12.CHAIKF.084].
   CHANG CLT, 2013, EVID-BASED COMPL ALT, DOI DOI 10.1155/2013/378657.
   Chang HY, 2007, J ADV NURS, V58, P307, DOI 10.1111/j.1365-2648.2007.04291.x.
   Chriett S, 2017, MOL CELL ENDOCRINOL, V439, P224, DOI 10.1016/j.mce.2016.09.006.
   Forrestel AC, 2017, DIABETOLOGIA, V60, P808, DOI 10.1007/s00125-016-4175-1.
   Galimov A, 2015, J MOL MED, V93, P1369, DOI 10.1007/s00109-015-1322-y.
   Ghorbani A, 2014, J INTEGR MED-JIM, V12, P336, DOI 10.1016/S2095-4964(14)60031-5.
   Gong ZJ, 2008, HEPATOL INT, V2, P346, DOI 10.1007/s12072-008-9082-1.
   Ikink GJ, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2017.1279722.
   Jiang FJ, 2012, FITOTERAPIA, V83, P415, DOI 10.1016/j.fitote.2011.12.009.
   Kang H, 2004, BIOL PHARM BULL, V27, P1946, DOI 10.1248/bpb.27.1946.
   Lai PKK, 2014, PHYTOTHER RES, V28, P395, DOI 10.1002/ptr.5002.
   Lau TW, 2008, EUR SURG RES, V41, P15, DOI 10.1159/000122834.
   Lee SC, 2005, ARCH PHARM RES, V28, P775, DOI 10.1007/BF02977342.
   Li W, 2014, ARCH PHARM RES, V37, P186, DOI 10.1007/s12272-013-0174-7.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117.
   Mokashi P, 2017, BIOMED PHARMACOTHER, V90, P268, DOI 10.1016/j.biopha.2017.03.047.
   Nesca V, 2013, DIABETOLOGIA, V56, P2203, DOI 10.1007/s00125-013-2993-y.
   Ortega FJ, 2014, DIABETES CARE, V37, P1375, DOI 10.2337/dc13-1847.
   Qi LW, 2010, CURR TOP MED CHEM, V10, P434, DOI 10.2174/156802610790980620.
   Rakhi Mishra Rakhi Mishra, 2011, Journal of Applied Pharmaceutical Science, V1, P235.
   Rawal S, 2017, CARDIOVASC RES, V113, P90, DOI 10.1093/cvr/cvw235.
   Resch M, 2001, PLANTA MED, V67, P437, DOI 10.1055/s-2001-15817.
   Samad A, 2009, CURR DIABETES REV, V5, P102, DOI 10.2174/157339909788166837.
   Scortegagna M, 2015, CANCER RES, V75, P1399, DOI 10.1158/0008-5472.CAN-14-2785.
   Sekiya N, 2004, PHYTOTHER RES, V18, P247, DOI 10.1002/ptr.1396.
   Wang R, 2012, INT J MOL SCI, V13, P14634, DOI 10.3390/ijms131114634.
   Wei ZT, 2018, MOL MED REP, V17, P1617, DOI 10.3892/mmr.2017.8084.
   Willeit P, 2016, EUR HEART J, V37, P3260, DOI 10.1093/eurheartj/ehw146.
   Xu AM, 2009, ENDOCRINOLOGY, V150, P625, DOI 10.1210/en.2008-0999.
   Yang H., 2017, STUDY PROTECTIVE EFF, DOI {[}10.13633/j.cnki.zjtcm.2017.03.011, DOI 10.13633/J.CNKI.ZJTCM.2017.03.011].
   Zhang X., 2010, HENAN TRADITIONAL CH, DOI {[}10.16367/j.issn.1003-5028.2010.08.028, DOI 10.16367/J.ISSN.1003-5028.2010.08.028].
   Zhao EP, 2009, MAMM GENOME, V20, P476, DOI 10.1007/s00335-009-9217-2.},
Number-of-Cited-References = {37},
Times-Cited = {9},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {37},
Journal-ISO = {J. Ethnopharmacol.},
Doc-Delivery-Number = {JC0VM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000488997900007},
DA = {2026-02-04},
}

@article{ WOS:000490860900005,
Author = {Spirina, L. V. and Kondakova, I. V. and Yurmazov, Z. A. and Usynin, E.
   A. and Slonimskaya, E. M. and Lushnikova, N. A. and Podnebesnova, D. V.},
Title = {VHL Expression in Kidney Cancer: Relation to Metastasis Development,
   Transcription and Growth Factors and Component of Akt/m-TOR Signaling
   Pathway},
Journal = {BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE},
Year = {2019},
Volume = {167},
Number = {5},
Pages = {671-675},
Month = {SEP},
Abstract = {Von Hippel-Lindau protein (VHL) is associated with the development and
   progression of kidney cancer. An increase in VHL expression was found in
   patients with the disseminated form of the disease compared to the
   localized cancer, which was combined with a uniform distribution of
   decreased (<1.0) and increased (>1.0) VHL mRNA levels in renal cancer
   patients depending on the dissemination of the process. The increase in
   VHL expression was accompanied an increase in the level of mRNA for
   NF-kappa B p65 and kinases PDK1 and Akt. The revealed data indicate the
   importance of molecular biological parameters in oncogenesis.},
Publisher = {SPRINGER},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Spirina, LV (Corresponding Author), Russian Acad Sci, Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia.
   Spirina, LV (Corresponding Author), Siberian State Med Univ, Tomsk, Russia.
   Spirina, L. V.; Kondakova, I. V.; Yurmazov, Z. A.; Usynin, E. A.; Slonimskaya, E. M.; Lushnikova, N. A., Russian Acad Sci, Tomsk Natl Res Med Ctr, Canc Res Inst, Tomsk, Russia.
   Spirina, L. V.; Slonimskaya, E. M.; Podnebesnova, D. V., Siberian State Med Univ, Tomsk, Russia.},
DOI = {10.1007/s10517-019-04596-9},
EarlyAccessDate = {OCT 2019},
ISSN = {0007-4888},
EISSN = {1573-8221},
Keywords = {VHL; kidney cancer; growth factors; nuclear factors; components of Akt;
   m-TOR signaling pathway},
Keywords-Plus = {RENAL-CELL CARCINOMA; KAPPA-B},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {spirinalvl@mail.ru},
Affiliations = {Russian Academy of Sciences; Tomsk National Research Medical Center;
   Cancer Research Institute of the RAS; Siberian State Medical University},
ResearcherID-Numbers = {Slonimskaya, Elena/C-7405-2012
   Лушникова, Надежда/ABB-7830-2021
   Усынин, Евгений/D-1505-2012
   Evgeny, Usynin/D-1505-2012
   Spirina, Liudmila V/A-7760-2012},
ORCID-Numbers = {Усынин, Евгений/0000-0001-7127-0188
   Spirina, Liudmila V/0000-0002-5269-736X},
Funding-Acknowledgement = {Russian Foundation for Basic Research {[}19-415-703001 p\_ mol\_a]},
Funding-Text = {The study was supported by the Russian Foundation for Basic Research
   (grant No. 19-415-703001 p\_ mol\_a)},
Cited-References = {Cho D, 2013, CANCER J, V19, P311, DOI 10.1097/PPO.0b013e31829d5cea.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Guo JP, 2016, SCIENCE, V353, P929, DOI 10.1126/science.aad5755.
   Heng DY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114264.
   Ito H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2418-7.
   Kaprin AD, 2020, MALIGNANT NEOPLASMS.
   Kim BJ, 2017, ONCOTARGET, V8, P13979, DOI 10.18632/oncotarget.14704.
   Kroeger N, 2014, EUR J CANCER, V50, P1531, DOI 10.1016/j.ejca.2014.01.031.
   Labrousse-Arias D, 2017, J CELL BIOL, V216, P835, DOI 10.1083/jcb.201608024.
   Menke J, 2009, J CLIN INVEST, V119, P2330, DOI 10.1172/JCI39087.
   Morais C, 2011, INT J BIOCHEM CELL B, V43, P1537, DOI 10.1016/j.biocel.2011.08.003.
   Spirina LV, 2017, MOL BIOL+, V51, P328, DOI 10.1134/S0026893317020194.
   Spirina Liudmila V, 2017, Asian Pac J Cancer Prev, V18, P2977.
   Wu XF, 2016, OPEN MED-WARSAW, V11, P226, DOI 10.1515/med-2016-0043.
   Yamaguchi R, 2016, TUMOR BIOL, V37, P13295, DOI 10.1007/s13277-016-5260-2.},
Number-of-Cited-References = {15},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Bull. Exp. Biol. Med.},
Doc-Delivery-Number = {JL8PW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000490860900005},
DA = {2026-02-04},
}

@article{ WOS:000486612500016,
Author = {Cao, Wei and Wang, Zhan and Han, Xingwen and Liu, Jianhua and Wang,
   Wenji},
Title = {In vitro cytotoxicity screening to identify novel anti-osteosarcoma
   therapeutics targeting pyruvate dehydrogenase kinase 2},
Journal = {BIOORGANIC \& MEDICINAL CHEMISTRY LETTERS},
Year = {2019},
Volume = {29},
Number = {20},
Month = {OCT 15},
Abstract = {Pyruvate dehydrogenase kinases (PDKs) act as negative modulator of
   mitochondrial pyruvate dehydrogenase complex (PDC) and play a crucial
   role in the regulation of oxidative glycolysis, which recently have been
   considered as a potential drug target for varying types of cancer and
   diabetes. Herein, we describe the discovery and biological validation of
   novel anti-osteosarcoma therapeutics targeting PDK2. We identified 14
   anti-osteosarcoma compounds from an in-house small molecule library,
   which were then evaluated in a PDK2 kinase inhibition assay. We found
   that compounds with
   2-((4-oxo-6-((4-phenylpiperazin-1-yl)methyl)-4H-pyran-3-yl)
   oxy)acetamide moiety showed promising inhibitory potencies to PDK2.
   Especial for 12, which bound to PDK2 with a K-d value of 2.3 mu M, and
   inhibited PDK2 activity with an EC50 value of 1.1 mu M. In addition, 12
   selectively inhibited PDK2, the selectivity indexes are 10.6, 22.0, and
   60.9 for PDK2 as compared to PDK1, 2 and 4, respectively. The MTT assay
   suggested that 12 reduced MG-63 cancer cell proliferation with an IC50
   value of 4.7 mu M. All these observations indicated that 12 was a novel
   anti-osteosarcoma therapeutic, which deserved for further investigation.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, WJ (Corresponding Author), Lanzhou Univ, Hosp 1, Lanzhou 730000, Gansu, Peoples R China.
   Cao, Wei; Liu, Jianhua, Capital Med Univ, Beijing Rehabil Hosp, Clin Lab, Beijing 100144, Peoples R China.
   Wang, Zhan, Gansu Prov Hosp, Lanzhou 730000, Gansu, Peoples R China.
   Han, Xingwen; Wang, Wenji, Lanzhou Univ, Hosp 1, Lanzhou 730000, Gansu, Peoples R China.},
DOI = {10.1016/j.bmcl.2019.126665},
Article-Number = {126665},
ISSN = {0960-894X},
EISSN = {1464-3405},
Keywords = {Cancer metabolism; Anticancer; Pyruvate dehydrogenase kinase 2},
Keywords-Plus = {INHIBITORS; METABOLISM; DICHLOROACETATE},
Research-Areas = {Pharmacology \& Pharmacy; Chemistry},
Web-of-Science-Categories  = {Chemistry, Medicinal; Chemistry, Organic},
Author-Email = {Wenji\_Wang001@hotmail.com},
Affiliations = {Capital Medical University; Lanzhou University},
Funding-Acknowledgement = {National Natural Science Foundation of Gansu province {[}1606RJZA126]},
Funding-Text = {We thank the financial support from National Natural Science Foundation
   of Gansu province (No. 1606RJZA126).},
Cited-References = {Aicher TD, 1999, J MED CHEM, V42, P2741, DOI 10.1021/jm9902584.
   Brough PA, 2017, J MED CHEM, V60, P2271, DOI 10.1021/acs.jmedchem.6b01478.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Sun H, 2017, ONCOTARGET, V8, P52642, DOI 10.18632/oncotarget.16991.
   Sutendra G, 2013, ONCOGENE, V32, P1638, DOI 10.1038/onc.2012.198.
   Tso SC, 2017, J MED CHEM, V60, P1142, DOI 10.1021/acs.jmedchem.6b01540.
   Tso SC, 2014, J BIOL CHEM, V289, P4432, DOI 10.1074/jbc.M113.533885.
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504.
   Yu XK, 2008, STRUCTURE, V16, P104, DOI 10.1016/j.str.2007.10.024.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.},
Number-of-Cited-References = {19},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Bioorg. Med. Chem. Lett.},
Doc-Delivery-Number = {IY7ZA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000486612500016},
DA = {2026-02-04},
}

@article{ WOS:000506401900005,
Author = {Ma, Jun and Chen, Xiao-li and Sun, Qin},
Title = {microRNA-579 upregulation mediates death of human macrophages with
   mycobacterium tuberculosis infection},
Journal = {BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS},
Year = {2019},
Volume = {518},
Number = {2},
Pages = {219-226},
Month = {OCT 15},
Abstract = {Mycobacterium tuberculosis (MTB) infection could induce death of host
   human macrophages, promoting bacterial spread. In the current study we
   tested the potential role of microRNA-579 (miR-579) in the death of
   macrophages infected with MTB. In the primary human macrophages MTB
   infection induced upregulation of miR-579 but downregulation of its mRNA
   targets, S1RT1 and PDK1, which were accompanied by significant
   macrophage death and apoptosis. miR-579 inhibition, by its anti-sense
   sequence, restored SIRT1-PDK1 expression and significantly attenuated
   MTB-induced cytotoxicity and apoptosis in human macrophages. Conversely,
   ectopic overexpression of miR-579 further downregulated SIRT1-PDK1
   expression and exacerbated MTB-induced cytotoxicity in human
   macrophages. Further studies showed that cPWWP2A, the miR-579's
   endogenous sponge circRNA, was downregulated in MTB-infected
   macrophages. Conversely, forced overexpression of cPWWP2A, by a
   recombinant adeno-associated virus construct, reversed MTB-induced
   miR-579 upregulation and macrophage cytotoxicity. Taken together, our
   results show that miR-579 upregulation mediates MTB-induced macrophage
   cytotoxicity. Targeting cPWWP2A-miR-579 axis could be a novel strategy
   to protect human macrophages from MTB infection. (C) 2019 Elsevier Inc.
   All rights reserved.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Sun, Q (Corresponding Author), Tongji Univ, Shanghai Pulm Hosp, Clin \& Res Ctr TB, Shanghai Key Lab TB,Sch Med, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.
   Ma, Jun; Sun, Qin, Tongji Univ, Shanghai Pulm Hosp, Clin \& Res Ctr TB, Shanghai Key Lab TB,Sch Med, 507 Zhengmin Rd, Shanghai 200433, Peoples R China.
   Chen, Xiao-li, Sixth Peoples Hosp Nantong, Dept TB, Nantong, Jiangsu, Peoples R China.},
DOI = {10.1016/j.bbrc.2019.08.035},
ISSN = {0006-291X},
EISSN = {1090-2104},
Keywords = {Mycobacterium tuberculosis (MTB); Macrophages; miR-579; cPWWP2A and cell
   death},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {sunqinbonjour@aliyun.com},
Affiliations = {Tongji University},
ORCID-Numbers = {Sun, Qin/0000-0003-3445-920X},
Funding-Acknowledgement = {National Nature Science Foundation of China {[}81400006]; Shanghai
   Pujiang Program {[}16PJD041]; Clinical Research Plan of SHDC
   {[}16CR1028B]},
Funding-Text = {This study was supported by National Nature Science Foundation of China
   (No. 81400006), the Shanghai Pujiang Program (No.16PJD041) and by the
   Clinical Research Plan of SHDC (16CR1028B).},
Cited-References = {Amaral EP, 2019, J EXP MED, V216, P556, DOI 10.1084/jem.20181776.
   Byrne AL, 2015, INT J INFECT DIS, V32, P138, DOI 10.1016/j.ijid.2014.12.016.
   Ebbesen KK, 2017, RNA BIOL, V14, P1035, DOI 10.1080/15476286.2016.1271524.
   Fattore L, 2016, P NATL ACAD SCI USA, V113, pE5005, DOI 10.1073/pnas.1607753113.
   Guo L, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00134.
   He ML, 2017, J PATHOL, V242, P309, DOI 10.1002/path.4905.
   HOUBEN RM, 2016, PLOS MED, V13, DOI DOI 10.1371/JOURNAL.PMED.1002119.
   Huang ZK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129744.
   Jenkins HE, 2016, PNEUMONIA, V8, DOI 10.1186/s41479-016-0018-6.
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965.
   Kalhori M.R., 2019, J CELL BIOCH.
   Kiran D, 2016, SEMIN IMMUNOPATHOL, V38, P167, DOI 10.1007/s00281-015-0537-x.
   Korb VC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030131.
   Kumar R, 2016, CELL MICROBIOL, V18, P679, DOI 10.1111/cmi.12540.
   Ley S, 2013, IMMUNOBIOLOGY, V218, P40, DOI 10.1016/j.imbio.2012.01.019.
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116.
   Liu YY, 2018, ONCOGENE, V37, P2890, DOI 10.1038/s41388-018-0184-5.
   McDougald DS, 2018, INVEST OPHTH VIS SCI, V59, P1212, DOI 10.1167/iovs.17-22972.
   Meng XW, 2017, BRIEF BIOINFORM, V18, P547, DOI 10.1093/bib/bbw045.
   Mu N., 2019, APOPTOSIS.
   Raja A, 2004, INDIAN J MED RES, V120, P213.
   Roy S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24509-6.
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x.
   Sun J, 2018, THERANOSTICS, V8, P4695, DOI 10.7150/thno.26203.
   Sun WW, 2017, ONCOTARGET, V8, P57537, DOI 10.18632/oncotarget.15734.
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20.
   Treiber T, 2019, NAT REV MOL CELL BIO, V20, P5, DOI 10.1038/s41580-018-0059-1.
   Yi ZJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043184.
   Zhang GL, 2016, CELL CYCLE, V15, P2527, DOI 10.1080/15384101.2016.1215386.
   Zuñiga J, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/193923.},
Number-of-Cited-References = {30},
Times-Cited = {28},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Biochem. Biophys. Res. Commun.},
Doc-Delivery-Number = {KB3LS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000506401900005},
DA = {2026-02-04},
}

@article{ WOS:000489555200039,
Author = {de las Heras-Martinez, Gloria and Calleja, Veronique and Bailly, Remy
   and Dessolin, Jean and Larijani, Banafshe and Requejo-Isidro, Jose},
Title = {A Complex Interplay of Anionic Phospholipid Binding Regulates
   3′-Phosphoinositide-Dependent-Kinase-1 Homodimer Activation},
Journal = {SCIENTIFIC REPORTS},
Year = {2019},
Volume = {9},
Month = {OCT 10},
Abstract = {3'-Phosphoinositide-dependent-Kinase-1(PDK1) is a master regulator
   whereby its PI3- kinase-dependent dysregulation in human pathologies is
   well documented. Understanding the direct role for Ptdlns(3,4,5)P-3 and
   other anionic phospholipids in the regulation of PDK1 conformational
   dynamics and its downstream activation remains incomplete. Using
   advanced quantitative-time-resolved imaging (Fluorescence Lifetime
   Imaging and Fluorescence Correlation Spectroscopy) and molecular
   modelling, we show an interplay of antagonistic binding effects of
   Ptdlns(3,4,5)P-3 and other anionic phospholipids, regulating activated
   PDK1 homodimers. We demonstrate that phosphatidylserine maintains PDK1
   in an inactive conformation. The dysregulation of the PI3K pathway
   affects the spatio-temporal and conformational dynamics of PDK1 and the
   activation of its downstream substrates. We have established a new
   anionic-phospholipid-dependent model for PDK1 regulation, depicting the
   conformational dynamics of multiple homodimer states. We show that the
   dysregulation of the PI3K pathway perturbs equilibrium between the PDK1
   homodimer conformations. Our findings provide a role for the PtdSer
   binding site and its previously unrewarding role in PDK1 downregulation,
   suggesting a possible therapeutic strategy where the constitutively
   active dimer conformer of PDK1 may be rendered inactive by small
   molecules that drive it to its PtdSer-bound conformer.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Requejo-Isidro, J (Corresponding Author), Univ Basque Country, CSIC, Inst Biofis, E-48940 Leioa, Spain.
   Larijani, B (Corresponding Author), Univ Basque Country UPV EHU, Cell Biophys Lab, Ikerbasque Basque Fdn Sci, Inst Biofis,CSIC,UPV EHU, Leioa, Spain.
   Larijani, B (Corresponding Author), Univ Basque Country UPV EHU, Res Ctr Expt Marine Biol \& Biotechnol PiE, Leioa, Spain.
   Larijani, B (Corresponding Author), Univ Bath, Ctr Therapeut Innovat CTI Bath, Bath BA2 7AY, Avon, England.
   Larijani, B (Corresponding Author), Univ Bath, Cell Biophys Lab, Dept Pharm \& Pharmacol, Bath BA2 7AY, Avon, England.
   Requejo-Isidro, J (Corresponding Author), Ctr Nacl Biotecnol CSIC, Darwin,3, E-28049 Madrid, Spain.
   Requejo-Isidro, J (Corresponding Author), CSIC, CNB, IMDEA, Unidad Nanobiotecnol,Nanociencia Associated Unit, Madrid 28049, Spain.
   de las Heras-Martinez, Gloria; Requejo-Isidro, Jose, Univ Basque Country, CSIC, Inst Biofis, E-48940 Leioa, Spain.
   Calleja, Veronique, Francis Crick Inst, Prot Phosphorylat Lab, 1 Midland Rd, London NW1 1AT, England.
   Bailly, Remy; Dessolin, Jean, Univ Bordeaux, CNRS, Inst Chem \& Biol Membranes \& Nanoobjects, UMR 5248,CBMN,Bordeaux INP, F-33600 Bordeaux, France.
   de las Heras-Martinez, Gloria; Larijani, Banafshe, Univ Basque Country UPV EHU, Cell Biophys Lab, Ikerbasque Basque Fdn Sci, Inst Biofis,CSIC,UPV EHU, Leioa, Spain.
   de las Heras-Martinez, Gloria; Larijani, Banafshe, Univ Basque Country UPV EHU, Res Ctr Expt Marine Biol \& Biotechnol PiE, Leioa, Spain.
   Larijani, Banafshe, Univ Bath, Ctr Therapeut Innovat CTI Bath, Bath BA2 7AY, Avon, England.
   Larijani, Banafshe, Univ Bath, Cell Biophys Lab, Dept Pharm \& Pharmacol, Bath BA2 7AY, Avon, England.
   Requejo-Isidro, Jose, Ctr Nacl Biotecnol CSIC, Darwin,3, E-28049 Madrid, Spain.
   Requejo-Isidro, Jose, CSIC, CNB, IMDEA, Unidad Nanobiotecnol,Nanociencia Associated Unit, Madrid 28049, Spain.},
DOI = {10.1038/s41598-019-50742-8},
Article-Number = {14527},
ISSN = {2045-2322},
Keywords-Plus = {PROTEIN-KINASE B; PHOSPHOINOSITIDE-DEPENDENT KINASE-1; PLASMA-MEMBRANE
   RECRUITMENT; PLECKSTRIN HOMOLOGY DOMAINS; PHOSPHATIDYLINOSITOL
   3,4,5-TRISPHOSPHATE; SINGLE-MOLECULE; PH DOMAIN; PDK1;
   PHOSPHATIDYLSERINE; PHOSPHORYLATION},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {banafshe.larijani@ikerbasque.org
   jose.requejo@csic.es},
Affiliations = {Consejo Superior de Investigaciones Cientificas (CSIC); University of
   Basque Country; CSIC - UPV EHU - Instituto Biofisika; Francis Crick
   Institute; Universite de Bordeaux; Centre National de la Recherche
   Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Basque
   Foundation for Science; Consejo Superior de Investigaciones Cientificas
   (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto
   Biofisika; University of Basque Country; University of Bath; University
   of Bath; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC -
   Centro Nacional de Biotecnologia (CNB); IMDEA Materials Institute;
   Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro
   Nacional de Biotecnologia (CNB)},
ResearcherID-Numbers = {Requejo-Isio, Jose/G-2663-2015
   LARIJANI, Banafshé/OPN-4239-2025},
ORCID-Numbers = {Calleja, Véronique Françoise/0000-0002-6537-2660
   Requejo-Isio, Jose/0000-0002-2465-6288
   LARIJANI, Banafshé/0000-0003-4735-1169},
Funding-Acknowledgement = {Spanish Ministry of Economy grant {[}BFU2015-65625-P]; Ministerio de
   Economia y Competitividad in Spain grant {[}MINECO FIS2009-07966]; Royal
   Society grants {[}IE120953]; Basque Government; Cancer Research UK;
   Ikerbasque Foundation of Science; Centre National de la Recherche
   Scientifique (CNRS); Ministere de l'Education Nationale et de
   l'Enseignement Superieur et de la Recherche (MENSR); The Francis Crick
   Institute {[}10130] Funding Source: researchfish},
Funding-Text = {We are grateful to Peter J Parker, Len Stephens, Patrick Williamson and
   Vytas Bankaitis for scientific discussions and constructively reading
   the paper. Sonia Lopez Fernandez for her help in the cloning and Unai
   Lopez Sierra for technical assistance at the microscope. Supported by
   the Spanish Ministry of Economy grant to B.L. {[}BFU2015-65625-P] \&
   Ministerio de Economia y Competitividad in Spain grant to J.R.-I.,
   (MINECO FIS2009-07966); Royal Society grants to J.R.-I. and V.C.
   (IE120953). Basque Government PhD studentship to G.d.H.; Cancer Research
   UK Core Funding grants to B.L.; We also acknowledge the support of the
   Ikerbasque Foundation of Science to BL; Centre National de la Recherche
   Scientifique (CNRS) and Ministere de l'Education Nationale et de
   l'Enseignement Superieur et de la Recherche (MENSR) grants to J.D.},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Calleja V, 2014, BIOCHEM SOC T, V42, P1435, DOI 10.1042/BST20140222.
   Cameron AJ, 2007, BIOCHEM SOC T, V35, P1013, DOI 10.1042/BST0351013.
   Carravilla P, 2015, LANGMUIR, V31, P2808, DOI 10.1021/la504251u.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Chen H, 2001, BIOCHEMISTRY-US, V40, P11851, DOI 10.1021/bi010743c.
   Corbin JA, 2004, BIOCHEMISTRY-US, V43, P16161, DOI 10.1021/bi049017a.
   Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575.
   de las Heras-Martínez G, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201600272.
   Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000.
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075.
   Gao M, 2014, ONCOGENE, V33, P745, DOI 10.1038/onc.2013.2.
   Gao XX, 2006, BIOORG CHEM, V34, P200, DOI 10.1016/j.bioorg.2006.05.002.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   Gray A, 1999, BIOCHEM J, V344, P929, DOI 10.1042/0264-6021:3440929.
   Heinemann F, 2012, LANGMUIR, V28, P13395, DOI 10.1021/la302596h.
   Huang BX, 2011, J CELL BIOL, V192, P979, DOI 10.1083/jcb.201005100.
   Inoue T, 2005, NAT METHODS, V2, P415, DOI 10.1038/NMETH763.
   Jethwa N, 2015, J CELL SCI, V128, P3456, DOI 10.1242/jcs.172775.
   Kahya N, 2006, J FLUORESC, V16, P671, DOI 10.1007/s10895-006-0108-6.
   Kang JA, 2013, J IMMUNOL, V190, P4508, DOI 10.4049/jimmunol.1202923.
   Kikani CK, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003065.
   King CC, 2004, J BIOL CHEM, V279, P37518, DOI 10.1074/jbc.M405340200.
   Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200.
   Knight JD, 2010, BIOPHYS J, V99, P2879, DOI 10.1016/j.bpj.2010.08.046.
   Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379.
   Lasserre R, 2008, NAT CHEM BIOL, V4, P538, DOI 10.1038/nchembio.103.
   Leventis PA, 2010, ANNU REV BIOPHYS, V39, P407, DOI 10.1146/annurev.biophys.093008.131234.
   Lucas N, 2011, J BIOL CHEM, V286, P41265, DOI 10.1074/jbc.M111.300806.
   Masters TA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000738.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Ries J, 2006, BIOPHYS J, V91, P1915, DOI 10.1529/biophysj.106.082297.
   Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710.
   Szymczak AL, 2004, NAT BIOTECHNOL, V22, P589, DOI 10.1038/nbt957.
   Vonkova I, 2015, CELL REP, V12, P1519, DOI 10.1016/j.celrep.2015.07.054.
   Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200.
   Yeung T, 2008, SCIENCE, V319, P210, DOI 10.1126/science.1152066.
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333.
   Ziemba BP, 2013, BIOCHEMISTRY-US, V52, P4820, DOI 10.1021/bi400488f.},
Number-of-Cited-References = {43},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {JC8VW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000489555200039},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000532467000016,
Author = {Sankar, Krishana S. and Altamentova, Svetlana M. and Rocheleau, V,
   Jonathan},
Title = {Hypoxia induction in cultured pancreatic islets enhances endothelial
   cell morphology and survival while maintaining beta-cell function},
Journal = {PLOS ONE},
Year = {2019},
Volume = {14},
Number = {10},
Month = {OCT 10},
Abstract = {Background
   Pancreatic islets are heavily vascularized in vivo yet lose this
   vasculature after only a few days in culture. Determining how to
   maintain islet vascularity in culture could lead to better outcomes in
   transplanting this tissue for the treatment of type 1 diabetes as well
   as provide insight into the complex communication between beta-cells and
   endothelial cells (ECs). We previously showed that islet ECs die in part
   due to limited diffusion of serum albumin into the tissue. We now aim to
   determine the impact of hypoxia on islet vascularization.
   Methods
   We induced hypoxia in cultured mouse islets using the hypoxia mimetic
   cobalt chloride (100 mu M CoCl2). We measured the impact on islet
   metabolism (two-photon NAD(P)H and Rh123 imaging) and function (insulin
   secretion and survival). We also measured the impact on hypoxia related
   transcripts (HIF-1 alpha, VEGF-A, PDK-1, LDHA, COX4) and confirmed
   increased VEGF-A expression and secretion. Finally, we measured the
   vascularization of islets in static and flowing culture using PECAM-1
   immunofluorescence.
   Results
   CoCl2 did not induce significant changes in beta cell metabolism
   (NAD(P)H and Rh123), insulin secretion, and survival. Consistent with
   hypoxia induction, CoCl2 stimulated HIF-1 alpha, PDK-1, and LDHA
   transcripts and also stimulated VEGF expression and secretion. We
   observed a modest switch to the less oxidative isoform of COX4 (isoform
   1 to 2) and this switch was noted in the glucose-stimulated cytoplasmic
   NAD(P)H responses. EC morphology and survival were greater in CoCl2
   treated islets compared to exogenous VEGF-A in both static (dish) and
   microfluidic flow culture.
   Conclusions
   Hypoxia induction using CoCl2 had a positive effect on islet EC
   morphology and survival with limited impact on beta-cell metabolism,
   function, and survival. The EC response appears to be due to endogenous
   production and secretion of angiogenic factors (e.g. VEGF-A), and
   mechanistically independent from survival induced by serum albumin.},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Article},
Language = {English},
Affiliation = {Rocheleau, JV (Corresponding Author), Univ Toronto, Dept Physiol, Toronto, ON, Canada.
   Rocheleau, JV (Corresponding Author), Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON, Canada.
   Rocheleau, JV (Corresponding Author), Univ Toronto, Inst Biomat \& Biomed Engn, Toronto, ON, Canada.
   Rocheleau, JV (Corresponding Author), Univ Toronto, Dept Med, Toronto, ON, Canada.
   Sankar, Krishana S.; Rocheleau, Jonathan, V, Univ Toronto, Dept Physiol, Toronto, ON, Canada.
   Sankar, Krishana S.; Altamentova, Svetlana M.; Rocheleau, Jonathan, V, Univ Hlth Network, Toronto Gen Hosp, Res Inst, Toronto, ON, Canada.
   Rocheleau, Jonathan, V, Univ Toronto, Inst Biomat \& Biomed Engn, Toronto, ON, Canada.
   Rocheleau, Jonathan, V, Univ Toronto, Dept Med, Toronto, ON, Canada.},
DOI = {10.1371/journal.pone.0222424},
Article-Number = {e0222424},
ISSN = {1932-6203},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {jon.rocheleau@utoronto.ca},
Affiliations = {University of Toronto; University of Toronto; University Health Network
   Toronto; Toronto General Hospital; University of Toronto; University of
   Toronto},
ORCID-Numbers = {Rocheleau, Jonathan/0000-0002-1760-2564},
Funding-Acknowledgement = {Natural Sciences and Engineering Research Council (NSERC) of Canada;
   Faculty of Applied Science and Engineering, University of Toronto},
Funding-Text = {This work was supported by the Natural Sciences and Engineering Research
   Council (NSERC) of Canada and the Percy Edward Hart and Erwin Edward
   Hart Professorship from the Faculty of Applied Science and Engineering,
   University of Toronto. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.},
Cited-References = {Ardyanto TD, 2006, INT J ONCOL.
   Bretzel RG, 2007, LANGENBECKS ARCH SUR.
   Brissova M, 2008, DIABETES.
   Brissova M, 2004, DIABETES.
   Carmeliet P, 1999, CELL.
   Crawford SE, 1998, CELL.
   Duffy DC, 1998, ANAL CHEM.
   Fantin VR, 2006, CANC CELL.
   Hatanaka K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037600.
   Hiriart M, 2008, AM J PHYSL ENDOCRINO.
   Kelly BD, 2003, CIRC RES.
   Kerendi F, 2006, ANN THORAC SURG.
   Kim JW, 2006, CELL METAB.
   Li J, 2002, J CELL SCI.
   Narang AS, 2004, PHARM RES.
   Nyqvist D, 2005, DIABETES.
   Olerud J, 2008, DIABETES.
   Olsson R, 2006, INT J BIOCH CELL BIO.
   Olsson R, 2006, TRANSPLANTATION.
   Papandreou I, 2006, CELL METAB.
   Peiris H, 2014, DIABETES.
   Richards OC, 2010, ENDOCRINE REV.
   Rocheleau JV, 2002, J BIOL CHEM.
   Rocheleau JV., 2004, J BIOL CHEM.
   RyFukuda O, 2007, CELL.
   Sankar KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024904.
   Sato Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.194738.
   Spilsbury K, 2000, AM J PATHOL.
   Stefan Y, 1987, J CLIN INVEST.
   Su D, 2007, DIABETES.
   Woolf AS, 2001, PEDIAT NEPHROL.
   Yuan Y, 2003, J BIOL CHEM.
   Zhang N, 2004, DIABETES.},
Number-of-Cited-References = {33},
Times-Cited = {11},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {PLoS One},
Doc-Delivery-Number = {LM7ZE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000532467000016},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000488988500019,
Author = {Lu, Haiquan and Lu, Yang and Xie, Yangyiran and Qiu, Songbo and Li,
   Xinqun and Fan, Zhen},
Title = {Rational combination with PDK1 inhibition overcomes cetuximab resistance
   in head and neck squamous cell carcinoma},
Journal = {JCI INSIGHT},
Year = {2019},
Volume = {4},
Number = {19},
Month = {OCT 3},
Abstract = {Cetuximab, an EGFR-blocking antibody, is currently approved for
   treatment of metastatic head and neck squamous cell carcinoma (HNSCC),
   but its response rate is limited. In addition to blocking
   EGFR-stimulated cell signaling, cetuximab can induce endocytosis of
   ASCT2, a glutamine transporter associated with EGFR in a complex,
   leading to glutathione biosynthesis inhibition and cellular
   sensitization to ROS. Pyruvate dehydrogenase kinase-1 (PDK1), a key
   mitochondrial enzyme overexpressed in cancer cells, redirects glucose
   metabolism from oxidative phosphorylation toward aerobic glycolysis. In
   this study, we tested the hypothesis that targeting PDK1 is a rational
   approach to synergize with cetuximab through ROS overproduction. We
   found that combination of PDK1 knockdown or inhibition by dichloroacetic
   acid (DCA) with ASCT2 knockdown or with cetuximab treatment induced ROS
   overproduction and apoptosis in HNSCC cells, and this effect was
   independent of effective inhibition of EGFR downstream pathways but
   could be lessened by N-acetyl cysteine, an anti-oxidative agent. In
   several cetuximab-resistant HNSCC xenograft models, DCA plus cetuximab
   induced marked tumor regression, whereas either agent alone failed to
   induce tumor regression. Our findings call for potentially novel
   clinical trials of combining cetuximab and DCA in patients with
   cetuximab-sensitive EGFR-overexpressing tumors and patients with
   cetuximab-resistant EGFR-overexpressing tumors.},
Publisher = {AMER SOC CLINICAL INVESTIGATION INC},
Address = {2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA},
Type = {Article},
Language = {English},
Affiliation = {Fan, Z (Corresponding Author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21218 USA.
   Lu, Haiquan; Lu, Yang; Qiu, Songbo; Li, Xinqun; Fan, Zhen, Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   Lu, Haiquan; Fan, Zhen, MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX USA.
   Xie, Yangyiran, Johns Hopkins Univ, Program Neurosci, Krieger Sch Arts \& Sci, Baltimore, MD USA.},
DOI = {10.1172/jci.insight.131106},
Article-Number = {e131106},
EISSN = {2379-3708},
Keywords-Plus = {TARGETING CANCER METABOLISM; DICHLOROACETATE DCA; ASCT2 SLC1A5; EGFR
   INTERACTOME; DOWN-REGULATION; SINGLE-AGENT; OPEN-LABEL; GLUTAMINE;
   GROWTH; RECURRENT},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {zfan@mdanderson.org},
Affiliations = {University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Johns Hopkins University},
ResearcherID-Numbers = {Xie, Yangyiran/HJG-4955-2022},
ORCID-Numbers = {Xie, Yangyiran/0000-0001-9194-2439},
Funding-Acknowledgement = {US NIH R01 award {[}CA179015]; NIH R21 award {[}DE021883]; NIH through
   MD Anderson's Cancer Center Support Grant {[}CA016672]; National Cancer
   Institute {[}P30CA016672] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported in part by a US NIH R01 award (CA179015) and an
   NIH R21 award (DE021883) to ZF. The work was also supported in part by
   the NIH through MD Anderson's Cancer Center Support Grant, CA016672. We
   thank Stephanie Deming in Scientific Publications, Research Medical
   Library, at MD Anderson Cancer Center for editing this manuscript. This
   work is dedicated to the memory of John Mendelsohn, a pioneer in
   targeted cancer therapy whose groundbreaking work led to the development
   of cetuximab.},
Cited-References = {Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Bröer A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00785.
   Bröer A, 2016, J BIOL CHEM, V291, P13194, DOI 10.1074/jbc.M115.700534.
   Chakravarti N, 2010, CANCER PREV RES, V3, P331, DOI 10.1158/1940-6207.CAPR-09-0076.
   Chen XF, 2018, ANTIOXID REDOX SIGN, V29, P1660, DOI 10.1089/ars.2017.7423.
   Chiu M, 2017, AMINO ACIDS, V49, P1365, DOI 10.1007/s00726-017-2436-z.
   Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6.
   Cormerais Y, 2018, J BIOL CHEM, V293, P2877, DOI 10.1074/jbc.RA117.001342.
   Dang CV, 2010, CELL CYCLE, V9, P3884, DOI 10.4161/cc.9.19.13302.
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358.
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637-013-0047-4.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Erickson JW, 2010, ONCOTARGET, V1, P734, DOI 10.18632/oncotarget.208.
   Ferris RL, 2016, NEW ENGL J MED, V375, P1856, DOI 10.1056/NEJMoa1602252.
   Foerster S, 2013, PROTEOMICS, V13, P3131, DOI 10.1002/pmic.201300154.
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339.
   Garon EB, 2014, J CANCER RES CLIN, V140, P443, DOI 10.1007/s00432-014-1583-9.
   Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Ho C, 2010, CURR ONCOL, V17, P174.
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021.
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI {[}10.3322/caac.21254, 10.3322/caac.20073].
   Jenkins G, 2013, INT J GENOMICS, V2013, DOI 10.1155/2013/464720.
   Jones NP, 2012, DRUG DISCOV TODAY, V17, P232, DOI 10.1016/j.drudis.2011.12.017.
   Kamarajan P, 2017, J PROTEOME RES, V16, P1315, DOI 10.1021/acs.jproteome.6b00936.
   Kanai Y, 2004, PFLUG ARCH EUR J PHY, V447, P469, DOI 10.1007/s00424-003-1146-4.
   Li XQ, 2008, MOL CANCER THER, V7, P1207, DOI 10.1158/1535-7163.MCT-07-2187.
   Li XQ, 2015, ONCOTARGET, V6, P11507, DOI 10.18632/oncotarget.3432.
   Liu RQ, 2007, MOL PHARMACOL, V72, P1637, DOI 10.1124/mol.107.039644.
   Liu Y, 2018, EUR J PHARMACOL, V837, P81, DOI 10.1016/j.ejphar.2018.07.007.
   Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366.
   Lu HQ, 2016, CANCER LETT, V381, P23, DOI 10.1016/j.canlet.2016.07.020.
   Lu HQ, 2013, MOL CANCER THER, V12, P2187, DOI 10.1158/1535-7163.MCT-12-1245.
   Lu HQ, 2012, CANCER LETT, V322, P78, DOI 10.1016/j.canlet.2012.02.012.
   Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008.
   Lu WQ, 2010, CANCER CELL, V18, P199, DOI 10.1016/j.ccr.2010.08.017.
   Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103.
   Luo JT, 2017, CANCER LETT, V384, P39, DOI 10.1016/j.canlet.2016.09.020.
   Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701.
   Malone E, 2018, CLIN MED INSIGHTS-ON, V12, DOI 10.1177/1179554918779581.
   McGivan JD, 2007, FRONT BIOSCI, V12, P874, DOI 10.2741/2109.
   Michelakis ED, 2008, BRIT J CANCER, V99, P989, DOI 10.1038/sj.bjc.6604554.
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677.
   Modjtahedi H, 2003, INT J CANCER, V105, P273, DOI 10.1002/ijc.11055.
   Modjtahedi H, 1998, INT J ONCOL, V13, P335.
   Okuno S, 2003, BRIT J CANCER, V88, P951, DOI 10.1038/sj.bjc.6600786.
   Ozawa H, 2017, CLIN CANCER RES, V23, P5162, DOI 10.1158/1078-0432.CCR-16-1686.
   Pathania D, 2009, ADV DRUG DELIVER REV, V61, P1250, DOI 10.1016/j.addr.2009.05.010.
   Pollock NI, 2015, CLIN CANCER RES, V21, P4597, DOI 10.1158/1078-0432.CCR-14-3338.
   Pollock NI, 2015, CLIN CANCER RES, V21, P526, DOI 10.1158/1078-0432.CCR-14-1432.
   Rajagopalan KN, 2011, J NUCL MED, V52, P1005, DOI 10.2967/jnumed.110.084244.
   Riaz N, 2014, GENES DIS, V1, P75, DOI 10.1016/j.gendis.2014.07.002.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   ROLAND NJ, 1992, HEAD NECK-J SCI SPEC, V14, P224, DOI 10.1002/hed.2880140310.
   Sandulache VC, 2012, HEAD NECK-J SCI SPEC, V34, P282, DOI 10.1002/hed.21664.
   Seiwert TY, 2016, LANCET ONCOL, V17, P956, DOI 10.1016/S1470-2045(16)30066-3.
   Specenier P, 2013, BIOL-TARGETS THER, V7, P77, DOI 10.2147/BTT.S43628.
   Stacpoole PW, 2006, PEDIATRICS, V117, P1519, DOI 10.1542/peds.2005-1226.
   Stacpoole PW, 2003, J CLIN PHARMACOL, V43, P683, DOI 10.1177/0091270003254637.
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6.
   Strum SB, 2013, J BIOENERG BIOMEMBR, V45, P307, DOI 10.1007/s10863-012-9496-2.
   Subramanian K, 2010, BIOINFORMATION, V5, P73, DOI 10.6026/97320630005073.
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tao XA, 2017, CANCER LETT, V408, P33, DOI 10.1016/j.canlet.2017.08.012.
   Tong JF, 2014, MOL CELL PROTEOMICS, V13, P1644, DOI 10.1074/mcp.M114.038596.
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803.
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504.
   Vermorken JB, 2007, J CLIN ONCOL, V25, P2171, DOI 10.1200/JCO.2006.06.7447.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.
   Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690.},
Number-of-Cited-References = {75},
Times-Cited = {25},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {17},
Journal-ISO = {JCI Insight},
Doc-Delivery-Number = {JC0RW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000488988500019},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000490874100001,
Author = {Shao, Fei and Yang, Xueying and Wang, Wei and Wang, Juhong and Guo, Wei
   and Feng, Xiaoli and Shi, Susheng and Xue, Qi and Gao, Shugeng and Gao,
   Yibo and Lu, Zhimin and He, Jie},
Title = {Associations of PGK1 promoter hypomethylation and PGK1-mediated PDHK1
   phosphorylation with cancer stage and prognosis: a TCGA pan-cancer
   analysis},
Journal = {CANCER COMMUNICATIONS},
Year = {2019},
Volume = {39},
Number = {1},
Month = {OCT 2},
Abstract = {Background: Cancer cells reprogram metabolism for proliferation.
   Phosphoglycerate kinase 1 (PGK1), as a glycolytic enzyme and newly
   identified protein kinase, coordinates glycolysis and mitochondrial
   metabolism. However, the clinical significance of PGK1 expression and
   function in cancer progression is unclear. Here, we investigated the
   relationship between the progression and prognosis of multiple cancer
   types and PGK1 expression and its function in the mitochondrial
   metabolism regulation.
   Methods: We performed pan-cancer analyses of PGK1 mRNA level and DNA
   methylation in 11,908 tumor tissues and 1582 paired normal tissues
   across 34 cancer types in The Cancer Genome Atlas datasets. Using
   specific antibodies against PGK1 S203 and PDHK1 T338 phosphorylation, we
   performed immunohistochemistry with tissue microarray assay in
   additional 818 cancer cases with 619 paired normal tissues from five
   cancer types.
   Results: The PGK1 mRNA level was significantly elevated with
   hypomethylation in promotor regions and associated with advanced TNM
   stage in 15 and four cancer types, respectively. In breast carcinoma,
   elevated PGK1 mRNA level and promoter hypomethylation were associated
   with poor prognosis. Positively correlated PGK1 S203 and PDHK1 T338
   phosphorylation levels were significantly associated with short overall
   survival (OS) in cancers of the breast, liver, lung, stomach, and
   esophagus and with advanced TNM stage in breast and esophageal cancers.
   PGK1 p5203 and PDHK1 pT338 were also independent predictors of short OS
   in liver, lung, and stomach cancer.
   Conclusions: The elevated expression, promoter hypomethylation, and
   phosphorylation of PGK1 and PDHK1 were related with disease progression
   and short OS in diverse types of cancer. PGK1 and PDHK1 phosphorylation
   may be potential prognostic biomarkers.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Gao, YB; He, J (Corresponding Author), Chinese Acad Med Sci, Canc Hosp, Natl Clin Res Ctr Canc, Dept Thorac Surg,Natl Canc Ctr, 17 Panjiayuannanli, Beijing 100021, Peoples R China.
   Gao, YB; Lu, ZM; He, J (Corresponding Author), Peking Union Med Coll, 17 Panjiayuannanli, Beijing 100021, Peoples R China.
   Lu, ZM (Corresponding Author), Zhejiang Univ, Sch Med, Zhejiang Prov Key Lab Pancreat Dis, Hangzhou 310029, Zhejiang, Peoples R China.
   Lu, ZM (Corresponding Author), Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310029, Zhejiang, Peoples R China.
   Shao, Fei; Yang, Xueying; Wang, Wei; Wang, Juhong; Guo, Wei; Xue, Qi; Gao, Shugeng; Gao, Yibo; He, Jie, Chinese Acad Med Sci, Canc Hosp, Natl Clin Res Ctr Canc, Dept Thorac Surg,Natl Canc Ctr, 17 Panjiayuannanli, Beijing 100021, Peoples R China.
   Shao, Fei; Yang, Xueying; Wang, Wei; Wang, Juhong; Guo, Wei; Feng, Xiaoli; Shi, Susheng; Xue, Qi; Gao, Shugeng; Gao, Yibo; Lu, Zhimin; He, Jie, Peking Union Med Coll, 17 Panjiayuannanli, Beijing 100021, Peoples R China.
   Shao, Fei, Qingdao Univ, Affiliated Hosp, Canc Inst, Qingdao Canc Inst, Qingdao 266003, Shandong, Peoples R China.
   Shao, Fei; Lu, Zhimin, Zhejiang Univ, Sch Med, Zhejiang Prov Key Lab Pancreat Dis, Hangzhou 310029, Zhejiang, Peoples R China.
   Shao, Fei; Lu, Zhimin, Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou 310029, Zhejiang, Peoples R China.
   Feng, Xiaoli; Shi, Susheng, Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Canc Hosp, Dept Pathol,Natl Canc Ctr, Beijing 100021, Peoples R China.
   Xue, Qi; Gao, Shugeng; Lu, Zhimin; He, Jie, Chinese Acad Med Sci, Natl Clin Res Ctr Canc, Canc Hosp, State Key Lab Mol Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China.},
DOI = {10.1186/s40880-019-0401-9},
Article-Number = {54},
EISSN = {2523-3548},
Keywords = {PGK1; Cancer metabolism; Epigenetics; Phosphorylation; Methylation; The
   Cancer Genome Atlas; Pancancer analysis; Prognosis; Overall survival},
Keywords-Plus = {PHOSPHOGLYCERATE KINASE 1; ACUTE MYELOID-LEUKEMIA; IDH2 MUTATIONS;
   HISTONE H3; CLASSIFICATION; TRANSCRIPTION; CRITERIA},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {gaoyibo@cicams.ac.cn
   zhiminlu@zju.edu.cn
   prof.jiehe@gmail.com},
Affiliations = {Chinese Academy of Medical Sciences - Peking Union Medical College;
   Cancer Institute \& Hospital - CAMS; Chinese Academy of Medical Sciences
   - Peking Union Medical College; Peking Union Medical College; Qingdao
   University; Zhejiang University; Zhejiang University; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Cancer Institute \&
   Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Cancer Institute \& Hospital - CAMS},
ResearcherID-Numbers = {Lu, Zhimin/LZF-0860-2025
   Guo, Wei/KJM-4941-2024
   GAO, SHU/KCK-6532-2024
   He, Jie/AGM-9610-2022},
ORCID-Numbers = {Yang, Xueying/0000-0002-4559-1268
   Gao, Yi-Bo/0000-0002-0501-9814
   },
Funding-Acknowledgement = {National Key R\&D Program of China {[}2017YFC1308702, 2017YFC1311000,
   2018YFC1312100]; Beijing Municipal Science \& Technology Commission
   {[}Z181100006218032, Z181100001918002]; CAMS Initiative for Innovative
   Medicine {[}2017-I2M-1-005, 2017-I2M-2003, 2019-I2M-2-002]; Non-profit
   Central Research Institute Fund of Chinese Academy of Medical Sciences
   {[}2017PT32001, 2017PT32017]},
Funding-Text = {This study was funded by The National Key R\&D Program of China
   (2017YFC1308702, 2017YFC1311000, 2018YFC1312100), the Beijing Municipal
   Science \& Technology Commission (Z181100006218032, Z181100001918002),
   the CAMS Initiative for Innovative Medicine (2017-I2M-1-005,
   2017-I2M-2003, 2019-I2M-2-002), Non-profit Central Research Institute
   Fund of Chinese Academy of Medical Sciences (2017PT32001, 2017PT32017).
   The funding sources had no role in the design and conduct of this study,
   the analysis and interpretation of data, nor the preparation and
   submission of the manuscript. The corresponding author had full access
   to all the data in the study and had final responsibility for the
   decision to submit for publication.},
Cited-References = {Ahmad SS, 2013, INT J ONCOL, V43, P586, DOI 10.3892/ijo.2013.1971.
   BENNETT JM, 1985, ANN INTERN MED, V103, P460, DOI 10.7326/0003-4819-103-3-460.
   BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x.
   BENNETT JM, 1991, BRIT J HAEMATOL, V78, P325, DOI 10.1111/j.1365-2141.1991.tb04444.x.
   BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620.
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI {[}10.3322/caac.21492, 10.3322/caac.21609].
   Chen L, 2017, GENE, V628, P200, DOI 10.1016/j.gene.2017.07.056.
   Dang L, 2016, ANN ONCOL, V27, P599, DOI 10.1093/annonc/mdw013.
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270.
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021.
   Hu HG, 2017, HEPATOLOGY, V65, P515, DOI 10.1002/hep.28887.
   Hwang TL, 2006, PROTEOMICS, V6, P2259, DOI 10.1002/pmic.200500345.
   Jing C, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0789-0.
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230.
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038.
   Li XJ, 2018, MOL CELL, V72, P650, DOI 10.1016/j.molcel.2018.09.007.
   Li XJ, 2018, NAT REV MOL CELL BIO, V19, P563, DOI 10.1038/s41580-018-0029-7.
   Li XJ, 2016, CELL CYCLE, V15, P1803, DOI 10.1080/15384101.2016.1179037.
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009.
   Lu S, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0336-6.
   Lu ZM, 2018, TRENDS BIOCHEM SCI, V43, P301, DOI 10.1016/j.tibs.2018.01.006.
   MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M.
   Paschka P, 2010, J CLIN ONCOL, V28, P3636, DOI 10.1200/JCO.2010.28.3762.
   Qian X, 2017, MOL CELL, V65, P917, DOI 10.1016/j.molcel.2017.01.027.
   Sanson M, 2009, J CLIN ONCOL, V27, P4150, DOI 10.1200/JCO.2009.21.9832.
   Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7.
   Walter RB, 2013, BLOOD, V121, P2424, DOI 10.1182/blood-2012-10-462440.
   Wang SW, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002243.
   Wang YP, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0302-3.
   Wang YG, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0335-7.
   Wang YG, 2017, NATURE, V552, P273, DOI 10.1038/nature25003.
   Xu DQ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4570.
   Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710.
   Yan H, 2012, CNS NEUROSCI THER, V18, P729, DOI 10.1111/j.1755-5949.2012.00353.x.
   Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629.
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018.
   Yoshida GJ, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0221-y.
   Zhang DH, 2005, MOL CELL PROTEOMICS, V4, P1686, DOI 10.1074/mcp.M400221-MCP200.
   Zhu XF, 2018, J CELL PHYSIOL, V233, P6777, DOI 10.1002/jcp.26531.
   Zieker D, 2010, INT J CANCER, V126, P1513, DOI 10.1002/ijc.24835.},
Number-of-Cited-References = {43},
Times-Cited = {41},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Cancer Commun.},
Doc-Delivery-Number = {JE7MN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000490874100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000485786400007,
Author = {Akhoon, Bashir A. and Gandhi, Neha S. and Pandey, Rakesh},
Title = {Computational insights into the active structure of SGK1 and its
   implication for ligand design},
Journal = {BIOCHIMIE},
Year = {2019},
Volume = {165},
Pages = {57-66},
Month = {OCT},
Abstract = {Serum-and glucocorticoid-inducible kinase 1 (SGK1), a protein kinase,
   shares significant structural similarity with other members of the AGC
   protein kinase family. It has been reported that the inactive SGK1
   structure lacks alpha C helix and this unique feature makes it distinct
   from other protein kinases. Activation of SGK1 by PDK1 requires
   phosphorylation at Thr256, but the structural insights of the activation
   remain unclear. The co-crystal structures of small molecule inhibitors,
   Magnesium (Mg+2) and ATP bound to the inactive SGK1 are reported however
   the important regulatory domains such as aC helix are missing in these
   crystal structures. We modelled the missing alpha C domain and employed
   computational molecular dynamics simulations to study the conformational
   changes in the WT and phosphorylated human SGK1 to systematically
   investigate how the individual domain motions are modulated by the
   binding of substrate and Mg+2. The MD results corroborate with the
   experiential findings and has shown that the inactive SGK1 lacks alpha C
   helix content. Surprisingly, we find that the active SGK1 structure
   closely resembles with other protein kinases and adopt the alpha C helix
   content up on SGK1 phosphorylation. However, the residues participating
   in alpha C helix formation are fewer than reported in protein kinase A
   structure, a close relative of SGK1. The computational binding analysis
   reveals that most of the SGK1 selective inhibitors have less binding
   affinity for active SGK1 than some FDA-approved kinase inhibitors such
   as Afatinib, Tofacitinib, Dabrafenib, and Palbociclib. Only EMD638683
   was seen as a strong candidate for selective SGK1 inhibition. To our
   knowledge, this is the first dynamic study of SGK1 that provides new
   structural insights around the active site that would surely help the
   experimental biologists for the design of suitable selective ligands
   able to inhibit or activate SGK1 function. (C) 2019 Published by
   Elsevier B.V.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Pandey, R (Corresponding Author), CSIR, CIMAP, Microbial Technol \& Nematol, Lucknow 226015, Uttar Pradesh, India.
   Akhoon, Bashir A.; Pandey, Rakesh, CSIR Cent Inst Med \& Aromat Plants, Microbial Technol \& Nematol Dept, Lucknow 226015, Uttar Pradesh, India.
   Gandhi, Neha S., Queensland Univ Technol, Sci \& Engn Fac, Sch Math Sci, Brisbane, Qld 4000, Australia.
   Gandhi, Neha S., Queensland Univ Technol, Sci \& Engn Fac, Inst Hlth \& Biomed Innovat, Brisbane, Qld 4000, Australia.},
DOI = {10.1016/j.biochi.2019.07.007},
ISSN = {0300-9084},
EISSN = {1638-6183},
Keywords = {Active SGK1; alpha C helix; Kinase inhibitors; Protein phosphorylation;
   Molecular dynamics simulation},
Keywords-Plus = {GLUCOCORTICOID-INDUCIBLE KINASE; CELL-SURVIVAL RESPONSE; PROTEIN-KINASE;
   MOLECULAR-DYNAMICS; CRYSTAL-STRUCTURE; GENE-EXPRESSION; SIDE-CHAIN;
   SERUM; ACTIVATION; STRESS},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {bashirakklaq@gmail.com
   Neha.Gandhi@qut.edu.au
   r.pandey@cimap.res.in},
Affiliations = {Council of Scientific \& Industrial Research (CSIR) - India; CSIR -
   Central Institute of Medicinal \& Aromatic Plants (CIMAP); Queensland
   University of Technology (QUT); Queensland University of Technology
   (QUT)},
ResearcherID-Numbers = {Gandhi, Neha/E-7688-2010
   },
ORCID-Numbers = {Gandhi, Neha/0000-0003-3119-6731
   Pandey, Rakesh/0000-0003-0673-3179},
Funding-Acknowledgement = {CSIR India {[}31/029(0251)/2013-EMR-I]; QUT Vice-Chancellor's fellowship},
Funding-Text = {BAA is highly grateful to the Prof. Manju Bansal (IISC Bangalore, India)
   for providing the lab space, access to the cluster facility (ARJUN) and
   useful comments on this work. BAA would also like to thank Prof. Manju
   Bansal for offering a Visiting Scholar opportunity in her group. We
   acknowledge the DBT-IISC Partnership Program and VLSCI, Australia for
   providing the computing facilities to carry out this research work. We
   also acknowledge computing resources provided by QUT HPC and NCI. The
   work was financially supported by CSIR India (31/029(0251)/2013-EMR-I)
   and QUT Vice-Chancellor's fellowship to NSG.},
Cited-References = {ADELMAN SA, 1974, J CHEM PHYS, V61, P4242, DOI 10.1063/1.1681723.
   Akhoon BA, 2016, EXP GERONTOL, V78, P47, DOI 10.1016/j.exger.2016.03.004.
   Andres-Mateos E, 2013, EMBO MOL MED, V5, P80, DOI 10.1002/emmm.201201443.
   Autore F, 2010, BIOPHYS J, V99, P3716, DOI 10.1016/j.bpj.2010.09.008.
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118.
   Berteotti A, 2009, J AM CHEM SOC, V131, P244, DOI 10.1021/ja806846q.
   Bezzerides VJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00413-3.
   Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616.
   Case D.A., 2016, AmberTools16.
   Cheng S, 2010, J CHEM INF MODEL, V50, P1602, DOI 10.1021/ci100076j.
   D'Antona L, 2015, CELL PHYSIOL BIOCHEM, V35, P2006, DOI 10.1159/000374008.
   Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.0.CO;2-M.
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117.
   Feig M, 2004, J COMPUT CHEM, V25, P265, DOI 10.1002/jcc.10378.
   Ferrelli F, 2015, ACTA DIABETOL, V52, P55, DOI 10.1007/s00592-014-0600-4.
   Hertweck M, 2004, DEV CELL, V6, P577, DOI 10.1016/S1534-5807(04)00095-4.
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5.
   Iwata SI, 2004, SYNAPSE, V51, P279, DOI 10.1002/syn.10307.
   KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342.
   Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189.
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j.
   Kornev AP, 2006, P NATL ACAD SCI USA, V103, P17783, DOI 10.1073/pnas.0607656103.
   Kornev AP, 2010, BBA-PROTEINS PROTEOM, V1804, P440, DOI 10.1016/j.bbapap.2009.10.017.
   Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005.
   Lang F, 2013, HORM-INT J ENDOCRINO, V12, P160, DOI 10.14310/horm.2002.1401.
   Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230.
   Lang F, 2012, CLIN EXP NEPHROL, V16, P73, DOI 10.1007/s10157-011-0488-z.
   Lang F, 2010, J PHYSIOL-LONDON, V588, P3349, DOI 10.1113/jphysiol.2010.190926.
   Lang F, 2010, EXPERT OPIN THER PAT, V20, P129, DOI 10.1517/13543770903365209.
   Lang F, 2009, EXPERT OPIN THER TAR, V13, P1303, DOI 10.1517/14728220903260807.
   Lang F, 2009, CURR OPIN NEPHROL HY, V18, P439, DOI 10.1097/MNH.0b013e32832f125e.
   Laurent B, 2015, BIOINFORMATICS, V31, P1478, DOI 10.1093/bioinformatics/btu822.
   Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200.
   Li PF, 2015, J CHEM THEORY COMPUT, V11, P1645, DOI 10.1021/ct500918t.
   Liang XC, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.184.
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711.
   Lu M, 2010, J AM SOC NEPHROL, V21, P811, DOI 10.1681/ASN.2009111168.
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255.
   Meijles DN, 2014, J BIOL CHEM, V289, P22759, DOI 10.1074/jbc.M114.561159.
   Murphy Coleen T, 2013, WormBook, P1, DOI 10.1895/wormbook.1.164.1.
   Nishida Y, 2004, MOL BRAIN RES, V123, P121, DOI 10.1016/j.molbrainres.2004.01.008.
   Palmieri L, 2013, DRUG DISCOV TODAY, V18, P407, DOI 10.1016/j.drudis.2012.11.009.
   Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200.
   Raghav PK, 2018, MUTAT RES-FUND MOL M, V808, P28, DOI 10.1016/j.mrfmmm.2018.02.001.
   Raghav PK, 2012, J MOL MODEL, V18, P1885, DOI 10.1007/s00894-011-1201-6.
   Raghav PK, 2012, INT J BIOL MACROMOL, V50, P796, DOI 10.1016/j.ijbiomac.2011.11.021.
   Sakkiah S, 2011, J MOL STRUCT, V985, P14, DOI 10.1016/j.molstruc.2010.08.050.
   Schoenebeck B, 2005, MOL CELL NEUROSCI, V30, P249, DOI 10.1016/j.mcn.2005.07.017.
   Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047.
   Stichel CC, 2005, EUR J NEUROSCI, V21, P301, DOI 10.1111/j.1460-9568.2005.03859.x.
   Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200.
   Taylor SS, 2011, TRENDS BIOCHEM SCI, V36, P65, DOI 10.1016/j.tibs.2010.09.006.
   Towhid ST, 2013, CELL PHYSIOL BIOCHEM, V32, P838, DOI 10.1159/000354486.
   Treiber DK, 2013, CHEM BIOL, V20, P745, DOI 10.1016/j.chembiol.2013.06.001.
   Weiser J, 1999, J COMPUT CHEM, V20, P217, DOI 10.1002/(SICI)1096-987X(19990130)20:2<217::AID-JCC4>3.0.CO;2-A.
   Zhao B, 2007, PROTEIN SCI, V16, P2761, DOI 10.1110/ps.073161707.},
Number-of-Cited-References = {58},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Biochimie},
Doc-Delivery-Number = {IX6IK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000485786400007},
DA = {2026-02-04},
}

@article{ WOS:000490362500013,
Author = {Barker, William T. and Nemeth, Ansley M. and Brackett, Sara M. and
   Basak, Akash K. and Chandler, Courtney E. and Jania, Leigh A. and
   Zuercher, William J. and Melander, Roberta J. and Koller, Beverly H. and
   Ernst, Robert K. and Melander, Christian},
Title = {Repurposing Eukaryotic Kinase Inhibitors as Colistin Adjuvants in
   Gram-Negative Bacteria},
Journal = {ACS INFECTIOUS DISEASES},
Year = {2019},
Volume = {5},
Number = {10},
Pages = {1764-1771},
Month = {OCT},
Abstract = {Kinase inhibitors comprise a diverse cohort of chemical scaffolds that
   are active in multiple biological systems. Currently, thousands of
   eukaryotic kinase inhibitors are commercially available, have
   well-characterized targets, and often carry pharmaceutically favorable
   toxicity profiles. Recently, our group disclosed that derivatives of the
   natural product meridianin D, a known inhibitor of eukaryotic kinases,
   modulated behaviors of both Gram-positive and Gram-negative bacteria.
   Herein, we expand our exploration of kinase inhibitors in Gram-negative
   bacilli utilizing three commercially available kinase inhibitor
   libraries and, ultimately, identify two chemical structures that
   potentiate colistin (polymyxin E) in multiple strains. We report
   IMD-0354, an inhibitor of IKK-beta, as a markedly effective adjuvant in
   colistin-resistant bacteria and also describe AR-12 (OSU-03012), an
   inhibitor of pyruvate dehydrogenase kinase-1 (PDK-1), as a potentiator
   in colistin-sensitive strains. This report comprises the first
   description of the novel cross-reactivity of these molecules.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Melander, C (Corresponding Author), Univ Notre Dame, Dept Chem \& Biochem, 240 McCourtney Hall, Notre Dame, IN 46556 USA.
   Barker, William T.; Nemeth, Ansley M.; Brackett, Sara M.; Basak, Akash K.; Melander, Roberta J.; Melander, Christian, Univ Notre Dame, Dept Chem \& Biochem, 240 McCourtney Hall, Notre Dame, IN 46556 USA.
   Chandler, Courtney E.; Ernst, Robert K., Univ Maryland, Dept Microbial Pathogenesis, 650 W Baltimore St, Baltimore, MD 21201 USA.
   Jania, Leigh A.; Koller, Beverly H., Univ N Carolina, Dept Genet, 120 Mason Farm Rd, Chapel Hill, NC 27599 USA.
   Zuercher, William J., Univ N Carolina, Eshelman Sch Pharm, 120 Mason Farm Rd, Chapel Hill, NC 27599 USA.},
DOI = {10.1021/acsinfecdis.9b00212},
ISSN = {2373-8227},
Keywords = {colistin; antibiotic adjuvants; multidrug-resistant Gram-negative
   bacteria; lipid A},
Keywords-Plus = {RESISTANCE; LIPOPOLYSACCHARIDE; HETEROGENEITY; ANTIBIOTICS; DERIVATIVES;
   EFFICACY},
Research-Areas = {Pharmacology \& Pharmacy; Infectious Diseases},
Web-of-Science-Categories  = {Chemistry, Medicinal; Infectious Diseases},
Author-Email = {cmelande@nd.edu},
Affiliations = {University of Notre Dame; University System of Maryland; University of
   Maryland Baltimore; University of North Carolina; University of North
   Carolina Chapel Hill; University of North Carolina; University of North
   Carolina Chapel Hill},
ORCID-Numbers = {Chandler, Courtney/0000-0003-2076-3665
   Ernst, Robert/0000-0001-5016-8694
   Basak, Akash/0000-0001-9049-2018},
Funding-Acknowledgement = {National Institutes of Health {[}AI106721]; National Institute of
   Allergy and Infectious Diseases {[}R01AI136904] Funding Source: NIH
   RePORTER},
Funding-Text = {We would like to thank the National Institutes of Health for funding
   (AI106721 to C.M., R.K.E., and B.H.K.). We would also like to thank Tim
   Willson, Carrow Wells, Nadine Russ, and Stephan Knapp of the Structural
   Genomics Consortium based at both the University of North Carolina,
   Chapel Hill, NC (TW and CW) and the Goethe University of Frankfurt,
   Frankfurt, Germany (NR and SK) for their assistance in this project and
   Carlos N. for insight.},
Cited-References = {Annamanedi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099285.
   {[}Anonymous], 2014, Antimicrobial Resistance: Tackling a crisis forthe health and wealth of nations, DOI DOI 10.1088/2053-1591/1/4/046305.
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j.
   Barker WT, 2019, BIOORGAN MED CHEM, V27, P1776, DOI 10.1016/j.bmc.2019.03.019.
   Barker WT, 2017, BIOORGAN MED CHEM, V25, P5749, DOI 10.1016/j.bmc.2017.08.055.
   Brackett CM, 2016, TETRAHEDRON, V72, P3549, DOI 10.1016/j.tet.2015.09.019.
   Bressanin D, 2012, ONCOTARGET, V3, P811.
   Chen L, 2017, MMWR-MORBID MORTAL W, V66, P33, DOI 10.15585/mmwr.mm6601a7.
   Clatworthy AE, 2007, NAT CHEM BIOL, V3, P541, DOI 10.1038/nchembio.2007.24.
   CLSI, 2018, PERFORMANCE STANDARD, pM100.
   Dixon DR, 2005, J DENT RES, V84, P584, DOI 10.1177/154405910508400702.
   Domalaon R, 2019, ANTIMICROB AGENTS CH, V63, DOI {[}10.1128/AAC.02574-18, 10.1128/aac.02574-18].
   Fan B., 2016, PLOS ONE, V11.
   Garonzik SM, 2011, ANTIMICROB AGENTS CH, V55, P3284, DOI 10.1128/AAC.01733-10.
   Harris TL, 2014, ACS CHEM BIOL, V9, P122, DOI 10.1021/cb400490k.
   Harris TL, 2012, ANGEW CHEM INT EDIT, V51, P11254, DOI 10.1002/anie.201206911.
   Hegazy R, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/862153.
   Huggins WM, 2018, ACS MED CHEM LETT, V9, P702, DOI 10.1021/acsmedchemlett.8b00161.
   Jacobs AC, 2014, MBIO, V5, DOI 10.1128/mBio.01076-14.
   Kanduri M, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.9.
   Kang S, 2013, BIOORG MED CHEM LETT, V23, P1748, DOI 10.1016/j.bmcl.2013.01.055.
   Liu YY, 2017, ANTIMICROB AGENTS CH, V61, DOI 10.1128/AAC.00580-17.
   Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7.
   Minrovic BM, 2019, ACS MED CHEM LETT, V10, P828, DOI 10.1021/acsmedchemlett.9b00135.
   Nation RL, 2009, CURR OPIN INFECT DIS, V22, P535, DOI 10.1097/QCO.0b013e328332e672.
   Nguyen UT, 2012, APPL ENVIRON MICROB, V78, P1454, DOI 10.1128/AEM.07227-11.
   OFEK I, 1994, ANTIMICROB AGENTS CH, V38, P374, DOI 10.1128/AAC.38.2.374.
   Park YK, 2014, BIOCHEM BIOPH RES CO, V452, P1078, DOI 10.1016/j.bbrc.2014.09.050.
   Pelletier MR, 2013, ANTIMICROB AGENTS CH, V57, P4831, DOI 10.1128/AAC.00865-13.
   Rogers SA, 2010, ANTIMICROB AGENTS CH, V54, P2112, DOI 10.1128/AAC.01418-09.
   Shaffer SA, 2007, J AM SOC MASS SPECTR, V18, P1080, DOI 10.1016/j.jasms.2007.03.008.
   Wang X, 2018, COMPUTER APPL RES, V7, P1.
   Wanty C, 2013, J MOL BIOL, V425, P3389, DOI 10.1016/j.jmb.2013.06.029.
   Zhang S, 2007, CLIN CANCER RES, V13, P4750, DOI 10.1158/1078-0432.CCR-07-0136.},
Number-of-Cited-References = {34},
Times-Cited = {31},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {ACS Infect. Dis.},
Doc-Delivery-Number = {JE0EV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000490362500013},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000505712400047,
Author = {Borreguero-Munoz, Nerea and Fletcher, Georgina C. and Aguilar-Aragon,
   Mario and Elbediwy, Ahmed and Vincent-Mistiaen, Zoe I. and Thompson,
   Barry J.},
Title = {The Hippo pathway integrates PI3K-Akt signals with mechanical and
   polarity cues to control tissue growth},
Journal = {PLOS BIOLOGY},
Year = {2019},
Volume = {17},
Number = {10},
Month = {OCT},
Abstract = {The Hippo signalling pathway restricts cell proliferation in animal
   tissues by inhibiting Yes-associated protein (YAP or YAP1) and
   Transcriptional Activator with a PDZ domain (TAZ or WW-domain-containing
   transcriptional activator {[}WWTR1]), coactivators of the Scalloped (Sd
   or TEAD) DNA-binding transcription factor. Drosophila has a single
   YAP/TAZ homolog named Yorkie (Yki) that is regulated by Hippo pathway
   signalling in response to epithelial polarity and tissue mechanics
   during development. Here, we show that Yki translocates to the nucleus
   to drive Sd-mediated cell proliferation in the ovarian follicle cell
   epithelium in response to mechanical stretching caused by the growth of
   the germline. Importantly, mechanically induced Yki nuclear localisation
   also requires nutritionally induced insulin/insulin-like growth factor 1
   (IGF-1) signalling (IIS) via phosphatidyl inositol-3-kinase (PI3K),
   phosphoinositide-dependent kinase 1 (PDK1 or PDPK1), and protein kinase
   B (Akt or PKB) in the follicular epithelium. We find similar results in
   the developing Drosophila wing, where Yki becomes nuclear in the
   mechanically stretched cells of the wing pouch during larval feeding,
   which induces IIS, but translocates to the cytoplasm upon cessation of
   feeding in the third instar stage. Inactivating Akt prevents nuclear Yki
   localisation in the wing disc, while ectopic activation of the insulin
   receptor, PI3K, or Akt/PKB is sufficient to maintain nuclear Yki in
   mechanically stimulated cells of the wing pouch even after feeding
   ceases. Finally, IIS also promotes YAP nuclear localisation in response
   to mechanical cues in mammalian skin epithelia. Thus, the Hippo pathway
   has a physiological function as an integrator of epithelial cell
   polarity, tissue mechanics, and nutritional cues to control cell
   proliferation and tissue growth in both Drosophila and mammals.},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Article},
Language = {English},
Affiliation = {Thompson, BJ (Corresponding Author), Francis Crick Inst, Epithelial Biol Lab, London, England.
   Thompson, BJ (Corresponding Author), Australian Natl Univ, John Curtin Sch Med Res, Dept Canc Biol \& Therapeut, EMBL Australia, Acton, Australia.
   Borreguero-Munoz, Nerea; Fletcher, Georgina C.; Aguilar-Aragon, Mario; Elbediwy, Ahmed; Vincent-Mistiaen, Zoe I.; Thompson, Barry J., Francis Crick Inst, Epithelial Biol Lab, London, England.
   Thompson, Barry J., Australian Natl Univ, John Curtin Sch Med Res, Dept Canc Biol \& Therapeut, EMBL Australia, Acton, Australia.},
DOI = {10.1371/journal.pbio.3000509},
Article-Number = {e3000509},
ISSN = {1544-9173},
EISSN = {1545-7885},
Keywords-Plus = {PROTEIN-KINASE-B; TUMOR-SUPPRESSOR PATHWAY; INSULIN-LIKE PEPTIDES; WING
   IMAGINAL DISC; FACTOR-I IGF-1; CELL-GROWTH; PHOSPHOINOSITIDE 3-KINASE;
   DROSOPHILA HOMOLOG; PHOSPHATIDYLINOSITOL 3-KINASE; YORKIE
   PHOSPHORYLATION},
Research-Areas = {Biochemistry \& Molecular Biology; Life Sciences \& Biomedicine - Other
   Topics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biology},
Author-Email = {barry.thompson@anu.edu.au},
Affiliations = {Francis Crick Institute; Australian National University; John Curtin
   School of Medical Research},
ORCID-Numbers = {Aguilar-Aragon, Mario/0000-0002-0018-3981
   Elbediwy, Ahmed/0000-0002-2102-7339
   Thompson, Barry/0000-0002-0103-040X
   Vincent-Mistiaen, Zoé/0000-0002-5224-1282
   Borreguero-Muñoz, Nerea/0000-0001-5594-930X},
Funding-Acknowledgement = {Francis Crick Institute {[}FC0011080]; EMBL Australia; John Curtin
   School of Medical Research at The Australian National University; The
   Francis Crick Institute {[}10180] Funding Source: researchfish},
Funding-Text = {This work was funded by the Francis Crick Institute core funding to BT
   (FC0011080). It was also funded by EMBL Australia \& The John Curtin
   School of Medical Research at The Australian National University. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.},
Cited-References = {Aegerter-Wilmsen T, 2007, MECH DEVELOP, V124, P318, DOI 10.1016/j.mod.2006.12.005.
   Aegerter-Wilmsen T, 2012, DEVELOPMENT, V139, P3221, DOI 10.1242/dev.082800.
   Aegerter-Wilmsen T, 2010, DEVELOPMENT, V137, P499, DOI 10.1242/dev.041731.
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x.
   {[}Anonymous], 2018, DEVELOPMENT, V145, pe0201.
   BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O.
   Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25.
   Bastock R, 2008, CURR BIOL, V18, pR1082, DOI 10.1016/j.cub.2008.09.011.
   BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819.
   Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559.
   Böhni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0.
   Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990.
   Britton JS, 1998, DEVELOPMENT, V125, P2149.
   Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X.
   Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9.
   Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161.
   BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0.
   Burn KM, 2015, DEV BIOL, V398, P206, DOI 10.1016/j.ydbio.2014.11.021.
   CARPENTER CL, 1990, J BIOL CHEM, V265, P19704.
   Chan JC, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001754.
   Chen HJ, 2011, DEV BIOL, V357, P370, DOI 10.1016/j.ydbio.2011.07.003.
   Colombani J, 2005, SCIENCE, V310, P667, DOI 10.1126/science.1119432.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Debaugnies M, 2018, EMBO REP, V19, DOI 10.15252/embr.201845809.
   Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235.
   Dibble CC, 2015, TRENDS CELL BIOL, V25, P545, DOI 10.1016/j.tcb.2015.06.002.
   DiGiovanni J, 2000, CANCER RES, V60, P1561.
   Djiane A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106211.
   Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504.
   Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135.
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137.
   Dutta S, 2018, EMBO REP, V19, P337, DOI 10.15252/embr.201744777.
   Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8.
   Edgar BA, 2006, NAT REV GENET, V7, P907, DOI 10.1038/nrg1989.
   Edgar BA, 2014, NAT REV MOL CELL BIO, V15, P197, DOI 10.1038/nrm3756.
   Elbediwy A, 2018, CURR OPIN CELL BIOL, V51, P117, DOI 10.1016/j.ceb.2018.02.003.
   Elbediwy A, 2016, BIOESSAYS, V38, P644, DOI 10.1002/bies.201600037.
   Elbediwy A, 2016, DEVELOPMENT, V143, P1674, DOI 10.1242/dev.133728.
   Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110.
   Fletcher GC, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.159467.
   Fletcher GC, 2015, EMBO J, V34, P940, DOI 10.15252/embj.201489642.
   FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0.
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8.
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665.
   Fruman DA, 2017, CELL, V170, P605, DOI 10.1016/j.cell.2017.07.029.
   Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101.
   Goulev Y, 2008, CURR BIOL, V18, P435, DOI 10.1016/j.cub.2008.02.034.
   Grewal SS, 2007, J CELL BIOL, V179, P1105, DOI 10.1083/jcb.200709044.
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500.
   Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339.
   Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003.
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4.
   Harvey KF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011288.
   Hietakangas V, 2009, ANNU REV GENET, V43, P389, DOI 10.1146/annurev-genet-102108-134815.
   Horne-Badovinac S, 2005, DEV DYNAM, V232, P559, DOI 10.1002/dvdy.20286.
   Hsu TH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04052-6.
   Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007.
   Hufnagel L, 2007, P NATL ACAD SCI USA, V104, P3835, DOI 10.1073/pnas.0607134104.
   Ibar C, 2018, J CELL SCI, V131, DOI 10.1242/jcs.214700.
   Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6.
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839.
   Junger Martin A, 2003, J Biol, V2, P20, DOI 10.1186/1475-4924-2-20.
   KAPELLER R, 1991, MOL ENDOCRINOL, V5, P769, DOI 10.1210/mend-5-6-769.
   Killip LE, 2012, DEV BIOL, V371, P191, DOI 10.1016/j.ydbio.2012.08.020.
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5.
   Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025.
   Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200.
   Kockel L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000990.
   Koontz LM, 2013, DEV CELL, V25, P388, DOI 10.1016/j.devcel.2013.04.021.
   Kramer Jamie M, 2003, BMC Dev Biol, V3, P5, DOI 10.1186/1471-213X-3-5.
   LaFever L, 2005, SCIENCE, V309, P1071, DOI 10.1126/science.1111410.
   Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0.
   Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x.
   Levayer R, 2015, NATURE, V524, P476, DOI 10.1038/nature14684.
   Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115.
   LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4.
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6.
   López-Schier H, 2001, GENE DEV, V15, P1393, DOI 10.1101/gad.200901.
   Marshall L, 2012, EMBO J, V31, P1916, DOI 10.1038/emboj.2012.33.
   Matallanas D, 2011, MOL CELL, V44, P893, DOI 10.1016/j.molcel.2011.10.016.
   Mathew G, 2016, P NATL ACAD SCI USA, V113, P13156, DOI 10.1073/pnas.1604450113.
   Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504.
   Menon S, 2014, CELL, V156, P771, DOI 10.1016/j.cell.2013.11.049.
   Miron M, 2003, MOL CELL BIOL, V23, P9117, DOI 10.1128/MCB.23.24.9117-9126.2003.
   Miron M, 2001, NAT CELL BIOL, V3, P596, DOI 10.1038/35078571.
   Mitchell NC, 2015, CELL SIGNAL, V27, P2045, DOI 10.1016/j.cellsig.2015.07.018.
   Neto-Silva RM, 2010, DEV CELL, V19, P507, DOI 10.1016/j.devcel.2010.09.009.
   Nolo R, 2006, CURR BIOL, V16, P1895, DOI 10.1016/j.cub.2006.08.057.
   Nowak K, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007347.
   Oh H, 2009, ONCOGENE, V28, P1916, DOI 10.1038/onc.2009.43.
   Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255.
   Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9.
   Oldham S, 2002, DEVELOPMENT, V129, P4103.
   Pallares-Cartes C, 2012, DEV CELL, V22, P172, DOI 10.1016/j.devcel.2011.10.029.
   Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011.
   Pan YW, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.165712.
   Pan YW, 2016, P NATL ACAD SCI USA, V113, pE6974, DOI 10.1073/pnas.1615012113.
   Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488.
   Parker J, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002274.
   Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403.
   Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108.
   Piwko-Czuchra A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005488.
   Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840.
   Puig O, 2003, GENE DEV, V17, P2006, DOI 10.1101/gad.1098703.
   Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149.
   Rauskolb C, 2014, CELL, V158, P143, DOI 10.1016/j.cell.2014.05.035.
   Ren FF, 2010, DEV BIOL, V337, P303, DOI 10.1016/j.ydbio.2009.10.046.
   Rideout EJ, 2012, P NATL ACAD SCI USA, V109, P1139, DOI 10.1073/pnas.1113311109.
   Rintelen F, 2001, P NATL ACAD SCI USA, V98, P15020, DOI 10.1073/pnas.011318098.
   Romano D, 2014, NAT CELL BIOL, V16, P673, DOI 10.1038/ncb2986.
   Romano D, 2013, MOL CELL BIOL, V33, P1859, DOI 10.1128/MCB.01414-12.
   Romano D, 2010, CANCER RES, V70, P1195, DOI 10.1158/0008-5472.CAN-09-3147.
   Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794.
   RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411.
   Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058.
   Sabra H, 2017, J BIOL CHEM, V292, P19179, DOI 10.1074/jbc.M117.808063.
   Sadagurski M, 2006, MOL CELL BIOL, V26, P2675, DOI 10.1128/MCB.26.7.2675-2687.2006.
   Saito K, 2005, J BIOCHEM, V137, P423, DOI 10.1093/jb/mvi046.
   Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003.
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024.
   Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286.
   Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996.
   Saucedo LJ, 2002, CURR OPIN GENET DEV, V12, P565, DOI 10.1016/S0959-437X(02)00341-6.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031.
   Shraiman BI, 2005, P NATL ACAD SCI USA, V102, P3318, DOI 10.1073/pnas.0404782102.
   Si Y, 2017, CANCER RES, V77, P4868, DOI 10.1158/0008-5472.CAN-17-0391.
   SPRADLING AC, 1993, CELL, V72, P649, DOI 10.1016/0092-8674(93)90393-5.
   Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3.
   Stocker H, 2000, CURR OPIN GENET DEV, V10, P529, DOI 10.1016/S0959-437X(00)00123-4.
   Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science.1068094.
   Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995.
   Strassburger K, 2012, DEV BIOL, V367, P187, DOI 10.1016/j.ydbio.2012.05.008.
   Sun JJ, 2008, J CELL BIOL, V182, P885, DOI 10.1083/jcb.200802084.
   Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142.
   Teleman AA, 2008, CELL METAB, V7, P21, DOI 10.1016/j.cmet.2007.11.010.
   Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013.
   Thompson BJ, 2010, CURR OPIN CELL BIOL, V22, P788, DOI 10.1016/j.ceb.2010.08.018.
   Vachias C, 2014, CELL REP, V9, P531, DOI 10.1016/j.celrep.2014.09.035.
   Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547.
   Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293.
   Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987.
   Wang Y, 2007, CURR BIOL, V17, P1349, DOI 10.1016/j.cub.2007.06.067.
   Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3.
   West MJ, 1998, ONCOGENE, V17, P769, DOI 10.1038/sj.onc.1201990.
   Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132.
   Wu S, 2008, DEV CELL, V14, P388, DOI 10.1016/j.devcel.2008.01.007.
   Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200.
   Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025.
   Zhang HY, 2011, P NATL ACAD SCI USA, V108, P2270, DOI 10.1073/pnas.1019603108.
   Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000.
   Zhang L, 2008, DEV CELL, V14, P377, DOI 10.1016/j.devcel.2008.01.006.
   Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015.
   Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999.},
Number-of-Cited-References = {154},
Times-Cited = {94},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {19},
Journal-ISO = {PLoS. Biol.},
Doc-Delivery-Number = {KA3QC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000505712400047},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000486034100010,
Author = {Curless, Blair P. and Uko, Nne E. and Matesic, Diane F.},
Title = {Modulator of the PI3K/Akt oncogenic pathway affects mTOR complex 2 in
   human adenocarcinoma cells},
Journal = {INVESTIGATIONAL NEW DRUGS},
Year = {2019},
Volume = {37},
Number = {5},
Pages = {902-911},
Month = {OCT},
Abstract = {Chaetoglobosin K (ChK) is a natural product that has been shown to
   promote F-actin capping, inhibit growth, arrest cell cycle G2 phase, and
   induce apoptosis. ChK also has been shown to downregulate two important
   kinases involved in oncogenic pathways, Akt and JNK. This report
   investigates how ChK is involved in the receptor tyrosine kinase pathway
   (RTK/PI3K/mTORC2/Akt) to the centrally located protein kinase, Akt.
   Studies have reported that ChK does not inhibit PI3K comparable to
   wortmannin and does not affect PDK1 activation. PDK1 is responsible for
   phosphorylation on Akt T308, while mTORC2 phosphorylates Akt S473. Yet,
   Akt's two activation sites, T308 and S473, are known to be affected by
   ChK treatment. It was our hypothesis that ChK acts on the mTORC2 complex
   to inhibit the phosphorylation seen at Akt S473. This inhibition at
   mTORC2 should decrease phosphorylation at both these proteins, Akt and
   mTORC2 complex, compared to a known mTOR specific inhibitor, Torin1.
   Human lung adenocarcinoma H1299 and H2009 cells were treated with IGF-1
   or calyculin A to increase phosphorylation at complex mTORC2 and Akt.
   Pretreatment with ChK was able to significantly decrease phosphorylation
   at Akt S473 similarly to Torin1 with either IGF-1 or calyculin A
   treatment. Moreover, the autophosphorylation site on complex mTORC2,
   S2481, was also significantly reduced with ChK pretreatment, similar to
   Torin1. This is the first report to illustrate that ChK has a
   significant effect at mTORC2 S2481 and Akt S473 comparable to Torin1,
   indicating that it may be a mTOR inhibitor.},
Publisher = {SPRINGER},
Address = {VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Curless, BP (Corresponding Author), Mercer Univ, Coll Pharm, 3001 Mercer Univ Dr, Atlanta, GA 30341 USA.
   Curless, Blair P.; Uko, Nne E.; Matesic, Diane F., Mercer Univ, Coll Pharm, 3001 Mercer Univ Dr, Atlanta, GA 30341 USA.},
DOI = {10.1007/s10637-018-0705-7},
ISSN = {0167-6997},
EISSN = {1573-0646},
Keywords = {Akt; mTORC2; Adenocarcinoma; Chaetoglobosin K; Torin1},
Keywords-Plus = {CHAETOGLOBOSIN-K; MAMMALIAN TARGET; LUNG-CANCER; INHIBITOR; AKT;
   PHOSPHORYLATION; RAPAMYCIN; GENERATION; POTENT},
Research-Areas = {Oncology; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Oncology; Pharmacology \& Pharmacy},
Author-Email = {Blair.curless@live.mercer.edu},
Affiliations = {Mercer University},
ORCID-Numbers = {Curless, Blair/0000-0003-3158-745X},
Funding-Acknowledgement = {Mercer University College of Pharmacy},
Funding-Text = {This work was supported by the Mercer University College of Pharmacy.},
Cited-References = {Ali A, 2013, INVEST NEW DRUG, V31, P525, DOI 10.1007/s10637-012-9883-x.
   Barlow AD, 2012, DIABETOLOGIA, V55, P1355, DOI 10.1007/s00125-012-2475-7.
   Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028.
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x.
   Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014.
   CUTLER HG, 1980, J AGR FOOD CHEM, V28, P139, DOI 10.1021/jf60227a011.
   Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120.
   Feldman ME, 2011, CURR TOP MICROBIOL, V347, P241, DOI 10.1007/82\_2010\_64.
   Hart S, 2013, MOL CANCER THER, V12, P151, DOI 10.1158/1535-7163.MCT-12-0466.
   Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119.
   Jordan NJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3604.
   Li B, 2015, CANCER LETT, V356, P418, DOI 10.1016/j.canlet.2014.09.023.
   Liao Y, 2010, AM J TRANSL RES, V2, P19.
   Liu QS, 2013, CANCER RES, V73, P2574, DOI 10.1158/0008-5472.CAN-12-1702.
   Liu QS, 2010, J MED CHEM, V53, P7146, DOI 10.1021/jm101144f.
   Luo HT, 2013, ANTI-CANCER DRUG, V24, P715, DOI 10.1097/CAD.0b013e3283627a0b.
   del Campo JM, 2016, GYNECOL ONCOL, V142, P62, DOI 10.1016/j.ygyno.2016.04.019.
   Markham A, 2017, DRUGS, V77, P1247, DOI 10.1007/s40265-017-0771-8.
   Matesic D., 2014, Curr. Bioact. Compd, V9, P255.
   Matesic DF, 2006, CANCER CHEMOTH PHARM, V57, P741, DOI 10.1007/s00280-005-0113-5.
   Moore SF, 2011, J BIOL CHEM, V286, P24553, DOI 10.1074/jbc.M110.202341.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925.
   Peterson RT, 2000, J BIOL CHEM, V275, P7416, DOI 10.1074/jbc.275.10.7416.
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046.
   Pozuelo-Rubio M, 2010, CELL BIOCHEM BIOPHYS, V58, P147, DOI 10.1007/s12013-010-9101-4.
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085.
   Rosner M, 2010, AMINO ACIDS, V38, P223, DOI 10.1007/s00726-008-0230-7.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Shah A, 2015, ANN PHARMACOTHER, V49, P1162, DOI 10.1177/1060028015594813.
   Soliman GA, 2010, J BIOL CHEM, V285, P7866, DOI 10.1074/jbc.M109.096222.
   Sparks CA, 2010, ONCOGENE, V29, P3733, DOI 10.1038/onc.2010.139.
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200.
   Vu T, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00062.
   Tikoo A, 1999, CANCER J SCI AM, V5, P293.
   Vadlakonda L, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00165.
   Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145.
   Wang YS, 2012, THER ADV MED ONCOL, V4, P19, DOI 10.1177/1758834011427927.
   Watanabe R, 2011, J NUCL MED, V52, P497, DOI 10.2967/jnumed.111.089623.
   Xie J, 2016, F1000 RES, V5.
   Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508.
   Yuan J, 2011, MOL CANCER THER, V10, P2189, DOI 10.1158/1535-7163.MCT-11-0185.
   Zheng Yin, 2015, Mol Cell Pharmacol, V7, P15.},
Number-of-Cited-References = {43},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Invest. New Drugs},
Doc-Delivery-Number = {IX9TX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000486034100010},
DA = {2026-02-04},
}

@article{ WOS:000494641300196,
Author = {Fukui, Makoto and Katayama, Syouichi and Ikeya, Yukinobu and Inazu,
   Tetsuya},
Title = {Yokukansan, a Kampo medicine, enhances the level of neuronal lineage
   markers in differentiated P19 embryonic carcinoma cells},
Journal = {HELIYON},
Year = {2019},
Volume = {5},
Number = {10},
Month = {OCT},
Abstract = {Yokukansan (YKS), a traditional Japanese Kampo medicine, affects
   neurological and psychiatric disorders. It ameliorates hippocampal
   neurogenesis in animals. However, its effect on neuronal cell
   differentiation remains unclear. Therefore, we investigated the effects
   of YKS on pluripotent P19 embryonic carcinoma cells as neuronal
   differentiation model cells.
   Western blotting and immunocytochemistry revealed that 10 mu g/mL YKS
   treatment during embryoid body formation or neuronal differentiation
   increased the expression of the neuronal stem cell marker, Nestin, by
   1.9-fold and 1.7-fold, respectively, and of the mature neuron marker,
   NeuN, by 1.5-fold and 1.4-fold, respectively.
   We examined the effect of YKS on intracellular signaling pathways in P19
   cells and found significant elevation in phospho-PDK1 and phospho-mTOR
   expression (1.1-fold and 1.2-fold, respectively). Therefore, we
   investigated the effect of PDK1 and mTOR inhibitors on the level of
   neuronal lineage markers. We found that the mTOR inhibitor significantly
   abolished the YKS effect on the level of neuronal lineage markers.
   Moreover, to identify the target(s) of YKS, antibody array analysis that
   simultaneously detects 16 phosphorylated proteins was performed. YKS
   significantly upregulated 10 phosphorylated proteins including PDK1,
   Akt, AMPK, PRAS40, mTOR, p70 S6 kinase, GSK-3 alpha, Bad and ERK1/2
   under cell proliferation conditions. These results suggest that YKS
   simultaneously activates multiple signaling pathways.
   Thus, we concluded that YKS enhances the level of neuronal lineage
   markers in differentiated P19 cells, however it does not induce neuronal
   differentiation. Furthermore, mTOR is the predominant mediator of the
   YKS effect on these cells.},
Publisher = {ELSEVIER SCI LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Inazu, T (Corresponding Author), Ritsumeikan Univ, Coll Pharmaceut Sci, Dept Pharm, Kusatsu, Shiga 5258577, Japan.
   Fukui, Makoto; Katayama, Syouichi; Inazu, Tetsuya, Ritsumeikan Univ, Coll Pharmaceut Sci, Dept Pharm, Kusatsu, Shiga 5258577, Japan.
   Ikeya, Yukinobu, Daiichi Univ Pharm, Ctr Supporting Pharmaceut Educ, Minami Ku, Fukuoka, Fukuoka 8158511, Japan.},
DOI = {10.1016/j.heliyon.2019.e02662},
Article-Number = {e02662},
EISSN = {2405-8440},
Keywords = {Neuroscience; Cell biology; Pharmaceutical science; Biochemistry;
   Molecular biology; Yokukansan; Neural stem cell; Neuronal
   differentiation; Pluripotent P19 cells; Signal transduction},
Keywords-Plus = {MTOR PATHWAY; NESTIN; PHOSPHORYLATION; ACTIVATION; PROMOTES},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {tinazu@fc.ritsumei.ac.jp},
Affiliations = {Ritsumeikan University},
ORCID-Numbers = {Katayama, Syouichi/0000-0002-6054-5569},
Funding-Acknowledgement = {JSPS KAKENHI {[}19K08264]; MEXT; Takeda Science Foundation;
   Grants-in-Aid for Scientific Research {[}19K08264] Funding Source: KAKEN},
Funding-Text = {This work was supported in part by JSPS KAKENHI, Grant Number 19K08264
   (T.I.), MEXT-Supported Program for the Strategic Research Foundation at
   Private Universities (2015-2019 to T.I.) and Takeda Science Foundation.},
Cited-References = {Azuma K, 2018, BIOL PHARM BULL, V41, P1593, DOI 10.1248/bpb.b18-00359.
   Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020.
   Chou YH, 2003, MOL BIOL CELL, V14, P1468, DOI 10.1091/mbc.E02-08-0545.
   Doo AR, 2010, J ETHNOPHARMACOL, V131, P433, DOI 10.1016/j.jep.2010.07.008.
   Gusel'nikova VV, 2015, ACTA NATURAE, V7, P42, DOI 10.32607/20758251-2015-7-2-42-47.
   Han DW, 2009, STEM CELLS, V27, P1088, DOI 10.1002/stem.43.
   Hartman NW, 2013, CELL REP, V5, P433, DOI 10.1016/j.celrep.2013.09.017.
   JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253.
   Ka MH, 2014, DEVELOPMENT, V141, P4076, DOI 10.1242/dev.108282.
   Katayama S, 2018, BIOCHEM BIOPH RES CO, V498, P45, DOI 10.1016/j.bbrc.2018.02.195.
   Kaushik R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00411.
   Kubota K., 2013, Journal of Traditional Medicines, V30, P102.
   Law BYK, 2014, CHIN MED-UK, V9, DOI 10.1186/1749-8546-9-21.
   LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X.
   Lindqvist J, 2016, METHOD ENZYMOL, V568, P509, DOI 10.1016/bs.mie.2015.09.019.
   Magri L, 2011, CELL STEM CELL, V9, P447, DOI 10.1016/j.stem.2011.09.008.
   Makanga JO, 2015, BIOL PHARM BULL, V38, P127, DOI 10.1248/bpb.b14-00697.
   MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4.
   Mizoguchi K, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00655.
   Mizukami K, 2009, INT J NEUROPSYCHOPH, V12, P191, DOI 10.1017/S146114570800970X.
   Namiki J, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/430138.
   Obara Y, 2002, J PHARMACOL EXP THER, V301, P803, DOI 10.1124/jpet.301.3.803.
   Park SY, 2017, STEM CELL REP, V8, P95, DOI 10.1016/j.stemcr.2016.11.009.
   Raman L, 2013, NEUROSCI LETT, V541, P9, DOI 10.1016/j.neulet.2013.01.045.
   Resende RR, 2007, NEUROSCIENCE, V146, P1169, DOI 10.1016/j.neuroscience.2007.02.041.
   Sahlgren CM, 2003, MOL CELL BIOL, V23, P5090, DOI 10.1128/MCB.23.14.5090-5106.2003.
   Sahlgren CM, 2001, J BIOL CHEM, V276, P16456, DOI 10.1074/jbc.M009669200.
   Tanaka Y, 2009, NEUROSCIENCE, V164, P1224, DOI 10.1016/j.neuroscience.2009.08.060.
   Terada K, 2018, BOSNIAN J BASIC MED, V18, P224, DOI 10.17305/bjbms.2017.2248.
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217.
   Yu S., 2010, J BIOL CHEM, V287, P42195.
   Zordan P, 2018, J CLIN INVEST, V128, P1688, DOI 10.1172/JCI96342.
   Zurashvili T, 2013, MOL CELL BIOL, V33, P1027, DOI 10.1128/MCB.01052-12.},
Number-of-Cited-References = {33},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Heliyon},
Doc-Delivery-Number = {JK1XQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000494641300196},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000485780700005,
Author = {He, Junming and Wang, Yuande and Liu, Tian and Liu, Guangao and Chen,
   Shasha and Li, Qiaozhen and Quan, Yuhe and Yang, Haoyan and Feng, Jin
   and Wang, Song and Yang, Meixiang and Dong, Zhongjun},
Title = {Stage-specific requirement of kinase PDK1 for NK cells development and
   activation},
Journal = {CELL DEATH AND DIFFERENTIATION},
Year = {2019},
Volume = {26},
Number = {10},
Pages = {1918-1928},
Month = {OCT},
Abstract = {Phosphoinositide-dependent kinase-1 (PDK1) is an important enzyme for
   immune cell development by connecting PI3K to downstream mTOR signaling.
   It is needed to investigate how PDK1 spatiotemporally orchestrates NK
   cells development and whether this kinase is required for NK cells
   effector function. In this study, we used three genetic models to delete
   pdk1 at respective developmental stages, including hematopoietic stem
   cells (Vav1-Cre used), NK cell progenitor (NKp, CD122-Cre used) and
   terminal NK cells (Ncr1-Cre used). We found that CD122-Cre mediated
   deletion of pdk1 caused a severe loss of NK cells to an extent
   comparable to that of deletion by Vav1-Cre, and further revealed that
   PDK1 was necessary for NK cells master transcription factor E4BP4
   expression at the NKp stage. Moreover, Ncr1-Cre-mediated inactivation of
   pdk1 delayed NK cells terminal differentiation. These PDK1-deficient NK
   cells secreted decreased amounts of the cytokine IFN-gamma, likely due
   to impaired downstream mTOR activation. They also exhibited reduced
   degranulation in response to tumor cells. Mechanistically, PDK1 was
   critical for the formation of NK-target conjugates and lytic synapses.
   Therefore, we clarify the stage-specific roles of the metabolic
   regulator PDK1 in NK cells biology.},
Publisher = {NATURE PUBLISHING GROUP},
Address = {MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yang, MX (Corresponding Author), Jinan Univ, Affiliated Hosp 1, Biomed Translat Res Inst, Guangdong Prov Key Lab Mol Immunol \& Antibody Eng, Guangzhou, Guangdong, Peoples R China.
   Dong, ZJ (Corresponding Author), Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.
   Dong, ZJ (Corresponding Author), Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.
   He, Junming; Wang, Yuande; Liu, Tian; Liu, Guangao; Yang, Meixiang, Jinan Univ, Affiliated Hosp 1, Biomed Translat Res Inst, Guangdong Prov Key Lab Mol Immunol \& Antibody Eng, Guangzhou, Guangdong, Peoples R China.
   He, Junming; Wang, Yuande; Chen, Shasha; Li, Qiaozhen; Quan, Yuhe; Yang, Haoyan; Feng, Jin; Dong, Zhongjun, Tsinghua Univ, Sch Med, Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.
   He, Junming; Wang, Yuande; Chen, Shasha; Li, Qiaozhen; Quan, Yuhe; Yang, Haoyan; Feng, Jin; Dong, Zhongjun, Tsinghua Univ, Inst Immunol, Beijing Key Lab Immunol Res Chron Dis, Beijing 100084, Peoples R China.
   Wang, Song, Wuhan Sports Univ, Exercise Immunol Ctr, Wuhan 340036, Hubei, Peoples R China.},
DOI = {10.1038/s41418-018-0263-8},
ISSN = {1350-9047},
EISSN = {1476-5403},
Keywords-Plus = {NATURAL-KILLER; P110-DELTA; MATURATION; EFFECTOR; E4BP4; MTOR},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {yangmxqilu@163.com
   dongzj@biomed.tsinghua.edu.cn},
Affiliations = {Jinan University; Tsinghua University; Tsinghua University; Wuhan Sports
   University},
ResearcherID-Numbers = {Yang, Haoyan/OZD-9313-2025
   liu, tiansu/NZO-5202-2025},
ORCID-Numbers = {Wang, Yuande/0000-0002-9998-0154
   },
Funding-Acknowledgement = {Natural Science Foundation of China {[}81725007, 31830027, 31821003,
   81771666, 81471523]; Beijing Natural Science Foundation {[}5172018];
   Guangzhou Science and Technology Project {[}201707010395]; 111 Project
   {[}B16201]},
Funding-Text = {Research reported in this publication was supported by the Natural
   Science Foundation of China (to ZD, 81725007, 31830027 and 31821003, to
   MY, 81771666 and 81471523), Beijing Natural Science Foundation (5172018
   to ZD), Guangzhou Science and Technology Project (to MY, 201707010395)
   and by 111 Project (B16201).},
Cited-References = {Baracho GV, 2014, P NATL ACAD SCI USA, V111, P9573, DOI 10.1073/pnas.1314562111.
   Chiossone L, 2009, BLOOD, V113, P5488, DOI 10.1182/blood-2008-10-187179.
   DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377.
   Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558.
   Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607.
   Gascoyne DM, 2009, NAT IMMUNOL, V10, P1118, DOI 10.1038/ni.1787.
   Giurisato E, 2007, MOL CELL BIOL, V27, P8583, DOI 10.1128/MCB.01477-07.
   Guo HL, 2008, J EXP MED, V205, P2419, DOI 10.1084/jem.20072327.
   Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062.
   Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268.
   Jandus C, 2014, J CLIN INVEST, V124, P1810, DOI 10.1172/JCI65899.
   Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859.
   Kamizono S, 2009, J EXP MED, V206, P2977, DOI 10.1084/jem.20092176.
   Kärre K, 2008, NAT IMMUNOL, V9, P477, DOI 10.1038/ni0508-477.
   Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771.
   Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581.
   Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005.
   Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936.
   Nandagopal N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00187.
   Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381.
   Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199.
   Robinette ML, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14601.
   Sathe P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5539.
   Tassi I, 2007, IMMUNITY, V27, P214, DOI 10.1016/j.immuni.2007.07.014.
   Upshaw JL, 2006, NAT IMMUNOL, V7, P524, DOI 10.1038/ni1325.
   Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582.
   Yang MX, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12730.
   Yang MX, 2015, J EXP MED, V212, P253, DOI 10.1084/jem.20141703.
   Yu JH, 2013, TRENDS IMMUNOL, V34, P573, DOI 10.1016/j.it.2013.07.005.},
Number-of-Cited-References = {29},
Times-Cited = {20},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Cell Death Differ.},
Doc-Delivery-Number = {IX6GJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000485780700005},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000483551100043,
Author = {Kalhori, Mohammad Reza and Irani, Shiva and Soleimani, Masoud and
   Arefian, Ehsan and Kouhkan, Fatemeh},
Title = {The effect of miR-579 on the PI3K/AKT pathway in human glioblastoma PTEN
   mutant cell lines},
Journal = {JOURNAL OF CELLULAR BIOCHEMISTRY},
Year = {2019},
Volume = {120},
Number = {10},
Pages = {16760-16774},
Month = {OCT},
Abstract = {Glioblastoma multiform (GBM) is a type of aggressive brain cancer with
   limited success in standard treatment. MicroRNAs are one of the most
   beneficial tools for diagnosis, prognosis, and treatment of cancer. This
   study aimed to investigate the effect of miR-579 on cellular behaviors
   and expression of PI3K/AKT signaling pathway in GBM cell lines. In the
   present study, miR-579 was overexpressed in U251 and A-172 cell lines by
   using lentil vector, and its effect on cellular behavior such as
   proliferation and migration was investigated by the cell cycle,
   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),
   Annexin V, colony formation, Transwell and wound healing assays. MiR-579
   predicted target genes (AKT1, Rheb, PDK1, and a few others) were also
   evaluated by real-time polymerase chain reaction or luciferase assay and
   Western blot analysis. Our results represented that overexpression of
   miR-579 could inhibit proliferation, migration, cell cycle and also
   promoted the apoptosis of GBM cell lines. The luciferase reporter assay
   showed miR-579 directly targets the 3 UTR of mTOR, Rheb, and PDK1 and
   repressed their expressions. Furthermore, the Western blot analysis
   showed that miR-579 could downregulate the AKT1 and Rheb protein
   expression. Overall, our findings propose that miR-579 functions as a
   novel tumor suppressor gene in GBM by regulating the PI3K/AKT signaling
   pathway and may serve as a therapeutic target for clinical therapy of
   glioblastoma multiform.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Soleimani, M (Corresponding Author), Tarbiat Modares Univ, Sch Med, Dept Hematol, POB 14115-331, Tehran 14115111, Iran.
   Kalhori, Mohammad Reza; Irani, Shiva, Islamic Azad Univ, Sci \& Res Branch, Dept Biol, Tehran, Iran.
   Soleimani, Masoud, Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.
   Arefian, Ehsan, Univ Tehran, Sch Biol, Coll Sci, Dept Microbiol,Mol Virol Lab, Tehran, Iran.
   Kouhkan, Fatemeh, Stem Cell Technol Res Ctr, Dept Mol Biol \& Genet Engn, Tehran, Iran.},
DOI = {10.1002/jcb.28935},
ISSN = {0730-2312},
EISSN = {1097-4644},
Keywords = {AKT1; GBM; miR-579; PDK1; PI3K; PTEN; Rheb},
Keywords-Plus = {MICRORNA; EXPRESSION; BCL-2; PROLIFERATION; MODULATION; MECHANISMS;
   MULTIFORME; APOPTOSIS; MIGRATION; KINASE},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {Soleim\_m@modares.ac.ir},
Affiliations = {Islamic Azad University; Tarbiat Modares University; University of
   Tehran},
ResearcherID-Numbers = {Irani, shiva/AAE-8167-2020
   kalhori, Mohammad Reza/O-3345-2019
   Arefian, Ehsan/N-3912-2017},
ORCID-Numbers = {kalhori, Mohammad Reza/0000-0002-3652-0927
   Arefian, Ehsan/0000-0002-0758-4710},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Azizian A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040568.
   Chakrabarti M, 2015, GENE, V573, P141, DOI 10.1016/j.gene.2015.07.034.
   Chen WL, 2015, MAR DRUGS, V13, P2505, DOI 10.3390/md13042505.
   Chène P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991.
   Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025.
   Ciafrè SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030.
   Cui Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156915.
   Dharmendra KM, 2017, COLONYCOUNTJ USER FR, V7, P1, DOI {[}10.4172/2161-0495.1000358, DOI 10.4172/2161-0495.1000358].
   Fattore L, 2016, P NATL ACAD SCI USA, V113, pE5005, DOI 10.1073/pnas.1607753113.
   Feng Y, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011591.
   Fischer U, 2007, ONCOGENE, V26, P7809, DOI 10.1038/sj.onc.1210878.
   Fukushima T, 2006, J NEUROPATH EXP NEUR, V65, P12, DOI 10.1097/01.jnen.0000196132.66464.96.
   Gallia GL, 2009, MOL CANCER THER, V8, P386, DOI 10.1158/1535-7163.MCT-08-0680.
   Haffty BG, 2003, ONCOGENE, V22, P5915, DOI 10.1038/sj.onc.1206704.
   Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x.
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008.
   Li JZH, 2016, ONCOTARGET, V7, P58218, DOI 10.18632/oncotarget.11280.
   Li RH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101903.
   Lin MS, 2011, ONCOL REP, V25, P739, DOI 10.3892/or.2010.1112.
   Liu CC, 2018, ONCOTARGET, V9, P1656, DOI {[}10.18632/oncotarget.24651, 10.18632/oncotarget.11208].
   Liu Qingsong, 2009, Drug Discov Today Ther Strateg, V6, P47.
   Low SYY, 2014, J CLIN NEUROSCI, V21, P395, DOI 10.1016/j.jocn.2013.07.033.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198.
   Memmott RM, 2009, CELL SIGNAL, V21, P656, DOI 10.1016/j.cellsig.2009.01.004.
   Piran M, 2017, BIOLOGICALS, V46, P23, DOI 10.1016/j.biologicals.2016.12.004.
   Pirocanac EC, 2002, J SURG RES, V106, P346, DOI 10.1006/jsre.2002.6473.
   Piwecka M, 2015, MOL ONCOL, V9, P1324, DOI 10.1016/j.molonc.2015.03.007.
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761.
   Sami A, 2013, TUMOR BIOL, V34, P1991, DOI 10.1007/s13277-013-0800-5.
   Shea A, 2016, CANCER MED-US, V5, P1917, DOI 10.1002/cam4.775.
   Simpson DR, 2015, ORAL ONCOL, V51, P291, DOI 10.1016/j.oraloncology.2014.11.012.
   Wang JL, 2018, ENVIRON TOXICOL PHAR, V62, P227, DOI 10.1016/j.etap.2018.08.002.
   Wang P, 2010, MOL BIOL REP, V37, P1891, DOI 10.1007/s11033-009-9629-9.
   Wu H, 2003, ONCOGENE, V22, P3113, DOI 10.1038/sj.onc.1206451.
   Ying HC, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-9.},
Number-of-Cited-References = {37},
Times-Cited = {24},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {4},
Journal-ISO = {J. Cell. Biochem.},
Doc-Delivery-Number = {IU4IQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000483551100043},
DA = {2026-02-04},
}

@article{ WOS:000490946400002,
Author = {Pendleton, Alexander L. and Humphreys, Laurel R. and Davis, Melissa A.
   and Camacho, Leticia E. and Anderson, Miranda J. and Limesand, Sean W.},
Title = {Increased pyruvate dehydrogenase activity in skeletal muscle of
   growth-restricted ovine fetuses},
Journal = {AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE
   PHYSIOLOGY},
Year = {2019},
Volume = {317},
Number = {4},
Pages = {R513-R520},
Month = {OCT},
Abstract = {Fetal sheep with placental insufficiency-induced intrauterine growth
   restriction (IUGR) have lower fractional rates of glucose oxidation and
   greater gluconeogenesis, indicating lactate shuttling between skeletal
   muscle and liver. Suppression of pyruvate dehydrogenase (PDH) activity
   was proposed because of greater pyruvate dehydrogenase kinase (PDK) 4
   and PDK1 mRNA concentrations in IUGR muscle. Although PDK1 and PDK4
   inhibit PDH activity to reduce pyruvate metabolism, PDH protein
   concentrations and activity have not been examined in skeletal muscle
   from IUGR fetuses. Therefore, we evaluated the protein concentrations
   and activity of PDH and the kinases and phosphatases that regulate PDH
   phosphorylation status in the semitendinosus muscle from placenta
   insufficiency-induced IUGR sheep fetuses and control fetuses.
   Immunoblots were performed for PDH, phosphorylated PDH (E1 alpha), PDK1,
   PDK4, and pyruvate dehydrogenase phosphatase 1 and 2 (PDP1 and PDP2,
   respectively). Additionally, the PDH, lactate dehydrogenase (LDH), and
   citrate synthase (CS) enzymatic activities were measured. Phosphorylated
   PDH concentrations were 28\% lower (P < 0.01) and PDH activity was 67\%
   greater (P < 0.01) in IUGR fetal muscle compared with control. PDK1,
   PDK4, PDP1, PDP2, and PDH concentrations were not different between
   groups. CS and LDH activities were also unaffected. Contrary to the
   previous speculation, PDH activity was greater in skeletal muscle from
   IUGR fetuses, which parallels lower phosphorylated PDH. Therefore,
   greater expression of PDK1 and PDK4 mRNA did not translate to greater
   PDK1 or PDK4 protein concentrations or inhibition of PDH as proposed.
   Instead, these findings show greater PDH activity in IUGR fetal muscle,
   which indicates that alternative regulatory mechanisms are responsible
   for lower pyruvate catabolism.},
Publisher = {AMER PHYSIOLOGICAL SOC},
Address = {9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA},
Type = {Article},
Language = {English},
Affiliation = {Limesand, SW (Corresponding Author), Univ Arizona, Sch Anim \& Comparat Biomed Sci, 1650 E Limberlost Dr, Tucson, AZ 85719 USA.
   Pendleton, Alexander L.; Limesand, Sean W., Univ Arizona, Physiol Sci Grad Interdisciplinary Program, Tucson, AZ USA.
   Humphreys, Laurel R.; Davis, Melissa A.; Camacho, Leticia E.; Anderson, Miranda J.; Limesand, Sean W., Univ Arizona, Sch Anim \& Comparat Biomed Sci, 1650 E Limberlost Dr, Tucson, AZ 85719 USA.},
DOI = {10.1152/ajpregu.00106.2019},
ISSN = {0363-6119},
EISSN = {1522-1490},
Keywords = {glucose metabolism; oxidative phosphorylation; placental insufficiency},
Keywords-Plus = {CORI CYCLE ACTIVITY; PLACENTAL INSUFFICIENCY; TRANSCRIPTIONAL
   REGULATION; INSULIN SENSITIVITY; PROLYL HYDROXYLASE; GLUCOSE-METABOLISM;
   LUNG MATURATION; FETAL SHEEP; KINASE; EXPRESSION},
Research-Areas = {Physiology},
Web-of-Science-Categories  = {Physiology},
Author-Email = {limesand@email.arizona.edu},
Affiliations = {University of Arizona; University of Arizona},
ResearcherID-Numbers = {Limesand, Sean/AAA-2568-2021
   Humphreys, Laurel Renee/KEI-4864-2024},
ORCID-Numbers = {Pendleton, Alexander/0000-0003-2290-9074
   Humphreys, Laurel Renee/0009-0005-6584-9966},
Funding-Acknowledgement = {NIH {[}R01-DK-084842]; National Institute of Food and Agriculture
   Postdoctoral Fellowship Award {[}T32-HL-007249, 2015-03545]; National
   Heart Lung and Blood Institute {[}T32HL007249] Funding Source: NIH
   RePORTER; National Institute of Diabetes and Digestive and Kidney
   Diseases {[}R01DK084842] Funding Source: NIH RePORTER},
Funding-Text = {This work was supported by NIH Grant R01-DK-084842 (Principal
   Investigator, S. W. Limesand). A. Pendleton was supported by Grant
   T32-HL-007249 (Principal Investigator, C. C. Gregorio). L. E. Camacho
   was supported by National Institute of Food and Agriculture Postdoctoral
   Fellowship Award no. 2015-03545 and Grant T32-HL-007249 (Principal
   Investigator, C. C. Gregorio).},
Cited-References = {Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001.
   Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019.
   Barry JS, 2016, EXP BIOL MED, V241, P839, DOI 10.1177/1535370216632621.
   Barry JS, 2006, EXP BIOL MED, V231, P566.
   Botting KJ, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000531.
   Brown LD, 2015, AM J PHYSIOL-REG I, V309, pR920, DOI 10.1152/ajpregu.00197.2015.
   Brown LD, 2014, J ENDOCRINOL, V221, pR13, DOI 10.1530/JOE-13-0567.
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797.
   Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104.
   Camacho LE, 2017, AM J PHYSIOL-REG I, V313, pR101, DOI 10.1152/ajpregu.00068.2017.
   Caruso M, 2001, J BIOL CHEM, V276, P45088, DOI 10.1074/jbc.M105451200.
   Connaughton S, 2010, MOL CELL ENDOCRINOL, V315, P159, DOI 10.1016/j.mce.2009.08.011.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Gagnon R, 2003, EUR J OBSTET GYN R B, V110, pS99, DOI 10.1016/S0301-2115(03)00179-9.
   García-Cazorla A, 2006, ANN NEUROL, V59, P121, DOI 10.1002/ana.20709.
   Ginouvès A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105.
   HAY WW, 1983, P SOC EXP BIOL MED, V173, P553, DOI 10.3181/00379727-173-41686.
   Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276.
   Jeong JY, 2012, DIABETES METAB J, V36, P328.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Kelly AC, 2018, ENDOCRINOLOGY, V159, P3565, DOI 10.1210/en.2018-00540.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Lee JH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046324.
   Limesand SW, 2007, AM J PHYSIOL-ENDOC M, V293, pE1716, DOI 10.1152/ajpendo.00459.2007.
   Limesand SW, 2018, ANIM REPROD, V15, P886, DOI 10.21451/1984-3143-AR2018-0056.
   Limesand SW, 2009, AM J PHYSIOL-ENDOC M, V296, pE879, DOI 10.1152/ajpendo.90832.2008.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Macko AR, 2016, ENDOCRINOLOGY, V157, P2104, DOI 10.1210/en.2015-1850.
   McGillick EV, 2016, AM J PHYSIOL-REG I, V310, pR1226, DOI 10.1152/ajpregu.00469.2015.
   McGillick EV, 2016, J PHYSIOL-LONDON, V594, P1399, DOI 10.1113/JP271113.
   Muhlhausler BS, 2009, J PHYSIOL-LONDON, V587, P4199, DOI 10.1113/jphysiol.2009.173161.
   Nicholas LM, 2013, FASEB J, V27, P3786, DOI 10.1096/fj.13-227918.
   Orgeig S, 2015, AM J PHYSIOL-LUNG C, V309, pL84, DOI 10.1152/ajplung.00275.2014.
   OWENS JA, 1989, AM J PHYSIOL, V257, pR350, DOI 10.1152/ajpregu.1989.257.2.R350.
   Owens JA, 2007, J PHYSIOL-LONDON, V584, P935, DOI 10.1113/jphysiol.2007.142141.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101.
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32.
   Peters SJ, 2001, AM J PHYSIOL-REG I, V280, pR661, DOI 10.1152/ajpregu.2001.280.3.R661.
   Pilegaard H, 2004, P NUTR SOC, V63, P221, DOI 10.1079/PNS2004345.
   Pilegaard H, 2003, DIABETES, V52, P657, DOI 10.2337/diabetes.52.3.657.
   Pilegaard H, 2006, DIABETES, V55, P3020, DOI 10.2337/db06-0152.
   Rardin MJ, 2009, ANAL BIOCHEM, V389, P157, DOI 10.1016/j.ab.2009.03.040.
   Regnault TRH, 2007, PLACENTA, V28, P714, DOI 10.1016/j.placenta.2006.06.007.
   Regnault TRH, 2003, J PHYSIOL-LONDON, V550, P641, DOI 10.1113/jphysiol.2003.039511.
   Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595.
   Rozance PJ, 2018, J PHYSIOL-LONDON, V596, P67, DOI 10.1113/JP275230.
   Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389.
   Soto SM, 2017, J ENDOCRINOL, V232, P475, DOI 10.1530/JOE-16-0123.
   Sugden MC, 2000, BIOCHEM J, V346, P651, DOI 10.1042/0264-6021:3460651.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Tao RY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071997.
   Thorn S, 2013, PEDIATR RES, V74, P481.
   Thorn SR, 2013, DIABETES, V62, P65, DOI 10.2337/db11-1727.
   Thorn SR, 2009, ENDOCRINOLOGY, V150, P3021, DOI 10.1210/en.2008-1789.
   Usha K, 2011, J OBSTET GYN INDIA, V61, P505, DOI 10.1007/s13224-011-0092-x.
   Venhoff N, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4076.
   Wang YX, 2005, PLOS BIOL, V3, P177, DOI 10.1371/journal.pbio.0030061.
   WATERHOUSE C, 1969, J CLIN INVEST, V48, P2359, DOI 10.1172/JCI106202.
   Wesolowski SR, 2016, MOL CELL ENDOCRINOL, V435, P61, DOI 10.1016/j.mce.2015.12.016.
   Wu PF, 1999, DIABETES, V48, P1593, DOI 10.2337/diabetes.48.8.1593.
   Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605.
   Yates DT, 2012, J PREGNANCY, V2012, DOI 10.1155/2012/631038.
   Yates DT, 2016, AM J PHYSIOL-REG I, V310, pR1020, DOI 10.1152/ajpregu.00528.2015.
   Yates DT, 2014, J PHYSIOL-LONDON, V592, P3113, DOI 10.1113/jphysiol.2014.272591.
   YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017.},
Number-of-Cited-References = {66},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Am. J. Physiol.-Regul. Integr. Comp. Physiol.},
Doc-Delivery-Number = {JE8NH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000490946400002},
OA = {Green Published, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000486535700003,
Author = {Zhang, X. and Yu, Z.},
Title = {Expression of PDK1 in malignant pheochromocytoma as a new promising
   potential therapeutic target},
Journal = {CLINICAL \& TRANSLATIONAL ONCOLOGY},
Year = {2019},
Volume = {21},
Number = {10},
Pages = {1312-1318},
Month = {OCT},
Abstract = {Purpose Phosphoinositide-dependent kinase 1 (PDK1) is highly expressed
   in many solid tumors. And several studies have demonstrated that PDK1
   has been an emerging and promising target for anti-cancer therapies.
   However, the role of PDK1 has not been studied so far in malignant
   pheochromocytoma (PCC). Methods In this study, immunohistochemical
   staining was performed to investigate the protein level of PDK1 in 63
   PCC tissue samples, of which 49 were benign and 14 were malignant. In
   addition, we evaluated the effect of inhibition of PDK1 with siRNA on
   cell growth, apoptosis and invasive capacity in PC12 cells and
   identified the underlying mechanisms. Results We found that PDK1 was
   overexpressed in malignant PCC tissues, and knockdown of PDK1 with siRNA
   significantly inhibited cell proliferation, increased apoptosis
   induction, and attenuated cell migration and invasive capacity in PC12
   cells. We also showed that knockdown of PDK1 significantly reduced the
   phosphorylation of Akt at threonine 308 (p-Akt T308) but did not alter
   the serine phosphorylation of Akt on the S473 site (p-Akt S473).
   Furthermore, we found that the p-Akt expression was noticeably decreased
   after knockdown of PDK1, but the t-Akt expression did not show a
   significant decrease. Conclusion We have demonstrated for the first time
   that PDK1 is overexpressed in human malignant PCC and plays an important
   role in the malignant biological behaviors of PC12 cell. Specifically,
   we have revealed that knockdown of PDK1 could attenuate activation of
   the Akt signaling. These data suggest that PDK1 could be a new promising
   potential therapeutic target in human cancer treatment for malignant
   PCC.},
Publisher = {SPRINGER INTERNATIONAL PUBLISHING AG},
Address = {GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Yu, Z (Corresponding Author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Urol, Wenzhou, Zhejiang, Peoples R China.
   Zhang, X., Fudan Univ, Dept Urol, Huashan Hosp, Shanghai, Peoples R China.
   Yu, Z., Wenzhou Med Univ, Affiliated Hosp 1, Dept Urol, Wenzhou, Zhejiang, Peoples R China.},
DOI = {10.1007/s12094-019-02055-5},
ISSN = {1699-048X},
EISSN = {1699-3055},
Keywords = {Phosphoinositide-dependent kinase 1; PDK1; Adrenal gland; Malignant
   pheochromocytoma; Target},
Keywords-Plus = {METASTASIS; THERAPIES; SURVIVAL; OVARIAN},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {yuzx515@126.com},
Affiliations = {Fudan University; Wenzhou Medical University},
ORCID-Numbers = {Yu, Zhixian/0000-0001-9076-5071},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81502315]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (No. 81502315).},
Cited-References = {Brasseur K, 2017, ONCOTARGET, V8, P4008, DOI 10.18632/oncotarget.14021.
   Coant N, 2018, ONCOGENE, V37, P3852, DOI 10.1038/s41388-018-0236-x.
   Druce MR, 2009, HORM METAB RES, V41, P697, DOI 10.1055/s-0029-1220687.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Eisenhofer G, 2012, EUR J CANCER, V48, P1739, DOI 10.1016/j.ejca.2011.07.016.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Hisamatsu Y, 2016, ANN SURG ONCOL, V23, P1986, DOI 10.1245/s10434-016-5097-3.
   Jimenez C, 2013, CURR ONCOL REP, V15, P356, DOI 10.1007/s11912-013-0320-x.
   Jouali F, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4811-x.
   Lenders JWM, 2017, ENDOCRINOL METAB, V32, P152, DOI 10.3803/EnM.2017.32.2.152.
   Lohneis P, 2015, ANTICANCER RES, V35, P6329.
   Parenti G, 2012, J ONCOL, V2012, DOI 10.1155/2012/872713.
   Suber TL, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0910-0.
   Wang YH, 2017, CANCER LETT, V393, P8, DOI 10.1016/j.canlet.2017.01.036.
   Zabkiewicz J, 2014, HAEMATOLOGICA, V99, P858, DOI 10.3324/haematol.2013.096487.
   Zhang JY, 2010, MAR DRUGS, V8, P1469, DOI 10.3390/md8041469.
   Zhang XH, 2015, TUMOR BIOL, V36, P5273, DOI 10.1007/s13277-015-3187-7.},
Number-of-Cited-References = {18},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Clin. Transl. Oncol.},
Doc-Delivery-Number = {IY6VZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000486535700003},
DA = {2026-02-04},
}

@article{ WOS:000506400800015,
Author = {Hong, Hongxiang and Sun, Yuyu and Deng, Hongjian and Yuan, Kun and Chen,
   Jinyu and Liu, Wei and Cui, Zhiming},
Title = {Dysregulation of cPWWP2A-miR-579 axis mediates dexamethasone-induced
   cytotoxicity in human osteoblasts},
Journal = {BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS},
Year = {2019},
Volume = {517},
Number = {3},
Pages = {491-498},
Month = {SEP 24},
Abstract = {Dexamethasone (DEX) induces significant cytotoxicity to human
   osteoblasts. cPWWP2A is recently-indentifled novel circular RNA
   (circRNA), acting as an endogenous sponge of microRNA-579 (miR-579). The
   present study tested the expression and potential functions of the
   cPWWP2A-miR-579 axis in DEX-treated osteoblasts. We show that cPWWP2A is
   downregulated in the necrotic femoral head tissues of DEX-taking human
   patients as well as in DEX-treated human osteoblasts. In 06-6
   osteoblastic cells and primary human osteoblasts ectopic overexpression
   of cPWWP2A potently inhibited DEX-induced miR-579 accumulation, cell
   death, apoptosis and programmed necrosis. Silencing miR-579, by targeted
   siR-NAs, also attenuated DEX-induced cytotoxicity in human osteoblasts.
   Significantly, mimicking DEX-induced actions, cPWWP2A silencing or
   forced miR-579 overexpression induced significant cytotoxicity in human
   osteoblasts. Further analyses demonstrated that miR-579's targets,
   including SIRT1 and PDK1 (phosphoinositide-dependent protein kinase 1),
   were downregulated in DEX-treated osteoblasts. Their levels were
   decreased as well in the necrotic femoral head tissues of DEX-taking
   human patients. Taken together we show that dysregulation of the
   cPWWP2A-miR-579 axis is involved in DEX-induced cytotoxicity in human
   osteoblasts. (C) 2019 Elsevier Inc. All rights reserved.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Cui, ZM (Corresponding Author), Nantong Univ, Affiliated Hosp 2, Dept Orthopaed, 6 North Hai Er Xiang Rd, Nantong 226001, Jiangsu, Peoples R China.
   Hong, Hongxiang; Sun, Yuyu; Deng, Hongjian; Yuan, Kun; Chen, Jinyu; Liu, Wei; Cui, Zhiming, Nantong Univ, Affiliated Hosp 2, Dept Orthopaed, 6 North Hai Er Xiang Rd, Nantong 226001, Jiangsu, Peoples R China.},
DOI = {10.1016/j.bbrc.2019.07.095},
ISSN = {0006-291X},
EISSN = {1090-2104},
Keywords = {Osteoblasts; Dexamethasone; cPWWP2A; miR-579 Cell death},
Keywords-Plus = {OXIDATIVE STRESS; CELLS; GLUCOCORTICOIDS; ACTIVATION; KINASE; MTOR},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {ntgkczmy@163.com},
Affiliations = {Nantong University},
ResearcherID-Numbers = {WEI, LIU/GPS-4337-2022
   },
ORCID-Numbers = {Sun, Yuyu/0000-0002-1614-6368},
Funding-Acknowledgement = {Science and Technology Programof Nantong {[}MS12017001-7]},
Funding-Text = {This project was supported by the Science and Technology Programof
   Nantong (MS12017001-7). The funder had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.},
Cited-References = {Almeida M, 2011, J BIOL CHEM, V286, P44326, DOI 10.1074/jbc.M111.283481.
   Brooks MM, 2013, MOL VIS, V19, P1406.
   Cheng LB, 2014, BIOCHEM BIOPH RES CO, V443, P447, DOI 10.1016/j.bbrc.2013.11.113.
   den Uyl D, 2011, CURR RHEUMATOL REP, V13, P233, DOI 10.1007/s11926-011-0173-y.
   Ding HY, 2015, BIOCHEM BIOPH RES CO, V460, P157, DOI 10.1016/j.bbrc.2015.02.161.
   Ebbesen KK, 2017, RNA BIOL, V14, P1035, DOI 10.1080/15476286.2016.1271524.
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138.
   Fattore L, 2016, P NATL ACAD SCI USA, V113, pE5005, DOI 10.1073/pnas.1607753113.
   Fei HD, 2017, ONCOTARGET, V8, P49646, DOI 10.18632/oncotarget.17911.
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111.
   Himburg HA, 2010, NAT MED, V16, P475, DOI 10.1038/nm.2119.
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007.
   Kalhori M.R., 2019, J CELL BIOCH.
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007.
   Li ST, 2016, BIOCHEM BIOPH RES CO, V479, P54, DOI 10.1016/j.bbrc.2016.09.027.
   Liu C, 2019, P NATL ACAD SCI USA, V116, P7455, DOI 10.1073/pnas.1814874116.
   Liu H, 2018, CELL PHYSIOL BIOCHEM, V51, P1908, DOI 10.1159/000495716.
   Meng XW, 2017, BRIEF BIOINFORM, V18, P547, DOI 10.1093/bib/bbw045.
   Souttou B, 2001, J CELL PHYSIOL, V187, P59, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1051>3.0.CO;2-F.
   Weinstein RS, 2011, NEW ENGL J MED, V365, P62, DOI 10.1056/NEJMcp1012926.
   Xu Y, 2014, BIOCHEM BIOPH RES CO, V453, P362, DOI 10.1016/j.bbrc.2014.09.088.
   Yun SI, 2009, J BONE MINER METAB, V27, P140, DOI 10.1007/s00774-008-0019-5.
   Zhang XY, 2018, BIOCHEM BIOPH RES CO, V503, P2255, DOI 10.1016/j.bbrc.2018.06.146.
   Zhao S, 2017, ONCOTARGET, V8, P104867, DOI 10.18632/oncotarget.20452.
   Zhao S, 2016, BIOCHEM BIOPH RES CO, V481, P212, DOI 10.1016/j.bbrc.2016.10.104.
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589.
   Zhu CY, 2019, BIOCHEM BIOPH RES CO, V516, P645, DOI 10.1016/j.bbrc.2019.06.073.},
Number-of-Cited-References = {27},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Biochem. Biophys. Res. Commun.},
Doc-Delivery-Number = {KB3LH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000506400800015},
DA = {2026-02-04},
}

@article{ WOS:000487365300028,
Author = {Maruhashi, Ryohei and Eguchi, Hiroaki and Akizuki, Risa and Hamada,
   Shohei and Furuta, Takumi and Matsunaga, Toshiyuki and Endo, Satoshi and
   Ichihara, Kenji and Ikari, Akira},
Title = {Chrysin enhances anticancer drug-induced toxicity mediated by the
   reduction of claudin-1 and 11 expression in a spheroid culture model of
   lung squamous cell carcinoma cells},
Journal = {SCIENTIFIC REPORTS},
Year = {2019},
Volume = {9},
Month = {SEP 24},
Abstract = {The aberrant expression of claudins (CLDNs), which are tight junctional
   proteins, is seen in various solid tumors, but the regulatory mechanisms
   and their pathophysiological role are not well understood. Both CLDN1
   and CLDN11 were highly expressed in human lung squamous cell carcinoma
   (SCC). Chrysin, found in high concentration in honey and propolis,
   decreased CLDN1 and CLDN11 expression in RERF-LC-Al cells derived from
   human lung SCC. The phosphorylation level of Akt was decreased by
   chrysin, but those of ERK1/2 and c-Jun were not. LY-294002, an inhibitor
   of phosphatidylinositol 3-kinase, inhibited the phosphorylation of Akt
   and decreased the expression levels of CLDN1 and CLDN11. The association
   between phosphoinositide-dependent kinase 1 (PDK1) and Akt was inhibited
   by chrysin, but the phosphorylation of PDK1 was not. Immunoprecipitation
   and quartz-crystal microba lance assays revealed that
   biotinylated-chrysin binds directly to Akt. The knockdown of CLDN1 and
   CLDN11 using small interfering RNAs increased the transepithelial flux
   of doxorubicin (DXR), an anthracycline anticancer drug. Similarly, both
   chrysin and LY-294002 increased DXR flux. Neither CLDN1 knockdown,
   CLDN11 knockdown, nor chrysin changed the anticancer drug-induced
   cytotoxicity in a two-dimensional culture model, whereas they enhanced
   cytotoxicity in a spheroid culture model. Taken together, chrysin may
   bind to Akt and inhibit its phosphorylation, resulting in the elevation
   of anticancer drug-induced toxicity mediated by reductions in CLDN1 and
   CLDN11 expression in RERFLC-Al cells. We suggest that chrysin may be
   useful as an adjuvant chemotherapy in lung SCC.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Ikari, A (Corresponding Author), Gifu Pharmaceut Univ, Dept Biopharmaceut Sci, Lab Biochem, Gifu 5011196, Japan.
   Maruhashi, Ryohei; Eguchi, Hiroaki; Akizuki, Risa; Endo, Satoshi; Ikari, Akira, Gifu Pharmaceut Univ, Dept Biopharmaceut Sci, Lab Biochem, Gifu 5011196, Japan.
   Hamada, Shohei; Furuta, Takumi, Kyoto Pharmaceut Univ, Dept Pharmaceut Chem, Yamashina Ku, Kyoto 6078414, Japan.
   Matsunaga, Toshiyuki, Gifu Pharmaceut Univ, Educ Ctr Green Pharmaceut Sci, Gifu 5028585, Japan.
   Ichihara, Kenji, API Co Ltd, Nagaragawa Res Ctr, Gifu 5020071, Japan.},
DOI = {10.1038/s41598-019-50276-z},
Article-Number = {13753},
ISSN = {2045-2322},
Keywords-Plus = {SIGNALING PATHWAY; TIGHT JUNCTION; ADENOCARCINOMA; AKT;
   MICROENVIRONMENT; INHIBITION; ACTIVATION; MECHANISMS; RESISTANCE;
   DOCETAXEL},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {ikari@gifu-pu.ac.jp},
Affiliations = {Gifu Pharmaceutical University; Kyoto Pharmaceutical University; Gifu
   Pharmaceutical University},
ResearcherID-Numbers = {Endo, Satoshi/F-8059-2011},
ORCID-Numbers = {Hamada, Shohei/0000-0003-4352-0017
   Endo, Satoshi/0000-0003-0578-9672},
Funding-Acknowledgement = {JSPS KAKENHI {[}19H03373]; Takahashi Sangyo-Keizai Research Foundation;
   Ogawa Science and Technology Foundation; Smoking Research Foundation;
   API Co., Ltd.; Takeda Science Foundation; Grants-in-Aid for Scientific
   Research {[}19H03373] Funding Source: KAKEN},
Funding-Text = {This work was supported in part by JSPS KAKENHI Grant Number 19H03373
   (A.I.) and the grants from the Takahashi Sangyo-Keizai Research
   Foundation, Takeda Science Foundation, Ogawa Science and Technology
   Foundation, and Smoking Research Foundation (to A.I.), and collaborative
   research grant from API Co., Ltd.},
Cited-References = {Akimoto T, 2018, NEOPLASIA, V20, P1083, DOI 10.1016/j.neo.2018.08.010.
   Akizuki R, 2018, BBA-MOL CELL RES, V1865, P769, DOI 10.1016/j.bbamcr.2018.03.001.
   Akizuki R, 2017, BBA-MOL CELL RES, V1864, P293, DOI 10.1016/j.bbamcr.2016.11.018.
   Castells M, 2012, INT J MOL SCI, V13, P9545, DOI 10.3390/ijms13089545.
   Che JJ, 2015, TUMOR BIOL, V36, P6559, DOI 10.1007/s13277-015-3350-1.
   Coyne CB, 2003, AM J PHYSIOL-LUNG C, V285, pL1166, DOI 10.1152/ajplung.00182.2003.
   Daugherty BL, 2004, AM J PHYSIOL-LUNG C, V287, pL1266, DOI 10.1152/ajplung.00423.2003.
   Domenichini A, 2019, BBA-GEN SUBJECTS, V1863, P52, DOI 10.1016/j.bbagen.2018.09.019.
   Fu BB, 2007, MOL CANCER THER, V6, P220, DOI 10.1158/1535-7163.MCT-06-0526.
   Furuse M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002907.
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404.
   Hatzakis NS, 2006, CHEM COMMUN, P2012, DOI 10.1039/b516551b.
   Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5.
   Kartal-Yandim M, 2016, CRIT REV BIOTECHNOL, V36, P716, DOI 10.3109/07388551.2015.1015957.
   Kasala ER, 2015, TOXICOL LETT, V233, P214, DOI 10.1016/j.toxlet.2015.01.008.
   Khoo BY, 2010, INT J MOL SCI, V11, P2188, DOI 10.3390/ijms11052188.
   Kuo KT, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.46.
   Lee SH, 2002, APMIS, V110, P587, DOI 10.1034/j.1600-0463.2002.11007811.x.
   Lim HK, 2017, INTEGR CANCER THER, V16, P496, DOI 10.1177/1534735416645184.
   Longati P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-95.
   Lv PC, 2010, BIOORGAN MED CHEM, V18, P1117, DOI 10.1016/j.bmc.2009.12.048.
   Maruhashi R, 2018, BBA-MOL CELL RES, V1865, P470, DOI 10.1016/j.bbamcr.2017.12.005.
   Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055.
   Meier JL, 2006, J AM CHEM SOC, V128, P12174, DOI 10.1021/ja063217n.
   Middleton E Jr, 2000, PHARMACOL REV, V52, P673.
   Miwa N, 2001, ONCOL RES, V12, P469, DOI 10.3727/096504001108747477.
   Paschoud S, 2007, MODERN PATHOL, V20, P947, DOI 10.1038/modpathol.3800835.
   POWELL DW, 1981, AM J PHYSIOL, V241, pG275, DOI 10.1152/ajpgi.1981.241.4.G275.
   Raffa D, 2017, EUR J MED CHEM, V142, P213, DOI 10.1016/j.ejmech.2017.07.034.
   Resnick MB, 2005, HUM PATHOL, V36, P886, DOI 10.1016/j.humpath.2005.05.019.
   Sechler M, 2013, PHARMACOGN PERS MED, V6, P25, DOI 10.2147/PGPM.S26058.
   Senthebane DA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071586.
   Shao JJ, 2012, BIOCHEM BIOPH RES CO, V423, P448, DOI 10.1016/j.bbrc.2012.05.123.
   Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095.
   Sui HS, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/6984948.
   Sun LP, 2012, J AGR FOOD CHEM, V60, P11748, DOI 10.1021/jf303261r.
   Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344.
   Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179.
   Woo KJ, 2004, BIOCHEM BIOPH RES CO, V325, P1215, DOI 10.1016/j.bbrc.2004.09.225.
   Xu D, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0514-4.
   Yamamoto T, 2010, ONCOL LETT, V1, P501, DOI 10.3892/ol\_00000088.
   Yang B, 2014, J APPL TOXICOL, V34, P105, DOI 10.1002/jat.2941.
   Yeldag G, 2018, CANCERS, V10, DOI 10.3390/cancers10120471.
   Yip PY, 2015, TRANSL LUNG CANCER R, V4, P165, DOI 10.3978/j.issn.2218-6751.2015.01.04.
   Yu XM, 2013, CANCER-AM CANCER SOC, V119, P774, DOI 10.1002/cncr.27742.},
Number-of-Cited-References = {45},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {IZ8OP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000487365300028},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000490023500003,
Author = {Lin, Jian-Xian and Xie, Xin-Sheng and Weng, Xiong-Feng and Qiu,
   Sheng-Liang and Yoon, Changhwan and Lian, Ning-Zi and Xie, Jian-Wei and
   Wang, Jia-Bin and Lu, Jun and Chen, Qi-Yue and Cao, Long-Long and Lin,
   Mi and Tu, Ru-Hong and Yang, Ying-Hong and Huang, Chang-Ming and Zheng,
   Chao-Hui and Li, Ping},
Title = {UFM1 suppresses invasive activities of gastric cancer cells by
   attenuating the expres7sion of PDK1 through PI3K/AKT signaling},
Journal = {JOURNAL OF EXPERIMENTAL \& CLINICAL CANCER RESEARCH},
Year = {2019},
Volume = {38},
Number = {1},
Month = {SEP 18},
Abstract = {Background: UFM1 has been found to be involved in the regulation of
   tumor development. This study aims to clarify the role and potential
   molecular mechanisms of UFM1 in the invasion and metastasis of gastric
   cancer.
   Methods: Expression of UFM1 in gastric tumor and paired adjacent
   noncancerous tissues from 437 patients was analyzed by Western blotting,
   immunohistochemistry, and realtime PCR. Its correlation with the
   clinicopathological characteristics and prognosis of gastric cancer
   patients was analyzed. The effects of UFM1 on the invasion and migration
   of gastric cancer cells were determined by the wound and trans-well
   assays, and the effect of UFM1 on subcutaneous tumor formation was
   verified in nude mice. The potential downstream targets of UFM1 and
   related molecular mechanisms were clarified by the human protein kinase
   assay and co-immunoprecipitation technique.
   Results: Compared with the corresponding adjacent tissues, the
   transcription level and protein expression level of UFM1 in gastric
   cancer tissues were significantly downregulated (P < 0.05). The 5-year
   survival rate of gastric cancer patients with low UFM1 expression was
   significantly lower than the patients with high UFM1 expression (42.1\%
   vs 63.0\%, P < 0.05). The invasion and migration abilities of gastric
   cancer cells with stable UFM1 overexpression were significantly
   decreased, and the gastric cancer cells with UFM1 stable knockdown
   showed the opposite results; similar results were also obtained in the
   nude mouse model. Further studies have revealed that UFM1 could increase
   the ubiquitination level of PDK1 and decrease the expression of PDK1 at
   protein level, thereby inhibiting the phosphorylation level of AKT at
   Ser473. Additionally, the effect of UFM1 on gastric cancer cell function
   is dependent on the expression of PDK1. The expression level of UFM1 can
   improve the poor prognosis of PDK1 in patients with gastric cancer.
   Conclusion: UFM1 suppresses the invasion and metastasis of gastric
   cancer by increasing the ubiquitination of PDK1 through negatively
   regulating PI3K/AKT signaling.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Huang, CM; Zheng, CH; Li, P (Corresponding Author), Fujian Med Univ, Union Hosp, Dept Gastr Surg, Fuzhou 350001, Fujian, Peoples R China.
   Lin, Jian-Xian; Xie, Xin-Sheng; Weng, Xiong-Feng; Lian, Ning-Zi; Xie, Jian-Wei; Wang, Jia-Bin; Lu, Jun; Chen, Qi-Yue; Cao, Long-Long; Lin, Mi; Tu, Ru-Hong; Huang, Chang-Ming; Zheng, Chao-Hui; Li, Ping, Fujian Med Univ, Union Hosp, Dept Gastr Surg, Fuzhou 350001, Fujian, Peoples R China.
   Lin, Jian-Xian; Xie, Xin-Sheng; Weng, Xiong-Feng; Lian, Ning-Zi; Xie, Jian-Wei; Wang, Jia-Bin; Lu, Jun; Chen, Qi-Yue; Cao, Long-Long; Lin, Mi; Tu, Ru-Hong; Huang, Chang-Ming; Zheng, Chao-Hui; Li, Ping, Fujian Med Univ, Gastrointestinal Canc, Minist Educ, Key Lab, Fuzhou 350108, Fujian, Peoples R China.
   Lin, Jian-Xian; Xie, Xin-Sheng; Weng, Xiong-Feng; Lian, Ning-Zi; Xie, Jian-Wei; Wang, Jia-Bin; Lu, Jun; Chen, Qi-Yue; Cao, Long-Long; Huang, Chang-Ming; Zheng, Chao-Hui; Li, Ping, Fujian Med Univ, Fujian Key Lab Tumor Microbiol, Fuzhou 350108, Fujian, Peoples R China.
   Qiu, Sheng-Liang; Yang, Ying-Hong, Fujian Med Univ, Union Hosp, Dept Pathol, Fuzhou 350001, Fujian, Peoples R China.
   Yoon, Changhwan, Mem Sloan Kettering Canc Ctr, Dept Surg, 1275 York Ave, New York, NY 10021 USA.},
DOI = {10.1186/s13046-019-1416-4},
Article-Number = {410},
EISSN = {1756-9966},
Keywords = {UFM1; PDK1; Gastric cancer; EMT},
Keywords-Plus = {GENE-EXPRESSION; EPIDEMIOLOGY; METASTASIS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {hcmlr2002@163.com
   wwkzch@163.com
   pingli811002@163.com},
Affiliations = {Fujian Medical University; Fujian Medical University; Fujian Medical
   University; Fujian Medical University; Memorial Sloan Kettering Cancer
   Center},
ResearcherID-Numbers = {Yoon, Changhwan/AAK-7842-2021
   Zheng, Chao-hui/HGE-3348-2022
   Li, Ping/GYV-4914-2022
   cao, longlong/NRX-8300-2025
   Lu, Jun/AAP-1222-2021},
ORCID-Numbers = {Yoon, Changhwan/0000-0002-8420-9818
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81871899]; Science
   Foundation of the Fujian Province, China {[}2018 J01307]; Startup Fund
   for Scientific Research, Fujian Medical University {[}2016QH024];
   Scientific and Technological Innovation Joint Capital Projects of Fujian
   Province {[}2016Y9031, 2018Y9008]; Minimally Invasive Medical Center of
   Fujian Province {[}2011708]; Science Foundation of Fujian Province
   {[}2016 J01463]},
Funding-Text = {This study was funded by the National Natural Science Foundation of
   China (grant no. 81871899), the Science Foundation of the Fujian
   Province, China (grant no. 2018 J01307), the Startup Fund for Scientific
   Research, Fujian Medical University (grant no. 2016QH024), the
   Scientific and Technological Innovation Joint Capital Projects of Fujian
   Province (grant no. 2016Y9031), the Minimally Invasive Medical Center of
   Fujian Province (grant no. 2011708) and the Science Foundation of Fujian
   Province (grant no. 2016 J01463), Scientific and technological
   innovation joint capital projects of Fujian Province (2018Y9008).},
Cited-References = {Amin MB, 2017, AJCC CANC STAGING MA, P203.
   Biondi RM, 2004, TRENDS BIOCHEM SCI, V29, P136, DOI 10.1016/j.tibs.2004.01.005.
   Cao LL, 2015, CLIN CANCER RES, V21, P1419, DOI 10.1158/1078-0432.CCR-14-1950.
   Chan THM, 2016, GASTROENTEROLOGY, V151, P637, DOI 10.1053/j.gastro.2016.06.043.
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002.
   Deng YZ, 2012, GASTROENTEROLOGY, V142, P812, DOI 10.1053/j.gastro.2011.12.046.
   Feng QT, 2010, MOL CELL BIOL, V30, P3711, DOI 10.1128/MCB.00420-10.
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748.
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gannavaram S, 2012, MOL MICROBIOL, V86, P187, DOI 10.1111/j.1365-2958.2012.08183.x.
   Ha BH, 2011, J BIOL CHEM, V286, P10248, DOI 10.1074/jbc.M110.172171.
   Hertel P, 2013, J BIOL CHEM, V288, P10661, DOI 10.1074/jbc.M113.458000.
   Hu XL, 2014, INT J MOL MED, V33, P1539, DOI 10.3892/ijmm.2014.1728.
   Ishimura R, 2017, FEBS LETT, V591, P196, DOI 10.1002/1873-3468.12518.
   Jang SH, 2016, J GASTRIC CANCER, V16, P85, DOI 10.5230/jgc.2016.16.2.85.
   Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057.
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758.
   Li DC, 2007, DNA SEQUENCE, V18, P421, DOI 10.1080/10425170701318443.
   Li WS, 2012, BIOCHEM PHARMACOL, V84, P172, DOI 10.1016/j.bcp.2012.04.006.
   Li YY, 2017, INT J MOL MED, V39, P1119, DOI 10.3892/ijmm.2017.2947.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Masaaki K, 2014, EMBO J, V23, P1977.
   Mizushima T, 2007, BIOCHEM BIOPH RES CO, V362, P1079, DOI 10.1016/j.bbrc.2007.08.129.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Sasakawa H, 2006, BIOCHEM BIOPH RES CO, V343, P21, DOI 10.1016/j.bbrc.2006.02.107.
   Saunders LR, 2014, DEVELOPMENT, V141, P1503, DOI 10.1242/dev.101436.
   Sehdev A, 2013, DISCOV MED, V16, P103.
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007.
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822.
   Uras IZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031003.
   Valcourt U, 2016, METHODS MOL BIOL, V1344, P147, DOI 10.1007/978-1-4939-2966-5\_9.
   Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090.
   Wang JB, 2017, CANCER LETT, V385, P188, DOI 10.1016/j.canlet.2016.10.024.
   Warde-Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI {[}10.1093/nar/gkq537, 10.1002/adma.202504015].
   Xi P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064231.
   Yoo HM, 2014, MOL CELL, V56, P261, DOI 10.1016/j.molcel.2014.08.007.},
Number-of-Cited-References = {38},
Times-Cited = {58},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {18},
Journal-ISO = {J. Exp. Clin. Cancer Res.},
Doc-Delivery-Number = {JD5LC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000490023500003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000484035300026,
Author = {Shan, Haiyan and He, Yini and Hao, Sijia and Wang, Bofu and Xu, Ming and
   Qi, Huimeng and Liu, Shen and Du, Yanmei and Yu, Xiaosong},
Title = {Vps15 is critical to mediate autophagy in AngII treated HUVECs probably
   by PDK1/PKC signaling pathway},
Journal = {LIFE SCIENCES},
Year = {2019},
Volume = {233},
Month = {SEP 15},
Abstract = {Aims: Vps15 is an important regulator on the activity of class III PI3K
   in autophagy induction. AngII plays a positive role of autophagy in the
   early protection of endothelial cells. In this study, the expression of
   Vps15 was knocked down using the specific shRNA to investigate the
   effects of Vps15 on cell autophagy, senescence and apoptosis in HUVECs
   stimulated by AngII. The associated cell signaling pathway was also
   explored.
   Materials and methods: MDC staining was applied to show autophagic
   bodies. Cell senescence was detected using beta-galactosidase staining.
   Cell apoptosis was examined by flow cytometry using Annexin V-FITC/PI
   staining. And western blot was used to evaluate the ratio of LC3-II/I
   and the activation of associated cell signaling pathway.
   Key findings: Cell autophagy induced by AngII was inhibited in HUVECs
   transfected with Vps15-shRNA, while cell senescence and apoptosis were
   enhanced. Rescue experiment revealed that cell autophagy was activated
   after Vps15 reexpression, while cell senescence and apoptosis were
   inhibited. Moreover, the phosphorylations of PDK1 and PKC substrates
   were increased after AngII treatment, which were decreased by Vps15
   knockdown. Pretreatment of cells with the inhibitor for PDK1 or PKC
   attenuated cell autophagy after AngII stimulation, yet promoted cell
   senescence and apoptosis. The phosphorylations of both PDK1 and PKC were
   inhibited in cells pretreated with PDK1 inhibitor. Only the activation
   of PKC was inhibited when the inhibitor for pan-PKC was used.
   Significance: These results suggested that Vps15 was critical to the
   protective autophagy in HUVECs induced by AngII, and PDK1/PKC signaling
   pathway was probably involved.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Yu, XS (Corresponding Author), China Med Univ, Affiliated Hosp 1, Gen Practice, Shenyang 110001, Liaoning, Peoples R China.
   Shan, Haiyan; He, Yini; Hao, Sijia; Wang, Bofu; Xu, Ming; Qi, Huimeng; Liu, Shen; Du, Yanmei; Yu, Xiaosong, China Med Univ, Affiliated Hosp 1, Gen Practice, Shenyang 110001, Liaoning, Peoples R China.},
DOI = {10.1016/j.lfs.2019.116701},
Article-Number = {116701},
ISSN = {0024-3205},
EISSN = {1879-0631},
Keywords = {Vps15; Angiotensin II; HUVEC; Autophagy; Senescence},
Keywords-Plus = {SENESCENCE; DISEASE; HEALTH},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {63316575@qq.com},
Affiliations = {China Medical University},
ResearcherID-Numbers = {Chong, Kai Leong/GYA-4637-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81771509, 81200245];
   Science and Technology Project of Liaoning Province {[}20170541046,
   201202263]; Science Foundation Project of Shenyang {[}F16-205-1-42]},
Funding-Text = {The study was supported by grants from the National Natural Science
   Foundation of China (No. 81771509, No. 81200245), the Science and
   Technology Project of Liaoning Province (No. 20170541046, No.
   201202263), and the Science Foundation Project of Shenyang (No.
   F16-205-1-42).},
Cited-References = {Baskaran S, 2014, ELIFE, V3, DOI 10.7554/eLife.05115.
   Donato AJ, 2015, J MOL CELL CARDIOL, V89, P122, DOI 10.1016/j.yjmcc.2015.01.021.
   Flynn JM, 2013, AGING CELL, V12, P851, DOI 10.1111/acel.12109.
   Funderburk SF, 2010, TRENDS CELL BIOL, V20, P355, DOI 10.1016/j.tcb.2010.03.002.
   Gliemann L, 2016, FREE RADICAL BIO MED, V98, P165, DOI 10.1016/j.freeradbiomed.2016.03.037.
   Gstrein T, 2018, NAT NEUROSCI, V21, P207, DOI 10.1038/s41593-017-0053-5.
   He J, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00681.
   Huang J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1268-z.
   Kim BW, 2018, AUTOPHAGY, V14, P2104, DOI 10.1080/15548627.2018.1504716.
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9.
   Kishore R, 2015, J MOL CELL CARDIOL, V89, P203, DOI 10.1016/j.yjmcc.2015.11.004.
   Lekli I, 2017, J CELL MOL MED, V21, P1058, DOI 10.1111/jcmm.13053.
   Li JY, 2016, ONCOTARGET, V7, P86648, DOI 10.18632/oncotarget.13429.
   Li Y, 2018, P NATL ACAD SCI USA, V115, pE10849, DOI 10.1073/pnas.1803377115.
   McManus S, 2016, J BONE MINER RES, V31, P1334, DOI 10.1002/jbmr.2806.
   Mialet-Perez J, 2017, ESSAYS BIOCHEM, V61, P721, DOI 10.1042/EBC20170022.
   Ohashi Y, 2016, AUTOPHAGY, V12, P2129, DOI 10.1080/15548627.2016.1226736.
   Sasaki Y, 2017, INT HEART J, V58, P666, DOI 10.1536/ihj.17-246.
   Shan HY, 2014, APMIS, V122, P985, DOI 10.1111/apm.12242.
   Wang F, 2018, INT J BIOCHEM CELL B, V99, P91, DOI 10.1016/j.biocel.2018.04.005.
   Wang TY, 2018, J CANCER RES CLIN, V144, P2303, DOI 10.1007/s00432-018-2731-4.
   Yan Y, 2009, BIOCHEM J, V417, P747, DOI 10.1042/BJ20081865.
   Zhou LC, 2016, J MOL ENDOCRINOL, V57, pR143, DOI 10.1530/JME-16-0086.},
Number-of-Cited-References = {23},
Times-Cited = {8},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {19},
Journal-ISO = {Life Sci.},
Doc-Delivery-Number = {IV1KG},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000484035300026},
DA = {2026-02-04},
}

@article{ WOS:000485285100001,
Author = {Hou, Ning and Mai, Yunpei and Qiu, Xiaoxia and Yuan, Wenchang and Li,
   Yilang and Luo, Chengfeng and Liu, Yun and Zhang, Guiping and Zhao,
   Ganjiang and Luo, Jian-dong},
Title = {Carvacrol Attenuates Diabetic Cardiomyopathy by Modulating the
   PI3K/AKT/GLUT4 Pathway in Diabetic Mice},
Journal = {FRONTIERS IN PHARMACOLOGY},
Year = {2019},
Volume = {10},
Month = {SEP 12},
Abstract = {Background: Diabetic cardiomyopathy (DCM), a common complication of
   diabetes mellitus, eventually leads to heart failure. Carvacrol is a
   food additive with diverse bioactivities. We aimed to study the
   protective effects and mechanisms of carvacrol in DCM.
   Methods: We used a streptozotocin-induced and db/db mouse model of types
   1 and 2 diabetes mellitus (T1DM and T2DM), respectively. Both study
   groups received daily intraperitoneal injections of carvacrol for 6
   weeks. Cardiac remodeling was evaluated by histological analysis. We
   determined gene expression of cardiac remodeling markers (Nppa and Myh7)
   by quantitative real-time PCR and cardiac function by echocardiography.
   Changes of PI3K/AKT signaling were determined with Western blotting.
   GLUT4 translocation was evaluated by Western blotting and
   immunofluorescence staining.
   Results: Compared with control mice, both T1DM and T2DM mice showed
   cardiac remodeling and left ventricular dysfunction. Carvacrol
   significantly reduced blood glucose levels and suppressed cardiac
   remodeling in mice with T1DM and T2DM. At the end of the treatment
   period, both T1DM and T2DM mice showed lesser cardiac hypertrophy, Nppa
   and Myh7 mRNA expressions, and cardiac fibrosis, compared to mice
   administered only the vehicle. Moreover, carvacrol significantly
   restored PI3K/AKT signaling, which was impaired in mice with T1DM and
   T2DM. Carvacrol increased levels of phosphorylated PI3K, PDK1, AKT, and
   AS160 and inhibited PTEN phosphorylation in mice with T1DM and T2DM.
   Carvacrol treatment promoted GLUT4 membrane translocation in mice with
   T1DM and T2DM. Metformin was used as the positive drug control in T2DM
   mice, and carvacrol showed comparable effects to that of metformin on
   cardiac remodeling and modulation of signaling pathways.
   Conclusion: Carvacrol protected against DCM in mice with T1DM and T2DM
   by restoring PI3K/AKT signaling-mediated GLUT4 membrane translocation
   and is a potential treatment of DCM.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Hou, N; Luo, JD (Corresponding Author), Guangzhou Med Univ, Sch Pharmaceut Sci, Key Lab Mol Target \& Clin Pharmacol, Guangzhou, Guangdong, Peoples R China.
   Hou, N; Luo, JD (Corresponding Author), Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou, Guangdong, Peoples R China.
   Hou, N; Luo, JD (Corresponding Author), Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Key Lab Cardiovasc Dis, Guangzhou Inst Cardiovasc Dis, Guangzhou, Guangdong, Peoples R China.
   Hou, Ning; Mai, Yunpei; Qiu, Xiaoxia; Li, Yilang; Liu, Yun; Zhang, Guiping; Luo, Jian-dong, Guangzhou Med Univ, Sch Pharmaceut Sci, Key Lab Mol Target \& Clin Pharmacol, Guangzhou, Guangdong, Peoples R China.
   Hou, Ning; Mai, Yunpei; Qiu, Xiaoxia; Li, Yilang; Liu, Yun; Zhang, Guiping; Luo, Jian-dong, Guangzhou Med Univ, Affiliated Hosp 5, Guangzhou, Guangdong, Peoples R China.
   Hou, Ning; Mai, Yunpei; Qiu, Xiaoxia; Li, Yilang; Luo, Chengfeng; Liu, Yun; Zhang, Guiping; Zhao, Ganjiang; Luo, Jian-dong, Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou Key Lab Cardiovasc Dis, Guangzhou Inst Cardiovasc Dis, Guangzhou, Guangdong, Peoples R China.
   Mai, Yunpei, Forevergen Biosci Ctr, Dept Med Technol, Guangzhou, Guangdong, Peoples R China.
   Yuan, Wenchang, Guangzhou Med Univ, Dept Clin Lab, Affiliated Hosp 5, Guangzhou, Guangdong, Peoples R China.},
DOI = {10.3389/fphar.2019.00998},
Article-Number = {998},
ISSN = {1663-9812},
Keywords = {diabetes mellitus; cardiac remodelling; carvacrol; cardiac function;
   PI3K/AKT pathway},
Keywords-Plus = {HEART; CARDIOPROTECTION; DYSFUNCTION; EXPRESSION},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {houning@gzhmu.edu.cn
   jiandongluo@hotmail.com},
Affiliations = {Guangzhou Medical University; Guangzhou Medical University; Guangzhou
   Medical University; Guangzhou Medical University},
ResearcherID-Numbers = {Luo, Chengfeng/AAU-7374-2020
   guiping, zhang/E-9127-2018
   },
ORCID-Numbers = {Li, Yilang/0009-0004-3978-097X},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81402928, 81773720,
   81573433]; Guangzhou Education Bureau {[}1201610064]; Guangzhou Science
   and Technology Project {[}201804010490]; Guangzhou Health Science and
   Technology Project {[}20191A011094]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (grant numbers 81402928, 81773720, 81573433), Guangzhou Education
   Bureau (grant number 1201610064), Guangzhou Science and Technology
   Project (grant number 201804010490), and Guangzhou Health Science and
   Technology Project (grant number 20191A011094).},
Cited-References = {Bayramoglu G, 2014, CYTOTECHNOLOGY, V66, P251, DOI 10.1007/s10616-013-9563-5.
   CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765.
   Chenet AL, 2019, NEUROCHEM RES, V44, P884, DOI 10.1007/s11064-019-02724-5.
   Dandamudi S, 2014, J CARD FAIL, V20, P304, DOI 10.1016/j.cardfail.2014.02.007.
   Deng WJ, 2013, J MOL NEUROSCI, V51, P813, DOI 10.1007/s12031-013-0069-6.
   Desrois M, 2004, CARDIOVASC RES, V61, P288, DOI 10.1016/j.cardiores.2003.11.021.
   Ezhumalai M, 2014, MOL CELL BIOCHEM, V385, P23, DOI 10.1007/s11010-013-1810-8.
   Fuentes-Antrás J, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/656795.
   Hou N, 2017, EXP MOL PATHOL, V103, P267, DOI 10.1016/j.yexmp.2017.11.006.
   Huang JP, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-77.
   Jia GH, 2018, DIABETOLOGIA, V61, P21, DOI 10.1007/s00125-017-4390-4.
   Jia GH, 2016, NAT REV ENDOCRINOL, V12, P144, DOI 10.1038/nrendo.2015.216.
   Kim HY, 2011, AM J PHYSIOL-RENAL, V301, pF151, DOI 10.1152/ajprenal.00519.2010.
   Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372.
   Mbese Zintle, 2018, Recent Pat Antiinfect Drug Discov, V13, P207, DOI {[}10.2174/1574891x14666181205111821, 10.2174/1574891X14666181205111821].
   Mueckler M, 2013, MOL ASPECTS MED, V34, P121, DOI 10.1016/j.mam.2012.07.001.
   Murtaza G, 2019, PROG CARDIOVASC DIS, V62, P315, DOI 10.1016/j.pcad.2019.03.003.
   Nemoto S, 2006, CIRC J, V70, P327, DOI 10.1253/circj.70.327.
   Oudit GY, 2009, CARDIOVASC RES, V82, P250, DOI 10.1093/cvr/cvp014.
   Parnas M, 2009, CELL CALCIUM, V45, P300, DOI 10.1016/j.ceca.2008.11.009.
   Qi K, 2018, EXP THER MED, V16, P4817, DOI 10.3892/etm.2018.6755.
   Qin Y, 2016, MOL CELL ENDOCRINOL, V423, P30, DOI 10.1016/j.mce.2016.01.005.
   Sharifi-Rad M, 2018, PHYTOTHER RES, V32, P1675, DOI 10.1002/ptr.6103.
   Shoorei H, 2019, BIOMED PHARMACOTHER, V111, P568, DOI 10.1016/j.biopha.2018.12.054.
   Siddall HK, 2008, BASIC RES CARDIOL, V103, P560, DOI 10.1007/s00395-008-0735-y.
   Szablewski L, 2017, INT J CARDIOL, V230, P70, DOI 10.1016/j.ijcard.2016.12.083.
   Xiao Q, 2012, CARDIOVASC RES, V95, P507, DOI 10.1093/cvr/cvs216.
   Yao H, 2014, AM J CARDIOVASC DRUG, V14, P433, DOI 10.1007/s40256-014-0089-9.
   Yuan X, 2016, DRUG DES DEV THER, V10, P2729, DOI 10.2147/DDDT.S111253.
   Zhao GJ, 2018, J PHARMACOL EXP THER, V366, P458, DOI 10.1124/jpet.118.248369.},
Number-of-Cited-References = {30},
Times-Cited = {78},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {36},
Journal-ISO = {Front. Pharmacol.},
Doc-Delivery-Number = {IW9AH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000485285100001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000484985500021,
Author = {Qin, Wenjuan and Tian, Yun and Zhang, Jing and Liu, Wenjian and Zhou,
   Qiming and Hu, Sheng and Yang, Fei and Lu, Li and Lu, Haijie and Cui,
   Shuzhong and Wen, Lu and Wei, Shaozhong},
Title = {The double inhibition of PDK1 and STAT3-Y705 prevents liver metastasis
   in colorectal cancer},
Journal = {SCIENTIFIC REPORTS},
Year = {2019},
Volume = {9},
Month = {SEP 10},
Abstract = {As a key glycolysis enzyme, the significance of pyruvate dehydrogenase
   kinase 1 (PDK1) in the development of colorectal cancer (CRC) remains
   unknown. This study revealed that the prognosis of CRC patients with
   high levels of PDK1 was poor, and PDK1 knockdown significantly reduced
   liver metastasis of CRC in both nude mice and immune competent BALB/C
   mice. When combined with cryptotanshinone (CPT), an inhibitor of
   STAT3-p-Y705, the liver metastasis was further inhibited. PDK1 knockdown
   obviously increased reactive oxygen species level in anoikis conditions
   and subsequently resulted in an elevated anoikis, but the combination of
   PDK1 knockdown and CPT showed a reduced effect on anoikis. Based on this
   discrepancy, the adherence ability of CRC cells to matrix protein
   fibronectin was further detected. It showed that PDK1 knockdown
   significantly decreased the adherence of CRC cells to fibronectin when
   combined with CPT. These results suggest that inhibition of PDK1 can
   decrease the surviving CRC cells in blood circulation via up-regulation
   of anoikis, and inhibition of STAT3-p-Y705 can prevent it to settle down
   on the liver premetastatic niche, which ultimately reduces liver
   metastasis.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Wei, SZ (Corresponding Author), Huazhong Univ Sci \& Technol, Tongji Med Coll, Hubei Canc Hosp, Dept Gastrointestinal Surg, Wuhan, Hubei, Peoples R China.
   Wei, SZ (Corresponding Author), Huazhong Univ Sci \& Technol, Tongji Med Coll, Hubei Canc Hosp, Colorectal Canc Ctr Hubei Prov, Wuhan, Hubei, Peoples R China.
   Wen, L (Corresponding Author), Huazhong Univ Sci \& Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China.
   Qin, Wenjuan; Lu, Haijie, Xiamen Univ, Zhongshan Hosp, Dept Radiat Oncol, Xiamen, Fujian, Peoples R China.
   Tian, Yun; Cui, Shuzhong, Guangzhou Med Univ, Canc Hosp, Dept Abdominal Surg, Guangzhou, Guangdong, Peoples R China.
   Zhang, Jing; Hu, Sheng, Huazhong Univ Sci \& Technol, Hubei Canc Hosp, Dept Med Oncol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   Liu, Wenjian, Sun Yat Sen Canc Ctr, Dept Hematol Oncol, Guangzhou, Guangdong, Peoples R China.
   Zhou, Qiming, Sixth Peoples Hosp, Dept Oncol, Shenzhen, Guangdong, Peoples R China.
   Yang, Fei, Huazhong Univ Sci \& Technol, Hubei Canc Hosp, Dept Pathol, Tongji Med Coll, Wuhan, Hubei, Peoples R China.
   Lu, Li; Wei, Shaozhong, Huazhong Univ Sci \& Technol, Tongji Med Coll, Hubei Canc Hosp, Dept Gastrointestinal Surg, Wuhan, Hubei, Peoples R China.
   Lu, Li; Wei, Shaozhong, Huazhong Univ Sci \& Technol, Tongji Med Coll, Hubei Canc Hosp, Colorectal Canc Ctr Hubei Prov, Wuhan, Hubei, Peoples R China.
   Wen, Lu, Huazhong Univ Sci \& Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China.},
DOI = {10.1038/s41598-019-49480-8},
Article-Number = {12973},
ISSN = {2045-2322},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE; METABOLIC SWITCH; TUMOR; ONCOGENE; SURVIVAL;
   CELLS; RESECTION; PATHWAYS; ANOIKIS},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {wenlu2808@126.com
   weishaozhong1@163.com},
Affiliations = {Xiamen University; Guangzhou Medical University; Huazhong University of
   Science \& Technology; Huazhong University of Science \& Technology;
   Huazhong University of Science \& Technology; Huazhong University of
   Science \& Technology; Huazhong University of Science \& Technology},
Funding-Acknowledgement = {Key Project of Health and Family Commission of Hubei Province
   {[}JX6A06]; Middle-aged and Young Medical Core Talent Project of Wuhan
   {[}59]; Natural Science Foundation of Hubei Province, China
   {[}2017CFB459]; Natural Science Foundation of China {[}81602721]},
Funding-Text = {This study was supported in part by grants from the Key Project of
   Health and Family Commission of Hubei Province (JX6A06), Middle-aged and
   Young Medical Core Talent Project of Wuhan (59, 2016), the Natural
   Science Foundation of Hubei Province, China (2017CFB459), and the
   Natural Science Foundation of China (81602721).},
Cited-References = {Akiyama Y, 2015, CANCER GENOM PROTEOM, V12, P133.
   Andersen JL, 2013, MOL CELL, V49, P399, DOI 10.1016/j.molcel.2012.12.026.
   Barbazán J, 2017, CANCER RES, V77, P3431, DOI 10.1158/0008-5472.CAN-16-1917.
   Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789.
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004.
   Dai ZJ, 2016, TUMOR BIOL, V37, P5145, DOI 10.1007/s13277-015-4107-6.
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104.
   Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X.
   Giannoni E, 2014, ANTIOXID REDOX SIGN, V20, P2011, DOI 10.1089/ars.2013.5525.
   Guadamillas MC, 2011, J CELL SCI, V124, P3189, DOI 10.1242/jcs.072165.
   Han XY, 2019, J CANCER, V10, P843, DOI 10.7150/jca.27856.
   House MG, 2011, ANN SURG, V254, P851, DOI 10.1097/SLA.0b013e31822f4f88.
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43.
   Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012.
   Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27.
   Koukourakis MI, 2006, CANCER RES, V66, P632, DOI 10.1158/0008-5472.CAN-05-3260.
   Leclerc D, 2017, BRIT J CANCER, V116, P930, DOI 10.1038/bjc.2017.38.
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122.
   Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394.
   Reticker-Flynn NE, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2128.
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1.
   Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268.
   Srivastava J, 2016, MOL CARCINOGEN, V55, P1889, DOI 10.1002/mc.22438.
   Strowitzki MJ, 2019, BRIT J CANCER, V120, P675, DOI 10.1038/s41416-019-0406-9.
   Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833.
   van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002.
   Wake MS, 2015, FEBS J, V282, P2600, DOI 10.1111/febs.13285.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.
   Zhou ZX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8984.},
Number-of-Cited-References = {36},
Times-Cited = {28},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {10},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {IW4YK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000484985500021},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000486048800001,
Author = {Roula, David and Theiler, Anna and Luschnig, Petra and Sturm, Gunter J.
   and Tomazic, Peter V. and Marsche, Gunther and Heinemann, Akos and
   Sturm, Eva M.},
Title = {Apolipoprotein A-IV acts as an endogenous anti-inflammatory protein and
   is reduced in treatment-naive allergic patients and allergen-challenged
   mice},
Journal = {ALLERGY},
Year = {2020},
Volume = {75},
Number = {2},
Pages = {392-402},
Month = {FEB},
Abstract = {Background Recent studies pointed to a crucial role for apolipoproteins
   in the pathogenesis of inflammatory diseases. However, the role of
   apolipoprotein-IV (ApoA-IV) in allergic inflammation has not been
   addressed thoroughly thus far. Objective Here, we explored the
   anti-inflammatory effects and underlying signaling pathways of ApoA-IV
   on eosinophil effector function in vitro and in vivo. Methods Migratory
   responsiveness, Ca2+-flux and apoptosis of human peripheral blood
   eosinophils were assessed in vitro. Allergen-driven airway inflammation
   was assessed in a mouse model of acute house dust mite-induced asthma.
   ApoA-IV serum levels were determined by ELISA. Results Recombinant
   ApoA-IV potently inhibited eosinophil responsiveness in vitro as
   measured by Ca2+-flux, shape change, integrin (CD11b) expression, and
   chemotaxis. The underlying molecular mechanism involved the activation
   of Rev-ErbA-alpha and induced a PI3K/PDK1/PKA-dependent signaling
   cascade. Systemic application of ApoA-IV prevented airway
   hyperresponsiveness (AHR) and airway eosinophilia in mice following
   allergen challenge. ApoA-IV levels were decreased in serum from allergic
   patients compared to healthy controls. Conclusion Our data suggest that
   ApoA-IV is an endogenous anti-inflammatory protein that potently
   suppresses effector cell functions in eosinophils. Thus, exogenously
   applied ApoA-IV may represent a novel pharmacological approach for the
   treatment of allergic inflammation and other eosinophil-driven
   disorders.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Sturm, EM (Corresponding Author), Med Univ Graz, Otto Loewi Res Ctr Vasc Biol Immunol \& Inflammat, Div Pharmacol, Univ Pl 4, A-8010 Graz, Austria.
   Roula, David; Theiler, Anna; Luschnig, Petra; Marsche, Gunther; Heinemann, Akos; Sturm, Eva M., Med Univ Graz, Otto Loewi Res Ctr Vasc Biol Immunol \& Inflammat, Div Pharmacol, Univ Pl 4, A-8010 Graz, Austria.
   Sturm, Gunter J., Med Univ Graz, Dept Dermatol \& Venerol, Graz, Austria.
   Sturm, Gunter J., Allergy Outpatient Clin Reumannpl, Vienna, Austria.
   Tomazic, Peter V., Med Univ Graz, ENT Univ Hosp, Graz, Austria.},
DOI = {10.1111/all.14022},
EarlyAccessDate = {SEP 2019},
ISSN = {0105-4538},
EISSN = {1398-9995},
Keywords = {allergic inflammation; apolipoprotein A-IV; chronic rhinosinusitis;
   eosinophils; house dust mite-induced asthma model; PI3-kinase;
   Rev-Erb-alpha},
Keywords-Plus = {HIGH-DENSITY-LIPOPROTEIN; REV-ERB-ALPHA; FREE-CHOLESTEROL ACCUMULATION;
   TOLL-LIKE RECEPTORS; PROINFLAMMATORY CYTOKINES; GENE-EXPRESSION;
   EOSINOPHILS; ASTHMA; CELLS; DISEASE},
Research-Areas = {Allergy; Immunology},
Web-of-Science-Categories  = {Allergy; Immunology},
Author-Email = {eva.sturm@medunigraz.at},
Affiliations = {Medical University of Graz; Medical University of Graz; Medical
   University of Graz},
ORCID-Numbers = {Roula, David/0000-0003-0472-6784
   Marsche, Gunther/0000-0002-2422-5381
   Heinemann, Akos/0000-0002-8554-2372
   Sturm, Gunter/0000-0002-7245-121X},
Funding-Acknowledgement = {Austrian science fund (DK-MOLIN) {[}FWF W1241]; DOC Fellowship of the
   Austrian Academy of Sciences at the Otto Loewi Research Center for
   Vascular Biology, Immunology and Inflammation, Division of Pharmacology,
   Medical University of Graz; Austrian Science Fund (FWF) {[}W1241]
   Funding Source: Austrian Science Fund (FWF)},
Funding-Text = {DR and AT were funded by the Austrian science fund (FWF W1241,
   DK-MOLIN). AT is recipient of a DOC Fellowship of the Austrian Academy
   of Sciences at the Otto Loewi Research Center for Vascular Biology,
   Immunology and Inflammation, Division of Pharmacology, Medical
   University of Graz.},
Cited-References = {Barochia AV, 2015, AM J RESP CRIT CARE, V191, P990, DOI 10.1164/rccm.201411-1990OC.
   Bondeson J, 1996, GEN PHARMACOL, V27, P943, DOI 10.1016/0306-3623(95)02049-7.
   BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q.
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655.
   Castro M, 2015, LANCET RESP MED, V3, P355, DOI {[}10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8].
   Curcic S, 2015, BBA-MOL CELL BIOL L, V1851, P184, DOI 10.1016/j.bbalip.2014.11.010.
   Dai Y, 2008, LUPUS, V17, P799, DOI 10.1177/0961203308089444.
   Dieplinger H, 2009, CANCER EPIDEM BIOMAR, V18, P1127, DOI 10.1158/1055-9965.EPI-08-0653.
   Duan RS, 2006, EXP NEUROL, V202, P373, DOI 10.1016/j.expneurol.2006.06.013.
   Duez H, 2009, J APPL PHYSIOL, V107, P1972, DOI 10.1152/japplphysiol.00570.2009.
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397.
   Frei RB, 2016, ALLERGY, V71, P944, DOI 10.1111/all.12858.
   Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423.
   GHISELLI G, 1986, J LIPID RES, V27, P813.
   Gibbs JE, 2012, P NATL ACAD SCI USA, V109, P582, DOI 10.1073/pnas.1106750109.
   Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X.
   Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5.
   Grünig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261.
   Guo DK, 2019, ACTA PHARMACOL SIN, V40, P26, DOI 10.1038/s41401-018-0064-0.
   Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x.
   Hogan SP, 2007, INT ARCH ALLERGY IMM, V143, P3, DOI 10.1159/000101398.
   Hutcheson PS, 2010, AM J RHINOL ALLERGY, V24, P405, DOI 10.2500/ajra.2010.24.3533.
   Kim M, 2006, ONCOL REP, V16, P663.
   Kojima Fumiaki, 2006, Expert Rev Clin Immunol, V2, P277, DOI 10.1586/1744666X.2.2.277.
   Konya V, 2013, J ALLERGY CLIN IMMUN, V131, P532, DOI 10.1016/j.jaci.2012.05.008.
   Konya V, 2011, EUR J IMMUNOL, V41, P2379, DOI 10.1002/eji.201141460.
   Lamina C, 2016, HUM MOL GENET, V25, P3635, DOI 10.1093/hmg/ddw211.
   Lefevre M, 2000, INT J OBESITY, V24, P945, DOI 10.1038/sj.ijo.0801260.
   Li XM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41289.
   Li XM, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0069-0.
   Li XM, 2014, J BIOL CHEM, V289, P2396, DOI 10.1074/jbc.M113.511766.
   Liagre B, 1997, FEBS LETT, V414, P159, DOI 10.1016/S0014-5793(97)00904-6.
   Liu M, 2004, AM J PHYSIOL-ENDOC M, V287, pE366, DOI 10.1152/ajpendo.00448.2003.
   Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183.
   MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146.
   Makino Y, 2010, J ALLERGY CLIN IMMUN, V126, P1163, DOI 10.1016/j.jaci.2010.06.031.
   Murphy AJ, 2008, ARTERIOSCL THROM VAS, V28, P2071, DOI 10.1161/ATVBAHA.108.168690.
   Murphy AJ, 2011, ARTERIOSCL THROM VAS, V31, P1333, DOI 10.1161/ATVBAHA.111.226258.
   Nagel G, 2009, INT ARCH ALLERGY IMM, V149, P259, DOI 10.1159/000199722.
   Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435.
   Nandedkar SD, 2011, J LIPID RES, V52, P499, DOI 10.1194/jlr.M012724.
   Navarro MA, 2005, CYTOKINE, V31, P52, DOI 10.1016/j.cyto.2005.03.002.
   Ostos MA, 2001, ARTERIOSCL THROM VAS, V21, P1023, DOI 10.1161/01.ATV.21.6.1023.
   Ota VK, 2011, J INVEST MED, V59, P966, DOI 10.2310/JIM.0b013e31822467cd.
   Pariollaud M, 2018, J CLIN INVEST, V128, P2281, DOI 10.1172/JCI93910.
   Park SW, 2013, CLIN EXP ALLERGY, V43, P914, DOI 10.1111/cea.12143.
   Park YM, 2010, ALLERGY ASTHMA IMMUN, V2, P87, DOI 10.4168/aair.2010.2.2.87.
   Parra A, 1999, J INVEST ALLERG CLIN, V9, P27.
   Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016.
   Raines EW, 2005, J LIPID RES, V46, P1081, DOI 10.1194/jlr.R500004-JLR200.
   Rauniyar N, 2017, BIOMARK INSIGHTS, V12, DOI 10.1177/1177271917710948.
   Recalde D, 2004, ARTERIOSCL THROM VAS, V24, P756, DOI 10.1161/01.ATV.0000119353.03690.22.
   Richardson D, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2401.
   Sanecka A, 2012, MOL IMMUNOL, V50, P66, DOI 10.1016/j.molimm.2011.12.003.
   Sato S, 2014, J IMMUNOL, V192, P407, DOI 10.4049/jimmunol.1301982.
   Schratl P, 2006, EUR J IMMUNOL, V36, P2401, DOI 10.1002/eji.200535672.
   Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057.
   Shen L, 2017, BIOCHEM BIOPH RES CO, V494, P152, DOI 10.1016/j.bbrc.2017.10.063.
   Shi HZ, 2004, ALLERGY, V59, P428, DOI 10.1046/j.1398-9995.2003.00405.x.
   Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x.
   Simon D, 2007, J ALLERGY CLIN IMMUN, V119, P1291, DOI 10.1016/j.jaci.2007.02.010.
   Spoelstra FM, 2001, CLIN EXP ALLERGY, V31, P808, DOI 10.1046/j.1365-2222.2001.01111.x.
   Steiner G, 1999, RHEUMATOLOGY, V38, P202, DOI 10.1093/rheumatology/38.3.202.
   Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006.
   Sturm EM, 2008, J IMMUNOL, V181, P7273, DOI 10.4049/jimmunol.181.10.7273.
   Sturm EM, 2015, EUR J IMMUNOL, V45, P1548, DOI 10.1002/eji.201445196.
   Sun Y, 2009, CIRC RES, V104, P455, DOI 10.1161/CIRCRESAHA.108.182568.
   Svensson L, 2004, EUR J IMMUNOL, V34, P1744, DOI 10.1002/eji.200324798.
   Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487, DOI 10.1164/ajrccm.159.2.9805115.
   Tso P, 1999, J NUTR, V129, P1503, DOI 10.1093/jn/129.8.1503.
   Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233.
   Walsh GM, 2001, CLIN EXP ALLERGY, V31, P351, DOI 10.1046/j.1365-2222.2001.01032.x.
   Watt A. P., 2005, Current Drug Targets - Inflammation and Allergy, V4, P415, DOI 10.2174/1568010054526313.
   Wedemeyer J, 2008, BEST PRACT RES CL GA, V22, P537, DOI 10.1016/j.bpg.2007.12.001.
   Wittenberg M, 2017, ALLERGY, V72, P1801, DOI 10.1111/all.13176.
   Woerly G, 1999, INT ARCH ALLERGY IMM, V118, P95, DOI 10.1159/000024038.
   Wong WR, 2003, CIRC RES, V92, P969, DOI 10.1161/01.RES.0000069688.94567.7A.
   Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151.
   Yao XL, 2011, J IMMUNOL, V186, P576, DOI 10.4049/jimmunol.1001534.
   Yao XL, 2010, AM J RESP CRIT CARE, V182, P1228, DOI 10.1164/rccm.201002-0308OC.
   Yvan-Charvet L, 2008, CIRCULATION, V118, P1837, DOI 10.1161/CIRCULATIONAHA.108.793869.
   Zhang YP, 2017, BIOCHEM BIOPH RES CO, V487, P327, DOI 10.1016/j.bbrc.2017.04.058.},
Number-of-Cited-References = {82},
Times-Cited = {37},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Allergy},
Doc-Delivery-Number = {KS3MQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000486048800001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000485591400001,
Author = {Yang, Lei-Lei and Zhang, Peng-Fei and Zhang, Tian-Yu and Shen, Wei and
   Zhao, Yong and Yin, Shen},
Title = {Ortho-phenylphenol exposure impairs porcine sperm motility through
   AMPK/AKT signaling pathway},
Journal = {ENVIRONMENTAL AND MOLECULAR MUTAGENESIS},
Year = {2019},
Volume = {60},
Number = {9},
Pages = {830-836},
Month = {DEC},
Abstract = {Ortho-phenylphenol (OPP), as an active ingredient of disinfectants, has
   been worldwide utilized as fungicides and antibacterial agents in
   hospital, agriculture, wood preservation, and veterinary products.
   However, little is known about the toxic effects of OPP on male
   reproduction, especially sperm motility, and the underlying mechanisms.
   In this study, we chose porcine sperms as in vitro model to investigate
   the effects and mechanisms of OPP exposure on sperm motility. Our
   results indicated that porcine sperm motility decreases significantly in
   a dose-dependent manner after exposed to OPP. Additionally, ATP
   synthesis deficiency was revealed by downregulation of ATP synthase
   subunit beta and adenosine 5 `-monophosphate-activated protein kinase
   expression. Furthermore, OPP disturbed the expression of TP53 and PTEN,
   which contributed to AKT pathway deactivation. OPP exposure also
   disrupted platelet-derived growth factor receptor A expression, which
   further inhibited 3-phosphoinositide-dependent protein kinase 1
   activation, resulting in protein kinase B and pyruvate dehydrogenase
   phosphatase catalytic subunit 1 deactivation. In conclusion, these
   observations suggest that OPP exposure decreases porcine sperm motility
   by disturbing the AMPK/AKT signaling pathway. Environ. Mol. Mutagen.
   2019. (c) 2019 Wiley Periodicals, Inc.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Yin, S (Corresponding Author), Qingdao Agr Univ, Changcheng Rd 700, Qingdao 266109, Shandong, Peoples R China.
   Yang, Lei-Lei; Zhang, Peng-Fei; Zhang, Tian-Yu; Shen, Wei; Zhao, Yong; Yin, Shen, Qingdao Agr Univ, Coll Life Sci, Inst Reprod Sci, Key Lab Anim Reprod \& Germplasm Enhancement Univ, Qingdao, Shandong, Peoples R China.},
DOI = {10.1002/em.22324},
EarlyAccessDate = {SEP 2019},
ISSN = {0893-6692},
EISSN = {1098-2280},
Keywords = {AMPK; AKT pathway; ortho-phenylphenol; PDP1-PDK1; porcine sperm motility},
Keywords-Plus = {SULFIDE AND/OR AMMONIA; O-PHENYLPHENOL; MECHANISMS; GLYCOLYSIS; SODIUM;
   PTEN; CAPACITATION; CYTOTOXICITY; INHIBITION; INDUCTION},
Research-Areas = {Environmental Sciences \& Ecology; Genetics \& Heredity; Toxicology},
Web-of-Science-Categories  = {Environmental Sciences; Genetics \& Heredity; Toxicology},
Author-Email = {syin@qau.edu.cn},
Affiliations = {Qingdao Agricultural University},
ResearcherID-Numbers = {Yang, Lei-Lei/AAM-4080-2021
   },
ORCID-Numbers = {Zhang, Pengfei/0000-0002-7090-0325
   Yang, Lei-Lei/0000-0002-5082-2075
   Yin, Shen/0000-0003-4792-7885},
Funding-Acknowledgement = {High-level Personnel Scientific Research Fund of Qingdao Agricultural
   University {[}6631115025]; National Key Research and Development Program
   of China {[}2018YFC1003400]; National Natural Science Foundation of
   China {[}31571550]},
Funding-Text = {Grant sponsor: High-level Personnel Scientific Research Fund of Qingdao
   Agricultural University; Grant number: 6631115025.Grant sponsor:
   National Key Research and Development Program of China; Grant number:
   2018YFC1003400.Grant sponsor: National Natural Science Foundation of
   China; Grant number: 31571550.},
Cited-References = {Appel KE, 2000, ARCH TOXICOL, V74, P61, DOI 10.1007/s002040050654.
   Asano A, 2010, PROTEOMICS, V10, P3494, DOI 10.1002/pmic.201000002.
   Bomhard EM, 2002, CRIT REV TOXICOL, V32, P551, DOI 10.1080/20024091064318.
   Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004.
   Davoren M, 2006, TOXICOL IN VITRO, V20, P1190, DOI 10.1016/j.tiv.2006.03.005.
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115.
   Freitas MJ, 2017, BIOL REPROD, V96, P2, DOI 10.1095/biolreprod.116.144337.
   Freyberger A, 1998, ARCH TOXICOL, V72, P637, DOI 10.1007/s002040050554.
   Galantino-Homer HL, 2004, MOL REPROD DEV, V67, P487, DOI 10.1002/mrd.20034.
   Garg P, 2012, RETINA-J RET VIT DIS, V32, P856, DOI 10.1097/IAE.0b013e318236e3d7.
   Hereng TH, 2011, HUM REPROD, V26, P3249, DOI 10.1093/humrep/der317.
   HIRAGA K, 1984, FOOD CHEM TOXICOL, V22, P865, DOI 10.1016/0278-6915(84)90166-2.
   de Llera AH, 2015, MOL HUM REPROD, V21, P31, DOI 10.1093/molehr/gau091.
   Jang HJ, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-411.
   Kim SA, 2012, BIOCHEM BIOPH RES CO, V425, P866, DOI 10.1016/j.bbrc.2012.07.165.
   Kitagishi Y, 2013, INT J MOL MED, V31, P511, DOI 10.3892/ijmm.2013.1235.
   Lehti MS, 2017, BIOL REPROD, V97, P522, DOI 10.1093/biolre/iox096.
   Li CJ, 2016, ANIM REPROD SCI, V173, P1, DOI 10.1016/j.anireprosci.2016.08.008.
   McKnight K, 2014, SCIENCE, V344, P754, DOI 10.1126/science.1250598.
   Miki K, 2004, P NATL ACAD SCI USA, V101, P16501, DOI 10.1073/pnas.0407708101.
   Miki Kiyoshi, 2007, Soc Reprod Fertil Suppl, V65, P309.
   Mukai C, 2004, BIOL REPROD, V71, P540, DOI 10.1095/biolreprod.103.026054.
   NAKAGAWA Y, 1988, ARCH TOXICOL, V62, P452, DOI 10.1007/BF00288349.
   Nixon E, 2017, J APPL TOXICOL, V37, P508, DOI 10.1002/jat.3380.
   Paoli D, 2011, FERTIL STERIL, V95, P2315, DOI 10.1016/j.fertnstert.2011.03.059.
   Pereira R, 2017, ASIAN J ANDROL, V19, P5, DOI 10.4103/1008-682X.167716.
   Piomboni P, 2012, INT J ANDROL, V35, P109, DOI 10.1111/j.1365-2605.2011.01218.x.
   Reid AT, 2011, ASIAN J ANDROL, V13, P88, DOI 10.1038/aja.2010.74.
   Ren DJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002102.
   Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027.
   Routledge EJ, 1997, J BIOL CHEM, V272, P3280, DOI 10.1074/jbc.272.6.3280.
   Stouten H, 1998, J APPL TOXICOL, V18, P261, DOI 10.1002/(SICI)1099-1263(199807/08)18:4<261::AID-JAT505>3.0.CO;2-9.
   Swegen A, 2016, BIOL REPROD, V95, DOI 10.1095/biolreprod.116.142687.
   TAYAMANAWAI S, 1984, MUTAT RES, V141, P95, DOI 10.1016/0165-7992(84)90017-4.
   Tourmente M, 2015, J BIOL CHEM, V290, P20613, DOI 10.1074/jbc.M115.664813.
   Walton K, 1999, FOOD CHEM TOXICOL, V37, P1175, DOI 10.1016/S0278-6915(99)00107-6.
   Yang LL, 2018, TOXICOL LETT, V285, P20, DOI 10.1016/j.toxlet.2017.12.019.
   Zhang HQ, 2013, ASIAN PAC J CANCER P, V14, P4685, DOI 10.7314/APJCP.2013.14.8.4685.
   Zhang TY, 2018, TOXICOL APPL PHARM, V340, P49, DOI 10.1016/j.taap.2017.12.011.
   Zhao Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37884.},
Number-of-Cited-References = {40},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Environ. Mol. Mutagen.},
Doc-Delivery-Number = {JM1JR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000485591400001},
DA = {2026-02-04},
}

@article{ WOS:000485773800001,
Author = {Wang, Jing-Jing and Siu, Michelle K. and Jiang, Yu-Xin and Leung, Thomas
   H. and Chan, David W. and Cheng, Ran-Ran and Cheung, Annie N. and Ngan,
   Hextan Y. and Chan, Karen K.},
Title = {Aberrant upregulation of PDK1 in ovarian cancer cells impairs
   CD8+ T cell function and survival through elevation of PD-L1},
Journal = {ONCOIMMUNOLOGY},
Year = {2019},
Volume = {8},
Number = {11},
Month = {NOV 2},
Abstract = {Blockade of the programmed cell death 1(PD-1)/PD-1 ligand-1(PD-L1)
   pathway has been exploited therapeutically in many cancer types.
   Upregulation of PD-L1 in tumor cells contributes to malignancy through
   suppression of the T cell-mediated antitumor response. Pyruvate
   dehydrogenase kinase 1 (PDK1), a glycolytic gate-keeping enzyme, is also
   known to promote tumor development. Here, we have uncovered a mechanism
   of regulation of PD-L1 by PDK1 through activation of c-Jun-NH2-kinase
   (JNK)-c-Jun in ovarian cancer cells. Elevated PDK1 expression was
   correlated with that of PD-L1 in the TCGA ovarian cancer dataset and
   ovarian cancer tissue array. Overexpression of PDK1 in ovarian cancer
   cells impaired CD8(+) T cell function by suppressing IFN-gamma secretion
   through the PD-1/PD-L1 pathway. Conversely, knockdown of PDK1 in ovarian
   cancer cells relieved suppression of CD8(+) T cell function. CD8(+) T
   cell apoptosis induced by binding of PD-1 with PD-L1 was increased after
   co-culture with ovarian cancer cells overexpressing PDK1, while
   depletion of PDK1 exerted the opposite effect. In vivo experiments
   revealed synergistic improved overall survival and enhanced inhibition
   of tumor growth upon co-treatment with dichloroacetate (DCA), a PDK
   inhibitor, and PD-L1 antibody, accompanied by increased IFN-gamma
   secretion by monocytes infiltrating tumor islets. Moreover, PDK1
   expression and CD8(+) T cell infiltration were inversely correlated in
   the ovarian cancer tissue array. Our collective findings provide a novel
   explanation of how PDK1 contributes to upregulation of PD-L1 in ovarian
   cancer and highlight its potential as a target therapeutic molecule that
   cooperates with the immune checkpoint blockade.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Chan, KK (Corresponding Author), Queen Mary Hosp, Dept Obstet \& Gynaecol, Pokfulam, 6-F Professorial Block, Hong Kong, Peoples R China.
   Wang, Jing-Jing; Siu, Michelle K.; Jiang, Yu-Xin; Leung, Thomas H.; Chan, David W.; Cheng, Ran-Ran; Ngan, Hextan Y.; Chan, Karen K., Univ Hong Kong, Dept Obstet \& Gynaecol, Hong Kong, Peoples R China.
   Cheung, Annie N., Univ Hong Kong, Dept Pathol, Hong Kong, Peoples R China.},
DOI = {10.1080/2162402X.2019.1659092},
EarlyAccessDate = {SEP 2019},
Article-Number = {1659092},
ISSN = {2162-402X},
Keywords = {Ovarian cancer; PDK1; PD-L1; PD-1; CD8(+) T cell},
Keywords-Plus = {ANTI-PD-1 ANTIBODY; LUNG-CANCER; LACTIC-ACID; EXPRESSION; KINASE;
   SAFETY; INFILTRATION; ACTIVATION; GLYCOLYSIS; PHENOTYPE},
Research-Areas = {Oncology; Immunology},
Web-of-Science-Categories  = {Oncology; Immunology},
Author-Email = {kklchan@hku.hk},
Affiliations = {University of Hong Kong; University of Hong Kong},
ResearcherID-Numbers = {JIANG, Yuxin/AAB-9309-2022
   Cheng, Ranran/HGA-8919-2022
   Chan, David/O-9896-2018},
ORCID-Numbers = {Ngan, Hextan Y S/0000-0003-3945-159X
   Chan, David/0000-0002-6951-3467},
Funding-Acknowledgement = {University of Hong Kong {[}HKU 17101414]; Hong Kong Research Grants
   Council General Research Fund {[}HKU 17101414]; Wong Check She
   Charitable Foundation; Department of Obstetrics and Gynecology},
Funding-Text = {This research was jointly funded by the University of Hong Kong and the
   Hong Kong Research Grants Council General Research Fund {[}HKU
   17101414], the Wong Check She Charitable Foundation and the Research
   Fund from the Department of Obstetrics and Gynecology.},
Cited-References = {Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296.
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694.
   Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011.
   Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016.
   Chiyoda T, 2017, CANCER PREV RES, V10, P255, DOI 10.1158/1940-6207.CAPR-16-0281.
   Disis ML, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15\_suppl.5533.
   Dong H, 2002, NAT REV IMMUNOL, V2, P545.
   Drakes ML, 2018, J OVARIAN RES, V11, DOI 10.1186/s13048-018-0414-z.
   Feng J, 2017, ONCOGENE, V36, P5829, DOI 10.1038/onc.2017.188.
   Golias T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31146.
   Györffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329.
   Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104.
   Hamanishi J, 2015, J CLIN ONCOL, V33, P4015, DOI 10.1200/JCO.2015.62.3397.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Huang YW, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009380.
   Hwang WT, 2012, GYNECOL ONCOL, V124, P192, DOI 10.1016/j.ygyno.2011.09.039.
   Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001.
   Jiang XF, 2013, CLIN CANCER RES, V19, P598, DOI 10.1158/1078-0432.CCR-12-2731.
   Juneja VR, 2017, J EXP MED, V214, P895, DOI 10.1084/jem.20160801.
   Kim J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30277-0.
   Kouidhi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00270.
   Langer CJ, 2016, LANCET ONCOL, V17, P1497, DOI 10.1016/S1470-2045(16)30498-3.
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009.
   Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482.
   Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630.
   Ma GZ, 2018, CLIN CHIM ACTA, V482, P101, DOI 10.1016/j.cca.2018.03.038.
   Madore J, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12340.
   Mandai M, 2016, INT J CLIN ONCOL, V21, P456, DOI 10.1007/s10147-016-0968-y.
   Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761.
   Matsuo K, 2018, GYNECOL ONCOL REP, V25, P98, DOI 10.1016/j.gore.2018.06.011.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Neff RT, 2017, THER ADV MED ONCOL, V9, P519, DOI 10.1177/1758834017714993.
   Ohashi T, 2013, INT J CANCER, V133, P1107, DOI 10.1002/ijc.28114.
   Ottensmeier CH, 2016, CANCER RES, V76, P4136, DOI 10.1158/0008-5472.CAN-15-3121.
   Palsson-McDermott EM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01300.
   Qian YG, 2008, CANCER INVEST, V26, P816, DOI 10.1080/07357900801941852.
   Quezada SA, 2011, IMMUNOL REV, V241, P104, DOI 10.1111/j.1600-065X.2011.01007.x.
   Ramus SJ, 2009, MOL ONCOL, V3, P138, DOI 10.1016/j.molonc.2009.02.001.
   Schütz F, 2017, ONCOL RES TREAT, V40, P294, DOI 10.1159/000464353.
   Seth P, 2017, CANCER RES, V77, P3632, DOI 10.1158/0008-5472.CAN-16-2938.
   Shepherd TG, 2015, NAT PROTOC, V10, P1457, DOI 10.1038/nprot0915-1457b.
   Singer K, 2011, INT J CANCER, V128, P2085, DOI 10.1002/ijc.25543.
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001.
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690.
   Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456.
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954.
   Wang Z, 2018, CLIN EXP MED, V18, P165, DOI 10.1007/s10238-018-0488-3.
   Xu SH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11406.
   Zerdes I, 2018, ONCOGENE, V37, P4639, DOI 10.1038/s41388-018-0303-3.
   Zhang JY, 2012, AM J CANCER RES, V2, P691.
   Zhang SL, 2018, EUR J PHARM SCI, V123, P43, DOI 10.1016/j.ejps.2018.07.026.
   Zhang YL, 2004, NATURE, V430, P793, DOI 10.1038/nature02764.},
Number-of-Cited-References = {52},
Times-Cited = {35},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {27},
Journal-ISO = {OncoImmunology},
Doc-Delivery-Number = {IZ4WS},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000485773800001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000477804500088,
Author = {He, Junlin and Yu, Si and Guo, Chuanjie and Tan, Lu and Song,
   Xiaominting and Wang, Miao and Wu, Jing and Long, Yuling and Gong,
   Daoyin and Zhang, Ruoqi and Can, Zhixing and Li, Yuzhi and Peng, Cheng},
Title = {Polyphyllin I induces autophagy and cell cycle arrest via inhibiting
   PDK1/Akt/mTOR signal and downregulating cyclin B1 in human gastric
   carcinoma HGC-27 cells},
Journal = {BIOMEDICINE \& PHARMACOTHERAPY},
Year = {2019},
Volume = {117},
Month = {SEP},
Abstract = {Paris polyphylla. is a traditional medicinal herb that has long been
   used to prevent cancer in many Asian countries. Polyphyllin I (PPI), an
   important bioactive constituent of Paris polyphylla, has been found to
   exhibit a wide variety of anticancer activities in many types of cancer
   cells. However, the effects of PPI on human gastric carcinoma cells and
   its mechanism of action remain unclear. In this study, we examined the
   effective anti-gastric carcinoma activity of PPI and its underlying
   mechanism of action in HGC-27 cells. In vitro, sub-micromolar
   concentrations of PPI inhibited HGC-27 cell proliferation with an IC50
   of 0.34 +/- 0.06 mu M after a 72-h treatment. In vivo, 3 mg/kg PPI
   significantly inhibited proliferation of HGC-27 tumor cells, with a
   78.8\% inhibition rate compared to paclitaxel, and demonstrated higher
   safety. Analysis of MDC and mGFP-LC3 fluorescence, Western blotting and
   flow cytometry indicated that PPI induced cell cycle arrest in HGC-27
   cells by promoting the conversion of LC3-I to LC3-II and by
   downregulating cyclin B1. Furthermore, Western blotting showed that PPI
   inhibited the autophagy-regulating PDK1/Akt/mTOR signaling pathway in
   vitro and in vivo. In addition, immunohistochemistry and TUNEL staining
   revealed that PPI decreased Ki67 expression and increased the percentage
   of apoptotic cells in HGC-27 xenograft tumors. These data indicate that
   PPI is an PDK1/Akt/mTOR signaling inhibitor and of therapeutic relevance
   for gastric cancer treatment and that the rhizome of Paris polyphylla
   deserves further clinical investigation as an alternative therapy for
   gastric cancer.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Li, YZ; Peng, C (Corresponding Author), Chengdu Univ Tradit Chinese Med, Sch Pharm, Key Lab Standardizat Chinese Herbal Med, Minist Educ,Natl Key Lab Breeding Base Systemat R, Chengdu 611137, Sichuan, Peoples R China.
   He, Junlin; Yu, Si; Guo, Chuanjie; Tan, Lu; Song, Xiaominting; Wang, Miao; Wu, Jing; Long, Yuling; Gong, Daoyin; Zhang, Ruoqi; Can, Zhixing; Li, Yuzhi; Peng, Cheng, Chengdu Univ Tradit Chinese Med, Sch Pharm, Key Lab Standardizat Chinese Herbal Med, Minist Educ,Natl Key Lab Breeding Base Systemat R, Chengdu 611137, Sichuan, Peoples R China.
   Yu, Si, Chengdu Med Coll, Chengdu 610500, Sichuan, Peoples R China.},
DOI = {10.1016/j.biopha.2019.109189},
Article-Number = {109189},
ISSN = {0753-3322},
EISSN = {1950-6007},
Keywords = {Polyphyllin I; Gastric cancer; Autophagy; Cell cycle; PDK1/Akt/mTOR},
Keywords-Plus = {CANCER CELLS; APOPTOSIS; PDK1; SAPONINS; DEATH},
Research-Areas = {Research \& Experimental Medicine; Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Medicine, Research \& Experimental; Pharmacology \& Pharmacy},
Author-Email = {liyuzhi5654@163.com
   pengchengchengdu@126.com},
Affiliations = {Chengdu University of Traditional Chinese Medicine; Chengdu Medical
   College},
ResearcherID-Numbers = {Zhang, Ruoqi/ACX-2846-2022
   Yu, Simon/D-1046-2011},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81503346, 81873073,
   81403149, 81630101, 81891012]; National Major Scientific and
   Technological Special Project of China {[}2017ZX09201001-008]; Sichuan
   Science and Technology Program {[}2018SZDZX0017]; Youth Scientific
   Research Fund of CDUTCM {[}ZRQN1764, ZRQN1770]},
Funding-Text = {This study was supported by the National Natural Science Foundation of
   China (81503346, 81873073, 81403149, 81630101, 81891012), National Major
   Scientific and Technological Special Project of China
   (2017ZX09201001-008), Sichuan Science and Technology Program
   (2018SZDZX0017). Youth Scientific Research Fund of CDUTCM (ZRQN1764,
   ZRQN1770)},
Cited-References = {Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802.
   Chu BY, 2016, INT J PHARMACEUT, V513, P118, DOI 10.1016/j.ijpharm.2016.09.005.
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625.
   Dong RZ, 2018, BIOCHEM BIOPH RES CO, V497, P1129, DOI 10.1016/j.bbrc.2018.02.193.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fan C, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/1231820.
   Fu YL, 2008, J THROMB HAEMOST, V6, P524, DOI 10.1111/j.1538-7836.2007.02881.x.
   Hsieh MJ, 2016, PHYTOMEDICINE, V23, P1545, DOI 10.1016/j.phymed.2016.09.004.
   Hsieh MJ, 2015, EXPERT OPIN THER TAR, V19, P455, DOI 10.1517/14728222.2014.998200.
   Kim EJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1702-7.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53.
   Li GB, 2017, ONCOTARGET, V8, P10359, DOI 10.18632/oncotarget.14413.
   Li LM, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0388-x.
   Liu JX, 2017, ACTA BIOCH BIOPH SIN, V49, P479, DOI 10.1093/abbs/gmx033.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Ong RCY, 2008, CANCER LETT, V261, P158, DOI 10.1016/j.canlet.2007.11.005.
   Pourhoseingholi Mohamad Amin, 2015, Gastroenterol Hepatol Bed Bench, V8, P19.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   Saran U, 2015, CLIN SCI, V129, P895, DOI 10.1042/CS20150149.
   Sawaki A, 2018, GASTRIC CANCER, V21, P429, DOI 10.1007/s10120-017-0773-y.
   Shi YM, 2015, PHYTOMEDICINE, V22, P1139, DOI 10.1016/j.phymed.2015.08.014.
   Su H, 2016, THERANOSTICS, V6, P1065, DOI 10.7150/thno.15420.
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777.
   Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3.
   Wagner AD, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub4.
   Wang GX, 2010, PHYTOMEDICINE, V17, P1102, DOI 10.1016/j.phymed.2010.04.012.
   Wang PW, 2019, EUR J PHARMACOL, V851, P161, DOI 10.1016/j.ejphar.2019.02.041.
   Wang YZ, 2018, PLANT GROWTH REGUL, V84, P373, DOI 10.1007/s10725-017-0348-2.
   Xiang ST, 2018, CELL PHYSIOL BIOCHEM, V47, P759, DOI 10.1159/000490028.
   Xie SB, 2016, MED RES REV, V36, P300, DOI 10.1002/med.21378.
   Yu S, 2018, NAT PROD RES, V32, P1489, DOI 10.1080/14786419.2017.1353512.
   Zhang C, 2017, REDOX BIOL, V11, P1, DOI 10.1016/j.redox.2016.10.019.
   Zhang W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173006.
   Zhang YF, 2018, J PHARMACOL SCI, V137, P305, DOI 10.1016/j.jphs.2018.07.008.},
Number-of-Cited-References = {35},
Times-Cited = {47},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {31},
Journal-ISO = {Biomed. Pharmacother.},
Doc-Delivery-Number = {IM2EA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000477804500088},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000487675500083,
Author = {Sun, Zhichao and Xu, Lei},
Title = {Expression of PDK-1 and DMBT1 in the thyroid carcinoma and its
   clinicopathological significance},
Journal = {ONCOLOGY LETTERS},
Year = {2019},
Volume = {18},
Number = {3},
Pages = {2819-2824},
Month = {SEP},
Abstract = {This study was designed to explore the expression of
   phosphoinositide-dependent protein kinase 1 (PDK-1), deleted in
   malignant brain tumors (DMBT1) in the thyroid carcinoma. A total of 87
   fresh samples of thyroid carcinoma from surgical resection in The Second
   People's Hospital of Lianyungang from June 2016 to March 2018 were
   collected for the ELISA to detect the protein expression of PDK-1 and
   DMBT1. Then the pathological significance of the expression of PDK-1 and
   DMBT1 in the thyroid carcinoma and the correlation between them were
   analyzed, using the ROC curve to study the diagnostic value of each
   index. The expression of PDK-1 in the thyroid carcinoma tissue was
   significantly higher than that in the normal thyroid tissue with a
   statistical difference between them (P<0.05); the expression of DMBT1 in
   the thyroid carcinoma was statistically significantly lower than that in
   the normal thyroid tissue (P<0.05); the PDK-1 and DMBT1 expressions were
   in negative correlation in the thyroid carcinoma (r=-0.889, P<0.001).
   The AUG, specificity and the sensitivity of the PDK-1 in diagnosing the
   thyroid carcinoma were 0.862, 86.21\% and 78.16\%, respectively; the
   AUG, specificity and the sensitivity of the DMBT1 in diagnosing the
   thyroid carcinoma were 0.708, 66.67\% and 67.82\%, respectively; while
   the AUG, the specificity and the sensitivity of the combination of PDK-1
   and DMBT1 in diagnosing the thyroid carcinoma were 0.888, 89.66\% and
   81.61\%. In conclusion, the occurrence and progression of the thyroid
   carcinoma were related to the high expression of the PDK-1 and the low
   expression of the DMBT1 in the thyroid carcinoma tissues, the two of
   which were in connection with factors involving lymph node metastasis,
   pathological type, neoplasm staging, and clinical staging. Thus, the
   combined detection of PDK-1 and DMBT1 could be used as an effective
   index to determine the occurrence of thyroid carcinoma.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Sun, ZC (Corresponding Author), Second Peoples Hosp Lianyungang, Dept Pathol, 41 Hailian East Rd, Lianyungang 222006, Jiangsu, Peoples R China.
   Sun, Zhichao; Xu, Lei, Second Peoples Hosp Lianyungang, Dept Pathol, 41 Hailian East Rd, Lianyungang 222006, Jiangsu, Peoples R China.},
DOI = {10.3892/ol.2019.10639},
ISSN = {1792-1074},
EISSN = {1792-1082},
Keywords = {thyroid carcinoma; phosphoinositide-dependent protein kinase 1; deleted
   in malignant brain tumors; case parameters},
Keywords-Plus = {BRAIN-TUMORS 1; CANCER; PROLIFERATION; INVASION; GENE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {cdb7ta@163.com},
ResearcherID-Numbers = {Sun, Zhichao/KIC-2765-2024},
Cited-References = {Arsenic R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-82.
   Braidotti P, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-46.
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338.
   Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164.
   Deng H, 2012, HISTOPATHOLOGY, V60, P249, DOI 10.1111/j.1365-2559.2011.04082.x.
   Du JH, 2011, UROLOGY, V77, DOI 10.1016/j.urology.2010.09.023.
   Ferro R, 2014, WORLD J GASTROENTERO, V20, P10752, DOI 10.3748/wjg.v20.i31.10752.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Han LH, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0129-y.
   Hernandez Brenda Y, 2010, Hawaii Med J, V69, P223.
   Imai MA, 2005, INT J MOL MED, V15, P585.
   Jabbour E, 2011, LEUKEMIA, V25, P201, DOI 10.1038/leu.2010.215.
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Lian SX, 2015, ONCOTARGET, V6, P29076, DOI 10.18632/oncotarget.4931.
   MAZZAFERRI EL, 1994, AM J MED, V97, P418, DOI 10.1016/0002-9343(94)90321-2.
   Mollenhauer J, 1997, NAT GENET, V17, P32, DOI 10.1038/ng0997-32.
   Mollenhauer J, 2001, CANCER RES, V61, P8880.
   Mollenhauer J, 1999, ONCOGENE, V18, P6233, DOI 10.1038/sj.onc.1203071.
   Ridnour LA, 2013, CLIN CANCER RES, V19, P1340, DOI 10.1158/1078-0432.CCR-12-0408.
   Smith HA, 2013, J MOL MED, V91, P411, DOI 10.1007/s00109-013-1021-5.
   Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978.
   Zheng NN, 2015, CELL PHYSIOL BIOCHEM, V36, P1903, DOI 10.1159/000430159.
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249.},
Number-of-Cited-References = {24},
Times-Cited = {6},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Oncol. Lett.},
Doc-Delivery-Number = {JA2UX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000487675500083},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000483594700001,
Author = {Xia, Xin and Li, Xixi and Li, Fanying and Wu, Xujia and Zhang, Maolei
   and Zhou, Huangkai and Huang, Nunu and Yang, Xuesong and Xiao, Feizhe
   and Liu, Dawei and Yang, Lixuan and Zhang, Nu},
Title = {A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits
   glioblastoma tumorigenicity by competing with active
   phosphoinositide-dependent Kinase-1},
Journal = {MOLECULAR CANCER},
Year = {2019},
Volume = {18},
Number = {1},
Month = {AUG 30},
Abstract = {Background The RTK/PI3K/AKT pathway plays key roles in the development
   and progression of many cancers, including GBM. As a regulatory molecule
   and a potential drug target, the oncogenic role of AKT has been
   substantially studied. Three isoforms of AKT have been identified,
   including AKT1, AKT2 and AKT3, but their individual functions in GBM
   remain controversial. Moreover, it is not known if there are more AKT
   alternative splicing variants. Methods High-throughput RNA sequencing
   and quantitative reverse transcription-PCR were used to identify the
   differentially expressed circRNAs in GBM samples and in paired normal
   tissues. High throughput RNA sequencing was used to identify circ-AKT3
   regulated signaling pathways. Mass spectrometry, western blotting and
   immunofluorescence staining analyses were used to validate AKT3-174aa
   expression. The tumor suppressive role of AKT3-174aa was validated in
   vitro and in vivo. The competing interaction between AKT3-174aa and
   p-PDK1 was investigated by mass spectrometry and immunoprecipitation
   analyses. Results Circ-AKT3 is a previously uncharacterized AKT
   transcript variant. Circ-AKT3 is expressed at low levels in GBM tissues
   compared with the expression in paired adjacent normal brain tissues.
   Circ-AKT3 encodes a 174 amino acid (aa) novel protein, which we named
   AKT3-174aa, by utilizing overlapping start-stop codons. AKT3-174aa
   overexpression decreased the cell proliferation, radiation resistance
   and in vivo tumorigenicity of GBM cells, while the knockdown of
   circ-AKT3 enhanced the malignant phenotypes of astrocytoma cells.
   AKT3-174aa competitively interacts with phosphorylated PDK1, reduces
   AKT-thr308 phosphorylation, and plays a negative regulatory role in
   modulating the PI3K/AKT signal intensity. Conclusions Our data indicate
   that the impaired circRNA expression of the AKT3 gene contributes to GBM
   tumorigenesis, and our data corroborate the hypothesis that restoring
   AKT3-174aa while inhibiting activated AKT may provide more benefits for
   certain GBM patients.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhang, N (Corresponding Author), Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 1, 58,Zhongshan 2 Rd, Guangzhou 510080, Guangdong, Peoples R China.
   Zhang, N (Corresponding Author), Sun Yat Sen Univ, Guangdong Prov Key Lab Brain Funct \& Dis, Affiliated Hosp 1, Precise Med Inst, Guangzhou 510080, Guangdong, Peoples R China.
   Xia, Xin; Li, Xixi; Li, Fanying; Wu, Xujia; Zhang, Maolei; Zhou, Huangkai; Huang, Nunu; Yang, Xuesong; Yang, Lixuan; Zhang, Nu, Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 1, 58,Zhongshan 2 Rd, Guangzhou 510080, Guangdong, Peoples R China.
   Xia, Xin; Li, Xixi; Li, Fanying; Wu, Xujia; Zhang, Maolei; Zhou, Huangkai; Huang, Nunu; Yang, Xuesong; Yang, Lixuan; Zhang, Nu, Sun Yat Sen Univ, Guangdong Prov Key Lab Brain Funct \& Dis, Affiliated Hosp 1, Precise Med Inst, Guangzhou 510080, Guangdong, Peoples R China.
   Xiao, Feizhe, Sun Yat Sen Univ, Affiliated Hosp 1, Dept Sci Res Sect, Guangzhou 510080, Guangdong, Peoples R China.
   Liu, Dawei, Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China.},
DOI = {10.1186/s12943-019-1056-5},
Article-Number = {131},
EISSN = {1476-4598},
Keywords = {circRNA; AKT3; PDK1; Glioblastoma},
Keywords-Plus = {ACTIVATION; GROWTH; RESISTANCE; LANDSCAPE; APOPTOSIS; ISOFORMS; REVEALS;
   PATHWAY; GLIOMA; PTEN},
Research-Areas = {Biochemistry \& Molecular Biology; Oncology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Oncology},
Author-Email = {zhangnu2@mail.sysu.edu.cn},
Affiliations = {Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University;
   Sun Yat Sen University},
ResearcherID-Numbers = {Zhou, Huangkai/KHC-5521-2024
   },
ORCID-Numbers = {Zhang, Nu/0000-0002-6783-3811
   Fanying, Li/0000-0001-9281-6370},
Funding-Acknowledgement = {National Natural Science Outstanding Youth Foundation of China
   {[}81822033]; National Key Research and Development Program of China
   {[}2016YFA0503000]; National Natural Science Foundation of China
   {[}81572477, 81772683, 81602185]; Science and Technology Program Key
   project of Guangzhou {[}201704020068, 201903010093, 201604020004]},
Funding-Text = {This work was supported in part by the National Natural Science
   Outstanding Youth Foundation of China (81822033 to N.Z.), the National
   Key Research and Development Program of China (2016YFA0503000 to N.Z.),
   the National Natural Science Foundation of China (81572477 and 81772683
   to N.Z., 81602185 to N.H.), and Science and Technology Program Key
   project of Guangzhou (201704020068, 201903010093 and 201604020004).},
Cited-References = {Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9.
   Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515.
   Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947.
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034.
   Ceccarelli M, 2016, CELL, V164, P550, DOI 10.1016/j.cell.2015.12.028.
   Chautard E, 2014, J NEURO-ONCOL, V117, P205, DOI 10.1007/s11060-014-1382-9.
   Chen SJ, 2019, CELL, V176, P831, DOI 10.1016/j.cell.2019.01.025.
   Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901.
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385.
   Chin YR, 2014, CANCER DISCOV, V4, P942, DOI 10.1158/2159-8290.CD-13-0873.
   Chin YR, 2014, CANCER RES, V74, P964, DOI 10.1158/0008-5472.CAN-13-2175.
   Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728.
   Endersby R, 2011, CANCER RES, V71, P4106, DOI 10.1158/0008-5472.CAN-10-3597.
   Glazar P, 2014, RNA, V20, P1666, DOI 10.1261/rna.043687.113.
   Guo JP, 2019, NAT CELL BIOL, V21, P226, DOI 10.1038/s41556-018-0261-6.
   Huang XX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0969-3.
   Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087.
   Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374.
   Joy A, 2016, J NEURO-ONCOL, V130, P43, DOI 10.1007/s11060-016-2220-z.
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36.
   Knisely JP, 2009, LANCET ONCOL, V10, P434, DOI 10.1016/S1470-2045(09)70124-X.
   Knobbe CB, 2004, J NATL CANCER I, V96, P483, DOI 10.1093/jnci/djh064.
   Kondapaka SB, 2003, MOL CANCER THER, V2, P1093.
   Langmead B, 2012, NAT METHODS, V9, P357, DOI {[}10.1038/nmeth.1923, 10.1038/NMETH.1923].
   Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017.
   Liby TA, 2012, INT J CANCER, V130, P532, DOI 10.1002/ijc.26010.
   Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103.
   Marín-Béjar O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1331-y.
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928.
   Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324.
   Mure H, 2010, NEURO-ONCOLOGY, V12, P221, DOI 10.1093/neuonc/nop026.
   Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021.
   Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471.
   Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567.
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330.
   Suzuki H, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl151.
   Tschopp O, 2005, DEVELOPMENT, V132, P2943, DOI 10.1242/dev.01864.
   Turner KM, 2015, P NATL ACAD SCI USA, V112, P3421, DOI 10.1073/pnas.1414573112.
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839.
   Vo JN, 2019, CELL, V176, P869, DOI 10.1016/j.cell.2018.12.021.
   Wang GH, 2019, NAT CELL BIOL, V21, P214, DOI 10.1038/s41556-018-0266-1.
   Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166.
   Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2.
   Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9.
   Zhao HF, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0670-3.},
Number-of-Cited-References = {47},
Times-Cited = {261},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {59},
Journal-ISO = {Mol. Cancer},
Doc-Delivery-Number = {IU4ZC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000483594700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000484023300001,
Author = {Ruicci, Kara M. and Plantinga, Paul and Pinto, Nicole and Khan, Mohammed
   I. and Stecho, William and Dhaliwal, Sandeep S. and Yoo, John and Fung,
   Kevin and MacNeil, Danielle and Mymryk, Joe S. and Barrett, John W. and
   Howlett, Christopher J. and Nichols, Anthony C.},
Title = {Disruption of the RICTOR/mTORC2 complex enhances the response of head
   and neck squamous cell carcinoma cells to PI3K inhibition},
Journal = {MOLECULAR ONCOLOGY},
Year = {2019},
Volume = {13},
Number = {10},
Pages = {2160-2177},
Month = {OCT},
Abstract = {Phosphoinositide 3-kinase (PI3K) is aberrantly activated in head and
   neck squamous cell carcinomas (HNSCC) and plays a pivotal role in
   tumorigenesis by driving Akt signaling, leading to cell survival and
   proliferation. Phosphorylation of Akt Thr308 by PI3K-PDK1 and Akt Ser473
   by mammalian target of rapamycin complex 2 (mTORC2) activates Akt.
   Targeted inhibition of PI3K is a major area of preclinical and clinical
   investigation as it reduces Akt Thr308 phosphorylation, suppressing
   downstream mTORC1 activity. However, inhibition of mTORC1 releases
   feedback inhibition of mTORC2, resulting in a resurgence of Akt
   activation mediated by mTORC2. While the role of PI3K-activated Akt
   signaling is well established in HNSCC, the significance of
   mTORC2-driven Akt signaling has not been thoroughly examined. Here we
   explore the expression and function of mTORC2 and its obligate subunit
   RICTOR in HNSCC primary tumors and cell lines. We find RICTOR to be
   overexpressed in a subset of HNSCC tumors, including those with PIK3CA
   or EGFR gene amplifications. Whereas overexpression of RICTOR reduced
   susceptibility of HNSCC tumor cells to PI3K inhibition, genetic ablation
   of RICTOR using CRISPR/Cas9 sensitized cells to PI3K inhibition, as well
   as to EGFR inhibition and cisplatin treatment. Further, mTORC2
   disruption led to reduced viability and colony forming abilities of
   HNSCC cells relative to their parental lines and induced loss of both
   activating Akt phosphorylation modifications (Thr308 and Ser473). Taken
   together, our findings establish RICTOR/mTORC2 as a critical oncogenic
   complex in HNSCC and rationalize the development of an mTORC2-specific
   inhibitor for use in HNSCC, either combined with agents already under
   investigation, or as an independent therapy.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Nichols, AC (Corresponding Author), Victoria Hosp, London Hlth Sci Ctr, Dept Otolaryngol Head \& Neck Surg, Room B3-431A,800 Commissioners Rd East, London, ON N6A 5W9, Canada.
   Ruicci, Kara M.; Pinto, Nicole; Khan, Mohammed I.; Dhaliwal, Sandeep S.; Yoo, John; Fung, Kevin; MacNeil, Danielle; Mymryk, Joe S.; Barrett, John W.; Nichols, Anthony C., Western Univ, Schulich Sch Med \& Dent, Dept Otolaryngol Head \& Neck Surg, London, ON, Canada.
   Ruicci, Kara M.; Plantinga, Paul; Stecho, William; Howlett, Christopher J.; Nichols, Anthony C., Western Univ, Schulich Sch Med \& Dent, Dept Pathol \& Lab Med, London, England.
   Dhaliwal, Sandeep S.; Yoo, John; Fung, Kevin; MacNeil, Danielle; Mymryk, Joe S.; Nichols, Anthony C., Western Univ, Schulich Sch Med \& Dent, Dept Oncol, London, ON, Canada.
   Mymryk, Joe S., Western Univ, Dept Microbiol \& Immunol, Schulich Sch Med \& Dent, London, ON, Canada.},
DOI = {10.1002/1878-0261.12558},
EarlyAccessDate = {AUG 2019},
ISSN = {1574-7891},
EISSN = {1878-0261},
Keywords = {head and neck cancer; mTORC2; PI3-kinase; RICTOR; targeted therapy},
Keywords-Plus = {DUAL MTORC1; RICTOR; CANCER; PATHWAY; ACTIVATION; RESISTANCE; DEFINES;
   PHOSPHORYLATION; GROWTH},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {Anthony.Nichols@lhsc.on.ca},
Affiliations = {Western University (University of Western Ontario); Western University
   (University of Western Ontario); Western University (University of
   Western Ontario)},
ResearcherID-Numbers = {Stecho, William/E-1656-2013
   Nichols, Anthony/H-9595-2019
   barrett, john/ABD-8414-2020
   Khan, Mohammed Imran/I-9621-2017},
ORCID-Numbers = {Nichols, Anthony/0000-0002-0760-980X
   MacNeil, S Danielle/0000-0001-6666-9055
   Mymryk, Joe/0000-0002-3521-8005
   Fung, Kevin/0009-0006-9293-5082
   Yoo, John/0000-0002-2815-893X
   Khan, Mohammed Imran/0000-0003-3020-1324},
Funding-Acknowledgement = {Canadian Institutes for Health Research (CIHR) {[}MOP 340674]; CIHR New
   Investigator Award; Terry Fox Research New Investigator Award; Ontario
   Institute for Cancer Research; Wolfe Surgical Research Professorship in
   the Biology of Head and Neck Cancers Fund},
Funding-Text = {The spSpCas9(BB)-2A-GFP (PX458) was a gift deposited to Addgene by Feng
   Zheng (Addgene plasmid \#48138). PX458 was modified to contain a CMV
   promoter (PX458-CMV) by Pirunthan Perampalam (Western University), which
   was used in this manuscript. This study was funded by a Canadian
   Institutes for Health Research (CIHR) grant MOP 340674 to ACN, and
   PCB/PCB was supported by CIHR and Terry Fox Research New Investigator
   Awards and by the Ontario Institute for Cancer Research. ACN was
   supported by the Wolfe Surgical Research Professorship in the Biology of
   Head and Neck Cancers Fund.},
Cited-References = {Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923.
   Benavides-Serrato A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176599.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chen XZ, 2018, CELL RES, V28, P518, DOI 10.1038/s41422-018-0029-3.
   Cheng HY, 2015, CANCER DISCOV, V5, P1262, DOI 10.1158/2159-8290.CD-14-0971.
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664.
   Gkountakos A., 2018, Carcinogenesis, V149, P274.
   Huang KZ, 2014, SEMIN CELL DEV BIOL, V36, P79, DOI 10.1016/j.semcdb.2014.09.011.
   Huang Y, 2013, ANTI-CANCER DRUG, V24, P889, DOI 10.1097/CAD.0b013e328363c64e.
   Im-Aram A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075455.
   Janku F, 2011, MOL CANCER THER, V10, P558, DOI 10.1158/1535-7163.MCT-10-0994.
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107.
   Jimeno A, 2015, ORAL ONCOL, V51, P383, DOI 10.1016/j.oraloncology.2014.12.013.
   Joly MM, 2016, CANCER RES, V76, P4752, DOI 10.1158/0008-5472.CAN-15-3393.
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107.
   Kim SJ, 2016, J OPEN INNOV-TECHNOL, V2, P1, DOI {[}10.1186/s40852-016-0032-1, 10.1186/s40852-016-0032-1, DOI 10.1186/S40852-016-0032-1].
   Laugier F, 2015, ONCOTARGET, V6, P28120, DOI 10.18632/oncotarget.4866.
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129.
   Li Q, 2013, BIOCHEM BIOPH RES CO, V440, P701, DOI 10.1016/j.bbrc.2013.09.130.
   Liu PD, 2015, CANCER DISCOV, V5, P1194, DOI 10.1158/2159-8290.CD-15-0460.
   Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103.
   Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836.
   Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223.
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006.
   Naruse T, 2017, ORAL ONCOL, V65, P23, DOI 10.1016/j.oraloncology.2016.12.012.
   Nichols AC, 2013, CURR ONCOL, V20, P212, DOI 10.3747/co.20.1375.
   Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586.
   Rodon J, 2014, INVEST NEW DRUG, V32, P670, DOI 10.1007/s10637-014-0082-9.
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10.
   Rosner M, 2008, HUM MOL GENET, V17, P2934, DOI 10.1093/hmg/ddn192.
   Ruicci KM, 2019, INT J CANCER, V145, P2100, DOI 10.1002/ijc.32009.
   Ruicci KM, 2018, ORAL ONCOL, V84, P95, DOI 10.1016/j.oraloncology.2018.07.010.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054.
   Scheid MP, 2002, MOL CELL BIOL, V22, P6247, DOI 10.1128/MCB.22.17.6247-6260.2002.
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130.
   Zhang JF, 2016, MOL CELL, V62, P929, DOI 10.1016/j.molcel.2016.04.023.
   Zhou P, 2015, J COMPUT BIOL, V22, P876, DOI 10.1089/cmb.2015.0103.},
Number-of-Cited-References = {38},
Times-Cited = {27},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Mol. Oncol.},
Doc-Delivery-Number = {JA4YK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000484023300001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000483397100008,
Author = {Chatterjee, Nilanjana and Pazarentzos, Evangelos and Mayekar, Manasi K.
   and Gui, Philippe and Allegakoen, David V. and Hrustanovic, Gorjan and
   Olivas, Victor and Lin, Luping and Verschueren, Erik and Johnson,
   Jeffrey R. and Hofree, Matan and Yan, Jenny J. and Newton, Billy W. and
   Dollen, John V. and Earnshaw, Charles H. and Flanagan, Jennifer and
   Chan, Elton and Asthana, Saurabh and Ideker, Trey and Wu, Wei and
   Suzuki, Junji and Barad, Benjamin A. and Kirichok, Yuriy and Fraser,
   James S. and Weiss, William A. and Krogan, Nevan J. and Tulpule, Asmin
   and Sabnis, Amit J. and Bivona, Trever G.},
Title = {Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient
   Cells and Cancers},
Journal = {CELL REPORTS},
Year = {2019},
Volume = {28},
Number = {9},
Pages = {2317+},
Month = {AUG 27},
Abstract = {Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a
   tumor suppressor and bi-functional lipid and protein phosphatase. We
   report that the metabolic regulator pyruvate dehydrogenase kinasel
   (PDHK1) is a synthetic-essential gene in PTEN-deficient cancer and
   normal cells. The PTEN protein phosphatase dephosphorylates nuclear
   factor kappa B (NF-kappa B)-activating protein (NKAP) and limits NF
   kappa B activation to suppress expression of PDHK1, a NF-kappa B target
   gene. Loss of the PTEN protein phosphatase upregulates PDHK1 to induce
   aerobic glycolysis and PDHK1 cellular dependence. PTEN-deficient human
   tumors harbor increased PDHK1, a biomarker of decreased patient
   survival. This study uncovers a PTEN-regulated signaling pathway and
   reveals PDHK1 as a potential target in PTEN-deficient cancers.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Chatterjee, N; Bivona, TG (Corresponding Author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
   Chatterjee, N; Bivona, TG (Corresponding Author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
   Bivona, TG (Corresponding Author), Univ Calif San Francisco, Dept Cellular \& Mol Pharmacol, San Francisco, CA 94158 USA.
   Bivona, TG (Corresponding Author), Calif Inst Quantitat Biosci, QB3, San Francisco, CA 94158 USA.
   Chatterjee, Nilanjana; Pazarentzos, Evangelos; Mayekar, Manasi K.; Gui, Philippe; Allegakoen, David V.; Hrustanovic, Gorjan; Olivas, Victor; Lin, Luping; Yan, Jenny J.; Earnshaw, Charles H.; Flanagan, Jennifer; Chan, Elton; Wu, Wei; Bivona, Trever G., Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA.
   Chatterjee, Nilanjana; Pazarentzos, Evangelos; Mayekar, Manasi K.; Gui, Philippe; Allegakoen, David V.; Hrustanovic, Gorjan; Olivas, Victor; Lin, Luping; Yan, Jenny J.; Flanagan, Jennifer; Chan, Elton; Asthana, Saurabh; Wu, Wei; Tulpule, Asmin; Sabnis, Amit J.; Bivona, Trever G., Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
   Verschueren, Erik; Johnson, Jeffrey R.; Newton, Billy W.; Dollen, John V.; Krogan, Nevan J., J David Gladstone Inst, San Francisco, CA 94158 USA.
   Verschueren, Erik; Johnson, Jeffrey R.; Newton, Billy W.; Dollen, John V.; Krogan, Nevan J.; Bivona, Trever G., Univ Calif San Francisco, Dept Cellular \& Mol Pharmacol, San Francisco, CA 94158 USA.
   Verschueren, Erik; Johnson, Jeffrey R.; Newton, Billy W.; Dollen, John V.; Krogan, Nevan J.; Bivona, Trever G., Calif Inst Quantitat Biosci, QB3, San Francisco, CA 94158 USA.
   Hofree, Matan; Ideker, Trey, Univ Calif San Diego, Dept Bioengn, San Diego, CA 92093 USA.
   Barad, Benjamin A.; Fraser, James S., Univ Calif San Francisco, Dept Bioengn \& Therapeut Sci, San Francisco, CA 94158 USA.
   Suzuki, Junji; Kirichok, Yuriy, Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94158 USA.
   Weiss, William A., Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.},
DOI = {10.1016/j.celrep.2019.07.063},
ISSN = {2211-1247},
Keywords-Plus = {NF-KAPPA-B; PYRUVATE-DEHYDROGENASE KINASE; PROTEIN-TYROSINE-PHOSPHATASE;
   I PI3 KINASE; TUMOR-SUPPRESSOR; LUNG-CANCER; INHIBITION; ACTIVATION;
   EXPRESSION; BCL-2},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {nilanjana.chatterjee@ucsf.edu
   trever.bivona@ucsf.edu},
Affiliations = {University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; University of California System; University of California San
   Francisco; The J David Gladstone Institutes; University of California
   System; University of California San Francisco; University of California
   System; University of California San Diego; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco},
ResearcherID-Numbers = {Earnshaw, Charles/AAN-6210-2021
   verschueren, erik/D-4436-2015
   Sabnis, Amit/KHV-6416-2024
   Ideker, Trey/AEN-0266-2022
   Suzuki, Junji/LDE-5555-2024
   },
ORCID-Numbers = {Earnshaw, Charles/0000-0002-7926-8506
   verschueren, erik/0000-0001-5842-6344
   WU, WEI/0000-0002-6556-067X
   Allegakoen, David/0000-0002-0261-2962
   Hofree, Matan/0000-0001-8368-0299
   Pazarentzos, Evangelos/0000-0002-5453-1646
   Weiss, William/0000-0003-2230-9132
   Ideker, Trey/0000-0002-1708-8454
   Suzuki, Junji/0000-0003-1648-5471
   Johnson, Jeffrey/0000-0002-4221-298X
   Barad, Benjamin/0000-0002-1016-862X},
Funding-Acknowledgement = {NIH/NCI {[}U54CA224081, R01CA204302, R01CA211052, R01CA169338,
   T32CA108462-14]; Pew Foundation; Stewart Foundation;  {[}U54 CA209891]; 
   {[}R01GM123159];  {[}R01GM118939]; National Cancer Institute
   {[}U54CA224081, R01CA169338, R01CA204302, U01CA217882, R01CA211052]
   Funding Source: NIH RePORTER},
Funding-Text = {We would like to thank all members of the Bivona laboratory for critical
   review of the manuscript and acknowledge funding support from NIH/NCI
   grants U54CA224081, R01CA204302, R01CA211052, and R01CA169338 and the
   Pew Foundation and Stewart Foundation (to T.G.B.); U54 CA209891 (to
   N.J.K.); R01GM123159 (to J.S.F.); R01GM118939 (to Y.K.); and NIH/NCI
   T32CA108462-14 (to N.C.). We thank Timothy Fouts and Jeffrey Meshulam at
   Profectus Biosciences, Inc., for generously providing PBS-1086. We thank
   Bhagyashri Burgute and Angelika Noegel at the University of Cologne,
   Germany, for kindly providing the NKAP mouse mAb (K85-80-5). We thank
   Albertas Navickas and Hani Goodarzi at UCSF for the hypoxia chamber.},
Cited-References = {Aguissa-Touré AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0.
   Aoki Y, 1997, BIOCHEM BIOPH RES CO, V234, P424, DOI 10.1006/bbrc.1997.6658.
   Beltrao P, 2012, CELL, V150, P413, DOI 10.1016/j.cell.2012.05.036.
   Berger N, 2007, EXP HEMATOL, V35, P1495, DOI 10.1016/j.exphem.2007.07.006.
   Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Burger MT, 2011, ACS MED CHEM LETT, V2, P774, DOI 10.1021/ml200156t.
   Burgute BD, 2014, NUCLEIC ACIDS RES, V42, P3177, DOI 10.1093/nar/gkt1311.
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311.
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031.
   Chen DY, 2003, BIOCHEM BIOPH RES CO, V310, P720, DOI 10.1016/j.bbrc.2003.09.074.
   Chesney J, 2014, ONCOTARGET, V5, P6670, DOI 10.18632/oncotarget.2213.
   Chiao PJ, 2011, CANCER DISCOV, V1, P103, DOI 10.1158/2159-8290.CD-11-0115.
   Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573.
   Choi M, 2014, BIOINFORMATICS, V30, P2524, DOI 10.1093/bioinformatics/btu305.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308.
   Davidson L, 2010, ONCOGENE, V29, P687, DOI 10.1038/onc.2009.384.
   Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182.
   Fabre C, 2012, CLIN CANCER RES, V18, P4669, DOI 10.1158/1078-0432.CCR-12-0779.
   Figueiredo AL, 2017, DEVELOPMENT, V144, P4183, DOI 10.1242/dev.157644.
   Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d.
   Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7.
   Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218.
   Ghosh S, 2013, CANCER RES, V73, P5218, DOI 10.1158/0008-5472.CAN-13-0429.
   Gildea JJ, 2004, ONCOGENE, V23, P6788, DOI 10.1038/sj.onc.1207599.
   Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954.
   Goo CK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045806.
   Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901.
   Grassian AR, 2011, GENE DEV, V25, P1716, DOI 10.1101/gad.16771811.
   Gu TT, 2011, CANCER RES, V71, P2821, DOI 10.1158/0008-5472.CAN-10-3399.
   Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012.
   Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867.
   Houddane A, 2017, CELL SIGNAL, V34, P23, DOI 10.1016/j.cellsig.2017.02.019.
   Jäger S, 2012, NATURE, V481, P365, DOI 10.1038/nature10719.
   Jang M, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.85.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kinoshita E, 2009, NAT PROTOC, V4, P1513, DOI 10.1038/nprot.2009.154.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P5731, DOI 10.1074/jbc.M007558200.
   Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200.
   Koul D, 2008, CANCER BIOL THER, V7, P1321, DOI 10.4161/cbt.7.9.6954.
   LARDY HA, 1958, ARCH BIOCHEM BIOPHYS, V78, P587, DOI 10.1016/0003-9861(58)90383-7.
   Lee HJ, 2014, J UROLOGY, V192, P940, DOI 10.1016/j.juro.2014.03.097.
   Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3.
   Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026.
   Leslie NR, 2009, ADV ENZYME REGUL, V49, P190, DOI 10.1016/j.advenzreg.2008.12.002.
   Li DM, 1997, CANCER RES, V57, P2124.
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943.
   Li T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12969.
   LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234.
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237.
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375.
   Maehama T, 2000, Tanpakushitsu Kakusan Koso, V45, P2405.
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6.
   Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100.
   Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200.
   Millán-Uclés A, 2016, ONCOTARGET, V7, P84054, DOI 10.18632/oncotarget.13414.
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052.
   Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513.
   Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798.
   Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400.
   Pajerowski AG, 2009, IMMUNITY, V30, P696, DOI 10.1016/j.immuni.2009.02.011.
   PALMER G, 1968, J BIOL CHEM, V243, P844.
   PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213.
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148.
   Pathak RR, 2013, J BIOL CHEM, V288, P29821, DOI 10.1074/jbc.M113.481523.
   Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610.
   Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459.
   Poburko D, 2011, J BIOL CHEM, V286, P11672, DOI 10.1074/jbc.M110.159962.
   Popov KM, 1997, ADV SEC MESS PHOSPH, V31, P105.
   Pourmand Gholamreza, 2007, Urol J, V4, P95.
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10.
   Rodríguez-Escudero I, 2011, HUM MOL GENET, V20, P4132, DOI 10.1093/hmg/ddr337.
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089.
   Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706.
   Schulze A, 2011, MOL CELL, V44, P846, DOI 10.1016/j.molcel.2011.12.004.
   Semenza GL, 2008, J CLIN INVEST, V118, P3835, DOI 10.1172/JCI37373.
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042.
   Shi YJ, 2014, NAT STRUCT MOL BIOL, V21, P522, DOI 10.1038/nsmb.2828.
   Shimizu S, 1996, ONCOGENE, V13, P21.
   Shimizu S, 1996, ONCOGENE, V12, P2251.
   Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455.
   Shinde SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10689.
   Soria JC, 2002, CLIN CANCER RES, V8, P1178.
   Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055.
   St-Denis N, 2016, CELL REP, V17, P2488, DOI 10.1016/j.celrep.2016.10.078.
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6.
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8.
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356.
   Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121.
   Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199.
   Sun SY, 2010, CANCER BIOL THER, V9, P109, DOI 10.4161/cbt.9.2.10583.
   Suzuki J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5153.
   Suzuki Keiko, 2010, BMC Res Notes, V3, P294, DOI 10.1186/1756-0500-3-294.
   Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979.
   Taylor GS, 2003, METHOD ENZYMOL, V366, P43.
   TEAGUE WM, 1979, BIOCHEM BIOPH RES CO, V87, P244, DOI 10.1016/0006-291X(79)91672-3.
   Thapa P, 2016, J IMMUNOL, V196, P4987, DOI 10.4049/jimmunol.1501653.
   Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138.
   Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x.
   Tsunoda T, 1999, BIOINFORMATICS, V15, P622, DOI 10.1093/bioinformatics/15.7.622.
   Wan FY, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000067.
   Wang L, 2014, CELL REP, V8, P1461, DOI 10.1016/j.celrep.2014.07.053.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761.
   Wittenberg AD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149995.
   Wozniak DJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01574-5.
   Wykoff CC, 2000, CANCER RES, V60, P7075.
   You DW, 2015, CELL REP, V10, P2055, DOI 10.1016/j.celrep.2015.02.056.
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60.},
Number-of-Cited-References = {113},
Times-Cited = {16},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Cell Reports},
Doc-Delivery-Number = {IU2GL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000483397100008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000477917500009,
Author = {Hu, Heng-Jing and Zhang, Chi and Tang, Zhi-Han and Qu, Shun-Lin and
   Jiang, Zhi-Sheng},
Title = {Regulating the Warburg effect on metabolic stress and myocardial
   fibrosis remodeling and atrial intracardiac waveform activity induced by
   atrial fibrillation},
Journal = {BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS},
Year = {2019},
Volume = {516},
Number = {3},
Pages = {653-660},
Month = {AUG 27},
Abstract = {Atrial fibrillation (AF) is associated with metabolic stress and induces
   myocardial fibrosis reconstruction by increasing glycolysis. One goal in
   the treatment of paroxysmal AF (p-AF) is to improve myocardial fibrosis
   reconstruction and myocardial metabolic stress caused by the Warburg
   effect. Adopted male canine that rapid right atrial pacing (RAP) for 6
   days to establish a p-AF model. The canines were pre-treated with
   phenylephrine (PE) or dichloroacetic acid (DCA) before exposure to p-AF
   or non-p-AF. P-wave duration (P-max), minimum P-wave duration (P-min), P
   wave dispersion (PWD), atrial effective refractory period (AERP) and
   AERP dispersion (AERPd) were measured in canine atrial cardiomyocytes.
   Pyruvate dehydrogenase kinase-1 (PDK-1), PDK-4, lactate dehydrogenase A
   (LDHA), pyruvate dehydrogenase (PDH), citrate synthase (CS), isocitrate
   dehydrogenase (IDH), and matrix metalloproteinase 9 (MMP-9) were
   evaluated by western blotting and reverse transcription polymerase chain
   reaction (RTPCR), content of adenosine monophosphate (AMP), adenosine
   triphosphate (ATP), lactic acid and glycogen, and activity of LDHA,
   PDK-1 and PDK-4 were evaluated by enzyme-linked immunosorbent assay
   (ELISA), myocardial tissue glycogen content was evaluated by PAS,
   myocardial fibrosis remodeling was evaluated by hematoxylin and eosin
   (H\&E) and Masson staining. Our findings demonstrated that p-AF
   increases the Warburg effect-related metabolic stress and myocardial
   fibrosis remodeling by increasing the expression and activity of PDK-1,
   PDK-4, and LDHA, content of AMP and lactic acid, and the ratio of
   AMP/ATP and decreasing the expression of PDH, CS, and IDH, and glycogen
   content. In addition, p-AF can induce cardiomyocyte fibrosis remodeling
   and increase MMP-9 expression, and p-AF also increases atrial
   intracardiac waveform activity by prolonging P-max, P-min, PWD, and
   AERPd and shortening AERP. PDK isoforms agonists (PE) produce a similar
   p-AF pathological effect and can produce synergistic effects with p-AF,
   further increasing Warburg effect-related metabolic stress, myocardial
   fibrosis remodeling, and atrial intracardiac waveform activity. In
   contrast, the use of PDK-specific inhibitors (DCA) completely reverses
   these pathophysiological changes induced by p-AF. We demonstrate that
   p-AF can induce the Warburg effect in canine atrial cardiomyocytes and
   significantly improve p-AF-induced metabolic stress, myocardial fibrosis
   remodeling, and atrial intracardiac waveform activity by inhibiting the
   Warburg effect. (C) 2019 Elsevier Inc. All rights reserved.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Jiang, ZS (Corresponding Author), Univ South China, Inst Cardiovasc Dis, 28 W Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
   Jiang, ZS (Corresponding Author), Univ South China, Key Lab Arteriosclerol Hunan Prov, 28 W Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
   Hu, Heng-Jing; Jiang, Zhi-Sheng, Univ South China, Dept Cardiol Lab, Affiliated Hosp 1, Hengyang, Hunan, Peoples R China.
   Zhang, Chi; Tang, Zhi-Han; Qu, Shun-Lin; Jiang, Zhi-Sheng, Univ South China, Inst Cardiovasc Dis, 28 W Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
   Zhang, Chi; Tang, Zhi-Han; Qu, Shun-Lin; Jiang, Zhi-Sheng, Univ South China, Key Lab Arteriosclerol Hunan Prov, 28 W Changsheng Rd, Hengyang 421001, Hunan, Peoples R China.
   Hu, Heng-Jing; Jiang, Zhi-Sheng, Univ South China, Postdoctoral Res Stn Basic Med, Hengyang, Hunan, Peoples R China.},
DOI = {10.1016/j.bbrc.2019.06.055},
ISSN = {0006-291X},
EISSN = {1090-2104},
Keywords = {Warburg effect; Pyruvate dehydrogenase kinase-1; Pyruvate dehydrogenase
   kinase-4; Atrial fibrillation},
Keywords-Plus = {EFFECTIVE REFRACTORY PERIOD; GLUCOSE-OXIDATION; STIMULATION; VAGAL;
   HEART; MODEL},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics},
Author-Email = {zsjiang2005@163.com},
Affiliations = {University of South China; University of South China; University of
   South China; University of South China},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81700306]; Natural
   Science Foundation of Hunan Province {[}2018JJ3469]; China Postdoctoral
   Science Foundation {[}2017M622588]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (81700306), Natural Science Foundation of Hunan
   Province (2018JJ3469), and the China Postdoctoral Science Foundation
   (2017M622588).},
Cited-References = {Archer SL, 2013, PULM CIRC, V3, P144, DOI 10.4103/2045-8932.109960.
   Barth AS, 2009, CIRC-ARRHYTHMIA ELEC, V2, P327, DOI 10.1161/CIRCEP.108.817320.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Chen Z, 2018, J CELL PHYSIOL, V233, P2839, DOI 10.1002/jcp.25998.
   Chong CR, 2017, CARDIOVASC RES, V113, P422, DOI 10.1093/cvr/cvx018.
   Crewe C, 2017, J BIOL CHEM, V292, P305, DOI 10.1074/jbc.M116.754127.
   Ding H, 2017, AM J PHYSIOL-RENAL, V313, pF561, DOI 10.1152/ajprenal.00036.2017.
   Driesen RB, 2009, J CELL MOL MED, V13, P896, DOI 10.1111/j.1582-4934.2008.00523.x.
   Fujimoto Y, 2017, HEART VESSELS, V32, P1375, DOI 10.1007/s00380-017-1008-1.
   Ghezelbash S, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.001808.
   Harada M, 2015, J AM COLL CARDIOL, V66, P47, DOI 10.1016/j.jacc.2015.04.056.
   Ivanisevic J, 2016, AGING-US, V8, P1000, DOI 10.18632/aging.100961.
   Iwasaki Y, 2016, CAN J CARDIOL, V32, P767, DOI 10.1016/j.cjca.2015.09.006.
   Johansen OE, 2008, CARDIOVASC DIABETOL, V7, DOI 10.1186/1475-2840-7-28.
   Lazzeroni D, 2016, INT J CARDIOL, V203, P131, DOI 10.1016/j.ijcard.2015.10.143.
   Lenski M, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0497-2.
   Lin H, 2016, AM J PHYSIOL-CELL PH, V311, pC710, DOI 10.1152/ajpcell.00137.2016.
   Liu CL, 2017, CARDIOVASC THER, V35, DOI 10.1111/1755-5922.12284.
   Magistretti PJ, 2014, CELL METAB, V19, P4, DOI 10.1016/j.cmet.2013.12.012.
   MOE GK, 1964, AM HEART J, V67, P200, DOI 10.1016/0002-8703(64)90371-0.
   Mori J, 2012, CIRC-HEART FAIL, V5, P493, DOI 10.1161/CIRCHEARTFAILURE.112.966705.
   Noszczyk-Nowak A, 2011, ACTA VET SCAND, V53, DOI 10.1186/1751-0147-53-18.
   Ong SG, 2014, CARDIOVASC RES, V104, P24, DOI 10.1093/cvr/cvu172.
   Pan GZ, 2019, BIOCHEM BIOPH RES CO, V514, P450, DOI 10.1016/j.bbrc.2019.04.129.
   Piao L, 2013, J MOL MED, V91, P333, DOI 10.1007/s00109-012-0982-0.
   Raitt MH, 2012, J ELECTROCARDIOL, V45, P296, DOI 10.1016/j.jelectrocard.2011.12.006.
   Saengklub N, 2017, EXP ANIM TOKYO, V66, P251, DOI 10.1538/expanim.17-0002.
   Shingu Y, 2018, J CARDIOL, V71, P65, DOI 10.1016/j.jjcc.2017.07.003.
   Wang J, 2017, MOL MED REP, V16, P1973, DOI 10.3892/mmr.2017.6848.
   Zhao QY, 2009, REV ESP CARDIOL, V62, P742, DOI 10.1016/S0300-8932(09)71687-2.
   ZIPES DP, 1974, CARDIOVASC RES, V8, P647, DOI 10.1093/cvr/8.5.647.},
Number-of-Cited-References = {31},
Times-Cited = {28},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Biochem. Biophys. Res. Commun.},
Doc-Delivery-Number = {IM3TK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000477917500009},
DA = {2026-02-04},
}

@article{ WOS:000483365200001,
Author = {Pan, Weidong and Li, Wen and Zhao, Jun and Huang, Zhiyi and Zhao,
   Jingyuan and Chen, Shuxian and Wang, Chusi and Xue, Youqiu and Huang,
   Feng and Fang, Qiannan and Wang, Julie and Brand, David and Zheng, Song
   Guo},
Title = {RETRACTED: lncRNA-PDPK2P promotes hepatocellular carcinoma progression
   through the PDK1/AKT/Caspase 3 pathway (Retracted article. See vol. 19,
   pg. 2458, 2025)},
Journal = {MOLECULAR ONCOLOGY},
Year = {2019},
Volume = {13},
Number = {10},
Pages = {2246-2258},
Month = {OCT},
Abstract = {Hepatocellular carcinoma (HCC) is a malignancy with one of the worst
   prognoses. Long noncoding RNA (lncRNA) are emerging as an important
   regulator of gene expression and function, leading to the development of
   cancer. The aim of this study was to determine the relationship between
   lncRNA and HCC and to further guide clinical therapy. lncRNA in HCC and
   adjacent tissues were screened, and the correlation between
   lncRNA-PDPK2P expression in liver tissues and the pathological
   characteristics and severity of HCC was assessed. The effects of PDPK2P
   on HCC proliferation, apoptosis, metastasis, and invasion were also
   systematically investigated via CCK-8 assay, flow cytometry, scratch
   wound healing, and transwell assay, respectively. The relationship
   between PDPK2P and PDK1 was verified by RNA pull-down, rescue
   experiments and western blot. lncRNA-PDPK2P was highly expressed in HCC
   tissues with a distinct positive correlation between PDPK2P and PDK1,
   and the upregulation was clinically associated with a larger tumor
   embolus, low differentiation, and poor survival. Mechanistically,
   lncRNA-PDPK2P interacted with PDK1 and promoted HCC progression through
   the PDK1/AKT/caspase 3 signaling pathway. lncRNA-PDPK2P can promote HCC
   progression, suggesting it may be a clinically valuable biomarker and
   serve as a molecular target for the diagnosis, prognosis, and therapy of
   hepatocellular carcinoma.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article; Retracted Publication},
Language = {English},
Affiliation = {Pan, WD (Corresponding Author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China.
   Zheng, SG (Corresponding Author), Ohio State Univ, Coll Med, Dept Internal Med, 1581 Dodd Dr, Columbus, OH 43201 USA.
   Pan, Weidong; Zhao, Jingyuan; Chen, Shuxian; Wang, Chusi, Sun Yat Sen Univ, Affiliated Hosp 3, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China.
   Li, Wen, Nanchang Univ, Affiliated Hosp 2, Dept Hepatobiliary Surg, Nanchang, Jiangxi, Peoples R China.
   Zhao, Jun; Huang, Zhiyi; Xue, Youqiu; Huang, Feng; Fang, Qiannan, Sun Yat Sen Univ, Hosp 3, Dept Clin Immunol, Guangzhou, Guangdong, Peoples R China.
   Xue, Youqiu; Wang, Julie; Zheng, Song Guo, Ohio State Univ, Coll Med, Dept Internal Med, 1581 Dodd Dr, Columbus, OH 43201 USA.
   Brand, David, Memphis VA Med Ctr, Res Serv, Memphis, TN USA.},
DOI = {10.1002/1878-0261.12553},
EarlyAccessDate = {AUG 2019},
ISSN = {1574-7891},
EISSN = {1878-0261},
Keywords = {hepatocellular carcinoma; inflammatory injury; long noncoding RNA;
   molecular marker; pseudogenes},
Keywords-Plus = {LONG NONCODING RNA; HEPATITIS-B; TGF-BETA; METASTASIS; EXPRESSION;
   INVASION; ANGIOGENESIS; REGENERATION; INFLAMMATION; SURVIVAL},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {panwd@mail.sysu.edu.cn
   SongGuo.Zheng@osumc.edu},
Affiliations = {Sun Yat Sen University; Nanchang University; Sun Yat Sen University;
   University System of Ohio; Ohio State University; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Memphis VA
   Medical Center},
ResearcherID-Numbers = {Zhao, Jun/IRZ-9880-2023
   Huang, Zhiyi/MBV-5893-2025
   fang, qiannan/KVB-7927-2024},
ORCID-Numbers = {Zhao, Jun/0000-0001-9724-7226
   Zheng, Song Guo/0000-0002-5611-4774
   Brand, David/0000-0002-9260-7963
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81172783, 81671611]},
Funding-Text = {This work was supported by project grants from the National Natural
   Science Foundation of China (81172783 and 81671611).},
Cited-References = {Abouzied MMM, 2015, TUMOR BIOL, V36, P1763, DOI 10.1007/s13277-014-2778-z.
   Camp JG, 2017, NATURE, V546, P533, DOI 10.1038/nature22796.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Elgar G, 2008, TRENDS GENET, V24, P344, DOI 10.1016/j.tig.2008.04.005.
   Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023.
   Fang JH, 2011, HEPATOLOGY, V54, P1729, DOI 10.1002/hep.24577.
   Fung J, 2009, CLIN MICROBIOL INFEC, V15, P964, DOI 10.1111/j.1469-0691.2009.03035.x.
   Grandér D, 2016, CURR TOP MICROBIOL, V394, P111, DOI 10.1007/82\_2015\_442.
   Guo JT, 2000, J VIROL, V74, P1495, DOI 10.1128/JVI.74.3.1495-1505.2000.
   Haga S, 2009, HEPATOLOGY, V49, P204, DOI 10.1002/hep.22583.
   Huang JF, 2013, HEPATOLOGY, V57, P1882, DOI 10.1002/hep.26195.
   Isashiki Yasushi, 2009, Nippon Ganka Gakkai Zasshi, V113, P1172.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Li W, 2017, INT J CLIN EXP PATHO, V10, P4431.
   Lu ZM, 2010, MOL CANCER RES, V8, P421, DOI 10.1158/1541-7786.MCR-09-0179.
   Luo X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157708.
   Marchese FP, 2017, CELL CYCLE, V16, P151, DOI 10.1080/15384101.2016.1241604.
   Poliseno L, 2015, METHODS, V77-78, P41, DOI 10.1016/j.ymeth.2015.01.013.
   Ponting CP, 2010, HUM MOL GENET, V19, pR162, DOI 10.1093/hmg/ddq362.
   Shim JH, 2012, J CLIN INVEST, V122, P91, DOI 10.1172/JCI59466.
   Surucu B, 2008, J BIOL CHEM, V283, P30025, DOI 10.1074/jbc.M803053200.
   Tarao K, 2013, SCAND J GASTROENTERO, V48, P729, DOI 10.3109/00365521.2013.782064.
   Wang LL, 2017, J MATER CHEM C, V5, P65, DOI 10.1039/c6tc03791g.
   Wen YZ, 2011, P NATL ACAD SCI USA, V108, P8345, DOI 10.1073/pnas.1103894108.
   Xiao ZL, 2003, HEPATOLOGY, V37, P1442, DOI 10.1053/jhep.2003.50243.
   Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010.
   Yuan SX, 2012, HEPATOLOGY, V56, P2231, DOI 10.1002/hep.25895.
   Zuo TT, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0056-0.},
Number-of-Cited-References = {28},
Times-Cited = {103},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Mol. Oncol.},
Doc-Delivery-Number = {JA4YK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000483365200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000478013400003,
Author = {Ezpeleta, Juliette and Baudouin, Vincent and Arellano-Anaya, Zaira E.
   and Boudet-Deyaud, Francois and Pietri, Mathea and Baudry, Anne and
   Haeberle, Anne-Marie and Bailly, Yannick and Kellermann, Odile and
   Launay, Jean-Marie and Schneider, Benoit},
Title = {Production of seedable Amyloid-β peptides in model of prion diseases
   upon PrPSc-induced PDK1 overactivation},
Journal = {NATURE COMMUNICATIONS},
Year = {2019},
Volume = {10},
Month = {AUG 1},
Abstract = {The presence of amyloid beta (A beta) plaques in the brain of some
   individuals with Creutzfeldt-Jakob or Gertsmann-Straussler-Scheinker
   diseases suggests that pathogenic prions (PrPSc) would have stimulated
   the production and deposition of A beta peptides. We here show in
   prion-infected neurons and mice that deregulation of the PDK1-TACE
   alpha-secretase pathway reduces the Amyloid Precursor Protein (APP)
   alpha-cleavage in favor of APP beta-processing, leading to A beta 40/42
   accumulation. A beta predominates as monomers, but is also found as
   trimers and tetramers. Prion-induced A beta peptides do not affect prion
   replication and infectivity, but display seedable properties as they can
   deposit in the mouse brain only when seeds of A beta trimers are
   co-transmitted with PrPSc. Importantly, brain A beta deposition
   accelerates death of prion-infected mice. Our data stress that PrPSc,
   through deregulation of the PDK1-TACE-APP pathway, provokes the
   accumulation of A beta, a prerequisite for the onset of an A beta
   seeds-induced A beta pathology within a prion-infectious context.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Schneider, B (Corresponding Author), Univ Paris 05, Sorbonne Paris Cite, UFR Sci Fondamentales \& Biomed, UMR 1124, F-75006 Paris, France.
   Schneider, B (Corresponding Author), INSERM, UMR 1124, F-75006 Paris, France.
   Launay, JM (Corresponding Author), Hop Lariboisiere, AP HP, INSERM UMR 942, F-75010 Paris, France.
   Launay, JM (Corresponding Author), Hoffmann La Roche Ltd, Pharma Res Dept, CH-4070 Basel, Switzerland.
   Ezpeleta, Juliette; Baudouin, Vincent; Arellano-Anaya, Zaira E.; Boudet-Deyaud, Francois; Pietri, Mathea; Baudry, Anne; Kellermann, Odile; Schneider, Benoit, Univ Paris 05, Sorbonne Paris Cite, UFR Sci Fondamentales \& Biomed, UMR 1124, F-75006 Paris, France.
   Ezpeleta, Juliette; Baudouin, Vincent; Arellano-Anaya, Zaira E.; Boudet-Deyaud, Francois; Pietri, Mathea; Baudry, Anne; Kellermann, Odile; Schneider, Benoit, INSERM, UMR 1124, F-75006 Paris, France.
   Haeberle, Anne-Marie; Bailly, Yannick, CNRS, Inst Neurosci Cellulaires \& Integrat, Traf Membranaire Cellules Syst Nerveux, UPR 3212, F-67000 Strasbourg, France.
   Launay, Jean-Marie, Hop Lariboisiere, AP HP, INSERM UMR 942, F-75010 Paris, France.
   Launay, Jean-Marie, Hoffmann La Roche Ltd, Pharma Res Dept, CH-4070 Basel, Switzerland.},
DOI = {10.1038/s41467-019-11333-3},
Article-Number = {3442},
EISSN = {2041-1723},
Keywords-Plus = {CREUTZFELDT-JAKOB-DISEASE; ALZHEIMER-TYPE NEUROPATHOLOGY; A-BETA;
   NEUROFIBRILLARY TANGLES; SECRETASE CLEAVAGE; PROTEIN; TRANSMISSION;
   MICE; TACE; ACCUMULATION},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {jean-marie.launay@inserm.fr
   benoit.schneider@parisdescartes.fr},
Affiliations = {Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Paris Cite; Universites de Strasbourg
   Etablissements Associes; Universite de Strasbourg; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Roche Holding},
ResearcherID-Numbers = {Schneider, Benoit/AAF-3850-2019
   Bauy, Anne/O-2624-2017},
ORCID-Numbers = {Schneider, Benoit/0000-0002-1377-2670
   launay, jean-marie/0000-0003-4809-1020
   ARELLANO-ANAYA, Zaira E/0000-0001-7847-0342
   PIETRI, Mathéa/0000-0002-1819-2878
   Bauy, Anne/0000-0002-7729-1753},
Funding-Acknowledgement = {French Agence Nationale de la Recherche (TargetingPDK1inAD)
   {[}ANR-16-CE16-0021-01]; European Joint Program on Neurodegenerative
   Diseases; Agence Nationale de la Recherche (PrPCPDK1)
   {[}ANR-14-JPCD-0003-01]; foundation Vaincre ALZHEIMER {[}FR-15033];
   INSERM; Domaine D'Interet Majeur - Cerveau\&Pensee - Region Ile de
   France; ANR PrPC\&PDK1 European project; ANR TargetingPDK1inAD program;
   Agence Nationale de la Recherche (ANR) {[}ANR-14-JPCD-0003,
   ANR-16-CE16-0021] Funding Source: Agence Nationale de la Recherche (ANR)},
Funding-Text = {We thank V. Mutel, G. Zurcher, E. Borroni, Z. Lam, M. Buhler, N.
   Pierron, and R. Hochkoppler for providing skillful methodological
   assistance for all data acquisition and statistical analyses. We
   acknowledge M. Briley for helpful discussions and critical reading of
   the manuscript. This work was supported by the French Agence Nationale
   de la Recherche (TargetingPDK1inAD, no ANR-16-CE16-0021-01), the
   European Joint Program on Neurodegenerative Diseases and Agence
   Nationale de la Recherche (PrPC\&PDK1, no
   ANR-14-JPCD-0003-01), the foundation Vaincre ALZHEIMER (grant no
   FR-15033) and INSERM. JE is funded by Domaine D'Interet Majeur -
   Cerveau\&Pensee - Region Ile de France. ZAA is a post-doctoral fellow
   funded by the ANR PrPC\&PDK1 European project and the ANR
   TargetingPDK1inAD program. VB is funded by the ANR PrPC\&PDK1
   European project.},
Cited-References = {Alleaume-Butaux A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005073.
   AMANO N, 1992, ACTA NEUROPATHOL, V84, P15, DOI 10.1007/BF00427210.
   Arima K, 2005, J VIROL, V79, P7104, DOI 10.1128/JVI.79.11.7104-7112.2005.
   ARMBRUSTER DA, 1994, CLIN CHEM, V40, P1233.
   Baier M, 2008, INT J DEV NEUROSCI, V26, P821, DOI 10.1016/j.ijdevneu.2008.07.001.
   BARCIKOWSKA M, 1995, HISTOPATHOLOGY, V26, P445.
   Bate C, 2004, J NEUROSCI METH, V138, P217, DOI 10.1016/j.jneumeth.2004.04.001.
   Bateman RJ, 2007, J AM SOC MASS SPECTR, V18, P997, DOI 10.1016/j.jasms.2007.02.009.
   Randall JB, 2006, NAT MED, V12, P856, DOI 10.1038/nm1438.
   BERNSTINE EG, 1973, P NATL ACAD SCI USA, V70, P3899, DOI 10.1073/pnas.70.12.3899.
   BROWN P, 1990, NEUROLOGY, V40, P226, DOI 10.1212/WNL.40.2.226.
   BUCCARON MH, 1990, P NATL ACAD SCI USA, V87, P1922, DOI 10.1073/pnas.87.5.1922.
   Bush MF, 2010, ANAL CHEM, V82, P9557, DOI 10.1021/ac1022953.
   Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765.
   Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351.
   Calleja V, 2014, BIOCHEM SOC T, V42, P1435, DOI 10.1042/BST20140222.
   Ciccimaro E, 2010, BIOANALYSIS, V2, P311, DOI 10.4155/BIO.09.185.
   Condello C, 2018, NEUROBIOL DIS, V109, P191, DOI 10.1016/j.nbd.2017.03.014.
   De Strooper B, 2010, PHYSIOL REV, V90, P465, DOI 10.1152/physrev.00023.2009.
   Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200.
   Duyckaerts C, 2018, ACTA NEUROPATHOL, V135, P201, DOI 10.1007/s00401-017-1791-x.
   Fasano C, 2006, J MOL NEUROSCI, V29, P195, DOI 10.1385/JMN:29:3:195.
   Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744.
   Gibbons R. D, 2001, STAT METHODS DETECTI, P48.
   GRAY F, 1994, ACTA NEUROPATHOL, V88, P106, DOI 10.1007/BF00294366.
   Hainfellner JA, 1998, ACTA NEUROPATHOL, V96, P116, DOI 10.1007/s004010050870.
   Hervé D, 2018, ACTA NEUROPATHOL, V135, P801, DOI 10.1007/s00401-018-1828-9.
   Hofler A, 2011, ANAL BIOCHEM, V414, P179, DOI 10.1016/j.ab.2011.03.013.
   Jaunmuktane Z, 2018, ACTA NEUROPATHOL, V135, P671, DOI 10.1007/s00401-018-1822-2.
   Jaunmuktane Z, 2015, NATURE, V525, P247, DOI 10.1038/nature15369.
   KELLERMANN O, 1987, DIFFERENTIATION, V35, P197, DOI 10.1111/j.1432-0436.1987.tb00169.x.
   Kempster S, 2007, NEUROREPORT, V18, P479, DOI 10.1097/WNR.0b013e328058678d.
   Kloniecki M, 2011, J MOL BIOL, V407, P110, DOI 10.1016/j.jmb.2011.01.012.
   Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P911, DOI 10.1007/s00401-016-1565-x.
   Kreutzer AG, 2016, J AM CHEM SOC, V138, P4634, DOI 10.1021/jacs.6b01332.
   Lesné S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533.
   Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007.
   Loubet D, 2012, FASEB J, V26, P678, DOI 10.1096/fj.11-185579.
   Manook A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031310.
   Manterola L, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.147.
   Meyer-Luehmann M, 2006, SCIENCE, V313, P1781, DOI 10.1126/science.1131864.
   Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925.
   Mouillet-Richard S, 2000, J BIOL CHEM, V275, P9186, DOI 10.1074/jbc.275.13.9186.
   Mouillet-Richard S, 2008, J BIOL CHEM, V283, P23782, DOI 10.1074/jbc.M802433200.
   Parkin ET, 2007, P NATL ACAD SCI USA, V104, P11062, DOI 10.1073/pnas.0609621104.
   Pierson-Perry J. F., 2012, EVALUATION DETECTION, V32.
   Pietri M, 2013, NAT MED, V19, P1124, DOI 10.1038/nm.3302.
   POWERS JM, 1991, ACTA NEUROPATHOL, V83, P95, DOI 10.1007/BF00294437.
   Pradines E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.195.
   Pradines E, 2009, J NEUROCHEM, V110, P912, DOI 10.1111/j.1471-4159.2009.06176.x.
   Preusser M, 2006, J NEUROL NEUROSUR PS, V77, P413, DOI 10.1136/jnnp.2005.070805.
   Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0.
   Pujol-Pina R, 2015, SCI REP-UK, V5, DOI 10.1038/srep14809.
   Purro SA, 2018, NATURE, V564, P415, DOI 10.1038/s41586-018-0790-y.
   Rasmussen J, 2018, ACTA NEUROPATHOL, V135, P965, DOI 10.1007/s00401-018-1848-5.
   Ritchie DL, 2017, ACTA NEUROPATHOL, V134, P221, DOI 10.1007/s00401-017-1703-0.
   Ruotolo BT, 2008, NAT PROTOC, V3, P1139, DOI 10.1038/nprot.2008.78.
   Sarell CJ, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170158.
   Schneider B, 2003, P NATL ACAD SCI USA, V100, P13326, DOI 10.1073/pnas.2235648100.
   Schneider B, 2011, FRONT BIOSCI-LANDMRK, V16, P169, DOI 10.2741/3682.
   Selkoe DJ, 2008, BEHAV BRAIN RES, V192, P106, DOI 10.1016/j.bbr.2008.02.016.
   Senechal Y, 2007, J NEUROCHEM, V102, P1928, DOI 10.1111/j.1471-4159.2007.04672.x.
   Sherman MA, 2016, J NEUROSCI, V36, P9647, DOI 10.1523/JNEUROSCI.1899-16.2016.
   SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287.
   Tamgüney G, 2008, J GEN VIROL, V89, P1777, DOI 10.1099/vir.0.2008/001255-0.
   TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8.
   Tousseyn T, 2015, J NEUROPATH EXP NEUR, V74, P873, DOI 10.1097/NEN.0000000000000228.
   van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865.
   Villarreal S, 2017, J ALZHEIMERS DIS, V59, P1393, DOI 10.3233/JAD-170056.
   Weskamp G, 2004, J BIOL CHEM, V279, P4241, DOI 10.1074/jbc.M307974200.
   Whitehouse IJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159119.
   Winkler DT, 2001, J NEUROSCI, V21, P1619, DOI 10.1523/JNEUROSCI.21-05-01619.2001.
   Yamada M, 2012, PROG MOL BIOL TRANSL, V107, P41, DOI 10.1016/B978-0-12-385883-2.00006-0.
   Yang S, 2018, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00435.},
Number-of-Cited-References = {74},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Nat. Commun.},
Doc-Delivery-Number = {IM5DC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000478013400003},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000467240800034,
Author = {Farkhondeh, Tahereh and Samarghandian, Saeed and Azimi-Nezhad, Mohsen},
Title = {The role of arsenic in obesity and diabetes},
Journal = {JOURNAL OF CELLULAR PHYSIOLOGY},
Year = {2019},
Volume = {234},
Number = {8},
Pages = {12516-12529},
Month = {AUG},
Abstract = {As many individuals worlwide are exposed to arsenic, it is necessary to
   unravel the role of arsenic in the risk of obesity and diabetes.
   Therefore, the present study reviewed the effects of arsenic exposure on
   the risk and potential etiologic mechanisms of obesity and diabetes. It
   has been suggested that inflammation, oxidative stress, and apoptosis
   contribute to the pathogenesis of arsenic-induced diabetes and obesity.
   Though arsenic is known to cause diabetes through different mechanisms,
   the role of adipose tissue in diabetes is still unclear. This review
   exhibited the effects of arsenic on the metabolism and signaling
   pathways within adipose tissue (such as sirtuin 3 {[}SIRT3]- forkhead
   box O3 {[}FOXO3a], mitogen-activated protein kinase {[}MAPK],
   phosphoinositide-dependant kinase-1 {[}PDK-1], unfolded protein
   response, and C/EBP homologous protein {[}CHOP10]). Different types of
   adipokines involved in arsenic-induced diabetes are yet to be
   elucidated. Arsenic exerts negative effects on the white adipose tissue
   by decreasing adipogenesis and enhancing lipolysis. Some epidemiological
   studies have shown that arsenic can promote obesity. Nevertheless, few
   studies have indicated that arsenic may induce lipodystrophy. Arsenic
   multifactorial effects include accelerating birth and postnatal weight
   gains, elevated body fat content, glucose intolerance, insulin
   resistance, and increased serum lipid profile. Arsenic also elevated
   cord blood and placental, as well as postnatal serum leptin levels. The
   data from human studies indicate an association between inorganic
   arsenic exposure and the risk of diabetes and obesity. However, the
   currently available evidence is insufficient to conclude that
   low-moderate dose arsenic is associated with diabetes or obesity
   development. Therefore, more investigations are needed to determine
   biological mechanisms linking arsenic exposure to obesity and diabetes.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Review},
Language = {English},
Affiliation = {Samarghandian, S (Corresponding Author), Neyshabur Univ Med Sci, Dept Basic Med Sci, Neyshabur 1413993186, Iran.
   Farkhondeh, Tahereh, Birjand Univ Med Sci, Cardiovasc Dis Res Ctr, Birjand, Iran.
   Samarghandian, Saeed; Azimi-Nezhad, Mohsen, Neyshabur Univ Med Sci, Dept Basic Med Sci, Neyshabur 1413993186, Iran.},
DOI = {10.1002/jcp.28112},
ISSN = {0021-9541},
EISSN = {1097-4652},
Keywords = {apoptosis; arsenic; diabetes; inflammation; obesity; oxidative stress},
Keywords-Plus = {ADIPOSE-TISSUE DYSFUNCTION; OXIDATIVE STRESS; METABOLIC SYNDROME;
   DRINKING-WATER; LOW-LEVEL; GLUCOSE-INTOLERANCE; INSULIN-RESISTANCE;
   NATIONAL-HEALTH; EXPOSURE; LEAD},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {samarghandians1@nums.ac.ir},
Affiliations = {Birjand University of Medical Sciences},
ResearcherID-Numbers = {farkhondeh, tahereh/Y-2083-2018
   },
ORCID-Numbers = {farkhondeh, tahereh/0000-0002-9579-8339
   , Saeed/0000-0001-5461-9579},
Cited-References = {Agrawal S, 2015, FOOD CHEM TOXICOL, V86, P208, DOI 10.1016/j.fct.2015.10.013.
   Ahangarpour A, 2018, IRAN J PHARM RES, V17, P164.
   Ahmed S, 2011, ENVIRON HEALTH PERSP, V119, P258, DOI 10.1289/ehp.1002086.
   Alinejad S, 2018, BASIC CLIN PHARMACOL, V122, P56, DOI 10.1111/bcpt.12855.
   Alizadeh AM, 2014, BASIC CLIN PHARMACOL, V115, P297, DOI 10.1111/bcpt.12210.
   Ambrosio F, 2014, FREE RADICAL BIO MED, V74, P64, DOI 10.1016/j.freeradbiomed.2014.06.012.
   Andersen M. E., 2013, ENVIRON HEALTH PERSP, V121.
   Ashley-Martin J, 2018, ENVIRON INT, V121, P714, DOI 10.1016/j.envint.2018.10.008.
   Bae HS, 2013, TOX RESEARCH, V29, P137, DOI 10.5487/TR.2013.29.2.137.
   Baek K, 2017, ANN OCCUP ENVIRON ME, V29, DOI 10.1186/s40557-017-0181-0.
   Bräuner EV, 2014, ENVIRON HEALTH PERSP, V122, P1059, DOI 10.1289/ehp.1408198.
   Bulka CM, 2017, ENVIRON HEALTH PERSP, V125, DOI 10.1289/EHP1202.
   Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166.
   Castriota F, 2018, ENVIRON RES, V167, P248, DOI 10.1016/j.envres.2018.07.022.
   Chen Y, 2010, ENVIRON HEALTH PERSP, V118, P1299, DOI 10.1289/ehp.0901559.
   Díaz-Villaseñor A, 2008, TOXICOL APPL PHARM, V231, P291, DOI 10.1016/j.taap.2008.05.018.
   Ditzel E. J., 2015, ENV HLTH PERSPECT, V124, P201.
   Divya SP, 2015, TOXICOL SCI, V146, P290, DOI 10.1093/toxsci/kfv089.
   Duan XX, 2017, MOL IMMUNOL, V81, P160, DOI 10.1016/j.molimm.2016.12.005.
   Ettinger AS, 2009, ENVIRON HEALTH PERSP, V117, P1059, DOI 10.1289/ehp0800533.
   Falagas ME, 2006, LANCET INFECT DIS, V6, P438, DOI 10.1016/S1473-3099(06)70523-0.
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023.
   Farzan SF, 2016, ENVIRON HEALTH-GLOB, V15, DOI 10.1186/s12940-016-0194-0.
   Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI 10.1172/JCI20042162S.
   Gao N., 2018, J CELLULAR PHYSL.
   Garciafigueroa DY, 2013, TOXICOL SCI, V134, P335, DOI 10.1093/toxsci/kft108.
   Ghaderi A, 2015, DARU, V23, P1.
   Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762.
   Gomez-Rubio P, 2011, TOXICOL APPL PHARM, V252, P176, DOI 10.1016/j.taap.2011.02.007.
   Goodarzi F, 2011, INDIAN J FORENSIC ME, V5, P66.
   Gossai A, 2015, ENVIRON RES, V136, P180, DOI 10.1016/j.envres.2014.10.005.
   Grashow R, 2014, ENVIRON RES, V131, P131, DOI 10.1016/j.envres.2014.03.010.
   Gribble MO, 2012, AM J EPIDEMIOL, V176, P865, DOI 10.1093/aje/kws153.
   Gruber JF, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-45.
   Hajer GR, 2008, EUR HEART J, V29, P2959, DOI 10.1093/eurheartj/ehn387.
   HALL IH, 1994, ENVIRON HEALTH PERSP, V102, P21, DOI 10.2307/3431958.
   Haque R, 2017, ENDOCR METAB IMMUNE, V17, P176, DOI 10.2174/1871530317666170818114454.
   Hirosumi J, 2002, NATURE, V420, P333, DOI 10.1038/nature01137.
   Holcomb N, 2017, DNA REPAIR, V52, P70, DOI 10.1016/j.dnarep.2017.02.009.
   Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x.
   Huang JW, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/683124.
   Iantorno M, 2014, J BIOL REG HOMEOS AG, V28, P169.
   Islam MR, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-38.
   Kain V, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0444-7.
   Karoutsou E, 2012, Endocr Regul, V46, P37.
   Karrari P, 2013, J PAK MED ASSOC, V63, P711.
   KAWAGUCHI I, 1981, FOLIA PHARMACOL JPN, V78, P213, DOI 10.1254/fpj.78.213.
   Kozul-Horvath CD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038249.
   Kuo C. C., 2017, ENVIRON HEALTH PERSP, P125.
   Lasram MM, 2014, TOXICOLOGY, V322, P1, DOI 10.1016/j.tox.2014.04.009.
   LEE TC, 1994, ENVIRON HEALTH PERSP, V102, P101, DOI 10.2307/3431770.
   Li SX, 2017, ADV EXP MED BIOL, V975, P855, DOI 10.1007/978-94-024-1079-2\_67.
   Li SW, 2017, ECOTOXICOLOGY, V26, P1078, DOI 10.1007/s10646-017-1835-y.
   Li SW, 2017, CHEMOSPHERE, V185, P618, DOI 10.1016/j.chemosphere.2017.07.055.
   Lu TH, 2011, TOXICOL LETT, V201, P15, DOI 10.1016/j.toxlet.2010.11.019.
   Mahram M, 2013, J RES MED SCI, V18, P408.
   Bonaventura MM, 2017, FOOD CHEM TOXICOL, V100, P207, DOI 10.1016/j.fct.2016.12.025.
   Maury E, 2010, MOL CELL ENDOCRINOL, V314, P1, DOI 10.1016/j.mce.2009.07.031.
   Mehrpour O, 2009, CLIN TOXICOL, V47, P838, DOI 10.1080/15563650903203684.
   Moon KA, 2017, INT J EPIDEMIOL, V46, P1924, DOI 10.1093/ije/dyx202.
   Moon KA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182435.
   Navas-Acien A, 2009, EPIDEMIOLOGY, V20, P816, DOI 10.1097/EDE.0b013e3181afef88.
   Oyagbemi A. A., 2017, REDOX REPORT, V2, P1.
   Özcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160.
   Palacios J, 2012, BIOL TRACE ELEM RES, V148, P224, DOI 10.1007/s12011-012-9355-3.
   Park SJ, 2016, J ENDOCRINOL INVEST, V39, P1031, DOI 10.1007/s40618-016-0459-z.
   Park SK, 2006, ENVIRON HEALTH PERSP, V114, P1718, DOI 10.1289/ehp.8992.
   Paul DS, 2007, TOXICOL APPL PHARM, V222, P305, DOI 10.1016/j.taap.2007.01.010.
   Paul DS, 2007, ENVIRON HEALTH PERSP, V115, P734, DOI 10.1289/ehp.9867.
   Peters BA, 2015, FREE RADICAL BIO MED, V85, P174, DOI 10.1016/j.freeradbiomed.2015.04.020.
   Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872.
   Renu K, 2018, TOXICOL LETT, V284, P86, DOI 10.1016/j.toxlet.2017.11.032.
   Rezaei M, 2017, CAN J DIABETES, V41, P273, DOI 10.1016/j.jcjd.2016.10.008.
   Rhee SY, 2013, J KOREAN MED SCI, V28, P861, DOI 10.3346/jkms.2013.28.6.861.
   Rodriguez KF, 2016, ENVIRON HEALTH PERSP, V124, P336, DOI 10.1289/ehp.1509703.
   Ronco AM, 2010, BIOL TRACE ELEM RES, V136, P269, DOI 10.1007/s12011-009-8546-z.
   Saggese G, 2013, J MATERN-FETAL NEO M, V26, P64, DOI 10.3109/14767058.2013.832870.
   Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2.
   Samarghandian S, 2016, CYTOKINE, V88, P20, DOI 10.1016/j.cyto.2016.08.002.
   Samarghandian Saeed, 2015, Interdiscip Toxicol, V8, P151, DOI {[}10.1515/intox-2015-0023, 10.1515/intox-2015-0023].
   Samarghandian S, 2016, CAN J PHYSIOL PHARM, V94, P388, DOI 10.1139/cjpp-2014-0412.
   Samarghandian S, 2013, TOXICOL MECH METHOD, V23, P432, DOI 10.3109/15376516.2013.777136.
   Sarker M, 2017, J HAZARD MATER, V335, P162, DOI 10.1016/j.jhazmat.2017.04.044.
   Schleicher SB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178857.
   Sripaoraya K, 2017, RISK MANAG HEALTHC P, V10, P41, DOI 10.2147/RMHP.S128277.
   Srivastava S, 2009, TOXICOL APPL PHARM, V241, P90, DOI 10.1016/j.taap.2009.08.004.
   Tinkov AA, 2015, BIOMETALS, V28, P231, DOI 10.1007/s10534-015-9823-2.
   Tseng CH, 2000, ENVIRON HEALTH PERSP, V108, P847, DOI 10.2307/3434992.
   Urriade V, 2017, MICROBIOL RES, V203, P10, DOI 10.1016/j.micres.2017.06.004.
   Wang CH, 2002, CIRCULATION, V105, P1804, DOI 10.1161/01.CIR.0000015862.64816.B2.
   Wang SL, 2007, ENVIRON INT, V33, P805, DOI 10.1016/j.envint.2007.03.004.
   Wang SL, 2010, ARSEN ENVIR, P254.
   Wang XM, 2014, AM J PHYSIOL-RENAL, V306, pF205, DOI 10.1152/ajprenal.90005.2013.
   Wauson EM, 2002, TOXICOL SCI, V65, P211, DOI 10.1093/toxsci/65.2.211.
   Wei M, 2018, BIOL TRACE ELEM RES, V183, P80, DOI 10.1007/s12011-017-1111-2.
   Xue P, 2011, BIOCHEM BIOPH RES CO, V407, P360, DOI 10.1016/j.bbrc.2011.03.024.
   ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0.},
Number-of-Cited-References = {97},
Times-Cited = {82},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {60},
Journal-ISO = {J. Cell. Physiol.},
Doc-Delivery-Number = {HX2SA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000467240800034},
DA = {2026-02-04},
}

@article{ WOS:000474329700095,
Author = {How, Chun Ming and Yen, Pei-Ling and Wei, Chia-Cheng and Li, Shang-Wei
   and Liao, Vivian Hsiu-Chuan},
Title = {Early life exposure to di(2-ethylhexyl)phthalate causes age-related
   declines associated with insulin/IGF-1-like signaling pathway and SKN-1
   in Caenorhabditis elegans},
Journal = {ENVIRONMENTAL POLLUTION},
Year = {2019},
Volume = {251},
Pages = {871-878},
Month = {AUG},
Abstract = {Di(2-ethylhexyl)phthalate (DEHP) is an ubiquitous and emerging
   contaminant that is widely present in food, agricultural crop, and the
   environment, posing a potential risk to human health. This study
   utilized the nematode Caenorhabditis elegans to decipher the toxic
   effects of early life exposure to DEHP on aging and its underlying
   mechanisms. The results showed that exposure to DEHP at 0.1 and 1.5 mg/L
   inhibited locomotive behaviors. In addition, DEHP exposure significantly
   shortened the mean lifespan of the worms and further adversely affected
   pharyngeal pumping rate and defecation cycle in aged worms. Moreover,
   DEHP exposure also further enhanced accumulation of age-related
   biomarkers including lipofuscin, lipid peroxidation, and intracellular
   reactive oxygen species in aged worms. In addition, exposure to DEHP
   significantly suppressed gene expression of hsp-16.1, hsp-16.49, and
   hsp-70 in aged worms. Further evidences showed that mutation of genes
   involved in insulin/IGF-1-like signaling (IIS) pathway (daf-2, age-1,
   pdk-1, akt-1, akt-2, and daf-16) restored lipid peroxidation
   accumulation upon DEHP exposure in aged worms, whereas skn-1 mutation
   resulted in enhanced lipid peroxidation accumulation. Therefore, IIS and
   SKN-1 may serve as an important molecular basis for DEHP-induced
   age-related declines in C. elegans. Since IIS and SKN-1 are highly
   conserved among species, the age-related declines caused by DEHP
   exposure may not be exclusive in C elegans, leading to adverse human
   health consequences due to widespread and persistent DEHP contamination
   in the environment. (C) 2019 Published by Elsevier Ltd.},
Publisher = {ELSEVIER SCI LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Liao, VHC (Corresponding Author), Natl Taiwan Univ, Dept Bioenvironm Syst Engn, Taipei 106, Taiwan.
   How, Chun Ming; Yen, Pei-Ling; Wei, Chia-Cheng; Li, Shang-Wei; Liao, Vivian Hsiu-Chuan, Natl Taiwan Univ, Dept Bioenvironm Syst Engn, Taipei 106, Taiwan.},
DOI = {10.1016/j.envpol.2019.04.141},
ISSN = {0269-7491},
EISSN = {1873-6424},
Keywords = {DEHP; Age-related declines; Caenorhabditis elegans; Insulin/IGF-1
   signaling; SKN-1},
Keywords-Plus = {DI-(2-ETHYLHEXYL) PHTHALATE DEHP; OXIDATIVE STRESS; REPRODUCTIVE
   OUTCOMES; PRENATAL EXPOSURE; AGING PROCESS; ESTERS; SPAN; BIOMARKERS;
   SEDIMENTS; PROTEINS},
Research-Areas = {Environmental Sciences \& Ecology},
Web-of-Science-Categories  = {Environmental Sciences},
Author-Email = {vivianliao@ntu.edu.tw},
Affiliations = {National Taiwan University},
ResearcherID-Numbers = {How, Chun Ming/JPK-6038-2023},
ORCID-Numbers = {Wei, Chia-Cheng/0000-0002-0694-7284
   How, Chun Ming/0000-0001-5219-3826},
Funding-Acknowledgement = {Ministry of Science and Technology, Taiwan {[}MOST
   105-2320-B002-024-MY3]},
Funding-Text = {This work was financially supported in part by grant (MOST
   105-2320-B002-024-MY3) from Ministry of Science and Technology, Taiwan
   to Professor Vivian Liao.},
Cited-References = {Abdel-Kawi SH, 2016, FOOD CHEM TOXICOL, V90, P64, DOI 10.1016/j.fct.2016.02.003.
   Adeniyi AA, 2011, ENVIRON MONIT ASSESS, V172, P561, DOI 10.1007/s10661-010-1354-2.
   Akintola AA, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00013.
   Aranda A, 2013, TOXICOL IN VITRO, V27, P954, DOI 10.1016/j.tiv.2013.01.016.
   Axelsson J, 2015, ENVIRON RES, V138, P264, DOI 10.1016/j.envres.2015.02.024.
   Barakat R, 2017, TOXICOL SCI, V156, P96, DOI 10.1093/toxsci/kfw248.
   Blackwell TK, 2015, FREE RADICAL BIO MED, V88, P290, DOI 10.1016/j.freeradbiomed.2015.06.008.
   Calderwood SK, 2009, GERONTOLOGY, V55, P550, DOI 10.1159/000225957.
   Cao XL, 2010, COMPR REV FOOD SCI F, V9, P21, DOI 10.1111/j.1541-4337.2009.00093.x.
   Chen CF, 2017, MAR POLLUT BULL, V124, P767, DOI 10.1016/j.marpolbul.2016.11.064.
   Collins James J, 2008, WormBook, P1, DOI 10.1895/wormbook.1.137.1.
   Dai YH, 2015, HORM BEHAV, V71, P41, DOI 10.1016/j.yhbeh.2015.03.008.
   DEFOE DL, 1990, ENVIRON TOXICOL CHEM, V9, P623, DOI 10.1002/etc.5620090509.
   DiLoreto R, 2015, MOL BIOL CELL, V26, P4524, DOI 10.1091/mbc.E14-06-1084.
   Dmitriev LF, 2010, AGEING RES REV, V9, P200, DOI 10.1016/j.arr.2009.09.004.
   Drummen GPC, 2002, FREE RADICAL BIO MED, V33, P473, DOI 10.1016/S0891-5849(02)00848-1.
   Gerstbrein B, 2005, AGING CELL, V4, P127, DOI 10.1111/j.1474-9726.2005.00153.x.
   Hannon PR, 2016, TOXICOL SCI, V150, P97, DOI 10.1093/toxsci/kfv317.
   Herrero O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171719.
   Höhn A, 2013, REDOX BIOL, V1, P140, DOI 10.1016/j.redox.2013.01.006.
   Hoogewijs D, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-9.
   How CM, 2018, SCI TOTAL ENVIRON, V640, P485, DOI 10.1016/j.scitotenv.2018.05.314.
   Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701.
   Huang C, 2004, P NATL ACAD SCI USA, V101, P8084, DOI 10.1073/pnas.0400848101.
   Kim JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071392.
   Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8.
   Leung MCK, 2008, TOXICOL SCI, V106, P5, DOI 10.1093/toxsci/kfn121.
   Li SW, 2018, SCI TOTAL ENVIRON, V634, P260, DOI 10.1016/j.scitotenv.2018.03.355.
   Liguori I, 2018, CLIN INTERV AGING, V13, P757, DOI 10.2147/CIA.S158513.
   Lin CY, 2017, ENVIRONMENTAL TECHNOLOGY AND INNOVATIONS, P7.
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039.
   Magdouli S, 2013, J ENVIRON MANAGE, V127, P36, DOI 10.1016/j.jenvman.2013.04.013.
   Martinez-Arguelles DB, 2016, ANDROLOGY-US, V4, P573, DOI 10.1111/andr.12175.
   Mu XY, 2015, J HAZARD MATER, V298, P232, DOI 10.1016/j.jhazmat.2015.05.052.
   Murphy Coleen T, 2013, WormBook, P1, DOI 10.1895/wormbook.1.164.1.
   Murshid A, 2013, INT J HYPERTHER, V29, P442, DOI 10.3109/02656736.2013.798873.
   Niermann S, 2015, REPROD TOXICOL, V53, P23, DOI 10.1016/j.reprotox.2015.02.013.
   Pradhan A, 2018, CHEMOSPHERE, V190, P375, DOI 10.1016/j.chemosphere.2017.09.123.
   Rowdhwal SSS, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1750368.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Sorrentino JA, 2014, TRENDS MOL MED, V20, P375, DOI 10.1016/j.molmed.2014.04.004.
   Sugawara S, 2013, J CLIN BIOCHEM NUTR, V52, P139, DOI 10.3164/jcbn.12-88.
   Sui HX, 2014, INT J HYG ENVIR HEAL, V217, P695, DOI 10.1016/j.ijheh.2014.02.006.
   Sykiotis GP, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3112re3.
   Tan L, 2015, TOXICOL LETT, V235, P75, DOI 10.1016/j.toxlet.2015.03.010.
   Tsalik EL, 2003, J NEUROBIOL, V56, P178, DOI 10.1002/neu.10245.
   Tseng IL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082657.
   Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030.
   Viswanathan MP, 2017, TOXICOLOGY, V386, P60, DOI 10.1016/j.tox.2017.05.005.
   Xu K, 2018, IEEE ASIAN SOLID STA, P293.
   You HH, 2014, FOOD CHEM TOXICOL, V71, P272, DOI 10.1016/j.fct.2014.06.012.
   Yu CW, 2016, CHEMOSPHERE, V150, P632, DOI 10.1016/j.chemosphere.2016.01.004.
   Zarean M, 2016, ENVIRON SCI POLLUT R, V23, P24642, DOI 10.1007/s11356-016-7648-3.
   Zhang W, 2017, TOXICOL APPL PHARM, V316, P17, DOI 10.1016/j.taap.2016.12.010.
   Zota AR, 2014, ENVIRON HEALTH PERSP, V122, P235, DOI 10.1289/ehp.1306681.},
Number-of-Cited-References = {55},
Times-Cited = {32},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {85},
Journal-ISO = {Environ. Pollut.},
Doc-Delivery-Number = {IH2MU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000474329700095},
DA = {2026-02-04},
}

@article{ WOS:000478017700006,
Author = {Kennedy, Barry E. and Murphy, John Patrick and Clements, Derek R. and
   Konda, Prathyusha and Holay, Namit and Kim, Youra and Pathak, Gopal P.
   and Giacomantonio, Michael A. and El Hiani, Yassine and Gujar, Shashi},
Title = {Inhibition of Pyruvate Dehydrogenase Kinase Enhances the Antitumor
   Efficacy of Oncolytic Reovirus},
Journal = {CANCER RESEARCH},
Year = {2019},
Volume = {79},
Number = {15},
Pages = {3824-3836},
Month = {AUG 1},
Abstract = {Oncolytic viruses (OV) such as reovirus preferentially infect and kill
   cancer cells. Thus, the mechanisms that dictate the susceptibility of
   cancer cells to OV-induced cytotoxicity hold the key to their success in
   clinics. Here, we investigated whether cancer cell metabolism defines
   its susceptibility to OV and if OV-induced metabolic perturbations can
   be therapeutically targeted. Using mass spectrometrybased metabolomics
   and extracellular flux analysis on a panel of cancer cell lines with
   varying degrees of susceptibility to reovirus, we found that OV-induced
   changes in central energy metabolism, pyruvate metabolism, and oxidative
   stress correlate with their susceptibility to reovirus. In particular,
   reovirus infection accentuated Warburg-like metabolic perturbations in
   cell lines relatively resistant to oncolysis. These metabolic changes
   were facilitated by oxidative stress-induced inhibitory phosphorylation
   of pyruvate dehydrogenase (PDH) that impaired the routing of pyruvate
   into the tricarboxylic acid cycle and established a metabolic state
   unsupportive of OV replication. From the therapeutic perspective,
   reactivation of PDH in cancer cells that were weakly sensitive for
   reovirus, either through PDH kinase (PDK) inhibitors dichloroacetate and
   AZD7545 or short hairpin RNAspecific depletion of PDK1, enhanced the
   efficacy of reovirus-induced oncolysis in vitro and in vivo. These
   findings identify targeted metabolic reprogramming as a possible
   combination strategy to enhance the antitumor effects of OV in clinics.
   Significance: This study proposes targeted metabolic reprogramming as a
   valid combinatorial strategy to enhance the translational efficacy of
   oncolytic virus-based cancer therapies.},
Publisher = {AMER ASSOC CANCER RESEARCH},
Address = {615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA},
Type = {Article},
Language = {English},
Affiliation = {Gujar, S (Corresponding Author), Dalhousie Univ, Fac Med, Sir Charles Tupper Bldg, Halifax, NS B3H 1X5, Canada.
   Kennedy, Barry E.; Murphy, John Patrick; Clements, Derek R.; Holay, Namit; Kim, Youra; Pathak, Gopal P.; Giacomantonio, Michael A.; Gujar, Shashi, Dalhousie Univ, Dept Pathol, Halifax, NS, Canada.
   Konda, Prathyusha; Gujar, Shashi, Dalhousie Univ, Dept Microbiol \& Immunol, Halifax, NS, Canada.
   El Hiani, Yassine, Dalhousie Univ, Dept Physiol \& Biophys, Halifax, NS, Canada.
   Gujar, Shashi, Dalhousie Univ, Dept Biol, Halifax, NS, Canada.
   Gujar, Shashi, IWK Hlth Ctr, Ctr Innovat \& Collaborat Hlth Syst Res, Halifax, NS, Canada.},
DOI = {10.1158/0008-5472.CAN-18-2414},
ISSN = {0008-5472},
EISSN = {1538-7445},
Keywords-Plus = {DICHLOROACETATE; CANCER; METABOLISM; PHOSPHORYLATION; INDUCTION;
   APOPTOSIS; COMPONENT; AZD7545; GROWTH; VIRUS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {shashi.gujar@dal.ca},
Affiliations = {Dalhousie University; Dalhousie University; Dalhousie University;
   Dalhousie University; Dalhousie University; Dalhousie University
   Hospital},
ResearcherID-Numbers = {Konda, Prathyusha/AAX-4774-2020
   Pathak, Gopal/NPJ-3009-2025},
ORCID-Numbers = {Clements, Derek/0000-0002-0796-8845
   Konda, Prathyusha/0000-0002-6861-4442
   Gujar, Shashi/0000-0002-5427-0829
   El Hiani, Yassine/0000-0002-1251-5066
   Pathak, Gopal/0009-0005-2991-5575},
Funding-Acknowledgement = {Canadian Institutes of Health Research (CIHR); Canadian Cancer Society
   Research Institute; Terry Fox Research Institute (TFRI); Beatrice Hunter
   Cancer Research Institute's (BHCRI) Cancer Research Training Program
   (CRTP); TFRI; Dalhousie Medical Research Foundation (DMRF); BHCRI CRTP
   program; QEII Health Sciences Centre Foundation; GIVETOLIVE Becky Beaton
   Award; CIHR; Nova Scotia Graduate Scholarship; DMRF},
Funding-Text = {We thank Alejandro Cohen formass spectrometry help and Nadia Farbstein
   for animal work. This work was supported by Canadian Institutes of
   Health Research (CIHR), Canadian Cancer Society Research Institute, and
   Terry Fox Research Institute (TFRI). B.E. Kennedy and J.P. Murphy are
   funded by Beatrice Hunter Cancer Research Institute's (BHCRI) Cancer
   Research Training Program (CRTP), with B.E. Kennedy's support coming
   from TFRI and Dalhousie Medical Research Foundation (DMRF). M.A.
   Giacomantonio is funded by BHCRI CRTP program with funds provided by
   QEII Health Sciences Centre Foundation and GIVETOLIVE Becky Beaton
   Award. D.R. Clements and Y. Kim are funded by CIHR, P. Konda and N.
   Holay are funded by Nova Scotia Graduate Scholarship, and S. Gujar is
   supported by DMRF.},
Cited-References = {ACKERMANN WW, 1951, J BIOL CHEM, V189, P421.
   Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Burke JD, 2014, J VIROL, V88, P3485, DOI 10.1128/JVI.02649-13.
   Chang CW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0250-x.
   Coffey MC, 1998, SCIENCE, V282, P1332, DOI 10.1126/science.282.5392.1332.
   da Costa LS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033871.
   Delgado T, 2010, P NATL ACAD SCI USA, V107, P10696, DOI 10.1073/pnas.1004882107.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Gujar SA, 2010, MOL CANCER THER, V9, P2924, DOI 10.1158/1535-7163.MCT-10-0590.
   Hingorani P, 2011, CANCER-AM CANCER SOC, V117, P1764, DOI 10.1002/cncr.25741.
   Ikeda Y, 2004, AURIS NASUS LARYNX, V31, P407, DOI 10.1016/j.anl.2004.07.003.
   Jiang H, 2016, J IMMUNOL, V197, P2880, DOI 10.4049/jimmunol.1600474.
   Jung GS, 2016, SCI REP-UK, V6, DOI 10.1038/srep30846.
   Kaarbo M, 2011, MITOCHONDRION, V11, P935, DOI 10.1016/j.mito.2011.08.008.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Korotchkina LG, 2001, J BIOL CHEM, V276, P37223, DOI 10.1074/jbc.M103069200.
   Li CY, 2015, ONCOTARGET, V6, P1544, DOI 10.18632/oncotarget.2838.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Marcato P, 2007, MOL THER, V15, P1522, DOI 10.1038/sj.mt.6300179.
   Mazzon M, 2013, P NATL ACAD SCI USA, V110, P12444, DOI 10.1073/pnas.1302140110.
   Morrell JA, 2003, BIOCHEM SOC T, V31, P1168.
   Murphy JP, 2015, MOL CELL PROTEOMICS, V14, P2454, DOI 10.1074/mcp.M114.045849.
   Pol J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115641.
   Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i.
   Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187.
   Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585.
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089.
   Shmulevitz M, 2010, CANCER RES, V70, P4912, DOI 10.1158/0008-5472.CAN-09-4676.
   SMITH RE, 1969, VIROLOGY, V39, P791, DOI 10.1016/0042-6822(69)90017-8.
   Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499.
   Stuart SD, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-4.
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9.
   Ting L, 2011, NAT METHODS, V8, P937, DOI {[}10.1038/NMETH.1714, 10.1038/nmeth.1714].
   Xiao LL, 2010, MOL CELL BIOCHEM, V340, P31, DOI 10.1007/s11010-010-0397-6.
   Yamane K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098032.
   Yaromina A, 2012, STRAHLENTHER ONKOL, V188, P431, DOI 10.1007/s00066-011-0054-3.
   Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024.
   Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8.},
Number-of-Cited-References = {40},
Times-Cited = {25},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Cancer Res.},
Doc-Delivery-Number = {IM5ES},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000478017700006},
DA = {2026-02-04},
}

@article{ WOS:000472694500009,
Author = {Kolekar, Parag D. and Patil, Swapnil M. and Suryavanshi, V, Mangesh and
   Suryawanshi, Suresh S. and Khandare, V, Rahul and Govindwar, Sanjay P.
   and Jadhav, Jyoti P.},
Title = {Microcosm study of atrazine bioremediation by indigenous microorganisms
   and cytotoxicity of biodegraded metabolites},
Journal = {JOURNAL OF HAZARDOUS MATERIALS},
Year = {2019},
Volume = {374},
Pages = {66-73},
Month = {JUL 15},
Abstract = {Intensive use of atrazine in agriculture to increase crop productivity
   has resulted in pollution and consequently deteriorated the environment.
   Three isolated bacteria, Rhodococcus sp. BCH2 (RB), Bacillus sp. PDK1
   (BP1) and Bacillus sp. PDK2 (BP2) possessing capability to degrade
   atrazine were used in different combinations (RB + BP1, RB + BP2, BP1 +
   BP2, RB + BP1 + BP2) to prepare a highly effective bacterial consortium
   which can significantly reduce the toxicity of atrazine. Cytotoxicity
   tests evaluated by MTT assay on HepG2 indicated significant decrease in
   the toxicity of atrazine by the consortium RB + BP1 + BP2 due to its
   effective degradation and formation of simpler and less/nontoxic
   metabolites compared to other combinations of consortia. A microcosm
   study was conducted to check the survivability of this consortium (RB +
   BP1 + BP2) in the presence of atrazine and indigenous soil microflora
   for four weeks. LC-Q-TOF/MS analysis revealed that RB + BP1 + BP2 could
   degrade atrazine to various simple metabolites in the microcosm. The
   cluster analysis of the DGGE patterns of the microcosm of control-soil,
   soil exposed to atrazine and soil augmented with consortium in the
   presence of atrazine (1000 mg kg(-1)) revealed a shift in microbial
   community of soil. The microbial dynamics studies suggested that the
   augmented bacteria were well-thrived with natural microflora during four
   weeks of exposure to atrazine.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Jadhav, JP (Corresponding Author), Shivaji Univ, Dept Biotechnol, Kolhapur 416004, Maharashtra, India.
   Kolekar, Parag D.; Jadhav, Jyoti P., Shivaji Univ, Dept Biotechnol, Kolhapur 416004, Maharashtra, India.
   Kolekar, Parag D.; Suryawanshi, Suresh S.; Jadhav, Jyoti P., Shivaji Univ, Dept Biochem, Kolhapur 416004, Maharashtra, India.
   Patil, Swapnil M.; Govindwar, Sanjay P., Hanyang Univ, Dept Earth Resources \& Environm Engn, Seoul 04763, South Korea.
   Suryavanshi, Mangesh, V, Natl Ctr Cell Sci, Pune 411007, Maharashtra, India.
   Khandare, Rahul, V, Amity Univ, Amity Inst Biotechnol, Mumbai 410206, Maharashtra, India.},
DOI = {10.1016/j.jhazmat.2019.01.023},
ISSN = {0304-3894},
EISSN = {1873-3336},
Keywords = {Atrazine; Microcosm; Bioremediation; LC-Q-TOF/MS analysis; Cytotoxicity},
Keywords-Plus = {BACTERIAL COMMUNITY; HERBICIDE ATRAZINE; SOIL; DEGRADATION; DIVERSITY;
   TOXICITY; BIODIVERSITY; PHYLOGENIES; EXPOSURE; LAB},
Research-Areas = {Engineering; Environmental Sciences \& Ecology},
Web-of-Science-Categories  = {Engineering, Environmental; Environmental Sciences},
Author-Email = {jpjbiochem@gmail.com},
Affiliations = {Shivaji University; Shivaji University; Hanyang University; Department
   of Biotechnology (DBT) India; National Centre for Cell Science, Pune
   (NCCS)},
ResearcherID-Numbers = {Suryavanshi, Mangesh Vasant/Y-5630-2019
   Patil, Swapnil/AAJ-8444-2021
   Suryawanshi, Suresh/PGA-1099-2026
   Govindwar, Sanjay/E-7387-2010
   Khandare, Rahul/AGM-1047-2022},
ORCID-Numbers = {Suryavanshi, Mangesh Vasant/0000-0002-6054-3926
   Patil, Swapnil/0000-0001-8706-6325
   Suryawanshi, Suresh/0000-0001-5923-175X
   Govindwar, Sanjay/0000-0002-2098-6538
   Khandare, Rahul/0000-0003-0116-9847},
Funding-Acknowledgement = {UGC, New Delhi (DRS-SAP II) {[}F.4-8/2015/DRS II (SAP-II)]},
Funding-Text = {We sincerely thanks to UGC, New Delhi (DRS-SAP II, Grant
   No.F.4-8/2015/DRS II (SAP-II) for providing fellowship. Thanks, are also
   due to Dr. Manoj Mahimkar ACTREC, New Mumbai for providing HepG2 cell
   line and lab facility as well as Dr. Priyanka Bhosale for assistance in
   cell culture study.},
Cited-References = {Altieri MA, 1999, AGR ECOSYST ENVIRON, V74, P19, DOI 10.1016/S0167-8809(99)00028-6.
   Fernández LA, 2013, ANN MICROBIOL, V63, P207, DOI 10.1007/s13213-012-0463-2.
   Briceño G, 2010, SCI TOTAL ENVIRON, V408, P2833, DOI 10.1016/j.scitotenv.2010.03.014.
   Chen QL, 2015, ENVIRON SCI POLLUT R, V22, P996, DOI 10.1007/s11356-014-3369-7.
   Christin MS, 2004, AQUAT TOXICOL, V67, P33, DOI 10.1016/j.aquatox.2003.11.007.
   Dar SA, 2005, APPL ENVIRON MICROB, V71, P2325, DOI 10.1128/AEM.71.5.2325-2330.2005.
   de Lorenzo V, 2009, CLIN MICROBIOL INFEC, V15, P63, DOI 10.1111/j.1469-0691.2008.02683.x.
   Fakhouri WD, 2010, ENVIRON HEALTH PERSP, V118, P1400, DOI 10.1289/ehp.0900738.
   Fazlurrahman, 2009, LETT APPL MICROBIOL, V49, P721, DOI 10.1111/j.1472-765X.2009.02724.x.
   FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325.
   Gao JP, 2018, ECOTOX ENVIRON SAFE, V159, P317, DOI 10.1016/j.ecoenv.2018.05.017.
   Govantes F, 2009, MICROB BIOTECHNOL, V2, P178, DOI 10.1111/j.1751-7915.2008.00073.x.
   Graziano N, 2006, ENVIRON SCI TECHNOL, V40, P1163, DOI 10.1021/es051586y.
   Hase Y, 2008, BIOCHEM BIOPH RES CO, V366, P66, DOI 10.1016/j.bbrc.2007.11.107.
   Hayes TB, 2002, P NATL ACAD SCI USA, V99, P5476, DOI 10.1073/pnas.082121499.
   Hussain R, 2011, ECOTOXICOLOGY, V20, P1, DOI 10.1007/s10646-010-0515-y.
   Iwasaki A, 2007, PEST MANAG SCI, V63, P261, DOI 10.1002/ps.1334.
   Johnsen K, 2001, BIOL FERT SOILS, V33, P443, DOI 10.1007/s003740100351.
   Kadam AA, 2013, BIORESOURCE TECHNOL, V132, P276, DOI 10.1016/j.biortech.2013.01.059.
   Kolekar PD, 2014, ENVIRON SCI POLLUT R, V21, P2334, DOI 10.1007/s11356-013-2151-6.
   Krutz LJ, 2010, J ENVIRON QUAL, V39, P1369, DOI 10.2134/jeq2009.0197.
   Lin T, 2008, CHEMOSPHERE, V72, P122, DOI 10.1016/j.chemosphere.2007.11.059.
   Mäder P, 2002, SCIENCE, V296, P1694, DOI 10.1126/science.1071148.
   Matsushita Y, 2015, J MICROBIOL METH, V112, P11, DOI 10.1016/j.mimet.2015.02.011.
   Ros M, 2006, APPL SOIL ECOL, V34, P93, DOI 10.1016/j.apsoil.2006.03.010.
   Sagarkar S, 2016, INDIAN J PHARMACOL, V48, P200, DOI 10.4103/0253-7613.178842.
   Sagarkar S, 2014, J ENVIRON MANAGE, V139, P208, DOI 10.1016/j.jenvman.2014.02.016.
   Sagarkar S, 2013, ENVIRON POLLUT, V172, P108, DOI 10.1016/j.envpol.2012.07.048.
   SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454.
   Sass JB, 2006, INT J OCCUP ENV HEAL, V12, P260.
   Seghers D, 2003, FEMS MICROBIOL ECOL, V46, P139, DOI 10.1016/S0168-6496(03)00205-8.
   Sene L, 2010, BRAZ ARCH BIOL TECHN, V53, P487, DOI 10.1590/S1516-89132010000200030.
   Shapir N, 1997, J AGR FOOD CHEM, V45, P4481, DOI 10.1021/jf970423t.
   Shipitalo MJ, 2003, ENVIRON SCI TECHNOL, V37, P944, DOI 10.1021/es020870b.
   Singh B, 2016, CRIT REV MICROBIOL, V42, P245, DOI 10.3109/1040841X.2014.929564.
   Siripattanakul S, 2009, J APPL MICROBIOL, V106, P986, DOI 10.1111/j.1365-2672.2008.04075.x.
   Smith D, 2005, FEMS MICROBIOL ECOL, V53, P265, DOI 10.1016/j.femsec.2004.12.011.
   Song Y, 2009, SOIL BIOL BIOCHEM, V41, P905, DOI 10.1016/j.soilbio.2008.09.009.
   TAKEZAKI N, 1995, MOL BIOL EVOL, V12, P823.
   Tamura K, 2004, P NATL ACAD SCI USA, V101, P11030, DOI 10.1073/pnas.0404206101.
   Tamura K, 2007, MOL BIOL EVOL, V24, P1596, DOI 10.1093/molbev/msm092.
   Tourlomousis P, 2010, MICROB ECOL, V59, P776, DOI 10.1007/s00248-009-9613-x.
   Wang J, 2014, PLOS ONE, V9, DOI {[}10.1371/journal.pone.0104882, 10.1371/journal.pone.0087451, 10.1371/journal.pone.0107012].
   Wang QF, 2013, INT BIODETER BIODEGR, V77, P63, DOI 10.1016/j.ibiod.2012.11.003.
   Watharkar AD, 2018, ECOTOX ENVIRON SAFE, V161, P70, DOI 10.1016/j.ecoenv.2018.05.078.
   Weiner JA, 2004, AQUAT TOXICOL, V68, P121, DOI 10.1016/j.aquatox.2004.03.004.
   WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991.
   Winchester PD, 2009, ACTA PAEDIATR, V98, P664, DOI 10.1111/j.1651-2227.2008.01207.x.},
Number-of-Cited-References = {49},
Times-Cited = {45},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {105},
Journal-ISO = {J. Hazard. Mater.},
Doc-Delivery-Number = {IE9KY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000472694500009},
DA = {2026-02-04},
}

@article{ WOS:000476475900007,
Author = {Li, Chen and Niu, Yan and Zheng, Hong and Shan, Congjia and Chen, Qinbo
   and Yang, Zhongzhou and Zhao, Liangcai and Yang, Changwei and Gao,
   Hongchang},
Title = {Metabolic remodeling of cardiomyocytes identified in
   phosphoinositide-dependent kinase 1-deficient mice},
Journal = {BIOCHEMICAL JOURNAL},
Year = {2019},
Volume = {476},
Number = {13},
Pages = {1943-1954},
Month = {JUL 15},
Abstract = {Metabolic remodeling plays an essential role in the pathophysiology of
   heart failure (HF). Many studies have shown that the disruption of
   phosphoinositide-dependent protein kinase-1 (PDK1) caused severe and
   lethal HF; however, the metabolic pattern of PDK1 deletion remains
   ambiguous. H-1 nuclear magnetic resonance-based metabolomics was applied
   to explore the altered metabolic pattern in Pdk1-deficient mice.
   Principle component analysis showed significant separation as early as 4
   weeks of age, and dysfunction of metabolism precedes a morphological
   change in Pdk1-deficient mice. A time trajectory plot indicated that
   disturbed metabolic patterns were related to the pathological process of
   the HF in Pdk1-deficient mice, rather than the age of mice. Metabolic
   profiles demonstrated significantly increased levels of acetate,
   glutamate, glutamine, and O-phosphocholine in Pdk1 deletion mice. Levels
   of lactate, alanine, glycine, taurine, choline, fumarate, IMP, AMP, and
   ATP were significantly decreased compared with controls. Furthermore,
   PDK1 knockdown decreased the oxygen consumption rate in H9C2 cells as
   determined using a Seahorse XF96 Analyzer. These findings imply that the
   disruption of metabolism and impaired mitochondrial activity might be
   involved in the pathogenesis of HF with PDK1 deletion.},
Publisher = {PORTLAND PRESS LTD},
Address = {1ST FLR, 10 QUEEN STREET PLACE, LONDON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Gao, HC (Corresponding Author), Wenzhou Med Univ, Inst Metabon \& Med NMR, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China.
   Li, Chen; Niu, Yan; Zheng, Hong; Chen, Qinbo; Zhao, Liangcai; Yang, Changwei; Gao, Hongchang, Wenzhou Med Univ, Inst Metabon \& Med NMR, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China.
   Shan, Congjia; Yang, Zhongzhou, Nanjing Univ, Model Anim Res Ctr, Nanjing 210061, Jiangsu, Peoples R China.},
DOI = {10.1042/BCJ20190105},
ISSN = {0264-6021},
EISSN = {1470-8728},
Keywords-Plus = {HEART-FAILURE; PDK1; DEFICIENCY},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {gaohc27@wmu.edu.cn},
Affiliations = {Wenzhou Medical University; Nanjing University},
ResearcherID-Numbers = {Zheng, Hong/ABG-7392-2021
   Yang, Zhongzhou/H-3015-2014},
ORCID-Numbers = {Zheng, Hong/0000-0002-3401-721X
   Li, Chen/0000-0003-1947-0881
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81771386, 21575105,
   81770830]; Zhejiang Provincial Natural Science Foundation
   {[}LQ18H160027, LY17H160049]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China {[}nos. 81771386, 21575105, and 81770830], the Zhejiang Provincial
   Natural Science Foundation {[}nos. LQ18H160027 and LY17H160049].},
Cited-References = {{[}Anonymous], JOURNAL OF THE AMERICAN.
   Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI {[}10.1161/CIR.0000000000000485, 10.1161/CIR.0000000000000558].
   Budas GR, 2006, FASEB J, V20, P2556, DOI 10.1096/fj.06-6252fje.
   Di RM, 2010, CHINESE MED J-PEKING, V123, P2358, DOI 10.3760/cma.j.issn.0366-6999.2010.17.014.
   Doenst T, 2013, CIRC RES, V113, P709, DOI 10.1161/CIRCRESAHA.113.300376.
   Feng QT, 2010, MOL CELL BIOL, V30, P3711, DOI 10.1128/MCB.00420-10.
   Froger N, 2014, PROG RETIN EYE RES, V41, P44, DOI 10.1016/j.preteyeres.2014.03.001.
   Gao HC, 2013, MOL NEUROBIOL, V47, P123, DOI 10.1007/s12035-012-8336-z.
   Guasch-Ferré M, 2017, J AM HEART ASSOC, V6, DOI {[}10.1161/JAHA.117.006524, 10.1161/jaha.117.006524].
   Harjola VP, 2016, EUR J HEART FAIL, V18, P226, DOI 10.1002/ejhf.478.
   Heather LC, 2013, J MOL CELL CARDIOL, V55, P2, DOI 10.1016/j.yjmcc.2012.12.001.
   Ho JE, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008108.
   Hoes MF, 2018, EUR J HEART FAIL, V20, P910, DOI 10.1002/ejhf.1154.
   Hunter Wynn G, 2016, Curr Heart Fail Rep, V13, P119, DOI {[}10.1007/s11897-016-0289-5, 10.1007/s11897-016-0289-5].
   Ikegami R, 2018, CIRC J, V82, P10, DOI 10.1253/circj.CJ-17-1184.
   Ito K, 2009, P NATL ACAD SCI USA, V106, P8689, DOI 10.1073/pnas.0900064106.
   Lai L, 2014, CIRC-HEART FAIL, V7, P1022, DOI 10.1161/CIRCHEARTFAILURE.114.001469.
   Liu HL, 2013, CELL PHYSIOL BIOCHEM, V32, P1497, DOI 10.1159/000356586.
   McGarrah RW, 2018, CIRC RES, V122, P1238, DOI 10.1161/CIRCRESAHA.117.311002.
   Melenovsky V, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005290.
   Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469.
   Nguyen HM, 2016, J NEUROCHEM, V139, P68, DOI 10.1111/jnc.13753.
   Ni QZ, 2017, J PHYS CHEM B, V121, P8132, DOI 10.1021/acs.jpcb.7b07213.
   Peoples JNR, 2018, J BIOL CHEM, V293, P6925, DOI 10.1074/jbc.RA118.002566.
   Pointon AV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012733.
   Ruiz-Meana M, 2004, J PHYSIOL-LONDON, V558, P873, DOI 10.1113/jphysiol.2004.068320.
   Tanai E, 2016, COMPR PHYSIOL, V6, P187, DOI {[}10.1002/j.2040-4603.2016.tb00669.x, 10.1002/cphy.c140055].
   Van Bilsen M, 2004, ANN NY ACAD SCI, V1015, P238, DOI 10.1196/annals.1302.020.
   Weitzel LB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060292.
   Wende Adam R, 2017, JACC Basic Transl Sci, V2, P297, DOI {[}10.1016/j.jacbts.2016.11.009, 10.1016/j.jacbts.2016.11.009].},
Number-of-Cited-References = {30},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Biochem. J.},
Doc-Delivery-Number = {IK3FW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000476475900007},
DA = {2026-02-04},
}

@article{ WOS:000476606000090,
Author = {Di, Ruomin and Yang, Zhongzhou and Xu, Peng and Xu, Yingjia},
Title = {Silencing PDK1 limits hypoxia-induced pulmonary arterial hypertension in
   mice via the Akt/p70S6K signaling pathway},
Journal = {EXPERIMENTAL AND THERAPEUTIC MEDICINE},
Year = {2019},
Volume = {18},
Number = {1},
Pages = {699-704},
Month = {JUL},
Abstract = {The present study aimed to investigate the effect of
   phosphoinositide-dependent protein kinase-1 (PDK1) on hypoxia-induced
   pulmonary arterial hypertension (PAH). A mouse model of hypoxia-induced
   PAH was generated using normal or PDK1-knockout mice. Histological
   analysis and hemodynamic evaluations were performed to identify the
   progression of PAH. The expression and phosphorylation of PDK1/protein
   kinase B (Akt) signaling pathway associated proteins were detected by
   western blot analysis. Increased lung vessel thickness, right
   ventricular (RV) systolic pressure (RVSP), RV hypertrophy index (RVHI)
   values {[}the RV weight-to-left ventricular (LV) plus septum (S) weight
   ratio] and PDK1 expression were observed in the hypoxia-induced PAH
   model compared with the normal control. The phosphorylation of
   Akt(T308), proline-rich Akt1 substrate 1 (PRAS40) and S6KT(229) was also
   notably increased in the PAH model compared with the control. The
   changes of proteins were not observed in the hypoxia treated
   PDK1(flox/+): Tie2-Cre mice. Similarly, the RVSP and RVHI values, and
   PDK1 expression were reduced in the hypoxia treated PDK1(flox/+):
   Tie2-Cre mice to a level comparable with those in the control,
   suggesting that PDK1 partial knockout significantly limited
   hypoxia-induced PAH. The results of the present study indicate that PDK1
   is essential for hypoxia-induced PAH through the PDK1/Akt/S6K signaling
   cascades.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Xu, YJ (Corresponding Author), Fudan Univ, Peoples Hosp Shanghai 5, Dept Cardiol, 128 Ruili Rd, Shanghai 200240, Peoples R China.
   Di, Ruomin; Xu, Peng; Xu, Yingjia, Fudan Univ, Peoples Hosp Shanghai 5, Dept Cardiol, 128 Ruili Rd, Shanghai 200240, Peoples R China.
   Yang, Zhongzhou, Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing 210061, Jiangsu, Peoples R China.},
DOI = {10.3892/etm.2019.7627},
ISSN = {1792-0981},
EISSN = {1792-1015},
Keywords = {phosphoinositide-dependent protein kinase-1; pulmonary arterial
   hypertension; protein kinase B; hypoxia},
Keywords-Plus = {SMOOTH-MUSCLE-CELLS; PROLIFERATION; SURVIVAL; SENSITIVITY; DEFICIENCY;
   ACTIVATION; PROMOTES},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {anjiaozibbk3307@163.com},
Affiliations = {Fudan University; Nanjing University},
ResearcherID-Numbers = {Yang, Zhongzhou/H-3015-2014},
Funding-Acknowledgement = {Shanghai Science and Technology Commission {[}14ZR1432800]; Scientific
   Research Project of Minhang District Health and Family Planning
   Commission of Shanghai {[}2012MW02]},
Funding-Text = {The study was funded by the Shanghai Science and Technology Commission
   (grant no. 14ZR1432800) and the Scientific Research Project of Minhang
   District Health and Family Planning Commission of Shanghai (grant no.
   2012MW02).},
Cited-References = {Abdalla M, 2015, BRIT J PHARMACOL, V172, P4173, DOI 10.1111/bph.13203.
   Allard D, 2008, J BIOL CHEM, V283, P19739, DOI 10.1074/jbc.M710098200.
   Belgardt BF, 2008, CELL METAB, V7, P291, DOI 10.1016/j.cmet.2008.01.006.
   Cai CX, 2017, DIGEST DIS SCI, V62, P968, DOI 10.1007/s10620-017-4470-9.
   Chai XQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14404.
   Ciuclan L, 2011, AM J RESP CRIT CARE, V184, P1171, DOI 10.1164/rccm.201103-0412OC.
   Conejo R, 2002, ONCOGENE, V21, P3739, DOI 10.1038/sj.onc.1205469.
   Dai W, 2017, J INVEST DERMATOL, V137, P2407, DOI 10.1016/j.jid.2017.06.026.
   Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fang BJ, 2015, BIOMED PHARMACOTHER, V75, P148, DOI 10.1016/j.biopha.2015.07.029.
   Humar R, 2002, FASEB J, V16, DOI 10.1096/fj.01-0658com.
   Larson-Casey JL, 2014, J BIOL CHEM, V289, P36204, DOI 10.1074/jbc.M114.593285.
   Li GB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117440.
   Li W, 2017, ONCOTARGET, V8, P65143, DOI 10.18632/oncotarget.17821.
   Liu Y, 2015, EXP LUNG RES, V41, P363, DOI 10.3109/01902148.2015.1041581.
   Lu YJ, 2010, AM J RESP CELL MOL, V42, P432, DOI 10.1165/rcmb.2009-0002OC.
   Mora A, 2003, EMBO J, V22, P4666, DOI 10.1093/emboj/cdg469.
   Orlacchio A, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-4776.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Sankhe S, 2017, BBA-MOL CELL RES, V1864, P1631, DOI 10.1016/j.bbamcr.2017.06.018.
   Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225.
   Seufferlein T, 2004, CANCER RES, V56, P3895.
   Song YL, 2008, AM J PHYSIOL-HEART C, V295, pH677, DOI 10.1152/ajpheart.91519.2007.
   Song YL, 2005, CIRCULATION, V112, P553, DOI 10.1161/CIRCULATIONAHA.104.492488.
   Syed DN, 2014, BIOCHEM PHARMACOL, V89, P349, DOI 10.1016/j.bcp.2014.03.007.
   TANG H, 2014, AM J RESP CRIT CARE, V189.
   Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547.
   Wang J, 2015, 2015 IEEE INTERNATIONAL CONFERENCE ON MECHATRONICS AND AUTOMATION, P6, DOI 10.1109/ICMA.2015.7237447.
   Xia H, 2008, J EXP MED, V205, P1659, DOI 10.1084/jem.20080001.
   Yu ZL, 2015, J CARDIOVASC PHARM T, V20, P563, DOI 10.1177/1074248415574743.},
Number-of-Cited-References = {31},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Exp. Ther. Med.},
Doc-Delivery-Number = {IK5DN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000476606000090},
OA = {Green Published, gold},
DA = {2026-02-04},
}

@article{ WOS:000498849800004,
Author = {Liu, Tianze and Jin, Lizi and Chen, Miao and Zheng, Zongheng and Lu,
   Wenjing and Fan, Wenhua and Li, Liren and Zheng, Fufu and Zhu, Qiaohua
   and Qiu, Huijuan and Liu, Jiani and Chen, Manyu and Tian, Chunfang and
   Hu, Zheng and Zhang, Changlin and Luo, Meihua and Li, Jian and Kang,
   Tiebang and Yang, Lukun and Li, Yizhuo and Deng, Wuguo},
Title = {Ku80 promotes melanoma growth and regulates antitumor effect of
   melatonin by targeting HIF1-α dependent PDK-1 signaling pathway},
Journal = {REDOX BIOLOGY},
Year = {2019},
Volume = {25},
Month = {JUL},
Abstract = {Melanoma is one of the most malignant and aggressive cancers with high
   cancer-related deaths. However, it is unclear whether Ku80 regulates
   tumor growth in human melanoma. In this study, we screened a siRNA
   library targeting 6024 human genes and identified Ku80 as a potential
   therapeutic target in melanoma cells. Knockdown of Ku80 significantly
   suppressed melanoma cell proliferation and induced apoptosis, as well as
   enhanced the antitumor effect of melatonin in melanoma in vitro and in
   vivo. Overexpression of Ku80, however, promoted melanoma growth and
   increased the insensitivity of melanoma cells to melatonin.
   Mechanistically, we found that Ku80 bound to the PDK1 promoter and
   activated the transcription of PDK1. Moreover, we showed that the
   binding of Ku80 at the PDK-1 promoter was HIF1-alpha dependent, and
   melatonin degraded HIF1-alpha in melanoma cells. Furthermore, clinical
   data revealed that the expression of Ku80 and PDK-1 proteins were
   positively correlated and elevated in the tumor tissues of melanoma
   patients, and high expression of Ku80 predicted a poor prognosis in
   melanoma. Collectively, our study demonstrated that Ku80 promoted
   melanoma growth and regulated antitumor activity of melatonin by
   targeting HIF1-alpha dependent PDK-1 signaling pathway, suggesting that
   Ku80 may be a potential molecular target for melanoma treatment.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Yang, LK (Corresponding Author), Sun Yat sen Univ Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.
   Li, YZ (Corresponding Author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Anesthesiol, Zhuhai 519000, Peoples R China.
   Deng, WG (Corresponding Author), Sun Yat Sen Univ, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
   Liu, Tianze; Chen, Miao; Fan, Wenhua; Li, Liren; Qiu, Huijuan; Zhang, Changlin; Kang, Tiebang; Li, Yizhuo; Deng, Wuguo, Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou, Guangdong, Peoples R China.
   Zheng, Zongheng, Sun Yat Sen Univ, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China.
   Zheng, Fufu, Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.
   Zhu, Qiaohua; Luo, Meihua, Southern Med Univ, Shunde Hosp, Foshan, Peoples R China.
   Chen, Manyu; Tian, Chunfang; Hu, Zheng, Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China.
   Liu, Tianze; Jin, Lizi; Lu, Wenjing; Liu, Jiani; Li, Jian; Yang, Lukun, Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Guangdong, Peoples R China.},
DOI = {10.1016/j.redox.2019.101197},
Article-Number = {101197},
ISSN = {2213-2317},
Keywords = {Ku80; PDK-1; Melatonin; HIF1-alpha; Melanoma},
Keywords-Plus = {ISCHEMIA-REPERFUSION INJURY; IMPROVED SURVIVAL; OXIDATIVE STRESS; MEK
   INHIBITION; DNA-REPAIR; BRAF; EXPRESSION; CELLS; APOPTOSIS; VEMURAFENIB},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {yanglk@mail.sysu.edu.cn
   liyzh@sysucc.org.cn
   dengwg@sysucc.org.cn},
Affiliations = {State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen
   University; Sun Yat Sen University; Southern Medical University - China;
   Dalian Medical University; Sun Yat Sen University},
ResearcherID-Numbers = {Liu, Jiani/IRZ-3975-2023
   Li, Li-ren/HGF-3027-2022
   chen, manyu/OTI-9117-2025
   Li, Yizhuo/PBW-5695-2025
   Zhang, Changlin/ABI-4611-2020},
ORCID-Numbers = {Deng, wuguo/0000-0002-1193-1500
   Liu, Jiani/0000-0001-5291-1103
   Li, Li-ren/0000-0002-2803-3803
   },
Funding-Acknowledgement = {Sci-Tech Project Foundation of Guangzhou City, China {[}201607020038];
   National Natural Science Foundation of China, China {[}81702761,
   81802936, 81872267, 81772925]; China Postdoctoral Science Foundation,
   China {[}2018M643320]; Natural Science Foundation of Guangdong Province,
   China {[}2016A030311002, 2017A030313615, 2015A030313018]; Science and
   Technology Project Foundation of Zhuhai, China {[}20181117E030084]},
Funding-Text = {This work was supported by funds from the Sci-Tech Project Foundation of
   Guangzhou City, China (201607020038), National Natural Science
   Foundation of China, China (81702761, 81802936, 81872267, 81772925),
   China Postdoctoral Science Foundation, China (2018M643320), Natural
   Science Foundation of Guangdong Province, China (2016A030311002,
   2017A030313615, 2015A030313018), and the Science and Technology Project
   Foundation of Zhuhai, China (20181117E030084).},
Cited-References = {Abdelbaqi K, 2013, J CANCER, V4, P358, DOI 10.7150/jca.6289.
   Bejarano I, 2011, MOL CELL BIOCHEM, V353, P167, DOI 10.1007/s11010-011-0783-8.
   Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639.
   Cabrera J, 2010, J PINEAL RES, V49, P45, DOI 10.1111/j.1600-079X.2010.00765.x.
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782.
   Cheng XW, 2015, MOL MED REP, V11, P99, DOI 10.3892/mmr.2014.2753.
   Cutando A, 2012, ANTICANCER RES, V32, P2747.
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766.
   Espino J, 2013, J PINEAL RES, V54, P442, DOI 10.1111/jpi.12042.
   Espino J, 2011, J PINEAL RES, V51, P195, DOI 10.1111/j.1600-079X.2011.00876.x.
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5.
   Fan TF, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12457.
   Fell VL, 2015, MUTAT RES-REV MUTAT, V763, P15, DOI 10.1016/j.mrrev.2014.06.002.
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421.
   Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0.
   Guo WN, 2017, THERANOSTICS, V7, P2231, DOI 10.7150/thno.18835.
   Harima Yoko, 2003, Am J Clin Oncol, V26, pe80, DOI 10.1097/00000421-200308000-00028.
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466.
   Hoeflich KP, 2012, CANCER RES, V72, P210, DOI 10.1158/0008-5472.CAN-11-1515.
   Jang S, 2013, LANCET ONCOL, V14, pE60, DOI 10.1016/S1470-2045(12)70539-9.
   Kauffmann A, 2008, ONCOGENE, V27, P565, DOI 10.1038/sj.onc.1210700.
   Kim CH, 2002, J PHARMACOL EXP THER, V303, P753, DOI 10.1124/jpet.102.038505.
   Komuro Y, 2002, CANCER-AM CANCER SOC, V95, P1199, DOI 10.1002/cncr.10807.
   Kudová J, 2016, J PINEAL RES, V61, P493, DOI 10.1111/jpi.12366.
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868.
   Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200.
   Lin S, 2017, 2017 INTERNATIONAL CONFERENCE ON DIGITAL IMAGE COMPUTING - TECHNIQUES AND APPLICATIONS (DICTA), P628.
   Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037.
   Mariño G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016.
   Muñoz P, 1998, MOL CELL BIOL, V18, P5797, DOI 10.1128/MCB.18.10.5797.
   Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0.
   O'Sullivan D, 2014, TUMOR BIOL, V35, P6983, DOI 10.1007/s13277-014-1857-5.
   Ono M, 1996, MOL IMMUNOL, V33, P787, DOI 10.1016/0161-5890(96)00030-2.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Pariente R, 2017, CANCER CHEMOTH PHARM, V80, P985, DOI 10.1007/s00280-017-3441-3.
   Pariente R, 2016, J PINEAL RES, V60, P55, DOI 10.1111/jpi.12288.
   Parrella P, 2006, J CLIN PATHOL, V59, P1181, DOI 10.1136/jcp.2005.031088.
   Postow Michael A, 2015, Am Soc Clin Oncol Educ Book, P76, DOI {[}10.14694/edbook\_am.2015.35.76, 10.14694/EdBook\_AM.2015.35.76].
   Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338.
   Robert C, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15\_supll.9503.
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082.
   Sánchez DI, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12369.
   Saviozzi S, 2009, CANCER RES, V69, P3390, DOI 10.1158/0008-5472.CAN-08-2981.
   Song L, 2013, HISTOPATHOLOGY, V62, P343, DOI 10.1111/j.1365-2559.2012.04362.x.
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105.
   Tse AKW, 2017, REDOX BIOL, V11, P562, DOI 10.1016/j.redox.2017.01.010.
   Wang HX, 2015, CELL RES, V25, P370, DOI 10.1038/cr.2015.17.
   Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3.
   Yu LM, 2015, J PINEAL RES, V59, P420, DOI 10.1111/jpi.12272.
   Yu LM, 2015, J PINEAL RES, V59, P376, DOI 10.1111/jpi.12269.
   Zhao Cheng, 2016, HEBEI ENTERPRISES, V02, P61.
   Zhu L, 2017, THERANOSTICS, V7, P2732, DOI 10.7150/thno.18752.},
Number-of-Cited-References = {54},
Times-Cited = {22},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {22},
Journal-ISO = {Redox Biol.},
Doc-Delivery-Number = {JQ3LD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000498849800004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000471605300001,
Author = {Liu, Wei and Li, Pengfei and Mei, Ye},
Title = {Discovery of SBF1 as an allosteric inhibitor targeting the PIF-pocket of
   3-phosphoinositide-dependent protein kinase-1},
Journal = {JOURNAL OF MOLECULAR MODELING},
Year = {2019},
Volume = {25},
Number = {7},
Month = {JUL},
Abstract = {3-phosphoinositide-dependent protein kinase-1 (PDK1) plays a crucial
   role in the signal transduction of massive growth-related protein
   kinases. In this work, a computational study has been performed to
   investigate the binding pose of the hydrolyzed product of SBF1 (SBF1(-))
   with PDK1. The binding pose was predicted by Vina and was further
   refined in a molecular dynamics simulation. For comparison, four
   published low molecular weight compounds (PS48, PS171, PS182, and PS210)
   binding with PDK1 were also studied. SBF1(-) was anchored in the
   PIF-pocket of PDK1 with salt bridge interaction using its carboxylate
   moiety, which is a common feature among the known ligands. Hydrogen
   bonds to THR148 and vdW interactions with GLN150 also have contributions
   to the association affinity. The allosteric regulation on PDK1 via the
   binding of SBF1(-) was further addressed. The binding affinity of
   SBF1(-) in complex with PDK1 is comparable to those of PS171 and PS182,
   with an estimated IC50 in a range from 2.0 to 10.0 molar. Comparison
   between the free energy profiles with the presence or absence of SBF1(-)
   in the binding pocket indicates that the binding of SBF1(-) enhances the
   hinge motion and suppresses the fluctuation of the end-to-end distance
   in B of PDK1. These results demonstrate that SBF1(-) is a promising
   allosteric regulator of PDK1 targeting the PIF-binding pocket and can
   serve as a new scaffold template for the design of new drugs targeting
   PDK1.},
Publisher = {SPRINGER},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Mei, Y (Corresponding Author), East China Normal Univ, Sch Phys \& Mat Sci, State Key Lab Precis Spect, Shanghai 200062, Peoples R China.
   Mei, Y (Corresponding Author), NYU Shanghai, NYU ECNU Ctr Computat Chem, Shanghai 200062, Peoples R China.
   Mei, Y (Corresponding Author), Shanxi Univ, Collaborat Innovat Ctr Extreme Opt, Taiyuan 030006, Shanxi, Peoples R China.
   Liu, Wei; Li, Pengfei; Mei, Ye, East China Normal Univ, Sch Phys \& Mat Sci, State Key Lab Precis Spect, Shanghai 200062, Peoples R China.
   Mei, Ye, NYU Shanghai, NYU ECNU Ctr Computat Chem, Shanghai 200062, Peoples R China.
   Mei, Ye, Shanxi Univ, Collaborat Innovat Ctr Extreme Opt, Taiyuan 030006, Shanxi, Peoples R China.},
DOI = {10.1007/s00894-019-4069-5},
Article-Number = {187},
ISSN = {1610-2940},
EISSN = {0948-5023},
Keywords = {3-phosphoinositide-dependent protein kinase-1; SBF1; Allosteric; Free
   energy},
Keywords-Plus = {POTENT ANTITUMOR SAPONIN; PARTICLE MESH EWALD; GROWTH-FACTOR;
   SIDE-CHAIN; PDK1; MECHANISM; ANALOGS; BINDING; DOMAIN; ACTIVATION},
Research-Areas = {Biochemistry \& Molecular Biology; Biophysics; Chemistry; Computer
   Science},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Biophysics; Chemistry,
   Multidisciplinary; Computer Science, Interdisciplinary Applications},
Author-Email = {ymei@phy.ecnu.edu.cn},
Affiliations = {East China Normal University; New York University; NYU Shanghai; Shanxi
   University},
ResearcherID-Numbers = {Li, Pengfei/L-2703-2018
   Mei, Ye/C-5843-2009
   Liu, Wei/AAH-3615-2021},
ORCID-Numbers = {Mei, Ye/0000-0002-3953-8508
   Liu, Wei/0000-0001-6095-0217},
Funding-Acknowledgement = {Ministry of Science and Technology of China {[}2016YFA0501700]; National
   Natural Science Foundation of China {[}21773066]; Fundamental Research
   Funds for the Central Universities {[}001]},
Funding-Text = {Y.M. is supported by the Ministry of Science and Technology of China
   (Grant No. 2016YFA0501700), the National Natural Science Foundation of
   China (Grant No. 21773066) and the Fundamental Research Funds for the
   Central Universities. CPU time was supported by the Supercomputer Center
   of East China Normal University (ECNU Public Platform for Innovation No.
   001).},
Cited-References = {Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979.
   BROOKS BR, 1995, J COMPUT CHEM, V16, P1522, DOI 10.1002/jcc.540161209.
   Busschots K, 2012, CHEM BIOL, V19, P1152, DOI 10.1016/j.chembiol.2012.07.017.
   Case D. A., 2015, AMBER 2015.
   CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106.
   CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985.
   CORNELL WD, 1993, J AM CHEM SOC, V115, P9620, DOI 10.1021/ja00074a030.
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397.
   Deng SJ, 1999, J ORG CHEM, V64, P202, DOI 10.1021/jo981685c.
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117.
   Frisch M.J., 2009, GAUSSIAN 09 REV.
   Gohlke H, 2003, J MOL BIOL, V330, P891, DOI 10.1016/S0022-2836(03)00610-7.
   Guo CX, 1998, TETRAHEDRON LETT, V39, P1099, DOI 10.1016/S0040-4039(97)10814-0.
   Hauge C, 2007, EMBO J, V26, P2251, DOI 10.1038/sj.emboj.7601682.
   Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004.
   Hindie V, 2009, NAT CHEM BIOL, V5, P758, DOI 10.1038/nchembio.208.
   Hou TJ, 2012, J PROTEOME RES, V11, P2982, DOI 10.1021/pr3000688.
   Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9.
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869.
   Klimovich PV, 2015, J COMPUT AID MOL DES, V29, P397, DOI 10.1007/s10822-015-9840-9.
   KUBO S, 1992, PHYTOCHEMISTRY, V31, P2445, DOI 10.1016/0031-9422(92)83296-B.
   Li W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.538.
   Li WS, 2012, BIOCHEM PHARMACOL, V84, P172, DOI 10.1016/j.bcp.2012.04.006.
   Lopez-Garcia LA, 2011, CHEM BIOL, V18, P1463, DOI 10.1016/j.chembiol.2011.08.010.
   Luo R, 2002, J COMPUT CHEM, V23, P1244, DOI 10.1002/jcc.10120.
   Ma XQ, 2001, BIOORG MED CHEM LETT, V11, P2153, DOI 10.1016/S0960-894X(01)00389-4.
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255.
   Maj J, 2011, J MED CHEM, V54, P3298, DOI 10.1021/jm101648h.
   Miller BR, 2012, J CHEM THEORY COMPUT, V8, P3314, DOI 10.1021/ct300418h.
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256.
   Morzycki JW, 2004, BIOORG MED CHEM LETT, V14, P3323, DOI 10.1016/j.bmcl.2004.03.102.
   Pawson T, 2005, TRENDS BIOCHEM SCI, V30, P286, DOI 10.1016/j.tibs.2005.04.013.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pearl LH, 2002, CURR OPIN STRUC BIOL, V12, P761, DOI 10.1016/S0959-440X(02)00386-X.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5.
   Schulze JO, 2016, CELL CHEM BIOL, V23, P1193, DOI 10.1016/j.chembiol.2016.06.017.
   Shi BF, 2004, ANGEW CHEM INT EDIT, V43, P4324, DOI 10.1002/anie.200454237.
   Shirts MR, 2008, J CHEM PHYS, V129, DOI 10.1063/1.2978177.
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334.
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035.
   Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6.
   Yu WS, 2001, J AM CHEM SOC, V123, P3369, DOI 10.1021/ja004098t.},
Number-of-Cited-References = {46},
Times-Cited = {9},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {9},
Journal-ISO = {J. Mol. Model.},
Doc-Delivery-Number = {ID3VN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000471605300001},
DA = {2026-02-04},
}

@article{ WOS:000475960500001,
Author = {Macias-Garcia, Beatriz and Garcia-Marin, Luis J. and Bragado, Maria J.
   and Gonzalez-Fernandez, Lauro},
Title = {The calcium-sensing receptor regulates protein tyrosine phosphorylation
   through PDK1 in boar spermatozoa},
Journal = {MOLECULAR REPRODUCTION AND DEVELOPMENT},
Year = {2019},
Volume = {86},
Number = {7},
Pages = {751-761},
Month = {JUL},
Abstract = {Regulation of protein tyrosine phosphorylation is required for sperm
   capacitation and oocyte fertilization. The objective of the present work
   was to study the role of the calcium-sensing receptor (CaSR) on protein
   tyrosine phosphorylation in boar spermatozoa under capacitating
   conditions. To do this, boar spermatozoa were incubated in Tyrode's
   complete medium for 4 hr and the specific inhibitor of the CaSR,
   NPS2143, was used. Also, to study the possible mechanism(s) by which
   this receptor exerts its function, spermatozoa were incubated in the
   presence of specific inhibitors of the 3-phosphoinositide dependent
   protein kinase 1 (PDK1) and protein kinase A (PKA). Treatment with
   NPS2143, GSK2334470, an inhibitor of PDK1 and H-89, an inhibitor of PKA
   separately induced an increase in tyrosine phosphorylation of 18 and 32
   kDa proteins, a decrease in the serine/threonine phosphorylation of the
   PKA substrates together with a drop in sperm motility and viability. The
   present work proposes a new signalling pathway of the CaSR, mediated by
   PDK1 and PKA in boar spermatozoa under capacitating conditions. Our
   results show that the inhibition of the CaSR induces the inhibition of
   PDK1 that blocks PKA activity resulting in a rise in tyrosine
   phosphorylation of p18 and p32 proteins. This novel signalling pathway
   has not been described before and could be crucial to understand boar
   sperm capacitation within the female reproductive tract.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {González-Fernández, L (Corresponding Author), Univ Extremadura, Res Inst Biotechnol Livestock \& Cyneget INBIO GC, Ave Univ S-N, Caceres 10003, Spain.
   Macias-Garcia, Beatriz; Garcia-Marin, Luis J.; Bragado, Maria J.; Gonzalez-Fernandez, Lauro, Univ Extremadura, Res Inst Biotechnol Livestock \& Cyneget INBIO GC, Ave Univ S-N, Caceres 10003, Spain.
   Macias-Garcia, Beatriz, Univ Extremadura, Fac Vet Sci, Anim Med Dept, Caceres, Spain.
   Garcia-Marin, Luis J., Univ Extremadura, Fac Vet Sci, Dept Physiol, Caceres, Spain.
   Bragado, Maria J.; Gonzalez-Fernandez, Lauro, Univ Extremadura, Fac Vet Sci, Dept Biochem \& Mol Biol \& Genet, Caceres, Spain.},
DOI = {10.1002/mrd.23160},
ISSN = {1040-452X},
EISSN = {1098-2795},
Keywords = {boar; calcium-sensing receptor; protein kinases; protein tyrosine
   phosphorylation; spermatozoa},
Keywords-Plus = {PORCINE SPERM CAPACITATION; KINASE-A; MOUSE SPERMATOZOA; CYTOCHROME-C;
   CAMP; ACTIVATION; APOPTOSIS; CASR; MECHANISM; PATHWAYS},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology; Developmental Biology;
   Reproductive Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology; Developmental Biology;
   Reproductive Biology},
Author-Email = {lgonfer@unex.es},
Affiliations = {Universidad de Extremadura; Universidad de Extremadura; Universidad de
   Extremadura; Universidad de Extremadura},
ResearcherID-Numbers = {Macias Garcia, Beatriz/H-7301-2013
   Bragado, Maria Julia/L-6988-2014
   González Fernández, Lauro/A-2055-2019
   Garcia-Marin, Luis/L-4680-2014},
ORCID-Numbers = {Macias Garcia, Beatriz/0000-0001-5331-9793
   Bragado, Maria Julia/0000-0001-7770-0775
   González Fernández, Lauro/0000-0001-5568-548X
   },
Funding-Acknowledgement = {Agencia Estatal de Investigacion (AEI) of the Spanish Ministry of
   Economy, Industry and Competitiveness; Fondo Europeo de Desarrollo
   Regional (FEDER) {[}AGL2015-73249-JIN, RYC-2017-21545]; Agencia Estatal
   de Investigacion (AEI); Spanish Ministry of Economy, Industry and
   Competitiveness; Fondo Europeo de Desarrollo Regional (FEDER)},
Funding-Text = {Agencia Estatal de Investigacion (AEI) of the Spanish Ministry of
   Economy, Industry and Competitiveness and Fondo Europeo de Desarrollo
   Regional (FEDER), Grant/Award Number: AGL2015-73249-JIN and
   RYC-2017-21545; Agencia Estatal de Investigacion (AEI); Fondo Europeo de
   Desarrollo Regional (FEDER); Spanish Ministry of Economy, Industry and
   Competitiveness},
Cited-References = {Aitken RJ, 2013, MOL HUM REPROD, V19, P785, DOI 10.1093/molehr/gat067.
   Aitken RJ, 2013, INT J DEV BIOL, V57, P265, DOI 10.1387/ijdb.130146ja.
   Aitken RJ, 2015, ASIAN J ANDROL, V17, P633, DOI 10.4103/1008-682X.153850.
   Aparicio IM, 2007, MOL REPROD DEV, V74, P1035, DOI 10.1002/mrd.20663.
   AUSTIN CR, 1951, AUST J SCI RES SER B, V4, P581, DOI 10.1071/BI9510581.
   Bailey JL, 2005, THERIOGENOLOGY, V63, P599, DOI 10.1016/j.theriogenology.2004.09.034.
   Battistone MA, 2014, MOL HUM REPROD, V20, P1054, DOI 10.1093/molehr/gau073.
   Bravo MM, 2005, MOL REPROD DEV, V71, P88, DOI 10.1002/mrd.20286.
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0.
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   CHANG MC, 1951, NATURE, V168, P697, DOI 10.1038/168697b0.
   Chang WH, 2004, CELL CALCIUM, V35, P183, DOI 10.1016/j.ceca.2003.10.012.
   Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849.
   Choi YJ, 2008, J REPROD DEVELOP, V54, P68, DOI 10.1262/jrd.19116.
   De Santis T, 2009, REPRODUCTION, V138, P439, DOI 10.1530/REP-09-0078.
   Dubé C, 2005, J ANDROL, V26, P519, DOI 10.2164/jandrol.04163.
   Dubé C, 2003, J ANDROL, V24, P727.
   Ellinger I, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00371.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   GalantinoHomer HL, 1997, BIOL REPROD, V56, P707, DOI 10.1095/biolreprod56.3.707.
   González-Fernández L, 2012, REPRODUCTION, V144, P411, DOI 10.1530/REP-12-0067.
   González-Fernández L, 2009, BIOL REPROD, V80, P1239, DOI 10.1095/biolreprod.108.073486.
   González-Fernández L, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.107078.
   Harayama H, 2004, MOL REPROD DEV, V69, P436, DOI 10.1002/mrd.20176.
   Harayama H, 2004, MOL REPROD DEV, V69, P194, DOI 10.1002/mrd.20099.
   Harayama H, 2008, MOL REPROD DEV, V75, P1396, DOI 10.1002/mrd.20882.
   Harrison RAP, 2000, MOL REPROD DEV, V55, P220, DOI 10.1002/(SICI)1098-2795(200002)55:2<220::AID-MRD12>3.0.CO;2-I.
   Ickowicz D, 2012, ASIAN J ANDROL, V14, P816, DOI 10.1038/aja.2012.81.
   Kwon WS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15654.
   Li XH, 2016, ANIM REPROD SCI, V172, P39, DOI 10.1016/j.anireprosci.2016.07.001.
   Liu C, 2018, REPROD FERT DEVELOP, V30, P391, DOI 10.1071/RD16338.
   Liu C, 2015, BIOL REPROD, V93, DOI 10.1095/biolreprod.115.128579.
   Luna C, 2017, BIOL REPROD, V96, P800, DOI 10.1093/biolre/iox017.
   Macías-García B, 2017, THERIOGENOLOGY, V95, P69, DOI 10.1016/j.theriogenology.2017.03.002.
   Macías-García B, 2016, MOL REPROD DEV, V83, P236, DOI 10.1002/mrd.22615.
   Mendoza FJ, 2011, J ANDROL, V33, P96, DOI 10.2164/jandrol.110.011254.
   Mohan R, 2015, CRYOBIOLOGY, V70, P253, DOI 10.1016/j.cryobiol.2015.03.007.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Navarrete FA, 2015, J CELL PHYSIOL, V230, P1758, DOI 10.1002/jcp.24873.
   Saidak Z, 2009, MOL PHARMACOL, V76, P1131, DOI 10.1124/mol.109.058784.
   Seino S, 2005, PHYSIOL REV, V85, P1303, DOI 10.1152/physrev.00001.2005.
   Signorelli J, 2012, CELL TISSUE RES, V349, P765, DOI 10.1007/s00441-012-1370-3.
   Tabuchi T, 2008, J REPROD DEVELOP, V54, P502, DOI 10.1262/jrd.20021.
   Tang Y, 2004, GENETICS, V168, P1843, DOI 10.1534/genetics.104.032466.
   Tardif S, 2004, MOL REPROD DEV, V69, P428, DOI 10.1002/mrd.20178.
   Tardif S, 2003, BIOL REPROD, V68, P207, DOI 10.1095/biolreprod.102.005082.
   Visconti PE, 1997, DEV BIOL, V192, P351, DOI 10.1006/dbio.1997.8768.
   VISCONTI PE, 1995, DEVELOPMENT, V121, P1139.
   VISCONTI PE, 1995, DEVELOPMENT, V121, P1129.
   Visconti PE, 1998, BIOL REPROD, V59, P1, DOI 10.1095/biolreprod59.1.1.
   Zhang C, 2015, SCI CHINA LIFE SCI, V58, P14, DOI 10.1007/s11427-014-4779-y.},
Number-of-Cited-References = {52},
Times-Cited = {15},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Mol. Reprod. Dev.},
Doc-Delivery-Number = {IJ5RM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000475960500001},
DA = {2026-02-04},
}

@article{ WOS:000472500500007,
Author = {Mukaneza, Yvette and Cohen, Aaron and Rivard, Marie-Eve and Tardif,
   Jessica and Deschenes, Sonia and Ruiz, Matthieu and Laprise, Catherine
   and Des Rosiers, Christine and Coderre, Lise and Allen, Bruce G. and
   Beauchamp, Claudine and Bemeur, Chantal and Burelle, Yan and Charron,
   Guy and Labarthe, Francois and Landry, Jeannine and Lavallee, Genevieve
   and Lavoie, Pierre and Lesage, Sylvie and Maranda, Bruno and Morin,
   Charles and Rioux, John D. and Shoubridge, Eric A. and Legault, Julie
   Thompson and Tremblay, Nancy and Tremblay-Vaillancourt, Vanessa and
   Vachon, Luc and Villeneuve, Josee and LSFC Consortium},
Title = {mTORC1 is required for expression of LRPPRC and cytochrome-c
   oxidase but not HIF-1α in Leigh syndrome French Canadian type patient
   fibroblasts},
Journal = {AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY},
Year = {2019},
Volume = {317},
Number = {1},
Pages = {C58-C67},
Month = {JUL},
Abstract = {Leigh syndrome French Canadian type (LSFC) is a mitochondrial disease
   caused by mutations in the leucine-rich pentatricopeptide
   repeat-containing (LRPPRC) gene leading to a reduction of cytochrome-c
   oxidase (COX) expression reaching 50\% in skin fibroblasts. We have
   shown that under basal conditions, LSFC and control cells display
   similar ATP levels. We hypothesized that this occurs through
   upregulation of mechanistic target of rapamycin (mTOR)-mediated
   metabolic reprogramming. Our results showed that compared with controls,
   LSFC cells exhibited an upregulation of the mTOR complex 1 (mTORC1)/p70
   ribosomal S6 kinase pathway and higher levels of hypoxia-inducible
   factor 1 alpha (HIF-1 alpha) and its downstream target pyruvate
   dehydrogenase kinase 1 (PDHK1), a regulator of mitochondrial pyruvate
   dehydrogenase 1 (PDH1). Consistent with these signaling alterations,
   LSFC cells displayed a 40-61\% increase in {[}U-C-1(3)6]glucose
   contribution to pyruvate, lactate, and alanine formation, as well as
   higher levels of the phosphorylated and inactive form of PDH1-alpha.
   Interestingly. inhibition of mTOR with rapamycin did not alter HIF-1
   alpha or PDHK1 protein levels in LSFC fibroblasts. However, this
   treatment increased PDH1-a phosphorylation in control and LSFC cells and
   reduced ATP levels in control cells. Rapamycin also decreased LRPPRC
   expression by 41 and 11\% in LSFC and control cells. respectively, and
   selectively reduced COX subunit IV expression in LSFC fibroblasts. Taken
   together. our data demonstrate the importance of mTORC1, independent of
   the HIF-1 alpha/PDHK1 axis, in maintaining LRPPRC and COX expression in
   LSFC cells.},
Publisher = {AMER PHYSIOLOGICAL SOC},
Address = {9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA},
Type = {Article},
Language = {English},
Affiliation = {Coderre, L (Corresponding Author), Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
   Mukaneza, Yvette; Des Rosiers, Christine, Univ Montreal, Dept Nutr, Montreal, PQ, Canada.
   Ruiz, Matthieu; Coderre, Lise, Univ Montreal, Dept Med, Montreal, PQ, Canada.
   Mukaneza, Yvette; Cohen, Aaron; Rivard, Marie-Eve; Deschenes, Sonia; Ruiz, Matthieu; Des Rosiers, Christine; Coderre, Lise, Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
   Tardif, Jessica; Laprise, Catherine, Univ Quebec Chicoutimi, Dept Sci Fondamentales, Chicoutimi, PQ, Canada.
   Cohen, Aaron, Hebrew Univ Jerusalem, Alexander Grass Ctr Bioengn, Silberman 3-512, IL-91904 Jerusalem, Israel.},
DOI = {10.1152/ajpcell.00160.2017},
ISSN = {0363-6143},
EISSN = {1522-1563},
Keywords = {COX; LRPPRC; LSFC; mTORC1; mitochondrial diseases; rapamycin},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE; MITOCHONDRIAL DISORDERS; METABOLISM;
   MUTATION; COMPLEX; GROWTH; GENE; DEFICIENCY; ACTIVATION; PATHWAYS},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {lise.coderre@umontreal.ca},
Affiliations = {Universite de Montreal; Universite de Montreal; Universite de Montreal;
   University of Quebec; University of Quebec Chicoutimi; Hebrew University
   of Jerusalem},
ResearcherID-Numbers = {Laprise, Catherine/KBA-8790-2024
   Rioux, John/A-9599-2015
   Burelle, Yan/AAF-8104-2021},
ORCID-Numbers = {Ruiz, Matthieu/0000-0003-4583-9718
   Laprise, Catherine/0000-0001-5526-9945
   },
Funding-Acknowledgement = {Canadian Institutes of Health Research Emerging Team Grant on LSFC
   {[}CPG 102168]; Fondation du Grand defi Pierre Lavoie; Universite de
   Montreal and Corporation de Recherche et d'Action sur les Maladies
   Hereditaires},
Funding-Text = {This work was supported by a Canadian Institutes of Health Research
   Emerging Team Grant on LSFC (CPG 102168) and by the Fondation du Grand
   defi Pierre Lavoie. Y. Mukaneza was supported by a studentship from the
   Universite de Montreal and Corporation de Recherche et d'Action sur les
   Maladies Hereditaires.},
Cited-References = {Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27.
   Burelle Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120767.
   Cerniglia GJ, 2015, MOL CANCER THER, V14, P1928, DOI 10.1158/1535-7163.MCT-14-0888.
   Cheng SC, 2014, SCIENCE, V346, P821.
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684.
   Cooper MP, 2008, J BIOL CHEM, V283, P31960, DOI 10.1074/jbc.M805431200.
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200.
   Huang D, 2014, CELL REP, V8, P1930, DOI 10.1016/j.celrep.2014.08.028.
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002.
   Jain IH, 2016, SCIENCE, V352, P54, DOI 10.1126/science.aad9642.
   Ji KQ, 2015, FREE RADICAL BIO MED, V84, P161, DOI 10.1016/j.freeradbiomed.2015.03.020.
   Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360.
   Khan NA, 2015, INDIAN J MED RES, V141, P13, DOI 10.4103/0971-5916.154489.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002.
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017.
   Lauzier B, 2013, J MOL CELL CARDIOL, V55, P92, DOI 10.1016/j.yjmcc.2012.11.008.
   Legault JT, 2015, CELL REP, V13, P981, DOI 10.1016/j.celrep.2015.09.054.
   Liko D, 2015, J MOL MED, V93, P1061, DOI 10.1007/s00109-015-1326-7.
   Lu HS, 2002, J BIOL CHEM, V277, P23111, DOI 10.1074/jbc.M202487200.
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699.
   MORIN C, 1993, AM J HUM GENET, V53, P488.
   Morita M, 2015, CELL CYCLE, V14, P473, DOI 10.4161/15384101.2014.991572.
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001.
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035.
   Oláhová M, 2015, BRAIN, V138, P3503, DOI 10.1093/brain/awv291.
   Picard M, 2016, MITOCHONDRION, V30, P105, DOI 10.1016/j.mito.2016.07.003.
   Riazi R, 2009, MOL GENET METAB, V98, P349, DOI 10.1016/j.ymgme.2009.06.015.
   Ruiz M, 2015, METHOD ENZYMOL, V561, P107, DOI 10.1016/bs.mie.2015.06.026.
   Ruzzenente B, 2012, EMBO J, V31, P443, DOI 10.1038/emboj.2011.392.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   Sasarman F, 2015, HUM MOL GENET, V24, P480, DOI 10.1093/hmg/ddu468.
   Sasarman F, 2010, MOL BIOL CELL, V21, P1315, DOI 10.1091/mbc.E10-01-0047.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022.
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009.
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026.
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI {[}10.1152/physrev.00011.2008, 10.15252/embj.201488104].
   Tan Z, 2015, J IMMUNOL, V194, P6082, DOI 10.4049/jimmunol.1402469.
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469.
   Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541.
   Yasinska IM, 2014, CELL MOL LIFE SCI, V71, P699, DOI 10.1007/s00018-013-1421-2.
   Yoo H, 2015, BIOCHEM BIOPH RES CO, V460, P504, DOI 10.1016/j.bbrc.2015.03.060.
   Zhang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069282.
   Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014.},
Number-of-Cited-References = {48},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Am. J. Physiol.-Cell Physiol.},
Doc-Delivery-Number = {IE6QK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000472500500007},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000473283800004,
Author = {Pandey, Surya P. and Yan, Jie and Turner, Jerrold R. and Abraham, Clara},
Title = {Reducing IRF5 expression attenuates colitis in mice, but impairs the
   clearance of intestinal pathogens},
Journal = {MUCOSAL IMMUNOLOGY},
Year = {2019},
Volume = {12},
Number = {4},
Pages = {874-887},
Month = {JUL},
Abstract = {IRF5 genetic variants leading to decreased IRF5 expression reduce risk
   for ulcerative colitis. However, how IRF5 regulates intestinal
   inflammation and contributes to the balance between defenses against
   intestinal pathogens and inflammation in vivo, and the cells mediating
   this balance, are not known. We found that deleting IRF5 in mice led to
   reduced intestinal inflammation in the T cell transfer colitis model,
   with reduced Th1 and Th17, and increased Th2 cytokines. However, with
   orally-administered invasive S. Typhimurium, IRF5(-/-) mice demonstrated
   an increased bacterial burden in the context of reduced Th1 and Th17
   cytokines. IRF5 in macrophages was required for PDK1-dependent
   phagocytosis and for NF kappa B-dependent pathways mediating
   intracellular bacterial clearance. Despite reduced bacterial clearance
   pathways, in IRF5(-/-) mice exposed to high levels of resident
   intestinal bacteria after DSS-induced injury, the lower levels of
   inflammatory cytokines were associated with reduced intestinal
   permeability, and in turn, reduced bacterial translocation and
   intestinal inflammation. Consistent with the myeloid cell-intrinsic
   roles for IRF5 in vitro, mice with IRF5 deleted from myeloid cells
   demonstrated outcomes similar to those observed in IRF5(-/-) mice. While
   these data suggest that inhibition of IRF5 may be therapeutic in
   colitis, this needs to be balanced with the identified IRF5 role in
   protecting against intestinal pathogens.
   yyy},
Publisher = {NATURE PUBLISHING GROUP},
Address = {75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA},
Type = {Article},
Language = {English},
Affiliation = {Abraham, C (Corresponding Author), Yale Univ, Dept Internal Med, New Haven, CT 06510 USA.
   Pandey, Surya P.; Yan, Jie; Abraham, Clara, Yale Univ, Dept Internal Med, New Haven, CT 06510 USA.
   Turner, Jerrold R., Harvard Med Sch, Brigham \& Womens Hosp, Dept Pathol, Boston, MA 02115 USA.},
DOI = {10.1038/s41385-019-0165-1},
ISSN = {1933-0219},
EISSN = {1935-3456},
Keywords-Plus = {REGULATORY FACTOR 5; MACROPHAGE POLARIZATION; CYTOKINE SECRETION; RISK;
   PROMOTES; DISEASE; INNATE; SUSCEPTIBILITY; INFLAMMATION; ACTIVATION},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Author-Email = {clara.abraham@yale.edu},
Affiliations = {Yale University; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Brigham \& Women's Hospital},
ResearcherID-Numbers = {Pandey, Surya/AAD-8355-2021},
Funding-Acknowledgement = {Crohn's and Colitis Foundation {[}R01AI120369, R01DK099097,
   DKP30-34989]; National Center for Advancing Translational Sciences
   {[}UL1TR001863] Funding Source: NIH RePORTER; National Institute of
   Diabetes and Digestive and Kidney Diseases {[}R01DK099097] Funding
   Source: NIH RePORTER},
Funding-Text = {This work was supported by R01AI120369, R01DK099097, and DKP30-34989,
   and the Crohn's and Colitis Foundation. We thank Betsy Barnes for
   generously providing mice, Emiko Mizoguchi for reagents, and Matija Hedl
   for critical reading of the manuscript.},
Cited-References = {Abraham C, 2011, GASTROENTEROLOGY, V140, P1729, DOI 10.1053/j.gastro.2011.02.012.
   Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89.
   Balkhi MY, 2008, MOL CELL BIOL, V28, P7296, DOI 10.1128/MCB.00662-08.
   Bamias G, 2015, CURR OPIN GASTROEN, V31, P471, DOI 10.1097/MOG.0000000000000212.
   Barnes BJ, 2002, MOL CELL BIOL, V22, P5721, DOI 10.1128/MCB.22.16.5721-5740.2002.
   Byrne AJ, 2017, MUCOSAL IMMUNOL, V10, P716, DOI 10.1038/mi.2016.92.
   Castiglia V, 2016, CELL HOST MICROBE, V19, P375, DOI 10.1016/j.chom.2016.02.003.
   Cevik O, 2017, J BIOL CHEM, V292, P21676, DOI {[}10.1074/jbc.M117.792721, 10.1074/jbc.m117.792721].
   Chassaing B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044328.
   Courties G, 2014, J AM COLL CARDIOL, V63, P1556, DOI 10.1016/j.jacc.2013.11.023.
   Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061.
   Dhillon SS, 2014, GASTROENTEROLOGY, V147, P680, DOI 10.1053/j.gastro.2014.06.005.
   Dideberg V, 2007, HUM MOL GENET, V16, P3008, DOI 10.1093/hmg/ddm259.
   Eames HL, 2016, TRANSL RES, V167, P167, DOI 10.1016/j.trsl.2015.06.018.
   Feng D, 2012, EUR J IMMUNOL, V42, P1477, DOI 10.1002/eji.201141642.
   Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836.
   Freeman SA, 2014, IMMUNOL REV, V262, P193, DOI 10.1111/imr.12212.
   Graham RR, 2006, NAT GENET, V38, P550, DOI 10.1038/ng1782.
   Gratz N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001345.
   Hedl M, 2019, J IMMUNOL, V202, P920, DOI 10.4049/jimmunol.1800226.
   Hedl M, 2016, CELL REP, V16, P2442, DOI 10.1016/j.celrep.2016.07.060.
   Hedl M, 2012, J IMMUNOL, V188, P5348, DOI 10.4049/jimmunol.1103319.
   Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099.
   Inoue M, 2014, P NATL ACAD SCI USA, V111, P5295, DOI 10.1073/pnas.1321427111.
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582.
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990.
   Lahiri A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15614.
   Lahiri A, 2014, GASTROENTEROLOGY, V147, P835, DOI 10.1053/j.gastro.2014.06.024.
   Lee JC, 2013, CELL, V155, P57, DOI 10.1016/j.cell.2013.08.034.
   Li J, 2016, INFLAMMATION, V39, P1704, DOI 10.1007/s10753-016-0405-4.
   Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359.
   Lupp C, 2007, CELL HOST MICROBE, V2, P119, DOI 10.1016/j.chom.2007.06.010.
   Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339.
   Pandey AK, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000500.
   Patel S, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00311.
   Paun A, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001246.
   Saliba DG, 2014, CELL REP, V8, P1308, DOI 10.1016/j.celrep.2014.07.034.
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421.
   Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7.
   Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308.
   Wang FJ, 2006, GASTROENTEROLOGY, V131, P1153, DOI 10.1053/j.gastro.2006.08.022.
   Weiss M, 2015, P NATL ACAD SCI USA, V112, P11001, DOI 10.1073/pnas.1506254112.
   West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973.
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034.
   Xu Y, 2012, J IMMUNOL, V188, P4113, DOI 10.4049/jimmunol.1103113.
   Xu ZP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16035.
   Yang LS, 2012, J IMMUNOL, V189, P3741, DOI 10.4049/jimmunol.1201162.
   Zheng SS, 2013, MOL CELL BIOL, V33, P4857, DOI 10.1128/MCB.00797-13.},
Number-of-Cited-References = {48},
Times-Cited = {19},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Mucosal Immunol.},
Doc-Delivery-Number = {IF7SI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000473283800004},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000472769400012,
Author = {Ucha, Marcos and Coria, Santiago M. and Nunez, Adrian E. and
   Santos-Toscano, Raquel and Roura-Martinez, David and Fernandez-Ruiz,
   Javier and Higuera-Matas, Alejandro and Ambrosio, Emilio},
Title = {Morphine self-administration alters the expression of translational
   machinery genes in the amygdala of male Lewis rats},
Journal = {JOURNAL OF PSYCHOPHARMACOLOGY},
Year = {2019},
Volume = {33},
Number = {7},
Pages = {882-893},
Month = {JUL},
Abstract = {Background: Addiction is a chronic disorder with a high risk of relapse.
   The neural mechanisms mediating addictions require protein synthesis,
   which could be relevant for the development of more effective
   treatments. The mTOR signaling pathway regulates protein synthesis
   processes that have recently been linked to the development of drug
   addiction. Aims: To assess the effects of morphine self-administration
   and its subsequent extinction on the expression of several genes that
   act in this pathway, and on the levels of specific phosphoproteins (Akt,
   Gsk3 alpha/beta, mTOR, PDK1 and p70 S6 kinase) in the amygdala, nucleus
   accumbens, and the prefrontal cortex. Methods: Male Lewis rats underwent
   morphine self-administration (1 mg/kg) for 19 days. They subsequently
   were submitted to extinction training for 15 days. Rats were killed
   either after self-administration or extinction, their brains extracted,
   and gene expression or phosphoprotein levels were assessed. Results: We
   found an increase in Raptor and Eif4ebp2 expression in the amygdala of
   rats that self-administered morphine, even after extinction. The
   expression of Insr in the amygdala of control animals decreased over
   time while the opposite effect was seen in the rats that
   self-administered morphine. Conclusions: Our results suggest that
   morphine self-administration affects the gene expression of some
   elements of the translational machinery in the amygdala.},
Publisher = {SAGE PUBLICATIONS LTD},
Address = {1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Higuera-Matas, A (Corresponding Author), UNED, Sch Psychol, Dept Psychobiol, C Juan del Rosal 10, Madrid 28040, Spain.
   Ucha, Marcos; Coria, Santiago M.; Santos-Toscano, Raquel; Roura-Martinez, David; Higuera-Matas, Alejandro; Ambrosio, Emilio, UNED, Sch Psychol, Dept Psychobiol, C Juan del Rosal 10, Madrid 28040, Spain.
   Nunez, Adrian E., Univ Guadalajara, Lab Neuropsicol Adicc, Zapopan, Mexico.
   Santos-Toscano, Raquel, Univ Cent Lancashire, Sch Pharm \& Biomed Sci, Preston, Lancs, England.
   Fernandez-Ruiz, Javier, Univ Complutense, Fac Med, Dept Bioquim \& Biol Mol, Madrid, Spain.
   Fernandez-Ruiz, Javier, Inst Ramon y Cajal Invest Sanitaria IRYCIS, CIBER Enfermedades Neurodegenerat CIBERNED, Madrid, Spain.},
DOI = {10.1177/0269881119836206},
ISSN = {0269-8811},
EISSN = {1461-7285},
Keywords = {Morphine self-administration; Lewis rats; mTOR pathway; extinction;
   protein synthesis},
Keywords-Plus = {RAPAMYCIN SIGNALING PATHWAY; INDUCED PLACE PREFERENCE; SYNAPTIC
   PLASTICITY; MAMMALIAN TARGET; MOLECULAR-MECHANISMS; BINDING PARTNER;
   MTOR; KINASE; ACTIVATION; INSULIN},
Research-Areas = {Neurosciences \& Neurology; Pharmacology \& Pharmacy; Psychiatry},
Web-of-Science-Categories  = {Clinical Neurology; Neurosciences; Pharmacology \& Pharmacy; Psychiatry},
Author-Email = {ahiguera@psi.uned.es},
Affiliations = {Universidad Nacional de Educacion a Distancia (UNED); Universidad de
   Guadalajara; University of Lancashire; Complutense University of Madrid;
   CIBERNED},
ResearcherID-Numbers = {Higuera-Matas, Alejano/E-6565-2013
   Ucha, Marcos/GQO-7487-2022
   FERNANDEZ RUIZ, JOSE JAVIER/S-3875-2018
   AMBROSIO, EMILIO/G-3020-2015},
ORCID-Numbers = {Higuera-Matas, Alejano/0000-0003-3438-9387
   Ucha, Marcos/0000-0002-2786-025X
   FERNANDEZ RUIZ, JOSE JAVIER/0000-0002-4490-0604
   Santos Toscano, Raquel/0000-0003-3129-6732
   AMBROSIO, EMILIO/0000-0002-9190-7550},
Funding-Acknowledgement = {Spanish Ministerio de Economia y Competitividad {[}PSI2016-80541-P];
   Ministerio de Sanidad, Servicios Sociales e Igualdad (Red de Trastornos
   Adictivos of the Instituto de Salud Carlos III) {[}RTA-RD16/020/0022];
   Ministerio de Sanidad, Servicios Sociales e Igualdad (Plan Nacional
   sobre Drogas) {[}2016I073]; Direccion General de Investigacion de la
   Comunidad de Madrid {[}S-2011/BMD-2308]; UNED (Plan de Promocion de la
   Investigacion); European Union {[}JUST/2013/DPIP/AG/4823-EU MADNESS]},
Funding-Text = {The author(s) disclosed receipt of the following financial support for
   the research, authorship and/or publication of this article: This work
   was supported by the Spanish Ministerio de Economia y Competitividad
   (grant number PSI2016-80541-P), the Ministerio de Sanidad, Servicios
   Sociales e Igualdad (Red de Trastornos Adictivos, grant number
   RTA-RD16/020/0022 of the Instituto de Salud Carlos III; the Plan
   Nacional sobre Drogas, grant number 2016I073), the Direccion General de
   Investigacion de la Comunidad de Madrid (grant number S-2011/BMD-2308,
   Programa de Actividades I+ D+ I CANNAB-CM), UNED (Plan de Promocion de
   la Investigacion), and the European Union (grant number
   JUST/2013/DPIP/AG/4823-EU MADNESS).},
Cited-References = {Abcam, STRIPPING REPROBING.
   Bailey J, 2012, ADDICT BIOL, V17, P248, DOI 10.1111/j.1369-1600.2010.00311.x.
   Bakeman R, 2005, BEHAV RES METHODS, V37, P379, DOI 10.3758/BF03192707.
   Beckley JT, 2016, J NEUROSCI, V36, P701, DOI 10.1523/JNEUROSCI.2254-15.2016.
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320.
   Brown AL, 2011, INT J NEUROPSYCHOPH, V14, P1099, DOI 10.1017/S1461145710001367.
   Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0.
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2.
   Conover W.J., 1999, Practical nonparametric statistics.
   Costa-Mattioli M, 2009, NEURON, V61, P10, DOI 10.1016/j.neuron.2008.10.055.
   Cui Y, 2010, NEUROSCIENCE, V171, P134, DOI 10.1016/j.neuroscience.2010.08.064.
   Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322.
   Dayas CV, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00013.
   Düvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022.
   Everitt BJ, 2003, ANN NY ACAD SCI, V985, P233.
   Franklin BM, 2007, SECOND EDUC CHANG WO, P3.
   Gao Y, 2014, INT J NEUROPSYCHOPH, V17, P1881, DOI 10.1017/S1461145714000650.
   García-Martínez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668.
   Guo N, 2008, BEHAV NEUROSCI, V122, P1078, DOI 10.1037/a0012595.
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4.
   Hassan HE, 2010, DRUG METAB DISPOS, V38, P157, DOI 10.1124/dmd.109.029199.
   Heller EA, 2015, J NEUROCHEM, V132, P243, DOI 10.1111/jnc.12925.
   James MH, 2016, EUR J PHARMACOL, V784, P147, DOI 10.1016/j.ejphar.2016.05.013.
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564.
   Kauer JA, 2007, NAT REV NEUROSCI, V8, P844, DOI 10.1038/nrn2234.
   Kim DH, 2003, CURR TOP MICROBIOL, V279, P259.
   Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100.
   Ladner CL, 2004, ANAL BIOCHEM, V326, P13, DOI 10.1016/j.ab.2003.10.047.
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011.
   Law PY, 2000, ANNU REV PHARMACOL, V40, P389, DOI 10.1146/annurev.pharmtox.40.1.389.
   Lee CT, 2006, EUR J NEUROSCI, V23, P1311, DOI 10.1111/j.1460-9568.2006.04650.x.
   Li Y, 2003, MOL CELL BIOL, V23, P6255, DOI 10.1128/MCB.23.17.6255-6266.2003.
   Lin J, 2014, INT J NEUROPSYCHOPH, V17, P127, DOI 10.1017/S1461145713001156.
   Liu-Yesucevitz L, 2011, J NEUROSCI, V31, P16086, DOI 10.1523/JNEUROSCI.4105-11.2011.
   Lüscher C, 2011, NEURON, V69, P650, DOI 10.1016/j.neuron.2011.01.017.
   Luo YX, 2013, NEUROBIOL LEARN MEM, V105, P159, DOI 10.1016/j.nlm.2013.06.017.
   Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672.
   Ma XM, 2004, NAT REV MOL CELL BIO, V5, P827.
   Ma YL, 2006, LEARN MEMORY, V13, P114, DOI 10.1101/lm.179206.
   Mazei-Robison MS, 2011, NEURON, V72, P977, DOI 10.1016/j.neuron.2011.10.012.
   McLellan AT, 2000, JAMA-J AM MED ASSOC, V284, P1689, DOI 10.1001/jama.284.13.1689.
   Narita W, 2005, NEUROSCIENCE, V132, P553, DOI 10.1016/j.neuroscience.2004.12.050.
   Neasta J, 2014, J NEUROCHEM, V130, P172, DOI 10.1111/jnc.12725.
   Niswender KD, 2003, J HISTOCHEM CYTOCHEM, V51, P275, DOI 10.1177/002215540305100302.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45.
   Polakiewicz RD, 1998, J BIOL CHEM, V273, P23534, DOI 10.1074/jbc.273.36.23534.
   Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007.
   Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205.
   Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045.
   Russo SJ, 2007, NAT NEUROSCI, V10, P93, DOI 10.1038/nn1812.
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054.
   Schieke SM, 2006, J BIOL CHEM, V281, P27643, DOI 10.1074/jbc.M603536200.
   Shi J, 2009, EUR J PHARMACOL, V615, P108, DOI 10.1016/j.ejphar.2009.05.011.
   Shimobayashi M, 2014, NAT REV MOL CELL BIO, V15, P155, DOI 10.1038/nrm3757.
   Singh P, 2015, PSYCHOPHARMACOLOGY, V232, P465, DOI 10.1007/s00213-014-3680-5.
   Stoica L, 2011, P NATL ACAD SCI USA, V108, P3791, DOI 10.1073/pnas.1014715108.
   Taha C, 1999, J MEMBRANE BIOL, V169, P1, DOI 10.1007/PL00005896.
   Tsai KJ, 2002, P NATL ACAD SCI USA, V99, P3990, DOI 10.1073/pnas.062405399.
   Wang X, 2010, J NEUROSCI, V30, P12632, DOI 10.1523/JNEUROSCI.1264-10.2010.
   Wu J, 2011, NEUROSCIENCE, V172, P104, DOI 10.1016/j.neuroscience.2010.10.041.
   Zhou J, 2009, J NEUROSCI, V29, P1773, DOI 10.1523/JNEUROSCI.5685-08.2009.},
Number-of-Cited-References = {62},
Times-Cited = {11},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {10},
Journal-ISO = {J. Psychopharmacol.},
Doc-Delivery-Number = {IF0LU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000472769400012},
DA = {2026-02-04},
}

@article{ WOS:000472906500005,
Author = {Wang, Ziyi and Ishihara, Yoshihito and Ishikawa, Takanori and Hoshijima,
   Mitsuhiro and Odagaki, Naoya and Hlaing, Ei Ei Hsu and Kamioka, Hiroshi},
Title = {Screening of key candidate genes and pathways for osteocytes involved in
   the differential response to different types of mechanical stimulation
   using a bioinformatics analysis},
Journal = {JOURNAL OF BONE AND MINERAL METABOLISM},
Year = {2019},
Volume = {37},
Number = {4},
Pages = {614-626},
Month = {JUL},
Abstract = {This study aimed to predict the key genes and pathways that are
   activated when different types of mechanical loading are applied to
   osteocytes. mRNA expression datasets (series number of GSE62128 and
   GSE42874) were obtained from Gene Expression Omnibus database (GEO).
   High gravity-treated osteocytic MLO-Y4 cell-line samples from GSE62128
   (Set1), and fluid flow-treated MLO-Y4 samples from GSE42874 (Set2) were
   employed. After identifying the differentially expressed genes (DEGs),
   functional enrichment was performed. The common DEGs between Set1 and
   Set2 were considered as key DEGs, then a protein-protein interaction
   (PPI) network was constructed using the minimal nodes from all of the
   DEGs in Set1 and Set2, which linked most of the key DEGs. Several open
   source software programs were employed to process and analyze the
   original data. The bioinformatic results and the biological meaning were
   validated by in vitro experiments. High gravity and fluid flow induced
   opposite expression trends in the key DEGs. The hypoxia-related
   biological process and signaling pathway were the common functional
   enrichment terms among the DEGs from Set1, Set2 and the PPI network. The
   expression of almost all the key DEGs (Pdk1, Ccng2, Eno2, Egln1, Higd1a,
   Slc5a3 and Mxi1) were mechano-sensitive. Eno2 was identified as the hub
   gene in the PPI network. Eno2 knockdown results in expression changes of
   some other key DEGs (Pdk1, Mxi1 and Higd1a). Our findings indicated that
   the hypoxia response might have an important role in the differential
   responses of osteocytes to the different types of mechanical force.},
Publisher = {SPRINGER JAPAN KK},
Address = {SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN},
Type = {Article},
Language = {English},
Affiliation = {Kamioka, H (Corresponding Author), Okayama Univ, Grad Sch Med Dent \& Pharmaceut Sci, Dept Orthodont, Kita Ku, 2-5-1 Shikata, Okayama 7008525, Japan.
   Wang, Ziyi; Hoshijima, Mitsuhiro; Hlaing, Ei Ei Hsu; Kamioka, Hiroshi, Okayama Univ, Grad Sch Med Dent \& Pharmaceut Sci, Dept Orthodont, Kita Ku, 2-5-1 Shikata, Okayama 7008525, Japan.
   Ishihara, Yoshihito; Ishikawa, Takanori; Odagaki, Naoya, Okayama Univ Hosp, Dept Orthodont, Okayama, Japan.},
DOI = {10.1007/s00774-018-0963-7},
ISSN = {0914-8779},
EISSN = {1435-5604},
Keywords = {Osteocyte; Mechanical stimulation; Bioinformatics analysis; Microarray;
   Fluid flow},
Keywords-Plus = {PARATHYROID-HORMONE; INDUCED APOPTOSIS; BONE-FORMATION; SCLEROSTIN;
   ACTIVATION; EXPRESSION; FRACTURE; KINASE; CELLS; STRESS},
Research-Areas = {Endocrinology \& Metabolism; Research \& Experimental Medicine},
Web-of-Science-Categories  = {Endocrinology \& Metabolism; Medicine, Research \& Experimental},
Author-Email = {kamioka@md.okayama-u.ac.jp},
Affiliations = {Okayama University; Okayama University},
ResearcherID-Numbers = {Ishihara, Yoshihito/B-2345-2011
   Wang, Ziyi/AAW-6082-2020
   Ei Hsu Hlaing, Ei/ABF-3646-2020},
ORCID-Numbers = {Ishihara, Yoshihito/0000-0002-5999-8253
   Wang, Ziyi/0000-0003-1884-8053
   Ei Hsu Hlaing, Ei/0000-0002-5539-9499},
Funding-Acknowledgement = {Japan Society for the Promotion of Science, Japan {[}16H05549, 16K15837,
   17H04413]; Grants-in-Aid for Scientific Research {[}17H04413, 16H05549,
   16K15837] Funding Source: KAKEN},
Funding-Text = {The present work was supported by Grant-in-Aid for Scientific Research
   (to H. Kamioka {[}16H05549] and {[}16K15837], to Y. Ishihara
   {[}17H04413]) from the Japan Society for the Promotion of Science,
   Japan. Lastly, Ziyi Wang would like to dedicate this article to his
   wife, Yao Weng, who saw too much of the back of his head as he looked at
   the computer screen while he was coding, processing data and revising
   the manuscript before the deadline. His wife's tolerance is best
   described as remarkable.},
Cited-References = {Adachi T, 2009, J BIOMECH, V42, P2507, DOI 10.1016/j.jbiomech.2009.07.006.
   Aguirre JI, 2006, J BONE MINER RES, V21, P605, DOI 10.1359/JBMR.060107.
   Ameri K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062758.
   An HJ, 2011, BBA-MOL CELL RES, V1813, P2088, DOI 10.1016/j.bbamcr.2011.07.017.
   {[}Anonymous], J DIABETES RES.
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556.
   Bellido T, 2005, ENDOCRINOLOGY, V146, P4577, DOI 10.1210/en.2005-0239.
   Bentovim L, 2013, DEVELOPMENT, V140, P248, DOI 10.1242/dev.092023.
   Bruno S, 2009, J AM SOC NEPHROL, V20, P1053, DOI 10.1681/ASN.2008070798.
   Carbon S, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI 10.1093/nar/gkw1108.
   Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989.
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948.
   Dai ZJ, 2011, J BONE MINER RES, V26, P582, DOI 10.1002/jbmr.240.
   de Araujo RMS, 2007, J PERIODONTAL RES, V42, P15, DOI 10.1111/j.1600-0765.2006.00906.x.
   Ellies DL, 2006, J BONE MINER RES, V21, P1738, DOI 10.1359/JBMR.060810.
   FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488.
   Fujiwara M, 2016, BONE, V85, P91, DOI 10.1016/j.bone.2016.01.024.
   Galea GL, 2017, BONE, V96, P38, DOI 10.1016/j.bone.2016.10.008.
   Hamamura K, 2008, J BONE MINER METAB, V26, P231, DOI 10.1007/s00774-007-0825-1.
   Herrera MB, 2010, J CELL MOL MED, V14, P1605, DOI 10.1111/j.1582-4934.2009.00860.x.
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183.
   Huang J, 2015, MOL MED REP, V12, P5951, DOI 10.3892/mmr.2015.4122.
   HUKKANEN M, 1993, NEUROSCIENCE, V54, P969, DOI 10.1016/0306-4522(93)90588-7.
   Jing D, 2014, FASEB J, V28, P1582, DOI 10.1096/fj.13-237578.
   Kamioka H, 2001, BONE, V28, P145, DOI 10.1016/S8756-3282(00)00421-X.
   Kamioka H, 2006, J BONE MINER RES, V21, P1012, DOI 10.1359/JBMR.060408.
   Kim HS, 2012, J PROTEOME RES, V11, P839, DOI 10.1021/pr200682z.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kohl M, 2011, METHODS MOL BIOL, V696, P291, DOI 10.1007/978-1-60761-987-1\_18.
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003.
   Li R, 2001, J BONE MINER RES, V16, P1505.
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI {[}10.1359/jbmr.090411, 10.1359/JBMR.090411].
   Liu J, 2017, MOL MED REP, V16, P7253, DOI 10.3892/mmr.2017.7550.
   Liu J, 2012, JOINT BONE SPINE, V79, P186, DOI 10.1016/j.jbspin.2011.04.011.
   Liu XD, 2014, CELL BIOCHEM BIOPHYS, V69, P141, DOI 10.1007/s12013-013-9780-8.
   Manolagas SC, 2010, TRENDS ENDOCRIN MET, V21, P369, DOI 10.1016/j.tem.2010.01.010.
   McGee-Lawrence ME, 2013, BIOCHEM BIOPH RES CO, V441, P886, DOI 10.1016/j.bbrc.2013.10.155.
   Odagaki N., 2018, J DENT RES.
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29.
   Peng J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112744.
   Phipson B, 2016, ANN APPL STAT, V10, P946, DOI 10.1214/16-AOAS920.
   Plotkin LI, 2014, CURR OSTEOPOROS REP, V12, P121, DOI 10.1007/s11914-014-0194-3.
   Prideaux M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125731.
   Qin YW, 2017, J BIOL CHEM, V292, P11021, DOI 10.1074/jbc.M116.770941.
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322.
   Sapir-Koren R, 2014, OSTEOPOROSIS INT, V25, P2685, DOI 10.1007/s00198-014-2808-0.
   Shen X, 2009, J ORTHOP RES, V27, P1298, DOI 10.1002/jor.20886.
   Stewart R, 2011, J ORTHOP TRAUMA, V25, P472, DOI 10.1097/BOT.0b013e31822588d8.
   StrangeVognsen HH, 1997, J PEDIATR ORTHOP B, V6, P56, DOI 10.1097/01202412-199701000-00012.
   Sugawara Y, 2013, BONE, V52, P189, DOI 10.1016/j.bone.2012.09.033.
   Takano-Yamamoto T, 2014, JPN DENT SCI REV, V50, P29, DOI 10.1016/j.jdsr.2013.10.004.
   Takeno A, 2015, BONE, V77, P135, DOI 10.1016/j.bone.2015.04.025.
   Tascau L, 2016, ENDOCRINOLOGY, V157, P112, DOI 10.1210/en.2015-1614.
   Ullah M, 2013, DIFFERENTIATION, V85, P78, DOI 10.1016/j.diff.2013.02.001.
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000.
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034.
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105.
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8.
   Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12.
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599.
   Wu C, 2015, GENE DEV, V29, P817, DOI 10.1101/gad.255000.114.
   Yip KY, 2006, BIOINFORMATICS, V22, P2968, DOI 10.1093/bioinformatics/btl488.
   Yokomoto-Umakoshi M, 2016, BIOCHEM BIOPH RES CO, V469, P791, DOI 10.1016/j.bbrc.2015.12.072.
   Yu KL, 2018, J ORTHOP RES, V36, P653, DOI 10.1002/jor.23665.
   Zhan PP, 2017, MOL CARCINOGEN, V56, P1427, DOI 10.1002/mc.22603.
   Zhang WB, 2012, J ORTHOP SCI, V17, P289, DOI 10.1007/s00776-012-0206-z.},
Number-of-Cited-References = {66},
Times-Cited = {5},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {J. Bone Miner. Metab.},
Doc-Delivery-Number = {IF2KQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000472906500005},
DA = {2026-02-04},
}

@article{ WOS:000472689000004,
Author = {Yin, Wenjuan and Guo, Jian and Zhang, Chongyu and Alibhai, Faisal J. and
   Li, Shu-Hong and Billia, Phyllis and Wu, Jun and Yau, Terrence M. and
   Weisel, Richard D. and Li, Ren-Ke},
Title = {Knockout of Canopy 2 activates p16INK4a pathway to impair
   cardiac repair},
Journal = {JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY},
Year = {2019},
Volume = {132},
Pages = {36-48},
Month = {JUL},
Abstract = {Background. Cardiac repair depends on angiogenesis and cell
   proliferation. Previously we identified Canopy 2 (CNPY2) as a secreted
   angiogenic growth factor which promotes neovascularization. We
   investigated the role of CNPY2 in cardiac repair following myocardial
   infarction (MI) and the possible mediators involved using Cnpy2 knockout
   (KO) mice and human cardiac tissue.
   Methods and results: Cardiac tissue from patients with end-stage heart
   failure had significantly lower endogenous CNPY2 expression compared to
   samples from control patients. CNPY2 expression in mouse hearts
   significantly decreased following MI. Significantly less leukocyte and
   endothelial cell proliferation was found in Cnpy2 KO than wild-type (WT)
   mice post MI which contributed to impaired angiogenesis, tissue repair,
   and decreased cardiac function (fractional shortening: WT: 21.1 +/-
   2.1\% vs. KO: 16.4 +/- 1.6\%, p < .01 at day 28 post MI). RT-qPCR
   revealed significantly increased p16(INK4a) expression in Cnpy2 KO mouse
   hearts (WT: 1.0 +/- 0.04 vs. KO: 2.33 +/- 0.11 {[}relative expression of
   p16 (INK4a)], p < .01) which was confirmed by immunostaining (WT: 8.47
   +/- 1.22 vs. KO: 12.9 +/- 1.22 {[}\% total cells], p < .05) for the
   p16(INK4a) protein. Expression of cell cycle related proteins, cyclin
   D1, cyclin-dependent kinases 4 and 6, and phosphorylated retinoblastoma
   protein (pRb) was significantly decreased in Cnpy2 KO mouse hearts. The
   up-regulation of the p16(INK4a)/cyclin D1/Rb pathway by knockout of
   Cnpy2 was accompanied by attenuation of PDK1/Akt phosphorylation. MI
   exacerbated the detrimental effects of p16(INK4a) on tissue repair in
   Cnpy2 KO mice. Overexpression of CNPY2 in the cardiac tissue of
   transgenic mice reversed the inhibition of cell proliferation through
   suppression of the p16(INK4a) pathway.
   Conclusions: Cardiac injury and progressive heart failure were
   associated with decreased CNPY2 levels in both humans and mice. Knockout
   of Cnpy2 resulted in up-regulation of p16(INH4a) which impaired cardiac
   function and tissue repair. These data suggest that CNPY2 is an
   important regulator of p16(INK4a) and promotes cell proliferation and
   tissue repair through inhibition of the p16(INK4a) pathway. CNPY2
   treatment may offer a new approach to restore cardiac function after an
   MI.},
Publisher = {ELSEVIER SCI LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Li, RK (Corresponding Author), PMCRT, 101 Coll St,Room 3-702, Toronto, ON M5G 1L7, Canada.
   Yin, Wenjuan, Shanxi Med Univ, Dept Pathol, Shanxi Key Lab Birth Defect \& Cell Regenerat, Taiyuan, Shanxi, Peoples R China.
   Yin, Wenjuan; Guo, Jian; Zhang, Chongyu; Alibhai, Faisal J.; Li, Shu-Hong; Billia, Phyllis; Wu, Jun; Yau, Terrence M.; Weisel, Richard D.; Li, Ren-Ke, Univ Hlth Network, Div Cardiovasc Surg, Toronto Gen Hosp Res Inst, Toronto, ON, Canada.
   Billia, Phyllis, Univ Hlth Network, Div Cardiol, Toronto, ON, Canada.
   Yau, Terrence M.; Weisel, Richard D.; Li, Ren-Ke, Univ Toronto, Dept Surg, Div Cardiac Surg, Toronto, ON, Canada.
   Billia, Phyllis, Univ Toronto, Dept Physiol, Toronto, ON, Canada.},
DOI = {10.1016/j.yjmcc.2019.04.018},
ISSN = {0022-2828},
EISSN = {1095-8584},
Keywords = {Canopy 2; p16(INK4a); Myocardial infarction; Heart failure; Cardiac
   repair},
Keywords-Plus = {CELL-CYCLE ARREST; CDK INHIBITORS; EXPRESSION; CANCER; PROLIFERATION;
   SENESCENCE; GROWTH; MOTIF},
Research-Areas = {Cardiovascular System \& Cardiology; Cell Biology},
Web-of-Science-Categories  = {Cardiac \& Cardiovascular Systems; Cell Biology},
Author-Email = {renkeli@uhnresearch.ca},
Affiliations = {Shanxi Medical University; University of Toronto; University Health
   Network Toronto; University of Toronto; University Health Network
   Toronto; University of Toronto; University of Toronto},
ResearcherID-Numbers = {Billia, Filio/B-3011-2014
   Alibhai, Faisal/MGW-0772-2025
   LI, SHUHONG/NSV-3726-2025},
ORCID-Numbers = {Billia, Filio/0000-0002-2824-1215
   Alibhai, Faisal/0000-0002-8145-4682
   Li, Ren-Ke/0000-0002-2584-060X
   },
Funding-Acknowledgement = {Canadian Institutes of Health Research Postdoctoral Fellowship; Canadian
   Institutes of Health Research {[}332652]; Ontario Research Fund
   {[}RE07-010]},
Funding-Text = {We thank Dr. Leigh Body for help with manuscript preparation and
   editing. FJA is a recipient of a Canadian Institutes of Health Research
   Postdoctoral Fellowship. This work was supported by the Canadian
   Institutes of Health Research {[}grant number 332652 to R-K.L.] and the
   Ontario Research Fund {[}grant number RE07-010 to R-K.L.]. R-K.L. holds
   a Tier 1 Canada Research Chair in Cardiac Regeneration.},
Cited-References = {Baker DJ, 2016, NATURE, V530, P184, DOI 10.1038/nature16932.
   Bornhauser BC, 2003, J BIOL CHEM, V278, P35412, DOI 10.1074/jbc.M306271200.
   Bornhauser BC, 2005, CELL MOL LIFE SCI, V62, P1260, DOI 10.1007/s00018-005-5055-x.
   Bruhn H, 2005, BIOCHEM J, V389, P249, DOI 10.1042/BJ20050051.
   Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200.
   Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003.
   Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987.
   Guo J, 2015, EUR HEART J, V36, P2530, DOI 10.1093/eurheartj/ehv294.
   Guo J, 2015, CARDIOVASC RES, V105, P383, DOI 10.1093/cvr/cvv010.
   Hatta K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111370.
   Hemmings Brian A, 2015, Cold Spring Harb Perspect Biol, V7, DOI {[}10.1101/cshperspect.a026609, 10.1101/cshperspect.a026609].
   Johnson David G., 1998, Frontiers in Bioscience, V3, pD447.
   Korf-Klingebiel M, 2015, NAT MED, V21, P140, DOI 10.1038/nm.3778.
   Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475.
   Li YY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017421.
   Lloyd-Jones D, 2010, CIRCULATION, V121, P948, DOI 10.1161/CIRCULATIONAHA.109.192666.
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5.
   Melk A, 2004, KIDNEY INT, V65, P510, DOI 10.1111/j.1523-1755.2004.00438.x.
   Meyer K, 2016, J AM COLL CARDIOL, V67, P2018, DOI 10.1016/j.jacc.2016.02.047.
   Olsen MB, 2017, CELL REP, V18, P82, DOI 10.1016/j.celrep.2016.12.009.
   Oodi A, 2012, HEMATOLOGY, V17, P334, DOI 10.1179/1607845412Y.0000000009.
   PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x.
   REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831.
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148.
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0.
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672.
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501.
   Swarbrick A, 2000, MOL CELL BIOL, V20, P2581, DOI 10.1128/MCB.20.7.2581-2591.2000.
   Taniguchi H, 2017, BIOCHEM BIOPH RES CO, V485, P267, DOI 10.1016/j.bbrc.2017.02.095.
   WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0.
   Wang YS, 2014, J MOL CELL CARDIOL, V66, P94, DOI 10.1016/j.yjmcc.2013.08.007.
   Yan P, 2016, AM J PATHOL, V186, P1015, DOI 10.1016/j.ajpath.2015.11.012.},
Number-of-Cited-References = {32},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {12},
Journal-ISO = {J. Mol. Cell. Cardiol.},
Doc-Delivery-Number = {IE9IV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000472689000004},
DA = {2026-02-04},
}

@article{ WOS:000473547000001,
Author = {Subbiah, Vivek and Gervais, Radj and Riely, Gregory and Hollebecque,
   Antoine and Blay, Jean-Yves and Felip, Enriqueta and Schuler, Martin and
   Goncalves, Anthony and Italiano, Antonio and Keedy, Vicki and Chau, Ian
   and Puzanov, Igor and Raje, Noopur S. and Meric-Bernstam, Funda and
   Makrutzki, Martina and Riehl, Todd and Pitcher, Bethany and Baselga,
   Jose and Hyman, David M.},
Title = {Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With
   BRAF V600 Mutation: An Open-Label, Single-Arm Cohort of the
   Histology-Independent VE-BASKET Study},
Journal = {JCO PRECISION ONCOLOGY},
Year = {2019},
Volume = {3},
Month = {JUN 27},
Abstract = {PURPOSE To study whether BRAF V600 mutations in non-small-cell lung
   cancer (NSCLC) may indicate sensitivity to the BRAF inhibitor
   vemurafenib, we included a cohort of patients with NSCLC in the
   vemurafenib basket (VE-BASKET) study. On the basis of observed early
   clinical activity, we expanded the cohort of patients with NSCLC. We
   present results from this cohort.
   METHODS This open-label, histology-independent, phase II study included
   six prespecified cohorts, including patients with NSCLC, and a seventh
   all-comers cohort. Patients received vemurafenib (960 mg two times per
   day) until disease progression or unacceptable toxicity. The primary end
   point of the final analysis was objective response rate (Response
   Evaluation Criteria in Solid Tumors, version 1.1). Secondary end points
   included progression-free survival, overall survival, and safety.
   Because the prespecified clinical benefit endpoint was met in the
   initial NSCLC cohort, the cohort was expanded.
   RESULTS Sixty-two patients with BRAF V600-mutant NSCLC were enrolled and
   treated: 13\% (n = 8) had received no prior systemic therapy, and 87\%
   (n = 54) had received prior therapies. The objective response rate was
   37.1\% (95\% CI, 25.2\% to 50.3\%) overall, 37.5\% (95\% CI, 8.5\% to
   75.5\%) in previously untreated patients, and 37.0\% (24.3\% to 51.3\%)
   in previously treated patients. Median progression-free survival was 6.5
   months (95\% CI, 5.2 to 9.0 months), and median overall survival was
   15.4 months (95\% CI, 9.6 to 22.8 months). The most common all-grade
   adverse event was nausea (40\%). The safety profile of vemurafenib was
   similar to that observed in melanoma studies.
   CONCLUSION Vemurafenib showed promising activity in patients with NSCLC
   harboring BRAF V600 mutations. The safety profile of vemurafenib was
   similar to previous observations in patients with melanoma. Our results
   suggest a role for single-agent BRAF inhibition in patients with NSCLC
   and BRAF V600 mutations. (C) 2019 by American Society of Clinical
   Oncology.},
Publisher = {LIPPINCOTT WILLIAMS \& WILKINS},
Address = {TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA},
Type = {Article},
Language = {English},
Affiliation = {Subbiah, V (Corresponding Author), Univ Texas MD Anderson Canc Ctr, Phase Clin Trials Program 1, Dept Invest Canc Therapeut, Div Canc Med,Unit 455, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   Subbiah, Vivek; Meric-Bernstam, Funda, Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   Gervais, Radj, Ctr Francois Baclesse, Caen, France.
   Riely, Gregory; Baselga, Jose; Hyman, David M., Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.
   Hollebecque, Antoine, Inst Gustave Roussy, Villejuif, France.
   Blay, Jean-Yves, Ctr Leon Berard, Lyon, France.
   Felip, Enriqueta, Vall dHebron Univ Hosp, Barcelona, Spain.
   Felip, Enriqueta, Vall dHebron Inst Oncol, Barcelona, Spain.
   Schuler, Martin, Univ Hosp Essen, Essen, Germany.
   Goncalves, Anthony, Aix Marseille Univ, Marseille, France.
   Italiano, Antonio, Inst Bergonie, Bordeaux, France.
   Keedy, Vicki, Vanderbilt Univ, 221 Kirkland Hall, Nashville, TN 37235 USA.
   Chau, Ian, Royal Marsden NHS Fdn Trust, London, England.
   Puzanov, Igor, Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
   Raje, Noopur S., Massachusetts Gen Hosp, Boston, MA 02114 USA.
   Makrutzki, Martina, F Hoffmann La Roche, Basel, Switzerland.
   Riehl, Todd, Genentech Inc, San Francisco, CA USA.
   Pitcher, Bethany, F Hoffmann La Roche, Mississauga, ON, Canada.
   Baselga, Jose; Hyman, David M., Weill Cornell Med Coll, New York, NY USA.},
DOI = {10.1200/PO.18.00266},
EISSN = {2473-4284},
Keywords-Plus = {DABRAFENIB PLUS TRAMETINIB; METASTATIC MELANOMA; DOUBLE-BLIND;
   MULTICENTER; PHASE-3; CRIZOTINIB},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {vsubbiah@mdanderson.org},
Affiliations = {University of Texas System; UTMD Anderson Cancer Center; UNICANCER;
   Centre Francois Baclesse; Memorial Sloan Kettering Cancer Center;
   UNICANCER; Gustave Roussy; UNICANCER; Centre Leon Berard; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia (VHIO);
   University of Duisburg Essen; Aix-Marseille Universite; UNICANCER;
   Institut Bergonie; Vanderbilt University; Royal Marsden NHS Foundation
   Trust; Roswell Park Comprehensive Cancer Center; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital;
   Roche Holding; Roche Holding; Genentech; Roche Holding USA; Roche
   Holding; Roche Holding Canada; Cornell University; Weill Cornell
   Medicine},
ResearcherID-Numbers = {Schuler, Martin/OUH-7933-2025
   Meric-Bernstam, Funda/JRZ-1866-2023
   Keedy, Vicki/MGT-9232-2025
   Blay, Jean-Yves/N-3966-2016
   Chau, Ian/ABC-2023-2020
   PUZANOV, IGOR/AAP-2966-2020
   Subbiah, Vivek/O-3347-2019
   Hollebecque, Antoine/M-2695-2013
   Baselga, Jose/L-1629-2016
   Riely, Gregory/AAF-4300-2019
   ITALIANO, ANTOINE/JRW-6637-2023},
ORCID-Numbers = {Schuler, Martin/0000-0002-2166-3394
   Chau, Ian/0000-0003-0286-8703
   Hollebecque, Antoine/0000-0003-2869-7551
   ITALIANO, ANTOINE/0000-0002-8540-5351},
Funding-Acknowledgement = {F. Hoffmann-La Roche (Basel, Switzerland); National Institutes of Health
   {[}P30 CA008748]; CPRIT {[}RP150535]; F. Hoffmann-La Roche},
Funding-Text = {Supported by F. Hoffmann-La Roche (Basel, Switzerland) and in part by
   the National Institutes of Health (Grant No. P30 CA008748). University
   of Texas MD Anderson Cancer Center Precision Oncology Decision Support
   Core was funded through CPRIT RP150535. Editorial support, provided by
   Miller Medical Communications (Brindle, United Kingdom), was funded by
   F. Hoffmann-La Roche.},
Cited-References = {Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X.
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782.
   Cui GH, 2017, MEDICINE, V96, DOI {[}10.1097/md.0000000000006552, 10.1097/MD.0000000000006552].
   Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625.
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X.
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309.
   Larkin J, 2014, LANCET ONCOL, V15, P436, DOI 10.1016/S1470-2045(14)70051-8.
   Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4.
   McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9.
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699.
   Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280.
   Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4.
   Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2.
   Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2.
   Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766.
   Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI {[}10.1056/NEJMoa1408440, 10.1056/NEJMx150034].
   Thomas A, 2015, NAT REV CLIN ONCOL, V12, P511, DOI 10.1038/nrclinonc.2015.90.},
Number-of-Cited-References = {17},
Times-Cited = {70},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {JCO Precis. Oncol.},
Doc-Delivery-Number = {IG1JJ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000473547000001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000479322800137,
Author = {Marco-Brualla, Joaquin and Al-Wasaby, Sameer and Soler, Ruth and
   Romanos, Eduardo and Conde, Blanca and Justo-Mendez, Raquel and
   Enriquez, Jose A. and Fernandez-Silva, Patricio and Martinez-Lostao,
   Luis and Villalba, Martin and Moreno-Loshuertos, Raquel and Anel,
   Alberto},
Title = {Mutations in the ND2 Subunit of Mitochondrial Complex I Are
   Sufficient to Confer Increased Tumorigenic and Metastatic Potential to
   Cancer Cells},
Journal = {CANCERS},
Year = {2019},
Volume = {11},
Number = {7},
Month = {JUN 26},
Abstract = {Multiprotein complexes of the mitochondrial electron transport chain
   form associations to generate supercomplexes. The relationship between
   tumor cell ability to assemble mitochondrial supercomplexes,
   tumorigenesis and metastasis has not been studied thoroughly. The
   mitochondrial and metabolic differences between L929dt cells, which lost
   matrix attachment and MHC-I expression, and their parental cell line
   L929, were analyzed. L929dt cells have lower capacity to generate energy
   through OXPHOS and lower respiratory capacity than parental L929 cells.
   Most importantly, L929dt cells show defects in mitochondrial
   supercomplex assembly, especially in those that contain complex I. These
   defects correlate with mtDNA mutations in L929dt cells at the ND2
   subunit of complex I and are accompanied by a glycolytic shift. In
   addition, L929dt cells show higher in vivo tumorigenic and metastatic
   potential than the parental cell line. Cybrids with L929dt mitochondria
   in L929 nuclear background reproduce all L929dt properties,
   demonstrating that mitochondrial mutations are responsible for the
   aggressive tumor phenotype. In spite of their higher tumorigenic
   potential, L929dt or mitochondrial L929dt cybrid cells are sensitive
   both in vitro and in vivo to the PDK1 inhibitor dichloroacetate, which
   favors OXPHOS, suggesting benefits for the use of metabolic inhibitors
   in the treatment of especially aggressive tumors.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Anel, A (Corresponding Author), Univ Zaragoza, Fac Sci, Aragon Hlth Res Inst IIS Aragon, Immun Canc \& Stem Cells Grp,Dept Biochem \& Mol \&, Campus San Francisco Sq, E-50009 Zaragoza, Spain.
   Moreno-Loshuertos, R (Corresponding Author), Univ Zaragoza, Fac Sci, Dept Biochem \& Mol \& Cell Biol, GENOXPHOS Grp,Biocomputat \& Complex Syst Phys Ins, Campus San Francisco Sq, E-50009 Zaragoza, Spain.
   Marco-Brualla, Joaquin; Al-Wasaby, Sameer; Soler, Ruth; Anel, Alberto, Univ Zaragoza, Fac Sci, Aragon Hlth Res Inst IIS Aragon, Immun Canc \& Stem Cells Grp,Dept Biochem \& Mol \&, Campus San Francisco Sq, E-50009 Zaragoza, Spain.
   Romanos, Eduardo, Aragon Hlth Res Inst IIS Aragon, Ctr Res Biomed, E-50009 Zaragoza, Spain.
   Conde, Blanca, Univ Zaragoza, Dept Human Anat \& Histol, Fac Med, Campus San Francisco Sq, E-50009 Zaragoza, Spain.
   Justo-Mendez, Raquel; Enriquez, Jose A., Carlos III Natl Ctr Cardiovasc Res, Madrid 28029, Spain.
   Fernandez-Silva, Patricio; Moreno-Loshuertos, Raquel, Univ Zaragoza, Fac Sci, Dept Biochem \& Mol \& Cell Biol, GENOXPHOS Grp,Biocomputat \& Complex Syst Phys Ins, Campus San Francisco Sq, E-50009 Zaragoza, Spain.
   Martinez-Lostao, Luis, Lozano Blesa Clin Hosp, Immunol Dept, E-50009 Zaragoza, Spain.
   Villalba, Martin, Univ Montpellier, CHU Montpellier, Natl Inst Biomed Res INSERM, Inst Regenerat Med \& Biotherapy, F-34090 Montpellier, France.
   Villalba, Martin, CHU Montpellier, IRMB, F-34090 Montpellier, France.},
DOI = {10.3390/cancers11071027},
Article-Number = {1027},
EISSN = {2072-6694},
Keywords = {mitochondria; dichloroacetate; complex I; ND2; metastasis; cybrids},
Keywords-Plus = {MHC CLASS-I; DNA MUTATIONS; METABOLISM; ERK5; EXPRESSION; GENERATION;
   CONTRIBUTE; HEAD},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {raquelml@unizar.es
   anel@unizar.es},
Affiliations = {University of Zaragoza; University of Zaragoza; Centro Nacional de
   Investigaciones Cardiovasculares (CNIC); University of Zaragoza; Lozano
   Blesa University Clinical Hospital; Universite de Montpellier; CHU de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Montpellier; CHU de Montpellier},
ResearcherID-Numbers = {Silva, Patricio/U-2256-2017
   Romanos, Eduardo/T-3794-2017
   Anel, Alberto/Z-3068-2019
   Enríquez, José Antonio/M-8468-2016
   villalba, martin/AAG-2604-2020
   Martinez-Lostao, Luis/AAI-3090-2021
   Marco-Brualla, Joaquín/AAK-6666-2021
   Moreno Loshuertos, Raquel/H-4545-2015},
ORCID-Numbers = {Romanos, Eduardo/0000-0002-9918-3374
   Enríquez, José Antonio/0000-0002-3671-2961
   villalba, martin/0000-0002-4385-4888
   Justo-Méndez, Raquel/0000-0002-7648-3550
   Martinez-Lostao, Luis/0000-0003-3043-147X
   Marco-Brualla, Joaquín/0000-0002-1710-4821
   Mohammed Salem Alwasaby, Sameer/0000-0001-8478-1956
   Moreno Loshuertos, Raquel/0000-0002-6600-1618},
Funding-Acknowledgement = {Ministerio de Economia y Competitividad (MINECO)
   {[}SAF2013-48626-C2-1-R, SAF2016-76338-R]; Gobierno de Aragon
   {[}B31\_17R]; Feder; EMBO short-term fellowship; PHISIUP; PRT-K program},
Funding-Text = {This work was supported by grants SAF2013-48626-C2-1-R and
   SAF2016-76338-R from Ministerio de Economia y Competitividad (MINECO) to
   AA, by the PRT-K program 2018 to MV and by Gobierno de Aragon (Group
   B31\_17R) cofinanced by Feder 2014-2020 ``Building Europe from
   Aragon{''}. JMB was supported by an EMBO short-term fellowship and by
   PHISIUP.},
Cited-References = {Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8.
   Acin-Pérez R, 2008, MOL CELL, V32, P529, DOI 10.1016/j.molcel.2008.10.021.
   Agnoletto C, 2015, ONCOTARGET, V6, P2385, DOI 10.18632/oncotarget.2960.
   Agnoletto C, 2014, ONCOTARGET, V5, P4347, DOI 10.18632/oncotarget.2018.
   Allende-Vega N, 2015, ONCOTARGET, V6, P19228, DOI 10.18632/oncotarget.4653.
   ALLEY MC, 1988, CANCER RES, V48, P589.
   Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739.
   Blackburn RV, 1997, INT J CANCER, V72, P871, DOI 10.1002/(SICI)1097-0215(19970904)72:5<871::AID-IJC26>3.0.CO;2-A.
   Bosque A, 2007, BLOOD, V109, P1627, DOI 10.1182/blood-2006-05-022319.
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3.
   Catalán E, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.985924.
   Charni S, 2010, J IMMUNOL, V185, P3498, DOI 10.4049/jimmunol.1001250.
   Charni S, 2009, J IMMUNOL, V182, P3398, DOI 10.4049/jimmunol.0803006.
   Chen EI, 2012, J BIOENERG BIOMEMBR, V44, P619, DOI 10.1007/s10863-012-9465-9.
   Chomyn A, 1996, Methods Enzymol, V264, P334, DOI 10.1016/S0076-6879(96)64031-2.
   Cruz-Bermúdez A, 2015, ONCOTARGET, V6, P13628, DOI 10.18632/oncotarget.3698.
   Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659.
   Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972.
   Garaude J, 2016, NAT IMMUNOL, V17, P1037, DOI 10.1038/ni.3509.
   Garrido F, 2016, INT J CANCER, V138, P271, DOI 10.1002/ijc.29375.
   Gasparre G, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011411.
   Greggio C, 2017, CELL METAB, V25, P301, DOI 10.1016/j.cmet.2016.11.004.
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013.
   Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9.
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906.
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066.
   Koshikawa N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15592-2.
   Lam ET, 2012, CANCER RES, V72, P686, DOI 10.1158/0008-5472.CAN-11-1682.
   Lapuente-Brun E, 2013, SCIENCE, V340, P1567, DOI 10.1126/science.1230381.
   Li LH, 2014, INT J MOL MED, V33, P77, DOI 10.3892/ijmm.2013.1559.
   Martínez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685.
   Molon B, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00020.
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897.
   Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726.
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155.
   Prior SL, 2006, CARCINOGENESIS, V27, P945, DOI 10.1093/carcin/bgi326.
   Qiao Chun, 2014, Zhonghua Xue Ye Xue Za Zhi, V35, P708, DOI 10.3760/cma.j.issn.0253-2727.2014.08.009.
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264.
   Sawhney RS, 2009, J CELL PHYSIOL, V219, P152, DOI 10.1002/jcp.21662.
   Schägger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777.
   Selinsky CL, 2000, CELL IMMUNOL, V200, P81, DOI 10.1006/cimm.2000.1622.
   Srinivasan S, 2016, ONCOGENE, V35, P1585, DOI 10.1038/onc.2015.227.
   Sun WY, 2009, CLIN CANCER RES, V15, P476, DOI 10.1158/1078-0432.CCR-08-0930.
   Tan DJ, 2002, CANCER RES, V62, P972.
   Villalba M, 2013, INT J BIOCHEM CELL B, V45, P106, DOI 10.1016/j.biocel.2012.04.024.
   WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267.
   Yeung KY, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-1.
   Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533.
   Zhou SY, 2007, P NATL ACAD SCI USA, V104, P7540, DOI 10.1073/pnas.0610818104.},
Number-of-Cited-References = {49},
Times-Cited = {28},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Cancers},
Doc-Delivery-Number = {IO4AV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000479322800137},
OA = {Green Submitted, Green Published, gold},
DA = {2026-02-04},
}

@article{ WOS:000472841200002,
Author = {Ma, Jian-Da and Jing, Jun and Wang, Jun-Wei and Yan, Tao and Li,
   Qian-Hua and Mo, Ying-Qian and Zheng, Dong-Hui and Gao, Jin-Long and
   Ky-Anh Nguyen and Dai, Lie},
Title = {A novel function of artesunate on inhibiting migration and invasion of
   fibroblast-like synoviocytes from rheumatoid arthritis patients},
Journal = {ARTHRITIS RESEARCH \& THERAPY},
Year = {2019},
Volume = {21},
Month = {JUN 24},
Abstract = {IntroductionAnti-malarial drug artesunate can suppress inflammation and
   prevent cartilage and bone destruction in collagen-induced arthritis
   model in ratssuggesting it may be a potent drug for rheumatoid arthritis
   (RA) therapy. We aimed to investigate its effect on the invasive
   property of fibroblast-like synoviocytes (FLS) from patients with
   RA.MethodsSynovial tissues were obtained by closed needle biopsy from
   active RA patients, and FLS were isolated and cultured in vitro. RA-FLS
   were treated with artesunate at various concentrations, while
   methotrexate or hydroxychloroquine was employed as comparator drugs.
   Cell viability, proliferation, cell cycle, apoptosis, migration,
   invasion, and pseudopodium formation of RA-FLS were assessed by CCK-8
   assays, EdU staining, Annexin V-FITC/PI staining, transwell assays, or
   F-actin staining, respectively. Further, relative changes of expressed
   proteases were analyzed by Proteome profiler human protease array and
   verified by quantitative real-time PCR (qPCR), Western blot, and ELISA.
   The expression of signaling molecules of MAPK, NF-B, AP-1, and PI3K/Akt
   pathways were measured by qPCR and Western blot. PDK-1 knockdown by
   specific inhibitor AR-12 or siRNA transfection was used to verify the
   pharmacological mechanism of artesunate on RA-FLS.ResultsArtesunate
   significantly inhibited the migration and invasion of RA-FLS in a
   dose-dependent manner with or without TNF- stimulation. The effect was
   mediated through artesunate inhibition of MMP-2 and MMP-9 production,
   and pre-treatment with exogenous MMP-9 reversed the inhibitory effect of
   artesunate on RA-FLS invasion. Artesunate had a stronger inhibitory
   effect on migration and invasion of RA-FLS as well as greater
   anti-inflammatory effect than those of hydroxychloroquine. Similar
   inhibitory effect was detected between artesunate and methotrexate, and
   synergy was observed when combined. Mechanistically, artesunate
   significantly inhibited PDK-1 expression as well as Akt and RSK2
   phosphorylationin a similar manner to PDK-1-specific inhibitor AR-12 or
   PDK-1 knockdown by siRNA transfection. This inhibition results in
   suppression of RA-FLS migration and invasion as well as decreased MMP-2
   and MMP-9 expression.ConclusionsOur study demonstrates artesunate is
   capable of inhibiting migration and invasion of RA-FLS through
   suppression of PDK1-induced activation of Akt and RSK2
   phosphorylationsuggesting that artesunate may be a potential
   disease-modifying anti-rheumatic drug for RA.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Dai, L (Corresponding Author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou 510120, Peoples R China.
   Ma, Jian-Da; Jing, Jun; Wang, Jun-Wei; Li, Qian-Hua; Mo, Ying-Qian; Zheng, Dong-Hui; Dai, Lie, Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Rheumatol, Guangzhou 510120, Peoples R China.
   Yan, Tao, Sun Yat Sen Univ, Zhongshan Sch Med, Guangzhou, Guangdong, Peoples R China.
   Gao, Jin-Long; Ky-Anh Nguyen, Univ Sydney, Sydney Dent Sch, Inst Dent Res, Sydney, NSW, Australia.},
DOI = {10.1186/s13075-019-1935-6},
Article-Number = {153},
ISSN = {1478-6354},
EISSN = {1478-6362},
Keywords = {Artesunate; Rheumatoid arthritis; Fibroblast-like synoviocytes;
   Migration; Invasion},
Keywords-Plus = {RANKL-INDUCED OSTEOCLASTOGENESIS; ANTIMALARIAL AGENT ARTESUNATE;
   MODIFYING ANTIRHEUMATIC DRUGS; COLLAGEN-INDUCED ARTHRITIS;
   AMERICAN-COLLEGE; KAPPA-B; INFLAMMATION; CELLS; RECOMMENDATIONS;
   CLASSIFICATION},
Research-Areas = {Rheumatology},
Web-of-Science-Categories  = {Rheumatology},
Author-Email = {majd@mail.sysu.edu.cn
   dailie@mail.sysu.edu.cn},
Affiliations = {Sun Yat Sen University; Sun Yat Sen University; University of Sydney},
ResearcherID-Numbers = {Nguyen, Ky-Anh/A-4971-2010
   Zhao, Haifeng/AAE-6063-2021
   },
ORCID-Numbers = {Yan, Tao/0000-0002-2464-2361
   Mo, yingqian/0000-0001-9617-8927
   Gao, Jinlong/0000-0002-5153-5393},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81671612, 81801606];
   Guangdong Natural Science Foundation {[}2017A030313576, 2017A030310236,
   2018A030313541]; Guangdong Medical Scientific Research Foundation
   {[}A2017109]; Fundamental Research Funds for the Central Universities
   {[}17ykjc12]; Scientific Program of Traditional Chinese Medicine Bureau
   of Guangdong Province {[}20161058, 20181058]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (no. 81671612 and 81801606), Guangdong Natural Science Foundation
   (no. 2017A030313576, 2017A030310236, and 2018A030313541), Guangdong
   Medical Scientific Research Foundation (no. A2017109), Fundamental
   Research Funds for the Central Universities (no. 17ykjc12), and
   Scientific Program of Traditional Chinese Medicine Bureau of Guangdong
   Province (no. 20161058, 20181058).},
Cited-References = {Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI {[}10.1136/ard.2010.138461, 10.1002/art.27584].
   An J, 2017, ANNU REV MED, V68, P317, DOI 10.1146/annurev-med-043015-123453.
   {[}Anonymous], 2015, GUIDELINES TREATMENT.
   ARNETT FC, 1988, ARTHRITIS RHEUM-US, V31, P315, DOI 10.1002/art.1780310302.
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105-2896.2009.00859.x.
   Brown PM, 2016, NAT REV RHEUMATOL, V12, P731, DOI 10.1038/nrrheum.2016.175.
   Chao W, 2017, INT IMMUNOPHARMACOL, V50, P77, DOI 10.1016/j.intimp.2017.06.014.
   Chen X, 2019, CLIN CANCER RES, V25, P1389, DOI 10.1158/1078-0432.CCR-18-1656.
   Feng X, 2017, LUPUS, V26, P62, DOI 10.1177/0961203316651738.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gu P, 2017, MOL THER, V25, P1959, DOI 10.1016/j.ymthe.2017.04.016.
   Guruprasad B, 2015, INFLAMMATION, V38, P1028, DOI 10.1007/s10753-014-0067-z.
   Hayer S, 2009, FASEB J, V23, P4288, DOI 10.1096/fj.09-135160.
   He Y, 2011, RHEUMATOL INT, V31, P53, DOI 10.1007/s00296-009-1218-7.
   Hou LF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104762.
   Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499.
   Korb-Pap A, 2016, RHEUMATOLOGY, V55, P64, DOI 10.1093/rheumatology/kew347.
   Li YM, 2013, TRANSL RES, V161, P89, DOI 10.1016/j.trsl.2012.06.001.
   Lin ZM, 2016, SCI REP-UK, V6, DOI 10.1038/srep38115.
   MA JD, 2014, MEDIAT INFLAMM, V2014, DOI DOI 10.1155/2014/179284.
   Ma JD, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0803-2.
   Noack M, 2017, SEMIN IMMUNOPATHOL, V39, P365, DOI 10.1007/s00281-017-0619-z.
   Orr C, 2017, NAT REV RHEUMATOL, V13, P630, DOI 10.1038/nrrheum.2017.161.
   Rempenault C, 2018, ANN RHEUM DIS, V77, P98, DOI 10.1136/annrheumdis-2017-211836.
   Saag KG, 2008, ARTHRIT RHEUM-ARTHR, V59, P762, DOI 10.1002/art.23721.
   SCHUMACHER HR, 1972, NEW ENGL J MED, V286, P416, DOI 10.1056/NEJM197202242860807.
   Shi GX, 2018, P NATL ACAD SCI USA, V115, pE190, DOI 10.1073/pnas.1708584115.
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8.
   Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715.
   Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573.
   Tanner MR, 2017, FASEB J, V31, P3309, DOI 10.1096/fj.201601097R.
   Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471.
   Wei CM, 2018, J CELL PHYSIOL, V233, P476, DOI 10.1002/jcp.25907.
   Xu H, 2007, RHEUMATOLOGY, V46, P920, DOI 10.1093/rheumatology/kem014.
   Xu K, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0892-y.
   Xue ML, 2014, RHEUMATOLOGY, V53, P2270, DOI 10.1093/rheumatology/keu254.
   Zeng XZ, 2017, BIOCHEM PHARMACOL, V124, P57, DOI 10.1016/j.bcp.2016.10.007.
   Zheng HQ, 2017, NAT CHEM BIOL, V13, P218, DOI {[}10.1038/nchembio.2259, 10.1038/NCHEMBIO.2259].
   Zhou JJ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0472-6.},
Number-of-Cited-References = {39},
Times-Cited = {124},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {42},
Journal-ISO = {Arthritis Res. Ther.},
Doc-Delivery-Number = {IF1LX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000472841200002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000470803500003,
Author = {Jin, Hengwei and Wang, Huijuan and Li, Jie and Yu, Shan and Xu, Mingjie
   and Qiu, Zhiqian and Xia, Meng and Zhu, Jingai and Feng, Qiuting and
   Xie, Jun and Xu, Biao and Yang, Zhongzhou},
Title = {Differential contribution of the two waves of cardiac progenitors and
   their derivatives to aorta and pulmonary artery},
Journal = {DEVELOPMENTAL BIOLOGY},
Year = {2019},
Volume = {450},
Number = {2},
Pages = {82-89},
Month = {JUN 15},
Abstract = {During mouse development, part of the cells derived from the second
   heart field (SHF) progenitors contributes to the elongation and
   enlargement of the outflow tract (OFT) that subsequently septates into
   the trunks of aorta (Ao) and pulmonary artery (PA). Thus, the cardiac
   progenitor-originated cells are distributed to both Ao and PA. Here, we
   investigated that how these cells are assigned to the two great arteries
   during OFT septation through lineage tracing technology. By use of the
   inducible Mef2c-AHF-CreERT2; Rosa26-mTmG reporter system, two waves of
   SHF progenitors and their derivatives were identified, and they made
   differential contribution to the Ao and PA, respectively. While the
   early wave of cells (at E7.5) was preferentially destined to the Ao, the
   second wave of cells (from E8.5 till E11.5) made its favorite path to
   the PA. In addition, we unveiled PDK1 as a critical regulator of the
   second wave of cells as deletion of Pdk1 resulted in poorly developed PA
   leading to pulmonary stenosis. Thus, this study provides insights into
   the understanding of the pre-determined cell fate of the cardiac
   progenitor-derived cells with preferential contribution to the Ao and
   PA, as well as of the pathogenesis of pulmonary stenosis.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Yang, ZZ (Corresponding Author), Nanjing Univ, Nanjing Drum Tower Hosp, State Key Lab Pharmaceut Biotechnol, Dept Cardiol,Affiliated Hosp,Med Sch, Nanjing 210061, Jiangsu, Peoples R China.
   Jin, Hengwei; Wang, Huijuan; Li, Jie; Yu, Shan; Xu, Mingjie; Qiu, Zhiqian; Xia, Meng; Zhu, Jingai; Feng, Qiuting; Xie, Jun; Xu, Biao; Yang, Zhongzhou, Nanjing Univ, Nanjing Drum Tower Hosp, State Key Lab Pharmaceut Biotechnol, Dept Cardiol,Affiliated Hosp,Med Sch, Nanjing 210061, Jiangsu, Peoples R China.
   Jin, Hengwei; Wang, Huijuan; Li, Jie; Yu, Shan; Xu, Mingjie; Qiu, Zhiqian; Xia, Meng; Zhu, Jingai; Feng, Qiuting; Xie, Jun; Xu, Biao; Yang, Zhongzhou, Nanjing Univ, Model Anim Res Ctr, MOE Key Lab Model Anim Dis Study, Nanjing 210061, Jiangsu, Peoples R China.},
DOI = {10.1016/j.ydbio.2019.03.019},
ISSN = {0012-1606},
EISSN = {1095-564X},
Keywords = {Outflow tract; Aorta; Pulmonary artery; Cardiac progenitors; PDK1;
   Pulmonary stenosis},
Keywords-Plus = {2ND HEART FIELD; OUTFLOW TRACT; SMOOTH-MUSCLE; CELLS; MYOCARDIUM;
   GENETICS; PDK1},
Research-Areas = {Developmental Biology},
Web-of-Science-Categories  = {Developmental Biology},
Author-Email = {zhongzhouyang@nju.edu.cn},
Affiliations = {Nanjing University; Nanjing University},
ResearcherID-Numbers = {xie, jun/OMK-5101-2025
   XU, MIN JIE/JFA-7139-2023
   Yang, Zhongzhou/H-3015-2014},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31571490, 81741003,
   91854111, 91519312]; National Key Basic Research Program of China
   {[}2012CB966600, 2011CB943904]; State Key Laboratory of Genetic
   Engineering of Fudan University {[}SKLGE-1604]},
Funding-Text = {The authors thank Dr. Dario Alessi for providing the Pdk1 floxed
   (PdkF/F) mice (Lawlor et al., 2002). This work was supported
   by grants from the National Natural Science Foundation of China
   (31571490, 81741003, 91854111 and 91519312) to Zhongzhou Yang and by
   grants from the National Key Basic Research Program of China
   (2012CB966600 and 2011CB943904) and the State Key Laboratory of Genetic
   Engineering of Fudan University (SKLGE-1604) to Zhongzhou Yang.},
Cited-References = {Bajolle F, 2006, CIRC RES, V98, P421, DOI 10.1161/01.RES.0000202800.85341.6e.
   Bajolle F, 2008, DEV BIOL, V313, P25, DOI 10.1016/j.ydbio.2007.09.023.
   Bruneau BG, 2008, NATURE, V451, P943, DOI 10.1038/nature06801.
   Buckingham M, 2005, NAT REV GENET, V6, P826, DOI 10.1038/nrg1710.
   Dyer LA, 2009, DEV BIOL, V336, P137, DOI 10.1016/j.ydbio.2009.10.009.
   Fahed AC, 2013, CIRC RES, V112, P707, DOI 10.1161/CIRCRESAHA.112.300853.
   Francou A, 2013, BBA-MOL CELL RES, V1833, P795, DOI 10.1016/j.bbamcr.2012.10.003.
   KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Luo W, 2015, DEVELOPMENT, V142, P732, DOI 10.1242/dev.119016.
   Meilhac Sigolene M, 2015, Cold Spring Harb Perspect Med, V5, pa026344, DOI {[}10.1101/cshperspect.a026344, 10.1101/cshperspect.a026344].
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Neeb Z, 2013, WIRES DEV BIOL, V2, P499, DOI 10.1002/wdev.98.
   Plein A, 2015, J CLIN INVEST, V125, P2661, DOI 10.1172/JCI79668.
   Sawada H, 2017, ARTERIOSCL THROM VAS, V37, P1722, DOI 10.1161/ATVBAHA.117.309599.
   Srivastava D, 2006, CELL, V126, P1037, DOI 10.1016/j.cell.2006.09.003.
   van den Hoff MJB, 1999, DEV BIOL, V212, P477, DOI 10.1006/dbio.1999.9366.
   Verzi MP, 2005, DEV BIOL, V287, P134, DOI 10.1016/j.ydbio.2005.08.041.
   Waldo KL, 2005, DEV BIOL, V281, P78, DOI 10.1016/j.ydbio.2005.02.012.
   Webb S, 2003, J ANAT, V202, P327, DOI 10.1046/j.1469-7580.2003.00168.x.
   Xiao Q, 2017, DEVELOPMENT, V144, P580, DOI 10.1242/dev.147827.
   Zeigler Vicki L, 2008, Crit Care Nurs Clin North Am, V20, P159, DOI 10.1016/j.ccell.2008.01.008.
   Zhao X, 2014, MOL CELL BIOL, V34, P1966, DOI 10.1128/MCB.00144-14.},
Number-of-Cited-References = {23},
Times-Cited = {13},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Dev. Biol.},
Doc-Delivery-Number = {IC2PZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000470803500003},
DA = {2026-02-04},
}

@article{ WOS:000469157700004,
Author = {Lachen-Montes, Mercedes and Gonzalez-Morales, Andrea and Schvartz,
   Domitille and Victoria Zelaya, Maria and Ausin, Karina and
   Fernandez-Irigoyen, Joaquin and Sanchez, Jean Charles and Santamaria,
   Enrique},
Title = {The olfactory bulb proteotype differs across frontotemporal dementia
   spectrum},
Journal = {JOURNAL OF PROTEOMICS},
Year = {2019},
Volume = {201},
Pages = {37-47},
Month = {JUN 15},
Abstract = {Mild olfactory dysfunction has been observed in frontotemporal dementias
   (FTD). However, the underlying molecular mechanisms associated to this
   deficit are poorly understood. We applied quantitative proteomics to
   analyze pathological effects on the olfactory bulb (OB) from progressive
   supranuclear palsy (PSP) and frontotemporal lobar degeneration
   (FTLD-TDP43) subjects respect to elderly non-FTD group. Our data
   revealed: i) a mitochondrial and calcium homeostasis impairment in PSP
   and ii) a disruption of protein synthesis and vesicle trafficking in
   FTLD-TDP43. Although differential OB proteomes clearly differ between
   both FTD phenotypes, functional analyses pointed out an imbalance in
   survival signaling in both pathologies. A common alteration of olfactory
   mitogen-activated protein kinases (MAPKs), calcium/calmodulin dependent
   protein kinase II (CAMKII), and protein kinase C (PKC) signaling
   pathways was observed in PSP and FTLD subjects. In contrast, a specific
   shut off in mitogen-activated protein kinase kinase 4
   (SEK1/MKK4)/stress-activated protein kinase (SAPK) axis was exclusively
   observed in PSP, whereas a specific phosphoinositide-dependent protein
   kinase 1 (PDK1) inactivation was observed in FTLD-TDP43. In summary, our
   data contribute to a better understanding of the molecular mechanisms
   that are modulated in PSP and FTLD-TDP43 at olfactory level,
   highlighting cross disease similarities and differences in the
   regulation of survival pathways across FTD spectrum.
   Significance: This work reflects differential olfactory molecular
   disarrangements in PSP and FTLD-TDP43, two clinically similar FTD
   disorders, but with different neuropathological signature. Besides FTDs
   present mild olfactory dysfunction, our data provide basic information
   for understanding the implication of the OB in the pathophysiology of
   FTDs.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Santamaría, E (Corresponding Author), Inst Invest Sanitaria Navarra IdiSNA, Prote Unit, Navarrabiomed, Pamplona, Spain.
   Lachen-Montes, Mercedes; Gonzalez-Morales, Andrea; Victoria Zelaya, Maria; Fernandez-Irigoyen, Joaquin; Santamaria, Enrique, Univ Publ Navarra UPNA, CHN, Clin Neuroprote Unit, Navarrabiomed, Irunlarrea 3, Pamplona 31008, Spain.
   Lachen-Montes, Mercedes; Gonzalez-Morales, Andrea; Ausin, Karina; Fernandez-Irigoyen, Joaquin; Santamaria, Enrique, Univ Publ Navarra UPNA, CHN, Prote Unit, Proteored ISCIII,Navarrabiomed, Irunlarrea 3, Pamplona 31008, Spain.
   Lachen-Montes, Mercedes; Gonzalez-Morales, Andrea; Victoria Zelaya, Maria; Ausin, Karina; Fernandez-Irigoyen, Joaquin; Santamaria, Enrique, Navarra Inst Hlth Res, IdiSNA, Irunlarrea 3, Pamplona 31008, Spain.
   Schvartz, Domitille; Sanchez, Jean Charles, Univ Geneva, Dept Human Prot Sci, Translat Biomarker Grp, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.
   Victoria Zelaya, Maria, CHN, Pathol Anat Dept, Pamplona, Spain.},
DOI = {10.1016/j.jprot.2019.04.011},
ISSN = {1874-3919},
EISSN = {1876-7737},
Keywords-Plus = {PROGRESSIVE SUPRANUCLEAR PALSY; ACTIVATED PROTEIN-KINASE; BETA-AMYLOID
   DEPOSITION; LOBAR DEGENERATION; NEURODEGENERATIVE DISEASE;
   PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; DISTINCT PATTERNS; DYSFUNCTION;
   NEURONS},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemical Research Methods},
Author-Email = {esantamma@navarra.es},
Affiliations = {Navarrabiomed; Universidad Publica de Navarra; Universidad Publica de
   Navarra; Navarrabiomed; University of Navarra; University of Geneva},
ResearcherID-Numbers = {Ausín, Karina/R-6817-2019
   Zelaya, Maria Victoria/Y-5778-2019
   Fernandez-Irigoyen, Joaquin/JBR-8052-2023
   Lachen-Montes, Mercedes/R-6771-2019
   SANTAMARIA, ENRIQUE/A-6012-2017
   Gonzalez Morales, Anea/R-9439-2019},
ORCID-Numbers = {Ausín, Karina/0000-0003-4914-9466
   Zelaya, Maria Victoria/0000-0002-3692-3515
   Fernandez-Irigoyen, Joaquin/0000-0001-5072-4099
   Lachen-Montes, Mercedes/0000-0003-2449-8117
   SANTAMARIA, ENRIQUE/0000-0001-8046-8102
   Gonzalez Morales, Anea/0000-0003-3063-1885},
Funding-Acknowledgement = {Spanish Ministry of Economy and Competitiveness (MINECO)
   {[}SAF2014-59340-R]; Department of Economic Development from Government
   of Navarra {[}PC023-24, PC025, PC081-82, PI059]; Obra Social la Caixa;
   Public University of Navarra (UPNA); UPNA, La Caixa {[}810/2016];
   Navarra Heath Department {[}993/2016]; MINECO {[}PEJ-2014-A-61949,
   PEJ-2014-A-72151]},
Funding-Text = {This work was funded by grants from the Spanish Ministry of Economy and
   Competitiveness (MINECO) (Ref. SAF2014-59340-R), Department of Economic
   Development from Government of Navarra (Ref. PC023-24, PC025, PC081-82
   and PI059) and Obra Social la Caixa to E.S. A.G-M and K.A were supported
   by PEJ-2014-A-61949 and PEJ-2014-A-72151 (MINECO). M.L-M was supported
   by a predoctoral fellowship from the Public University of Navarra (UPNA)
   and mobility fellowships from UPNA, La Caixa (Res. No 810/2016) and the
   Navarra Heath Department (Res. No 993/2016).},
Cited-References = {Ackermann TF, 2008, CELL PHYSIOL BIOCHEM, V22, P735, DOI 10.1159/000185557.
   Albers DS, 2002, NEUROCHEM INT, V40, P559, DOI 10.1016/S0197-0186(01)00126-7.
   Attems J, 2014, ACTA NEUROPATHOL, V127, P459, DOI 10.1007/s00401-014-1261-7.
   Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042.
   Breton-Provencher V, 2012, BEHAV BRAIN RES, V227, P480, DOI 10.1016/j.bbr.2011.08.001.
   Brini M, 2009, PFLUG ARCH EUR J PHY, V457, P657, DOI 10.1007/s00424-008-0505-6.
   Bronner IF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006826.
   Cumberworth SL, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12737.
   Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.0.CO;2-R.
   Dayon L, 2010, J PROTEOMICS, V73, P769, DOI 10.1016/j.jprot.2009.10.015.
   De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227.
   Di Leva F, 2008, ARCH BIOCHEM BIOPHYS, V476, P65, DOI 10.1016/j.abb.2008.02.026.
   Doty RL, 2008, ANN NEUROL, V63, P7, DOI 10.1002/ana.21327.
   Doty RL, 2017, LANCET NEUROL, V16, P478, DOI 10.1016/S1474-4422(17)30123-0.
   Doty RL, 2012, NAT REV NEUROL, V8, P329, DOI 10.1038/nrneurol.2012.80.
   Duda JE, 2010, J NEUROL SCI, V289, P49, DOI 10.1016/j.jns.2009.08.042.
   Fernández-Irigoyen J, 2019, NEURAL REGEN RES, V14, P979, DOI 10.4103/1673-5374.249220.
   Ferrer I., 2005, Current Alzheimer Research, V2, P3, DOI 10.2174/1567205052772713.
   Ferrer I, 2001, J NEURAL TRANSM, V108, P1383, DOI 10.1007/s007020100015.
   Ferrer I, 2001, BRAIN PATHOL, V11, P144.
   Fullard ME, 2017, NEUROSCI BULL, V33, P515, DOI 10.1007/s12264-017-0170-x.
   Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555.
   HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0.
   Heyanka DJ, 2014, APPL NEUROPSYCH-ADUL, V21, P176, DOI 10.1080/09084282.2013.782031.
   Hubbard PS, 2007, J ANAT, V211, P117, DOI 10.1111/j.1469-7580.2007.00748.x.
   Kotlyar M, 2015, NAT METHODS, V12, P79, DOI {[}10.1038/NMETH.3178, 10.1038/nmeth.3178].
   Kovács T, 1999, NEUROPATH APPL NEURO, V25, P481.
   Lachén-Montes M, 2019, NEUROBIOL AGING, V73, P123, DOI 10.1016/j.neurobiolaging.2018.09.018.
   Lachén-Montes M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09481-x.
   Lachén-Montes M, 2016, PROTEOM CLIN APPL, V10, P1178, DOI 10.1002/prca.201500147.
   Lachén-Montes M, 2016, J PROTEOMICS, V148, P149, DOI 10.1016/j.jprot.2016.07.032.
   Lagalwar S, 2007, ACTA NEUROPATHOL, V113, P63, DOI 10.1007/s00401-006-0159-4.
   Li YQ, 2016, MOL NEUROBIOL, V53, P6091, DOI 10.1007/s12035-015-9507-5.
   Litvan I, 1996, J NEUROPATH EXP NEUR, V55, P97, DOI 10.1097/00005072-199601000-00010.
   Luzzi S, 2007, NEUROPSYCHOLOGIA, V45, P1823, DOI 10.1016/j.neuropsychologia.2006.12.008.
   Mackenzie IRA, 2016, J NEUROCHEM, V138, P54, DOI 10.1111/jnc.13588.
   Mackenzie IRA, 2011, ACTA NEUROPATHOL, V122, P87, DOI 10.1007/s00401-011-0838-7.
   Mackenzie IRA, 2011, ACTA NEUROPATHOL, V121, P207, DOI 10.1007/s00401-010-0764-0.
   Mann DMA, 2017, BRAIN PATHOL, V27, P723, DOI 10.1111/bpa.12486.
   McLaughlin NCR, 2008, ARCH CLIN NEUROPSYCH, V23, P119, DOI 10.1016/j.acn.2007.07.008.
   MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4.
   Mundiñano IC, 2011, ACTA NEUROPATHOL, V122, P61, DOI 10.1007/s00401-011-0830-2.
   Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108.
   NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0.
   Nonaka T, 2013, CELL REP, V4, P124, DOI 10.1016/j.celrep.2013.06.007.
   Orasji SSS, 2016, CLIN NEUROL NEUROSUR, V141, P106, DOI 10.1016/j.clineuro.2016.01.003.
   Palluzzi F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185797.
   Pardini M, 2009, ARCH NEUROL-CHICAGO, V66, P92, DOI 10.1001/archneurol.2008.521.
   Rey NL, 2018, ACTA NEUROPATHOL, V135, P65, DOI 10.1007/s00401-017-1792-9.
   Rey NL, 2018, NEUROBIOL DIS, V109, P226, DOI 10.1016/j.nbd.2016.12.013.
   Shao CY, 2006, J NEUROPATH EXP NEUR, V65, P327, DOI 10.1097/01.jnen.0000218441.00040.82.
   Shi J, 2005, ACTA NEUROPATHOL, V110, P501, DOI 10.1007/s00401-005-1079-4.
   Silveira-Moriyama L, 2010, MOVEMENT DISORD, V25, P570, DOI 10.1002/mds.22688.
   Sochivko D, 2002, J PHYSIOL-LONDON, V542, P699, DOI 10.1113/jphysiol.2002.020677.
   Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21.
   Sun MK, 2012, ADV PHARMACOL, V64, P273, DOI 10.1016/B978-0-12-394816-8.00008-8.
   Sun MK, 2010, PHARMACOL THERAPEUT, V127, P66, DOI 10.1016/j.pharmthera.2010.03.001.
   Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415.
   Tepe B, 2018, CELL REP, V25, P2689, DOI 10.1016/j.celrep.2018.11.034.
   Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI {[}10.11772/j.issn.1001-9081.2014.07.1929, 10.1523/JNEUROSCI.1860-14.2014].
   Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x.},
Number-of-Cited-References = {61},
Times-Cited = {19},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {3},
Journal-ISO = {J. Proteomics},
Doc-Delivery-Number = {HZ9ED},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000469157700004},
DA = {2026-02-04},
}

@article{ WOS:000473756000052,
Author = {Mathew, Omana P. and Ranganna, Kasturi and Mathew, Joseph and Zhu,
   Meiling and Yousefipour, Zivar and Selvam, Chelliah and Milton,
   Shirlette G.},
Title = {Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are
   Mediated through Disparate Actions on Dual Targets, Histone Deacetylase
   (HDAC) Activity and PI3K/Akt Signaling Network},
Journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
Year = {2019},
Volume = {20},
Number = {12},
Month = {JUN 2},
Abstract = {Vascular remodeling is a characteristic feature of cardiovascular
   diseases. Altered cellular processes of vascular smooth muscle cells
   (VSMCs) is a crucial component in vascular remodeling. Histone
   deacetylase inhibitor (HDACI), butyrate, arrests VSMC proliferation and
   promotes cell growth. The objective of the study is to determine the
   mechanism of butyrate-induced VSMC growth. Using proliferating VSMCs
   exposed to 5 mM butyrate, immunoblotting studies are performed to
   determine whether PI3K/Akt pathway that regulates different cellular
   effects is a target of butyrate-induced VSMC growth. Butyrate inhibits
   phosphorylation-dependent activation of PI3K, PDK1, and Akt, eliciting
   differential effects on downstream targets of Akt. Along with previously
   reported Ser9 phosphorylation-mediated GSK3 inactivation leading to
   stability, increased expression and accumulation of cyclin D1, and
   epigenetic histone modifications, inactivation of Akt by butyrate
   results in: transcriptional activation of FOXO1 and FOXO3 promoting G1
   arrest through p21Cip1/Waf1 and p15INK4B upregulation; inactivation of
   mTOR inhibiting activation of its targets p70S6K and 4E-BP1 impeding
   protein synthesis; inhibition of caspase 3 cleavage and downregulation
   of PARP preventing apoptosis. Our findings imply butyrate abrogates Akt
   activation, causing differential effects on Akt targets promoting
   convergence of cross-talk between their complimentary actions leading to
   VSMC growth by arresting proliferation and inhibiting apoptosis through
   its effect on dual targets, HDAC activity and PI3K/Akt pathway network.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Ranganna, K (Corresponding Author), Texas Southern Univ, Coll Pharm \& Hlth Sci, Dept Pharmaceut \& Environm Hlth Sci, 3100 Cleburne St, Houston, TX 77004 USA.
   Mathew, Omana P.; Ranganna, Kasturi; Mathew, Joseph; Zhu, Meiling; Yousefipour, Zivar; Selvam, Chelliah; Milton, Shirlette G., Texas Southern Univ, Coll Pharm \& Hlth Sci, Dept Pharmaceut \& Environm Hlth Sci, 3100 Cleburne St, Houston, TX 77004 USA.},
DOI = {10.3390/ijms20122902},
Article-Number = {2902},
EISSN = {1422-0067},
Keywords = {vascular smooth muscle cells; butyrate; histone deacetylase inhibitor;
   signaling; Akt},
Keywords-Plus = {SODIUM-BUTYRATE; DNA METHYLATION; CANCER CELLS; PROLIFERATION;
   EPIGENETICS; GROWTH; AKT; ACETYLATION; INVOLVEMENT; INHIBITORS},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {Omanapmathew@yahoo.com
   Ranganna\_kx@tsu.edu
   josephmk@tsu.edu
   anniezhu2010@gmail.com
   Yousefipour\_zx@tsu.edu
   chelliahs@tsu.edu
   Shirlette.milton@tsu.edu},
Affiliations = {Texas Southern University},
ResearcherID-Numbers = {SELVAM, CHELLIAH/L-9434-2013},
ORCID-Numbers = {Yousefipour, Zivar/0000-0002-3330-6773
   SELVAM, CHELLIAH/0000-0003-1394-9349},
Funding-Acknowledgement = {NIMHD/NIH {[}5G12MD007605]},
Funding-Text = {This research was made possible, in part, by the Molecular Biology
   research infrastructure support from grant number 5G12MD007605 from the
   NIMHD/NIH.},
Cited-References = {Abeyrathna P, 2015, VASC PHARMACOL, V74, P38, DOI 10.1016/j.vph.2015.05.008.
   Aguilar EC, 2014, NUTR METAB CARDIOVAS, V24, P606, DOI 10.1016/j.numecd.2014.01.002.
   Alfonso F, 2014, J AM COLL CARDIOL, V63, P2659, DOI 10.1016/j.jacc.2014.02.545.
   Allard D, 2008, J BIOL CHEM, V283, P19739, DOI 10.1074/jbc.M710098200.
   {[}Anonymous], 2008, NAT ED.
   Baccarelli A, 2012, CURR OPIN CLIN NUTR, V15, P323, DOI 10.1097/MCO.0b013e328354bf5c.
   Bai ZG, 2010, CELL BIOL INT, V34, P1141, DOI 10.1042/CBI20090481.
   Ballestar E, 2011, ADV EXP MED BIOL, V711, P1.
   Banasik M, 2012, MOL NEUROBIOL, V46, P55, DOI 10.1007/s12035-012-8257-x.
   Barkauskaite E, 2015, MOL CELL, V58, P935, DOI 10.1016/j.molcel.2015.05.007.
   Bergmann A, 2003, TRENDS BIOCHEM SCI, V28, P461, DOI 10.1016/S0968-0004(03)00175-0.
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4.
   Cantoni S, 2013, FEBS J, V280, P2042, DOI 10.1111/febs.12227.
   Chen JH, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-71.
   Clarke MCH, 2006, NAT MED, V12, P1075, DOI 10.1038/nm1459.
   Daitoku H, 2011, BBA-MOL CELL RES, V1813, P1954, DOI 10.1016/j.bbamcr.2011.03.001.
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013.
   Domínguez-Calderón A, 2016, MOL BIOL CELL, V27, P1581, DOI 10.1091/mbc.E15-08-0598.
   Feinberg AP, 2008, JAMA-J AM MED ASSOC, V299, P1345, DOI 10.1001/jama.299.11.1345.
   Feng P, 1996, CELL PROLIFERAT, V29, P231, DOI 10.1046/j.1365-2184.1996.00998.x.
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802.
   FRANCH HA, 1995, J CELL BIOL, V129, P245, DOI 10.1083/jcb.129.1.245.
   Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959.
   Gibbons James J, 2009, Semin Oncol, V36 Suppl 3, pS3, DOI 10.1053/j.seminoncol.2009.10.011.
   Go AS, 2013, CIRCULATION, V127, pE6, DOI 10.1161/CIR.0b013e31828124ad.
   Guan FF, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.118.009871.
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704.
   Ho KJ, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12627.
   Jakovcevski M, 2012, NAT MED, V18, P1194, DOI 10.1038/nm.2828.
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230.
   Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8.
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005.
   Li CJ, 2005, J ANIM SCI, V83, P89.
   Li HY, 2018, SENSYS'18: PROCEEDINGS OF THE 16TH CONFERENCE ON EMBEDDED NETWORKED SENSOR SYSTEMS, P15, DOI 10.1145/3274783.3274838.
   Li QR, 2017, J PHARMACOL SCI, V135, P148, DOI 10.1016/j.jphs.2017.11.004.
   Lim SJ, 2009, MOL MED REP, V2, P497, DOI 10.3892/mmr\_00000127.
   Liu BL, 1999, AM J PHYSIOL-RENAL, V277, pF186, DOI 10.1152/ajprenal.1999.277.2.F186.
   Liu K, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.51.
   Lloyd AC, 2013, CELL, V154, P1194, DOI 10.1016/j.cell.2013.08.053.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008.
   Mathew OP, 2014, PHARMACEUTICALS, V7, P1008, DOI 10.3390/ph7111008.
   Mathew OP, 2010, BIOMED PHARMACOTHER, V64, P733, DOI 10.1016/j.biopha.2010.09.017.
   Mattick JS, 2009, BIOESSAYS, V31, P51, DOI 10.1002/bies.080099.
   McCubrey JA, 2014, ONCOTARGET, V5, P2881, DOI 10.18632/oncotarget.2037.
   Mckay JA, 2011, ACTA PHYSIOL, V202, P103, DOI 10.1111/j.1748-1716.2011.02278.x.
   Milton SG, 2012, PHARMACEUTICALS, V5, P925, DOI 10.3390/ph5090925.
   Monkawa T, 2002, J AM SOC NEPHROL, V13, P1172, DOI 10.1097/01.ASN.0000013162.29833.45.
   Morello F, 2009, CARDIOVASC RES, V82, P261, DOI 10.1093/cvr/cvn325.
   Nim TH, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004505.
   Nunes RO, 2008, AM J PHYSIOL-LUNG C, V294, pL1110, DOI 10.1152/ajplung.00500.2007.
   Ocker Matthias, 2010, World J Biol Chem, V1, P55, DOI 10.4331/wjbc.v1.i5.55.
   Park Jung Kyu, 2006, Cancer Res Treat, V38, P112, DOI 10.4143/crt.2006.38.2.112.
   Pons D, 2009, EUR HEART J, V30, P266, DOI 10.1093/eurheartj/ehn603.
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685.
   Ranganna K, 2000, MOL CELL BIOCHEM, V205, P149, DOI 10.1023/A:1007078200482.
   Ranganna K, 2006, VASC DISE PREV, V3, P375.
   Ranganna K., 2014, BIOCH RES TRENDS SER, P219.
   Ranganna K., 2011, Atherogenesis, DOI DOI 10.5772/25367.
   Ranganna K, 2007, FEBS J, V274, P5962, DOI 10.1111/j.1742-4658.2007.06119.x.
   Ranganna K, 2005, RRD MOL CELL BIOCHEM, P123.
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197.
   Rosner M, 2010, AMINO ACIDS, V38, P223, DOI 10.1007/s00726-008-0230-7.
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81.
   Roy Sanjit K, 2010, J Mol Signal, V5, P10, DOI 10.1186/1750-2187-5-10.
   Saxton RA, 2017, CELL, V168, P960, DOI {[}10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035].
   SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445.
   Shawky NM, 2017, PHARMACOL RES, V119, P251, DOI 10.1016/j.phrs.2017.02.010.
   Shirodkar AV, 2011, CURR OPIN CARDIOL, V26, P209, DOI 10.1097/HCO.0b013e328345986e.
   Simmons Danielle., 2008, Nature Education, V1, P1.
   Spange S, 2009, INT J BIOCHEM CELL B, V41, P185, DOI 10.1016/j.biocel.2008.08.027.
   Storz P, 2002, FRONT BIOSCI-LANDMRK, V7, pD886, DOI 10.2741/storz.
   Udali S, 2013, MOL ASPECTS MED, V34, P883, DOI 10.1016/j.mam.2012.08.001.
   Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290.
   Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041.
   Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965.
   Weinhold B, 2006, ENVIRON HEALTH PERSP, V114, pA160, DOI 10.1289/ehp.114-a160.
   Wolf G, 2003, KIDNEY INT, V64, P71, DOI 10.1046/j.1523-1755.2003.00076.x.
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010.},
Number-of-Cited-References = {79},
Times-Cited = {41},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Int. J. Mol. Sci.},
Doc-Delivery-Number = {IG4ED},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000473756000052},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000475454600003,
Author = {Lee, Hsiu-Chi and Lin, Shih-Chieh and Wu, Meng-Hsing and Tsai, Shaw-Jenq},
Title = {Induction of Pyruvate Dehydrogenase Kinase 1 by Hypoxia Alters Cellular
   Metabolism and Inhibits Apoptosis in Endometriotic Stromal Cells},
Journal = {REPRODUCTIVE SCIENCES},
Year = {2019},
Volume = {26},
Number = {6},
Pages = {734-744},
Month = {JUN},
Abstract = {Endometriosis is a common gynecological disease, which is defined as the
   growth of endometrial tissues outside the uterine cavity. It often
   causes dysmenorrhea, dyspareunia, chronic pelvic pain, and infertility
   in reproductive-age women. However, the pathogenesis of endometriosis
   remains largely unclear. Since our previous study revealed that ectopic
   endometriotic stromal cells experience greater hypoxic stress than their
   eutopic counterparts, we aim to investigate whether the metabolic
   properties are changed in the ectopic endometriotic stromal cell when
   compared to its eutopic counterpart. Here, we found the expression of
   pyruvate dehydrogenase kinase 1 (PDK1), a critical enzyme in regulating
   glucose metabolism, was increased in ectopic stromal cells. Molecular
   characterization reveals that overexpression of PDK1 is induced by
   hypoxia through transcriptional regulation. Upregulation of PDK1 in
   ectopic endometriotic stromal cells was accompanied by increases in
   lactate production and oxygen consumption rate when compared to eutopic
   endometrial stromal cells. Furthermore, our data showed that inhibition
   of PDK1 activity by treatment with dichloroacetate inhibits the lactate
   production and oxygen consumption rate of ectopic stromal cells. In
   addition, hypoxia-induced PDK1 expression prevented cells from H2O2- and
   low nutrient-induced cell death. These data indicate that ectopic
   endometriotic cells may adapt to hypoxic microenvironment via
   upregulating PDK1 and reprogramming metabolism, which provides a
   survival advantage in the hostile peritoneal microenvironment.},
Publisher = {SAGE PUBLICATIONS INC},
Address = {2455 TELLER RD, THOUSAND OAKS, CA 91320 USA},
Type = {Article},
Language = {English},
Affiliation = {Wu, MH (Corresponding Author), Natl Cheng Kung Univ, Coll Med \& Hosp, Dept Obstet \& Gynecol, 138 Sheng Li Rd, Tainan 704, Taiwan.
   Tsai, SJ (Corresponding Author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan.
   Lee, Hsiu-Chi; Lin, Shih-Chieh; Tsai, Shaw-Jenq, Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan, Taiwan.
   Wu, Meng-Hsing, Natl Cheng Kung Univ, Coll Med \& Hosp, Dept Obstet \& Gynecol, 138 Sheng Li Rd, Tainan 704, Taiwan.
   Tsai, Shaw-Jenq, Natl Cheng Kung Univ, Coll Med, Dept Physiol, 1 Univ Rd, Tainan 70101, Taiwan.},
DOI = {10.1177/1933719118789513},
ISSN = {1933-7191},
EISSN = {1933-7205},
Keywords = {PDK1; oxygen consumption; glycolysis; cellular metabolism; apoptosis},
Keywords-Plus = {GLUTAMINE-METABOLISM; GLUCOSE-METABOLISM; CANCER; EXPRESSION;
   DICHLOROACETATE; PHOSPHORYLATION; ADAPTATION; PROTEIN; GROWTH; SWITCH},
Research-Areas = {Obstetrics \& Gynecology; Reproductive Biology},
Web-of-Science-Categories  = {Obstetrics \& Gynecology; Reproductive Biology},
Author-Email = {mhwu68@mail.ncku.edu.tw
   seantsai@mail.ncku.edu.tw},
Affiliations = {National Cheng Kung University; National Cheng Kung University; National
   Cheng Kung University},
ResearcherID-Numbers = {Wu, Meng-Hsing/AAU-1985-2020
   TSAI, SHAW-JENQ/AAG-6569-2019
   },
ORCID-Numbers = {TSAI, SHAW-JENQ/0000-0002-3569-5813
   lin, shih-chieh/0000-0002-9967-5037},
Funding-Acknowledgement = {Ministry of Science and Technology, Taiwan {[}MOST
   104-2320-B-006-036-MY3, MOST 105-2314-B-006-059-MY3]},
Funding-Text = {The author(s) declared the following potential conflicts of interest
   with respect to the research, authorship, and/or publication of this
   article: This work was supported by grants from Ministry of Science and
   Technology, Taiwan (MOST 104-2320-B-006-036-MY3 to S.-J. T. and MOST
   105-2314-B-006-059-MY3 to M.-H. W.).},
Cited-References = {Acien Pedro, 2013, ISRN Obstet Gynecol, V2013, P242149, DOI 10.1155/2013/242149.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Choi YW, 2014, CANCER LETT, V346, P300, DOI 10.1016/j.canlet.2014.01.015.
   de Moura MB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106028.
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104.
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468.
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741.
   Erkkilä K, 2002, MOL HUM REPROD, V8, P109, DOI 10.1093/molehr/8.2.109.
   Eskenazi B, 1997, OBSTET GYN CLIN N AM, V24, P235, DOI 10.1016/S0889-8545(05)70302-8.
   Giudice LC, 2004, LANCET, V364, P1789, DOI 10.1016/S0140-6736(04)17403-5.
   Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   HALME J, 1984, OBSTET GYNECOL, V64, P151.
   Hsiao Kuei-Yang, 2015, Front Biosci (Elite Ed), V7, P309, DOI {[}10.2741/736, 10.2741/e736].
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Krivoruchko A, 2015, METAB ENG, V28, P28, DOI 10.1016/j.ymben.2014.11.009.
   Lin SC, 2012, J CLIN ENDOCR METAB, V97, pE1515, DOI 10.1210/jc.2012-1450.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022.
   Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Rodrigues MF, 2016, BIOCHEM J, V473, P703, DOI 10.1042/BJ20150645.
   Shyh-Chang N, 2013, CELL, V155, P778, DOI 10.1016/j.cell.2013.09.059.
   Smolková K, 2011, INT J BIOCHEM CELL B, V43, P950, DOI 10.1016/j.biocel.2010.05.003.
   Stander XX, 2015, CELL PHYSIOL BIOCHEM, V35, P1499, DOI 10.1159/000369710.
   Tsai SJ, 2001, J CLIN ENDOCR METAB, V86, P5765, DOI 10.1210/jc.86.12.5765.
   Wagner BA, 2011, FREE RADICAL BIO MED, V51, P700, DOI 10.1016/j.freeradbiomed.2011.05.024.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.
   Weljie AM, 2011, INT J BIOCHEM CELL B, V43, P981, DOI 10.1016/j.biocel.2010.08.009.
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108.
   Wu MH, 2007, AM J PATHOL, V170, P590, DOI 10.2353/ajpath.2007.060477.
   Wu MH, 2011, J PATHOL, V225, P390, DOI 10.1002/path.2963.
   Young VJ, 2014, J CLIN ENDOCR METAB, V99, P3450, DOI 10.1210/jc.2014-1026.},
Number-of-Cited-References = {35},
Times-Cited = {30},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {16},
Journal-ISO = {Reprod. Sci.},
Doc-Delivery-Number = {II8PT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000475454600003},
DA = {2026-02-04},
}

@article{ WOS:000469783200003,
Author = {Li, Guomin and Zeng, Lirong and Cheng, Haiyan and Han, Jingxian and
   Zhang, Xuezhu and Xie, Hui},
Title = {Acupuncture Administration Improves Cognitive Functions and Alleviates
   Inflammation and Nuclear Damage by Regulating Phosphatidylinositol 3
   Kinase (PI3K)/Phosphoinositol-Dependent Kinase 1 (PDK1)/Novel Protein
   Kinase C (nPKC)/Rac 1 Signaling Pathway in Senescence-Accelerated Prone
   8 (SAM-P8) Mice},
Journal = {MEDICAL SCIENCE MONITOR},
Year = {2019},
Volume = {25},
Pages = {4082-4093},
Month = {JUN 1},
Abstract = {Background: Alzheimer's disease (AD) is an age-associated
   neurodegenerative disorder. This study aimed to investigate effects of
   acupuncture administration on cognitive function and associated
   mechanisms.
   Material/Methods: Senescence-accelerated prone 8 (SAM-P8) mice were
   randomly divided into 3 groups: the SAM-P8 group (P8-CN), the SAM-P8
   administrating with acupuncture (P8-Acup) group, and the SAM-P8
   administrating without acupuncture (P8-Sham) group. Morris water maze
   test was conducted to evaluate cognitive functions (memory and learning
   ability). PDK1, nPKC, and Rac1 inhibitors were used to treat SAM-P8
   mice. Transmission electron microscope analysis was used to examine
   nuclear damage hippocampal tissues. Hematoxylin and eosin (H\&E)
   staining was employed to evaluate inflammation. Western blot was used to
   detect PI3K, PDK1, nPKC, and Rac 1 expression in hippocampal tissues.
   Results: Acupuncture administration significantly reduced PI3K, PDK1,
   nPKC, and Rac 1 levels compared to P8-CN group (P<0.05). Both
   acupuncture and enzyme inhibitors (NSC23766, Rottlerin, OSU03012)
   significantly improved cognitive functions, reduced inflammation, and
   alleviated nuclear damages of SAM-P8 mice compared to P8-CN group
   (P<0.05). Acupuncture significantly enhanced effects of inhibitors on
   inflammation and nuclear damages compared to inhibitor treatment single
   (P<0.05). Acupuncture significantly enhanced down-regulative effects of
   OSU03012 on PI3K and PDK1 levels, increased down-regulative effects of
   Rottlerin on nPKC and Rac 1 levels and enhanced effects of Rottlerin on
   Rac 1 compared to P8-CN group (P<0.05).
   Conclusions: Acupuncture administration improved cognitive functions and
   alleviated inflammatory response and nuclear damage of SAM-P8 mice, by
   downregulating PI3K/PDK1/nPKC/Rac 1 signaling pathway. This study could
   provide potential insight for treating cognitive dysfunction and aging
   of AD patients.},
Publisher = {INT SCIENTIFIC INFORMATION, INC},
Address = {150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA},
Type = {Article},
Language = {English},
Affiliation = {Xie, H (Corresponding Author), First Peoples Hosp Chenzhou, Dept Rehabil Med, Chenzhou, Hunan, Peoples R China.
   Zhang, XZ (Corresponding Author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Acupunture \& Moxibust Res Inst, Tianjin, Peoples R China.
   Li, Guomin; Zeng, Lirong; Xie, Hui, First Peoples Hosp Chenzhou, Dept Rehabil Med, Chenzhou, Hunan, Peoples R China.
   Cheng, Haiyan, Hubei Jianghan Oilfield Gen Hosp, Dept Tradit Chinese Med, Jianghan, Hubei, Peoples R China.
   Han, Jingxian; Zhang, Xuezhu, Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Acupunture \& Moxibust Res Inst, Tianjin, Peoples R China.},
DOI = {10.12659/MSM.913858},
ISSN = {1643-3750},
Keywords = {Acupuncture; Aging; Alzheimer Disease; Cognition},
Keywords-Plus = {ALZHEIMERS-DISEASE; MOUSE MODEL; SYNAPTIC PLASTICITY; SAMP8 MOUSE;
   DEMENTIA; THERAPY; HIPPOCAMPUS; PROFILE; MEMORY},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {qruuis@126.com
   chenyyshu@yeah.net},
Affiliations = {Tianjin University of Traditional Chinese Medicine},
ResearcherID-Numbers = {Cheng, Haiyan/OZG-0486-2025
   Li, Guo-Min/I-5016-2014},
Funding-Acknowledgement = {National Natural Science Foundation Youth Project {[}81403471]; National
   Natural Science Foundation General Program {[}81674070, 81473766]},
Funding-Text = {This study was granted by the National Natural Science Foundation Youth
   Project (Grant No. 81403471) and the National Natural Science Foundation
   General Program (Grant No. 81674070 and 81473766)},
Cited-References = {Alcántara-Hernández R, 2014, EUR J PHARMACOL, V740, P88, DOI 10.1016/j.ejphar.2014.06.057.
   Becel S, 2016, J ACUPUNCT MERIDIAN, V9, P264, DOI 10.1016/j.jams.2016.07.003.
   Belivani M, 2013, ACUPUNCT MED, V31, P88, DOI 10.1136/acupmed-2012-010247.
   Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7.
   Cai DX, 2016, MED SCI MONITOR, V22, P4037, DOI 10.12659/MSM.897884.
   Cao Y, 2016, CURR TOP MED CHEM, V16, P574, DOI 10.2174/1568026615666150813144942.
   Carrizzo A, 2014, CURR DRUG TARGETS, V15, P1231, DOI 10.2174/1389450115666141027110156.
   de Senna PN, 2011, METAB BRAIN DIS, V26, P269, DOI 10.1007/s11011-011-9262-x.
   Du SQ, 2018, CNS NEUROSCI THER, V24, P39, DOI 10.1111/cns.12773.
   Fu SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181948.
   Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200.
   Gauthier S, 2016, LANCET, V388, P2873, DOI 10.1016/S0140-6736(16)31275-2.
   Hansen HH, 2015, J ALZHEIMERS DIS, V46, P877, DOI 10.3233/JAD-143090.
   Huang J, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1974-y.
   Jia YJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2064-x.
   Jiang Y, 2018, MED SCI MONITOR, V24, P5635, DOI 10.12659/MSM.908765.
   Kavoussi B, 2007, INTEGR CANCER THER, V6, P251, DOI 10.1177/1534735407305892.
   Kitzlerová E, 2018, MED SCI MONITOR, V24, P2599, DOI 10.12659/MSM.907202.
   Kobayashi K, 2011, EUR J PHARMACOL, V660, P375, DOI 10.1016/j.ejphar.2011.03.032.
   Lanza G, 2018, COMPLEMENT THER MED, V38, P74, DOI 10.1016/j.ctim.2018.04.013.
   Lattanzi S, 2018, J CLIN HYPERTENS, V20, P918, DOI 10.1111/jch.13290.
   Lattanzi S, 2018, J CLIN HYPERTENS, V20, P645, DOI 10.1111/jch.13232.
   Lattanzi S, 2018, J NEUROL SCI, V387, P98, DOI 10.1016/j.jns.2018.01.038.
   Lattanzi S, 2018, NEUROLOGY, V90, pE307, DOI 10.1212/WNL.0000000000004862.
   Lattanzi S, 2017, ONCOTARGET, V8, P57489, DOI 10.18632/oncotarget.15423.
   Lattanzi S, 2015, J ALZHEIMERS DIS, V45, P387, DOI 10.3233/JAD-142532.
   Li DZ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/279478.
   Ma QY, 2011, EXP GERONTOL, V46, P533, DOI 10.1016/j.exger.2011.02.006.
   Manterola L, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.147.
   Maulik M, 2013, MOL NEUROBIOL, V47, P37, DOI 10.1007/s12035-012-8337-y.
   Morley JE, 2012, CURR PHARM DESIGN, V18, P1123.
   Mullane K, 2013, BIOCHEM PHARMACOL, V85, P289, DOI 10.1016/j.bcp.2012.11.014.
   Qian W, 2018, MED SCI MONITOR, V24, P2693, DOI 10.12659/MSM.906933.
   Qiu ZD, 2018, MED SCI MONITOR, V24, P880, DOI 10.12659/MSM.907939.
   Ramakers GJA, 2012, HUM MOL GENET, V21, P268, DOI 10.1093/hmg/ddr457.
   Ren HL, 2018, MED SCI MONITOR, V24, P1132, DOI 10.12659/MSM.908954.
   Rubio-Perez J. M., 2012, THESCIENTIFICWORLDJO, V2012, P2012, DOI DOI 10.1100/2012/756357.
   Suh SW, 2008, ANN NEUROL, V64, P654, DOI 10.1002/ana.21511.
   Takahashi R, 2010, YAKUGAKU ZASSHI, V130, P11, DOI 10.1248/yakushi.130.11.
   Takano Y, 2018, AM J CASE REP, V19, P153, DOI 10.12659/AJCR.907799.
   Tian T, 2016, SCI REP-UK, V6, DOI 10.1038/srep19714.
   Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479.
   Wang Bing, 2017, Zhongguo Zhen Jiu, V37, P463, DOI 10.13703/j.0255-2930.2017.05.003.
   Wang HL, 2014, J ALZHEIMERS DIS, V39, P841, DOI 10.3233/JAD-131463.
   Wang JH, 2017, AGING DIS, V8, P101, DOI 10.14336/AD.2016.0522.
   Zhou J, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000933.},
Number-of-Cited-References = {46},
Times-Cited = {18},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {47},
Journal-ISO = {Med. Sci. Monitor},
Doc-Delivery-Number = {IA8BT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000469783200003},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000468505100016,
Author = {Luo, Wei and Hawse, William and Conter, Laura and Trivedi, Nikita and
   Weisel, Florian and Wikenheiser, Daniel and Cattley, Richard T. and
   Shlomchik, Mark J.},
Title = {The AKT kinase signaling network is rewired by PTEN to control proximal
   BCR signaling in germinal center B cells},
Journal = {NATURE IMMUNOLOGY},
Year = {2019},
Volume = {20},
Number = {6},
Pages = {736+},
Month = {JUN},
Abstract = {B cell antigen receptor (BCR) and CD40 signaling are rewired in germinal
   center (GC) B cells (GCBCs) to optimize selection for high-affinity B
   cells. In GCBC, BCR signals are constrained, but the mechanisms are not
   well understood. Here we describe a GC-specific, AKT-kinase-driven
   negative feedback loop that attenuates BCR signaling. Mass spectrometry
   revealed that AKT target activity was altered in GCBCs compared with
   naive B cells. Retargeting was linked to differential AKT T308 and S473
   phosphorylation, in turn controlled by GC-specific upregulation of
   phosphoinositide-dependent protein kinase PDK1 and the phosphatase PTEN.
   In GCBCs, AKT preferentially targeted CSK, SHP-1 and HPK1, which are
   negative regulators of BCR signaling. We found that phosphorylation
   enhances enzymatic activity of these proteins, creating a negative
   feedback loop that dampens upstream BCR signaling. AKT inhibition
   relieved this negative feedback and enhanced activation of BCR-proximal
   kinase LYN, as well as downstream BCR signaling molecules in GCBCs.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Shlomchik, MJ (Corresponding Author), Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA.
   Luo, Wei; Hawse, William; Conter, Laura; Trivedi, Nikita; Weisel, Florian; Wikenheiser, Daniel; Cattley, Richard T.; Shlomchik, Mark J., Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA.},
DOI = {10.1038/s41590-019-0376-3},
ISSN = {1529-2908},
EISSN = {1529-2916},
Keywords-Plus = {TRANSCRIPTION FACTOR; CUTTING EDGE; MEMORY B; CENTER SELECTION;
   HIGH-AFFINITY; C-MYC; RECEPTOR; PHOSPHORYLATION; PHOSPHATASE; ANTIGEN},
Research-Areas = {Immunology},
Web-of-Science-Categories  = {Immunology},
Author-Email = {mshlomch@pitt.edu},
Affiliations = {Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh},
ResearcherID-Numbers = {Luo, Wei/ABD-3082-2021
   Shlomchik, Mark/AAN-6189-2020
   },
ORCID-Numbers = {Luo, Wei/0000-0003-2826-1723
   Shlomchik, Mark/0000-0002-2152-0959
   Trivedi, Nikita Harikrishna/0009-0004-2468-0896},
Funding-Acknowledgement = {National Institutes of Health {[}R01 AI105018]; National Institute of
   Allergy and Infectious Diseases {[}R01AI105018, R01AI043603] Funding
   Source: NIH RePORTER},
Funding-Text = {We thank L. Garrett-Sinha, L. Kane, G. Delgoffe and B. Su for critical
   reading of the manuscript. We thank R. Elsner for useful discussions. We
   thank S. Joachim for supporting experimental procedures. This work was
   supported by National Institutes of Health grant no. R01 AI105018 to
   M.J.S.},
Cited-References = {Akerlund J, 2015, J AUTOIMMUN, V62, P45, DOI 10.1016/j.jaut.2015.06.007.
   {[}Anonymous], BIOCH J.
   {[}Anonymous], CANC DISCOV.
   Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8.
   Bunting KL, 2016, IMMUNITY, V45, P497, DOI 10.1016/j.immuni.2016.08.012.
   Calado DP, 2012, NAT IMMUNOL, V13, P1092, DOI 10.1038/ni.2418.
   Crellin NK, 2007, BLOOD, V109, P2014, DOI 10.1182/blood-2006-07-035279.
   Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575.
   De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804.
   Dominguez-Sola D, 2015, IMMUNITY, V43, P1064, DOI 10.1016/j.immuni.2015.10.015.
   Dominguez-Sola D, 2012, NAT IMMUNOL, V13, P1083, DOI 10.1038/ni.2428.
   Ersching J, 2017, IMMUNITY, V46, P1045, DOI 10.1016/j.immuni.2017.06.005.
   Franks SE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00665.
   Gan XQ, 2011, J BIOL CHEM, V286, P10998, DOI 10.1074/jbc.M110.195016.
   Getahun A, 2016, J EXP MED, V213, P751, DOI 10.1084/jem.20150537.
   Good-Jacobson KL, 2014, P NATL ACAD SCI USA, V111, P9585, DOI 10.1073/pnas.1402485111.
   Haniuda K, 2016, NAT IMMUNOL, V17, P1109, DOI 10.1038/ni.3508.
   Hannum LG, 2000, J EXP MED, V192, P931, DOI 10.1084/jem.192.7.931.
   Harwood NE, 2008, IMMUNITY, V28, P609, DOI 10.1016/j.immuni.2008.04.007.
   Hawse WF, 2017, J IMMUNOL, V199, P589, DOI 10.4049/jimmunol.1700369.
   Hawse WF, 2015, J IMMUNOL, V194, P4615, DOI 10.4049/jimmunol.1402554.
   He JS, 2013, J EXP MED, V210, P2755, DOI 10.1084/jem.20131539.
   Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531.
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267.
   Ingley E, 2008, BBA-PROTEINS PROTEOM, V1784, P56, DOI 10.1016/j.bbapap.2007.08.012.
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033.
   Karnell FG, 2005, J BIOL CHEM, V280, P25621, DOI 10.1074/jbc.M503162200.
   Khalil AM, 2012, SCIENCE, V336, P1178, DOI 10.1126/science.1213368.
   King LB, 1999, J IMMUNOL, V162, P2655.
   Kräutler NJ, 2017, J EXP MED, V214, P1259, DOI 10.1084/jem.20161533.
   Levinson NM, 2008, CELL, V134, P124, DOI 10.1016/j.cell.2008.05.051.
   Liu D, 2015, NATURE, V517, P214, DOI 10.1038/nature13803.
   Lu PW, 2017, SCIENCE, V356, DOI 10.1126/science.aai9264.
   Luo W, 2018, IMMUNITY, V48, P313, DOI 10.1016/j.immuni.2018.01.008.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001.
   Mi HY, 2013, NAT PROTOC, V8, P1551, DOI 10.1038/nprot.2013.092.
   Mueller J, 2015, J IMMUNOL, V194, P2993, DOI 10.4049/jimmunol.1403086.
   Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052.
   Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955.
   Nowosad CR, 2016, NAT IMMUNOL, V17, P870, DOI 10.1038/ni.3458.
   O'Neill SK, 2011, IMMUNITY, V35, P746, DOI 10.1016/j.immuni.2011.10.011.
   Palomba ML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0079987.
   Polikowsky HG, 2015, J IMMUNOL, V195, P1364, DOI 10.4049/jimmunol.1500904.
   Ramadani F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001104.
   Saito K, 2003, IMMUNITY, V19, P669, DOI 10.1016/S1074-7613(03)00297-8.
   Sander S, 2015, IMMUNITY, V43, P1075, DOI 10.1016/j.immuni.2015.10.021.
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089.
   Shlomchik MJ, 2012, IMMUNOL REV, V247, P52, DOI 10.1111/j.1600-065X.2012.01124.x.
   Sonoda E, 1997, IMMUNITY, V6, P225, DOI 10.1016/S1074-7613(00)80325-8.
   Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199.
   Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0.
   Wang XH, 2012, J BIOL CHEM, V287, P11037, DOI 10.1074/jbc.M111.310946.
   Wang YF, 2017, NAT IMMUNOL, V18, P921, DOI 10.1038/ni.3788.
   Weisel FJ, 2016, IMMUNITY, V44, P116, DOI 10.1016/j.immuni.2015.12.004.
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI {[}10.1038/NMETH.1322, 10.1038/nmeth.1322].
   Xu CG, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan0787.
   Yan H, 2017, CELL REP, V19, P995, DOI 10.1016/j.celrep.2017.04.022.
   Yung HW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017894.
   Zaretsky I, 2017, J EXP MED, V214, P3435, DOI 10.1084/jem.20171129.
   Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223.
   Zhang ZS, 2003, J BIOL CHEM, V278, P4668, DOI 10.1074/jbc.M210028200.},
Number-of-Cited-References = {62},
Times-Cited = {52},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {14},
Journal-ISO = {Nat. Immunol.},
Doc-Delivery-Number = {HZ0BI},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000468505100016},
DA = {2026-02-04},
}

@article{ WOS:000465050300026,
Author = {Raghubeer, Shanel and Nagiah, Savania and Chuturgoon, Anil},
Title = {Ochratoxin A upregulates biomarkers associated with hypoxia and
   transformation in human kidney cells},
Journal = {TOXICOLOGY IN VITRO},
Year = {2019},
Volume = {57},
Pages = {211-216},
Month = {JUN},
Abstract = {Cellular adaptation to hypoxia is controlled by hypoxia-inducible factor
   1 alpha (HIF1 alpha), a transcription factor activated in response to
   oxygen tension, reactive oxygen species (ROS) and inflammation.
   Overexpression of HIFla and HSP90 has been associated with cancer
   induction. Ochratoxin A (OTA), a mycotoxin contaminant of food and
   beverages, has been linked to renal tumours and progressive
   nephropathies, inflammation and pro-oxidation. The aim of this study was
   to examine the effect of OTA on hypoxic and transformative regulators in
   human embryonic kidney (HEK293) cells. We evaluated the protein
   expression of HIF1 alpha, HSP90 and PDK1 (western blotting), mRNA
   expression of HIF1 alpha, VEGF, EPO and TGF beta (qPCR), and ATP levels
   (luminometry) in HEK293 cells exposed to a range of OTA concentrations
   (0.125 mu M-0.5 mu M) over two time periods (24 h and 48 h). After 24 h,
   OTA increased HIF1 alpha protein (p < 0.005) and EPO gene expression (p
   < 0.05), while VEGF and TGF beta was significantly increased at 48 h. We
   also observed a correlation between PDK1 expression and ATP levels. In
   conclusion, OTA disrupts hypoxia regulation, modulates metabolic
   activity, and alters growth signalling (VEGF, TGF beta), which may lead
   to tumourigenesis.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Chuturgoon, A (Corresponding Author), Univ KwaZulu Natal, Discipline Med Biochem, Sch Lab Med \& Med Sci, Coll Hlth Sci, ZA-4041 Durban, South Africa.
   Raghubeer, Shanel; Nagiah, Savania; Chuturgoon, Anil, Univ KwaZulu Natal, Discipline Med Biochem, Sch Lab Med \& Med Sci, Coll Hlth Sci, ZA-4041 Durban, South Africa.},
DOI = {10.1016/j.tiv.2019.03.016},
ISSN = {0887-2333},
Keywords = {Ochratoxin A; Inflammation; Hypoxic response; HIF1 alpha; VEGF; TGF beta},
Keywords-Plus = {OXIDATIVE STRESS; VEGF EXPRESSION; DNA-DAMAGE; NEPHROPATHY; APOPTOSIS;
   TOXICITY; CANCER; HSP90},
Research-Areas = {Toxicology},
Web-of-Science-Categories  = {Toxicology},
Author-Email = {chutur@ukzn.ac.za},
Affiliations = {University of Kwazulu Natal},
ResearcherID-Numbers = {Chuturgoon, Anil/AAE-5068-2021
   Raghubeer, Shanel/GPX-1774-2022
   Nagiah, Savania/AAC-4388-2020},
ORCID-Numbers = {Raghubeer, Shanel/0000-0002-8161-5458
   },
Funding-Acknowledgement = {National Research Foundation of South Africa Innovation PhD Scholarship
   {[}UID: 98323]},
Funding-Text = {National Research Foundation of South Africa Innovation PhD Scholarship
   (Grant UID: 98323).},
Cited-References = {Abid S, 2003, HUM EXP TOXICOL, V22, P77, DOI 10.1191/0960327103ht328oa.
   Arbillaga L, 2007, MUTAGENESIS, V22, P35, DOI 10.1093/mutage/gel049.
   Bennour EEG, 2009, J BIOCHEM MOL TOXIC, V23, P87, DOI 10.1002/jbt.20268.
   Bernardini C, 2014, RES VET SCI, V97, P244, DOI 10.1016/j.rvsc.2014.07.018.
   Boesch-Saadatmandi C, 2008, FOOD CHEM TOXICOL, V46, P2665, DOI 10.1016/j.fct.2008.04.023.
   Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc.
   Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0.
   Calderwood SK, 2006, TRENDS BIOCHEM SCI, V31, P164, DOI 10.1016/j.tibs.2006.01.006.
   Castegnaro M, 2006, MOL NUTR FOOD RES, V50, P519, DOI 10.1002/mnfr.200500182.
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715.
   Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581.
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50.
   Fuhrmann DC, 2017, REDOX BIOL, V12, P208, DOI 10.1016/j.redox.2017.02.012.
   Ghazi T, 2017, J CELL BIOCHEM, V118, P3866, DOI 10.1002/jcb.26037.
   Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0.
   Higashi T, 2001, JPN J CANCER RES, V92, P506, DOI 10.1111/j.1349-7006.2001.tb01123.x.
   Cabañes FJ, 2010, TOXINS, V2, P1111, DOI 10.3390/toxins2051111.
   Jelkmann W, 2011, J PHYSIOL-LONDON, V589, P1251, DOI 10.1113/jphysiol.2010.195057.
   Jonsyn-Ellis FE, 2001, MYCOPATHOLOGIA, V152, P35, DOI 10.1023/A:1011950512675.
   Kallergi G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2452.
   Kuschel A, 2012, J CELL PHYSIOL, V227, P514, DOI 10.1002/jcp.22798.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262.
   Malir F, 2016, TOXINS, V8, DOI 10.3390/toxins8070191.
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5.
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239.
   Pillay Y, 2015, TOXICON, V99, P1, DOI 10.1016/j.toxicon.2015.03.004.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Raghubeer S, 2017, TOXICON, V137, P48, DOI 10.1016/j.toxicon.2017.07.013.
   Raghubeer S, 2015, J CELL BIOCHEM, V116, P2947, DOI 10.1002/jcb.25242.
   Ramyaa P, 2013, FOOD CHEM TOXICOL, V62, P205, DOI 10.1016/j.fct.2013.08.048.
   Reis ST, 2011, CLINICS, V66, P1143.
   Ringot D, 2006, CHEM-BIOL INTERACT, V159, P18, DOI 10.1016/j.cbi.2005.10.106.
   Semenza CL, 2001, PEDIATR RES, V49, P614, DOI 10.1203/00006450-200105000-00002.
   Stachurska A, 2011, TOXICOL LETT, V204, P118, DOI 10.1016/j.toxlet.2011.04.022.
   Vaupel P, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-90005-10.
   Wafa EW, 1998, HUM EXP TOXICOL, V17, P124, DOI 10.1191/096032798678908369.
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510.
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716.
   Yasuda S, 2004, J HEPATOL, V40, P117, DOI 10.1016/S0168-8278(03)00503-8.
   Yuan JL, 1998, MUTAT RES-FUND MOL M, V400, P439, DOI 10.1016/S0027-5107(98)00042-6.},
Number-of-Cited-References = {41},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {15},
Journal-ISO = {Toxicol. Vitro},
Doc-Delivery-Number = {HU1RU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000465050300026},
DA = {2026-02-04},
}

@article{ WOS:000470293000015,
Author = {Sambandam, Vaishnavi and Frederick, Mitchell J. and Shen, Li and Tong,
   Pan and Rao, Xiayu and Peng, Shaohua and Singh, Ratnakar and Mazumdar,
   Tuhina and Huang, Chenfei and Li, Qiuli and Pickering, Curtis R. and
   Myers, Jeffery N. and Wang, Jing and Johnson, Faye M.},
Title = {PDK1 Mediates NOTCH1-Mutated Head and Neck Squamous Carcinoma
   Vulnerability to Therapeutic PI3K/mTOR Inhibition},
Journal = {CLINICAL CANCER RESEARCH},
Year = {2019},
Volume = {25},
Number = {11},
Pages = {3329-3340},
Month = {JUN 1},
Abstract = {Purpose: Head and neck squamous cell carcinoma (HNSCC) is driven largely
   by the loss of tumor suppressor genes, including NOTCH1, but lacks a
   biomarker-driven targeted therapy. Although the PI3K/mTOR pathway is
   frequently altered in HNSCC, the disease has modest clinical response
   rates to PI3K/mTOR inhibitors and lacks validated biomarkers of
   response. We tested the hypothesis that an unbiased pharmacogenomics
   approach to PI3K/ mTOR pathway inhibitors would identify novel,
   clinically relevant molecular vulnerabilities in HNSCC with loss of
   tumor suppressor function.
   Experimental Design: We assessed the degree to which responses to
   PI3K/mTOR inhibitors are associated with gene mutations in 59 HNSCC cell
   lines. Apoptosis in drug-sensitive cell lines was confirmed in vitro and
   in vivo. NOTCH1 pathway components and PDK1 were manipulated with drugs,
   gene editing, knockdown, and overexpression.
   Results: PI3K/mTOR inhibition caused apoptosis and decreased colony
   numbers in HNSCC cell lines harboring NOTCH1 loss-of-function mutations
   (NOTCH1(MUT)) and reduced tumor size in subcutaneous and orthotopic
   xenograft models. In all cell lines, NOTCH1(MUT) was strongly associated
   with sensitivity to six PI3K/mTOR inhibitors. NOTCH1 inhibition or
   knockout increasedNOTCH1(WT)HNSCC sensitivity to PI3K/mTOR inhibition.
   PDK1 levels dropped following PI3K/mTORinhibitioninNOTCH1(MUT)
   butnotNOTCH1(WT)HNSCC, and PDK1 overexpression rescued apoptosis in
   NOTCH1(MUT) cells. PDK1 and AKT inhibitors together caused apoptosis in
   NOTCH1(WT) HNSCC but had little effect as single agents.
   Conclusions: Our findings suggest that NOTCH1MUT predicts response to
   PI3K/mTOR inhibitors, which may lead to the first biomarker-driven
   targeted therapy for HNSCC, and that targeting PDK1 sensitizes NOTCH1WT
   HNSCC to PI3K/ mTOR pathway inhibitors.},
Publisher = {AMER ASSOC CANCER RESEARCH},
Address = {615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA},
Type = {Article},
Language = {English},
Affiliation = {Johnson, FM (Corresponding Author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 432, Houston, TX 77030 USA.
   Sambandam, Vaishnavi; Peng, Shaohua; Singh, Ratnakar; Mazumdar, Tuhina; Johnson, Faye M., Univ Texas MD Anderson Canc Ctr, Dept Thorac Head \& Neck Med Oncol, Houston, TX 77030 USA.
   Frederick, Mitchell J.; Huang, Chenfei, Baylor Coll Med, Dept Otolaryngol, Houston, TX 77030 USA.
   Shen, Li; Tong, Pan; Rao, Xiayu; Wang, Jing, Univ Texas MD Anderson Canc Ctr, Dept Bioinformat \& Computat Biol, Houston, TX 77030 USA.
   Singh, Ratnakar; Pickering, Curtis R.; Myers, Jeffery N., Univ Texas MD Anderson Canc Ctr, Dept Head \& Neck Surg, Houston, TX 77030 USA.
   Li, Qiuli, Sun Yat Sen Univ, Canc Ctr, Dept Head \& Neck Surg, Guangzhou, Guangdong, Peoples R China.
   Pickering, Curtis R.; Myers, Jeffery N.; Wang, Jing; Johnson, Faye M., Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA.
   Singh, Ratnakar, Univ Illinois, Urbana, IL 61801 USA.},
DOI = {10.1158/1078-0432.CCR-18-3276},
ISSN = {1078-0432},
EISSN = {1557-3265},
Keywords-Plus = {PI3K INHIBITORS; CELL CARCINOMA; DOSE-ESCALATION; SCREEN REVEALS;
   PHASE-I; RESISTANCE; POTENT; MODEL; LINES; BETA},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {fmjohns@mdanderson.org},
Affiliations = {University of Texas System; UTMD Anderson Cancer Center; Baylor College
   of Medicine; University of Texas System; UTMD Anderson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen
   University; University of Texas System; University of Texas Health
   Science Center Houston; University of Illinois System; University of
   Illinois Urbana-Champaign},
ResearcherID-Numbers = {Singh, Ratnakar/K-2848-2018
   Tong, Pan/O-6097-2015
   Sambandam, Vaishnavi/I-4247-2018
   },
ORCID-Numbers = {Singh, Ratnakar/0000-0002-3226-3847
   Pickering, Curtis/0000-0002-7942-728X
   Sambandam, Vaishnavi/0000-0003-0013-8838
   SHEN, LI/0000-0001-8427-9448},
Funding-Acknowledgement = {National Institutes of Health/National Institute of Dental and
   Craniofacial Research {[}U01DE025181, R01 DE024179-01A1]; PIQUR
   Therapeutics AG; NIH through MD Anderson's Cancer Center Support Grant
   {[}P30CA016672]; National Cancer Institute {[}P30CA016672] Funding
   Source: NIH RePORTER},
Funding-Text = {We thank Doriano Fabbro, PhD, of PIQUR Therapeutics AG for guidance
   regarding PQR309 use in experiments and Joe Munch in MD Anderson's
   Department of Scientific Publications for editing the manuscript. This
   work was supported by philanthropic contributions to The University of
   Texas MD Anderson Cancer Center's Oropharynx Discovery Program (to J.N.
   Myers, F.M. Johnson); by grants from the National Institutes of
   Health/National Institute of Dental and Craniofacial Research
   (U01DE025181, to J.N. Myers and M.J. Frederick; R01 DE024179-01A1, to
   M.J. Frederick); and by PIQUR Therapeutics AG. This work used the
   services of MD Anderson's Flow Cytometry and Cellular Imaging Core and
   Bioinformatics Shared Resource, which are supported by the NIH through
   MD Anderson's Cancer Center Support Grant (P30CA016672).},
Cited-References = {Abad M, 2017, STEM CELL REP, V8, P548, DOI 10.1016/j.stemcr.2017.01.025.
   Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923.
   {[}Anonymous], CANC MED.
   Beaufils F, 2017, J MED CHEM, V60, P7524, DOI 10.1021/acs.jmedchem.7b00930.
   Bendell JC, 2015, INVEST NEW DRUG, V33, P187, DOI 10.1007/s10637-014-0177-3.
   Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360.
   Bohnacker T, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14683.
   Cai Y, 2017, ONCOTARGET, V8, P22203, DOI 10.18632/oncotarget.14729.
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031.
   De Buck SS, 2014, BRIT J CLIN PHARMACO, V78, P543, DOI 10.1111/bcp.12378.
   Di-Poï N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9.
   Elkabets M, 2015, CANCER CELL, V27, P533, DOI 10.1016/j.ccell.2015.03.010.
   Ferrarotto R, 2016, CLIN CANCER RES, V22, P1674, DOI 10.1158/1078-0432.CCR-14-2890.
   Hales EC, 2014, CELL SIGNAL, V26, P149, DOI 10.1016/j.cellsig.2013.09.021.
   Herzog A, 2013, CLIN CANCER RES, V19, P3808, DOI 10.1158/1078-0432.CCR-12-2716.
   Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239.
   Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196.
   Jimeno A, 2015, ANN ONCOL, V26, P556, DOI 10.1093/annonc/mdu574.
   Juric D, 2015, NATURE, V518, P240, DOI 10.1038/nature13948.
   Kalu NN, 2018, CANCER LETT, V431, P64, DOI 10.1016/j.canlet.2018.05.029.
   Kalu NN, 2017, ONCOTARGET, V8, P86369, DOI 10.18632/oncotarget.21174.
   Kelly AP, 2007, EMBO J, V26, P3441, DOI 10.1038/sj.emboj.7601761.
   Keysar SB, 2013, MOL ONCOL, V7, P776, DOI 10.1016/j.molonc.2013.03.004.
   Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129.
   Lee K, 2012, J EXP MED, V209, P713, DOI 10.1084/jem.20111470.
   Li H, 2014, MOL CANCER RES, V12, P571, DOI 10.1158/1541-7786.MCR-13-0396.
   Liu NS, 2013, MOL CANCER THER, V12, P2319, DOI 10.1158/1535-7163.MCT-12-0993-T.
   Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103.
   Mazumdar T, 2014, MOL CANCER THER, V13, P2738, DOI 10.1158/1535-7163.MCT-13-1090.
   Mohan S, 2015, CLIN CANCER RES, V21, P3946, DOI 10.1158/1078-0432.CCR-14-3377.
   Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695.
   Munster P, 2016, CLIN CANCER RES, V22, P1932, DOI 10.1158/1078-0432.CCR-15-1665.
   Myers JN, 2002, CLIN CANCER RES, V8, P293.
   Rodon J, 2017, CANCER DISCOV, V7, P666, DOI 10.1158/2159-8290.CD-17-0500.
   Salphati L, 2012, DRUG METAB DISPOS, V40, P1785, DOI 10.1124/dmd.112.046052.
   Song NJ, 2016, SCI REP, V6, P1.
   Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137.
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6.
   Venkatesh Vandana, 2018, Stem Cell Investig, V5, P5, DOI {[}10.21037/sci.2018.02.02, 10.21037/sci.2018.02.02].
   Wang Z., 2014, JNCI-J NATL CANCER I, V106, P1.
   Wang ZY, 2017, CANCER METAST REV, V36, P491, DOI 10.1007/s10555-017-9688-7.
   Wicki A, 2018, EUR J CANCER, V96, P6, DOI 10.1016/j.ejca.2018.03.012.
   Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250.
   Yamaguchi K, 2016, ONCOTARGET, V7, P10696, DOI 10.18632/oncotarget.7372.
   Zhang M, 2016, CANCER MED-US, V5, P2048, DOI 10.1002/cam4.731.
   Zhang M, 2017, CANCER LETT, V392, P71, DOI 10.1016/j.canlet.2017.01.024.
   Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690.
   Zumsteg ZS, 2016, CLIN CANCER RES, V22, P2009, DOI 10.1158/1078-0432.CCR-15-2245.},
Number-of-Cited-References = {49},
Times-Cited = {45},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Clin. Cancer Res.},
Doc-Delivery-Number = {IB5EB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000470293000015},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000471330400066,
Author = {Sanmai, Surangkana and Proungvitaya, Tanakorn and Limpaiboon, Temduang
   and Chua-On, Daraporn and Seubwai, Wunchana and Roytrakul, Sittiruk and
   Wongkham, Sopit and Wongkham, Chaisiri and Somintara, Ongart and
   Sangkhamanon, Sakkarn and Proungvitaya, Siriporn},
Title = {Serum pyruvate dehydrogenase kinase as a prognostic marker for
   cholangiocarcinoma},
Journal = {ONCOLOGY LETTERS},
Year = {2019},
Volume = {17},
Number = {6},
Pages = {5275-5282},
Month = {JUN},
Abstract = {Pyruvate dehydrogenase kinase (PDK) is a Ser/Thr kinase that inactivates
   mitochondrial pyruvate dehydrogenase and serves a key role in aerobic
   glycolysis, which is a hallmark of cancer cells. The present study
   determined the PDK expression in cholangiocarcinoma (CCA) tissues and
   sera to evaluate their applicability as a biomarker for CCA. Using
   proteomic analysis, PDK was revealed to be the most overexpressed
   mitochondrial protein in CCA tissues. Then, the expression of PDK
   isoforms in CCA tissues was examined in 15 CCA cases by
   immunohistochemistry. The PDK3 isoform levels in the sera were measured
   using a dot blot assay for 39 patients with CCA, 20 patients with benign
   biliary disease and 19 healthy volunteers. The results revealed a
   27-fold overexpression of PDK3 in cancerous tissues when compared with
   adjacent non-cancerous tissues. The immunohistochemical results
   demonstrated that the PDK1, 2 and 3, but not the PDK4, isoforms were
   overexpressed in cancerous tissues. When the PDK3 levels in the sera
   were examined, they were significantly higher in CCA when compared with
   the BBD and healthy groups. The specificity and sensitivity of PDK3 as a
   marker for CCA were 97.5 and 33.0\%, respectively, and high PDK3 levels
   in the sera were correlated with a short survival time for CCA. In
   conclusion, PDK3 can be used as a diagnostic/prognostic marker for CCA.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Proungvitaya, S (Corresponding Author), Khon Kaen Univ, Fac Associated Med Sci, Ctr Res \& Dev, Med Diagnost Labs, 123 Moo 16 Mittapap Rd, Khon Kaen 40002, Thailand.
   Sanmai, Surangkana; Proungvitaya, Tanakorn; Limpaiboon, Temduang; Chua-On, Daraporn; Proungvitaya, Siriporn, Khon Kaen Univ, Fac Associated Med Sci, Ctr Res \& Dev, Med Diagnost Labs, 123 Moo 16 Mittapap Rd, Khon Kaen 40002, Thailand.
   Limpaiboon, Temduang; Wongkham, Sopit; Wongkham, Chaisiri; Proungvitaya, Siriporn, Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand.
   Seubwai, Wunchana, Khon Kaen Univ, Fac Med, Dept Forens Med, Khon Kaen 40002, Thailand.
   Roytrakul, Sittiruk, Natl Sci \& Technol Dev Agcy, Natl Ctr Genet Engn \& Biotechnol, Pathum Thani 12120, Thailand.
   Wongkham, Sopit; Wongkham, Chaisiri, Khon Kaen Univ, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand.
   Somintara, Ongart, Khon Kaen Univ, Fac Med, Dept Surg, Khon Kaen 40002, Thailand.
   Sangkhamanon, Sakkarn, Khon Kaen Univ, Fac Med, Dept Pathol, Khon Kaen 40002, Thailand.},
DOI = {10.3892/ol.2019.10185},
ISSN = {1792-1074},
EISSN = {1792-1082},
Keywords = {pyruvate dehydrogenase kinase; cholangiocarcinoma; serum; prognostic
   marker},
Keywords-Plus = {PATHOGENESIS; RESISTANCE; EXPRESSION; DIAGNOSIS; PATHWAYS; CANCER; POWER},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {sirpat@kku.ac.th},
Affiliations = {Khon Kaen University; Khon Kaen University; Khon Kaen University;
   National Science \& Technology Development Agency - Thailand; National
   Center Genetic Engineering \& Biotechnology (BIOTEC); Khon Kaen
   University; Khon Kaen University; Khon Kaen University},
ResearcherID-Numbers = {Sangkhamanon, Sakkarn/JFK-9515-2023
   Wongkham, Sopit/ABB-6966-2021
   },
ORCID-Numbers = {Sangkhamanon, Sakkarn/0000-0002-5203-8700
   Roytrakul, Sittiruk/0000-0003-3696-8390},
Funding-Acknowledgement = {Khon Kean University (Khon Kaen, Thailand) {[}601804]; Centre for
   Research and Development of Medical Diagnostic Laboratories, Faculty of
   Associated Medical Sciences; Cholangiocarcinoma Research Institute, Khon
   Kaen University; Research Fund for Supporting Lecturer to Admit High
   Potential Student to Study and Research on His Expert Program Year 2014;
   Graduate School, Khon Kaen University {[}571H107]; Publication Clinic of
   the Research Affairs, Khon Kaen University},
Funding-Text = {The project was supported by grants from Khon Kean University (Khon
   Kaen, Thailand; grant no. 601804), the Centre for Research and
   Development of Medical Diagnostic Laboratories, Faculty of Associated
   Medical Sciences and the Cholangiocarcinoma Research Institute, Khon
   Kaen University, the Research Fund for Supporting Lecturer to Admit High
   Potential Student to Study and Research on His Expert Program Year 2014,
   Graduate School, Khon Kaen University (grant no. 571H107) and the
   Publication Clinic of the Research Affairs, Khon Kaen University.},
Cited-References = {Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Chua-on D, 2016, TUMOR BIOL, V37, P13659, DOI 10.1007/s13277-016-5204-x.
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Icard P, 2012, BBA-REV CANCER, V1826, P423, DOI 10.1016/j.bbcan.2012.07.001.
   Ilyas SI, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013.
   Janan M, 2012, ASIAN PAC J CANCER P, V13, P107, DOI 10.7314/APJCP.2012.13.KKSuppl.107.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Khan SA, 2008, HPB, V10, P77, DOI 10.1080/13651820801992641.
   Lim HY, 2015, BIOCHEM BIOPH RES CO, V460, P938, DOI 10.1016/j.bbrc.2015.03.130.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Ma HY, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3486.
   Mi HY, 2016, NUCLEIC ACIDS RES, V44, pD336, DOI 10.1093/nar/gkv1194.
   Pattanapairoj S, 2015, CLIN BIOCHEM, V48, P668, DOI 10.1016/j.clinbiochem.2015.03.022.
   Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701.
   Roh JL, 2016, CANCER LETT, V371, P20, DOI 10.1016/j.canlet.2015.11.023.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Sombattheera Sutthikan, 2015, Asian Pac J Cancer Prev, V16, P1367, DOI 10.7314/apjcp.2015.16.4.1367.
   Sripa B, 2012, TRENDS PARASITOL, V28, P395, DOI 10.1016/j.pt.2012.07.006.
   Tan LD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018764.
   Wongkham S, 2012, ASIAN PAC J CANCER P, V13, P17, DOI 10.7314/APJCP.2012.13.KKSuppl.17.},
Number-of-Cited-References = {24},
Times-Cited = {17},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Oncol. Lett.},
Doc-Delivery-Number = {IC9US},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000471330400066},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000468879500008,
Author = {Schelski, Nadeshda and Luong, Trang T. D. and Lang, Florian and Pieske,
   Burkert and Voelkl, Jakob and Alesutan, Ioana},
Title = {SGK1-dependent stimulation of vascular smooth muscle cell
   osteo-/chondrogenic transdifferentiation by interleukin-18},
Journal = {PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY},
Year = {2019},
Volume = {471},
Number = {6},
Pages = {889-899},
Month = {JUN},
Abstract = {The serum- and glucocorticoid-inducible kinase 1 (SGK1) is a key
   regulator of osteo-/chondrogenic transdifferentiation and subsequent
   calcification of vascular smooth muscle cells (VSMCs). The phenotypical
   transdifferentiation of VSMCs is associated with increased
   interleukin-18 (IL-18) levels and generalized inflammation. Therefore,
   the present study investigated the possible involvement of SGK1 in
   IL-18-induced vascular calcification. Experiments were performed in
   primary human aortic smooth muscle cells (HAoSMCs) treated with
   recombinant human IL-18 protein in control or high phosphate conditions
   and following SGK1 knockdown by siRNA or pharmacological inhibition of
   SGK1, PI3K, and PDK1. As a result, IL-18 treatment increased SGK1 mRNA
   and protein expression in HAoSMCs. IL-18 upregulated SGK1 mRNA
   expression in a dose-dependent manner. This effect was paralleled by
   upregulation of the mRNA expression of MSX2 and CBFA1, osteogenic
   transcription factors, and of tissue-nonspecific alkaline phosphatase
   (ALPL), an osteogenic enzyme, as markers of increased
   osteo-/chondrogenic transdifferentiation. Phosphate treatment increased
   SGK1 and osteogenic markers mRNA expression as well as ALPL activity and
   induced calcification of HAoSMCs, all effects significantly augmented by
   additional treatment with IL-18. Conversely, silencing of SGK1 or
   cotreatment with the SGK1 inhibitor EMD638683 blunted the effects of
   IL-18 on osteo-/chondrogenic transdifferentiation and calcification of
   HAoSMCs. The procalcific effects of IL-18 were similarly suppressed in
   the presence of PI3K or PDK1 inhibitors. In conclusion, SGK1 expression
   is upregulated by IL-18 in VSMCs and SGK1 participates in the
   intracellular signaling of IL-18-induced osteo-/chondrogenic
   transdifferentiation of VSMCs. Thus, SGK1 may serve as therapeutic
   target to limit the progression of medial vascular calcification during
   vascular inflammation.},
Publisher = {SPRINGER HEIDELBERG},
Address = {TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Voelkl, J (Corresponding Author), Charite Univ Med Berlin, Dept Internal Med \& Cardiol, Campus Virchow Klinikum,Augustenburgeipl 1, D-13353 Berlin, Germany.
   Voelkl, J (Corresponding Author), DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Hess Str 3-4, D-10115 Berlin, Germany.
   Voelkl, J (Corresponding Author), Johannes Kepler Univ Linz, Inst Physiol, Altenberger Str 69, A-4040 Linz, Austria.
   Schelski, Nadeshda; Luong, Trang T. D.; Pieske, Burkert; Voelkl, Jakob; Alesutan, Ioana, Charite Univ Med Berlin, Dept Internal Med \& Cardiol, Campus Virchow Klinikum,Augustenburgeipl 1, D-13353 Berlin, Germany.
   Lang, Florian, Eberhard Karts Univ, Dept Physiol 1, Wilhelmstr 56, D-72076 Tubingen, Germany.
   Pieske, Burkert; Alesutan, Ioana, BIH, Anna Louisa Karsch 2, D-10178 Berlin, Germany.
   Pieske, Burkert, German Heart Inst Berlin, Dept Internal Med \& Cardiol, Augustenburger Pl 1, D-13353 Berlin, Germany.
   Pieske, Burkert; Voelkl, Jakob; Alesutan, Ioana, DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Hess Str 3-4, D-10115 Berlin, Germany.
   Voelkl, Jakob, Johannes Kepler Univ Linz, Inst Physiol, Altenberger Str 69, A-4040 Linz, Austria.},
DOI = {10.1007/s00424-019-02256-5},
ISSN = {0031-6768},
EISSN = {1432-2013},
Keywords = {SGK1; interleukin-18; PI3K; Vascular calcification; Osteo-; chondrogenic
   signaling; Vascular smooth muscle cells},
Keywords-Plus = {NF-KAPPA-B; CARDIOVASCULAR RISK; AORTIC STIFFNESS; KINASE 1;
   CALCIFICATION; SERUM; EXPRESSION; IL-18; PHOSPHATE; ALDOSTERONE},
Research-Areas = {Physiology},
Web-of-Science-Categories  = {Physiology},
Author-Email = {jakob.voelkl@jku.at},
Affiliations = {Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Humboldt University of Berlin; Free
   University of Berlin; Charite Universitatsmedizin Berlin; Berlin
   Institute of Health; German Heart Center Berlin; German Centre for
   Cardiovascular Research; Johannes Kepler University Linz},
ResearcherID-Numbers = {Pieske, Burkert/M-8089-2016},
ORCID-Numbers = {Voelkl, Jakob/0000-0002-6318-5087
   Luong, Thi Doan Trang/0009-0000-4573-0427
   Pieske, Burkert/0000-0002-6466-5306},
Funding-Acknowledgement = {Johannes Kepler University Linz; Berlin Institute of Health (BIH)
   Translational Postdoc Grant; Deutsche Forschungsgemeinschaft
   {[}AL2054/1-1, VO2259/2-1]; European Union Seventh Framework Programme
   {[}FP7/2007-2013-603288-SysVasc]; Else Kroner-Fresenius-Stiftung; DZHK
   (German Centre for Cardiovascular Research)},
Funding-Text = {Open access funding provided by Johannes Kepler University Linz. This
   work was supported by the Berlin Institute of Health (BIH) Translational
   Postdoc Grant, the Deutsche Forschungsgemeinschaft (AL2054/1-1;
   VO2259/2-1), the European Union Seventh Framework Programme
   (FP7/2007-2013-603288-SysVasc), and the Else Kroner-Fresenius-Stiftung
   and the DZHK (German Centre for Cardiovascular Research).},
Cited-References = {Alesutan I, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01882-2.
   Alesutan I, 2017, J HYPERTENS, V35, P523, DOI 10.1097/HJH.0000000000001202.
   Alesutan I, 2016, CARDIOVASC RES, V110, P408, DOI 10.1093/cvr/cvw062.
   Alesutan I, 2015, KIDNEY BLOOD PRESS R, V40, P490, DOI 10.1159/000368524.
   Alesutan I, 2013, KIDNEY BLOOD PRESS R, V37, P475, DOI 10.1159/000355728.
   BelAiba RS, 2006, CIRC RES, V98, P828, DOI 10.1161/01.RES.0000210539.54861.27.
   Borst O, 2015, ARTERIOSCL THROM VAS, V35, P547, DOI 10.1161/ATVBAHA.114.304454.
   Chandrasekar B, 2005, J BIOL CHEM, V280, P4553, DOI 10.1074/jbc.M411787200.
   Chen NX, 2015, CURR OSTEOPOROS REP, V13, P372, DOI 10.1007/s11914-015-0293-9.
   Cheng JZ, 2010, KIDNEY INT, V78, P668, DOI 10.1038/ki.2010.214.
   Cheng SL, 2014, DIABETES, V63, P4326, DOI 10.2337/db14-0326.
   Chiang CK, 2005, BLOOD PURIFICAT, V23, P144, DOI 10.1159/000083620.
   Di Cristofano A, 2017, CURR TOP DEV BIOL, V123, P49, DOI 10.1016/bs.ctdb.2016.11.006.
   Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837.
   Gan WQ, 2018, BBA-MOL BASIS DIS, V1864, P1, DOI 10.1016/j.bbadis.2017.10.001.
   Gangemi S, 2002, AM J NEPHROL, V22, P417, DOI 10.1159/000065269.
   Gerdes N, 2002, J EXP MED, V195, P245, DOI 10.1084/jem.20011022.
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644.
   Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283.
   Guerin AP, 2001, CIRCULATION, V103, P987.
   Gukovsky I, 2004, GASTROENTEROLOGY, V126, P554, DOI 10.1053/j.gastro.2003.11.017.
   Inoue K, 2016, J NEUROCHEM, V138, P354, DOI 10.1111/jnc.13650.
   Kojima H, 1999, J IMMUNOL, V162, P5063.
   Lang F, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00207.
   Lang F, 2014, NEPHRON PHYSIOL, V128, P40, DOI 10.1159/000368268.
   Lang F, 2014, MOL MEMBR BIOL, V31, P29, DOI 10.3109/09687688.2013.874598.
   Lang F, 2013, EXPERT OPIN INV DRUG, V22, P701, DOI 10.1517/13543784.2013.778971.
   Lang F, 2013, NEPHROL DIAL TRANSPL, V28, P1080, DOI 10.1093/ndt/gft041.
   Lang F, 2010, J NEPHROL, V23, pS124.
   Lang F, 2009, EXPERT OPIN THER TAR, V13, P1303, DOI 10.1517/14728220903260807.
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163.
   Leibrock CB, 2015, J AM SOC NEPHROL, V26, P2423, DOI 10.1681/ASN.2014030230.
   Luong TTD, 2018, CELL PHYSIOL BIOCHEM, V46, P1305, DOI 10.1159/000489144.
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692.
   Montezano AC, 2010, HYPERTENSION, V56, P453, DOI 10.1161/HYPERTENSIONAHA.110.152058.
   O'Brien LC, 2014, MOL MED, V20, P221, DOI 10.2119/molmed.2014.00034.
   Olee T, 1999, J IMMUNOL, V162, P1096.
   Paloian NJ, 2014, AM J PHYSIOL-RENAL, V307, pF891, DOI 10.1152/ajprenal.00163.2014.
   Reddy VS, 2011, J CELL PHYSIOL, V226, P3303, DOI 10.1002/jcp.22676.
   Rennenberg RJMW, 2009, VASC HEALTH RISK MAN, V5, P185.
   Sahar S, 2005, CIRC RES, V96, P1064, DOI 10.1161/01.RES.0000168210.10358.f4.
   Sheen CR, 2015, J BONE MINER RES, V30, P824, DOI 10.1002/jbmr.2420.
   Shroff R, 2013, J AM SOC NEPHROL, V24, P179, DOI 10.1681/ASN.2011121191.
   Tuffaha R, 2018, BIOCHEM BIOPH RES CO, V503, P2068, DOI 10.1016/j.bbrc.2018.07.161.
   Turner CM, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-21.
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005.
   Valente AJ, 2013, CELL SIGNAL, V25, P1447, DOI 10.1016/j.cellsig.2013.03.007.
   Valinsky WC, 2016, J BIOL CHEM, V291, P20163, DOI 10.1074/jbc.M116.735175.
   Victor AR, 2017, J IMMUNOL, V199, P2333, DOI 10.4049/jimmunol.1601554.
   Vilaysane A, 2010, J AM SOC NEPHROL, V21, P1732, DOI 10.1681/ASN.2010020143.
   Villa-Bellosta R, 2011, AM J PHYSIOL-CELL PH, V300, pC210, DOI 10.1152/ajpcell.00229.2010.
   Voelkl J, 2018, J CLIN INVEST, V128, P3024, DOI 10.1172/JCI96477.
   Voelkl J, 2018, J AM SOC NEPHROL, V29, P1636, DOI {[}10.1681/ASN.2017050492, 10.1681/asn.2017050492].
   Voelkl J, 2015, CELL PHYSIOL BIOCHEM, V37, P603, DOI 10.1159/000430380.
   Voelkl J, 2013, KIDNEY BLOOD PRESS R, V38, P156, DOI 10.1159/000355763.
   Voelkl J, 2013, CELL PHYSIOL BIOCHEM, V32, P25, DOI 10.1159/000350120.
   Voelkl J, 2013, J CLIN INVEST, V123, P812, DOI 10.1172/JCI64093.
   Voelkl J, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-011-0236-2.
   Weber CIK, 2014, CLIN KIDNEY J, V7, P167, DOI 10.1093/ckj/sfu017.
   Weinstock JV, 2003, J IMMUNOL, V170, P5003, DOI 10.4049/jimmunol.170.10.5003.
   Yoo JK, 2005, J IMMUNOL, V175, P8280, DOI 10.4049/jimmunol.175.12.8280.
   Zhang K, 2017, ARTERIOSCL THROM VAS, V37, P1933, DOI 10.1161/ATVBAHA.117.309161.
   Zhou J, 2014, CYTOKINE, V69, P29, DOI 10.1016/j.cyto.2014.05.003.},
Number-of-Cited-References = {63},
Times-Cited = {19},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Pflugers Arch.},
Doc-Delivery-Number = {HZ5GK},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000468879500008},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000469026400015,
Author = {Tan, Yu-Zhu and Peng, Cheng and Hu, Chang-Jiang and Li, Hong-Xiang and
   Li, Wen-Bing and He, Jun-Lin and Li, Yu-Zhi and Zhang, Hai and Zhang,
   Ruo-Qi and Wang, Li-Xia and Cao, Zhi-Xing},
Title = {Iridoids from Valeriana jatamansi induce autophagy-associated
   cell death via the PDK1/Akt/mTOR pathway in HCT116 human
   colorectal carcinoma cells},
Journal = {BIOORGANIC CHEMISTRY},
Year = {2019},
Volume = {87},
Pages = {136-141},
Month = {JUN},
Abstract = {Chlorovaltrates U-W (1-3), three previously undescribed iridoids,
   together with four known analogues were isolated from the roots of
   Valeriana jatamansi. Their structures were elucidated by means of
   spectroscopic analyses (HRESIMS, NMR). The cytotoxicity of all isolates
   was evaluated. Compounds 5-7 exhibited selective cytotoxicity against
   HCT116 cells, with IC50 values of 9.3, 1.7 and 2.2 mu M, respectively.
   The preliminary mechanistic study revealed that, the cytotoxicity effect
   of 6 was attributed to Akt/mTOR activation blockade via inhibition of
   PDK1 phosphorylation. Meanwhile, compound 6 could induce autophagosome
   formation in HCT116 cells via suppressing its downstream Akt/mTOR. These
   findings show that compound 6 could be of great importance to the
   development of anti-colon cancer agents.},
Publisher = {ACADEMIC PRESS INC ELSEVIER SCIENCE},
Address = {525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA},
Type = {Article},
Language = {English},
Affiliation = {Peng, C; Cao, ZX (Corresponding Author), Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Breeding Base Systemat Res Dev \& Ut, Chengdu 611137, Sichuan, Peoples R China.
   Tan, Yu-Zhu; Peng, Cheng; He, Jun-Lin; Li, Yu-Zhi; Zhang, Hai; Zhang, Ruo-Qi; Wang, Li-Xia; Cao, Zhi-Xing, Chengdu Univ Tradit Chinese Med, State Key Lab Breeding Base Systemat Res Dev \& Ut, Chengdu 611137, Sichuan, Peoples R China.
   Tan, Yu-Zhu; Peng, Cheng; Hu, Chang-Jiang; He, Jun-Lin; Li, Yu-Zhi; Zhang, Hai; Zhang, Ruo-Qi; Wang, Li-Xia; Cao, Zhi-Xing, Chengdu Univ Tradit Chinese Med, Sch Pharm, Chengdu 611137, Sichuan, Peoples R China.
   Li, Hong-Xiang, Chengdu Univ Tradit Chinese Med, Innovat Inst Chinese Med \& Pharm, Chengdu 611137, Sichuan, Peoples R China.
   Li, Wen-Bing, Sichuan New Green Med Sci \& Technol Dev Co Ltd, Key Lab Qual Control \& Efficacy Evaluat Tradit Ch, Pengzhou 611930, Peoples R China.},
DOI = {10.1016/j.bioorg.2019.03.020},
ISSN = {0045-2068},
EISSN = {1090-2120},
Keywords = {Valeriana jatamansi; Caprifoliaceae; Iridoids; Cytotoxicity;
   PDK1/Akt/mTOR},
Keywords-Plus = {NATURAL-PRODUCTS; PLUS CETUXIMAB; ROOTS; PI3K/AKT/MTOR; CANCER;
   SESQUITERPENOIDS; MUTATIONS; DIVERSITY; DRUGS},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Organic},
Author-Email = {pengchengchengdu@126.com
   caozhixing007@163.com},
Affiliations = {Chengdu University of Traditional Chinese Medicine; Chengdu University
   of Traditional Chinese Medicine; Chengdu University of Traditional
   Chinese Medicine},
ResearcherID-Numbers = {Hai, Zhang/AAE-3173-2019
   Zhang, Ruoqi/ACX-2846-2022
   tan, yuzhu/AGP-2121-2022},
ORCID-Numbers = {Hu, Changjiang/0000-0002-6080-5594
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81703693, 81503346]; key
   fund project for Education Department of Sichuan {[}18ZA0181]; Youth
   Science and Technology Innovative Research Team fund project of Sichuan
   {[}2016TD0006]; Fund Project of Science and Technology of Chengdu
   {[}2016-HM01-00457-SF]},
Funding-Text = {This work was financially supported by the National Natural Science
   Foundation of China (No. 81703693, 81503346), the key fund project for
   Education Department of Sichuan (No. 18ZA0181), the Youth Science and
   Technology Innovative Research Team fund project of Sichuan (No.
   2016TD0006), and the Fund Project of Science and Technology of Chengdu
   {[}No. 2016-HM01-00457-SF].},
Cited-References = {BECKER H, 1984, PLANTA MED, V50, P245, DOI 10.1055/s-2007-969689.
   BOUNTHANH C, 1981, PLANTA MED, V41, P21, DOI 10.1055/s-2007-971668.
   Cao ZX, 2017, J ETHNOPHARMACOL, V202, P20, DOI 10.1016/j.jep.2016.07.028.
   Cragg GM, 1997, J NAT PROD, V60, P52, DOI 10.1021/np9604893.
   Fernández S, 2004, PHARMACOL BIOCHEM BE, V77, P399, DOI 10.1016/j.pbb.2003.12.003.
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4.
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019.
   Jillson I, 2015, J CANCER EDUC, V30, P284, DOI 10.1007/s13187-015-0813-4.
   Li YD, 2013, HELV CHIM ACTA, V96, P424, DOI 10.1002/hlca.201100465.
   Lin S, 2015, J ASIAN NAT PROD RES, V17, P455, DOI 10.1080/10286020.2015.1041933.
   Lin S, 2013, PHYTOCHEMISTRY, V85, P185, DOI 10.1016/j.phytochem.2012.08.015.
   Lin S, 2010, J NAT PROD, V73, P1723, DOI 10.1021/np100426j.
   Lin S, 2010, J NAT PROD, V73, P632, DOI 10.1021/np900795c.
   Liu F.L., 2010, PHARMA CLIN RES, V20, P356, DOI {[}10.3969/j.issn.1673-7806.2010.04.011, DOI 10.3969/J.ISSN.1673-7806.2010.04.011].
   Liu YH, 2017, FITOTERAPIA, V123, P73, DOI 10.1016/j.fitote.2017.09.011.
   Ma CH, 2015, J ETHNOPHARMACOL, V168, P349, DOI 10.1016/j.jep.2015.03.068.
   Mathela CS, 2005, CHEM BIODIVERS, V2, P1174, DOI 10.1002/cbdv.200590087.
   Ming DS, 1997, TETRAHEDRON LETT, V38, P5205, DOI 10.1016/S0040-4039(97)01112-X.
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v.
   Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l.
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201.
   Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a.
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132.
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381.
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590.
   Sun JZ, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-3738.
   Sun Y, 2018, BIOMED PHARMACOTHER, V104, P817, DOI 10.1016/j.biopha.2018.04.136.
   Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021.
   Tan YZ, 2016, PHYTOCHEM LETT, V17, P177, DOI 10.1016/j.phytol.2016.07.020.
   Tang YP, 2002, J NAT PROD, V65, P1949, DOI 10.1021/np0203335.
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325.
   Van C.E., 2010, ANN ONCOL, V21, P155.
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812.
   Verma RS, 2011, CHEM BIODIVERS, V8, P1921, DOI 10.1002/cbdv.201100059.
   Wang RJ, 2017, PHYTOCHEMISTRY, V141, P156, DOI 10.1016/j.phytochem.2017.05.010.
   Xu J, 2012, NAT PROD RES, V26, P1996, DOI 10.1080/14786419.2011.636747.
   Xu J, 2011, FITOTERAPIA, V82, P1133, DOI 10.1016/j.fitote.2011.07.013.
   Xu J, 2011, FITOTERAPIA, V82, P849, DOI 10.1016/j.fitote.2011.04.012.
   Xu ZL, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0645-4.
   Yu LL, 2005, HELV CHIM ACTA, V88, P1059, DOI 10.1002/hlca.200590077.
   Zhang B, 2017, RSC ADV, V7, P31899, DOI 10.1039/c6ra27478a.
   Zhang W.D., 2010, Faming Zhuanli Shenqing, Patent No. 101829080.
   Zhang XM, 2018, NAT PROD RES, V32, P2071, DOI 10.1080/14786419.2017.1360881.},
Number-of-Cited-References = {43},
Times-Cited = {17},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {29},
Journal-ISO = {Bioorganic Chem.},
Doc-Delivery-Number = {HZ7IC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)},
Unique-ID = {WOS:000469026400015},
DA = {2026-02-04},
}

@article{ WOS:000467908800014,
Author = {Tumova, Sarka and Kerimi, Asimina and Williamson, Gary},
Title = {Long term treatment with quercetin in contrast to the sulfate and
   glucuronide conjugates affects HIF1α stability and Nrf2 signaling in
   endothelial cells and leads to changes in glucose metabolism},
Journal = {FREE RADICAL BIOLOGY AND MEDICINE},
Year = {2019},
Volume = {137},
Pages = {158-168},
Month = {JUN},
Abstract = {Endothelial functionality profoundly contributes to cardiovascular
   health. The effects of flavonoids shown to improve endothelial
   performance include regulating blood pressure by modulating endothelial
   nitric oxide synthase and NADPH oxidases, but their impact on glucose
   uptake and metabolism has not been explored. We treated human umbilical
   vein endothelial cells (HUVEC) with the flavonoid quercetin and its
   circulating metabolites acutely and chronically, then assessed glucose
   uptake, glucose metabolism, gene transcription and protein expression.
   Acute treatment had no effect on glucose uptake, ruling out any direct
   interaction with sugar transporters. Long term treatment with quercetin,
   but not quercetin 3-O-glucuronide or 3'-O-sulfate, significantly
   increased glucose uptake. Heme oxygenase-1 (HO-1) was induced by
   quercetin but not its conjugates, but was not implicated in the glucose
   uptake stimulation since hemin, a classical inducer of HO-1, did not
   affect glucose metabolism. Quercetin increased stability of the
   transcription factor hypoxia induced factor 1 alpha (HIF1 alpha), a
   powerful stimulant of glucose metabolism, which was also paralleled by
   treatment with a prolyl-4-hydroxylase inhibitor dimethyloxalylglycine
   (DMOG). 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3),
   which regulates the rate of glycolysis, was upregulated by both
   quercetin and DMOG. Pyruvate dehydrogenase kinase (PDK) isoforms
   regulate pyruvate dehydrogenase; PDK2 and PDK4 were down-regulated by
   both effectors, but only DMOG also upregulated PDK1 and PDK3. Quercetin,
   but not DMOG, increased glucose-6-phosphate dehydrogenase. Chronic
   quercetin treatment also stimulated glucose transport across the HUVEC
   monolyer in a 3D culture model. Gene expression of several flavonoid
   transporters was repressed by quercetin, but this was either abolished
   (Organic anion transporter polypeptide 4C1) or reversed (Multidrug
   resistance gene 1) by both conjugates. We conclude that quercetin and
   its circulating metabolites differentially modulate glucose
   uptake/metabolism in endothelial cells, through effects on HIF1 alpha
   and transcriptional regulation of energy metabolism.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Williamson, G (Corresponding Author), Monash Univ, Notting Hill BASE Facil, Fac Med Nursing \& Hlth Sci, Dept Nutr Dietet \& Food,Sch Clin Sci,Monash Hlth, 264 Ferntree Gully Rd, Notting Hill, Vic 3168, Australia.
   Tumova, Sarka; Kerimi, Asimina; Williamson, Gary, Univ Leeds, Sch Food Sci \& Nutr, Leeds LS2 9JT, W Yorkshire, England.
   Williamson, Gary, Monash Univ, Notting Hill BASE Facil, Fac Med Nursing \& Hlth Sci, Dept Nutr Dietet \& Food,Sch Clin Sci,Monash Hlth, 264 Ferntree Gully Rd, Notting Hill, Vic 3168, Australia.},
DOI = {10.1016/j.freeradbiomed.2019.04.023},
ISSN = {0891-5849},
EISSN = {1873-4596},
Keywords-Plus = {GREEN TEA POLYPHENOL; DIETARY POLYPHENOLS; EPIGALLOCATECHIN GALLATE;
   DEPENDENT VASODILATION; INSULIN-RESISTANCE; IN-VITRO; DYSFUNCTION;
   ACTIVATION; INHIBITION; FLAVONOIDS},
Research-Areas = {Biochemistry \& Molecular Biology; Endocrinology \& Metabolism},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Endocrinology \& Metabolism},
Author-Email = {gary.williamson1@monash.edu},
Affiliations = {University of Leeds; Monash University},
ResearcherID-Numbers = {Williaon, Gary/C-9684-2010
   Tumova, Sarka/AAD-6353-2019},
ORCID-Numbers = {Williaon, Gary/0000-0002-5624-6267
   Tumova, Sarka/0000-0003-2044-4998},
Funding-Acknowledgement = {European Research Council {[}322467]; European Research Council (ERC)
   {[}322467] Funding Source: European Research Council (ERC)},
Funding-Text = {This research was supported by funding from the European Research
   Council Advanced Grant no. 322467 ('POLYTRUE?').},
Cited-References = {al Taleb Z, 2016, J MOL MED, V94, P1153, DOI 10.1007/s00109-016-1439-7.
   Bahadoran Z, 2013, J DIABETES METAB DIS, V12, DOI 10.1186/2251-6581-12-43.
   Bauer V, 2010, GEN PHYSIOL BIOPHYS, V29, P319, DOI 10.4149/gpb\_2010\_04\_319.
   Cersosimo E, 2006, DIABETES-METAB RES, V22, P423, DOI 10.1002/dmrr.634.
   Chen F, 2013, CNS NEUROSCI THER, V19, P675, DOI 10.1111/cns.12131.
   Collins QF, 2007, J BIOL CHEM, V282, P30143, DOI 10.1074/jbc.M702390200.
   Day AJ, 2001, FREE RADICAL RES, V35, P941, DOI 10.1080/10715760100301441.
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037.
   Duarte J, 2014, FOOD FUNCT, V5, P1653, DOI {[}10.1039/c4fo00144c, 10.1039/C4FO00144C].
   Durand MJ, 2013, MICROCIRCULATION, V20, P239, DOI 10.1111/micc.12040.
   Ellinsworth DC, 2014, PFLUG ARCH EUR J PHY, V466, P389, DOI 10.1007/s00424-013-1303-3.
   Galley HF, 2004, BRIT J ANAESTH, V93, P105, DOI 10.1093/bja/aeh163.
   Goveia J, 2014, EMBO MOL MED, V6, P1105, DOI 10.15252/emmm.201404156.
   Grassi D, 2013, AM J CLIN NUTR, V98, p1660S, DOI 10.3945/ajcn.113.058313.
   Guo SH, 2009, J NEUROCHEM, V108, P1309, DOI 10.1111/j.1471-4159.2009.05877.x.
   Guo XD, 2013, MOL NUTR FOOD RES, V57, P1037, DOI 10.1002/mnfr.201200569.
   Hanhineva K, 2010, INT J MOL SCI, V11, P1365, DOI 10.3390/ijms11041365.
   Huang Y, 2012, P NATL ACAD SCI USA, V109, P17478, DOI 10.1073/pnas.1209281109.
   Huggett JF, 2013, CLIN CHEM, V59, P892, DOI 10.1373/clinchem.2013.206375.
   Jeon H, 2007, MOL PHARMACOL, V71, P1676, DOI 10.1124/mol.107.034041.
   Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099.
   Kawai Y, 2014, J CLIN BIOCHEM NUTR, V54, P145, DOI 10.3164/jcbn.14-9.
   Kerimi A, 2019, EUR J NUTR, V58, P1315, DOI 10.1007/s00394-018-1662-9.
   Kerimi A, 2016, MOL NUTR FOOD RES, V60, P1770, DOI 10.1002/mnfr.201500940.
   Kim JA, 2007, J BIOL CHEM, V282, P13736, DOI 10.1074/jbc.M609725200.
   Kim JH, 2014, CURR PHARM DESIGN, V20, P3521, DOI 10.2174/13816128113196660751.
   Kwon O, 2007, FASEB J, V21, P366, DOI 10.1096/fj.06-6620com.
   Lee J, 2014, PHARMACOL REV, V66, P815, DOI 10.1124/pr.113.007757.
   Leopold JA, 2003, ARTERIOSCL THROM VAS, V23, P411, DOI 10.1161/01.ATV.0000056744.26901.BA.
   Li JQ, 2009, EXPERT OPIN THER TAR, V13, P785, DOI 10.1517/14728220903025762.
   Lin CM, 2010, J NUTR BIOCHEM, V21, P627, DOI 10.1016/j.jnutbio.2009.04.001.
   Losso JN, 2005, J AGR FOOD CHEM, V53, P3751, DOI 10.1021/jf0479719.
   Malec V, 2010, FREE RADICAL BIO MED, V48, P1626, DOI 10.1016/j.freeradbiomed.2010.03.008.
   Mann GE, 2009, CURR OPIN PHARMACOL, V9, P139, DOI 10.1016/j.coph.2008.12.012.
   Manzano S, 2010, MOL NUTR FOOD RES, V54, P1773, DOI 10.1002/mnfr.201000019.
   Menezes R, 2017, NUTRIENTS, V9, DOI 10.3390/nu9020117.
   Nagle DG, 2006, CURR PHARM DESIGN, V12, P2673, DOI 10.2174/138161206777698783.
   Noad RL, 2016, HEART, V102, P1371, DOI 10.1136/heartjnl-2015-309218.
   Oh ET, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13593.
   Park SS, 2008, J CELL BIOCHEM, V103, P1989, DOI 10.1002/jcb.21588.
   Prieto D, 2014, CURR VASC PHARMACOL, V12, P412, DOI 10.2174/1570161112666140423221008.
   Radreau P, 2009, EXP EYE RES, V89, P995, DOI 10.1016/j.exer.2009.08.011.
   Schewe T, 2008, ARCH BIOCHEM BIOPHYS, V476, P102, DOI 10.1016/j.abb.2008.03.004.
   Schnorr O, 2008, ARCH BIOCHEM BIOPHYS, V476, P211, DOI 10.1016/j.abb.2008.02.040.
   Shen Y, 2013, FREE RADICAL BIO MED, V65, P908, DOI 10.1016/j.freeradbiomed.2013.08.185.
   Smirnova NA, 2016, AGING DIS, V7, P745, DOI 10.14336/AD.2016.0505.
   Steffen Y, 2008, ARCH BIOCHEM BIOPHYS, V469, P209, DOI 10.1016/j.abb.2007.10.012.
   Sudano I, 2006, J CARDIOVASC PHARM, V47, pS136, DOI 10.1097/00005344-200606001-00008.
   Suganya N, 2016, BRIT J NUTR, V116, P223, DOI 10.1017/S0007114516001884.
   Thomas R, 2005, BIOCHEM BIOPH RES CO, V334, P543, DOI 10.1016/j.bbrc.2005.06.114.
   Tumova S, 2016, VASC PHARMACOL, V87, P219, DOI 10.1016/j.vph.2016.11.001.
   Vandekeere S, 2015, MICROCIRCULATION, V22, P509, DOI 10.1111/micc.12229.
   Varela L, 2017, DIABETES, V66, P1511, DOI 10.2337/db16-1106.
   Wang H, 2011, CARCINOGENESIS, V32, P1881, DOI 10.1093/carcin/bgr218.
   Wilson WJ, 2002, BIOCHEM BIOPH RES CO, V293, P446, DOI 10.1016/S0006-291X(02)00244-9.
   Xia N, 2013, NITRIC OXIDE-BIOL CH, V32, P29, DOI 10.1016/j.niox.2013.04.001.
   Yamagata K, 2015, NUTRITION, V31, P28, DOI 10.1016/j.nut.2014.04.011.
   Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480.
   Zhou Q, 2018, INFLAMMATION, V41, P2068, DOI 10.1007/s10753-018-0850-3.
   Zhou YD, 2004, J NAT PROD, V67, P2063, DOI 10.1021/np040140c.
   2013, J HEPATOL, V59, P1200, DOI DOI 10.1016/J.JHEP.2013.07.016.},
Number-of-Cited-References = {61},
Times-Cited = {22},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {32},
Journal-ISO = {Free Radic. Biol. Med.},
Doc-Delivery-Number = {HY1WT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000467908800014},
DA = {2026-02-04},
}

@article{ WOS:000469797700001,
Author = {Ge, Xiao-Li and Wang, Jin-Li and Liu, Xin and Zhang, Jia and Liu, Chang
   and Guo, Li},
Title = {Inhibition of miR-19a protects neurons against ischemic stroke through
   modulating glucose metabolism and neuronal apoptosis},
Journal = {CELLULAR \& MOLECULAR BIOLOGY LETTERS},
Year = {2019},
Volume = {24},
Month = {MAY 31},
Abstract = {Background: Accumulating evidence has shown that altered microRNA (miR)
   modulation is implicated in the pathologies of ischemic stroke. However,
   it is unclear whether and how hsa-miR-19a-3p mediates cerebral ischemic
   injury. Herein, we investigated the functional role of miR-19a-3p in
   cerebral ischemic injury and explored its underlying regulatory
   mechanism.
   Methods: In vivo ischemic/reperfusion (I/R) neuronal injury and in vitro
   oxygen-glucose deprivation (OGD) were established. Expression of
   miR-19a-3p was determined by quantitative real-time polymerase chain
   reaction (qRT-PCR). Glucose uptake, lactate production, and apoptosis
   were determined. ADIPOR2 was predicted as a target of miR-19a-3p in
   silico and experimentally validated by qRT-PCR, Western blot analysis
   and luciferase assay assays.
   Results: MiR-19a expression was significantly downregulated and
   upregulated in rat neurons and astrocytes, respectively (P < 0.01). A
   significantly elevated level of miR-19a-3p was found in I/R and OGD
   models in comparison to sham/control groups (P < 0.01). Expression of
   the glycolysis enzyme markers LDHA, PKM2, HK2, Glut1 and PDK1,
   apoptosis-related factors levels, apoptosis, glucose uptake, and lactate
   production were significantly repressed by both I/R and OGD (P < 0.01 in
   each case). Moreover, miR-19a-3p mimic aggravated, while miR-19a-3p
   inhibitor alleviated, the above observations. Adipor2 was predicted and
   confirmed to be a direct target of miR-19a. Furthermore, restoration of
   Adipor2 reversed miR-19a-3p-induced effects.
   Conclusions: Collectively, our results indicate that elevated miR-19a-3p
   mediates cerebral ischemic injury by targeting ADIPOR2. MiR-19a-3p
   attenuation thus might offer hope of a novel therapeutic target for
   ischemic stroke injury treatment.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Guo, L (Corresponding Author), Hebei Med Univ, Hosp 2, Dept Neurol, Shijiazhuang 050000, Hebei, Peoples R China.
   Ge, Xiao-Li; Wang, Jin-Li; Guo, Li, Hebei Med Univ, Hosp 2, Dept Neurol, Shijiazhuang 050000, Hebei, Peoples R China.
   Liu, Xin, Hebei Med Univ, Hosp 2, Dept Neurosurg, Shijiazhuang 050000, Hebei, Peoples R China.
   Zhang, Jia, Hebei Med Univ, Hosp 2, Dept Obstet, Shijiazhuang 050000, Hebei, Peoples R China.
   Liu, Chang, Hebei Med Univ, Hosp 2, Dept Rehabil, Shijiazhuang 050000, Hebei, Peoples R China.},
DOI = {10.1186/s11658-019-0160-2},
Article-Number = {37},
ISSN = {1425-8153},
EISSN = {1689-1392},
Keywords = {Ischemic stroke; miR-19a-3p; ADIPOR2; Glucose metabolism; Apoptosis},
Keywords-Plus = {OXIDATIVE STRESS; BRAIN; PATHWAY; CLUSTER; INJURY; PROLIFERATION;
   POLYMORPHISMS; ACTIVATION; ADIPOR1},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {guoli\_med@126.com},
Affiliations = {Hebei Medical University; Hebei Medical University; Hebei Medical
   University; Hebei Medical University},
Cited-References = {Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623.
   Belisário AR, 2018, HEMATOL TRANSF CELL, V40, P166, DOI 10.1016/j.bjhh.2017.08.008.
   Brekke E, 2017, NEUROCHEM RES, V42, P115, DOI 10.1007/s11064-016-2149-9.
   Cabral NL, 2018, INT J STROKE, V13, P725, DOI 10.1177/1747493018763906.
   China SP, 2018, CYTOKINE, V112, P116, DOI 10.1016/j.cyto.2018.06.012.
   Falkowska A, 2015, INT J MOL SCI, V16, P25959, DOI 10.3390/ijms161125939.
   Fan F, 2018, NEUROCHEM RES, V43, P2260, DOI 10.1007/s11064-018-2646-0.
   Geng JL, 2019, J PROTEOME RES, V18, P57, DOI 10.1021/acs.jproteome.8b00339.
   Guo F, 2015, MOL NEUROBIOL, V51, P685, DOI 10.1007/s12035-014-8765-y.
   Jia ZF, 2013, PATHOL ONCOL RES, V19, P847, DOI 10.1007/s12253-013-9653-x.
   Jiang XM, 2018, BIOMED PHARMACOTHER, V105, P1147, DOI 10.1016/j.biopha.2018.06.097.
   Kim Y, 2018, J AM SOC NEPHROL, V29, P1108, DOI 10.1681/ASN.2017060627.
   Kovacs GG, 2018, HAND CLINIC, V145, P13, DOI 10.1016/B978-0-12-802395-2.00003-1.
   Kraner SD, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00287.
   Lei L, 2018, CLIN EXP PHARMACOL P, V45, P819, DOI 10.1111/1440-1681.12940.
   Li MS, 2017, P NATL ACAD SCI USA, V114, pE396, DOI 10.1073/pnas.1612930114.
   Li YX, 2018, BIOMED PHARMACOTHER, V108, P1775, DOI 10.1016/j.biopha.2018.09.181.
   Liu XS, 2013, J BIOL CHEM, V288, P12478, DOI 10.1074/jbc.M112.449025.
   Liu Xiangrong, 2017, Brain Circ, V3, P219, DOI {[}10.4103/bc.bc\_15\_17, 10.4103/bc.bc\_15\_17].
   Ma J, 2019, WORLD NEUROSURG, V123, pE245, DOI 10.1016/j.wneu.2018.11.144.
   McKenna MC, 2015, NEUROCHEM RES, V40, P2527, DOI 10.1007/s11064-015-1600-7.
   Mohr AM, 2015, SEMIN LIVER DIS, V35, P3, DOI 10.1055/s-0034-1397344.
   Navis A, 2019, J STROKE CEREBROVASC, V28, P84, DOI 10.1016/j.jstrokecerebrovasdis.2018.09.013.
   Nortley R, 2017, CURR OPIN NEUROBIOL, V47, P80, DOI 10.1016/j.conb.2017.09.012.
   Pekny M, 2019, NEUROSCI LETT, V689, P45, DOI 10.1016/j.neulet.2018.07.021.
   Radak D, 2017, CURR VASC PHARMACOL, V15, P115, DOI 10.2174/1570161115666161104095522.
   Rana AK, 2018, NEUROPHARMACOLOGY, V139, P124, DOI 10.1016/j.neuropharm.2018.07.006.
   Randolph SA, 2016, WORKPLACE HEALTH SAF, V64, P444, DOI {[}10.29309/tpmj/2016.23.04.1503, 10.1177/2165079916665400].
   Rastegar S, 2019, J COMP NEUROL, DOI {[}10.1002/cne.24669, DOI 10.1002/CNE.24669.{[}].
   Rodrigo R, 2013, CNS NEUROL DISORD-DR, V12, P698.
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486.
   Sarkar S, 2019, FRONT BIOSCI-LANDMRK, V24, P435, DOI 10.2741/4727.
   Shen XH, 2017, BIOMED PHARMACOTHER, V95, P129, DOI 10.1016/j.biopha.2017.08.041.
   Stack CA, 2018, CURR OPIN CARDIOL, V33, P594, DOI 10.1097/HCO.0000000000000564.
   Stary CM, 2015, NEUROCHEM RES, V40, P301, DOI 10.1007/s11064-014-1373-4.
   Wang W, 2008, J CLIN NEUROSCI, V15, P278, DOI 10.1016/j.jocn.2007.02.004.
   Wu JS, 2018, TOXICOL LETT, V295, P124, DOI 10.1016/j.toxlet.2018.05.040.
   Xie Z, 2018, BRAIN RES BULL, V142, P216, DOI 10.1016/j.brainresbull.2018.07.017.
   Ye XC, 2017, EXP NEUROL, V292, P46, DOI 10.1016/j.expneurol.2017.03.002.
   Yu S, 2018, NEUROSCIENCE, V391, P60, DOI 10.1016/j.neuroscience.2018.09.006.
   Yuan B, 2014, GENET MOL RES, V13, P7808, DOI 10.4238/2014.September.26.19.
   Zhang XJ, 2018, INT J MED SCI, V15, P1443, DOI 10.7150/ijms.27341.
   Zhang Y, 2013, J NEUROSCI, V33, P6885, DOI 10.1523/JNEUROSCI.5180-12.2013.
   Zhang ZY, 2018, GENE, V658, P10, DOI 10.1016/j.gene.2018.03.022.
   Zhi F, 2015, NEURO-ONCOLOGY, V17, P383, DOI 10.1093/neuonc/nou169.
   Zhu PH, 2018, CHEM BIOL DRUG DES, V92, P1525, DOI 10.1111/cbdd.13319.},
Number-of-Cited-References = {46},
Times-Cited = {66},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {17},
Journal-ISO = {Cell. Mol. Biol. Lett.},
Doc-Delivery-Number = {IA8GX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000469797700001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000468820900004,
Author = {Li, Baojun and Wang, Wei and Miao, Susheng and Li, Guofu and Lv,
   Yuanjing and Xiang, Cheng and Pei, Rong},
Title = {HOXA11-AS promotes the progression of oral squamous cell carcinoma by
   targeting the miR-518a-3p/PDK1 axis},
Journal = {CANCER CELL INTERNATIONAL},
Year = {2019},
Volume = {19},
Month = {MAY 21},
Abstract = {BackgroundLong non-coding RNAs (lncRNAs) are promising therapeutic
   molecules of cancer. Here we aim to study the therapeutic effect and
   mechanism of a lncRNA, HOXA11-AS, in oral squamous cell carcinoma
   (OSCC).MethodsOSCC tissues and adjacent matched paraneoplastic normal
   tissues used in this study were collected from 42 OSCC patients. The
   significant downregulation or upregulation of HOXA11-AS expression in
   OSCC cells was confirmed by quantitative real-time PCR (qRT-PCR).
   Bioinformatics analysis of StarBase were performed to investigate the
   potential microRNAs mediated by HOXA11-AS. HOXA11-AS-transfected cells
   or control cells were subcutaneously injected into nude mice to further
   determine the effects of HOXA11-AS on OSCC progression in
   vivo.ResultsqRT-PCR analysis indicated that HOXA11-AS expression was
   significantly upregulated in OSCC tissues. Functional studies revealed
   that HOXA11-AS significantly promotes cell proliferation, reduces the
   percentage of G0/G1 phase cells and enhances the cell invasion in OSCC.
   Bioinformatics analysis suggested that a microRNA (miRNA), miR-518a-3p,
   is as a target of HOXA11-AS. Alteration of miR-518a-3p levels by
   HOXA11-AS transduced to changes in PDK1 expression. In a mouse model of
   OSCC, HOXA11-AS overexpression promoted tumor growth, concomitant with
   reduced miR-518a-3p expression and increased PDK1
   expression.ConclusionTaken together, our study demonstrates that
   HOXA11-AS/miR-518a-3p/PDK1 axis is an important regulator of OSCC
   progression and may serve as a potential therapeutic target in OSCC.
   HARMU20150128, registered at Jan, 28 2018.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Xiang, C; Pei, R (Corresponding Author), Harbin Med Univ, Dept Neurosurg, Affiliated Tumour Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China.
   Li, Baojun; Miao, Susheng, Harbin Med Univ, Dept Head \& Neck Surg, Affiliated Tumour Hosp, Harbin 150081, Heilongjiang, Peoples R China.
   Wang, Wei, Harbin Med Univ, Dept Oral Maxillofacial Surg, Affiliated Hosp 1, Harbin 150001, Heilongjiang, Peoples R China.
   Li, Guofu; Lv, Yuanjing; Xiang, Cheng; Pei, Rong, Harbin Med Univ, Dept Neurosurg, Affiliated Tumour Hosp, 150 Haping Rd, Harbin 150081, Heilongjiang, Peoples R China.},
DOI = {10.1186/s12935-019-0838-6},
Article-Number = {140},
ISSN = {1475-2867},
Keywords = {Oral squamous cell carcinoma; HOXA11-AS; miR-518a-3p; PDK1},
Keywords-Plus = {LONG NONCODING RNA; CANCER; METASTASIS; INVASION; LNCRNA; PROLIFERATION;
   PATHWAY; LESIONS},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {gryh076@163.com
   chengxiang033@yeah.net
   if88898@163.com},
Affiliations = {Harbin Medical University; Harbin Medical University; Harbin Medical
   University},
ResearcherID-Numbers = {Li, guofu/JJC-4546-2023},
Funding-Acknowledgement = {Haiyan Research Fund Project {[}JJMS2016-03]},
Funding-Text = {This work was supported by financial support from Haiyan Research Fund
   Project (No: JJMS2016-03).},
Cited-References = {Chen JH, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0433-7.
   Choi S, 2008, J DENT RES, V87, P14, DOI 10.1177/154405910808700104.
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641.
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI {[}10.14343/jcscr.2016.4e1003, 10.1002/ijc.29210].
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975.
   Huang WC, 2014, CANCER RES, V74, P751, DOI 10.1158/0008-5472.CAN-13-1297.
   Hunt S, 2011, FEBS LETT, V585, P187, DOI 10.1016/j.febslet.2010.11.038.
   Jia LF, 2014, INT J CANCER, V135, P2282, DOI 10.1002/ijc.28667.
   Johnson NW, 2011, PERIODONTOL 2000, V57, P19, DOI 10.1111/j.1600-0757.2011.00401.x.
   Li WL, 2017, MED SCI MONITOR, V23, P3393, DOI 10.12659/MSM.904892.
   Liang S, 2017, GENE, V608, P49, DOI 10.1016/j.gene.2017.01.024.
   Liu ZX, 2017, ONCOL LETT, V14, P4053, DOI 10.3892/ol.2017.6682.
   Lu MY, 2017, ONCOTARGET, V8, P98542, DOI 10.18632/oncotarget.21614.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Mehrotra R, 2006, Indian J Cancer, V43, P60.
   Muhammad N, 2016, ONCOTARGET, V7, P58595, DOI 10.18632/oncotarget.11193.
   Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803.
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209.
   Qu LL, 2015, INT J MOL MED, V35, P1266, DOI 10.3892/ijmm.2015.2145.
   Richards EJ, 2015, ONCOTARGET, V6, P34745, DOI 10.18632/oncotarget.5784.
   Scott SE, 2006, PSYCHO-ONCOLOGY, V15, P474, DOI 10.1002/pon.976.
   Shin KH, 2011, BIOCHEM BIOPH RES CO, V404, P896, DOI 10.1016/j.bbrc.2010.12.055.
   Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356.
   Wang QX, 2016, CANCER LETT, V373, P251, DOI 10.1016/j.canlet.2016.01.039.
   Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002.
   Wu YS, 2015, INT J ONCOL, V46, P2586, DOI 10.3892/ijo.2015.2976.
   Xue JY, 2018, ONCOTARGETS THER, V11, P4387, DOI 10.2147/OTT.S166961.
   Yu WJ, 2017, TUMOR BIOL, V39, DOI {[}10.1177/1010428317721440, 10.1177/1010428317721440, DOI 10.1177/1010428317721440].},
Number-of-Cited-References = {28},
Times-Cited = {26},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Cancer Cell Int.},
Doc-Delivery-Number = {HZ4MA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000468820900004},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000468037500002,
Author = {Emmanouilidi, Aikaterini and Fyffe, Chanse A. and Ferro, Riccardo and
   Edling, Charlotte E. and Capone, Emily and Sestito, Simona and
   Rapposelli, Simona and Lattanzio, Rossano and Iacobelli, Stefano and
   Sala, Gianluca and Maffucci, Tania and Falasca, Marco},
Title = {Preclinical validation of 3-phosphoinositide-dependent protein kinase 1
   inhibition in pancreatic cancer},
Journal = {JOURNAL OF EXPERIMENTAL \& CLINICAL CANCER RESEARCH},
Year = {2019},
Volume = {38},
Month = {MAY 14},
Abstract = {BackgroundThe very aggressive nature and low survival rate of pancreatic
   ductal adenocarcinoma (PDAC) dictates the necessity to find novel
   efficacious therapies. Recent evidence suggests that phosphoinositide
   3-kinase (PI3K) and 3-phosphoinositide-dependent protein kinase 1 (PDK1)
   are key effectors of oncogenic KRAS in PDAC. Herein, we report the role
   and mechanism of action of PDK1, a protein kinase of the AGC family, in
   PDAC.MethodsPDAC cell lines were treated with selective PDK1 inhibitors
   or transfected with specific PDK1-targeting siRNAs. In vitro and in vivo
   assays were performed to investigate the functional role of PDK1 in
   PDAC. Specifically, anchorage-dependent and anchorage-independent growth
   was assessed in PDAC cells upon inhibition or downregulation of PDK1.
   Detailed investigation of the effect of PDK1 inhibition/downregulation
   on specific signalling pathways was also performed by Western blotting
   analysis. A xenograft tumour mouse model was used to determine the
   effect of pharmacological inhibition of PDK1 on PDAC cells growth in
   vivo.ResultsTreatment with specific inhibitors of PDK1 impaired
   anchorage-dependent and anchorage-independent growth of pancreatic
   cancer cell lines, as well as pancreatic tumour growth in a xenograft
   model. Mechanistically, inhibition or downregulation of PDK1 resulted in
   reduced activation of the serum/glucocorticoid regulated kinase family
   member 3 and subsequent reduced phosphorylation of its target N-Myc
   downstream regulated 1. Additionally, we found that combination of
   sub-optimal concentrations of inhibitors selective for PDK1 and the
   class IB PI3K isoform p110 inhibits pancreatic cancer cell growth and
   colonies formation more potently than each single
   treatment.ConclusionsOur data indicate that PDK1 is a suitable target
   for therapeutic intervention in PDAC and support the clinical
   development of PDK1 inhibitors for PDAC.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Falasca, M (Corresponding Author), Curtin Univ, Metab Signalling Grp, Sch Pharm \& Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia.
   Falasca, M (Corresponding Author), Queen Mary Univ London, Barts \& London Sch Med \& Dent, Blizard Inst, Ctr Cell Biol \& Cutaneous Res, London E1 2AT, England.
   Emmanouilidi, Aikaterini; Falasca, Marco, Curtin Univ, Metab Signalling Grp, Sch Pharm \& Biomed Sci, Curtin Hlth Innovat Res Inst, Perth, WA 6102, Australia.
   Fyffe, Chanse A.; Ferro, Riccardo; Edling, Charlotte E.; Maffucci, Tania; Falasca, Marco, Queen Mary Univ London, Barts \& London Sch Med \& Dent, Blizard Inst, Ctr Cell Biol \& Cutaneous Res, London E1 2AT, England.
   Capone, Emily; Lattanzio, Rossano; Iacobelli, Stefano; Sala, Gianluca, Univ G Annunzio Chieti Pescara, Dipartimento Sci Med Orali \& Biotecnol, Ctr Studi Sull Invecchiamento, CeSI MeT, I-66100 Chieti, Italy.
   Sestito, Simona; Rapposelli, Simona, Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy.
   Iacobelli, Stefano, MediaPharma Srl, Via Colonnetta 50-A, I-66100 Chieti, Italy.},
DOI = {10.1186/s13046-019-1191-2},
Article-Number = {191},
ISSN = {1756-9966},
Keywords = {Pancreatic ductal adenocarcinoma; Signal transduction; Targeted therapy;
   Phosphoinositide 3-kinase; 3-phosphoinositide-dependent protein kinase
   1; Serum; glucocorticoid regulated kinase family member 3},
Keywords-Plus = {PDK1; PATHWAY; CELLS; AKT},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {marco.falasca@curtin.edu.au},
Affiliations = {Curtin University; University of London; Queen Mary University London; G
   d'Annunzio University of Chieti-Pescara; University of Pisa},
ResearcherID-Numbers = {Sala, Gianluca/C-2056-2017
   Rapposelli, Simona/D-1595-2010
   Capone, Emily/AAH-7904-2021
   SESTITO, SIMONA/AAE-6210-2019
   Ferro, Riccardo/AAD-3882-2019
   Lattanzio, Rossano/K-1927-2018},
ORCID-Numbers = {Sala, Gianluca/0000-0002-4494-915X
   Rapposelli, Simona/0000-0003-0146-6358
   Capone, Emily/0000-0001-6719-2535
   SESTITO, SIMONA/0000-0002-6173-525X
   Ferro, Riccardo/0000-0001-6532-4856
   },
Funding-Acknowledgement = {Pancreatic Cancer Research Fund; Avner Pancreatic Cancer Foundation; AB
   Analitica; Ministero Sanita Finalizzata 2011/2012},
Funding-Text = {This work was supported by Pancreatic Cancer Research Fund (grants to
   M.F.) and Avner Pancreatic Cancer Foundation. C.A.F., R.F., C.E.E. were
   supported by Pancreatic Cancer Research Fund (grants to M.F.). A.E. is
   supported by AB Analitica. G.S. was supported by Ministero Sanita
   Finalizzata 2011/2012.},
Cited-References = {Adamska A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071338.
   Bago R, 2016, EMBO J, V35, P1902, DOI 10.15252/embj.201693929.
   Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066.
   Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178.
   Choucair KA, 2012, TRANSL ONCOL, V5, P453, DOI 10.1593/tlo.12286.
   Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Dituri F, 2012, INT J CANCER, V130, P2505, DOI 10.1002/ijc.26319.
   Edling CE, 2010, CLIN CANC RES, P1078.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Erlanson DA, 2011, BIOORG MED CHEM LETT, V21, P3078, DOI 10.1016/j.bmcl.2011.03.032.
   Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023.
   Falasca M, 2010, BRIT J CANCER, V102, P104, DOI 10.1038/sj.bjc.6605408.
   Falasca M, 2016, BBA-REV CANCER, V1865, P123, DOI 10.1016/j.bbcan.2016.01.001.
   Falasca M, 2010, CURR PHARM DESIGN, V16, P1410, DOI 10.2174/138161210791033950.
   Ferro R, 2014, WORLD J GASTROENTERO, V20, P10752, DOI 10.3748/wjg.v20.i31.10752.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Gasser JA, 2014, MOL CELL, V56, P595, DOI 10.1016/j.molcel.2014.09.023.
   Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Liu M, 2012, HEPATOLOGY, V55, P1754, DOI 10.1002/hep.25584.
   Liu Y, 2009, MOL CANC RES.
   Maurer M, 2009, CANC RES.
   Mora A, 2004, SEMINARS CELL DEV BI.
   Moxley KM, 2016, GENES CANCER, V7, P169, DOI 10.18632/genesandcancer.109.
   Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463.
   Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Raimondi C, 2012, J CELL SCI.
   Scortegagna M, 2015, CANC RES.
   Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012.
   Wang JR, 2016, ONCOTARGETS THER, V9, P5597, DOI 10.2147/OTT.S110646.
   Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002.
   Wu YH, 2015, ONCOTARGET, V6, P23748, DOI 10.18632/oncotarget.4250.
   Zhang SB, 2018, ONCOL LETT, V15, P2105, DOI 10.3892/ol.2017.7551.},
Number-of-Cited-References = {35},
Times-Cited = {16},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {6},
Journal-ISO = {J. Exp. Clin. Cancer Res.},
Doc-Delivery-Number = {HY3PA},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000468037500002},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000469170500001,
Author = {Wang, Guofang and Liu, Xiaomei and Xie, Jiali and Meng, Jinfei and Ni,
   Xiaoqin},
Title = {PDK-1 mediated Hippo-YAP-IRS2 signaling pathway and involved in the
   apoptosis of non-small cell lung cancer cells},
Journal = {BIOSCIENCE REPORTS},
Year = {2019},
Volume = {39},
Number = {5},
Month = {MAY 14},
Abstract = {Pyruvate dehydrogenase kinase-1 (PDK-1), a gatekeeper enzyme, was
   involved in cancer progression, such as tumor angiogenesis, cell
   survival, and growth. Recent evidence indicated that PDK-1 may be
   involved in lung cancer, however, the function and underlying mechanism
   of PDK-1 is remaining unclear. In the present study, our aim was to
   investigate the role and mechanisms of PDK-1 in human non-small cell
   lung cancer (NSCLC) cells. We first observed that PDK-1 was highly
   expressed in NSCLC cell lines. PDK-1 silence resulted in the inhibition
   of NSCLC cell survival. Also, cell apoptosis and caspase-3 activity were
   increased by PDK-1 knockdown in H1299 and A549 cells. Attenuation of
   PDK-1 expression blocked YAP and insulin receptor substrate 2 (IRS2)
   expression, and PDK-1 silence suppressed IRS2 expression dependent on
   Hippo-YAP signaling pathway. Moreover, further studies confirmed that
   YAP or IRS2 overexpression reversed the action of PDK-1 in NSCLC cells.
   In conclusion, our findings indicate that PDK1/Hippo-YAP/IRS2 signaling
   pathway plays a critical role in NSCLC cell survival and apoptosis.},
Publisher = {PORTLAND PRESS LTD},
Address = {CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Ni, XQ (Corresponding Author), Yanan Univ Affiliated Hosp, Resp Med, Yanan 716000, Peoples R China.
   Wang, Guofang; Xie, Jiali; Meng, Jinfei; Ni, Xiaoqin, Yanan Univ Affiliated Hosp, Resp Med, Yanan 716000, Peoples R China.
   Liu, Xiaomei, Yanan Univ Affiliated Hosp, Dept Nursing, Yanan 716000, Peoples R China.},
DOI = {10.1042/BSR20182099},
Article-Number = {BSR20182099},
ISSN = {0144-8463},
EISSN = {1573-4935},
Keywords-Plus = {PYRUVATE-DEHYDROGENASE KINASE-1; HIPPO PATHWAY; CONTACT INHIBITION; YAP
   ACTIVATION; EXPRESSION; PROLIFERATION; CARCINOMA; MAPK},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {xiaoqin\_ni1@163.com},
Affiliations = {Yanan University; Yanan University},
Cited-References = {Baumunk D, 2013, WORLD J UROL, V31, P1191, DOI 10.1007/s00345-012-0874-5.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527.
   Gerber DE, 2013, J CLIN ONCOL, V31, P1009, DOI 10.1200/JCO.2012.43.7459.
   Gridelli C, 2015, NAT REV DIS PRIMERS, V1, DOI {[}10.1038/nrdp.2015.48, 10.1038/nrdp.2015.9, 10.1038/nrdp.2015.48].
   Hong AW, 2017, EMBO REP, V18, P72, DOI 10.15252/embr.201642681.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Jeong SH, 2018, BMB REP, V51, P209, DOI 10.5483/BMBRep.2018.51.5.095.
   Jeong SH, 2018, J CLIN INVEST, V128, P1010, DOI 10.1172/JCI95802.
   Jha Mithilesh Kumar, 2013, Brain Tumor Res Treat, V1, P57, DOI 10.14791/btrt.2013.1.2.57.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Kim NG, 2015, J CELL BIOL, V210, P503, DOI 10.1083/jcb.201501025.
   Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373.
   Leighl NB, 2012, CURR ONCOL, V19, pS52, DOI 10.3747/co.19.1114.
   Ling HH, 2017, EXP CELL RES, V350, P218, DOI 10.1016/j.yexcr.2016.11.024.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Mayrhofer M, 2017, DIS MODEL MECH, V10, P15, DOI 10.1242/dmm.026500.
   Muranen T, 2016, CANCER RES, V76, P7168, DOI 10.1158/0008-5472.CAN-16-0155.
   Nallet-Staub F, 2014, J INVEST DERMATOL, V134, P123, DOI 10.1038/jid.2013.319.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Pierson J, 2008, J NEURO-ONCOL, V90, P1, DOI 10.1007/s11060-008-9624-3.
   Saladi SV, 2017, CANCER CELL, V31, P35, DOI 10.1016/j.ccell.2016.12.001.
   Sharma A, 2017, BIOCHIMIE, V133, P56, DOI 10.1016/j.biochi.2016.12.009.
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166.
   Strassburger K, 2012, DEV BIOL, V367, P187, DOI 10.1016/j.ydbio.2012.05.008.
   Sutendra G, 2014, CELL, V158, P84, DOI 10.1016/j.cell.2014.04.046.
   Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221.
   Tumaneng K, 2012, CURR BIOL, V22, pR368, DOI 10.1016/j.cub.2012.03.003.
   Wan J, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0399-7.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V296, P877, DOI 10.1016/S0006-291X(02)00940-3.
   Yeung B, 2016, INT J CANCER, V138, P533, DOI 10.1002/ijc.29457.
   You B, 2015, ONCOTARGET, V6, P4357, DOI 10.18632/oncotarget.2974.
   Zhang C, 2018, ONCOTARGET, V9, P2175, DOI {[}10.18632/oncotarget.24040, 10.18632/oncotarget.25667, 10.18632/oncotarget.23299, 10.18632/oncotarget.25667].
   Zhang W, 2015, INT J BIOL SCI, V11, P1390, DOI 10.7150/ijbs.13325.
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907.
   Zheng CH, 2018, CELL BIOL INT, V42, P1386, DOI 10.1002/cbin.11024.},
Number-of-Cited-References = {38},
Times-Cited = {17},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Biosci. Rep.},
Doc-Delivery-Number = {HZ9JB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000469170500001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000470153300023,
Author = {Hong, Sun Mi and Lee, Young-Kyoung and Park, Imkyong and Kwon, So Mee
   and Min, Seongki and Yoon, Gyesoon},
Title = {Lactic acidosis caused by repressed lactate dehydrogenase subunit B
   expression down-regulates mitochondrial oxidative phosphorylation via
   the pyruvate dehydrogenase (PDH)-PDH kinase axis},
Journal = {JOURNAL OF BIOLOGICAL CHEMISTRY},
Year = {2019},
Volume = {294},
Number = {19},
Pages = {7810-7820},
Month = {MAY 10},
Abstract = {Aerobic glycolysis and mitochondrial dysfunction are key metabolic
   features of cancer cells, but their interplay during cancer development
   remains unclear. We previously reported that human hepatoma cells with
   mitochondrial defects exhibit down-regulated lactate dehydrogenase
   subunit B (LDHB) expression. Here, using several molecular and
   biochemical assays and informatics analyses, we investigated how LDHB
   suppression regulates mitochondrial respiratory activity and contributes
   to liver cancer progression. We found that transcriptional LDHB
   down-regulation is an upstream event during suppressed oxidative
   phosphorylation. We also observed that LDHB knockdown increases
   inhibitory phosphorylation of pyruvate dehydrogenase (PDH) via
   lactate-mediated PDH kinase (PDK) activation and thereby attenuates
   oxidative phosphorylation activity. Interestingly, monocarboxylate
   transporter 1 was the major lactate transporter in hepatoma cells, and
   its expression was essential for PDH phosphorylation by modulating
   intracellular lactate levels. Finally, bioinformatics analysis of the
   hepatocellular carcinoma cohort from The Cancer Genome Atlas revealed
   that a low LDHB/LDHA ratio is statistically significantly associated
   with poor prognostic outcomes. A low ratio was also associated with a
   significant enrichment in glycolysis genes and negatively correlated
   with PDK1 and 2 expression, supporting a close link between LDHB
   suppression and the PDK-PDH axis. These results suggest that LDHB
   suppression is a key mechanism that enhances glycolysis and is
   critically involved in the maintenance and propagation of mitochondrial
   dysfunction via lactate release in liver cancer progression.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Yoon, G (Corresponding Author), Ajou Univ, Sch Med, Dept Biochem, Suwon 16499, South Korea.
   Hong, Sun Mi; Lee, Young-Kyoung; Park, Imkyong; Kwon, So Mee; Min, Seongki; Yoon, Gyesoon, Ajou Univ, Sch Med, Dept Biochem, Suwon 16499, South Korea.
   Hong, Sun Mi; Park, Imkyong; Min, Seongki; Yoon, Gyesoon, Ajou Univ, Sch Med, Dept Biomed Sci BK21 Plus, Suwon 16499, South Korea.},
DOI = {10.1074/jbc.RA118.006095},
EISSN = {1083-351X},
Keywords = {hepatocellular carcinoma; lactic acid; mitochondria; pyruvate
   dehydrogenase complex (PDC); liver cancer; mitochondrial respiratory
   chain complex},
Keywords-Plus = {MONOCARBOXYLATE TRANSPORTERS MCTS; CANCER; HYPOXIA; DYSFUNCTION;
   METABOLISM; TARGET; MYC; PROMOTES; ISOENZYMES; SIGNATURE},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {ypeace@ajou.ac.kr},
Affiliations = {Ajou University; Ajou University},
Funding-Acknowledgement = {Basic Science Research Program through the National Research Foundation
   - Ministry of Science, ICT, and Future Planning of Korea
   {[}2012R1A5A2048183, 2015R1A2 A1A10055038, 2016R1A6A3A11932420]},
Funding-Text = {This work was supported by Grants 2012R1A5A2048183, 2015R1A2
   A1A10055038, and 2016R1A6A3A11932420 from the Basic Science Research
   Program through the National Research Foundation funded by the Ministry
   of Science, ICT, and Future Planning of Korea. The authors declare that
   they have no conflicts of interest with the contents of this article.},
Cited-References = {Chang C. J., 2009, CELL MOL LIFE SCI, V66, P1755, DOI {[}10.1007/s00018-009-8767-519337692, DOI 10.1007/S00018-009-8767-519337692].
   Chen EI, 2012, J BIOENERG BIOMEMBR, V44, P619, DOI 10.1007/s10863-012-9465-9.
   Cuezva JM, 2002, CANCER RES, V62, P6674.
   Cui JJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0589-8.
   Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274.
   Dang CV, 1999, MOL CELL BIOL, V19, P1.
   Doherty JR, 2014, CANCER RES, V74, P908, DOI 10.1158/0008-5472.CAN-13-2034.
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741.
   Drent M, 1996, EUR RESPIR J, V9, P1736, DOI 10.1183/09031936.96.09081736.
   Enerson BE, 2003, J PHARM SCI-US, V92, P1531, DOI 10.1002/jps.10389.
   Fan J, 2014, J BIOL CHEM, V289, P26533, DOI 10.1074/jbc.M114.593970.
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478.
   Guo M, 2006, APOPTOSIS, V11, P67, DOI 10.1007/s10495-005-3085-3.
   Halestrap AP, 2012, IUBMB LIFE, V64, P109, DOI 10.1002/iub.572.
   Halestrap AP, 2012, IUBMB LIFE, V64, P1, DOI 10.1002/iub.573.
   Halestrap AP, 2004, PFLUG ARCH EUR J PHY, V447, P619, DOI 10.1007/s00424-003-1067-2.
   Harris RA, 2002, ADV ENZYME REGUL, V42, P249, DOI 10.1016/S0065-2571(01)00061-9.
   Hiromasa Y, 2004, J BIOL CHEM, V279, P6921, DOI 10.1074/jbc.M308172200.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hsu CC, 2016, EXP BIOL MED, V241, P1281, DOI 10.1177/1535370216641787.
   Hung WY, 2012, BBA-GEN SUBJECTS, V1820, P1102, DOI 10.1016/j.bbagen.2012.04.016.
   Ji YP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15308.
   Jin L, 2017, ONCOGENE, V36, P3797, DOI 10.1038/onc.2017.6.
   Kamp WM, 2016, CURR OPIN GENET DEV, V38, P16, DOI 10.1016/j.gde.2016.02.007.
   Kato Y, 2018, JPN DENT SCI REV, V54, P8, DOI 10.1016/j.jdsr.2017.08.003.
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643.
   Kim JH, 2011, EXP CELL RES, V317, P1108, DOI 10.1016/j.yexcr.2011.02.011.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Koukourakis MI, 2003, BRIT J CANCER, V89, P877, DOI 10.1038/sj.bjc.6601205.
   Koukourakis MI, 2005, CLIN EXP METASTAS, V22, P25, DOI 10.1007/s10585-005-2343-7.
   Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011.
   Lee YK, 2017, J BIOL CHEM, V292, P20208, DOI 10.1074/jbc.M117.809012.
   Lee YK, 2015, HEPATOLOGY, V62, P1174, DOI 10.1002/hep.27976.
   Lewis BC, 2000, CANCER RES, V60, P6178.
   Lutz NW, 2013, CANCER RES, V73, P4616, DOI 10.1158/0008-5472.CAN-13-0767.
   Ma JC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064912.
   Maekawa M, 2003, CLIN CHEM, V49, P1518, DOI 10.1373/49.9.1518.
   Miao P, 2013, IUBMB LIFE, V65, P904, DOI 10.1002/iub.1216.
   Miranda-Gonçalves V, 2013, NEURO-ONCOLOGY, V15, P172, DOI 10.1093/neuonc/nos298.
   Parks SK, 2013, NAT REV CANCER, V13, P611, DOI 10.1038/nrc3579.
   Pérez-Escuredo J, 2016, BBA-MOL CELL RES, V1863, P2481, DOI 10.1016/j.bbamcr.2016.03.013.
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500.
   Romero-Garcia S, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00052.
   Ruan GX, 2013, J BIOL CHEM, V288, P21161, DOI 10.1074/jbc.M113.474619.
   San-Millán I, 2017, CARCINOGENESIS, V38, P119, DOI 10.1093/carcin/bgw127.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230.
   Singh KK, 2004, ANN NY ACAD SCI, V1019, P260, DOI 10.1196/annals.1297.043.
   Srinivasan S, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1085120.
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102.
   Thomson JM, 2005, NAT GENET, V37, P630, DOI 10.1038/ng1553.
   Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299.
   Walenta S, 2004, CURR MED CHEM, V11, P2195, DOI 10.2174/0929867043364711.
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309.},
Number-of-Cited-References = {55},
Times-Cited = {41},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {21},
Journal-ISO = {J. Biol. Chem.},
Doc-Delivery-Number = {IB3FL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000470153300023},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000469884900031,
Author = {Ghanakota, Phani and DasGupta, Debarati and Carlson, Heather A.},
Title = {Free Energies and Entropies of Binding Sites Identified by MixMD
   Cosolvent Simulations},
Journal = {JOURNAL OF CHEMICAL INFORMATION AND MODELING},
Year = {2019},
Volume = {59},
Number = {5, SI},
Pages = {2035-2045},
Month = {MAY},
Abstract = {In our recent efforts to map protein surfaces using mixed-solvent
   molecular dynamics (MixMD) (Ghanakota, P.; Carlson, H. A. Moving Beyond
   Active-Site Detection: MixMD Applied to Allosteric Systems. J. Phys.
   Chem. B 2016, 120, 8685-8695), we were able to successfully capture
   active sites and allosteric sites within the top-four most occupied
   hotspots. In this study, we describe our approach for estimating the
   thermodynamic profile of the binding sites identified by MixMD. First,
   we establish a framework for calculating free energies from MixMD
   simulations, and we compare our approach to alternative methods. Second,
   we present a means to obtain a relative ranking of the binding sites by
   their configurational entropy. The theoretical maximum and minimum free
   energy and entropy values achievable under such a framework along with
   the limitations of the techniques are discussed. Using this approach,
   the free energy and relative entropy ranking of the top-four MixMD
   binding sites were computed and analyzed across our allosteric protein
   targets: Abl Kinase, Androgen Receptor, Pdkl Kinase, Farnesyl
   Pyrophosphate Synthase, Chk1 Kinase, Glucokinase, and Protein Tyrosine
   Phosphatase 1B.},
Publisher = {AMER CHEMICAL SOC},
Address = {1155 16TH ST, NW, WASHINGTON, DC 20036 USA},
Type = {Article},
Language = {English},
Affiliation = {Carlson, HA (Corresponding Author), Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.
   Ghanakota, Phani; DasGupta, Debarati; Carlson, Heather A., Univ Michigan, Coll Pharm, Dept Med Chem, 428 Church St, Ann Arbor, MI 48109 USA.},
DOI = {10.1021/acs.jcim.8b00925},
ISSN = {1549-9596},
EISSN = {1549-960X},
Keywords-Plus = {MOLECULAR-DYNAMICS; INHIBITION; PROTEINS; AFFINITY},
Research-Areas = {Pharmacology \& Pharmacy; Chemistry; Computer Science},
Web-of-Science-Categories  = {Chemistry, Medicinal; Chemistry, Multidisciplinary; Computer Science,
   Information Systems; Computer Science, Interdisciplinary Applications},
Author-Email = {carlsonh@umich.edu},
Affiliations = {University of Michigan System; University of Michigan},
ResearcherID-Numbers = {DasGupta, Debarati/AAR-6654-2021
   },
ORCID-Numbers = {Carlson, Heather/0000-0002-7495-1699
   DasGupta, Debarati/0000-0002-6289-5749
   Ghanakota, Phani/0000-0002-2249-3681},
Funding-Acknowledgement = {National Institutes of Health {[}R01 GM065372]; National Institute of
   General Medical Sciences {[}R01GM065372] Funding Source: NIH RePORTER},
Funding-Text = {We thank Dr. Charles L. Brooks III for providing access to the Gollum
   clusters at the University of Michigan. We also thank the IBM Matching
   Grants Program for granting the GPU units for high-performance MD
   simulations. We greatly appreciate the generous donation of the MOE
   software from Chemical Computing Group. This work has been supported by
   the National Institutes of Health (R01 GM065372).},
Cited-References = {Ala PJ, 2006, J BIOL CHEM, V281, P32784, DOI 10.1074/jbc.M606873200.
   Alvarez-Garcia D, 2014, J CHEM THEORY COMPUT, V10, P2608, DOI 10.1021/ct500182z.
   Åqvist J, 2002, ACCOUNTS CHEM RES, V35, P358, DOI 10.1021/ar010014p.
   Bakan A, 2012, J CHEM THEORY COMPUT, V8, P2435, DOI 10.1021/ct300117j.
   Case D.A., 2016, AMBER16.
   De Jesus-Tran KP, 2006, PROTEIN SCI, V15, P987, DOI 10.1110/ps.051905906.
   Erlanson DA, 2016, NAT REV DRUG DISCOV, V15, P605, DOI 10.1038/nrd.2016.109.
   Faller Christina E, 2015, Methods Mol Biol, V1289, P75, DOI 10.1007/978-1-4939-2486-8\_7.
   Ghanakota P, 2016, J MED CHEM, V59, P10383, DOI 10.1021/acs.jmedchem.6b00399.
   Ghanakota P, 2016, J PHYS CHEM B, V120, P8685, DOI 10.1021/acs.jpcb.6b03515.
   Huang DZ, 2014, CHEMMEDCHEM, V9, P573, DOI 10.1002/cmdc.201300156.
   Huang DZ, 2011, CHEMMEDCHEM, V6, P1578, DOI 10.1002/cmdc.201100237.
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869.
   Klebe G, 2015, NAT REV DRUG DISCOV, V14, P95, DOI 10.1038/nrd4486.
   Kuntz ID, 1999, P NATL ACAD SCI USA, V96, P9997, DOI 10.1073/pnas.96.18.9997.
   Lexa KW, 2014, J CHEM INF MODEL, V54, P2190, DOI 10.1021/ci400741u.
   Lexa KW, 2013, J CHEM INF MODEL, V53, P391, DOI 10.1021/ci300430v.
   Lexa KW, 2012, Q REV BIOPHYS, V45, P301, DOI 10.1017/S0033583512000066.
   Lexa KW, 2011, J AM CHEM SOC, V133, P200, DOI 10.1021/ja1079332.
   Lin YS, 2012, J MED CHEM, V55, P3201, DOI 10.1021/jm201657x.
   Merkul E, 2011, ORG BIOMOL CHEM, V9, P5129, DOI 10.1039/c1ob05586k.
   Nguyen CN, 2012, J CHEM PHYS, V137, DOI 10.1063/1.4733951.
   Oleinikovas V, 2016, J AM CHEM SOC, V138, P14257, DOI 10.1021/jacs.6b05425.
   Petit P, 2011, ACTA CRYSTALLOGR D, V67, P929, DOI 10.1107/S0907444911036729.
   Raman EP, 2015, J AM CHEM SOC, V137, P2608, DOI 10.1021/ja512054f.
   Raman EP, 2011, J CHEM INF MODEL, V51, P877, DOI 10.1021/ci100462t.
   Roe DR, 2013, J CHEM THEORY COMPUT, V9, P3084, DOI 10.1021/ct400341p.
   RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5.
   Seco J, 2009, J MED CHEM, V52, P2363, DOI 10.1021/jm801385d.
   Smith RD, 2012, J CHEM INF MODEL, V52, P2098, DOI {[}10.1021/ci200612f, 10.1021/cI2006612f].
   Stavenger R. A., CITATION STRUCTURE I.
   Suárez D, 2015, WIRES COMPUT MOL SCI, V5, P1, DOI 10.1002/wcms.1195.
   Tan YS, 2014, J CHEM INF MODEL, V54, P1821, DOI 10.1021/ci500215x.
   Ung PMU, 2016, BIOPOLYMERS, V105, P21, DOI 10.1002/bip.22742.
   Zhou TJ, 2010, CHEM BIOL DRUG DES, V75, P18, DOI 10.1111/j.1747-0285.2009.00905.x.},
Number-of-Cited-References = {35},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {18},
Journal-ISO = {J. Chem Inf. Model.},
Doc-Delivery-Number = {IA9NW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000469884900031},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000462916400020,
Author = {Moure, Anne and Bacou, Elodie and Bosch, Steffi and Jegou, Dominique and
   Salama, Apolline and Riochet, David and Gauthier, Olivier and Blancho,
   Gilles and Soulillou, Jean-Paul and Poncelet, Denis and Olmos, Eric and
   Bach, Jean-Marie and Mosser, Mathilde},
Title = {Extracellular hemoglobin combined with an O2-generating
   material overcomes O2 limitation in the bioartificial
   pancreas},
Journal = {BIOTECHNOLOGY AND BIOENGINEERING},
Year = {2019},
Volume = {116},
Number = {5},
Pages = {1176-1189},
Month = {MAY},
Abstract = {The bioartificial pancreas encapsulating pancreatic islets in
   immunoprotective hydrogel is a promising therapy for Type 1 diabetes. As
   pancreatic islets are highly metabolically active and exquisitely
   sensitive to hypoxia, maintaining O-2 supply after transplantation
   remains a major challenge. In this study, we address the O-2 limitation
   by combining silicone-encapsulated CaO2 (silicone-CaO2) to generate O-2
   with an extracellular hemoglobin O-2-carrier coencapsulated with islets.
   We showed that the hemoglobin improved by 37\% the O-2-diffusivity
   through an alginate hydrogel and displayed antioxidant properties
   neutralizing deleterious reactive O-2 species produced by silicone-CaO2.
   While the hemoglobin alone failed to maintain alginate macroencapsulated
   neonate pig islets under hypoxia, silicone-CaO2 alone or combined to the
   hemoglobin restored islet viability and insulin secretion and prevented
   proinflammatory metabolism (PTGS2 expression). Interestingly, the
   combination took the advantages of the two individual strategies,
   improved neonate pig islet viability and insulin secretion in normoxia,
   and VEGF secretion and PDK1 normalization in hypoxia. Moreover, we
   confirmed the specific benefits of the combination compared to
   silicone-CaO2 alone on murine pseudo-islet viability in normoxia and
   hypoxia. For the first time, our results show the interest of combining
   an O-2 provider with hemoglobin as an effective strategy to overcome O-2
   limitations in tissue engineering.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Bach, JM; Mosser, M (Corresponding Author), Immunoendocrinol Unit, CS40706, F-44307 Nantes 03, France.
   Moure, Anne; Bacou, Elodie; Bosch, Steffi; Jegou, Dominique; Salama, Apolline; Bach, Jean-Marie; Mosser, Mathilde, Univ Bretagne Loire, Immunoendocrinol Unit IECM, INRA, Oniris, Nantes, France.
   Salama, Apolline; Blancho, Gilles; Soulillou, Jean-Paul, Univ Nantes, Ctr Rech Transplantat \& Immunol UMR 1064, INSERM, Nantes, France.
   Riochet, David, CHU Nantes, Serv Pediat Malad Chron, Nantes, France.
   Gauthier, Olivier, Oniris, CRIP, Dept Expt Surg, Nantes, France.
   Blancho, Gilles; Soulillou, Jean-Paul, CHU Nantes, ITUN, Nantes, France.
   Poncelet, Denis, Oniris, UMR CNRS 6144, Dept Proc Engn Environm \& Food Lab GEPEA, Nantes, France.
   Olmos, Eric, Univ Lorraine, CNRS, LRGP, Nancy, France.},
DOI = {10.1002/bit.26913},
ISSN = {0006-3592},
EISSN = {1097-0290},
Keywords = {bioartificial pancreas; extracellular hemoglobin; oxygen supply;
   pancreatic islet; tissue engineering; Type 1 diabetes},
Keywords-Plus = {MARINE OXYGEN CARRIER; ISLET XENOTRANSPLANTATION; INSULIN-SECRETION;
   RAT; HYPOXIA; TRANSPLANTATION; EXPRESSION; TENSION; STRESS; CELLS},
Research-Areas = {Biotechnology \& Applied Microbiology},
Web-of-Science-Categories  = {Biotechnology \& Applied Microbiology},
Author-Email = {jean-marie.bach@oniris-nantes.fr
   mathilde.mosser@oniris-nantes.fr},
Affiliations = {Oniris VetAgroBio Nantes; INRAE; Nantes Universite; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de
   Nantes; Oniris VetAgroBio Nantes; Nantes Universite; CHU de Nantes;
   Oniris VetAgroBio Nantes; Universite de Lorraine; Centre National de la
   Recherche Scientifique (CNRS)},
ResearcherID-Numbers = {Salama, Apolline/A-9750-2013
   Bach, Jean-Marie/AAR-1086-2020
   Bosch, Steffi/A-1557-2009
   },
ORCID-Numbers = {Bach, Jean-Marie/0000-0002-5265-8854
   Mouré, Anne/0000-0002-1891-3698
   Bosch, Steffi/0000-0002-0995-2775
   Mosser, Mathilde/0000-0003-3556-292X},
Funding-Acknowledgement = {Agence Nationale de la Recherche (ECTIS IHU program, France)
   {[}ANR-10-IBHU-005]; Pays de la Loire Region (Xenothera program, Nantes,
   France) {[}2011-1296]; University of Nantes (Interdisciplinary program,
   Nantes, France) {[}2017-2203]},
Funding-Text = {Agence Nationale de la Recherche (ECTIS IHU program, France),
   Grant/Award Number: ANR-10-IBHU-005; Pays de la Loire Region (Xenothera
   program, Nantes, France), Grant/Award Number: 2011-1296; University of
   Nantes (Interdisciplinary program, Nantes, France), Grant/Award Number:
   2017-2203},
Cited-References = {Alayash AI, 2014, TRENDS BIOTECHNOL, V32, P177, DOI 10.1016/j.tibtech.2014.02.006.
   Llacua LA, 2018, DIABETOLOGIA, V61, P1261, DOI 10.1007/s00125-017-4524-8.
   Avila JG, 2006, AM J TRANSPLANT, V6, P2861, DOI 10.1111/j.1600-6143.2006.01551.x.
   Barkai Uriel, 2016, World J Transplant, V6, P69, DOI {[}10.5500/wjt.v6.i1.69, 10.5500/wjt.v6.i1.69].
   Brandhorst D, 2016, CELL TRANSPLANT, V25, P1539, DOI 10.3727/096368915X689929.
   Camci-Unal G, 2013, POLYM INT, V62, P843, DOI 10.1002/pi.4502.
   Cantley J, 2013, CELL TRANSPLANT, V22, P2147, DOI 10.3727/096368912X658728.
   Carlsson PO, 2018, AM J TRANSPLANT, V18, P1735, DOI 10.1111/ajt.14642.
   Carlsson PO, 2002, TRANSPL INT, V15, P581, DOI 10.1007/s00147-002-0460-7.
   Carlsson PO, 2001, DIABETES, V50, P489, DOI 10.2337/diabetes.50.3.489.
   Coronel MM, 2017, BIOMATERIALS, V129, P139, DOI 10.1016/j.biomaterials.2017.03.018.
   Dahlgren Claes, 2007, V412, P349, DOI 10.1007/978-1-59745-467-4\_23.
   de Groot M, 2003, CELL TRANSPLANT, V12, P867, DOI 10.3727/000000003771000219.
   DIONNE KE, 1993, DIABETES, V42, P12, DOI 10.2337/diabetes.42.1.12.
   Dufrane D, 2010, TRANSPLANTATION, V90, P1054, DOI 10.1097/TP.0b013e3181f6e267.
   Dulong JL, 2007, BIOTECHNOL BIOENG, V96, P990, DOI 10.1002/bit.21140.
   Elliott RB, 2011, CURR OPIN ORGAN TRAN, V16, P195, DOI 10.1097/MOT.0b013e3283449dec.
   Emamaullee JA, 2006, TRANSPLANTATION, V82, P945, DOI 10.1097/01.tp.0000238677.00750.32.
   Everse J, 1997, FREE RADICAL BIO MED, V22, P1075, DOI 10.1016/S0891-5849(96)00499-6.
   Forget A, 2017, ACS BIOMATER SCI ENG, V3, P2384, DOI 10.1021/acsbiomaterials.7b00297.
   Giuliani M, 2005, CELL TRANSPLANT, V14, P67, DOI 10.3727/000000005783983287.
   González-Sánchez MI, 2011, ARCH BIOCHEM BIOPHYS, V516, P10, DOI 10.1016/j.abb.2011.09.006.
   Goto M, 2010, TRANSPL P, V42, P2040, DOI 10.1016/j.transproceed.2010.05.101.
   Hals IK, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/374925.
   Jansson L, 2002, DIABETOLOGIA, V45, P749, DOI 10.1007/s00125-002-0827-4.
   Jones GL, 2007, CELL TRANSPLANT, V16, P505, DOI 10.3727/000000007783464993.
   Khattak SF, 2007, BIOTECHNOL BIOENG, V96, P156, DOI 10.1002/bit.21151.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Komatsu H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183780.
   Korbutt GS, 1996, J CLIN INVEST, V97, P2119, DOI 10.1172/JCI118649.
   Lablanche S, 2015, DIABETES CARE, V38, P1714, DOI 10.2337/dc15-0094.
   Lai Y, 2009, ISLETS, V1, P19, DOI 10.4161/isl.1.1.8530.
   Le Pape F, 2018, ARTIF CELL NANOMED B, V46, P95, DOI 10.1080/21691401.2017.1365724.
   Le Pape F, 2017, ARTIF ORGANS, V41, P359, DOI 10.1111/aor.12892.
   Le Pape F, 2015, ARTIF CELL NANOMED B, V43, P186, DOI 10.3109/21691401.2015.1029632.
   Lee EM, 2018, XENOTRANSPLANTATION, V25, DOI 10.1111/xen.12378.
   Lenzen S, 1996, FREE RADICAL BIO MED, V20, P463, DOI 10.1016/0891-5849(96)02051-5.
   Li N, 2009, J BIOL CHEM, V284, P23602, DOI 10.1074/jbc.M109.024323.
   Ludwig B, 2017, P NATL ACAD SCI USA, V114, P11745, DOI 10.1073/pnas.1708420114.
   Ludwig B, 2013, P NATL ACAD SCI USA, V110, P19054, DOI 10.1073/pnas.1317561110.
   Maechler P, 1999, J BIOL CHEM, V274, P27905, DOI 10.1074/jbc.274.39.27905.
   Matsumoto S, 2016, EBIOMEDICINE, V12, P255, DOI 10.1016/j.ebiom.2016.08.034.
   McQuilling JP, 2017, BIOMATER SCI-UK, V5, P2437, DOI 10.1039/c7bm00790f.
   MENGER MD, 1989, DIABETES, V38, P199, DOI 10.2337/diab.38.1.S199.
   Morini S, 2007, J ANAT, V210, P565, DOI 10.1111/j.1469-7580.2007.00717.x.
   Moritz W, 2002, FASEB J, V16, P745, DOI 10.1096/fj.01-0403fje.
   Naziruddin B, 2014, AM J TRANSPLANT, V14, P428, DOI 10.1111/ajt.12558.
   Okere B, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0273-4.
   Pedraza E, 2012, P NATL ACAD SCI USA, V109, P4245, DOI 10.1073/pnas.1113560109.
   RICORDI C, 1990, ACTA DIABETOL LAT, V27, P185, DOI 10.1007/BF02581331.
   Rodriguez-Brotons A, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/3615286.
   Rodriguez-Brotons A, 2016, TISSUE ENG PT A, V22, P1327, DOI 10.1089/ten.tea.2016.0064.
   Rousselot Morgane, 2006, Biotechnology Journal, V1, P333, DOI 10.1002/biot.200500049.
   Sato Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114868.
   Sato Y, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.194738.
   Schrezenmeir J, 2001, TRANSPLANT P, V33, P3511, DOI 10.1016/S0041-1345(01)02418-6.
   Shapiro AMJ, 2006, NEW ENGL J MED, V355, P1318, DOI 10.1056/NEJMoa061267.
   Tiedge M, 1998, DIABETES, V47, P1578, DOI 10.2337/diabetes.47.10.1578.
   Vasir B, 1998, DIABETES, V47, P1894, DOI 10.2337/diabetes.47.12.1894.
   Vivot K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107656.
   Xiong FL, 2006, EUR J PHARMACOL, V529, P1, DOI 10.1016/j.ejphar.2005.10.024.},
Number-of-Cited-References = {61},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {43},
Journal-ISO = {Biotechnol. Bioeng.},
Doc-Delivery-Number = {HR1SX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000462916400020},
DA = {2026-02-04},
}

@article{ WOS:000466707400005,
Author = {Mucha, Bettina E. and Banka, Siddharth and Ajeawung, Norbert Fonya and
   Molidperee, Sirinart and Chen, Gary G. and Koenig, Mary Kay and Adejumo,
   Rhamat B. and Till, Marianne and Harbord, Michael and Perrier, Renee and
   Lemyre, Emmanuelle and Boucher, Renee-Myriam and Skotko, Brian G. and
   Waxler, Jessica L. and Thomas, Mary Ann and Hodge, Jennelle C. and Gecz,
   Jozef and Nicholl, Jillian and McGregor, Lesley and Linden, Tobias and
   Sisodiya, Sanjay M. and Sanlaville, Damien and Cheung, Sau W. and Ernst,
   Carl and Campeau, Philippe M.},
Title = {A new microdeletion syndrome involving TBC1D24, ATP6V0C, and
   PDPK1 causes epilepsy, microcephaly, and developmental delay},
Journal = {GENETICS IN MEDICINE},
Year = {2019},
Volume = {21},
Number = {5},
Pages = {1058-1064},
Month = {MAY},
Abstract = {Purpose: Contiguous gene deletions are known to cause several
   neurodevelopmental syndromes, many of which are caused by recurrent
   events on chromosome 16. However, chromosomal microarray studies (CMA)
   still yield copy-number variants (CNVs) of unknown clinical
   significance. We sought to characterize eight individuals with
   overlapping 205-kb to 504-kb 16p13.3 microdeletions that are distinct
   from previously published deletion syndromes.
   Methods: Clinical information on the patients and bioinformatic scores
   for the deleted genes were analyzed.
   Results: All individuals in our cohort displayed developmental delay,
   intellectual disability, and various forms of seizures. Six individuals
   were microcephalic and two had strabismus. The deletion was absent in
   all 13 parents who were available for testing. The area of overlap
   encompasses seven genes including TBC1D24, ATP6V0C, and PDPK1 (also
   known as PDK1). Bi-allelic TBC1D24 pathogenic variants are known to
   cause nonsyndromic deafness, epileptic disorders, or DOORS syndrome
   (deafness, onychodystrophy, osteodystrophy, mental retardation,
   seizures). Sanger sequencing of the nondeleted TBC1D24 allele did not
   yield any additional pathogenic variants.
   Conclusions: We propose that 16p13.3 microdeletions resulting in
   simultaneous haploinsufficiencies of TBC1D24, ATP6V0C, and PDPK1 cause a
   novel rare contiguous gene deletion syndrome of microcephaly,
   developmental delay, intellectual disability, and epilepsy.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Campeau, PM (Corresponding Author), Univ Montreal, Dept Pediat, Montreal, PQ, Canada.
   Mucha, Bettina E., McGill Univ, Div Med Genet, Ctr Hlth, Dept Specialized Med, Montreal, PQ, Canada.
   Banka, Siddharth, Univ Manchester, Sch Biol Sci, Div Evolut \& Genom Sci, Fac Biol, Manchester M13 9PL, Lancs, England.
   Ajeawung, Norbert Fonya; Molidperee, Sirinart, CHU St Justine, Ctr Rech, Montreal, PQ, Canada.
   Chen, Gary G.; Ernst, Carl, McGill Univ, Dept Psychiat, Montreal, PQ, Canada.
   Koenig, Mary Kay; Adejumo, Rhamat B., Univ Texas McGovern Med Sch, Dept Pediat, Div Child \& Adolescent Neurol, Houston, TX USA.
   Till, Marianne; Sanlaville, Damien, CHU Lyon GH Est, Serv Genet, Lyon, France.
   Harbord, Michael, Flinders Med Ctr, Dept Pediat, Bedford Pk, SA, Australia.
   Perrier, Renee; Thomas, Mary Ann, Univ Calgary, Dept Med Genet, Calgary, AB, Canada.
   Lemyre, Emmanuelle; Campeau, Philippe M., Univ Montreal, Dept Pediat, Montreal, PQ, Canada.
   Boucher, Renee-Myriam, CHU Laval, Dept Pediat, Quebec City, PQ, Canada.
   Skotko, Brian G.; Waxler, Jessica L., Massachusetts Gen Hosp, Dept Pediat, Div Med Genet, Boston, MA 02114 USA.
   Hodge, Jennelle C., Indiana Univ Sch Med, Dept Med \& Mol Genet, Indianapolis, IN 46202 USA.
   Gecz, Jozef, Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   Gecz, Jozef, Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   Nicholl, Jillian; McGregor, Lesley, Womens \& Childrens Hosp, SA Pathol, South Australian Clin Genet Serv, Adelaide, SA, Australia.
   Linden, Tobias, Zentrum Kinder \& Jugendmed, Klin Neuropadiatrie \& Stoffwechselerkrankungen, Oldenburg, Germany.
   Sisodiya, Sanjay M., UCL, Inst Neurol, Dept Clin \& Expt Epilepsy, London, England.
   Sisodiya, Sanjay M., Chalfont Ctr Epilepsy, Gerrards Cross, Bucks, England.
   Cheung, Sau W., Baylor Coll Med, Dept Mol \& Human Genet, Houston, TX 77030 USA.},
DOI = {10.1038/s41436-018-0290-3},
ISSN = {1098-3600},
EISSN = {1530-0366},
Keywords = {Microdeletion; TBC1D24; Microcephaly; Epilepsy; 16p 13.3},
Keywords-Plus = {DE-NOVO MUTATIONS; PDK1; GENES; EXPRESSION; MIGRATION; SIZE},
Research-Areas = {Genetics \& Heredity},
Web-of-Science-Categories  = {Genetics \& Heredity},
Author-Email = {p.campeau@umontreal.ca},
Affiliations = {McGill University; University of Manchester; Universite de Montreal;
   Centre Hospitalier Universitaire Sainte-Justine; McGill University; CHU
   Lyon; Flinders Medical Centre; University of Calgary; Universite de
   Montreal; Laval University; Laval University Hospital; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Indiana University System; Indiana University Bloomington;
   Adelaide University; University of Adelaide; Robinson Research
   Institute; Adelaide University; University of Adelaide; SA Pathology;
   University of London; University College London; Baylor College of
   Medicine},
ResearcherID-Numbers = {Hodge, Jennelle/AAW-5082-2020
   Gecz, Jozef/X-3469-2019
   Campeau, Philippe/J-8614-2015
   sanlaville, damien/M-4716-2014
   Skotko, Brian/D-1375-2013
   },
ORCID-Numbers = {Harbord, Michael/0000-0002-3128-4670
   Banka, Siddharth/0000-0002-8527-2210
   Ernst, Carl/0000-0002-2959-221X
   Gecz, Jozef/0000-0002-7884-6861
   Campeau, Philippe/0000-0001-9713-7107
   sanlaville, damien/0000-0001-9939-2849
   Skotko, Brian/0000-0002-5232-9882
   Cheung, Sau W/0000-0002-3813-5256},
Cited-References = {Alvarez-Pérez MA, 2006, BONE, V38, P409, DOI 10.1016/j.bone.2005.09.009.
   {[}Anonymous], EUR J MED GENET.
   {[}Anonymous], 2017, GENOME MED.
   Balestrini S, 2016, NEUROLOGY, V87, P77, DOI 10.1212/WNL.0000000000002807.
   Banuelos Erika, 2017, F1000Res, V6, P553, DOI {[}10.12688/f1000research.10588.1, 10.12688/f1000research.10588.1].
   Bartsch O, 2006, HUM GENET, V120, P179, DOI 10.1007/s00439-006-0215-0.
   Bayascas JR, 2008, MOL CELL BIOL, V28, P3258, DOI 10.1128/MCB.02032-07.
   Bergfeld AK, 2012, J BIOL CHEM, V287, P28865, DOI 10.1074/jbc.M112.363549.
   Campeau PM, 2014, LANCET NEUROL, V13, P44, DOI 10.1016/S1474-4422(13)70265-5.
   Carvill GL, 2014, NEUROLOGY, V82, P1245, DOI 10.1212/WNL.0000000000000291.
   Chung AY, 2010, DEV DYNAM, V239, P2501, DOI 10.1002/dvdy.22383.
   Coe BP, 2014, NAT GENET, V46, P1063, DOI 10.1038/ng.3092.
   Cooper GM, 2011, NAT GENET, V43, P838, DOI 10.1038/ng.909.
   di Blasio L, 2015, J CELL SCI, V128, P863, DOI 10.1242/jcs.149294.
   Diaz SL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004241.
   Falace A, 2014, P NATL ACAD SCI USA, V111, P2337, DOI 10.1073/pnas.1316294111.
   Fischer B, 2016, NAT STRUCT MOL BIOL, V23, P965, DOI 10.1038/nsmb.3297.
   Fitzgerald TW, 2015, NATURE, V519, P223, DOI 10.1038/nature14135.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Ghebranious N, 2007, AM J MED GENET A, V143A, P1462, DOI 10.1002/ajmg.a.31837.
   Gilissen C, 2014, NATURE, V511, P344, DOI {[}10.1038/nature13394, 10.3389/fnhum.2013.00444].
   Hamdan FF, 2017, AM J HUM GENET, V101, P664, DOI 10.1016/j.ajhg.2017.09.008.
   Helbig KL, 2016, GENET MED, V18, P898, DOI 10.1038/gim.2015.186.
   Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3.
   Huang N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001154.
   Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1.
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057.
   Li W, 2015, BIOCHEM BIOPH RES CO, V464, P881, DOI 10.1016/j.bbrc.2015.07.057.
   Männik K, 2015, JAMA-J AM MED ASSOC, V313, P2044, DOI 10.1001/jama.2015.4845.
   Mangieri LR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093257.
   Mcrae JF, 2017, NATURE, V542, P433, DOI 10.1038/nature21062.
   Nelson M, 2011, AM J MED GENET A, V155A, P612, DOI 10.1002/ajmg.a.33808.
   Quinodoz M, 2017, AM J HUM GENET, V101, P623, DOI 10.1016/j.ajhg.2017.09.001.
   Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963.
   Vulto-van Silfhout AT, 2013, HUM MUTAT, V34, P1679, DOI 10.1002/humu.22442.
   Zara F, 2000, AM J HUM GENET, V66, P1552, DOI 10.1086/302876.
   Zurashvili T, 2013, MOL CELL BIOL, V33, P1027, DOI 10.1128/MCB.01052-12.},
Number-of-Cited-References = {39},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Genet. Med.},
Doc-Delivery-Number = {HW5CT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000466707400005},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000470208000049,
Author = {Scholz, Sebastian and Plessmann, Janys and Enugutti, Balaji and Huettl,
   Regina and Wassmer, Katrin and Schneitz, Kay},
Title = {The AGC protein kinase UNICORN controls planar growth by attenuating
   PDK1 in Arabidopsis thaliana (vol 15, e1007927, 2019)},
Journal = {PLOS GENETICS},
Year = {2019},
Volume = {15},
Number = {5},
Month = {MAY},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Correction},
Language = {English},
DOI = {10.1371/journal.pgen.1008170},
Article-Number = {e1008170},
ISSN = {1553-7404},
Research-Areas = {Genetics \& Heredity},
Web-of-Science-Categories  = {Genetics \& Heredity},
ResearcherID-Numbers = {Scholz, Sebastian/H-6237-2015
   ENUGUTTI, Balaji/B-9795-2013},
ORCID-Numbers = {ENUGUTTI, Balaji/0000-0002-0816-024X},
Cited-References = {Scholz S, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1007927.},
Number-of-Cited-References = {1},
Times-Cited = {0},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {PLoS Genet.},
Doc-Delivery-Number = {IB3ZP},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000470208000049},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000469272500041,
Author = {Xu, Lei and Li, Yang and Zhou, Lixing and Dorfman, Robert Gregory and
   Liu, Li and Cai, Rui and Jiang, Chenfei and Tang, Dehua and Wang, Yuming
   and Zou, Xiaoping and Wang, Lei and Zhang, Mingming},
Title = {SIRT3 elicited an anti-Warburg effect through HIF1α/PDK1/PDHA1 to
   inhibit cholangiocarcinoma tumorigenesis},
Journal = {CANCER MEDICINE},
Year = {2019},
Volume = {8},
Number = {5},
Pages = {2380-2391},
Month = {MAY},
Abstract = {Cholangiocarcinoma (CCA) is an extremely invasive malignancy with late
   diagnosis and unfavorable prognosis. Surgery and chemotherapy are still
   not effective in improving outcomes in CCA patients. It is crucial to
   explore a novel therapeutic target for treating CCA. An NAD-dependent
   deacetylase also known as Sirtuin-3 (SIRT3) has been shown to regulate
   cellular metabolism in various cancers dynamically. However, the
   biological function of SIRT3 in CCA remains unclear. In this study,
   bioinformatics analyses were performed to identify the differentially
   expressed genes and pathways enriched. CCA samples were collected for
   immunohistochemical analysis. Three human CCA cell lines (HuCCT1, RBE,
   and HCCC9810) were used to explore the molecular mechanism of SIRT3
   regulation of metabolic reprogramming and malignant behavior in CCA. A
   CCA xenograft model was then established for further validation in vivo.
   The data showed that SIRT3 expression was decreased and glycolysis was
   enhanced in CCA. Similar metabolic reprogramming was also observed in
   SIRT3 knockout mice. Furthermore, we demonstrated that SIRT3 could play
   an anti-Warburg effect by inhibiting the hypoxia-inducible factor-1
   alpha (HIF1 alpha)/pyruvate dehydrogenase kinase 1 (PDK1)/pyruvate
   dehydrogenase (PDHA1) pathway in CCA cells. CCA cell proliferation and
   apoptosis were regulated by SIRT3-mediated metabolic reprogramming.
   These findings were further confirmed in CCA clinical samples and the
   xenograft model. Collectively, this study suggests that in the
   inhibition of CCA progression, SIRT3 acts through an anti-Warburg effect
   on the downstream pathway HIF1 alpha/PDK1/PDHA1.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zou, XP; Wang, L; Zhang, MM (Corresponding Author), Nanjing Med Univ, Drum Tower Clin Med Coll, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China.
   Xu, Lei; Liu, Li; Cai, Rui; Zou, Xiaoping; Wang, Lei; Zhang, Mingming, Nanjing Med Univ, Drum Tower Clin Med Coll, Dept Gastroenterol, Nanjing, Jiangsu, Peoples R China.
   Li, Yang, Anhui Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Hefei, Anhui, Peoples R China.
   Zhou, Lixing, Sichuan Univ, West China Hosp, Ctr Gerontol \& Geriatr, Chengdu, Sichuan, Peoples R China.
   Dorfman, Robert Gregory, Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
   Xu, Lei; Jiang, Chenfei; Tang, Dehua; Wang, Yuming; Zou, Xiaoping; Wang, Lei; Zhang, Mingming, Nanjing Univ, Affiliated Hosp, Dept Gastroenterol, Nanjing Drum Tower Hosp,Med Sch, Nanjing, Jiangsu, Peoples R China.},
DOI = {10.1002/cam4.2089},
ISSN = {2045-7634},
Keywords = {Cholangiocarcinoma; Metabolic reprogramming; SIRT3; Warburg effect},
Keywords-Plus = {BILIARY EPITHELIAL-CELLS; TUMOR-SUPPRESSOR; UP-REGULATION; CANCER-CELLS;
   METABOLISM; HIF1-ALPHA; HYPOXIA; ACETYLATION; GLYCOLYSIS; GUIDELINES},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {13770771661@163.com
   867152094@qq.com
   zhangchimei@126.com},
Affiliations = {Nanjing Medical University; Anhui Medical University; Sichuan
   University; Northwestern University; Feinberg School of Medicine;
   Nanjing University},
ResearcherID-Numbers = {xu, lei/AGT-6964-2022
   Zhang, Mingming/HTN-9682-2023
   },
ORCID-Numbers = {xu, lei/0009-0004-1374-2211
   Zhang, Mingming/0000-0001-6907-4049
   Zhou, Lixing/0009-0001-1146-7808},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81602076, 81672935,
   81472756]; Outstanding Youth Project of Nanjing City {[}JQX17002];
   Jiangsu Clinical Medical Center of Digestive Disease {[}BL2012001];
   Natural Science Foundation from the Department of Science \& Technology
   of Jiangsu Province {[}BK20160113]; Fund of Jiangsu Provincial
   Commission of Health and Family Planning {[}Q201611]; Fundamental
   Research Funds for the Central Universities {[}021414380244]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (Nos. 81602076, 81672935, and 81472756), the
   Outstanding Youth Project of Nanjing City (No. JQX17002), the Jiangsu
   Clinical Medical Center of Digestive Disease (BL2012001), the Natural
   Science Foundation from the Department of Science \& Technology of
   Jiangsu Province (BK20160113), the Fund of Jiangsu Provincial Commission
   of Health and Family Planning (No. Q201611), and the Fundamental
   Research Funds for the Central Universities (No. 021414380244).},
Cited-References = {Battello N, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0141-0.
   Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021.
   Chen Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.14.
   Chen YH, 2011, EMBO REP, V12, P534, DOI 10.1038/embor.2011.65.
   Courtney KD, 2018, CELL METAB, V28, P793, DOI 10.1016/j.cmet.2018.07.020.
   Cui Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129834.
   Dittenhafer-Reed KE, 2015, CELL METAB, V21, P637, DOI 10.1016/j.cmet.2015.03.007.
   Eastlack SC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0851-8.
   Erice O, 2017, CURR DRUG TARGETS, V18, P932, DOI 10.2174/1389450116666150825113035.
   Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014.
   Geng H, 2012, J BIOL CHEM, V287, P35496, DOI 10.1074/jbc.M112.400697.
   Golias T, 2019, INT J CANCER, V144, P674, DOI 10.1002/ijc.31812.
   Haigis MC, 2012, CANCER RES, V72, P2468, DOI 10.1158/0008-5472.CAN-11-3633.
   Han HW, 2018, BIOMED PHARMACOTHER, V97, P656, DOI 10.1016/j.biopha.2017.10.159.
   Han JE, 2017, EXP NEUROBIOL, V26, P295, DOI 10.5607/en.2017.26.5.295.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Khan SA, 2012, GUT, V61, P1657, DOI 10.1136/gutjnl-2011-301748.
   Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023.
   Lai JH, 2013, NEURO-ONCOLOGY, V15, P1330, DOI 10.1093/neuonc/not086.
   Lee JJ, 2018, P NATL ACAD SCI USA, V115, P7057, DOI 10.1073/pnas.1800440115.
   Li WL, 2018, ONCOGENE, V37, P6383, DOI 10.1038/s41388-018-0402-1.
   Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009.
   Liu H, 2018, J PROTEOME RES, V17, P3143, DOI 10.1021/acs.jproteome.8b00260.
   López-Lázaro M, 2008, ANTI-CANCER AGENT ME, V8, P305, DOI 10.2174/187152008783961932.
   Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001.
   Molck C, 2016, CANCER LETT, V383, P135, DOI 10.1016/j.canlet.2016.09.018.
   Nagaya M, 2009, J ENDOCRINOL, V201, P37, DOI 10.1677/JOE-08-0482.
   Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105.
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101.
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006.
   Pillai VB, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7656.
   Prigione A, 2014, STEM CELLS, V32, P364, DOI 10.1002/stem.1552.
   Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140-6736(13)61903-0.
   Regan JN, 2014, P NATL ACAD SCI USA, V111, P8673, DOI 10.1073/pnas.1324290111.
   Robey IF, 2008, NEOPLASIA, V10, P745, DOI 10.1593/neo.07724.
   Sena JA, 2014, MOL CANCER RES, V12, P1233, DOI 10.1158/1541-7786.MCR-14-0149.
   Shen H, 2015, MOL CANCER THER, V14, P1794, DOI 10.1158/1535-7163.MCT-15-0247.
   Skipworth JRA, 2011, ALIMENT PHARM THER, V34, P1063, DOI 10.1111/j.1365-2036.2011.04851.x.
   Squadroni M, 2017, CRIT REV ONCOL HEMAT, V116, P11, DOI 10.1016/j.critrevonc.2016.11.012.
   Torgeson A, 2017, ANN SURG ONCOL, V24, P4001, DOI 10.1245/s10434-017-6131-9.
   Wang G, 2019, J CELL PHYSIOL, V234, P5888, DOI 10.1002/jcp.26474.
   Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687.
   Wang SJ, 2018, ONCOGENE, V37, P4164, DOI 10.1038/s41388-018-0252-x.
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Yan C, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1171-0.
   Yao WT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-187.
   Yonashiro R, 2018, CANCER RES, V78, P1592, DOI 10.1158/0008-5472.CAN-17-1751.
   Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051703.
   Zhang W, 2017, EUR J PHARM SCI, V110, P93, DOI 10.1016/j.ejps.2017.04.018.
   Zhang XD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0882-1.
   Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689.},
Number-of-Cited-References = {52},
Times-Cited = {56},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {25},
Journal-ISO = {Cancer Med.},
Doc-Delivery-Number = {IA0UC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000469272500041},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000458138600088,
Author = {Zhang, Meng and Cong, Qing and Zhang, Xiao-Yan and Zhang, Ming-Xing and
   Lu, Ying-Ying and Xu, Cong-Jian},
Title = {Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of
   ovarian cancer through EGFR activation},
Journal = {JOURNAL OF CELLULAR PHYSIOLOGY},
Year = {2019},
Volume = {234},
Number = {5},
Pages = {6361-6370},
Month = {MAY},
Abstract = {Patients with ovarian cancer frequently develop acquired drug resistance
   after the long-term chemotherapy, leading to disease progression.
   Enhanced epithelial-mesenchymal transition (EMT) has been implicated in
   chemoresistance of ovarian cancer cells; however, the molecular
   mechanisms involved are largely undefined. Pyruvate dehydrogenase kinase
   1 (PDK1), a key regulatory enzyme in glucose metabolism, has been
   recognized as a gatekeeper of the Warburg effect, a hallmark of cancer.
   In this study, the function of PDK1 in cisplatin resistance of ovarian
   cancer in terms of growth and EMT was investigated. PDK1 was upregulated
   in cisplatin-resistant ovarian cancer cells. PDK1 knockdown in resistant
   cells led to increased sensitivity to cisplatin-induced cell death and
   apoptosis. PDK1 downregulation also reversed the EMT and cell motility
   in cisplatin-resistant cells. In a mouse xenograft model, tumors derived
   from PDK1-silenced ovarian cancer cells exhibited decreased tumor growth
   and EMT compared with control after the cisplatin treatment.
   Mechanistically, PDK1 overexpression led to increased phosphorylation of
   EGFR, and blocking EGFR kinase activity by erlotinib reversed cisplatin
   resistance induced by PDK1 overexpression. Furthermore, in patients with
   ovarian cancer, higher PDK1 and p-EGFR levels were associated with
   chemoresistance. These results supported that PDK1 contributes to
   chemoresistance of ovarian cancer by activating EGFR. Therefore, PDK1
   may serve as a promising target to combat chemoresistance of ovarian
   cancer.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zhang, XY (Corresponding Author), Fudan Univ, Obstet \& Gynecol Hosp, Dept Gynecol, Shanghai, Peoples R China.
   Zhang, XY (Corresponding Author), Fudan Univ, Obstet \& Gynecol Hosp, Shanghai 200011, Peoples R China.
   Zhang, Meng; Cong, Qing; Zhang, Xiao-Yan; Zhang, Ming-Xing; Lu, Ying-Ying; Xu, Cong-Jian, Fudan Univ, Obstet \& Gynecol Hosp, Dept Gynecol, Shanghai, Peoples R China.
   Zhang, Meng; Cong, Qing; Zhang, Xiao-Yan; Zhang, Ming-Xing; Lu, Ying-Ying; Xu, Cong-Jian, Fudan Univ, Shanghai Med Sch, Dept Obstet \& Gynecol, Shanghai, Peoples R China.
   Zhang, Xiao-Yan; Xu, Cong-Jian, Shanghai Key Lab Female Reprod Endocrine Related, Shanghai, Peoples R China.},
DOI = {10.1002/jcp.27369},
ISSN = {0021-9541},
EISSN = {1097-4652},
Keywords = {chemoresistance; EGFR; EMT; ovarian cancer; PDK1},
Keywords-Plus = {PLATINUM-BASED CHEMOTHERAPY; TYROSINE PHOSPHORYLATION; MESENCHYMAL
   TRANSITION; LACTATE PRODUCTION; DICHLOROACETATE; METABOLISM; PDK1;
   EXPRESSION; CELLS},
Research-Areas = {Cell Biology; Physiology},
Web-of-Science-Categories  = {Cell Biology; Physiology},
Author-Email = {zhxy@fudan.edu.cn
   xucongjian@fudan.edu.cn},
Affiliations = {Fudan University; Fudan University; Shanghai Academy of Science \&
   Technology},
Funding-Acknowledgement = {National Key R\&D Program of China {[}2016YFC1303100]; National Natural
   Sciences Foundation of China {[}81472424]; Youth Talent Foundation of
   Shanghai Health System {[}XYQ2011054]; Shanghai Medical Center of Key
   Programs for Female Reproductive Diseases {[}2017ZZ01016]},
Funding-Text = {National Key R\&D Program of China, Grant/Award Number: 2016YFC1303100;
   National Natural Sciences Foundation of China, Grant/Award Number:
   81472424; Youth Talent Foundation of Shanghai Health System, Grant/Award
   Number: XYQ2011054; Shanghai Medical Center of Key Programs for Female
   Reproductive Diseases, Grant/Award Number: 2017ZZ01016},
Cited-References = {Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5.
   Armstrong DK, 2002, ONCOLOGIST, V7, P20, DOI 10.1634/theoncologist.7-suppl\_5-20.
   Dupuy F, 2015, CELL METAB, V22, P577, DOI 10.1016/j.cmet.2015.08.007.
   Gui T, 2012, CANCER EPIDEMIOL, V36, P490, DOI 10.1016/j.canep.2012.06.005.
   Haslehurst AM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-91.
   Haugrud AB, 2014, BREAST CANCER RES TR, V147, P539, DOI 10.1007/s10549-014-3128-y.
   Helleman J, 2010, GYNECOL ONCOL, V117, P170, DOI 10.1016/j.ygyno.2010.01.010.
   Hitosugi T, 2011, MOL CELL, V44, P864, DOI 10.1016/j.molcel.2011.10.015.
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005.
   Kellenberger LD, 2010, J ONCOL, V2010, DOI 10.1155/2010/514310.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   Koukourakis MI, 2007, CANCER BIOL THER, V6, P1476, DOI 10.4161/cbt.6.9.4635.
   Liu T, 2017, ONCOL REP, V37, P193, DOI 10.3892/or.2016.5253.
   Liu YF, 2017, J MED CHEM, V60, P2227, DOI 10.1021/acs.jmedchem.6b01245.
   Marchini S, 2013, EUR J CANCER, V49, P520, DOI 10.1016/j.ejca.2012.06.026.
   Patel MS, 2014, J BIOL CHEM, V289, P16615, DOI 10.1074/jbc.R114.563148.
   Popov KM, 1997, ADV SEC MESS PHOSPH, V31, P105.
   Schulze A, 2011, MOL CELL, V44, P846, DOI 10.1016/j.molcel.2011.12.004.
   Stapoole PW, 2008, ADV DRUG DELIVER REV, V60, P1478, DOI 10.1016/j.addr.2008.02.014.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Xu QL, 2017, ONCOTARGET, V8, P9557, DOI 10.18632/oncotarget.13771.
   Zachar Z, 2011, J MOL MED, V89, P1137, DOI 10.1007/s00109-011-0785-8.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.
   Zhang WJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179672.},
Number-of-Cited-References = {28},
Times-Cited = {50},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {43},
Journal-ISO = {J. Cell. Physiol.},
Doc-Delivery-Number = {HK7AQ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458138600088},
DA = {2026-02-04},
}

@article{ WOS:000464955400001,
Author = {Liu, Chang and Mu, Xiuli and Wang, Xuan and Zhang, Chan and Zhang, Lina
   and Yu, Baofeng and Sun, Gongqin},
Title = {Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer
   Cells, but Its Efficacy Is Compromised by Its Activation on
   PDK1/Akt/mTOR Signaling},
Journal = {MOLECULES},
Year = {2019},
Volume = {24},
Number = {7},
Month = {APR 7},
Abstract = {Ponatinib is a multi-target protein tyrosine kinase inhibitor, and its
   effects on hepatocellular carcinoma cells have not been previously
   explored. In the present study, we investigated its effects on
   hepatocellular carcinoma cell growth and the underlying mechanisms.
   Toward SK-Hep-1 and SNU-423 cells, ponatinib induces apoptosis by
   upregulation of cleaved caspase-3 and -7 and promotes cell cycle arrest
   in the G1 phase by inhibiting CDK4/6/CyclinD1 complex and
   phosphorylation of retinoblastoma protein. It inhibits the
   growth-stimulating mitogen-activated protein (MAP) kinase pathway, the
   phosphorylation of Src on both negative and positive regulation sites,
   and Jak2 and Stat3 phosphorylation. Surprisingly, it also activates the
   PDK1, the protein kinase B (Akt), and the mechanistic target of
   rapamycin (mTOR) signaling pathway. Blocking mTOR signaling strongly
   sensitizes cells to inhibition by ponatinib and makes ponatinib a much
   more potent inhibitor of hepatocellular carcinoma cell proliferation.
   These findings demonstrate that ponatinib exerts both positive and
   negative effects on hepatocellular cell proliferation, and eliminating
   its growth-stimulating effects by drug combination or potentially by
   chemical medication can significantly improve its efficacy as an
   anti-cancer drug.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Yu, BF; Sun, GQ (Corresponding Author), Shanxi Med Univ, Dept Biochem \& Mol Biol, Taiyuan 030001, Shanxi, Peoples R China.
   Sun, GQ (Corresponding Author), Univ Rhode Isl, Dept Cell \& Mol Biol, Kingston, RI 02881 USA.
   Liu, Chang; Mu, Xiuli; Wang, Xuan; Zhang, Chan; Zhang, Lina; Yu, Baofeng; Sun, Gongqin, Shanxi Med Univ, Dept Biochem \& Mol Biol, Taiyuan 030001, Shanxi, Peoples R China.
   Sun, Gongqin, Univ Rhode Isl, Dept Cell \& Mol Biol, Kingston, RI 02881 USA.},
DOI = {10.3390/molecules24071363},
Article-Number = {1363},
EISSN = {1420-3049},
Keywords = {ponatinib; proliferation; apoptosis; liver cancer cells; PDK1; Akt; mTOR
   signaling},
Keywords-Plus = {ADVANCED HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE INHIBITORS;
   MYELOID-LEUKEMIA; TARGETED THERAPY; AP24534; MECHANISMS; SORAFENIB;
   TOXICITY; PATHWAYS; SRC},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {xiaophailch@163.com
   mu13333499415@163.com
   airourouxuan@163.com
   qlgcj1120@sina.com
   18335183328@163.com
   shanxiyangcheng@126.com
   gsun@uri.edu},
Affiliations = {Shanxi Medical University; University of Rhode Island},
Funding-Acknowledgement = {Hundred Talent Program of Shanxi Province {[}0128532]},
Funding-Text = {This research was funded by grant from Hundred Talent Program of Shanxi
   Province (No. 0128532; to Gongqin Sun).},
Cited-References = {Baro M, 2014, BRIT J CANCER, V111, P1310, DOI 10.1038/bjc.2014.432.
   Bodzin AS, 2015, WORLD J HEPATOL, V7, P1157, DOI 10.4254/wjh.v7.i9.1157.
   Bostner J, 2013, BREAST CANCER RES TR, V137, P397, DOI 10.1007/s10549-012-2376-y.
   Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617.
   Bruix J, 2013, EUR J CANCER, V49, P3412, DOI 10.1016/j.ejca.2013.05.028.
   Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006.
   Chase A, 2013, HAEMATOL-HEMATOL J, V98, P103, DOI 10.3324/haematol.2012.066407.
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4.
   Chuma M, 2015, HEPATOL RES, V45, pE1, DOI 10.1111/hepr.12459.
   Colombino M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.136.
   Coppo P, 2006, BRIT J HAEMATOL, V134, P171, DOI 10.1111/j.1365-2141.2006.06161.x.
   Cortes JE, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0685-2.
   De Falco V, 2013, J CLIN ENDOCR METAB, V98, pE811, DOI 10.1210/jc.2012-2672.
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI {[}10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706].
   Gozgit JM, 2012, MOL CANCER THER, V11, P690, DOI 10.1158/1535-7163.MCT-11-0450.
   Gozgit JM, 2011, MOL CANCER THER, V10, P1028, DOI 10.1158/1535-7163.MCT-10-1044.
   Greten TF, 2009, BRIT J CANCER, V100, P19, DOI 10.1038/sj.bjc.6604784.
   HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298.
   Hasinoff BB, 2017, CARDIOVASC TOXICOL, V17, P297, DOI 10.1007/s12012-016-9386-7.
   Ito Y, 2001, J HEPATOL, V35, P68, DOI 10.1016/S0168-8278(01)00077-0.
   Ji JS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0667-x.
   Jiang SS, 2017, APPL MICROBIOL BIOT, V101, P1535, DOI 10.1007/s00253-016-7930-9.
   Jin B, 2014, MOL CANCER THER, V13, P1217, DOI 10.1158/1535-7163.MCT-13-0397.
   Kim DH, 2016, CANCER BIOL THER, V17, P65, DOI 10.1080/15384047.2015.1108492.
   Kimura T, 2018, CANCER SCI, V109, P3993, DOI 10.1111/cas.13806.
   Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078-0432.CCR-07-1902.
   Kuribayashi K, 2006, CANCER BIOL THER, V5, P763, DOI 10.4161/cbt.5.7.3228.
   Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035.
   Lee YH, 2014, CANCER RES, V74, P4752, DOI 10.1158/0008-5472.CAN-13-3531.
   Levitzki A, 2010, MOL ASPECTS MED, V31, P287, DOI 10.1016/j.mam.2010.04.001.
   Lierman E, 2012, LEUKEMIA, V26, P1693, DOI 10.1038/leu.2012.8.
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857.
   Mingard C, 2018, J APPL TOXICOL, V38, P418, DOI 10.1002/jat.3551.
   Morrison DK, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011254.
   Moslehi JJ, 2015, J CLIN ONCOL, V33, P4210, DOI 10.1200/JCO.2015.62.4718.
   Mu CF, 2017, MOL PHARMACEUT, V14, P274, DOI 10.1021/acs.molpharmaceut.6b00872.
   O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028.
   Paech F, 2018, TOXICOLOGY, V395, P34, DOI 10.1016/j.tox.2018.01.005.
   Petrilli AM, 2017, ONCOTARGET, V8, P31666, DOI 10.18632/oncotarget.15912.
   Pilati C, 2011, J EXP MED, V208, P1359, DOI 10.1084/jem.20110283.
   Rhim JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep26547.
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085.
   Rossari F, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0624-2.
   Sahu N, 2017, MOL CANCER THER, V16, P1729, DOI 10.1158/1535-7163.MCT-17-0009.
   Shao JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146968.
   Shao W, 2019, PROTEIN CELL, V10, P161, DOI 10.1007/s13238-018-0533-8.
   Sidarovich V, 2018, MOL CANCER THER, V17, P1405, DOI 10.1158/1535-7163.MCT-17-0841.
   Spraggs CF, 2013, PHARMACOGENOMICS, V14, P541, DOI {[}10.2217/PGS.13.24, 10.2217/pgs.13.24].
   Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076.
   Thillai K, 2016, WORLD J GASTRO ONCOL, V8, P173, DOI 10.4251/wjgo.v8.i2.173.
   Tomicic MT, 2013, BBA-REV CANCER, V1835, P11, DOI 10.1016/j.bbcan.2012.09.002.
   Villanueva A, 2013, NAT REV GASTRO HEPAT, V10, P34, DOI 10.1038/nrgastro.2012.199.
   Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012.
   Zirm E, 2012, BRIT J HAEMATOL, V157, P483, DOI 10.1111/j.1365-2141.2012.09085.x.},
Number-of-Cited-References = {54},
Times-Cited = {21},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {4},
Journal-ISO = {Molecules},
Doc-Delivery-Number = {HU0IU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000464955400001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000463313600031,
Author = {Allende-Vega, Nerea and Villalba, Martin},
Title = {Metabolic stress controls mutant p53 R248Q stability in acute myeloid
   leukemia cells},
Journal = {SCIENTIFIC REPORTS},
Year = {2019},
Volume = {9},
Month = {APR 4},
Abstract = {Eliminating mutant p53 (mt p53) protein could be a useful strategy to
   treat mt p53 tumors and potentially improve the prognosis of cancer
   patients. In this study, we unveil different mechanisms that eliminate
   p53-R248Q, one of the most frequent mutants found in human cancers. We
   show that the Hsp90 inhibitor 17-AAG eliminates R248Q by stimulating
   macroautophagy under normal growth conditions. Metabolic stress induced
   by the pyruvate dehydrogenase kinase-1 (PDK1) inhibitor dichloroacetate
   (DCA) inhibits the macroautophagy pathway. This induces the accumulation
   of R248Q, which in addition further inhibits macroautophagy. Combination
   of DCA and 17-AAG further decreases the autophagy flux compared to DCA
   alone. Despite this, this co-treatment strongly decreases R248Q levels.
   In this situation of metabolic stress, 17-AAG induces the binding of
   p53-R248Q to Hsc70 and the activation of Chaperone-Mediated Autophagy
   (CMA), leading to higher R248Q degradation than in non-stress
   conditions. Thus, different metabolic contexts induce diverse autophagy
   mechanisms that degrade p53-R248Q, and under metabolic stress, its
   degradation is CMA-mediated. Hence, we present different strategies to
   eliminate this mutant and provide new evidence of the crosstalk between
   macroautophagy and CMA and their potential use to target mutant p53.},
Publisher = {NATURE PORTFOLIO},
Address = {HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY},
Type = {Article},
Language = {English},
Affiliation = {Allende-Vega, N; Villalba, M (Corresponding Author), Univ Montpellier, CHU Montpellier, INSERM, IRMB, Montpellier, France.
   Allende-Vega, N; Villalba, M (Corresponding Author), CHU Montpellier, IRMB, Montpellier, France.
   Allende-Vega, Nerea; Villalba, Martin, Univ Montpellier, CHU Montpellier, INSERM, IRMB, Montpellier, France.
   Allende-Vega, Nerea; Villalba, Martin, CHU Montpellier, IRMB, Montpellier, France.},
DOI = {10.1038/s41598-019-42220-y},
Article-Number = {5637},
ISSN = {2045-2322},
Keywords-Plus = {LYSOSOMAL DEGRADATION; AUTOPHAGY; CANCER; PROTEIN; HSP90; TP53; GAIN;
   MUTATIONS; PATHWAYS; COMPLEX},
Research-Areas = {Science \& Technology - Other Topics},
Web-of-Science-Categories  = {Multidisciplinary Sciences},
Author-Email = {nerea.allende-vega@inserm.fr
   martin.villalba@inserm.fr},
Affiliations = {Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); CHU de Montpellier; Universite de
   Montpellier; CHU de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm)},
ResearcherID-Numbers = {villalba, martin/AAG-2604-2020
   },
ORCID-Numbers = {villalba, martin/0000-0002-4385-4888
   Allende-Vega, Nerea/0000-0001-5569-6461},
Funding-Acknowledgement = {PRT-K program 2018 {[}2018-021]; Canceropole GSO Emergence},
Funding-Text = {This work was supported by the PRT-K program 2018 (MV; 2018-021) and
   Canceropole GSO Emergence (MV; 2018/2019).},
Cited-References = {Akakura S, 2001, J BIOL CHEM, V276, P14649, DOI 10.1074/jbc.M100200200.
   Allende-Vega N, 2010, ONCOGENE, V29, P432, DOI 10.1038/onc.2009.330.
   Allende-Vega N, 2015, ONCOTARGET, V6, P19228, DOI 10.18632/oncotarget.4653.
   Bandyopadhyay U, 2008, MOL CELL BIOL, V28, P5747, DOI 10.1128/MCB.02070-07.
   BARTEK J, 1990, ONCOGENE, V5, P893.
   Bom APDA, 2012, J BIOL CHEM, V287, P28152, DOI 10.1074/jbc.M112.340638.
   Boschelli F, 2010, CELL STRESS CHAPERON, V15, P913, DOI 10.1007/s12192-010-0200-3.
   Bougeard G, 2008, J MED GENET, V45, P535, DOI 10.1136/jmg.2008.057570.
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693.
   CHIANG HL, 1989, SCIENCE, V246, P382, DOI 10.1126/science.2799391.
   CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157.
   Choudhury S, 2013, CELL CYCLE, V12, P1022, DOI 10.4161/cc.24128.
   Cordani M, 2016, MOL ONCOL, V10, P1008, DOI 10.1016/j.molonc.2016.04.001.
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784.
   Gudkov AV, 2005, BIOCHEM BIOPH RES CO, V331, P726, DOI 10.1016/j.bbrc.2005.03.153.
   Han SY, 2017, CANCER RES, V77, P343, DOI 10.1158/0008-5472.CAN-16-0613.
   Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17.
   Kadia TM, 2016, CANCER.
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191.
   Khan AUH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23884-4.
   Khan AU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10339-5.
   Khan AU, 2016, EBIOMEDICINE, V3, P43, DOI 10.1016/j.ebiom.2015.11.045.
   Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185.
   LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0.
   Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534.
   Lindsley RC, 2017, NEW ENGL J MED, V376, P536, DOI 10.1056/NEJMoa1611604.
   Massey AC, 2006, P NATL ACAD SCI USA, V103, P5805, DOI 10.1073/pnas.0507436103.
   Mello SS, 2013, CELL DEATH DIFFER, V20, P855, DOI 10.1038/cdd.2013.53.
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751.
   Morselli E, 2011, CELL CYCLE, V10, P2763, DOI 10.4161/cc.10.16.16868.
   Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059.
   Neckers Len, 2002, Expert Opin Emerg Drugs, V7, P277, DOI 10.1517/14728214.7.2.277.
   Ng JWK, 2015, PROTEINS, V83, P2240, DOI 10.1002/prot.24940.
   Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107.
   Peller S, 2003, HUM MUTAT, V21, P277, DOI 10.1002/humu.10190.
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495.
   Riedel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008753.
   Rodriguez OC, 2012, CELL CYCLE, V11, P4436, DOI 10.4161/cc.22778.
   Rückner FG, 2012, BLOOD, V119, P2114, DOI 10.1182/blood-2011-08-375758.
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107.
   Shen SS, 2009, J CELL BIOL, V185, P629, DOI 10.1083/jcb.200810183.
   Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459.
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730.
   Tasset I, 2016, FEBS J, V283, P2403, DOI 10.1111/febs.13677.
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113.
   Vijayakumaran R, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00284.
   Viry E, 2014, BIOCHEM PHARMACOL, V92, P31, DOI 10.1016/j.bcp.2014.07.006.
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716.
   Wu HJ, 2015, MOL NEUROBIOL, V52, P1284, DOI 10.1007/s12035-014-8933-0.
   Yoshikawa K, 2010, BIOMED RES-TOKYO, V31, P401, DOI 10.2220/biomedres.31.401.
   Zerdoumi Y, 2013, HUM MUTAT, V34, P453, DOI 10.1002/humu.22254.
   Zhang H, 2004, J MOL MED, V82, P488, DOI 10.1007/s00109-004-0549-9.},
Number-of-Cited-References = {52},
Times-Cited = {24},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Sci Rep},
Doc-Delivery-Number = {HR7EB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000463313600031},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000467690000005,
Author = {Sestito, Simona and Rapposelli, Simona},
Title = {A patent update on PDK1 inhibitors (2015-present)},
Journal = {EXPERT OPINION ON THERAPEUTIC PATENTS},
Year = {2019},
Volume = {29},
Number = {4},
Pages = {271-282},
Month = {APR 3},
Abstract = {Introduction: 3-Phosphoinositide-dependent kinase 1 (PDK1), the master
   kinase of the AGC protein kinase family', plays a key role in cancer
   development and progression. Although it has been rather overlooked, in
   the last decades a growing number of molecules have been developed to
   effectively modulate the PDK1 enzyme.Areas covered: This review collects
   different PDK1 inhibitors patented from October 2014 to December 2018.
   The molecules have been classified on the basis of the chemical
   structure/type of inhibition, and for each general structure, examples
   have been discussed in extenso.Expert opinion: The role of PDK1 in
   cancer development and progression as well as in metastasis formation
   and in chemoresistance has been confirmed by many studies. Therefore,
   the pharmaceutical discovery in both public and private institutions is
   still ongoing despite the plentiful molecules already published. The
   majority of the new molecules synthetized interact with binding sites
   different from the ATP binding site (i.e. PIF pocket or DFG-out
   conformation). However, many researchers are still looking for
   innovative PDK1 modulation strategy such as combination of well-known
   inhibitory agents or multitarget ligands, aiming to block, together with
   PDK1, other different critical players in the wide panorama of proteins
   involved in tumor pathways.},
Publisher = {TAYLOR \& FRANCIS LTD},
Address = {2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND},
Type = {Review},
Language = {English},
Affiliation = {Rapposelli, S (Corresponding Author), Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy.
   Sestito, Simona; Rapposelli, Simona, Univ Pisa, Dept Pharm, Via Bonanno 6, I-56126 Pisa, Italy.},
DOI = {10.1080/13543776.2019.1597852},
ISSN = {1354-3776},
EISSN = {1744-7674},
Keywords = {Allosteric inhibitors; chemoresistance; DFG-out inhibitor; drug
   discovery; metastasis; 3-phosphoinositide-dependent kinase 1; PDK1
   inhibitor; PIF-pocket inhibitor; PH-domain inhibitor; PI3K; PDK1; Akt
   pathway},
Keywords-Plus = {CANCER STEM-CELLS; 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1;
   SMALL-MOLECULE INHIBITORS; PIF-BINDING POCKET; DRUG DISCOVERY; SIGNALING
   PATHWAY; TARGETING CANCER; PI3K/AKT PATHWAY; HYBRID COMPOUNDS;
   TUMOR-GROWTH},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal; Pharmacology \& Pharmacy},
Author-Email = {simona.rapposelli@unipi.it},
Affiliations = {University of Pisa},
ResearcherID-Numbers = {SESTITO, SIMONA/AAE-6210-2019
   Rapposelli, Simona/D-1595-2010},
ORCID-Numbers = {SESTITO, SIMONA/0000-0002-6173-525X
   Rapposelli, Simona/0000-0003-0146-6358},
Cited-References = {Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X.
   Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010.
   Arndt J., 2018, Heterocyclic Compounds Useful as PDK1 Inhibitors, Patent No. 2018222943.
   Avruch J, 2001, Prog Mol Subcell Biol, V26, P115.
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236.
   Barile E, 2012, PHARM PAT ANAL, V1, P145, DOI {[}10.4155/ppa.12.17, 10.4155/PPA.12.17].
   Basnet R, 2018, ACTA PHARM SIN B, V8, P767, DOI 10.1016/j.apsb.2018.07.001.
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409.
   Baxter BK, 2011, ACS CHEM BIOL, V6, P502, DOI 10.1021/cb100399x.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Busschots K, 2012, CHEM BIOL, V19, P1152, DOI 10.1016/j.chembiol.2012.07.017.
   Calleja V, 2014, BIOCHEM SOC T, V42, P1435, DOI 10.1042/BST20140222.
   Carlino L, 2016, J MED CHEM, V59, P9305, DOI 10.1021/acs.jmedchem.6b00438.
   Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287.
   Castel P, 2018, Patent No. {[}WO2017015152, 2017015152].
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004.
   Colak S, 2014, FEBS J, V281, P4779, DOI 10.1111/febs.13023.
   Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575.
   Daniele S, 2017, ACS CHEM NEUROSCI, V8, P100, DOI 10.1021/acschemneuro.6b00251.
   Dessain SK, 2016, Patent No. {[}US2016319035 (A1), 2016319035].
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   di Blasio L, 2015, J CELL SCI, V128, P863, DOI 10.1242/jcs.149294.
   Du J, 2016, ONCOGENE, V35, P3314, DOI 10.1038/onc.2015.393.
   Elf S, 2011, BLOOD, V117, P6885, DOI 10.1182/blood-2010-10-315721.
   Emmanouilidi A, 2017, CANCERS, V9, DOI 10.3390/cancers9100140.
   Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872.
   Erlanson DA, 2011, BIOORG MED CHEM LETT, V21, P3078, DOI 10.1016/j.bmcl.2011.03.032.
   Feldman RI, 2005, J BIOL CHEM, V280, P19867, DOI 10.1074/jbc.M501367200.
   Ferro R, 2014, WORLD J GASTROENTERO, V20, P10752, DOI 10.3748/wjg.v20.i31.10752.
   Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000.
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8.
   Frödin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Gagliardi PA, 2014, J CELL BIOL, V206, P415, DOI 10.1083/jcb.201312090.
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856.
   Galli SJ, 2012, NAT MED, V18, P693, DOI 10.1038/nm.2755.
   Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246.
   Hansen SK, 2017, Patent No. {[}WO2017070565, 2017070565].
   Hossen MJ, 2015, EXPERT OPIN THER PAT, V25, P513, DOI 10.1517/13543776.2015.1014801.
   Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Jethwa N, 2015, J CELL SCI, V128, P3456, DOI 10.1242/jcs.172775.
   Jimenez AI, 2016, Patent No. {[}US2016237440, 2016237440].
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634.
   Kang SM, 2009, MOL CELL BIOL, V29, P2105, DOI 10.1128/MCB.00998-08.
   Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319.
   Kucuksayan E, 2017, CURR TOP MED CHEM, V17, P907, DOI 10.2174/1568026616666160927155515.
   Lang F, 2013, FASEB J, V27, P3, DOI 10.1096/fj.12-218230.
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Lind K. E., 2008, Patent No. 2008005457.
   Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799.
   Liu Y, 2009, NATURE, V461, P484, DOI 10.1038/461484a.
   Liu Y, 2009, MOL CANCER RES, V7, P944, DOI 10.1158/1541-7786.MCR-08-0368.
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343.
   Medina JR, 2013, J MED CHEM, V56, P2726, DOI 10.1021/jm4000227.
   Meulmeester E, 2008, CURR CANCER DRUG TAR, V8, P87, DOI 10.2174/156800908783769337.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Naderali E, 2018, MOL BIOL REP, V45, P2869, DOI 10.1007/s11033-018-4321-6.
   Nagashima K, 2011, J BIOL CHEM, V286, P6433, DOI 10.1074/jbc.M110.156463.
   Orlacchio A, 2017, CANCER RES, V77, P6914, DOI 10.1158/0008-5472.CAN-17-2105.
   Pastor-Flores D, 2013, ACS CHEM BIOL, V8, P2283, DOI 10.1021/cb400452z.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pedrosa MD, 2017, CURR TOP MED CHEM, V17, P1044, DOI 10.2174/1568026616666160927160620.
   Peifer C, 2008, CHEMMEDCHEM, V3, P1810, DOI 10.1002/cmdc.200800195.
   Petrelli A, 2008, CURR MED CHEM, V15, P422.
   Pianalto KM, 2016, J FUNGI, V2, DOI 10.3390/jof2040026.
   Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675.
   Primo L, 2007, J CELL BIOL, V176, P1035, DOI 10.1083/jcb.200607053.
   Raimondi C, 2012, J CELL SCI, V125, P3153, DOI 10.1242/jcs.100511.
   Ramsay RR, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-017-0181-2.
   Sadowsky JD, 2011, P NATL ACAD SCI USA, V108, P6056, DOI 10.1073/pnas.1102376108.
   Sells TB, 2015, ACS MED CHEM LETT, V6, P630, DOI 10.1021/ml500409n.
   Serra V, 2013, J CLIN INVEST, V123, P2551, DOI 10.1172/JCI66343.
   Sestito S, 2017, Patent No. {[}WO2017211946, 2017211946].
   Sestito S, 2018, US Patent App, Patent No. {[}15/735,468, 15735468].
   Sestito S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00874.
   Sestito S, 2016, EUR J MED CHEM, V118, P47, DOI 10.1016/j.ejmech.2016.04.003.
   Shiozawa Y, 2013, PHARMACOL THERAPEUT, V138, P285, DOI 10.1016/j.pharmthera.2013.01.014.
   Shumilina E, 2010, CELL PHYSIOL BIOCHEM, V26, P699, DOI 10.1159/000322337.
   Signore M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.188.
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342.
   Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296.
   Stockman BJ, 2009, CHEM BIOL DRUG DES, V73, P179, DOI 10.1111/j.1747-0285.2008.00768.x.
   Stroba A, 2009, J MED CHEM, V52, P4683, DOI 10.1021/jm9001499.
   Treiber DK, 2013, CHEM BIOL, V20, P745, DOI 10.1016/j.chembiol.2013.06.001.
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007.
   Vennila KN, 2018, BIOORG CHEM, V81, P184, DOI 10.1016/j.bioorg.2018.08.007.
   Wang Z, 2018, ONCOTARGET, V9, P192, DOI 10.18632/oncotarget.22773.
   Waniczek D, 2018, ONCOL LETT, V15, P1236, DOI 10.3892/ol.2017.7392.
   WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0.
   Wu CX, 2018, THERANOSTICS, V8, P3737, DOI 10.7150/thno.25487.
   Wu P, 2015, PHARMACOL THERAPEUT, V156, P59, DOI 10.1016/j.pharmthera.2015.10.002.
   Xie ZH, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-77.
   Xu XY, 2019, J ENZYM INHIB MED CH, V34, P361, DOI 10.1080/14756366.2018.1553167.
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559.},
Number-of-Cited-References = {97},
Times-Cited = {17},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {28},
Journal-ISO = {Expert Opin. Ther. Patents},
Doc-Delivery-Number = {HX8XF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000467690000005},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000468710300003,
Author = {Liu, Ziwei and Cao, Shuang and Jin, Can and He, Yu and Zhou, Xiaoshun
   and Zhang, Heng and Liu, Zhimei},
Title = {The antagonism between apigenin and protoapigenone to the PDK-1 target
   in Macrothelypteris torresiana},
Journal = {FITOTERAPIA},
Year = {2019},
Volume = {134},
Pages = {14-22},
Month = {APR},
Abstract = {Apigenin and protoapigenone that both have the activities against
   various cancer cell lines co-exist in Macrothelypteris torresiana, while
   the extracts of M. torresiana couldn't achieve the fine anti-tumor
   effects for the existence of potent anti-tumor compounds. This study
   disclosed an antagonism between the two compounds on the protein level
   to elucidate the paradox. First, the study established the fingerprint
   for M. torresiana extract. The following anti-proliferation assay
   verified that the antagonism occurs between protoapigenone and apigenin.
   And then Western blot and qt-PCR were applied to evaluate the expression
   and transcription level of the Akt phosphorylation related targets to
   validate the antagonism at the protein level. Moreover, CETSA further
   validated the binding of PDK-1 with apigenin and protoapigenone, as well
   as the antagonism between the two compounds. Finally, the
   compound-protein complexes predicted by SYBYL-X gave the visual results
   for the antagonism. The results demonstrated that: Due to the structural
   similarity and close binding coefficients to the identical targets, when
   the cells were treated with apigenin and protoapigenone simultaneously,
   the Akt phosphorylation inhibition induced by protoapigenone would
   attenuate significantly. The antagonism disclosed in this paper could be
   a new explanation for the unsatisfied efficacy of M. torresiana extract.},
Publisher = {ELSEVIER SCIENCE BV},
Address = {PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Zhang, H (Corresponding Author), Wuhan Inst Technol, Sch Chem Engn \& Pharm, Xiongchu Ave 693, Wuhan, Hubei, Peoples R China.
   Liu, ZM (Corresponding Author), Humanwell Healthcare Grp Co Ltd, Conform Pharm Engn Ctr, Gaoxing Ave,Biolake Pk, Wuhan, Hubei, Peoples R China.
   Liu, Ziwei; Cao, Shuang; Jin, Can; He, Yu; Zhang, Heng, Wuhan Inst Technol, Sch Chem Engn \& Pharm, Xiongchu Ave 693, Wuhan, Hubei, Peoples R China.
   Zhou, Xiaoshun; Liu, Zhimei, Humanwell Healthcare Grp Co Ltd, Conform Pharm Engn Ctr, Gaoxing Ave,Biolake Pk, Wuhan, Hubei, Peoples R China.},
DOI = {10.1016/j.fitote.2019.02.005},
ISSN = {0367-326X},
EISSN = {1873-6971},
Keywords = {Antagonism; Macrothelypteris torresiana; Akt phosphorylation; Apigenin;
   Protoapigenone},
Keywords-Plus = {OXIDATIVE STRESS; PROTEIN-KINASE; CANCER CELLS; THERAPY; SYNERGY},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal; Pharmacology \& Pharmacy},
Author-Email = {zhzpthm@163.com
   zmeileo@yeah.net},
Affiliations = {Wuhan Institute of Technology},
Funding-Acknowledgement = {Nature Science Foundation of Hubei Province {[}2017CDA067]; National
   Nature Science Foundation of China {[}81502906]; open fund of Key
   Laboratory for Green Chemical Process of Ministry of Education
   {[}201701-GZZ]},
Funding-Text = {This work was supported by the Nature Science Foundation of Hubei
   Province {[}grant numbers 2017CDA067], the National Nature Science
   Foundation of China {[}grant numbers 81502906] and the open fund of Key
   Laboratory for Green Chemical Process of Ministry of Education {[}grant
   numbers 201701-GZZ].},
Cited-References = {AMOROS M, 1992, J NAT PROD, V55, P1732, DOI 10.1021/np50090a003.
   Chang HL, 2008, J PHARMACOL EXP THER, V325, P841, DOI 10.1124/jpet.107.135442.
   Chen JL, 2012, J ETHNOPHARMACOL, V139, P207, DOI 10.1016/j.jep.2011.11.002.
   Chen WY, 2011, INVEST NEW DRUG, V29, P1347, DOI 10.1007/s10637-010-9497-0.
   Clark K, 2009, J BIOL CHEM, V284, P14136, DOI 10.1074/jbc.M109.000414.
   Fang W, 2011, NAT PROD RES, V25, P36, DOI 10.1080/14786411003766888.
   Harrison ME, 2014, EXP MOL PATHOL, V97, P211, DOI 10.1016/j.yexmp.2014.07.006.
   Heinemann V, 2012, CANCER TREAT REV, V38, P843, DOI 10.1016/j.ctrv.2011.12.004.
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138.
   Klauser E, 2014, FOOD CHEM TOXICOL, V67, P212, DOI 10.1016/j.fct.2014.02.039.
   Li FF, 2014, INT J CANCER, V134, P1257, DOI 10.1002/ijc.28261.
   Lin AS, 2007, J MED CHEM, V50, P3921, DOI 10.1021/jm070363a.
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Raimondi C, 2011, CURR MED CHEM, V18, P2763, DOI 10.2174/092986711796011238.
   Santi SA, 2010, AM J PHYSIOL-CELL PH, V298, pC580, DOI 10.1152/ajpcell.00375.2009.
   Shi S, 2012, CANCER LETT, V317, P127, DOI 10.1016/j.canlet.2011.11.029.
   Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200.
   Sumanta Mondal Sumanta Mondal, 2016, Pharmacognosy Communications, V6, P57, DOI 10.5530/pc.2016.2.2.
   Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0.
   Wagner H, 2009, PHYTOMEDICINE, V16, P97, DOI {[}10.1016/j.fitote.2010.11.016, 10.1016/j.phymed.2008.12.018].
   Wang L, 2014, FITOTERAPIA, V99, P92, DOI 10.1016/j.fitote.2014.09.008.
   Williamson EM, 2001, PHYTOMEDICINE, V8, P401, DOI 10.1078/0944-7113-00060.
   Xiong CM, 2009, CHROMATOGRAPHIA, V70, P117, DOI 10.1365/s10337-009-1115-y.
   Zhu S. G., 2017, ENZYMATIC KINETICS.},
Number-of-Cited-References = {25},
Times-Cited = {3},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {24},
Journal-ISO = {Fitoterapia},
Doc-Delivery-Number = {HZ2WU},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000468710300003},
DA = {2026-02-04},
}

@article{ WOS:000465057300002,
Author = {Pan, Hehai and Strickland, Adam and Madhu, Vedavathi and Johnson, Zariel
   I. and Chand, Saswati N. and Brody, Jonathan R. and Fertala, Andrzej and
   Zheng, Zhaomin and Shapiro, Irving M. and Risbud, Makarand V.},
Title = {RNA binding protein HuR regulates extracellular matrix gene expression
   and pH homeostasis independent of controlling HIF-1α signaling in
   nucleus pulposus cells},
Journal = {MATRIX BIOLOGY},
Year = {2019},
Volume = {77},
Pages = {23-40},
Month = {APR},
Abstract = {Nucleus pulposus (NP) cells reside in the hypoxic niche of the
   intervertebral disc. Studies have demonstrated that RNA-binding protein
   HuR modulates hypoxic signaling in several cancers, however, its
   function in the disc is unknown. HuR did not show cytoplasmic
   translocation in hypoxia and its silencing did not alter levels of Hif-1
   alpha or HIF-targets in NP cells. RNA-Sequencing data revealed that
   important extracellular matrix-related genes including several
   collagens, MMPs, aggrecan, Tgf-beta 3and Sdc4 were regulated by HuR.
   Further analysis of HuR-silenced NP cells confirmed that HuR maintained
   expression of these matrix genes. We confirmed decreased levels of
   secreted collagen I and Sdc4 and increased pro-MMP13 in HuR-knockdown
   cells. In addition, messenger ribonucleoprotein immunoprecipitation
   demonstrated HuR binding to Tgf-beta 3and Sdc4 mRNAs. Interestingly,
   while HuR bound to Hif-1 alpha and Vegf mRNAs, it was clear that
   compensatory mechanisms sustained their expression when HuR was
   silenced. Noteworthy, despite the presence of multiple HuR-binding sites
   and reported interaction in other cell types, HuR showed no binding to
   Pgk1, Eno1, Pdk1 and Pfkfb3 in NP cells. Metabolic studies showed a
   significant decrease in the extracellular acidification rate (ECAR) and
   mitochondrial oxygen consumption rate (OCR) and acidic pH in
   HuR-silenced NP cells, without appreciable change in total OCR. These
   changes were likely due to decreased Ca12 expression in HuR silenced
   cells. Taken together, our study demonstrates for the first time that
   HuR regulates extracellular matrix (ECM) and pH homeostasis of NP cells
   and has important implications in the maintenance of intervertebral disc
   health. (C) 2018 Elsevier B.V. All rights reserved.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Risbud, MV (Corresponding Author), Thomas Jefferson Univ, Dept Orthopaed Surg, 1025 Walnut St,Suite 511,Coll Bldg, Philadelphia, PA 19107 USA.
   Pan, Hehai; Strickland, Adam; Madhu, Vedavathi; Johnson, Zariel I.; Fertala, Andrzej; Shapiro, Irving M.; Risbud, Makarand V., Thomas Jefferson Univ, Dept Orthopaed Surg, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA.
   Pan, Hehai; Zheng, Zhaomin, Sun Yat Sen Univ, Affiliated Hosp 1, Dept Spine Surg, Guangzhou, Guangdong, Peoples R China.
   Chand, Saswati N.; Brody, Jonathan R., Thomas Jefferson Univ, Dept Surg, Jefferson Pancreas Billary \& Related Canc Ctr, Philadelphia, PA 19107 USA.},
DOI = {10.1016/j.matbio.2018.08.003},
ISSN = {0945-053X},
EISSN = {1569-1802},
Keywords = {Human antigen R (HuR); HIF-1 alpha; Intervertebral disc; Nucleus
   pulposus; Extracellular matrix (ECM)},
Keywords-Plus = {ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; STABILITY
   FACTOR HUR; LOW-BACK-PAIN; MESSENGER-RNA; INTERVERTEBRAL DISC; GLOBAL
   BURDEN; TRANSCRIPTION FACTOR; TARGET; STABILIZATION},
Research-Areas = {Biochemistry \& Molecular Biology; Cell Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Cell Biology},
Author-Email = {makarand.risbud@jefferson.edu},
Affiliations = {Thomas Jefferson University; Sun Yat Sen University; Thomas Jefferson
   University},
ResearcherID-Numbers = {Madhu, Veda/AAP-3465-2020
   Risbud, Makarand/NYS-9482-2025},
Funding-Acknowledgement = {National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) {[}AR055655, AR064733, T32AR052273]; National Cancer Institute
   (NCI) {[}1R01CA212600-01]; China Scholarship Council; National Institute
   of Arthritis and Musculoskeletal and Skin Diseases {[}R01AR055655]
   Funding Source: NIH RePORTER},
Funding-Text = {This study is supported by grants from the National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (NIAMS) AR055655 and
   AR064733 to MVR and T32AR052273 (USA), which supported ZIJ, and the
   National Cancer Institute (NCI) 1R01CA212600-01 (USA) to JRB. The
   authors would like to thank Steven Tessier for helping with
   immunohistochemistry staining, Andrzej Steplewski for helping with
   collagen precipitation, Erin L. Seifert and Elizabeth S. Silagi for
   assistance with Seahorse experiments. In addition, we would like to
   thank the China Scholarship Council for supporting},
Cited-References = {Agrawal A, 2007, AM J PHYSIOL-CELL PH, V293, pC621, DOI 10.1152/ajpcell.00538.2006.
   Agrawal A, 2008, ARTHRITIS RHEUM-US, V58, P3798, DOI 10.1002/art.24073.
   {[}Anonymous], MATRIX BIOL.
   {[}Anonymous], WIRES.
   Bai DN, 2012, CELL SIGNAL, V24, P1426, DOI 10.1016/j.cellsig.2012.03.003.
   Balagué F, 2012, LANCET, V379, P482, DOI 10.1016/S0140-6736(11)60610-7.
   Battié MC, 2006, J BONE JOINT SURG AM, V88A, P3, DOI 10.2106/JBJS.E.01313.
   Binch ALA, 2016, MATRIX BIOL, V52-54, P355, DOI 10.1016/j.matbio.2016.01.005.
   Blanco FF, 2016, ONCOGENE, V35, P2529, DOI 10.1038/onc.2015.325.
   Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854.
   Bridgen DT, 2013, J ORTHOP RES, V31, P1661, DOI 10.1002/jor.22395.
   Burkhart RA, 2013, RNA BIOL, V10, P1312, DOI 10.4161/rna.25274.
   Chamboredon S, 2011, MOL BIOL CELL, V22, P3366, DOI 10.1091/mbc.E10-07-0617.
   Chand SN, 2017, CANCER RES, V77, P5011, DOI 10.1158/0008-5472.CAN-16-2704.
   Costantino CL, 2009, CANCER RES, V69, P4567, DOI 10.1158/0008-5472.CAN-09-0371.
   Cozzitorto JA, 2015, METHODS MOL BIOL, V1262, P239, DOI 10.1007/978-1-4939-2253-6\_14.
   de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101.
   Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973.
   DuMond JF, 2016, PHYSIOL GENOMICS, V48, P290, DOI 10.1152/physiolgenomics.00110.2015.
   Fujita N, 2012, J BIOL CHEM, V287, P16975, DOI 10.1074/jbc.M111.334466.
   Fujita N, 2012, J BONE MINER RES, V27, P401, DOI 10.1002/jbmr.538.
   Galbán S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07.
   Galbán S, 2009, CURR PHARM DESIGN, V15, P3853, DOI 10.2174/138161209789649376.
   Gauchotte G, 2017, J PATHOL, V242, P421, DOI 10.1002/path.4916.
   Guo X, 2006, CANCER RES, V66, P7948, DOI 10.1158/0008-5472.CAN-05-4362.
   Hägele S, 2009, BIOCHEM J, V417, P235, DOI 10.1042/BJ20081353.
   He Y, 2012, J NUTR BIOCHEM, V23, P1285, DOI 10.1016/j.jnutbio.2011.07.009.
   Hinman MN, 2008, CELL MOL LIFE SCI, V65, P3168, DOI 10.1007/s00018-008-8252-6.
   Hirose Y, 2014, J BIOL CHEM, V289, P20594, DOI 10.1074/jbc.M114.565101.
   Hiyama A, 2009, J BIOL CHEM, V284, P9824, DOI 10.1074/jbc.M807081200.
   Hoy D, 2014, ANN RHEUM DIS, V73, P968, DOI 10.1136/annrheumdis-2013-204428.
   Huwiler A, 2003, J BIOL CHEM, V278, P51758, DOI 10.1074/jbc.M305722200.
   Johnson ZI, 2016, J BIOL CHEM, V291, P26686, DOI 10.1074/jbc.M116.757732.
   Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111.
   Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08.
   Le Maitre CL, 2004, J PATHOL, V204, P47, DOI 10.1002/path.1608.
   Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417.
   Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144.
   McDermott BT, 2016, OSTEOARTHR CARTILAGE, V24, P1263, DOI 10.1016/j.joca.2016.01.988.
   Merceron C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110768.
   Miyata Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059095.
   Mookerjee SA, 2015, BBA-BIOENERGETICS, V1847, P171, DOI 10.1016/j.bbabio.2014.10.005.
   Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007.
   Muralidharan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07787-4.
   Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805.
   Nabors LB, 2001, CANCER RES, V61, P2154.
   Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102.
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160.
   Risbud MV, 2006, J CELL BIOCHEM, V98, P152, DOI 10.1002/jcb.20765.
   Roughley PJ, 2004, SPINE, V29, P2691, DOI 10.1097/01.brs.0000146101.53784.b1.
   Sakuma T, 2008, J NEURO-ONCOL, V88, P143, DOI 10.1007/s11060-008-9559-8.
   Schepens B, 2005, NUCLEIC ACIDS RES, V33, P6884, DOI 10.1093/nar/gki1000.
   Schoepflin ZR, 2017, FASEB J, V31, P3831, DOI 10.1096/fj.201601291R.
   Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173.
   Silagi ES, 2018, MATRIX BIOL, V71-72, P368, DOI 10.1016/j.matbio.2018.02.025.
   Silagi ES, 2018, J BONE MINER RES, V33, P338, DOI 10.1002/jbmr.3293.
   Srikantan S, 2012, FRONT BIOSCI-LANDMRK, V17, P189, DOI 10.2741/3921.
   Steenstra IA, 2005, OCCUP ENVIRON MED, V62, P851, DOI 10.1136/oem.2004.015842.
   Suyama K, 2016, ONCOTARGET, V7, P23056, DOI 10.18632/oncotarget.8521.
   Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460.
   Tian Y, 2016, MATRIX BIOL, V50, P39, DOI 10.1016/j.matbio.2015.11.008.
   Tsai TT, 2007, J BONE MINER RES, V22, P965, DOI 10.1359/JBMR.070322.
   Tsai TT, 2006, J BIOL CHEM, V281, P25416, DOI 10.1074/jbc.M601969200.
   Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200.
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4.
   Yang GH, 2013, LANCET, V381, P1987, DOI 10.1016/S0140-6736(13)61097-1.
   Yi J, 2010, NUCLEIC ACIDS RES, V38, P1547, DOI 10.1093/nar/gkp1114.
   Zarei M, 2017, CANCER RES, V77, P4460, DOI 10.1158/0008-5472.CAN-17-0015.},
Number-of-Cited-References = {68},
Times-Cited = {33},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {13},
Journal-ISO = {Matrix Biol.},
Doc-Delivery-Number = {HU1UM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000465057300002},
DA = {2026-02-04},
}

@article{ WOS:000458939700001,
Author = {Zhou, Wei-Min and Wu, Gao-Liang and Huang, Ji and Li, Jin-Gao and Hao,
   Chao and He, Qiu-Ming and Chen, Xiao-Dan and Wang, Gong-Xian and Tu,
   Xin-Hua},
Title = {Low expression of PDK1 inhibits renal cell carcinoma cell proliferation,
   migration, invasion and epithelial mesenchymal transition through
   inhibition of the PI3K-PDK1-Akt pathway},
Journal = {CELLULAR SIGNALLING},
Year = {2019},
Volume = {56},
Pages = {1-14},
Month = {APR},
Abstract = {As the most commonly occurring form of primary renal tumor, renal cell
   carcinoma (RCC) is a malignancy accompanied by a high mortality rate.
   3-phosphoinositide-dependent protein kinase 1 (PDK1) has been
   established as a protein target and generated considerable interest in
   both the pharmaceutical and academia industry. The aim of the current
   study was to investigate the effect of si-PDK1 on the RCC cell
   apoptosis, proliferation, migration, invasion and epithelial mesenchymal
   transition (EMT) in connection with the PI3K-PDK1-Akt pathway.
   Microarray analysis from the GEO database was adopted to identify
   differentially expressed genes (DEGs) related to RCC, after which the
   positive expression of the PDK1 protein in tissue was determined
   accordingly. The optimal silencing si-RNA was subsequently selected and
   RCC cell lines 786-O and A498 were selected and transfected with either
   a si-PDK1 or activator of the PI3K-PDK1-Akt pathway for grouping
   purposes. The mRNA and protein expressions of PDK1, the PI3K-PDK1-Akt
   pathway-, EMT- and apoptosis-related genes were then evaluated. The
   effect of si-PDK1 on cell proliferation, apoptosis, invasion and
   migration was then analyzed. Through microarray analysis of GSE6344,
   GSE53757, GSE14762 and GSE781, PDK1 was examined. PDK1 was determined to
   be highly expressed in RCC tissues. Si-PDK1 exhibited marked reductions
   in relation to the mRNA and protein expression of PDK1, PI3K, AKT as
   well as Vimentin while elevated mRNA and protein expressions of
   E-cadherin were detected, which ultimately suggested that cell
   migration, proliferation and invasion had been inhibited coupled with
   enhanced levels of cell apoptosis. While a notable observation was made
   highlighting that the PI3K-PDK1-Akt pathway antagonized the effect of
   PDK1 silencing. Taken together, the key observations of this study
   provide evidence suggesting that high expressions of PDK1 are found in
   RCC, while highlighting that silencing PDK1 could inhibit RCC cell
   proliferation, migration, invasion and EMT by repressing the
   PI3K-PDK1-Akt pathway.},
Publisher = {ELSEVIER SCIENCE INC},
Address = {STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, GX (Corresponding Author), Nanchang Univ, Jiangxi Med Coll, 461 Bayi Ave, Nanchang 330006, Jiangxi, Peoples R China.
   Tu, XH (Corresponding Author), Jiangxi Canc Hosp, Dept Urol, 519 Beijing East Rd, Nanchang 330029, Jiangxi, Peoples R China.
   Zhou, Wei-Min; Wang, Gong-Xian, Nanchang Univ, Jiangxi Med Coll, 461 Bayi Ave, Nanchang 330006, Jiangxi, Peoples R China.
   Zhou, Wei-Min; Wu, Gao-Liang; Huang, Ji; Hao, Chao; He, Qiu-Ming; Tu, Xin-Hua, Jiangxi Canc Hosp, Dept Urol, 519 Beijing East Rd, Nanchang 330029, Jiangxi, Peoples R China.
   Li, Jin-Gao, Jiangxi Canc Hosp, Dept Radiotherapy, Nanchang 330029, Jiangxi, Peoples R China.
   Chen, Xiao-Dan, Jiangxi Canc Hosp, Dept Sci \& Educ, Nanchang 330029, Jiangxi, Peoples R China.
   Wang, Gong-Xian, Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330006, Jiangxi, Peoples R China.},
DOI = {10.1016/j.cellsig.2018.11.016},
ISSN = {0898-6568},
EISSN = {1873-3913},
Keywords = {Renal cell carcinoma; PDK1; Epithelial mesenchymal transition;
   PI3K-PDK1-Akt pathway; Proliferation; Migration; Invasion},
Keywords-Plus = {PI3K/AKT; PHOSPHORYLATION; KINASE; IGF-1},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {gongxianwang118@163.com
   tu\_xinhua@126.com},
Affiliations = {Nanchang University; Nanchang University},
Cited-References = {Ayuk SM, 2016, J PHOTOCH PHOTOBIO B, V161, P368, DOI 10.1016/j.jphotobiol.2016.05.027.
   Baumunk D, 2013, WORLD J UROL, V31, P1191, DOI 10.1007/s00345-012-0874-5.
   Cai B, 2017, ONCOL LETT, V14, P1536, DOI 10.3892/ol.2017.6350.
   Chaurasia B, 2010, MOL CELL BIOL, V30, P4354, DOI 10.1128/MCB.00069-10.
   Chen PJ, 2018, EXP THER MED, V15, P4039, DOI 10.3892/etm.2018.5881.
   Chen PJ, 2018, ONCOL LETT, V15, P5995, DOI 10.3892/ol.2018.8081.
   Chen SR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173725.
   Choi JH, 2008, ANN NY ACAD SCI, V1138, P393, DOI 10.1196/annals.1414.041.
   Dagher J, 2017, HISTOPATHOLOGY, V71, P918, DOI 10.1111/his.13311.
   Ertekin E, 2017, POL J RADIOL, V82, P384, DOI 10.12659/PJR.901957.
   Feng Q., 2010, MOL CELL BIOL, V30.
   Franzen AM, 2018, CASE REP MED, V2018, DOI 10.1155/2018/7301727.
   Gagliardi PA, 2015, BBA-REV CANCER, V1856, P178, DOI 10.1016/j.bbcan.2015.07.003.
   Guo HF, 2015, J GENET GENOMICS, V42, P343, DOI 10.1016/j.jgg.2015.03.003.
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249.
   Kilic U, 2017, REDOX BIOL, V12, P657, DOI 10.1016/j.redox.2017.04.006.
   Kim C, 2018, ENDOCR CONNECT, V7, P443, DOI 10.1530/EC-17-0350.
   King CC, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0543-0.
   Lian SX, 2015, ONCOTARGET, V6, P29076, DOI 10.18632/oncotarget.4931.
   Liu JJ, 2010, ANN HEMATOL, V89, P1089, DOI 10.1007/s00277-010-0996-z.
   Ma YL, 2018, ONCOTARGETS THER, V11, P1385, DOI 10.2147/OTT.S153798.
   Masannat J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23212-w.
   May M, 2017, SCAND J UROL, V51, P269, DOI 10.1080/21681805.2017.1300187.
   Piñero J, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav028.
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303.
   Shimobaba S, 2016, BBA-MOL CELL RES, V1863, P1170, DOI 10.1016/j.bbamcr.2016.02.015.
   Terasaki M, 2018, ONCOL REP, V40, P414, DOI 10.3892/or.2018.6398.
   Thillai K, 2017, ONCOTARGET, V8, P14173, DOI 10.18632/oncotarget.13309.
   Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561.
   Wang XF, 2017, SAUDI J BIOL SCI, V24, P1787, DOI 10.1016/j.sjbs.2017.11.013.
   Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686.
   Zhang L, 2017, NEUROCHEM RES, V42, P1403, DOI 10.1007/s11064-017-2192-1.
   Zhang SW, 2018, MOL MED REP, V17, P7403, DOI 10.3892/mmr.2018.8732.
   Zhu Y., 2013, CANC SCI, V104.},
Number-of-Cited-References = {34},
Times-Cited = {29},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {33},
Journal-ISO = {Cell. Signal.},
Doc-Delivery-Number = {HL7RW},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458939700001},
DA = {2026-02-04},
}

@article{ WOS:000462576600001,
Author = {Shoop, Shanell and Maria, Zahra and Campoloo, Allison and Rashdan, Nabil
   and Martin, Dominic and Lovern, Pamela and Lacombe, Veronique A.},
Title = {Glial Growth Factor 2 Regulates Glucose Transport in Healthy Cardiac
   Myocytes and During Myocardial Infarction via an Akt-Dependent Pathway},
Journal = {FRONTIERS IN PHYSIOLOGY},
Year = {2019},
Volume = {10},
Month = {MAR 27},
Abstract = {Neuregulin (NRG), a paracrine factor in myocytes, promotes cardiac
   development via the ErbB receptors. NRG-1 beta also improves cardiac
   function and cell survival after myocardial infarction (MI), although
   the mechanisms underlying these cardioprotective effects are not well
   elucidated. Increased glucose uptake has been shown to be
   cardioprotective during MI. We hypothesized that treatment with a
   recombinant version of NRG-1 beta, glial growth factor 2 (GGF2), will
   enhance glucose transport in the healthy myocardium and during MI.
   Cardiac myocytes were isolated from MI and healthy adult rats, and
   subsequently incubated with or without insulin or GGF2. Glucose uptake
   was measured using a fluorescent D-glucose analog. The translocation of
   glucose transporter (GLUT) 4 to the cell surface, the rate-limiting step
   in glucose uptake, was measured using a photolabeled biotinylation assay
   in isolated myocytes. Similar to insulin, acute in vitro GGF2 treatment
   increased glucose uptake in healthy cardiac myocytes (by 40 and 49\%,
   respectively, P = 0.002). GGF2 treatment also increased GLUT4
   translocation in healthy myocytes by 184\% (P < 0.01), while ErbB 2/4
   receptor blockade (by afatinib) abolished these effects. In addition,
   GGF2 treatment enhanced Akt phosphorylation (at both threonine and
   serine sites, by 75 and 139\%, respectively, P = 0.029 and P = 0.01),
   which was blunted by ErbB 2/4 receptor blockade. GGF2 treatment
   increased the phosphorylation of AS160 (an Akt effector) by 72\% (P <
   0.05), as well as the phosphorylation of PDK-1 and PKC (by 118 and 92\%,
   respectively, P < 0.05). During MI, cardiac GLUT4 translocation was
   downregulated by 44\% (P = 0.004) and was partially rescued by both in
   vitro insulin and GGF2 treatment. Our data demonstrate that acute GGF2
   treatment increased glucose transport in cardiac myocytes by activating
   the ErbB 2/4 receptors and subsequent key downstream effectors (i.e.,
   PDK-1, Akt, AS160, and PKC). These findings highlight novel mechanisms
   of action of GGF2, which warrant further investigation in patients with
   heart failure.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Lacombe, VA (Corresponding Author), Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA.
   Lacombe, VA (Corresponding Author), Oklahoma State Univ, Dept Biochem \& Mol Biol, Stillwater, OK 74078 USA.
   Lacombe, VA (Corresponding Author), Univ Oklahoma, Harold Hamm Diabet Ctr, Oklahoma City, OK 73106 USA.
   Shoop, Shanell; Maria, Zahra; Campoloo, Allison; Rashdan, Nabil; Lovern, Pamela; Lacombe, Veronique A., Oklahoma State Univ, Dept Physiol Sci, Stillwater, OK 74078 USA.
   Shoop, Shanell; Martin, Dominic; Lacombe, Veronique A., Oklahoma State Univ, Dept Biochem \& Mol Biol, Stillwater, OK 74078 USA.
   Maria, Zahra; Campoloo, Allison; Lacombe, Veronique A., Univ Oklahoma, Harold Hamm Diabet Ctr, Oklahoma City, OK 73106 USA.
   Maria, Zahra, Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.
   Rashdan, Nabil, Louisiana State Univ, Dept Mol \& Cellular Physiol, Hlth Sci Ctr Shreveport, Shreveport, LA 71105 USA.},
DOI = {10.3389/fphys.2019.00189},
Article-Number = {189},
ISSN = {1664-042X},
Keywords = {neuregulin; myocardial infarction; glucose transporters; AS160; heart},
Keywords-Plus = {CHRONIC HEART-FAILURE; FUNCTIONAL RECOVERY; ENERGY-METABOLISM;
   NEUREGULIN; ERBB2; RESISTANCE; EXPRESSION; MUSCLE; MECHANISMS; RECEPTORS},
Research-Areas = {Physiology},
Web-of-Science-Categories  = {Physiology},
Author-Email = {veronique.lacombe@okstate.edu},
Affiliations = {Oklahoma State University System; Oklahoma State University -
   Stillwater; Oklahoma State University System; Oklahoma State University
   - Stillwater; University of Oklahoma System; University of Oklahoma
   Health Sciences Center; Oklahoma Medical Research Foundation; Louisiana
   State University System; Louisiana State University Health Sciences
   Center at Shreveport},
ResearcherID-Numbers = {Lovern, Pamela/LPQ-4723-2024
   Rashdan, Nabil/ABH-2753-2020
   Lacombe, VA/I-6473-2013},
ORCID-Numbers = {Lovern, Pamela/0000-0001-7943-4722
   },
Funding-Acknowledgement = {Acorda Therapeutics},
Funding-Text = {This work was supported by Acorda Therapeutics.},
Cited-References = {Amorim PA, 2010, J THORAC CARDIOV SUR, V140, P1160, DOI 10.1016/j.jtcvs.2010.08.003.
   Babar T, 2014, CURR PHARM DESIGN, V20, P4911.
   Baliga RR, 1999, AM J PHYSIOL-HEART C, V277, pH2026, DOI 10.1152/ajpheart.1999.277.5.H2026.
   Bandyopadhyay G, 1997, ENDOCRINOLOGY, V138, P4721, DOI 10.1210/en.138.11.4721.
   Bayascas JR, 2005, MOL CELL, V18, P143, DOI 10.1016/j.molcel.2005.03.020.
   Brittain E, 2013, J AM COLL CARDIOL, V61, pE715, DOI 10.1016/S0735-1097(13)60715-9.
   Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5.
   Canfield K, 2015, CELL CYCLE, V14, P648, DOI 10.4161/15384101.2014.994966.
   Canto C, 2004, J BIOL CHEM, V279, P12260, DOI 10.1074/jbc.M308554200.
   Cantó C, 2006, J BIOL CHEM, V281, P21690, DOI 10.1074/jbc.M600475200.
   Coffer PJ, 1998, BIOCHEM J, V335, P1.
   Dirksen WP, 2007, CARDIOVASC RES, V75, P69, DOI 10.1016/j.cardiores.2007.03.002.
   Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X.
   Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7.
   Florini JR, 1996, J BIOL CHEM, V271, P12699, DOI 10.1074/jbc.271.22.12699.
   Galindo Cristi L, 2014, Curr Heart Fail Rep, V11, P40.
   Gao HB, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13606.
   Gao RL, 2010, J AM COLL CARDIOL, V55, P1907, DOI 10.1016/j.jacc.2009.12.044.
   GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0.
   Hill MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055741.
   Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440.
   HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205.
   Iaci JF, 2010, NEUROPHARMACOLOGY, V59, P640, DOI 10.1016/j.neuropharm.2010.07.017.
   Jaswal JS, 2011, BBA-MOL CELL RES, V1813, P1333, DOI 10.1016/j.bbamcr.2011.01.015.
   Kim H, 2018, U.S. Patent, Patent No. 20180055909.
   Klip A, 2014, AM J PHYSIOL-CELL PH, V306, pC879, DOI 10.1152/ajpcell.00069.2014.
   Lacombe VA, 2003, AM J VET RES, V64, P1500, DOI 10.2460/ajvr.2003.64.1500.
   Lacombe VA, 2007, AM J PHYSIOL-REG I, V293, pR1787, DOI 10.1152/ajpregu.00059.2007.
   Lacombe Veronique A, 2014, ISRN Vet Sci, V2014, P409547, DOI 10.1155/2014/409547.
   LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0.
   Lenihan DJ, 2013, J AM COLL CARDIOL, V61, pE707, DOI 10.1016/S0735-1097(13)60707-X.
   Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109.
   Liepinsh E, 2014, METABOLISM, V63, P127, DOI 10.1016/j.metabol.2013.09.014.
   Long YC, 2011, MOL CELL BIOL, V31, P430, DOI 10.1128/MCB.00983-10.
   Luptak I, 2007, CIRCULATION, V116, P901, DOI 10.1161/CIRCULATIONAHA.107.691253.
   MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0.
   Maria Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146033.
   MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0.
   Morrison A, 2011, AM J PHYSIOL-HEART C, V301, pH895, DOI 10.1152/ajpheart.00137.2011.
   Mozaffarian D, 2016, CIRCULATION, V133, pE38, DOI 10.1161/CIR.0000000000000350.
   Murray AJ, 2006, CARDIOVASC RES, V71, P149, DOI 10.1016/j.cardiores.2006.02.031.
   Mythili S, 2015, BIOMED REP, V3, P743, DOI 10.3892/br.2015.500.
   Peñuelas I, 2007, NUKLEARMED-NUCL MED, V46, P149, DOI 10.1160/nukmed-0065.
   Povlsen JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064093.
   RIEHLE C, 2016, CIRC RES, V118, P1151, DOI DOI 10.1161/CIRCRESAHA.116.306206.
   Rohrbach S, 2005, BASIC RES CARDIOL, V100, P240, DOI 10.1007/s00395-005-0514-4.
   SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8.
   Suárez E, 2001, J BIOL CHEM, V276, P18257, DOI 10.1074/jbc.M008100200.
   Ventura-Clapier R, 2004, J PHYSIOL-LONDON, V555, P1, DOI 10.1113/jphysiol.2003.055095.
   Wadugu B, 2012, AM J PHYSIOL-HEART C, V302, pH2139, DOI 10.1152/ajpheart.00063.2012.
   Waller AP, 2011, BBA-MOL BASIS DIS, V1812, P1098, DOI 10.1016/j.bbadis.2011.02.007.
   Waller AP, 2011, J VET INTERN MED, V25, P315, DOI 10.1111/j.1939-1676.2010.0674.x.
   Waller AP, 2015, BBA-MOL BASIS DIS, V1852, P873, DOI 10.1016/j.bbadis.2015.01.009.
   Waller AP, 2013, BBA-MOL BASIS DIS, V1832, P121, DOI 10.1016/j.bbadis.2012.09.013.
   Ware B, 2011, AM J PHYSIOL-REG I, V301, pR1300, DOI 10.1152/ajpregu.00822.2010.
   Wu MZ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006430.
   Xu YB, 2010, ADV PHARMACOL, V59, P31, DOI 10.1016/S1054-3589(10)59002-1.
   Zhang HX, 2006, J CARDIOVASC PHARM, V48, P306, DOI 10.1097/01.fjc.0000249873.73197.c3.
   Zhao YY, 1998, J BIOL CHEM, V273, P10261, DOI 10.1074/jbc.273.17.10261.},
Number-of-Cited-References = {59},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Front. Physiol.},
Doc-Delivery-Number = {HQ7CH},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000462576600001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000462478700003,
Author = {Yu, Zutao and Chen, Zhuo and Su, Qiongli and Ye, Shiqi and Yuan, Hongbo
   and Kuai, Mengni and Lv, Meng and Tu, Zhijun and Yang, Xiaoping and Liu,
   RangRu and Hu, Gaoyun and Li, Qianbin},
Title = {Dual inhibitors of RAF-MEK-ERK and PI3K-PDK1-AKT pathways: Design,
   synthesis and preliminary anticancer activity studies of
   3-substituted-5(phenylamino) indolone derivatives},
Journal = {BIOORGANIC \& MEDICINAL CHEMISTRY},
Year = {2019},
Volume = {27},
Number = {6},
Pages = {944-954},
Month = {MAR 15},
Abstract = {The dysfunction and mutual compensatory activation of RAF-MEK-ERK and
   PI3K-PDK1-AKT pathways have been demonstrated as the hallmarks in
   several primary and recurrent cancers. The strategy of concurrent
   blocking of these two pathways shows clinical merits on effective cancer
   therapy, such as combinatory treatments and dual-pathway inhibitors.
   Herein, we report a novel prototype of dual-pathway inhibitors by means
   of merging the core structural scaffolds of a MEK1 inhibitor and a PDK1
   inhibitor. A library of 43 compounds that categorized into three series
   (Series I-III) was synthesized and tested for antitumor activity in lung
   cancer cells. The results from structure-activity relationship (SAR)
   analysis showed the following order of antitumor activity that
   3-hydroxy-5-(phenylamino) indolone (Series III) >
   3-alkenyl-5-(phenylamino) indolone (Series I) > 3-alkyl-5-(phenylamino)
   indolone (Series II). A lead compound 9za in Series III showed most
   potent antitumor activity with IC50, value of 1.8 +/- 0.8 mu M in A549
   cells. Moreover, antitumor mechanism study demonstrated that 9za exerted
   significant apoptotic effect, and cellular signal pathway analysis
   revealed the potent blockage of phosphorylation levels of ERK and AKT in
   RAF-MEK-ERK and PI3K-PDK1-AKT pathways, respectively. The results
   reported here provide robust experimental basis for the discovery and
   optimization of dual pathway agents for anti-lung cancer therapy.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Li, QB (Corresponding Author), Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Med Chem, Changsha 410013, Hunan, Peoples R China.
   Yu, Zutao; Chen, Zhuo; Kuai, Mengni; Lv, Meng; Tu, Zhijun; Hu, Gaoyun; Li, Qianbin, Cent South Univ, Xiangya Sch Pharmaceut Sci, Dept Med Chem, Changsha 410013, Hunan, Peoples R China.
   Su, Qiongli; Kuai, Mengni; Yang, Xiaoping, Hunan Normal Univ, Sch Med, Dept Pharm, Changsha 410013, Hunan, Peoples R China.
   Ye, Shiqi, Shenzhen Univ, Sch Med, Shenzhen 518060, Guangdong, Peoples R China.
   Yuan, Hongbo, Hunan Qianjin Xiangjiang Pharmaceut Co Ltd, Changsha 410013, Hunan, Peoples R China.
   Liu, RangRu, Hainan Med Coll, Minist Educ, Key Lab Trop Dis \& Translat Med, Haikou, Hainan, Peoples R China.
   Liu, RangRu, Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou, Hainan, Peoples R China.},
DOI = {10.1016/j.bmc.2019.01.028},
ISSN = {0968-0896},
EISSN = {1464-3391},
Keywords = {Dual inhibitor; RAF-MEK-ERK pathway; PI3K-PDK1-AKT pathway; Lung cancer;
   5-(Phenylamino) indolone; Structure-activity relationship},
Keywords-Plus = {KINASE-1 PDK1 INHIBITORS; DISCOVERY; ALKYLATION; AMPK},
Research-Areas = {Biochemistry \& Molecular Biology; Pharmacology \& Pharmacy; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic},
Author-Email = {qbli@csu.edu.cn},
Affiliations = {Central South University; Hunan Normal University; Shenzhen University;
   Hainan Medical University; Hainan Medical University},
ResearcherID-Numbers = {Yu, Zutao/HNI-7729-2023
   Y, q/MBH-2398-2025
   Yuan, Hongbo/P-4464-2018},
ORCID-Numbers = {Li, Qianbin/0000-0003-4522-3067
   Yu, Zutao/0000-0003-1389-0818
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}21102184, 81773640];
   Specialized Research Fund for the Doctoral Program of Higher Education
   of China {[}20110162120033]; Natural Science Foundation of Hunan
   Province {[}2016JJ2162]; Hunan Province Strategic Emerging Industry
   Science and Technology Key Project {[}2016GK4028]; Key research and
   development project of Hainan Province {[}ZDYF2017092]; Haikou, China;
   Nuclear Magnetic Resonance Laboratory of Advanced Research Center in
   Central South University},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (No. 21102184, 81773640), the Specialized Research Fund for the
   Doctoral Program of Higher Education of China (No. 20110162120033), and
   Natural Science Foundation of Hunan Province (No. 2016JJ2162). Hunan
   Province Strategic Emerging Industry Science and Technology Key Project,
   NO. 2016GK4028. Key research and development project of Hainan Province
   (project number: ZDYF2017092), Haikou, China. We also would like to
   thank the Nuclear Magnetic Resonance Laboratory of Advanced Research
   Center in Central South University for the technological assistance in
   chemical characterization.},
Cited-References = {Ai JT, 2018, MED CHEM RES, V27, P161, DOI 10.1007/s00044-017-2050-3.
   Albaugh P, 2012, ACS MED CHEM LETT, V3, P140, DOI 10.1021/ml200261d.
   Aronson SJ, 2015, NATURE, V526, P336, DOI 10.1038/nature15816.
   Chouhan M, 2011, APPL ORGANOMET CHEM, V25, P470, DOI 10.1002/aoc.1789.
   Fischmann TO, 2009, BIOCHEMISTRY-US, V48, P2661, DOI 10.1021/bi801898e.
   Grigg R, 2009, TETRAHEDRON, V65, P4375, DOI 10.1016/j.tet.2009.03.065.
   Hood L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/nrclinonc.2010.227.
   Houédé N, 2015, PHARMACOL THERAPEUT, V145, P1, DOI 10.1016/j.pharmthera.2014.06.004.
   Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930.
   Islam I, 2007, BIOORG MED CHEM LETT, V17, P3814, DOI 10.1016/j.bmcl.2007.04.071.
   Islam I, 2007, BIOORG MED CHEM LETT, V17, P3819, DOI 10.1016/j.bmcl.2007.05.060.
   Jensen T, 2009, J ORG CHEM, V74, P3990, DOI 10.1021/jo900341w.
   Kraatz BP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012838.
   Lee HJ, 2014, TETRAHEDRON LETT, V55, P1183, DOI 10.1016/j.tetlet.2013.12.097.
   Li QB, 2010, BIOORG MED CHEM LETT, V20, P4526, DOI 10.1016/j.bmcl.2010.06.030.
   McCarroll JA, 2015, CANCER RES, V75, P415, DOI 10.1158/0008-5472.CAN-14-2740.
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006.
   Morita K, 2017, J CLIN INVEST, V127, P2815, DOI 10.1172/JCI91788.
   Oronsky BT, 2012, TRANSL ONCOL, V5, P226, DOI 10.1593/tlo.12187.
   Park H, 2012, BIOORG MED CHEM LETT, V22, P4946, DOI 10.1016/j.bmcl.2012.06.041.
   Peddibhotla S., 2009, Curr. Bioact. Compd, V5, P20, DOI {[}DOI 10.2174/157340709787580900, 10.2174/157340709787580900].
   Peng M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28611.
   Prakash CR, 2012, MINI-REV MED CHEM, V12, P98.
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612.
   Ralhan R, 2007, EXPERT OPIN THER PAT, V17, P1061, DOI 10.1517/13543776.17.9.1061.
   Sestito S, 2016, EUR J MED CHEM, V118, P47, DOI 10.1016/j.ejmech.2016.04.003.
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387.
   Su QL, 2016, AM J CANCER RES, V6, P498.
   Surry DS, 2010, CHEM SCI, V1, P13, DOI 10.1039/c0sc00107d.
   Temraz S, 2015, INT J MOL SCI, V16, P22976, DOI 10.3390/ijms160922976.
   Van Dort ME, 2017, ACS MED CHEM LETT, V8, P808, DOI 10.1021/acsmedchemlett.7b00111.
   Van Dort ME, 2016, J MED CHEM, V59, P2512, DOI 10.1021/acs.jmedchem.5b01655.
   Yu ZT, 2019, ADV DRUG DELIVER REV, V147, P66, DOI 10.1016/j.addr.2019.02.001.
   Yu ZT, 2018, J AM CHEM SOC, V140, P2426, DOI 10.1021/jacs.7b13275.
   Yu ZT, 2017, EUR J MED CHEM, V138, P320, DOI 10.1016/j.ejmech.2017.06.037.
   Yu ZT, 2015, FUTURE MED CHEM, V7, P269, DOI {[}10.4155/FMC.14.143, 10.4155/fmc.14.143].
   Yu ZT, 2016, CHINESE J ORG CHEM, V36, P1672, DOI 10.6023/cjoc201512007.
   Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83.},
Number-of-Cited-References = {38},
Times-Cited = {19},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {46},
Journal-ISO = {Bioorg. Med. Chem.},
Doc-Delivery-Number = {HQ5US},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)},
Unique-ID = {WOS:000462478700003},
DA = {2026-02-04},
}

@article{ WOS:000460914700012,
Author = {Ou, Zhimin and Ma, Yanchen and Sun, Yuxia and Zheng, Gege and Wang,
   Shiyun and Xing, Rui and Chen, Xiang and Han, Ying and Wang, Jiajia and
   Lu, Q. Richard and Zhao, Tong-Jin and Chen, Ying},
Title = {A GPR17-cAMP-Lactate Signaling Axis in Oligodendrocytes Regulates
   Whole-Body Metabolism},
Journal = {CELL REPORTS},
Year = {2019},
Volume = {26},
Number = {11},
Pages = {2984+},
Month = {MAR 12},
Abstract = {The CNS plays a pivotal role in energy homeostasis, but whether
   oligodendrocytes are involved has been largely unexplored. Here, we show
   that signaling through GPR17, a G-protein-coupled receptor predominantly
   expressed in the oligodendrocyte lineage, regulates food intake by
   modulating hypothalamic neuronal activities. GPR17-null mice and mice
   with an oligodendrocyte-specific knockout of GPR17 have lean phenotypes
   on a high-fat diet, suggesting that GPR17 regulates body weight by way
   of oligodendrocytes. Downregulation of GPR17 results in activation of
   cAMP-protein kinase A (PKA) signaling in oligodendrocytes and
   upregulated expression of pyruvate dehydrogenase kinase 1 (PDK1), which
   promotes lactate production. Elevation of lactate activates AKT and
   STAT3 signaling in the hypothalamic neurons, leading to increased
   expression of Pomc and suppression of Agrp. Our findings uncover a
   critical role of oligodendrocytes in metabolic homeostasis, where GPR17
   modulates the production of lactate, which, in turn, acts as a metabolic
   signal to regulate neuronal activity.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {Zhao, TJ; Chen, Y (Corresponding Author), Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China.
   Lu, QR (Corresponding Author), Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Expt Hematol \& Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.
   Ou, Zhimin; Ma, Yanchen; Sun, Yuxia; Zheng, Gege; Wang, Shiyun; Xing, Rui; Chen, Xiang; Zhao, Tong-Jin; Chen, Ying, Xiamen Univ, State Key Lab Cellular Stress Biol, Sch Life Sci, Xiamen 361005, Fujian, Peoples R China.
   Han, Ying, Xiamen Univ, Affiliated Hosp 1, Xiamen 361101, Fujian, Peoples R China.
   Xing, Rui; Wang, Jiajia; Lu, Q. Richard, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Expt Hematol \& Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.},
DOI = {10.1016/j.celrep.2019.02.060},
ISSN = {2211-1247},
Keywords-Plus = {COUPLED RECEPTOR GPR17; GLUCOSE-HOMEOSTASIS; ARCUATE NUCLEUS; AGRP
   NEURONS; C-FOS; OBESITY; BRAIN; PATHWAY; LEPTIN; REQUIREMENT},
Research-Areas = {Cell Biology},
Web-of-Science-Categories  = {Cell Biology},
Author-Email = {richard.lu@cchmc.org
   chaotj@xmu.edu.cn
   yingchen@xmu.edu.cn},
Affiliations = {Xiamen University; Xiamen University; Cincinnati Children's Hospital
   Medical Center},
ResearcherID-Numbers = {Zhao, Tong-Jin/AFH-2915-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31471039, 31771122,
   81601080]; National Key R\&D Program of China {[}2016YFA0502003];
   Project 111 - State Bureau of Foreign Experts; Ministry of Education of
   China {[}BP2018017]},
Funding-Text = {This work was supported by grants from the National Natural Science
   Foundation of China (31471039, 31771122, and 81601080), the National Key
   R\&D Program of China (2016YFA0502003), and Project 111 sponsored by the
   State Bureau of Foreign Experts and Ministry of Education of China
   (BP2018017).},
Cited-References = {Balland E, 2014, CELL METAB, V19, P293, DOI 10.1016/j.cmet.2013.12.015.
   Bouret SG, 2004, J NEUROSCI, V24, P2797, DOI 10.1523/JNEUROSCI.5369-03.2004.
   Bozzo L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071721.
   Chan JR, 2004, NEURON, V43, P183, DOI 10.1016/j.neuron.2004.06.024.
   Chen Y, 2009, NAT NEUROSCI, V12, P1398, DOI 10.1038/nn.2410.
   Coppari R, 2005, CELL METAB, V1, P63, DOI 10.1016/j.cmet.2004.12.004.
   Day HEW, 2008, BRAIN RES, V1229, P137, DOI 10.1016/j.brainres.2008.06.085.
   Djogo T, 2016, CELL METAB, V23, P797, DOI 10.1016/j.cmet.2016.04.013.
   DRAGUNOW M, 1989, J NEUROSCI METH, V29, P261, DOI 10.1016/0165-0270(89)90150-7.
   Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704.
   Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0.
   García-Cáceres C, 2016, CELL, V166, P867, DOI 10.1016/j.cell.2016.07.028.
   Hennen S, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004350.
   Hofmann K, 2017, GLIA, V65, P231, DOI 10.1002/glia.23088.
   Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6.
   Kaelin CB, 2004, ENDOCRINOLOGY, V145, P5798, DOI 10.1210/en.2004-0956.
   Kim JG, 2014, NAT NEUROSCI, V17, P908, DOI 10.1038/nn.3725.
   Kim JD, 2017, DIABETES, V66, P2102, DOI 10.2337/db16-1558.
   Lauritzen KH, 2014, CEREB CORTEX, V24, P2784, DOI 10.1093/cercor/bht136.
   Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314.
   Loktev AV, 2013, CELL REP, V5, P1316, DOI 10.1016/j.celrep.2013.11.011.
   Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5.
   MacLaren D. A., 2016, ENEURO, DOI DOI 10.1523/ENEURO.0219-16.2016.
   Manvich DF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22116-z.
   Mastaitis J, 2015, P NATL ACAD SCI USA, V112, P1845, DOI 10.1073/pnas.1424968112.
   Miura GI, 2003, TRANSGENIC RES, V12, P131, DOI 10.1023/A:1022118627058.
   Nonogaki K, 2016, NEUROSCI LETT, V612, P14, DOI 10.1016/j.neulet.2015.12.011.
   Ou ZM, 2016, J NEUROSCI, V36, P10560, DOI 10.1523/JNEUROSCI.0898-16.2016.
   Pellerin L, 1998, DEV NEUROSCI-BASEL, V20, P291, DOI 10.1159/000017324.
   Ren HX, 2015, DIABETES, V64, P3670, DOI 10.2337/db15-0390.
   Ren HX, 2012, CELL, V149, P1314, DOI 10.1016/j.cell.2012.04.032.
   Saab AS, 2016, NEURON, V91, P119, DOI 10.1016/j.neuron.2016.05.016.
   SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817.
   Trevisiol A, 2015, CELL METAB, V22, P361, DOI 10.1016/j.cmet.2015.08.010.
   Valdearcos M, 2017, CELL METAB, V26, P185, DOI 10.1016/j.cmet.2017.05.015.
   VanElzakker M, 2008, LEARN MEMORY, V15, P899, DOI 10.1101/lm.1196508.
   Xin M, 2005, J NEUROSCI, V25, P1354, DOI 10.1523/JNEUROSCI.3034-04.2005.
   Xing F, 2017, CELL REP, V18, P468, DOI 10.1016/j.celrep.2016.12.037.
   Yang XJ, 1999, DIABETES, V48, P1763, DOI 10.2337/diabetes.48.9.1763.
   Yang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06951-0.
   ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753.
   Zhang XQ, 2008, CELL, V135, P61, DOI 10.1016/j.cell.2008.07.043.
   Zhao B, 2012, NEUROSCIENCE, V202, P42, DOI 10.1016/j.neuroscience.2011.11.066.
   Zhao CT, 2018, DEV CELL, V45, P753, DOI 10.1016/j.devcel.2018.05.022.
   Zhu H, 2014, NEUROPSYCHOPHARMACOL, V39, P1880, DOI 10.1038/npp.2014.35.},
Number-of-Cited-References = {45},
Times-Cited = {53},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {31},
Journal-ISO = {Cell Reports},
Doc-Delivery-Number = {HO4TE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000460914700012},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000460501200001,
Author = {Gong, Wenxia and Zhu, Shiwei and Chen, Congcong and Yin, Qicai and Li,
   Xiao and Du, Guanhua and Zhou, Yuzhi and Qin, Xuemei},
Title = {The Anti-depression Effect of Angelicae Sinensis Radix Is Related to the
   Pharmacological Activity of Modulating the Hematological Anomalies},
Journal = {FRONTIERS IN PHARMACOLOGY},
Year = {2019},
Volume = {10},
Month = {MAR 6},
Abstract = {Angelicae Sinensis Radix (AS), a well-known herb in traditional Chinese
   medicine (TCM), has been wildly used for replenishing the blood and
   promoting circulation, in Asia for thousands of years. It has been
   confirmed that AS also possesses the pharmacological activity of
   anti-depression. At the same time, recent studies suggested that
   depression is associated with anemia, and depression could be
   ameliorated via modulating the blood system. However, it is still
   unknown whether the anti-depression effect of AS is related to its
   pharmacological activity of modulating the blood system. In the current
   study, hematological examination and metabonomic techniques were
   performed to explore potential anti-depression mechanisms of AS, related
   to the function of modulating the blood system in a chronic
   unpredictable mild stress (CUMS) model. The results demonstrated that AS
   could significantly improve CUMS-induced depressive symptom,
   hematological anomalies, and hypoxia symptoms. The analysis of
   metabonomics demonstrated that 26 potential biomarkers in depression
   could be regulated by the administration of AS. Among them, eight
   biomarkers participate in the metabolic pathways of amino acid and
   sphingolipid, and energy metabolism could also be regulated in an anemia
   model through the administration of AS, as reported in previous
   literatures. Further results proved that AS modulated energy metabolism
   in depression through the inhibition of the expression of pyruvate
   dehydrogenase lipoamide kinase isozyme 1 (PDK-1) and lactate
   dehydrogenase A (LDHA). These results suggested that the modulation of
   the blood system was involved in the anti-depression effect of AS. The
   mechanism may be associated with the promotion of the body's energy
   metabolism, the stabilization of cell membranes, the promotion of serum
   protein synthesis, and the enhancement of immunity.},
Publisher = {FRONTIERS MEDIA SA},
Address = {AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhou, YZ; Qin, XM (Corresponding Author), Shanxi Univ, Modern Res Ctr Tradit Chinese Med, Taiyuan, Shanxi, Peoples R China.
   Gong, Wenxia; Zhu, Shiwei; Chen, Congcong; Yin, Qicai; Li, Xiao; Du, Guanhua; Zhou, Yuzhi; Qin, Xuemei, Shanxi Univ, Modern Res Ctr Tradit Chinese Med, Taiyuan, Shanxi, Peoples R China.
   Du, Guanhua, Chinese Acad Med Sci, Inst Mat Med, Beijing, Peoples R China.
   Du, Guanhua, Peking Union Med Coll, Beijing, Peoples R China.},
DOI = {10.3389/fphar.2019.00192},
Article-Number = {192},
ISSN = {1663-9812},
Keywords = {Angelicae Sinensis Radix; anti-depression; anemia; metabonomics;
   hypoxia; sphingolipid metabolism},
Keywords-Plus = {COMPARATIVE METABOLOMICS ANALYSIS; TRADITIONAL CHINESE MEDICINE;
   DANGGUI-SHAOYAO-SAN; RAT MODEL; ANEMIA; ACID; METABOLISM; MECHANISM;
   MICE; INVOLVEMENT},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {zhouyuzhi@sxu.edu.cn
   qinxm@sxu.edu.cn},
Affiliations = {Shanxi University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Institute of Materia Medica - CAMS; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College},
ResearcherID-Numbers = {Zhu, Shiwei/T-8673-2019
   Chen, Congcong/NKP-8894-2025},
Funding-Acknowledgement = {National Nature Science Foundation of China {[}81673572]; Applied Basic
   Research Project of Shanxi Province {[}201601D021164]; Innovation
   Project of Higher Education Institutions in Shanxi Province {[}2016120];
   Major Research and Development Plan Project of Shanxi Province
   {[}201703D321023-3]},
Funding-Text = {This study was funded by the National Nature Science Foundation of China
   (No. 81673572), the Applied Basic Research Project of Shanxi Province
   (No. 201601D021164), the Innovation Project of Higher Education
   Institutions in Shanxi Province (No. 2016120), and the Major Research
   and Development Plan Project of Shanxi Province (No. 201703D321023-3).},
Cited-References = {Allen PJ, 2015, METABOLOMICS, V11, P1131, DOI 10.1007/s11306-014-0767-2.
   {[}Anonymous], 2016, THESIS.
   Aulakh R, 2009, INDIAN J PEDIATR, V76, P265, DOI 10.1007/s12098-009-0014-4.
   Buttarello M, 2016, INT J LAB HEMATOL, V38, P123, DOI 10.1111/ijlh.12500.
   Cai Liqiang, 2017, Shanghai Arch Psychiatry, V29, P21, DOI 10.11919/j.issn.1002-0829.216082.
   Chen CK, 2010, PSYCHOSOMATICS, V51, P528, DOI 10.1176/appi.psy.51.6.528.
   Chen H. M., 2005, GUID J TCM, V11, P4.
   Demircan F, 2016, NEUROL THER, V5, P27, DOI 10.1007/s40120-015-0039-8.
   Dorgalaleh Akbar, 2013, Int J Hematol Oncol Stem Cell Res, V7, P34.
   Du J, 2009, P NATL ACAD SCI USA, V106, P3543, DOI 10.1073/pnas.0812671106.
   Fournier NM, 2012, BEHAV BRAIN RES, V227, P440, DOI 10.1016/j.bbr.2011.04.022.
   Fraenkel PG, 2017, MED CLIN N AM, V101, P285, DOI 10.1016/j.mcna.2016.09.005.
   Gao L, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01098.
   Hunter RG, 2016, P NATL ACAD SCI USA, V113, P9099, DOI 10.1073/pnas.1602185113.
   Ji P, 2018, J ETHNOPHARMACOL, V211, P101, DOI 10.1016/j.jep.2017.09.028.
   Joharapurkar AA, 2018, J MED CHEM, V61, P6964, DOI 10.1021/acs.jmedchem.7b01686.
   Li P., 2013, BR J NUTR, V98, P237.
   Li PL, 2015, J ETHNOPHARMACOL, V166, P261, DOI 10.1016/j.jep.2015.03.010.
   Li WX, 2014, J CHROMATOGR A, V1346, P49, DOI 10.1016/j.chroma.2014.04.042.
   {[}刘亚敏 Liu Yamin], 2017, {[}中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V33, P106.
   Mitrache C, 2001, ANN HEMATOL, V80, P295, DOI 10.1007/s002770100287.
   Murakami M., 1999, J PSYCHOSOM MED, V39, P145.
   Newsholme P, 2007, BIOCHEM SOC T, V35, P1180, DOI 10.1042/BST0351180.
   Ostergaard L, 2018, NEUROSCI BIOBEHAV R, V94, P248, DOI 10.1016/j.neubiorev.2018.08.007.
   Pamuk GE, 2016, WIEN KLIN WOCHENSCHR, V128, pS576, DOI 10.1007/s00508-015-0740-8.
   Pang HQ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00165.
   Penninx BWJH, 2004, J AM GERIATR SOC, V52, P719, DOI 10.1111/j.1532-5415.2004.52208.x.
   Pferschy-Wenzig EM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00893.
   Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2.
   Quirk SE, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-175.
   Ren L, 2017, J ETHNOPHARMACOL, V203, P226, DOI 10.1016/j.jep.2017.03.042.
   Shen J., 2016, ALTERNAT MED, V2016, P1.
   Singh JCH, 2015, PHARM BIOL, V53, P630, DOI 10.3109/13880209.2014.935866.
   Tacchi R, 2008, PHARMACOL RES, V57, P464, DOI 10.1016/j.phrs.2008.05.004.
   Testai FD, 2014, J NEUROCHEM, V131, P530, DOI 10.1111/jnc.12836.
   Urrechaga E, 2015, INT J LAB HEMATOL, V37, P334, DOI 10.1111/ijlh.12290.
   Vulser H, 2016, ACTA PSYCHIAT SCAND, V134, P150, DOI 10.1111/acps.12595.
   Wang JJ, 2018, J ETHNOPHARMACOL, V214, P13, DOI 10.1016/j.jep.2017.11.037.
   Wang T, 2016, CHIN J NAT MEDICINES, V14, P210, DOI 10.1016/S1875-5364(16)30018-8.
   Wu FZ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00956.
   Xu F, 2011, PHYTOMEDICINE, V18, P1130, DOI 10.1016/j.phymed.2011.05.002.
   Yang MQ, 2018, PSYCHOPHARMACOLOGY, V235, P2573, DOI 10.1007/s00213-018-4949-x.
   Zeni ALB, 2012, EUR J PHARMACOL, V679, P68, DOI 10.1016/j.ejphar.2011.12.041.
   Zhang G., 2013, THESIS.
   Zhang XY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00282.
   Zhang YJ, 2011, BRAIN RES BULL, V86, P222, DOI 10.1016/j.brainresbull.2011.07.002.
   Zhang Y, 2017, BRAIN RES BULL, V135, P77, DOI 10.1016/j.brainresbull.2017.09.015.
   Zhou KC, 2015, NEUROSCI LETT, V597, P26, DOI 10.1016/j.neulet.2015.04.030.
   Zhou YZ, 2011, J ETHNOPHARMACOL, V137, P236, DOI 10.1016/j.jep.2011.05.016.
   Zhu SQ, 2017, MOLECULES, V22, DOI 10.3390/molecules22060918.},
Number-of-Cited-References = {50},
Times-Cited = {38},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {73},
Journal-ISO = {Front. Pharmacol.},
Doc-Delivery-Number = {HN9EC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000460501200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000460323000008,
Author = {Fu, Hongyong and Zhou, Fan and Yuan, Qingqing and Zhang, Wenhui and Qiu,
   Qianqian and Yu, Xing and He, Zuping},
Title = {miRNA-31-5p Mediates the Proliferation and Apoptosis of Human
   Spermatogonial Stem Cells via Targeting JAZF1 and Cyclin A2},
Journal = {MOLECULAR THERAPY-NUCLEIC ACIDS},
Year = {2019},
Volume = {14},
Pages = {90-100},
Month = {MAR 1},
Abstract = {Several lines of evidence highlight the important application of human
   spermatogonial stem cells (SSCs) in translational medicine. The fate
   decisions of SSCs are mainly mediated by genetic and epigenetic factors.
   We have recently demonstrated that PAK1 regulates the proliferation, DNA
   synthesis, and early apoptosis of human SSCs through the PDK1/KDR/ZNF367
   and ERK1/2 and AKT pathway. However, the underlying epigenetic mechanism
   of PAK1 in human SSCs remains unknown. In this study, we found that the
   level of miRNA-31-5p was elevated by PAK1 knockdown. CCK-8, PCNA, and
   5-ethynyl-2'-deoxyuridine (EDU) assays revealed that miRNA-31-5p mimics
   inhibited cell proliferation and DNA synthesis of human SSCs. Annexin
   V/propidium iodide (PI) staining and flow cytometry showed that
   miRNA-31-5p increased the early and late apoptosis of human SSCs.
   Furthermore, JAZF1 was predicted and verified as a target of
   miRNA-31-5p, and the three-dimensional (3D) structure model of JAZF1
   protein was illustrated. JAZF1 silencing led to a reduction of cell
   proliferation and DNA synthesis as well as an enhancement of the early
   and late apoptosis of human SSCs. Finally, miRNA-31-5p mimics decreased
   the level of cyclin A2 rather than cyclin D1 or cyclin E1, and JAZF1
   knockdown led to the reduction of cyclin A2 in human SSCs. Collectively,
   miRNA-31-5p regulates the proliferation, DNA synthesis, and apoptosis of
   human SSCs by the PAK1-JAZF1-cyclin A2 pathway. This study thus offers a
   novel insight into the molecular mechanisms underlying the fate
   determinations of human SSCs and might provide novel targets for
   molecular therapy of male infertility.},
Publisher = {CELL PRESS},
Address = {50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA},
Type = {Article},
Language = {English},
Affiliation = {He, ZP (Corresponding Author), Hunan Normal Univ, Sch Med, 371 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
   Yu, Xing; He, Zuping, Hunan Normal Univ, Sch Med, 371 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.
   Fu, Hongyong; Zhou, Fan; Yuan, Qingqing; Zhang, Wenhui; Qiu, Qianqian; He, Zuping, Shanghai Jiao Tong Univ, Sch Med, Ren Ji Hosp, Renji Med Clin Stem Cell Res Ctr 10, 160 Pu Jian Rd, Shanghai 200127, Peoples R China.
   Fu, Hongyong, Zhengzhou Univ, Henan Canc Hosp, Affiliated Canc Hosp, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.
   He, Zuping, Shanghai Key Lab Assisted Reprod \& Reprod Genet, Shanghai 200127, Peoples R China.
   He, Zuping, Shanghai Key Lab Reprod Med, Shanghai 200025, Peoples R China.},
DOI = {10.1016/j.omtn.2018.11.004},
ISSN = {2162-2531},
Keywords-Plus = {HUMAN SERTOLI-CELLS; SELF-RENEWAL; MOUSE; GERM; SPERMATOGENESIS; LINE;
   ESTABLISHMENT; MECHANISMS; MICRORNA; PATHWAY},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {zupinghe@sjtu.edu.cn},
Affiliations = {Hunan Normal University; Shanghai Jiao Tong University; Zhengzhou
   University},
ORCID-Numbers = {HE, ZUPING/0000-0003-3741-9350
   , Hongyong/0000-0002-2777-5645},
Funding-Acknowledgement = {National Nature Science Foundation of China {[}31671550, 31872845,
   31230048]; Chinese Ministry of Science and Technology {[}2016YFC1000606,
   2014CB943101]; Shanghai Hospital Development Center {[}SHDC12015122]},
Funding-Text = {This work was supported by grants from the National Nature Science
   Foundation of China (31671550, 31872845, 31230048), Chinese Ministry of
   Science and Technology (2016YFC1000606, 2014CB943101), and Shanghai
   Hospital Development Center (SHDC12015122).},
Cited-References = {Björk JK, 2010, DEVELOPMENT, V137, P3177, DOI 10.1242/dev.050955.
   Boitani C, 2016, SEMIN CELL DEV BIOL, V59, P79, DOI 10.1016/j.semcdb.2016.03.002.
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035.
   Chen SR, 2015, REPRODUCTION, V149, pR159, DOI 10.1530/REP-14-0481.
   Crisóstomo L, 2018, METHODS MOL BIOL, V1748, P129, DOI 10.1007/978-1-4939-7698-0\_11.
   Cui N, 2016, J CELL MOL MED, V20, P1503, DOI 10.1111/jcmm.12838.
   de Rooij DG, 2017, DEVELOPMENT, V144, P3022, DOI 10.1242/dev.146571.
   DenBesten PK, 1999, EUR J ORAL SCI, V107, P276, DOI 10.1046/j.0909-8836.1999.eos107407.x.
   Esteves SC, 2015, ASIAN J ANDROL, V17, P459, DOI 10.4103/1008-682X.148719.
   Fu HY, 2018, MOL THER-NUCL ACIDS, V12, P769, DOI 10.1016/j.omtn.2018.06.006.
   Garcia TX, 2015, ANIM REPROD, V12, P35.
   Gunes S, 2016, J ASSIST REPROD GEN, V33, P553, DOI 10.1007/s10815-016-0682-8.
   Harchegani A. B, 2018, REPROD SCI.
   Hayashi K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001738.
   He ZP, 2013, STEM CELLS, V31, P2205, DOI 10.1002/stem.1474.
   Hentrich A, 2011, MODERN PATHOL, V24, P1380, DOI 10.1038/modpathol.2011.97.
   Hermann BP, 2010, REPRODUCTION, V139, P479, DOI 10.1530/REP-09-0255.
   Hofmann MC, 2005, STEM CELLS, V23, P200, DOI 10.1634/stemcells.2003-0036.
   Hou JM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16922.
   Jamsai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077311.
   Kanatsu-Shinohara M, 2013, ANNU REV CELL DEV BI, V29, P163, DOI 10.1146/annurev-cellbio-101512-122353.
   Komeya M, 2015, ASIAN J ANDROL, V17, P771, DOI 10.4103/1008-682X.154995.
   Li M, 2013, CELL PROLIFERAT, V46, P223, DOI 10.1111/cpr.12013.
   Lim JJ, 2010, CELL PROLIFERAT, V43, P405, DOI 10.1111/j.1365-2184.2010.00691.x.
   Medrano JV, 2016, FERTIL STERIL, V106, P1539, DOI 10.1016/j.fertnstert.2016.07.1065.
   Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489.
   Montoya V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138366.
   Moritoki Y, 2014, J UROLOGY, V191, P1174, DOI 10.1016/j.juro.2013.10.137.
   Niu BW, 2016, REJUV RES, V19, P120, DOI 10.1089/rej.2015.1719.
   Niu ZY, 2011, P NATL ACAD SCI USA, V108, P12740, DOI 10.1073/pnas.1109987108.
   Procópio MS, 2017, CELL TISSUE RES, V370, P335, DOI 10.1007/s00441-017-2667-z.
   Qin YF, 2012, REPROD BIOMED ONLINE, V24, P454, DOI 10.1016/j.rbmo.2012.01.006.
   Romero Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025241.
   Song WC, 2015, J CELL BIOCHEM, V116, P2155, DOI 10.1002/jcb.25172.
   Tahmasbpour E, 2014, J ASSIST REPROD GEN, V31, P1115, DOI 10.1007/s10815-014-0280-6.
   Tüttelmann F, 2018, MED GENET-BERLIN, V30, P12, DOI 10.1007/s11825-018-0181-7.
   Wang H, 2017, SCI REP-UK, V7, DOI 10.1038/srep45298.
   Wang H, 2016, REPRODUCTION, V152, pR31, DOI 10.1530/REP-15-0546.
   Wang X, 2017, EXP CELL RES, V361, P201, DOI 10.1016/j.yexcr.2017.09.009.
   Wosnitzer Matthew, 2014, Spermatogenesis, V4, pe28218.
   Wu JW, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-64.
   Yao CC, 2016, ONCOTARGET, V7, P2201, DOI 10.18632/oncotarget.6876.
   Zimmermann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107023.},
Number-of-Cited-References = {43},
Times-Cited = {44},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {38},
Journal-ISO = {Mol. Ther.-Nucl. Acids},
Doc-Delivery-Number = {HN6UZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000460323000008},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000455692600001,
Author = {Jeong, Seong-Gu and Kim, Sunggyu and Kim, Han Gyung and Kim, Eunji and
   Jeong, Deok and Kim, Ji Hye and Yang, Woo Seok and Oh, Junsang and Sung,
   Gi-Ho and Hossain, Mohammad Amjad and Lee, Jongsung and Kim, Jong-Hoon
   and Cho, Jae Youl},
Title = {Mycetia caulifiora methanol extract exerts anti-inflammatory
   activity by directly targeting PDK1 in the NF-κB pathway},
Journal = {JOURNAL OF ETHNOPHARMACOLOGY},
Year = {2019},
Volume = {231},
Pages = {1-9},
Month = {MAR 1},
Abstract = {Ethnopharmacological relevance: Mycetia cauliflora Reinw. (Rubiaceae)
   has been used as a traditional remedy to ameliorate clinical signs of
   inflammatory diseases, including pain, inflammation, ulcers, and wounds.
   Among the Mycetia subfamilies, the molecular and cellular mechanisms of
   Mycetia longifolia (Rubiaceae) have been studied. However, those of
   Mycetia caulifiora are not clearly understood. Comprehensive
   investigation of this plant is necessary to evaluate its potential for
   ethnopharmacological use.
   Materials: and methods: The activities of Mycetia cauliflora methanol
   extract (Mc-ME) on the secretion of inflammatory mediators, the mRNA
   expression of proinflammatory cytokines, and identification of its
   molecular targets were elucidated using lipopolysaccharide (LPS)-induced
   macrophage-like cells. Moreover, the suppressive actions of Mc-ME were
   examined in an LPS-induced peritonitis mouse model.
   Results: At nontoxic concentrations, Mc-ME downregulated the release of
   nitric oxide (NO), the mRNA expression of inducible nitric oxide
   synthase (iNOS), and the mRNA expression of interleukin (IL)-1 beta from
   LPS-activated RAW264.7 cells. This extract also inhibited the nuclear
   translocation of p65 and p50 and the phosphorylation of I kappa B alpha,
   IKK, and AKT. Western blot analysis and in vitro kinase assays confirmed
   that phosphoinositide-dependent kinase-1 (PDK1) is the direct
   immunopharmacological target of Mc-ME effect. In addition, Mc-ME
   significantly reduced inflammatory signs in an animal model of acute
   peritonitis. These effects were associated with decreased NO production
   and decreased AKT phosphorylation.
   Conclusion: Our results suggest that Mc-ME displays anti-inflammatory
   actions in LPS-treated macrophage-like cells and in an animal model of
   acute inflammatory disease. These actions are preferentially managed by
   targeting PDK1 in the nuclear factor (NF)-kappa B signaling pathway.},
Publisher = {ELSEVIER IRELAND LTD},
Address = {ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND},
Type = {Article},
Language = {English},
Affiliation = {Lee, J; Cho, JY (Corresponding Author), Sungkyunkwan Univ, Dept Integrat Biotechnol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Kim, JH (Corresponding Author), Chonbuk Natl Univ, Coll Med, Dept Vet Physiol, 79 Gobong Ro, Iksan 54596, South Korea.
   Jeong, Seong-Gu; Kim, Han Gyung; Kim, Eunji; Jeong, Deok; Kim, Ji Hye; Yang, Woo Seok; Lee, Jongsung; Cho, Jae Youl, Sungkyunkwan Univ, Dept Integrat Biotechnol, 2066 Seobu Ro, Suwon 16419, South Korea.
   Kim, Sunggyu, Sungkyunkwan Univ, Res \& Business Fdn, Suwon 16419, South Korea.
   Oh, Junsang; Sung, Gi-Ho, Catholic Kwandong Univ, Int St Marys Hosp, Inst Biomed Convergence, Incheon, South Korea.
   Oh, Junsang; Sung, Gi-Ho, Catholic Kwandong Univ, Coll Med, Incheon, South Korea.
   Hossain, Mohammad Amjad; Kim, Jong-Hoon, Chonbuk Natl Univ, Coll Vet Med, Iksan 54596, South Korea.},
DOI = {10.1016/j.jep.2018.11.013},
ISSN = {0378-8741},
EISSN = {1872-7573},
Keywords = {Mycetia caulifiora; Anti-inflammatory activity; Peritonitis; NF-kappa B;
   PDK1},
Keywords-Plus = {INFLAMMATORY MEDIATORS; IN-VITRO; SRC; SYK; QUERCETIN; KINASE;
   SUPPRESSION; ACTIVATION; RESPONSES},
Research-Areas = {Plant Sciences; Pharmacology \& Pharmacy; Integrative \& Complementary
   Medicine},
Web-of-Science-Categories  = {Plant Sciences; Chemistry, Medicinal; Integrative \& Complementary
   Medicine; Pharmacology \& Pharmacy},
Author-Email = {sukim590@skku.edu
   hanks523@skku.edu
   kjhmlkjhml@hanmail.net
   bioneer@skku.edu
   jhkim1@jbnu.ac.kr
   jaecho@skku.edu},
Affiliations = {Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Catholic
   Kwandong University; Catholic Kwandong University; Jeonbuk National
   University},
ResearcherID-Numbers = {Kim, Han Gyung/AAN-5655-2021
   Hossain, Mohammad Amjad/AAP-3855-2021},
ORCID-Numbers = {Kim, Han Gyung/0000-0002-4730-9801
   Kim, Han Gyung/0000-0002-4730-9801
   Hossain, Mohammad Amjad/0000-0001-8941-1065},
Funding-Acknowledgement = {Leades Industry-University Cooperation (LINC) Project through the
   National Research Foundation of Korea (NRF) - Ministry of Education,
   Korea; Basic Science Research Program through the National Research
   Foundation of Korea (NRF) - Ministry of Education, Korea
   {[}2017R1A6A1A03015642]},
Funding-Text = {This research was supported by Leades Industry-University Cooperation
   (LINC) Project and Basic Science Research Program (2017R1A6A1A03015642)
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Korea.},
Cited-References = {{[}Anonymous], FLORA CHINA.
   {[}Anonymous], 2018, THER ADV MED ONCOL.
   Aziz N, 2018, J ETHNOPHARMACOL, V225, P342, DOI 10.1016/j.jep.2018.05.019.
   Baek KS, 2017, J GINSENG RES, V41, P386, DOI 10.1016/j.jgr.2016.11.001.
   Brown J, 2011, J DENT RES, V90, P417, DOI 10.1177/0022034510381264.
   Byeon SE, 2013, FREE RADICAL BIO MED, V57, P105, DOI 10.1016/j.freeradbiomed.2012.12.013.
   Chen S, 2016, THER ADV MED ONCOL, V8, P160, DOI 10.1177/1758834016638019.
   Cho JY, 2001, J PHARM PHARMACOL, V53, P1287, DOI 10.1211/0022357011776577.
   Endale M, 2013, IMMUNOBIOLOGY, V218, P1452, DOI 10.1016/j.imbio.2013.04.019.
   Fahrurozi I., 2014, THESIS.
   Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x.
   Govaerts R, 2022, World Checklist of Rubiaceae.
   Hossen MJ, 2017, J GINSENG RES, V41, P43, DOI 10.1016/j.jgr.2015.12.009.
   Jeong D, 2013, J ETHNOPHARMACOL, V146, P205, DOI 10.1016/j.jep.2012.12.034.
   Jeong HY, 2014, J ETHNOPHARMACOL, V151, P960, DOI 10.1016/j.jep.2013.12.009.
   Jung YY, 2015, IMMUNE NETW, V15, P325, DOI 10.4110/in.2015.15.6.325.
   Kaur M, 2013, EUR J MED CHEM, V67, P434, DOI 10.1016/j.ejmech.2013.04.070.
   Kim E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071828.
   Kim H.G., 2018, EVID-BASED COMPL ALT, V2018, DOI DOI 10.1155/2018/3909038.
   Kim HG, 2018, J ETHNOPHARMACOL, V219, P202, DOI 10.1016/j.jep.2018.03.022.
   Kim J, 2015, J NANOSCI NANOTECHNO, V15, P269, DOI 10.1166/jnn.2015.8402.
   Kim JH, 2015, BIOMOL THER, V23, P414, DOI 10.4062/biomolther.2015.036.
   Kim KS, 2012, BIOMOL THER, V20, P50, DOI 10.4062/biomolther.2012.20.1.050.
   Kim SH, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/904142.
   Kim YJ, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/4606459.
   Lee JO, 2017, J ETHNOPHARMACOL, V206, P1, DOI 10.1016/j.jep.2017.05.013.
   Lee JO, 2018, J GINSENG RES, V42, P389.
   Leite JA, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/265798.
   Massarotti EM, 2008, CLIN THER, V30, P429, DOI 10.1016/j.clinthera.2008.03.002.
   Motaleb M.A., 2013, COMMONLY USED MED HE.
   Puff C., 2005, RUBIACEAE THAILAND P.
   Rauf A, 2018, PHYTOTHER RES, V32, P2109, DOI 10.1002/ptr.6155.
   Remppis A, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/194896.
   Rydin C, 2009, TAXON, V58, P793, DOI 10.1002/tax.583009.
   Strober W, 2001, CURR PROTOC IMMUNOL.
   Suh W, 2017, BIOMOL THER, V25, P165, DOI 10.4062/biomolther.2016.063.
   Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816.
   Yang WS, 2017, AM J CHINESE MED, V45, P1217, DOI 10.1142/S0192415X17500677.
   Yang WS, 2017, J GINSENG RES, V41, P298, DOI 10.1016/j.jgr.2016.06.004.
   Yang WS, 2017, J ETHNOPHARMACOL, V201, P82, DOI 10.1016/j.jep.2017.03.001.
   Yang WS, 2014, J ETHNOPHARMACOL, V151, P1165, DOI 10.1016/j.jep.2013.12.033.
   Yang Y, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/352371.
   Yi YS, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/270302.
   Yoo S, 2018, BIOCHEM PHARMACOL, V148, P1, DOI 10.1016/j.bcp.2017.12.006.
   Yu T, 2017, J GINSENG RES, V41, P127, DOI 10.1016/j.jgr.2016.02.001.
   Yu T, 2011, J ETHNOPHARMACOL, V134, P11, DOI 10.1016/j.jep.2010.08.060.},
Number-of-Cited-References = {46},
Times-Cited = {12},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {31},
Journal-ISO = {J. Ethnopharmacol.},
Doc-Delivery-Number = {HH4KZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000455692600001},
DA = {2026-02-04},
}

@article{ WOS:000459236900013,
Author = {Jiao, Lin and Wang, Shengqi and Zheng, Yifeng and Wang, Neng and Yang,
   Bowen and Wang, Dongmei and Yang, Depo and Mei, Wenjie and Zhao, Zhimin
   and Wang, Zhiyu},
Title = {Betulinic acid suppresses breast cancer aerobic glycolysis via
   caveolin-1/NF-κB/c-Myc pathway},
Journal = {BIOCHEMICAL PHARMACOLOGY},
Year = {2019},
Volume = {161},
Pages = {149-162},
Month = {MAR},
Abstract = {Emerging evidence has suggested that targeting glycolysis may be a
   promising strategy for cancer treatment. Betulinic acid (BA) is a
   natural pentacyclic terpene that has been reported to be active in
   inhibiting various malignancies. Here, we showed that BA could inhibit
   aerobic glycolysis activity in breast cancer cell lines MCF-7 and
   MDA-MB-231 by hampering lactate production, glucose uptake and
   extracellular acidification rate (ECAR), as well as suppressing aerobic
   glycolysis-related proteins including c-Myc, lactate dehydrogenase A
   (LDH-A) and p-PDK1/PDK1 (pyruvate dehydrogenase kinase 1). Mechanistic
   studies validated Caveolin-1 (Cav-1) as one of key targets of BA in
   suppressing aerobic glycolysis, as BA administration resulted in Cav-1
   upregulation, whereas silencing Cav-1 abrogated the inhibitory effect of
   BA on aerobic glycolysis. Further investigations demonstrated that BA
   suppressed aerobic glycolysis in breast cancer cells by regulating the
   Cav-1/NF-kappa B/c-Myc pathway. More meaningfully, BA significantly
   inhibited breast cancer growth and glycolytic activity in both the
   transgenic MMTV-PyVT+/- breast cancer spontaneous model and the
   zebrafish breast cancer xenotransplantation model without any detectable
   side effects in vivo. Taken together, our study sheds novel insights
   into BA as a promising candidate drug for suppressing aerobic
   glycolysis, highlighting Cav-1 as a potential molecular target of BA and
   aerobic glycolysis regulation.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Zhao, ZM (Corresponding Author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
   Wang, ZY (Corresponding Author), Guangzhou Univ Chinese Med, Integrat Res Lab Breast Canc, Discipline Integrated Chinese \& Western Med, Res Ctr Integrat Med,Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.
   Wang, ZY (Corresponding Author), Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
   Wang, ZY (Corresponding Author), Guangdong Prov Hosp Chinese Med, Guangdong Prov Key Lab Clin Res Tradit Chinese Me, Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China.
   Wang, ZY (Corresponding Author), Guangzhou Univ Chinese Med, Postdoctoral Res Ctr, Guangzhou, Guangdong, Peoples R China.
   Jiao, Lin; Wang, Dongmei; Yang, Depo; Zhao, Zhimin, Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou, Guangdong, Peoples R China.
   Jiao, Lin; Wang, Shengqi; Zheng, Yifeng; Wang, Neng; Yang, Bowen; Wang, Zhiyu, Guangzhou Univ Chinese Med, Integrat Res Lab Breast Canc, Discipline Integrated Chinese \& Western Med, Res Ctr Integrat Med,Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.
   Jiao, Lin; Wang, Shengqi; Zheng, Yifeng; Wang, Neng; Yang, Bowen; Wang, Zhiyu, Guangzhou Univ Chinese Med, Clin Coll 2, Guangzhou, Guangdong, Peoples R China.
   Wang, Shengqi; Zheng, Yifeng; Yang, Bowen; Wang, Zhiyu, Guangdong Prov Hosp Chinese Med, Guangdong Prov Key Lab Clin Res Tradit Chinese Me, Guangdong Prov Acad Chinese Med Sci, Guangzhou, Guangdong, Peoples R China.
   Wang, Shengqi; Zheng, Yifeng; Wang, Zhiyu, Guangzhou Univ Chinese Med, Postdoctoral Res Ctr, Guangzhou, Guangdong, Peoples R China.
   Mei, Wenjie, Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou, Guangdong, Peoples R China.},
DOI = {10.1016/j.bcp.2019.01.016},
ISSN = {0006-2952},
EISSN = {1873-2968},
Keywords = {Betulinic acid; Aerobic glycolysis; Caveolin-1; NF-kappa B/c-Myc; Breast
   cancer},
Keywords-Plus = {KAPPA-B; DRUG-RESISTANCE; GENE-EXPRESSION; CELL-LINES; IN-VIVO; C-MYC;
   CAVEOLIN-1; GROWTH; METASTASIS; INHIBITION},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Pharmacology \& Pharmacy},
Author-Email = {zhaozhm2@mail.sysu.edu.cn
   wangzhiyu@gzucm.edu.cn},
Affiliations = {Sun Yat Sen University; Guangzhou University of Chinese Medicine;
   Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine; Guangzhou University of Chinese Medicine; Guangdong
   Pharmaceutical University},
ResearcherID-Numbers = {wang, zhiyu/K-5255-2016
   Zheng, Yifeng/H-2067-2017},
ORCID-Numbers = {Mei, Wenjie/0000-0003-1468-6317
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81703749, 81703764,
   81573651, 81873306]; Guangdong Science and Technology Department
   {[}2016A030306025]; Guangzhou Science, Technology and Innovation
   Commission {[}805296345055]; Pearl River S\&T Nova Program of Guangzhou
   {[}201506010098]; Guangdong Provincial Science and Technology Agency;
   Guangdong Provincial Academy of Traditional Chinese Medicine
   {[}2014A020221047]; Natural Science Foundation of Guangdong Province
   {[}2016A030313855]; Guangdong High-level University Construction Project
   {[}A1-AFD018161Z1510, A1-AFD018171Z11102, A1-AFD018171Z11101]; Guangdong
   High-level Personnel of Special Support Program {[}A1-3002-16-111-003];
   Guangdong Traditional Chinese Medicine Bureau Project {[}20181132,
   20182044]; Postdoctoral Science Foundation of China {[}2017 M612644,
   2018 T110861, 2017 M622669]; PhD Start-up Fund of Natural Science
   Foundation of Guangdong Province {[}2017A030310213]; Guangdong
   Provincial Key Project {[}2016kzdxm032]; Science and Technology Planning
   Project of Guangdong Province {[}2017B030314166]; Specific Research Fund
   for TCM Science and Technology of Guangdong Provincial Hospital of
   Chinese Medicine {[}YN2018MJ07, YN2018QJ08]},
Funding-Text = {This work was supported by the National Natural Science Foundation of
   China (81703749, 81703764, 81573651 and 81873306), Guangdong Science and
   Technology Department (2016A030306025), Guangzhou Science, Technology
   and Innovation Commission (805296345055), Pearl River S\&T Nova Program
   of Guangzhou (201506010098), Combined Scientific Project Funded by
   Guangdong Provincial Science and Technology Agency and Guangdong
   Provincial Academy of Traditional Chinese Medicine (2014A020221047), the
   Natural Science Foundation of Guangdong Province (2016A030313855),
   Guangdong High-level University Construction Project (A1-AFD018161Z1510,
   A1-AFD018171Z11102 and A1-AFD018171Z11101), Guangdong High-level
   Personnel of Special Support Program (A1-3002-16-111-003), Guangdong
   Traditional Chinese Medicine Bureau Project (20181132 and 20182044), the
   Postdoctoral Science Foundation of China (2017 M612644, 2018 T110861 and
   2017 M622669), the PhD Start-up Fund of Natural Science Foundation of
   Guangdong Province (2017A030310213) and Guangdong Provincial Key Project
   (2016kzdxm032), Science and Technology Planning Project of Guangdong
   Province (2017B030314166), the Specific Research Fund for TCM Science
   and Technology of Guangdong Provincial Hospital of Chinese Medicine
   (YN2018MJ07, YN2018QJ08).},
Cited-References = {{[}Anonymous], 2011, CANC THER.
   Bender FC, 2000, CANCER RES, V60, P5870.
   Cai YL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0669-8.
   Chen F, 2001, AM J PATHOL, V159, P387, DOI 10.1016/S0002-9440(10)61708-7.
   Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137.
   Chen Z, 2007, J BIOENERG BIOMEMBR, V39, P267, DOI 10.1007/s10863-007-9086-x.
   Chintharlapalli S, 2007, CANCER RES, V67, P2816, DOI 10.1158/0008-5472.CAN-06-3735.
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371.
   Galgon T, 2005, EXP DERMATOL, V14, P736, DOI 10.1111/j.1600-0625.2005.00352.x.
   Garrean S, 2006, J IMMUNOL, V177, P4853, DOI 10.4049/jimmunol.177.7.4853.
   Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193.
   Glait C, 2006, FEBS LETT, V580, P5268, DOI 10.1016/j.febslet.2006.08.071.
   Heiss EH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115683.
   Hsu TI, 2012, MOL PHARMACOL, V82, P1115, DOI 10.1124/mol.112.078485.
   Jin S, 2013, RECENT PAT ANTI-CANC, V8, P143.
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6.
   Kitajima K, 2018, ANN NUCL MED, V32, P44, DOI 10.1007/s12149-017-1217-9.
   Lamaze C, 2015, BIOMED J, V38, P367, DOI 10.4103/2319-4170.164229.
   LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039.
   Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661.
   Li L, 2013, CLIN CANCER RES, V19, P4651, DOI 10.1158/1078-0432.CCR-12-3630.
   Liao HH, 2015, INT J CLIN EXP MED, V8, P8948.
   Liu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091606.
   Liu T., 2016, ONCOL REP, V37, P193.
   Maiso P, 2015, CANCER RES, V75, P2071, DOI 10.1158/0008-5472.CAN-14-3400.
   Mayevsky A, 2009, MITOCHONDRION, V9, P165, DOI 10.1016/j.mito.2009.01.009.
   Mertens-Talcott SU, 2013, MOL CARCINOGEN, V52, P591, DOI 10.1002/mc.21893.
   Misra Sanjukta, 2013, J Assoc Physicians India, V61, P127.
   Nijsten MWN, 2009, MED HYPOTHESES, V73, P48, DOI 10.1016/j.mehy.2009.01.041.
   Nwosu ZC, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0558-7.
   Park H, 2015, J CELL BIOL, V211, P619, DOI 10.1083/jcb.201503113.
   Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005.
   Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x.
   Raikar LS., 2010, J CELL BIOCHEM, V98, P861.
   Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100.
   Shin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021492.
   Steinle AU, 1999, GASTROENTEROLOGY, V116, P420, DOI 10.1016/S0016-5085(99)70140-X.
   Tang Y, 2016, CLIN BREAST CANCER, V16, P335, DOI 10.1016/j.clbc.2016.05.012.
   Thou M., 2010, MOL CANCER, V9, P1.
   Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654.
   Tzenov YR, 2016, J CLIN PATHOL, V69, P518, DOI 10.1136/jclinpath-2015-203395.
   Wang XM, 2011, J VIROL, V85, P5483, DOI 10.1128/JVI.00254-11.
   Williams TM, 2003, MOL BIOL CELL, V14, P1027, DOI 10.1091/mbc.E02-08-0503.
   Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200.
   Witkiewicz AK, 2011, CELL CYCLE, V10, P1794, DOI 10.4161/cc.10.11.15675.
   Xu T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105768.
   Zeng AQ, 2018, ONCOTARGET, V9, P3794, DOI 10.18632/oncotarget.23376.
   Zeng X, 2002, CANCER RES, V62, P3538.
   Zhang Qianwen, 2014, Genes Cancer, V5, P100.
   Zhao BX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071071.
   Zhao GL, 2007, J PHARMACEUT BIOMED, V43, P959, DOI 10.1016/j.jpba.2006.09.026.
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60.
   Zuco V, 2002, CANCER LETT, V175, P17, DOI 10.1016/S0304-3835(01)00718-2.},
Number-of-Cited-References = {53},
Times-Cited = {93},
Usage-Count-Last-180-days = {3},
Usage-Count-Since-2013 = {64},
Journal-ISO = {Biochem. Pharmacol.},
Doc-Delivery-Number = {HM1TV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000459236900013},
DA = {2026-02-04},
}

@article{ WOS:000458730600021,
Author = {Katase, Naoki and Nishimatsu, Shin-Ichiro and Yamauchi, Akira and
   Yamamura, Masahiro and Fujita, Shuichi},
Title = {DKK3 knockdown confers negative effects on the malignant potency of head
   and neck squamous cell carcinoma cells via the PI3K/Akt and MAPK
   signaling pathways},
Journal = {INTERNATIONAL JOURNAL OF ONCOLOGY},
Year = {2019},
Volume = {54},
Number = {3},
Pages = {1021-1032},
Month = {MAR},
Abstract = {Dickkopf-related protein 3 (DKK3), which is a member of the Dickkopf WNT
   signaling pathway inhibitor family, is considered to be a tumor
   suppressor, due to its reduced expression in cancer cells and its
   ability to induce apoptosis when overexpressed by adenovirus. However,
   our previous study demonstrated alternative functions for DKK3 in head
   and neck squamous cell carcinoma (HNSCC). Our study reported that DKK3
   expression was predominantly upregulated in HNSCC cell lines and tissue
   samples, and its expression was significantly correlated with poor
   prognosis. Furthermore, DKK3 overexpression in HNSCC cells significantly
   increased cancer cell proliferation, migration, invasion and in vivo
   tumor growth. These data have led to the hypothesis that DKK3 may exert
   oncogenic functions and may increase the malignant properties of HNSCC.
   The present study established a stable DKK3 knockdown cell line (HSC-3
   shDKK3) using lentivirus-mediated short hairpin RNA, and assessed its
   effects on cancer cell behavior using MTT, migration and invasion
   assays. In addition, its effects on in vivo tumor growth were assessed
   using a xenograft model. Furthermore, the molecular mechanisms
   underlying the effects of DKK3 knockdown were investigated by microarray
   analysis, pathway analysis and western blotting. Compared with control
   cells, HSC-3 shDKK3 cells exhibited significantly reduced proliferation,
   migration and invasion, and formed significantly smaller tumor masses
   when subcutaneously transplanted into nude mice. In addition, in HSC-3
   shDKK3 cells, the expression levels of phosphorylated (p)-protein kinase
   B (Akt) (Ser473), p-phosphoinositide 3-kinase (PI3K) p85 (Tyr467),
   p-PI3K p55 (Try199), p-3-phosphoinositide-dependent protein kinase-1
   (PDK1) (Ser241) and total p38 mitogen-activated protein kinase (MAPK)
   were reduced. Furthermore, phosphorylation of mechanistic target of
   rapamycin (mTOR) (Ser2448) was slightly decreased in HSC-3 shDKK3 cells,
   which may be due to the increased expression of DEP domain-containing
   mTOR-interacting protein. Conversely, DKK3 overexpression in HSC-3
   shDKK3 cells rescued cellular proliferation, migration and invasion.
   With regards to expression levels, p-PI3K and p-PDK1 expression was not
   altered, whereas mTOR and p-p38 MAPK expression was elevated. These data
   supported the hypothesis and indicated that DKK3 may contribute to the
   malignant phenotype of HNSCC cells via the PI3K/Akt/mTOR and MAPK
   signaling pathways.},
Publisher = {SPANDIDOS PUBL LTD},
Address = {POB 18179, ATHENS, 116 10, GREECE},
Type = {Article},
Language = {English},
Affiliation = {Katase, N (Corresponding Author), Nagasaki Univ, Inst Biomed Sci, Dept Oral Pathol, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528588, Japan.
   Katase, Naoki; Fujita, Shuichi, Nagasaki Univ, Inst Biomed Sci, Dept Oral Pathol, 1-7-1 Sakamoto, Nagasaki, Nagasaki 8528588, Japan.
   Katase, Naoki; Nishimatsu, Shin-Ichiro, Kawasaki Med Sch, Dept Mol \& Dev Biol, Kurashiki, Okayama 7010192, Japan.
   Nishimatsu, Shin-Ichiro, Kawasaki Med Sch, Dept Nat Sci, Kurashiki, Okayama 7010192, Japan.
   Yamauchi, Akira, Kawasaki Med Sch, Dept Biochem, Kurashiki, Okayama 7010192, Japan.
   Yamamura, Masahiro, Kawasaki Med Sch, Dept Clin Oncol, Kurashiki, Okayama 7010192, Japan.},
DOI = {10.3892/ijo.2018.4667},
ISSN = {1019-6439},
EISSN = {1791-2423},
Keywords = {head and neck squamous cell carcinoma; Dickkopf- related protein 3;
   phosphoinositide 3-kinase; protein kinase B; mitogen-activated protein
   kinase},
Keywords-Plus = {DICKKOPF (DKK)-3; GENOMIC CHARACTERIZATION; CANCER; PROGRESSION;
   METASTASIS; PROGNOSIS; INVASION; OVEREXPRESSION; EXPRESSION; MIGRATION},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {katase@nagasaki-u.ac.jp},
Affiliations = {Nagasaki University; Kawasaki Medical School; Kawasaki Medical School;
   Kawasaki Medical School; Kawasaki Medical School},
ResearcherID-Numbers = {Katase, Naoki/ACI-2910-2022
   Yamauchi, Akira/F-2202-2010},
ORCID-Numbers = {Katase, Naoki/0000-0002-5486-6630
   },
Funding-Acknowledgement = {MEXT KAKENHI {[}25861742, 16K11470]; Kawasaki Medical School {[}25-S-3,
   26-B-34, 27-B-063]; KAWASAKI Foundation for Medical Science and Medical
   Welfare; Wesco Scientific Promotion Foundation {[}2013-06]; Takeda
   Science Foundation {[}2016-39];  {[}2018047114]; Grants-in-Aid for
   Scientific Research {[}16K11470, 25861742] Funding Source: KAKEN},
Funding-Text = {The present study was supported by a Grant-in-Aid for Young Scientists
   (B) (grant no. 25861742 to NK) and a Grant-in-Aid for Scientific
   Research (C) (grant no. 16K11470 to NK) from MEXT KAKENHI; Research
   Project grants from Kawasaki Medical School (grant nos. 25-S-3, 26-B-34
   and 27-B-063 to NK), and grants from the KAWASAKI Foundation for Medical
   Science and Medical Welfare (grant no. 2013-06 to NK), the Wesco
   Scientific Promotion Foundation (grant no. 2016-39 to NK) and the Takeda
   Science Foundation (grant no. 2018047114 to NK).},
Cited-References = {Ali J, 2017, ORAL ONCOL, V70, P23, DOI 10.1016/j.oraloncology.2017.05.004.
   Baldassarri M, 2018, CANCER RES TREAT, V50, P356, DOI 10.4143/crt.2017.125.
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095.
   Chang KY, 2013, J BIOMED SCI, V20, DOI {[}10.1186/1423-0127-20-43, 10.5953/JMJH.2013.20.1.1].
   Chen LJ, 2008, J BIOL CHEM, V283, P23364, DOI 10.1074/jbc.M802375200.
   de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898.
   Edamura K, 2007, CANCER GENE THER, V14, P765, DOI 10.1038/sj.cgt.7701071.
   Fujii M, 2011, J MOL HISTOL, V42, P499, DOI 10.1007/s10735-011-9357-z.
   Fujii Y, 2014, ACTA MED OKAYAMA, V68, P63.
   Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030.
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088.
   Hosono M, 2017, ONCOTARGET, V8, P106071, DOI 10.18632/oncotarget.22526.
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211.
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923.
   Ji YM, 2016, ONCOTARGET, V7, P14188, DOI 10.18632/oncotarget.7420.
   Katase N, 2013, ATLAS GENET CYTOGENE, V17, P678.
   Katase N, 2018, ONCOL RES, V26, P45, DOI 10.3727/096504017X14926874596386.
   Katase N, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860-015-0061-9.
   Katase N, 2013, ONCOL REP, V29, P1349, DOI 10.3892/or.2013.2251.
   Katase N, 2012, ONCOL LETT, V3, P273, DOI 10.3892/ol.2011.473.
   Katase N, 2010, CANCER INVEST, V28, P103, DOI 10.3109/07357900903095680.
   Katase N, 2008, ONCOL RES, V17, P273, DOI 10.3727/096504008786991594.
   Kawasaki K, 2009, CANCER GENE THER, V16, P65, DOI 10.1038/cgt.2008.58.
   Khayer Nasibeh, 2017, Gastroenterol Hepatol Bed Bench, V10, P118.
   Lee EJ, 2009, INT J CANCER, V124, P287, DOI 10.1002/ijc.23913.
   Leonard JL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181724.
   Li SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08345-8.
   Lin PY, 2008, J ORAL PATHOL MED, V37, P18, DOI 10.1111/j.1600-0714.2007.0057.x.
   Nayak S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138801.
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046.
   Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537.
   Rogers SJ, 2005, EXPERT OPIN THER TAR, V9, P769, DOI 10.1517/14728222.9.4.769.
   Sarode GS, 2018, J ORAL PATHOL MED, V47, P547, DOI 10.1111/jop.12667.
   Sharma V., 2017, Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine, V39, DOI 10.1177/1010428317725923.
   Simpson DR, 2015, ORAL ONCOL, V51, P291, DOI 10.1016/j.oraloncology.2014.11.012.
   Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067.
   Uhlen M, 2017, SCIENCE, V357, P660, DOI 10.1126/science.aan2507.
   Upadhyay P, 2017, ORAL ONCOL, V73, P56, DOI 10.1016/j.oraloncology.2017.08.003.
   Van Waes C, 2017, LARYNGOSCOPE INVEST, V2, P310, DOI 10.1002/lio2.86.
   Veeck J, 2012, BBA-REV CANCER, V1825, P18, DOI 10.1016/j.bbcan.2011.09.003.
   Wang SQ, 2017, BIOCHEM BIOPH RES CO, V493, P534, DOI 10.1016/j.bbrc.2017.08.156.
   Wang ZY, 2017, CANCER METAST REV, V36, P491, DOI 10.1007/s10555-017-9688-7.
   Warner KA, 2008, NEOPLASIA, V10, P131, DOI 10.1593/neo.07815.
   Zhang JB, 2015, INT J CLIN EXP PATHO, V8, P244.},
Number-of-Cited-References = {44},
Times-Cited = {20},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {12},
Journal-ISO = {Int. J. Oncol.},
Doc-Delivery-Number = {HL4XY},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458730600021},
OA = {Bronze},
DA = {2026-02-04},
}

@article{ WOS:000457578600010,
Author = {Mei, Jie and Yan, Yuan and Li, Shi-Yuan and Zhou, Wen-Jie and Zhang, Qun
   and Li, Ming-Qing and Sun, Hai-Xiang},
Title = {CXCL16/CXCR6 interaction promotes endometrial decidualization via the
   PI3K/AKT pathway},
Journal = {REPRODUCTION},
Year = {2019},
Volume = {157},
Number = {3},
Pages = {273-282},
Month = {MAR},
Abstract = {Decidualization renders the endometrium transiently receptive to an
   implanting blastocyst although the underlying mechanisms remain
   incompletely understood. The aim of this study was to determine the role
   of chemokine CXCL16 and its receptor CXCR6 in the decidualization during
   pregnancy. Here, the expression of CXCL16 was investigated in
   endometrial tissues, decidua and placenta in this study. Compared with
   endometrial tissue, protein expression of CXCL16 was significantly
   higher in tissues from the fertile control samples, especially in
   villus. Meanwhile, the primary trophoblast cells and decidual stromal
   cells (DSCs) secreted more CXCL16 and expressed higher CXCR6 compared to
   endometrial stromal cells (ESCs) in vitro. Stimulation with the inducer
   of decidualization (8-bromoadenosine 3',5'-cyclic with
   medroxyprogesterone acetate, 8-Br-cAMP plus MPA) significantly
   upregulated the expression of CXCL16 and CXCR6 in ESCs in vitro. After
   treatment with exogenous recombinant human CXCL16 (rhCXCL16) or
   trophoblast-secreted CXLC16, decidualised ESCs showed a significant
   decidual response, mainly characterised by increased prolactin (PRL)
   secretion. Simultaneously, PI3K/PDK1/AKT/Cyclin D1 pathway in
   decidualised ESCs were activated by rhCXCL16, and AKT inhibitor GS
   690693 abolished the PRL secretion of ESCs that was triggered by
   rhCXCL16. Finally, the impaired CXCL16/CXCR6 expression could be
   observed at the maternal-foetal interface from patients who have
   experienced spontaneous abortion. This study suggests that the
   CXCL16/CXCR6 axis contributes to the progression of ESC decidualization
   by activating PI3K/PDK1/AKT/Cyclin D1 pathway. It unveils a new paradigm
   at the maternal-foetal interface in which CXCL16 is an initiator for the
   molecular crosstalk that enhances decidualization of ESCs.},
Publisher = {BIOSCIENTIFICA LTD},
Address = {EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Sun, HX (Corresponding Author), Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Reprod Med Ctr,Dept Obstet \& Gynecol,Med Sch, Nanjing, Jiangsu, Peoples R China.
   Li, MQ (Corresponding Author), Fudan Univ, Lab Reprod Immunol, Key Lab Reprod Regulat NPFPC, Hosp Obstet \& Gynecol,SIPPR,IRD, Shanghai, Peoples R China.
   Mei, Jie; Yan, Yuan; Sun, Hai-Xiang, Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Reprod Med Ctr,Dept Obstet \& Gynecol,Med Sch, Nanjing, Jiangsu, Peoples R China.
   Li, Shi-Yuan, Nanjing Univ, Sch Med, Nanjing, Jiangsu, Peoples R China.
   Zhou, Wen-Jie; Li, Ming-Qing, Fudan Univ, Lab Reprod Immunol, Key Lab Reprod Regulat NPFPC, Hosp Obstet \& Gynecol,SIPPR,IRD, Shanghai, Peoples R China.
   Zhang, Qun, Nanjing Univ, Nanjing Drum Tower Hosp, Affiliated Hosp, Dept Obstet \& Gynecol,Med Sch, Nanjing, Jiangsu, Peoples R China.},
DOI = {10.1530/REP-18-0417},
ISSN = {1470-1626},
Keywords-Plus = {STROMAL CELLS; CHEMOKINE CXCL16; IMPLANTATION; TROPHOBLASTS;
   PROLIFERATION; PROGRESSION; LEUKOCYTES; DECIDUA; GROWTH; CXCR6},
Research-Areas = {Developmental Biology; Reproductive Biology},
Web-of-Science-Categories  = {Developmental Biology; Reproductive Biology},
Author-Email = {mqli@fudan.edu.cn
   stevensunz@163.com},
Affiliations = {Nanjing University; Nanjing University; Fudan University; Nanjing
   University},
ResearcherID-Numbers = {Li, Ming-Qing/AFK-9650-2022
   LI, SHI-YUAN/Z-4156-2019
   mei, jie/KMA-6084-2024},
ORCID-Numbers = {Li, Ming-Qing/0000-0002-9276-0722
   Sun, Haixiang/0000-0002-1215-1792
   LI, SHI-YUAN/0000-0001-6253-5885
   },
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81601354, 31671200,
   81471513, 91542108, 81601278]; National Science Foundation of Jiangsu
   Province, China {[}BK20160128, BK20160109]; Fundamental Research Funds
   for the Central Universities {[}021414380180]; Open Project Program of
   Shanghai Key Laboratory of Female Reproductive Endocrine-Related
   Diseases {[}14DZ2271700]; Development Fund of Shanghai Talents
   {[}201557]; Shanghai Rising-Star Program {[}16QA1400800]; NPFPC Key
   Laboratory of Reproduction Regulation {[}CX2017-2]},
Funding-Text = {The present study was supported by the National Natural Science
   Foundation of China (grant no. 81601354), the National Science
   Foundation of Jiangsu Province, China (grant no. BK20160128), the
   Fundamental Research Funds for the Central Universities (grant no.
   021414380180), the Open Project Program of Shanghai Key Laboratory of
   Female Reproductive Endocrine-Related Diseases (grant no. 14DZ2271700)
   (all to J M), the National Natural Science Foundation of China (grant
   no. 31671200, 81471513 and 91542108), the Development Fund of Shanghai
   Talents (grant no. 201557), the Shanghai Rising-Star Program (grant no.
   16QA1400800) and the Innovation-oriented Science and Technology Grant
   from NPFPC Key Laboratory of Reproduction Regulation (CX2017-2) (all to
   M-Q L), the National Natural Science Foundation of China (grant no.
   81601278), the National Science Foundation of Jiangsu Province, China
   (grant no. BK20160109) (all to Q Z).},
Cited-References = {Al-Sabbagh M, 2011, ENDOCRINOLOGY, V152, P730, DOI 10.1210/en.2010-0899.
   Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012.
   Cloke B, 2008, ENDOCRINOLOGY, V149, P4462, DOI 10.1210/en.2008-0356.
   Deng L, 2010, BBA-REV CANCER, V1806, P42, DOI 10.1016/j.bbcan.2010.01.004.
   Di Castro MA, 2016, SCI REP-UK, V6, DOI 10.1038/srep34633.
   Fan DX, 2019, REPROD SCI, V26, P532, DOI 10.1177/1933719118777638.
   Guo PF, 2010, BLOOD, V116, P2061, DOI 10.1182/blood-2009-11-252940.
   Guzelogiu-Kayisli Z, 2009, SEMIN REPROD MED, V27, P62, DOI 10.1055/s-0028-1108011.
   Hajipour H, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12853.
   He YY, 2012, CLIN IMMUNOL, V145, P161, DOI 10.1016/j.clim.2012.07.017.
   Huang Y, 2006, HUM REPROD, V21, P1083, DOI 10.1093/humrep/dei436.
   Huang Y, 2008, J IMMUNOL, V180, P2367, DOI 10.4049/jimmunol.180.4.2367.
   Klemmt PAB, 2006, FERTIL STERIL, V85, P564, DOI 10.1016/j.fertnstert.2005.08.046.
   Lang E, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/513518.
   Lekva T, 2017, DIABETES VASC DIS RE, V14, P525, DOI 10.1177/1479164117728011.
   Li MQ, 2012, HUM REPROD, V27, P2107, DOI 10.1093/humrep/des132.
   Menkhorst EM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05947-0.
   Nancy P, 2012, SCIENCE, V336, P1317, DOI 10.1126/science.1220030.
   Ramhorst R, 2016, CELL ADHES MIGR, V10, P197, DOI 10.1080/19336918.2015.1135285.
   Sakumoto R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040742.
   Salker M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010287.
   Stone MJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020342.
   Vinketova K, 2016, J PREGNANCY, V2016, DOI 10.1155/2016/8689436.
   Wang HB, 2006, NAT REV GENET, V7, P185, DOI 10.1038/nrg1808.
   Wang JH, 2008, CANCER RES, V68, P10367, DOI 10.1158/0008-5472.CAN-08-2780.
   Weingrill RB, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12783.
   Yin RH, 2017, CLIN CHIM ACTA, V475, P164, DOI 10.1016/j.cca.2017.10.028.
   Yu XW, 2016, ONCOL REP, V35, P1557, DOI 10.3892/or.2015.4520.
   Zhou WH, 2008, HUM REPROD, V23, P2669, DOI 10.1093/humrep/den308.},
Number-of-Cited-References = {29},
Times-Cited = {30},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {9},
Journal-ISO = {Reproduction},
Doc-Delivery-Number = {HK0HB},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000457578600010},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000459051300022,
Author = {Serebrovska, Tetiana V. and Portnychenko, Alla G. and Portnichenko,
   Vladimir I. and Xi, Lei and Egorov, Egor and Antoniuk-Shcheglova, Ivanna
   and Naskalova, Svitlana and Shatylo, Valeriy B.},
Title = {Effects of intermittent hypoxia training on leukocyte pyruvate
   dehydrogenase kinase 1 (PDK-1) mRNA expression and blood insulin level
   in prediabetes patients},
Journal = {EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY},
Year = {2019},
Volume = {119},
Number = {3},
Pages = {813-823},
Month = {MAR},
Abstract = {PurposeIntermittent hypoxia training/treatment (IHT) is an emerging
   therapeutic approach to alleviate chronic diseases, such as diabetes.
   The present study investigated the effects of IHT on blood leucocyte
   pyruvate dehydrogenase kinase 1 (PDK-1) mRNA expression and its
   relationship with the changes in blood insulin level.MethodsSeven adult
   healthy volunteers and 11 prediabetic patients participated in this
   study. A 3-week course of IHT consisted of a 40-min session of 4 cycles
   of 5-min 12\% O-2 and 5-min room air breathing per day, 3 sessions per
   week for 3 weeks (i.e., total 9 sessions of IHT). Plasma insulin levels
   and leukocyte PDK-1 mRNA expression were determined at various time
   points either under fasting condition or following oral glucose
   tolerance test (OGTT). Correlation between the IHT-induced changes in
   PDK-1 mRNA and insulin or glucose levels in the same serological samples
   was analyzed.ResultsAt pre-IHT baseline, PDK-1 mRNA expression was two
   times higher in prediabetes than control subjects. IHT resulted in
   significant augmentation in PDK-1 mRNA expression (>twofold) in
   prediabetes at the end of 3-week IHT and remained elevated 1month after
   IHT, which was correlated with a significantly reduced insulin release
   and lower blood glucose after glucose loading with OGTT.ConclusionIHT
   can trigger beneficial effects in normalizing blood insulin levels in
   prediabetic patients under oral glucose load, which were closely
   correlated with an enhanced mRNA expression of PDK-1 in leukocytes.
   Further clinical trials are warranted to validate the utility of IHT as
   a non-invasive complementary therapy against diabetes-associated
   pathologies.},
Publisher = {SPRINGER},
Address = {233 SPRING ST, NEW YORK, NY 10013 USA},
Type = {Article},
Language = {English},
Affiliation = {Serebrovska, TV (Corresponding Author), Bogomoletz Inst Physiol, UA-01024 Kiev, Ukraine.
   Xi, L (Corresponding Author), Virginia Commonwealth Univ, Pauley Heart Ctr, Dept Internal Med, 1101 East Marshall St,Room 7-020C, Richmond, VA 23298 USA.
   Xi, L (Corresponding Author), Chengdu Sport Univ, Sch Sports Med \& Hlth, Chengdu 610041, Sichuan, Peoples R China.
   Serebrovska, Tetiana V.; Portnychenko, Alla G.; Portnichenko, Vladimir I., Bogomoletz Inst Physiol, UA-01024 Kiev, Ukraine.
   Portnychenko, Alla G.; Portnichenko, Vladimir I., Natl Acad Sci Ukraine, ICAMER, UA-03680 Kiev, Ukraine.
   Xi, Lei, Virginia Commonwealth Univ, Pauley Heart Ctr, Dept Internal Med, 1101 East Marshall St,Room 7-020C, Richmond, VA 23298 USA.
   Xi, Lei, Chengdu Sport Univ, Sch Sports Med \& Hlth, Chengdu 610041, Sichuan, Peoples R China.
   Egorov, Egor, CELLGYM Technol GmbH, D-10623 Berlin, Germany.
   Antoniuk-Shcheglova, Ivanna; Naskalova, Svitlana; Shatylo, Valeriy B., DF Chebotarev State Inst Gerontol, UA-04114 Kiev, Ukraine.},
DOI = {10.1007/s00421-019-04072-2},
ISSN = {1439-6319},
EISSN = {1439-6327},
Keywords = {Hypoxia; Insulin; Diabetes; Pyruvate dehydrogenase kinase; Adaptation;
   Gene Expression},
Keywords-Plus = {ACTIVATED RECEPTOR-ALPHA; CARDIOVASCULAR-DISEASES; ISOFORM EXPRESSION;
   GLUCOSE-METABOLISM; FATTY-ACID; SECRETION; ALTITUDE; ADAPTATION;
   COMPLEX; GENE},
Research-Areas = {Physiology; Sport Sciences},
Web-of-Science-Categories  = {Physiology; Sport Sciences},
Author-Email = {sereb@biph.kiev.ua
   lxi@vcu.edu},
Affiliations = {National Academy of Sciences Ukraine; A.A. Bogomoletz Institute of
   Physiology; National Academy of Sciences Ukraine; Virginia Commonwealth
   University; Chengdu Sport University; National Academy of Medical
   Sciences of Ukraine; D. F. Chebotarev Institute of Gerontology of the
   National Academy of Medical Sciences of Ukraine},
ResearcherID-Numbers = {Portnichenko, Volodymyr/Y-1905-2019
   Antoniuk-Shcheglova, Ivanna/JTS-3444-2023
   Shatylo, Valeriy/JXY-3176-2024
   Xi, Lei/A-3078-2008
   Naskalova, Svitlana/JTS-3732-2023
   Portnychenko, Alla/AAS-8321-2020},
ORCID-Numbers = {Serebrovska, Tetiana/0000-0002-5468-8555
   Portnichenko, Volodymyr/0000-0003-1473-2408
   Antoniuk-Shcheglova, Ivanna/0000-0003-2606-6975
   Shatylo, Valeriy/0000-0001-7114-9150
   Xi, Lei/0000-0002-7569-3329
   Naskalova, Svitlana/0000-0001-9518-2633
   Portnychenko, Alla/0000-0003-2509-101X},
Cited-References = {Camacho-Cardenosa A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00060.
   Carreras A, 2012, AM J PHYSIOL-REG I, V303, pR700, DOI 10.1152/ajpregu.00258.2012.
   Costalat G, 2018, SLEEP BREATH, V22, P267, DOI 10.1007/s11325-017-1459-8.
   Dudnik E, 2018, HIGH ALT MED BIOL, V19, P339, DOI 10.1089/ham.2018.0014.
   Essop MF, 2007, J PHYSIOL-LONDON, V584, P715, DOI 10.1113/jphysiol.2007.143511.
   Ferriero R, 2015, J INHERIT METAB DIS, V38, P895, DOI 10.1007/s10545-014-9808-2.
   Genuth S, 2003, DIABETES CARE, V26, P3160.
   Göhring I, 2014, J BIOL CHEM, V289, P3786, DOI 10.1074/jbc.M113.507335.
   Gozal D, 2017, AM J RESP CELL MOL, V56, P477, DOI 10.1165/rcmb.2016-0243OC.
   Halvarsson C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171714.
   Hao K, 2015, DIABETES, V64, P785, DOI 10.2337/db14-0500.
   Hollinshead KER, 2016, WIRES SYST BIOL MED, V8, P272, DOI 10.1002/wsbm.1334.
   Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276.
   Jeoung NH, 2015, DIABETES METAB J, V39, P188, DOI 10.4093/dmj.2015.39.3.188.
   Kelly KR, 2010, METABOLISM, V59, P200, DOI 10.1016/j.metabol.2009.07.014.
   Khan AU, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10339-5.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kolesnyk I U, 1994, Fiziol Zh, V40, P87.
   Kolesnyk Iu M, 2013, Fiziol Zh, V59, P25.
   Krus U, 2010, BIOCHEM J, V429, P205, DOI 10.1042/BJ20100142.
   Kulkarni SS, 2012, METABOLISM, V61, P175, DOI 10.1016/j.metabol.2011.06.014.
   Lee EJ, 2013, EUR J APPL PHYSIOL, V113, P467, DOI 10.1007/s00421-012-2452-3.
   Lee IK, 2014, DIABETES METAB J, V38, P181, DOI 10.4093/dmj.2014.38.3.181.
   Louis M, 2009, J APPL PHYSIOL, V106, P1538, DOI 10.1152/japplphysiol.91523.2008.
   Mackenzie R, 2012, J CLIN ENDOCR METAB, V97, pE546, DOI 10.1210/jc.2011-2829.
   Mackenzie RWA, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/6934937.
   Mallet RT, 2018, AM J PHYSIOL-HEART C, V315, pH216, DOI 10.1152/ajpheart.00060.2018.
   Minchenko O, 2004, FEBS LETT, V576, P14, DOI 10.1016/j.febslet.2004.08.053.
   Morishima T, 2015, CLIN PHYSIOL FUNCT I, V35, P104, DOI 10.1111/cpf.12133.
   Nam H, 2016, DIABETES, V65, P1521, DOI 10.2337/db15-0580.
   Navarrete-Opazo A, 2014, AM J PHYSIOL-REG I, V307, pR1181, DOI 10.1152/ajpregu.00208.2014.
   Newhouse LP, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13106.
   Nguyen DD, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00604.
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012.
   Park S, 2018, DIABETES METAB J, V42, P270, DOI 10.4093/dmj.2018.0101.
   Peltonen GL, 2012, J PHYSIOL-LONDON, V590, P2801, DOI 10.1113/jphysiol.2011.227090.
   Peters SJ, 2001, AM J PHYSIOL-ENDOC M, V281, pE1151, DOI 10.1152/ajpendo.2001.281.6.E1151.
   Portnichenko V I, 2012, Fiziol Zh, V58, P56.
   Portnichenko V I, 2012, Fiziol Zh, V58, P3.
   Portnichenko VI, 2009, ACHIEV CLIN EXP MED, V2, P65.
   Roberts AC, 1996, J APPL PHYSIOL, V80, P605, DOI 10.1152/jappl.1996.80.2.605.
   Rydén L, 2007, EUR HEART J, V28, P88, DOI {[}10.1093/eurheartj/ehm124, 10.1093/eurheartj/ehl260].
   Sakata S, 2000, JPN J PHYSIOL, V50, P285, DOI 10.2170/jjphysiol.50.285.
   Serebrovska TV, 2017, EXP BIOL MED, V242, P1542, DOI 10.1177/1535370217723578.
   Serebrovskaya TV, 2016, EXP BIOL MED, V241, P1708, DOI 10.1177/1535370216657614.
   Serebrovskaya TV, 2002, HIGH ALT MED BIOL, V3, P205, DOI 10.1089/15270290260131939.
   Sugden MC, 2001, DIABETES, V50, P2729, DOI 10.2337/diabetes.50.12.2729.
   Sutendra G, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00038.
   Tian YM, 2016, LIFE SCI, V150, P1, DOI 10.1016/j.lfs.2016.02.053.
   Verges S, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00058.
   Wang YY, 2017, BIOCHEM CELL BIOL, V95, P415, DOI 10.1139/bcb-2016-0167.
   Wu CY, 2018, MOL METAB, V12, P12, DOI 10.1016/j.molmet.2018.03.014.
   Xu JX, 2006, BIOCHEM BIOPH RES CO, V344, P827, DOI 10.1016/j.bbrc.2006.03.211.
   Zhou XL, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030340.},
Number-of-Cited-References = {54},
Times-Cited = {15},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {18},
Journal-ISO = {Eur. J. Appl. Physiol.},
Doc-Delivery-Number = {HL9GN},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000459051300022},
DA = {2026-02-04},
}

@article{ WOS:000456638800004,
Author = {Sun, Rongli and Meng, Xing and Pu, Yunqiu and Sun, Fengxia and Man,
   Zhaodi and Zhang, Juan and Yin, Lihong and Pu, Yuepu},
Title = {Overexpression of HIF-1a could partially protect K562 cells from
   1,4-benzoquinone induced toxicity by inhibiting ROS, apoptosis and
   enhancing glycolysis},
Journal = {TOXICOLOGY IN VITRO},
Year = {2019},
Volume = {55},
Pages = {18-23},
Month = {MAR},
Abstract = {Benzene is an environmental contaminant which causes hematological
   diseases. Previously, hypoxia inducible factor-1a (HIF-1a) was found to
   be involved in benzene-induced hematotoxicity. This study aims to
   explore whether overexpression of HIF-la in K562 cell line could
   influence the toxicity caused by 1,4-BQ. HIF-1a overexpression K562 cell
   line was constructed with a lentiviral vector. Results showed that
   HIF-1a was significantly elevated in control K562 cells and HIF-1a
   overexpression cells exposed to 1,4-BQ. Compared with 1,4-BQ exposed
   control cells, HIF-1a overexpression blocked cell cycle at G2/M phase,
   remarkably reduced apoptosis and ROS level. And HIF-1a overexpression
   caused downregulation of Nox4 and upregulation of Bcl-2. In addition,
   the lactic acid (LD)/pyruvic acid (PA) ratio was significantly higher in
   HIF-1a overexpression cells than that in control cells at the same
   1,4-BQ dose. Furthermore, significant increases in Glut1, Ldha, Pkm2,
   Pgk1, Pdk1, Pfk1, Pfkfb3 protein levels was also observed in HIF-1a
   overexpression cells. Overall, our results indicated that HIF-1a
   overexpression could alleviate ROS and apoptosis caused by 1,4-BQ
   through targeting Nox4, Bcl-2 and key enzymes in glycolysis.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Pu, YP (Corresponding Author), Southeast Univ, Sch Publ Hlth, Minist Educ China, Key Lab Environm Med Engn, Nanjing 210009, Jiangsu, Peoples R China.
   Sun, Rongli; Meng, Xing; Pu, Yunqiu; Sun, Fengxia; Man, Zhaodi; Zhang, Juan; Yin, Lihong; Pu, Yuepu, Southeast Univ, Sch Publ Hlth, Minist Educ China, Key Lab Environm Med Engn, Nanjing 210009, Jiangsu, Peoples R China.},
DOI = {10.1016/j.tiv.2018.11.005},
ISSN = {0887-2333},
Keywords = {1,4-BQ; Toxicity; HIF-1a; ROS; Apoptosis; Glycolysis},
Keywords-Plus = {PYRUVATE-KINASE M2; BENZENE TOXICITY; HYPOXIA; CANCER; HIF-1-ALPHA;
   MECHANISM; LEUKEMIA; MODULATION; STRESS; GROWTH},
Research-Areas = {Toxicology},
Web-of-Science-Categories  = {Toxicology},
Author-Email = {yppu@seu.edu.cn},
Affiliations = {Southeast University - China},
ResearcherID-Numbers = {Zhang, Juan/GRX-2638-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81573189, 81730087]},
Funding-Text = {We thank Professor Chen Rui (Southeast University, China) for providing
   plasmid P1P2N-HIF1. This study was supported by research grants from
   National Natural Science Foundation of China (81573189, 81730087).},
Cited-References = {Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485.
   Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082.
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981.
   Chen YJ, 2017, ENVIRON POLLUT, V221, P256, DOI 10.1016/j.envpol.2016.11.072.
   Chowdhury AR, 2017, ONCOGENE, V36, P397, DOI 10.1038/onc.2016.211.
   Deng D, 2014, NATURE, V510, P121, DOI 10.1038/nature13306.
   Diebold L, 2016, FREE RADICAL BIO MED, V100, P86, DOI 10.1016/j.freeradbiomed.2016.04.198.
   Duarte-Davidson R, 2001, OCCUP ENVIRON MED, V58, P2, DOI 10.1136/oem.58.1.2.
   Fu ZC, 2015, MED SCI MONITOR, V21, P318, DOI {[}10.12659/msm.893265, 10.12659/MSM.893265].
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hustedt N, 2017, NAT CELL BIOL, V19, P1, DOI 10.1038/ncb3452.
   Kalashnikova I, 2017, NANOSCALE, V9, P10375, DOI 10.1039/c7nr02770b.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kim KY, 2016, J MICROBIOL BIOTECHN, V26, P287, DOI 10.4014/jmb.1511.11054.
   Kocabas F, 2012, BLOOD, V120, P4963, DOI 10.1182/blood-2012-05-432260.
   Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5.
   Ludin A, 2014, ANTIOXID REDOX SIGN, V21, P1605, DOI 10.1089/ars.2014.5941.
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054.
   Meng X, 2016, J TOXICOL ENV HEAL A, V79, P402, DOI 10.1080/15287394.2016.1176616.
   Movafagh S, 2015, J CELL BIOCHEM, V116, P696, DOI 10.1002/jcb.25074.
   Nisimoto Y, 2014, BIOCHEMISTRY-US, V53, P5111, DOI 10.1021/bi500331y.
   Obacz J, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-93.
   Richardson C, 2015, INT J MOL SCI, V16, P2366, DOI 10.3390/ijms16022366.
   Saito S, 2015, KAOHSIUNG J MED SCI, V31, P279, DOI 10.1016/j.kjms.2015.03.002.
   Santos JM, 2018, J NUTR BIOCHEM, V53, P111, DOI 10.1016/j.jnutbio.2017.10.013.
   Shen Y, 1996, HUM EXP TOXICOL, V15, P422, DOI 10.1177/096032719601500510.
   Snyder R, 2012, INT J ENV RES PUB HE, V9, P2875, DOI 10.3390/ijerph9082875.
   Son MY, 2016, ONCOTARGET, V7, P46433, DOI 10.18632/oncotarget.10184.
   Sun SR, 2017, PHYSIOLOGY, V32, P453, DOI 10.1152/physiol.00016.2017.
   Takubo K, 2010, CELL STEM CELL, V7, P391, DOI 10.1016/j.stem.2010.06.020.
   Tang CT, 2018, CELL SIGNAL, V46, P52, DOI 10.1016/j.cellsig.2018.02.007.
   Tang D, 2017, BIOMED PHARMACOTHER, V87, P145, DOI 10.1016/j.biopha.2016.12.058.
   Wang Y, 2011, CELL STEM CELL, V8, P399, DOI 10.1016/j.stem.2011.02.006.
   Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010.
   Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783.
   Xiao HJ, 2018, PROSTATE, V78, P86, DOI 10.1002/pros.23448.
   Yoon BI, 2001, EXP HEMATOL, V29, P278, DOI 10.1016/S0301-472X(00)00671-8.
   Zhang CC, 2014, ANTIOXID REDOX SIGN, V20, P1891, DOI 10.1089/ars.2012.5019.
   Zhang J, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3912515.
   Zheng JH, 2016, FEBS J, V283, P2690, DOI 10.1111/febs.13527.
   Zheng QQ, 2017, LEUKEMIA RES, V58, P55, DOI 10.1016/j.leukres.2017.04.005.
   Zhu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113733.},
Number-of-Cited-References = {42},
Times-Cited = {47},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {80},
Journal-ISO = {Toxicol. Vitro},
Doc-Delivery-Number = {HI7LX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000456638800004},
DA = {2026-02-04},
}

@article{ WOS:000462664200117,
Author = {Visalli, Giuseppa and Facciola, Alessio and Curro, Monica and Lagana,
   Pasqualina and La Fauci, Vincenza and Iannazzo, Daniela and Pistone,
   Alessandro and Di Pietro, Angela},
Title = {Mitochondrial Impairment Induced by Sub-Chronic Exposure to Multi-Walled
   Carbon Nanotubes},
Journal = {INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH},
Year = {2019},
Volume = {16},
Number = {5},
Month = {MAR 1},
Abstract = {Human exposure to carbon nanotubes (CNTs) can cause health issues due to
   their chemical-physical features and biological interactions. These
   nanostructures cause oxidative stress, also due to endogenous reactive
   oxygen species (ROS) production, which increases following mitochondrial
   impairment. The aim of this in vitro study was to assess the health
   effects, due to mitochondrial dysfunction, caused by a sub-chronic
   exposure to a non-acutely toxic dose of multi walled CNTs (raw and
   functionalised). The A549 cells were exposed to multi-walled carbon
   nanotubes (MWCNTs) (2 mu g mL(-1)) for 36 days. Periodically, cellular
   dehydrogenases, pyruvate dehydrogenase kinase 1 (PDK1), cytochrome c
   release, permeability transition pore (mPTP) opening, transmembrane
   potential ( m), apoptotic cells, and intracellular ROS were measured.
   The results, compared to untreated cells and to positive control formed
   by cells treated with MWCNTs (20 mu g mL(-1)), highlighted the
   efficiency of homeostasis to counteract ROS overproduction, but a
   restitutio ad integrum of mitochondrial functionality was not observed.
   Despite the tendency to restore, the mitochondrial impairment persisted.
   Overall, the results underlined the tissue damage that can arise
   following sub-chronic exposure to MWCNTs.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Di Pietro, A (Corresponding Author), Univ Messina, Dept Biomed \& Dent Sci \& Morphofunct Imaging, I-98125 Messina, Italy.
   Visalli, Giuseppa; Curro, Monica; Lagana, Pasqualina; La Fauci, Vincenza; Di Pietro, Angela, Univ Messina, Dept Biomed \& Dent Sci \& Morphofunct Imaging, I-98125 Messina, Italy.
   Facciola, Alessio, Univ Messina, Dept Clin \& Expt Med, Infect Dis Unit, I-98125 Messina, Italy.
   Iannazzo, Daniela; Pistone, Alessandro, Univ Messina, Dept Elect Engn Ind Chem \& Engn, I-98125 Messina, Italy.},
DOI = {10.3390/ijerph16050792},
Article-Number = {792},
ISSN = {1661-7827},
EISSN = {1660-4601},
Keywords = {MWCNTs; oxidative stress; mitochondria},
Keywords-Plus = {PERMEABILITY TRANSITION PORE; OXIDATIVE STRESS; CELLS; TOXICITY;
   DYSFUNCTION; MECHANISMS; THERAPY},
Research-Areas = {Environmental Sciences \& Ecology; Public, Environmental \& Occupational
   Health},
Web-of-Science-Categories  = {Environmental Sciences; Public, Environmental \& Occupational Health},
Author-Email = {gvisalli@unime.it
   afacciola@unime.it
   moncurro@unime.it
   plagana@unime.it
   vlafauci@unime.it
   diannazzo@unime.it
   pistone@unime.it
   adipietr@unime.it},
Affiliations = {University of Messina; University of Messina; University of Messina},
ResearcherID-Numbers = {PISTONE, Alessano/JEF-4081-2023
   Curro, Monica/KHD-5604-2024
   },
ORCID-Numbers = {PISTONE, Alessano/0000-0001-9298-944X
   la fauci, vincenza/0000-0002-5038-8811
   Visalli, Giuseppa/0000-0002-9072-1148
   Laganà, Pasqualina/0000-0002-6078-9520
   Iannazzo, Daniela/0000-0003-2190-0035},
Cited-References = {Bause AS, 2013, EXP GERONTOL, V48, P634, DOI 10.1016/j.exger.2012.08.007.
   Bonora M, 2016, NAT PROTOC, V11, P1067, DOI 10.1038/nprot.2016.064.
   Braymer JJ, 2017, J BIOL CHEM, V292, P12754, DOI 10.1074/jbc.R117.787101.
   Bussy C, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-24.
   Cha CY, 2013, ACS NANO, V7, P2891, DOI 10.1021/nn401196a.
   Cheng WW, 2011, INT J BIOCHEM CELL B, V43, P564, DOI 10.1016/j.biocel.2010.12.013.
   De Marchi E, 2014, CELL CALCIUM, V56, P1, DOI 10.1016/j.ceca.2014.03.004.
   Di Pietro A, 2011, INT J HYG ENVIR HEAL, V214, P138, DOI 10.1016/j.ijheh.2010.10.003.
   Donaldson K, 2011, NANOMEDICINE-UK, V6, P143, DOI 10.2217/NNM.10.139.
   Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1\_7.
   Facciolà A, 2019, ENVIRON TOXICOL PHAR, V65, P23, DOI 10.1016/j.etap.2018.11.006.
   Fubini B, 2011, NANOMEDICINE-UK, V6, P899, DOI {[}10.2217/nnm.11.80, 10.2217/NNM.11.80].
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080.
   Groebe K, 2007, EXP GERONTOL, V42, P887, DOI 10.1016/j.exger.2007.07.001.
   Helland A, 2007, ENVIRON HEALTH PERSP, V115, P1125, DOI 10.1289/ehp.9652.
   Huang SXL, 2012, ENVIRON HEALTH PERSP, V120, P840, DOI 10.1289/ehp.1104287.
   Iannazzo D, 2012, ORG BIOMOL CHEM, V10, P1025, DOI 10.1039/c1ob06598j.
   Kayat J, 2011, NANOMED-NANOTECHNOL, V7, P40, DOI 10.1016/j.nano.2010.06.008.
   Kolosnjaj-Tabi J, 2010, ACS NANO, V4, P1481, DOI 10.1021/nn901573w.
   Kumarathasan P, 2015, NANOTOXICOLOGY, V9, P148, DOI 10.3109/17435390.2014.902519.
   Liu ZB, 2014, J BIOMED MATER RES A, V102, P665, DOI 10.1002/jbm.a.34729.
   Lopez-Fabuel I, 2016, P NATL ACAD SCI USA, V113, P13063, DOI 10.1073/pnas.1613701113.
   López-Otín C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039.
   Mercer RR, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-28.
   Milane L, 2015, J CONTROL RELEASE, V207, P40, DOI 10.1016/j.jconrel.2015.03.036.
   Moller P, 2014, ARCH TOXICOL, V88, P1939, DOI 10.1007/s00204-014-1356-x.
   Monian P., 2012, Experimental Oncology, V34, P185.
   Mu QX, 2009, NANO LETT, V9, P4370, DOI 10.1021/nl902647x.
   Nagai H, 2011, P NATL ACAD SCI USA, V108, pE1330, DOI 10.1073/pnas.1110013108.
   Nelson G, 2012, AGING CELL, V11, P345, DOI 10.1111/j.1474-9726.2012.00795.x.
   Paradies G, 2014, BBA-BIOENERGETICS, V1837, P408, DOI 10.1016/j.bbabio.2013.10.006.
   Peña-Blanco A, 2018, FEBS J, V285, P416, DOI 10.1111/febs.14186.
   Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5.
   Pistone A, 2012, J NANOSCI NANOTECHNO, V12, P5054, DOI 10.1166/jnn.2012.4928.
   Schrurs F, 2012, NAT NANOTECHNOL, V7, P546, DOI 10.1038/nnano.2012.148.
   Shvedova AA, 2012, TOXICOL APPL PHARM, V261, P121, DOI 10.1016/j.taap.2012.03.023.
   Sobhani Z, 2017, INT J NANOMED, V12, P4509, DOI 10.2147/IJN.S134661.
   Szklarczyk R, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0439.
   Tabet L, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-3.
   Trifunovic A, 2008, J INTERN MED, V263, P167, DOI 10.1111/j.1365-2796.2007.01905.x.
   Trovato MC, 2018, REV ENVIRON HEALTH, V33, P305, DOI 10.1515/reveh-2017-0036.
   Velali E, 2016, ENVIRON POLLUT, V208, P774, DOI 10.1016/j.envpol.2015.10.058.
   Visalli G, 2017, ENVIRON TOXICOL PHAR, V56, P121, DOI 10.1016/j.etap.2017.09.005.
   Visalli G, 2017, J TRACE ELEM MED BIO, V43, P153, DOI 10.1016/j.jtemb.2017.01.005.
   Visalli G, 2015, J TOXICOL ENV HEAL A, V78, P697, DOI 10.1080/15287394.2015.1024081.
   Visalli G, 2015, ENVIRON TOXICOL PHAR, V39, P93, DOI 10.1016/j.etap.2014.11.008.
   Visalli G, 2015, TOXICOL IN VITRO, V29, P352, DOI 10.1016/j.tiv.2014.12.004.
   Wang JTW, 2016, J CONTROL RELEASE, V224, P22, DOI 10.1016/j.jconrel.2015.12.039.
   Wu YT, 2014, CURR PHARM DESIGN, V20, P5510, DOI 10.2174/1381612820666140306103401.
   Zhang J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.167.
   Zhang YY, 2011, ANN BIOMED ENG, V39, P414, DOI 10.1007/s10439-010-0151-y.
   Zhou W, 2017, ENVIRON POLLUT, V226, P412, DOI 10.1016/j.envpol.2017.04.010.},
Number-of-Cited-References = {52},
Times-Cited = {26},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Int. J. Environ. Res. Public Health},
Doc-Delivery-Number = {HQ8HD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)},
Unique-ID = {WOS:000462664200117},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000462494100020,
Author = {Xu, Min and Han, Xiaoning and Liu, Rui and Li, Yanjun and Qi, Cui and
   Yang, Zhongzhou and Zhao, Chunjie and Gao, Jun},
Title = {PDK1 Deficit Impairs the Development of the Dentate Gyrus in Mice},
Journal = {CEREBRAL CORTEX},
Year = {2019},
Volume = {29},
Number = {3},
Pages = {1185-1198},
Month = {MAR},
Abstract = {3-Phosphoinositide-dependent protein kinase-1 (PDK1) is crucial for the
   development of the dentate gyrus (DG), the first gateway receiving
   afferent inputs from the entorhinal cortex. However, the role of PDK1 in
   DG development is unclear. In the present study, by crossing Pdk1(fl/fl)
   mice with the Emx1-cre line, we identified that the ablation of PDK1
   disrupted the development of DG via decreasing the proliferation, and
   increasing the differentiation of dentate neural progenitor cells,
   downregulating AKT activity and upregulating GSK3 signaling. Moreover,
   PDK1 deletion disrupted the distribution of Reelin(+) cells and
   decreased the level of Reelin mRNA which may contribute to the defective
   migration of progenitor cells and the disrupted radial glial scaffolds.
   Furthermore, the inhibition of GSK3 activity partially restored the
   decreased proliferation of primary neural stem cells in vitro. Taken
   together, our data indicated that the ablation of PDK1 affected the
   proliferation and differentiation of dentate neural progenitor cells in
   mice.},
Publisher = {OXFORD UNIV PRESS INC},
Address = {JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA},
Type = {Article},
Language = {English},
Affiliation = {Gao, J (Corresponding Author), Nanjing Med Univ, Dept Neurobiol, Longmian Rd 101, Nanjing 2111666, Jiangsu, Peoples R China.
   Zhao, CJ (Corresponding Author), Southeast Univ, Sch Med, Key Lab Dev Genes \& Human Dis, Dingjiaqiao 87, Nanjing 210009, Jiangsu, Peoples R China.
   Xu, Min; Liu, Rui; Qi, Cui; Gao, Jun, Nanjing Med Univ, Dept Neurobiol, Longmian Rd 101, Nanjing 2111666, Jiangsu, Peoples R China.
   Xu, Min; Liu, Rui; Qi, Cui; Gao, Jun, Nanjing Med Univ, Key Lab Human Funct Genom Jiangsu, Nanjing 211166, Jiangsu, Peoples R China.
   Han, Xiaoning; Zhao, Chunjie, Southeast Univ, Sch Med, Dept Histol \& Embryol, Key Lab Dev Genes \& Human Dis,MOE, Nanjing 210009, Jiangsu, Peoples R China.
   Li, Yanjun; Yang, Zhongzhou, Nanjing Univ, Model Anim Res Ctr, Nanjing 210061, Jiangsu, Peoples R China.
   Li, Yanjun; Yang, Zhongzhou, MOE Key Lab Model Animals Dis Study, Nanjing 210061, Jiangsu, Peoples R China.
   Zhao, Chunjie, Beijing Inst Brain Disorders, Ctr Depress, Beijing 100069, Peoples R China.},
DOI = {10.1093/cercor/bhy024},
ISSN = {1047-3211},
EISSN = {1460-2199},
Keywords = {dentate gyrus; GSK3; neural progenitor cells; PDK1; radial glial
   scaffolds},
Keywords-Plus = {RADIAL GLIAL SCAFFOLD; ADULT HIPPOCAMPAL NEUROGENESIS; PROTEIN-KINASE 1;
   PATTERN SEPARATION; GABAERGIC NEURONS; MASTER REGULATOR; REELIN; PTEN;
   MIGRATION; PATHWAY},
Research-Areas = {Neurosciences \& Neurology},
Web-of-Science-Categories  = {Neurosciences},
Author-Email = {zhaocj@seu.edu.cn
   gaojun@njmu.edu.cn},
Affiliations = {Nanjing Medical University; Nanjing Medical University; Southeast
   University - China; Nanjing University},
ResearcherID-Numbers = {Yang, Zhongzhou/H-3015-2014
   },
ORCID-Numbers = {Han, Xiaoning/0000-0003-0291-7966
   Gao, Jun/0000-0002-5925-537X
   Liu, Rui/0000-0002-9641-5280},
Funding-Acknowledgement = {National Basic Research Program of China {[}2016YFA0501001]; National
   Natural Science Foundation of China {[}91232301, 31471041]; Key R\&D
   Program of Jiangsu Province {[}BE2016761]; Excellent scientific and
   technological innovation team of colleges and universities in Jiangsu},
Funding-Text = {National Basic Research Program of China (2013CB835100, 2011CBA01104),
   the National Natural Science Foundation of China (81222013 and
   81673416), the Key R\&D Program of Jiangsu Province (BE2016761) and the
   Excellent scientific and technological innovation team of colleges and
   universities in Jiangsu to J.G., and the grants from the National Basic
   Research Program of China (2016YFA0501001), the National Natural Science
   Foundation of China (91232301 and 31471041) to C.Z.},
Cited-References = {Aimone JB, 2006, NAT NEUROSCI, V9, P723, DOI 10.1038/nn1707.
   Anacker C, 2017, NAT REV NEUROSCI, V18, P335, DOI 10.1038/nrn.2017.45.
   Bago R, 2016, EMBO J, V35, P2263, DOI 10.15252/embj.201670010.
   Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002.
   Bakker A, 2008, SCIENCE, V319, P1640, DOI 10.1126/science.1152882.
   Barry G, 2008, J NEUROSCI, V28, P12328, DOI 10.1523/JNEUROSCI.4000-08.2008.
   Breunig JJ, 2007, P NATL ACAD SCI USA, V104, P20558, DOI 10.1073/pnas.0710156104.
   Brunne B, 2010, GLIA, V58, P1553, DOI 10.1002/glia.21029.
   Bultje RS, 2009, NEURON, V63, P189, DOI 10.1016/j.neuron.2009.07.004.
   Caruncho HJ, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00048.
   Chalhoub N, 2009, GENE DEV, V23, P1619, DOI 10.1101/gad.1799609.
   Choe Y, 2012, DEV NEUROSCI-BASEL, V34, P502, DOI 10.1159/000345353.
   Cordón-Barris L, 2016, MOL CELL BIOL, V36, P2967, DOI 10.1128/MCB.00230-16.
   Dragoi AM, 2005, EMBO J, V24, P779, DOI 10.1038/sj.emboj.7600539.
   Du KY, 2005, ONCOGENE, V24, P7401, DOI 10.1038/sj.onc.1209099.
   Feng QT, 2010, MOL CELL BIOL, V30, P3711, DOI 10.1128/MCB.00420-10.
   Förster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899.
   Fotaki V, 2010, DEV DYNAM, V239, P284, DOI 10.1002/dvdy.22137.
   Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001.
   Fraser MM, 2004, CANCER RES, V64, P7773, DOI 10.1158/0008-5472.CAN-04-2487.
   Frotscher M, 2003, CEREB CORTEX, V13, P634, DOI 10.1093/cercor/13.6.634.
   Galichet C, 2008, DEVELOPMENT, V135, P2031, DOI 10.1242/dev.015115.
   Gao J, 2010, NATURE, V466, P1105, DOI 10.1038/nature09271.
   Gorski JA, 2002, J NEUROSCI, V22, P6309.
   Götz M, 2005, NEURON, V46, P369, DOI 10.1016/j.neuron.2005.04.012.
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870.
   Itoh Y, 2016, P NATL ACAD SCI USA, V113, pE2955, DOI 10.1073/pnas.1516321113.
   Iwanami A, 2009, GENE DEV, V23, P1699, DOI 10.1101/gad.1832909.
   Kharebava G, 2008, J NEUROSCI, V28, P11409, DOI 10.1523/JNEUROSCI.2135-08.2008.
   Kim WY, 2009, NAT NEUROSCI, V12, P1390, DOI 10.1038/nn.2408.
   Kohn M, 2003, GENE EXPR PATTERNS, V3, P173, DOI 10.1016/S1567-133X(03)00004-8.
   Lavado A, 2013, DEVELOPMENT, V140, P3323, DOI 10.1242/dev.096537.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lee SMK, 2000, DEVELOPMENT, V127, P457.
   Leutgeb JK, 2007, SCIENCE, V315, P961, DOI 10.1126/science.1135801.
   Li GN, 2005, DEV NEUROSCI-BASEL, V27, P93, DOI 10.1159/000085980.
   Li GN, 2009, DEVELOPMENT, V136, P327, DOI 10.1242/dev.025742.
   Liu R, 2015, MOL BRAIN, V8, DOI 10.1186/s13041-015-0144-8.
   Mangale VS, 2008, SCIENCE, V319, P304, DOI 10.1126/science.1151695.
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009.
   Mao YW, 2009, CELL, V136, P1017, DOI 10.1016/j.cell.2008.12.044.
   McHugh TJ, 2007, SCIENCE, V317, P94, DOI 10.1126/science.1140263.
   Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022.
   Nicola Z, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00053.
   Oishi K, 2009, P NATL ACAD SCI USA, V106, P13064, DOI 10.1073/pnas.0808400106.
   Parisot J, 2017, DEVELOPMENT, V144, P2045, DOI 10.1242/dev.139949.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Bayascas JR, 2010, CURR TOP MICROBIOL, V346, P9, DOI 10.1007/82\_2010\_43.
   Sahay A, 2007, NAT NEUROSCI, V10, P1110, DOI 10.1038/nn1969.
   Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328.
   Sarthy V, 2007, EXP EYE RES, V84, P381, DOI 10.1016/j.exer.2005.12.014.
   Sibbe M, 2009, J NEUROSCI, V29, P8578, DOI 10.1523/JNEUROSCI.0958-09.2009.
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330.
   Sugiyama T, 2013, DEV DYNAM, V242, P1442, DOI 10.1002/dvdy.24035.
   Tian CX, 2012, J NEUROSCI, V32, P2931, DOI 10.1523/JNEUROSCI.5240-11.2012.
   Wang QH, 2003, NEURON, V38, P915, DOI 10.1016/S0896-6273(03)00356-8.
   Weiss KH, 2003, J COMP NEUROL, V460, P56, DOI 10.1002/cne.10644.
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3.
   Xu L, 2015, MOL NEUROBIOL, V51, P131, DOI 10.1007/s12035-014-8692-y.
   Yokota Y, 2010, DEVELOPMENT, V137, P4101, DOI 10.1242/dev.048637.
   Yoshida S, 1999, TOHOKU J EXP MED, V187, P249, DOI 10.1620/tjem.187.249.
   Yu DX, 2014, DEVELOPMENT, V141, P2366, DOI 10.1242/dev.096776.
   Yu SL, 2012, J BIOL CHEM, V287, P42195, DOI 10.1074/jbc.M112.410381.
   Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033.
   Zhou CJ, 2004, J NEUROSCI, V24, P121, DOI 10.1523/JNEUROSCI.4071-03.2004.
   Zurashvili T, 2013, MOL CELL BIOL, V33, P1027, DOI 10.1128/MCB.01052-12.},
Number-of-Cited-References = {66},
Times-Cited = {10},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {29},
Journal-ISO = {Cereb. Cortex},
Doc-Delivery-Number = {HQ6AL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000462494100020},
DA = {2026-02-04},
}

@article{ WOS:000461485000013,
Author = {Gao, Wen and Wang, Kemin and Zhang, Lin and Li, Jian and Liu, Junling
   and Chen, Xue and Luo, Xinping},
Title = {Pharmacological inhibition of S6K1 facilitates platelet activation by
   enhancing Akt phosphorylation},
Journal = {PLATELETS},
Year = {2019},
Volume = {30},
Number = {2},
Pages = {241-250},
Month = {FEB 17},
Abstract = {Platelet activation and thrombus formation is a delicate process
   involving a series of crosstalk between different pathways. P70
   ribosomal S6 kinase1 (S6K1) is a member of serine/threonine kinases and
   can be phosphorylated by 3-phosphoinositide-dependent protein kinase 1
   (PDK1). S6K1 is widely reported to play important roles in cancers and
   metabolic diseases, but the role of S6K1 and the importance of
   phosphorylation on Thr229 in platelet activation have not been defined.
   PF-4708671 is a recently synthesized highly specific inhibitor of S6K1.
   In this study, we tested PF-4708671 to assess the role of S6K1 in
   platelet. PF-4708671 facilitated mouse and human platelet aggregation
   and ATP secretion induced by collagen, thrombin, and adenosine
   diphosphate through enhanced Akt and Gsk3 beta phosphorylation.
   PF-4708671 also accelerated integrin alpha IIb beta 3-mediated clot
   retraction and spreading. Intravenously given PF-4708671 shortened the
   occlusion time in arterial thrombosis model. Further results
   demonstrated that S6K1 was phosphorylated by PDK1 on Thr229 in the
   resting platelets and dephosphorylated in response to agonist
   stimulation. PDK1-deficient mice showed higher aggregation when
   PI3K-Akt-Gsk3 beta signaling was blocked by the Gsk3 beta-inhibitor
   SB216763. Thus, S6K1 Thr229 phosphorylation might function as a
   regulator that prevents platelets from activation. S6K1 inhibition may
   yield potential pro-thrombotic effects and should be used cautiously
   when considered as a therapy.},
Publisher = {TAYLOR \& FRANCIS INC},
Address = {530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA},
Type = {Article},
Language = {English},
Affiliation = {Luo, XP (Corresponding Author), Fudan Univ, Huashan Hosp, Dept Cardiol, 12 Middle Urumqi Rd, Shanghai 200040, Peoples R China.
   Chen, X (Corresponding Author), Shanghai Jiao Tong Univ, Inst Med Sci, Dept Biochem \& Mol Cell Biol, Sch Med, 280 South Chongqing Rd, Shanghai 200025, Peoples R China.
   Gao, Wen; Li, Jian; Luo, Xinping, Fudan Univ, Huashan Hosp, Dept Cardiol, 12 Middle Urumqi Rd, Shanghai 200040, Peoples R China.
   Wang, Kemin; Zhang, Lin; Liu, Junling; Chen, Xue, Shanghai Jiao Tong Univ, Dept Biochem \& Mol Cell Biol, Sch Med, Shanghai, Peoples R China.},
DOI = {10.1080/09537104.2017.1416075},
ISSN = {0953-7104},
EISSN = {1369-1635},
Keywords = {PDK1; platelet activation; signaling pathway},
Keywords-Plus = {GLYCOGEN-SYNTHASE KINASE-3; TYROSINE KINASE; PDK1; MECHANISMS; COMPLEX;
   FAMILY; IMPACT; RAPTOR; PTEN},
Research-Areas = {Cell Biology; Hematology},
Web-of-Science-Categories  = {Cell Biology; Hematology},
Author-Email = {chenxue-snow@163.com
   luoxp206@163.com},
Affiliations = {Fudan University; Shanghai Jiao Tong University},
ResearcherID-Numbers = {Luo, Xin/LOS-0705-2024
   Gao, Wen/GLQ-7410-2022
   },
ORCID-Numbers = {Chen, Xue/0000-0003-3956-5431},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81270278, 81770348,
   81500106]; Shanghai Science and Technology Fund {[}16411965600]; special
   Financial Grant from the China Postdoctoral Science Fund {[}2015T80434]},
Funding-Text = {This work was partially supported by the National Natural Science
   Foundation of China {[}grant number 81270278], {[}grant number
   81770348], {[}grant number 81500106]; Shanghai Science and Technology
   Fund {[}grant number 16411965600]; and the special Financial Grant from
   the China Postdoctoral Science Fund {[}grant number 2015T80434].},
Cited-References = {Aslan JE, 2011, BLOOD, V118, P3129, DOI 10.1182/blood-2011-02-331579.
   Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810.
   Beurel E, 2015, PHARMACOL THERAPEUT, V148, P114, DOI 10.1016/j.pharmthera.2014.11.016.
   Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380.
   Chen X, 2013, BLOOD, V121, P3718, DOI 10.1182/blood-2012-10-461897.
   Cho MJ, 2003, BLOOD, V101, P2646, DOI 10.1182/blood-2002-05-1363.
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0.
   Di RM, 2012, BIOCHEM J, V441, P199, DOI 10.1042/BJ20110033.
   Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09.
   Fan XM, 2014, BLOOD, V124, P2421, DOI 10.1182/blood-2014-03-557645.
   Fenton TR, 2011, INT J BIOCHEM CELL B, V43, P47, DOI 10.1016/j.biocel.2010.09.018.
   Furie B, 2008, NEW ENGL J MED, V359, P938, DOI 10.1056/NEJMra0801082.
   Goh ETH, 2010, J BIOL CHEM, V285, P17065, DOI 10.1074/jbc.M109.078782.
   Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4.
   Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281.
   Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09.
   Kaidanovich-Beilin O, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00040.
   Keshwani MM, 2011, J BIOL CHEM, V286, P23552, DOI 10.1074/jbc.M111.258004.
   Keshwani MM, 2009, J BIOL CHEM, V284, P22611, DOI 10.1074/jbc.M109.032177.
   Khotskaya YB, 2014, AM J TRANSL RES, V6, P361.
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5.
   Laurent Pierre-Alexandre, 2014, Advances in Biological Regulation, V54, P162, DOI 10.1016/j.jbior.2013.09.006.
   Lee D, 2012, BIOPHYS J, V102, P472, DOI 10.1016/j.bpj.2011.10.056.
   Li DJ, 2008, BLOOD, V111, P3522, DOI 10.1182/blood-2007-09-111518.
   Li ZY, 2010, ARTERIOSCL THROM VAS, V30, P2341, DOI 10.1161/ATVBAHA.110.207522.
   Linden MD, 2010, INT J BIOCHEM CELL B, V42, P1762, DOI 10.1016/j.biocel.2010.07.012.
   Liu JL, 2006, BLOOD, V108, P2596, DOI 10.1182/blood-2006-01-011817.
   Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892.
   Margadant C, 2011, CURR OPIN CELL BIOL, V23, P607, DOI 10.1016/j.ceb.2011.08.005.
   Moroi AJ, 2015, BIOCHEM PHARMACOL, V94, P186, DOI 10.1016/j.bcp.2015.02.004.
   NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656.
   O'Brien KA, 2011, BLOOD, V118, P4215, DOI 10.1182/blood-2010-12-323204.
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925.
   Pearce LR, 2010, BIOCHEM J, V431, P245, DOI 10.1042/BJ20101024.
   Schoenwaelder SM, 2010, J BIOL CHEM, V285, P2886, DOI 10.1074/jbc.M109.029132.
   Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108.
   Shum M, 2016, DIABETOLOGIA, V59, P592, DOI 10.1007/s00125-015-3839-6.
   Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200.
   Tavares MR, 2015, LIFE SCI, V131, P1, DOI 10.1016/j.lfs.2015.03.001.
   Weng Z, 2010, BLOOD, V116, P2579, DOI 10.1182/blood-2010-03-277236.
   Xu Z, 2017, ACTA PHARMACOL SIN, V38, P651, DOI 10.1038/aps.2016.155.
   Yin H, 2008, BLOOD, V112, P1139, DOI 10.1182/blood-2008-02-140970.},
Number-of-Cited-References = {42},
Times-Cited = {2},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Platelets},
Doc-Delivery-Number = {HP2FZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000461485000013},
DA = {2026-02-04},
}

@article{ WOS:000458738900020,
Author = {Jansen, Valerie M. and Bhola, Neil E. and Bauer, Joshua A. and
   Formisano, Luigi and Lee, Kyung-Min and Hutchinson, Katherine E. and
   Witkiewicz, Agnieszka K. and Moore, Preston D. and Estrada, Onica
   Valeria and Sanchez, Violeta and Ericsson, Paula G. and Sanders, Melinda
   E. and Pohlmann, Paula R. and Pishvaian, Michael J. and Riddle, David A.
   and Dugger, Teresa C. and Wei, Wenyi and Knudsen, Erik S. and Arteaga,
   Carlos L.},
Title = {Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired
   Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer (vol 77, pg
   2488, 2017)},
Journal = {CANCER RESEARCH},
Year = {2019},
Volume = {79},
Number = {4},
Pages = {874},
Month = {FEB 15},
Publisher = {AMER ASSOC CANCER RESEARCH},
Address = {615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA},
Type = {Correction},
Language = {English},
DOI = {10.1158/0008-5472.CAN-18-4086},
ISSN = {0008-5472},
EISSN = {1538-7445},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
ResearcherID-Numbers = {Formisano, Luigi/I-7858-2015
   Lee, kyung-min/ABH-7692-2020},
ORCID-Numbers = {Formisano, Luigi/0000-0001-7205-5105
   },
Funding-Acknowledgement = {NCI NIH HHS {[}K12 CA090625, K12 CA088084] Funding Source: Medline;
   National Cancer Institute {[}K12CA090625, K12CA088084] Funding Source:
   NIH RePORTER},
Cited-References = {Jansen VM, 2017, CANCER RES, V77, P2488, DOI 10.1158/0008-5472.CAN-16-2653.},
Number-of-Cited-References = {1},
Times-Cited = {1},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {5},
Journal-ISO = {Cancer Res.},
Doc-Delivery-Number = {HL5AT},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458738900020},
DA = {2026-02-04},
}

@article{ WOS:000458221400015,
Author = {Wu, Dong-Mei and Wang, Yong-Jian and Fan, Shao-Hua and Zhang, Zi-Feng
   and Shan, Qun and Lu, Jun and Chen, Gui-Quan and Zheng, Yuan-Lin},
Title = {High-throughput screening of novel pyruvate dehydrogenase kinases
   inhibitors and biological evaluation of their in vitro and in
   vivo antiproliferative activity},
Journal = {EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY},
Year = {2019},
Volume = {164},
Pages = {252-262},
Month = {FEB 15},
Abstract = {Overexpression of pyruvate dehydrogenase kinases (PDKs) has been widely
   noticed in a variety of human solid tumors, which could be regarded as
   an attractive therapeutic target for cancer therapy. In this paper, we
   present an enzymatic screening assay and multiple biological evaluations
   for the identification of potential PDKs, especially PDK1 inhibitors. We
   identified 9 potential PDKs inhibitors from the screening of an in-house
   small molecule library, all of the identified inhibitors reduced
   pyruvate dehydrogenase (PDH) complex phosphorylation. Among which, 4, 5,
   and 9 displayed the most potent PDKs inhibitory activities, with EC50
   values of 0.34, 1.4, and 1.6 mu M in an enzymatic assay, respectively. A
   kinase inhibition assay suggested that 4, 5, and 9 were pan-isoform PDK
   inhibitors, but more sensitive to PDK1. Meanwhile, the three compounds
   inhibited HSP90, with IC50 values of 0.78, 3.58, and 2.70 mu M,
   respectively. The cell viability assay indicated that 4 inhibited all of
   the tested cancer cells proliferation, with a GC(50) value of 2.3 mu M
   against NCI-H1975 cell, but has little effect on human normal lung cell
   BEAS-2B cell. In the NCI-H1975 xenograft models, 4 displayed strong
   antitumor activities at a dose of 10 and 20 mg/kg, but with no negative
   effect on the mice weight. In addition, 4 decreased the ECAR and lactate
   formation, increased OCR and ROS level in NCI-H1975 cancer cell, which
   could be used as a promising modulator to reprogram the glucose
   metabolic pathways in NCI-H1975 cancer cells. (C) 2018 Elsevier Masson
   SAS. All rights reserved.},
Publisher = {ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER},
Address = {65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE},
Type = {Article},
Language = {English},
Affiliation = {Lu, J; Zheng, YL (Corresponding Author), Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou 221116, Jiangsu, Peoples R China.
   Chen, GQ (Corresponding Author), Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, MOE,Key Lab Model Anim Dis Study, Nanjing 210061, Jiangsu, Peoples R China.
   Wu, Dong-Mei; Wang, Yong-Jian; Fan, Shao-Hua; Zhang, Zi-Feng; Shan, Qun; Lu, Jun; Zheng, Yuan-Lin, Jiangsu Normal Univ, Sch Life Sci, Key Lab Biotechnol Med Plants Jiangsu Prov, Xuzhou 221116, Jiangsu, Peoples R China.
   Wu, Dong-Mei; Wang, Yong-Jian; Fan, Shao-Hua; Zhang, Zi-Feng; Shan, Qun; Lu, Jun; Zheng, Yuan-Lin, Jiangsu Normal Univ, Coll Hlth Sci, Xuzhou 221116, Jiangsu, Peoples R China.
   Chen, Gui-Quan, Nanjing Univ, Model Anim Res Ctr, State Key Lab Pharmaceut Biotechnol, MOE,Key Lab Model Anim Dis Study, Nanjing 210061, Jiangsu, Peoples R China.},
DOI = {10.1016/j.ejmech.2018.12.051},
ISSN = {0223-5234},
EISSN = {1768-3254},
Keywords = {Anticancer drug; Cancer metabolism; Kinase inhibition; Pyruvate
   dehydrogenase kinase},
Keywords-Plus = {METABOLIC TRANSFORMATION; LIPOYL DOMAIN; CELL-GROWTH; CANCER; PDK1;
   PYRUVATE-DEHYDROGENASE-KINASE-2; DICHLOROACETATE; IDENTIFICATION;
   PERMEABILITY; DISCOVERY},
Research-Areas = {Pharmacology \& Pharmacy},
Web-of-Science-Categories  = {Chemistry, Medicinal},
Author-Email = {lu-jun75@163.com
   chenguiquan@nju.edu.cn
   yuanlin\_zheng@hotmail.com},
Affiliations = {Jiangsu Normal University; Jiangsu Normal University; Nanjing University},
ResearcherID-Numbers = {Wu, Dongmei/AAS-6647-2020
   Lu, Jun/N-6109-2019},
Funding-Acknowledgement = {Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); 2016 ``333 Project{''} Award of Jiangsu Province;
   2013 ``Qinglan Project{''} of the Young and Middle-aged Academic Leader
   of Jiangsu College and University; National Natural Science Foundation
   of China {[}81571055, 81400902, 81271225, 31201039, 81171012, 30950031];
   Major Fundamental Research Program of the Natural Science Foundation of
   the Jiangsu Higher Education Institutions of China {[}13KJA180001];
   Cultivate National Science Fund for Distinguished Young Scholars of
   Jiangsu Normal University},
Funding-Text = {This work was supported by the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD); the 2016 ``333 Project{''}
   Award of Jiangsu Province; the 2013 ``Qinglan Project{''} of the Young
   and Middle-aged Academic Leader of Jiangsu College and University; the
   National Natural Science Foundation of China (81571055, 81400902,
   81271225, 31201039, 81171012, and 30950031); the Major Fundamental
   Research Program of the Natural Science Foundation of the Jiangsu Higher
   Education Institutions of China (13KJA180001); and grants from the
   Cultivate National Science Fund for Distinguished Young Scholars of
   Jiangsu Normal University.},
Cited-References = {Blanchfield JT, 2003, J MED CHEM, V46, P1266, DOI 10.1021/jm020426j.
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020.
   Brough PA, 2017, J MED CHEM, V60, P2271, DOI 10.1021/acs.jmedchem.6b01478.
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002.
   ESPINAL J, 1995, DRUG DEVELOP RES, V35, P130, DOI 10.1002/ddr.430350303.
   Hiromasa Y, 2008, BIOCHEMISTRY-US, V47, P2312, DOI 10.1021/bi7014772.
   Howes R, 2006, ANAL BIOCHEM, V350, P202, DOI 10.1016/j.ab.2005.12.023.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Jackson JC, 1998, BIOCHEM J, V334, P703, DOI 10.1042/bj3340703.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s.
   Liu YF, 2017, J MED CHEM, V60, P2227, DOI 10.1021/acs.jmedchem.6b01245.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Mayers RM, 2003, BIOCHEM SOC T, V31, P1165.
   Meng T, 2014, J MED CHEM, V57, P9832, DOI 10.1021/jm5010144.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Patel MS, 2009, J MOL CATAL B-ENZYM, V61, P2, DOI 10.1016/j.molcatb.2009.05.001.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Roe SM, 1999, J MED CHEM, V42, P260, DOI 10.1021/jm980403y.
   Sun H, 2017, ONCOTARGET, V8, P52642, DOI 10.18632/oncotarget.16991.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817.
   Tennant DA, 2009, CARCINOGENESIS, V30, P1269, DOI 10.1093/carcin/bgp070.
   Trinidad AG, 2017, ONCOGENE, V36, P6164, DOI 10.1038/onc.2017.224.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Xu B, 2018, EUR J MED CHEM, V155, P275, DOI 10.1016/j.ejmech.2018.06.012.
   Yee SY, 1997, PHARMACEUT RES, V14, P763, DOI 10.1023/A:1012102522787.
   Yu XK, 2008, STRUCTURE, V16, P104, DOI 10.1016/j.str.2007.10.024.
   Zhang SL, 2016, J MED CHEM, V59, P3562, DOI 10.1021/acs.jmedchem.5b01828.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.},
Number-of-Cited-References = {31},
Times-Cited = {7},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {28},
Journal-ISO = {Eur. J. Med. Chem.},
Doc-Delivery-Number = {HK8EE},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458221400015},
DA = {2026-02-04},
}

@article{ WOS:000462055500004,
Author = {Betts, Corinne A. and McClorey, Graham and Healicon, Richard and
   Hammond, Suzan M. and Manzano, Raquel and Muses, Sofia and Ball, Vicky
   and Godfrey, Caroline and Merritt, Thomas M. and van Westering, Tirsa
   and O'Donovan, Liz and Wells, Kim E. and Gait, Michael J. and Wells,
   Dominic J. and Tyler, Damian and Wood, Matthew J.},
Title = {Cmah-dystrophin deficient mdx mice display an accelerated
   cardiac phenotype that is improved following peptide-PMO exon skipping
   treatment},
Journal = {HUMAN MOLECULAR GENETICS},
Year = {2019},
Volume = {28},
Number = {3},
Pages = {396-406},
Month = {FEB 1},
Abstract = {Duchenne muscular dystrophy (DMD) is caused by loss of dystrophin
   protein, leading to progressive muscle weakness and premature death due
   to respiratory and/or cardiac complications. Cardiac involvement is
   characterized by progressive dilated cardiomyopathy, decreased
   fractional shortening and metabolic dysfunction involving reduced
   metabolism of fatty acids-the major cardiac metabolic substrate. Several
   mouse models have been developed to study molecular and pathological
   consequences of dystrophin deficiency, but do not recapitulate all
   aspects of human disease pathology and exhibit a mild cardiac phenotype.
   Here we demonstrate that Cmah (cytidine monophosphate-sialic acid
   hydroxylase)-deficient mdx mice (Cmah-/-; mdx) have an accelerated
   cardiac phenotype compared to the established mdx model. Cmah-/-; mdx
   mice display earlier functional deterioration, specifically a reduction
   in right ventricle (RV) ejection fraction and stroke volume (SV) at 12
   weeks of age and decreased left ventricle diastolic volume with
   subsequent reduced SV compared to mdx mice by 24 weeks. They further
   show earlier elevation of cardiac damage markers for fibrosis (Ctgf),
   oxidative damage (Nox4) and haemodynamic load (Nppa). Cardiac metabolic
   substrate requirement was assessed using hyperpolarized magnetic
   resonance spectroscopy indicating increased in vivo glycolytic flux in
   Cmah-/-; mdx mice. Early upregulation of mitochondrial genes (Ucp3 and
   Cpt1) and downregulation of key glycolytic genes (Pdk1, Pdk4, Ppara),
   also denote disturbed cardiac metabolism and shift towards glucose
   utilization in Cmah-/-; mdx mice. Moreover, we show long-term treatment
   with peptide-conjugated exon skipping antisense oligonucleotides
   (20-week regimen), resulted in 20\% cardiac dystrophin protein
   restoration and significantly improved RV cardiac function. Therefore,
   Cmah-/-; mdx mice represent an appropriate model for evaluating cardiac
   benefit of novel DMD therapeutics.},
Publisher = {OXFORD UNIV PRESS},
Address = {GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wood, MJ (Corresponding Author), Univ Oxford, Dept Physiol Anat \& Genet, South Parks Rd, Oxford OX1 3QX, England.
   Betts, Corinne A.; McClorey, Graham; Healicon, Richard; Hammond, Suzan M.; Manzano, Raquel; Ball, Vicky; Godfrey, Caroline; van Westering, Tirsa; Tyler, Damian; Wood, Matthew J., Univ Oxford, Dept Physiol Anat \& Genet, South Parks Rd, Oxford OX1 3QX, England.
   Muses, Sofia; Wells, Kim E.; Wells, Dominic J., Royal Vet Coll, Dept Comparat Biomed Sci, Royal Coll St, London NW1 0TU, England.
   Merritt, Thomas M., Univ Oxford, Nuffield Dept Clin Med, Clin Biomfg Facil, Old Rd, Oxford OX3 7JT, England.
   O'Donovan, Liz; Gait, Michael J., MRC, Lab Mol Biol, Francis Crick Ave, Cambridge CB2 0QH, England.},
DOI = {10.1093/hmg/ddy346},
ISSN = {0964-6906},
EISSN = {1460-2083},
Keywords-Plus = {DUCHENNE MUSCULAR-DYSTROPHY; FATTY-ACID-METABOLISM; MOLECULAR-BASIS;
   HEART-FAILURE; CARDIOMYOPATHY; MOUSE},
Research-Areas = {Biochemistry \& Molecular Biology; Genetics \& Heredity},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Genetics \& Heredity},
Author-Email = {matthew.wood@dpag.ox.ac.uk},
Affiliations = {University of Oxford; University of London; University of London Royal
   Veterinary College; University of Oxford; MRC Laboratory Molecular
   Biology},
ResearcherID-Numbers = {Tyler, Damian/E-6296-2011
   , RAQUEL MANZANO/ACS-3663-2022
   Godfrey, Caroline/GYN-0799-2022
   Wood, Matthew/HDN-1469-2022},
ORCID-Numbers = {Wells, Dominic/0000-0002-1425-6344
   Betts, Corinne/0000-0003-0579-8843
   van Westering, Tirsa/0000-0003-0278-1245
   Tyler, Damian/0000-0002-0780-8905
   , RAQUEL MANZANO/0000-0002-7477-8742
   Wood, Matthew/0000-0002-5436-6011},
Funding-Acknowledgement = {British Heart Foundation {[}FS/10/002/28078, FS/14/17/30634,
   RG/11/9/28921, PG/14/2/30595]; Muscular Dystrophy UK {[}AVRZFL00];
   Medical Research Council {[}G0900887]; Association Francaise contre les
   Myopathies (AFM) {[}14784]; OXFORD-BHF Centre for Research Excellence;
   National Institute for Health Research (NIHR) Oxford Biomedical Research
   Centre; Medical Rearch Council program {[}U105178803]; Medical Research
   Council Developmental Pathway Funding Scheme (MRC) DPFS Grant
   {[}MR/L013142/1]; AFM; British Heart Foundation {[}PG/14/2/30595,
   RG/11/9/28921, FS/10/002/28078, FS/14/17/30634] Funding Source:
   researchfish; Medical Research Council {[}G0601490, MC\_U105178803,
   MR/L013142/1, G0900887] Funding Source: researchfish; MRC
   {[}MR/N024850/1, G0900887, MR/L013142/1, MC\_U105178803, MR/R025312/1,
   G0601490] Funding Source: UKRI},
Funding-Text = {British Heart Foundation (PG/14/2/30595 to C.A.B. and T.V.W.); Muscular
   Dystrophy UK (AVRZFL00 to C.A.B. and T.V.W.); Medical Research Council
   (G0900887) and AFM; Association Francaise contre les Myopathies (AFM;
   14784 to G.M., SM, KEW, DJW and R.M.); British Heart Foundation
   (Fellowships FS/10/002/28078 \& FS/14/17/30634, Programme Grant
   RG/11/9/28921 to R.H., V.B. and D.T); the OXFORD-BHF Centre for Research
   Excellence and the National Institute for Health Research (NIHR) Oxford
   Biomedical Research Centre (to R.H., V.B. and D.T.); LOD and MG- Medical
   Rearch Council program no. U105178803; Medical Research Council
   Developmental Pathway Funding Scheme (MRC) DPFS Grant MR/L013142/1 (to
   S.M.H.).},
Cited-References = {Betts C, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.30.
   Betts CA, 2015, SCI REP-UK, V5, DOI 10.1038/srep08986.
   Bushby K, 2004, Neuromuscul Disord, V14, P526, DOI 10.1016/j.nmd.2004.05.006.
   Chandrasekharan K, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000692.
   Connuck DM, 2008, AM HEART J, V155, P998, DOI 10.1016/j.ahj.2008.01.018.
   D'Amario D, 2017, HEART, V103, P1770, DOI 10.1136/heartjnl-2017-311269.
   Dodd MS, 2013, J CARDIOVASC MAGN R, V15, DOI 10.1186/1532-429X-15-19.
   Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2.
   Godfrey C, 2015, HUM MOL GENET, V24, P4225, DOI 10.1093/hmg/ddv155.
   Gulston MK, 2008, J PROTEOME RES, V7, P2069, DOI 10.1021/pr800070p.
   Holland A, 2013, PROTEOMICS, V13, P2312, DOI 10.1002/pmic.201200578.
   Kerr M, 2017, CLIN SCI, V131, P2079, DOI {[}10.1042/CS20160671, 10.1042/cs20160671].
   Khairallah M, 2007, J MOL CELL CARDIOL, V43, P119, DOI 10.1016/j.yjmcc.2007.05.015.
   Kirchmann C, 2005, PEDIATR CARDIOL, V26, P66, DOI 10.1007/s00246-004-0689-2.
   KOENIG M, 1989, AM J HUM GENET, V45, P498.
   LoMauro A, 2015, THER CLIN RISK MANAG, V11, P1475, DOI 10.2147/TCRM.S55889.
   López-Bernardo E, 2015, FREE RADICAL BIO MED, V88, P427, DOI 10.1016/j.freeradbiomed.2015.03.032.
   Matthews E, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003725.pub4.
   Mehmood M, 2016, PEDIATR CARDIOL, V37, P878, DOI 10.1007/s00246-016-1362-2.
   Meyers TA, 2015, AM J PHYSIOL-HEART C, V308, pH303, DOI 10.1152/ajpheart.00485.2014.
   Momose M, 2001, NEUROMUSCULAR DISORD, V11, P464, DOI 10.1016/S0960-8966(01)00191-2.
   NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G.
   Potter Lincoln R., 2009, V191, P341, DOI 10.1007/978-3-540-68964-5\_15.
   Saini-Chohan HK, 2012, J LIPID RES, V53, P4, DOI 10.1194/jlr.R012120.
   SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404.
   Stuckey DJ, 2008, NMR BIOMED, V21, P765, DOI 10.1002/nbm.1268.
   Stuckey DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028569.
   Sultan Ambreen, 2008, J Ayub Med Coll Abbottabad, V20, P7.
   Sun WQ, 2015, LIFE SCI, V121, P97, DOI 10.1016/j.lfs.2014.11.030.
   Vry Julia, 2016, J Neuromuscul Dis, V3, P517, DOI 10.3233/jnd-160185.
   YOTSUKURA M, 1988, JPN CIRC J, V52, P321, DOI 10.1253/jcj.52.321.
   Zhang M, 2013, ANTIOXID REDOX SIGN, V18, P1024, DOI 10.1089/ars.2012.4550.},
Number-of-Cited-References = {32},
Times-Cited = {10},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {8},
Journal-ISO = {Hum. Mol. Genet.},
Doc-Delivery-Number = {HQ0AV},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000462055500004},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000458934000010,
Author = {Cao, Yufeng and Li, Fu and Luo, Yanyan and Zhang, Liang and Lu, Shuya
   and Xing, Rui and Yan, Bingjun and Zhang, Hongyin and Hu, Weicheng},
Title = {20-Hydroxy-3-Oxolupan-28-Oic Acid Attenuates Inflammatory Responses by
   Regulating PI3K-Akt and MAPKs Signaling Pathways in LPS-Stimulated
   RAW264.7 Macrophages},
Journal = {MOLECULES},
Year = {2019},
Volume = {24},
Number = {3},
Month = {FEB 1},
Abstract = {20-Hydroxy-3-oxolupan-28-oic acid (HOA), a lupane-type triterpene, was
   obtained from the leaves of Mahonia bealei, which is described in the
   Chinese Pharmacopeia as a remedy for inflammation and related diseases.
   The anti-inflammatory mechanisms of HOA, however, have not yet been
   fully elucidated. Therefore, the objective of this study was to
   characterize the molecular mechanisms of HOA in lipopolysaccharide
   (LPS)-stimulated RAW264.7 cells. HOA suppressed the release of nitric
   oxide (NO), pro-inflammatory cytokine tumor necrosis factor alpha
   (TNF-alpha), and interleukin 6 (IL-6) in LPS-stimulated RAW264.7
   macrophages without affecting cell viability. Quantitative real-time
   reverse-transcription polymerase chain reaction (RT-qPCR) analysis
   indicated that HOA also suppressed the gene expression of inducible NO
   synthase (iNOS), TNF-alpha, and IL-6. Further analyses demonstrated that
   HOA inhibited the phosphorylation of upstream signaling molecules,
   including p85, PDK1, Akt, I kappa B alpha, ERK, and JNK, as well as the
   nuclear translocation of nuclear factor kappa B (NF-kappa B) p65.
   Interestingly, HOA had no effect on the LPS-induced nuclear
   translocation of activator protein 1 (AP-1). Taken together, these
   results suggest that HOA inhibits the production of cytokine by
   downregulating iNOS, TNF-alpha, and IL-6 gene expression via the
   downregulation of phosphatidylinositol 3-kinase (PI3K)/Akt and
   mitogen-activated protein kinases (MAPKs), and the inhibition of
   NF-kappa B activation. Our findings indicate that HOA could potentially
   be used as an anti-inflammatory agent for medical use.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Hu, WC (Corresponding Author), Huaiyin Normal Univ, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Huaian 223300, Peoples R China.
   Zhang, HY (Corresponding Author), Jiangsu Univ, Sch Food \& Biol Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
   Cao, Yufeng, Jiangsu Univ, Inst Life Sci, Zhenjiang 212013, Jiangsu, Peoples R China.
   Cao, Yufeng; Luo, Yanyan; Zhang, Liang; Lu, Shuya; Xing, Rui; Yan, Bingjun; Hu, Weicheng, Huaiyin Normal Univ, Jiangsu Key Lab Ecoagr Biotechnol Hongze Lake, Jiangsu Collaborat Innovat Ctr Reg Modern Agr \& E, Huaian 223300, Peoples R China.
   Li, Fu, Chinese Acad Sci, Chengdu Inst Biol, Key Lab Sichuan Prov, Key Lab Mt Ecol Restorat \& Bioresource Utilizat \&, Chengdu 610041, Sichuan, Peoples R China.
   Zhang, Hongyin, Jiangsu Univ, Sch Food \& Biol Engn, Zhenjiang 212013, Jiangsu, Peoples R China.},
DOI = {10.3390/molecules24030386},
Article-Number = {386},
ISSN = {1420-3049},
Keywords = {inflammation; nitric oxide; macrophage; NF-kappa B; lupane-type
   triterpene},
Keywords-Plus = {NF-KAPPA-B; LIPOPOLYSACCHARIDE-INDUCED INFLAMMATION; RAW 264.7
   MACROPHAGES; NEGATIVE REGULATION; AP-1 ACTIVATION; NO PRODUCTION;
   TNF-ALPHA; INHIBITION; MAHONIA; INACTIVATION},
Research-Areas = {Biochemistry \& Molecular Biology; Chemistry},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Chemistry, Multidisciplinary},
Author-Email = {17851567661@163.com
   lifu@cib.ac.cn
   lyy122525@163.com
   liangzhang\_xj@163.com
   lushuyawork@163.com
   xingrui0707@163.com
   15380617203@163.com
   zhanghongyin126@126.com
   hu\_weicheng@163.com},
Affiliations = {Jiangsu University; Huaiyin Normal University; Chinese Academy of
   Sciences; Chengdu Institute of Biology, CAS; Jiangsu University},
ResearcherID-Numbers = {Zhang, Hongyin/MIJ-9219-2025
   },
ORCID-Numbers = {Zhang, Hongyin/0000-0001-6906-4713
   Hu, Weicheng/0000-0002-6730-811X},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}31600281]; Natural
   Science Foundation of Jiangsu Province {[}BK20171269]; Qing Lan Project
   of Jiangsu Province},
Funding-Text = {This study was supported financially by National Natural Science
   Foundation of China (31600281), Natural Science Foundation of Jiangsu
   Province (BK20171269), and Qing Lan Project of Jiangsu Province.},
Cited-References = {Afonina IS, 2017, NAT IMMUNOL, V18, P861, DOI 10.1038/ni.3772.
   Ahmed SMU, 2017, BBA-MOL BASIS DIS, V1863, P585, DOI 10.1016/j.bbadis.2016.11.005.
   Arora S, 2018, IMMUNOBIOLOGY, V223, P383, DOI 10.1016/j.imbio.2017.11.001.
   Bai YJ, 2019, J ETHNOPHARMACOL, V228, P179, DOI 10.1016/j.jep.2018.09.032.
   Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011.
   Bian XB, 2017, RSC ADV, V7, P41640, DOI 10.1039/c7ra08041g.
   Branzk N, 2018, IMMUNOL REV, V286, P86, DOI 10.1111/imr.12718.
   Cao TQ, 2015, BIOORG MED CHEM LETT, V25, P5087, DOI 10.1016/j.bmcl.2015.10.020.
   Chen CY, 2007, LIFE SCI, V81, P1602, DOI 10.1016/j.lfs.2007.09.028.
   Chong CM, 2018, MOL NEUROBIOL, V55, P2645, DOI 10.1007/s12035-017-0513-7.
   Courtois G, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020043.
   Covarrubias AJ, 2015, SEMIN IMMUNOL, V27, P286, DOI 10.1016/j.smim.2015.08.001.
   Cuadrado I, 2018, MOLECULES, V23, DOI 10.3390/molecules23123197.
   Durham WJ, 2004, J APPL PHYSIOL, V97, P1740, DOI 10.1152/japplphysiol.00088.2004.
   El-Gamal AA, 2008, NAT PROD RES, V22, P191, DOI 10.1080/14786410701761019.
   Genovese S, 2017, PHYTOCHEM LETT, V20, P181, DOI 10.1016/j.phytol.2017.04.032.
   Han HS, 2018, CHEM-BIOL INTERACT, V293, P38, DOI 10.1016/j.cbi.2018.07.024.
   He JM, 2015, J ETHNOPHARMACOL, V175, P668, DOI 10.1016/j.jep.2015.09.013.
   Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363.
   Hu WC, 2016, J ETHNOPHARMACOL, V188, P134, DOI 10.1016/j.jep.2016.05.013.
   Hu WC, 2016, FOOD FUNCT, V7, P1002, DOI 10.1039/c5fo01212k.
   Hu WC, 2011, FOOD CHEM TOXICOL, V49, P799, DOI 10.1016/j.fct.2010.12.001.
   Jeong YJ, 2015, INT IMMUNOPHARMACOL, V25, P400, DOI 10.1016/j.intimp.2015.02.021.
   Jung DH, 2010, INT IMMUNOPHARMACOL, V10, P1047, DOI 10.1016/j.intimp.2010.06.004.
   Khajuria V, 2017, BIOMED PHARMACOTHER, V92, P175, DOI 10.1016/j.biopha.2017.05.063.
   Kim AR, 2011, TOXICOL IN VITRO, V25, P1789, DOI 10.1016/j.tiv.2011.09.012.
   Kim EA, 2018, INT IMMUNOPHARMACOL, V59, P339, DOI 10.1016/j.intimp.2018.03.034.
   Kim HG, 2006, EUR J PHARMACOL, V545, P192, DOI 10.1016/j.ejphar.2006.06.047.
   Kipanyula MJ, 2013, CELL SIGNAL, V25, P403, DOI 10.1016/j.cellsig.2012.10.014.
   Kohoutková M, 2017, HISTOCHEM CELL BIOL, V148, P607, DOI 10.1007/s00418-017-1601-5.
   Ku KT, 2008, J AGR FOOD CHEM, V56, P8911, DOI 10.1021/jf8019369.
   Kwon DJ, 2013, FOOD CHEM TOXICOL, V58, P479, DOI 10.1016/j.fct.2013.05.031.
   Lavieri R, 2016, J LEUKOCYTE BIOL, V99, P79, DOI 10.1189/jlb.3MR0415-159R.
   Lee SB, 2017, INT IMMUNOPHARMACOL, V49, P21, DOI 10.1016/j.intimp.2017.05.021.
   Lee WS, 2016, INT IMMUNOPHARMACOL, V40, P146, DOI 10.1016/j.intimp.2016.08.021.
   Li KK, 2016, J ETHNOPHARMACOL, V192, P192, DOI 10.1016/j.jep.2016.07.020.
   Liu L, 2017, EXP THER MED, V14, P6125, DOI 10.3892/etm.2017.5316.
   Lu XG, 2017, BIOMED PHARMACOTHER, V88, P102, DOI 10.1016/j.biopha.2017.01.041.
   Mabhida SE, 2018, PHARMACOL RES, V137, P179, DOI 10.1016/j.phrs.2018.10.004.
   Mao RZ, 2018, J AFFECT DISORDERS, V237, P65, DOI 10.1016/j.jad.2018.04.115.
   Moldogazieva NT, 2018, FREE RADICAL RES, V52, P507, DOI 10.1080/10715762.2018.1457217.
   Naseem S, 2018, CYTOKINE GROWTH F R, V39, P36, DOI 10.1016/j.cytogfr.2018.01.002.
   Oh WJ, 2013, MOLECULES, V18, P9195, DOI 10.3390/molecules18089195.
   Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015.
   Paul A, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100176.
   Perez-Lopez A, 2016, NAT REV IMMUNOL, V16, P135, DOI 10.1038/nri.2015.17.
   Rahimifard M, 2017, AGEING RES REV, V36, P11, DOI 10.1016/j.arr.2017.02.004.
   Silva DF, 2016, FITOTERAPIA, V113, P139, DOI 10.1016/j.fitote.2016.07.021.
   Takano K, 2018, NEUROCHEM INT, V119, P126, DOI 10.1016/j.neuint.2017.04.002.
   Valilou SF, 2018, CYTOKINE GROWTH F R, V39, P46, DOI 10.1016/j.cytogfr.2018.01.007.
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002.
   Yoo S, 2018, BIOCHEM PHARMACOL, V148, P1, DOI 10.1016/j.bcp.2017.12.006.
   Zeng XY, 2006, J ETHNOPHARMACOL, V108, P317, DOI 10.1016/j.jep.2006.05.014.
   Zhang L, 2014, J PROTEOMICS, V110, P59, DOI 10.1016/j.jprot.2014.07.036.
   Zhang L, 2014, HEPATOB PANCREAT DIS, V13, P138, DOI 10.1016/S1499-3872(14)60024-2.
   Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012.
   Zhang SB, 2018, PHYTOCHEMISTRY, V152, P105, DOI 10.1016/j.phytochem.2018.05.002.
   Zhang SL, 2014, PHYTOMEDICINE, V21, P1356, DOI 10.1016/j.phymed.2014.07.007.
   Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004.
   Zhu JJ, 2019, J ASIAN NAT PROD RES, V21, P597, DOI 10.1080/10286020.2018.1460363.},
Number-of-Cited-References = {60},
Times-Cited = {13},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {Molecules},
Doc-Delivery-Number = {HL7PR},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458934000010},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000465093900005,
Author = {Feng, Yuhua and Lin, Jinguan and Liu, Yiping and Tang, Youhong and Zhou,
   Yangying and Zhong, Meizuo},
Title = {Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large
   B-cell lymphoma},
Journal = {INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY},
Year = {2019},
Volume = {100},
Number = {1},
Pages = {32-40},
Month = {FEB},
Abstract = {Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of
   non-Hodgkin lymphoma. Because the prognosis of DLBCL patients varies
   considerably, there is an urgent need to identify novel prognostic
   factors. In this study, we investigated the expression levels of the
   signalling enzyme 3-phosphoinositide-dependent protein kinase-1 (PDK1),
   the cell cycle regulatory enzyme Polo-like kinase 1 (PLK1) and the
   transcription factor (c-Myc) in DLBCL tissues and evaluated their
   clinical and prognostic significance. PDK1, PLK1 and c-Myc were detected
   by immunohistochemical staining of paraffin-embedded specimens from 152
   DLBCL and 48 lymphadenitis patients. Expression levels were correlated
   with clinicopathological factors. PDK1, PLK1 and c-Myc were more
   commonly expressed in DLBCL specimens than in lymphadenitis specimens,
   and the expression of each protein correlated positively with that of
   the other two molecules. High PDK1, PLK1 and c-Myc expression, high
   international prognostic index score, high lactate dehydrogenase levels
   and late Ann Arbor stage were shown to correlate with shorter overall
   survival time. A multivariate Cox regression model showed that high
   expression levels of PLK1 and c-Myc were independent prognostic factors
   for DLBCL. Our findings indicate that PLK1 and c-Myc expression might be
   promising predictive biomarkers for DLBCL patients.},
Publisher = {WILEY},
Address = {111 RIVER ST, HOBOKEN 07030-5774, NJ USA},
Type = {Article},
Language = {English},
Affiliation = {Zhong, MZ (Corresponding Author), Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China.
   Feng, Yuhua; Liu, Yiping; Tang, Youhong; Zhou, Yangying; Zhong, Meizuo, Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha, Hunan, Peoples R China.
   Lin, Jinguan, Cent S Univ, Xiangya Sch Med, Hunan Canc Hosp, Dept Daytime Chemotherapy, Changsha, Hunan, Peoples R China.},
DOI = {10.1111/iep.12307},
ISSN = {0959-9673},
EISSN = {1365-2613},
Keywords = {c-Myc; diffuse large B-cell lymphoma; immunohistochemistry; PDK1; PLK1},
Keywords-Plus = {POLO-LIKE KINASES; RESISTANCE; PROGNOSIS; CANCER; PHOSPHORYLATION;
   OVEREXPRESSION; CARCINOMA},
Research-Areas = {Pathology},
Web-of-Science-Categories  = {Pathology},
Author-Email = {zhongmzuo@163.com},
Affiliations = {Central South University; Central South University},
ResearcherID-Numbers = {FENG, YUHUA/O-6866-2016
   Zhou, Yangying/HJG-6592-2022},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81570200]},
Funding-Text = {National Natural Science Foundation of China, Grant/Award Number:
   81570200},
Cited-References = {Ansell SM, 2015, MAYO CLIN PROC, V90, P1152, DOI 10.1016/j.mayocp.2015.04.025.
   Arsenic R, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-82.
   Bai XF, 2016, TUMOR BIOL, V37, P2333, DOI 10.1007/s13277-015-4024-8.
   Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Carroll PA, 2015, CANCER CELL, V27, P271, DOI 10.1016/j.ccell.2014.11.024.
   Cholewa BD, 2013, CANCER RES, V73, P6848, DOI 10.1158/0008-5472.CAN-13-2197.
   Conacci-Sorrell M., 2014, Cold Spring Harbor Persp. Med., V4, P1, DOI DOI 10.1101/CSHPERSPECT.A014357.
   de Oliveira JC, 2012, J DRUGS DERMATOL, V11, P587.
   Di Blasio L, 2017, CANCERS, V9, DOI 10.3390/cancers9030025.
   Galgano MT, 2009, HUM PATHOL, V40, P1434, DOI 10.1016/j.humpath.2009.02.008.
   Green AR, 2016, BRIT J CANCER, V114, P917, DOI 10.1038/bjc.2016.46.
   Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342.
   Hofmann JW, 2015, CELL, V160, P477, DOI 10.1016/j.cell.2014.12.016.
   Jiang JN, 2016, ADV IND CONTROL, P1, DOI 10.1007/978-3-319-39135-9\_1.
   Kawamoto K, 2016, CANCER SCI, V107, P853, DOI 10.1111/cas.12942.
   Kubuschok Boris, 2015, Cancer Treat Res, V165, P271, DOI 10.1007/978-3-319-13150-4\_11.
   Lee KS, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-4.
   Lens SMA, 2010, NAT REV CANCER, V10, P825, DOI 10.1038/nrc2964.
   Li J, 2016, PATHOL RES PRACT, V212, P204, DOI 10.1016/j.prp.2015.12.010.
   Liu L, 2007, LEUKEMIA LYMPHOMA, V48, P2179, DOI 10.1080/10428190701615918.
   Liu XS, 2010, PROTEIN CELL, V1, P999, DOI 10.1007/s13238-010-0131-x.
   Lohneis P, 2015, ANTICANCER RES, V35, P6329.
   Lu CW, 2011, AM J PATHOL, V179, P1405, DOI 10.1016/j.ajpath.2011.05.050.
   Martelli M, 2013, CRIT REV ONCOL HEMAT, V87, P146, DOI 10.1016/j.critrevonc.2012.12.009.
   Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836.
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231.
   Morton LM, 2006, BLOOD, V107, P265, DOI 10.1182/blood-2005-06-2508.
   Ninan MJ, 2011, LEUKEMIA LYMPHOMA, V52, P360, DOI 10.3109/10428194.2010.543716.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Riojas RA, 2006, J BIOL CHEM, V281, P21588, DOI 10.1074/jbc.M600393200.
   Shi JQ, 2012, MOL CANCER THER, V11, P2045, DOI 10.1158/1535-7163.MCT-11-1036.
   Song B, 2011, MOL CELL BIOL, V31, P4844, DOI 10.1128/MCB.06110-11.
   Song ZB, 2003, WORLD J GASTROENTERO, V9, P404, DOI 10.3748/wjg.v9.i3.404.
   Strebhardt K, 2006, NAT REV CANCER, V6, P321, DOI 10.1038/nrc1841.
   Swerdlow SH, 2008, WHO CLASSIFICATION T, P313.
   Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272.
   Tamgüney T, 2008, EXP CELL RES, V314, P2299, DOI 10.1016/j.yexcr.2008.04.006.
   Tan J, 2013, CANCER DISCOV, V3, P1156, DOI 10.1158/2159-8290.CD-12-0595.
   Tut TG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129313.
   Watanabe N, 2009, J BIOL CHEM, V284, P2344, DOI 10.1074/jbc.M805308200.
   Wu HW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116803.},
Number-of-Cited-References = {42},
Times-Cited = {17},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Int. J. Exp. Pathol.},
Doc-Delivery-Number = {HU2IF},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000465093900005},
OA = {Green Submitted},
DA = {2026-02-04},
}

@article{ WOS:000458630000001,
Author = {Juric, Dejan and Janku, Filip and Rodon, Jordi and Burris, Howard A. and
   Mayer, Ingrid A. and Schuler, Martin and Seggewiss-Bernhardt, Ruth and
   Gil-Martin, Marta and Middleton, Mark R. and Baselga, Jose and Bootle,
   Douglas and Demanse, David and Blumenstein, Lars and Schumacher, Karl
   and Huang, Alan and Quadt, Cornelia and Rugo, Hope S.},
Title = {Alpelisib Plus Fulvestrant in PIK3CA-Altered and
   PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast
   Cancer A Phase 1b Clinical Trial},
Journal = {JAMA ONCOLOGY},
Year = {2019},
Volume = {5},
Number = {2},
Month = {FEB},
Abstract = {IMPORTANCE The phosphatidylinositol 3-kinase (PI3K) pathway is
   frequently activated in patients with estrogen receptor-positive (ER+),
   endocrine therapy-resistant breast cancers.
   OBJECTIVE To assess the maximum tolerated dose (MTD), safety, and
   activity of alpelisib, an oral, PI3K alpha-specific inhibitor, plus
   fulvestrant in patients with ER+ advanced breast cancer (ABC).
   DESIGN, SETTING, AND PARTICIPANTS An open-label, single-arm, phase 1b
   study of alpelisib plus fulvestrant was conducted at 10 centers in 5
   countries. Participants were 87 postmenopausal women with PIK3CA-altered
   or PIK3CA-wild-type ER+ ABC, whose cancer progressed during or after
   antiestrogen therapy. The study began enrolling patients October 5,
   2010, and the data cutoff was March 22, 2017.
   INTERVENTIONS Escalating doses of alpelisib were administered once
   daily, starting at 300 mg, plus fixed-dose fulvestrant, 500 mg, in the
   dose-escalation phase; alpelisib at the recommended phase 2 dose plus
   fulvestrant in the dose-expansion phase.
   MAIN OUTCOMES AND MEASURES The primary end point was determination of
   the MTD of once-daily alpelisib plus fulvestrant. Secondary end points
   included safety and preliminary activity.
   RESULTS From October 5, 2010, to March 22, 2017, 87 women (median age:
   58 years {[}range, 37-79 years]; median of 5 prior lines of
   antineoplastic therapy) received escalating once-daily doses of
   alpelisib (300 mg, n = 9; 350 mg, n = 8; 400 mg, n = 70) plus fixed-dose
   fulvestrant (500 mg). During dose escalation, dose-limiting toxic
   effects were reported in 1 patient (alpelisib, 400 mg): diarrhea (grade
   2), vomiting, fatigue, and decreased appetite (all grade 3). The MTD of
   alpelisib when combined with fulvestrant was 400 mg once daily, and the
   recommended phase 2 dose was 300 mg once daily. Overall, the most
   frequent grade 3/4 adverse events with alpelisib, 400 mg, once daily (>=
   10\% of patients), regardless of causality, were hyperglycemia (19
   {[}22\%]) and maculopapular rash (11 {[}13\%]); 9 patients permanently
   discontinued therapy owing to adverse events. Median progression-free
   survival at the MTD was 5.4 months (95\% CI, 4.6-9.0 months). Median
   progression-free survival with alpelisib, 300 to 400 mg, once daily plus
   fulvestrant was longer in patients with PIK3CA-altered tumors
   (9.1months; 95\% CI, 6.6-14.6 months) vs wild-type tumors (4.7 months;
   95\% CI, 1.9-5.6 months). Overall response rate in the PIK3CA-altered
   group was 29\% (95\% CI, 17\%-43\%), with no objective tumor responses
   in the wild-type group.
   CONCLUSIONS AND RELEVANCE Alpelisib plus fulvestrant has a manageable
   safety profile in patients with ER+ ABC, and data suggest that this
   combination may have greater clinical activity in PIK3CA-altered vs
   wild-type tumors.},
Publisher = {AMER MEDICAL ASSOC},
Address = {330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA},
Type = {Article},
Language = {English},
Affiliation = {Juric, D (Corresponding Author), Massachusetts Gen Hosp, Canc Ctr, 55 Fruit St, Boston, MA 02114 USA.
   Juric, Dejan, Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Dept Med, Boston, MA USA.
   Janku, Filip; Rodon, Jordi, Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut Phase Clin Trials Program 1, Houston, TX 77030 USA.
   Rodon, Jordi, Vall dHebron Inst Oncol, Barcelona, Spain.
   Burris, Howard A., Tennessee Oncol Profess Ltd Liabil Corp, Dept Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
   Mayer, Ingrid A., Vanderbilt Ingram Canc Ctr, Dept Hematol Oncol, Nashville, TN USA.
   Schuler, Martin, Univ Hosp Essen, West German Canc Ctr, German Canc Consortium, Dept Med Oncol, Essen, Germany.
   Seggewiss-Bernhardt, Ruth, Univ Hosp Wurzburg, Comprehens Canc Ctr Mainfranken, Wurzburg, Germany.
   Seggewiss-Bernhardt, Ruth, SozialStiftung Bamberg, Dept Hematol Oncol, Bamberg, Germany.
   Gil-Martin, Marta, Bellvitge Biomed Res Inst, Catalan Inst Oncol, Dept Med Oncol, Barcelona, Spain.
   Middleton, Mark R., Churchill Hosp Canc Ctr, Dept Oncol, Oxford, England.
   Baselga, Jose, Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.
   Baselga, Jose, Cellex Ctr, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain.
   Bootle, Douglas; Demanse, David; Blumenstein, Lars; Schumacher, Karl; Quadt, Cornelia, Novartis Pharma AG, Translat Clin Oncol, Basel, Switzerland.
   Huang, Alan, Novartis Inst BioMed Res, Novartis Oncol Translat Res, Cambridge, MA USA.
   Huang, Alan, Tango Therapeut, Cambridge, MA USA.
   Rugo, Hope S., Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.},
DOI = {10.1001/jamaoncol.2018.4475},
Article-Number = {e184475},
ISSN = {2374-2437},
EISSN = {2374-2445},
Keywords-Plus = {DOUBLE-BLIND; INHIBITOR; 3-KINASE},
Research-Areas = {Oncology},
Web-of-Science-Categories  = {Oncology},
Author-Email = {juric.dejan@mgh.harvard.edu},
Affiliations = {Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; University of Texas System;
   UTMD Anderson Cancer Center; Vall d'Hebron Institut d'Oncologia (VHIO);
   Sarah Cannon Research Institute; Tennessee Oncology; Vanderbilt
   University; Helmholtz Association; German Cancer Research Center (DKFZ);
   University of Duisburg Essen; University of Wurzburg; Institut Catala
   d'Oncologia; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL);
   Memorial Sloan Kettering Cancer Center; Vall d'Hebron Institut
   d'Oncologia (VHIO); Novartis; Novartis; Novartis USA; University of
   California System; University of California San Francisco; UCSF Medical
   Center; UCSF Helen Diller Family Comprehensive Cancer Center},
ResearcherID-Numbers = {Janku, Filip/ABB-9136-2020
   Baselga, Jose/L-1629-2016
   Schuler, Martin/OUH-7933-2025
   Rugo, Hope S./NRX-7907-2025
   Juric, Dejan/C-5214-2008
   },
ORCID-Numbers = {Rodon, Jordi/0000-0001-6467-3632
   Schuler, Martin/0000-0002-2166-3394
   Juric, Dejan/0000-0003-2983-7704},
Funding-Acknowledgement = {Novartis Pharmaceuticals Corporation; National Cancer Institute
   {[}P30CA016672] Funding Source: NIH RePORTER},
Funding-Text = {This study was supported by Novartis Pharmaceuticals Corporation.},
Cited-References = {{[}Anonymous], 2017, BREAST CANC.
   Baselga J, 2017, LANCET ONCOL, V18, P904, DOI 10.1016/S1470-2045(17)30376-5.
   Bosch A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4442.
   Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200.
   Cardoso F, 2017, BREAST, V31, P244, DOI 10.1016/j.breast.2016.10.001.
   Di Leo A, 2018, LANCET ONCOL, V19, P87, DOI 10.1016/S1470-2045(17)30688-5.
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879.
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI {[}10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706].
   Fritsch C, 2014, MOL CANCER THER, V13, P1117, DOI 10.1158/1535-7163.MCT-13-0865.
   García-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108.
   James A, 2015, CANCER CHEMOTH PHARM, V76, P751, DOI 10.1007/s00280-015-2842-4.
   Janku F, 2012, J CLIN ONCOL, V30, P777, DOI 10.1200/JCO.2011.36.1196.
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107.
   Juric D, 2017, CANCER DISCOV, V7, P704, DOI 10.1158/2159-8290.CD-16-1080.
   Krop IE, 2016, LANCET ONCOL, V17, P811, DOI 10.1016/S1470-2045(16)00106-6.
   Martinello R, 2016, EXPERT OPIN PHARMACO, V17, P2179, DOI 10.1080/14656566.2016.1236914.
   Mayer IA, 2017, CLIN CANCER RES, V23, P26, DOI 10.1158/1078-0432.CCR-16-0134.
   Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879.
   Neuenschwander B, 2008, STAT MED, V27, P2420, DOI 10.1002/sim.3230.
   Rugo HS, 2016, J CLIN ONCOL, V34, P3069, DOI 10.1200/JCO.2016.67.1487.
   Sabine VS, 2014, J CLIN ONCOL, V32, P2951, DOI 10.1200/JCO.2013.53.8272.
   Shah Payal D, 2014, Clin Adv Hematol Oncol, V12, P214.
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053.
   Zardavas D, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3605.},
Number-of-Cited-References = {24},
Times-Cited = {210},
Usage-Count-Last-180-days = {1},
Usage-Count-Since-2013 = {33},
Journal-ISO = {JAMA Oncol.},
Doc-Delivery-Number = {HL3QD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458630000001},
OA = {Green Submitted, hybrid},
DA = {2026-02-04},
}

@article{ WOS:000461572900006,
Author = {Li, Xiang and Zhang, Ze-sheng and Zhang, Xiao-han and Yang, Sheng-nan
   and Liu, Dong and Diao, Cui-ru and Wang, Hao and Zheng, Fu-ping},
Title = {Cyanidin inhibits EMT induced by oxaliplatin via targeting the
   PDK1-PI3K/Akt signaling pathway},
Journal = {FOOD \& FUNCTION},
Year = {2019},
Volume = {10},
Number = {2},
Pages = {592-601},
Month = {FEB 1},
Abstract = {Anthocyanins have been shown to exhibit antitumor activity in several
   cancers in vitro and in vivo. Oxaliplatin is widely used as an
   anti-cancer drug. However, a large proportion of patients receiving
   platinum-based anti-cancer drug treatments will relapse because of
   metastasis and drug resistance. The aim of this study is to discover an
   effective anthocyanin that possesses the combinational anti-metastatic
   effects of oxaliplatin. Our results showed that cyanidin, one of the
   main constituents of anthocyanins, widely found in black rice, black
   bean, Hawthorn and other foods, could reverse drug resistance and
   enhance the effects of oxaliplatin on hepatic cellular cancer (HCC).
   Cyanidin inhibited migration and reversed EMT biomarker changes induced
   by low dose OXA. Moreover, 3-phosphoinositide-dependent protein kinase 1
   (PDK1) can be considered a potential target and cyanidin significantly
   increased OXA sensitivity and inhibited the EMT induced by OXA via
   PI3K/Akt signaling in HCC.},
Publisher = {ROYAL SOC CHEMISTRY},
Address = {THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, H; Zheng, FP (Corresponding Author), Beijing Technol \& Business Univ, Beijing Lab Food Qual \& Safety, Beijing 100048, Peoples R China.
   Li, Xiang, Yancheng Teachers Univ, Sch Marine \& Biol Engn, Yancheng 224051, Peoples R China.
   Li, Xiang; Wang, Hao; Zheng, Fu-ping, Beijing Technol \& Business Univ, Beijing Lab Food Qual \& Safety, Beijing 100048, Peoples R China.
   Li, Xiang; Zhang, Ze-sheng; Zhang, Xiao-han; Yang, Sheng-nan; Liu, Dong; Diao, Cui-ru, Tianjin Univ Sci \& Technol, State Key Lab Food Nutr \& Safety, Tianjin 300457, Peoples R China.},
DOI = {10.1039/c8fo01611a},
ISSN = {2042-6496},
EISSN = {2042-650X},
Keywords-Plus = {EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA; CANCER;
   INDUCTION; CELLS; ANTHOCYANINS; CHEMOTHERAPY; SUPPRESSION; METASTASIS;
   PROLIFERATION},
Research-Areas = {Biochemistry \& Molecular Biology; Food Science \& Technology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology; Food Science \& Technology},
Author-Email = {Lix01@yctu.edu.cn
   zhengfp@btbu.edu.cn},
Affiliations = {Yancheng Teachers University; Beijing Technology \& Business University;
   Tianjin University of Science \& Technology},
ResearcherID-Numbers = {xiaohan, zhang/KBC-0720-2024
   Zheng, Fuping/C-8955-2017
   Zhang, zs/GXN-3521-2022
   Liu, Dong/AEM-1824-2022},
ORCID-Numbers = {xiaohan, zhang/0000-0001-5939-4700
   Liu, Dong/0000-0003-2043-5346},
Funding-Acknowledgement = {Beijing Laboratory of Food Quality and Safety, Beijing Technology and
   Business University {[}FQS-201714]},
Funding-Text = {This work was funded by the Beijing Laboratory of Food Quality and
   Safety, Beijing Technology and Business University No: FQS-201714.},
Cited-References = {Bobkova EV, 2010, J BIOL CHEM, V285, P18838, DOI 10.1074/jbc.M109.089946.
   BOURHIS J, 1994, LARYNGOSCOPE, V104, P468.
   Chen XY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/414250.
   Chow AKM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078675.
   Cooper-Driver GA, 2001, PHYTOCHEMISTRY, V56, P229, DOI 10.1016/S0031-9422(00)00455-6.
   Daenen LGM, 2011, CANCER RES, V71, P6976, DOI 10.1158/0008-5472.CAN-11-0627.
   Deng Q, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.324.
   Eser S, 2013, CANCER CELL, V23, P406, DOI 10.1016/j.ccr.2013.01.023.
   Giannelli G, 2016, J HEPATOL, V65, P798, DOI 10.1016/j.jhep.2016.05.007.
   Hakimuddin F, 2004, BREAST CANCER RES TR, V85, P65, DOI 10.1023/B:BREA.0000021048.52430.c0.
   HOLTON TA, 1995, PLANT CELL, V7, P1071, DOI 10.1105/tpc.7.7.1071.
   Jiao L, 2016, TUMOR BIOL, V37, P8413, DOI 10.1007/s13277-015-4736-9.
   Kang SY, 2003, CANCER LETT, V194, P13, DOI 10.1016/S0304-3940(02)00583-9.
   Khaw A. K., 2007, CLIN CANCER RES, P13.
   Kuhnau J, 1976, World Rev Nutr Diet, V24, P117.
   Landen CN, 2010, MOL CANCER THER, V9, P3186, DOI 10.1158/1535-7163.MCT-10-0563.
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018.
   Ma JL, 2016, TUMOR BIOL, V37, P6177, DOI 10.1007/s13277-015-4458-z.
   Maurer M, 2009, CANCER RES, V69, P6299, DOI 10.1158/0008-5472.CAN-09-0820.
   Mundy-Bosse BL, 2011, CANCER IMMUNOL IMMUN, V60, P1269, DOI 10.1007/s00262-011-1029-z.
   Nessa MU, 2012, ANTICANCER RES, V32, P4843.
   Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd.
   PESONEN M, 1991, XENOBIOTICA, V21, P461, DOI 10.3109/00498259109039486.
   Ran S, 2015, CANCER RES, V75, P2405, DOI 10.1158/0008-5472.CAN-14-3525.
   Rodrigo KA, 2006, NUTR CANCER, V54, P58, DOI 10.1207/s15327914nc5401\_7.
   Shin DY, 2009, INT J ONCOL, V35, P1499, DOI 10.3892/ijo\_00000469.
   Teller N, 2009, J AGR FOOD CHEM, V57, P3094, DOI 10.1021/jf803094a.
   Uchibori K, 2012, INT J ONCOL, V40, P1005, DOI 10.3892/ijo.2011.1300.
   Wang LS, 2008, CANCER LETT, V269, P281, DOI 10.1016/j.canlet.2008.05.020.
   Wegiel B, 2008, INT J CANCER, V122, P1521, DOI 10.1002/ijc.23261.
   Wen QC, 2017, ONCOTARGET, V8, P47998, DOI 10.18632/oncotarget.18208.
   Xiong W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-219.
   Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008-5472.CAN-07-3063.
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245.
   Zhao J, 2008, GASTROENTEROLOGY, V135, P956, DOI 10.1053/j.gastro.2008.05.025.
   Zhao YJ, 2011, HEPATOLOGY, V53, P493, DOI 10.1002/hep.24079.},
Number-of-Cited-References = {36},
Times-Cited = {33},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {20},
Journal-ISO = {Food Funct.},
Doc-Delivery-Number = {HP3JM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000461572900006},
DA = {2026-02-04},
}

@article{ WOS:000459970100021,
Author = {Scholz, Sebastian and Plessmann, Janys and Enugutti, Balaji and Huettl,
   Regina and Wassmer, Katrin and Schneitz, Kay},
Title = {The AGC protein kinase UNICORN controls planar growth by attenuating
   PDK1 in Arabidopsis thaliana},
Journal = {PLOS GENETICS},
Year = {2019},
Volume = {15},
Number = {2},
Month = {FEB},
Abstract = {Tissue morphogenesis critically depends on the coordination of cellular
   growth patterns. In plants, many organs consist of clonally distinct
   cell layers, such as the epidermis, whose cells undergo divisions that
   are oriented along the plane of the layer. The developmental control of
   such planar growth is poorly understood. We have previously identified
   the Arabidopsis AGCVIII-class protein kinase UNICORN (UCN) as a central
   regulator of this process. Plants lacking UCN activity show spontaneous
   formation of ectopic multicellular protrusions in integuments and
   malformed petals indicating that UCN suppresses uncontrolled growth in
   those tissues. In the current model UCN regulates planar growth of
   integuments in part by directly repressing the putative transcription
   factor ABERRANT TESTA SHAPE (ATS). Here we report on the identification
   of 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1 (PDK1) as a novel
   factor involved in UCN-mediated growth control. PDK1 constitutes a basic
   component of signaling mediated by AGC protein kinases throughout
   eukaryotes. Arabidopsis PDK1 is implied in stress responses and growth
   promotion. Here we show that loss-of-function mutations in PDK1 suppress
   aberrant growth in integuments and petals of ucn mutants. Additional
   genetic, in vitro, and cell biological data support the view that UCN
   functions by repressing PDK1. Furthermore, our data indicate that PDK1
   is indirectly required for deregulated growth caused by ATS
   overexpression. Our findings support a model proposing that UCN
   suppresses ectopic growth in integuments through two independent
   processes: the attenuation of the protein kinase PDK1 in the cytoplasm
   and the repression of the transcription factor ATS in the nucleus.
   Author summary Plant organs, such as petals or roots, are composites of
   distinct cell layers. As a rule, cells making up a layer, for example
   the epidermis, the outermost layer of a tissue, divide within the plane
   of the layer. This cellular behavior results in the two-dimensional
   sheet-like or planar growth of the cell layer. The mechanism
   orchestrating such a growth pattern is poorly understood. In particular,
   it is unclear how uncontrolled and out-of-plane growth is avoided. Here
   we provide insight into this process. Our data indicate that higher than
   normal activity of a central regulator of growth and stress responses
   results in wavy and malformed petals and in protrusion-like aberrant
   outgrowths in the tissue that will develop into the seed coat. It is
   therefore important to keep this factor in check to allow proper
   formation of those tissues. We further show that a protein called
   UNICORN attenuates the activity of this regulator thereby ensuring the
   sheet-like growth of young petals or the developing seed coat.},
Publisher = {PUBLIC LIBRARY SCIENCE},
Address = {1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA},
Type = {Article},
Language = {English},
Affiliation = {Schneitz, K (Corresponding Author), Tech Univ Munich, Wissensch Zentrum Weihenstephan, Entwicklungsbiol Pflanzen, Freising Weihenstephan, Germany.
   Scholz, Sebastian; Plessmann, Janys; Enugutti, Balaji; Huettl, Regina; Wassmer, Katrin; Schneitz, Kay, Tech Univ Munich, Wissensch Zentrum Weihenstephan, Entwicklungsbiol Pflanzen, Freising Weihenstephan, Germany.
   Enugutti, Balaji, Gregor Mendel Inst Mol Plant Biol, Vienna, Austria.
   Huettl, Regina, Tech Univ Munich, Wissensch Zentrum Weihenstephan, Pflanzengenet, Freising Weihenstephan, Germany.},
DOI = {10.1371/journal.pgen.1007927},
Article-Number = {e1007927},
ISSN = {1553-7404},
Keywords-Plus = {CLASS IIIHD-ZIP; OVULE DEVELOPMENT; POLARITY DETERMINATION;
   CELL-PROLIFERATION; SIGNALING PATHWAYS; PATTERN-FORMATION; KANADI;
   GENES; PHOSPHORYLATION; EXPRESSION},
Research-Areas = {Genetics \& Heredity},
Web-of-Science-Categories  = {Genetics \& Heredity},
Author-Email = {kay.schneitz@tum.de},
Affiliations = {Technical University of Munich; Austrian Academy of Sciences; Vienna
   Biocenter (VBC); Gregor Mendel Institute of Molecular Plant Biology
   (GMI); Technical University of Munich},
ResearcherID-Numbers = {ENUGUTTI, Balaji/B-9795-2013
   Scholz, Sebastian/H-6237-2015},
ORCID-Numbers = {ENUGUTTI, Balaji/0000-0002-0816-024X
   Schneitz, Kay/0000-0001-6688-0539
   Scholz, Sebastian/0000-0001-5142-0003},
Funding-Acknowledgement = {German Research Council (DFG) {[}SCHN 723/7-1]},
Funding-Text = {This work was funded by the German Research Council (DFG, www.dfg.de)
   through grant SCHN 723/7-1 to KS. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.},
Cited-References = {Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068.
   Anthony RG, 2006, J BIOL CHEM, V281, P37536, DOI 10.1074/jbc.M607341200.
   Balasubramanian S, 2002, DEVELOPMENT, V129, P4291.
   Barbosa ICR, 2018, TRENDS PLANT SCI, V23, P523, DOI 10.1016/j.tplants.2018.03.009.
   Benjamins R, 2001, DEVELOPMENT, V128, P4057.
   Bögre L, 2003, TRENDS PLANT SCI, V8, P424, DOI 10.1016/S1360-1385(03)00188-2.
   Box MS, 2011, PLANT METHODS, V7, DOI 10.1186/1746-4811-7-7.
   Calleja V, 2007, PLOS BIOL, V5, P780, DOI 10.1371/journal.pbio.0050095.
   Camehl I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002051.
   Ceccato L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066148.
   Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x.
   Coen E, 2016, DEV CELL, V38, P579, DOI 10.1016/j.devcel.2016.09.006.
   Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575.
   Curtis MD, 2003, PLANT PHYSIOL, V133, P462, DOI 10.1104/pp.103.027979.
   Deak M, 1999, FEBS LETT, V451, P220, DOI 10.1016/S0014-5793(99)00556-6.
   Devarenne TP, 2006, EMBO J, V25, P255, DOI 10.1038/sj.emboj.7600910.
   Dhonukshe P, 2010, DEVELOPMENT, V137, P3245, DOI 10.1242/dev.052456.
   Dittrich ACN, 2012, PLANT PHYSIOL, V158, P1018, DOI 10.1104/pp.111.184572.
   DOLAN L, 1993, DEVELOPMENT, V119, P71.
   Emery JF, 2003, CURR BIOL, V13, P1768, DOI 10.1016/j.cub.2003.09.035.
   Enugutti B, 2013, PROTOPLASMA, V250, P651, DOI 10.1007/s00709-012-0452-0.
   Enugutti B, 2013, BMC PLANT BIOL, V13, DOI 10.1186/1471-2229-13-2.
   Enugutti B, 2012, P NATL ACAD SCI USA, V109, P15060, DOI 10.1073/pnas.1205089109.
   Eshed Y, 2004, DEVELOPMENT, V131, P2997, DOI 10.1242/dev.01186.
   Eshed Y, 2001, CURR BIOL, V11, P1251, DOI 10.1016/S0960-9822(01)00392-X.
   Flynn P, 2000, CURR BIOL, V10, P1439, DOI 10.1016/S0960-9822(00)00801-0.
   Forzani C, 2011, FEBS J, V278, P1126, DOI 10.1111/j.1742-4658.2011.08033.x.
   Fulton L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000355.
   Gagliardi PA, 2018, SEMIN CANCER BIOL, V48, P27, DOI 10.1016/j.semcancer.2017.04.014.
   Gälweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226.
   Gao P, 2010, PLANT BIOTECHNOL J, V8, P979, DOI 10.1111/j.1467-7652.2010.00525.x.
   Garcia AV, 2012, CELL MOL LIFE SCI, V69, P3259, DOI 10.1007/s00018-012-1093-3.
   Genevet A, 2011, BIOCHEM J, V436, P213, DOI 10.1042/BJ20110217.
   Haffani YZ, 2004, CAN J BOT, V82, P1, DOI {[}10.1139/b03-126, 10.1139/B03-126].
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500.
   Hejátko J, 2006, NAT PROTOC, V1, P1939, DOI 10.1038/nprot.2006.333.
   Izhaki A, 2007, PLANT CELL, V19, P495, DOI 10.1105/tpc.106.047472.
   Jenik PD, 2000, DEVELOPMENT, V127, P1267.
   JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534.
   Kelley DR, 2012, DEVELOPMENT, V139, P1105, DOI 10.1242/dev.067918.
   Kelley DR, 2009, PLANT J, V57, P1054, DOI 10.1111/j.1365-313X.2008.03752.x.
   Kerstetter RA, 2001, NATURE, V411, P706, DOI 10.1038/35079629.
   Komander D, 2004, EMBO J, V23, P3918, DOI 10.1038/sj.emboj.7600379.
   KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014.
   Krecek P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-249.
   Kuhlemeier C, 2016, DEVELOPMENT, V143, P3230, DOI 10.1242/dev.131888.
   Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387.
   Lee SH, 2006, PLANT CELL, V18, P1604, DOI 10.1105/tpc.105.035972.
   LEONKLOOSTERZIEL KM, 1994, PLANT CELL, V6, P385, DOI 10.1105/tpc.6.3.385.
   Leroux AE, 2018, SEMIN CANCER BIOL, V48, P1, DOI 10.1016/j.semcancer.2017.05.011.
   Lim MA, 2003, P NATL ACAD SCI USA, V100, P14006, DOI 10.1073/pnas.2335486100.
   Masters TA, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000738.
   Matsui H, 2010, PLANT CELL PHYSIOL, V51, P2082, DOI 10.1093/pcp/pcq167.
   Matsui H, 2010, PLANT CELL PHYSIOL, V51, P1731, DOI 10.1093/pcp/pcq132.
   McAbee JM, 2006, PLANT J, V46, P522, DOI 10.1111/j.1365-313X.2006.02717.x.
   Michniewicz M, 2007, CELL, V130, P1044, DOI 10.1016/j.cell.2007.07.033.
   Musielak TJ, 2015, PLANT REPROD, V28, P161, DOI 10.1007/s00497-015-0267-1.
   Pagnussat GC, 2009, SCIENCE, V324, P1684, DOI 10.1126/science.1167324.
   Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822.
   Pekker I, 2005, PLANT CELL, V17, P2899, DOI 10.1105/tpc.105.034876.
   Petersen LN, 2009, J EXP BOT, V60, P3727, DOI 10.1093/jxb/erp219.
   Pinon V, 2008, DEVELOPMENT, V135, P1315, DOI 10.1242/dev.016469.
   Prigge MJ, 2005, PLANT CELL, V17, P61, DOI 10.1105/tpc.104.026161.
   Rademacher EH, 2012, FRONT PLANT SCI, V3, DOI 10.3389/fpls.2012.00250.
   Rentel MC, 2004, NATURE, V427, P858, DOI 10.1038/nature02353.
   ROBINSONBEERS K, 1992, PLANT CELL, V4, P1237, DOI 10.1105/tpc.4.10.1237.
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z.
   Satina S, 1940, AM J BOT, V27, P895, DOI 10.2307/2436558.
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI {[}10.1038/NMETH.2019, 10.1038/nmeth.2019].
   Schmid M, 2005, NAT GENET, V37, P501, DOI 10.1038/ng1543.
   Schneitz K, 1997, DEVELOPMENT, V124, P1367.
   SCHNEITZ K, 1995, PLANT J, V7, P731, DOI 10.1046/j.1365-313X.1995.07050731.x.
   Sieber P, 2004, DEV BIOL, V273, P321, DOI 10.1016/j.ydbio.2004.05.037.
   SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755.
   Truernit E, 2008, BMC PLANT BIOL, V8, DOI 10.1186/1471-2229-8-35.
   Vaddepalli P, 2014, DEVELOPMENT, V141, P4139, DOI 10.1242/dev.113878.
   Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x.
   XU TA, 1995, DEVELOPMENT, V121, P1053.
   Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199.
   Zegzouti H, 2006, P NATL ACAD SCI USA, V103, P6404, DOI 10.1073/pnas.0510283103.
   Zegzouti H, 2006, J BIOL CHEM, V281, P35520, DOI 10.1074/jbc.M605167200.
   Zourelidou M, 2014, ELIFE, V3, DOI 10.7554/eLife.02860.
   Zulawski M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-548.},
Number-of-Cited-References = {83},
Times-Cited = {16},
Usage-Count-Last-180-days = {2},
Usage-Count-Since-2013 = {8},
Journal-ISO = {PLoS Genet.},
Doc-Delivery-Number = {HN1TO},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000459970100021},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000460176500006,
Author = {Xin, Xiaoping and Li, Zhonghui and Zhong, Yuyi and Li, Qingqing and
   Wang, Jiaying and Zhang, Hao and Yuan, Xiaolong and Li, Jiaqi and Zhang,
   Zhe},
Title = {KISS1 Suppresses Apoptosis and Stimulates the Synthesis of E2 in Porcine
   Ovarian Granulosa Cells},
Journal = {ANIMALS},
Year = {2019},
Volume = {9},
Number = {2},
Month = {FEB},
Abstract = {Previous studies have strongly recommended that KISS-1 metastasis
   suppressor (KISS1) plays an essential gatekeeper of the initiation of
   reproductive maturation in mammals. However, KISS1 has been recently
   reported to highly express in ovarian granulosa cells (GCs). But the
   biological functionalities of KISS1 on cell apoptosis, cell cycle, and
   synthesis of estradiol-17 beta (E2) have not been explored in GCs. In
   this study, using porcine GCs as a cellular model, the overexpression
   plasmid of KISS1 was built to explore the biological effects of KISS1 on
   the PI3K signaling pathway, estrogen signaling pathway, cell apoptosis,
   cell cycle, and E2 secretion. We found that mRNA of KISS1 highly
   expressed in the ovary and significantly increased from immature to
   mature follicles in gilts. Overexpression of KISS1 could significantly
   increase the mRNA expression of PIK3CG, PIK3C1, and PDK1, and
   significantly decreased the mRNA levels of FOXO3, TSC2, and BAD of PI3K
   signaling pathway. Furthermore, results of the flow cytometry showed
   that overexpression of KISS1 significantly inhibited the apoptosis of
   GCs and decreased the percentage of GCs at G0/G1 phase of the cell
   cycle. Additionally, overexpression of KISS1 could increase the mRNA
   levels of Star, CYP17, 3B-HSD, 17B-HSD of estrogen synthesis signaling
   pathway, significantly increase the concentration of E2 in the
   supernatant of the cultured GCs, and up-regulate the mRNA expression
   levels of ESR1 and ESR2. These results suggested that KISS1 might
   suppress cell apoptosis through activating the PI3K signaling pathway
   and stimulate synthesis of E2 via boosting the estrogen synthesis
   signaling pathway. This study would be of great interests for exploring
   the biological functionalities of KISS1 in the folliculogenesis and sex
   steroid production of the ovaries in mammals.},
Publisher = {MDPI},
Address = {ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND},
Type = {Article},
Language = {English},
Affiliation = {Li, JQ (Corresponding Author), South China Agr Univ, Coll Anim Sci, Natl Engn Res Ctr Breeding Swine Ind, Guangdong Prov Key Lab Agroanim Genom \& Mol Breed, Guangzhou 510642, Guangdong, Peoples R China.
   Xin, Xiaoping; Li, Zhonghui; Zhong, Yuyi; Li, Qingqing; Wang, Jiaying; Zhang, Hao; Yuan, Xiaolong; Li, Jiaqi; Zhang, Zhe, South China Agr Univ, Coll Anim Sci, Natl Engn Res Ctr Breeding Swine Ind, Guangdong Prov Key Lab Agroanim Genom \& Mol Breed, Guangzhou 510642, Guangdong, Peoples R China.},
DOI = {10.3390/ani9020054},
Article-Number = {54},
ISSN = {2076-2615},
Keywords = {KISS1; Granulosa cells; Cell apoptosis; Cell cycle; Synthesis of E2},
Keywords-Plus = {FOLLICULAR-GROWTH; KISSPEPTIN; EXPRESSION; REGULATOR; GENETICS;
   SURVIVAL; RECEPTOR; DEATH; GPR54},
Research-Areas = {Agriculture; Veterinary Sciences; Zoology},
Web-of-Science-Categories  = {Agriculture, Dairy \& Animal Science; Veterinary Sciences; Zoology},
Author-Email = {xiaopingxin1991@163.com
   lizh\_scau@163.com
   yyzhong04@163.com
   qingqingli87@163.com
   jiayingwang1993@163.com
   zhanghao@scau.edu.cn
   yxl@scau.edu.cn
   jqli@scau.edu.cn
   zhezhang@scau.edu.cn},
Affiliations = {South China Agricultural University},
ResearcherID-Numbers = {Zhang, Hao/KHY-2098-2024
   Zhang, Zhe/AAG-9641-2019
   zhong, yuyi/OCL-1697-2025
   Xin, Xiaoping/ACJ-8703-2022},
ORCID-Numbers = {zhong, yuyi/0000-0002-5899-4779
   },
Funding-Acknowledgement = {earmarked fund for China Agriculture Research System {[}CARS-35]; Basic
   Work of Science and Technology Project {[}2014FY120800]; Guangdong
   Sailing Program {[}2014YT02H042]},
Funding-Text = {This work was supported by the earmarked fund for China Agriculture
   Research System (CARS-35), the Basic Work of Science and Technology
   Project (2014FY120800) and Guangdong Sailing Program (2014YT02H042).},
Cited-References = {Adekunbi DA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183596.
   Adhikari D, 2009, MOL HUM REPROD, V15, P765, DOI 10.1093/molehr/gap092.
   Basini G, 2018, THERIOGENOLOGY, V115, P1, DOI 10.1016/j.theriogenology.2018.04.006.
   Bhattacharya M, 2015, ENDOCRINOLOGY, V156, P1218, DOI 10.1210/en.2014-1915.
   Blasco V, 2019, J ASSIST REPROD GEN, V36, P113, DOI 10.1007/s10815-018-1338-7.
   Cao XH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00512.
   Castellano JM, 2006, ENDOCRINOLOGY, V147, P4852, DOI 10.1210/en.2006-0117.
   Chakravarthi VP, 2018, ENDOCRINOLOGY, V159, P3860, DOI 10.1210/en.2018-00608.
   Choi JH, 2013, CURR OPIN ENDOCRINOL, V20, P62, DOI 10.1097/MED.0b013e32835b7ec7.
   Chou CH, 2018, VITAM HORM, V107, P155, DOI 10.1016/bs.vh.2018.01.013.
   Colledge WH, 2009, PEPTIDES, V30, P34, DOI 10.1016/j.peptides.2008.05.006.
   CONLEY AJ, 1994, BIOL REPROD, V51, P655, DOI 10.1095/biolreprod51.4.655.
   Douville G, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-50.
   Fernandois D, 2017, J ENDOCRINOL, V232, P97, DOI 10.1530/JOE-16-0181.
   Funes S, 2003, BIOCHEM BIOPH RES CO, V312, P1357, DOI 10.1016/j.bbrc.2003.11.066.
   Gorkem U, 2018, GYNECOL ENDOCRINOL, V34, P157, DOI 10.1080/09513590.2017.1379499.
   Hu CL, 2004, MOL ENDOCRINOL, V18, P326, DOI 10.1210/me.2003-0178.
   Hu KL, 2019, REPROD SCI, V26, P1429, DOI 10.1177/1933719118818899.
   Hu KL, 2018, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00365.
   Hunter MG, 2000, REV REPROD, V5, P122, DOI 10.1530/revreprod/5.2.122.
   Ieda N, 2014, J REPROD DEVELOP, V60, P312, DOI 10.1262/jrd.2013-129.
   Khan MIUR, 2016, REPROD FERT DEVELOP, V28, P795, DOI 10.1071/RD14089.
   Khristi V, 2018, MOL CELL ENDOCRINOL, V474, P214, DOI 10.1016/j.mce.2018.03.012.
   Lapatto R, 2007, ENDOCRINOLOGY, V148, P4927, DOI 10.1210/en.2007-0078.
   Leka-Emiri S, 2017, J ENDOCRINOL INVEST, V40, P789, DOI 10.1007/s40618-017-0627-9.
   Li Q, 2013, MOL ENDOCRINOL, V27, P1468, DOI 10.1210/me.2013-1082.
   Liu JY, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.122788.
   Liu ZL, 2013, MOL ENDOCRINOL, V27, P238, DOI 10.1210/me.2012-1296.
   Makker A, 2014, J MOL ENDOCRINOL, V53, pR103, DOI 10.1530/JME-14-0220.
   Matsuda F, 2012, J REPROD DEVELOP, V58, P44, DOI 10.1262/jrd.2011-012.
   McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200.
   Naniwa Y, 2013, J REPROD DEVELOP, V59, P588, DOI 10.1262/jrd.2013-064.
   Ozay OE, 2016, GYNECOL ENDOCRINOL, V32, P718, DOI 10.3109/09513590.2016.1161019.
   Patterson JL, 2002, THERIOGENOLOGY, V57, P2015, DOI 10.1016/S0093-691X(02)00674-X.
   Plant TM, 2015, FRONT NEUROENDOCRIN, V38, P73, DOI 10.1016/j.yfrne.2015.04.002.
   Reddy P, 2009, HUM MOL GENET, V18, P2813, DOI 10.1093/hmg/ddp217.
   Ricu MA, 2012, ENDOCRINOLOGY, V153, P4966, DOI 10.1210/en.2012-1279.
   Saatcioglu HD, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006215.
   Schams D, 2002, DOMEST ANIM ENDOCRIN, V23, P53, DOI 10.1016/S0739-7240(02)00145-5.
   Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322.
   Tanyapanyachon P, 2018, THERIOGENOLOGY, V117, P40, DOI 10.1016/j.theriogenology.2018.05.019.
   Toro CA, 2018, J NEUROENDOCRINOL, V30, DOI 10.1111/jne.12589.
   Valdez KE, 2005, MOL CELL ENDOCRINOL, V243, P66, DOI 10.1016/j.mce.2005.09.004.
   Yamamoto H, 2017, J OBSTET GYNAECOL RE, V43, P1021, DOI 10.1111/jog.13307.
   Yan H, 2018, BMC BIOL, V16, DOI 10.1186/s12915-018-0541-4.
   Yuan XL, 2018, IN VITRO CELL DEV-AN, V54, P715, DOI 10.1007/s11626-018-0292-0.
   Yuan XL, 2018, GENES-BASEL, V9, DOI 10.3390/genes9060295.
   Zhang L, 2007, CLIN CANCER RES, V13, P5314, DOI 10.1158/1078-0432.CCR-06-2660.
   Zheng WJ, 2012, MOL CELL ENDOCRINOL, V356, P24, DOI 10.1016/j.mce.2011.05.027.
   Zhuo Y, 2014, NUTRITION, V30, P890, DOI 10.1016/j.nut.2013.12.019.},
Number-of-Cited-References = {50},
Times-Cited = {16},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {23},
Journal-ISO = {Animals},
Doc-Delivery-Number = {HN4TL},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000460176500006},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000457479300028,
Author = {Zhou, Xuexia and Wang, Run and Li, Xuebing and Yu, Lin and Hua, Dan and
   Sun, Cuiyun and Shi, Cuijuan and Luo, Wenjun and Rao, Chun and Jiang,
   Zhendong and Feng, Ying and Wang, Qian and Yu, Shizhu},
Title = {Splicing factor SRSF1 promotes gliomagenesis via oncogenic
   splice-switching of MYO1B},
Journal = {JOURNAL OF CLINICAL INVESTIGATION},
Year = {2019},
Volume = {129},
Number = {2},
Pages = {676-693},
Month = {FEB 1},
Abstract = {Abnormal alternative splicing (AS) caused by alterations to splicing
   factors contributes to tumor progression. Serine/arginine splicing
   factor 1 (SRSF1) has emerged as a key oncodriver in numerous solid
   tumors, leaving its roles and mechanisms largely obscure in glioma.
   Here, we demonstrate that SRSF1 is increased in glioma tissues and cell
   lines. Moreover, its expression was correlated positively with tumor
   grade and Ki-67 index, but inversely with patient survival. Using
   RNA-Seq, we comprehensively screened and identified multiple
   SRSF1-affected AS events. Motif analysis revealed a position-dependent
   modulation of AS by SRSF1 in glioma. Functionally, we verified that
   SRSF1 promoted cell proliferation, survival, and invasion by
   specifically switching the AS of the myosin IB (MYO1B) gene and
   facilitating the expression of the oncogenic and membrane-localized
   isoform, MYO1B-fl. Strikingly, MYO1B splicing was dysregulated in
   parallel with SRSF1 expression in gliomas and predicted the poor
   prognosis of the patients. Further investigation revealed that
   SRSF1-guided AS of the MYO1B gene increased the tumorigenic potential of
   glioma cells through the PDK1/AKT and PAK/LIMK pathways. Taken together,
   we identify SRSF1 as an important oncodriver that integrates AS control
   of MYO1B into promotion of gliomagenesis and represents a potential
   prognostic biomarker and target for glioma therapy.},
Publisher = {AMER SOC CLINICAL INVESTIGATION INC},
Address = {2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA},
Type = {Article},
Language = {English},
Affiliation = {Wang, Q; Yu, SZ (Corresponding Author), Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neuropathol, 154 Anshan Roa, Tianjin 300052, Peoples R China.
   Zhou, Xuexia; Wang, Run; Hua, Dan; Sun, Cuiyun; Shi, Cuijuan; Luo, Wenjun; Rao, Chun; Jiang, Zhendong; Wang, Qian; Yu, Shizhu, Tianjin Med Univ, Gen Hosp, Tianjin Neurol Inst, Dept Neuropathol, 154 Anshan Roa, Tianjin 300052, Peoples R China.
   Zhou, Xuexia; Wang, Run; Hua, Dan; Sun, Cuiyun; Shi, Cuijuan; Luo, Wenjun; Rao, Chun; Jiang, Zhendong; Wang, Qian; Yu, Shizhu, Tianjin Key Lab Injuries Variat \& Regenerat Nervo, Tianjin, Peoples R China.
   Zhou, Xuexia; Wang, Run; Hua, Dan; Sun, Cuiyun; Shi, Cuijuan; Luo, Wenjun; Rao, Chun; Jiang, Zhendong; Wang, Qian; Yu, Shizhu, Minist Educ, Key Lab Posttrauma Neurorepair \& Regenerat Cent N, Tianjin, Peoples R China.
   Li, Xuebing, Tianjin Med Univ, Tianjin Lung Canc Inst, Tianjin Key Lab Lung Canc Metastasis \& Tumor Envi, Gen Hosp, Tianjin, Peoples R China.
   Yu, Lin, Tianjin Med Univ, Sch Basic Med Sci, Dept Biochem \& Mol Biol, Tianjin, Peoples R China.
   Feng, Ying, Univ Chinese Acad Sci, Chinese Acad Sci, Inst Nutr Sci, Key Lab Food Safety Res,Shanghai Inst Biol Sci, Shanghai, Peoples R China.},
DOI = {10.1172/JCI120279},
ISSN = {0021-9738},
EISSN = {1558-8238},
Keywords-Plus = {CANCER; SF2/ASF; ORGANIZATION; EXPRESSION; MIGRATION; COFILIN; GLIOMA;
   TUMORS; 17Q23},
Research-Areas = {Research \& Experimental Medicine},
Web-of-Science-Categories  = {Medicine, Research \& Experimental},
Author-Email = {wangqiantni@163.com
   tjyushizhu@163.com},
Affiliations = {Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Chinese Academy of Sciences; University of Chinese Academy
   of Sciences, CAS},
ResearcherID-Numbers = {Yu, Lin/ADI-3407-2022
   Li, Xuebing/HPF-4991-2023
   Feng, Ying/KWU-9364-2024},
ORCID-Numbers = {Yu, Lin/0000-0002-9972-3799
   Feng, Ying/0000-0001-9501-156X},
Funding-Acknowledgement = {National Natural Science Foundation of China {[}81302002, 81402050,
   81502166, 81672592, 81872061]; Programs of Science and Technology
   Commission Foundation of Tianjin Municipality {[}14JCQNJC12300,
   15JCZDJC34600, 15JCYBJC49900, 16JCQNJC13400, 17JCYBJC27100]; Program of
   Tianjin Municipal Health Bureau {[}15KJ147]; Foundation of Tianjin
   Medical University and General Hospital {[}2015KYZQ11, ZYYFY2015032];
   ``New Century{''} Talent Training Project of TMUGH (2016)},
Funding-Text = {This project was supported by grants from the National Natural Science
   Foundation of China (nos. 81302002, 81402050, 81502166, 81672592, and
   81872061), the Programs of Science and Technology Commission Foundation
   of Tianjin Municipality (14JCQNJC12300, 15JCZDJC34600, 15JCYBJC49900,
   16JCQNJC13400, and 17JCYBJC27100), the Program of Tianjin Municipal
   Health Bureau (15KJ147), the Foundation of Tianjin Medical University
   and General Hospital (2015KYZQ11 and ZYYFY2015032), and the ``New
   Century{''} Talent Training Project of TMUGH (2016, to X. Zhou). We
   thank Liqun He (Tianjin Neurological Institute, TMUGH, Tianjin, China)
   for providing help with the bioinformatics analysis.},
Cited-References = {Anczuków O, 2015, MOL CELL, V60, P105, DOI 10.1016/j.molcel.2015.09.005.
   Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2.
   Asrani K, 2017, J CLIN INVEST, V127, P4001, DOI 10.1172/JCI92893.
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655.
   Chautard E, 2014, J NEURO-ONCOL, V117, P205, DOI 10.1007/s11060-014-1382-9.
   Correa BR, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0990-4.
   Das S, 2012, CELL REP, V1, P110, DOI 10.1016/j.celrep.2011.12.001.
   David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010.
   de Miguel FJ, 2014, CANCER RES, V74, P1105, DOI 10.1158/0008-5472.CAN-13-1481.
   Dehm SM, 2013, CANCER RES, V73, P5309, DOI 10.1158/0008-5472.CAN-13-0444.
   Ensign SPF, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00241.
   Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026.
   Golan-Gerstl R, 2011, CANCER RES, V71, P4464, DOI 10.1158/0008-5472.CAN-10-4410.
   Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3.
   Hartman MA, 2012, J CELL SCI, V125, P1627, DOI 10.1242/jcs.094300.
   Jiang LY, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005895.
   Karni R, 2008, P NATL ACAD SCI USA, V105, P15323, DOI 10.1073/pnas.0801376105.
   Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209.
   LeFave CV, 2011, EMBO J, V30, P4084, DOI 10.1038/emboj.2011.259.
   Li HZ, 2017, TURK NEUROSURG, V27, P894, DOI 10.5137/1019-5149.JTN.17746-16.1.
   Li HN, 2017, ONCOTARGET, V8, P19723, DOI 10.18632/oncotarget.14975.
   Li HW, 1997, J NEUROPATH EXP NEUR, V56, P872, DOI 10.1097/00005072-199708000-00005.
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007.
   Liu JN, 2015, ONCOTARGET, V6, P21341, DOI 10.18632/oncotarget.4179.
   Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501.
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1.
   Luo CL, 2017, CANCER RES, V77, P1168, DOI 10.1158/0008-5472.CAN-16-1919.
   Makowska KA, 2015, CELL REP, V13, P2118, DOI 10.1016/j.celrep.2015.11.012.
   Matlin AJ, 2005, NAT REV MOL CELL BIO, V6, P386, DOI 10.1038/nrm1645.
   Ohashi K, 2015, DEV GROWTH DIFFER, V57, P275, DOI 10.1111/dgd.12213.
   Ohmura G, 2015, MOL CANCER RES, V13, P721, DOI 10.1158/1541-7786.MCR-14-0410.
   Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533.
   Pandit S, 2013, MOL CELL, V50, P223, DOI 10.1016/j.molcel.2013.03.001.
   Park JB, 2014, ONCOTARGET, V5, P9382, DOI 10.18632/oncotarget.2412.
   Ricard D, 2012, LANCET, V379, P1984, DOI 10.1016/S0140-6736(11)61346-9.
   Shi CJ, 2017, BRIT J CANCER, V117, P1036, DOI 10.1038/bjc.2017.255.
   Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133.
   Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053.
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330.
   Tang NY, 2001, CURR BIOL, V11, P1131, DOI 10.1016/S0960-9822(01)00320-7.
   Wang HX, 2009, J BIOL CHEM, V284, P5685, DOI 10.1074/jbc.M807632200.
   Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308.
   Zhou XX, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5581.
   Zhou XX, 2014, NUCLEIC ACIDS RES, V42, P4019, DOI 10.1093/nar/gkt1387.},
Number-of-Cited-References = {44},
Times-Cited = {119},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {25},
Journal-ISO = {J. Clin. Invest.},
Doc-Delivery-Number = {HJ8VX},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000457479300028},
OA = {Green Submitted, Bronze},
DA = {2026-02-04},
}

@article{ WOS:000464840200001,
Author = {Zhuang, Yongxian and Ly, Reynold C. and Frazier, Carleigh V. and Yu, Jia
   and Qin, Sisi and Fan, Xiao-Yang and Goetz, Matthew P. and Boughey, Judy
   C. and Weinshilboum, Richard and Wang, Liewei},
Title = {The novel function of tumor protein D54 in regulating pyruvate
   dehydrogenase and metformin cytotoxicity in breast cancer},
Journal = {CANCER \& METABOLISM},
Year = {2019},
Volume = {7},
Month = {JAN 24},
Abstract = {Background: The role of tumor protein D54 in breast cancer has not been
   studied and its function in breast cancer remains unclear. In our
   previous pharmacogenomic studies using lymphoblastoid cell line (LCL),
   this protein has been identified to affect metformin response. Although
   metformin has been widely studied as a prophylactic and chemotherapeutic
   drug, there is still a lack of biomarkers predicting the response to
   metformin in breast cancer. In this study, we revealed the novel
   function of TPD54 in breast cancer through understanding how TPD54
   altered the cancer cell sensitivity to metformin.
   Methods: The role of TPD54 in altering cellular sensitivity to metformin
   treatment was carried out by either knockdown or overexpression of
   TPD54, followed by measuring cell viability and reactive oxygen species
   (ROS) production in MCF7 breast cancer cell line and breast cancer
   patient-derived xenografts. Functional analysis of TPD54 in breast
   cancer cells was demonstrated by studying TPD54 protein localization and
   identification of potential binding partners of TPD54 through
   immunoprecipitation followed by mass spectrometry. The effect of TPD54
   on pyruvate dehydrogenase (PDH) protein regulation was demonstrated by
   western blot, immunoprecipitation, and site-directed mutagenesis.
   Results: TPD54 inhibited colony formation and enhanced cellular
   sensitivity to metformin treatment in MCF7 cells and breast cancer
   patient-derived xenografts. Mechanistic study indicated that TPD54 had
   mitochondrial localization, bound to and stabilized pyruvate
   dehydrogenase E1 by blocking pyruvate dehydrogenase kinase 1
   (PDK1)-mediated serine 232 phosphorylation. TPD54 knockdown increased
   PDH E1 protein degradation and led to decreased PDH enzyme activity,
   which reduced mitochondrial oxygen consumption and reactive oxygen
   species (ROS) production, thus contributing to the resistance of breast
   cancer cells to metformin treatment.
   Conclusion: We have discovered a novel mechanism by which TPD54
   regulates pyruvate dehydrogenase and affects the sensitivity of breast
   cancer to metformin treatment. Our findings highlight the important
   post-translational regulation of PDK1 on PDH E1 and the potential
   application of TPD54 as a biomarker for selecting tumors that may be
   sensitive to metformin therapy. These provide new insights into
   understanding the regulation of PDH complexes and the resistance
   mechanisms of cancer cells to metformin treatment.},
Publisher = {BMC},
Address = {CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Wang, LW (Corresponding Author), Mayo Clin, Dept Mol Pharmacol \& Expt Therapeut, Div Clin Pharmacol, 200 First St SW, Rochester, MN 55905 USA.
   Zhuang, Yongxian; Yu, Jia; Qin, Sisi; Fan, Xiao-Yang; Goetz, Matthew P.; Weinshilboum, Richard; Wang, Liewei, Mayo Clin, Dept Mol Pharmacol \& Expt Therapeut, Div Clin Pharmacol, 200 First St SW, Rochester, MN 55905 USA.
   Ly, Reynold C., Mayo Clin, Grad Sch Biomed Sci, Dept Mol Pharmacol \& Expt Therapeut, Div Clin Pharmacol, Rochester, MN 55905 USA.
   Frazier, Carleigh V., Fisk Univ, Dept Biol, Nashville, TN 37208 USA.
   Goetz, Matthew P., Mayo Clin, Dept Oncol, Rochester, MN 55905 USA.
   Boughey, Judy C., Mayo Clin, Dept Surg, Rochester, MN 55905 USA.},
DOI = {10.1186/s40170-018-0193-4},
Article-Number = {1},
EISSN = {2049-3002},
Keywords = {Tumor protein D54 (TPD54); Pyruvate dehydrogenase (PDH); Pyruvate
   dehydrogenase kinase (PDK); Metformin; Mitochondrial reactive oxygen
   species (ROS)},
Keywords-Plus = {CELL SENSITIVITY; TPD52; COMPLEX; AMPLIFICATION; PHARMACOGENOMICS;
   DICHLOROACETATE; METABOLISM; BIOMARKERS; MIGRATION; DEATH},
Research-Areas = {Oncology; Cell Biology},
Web-of-Science-Categories  = {Oncology; Cell Biology},
Author-Email = {wang.liewei@mayo.edu},
Affiliations = {Mayo Clinic; Mayo Clinic; Fisk University; Mayo Clinic; Mayo Clinic},
ResearcherID-Numbers = {Goetz, Matthew/AAH-2333-2020},
ORCID-Numbers = {Ly, Reynold/0000-0002-3016-6859
   },
Funding-Acknowledgement = {National Institute of General Medical Sciences of the National
   Institutes of Health {[}T32 GM008685]; National Cancer Institute
   {[}CA196648]; Mayo Clinic Center for Individualized Medicine; Mayo
   Clinic Breast SPORE {[}P50CA 116201-9]; Minnesota Partnership for
   Biotechnology \& Medical Genomics award MNP IF {[}16.09]; National
   Cancer Institute {[}P50CA116201] Funding Source: NIH RePORTER; National
   Institute of General Medical Sciences {[}T32GM008685] Funding Source:
   NIH RePORTER},
Funding-Text = {The study was supported by the National Institute of General Medical
   Sciences of the National Institutes of Health under award number T32
   GM008685 and by the National Cancer Institute under award CA196648 L.W,
   the Mayo Clinic Center for Individualized Medicine, and the Mayo Clinic
   Breast SPORE (grant P50CA 116201-9). Seahorse XFp was supported by a
   Minnesota Partnership for Biotechnology \& Medical Genomics award MNP IF
   \#16.09.},
Cited-References = {Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940-6207.CAPR-11-0536.
   Asgari Y, 2015, GENOMICS, V105, P275, DOI 10.1016/j.ygeno.2015.03.001.
   BALLEINE RL, 2003, GCC, V29, P48, DOI DOI 10.1002/1098-2264(2000)9999:9999.
   Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110.
   Brand MD, 2016, FREE RADICAL BIO MED, V100, P14, DOI 10.1016/j.freeradbiomed.2016.04.001.
   Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620.
   Byrne JA, 1996, GENOMICS, V35, P523, DOI 10.1006/geno.1996.0393.
   Byrne JA, 2005, INT J CANCER, V117, P1049, DOI 10.1002/ijc.21250.
   Byrne JA, 2014, TUMOR BIOL, V35, P7369, DOI 10.1007/s13277-014-2006-x.
   Chen Y, 2008, INVEST OPHTH VIS SCI, V49, P1721, DOI 10.1167/iovs.07-1121.
   Choschzick M, 2010, MODERN PATHOL, V23, P603, DOI 10.1038/modpathol.2010.5.
   Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007.
   EBOLI ML, 1994, CANCER LETT, V85, P239, DOI 10.1016/0304-3835(94)90281-X.
   Goetz MP, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw306.
   Golias T, 2016, SCI REP-UK, V6, DOI 10.1038/srep31146.
   Gui DY, 2016, CELL METAB, V24, P716, DOI 10.1016/j.cmet.2016.09.006.
   Han Z, 2008, J BIOL CHEM, V283, P237, DOI 10.1074/jbc.M704748200.
   Haugrud AB, 2014, BREAST CANCER RES TR, V147, P539, DOI 10.1007/s10549-014-3128-y.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Ito C, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/6014278.
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154.
   Kato K, 2017, INT J ONCOL, V50, P1634, DOI 10.3892/ijo.2017.3929.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Lee JD, 2016, EXP THER MED, V12, P2974, DOI 10.3892/etm.2016.3722.
   Lee Minjong, 2015, World J Biol Chem, V6, P148, DOI {[}10.4331/wjbc.v6.i3.148, 10.4331/wjbc.v6.i3.148].
   Leverve XM, 2003, DIABETES METAB, V29, p6S88.
   Lewis JD, 2007, MOL CANCER RES, V5, P133, DOI 10.1158/1541-7786.MCR-06-0245.
   McFate T, 2008, J BIOL CHEM, V283, P22700, DOI 10.1074/jbc.M801765200.
   Mukudai Y, 2013, CELL ONCOL, V36, P233, DOI 10.1007/s13402-013-0131-y.
   Niu NF, 2016, HUM MOL GENET, V25, P4819, DOI 10.1093/hmg/ddw301.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881.
   Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Shahheydari H, 2014, MOL BIOL REP, V41, P4565, DOI 10.1007/s11033-014-3327-y.
   Shehata M, 2008, CLIN CANCER RES, V14, P5050, DOI 10.1158/1078-0432.CCR-07-4994.
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071.
   Ummanni R, 2008, FEBS J, V275, P5703, DOI 10.1111/j.1742-4658.2008.06697.x.
   Venditti P, 2013, MITOCHONDRION, V13, P71, DOI 10.1016/j.mito.2013.01.008.
   Wang LW, 2014, DIABETES, V63, P2609, DOI 10.2337/db14-0609.
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519.
   Wheaton WW, 2014, ELIFE, V3, DOI 10.7554/eLife.02242.
   Wilson SHD, 2001, GENOMICS, V76, P81, DOI 10.1006/geno.2001.6610.
   Yonashiro R, 2018, CANCER RES, V78, P1592, DOI 10.1158/0008-5472.CAN-17-1751.
   Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924.
   Yu J, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0920-8.
   Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750-2187-3-18.
   Zhuang YX, 2011, MOL CANCER RES, V9, P603, DOI 10.1158/1541-7786.MCR-10-0343.},
Number-of-Cited-References = {48},
Times-Cited = {14},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {2},
Journal-ISO = {Cancer Metab.},
Doc-Delivery-Number = {HT8UM},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000464840200001},
OA = {Green Submitted, gold},
DA = {2026-02-04},
}

@article{ WOS:000458670200010,
Author = {Klyuyeva, Alla and Tuganova, Alina and Kedishvili, Natalia and Popov,
   Kirill M.},
Title = {Tissue-specific kinase expression and activity regulate flux through the
   pyruvate dehydrogenase complex},
Journal = {JOURNAL OF BIOLOGICAL CHEMISTRY},
Year = {2019},
Volume = {294},
Number = {3},
Pages = {838-851},
Month = {JAN 18},
Abstract = {The pyruvate dehydrogenase complex (PDC) is a multienzyme assembly that
   converts pyruvate to acetyl-CoA. As pyruvate and acetyl-CoA play central
   roles in cellular metabolism, understanding PDC regulation is pivotal to
   understanding the larger metabolic network. The activity of mammalian
   PDC is regulated through reversible phosphorylation governed by at least
   four isozymes of pyruvate dehydrogenase kinase (PDK). Deciphering which
   kinase regulates PDC in organisms at specific times or places has been
   challenging. In this study, we analyzed mouse strains carrying targeted
   mutations of individual isozymes to explore their role in regulating PDC
   activity. Analysis of protein content of PDK isozymes in major metabolic
   tissues revealed that PDK1 and PDK2 were ubiquitously expressed, whereas
   PDK3 and PDK4 displayed a rather limited tissue distribution.
   Measurement of kinase activity showed that PDK1 is the principal isozyme
   regulating hepatic PDC. PDK2 was largely responsible for inactivation of
   PDC in tissues of muscle origin and brown adipose tissue (BAT). PDK3 was
   the principal kinase regulating pyruvate dehydrogenase activity in
   kidney and brain. In a well-fed state, the tissue levels of PDK4 protein
   were fairly low. In most tissues tested, PDK4 ablation had little effect
   on the overall rates of inactivation of PDC in kinase reaction. Taken
   together, these data strongly suggest that the activity of PDC is
   regulated by different isozymes in different tissues. Furthermore, it
   appears that the overall flux through PDC in a given tissue largely
   reflects the properties of the PDK isozyme that is principally
   responsible for the regulation of PDC activity in that tissue.},
Publisher = {ELSEVIER},
Address = {RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS},
Type = {Article},
Language = {English},
Affiliation = {Popov, KM (Corresponding Author), Univ Alabama Birmingham, Dept Biochem \& Mol Genet, Sch Med, KAUL 440A,720 20th St S, Birmingham, AL 35294 USA.
   Popov, KM (Corresponding Author), Univ Alabama Birmingham, Dept Biochem \& Mol Genet, Sch Dent, KAUL 440A,720 20th St S, Birmingham, AL 35294 USA.
   Tuganova, Alina; Kedishvili, Natalia; Popov, Kirill M., Univ Alabama Birmingham, Dept Biochem \& Mol Genet, Sch Med, KAUL 440A,720 20th St S, Birmingham, AL 35294 USA.
   Tuganova, Alina; Kedishvili, Natalia; Popov, Kirill M., Univ Alabama Birmingham, Dept Biochem \& Mol Genet, Sch Dent, KAUL 440A,720 20th St S, Birmingham, AL 35294 USA.
   Klyuyeva, Alla, Avanti Polar Lipids Inc, 700 Ind Pk Dr, Alabaster, AL 35007 USA.},
DOI = {10.1074/jbc.RA118.006433},
EISSN = {1083-351X},
Keywords = {pyruvate dehydrogenase complex (PDC); pyruvate dehydrogenase kinase (PDC
   kinase); mitochondria; carbohydrate metabolism; protein phosphorylation;
   carbohydrate metabolism; mitochondria; oxidative decarboxylation of
   pyruvate; protein kinase; protein phosphorylation; metabolic flux},
Keywords-Plus = {GLUCOSE-HOMEOSTASIS; METABOLISM; INHIBITION; MECHANISMS; HEART;
   PHOSPHORYLATION; PROTEIN; PHOSPHATASE; ISOENZYME; ISOFORMS},
Research-Areas = {Biochemistry \& Molecular Biology},
Web-of-Science-Categories  = {Biochemistry \& Molecular Biology},
Author-Email = {kpopov@uab.edu},
Affiliations = {University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham},
ResearcherID-Numbers = {Popov, Kirill/R-6450-2017},
Funding-Acknowledgement = {NIGMS, National Institutes of Health {[}GM51262]},
Funding-Text = {This work was supported by NIGMS, National Institutes of Health, Grant
   GM51262. The authors declare that they have no conflicts of interest
   with the contents of this article. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.},
Cited-References = {Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199.
   Boussouar F, 2004, TRENDS ENDOCRIN MET, V15, P345, DOI 10.1016/j.tem.2004.07.003.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Chih CP, 2003, J CEREBR BLOOD F MET, V23, P1263, DOI 10.1097/01.WCB.0000081369.51727.6F.
   Desagher S, 1997, J NEUROSCI, V17, P9060.
   Dunford EC, 2011, AM J PHYSIOL-REG I, V300, pR1487, DOI 10.1152/ajpregu.00498.2010.
   Gerich JE, 2001, DIABETES CARE, V24, P382, DOI 10.2337/diacare.24.2.382.
   GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989.
   Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746.
   Hinoi E, 2006, MOL PHARMACOL, V70, P925, DOI 10.1124/mol.106.024398.
   Hollidge-Horvat MG, 1999, AM J PHYSIOL-ENDOC M, V277, pE647, DOI 10.1152/ajpendo.1999.277.4.E647.
   HOLNESS MJ, 1989, BIOCHEM J, V258, P529, DOI 10.1042/bj2580529.
   Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680.
   Jeoung NH, 2006, BIOCHEM J, V397, P417, DOI 10.1042/BJ20060125.
   Jeoung NH, 2012, BIOCHEM J, V443, P829, DOI 10.1042/BJ20112197.
   Karpova T, 2003, BBA-PROTEINS PROTEOM, V1652, P126, DOI 10.1016/j.bbapap.2003.08.010.
   Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001.
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002.
   Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069.
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0.
   Lee YJ, 2003, MICROVASC RES, V66, P91, DOI 10.1016/S0026-2862(03)00052-9.
   LINN TC, 1969, P NATL ACAD SCI USA, V64, P227, DOI 10.1073/pnas.64.1.227.
   Martin E, 2005, J NEUROSCI RES, V79, P240, DOI 10.1002/jnr.20293.
   Mohanty I, 2002, MOL CELL BIOCHEM, V238, P129, DOI 10.1023/A:1019961922260.
   O'Donnell-Tormey J, 1987, J Exp Med, V165, P500.
   Ohlrogge J, 2000, BIOCHEM SOC T, V28, P567, DOI 10.1042/BST0280567.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213.
   Perrin A, 2002, BIOCHIMIE, V84, P1003, DOI 10.1016/S0300-9084(02)00008-1.
   PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4.
   Pithukpakorn M, 2005, MOL GENET METAB, V85, P243, DOI 10.1016/j.ymgme.2005.06.006.
   Popov K M, 1991, Protein Expr Purif, V2, P278, DOI 10.1016/1046-5928(91)90084-V.
   POPOV KM, 1994, J BIOL CHEM, V269, P29720.
   PRIESTMAN DA, 1992, FEBS LETT, V308, P83, DOI 10.1016/0014-5793(92)81056-R.
   Rajendran P, 2011, CRIT REV BIOCHEM MOL, V46, P181, DOI 10.3109/10409238.2011.557713.
   Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z.
   Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354.
   Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376.
   SALE GJ, 1982, BIOCHEM J, V203, P99, DOI 10.1042/bj2030099.
   Skarnes WC, 2011, NATURE, V474, P337, DOI 10.1038/nature10163.
   Soga T, 2013, CANCER SCI, V104, P275, DOI 10.1111/cas.12085.
   Story J A, 1984, Lab Res Methods Biol Med, V10, P217.
   Sugden Mary C., 2006, Archives of Physiology and Biochemistry, V112, P139, DOI 10.1080/13813450600935263.
   Sugden MC, 2003, OBES RES, V11, P167, DOI 10.1038/oby.2003.26.
   SUGDEN PH, 1978, BIOCHEM J, V169, P433, DOI 10.1042/bj1690433.
   Thangaraju M, 2009, BIOCHEM J, V417, P379, DOI 10.1042/BJ20081132.
   TONKS NK, 1982, EUR J BIOCHEM, V122, P549.
   Wagman AS, 2001, CURR PHARM DESIGN, V7, P417, DOI 10.2174/1381612013397915.
   Wahren J, 2007, ANNU REV NUTR, V27, P329, DOI 10.1146/annurev.nutr.27.061406.093806.
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063.
   Wu PF, 1998, BIOCHEM J, V329, P197, DOI 10.1042/bj3290197.},
Number-of-Cited-References = {51},
Times-Cited = {39},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {7},
Journal-ISO = {J. Biol. Chem.},
Doc-Delivery-Number = {HL4FC},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000458670200010},
OA = {hybrid},
DA = {2026-02-04},
}

@article{ WOS:000454616600033,
Author = {Guo, Fuyun and Zhao, Shufen and Li, Xiao'e},
Title = {Discovery of novel pyruvate dehydrogenase kinases inhibitors by
   screening of an in-house small molecule library for anti-lung cancer
   therapeutics},
Journal = {BIOORGANIC \& MEDICINAL CHEMISTRY LETTERS},
Year = {2019},
Volume = {29},
Number = {2},
Pages = {291-296},
Month = {JAN 15},
Abstract = {Pyruvate dehydrogenase kinases (PDKs) are widely over-expressed in
   various human solid cancers, making them attractive therapeutic targets
   for cancer treatment. Herein, we report the identification of
   structurally novel PDKs inhibitors by screening of an in-house small
   molecule library. Biochemical assay indicated that the identified
   compounds 1-4 inhibited PDK1 activity with EC50 values of 0.50, 1.99,
   4.64, and 0.42 mu M, respectively. The ITC analysis suggested that the
   identified compounds 1-4 were pan-isoform PDK inhibitors, which bound to
   and inhibited the four PDK isoforms. Moreover, 1-4 dose-dependently
   reduced pyruvate dehydrogenase complex phosphorylation in NCI-H1975
   cell. Molecular docking suggested that the most potent compound 4 docked
   well in the ATP binding pocket of the four PDK isoforms, forming direct
   hydrogen bond interactions with the conserved amino acids Thr and Asp in
   ATP binding pocket of PDKs. The cell viability assay demonstrated that 4
   potently blocked NCI-H1975 cell proliferation (IC50 = 3.32 mu M), but
   had little effect on human normal lung cell MRC-5 even with the tested
   concentration up to 40 mu M. All the data demonstrated that 4 was a
   promising lead for the development of structurally novel PDKs inhibitor
   for the cancer treatment.},
Publisher = {PERGAMON-ELSEVIER SCIENCE LTD},
Address = {THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND},
Type = {Article},
Language = {English},
Affiliation = {Li, XE (Corresponding Author), Ankang Cent Hosp, Dept Pharm, Ankang 725000, Shaanxi, Peoples R China.
   Guo, Fuyun, Shaanxi Prov TB Prevent \& Treatment Inst, Dept Med 7, Xian 710100, Shaanxi, Peoples R China.
   Guo, Fuyun, Shaanxi Prov Fifth Peoples Hosp, Dept Med 7, Xian 710100, Shaanxi, Peoples R China.
   Zhao, Shufen, Qingdao Univ, Affiliated Hosp, Dept Oncol, Qingdao 266003, Shandong, Peoples R China.
   Li, Xiao'e, Ankang Cent Hosp, Dept Pharm, Ankang 725000, Shaanxi, Peoples R China.},
DOI = {10.1016/j.bmcl.2018.11.035},
ISSN = {0960-894X},
EISSN = {1464-3405},
Keywords = {Pyruvate dehydrogenase kinase; Anticancer; Proliferation; Biochemical
   assay},
Keywords-Plus = {PDK1; METABOLISM; EXPRESSION; HYPOXIA},
Research-Areas = {Pharmacology \& Pharmacy; Chemistry},
Web-of-Science-Categories  = {Chemistry, Medicinal; Chemistry, Organic},
Author-Email = {XiaoeLi\_1988@hotmail.com},
Affiliations = {Qingdao University},
Funding-Acknowledgement = {affiliated hospital of Qingdao University, Province of Shandong, China
   {[}201708529]},
Funding-Text = {This work was supported by grant from the affiliated hospital of Qingdao
   University, Province of Shandong, China (Grant No: 201708529).},
Cited-References = {Bersin RM, 1997, AM HEART J, V134, P841, DOI 10.1016/S0002-8703(97)80007-5.
   Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191.
   Fang AP, 2017, BIOORG MED CHEM LETT, V27, P5450, DOI 10.1016/j.bmcl.2017.10.073.
   Fujiwara S, 2013, BRIT J CANCER, V108, P170, DOI 10.1038/bjc.2012.527.
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809.
   Hur H, 2013, INT J ONCOL, V42, P44, DOI 10.3892/ijo.2012.1687.
   Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11.
   Koukourakis MI, 2005, NEOPLASIA, V7, P1, DOI 10.1593/neo.04373.
   Liu YF, 2017, J MED CHEM, V60, P2227, DOI 10.1021/acs.jmedchem.6b01245.
   Liu ZB, 2014, J BIOL CHEM, V289, P29739, DOI 10.1074/jbc.M114.584821.
   Lu CW, 2008, J BIOL CHEM, V283, P28106, DOI 10.1074/jbc.M803508200.
   Meng T, 2014, J MED CHEM, V57, P9832, DOI 10.1021/jm5010144.
   Moore JD, 2014, ONCOTARGET, V5, P12862, DOI 10.18632/oncotarget.2656.
   Patel MS, 2006, BIOCHEM SOC T, V34, P217, DOI 10.1042/BST0340217.
   Patel MS, 2009, J MOL CATAL B-ENZYM, V61, P2, DOI 10.1016/j.molcatb.2009.05.001.
   Qin LJ, 2016, ONCOTARGET, V7, P1395, DOI 10.18632/oncotarget.6366.
   Saunier E, 2016, INT J CANCER, V138, P809, DOI 10.1002/ijc.29564.
   Sun H, 2017, ONCOTARGET, V8, P52642, DOI 10.18632/oncotarget.16991.
   Sun WY, 2015, CANCER RES, V75, P4923, DOI 10.1158/0008-5472.CAN-15-1023.
   Tso SC, 2006, J BIOL CHEM, V281, P27197, DOI 10.1074/jbc.M604339200.
   Tso SC, 2017, J MED CHEM, V60, P1142, DOI 10.1021/acs.jmedchem.6b01540.
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504.
   Wigfield SM, 2008, BRIT J CANCER, V98, P1975, DOI 10.1038/sj.bjc.6604356.
   Xu B, 2018, EUR J MED CHEM, V155, P275, DOI 10.1016/j.ejmech.2018.06.012.
   Yu XK, 2008, STRUCTURE, V16, P104, DOI 10.1016/j.str.2007.10.024.
   Zhang SL, 2015, DRUG DISCOV TODAY, V20, P1112, DOI 10.1016/j.drudis.2015.03.012.},
Number-of-Cited-References = {26},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {11},
Journal-ISO = {Bioorg. Med. Chem. Lett.},
Doc-Delivery-Number = {HG0EZ},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000454616600033},
DA = {2026-02-04},
}
